27373648|t|Acceleration of Acid-Catalyzed Hydrolysis in a Biphasic System by Sodium Tetracyanocyclopentadienides
27373648|a|The hydrolysis of tert-butyldimethylsilyl L-menthyl ether (3) in a CH2Cl2 -1 M HCl biphasic solvent system was accelerated by the addition of sodium tetracyanocyclopentadienides 1. Particularly, the reaction rate was enhanced using sodium salt 1a-c with a lipophilic substituent on the cyclopentadienide ring. From the results obtained by a triphasic experiment, hydrolysis proceeds via the formation of hydronium ion 2 in the aqueous phase by ion exchange, followed by the transfer of 2 to the CH2Cl2 phase.
27373648	0	12	Acceleration	T067	C0000894
27373648	16	30	Acid-Catalyzed	T067	C0175921
27373648	31	41	Hydrolysis	T070	C0020291
27373648	47	62	Biphasic System	T079	C0205184
27373648	66	101	Sodium Tetracyanocyclopentadienides	T109	C0029224
27373648	106	116	hydrolysis	T070	C0020291
27373648	120	159	tert-butyldimethylsilyl L-menthyl ether	T109,T121	C0014996
27373648	169	175	CH2Cl2	T109,T121,T131	C0025748
27373648	181	184	HCl	T130,T197	C0020259
27373648	185	193	biphasic	T079	C0205184
27373648	194	208	solvent system	T130	C0037638
27373648	213	224	accelerated	T067	C0000894
27373648	244	281	sodium tetracyanocyclopentadienides 1	T109	C0029224
27373648	301	314	reaction rate	T079	C0678608
27373648	319	327	enhanced	T052	C2349975
27373648	334	350	sodium salt 1a-c	T109	C0029224
27373648	358	380	lipophilic substituent	T167	C0439861
27373648	388	410	cyclopentadienide ring	T109	C0029224
27373648	443	452	triphasic	T079	C0205185
27373648	453	463	experiment	T062	C0681814
27373648	465	475	hydrolysis	T070	C0020291
27373648	493	502	formation	T169	C1522492
27373648	506	521	hydronium ion 2	T196	C0063096
27373648	529	542	aqueous phase	T080	C0599956
27373648	546	558	ion exchange	T044	C0022013
27373648	597	609	CH2Cl2 phase	T130	C0037638

28494350|t|Liquid chromatography-tandem mass spectrometry quantification of acetamiprid and thiacloprid residues in butterbur grown under regulated conditions
28494350|a|An analytical method was developed to quantify the residual levels of the neonicotinoid insecticides, acetamiprid and thiacloprid, in field-incurred butterbur samples using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Samples were extracted with acetonitrile and partitioned with dichloromethane. After partitioning, purification was conducted using a Florisil(®) cartridge. Linearity of a matrix-matched calibration curve of the two compounds over a concentration range of 0.004-0.4μg/g was excellent, with determination coefficients (R(2))≥0.9998. The limits of detection (LOD) and quantitation (LOQ) for both acetamiprid and thiacloprid were 0.0006 and 0.002mg/kg, respectively. The average recoveries for acetamiprid and thiacloprid at two spiking levels (0.02 and 0.1mg/kg, i.e., 10× LOQ and 50× LOQ) were between 78.23 to 82.17%, with relative standard deviations (RSDs)≤7.22%. The method was successfully applied to field-incurred samples treated with a commercial pesticide product, either once (zero or 7 days before harvest) or twice (0 and 7, 7 and 14, or 14 and 21 days before harvest). The highest and lowest residues were obtained for the 7 and 0 days ' treatment and the 21 and 14 days ' treatment, respectively. The developed method is simple and accurate and can be extrapolated to other leafy vegetables.
28494350	0	46	Liquid chromatography-tandem mass spectrometry	T059	C4049918
28494350	47	61	quantification	T081	C1709793
28494350	65	76	acetamiprid	T109	C1142891
28494350	81	92	thiacloprid	T109,T121	C0962702
28494350	93	101	residues	T131	C1254354
28494350	105	114	butterbur	T002	C1019150
28494350	127	147	regulated conditions	T082	C0014406
28494350	151	168	analytical method	T170	C0178476
28494350	186	194	quantify	T081	C1709793
28494350	199	207	residual	T131	C1254354
28494350	208	214	levels	T080	C0441889
28494350	222	248	neonicotinoid insecticides	T131	C1997222
28494350	250	261	acetamiprid	T109	C1142891
28494350	266	277	thiacloprid	T109,T121	C0962702
28494350	282	296	field-incurred	T169	C0443318
28494350	297	306	butterbur	T002	C1019150
28494350	307	314	samples	T167	C0370003
28494350	321	367	liquid chromatography-tandem mass spectrometry	T059	C4049918
28494350	369	377	LC-MS/MS	T059	C4049918
28494350	380	387	Samples	T167	C0370003
28494350	393	402	extracted	T059	C0684295
28494350	408	420	acetonitrile	T109	C0050456
28494350	442	457	dichloromethane	T109,T121,T131	C0025748
28494350	479	491	purification	T169	C1998793
28494350	514	535	Florisil(®) cartridge	T074	C1504285
28494350	537	546	Linearity	T082	C0205132
28494350	552	584	matrix-matched calibration curve	T081	C0006751
28494350	596	605	compounds	T131	C1254354
28494350	613	626	concentration	T081	C1446561
28494350	627	632	range	T081	C1514721
28494350	670	696	determination coefficients	T081	C2827748
28494350	698	702	R(2)	T081	C2827748
28494350	716	735	limits of detection	T081	C2718050
28494350	737	740	LOD	T081	C2718050
28494350	746	758	quantitation	T081	C1709793
28494350	760	763	LOQ	T081	C1709793
28494350	774	785	acetamiprid	T109	C1142891
28494350	790	801	thiacloprid	T109,T121	C0962702
28494350	871	882	acetamiprid	T109	C1142891
28494350	887	898	thiacloprid	T109,T121	C0962702
28494350	906	920	spiking levels	T080	C0441889
28494350	951	954	LOQ	T081	C1709793
28494350	963	966	LOQ	T081	C1709793
28494350	1003	1031	relative standard deviations	T081	C0871420
28494350	1033	1037	RSDs	T081	C0871420
28494350	1050	1056	method	T170	C0178476
28494350	1085	1099	field-incurred	T169	C0443318
28494350	1100	1107	samples	T167	C0370003
28494350	1108	1115	treated	T169	C1522326
28494350	1123	1133	commercial	T170	C0680536
28494350	1134	1151	pesticide product	T131	C0031253
28494350	1176	1180	days	T079	C0439228
28494350	1188	1195	harvest	T169	C0205245
28494350	1239	1243	days	T079	C0439228
28494350	1251	1258	harvest	T169	C0205245
28494350	1284	1292	residues	T131	C1254354
28494350	1323	1327	days	T079	C0439228
28494350	1330	1339	treatment	T169	C1522326
28494350	1358	1362	days	T079	C0439228
28494350	1365	1374	treatment	T169	C1522326
28494350	1404	1410	method	T170	C0178476
28494350	1425	1433	accurate	T080	C0443131
28494350	1467	1483	leafy vegetables	T168	C0042440

27329050|t|Utility of a mHealth App for Self-Management and Education of Cardiac Diseases in Spanish Urban and Rural Areas
27329050|a|Analyze the utility of a mobile health app named HeartKeeper in several groups of population and obtain conclusions to be applied to other similar apps. A questionnaire has been designed to evaluate the usage and utility of the HeartKeeper app. The questionnaire information was collected by collaborating cardiologists from 32 patients before and after they used the app. Patients were randomly selected with established quotas within interest groups, so that men and women, patients older or younger than 60 years old and patients living in urban or rural areas were equally represented. Using the appropriate statistical techniques we see that the HeartKeeper app was useful for patients as they qualify with 70 points (out of 100) the overall opinion of the app, it helps them remember more easily taking their pills with a mean improvement of 20.94 points (p < 0.001) and they perceive a global improvement of their health (8.28 points, p < 0.001). We also observe that these improvements do not depend, in general, on the area (urban or rural) where the patient comes from or on their sex. Although older patients needed more help to use the app and used it slightly less frequently, the improvements on several measures considered, such as remembering taking pills, breathing problems or trouble developing activities, depend significantly (p < 0.05) on age with older patients reporting higher improvements than younger ones. The results obtained with the sample of patients considered in this research prove the utility of the HeartKeeper app. This utility is similar in urban and rural areas and for patients of both sexes and, to some extent, depends on the age of the patient with older patients reporting slightly lower frequency of use but higher health improvements than younger ones.
27329050	0	7	Utility	T169	C0457083
27329050	13	24	mHealth App	T170	C3658310
27329050	29	44	Self-Management	T058	C0086969
27329050	49	58	Education	T065	C0013621
27329050	62	78	Cardiac Diseases	T047	C0018799
27329050	82	89	Spanish	T083	C0037747
27329050	90	111	Urban and Rural Areas	T083	C0017446
27329050	112	119	Analyze	T062	C0936012
27329050	124	131	utility	T169	C0457083
27329050	137	154	mobile health app	T170	C3658310
27329050	161	172	HeartKeeper	T170	C3827995
27329050	176	204	several groups of population	T098	C1257890
27329050	209	215	obtain	T169	C1301820
27329050	216	227	conclusions	T078	C1707703
27329050	234	241	applied	T169	C4048755
27329050	245	263	other similar apps	T170	C3658310
27329050	267	280	questionnaire	T170	C0034394
27329050	290	298	designed	T052	C1707689
27329050	315	320	usage	T169	C0457083
27329050	325	332	utility	T169	C0457083
27329050	340	355	HeartKeeper app	T170	C3658310
27329050	361	374	questionnaire	T170	C0034394
27329050	375	386	information	T078	C1533716
27329050	391	400	collected	T169	C1516698
27329050	418	431	cardiologists	T097	C0175906
27329050	440	448	patients	T101	C0030705
27329050	449	465	before and after	UnknownType	C0150091
27329050	471	475	used	T169	C0457083
27329050	480	483	app	T170	C3658310
27329050	485	493	Patients	T101	C0030705
27329050	499	516	randomly selected	T062	C0150105
27329050	534	540	quotas	T062	C2347740
27329050	548	563	interest groups	T098	C1705429
27329050	573	576	men	T098	C0025266
27329050	581	586	women	T098	C0043210
27329050	588	596	patients	T101	C0030705
27329050	597	602	older	T098	C0001792
27329050	606	613	younger	T079	C0332239
27329050	622	631	years old	T079	C0439234
27329050	636	644	patients	T101	C0030705
27329050	655	675	urban or rural areas	T083	C0017446
27329050	681	700	equally represented	T052	C1882932
27329050	724	746	statistical techniques	T062	C1710191
27329050	763	778	HeartKeeper app	T170	C3658310
27329050	794	802	patients	T101	C0030705
27329050	811	818	qualify	T080	C1548635
27329050	851	866	overall opinion	T033	C3272903
27329050	874	877	app	T170	C3658310
27329050	893	901	remember	T041	C0034770
27329050	927	932	pills	T122	C0994475
27329050	945	956	improvement	T077	C2986411
27329050	1005	1023	global improvement	T077	C2986411
27329050	1074	1081	observe	T169	C1441672
27329050	1093	1105	improvements	T077	C2986411
27329050	1140	1161	area (urban or rural)	T083	C0017446
27329050	1172	1179	patient	T101	C0030705
27329050	1203	1206	sex	T032	C0079399
27329050	1217	1231	older patients	T098	C1518563
27329050	1232	1238	needed	T080	C0027552
27329050	1252	1255	use	T169	C0457083
27329050	1260	1263	app	T170	C3658310
27329050	1268	1272	used	T169	C0457083
27329050	1285	1300	less frequently	T079	C0205213
27329050	1306	1318	improvements	T077	C2986411
27329050	1322	1338	several measures	T081	C0079809
27329050	1359	1370	remembering	T041	C0034770
27329050	1378	1383	pills	T122	C0994475
27329050	1385	1403	breathing problems	T184	C0497337
27329050	1407	1436	trouble developing activities	T184	C0858854
27329050	1482	1496	older patients	T098	C1518563
27329050	1507	1513	higher	T080	C0205250
27329050	1514	1526	improvements	T077	C2986411
27329050	1532	1544	younger ones	T100	C0238598
27329050	1550	1557	results	T169	C1274040
27329050	1576	1582	sample	T081	C0079809
27329050	1586	1594	patients	T101	C0030705
27329050	1614	1622	research	T062	C0035168
27329050	1633	1640	utility	T169	C0457083
27329050	1648	1663	HeartKeeper app	T170	C3658310
27329050	1670	1677	utility	T169	C0457083
27329050	1692	1713	urban and rural areas	T083	C0017446
27329050	1722	1730	patients	T101	C0030705
27329050	1734	1744	both sexes	T032	C0079399
27329050	1750	1764	to some extent	T080	C1555600
27329050	1781	1784	age	T100	C0027362
27329050	1792	1799	patient	T101	C0030705
27329050	1805	1819	older patients	T098	C1518563
27329050	1830	1854	slightly lower frequency	T079	C0205213
27329050	1858	1861	use	T169	C0457083
27329050	1866	1872	higher	T080	C0205250
27329050	1873	1892	health improvements	T077	C2986411
27329050	1898	1910	younger ones	T100	C0238598

27233260|t|Expression and Purification of E2 Glycoprotein from Insect Cells (Sf9) for Use in Serology
27233260|a|Chikungunya virus (CHIKV) is a mosquito - borne arbovirus which poses a major threat to global public health. Definitive CHIKV diagnosis is crucial, especially in distinguishing the disease from dengue virus, which co-circulates in endemic areas and shares the same mosquito vectors. Laboratory diagnosis is mainly based on serological or molecular approaches. The E2 glycoprotein is a good candidate for serological diagnosis since it is the immunodominant antigen during the course of infection, and reacts with seropositive CHIKV sera. In this chapter, we describe the generation of stable clone Sf9 (Spodoptera frugiperda) cells expressing secreted, soluble, and native recombinant CHIKV E2 glycoprotein. We use direct plasmid expression in insect cells, rather than the traditional technique of generating recombinant baculovirus. This recombinant protein is useful for serological diagnosis of CHIKV infection.
27233260	0	10	Expression	T045	C1171362
27233260	15	27	Purification	T059	C0597301
27233260	31	46	E2 Glycoprotein	T116,T123	C0017968
27233260	52	58	Insect	T204	C0021585
27233260	59	64	Cells	T025	C0007634
27233260	66	69	Sf9	T025	C3494245
27233260	82	90	Serology	T059	C0036743
27233260	91	108	Chikungunya virus	T005	C0008056
27233260	110	115	CHIKV	T005	C0008056
27233260	122	130	mosquito	T204	C0026584
27233260	133	138	borne	T033	C0699809
27233260	139	148	arbovirus	T005	C0003725
27233260	169	175	threat	T078	C0749385
27233260	179	185	global	T080	C2348867
27233260	186	199	public health	T058	C0699943
27233260	201	211	Definitive	T079	C0443196
27233260	212	217	CHIKV	T005	C0008056
27233260	218	227	diagnosis	T033	C0011900
27233260	273	280	disease	T047	C0012634
27233260	286	298	dengue virus	T005	C0011315
27233260	306	319	co-circulates	T169	C0175630
27233260	323	330	endemic	T082	C1254362
27233260	331	336	areas	T082	C0205146
27233260	357	373	mosquito vectors	T204	C4277713
27233260	375	395	Laboratory diagnosis	T060	C0011911
27233260	406	411	based	T169	C1527178
27233260	415	426	serological	T169	C0220911
27233260	430	439	molecular	T080	C1521991
27233260	456	471	E2 glycoprotein	T116,T123	C0017968
27233260	496	517	serological diagnosis	T059	C0036743
27233260	534	556	immunodominant antigen	T129	C0078968
27233260	557	563	during	T079	C0347984
27233260	568	574	course	T079	C0750729
27233260	578	587	infection	T046	C3714514
27233260	593	599	reacts	T169	C0443286
27233260	605	617	seropositive	T080	C0521143
27233260	618	623	CHIKV	T005	C0008056
27233260	624	628	sera	T031	C0229671
27233260	638	645	chapter	T078	C1552857
27233260	650	658	describe	T078	C1552738
27233260	663	673	generation	T052	C3146294
27233260	677	683	stable	T080	C0205360
27233260	684	689	clone	T025	C0009013
27233260	690	693	Sf9	T025	C3494245
27233260	695	716	Spodoptera frugiperda	T204	C0242626
27233260	718	723	cells	T025	C0009013
27233260	724	734	expressing	T045	C1171362
27233260	735	743	secreted	T043	C1327616
27233260	745	752	soluble	T026	C1749467
27233260	758	764	native	T169	C0302891
27233260	765	776	recombinant	T001	C1514798
27233260	777	782	CHIKV	T005	C0008056
27233260	783	798	E2 glycoprotein	T116,T123	C0017968
27233260	814	821	plasmid	T114,T123	C0032136
27233260	822	832	expression	T061	C0185117
27233260	836	842	insect	T204	C0021585
27233260	843	848	cells	T025	C0007634
27233260	866	877	traditional	T169	C0443324
27233260	878	887	technique	T169	C0449851
27233260	891	901	generating	T052	C3146294
27233260	902	925	recombinant baculovirus	T005	C0597363
27233260	932	951	recombinant protein	T116	C0034861
27233260	966	987	serological diagnosis	T059	C0036743
27233260	991	996	CHIKV	T005	C0008056
27233260	997	1006	infection	T046	C3714514

28210659|t|Medial Patellofemoral Ligament Reconstruction Femoral Tunnel Accuracy: Relationship to Disease - Specific Quality of Life
28210659|a|Medial patellofemoral ligament (MPFL) reconstruction is a procedure aimed to reestablish the checkrein to lateral patellar translation in patients with symptomatic patellofemoral instability. Correct femoral tunnel position is thought to be crucial to successful MPFL reconstruction, but the accuracy of this statement in terms of patient outcomes has not been tested. To assess the accuracy of femoral tunnel placement in an MPFL reconstruction cohort and to determine the correlation between tunnel accuracy and a validated disease - specific, patient -reported quality-of-life outcome measure. Case series; Level of evidence, 4. Between June 2008 and February 2014, a total of 206 subjects underwent an MPFL reconstruction. Lateral radiographs were measured to determine the accuracy of the femoral tunnel by measuring the distance from the center of the femoral tunnel to the Schöttle point. Banff Patella Instability Instrument (BPII) scores were collected a mean 24 months postoperatively. A total of 155 (79.5%) subjects had adequate postoperative lateral radiographs and complete BPII scores. The mean duration of follow-up (± SD) was 24.4 ± 8.2 months (range, 12-74 months). Measurement from the center of the femoral tunnel to the Schöttle point resulted in 143 (92.3%) tunnel s being categorized as " good " or " ideal ." There were 8 failures in the cohort, none of which occurred in malpositioned tunnels. The mean distance from the center of the MPFL tunnel to the center of the Schöttle point was 5.9 ± 4.2 mm (range, 0.5-25.9 mm). The mean postoperative BPII score was 65.2 ± 22.5 (range, 9.2-100). Pearson r correlation demonstrated no statistically significant relationship between accuracy of femoral tunnel position and BPII score (r = -0.08; 95% CI, -0.24 to 0.08). There was no evidence of a correlation between the accuracy of MPFL reconstruction femoral tunnel in relation to the Schöttle point and disease - specific quality-of-life scores. Graft failure was not related to femoral tunnel placement. The patellofemoral instability population is complex, and patients present with multiple risk factors that, in addition to the accuracy of femoral tunnel position, contribute to quality of life and warrant further investigation.
28210659	0	30	Medial Patellofemoral Ligament	T023	C4254914
28210659	31	45	Reconstruction	T061	C0547071
28210659	46	53	Femoral	T023	C0015811
28210659	54	60	Tunnel	T082	C1254362
28210659	61	69	Accuracy	T080	C0443131
28210659	87	94	Disease	T047	C0012634
28210659	97	105	Specific	T080	C0205369
28210659	106	121	Quality of Life	T078	C0034380
28210659	122	152	Medial patellofemoral ligament	T023	C4254914
28210659	154	158	MPFL	T023	C4254914
28210659	160	174	reconstruction	T061	C0547071
28210659	228	256	lateral patellar translation	T037	C0559397
28210659	260	268	patients	T101	C0030705
28210659	274	312	symptomatic patellofemoral instability	T037	C0856775
28210659	322	329	femoral	T023	C0015811
28210659	330	336	tunnel	T082	C1254362
28210659	337	345	position	T082	C0733755
28210659	385	389	MPFL	T023	C4254914
28210659	390	404	reconstruction	T061	C0547071
28210659	414	422	accuracy	T080	C0443131
28210659	453	469	patient outcomes	T058	C0030698
28210659	505	513	accuracy	T080	C0443131
28210659	517	524	femoral	T023	C0015811
28210659	525	531	tunnel	T082	C1254362
28210659	532	541	placement	T058	C1533810
28210659	548	552	MPFL	T023	C4254914
28210659	553	567	reconstruction	T061	C0547071
28210659	568	574	cohort	T098	C0599755
28210659	596	607	correlation	T080	C1707520
28210659	616	622	tunnel	T082	C1254362
28210659	623	631	accuracy	T080	C0443131
28210659	638	647	validated	T062	C1519941
28210659	648	655	disease	T047	C0012634
28210659	658	666	specific	T080	C0205369
28210659	668	675	patient	T101	C0030705
28210659	686	701	quality-of-life	T078	C0034380
28210659	702	717	outcome measure	T081	C0086749
28210659	762	766	June	T079	C3829443
28210659	776	784	February	T080	C3830166
28210659	806	814	subjects	T098	C0080105
28210659	828	832	MPFL	T023	C4254914
28210659	833	847	reconstruction	T061	C0547071
28210659	849	856	Lateral	T082	C0205093
28210659	857	868	radiographs	T060	C1306645
28210659	900	908	accuracy	T080	C0443131
28210659	916	923	femoral	T023	C0015811
28210659	924	930	tunnel	T082	C1254362
28210659	980	987	femoral	T023	C0015811
28210659	988	994	tunnel	T082	C1254362
28210659	1002	1016	Schöttle point	T082	C1254362
28210659	1018	1068	Banff Patella Instability Instrument (BPII) scores	T081	C0086749
28210659	1086	1090	mean	T081	C0444504
28210659	1094	1100	months	T079	C0439231
28210659	1101	1116	postoperatively	T079	C0032790
28210659	1163	1176	postoperative	T079	C0032790
28210659	1177	1184	lateral	T082	C0205093
28210659	1185	1196	radiographs	T060	C1306645
28210659	1210	1221	BPII scores	T081	C0086749
28210659	1227	1231	mean	T081	C0444504
28210659	1232	1240	duration	T079	C0449238
28210659	1244	1253	follow-up	T058	C1522577
28210659	1257	1259	SD	T081	C0871420
28210659	1276	1282	months	T079	C0439231
28210659	1297	1303	months	T079	C0439231
28210659	1306	1317	Measurement	T169	C0242485
28210659	1327	1333	center	T082	C0205099
28210659	1341	1348	femoral	T023	C0015811
28210659	1349	1355	tunnel	T082	C1254362
28210659	1363	1377	Schöttle point	T082	C1254362
28210659	1402	1408	tunnel	T082	C1254362
28210659	1434	1438	good	T080	C0205170
28210659	1446	1451	ideal	T080	C1512612
28210659	1468	1476	failures	T046	C1262018
28210659	1484	1490	cohort	T098	C0599755
28210659	1518	1531	malpositioned	T082	C0333042
28210659	1532	1539	tunnels	T082	C1254362
28210659	1545	1549	mean	T081	C0444504
28210659	1568	1574	center	T082	C0205099
28210659	1582	1586	MPFL	T023	C4254914
28210659	1587	1593	tunnel	T082	C1254362
28210659	1601	1607	center	T082	C0205099
28210659	1615	1629	Schöttle point	T082	C1254362
28210659	1673	1677	mean	T081	C0444504
28210659	1678	1691	postoperative	T079	C0032790
28210659	1692	1702	BPII score	T081	C0086749
28210659	1737	1758	Pearson r correlation	T170	C1709490
28210659	1772	1800	no statistically significant	T033	C1273937
28210659	1801	1813	relationship	T080	C0439849
28210659	1822	1830	accuracy	T080	C0443131
28210659	1834	1841	femoral	T023	C0015811
28210659	1842	1848	tunnel	T082	C1254362
28210659	1849	1857	position	T082	C0733755
28210659	1862	1872	BPII score	T081	C0086749
28210659	1919	1933	no evidence of	T080	C0332125
28210659	1936	1947	correlation	T080	C1707520
28210659	1960	1968	accuracy	T080	C0443131
28210659	1972	1976	MPFL	T023	C4254914
28210659	1977	1991	reconstruction	T061	C0547071
28210659	1992	1999	femoral	T023	C0015811
28210659	2000	2006	tunnel	T082	C1254362
28210659	2026	2040	Schöttle point	T082	C1254362
28210659	2045	2052	disease	T047	C0012634
28210659	2055	2063	specific	T080	C0205369
28210659	2064	2086	quality-of-life scores	T080	C3476431
28210659	2088	2101	Graft failure	T046	C1262018
28210659	2121	2128	femoral	T023	C0015811
28210659	2129	2135	tunnel	T082	C1254362
28210659	2136	2145	placement	T058	C1533810
28210659	2151	2177	patellofemoral instability	T037	C0856775
28210659	2205	2213	patients	T101	C0030705
28210659	2236	2248	risk factors	T033	C0035648
28210659	2274	2282	accuracy	T080	C0443131
28210659	2294	2300	tunnel	T082	C1254362
28210659	2301	2309	position	T082	C0733755
28210659	2325	2340	quality of life	T078	C0034380
28210659	2361	2374	investigation	T058	C0220825

28514681|t|Only Two Can Tango: Mast Cells Displace Epithelial Cells to Dance with ILC2s
28514681|a|Mast cells have been implicated in protective immunity to helminth infection, but the precise mechanism remains unclear. In this issue of Immunity, Shimokawa et al., 2017 report that mast cells are a bridge linking dying epithelial cells with effector type 2 innate lymphoid cells.
28514681	20	30	Mast Cells	T025	C0024880
28514681	31	39	Displace	T169	C0559956
28514681	40	56	Epithelial Cells	T025	C0014597
28514681	60	65	Dance	T052	C2986575
28514681	71	76	ILC2s	T025	C0086574
28514681	77	87	Mast cells	T025	C0024880
28514681	98	108	implicated	T080	C0205556
28514681	112	131	protective immunity	T039	C0020964
28514681	135	153	helminth infection	T047	C0018889
28514681	163	170	precise	T080	C2828393
28514681	171	180	mechanism	T169	C0441712
28514681	189	196	unclear	T033	C3845108
28514681	206	211	issue	T170	C1706387
28514681	215	223	Immunity	T039	C0020964
28514681	225	234	Shimokawa	T016	C0086418
28514681	248	254	report	T170	C0684224
28514681	260	270	mast cells	T025	C0024880
28514681	277	291	bridge linking	T052	C2986575
28514681	292	297	dying	T043	C0007587
28514681	298	314	epithelial cells	T025	C0014597
28514681	320	357	effector type 2 innate lymphoid cells	T025	C0086574

27374165|t|Early hippocampal volume loss as a marker of eventual memory deficits caused by repeated stress
27374165|a|Exposure to severe and prolonged stress has detrimental effects on the hippocampus. However, relatively little is known about the gradual changes in hippocampal structure, and its behavioral consequences, over the course of repeated stress. Behavioral analyses during 10 days of chronic stress pointed to a delayed decline in spatial memory, the full impact of which is evident only after the end of stress. In contrast, concurrent volumetric measurements in the same animals revealed significant reduction in hippocampal volumes in stressed animals relative to their unstressed counterparts, as early as the third day of stress. Notably, animals that were behaviorally the worst affected at the end of chronic stress suffered the most pronounced early loss in hippocampal volume. Together, these findings support the view that not only is smaller hippocampal volume linked to stress - induced memory deficits, but it may also act as an early risk factor for the eventual development of cognitive impairments seen in stress-related psychiatric disorders.
27374165	6	17	hippocampal	T023	C0019564
27374165	18	29	volume loss	T033	C0243095
27374165	35	41	marker	T201	C0005516
27374165	54	69	memory deficits	T048	C0233794
27374165	80	95	repeated stress	T033	C0038435
27374165	96	107	Exposure to	T080	C0332157
27374165	108	114	severe	T080	C0205082
27374165	119	128	prolonged	T079	C0439590
27374165	129	135	stress	T033	C0038435
27374165	140	159	detrimental effects	T033	C0243095
27374165	167	178	hippocampus	T023	C0019564
27374165	189	199	relatively	T080	C0205345
27374165	200	206	little	T081	C0700321
27374165	210	215	known	T080	C0205309
27374165	226	233	gradual	T080	C0439833
27374165	234	241	changes	T169	C0392747
27374165	245	266	hippocampal structure	T023	C0019564
27374165	276	286	behavioral	T053	C0004927
27374165	287	299	consequences	T169	C0686907
27374165	320	335	repeated stress	T033	C0038435
27374165	337	356	Behavioral analyses	T058	C1160858
27374165	375	389	chronic stress	UnknownType	C1510527
27374165	411	418	decline	T081	C0547047
27374165	422	436	spatial memory	T041	C0814087
27374165	447	453	impact	T080	C4049986
27374165	496	502	stress	T033	C0038435
27374165	517	527	concurrent	T079	C0205420
27374165	528	551	volumetric measurements	T081	C0079809
27374165	564	571	animals	T008	C0003062
27374165	593	602	reduction	T080	C0392756
27374165	606	617	hippocampal	T023	C0019564
27374165	618	625	volumes	T081	C0392762
27374165	629	637	stressed	T033	C0038435
27374165	638	645	animals	T008	C0003062
27374165	664	687	unstressed counterparts	T033	C0231300
27374165	718	724	stress	T033	C0038435
27374165	735	742	animals	T008	C0003062
27374165	753	765	behaviorally	T053	C0004927
27374165	770	775	worst	T080	C1522166
27374165	776	784	affected	T169	C1292725
27374165	799	813	chronic stress	UnknownType	C1510527
27374165	814	822	suffered	T048	C0683278
27374165	843	875	early loss in hippocampal volume	T033	C0243095
27374165	944	955	hippocampal	T023	C0019564
27374165	956	962	volume	T081	C0392762
27374165	973	979	stress	T033	C0038435
27374165	982	989	induced	T169	C0205263
27374165	990	1005	memory deficits	T048	C0233794
27374165	1039	1050	risk factor	T033	C0035648
27374165	1083	1104	cognitive impairments	T048	C0338656
27374165	1113	1149	stress-related psychiatric disorders	T048	C0599909

28538914|t|The regulation and adoption of health technologies under Brazil's Unified Health System: barriers to access to medicines for diseases of poverty?
28538914|a|The study aimed to examine the regulation and adoption of health technologies for the diseases of poverty in the Brazil's Unified Health System (SUS). An exploratory, descriptive study was conducted between January and May 2016 consisting of the search and analysis of relevant documents on the websites of Brazil's National Health Surveillance Agency, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the National Commission for the Adoption of Technologies by the SUS, and Saúde Legis (the Ministry of Health's Legislation System). The 2014 version of the Brazilian National List of Essential Medicines (RENAME, acronym in Portuguese) contained 132 medicines for diseases of poverty. Over one-third of these (49) had only one national producer, while 24 were not registered in the country. The number of medicines contained in the RENAME dedicated to this group of diseases increased by 46% between 2006 and 2014. Despite advances in the regulation and incorporation of technologies by the SUS, given the lack of market interest and neglect of diseases of poverty, the government has a vital role to play in ensuring access to the best available therapies in order to reduce health inequalities. It therefore follows that Brazil needs to improve the regulation of medicines that do not attract market interest.
28538914	4	14	regulation	T064	C0851285
28538914	31	50	health technologies	T058	C0752189
28538914	57	65	Brazil's	T083	C0006137
28538914	66	87	Unified Health System	T093	C0018696
28538914	111	120	medicines	T121	C0013227
28538914	125	133	diseases	T047	C0012634
28538914	137	144	poverty	T102	C0032854
28538914	177	187	regulation	T064	C0851285
28538914	204	223	health technologies	T058	C0752189
28538914	232	240	diseases	T047	C0012634
28538914	244	251	poverty	T102	C0032854
28538914	259	267	Brazil's	T083	C0006137
28538914	268	289	Unified Health System	T093	C0018696
28538914	291	294	SUS	T093	C0018696
28538914	453	461	Brazil's	T083	C0006137
28538914	462	497	National Health Surveillance Agency	T093	C1708333
28538914	503	536	U.S. Food and Drug Administration	T093	C0041714
28538914	538	541	FDA	T093	C0041714
28538914	548	573	European Medicines Agency	T093	C1708333
28538914	575	578	EMA	T093	C1708333
28538914	585	637	National Commission for the Adoption of Technologies	T093	C1708333
28538914	645	648	SUS	T093	C0018696
28538914	671	710	Ministry of Health's Legislation System	T093	C0018696
28538914	722	729	version	T170	C0333052
28538914	737	746	Brazilian	T033	C0238815
28538914	747	783	National List of Essential Medicines	T170	C0282574
28538914	785	791	RENAME	T170	C0282574
28538914	804	814	Portuguese	T171	C0376250
28538914	830	839	medicines	T121	C0013227
28538914	844	852	diseases	T047	C0012634
28538914	856	863	poverty	T102	C0032854
28538914	907	915	national	T082	C0681788
28538914	916	924	producer	T098	C1709696
28538914	962	969	country	T083	C0454664
28538914	975	981	number	T081	C0237753
28538914	985	994	medicines	T121	C0013227
28538914	1012	1018	RENAME	T170	C0282574
28538914	1037	1042	group	T078	C0441833
28538914	1046	1054	diseases	T047	C0012634
28538914	1055	1064	increased	T081	C0205217
28538914	1103	1111	advances	T079	C3854260
28538914	1119	1129	regulation	T064	C0851285
28538914	1134	1147	incorporation	T169	C0243126
28538914	1151	1163	technologies	T058	C0752189
28538914	1171	1174	SUS	T093	C0018696
28538914	1186	1190	lack	T080	C0332268
28538914	1194	1200	market	T169	C0525052
28538914	1201	1209	interest	T065	C0237439
28538914	1225	1233	diseases	T047	C0012634
28538914	1237	1244	poverty	T102	C0032854
28538914	1250	1260	government	T092	C0018104
28538914	1327	1336	therapies	T061	C0087111
28538914	1356	1362	health	T078	C0018684
28538914	1363	1375	inequalities	T080	C0242503
28538914	1403	1409	Brazil	T083	C0006137
28538914	1410	1415	needs	T080	C0027552
28538914	1419	1426	improve	T033	C0184511
28538914	1431	1441	regulation	T064	C0851285
28538914	1445	1454	medicines	T121	C0013227
28538914	1475	1481	market	T169	C0525052
28538914	1482	1490	interest	T065	C0237439

27524208|t|Doctor Competence and the Demand for Healthcare: Evidence from Rural China
27524208|a|The agency problem between patients and doctors has long been emphasised in the health economics literature, but the empirical evidence on whether patients can evaluate and respond to better quality care remains mixed and inconclusive. Using household data linked to an assessment of village doctors' clinical competence in rural China, we show that there is no correlation between doctor competence and patients' healthcare utilisation, with confidence intervals reasonably tight around zero. Household perceptions of quality are an important determinant of care-seeking behaviour, yet patients appear unable to recognise more competent doctors - there is no relationship between doctor competence and perceptions of quality. Copyright © 2016 John Wiley & Sons, Ltd. JOURNAL ARTICLE
27524208	0	6	Doctor	T097	C0031831
27524208	7	17	Competence	T080	C0086035
27524208	26	32	Demand	T061	C0441516
27524208	37	47	Healthcare	T058	C0086388
27524208	49	57	Evidence	T078	C3887511
27524208	63	74	Rural China	T083	C0008115
27524208	79	85	agency	T092	C0237463
27524208	86	93	problem	T033	C0033213
27524208	102	110	patients	T101	C0030705
27524208	115	122	doctors	T097	C0031831
27524208	155	182	health economics literature	T170	C0023866
27524208	192	201	empirical	T080	C1880496
27524208	202	210	evidence	T078	C3887511
27524208	222	230	patients	T101	C0030705
27524208	235	243	evaluate	T052	C1516048
27524208	259	265	better	T080	C0332272
27524208	266	278	quality care	T058	C0034379
27524208	287	292	mixed	T169	C0205430
27524208	297	309	inconclusive	T080	C1629507
27524208	317	326	household	T099	C0020052
27524208	327	331	data	T078	C1511726
27524208	345	355	assessment	T052	C1516048
27524208	359	366	village	T083	C0562518
27524208	367	375	doctors'	T097	C0031831
27524208	376	395	clinical competence	T080	C0008956
27524208	399	410	rural China	T083	C0008115
27524208	434	448	no correlation	T080	C0205556
27524208	457	463	doctor	T097	C0031831
27524208	464	474	competence	T080	C0086035
27524208	479	488	patients'	T101	C0030705
27524208	489	499	healthcare	T058	C0086388
27524208	500	511	utilisation	T169	C0042153
27524208	518	538	confidence intervals	T081	C0009667
27524208	569	578	Household	T099	C0020052
27524208	579	590	perceptions	T041	C0030971
27524208	594	601	quality	T080	C0332306
27524208	609	618	important	T080	C3898777
27524208	619	630	determinant	T169	C1521761
27524208	634	656	care-seeking behaviour	T055	C0018695
27524208	662	670	patients	T101	C0030705
27524208	671	677	appear	T080	C0700364
27524208	678	684	unable	T033	C1299582
27524208	688	697	recognise	T080	C0205396
27524208	703	712	competent	T080	C0086035
27524208	713	720	doctors	T097	C0031831
27524208	735	747	relationship	T080	C0439849
27524208	756	762	doctor	T097	C0031831
27524208	763	773	competence	T080	C0086035
27524208	778	789	perceptions	T041	C0030971
27524208	793	800	quality	T080	C0332306

27267388|t|Quantitative fetal fibronectin and cervical length to predict preterm birth in asymptomatic women with previous cervical surgery
27267388|a|Quantitative fetal fibronectin testing has demonstrated accuracy for prediction of spontaneous preterm birth in asymptomatic women with a history of preterm birth. Predictive accuracy in women with previous cervical surgery (a potentially different risk mechanism) is not known. We sought to compare the predictive accuracy of cervicovaginal fluid quantitative fetal fibronectin and cervical length testing in asymptomatic women with previous cervical surgery to that in women with 1 previous preterm birth. We conducted a prospective blinded secondary analysis of a larger observational study of cervicovaginal fluid quantitative fetal fibronectin concentration in asymptomatic women measured with a Hologic 10Q system (Hologic, Marlborough, MA). Prediction of spontaneous preterm birth (<30, <34, and <37 weeks) with cervicovaginal fluid quantitative fetal fibronectin concentration in primiparous women who had undergone at least 1 invasive cervical procedure (n = 473) was compared with prediction in women who had previous spontaneous preterm birth, preterm prelabor rupture of membranes, or late miscarriage (n = 821). Relationship with cervical length was explored. The rate of spontaneous preterm birth <34 weeks in the cervical surgery group was 3% compared with 9% in previous spontaneous preterm birth group. Receiver operating characteristic curves comparing quantitative fetal fibronectin for prediction at all 3 gestational end points were comparable between the cervical surgery and previous spontaneous preterm birth groups (34 weeks: area under the curve, 0.78 [95% confidence interval 0.64-0.93] vs 0.71 [95% confidence interval 0.64-0.78]; P = .39). Prediction of spontaneous preterm birth using cervical length compared with quantitative fetal fibronectin for prediction of preterm birth <34 weeks of gestation offered similar prediction (area under the curve, 0.88 [95% confidence interval 0.79-0.96] vs 0.77 [95% confidence interval 0.62-0.92], P = .12 in the cervical surgery group; and 0.77 [95% confidence interval 0.70-0.84] vs 0.74 [95% confidence interval 0.67-0.81], P = .32 in the previous spontaneous preterm birth group). Prediction of spontaneous preterm birth using cervicovaginal fluid quantitative fetal fibronectin in asymptomatic women with cervical surgery is valid, and has comparative accuracy to that in women with a history of spontaneous preterm birth.
27267388	0	30	Quantitative fetal fibronectin	T059	C3837520
27267388	35	50	cervical length	T060	C1956055
27267388	54	61	predict	T078	C0681842
27267388	62	75	preterm birth	T033	C0151526
27267388	79	91	asymptomatic	T033	C0231221
27267388	92	97	women	T098	C0043210
27267388	112	128	cervical surgery	T061	C2044988
27267388	129	167	Quantitative fetal fibronectin testing	T059	C3837520
27267388	172	184	demonstrated	T060	C2729318
27267388	185	193	accuracy	T080	C0443131
27267388	198	208	prediction	T078	C0681842
27267388	212	237	spontaneous preterm birth	T033	C3827961
27267388	241	253	asymptomatic	T033	C0231221
27267388	254	259	women	T098	C0043210
27267388	267	274	history	T033	C0262926
27267388	278	291	preterm birth	T033	C0151526
27267388	293	303	Predictive	T080	C0681890
27267388	304	312	accuracy	T080	C0443131
27267388	316	321	women	T098	C0043210
27267388	336	352	cervical surgery	T061	C2044988
27267388	433	443	predictive	T080	C0681890
27267388	444	452	accuracy	T080	C0443131
27267388	456	476	cervicovaginal fluid	T031	C0392908
27267388	477	507	quantitative fetal fibronectin	T059	C3837520
27267388	512	535	cervical length testing	T060	C1956055
27267388	539	551	asymptomatic	T033	C0231221
27267388	552	557	women	T098	C0043210
27267388	572	588	cervical surgery	T061	C2044988
27267388	600	605	women	T098	C0043210
27267388	622	635	preterm birth	T033	C0151526
27267388	652	663	prospective	T062	C0033522
27267388	664	671	blinded	T062	C0150108
27267388	682	690	analysis	T062	C0936012
27267388	703	722	observational study	T062	C1518527
27267388	726	746	cervicovaginal fluid	T031	C0392908
27267388	747	777	quantitative fetal fibronectin	T059	C3837520
27267388	778	791	concentration	T081	C1446561
27267388	795	807	asymptomatic	T033	C0231221
27267388	808	813	women	T098	C0043210
27267388	830	848	Hologic 10Q system	T170	C0282574
27267388	850	857	Hologic	T170	C0947322
27267388	859	870	Marlborough	T083	C0017446
27267388	872	874	MA	T083	C0024874
27267388	877	887	Prediction	T078	C0681842
27267388	891	916	spontaneous preterm birth	T033	C3827961
27267388	936	941	weeks	T079	C0439230
27267388	948	968	cervicovaginal fluid	T031	C0392908
27267388	969	999	quantitative fetal fibronectin	T059	C3837520
27267388	1000	1013	concentration	T081	C1446561
27267388	1017	1028	primiparous	T033	C0033150
27267388	1029	1034	women	T098	C0043210
27267388	1064	1072	invasive	T080	C0205281
27267388	1073	1091	cervical procedure	T060	C0195314
27267388	1120	1130	prediction	T078	C0681842
27267388	1134	1139	women	T098	C0043210
27267388	1157	1182	spontaneous preterm birth	T033	C3827961
27267388	1184	1221	preterm prelabor rupture of membranes	T046	C0015944
27267388	1226	1242	late miscarriage	T046	C0000786
27267388	1272	1280	cervical	T082	C0205064
27267388	1281	1287	length	T081	C1444754
27267388	1314	1339	spontaneous preterm birth	T033	C3827961
27267388	1344	1349	weeks	T079	C0439230
27267388	1357	1373	cervical surgery	T061	C2044988
27267388	1374	1379	group	T078	C0441833
27267388	1416	1441	spontaneous preterm birth	T033	C3827961
27267388	1442	1447	group	T078	C0441833
27267388	1449	1489	Receiver operating characteristic curves	T081	C0035787
27267388	1500	1530	quantitative fetal fibronectin	T059	C3837520
27267388	1535	1545	prediction	T078	C0681842
27267388	1555	1566	gestational	T079	C0439671
27267388	1567	1577	end points	T080	C2349179
27267388	1606	1622	cervical surgery	T061	C2044988
27267388	1636	1661	spontaneous preterm birth	T033	C3827961
27267388	1662	1668	groups	T078	C0441833
27267388	1673	1678	weeks	T079	C0439230
27267388	1680	1700	area under the curve	T081	C0376690
27267388	1712	1731	confidence interval	T081	C0009667
27267388	1756	1775	confidence interval	T081	C0009667
27267388	1798	1808	Prediction	T078	C0681842
27267388	1812	1837	spontaneous preterm birth	T033	C3827961
27267388	1844	1859	cervical length	T060	C1956055
27267388	1874	1904	quantitative fetal fibronectin	T059	C3837520
27267388	1909	1919	prediction	T078	C0681842
27267388	1923	1936	preterm birth	T033	C0151526
27267388	1941	1946	weeks	T079	C0439230
27267388	1950	1959	gestation	T040	C0032961
27267388	1976	1986	prediction	T078	C0681842
27267388	1988	2008	area under the curve	T081	C0376690
27267388	2020	2039	confidence interval	T081	C0009667
27267388	2064	2083	confidence interval	T081	C0009667
27267388	2111	2127	cervical surgery	T061	C2044988
27267388	2128	2133	group	T078	C0441833
27267388	2149	2168	confidence interval	T081	C0009667
27267388	2193	2212	confidence interval	T081	C0009667
27267388	2249	2274	spontaneous preterm birth	T033	C3827961
27267388	2275	2280	group	T078	C0441833
27267388	2283	2293	Prediction	T078	C0681842
27267388	2297	2322	spontaneous preterm birth	T033	C3827961
27267388	2329	2349	cervicovaginal fluid	T031	C0392908
27267388	2350	2380	quantitative fetal fibronectin	T059	C3837520
27267388	2384	2396	asymptomatic	T033	C0231221
27267388	2397	2402	women	T098	C0043210
27267388	2408	2424	cervical surgery	T061	C2044988
27267388	2455	2463	accuracy	T080	C0443131
27267388	2475	2480	women	T098	C0043210
27267388	2488	2495	history	T033	C0262926
27267388	2499	2524	spontaneous preterm birth	T033	C3827961

28364927|t|Preliminary results from direct-to-facility vaccine deliveries in Kano, Nigeria
28364927|a|As part of its vaccine supply chain redesign efforts, Kano state now pushes vaccines directly from 6 state stores to primary health centers equipped with solar refrigerators. Our objective is to describe preliminary results from the first 20 months of Kano's direct vaccine delivery operations. This is a retrospective review of Kano's direct vaccine delivery program. We analyzed trends in health facility vaccine stock levels, and examined the relationship between stock-out rates and each of cascade vaccine deliveries and timeliness of deliveries. Analysis of vaccination trends was based on administrative data from 27 sentinel health facilities. Costs for both the in-sourced and out-sourced approaches were estimated using a bottoms-up model-based approach. Overall stock adequacy increased from 54% in the first delivery cycle to 68% by cycle 33. Conversely, stock-out rates decreased from 41% to 10% over the same period. Similar trends were observed in the out-sourced and in-sourced programs. Stock-out rates rose incrementally with increasing number of cascade facilities, and delays in vaccine deliveries correlated strongly with stock-out rates. Recognizing that stock availability is one of many factors contributing to vaccinations, we nonetheless compared pre - and post - direct deliveries vaccinations in sentinel facilities, and found statistically significant upward trends for 4 out of 6 antigens. 1 antigen (measles) showed an upward trend that was not statistically significant. Hepatitis b vaccinations declined during the period. Overall, there appeared to be a one- year lag between commencement of direct deliveries and the increase in number of vaccinations. Weighted average cost per delivery is US$29.8 and cost per child immunized is US$0.7 per year. Direct vaccine delivery to health facilities in Kano, through a streamlined architecture, has resulted in decreased stock-outs and improved stock adequacy. Concurrent operation of insourced and outsourced programs has enabled Kano build in-house logistics capabilities.
28364927	0	19	Preliminary results	T078	C1548161
28364927	44	51	vaccine	T121,T129	C0042210
28364927	52	62	deliveries	T169	C1705822
28364927	66	70	Kano	T083	C0017446
28364927	72	79	Nigeria	T083	C0028075
28364927	95	102	vaccine	T121,T129	C0042210
28364927	103	115	supply chain	T078	C0243163
28364927	116	132	redesign efforts	T040	C0015264
28364927	134	144	Kano state	T083	C0017446
28364927	156	164	vaccines	T121,T129	C0042210
28364927	181	186	state	T083	C1301808
28364927	187	193	stores	T073	C3273359
28364927	197	204	primary	T080	C0205225
28364927	205	219	health centers	T073,T093	C0475309
28364927	234	239	solar	T070	C0037605
28364927	240	253	refrigerators	T073	C0034958
28364927	259	268	objective	T170	C0018017
28364927	284	303	preliminary results	T078	C1548161
28364927	322	328	months	T079	C0439231
28364927	332	338	Kano's	T083	C0017446
28364927	339	345	direct	T080	C1947931
28364927	346	353	vaccine	T121,T129	C0042210
28364927	354	362	delivery	T169	C1705822
28364927	385	405	retrospective review	T062	C0035363
28364927	409	415	Kano's	T083	C0017446
28364927	416	422	direct	T080	C1947931
28364927	423	430	vaccine	T121,T129	C0042210
28364927	431	439	delivery	T169	C1705822
28364927	440	447	program	T170	C0376691
28364927	471	486	health facility	T058	C1254363
28364927	487	494	vaccine	T121,T129	C0042210
28364927	495	500	stock	T078	C1710198
28364927	501	507	levels	T080	C0441889
28364927	547	556	stock-out	T033	C3858634
28364927	557	562	rates	T081	C1521828
28364927	583	590	vaccine	T121,T129	C0042210
28364927	591	601	deliveries	T169	C1705822
28364927	620	630	deliveries	T169	C1705822
28364927	632	640	Analysis	T062	C0936012
28364927	644	662	vaccination trends	T061	C0042196
28364927	691	695	data	T078	C1511726
28364927	704	730	sentinel health facilities	T058	C1254363
28364927	732	737	Costs	T081	C0010186
28364927	751	761	in-sourced	T033	C0449416
28364927	766	777	out-sourced	T033	C0449416
28364927	778	788	approaches	T082	C0449445
28364927	812	843	bottoms-up model-based approach	T170	C3161035
28364927	853	858	stock	T078	C1710198
28364927	859	867	adequacy	T080	C0205411
28364927	868	877	increased	T081	C0205217
28364927	900	908	delivery	T081	C0205217
28364927	947	956	stock-out	T033	C3858634
28364927	957	962	rates	T081	C1521828
28364927	963	972	decreased	T081	C0205216
28364927	1003	1009	period	T079	C1948053
28364927	1047	1058	out-sourced	T033	C0449416
28364927	1063	1073	in-sourced	T033	C0449416
28364927	1074	1082	programs	T170	C0376691
28364927	1084	1093	Stock-out	T033	C3858634
28364927	1094	1099	rates	T081	C1521828
28364927	1124	1134	increasing	T169	C0442808
28364927	1169	1175	delays	T079	C0205421
28364927	1179	1186	vaccine	T121,T129	C0042210
28364927	1187	1197	deliveries	T169	C1705822
28364927	1223	1232	stock-out	T033	C3858634
28364927	1233	1238	rates	T081	C1521828
28364927	1257	1262	stock	T078	C1710198
28364927	1263	1275	availability	T169	C0470187
28364927	1315	1327	vaccinations	T061	C0042196
28364927	1353	1356	pre	T079	C3847846
28364927	1363	1367	post	T079	C0687676
28364927	1377	1387	deliveries	T169	C1705822
28364927	1388	1400	vaccinations	T061	C0042196
28364927	1404	1423	sentinel facilities	T058	C1254363
28364927	1435	1460	statistically significant	T081	C0237881
28364927	1490	1498	antigens	T129	C0003320
28364927	1502	1509	antigen	T129	C0003320
28364927	1511	1518	measles	T047	C0025007
28364927	1556	1581	statistically significant	T081	C0237881
28364927	1583	1607	Hepatitis b vaccinations	T061	C0474232
28364927	1628	1634	period	T079	C1948053
28364927	1673	1677	year	T079	C0439234
28364927	1713	1723	deliveries	T169	C1705822
28364927	1732	1740	increase	T169	C0442805
28364927	1754	1766	vaccinations	T061	C0042196
28364927	1785	1789	cost	T081	C0010186
28364927	1794	1802	delivery	T169	C1705822
28364927	1818	1822	cost	T081	C0010186
28364927	1827	1832	child	T100	C0008059
28364927	1833	1842	immunized	T061	C0020971
28364927	1857	1861	year	T079	C0439234
28364927	1870	1877	vaccine	T121,T129	C0042210
28364927	1878	1886	delivery	T169	C1705822
28364927	1890	1907	health facilities	T058	C1254363
28364927	1911	1915	Kano	T083	C0017446
28364927	1969	1978	decreased	T081	C0205216
28364927	1979	1989	stock-outs	T033	C3858634
28364927	1994	2002	improved	T080	C0332272
28364927	2003	2008	stock	T078	C1710198
28364927	2009	2017	adequacy	T080	C0205411
28364927	2043	2052	insourced	T033	C0243095
28364927	2057	2067	outsourced	T033	C0243095
28364927	2068	2076	programs	T170	C0376691
28364927	2089	2093	Kano	T083	C0017446
28364927	2109	2118	logistics	T057	C0242415
28364927	2119	2131	capabilities	T080	C2698977

28460374|t|LDL particle number and size and cardiovascular risk: anything new under the sun?
28460374|a|We provide here an up-to-date perspective on the potential use of LDL particle number and size as complementary risk factors to predict and manage cardiovascular disease (CVD) risk in the clinical realm. Studies show that a significant proportion of the population has discordant LDL particle number and cholesterol indices [non-HDL cholesterol (HDL-C)]. Data also show that risk prediction may be improved when using information on LDL particle number in patients with discordant particle number and cholesterol data. Yet, most of the current CVD guidelines conclude that LDL particle number is not superior to cholesterol indices, including non-HDL-C concentrations, in predicting CVD risk. LDL particle size, on the other hand, has not been independently associated with CVD risk after adjustment for other risk factors such as LDL cholesterol, triglycerides, and HDL-C and that routine use of information pertaining to particle size to determine and manage patients' risk is not yet justified. Additional studies are required to settle the debate on which of cholesterol indices and LDL particle number is the best predictor of CVD risk, and if such measures should be integrated in clinical practice.
28460374	0	3	LDL	T109,T123	C0023823
28460374	4	19	particle number	T081	C0392762
28460374	24	28	size	T081	C0030608
28460374	33	47	cardiovascular	T029	C3887460
28460374	48	52	risk	T078	C0035647
28460374	131	140	potential	T080	C3245505
28460374	141	144	use	T169	C0457083
28460374	148	151	LDL	T109,T123	C0023823
28460374	152	167	particle number	T081	C0392762
28460374	172	176	size	T081	C0030608
28460374	194	206	risk factors	T033	C0035648
28460374	229	251	cardiovascular disease	T047	C0007222
28460374	253	256	CVD	T047	C0007222
28460374	258	262	risk	T078	C0035647
28460374	270	278	clinical	T080	C0205210
28460374	286	293	Studies	T062	C0008972
28460374	306	317	significant	T078	C0750502
28460374	318	328	proportion	T081	C1709707
28460374	336	346	population	T098	C1257890
28460374	351	361	discordant	T077	C3639994
28460374	362	365	LDL	T109,T123	C0023823
28460374	366	381	particle number	T081	C0392762
28460374	386	397	cholesterol	T109,T123	C0008377
28460374	398	405	indices	T170	C0918012
28460374	407	426	non-HDL cholesterol	T109,T123	C0729627
28460374	428	433	HDL-C	T109,T123	C0023822
28460374	500	511	information	T078	C1533716
28460374	515	518	LDL	T109,T123	C0023823
28460374	519	534	particle number	T081	C0392762
28460374	538	546	patients	T101	C0030705
28460374	552	562	discordant	T077	C3639994
28460374	563	578	particle number	T081	C0392762
28460374	583	594	cholesterol	T109,T123	C0008377
28460374	626	629	CVD	T047	C0007222
28460374	630	640	guidelines	T170	C0282451
28460374	655	658	LDL	T109,T123	C0023823
28460374	659	674	particle number	T081	C0392762
28460374	694	705	cholesterol	T109,T123	C0008377
28460374	706	713	indices	T170	C0918012
28460374	725	734	non-HDL-C	T109,T123	C0729627
28460374	735	749	concentrations	T081	C1446561
28460374	765	768	CVD	T047	C0007222
28460374	769	773	risk	T078	C0035647
28460374	775	778	LDL	T109,T123	C0023823
28460374	779	792	particle size	T081	C0030608
28460374	840	855	associated with	T080	C0332281
28460374	856	859	CVD	T047	C0007222
28460374	860	864	risk	T078	C0035647
28460374	871	881	adjustment	T169	C0456081
28460374	892	904	risk factors	T033	C0035648
28460374	913	928	LDL cholesterol	T109,T123	C0023824
28460374	930	943	triglycerides	T109,T123	C0041004
28460374	949	954	HDL-C	T109,T123	C0023822
28460374	979	990	information	T078	C1533716
28460374	1005	1018	particle size	T081	C0030608
28460374	1043	1052	patients'	T101	C0030705
28460374	1053	1057	risk	T078	C0035647
28460374	1080	1090	Additional	T169	C1524062
28460374	1091	1098	studies	T062	C0008972
28460374	1126	1132	debate	T052	C0870392
28460374	1145	1156	cholesterol	T109,T123	C0008377
28460374	1157	1164	indices	T170	C0918012
28460374	1169	1172	LDL	T109,T123	C0023823
28460374	1173	1188	particle number	T081	C0392762
28460374	1214	1217	CVD	T047	C0007222
28460374	1218	1222	risk	T078	C0035647
28460374	1236	1244	measures	T081	C0079809
28460374	1269	1286	clinical practice	T061	C0087111

27447000|t|Effect of endodontic access cavity preparation on monolithic and ceramic veneered zirconia restorations
27447000|a|Due to the high chipping rates observed in veneered zirconia ceramic restorations, the use of monolithic zirconia restorations has been recommended. This study tried to compare veneered and monolithic zirconia fixed dental prostheses (FDPs) with respect to the amount of damage induced by endodontic access preparation. Monolithic and ceramic veneered (n = 10) three-unit restorations (retainers: first premolar and first molar; pontic: second premolar) were subject to endodontic access cavity preparation in both retainers using a diamond rotary instrument under continuous water cooling. The number of chipping fractures and microfractures detected using the fluorescent penetrant method were recorded. Statistical analysis was based on Wilcoxon rank sum tests with Bonferroni correction (level of significance α = .05). Only one microfracture could be identified in the group of monolithic FDPs while a maximum of seven microfractures and three chipping fractures per retainer crown were recorded in the group of veneered restorations. At the premolar site, the veneered restorations showed significantly more microfractures (P = .0055) and chipping fractures (P = .0008). At the molar site, no significant difference with respect to microfractures could be detected (P = .0767), while significantly more chipping fractures occurred in the veneered samples (P = .0293). Monolithic zirconia restorations seem to be less susceptible to damage when endodontic access cavities have to be prepared as compared to veneered zirconia reconstructions. However, no conclusions can be drawn on the longterm performance of a specific restoration based on this study.
27447000	0	6	Effect	T080	C1280500
27447000	10	46	endodontic access cavity preparation	T061	C0398979
27447000	50	60	monolithic	T080	C0205556
27447000	65	72	ceramic	T122	C0440171
27447000	73	81	veneered	T122	C0441364
27447000	82	90	zirconia	T121,T197	C0078814
27447000	91	103	restorations	T061	C0399059
27447000	120	128	chipping	T037	C0332757
27447000	147	155	veneered	T122	C0441364
27447000	156	164	zirconia	T121,T197	C0078814
27447000	165	172	ceramic	T122	C0440171
27447000	173	185	restorations	T061	C0399059
27447000	198	208	monolithic	T080	C0205556
27447000	209	217	zirconia	T121,T197	C0078814
27447000	218	230	restorations	T061	C0399059
27447000	281	289	veneered	T122	C0441364
27447000	294	304	monolithic	T080	C0205556
27447000	305	313	zirconia	T121,T197	C0078814
27447000	314	337	fixed dental prostheses	T074	C0182448
27447000	339	343	FDPs	T074	C0182448
27447000	375	381	damage	T169	C1883709
27447000	393	422	endodontic access preparation	T061	C0398979
27447000	424	434	Monolithic	T080	C0205556
27447000	439	446	ceramic	T122	C0440171
27447000	447	455	veneered	T122	C0441364
27447000	476	488	restorations	T061	C0399059
27447000	490	499	retainers	T074	C0242919
27447000	501	515	first premolar	T023	C1827002
27447000	520	531	first molar	T023	C0932487
27447000	533	539	pontic	T074	C0449934
27447000	541	556	second premolar	T023	C1827004
27447000	574	610	endodontic access cavity preparation	T061	C0398979
27447000	619	628	retainers	T074	C0242919
27447000	637	662	diamond rotary instrument	T074	C1738351
27447000	669	679	continuous	T078	C0549178
27447000	680	685	water	T121,T197	C0043047
27447000	686	693	cooling	T070	C0678568
27447000	709	727	chipping fractures	T037	C0332757
27447000	732	746	microfractures	T037	C1265651
27447000	766	794	fluorescent penetrant method	T059	C1318786
27447000	810	830	Statistical analysis	T062	C0871424
27447000	844	867	Wilcoxon rank sum tests	T081	C0242928
27447000	873	894	Bonferroni correction	T081	C2347434
27447000	896	917	level of significance	T062	C0814896
27447000	937	950	microfracture	T037	C1265651
27447000	987	997	monolithic	T080	C0205556
27447000	998	1002	FDPs	T074	C0182448
27447000	1028	1042	microfractures	T037	C1265651
27447000	1053	1071	chipping fractures	T037	C0332757
27447000	1076	1090	retainer crown	T074	C0812679
27447000	1121	1129	veneered	T122	C0441364
27447000	1130	1142	restorations	T061	C0399059
27447000	1170	1178	veneered	T122	C0441364
27447000	1179	1191	restorations	T061	C0399059
27447000	1218	1232	microfractures	T037	C1265651
27447000	1249	1267	chipping fractures	T037	C0332757
27447000	1288	1298	molar site	T023	C0026367
27447000	1300	1325	no significant difference	T033	C3842396
27447000	1342	1356	microfractures	T037	C1265651
27447000	1413	1431	chipping fractures	T037	C0332757
27447000	1448	1456	veneered	T122	C0441364
27447000	1478	1488	Monolithic	T080	C0205556
27447000	1489	1497	zirconia	T121,T197	C0078814
27447000	1498	1510	restorations	T061	C0399059
27447000	1527	1538	susceptible	T169	C0231204
27447000	1542	1548	damage	T169	C1883709
27447000	1554	1580	endodontic access cavities	T061	C0398979
27447000	1616	1624	veneered	T122	C0441364
27447000	1625	1633	zirconia	T121,T197	C0078814
27447000	1634	1649	reconstructions	T061	C0399059
27447000	1695	1715	longterm performance	T067	C0023983
27447000	1730	1741	restoration	T061	C0399059

28112192|t|STAC3 stably interacts through its C1 domain with CaV1.1 in skeletal muscle triads
28112192|a|The adaptor protein STAC3 is essential for skeletal muscle excitation-contraction (EC) coupling and a mutation in the STAC3 gene has been linked to a severe muscle disease, Native American myopathy (NAM). However the function of STAC3, its interaction partner, and the mode of interaction within the EC-coupling complex remained elusive. Here we demonstrate that STAC3 forms a stable interaction with the voltage-sensor of EC-coupling, CaV1.1, and that this interaction depends on a hitherto unidentified protein-protein binding pocket in the C1 domain of STAC3. While the NAM mutation does not affect the stability of the STAC3 - CaV1.1 interaction, mutation of two crucial residues in the C1 binding pocket increases the turnover of STAC3 in skeletal muscle triads. Thus, the C1 domain of STAC3 is responsible for its stable incorporation into the CaV1.1 complex, whereas the SH3 domain containing the NAM mutation site may be involved in low-affinity functional interactions in EC-coupling.
28112192	0	5	STAC3	T116,T123	C3713078
28112192	13	22	interacts	T044	C0872079
28112192	35	44	C1 domain	T087	C0002518
28112192	50	56	CaV1.1	T116,T123	C0006685
28112192	60	82	skeletal muscle triads	T024	C0242692
28112192	87	102	adaptor protein	T116,T123	C3713078
28112192	103	108	STAC3	T116,T123	C3713078
28112192	126	141	skeletal muscle	T024	C0242692
28112192	142	178	excitation-contraction (EC) coupling	T039	C2717948
28112192	185	193	mutation	T045	C0026882
28112192	201	211	STAC3 gene	T028	C1539880
28112192	240	254	muscle disease	T047	C0026848
28112192	256	280	Native American myopathy	T047	C1850625
28112192	282	285	NAM	T047	C1850625
28112192	300	308	function	T169	C0542341
28112192	312	317	STAC3	T116,T123	C3713078
28112192	352	371	mode of interaction	T169	C1704675
28112192	383	394	EC-coupling	T039	C2717948
28112192	395	402	complex	T116,T123	C1180347
28112192	446	451	STAC3	T116,T123	C3713078
28112192	467	478	interaction	T044	C0872079
28112192	488	502	voltage-sensor	T116,T192	C0597357
28112192	506	517	EC-coupling	T039	C2717948
28112192	519	525	CaV1.1	T116,T123	C0006685
28112192	541	552	interaction	T044	C0872079
28112192	588	618	protein-protein binding pocket	T192	C0005456
28112192	626	635	C1 domain	T087	C0002518
28112192	639	644	STAC3	T116,T123	C3713078
28112192	656	659	NAM	T047	C1850625
28112192	660	668	mutation	T045	C0026882
28112192	689	698	stability	T044	C0314668
28112192	706	711	STAC3	T116,T123	C3713078
28112192	714	720	CaV1.1	T116,T123	C0006685
28112192	721	732	interaction	T044	C0872079
28112192	734	742	mutation	T045	C0026882
28112192	758	766	residues	T116,T121,T123	C0002520
28112192	774	791	C1 binding pocket	T192	C0005456
28112192	818	823	STAC3	T116,T123	C3713078
28112192	827	849	skeletal muscle triads	T024	C0242692
28112192	861	870	C1 domain	T087	C0002518
28112192	874	879	STAC3	T116,T123	C3713078
28112192	910	923	incorporation	T169	C0243126
28112192	933	939	CaV1.1	T116,T123	C0006685
28112192	940	947	complex	T116,T123	C1180347
28112192	961	971	SH3 domain	T087	C0282535
28112192	987	990	NAM	T047	C1850625
28112192	991	999	mutation	T045	C0026882
28112192	1000	1004	site	T082	C0205145
28112192	1024	1060	low-affinity functional interactions	T044	C0872079
28112192	1064	1075	EC-coupling	T039	C2717948

27754446|t|Synthesis and In Vitro Cytotoxic Properties of Polycarbo-Substituted 4-(Arylamino)quinazolines
27754446|a|Herein, we describe the synthesis of novel unsymmetrical polycarbo-substituted 4-anilinoquinazolines derived from the 2-aryl-6-bromo-8-iodoquinazolines via one-pot three-step reaction sequences involving initial amination and subsequent double cross-coupling (bis-Suzuki, Sonogashira/Stille or Sonogashira/Suzuki-Miyaura) reactions with different cross coupling partners for the two carbon-carbon bond formation steps. The 4-anilinoquinazolines were evaluated for potential cytotoxicity against three cancer cell lines, namely, human breast adenocarcinoma (MCF-7) cells, human cervical cancer (HeLa) and human lung cancer (A549) cells. The most active compounds, 2b, 2c, 3c, 4a, 4c and 5a, were found to be more selective against the MCF-7 and HeLa cell lines than the human lung carcinoma (A549) cells. We selected compounds 2c, 3c and 7a as representatives for further evaluation for potential to induce apoptosis and/or necrotic properties in the three cancer cell lines. Compound 2c induced apoptosis of MCF-7 cells through cell membrane alteration. Treatment of Hela and A549 cell lines with compounds 3c and 7a, respectively, led to caspase-3 activation in both cell lines. Compound 3c, on the other hand, caused more necrosis than apoptosis induction in the membrane alteration assay.
27754446	0	9	Synthesis	T052	C1883254
27754446	14	22	In Vitro	T080	C1533691
27754446	23	32	Cytotoxic	T169	C1511636
27754446	33	43	Properties	T080	C0871161
27754446	47	94	Polycarbo-Substituted 4-(Arylamino)quinazolines	T109	C0034407
27754446	119	128	synthesis	T052	C1883254
27754446	132	137	novel	T080	C0205314
27754446	138	195	unsymmetrical polycarbo-substituted 4-anilinoquinazolines	T109	C0034407
27754446	196	203	derived	T080	C1441547
27754446	213	246	2-aryl-6-bromo-8-iodoquinazolines	T109	C0034407
27754446	251	288	one-pot three-step reaction sequences	T067	C0596319
27754446	307	316	amination	T070	C0002505
27754446	321	331	subsequent	T079	C0332282
27754446	332	426	double cross-coupling (bis-Suzuki, Sonogashira/Stille or Sonogashira/Suzuki-Miyaura) reactions	T067	C0596319
27754446	442	465	cross coupling partners	T109	C0029224
27754446	478	506	carbon-carbon bond formation	T070	C0596391
27754446	518	539	4-anilinoquinazolines	T109	C0034407
27754446	559	568	potential	T080	C3245505
27754446	569	581	cytotoxicity	T049	C0596402
27754446	582	589	against	T080	C0521124
27754446	596	613	cancer cell lines	T025	C0085983
27754446	623	664	human breast adenocarcinoma (MCF-7) cells	T025	C0596890
27754446	666	687	human cervical cancer	T025	C0018873
27754446	689	693	HeLa	T025	C0018873
27754446	699	729	human lung cancer (A549) cells	T025	C4277577
27754446	740	756	active compounds	T103	C1706082
27754446	758	760	2b	T109	C0034407
27754446	762	764	2c	T109	C0034407
27754446	766	768	3c	T109	C0034407
27754446	770	772	4a	T109	C0034407
27754446	774	776	4c	T109	C0034407
27754446	781	783	5a	T109	C0034407
27754446	829	834	MCF-7	T025	C0596890
27754446	839	843	HeLa	T025	C0018873
27754446	844	854	cell lines	T025	C0085983
27754446	864	897	human lung carcinoma (A549) cells	T025	C4277577
27754446	911	920	compounds	T103	C1706082
27754446	921	923	2c	T109	C0034407
27754446	925	927	3c	T109	C0034407
27754446	932	934	7a	T109	C0034407
27754446	981	990	potential	T080	C3245505
27754446	994	1000	induce	T169	C0205263
27754446	1001	1010	apoptosis	T043	C0162638
27754446	1018	1037	necrotic properties	T042	C0027540
27754446	1051	1068	cancer cell lines	T025	C0085983
27754446	1070	1081	Compound 2c	T109	C0034407
27754446	1082	1089	induced	T169	C0205263
27754446	1090	1099	apoptosis	T043	C0162638
27754446	1103	1114	MCF-7 cells	T025	C0596890
27754446	1123	1147	cell membrane alteration	T049	C0544958
27754446	1149	1158	Treatment	T169	C1522326
27754446	1162	1166	Hela	T025	C0018873
27754446	1171	1175	A549	T025	C4277577
27754446	1176	1186	cell lines	T025	C0085983
27754446	1192	1204	compounds 3c	T109	C0034407
27754446	1209	1211	7a	T109	C0034407
27754446	1234	1254	caspase-3 activation	T044	C1159825
27754446	1263	1273	cell lines	T025	C0085983
27754446	1275	1286	Compound 3c	T109	C0034407
27754446	1319	1327	necrosis	T042	C0027540
27754446	1333	1342	apoptosis	T043	C0162638
27754446	1343	1352	induction	T169	C0205263
27754446	1360	1379	membrane alteration	UnknownType	C0541642
27754446	1380	1385	assay	T059	C1510438

28433844|t|Neurological Decline in an Elderly with Repaired Myelomeningocele Complicated with Lumbar Canal Stenosis: a case report
28433844|a|Tethered cord syndrome is a well-known complication after myelomeningocele (MMC) repair in childhood. However, late complications in adults with a repaired MMC are not well understood. In particular, the influence of a degenerative spinal deformity on a sustained tethered cord is still unclear. A 63-year-old man with a repaired MMC presented with a progressive gait disturbance and numbness in both lower limbs. Magnetic resonance images demonstrated that the tethered spinal cord was compressed by severe canal stenosis along the entire lumbar spine. After a multi-level lumbar decompression surgery, the patient recovered to baseline neurological status. In adults with a repaired MMC, lumbar canal stenosis should be investigated as a possible cause of late neurological decline. Clinical manifestations may be complicated by the coexistence of both the original and subsequent neurological disorders. Because these additional disorders result from compressive myelopathy, early surgical decompression is indicated to avoid irreversible spinal cord dysfunction.
28433844	0	20	Neurological Decline	T033	C4314692
28433844	27	34	Elderly	T098	C0001792
28433844	40	48	Repaired	T169	C0205340
28433844	49	65	Myelomeningocele	T019	C0025312
28433844	66	77	Complicated	T169	C0231242
28433844	83	104	Lumbar Canal Stenosis	T047	C0158288
28433844	108	119	case report	T170	C0085973
28433844	120	142	Tethered cord syndrome	T047	C0080218
28433844	159	171	complication	T046	C0009566
28433844	178	194	myelomeningocele	T019	C0025312
28433844	196	199	MMC	T019	C0025312
28433844	201	207	repair	T058	C1705181
28433844	211	220	childhood	T079	C0231335
28433844	236	249	complications	T046	C0009566
28433844	253	259	adults	T100	C0001675
28433844	267	275	repaired	T169	C0205340
28433844	276	279	MMC	T019	C0025312
28433844	324	333	influence	T077	C4054723
28433844	339	368	degenerative spinal deformity	T190	C0575157
28433844	374	383	sustained	T169	C0443318
28433844	384	397	tethered cord	T033	C1842369
28433844	418	429	63-year-old	T100	C0001675
28433844	430	433	man	T032	C0086582
28433844	441	449	repaired	T169	C0205340
28433844	450	453	MMC	T019	C0025312
28433844	471	499	progressive gait disturbance	T033	C0243095
28433844	504	512	numbness	T184	C0028643
28433844	521	532	lower limbs	T023	C0023216
28433844	534	559	Magnetic resonance images	T170	C1704922
28433844	582	602	tethered spinal cord	T033	C1842369
28433844	607	617	compressed	T169	C0332260
28433844	621	627	severe	T080	C0205082
28433844	628	642	canal stenosis	T047	C0158288
28433844	653	672	entire lumbar spine	T029	C1269871
28433844	682	714	multi-level lumbar decompression	T061	C0578803
28433844	715	722	surgery	T061	C0543467
28433844	728	745	patient recovered	T032	C1115804
28433844	749	757	baseline	T081	C1442488
28433844	758	770	neurological	T080	C0205494
28433844	782	788	adults	T100	C0001675
28433844	796	804	repaired	T169	C0205340
28433844	805	808	MMC	T019	C0025312
28433844	810	831	lumbar canal stenosis	T047	C0158288
28433844	842	854	investigated	T169	C1292732
28433844	883	903	neurological decline	T033	C4314692
28433844	936	947	complicated	T169	C0231242
28433844	1003	1025	neurological disorders	T047	C0027765
28433844	1052	1061	disorders	T047	C0012634
28433844	1074	1096	compressive myelopathy	T047	C0037926
28433844	1104	1126	surgical decompression	T061	C0376530
28433844	1162	1185	spinal cord dysfunction	T047	C0012634

28470482|t|New Diterpenoids from Clerodendranthus spicatus
28470482|a|Two new diterpenoids, neoorthosiphonones B and C (1 and 2), and one known diterpenoid, were isolated from the aerial parts of Clerodendranthus spicatus. Their structures including absolute configurations were determined by comprehensive spectroscopic analyses and X-ray crystallographic methods. No compound was found to inhibit fibronectin production at the concentration of 20 μM.
28470482	0	3	New	T080	C0205314
28470482	4	16	Diterpenoids	T109	C0012780
28470482	22	47	Clerodendranthus spicatus	T002	C2311252
28470482	52	55	new	T080	C0205314
28470482	56	68	diterpenoids	T109	C0012780
28470482	70	90	neoorthosiphonones B	T109	C0012780
28470482	95	96	C	T109	C0012780
28470482	98	99	1	T109	C0012780
28470482	104	105	2	T109	C0012780
28470482	122	133	diterpenoid	T109	C0012780
28470482	140	148	isolated	T169	C0205409
28470482	158	170	aerial parts	T002	C1136056
28470482	174	199	Clerodendranthus spicatus	T002	C2311252
28470482	207	217	structures	T082	C0678594
28470482	228	236	absolute	T080	C0205344
28470482	237	251	configurations	T082	C0449830
28470482	257	270	determined by	T080	C0521095
28470482	285	307	spectroscopic analyses	T059	C0022885
28470482	312	342	X-ray crystallographic methods	T059	C0206755
28470482	347	355	compound	T080	C0205198
28470482	369	376	inhibit	T080	C0521111
28470482	377	388	fibronectin	T116,T123	C0016055
28470482	389	399	production	T057	C0033268
28470482	407	420	concentration	T081	C1446561

28071754|t|Far-infrared protects vascular endothelial cells from advanced glycation end products - induced injury via PLZF -mediated autophagy in diabetic mice
28071754|a|The accumulation of advanced glycation end products (AGEs) in diabetic patients induces vascular endothelial injury. Promyelocytic leukemia zinc finger protein (PLZF) is a transcription factor that can be activated by low-temperature far-infrared (FIR) irradiation to exert beneficial effects on the vascular endothelium. In the present study, we investigated the influence of FIR - induced PLZF activation on AGE - induced endothelial injury both in vitro and in vivo. FIR irradiation inhibited AGE - induced apoptosis in human umbilical vein endothelial cells (HUVECs). PLZF activation increased the expression of phosphatidylinositol-3 kinases (PI3K), which are important kinases in the autophagic signaling pathway. FIR - induced PLZF activation led to autophagy in HUVEC, which was mediated through the upregulation of PI3K. Immunofluorescence staining showed that AGEs were engulfed by HUVECs and localized to lysosomes. FIR - induced autophagy promoted AGEs degradation in HUVECs. In nicotinamide / streptozotocin - induced diabetic mice, FIR therapy reduced serum AGEs and AGEs deposition at the vascular endothelium. FIR therapy also reduced diabetes - induced inflammatory markers in the vascular endothelium and improved vascular endothelial function. These protective effects of FIR therapy were not found in PLZF - knockout mice. Our data suggest that FIR - induced PLZF activation in vascular endothelial cells protects the vascular endothelium in diabetic mice from AGE - induced injury.
28071754	0	12	Far-infrared	T070	C1289903
28071754	13	21	protects	T033	C1545588
28071754	22	48	vascular endothelial cells	T025	C1257792
28071754	54	85	advanced glycation end products	T109,T123	C0162574
28071754	88	95	induced	T169	C0205263
28071754	96	102	injury	T037	C0178314
28071754	107	111	PLZF	T116,T123	C1674035
28071754	122	131	autophagy	T043	C0004391
28071754	135	148	diabetic mice	T015	C0085243
28071754	169	200	advanced glycation end products	T109,T123	C0162574
28071754	202	206	AGEs	T109,T123	C0162574
28071754	211	219	diabetic	T047	C0011847
28071754	220	228	patients	T101	C0030705
28071754	229	236	induces	T169	C0205263
28071754	237	257	vascular endothelial	T024	C0014261
28071754	258	264	injury	T037	C0178314
28071754	266	308	Promyelocytic leukemia zinc finger protein	T116,T123	C1674035
28071754	310	314	PLZF	T116,T123	C1674035
28071754	321	341	transcription factor	T116,T123	C0040648
28071754	354	363	activated	T039	C2253861
28071754	367	382	low-temperature	T070	C0009264
28071754	383	395	far-infrared	T070	C1289903
28071754	397	400	FIR	T070	C1289903
28071754	402	413	irradiation	T070	C1282930
28071754	417	441	exert beneficial effects	T038	C3714634
28071754	449	469	vascular endothelium	T024	C0014261
28071754	486	491	study	T062	C2603343
28071754	496	508	investigated	T169	C1292732
28071754	513	522	influence	T077	C4054723
28071754	526	529	FIR	T070	C1289903
28071754	532	539	induced	T169	C0205263
28071754	540	544	PLZF	T116,T123	C1674035
28071754	545	555	activation	T039	C2253861
28071754	559	562	AGE	T109,T123	C0162574
28071754	565	572	induced	T169	C0205263
28071754	573	584	endothelial	T024	C0014261
28071754	585	591	injury	T037	C0178314
28071754	592	596	both	T080	C1706086
28071754	597	605	in vitro	T062	C0681828
28071754	610	617	in vivo	T062	C0681829
28071754	619	622	FIR	T070	C1289903
28071754	623	634	irradiation	T070	C1282930
28071754	635	644	inhibited	T080	C0311403
28071754	645	648	AGE	T109,T123	C0162574
28071754	651	658	induced	T169	C0205263
28071754	659	668	apoptosis	T043	C0162638
28071754	672	710	human umbilical vein endothelial cells	T025	C3179121
28071754	712	718	HUVECs	T025	C3179121
28071754	721	725	PLZF	T116,T123	C1674035
28071754	726	736	activation	T039	C2253861
28071754	737	746	increased	T081	C0205217
28071754	751	761	expression	T045	C1171362
28071754	765	795	phosphatidylinositol-3 kinases	T116,T126	C2936824
28071754	797	801	PI3K	T116,T126	C2936824
28071754	814	823	important	T080	C3898777
28071754	824	831	kinases	T116,T126	C0031727
28071754	839	849	autophagic	T043	C0004391
28071754	850	867	signaling pathway	T044	C0037080
28071754	869	872	FIR	T070	C1289903
28071754	875	882	induced	T169	C0205263
28071754	883	887	PLZF	T116,T123	C1674035
28071754	888	898	activation	T039	C2253861
28071754	906	915	autophagy	T043	C0004391
28071754	919	924	HUVEC	T025	C3179121
28071754	945	952	through	T169	C0332273
28071754	957	969	upregulation	T044	C0041904
28071754	973	977	PI3K	T116,T126	C2936824
28071754	979	997	Immunofluorescence	T059	C0016318
28071754	998	1006	staining	T059	C0487602
28071754	1019	1023	AGEs	T109,T123	C0162574
28071754	1041	1047	HUVECs	T025	C3179121
28071754	1052	1061	localized	T082	C0392752
28071754	1065	1074	lysosomes	T026	C0024369
28071754	1076	1079	FIR	T070	C1289903
28071754	1082	1089	induced	T169	C0205263
28071754	1090	1099	autophagy	T043	C0004391
28071754	1100	1108	promoted	T052	C0033414
28071754	1109	1113	AGEs	T109,T123	C0162574
28071754	1114	1125	degradation	T169	C0243125
28071754	1129	1135	HUVECs	T025	C3179121
28071754	1140	1152	nicotinamide	T109,T121,T127	C0028027
28071754	1155	1169	streptozotocin	T109,T195	C0038432
28071754	1172	1179	induced	T169	C0205263
28071754	1180	1193	diabetic mice	T015	C0085243
28071754	1195	1198	FIR	T070	C1289903
28071754	1199	1206	therapy	T061	C0087111
28071754	1207	1214	reduced	T080	C0392756
28071754	1215	1225	serum AGEs	T116	C0217068
28071754	1230	1234	AGEs	T109,T123	C0162574
28071754	1235	1245	deposition	T169	C0333562
28071754	1253	1273	vascular endothelium	T024	C0014261
28071754	1275	1278	FIR	T070	C1289903
28071754	1279	1286	therapy	T061	C0087111
28071754	1292	1299	reduced	T080	C0392756
28071754	1300	1308	diabetes	T047	C0011847
28071754	1311	1318	induced	T169	C0205263
28071754	1319	1339	inflammatory markers	T033	C4087233
28071754	1347	1367	vascular endothelium	T024	C0014261
28071754	1372	1380	improved	T033	C0184511
28071754	1381	1401	vascular endothelial	T024	C0014261
28071754	1402	1410	function	T042	C1254358
28071754	1418	1436	protective effects	T039	C3179279
28071754	1440	1443	FIR	T070	C1289903
28071754	1444	1451	therapy	T061	C0087111
28071754	1457	1466	not found	T033	C0442737
28071754	1470	1474	PLZF	T116,T123	C1674035
28071754	1477	1490	knockout mice	T015	C0206745
28071754	1496	1500	data	T078	C1511726
28071754	1501	1508	suggest	T078	C1705535
28071754	1514	1517	FIR	T070	C1289903
28071754	1520	1527	induced	T169	C0205263
28071754	1528	1532	PLZF	T116,T123	C1674035
28071754	1533	1543	activation	T039	C2253861
28071754	1547	1573	vascular endothelial cells	T025	C1257792
28071754	1587	1607	vascular endothelium	T024	C0014261
28071754	1611	1624	diabetic mice	T015	C0085243
28071754	1630	1633	AGE	T109,T123	C0162574
28071754	1636	1643	induced	T169	C0205263
28071754	1644	1650	injury	T037	C0178314

28549352|t|Eye abduction reduces but does not eliminate competition in the oculomotor system
28549352|a|Although it is well established that there is a tight coupling between covert attention and the eye movement system there is an ongoing controversy whether this relationship is functional. Previous studies demonstrated that disrupting the ability to execute an eye movement interferes with the allocation of covert attention. One technique that prevents the execution of an eye movement involves the abduction of the eye in the orbit while presenting the stimuli outside of the effective oculomotor range (Craighero, Nascimben, & Fadiga, 2004). Although eye abduction is supposed to disrupt activation of the oculomotor program responsible for the shift of covert attention, this crucial assumption has never been tested experimentally. In the present study we used saccadic curvature to examine whether eye abduction eliminates the target-distractor competition in the oculomotor system. We experimentally reduced the ability to execute saccades by abducting the eye by 30° (monocular vision). This way the peripheral part of the temporal hemifield was located outside the oculomotor range. Participants made a vertical eye movement while on some trials a distractor was shown either inside or outside of the oculomotor range. The curvature away from distractors located outside the oculomotor range was reduced, but not completely eliminated. This confirms that eye abduction influences the activation of the oculomotor program, but points to the fact that other forms of motor planning, such as head movements are also represented in the oculomotor system. The results are in line with the idea that covert attention is an emerging property of movement planning, but is not restricted to saccade planning.
28549352	0	3	Eye	T023	C0015392
28549352	4	13	abduction	T039	C0231456
28549352	14	21	reduces	T080	C0392756
28549352	45	56	competition	T054	C0679932
28549352	64	81	oculomotor system	T022	C1298729
28549352	153	169	covert attention	T041	C0004268
28549352	178	190	eye movement	T039	C0015413
28549352	191	197	system	T169	C0449913
28549352	243	255	relationship	T080	C0439849
28549352	259	269	functional	T169	C0205245
28549352	280	287	studies	T062	C2603343
28549352	306	316	disrupting	T169	C0332453
28549352	321	328	ability	T032	C0085732
28549352	332	339	execute	T052	C1705848
28549352	343	355	eye movement	T039	C0015413
28549352	356	371	interferes with	T169	C0521102
28549352	376	386	allocation	T052	C1706778
28549352	390	406	covert attention	T041	C0004268
28549352	412	421	technique	T169	C0449851
28549352	427	435	prevents	T169	C1292733
28549352	440	449	execution	T052	C1705848
28549352	456	468	eye movement	T039	C0015413
28549352	482	491	abduction	T039	C0231456
28549352	499	502	eye	T023	C0015392
28549352	510	515	orbit	T030	C0029180
28549352	537	544	stimuli	T078	C0010439
28549352	545	552	outside	T082	C0205101
28549352	560	569	effective	T080	C1704419
28549352	570	580	oculomotor	T042	C0872237
28549352	581	586	range	T081	C1514721
28549352	636	639	eye	T023	C0015392
28549352	640	649	abduction	T039	C0231456
28549352	665	672	disrupt	T169	C0332453
28549352	673	683	activation	T052	C1879547
28549352	691	701	oculomotor	T042	C0872237
28549352	730	735	shift	T169	C0333051
28549352	739	755	covert attention	T041	C0004268
28549352	796	802	tested	T169	C0039593
28549352	803	817	experimentally	T077	C1254372
28549352	834	839	study	T062	C2603343
28549352	848	856	saccadic	T042	C0036019
28549352	857	866	curvature	T082	C1254362
28549352	870	877	examine	T033	C0332128
28549352	886	889	eye	T023	C0015392
28549352	890	899	abduction	T039	C0231456
28549352	915	944	target-distractor competition	T054	C0679932
28549352	952	969	oculomotor system	T022	C1298729
28549352	974	988	experimentally	T077	C1254372
28549352	989	996	reduced	T080	C0392756
28549352	1001	1008	ability	T032	C0085732
28549352	1012	1019	execute	T052	C1705848
28549352	1020	1028	saccades	T042	C0036019
28549352	1032	1041	abducting	T039	C0231456
28549352	1046	1049	eye	T023	C0015392
28549352	1058	1074	monocular vision	T042	C0042797
28549352	1090	1105	peripheral part	T082	C0205100
28549352	1113	1131	temporal hemifield	T082	C1254362
28549352	1144	1151	outside	T082	C0205101
28549352	1156	1166	oculomotor	T042	C0872237
28549352	1167	1172	range	T081	C1514721
28549352	1174	1186	Participants	T098	C0679646
28549352	1194	1202	vertical	T082	C0205128
28549352	1203	1215	eye movement	T039	C0015413
28549352	1267	1273	inside	T082	C0205102
28549352	1277	1284	outside	T082	C0205101
28549352	1292	1302	oculomotor	T042	C0872237
28549352	1303	1308	range	T081	C1514721
28549352	1314	1323	curvature	T082	C1254362
28549352	1354	1361	outside	T082	C0205101
28549352	1366	1376	oculomotor	T042	C0872237
28549352	1377	1382	range	T081	C1514721
28549352	1387	1394	reduced	T080	C0392756
28549352	1446	1449	eye	T023	C0015392
28549352	1450	1459	abduction	T039	C0231456
28549352	1460	1470	influences	T077	C4054723
28549352	1475	1485	activation	T052	C1879547
28549352	1493	1503	oculomotor	T042	C0872237
28549352	1556	1561	motor	T169	C1513492
28549352	1562	1570	planning	T041	C0032074
28549352	1580	1594	head movements	T040	C0376591
28549352	1623	1640	oculomotor system	T022	C1298729
28549352	1646	1653	results	T169	C1274040
28549352	1685	1701	covert attention	T041	C0004268
28549352	1717	1725	property	T080	C0871161
28549352	1729	1737	movement	T040	C0026649
28549352	1738	1746	planning	T041	C0032074
28549352	1773	1780	saccade	T042	C0036019

28009593|t|A Rasch Rating Scale Analysis of the Presence of Nursing Scale - RN
28009593|a|The phenomenon of nursing presence encompasses the emotional connection between nurse and patient, and technical skills performed by the nurse. The Presence of Nursing Scale - RN version (PONS - RN) was developed to measure nurses' perceptions of their ability to be present to their patients. This study summarizes the process of re-evaluation of the psychometric properties of the PONS - RN instrument. A sample of 76 registered nurses providing direct patient care responded to the 31- item questionnaire. The Rasch rating scale model was used for assessing construct validity of PONS - RN data. A principal component analysis (PCA) of residuals supported appropriateness of the subscales defined by a 2-dimensional structure. The results of item and person fit analysis, rating scale functioning analysis and reliability analysis have demonstrated that the thirty-one item Presence of Nursing Scale - RN instrument yielded measures with high validity and reliability as two sub-scales. Jou rn
28009593	2	20	Rasch Rating Scale	T062,T170	C0871207
28009593	21	29	Analysis	T062	C0936012
28009593	37	45	Presence	T033	C0150312
28009593	49	56	Nursing	T091	C0028677
28009593	57	62	Scale	T081,T170	C0681889
28009593	65	67	RN	T097	C0687673
28009593	72	82	phenomenon	T067	C1882365
28009593	86	93	nursing	T091	C0028677
28009593	94	102	presence	T033	C0150312
28009593	119	128	emotional	T033	C0849912
28009593	129	139	connection	T082	C0449379
28009593	148	153	nurse	T097	C0028661
28009593	158	165	patient	T101	C0030705
28009593	171	187	technical skills	T169	C0449851
28009593	188	197	performed	T169	C0884358
28009593	205	210	nurse	T097	C0028661
28009593	216	224	Presence	T033	C0150312
28009593	228	235	Nursing	T091	C0028677
28009593	236	241	Scale	T081,T170	C0681889
28009593	244	246	RN	T097	C0687673
28009593	247	254	version	T170	C0333052
28009593	256	260	PONS	T081,T170	C0681889
28009593	263	265	RN	T097	C0687673
28009593	271	280	developed	T169	C1527148
28009593	284	291	measure	T081	C0079809
28009593	292	299	nurses'	T097	C0028661
28009593	300	311	perceptions	T041	C0030971
28009593	321	328	ability	T032	C0085732
28009593	335	342	present	T033	C0150312
28009593	352	360	patients	T101	C0030705
28009593	367	372	study	T062	C2603343
28009593	373	383	summarizes	T170	C1706244
28009593	388	395	process	T067	C1522240
28009593	399	412	re-evaluation	T062	C0681840
28009593	420	443	psychometric properties	T060	C0033920
28009593	451	455	PONS	T081,T170	C0681889
28009593	458	460	RN	T097	C0687673
28009593	475	481	sample	T098	C1257890
28009593	488	505	registered nurses	T097	C0687673
28009593	506	515	providing	T052	C1999230
28009593	516	522	direct	T080	C1947931
28009593	523	535	patient care	T058	C0017313
28009593	536	545	responded	T041	C2911692
28009593	557	561	item	T071	C1551338
28009593	562	575	questionnaire	T170	C0034394
28009593	581	605	Rasch rating scale model	T062,T170	C0871207
28009593	619	628	assessing	T058	C0184514
28009593	629	647	construct validity	T080	C0681897
28009593	651	655	PONS	T081,T170	C0681889
28009593	658	660	RN	T097	C0687673
28009593	661	665	data	T078	C1511726
28009593	669	697	principal component analysis	T081	C0429865
28009593	699	702	PCA	T081	C0429865
28009593	707	716	residuals	T080	C1609982
28009593	717	726	supported	T077	C1521721
28009593	727	742	appropriateness	T080	C0814634
28009593	750	759	subscales	T081	C0459443
28009593	773	786	2-dimensional	T082	C1705052
28009593	787	796	structure	T082	C0678594
28009593	802	809	results	T033	C0683954
28009593	813	817	item	T071	C1551338
28009593	822	828	person	T098	C0027361
28009593	829	832	fit	T052	C2349186
28009593	833	841	analysis	T062	C0936012
28009593	843	855	rating scale	T081,T170	C0681889
28009593	856	867	functioning	T169	C0205245
28009593	868	876	analysis	T062	C0936012
28009593	881	901	reliability analysis	UnknownType	C0814892
28009593	907	919	demonstrated	T080	C0443289
28009593	940	944	item	T071	C1551338
28009593	945	953	Presence	T033	C0150312
28009593	957	964	Nursing	T091	C0028677
28009593	965	970	Scale	T081,T170	C0681889
28009593	973	975	RN	T097	C0687673
28009593	995	1003	measures	T081	C0079809
28009593	1009	1013	high	T080	C0205250
28009593	1014	1038	validity and reliability	UnknownType	C0814892
28009593	1046	1056	sub-scales	T081	C0459443
28009593	1062	1064	rn	T097	C0687673

28253085|t|Water pipe (Shisha, Hookah, Arghile) Smoking and Secondhand Tobacco Smoke Effects on CYP1A2 and CYP2A6 Phenotypes as Measured by Caffeine Urine Test
28253085|a|Public policies to stop or reduce cigarette smoking and exposure to secondhand smoke and associated diseases have yielded successful results over the past decade. Yet, the growing worldwide popularity of another form of tobacco consumption, water pipe smoking, has received relatively less attention. To the best of our knowledge, no study to date has evaluated the effects of water pipe smoking on cytochrome P450 (CYP450) activities and drug interaction potential in humans, whereas only limited information is available on the impact of secondhand smoke on drug metabolism. In a sample of 99 healthy volunteers (28 water pipe smokers, 30 secondhand tobacco smoke exposed persons, and 41 controls), we systematically compared CYP1A2 and CYP2A6 enzyme activities in vivo using caffeine urine test. The median self-reported duration of water pipe smoking was 7.5 h / week and 3 years of exposure in total. The secondhand smoke group had a median of 14 h of self-reported weekly exposure to tobacco smoke indoor where a minimum of five cigarettes were smoked / hour for a total of 3.5 years (median). Analysis of variance did not find a significant difference in CYP1A2 and CYP2A6 activities among the three study groups (p > 0.05). Nor was there a significant association between the extent of water pipe or secondhand smoke exposure and the CYP1A2 and CYP2A6 activities (p > 0.05). Further analysis in a subsample with smoke exposure more than the median values also did not reveal a significant difference from the controls. Although we do not rule out an appreciable possible impact of water pipe smoke and secondhand smoke on in vivo activities of these two drug metabolism pathways, variability in smoke constituents from different tobacco consumption methods (e.g., water pipe) might affect drug metabolism in ways that might differ from that of cigarette smoke. Further studies in larger prospective samples are recommended to evaluate water pipe and secondhand tobacco smoke effects on CYP450 function, particularly at higher smoke exposure conditions.
28253085	0	10	Water pipe	T073	C4302493
28253085	37	44	Smoking	T055	C0037369
28253085	49	73	Secondhand Tobacco Smoke	T037	C0375734
28253085	74	81	Effects	T080	C1280500
28253085	85	91	CYP1A2	T116,T126	C1620185
28253085	96	102	CYP2A6	T116,T126	C3884187
28253085	103	113	Phenotypes	T032	C0031437
28253085	129	148	Caffeine Urine Test	T059	C0042014
28253085	149	164	Public policies	T097	C0085098
28253085	183	200	cigarette smoking	T055	C0700219
28253085	205	213	exposure	T080	C0332157
28253085	217	233	secondhand smoke	T037	C0375734
28253085	238	257	associated diseases	T046	C0243083
28253085	369	388	tobacco consumption	T055	C0543414
28253085	390	400	water pipe	T073	C4302493
28253085	401	408	smoking	T055	C0037369
28253085	526	536	water pipe	T073	C4302493
28253085	537	544	smoking	T055	C0037369
28253085	548	583	cytochrome P450 (CYP450) activities	T044	C1149063
28253085	588	604	drug interaction	T044	C0687133
28253085	605	614	potential	T080	C3245505
28253085	618	624	humans	T016	C0086418
28253085	689	705	secondhand smoke	T037	C0375734
28253085	709	724	drug metabolism	T044	C0683140
28253085	744	762	healthy volunteers	T098	C1708335
28253085	767	785	water pipe smokers	T055	C3697029
28253085	790	814	secondhand tobacco smoke	T037	C0375734
28253085	823	830	persons	T098	C0027361
28253085	839	847	controls	T096	C0009932
28253085	853	876	systematically compared	T052	C1707455
28253085	877	883	CYP1A2	T116,T126	C1620185
28253085	888	894	CYP2A6	T116,T126	C3884187
28253085	895	912	enzyme activities	T044	C0243102
28253085	913	920	in vivo	T082	C1515655
28253085	927	946	caffeine urine test	T059	C0042014
28253085	959	972	self-reported	T062	C2700446
28253085	973	981	duration	T079	C0449238
28253085	985	995	water pipe	T073	C4302493
28253085	996	1003	smoking	T055	C0037369
28253085	1012	1013	h	T079	C0439227
28253085	1016	1020	week	T079	C0439230
28253085	1027	1032	years	T079	C0439234
28253085	1036	1044	exposure	T080	C0332157
28253085	1059	1075	secondhand smoke	T037	C0375734
28253085	1076	1081	group	T098	C1257890
28253085	1101	1102	h	T079	C0439227
28253085	1106	1119	self-reported	T062	C2700446
28253085	1120	1126	weekly	T079	C0332174
28253085	1127	1135	exposure	T080	C0332157
28253085	1139	1152	tobacco smoke	T131	C0439994
28253085	1184	1194	cigarettes	T073	C0677453
28253085	1200	1206	smoked	T131	C0239059
28253085	1209	1213	hour	T079	C0439227
28253085	1233	1238	years	T079	C0439234
28253085	1249	1257	Analysis	T062	C0936012
28253085	1261	1269	variance	T080	C1711260
28253085	1311	1317	CYP1A2	T116,T126	C1620185
28253085	1322	1328	CYP2A6	T116,T126	C3884187
28253085	1329	1339	activities	T044	C0243102
28253085	1356	1361	study	T062	C2603343
28253085	1362	1368	groups	T098	C1257890
28253085	1443	1453	water pipe	T073	C4302493
28253085	1457	1473	secondhand smoke	T037	C0375734
28253085	1474	1482	exposure	T080	C0332157
28253085	1491	1497	CYP1A2	T116,T126	C1620185
28253085	1502	1508	CYP2A6	T116,T126	C3884187
28253085	1509	1519	activities	T044	C0243102
28253085	1540	1548	analysis	T062	C0936012
28253085	1575	1583	exposure	T080	C0332157
28253085	1666	1674	controls	T096	C0009932
28253085	1738	1748	water pipe	T073	C4302493
28253085	1759	1775	secondhand smoke	T037	C0375734
28253085	1779	1786	in vivo	T082	C1515655
28253085	1787	1797	activities	T044	C0243102
28253085	1811	1826	drug metabolism	T044	C0683140
28253085	1827	1835	pathways	T044	C1704259
28253085	1858	1870	constituents	T167	C0729650
28253085	1886	1905	tobacco consumption	T055	C0543414
28253085	1921	1931	water pipe	T073	C4302493
28253085	1946	1961	drug metabolism	T044	C0683140
28253085	2001	2016	cigarette smoke	T131	C0239059
28253085	2026	2033	studies	T062	C2603343
28253085	2092	2102	water pipe	T073	C4302493
28253085	2107	2131	secondhand tobacco smoke	T037	C0375734
28253085	2143	2149	CYP450	T116,T126	C0010762
28253085	2183	2188	smoke	T131	C0439994
28253085	2189	2197	exposure	T080	C0332157

28542952|t|Compensatory and decompensatory alterations in cardiomyocyte Ca(2+) dynamics in hearts with diastolic dysfunction following aortic banding
28542952|a|At the cellular level cardiac hypertrophy causes remodelling, leading to changes in ionic channel, pump and exchanger densities and kinetics. Previous studies have focused on quantifying changes in channels, pump s and exchangers without quantitatively linking these changes with emergent cellular scale functionality. Two biophysical cardiac cell models were created, parameterized and validated and are able to simulate electrophysiology and calcium dynamics in myocytes from control sham operated rats and aortic - banded rats exhibiting diastolic dysfunction. The contribution of each ionic pathway to the calcium kinetics was calculated, identifying the L-type Ca(2+) channel and sarco/endoplasmic reticulum Ca(2+) ATPase as the principal regulators of systolic and diastolic Ca(2+), respectively. Results show that the ability to dynamically change systolic Ca(2+), through changes in expression of key Ca(2+) modelling protein densities, is drastically reduced following the aortic banding procedure; however the cells are able to compensate Ca(2+) homeostasis in an efficient way to minimize systolic dysfunction. Elevated left ventricular afterload leads to myocardial hypertrophy, diastolic dysfunction, cellular remodelling and compromised calcium dynamics. At the cellular scale this remodelling of the ionic channels, pumps and exchangers gives rise to changes in the Ca(2+) transient. However, the relative roles of the underlying subcellular processes and the positive or negative impact of each remodelling mechanism are not fully understood. Biophysical cardiac cell models were created to simulate electrophysiology and calcium dynamics in myocytes from control rats (SHAM) and aortic - banded rats exhibiting diastolic dysfunction. The model parameters and framework were validated and the fitted parameters demonstrated to be unique for explaining our experimental data. The contribution of each ionic pathway to the calcium kinetics was calculated, identifying the L-type Ca(2+) channel (LCC) and the sarco/endoplasmic reticulum Ca(2+) -ATPase (SERCA) as the principal regulators of systolic and diastolic Ca(2+), respectively. In the aortic banding model, the sensitivity of systolic Ca(2+) to LCC density and diastolic Ca(2+) to SERCA density decreased by 16-fold and increased by 23%, respectively, relative to the SHAM model. The energy cost of ionic homeostasis is maintained across the two models. The models predict that changes in ionic pathway densities in compensated aortic banding rats maintain Ca(2+) function and efficiency. The ability to dynamically alter systolic function is significantly diminished, while the capacity to maintain diastolic Ca(2+) is moderately increased.
28542952	0	12	Compensatory	T169	C0231186
28542952	17	31	decompensatory	T033	C0231187
28542952	32	43	alterations	T078	C1515926
28542952	47	60	cardiomyocyte	T025	C0225828
28542952	61	67	Ca(2+)	T121,T196	C0596235
28542952	68	76	dynamics	T070	C3826426
28542952	80	86	hearts	T023	C0018787
28542952	92	113	diastolic dysfunction	T046	C0520863
28542952	124	130	aortic	T023	C0003483
28542952	131	138	banding	T061	C0185014
28542952	146	160	cellular level	T043	C1155939
28542952	161	180	cardiac hypertrophy	T046	C1383860
28542952	188	199	remodelling	UnknownType	C0678692
28542952	212	219	changes	T169	C0392747
28542952	223	236	ionic channel	T116,T123	C0022009
28542952	238	242	pump	T116,T123	C0085193
28542952	247	256	exchanger	T116,T123	C0598847
28542952	257	266	densities	T081	C0178587
28542952	271	279	kinetics	T070	C0022702
28542952	290	297	studies	T062	C2603343
28542952	314	325	quantifying	T081	C1709793
28542952	326	333	changes	T169	C0392747
28542952	337	345	channels	T116,T123	C0022009
28542952	347	351	pump	T116,T123	C0085193
28542952	358	368	exchangers	T116,T123	C0598847
28542952	377	391	quantitatively	T081	C0392762
28542952	406	413	changes	T169	C0392747
28542952	419	427	emergent	T078	C0750573
28542952	428	456	cellular scale functionality	T043	C0007613
28542952	462	473	biophysical	T070	C2350452
28542952	474	486	cardiac cell	T025	C0920751
28542952	487	493	models	T170	C0026344
28542952	508	521	parameterized	T077	C0549193
28542952	526	535	validated	T062	C1519941
28542952	552	560	simulate	T062	C0679083
28542952	561	578	electrophysiology	T091	C0013865
28542952	583	590	calcium	T121,T123,T196	C0006675
28542952	591	599	dynamics	T070	C3826426
28542952	603	611	myocytes	T025	C0596981
28542952	617	643	control sham operated rats	T015	C0086893
28542952	648	654	aortic	T023	C0003483
28542952	657	663	banded	T061	C0185014
28542952	664	668	rats	T015	C0034721
28542952	680	701	diastolic dysfunction	T046	C0520863
28542952	707	719	contribution	T052	C1880177
28542952	728	741	ionic pathway	T044	C0037080
28542952	749	756	calcium	T121,T123,T196	C0006675
28542952	757	765	kinetics	T070	C0022702
28542952	770	780	calculated	T169	C0444686
28542952	782	793	identifying	T033	C0489557
28542952	798	819	L-type Ca(2+) channel	T116,T123	C0288263
28542952	824	865	sarco/endoplasmic reticulum Ca(2+) ATPase	T116,T126	C0916181
28542952	873	882	principal	T080	C0205225
28542952	883	893	regulators	T077	C1704735
28542952	897	905	systolic	T079	C0039155
28542952	910	919	diastolic	T201	C0012000
28542952	920	926	Ca(2+)	T121,T196	C0596235
28542952	942	949	Results	T033	C0683954
28542952	975	986	dynamically	T169	C0729333
28542952	987	993	change	T169	C0392747
28542952	994	1002	systolic	T079	C0039155
28542952	1003	1009	Ca(2+)	T121,T196	C0596235
28542952	1019	1026	changes	T169	C0392747
28542952	1030	1040	expression	T045	C1171362
28542952	1044	1047	key	T077	C1706198
28542952	1048	1054	Ca(2+)	T121,T196	C0596235
28542952	1055	1064	modelling	T062,T170	C0600115
28542952	1065	1072	protein	T116,T123	C0033684
28542952	1073	1082	densities	T081	C0178587
28542952	1099	1106	reduced	T080	C0392756
28542952	1121	1127	aortic	T023	C0003483
28542952	1128	1145	banding procedure	T061	C0185014
28542952	1159	1164	cells	T025	C0920751
28542952	1177	1187	compensate	T080	C0205432
28542952	1188	1194	Ca(2+)	T121,T196	C0596235
28542952	1195	1206	homeostasis	T039	C1326962
28542952	1213	1222	efficient	T080	C0442799
28542952	1239	1259	systolic dysfunction	T046	C0749225
28542952	1261	1296	Elevated left ventricular afterload	T033	C0919821
28542952	1306	1328	myocardial hypertrophy	T046	C3495916
28542952	1330	1351	diastolic dysfunction	T046	C0520863
28542952	1353	1361	cellular	T025	C0007634
28542952	1362	1373	remodelling	UnknownType	C0678692
28542952	1378	1389	compromised	T033	C2945640
28542952	1390	1397	calcium	T121,T123,T196	C0006675
28542952	1398	1406	dynamics	T070	C3826426
28542952	1415	1423	cellular	T025	C0007634
28542952	1424	1429	scale	T077	C1522412
28542952	1435	1446	remodelling	UnknownType	C0678692
28542952	1454	1468	ionic channels	T116,T123	C0022009
28542952	1470	1475	pumps	T116,T123	C0085193
28542952	1480	1490	exchangers	T116,T123	C0598847
28542952	1505	1512	changes	T169	C0392747
28542952	1520	1526	Ca(2+)	T121,T196	C0596235
28542952	1527	1536	transient	T079	C0205374
28542952	1584	1605	subcellular processes	T043	C0007613
28542952	1614	1622	positive	T033	C1446409
28542952	1626	1634	negative	T033	C0205160
28542952	1635	1641	impact	T080	C4049986
28542952	1650	1661	remodelling	UnknownType	C0678692
28542952	1662	1671	mechanism	T169	C0441712
28542952	1698	1709	Biophysical	T070	C2350452
28542952	1710	1722	cardiac cell	T025	C0920751
28542952	1723	1729	models	T075	C0026339
28542952	1746	1754	simulate	T062	C0679083
28542952	1755	1772	electrophysiology	T091	C0013865
28542952	1777	1784	calcium	T121,T123,T196	C0006675
28542952	1785	1793	dynamics	T070	C3826426
28542952	1797	1805	myocytes	T025	C0596981
28542952	1811	1830	control rats (SHAM)	T015	C0086893
28542952	1835	1841	aortic	T023	C0003483
28542952	1844	1850	banded	T061	C0185014
28542952	1851	1855	rats	T015	C0086893
28542952	1867	1888	diastolic dysfunction	T046	C0520863
28542952	1894	1899	model	T170	C0026344
28542952	1900	1910	parameters	T077	C0549193
28542952	1915	1924	framework	T080	C0205556
28542952	1930	1939	validated	T062	C1519941
28542952	1955	1965	parameters	T077	C0549193
28542952	1985	1991	unique	T080	C1710548
28542952	2011	2028	experimental data	T078	C1511726
28542952	2034	2046	contribution	T052	C1880177
28542952	2055	2068	ionic pathway	T044	C0037080
28542952	2076	2083	calcium	T121,T123,T196	C0006675
28542952	2084	2092	kinetics	T070	C0022702
28542952	2097	2107	calculated	T169	C0444686
28542952	2109	2120	identifying	T033	C0489557
28542952	2125	2146	L-type Ca(2+) channel	T116,T123	C0288263
28542952	2148	2151	LCC	T116,T123	C0288263
28542952	2161	2203	sarco/endoplasmic reticulum Ca(2+) -ATPase	T116,T126	C0916181
28542952	2205	2210	SERCA	T116,T126	C0916181
28542952	2219	2228	principal	T080	C0205225
28542952	2229	2239	regulators	T077	C1704735
28542952	2243	2251	systolic	T079	C0039155
28542952	2256	2265	diastolic	T201	C0012000
28542952	2266	2272	Ca(2+)	T121,T196	C0596235
28542952	2295	2301	aortic	T023	C0003483
28542952	2302	2309	banding	T061	C0185014
28542952	2310	2315	model	T170	C0026344
28542952	2321	2332	sensitivity	T080	C1522640
28542952	2336	2344	systolic	T079	C0039155
28542952	2345	2351	Ca(2+)	T121,T196	C0596235
28542952	2355	2358	LCC	T116,T123	C0288263
28542952	2359	2366	density	T081	C0178587
28542952	2371	2380	diastolic	T201	C0012000
28542952	2381	2387	Ca(2+)	T121,T196	C0596235
28542952	2391	2396	SERCA	T116,T126	C0916181
28542952	2397	2404	density	T081	C0178587
28542952	2405	2414	decreased	T081	C0205216
28542952	2430	2439	increased	T081	C0205217
28542952	2478	2488	SHAM model	T015	C0086893
28542952	2494	2505	energy cost	T081	C1442080
28542952	2509	2526	ionic homeostasis	T039	C1326962
28542952	2530	2540	maintained	T052	C0024501
28542952	2556	2562	models	T170	C0026344
28542952	2568	2574	models	T170	C0026344
28542952	2588	2595	changes	T169	C0392747
28542952	2599	2612	ionic pathway	T044	C0037080
28542952	2613	2622	densities	T081	C0178587
28542952	2626	2637	compensated	T080	C0205432
28542952	2638	2644	aortic	T023	C0003483
28542952	2645	2652	banding	T061	C0185014
28542952	2653	2657	rats	T015	C0034721
28542952	2658	2666	maintain	T052	C0024501
28542952	2667	2673	Ca(2+)	T121,T196	C0596235
28542952	2674	2682	function	T039	C0031843
28542952	2687	2697	efficiency	T081	C0013682
28542952	2703	2710	ability	T032	C0085732
28542952	2714	2725	dynamically	T169	C0729333
28542952	2732	2749	systolic function	T042	C0442710
28542952	2753	2766	significantly	T078	C0750502
28542952	2767	2777	diminished	T081	C0205216
28542952	2789	2797	capacity	T081	C1516240
28542952	2801	2809	maintain	T052	C0024501
28542952	2810	2819	diastolic	T201	C0012000
28542952	2820	2826	Ca(2+)	T121,T196	C0596235
28542952	2830	2840	moderately	T080	C0205081
28542952	2841	2850	increased	T081	C0205217

28261242|t|Identification and Functional Characterization of a Tonoplast Dicarboxylate Transporter in Tomato (Solanum lycopersicum)
28261242|a|Acidity plays an important role in flavor and overall organoleptic quality of fruit and is mainly due to the presence of organic acids. Understanding the molecular basis of organic acid metabolism is thus of primary importance for fruit quality improvement. Here, we cloned a putative tonoplast dicarboxylate transporter gene (SlTDT) from tomato, and submitted it to the NCBI database (GenBank accession number: KC733165). SlTDT protein contained 13 putative transmembrane domains in silico analysis. Confocal microscopic study using green fluorescent fusion proteins revealed that SlTDT was localized on tonoplast. The expression patterns of SlTDT in tomato were analyzed by RT-qPCR. The results indicated that SlTDT expressed in leaves, roots, flowers and fruits at different ripening stages, suggesting SlTDT may be associated with the development of different tissues. To further explore the function of SlTDT, we constructed both overexpression and RNAi vectors and obtained transgenic tomato plants by agrobacterium -mediated method. Gas chromatography-mass spectrometer (GC-MS) analysis showed that overexpression of SlTDT significantly increased malate content, and reduced citrate content in tomato fruit. By contrast, repression of SlTDT in tomato reduced malate content of and increased citrate content. These results indicated that SlTDT played an important role in remobilization of malate and citrate in fruit vacuoles.
28261242	0	14	Identification	T080	C0205396
28261242	19	29	Functional	T169	C0205245
28261242	30	46	Characterization	T052	C1880022
28261242	52	61	Tonoplast	T026	C1167046
28261242	62	87	Dicarboxylate Transporter	T116,T123	C0057823
28261242	91	97	Tomato	T002	C1140676
28261242	99	119	Solanum lycopersicum	T002	C1140676
28261242	121	128	Acidity	T081	C0020283
28261242	138	147	important	T080	C3898777
28261242	156	162	flavor	T080	C0596585
28261242	175	187	organoleptic	T080	C0205556
28261242	188	195	quality	T080	C0332306
28261242	199	204	fruit	T168	C0016767
28261242	230	238	presence	T033	C0150312
28261242	242	255	organic acids	T109	C0369760
28261242	275	290	molecular basis	T078	C1853126
28261242	294	317	organic acid metabolism	T044	C1158838
28261242	337	347	importance	T080	C3898777
28261242	352	357	fruit	T168	C0016767
28261242	358	365	quality	T080	C0332306
28261242	366	377	improvement	T077	C2986411
28261242	388	394	cloned	T059,T063	C0598888
28261242	397	446	putative tonoplast dicarboxylate transporter gene	T028	C0017337
28261242	448	453	SlTDT	T028	C0017337
28261242	460	466	tomato	T002	C1140676
28261242	472	481	submitted	T169	C1515023
28261242	492	505	NCBI database	T170	C0995203
28261242	507	514	GenBank	T170	C0598211
28261242	515	531	accession number	T170	C1510755
28261242	544	557	SlTDT protein	T116,T123	C0057823
28261242	571	601	putative transmembrane domains	T087	C1519623
28261242	602	611	in silico	T066	C3489666
28261242	612	620	analysis	T169	C1524024
28261242	622	642	Confocal microscopic	T059	C0242842
28261242	643	648	study	T062	C2603343
28261242	655	688	green fluorescent fusion proteins	T116,T130	C0120285
28261242	689	697	revealed	T080	C0443289
28261242	703	708	SlTDT	T028	C0017337
28261242	713	722	localized	T082	C0392752
28261242	726	735	tonoplast	T026	C1167046
28261242	741	751	expression	T045	C0017262
28261242	752	760	patterns	T082	C0449774
28261242	764	769	SlTDT	T028	C0017337
28261242	773	779	tomato	T002	C1140676
28261242	785	793	analyzed	T062	C0936012
28261242	797	804	RT-qPCR	T063	C4297012
28261242	810	817	results	T169	C1274040
28261242	818	827	indicated	T033	C1444656
28261242	833	838	SlTDT	T028	C0017337
28261242	839	848	expressed	T045	C0017262
28261242	852	858	leaves	T002	C0242724
28261242	860	865	roots	T002	C0242726
28261242	867	874	flowers	T002	C0330090
28261242	879	885	fruits	T168	C0016767
28261242	889	898	different	T080	C1705242
28261242	899	907	ripening	T038	C1160534
28261242	908	914	stages	T079	C1306673
28261242	927	932	SlTDT	T028	C0017337
28261242	940	955	associated with	T080	C0332281
28261242	960	971	development	T169	C1527148
28261242	975	984	different	T080	C1705242
28261242	985	992	tissues	T025	C1514137
28261242	1017	1025	function	T169	C0542341
28261242	1029	1034	SlTDT	T028	C0017337
28261242	1056	1070	overexpression	T045	C0017262
28261242	1075	1079	RNAi	T045	C1136031
28261242	1080	1087	vectors	T114	C0086022
28261242	1092	1100	obtained	T169	C1301820
28261242	1101	1125	transgenic tomato plants	T002	C0085245
28261242	1129	1142	agrobacterium	T007	C0001830
28261242	1153	1159	method	T170	C0025663
28261242	1161	1197	Gas chromatography-mass spectrometer	T059	C0024868
28261242	1199	1214	GC-MS) analysis	T059	C0024868
28261242	1227	1241	overexpression	T045	C0017262
28261242	1245	1250	SlTDT	T028	C0017337
28261242	1265	1274	increased	T081	C0205217
28261242	1275	1281	malate	T109,T123,T130	C0220873
28261242	1282	1289	content	T081	C1264655
28261242	1295	1302	reduced	T080	C0392756
28261242	1303	1310	citrate	T109,T121	C0376259
28261242	1311	1318	content	T081	C1264655
28261242	1322	1328	tomato	T002	C1140676
28261242	1329	1334	fruit	T168	C0016767
28261242	1349	1359	repression	T045	C0178656
28261242	1363	1368	SlTDT	T028	C0017337
28261242	1372	1378	tomato	T002	C1140676
28261242	1379	1386	reduced	T080	C0392756
28261242	1387	1393	malate	T109,T123,T130	C0220873
28261242	1394	1401	content	T081	C1264655
28261242	1409	1418	increased	T081	C0205217
28261242	1419	1426	citrate	T109,T121	C0376259
28261242	1427	1434	content	T081	C1264655
28261242	1442	1449	results	T169	C1274040
28261242	1465	1470	SlTDT	T028	C0017337
28261242	1481	1490	important	T080	C3898777
28261242	1499	1513	remobilization	T169	C0300926
28261242	1517	1523	malate	T109,T123,T130	C0220873
28261242	1528	1535	citrate	T109,T121	C0376259
28261242	1539	1544	fruit	T168	C0016767
28261242	1545	1553	vacuoles	T026	C0042219

27578894|t|The Heater Cooler as a Source of Infection from Nontuberculous Mycobacteria
27578894|a|Nosocomial infections acquired during the course of cardiac surgery and hospitalization can have devastating patient consequences. The source of these infections is often difficult to determine which complicates eradication efforts. Recently it has become apparent that the heater-cooler devices used in conjunction with cardiopulmonary bypass may become contaminated with bacteria that are normally found in hospital water sources. The culprit organisms are nontuberculous mycobacteria which coat the intrinsic surfaces found within the circuits of the heater-coolers. Aerosolization of the bacteria occurs during normal heater-cooler operation which can disperse the organisms throughout the operating room. The bacteria are slow-growing and may not present for months, or years, following exposure which makes epidemiological determination a challenge. The ensuing report summarizes a recent outbreak in these infections that have been reported both in Europe and the United States, along with efforts to reduce the risk for patient infection.
27578894	4	17	Heater Cooler	T074	C0181255
27578894	23	42	Source of Infection	T033	C0449426
27578894	48	75	Nontuberculous Mycobacteria	T007	C1265234
27578894	76	97	Nosocomial infections	T047	C0205721
27578894	107	113	during	T079	C0347984
27578894	118	124	course	T079	C0750729
27578894	128	143	cardiac surgery	T061	C0018821
27578894	148	163	hospitalization	T058	C0019993
27578894	173	184	devastating	T080	C0205556
27578894	185	192	patient	T101	C0030705
27578894	193	205	consequences	T169	C0686907
27578894	211	237	source of these infections	T033	C0449426
27578894	247	256	difficult	T080	C0332218
27578894	276	287	complicates	T169	C0231242
27578894	288	299	eradication	T058	C3178994
27578894	332	340	apparent	T078	C0750489
27578894	350	371	heater-cooler devices	T074	C0181255
27578894	380	391	conjunction	T078	C2699427
27578894	397	419	cardiopulmonary bypass	T061	C0007202
27578894	431	443	contaminated	T169	C0205279
27578894	449	457	bacteria	T007	C0004611
27578894	467	475	normally	T080	C0205307
27578894	485	493	hospital	T080	C1510665
27578894	494	499	water	T121,T197	C0043047
27578894	500	507	sources	T033	C0449416
27578894	521	530	organisms	T001	C0029235
27578894	535	562	nontuberculous mycobacteria	T007	C1265234
27578894	569	573	coat	T080	C1522408
27578894	578	587	intrinsic	T082	C0205102
27578894	588	596	surfaces	T082	C0205148
27578894	614	622	circuits	T073	C1707396
27578894	630	644	heater-coolers	T074	C0181255
27578894	646	660	Aerosolization	T070	C1254365
27578894	668	676	bacteria	T007	C0004611
27578894	684	690	during	T079	C0347984
27578894	691	697	normal	T080	C0205307
27578894	698	711	heater-cooler	T074	C0181255
27578894	712	721	operation	T052	C3241922
27578894	732	740	disperse	T169	C1704711
27578894	745	754	organisms	T001	C0029235
27578894	755	765	throughout	T082	C1254362
27578894	770	784	operating room	T073,T093	C0029064
27578894	790	798	bacteria	T007	C0004611
27578894	803	815	slow-growing	T033	C4086857
27578894	840	846	months	T079	C0439231
27578894	851	856	years	T079	C0439234
27578894	868	876	exposure	T080	C0332157
27578894	889	904	epidemiological	T091	C0014507
27578894	905	918	determination	T059	C1148554
27578894	971	979	outbreak	T067	C0012652
27578894	989	999	infections	T047	C0009450
27578894	1032	1038	Europe	T083	C0015176
27578894	1047	1060	United States	T083	C0041703
27578894	1084	1090	reduce	T080	C0392756
27578894	1095	1099	risk	T078	C0035647
27578894	1104	1111	patient	T101	C0030705
27578894	1112	1121	infection	T047	C0009450

27765603|t|Different microRNA alterations contribute to diverse outcomes following EV71 and CA16 infections: Insights from high-throughput sequencing in rhesus monkey peripheral blood mononuclear cells
27765603|a|Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16) are the predominant pathogens of hand, foot, and mouth disease (HFMD). Although these viruses exhibit genetic homology, the clinical manifestations caused by the two viruses have some discrepancies. In addition, the underlying mechanisms leading to these differences remain unclear. microRNAs (miRNAs) participate in numerous biological or pathological processes, including host responses to viral infections. Here, we focused on differences in miRNA expression patterns in rhesus monkey peripheral blood mononuclear cells (PBMCs) infected with EV71 and CA16 at various time points using high-throughput sequencing. The results demonstrated that 106 known and 13 novel miRNAs exhibited significant differences, and 32 key miRNAs among them for target prediction presented opposite trends in the EV71 - and CA16 - infected samples. GO and pathway analysis of the predicted targets showed enrichment in 14 biological processes, 10 molecular functions, 8 cellular components and 104 pathways. Subsequently, regulatory networks of miRNA - transcription factors, miRNA - predicted targets, miRNA - GOs and miRNA - pathways were constructed to reveal the complex regulatory mechanisms of miRNAs during the infection phase. Ultimately, we analysed hierarchical GO categories of the predicted targets involved in immune system processes, which indicated that the innate and adaptive immunity following EV71 and CA16 infections may be remarkably distinct. In conclusion, this report is the first describing miRNA expression profiles in PBMCs with EV71 and CA16 infections using high-throughput sequencing. Our findings could provide a valuable basis for further studies on the regulatory roles of miRNAs related to the different immune responses caused by EV71 and CA16 infections.
27765603	10	18	microRNA	T028	C2825314
27765603	19	30	alterations	T078	C1515926
27765603	45	61	diverse outcomes	T169	C1274040
27765603	72	76	EV71	T047	C3853962
27765603	81	85	CA16	T129	C1440505
27765603	86	96	infections	T046	C3714514
27765603	112	138	high-throughput sequencing	T063	C2936623
27765603	142	155	rhesus monkey	T015	C0024400
27765603	156	190	peripheral blood mononuclear cells	T025	C1321301
27765603	191	205	Enterovirus 71	T005	C2963492
27765603	207	211	EV71	T005	C2963492
27765603	217	235	Coxsackievirus A16	T129	C1440505
27765603	237	241	CA16	T129	C1440505
27765603	251	272	predominant pathogens	T001	C0450254
27765603	276	305	hand, foot, and mouth disease	T047	C0018572
27765603	307	311	HFMD	T047	C0018572
27765603	329	336	viruses	T005	C0042776
27765603	345	361	genetic homology	T045	C0314643
27765603	367	390	clinical manifestations	T080	C1280464
27765603	409	416	viruses	T005	C0042776
27765603	427	440	discrepancies	T033	C1290905
27765603	459	480	underlying mechanisms	T169	C0441712
27765603	526	535	microRNAs	T114,T123	C1101610
27765603	537	543	miRNAs	T114,T123	C1101610
27765603	569	579	biological	T038	C3714634
27765603	583	605	pathological processes	T046	C0030660
27765603	617	631	host responses	T042	C0301872
27765603	635	651	viral infections	T047	C0042769
27765603	688	693	miRNA	T028	C2825314
27765603	694	704	expression	T045	C0017262
27765603	705	713	patterns	T082	C0449774
27765603	717	730	rhesus monkey	T015	C0024400
27765603	731	765	peripheral blood mononuclear cells	T025	C1321301
27765603	767	772	PBMCs	T025	C1321301
27765603	774	782	infected	T033	C0439663
27765603	788	792	EV71	T005	C2963492
27765603	797	801	CA16	T129	C1440505
27765603	831	857	high-throughput sequencing	T063	C2936623
27765603	893	898	known	T080	C0205309
27765603	906	911	novel	T080	C0205314
27765603	912	918	miRNAs	T114,T123	C1101610
27765603	965	971	miRNAs	T114,T123	C1101610
27765603	987	993	target	T169	C1521840
27765603	994	1004	prediction	T078	C0681842
27765603	1038	1042	EV71	T047	C3853962
27765603	1049	1053	CA16	T129	C1440505
27765603	1056	1064	infected	T033	C0439663
27765603	1074	1076	GO	T170	C1138831
27765603	1081	1097	pathway analysis	T170	C0868995
27765603	1105	1114	predicted	T078	C0681842
27765603	1115	1122	targets	T169	C1521840
27765603	1147	1167	biological processes	T038	C3714634
27765603	1172	1191	molecular functions	T044	C1148560
27765603	1195	1214	cellular components	T026	C1166607
27765603	1223	1231	pathways	T077	C1705987
27765603	1247	1266	regulatory networks	T044	C1720950
27765603	1270	1275	miRNA	T114,T123	C1101610
27765603	1278	1299	transcription factors	T116,T123	C0040648
27765603	1301	1306	miRNA	T114,T123	C1101610
27765603	1309	1318	predicted	T078	C0681842
27765603	1319	1326	targets	T169	C1521840
27765603	1328	1333	miRNA	T114,T123	C1101610
27765603	1336	1339	GOs	T170	C1138831
27765603	1344	1349	miRNA	T114,T123	C1101610
27765603	1352	1360	pathways	T077	C1705987
27765603	1392	1421	complex regulatory mechanisms	T169	C0441712
27765603	1425	1431	miRNAs	T114,T123	C1101610
27765603	1443	1458	infection phase	T047	C1321909
27765603	1475	1483	analysed	T062	C0936012
27765603	1484	1496	hierarchical	T169	C0699032
27765603	1497	1499	GO	T170	C1138831
27765603	1500	1510	categories	T170	C0683312
27765603	1518	1527	predicted	T078	C0681842
27765603	1528	1535	targets	T169	C1521840
27765603	1548	1571	immune system processes	T042	C1817756
27765603	1598	1604	innate	T032	C0020969
27765603	1609	1626	adaptive immunity	T039	C0678209
27765603	1637	1641	EV71	T047	C3853962
27765603	1646	1650	CA16	T129	C1440505
27765603	1651	1661	infections	T046	C3714514
27765603	1710	1716	report	T170	C0684224
27765603	1741	1746	miRNA	T028	C2825314
27765603	1747	1766	expression profiles	T081	C1956267
27765603	1770	1775	PBMCs	T025	C1321301
27765603	1781	1785	EV71	T047	C3853962
27765603	1790	1794	CA16	T129	C1440505
27765603	1795	1805	infections	T046	C3714514
27765603	1812	1838	high-throughput sequencing	T063	C2936623
27765603	1896	1903	studies	T062	C2603343
27765603	1931	1937	miRNAs	T114,T123	C1101610
27765603	1963	1979	immune responses	T042	C0301872
27765603	1990	1994	EV71	T047	C3853962
27765603	1999	2003	CA16	T129	C1440505
27765603	2004	2014	infections	T046	C3714514

27236097|t|The influence of liposomal formulation on the incorporation and retention of PNA oligomers
27236097|a|Liposomal formulations composed of phospholipids with different unsaturation degrees, head groups and at different cholesterol content have been tested for the encapsulation of Peptide Nucleic Acid (PNA) oligomers. The best loading capability (177μg, ER %=87.2) was obtained for pure liposomes of phosphatidylglycerol (DOPG) with negatively charged head group. The insertion of a 10-20% of cholesterol in DOPG based liposomes provides a slight decrease (∼160μg) of the PNA loading. On the other hand, the cholesterol addition (20-30%) slows down the PNA's release (∼27%) in fetal bovine serum from the liposomal formulation. Based on the encapsulation and the release properties, PEGylated DOPG liposomes with a percentage of cholesterol of 10-20% are the optimal formulation for the loading of PNA-a210.
27236097	17	26	liposomal	T109	C0023828
27236097	27	38	formulation	T077	C1705957
27236097	46	59	incorporation	T169	C0243126
27236097	64	73	retention	T169	C0333117
27236097	77	90	PNA oligomers	T114	C0600500
27236097	91	100	Liposomal	T109	C0023828
27236097	101	113	formulations	T077	C1705957
27236097	126	139	phospholipids	T109,T123	C0031676
27236097	155	175	unsaturation degrees	T080	C0522535
27236097	177	188	head groups	T169	C0205245
27236097	206	242	cholesterol content have been tested	T059	C0201950
27236097	251	264	encapsulation	T067	C2348438
27236097	268	304	Peptide Nucleic Acid (PNA) oligomers	T114	C0600500
27236097	310	333	best loading capability	T081	C3714444
27236097	342	344	ER	T081	C0456603
27236097	375	384	liposomes	T109	C0023828
27236097	388	408	phosphatidylglycerol	T109	C0043840
27236097	410	414	DOPG	T109	C0043840
27236097	421	439	negatively charged	T196	C0003075
27236097	440	450	head group	T169	C0205245
27236097	456	465	insertion	T058	C0441587
27236097	481	492	cholesterol	T109,T123	C0008377
27236097	496	500	DOPG	T109	C0043840
27236097	507	516	liposomes	T109	C0023828
27236097	535	543	decrease	T081	C0547047
27236097	560	563	PNA	T114	C0600500
27236097	564	571	loading	T052	C1708715
27236097	596	607	cholesterol	T109,T123	C0008377
27236097	608	616	addition	T169	C1524062
27236097	641	646	PNA's	T114	C0600500
27236097	647	654	release	T070	C3850077
27236097	665	683	fetal bovine serum	T130	C3812213
27236097	693	702	liposomal	T109	C0023828
27236097	703	714	formulation	T077	C1705957
27236097	729	742	encapsulation	T067	C2348438
27236097	751	769	release properties	T070	C3850077
27236097	771	780	PEGylated	T109,T121,T122	C0032483
27236097	781	785	DOPG	T109	C0043840
27236097	786	795	liposomes	T109	C0023828
27236097	817	828	cholesterol	T109,T123	C0008377
27236097	847	866	optimal formulation	T062	C0524527
27236097	875	882	loading	T052	C1708715
27236097	886	894	PNA-a210	T114	C0600500

28298224|t|Transcriptional reprogramming in yeast using dCas9 and combinatorial gRNA strategies
28298224|a|Transcriptional reprogramming is a fundamental process of living cells in order to adapt to environmental and endogenous cues. In order to allow flexible and timely control over gene expression without the interference of native gene expression machinery, a large number of studies have focused on developing synthetic biology tools for orthogonal control of transcription. Most recently, the nuclease-deficient Cas9 (dCas9) has emerged as a flexible tool for controlling activation and repression of target genes, by the simple RNA-guided positioning of dCas9 in the vicinity of the target gene transcription start site. In this study we compared two different systems of dCas9 -mediated transcriptional reprogramming, and applied them to genes controlling two biosynthetic pathways for biobased production of isoprenoids and triacylglycerols (TAGs) in baker's yeast Saccharomyces cerevisiae. By testing 101 guide-RNA (gRNA) structures on a total of 14 different yeast promoters, we identified the best-performing combinations based on reporter assays. Though a larger number of gRNA - promoter combinations do not perturb gene expression, some gRNAs support expression perturbations up to ~threefold. The best-performing gRNAs were used for single and multiplex reprogramming strategies for redirecting flux related to isoprenoid production and optimization of TAG profiles. From these studies, we identified both constitutive and inducible multiplex reprogramming strategies enabling significant changes in isoprenoid production and increases in TAG. Taken together, we show similar performance for a constitutive and an inducible dCas9 approach, and identify multiplex gRNA designs that can significantly perturb isoprenoid production and TAG profiles in yeast without editing the genomic context of the target genes. We also identify a large number of gRNA positions in 14 native yeast target pomoters that do not affect expression, suggesting the need for further optimization of gRNA design tools and dCas9 engineering.
28298224	0	29	Transcriptional reprogramming	T043	C3850096
28298224	33	38	yeast	T004	C0043393
28298224	45	50	dCas9	T116,T123	C0033684
28298224	69	73	gRNA	T114,T123	C0082774
28298224	85	114	Transcriptional reprogramming	T043	C3850096
28298224	143	155	living cells	T025	C0007634
28298224	177	190	environmental	T082	C0014406
28298224	195	205	endogenous	T169	C0205227
28298224	206	210	cues	T078	C0010439
28298224	250	257	control	T169	C2587213
28298224	263	278	gene expression	T045	C0017262
28298224	291	303	interference	T169	C0521102
28298224	307	339	native gene expression machinery	T045	C1517486
28298224	394	411	synthetic biology	T090	C2936469
28298224	412	417	tools	T169	C0449851
28298224	433	440	control	T169	C2587213
28298224	444	457	transcription	T045	C0040649
28298224	478	501	nuclease-deficient Cas9	T116,T123	C0033684
28298224	503	508	dCas9	T116,T123	C0033684
28298224	545	556	controlling	T169	C2587213
28298224	557	567	activation	T052	C1879547
28298224	572	582	repression	T045	C0178656
28298224	586	598	target genes	T028	C0017337
28298224	614	624	RNA-guided	T114,T123	C0082774
28298224	640	645	dCas9	T116,T123	C0033684
28298224	669	705	target gene transcription start site	T114,T123	C0949639
28298224	715	720	study	T062	C2603343
28298224	758	763	dCas9	T116,T123	C0033684
28298224	774	803	transcriptional reprogramming	T043	C3850096
28298224	825	830	genes	T028	C0017337
28298224	831	842	controlling	T169	C2587213
28298224	847	868	biosynthetic pathways	T044	C1721101
28298224	896	907	isoprenoids	T109	C0682996
28298224	912	928	triacylglycerols	T109,T123	C0041004
28298224	930	934	TAGs	T109,T123	C0041004
28298224	939	952	baker's yeast	T004	C0036025
28298224	953	977	Saccharomyces cerevisiae	T004	C0036025
28298224	994	1003	guide-RNA	T114,T123	C0082774
28298224	1005	1009	gRNA	T114,T123	C0082774
28298224	1049	1054	yeast	T004	C0043393
28298224	1055	1064	promoters	T114,T123	C0086860
28298224	1100	1112	combinations	T080	C0205195
28298224	1131	1137	assays	T059	C0005507
28298224	1165	1169	gRNA	T114,T123	C0082774
28298224	1172	1180	promoter	T114,T123	C0086860
28298224	1181	1193	combinations	T080	C0205195
28298224	1201	1208	perturb	T169	C0332453
28298224	1209	1224	gene expression	T045	C0017262
28298224	1231	1236	gRNAs	T114,T123	C0082774
28298224	1245	1255	expression	T045	C0017262
28298224	1256	1269	perturbations	T169	C0332453
28298224	1308	1313	gRNAs	T114,T123	C0082774
28298224	1328	1334	single	T043	C3850096
28298224	1339	1362	multiplex reprogramming	T043	C3850096
28298224	1390	1394	flux	T070	C2348693
28298224	1406	1416	isoprenoid	T109	C0682996
28298224	1432	1444	optimization	T052	C2698650
28298224	1448	1451	TAG	T109,T123	C0041004
28298224	1528	1551	multiplex reprogramming	T043	C3850096
28298224	1595	1605	isoprenoid	T109	C0682996
28298224	1634	1637	TAG	T109,T123	C0041004
28298224	1671	1682	performance	T052	C1882330
28298224	1719	1724	dCas9	T116,T123	C0033684
28298224	1748	1762	multiplex gRNA	T114,T123	C0082774
28298224	1794	1801	perturb	T169	C0332453
28298224	1802	1812	isoprenoid	T109	C0682996
28298224	1828	1831	TAG	T109,T123	C0041004
28298224	1844	1849	yeast	T004	C0043393
28298224	1870	1877	genomic	T028	C0017428
28298224	1893	1905	target genes	T028	C0017337
28298224	1942	1946	gRNA	T114,T123	C0082774
28298224	1970	1975	yeast	T004	C0043393
28298224	1983	1991	pomoters	T114,T123	C0086860
28298224	2011	2021	expression	T045	C0017262
28298224	2055	2067	optimization	T052	C2698650
28298224	2071	2075	gRNA	T114,T123	C0082774
28298224	2093	2110	dCas9 engineering	T063	C0017387

28198592|t|Bone Marrow -Derived Mesenchymal Stem Cells -Derived Exosomes Promote Survival of Retinal Ganglion Cells Through miRNA -Dependent Mechanisms
28198592|a|The loss of retinal ganglion cells (RGC) and their axons is one of the leading causes of blindness and includes traumatic (optic neuropathy) and degenerative (glaucoma) eye diseases. Although no clinical therapies are in use, mesenchymal stem cells (MSC) have demonstrated significant neuroprotective and axogenic effects on RGC in both of the aforementioned models. Recent evidence has shown that MSC secrete exosomes, membrane enclosed vesicles (30-100 nm) containing proteins, mRNA and miRNA which can be delivered to nearby cells. The present study aimed to isolate exosomes from bone marrow -derived MSC (BMSC) and test them in a rat optic nerve crush (ONC) model. Treatment of primary retinal cultures with BMSC - exosomes demonstrated significant neuroprotective and neuritogenic effects. Twenty-one days after ONC and weekly intravitreal exosome injections; optical coherence tomography, electroretinography, and immunohistochemistry was performed. BMSC -derived exosomes promoted statistically significant survival of RGC and regeneration of their axons while partially preventing RGC axonal loss and RGC dysfunction. Exosomes successfully delivered their cargo into inner retinal layers and the effects were reliant on miRNA, demonstrated by the diminished therapeutic effects of exosomes derived from BMSC after knockdown of Argonaute-2, a key miRNA effector molecule. This study supports the use of BMSC -derived exosomes as a cell-free therapy for traumatic and degenerative ocular disease. Stem Cells Translational Medicine 2017;6:1273-1285.
28198592	0	11	Bone Marrow	T024	C0005953
28198592	21	43	Mesenchymal Stem Cells	T025	C1257975
28198592	53	61	Exosomes	T026	C2350332
28198592	70	78	Survival	T043	C0007620
28198592	82	104	Retinal Ganglion Cells	T025	C0035316
28198592	113	118	miRNA	T114,T123	C1101610
28198592	130	140	Mechanisms	T044	C0678659
28198592	145	149	loss	T081	C1517945
28198592	153	175	retinal ganglion cells	T025	C0035316
28198592	177	180	RGC	T025	C0035316
28198592	192	197	axons	T026	C0004461
28198592	230	239	blindness	T033	C0456909
28198592	253	262	traumatic	T037	C0015408
28198592	264	280	optic neuropathy	T047	C3887709
28198592	286	298	degenerative	T047	C0154777
28198592	300	308	glaucoma	T047	C0017601
28198592	310	322	eye diseases	T047	C0015397
28198592	333	335	no	T033	C1513916
28198592	336	354	clinical therapies	T061	C0087111
28198592	367	389	mesenchymal stem cells	T025	C1257975
28198592	391	394	MSC	T025	C1257975
28198592	426	441	neuroprotective	T169	C0815279
28198592	446	462	axogenic effects	T043	C0007613
28198592	466	469	RGC	T025	C0035316
28198592	539	542	MSC	T025	C1257975
28198592	551	559	exosomes	T026	C2350332
28198592	561	569	membrane	T026	C0596901
28198592	579	587	vesicles	T026	C1622418
28198592	611	619	proteins	T116,T123	C0033684
28198592	621	625	mRNA	T114,T123	C0035696
28198592	630	635	miRNA	T114,T123	C1101610
28198592	669	674	cells	T025	C0007634
28198592	688	693	study	T062	C2603343
28198592	711	719	exosomes	T026	C2350332
28198592	725	736	bone marrow	T024	C0005953
28198592	746	749	MSC	T025	C1257975
28198592	751	755	BMSC	T025	C1257975
28198592	776	779	rat	T015	C0034693
28198592	780	809	optic nerve crush (ONC) model	T050	C0012644
28198592	811	820	Treatment	T169	C1522326
28198592	824	848	primary retinal cultures	T059	C0430400
28198592	854	858	BMSC	T025	C1257975
28198592	861	869	exosomes	T026	C2350332
28198592	895	910	neuroprotective	T169	C0815279
28198592	915	935	neuritogenic effects	T043	C0007613
28198592	948	952	days	T079	C0439228
28198592	959	962	ONC	T050	C0012644
28198592	967	973	weekly	T079	C0332174
28198592	974	1005	intravitreal exosome injections	T169	C1554888
28198592	1007	1035	optical coherence tomography	T060	C0920367
28198592	1037	1056	electroretinography	T060	C0013867
28198592	1062	1082	immunohistochemistry	T060	C0021044
28198592	1098	1102	BMSC	T025	C1257975
28198592	1112	1120	exosomes	T026	C2350332
28198592	1156	1164	survival	T043	C0007620
28198592	1168	1171	RGC	T025	C0035316
28198592	1176	1188	regeneration	T043	C0598425
28198592	1198	1203	axons	T026	C0004461
28198592	1231	1234	RGC	T025	C0035316
28198592	1251	1254	RGC	T025	C0035316
28198592	1255	1266	dysfunction	T077	C3887504
28198592	1268	1276	Exosomes	T026	C2350332
28198592	1317	1337	inner retinal layers	T023	C0229211
28198592	1370	1375	miRNA	T114,T123	C1101610
28198592	1408	1427	therapeutic effects	T201	C1527144
28198592	1431	1439	exosomes	T026	C2350332
28198592	1453	1457	BMSC	T025	C1257975
28198592	1464	1473	knockdown	T063	C2350567
28198592	1477	1488	Argonaute-2	T028	C1414333
28198592	1496	1501	miRNA	T114,T123	C1101610
28198592	1526	1531	study	T062	C2603343
28198592	1552	1556	BMSC	T025	C1257975
28198592	1566	1574	exosomes	T026	C2350332
28198592	1580	1597	cell-free therapy	T061	C0087111
28198592	1602	1611	traumatic	T037	C0015408
28198592	1616	1643	degenerative ocular disease	T047	C0154777

28144189|t|Correlation of the Lipid Profile, BMI and Bone Mineral Density in Postmenopausal Women
28144189|a|To the reduction of bone density and osteoporosis in postmenopausal women contribute elevated lipid parameters and Body Mass Index (BMI). The goal of our study was to determine the correlation between lipid parameters, BMI and osteoporosis in postmenopausal women. The study was carried out by matched type between experimental group and controls. The experimental group consisted of 100 females at postmenopausal age, in which by the DEXA method was diagnosed osteoporosis at the Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center of RS during 2015-2016, while the control group consisted of 100 females in a postmenopausal age but without diagnosed osteoporosis. The groups were matched by age (± 2 years). To all participants of the study were carried out biochemical analysis of blood, or the analysis of the lipid profile that included total cholesterol, LDL cholesterol, triglycerides (TG) and HDL cholesterol, and was determined the values of BMI and waist circumference (WC). Analysis of the data of our research shows that by the univariate logistic regression the values of lipid parameters total cholesterol (p=0.000), LDL (p=0.005) and TG (p=0.033) were significantly associated with osteoporosis, while in multivariate logistic model only total cholesterol (p= 0.018) was found as an independent risk factor for osteoporosis in postmenopausal women. BMI values were not statistically significantly associated with osteoporosis (p=0.727). On the decrease in bone mineral density and osteoporosis in postmenopausal women influence many risk factors whose identification has the aim to develop more effective prevention of this disease in the elderly.
28144189	0	11	Correlation	T080	C1707520
28144189	19	24	Lipid	T109	C0023779
28144189	25	32	Profile	T059	C1979963
28144189	34	37	BMI	T201	C1305855
28144189	42	62	Bone Mineral Density	T201	C0005938
28144189	66	80	Postmenopausal	T040	C0206159
28144189	81	86	Women	T098	C0043210
28144189	94	103	reduction	T080	C0392756
28144189	107	119	bone density	T201	C0005938
28144189	124	136	osteoporosis	T047	C0029456
28144189	140	154	postmenopausal	T040	C0206159
28144189	155	160	women	T098	C0043210
28144189	172	180	elevated	T080	C3163633
28144189	181	186	lipid	T109	C0023779
28144189	187	197	parameters	T033	C0449381
28144189	202	217	Body Mass Index	T201	C1305855
28144189	219	222	BMI	T201	C1305855
28144189	241	246	study	T062	C2603343
28144189	268	279	correlation	T080	C1707520
28144189	288	293	lipid	T109	C0023779
28144189	294	304	parameters	T033	C0449381
28144189	306	309	BMI	T201	C1305855
28144189	314	326	osteoporosis	T047	C0029456
28144189	330	344	postmenopausal	T040	C0206159
28144189	345	350	women	T098	C0043210
28144189	356	361	study	T062	C2603343
28144189	381	388	matched	T080	C1708943
28144189	389	393	type	T080	C0332307
28144189	402	414	experimental	T080	C1517586
28144189	415	420	group	T078	C0441833
28144189	425	433	controls	T096	C0009932
28144189	439	451	experimental	T080	C1517586
28144189	452	457	group	T078	C0441833
28144189	475	482	females	T098	C0043210
28144189	486	500	postmenopausal	T040	C0206159
28144189	501	504	age	T032	C0001779
28144189	522	533	DEXA method	T060	C1510486
28144189	538	547	diagnosed	T033	C0011900
28144189	548	560	osteoporosis	T047	C0029456
28144189	630	661	University Medical Center of RS	T073,T093	C0000872
28144189	690	703	control group	T096	C0009932
28144189	721	728	females	T098	C0043210
28144189	734	748	postmenopausal	T040	C0206159
28144189	749	752	age	T032	C0001779
28144189	765	774	diagnosed	T033	C0011900
28144189	775	787	osteoporosis	T047	C0029456
28144189	793	799	groups	T078	C0441833
28144189	805	812	matched	T080	C1708943
28144189	816	819	age	T032	C0001779
28144189	825	830	years	T079	C1510829
28144189	840	852	participants	T098	C0679646
28144189	860	865	study	T062	C2603343
28144189	883	912	biochemical analysis of blood	T059	C0005774
28144189	921	929	analysis	T062	C0936012
28144189	937	942	lipid	T109	C0023779
28144189	943	950	profile	T059	C1979963
28144189	965	982	total cholesterol	T109	C0543421
28144189	984	999	LDL cholesterol	T109,T123	C0023824
28144189	1001	1014	triglycerides	T109,T123	C0041004
28144189	1016	1018	TG	T109,T123	C0041004
28144189	1024	1039	HDL cholesterol	T109,T123	C0023822
28144189	1064	1070	values	T080	C0042295
28144189	1074	1077	BMI	T201	C1305855
28144189	1082	1101	waist circumference	T201	C0455829
28144189	1103	1105	WC	T201	C0455829
28144189	1108	1116	Analysis	T062	C0936012
28144189	1124	1128	data	T078	C1511726
28144189	1136	1144	research	T062	C0035168
28144189	1163	1193	univariate logistic regression	T062	C0206031
28144189	1198	1204	values	T080	C0042295
28144189	1208	1213	lipid	T109	C0023779
28144189	1214	1224	parameters	T033	C0449381
28144189	1225	1242	total cholesterol	T109	C0543421
28144189	1254	1257	LDL	T109,T123	C0023824
28144189	1272	1274	TG	T109,T123	C0041004
28144189	1290	1303	significantly	T078	C0750502
28144189	1304	1319	associated with	T080	C0332281
28144189	1320	1332	osteoporosis	T047	C0029456
28144189	1343	1370	multivariate logistic model	T081,T170	C0023965
28144189	1376	1393	total cholesterol	T109	C0543421
28144189	1421	1432	independent	T078	C0085862
28144189	1433	1444	risk factor	T033	C0035648
28144189	1449	1461	osteoporosis	T047	C0029456
28144189	1465	1479	postmenopausal	T040	C0206159
28144189	1480	1485	women	T098	C0043210
28144189	1487	1490	BMI	T201	C1305855
28144189	1491	1497	values	T080	C0042295
28144189	1503	1506	not	T033	C1513916
28144189	1507	1534	statistically significantly	T081	C0237881
28144189	1535	1550	associated with	T080	C0332281
28144189	1551	1563	osteoporosis	T047	C0029456
28144189	1582	1590	decrease	T081	C0547047
28144189	1594	1614	bone mineral density	T201	C0005938
28144189	1619	1631	osteoporosis	T047	C0029456
28144189	1635	1649	postmenopausal	T040	C0206159
28144189	1650	1655	women	T098	C0043210
28144189	1671	1683	risk factors	T033	C0035648
28144189	1690	1704	identification	T080	C0205396
28144189	1733	1742	effective	T080	C1704419
28144189	1743	1753	prevention	T080	C2700409
28144189	1762	1769	disease	T047	C0029456
28144189	1777	1784	elderly	T098	C0001792

27823893|t|Sepsis Clinical Criteria in Emergency Department Patients Admitted to an Intensive Care Unit: An External Validation Study of Quick Sequential Organ Failure Assessment
27823893|a|Quick Sequential Organ Failure Assessment (qSOFA) is a prognostic score for patients with sepsis. Our aim was to compare the area under the receiver operating curve (AUROC), sensitivity, specificity, and likelihood ratios of qSOFA vs. systemic inflammation response syndrome (SIRS) in predicting in-hospital mortality among emergency department (ED) patients with suspected infection admitted to intensive care units (ICUs). We conducted a retrospective cohort chart review study of ED patients admitted to an ICU with suspected infection from August 1, 2012 to February 28, 2015. We included all patients with body fluid cultures sampled either during their ED stay without antibiotic administration or within 24 h of antibiotics administered in the ED. Trained chart abstractors blinded to the study hypothesis double-entered data from each patient's electronic medical record including demographic characteristics, vital signs, laboratory study results, physical examination findings, and in-hospital mortality. We then calculated the AUROC, sensitivity, specificity, and likelihood ratios for qSOFA and SIRS for predicting in-hospital mortality. Of 214 patients admitted to an ICU with presumed sepsis, 39 (18.2%) died during hospitalization. The AUROC value was 0.65 (95% confidence interval [CI] 0.56-0.74) for SIRS vs. 0.66 (95% CI 0.57-0.76) for qSOFA; 2+ qSOFA criteria predicted in-hospital mortality with 89.7% sensitivity, 27.4% specificity, 1.2 positive likelihood ratio, and 0.4 negative likelihood ratio. Among ED patients admitted to an ICU, the SIRS and qSOFA criteria had comparable prognostic value for predicting in-hospital mortality. These prognostic values are similar to those reported by the Sepsis-3 guidelines for ICU encounters.
27823893	0	6	Sepsis	T047	C0243026
27823893	7	24	Clinical Criteria	T080	C1516637
27823893	28	48	Emergency Department	T073,T093	C0562508
27823893	49	57	Patients	T101	C0030705
27823893	58	66	Admitted	T058	C0184666
27823893	73	92	Intensive Care Unit	T073,T093	C0021708
27823893	97	122	External Validation Study	T062,T170	C0681836
27823893	126	167	Quick Sequential Organ Failure Assessment	T033	C3494459
27823893	168	209	Quick Sequential Organ Failure Assessment	T033	C3494459
27823893	211	216	qSOFA	T033	C3494459
27823893	223	239	prognostic score	T081	C0449821
27823893	244	252	patients	T101	C0030705
27823893	258	264	sepsis	T047	C0243026
27823893	270	273	aim	T078	C1947946
27823893	293	332	area under the receiver operating curve	T081	C0035787
27823893	334	339	AUROC	T081	C0035787
27823893	342	353	sensitivity	T081	C0036667
27823893	355	366	specificity	T081	C0037791
27823893	372	389	likelihood ratios	T081	C0150102
27823893	393	398	qSOFA	T033	C3494459
27823893	403	442	systemic inflammation response syndrome	T047	C0242966
27823893	444	448	SIRS	T047	C0242966
27823893	464	485	in-hospital mortality	T080	C0085556
27823893	492	512	emergency department	T073,T093	C0562508
27823893	514	516	ED	T073,T093	C0562508
27823893	518	526	patients	T101	C0030705
27823893	532	551	suspected infection	T046	C3714514
27823893	552	560	admitted	T058	C0184666
27823893	564	584	intensive care units	T073,T093	C0021708
27823893	586	590	ICUs	T073,T093	C0021708
27823893	608	647	retrospective cohort chart review study	T062	C2985505
27823893	651	653	ED	T073,T093	C0562508
27823893	654	662	patients	T101	C0030705
27823893	663	671	admitted	T058	C0184666
27823893	678	681	ICU	T073,T093	C0021708
27823893	687	706	suspected infection	T046	C3714514
27823893	712	718	August	T080	C3831448
27823893	730	738	February	T080	C3830166
27823893	765	773	patients	T101	C0030705
27823893	779	806	body fluid cultures sampled	T031	C1292527
27823893	827	829	ED	T073,T093	C0562508
27823893	843	868	antibiotic administration	T061	C0199779
27823893	887	911	antibiotics administered	T061	C0199779
27823893	919	921	ED	T073,T093	C0562508
27823893	923	948	Trained chart abstractors	T097	C1522486
27823893	964	969	study	T062	C2603343
27823893	981	1000	double-entered data	T078	C1511726
27823893	1011	1020	patient's	T101	C0030705
27823893	1021	1046	electronic medical record	T170	C2362543
27823893	1057	1084	demographic characteristics	T102	C0683970
27823893	1086	1097	vital signs	T201	C0518766
27823893	1099	1123	laboratory study results	T059	C0681827
27823893	1125	1145	physical examination	T058	C0031809
27823893	1146	1154	findings	T033	C0243095
27823893	1160	1181	in-hospital mortality	T080	C0085556
27823893	1206	1211	AUROC	T081	C0035787
27823893	1213	1224	sensitivity	T081	C0036667
27823893	1226	1237	specificity	T081	C0037791
27823893	1243	1260	likelihood ratios	T081	C0150102
27823893	1265	1270	qSOFA	T033	C3494459
27823893	1275	1279	SIRS	T047	C0242966
27823893	1295	1316	in-hospital mortality	T080	C0085556
27823893	1325	1333	patients	T101	C0030705
27823893	1334	1342	admitted	T058	C0184666
27823893	1349	1352	ICU	T073,T093	C0021708
27823893	1358	1373	presumed sepsis	T047	C0243026
27823893	1386	1413	died during hospitalization	T033	C3260027
27823893	1419	1424	AUROC	T081	C0035787
27823893	1445	1464	confidence interval	T081	C0009667
27823893	1466	1468	CI	T081	C0009667
27823893	1485	1489	SIRS	T047	C0242966
27823893	1504	1506	CI	T081	C0009667
27823893	1522	1527	qSOFA	T033	C3494459
27823893	1532	1537	qSOFA	T033	C3494459
27823893	1557	1578	in-hospital mortality	T080	C0085556
27823893	1590	1601	sensitivity	T081	C0036667
27823893	1609	1620	specificity	T081	C0037791
27823893	1626	1651	positive likelihood ratio	T081	C0150102
27823893	1661	1686	negative likelihood ratio	T081	C0150102
27823893	1694	1696	ED	T073,T093	C0562508
27823893	1697	1705	patients	T101	C0030705
27823893	1706	1714	admitted	T058	C0184666
27823893	1721	1724	ICU	T073,T093	C0021708
27823893	1730	1734	SIRS	T047	C0242966
27823893	1739	1744	qSOFA	T033	C3494459
27823893	1769	1785	prognostic value	T081	C0449821
27823893	1801	1822	in-hospital mortality	T080	C0085556
27823893	1830	1847	prognostic values	T081	C0449821
27823893	1885	1904	Sepsis-3 guidelines	T170	C0282451
27823893	1909	1912	ICU	T073,T093	C0021708
27823893	1913	1923	encounters	T170	C3889614

27742373|t|Scutellarin attenuates vasospasm through the Erk5 - KLF2 - eNOS pathway after subarachnoid hemorrhage in rats
27742373|a|Angiographic vasospasm, especially in the early phases (<72h) of subarachnoid hemorrhage (SAH), is one of the major complications after an aneurysm rupture and is often the cause of delayed neurological deterioration. Scutellarin (SCU), a flavonoid extracted from the traditional Chinese herb Erigeron breviscapus, has been widely accepted as an antioxidant, but the effect of SCU on vasospasm after SAH remains elusive. Endovascular perforation was conducted to induce SAH in Sprague-Dawley rats. Then, the underlying mechanism of the anti-vasospasm effect of SCU was investigated using a modified Garcia scale, India ink angiography, cross-sectional area analysis, immunohistochemistry staining and western blot. SCU (50μM, 100mg/kg) alleviated angiographic vasospasm and improved neurological function 48h after SAH and enhanced the expression of endothelial nitric oxide synthase (eNOS) at the intima of cerebral arteries. In addition, SCU upregulated the expression of phosphorylated extracellular-regulated kinase 5 (p-Erk5) and Kruppel-like factor 2 (KLF2) at 48h after SAH. However, the effects of SCU were reversed by the Erk5 inhibitor XMD8-92. Our results indicate that SCU could attenuate vasospasm and neurological deficits via modulating the Erk5 - KLF2 - eNOS pathway after SAH, which may provide an experimental basis for the clinical use of SCU treatment in SAH patients.
27742373	0	11	Scutellarin	T109	C0141783
27742373	23	32	vasospasm	T046	C0085616
27742373	45	49	Erk5	T116,T126	C0380568
27742373	52	56	KLF2	T116,T123	C1451409
27742373	59	63	eNOS	T116,T126	C1565682
27742373	64	71	pathway	T044	C0037080
27742373	78	101	subarachnoid hemorrhage	T047	C0038525
27742373	105	109	rats	T015	C0034715
27742373	110	122	Angiographic	T060	C0007767
27742373	123	132	vasospasm	T046	C0085616
27742373	175	198	subarachnoid hemorrhage	T047	C0038525
27742373	200	203	SAH	T047	C0038525
27742373	249	265	aneurysm rupture	T047	C0162869
27742373	292	326	delayed neurological deterioration	T184	C1536136
27742373	328	339	Scutellarin	T109	C0141783
27742373	341	344	SCU	T109	C0141783
27742373	349	358	flavonoid	T109	C0596577
27742373	390	402	Chinese herb	T121	C1134558
27742373	403	423	Erigeron breviscapus	T002	C1493752
27742373	456	467	antioxidant	T121	C0003402
27742373	487	490	SCU	T109	C0141783
27742373	494	503	vasospasm	T046	C0085616
27742373	510	513	SAH	T047	C0038525
27742373	531	543	Endovascular	T029	C0524425
27742373	544	555	perforation	T033	C0549099
27742373	580	583	SAH	T047	C0038525
27742373	587	606	Sprague-Dawley rats	T015	C0034715
27742373	646	667	anti-vasospasm effect	T033	C0243095
27742373	671	674	SCU	T109	C0141783
27742373	723	744	India ink angiography	T060	C0007767
27742373	746	775	cross-sectional area analysis	T081	C0003745
27742373	777	806	immunohistochemistry staining	T060	C0021044
27742373	811	823	western blot	T059	C0949466
27742373	825	828	SCU	T109	C0141783
27742373	846	856	alleviated	T080	C0392756
27742373	857	869	angiographic	T060	C0007767
27742373	870	879	vasospasm	T046	C0085616
27742373	893	914	neurological function	T042	C0027767
27742373	925	928	SAH	T047	C0038525
27742373	960	993	endothelial nitric oxide synthase	T116,T126	C1565682
27742373	995	999	eNOS	T116,T126	C1565682
27742373	1008	1014	intima	T024	C1256463
27742373	1018	1035	cerebral arteries	T023	C0007770
27742373	1050	1053	SCU	T109	C0141783
27742373	1054	1065	upregulated	T044	C0041904
27742373	1084	1131	phosphorylated extracellular-regulated kinase 5	T116,T126	C0380568
27742373	1133	1139	p-Erk5	T116,T126	C0380568
27742373	1145	1166	Kruppel-like factor 2	T116,T123	C1451409
27742373	1168	1172	KLF2	T116,T123	C1451409
27742373	1187	1190	SAH	T047	C0038525
27742373	1216	1219	SCU	T109	C0141783
27742373	1256	1263	XMD8-92	T109,T121	C3252765
27742373	1291	1294	SCU	T109	C0141783
27742373	1311	1320	vasospasm	T046	C0085616
27742373	1325	1346	neurological deficits	T033	C0521654
27742373	1366	1370	Erk5	T116,T126	C0380568
27742373	1373	1377	KLF2	T116,T123	C1451409
27742373	1380	1384	eNOS	T116,T126	C1565682
27742373	1385	1392	pathway	T044	C0037080
27742373	1399	1402	SAH	T047	C0038525
27742373	1468	1471	SCU	T109	C0141783
27742373	1472	1481	treatment	T061	C0087111
27742373	1485	1488	SAH	T047	C0038525
27742373	1489	1497	patients	T101	C0030705

28451474|t|Adjuvant Radiotherapy for Thymic Neuroendocrine Tumors: A Case Report and Review of the Literature
28451474|a|Thymic carcinoid tumors are very rare. Between two and four percent of carcinoids originate from the thymus with an estimated incidence of 1.5 to 3 per 10,000,000 persons per year. Thymic carcinoids can be associated with the multiple endocrine neoplasia (MEN) type 1. The principal treatment is surgical resection. The potential roles of systemic and radiation treatments are a matter of debate. We describe the successful multidisciplinary treatment of a case of thymic carcinoid associated with MEN and review the literature pertaining to the use of adjuvant thoracic radiation.
28451474	0	21	Adjuvant Radiotherapy	T061	C0242939
28451474	26	54	Thymic Neuroendocrine Tumors	T191	C2210965
28451474	58	69	Case Report	T170	C0007320
28451474	74	98	Review of the Literature	T170	C0282441
28451474	99	122	Thymic carcinoid tumors	T191	C2210965
28451474	132	136	rare	T080	C0522498
28451474	170	180	carcinoids	T191	C0007095
28451474	181	190	originate	T079	C0439659
28451474	200	206	thymus	T023	C0040113
28451474	215	224	estimated	T081	C0750572
28451474	225	234	incidence	T081	C0021149
28451474	262	269	persons	T098	C0027361
28451474	270	278	per year	T079	C0439508
28451474	280	297	Thymic carcinoids	T191	C1336746
28451474	305	320	associated with	T080	C0332281
28451474	325	366	multiple endocrine neoplasia (MEN) type 1	T191	C0025267
28451474	372	381	principal	T080	C0205225
28451474	382	391	treatment	T169	C1522326
28451474	395	413	surgical resection	T061	C0728940
28451474	419	428	potential	T080	C3245505
28451474	438	446	systemic	T169	C0205373
28451474	451	471	radiation treatments	T061	C3871222
28451474	512	522	successful	T080	C1272703
28451474	523	550	multidisciplinary treatment	T061	C0870721
28451474	556	560	case	T077	C1706256
28451474	564	580	thymic carcinoid	T191	C2210965
28451474	581	596	associated with	T080	C0332281
28451474	597	600	MEN	T191	C0027662
28451474	605	626	review the literature	T170	C0282441
28451474	652	679	adjuvant thoracic radiation	T061	C0242939

27849093|t|A rapid and clean synthetic approach to cyclic peptides via micro-flow peptide chain elongation and photochemical cyclization: synthesis of a cyclic RGD peptide
27849093|a|A cyclic RGD peptide was efficiently synthesized based on micro-flow, triphosgene-mediated peptide chain elongation and micro-flow photochemical macrolactamization. Our approach enabled a rapid (amidation for peptide chain elongation <5 s, macrolactamization <5 min) and clean (only one column chromatographic separation) synthesis of a cyclic peptide.
27849093	2	7	rapid	T080	C0456962
27849093	18	36	synthetic approach	T062	C1518961
27849093	40	55	cyclic peptides	T116	C0030957
27849093	60	95	micro-flow peptide chain elongation	T067	C1254366
27849093	100	125	photochemical cyclization	T070	C2350502
27849093	127	136	synthesis	T068	C0599100
27849093	142	148	cyclic	T116	C0030957
27849093	149	160	RGD peptide	T116,T123	C0052350
27849093	163	169	cyclic	T116	C0030957
27849093	170	181	RGD peptide	T116,T123	C0052350
27849093	219	276	micro-flow, triphosgene-mediated peptide chain elongation	T067	C1254366
27849093	281	324	micro-flow photochemical macrolactamization	T070	C2350502
27849093	349	354	rapid	T080	C0456962
27849093	370	394	peptide chain elongation	T067	C1254366
27849093	401	419	macrolactamization	T067	C1254366
27849093	448	481	column chromatographic separation	T075	C1705246
27849093	483	492	synthesis	T068	C0599100
27849093	498	512	cyclic peptide	T116	C0030957

27287247|t|Inflamed skin predisposes to sensitization to less potent allergens
27287247|a|Irritant dermatitis, caused by genetic barrier dysfunction in atopic dermatitis or wet work in hand dermatitis, induces innate immune response that might predispose to allergic contact sensitization to less potent sensitizers. We sought to determine if positive patch test results to less potent allergens are more prevalent in patients with a history of childhood flexural dermatitis or current wet work. We examined our database of patients presenting to a contact dermatitis clinic tested to potential contact allergens as indicated by their history. Allergens from our most recent standard were studied if they could be classified as weak, moderate, or strong sensitizers based on published data from the local lymph node assay. Patients were stratified by a history of childhood - onset flexural dermatitis as a proxy for atopic dermatitis and by occupation. History of childhood - onset dermatitis predisposed to contact allergy to weak sensitizers and wet work to medium - potency sensitizers. Neither predisposed to contact allergy from strong sensitizers. Association cannot prove causation. We conclude that strong sensitizers do not require wet work or atopy to cause sensitization. Barrier defects associated with childhood eczema and wet work may promote sensitization to weak antigens.
27287247	0	8	Inflamed	T169	C0333348
27287247	9	13	skin	T022	C1123023
27287247	14	25	predisposes	T169	C0231203
27287247	29	42	sensitization	T040	C1325847
27287247	46	50	less	T080	C0205251
27287247	51	57	potent	T077	C4054723
27287247	58	67	allergens	T129	C0002092
27287247	68	87	Irritant dermatitis	T047	C0162823
27287247	99	114	genetic barrier	T169	C0314603
27287247	115	126	dysfunction	T077	C3887504
27287247	130	147	atopic dermatitis	T047	C0011615
27287247	151	159	wet work	T057	C0443352
27287247	163	178	hand dermatitis	T047	C0239816
27287247	180	187	induces	T169	C0205263
27287247	188	210	innate immune response	T032	C0020969
27287247	222	232	predispose	T169	C0231203
27287247	236	252	allergic contact	T047	C0162820
27287247	253	266	sensitization	T040	C1325847
27287247	270	274	less	T080	C0205251
27287247	275	281	potent	T077	C4054723
27287247	282	293	sensitizers	T129	C0002092
27287247	321	340	positive patch test	T034	C0856592
27287247	341	348	results	T169	C1274040
27287247	352	356	less	T080	C0205251
27287247	357	363	potent	T077	C4054723
27287247	364	373	allergens	T129	C0002092
27287247	378	392	more prevalent	T081	C1512456
27287247	396	404	patients	T101	C0030705
27287247	412	432	history of childhood	T033	C0489532
27287247	433	452	flexural dermatitis	T047	C0263224
27287247	456	472	current wet work	T057	C0443352
27287247	490	498	database	T170	C0242356
27287247	502	510	patients	T101	C0030705
27287247	527	545	contact dermatitis	T047	C0011616
27287247	546	552	clinic	T073,T093	C0442592
27287247	553	559	tested	T169	C0039593
27287247	563	572	potential	T080	C3245505
27287247	573	590	contact allergens	T129	C1320247
27287247	613	620	history	T058	C0679831
27287247	622	631	Allergens	T129	C0002092
27287247	653	661	standard	T080	C1442989
27287247	667	674	studied	T062	C2603343
27287247	706	710	weak	T080	C1762617
27287247	712	720	moderate	T080	C0205081
27287247	725	731	strong	T080	C0442821
27287247	732	743	sensitizers	T129	C0002092
27287247	753	767	published data	T170	C0993637
27287247	777	799	local lymph node assay	T081	C0887969
27287247	801	809	Patients	T169	C0314603
27287247	815	825	stratified	T080	C0205363
27287247	831	851	history of childhood	T033	C0489532
27287247	854	879	onset flexural dermatitis	T047	C0263224
27287247	895	912	atopic dermatitis	T047	C0011615
27287247	920	930	occupation	T033	C0421456
27287247	932	952	History of childhood	T033	C0489532
27287247	955	971	onset dermatitis	T047	C0011615
27287247	972	983	predisposed	T169	C0231203
27287247	987	1002	contact allergy	T047	C0162820
27287247	1006	1010	weak	T080	C1762617
27287247	1011	1022	sensitizers	T129	C0002092
27287247	1027	1035	wet work	T057	C0443352
27287247	1039	1045	medium	T081	C0439536
27287247	1048	1055	potency	T077	C4054723
27287247	1056	1067	sensitizers	T129	C0002092
27287247	1077	1088	predisposed	T169	C0231203
27287247	1092	1107	contact allergy	T047	C0162820
27287247	1113	1119	strong	T080	C0442821
27287247	1120	1131	sensitizers	T129	C0002092
27287247	1133	1144	Association	T080	C0439849
27287247	1158	1167	causation	T078	C0085978
27287247	1186	1192	strong	T080	C0442821
27287247	1193	1204	sensitizers	T129	C0002092
27287247	1220	1228	wet work	T057	C0443352
27287247	1232	1237	atopy	T046	C0392707
27287247	1247	1260	sensitization	T040	C1325847
27287247	1262	1277	Barrier defects	T169	C1457869
27287247	1278	1293	associated with	T080	C0332281
27287247	1294	1310	childhood eczema	T047	C1276071
27287247	1315	1323	wet work	T057	C0443352
27287247	1328	1335	promote	T052	C0033414
27287247	1336	1349	sensitization	T040	C1325847
27287247	1353	1357	weak	T080	C1762617
27287247	1358	1366	antigens	T129	C0003320

28159606|t|Recent coating developments for combination devices in orthopedic and dental applications: A literature review
28159606|a|Orthopedic and dental implants have been used successfully for decades to replace or repair missing or damaged bones, joints, and teeth, thereby restoring patient function subsequent to disease or injury. However, although device success rates are generally high, patient outcomes are sometimes compromised due to device -related problems such as insufficient integration, local tissue inflammation, and infection. Many different types of surface coatings have been developed to address these shortcomings, including those that incorporate therapeutic agents to provide localized delivery to the surgical site. While these coatings hold enormous potential for improving device function, the list of requirements that an ideal combination coating must fulfill is extensive, and no single coating system today simultaneously addresses all of the criteria. Some of the primary challenges related to current coatings are non-optimal release kinetics, which most often are too rapid, the potential for inducing antibiotic resistance in target organisms, high susceptibility to mechanical abrasion and delamination, toxicity, difficult and expensive regulatory approval pathways, and high manufacturing costs. This review provides a survey of the most recent developments in the field, i.e., those published in the last 2-3years, with a particular focus on technologies that have potential for overcoming the most significant challenges facing therapeutically - loaded coatings. It is concluded that the ideal coating remains an unrealized target, but that advances in the field and emerging technologies are bringing it closer to reality. The significant amount of research currentl y being conducted in the field provides a level of optimism that many functional combination coating s will ultimately transition into clinical practice, significant ly improving patient outcomes.
28159606	0	6	Recent	T079	C0332185
28159606	7	14	coating	T080	C1522408
28159606	15	27	developments	T169	C1527148
28159606	32	51	combination devices	T074	C1445094
28159606	55	65	orthopedic	T091	C0029355
28159606	70	89	dental applications	T061	C0398998
28159606	93	110	literature review	T170	C0282441
28159606	111	121	Orthopedic	T091	C0029355
28159606	126	141	dental implants	T074	C0011373
28159606	157	169	successfully	T080	C1272703
28159606	174	181	decades	T081	C2981279
28159606	185	192	replace	T169	C0559956
28159606	196	202	repair	T058	C1705181
28159606	203	210	missing	T080	C1705492
28159606	214	221	damaged	T169	C1883709
28159606	222	227	bones	T023	C0262950
28159606	229	235	joints	T030	C0022417
28159606	241	246	teeth	T023	C0040426
28159606	256	265	restoring	T061	C1283255
28159606	266	273	patient	T101	C0030705
28159606	274	282	function	T169	C0542341
28159606	283	293	subsequent	T079	C0332282
28159606	297	304	disease	T047	C0012634
28159606	308	314	injury	T037	C3263722
28159606	334	340	device	T074	C0025080
28159606	341	348	success	T080	C0679864
28159606	349	354	rates	T081	C1521828
28159606	369	373	high	T080	C0205250
28159606	375	382	patient	T101	C0030705
28159606	383	391	outcomes	T080	C0085415
28159606	406	417	compromised	T033	C2945640
28159606	425	431	device	T074	C0025080
28159606	441	449	problems	T033	C0033213
28159606	458	470	insufficient	T080	C0231180
28159606	471	482	integration	T080	C0205195
28159606	484	489	local	T082	C1947913
28159606	490	496	tissue	T024	C0040300
28159606	497	509	inflammation	T046	C0021368
28159606	515	524	infection	T046	C3714514
28159606	531	540	different	T080	C1705242
28159606	550	557	surface	T082	C0205148
28159606	558	566	coatings	T080	C1522408
28159606	577	586	developed	T169	C1527148
28159606	604	616	shortcomings	T169	C1457869
28159606	618	627	including	T169	C0332257
28159606	639	650	incorporate	T052	C2700399
28159606	651	669	therapeutic agents	T121	C1611640
28159606	673	680	provide	T052	C1999230
28159606	681	690	localized	T082	C1947913
28159606	691	699	delivery	T169	C1705822
28159606	707	720	surgical site	T082	C0449681
28159606	734	742	coatings	T080	C1522408
28159606	748	756	enormous	T080	C0205250
28159606	757	766	potential	T080	C3245505
28159606	771	780	improving	T080	C1272745
28159606	781	787	device	T074	C0025080
28159606	788	796	function	T169	C0542341
28159606	810	822	requirements	T169	C1514873
28159606	831	836	ideal	T080	C1512612
28159606	837	848	combination	T080	C0205195
28159606	849	856	coating	T080	C1522408
28159606	873	882	extensive	T080	C0205231
28159606	891	897	single	T081	C0205171
28159606	898	905	coating	T080	C1522408
28159606	906	912	system	T169	C0449913
28159606	919	933	simultaneously	T079	C0521115
28159606	955	963	criteria	T078	C0243161
28159606	977	984	primary	T080	C0205225
28159606	985	995	challenges	T201	C0798503
28159606	1007	1014	current	T079	C0521116
28159606	1015	1023	coatings	T080	C1522408
28159606	1028	1039	non-optimal	T080	C0205556
28159606	1040	1047	release	T169	C1283071
28159606	1048	1056	kinetics	T070	C0022702
28159606	1064	1068	most	T081	C0205393
28159606	1069	1074	often	T079	C0332183
28159606	1083	1088	rapid	T080	C0456962
28159606	1094	1103	potential	T080	C3245505
28159606	1108	1116	inducing	T169	C0205263
28159606	1117	1138	antibiotic resistance	T046	C0860044
28159606	1142	1148	target	T169	C1521840
28159606	1149	1158	organisms	T001	C0029235
28159606	1160	1164	high	T080	C0205250
28159606	1165	1179	susceptibility	T032	C0220898
28159606	1183	1202	mechanical abrasion	T067	C0563595
28159606	1207	1219	delamination	T061	C0441514
28159606	1221	1229	toxicity	T080	C0040539
28159606	1231	1240	difficult	T080	C0332218
28159606	1245	1254	expensive	T081	C0392762
28159606	1255	1283	regulatory approval pathways	T169	C1514829
28159606	1289	1293	high	T080	C0205250
28159606	1294	1307	manufacturing	T057	C0870840
28159606	1308	1313	costs	T081	C0010186
28159606	1320	1326	review	T170	C0282443
28159606	1327	1335	provides	T052	C1999230
28159606	1338	1344	survey	T170	C0038951
28159606	1352	1356	most	T081	C0205393
28159606	1357	1363	recent	T079	C0332185
28159606	1364	1376	developments	T169	C1527148
28159606	1384	1389	field	T077	C1521738
28159606	1403	1412	published	T057	C0034037
28159606	1442	1458	particular focus	T041	C0004268
28159606	1462	1474	technologies	T090	C0039421
28159606	1485	1494	potential	T080	C3245505
28159606	1499	1509	overcoming	T052	C2983310
28159606	1514	1518	most	T081	C0205393
28159606	1519	1530	significant	T078	C0750502
28159606	1531	1541	challenges	T201	C0798503
28159606	1549	1564	therapeutically	T169	C0302350
28159606	1567	1573	loaded	T081	C0870301
28159606	1574	1582	coatings	T080	C1522408
28159606	1590	1599	concluded	T078	C1707478
28159606	1609	1614	ideal	T080	C1512612
28159606	1615	1622	coating	T080	C1522408
28159606	1645	1651	target	T169	C1521840
28159606	1662	1670	advances	T079	C3854260
28159606	1678	1683	field	T077	C1521738
28159606	1697	1709	technologies	T090	C0039421
28159606	1736	1743	reality	T078	C0871222
28159606	1749	1760	significant	T078	C0750502
28159606	1761	1767	amount	T081	C1265611
28159606	1771	1779	research	T062	C0035168
28159606	1780	1788	currentl	T079	C0521116
28159606	1814	1819	field	T077	C1521738
28159606	1820	1828	provides	T052	C1999230
28159606	1840	1848	optimism	T041	C0237428
28159606	1859	1869	functional	T169	C0542341
28159606	1870	1881	combination	T080	C0205195
28159606	1882	1889	coating	T080	C1522408
28159606	1897	1907	ultimately	T079	C3853528
28159606	1908	1918	transition	T052	C2700061
28159606	1924	1941	clinical practice	T057	C0205897
28159606	1943	1954	significant	T078	C0750502
28159606	1958	1967	improving	T080	C1272745
28159606	1968	1975	patient	T101	C0030705
28159606	1976	1984	outcomes	T080	C0085415

28434980|t|Thaw -and-use target cells pre-labeled with calcein AM for antibody-dependent cell-mediated cytotoxicity assays
28434980|a|In vitro antibody-dependent cell-mediated cytotoxicity (ADCC) assays are routinely performed to support the research and development of therapeutic antibodies. In ADCC assays, target cells bound by the antibodies are lysed by activated effector cells following interactions between the Fc region of the bound antibody and Fcγ receptors on effector cells. Target cell lysis is typically measured by quantification of released endogenous enzymes, e.g., lactate dehydrogenase, or measurement of released exogenous labels, e.g., (51)Cr, europium or calcein. ADCC assays based on the detection of exogenous labels released from lysed target cells generally show higher sensitivity and require shorter incubation times. However, target cells are usually labeled immediately prior to assay, which inadvertently introduces additional assay variations due to differences in target cell conditions and labeling / handling processes. In this report, we describe the use of thaw -and-use pre-labeled target cells for ADCC assays. Thaw -and-use target cells in our experiments were pre-labeled with the fluorescent dye calcein AM, cryopreserved in single-use aliquots and used directly in assays after thawing. Upon thaw, the pre-labeled cells displayed viability and label retention comparable to freshly labeled cells, responded to ADCC mediated by both peripheral blood mononuclear cells and engineered natural killer cells, performed stably for at least 3 years and provided favorable precision and accuracy to ADCC assays. Implementation of thaw -and-use pre-labeled target cells in ADCC assays can help to alleviate both cell culture and dye labeling derived variability, increase the flexibility of assay scheduling and improve assay consistency and robustness.
28434980	0	4	Thaw	T059	C1710378
28434980	14	26	target cells	T025	C0221284
28434980	27	38	pre-labeled	T080	C1708632
28434980	44	54	calcein AM	T130	C0016320
28434980	59	111	antibody-dependent cell-mediated cytotoxicity assays	T059	C0201624
28434980	112	120	In vitro	T080	C1533691
28434980	121	180	antibody-dependent cell-mediated cytotoxicity (ADCC) assays	T059	C0201624
28434980	248	270	therapeutic antibodies	T116,T129	C0003241
28434980	275	286	ADCC assays	T059	C0201624
28434980	288	300	target cells	T025	C0221284
28434980	314	324	antibodies	T116,T129	C0003241
28434980	329	334	lysed	T046	C0024348
28434980	338	347	activated	T052	C1879547
28434980	348	362	effector cells	T025	C0312740
28434980	398	407	Fc region	T116,T129	C0021032
28434980	421	429	antibody	T116,T129	C0003241
28434980	434	447	Fcγ receptors	T116,T129,T192	C0034805
28434980	451	465	effector cells	T025	C0312740
28434980	467	478	Target cell	T025	C0221284
28434980	479	484	lysis	T046	C0024348
28434980	510	524	quantification	T081	C1709793
28434980	537	547	endogenous	T169	C0205227
28434980	548	555	enzymes	T116,T126	C0014442
28434980	563	584	lactate dehydrogenase	T116,T126	C0022917
28434980	613	622	exogenous	T169	C0205228
28434980	623	629	labels	T130	C1522485
28434980	637	643	(51)Cr	T121,T130,T196	C0303212
28434980	645	653	europium	T196	C0015180
28434980	657	664	calcein	T109,T130	C0060549
28434980	666	677	ADCC assays	T059	C0201624
28434980	704	713	exogenous	T169	C0205228
28434980	714	720	labels	T130	C1522485
28434980	735	740	lysed	T046	C0024348
28434980	741	753	target cells	T025	C0221284
28434980	808	824	incubation times	T033	C1320226
28434980	835	847	target cells	T025	C0221284
28434980	860	867	labeled	T080	C1708632
28434980	889	894	assay	T059	C1510438
28434980	938	943	assay	T059	C1510438
28434980	944	954	variations	T080	C0205419
28434980	977	988	target cell	T025	C0221284
28434980	1004	1012	labeling	T059	C2347885
28434980	1015	1033	handling processes	T059	C0037793
28434980	1074	1078	thaw	T059	C1710378
28434980	1088	1099	pre-labeled	T080	C1708632
28434980	1100	1112	target cells	T025	C0221284
28434980	1117	1128	ADCC assays	T059	C0201624
28434980	1130	1134	Thaw	T059	C1710378
28434980	1144	1156	target cells	T025	C0221284
28434980	1181	1192	pre-labeled	T080	C1708632
28434980	1202	1228	fluorescent dye calcein AM	T130	C0016320
28434980	1230	1243	cryopreserved	T059	C0010405
28434980	1288	1294	assays	T059	C1510438
28434980	1301	1308	thawing	T059	C2025613
28434980	1315	1319	thaw	T059	C1710378
28434980	1325	1336	pre-labeled	T080	C1708632
28434980	1337	1342	cells	T025	C0007634
28434980	1353	1362	viability	T043	C0007620
28434980	1367	1372	label	T130	C1522485
28434980	1373	1382	retention	T169	C0333118
28434980	1405	1412	labeled	T080	C1708632
28434980	1413	1418	cells	T025	C0007634
28434980	1433	1437	ADCC	T043	C0003272
28434980	1455	1489	peripheral blood mononuclear cells	T025	C1321301
28434980	1494	1525	engineered natural killer cells	T025	C0022688
28434980	1614	1625	ADCC assays	T059	C0201624
28434980	1645	1649	thaw	T059	C1710378
28434980	1659	1670	pre-labeled	T080	C1708632
28434980	1671	1683	target cells	T025	C0221284
28434980	1687	1698	ADCC assays	T059	C0201624
28434980	1726	1738	cell culture	T059	C0007585
28434980	1743	1755	dye labeling	T059	C0886517
28434980	1805	1810	assay	T059	C1510438
28434980	1834	1851	assay consistency	T080	C0332529
28434980	1856	1866	robustness	T080	C2986815

28051306|t|H2O2 -Responsive Vesicles Integrated with Transcutaneous Patches for Glucose -Mediated Insulin Delivery
28051306|a|A self-regulated "smart" insulin administration system would be highly desirable for diabetes management. Here, a glucose -responsive insulin delivery device, which integrates H2O2 -responsive polymeric vesicles (PVs) with a transcutaneous microneedle -array patch was prepared to achieve a fast response, excellent biocompatibility, and painless administration. The PVs are self-assembled from block copolymer incorporated with polyethylene glycol (PEG) and phenylboronic ester (PBE)- conjugated polyserine (designated mPEG-b-P(Ser-PBE)) and loaded with glucose oxidase (GOx) and insulin. The polymeric vesicles function as both moieties of the glucose sensing element (GOx) and the insulin release actuator to provide basal insulin release as well as promote insulin release in response to hyperglycemic states. In the current study, insulin release responds quickly to elevated glucose and its kinetics can be modulated by adjusting the concentration of GOx loaded into the microneedles. In vivo testing indicates that a single patch can regulate glucose levels effectively with reduced risk of hypoglycemia.
28051306	0	4	H2O2	T121,T130,T197	C0020281
28051306	17	25	Vesicles	T026	C1622418
28051306	42	56	Transcutaneous	T061	C0443325
28051306	57	64	Patches	T122	C1707974
28051306	69	76	Glucose	T109,T121,T123	C0017725
28051306	87	94	Insulin	T116,T121,T125	C0021641
28051306	95	103	Delivery	T169	C1705822
28051306	106	120	self-regulated	T033	C0243095
28051306	129	136	insulin	T116,T121,T125	C0021641
28051306	137	158	administration system	T057	C3242277
28051306	175	184	desirable	T080	C0205556
28051306	189	208	diabetes management	T061	C0948092
28051306	218	225	glucose	T109,T121,T123	C0017725
28051306	238	261	insulin delivery device	T074	C1650879
28051306	280	284	H2O2	T121,T130,T197	C0020281
28051306	297	315	polymeric vesicles	T074	C1720563
28051306	317	320	PVs	T074	C1720563
28051306	329	343	transcutaneous	T061	C0443325
28051306	344	355	microneedle	T074	C0025080
28051306	363	368	patch	T122	C1707974
28051306	395	408	fast response	T201	C0521982
28051306	420	436	biocompatibility	T044	C0596177
28051306	442	450	painless	T169	C0234226
28051306	451	465	administration	T061	C1533734
28051306	471	474	PVs	T074	C1720563
28051306	479	493	self-assembled	T044	C0872376
28051306	499	514	block copolymer	T104	C0596383
28051306	533	552	polyethylene glycol	T109,T121,T122	C0032483
28051306	554	557	PEG	T109,T121,T122	C0032483
28051306	563	582	phenylboronic ester	T109	C0014898
28051306	584	587	PBE	T109	C0014898
28051306	590	600	conjugated	T082	C0522529
28051306	601	611	polyserine	T116	C0163553
28051306	624	641	mPEG-b-P(Ser-PBE)	T122	C0005479
28051306	659	674	glucose oxidase	T116,T126	C0017735
28051306	676	679	GOx	T116,T126	C0017735
28051306	685	692	insulin	T116,T121,T125	C0021641
28051306	698	716	polymeric vesicles	T074	C1720563
28051306	734	742	moieties	T120	C1552018
28051306	750	773	glucose sensing element	T116,T126	C0017735
28051306	775	778	GOx	T116,T126	C0017735
28051306	788	795	insulin	T116,T121,T125	C0021641
28051306	796	803	release	T169	C1283071
28051306	804	812	actuator	T073	C1706706
28051306	824	829	basal	T082	C0205112
28051306	830	837	insulin	T116,T121,T125	C0021641
28051306	838	845	release	T169	C1283071
28051306	865	872	insulin	T116,T121,T125	C0021641
28051306	873	880	release	T169	C1283071
28051306	896	916	hyperglycemic states	T047	C0020456
28051306	940	947	insulin	T116,T121,T125	C0021641
28051306	948	955	release	T169	C1283071
28051306	976	992	elevated glucose	T033	C0495706
28051306	1001	1009	kinetics	T070	C0022702
28051306	1017	1026	modulated	T082	C0443264
28051306	1044	1057	concentration	T081	C1446561
28051306	1061	1064	GOx	T116,T126	C0017735
28051306	1081	1093	microneedles	T074	C0025080
28051306	1095	1102	In vivo	T082	C1515655
28051306	1103	1110	testing	T169	C0039593
28051306	1135	1140	patch	T122	C1707974
28051306	1154	1168	glucose levels	T034	C0428548
28051306	1186	1193	reduced	T080	C0392756
28051306	1194	1198	risk	T078	C0035647
28051306	1202	1214	hypoglycemia	T047	C0020615

28190759|t|Temporal Trends in Sudden Cardiac Death From 1997 to 2010: A Data Linkage Study
28190759|a|Community-wide trends data for sudden cardiac death (SCD) are scarce, unlike widely reported declines in cardiovascular disease (CVD) mortality. Using administrative data, we aimed to examine population-level trends in SCD, stratified by sex, age and prior CVD hospitalisation. Person-linked mortality and hospital morbidity data were used to identify SCD and determine hospitalisation and comorbidity using a 10-year hospitalisation lookback period. Log-linear Poisson regression was used to calculate annual rate changes and rate ratios. In Western Australia, 7160 SCD cases were identified from 1997 to 2010 with males comprising 69%. Overall age-standardised SCD rates decreased by 17% in men and 31% in women from 1997-2001 to 2007-2010. The annual rate reduction was higher in women than men (-4.0%/year versus -2.3%/year; p=0.0039). Significant reductions were observed for 55-69 year-old and 70-84 year-old men and women but not for the 35-54 year-olds. The overall relative risk comparing men to women increased slightly from 2.4 in 1997 to 3.0 in 2010 (trend p=0.0039) but differed across age groups. The relative risk declined in 35-54 year-olds from 5.1 to 3.2 whereas it increased from 2.9 to 3.9 in 55-69 year-olds and 1.9 to 2.3 in 70-84 year-olds. Declining trends in SCD rates were observed in those with and without prior CVD and were similar to CVD mortality trends (-4.9%/year in men and -5.5%/year in women). Trends in rates of SCD fell in middle to older aged men and women, with and without CVD, and mirrored the fall in fatal CVD. Limited improvement in 35-54 year-olds requires further investigation.
28190759	0	15	Temporal Trends	T079	C0030633
28190759	19	39	Sudden Cardiac Death	T046	C0085298
28190759	61	73	Data Linkage	T062	C0242239
28190759	74	79	Study	T062	C2603343
28190759	80	94	Community-wide	T058	C0009485
28190759	95	101	trends	T079	C1521798
28190759	102	106	data	T078	C1511726
28190759	111	131	sudden cardiac death	T046	C0085298
28190759	133	136	SCD	T046	C0085298
28190759	164	172	reported	T058	C0700287
28190759	173	181	declines	T081	C0282251
28190759	185	207	cardiovascular disease	T047	C0007222
28190759	209	212	CVD	T047	C0007222
28190759	214	223	mortality	T081	C0205848
28190759	231	250	administrative data	T078	C1511726
28190759	272	288	population-level	T098	C1257890
28190759	289	295	trends	T079	C1521798
28190759	299	302	SCD	T046	C0085298
28190759	304	314	stratified	T080	C0205363
28190759	318	321	sex	T032	C0079399
28190759	323	326	age	T032	C0001779
28190759	331	336	prior	T079	C0332152
28190759	337	340	CVD	T047	C0007222
28190759	341	356	hospitalisation	T058	C0019993
28190759	358	371	Person-linked	T080	C0205556
28190759	372	381	mortality	T081	C0205848
28190759	386	394	hospital	T073,T093	C0019994
28190759	395	404	morbidity	T081	C0178685
28190759	405	409	data	T078	C1511726
28190759	423	431	identify	T080	C0205396
28190759	432	435	SCD	T046	C0085298
28190759	450	465	hospitalisation	T058	C0019993
28190759	470	481	comorbidity	T078	C0009488
28190759	498	513	hospitalisation	T058	C0019993
28190759	514	529	lookback period	T079	C1948053
28190759	531	541	Log-linear	UnknownType	C0681924
28190759	542	560	Poisson regression	T081	C0032347
28190759	573	582	calculate	T052	C1441506
28190759	583	589	annual	T079	C0332181
28190759	590	594	rate	T081	C1521828
28190759	595	602	changes	T169	C0392747
28190759	607	618	rate ratios	T081	C0456603
28190759	623	640	Western Australia	T083	C0043128
28190759	647	650	SCD	T046	C0085298
28190759	662	672	identified	T080	C0205396
28190759	696	701	males	T032	C0086582
28190759	726	742	age-standardised	T058	C1255664
28190759	743	746	SCD	T046	C0085298
28190759	747	752	rates	T081	C1521828
28190759	753	762	decreased	T081	C0205216
28190759	773	776	men	T098	C0025266
28190759	788	793	women	T098	C0043210
28190759	827	833	annual	T079	C0332181
28190759	834	838	rate	T081	C1521828
28190759	839	848	reduction	T080	C0392756
28190759	853	859	higher	T080	C0205250
28190759	863	868	women	T098	C0043210
28190759	874	877	men	T098	C0025266
28190759	932	942	reductions	T080	C0392756
28190759	948	956	observed	T169	C1441672
28190759	967	975	year-old	T100	C0027362
28190759	986	994	year-old	T100	C0027362
28190759	995	998	men	T098	C0025266
28190759	1003	1008	women	T098	C0043210
28190759	1031	1040	year-olds	T100	C0027362
28190759	1054	1067	relative risk	T081	C0242492
28190759	1078	1081	men	T098	C0025266
28190759	1085	1090	women	T098	C0043210
28190759	1091	1100	increased	T081	C0205217
28190759	1143	1148	trend	T079	C1521798
28190759	1179	1189	age groups	T100	C0027362
28190759	1195	1208	relative risk	T081	C0242492
28190759	1227	1236	year-olds	T100	C0027362
28190759	1264	1273	increased	T081	C0205217
28190759	1299	1308	year-olds	T100	C0027362
28190759	1333	1342	year-olds	T100	C0027362
28190759	1344	1353	Declining	T081	C0282251
28190759	1354	1360	trends	T079	C1521798
28190759	1364	1367	SCD	T046	C0085298
28190759	1368	1373	rates	T081	C1521828
28190759	1379	1387	observed	T169	C1441672
28190759	1414	1419	prior	T079	C0332152
28190759	1420	1423	CVD	T047	C0007222
28190759	1433	1440	similar	T080	C2348205
28190759	1444	1447	CVD	T047	C0007222
28190759	1448	1457	mortality	T081	C0205848
28190759	1458	1464	trends	T079	C1521798
28190759	1480	1483	men	T098	C0025266
28190759	1502	1507	women	T098	C0043210
28190759	1510	1516	Trends	T079	C1521798
28190759	1520	1525	rates	T081	C1521828
28190759	1529	1532	SCD	T046	C0085298
28190759	1557	1561	aged	T032	C0001779
28190759	1562	1565	men	T098	C0025266
28190759	1570	1575	women	T098	C0043210
28190759	1594	1597	CVD	T047	C0007222
28190759	1616	1620	fall	T081	C0205216
28190759	1624	1629	fatal	T080	C1302234
28190759	1630	1633	CVD	T047	C0007222
28190759	1635	1654	Limited improvement	T077	C2986411
28190759	1664	1673	year-olds	T100	C0027362
28190759	1674	1682	requires	T169	C1514873
28190759	1691	1704	investigation	T058	C0220825

28331599|t|Species distribution modeling and molecular markers suggest longitudinal range shifts and cryptic northern refugia of the typical calcareous grassland species Hippocrepis comosa (horseshoe vetch)
28331599|a|Calcareous grasslands belong to the most diverse, endangered habitats in Europe, but there is still insufficient information about the origin of the plant species related to these grasslands. In order to illuminate this question, we chose for our study the representative grassland species Hippocrepis comosa (Horseshoe vetch). Based on species distribution modeling and molecular markers, we identified the glacial refugia and the postglacial migration routes of the species to Central Europe. We clearly demonstrate that H. comosa followed a latitudinal and due to its oceanity also a longitudinal gradient during the last glacial maximum (LGM), restricting the species to southern refugia situated on the Peninsulas of Iberia, the Balkans, and Italy during the last glaciation. However, we also found evidence for cryptic northern refugia in the UK, the Alps, and Central Germany. Both species distribution modeling and molecular markers underline that refugia of temperate, oceanic species such as H. comosa must not be exclusively located in southern but also in western of parts of Europe. The analysis showed a distinct separation of the southern refugia into a western cluster embracing Iberia and an eastern group including the Balkans and Italy, which determined the postglacial recolonization of Central Europe. At the end of the LGM, H. comosa seems to have expanded from the Iberian refugium, to Central and Northern Europe, including the UK, Belgium, and Germany.
28331599	0	7	Species	T185	C1705920
28331599	8	20	distribution	T169	C1704711
28331599	21	29	modeling	T062	C0870071
28331599	34	51	molecular markers	T201	C0005516
28331599	60	85	longitudinal range shifts	T169	C0333051
28331599	90	114	cryptic northern refugia	T070	C4042836
28331599	130	150	calcareous grassland	T082	C0442534
28331599	151	158	species	T185	C1705920
28331599	159	177	Hippocrepis comosa	T002	C1939912
28331599	179	194	horseshoe vetch	T002	C1939912
28331599	196	217	Calcareous grasslands	T082	C0442534
28331599	237	244	diverse	T080	C1880371
28331599	246	265	endangered habitats	T082	C0871648
28331599	269	275	Europe	T083	C0015176
28331599	309	320	information	T078	C1533716
28331599	331	337	origin	T079	C0439659
28331599	345	350	plant	T002	C0032098
28331599	351	358	species	T185	C1705920
28331599	376	386	grasslands	T082	C0442534
28331599	468	477	grassland	T082	C0442534
28331599	478	485	species	T185	C1705920
28331599	486	504	Hippocrepis comosa	T002	C1939912
28331599	506	521	Horseshoe vetch	T002	C1939912
28331599	533	540	species	T185	C1705920
28331599	541	553	distribution	T169	C1704711
28331599	554	562	modeling	T062	C0870071
28331599	567	584	molecular markers	T201	C0005516
28331599	604	619	glacial refugia	T070	C4042836
28331599	628	656	postglacial migration routes	T082	C1254362
28331599	664	671	species	T185	C1705920
28331599	675	689	Central Europe	T083	C0682369
28331599	719	728	H. comosa	T002	C1939912
28331599	740	751	latitudinal	T080	C0205556
28331599	767	775	oceanity	T080	C0205556
28331599	783	804	longitudinal gradient	T081	C0812409
28331599	816	836	last glacial maximum	T079	C1948053
28331599	838	841	LGM	T079	C1948053
28331599	844	855	restricting	T169	C0443288
28331599	860	867	species	T185	C1705920
28331599	871	887	southern refugia	T070	C4042836
28331599	904	924	Peninsulas of Iberia	T083	C3829576
28331599	930	937	Balkans	T083	C3494471
28331599	943	948	Italy	T083	C0022277
28331599	960	975	last glaciation	T070	C1254365
28331599	1000	1008	evidence	T078	C3887511
28331599	1013	1037	cryptic northern refugia	T070	C4042836
28331599	1045	1047	UK	T083	C0041700
28331599	1049	1057	the Alps	T083	C0017446
28331599	1063	1078	Central Germany	T083	C0017480
28331599	1085	1092	species	T185	C1705920
28331599	1093	1105	distribution	T169	C1704711
28331599	1106	1114	modeling	T062	C0870071
28331599	1119	1136	molecular markers	T201	C0005516
28331599	1152	1159	refugia	T070	C4042836
28331599	1174	1189	oceanic species	T185	C1705920
28331599	1198	1207	H. comosa	T002	C1939912
28331599	1243	1251	southern	T083	C0037724
28331599	1264	1290	western of parts of Europe	T083	C0043129
28331599	1296	1304	analysis	T062	C0936012
28331599	1323	1333	separation	T080	C0443299
28331599	1341	1357	southern refugia	T070	C4042836
28331599	1365	1380	western cluster	T081	C1704332
28331599	1391	1397	Iberia	T083	C3829576
28331599	1405	1412	eastern	T082	C1707877
28331599	1413	1418	group	T078	C0441833
28331599	1433	1440	Balkans	T083	C3494471
28331599	1445	1450	Italy	T083	C0022277
28331599	1473	1499	postglacial recolonization	T070	C1254365
28331599	1503	1517	Central Europe	T083	C0682369
28331599	1537	1540	LGM	T079	C1948053
28331599	1542	1551	H. comosa	T002	C1939912
28331599	1584	1600	Iberian refugium	T083	C3829576
28331599	1605	1612	Central	T083	C0682369
28331599	1617	1632	Northern Europe	T083	C0028413
28331599	1648	1650	UK	T083	C0041700
28331599	1652	1659	Belgium	T083	C0004950
28331599	1665	1672	Germany	T083	C0017480

27671016|t|Size effect of Au / PAMAM contrast agent on CT imaging of reticuloendothelial system and tumor tissue
27671016|a|Polyamidoamine (PAMAM)-entrapped Au nanoparticles were synthesized with distinct sizes to figure out the size effect of Au -based contrast agent on CT imaging of passively targeted tissues. Au / PAMAM nanoparticles were first synthesized with narrow distribution of particles size of 22.2 ± 3.1, 54.2 ± 3.7, and 104.9 ± 4.7 nm in diameters. Size effect leads no significant difference on X-ray attenuation when Au / PAMAM was ≤0.05 mol/L. For CT imaging of a tumor model, small Au / PAMAM were more easily internalized via endocytosis in the liver, leading to more obviously enhanced contrast. Similarly, contrast agents with small sizes were more effective in tumor imaging because of the enhanced permeability and retention effect. Overall, the particle size of Au / PAMAM heavily affected the efficiency of CT enhancement in imaging RES and tumors.
27671016	0	11	Size effect	T081	C0814843
27671016	15	17	Au	T121,T196	C0018026
27671016	20	25	PAMAM	T109	C1609342
27671016	26	40	contrast agent	T130	C0009924
27671016	44	54	CT imaging	T060	C0040405
27671016	58	84	reticuloendothelial system	T022	C0035287
27671016	89	101	tumor tissue	T024	C0475358
27671016	102	116	Polyamidoamine	T109	C1609342
27671016	118	123	PAMAM	T109	C1609342
27671016	135	137	Au	T121,T196	C0018026
27671016	138	151	nanoparticles	T073	C1721060
27671016	174	188	distinct sizes	T081	C0030608
27671016	207	218	size effect	T081	C0814843
27671016	222	224	Au	T121,T196	C0018026
27671016	232	246	contrast agent	T130	C0009924
27671016	250	260	CT imaging	T060	C0040405
27671016	274	282	targeted	T043	C0599894
27671016	283	290	tissues	T024	C0475358
27671016	292	294	Au	T121,T196	C0018026
27671016	297	302	PAMAM	T109	C1609342
27671016	303	316	nanoparticles	T073	C1721060
27671016	328	339	synthesized	T052	C1883254
27671016	352	364	distribution	T082	C0037775
27671016	368	382	particles size	T081	C0030608
27671016	443	454	Size effect	T081	C0814843
27671016	461	486	no significant difference	T033	C3842396
27671016	490	495	X-ray	T060	C1306645
27671016	496	507	attenuation	T052	C0599946
27671016	513	515	Au	T121,T196	C0018026
27671016	518	523	PAMAM	T109	C1609342
27671016	545	555	CT imaging	T060	C0040405
27671016	561	572	tumor model	T024	C0475358
27671016	580	582	Au	T121,T196	C0018026
27671016	585	590	PAMAM	T109	C1609342
27671016	625	636	endocytosis	T043	C0014139
27671016	644	649	liver	T023	C0023884
27671016	677	694	enhanced contrast	T060	C1512095
27671016	707	722	contrast agents	T130	C0009924
27671016	728	739	small sizes	T033	C0748864
27671016	763	768	tumor	T024	C0475358
27671016	769	776	imaging	T060	C0011923
27671016	792	813	enhanced permeability	T043	C0007605
27671016	818	834	retention effect	T043	C1753315
27671016	849	862	particle size	T081	C0030608
27671016	866	868	Au	T121,T196	C0018026
27671016	871	876	PAMAM	T109	C1609342
27671016	898	908	efficiency	T081	C0013682
27671016	912	914	CT	T074	C1139717
27671016	915	926	enhancement	T080	C2985747
27671016	930	937	imaging	T060	C0011923
27671016	938	941	RES	T022	C0035287
27671016	946	952	tumors	T024	C0475358

28334784|t|Testing the Ret and Sema3d genetic interaction in mouse enteric nervous system development
28334784|a|For most multigenic disorders, clinical manifestation (penetrance) and presentation (expressivity) are likely to be an outcome of genetic interaction between multiple susceptibility genes. Here, using gene knockouts in mice we evaluated genetic interaction between loss of Ret and loss of Sema3d, two Hirschsprung disease susceptibility genes. We intercrossed Ret and Sema3d double null heterozygotes to generate mice with the nine possible genotypes and assessed survival by counting various genotypes, myenteric plexus presence by acetylcholinesterase staining and embryonic day 12.5 (E12.5) intestine transcriptome by RNA-sequencing. Survival rates of Ret wildtype, null heterozygote and null homozygote mice at E12.5, birth and weaning were not influenced by the genotypes at Sema3d locus and vice-versa. Loss of myenteric plexus was observed only in all Ret null homozygotes, irrespective of the genotypes at Sema3d locus, and Sema3d null heterozygote and homozygote mice had normal intestinal innervation. As compared to wildtype mice intestinal gene expression, loss of Ret in null homozygotes led to differential expression of ∼300 genes, whereas loss of Sema3d in null homozygotes had no major consequence and there was no evidence supporting major interaction between the two genes influencing intestine transcriptome. Overall, given the null alleles and phenotypic assays used, we did not find evidence for genetic interaction between Ret and Sema3d affecting survival, presence of myenteric plexus or intestine transcriptome.
28334784	12	15	Ret	T028	C0694890
28334784	20	26	Sema3d	T028	C1419945
28334784	27	46	genetic interaction	T045	C0596610
28334784	50	55	mouse	T015	C0025929
28334784	56	90	enteric nervous system development	T042	C1522995
28334784	100	120	multigenic disorders	T047	C0567439
28334784	122	144	clinical manifestation	T080	C1280464
28334784	146	156	penetrance	T081	C0524899
28334784	162	174	presentation	T078	C0449450
28334784	176	188	expressivity	T078	C0449450
28334784	210	217	outcome	T169	C1274040
28334784	221	240	genetic interaction	T045	C0596610
28334784	258	278	susceptibility genes	T028	C0919542
28334784	292	306	gene knockouts	UnknownType	C0814039
28334784	310	314	mice	T015	C0025929
28334784	328	347	genetic interaction	T045	C0596610
28334784	364	367	Ret	T028	C0694890
28334784	380	386	Sema3d	T028	C1419945
28334784	392	412	Hirschsprung disease	T019,T047	C0019569
28334784	413	433	susceptibility genes	T028	C0919542
28334784	451	454	Ret	T028	C0694890
28334784	459	465	Sema3d	T028	C1419945
28334784	495	508	generate mice	T169	C0205245
28334784	532	541	genotypes	T032	C0017431
28334784	546	563	assessed survival	T052	C1516048
28334784	567	593	counting various genotypes	T059	C1285573
28334784	595	611	myenteric plexus	T023	C0027028
28334784	624	653	acetylcholinesterase staining	T059	C0201829
28334784	658	676	embryonic day 12.5	UnknownType	C0815083
28334784	678	683	E12.5	UnknownType	C0815083
28334784	685	708	intestine transcriptome	T086	C3178810
28334784	712	726	RNA-sequencing	T086	C0162327
28334784	728	742	Survival rates	T081	C0038954
28334784	746	749	Ret	T028	C0694890
28334784	750	758	wildtype	T028	C0694890
28334784	798	802	mice	T015	C0025929
28334784	806	811	E12.5	UnknownType	C0815083
28334784	813	818	birth	T040	C0005615
28334784	823	830	weaning	T033	C0043084
28334784	858	867	genotypes	T032	C0017431
28334784	871	877	Sema3d	T028	C1419945
28334784	878	883	locus	T082	C1708726
28334784	908	924	myenteric plexus	T023	C0027028
28334784	950	953	Ret	T028	C0694890
28334784	992	1001	genotypes	T032	C0017431
28334784	1005	1011	Sema3d	T028	C1419945
28334784	1012	1017	locus	T082	C1708726
28334784	1023	1029	Sema3d	T028	C1419945
28334784	1035	1047	heterozygote	T032	C0019425
28334784	1052	1067	homozygote mice	T032	C0019904
28334784	1079	1101	intestinal innervation	T080	C1619351
28334784	1118	1142	wildtype mice intestinal	T028	C1883559
28334784	1143	1158	gene expression	T045	C0017262
28334784	1168	1171	Ret	T028	C0694890
28334784	1212	1237	expression of ∼300 genes,	T045	C0017262
28334784	1254	1260	Sema3d	T028	C1419945
28334784	1320	1331	no evidence	T080	C0332125
28334784	1349	1382	interaction between the two genes	T045	C0596610
28334784	1395	1418	intestine transcriptome	T086	C3178810
28334784	1439	1451	null alleles	T049	C2985437
28334784	1456	1473	phenotypic assays	T059	C1285572
28334784	1487	1504	not find evidence	T080	C0332125
28334784	1509	1528	genetic interaction	T045	C0596610
28334784	1537	1540	Ret	T028	C0694890
28334784	1545	1551	Sema3d	T028	C1419945
28334784	1584	1600	myenteric plexus	T023	C0027028
28334784	1604	1627	intestine transcriptome	T086	C3178810

28013377|t|Hospital clowning: a paediatrician's view
28013377|a|This study investigates the current position of hospital clowns from the perspective of paediatricians and paediatric residents. A total of 14 attending paediatricians and paediatric residents participated in two focus group sessions. Data were analysed using Atlas.ti 5.0. In general, physicians reported positive experiences regarding the interaction between hospital clowns and paediatric patients on the ward. Physicians were more interested in research on children's perception of hospital clowns than in research on the clinical efficacy of hospital clowning. No direct collaboration between physicians and hospital clowns was reported. However, physicians proposed conditions which may streamline their encounters with hospital clowns such as clear communication prior to hospital clown visits, and the condition that visits do not impede medical interventions. Overall, paediatricians and paediatric residents view the positive impact on paediatric patients as the most important aspect of hospital clown visits, rather than the clinical efficacy of hospital clowning. In light of the growing number of hospital clowns worldwide, this article provides recommendations for arranging their encounters with paediatricians and paediatric residents to maintain optimal health care. What is known: • Previous studies show a clinically significant pain - and anxiety - reducing effect of hospital clowning in paediatric patients admitted to hospitals or undergoing (invasive) medical procedures. • In general, paediatricians have positive ideas about hospital clowns, aside from personal prejudices. What is new: • This novel study gives deeper insight into day-to-day interaction between paediatricians and hospital clowns on the ward. • This study provides recommendations for clinical practice to arrange encounters between physicians and hospital clowns during hospital clown visits.
28013377	0	17	Hospital clowning	T073,T093	C0018704
28013377	21	36	paediatrician's	T097	C0237433
28013377	37	41	view	T041	C0030971
28013377	47	52	study	T062	C0681814
28013377	53	65	investigates	T169	C1292732
28013377	70	77	current	T079	C0521116
28013377	90	105	hospital clowns	T097	C0335094
28013377	115	126	perspective	T041	C0030971
28013377	130	144	paediatricians	T097	C0237433
28013377	149	169	paediatric residents	UnknownType	C0259967
28013377	173	178	total	T080	C0439810
28013377	185	209	attending paediatricians	T097	C0237433
28013377	214	234	paediatric residents	UnknownType	C0259967
28013377	235	247	participated	T169	C0679823
28013377	255	275	focus group sessions	T077	C1883017
28013377	277	281	Data	T078	C1511726
28013377	287	295	analysed	T062	C0936012
28013377	302	314	Atlas.ti 5.0	T073,T170	C0037585
28013377	319	326	general	T082	C0205246
28013377	328	338	physicians	T097	C0031831
28013377	339	347	reported	T170	C0684224
28013377	348	356	positive	T033	C1446409
28013377	357	368	experiences	T041	C0596545
28013377	383	394	interaction	T033	C0037420
28013377	403	418	hospital clowns	T097	C0335094
28013377	423	442	paediatric patients	T101	C0030705
28013377	450	454	ward	T073,T093	C1305702
28013377	456	466	Physicians	T097	C0031831
28013377	477	487	interested	T041	C0543488
28013377	491	499	research	T062	C0035168
28013377	503	524	children's perception	T041	C3825851
28013377	528	543	hospital clowns	T097	C0335094
28013377	552	560	research	T062	C0035168
28013377	568	585	clinical efficacy	T080	C3850123
28013377	589	606	hospital clowning	T073,T093	C0018704
28013377	608	617	No direct	T080	C0205556
28013377	618	631	collaboration	T054	C0282116
28013377	640	650	physicians	T097	C0031831
28013377	655	670	hospital clowns	T097	C0335094
28013377	675	683	reported	T170	C0684224
28013377	694	704	physicians	T097	C0031831
28013377	705	713	proposed	T080	C1553874
28013377	714	724	conditions	T080	C0348080
28013377	735	745	streamline	T080	C0442799
28013377	752	762	encounters	T053	C1947978
28013377	768	783	hospital clowns	T097	C0335094
28013377	792	811	clear communication	T054	C0009452
28013377	812	817	prior	T079	C0332152
28013377	821	835	hospital clown	T097	C0335094
28013377	836	842	visits	T058	C1512346
28013377	852	861	condition	T080	C0348080
28013377	867	873	visits	T053	C0545082
28013377	881	887	impede	T080	C0332454
28013377	888	909	medical interventions	T061	C0184661
28013377	911	918	Overall	T080	C1561607
28013377	920	934	paediatricians	T097	C0237433
28013377	939	959	paediatric residents	UnknownType	C0259967
28013377	960	964	view	T041	C0030971
28013377	969	977	positive	T033	C1446409
28013377	978	984	impact	T080	C4049986
28013377	988	1007	paediatric patients	T101	C0030705
28013377	1020	1029	important	T080	C3898777
28013377	1030	1036	aspect	T080	C1879746
28013377	1040	1054	hospital clown	T097	C0335094
28013377	1055	1061	visits	T058	C1512346
28013377	1079	1096	clinical efficacy	T080	C3850123
28013377	1100	1117	hospital clowning	T073,T093	C0018704
28013377	1153	1168	hospital clowns	T097	C0335094
28013377	1169	1178	worldwide	T098	C2700280
28013377	1185	1192	article	T170	C1706852
28013377	1202	1217	recommendations	T078	C0034866
28013377	1238	1248	encounters	T053	C1947978
28013377	1254	1268	paediatricians	T097	C0237433
28013377	1273	1293	paediatric residents	UnknownType	C0259967
28013377	1297	1305	maintain	T052	C0024501
28013377	1306	1313	optimal	T080	C2698651
28013377	1314	1325	health care	T058	C0086388
28013377	1344	1352	Previous	T079	C0205156
28013377	1353	1360	studies	T062	C0681814
28013377	1368	1390	clinically significant	T078	C0750502
28013377	1391	1395	pain	T184	C0030193
28013377	1402	1409	anxiety	T033	C0003467
28013377	1412	1427	reducing effect	T080	C1280500
28013377	1431	1448	hospital clowning	T073,T093	C0018704
28013377	1452	1471	paediatric patients	T101	C0030705
28013377	1472	1493	admitted to hospitals	T058	C0184666
28013377	1497	1507	undergoing	T080	C0205556
28013377	1509	1517	invasive	T080	C0205281
28013377	1519	1537	medical procedures	T058	C0199171
28013377	1553	1567	paediatricians	T097	C0237433
28013377	1573	1581	positive	T033	C1446409
28013377	1582	1587	ideas	T078	C1254370
28013377	1594	1609	hospital clowns	T097	C0335094
28013377	1622	1641	personal prejudices	T055	C0033023
28013377	1663	1668	novel	T080	C0205314
28013377	1669	1674	study	T062	C0681814
28013377	1688	1695	insight	T041	C0233820
28013377	1701	1711	day-to-day	T079	C1254367
28013377	1712	1723	interaction	T033	C0037420
28013377	1732	1746	paediatricians	T097	C0237433
28013377	1751	1766	hospital clowns	T097	C0335094
28013377	1774	1778	ward	T073,T093	C1305702
28013377	1787	1792	study	T062	C0681814
28013377	1802	1817	recommendations	T078	C0034866
28013377	1822	1839	clinical practice	T170	C0282451
28013377	1851	1861	encounters	T053	C1947978
28013377	1870	1880	physicians	T097	C0031831
28013377	1885	1900	hospital clowns	T097	C0335094
28013377	1908	1922	hospital clown	T097	C0335094
28013377	1923	1929	visits	T058	C1512346

27529135|t|Effect of Protein Repetitiveness on Protein-Protein Interaction Prediction Results Using Support Vector Machines
27529135|a|There are many computational approaches to predict the protein-protein interactions using support vector machines (SVMs) with high performance. In fact, performance of currently reported methods are significantly over-estimated and affected by the object repetitiveness in the datasets used. To study the effect of object repetitiveness of datasets on predicting results. We present novel methods to construct different positive datasets with or without repeating proteins using graph maximum matching in the protein-protein interaction datasets and corresponding series of negative datasets with different proteins repetitiveness are constructed using graph adjacency matrix. The relationship between the SVM prediction results and the repeated proteins (repeat numbers and repeat rates) and the distributions of repeated proteins in the datasets are analyzed. Protein repetitiveness of positive and negative datasets can affect the prediction result: high protein repetitiveness of positive or negative datasets yield high performance prediction result. This indicate that dealing with object repetitiveness of datasets is a key issue in protein-protein interactions prediction using SVMs since real world data contain certain degrees of repeat proteins.
27529135	0	6	Effect	T080	C1280500
27529135	10	17	Protein	T116,T123	C0033684
27529135	18	32	Repetitiveness	T169	C0205341
27529135	36	63	Protein-Protein Interaction	T044	C0872079
27529135	64	74	Prediction	T078	C0681842
27529135	75	82	Results	T169	C1274040
27529135	89	112	Support Vector Machines	T081	C2699740
27529135	128	152	computational approaches	T062	C1516769
27529135	168	196	protein-protein interactions	T044	C0872079
27529135	203	226	support vector machines	T081	C2699740
27529135	228	232	SVMs	T081	C2699740
27529135	300	307	methods	T170	C0025663
27529135	368	382	repetitiveness	T169	C0205341
27529135	390	398	datasets	T170	C0150098
27529135	408	413	study	T062	C2603343
27529135	435	449	repetitiveness	T169	C0205341
27529135	453	461	datasets	T170	C0150098
27529135	465	475	predicting	T078	C0681842
27529135	476	483	results	T169	C1274040
27529135	502	509	methods	T170	C0025663
27529135	533	541	positive	T033	C1446409
27529135	542	550	datasets	T170	C0150098
27529135	577	585	proteins	T116,T123	C0033684
27529135	592	597	graph	T170	C0681493
27529135	622	649	protein-protein interaction	T044	C0872079
27529135	650	658	datasets	T170	C0150098
27529135	687	695	negative	T033	C0205160
27529135	696	704	datasets	T170	C0150098
27529135	720	728	proteins	T116,T123	C0033684
27529135	729	743	repetitiveness	T169	C0205341
27529135	766	771	graph	T170	C0681493
27529135	772	788	adjacency matrix	T082	C1879629
27529135	794	806	relationship	T080	C0439849
27529135	819	822	SVM	T081	C2699740
27529135	823	833	prediction	T078	C0681842
27529135	834	841	results	T169	C1274040
27529135	850	858	repeated	T169	C0205341
27529135	859	867	proteins	T116,T123	C0033684
27529135	910	923	distributions	T169	C1704711
27529135	927	935	repeated	T169	C0205341
27529135	936	944	proteins	T116,T123	C0033684
27529135	952	960	datasets	T170	C0150098
27529135	975	982	Protein	T116,T123	C0033684
27529135	983	997	repetitiveness	T169	C0205341
27529135	1001	1009	positive	T033	C1446409
27529135	1014	1022	negative	T033	C0205160
27529135	1023	1031	datasets	T170	C0150098
27529135	1047	1057	prediction	T078	C0681842
27529135	1058	1064	result	T169	C1274040
27529135	1071	1078	protein	T116,T123	C0033684
27529135	1079	1093	repetitiveness	T169	C0205341
27529135	1097	1105	positive	T033	C1446409
27529135	1109	1117	negative	T033	C0205160
27529135	1118	1126	datasets	T170	C0150098
27529135	1161	1167	result	T169	C1274040
27529135	1208	1222	repetitiveness	T169	C0205341
27529135	1226	1234	datasets	T170	C0150098
27529135	1253	1281	protein-protein interactions	T044	C0872079
27529135	1282	1292	prediction	T078	C0681842
27529135	1299	1303	SVMs	T081	C2699740
27529135	1321	1325	data	T078	C1511726
27529135	1353	1359	repeat	T169	C0205341
27529135	1360	1368	proteins	T116,T123	C0033684

28358140|t|A pilot study on transient ischemic stroke induced with endothelin-1 in the rhesus monkeys
28358140|a|Endothelin-1 (ET-1), a vasoconstrictor, has recently been used to induce focal ischemia in rodents and marmoset monkeys. The rhesus monkey, however, has numerous advantages to the rodent and marmoset that make it a superior and irreplaceable animal model for studying stroke in the brain. In the present study, after mapping the preferred hand representation in two healthy male monkeys with intracortical micro-stimulation, ET-1 was microinjected into the contralateral motor cortex (M1) to its preferred hand. The monkeys had been trained in three manual dexterity tasks before the microinjection and were tested for these tasks following the ET-1 injection. Brain Magnetic Resonance Imaging scans were performed 1, 7, 14 and 28 days post ischemia. It was found that ET-1 impaired the manual dexterity of the monkeys in the vertical slot and rotating Brinkman board tasks 3-8 days after the injection. Brain imaging found that severe edema was present 7 days after the focal ischemia. This data suggest that ET-1 can induce transient ischemic stroke in rhesus monkey and that ET-1 induced focal ischemia in non-human primates is a potential model to study the mechanism of stroke and brain repair after stroke.
28358140	17	42	transient ischemic stroke	T047	C0007787
28358140	56	68	endothelin-1	T116,T123	C0079281
28358140	76	90	rhesus monkeys	T015	C0024400
28358140	91	103	Endothelin-1	T116,T123	C0079281
28358140	105	109	ET-1	T116,T123	C0079281
28358140	114	129	vasoconstrictor	T121	C0042397
28358140	164	178	focal ischemia	T047	C0007786
28358140	182	189	rodents	T015	C0035804
28358140	194	210	marmoset monkeys	T015	C0006764
28358140	216	229	rhesus monkey	T015	C0024400
28358140	271	277	rodent	T015	C0035804
28358140	282	290	marmoset	T015	C0006764
28358140	333	345	animal model	T008	C0599779
28358140	359	378	stroke in the brain	T047	C3844825
28358140	408	415	mapping	T052	C1283195
28358140	430	434	hand	T023	C0018563
28358140	435	449	representation	T052	C1882932
28358140	457	464	healthy	T080	C3898900
28358140	465	469	male	T032	C0086582
28358140	470	477	monkeys	T015	C0026447
28358140	516	520	ET-1	T116,T123	C0079281
28358140	525	538	microinjected	T061	C0025991
28358140	548	561	contralateral	T082	C0441988
28358140	562	574	motor cortex	T029	C0026607
28358140	576	578	M1	T029	C0026607
28358140	587	596	preferred	T078	C0558295
28358140	597	601	hand	T023	C0018563
28358140	607	614	monkeys	T015	C0026447
28358140	624	631	trained	T080	C2673163
28358140	641	657	manual dexterity	T033	C0565699
28358140	675	689	microinjection	T061	C0025991
28358140	736	740	ET-1	T116,T123	C0079281
28358140	741	750	injection	T061	C0021485
28358140	752	790	Brain Magnetic Resonance Imaging scans	T060	C0412675
28358140	832	840	ischemia	T047	C0007786
28358140	860	864	ET-1	T116,T123	C0079281
28358140	878	894	manual dexterity	T033	C0565699
28358140	902	909	monkeys	T015	C0026447
28358140	935	964	rotating Brinkman board tasks	T058	C1160858
28358140	984	993	injection	T061	C0021485
28358140	995	1008	Brain imaging	T060	C0203860
28358140	1020	1026	severe	T080	C0205082
28358140	1027	1032	edema	T184	C0013604
28358140	1062	1076	focal ischemia	T047	C0007786
28358140	1101	1105	ET-1	T116,T123	C0079281
28358140	1117	1142	transient ischemic stroke	T047	C0007787
28358140	1146	1159	rhesus monkey	T015	C0024400
28358140	1169	1173	ET-1	T116,T123	C0079281
28358140	1182	1196	focal ischemia	T047	C0007786
28358140	1200	1218	non-human primates	T015	C3687508
28358140	1266	1272	stroke	T047	C3844825
28358140	1277	1289	brain repair	T061	C0161849
28358140	1296	1302	stroke	T047	C3844825

28087491|t|Dynamics of bacterial class Bacilli in the deepest valley lake of Kashmir -the Manasbal Lake
28087491|a|In recognition of the importance of bacteria as ecological indicators of the aquatic systems a comprehensive and systematic analysis was carried out on Manasbal Lake, the deepest spring fed valley lake of Kashmir. The main objective envisaged was to analyze bacterial community composition (BCC) and for this purpose systematic and regular sampling of waters from ten different sampling stations, predetermined in the Lake according to differences in degree of human interference and also as zones of special ecological interests were selected. The isolated species were identified according to Bergey's Manual specification by examining their micro and macro morphological characteristics and biochemical characteristics on different culture media. Further confirmation was done by sequencing the 16s rRNA gene by using universal bacterial primers 27F and 1429R. From all the sampling stations the class Bacilli showed a maximum relative abundance with a contribution of 16 bacterial species. The whole process resulted in the identification of Bacillus aerius, Bacillus altitudinis, Bacillus anthracis, Bacillus cereus, Bacillus ginsengisoli, Bacillus pumilus, Bacillus safensis, Bacillus stratosphericus, Bacillus subtilis, Bacillus tequilensis, Bacillus thermocopriae, Bacillus thuringiensis, Brevibacillus agri strain, Lysinibacillus boronitolerans, Lysinibacillus pakistanensis and Lysinibacillus sphaericus.
28087491	0	8	Dynamics	T070	C3826426
28087491	12	21	bacterial	T080	C0521009
28087491	22	35	class Bacilli	T007	C1040746
28087491	43	62	deepest valley lake	T083	C0337049
28087491	66	73	Kashmir	UnknownType	C0681784
28087491	79	92	Manasbal Lake	T083	C0337049
28087491	129	137	bacteria	T007	C0004611
28087491	141	162	ecological indicators	T130	C0021212
28087491	170	185	aquatic systems	T070	C0162358
28087491	188	225	comprehensive and systematic analysis	T062	C0936012
28087491	245	258	Manasbal Lake	T083	C0337049
28087491	264	294	deepest spring fed valley lake	T083	C0337049
28087491	298	305	Kashmir	UnknownType	C0681784
28087491	343	350	analyze	T062	C0936012
28087491	351	382	bacterial community composition	T080	C2936393
28087491	384	387	BCC	T080	C2936393
28087491	410	420	systematic	T081	C1710275
28087491	425	451	regular sampling of waters	T057	C0597681
28087491	445	451	waters	T121,T197	C0043047
28087491	471	488	sampling stations	T082	C0449705
28087491	511	515	Lake	T083	C0337049
28087491	544	572	degree of human interference	T080	C0205556
28087491	585	590	zones	T082	C1710706
28087491	602	622	ecological interests	T078	C1254370
28087491	642	650	isolated	T169	C0205409
28087491	651	658	species	T185	C1705920
28087491	664	674	identified	T080	C0205396
28087491	688	717	Bergey's Manual specification	T170	C0282574
28087491	737	782	micro and macro morphological characteristics	T080	C1521970
28087491	787	814	biochemical characteristics	T080	C1521970
28087491	828	841	culture media	T130	C0010454
28087491	851	863	confirmation	T033	C0750484
28087491	876	886	sequencing	T169	C1561491
28087491	891	904	16s rRNA gene	T028	C0035899
28087491	914	941	universal bacterial primers	T114	C0073429
28087491	942	945	27F	T114	C0073429
28087491	950	955	1429R	T114	C0073429
28087491	970	987	sampling stations	T082	C0449705
28087491	992	1005	class Bacilli	T007	C1040746
28087491	1015	1022	maximum	T081	C0806909
28087491	1023	1041	relative abundance	T080	C2346714
28087491	1049	1061	contribution	T052	C1880177
28087491	1068	1085	bacterial species	T185	C1705920
28087491	1097	1104	process	T067	C1522240
28087491	1121	1135	identification	T080	C0205396
28087491	1139	1154	Bacillus aerius	T007	C2617064
28087491	1156	1176	Bacillus altitudinis	T007	C2617063
28087491	1178	1196	Bacillus anthracis	T007	C0004589
28087491	1198	1213	Bacillus cereus	T007	C0004590
28087491	1215	1236	Bacillus ginsengisoli	T007	C3717612
28087491	1238	1254	Bacillus pumilus	T007	C0314874
28087491	1256	1273	Bacillus safensis	T007	C2654376
28087491	1275	1299	Bacillus stratosphericus	T007	C2617062
28087491	1301	1318	Bacillus subtilis	T007	C0004595
28087491	1320	1340	Bacillus tequilensis	T007	C1462983
28087491	1342	1364	Bacillus thermocopriae	T007	C3721500
28087491	1366	1388	Bacillus thuringiensis	T007	C0004597
28087491	1390	1415	Brevibacillus agri strain	T007	C1015757
28087491	1417	1446	Lysinibacillus boronitolerans	T007	C1664577
28087491	1448	1476	Lysinibacillus pakistanensis	T007	C3557569
28087491	1481	1506	Lysinibacillus sphaericus	T007	C0314884

28235120|t|Prospective Evaluation of Opioid Consumption After Distal Radius Fracture Repair Surgery
28235120|a|Pain management and opioid consumption after distal radius fracture (DRF) open reduction and internal fixation (ORIF) are highly variable and poorly understood. To optimize postoperative opioid dosage and better understand opioid consumption patterns after DRF - ORIF, we conducted a prospective study with the hypothesis that opioid consumption would increase with worsening fracture classification and various patient demographics. All patients who underwent DRF - ORIF were consecutively enrolled over a 6-month period. Information collected included patient demographics, fracture type, anesthesia type, amount and type of opioid prescribed, number of pills taken, reason for stopping, and adverse events. Statistical analysis was performed. Ninety-eight patients (79 female, 19 male) were eligible for the study. Mean age was 58 years. Of the 98 patients, 45 received general anesthesia, and 53 received regional anesthesia with a single-shot peripheral nerve block. Mean opioid consumption (morphine equivalence) over a mean of 4.8 postoperative days (range, 0-16 days) was 58.5 mg (range, 0-280 mg). There were no significant differences in opioid consumption between the general and regional anesthesia groups. Mean opioid consumption for the 3 fracture-type groups (AO/OTA [Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association] classification) was 57.7 mg (class A), 60.3 mg (class B), and 62.0 mg (class C). Demographic analysis revealed an inverse relationship between age and opioid use. Similarly, there was a trend toward more opioid consumption among self-pay and Medicaid patients. Opioid consumption after DRF - ORIF was equivalent for general and regional anesthesia. A significant relationship was found between increasing age and decreasing opioid consumption. Worsening fracture classification and self-payment / Medicaid payment trended toward increasing opioid consumption. Mean overall opioid consumption (morphine equivalence) was 58.5 mg, or 14.6 pills of oxycodone/acetaminophen 5/325 mg. Surgeons should take these findings into account when optimizing opioid prescribing after DRF repair.
28235120	12	22	Evaluation	T058	C0220825
28235120	26	44	Opioid Consumption	T048	C0240602
28235120	51	73	Distal Radius Fracture	T037	C0435585
28235120	74	88	Repair Surgery	T061	C0543467
28235120	89	104	Pain management	T061	C0002766
28235120	109	127	opioid consumption	T048	C0240602
28235120	134	156	distal radius fracture	T037	C0435585
28235120	158	161	DRF	T037	C0435585
28235120	163	206	open reduction and internal fixation (ORIF)	T061	C0747060
28235120	253	261	optimize	T061	C1273380
28235120	262	275	postoperative	T079	C0032790
28235120	276	282	opioid	T109,T121	C0002772
28235120	283	289	dosage	T081	C0178602
28235120	312	330	opioid consumption	T048	C0240602
28235120	346	349	DRF	T037	C0435585
28235120	352	356	ORIF	T061	C0747060
28235120	373	390	prospective study	T062	C0033522
28235120	400	410	hypothesis	T078	C1512571
28235120	416	434	opioid consumption	T048	C0240602
28235120	441	449	increase	T169	C0442805
28235120	455	464	worsening	T080	C0332271
28235120	465	473	fracture	T037	C0016658
28235120	474	488	classification	T185	C0008902
28235120	501	521	patient demographics	T078	C1548106
28235120	527	535	patients	T101	C0030705
28235120	550	553	DRF	T037	C0435585
28235120	556	560	ORIF	T061	C0747060
28235120	596	610	6-month period	T079	C0439231
28235120	643	663	patient demographics	T078	C1548106
28235120	665	678	fracture type	T080	C0457357
28235120	680	695	anesthesia type	T185	C1305863
28235120	697	703	amount	T081	C0178602
28235120	708	712	type	T080	C0332307
28235120	716	722	opioid	T109,T121	C0002772
28235120	723	733	prescribed	T058	C0278329
28235120	735	741	number	T081	C0237753
28235120	745	750	pills	T109,T121	C0002772
28235120	751	756	taken	T077	C1883727
28235120	758	764	reason	T078	C1550000
28235120	769	777	stopping	T061	C0850893
28235120	783	797	adverse events	T046	C0877248
28235120	799	819	Statistical analysis	T062	C0871424
28235120	848	856	patients	T101	C0030705
28235120	861	867	female	T098	C0043210
28235120	872	876	male	T098	C0025266
28235120	940	948	patients	T101	C0030705
28235120	962	980	general anesthesia	T061	C0002915
28235120	998	1017	regional anesthesia	T061	C1304876
28235120	1037	1059	peripheral nerve block	T061	C0198807
28235120	1066	1084	opioid consumption	T048	C0240602
28235120	1086	1094	morphine	T109,T121	C0026549
28235120	1095	1106	equivalence	T080	C0205163
28235120	1127	1145	postoperative days	T079	C0032790
28235120	1207	1221	no significant	T033	C1273937
28235120	1237	1255	opioid consumption	T048	C0240602
28235120	1268	1275	general	T061	C0002915
28235120	1280	1299	regional anesthesia	T061	C1304876
28235120	1313	1331	opioid consumption	T048	C0240602
28235120	1342	1355	fracture-type	T080	C0457357
28235120	1364	1462	AO/OTA [Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association] classification	T170	C0559822
28235120	1477	1484	class A	T185	C0008902
28235120	1496	1503	class B	T185	C0008902
28235120	1519	1526	class C	T185	C0008902
28235120	1529	1549	Demographic analysis	T062	C0011289
28235120	1562	1569	inverse	T080	C0439850
28235120	1570	1582	relationship	T080	C0439849
28235120	1591	1594	age	T032	C0001779
28235120	1599	1609	opioid use	T048	C0240602
28235120	1652	1670	opioid consumption	T048	C0240602
28235120	1677	1685	self-pay	T033	C3530213
28235120	1690	1698	Medicaid	T064	C0025071
28235120	1699	1707	patients	T101	C0030705
28235120	1709	1727	Opioid consumption	T048	C0240602
28235120	1734	1737	DRF	T037	C0435585
28235120	1740	1744	ORIF	T061	C0747060
28235120	1749	1759	equivalent	T080	C0205163
28235120	1764	1771	general	T061	C0002915
28235120	1776	1795	regional anesthesia	T061	C1304876
28235120	1811	1823	relationship	T080	C0439849
28235120	1842	1856	increasing age	T033	C3550265
28235120	1861	1871	decreasing	T033	C0442797
28235120	1872	1890	opioid consumption	T048	C0240602
28235120	1892	1901	Worsening	T080	C0332271
28235120	1902	1925	fracture classification	T170	C0559822
28235120	1930	1942	self-payment	T033	C3530213
28235120	1945	1961	Medicaid payment	T064	C0025071
28235120	1977	1987	increasing	T169	C0442808
28235120	1988	2006	opioid consumption	T048	C0240602
28235120	2021	2039	opioid consumption	T048	C0240602
28235120	2041	2049	morphine	T109,T121	C0026549
28235120	2050	2061	equivalence	T080	C0205163
28235120	2084	2089	pills	T122	C0994475
28235120	2093	2116	oxycodone/acetaminophen	T121	C0717368
28235120	2127	2135	Surgeons	T097	C0582175
28235120	2181	2191	optimizing	T061	C1273380
28235120	2192	2198	opioid	T109,T121	C0002772
28235120	2217	2220	DRF	T037	C0435585
28235120	2221	2227	repair	T061	C0543467

27856909|t|The sacral autonomic outflow is sympathetic
27856909|a|A kinship between cranial and pelvic visceral nerves of vertebrates has been accepted for a century. Accordingly, sacral preganglionic neurons are considered parasympathetic, as are their targets in the pelvic ganglia that prominently control rectal, bladder, and genital functions. Here, we uncover 15 phenotypic and ontogenetic features that distinguish pre- and postganglionic neurons of the cranial parasympathetic outflow from those of the thoracolumbar sympathetic outflow in mice. By every single one, the sacral outflow is indistinguishable from the thoracolumbar outflow. Thus, the parasympathetic nervous system receives input from cranial nerves exclusively and the sympathetic nervous system from spinal nerves, thoracic to sacral inclusively. This simplified, bipartite architecture offers a new framework to understand pelvic neurophysiology as well as development and evolution of the autonomic nervous system.
27856909	4	10	sacral	T029	C0036033
27856909	11	43	autonomic outflow is sympathetic	T022	C0039044
27856909	62	69	cranial	T023	C0010268
27856909	74	96	pelvic visceral nerves	T023	C0446845
27856909	100	111	vertebrates	T010	C0042567
27856909	121	129	accepted	T080	C1272684
27856909	136	143	century	T079	C0681717
27856909	158	164	sacral	T029	C0036033
27856909	165	186	preganglionic neurons	T025	C1520027
27856909	191	201	considered	T078	C0750591
27856909	202	217	parasympathetic	T023	C0459522
27856909	232	239	targets	T169	C1521840
27856909	247	261	pelvic ganglia	T023	C0229048
27856909	287	293	rectal	T082	C0205052
27856909	295	302	bladder	T023	C0005682
27856909	308	325	genital functions	T042	C0678884
27856909	347	357	phenotypic	T032	C0031437
27856909	400	431	pre- and postganglionic neurons	T025	C0682693
27856909	439	470	cranial parasympathetic outflow	T022	C0030510
27856909	489	522	thoracolumbar sympathetic outflow	T022	C0039044
27856909	526	530	mice	T015	C0025929
27856909	557	563	sacral	T029	C0036033
27856909	564	571	outflow	T082	C0449651
27856909	602	615	thoracolumbar	T082	C0450219
27856909	616	623	outflow	T082	C0449651
27856909	635	665	parasympathetic nervous system	T022	C0030510
27856909	666	674	receives	T080	C1514756
27856909	675	680	input	T077	C1708517
27856909	686	700	cranial nerves	T023	C0010268
27856909	721	747	sympathetic nervous system	T022	C0039044
27856909	753	766	spinal nerves	T023	C0037941
27856909	768	776	thoracic	T029	C0817096
27856909	780	786	sacral	T029	C0036033
27856909	817	839	bipartite architecture	T082	C0332496
27856909	849	852	new	T080	C0205314
27856909	877	883	pelvic	T023	C0030797
27856909	884	899	neurophysiology	T039	C0700630
27856909	911	922	development	T169	C1527148
27856909	927	936	evolution	T058	C0220825
27856909	944	968	autonomic nervous system	T022	C0004388

27436635|t|Blood Pressure and All-Cause Mortality by Level of Cognitive Function in the Elderly: Results From a Population-Based Study in Rural Greece
27436635|a|This study aimed to investigate whether the effect of blood pressure (BP) on mortality differs by levels of cognitive function. The associations of brachial systolic BP, diastolic BP, mean arterial pressure (MAP), and pulse pressure with all-cause mortality were prospectively explored (follow-up 7.0±2.2 years) in 660 community-dwelling individuals (≥60 years) using adjusted Cox models, stratified by cognitive impairment (Mini-Mental State Examination [MMSE] <24). No association between brachial BP variables and mortality was shown for the total sample in quartiles analysis; however, MAP in the highest quartile, compared with the second, was associated with mortality (hazard ratio, 1.85; 95% confidence intervals, 1.09-3.12) among cognitively impaired individuals. The fractional-polynomials approach for BP confirmed this finding and further showed, solely in the MMSE <24 subcohort, U-shaped trends of MAP and systolic BP, with increased mortality risk in extremely low or high values; no such pattern was evident for patients with MMSE ≥24. Elderly individuals with cognitive impairment might be more susceptible to the detrimental effects of low and elevated MAP and systolic BP.
27436635	0	14	Blood Pressure	T040	C0005823
27436635	19	38	All-Cause Mortality	T033	C0007465
27436635	42	47	Level	T080	C0441889
27436635	51	69	Cognitive Function	T041	C0392335
27436635	77	84	Elderly	T098	C0001792
27436635	86	93	Results	T033	C0683954
27436635	101	123	Population-Based Study	T062	C1709599
27436635	127	139	Rural Greece	T083	C0018226
27436635	145	150	study	T062	C1709599
27436635	151	156	aimed	T078	C1947946
27436635	160	171	investigate	T169	C1292732
27436635	184	190	effect	T080	C1280500
27436635	194	208	blood pressure	T040	C0005823
27436635	210	212	BP	T040	C0005823
27436635	217	226	mortality	T033	C1306577
27436635	238	244	levels	T080	C0441889
27436635	248	266	cognitive function	T041	C0392335
27436635	272	284	associations	T080	C0439849
27436635	288	296	brachial	T082	C0445456
27436635	297	308	systolic BP	T201	C0871470
27436635	310	322	diastolic BP	T201	C0428883
27436635	324	346	mean arterial pressure	T033	C0428886
27436635	348	351	MAP	T033	C0428886
27436635	358	372	pulse pressure	T040	C0949236
27436635	378	397	all-cause mortality	T033	C0007465
27436635	403	425	prospectively explored	T033	C0243095
27436635	427	436	follow-up	T058	C1522577
27436635	445	450	years	T079	C0439234
27436635	459	477	community-dwelling	T056	C4045975
27436635	478	489	individuals	T098	C0237401
27436635	491	500	≥60 years	T033	C4062292
27436635	508	527	adjusted Cox models	T081,T170	C0010234
27436635	529	539	stratified	T080	C0205363
27436635	543	563	cognitive impairment	T048	C0338656
27436635	565	594	Mini-Mental State Examination	T060	C0451306
27436635	596	600	MMSE	T060	C0451306
27436635	608	622	No association	T080	C0205556
27436635	631	639	brachial	T082	C0445456
27436635	640	642	BP	T040	C0005823
27436635	643	652	variables	T080	C0439828
27436635	657	666	mortality	T033	C1306577
27436635	685	690	total	T080	C0439810
27436635	691	697	sample	T167	C0370003
27436635	701	719	quartiles analysis	T062	C0871424
27436635	730	733	MAP	T033	C0428886
27436635	741	757	highest quartile	T080	C2828255
27436635	759	767	compared	T052	C1707455
27436635	777	783	second	T081	C0205436
27436635	789	804	associated with	T080	C0332281
27436635	805	814	mortality	T033	C1306577
27436635	816	828	hazard ratio	T081	C2985465
27436635	840	860	confidence intervals	T081	C0009667
27436635	879	899	cognitively impaired	T048	C0338656
27436635	900	911	individuals	T098	C0237401
27436635	917	948	fractional-polynomials approach	T062	C0242481
27436635	953	955	BP	T040	C0005823
27436635	956	965	confirmed	T033	C0750484
27436635	971	978	finding	T033	C0243095
27436635	983	990	further	T082	C1517331
27436635	999	1005	solely	T081	C0205171
27436635	1013	1017	MMSE	T060	C0451306
27436635	1022	1031	subcohort	T081	C0009247
27436635	1033	1048	U-shaped trends	T079	C0040833
27436635	1052	1055	MAP	T033	C0428886
27436635	1060	1071	systolic BP	T201	C0871470
27436635	1078	1087	increased	T081	C0205217
27436635	1088	1102	mortality risk	T078	C0035647
27436635	1106	1115	extremely	T080	C0205403
27436635	1116	1134	low or high values	T080	C0205556
27436635	1144	1151	pattern	T082	C0449774
27436635	1156	1163	evident	T078	C3887511
27436635	1168	1176	patients	T101	C0030705
27436635	1182	1186	MMSE	T060	C0451306
27436635	1192	1199	Elderly	T098	C0001792
27436635	1200	1211	individuals	T098	C0237401
27436635	1217	1237	cognitive impairment	T048	C0338656
27436635	1247	1251	more	T081	C0205172
27436635	1252	1263	susceptible	T169	C0231204
27436635	1271	1290	detrimental effects	T046	C0879626
27436635	1294	1297	low	T080	C0205251
27436635	1302	1310	elevated	T080	C3163633
27436635	1311	1314	MAP	T033	C0428886
27436635	1319	1330	systolic BP	T201	C0871470

27826671|t|A Feasibility Study of Telementoring for Identifying the Appendix Using Smartphone -Based Telesonography
27826671|a|We investigated the feasibility of the clinical application of novice - practitioner - performed / offsite - mentor -guided ultrasonography for identifying the appendix. A randomized crossover study was conducted using a telesonography system that can transmit the ultrasound images displayed on the ultrasound monitor (ultrasound sequence video) and images showing the practitioner's operations (background video) to a smartphone without any interruption in motion over a Long-Term Evolution (LTE) network. Thirty novice practitioners were randomly assigned to two groups. The subjects in group A (n = 15) performed ultrasonography for the identification of the appendix under mentoring by an onsite expert, whereas those in group B (n = 15) performed the same procedure under mentoring by an offsite expert. Each subject performed the procedure on three simulated patients. After a 4- week interval, they performed the procedure again under the other type of mentoring. A total of 90 ultrasound examinations were performed in each scenario. The primary outcomes were the success rate for identifying the appendix and the time required to identify the appendix. The success rates for identifying the appendix were 91.1 % (82/90) in onsite - mentored ultrasonography and 87.8 % (79/90) in offsite - mentored ultrasonography; both rates were high, and there was no significant difference (p = 0.468) between them. The time required in the case of offsite mentoring (median, 242.9 s; interquartile range (IQR), 238.2) was longer than that for onsite mentoring (median, 291.4 s; IQR, 200.9); however, the difference was not significant (p = 0.051). It appears that offsite mentoring can allow novice onsite practitioners to perform ultrasonography as effectively as they can under onsite mentoring, even for examinations that require proficiency in rather complex practices, such as identifying the appendix.
27826671	2	19	Feasibility Study	T062,T170	C0015730
27826671	23	36	Telementoring	T065	C0013652
27826671	41	52	Identifying	T080	C0205396
27826671	57	65	Appendix	T023	C0003617
27826671	72	82	Smartphone	T073	C3204335
27826671	90	104	Telesonography	T060	C0430022
27826671	108	120	investigated	T169	C1292732
27826671	125	136	feasibility	T080	C0205556
27826671	144	152	clinical	T080	C0205210
27826671	153	164	application	T058	C0185125
27826671	168	174	novice	UnknownType	C0680250
27826671	177	189	practitioner	T097	C1709627
27826671	192	201	performed	T169	C0884358
27826671	204	211	offsite	T082	C3828730
27826671	214	220	mentor	T098	C0025369
27826671	229	244	ultrasonography	T060	C0041618
27826671	249	260	identifying	T080	C0205396
27826671	265	273	appendix	T023	C0003617
27826671	277	287	randomized	T062	C0034656
27826671	288	303	crossover study	T062	C0150097
27826671	326	347	telesonography system	T073	C3273359
27826671	357	365	transmit	T169	C0332289
27826671	370	380	ultrasound	T060	C0041618
27826671	381	387	images	T078	C1551337
27826671	405	423	ultrasound monitor	T074	C3688807
27826671	425	450	ultrasound sequence video	T170	C3463807
27826671	456	462	images	T078	C1551337
27826671	475	489	practitioner's	T097	C1709627
27826671	490	500	operations	T052	C3241922
27826671	502	512	background	T077	C1706907
27826671	513	518	video	T170	C3463807
27826671	525	535	smartphone	T073	C3204335
27826671	548	560	interruption	T079	C1512900
27826671	564	570	motion	T070	C0026597
27826671	578	611	Long-Term Evolution (LTE) network	T073	C0282112
27826671	620	626	novice	UnknownType	C0680250
27826671	627	640	practitioners	T097	C1709627
27826671	655	663	assigned	T169	C1516050
27826671	671	677	groups	UnknownType	C0681860
27826671	683	691	subjects	T098	C2349001
27826671	695	702	group A	UnknownType	C0681860
27826671	712	721	performed	T169	C0884358
27826671	722	737	ultrasonography	T060	C0041618
27826671	746	760	identification	T080	C0205396
27826671	768	776	appendix	T023	C0003617
27826671	783	792	mentoring	T065	C4255266
27826671	799	805	onsite	T082	C0205145
27826671	806	812	expert	T097	C0009817
27826671	831	838	group B	UnknownType	C0681860
27826671	848	857	performed	T169	C0884358
27826671	867	876	procedure	T060	C0430022
27826671	883	892	mentoring	T065	C4255266
27826671	899	906	offsite	T082	C3828730
27826671	907	913	expert	T097	C0009817
27826671	920	927	subject	T098	C2349001
27826671	928	937	performed	T169	C0884358
27826671	942	951	procedure	T060	C0430022
27826671	961	979	simulated patients	T065	C3825675
27826671	992	996	week	T079	C0439230
27826671	997	1005	interval	T079	C1272706
27826671	1012	1021	performed	T169	C0884358
27826671	1026	1035	procedure	T060	C0430022
27826671	1066	1075	mentoring	T065	C4255266
27826671	1091	1101	ultrasound	T060	C0041618
27826671	1102	1114	examinations	T058	C0582103
27826671	1120	1129	performed	T169	C0884358
27826671	1152	1168	primary outcomes	T080	C3274433
27826671	1178	1190	success rate	T081	C1521828
27826671	1195	1206	identifying	T080	C0205396
27826671	1211	1219	appendix	T023	C0003617
27826671	1228	1232	time	T079	C0040223
27826671	1233	1241	required	T169	C1514873
27826671	1245	1253	identify	T080	C0205396
27826671	1258	1266	appendix	T023	C0003617
27826671	1272	1285	success rates	T081	C1521828
27826671	1290	1301	identifying	T080	C0205396
27826671	1306	1314	appendix	T023	C0003617
27826671	1338	1344	onsite	T082	C0205145
27826671	1347	1355	mentored	T065	C4255266
27826671	1356	1371	ultrasonography	T060	C0041618
27826671	1394	1401	offsite	T082	C3828730
27826671	1404	1412	mentored	T065	C4255266
27826671	1413	1428	ultrasonography	T060	C0041618
27826671	1435	1440	rates	T081	C1521828
27826671	1466	1480	no significant	T033	C1273937
27826671	1481	1491	difference	T081	C1705241
27826671	1522	1526	time	T079	C0040223
27826671	1527	1535	required	T169	C1514873
27826671	1551	1558	offsite	T082	C3828730
27826671	1551	1558	offsite	T082	C3828730
27826671	1559	1568	mentoring	T065	C4255266
27826671	1570	1576	median	T081	C0876920
27826671	1587	1606	interquartile range	T081	C1711350
27826671	1608	1611	IQR	T081	C1711350
27826671	1625	1631	longer	T080	C0205166
27826671	1646	1652	onsite	T082	C0205145
27826671	1653	1662	mentoring	T065	C4255266
27826671	1664	1670	median	T081	C0876920
27826671	1681	1684	IQR	T081	C1711350
27826671	1707	1717	difference	T081	C1705241
27826671	1722	1737	not significant	T033	C1273937
27826671	1767	1774	offsite	T082	C3828730
27826671	1775	1784	mentoring	T065	C4255266
27826671	1795	1801	novice	UnknownType	C0680250
27826671	1802	1808	onsite	T082	C0205145
27826671	1809	1822	practitioners	T097	C1709627
27826671	1834	1849	ultrasonography	T060	C0041618
27826671	1853	1864	effectively	T080	C1704419
27826671	1883	1889	onsite	T082	C0205145
27826671	1890	1899	mentoring	T065	C4255266
27826671	1910	1922	examinations	T058	C0582103
27826671	1936	1947	proficiency	T080	C0205556
27826671	1958	1965	complex	T080	C0439855
27826671	1966	1975	practices	T058	C1254363
27826671	1985	1996	identifying	T080	C0205396
27826671	2001	2009	appendix	T023	C0003617

28386264|t|Factors Associated with Mortality in Patients with Autoimmune Diseases Admitted to the Intensive Care Unit in Bogota, Colombia
28386264|a|Patients with autoimmune diseases (ADs) are a challenge for the intensivist; it is hard to differentiate among infection, disease activity, and combinations of both, leading to high mortality. This study is a retrospective analysis of 124 critically ill patients admitted to the intensive care unit (ICU) in a university hospital between 2008 and 2016. Bivariate case-control analysis was performed, using patients who died as cases; later, analysis using a logistic regression model with variables that were associated with mortality was conducted. Four variables were consistently associated with mortality in the logistic regression model and had adequate prediction value (Hosmer and Lemeshow statistic = 0.760; Nagelkerke R-squared = 0.494). The risk of death was found to be statistically associated with the following: shock at admission to ICU [odds ratio (OR): 7.56; 95% confidence interval (CI): 1.78-31.97, p = 0.006], hemoglobin level <8 g/dL (OR: 16.12; 95% CI: 3.35-77.52, p = 0.001), use of cytostatic agents prior to admission to the ICU (OR: 8.71; 95% CI: 1.23-61.5, p = 0.03), and low levels ofcomplement C3 (OR: 5.23; 95% CI: 1.28-21.35, p = 0.02). These variables can guide clinicians in the early identification of patients with AD with increased risk of death during hospitalization, leading to initial therapies seeking to improve survival. These results should be evaluated prospectively in future studies to establish their predictive power.
28386264	0	7	Factors	T169	C1521761
28386264	8	23	Associated with	T080	C0332281
28386264	24	33	Mortality	T081	C0205848
28386264	37	45	Patients	T101	C0030705
28386264	51	70	Autoimmune Diseases	T047	C0004364
28386264	71	106	Admitted to the Intensive Care Unit	T058	C0583239
28386264	110	116	Bogota	UnknownType	C0681784
28386264	118	126	Colombia	T083	C3245499
28386264	127	135	Patients	T101	C0030705
28386264	141	160	autoimmune diseases	T047	C0004364
28386264	162	165	ADs	T047	C0004364
28386264	191	202	intensivist	T097	C0334886
28386264	238	247	infection	T046	C3714514
28386264	249	265	disease activity	T046	C0242656
28386264	271	283	combinations	T080	C0205195
28386264	304	318	high mortality	T081	C0205848
28386264	336	358	retrospective analysis	T062	C0035363
28386264	377	389	ill patients	T033	C2010702
28386264	390	425	admitted to the intensive care unit	T058	C0583239
28386264	427	430	ICU	T073,T093	C0021708
28386264	437	456	university hospital	T073,T093	C0020028
28386264	480	511	Bivariate case-control analysis	UnknownType	C0681927
28386264	533	541	patients	T101	C0030705
28386264	546	550	died	T040	C0011065
28386264	554	559	cases	T169	C0868928
28386264	568	576	analysis	T062	C0936012
28386264	585	610	logistic regression model	T081,T170	C0023965
28386264	616	625	variables	T080	C0439828
28386264	636	651	associated with	T080	C0332281
28386264	652	661	mortality	T081	C0205848
28386264	682	691	variables	T080	C0439828
28386264	710	725	associated with	T080	C0332281
28386264	726	735	mortality	T081	C0205848
28386264	743	768	logistic regression model	T081,T170	C0023965
28386264	786	796	prediction	T078	C0681842
28386264	797	802	value	T081	C1522609
28386264	804	833	Hosmer and Lemeshow statistic	T081	C0392762
28386264	843	863	Nagelkerke R-squared	T081	C0392762
28386264	878	882	risk	T058	C0086930
28386264	886	891	death	T040	C0011065
28386264	922	937	associated with	T080	C0332281
28386264	953	958	shock	T046	C0036974
28386264	962	978	admission to ICU	T058	C0583239
28386264	980	990	odds ratio	T081	C0028873
28386264	992	994	OR	T081	C0028873
28386264	1007	1026	confidence interval	T081	C0009667
28386264	1028	1030	CI	T081	C0009667
28386264	1057	1073	hemoglobin level	T034	C0019029
28386264	1083	1085	OR	T081	C0028873
28386264	1098	1100	CI	T081	C0009667
28386264	1133	1150	cytostatic agents	T121	C0010858
28386264	1160	1180	admission to the ICU	T058	C0583239
28386264	1182	1184	OR	T081	C0028873
28386264	1196	1198	CI	T081	C0009667
28386264	1226	1252	low levels ofcomplement C3	UnknownType	C0878610
28386264	1254	1256	OR	T081	C0028873
28386264	1268	1270	CI	T081	C0009667
28386264	1301	1310	variables	T080	C0439828
28386264	1321	1331	clinicians	T097	C0871685
28386264	1345	1359	identification	T080	C0205396
28386264	1363	1371	patients	T101	C0030705
28386264	1377	1379	AD	T047	C0004364
28386264	1385	1394	increased	T081	C0205217
28386264	1395	1399	risk	T078	C0035647
28386264	1403	1408	death	T040	C0011065
28386264	1416	1431	hospitalization	T058	C0019993
28386264	1452	1461	therapies	T061	C0087111
28386264	1473	1480	improve	T033	C0184511
28386264	1481	1489	survival	T052	C0038952
28386264	1497	1504	results	T169	C1274040
28386264	1542	1548	future	T079	C0016884
28386264	1549	1556	studies	T062	C2603343

28093575|t|Development process of an assessment tool for disruptive behavior problems in cross-cultural settings: the Disruptive Behavior International Scale - Nepal version (DBIS-N)
28093575|a|Systematic processes are needed to develop valid measurement instruments for disruptive behavior disorders (DBDs) in cross-cultural settings. We employed a four-step process in Nepal to identify and select items for a culturally valid assessment instrument: 1) We extracted items from validated scales and local free-list interviews. 2) Parents, teachers, and peers (n=30) rated the perceived relevance and importance of behavior problems. 3) Highly rated items were piloted with children (n=60) in Nepal. 4) We evaluated internal consistency of the final scale. We identified 49 symptoms from 11 scales, and 39 behavior problems from free-list interviews (n=72). After dropping items for low ratings of relevance and severity and for poor item-test correlation, low frequency, and/or poor acceptability in pilot testing, 16 items remained for the Disruptive Behavior International Scale-Nepali version (DBIS-N). The final scale had good internal consistency (α=0.86). A 4-step systematic approach to scale development including local participation yielded an internally consistent scale that included culturally relevant behavior problems.
28093575	0	11	Development	T169	C1527148
28093575	12	19	process	T067	C1522240
28093575	26	36	assessment	T058	C0220825
28093575	46	74	disruptive behavior problems	T048	C0012734
28093575	78	101	cross-cultural settings	T062	C0010358
28093575	107	146	Disruptive Behavior International Scale	T170	C0282574
28093575	149	154	Nepal	T083	C0027689
28093575	155	162	version	T170	C0333052
28093575	164	170	DBIS-N	T170	C0282574
28093575	172	182	Systematic	T169	C0220922
28093575	183	192	processes	T067	C1522240
28093575	215	220	valid	T080	C2349099
28093575	221	232	measurement	T169	C0242485
28093575	249	278	disruptive behavior disorders	T048	C0012734
28093575	280	284	DBDs	T048	C0012734
28093575	289	312	cross-cultural settings	T062	C0010358
28093575	338	345	process	T067	C1522240
28093575	349	354	Nepal	T083	C0027689
28093575	378	383	items	T062,T170	C0871509
28093575	390	400	culturally	T078	C0010447
28093575	401	406	valid	T080	C2349099
28093575	407	417	assessment	T058	C0220825
28093575	418	428	instrument	T074	C0348000
28093575	446	451	items	T062,T170	C0871509
28093575	467	473	scales	T170	C0349674
28093575	478	483	local	T082	C0205276
28093575	484	493	free-list	T080	C0205556
28093575	494	504	interviews	T052	C0021822
28093575	509	516	Parents	T099	C0030551
28093575	518	526	teachers	T097	C0221457
28093575	532	537	peers	T098	C0679739
28093575	555	564	perceived	T041	C0030971
28093575	565	574	relevance	T080	C2347946
28093575	579	589	importance	T080	C0205556
28093575	593	610	behavior problems	T048	C0233514
28093575	628	633	items	T062,T170	C0871509
28093575	652	660	children	T100	C0008059
28093575	671	676	Nepal	T083	C0027689
28093575	684	693	evaluated	T058	C0220825
28093575	694	714	internal consistency	T081	C0870731
28093575	728	733	scale	T170	C0349674
28093575	752	760	symptoms	T184	C1457887
28093575	769	775	scales	T170	C0349674
28093575	784	801	behavior problems	T048	C0233514
28093575	807	816	free-list	T080	C0205556
28093575	817	827	interviews	T052	C0021822
28093575	842	850	dropping	T052	C1705648
28093575	851	856	items	T062,T170	C0871509
28093575	865	872	ratings	T052	C0871208
28093575	876	885	relevance	T080	C2347946
28093575	890	898	severity	T080	C0439793
28093575	907	911	poor	T080	C0542537
28093575	912	933	item-test correlation	T080	C1707520
28093575	935	948	low frequency	T079	C0205213
28093575	957	961	poor	T080	C0542537
28093575	962	975	acceptability	T080	C0814633
28093575	985	992	testing	T169	C0039593
28093575	997	1002	items	T062,T170	C0871509
28093575	1020	1074	Disruptive Behavior International Scale-Nepali version	T170	C0282574
28093575	1076	1082	DBIS-N	T170	C0282574
28093575	1095	1100	scale	T170	C0349674
28093575	1110	1130	internal consistency	T081	C0870731
28093575	1150	1160	systematic	T169	C0220922
28093575	1173	1178	scale	T170	C0349674
28093575	1179	1190	development	T169	C1527148
28093575	1191	1200	including	T169	C0332257
28093575	1201	1206	local	T082	C0205276
28093575	1207	1220	participation	T169	C0679823
28093575	1232	1253	internally consistent	T081	C0870731
28093575	1254	1259	scale	T170	C0349674
28093575	1265	1273	included	T169	C0332257
28093575	1274	1284	culturally	T078	C0010447
28093575	1285	1293	relevant	T080	C2347946
28093575	1294	1311	behavior problems	T048	C0233514

28199934|t|Mixed corticomedullary adrenal carcinoma - case report: Comparison in features, treatment and prognosis with the other two reported cases
28199934|a|Adrenal corticomedullary adenoma was reviewed in many cases in PubMed Library, While the coincidence corticomedullary adrenal carcinoma in the same gland was just described in two cases in the medical literature. Our case is the third to be reported and was treated with surgery and adjuvant chemotherapy and followed for two years. A 50- year -old man suffered from a mass effect in the left abdominal side. While the laboratory showed a mild elevation in the levels of both serum cortisol and 24h urine cortisol, radiological images were highly suggested an adrenal malignant tumor without metastasis. At surgery a 22cm sized mass was completely resected. Immunohistochemical study identified expression of both adrenocortical carcinoma and pheochromocytoma markers. Cases of coincidence corticomedullary tumor have been published in many reviews, cortical and/or medulllary hypersecretion were not always detected preoperatively by biochemical tests. Mixed corticomedullary carcinoma are exceedingly rare, we came across three reported cases in medical literature, in one case laboratory tests confirmed both cortical and medulla hypersecretion, while the two others detected only cortical hypersecretion. The final diagnosis was always confirmed by immunohistochemical staining. It could be noted that this is the first comparison of presentation, diagnosis, treatments and follow-up of the three cases of Mixed corticomedullary carcinoma. This could contribute to understanding the behavior and management of this rare malignancy and make it more familiar in clinical practice.
28199934	6	22	corticomedullary	T023	C0927224
28199934	23	40	adrenal carcinoma	T191	C0206686
28199934	43	54	case report	T170	C0085973
28199934	56	66	Comparison	T052	C1707455
28199934	70	78	features	T080	C2348519
28199934	80	89	treatment	T169	C1522326
28199934	94	103	prognosis	T058	C0033325
28199934	132	137	cases	T169	C0868928
28199934	138	162	Adrenal corticomedullary	T030	C0229567
28199934	163	170	adenoma	T191	C0001430
28199934	175	183	reviewed	T080	C1709940
28199934	192	197	cases	T169	C0868928
28199934	201	215	PubMed Library	T170	C1138432
28199934	239	255	corticomedullary	T023	C0927224
28199934	256	273	adrenal carcinoma	T191	C0206686
28199934	286	291	gland	T023	C0001625
28199934	301	310	described	T078	C1552738
28199934	318	323	cases	T169	C0868928
28199934	331	349	medical literature	T078	C0025120
28199934	355	359	case	T169	C0868928
28199934	396	403	treated	T169	C1522326
28199934	409	416	surgery	T061	C0543467
28199934	421	442	adjuvant chemotherapy	T061	C0085533
28199934	464	469	years	T079	C0439234
28199934	477	481	year	T079	C0439234
28199934	487	490	man	T032	C0086582
28199934	507	518	mass effect	T033	C4086564
28199934	526	545	left abdominal side	T023	C1562302
28199934	557	567	laboratory	T059	C0022885
28199934	577	591	mild elevation	T082	C0702240
28199934	599	605	levels	T080	C0441889
28199934	614	628	serum cortisol	T059	C0236396
28199934	637	651	urine cortisol	T059	C1271705
28199934	653	672	radiological images	T170	C1704254
28199934	685	694	suggested	T078	C1705535
28199934	698	721	adrenal malignant tumor	T191	C0750887
28199934	730	740	metastasis	T046	C4255448
28199934	745	752	surgery	T061	C0543467
28199934	760	765	sized	T082	C0456389
28199934	766	770	mass	T033	C3273930
28199934	786	794	resected	T080	C1521996
28199934	796	815	Immunohistochemical	T060	C0021044
28199934	852	876	adrenocortical carcinoma	T191	C0206686
28199934	881	897	pheochromocytoma	T191	C0031511
28199934	898	905	markers	T201	C0005516
28199934	907	912	Cases	T169	C0868928
28199934	928	944	corticomedullary	T023	C0927224
28199934	945	950	tumor	T191	C0027651
28199934	961	970	published	T170	C0282411
28199934	988	996	cortical	T047	C1389845
28199934	1004	1029	medulllary hypersecretion	T047	C1386491
28199934	1046	1054	detected	T033	C0442726
28199934	1055	1069	preoperatively	T079	C0445204
28199934	1073	1090	biochemical tests	T059	C0430027
28199934	1098	1114	corticomedullary	T023	C0927224
28199934	1115	1124	carcinoma	T191	C0007097
28199934	1129	1145	exceedingly rare	T080	C0522498
28199934	1177	1182	cases	T169	C0868928
28199934	1186	1204	medical literature	T078	C0025120
28199934	1218	1234	laboratory tests	T059	C0022885
28199934	1235	1244	confirmed	T080	C0521093
28199934	1250	1258	cortical	T047	C1389845
28199934	1263	1285	medulla hypersecretion	T047	C1386491
28199934	1308	1316	detected	T033	C0442726
28199934	1322	1345	cortical hypersecretion	T047	C1389845
28199934	1357	1366	diagnosis	T062	C1704656
28199934	1378	1390	confirmed by	T080	C0521093
28199934	1391	1419	immunohistochemical staining	T059	C1508788
28199934	1462	1472	comparison	T052	C1707455
28199934	1476	1488	presentation	T078	C0449450
28199934	1490	1499	diagnosis	T080	C1704338
28199934	1501	1511	treatments	T169	C1522326
28199934	1539	1544	cases	T169	C0868928
28199934	1554	1570	corticomedullary	T023	C0927224
28199934	1571	1580	carcinoma	T191	C0007097
28199934	1625	1633	behavior	T169	C0474325
28199934	1638	1648	management	T058	C0376636
28199934	1662	1672	malignancy	T191	C4282132
28199934	1702	1719	clinical practice	T062	C0008972

27235789|t|Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma
27235789|a|There is no consensus regarding a protective effect on mortality due to a cause other than cancer in patients treated with elective nephron sparing surgery relative to their radical nephrectomy counterparts. We test whether the protective effect of nephron sparing surgery relative to radical nephrectomy is universal or present in specific subgroups of patients. A collaborative database of 5 institutions was queried to evaluate 1,783 patients without chronic kidney disease diagnosed with a clinical T1 renal mass that was treated with nephron sparing surgery or radical nephrectomy. Multivariable Cox regression analysis was done to assess the impact of surgery type (nephron sparing surgery vs radical nephrectomy) on other cause mortality after adjustment for patient and cancer characteristics. Interaction terms were used to test the hypothesis that the impact of surgery type varies according to specific subcohorts of patients. Ten-year other cause mortality -free survival rates were 90% and 88% after nephron sparing surgery and radical nephrectomy, respectively. In the overall population radical nephrectomy was not associated with an increased risk of other cause mortality on multivariable analysis compared to nephron sparing surgery (HR 0.91, 95% CI 0.6-1.38, p = 0.6). However, radical nephrectomy increased the risk of other cause mortality according to the increasing baseline Charlson comorbidity index (interaction test p = 0.0008). For example, in a patient with a Charlson comorbidity index of 4 the probability of 10-year other cause mortality -free survival was 86% after nephron sparing surgery and 60% after radical nephrectomy. Elective nephron sparing surgery does not improve other cause survival relative to radical nephrectomy consistently in all patients with kidney cancer. Patients who are more ill with relevant comorbidities are those who benefit the most from nephron sparing surgery in terms of other cause mortality.
27235789	0	8	Elective	T061	C0206058
27235789	9	32	Nephron Sparing Surgery	T061	C0194086
27235789	33	42	Decreases	T081	C0205216
27235789	43	64	Other Cause Mortality	T033	C0476465
27235789	65	73	Relative	T080	C0205345
27235789	77	96	Radical Nephrectomy	T061	C0401181
27235789	105	113	Specific	T080	C0205369
27235789	114	123	Subgroups	T185	C1515021
27235789	127	135	Patients	T101	C0030705
27235789	141	161	Renal Cell Carcinoma	T191	C0007134
27235789	174	183	consensus	T054	C0376298
27235789	196	213	protective effect	T033	C1545588
27235789	217	226	mortality	T081	C0205848
27235789	253	259	cancer	T191	C0006826
27235789	263	271	patients	T101	C0030705
27235789	272	284	treated with	T061	C0332293
27235789	285	293	elective	T061	C0206058
27235789	294	317	nephron sparing surgery	T061	C0194086
27235789	318	326	relative	T080	C0205345
27235789	336	355	radical nephrectomy	T061	C0401181
27235789	373	377	test	T169	C0039593
27235789	390	407	protective effect	T033	C1545588
27235789	411	434	nephron sparing surgery	T061	C0194086
27235789	435	443	relative	T080	C0205345
27235789	447	466	radical nephrectomy	T061	C0401181
27235789	470	479	universal	T080	C0175671
27235789	494	502	specific	T080	C0205369
27235789	503	512	subgroups	T185	C1515021
27235789	516	524	patients	T101	C0030705
27235789	528	541	collaborative	T081	C0392762
27235789	542	550	database	T170	C0242356
27235789	556	568	institutions	T078	C1272753
27235789	573	580	queried	T170	C1522634
27235789	584	592	evaluate	T058	C0220825
27235789	599	607	patients	T101	C0030705
27235789	616	638	chronic kidney disease	T047	C1561643
27235789	639	648	diagnosed	T033	C0011900
27235789	656	664	clinical	T080	C0205210
27235789	665	678	T1 renal mass	T191	C2217020
27235789	688	700	treated with	T061	C0332293
27235789	701	724	nephron sparing surgery	T061	C0194086
27235789	728	747	radical nephrectomy	T061	C0401181
27235789	749	786	Multivariable Cox regression analysis	T170	C0034980
27235789	799	805	assess	T058	C0184514
27235789	810	816	impact	T080	C4049986
27235789	820	827	surgery	T061	C0543467
27235789	834	857	nephron sparing surgery	T061	C0194086
27235789	861	880	radical nephrectomy	T061	C0401181
27235789	885	906	other cause mortality	T033	C0476465
27235789	928	935	patient	T101	C0030705
27235789	940	946	cancer	T191	C0006826
27235789	947	962	characteristics	T080	C1521970
27235789	964	975	Interaction	T169	C1704675
27235789	995	999	test	T169	C0039593
27235789	1024	1030	impact	T080	C4049986
27235789	1034	1041	surgery	T061	C0543467
27235789	1067	1075	specific	T080	C0205369
27235789	1076	1086	subcohorts	T098	C0599755
27235789	1090	1098	patients	T101	C0030705
27235789	1100	1108	Ten-year	T079	C1254367
27235789	1109	1130	other cause mortality	T033	C0476465
27235789	1137	1151	survival rates	T081	C0038954
27235789	1175	1198	nephron sparing surgery	T061	C0194086
27235789	1203	1222	radical nephrectomy	T061	C0401181
27235789	1245	1252	overall	T080	C1561607
27235789	1253	1263	population	T098	C1257890
27235789	1264	1283	radical nephrectomy	T061	C0401181
27235789	1292	1307	associated with	T080	C0332281
27235789	1311	1320	increased	T081	C0205217
27235789	1321	1325	risk	T078	C0035647
27235789	1329	1350	other cause mortality	T033	C0476465
27235789	1354	1376	multivariable analysis	T081	C0026777
27235789	1389	1412	nephron sparing surgery	T061	C0194086
27235789	1414	1416	HR	T081	C2985465
27235789	1427	1429	CI	T081	C0009667
27235789	1459	1478	radical nephrectomy	T061	C0401181
27235789	1479	1488	increased	T081	C0205217
27235789	1493	1497	risk	T078	C0035647
27235789	1501	1522	other cause mortality	T033	C0476465
27235789	1540	1550	increasing	T081	C0205217
27235789	1551	1559	baseline	T081	C1442488
27235789	1560	1586	Charlson comorbidity index	T170	C3714916
27235789	1588	1599	interaction	T169	C1704675
27235789	1600	1604	test	T169	C0039593
27235789	1636	1643	patient	T101	C0030705
27235789	1651	1677	Charlson comorbidity index	T170	C3714916
27235789	1687	1698	probability	T081	C0033204
27235789	1702	1709	10-year	T079	C1254367
27235789	1710	1731	other cause mortality	T033	C0476465
27235789	1738	1746	survival	T052	C0038952
27235789	1761	1784	nephron sparing surgery	T061	C0194086
27235789	1799	1818	radical nephrectomy	T061	C0401181
27235789	1820	1828	Elective	T061	C0206058
27235789	1829	1852	nephron sparing surgery	T061	C0194086
27235789	1862	1869	improve	T033	C0184511
27235789	1882	1890	survival	T052	C0038952
27235789	1891	1899	relative	T080	C0205345
27235789	1903	1922	radical nephrectomy	T061	C0401181
27235789	1943	1951	patients	T101	C0030705
27235789	1957	1970	kidney cancer	T191	C0740457
27235789	1972	1980	Patients	T101	C0030705
27235789	1994	1997	ill	T184	C0221423
27235789	2003	2011	relevant	T080	C2347946
27235789	2012	2025	comorbidities	T078	C0009488
27235789	2040	2047	benefit	T081	C0814225
27235789	2062	2085	nephron sparing surgery	T061	C0194086
27235789	2098	2119	other cause mortality	T033	C0476465

27388630|t|Effect of Hepatitis C Virus Coinfection on the Content of CD4(+) and CD8(+) T Cell Subpopulations in HIV - Infected Patients Receiving Antiretroviral Therapy
27388630|a|We studied the effect of hepatitis C virus coinfection on T cell subpopulations in HIV - infected patients receiving antiretroviral therapy. Coinfection with hepatitis C virus was followed by a decrease in the number of naive CD4(+) T cells and an increase in the count of central CD8(+) memory T cells in these patients. Hepatitis C virus had no effect on the number of CD4(+) memory T cells (main target for HIV). This can explain the absence of strong negative effect of hepatitis C virus on the course of HIV infection.
27388630	0	6	Effect	T080	C1280500
27388630	10	39	Hepatitis C Virus Coinfection	T047	C1698259
27388630	58	75	CD4(+) and CD8(+)	T025	C0483191
27388630	76	82	T Cell	T025	C0039194
27388630	83	97	Subpopulations	T185	C0079720
27388630	101	104	HIV	T005	C0019682
27388630	107	115	Infected	T033	C0439663
27388630	116	124	Patients	T101	C0030705
27388630	125	134	Receiving	T080	C1514756
27388630	135	157	Antiretroviral Therapy	T061	C1963724
27388630	173	179	effect	T080	C1280500
27388630	183	212	hepatitis C virus coinfection	T047	C1698259
27388630	216	222	T cell	T025	C0039194
27388630	223	237	subpopulations	T185	C0079720
27388630	241	244	HIV	T005	C0019682
27388630	247	255	infected	T033	C0439663
27388630	256	264	patients	T101	C0030705
27388630	275	297	antiretroviral therapy	T061	C1963724
27388630	299	310	Coinfection	T047	C0275524
27388630	316	333	hepatitis C virus	T005	C0220847
27388630	352	360	decrease	T081	C0547047
27388630	378	398	naive CD4(+) T cells	T025	C3273372
27388630	406	414	increase	T169	C0442805
27388630	422	427	count	T081	C0750480
27388630	439	460	CD8(+) memory T cells	T025	C0242629
27388630	470	478	patients	T101	C0030705
27388630	480	497	Hepatitis C virus	T005	C0220847
27388630	502	511	no effect	T080	C1301751
27388630	529	550	CD4(+) memory T cells	T025	C3273371
27388630	568	571	HIV	T005	C0019682
27388630	613	621	negative	T033	C0205160
27388630	622	628	effect	T080	C1280500
27388630	632	649	hepatitis C virus	T005	C0220847
27388630	657	663	course	T079	C0750729
27388630	667	670	HIV	T005	C0019682
27388630	671	680	infection	T046	C3714514

27320863|t|Alleviation of hepatic fat accumulation by betaine involves reduction of homocysteine via up-regulation of betaine-homocysteine methyltransferase (BHMT)
27320863|a|We investigated the anti-lipogenic effect of betaine in rats fed methionine and choline - deficient diet (MCD). Intake of MCD for 3 wk resulted in a significant accumulation of hepatic lipids, which was prevented by betaine supplementation in drinking water (1%). Phosphorylation of AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), sterol regulatory element-binding protein 1c (SREBP-1c), and liver kinase B1 (LKB1) was inhibited by MCD intake, and these changes were all inhibited by betaine feeding. Meanwhile, betaine supplementation reversed the reduction of methionine and S-adenosylmethionine (SAM), and the elevation of homocysteine levels in the liver, which could be attributable to the induction of betaine-homocysteine methyltransfease (BHMT) and methionine adenosyltransferase (MAT). Different cell lines were used to clarify the role of homocysteine on activation of the AMPK pathway. Homocysteine treatment decreased pAMPK, pACC, pSREBP-1c and pLKB1 in HepG2 cells. Metformin - induced activation of AMPK was also inhibited by homocysteine. Treatment with hydroxylamine, a cystathionine β-synthase inhibitor, resulted in a reduction of pAMPK, pACC and pSREBP-1c, accompanied by an elevation of intracellular homocysteine. Betaine treatment prevented the homocysteine - induced reduction of pAMPK, pACC, pSREBP-1c and pLKB1 in H4IIE cells, but not in HepG2 cells. Also the elevation of cellular homocysteine and inhibition of protein expression of BHMT were prevented by betaine only in H4IIE cells which express BHMT. The results suggest that the beneficial effect of betaine against hepatic lipid accumulation may be attributed, at least in part, to the depletion of homocysteine via up-regulation of BHMT in hepatocytes.
27320863	0	11	Alleviation	T080	C0392756
27320863	15	22	hepatic	T029	C0205054
27320863	23	39	fat accumulation	T033	C0333574
27320863	43	50	betaine	T109,T121	C0005304
27320863	60	69	reduction	T080	C0392756
27320863	73	85	homocysteine	T116,T123	C0019878
27320863	90	103	up-regulation	T044	C0041904
27320863	107	145	betaine-homocysteine methyltransferase	T116,T126	C0053518
27320863	147	151	BHMT	T116,T126	C0053518
27320863	156	168	investigated	T169	C1292732
27320863	173	194	anti-lipogenic effect	T169	C0205245
27320863	198	205	betaine	T109,T121	C0005304
27320863	209	213	rats	T015	C0086893
27320863	218	228	methionine	T116,T121,T123	C0025646
27320863	233	240	choline	T109,T121,T123	C0008405
27320863	243	252	deficient	T080	C0332268
27320863	253	257	diet	T168	C0012155
27320863	259	262	MCD	T168	C0012155
27320863	275	278	MCD	T168	C0012155
27320863	302	313	significant	T078	C0750502
27320863	314	326	accumulation	T033	C0333574
27320863	330	337	hepatic	T029	C0205054
27320863	338	344	lipids	T109	C0023779
27320863	356	365	prevented	T080	C2700409
27320863	369	376	betaine	T109,T121	C0005304
27320863	377	392	supplementation	T061	C0242297
27320863	396	410	drinking water	T167	C0599638
27320863	417	432	Phosphorylation	T044	C1158886
27320863	436	464	AMP-activated protein kinase	T116,T126	C2350345
27320863	466	470	AMPK	T116,T126	C2350345
27320863	473	495	acetyl-CoA carboxylase	T116,T126	C0001022
27320863	497	500	ACC	T116,T126	C0001022
27320863	503	547	sterol regulatory element-binding protein 1c	T116,T123	C0537474
27320863	549	557	SREBP-1c	T116,T123	C0537474
27320863	564	579	liver kinase B1	T116,T126	C1431123
27320863	581	585	LKB1	T116,T126	C1431123
27320863	591	600	inhibited	T080	C0311403
27320863	604	607	MCD	T168	C0012155
27320863	608	614	intake	T169	C1512806
27320863	643	652	inhibited	T080	C0311403
27320863	656	663	betaine	T109,T121	C0005304
27320863	664	671	feeding	T058	C3714845
27320863	684	691	betaine	T109,T121	C0005304
27320863	692	707	supplementation	T061	C0242297
27320863	708	716	reversed	T169	C1555029
27320863	721	730	reduction	T080	C0392756
27320863	734	769	methionine and S-adenosylmethionine	T044	C1325080
27320863	771	774	SAM	T044	C1325080
27320863	785	794	elevation	T080	C3163633
27320863	798	817	homocysteine levels	T059	C2242817
27320863	825	831	liver,	T023	C0023884
27320863	867	876	induction	T045	C0014431
27320863	880	917	betaine-homocysteine methyltransfease	T116,T126	C0053518
27320863	919	923	BHMT	T116,T126	C0053518
27320863	929	959	methionine adenosyltransferase	T116,T126	C0025647
27320863	961	964	MAT	T116,T126	C0025647
27320863	967	976	Different	T080	C1705242
27320863	977	987	cell lines	T025	C0007634
27320863	1021	1033	homocysteine	T116,T123	C0019878
27320863	1037	1047	activation	T044	C0014429
27320863	1055	1059	AMPK	T116,T126	C2350345
27320863	1060	1067	pathway	T044	C0598390
27320863	1069	1081	Homocysteine	T116,T123	C0019878
27320863	1082	1091	treatment	T169	C1522326
27320863	1092	1101	decreased	T081	C0205216
27320863	1102	1107	pAMPK	T116,T126	C2350345
27320863	1109	1113	pACC	T116,T126	C0001022
27320863	1115	1124	pSREBP-1c	T116,T123	C0537474
27320863	1129	1134	pLKB1	T116,T126	C1431123
27320863	1138	1149	HepG2 cells	T025	C2717940
27320863	1151	1160	Metformin	T109,T121	C0025598
27320863	1163	1170	induced	T169	C0205263
27320863	1171	1181	activation	T044	C0014429
27320863	1185	1189	AMPK	T116,T126	C2350345
27320863	1199	1208	inhibited	T080	C0311403
27320863	1212	1224	homocysteine	T116,T123	C0019878
27320863	1226	1235	Treatment	T169	C1522326
27320863	1241	1254	hydroxylamine	T197	C0020362
27320863	1258	1282	cystathionine β-synthase	T116,T126	C0010641
27320863	1283	1292	inhibitor	T121	C0014432
27320863	1308	1317	reduction	T080	C0392756
27320863	1321	1326	pAMPK	T116,T126	C2350345
27320863	1328	1332	pACC	T116,T126	C0001022
27320863	1337	1346	pSREBP-1c	T116,T123	C0537474
27320863	1366	1375	elevation	T080	C3163633
27320863	1379	1392	intracellular	T082	C0178719
27320863	1393	1405	homocysteine	T116,T123	C0019878
27320863	1407	1414	Betaine	T109,T121	C0005304
27320863	1415	1424	treatment	T061	C0087111
27320863	1425	1434	prevented	T080	C2700409
27320863	1439	1451	homocysteine	T116,T123	C0019878
27320863	1454	1461	induced	T169	C0205263
27320863	1462	1471	reduction	T080	C0392756
27320863	1475	1480	pAMPK	T116,T126	C2350345
27320863	1482	1486	pACC	T116,T126	C0001022
27320863	1488	1497	pSREBP-1c	T116,T123	C0537474
27320863	1502	1507	pLKB1	T116,T126	C1431123
27320863	1511	1522	H4IIE cells	T025	C0007634
27320863	1535	1546	HepG2 cells	T025	C2717940
27320863	1557	1566	elevation	T080	C3163633
27320863	1579	1591	homocysteine	T116,T123	C0019878
27320863	1596	1606	inhibition	T052	C3463820
27320863	1610	1628	protein expression	T045	C1171362
27320863	1632	1636	BHMT	T116,T126	C0053518
27320863	1642	1651	prevented	T080	C2700409
27320863	1655	1662	betaine	T109,T121	C0005304
27320863	1671	1682	H4IIE cells	T025	C0007634
27320863	1689	1696	express	T045	C1171362
27320863	1697	1701	BHMT	T116,T126	C0053518
27320863	1753	1760	betaine	T109,T121	C0005304
27320863	1769	1776	hepatic	T029	C0205054
27320863	1777	1782	lipid	T109	C0023779
27320863	1783	1795	accumulation	T033	C0333574
27320863	1803	1813	attributed	T078	C0449234
27320863	1840	1849	depletion	T169	C0333668
27320863	1853	1865	homocysteine	T116,T123	C0019878
27320863	1870	1883	up-regulation	T044	C0041904
27320863	1887	1891	BHMT	T116,T126	C0053518
27320863	1895	1906	hepatocytes	T025	C0227525

27796974|t|Methodology development on aquatic environmental assessment
27796974|a|The Water Framework Directive aims at reaching the good ecological status of the surface and ground water bodies (László et al. Microchem J 85(1):65-71, 2007). The paper deals with quality evaluation of waters with special focus on the water chemistry parameters as defined in the Water Framework Directive and pertaining legal regulations. The purpose of this paper is to devise a quantitative type of water quality assessment method which could provide rapid, accurate, and reliable information on the quality of the surface waters by using water chemistry parameters. Quality classes have been defined for every water chemistry parameter in light of the legal limit values of the water parameters. In addition to this, weight indices were calculated on the basis of the outcome of the paired comparison of water chemistry parameters and normalized matrix. This was followed by the parametric level analysis of the water chemistry parameters, and finally, the aquatic environment index (AEI) was calculated, which provided general information on the quality of water regarding the water chemistry parameters. The method was illustrated on Lake Balaton, Hungary in which case water samples taken from Balatonfüred City lake area were analyzed and evaluated with the method devised.
27796974	0	11	Methodology	T078	C3266812
27796974	12	23	development	T169	C1527148
27796974	27	48	aquatic environmental	T067	C0563034
27796974	49	59	assessment	T058	C0220825
27796974	64	89	Water Framework Directive	T170	C0282574
27796974	90	94	aims	T078	C1947946
27796974	116	126	ecological	T070	C0162358
27796974	127	133	status	T080	C0449438
27796974	141	148	surface	T082	C0205148
27796974	153	172	ground water bodies	T082	C0596631
27796974	241	248	quality	T080	C0332306
27796974	249	259	evaluation	T058	C0220825
27796974	263	269	waters	T121,T197	C0043047
27796974	275	282	special	T080	C0205555
27796974	296	301	water	T121,T197	C0043047
27796974	302	311	chemistry	T169	C0079107
27796974	312	322	parameters	T077	C0549193
27796974	341	366	Water Framework Directive	T170	C0282574
27796974	382	399	legal regulations	T089	C0680575
27796974	405	412	purpose	T169	C1285529
27796974	442	454	quantitative	T081	C0392762
27796974	463	468	water	T121,T197	C0043047
27796974	469	476	quality	T080	C0332306
27796974	477	487	assessment	T058	C0220825
27796974	488	494	method	T170	C0025663
27796974	507	514	provide	T052	C1999230
27796974	515	520	rapid	T080	C0456962
27796974	522	530	accurate	T080	C0443131
27796974	536	544	reliable	T170	C3858758
27796974	545	556	information	T078	C1533716
27796974	564	571	quality	T080	C0332306
27796974	579	586	surface	T082	C0205148
27796974	587	593	waters	T121,T197	C0043047
27796974	603	608	water	T121,T197	C0043047
27796974	609	618	chemistry	T169	C0079107
27796974	619	629	parameters	T077	C0549193
27796974	631	638	Quality	T080	C0332306
27796974	639	646	classes	T170	C0456387
27796974	657	664	defined	T080	C0442825
27796974	675	680	water	T121,T197	C0043047
27796974	681	690	chemistry	T169	C0079107
27796974	691	700	parameter	T077	C0549193
27796974	717	735	legal limit values	T089	C0752073
27796974	743	748	water	T121,T197	C0043047
27796974	749	759	parameters	T077	C0549193
27796974	782	796	weight indices	T081	C0392762
27796974	802	812	calculated	T059	C1443182
27796974	833	840	outcome	T169	C1274040
27796974	848	865	paired comparison	T081	C0086766
27796974	869	874	water	T121,T197	C0043047
27796974	875	884	chemistry	T169	C0079107
27796974	885	895	parameters	T077	C0549193
27796974	900	910	normalized	T062	C1882115
27796974	911	917	matrix	T082	C1704640
27796974	944	969	parametric level analysis	UnknownType	C0681933
27796974	977	982	water	T121,T197	C0043047
27796974	983	992	chemistry	T169	C0079107
27796974	993	1003	parameters	T077	C0549193
27796974	1022	1047	aquatic environment index	T170	C0282574
27796974	1049	1052	AEI	T170	C0282574
27796974	1058	1068	calculated	T059	C1443182
27796974	1076	1084	provided	T052	C1999230
27796974	1085	1104	general information	T185	C0332118
27796974	1112	1119	quality	T080	C0332306
27796974	1123	1128	water	T121,T197	C0043047
27796974	1143	1148	water	T121,T197	C0043047
27796974	1149	1158	chemistry	T169	C0079107
27796974	1159	1169	parameters	T077	C0549193
27796974	1175	1181	method	T170	C0025663
27796974	1201	1205	Lake	T083	C0337049
27796974	1206	1213	Balaton	T083	C0017446
27796974	1215	1222	Hungary	T083	C0020174
27796974	1237	1242	water	T121,T197	C0043047
27796974	1243	1250	samples	T167	C0370003
27796974	1262	1279	Balatonfüred City	T083	C0017446
27796974	1280	1284	lake	T083	C0337049
27796974	1285	1289	area	T083	C0017446
27796974	1295	1303	analyzed	T062	C0936012
27796974	1308	1317	evaluated	T058	C0220825
27796974	1327	1333	method	T170	C0025663

27703752|t|Low birth weight and features of neuroticism and mood disorder in 83 545 participants of the UK Biobank cohort
27703752|a|Low birth weight has been inconsistently associated with risk of developing affective disorders, including major depressive disorder (MDD). To date, studies investigating possible associations between birth weight and bipolar disorder (BD), or personality traits known to predispose to affective disorders such as neuroticism, have not been conducted in large cohorts. To assess whether very low birth weight (<1500 g) and low birth weight (1500-2490 g) were associated with higher neuroticism scores assessed in middle age, and lifetime history of either MDD or BD. We controlled for possible confounding factors. Retrospective cohort study using baseline data on the 83 545 UK Biobank participants with detailed mental health and birth weight data. Main outcomes were prevalent MDD and BD, and neuroticism assessed using the Eysenck Personality Inventory Neuroticism scale - Revised (EPIN-R). Referent to normal birth weight, very low / low birth weight were associated with higher neuroticism scores, increased MDD and BD. The associations between birth weight category and MDD were partially mediated by higher neuroticism. These findings suggest that intrauterine programming may play a role in lifetime vulnerability to affective disorders. None. © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.
27703752	0	16	Low birth weight	T033	C0024032
27703752	21	29	features	T080	C2348519
27703752	33	44	neuroticism	T048	C1842981
27703752	49	62	mood disorder	T048	C0525045
27703752	73	85	participants	T098	C0679646
27703752	93	95	UK	T083	C0041700
27703752	96	103	Biobank	T093	C0206512
27703752	104	110	cohort	T098	C0599755
27703752	111	127	Low birth weight	T033	C0024032
27703752	168	172	risk	T078	C0035647
27703752	187	206	affective disorders	T048	C0001723
27703752	218	243	major depressive disorder	T048	C1269683
27703752	245	248	MDD	T048	C1269683
27703752	260	267	studies	T062	C2603343
27703752	268	281	investigating	T169	C1292732
27703752	291	303	associations	T080	C0439849
27703752	312	324	birth weight	T032	C0005612
27703752	329	345	bipolar disorder	T048	C0005586
27703752	347	349	BD	T048	C0005586
27703752	355	373	personality traits	T033	C0233849
27703752	383	393	predispose	T032	C0220898
27703752	397	416	affective disorders	T048	C0001723
27703752	425	436	neuroticism	T048	C1842981
27703752	471	478	cohorts	T098	C0599755
27703752	483	489	assess	T052	C1516048
27703752	498	519	very low birth weight	T184	C0282666
27703752	534	550	low birth weight	T033	C0024032
27703752	570	585	associated with	T080	C0332281
27703752	586	604	higher neuroticism	T033	C0564512
27703752	605	611	scores	T081	C0449820
27703752	612	620	assessed	T052	C1516048
27703752	624	634	middle age	T079	C0026062
27703752	640	656	lifetime history	T032	C0598779
27703752	667	670	MDD	T048	C1269683
27703752	674	676	BD	T048	C0005586
27703752	705	724	confounding factors	T169	C0009673
27703752	726	739	Retrospective	T080	C1514923
27703752	740	752	cohort study	T081	C0009247
27703752	759	767	baseline	T081	C1442488
27703752	768	772	data	T078	C1511726
27703752	787	789	UK	T083	C0041700
27703752	790	797	Biobank	T093	C0206512
27703752	798	810	participants	T098	C0679646
27703752	825	838	mental health	T041	C0025353
27703752	843	855	birth weight	T032	C0005612
27703752	856	860	data	T078	C1511726
27703752	867	875	outcomes	T169	C1274040
27703752	891	894	MDD	T048	C1269683
27703752	899	901	BD	T048	C0005586
27703752	907	918	neuroticism	T048	C1842981
27703752	919	927	assessed	T052	C1516048
27703752	938	995	Eysenck Personality Inventory Neuroticism scale - Revised	T170	C0034394
27703752	997	1003	EPIN-R	T170	C0034394
27703752	1018	1037	normal birth weight	T033	C0456136
27703752	1039	1047	very low	T184	C0282666
27703752	1050	1066	low birth weight	T033	C0024032
27703752	1088	1106	higher neuroticism	T033	C0564512
27703752	1107	1113	scores	T081	C0449820
27703752	1115	1124	increased	T081	C0205217
27703752	1125	1128	MDD	T048	C1269683
27703752	1133	1135	BD	T048	C0005586
27703752	1141	1153	associations	T080	C0439849
27703752	1162	1174	birth weight	T032	C0005612
27703752	1175	1183	category	T170	C0683312
27703752	1188	1191	MDD	T048	C1269683
27703752	1219	1237	higher neuroticism	T033	C0564512
27703752	1245	1253	findings	T033	C0683954
27703752	1267	1279	intrauterine	T029	C0694756
27703752	1280	1291	programming	T038	C1720850
27703752	1303	1307	role	T077	C1705810
27703752	1311	1319	lifetime	T079	C4071830
27703752	1320	1333	vulnerability	T033	C1821973
27703752	1337	1356	affective disorders	T048	C0001723

27508512|t|A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays
27508512|a|Immunogenicity to therapeutic proteins has been linked to loss of response by a large percentage of patients taking anti-tumor necrosis factor-alpha agents. Drug monitoring can be extremely useful, allowing physicians to adjust the therapeutic scheme individually. This article aims to systematically review the published data with respect to cutoff levels of infliximab (IFX) and adalimumab (ADA) and relate them to the methodology adopted for quantification of IFX and ADA levels and clinical outcomes. The PubMed database was searched to identify studies focusing on the association between IFX or ADA cutoff levels and clinical outcomes in patients with inflammatory bowel disease. Of the 1654 articles initially selected by queries, 20 were included. A receiver operating characteristic curve analysis was performed to identify cutoff levels of IFX or ADA that correlated with a clinical outcome, but only 6 studies performed the same analysis for antidrug antibody levels. Cutoff levels were different between studies. The methodology chosen for level quantifications, clinical outcomes, and sample size and characteristics were also different. Nevertheless, measurement of drug levels should be performed during maintenance, and with loss of response, with persistent high levels of C-reactive protein, and when mucosal lesions are still present. In these scenarios, drug and antidrug levels were correlated with clinical outcomes. Concerning drug levels monitoring any methodology is adequate. With respect to antidrug antibody levels, it will be necessary to define a gold standard method or to establish different cutoff levels for different methodologies.
27508512	2	19	Systematic Review	T170	C1955832
27508512	23	33	Infliximab	T116,T121,T129	C0666743
27508512	38	48	Adalimumab	T116,T121,T129	C1122087
27508512	49	64	Drug Monitoring	T058	C0085421
27508512	66	72	Levels	T080	C0441889
27508512	74	91	Clinical Outcomes	T033	C2985631
27508512	96	102	Assays	T059	C1510438
27508512	103	117	Immunogenicity	T062	C4054739
27508512	121	141	therapeutic proteins	T121	C0872285
27508512	161	165	loss	T081	C1517945
27508512	169	177	response	T032	C0871261
27508512	183	188	large	T081	C0549177
27508512	189	199	percentage	T078	C1549488
27508512	203	211	patients	T101	C0030705
27508512	219	258	anti-tumor necrosis factor-alpha agents	T121	C1562242
27508512	260	275	Drug monitoring	T058	C0085421
27508512	283	292	extremely	T080	C0205403
27508512	293	299	useful	T080	C3827682
27508512	310	320	physicians	T097	C0031831
27508512	324	330	adjust	T169	C0456081
27508512	335	346	therapeutic	T169	C0302350
27508512	347	353	scheme	T170	C1519193
27508512	354	366	individually	T098	C0237401
27508512	373	380	article	T170	C1706852
27508512	381	385	aims	T078	C1947946
27508512	389	410	systematically review	T170	C1955832
27508512	415	429	published data	T170	C0993637
27508512	435	442	respect	T080	C0205345
27508512	446	459	cutoff levels	T169	C1442160
27508512	463	473	infliximab	T116,T121,T129	C0666743
27508512	475	478	IFX	T116,T121,T129	C0666743
27508512	484	494	adalimumab	T116,T121,T129	C1122087
27508512	496	499	ADA	T116,T121,T129	C1122087
27508512	524	535	methodology	T078	C3266812
27508512	536	543	adopted	T080	C1272684
27508512	548	562	quantification	T081	C1709793
27508512	566	569	IFX	T116,T121,T129	C0666743
27508512	574	577	ADA	T116,T121,T129	C1122087
27508512	578	584	levels	T080	C0441889
27508512	589	606	clinical outcomes	T033	C2985631
27508512	612	627	PubMed database	T170	C1138432
27508512	632	640	searched	T052	C1706202
27508512	644	652	identify	T041	C0020792
27508512	653	660	studies	T062	C2603343
27508512	661	669	focusing	T169	C1285542
27508512	677	688	association	T080	C0439849
27508512	689	696	between	T082	C0205103
27508512	697	700	IFX	T116,T121,T129	C0666743
27508512	704	707	ADA	T116,T121,T129	C1122087
27508512	708	721	cutoff levels	T169	C1442160
27508512	726	743	clinical outcomes	T033	C2985631
27508512	747	755	patients	T101	C0030705
27508512	761	787	inflammatory bowel disease	T047	C0021390
27508512	801	809	articles	T170	C1706852
27508512	810	819	initially	T079	C0205265
27508512	820	828	selected	T052	C1707391
27508512	832	839	queries	T170	C1522634
27508512	849	857	included	T169	C0332257
27508512	861	900	receiver operating characteristic curve	T081	C0035787
27508512	901	909	analysis	T062	C0936012
27508512	914	923	performed	T169	C0884358
27508512	927	935	identify	T041	C0020792
27508512	936	949	cutoff levels	T169	C1442160
27508512	953	956	IFX	T116,T121,T129	C0666743
27508512	960	963	ADA	T116,T121,T129	C1122087
27508512	969	979	correlated	T080	C1707520
27508512	987	1003	clinical outcome	T033	C2985631
27508512	1016	1023	studies	T062	C2603343
27508512	1024	1033	performed	T169	C0884358
27508512	1038	1042	same	T080	C0445247
27508512	1043	1051	analysis	T062	C0936012
27508512	1056	1073	antidrug antibody	T116,T129	C3811629
27508512	1074	1080	levels	T080	C0441889
27508512	1082	1095	Cutoff levels	T169	C1442160
27508512	1101	1110	different	T080	C1705242
27508512	1111	1118	between	T082	C0205103
27508512	1119	1126	studies	T062	C2603343
27508512	1132	1143	methodology	T078	C3266812
27508512	1144	1150	chosen	T052	C1707391
27508512	1155	1160	level	T080	C0441889
27508512	1161	1176	quantifications	T081	C1709793
27508512	1178	1195	clinical outcomes	T033	C2985631
27508512	1201	1212	sample size	T081	C0242618
27508512	1217	1232	characteristics	T080	C1521970
27508512	1243	1252	different	T080	C1705242
27508512	1268	1294	measurement of drug levels	T059	C1261153
27508512	1305	1314	performed	T169	C0884358
27508512	1322	1333	maintenance	T052	C0024501
27508512	1344	1348	loss	T081	C1517945
27508512	1352	1360	response	T032	C0871261
27508512	1367	1377	persistent	T079	C0205322
27508512	1383	1389	levels	T080	C0441889
27508512	1393	1411	C-reactive protein	T116,T129	C0006560
27508512	1422	1429	mucosal	T024	C0026724
27508512	1430	1437	lesions	T033	C0221198
27508512	1448	1455	present	T033	C0150312
27508512	1466	1475	scenarios	T169	C0683579
27508512	1477	1481	drug	T121	C0013227
27508512	1486	1494	antidrug	T123	C0005515
27508512	1495	1501	levels	T080	C0441889
27508512	1507	1517	correlated	T080	C1707520
27508512	1523	1540	clinical outcomes	T033	C2985631
27508512	1553	1557	drug	T121	C0013227
27508512	1558	1564	levels	T080	C0441889
27508512	1565	1575	monitoring	T058	C1283169
27508512	1580	1591	methodology	T078	C3266812
27508512	1595	1603	adequate	T080	C0205411
27508512	1610	1620	respect to	T080	C0205345
27508512	1621	1638	antidrug antibody	T116,T129	C3811629
27508512	1639	1645	levels	T080	C0441889
27508512	1658	1667	necessary	T080	C3898777
27508512	1680	1693	gold standard	T080	C0150110
27508512	1694	1700	method	T170	C0025663
27508512	1707	1716	establish	T080	C0443211
27508512	1717	1726	different	T080	C1705242
27508512	1727	1740	cutoff levels	T169	C1442160
27508512	1745	1754	different	T080	C1705242
27508512	1755	1768	methodologies	T078	C3266812

27373893|t|Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data
27373893|a|To determine whether time to treatment following symptom onset differs between RA patients according to autoantibody status. A single-centre retrospective analysis of a UK early RA inception cohort was first undertaken to identify those components of the patient journey that differed by serological subtype. Data from a UK national audit of early inflammatory arthritis patients was accessed to replicate the key finding. A total of 173 RA patients were diagnosed over a 31- month period, of whom 80 (46%) were ACPA/RF double-seropositive (ACPA(+)/RF(+)), 53 (31%) ACPA(-)/RF(-), 17 (10%) ACPA(+)/RF(-) and 23 (13%) RF(+)/ACPA(-) Overall, ACPA(+)/RF(+) patients experienced significantly longer symptom duration before DMARD initiation. This was accounted for by delays in their presentation to primary care following symptom onset -a finding that was robustly confirmed in an independent dataset of 2192 UK early RA patients. In contrast, ACPA(-)/RF(-) patients were significantly more likely to experience delays in DMARD initiation after presenting to secondary care. Causes of treatment delays in early RA differ according to patients ' autoantibody status. More insidious symptom onset and/or distinct health-seeking behaviours among ACPA(+)/RF(+) patients may contribute to late presentations in primary care, whereas ACPA(-)/RF(-) patients experience delayed diagnosis and treatment in secondary care. These observations inform the research agenda, potentially influencing the design of service delivery for early arthritis patients.
27373893	14	23	treatment	T061	C0087111
27373893	24	29	delay	T079	C0205421
27373893	33	53	rheumatoid arthritis	T047	C0003873
27373893	54	60	differ	T080	C1705242
27373893	74	86	autoantibody	T116,T129	C0004358
27373893	87	93	status	T080	C0449438
27373893	95	105	validation	T062	C1519941
27373893	125	136	observation	T169	C1441672
27373893	137	142	using	T169	C1524063
27373893	143	151	national	T082	C0681788
27373893	152	157	audit	T169	C1704775
27373893	158	162	data	T078	C1511726
27373893	184	201	time to treatment	T079	C3494202
27373893	202	211	following	T079	C0332282
27373893	212	225	symptom onset	T079	C4086878
27373893	226	233	differs	T080	C1705242
27373893	242	244	RA	T047	C0003873
27373893	245	253	patients	T101	C0030705
27373893	267	279	autoantibody	T116,T129	C0004358
27373893	280	286	status	T080	C0449438
27373893	304	317	retrospective	T080	C1514923
27373893	318	326	analysis	T062	C0936012
27373893	332	334	UK	T083	C0041700
27373893	341	343	RA	T047	C0003873
27373893	344	360	inception cohort	UnknownType	C0150101
27373893	385	393	identify	T080	C0205396
27373893	418	425	patient	T101	C0030705
27373893	426	433	journey	T169	C1280477
27373893	439	447	differed	T080	C1705242
27373893	451	462	serological	T169	C0205473
27373893	463	470	subtype	T185	C0449560
27373893	472	476	Data	T078	C1511726
27373893	484	486	UK	T083	C0041700
27373893	487	495	national	T082	C0681788
27373893	496	501	audit	T169	C1704775
27373893	511	533	inflammatory arthritis	T047	C0003864
27373893	534	542	patients	T101	C0030705
27373893	547	555	accessed	T082	C0444454
27373893	559	568	replicate	T080	C1883725
27373893	577	584	finding	T033	C0243095
27373893	601	603	RA	T047	C0003873
27373893	604	612	patients	T101	C0030705
27373893	618	627	diagnosed	T060	C0430022
27373893	628	632	over	T079	C0347984
27373893	639	644	month	T079	C0439231
27373893	645	651	period	T079	C1948053
27373893	675	702	ACPA/RF double-seropositive	T034	C1254360
27373893	704	717	ACPA(+)/RF(+)	T034	C1254360
27373893	729	742	ACPA(-)/RF(-)	T034	C1254360
27373893	753	766	ACPA(+)/RF(-)	T034	C1254360
27373893	780	793	RF(+)/ACPA(-)	T034	C1254360
27373893	803	816	ACPA(+)/RF(+)	T034	C1254360
27373893	817	825	patients	T101	C0030705
27373893	852	858	longer	T080	C0205166
27373893	859	875	symptom duration	T079	C0436359
27373893	883	888	DMARD	T121	C0242708
27373893	889	899	initiation	T169	C1704686
27373893	927	933	delays	T079	C0205421
27373893	959	971	primary care	T058	C0033137
27373893	972	981	following	T079	C0332282
27373893	982	995	symptom onset	T079	C4086878
27373893	999	1006	finding	T033	C0243095
27373893	1025	1034	confirmed	T080	C0521093
27373893	1041	1052	independent	T169	C0332291
27373893	1053	1060	dataset	T170	C0150098
27373893	1069	1071	UK	T083	C0041700
27373893	1078	1080	RA	T047	C0003873
27373893	1081	1089	patients	T101	C0030705
27373893	1104	1126	ACPA(-)/RF(-) patients	T034	C1254360
27373893	1118	1126	patients	T101	C0030705
27373893	1172	1178	delays	T079	C0205421
27373893	1182	1187	DMARD	T121	C0242708
27373893	1188	1198	initiation	T169	C1704686
27373893	1219	1233	secondary care	T058	C3494402
27373893	1235	1241	Causes	T169	C0015127
27373893	1245	1254	treatment	T061	C0087111
27373893	1255	1261	delays	T079	C0205421
27373893	1271	1273	RA	T047	C0003873
27373893	1274	1280	differ	T080	C1705242
27373893	1294	1302	patients	T101	C0030705
27373893	1305	1317	autoantibody	T116,T129	C0004358
27373893	1318	1324	status	T080	C0449438
27373893	1331	1340	insidious	T080	C1288298
27373893	1341	1354	symptom onset	T079	C4086878
27373893	1371	1396	health-seeking behaviours	T055	C1321107
27373893	1403	1425	ACPA(+)/RF(+) patients	T034	C1254360
27373893	1417	1425	patients	T101	C0030705
27373893	1430	1440	contribute	T052	C1880177
27373893	1466	1478	primary care	T058	C0033137
27373893	1488	1510	ACPA(-)/RF(-) patients	T034	C1254360
27373893	1502	1510	patients	T101	C0030705
27373893	1522	1539	delayed diagnosis	T080	C2718036
27373893	1544	1553	treatment	T061	C0087111
27373893	1557	1571	secondary care	T058	C3494402
27373893	1579	1591	observations	T169	C1441672
27373893	1592	1598	inform	T058	C0700287
27373893	1603	1618	research agenda	T062	C0681798
27373893	1632	1643	influencing	T077	C4054723
27373893	1648	1654	design	T052	C1707689
27373893	1658	1674	service delivery	T058	C0011211
27373893	1679	1694	early arthritis	T047	C3899278
27373893	1695	1703	patients	T101	C0030705

28282614|t|Inhibition of Drp1 protects against senecionine - induced mitochondria -mediated apoptosis in primary hepatocytes and in mice
28282614|a|Pyrrolizidine alkaloids (PAs) are a group of compounds found in various plants and some of them are widely consumed in the world as herbal medicines and food supplements. PAs are potent hepatotoxins that cause irreversible liver injury in animals and humans. However, the mechanisms by which PAs induce liver injury are not clear. In the present study, we determined the hepatotoxicity and molecular mechanisms of senecionine, one of the most common toxic PAs, in primary cultured mouse and human hepatocytes as well as in mice. We found that senecionine administration increased serum alanine aminotransferase levels in mice. H&E and TUNEL staining of liver tissues revealed increased hemorrhage and hepatocyte apoptosis in liver zone 2 areas. Mechanistically, senecionine induced loss of mitochondrial membrane potential, release of mitochondrial cytochrome c as well as mitochondrial JNK translocation and activation prior to the increased DNA fragmentation and caspase-3 activation in primary cultured mouse and human hepatocyte s. SP600125, a specific JNK inhibitor, and ZVAD-fmk, a general caspase inhibitor, alleviated senecionine -induced apoptosis in primary hepatocytes. Interestingly, senecionine also caused marked mitochondria fragmentation in hepatocytes. Pharmacological inhibition of dynamin-related protein1 (Drp1), a protein that is critical to regulate mitochondrial fission, blocked senecionine - induced mitochondrial fragmentation and mitochondrial release of cytochrome c and apoptosis. More importantly, hepatocyte -specific Drp1 knockout mice were resistant to senecionine - induced liver injury due to decreased mitochondrial damage and apoptosis. In conclusion, our results uncovered a novel mechanism of Drp1 -mediated mitochondrial fragmentation in senecionine - induced liver injury. Targeting Drp1 -mediated mitochondrial fragmentation and apoptosis may be a potential avenue to prevent and treat hepatotoxicity induced by PAs.
28282614	0	10	Inhibition	T044	C0021469
28282614	14	18	Drp1	T116,T126	C1957127
28282614	36	47	senecionine	T109,T121	C0074321
28282614	50	57	induced	T169	C0205263
28282614	58	70	mitochondria	T026	C0026237
28282614	81	90	apoptosis	T043	C0162638
28282614	102	113	hepatocytes	T025	C0227525
28282614	121	125	mice	T015	C0026809
28282614	126	149	Pyrrolizidine alkaloids	T109,T123,T131	C0034335
28282614	151	154	PAs	T109,T123,T131	C0034335
28282614	171	180	compounds	T109,T121	C0002062
28282614	198	204	plants	T002	C0032098
28282614	258	274	herbal medicines	T121	C2240391
28282614	279	295	food supplements	T168	C0242295
28282614	297	300	PAs	T109,T123,T131	C0034335
28282614	312	324	hepatotoxins	T131	C0596691
28282614	336	348	irreversible	T037	C0879537
28282614	349	361	liver injury	T037	C0160390
28282614	365	372	animals	T008	C0003062
28282614	377	383	humans	T016	C0086418
28282614	418	421	PAs	T109,T123,T131	C0034335
28282614	422	428	induce	T169	C0205263
28282614	429	441	liver injury	T037	C0160390
28282614	497	511	hepatotoxicity	T037	C0235378
28282614	516	536	molecular mechanisms	T044	C1258062
28282614	540	551	senecionine	T109,T121	C0074321
28282614	576	581	toxic	T131	C0032346
28282614	582	585	PAs	T109,T123,T131	C0034335
28282614	598	606	cultured	T059	C0007585
28282614	607	612	mouse	T015	C0026809
28282614	617	622	human	T016	C0086418
28282614	623	634	hepatocytes	T025	C0227525
28282614	649	653	mice	T015	C0026809
28282614	669	680	senecionine	T109,T121	C0074321
28282614	681	695	administration	T058	C3469597
28282614	696	743	increased serum alanine aminotransferase levels	T033	C0151905
28282614	747	751	mice	T015	C0026809
28282614	753	756	H&E	T059	C0523207
28282614	761	775	TUNEL staining	T063	C1515232
28282614	779	792	liver tissues	T023	C0736268
28282614	793	801	revealed	T080	C0443289
28282614	802	811	increased	T081	C0205217
28282614	812	822	hemorrhage	T046	C0019080
28282614	827	847	hepatocyte apoptosis	T043	C3269241
28282614	851	869	liver zone 2 areas	T029	C0507183
28282614	888	899	senecionine	T109,T121	C0074321
28282614	900	907	induced	T169	C0205263
28282614	908	912	loss	T081	C1517945
28282614	916	948	mitochondrial membrane potential	T043	C1720920
28282614	950	957	release	T169	C1283071
28282614	961	974	mitochondrial	T026	C0026237
28282614	975	987	cytochrome c	T116,T126	C0010749
28282614	999	1012	mitochondrial	T026	C0026237
28282614	1013	1016	JNK	T116,T126	C0380051
28282614	1017	1030	translocation	T043	C0599893
28282614	1059	1068	increased	T081	C0205217
28282614	1069	1086	DNA fragmentation	T044	C0376669
28282614	1091	1100	caspase-3	T116,T126	C0291573
28282614	1101	1111	activation	T045	C0599177
28282614	1123	1131	cultured	T059	C0007585
28282614	1132	1137	mouse	T015	C0026809
28282614	1142	1147	human	T016	C0086418
28282614	1148	1158	hepatocyte	T025	C0227525
28282614	1162	1170	SP600125	T109,T121	C0968383
28282614	1183	1186	JNK	T116,T126	C0380051
28282614	1187	1197	inhibitor,	T121	C0014432
28282614	1202	1210	ZVAD-fmk	T116,T121	C0383779
28282614	1222	1239	caspase inhibitor	T121	C1516312
28282614	1252	1263	senecionine	T109,T121	C0074321
28282614	1273	1282	apoptosis	T043	C0162638
28282614	1294	1305	hepatocytes	T025	C0227525
28282614	1322	1333	senecionine	T109,T121	C0074321
28282614	1353	1379	mitochondria fragmentation	T043	C0230871
28282614	1383	1394	hepatocytes	T025	C0227525
28282614	1396	1411	Pharmacological	T070	C2350477
28282614	1412	1422	inhibition	T044	C0021469
28282614	1426	1450	dynamin-related protein1	T116,T126	C1957127
28282614	1452	1456	Drp1	T116,T126	C1957127
28282614	1461	1468	protein	T116,T123	C0033684
28282614	1489	1519	regulate mitochondrial fission	T043	C2755551
28282614	1521	1528	blocked	T169	C0332206
28282614	1529	1540	senecionine	T109,T121	C0074321
28282614	1543	1550	induced	T169	C0205263
28282614	1551	1578	mitochondrial fragmentation	T043	C0230871
28282614	1583	1596	mitochondrial	T026	C0026237
28282614	1597	1604	release	T169	C1283071
28282614	1608	1620	cytochrome c	T116,T126	C0010749
28282614	1625	1634	apoptosis	T043	C0162638
28282614	1654	1664	hepatocyte	T025	C0227525
28282614	1675	1679	Drp1	T116,T126	C1957127
28282614	1680	1693	knockout mice	T015	C0206745
28282614	1699	1708	resistant	T169	C0332325
28282614	1712	1723	senecionine	T109,T121	C0074321
28282614	1726	1733	induced	T169	C0205263
28282614	1734	1746	liver injury	T037	C0160390
28282614	1754	1763	decreased	T081	C0205216
28282614	1764	1784	mitochondrial damage	T046	C1096176
28282614	1789	1798	apoptosis	T043	C0162638
28282614	1858	1862	Drp1	T116,T126	C1957127
28282614	1873	1900	mitochondrial fragmentation	T043	C0230871
28282614	1904	1915	senecionine	T109,T121	C0074321
28282614	1918	1925	induced	T169	C0205263
28282614	1926	1938	liver injury	T037	C0160390
28282614	1940	1949	Targeting	T044	C1159372
28282614	1950	1954	Drp1	T116,T126	C1957127
28282614	1965	1992	mitochondrial fragmentation	T043	C0230871
28282614	1997	2006	apoptosis	T043	C0162638
28282614	2048	2053	treat	T061	C0087111
28282614	2054	2068	hepatotoxicity	T037	C0235378
28282614	2069	2076	induced	T169	C0205263
28282614	2080	2083	PAs	T109,T123,T131	C0034335

27388786|t|Examining the contribution of motor movement and language dominance to increased left lateralization during sign generation in native signers
27388786|a|The neural systems supporting speech and sign processing are very similar, although not identical. In a previous fTCD study of hearing native signers (Gutierrez-Sigut, Daws, et al., 2015) we found stronger left lateralization for sign than speech. Given that this increased lateralization could not be explained by hand movement alone, the contribution of motor movement versus ' linguistic ' processes to the strength of hemispheric lateralization during sign production remains unclear. Here we directly contrast lateralization strength of covert versus overt signing during phonological and semantic fluency tasks. To address the possibility that hearing native signers ' elevated lateralization indices (LIs) were due to performing a task in their less dominant language, here we test deaf native signers, whose dominant language is British Sign Language (BSL). Signers were more strongly left lateralized for overt than covert sign generation. However, the strength of lateralization was not correlated with the amount of time producing movements of the right hand. Comparisons with previous data from hearing native English speakers suggest stronger laterality indices for sign than speech in both covert and overt tasks. This increased left lateralization may be driven by specific properties of sign production such as the increased use of self-monitoring mechanisms or the nature of phonological encoding of signs.
27388786	0	9	Examining	T169	C1292732
27388786	14	26	contribution	T052	C1880177
27388786	30	44	motor movement	T169	C1513492
27388786	49	57	language	T171	C0023008
27388786	58	67	dominance	T078	C0870441
27388786	71	80	increased	T081	C0205217
27388786	81	85	left	T082	C0205091
27388786	86	100	lateralization	T042	C0013010
27388786	108	112	sign	T171	C0037078
27388786	113	123	generation	T052	C3146294
27388786	127	133	native	T169	C0302891
27388786	134	141	signers	T098	C1257890
27388786	146	160	neural systems	T022	C0027763
27388786	172	178	speech	T040	C0037817
27388786	183	187	sign	T078	C1547188
27388786	188	198	processing	T041	C0025361
27388786	208	215	similar	T080	C2348205
27388786	255	265	fTCD study	T062	C2603343
27388786	269	276	hearing	T041	C0025361
27388786	277	283	native	T169	C0302891
27388786	284	291	signers	T098	C1257890
27388786	348	352	left	T082	C0205091
27388786	353	367	lateralization	T042	C0013010
27388786	372	376	sign	T078	C1547188
27388786	382	388	speech	T040	C0037817
27388786	406	415	increased	T081	C0205217
27388786	416	430	lateralization	T042	C0013010
27388786	457	461	hand	T023	C0018563
27388786	462	470	movement	T040	C0026649
27388786	498	512	motor movement	T169	C1513492
27388786	522	532	linguistic	T171	C0023008
27388786	535	544	processes	T041	C0025361
27388786	552	560	strength	T078	C0808080
27388786	564	575	hemispheric	T082	C0205139
27388786	576	590	lateralization	T042	C0013010
27388786	598	602	sign	T078	C1547188
27388786	603	613	production	T041	C0025361
27388786	648	656	contrast	T080	C1979874
27388786	657	671	lateralization	T042	C0013010
27388786	672	680	strength	T078	C0808080
27388786	684	690	covert	T078	C0871315
27388786	698	703	overt	T080	C2963144
27388786	704	711	signing	T078	C1547188
27388786	719	731	phonological	T169	C0542341
27388786	736	744	semantic	T078	C0036612
27388786	745	752	fluency	T080	C0870569
27388786	753	758	tasks	T169	C0542341
27388786	792	799	hearing	T041	C0025361
27388786	800	806	native	T169	C0302891
27388786	807	814	signers	T098	C1257890
27388786	817	825	elevated	T080	C3163633
27388786	826	848	lateralization indices	T081	C0392762
27388786	850	853	LIs	T081	C0392762
27388786	880	884	task	T169	C0542341
27388786	899	907	dominant	T169	C1527180
27388786	908	916	language	T171	C0023008
27388786	931	935	deaf	T101	C0525064
27388786	936	942	native	T169	C0302891
27388786	943	950	signers	T098	C1257890
27388786	958	966	dominant	T169	C1527180
27388786	967	975	language	T171	C0023008
27388786	979	1000	British Sign Language	T171	C3874914
27388786	1002	1005	BSL	T171	C3874914
27388786	1008	1015	Signers	T098	C1257890
27388786	1035	1039	left	T082	C0205091
27388786	1040	1051	lateralized	T042	C0013010
27388786	1056	1061	overt	T080	C2963144
27388786	1067	1073	covert	T078	C0871315
27388786	1074	1078	sign	T078	C1547188
27388786	1104	1112	strength	T078	C0808080
27388786	1116	1130	lateralization	T042	C0013010
27388786	1139	1149	correlated	T080	C1707520
27388786	1184	1193	movements	T040	C0026649
27388786	1201	1211	right hand	T023	C0230370
27388786	1213	1224	Comparisons	T052	C1707455
27388786	1239	1243	data	T078	C1511726
27388786	1249	1256	hearing	T041	C0025361
27388786	1257	1263	native	T169	C0302891
27388786	1264	1271	English	T171	C0376245
27388786	1272	1280	speakers	T098	C1257890
27388786	1298	1316	laterality indices	T081	C0392762
27388786	1321	1325	sign	T078	C1547188
27388786	1331	1337	speech	T040	C0037817
27388786	1346	1352	covert	T078	C0871315
27388786	1357	1362	overt	T080	C2963144
27388786	1363	1368	tasks	T169	C0542341
27388786	1375	1384	increased	T081	C0205217
27388786	1385	1389	left	T082	C0205091
27388786	1390	1404	lateralization	T042	C0013010
27388786	1431	1441	properties	T080	C0871161
27388786	1445	1449	sign	T078	C1547188
27388786	1450	1460	production	T041	C0025361
27388786	1473	1482	increased	T081	C0205217
27388786	1483	1486	use	T169	C0457083
27388786	1490	1505	self-monitoring	T055	C0237864
27388786	1506	1516	mechanisms	T169	C0441712
27388786	1524	1530	nature	T078	C0349590
27388786	1534	1555	phonological encoding	T041	C0679058
27388786	1559	1564	signs	T078	C1547188

27429532|t|Autoimmune Myelofibrosis in Systemic Lupus Erythematosus Report of Two Cases and Review of the Literature
27429532|a|Autoimmune myelofibrosis (AIMF) is a rare entity of steroid - responsive bone marrow fibrosis that accompanies a variety of autoimmune diseases, particularly systemic lupus erythematosus (SLE). Rarely it may occur in patients with autoimmune markers but no definable autoimmune disease (Primary-AIMF). We report the cases of two young women with SLE - associated AIMF (SLE - AIMF). The first patient was a young woman who had pancytopenia, massive splenomegaly and reticulin fibrosis in the marrow biopsy. The pancytopenia and splenomegaly resolved completely within weeks of treatment with corticosteroids. Repeat marrow biopsy showed marked regression of marrow fibrosis. The second patient was a young woman with fever, anasarca, bicytopenia and reticulin fibrosis in the marrow biopsy. Steroid therapy resulted in rapid clinical improvement and resolution of pancytopenia. A review of the literature revealed a total of 30 patients with SLE - AIMF reported to- date. Patients with SLE - AIMF are young women with SLE and blood cytopenia who are found to have increased bone marrow reticulin on marrow biopsy. Steroid therapy results in rapid hematological recovery and regression of marrow fibrosis. Whether AIMF is one of several hematological complications of SLE, or represents a unique and distinct subset of patients with SLE in not clear. Prospective studies with longer follow-up are needed to better define the prevalence and clinical spectrum of SLE - AIMF.
27429532	0	24	Autoimmune Myelofibrosis	T191	C0026987
27429532	28	56	Systemic Lupus Erythematosus	T047	C0024141
27429532	71	76	Cases	T169	C0868928
27429532	81	90	Review of	T169	C0699752
27429532	95	105	Literature	T170	C0023866
27429532	106	130	Autoimmune myelofibrosis	T191	C0026987
27429532	132	136	AIMF	T191	C0026987
27429532	143	154	rare entity	T071	C1551338
27429532	158	165	steroid	T109	C0038317
27429532	168	178	responsive	T169	C0205342
27429532	179	199	bone marrow fibrosis	T191	C0026987
27429532	230	249	autoimmune diseases	T047	C0004364
27429532	264	292	systemic lupus erythematosus	T047	C0024141
27429532	294	297	SLE	T047	C0024141
27429532	300	306	Rarely	T080	C0522498
27429532	314	319	occur	T052	C1709305
27429532	323	331	patients	T101	C0030705
27429532	337	355	autoimmune markers	T201	C0005516
27429532	373	391	autoimmune disease	T047	C0004364
27429532	393	405	Primary-AIMF	T191	C0001815
27429532	422	427	cases	T169	C0868928
27429532	435	440	young	T079	C0332239
27429532	441	446	women	T098	C0043210
27429532	452	455	SLE	T047	C0024141
27429532	458	468	associated	T080	C0332281
27429532	469	473	AIMF	T191	C0026987
27429532	475	478	SLE	T047	C0024141
27429532	481	485	AIMF	T191	C0026987
27429532	498	505	patient	T101	C0030705
27429532	512	517	young	T079	C0332239
27429532	518	523	woman	T098	C0043210
27429532	532	544	pancytopenia	T047	C0030312
27429532	546	566	massive splenomegaly	T033	C0241231
27429532	571	589	reticulin fibrosis	T033	C1335762
27429532	597	610	marrow biopsy	T060	C0005954
27429532	616	628	pancytopenia	T047	C0030312
27429532	633	645	splenomegaly	T033	C0038002
27429532	646	654	resolved	T033	C3714811
27429532	673	678	weeks	T079	C0439230
27429532	682	691	treatment	T169	C1522326
27429532	697	712	corticosteroids	T121	C3536709
27429532	721	734	marrow biopsy	T060	C0005954
27429532	742	759	marked regression	T046	C0684320
27429532	763	778	marrow fibrosis	T191	C0026987
27429532	791	798	patient	T101	C0030705
27429532	805	810	young	T079	C0332239
27429532	811	816	woman	T098	C0043210
27429532	822	827	fever	T184	C0015967
27429532	829	837	anasarca	T184	C0013604
27429532	839	850	bicytopenia	T034	C1142446
27429532	855	873	reticulin fibrosis	T033	C1335762
27429532	881	894	marrow biopsy	T060	C0005954
27429532	896	911	Steroid therapy	T061	C0149783
27429532	912	920	resulted	T169	C1274040
27429532	930	938	clinical	T080	C0205210
27429532	939	950	improvement	T077	C2986411
27429532	955	965	resolution	T077	C2699488
27429532	969	981	pancytopenia	T047	C0030312
27429532	985	994	review of	T169	C0699752
27429532	999	1009	literature	T170	C0023866
27429532	1010	1018	revealed	T080	C0443289
27429532	1033	1041	patients	T101	C0030705
27429532	1047	1050	SLE	T047	C0024141
27429532	1053	1057	AIMF	T191	C0026987
27429532	1071	1075	date	T079	C0011008
27429532	1077	1085	Patients	T101	C0030705
27429532	1091	1094	SLE	T047	C0024141
27429532	1097	1101	AIMF	T191	C0026987
27429532	1106	1111	young	T079	C0332239
27429532	1112	1117	women	T098	C0043210
27429532	1123	1126	SLE	T047	C0024141
27429532	1131	1146	blood cytopenia	T046	C0010828
27429532	1169	1178	increased	T081	C0205217
27429532	1179	1200	bone marrow reticulin	T033	C1335762
27429532	1204	1217	marrow biopsy	T060	C0005954
27429532	1219	1234	Steroid therapy	T061	C0149783
27429532	1235	1242	results	T169	C1274040
27429532	1252	1265	hematological	T169	C0205488
27429532	1266	1274	recovery	T052	C0237820
27429532	1279	1289	regression	T046	C0684320
27429532	1293	1308	marrow fibrosis	T191	C0026987
27429532	1318	1322	AIMF	T191	C0026987
27429532	1341	1354	hematological	T169	C0205488
27429532	1355	1368	complications	T046	C0009566
27429532	1372	1375	SLE	T047	C0024141
27429532	1393	1399	unique	T080	C1710548
27429532	1404	1412	distinct	T080	C1705242
27429532	1423	1431	patients	T101	C0030705
27429532	1437	1440	SLE	T047	C0024141
27429532	1455	1474	Prospective studies	T062	C0033522
27429532	1487	1496	follow-up	T058	C1522577
27429532	1511	1517	better	T080	C0332272
27429532	1529	1539	prevalence	T081	C0683921
27429532	1544	1561	clinical spectrum	T201	C0683325
27429532	1565	1568	SLE	T047	C0024141
27429532	1571	1575	AIMF	T191	C0026987

27657150|t|Comparison of Very Low Energy Diet Products Available in Australia and How to Tailor Them to Optimise Protein Content for Younger and Older Adult Men and Women
27657150|a|Very low energy diets (VLED) are efficacious in inducing rapid weight loss but may not contain adequate macronutrients or micronutrients for individuals with varying nutritional requirements. Adequate protein intake during weight loss appears particularly important to help preserve fat free mass and control appetite, and low energy and carbohydrate content also contributes to appetite control. Therefore, the purpose of this study was to compare the nutritional content (with a focus on protein), nutritional adequacy and cost of all commercially-available VLED brands in Australia. Nutritional content and cost were extracted and compared between brands and to the Recommended Dietary Intake (RDI) or adequate intake (AI) of macronutrients and micronutrients for men and women aged 19-70 years or >70 years. There was wide variability in the nutritional content, nutritional adequacy and cost of VLED brands. Most notably, even brands with the highest daily protein content, based on consuming three products/day (KicStart™ and Optislim(®), ~60 g/day), only met estimated protein requirements of the smallest and youngest women for whom a VLED would be indicated. Considering multiple options to optimise protein content, we propose that adding pure powdered protein is the most suitable option because it minimizes additional energy, carbohydrate and cost of VLEDs.
27657150	14	43	Very Low Energy Diet Products	T061	C0452268
27657150	57	66	Australia	T083	C0004340
27657150	102	109	Protein	T116,T123	C0033684
27657150	110	117	Content	T077	C0456205
27657150	122	129	Younger	T079	C0332239
27657150	134	139	Older	T079	C0580836
27657150	140	145	Adult	T100	C0001675
27657150	146	149	Men	T098	C0025266
27657150	154	159	Women	T098	C0043210
27657150	160	181	Very low energy diets	T061	C0452268
27657150	183	187	VLED	T061	C0452268
27657150	217	234	rapid weight loss	T033	C0750421
27657150	264	278	macronutrients	T077	C2346926
27657150	282	296	micronutrients	T123	C0282575
27657150	301	312	individuals	T098	C0237401
27657150	326	350	nutritional requirements	T032	C0028719
27657150	361	375	protein intake	T033	C0425424
27657150	383	394	weight loss	T033	C1262477
27657150	443	456	fat free mass	T033	C0424679
27657150	461	477	control appetite	T040	C0003622
27657150	483	518	low energy and carbohydrate content	T061	C0259836
27657150	539	555	appetite control	T040	C0003622
27657150	588	593	study	T062	C2603343
27657150	613	624	nutritional	T080	C1521739
27657150	625	632	content	T077	C0456205
27657150	650	657	protein	T116,T123	C0033684
27657150	660	680	nutritional adequacy	T033	C0392209
27657150	685	689	cost	T081	C0010186
27657150	720	724	VLED	T061	C0452268
27657150	725	731	brands	T170	C0592503
27657150	735	744	Australia	T083	C0004340
27657150	746	757	Nutritional	T080	C1521739
27657150	758	765	content	T077	C0456205
27657150	770	774	cost	T081	C0010186
27657150	811	817	brands	T170	C0592503
27657150	829	855	Recommended Dietary Intake	T170	C0524787
27657150	857	860	RDI	T170	C0524787
27657150	865	880	adequate intake	T033	C0243095
27657150	882	884	AI	T033	C0243095
27657150	889	903	macronutrients	T077	C2346926
27657150	908	922	micronutrients	T123	C0282575
27657150	927	930	men	T098	C0025266
27657150	935	940	women	T098	C0043210
27657150	1006	1017	nutritional	T080	C1521739
27657150	1018	1025	content	T077	C0456205
27657150	1027	1047	nutritional adequacy	T032	C0028719
27657150	1060	1064	VLED	T061	C0452268
27657150	1065	1071	brands	T170	C0592503
27657150	1092	1098	brands	T170	C0592503
27657150	1122	1129	protein	T116,T123	C0033684
27657150	1130	1137	content	T077	C0456205
27657150	1236	1256	protein requirements	T033	C0556043
27657150	1286	1291	women	T098	C0043210
27657150	1303	1307	VLED	T061	C0452268
27657150	1369	1376	protein	T116,T123	C0033684
27657150	1377	1384	content	T077	C0456205
27657150	1414	1430	powdered protein	T168	C0784146
27657150	1499	1511	carbohydrate	T109	C0012170
27657150	1516	1520	cost	T081	C0010186
27657150	1524	1529	VLEDs	T061	C0452268

28122499|t|Uridine stimulate laxative effect in the loperamide - induced constipation of SD rats through regulation of the mAChRs signaling pathway and mucin secretion
28122499|a|Uridine (Urd), which has been reported as a major component of RNA, plays an important role in various biological process including neuroprotection, biochemical modulation and glycolysis, although its role in constipation has yet to be established. Therefore, in this study, we investigated the laxative effects of Urd on chronic constipation. The constipation phenotypes and their related mechanisms were investigated in the transverse colons of SD rats with loperamide (Lop)- induced constipation after treatment with 100 mg/kg of Urd. The number, weight and water contents of stools were significantly higher in the Lop + Urd treated group than the Lop + Vehicle treated group, while food intake and water consumption of the same group were maintained at a constant level. The thickness of the mucosa layer, muscle and flat luminal surface, as well as the number of goblet cells, paneth cells and lipid droplets were enhanced in the Lop + Urd treated group. Furthermore, the expression of the muscarinic acetylcholine receptors M2 and M3 (mAChR M2 and M3) at the transcriptional and translational level was recovered in the Lop + Urd treated group, while some markers such as Gα and inositol triphosphate (IP3) in their downstream signaling pathway were completely recovered by Urd treatment. Moreover, the ability for mucin secretion and the expression of membrane water channel (aquaporine 8, AQP8) were increased significantly in the Lop + Urd treated group compared with Lop + Vehicle treated group. Finally, the activity of Urd was confirmed in primary smooth muscle of rat intestine cells (pRISMC) based on Gα expression and IP3 concentration. The results of the present study provide the first strong evidence that Urd can be considered an important candidate for improving chronic constipation induced by Lop treatment in animal models.
28122499	0	7	Uridine	T114,T121	C0041984
28122499	18	26	laxative	T121	C0282090
28122499	27	33	effect	T080	C1280500
28122499	41	51	loperamide	T109,T121	C0023992
28122499	54	61	induced	T169	C0205263
28122499	62	74	constipation	T184	C0009806
28122499	78	85	SD rats	T015	C2699239
28122499	94	104	regulation	T044	C1327386
28122499	112	118	mAChRs	T116,T192	C0034826
28122499	119	136	signaling pathway	T044	C0037080
28122499	141	146	mucin	T116,T123	C0026682
28122499	147	156	secretion	T038	C0036536
28122499	157	164	Uridine	T114,T121	C0041984
28122499	166	169	Urd	T114,T121	C0041984
28122499	187	195	reported	T058	C0700287
28122499	201	206	major	T080	C0205164
28122499	220	223	RNA	T114	C0035668
28122499	234	243	important	T080	C3898777
28122499	244	248	role	T077	C1705810
28122499	260	278	biological process	T038	C3714634
28122499	289	304	neuroprotection	T043	C0598958
28122499	306	328	biochemical modulation	UnknownType	C0678672
28122499	333	343	glycolysis	T044	C0017952
28122499	358	362	role	T077	C1705810
28122499	366	378	constipation	T184	C0009806
28122499	393	404	established	T080	C0443211
28122499	425	430	study	T062	C2603343
28122499	435	447	investigated	T169	C1292732
28122499	452	460	laxative	T121	C0282090
28122499	461	468	effects	T080	C1280500
28122499	472	475	Urd	T114,T121	C0041984
28122499	479	486	chronic	T079	C0205191
28122499	487	499	constipation	T184	C0009806
28122499	505	517	constipation	T184	C0009806
28122499	518	528	phenotypes	T032	C0031437
28122499	547	557	mechanisms	T169	C0441712
28122499	563	575	investigated	T169	C1292732
28122499	583	600	transverse colons	T023	C0227386
28122499	604	611	SD rats	T015	C2699239
28122499	617	627	loperamide	T109,T121	C0023992
28122499	629	632	Lop	T109,T121	C0023992
28122499	635	642	induced	T169	C0205263
28122499	643	655	constipation	T184	C0009806
28122499	662	671	treatment	T061	C0087111
28122499	690	693	Urd	T114,T121	C0041984
28122499	699	705	number	T081	C0237753
28122499	707	713	weight	T081	C0043100
28122499	718	723	water	T121,T197	C0043047
28122499	724	732	contents	T077	C0456205
28122499	736	742	stools	T031	C0015733
28122499	748	761	significantly	T078	C0750502
28122499	762	768	higher	T080	C0205250
28122499	776	779	Lop	T109,T121	C0023992
28122499	782	785	Urd	T114,T121	C0041984
28122499	786	793	treated	T033	C0332154
28122499	794	799	group	T078	C0441833
28122499	809	812	Lop	T109,T121	C0023992
28122499	815	822	Vehicle	T122	C0042444
28122499	823	830	treated	T033	C0332154
28122499	831	836	group	T078	C0441833
28122499	844	855	food intake	T040	C0013470
28122499	860	877	water consumption	T040	C0013123
28122499	890	895	group	T078	C0441833
28122499	917	925	constant	T080	C1948059
28122499	926	931	level	T080	C0441889
28122499	937	946	thickness	T080	C1280412
28122499	954	966	mucosa layer	T024	C0026724
28122499	968	974	muscle	T024	C0026845
28122499	979	999	flat luminal surface	T029	C1180160
28122499	1016	1022	number	T081	C0237753
28122499	1026	1038	goblet cells	T025	C0506994
28122499	1040	1052	paneth cells	T025	C0227276
28122499	1057	1071	lipid droplets	T026	C0230704
28122499	1077	1085	enhanced	T052	C2349975
28122499	1093	1096	Lop	T109,T121	C0023992
28122499	1099	1102	Urd	T114,T121	C0041984
28122499	1103	1110	treated	T033	C0332154
28122499	1111	1116	group	T078	C0441833
28122499	1135	1145	expression	T045	C1171362
28122499	1153	1190	muscarinic acetylcholine receptors M2	T116,T192	C0384752
28122499	1195	1197	M3	T116,T192	C0289799
28122499	1199	1207	mAChR M2	T116,T192	C0384752
28122499	1212	1214	M3	T116,T192	C0289799
28122499	1223	1238	transcriptional	T045	C1158770
28122499	1243	1256	translational	T045	C3537096
28122499	1257	1262	level	T080	C0441889
28122499	1267	1276	recovered	T080	C0521108
28122499	1284	1287	Lop	T109,T121	C0023992
28122499	1290	1293	Urd	T114,T121	C0041984
28122499	1294	1301	treated	T033	C0332154
28122499	1302	1307	group	T078	C0441833
28122499	1320	1327	markers	T201	C0005516
28122499	1336	1338	Gα	T116,T126	C0887847
28122499	1343	1364	inositol triphosphate	UnknownType	C0815032
28122499	1366	1369	IP3	UnknownType	C0815032
28122499	1380	1390	downstream	T082	C0522506
28122499	1391	1408	signaling pathway	T044	C0037080
28122499	1425	1434	recovered	T080	C0521108
28122499	1438	1441	Urd	T114,T121	C0041984
28122499	1442	1451	treatment	T061	C0087111
28122499	1479	1484	mucin	T116,T123	C0026682
28122499	1485	1494	secretion	T038	C0036536
28122499	1503	1513	expression	T045	C1171362
28122499	1517	1539	membrane water channel	T116,T123	C0599635
28122499	1541	1553	aquaporine 8	T116,T123	C1743716
28122499	1555	1559	AQP8	T116,T123	C1743716
28122499	1566	1575	increased	T081	C0205217
28122499	1576	1589	significantly	T078	C0750502
28122499	1597	1600	Lop	T109,T121	C0023992
28122499	1603	1606	Urd	T114,T121	C0041984
28122499	1607	1614	treated	T033	C0332154
28122499	1615	1620	group	T078	C0441833
28122499	1621	1629	compared	T052	C1707455
28122499	1635	1638	Lop	T109,T121	C0023992
28122499	1641	1648	Vehicle	T122	C0042444
28122499	1649	1656	treated	T033	C0332154
28122499	1657	1662	group	T078	C0441833
28122499	1677	1685	activity	T052	C0441655
28122499	1689	1692	Urd	T114,T121	C0041984
28122499	1710	1731	primary smooth muscle	T024	C1267092
28122499	1735	1738	rat	T015	C0086893
28122499	1739	1754	intestine cells	T025	C0814997
28122499	1756	1762	pRISMC	T025	C1135918
28122499	1773	1775	Gα	T116,T126	C0887847
28122499	1776	1786	expression	T045	C1171362
28122499	1791	1794	IP3	UnknownType	C0815032
28122499	1795	1808	concentration	T081	C1446561
28122499	1814	1821	results	T033	C0683954
28122499	1837	1842	study	T062	C2603343
28122499	1861	1867	strong	T080	C0442821
28122499	1868	1876	evidence	T078	C3887511
28122499	1882	1885	Urd	T114,T121	C0041984
28122499	1907	1916	important	T080	C3898777
28122499	1931	1940	improving	T080	C1272745
28122499	1941	1948	chronic	T079	C0205191
28122499	1949	1961	constipation	T184	C0009806
28122499	1962	1969	induced	T169	C0205263
28122499	1973	1976	Lop	T109,T121	C0023992
28122499	1977	1986	treatment	T061	C0087111
28122499	1990	2003	animal models	T008	C0599779

27683067|t|Assessment of the interaction of Portland cement-based materials with blood and tissue fluids using an animal model
27683067|a|Portland cement used in the construction industry improves its properties when wet. Since most dental materials are used in a moist environment, Portland cement has been developed for use in dentistry. The first generation material is mineral trioxide aggregate (MTA), used in surgical procedures, thus in contact with blood. The aim of this study was to compare the setting of MTA in vitro and in vivo in contact with blood by subcutaneous implantation in rats. The tissue reaction to the material was also investigated. ProRoot MTA (Dentsply) was implanted in the subcutaneous tissues of Sprague-Dawley rats in opposite flanks and left in situ for 3 months. Furthermore the material was also stored in physiological solution in vitro. At the end of the incubation time, tissue histology and material characterization were performed. Surface assessment showed the formation of calcium carbonate for both environments. The bismuth was evident in the tissues thus showing heavy element contamination of the animal specimen. The tissue histology showed a chronic inflammatory cell infiltrate associated with the MTA. MTA interacts with the host tissues and causes a chronic inflammatory reaction when implanted subcutaneously. Hydration in vivo proceeds similarly to the in vitro model with some differences particularly in the bismuth oxide leaching patterns.
27683067	0	29	Assessment of the interaction	T081	C0237688
27683067	33	64	Portland cement-based materials	T122	C1175041
27683067	70	75	blood	T031	C0005767
27683067	80	93	tissue fluids	UnknownType	C0682553
27683067	103	115	animal model	T008	C0599779
27683067	116	131	Portland cement	T122	C1175041
27683067	144	165	construction industry	T090	C0682031
27683067	166	174	improves	T033	C0184511
27683067	195	198	wet	T080	C0205381
27683067	211	227	dental materials	T122	C0011379
27683067	242	259	moist environment	T080	C0205381
27683067	261	276	Portland cement	T122	C1175041
27683067	307	316	dentistry	T091	C0011438
27683067	322	347	first generation material	T122	C0011379
27683067	351	377	mineral trioxide aggregate	T122	C0253527
27683067	379	382	MTA	T122	C0253527
27683067	393	412	surgical procedures	T061	C0543467
27683067	435	440	blood	T031	C0005767
27683067	458	463	study	T062	C2603343
27683067	494	497	MTA	T122	C0253527
27683067	498	506	in vitro	T080	C1533691
27683067	511	518	in vivo	T082	C1515655
27683067	535	540	blood	T031	C0005767
27683067	544	569	subcutaneous implantation	T169	C1553218
27683067	573	577	rats	T015	C0682511
27683067	583	614	tissue reaction to the material	T033	C1708386
27683067	638	649	ProRoot MTA	T109,T122	C0112984
27683067	651	659	Dentsply	T109,T122	C0112984
27683067	665	674	implanted	T061	C0021107
27683067	682	702	subcutaneous tissues	T024	C0278403
27683067	706	725	Sprague-Dawley rats	T015	C0034715
27683067	729	744	opposite flanks	T029	C0230171
27683067	754	761	in situ	T082	C0444498
27683067	768	774	months	T079	C0439231
27683067	792	800	material	T122	C0011379
27683067	820	842	physiological solution	T122	C0776637
27683067	843	851	in vitro	T080	C1533691
27683067	871	886	incubation time	T033	C1320226
27683067	888	894	tissue	T024	C0040300
27683067	895	904	histology	T059	C0344441
27683067	909	934	material characterization	T052	C1880022
27683067	951	969	Surface assessment	T058	C0031809
27683067	981	990	formation	T169	C1522492
27683067	994	1011	calcium carbonate	T121,T197	C0006681
27683067	1021	1033	environments	T082	C0014406
27683067	1039	1046	bismuth	T121	C2917658
27683067	1066	1073	tissues	T024	C0040300
27683067	1079	1114	showing heavy element contamination	T033	C1393812
27683067	1122	1128	animal	T008	C0003062
27683067	1129	1137	specimen	T167	C0370003
27683067	1143	1149	tissue	T024	C0040300
27683067	1150	1159	histology	T059	C0344441
27683067	1169	1176	chronic	T079	C0205191
27683067	1177	1205	inflammatory cell infiltrate	T031	C0541629
27683067	1226	1229	MTA	T122	C0253527
27683067	1231	1234	MTA	T122	C0253527
27683067	1254	1258	host	T001	C1167395
27683067	1259	1266	tissues	T024	C0040300
27683067	1280	1309	chronic inflammatory reaction	T046	C0021376
27683067	1315	1339	implanted subcutaneously	T169	C1553218
27683067	1341	1350	Hydration	T067	C0596317
27683067	1351	1358	in vivo	T082	C1515655
27683067	1385	1393	in vitro	T080	C1533691
27683067	1394	1399	model	T075	C0026336
27683067	1442	1455	bismuth oxide	T121,T197	C0053786
27683067	1456	1473	leaching patterns	T167	C1534704

27449508|t|Modulation of Interleukins in Sepsis - Associated Clotting Disorders: Interplay With Hemostatic Derangement
27449508|a|Interleukins play a central role in the immune system and are involved in a variety of immunological, inflammatory, and infectious disease states including sepsis syndrome. Levels of interleukins may correlate with overall survival and may directly or indirectly affect some of the regulators of coagulation and fibrinolysis, thereby disrupting hemostasis and thrombosis. Our hypothesis is that in sepsis-associated coagulopathies (SACs), interleukins may be upregulated, leading to hemostatic imbalance by generating thrombogenic mediators. We profiled the levels of interleukins IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10 in addition to d-dimer (DD) in patients with SAC and in normal donors. We observed the highest increase in interleukins IL-6 (322-fold), IL-8 (48-fold), IL-10 (72-fold), and DD (18-fold). This suggests that interleukins such as IL-6 and IL-10 have a close association with coagulopathy and fibrinolytic dysregulation in sepsis and can be considered as candidates for potential therapeutic targets in SAC.
27449508	0	10	Modulation	T082	C0443264
27449508	14	26	Interleukins	T116,T129	C0021764
27449508	30	36	Sepsis	T047	C0036690
27449508	39	49	Associated	T080	C0332281
27449508	50	68	Clotting Disorders	T047	C0005779
27449508	85	107	Hemostatic Derangement	T047	C0005779
27449508	108	120	Interleukins	T116,T129	C0021764
27449508	128	135	central	T082	C0205099
27449508	136	140	role	T077	C1705810
27449508	148	161	immune system	T022	C0020962
27449508	170	178	involved	T169	C1314939
27449508	195	208	immunological	T047	C0021053
27449508	210	222	inflammatory	T047	C1290884
27449508	228	246	infectious disease	T047	C0009450
27449508	247	253	states	T169	C1442792
27449508	264	279	sepsis syndrome	T047	C0036690
27449508	281	287	Levels	T080	C0441889
27449508	291	303	interleukins	T116,T129	C0021764
27449508	308	317	correlate	T080	C1707520
27449508	323	339	overall survival	T081	C4086681
27449508	348	356	directly	T080	C1947931
27449508	360	370	indirectly	T080	C0439852
27449508	371	377	affect	T041	C0001721
27449508	390	400	regulators	T121,T129	C0005525
27449508	404	415	coagulation	T042	C0005778
27449508	420	432	fibrinolysis	T039	C0016017
27449508	453	463	hemostasis	T042	C0019116
27449508	468	478	thrombosis	T046	C0040053
27449508	484	494	hypothesis	T078	C1512571
27449508	506	538	sepsis-associated coagulopathies	T047	C0005779
27449508	540	544	SACs	T047	C0005779
27449508	547	559	interleukins	T116,T129	C0021764
27449508	567	578	upregulated	T044	C0041904
27449508	591	611	hemostatic imbalance	T047	C0005779
27449508	626	648	thrombogenic mediators	T123	C0574031
27449508	653	661	profiled	T169	C2003903
27449508	666	672	levels	T080	C0441889
27449508	676	688	interleukins	T116,T129	C0021764
27449508	689	694	IL-1α	T116,T123	C0600251
27449508	696	701	IL-1β	T116,T129	C0021753
27449508	703	707	IL-2	T116,T129	C0021756
27449508	709	713	IL-4	T116,T129	C0021758
27449508	715	719	IL-6	T116,T129	C0021760
27449508	721	725	IL-8	T116,T129	C0079633
27449508	731	736	IL-10	T116,T129	C0085295
27449508	737	751	in addition to	T169	C0332287
27449508	752	759	d-dimer	T116,T123	C0060323
27449508	761	763	DD	T116,T123	C0060323
27449508	768	776	patients	T101	C0030705
27449508	782	785	SAC	T047	C0005779
27449508	793	799	normal	T080	C0205307
27449508	800	806	donors	T098	C0005795
27449508	811	819	observed	T169	C1441672
27449508	824	831	highest	T080	C1522410
27449508	832	840	increase	T169	C0442805
27449508	844	856	interleukins	T116,T129	C0021764
27449508	857	861	IL-6	T116,T129	C0021760
27449508	863	871	322-fold	T081	C1880833
27449508	874	878	IL-8	T116,T129	C0079633
27449508	880	887	48-fold	T081	C1880833
27449508	890	895	IL-10	T116,T129	C0085295
27449508	897	904	72-fold	T081	C1880833
27449508	911	913	DD	T116,T123	C0060323
27449508	915	922	18-fold	T081	C1880833
27449508	930	938	suggests	T078	C1705535
27449508	944	956	interleukins	T116,T129	C0021764
27449508	965	969	IL-6	T116,T129	C0021760
27449508	974	979	IL-10	T116,T129	C0085295
27449508	993	1009	association with	T080	C0332281
27449508	1010	1022	coagulopathy	T047	C0005779
27449508	1027	1053	fibrinolytic dysregulation	UnknownType	C0543673
27449508	1057	1063	sepsis	T047	C0036690
27449508	1075	1085	considered	T078	C0750591
27449508	1089	1099	candidates	T116,T129	C0021764
27449508	1104	1113	potential	T080	C3245505
27449508	1114	1125	therapeutic	T169	C0302350
27449508	1126	1133	targets	T169	C1521840
27449508	1137	1140	SAC	T047	C0005779

27252099|t|Comparison of Head Elevation Protocols Following Femoral Artery Sheath Removal After Coronary Angiography
27252099|a|To compare 2 standard protocols for head elevation following removal of a femoral artery sheath after coronary angiography and their effects on bleeding complications and reported levels of back pain. One protocol involved flat supine bed rest; the other allowed progressive head elevation. A prospective comparative study of 80 adult patients undergoing coronary angiography via the femoral approach. The Numeric Rating Scale was used as the measure of reported pain. No bleeding complications occurred in either group. Both groups had very low mean pain scores. Repeated- measures analysis demonstrated that the experience of pain differed significantly over time by location (F5,70 = 3.864, P = .004), with a notable decrease in pain scores more than 1 hour after sheath removal at the location that used the progressive head elevation protocol. Patients ' satisfaction scores after discharge did not differ significantly between the 2 groups. Patients with a history of chronic back pain had consistently higher pain scores, but those pain scores did not differ significantly by location (or protocol). It appears that using a progressive head - elevation protocol within the first 3 hours after diagnostic angiography is not associated with an increased risk of bleeding complications at the access site and warrants further exploration in the mitigation of back pain associated with prolonged supine bed rest.
27252099	0	10	Comparison	T052	C1707455
27252099	14	18	Head	T029	C0018670
27252099	19	38	Elevation Protocols	T061	C0439775
27252099	49	70	Femoral Artery Sheath	T023	C0015801
27252099	71	78	Removal	T061	C0015252
27252099	85	105	Coronary Angiography	T060	C0085532
27252099	109	116	compare	T052	C1707455
27252099	128	137	protocols	T061	C0008971
27252099	142	146	head	T029	C0018670
27252099	147	156	elevation	T061	C0439775
27252099	180	201	femoral artery sheath	T023	C0015801
27252099	208	228	coronary angiography	T060	C0085532
27252099	239	246	effects	T080	C1280500
27252099	250	258	bleeding	T046	C0019080
27252099	259	272	complications	T046	C0009566
27252099	296	305	back pain	T184	C0004604
27252099	311	319	protocol	T061	C0008971
27252099	334	340	supine	T082	C0038846
27252099	341	349	bed rest	T061	C0004910
27252099	381	385	head	T029	C0018670
27252099	386	395	elevation	T061	C0439775
27252099	411	428	comparative study	T062	C1579762
27252099	435	440	adult	T100	C0001675
27252099	441	449	patients	T101	C0030705
27252099	461	481	coronary angiography	T060	C0085532
27252099	490	497	femoral	T023	C0015811
27252099	498	506	approach	T082	C0449445
27252099	512	532	Numeric Rating Scale	T170	C4050142
27252099	549	556	measure	T081	C0079809
27252099	569	573	pain	T184	C0030193
27252099	578	586	bleeding	T046	C0019080
27252099	587	600	complications	T046	C0009566
27252099	620	625	group	T078	C0441833
27252099	632	638	groups	T078	C0441833
27252099	648	651	low	T080	C0205251
27252099	652	656	mean	T081	C0444504
27252099	657	668	pain scores	T033	C0582148
27252099	680	688	measures	T169	C1879489
27252099	689	697	analysis	T062	C0936012
27252099	734	738	pain	T184	C0030193
27252099	767	771	time	T079	C0040223
27252099	775	783	location	T029	C1515974
27252099	826	834	decrease	T081	C0547047
27252099	838	849	pain scores	T033	C0582148
27252099	862	866	hour	T079	C0439227
27252099	873	879	sheath	T023	C0015801
27252099	880	887	removal	T061	C0015252
27252099	895	903	location	T029	C1515974
27252099	930	934	head	T029	C0018670
27252099	935	953	elevation protocol	T061	C0439775
27252099	955	963	Patients	T101	C0030705
27252099	979	985	scores	T081	C0449820
27252099	1045	1051	groups	T078	C0441833
27252099	1053	1061	Patients	T101	C0030705
27252099	1069	1076	history	T033	C0262926
27252099	1080	1087	chronic	T079	C0205191
27252099	1088	1097	back pain	T184	C0004604
27252099	1122	1133	pain scores	T033	C0582148
27252099	1145	1156	pain scores	T033	C0582148
27252099	1189	1197	location	T029	C1515974
27252099	1202	1210	protocol	T061	C0008971
27252099	1249	1253	head	T029	C0018670
27252099	1256	1274	elevation protocol	T061	C0439775
27252099	1294	1299	hours	T079	C0439227
27252099	1306	1316	diagnostic	T169	C0348026
27252099	1317	1328	angiography	T060	C0002978
27252099	1365	1369	risk	T078	C0035647
27252099	1373	1381	bleeding	T046	C0019080
27252099	1382	1395	complications	T046	C0009566
27252099	1403	1414	access site	T082	C0589360
27252099	1455	1465	mitigation	T080	C0205556
27252099	1469	1478	back pain	T184	C0004604
27252099	1495	1504	prolonged	T079	C0439590
27252099	1505	1511	supine	T082	C0038846
27252099	1512	1520	bed rest	T061	C0004910

28466053|t|Analyzing the clinical profile of swine flu / influenza A H1N1 infection in central India: a retrospective study
28466053|a|Recently, India reported an increase in swine flu (influenza A H1N1) activity. There are limited studies on epidemiology of swine flu in Indian context. This study aims to analyze clinical and epidemiological profile of suspected swine flu cases in central India. 171 cases were included in a hospital based, observational, descriptive study conducted from December 2014 to April 2015. Demographics, clinical presentation and outcome of positive and negative cases were compared. Data was analyzed using STATA software. Distribution by age, sex and residence was found similar (p > 0.05) in positive and negative cases. Cough (89%), fever (85%) and throat irritation (51%) were chief complaints (avg. duration = 4.9 days). History of travel, history of contact with swine flu cases (p = 0.002) and history of visiting crowded places (p = 0.098) was reported considerably in higher proportion in positive cases as compared to negative cases. There were 14 deaths and they occurred significantly in younger age among positive cases as compared to negatives (Mean ± SD: 34 ± 2.8 vs 47 ± 8.4 years). Case fatality ratio (CFR) in positive cases showing history of travel, contact with swine flu cases, requiring invasive ventilator support and >3 X-ray zones involvement were significantly higher. Outbreak in later part of winter, high case fatality and younger population is more affected. In this study, swine flu infection and outbreaks started later in the year Hospital stay and CFR were increased. Understanding the swine flu infection, changing clinical presentation of swine flu and formulate new strategies for its prevention and management.
28466053	0	9	Analyzing	T062	C0936012
28466053	14	22	clinical	T080	C0205210
28466053	23	30	profile	T059	C1979963
28466053	34	43	swine flu	T047	C2076600
28466053	46	72	influenza A H1N1 infection	T047	C2076600
28466053	76	89	central India	T083	C0021201
28466053	93	112	retrospective study	T062	C0035363
28466053	123	128	India	T083	C0021201
28466053	141	149	increase	T169	C0442805
28466053	153	162	swine flu	T047	C2076600
28466053	164	180	influenza A H1N1	T047	C2076600
28466053	210	217	studies	T059	C0947630
28466053	221	233	epidemiology	T091	C0014507
28466053	237	246	swine flu	T047	C2076600
28466053	250	264	Indian context	T078	C0449255
28466053	271	276	study	T059	C0947630
28466053	277	281	aims	T078	C1947946
28466053	285	292	analyze	T062	C0936012
28466053	293	301	clinical	T080	C0205210
28466053	306	329	epidemiological profile	T062	C0002783
28466053	333	342	suspected	T080	C0332147
28466053	343	352	swine flu	T047	C2076600
28466053	353	358	cases	T077	C1706256
28466053	362	375	central India	T083	C0021201
28466053	381	386	cases	T077	C1706256
28466053	406	414	hospital	T073,T093	C0019994
28466053	422	435	observational	T062	C1518527
28466053	437	448	descriptive	T170	C0678257
28466053	499	511	Demographics	T090	C0011298
28466053	513	534	clinical presentation	T170	C2708283
28466053	539	546	outcome	T169	C1274040
28466053	550	558	positive	T033	C1514241
28466053	563	577	negative cases	T033	C1513916
28466053	593	597	Data	T078	C1511726
28466053	602	610	analyzed	T062	C0936012
28466053	617	631	STATA software	T073,T170	C0037585
28466053	633	645	Distribution	T169	C1704711
28466053	649	652	age	T081	C0001782
28466053	654	657	sex	T081	C0036878
28466053	662	671	residence	T082	C0237096
28466053	704	712	positive	T033	C1514241
28466053	717	731	negative cases	T033	C1513916
28466053	733	738	Cough	T184	C0010200
28466053	746	751	fever	T184	C0015967
28466053	762	779	throat irritation	T184	C0700184
28466053	791	807	chief complaints	T033	C0277786
28466053	836	853	History of travel	T033	C0489542
28466053	855	862	history	T033	C2004062
28466053	866	878	contact with	T169	C0332158
28466053	879	888	swine flu	T047	C2076600
28466053	889	894	cases	T077	C1706256
28466053	911	918	history	T033	C2004062
28466053	931	945	crowded places	T082	C0442504
28466053	987	993	higher	T080	C0205250
28466053	994	1004	proportion	T081	C1709707
28466053	1008	1022	positive cases	T033	C1514241
28466053	1038	1052	negative cases	T033	C1513916
28466053	1068	1074	deaths	T040	C0011065
28466053	1110	1121	younger age	T033	C4061789
28466053	1128	1142	positive cases	T033	C1514241
28466053	1158	1167	negatives	T033	C1513916
28466053	1209	1228	Case fatality ratio	T081	C0282250
28466053	1230	1233	CFR	T081	C0282250
28466053	1238	1252	positive cases	T033	C1514241
28466053	1261	1278	history of travel	T033	C0489542
28466053	1280	1292	contact with	T169	C0332158
28466053	1293	1302	swine flu	T047	C2076600
28466053	1303	1308	cases	T077	C1706256
28466053	1320	1347	invasive ventilator support	T074	C0183683
28466053	1355	1360	X-ray	T169	C0034571
28466053	1361	1366	zones	T082	C1710706
28466053	1406	1414	Outbreak	T067	C0012652
28466053	1432	1438	winter	T079	C0241737
28466053	1440	1458	high case fatality	T081	C0681679
28466053	1463	1481	younger population	T098	C1257890
28466053	1490	1498	affected	T169	C0392760
28466053	1508	1513	study	T059	C0947630
28466053	1515	1534	swine flu infection	T047	C2076600
28466053	1539	1548	outbreaks	T067	C0012652
28466053	1575	1583	Hospital	T073,T093	C0019994
28466053	1593	1596	CFR	T081	C0282250
28466053	1602	1611	increased	T169	C0442805
28466053	1631	1650	swine flu infection	T047	C2076600
28466053	1661	1682	clinical presentation	T170	C2708283
28466053	1686	1695	swine flu	T047	C2076600
28466053	1733	1743	prevention	T061	C0679698
28466053	1748	1758	management	T058	C0376636

27900133|t|The relationships between rugby players' tackle training attitudes and behaviour and their match tackle attitudes and behaviour
27900133|a|The tackle event in rugby is a technical and physical contest between opposing players. A player's ability to tolerate and contest during a tackle is a prerequisite for safe participation and success in rugby. Little is known about the relationship between tackle training and tackling in matches in rugby union. Therefore, we investigated the relationships between players' training attitudes and behaviour and their match attitudes and behaviour for tackling in rugby union. A questionnaire was designed to assess attitude (importance) and behaviours (frequency and quantity) among junior (under 19) players on a 5-point Likert Scale. Questionnaires were handed out to 220 players (10 schools) at a tournament and 75% (9 schools, n=164) were returned for analysis. Associations between training attitudes and behaviours were tested using the χ(2) test, Cramer's V and τ-b. The more time spent on emphasising proper technique to prevent injuries in training, the more important players rated 'own safety' (τ-b=0.21, moderate, z=3.1, p<0.01), 'going for the ball only' (τ-b=0.27, moderate, z=4.6, p<0.001) and 'staying on feet' (τ-b=0.23, moderate, z=3.6, p<0.001) in match play. The more time spent on emphasising proper technique to improve performance in training, the more important players rated actions 'going for ball only' (τ-b=0.23, moderate, z=3.7, p<0.001) and ' preventing the ball carrier from retaining position ' (τ-b=0.20, moderate, z=3.1, p<0.01) in match play. This is the first study to report on the relationships between players ' training attitudes and behaviour and their match attitudes and behaviour s for tackling in rugby union. The importance of tackle training to prevent injury, and the amount of time spent on technique to prevent injuries, was associated with behaviours that reduce the risk of injury in matches.
27900133	4	17	relationships	T080	C0439849
27900133	26	31	rugby	T056	C0035945
27900133	32	40	players'	T098	C0679646
27900133	41	47	tackle	T053	C0018578
27900133	48	56	training	T065	C0220931
27900133	57	66	attitudes	T041	C0004271
27900133	71	80	behaviour	T053	C0004927
27900133	91	113	match tackle attitudes	T041	C0004271
27900133	118	127	behaviour	T053	C0004927
27900133	132	138	tackle	T053	C0018578
27900133	148	153	rugby	T056	C0035945
27900133	159	168	technical	T080	C0205556
27900133	173	181	physical	T169	C0205485
27900133	182	189	contest	T056	C0040595
27900133	207	214	players	T098	C0679646
27900133	218	226	player's	T098	C0679646
27900133	238	246	tolerate	T054	C0680282
27900133	251	258	contest	T056	C0040595
27900133	268	274	tackle	T053	C0018578
27900133	280	292	prerequisite	T078	C0679209
27900133	297	301	safe	UnknownType	C0814103
27900133	302	315	participation	T169	C0679823
27900133	320	327	success	T054	C0597535
27900133	331	336	rugby	T056	C0035945
27900133	364	376	relationship	T080	C0439849
27900133	385	400	tackle training	T065	C0220931
27900133	405	413	tackling	T053	C0018578
27900133	417	424	matches	T056	C0150593
27900133	428	439	rugby union	T056	C0035945
27900133	455	467	investigated	T169	C1292732
27900133	472	485	relationships	T080	C0439849
27900133	494	502	players'	T098	C0679646
27900133	503	521	training attitudes	T041	C0004271
27900133	526	535	behaviour	T053	C0004927
27900133	546	561	match attitudes	T041	C0004271
27900133	566	575	behaviour	T053	C0004927
27900133	580	588	tackling	T053	C0018578
27900133	592	603	rugby union	T056	C0035945
27900133	607	620	questionnaire	T170	C0034394
27900133	637	643	assess	T058	C0184514
27900133	644	652	attitude	T041	C0004271
27900133	670	680	behaviours	T053	C0004927
27900133	682	691	frequency	T080	C1561548
27900133	696	704	quantity	T081	C1265611
27900133	712	718	junior	T078	C1708595
27900133	730	737	players	T098	C0679646
27900133	743	763	5-point Likert Scale	T170	C0451267
27900133	765	779	Questionnaires	T170	C0034394
27900133	803	810	players	T098	C0679646
27900133	815	822	schools	T073,T092	C0036375
27900133	829	839	tournament	T056	C0040595
27900133	851	858	schools	T073,T092	C0036375
27900133	885	893	analysis	T062	C0936012
27900133	895	907	Associations	T041	C0004083
27900133	916	934	training attitudes	T041	C0004271
27900133	939	949	behaviours	T053	C0004927
27900133	955	961	tested	T169	C0039593
27900133	972	1001	χ(2) test, Cramer's V and τ-b	T170	C0392366
27900133	1045	1054	technique	T169	C0449851
27900133	1058	1065	prevent	T080	C2700409
27900133	1066	1074	injuries	T037	C0004161
27900133	1078	1086	training	T065	C0220931
27900133	1107	1114	players	T098	C0679646
27900133	1145	1153	moderate	T080	C0205081
27900133	1186	1190	ball	T073	C1706910
27900133	1208	1216	moderate	T080	C0205081
27900133	1267	1275	moderate	T080	C0205081
27900133	1296	1306	match play	T056	C0150593
27900133	1350	1359	technique	T169	C0449851
27900133	1363	1370	improve	T033	C0184511
27900133	1371	1382	performance	T052	C1882330
27900133	1386	1394	training	T065	C0220931
27900133	1415	1422	players	T098	C0679646
27900133	1448	1452	ball	T073	C1706910
27900133	1470	1478	moderate	T080	C0205081
27900133	1502	1512	preventing	T080	C2700409
27900133	1517	1521	ball	T073	C1706910
27900133	1535	1544	retaining	T169	C0333118
27900133	1545	1553	position	T082	C0733755
27900133	1567	1575	moderate	T080	C0205081
27900133	1595	1605	match play	T056	C0150593
27900133	1625	1630	study	T062	C2603343
27900133	1648	1661	relationships	T080	C0439849
27900133	1670	1677	players	T098	C0679646
27900133	1680	1698	training attitudes	T041	C0004271
27900133	1703	1712	behaviour	T053	C0004927
27900133	1723	1738	match attitudes	T041	C0004271
27900133	1743	1752	behaviour	T053	C0004927
27900133	1759	1767	tackling	T053	C0018578
27900133	1771	1782	rugby union	T056	C0035945
27900133	1802	1808	tackle	T053	C0018578
27900133	1809	1817	training	T065	C0220931
27900133	1821	1828	prevent	T080	C2700409
27900133	1829	1835	injury	T037	C0004161
27900133	1869	1878	technique	T169	C0449851
27900133	1882	1889	prevent	T080	C2700409
27900133	1890	1898	injuries	T037	C0004161
27900133	1904	1919	associated with	T080	C0332281
27900133	1920	1930	behaviours	T053	C0004927
27900133	1936	1942	reduce	T080	C0392756
27900133	1947	1961	risk of injury	T033	C0582456
27900133	1965	1972	matches	T056	C0150593

27587390|t|Amino Acids Regulate mTORC1 by an Obligate Two-step Mechanism
27587390|a|The mechanistic target of rapamycin complex 1 (mTORC1) coordinates cell growth with its nutritional, hormonal, energy, and stress status. Amino acids are critical regulators of mTORC1 that permit other inputs to mTORC1 activity. However, the roles of individual amino acids and their interactions in mTORC1 activation are not well understood. Here we demonstrate that activation of mTORC1 by amino acids includes two discrete and separable steps: priming and activation. Sensitizing mTORC1 activation by priming amino acids is a prerequisite for subsequent stimulation of mTORC1 by activating amino acids. Priming is achieved by a group of amino acids that includes l-asparagine, l-glutamine, l-threonine, l-arginine, l-glycine, l-proline, l-serine, l-alanine, and l-glutamic acid. The group of activating amino acids is dominated by l-leucine but also includes l-methionine, l-isoleucine, and l-valine. l-Cysteine predominantly inhibits priming but not the activating step. Priming and activating steps differ in their requirements for amino acid concentration and duration of treatment. Priming and activating amino acids use mechanisms that are distinct both from each other and from growth factor signaling. Neither step requires intact tuberous sclerosis complex of proteins to activate mTORC1. Concerted action of priming and activating amino acids is required to localize mTORC1 to lysosomes and achieve its activation.
27587390	0	11	Amino Acids	T116,T121,T123	C0002520
27587390	21	27	mTORC1	T116	C3888046
27587390	52	61	Mechanism	T169	C0441712
27587390	66	107	mechanistic target of rapamycin complex 1	T116	C3888046
27587390	109	115	mTORC1	T116	C3888046
27587390	117	128	coordinates	T169	C0700114
27587390	129	140	cell growth	T043	C0007595
27587390	150	161	nutritional	T080	C1521739
27587390	163	171	hormonal	T080	C0458083
27587390	173	179	energy	T033	C0424589
27587390	185	191	stress	T046	C0449430
27587390	192	198	status	T080	C0449438
27587390	200	211	Amino acids	T116,T121,T123	C0002520
27587390	225	235	regulators	T077	C1704735
27587390	239	245	mTORC1	T116	C3888046
27587390	274	280	mTORC1	T116	C3888046
27587390	281	289	activity	T044	C1537044
27587390	324	335	amino acids	T116,T121,T123	C0002520
27587390	346	358	interactions	T169	C1704675
27587390	362	368	mTORC1	T116	C3888046
27587390	369	379	activation	T045	C0599177
27587390	430	440	activation	T045	C0599177
27587390	444	450	mTORC1	T116	C3888046
27587390	454	465	amino acids	T116,T121,T123	C0002520
27587390	502	507	steps	T077	C1261552
27587390	509	516	priming	T169	C0871133
27587390	521	531	activation	T045	C0599177
27587390	545	551	mTORC1	T116	C3888046
27587390	552	562	activation	T045	C0599177
27587390	566	573	priming	T169	C0871133
27587390	574	585	amino acids	T116,T121,T123	C0002520
27587390	619	630	stimulation	T061	C1292856
27587390	634	640	mTORC1	T116	C3888046
27587390	644	654	activating	T045	C0599177
27587390	655	666	amino acids	T116,T121,T123	C0002520
27587390	668	675	Priming	T169	C0871133
27587390	693	698	group	T078	C0441833
27587390	702	713	amino acids	T116,T121,T123	C0002520
27587390	728	740	l-asparagine	T116,T123	C0003995
27587390	742	753	l-glutamine	T116,T121,T123	C0017797
27587390	755	766	l-threonine	T116,T121,T123	C0040005
27587390	768	778	l-arginine	T116,T121,T123	C0003765
27587390	780	789	l-glycine	T116,T121,T123	C0017890
27587390	791	800	l-proline	T116,T123	C0033382
27587390	802	810	l-serine	T116,T121,T123	C0036720
27587390	812	821	l-alanine	T116,T123	C0001898
27587390	827	842	l-glutamic acid	T116,T121,T123	C0061472
27587390	848	853	group	T078	C0441833
27587390	857	867	activating	T045	C0599177
27587390	868	879	amino acids	T116,T121,T123	C0002520
27587390	896	905	l-leucine	T116,T121,T123	C0023401
27587390	924	936	l-methionine	T116,T121,T123	C0025646
27587390	938	950	l-isoleucine	T116,T121,T123	C0022192
27587390	956	964	l-valine	T116,T123	C0042285
27587390	966	976	l-Cysteine	T116,T123	C0010654
27587390	991	999	inhibits	T052	C3463820
27587390	1000	1007	priming	T169	C0871133
27587390	1020	1030	activating	T045	C0599177
27587390	1031	1035	step	T077	C1261552
27587390	1037	1044	Priming	T169	C0871133
27587390	1049	1059	activating	T045	C0599177
27587390	1060	1065	steps	T077	C1261552
27587390	1082	1094	requirements	T169	C1514873
27587390	1099	1109	amino acid	T116,T121,T123	C0002520
27587390	1110	1123	concentration	T081	C1446561
27587390	1128	1149	duration of treatment	T079	C0444921
27587390	1151	1158	Priming	T169	C0871133
27587390	1163	1173	activating	T045	C0599177
27587390	1174	1185	amino acids	T116,T121,T123	C0002520
27587390	1190	1200	mechanisms	T169	C0441712
27587390	1249	1262	growth factor	T116,T123	C0018284
27587390	1263	1272	signaling	T043	C0037083
27587390	1282	1286	step	T077	C1261552
27587390	1296	1302	intact	T080	C0205266
27587390	1303	1341	tuberous sclerosis complex of proteins	T026	C2247022
27587390	1345	1353	activate	T045	C0599177
27587390	1354	1360	mTORC1	T116	C3888046
27587390	1362	1378	Concerted action	T080	C1705294
27587390	1382	1389	priming	T169	C0871133
27587390	1382	1389	priming	T169	C0871133
27587390	1394	1404	activating	T045	C0599177
27587390	1405	1416	amino acids	T116,T121,T123	C0002520
27587390	1441	1447	mTORC1	T116	C3888046
27587390	1451	1460	lysosomes	T026	C0024369
27587390	1477	1487	activation	T045	C0599177

28532359|t|Visual Confidence
28532359|a|Visual confidence refers to an observer's ability to judge the accuracy of her perceptual decisions. Even though confidence judgments have been recorded since the early days of psychophysics, only recently have they been recognized as essential for a deeper understanding of visual perception. The reluctance to study visual confidence may have come in part from obtaining convincing experimental evidence in favor of metacognitive abilities rather than just perceptual sensitivity. Some effort has thus been dedicated to offer different experimental paradigms to study visual confidence in humans and nonhuman animals. To understand the origins of confidence judgments, investigators have developed two competing frameworks. The approach based on signal decision theory is popular but fails to account for response times. In contrast, the approach based on accumulation of evidence models naturally includes the dynamics of perceptual decisions. These models can explain a range of results, including the apparently paradoxical dissociation between performance and confidence that is sometimes observed.
28532359	0	6	Visual	T169	C0234621
28532359	7	17	Confidence	T041	C1704726
28532359	18	24	Visual	T169	C0234621
28532359	25	35	confidence	T041	C1704726
28532359	49	59	observer's	T096	C0870992
28532359	60	67	ability	T032	C0085732
28532359	71	76	judge	T041	C0022423
28532359	81	89	accuracy	T080	C0443131
28532359	97	117	perceptual decisions	T041	C0679006
28532359	131	141	confidence	T041	C1704726
28532359	142	151	judgments	T041	C0022423
28532359	195	208	psychophysics	T091	C0033930
28532359	293	310	visual perception	T041	C0042830
28532359	336	342	visual	T169	C0234621
28532359	343	353	confidence	T041	C1704726
28532359	402	423	experimental evidence	T078	C3887511
28532359	436	459	metacognitive abilities	T041	C0589513
28532359	477	499	perceptual sensitivity	T041	C0312418
28532359	556	578	experimental paradigms	T062	C0681797
28532359	582	587	study	T062	C2603343
28532359	588	594	visual	T169	C0234621
28532359	595	605	confidence	T041	C1704726
28532359	609	615	humans	T016	C0086418
28532359	620	636	nonhuman animals	T008	C0003062
28532359	656	663	origins	T079	C0439659
28532359	667	677	confidence	T041	C1704726
28532359	678	687	judgments	T041	C0022423
28532359	689	702	investigators	T097	C0035173
28532359	766	788	signal decision theory	T170	C0011114
28532359	804	809	fails	T169	C0231175
28532359	825	839	response times	T079	C0034746
28532359	892	900	evidence	T078	C3887511
28532359	901	907	models	T170	C3161035
28532359	931	939	dynamics	T070	C3826426
28532359	943	963	perceptual decisions	T041	C0679006
28532359	971	977	models	T170	C3161035
28532359	1001	1008	results	T169	C1274040
28532359	1035	1046	paradoxical	T080	C0205310
28532359	1047	1059	dissociation	T048	C0086168
28532359	1068	1079	performance	T055	C0597198
28532359	1084	1094	confidence	T041	C1704726

27801847|t|Different Susceptibilities between Apoe - and Ldlr - Deficient Mice to Inflammation - Associated Colorectal Carcinogenesis
27801847|a|Hypercholesterolemia resulting in atherosclerosis is associated with an increased risk of ischemic heart disease and colorectal cancer (CRC). However, the roles of apoliprotein (Apo) E (Apoe) and low-density lipoprotein (Ldl) receptor (Ldlr) in colorectal carcinogenesis have not yet been investigated. In this study, we examined the susceptibility of Apoe - deficient and Ldlr - deficient mice, which are genetic animal models of atherosclerosis to azoxymethane (AOM)/ dextran sodium sulfate (DSS)- induced colorectal carcinogenesis. In Experiment 1, male Apoe - deficient (n = 20) and wild type (WT) mice (C57BL/6J, n = 21) were treated with a single intraperitoneal (i.p.) injection of AOM (10 mg/kg body weight) and then given 1.5% DSS in drinking water for seven days. They were maintained up to week 20 and sacrificed for the histopathological examination of colorectal tumors. The mRNA expression of cyclooxygenase (Cox)-2, inducible nitric oxide synthase (Nos2), tumor necrosis factor (Tnf)-α interleukin (Il)-1β, and Il-6 was assayed in the colorectal mucosa. In Experiment 2, male Ldlr - deficient (n = 14) and WT mice (C57BL/6J, n = 10) were given a single i.p. injection of AOM (10 mg/kg body weight) and then given 2% DSS in drinking water for seven days. They were sacrificed at week 20 to evaluate their colorectum histopathologically. In Experiment 1, the multiplicity of CRCs was significantly higher in the Apoe - deficient mice (2.75 ± 1.48) than in the WT mice (0.62 ± 0.67). The serum lipoprotein levels in the Apoe - deficient mice were also significantly higher than in the WT mice. In Experiment 2, the incidence (29%) and multiplicity (0.50 ± 0.94) of CRCs in the Ldlr mice were significantly lower than in the WT mice (80% incidence and 3.10 ± 2.38 multiplicity). The mRNA expression of two inducible enzymes and certain pro-inflammatory cytokines in the colorectum of each genotype was greater than in the respective WT mice. The values in the Apoe - deficient mice were much greater than in the Ldlr mice. These findings suggest that Apoe - deficient mice showed increased susceptibility to inflammation - associated colorectal carcinogenesis due to their high reactivity to inflammatory stimuli.
27801847	10	26	Susceptibilities	T201	C0012655
27801847	35	39	Apoe	T028	C1412481
27801847	46	50	Ldlr	T028	C1366529
27801847	53	62	Deficient	T080	C2987487
27801847	63	67	Mice	T015	C0025929
27801847	71	83	Inflammation	T046	C0021368
27801847	86	96	Associated	T080	C0332281
27801847	97	122	Colorectal Carcinogenesis	T191	C0009404
27801847	123	143	Hypercholesterolemia	T047	C0020443
27801847	157	172	atherosclerosis	T047	C0004153
27801847	176	191	associated with	T080	C0332281
27801847	195	209	increased risk	T033	C1281905
27801847	213	235	ischemic heart disease	T047	C0151744
27801847	240	257	colorectal cancer	T191	C1527249
27801847	259	262	CRC	T191	C1527249
27801847	287	307	apoliprotein (Apo) E	T116,T123	C0003595
27801847	309	313	Apoe	T116,T123	C0003595
27801847	319	357	low-density lipoprotein (Ldl) receptor	T116,T192	C0034821
27801847	359	363	Ldlr	T116,T192	C0034821
27801847	368	393	colorectal carcinogenesis	T191	C0009404
27801847	434	439	study	T062	C0008972
27801847	444	452	examined	T058	C0220825
27801847	457	471	susceptibility	T201	C0012655
27801847	475	479	Apoe	T028	C1412481
27801847	482	491	deficient	T080	C2987487
27801847	496	500	Ldlr	T116,T192	C0034821
27801847	496	500	Ldlr	T028	C1366529
27801847	503	512	deficient	T080	C2987487
27801847	513	517	mice	T015	C0025929
27801847	529	550	genetic animal models	T008	C0599779
27801847	554	569	atherosclerosis	T047	C0004153
27801847	573	585	azoxymethane	T109,T131	C0004519
27801847	587	590	AOM	T109,T131	C0004519
27801847	593	615	dextran sodium sulfate	T109,T121	C0079225
27801847	617	620	DSS	T109,T121	C0079225
27801847	623	630	induced	T046	C0007994
27801847	631	656	colorectal carcinogenesis	T191	C0009404
27801847	661	671	Experiment	T062	C0205664
27801847	680	684	Apoe	T028	C1412481
27801847	687	696	deficient	T080	C2987487
27801847	710	729	wild type (WT) mice	T015	C1520150
27801847	754	761	treated	T169	C1522326
27801847	776	808	intraperitoneal (i.p.) injection	T169	C4282146
27801847	812	815	AOM	T109,T131	C0004519
27801847	826	837	body weight	T032	C0005910
27801847	859	862	DSS	T109,T121	C0079225
27801847	866	880	drinking water	T167	C0599638
27801847	891	895	days	T079	C0439228
27801847	907	917	maintained	T169	C1314677
27801847	924	928	week	T079	C0439230
27801847	936	946	sacrificed	T078	C0681205
27801847	955	972	histopathological	T169	C0243140
27801847	988	1005	colorectal tumors	T191	C0009404
27801847	1011	1026	mRNA expression	T045	C1515670
27801847	1030	1052	cyclooxygenase (Cox)-2	T116,T126	C0387583
27801847	1064	1092	nitric oxide synthase (Nos2)	T116,T126	C1565684
27801847	1094	1123	tumor necrosis factor (Tnf)-α	T116,T129	C1456820
27801847	1124	1143	interleukin (Il)-1β	T116,T129	C0021753
27801847	1149	1153	Il-6	T116,T129	C0021760
27801847	1173	1190	colorectal mucosa	T024	C0026724
27801847	1195	1205	Experiment	T062	C0205664
27801847	1214	1218	Ldlr	T028	C1366529
27801847	1221	1230	deficient	T080	C2987487
27801847	1244	1251	WT mice	T015	C1520150
27801847	1291	1305	i.p. injection	T169	C4282146
27801847	1309	1312	AOM	T109,T131	C0004519
27801847	1323	1334	body weight	T032	C0005910
27801847	1354	1357	DSS	T109,T121	C0079225
27801847	1361	1375	drinking water	T167	C0599638
27801847	1386	1390	days	T079	C0439228
27801847	1402	1412	sacrificed	T078	C0681205
27801847	1416	1420	week	T079	C0439230
27801847	1427	1435	evaluate	T058	C0220825
27801847	1442	1452	colorectum	T023	C0229983
27801847	1477	1487	Experiment	T062	C0205664
27801847	1495	1507	multiplicity	T081	C0449822
27801847	1511	1515	CRCs	T191	C1527249
27801847	1548	1552	Apoe	T028	C1412481
27801847	1555	1564	deficient	T080	C2987487
27801847	1565	1569	mice	T015	C0025929
27801847	1596	1603	WT mice	T015	C1520150
27801847	1623	1647	serum lipoprotein levels	T059	C0582826
27801847	1655	1659	Apoe	T028	C1412481
27801847	1662	1671	deficient	T080	C2987487
27801847	1672	1676	mice	T015	C0025929
27801847	1701	1707	higher	T080	C0205250
27801847	1720	1727	WT mice	T015	C1520150
27801847	1732	1742	Experiment	T062	C0205664
27801847	1750	1759	incidence	T081	C0021149
27801847	1770	1782	multiplicity	T081	C0449822
27801847	1800	1804	CRCs	T191	C1527249
27801847	1812	1816	Ldlr	T028	C1366529
27801847	1817	1821	mice	T015	C0025929
27801847	1841	1846	lower	T081	C1611820
27801847	1859	1866	WT mice	T015	C1520150
27801847	1872	1881	incidence	T081	C0021149
27801847	1898	1910	multiplicity	T081	C0449822
27801847	1917	1932	mRNA expression	T045	C1515670
27801847	1940	1957	inducible enzymes	T116,T126	C0014442
27801847	1970	1996	pro-inflammatory cytokines	T116,T129	C0079189
27801847	2004	2014	colorectum	T023	C0229983
27801847	2023	2031	genotype	T032	C0017431
27801847	2036	2043	greater	T081	C1704243
27801847	2067	2074	WT mice	T015	C1520150
27801847	2094	2098	Apoe	T028	C1412481
27801847	2101	2110	deficient	T080	C2987487
27801847	2111	2115	mice	T015	C0025929
27801847	2146	2150	Ldlr	T028	C1366529
27801847	2151	2155	mice	T015	C0025929
27801847	2163	2171	findings	T033	C2825141
27801847	2185	2189	Apoe	T028	C1412481
27801847	2192	2201	deficient	T080	C2987487
27801847	2202	2206	mice	T015	C0025929
27801847	2214	2223	increased	T169	C0442805
27801847	2224	2238	susceptibility	T201	C0012655
27801847	2242	2254	inflammation	T046	C0021368
27801847	2257	2267	associated	T080	C0332281
27801847	2268	2293	colorectal carcinogenesis	T191	C0009404
27801847	2312	2322	reactivity	T169	C0443286
27801847	2326	2338	inflammatory	T169	C0333348
27801847	2339	2346	stimuli	T067	C0234402

28416598|t|EBV MicroRNA BART16 Suppresses Type I IFN Signaling
28416598|a|Type I IFNs play critical roles in orchestrating the antiviral defense by inducing direct antiviral activities and shaping the adaptive immune response. Viruses have evolved numerous strategies to specifically interfere with IFN production or its downstream mediators, thereby allowing successful infection of the host to occur. The prototypic human gammaherpesvirus EBV, which is associated with infectious mononucleosis and malignant tumors, harbors many immune-evasion proteins that manipulate the adaptive and innate immune systems. In addition to proteins, the virus encodes >40 mature microRNAs for which the functions remain largely unknown. In this article, we identify EBV - encoded miR-BART16 as a novel viral immune-evasion factor that interferes with the type I IFN signaling pathway. miR-BART16 directly targets CREB-binding protein, a key transcriptional coactivator in IFN signaling, thereby inducing CREB-binding protein downregulation in EBV-transformed B cells and gastric carcinoma cells. miR-BART16 abrogates the production of IFN - stimulated genes in response to IFN-α stimulation and it inhibits the antiproliferative effect of IFN-α on latently infected BL cells. By obstructing the type I IFN - induced antiviral response, miR-BART16 provides a means to facilitate the establishment of latent EBV infection and enhance viral replication.
28416598	0	3	EBV	T005	C0014644
28416598	4	19	MicroRNA BART16	T114,T123	C1101610
28416598	20	30	Suppresses	T169	C1260953
28416598	31	51	Type I IFN Signaling	T043	C2610474
28416598	52	63	Type I IFNs	T116,T121,T129	C0021743
28416598	87	100	orchestrating	T169	C1300196
28416598	105	122	antiviral defense	T040	C1155328
28416598	126	134	inducing	T169	C0205263
28416598	142	162	antiviral activities	T040	C1155328
28416598	167	174	shaping	T082	C0332479
28416598	179	203	adaptive immune response	T040	C1749719
28416598	205	212	Viruses	T005	C0042776
28416598	262	276	interfere with	T169	C0521102
28416598	277	291	IFN production	T040	C1819430
28416598	299	319	downstream mediators	T129	C0021054
28416598	349	358	infection	T046	C3714514
28416598	366	370	host	T001	C1167395
28416598	374	379	occur	T052	C1709305
28416598	396	418	human gammaherpesvirus	UnknownType	C0682456
28416598	419	422	EBV	T005	C0014644
28416598	433	448	associated with	T080	C0332281
28416598	449	473	infectious mononucleosis	T047	C0021345
28416598	478	494	malignant tumors	T191	C0006826
28416598	496	503	harbors	T078	C3154893
28416598	509	523	immune-evasion	T040	C1654934
28416598	524	532	proteins	T116,T123	C0033684
28416598	553	561	adaptive	T039	C0678209
28416598	566	572	innate	T032	C0020969
28416598	573	587	immune systems	T022	C0020962
28416598	604	612	proteins	T116,T123	C0033684
28416598	618	623	virus	T005	C0042776
28416598	643	652	microRNAs	T114,T123	C1101610
28416598	667	676	functions	T169	C0542341
28416598	721	729	identify	T080	C0205396
28416598	730	733	EBV	T005	C0014644
28416598	736	743	encoded	T052	C2700640
28416598	744	754	miR-BART16	T114,T123	C1101610
28416598	766	771	viral	T169	C0521026
28416598	772	786	immune-evasion	T040	C1654934
28416598	787	793	factor	T169	C1521761
28416598	799	809	interferes	T169	C0521102
28416598	819	847	type I IFN signaling pathway	T043	C2610474
28416598	849	859	miR-BART16	T114,T123	C1101610
28416598	877	897	CREB-binding protein	T116	C0256079
28416598	905	932	transcriptional coactivator	T116,T123	C1336776
28416598	936	949	IFN signaling	T039	C1512827
28416598	959	967	inducing	T169	C0205263
28416598	968	988	CREB-binding protein	T116	C0256079
28416598	989	1003	downregulation	T044	C0013081
28416598	1007	1030	EBV-transformed B cells	T025	C2699839
28416598	1035	1058	gastric carcinoma cells	T191	C1333789
28416598	1060	1070	miR-BART16	T114,T123	C1101610
28416598	1085	1095	production	T169	C0005572
28416598	1099	1102	IFN	T116,T121,T129	C0021747
28416598	1105	1115	stimulated	T044	C0038337
28416598	1116	1121	genes	T028	C0017337
28416598	1125	1133	response	T032	C0871261
28416598	1137	1142	IFN-α	T116,T121,T129	C0002199
28416598	1143	1154	stimulation	T044	C0038337
28416598	1162	1170	inhibits	T080	C0311403
28416598	1175	1192	antiproliferative	T109,T121	C0003392
28416598	1193	1199	effect	T080	C1280500
28416598	1203	1208	IFN-α	T116,T121,T129	C0002199
28416598	1212	1220	latently	T080	C0205275
28416598	1221	1229	infected	T033	C0439663
28416598	1230	1238	BL cells	T025	C0004561
28416598	1259	1269	type I IFN	T116,T121,T129	C0021743
28416598	1272	1279	induced	T169	C0205263
28416598	1280	1298	antiviral response	T040	C1155328
28416598	1300	1310	miR-BART16	T114,T123	C1101610
28416598	1363	1369	latent	T080	C0205275
28416598	1370	1373	EBV	T005	C0014644
28416598	1374	1383	infection	T046	C3714514
28416598	1388	1395	enhance	T052	C2349975
28416598	1396	1413	viral replication	T043	C0042774

27470589|t|Description of Ancylomarina subtilis gen. nov., sp. nov., isolated from coastal sediment, proposal of Marinilabiliales ord. nov. and transfer of Marinilabiliaceae, Prolixibacteraceae and Marinifilaceae to the order Marinilabiliales
27470589|a|A Gram-stain-negative, facultatively anaerobic, moderately halophilic, filamentous, non-motile bacterium, designated FA102T, was isolated from marine sediment of the coast of Weihai, China. Phylogenetic analysis based on 16S rRNA gene sequences showed that strain FA102T formed a distinct evolutionary lineage within the family Marinifilaceae and its closest relative was Marinifilum fragile JCM 15579T (93.2% sequence similarity). The DNA G+C content of the novel strain was 36.5 mol%. The predominant cellular fatty acids and respiratory quinone were iso-C15:0 and iso-C15:0 3-OH, and MK-7, respectively. On the basis of the phylogenetic, phenotypic and physiological data, strain FA102T represents a novel genus and species, for which the name Ancylomarina subtilis gen. nov., sp. nov. is proposed. The type strain of Ancylomarina subtilis is FA102T (= KCTC 42257T = DSM 28825T = CICC 10902T). Furthermore, a new order named Marinilabiliales is proposed to accommodate three families previously classified in the order Bacteroidales. Marinilabiliales ord. nov. encompasses the families Marinilabiliaceae, Prolixibacteraceae and Marinifilaceae.
27470589	0	11	Description	T170	C0678257
27470589	15	56	Ancylomarina subtilis gen. nov., sp. nov.	T007	C0004611
27470589	58	66	isolated	T169	C0205409
27470589	72	88	coastal sediment	T082	C0557760
27470589	90	98	proposal	T078	C1555306
27470589	102	128	Marinilabiliales ord. nov.	T007	C0004611
27470589	133	141	transfer	T078	C3244299
27470589	145	162	Marinilabiliaceae	T007	C3557298
27470589	164	182	Prolixibacteraceae	T007	C3800560
27470589	187	201	Marinifilaceae	T007	C3986640
27470589	209	214	order	T185	C1705177
27470589	215	231	Marinilabiliales	T007	C0004611
27470589	234	253	Gram-stain-negative	T007	C0018150
27470589	255	278	facultatively anaerobic	T007	C1532741
27470589	280	301	moderately halophilic	T194	C0599691
27470589	303	314	filamentous	T080	C1979891
27470589	316	336	non-motile bacterium	T007	C1301466
27470589	338	348	designated	T169	C1524084
27470589	349	355	FA102T	T007	C0018149
27470589	361	369	isolated	T169	C0205409
27470589	375	390	marine sediment	T070	C0282589
27470589	398	403	coast	T082	C0442544
27470589	407	420	Weihai, China	T083	C0008115
27470589	422	443	Phylogenetic analysis	T062	C1519068
27470589	444	449	based	T169	C1527178
27470589	453	476	16S rRNA gene sequences	T114	C3537372
27470589	477	483	showed	T169	C0870432
27470589	489	495	strain	T080	C0456178
27470589	496	502	FA102T	T007	C0018149
27470589	512	520	distinct	T080	C2963144
27470589	521	533	evolutionary	T045	C0015219
27470589	534	541	lineage	T077	C1881379
27470589	553	559	family	T077	C1704727
27470589	560	574	Marinifilaceae	T007	C3986640
27470589	583	599	closest relative	T033	C1821461
27470589	604	634	Marinifilum fragile JCM 15579T	T007	C2990363
27470589	642	661	sequence similarity	T081	C1710052
27470589	668	671	DNA	T114,T123	C0012854
27470589	672	683	G+C content	T081	C1135899
27470589	691	696	novel	T080	C0205314
27470589	697	703	strain	T080	C0456178
27470589	723	734	predominant	T080	C1542147
27470589	735	743	cellular	T025	C0007634
27470589	744	755	fatty acids	T109	C0015684
27470589	760	771	respiratory	T169	C0521346
27470589	772	779	quinone	T109	C0034435
27470589	785	794	iso-C15:0	T109,T121	C0044840
27470589	799	813	iso-C15:0 3-OH	T116,T121	C0754432
27470589	819	823	MK-7	T109,T121,T127	C0078382
27470589	825	837	respectively	T080	C1548787
27470589	846	851	basis	T169	C1527178
27470589	859	871	phylogenetic	UnknownType	C0683236
27470589	873	883	phenotypic	T032	C0031437
27470589	888	901	physiological	T169	C0205463
27470589	902	906	data	T078	C1511726
27470589	908	914	strain	T080	C0456178
27470589	915	921	FA102T	T007	C0018149
27470589	922	932	represents	T052	C1882932
27470589	935	940	novel	T080	C0205314
27470589	941	946	genus	T185	C1708235
27470589	951	958	species	T185	C1705920
27470589	979	1020	Ancylomarina subtilis gen. nov., sp. nov.	T007	C0004611
27470589	1024	1032	proposed	T080	C1553874
27470589	1038	1042	type	T080	C0332307
27470589	1043	1049	strain	T080	C0456178
27470589	1053	1074	Ancylomarina subtilis	T007	C0018149
27470589	1078	1084	FA102T	T007	C0018149
27470589	1088	1099	KCTC 42257T	T007	C0004611
27470589	1102	1112	DSM 28825T	T007	C0004611
27470589	1115	1126	CICC 10902T	T007	C0004611
27470589	1144	1147	new	T080	C0205314
27470589	1148	1153	order	T185	C1705177
27470589	1160	1176	Marinilabiliales	T007	C0004611
27470589	1180	1188	proposed	T080	C1553874
27470589	1192	1203	accommodate	T033	C1832072
27470589	1210	1218	families	T077	C1704727
27470589	1219	1229	previously	T079	C0205156
27470589	1230	1240	classified	T185	C0008902
27470589	1248	1253	order	T185	C1705177
27470589	1254	1267	Bacteroidales	T007	C1080663
27470589	1269	1295	Marinilabiliales ord. nov.	T007	C0004611
27470589	1312	1320	families	T077	C1704727
27470589	1321	1338	Marinilabiliaceae	T007	C3557298
27470589	1340	1358	Prolixibacteraceae	T007	C3800560
27470589	1363	1377	Marinifilaceae	T007	C3986640

28516341|t|Fairness: the hidden challenge for competency-based postgraduate medical education programs
28516341|a|Competency-based medical education systems allow institutions to individualize teaching practices to meet the needs of diverse learners. Yet, the focus on continuous improvement and individualization of curricula does not exempt programs from treating learners in a fair manner. When learners fail to meet key competencies and are placed on probation or dismissed from training programs, issues of fairness may form the basis of their legal claims. In a literature search, we found no in-depth examination of fairness. In this paper, we utilize a systems lens to examine fairness within postgraduate medical education contexts, focusing on educational opportunities, assessment practices, decision-making processes, fairness from a legal standpoint, and fairness in the context of the learning environment. While we provide examples of fairness issues within US training programs, concerns regarding fairness are relevant in any medical education system which utilizes a competency-based education framework. Assessment oversight committees and annual programmatic evaluations, while recommended, will not guarantee fairness within postgraduate medical education programs, but they can provide a window into 'hidden' threats to fairness, as everything from training experiences to assessment practices may be examined by these committees. One of the first steps programs can take is to recognize that threats to fairness may exist in any educational program, including their own, and begin conversations about how to address these issues.
28516341	0	8	Fairness	T080	C2911689
28516341	21	30	challenge	T058	C0805586
28516341	35	91	competency-based postgraduate medical education programs	T065	C0150562
28516341	92	134	Competency-based medical education systems	UnknownType	C0681326
28516341	141	153	institutions	UnknownType	C0681325
28516341	157	170	individualize	T169	C0205245
28516341	171	189	teaching practices	T065	C0039403
28516341	193	197	meet	T067	C1550543
28516341	202	207	needs	T080	C0027552
28516341	211	227	diverse learners	T098	C0038492
28516341	258	269	improvement	T077	C2986411
28516341	274	291	individualization	T169	C0205245
28516341	295	304	curricula	T170	C0010478
28516341	321	329	programs	T169	C3484370
28516341	344	352	learners	T098	C0038492
28516341	358	369	fair manner	T033	C0243095
28516341	376	384	learners	T098	C0038492
28516341	402	414	competencies	T080	C0086035
28516341	433	442	probation	T089	C0687758
28516341	446	455	dismissed	T052	C2348301
28516341	461	478	training programs	T065	C0040607
28516341	480	486	issues	T033	C0033213
28516341	490	498	fairness	T080	C2911689
28516341	527	539	legal claims	T170	C0282574
28516341	586	597	examination	T057	C0033336
28516341	601	609	fairness	T080	C2911689
28516341	655	662	examine	T033	C0332128
28516341	663	671	fairness	T080	C2911689
28516341	679	709	postgraduate medical education	T065	C0013633
28516341	710	718	contexts	T078	C0449255
28516341	732	757	educational opportunities	T033	C0243095
28516341	759	779	assessment practices	T058	C0220825
28516341	781	806	decision-making processes	T057	C0011111
28516341	808	816	fairness	T080	C2911689
28516341	824	840	legal standpoint	T169	C1301860
28516341	846	854	fairness	T080	C2911689
28516341	862	869	context	T078	C0449255
28516341	877	897	learning environment	T082	C1510556
28516341	928	936	fairness	T080	C2911689
28516341	937	943	issues	T033	C0033213
28516341	951	953	US	T083	C0041703
28516341	954	971	training programs	T065	C0040607
28516341	992	1000	fairness	T080	C2911689
28516341	1021	1045	medical education system	UnknownType	C0681326
28516341	1063	1099	competency-based education framework	T078	C1254370
28516341	1101	1111	Assessment	T057	C0033336
28516341	1122	1132	committees	T097	C1522486
28516341	1137	1168	annual programmatic evaluations	T057	C0033336
28516341	1208	1216	fairness	T080	C2911689
28516341	1224	1263	postgraduate medical education programs	T065	C0150562
28516341	1320	1328	fairness	T080	C2911689
28516341	1349	1369	training experiences	T065	C0220931
28516341	1373	1393	assessment practices	T058	C0220825
28516341	1401	1409	examined	T033	C0332128
28516341	1419	1429	committees	T097	C1522486
28516341	1454	1462	programs	T169	C3484370
28516341	1504	1512	fairness	T080	C2911689
28516341	1530	1549	educational program	T065	C0150562
28516341	1582	1595	conversations	T054	C0871703
28516341	1623	1629	issues	T033	C0033213

27573702|t|Cerebral toxoplasmosis in patients with acquired immune deficiency syndrome in the neurological emergency department of a tertiary hospital
27573702|a|Cerebral toxoplasmosis is the most common cause of space occupying brain lesion in patients with HIV/AIDS in Brazil. In the post-HAART era, it is responsible for high rates of morbidity and mortality worldwide. This study consists of a case series of 56 patients diagnosed with cerebral toxoplasmosis whose clinical features, brain imaging and cerebrospinal fluid aspects were analyzed. Cerebral toxoplasmosis led to the diagnosis of infection by the human immunodeficiency virus (HIV) in 27 (48.2%) of the patients, while 29 (51.2%) others already knew to be HIV seropositive. However, at the time of diagnosis of cerebral toxoplasmosis, only 9 (16.6%) reported being under antiretroviral therapy and 5 (8.9%) were receiving primary prophylaxis for toxoplasmosis. Headache, strength deficit and fever were the most frequent signs and symptoms throughout the study. Fifty-three patients showed changes consistent with toxoplasmosis in CT or MRI. Thirty-four (60.7%) CSF samples were positive in the indirect haemagglutination test and for the reaction of Toxoplasma gondii IgG ELISA, while 31 (55.4%) were positive in the direct haemagglutination test. Fifty (89.3%) patients underwent first-line treatment for toxoplasmosis. Cerebral toxoplasmosis is still a very relevant neurological disease in individuals with AIDS admitted to neurology emergency departments. Early diagnosis and initiation of empiric treatment and antiretroviral therapy are important for good prognosis.
27573702	0	22	Cerebral toxoplasmosis	T047	C0085315
27573702	26	34	patients	T101	C0030705
27573702	40	75	acquired immune deficiency syndrome	T047	C0001175
27573702	83	116	neurological emergency department	T073,T093	C0562508
27573702	122	139	tertiary hospital	T073,T093	C0337954
27573702	140	162	Cerebral toxoplasmosis	T047	C0085315
27573702	182	187	cause	T169	C0015127
27573702	191	196	space	T082	C1883067
27573702	207	219	brain lesion	T047	C0221505
27573702	223	231	patients	T101	C0030705
27573702	237	245	HIV/AIDS	T047	C0497169
27573702	249	255	Brazil	T083	C0006137
27573702	264	278	post-HAART era	T079	C0681698
27573702	302	306	high	T080	C0205250
27573702	307	312	rates	T081	C1521828
27573702	316	325	morbidity	T081	C0026538
27573702	330	339	mortality	T081	C0205848
27573702	356	361	study	T062	C2603343
27573702	376	387	case series	T062	C0150093
27573702	394	402	patients	T101	C0030705
27573702	403	412	diagnosed	T033	C0011900
27573702	418	440	cerebral toxoplasmosis	T047	C0085315
27573702	447	455	clinical	T080	C0205210
27573702	456	464	features	T080	C1521970
27573702	466	479	brain imaging	T060	C0203860
27573702	484	503	cerebrospinal fluid	T031	C0007806
27573702	504	511	aspects	T080	C1879746
27573702	517	525	analyzed	T062	C0936012
27573702	527	549	Cerebral toxoplasmosis	T047	C0085315
27573702	561	570	diagnosis	T033	C0011900
27573702	574	583	infection	T046	C3714514
27573702	591	619	human immunodeficiency virus	T005	C0019682
27573702	621	624	HIV	T005	C0019682
27573702	647	655	patients	T101	C0030705
27573702	700	716	HIV seropositive	T034	C0019699
27573702	734	738	time	T079	C0040223
27573702	742	751	diagnosis	T033	C0011900
27573702	755	777	cerebral toxoplasmosis	T047	C0085315
27573702	794	802	reported	T058	C0700287
27573702	815	837	antiretroviral therapy	T061	C1963724
27573702	856	865	receiving	T080	C1514756
27573702	866	873	primary	T080	C0205225
27573702	874	885	prophylaxis	T061	C0199176
27573702	890	903	toxoplasmosis	T047	C0085315
27573702	905	913	Headache	T184	C0018681
27573702	915	931	strength deficit	T184	C1457887
27573702	936	941	fever	T184	C0015967
27573702	965	983	signs and symptoms	T184	C0037088
27573702	999	1004	study	T062	C2603343
27573702	1018	1026	patients	T101	C0030705
27573702	1034	1041	changes	T169	C0392747
27573702	1042	1057	consistent with	T078	C0332290
27573702	1058	1071	toxoplasmosis	T047	C0085315
27573702	1075	1077	CT	T060	C0040405
27573702	1081	1084	MRI	T060	C0024485
27573702	1106	1117	CSF samples	T031	C1292530
27573702	1123	1131	positive	T033	C1446409
27573702	1139	1170	indirect haemagglutination test	T059	C0022885
27573702	1183	1191	reaction	T169	C0443286
27573702	1195	1216	Toxoplasma gondii IgG	T116,T129	C0370074
27573702	1217	1222	ELISA	T059	C0014441
27573702	1246	1254	positive	T033	C1446409
27573702	1262	1291	direct haemagglutination test	T059	C0022885
27573702	1307	1315	patients	T101	C0030705
27573702	1326	1346	first-line treatment	T061	C1708063
27573702	1351	1364	toxoplasmosis	T047	C0085315
27573702	1366	1388	Cerebral toxoplasmosis	T047	C0085315
27573702	1405	1413	relevant	T080	C2347946
27573702	1414	1434	neurological disease	T047	C0027765
27573702	1438	1449	individuals	T098	C0237401
27573702	1455	1459	AIDS	T047	C0001175
27573702	1460	1468	admitted	T058	C0184666
27573702	1472	1481	neurology	T091	C0027855
27573702	1482	1503	emergency departments	T073,T093	C0562508
27573702	1505	1520	Early diagnosis	T060	C0596473
27573702	1525	1535	initiation	T169	C1704686
27573702	1539	1556	empiric treatment	T033	C0749647
27573702	1561	1583	antiretroviral therapy	T061	C1963724
27573702	1607	1616	prognosis	T058	C0033325

27426713|t|Development of Community Based Learning and Education system within Undergraduate Medical Curriculum of Patan Academy of Health Sciences
27426713|a|In response to continuing health disparities between rural and urban population, Patan Academy of Health Sciences (PAHS) was established in 2008. It aimed to produce physicians who would be able and willing to serve in the rural areas. In order to empower them with understanding and tools to address health issues of rural population, an innovative curriculum was developed. This paper aims to describe the community based learning and education (CBLE) system within the overall framework of PAHS undergraduate medical curriculum. A Medical School Steering Committee (MSSC) comprising of a group of committed medical educators led the curriculum development process. The committee reviewed different medical curricula, relevant literatures, and held a series of consultative meetings with the stakeholders and experts within and outside Nepal. This process resulted in defining the desirable attributes, terminal competencies of the graduates, and then the actual development of the entire curriculum including CBLE. Given the critical importance of population health, 25% of the curricular weightage was allocated to the Community Health Sciences (CHS). CBLE system was developed as the primary means of delivering CHS curriculum. The details of CBLE system was finalized for implementation with the first cohort of medical students commencing their studies from June 2010. The CBLE, a key educational strategy of PAHS curriculum, is envisaged to improve retention and performance of PAHS graduates and, thereby, health status of rural population. However, whether or not that goal will be achieved needs to be verified after the graduates join the health system.
27426713	15	24	Community	T096	C0009462
27426713	31	39	Learning	T041	C0023185
27426713	44	53	Education	T065	C0013621
27426713	54	60	system	T169	C0449913
27426713	68	89	Undergraduate Medical	T065	C0013634
27426713	90	100	Curriculum	T170	C0010478
27426713	104	136	Patan Academy of Health Sciences	T092	C1561598
27426713	163	181	health disparities	T033	C1171307
27426713	190	195	rural	T098	C0035962
27426713	200	216	urban population	T098	C0041935
27426713	218	250	Patan Academy of Health Sciences	T092	C1561598
27426713	252	256	PAHS	T092	C1561598
27426713	303	313	physicians	T097	C0031831
27426713	360	371	rural areas	T082	C0178837
27426713	385	392	empower	T041	C0562342
27426713	438	451	health issues	T033	C4060919
27426713	455	471	rural population	T098	C0035962
27426713	476	497	innovative curriculum	T170	C0010478
27426713	545	597	community based learning and education (CBLE) system	T169	C0449913
27426713	630	634	PAHS	T092	C1561598
27426713	635	656	undergraduate medical	T065	C0013634
27426713	657	667	curriculum	T170	C0010478
27426713	671	704	Medical School Steering Committee	T096	C2699414
27426713	706	710	MSSC	T096	C2699414
27426713	728	733	group	T078	C0441833
27426713	747	754	medical	T169	C0205476
27426713	755	764	educators	T097	C0259853
27426713	773	783	curriculum	T170	C0010478
27426713	784	803	development process	T067	C1522240
27426713	809	818	committee	T096	C2699414
27426713	838	855	medical curricula	T170	C0010478
27426713	857	877	relevant literatures	T170	C0023866
27426713	900	921	consultative meetings	T052	C0556656
27426713	975	980	Nepal	T083	C0027689
27426713	1042	1063	terminal competencies	T080	C0086035
27426713	1071	1080	graduates	T098	C0588053
27426713	1128	1138	curriculum	T170	C0010478
27426713	1149	1153	CBLE	T169	C0449913
27426713	1165	1184	critical importance	T080	C3898777
27426713	1188	1205	population health	T058	C3242284
27426713	1218	1228	curricular	T170	C0010478
27426713	1260	1285	Community Health Sciences	T058	C1254363
27426713	1287	1290	CHS	T058	C1254363
27426713	1293	1297	CBLE	T169	C0449913
27426713	1354	1357	CHS	T058	C1254363
27426713	1358	1368	curriculum	T170	C0010478
27426713	1385	1396	CBLE system	T169	C0449913
27426713	1415	1429	implementation	T052	C1708476
27426713	1445	1451	cohort	T098	C0599755
27426713	1455	1471	medical students	T097	C0038495
27426713	1489	1496	studies	T062	C2603343
27426713	1502	1506	June	T079	C3829443
27426713	1517	1521	CBLE	T169	C0449913
27426713	1525	1549	key educational strategy	T041	C0679199
27426713	1553	1557	PAHS	T092	C1561598
27426713	1558	1568	curriculum	T170	C0010478
27426713	1586	1593	improve	T033	C0184511
27426713	1608	1619	performance	T055	C0597198
27426713	1623	1627	PAHS	T092	C1561598
27426713	1628	1637	graduates	T098	C0588053
27426713	1652	1665	health status	T080	C0018759
27426713	1669	1685	rural population	T098	C0035962
27426713	1716	1720	goal	T170	C0018017
27426713	1769	1778	graduates	T098	C0588053
27426713	1788	1801	health system	T064	C1456613

27723444|t|Reduced Trauma Symptoms and Perceived Stress in Male Prison Inmates through the Transcendental Meditation Program: A Randomized Controlled Trial
27723444|a|Trauma events are four times more prevalent in inmates than in the general public and are associated with increased recidivism and other mental and physical health issues. To evaluate the effects of Transcendental Meditation (TM) on trauma symptoms in male inmates. One hundred eighty-one inmates with a moderate - to high-risk criminal profile were randomly assigned to either the TM program or to a usual care control group. The Trauma Symptom Checklist and the Perceived Stress Scale were administered at baseline and four-month posttest. Significant reductions in total trauma symptoms, anxiety, depression, dissociation, and sleep disturbance subscales, and perceived stress in the TM group were found compared with controls (all p values < 0.001). The high - trauma subgroup analysis further showed a higher magnitude of effects in the TM group compared with controls on all outcomes, with Cohen effect sizes ranging from 0.67 to 0.89. Results are consistent with those of prior studies of the TM program in other populations and its effects on trauma symptoms and perceived stress.
27723444	0	7	Reduced	T080	C0392756
27723444	8	14	Trauma	T037	C3714660
27723444	15	23	Symptoms	T184	C1457887
27723444	28	44	Perceived Stress	T041	C0030971
27723444	48	52	Male	T032	C0086582
27723444	53	67	Prison Inmates	T098	C0033167
27723444	80	113	Transcendental Meditation Program	T041	C0150814
27723444	117	144	Randomized Controlled Trial	T062,T170	C0206034
27723444	145	158	Trauma events	T037	C3714660
27723444	163	167	four	T081	C0205450
27723444	168	173	times	T081	C1632851
27723444	179	188	prevalent	T033	C0243095
27723444	192	199	inmates	T098	C0033167
27723444	212	226	general public	T098	C0683971
27723444	235	250	associated with	T080	C0332281
27723444	251	260	increased	T081	C0205217
27723444	261	271	recidivism	T055	C0680458
27723444	276	281	other	T080	C0205394
27723444	282	288	mental	T048	C4061796
27723444	293	315	physical health issues	T033	C4060919
27723444	333	340	effects	T080	C1280500
27723444	344	369	Transcendental Meditation	T041	C0150814
27723444	371	373	TM	T041	C0150814
27723444	378	384	trauma	T037	C3714660
27723444	385	393	symptoms	T184	C1457887
27723444	397	401	male	T032	C0086582
27723444	402	409	inmates	T098	C0033167
27723444	411	433	One hundred eighty-one	T081	C0392762
27723444	434	441	inmates	T098	C0033167
27723444	449	457	moderate	T080	C0205081
27723444	463	489	high-risk criminal profile	T170	C0282574
27723444	504	512	assigned	T169	C1516050
27723444	527	537	TM program	T041	C0150814
27723444	552	570	care control group	T058	C0030679
27723444	576	582	Trauma	T037	C3714660
27723444	583	600	Symptom Checklist	T170	C0451524
27723444	609	631	Perceived Stress Scale	T170	C0582653
27723444	637	649	administered	T169	C1521801
27723444	653	661	baseline	T081	C1442488
27723444	666	676	four-month	T081	C0392762
27723444	677	685	posttest	T062	C0871110
27723444	699	709	reductions	T061	C0441610
27723444	719	725	trauma	T037	C3714660
27723444	726	734	symptoms	T184	C1457887
27723444	736	743	anxiety	T033	C0003467
27723444	745	755	depression	T033	C0344315
27723444	757	769	dissociation	T048	C0086168
27723444	775	802	sleep disturbance subscales	T184	C0037317
27723444	808	817	perceived	T041	C0030971
27723444	818	824	stress	T033	C0038435
27723444	832	834	TM	T041	C0150814
27723444	835	840	group	T098	C1257890
27723444	852	860	compared	T052	C1707455
27723444	866	874	controls	T096	C0009932
27723444	882	888	values	T081	C1522609
27723444	903	907	high	T080	C0205250
27723444	910	916	trauma	T037	C3714660
27723444	917	925	subgroup	T185	C1515021
27723444	926	934	analysis	T062	C0936012
27723444	959	968	magnitude	T081	C1704240
27723444	972	979	effects	T080	C1280500
27723444	987	989	TM	T041	C0150814
27723444	990	995	group	T098	C1257890
27723444	996	1004	compared	T052	C1707455
27723444	1010	1018	controls	T096	C0009932
27723444	1026	1034	outcomes	T169	C1274040
27723444	1041	1059	Cohen effect sizes	T081	C0814843
27723444	1060	1067	ranging	T081	C1514721
27723444	1087	1094	Results	T169	C1274040
27723444	1099	1114	consistent with	T078	C0332290
27723444	1124	1129	prior	T079	C0332152
27723444	1130	1137	studies	T062	C2603343
27723444	1145	1147	TM	T041	C0150814
27723444	1165	1176	populations	T098	C1257890
27723444	1196	1202	trauma	T037	C3714660
27723444	1203	1211	symptoms	T184	C1457887
27723444	1216	1225	perceived	T041	C0030971
27723444	1226	1232	stress	T033	C0038435

27473429|t|Parallel-processing continuous-flow device for optimization - free polymerase chain reaction
27473429|a|A parallel-processing four-station polymerase chain reaction (PCR) device has been developed, which performs continuous-flow PCR without optimization of the annealing temperature. Since the annealing temperature of each station can be controlled independently, the device covers an annealing temperature range of 50-68 °C, which is wide enough to perform PCR for any DNA fragment regardless of its optimum annealing condition. This arrangement lets us continuously obtain an amplified amount of a DNA fragment at least from one of the stations. The device consists of four identical cylindrical stations (diameter 20 mm, height 55 mm). A polytetrafluoroethylene capillary reactor (length 2 m, I.D. 100 μm, O.D. 400 μm) is wound helically up around each station. The whole assembly is designed to minimize the number of heating blocks (for providing temperatures of denaturation, annealing, and extension) to be seven and to shape a compact cube (height 55 mm, base 60 mm × 60 mm). The reproducibility for continuous-flow PCR is reasonably high (run -to- run and station -to- station relative standard deviation of their amplification is lower than 6 % and about 4 %, respectively). Performance on the optimization - free DNA amplification has been evaluated with four DNA samples with different annealing conditions and product sizes (323, 608, 828, and 1101 bp), which has demonstrated that in all cases, PCR is successful at least on one station. In addition, three DNA fragment s with different lengths (323, 1101, and 2836 bp) have been successfully amplified in a segmented - flow mode without the carry-over contamination between segments. This result suggests that this device could serve as the PCR module of a continuous-flow high-throughput on-line total DNA analysis system integrating all necessary modules from cell lysis / DNA extraction to PCR product analysis.
27473429	0	19	Parallel-processing	T066	C0597171
27473429	20	42	continuous-flow device	T074	C0179969
27473429	47	59	optimization	T052	C2698650
27473429	62	66	free	T169	C0332296
27473429	67	92	polymerase chain reaction	T063	C0032520
27473429	95	114	parallel-processing	T066	C0597171
27473429	115	153	four-station polymerase chain reaction	T063	C0032520
27473429	155	158	PCR	T063	C0032520
27473429	160	166	device	T073	C0699733
27473429	193	201	performs	T169	C0884358
27473429	202	217	continuous-flow	T070	C0806140
27473429	218	221	PCR	T063	C0032520
27473429	230	242	optimization	T052	C2698650
27473429	250	259	annealing	T045	C0920681
27473429	260	271	temperature	T081	C0039476
27473429	283	292	annealing	T045	C0920681
27473429	293	304	temperature	T081	C0039476
27473429	313	320	station	T073	C1883167
27473429	328	338	controlled	T169	C2587213
27473429	339	352	independently	T169	C0332291
27473429	358	364	device	T073	C0699733
27473429	365	371	covers	T169	C1999244
27473429	375	384	annealing	T045	C0920681
27473429	385	396	temperature	T081	C0039476
27473429	397	402	range	T081	C1514721
27473429	425	429	wide	T082	C0332464
27473429	440	447	perform	T169	C0884358
27473429	448	451	PCR	T063	C0032520
27473429	460	472	DNA fragment	UnknownType	C0684192
27473429	491	498	optimum	T080	C2698651
27473429	499	508	annealing	T045	C0920681
27473429	509	518	condition	T080	C0348080
27473429	525	536	arrangement	T169	C0870432
27473429	545	557	continuously	T078	C0549178
27473429	558	564	obtain	T169	C1301820
27473429	568	577	amplified	T067	C1521871
27473429	578	584	amount	T081	C1265611
27473429	590	602	DNA fragment	UnknownType	C0684192
27473429	628	636	stations	T073	C1883167
27473429	642	648	device	T073	C0699733
27473429	666	675	identical	T080	C0205280
27473429	676	687	cylindrical	T082	C0205114
27473429	688	696	stations	T073	C1883167
27473429	698	706	diameter	T081	C1301886
27473429	714	720	height	T032	C0489786
27473429	731	754	polytetrafluoroethylene	T109,T122	C0032611
27473429	755	772	capillary reactor	T074	C0376432
27473429	774	780	length	T081	C1444754
27473429	815	830	wound helically	T082	C0231467
27473429	831	833	up	T082	C1282911
27473429	834	840	around	T078	C0750503
27473429	846	853	station	T073	C1883167
27473429	865	873	assembly	T052	C1706853
27473429	877	885	designed	T052	C1707689
27473429	889	897	minimize	T080	C1524031
27473429	902	908	number	T081	C0237753
27473429	912	926	heating blocks	T074	C0181153
27473429	932	941	providing	T052	C1999230
27473429	942	954	temperatures	T081	C0039476
27473429	958	970	denaturation	T044	C0301642
27473429	972	981	annealing	T045	C0920681
27473429	987	996	extension	T169	C0231448
27473429	1017	1022	shape	T082	C0332479
27473429	1025	1032	compact	T033	C1333134
27473429	1033	1037	cube	T082	C1880194
27473429	1039	1045	height	T032	C0489786
27473429	1053	1057	base	T081	C1626935
27473429	1078	1093	reproducibility	T080	C1514863
27473429	1098	1113	continuous-flow	T070	C0806140
27473429	1114	1117	PCR	T063	C0032520
27473429	1132	1136	high	T080	C0205250
27473429	1138	1141	run	T169	C1704688
27473429	1147	1150	run	T169	C1704688
27473429	1155	1162	station	T073	C1883167
27473429	1168	1175	station	T073	C1883167
27473429	1185	1203	standard deviation	T081	C0871420
27473429	1213	1226	amplification	T045	C0683230
27473429	1275	1286	Performance	T052	C1882330
27473429	1294	1306	optimization	T052	C2698650
27473429	1309	1313	free	T169	C0332296
27473429	1314	1331	DNA amplification	T045	C0683230
27473429	1341	1350	evaluated	T058	C0220825
27473429	1361	1372	DNA samples	T026	C0444245
27473429	1378	1387	different	T080	C1705242
27473429	1388	1397	annealing	T045	C0920681
27473429	1398	1408	conditions	T080	C0348080
27473429	1413	1420	product	T071	C1514468
27473429	1421	1426	sizes	T082	C0456389
27473429	1467	1479	demonstrated	T080	C0443289
27473429	1492	1497	cases	T169	C0868928
27473429	1499	1502	PCR	T063	C0032520
27473429	1506	1516	successful	T080	C1272703
27473429	1533	1540	station	T073	C1883167
27473429	1545	1553	addition	T169	C0332287
27473429	1561	1573	DNA fragment	UnknownType	C0684192
27473429	1581	1590	different	T080	C1705242
27473429	1591	1598	lengths	T081	C1444754
27473429	1634	1646	successfully	T080	C1272703
27473429	1647	1656	amplified	T067	C1521871
27473429	1662	1671	segmented	T082	C0442059
27473429	1674	1678	flow	T070	C0806140
27473429	1679	1683	mode	T169	C1513371
27473429	1707	1720	contamination	T078	C2349974
27473429	1729	1737	segments	T082	C0442059
27473429	1744	1750	result	T169	C1274040
27473429	1770	1776	device	T073	C0699733
27473429	1796	1799	PCR	T063	C0032520
27473429	1800	1806	module	T077	C1709061
27473429	1812	1827	continuous-flow	T070	C0806140
27473429	1828	1870	high-throughput on-line total DNA analysis	T060	C0872186
27473429	1871	1877	system	T169	C0449913
27473429	1878	1889	integrating	T080	C0205195
27473429	1904	1911	modules	T077	C1709061
27473429	1917	1921	cell	T025	C0007634
27473429	1922	1927	lysis	T046	C0024348
27473429	1930	1944	DNA extraction	T063	C3839098
27473429	1948	1951	PCR	T063	C0032520
27473429	1952	1959	product	T071	C1514468
27473429	1960	1968	analysis	T062	C0936012

28055142|t|Executive functions deficits impair extinction of generalization of fear of movement-related pain
28055142|a|Generalization of fear of movement-related pain across novel but similar movements can lead to fear responses to movements that are actually not associated with pain. The peak-shift effect describes a phenomenon whereby particular novel movements elicit even greater fear responses than the original pain-provoking movement (CS+), because they represent a more extreme version of the CS+. There is great variance in the propensity to generalize as well as the speed of extinction learning when these novel movements are not followed by pain. It can be argued that this variance may be associated with executive function capacity, as individuals may be unable to intentionally inhibit fear responses. This study examined whether executive function capacity contributes to generalization and extinction of generalization as well as peak-shift of conditioned fear of movement-related pain and expectancy. Healthy participants performed a proprioceptive fear conditioning task. Executive function tests assessing updating, switching, and inhibition were used to predict changes in (extinction of) fear of movement-related pain and pain expectancy generalization. Low inhibitory capacity was associated with slower extinction of generalized fear of movement-related pain and pain expectancy. Evidence was found in favor of an area-shift, rather than a peak-shift effect, which implies that the peak conditioned fear response extended to, but did not shift to a novel stimulus. Participants with low inhibitory capacity may have difficulties withholding fear responses, leading to a slower decrease of generalized fear over time. The findings may be relevant to inform treatments. Low inhibitory capacity is not associated with slower generalization, but extinction of fear generalization. Fear elicited by a novel safe movement, situated outside the CS+/- continuum on the CS+ side, can be as strong as to the original stimulus predicting the pain-onset.
28055142	0	19	Executive functions	T041	C0935584
28055142	20	28	deficits	T080	C2987487
28055142	29	35	impair	T169	C0221099
28055142	36	46	extinction	T041	C0015347
28055142	50	64	generalization	T041	C0017324
28055142	68	72	fear	T041	C0015726
28055142	76	97	movement-related pain	T033	C0240386
28055142	98	112	Generalization	T041	C0017324
28055142	116	120	fear	T041	C0015726
28055142	124	145	movement-related pain	T033	C0240386
28055142	171	180	movements	T040	C0026649
28055142	193	207	fear responses	T039	C1327613
28055142	211	220	movements	T040	C0026649
28055142	243	258	associated with	T080	C0332281
28055142	259	263	pain	T184	C0030193
28055142	269	286	peak-shift effect	T080	C1280500
28055142	299	309	phenomenon	T067	C1882365
28055142	335	344	movements	T040	C0026649
28055142	345	351	elicit	T080	C0449265
28055142	365	379	fear responses	T039	C1327613
28055142	398	412	pain-provoking	T184	C1960719
28055142	413	421	movement	T040	C0026649
28055142	423	426	CS+	T041	C0234404
28055142	482	485	CS+	T041	C0234404
28055142	502	510	variance	T080	C1711260
28055142	532	542	generalize	T041	C0017324
28055142	567	586	extinction learning	T041	C0237613
28055142	604	613	movements	T040	C0026649
28055142	634	638	pain	T184	C0030193
28055142	667	675	variance	T080	C1711260
28055142	683	698	associated with	T080	C0332281
28055142	699	726	executive function capacity	T041	C0935584
28055142	731	742	individuals	T098	C0237401
28055142	774	796	inhibit fear responses	T039	C3894332
28055142	809	817	examined	T033	C0332128
28055142	826	853	executive function capacity	T041	C0935584
28055142	869	883	generalization	T041	C0017324
28055142	888	898	extinction	T041	C0015347
28055142	902	916	generalization	T041	C0017324
28055142	928	938	peak-shift	T169	C0333051
28055142	942	958	conditioned fear	T041	C1510535
28055142	962	983	movement-related pain	T033	C0240386
28055142	988	998	expectancy	T078	C0679138
28055142	1000	1020	Healthy participants	T098	C1708335
28055142	1033	1047	proprioceptive	T039	C2370956
28055142	1048	1070	fear conditioning task	T041	C0009647
28055142	1072	1096	Executive function tests	T041	C0935584
28055142	1107	1115	updating	T079	C1519814
28055142	1132	1142	inhibition	T041	C0021467
28055142	1176	1186	extinction	T041	C0015347
28055142	1191	1195	fear	T041	C0015726
28055142	1199	1220	movement-related pain	T033	C0240386
28055142	1225	1229	pain	T184	C0030193
28055142	1230	1240	expectancy	T078	C0679138
28055142	1241	1255	generalization	T041	C0017324
28055142	1257	1280	Low inhibitory capacity	T041	C0021467
28055142	1285	1300	associated with	T080	C0332281
28055142	1308	1318	extinction	T041	C0015347
28055142	1322	1338	generalized fear	T041	C0015726
28055142	1342	1363	movement-related pain	T033	C0240386
28055142	1368	1372	pain	T184	C0030193
28055142	1373	1383	expectancy	T078	C0679138
28055142	1419	1429	area-shift	T169	C0333051
28055142	1445	1462	peak-shift effect	T080	C1280500
28055142	1487	1491	peak	T080	C0444505
28055142	1492	1517	conditioned fear response	T039	C1327613
28055142	1560	1568	stimulus	T067	C0234402
28055142	1570	1582	Participants	T098	C0679646
28055142	1592	1611	inhibitory capacity	T041	C0021467
28055142	1646	1660	fear responses	T039	C1327613
28055142	1694	1710	generalized fear	T041	C0015726
28055142	1716	1720	time	T079	C0040223
28055142	1726	1734	findings	T033	C0243095
28055142	1761	1771	treatments	T169	C1522326
28055142	1773	1796	Low inhibitory capacity	T041	C0021467
28055142	1804	1819	associated with	T080	C0332281
28055142	1827	1841	generalization	T041	C0017324
28055142	1847	1857	extinction	T041	C0015347
28055142	1861	1865	fear	T041	C0015726
28055142	1866	1880	generalization	T041	C0017324
28055142	1882	1886	Fear	T041	C0015726
28055142	1887	1898	elicited by	T080	C0449265
28055142	1912	1920	movement	T040	C0026649
28055142	1943	1948	CS+/-	T041	C0234404
28055142	1966	1969	CS+	T041	C0234404
28055142	2012	2020	stimulus	T067	C0234402
28055142	2036	2046	pain-onset	T033	C1507009

27244841|t|Improving Early Identification and Ongoing Care of Children With Autism Spectrum Disorder
27244841|a|Poor adherence to recommended screening for autism spectrum disorder (ASD) and pediatricians ' lack of confidence in providing care for children with ASD reflect quality gaps in primary care. This study aimed to increase the proportion of toddlers screened for ASD and improve physicians ' self-efficacy in providing care to children with ASD. Twenty-six Utah primary care practices participated in a 3 to 6 month learning collaborative (LC) to improve identification and ongoing care of children with ASD. Monthly chart audits assessed whether an ASD screening tool was administered at 18- and 24- month visits. Physicians completed pre-LC and post-LC surveys to assess changes in self-efficacy in providing care and changes in perceived barriers to implementation of screening and caring for children with ASD. Before the LC, 15% of 18- and 24- month visits had documented ASD screening, compared with 91% during the last month of the LC (P < .001). This rate of ASD screening was sustained 4 years after the LC by most practices. Compared with survey responses before the LC, physicians reported significant improvement in their ability to care for children with ASD and decreases in their perceived barriers to screening and caring for children with ASD. The LC was effective in increasing and sustaining recommended ASD screening of toddlers and improving physicians ' perceived self-efficacy in caring for children with ASD. Improving primary care screening, skills, and knowledge may improve the timing of diagnosis, initiation of treatment, quality of care, and outcomes for children with ASD.
27244841	0	9	Improving	T080	C1272745
27244841	10	30	Early Identification	T061	C0814435
27244841	43	47	Care	T052	C1947933
27244841	51	59	Children	T100	C0008059
27244841	65	89	Autism Spectrum Disorder	T033	C4315362
27244841	120	129	screening	T058	C1710032
27244841	134	158	autism spectrum disorder	T033	C4315362
27244841	160	163	ASD	T033	C4315362
27244841	169	182	pediatricians	T097	C0237433
27244841	185	203	lack of confidence	T033	C0558092
27244841	217	221	care	T052	C1947933
27244841	226	234	children	T100	C0008059
27244841	240	243	ASD	T033	C4315362
27244841	268	280	primary care	T058	C0033137
27244841	287	292	study	T062	C2603343
27244841	329	337	toddlers	T100	C0682053
27244841	351	354	ASD	T033	C4315362
27244841	359	366	improve	T033	C0184511
27244841	367	377	physicians	T097	C0031831
27244841	380	393	self-efficacy	T041	C0600564
27244841	407	411	care	T052	C1947933
27244841	415	423	children	T100	C0008059
27244841	429	432	ASD	T033	C4315362
27244841	450	472	primary care practices	T058	C0033137
27244841	498	503	month	T079	C0439231
27244841	504	526	learning collaborative	T092	C1561598
27244841	528	530	LC	T092	C1561598
27244841	535	542	improve	T033	C0184511
27244841	543	557	identification	T041	C0020792
27244841	570	574	care	T052	C1947933
27244841	578	586	children	T100	C0008059
27244841	592	595	ASD	T033	C4315362
27244841	597	604	Monthly	T079	C0332177
27244841	605	617	chart audits	UnknownType	C0184805
27244841	638	641	ASD	T033	C4315362
27244841	642	656	screening tool	T058	C1710032
27244841	689	694	month	T079	C0439231
27244841	695	701	visits	T058	C1512346
27244841	703	713	Physicians	T097	C0031831
27244841	724	730	pre-LC	T079	C1254367
27244841	735	742	post-LC	T079	C1254367
27244841	743	750	surveys	T170	C0038951
27244841	761	768	changes	T169	C0392747
27244841	772	785	self-efficacy	T041	C0600564
27244841	799	803	care	T052	C1947933
27244841	819	828	perceived	T041	C0030971
27244841	829	837	barriers	T080	C0679881
27244841	841	855	implementation	T052	C1708476
27244841	859	868	screening	T058	C1710032
27244841	873	879	caring	T052	C1947933
27244841	884	892	children	T100	C0008059
27244841	898	901	ASD	T033	C4315362
27244841	914	916	LC	T092	C1561598
27244841	937	942	month	T079	C0439231
27244841	943	949	visits	T058	C1512346
27244841	954	964	documented	T058	C1301725
27244841	965	968	ASD	T033	C4315362
27244841	969	978	screening	T058	C1710032
27244841	1014	1019	month	T079	C0439231
27244841	1027	1029	LC	T092	C1561598
27244841	1055	1058	ASD	T033	C4315362
27244841	1059	1068	screening	T058	C1710032
27244841	1085	1090	years	T079	C0439234
27244841	1101	1103	LC	T092	C1561598
27244841	1137	1143	survey	T062	C0018762
27244841	1165	1167	LC	T092	C1561598
27244841	1169	1179	physicians	T097	C0031831
27244841	1201	1212	improvement	T077	C2986411
27244841	1233	1237	care	T052	C1947933
27244841	1242	1250	children	T100	C0008059
27244841	1256	1259	ASD	T033	C4315362
27244841	1283	1292	perceived	T041	C0030971
27244841	1293	1301	barriers	T080	C0679881
27244841	1305	1314	screening	T058	C1710032
27244841	1319	1325	caring	T052	C1947933
27244841	1330	1338	children	T100	C0008059
27244841	1344	1347	ASD	T033	C4315362
27244841	1353	1355	LC	T092	C1561598
27244841	1411	1414	ASD	T033	C4315362
27244841	1415	1424	screening	T058	C1710032
27244841	1428	1436	toddlers	T100	C0682053
27244841	1451	1461	physicians	T097	C0031831
27244841	1474	1487	self-efficacy	T041	C0600564
27244841	1491	1497	caring	T055	C0150499
27244841	1502	1510	children	T100	C0008059
27244841	1516	1519	ASD	T033	C4315362
27244841	1531	1543	primary care	T058	C0033137
27244841	1544	1553	screening	T058	C1710032
27244841	1555	1561	skills	T080	C0008973
27244841	1567	1576	knowledge	T033	C0518904
27244841	1581	1588	improve	T033	C0184511
27244841	1593	1599	timing	T079	C0449243
27244841	1603	1612	diagnosis	T062	C1704656
27244841	1614	1624	initiation	T169	C1704686
27244841	1628	1637	treatment	T061	C0087111
27244841	1639	1654	quality of care	T058	C0034379
27244841	1660	1668	outcomes	T169	C1274040
27244841	1673	1681	children	T100	C0008059
27244841	1687	1690	ASD	T033	C4315362

28298837|t|A study of acute muscle dysfunction with particular reference to dengue myopathy
28298837|a|Acute myopathy is a common cause of acute motor quadriparesis which has various etiologies with different courses of illness and prognosis depending on the cause. Understanding this diversity helps us in proper approach toward diagnosis, predicting the prognosis, and possible complications and in improving the treatments that are being provided. This study was planned to study the clinical, electrophysiological, and etiological profile of patients presenting with acute myopathy. We also studied how dengue -related acute myopathy differs from other causes and also difference between myopathy due to myositis and hypokalemia in cases of dengue. This was a prospective, observational study involving all clinically suspected cases of acute myopathy of not more than 4 weeks duration with raised serum creatine kinase (CK) level. They were subjected to detailed clinical evaluation along with hematological, biochemical, microbiological, and electrophysiological studies and followed-up for outcome at 1 and 3 months. Muscle biopsy and histopathological examination were done in selected patients after taking informed consent. Statistical analysis was performed by appropriate methods using SPSS version 16.0 (Chicago, IL, USA). We evaluated thirty patients of acute myopathy with raised CK level. Seventeen patients had fever, 11 had myalgia, and 5 had skin lesions. All presented with symmetric weakness, 17 (56.7%) patients having predominantly proximal weakness, neck or truncal weakness in 6 (20%), hyporeflexia in 12 (40%), with mean Medical Research Council (MRC) sum score of 46.67 ± 6.0. Eight (mean modified Barthel index [MBI] at presentation - 15 ± 3.7) patients had poor functional status according to MBI and 15 according to modified Rankin scale (MRS) (mean MRS score - 2.5 ± 1.2). Etiology was dengue viral infection in 14 patients; hypokalemia due to various causes other than dengue in 8; pyomyositis in 3; dermatomyositis, polymyositis, thyrotoxicosis, systemic lupus erythematosus, and unknown etiology in one each. Only eight patients had abnormal electrophysiology and seven among nine biopsies done were abnormal. At 1 month, 24 (80.0%) and 23 (76.7%) patients had achieved normal MBI and MRS scores with 28 (93.3) and 27 (90%) patients, respectively, at 3 months. Dengue with hypokalemia had less myalgia, more of hyporeflexia, and lower serum CK compared to those without hypokalemia. Dengue infection and hypokalemia due to various causes are the most common causes of acute myopathy and are associated with rapid and complete recovery within 1 month. Shorter duration of illness, higher MRC sum score, better disability status at presentation, lower serum CK correlate with better outcome. Biopsy was decisive in <20% cases; hence, it is not primary investigation in acute myopathy.
28298837	2	7	study	T062	C2603343
28298837	11	16	acute	T079	C0205178
28298837	17	23	muscle	T024	C0026845
28298837	24	35	dysfunction	T077	C3887504
28298837	65	71	dengue	T047	C0011311
28298837	72	80	myopathy	T047	C0026848
28298837	81	95	Acute myopathy	T047	C1735371
28298837	117	142	acute motor quadriparesis	T184	C0270790
28298837	161	171	etiologies	T169	C0015127
28298837	187	194	courses	T079	C0750729
28298837	198	205	illness	T184	C0221423
28298837	210	219	prognosis	T058	C0033325
28298837	244	257	Understanding	T041	C0162340
28298837	263	272	diversity	T080	C1880371
28298837	308	317	diagnosis	T033	C0011900
28298837	319	329	predicting	T078	C0681842
28298837	334	343	prognosis	T058	C0033325
28298837	358	371	complications	T046	C0009566
28298837	379	388	improving	T080	C1272745
28298837	393	403	treatments	T061	C0087111
28298837	434	439	study	T062	C2603343
28298837	465	473	clinical	T080	C0205210
28298837	475	495	electrophysiological	T060	C0850293
28298837	501	520	etiological profile	T169	C0015127
28298837	524	532	patients	T101	C0030705
28298837	533	543	presenting	T078	C0449450
28298837	549	563	acute myopathy	T047	C1735371
28298837	585	591	dengue	T047	C0011311
28298837	601	615	acute myopathy	T047	C1735371
28298837	651	661	difference	T080	C1705242
28298837	670	678	myopathy	T047	C0026848
28298837	686	694	myositis	T047	C0027121
28298837	699	710	hypokalemia	T033	C0020621
28298837	714	719	cases	T169	C0868928
28298837	723	729	dengue	T047	C0011311
28298837	755	774	observational study	T062	C1518527
28298837	800	809	suspected	T078	C0750491
28298837	810	815	cases	T169	C0868928
28298837	819	833	acute myopathy	T047	C1735371
28298837	853	858	weeks	T079	C0439230
28298837	859	867	duration	T079	C0449238
28298837	873	879	raised	T080	C0442818
28298837	880	885	serum	T031	C0229671
28298837	886	901	creatine kinase	T116,T126	C0010287
28298837	903	905	CK	T116,T126	C0010287
28298837	907	912	level	T080	C0441889
28298837	946	965	clinical evaluation	T058	C4084924
28298837	977	990	hematological	T169	C0205488
28298837	992	1003	biochemical	T169	C0205474
28298837	1005	1020	microbiological	T170	C0025953
28298837	1026	1054	electrophysiological studies	T060	C0850293
28298837	1059	1070	followed-up	T058	C1522577
28298837	1075	1082	outcome	T169	C1274040
28298837	1094	1100	months	T079	C0439231
28298837	1102	1115	Muscle biopsy	T060	C0185283
28298837	1120	1137	histopathological	T169	C0243140
28298837	1138	1149	examination	T058	C0582103
28298837	1172	1180	patients	T101	C0030705
28298837	1212	1232	Statistical analysis	T062	C0871424
28298837	1237	1246	performed	T169	C0884358
28298837	1250	1269	appropriate methods	T170	C0025663
28298837	1276	1293	SPSS version 16.0	T073,T170	C0037585
28298837	1295	1302	Chicago	T083	C0008044
28298837	1304	1306	IL	T083	C0020898
28298837	1308	1311	USA	T083	C0041703
28298837	1334	1342	patients	T101	C0030705
28298837	1346	1360	acute myopathy	T047	C1735371
28298837	1366	1372	raised	T080	C0442818
28298837	1373	1375	CK	T116,T126	C0010287
28298837	1376	1381	level	T080	C0441889
28298837	1393	1401	patients	T101	C0030705
28298837	1406	1411	fever	T184	C0015967
28298837	1420	1427	myalgia	T184	C0231528
28298837	1439	1451	skin lesions	T047	C0037284
28298837	1472	1490	symmetric weakness	T184	C3714552
28298837	1503	1511	patients	T101	C0030705
28298837	1533	1550	proximal weakness	T184	C0750403
28298837	1552	1556	neck	T029	C0027530
28298837	1560	1576	truncal weakness	T033	C0241492
28298837	1589	1601	hyporeflexia	T033	C0151888
28298837	1620	1665	mean Medical Research Council (MRC) sum score	T081	C0449820
28298837	1689	1716	mean modified Barthel index	T170	C0282574
28298837	1718	1721	MBI	T170	C0282574
28298837	1726	1738	presentation	T078	C0449450
28298837	1751	1759	patients	T101	C0030705
28298837	1764	1768	poor	T080	C0542537
28298837	1769	1786	functional status	T033	C0598463
28298837	1800	1803	MBI	T170	C0282574
28298837	1824	1845	modified Rankin scale	T170	C2984908
28298837	1847	1850	MRS	T170	C2984908
28298837	1858	1867	MRS score	T170	C3828944
28298837	1882	1890	Etiology	T169	C1314792
28298837	1895	1901	dengue	T005	C0011315
28298837	1902	1917	viral infection	T047	C0042769
28298837	1924	1932	patients	T101	C0030705
28298837	1934	1945	hypokalemia	T033	C0020621
28298837	1979	1985	dengue	T047	C0011311
28298837	1992	2003	pyomyositis	T047	C1704275
28298837	2010	2025	dermatomyositis	T047	C0011633
28298837	2027	2039	polymyositis	T047	C0085655
28298837	2041	2055	thyrotoxicosis	T047	C0040156
28298837	2057	2085	systemic lupus erythematosus	T047	C0024141
28298837	2099	2107	etiology	T169	C1314792
28298837	2132	2140	patients	T101	C0030705
28298837	2145	2153	abnormal	T033	C0205161
28298837	2154	2171	electrophysiology	T060	C1446476
28298837	2193	2201	biopsies	T060	C0005558
28298837	2212	2220	abnormal	T033	C0205161
28298837	2227	2232	month	T079	C0439231
28298837	2260	2268	patients	T101	C0030705
28298837	2289	2292	MBI	T170	C0282574
28298837	2297	2307	MRS scores	T170	C3828944
28298837	2336	2344	patients	T101	C0030705
28298837	2365	2371	months	T079	C0439231
28298837	2373	2379	Dengue	T047	C0011311
28298837	2385	2396	hypokalemia	T033	C0020621
28298837	2406	2413	myalgia	T184	C0231528
28298837	2423	2435	hyporeflexia	T033	C0151888
28298837	2447	2452	serum	T031	C0229671
28298837	2453	2455	CK	T116,T126	C0010287
28298837	2482	2493	hypokalemia	T033	C0020621
28298837	2495	2511	Dengue infection	T047	C0011311
28298837	2516	2527	hypokalemia	T033	C0020621
28298837	2580	2594	acute myopathy	T047	C1735371
28298837	2619	2624	rapid	T080	C0456962
28298837	2629	2646	complete recovery	T033	C2826210
28298837	2656	2661	month	T079	C0439231
28298837	2663	2670	Shorter	T081	C1806781
28298837	2671	2679	duration	T079	C0449238
28298837	2683	2690	illness	T184	C0221423
28298837	2692	2698	higher	T080	C0205250
28298837	2699	2712	MRC sum score	T081	C0449820
28298837	2721	2738	disability status	UnknownType	C0682148
28298837	2742	2754	presentation	T078	C0449450
28298837	2756	2761	lower	T080	C0205251
28298837	2762	2767	serum	T031	C0229671
28298837	2768	2770	CK	T116,T126	C0010287
28298837	2771	2780	correlate	T080	C1707520
28298837	2793	2800	outcome	T169	C1274040
28298837	2802	2808	Biopsy	T060	C0005558
28298837	2830	2835	cases	T169	C0868928
28298837	2862	2875	investigation	T058	C0220825
28298837	2879	2893	acute myopathy	T047	C1735371

28102508|t|Simvastatin Promotes Hematoma Absorption and Reduces Hydrocephalus Following Intraventricular Hemorrhage in Part by Upregulating CD36
28102508|a|We previously found that hematoma worsens hydrocephalus after intraventricular hemorrhage (IVH) via increasing iron deposition and aggravating ependymal cilia injury; therefore, promoting hematoma absorption may be a promising strategy for IVH. Recently, some investigations imply that simvastatin has the ability of accelerating hematoma absorption. Thus, this study was designed to examine the efficacy of simvastatin for IVH in rats. Intracerebral hemorrhage with ventricular extension was induced in adult male Sprague-Dawley rats after autologous blood injection. Simvastatin or vehicle was administered orally at 1 day after IVH and then daily for 1 week. MRI studies were performed to measure the volumes of intracranial hematoma and lateral ventricle at days 1, 3, 7, 14, and 28 after IVH. Motor and neurocognitive functions were assessed at days 1 to 7 and 23 to 28, respectively. Iron deposition, iron -related protein expression, ependymal damage, and histology were detected at day 28. Expression of CD36 scavenger receptor (facilitating phagocytosis) was examined at day 3 after IVH using western blotting and immunofluorescence. Simvastatin significantly increased hematoma absorption ratio, reduced ventricular volume, and attenuated neurological dysfunction post- IVH. In addition, less iron accumulation and more cilia survival was observed in the simvastatin group when compared with the control. What's more, higher expression of CD36 was detected around the hematoma after simvastatin administration. Simvastatin significantly enhanced brain hematoma absorption, alleviated hydrocephalus, and improved neurological recovery after experimental IVH, which may in part by upregulating CD36 expression. Our data suggest that early simvastatin use may be a novel therapy for IVH patients.
28102508	0	11	Simvastatin	T109,T121	C0074554
28102508	21	29	Hematoma	T046	C0018944
28102508	30	40	Absorption	T070	C0000854
28102508	53	66	Hydrocephalus	T047	C0020255
28102508	77	104	Intraventricular Hemorrhage	T046	C0240059
28102508	116	128	Upregulating	T044	C0041904
28102508	129	133	CD36	T028	C1366645
28102508	159	167	hematoma	T046	C0018944
28102508	168	175	worsens	T033	C1457868
28102508	176	189	hydrocephalus	T047	C0020255
28102508	196	223	intraventricular hemorrhage	T046	C0240059
28102508	225	228	IVH	T046	C0240059
28102508	234	244	increasing	T169	C0442808
28102508	245	260	iron deposition	T046	C0333596
28102508	277	286	ependymal	T024	C0014472
28102508	287	292	cilia	T026	C0008778
28102508	293	299	injury	T037	C3263723
28102508	322	330	hematoma	T046	C0018944
28102508	331	341	absorption	T070	C0000854
28102508	374	377	IVH	T046	C0240059
28102508	420	431	simvastatin	T109,T121	C0074554
28102508	464	472	hematoma	T046	C0018944
28102508	473	483	absorption	T070	C0000854
28102508	530	538	efficacy	T080	C1280519
28102508	542	553	simvastatin	T109,T121	C0074554
28102508	558	561	IVH	T046	C0240059
28102508	565	569	rats	T015	C0086893
28102508	571	595	Intracerebral hemorrhage	T046	C0475526
28102508	638	648	adult male	T032	C0086582
28102508	649	668	Sprague-Dawley rats	T015	C0034715
28102508	675	701	autologous blood injection	T061	C0849679
28102508	703	714	Simvastatin	T109,T121	C0074554
28102508	718	725	vehicle	T122	C0042444
28102508	730	749	administered orally	T061	C0001563
28102508	765	768	IVH	T046	C0240059
28102508	796	807	MRI studies	T060	C3515983
28102508	826	833	measure	T169	C0242485
28102508	838	845	volumes	T059	C2700258
28102508	849	861	intracranial	T029	C0524466
28102508	862	870	hematoma	T046	C0018944
28102508	875	892	lateral ventricle	T030	C0152279
28102508	927	930	IVH	T046	C0240059
28102508	932	937	Motor	T038	C0234130
28102508	942	966	neurocognitive functions	T038	C3714634
28102508	972	980	assessed	T052	C1516048
28102508	1024	1039	Iron deposition	T046	C0333596
28102508	1041	1045	iron	T121,T123,T196	C0302583
28102508	1055	1073	protein expression	T045	C1171362
28102508	1075	1091	ependymal damage	T033	C3686783
28102508	1097	1106	histology	T169	C4048239
28102508	1112	1120	detected	T033	C0442726
28102508	1132	1142	Expression	T045	C0017262
28102508	1146	1150	CD36	T028	C1366645
28102508	1151	1169	scavenger receptor	T116,T192	C0074129
28102508	1184	1196	phagocytosis	T043	C0031308
28102508	1202	1210	examined	T033	C0332128
28102508	1226	1229	IVH	T046	C0240059
28102508	1236	1252	western blotting	T059,T063	C0005863
28102508	1257	1275	immunofluorescence	T059	C0079603
28102508	1277	1288	Simvastatin	T109,T121	C0074554
28102508	1303	1312	increased	T081	C0205217
28102508	1313	1321	hematoma	T046	C0018944
28102508	1322	1332	absorption	T070	C0000854
28102508	1333	1338	ratio	T081	C0456603
28102508	1340	1347	reduced	T080	C0392756
28102508	1348	1366	ventricular volume	T078	C1511726
28102508	1372	1407	attenuated neurological dysfunction	T033	C1709219
28102508	1414	1417	IVH	T046	C0240059
28102508	1432	1454	less iron accumulation	T033	C4021076
28102508	1464	1469	cilia	T026	C0008778
28102508	1470	1478	survival	T081	C1709301
28102508	1499	1510	simvastatin	T109,T121	C0074554
28102508	1540	1547	control	T096	C0009932
28102508	1562	1568	higher	T080	C0205250
28102508	1569	1579	expression	T045	C0017262
28102508	1583	1587	CD36	T028	C1366645
28102508	1592	1600	detected	T033	C0442726
28102508	1612	1620	hematoma	T046	C0018944
28102508	1627	1638	simvastatin	T109,T121	C0074554
28102508	1639	1653	administration	T061	C1533734
28102508	1655	1666	Simvastatin	T109,T121	C0074554
28102508	1690	1695	brain	T023	C0006104
28102508	1696	1704	hematoma	T046	C0018944
28102508	1705	1715	absorption	T070	C0000854
28102508	1717	1741	alleviated hydrocephalus	T047	C0020255
28102508	1747	1755	improved	T033	C0184511
28102508	1756	1768	neurological	T080	C0205494
28102508	1769	1777	recovery	T040	C2004454
28102508	1784	1796	experimental	T080	C1517586
28102508	1797	1800	IVH	T046	C0240059
28102508	1823	1835	upregulating	T044	C0041904
28102508	1836	1840	CD36	T028	C1366645
28102508	1841	1851	expression	T045	C0017262
28102508	1857	1861	data	T078	C1511726
28102508	1881	1892	simvastatin	T109,T121	C0074554
28102508	1906	1911	novel	T080	C0205314
28102508	1912	1919	therapy	T061	C0087111
28102508	1924	1927	IVH	T046	C0240059
28102508	1928	1936	patients	T101	C0030705

27858089|t|Oxidative Damage and Cytotoxicity of Perfluorooctane Sulfonate on Chlorella vulgaris
27858089|a|We studied the effects of perfluorooctane sulfonate (PFOS) on the chlorophyll content, cell permeability, and antioxidant defense systems of the green alga Chlorella vulgaris. The results showed that the production of reactive oxygen species increased in a concentration -dependent manner after exposure to PFOS for 96 h. Superoxide dismutase and catalase activity was elevated after exposure to the lower concentrations and then decreased with higher concentrations. Malondialdehyde content was significantly higher than that of controls at the higher PFOS concentrations. Cell membrane permeability increased. These results indicate that PFOS exposure leads to oxidative damage in C. vulgaris. At these concentrations, chlorophyll and the structure of chloroplasts were destroyed.
27858089	0	9	Oxidative	T044	C0030011
27858089	10	16	Damage	T037	C0010957
27858089	21	33	Cytotoxicity	T049	C0596402
27858089	37	62	Perfluorooctane Sulfonate	T109,T121	C0905462
27858089	66	84	Chlorella vulgaris	T002	C0996438
27858089	100	110	effects of	T080	C1704420
27858089	111	136	perfluorooctane sulfonate	T109,T121	C0905462
27858089	138	142	PFOS	T109,T121	C0905462
27858089	151	162	chlorophyll	T109,T123	C0008260
27858089	172	189	cell permeability	T043	C0007605
27858089	195	222	antioxidant defense systems	T044	C1148564
27858089	230	240	green alga	T002	C0002032
27858089	241	259	Chlorella vulgaris	T002	C0996438
27858089	303	326	reactive oxygen species	T123,T196	C0162772
27858089	342	355	concentration	T081	C1446561
27858089	380	391	exposure to	T080	C0332157
27858089	392	396	PFOS	T109,T121	C0905462
27858089	407	427	Superoxide dismutase	T116,T121,T126	C0038838
27858089	432	440	catalase	T116,T126	C0007367
27858089	441	449	activity	T044	C0243102
27858089	454	462	elevated	T080	C3163633
27858089	469	480	exposure to	T080	C0332157
27858089	491	505	concentrations	T081	C1446561
27858089	537	551	concentrations	T081	C1446561
27858089	553	568	Malondialdehyde	T109,T123	C0024643
27858089	581	601	significantly higher	T081	C4055637
27858089	638	642	PFOS	T109,T121	C0905462
27858089	643	657	concentrations	T081	C1446561
27858089	659	685	Cell membrane permeability	T043	C0007605
27858089	725	729	PFOS	T109,T121	C0905462
27858089	730	738	exposure	T080	C0332157
27858089	748	757	oxidative	T044	C0030011
27858089	758	764	damage	T037	C0010957
27858089	768	779	C. vulgaris	T002	C0996438
27858089	790	804	concentrations	T081	C1446561
27858089	806	817	chlorophyll	T109,T123	C0008260
27858089	839	851	chloroplasts	T026	C0008266

27921577|t|The efficiency and safety of trastuzumab for advanced gastric and gastroesophageal cancer: a meta-analysis of five randomized controlled trials
27921577|a|A meta-analysis was performed to examine the efficiency and safety of trastuzumab in patients with advanced gastric and gastroesophageal cancer (AGC). By searching multiple databases from 1990 to March 2016, all randomized controlled trials (RCTs) which compared the effect of trastuzumab - combined chemotherapy (TC) versus chemotherapy alone (CT) in gastric cancer would be included. Five RCTs with a total of 875 patients were included. Trastuzumab can improve the overall survival (OS) rate, progression-free survival (PFS), one-year survival rate, two-year survival rate and overall response rate (ORR) of patients with AGC. There were no difference between the two arms in terms of grade 3 / 4 adverse effects, such as vomiting, nausea, neutropenia, thrombocytopaenia and anemia. Diarrhea increased in TC group. Trastuzumab can significantly improve the survival rate, PFS, ORR of patients with AGC. It is safe and feasible and can be tolerated. It needs further prospective multinational multicenter RCTs with large samples to define the clinical benefits of trastuzumab.
27921577	4	14	efficiency	T081	C0013682
27921577	19	25	safety	T080	C0678800
27921577	29	40	trastuzumab	T116,T121,T129	C0728747
27921577	45	61	advanced gastric	T191	C0024623
27921577	66	89	gastroesophageal cancer	T191	C1112160
27921577	93	106	meta-analysis	T062	C0920317
27921577	115	143	randomized controlled trials	T062	C0206035
27921577	146	159	meta-analysis	T062	C0920317
27921577	164	173	performed	T169	C0884358
27921577	189	199	efficiency	T081	C0013682
27921577	204	210	safety	T080	C0678800
27921577	214	225	trastuzumab	T116,T121,T129	C0728747
27921577	229	237	patients	T101	C0030705
27921577	243	259	advanced gastric	T191	C0024623
27921577	264	287	gastroesophageal cancer	T191	C1112160
27921577	289	292	AGC	T191	C1112160
27921577	308	316	multiple	T081	C0439064
27921577	317	326	databases	T170	C0242356
27921577	356	384	randomized controlled trials	T062	C0206035
27921577	386	390	RCTs	T062	C0206035
27921577	398	406	compared	T052	C1707455
27921577	411	417	effect	T080	C1280500
27921577	421	432	trastuzumab	T116,T121,T129	C0728747
27921577	435	456	combined chemotherapy	T061	C0003393
27921577	458	460	TC	T061	C0003393
27921577	469	481	chemotherapy	T061	C3665472
27921577	489	491	CT	T061	C3665472
27921577	496	510	gastric cancer	T191	C0024623
27921577	520	528	included	T169	C0332257
27921577	535	539	RCTs	T062	C0206035
27921577	560	568	patients	T101	C0030705
27921577	574	582	included	T169	C0332257
27921577	584	595	Trastuzumab	T116,T121,T129	C0728747
27921577	596	607	can improve	T080	C1272747
27921577	612	628	overall survival	T081	C4086681
27921577	630	632	OS	T081	C4086681
27921577	634	638	rate	T081	C0038954
27921577	640	665	progression-free survival	T081	C0242792
27921577	667	670	PFS	T081	C0242792
27921577	673	695	one-year survival rate	T081	C0038954
27921577	697	719	two-year survival rate	T081	C0038954
27921577	724	745	overall response rate	T079	C0237629
27921577	747	750	ORR	T079	C0237629
27921577	755	763	patients	T101	C0030705
27921577	769	772	AGC	T191	C1112160
27921577	785	798	no difference	T033	C3842396
27921577	832	839	grade 3	T033	C0450094
27921577	842	843	4	T185	C0547054
27921577	844	859	adverse effects	T046	C0879626
27921577	869	877	vomiting	T184	C0042963
27921577	879	885	nausea	T184	C0027497
27921577	887	898	neutropenia	T047	C0027947
27921577	900	917	thrombocytopaenia	T047	C0040034
27921577	922	928	anemia	T047	C0002871
27921577	930	938	Diarrhea	T184	C0011991
27921577	939	948	increased	T081	C0205217
27921577	952	954	TC	T061	C0003393
27921577	962	973	Trastuzumab	T116,T121,T129	C0728747
27921577	978	991	significantly	T078	C0750502
27921577	992	999	improve	T033	C0184511
27921577	1004	1017	survival rate	T081	C0038954
27921577	1019	1022	PFS	T081	C0242792
27921577	1024	1027	ORR	T079	C0237629
27921577	1031	1039	patients	T101	C0030705
27921577	1045	1048	AGC	T191	C1112160
27921577	1056	1060	safe	T109,T121	C1951004
27921577	1085	1094	tolerated	T033	C0243095
27921577	1113	1124	prospective	T080	C0205556
27921577	1125	1138	multinational	T080	C0205556
27921577	1139	1150	multicenter	T062	C0206012
27921577	1151	1155	RCTs	T062	C0206035
27921577	1167	1174	samples	T077	C2347026
27921577	1189	1197	clinical	T080	C0205210
27921577	1198	1206	benefits	T081	C0814225
27921577	1210	1221	trastuzumab	T116,T121,T129	C0728747

28421317|t|Effect of oral carbohydrate with amino acid solution on serum oxidative/anti-oxidative status in healthy volunteers
28421317|a|The aim of this work was to investigate the effect of oral carbohydrate with amino acid [oral nutritional supplement (ONS)] solution on oxidative stress in healthy persons. Fourteen healthy volunteers were segregated into control and ONS groups. Volunteers in the ONS group ingested 250 ml of Arginaid Water (Nestle Japan, Tokyo, Japan) in the evening before the experiment and at 7:00 am on the day of the experiment. Volunteers in the control group fasted after dinner and drank only water until 7:00 am on the day of the experiment. In both groups, blood was collected at 9:00 am. The serum total oxidant levels and antioxidant capacity were assessed by d-ROMs (derivatives of reactive oxygen metabolites) test and BAP (biological antioxidant potential) test, respectively. In the ONS group, the serum d-ROMs level was significantly lower than in the control group (297 ± 43 and 327 ± 41 U.CARR, respectively, p = 0.018), while the serum BAP level was significantly higher than the control group (2410 ± 432 and 1979 ± 397 µmol/l, respectively, p = 0.005). The OXY level of Arginaid Water was much higher than preOp drink (Nutricia, Ireland). In conclusion, our study showed that an ONS with arginine loading could decrease oxidative stress and increase antioxidant capacity in healthy volunteers.
28421317	0	6	Effect	T080	C1280500
28421317	10	14	oral	T169	C1527415
28421317	15	27	carbohydrate	T121	C0556103
28421317	33	52	amino acid solution	UnknownType	C0308311
28421317	56	61	serum	T031	C0229671
28421317	62	93	oxidative/anti-oxidative status	T033	C2825141
28421317	97	115	healthy volunteers	T098	C1708335
28421317	144	155	investigate	T169	C1292732
28421317	160	166	effect	T080	C1280500
28421317	170	174	oral	T169	C1527415
28421317	175	187	carbohydrate	T121	C0556103
28421317	193	203	amino acid	UnknownType	C0308311
28421317	205	209	oral	T169	C1527415
28421317	210	232	nutritional supplement	T168	C0773323
28421317	234	237	ONS	T168	C0773323
28421317	240	248	solution	T167	C0037633
28421317	252	268	oxidative stress	T049	C0242606
28421317	272	287	healthy persons	T098	C0027361
28421317	298	316	healthy volunteers	T098	C1708335
28421317	338	345	control	T096	C0009932
28421317	350	353	ONS	T168	C0773323
28421317	354	360	groups	T078	C0441833
28421317	362	372	Volunteers	T098	C0020155
28421317	380	383	ONS	T168	C0773323
28421317	384	389	group	T078	C0441833
28421317	390	398	ingested	T038	C0232478
28421317	409	423	Arginaid Water	UnknownType	C2346224
28421317	425	431	Nestle	UnknownType	C0593737
28421317	432	437	Japan	T083	C0022341
28421317	439	444	Tokyo	T083	C0040371
28421317	446	451	Japan	T083	C0022341
28421317	460	467	evening	T079	C0587117
28421317	479	489	experiment	T062	C0681814
28421317	512	515	day	T079	C0439228
28421317	523	533	experiment	T062	C0681814
28421317	535	545	Volunteers	T098	C0020155
28421317	553	566	control group	T096	C0009932
28421317	567	573	fasted	T033	C0015663
28421317	580	586	dinner	T056	C4048877
28421317	602	607	water	T167	C0599638
28421317	629	632	day	T079	C0439228
28421317	640	650	experiment	T062	C0681814
28421317	660	666	groups	T078	C0441833
28421317	668	673	blood	T031	C0005767
28421317	678	687	collected	T169	C1516698
28421317	704	709	serum	T031	C0229671
28421317	710	715	total	T080	C0439810
28421317	716	723	oxidant	T120	C0085403
28421317	724	730	levels	T080	C0441889
28421317	735	755	antioxidant capacity	T034	C1254360
28421317	761	769	assessed	T052	C1516048
28421317	773	829	d-ROMs (derivatives of reactive oxygen metabolites) test	T059	C4048784
28421317	834	877	BAP (biological antioxidant potential) test	T059	C4049351
28421317	900	903	ONS	T168	C0773323
28421317	904	909	group	T078	C0441833
28421317	915	920	serum	T031	C0229671
28421317	921	933	d-ROMs level	T059	C4048784
28421317	952	957	lower	T080	C0205251
28421317	970	983	control group	T096	C0009932
28421317	1051	1056	serum	T031	C0229671
28421317	1057	1066	BAP level	T059	C4049351
28421317	1085	1091	higher	T080	C0205250
28421317	1101	1114	control group	T096	C0009932
28421317	1180	1189	OXY level	T034	C1254360
28421317	1193	1207	Arginaid Water	UnknownType	C2346224
28421317	1217	1223	higher	T080	C0205250
28421317	1229	1240	preOp drink	T168	C0452428
28421317	1242	1250	Nutricia	T168	C0016452
28421317	1252	1259	Ireland	T083	C0022067
28421317	1281	1286	study	T062	C2603343
28421317	1302	1305	ONS	T168	C0773323
28421317	1311	1319	arginine	T116,T121,T123	C0003765
28421317	1334	1342	decrease	T081	C0547047
28421317	1343	1359	oxidative stress	T049	C0242606
28421317	1364	1372	increase	T169	C0442805
28421317	1373	1393	antioxidant capacity	T034	C1254360
28421317	1397	1415	healthy volunteers	T098	C1708335

27707812|t|Spontaneous activity is correlated with coding density in primary auditory cortex
27707812|a|Sensory neurons across sensory modalities and specific processing areas have diverse levels of spontaneous firing rates (SFRs) in the absence of sensory stimuli. However, the functional significance of this spontaneous activity is not well-understood. Previous studies in the auditory system have demonstrated that different levels of spontaneous activity are correlated with a variety of physiological and anatomic properties, suggesting that neurons with differing SFRs make unique contributions to the encoding of auditory stimuli. Additionally, altered SFRs are a correlate of tinnitus, arising in several auditory areas after exposure to ototoxic substances and noise trauma. In this study, we recorded single-unit activity from primary auditory cortex of awake marmoset monkeys while delivering wide-band random-spectrum stimuli and white Gaussian noise (WGN) to examine any divergences in stimulus encoding properties across SFR classes. We found that higher levels of spontaneous activity were associated with both higher levels of activation relative to suppression across a variety of wide-band stimuli and higher driven rates in response to WGN. Moreover, response latencies to WGN were negatively correlated with the level of activation in response to both stimulus types. These findings are consistent with a novel view of the role spontaneous spiking may play during normal stimulus processing in primary auditory cortex and how it may malfunction in cases of tinnitus.
27707812	0	20	Spontaneous activity	T039	C0443158
27707812	24	34	correlated	T080	C1707520
27707812	40	46	coding	T052	C2700640
27707812	47	54	density	T081	C0178587
27707812	58	81	primary auditory cortex	T029	C2954070
27707812	82	97	Sensory neurons	T025	C0027883
27707812	105	123	sensory modalities	T067	C0234402
27707812	137	147	processing	T052	C1709694
27707812	177	201	spontaneous firing rates	T039	C1254359
27707812	203	207	SFRs	T039	C1254359
27707812	227	242	sensory stimuli	UnknownType	C0683107
27707812	257	267	functional	T169	C0205245
27707812	268	280	significance	T078	C0750502
27707812	289	309	spontaneous activity	T039	C0443158
27707812	343	350	studies	T062	C2603343
27707812	358	373	auditory system	T022	C0587901
27707812	417	437	spontaneous activity	T039	C0443158
27707812	442	452	correlated	T080	C1707520
27707812	471	484	physiological	T169	C0205463
27707812	489	497	anatomic	T080	C0220784
27707812	526	533	neurons	T025	C0027882
27707812	549	553	SFRs	T039	C1254359
27707812	587	595	encoding	T052	C2700640
27707812	599	615	auditory stimuli	T039	C0178490
27707812	639	643	SFRs	T039	C1254359
27707812	663	671	tinnitus	T033	C0040264
27707812	692	706	auditory areas	T023	C0004302
27707812	725	733	ototoxic	T037	C1407041
27707812	734	744	substances	T167	C0439861
27707812	749	754	noise	T067	C0028263
27707812	755	761	trauma	T037	C3714660
27707812	771	776	study	T062	C2603343
27707812	781	810	recorded single-unit activity	T059	C1537057
27707812	816	839	primary auditory cortex	T029	C2954070
27707812	849	857	marmoset	T015	C0006764
27707812	858	865	monkeys	T015	C0026447
27707812	883	916	wide-band random-spectrum stimuli	T067	C0234402
27707812	921	941	white Gaussian noise	T170	C3161035
27707812	943	946	WGN	T170	C3161035
27707812	963	974	divergences	T082	C0443204
27707812	978	986	stimulus	T067	C0234402
27707812	987	995	encoding	T052	C2700640
27707812	1058	1078	spontaneous activity	T039	C0443158
27707812	1122	1132	activation	T052	C1879547
27707812	1145	1156	suppression	T169	C1260953
27707812	1177	1194	wide-band stimuli	T067	C0234402
27707812	1222	1230	response	T032	C0871261
27707812	1234	1237	WGN	T170	C3161035
27707812	1249	1267	response latencies	T079	C0242465
27707812	1271	1274	WGN	T170	C3161035
27707812	1291	1301	correlated	T080	C1707520
27707812	1320	1330	activation	T052	C1879547
27707812	1334	1342	response	T032	C0871261
27707812	1351	1359	stimulus	T067	C0234402
27707812	1427	1446	spontaneous spiking	T039	C0443158
27707812	1470	1478	stimulus	T067	C0234402
27707812	1479	1489	processing	T052	C1709694
27707812	1493	1516	primary auditory cortex	T029	C2954070
27707812	1532	1543	malfunction	T169	C0231174
27707812	1556	1564	tinnitus	T033	C0040264

26316050|t|Prevascularized silicon membranes for the enhancement of transport to implanted medical devices
26316050|a|Recent advances in drug delivery and sensing devices for in situ applications are limited by the diffusion -limiting foreign body response of fibrous encapsulation. In this study, we fabricated prevascularized synthetic device ports to help mitigate this limitation. Membranes with rectilinear arrays of square pores with widths ranging from 40 to 200 μm were created using materials (50 μm thick double-sided polished silicon) and processes (photolithography and directed reactive ion etching) common in the manufacturing of microfabricated sensors. Vascular endothelial cells responded to membrane geometry by either forming vascular tubes that extended through the pore or completely filling membrane pores after 4 days in culture. Although tube formation began to predominate overgrowth around 75 μm and continued to increase at even larger pore sizes, tubes formed at these large pore sizes were not completely round and had relatively thin walls. Thus, the optimum range of pore size for prevascularization of these membranes was estimated to be 75-100 μm. This study lays the foundation for creating a prevascularized port that can be used to reduce fibrous encapsulation and thus enhance diffusion to implanted medical devices and sensors. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 104B: 1602-1609, 2016.
26316050	0	15	Prevascularized	T169	C0042382
26316050	16	23	silicon	T109,T122	C0037114
26316050	24	33	membranes	T073	C1706182
26316050	42	53	enhancement	T052	C2349975
26316050	57	66	transport	T169	C1705822
26316050	70	95	implanted medical devices	T033	C2828363
26316050	115	128	drug delivery	T074	C0085104
26316050	133	148	sensing devices	T073	C0183210
26316050	153	160	in situ	T082	C0444498
26316050	161	173	applications	T058	C0185125
26316050	178	185	limited	T169	C0439801
26316050	193	202	diffusion	T070	C0012222
26316050	213	234	foreign body response	T033	C1708386
26316050	238	245	fibrous	T080	C0439709
26316050	246	259	encapsulation	T067	C2348438
26316050	290	305	prevascularized	T169	C0042382
26316050	306	328	synthetic device ports	T073	C1706409
26316050	337	345	mitigate	T067	C1553901
26316050	351	361	limitation	T169	C0449295
26316050	363	372	Membranes	T073	C1706182
26316050	378	396	rectilinear arrays	T082	C1254362
26316050	400	406	square	T082	C0205120
26316050	407	412	pores	T082	C1254362
26316050	418	424	widths	T081	C0487742
26316050	470	479	materials	T167	C0520510
26316050	487	492	thick	T080	C1280412
26316050	493	505	double-sided	T082	C1254362
26316050	506	522	polished silicon	T109,T122	C0037114
26316050	528	537	processes	T067	C1522240
26316050	539	555	photolithography	T057	C0599199
26316050	560	589	directed reactive ion etching	T067	C1254366
26316050	605	618	manufacturing	T057	C0870840
26316050	622	645	microfabricated sensors	T073	C0183210
26316050	647	673	Vascular endothelial cells	T025	C1257792
26316050	687	704	membrane geometry	T073	C1706182
26316050	723	737	vascular tubes	T023	C0005847
26316050	743	751	extended	T082	C0231449
26316050	764	768	pore	T082	C1254362
26316050	772	782	completely	T080	C0205197
26316050	783	790	filling	T052	C0441655
26316050	783	790	filling	T052	C0441655
26316050	791	799	membrane	T073	C1706182
26316050	800	805	pores	T082	C1254362
26316050	822	829	culture	T059	C1331092
26316050	840	854	tube formation	T169	C0042382
26316050	864	875	predominate	T080	C0332251
26316050	876	886	overgrowth	T033	C1849265
26316050	917	925	increase	T169	C0442805
26316050	934	940	larger	T081	C0549177
26316050	941	951	pore sizes	T081	C3829176
26316050	953	965	tubes formed	T169	C0042382
26316050	975	980	large	T081	C0549177
26316050	981	991	pore sizes	T081	C3829176
26316050	1001	1011	completely	T080	C0205197
26316050	1012	1017	round	T082	C0332490
26316050	1037	1041	thin	T080	C0205168
26316050	1042	1047	walls	T082	C0442069
26316050	1059	1066	optimum	T080	C2698651
26316050	1067	1072	range	T081	C1514721
26316050	1076	1085	pore size	T081	C3829176
26316050	1090	1108	prevascularization	T169	C0042382
26316050	1118	1127	membranes	T073	C1706182
26316050	1132	1141	estimated	T081	C0750572
26316050	1164	1169	study	T062	C2603343
26316050	1205	1220	prevascularized	T169	C0042382
26316050	1221	1225	port	T073	C1706409
26316050	1253	1260	fibrous	T080	C0439709
26316050	1261	1274	encapsulation	T067	C2348438
26316050	1284	1291	enhance	T052	C2349975
26316050	1292	1301	diffusion	T070	C0012222
26316050	1305	1330	implanted medical devices	T033	C2828363
26316050	1335	1342	sensors	T073	C0183210

28192066|t|Performance of Debaryomyces hansenii as a Diet for Rotifers for Feeding Zebrafish Larvae
28192066|a|The zebrafish larval stage is a critical moment due to high mortality rates associated with inadequate supplies of nutritional requirements. Larval feeding has important challenges associated with such factors as small mouth gape (≈100 μm), the low activity of digestive enzymes, and the intake of live food. A common zebrafish live food at the onset of exogenous feeding is rotifers, mainly Brachionus plicatilis. These rotifers should be fed with other microorganisms such as microalgae or yeast, mostly from the Saccharomyces genus. In the laboratory, the culture of microalgae is more expensive than the culture of yeast. The aim of this study was to evaluate the performance of Debaryomyces hansenii as a diet for rotifers in comparison to a microalgae -based diet (Rotigrow(®)). To achieve this aim, we assessed the rotifer total protein content, the rotifers fatty acid profile, zebrafish larval growth performance, the expression of key growth, and endocrine appetite regulation genes. The total protein and fatty acids content were similar in both rotifer cultures, averaging 35% of dry matter (DM) and 18% of DM, respectively. Interestingly, the fatty acids profile showed differences between the two rotifer cultures: omega-3 fatty acids were only observed in the Microalgae / rotifer, whereas, omega-6 fatty acids presented similar levels in both rotifer cultures. No differences were observed in the larval body length distribution or mortalities between the rotifer cultures. However, gh, igf-1, and cck gene expression showed significantly higher upregulation in zebrafish fed the Microalgae / rotifer diet compared with those fed the Debaryomyces / rotifer diet. In conclusion, D. hansenii could be an alternative diet for rotifer used as a live food in zebrafish larvae at the onset of exogenous feeding. The gene responses observed in this work open up the opportunity to study the effect of omega-3 supply on growth regulation in zebrafish.
28192066	0	11	Performance	T052	C1882330
28192066	15	36	Debaryomyces hansenii	T004	C0446020
28192066	42	46	Diet	T168	C0012155
28192066	51	59	Rotifers	T204	C0035873
28192066	64	71	Feeding	T052	C2987508
28192066	72	81	Zebrafish	T013	C0043457
28192066	82	88	Larvae	T204	C0023047
28192066	93	102	zebrafish	T013	C0043457
28192066	103	109	larval	T204	C0023047
28192066	110	115	stage	T079	C1306673
28192066	149	164	mortality rates	T081	C0205848
28192066	165	180	associated with	T080	C0332281
28192066	181	191	inadequate	T080	C0205412
28192066	192	200	supplies	T081	C0016491
28192066	204	228	nutritional requirements	T032	C0028719
28192066	230	236	Larval	T204	C0023047
28192066	237	244	feeding	T052	C2987508
28192066	270	285	associated with	T080	C0332281
28192066	291	298	factors	T169	C1521761
28192066	302	307	small	T081	C0700321
28192066	308	313	mouth	T030	C0226896
28192066	314	318	gape	T082	C3887622
28192066	334	337	low	T080	C0205251
28192066	338	346	activity	T052	C0441655
28192066	350	367	digestive enzymes	T116,T121,T126	C0544420
28192066	377	383	intake	T169	C1512806
28192066	387	396	live food	T168	C0016452
28192066	407	416	zebrafish	T013	C0043457
28192066	417	426	live food	T168	C0016452
28192066	434	442	onset of	T080	C0332162
28192066	443	452	exogenous	T169	C0205228
28192066	453	460	feeding	T052	C2987508
28192066	464	472	rotifers	T204	C0035873
28192066	481	502	Brachionus plicatilis	T204	C1093043
28192066	510	518	rotifers	T204	C0035873
28192066	529	532	fed	T052	C2987508
28192066	544	558	microorganisms	T001	C0445623
28192066	567	577	microalgae	T204	C2936330
28192066	581	586	yeast	T004	C0043393
28192066	604	623	Saccharomyces genus	T004	C0036024
28192066	632	642	laboratory	T073,T093	C0022877
28192066	648	655	culture	T059	C0430400
28192066	659	669	microalgae	T204	C2936330
28192066	697	704	culture	T059	C0430400
28192066	708	713	yeast	T004	C0043393
28192066	731	736	study	T062	C2603343
28192066	744	752	evaluate	T033	C0243095
28192066	757	768	performance	T052	C1882330
28192066	772	793	Debaryomyces hansenii	T004	C0446020
28192066	799	803	diet	T168	C0012155
28192066	808	816	rotifers	T204	C0035873
28192066	836	846	microalgae	T204	C2936330
28192066	854	858	diet	T168	C0012155
28192066	860	871	Rotigrow(®)	T168	C0012155
28192066	898	906	assessed	T052	C1516048
28192066	911	918	rotifer	T204	C0035873
28192066	919	940	total protein content	T059	C0555903
28192066	946	954	rotifers	T204	C0035873
28192066	955	973	fatty acid profile	T059	C0202009
28192066	975	984	zebrafish	T013	C0043457
28192066	985	991	larval	T204	C0023047
28192066	992	998	growth	T040	C0018270
28192066	999	1010	performance	T052	C1882330
28192066	1016	1026	expression	T045	C0017262
28192066	1034	1040	growth	T040	C0018270
28192066	1046	1055	endocrine	T022	C0014136
28192066	1056	1075	appetite regulation	T040	C0003622
28192066	1076	1081	genes	T028	C0017337
28192066	1087	1100	total protein	T059	C0555903
28192066	1105	1124	fatty acids content	T059	C0202009
28192066	1146	1153	rotifer	T204	C0035873
28192066	1154	1162	cultures	T059	C0430400
28192066	1164	1173	averaging	T081	C1510992
28192066	1181	1191	dry matter	T167	C0439861
28192066	1193	1195	DM	T167	C0439861
28192066	1208	1210	DM	T167	C0439861
28192066	1245	1264	fatty acids profile	T059	C0202009
28192066	1272	1283	differences	T081	C1705241
28192066	1300	1307	rotifer	T204	C0035873
28192066	1308	1316	cultures	T059	C0430400
28192066	1318	1337	omega-3 fatty acids	T109,T121,T123	C0015689
28192066	1364	1374	Microalgae	T204	C2936330
28192066	1377	1384	rotifer	T204	C0035873
28192066	1395	1414	omega-6 fatty acids	T109,T123	C0133860
28192066	1433	1439	levels	T080	C0441889
28192066	1448	1455	rotifer	T204	C0035873
28192066	1456	1464	cultures	T059	C0430400
28192066	1466	1480	No differences	T033	C3842396
28192066	1502	1508	larval	T204	C0023047
28192066	1509	1520	body length	T032	C0005890
28192066	1521	1533	distribution	T169	C1704711
28192066	1537	1548	mortalities	T081	C0026565
28192066	1561	1568	rotifer	T204	C0035873
28192066	1569	1577	cultures	T059	C0430400
28192066	1588	1590	gh	T116,T121,T125	C0037663
28192066	1592	1597	igf-1	T116,T123	C0021665
28192066	1603	1606	cck	T028	C1413167
28192066	1607	1622	gene expression	T045	C0017262
28192066	1644	1650	higher	T080	C0205250
28192066	1651	1663	upregulation	T044	C0041904
28192066	1667	1676	zebrafish	T013	C0043457
28192066	1677	1680	fed	T052	C2987508
28192066	1685	1695	Microalgae	T204	C2936330
28192066	1698	1705	rotifer	T204	C0035873
28192066	1706	1710	diet	T168	C0012155
28192066	1731	1734	fed	T052	C2987508
28192066	1739	1751	Debaryomyces	T004	C0446020
28192066	1754	1761	rotifer	T204	C0035873
28192066	1762	1766	diet	T168	C0012155
28192066	1783	1794	D. hansenii	T004	C0446020
28192066	1807	1818	alternative	T077	C1523987
28192066	1819	1823	diet	T168	C0012155
28192066	1828	1835	rotifer	T204	C0035873
28192066	1846	1855	live food	T168	C0016452
28192066	1859	1868	zebrafish	T013	C0043457
28192066	1869	1875	larvae	T204	C0023047
28192066	1883	1891	onset of	T080	C0332162
28192066	1892	1901	exogenous	T169	C0205228
28192066	1902	1909	feeding	T052	C2987508
28192066	1964	1975	opportunity	T062	C0683937
28192066	1979	1984	study	T062	C2603343
28192066	1989	1998	effect of	T080	C1704420
28192066	1999	2006	omega-3	T109,T121,T123	C0015689
28192066	2007	2013	supply	T078	C0243163
28192066	2017	2034	growth regulation	T040	C1160191
28192066	2038	2047	zebrafish	T013	C0043457

27828852|t|Prognostic value of GLUT-1 expression in oral squamous cell carcinoma: A prisma-compliant meta-analysis
27828852|a|A variety of studies have evaluated the correlation between glucose transporter-1 (GLUT-1) expression and prognosis of oral squamous cell carcinoma (OSCC); however, the results were inconsistent and inconclusive. A meta-analysis was performed to assess the prognostic significance of GLUT-1 in OSCC. Electronic databases of PubMed, Embase, and Web of Science were searched for relevant studies. The last search was updated on July 2016. Odds ratio (OR) and 95% confidence interval (CI) were pooled to evaluate the relationship between GLUT-1 and clinical features and hazard ratio (HR) and 95% CI were combined to measure the effect of GLUT-1 on overall survival (OS). P value < 0.05 was considered as statistically significant. A total of 13 studies with 1301 subjects were included for meta-analysis. The pooled data showed that high GLUT-1 expression was associated with advanced tumor stages (n = 7, OR = 2.99, 95% CI: 2.01-4.46, P < 0.001), higher tumor grade (n = 5, OR = 3.34, 95% CI: 1.12-9.94, P = 0.031), tumor size (n = 5, OR = 3.36, 95% CI: 2.04-5.51, P < 0.001), lymph node metastasis (n = 5, OR = 3.15, 95% CI: 1.89-5.25, P < 0.001), tobacco use (n = 3, OR = 2.18, 95% CI: 1.18-4.01, P = 0.013), and distant metastasis (n = 2, OR = 3.06, 95% CI: 1.19-7.9, P = 0.02). Furthermore, increased GLUT-1 expression was also correlated with shorter OS (n = 8, HR = 1.88, 95% CI: 1.51-2.33, P < 0.001). No significant publication bias was detected in this meta-analysis. GLUT-1 overexpression was in connection with aggressive clinical features and worse OS in OSCC. However, further studies are still needed to verify whether GLUT-1 could serve as a prognostic biomarker for OSCC.
27828852	0	16	Prognostic value	T081	C0449821
27828852	20	26	GLUT-1	T116,T123	C0168458
27828852	27	37	expression	T045	C1171362
27828852	41	69	oral squamous cell carcinoma	T191	C0585362
27828852	73	103	prisma-compliant meta-analysis	T170	C0282574
27828852	117	124	studies	T062	C2603343
27828852	130	139	evaluated	T058	C0220825
27828852	144	155	correlation	T080	C1707520
27828852	164	185	glucose transporter-1	T116,T123	C0168458
27828852	187	193	GLUT-1	T116,T123	C0168458
27828852	195	205	expression	T045	C1171362
27828852	210	219	prognosis	T058	C0033325
27828852	223	251	oral squamous cell carcinoma	T191	C0585362
27828852	253	257	OSCC	T191	C0585362
27828852	273	280	results	T169	C1274040
27828852	286	298	inconsistent	T080	C0442809
27828852	303	315	inconclusive	T080	C1629507
27828852	319	332	meta-analysis	T062	C0920317
27828852	350	356	assess	T058	C0184514
27828852	361	371	prognostic	T170	C0220901
27828852	372	384	significance	T078	C0750502
27828852	388	394	GLUT-1	T116,T123	C0168458
27828852	398	402	OSCC	T191	C0585362
27828852	404	424	Electronic databases	T170	C3841595
27828852	428	434	PubMed	T170	C1138432
27828852	436	442	Embase	T170	C0282574
27828852	448	462	Web of Science	T170	C0282574
27828852	481	497	relevant studies	T062	C2603343
27828852	530	534	July	T080	C3829447
27828852	541	551	Odds ratio	T081	C0028873
27828852	553	555	OR	T081	C0028873
27828852	565	584	confidence interval	T081	C0009667
27828852	586	588	CI	T081	C0009667
27828852	605	613	evaluate	T058	C0220825
27828852	618	630	relationship	T078	C1705630
27828852	639	645	GLUT-1	T116,T123	C0168458
27828852	650	667	clinical features	T033	C3810252
27828852	672	684	hazard ratio	T081	C2985465
27828852	686	688	HR	T081	C2985465
27828852	698	700	CI	T081	C0009667
27828852	718	725	measure	T081	C0079809
27828852	730	736	effect	T080	C1280500
27828852	740	746	GLUT-1	T116,T123	C0168458
27828852	750	766	overall survival	T081	C4086681
27828852	768	770	OS	T081	C4086681
27828852	806	831	statistically significant	T081	C0237881
27828852	847	854	studies	T062	C2603343
27828852	865	873	subjects	T098	C0080105
27828852	892	905	meta-analysis	T062	C0920317
27828852	911	922	pooled data	T078	C1511726
27828852	940	946	GLUT-1	T116,T123	C0168458
27828852	947	957	expression	T045	C1171362
27828852	962	977	associated with	T080	C0332281
27828852	978	999	advanced tumor stages	T201	C1300072
27828852	1008	1010	OR	T081	C0028873
27828852	1023	1025	CI	T081	C0009667
27828852	1050	1068	higher tumor grade	T185	C0441800
27828852	1077	1079	OR	T081	C0028873
27828852	1092	1094	CI	T081	C0009667
27828852	1119	1129	tumor size	T082	C0475440
27828852	1138	1140	OR	T081	C0028873
27828852	1153	1155	CI	T081	C0009667
27828852	1180	1201	lymph node metastasis	T033	C0332397
27828852	1210	1212	OR	T081	C0028873
27828852	1225	1227	CI	T081	C0009667
27828852	1252	1263	tobacco use	T055	C0543414
27828852	1272	1274	OR	T081	C0028873
27828852	1287	1289	CI	T081	C0009667
27828852	1318	1336	distant metastasis	T201	C1302548
27828852	1345	1347	OR	T081	C0028873
27828852	1360	1362	CI	T081	C0009667
27828852	1398	1407	increased	T081	C0205217
27828852	1408	1414	GLUT-1	T116,T123	C0168458
27828852	1415	1425	expression	T045	C1171362
27828852	1435	1445	correlated	T080	C1707520
27828852	1451	1461	shorter OS	T081	C4086681
27828852	1470	1472	HR	T081	C2985465
27828852	1485	1487	CI	T081	C0009667
27828852	1515	1543	significant publication bias	T080	C0206086
27828852	1548	1556	detected	T033	C0442726
27828852	1565	1578	meta-analysis	T062	C0920317
27828852	1580	1586	GLUT-1	T116,T123	C0168458
27828852	1587	1601	overexpression	T045	C1514559
27828852	1625	1653	aggressive clinical features	T033	C3810252
27828852	1658	1666	worse OS	T081	C4086681
27828852	1670	1674	OSCC	T191	C0585362
27828852	1693	1700	studies	T062	C2603343
27828852	1736	1742	GLUT-1	T116,T123	C0168458
27828852	1760	1770	prognostic	T170	C0220901
27828852	1771	1780	biomarker	T201	C0005516
27828852	1785	1789	OSCC	T191	C0585362

28533814|t|Teenage Mothers Today: What We Know and How It Matters
28533814|a|Over the past two decades, births to U.S. teenagers have fallen and no longer follow overall fertility patterns. Yet the unique challenges faced by teenage mothers and their families justify continued research. Across disciplines, newer work has furthered our understanding of teenage motherhood today. In this article, I highlight four areas of progress: processes of selection into teenage motherhood, the broader consequences of teenage childbearing beyond the socioeconomic realm, heterogeneity of effects, and the application of life course principles. Emerging societal trends such as complex family structures, a stalled recovery from the recession for families of low socioeconomic status, and a rapidly evolving political environment for reproductive health care continue to challenge the lives of teenage mothers. Given that the consequences for teenagers of becoming mothers may change, continued research is needed. Shifts in policy to favor supporting teenage mothers and addressing the causes of both teenage pregnancy and social disadvantage may help improve the lives of these mothers and their families.
28533814	0	15	Teenage Mothers	T099	C0237404
28533814	16	21	Today	T109,T195	C0310367
28533814	73	80	decades	T081	C2981279
28533814	82	88	births	T040	C0005615
28533814	92	95	U.S	T083	C0041703
28533814	97	106	teenagers	T098	C1521910
28533814	112	118	fallen	T080	C0205386
28533814	133	139	follow	T169	C4281991
28533814	140	147	overall	T080	C1561607
28533814	148	157	fertility	T040	C0015895
28533814	158	166	patterns	T082	C0449774
28533814	176	182	unique	T080	C1710548
28533814	183	193	challenges	T058	C0805586
28533814	203	218	teenage mothers	T099	C0237404
28533814	229	237	families	T099	C0015576
28533814	256	264	research	T062	C0035168
28533814	273	284	disciplines	T058	C0237070
28533814	286	291	newer	T080	C0205314
28533814	292	296	work	T062	C0242481
28533814	332	339	teenage	T100	C0205653
28533814	340	350	motherhood	T032	C0337490
28533814	351	356	today	T109,T195	C0310367
28533814	366	373	article	T170	C0282420
28533814	401	409	progress	T169	C1280477
28533814	411	420	processes	T067	C1522240
28533814	424	433	selection	T052	C1707391
28533814	439	446	teenage	T100	C0205653
28533814	447	457	motherhood	T032	C0337490
28533814	471	486	consequences of	T169	C0686907
28533814	487	494	teenage	T079	C0001578
28533814	495	507	childbearing	T033	C1657137
28533814	519	532	socioeconomic	T077	C0748878
28533814	533	538	realm	T078	C3244047
28533814	540	553	heterogeneity	T080	C0019409
28533814	557	564	effects	T080	C1280500
28533814	574	585	application	T052	C1708476
28533814	589	600	life course	T079	C1510618
28533814	601	611	principles	T033	C1328746
28533814	622	637	societal trends	T078	C0237750
28533814	646	653	complex	T080	C0439855
28533814	654	671	family structures	T099	C0680034
28533814	675	682	stalled	T080	C0443239
28533814	683	691	recovery	T052	C0237820
28533814	701	710	recession	T190	C0333047
28533814	715	723	families	T099	C0015576
28533814	727	751	low socioeconomic status	T081	C1328812
28533814	759	766	rapidly	T080	C0456962
28533814	767	775	evolving	T169	C0332253
28533814	776	785	political	T090	C0032382
28533814	786	797	environment	T082	C0014406
28533814	802	826	reproductive health care	T058	C1136000
28533814	839	848	challenge	T058	C0805586
28533814	853	858	lives	T078	C0376558
28533814	862	877	teenage mothers	T099	C0237404
28533814	894	906	consequences	T169	C0686907
28533814	911	920	teenagers	T098	C1521910
28533814	933	940	mothers	T099	C0026591
28533814	945	951	change	T169	C0392747
28533814	963	971	research	T062	C0035168
28533814	983	989	Shifts	T169	C0333051
28533814	993	999	policy	T170	C0242456
28533814	1020	1035	teenage mothers	T099	C0237404
28533814	1055	1061	causes	T078	C0085978
28533814	1070	1087	teenage pregnancy	T033	C0032968
28533814	1092	1098	social	T169	C0728831
28533814	1121	1128	improve	T033	C0184511
28533814	1133	1138	lives	T078	C0376558
28533814	1148	1155	mothers	T099	C0026591
28533814	1166	1174	families	T099	C0015576

28278087|t|Laccase - immobilized dendritic nanofibrous membranes as a novel approach towards the removal of bisphenol A
28278087|a|Laccase enzymes from Rhus vernificera were covalently bound on hyperbranched polyethyleneimine / polyethersulfone (HPEI / PES) electrospun nanofibrous membranes and used for the removal of bisphenol A (BPA) from water. The laccase enzyme was anchored on the dendritic membranes through the abundant peripheral amine groups on the HPEI using glutaraldehyde as a crosslinker. The membranes were characterized with attenuated total reflectance-Fourier transform infrared spectroscopy, scanning electron microscopy coupled with energy-dispersive X-ray spectroscopy (SEM-EDS) and ultraviolet-visible spectroscopy and correlative light and electron microscopy (CLEM). Furthermore, contact-angle analyses, pure water flux measurements and rejection analyses were carried out. CLEM showed that the enzymes were uniformly dispersed on the nanofibres while SEM analysis revealed that the nanofibres had an average diameter of 354 ± 37 nm. EDS showed the presence of Cu, which is the active entity in laccase enzymes. The laccase -modified membranes were hydrophilic (50°-53° contact angle) and exhibited high BPA rejection of 89.6% as compared to the 52.4% demonstrated by pristine PES. The laccase -modified membranes also maintained a constant permeate flux (7.07 ± 5.54 L/m(2) h) throughout the filtration process. Recyclability studies indicated that the membranes still maintained a high BPA removal of up to 79% even after four filtration cycles.
28278087	0	7	Laccase	T116,T126	C0064566
28278087	10	21	immobilized	T116,T126,T130	C0014444
28278087	22	31	dendritic	T080	C0439640
28278087	32	53	nanofibrous membranes	T073	C1881960
28278087	59	73	novel approach	T082	C0449445
28278087	86	93	removal	T052	C1883720
28278087	97	108	bisphenol A	T109,T131	C0053800
28278087	109	124	Laccase enzymes	T116,T126	C0064566
28278087	130	146	Rhus vernificera	T002	C0330959
28278087	152	168	covalently bound	T044	C1511539
28278087	172	203	hyperbranched polyethyleneimine	T109,T130	C0032486
28278087	206	222	polyethersulfone	T109,T122	C0071556
28278087	224	228	HPEI	T109,T130	C0032486
28278087	231	234	PES	T109,T122	C0071556
28278087	236	247	electrospun	T170	C0025663
28278087	248	269	nanofibrous membranes	T073	C1881960
28278087	287	294	removal	T052	C1883720
28278087	298	309	bisphenol A	T109,T131	C0053800
28278087	311	314	BPA	T109,T131	C0053800
28278087	321	326	water	T121,T197	C0043047
28278087	332	346	laccase enzyme	T116,T126	C0064566
28278087	351	359	anchored	T061	C1293132
28278087	367	386	dendritic membranes	T073	C1706182
28278087	408	418	peripheral	T082	C0205100
28278087	419	431	amine groups	T109	C1879694
28278087	439	443	HPEI	T109,T130	C0032486
28278087	450	464	glutaraldehyde	T109,T122,T130	C0017814
28278087	470	481	crosslinker	T026	C1511546
28278087	487	496	membranes	T073	C1706182
28278087	521	531	attenuated	T052	C0599946
28278087	538	589	reflectance-Fourier transform infrared spectroscopy	T062	C0206055
28278087	591	619	scanning electron microscopy	T059	C0026020
28278087	620	632	coupled with	T169	C1948027
28278087	633	669	energy-dispersive X-ray spectroscopy	T059	C2699997
28278087	671	678	SEM-EDS	T059	C0022885
28278087	684	716	ultraviolet-visible spectroscopy	T059	C0260250
28278087	721	762	correlative light and electron microscopy	T059	C0026018
28278087	764	768	CLEM	T059	C0026018
28278087	784	806	contact-angle analyses	T062	C0936012
28278087	808	836	pure water flux measurements	T059	C0022885
28278087	841	859	rejection analyses	T062	C0936012
28278087	878	882	CLEM	T059	C0026018
28278087	899	906	enzymes	T116,T126	C0064566
28278087	912	931	uniformly dispersed	T082	C0332624
28278087	939	949	nanofibres	T073	C1881960
28278087	956	959	SEM	T059	C0026020
28278087	960	968	analysis	T062	C0936012
28278087	969	977	revealed	T080	C0443289
28278087	987	997	nanofibres	T073	C1881960
28278087	1005	1021	average diameter	T081	C1301886
28278087	1038	1041	EDS	T059	C2699997
28278087	1065	1067	Cu	T121,T123,T196	C0009968
28278087	1082	1095	active entity	T039	C0005529
28278087	1099	1114	laccase enzymes	T116,T126	C0064566
28278087	1120	1127	laccase	T116,T126	C0064566
28278087	1138	1147	membranes	T073	C1706182
28278087	1153	1164	hydrophilic	T080	C0475370
28278087	1203	1207	high	T080	C0205250
28278087	1208	1211	BPA	T109,T131	C0053800
28278087	1212	1221	rejection	T080	C1548437
28278087	1234	1242	compared	T052	C1707455
28278087	1272	1284	pristine PES	T109	C0029224
28278087	1290	1297	laccase	T116,T126	C0064566
28278087	1308	1317	membranes	T073	C1706182
28278087	1323	1333	maintained	T052	C0024501
28278087	1336	1358	constant permeate flux	T059	C0022885
28278087	1397	1415	filtration process	T068	C0016107
28278087	1417	1438	Recyclability studies	T062	C2603343
28278087	1458	1467	membranes	T073	C1706182
28278087	1474	1484	maintained	T052	C0024501
28278087	1487	1491	high	T080	C0205250
28278087	1492	1495	BPA	T109,T131	C0053800
28278087	1496	1503	removal	T052	C1883720
28278087	1533	1550	filtration cycles	T079	C1511572

28518216|t|Queen presence mediates the relationship between collective behavior and disease susceptibility in ant colonies
28518216|a|The success of social living can be explained, in part, by a group's ability to execute collective behaviors unachievable by solitary individuals. However, groups vary in their ability to execute these complex behaviors, often because they vary in their phenotypic composition. Group membership changes over time due to mortality or emigration, potentially leaving groups vulnerable to ecological challenges in times of flux. In some societies, the loss of important individuals (e.g., leaders, elites, queens) may have an especially detrimental effect on groups' ability to deal with these challenges. Here, we test whether the removal of queens in colonies of the acorn ant Temnothorax curvispinosus alters their ability to execute important collective behaviors and survive outbreaks of a generalist entomopathogen. We employed a split-colony design where one half of a colony was maintained with its queen, while the other half was separated from the queen. We then tested these subcolonies' performance in a series of collective behavior assays and finally exposed colonies to the entomopathogenic fungus Metarhizium robertsii by exposing two individuals from the colony and then sealing them back into the nest. We found that queenright subcolonies outperformed their queenless counterparts in nearly all collective behaviors. Queenless subcolonies were also more vulnerable to mortality from disease. However, queenless groups that displayed more interactions with brood experienced greater survivorship, a trend not present in queenright subcolonies. Queenless subcolonies that engage in more brood interactions may have had more resources available to cope with two physiological challenges (ovarian development after queen loss and immune activation after pathogen exposure). Our results indicate that queen presence can play an integral role in colony behavior, survivorship, and their relationship. They also suggest that interactions between workers and brood are integral to colonies survival. Overall, a social group's history of social reorganization may have strong consequences on their collective behaviors and their vulnerability to disease outbreaks. This article is protected by copyright. All rights reserved.
28518216	0	5	Queen	T097	C0027363
28518216	6	14	presence	T033	C0150312
28518216	15	23	mediates	T054	C0086597
28518216	28	40	relationship	T080	C0439849
28518216	49	68	collective behavior	T054	C0680406
28518216	73	95	disease susceptibility	T201	C0012655
28518216	99	102	ant	T204	C0003455
28518216	103	111	colonies	T025	C1947989
28518216	116	123	success	T054	C0597535
28518216	127	133	social	T169	C0728831
28518216	134	140	living	T078	C0376558
28518216	173	180	group's	T098	C1257890
28518216	181	188	ability	T032	C0085732
28518216	192	199	execute	T052	C1705848
28518216	200	220	collective behaviors	T054	C0680406
28518216	221	233	unachievable	T080	C0205556
28518216	237	245	solitary	T081	C0205171
28518216	246	257	individuals	T098	C0237401
28518216	268	274	groups	T098	C1257890
28518216	289	296	ability	T032	C0085732
28518216	300	307	execute	T052	C1705848
28518216	314	331	complex behaviors	T053	C1285661
28518216	366	376	phenotypic	T032	C0031437
28518216	366	388	phenotypic composition	T201	C0486616
28518216	390	395	Group	T098	C1257890
28518216	396	406	membership	T055	C0680038
28518216	407	414	changes	T169	C0392747
28518216	420	424	time	T079	C0040223
28518216	432	441	mortality	T081	C0205848
28518216	445	455	emigration	T052	C0013975
28518216	469	483	leaving groups	T098	C1257890
28518216	484	494	vulnerable	T169	C0231204
28518216	498	519	ecological challenges	T077	C0870460
28518216	523	536	times of flux	T070	C2348693
28518216	546	555	societies	T092	C0037455
28518216	561	565	loss	T081	C1517945
28518216	579	590	individuals	T098	C0237401
28518216	598	605	leaders	T097	C0027363
28518216	607	613	elites	T098	C0237401
28518216	615	621	queens	T097	C0027363
28518216	646	664	detrimental effect	T080	C1280500
28518216	668	675	groups'	T098	C1257890
28518216	676	683	ability	T032	C0085732
28518216	703	713	challenges	T080	C0205556
28518216	724	728	test	T169	C0039593
28518216	741	748	removal	T052	C1883720
28518216	752	758	queens	T097	C0027363
28518216	762	770	colonies	T025	C1947989
28518216	778	787	acorn ant	T204	C0003455
28518216	788	813	Temnothorax curvispinosus	T204	C1687415
28518216	827	834	ability	T032	C0085732
28518216	838	845	execute	T052	C1705848
28518216	856	876	collective behaviors	T054	C0680406
28518216	881	888	survive	T081	C0038954
28518216	889	898	outbreaks	T169	C0220888
28518216	904	929	generalist entomopathogen	T001	C0450254
28518216	945	964	split-colony design	T062	C0242481
28518216	975	979	half	T081	C2825407
28518216	985	991	colony	T025	C1947989
28518216	996	1006	maintained	T169	C1314677
28518216	1016	1021	queen	T097	C0027363
28518216	1039	1043	half	T081	C2825407
28518216	1048	1057	separated	T169	C0687118
28518216	1067	1072	queen	T097	C0027363
28518216	1095	1107	subcolonies'	T025	C1947989
28518216	1108	1119	performance	T052	C1882330
28518216	1135	1154	collective behavior	T054	C0680406
28518216	1155	1161	assays	T080	C0243073
28518216	1174	1181	exposed	T080	C0332157
28518216	1182	1190	colonies	T025	C1947989
28518216	1198	1221	entomopathogenic fungus	T004	C3826297
28518216	1222	1243	Metarhizium robertsii	T004	C2766746
28518216	1247	1255	exposing	T080	C0332157
28518216	1260	1271	individuals	T098	C0237401
28518216	1281	1287	colony	T025	C1947989
28518216	1297	1304	sealing	T169	C0349677
28518216	1324	1328	nest	T082	C1254362
28518216	1344	1366	queenright subcolonies	T025	C1947989
28518216	1423	1443	collective behaviors	T054	C0680406
28518216	1445	1466	Queenless subcolonies	T025	C1947989
28518216	1482	1492	vulnerable	T169	C0231204
28518216	1496	1505	mortality	T081	C0205848
28518216	1511	1518	disease	T047	C0012634
28518216	1529	1545	queenless groups	T098	C1257890
28518216	1551	1560	displayed	T169	C0870432
28518216	1566	1578	interactions	T169	C1704675
28518216	1584	1589	brood	T098	C1257890
28518216	1610	1622	survivorship	T079	C0038955
28518216	1647	1669	queenright subcolonies	T025	C1947989
28518216	1671	1692	Queenless subcolonies	T025	C1947989
28518216	1713	1718	brood	T098	C1257890
28518216	1719	1731	interactions	T169	C1704675
28518216	1773	1777	cope	T055	C0009967
28518216	1787	1811	physiological challenges	T039	C0442687
28518216	1813	1832	ovarian development	T042	C1160265
28518216	1839	1844	queen	T097	C0027363
28518216	1845	1849	loss	T081	C1517945
28518216	1854	1871	immune activation	T043	C1155000
28518216	1878	1895	pathogen exposure	T033	C4060607
28518216	1902	1909	results	T169	C1274040
28518216	1924	1929	queen	T097	C0027363
28518216	1930	1938	presence	T033	C0150312
28518216	1968	1974	colony	T025	C1947989
28518216	1975	1983	behavior	T053	C0004927
28518216	1985	1997	survivorship	T079	C0038955
28518216	2009	2021	relationship	T080	C0439849
28518216	2033	2040	suggest	T078	C1705535
28518216	2046	2058	interactions	T169	C1704675
28518216	2067	2074	workers	T098	C1527116
28518216	2079	2084	brood	T098	C1257890
28518216	2101	2109	colonies	T025	C1947989
28518216	2110	2118	survival	T081	C0038954
28518216	2131	2145	social group's	T098	C0687744
28518216	2157	2178	social reorganization	T078	C0680829
28518216	2188	2207	strong consequences	T169	C0686907
28518216	2217	2237	collective behaviors	T054	C0680406
28518216	2248	2261	vulnerability	T033	C1821973
28518216	2265	2272	disease	T047	C0012634
28518216	2273	2282	outbreaks	T169	C0220888

27729000|t|Gas assisted method synthesis nitrogen-doped carbon quantum dots and Hg (II) sensing
27729000|a|Nitrogen-doped fluorescent carbon quantum dots (CQDs) was prepared by gas-assisted method using cellulose as precursors under ammonia atmosphere, which not only exhibited excellent photoluminescent properties, but also showed highly selective and sensitive detection of mercury ion. The nitrogen-doped CQDs displayed excitation wavelength dependent fluorescent behavior with outstanding dispersibility. Moreover, they exhibited high tolerance to various external conditions, such as storage time, pH value, and ionic strength. The rapid detection of Hg (II) by one-step operation within 1 min and the good linear correlation between I0/I and Hg (II) concentration in the range of 10-100 nM made the nitrogen-doped CQDs a promising nanoprobe for Hg (II) detection. The detection limit of the nitrogen-doped CQDs is about 7.7 nM. Such a nanoprobe has been successfully applied for the analysis of Hg (II) in natural water samples, demonstrating excellent practical feasibility.
27729000	0	19	Gas assisted method	T059	C0201683
27729000	20	29	synthesis	T052	C1883254
27729000	30	44	nitrogen-doped	T123,T196	C0028158
27729000	45	51	carbon	T196	C0007009
27729000	52	64	quantum dots	T073	C1258084
27729000	69	76	Hg (II)	T196	C2347109
27729000	85	99	Nitrogen-doped	T123,T196	C0028158
27729000	100	111	fluorescent	T070	C0016315
27729000	112	118	carbon	T196	C0007009
27729000	119	131	quantum dots	T073	C1258084
27729000	133	137	CQDs	T073	C1258084
27729000	155	174	gas-assisted method	T059	C0201683
27729000	181	190	cellulose	T109,T123	C0007648
27729000	194	204	precursors	T078	C1709634
27729000	211	218	ammonia	T121,T197	C0002607
27729000	266	293	photoluminescent properties	T070	C0596835
27729000	332	341	sensitive	T169	C0332324
27729000	355	366	mercury ion	T131,T196	C0025424
27729000	372	386	nitrogen-doped	T123,T196	C0028158
27729000	387	391	CQDs	T073	C1258084
27729000	413	423	wavelength	T081	C0449819
27729000	434	454	fluorescent behavior	T070	C0016315
27729000	518	527	tolerance	T080	C1704410
27729000	568	575	storage	T169	C1698986
27729000	576	580	time	T079	C0040223
27729000	582	590	pH value	T081	C0020283
27729000	596	610	ionic strength	T081	C0086486
27729000	616	621	rapid	T080	C0456962
27729000	635	642	Hg (II)	T196	C2347109
27729000	691	709	linear correlation	T080	C1707520
27729000	727	734	Hg (II)	T196	C2347109
27729000	784	798	nitrogen-doped	T123,T196	C0028158
27729000	799	803	CQDs	T073	C1258084
27729000	816	825	nanoprobe	T073	C1881978
27729000	830	837	Hg (II)	T196	C2347109
27729000	876	890	nitrogen-doped	T123,T196	C0028158
27729000	891	895	CQDs	T073	C1258084
27729000	920	929	nanoprobe	T073	C1881978
27729000	968	976	analysis	T062	C0936012
27729000	980	987	Hg (II)	T196	C2347109
27729000	991	1012	natural water samples	T167	C0729789
27729000	1028	1059	excellent practical feasibility	T062,T170	C0015730

28414203|t|Self - assembled nanocomplex between polymerized phenylboronic acid and doxorubicin for efficient tumor - targeted chemotherapy
28414203|a|Since the discovery that nano-scaled particulates can easily be incorporated into tumors via the enhanced permeability and retention (EPR) effect, such nanostructures have been exploited as therapeutic small molecule delivery systems. However, the convoluted synthetic process of conventional nanostructures has impeded their feasibility and reproducibility in clinical applications. Herein, we report an easily prepared formulation of self - assembled nanostructures for systemic delivery of the anti-cancer drug doxorubicin (DOX). Phenylboronic acid (PBA) was grafted onto the polymeric backbone of poly(maleic anhydride). pPBA-DOX nanocomplexes were prepared by simple mixing, on the basis of the strong interaction between the 1,3-diol of DOX and the PBA moiety on pPBA. Three nanocomplexes (1, 2, 4) were designed on the basis of [PBA]:[DOX] molar ratios of 1:1, 2:1, and 4:1, respectively, to investigate the function of the residual PBA moiety as a targeting ligand. An acid-labile drug release profile was observed, owing to the intrinsic properties of the phenylboronic ester. Moreover, the tumor - targeting ability of the nanocomplexes was demonstrated, both in vitro by confocal microscopy and in vivo by fluorescence imaging, to be driven by an inherent property of the residual PBA. Ligand competition assays with free PBA pre-treatment demonstrated the targeting effect of the residual PBA from the nanocomplexes 2 and 4. Finally, the nanocomplexes 2 and 4, compared with the free DOX, exhibited significantly greater anti-cancer effects in vitro and even in vivo. Our pPBA-DOX nanocomplex enables a new paradigm for self - assembled nanostructures with potential biomedical applications.
28414203	0	4	Self	T078	C0036588
28414203	7	16	assembled	T052	C1706853
28414203	17	28	nanocomplex	T121	C1254351
28414203	37	48	polymerized	T067	C0314672
28414203	49	67	phenylboronic acid	T109,T130	C0053163
28414203	72	83	doxorubicin	T109,T195	C0013089
28414203	88	97	efficient	T080	C0442799
28414203	98	103	tumor	T191	C0027651
28414203	106	114	targeted	T169	C1521840
28414203	115	127	chemotherapy	T061	C3665472
28414203	138	147	discovery	T052	C1880355
28414203	153	177	nano-scaled particulates	T073	C1450053
28414203	210	216	tumors	T191	C0027651
28414203	225	273	enhanced permeability and retention (EPR) effect	T080	C1280500
28414203	280	294	nanostructures	T073	C1450053
28414203	318	329	therapeutic	T169	C0302350
28414203	345	361	delivery systems	T074	C0085104
28414203	376	386	convoluted	T080	C0205401
28414203	387	404	synthetic process	T052	C1883254
28414203	408	420	conventional	T080	C0439858
28414203	421	435	nanostructures	T073	C1450053
28414203	454	465	feasibility	T062,T170	C0015730
28414203	470	485	reproducibility	T080	C1514863
28414203	489	510	clinical applications	T058	C1880106
28414203	523	529	report	T058	C0700287
28414203	549	560	formulation	T062	C0524527
28414203	564	568	self	T078	C0036588
28414203	571	580	assembled	T052	C1706853
28414203	581	595	nanostructures	T073	C1450053
28414203	600	617	systemic delivery	T074	C0085104
28414203	625	641	anti-cancer drug	T109,T121	C0003392
28414203	642	653	doxorubicin	T109,T195	C0013089
28414203	655	658	DOX	T109,T195	C0013089
28414203	661	679	Phenylboronic acid	T109,T130	C0053163
28414203	681	684	PBA	T109,T130	C0053163
28414203	690	697	grafted	T080	C1527362
28414203	707	725	polymeric backbone	T104,T122	C0032521
28414203	729	751	poly(maleic anhydride)	T121	C1254351
28414203	753	775	pPBA-DOX nanocomplexes	T121	C1254351
28414203	793	799	simple	T080	C0205352
28414203	800	806	mixing	T169	C0205430
28414203	828	834	strong	T080	C0442821
28414203	835	846	interaction	T169	C1704675
28414203	871	874	DOX	T109,T195	C0013089
28414203	883	893	PBA moiety	T109,T130	C0053163
28414203	897	901	pPBA	T104,T122	C0032521
28414203	909	922	nanocomplexes	T121	C1254351
28414203	964	967	PBA	T109,T130	C0053163
28414203	970	973	DOX	T109,T195	C0013089
28414203	975	987	molar ratios	T081	C2825550
28414203	1027	1038	investigate	T169	C1292732
28414203	1043	1051	function	T169	C0542341
28414203	1059	1067	residual	T080	C1609982
28414203	1068	1078	PBA moiety	T109,T130	C0053163
28414203	1084	1093	targeting	T169	C1521840
28414203	1094	1100	ligand	T121	C1254351
28414203	1117	1129	drug release	T070	C3850077
28414203	1142	1150	observed	T169	C1441672
28414203	1165	1185	intrinsic properties	T169	C0439674
28414203	1193	1212	phenylboronic ester	T121	C1254351
28414203	1228	1233	tumor	T191	C0027651
28414203	1236	1245	targeting	T169	C1521840
28414203	1261	1274	nanocomplexes	T121	C1254351
28414203	1298	1306	in vitro	T080	C1533691
28414203	1310	1329	confocal microscopy	T059	C0242842
28414203	1334	1341	in vivo	T082	C1515655
28414203	1345	1365	fluorescence imaging	T060	C0430876
28414203	1386	1403	inherent property	T067	C1562679
28414203	1411	1419	residual	T080	C1609982
28414203	1420	1423	PBA	T109,T130	C0053163
28414203	1425	1450	Ligand competition assays	T059	C0005507
28414203	1461	1464	PBA	T109,T130	C0053163
28414203	1465	1478	pre-treatment	T079	C2709094
28414203	1496	1505	targeting	T169	C1521840
28414203	1506	1512	effect	T080	C1280500
28414203	1520	1528	residual	T080	C1609982
28414203	1529	1532	PBA	T109,T130	C0053163
28414203	1542	1555	nanocomplexes	T121	C1254351
28414203	1578	1591	nanocomplexes	T121	C1254351
28414203	1601	1609	compared	T052	C1707455
28414203	1619	1627	free DOX	T109,T195	C0013089
28414203	1653	1660	greater	T081	C1704243
28414203	1661	1672	anti-cancer	T109,T121	C0003392
28414203	1673	1680	effects	T080	C1280500
28414203	1681	1689	in vitro	T080	C1533691
28414203	1699	1706	in vivo	T082	C1515655
28414203	1712	1732	pPBA-DOX nanocomplex	T121	C1254351
28414203	1747	1755	paradigm	T062	C0681797
28414203	1760	1764	self	T078	C0036588
28414203	1767	1776	assembled	T052	C1706853
28414203	1777	1791	nanostructures	T073	C1450053
28414203	1797	1806	potential	T080	C3245505
28414203	1807	1830	biomedical applications	T058	C0752188

27871172|t|LIN-23, an E3 Ubiquitin Ligase Component, Is Required for the Repression of CDC-25.2 Activity during Intestinal Development in Caenorhabditis elegans
27871172|a|Caenorhabditis elegans (C. elegans) utilizes two different cell-cycle modes, binucleations during the L1 larval stage and endoreduplications at four larval moltings, for its postembryonic intestinal development. Previous genetic studies indicated that CDC-25.2 is specifically required for binucleations at the L1 larval stage and is repressed before endoreduplications. Furthermore, LIN-23, the C. elegans β-TrCP ortholog, appears to function as a repressor of CDC-25.2 to prevent excess intestinal divisions. We previously reported that intestinal hyperplasia in lin-23 (e1883) mutants was effectively suppressed by the RNAi depletion of cdc-25.2. Nevertheless, LIN-23 targeting CDC-25.2 for ubiquitination as a component of E3 ubiquitin ligase has not yet been tested. In this study, LIN-23 is shown to be the major E3 ubiquitin ligase component, recognizing CDC-25.2 to repress their activities for proper transition of cell-cycle modes during the C. elegans postembryonic intestinal development. In addition, for the first time that LIN-23 physically interacts with both CDC-25.1 and CDC-25.2 and facilitates ubiquitination for timely regulation of their activities during the intestinal development.
27871172	0	6	LIN-23	T116,T123	C1257560
27871172	11	40	E3 Ubiquitin Ligase Component	T116,T126	C0077678
27871172	62	72	Repression	T045	C0014438
27871172	76	84	CDC-25.2	T116,T126	C0246769
27871172	85	93	Activity	T044	C0243102
27871172	101	123	Intestinal Development	T042	C1656559
27871172	127	149	Caenorhabditis elegans	T204	C0162610
27871172	150	172	Caenorhabditis elegans	T204	C0162610
27871172	174	184	C. elegans	T204	C0162610
27871172	209	225	cell-cycle modes	T043	C0007586
27871172	227	240	binucleations	T043	C0007613
27871172	252	267	L1 larval stage	T043	C0007591
27871172	272	290	endoreduplications	T049	C0333688
27871172	299	314	larval moltings	T040	C1818619
27871172	324	360	postembryonic intestinal development	T040	C1657226
27871172	371	386	genetic studies	T062	C2827447
27871172	402	410	CDC-25.2	T116,T126	C0246769
27871172	440	453	binucleations	T043	C0007613
27871172	461	476	L1 larval stage	T043	C0007591
27871172	484	493	repressed	T045	C0014438
27871172	501	519	endoreduplications	T049	C0333688
27871172	534	540	LIN-23	T116,T123	C1257560
27871172	546	556	C. elegans	T204	C0162610
27871172	557	563	β-TrCP	T116,T123	C0218349
27871172	564	572	ortholog	T080	C1709346
27871172	599	608	repressor	T116,T123	C0035147
27871172	612	620	CDC-25.2	T116,T126	C0246769
27871172	639	649	intestinal	T023	C0021853
27871172	650	659	divisions	T043	C0007590
27871172	689	699	intestinal	T023	C0021853
27871172	700	711	hyperplasia	T046	C0020507
27871172	715	721	lin-23	T116,T123	C1257560
27871172	723	728	e1883	T116	C1564139
27871172	730	737	mutants	T116	C1564139
27871172	754	764	suppressed	T169	C1260953
27871172	772	776	RNAi	T045	C1136031
27871172	777	786	depletion	T045	C3548265
27871172	790	798	cdc-25.2	T116,T126	C0246769
27871172	814	820	LIN-23	T116,T123	C1257560
27871172	831	839	CDC-25.2	T116,T126	C0246769
27871172	844	858	ubiquitination	T044	C1519751
27871172	864	873	component	T116,T126	C0014442
27871172	877	896	E3 ubiquitin ligase	T116,T126	C0077678
27871172	937	943	LIN-23	T116,T123	C1257560
27871172	969	998	E3 ubiquitin ligase component	T116,T126	C0077678
27871172	1012	1020	CDC-25.2	T116,T126	C0246769
27871172	1024	1031	repress	T045	C0014438
27871172	1060	1070	transition	T043	C3544383
27871172	1074	1090	cell-cycle modes	T043	C0007586
27871172	1102	1112	C. elegans	T204	C0162610
27871172	1113	1149	postembryonic intestinal development	T040	C1657226
27871172	1188	1194	LIN-23	T116,T123	C1257560
27871172	1226	1234	CDC-25.1	T116,T126	C0246769
27871172	1239	1247	CDC-25.2	T116,T126	C0246769
27871172	1264	1278	ubiquitination	T044	C1519751
27871172	1290	1300	regulation	T038	C1327622
27871172	1332	1354	intestinal development	T042	C1656559

27716325|t|A scoping review of Australian allied health research in ehealth
27716325|a|Uptake of e-health, the use of information communication technologies (ICT) for health service delivery, in allied health appears to be lagging behind other health care areas, despite offering the potential to address problems with service access by rural and remote Australians. The aim of the study was to conduct a scoping review of studies into the application of or attitudes towards ehealth amongst allied health professionals conducted in Australia. Studies meeting inclusion criteria published from January 2004 to June 2015 were reviewed. Professions included were audiology, dietetics, exercise physiology, occupational therapy, physiotherapy, podiatry, social work, and speech pathology. Terms for these professions and forms of ehealth were combined in databases of CINAHL (EBSCO), Cochrane Library, PsycINFO (1806 - Ovid), MEDLINE (Ovid) and AMED (Ovid). Forty-four studies meeting inclusion criteria were summarised. They were either trials of aspects of ehealth service delivery, or clinician and/or client use of and attitudes towards ehealth. Trials of ehealth were largely from two research groups located at the Universities of Sydney and Queensland; most involved speech pathology and physiotherapy. Assessments through ehealth and intervention outcomes through ehealth were comparable with face-to-face delivery. Clinicians used ICT mostly for managing their work and for professional development, but were reticent about its use in service delivery, which contrasted with the more positive attitudes and experiences of clients. The potential of ehealth to address allied health needs of Australians living in rural and remote Australia appears unrealised. Clinicians may need to embrace ehealth as a means to radicalise practice, rather than replicate existing practices through a different mode of delivery.
27716325	10	16	review	T080	C1709940
27716325	20	30	Australian	T098	C0238711
27716325	31	44	allied health	T078	C0018684
27716325	45	53	research	T062	C0035168
27716325	57	64	ehealth	T058	C1328956
27716325	75	83	e-health	T058	C1328956
27716325	96	134	information communication technologies	T170	C0683867
27716325	136	139	ICT	T170	C0683867
27716325	145	159	health service	T058	C0018747
27716325	160	168	delivery	T169	C1705822
27716325	173	186	allied health	T078	C0018684
27716325	222	233	health care	T058	C0086388
27716325	283	291	problems	T033	C0033213
27716325	297	304	service	T058	C0018747
27716325	315	320	rural	T033	C0240919
27716325	325	331	remote	T082	C0205157
27716325	332	343	Australians	T098	C0238711
27716325	360	365	study	T062	C2603343
27716325	401	408	studies	T062	C2603343
27716325	418	429	application	T169	C4048755
27716325	436	445	attitudes	T041	C0004271
27716325	454	461	ehealth	T058	C1328956
27716325	470	497	allied health professionals	T097	C0002122
27716325	511	520	Australia	T083	C0004340
27716325	522	529	Studies	T062	C2603343
27716325	538	556	inclusion criteria	T080	C1512693
27716325	603	611	reviewed	T080	C1709940
27716325	613	624	Professions	T090	C0028811
27716325	639	648	audiology	T091	C0004285
27716325	650	659	dietetics	T091	C0012180
27716325	661	680	exercise physiology	T091	C1516990
27716325	682	702	occupational therapy	T058	C1318464
27716325	704	717	physiotherapy	T061	C0949766
27716325	719	727	podiatry	T091	C0032331
27716325	729	740	social work	T090	C0037441
27716325	746	762	speech pathology	T091	C0080355
27716325	780	791	professions	T090	C0028811
27716325	805	812	ehealth	T058	C1328956
27716325	830	839	databases	T170	C0242356
27716325	843	849	CINAHL	T170	C0242356
27716325	859	875	Cochrane Library	T170	C0242356
27716325	877	885	PsycINFO	T170	C1140129
27716325	901	908	MEDLINE	T170	C0025141
27716325	920	924	AMED	T170	C0242356
27716325	944	951	studies	T062	C2603343
27716325	960	978	inclusion criteria	T080	C1512693
27716325	1013	1019	trials	T062	C0681815
27716325	1034	1041	ehealth	T058	C1328956
27716325	1042	1049	service	T058	C0018747
27716325	1050	1058	delivery	T169	C1705822
27716325	1063	1072	clinician	T097	C0871685
27716325	1080	1086	client	T096	C0008942
27716325	1098	1107	attitudes	T041	C0004271
27716325	1116	1123	ehealth	T058	C1328956
27716325	1125	1131	Trials	T062	C0681815
27716325	1135	1142	ehealth	T058	C1328956
27716325	1165	1173	research	T062	C0035168
27716325	1196	1208	Universities	T073,T092	C0041740
27716325	1212	1218	Sydney	T083	C0017446
27716325	1223	1233	Queensland	T083	C0034391
27716325	1249	1265	speech pathology	T091	C0080355
27716325	1270	1283	physiotherapy	T061	C0949766
27716325	1285	1296	Assessments	T058	C0220825
27716325	1305	1312	ehealth	T058	C1328956
27716325	1317	1329	intervention	T061	C0184661
27716325	1330	1338	outcomes	T169	C1274040
27716325	1347	1354	ehealth	T058	C1328956
27716325	1389	1397	delivery	T169	C1705822
27716325	1399	1409	Clinicians	T097	C0871685
27716325	1415	1418	ICT	T170	C0683867
27716325	1445	1449	work	T057	C0043227
27716325	1458	1482	professional development	T057	C0871147
27716325	1519	1526	service	T058	C0018747
27716325	1527	1535	delivery	T169	C1705822
27716325	1577	1586	attitudes	T041	C0004271
27716325	1591	1602	experiences	T041	C0596545
27716325	1606	1613	clients	T096	C0008942
27716325	1632	1639	ehealth	T058	C1328956
27716325	1651	1664	allied health	T078	C0018684
27716325	1674	1685	Australians	T098	C0238711
27716325	1696	1701	rural	T033	C0240919
27716325	1706	1712	remote	T082	C0205157
27716325	1713	1722	Australia	T083	C0004340
27716325	1743	1753	Clinicians	T097	C0871685
27716325	1774	1781	ehealth	T058	C1328956
27716325	1807	1815	practice	T057	C0033284
27716325	1848	1857	practices	T057	C0033284
27716325	1886	1894	delivery	T169	C1705822

28343001|t|Comprehensive functional analysis of large lists of genes and proteins
28343001|a|The interpretation of high dimensional datasets resulting from genomic and proteomic experiments in a timely and efficient manner is challenging. ClueGO software is a Cytoscape App that extracts representative functional biological information for large lists of genes or proteins. The functional enrichment analysis is based on the latest publicly available data from multiple annotation and ontology resources that can be automatically accessed through ClueGO. Predefined settings for the selection of the terms are provided to facilitate the analysis. Results are visualized as networks in which Gene Ontology (GO) terms and pathways are grouped based on their biological role. Many species are now supported by ClueGO and additional organisms are added on demand. ClueGO can be used together with the CluePedia App to enable the visualization of protein-protein interactions within or between pathways.
28343001	0	13	Comprehensive	T080	C1880156
28343001	14	33	functional analysis	T062	C0936012
28343001	52	57	genes	T028	C0017337
28343001	62	70	proteins	T116,T123	C0033684
28343001	75	89	interpretation	T170	C0459471
28343001	93	118	high dimensional datasets	T170	C0150098
28343001	134	141	genomic	T062	C0681814
28343001	146	167	proteomic experiments	T062	C0681814
28343001	217	232	ClueGO software	T073,T170	C0037585
28343001	238	251	Cytoscape App	T170	C3658280
28343001	292	302	biological	T080	C0205460
28343001	303	314	information	T078	C1533716
28343001	334	339	genes	T028	C0017337
28343001	343	351	proteins	T116,T123	C0033684
28343001	357	387	functional enrichment analysis	T062	C0936012
28343001	430	434	data	T078	C1511726
28343001	449	459	annotation	T170	C1706814
28343001	464	472	ontology	T090	C1518584
28343001	473	482	resources	T078	C0035201
28343001	495	508	automatically	T169	C0205554
28343001	509	517	accessed	T082	C0444454
28343001	526	532	ClueGO	T073,T170	C0037585
28343001	534	553	Predefined settings	T170	C4281677
28343001	562	571	selection	T052	C1707391
28343001	579	584	terms	T078	C1705313
28343001	616	624	analysis	T062	C0936012
28343001	626	633	Results	T169	C1274040
28343001	652	660	networks	T169	C1882071
28343001	670	683	Gene Ontology	T170	C1138831
28343001	685	687	GO	T170	C1138831
28343001	699	707	pathways	T077	C1705987
28343001	757	764	species	T185	C1705920
28343001	786	792	ClueGO	T073,T170	C0037585
28343001	808	817	organisms	T001	C0029235
28343001	839	845	ClueGO	T073,T170	C0037585
28343001	876	889	CluePedia App	T170	C3658280
28343001	921	949	protein-protein interactions	T044	C0872079
28343001	968	976	pathways	T077	C1705987

27417211|t|Defining, Describing, and Categorizing Public Health Infrastructure Priorities for Tropical Cyclone, Flood, Storm, Tornado, and Tsunami-Related Disasters
27417211|a|The study aim was to undertake a qualitative research literature review to analyze available databases to define, describe, and categorize public health infrastructure (PHI) priorities for tropical cyclone, flood, storm, tornado, and tsunami-related disasters. Five electronic publication databases were searched to define, describe, or categorize PHI and discuss tropical cyclone, flood, storm, tornado, and tsunami-related disasters and their impact on PHI. The data were analyzed through aggregation of individual articles to create an overall data description. The data were grouped into PHI themes, which were then prioritized on the basis of degree of interdependency. Sixty-seven relevant articles were identified. PHI was categorized into 13 themes with a total of 158 descriptors. The highest priority PHI identified was workforce. This was followed by water, sanitation, equipment, communication, physical structure, power, governance, prevention, supplies, service, transport, and surveillance. This review identified workforce as the most important of the 13 thematic areas related to PHI and disasters. If its functionality fails, workforce has the greatest impact on the performance of health services. If addressed post-disaster, the remaining forms of PHI will then be progressively addressed. These findings are a step toward providing an evidence base to inform PHI priorities in the disaster setting. (Disaster Med Public Health Preparedness. 2016;10:598-610).
27417211	0	8	Defining	T058	C0509805
27417211	10	20	Describing	T170	C0678257
27417211	26	38	Categorizing	T052	C0871968
27417211	39	67	Public Health Infrastructure	T058	C0699943
27417211	68	78	Priorities	T079	C0439607
27417211	83	99	Tropical Cyclone	T070	C0337000
27417211	101	106	Flood	T070	C0016248
27417211	108	113	Storm	T070	C1254365
27417211	115	122	Tornado	T070	C0040476
27417211	128	153	Tsunami-Related Disasters	T070	C0027485
27417211	158	163	study	T062	C2603343
27417211	208	225	literature review	T170	C0282441
27417211	247	256	databases	T170	C0242356
27417211	260	266	define	T058	C0509805
27417211	268	276	describe	T170	C0678257
27417211	282	292	categorize	T052	C0871968
27417211	293	321	public health infrastructure	T058	C0699943
27417211	323	326	PHI	T058	C0699943
27417211	328	338	priorities	T079	C0439607
27417211	343	359	tropical cyclone	T070	C0337000
27417211	361	366	flood	T070	C0016248
27417211	368	373	storm	T070	C1254365
27417211	375	382	tornado	T070	C0040476
27417211	388	413	tsunami-related disasters	T070	C0027485
27417211	431	452	publication databases	T170	C0993637
27417211	470	476	define	T058	C0509805
27417211	478	486	describe	T170	C0678257
27417211	491	501	categorize	T052	C0871968
27417211	502	505	PHI	T058	C0699943
27417211	510	517	discuss	T054	C2584313
27417211	518	534	tropical cyclone	T070	C0337000
27417211	536	541	flood	T070	C0016248
27417211	543	548	storm	T070	C1254365
27417211	550	557	tornado	T070	C0040476
27417211	563	588	tsunami-related disasters	T070	C0027485
27417211	599	605	impact	T080	C4049986
27417211	609	612	PHI	T058	C0699943
27417211	618	622	data	T078	C1511726
27417211	645	656	aggregation	T169	C0332621
27417211	671	679	articles	T170	C1706852
27417211	723	727	data	T078	C1511726
27417211	733	740	grouped	T169	C1522242
27417211	746	749	PHI	T058	C0699943
27417211	750	756	themes	UnknownType	C0869035
27417211	774	785	prioritized	T079	C0439607
27417211	850	858	articles	T170	C1706852
27417211	876	879	PHI	T058	C0699943
27417211	884	895	categorized	T052	C0871968
27417211	904	910	themes	UnknownType	C0869035
27417211	931	942	descriptors	T170	C0282354
27417211	956	964	priority	T079	C0439607
27417211	965	968	PHI	T058	C0699943
27417211	984	993	workforce	T169	C0024752
27417211	1016	1021	water	T167	C0599638
27417211	1023	1033	sanitation	T090	C0036172
27417211	1035	1044	equipment	T073	C0014672
27417211	1046	1059	communication	T054	C0009452
27417211	1061	1079	physical structure	T073	C0556997
27417211	1081	1086	power	T073	C0032865
27417211	1088	1098	governance	T089	C0220842
27417211	1100	1110	prevention	T080	C2700409
27417211	1112	1120	supplies	T169	C1561604
27417211	1122	1129	service	T057	C0557854
27417211	1131	1140	transport	T073	C1317949
27417211	1146	1158	surveillance	T169	C0220920
27417211	1165	1171	review	T170	C0282443
27417211	1183	1192	workforce	T169	C0024752
27417211	1225	1239	thematic areas	UnknownType	C0869035
27417211	1251	1254	PHI	T058	C0699943
27417211	1259	1268	disasters	T070	C0027485
27417211	1298	1307	workforce	T169	C0024752
27417211	1354	1369	health services	T058	C0018747
27417211	1384	1397	post-disaster	T079	C1254367
27417211	1422	1425	PHI	T058	C0699943
27417211	1534	1537	PHI	T058	C0699943
27417211	1538	1548	priorities	T079	C0439607
27417211	1556	1564	disaster	T070	C0027485

27838149|t|Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine
27838149|a|The anti-folate pemetrexed is a radiosensitizer. In pre-clinical models, pemetrexed is more effective along with the base-excision-repair inhibitor methoxyamine. We tested whether methoxyamine enhances pemetrexed -mediated radiosensitization of lung adenocarcinoma cells and xenografts. A549 and H1299 cells were evaluated for cell cycle distribution by flow cytometry, radiosensitization by clonogenic assay, and DNA repair by neutral comet assay and repair protein activation. H460 cells were included in some studies. Xenografts in nude mice received drug (s) and/or radiation, and tumor growth was monitored by caliper and in vivo toxicity by animal weight. Exposure to pemetrexed / methoxyamine for 24 (H1299, H460) or 48 (A549)hours before irradiation resulted in accumulation of cells near the radiosensitive G1/S border; dose - enhancement factors of 1.62±0.19, 1.97±0.25, and 1.67±0.30, respectively; reduction of mean inactivation dose by 32%, 30%, and 46%, respectively; and significant reductions of SF2 and SF4 (p<0.05). Radiosensitization was associated with rapid DNA double-strand-break rejoining and increased levels of DNA-PKcs. Both tumor-growth rate and tumor-growth delay were significantly improved by adding methoxyamine to pemetrexed pre-irradiation (p<0.0001); no mice lost weight during treatment. Addition of methoxyamine to pemetrexed and fractionated radiotherapy may improve outcome for patients with locally advanced non-squamous non-small-cell lung cancer.
27838149	0	18	Radiosensitization	T061	C0279024
27838149	22	48	non-small-cell lung cancer	T191	C0007131
27838149	49	54	cells	T025	C0334227
27838149	59	69	xenografts	T061	C0520484
27838149	77	96	interactive effects	T169	C1704675
27838149	100	110	pemetrexed	T109,T121	C0210657
27838149	115	127	methoxyamine	T109,T121	C0066156
27838149	132	143	anti-folate	T121	C1254351
27838149	144	154	pemetrexed	T109,T121	C0210657
27838149	160	175	radiosensitizer	T121	C0034541
27838149	180	199	pre-clinical models	T170	C1514292
27838149	201	211	pemetrexed	T109,T121	C0210657
27838149	220	229	effective	T080	C1704419
27838149	245	265	base-excision-repair	T045	C1158530
27838149	266	275	inhibitor	T080	C1999216
27838149	276	288	methoxyamine	T109,T121	C0066156
27838149	293	299	tested	T169	C0039593
27838149	308	320	methoxyamine	T109,T121	C0066156
27838149	321	329	enhances	T052	C2349975
27838149	330	340	pemetrexed	T109,T121	C0210657
27838149	351	369	radiosensitization	T061	C0279024
27838149	373	392	lung adenocarcinoma	T191	C0152013
27838149	403	413	xenografts	T061	C0520484
27838149	415	419	A549	T025	C4277577
27838149	424	435	H1299 cells	T025	C0334227
27838149	455	465	cell cycle	T043	C0007586
27838149	466	478	distribution	T169	C1704711
27838149	482	496	flow cytometry	T059	C0016263
27838149	498	516	radiosensitization	T061	C0279024
27838149	520	536	clonogenic assay	T059	C0041372
27838149	542	552	DNA repair	T045	C0012899
27838149	556	575	neutral comet assay	T063	C0751980
27838149	580	594	repair protein	T044	C1159338
27838149	595	605	activation	T045	C0599177
27838149	607	617	H460 cells	T025	C0334227
27838149	649	659	Xenografts	T061	C0520484
27838149	663	672	nude mice	T015	C0025932
27838149	673	686	received drug	T033	C0332154
27838149	698	707	radiation	T070	C0851346
27838149	713	725	tumor growth	T191	C0598934
27838149	743	750	caliper	T074	C0175720
27838149	755	762	in vivo	T062	C0681829
27838149	763	771	toxicity	T037	C0600688
27838149	775	788	animal weight	T032	C0005910
27838149	790	801	Exposure to	T080	C0332157
27838149	802	812	pemetrexed	T109,T121	C0210657
27838149	815	827	methoxyamine	T109,T121	C0066156
27838149	836	841	H1299	T025	C0334227
27838149	843	847	H460	T025	C0334227
27838149	856	860	A549	T025	C4277577
27838149	874	885	irradiation	T070	C1282930
27838149	898	910	accumulation	T033	C4055506
27838149	914	919	cells	T025	C0334227
27838149	929	955	radiosensitive G1/S border	T082	C1254362
27838149	957	961	dose	T081	C0178602
27838149	964	975	enhancement	T052	C2349975
27838149	976	983	factors	T169	C1521761
27838149	1056	1068	inactivation	T169	C0544461
27838149	1069	1073	dose	T081	C0178602
27838149	1162	1180	Radiosensitization	T061	C0279024
27838149	1207	1240	DNA double-strand-break rejoining	T045	C3155842
27838149	1265	1273	DNA-PKcs	T116,T126	C0212694
27838149	1280	1292	tumor-growth	T191	C0598934
27838149	1293	1297	rate	T079	C0449249
27838149	1302	1314	tumor-growth	T191	C0598934
27838149	1315	1320	delay	T079	C0205421
27838149	1359	1371	methoxyamine	T109,T121	C0066156
27838149	1375	1385	pemetrexed	T109,T121	C0210657
27838149	1386	1401	pre-irradiation	T070	C1282930
27838149	1417	1421	mice	T015	C0025932
27838149	1441	1450	treatment	T169	C1522326
27838149	1464	1476	methoxyamine	T109,T121	C0066156
27838149	1480	1490	pemetrexed	T109,T121	C0210657
27838149	1545	1553	patients	T101	C0030705
27838149	1576	1615	non-squamous non-small-cell lung cancer	T191	C2585890

27528862|t|A proteomic evaluation of urinary changes associated with cardiopulmonary bypass
27528862|a|The urinary proteome of patients undergoing cardiopulmonary bypass (CPB) may provide important insights into systemic and renal changes associated with the procedure. Such information may ultimately provide a basis to differentiate changes or properties associated with the development of acute kidney injury. While mass spectrometry (MS) analysis offers the potential for in-depth compositional analysis it is often limited in coverage and relative quantitation capacity. The aim of this study was to develop a process flow for the preparation and comparison of the intraoperative urinary proteome. Urines were collected from patients at the start of CPB and 1-h into CPB. Pooled samples (n = 5) from each time point were processed using a modified Filter Assisted Sample Preparation protocol. The resulting peptides were analyzed by 2D-LC-MS / MS and by 1D-LC-MS / MS SWATH (Sequential Window acquisition of All Theoretical fragment ion spectra). The 2D-LC-MS / MS analysis identified 1324 proteins in the two pools, of which 744 were quantifiable. The SWATH approach provided quantitation for 730 proteins, 552 of which overlapped with the common population from the 2D-IDA results. Intensity correlation filtering between the two methods gave 475 proteins for biological interpretation. Proteins displaying greater than threefold changes (>log2 1.59) at 1-hour CPB relative to the initiation of CPB (26 down-regulated and 22 up-regulated) were selected for further analysis. Up-regulated proteins were enriched in GO terms related to humoral immune response, predominantly innate immunity (C4b, lactotransferrin, protein S100-A8, cathelicidin, myeloperoxidase) and extracellular matrix reorganization (e.g. MMP-9). This study describes a scheme for processing urine from patients undergoing CPB for mass spectrometry -based analysis. The introduction of SWATH into the workflow offers a sample and instrument sparing approach to obtaining consistent in-depth sample analysis. The design of the methodology is such that it can be readily applied to large numbers of clinical samples with the potential for automation. The results also suggest that activation of the innate immune responses occur during cardiac bypass surgery.
27528862	2	22	proteomic evaluation	T059	C1327760
27528862	26	41	urinary changes	T169	C0243172
27528862	42	57	associated with	T080	C0332281
27528862	58	80	cardiopulmonary bypass	T061	C0007202
27528862	85	92	urinary	T080	C1524119
27528862	93	101	proteome	T116,T123	C0751973
27528862	105	113	patients	T101	C0030705
27528862	125	147	cardiopulmonary bypass	T061	C0007202
27528862	149	152	CPB	T061	C0007202
27528862	190	198	systemic	UnknownType	C0749223
27528862	203	216	renal changes	T033	C0184571
27528862	217	232	associated with	T080	C0332281
27528862	237	246	procedure	T061	C0087111
27528862	253	264	information	T078	C1533716
27528862	335	350	associated with	T080	C0332281
27528862	355	366	development	T169	C1527148
27528862	370	389	acute kidney injury	T037	C2609414
27528862	397	414	mass spectrometry	T059	C0037813
27528862	416	418	MS	T059	C0037813
27528862	420	428	analysis	T062	C0936012
27528862	440	449	potential	T080	C3245505
27528862	463	476	compositional	T070	C0243176
27528862	477	485	analysis	T062	C0936012
27528862	531	543	quantitation	T081	C1709793
27528862	544	552	capacity	T081	C1516240
27528862	558	561	aim	T078	C1947946
27528862	570	575	study	T062	C0008972
27528862	648	662	intraoperative	T079	C0456904
27528862	663	670	urinary	T080	C1524119
27528862	671	679	proteome	T116,T123	C0751973
27528862	681	687	Urines	T031	C0042036
27528862	708	716	patients	T101	C0030705
27528862	733	736	CPB	T061	C0007202
27528862	750	753	CPB	T061	C0007202
27528862	755	769	Pooled samples	T167	C1709595
27528862	822	874	modified Filter Assisted Sample Preparation protocol	T059	C1720914
27528862	890	898	peptides	T116	C0030956
27528862	916	924	2D-LC-MS	T059	C0872318
27528862	927	929	MS	T059	C0037813
27528862	937	945	1D-LC-MS	T059	C0872318
27528862	948	950	MS	T059	C0037813
27528862	951	956	SWATH	T059	C0022885
27528862	958	1027	Sequential Window acquisition of All Theoretical fragment ion spectra	T059	C0022885
27528862	1034	1042	2D-LC-MS	T059	C0872318
27528862	1045	1047	MS	T059	C0037813
27528862	1048	1056	analysis	T062	C0936012
27528862	1073	1081	proteins	T116,T123	C0033684
27528862	1093	1098	pools	T201	C1509144
27528862	1136	1150	SWATH approach	T059	C0022885
27528862	1160	1172	quantitation	T081	C1709793
27528862	1181	1189	proteins	T116,T123	C0033684
27528862	1204	1214	overlapped	T079	C1948020
27528862	1251	1257	2D-IDA	T170	C0449859
27528862	1267	1288	Intensity correlation	T062,T170	C0010101
27528862	1289	1298	filtering	T062	C0242481
27528862	1315	1322	methods	T170	C0449309
27528862	1332	1340	proteins	T116,T123	C0033684
27528862	1372	1380	Proteins	T116,T123	C0033684
27528862	1446	1449	CPB	T061	C0007202
27528862	1480	1483	CPB	T061	C0007202
27528862	1488	1502	down-regulated	T044	C0013081
27528862	1510	1522	up-regulated	T044	C0041904
27528862	1550	1558	analysis	T062	C0936012
27528862	1560	1572	Up-regulated	T044	C0041904
27528862	1573	1581	proteins	T116,T123	C0033684
27528862	1599	1601	GO	T170	C1138831
27528862	1619	1642	humoral immune response	T043	C1155229
27528862	1658	1673	innate immunity	T032	C0020969
27528862	1675	1678	C4b	T116,T129	C1448577
27528862	1680	1696	lactotransferrin	T116,T123	C0022942
27528862	1698	1713	protein S100-A8	T116,T129	C4281719
27528862	1715	1727	cathelicidin	T116,T123	C0671062
27528862	1729	1744	myeloperoxidase	T116,T126	C0027021
27528862	1750	1770	extracellular matrix	T024	C0015350
27528862	1771	1785	reorganization	T043	C1511632
27528862	1792	1797	MMP-9	T116,T126	C0165519
27528862	1805	1810	study	T062	C0008972
27528862	1834	1844	processing	T059	C0037793
27528862	1845	1850	urine	T031	C0042036
27528862	1856	1864	patients	T101	C0030705
27528862	1876	1879	CPB	T061	C0007202
27528862	1884	1901	mass spectrometry	T059	C0037813
27528862	1909	1917	analysis	T059	C0002778
27528862	1939	1944	SWATH	T059	C0022885
27528862	1954	1962	workflow	T077	C1710679
27528862	2035	2059	in-depth sample analysis	T059	C1303103
27528862	2079	2090	methodology	T062	C0086912
27528862	2150	2166	clinical samples	T167	C0370003
27528862	2176	2185	potential	T080	C3245505
27528862	2190	2200	automation	T066	C2718029
27528862	2206	2213	results	T034	C0456984
27528862	2232	2273	activation of the innate immune responses	T040	C1817386
27528862	2287	2309	cardiac bypass surgery	T061	C1536078

27541815|t|Agglomeration of Luminescent Porous Silicon Nanoparticles in Colloidal Solutions
27541815|a|We have prepared colloidal solutions of clusters composed from porous silicon nanoparticles in methanol, water and phosphate-buffered saline (PBS). Even if the size of the nanoclusters is between 60 and 500 nm, due to their highly porous "cauliflower"-like structure, the porous silicon nanoparticles are composed of interconnected nanocrystals having around 2.5 nm in size and showing strong visible luminescence in the orange - red spectral region (centred at 600-700 nm). Hydrophilic behaviour and good solubility of the nanoclusters in water and water - based solutions were obtained by adding hydrogen peroxide into the etching solution during preparation and 16 min long after-bath in hydrogen peroxide. By simple filtration of the solutions with syringe filters, we have extracted smaller nanoclusters with sizes of approx. 60-70 nm; however, these nanoclusters in water and PBS solution (pH neutral) are prone to agglomeration, as was confirmed by zeta potential measurements. When the samples were left at ambient conditions for several weeks, the typical nanocluster size increased to approx. 330-400 nm and then remained stable. However, both freshly filtered and aged samples (with agglomerated porous silicon nanoparticles) of porous silicon in water and PBS solutions can be further used for biological studies or as luminescent markers in living cells.
27541815	0	13	Agglomeration	T081	C1704332
27541815	17	28	Luminescent	T070	C1450275
27541815	29	35	Porous	T082	C1881977
27541815	36	43	Silicon	T196	C0037107
27541815	44	57	Nanoparticles	T073	C1450054
27541815	61	80	Colloidal Solutions	T122	C0009361
27541815	89	97	prepared	T033	C4082130
27541815	98	117	colloidal solutions	T122	C0009361
27541815	121	129	clusters	T081	C1704332
27541815	144	150	porous	T082	C1881977
27541815	151	158	silicon	T196	C0037107
27541815	159	172	nanoparticles	T073	C1450054
27541815	176	184	methanol	T109,T131	C0001963
27541815	186	191	water	T121,T197	C0043047
27541815	196	221	phosphate-buffered saline	T167	C0036082
27541815	223	226	PBS	T167	C0036082
27541815	241	245	size	T082	C0456389
27541815	253	265	nanoclusters	T081	C1704332
27541815	305	311	highly	T080	C0205250
27541815	312	318	porous	T082	C1881977
27541815	319	347	"cauliflower"-like structure	T082	C0678594
27541815	353	359	porous	T082	C1881977
27541815	360	367	silicon	T196	C0037107
27541815	368	381	nanoparticles	T073	C1450054
27541815	398	412	interconnected	T082	C0449379
27541815	413	425	nanocrystals	T073	C1721058
27541815	450	454	size	T082	C0456389
27541815	467	473	strong	T080	C0442821
27541815	474	481	visible	T080	C0205379
27541815	482	494	luminescence	T070	C1450275
27541815	502	508	orange	T080	C1313858
27541815	511	514	red	T080	C1260956
27541815	515	523	spectral	T077	C2827424
27541815	524	530	region	T082	C0205147
27541815	556	577	Hydrophilic behaviour	T080	C0475370
27541815	582	586	good	T080	C0205170
27541815	587	597	solubility	T080	C0037628
27541815	605	617	nanoclusters	T081	C1704332
27541815	621	626	water	T121,T197	C0043047
27541815	631	636	water	T121,T197	C0043047
27541815	639	644	based	T078	C1705938
27541815	645	654	solutions	T167	C0037633
27541815	660	668	obtained	T169	C1301820
27541815	679	696	hydrogen peroxide	T121,T130,T197	C0020281
27541815	706	713	etching	T070	C2350458
27541815	714	722	solution	T167	C0037633
27541815	730	741	preparation	T052	C1521827
27541815	758	768	after-bath	T169	C1549544
27541815	772	789	hydrogen peroxide	T121,T130,T197	C0020281
27541815	794	800	simple	T080	C0205352
27541815	801	811	filtration	T068	C0016107
27541815	819	828	solutions	T167	C0037633
27541815	834	849	syringe filters	T074	C0180875
27541815	859	868	extracted	T080	C0849355
27541815	869	876	smaller	T081	C0700321
27541815	877	889	nanoclusters	T081	C1704332
27541815	895	900	sizes	T082	C0456389
27541815	904	910	approx	T080	C0332232
27541815	937	949	nanoclusters	T081	C1704332
27541815	953	958	water	T121,T197	C0043047
27541815	963	975	PBS solution	T167	C0036082
27541815	977	987	pH neutral	T080	C1882074
27541815	993	998	prone	T169	C0231204
27541815	1002	1015	agglomeration	T081	C1704332
27541815	1024	1033	confirmed	T033	C0750484
27541815	1037	1051	zeta potential	T067	C0597697
27541815	1052	1064	measurements	T169	C0242485
27541815	1075	1082	samples	T167	C0370003
27541815	1096	1114	ambient conditions	T080	C1879688
27541815	1119	1126	several	T081	C0443302
27541815	1138	1145	typical	T080	C3538928
27541815	1146	1157	nanocluster	T081	C1704332
27541815	1158	1162	size	T082	C0456389
27541815	1163	1172	increased	T081	C0205217
27541815	1176	1182	approx	T080	C0332232
27541815	1213	1219	stable	T080	C0205360
27541815	1235	1242	freshly	T080	C0443224
27541815	1243	1251	filtered	T077	C1704449
27541815	1256	1260	aged	T079	C2362314
27541815	1261	1268	samples	T167	C0370003
27541815	1275	1287	agglomerated	T081	C1704332
27541815	1288	1294	porous	T082	C1881977
27541815	1295	1302	silicon	T196	C0037107
27541815	1303	1316	nanoparticles	T073	C1450054
27541815	1321	1327	porous	T082	C1881977
27541815	1328	1335	silicon	T196	C0037107
27541815	1339	1344	water	T121,T197	C0043047
27541815	1349	1362	PBS solutions	T167	C0036082
27541815	1387	1397	biological	T080	C0205460
27541815	1398	1405	studies	T062	C2603343
27541815	1412	1423	luminescent	T070	C1450275
27541815	1424	1431	markers	T201	C0005516
27541815	1435	1447	living cells	T025	C0007634

27736955|t|Crystal Structure of Saccharomyces cerevisiae ECM4, a Xi-Class Glutathione Transferase that Reacts with Glutathionyl-(hydro)quinones
27736955|a|Glutathionyl-hydroquinone reductases (GHRs) belong to the recently characterized Xi-class of glutathione transferases (GSTXs) according to unique structural properties and are present in all but animal kingdoms. The GHR ScECM4 from the yeast Saccharomyces cerevisiae has been studied since 1997 when it was found to be potentially involved in cell-wall biosynthesis. Up to now and in spite of biological studies made on this enzyme, its physiological role remains challenging. The work here reports its crystallographic study. In addition to exhibiting the general GSTX structural features, ScECM4 shows extensions including a huge loop which contributes to the quaternary assembly. These structural extensions are probably specific to Saccharomycetaceae. Soaking of ScECM4 crystals with GS-menadione results in a structure where glutathione forms a mixed disulfide bond with the cysteine 46. Solution studies confirm that ScECM4 has reductase activity for GS-menadione in presence of glutathione. Moreover, the high resolution structures allowed us to propose new roles of conserved residues of the active site to assist the cysteine 46 during the catalytic act.
27736955	0	17	Crystal Structure	T104	C0444626
27736955	21	45	Saccharomyces cerevisiae	T004	C0036025
27736955	46	50	ECM4	T116,T123	C0033684
27736955	54	62	Xi-Class	T170	C0456387
27736955	63	86	Glutathione Transferase	T116,T126	C0017837
27736955	104	132	Glutathionyl-(hydro)quinones	T116,T123	C0017817
27736955	133	169	Glutathionyl-hydroquinone reductases	T116,T126	C0017837
27736955	171	175	GHRs	T116,T126	C0017837
27736955	200	213	characterized	T052	C1880022
27736955	214	222	Xi-class	T170	C0456387
27736955	226	250	glutathione transferases	T116,T126	C0017837
27736955	252	257	GSTXs	T116,T126	C0017837
27736955	272	278	unique	T080	C1710548
27736955	279	289	structural	T082	C0678594
27736955	290	300	properties	T080	C0871161
27736955	309	316	present	T033	C0150312
27736955	328	343	animal kingdoms	T008	C0003062
27736955	349	352	GHR	T116,T126	C0017837
27736955	353	359	ScECM4	T116,T123	C0033684
27736955	369	374	yeast	T004	C0036025
27736955	375	399	Saccharomyces cerevisiae	T004	C0036025
27736955	476	498	cell-wall biosynthesis	T043	C0007613
27736955	526	536	biological	T080	C0205460
27736955	537	544	studies	T062	C2603343
27736955	558	564	enzyme	T116,T126	C0014442
27736955	570	583	physiological	T169	C0205463
27736955	584	588	role	T077	C1705810
27736955	636	652	crystallographic	T059	C0010424
27736955	653	658	study	T062	C2603343
27736955	660	674	In addition to	T169	C0332287
27736955	698	702	GSTX	T116,T126	C0017837
27736955	703	713	structural	T082	C0678594
27736955	714	722	features	T080	C2348519
27736955	724	730	ScECM4	T116,T123	C0033684
27736955	737	747	extensions	T169	C0231448
27736955	765	769	loop	T082	C0445022
27736955	776	787	contributes	T052	C1880177
27736955	806	814	assembly	T044	C0872376
27736955	822	832	structural	T082	C0678594
27736955	833	843	extensions	T169	C0231448
27736955	857	865	specific	T080	C0205369
27736955	869	887	Saccharomycetaceae	T004	C1080944
27736955	889	896	Soaking	T061	C0204774
27736955	900	906	ScECM4	T116,T123	C0033684
27736955	907	915	crystals	T122	C1378554
27736955	921	933	GS-menadione	T116	C0080806
27736955	947	956	structure	T082	C0678594
27736955	963	974	glutathione	T116,T123	C0017817
27736955	983	988	mixed	T169	C0205430
27736955	989	1003	disulfide bond	T087	C1511997
27736955	1013	1024	cysteine 46	T116,T123	C0010654
27736955	1026	1034	Solution	T167	C0037633
27736955	1035	1042	studies	T062	C2603343
27736955	1043	1050	confirm	T033	C0750484
27736955	1056	1062	ScECM4	T116,T123	C0033684
27736955	1067	1085	reductase activity	T044	C1148566
27736955	1090	1102	GS-menadione	T116	C0080806
27736955	1106	1114	presence	T033	C0150312
27736955	1118	1129	glutathione	T116,T123	C0017817
27736955	1145	1160	high resolution	T059	C1719039
27736955	1161	1171	structures	T082	C0678594
27736955	1198	1203	roles	T077	C1705810
27736955	1207	1225	conserved residues	T086	C0009802
27736955	1233	1244	active site	T169	C0205681
27736955	1259	1270	cysteine 46	T116,T123	C0010654
27736955	1282	1295	catalytic act	T070	C0007382

27793144|t|Family and healthcare professionals ' perceptions of a pilot hospice at home programme for children: a qualitative study
27793144|a|Parents commonly report a significant improvement in quality of life following the provision of hospice and supportive care and have identified a need for such a service in the home. The purpose of this study was to understand the experiences of families receiving a nurse led pilot hospice at home programme and the experiences of healthcare professionals delivering and engaging with the programme. An exploratory, qualitative study was conducted, including telephone interviews with parents and focus groups and individual interviews with healthcare professionals. All parents of families who received the programme of care between June 2014 and September 2015 and healthcare professionals delivering and engaging with the programme were invited to participate. Seven parents participated in telephone interviews. Four focus groups took place, two with external stakeholders (18 participants in total), one with in-patient hospice staff (13 participants) and one with the hospice at home team (8 participants). Two additional interviews took place with individual stakeholders who were unable to attend a scheduled focus group. Themes from interviews with parents focused on the value of having consistent and expert care. The findings from healthcare professionals centred on communication within and across services, education and training and lone working. The pilot hospice at home programme was welcomed by all those who took part in the study. The programme may be improved by enhanced clarification of roles, enhanced access to multi-disciplinary services, greater communication across services and improved information provision to families.
27793144	0	6	Family	T099	C0015576
27793144	11	35	healthcare professionals	T097	C1704312
27793144	38	49	perceptions	T041	C0030971
27793144	61	68	hospice	T058	C0085555
27793144	72	76	home	T082	C0442519
27793144	77	86	programme	T058	C0679897
27793144	91	99	children	T100	C0008059
27793144	115	120	study	T062	C2603343
27793144	121	128	Parents	T099	C0030551
27793144	159	170	improvement	T077	C2986411
27793144	174	189	quality of life	T078	C0034380
27793144	204	213	provision	T058	C1283218
27793144	217	224	hospice	T058	C0085555
27793144	229	244	supportive care	T061	C0344211
27793144	283	290	service	T058	C0018747
27793144	298	302	home	T082	C0442519
27793144	324	329	study	T062	C2603343
27793144	367	375	families	T099	C0015576
27793144	388	393	nurse	T097	C0028661
27793144	404	411	hospice	T058	C0085555
27793144	415	419	home	T082	C0442519
27793144	420	429	programme	T058	C0679897
27793144	438	449	experiences	T041	C0596545
27793144	453	477	healthcare professionals	T097	C1704312
27793144	511	520	programme	T058	C0679897
27793144	550	555	study	T062	C2603343
27793144	581	601	telephone interviews	T062	C0021823
27793144	607	614	parents	T099	C0030551
27793144	619	631	focus groups	T096	C0016400
27793144	636	646	individual	T098	C0237401
27793144	647	657	interviews	T052	C0021822
27793144	663	687	healthcare professionals	T097	C1704312
27793144	693	700	parents	T099	C0030551
27793144	704	712	families	T099	C0015576
27793144	730	739	programme	T058	C0679897
27793144	743	747	care	T058	C0086388
27793144	789	813	healthcare professionals	T097	C1704312
27793144	847	856	programme	T058	C0679897
27793144	892	899	parents	T099	C0030551
27793144	916	936	telephone interviews	T062	C0021823
27793144	943	955	focus groups	T096	C0016400
27793144	977	998	external stakeholders	T098	C1257890
27793144	1003	1015	participants	T098	C0679646
27793144	1036	1046	in-patient	T101	C0030705
27793144	1047	1060	hospice staff	T097	C0025106
27793144	1065	1077	participants	T098	C0679646
27793144	1096	1103	hospice	T058	C0085555
27793144	1120	1132	participants	T098	C0679646
27793144	1150	1160	interviews	T052	C0021822
27793144	1177	1187	individual	T098	C0237401
27793144	1188	1200	stakeholders	T098	C1257890
27793144	1239	1250	focus group	T096	C0016400
27793144	1264	1274	interviews	T052	C0021822
27793144	1280	1287	parents	T099	C0030551
27793144	1341	1345	care	T058	C0086388
27793144	1365	1389	healthcare professionals	T097	C1704312
27793144	1401	1414	communication	T054	C0009452
27793144	1433	1441	services	T058	C0018747
27793144	1443	1465	education and training	T065	C0582584
27793144	1470	1482	lone working	T057	C0043227
27793144	1494	1501	hospice	T058	C0085555
27793144	1505	1509	home	T082	C0442519
27793144	1510	1519	programme	T058	C0679897
27793144	1567	1572	study	T062	C2603343
27793144	1578	1587	programme	T058	C0679897
27793144	1616	1629	clarification	T052	C2986669
27793144	1678	1686	services	T058	C0018747
27793144	1696	1709	communication	T054	C0009452
27793144	1717	1725	services	T058	C0018747
27793144	1764	1772	families	T099	C0015576

28137551|t|Bromocriptine Induces Autophagy -Dependent Cell Death in Pituitary Adenomas
28137551|a|Bromocriptine (BRC) is effective in patients with prolactinoma. However, the cytotoxic mechanism of BRC remains unknown. Slices for immunohistochemical pathology were randomly selected from 37 paraffin-embedded prolactinoma tissue sections. LC3 was detected by immunohistochemistry. GH3 and MMQ cells were treated by BRC and/or rapamycin (RAPA). Cell viability and the cell cycle were measured by CCK-8 and flow cytometry, respectively. Enzyme-linked immunosorbent assay measured prolactin secretion. Protein expression was detected by Western blot or immunofluorescence. LC3 was significantly expressed in prolactinoma in which patients were treated exclusively with BRC. LC3 expression was negative in normal tissues and prolactinoma in which patients were not treated with BRC. Treatment with 60 μM BRC for 24 hours induced cell death in MMQ cells by up to 50%. However, 110 μM BRC was required to produce a similar effect in GH3 cells. The cell cycle was arrested at the G0 - G1 phase and S phase. As the concentration and time increased, the conversion ratio of LC3-I to LC3-II increased and prolactin secretion decreased. In addition, Bcl-2 and BAX expression was decreased. The cell viability, prolactin level, and G0-G1 cells are similar in MMQ cells treated with RAPA and a low concentration of BRC and MMQ cells treated with a high concentration of BRC. Compared with the effects of a high concentration of BRC, treatment with RAPA and a low concentration of BRC effectively increase the conversion rate of LC3-I to LC3-II. BRC - treated pituitary adenoma cells mainly underwent autophagic cell death rather than apoptosis.
28137551	0	13	Bromocriptine	T109,T121	C0006230
28137551	14	21	Induces	T169	C0205263
28137551	22	31	Autophagy	T043	C0004391
28137551	43	53	Cell Death	T043	C0007587
28137551	57	75	Pituitary Adenomas	T191	C0032000
28137551	76	89	Bromocriptine	T109,T121	C0006230
28137551	91	94	BRC	T109,T121	C0006230
28137551	99	108	effective	T080	C1704419
28137551	112	120	patients	T101	C0030705
28137551	126	138	prolactinoma	T191	C0033375
28137551	153	162	cytotoxic	T169	C1511636
28137551	163	172	mechanism	T169	C0441712
28137551	176	179	BRC	T109,T121	C0006230
28137551	208	227	immunohistochemical	T059	C1441616
28137551	228	237	pathology	T091	C0030664
28137551	269	306	paraffin-embedded prolactinoma tissue	T024	C1519524
28137551	317	320	LC3	T116,T123	C2003747
28137551	325	333	detected	T033	C0442726
28137551	337	357	immunohistochemistry	T060	C0021044
28137551	359	362	GH3	T025	C0229535
28137551	367	376	MMQ cells	T025	C0229535
28137551	382	389	treated	T169	C1522326
28137551	393	396	BRC	T109,T121	C0006230
28137551	404	413	rapamycin	T109,T195	C0072980
28137551	415	419	RAPA	T109,T195	C0072980
28137551	422	436	Cell viability	T043	C0007620
28137551	445	455	cell cycle	T043	C0007586
28137551	473	478	CCK-8	T062	C2986858
28137551	483	497	flow cytometry	T059	C0016263
28137551	513	546	Enzyme-linked immunosorbent assay	T059	C0014441
28137551	556	575	prolactin secretion	T043	C2611224
28137551	577	595	Protein expression	T045	C1171362
28137551	600	608	detected	T033	C0442726
28137551	612	624	Western blot	T059,T063	C0005863
28137551	628	646	immunofluorescence	T059	C0079603
28137551	648	651	LC3	T116,T123	C2003747
28137551	670	679	expressed	T045	C1171362
28137551	683	695	prolactinoma	T191	C0033375
28137551	705	713	patients	T101	C0030705
28137551	719	726	treated	T169	C1522326
28137551	744	747	BRC	T109,T121	C0006230
28137551	749	763	LC3 expression	T045	C1171362
28137551	768	776	negative	T033	C0205160
28137551	780	786	normal	T080	C0205307
28137551	787	794	tissues	T024	C0040300
28137551	799	811	prolactinoma	T191	C0033375
28137551	821	829	patients	T101	C0030705
28137551	839	851	treated with	T061	C0332293
28137551	852	855	BRC	T109,T121	C0006230
28137551	857	866	Treatment	T061	C0087111
28137551	878	881	BRC	T109,T121	C0006230
28137551	889	894	hours	T079	C0439227
28137551	895	902	induced	T169	C0205263
28137551	903	913	cell death	T043	C0007587
28137551	917	926	MMQ cells	T025	C0229535
28137551	957	960	BRC	T109,T121	C0006230
28137551	995	1001	effect	T080	C1280500
28137551	1005	1014	GH3 cells	T025	C0229535
28137551	1020	1030	cell cycle	T043	C0007586
28137551	1035	1043	arrested	T043	C1155873
28137551	1051	1053	G0	T045	C0079394
28137551	1056	1064	G1 phase	T043	C1155840
28137551	1069	1076	S phase	T043	C1155869
28137551	1085	1098	concentration	T081	C1446561
28137551	1103	1107	time	T079	C0040223
28137551	1108	1117	increased	T081	C0205217
28137551	1123	1139	conversion ratio	T081	C0456603
28137551	1143	1148	LC3-I	T116,T123	C2003747
28137551	1152	1158	LC3-II	T116,T123	C2003747
28137551	1159	1168	increased	T081	C0205217
28137551	1173	1192	prolactin secretion	T043	C2611224
28137551	1193	1202	decreased	T081	C0547047
28137551	1217	1222	Bcl-2	T116,T123	C0293686
28137551	1227	1230	BAX	T116,T123	C0219474
28137551	1231	1241	expression	T045	C1171362
28137551	1246	1255	decreased	T081	C0547047
28137551	1261	1275	cell viability	T043	C0007620
28137551	1277	1292	prolactin level	T034	C0428411
28137551	1298	1309	G0-G1 cells	T025	C1988243
28137551	1325	1334	MMQ cells	T025	C0229535
28137551	1335	1347	treated with	T061	C0332293
28137551	1348	1352	RAPA	T109,T195	C0072980
28137551	1359	1362	low	T080	C0205251
28137551	1363	1376	concentration	T081	C1446561
28137551	1380	1383	BRC	T109,T121	C0006230
28137551	1388	1397	MMQ cells	T025	C0229535
28137551	1398	1410	treated with	T061	C0332293
28137551	1413	1417	high	T080	C0205250
28137551	1418	1431	concentration	T081	C1446561
28137551	1435	1438	BRC	T109,T121	C0006230
28137551	1458	1465	effects	T080	C1280500
28137551	1471	1475	high	T080	C0205250
28137551	1476	1489	concentration	T081	C1446561
28137551	1493	1496	BRC	T109,T121	C0006230
28137551	1498	1507	treatment	T061	C0087111
28137551	1513	1517	RAPA	T109,T195	C0072980
28137551	1524	1527	low	T080	C0205251
28137551	1528	1541	concentration	T081	C1446561
28137551	1545	1548	BRC	T109,T121	C0006230
28137551	1549	1560	effectively	T080	C1280500
28137551	1561	1569	increase	T081	C0205217
28137551	1574	1589	conversion rate	T081	C1521828
28137551	1593	1598	LC3-I	T116,T123	C2003747
28137551	1602	1608	LC3-II	T116,T123	C2003747
28137551	1610	1613	BRC	T109,T121	C0006230
28137551	1616	1623	treated	T169	C1522326
28137551	1624	1641	pituitary adenoma	T191	C0032000
28137551	1642	1647	cells	T025	C0334227
28137551	1665	1675	autophagic	T043	C0004391
28137551	1676	1686	cell death	T043	C0007587
28137551	1699	1708	apoptosis	T043	C0162638

28377051|t|Chlamydia pneumoniae infection promotes vascular endothelial cell angiogenesis through an IQGAP1 -related signaling pathway
28377051|a|Chlamydia pneumoniae (C. pneumoniae) infection plays a potential role in angiogenesis. However, it is still an enigma how C. pneumoniae is involved in this process. Therefore, we investigated the effect of C. pneumoniae infection on angiogenesis, and then explored the roles of IQGAP1 -related signaling in C. pneumoniae infection - induced angiogenesis. C. pneumoniae infection significantly enhanced angiogenesis as assessed by the tube formation assay possibly by inducing vascular endothelial cell (VEC) migration in the wound healing and Transwell migration assays. Subsequently, immunoprecipitation, Western blot and tube formation assay results showed that the phosphorylation of both IQGAP1 and N-WASP was required for the angiogenesis induced by C. pneumoniae infection. Our co-immunoprecipitation study revealed that IQGAP1 physically associated with N-WASP after C. pneumoniae infection of VECs. Actin polymerization assay further showed that in C. pneumoniae - infected VECs, both IQGAP1 and N-WASP were recruited to filamentous actin, and shared some common compartments localized at the leading edge of lamellipodia, which was impaired after the depletion of IQGAP1 by using the small interference RNA. Moreover, the knockdown of IQGAP1 also significantly decreased N-WASP phosphorylation at Tyr256 induced by C. pneumoniae infection. We conclude that C. pneumoniae infection promotes VEC migration and angiogenesis presumably through the IQGAP1 -related signaling pathway.
28377051	0	20	Chlamydia pneumoniae	T007	C0085504
28377051	21	30	infection	T046	C3714514
28377051	31	39	promotes	T052	C0033414
28377051	40	65	vascular endothelial cell	T025	C1257792
28377051	66	78	angiogenesis	T042	C0302600
28377051	90	96	IQGAP1	T116,T123	C0529338
28377051	106	123	signaling pathway	T044	C0037080
28377051	124	144	Chlamydia pneumoniae	T007	C0085504
28377051	146	159	C. pneumoniae	T007	C0085504
28377051	161	170	infection	T046	C3714514
28377051	179	193	potential role	T077	C1705810
28377051	197	209	angiogenesis	T042	C0302600
28377051	246	259	C. pneumoniae	T007	C0085504
28377051	263	271	involved	T169	C1314939
28377051	280	287	process	T067	C1522240
28377051	303	315	investigated	T169	C1292732
28377051	320	326	effect	T080	C1280500
28377051	330	343	C. pneumoniae	T007	C0085504
28377051	344	353	infection	T046	C3714514
28377051	357	369	angiogenesis	T042	C0302600
28377051	393	398	roles	T077	C1705810
28377051	402	408	IQGAP1	T116,T123	C0529338
28377051	418	427	signaling	T044	C0037080
28377051	431	444	C. pneumoniae	T007	C0085504
28377051	445	454	infection	T046	C3714514
28377051	457	464	induced	T169	C0205263
28377051	465	477	angiogenesis	T042	C0302600
28377051	479	492	C. pneumoniae	T007	C0085504
28377051	493	502	infection	T046	C3714514
28377051	503	525	significantly enhanced	T052	C2349975
28377051	526	538	angiogenesis	T042	C0302600
28377051	542	550	assessed	T052	C1516048
28377051	558	578	tube formation assay	T059	C1510438
28377051	579	587	possibly	T033	C0332149
28377051	591	599	inducing	T169	C0205263
28377051	600	625	vascular endothelial cell	T025	C1257792
28377051	627	630	VEC	T025	C1257792
28377051	632	641	migration	T052	C0013975
28377051	649	662	wound healing	T040	C0043240
28377051	667	693	Transwell migration assays	T059	C1510438
28377051	695	707	Subsequently	T079	C0332282
28377051	709	728	immunoprecipitation	T059	C0021069
28377051	730	742	Western blot	T059	C0949466
28377051	747	767	tube formation assay	T059	C1510438
28377051	768	775	results	T034	C1254595
28377051	792	807	phosphorylation	T044	C1158886
28377051	816	822	IQGAP1	T116,T123	C0529338
28377051	827	833	N-WASP	T116,T123	C0531254
28377051	838	846	required	T169	C1514873
28377051	855	867	angiogenesis	T042	C0302600
28377051	868	875	induced	T169	C0205263
28377051	879	892	C. pneumoniae	T007	C0085504
28377051	893	902	infection	T046	C3714514
28377051	908	930	co-immunoprecipitation	T059	C1449705
28377051	931	936	study	T059	C0681827
28377051	937	945	revealed	T080	C0443289
28377051	951	957	IQGAP1	T116,T123	C0529338
28377051	969	984	associated with	T080	C0332281
28377051	985	991	N-WASP	T116,T123	C0531254
28377051	998	1011	C. pneumoniae	T007	C0085504
28377051	1012	1021	infection	T046	C3714514
28377051	1025	1029	VECs	T025	C1257792
28377051	1031	1051	Actin polymerization	T043	C1155982
28377051	1052	1057	assay	T059	C1510438
28377051	1081	1094	C. pneumoniae	T007	C0085504
28377051	1097	1105	infected	T033	C0439663
28377051	1106	1110	VECs	T025	C1257792
28377051	1117	1123	IQGAP1	T116,T123	C0529338
28377051	1128	1134	N-WASP	T116,T123	C0531254
28377051	1153	1170	filamentous actin	T116,T123	C1180307
28377051	1188	1194	common	T081	C0205214
28377051	1208	1217	localized	T082	C0392752
28377051	1225	1237	leading edge	T026	C1621433
28377051	1241	1253	lamellipodia	T026	C0230628
28377051	1265	1273	impaired	T169	C0221099
28377051	1284	1293	depletion	T169	C0333668
28377051	1297	1303	IQGAP1	T116,T123	C0529338
28377051	1317	1339	small interference RNA	T114,T123	C1099354
28377051	1355	1364	knockdown	T063	C2350567
28377051	1368	1374	IQGAP1	T028	C1416471
28377051	1380	1403	significantly decreased	T081	C0205216
28377051	1404	1410	N-WASP	T116,T123	C0531254
28377051	1411	1426	phosphorylation	T044	C1158886
28377051	1430	1436	Tyr256	T116,T121,T123	C0041485
28377051	1437	1444	induced	T169	C0205263
28377051	1448	1461	C. pneumoniae	T007	C0085504
28377051	1462	1471	infection	T046	C3714514
28377051	1476	1484	conclude	T078	C1707478
28377051	1490	1503	C. pneumoniae	T007	C0085504
28377051	1504	1513	infection	T046	C3714514
28377051	1514	1522	promotes	T052	C0033414
28377051	1523	1526	VEC	T025	C1257792
28377051	1527	1536	migration	T052	C0013975
28377051	1541	1553	angiogenesis	T042	C0302600
28377051	1577	1583	IQGAP1	T116,T123	C0529338
28377051	1593	1610	signaling pathway	T044	C0037080

27766879|t|Ensemble Linear Neighborhood Propagation for Predicting Subchloroplast Localization of Multi-Location Proteins
27766879|a|In the postgenomic era, the number of unreviewed protein sequences is remarkably larger and grows tremendously faster than that of reviewed ones. However, existing methods for protein subchloroplast localization often ignore the information from these unlabeled proteins. This paper proposes a multi-label predictor based on ensemble linear neighborhood propagation (LNP), namely, LNP-Chlo, which leverages hybrid sequence-based feature information from both labeled and unlabeled proteins for predicting localization of both single- and multi-label chloroplast proteins. Experimental results on a stringent benchmark dataset and a novel independent dataset suggest that LNP-Chlo performs at least 6% (absolute) better than state-of-the-art predictors. This paper also demonstrates that ensemble LNP significantly outperforms LNP based on individual features. For readers ' convenience, the online Web server LNP-Chlo is freely available at http://bioinfo.eie.polyu.edu.hk/LNPChloServer/.
27766879	0	8	Ensemble	T080	C0205556
27766879	9	40	Linear Neighborhood Propagation	T170	C0002045
27766879	45	55	Predicting	T033	C0243095
27766879	56	83	Subchloroplast Localization	T038	C3158176
27766879	87	110	Multi-Location Proteins	T116,T123	C0033684
27766879	118	133	postgenomic era	T079	C1254367
27766879	149	159	unreviewed	T080	C0205556
27766879	160	177	protein sequences	T087	C0002518
27766879	242	250	reviewed	T080	C1709940
27766879	266	274	existing	T077	C2987476
27766879	275	282	methods	T170	C0025663
27766879	287	294	protein	T116,T123	C0033684
27766879	295	322	subchloroplast localization	T038	C3158176
27766879	340	351	information	T078	C1533716
27766879	363	381	unlabeled proteins	T116,T123	C0033684
27766879	388	393	paper	T170	C1706852
27766879	405	426	multi-label predictor	T078	C2698872
27766879	436	444	ensemble	T080	C0205556
27766879	445	476	linear neighborhood propagation	T170	C0002045
27766879	478	481	LNP	T170	C0002045
27766879	492	500	LNP-Chlo	T170	C0002045
27766879	518	559	hybrid sequence-based feature information	T077	C1708038
27766879	570	577	labeled	T116,T123	C0033684
27766879	582	600	unlabeled proteins	T116,T123	C0033684
27766879	605	615	predicting	T033	C0243095
27766879	616	681	localization of both single- and multi-label chloroplast proteins	T043	C3156659
27766879	683	703	Experimental results	T033	C2825142
27766879	719	728	benchmark	T081	C0525063
27766879	729	736	dataset	T170	C0150098
27766879	743	748	novel	T080	C0205314
27766879	749	760	independent	T078	C0085862
27766879	761	768	dataset	T170	C0150098
27766879	782	790	LNP-Chlo	T170	C0002045
27766879	813	821	absolute	T080	C0205344
27766879	835	851	state-of-the-art	T080	C0205556
27766879	852	862	predictors	T078	C2698872
27766879	869	874	paper	T170	C1706852
27766879	898	906	ensemble	T080	C0205556
27766879	907	910	LNP	T170	C0002045
27766879	911	924	significantly	T078	C0750502
27766879	937	940	LNP	T170	C0002045
27766879	950	969	individual features	T080	C2348519
27766879	975	982	readers	T098	C1257890
27766879	985	996	convenience	T080	C3831015
27766879	1002	1019	online Web server	T073,T170	C0029038
27766879	1020	1028	LNP-Chlo	T170	C0002045
27766879	1052	1098	http://bioinfo.eie.polyu.edu.hk/LNPChloServer/	T170	C1704666

28189069|t|Multitarget sensing of glucose and cholesterol based on Janus hydrogel microparticles
28189069|a|A visualized sensing method for glucose and cholesterol was developed based on the hemispheres of the same Janus hydrogel microparticles. Single-phase and Janus hydrogel microparticles were both generated using a centrifugal microfluidic chip. For glucose sensing, concanavalin A and fluorescein labeled dextran used for competitive binding assay were encapsulated in alginate microparticles, and the fluorescence of the microparticles was positively correlated with glucose concentration. For cholesterol sensing, the microparticles embedded with γ-Fe2O3 nanoparticles were used as catalyst for the oxidation of 3,3',5,5'-Tetramethylbenzidine by H2O2, an enzymatic hydrolysis product of cholesterol. And the color transition was more sensitive in the microparticles than in solutions, indicating the microparticles are more applicable for visualized determination. Furthermore, Janus microparticles were employed for multitarget sensing in the two hemespheres, and glucose and cholesterol were detected within the same microparticles without obvious interference. Besides, the particles could be manipulated by an external magnetic field. The glucose and cholesterol levels were measured in human serum utilizing the microparticles, which confirmed the potential application of the microparticles in real sample detection.
28189069	0	11	Multitarget	T169	C1521840
28189069	12	30	sensing of glucose	T059	C0337438
28189069	35	46	cholesterol	T059	C0201950
28189069	56	85	Janus hydrogel microparticles	T109,T121	C0063083
28189069	88	98	visualized	T169	C0234621
28189069	99	125	sensing method for glucose	T059	C0337438
28189069	130	141	cholesterol	T059	C0201950
28189069	193	222	Janus hydrogel microparticles	T109,T121	C0063083
28189069	241	270	Janus hydrogel microparticles	T109,T121	C0063083
28189069	299	310	centrifugal	T080	C1301962
28189069	311	328	microfluidic chip	T075	C1449582
28189069	334	349	glucose sensing	T059	C0337438
28189069	351	365	concanavalin A	T116,T123	C0009630
28189069	370	397	fluorescein labeled dextran	T109,T130	C0060538
28189069	407	432	competitive binding assay	T059	C0005507
28189069	438	450	encapsulated	T080	C0205223
28189069	454	462	alginate	T109,T121,T122	C0002040
28189069	463	477	microparticles	T104	C0597177
28189069	487	499	fluorescence	T070	C0016315
28189069	507	521	microparticles	T104	C0597177
28189069	526	536	positively	T033	C1446409
28189069	537	547	correlated	T080	C1707520
28189069	553	560	glucose	T109,T121,T123	C0017725
28189069	561	574	concentration	T081	C1446561
28189069	580	599	cholesterol sensing	T059	C0201950
28189069	605	619	microparticles	T104	C0597177
28189069	634	655	γ-Fe2O3 nanoparticles	T130,T197	C3652446
28189069	669	677	catalyst	T067	C0175921
28189069	686	695	oxidation	T044	C0030011
28189069	699	729	3,3',5,5'-Tetramethylbenzidine	T109,T130	C0046880
28189069	733	737	H2O2	T121,T130,T197	C0020281
28189069	742	751	enzymatic	T116,T126	C0014442
28189069	752	762	hydrolysis	T070	C0020291
28189069	763	770	product	T071	C1514468
28189069	774	785	cholesterol	T109,T123	C0008377
28189069	795	800	color	T080	C0009393
28189069	801	811	transition	T052	C2700061
28189069	821	830	sensitive	T169	C0332324
28189069	838	852	microparticles	T104	C0597177
28189069	861	870	solutions	T167	C0037633
28189069	887	901	microparticles	T104	C0597177
28189069	911	921	applicable	T080	C1706839
28189069	926	936	visualized	T169	C0234621
28189069	937	950	determination	T059	C1148554
28189069	965	985	Janus microparticles	T104	C0597177
28189069	991	999	employed	T033	C0557351
28189069	1004	1015	multitarget	T169	C1521840
28189069	1016	1023	sensing	T080	C0205396
28189069	1052	1059	glucose	T109,T121,T123	C0017725
28189069	1064	1075	cholesterol	T109,T123	C0008377
28189069	1081	1089	detected	T033	C0442726
28189069	1106	1120	microparticles	T104	C0597177
28189069	1137	1149	interference	T169	C0521102
28189069	1164	1173	particles	T104	C0597177
28189069	1201	1209	external	T082	C0205101
28189069	1210	1224	magnetic field	T070	C0563533
28189069	1230	1237	glucose	T034	C0428548
28189069	1242	1260	cholesterol levels	T034	C0428466
28189069	1266	1274	measured	T080	C0444706
28189069	1278	1283	human	T016	C0086418
28189069	1284	1289	serum	T031	C0229671
28189069	1304	1318	microparticles	T104	C0597177
28189069	1326	1335	confirmed	T033	C0750484
28189069	1340	1349	potential	T080	C3245505
28189069	1369	1383	microparticles	T104	C0597177
28189069	1392	1398	sample	T167	C0370003
28189069	1399	1408	detection	T061	C1511790

28263181|t|The cancer Warburg effect may be a testable example of the minimum entropy production rate principle
28263181|a|Cancer cells consume more glucose by glycolytic fermentation to lactate than by respiration, a characteristic known as the Warburg effect. In contrast with the 34 moles of ATP produced by respiration, fermentation produces two moles of ATP per mole of glucose consumed, which poses a puzzle on the function of the Warburg effect. Productions of free energy (ΔG), enthalpy (ΔH) and entropy (ΔS) per mole linearly vary with the fraction (x) of glucose consumed by fermentation that is frequently estimated around 0.9. Hence, calculation shows that, in respect to pure respiration, the predominant fermentative metabolism decreases around 10% the production of entropy per mole of glucose consumed in cancer cells. We hypothesize that increased fermentation could allow cancer cells to accomplish the Prigogine theorem of the trend to minimize the rate of production of entropy. According the theorem, open cellular systems near the steady state could evolve to minimize the rates of entropy production that may be reached by modified replicating cells producing entropy at low rate. Remarkably, at CO2 concentrations above 930 ppm, glucose respiration produces less entropy than fermentation, which suggests experimental tests to validate the hypothesis of minimization of the rate of entropy production through the Warburg effect.
28263181	4	10	cancer	T191	C0006826
28263181	11	25	Warburg effect	T049	C1520120
28263181	35	43	testable	T169	C0332265
28263181	44	51	example	T077	C1707959
28263181	59	66	minimum	T080	C1524031
28263181	67	74	entropy	T067	C0376522
28263181	75	90	production rate	T081	C0392762
28263181	91	100	principle	T078	C0178566
28263181	101	113	Cancer cells	T025	C0334227
28263181	114	121	consume	T169	C0205245
28263181	127	134	glucose	T109,T121,T123	C0017725
28263181	138	161	glycolytic fermentation	T044	C1158288
28263181	165	172	lactate	T109,T121	C0376261
28263181	181	192	respiration	T039	C0035203
28263181	196	210	characteristic	T080	C1521970
28263181	224	238	Warburg effect	T049	C1520120
28263181	264	269	moles	T081	C0439189
28263181	273	276	ATP	T114,T121,T123	C0001480
28263181	289	300	respiration	T039	C0035203
28263181	302	314	fermentation	T044	C0015852
28263181	328	333	moles	T081	C0439189
28263181	337	340	ATP	T114,T121,T123	C0001480
28263181	345	349	mole	T081	C0439189
28263181	353	360	glucose	T109,T121,T123	C0017725
28263181	361	369	consumed	T169	C0205245
28263181	399	407	function	T169	C0542341
28263181	415	429	Warburg effect	T049	C1520120
28263181	431	442	Productions	T169	C0205245
28263181	446	457	free energy	T070	C0678591
28263181	459	461	ΔG	T070	C1637382
28263181	464	472	enthalpy	T081	C0599530
28263181	474	476	ΔH	T081	C1710184
28263181	482	489	entropy	T067	C0376522
28263181	491	493	ΔS	T080	C1710185
28263181	499	503	mole	T081	C0439189
28263181	504	512	linearly	T082	C0205132
28263181	527	542	fraction (x) of	T081	C1264633
28263181	543	550	glucose	T109,T121,T123	C0017725
28263181	551	559	consumed	T169	C0205245
28263181	563	575	fermentation	T044	C0015852
28263181	584	594	frequently	T079	C0332183
28263181	595	604	estimated	T081	C0750572
28263181	624	635	calculation	T052	C1441506
28263181	662	666	pure	T080	C0237400
28263181	667	678	respiration	T039	C0035203
28263181	696	708	fermentative	T044	C0015852
28263181	709	719	metabolism	T040	C0025519
28263181	720	729	decreases	T081	C0547047
28263181	745	755	production	T169	C0205245
28263181	759	766	entropy	T067	C0376522
28263181	771	775	mole	T081	C0439189
28263181	779	786	glucose	T109,T121,T123	C0017725
28263181	787	795	consumed	T169	C0205245
28263181	799	811	cancer cells	T025	C0334227
28263181	816	827	hypothesize	T078	C1512571
28263181	833	842	increased	T081	C0205217
28263181	843	855	fermentation	T044	C0015852
28263181	868	880	cancer cells	T025	C0334227
28263181	884	894	accomplish	T080	C0205556
28263181	899	916	Prigogine theorem	T170	C0282574
28263181	924	929	trend	T079	C1521798
28263181	933	941	minimize	T081	C0392762
28263181	946	950	rate	T081	C1521828
28263181	954	964	production	T169	C0205245
28263181	968	975	entropy	T067	C0376522
28263181	991	998	theorem	T170	C0282574
28263181	1000	1021	open cellular systems	T025	C0007634
28263181	1031	1043	steady state	T070	C0678587
28263181	1050	1056	evolve	T169	C1280477
28263181	1060	1068	minimize	T081	C0392762
28263181	1073	1078	rates	T081	C1521828
28263181	1082	1089	entropy	T067	C0376522
28263181	1090	1100	production	T169	C0205245
28263181	1124	1132	modified	T033	C0184511
28263181	1133	1144	replicating	T080	C1883725
28263181	1145	1150	cells	T025	C0007634
28263181	1161	1168	entropy	T067	C0376522
28263181	1176	1180	rate	T081	C1521828
28263181	1197	1200	CO2	T123,T197	C0007012
28263181	1201	1215	concentrations	T081	C1446561
28263181	1226	1229	ppm	T081	C0439187
28263181	1231	1238	glucose	T109,T121,T123	C0017725
28263181	1239	1250	respiration	T039	C0035203
28263181	1265	1272	entropy	T067	C0376522
28263181	1278	1290	fermentation	T044	C0015852
28263181	1307	1319	experimental	T080	C1517586
28263181	1320	1325	tests	T059	C0022885
28263181	1329	1337	validate	T080	C1456348
28263181	1342	1352	hypothesis	T078	C1512571
28263181	1356	1368	minimization	T081	C0392762
28263181	1376	1380	rate	T081	C1521828
28263181	1384	1391	entropy	T067	C0376522
28263181	1392	1402	production	T169	C0205245
28263181	1415	1429	Warburg effect	T049	C1520120

27832159|t|A Novel Selective Inhibitor of Delta-5 Desaturase Lowers Insulin Resistance and Reduces Body Weight in Diet -Induced Obese C57BL/6J Mice
27832159|a|Obesity is now recognized as a state of chronic low-grade inflammation and is called as metabolic inflammation. Delta-5 desaturase (D5D) is an enzyme that metabolizes dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA). Thus, D5D inhibition increases DGLA (precursor to anti-inflammatory eicosanoids) while decreasing AA (precursor to pro-inflammatory eicosanoids), and could result in synergistic improvement in the low-grade inflammatory state. Here, we demonstrate reduced insulin resistance and the anti-obesity effect of a D5D selective inhibitor (compound-326), an orally active small-molecule, in a high-fat diet -induced obese (DIO) mouse model. In vivo D5D inhibition was confirmed by determining changes in blood AA / DGLA profiles. In DIO mice, chronic treatment with compound-326 lowered insulin resistance and caused body weight loss without significant impact on cumulative calorie intake. Decreased macrophage infiltration into adipose tissue was expected from mRNA analysis. Increased daily energy expenditure was also observed following administration of compound-326, in line with sustained body weight loss. These data indicate that the novel D5D selective inhibitor, compound-326, will be a new class of drug for the treatment of obese and diabetic patients.
27832159	18	27	Inhibitor	T121	C0014432
27832159	31	49	Delta-5 Desaturase	T116,T126	C0057338
27832159	57	75	Insulin Resistance	T046	C0021655
27832159	80	99	Reduces Body Weight	T033	C1262477
27832159	103	107	Diet	T168	C0012155
27832159	117	122	Obese	T047	C0028754
27832159	123	136	C57BL/6J Mice	T015	C1521751
27832159	137	144	Obesity	T047	C0028754
27832159	195	207	inflammation	T046	C0021368
27832159	225	234	metabolic	T169	C0311400
27832159	235	247	inflammation	T046	C0021368
27832159	249	267	Delta-5 desaturase	T116,T126	C0057338
27832159	269	272	D5D	T116,T126	C0057338
27832159	280	286	enzyme	T116,T126	C0014442
27832159	304	327	dihomo-γ-linolenic acid	T109	C0000658
27832159	329	333	DGLA	T109	C0000658
27832159	338	354	arachidonic acid	T109	C0003695
27832159	356	358	AA	T109	C0003695
27832159	367	370	D5D	T116,T126	C0057338
27832159	371	381	inhibition	T039	C1524081
27832159	392	396	DGLA	T109	C0000658
27832159	411	428	anti-inflammatory	T080	C1515999
27832159	429	440	eicosanoids	T109	C0013725
27832159	459	461	AA	T109	C0003695
27832159	493	504	eicosanoids	T109	C0013725
27832159	527	538	synergistic	T080	C2986495
27832159	539	550	improvement	T077	C2986411
27832159	609	616	reduced	T080	C0392756
27832159	617	635	insulin resistance	T046	C0021655
27832159	644	656	anti-obesity	T121	C0376607
27832159	669	672	D5D	T116,T126	C0057338
27832159	694	706	compound-326	T121	C1254351
27832159	712	718	orally	T082	C0442027
27832159	726	740	small-molecule	T109	C1328819
27832159	747	760	high-fat diet	T168	C0453819
27832159	770	787	obese (DIO) mouse	T015	C0025933
27832159	788	793	model	T050	C0012644
27832159	803	806	D5D	T116,T126	C0057338
27832159	807	817	inhibition	T039	C1524081
27832159	858	863	blood	T031	C0005767
27832159	864	866	AA	T109	C0003695
27832159	869	873	DGLA	T109	C0000658
27832159	874	882	profiles	T059	C2022317
27832159	887	895	DIO mice	T015	C0025933
27832159	920	932	compound-326	T121	C1254351
27832159	941	959	insulin resistance	T046	C0021655
27832159	971	987	body weight loss	T033	C1262477
27832159	1029	1043	calorie intake	T081	C4281687
27832159	1055	1098	macrophage infiltration into adipose tissue	T033	C4014887
27832159	1117	1130	mRNA analysis	T059,T062	C0872262
27832159	1148	1166	energy expenditure	T039	C0014272
27832159	1195	1209	administration	T061	C1533734
27832159	1213	1225	compound-326	T121	C1254351
27832159	1250	1266	body weight loss	T033	C1262477
27832159	1303	1306	D5D	T116,T126	C0057338
27832159	1317	1326	inhibitor	T121	C0014432
27832159	1328	1340	compound-326	T121	C1254351
27832159	1391	1396	obese	T047	C0028754
27832159	1401	1409	diabetic	T047	C0011847
27832159	1410	1418	patients	T101	C0030705

27454379|t|How Can We Estimate Sepsis Incidence and Mortality?
27454379|a|Sepsis is one of the oldest and complex syndromes in medicine that has been in debate for over two millennia. Valid and comparable data on the population burden of sepsis constitute an essential resource for guiding health policy and resource allocation. Despite current epidemiological data suggesting that the global burden of sepsis is huge, the knowledge of its incidence, prevalence, mortality, and case-fatality rates is subject to several flaws. The objective of this narrative review is to assess how sepsis incidence and mortality can be estimated, providing examples on how it has been done so far in medical literature and discussing its possible biases. Results of recent studies suggest that sepsis incidence rates are increasing consistently during the last decades. Although estimates might be biased, this probably reflects a real increase in incidence over time. Nevertheless, case fatality rates have decreased, which is a probable reflex of advances in critical care provision to this very sick population at high risk of death. This conclusion can only be drawn with a reasonable degree of certainty for high-income countries. Conversely, adequately designed studies from middle - and low-income countries are urgently needed. In these countries, sepsis incidence and case-fatality rates could be disproportionally higher due to health care provision constraints and ineffective preventive measures.
27454379	11	19	Estimate	T081	C0750572
27454379	20	26	Sepsis	T047	C0243026
27454379	27	36	Incidence	T081	C0021149
27454379	41	50	Mortality	T081	C0205848
27454379	52	58	Sepsis	T047	C0243026
27454379	73	101	oldest and complex syndromes	T047	C0039082
27454379	105	113	medicine	T091	C0025118
27454379	131	137	debate	T052	C0870392
27454379	147	160	two millennia	T079	C2362314
27454379	162	167	Valid	T080	C2349099
27454379	172	182	comparable	T080	C2348205
27454379	183	187	data	T078	C1511726
27454379	195	205	population	T098	C1257890
27454379	206	212	burden	T078	C2828008
27454379	216	222	sepsis	T047	C0243026
27454379	247	255	resource	T078	C0035201
27454379	268	281	health policy	T089	C0018735
27454379	286	305	resource allocation	T081	C0086914
27454379	323	343	epidemiological data	T169	C1516907
27454379	364	387	global burden of sepsis	T170	C4277729
27454379	381	387	sepsis	T047	C0243026
27454379	418	439	incidence, prevalence	T081	C0683919
27454379	441	450	mortality	T081	C0205848
27454379	456	475	case-fatality rates	T081	C0282250
27454379	527	543	narrative review	UnknownType	C0815257
27454379	561	567	sepsis	T047	C0243026
27454379	568	577	incidence	T081	C0021149
27454379	582	591	mortality	T081	C0205848
27454379	599	608	estimated	T081	C0750572
27454379	620	628	examples	T077	C1707959
27454379	663	670	medical	T169	C0205476
27454379	671	681	literature	T170	C0023866
27454379	710	716	biases	T078	C0242568
27454379	757	763	sepsis	T047	C0243026
27454379	764	779	incidence rates	T081	C1708485
27454379	784	794	increasing	T169	C0442808
27454379	824	831	decades	T081	C2981279
27454379	842	851	estimates	T081	C0750572
27454379	861	867	biased	T078	C0242568
27454379	899	907	increase	T169	C0442805
27454379	911	920	incidence	T081	C0021149
27454379	926	930	time	T079	C0040223
27454379	946	965	case fatality rates	T081	C0282250
27454379	971	980	decreased	T081	C0205216
27454379	1024	1047	critical care provision	T091	C1547142
27454379	1061	1065	sick	T184	C0221423
27454379	1066	1076	population	T098	C1257890
27454379	1080	1098	high risk of death	T033	C0243095
27454379	1105	1115	conclusion	T078	C1707478
27454379	1152	1171	degree of certainty	T080	C0205556
27454379	1176	1187	high-income	T033	C0948433
27454379	1188	1197	countries	T083	C0454664
27454379	1244	1250	middle	T033	C0243095
27454379	1257	1267	low-income	T033	C1331016
27454379	1268	1277	countries	T083	C0454664
27454379	1308	1317	countries	T083	C0454664
27454379	1319	1325	sepsis	T047	C0243026
27454379	1326	1335	incidence	T081	C0021149
27454379	1340	1359	case-fatality rates	T081	C0282250
27454379	1401	1422	health care provision	T033	C1821241
27454379	1423	1434	constraints	T169	C0443288
27454379	1439	1450	ineffective	T078	C3242229
27454379	1451	1470	preventive measures	UnknownType	C0814446

27650514|t|Bystander fatigue and CPR quality by older bystanders: a randomized crossover trial comparing continuous chest compressions and 30:2 compressions to ventilations
27650514|a|This study sought to measure bystander fatigue and cardiopulmonary resuscitation (CPR) quality after five minutes of CPR using the continuous chest compression (CCC) versus the 30:2 chest compression to ventilation method in older lay persons, a population most likely to perform CPR on cardiac arrest victims. This randomized crossover trial took place at three tertiary care hospitals and a seniors' center. Participants were aged ≥55 years without significant physical limitations (frailty score ≤3/7). They completed two 5-minute CPR sessions (using 30:2 and CCC) on manikins; sessions were separated by a rest period. We used concealed block randomization to determine CPR method order. Metronome feedback maintained a compression rate of 100/minute. We measured heart rate (HR), mean arterial pressure (MAP), and Borg Exertion Scale. CPR quality measures included total number of compressions and number of adequate compressions (depth ≥5 cm). Sixty-three participants were enrolled: mean age 70.8 years, female 66.7%, past CPR training 60.3%. Bystander fatigue was similar between CPR methods: mean difference in HR -0.59 (95% CI -3.51-2.33), MAP 1.64 (95% CI -0.23-3.50), and Borg 0.46 (95% CI 0.07-0.84). Compared to 30:2, participants using CCC performed more chest compressions (480.0 v. 376.3, mean difference 107.7; p<0.0001) and more adequate chest compressions (381.5 v. 324.9, mean difference. 62.0; p=0.0001), although good compressions/minute declined significantly faster with the CCC method (p=0.0002). CPR quality decreased significantly faster when performing CCC compared to 30:2. However, performing CCC produced more adequate compressions overall with a similar level of fatigue compared to the 30:2 method.
27650514	0	17	Bystander fatigue	T184	C0015672
27650514	22	25	CPR	T061	C0007203
27650514	26	33	quality	T080	C0332306
27650514	37	53	older bystanders	T098	C1257890
27650514	57	83	randomized crossover trial	T062,T170	C0206034
27650514	94	123	continuous chest compressions	T058	C4032596
27650514	133	145	compressions	T058	C4032596
27650514	149	161	ventilations	T033	C0035213
27650514	191	208	bystander fatigue	T184	C0015672
27650514	213	242	cardiopulmonary resuscitation	T061	C0007203
27650514	244	247	CPR	T061	C0007203
27650514	249	256	quality	T080	C0332306
27650514	279	282	CPR	T061	C0007203
27650514	293	321	continuous chest compression	T058	C4032596
27650514	323	326	CCC	T058	C4032596
27650514	344	361	chest compression	T058	C4032596
27650514	365	383	ventilation method	T033	C0035213
27650514	387	404	older lay persons	T033	C3841539
27650514	408	418	population	T098	C1257890
27650514	442	445	CPR	T061	C0007203
27650514	449	463	cardiac arrest	T047	C0018790
27650514	464	471	victims	T098	C0680681
27650514	478	504	randomized crossover trial	T062,T170	C0206034
27650514	525	548	tertiary care hospitals	T073,T093	C0337954
27650514	555	570	seniors' center	T092	C3658240
27650514	572	584	Participants	T098	C0679646
27650514	613	645	significant physical limitations	T033	C3533159
27650514	647	660	frailty score	T033	C4075885
27650514	696	708	CPR sessions	T058	C0204928
27650514	725	728	CCC	T058	C4032596
27650514	733	741	manikins	T073	C0024722
27650514	743	751	sessions	T051	C1883016
27650514	793	802	concealed	T080	C0443189
27650514	803	822	block randomization	T062	C0034656
27650514	836	839	CPR	T061	C0007203
27650514	854	863	Metronome	T073	C0870887
27650514	886	902	compression rate	T081	C1521828
27650514	930	940	heart rate	T201	C0018810
27650514	942	944	HR	T201	C0018810
27650514	947	969	mean arterial pressure	T033	C0428886
27650514	971	974	MAP	T033	C0428886
27650514	981	1000	Borg Exertion Scale	T170	C0449399
27650514	1002	1005	CPR	T061	C0007203
27650514	1006	1013	quality	T080	C0332306
27650514	1038	1060	number of compressions	T058	C4032596
27650514	1075	1096	adequate compressions	T058	C4032596
27650514	1124	1136	participants	T098	C0679646
27650514	1173	1179	female	T032	C0086287
27650514	1192	1204	CPR training	T058	C0204928
27650514	1212	1229	Bystander fatigue	T184	C0015672
27650514	1250	1253	CPR	T061	C0007203
27650514	1263	1278	mean difference	T081	C0444504
27650514	1282	1284	HR	T201	C0018810
27650514	1296	1298	CI	T081	C0009667
27650514	1312	1315	MAP	T033	C0428886
27650514	1326	1328	CI	T081	C0009667
27650514	1346	1355	Borg 0.46	T033	C1301608
27650514	1361	1363	CI	T081	C0009667
27650514	1394	1406	participants	T098	C0679646
27650514	1413	1416	CCC	T058	C4032596
27650514	1432	1450	chest compressions	T058	C4032596
27650514	1468	1483	mean difference	T081	C0444504
27650514	1510	1537	adequate chest compressions	T058	C4032596
27650514	1555	1570	mean difference	T081	C0444504
27650514	1598	1622	good compressions/minute	T058	C4032596
27650514	1662	1672	CCC method	T058	C4032596
27650514	1685	1688	CPR	T061	C0007203
27650514	1689	1696	quality	T080	C0332306
27650514	1697	1706	decreased	T081	C0205216
27650514	1744	1747	CCC	T058	C4032596
27650514	1786	1789	CCC	T058	C4032596
27650514	1804	1825	adequate compressions	T058	C4032596
27650514	1849	1865	level of fatigue	T033	C2586108

27446916|t|Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
27446916|a|Prostate cancer (PCa) is the most common malignancy and the second most common cause of cancer death in Western men. Despite its prevalence, PCa has proven very difficult to propagate in vitro. PCa represents a complex organ-like multicellular structure maintained by the dynamic interaction of tumoral cells with parenchymal stroma, endothelial and immune cells, and components of the extracellular matrix (ECM). The lack of PCa models that recapitulate this intricate system has hampered progress toward understanding disease progression and lackluster therapeutic responses. Tissue slices, monolayer cultures and genetically engineered mouse models (GEMM) fail to mimic the complexities of the PCa microenvironment or reproduce the diverse mechanisms of therapy resistance. Moreover, patient derived xenografts (PDXs) are expensive, time consuming, difficult to establish for prostate cancer, lack immune cell-tumor regulation, and often tumors undergo selective engraftments. Here, we describe an interdisciplinary approach using primary PCa and tumor initiating cells (TICs), three-dimensional (3D) tissue engineering, genetic and morphometric profiling, and humanized mice to generate patient - derived organoids for examining personalized therapeutic responses in vitro and in mice co-engrafted with a human immune system (HIS), employing adaptive T-cell- and chimeric antigen receptor- (CAR) immunotherapy. The development of patient specific therapies targeting the vulnerabilities of cancer, when combined with antiproliferative and immunotherapy approaches could help to achieve the full transformative power of cancer precision medicine.
27446916	0	32	Personalized Medicine Approaches	T061	C2718059
27446916	36	51	Prostate Cancer	T191	C0600139
27446916	52	61	Employing	T169	C0457083
27446916	62	69	Patient	T101	C0030705
27446916	70	77	Derived	T080	C1441547
27446916	78	80	3D	T082	C0450363
27446916	81	90	Organoids	T024	C0029250
27446916	95	109	Humanized Mice	T015	C0025929
27446916	110	125	Prostate cancer	T191	C0600139
27446916	127	130	PCa	T191	C0600139
27446916	144	150	common	T081	C0205214
27446916	151	161	malignancy	T191	C4282132
27446916	182	188	common	T081	C0205214
27446916	189	194	cause	T169	C0015127
27446916	198	210	cancer death	T081	C1516192
27446916	214	221	Western	T082	C1705493
27446916	222	225	men	T098	C0025266
27446916	251	254	PCa	T191	C0600139
27446916	271	280	difficult	T080	C0332218
27446916	294	302	in vitro	T080	C1533691
27446916	304	307	PCa	T191	C0600139
27446916	321	328	complex	T080	C0439855
27446916	329	339	organ-like	T023	C0178784
27446916	340	363	multicellular structure	T082	C0678594
27446916	364	374	maintained	T169	C1314677
27446916	382	389	dynamic	T169	C0729333
27446916	390	401	interaction	T169	C1704675
27446916	405	418	tumoral cells	T025	C0597032
27446916	424	442	parenchymal stroma	T025	C0682552
27446916	444	455	endothelial	T025	C0225336
27446916	460	472	immune cells	T025	C0312740
27446916	478	488	components	T026	C0243092
27446916	496	516	extracellular matrix	T024	C0015350
27446916	518	521	ECM	T024	C0015350
27446916	528	532	lack	T080	C0332268
27446916	536	539	PCa	T191	C0600139
27446916	540	546	models	T050	C1516211
27446916	591	599	hampered	T079	C0205421
27446916	600	608	progress	T169	C1280477
27446916	616	629	understanding	T041	C0162340
27446916	630	649	disease progression	T046	C0242656
27446916	654	664	lackluster	T080	C0205222
27446916	665	686	therapeutic responses	T201	C0521982
27446916	688	701	Tissue slices	T062	C1519528
27446916	703	721	monolayer cultures	T059	C1510803
27446916	726	761	genetically engineered mouse models	T050	C1522222
27446916	763	767	GEMM	T050	C1522222
27446916	769	773	fail	T169	C0231175
27446916	787	799	complexities	T169	C0237523
27446916	807	810	PCa	T191	C0600139
27446916	845	852	diverse	T080	C1880371
27446916	853	863	mechanisms	T169	C0441712
27446916	867	874	therapy	T061	C0087111
27446916	875	885	resistance	T169	C4281815
27446916	897	923	patient derived xenografts	T050	C4050317
27446916	925	929	PDXs	T050	C4050317
27446916	946	960	time consuming	T080	C3827829
27446916	962	971	difficult	T080	C0332218
27446916	975	984	establish	T080	C0443211
27446916	989	1004	prostate cancer	T191	C0600139
27446916	1006	1010	lack	T080	C0332268
27446916	1011	1039	immune cell-tumor regulation	T040	C1819849
27446916	1051	1057	tumors	T191	C0027651
27446916	1076	1088	engraftments	T039	C0301944
27446916	1111	1137	interdisciplinary approach	T061	C0870721
27446916	1144	1151	primary	T080	C0205225
27446916	1152	1155	PCa	T191	C0600139
27446916	1160	1182	tumor initiating cells	T025	C1956421
27446916	1184	1188	TICs	T025	C1956421
27446916	1191	1208	three-dimensional	T082	C0450363
27446916	1210	1212	3D	T082	C0450363
27446916	1214	1232	tissue engineering	T061	C0596171
27446916	1234	1241	genetic	T059	C2986505
27446916	1246	1268	morphometric profiling	T059	C0200760
27446916	1274	1288	humanized mice	T015	C0025929
27446916	1301	1308	patient	T101	C0030705
27446916	1311	1318	derived	T080	C1441547
27446916	1319	1328	organoids	T024	C0029250
27446916	1343	1355	personalized	T080	C1709510
27446916	1356	1377	therapeutic responses	T201	C0521982
27446916	1378	1386	in vitro	T080	C1533691
27446916	1394	1398	mice	T015	C0025929
27446916	1399	1411	co-engrafted	T169	C0700106
27446916	1419	1438	human immune system	T022	C0020962
27446916	1440	1443	HIS	T022	C0020962
27446916	1456	1464	adaptive	T169	C0231193
27446916	1465	1472	T-cell-	T025	C0039194
27446916	1477	1503	chimeric antigen receptor-	T116,T129,T192	C4039583
27446916	1505	1508	CAR	T116,T129,T192	C4039583
27446916	1510	1523	immunotherapy	T061	C0021083
27446916	1544	1551	patient	T101	C0030705
27446916	1552	1560	specific	T080	C0205369
27446916	1561	1570	therapies	T061	C0087111
27446916	1571	1580	targeting	T169	C1521840
27446916	1585	1600	vulnerabilities	T033	C1821973
27446916	1604	1610	cancer	T191	C0600139
27446916	1617	1625	combined	T080	C0205195
27446916	1631	1648	antiproliferative	T061	C0087111
27446916	1653	1666	immunotherapy	T061	C0021083
27446916	1667	1677	approaches	T061	C0087111
27446916	1709	1723	transformative	T169	C0205245
27446916	1724	1729	power	T081	C3854080
27446916	1733	1739	cancer	T191	C0600139
27446916	1740	1758	precision medicine	T061	C2718059

27768206|t|Straight configuration saphenous vein transposition to popliteal artery for vascular access
27768206|a|The saphenous vein is commonly used as a vascular graft in peripheral artery surgery but rarely used for vascular access. The literature on straight configuration saphenous vein transposition to the popliteal artery is scarce. Here we present two cases of straight configuration saphenous vein transposition to the popliteal artery for vascular access, the surgical technique and respective follow-up. Two young men, aged 29 and 36 years, were chosen for lower-limb vascular access for hemodialysis. The first patient was paraplegic since birth. He used his arms to move so upper extremity vascular access was avoided. The second patient presented with an infected upper extremity arteriovenous graft (AVG) and after multiple closed AVFs he had no more available arm veins. Both patients received autologous lower extremity straight configuration saphenous vein transpositions to the popliteal artery under spinal anesthesia in May and October 2012, respectively. Cannulation of the fistula was allowed after one month. There were no early complications. Slight swelling on the leg appeared in one of the patients. Both fistulas were still functional after 36 and 32 months, respectively. The straight configuration saphenous vein transposition to popliteal artery is simple to perform, offers a long and straight segment for cannulation and may be a suitable autologous vascular access in selected patients.
27768206	0	37	Straight configuration saphenous vein	T023	C0036186
27768206	38	51	transposition	T061	C1293442
27768206	55	71	popliteal artery	T023	C0032649
27768206	76	91	vascular access	T074	C0750138
27768206	96	110	saphenous vein	T023	C0036186
27768206	133	147	vascular graft	T023	C0740038
27768206	151	168	peripheral artery	T023	C0489868
27768206	169	176	surgery	T061	C0543467
27768206	181	187	rarely	T080	C0522498
27768206	197	212	vascular access	T074	C0750138
27768206	218	228	literature	T170	C0023866
27768206	232	269	straight configuration saphenous vein	T023	C0036186
27768206	270	283	transposition	T061	C1293442
27768206	291	307	popliteal artery	T023	C0032649
27768206	311	317	scarce	T080	C0522498
27768206	348	385	straight configuration saphenous vein	T023	C0036186
27768206	386	399	transposition	T061	C1293442
27768206	407	423	popliteal artery	T023	C0032649
27768206	428	443	vascular access	T074	C0750138
27768206	449	467	surgical technique	T060	C0011918
27768206	483	492	follow-up	T058	C1522577
27768206	498	503	young	T100	C0238598
27768206	504	507	men	T098	C0025266
27768206	524	529	years	T079	C0439234
27768206	547	573	lower-limb vascular access	T061	C0457913
27768206	578	590	hemodialysis	T061	C0019004
27768206	602	609	patient	T101	C0030705
27768206	614	624	paraplegic	T047	C0030486
27768206	666	697	upper extremity vascular access	UnknownType	C0749854
27768206	722	729	patient	T101	C0030705
27768206	748	756	infected	T033	C0439663
27768206	757	792	upper extremity arteriovenous graft	UnknownType	C0749781
27768206	793	797	(AVG	UnknownType	C0749781
27768206	818	824	closed	T169	C0587267
27768206	825	829	AVFs	T190	C0003855
27768206	855	864	arm veins	T023	C0042449
27768206	871	879	patients	T101	C0030705
27768206	880	888	received	T080	C1514756
27768206	889	899	autologous	T080	C0439859
27768206	900	915	lower extremity	T023	C4266545
27768206	916	953	straight configuration saphenous vein	T023	C0036186
27768206	954	968	transpositions	T061	C1293442
27768206	976	992	popliteal artery	T023	C0032649
27768206	999	1016	spinal anesthesia	T061	C0002928
27768206	1056	1067	Cannulation	T061	C0917707
27768206	1075	1082	fistula	T190	C0080304
27768206	1105	1110	month	T079	C0439231
27768206	1123	1145	no early complications	T184	C0231243
27768206	1147	1162	Slight swelling	T033	C0038999
27768206	1170	1173	leg	T023	C1140621
27768206	1174	1182	appeared	T080	C0700364
27768206	1197	1205	patients	T101	C0030705
27768206	1212	1220	fistulas	T190	C0080304
27768206	1232	1242	functional	T169	C0205245
27768206	1259	1265	months	T079	C0439231
27768206	1285	1322	straight configuration saphenous vein	T023	C0036186
27768206	1323	1336	transposition	T061	C1293442
27768206	1340	1356	popliteal artery	T023	C0032649
27768206	1388	1413	long and straight segment	T082	C0441635
27768206	1418	1429	cannulation	T061	C0917707
27768206	1452	1462	autologous	T080	C0439859
27768206	1463	1478	vascular access	T074	C0750138
27768206	1491	1499	patients	T101	C0030705

28541870|t|Palmoplantar pustulosis - a cross-sectional analysis in Germany
28541870|a|Palmoplantar pustulosis (PPP) is a recalcitrant chronic inflammatory skin disease. Data relevant for the medical care of patients with PPP are scarce. Thus, the aim of this work was to investigate the disease burden, clinical characteristics, and comorbidity of PPP patients in Germany. PPP patients were examined in a crosssectional study at seven specialized psoriasis centers in Germany. Of the 172 included patients with PPP, 79.1% were female and 69.8% were smokers .In addition, 25.0% suffered from psoriasis vulgaris, 28.2% had documented psoriatic arthritis, and 30.2% had a family history of psoriasis. In 77 patients the mean Dermatology Life Quality Index (DLQI) was 12.2 ± 7.7 (mean ± SD). The mean Psoriasis Palmoplantar Pustulosis Area and Severity Index (PPPASI) was 12.6 ± 8.6. Mean body mass index was above average at 27.1 ± 5.5. The PPP patients had previously received an average of 2.6 ± 2.1 different anti-psoriatic systemic drugs or UV-therapies. The systemic drugs that had been used most frequently were corticosteroids in 40.1% of patients, followed by acitretin (37.8%), and methotrexate (27.9%). The PPPASI was 13.4 ± 8.9 in patients without current systemic therapy and 10.4 ± 7.9 in patients with systemic therapy. Many PPP patients had a concomitant diagnosis of psoriasis vulgaris and/or psoriatic arthritis or had a family history of psoriasis. Despite the fact that many of the patients were using anti-psoriatic therapies, there was still a high burden of disease within this PPP cohort. This insufficient control of symptoms demonstrates the urgent need for new PPP treatments.
28541870	0	23	Palmoplantar pustulosis	T047	C0030246
28541870	28	52	cross-sectional analysis	T062	C0010362
28541870	56	63	Germany	T083	C0017480
28541870	64	87	Palmoplantar pustulosis	T047	C0030246
28541870	89	92	PPP	T047	C0030246
28541870	112	119	chronic	T079	C0205191
28541870	120	145	inflammatory skin disease	T047	C3875321
28541870	169	181	medical care	T033	C0496675
28541870	185	193	patients	T101	C0030705
28541870	199	202	PPP	T047	C0030246
28541870	265	279	disease burden	T081	C0162698
28541870	281	305	clinical characteristics	T201	C0683325
28541870	311	322	comorbidity	T078	C0009488
28541870	326	329	PPP	T047	C0030246
28541870	330	338	patients	T101	C0030705
28541870	342	349	Germany	T083	C0017480
28541870	351	354	PPP	T047	C0030246
28541870	355	363	patients	T101	C0030705
28541870	413	442	specialized psoriasis centers	T093	C1708333
28541870	446	453	Germany	T083	C0017480
28541870	475	483	patients	T101	C0030705
28541870	489	492	PPP	T047	C0030246
28541870	505	511	female	T098	C0043210
28541870	527	534	smokers	T033	C0337664
28541870	569	587	psoriasis vulgaris	T047	C0263361
28541870	610	629	psoriatic arthritis	T047	C0003872
28541870	647	674	family history of psoriasis	T033	C0455439
28541870	682	690	patients	T101	C0030705
28541870	700	730	Dermatology Life Quality Index	T170	C0451112
28541870	732	736	DLQI	T170	C0451112
28541870	754	758	mean	T081	C0444504
28541870	761	763	SD	T081	C0871420
28541870	770	774	mean	T081	C0444504
28541870	775	784	Psoriasis	T047	C0033860
28541870	785	808	Palmoplantar Pustulosis	T047	C0030246
28541870	809	813	Area	T032	C0005902
28541870	818	832	Severity Index	T081	C0036859
28541870	834	840	PPPASI	T081	C0036859
28541870	858	862	Mean	T081	C0444504
28541870	863	878	body mass index	T201	C1305855
28541870	916	919	PPP	T047	C0030246
28541870	920	928	patients	T101	C0030705
28541870	987	1016	anti-psoriatic systemic drugs	T121	C1516001
28541870	1020	1032	UV-therapies	T061	C0041626
28541870	1038	1046	systemic	T169	C0205373
28541870	1047	1052	drugs	T121	C1254351
28541870	1093	1108	corticosteroids	T109,T121,T125	C0001617
28541870	1121	1129	patients	T101	C0030705
28541870	1143	1152	acitretin	T109,T121	C0050559
28541870	1166	1178	methotrexate	T109,T121	C0025677
28541870	1192	1198	PPPASI	T081	C0036859
28541870	1217	1225	patients	T101	C0030705
28541870	1226	1233	without	T080	C0332288
28541870	1242	1258	systemic therapy	T061	C1515119
28541870	1277	1285	patients	T101	C0030705
28541870	1291	1307	systemic therapy	T061	C1515119
28541870	1314	1317	PPP	T047	C0030246
28541870	1318	1326	patients	T101	C0030705
28541870	1333	1344	concomitant	T079	C0521115
28541870	1345	1354	diagnosis	T033	C0011900
28541870	1358	1376	psoriasis vulgaris	T047	C0263361
28541870	1384	1403	psoriatic arthritis	T047	C0003872
28541870	1413	1440	family history of psoriasis	T033	C0455439
28541870	1476	1484	patients	T101	C0030705
28541870	1496	1520	anti-psoriatic therapies	T061	C3258078
28541870	1545	1562	burden of disease	T081	C0162698
28541870	1575	1578	PPP	T047	C0030246
28541870	1592	1604	insufficient	T080	C0231180
28541870	1605	1624	control of symptoms	T061	C1274136
28541870	1662	1665	PPP	T047	C0030246
28541870	1666	1676	treatments	T061	C0087111

28363782|t|Fyn regulates multipolar - bipolar transition and neurite morphogenesis of migrating neurons in the developing neocortex
28363782|a|Fyn is a non-receptor protein tyrosine kinase that belongs to Src family kinases. Fyn plays a critical role in neuronal migration, but the mechanism remains unclear. Here, we reported that suppression of Fyn expression in mouse cerebral cortex led to migration defects of both early-born and late-born neurons. Morphological analysis showed that loss of Fyn function impaired multipolar - bipolar transition of newly generated neurons and neurite formation in the early phase of migration. Moreover, Fyn inhibition increased the length of leading process and decreased the branching number of the migrating cortical neurons. Together, these results indicate that Fyn controls neuronal migration by regulating the cytoskeletal dynamics and multipolar - bipolar transition of newly generated neurons during cortical development.
28363782	0	3	Fyn	T116,T126	C1442788
28363782	14	24	multipolar	T082	C1254362
28363782	27	34	bipolar	T082	C0443156
28363782	35	45	transition	T052	C2700061
28363782	50	71	neurite morphogenesis	T043	C1753129
28363782	75	92	migrating neurons	T043	C1326504
28363782	100	120	developing neocortex	T042	C1818475
28363782	121	124	Fyn	T116,T126	C1442788
28363782	130	142	non-receptor	T033	C0243095
28363782	143	166	protein tyrosine kinase	T116,T126	C0033681
28363782	183	201	Src family kinases	T116,T126	C0282625
28363782	203	206	Fyn	T116,T126	C1442788
28363782	232	250	neuronal migration	T043	C1326504
28363782	260	269	mechanism	T169	C0441712
28363782	278	285	unclear	T033	C3845108
28363782	310	321	suppression	T045	C0038855
28363782	325	328	Fyn	T116,T126	C1442788
28363782	329	339	expression	T045	C1171362
28363782	343	364	mouse cerebral cortex	T024	C1522579
28363782	372	389	migration defects	T033	C2750249
28363782	398	408	early-born	T079	C1279919
28363782	413	422	late-born	T079	C0205087
28363782	423	430	neurons	T025	C0027882
28363782	432	445	Morphological	T082	C0543482
28363782	446	454	analysis	T062	C0936012
28363782	475	478	Fyn	T116,T126	C1442788
28363782	497	507	multipolar	T082	C1254362
28363782	510	517	bipolar	T082	C0443156
28363782	518	528	transition	T052	C2700061
28363782	538	547	generated	T052	C3146294
28363782	548	555	neurons	T025	C0027882
28363782	560	577	neurite formation	T043	C1753129
28363782	591	596	phase	T079	C0205390
28363782	600	609	migration	T043	C1326504
28363782	621	624	Fyn	T116,T126	C1442788
28363782	625	635	inhibition	T045	C1519619
28363782	660	675	leading process	T043	C0007613
28363782	694	703	branching	T082	C0205384
28363782	718	744	migrating cortical neurons	T043	C1326504
28363782	784	787	Fyn	T116,T126	C1442788
28363782	788	796	controls	T169	C2587213
28363782	797	815	neuronal migration	T043	C1326504
28363782	819	829	regulating	T038	C1327622
28363782	834	846	cytoskeletal	T026	C0010853
28363782	847	855	dynamics	T070	C3826426
28363782	860	870	multipolar	T082	C1254362
28363782	873	880	bipolar	T082	C0443156
28363782	881	891	transition	T052	C2700061
28363782	895	900	newly	T078	C0750546
28363782	901	910	generated	T052	C3146294
28363782	911	918	neurons	T025	C0027882
28363782	926	946	cortical development	T042	C1818475

27571385|t|Diagnostic Accuracy of Anthropometric Indicators in the Prediction of Urinary Incontinence in Physically Active Older Women
27571385|a|Purpose To determine the diagnostic accuracy and the cutoff point of the variables conicity index, waist to height ratio and fat percentage to detect urinary incontinence in physically active older women. Method A total of 152 women were analyzed. The instruments used were the International Physical Activity Questionnaire (IPAQ [Area 4]) to check the level of physical activity, and the Diagnostic Form to obtain sociodemographic data and presence of urinary incontinence. To calculate the conicity index, waist to height ratio and fat percentage, body mass, height and waist circumference were measured. Descriptive and inferential statistics were used. Cutoff points, sensitivity (S) and specificity (SP) were determined by receiver operating characteristic (ROC) curves. A 5% significance level was adopted. Results The prevalence of urinary incontinence was of 32.2%. The cutoff point with better sensitivity and specificity for the conicity index was 1.23 (S = 87.8; SP = 35.9); for the waist to height ratio, it was 0.57 (S = 79.6; SP = 45.6); and for the fat percentage, it was 39.71 (S = 89.8; SP = 42.7). The area under the ROC curve was 0.666 for the conicity index, 0.653 for the waist to height ratio, and 0.660 for the fat percentage. Conclusions The cutoff points for the anthropometric measurements conicity index, waist to height ratio and fat percentage indicate that these measures can be used to predict urinary incontinence in physically active older women. Furthermore, fat percentage seemed to be the best measure for this population.
27571385	0	19	Diagnostic Accuracy	T080	C0598285
27571385	23	48	Anthropometric Indicators	T170	C2598146
27571385	56	66	Prediction	T078	C0681842
27571385	70	90	Urinary Incontinence	T046	C0042024
27571385	94	111	Physically Active	T033	C0556453
27571385	112	123	Older Women	T098	C0043210
27571385	149	168	diagnostic accuracy	T080	C0598285
27571385	177	189	cutoff point	T080	C0205556
27571385	197	221	variables conicity index	T170	C0918012
27571385	223	244	waist to height ratio	T033	C1821269
27571385	249	263	fat percentage	T033	C0518026
27571385	267	273	detect	T033	C0442726
27571385	274	294	urinary incontinence	T046	C0042024
27571385	298	315	physically active	T033	C0556453
27571385	316	327	older women	T098	C0043210
27571385	351	356	women	T098	C0043210
27571385	362	370	analyzed	T062	C0936012
27571385	376	387	instruments	T074	C0348000
27571385	402	447	International Physical Activity Questionnaire	T170	C4264334
27571385	449	453	IPAQ	T170	C4264334
27571385	467	472	check	T052	C1283174
27571385	477	482	level	T080	C0441889
27571385	486	503	physical activity	T056	C0026606
27571385	513	523	Diagnostic	T169	C0348026
27571385	524	528	Form	T080	C0348078
27571385	539	555	sociodemographic	T033	C0578829
27571385	556	560	data	T078	C1511726
27571385	565	573	presence	T033	C0150312
27571385	577	597	urinary incontinence	T046	C0042024
27571385	602	611	calculate	T052	C1441506
27571385	616	630	conicity index	T170	C0918012
27571385	632	653	waist to height ratio	T033	C1821269
27571385	658	672	fat percentage	T033	C0518026
27571385	674	683	body mass	T033	C0518010
27571385	685	715	height and waist circumference	T081	C0332520
27571385	721	729	measured	T080	C0444706
27571385	731	742	Descriptive	T170	C0678257
27571385	747	769	inferential statistics	T081	C2828391
27571385	781	794	Cutoff points	T080	C0205556
27571385	796	807	sensitivity	T081	C1511883
27571385	809	810	S	T081	C1511883
27571385	816	827	specificity	T081	C0037791
27571385	829	831	SP	T081	C0037791
27571385	838	851	determined by	T080	C0521095
27571385	852	898	receiver operating characteristic (ROC) curves	T081	C0035787
27571385	905	923	significance level	T062	C0814896
27571385	949	959	prevalence	T081	C0033105
27571385	963	983	urinary incontinence	T046	C0042024
27571385	1002	1014	cutoff point	T080	C0205556
27571385	1027	1038	sensitivity	T081	C1511883
27571385	1043	1054	specificity	T081	C0037791
27571385	1063	1077	conicity index	T170	C0918012
27571385	1088	1089	S	T081	C1511883
27571385	1098	1100	SP	T081	C0037791
27571385	1118	1139	waist to height ratio	T033	C1821269
27571385	1154	1155	S	T081	C1511883
27571385	1164	1166	SP	T081	C0037791
27571385	1188	1202	fat percentage	T033	C0518026
27571385	1218	1219	S	T081	C1511883
27571385	1228	1230	SP	T081	C0037791
27571385	1259	1268	ROC curve	T081	C0035787
27571385	1287	1301	conicity index	T170	C0918012
27571385	1317	1338	waist to height ratio	T033	C1821269
27571385	1358	1372	fat percentage	T033	C0518026
27571385	1390	1403	cutoff points	T080	C0205556
27571385	1412	1439	anthropometric measurements	T170	C2598146
27571385	1440	1454	conicity index	T170	C0918012
27571385	1456	1477	waist to height ratio	T033	C1821269
27571385	1482	1496	fat percentage	T033	C0518026
27571385	1517	1525	measures	T081	C0079809
27571385	1549	1569	urinary incontinence	T046	C0042024
27571385	1573	1590	physically active	T033	C0556453
27571385	1591	1602	older women	T098	C0043210
27571385	1617	1631	fat percentage	T033	C0518026
27571385	1654	1661	measure	T081	C0079809
27571385	1671	1681	population	T098	C1257890

27821673|t|Effect of Core Stability Training on Trunk Function, Standing Balance, and Mobility in Stroke Patients
27821673|a|Trunk function is important for standing balance, mobility, and functional outcome after stroke, but few studies have evaluated the effects of exercises aimed at improving core stability in stroke patients. To investigate the effectiveness of core stability training on trunk function, standing balance, and mobility in stroke patients. An assessor-blinded, randomized controlled trial was undertaken in a stroke rehabilitation ward, with 32 participants randomly assigned to an experimental group or a control group (n = 16 each). The experimental group received 400 minutes of core stability training in place of conventional programs within total training time, while the control group received only conventional programs. Primary outcome measures were evaluated using the Trunk Impairment Scale (TIS), which reflects trunk function. Secondary outcome measures were evaluated by pelvic tilt active range of motion in the sagittal plane, the Balance Evaluation Systems Test-brief version (Brief-BESTest), Functional Reach test, Timed Up-and-Go test (TUG), and Functional Ambulation Categories (FAC). A general linear repeated-measures model was used to analyze the results. A treatment effect was found for the experimental group on the dynamic balance subscale and total score of the TIS (P = .002 and P < .001, respectively), pelvic tilt active range of motion (P < .001), Brief-BESTest (P < .001), TUG (P = .008), and FAC (P = .022). Core stability training has beneficial effects on trunk function, standing balance, and mobility in stroke patients. Our findings might provide support for introducing core stability training in stroke rehabilitation.
27821673	0	6	Effect	T080	C1280500
27821673	10	24	Core Stability	T042	C0231432
27821673	25	33	Training	T065	C0220931
27821673	37	42	Trunk	T029	C0460005
27821673	43	51	Function	T169	C0542341
27821673	53	69	Standing Balance	T033	C0516711
27821673	75	83	Mobility	T080	C0449580
27821673	87	93	Stroke	T047	C0038454
27821673	94	102	Patients	T101	C0030705
27821673	103	108	Trunk	T029	C0460005
27821673	109	117	function	T169	C0542341
27821673	135	151	standing balance	T033	C0516711
27821673	153	161	mobility	T080	C0449580
27821673	167	177	functional	T169	C0205245
27821673	178	185	outcome	T169	C1274040
27821673	192	198	stroke	T047	C0038454
27821673	221	230	evaluated	T058	C0220825
27821673	235	245	effects of	T080	C1704420
27821673	246	255	exercises	T061	C0452240
27821673	275	289	core stability	T042	C0231432
27821673	293	299	stroke	T047	C0038454
27821673	300	308	patients	T101	C0030705
27821673	313	324	investigate	T169	C1292732
27821673	329	342	effectiveness	T080	C1280519
27821673	346	360	core stability	T042	C0231432
27821673	361	369	training	T065	C0220931
27821673	373	378	trunk	T029	C0460005
27821673	379	387	function	T169	C0542341
27821673	389	405	standing balance	T033	C0516711
27821673	411	419	mobility	T080	C0449580
27821673	423	429	stroke	T047	C0038454
27821673	430	438	patients	T101	C0030705
27821673	443	459	assessor-blinded	T062	C0150108
27821673	461	488	randomized controlled trial	T062,T170	C0282440
27821673	509	515	stroke	T047	C0038454
27821673	516	535	rehabilitation ward	T073,T093	C0034993
27821673	545	557	participants	T098	C0679646
27821673	558	575	randomly assigned	UnknownType	C0814868
27821673	582	600	experimental group	T078	C0441833
27821673	606	619	control group	T096	C0009932
27821673	639	657	experimental group	T078	C0441833
27821673	682	696	core stability	T042	C0231432
27821673	697	705	training	T065	C0220931
27821673	718	730	conventional	T080	C0439858
27821673	731	739	programs	T169	C3484370
27821673	753	761	training	T065	C0220931
27821673	778	791	control group	T096	C0009932
27821673	806	818	conventional	T080	C0439858
27821673	819	827	programs	T169	C3484370
27821673	837	853	outcome measures	T081	C0086749
27821673	879	901	Trunk Impairment Scale	T170	C0349674
27821673	903	906	TIS	T170	C0349674
27821673	924	929	trunk	T029	C0460005
27821673	930	938	function	T169	C0542341
27821673	950	966	outcome measures	T081	C0086749
27821673	985	996	pelvic tilt	T033	C1629036
27821673	997	1019	active range of motion	T032	C1879548
27821673	1027	1041	sagittal plane	T029	C0935598
27821673	1047	1092	Balance Evaluation Systems Test-brief version	T170	C0392366
27821673	1094	1107	Brief-BESTest	T170	C0392366
27821673	1110	1131	Functional Reach test	T060	C1998271
27821673	1133	1153	Timed Up-and-Go test	T060	C3161512
27821673	1155	1158	TUG	T060	C3161512
27821673	1165	1197	Functional Ambulation Categories	T061	C1160972
27821673	1199	1202	FAC	T061	C1160972
27821673	1207	1245	general linear repeated-measures model	T081,T170	C0026348
27821673	1281	1297	treatment effect	T033	C1518681
27821673	1316	1334	experimental group	T078	C0441833
27821673	1342	1349	dynamic	T169	C0729333
27821673	1350	1366	balance subscale	T170	C0282574
27821673	1371	1382	total score	T081	C2964552
27821673	1390	1393	TIS	T170	C0349674
27821673	1433	1444	pelvic tilt	T033	C1629036
27821673	1445	1467	active range of motion	T032	C1879548
27821673	1480	1493	Brief-BESTest	T170	C0392366
27821673	1506	1509	TUG	T060	C3161512
27821673	1542	1556	Core stability	T042	C0231432
27821673	1557	1565	training	T065	C0220931
27821673	1570	1580	beneficial	T081	C0814225
27821673	1581	1588	effects	T080	C1280500
27821673	1592	1597	trunk	T029	C0460005
27821673	1598	1606	function	T169	C0542341
27821673	1608	1624	standing balance	T033	C0516711
27821673	1630	1638	mobility	T080	C0449580
27821673	1642	1648	stroke	T047	C0038454
27821673	1649	1657	patients	T101	C0030705
27821673	1710	1724	core stability	T042	C0231432
27821673	1725	1733	training	T065	C0220931
27821673	1737	1743	stroke	T047	C0038454
27821673	1744	1758	rehabilitation	T169	C0034992

27412144|t|Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke
27412144|a|To determine whether large (≥3 mm thick) but nonstenotic (<50%) carotid artery atherosclerotic plaque predominantly occurs ipsilateral rather than contralateral to cryptogenic stroke. This was a cross-sectional observational study. Using a stroke registry, we identified consecutive patients with anterior circulation embolic stroke of undetermined source (ESUS). Using CT angiography, we measured carotid plaque size (thickness, mm) and carotid artery stenosis (North American Symptomatic Carotid Endarterectomy Trial method) for each patient. We dichotomized plaque size at several predefined thresholds and calculated the frequency of plaque size above each threshold ipsilateral vs contralateral to stroke. We included 85 patients with ESUS. Plaque with thickness ≥5 mm was present ipsilateral to stroke in 11% of patients, and contralateral in 1% (9/85 vs 1/85; p = 0.008). Plaque with thickness ≥4 mm was present ipsilateral to stroke in 19% of patients, and contralateral in 5% (16/85 vs 4/85; p = 0.002). Plaque with thickness ≥3 mm was present ipsilateral to stroke in 35% of patients, and contralateral in 15% (30/85 vs 13/85; p = 0.001). There was no difference in percentage stenosis ipsilateral vs contralateral to stroke (p = 0.98), and weak correlation between plaque size and stenosis (R(2) = 0.26, p < 0.001). Large but nonstenotic carotid artery plaque is considerably more common ipsilateral than contralateral to cryptogenic stroke, suggesting that nonstenotic plaque is an underrecognized cause of stroke. We measured plaque size using CT angiography, a method that could be easily implemented in clinical practice.
27412144	0	11	Nonstenotic	T033	C0243095
27412144	12	26	carotid plaque	T020	C0751633
27412144	30	44	CT angiography	T060	C1536105
27412144	48	56	patients	T101	C0030705
27412144	62	73	cryptogenic	T169	C0332240
27412144	74	80	stroke	T047	C0038454
27412144	126	137	nonstenotic	T033	C0243095
27412144	145	182	carotid artery atherosclerotic plaque	T020	C0751633
27412144	204	215	ipsilateral	T082	C0441989
27412144	228	241	contralateral	T082	C0441988
27412144	245	256	cryptogenic	T169	C0332240
27412144	257	263	stroke	T047	C0038454
27412144	276	311	cross-sectional observational study	T062	C0010362
27412144	321	327	stroke	T047	C0038454
27412144	328	336	registry	T170	C0034975
27412144	352	363	consecutive	T080	C1707491
27412144	364	372	patients	T101	C0030705
27412144	378	436	anterior circulation embolic stroke of undetermined source	T047	C0393964
27412144	438	442	ESUS	T047	C3888970
27412144	451	465	CT angiography	T060	C1536105
27412144	479	493	carotid plaque	T020	C0751633
27412144	494	498	size	T082	C0456389
27412144	500	509	thickness	T080	C1280412
27412144	519	542	carotid artery stenosis	T047	C0007282
27412144	544	606	North American Symptomatic Carotid Endarterectomy Trial method	T170	C3889639
27412144	617	624	patient	T101	C0030705
27412144	629	641	dichotomized	T080	C0205556
27412144	642	648	plaque	T020	C0751633
27412144	649	653	size	T082	C0456389
27412144	676	686	thresholds	T080	C0449864
27412144	706	715	frequency	T080	C1561548
27412144	719	725	plaque	T020	C0751633
27412144	726	730	size	T082	C0456389
27412144	742	751	threshold	T080	C0449864
27412144	752	763	ipsilateral	T082	C0441989
27412144	767	780	contralateral	T082	C0441988
27412144	784	790	stroke	T047	C0038454
27412144	807	815	patients	T101	C0030705
27412144	821	825	ESUS	T047	C3888970
27412144	827	833	Plaque	T020	C0751633
27412144	839	848	thickness	T080	C1280412
27412144	867	878	ipsilateral	T082	C0441989
27412144	882	888	stroke	T047	C0038454
27412144	899	907	patients	T101	C0030705
27412144	913	926	contralateral	T082	C0441988
27412144	960	966	Plaque	T020	C0751633
27412144	972	981	thickness	T080	C1280412
27412144	1000	1011	ipsilateral	T082	C0441989
27412144	1015	1021	stroke	T047	C0038454
27412144	1032	1040	patients	T101	C0030705
27412144	1046	1059	contralateral	T082	C0441988
27412144	1094	1100	Plaque	T020	C0751633
27412144	1106	1115	thickness	T080	C1280412
27412144	1134	1145	ipsilateral	T082	C0441989
27412144	1149	1155	stroke	T047	C0038454
27412144	1166	1174	patients	T101	C0030705
27412144	1180	1193	contralateral	T082	C0441988
27412144	1268	1276	stenosis	T047	C0007282
27412144	1277	1288	ipsilateral	T082	C0441989
27412144	1292	1305	contralateral	T082	C0441988
27412144	1309	1315	stroke	T047	C0038454
27412144	1357	1363	plaque	T020	C0751633
27412144	1364	1368	size	T082	C0456389
27412144	1373	1381	stenosis	T047	C0007282
27412144	1418	1429	nonstenotic	T033	C0243095
27412144	1430	1451	carotid artery plaque	T020	C0751633
27412144	1480	1491	ipsilateral	T082	C0441989
27412144	1497	1510	contralateral	T082	C0441988
27412144	1514	1525	cryptogenic	T169	C0332240
27412144	1526	1532	stroke	T047	C0038454
27412144	1550	1561	nonstenotic	T033	C0243095
27412144	1562	1568	plaque	T020	C0751633
27412144	1600	1606	stroke	T047	C0038454
27412144	1620	1626	plaque	T020	C0751633
27412144	1627	1631	size	T082	C0456389
27412144	1638	1652	CT angiography	T060	C1536105
27412144	1699	1716	clinical practice	T201	C0683325

28373627|t|Effects of Transplanted Human Cord Blood - Mononuclear Cells on Pulmonary Hypertension in Immunodeficient Mice and Their Distribution
28373627|a|To investigate the effects of human umbilical cord blood -derived mononuclear cell (hUCB - MNC) transplantation on pulmonary hypertension (PH) induced by monocrotaline (MCT) in immunodeficient mice and their distribution. MCT was administered to BALB/c Slc-nu/nu mice, and PH was induced in mice 4 weeks later. Fresh hUCB - MNCs harvested from a human donor after her delivery were injected intravenously into those PH mice. The medial thickness of pulmonary arterioles, ratio of right ventricular to septum plus left ventricular weight (RV / S + LV), and ratio of acceleration time to ejection time of pulmonary blood flow waveform (AT / ET) were determined 4 weeks after hUCB - MNC transplantation. To reveal the incorporation into the lung, CMTMR - labeled hUCB - MNCs were observed in the lung by fluorescent microscopy. DiR-labeled hUCB - MNCs were detected in the lung and other organs by bioluminescence images. Medial thickness, RV / S + LV and AT / ET were significantly improved 4 weeks after hUCB - MNC transplantation compared with those in mice without hUCB - MNC transplantation. CMTMR - positive hUCB - MNCs were observed in the lung 3 hours after transplantation. Bioluminescence signals were detected more strongly in the lung than in other organs for 24 hours after transplantation. The results indicate that hUCB - MNCs are incorporated into the lung early after hUCB - MNC transplantation and improve MCT - induced PH. J. Med. Invest. 64: 43-49, February, 2017.
28373627	0	7	Effects	T080	C1280500
28373627	11	23	Transplanted	T061	C0935850
28373627	24	29	Human	T016	C0086418
28373627	30	40	Cord Blood	T031	C0162371
28373627	43	60	Mononuclear Cells	T025	C0806987
28373627	64	86	Pulmonary Hypertension	T046	C0020542
28373627	90	110	Immunodeficient Mice	T015	C0599920
28373627	121	133	Distribution	T169	C1704711
28373627	137	148	investigate	T058	C0220825
28373627	153	160	effects	T080	C1280500
28373627	164	169	human	T016	C0086418
28373627	170	190	umbilical cord blood	T031	C0162371
28373627	200	216	mononuclear cell	T025	C0806987
28373627	218	222	hUCB	T031	C0162371
28373627	225	228	MNC	T025	C0806987
28373627	230	245	transplantation	T061	C0935850
28373627	249	271	pulmonary hypertension	T046	C0020542
28373627	273	275	PH	T046	C0020542
28373627	277	284	induced	T169	C0205263
28373627	288	301	monocrotaline	T109,T131	C0085241
28373627	303	306	MCT	T109,T131	C0085241
28373627	311	331	immunodeficient mice	T015	C0599920
28373627	342	354	distribution	T169	C1704711
28373627	356	359	MCT	T109,T131	C0085241
28373627	364	376	administered	T169	C1521801
28373627	380	401	BALB/c Slc-nu/nu mice	T015	C0025919
28373627	407	409	PH	T046	C0020542
28373627	414	421	induced	T169	C0205263
28373627	425	429	mice	T015	C0025919
28373627	445	450	Fresh	T080	C0443224
28373627	451	455	hUCB	T031	C0162371
28373627	458	462	MNCs	T025	C0806987
28373627	463	472	harvested	T061	C0411265
28373627	480	485	human	T016	C0086418
28373627	486	491	donor	T098	C0013018
28373627	502	510	delivery	T169	C1705822
28373627	516	538	injected intravenously	T169	C0021494
28373627	550	552	PH	T046	C0020542
28373627	553	557	mice	T015	C0025919
28373627	563	569	medial	T082	C0205098
28373627	570	579	thickness	T080	C1280412
28373627	583	603	pulmonary arterioles	T023	C4243802
28373627	605	610	ratio	T081	C0456603
28373627	614	631	right ventricular	T023	C0225883
28373627	635	641	septum	T023	C0018819
28373627	642	646	plus	T169	C0332287
28373627	647	663	left ventricular	T023	C0225897
28373627	664	670	weight	T081	C0043100
28373627	672	674	RV	T023	C0225883
28373627	677	678	S	T023	C0018819
28373627	681	683	LV	T023	C0225897
28373627	690	695	ratio	T081	C0456603
28373627	699	716	acceleration time	T081	C3655682
28373627	720	733	ejection time	T201	C0812388
28373627	737	757	pulmonary blood flow	T201	C4071554
28373627	758	766	waveform	T070	C0450448
28373627	768	770	AT	T081	C3655682
28373627	773	775	ET	T201	C0812388
28373627	782	792	determined	T080	C0521095
28373627	807	811	hUCB	T031	C0162371
28373627	814	817	MNC	T025	C0806987
28373627	818	833	transplantation	T061	C0935850
28373627	838	844	reveal	T080	C0443289
28373627	849	862	incorporation	T169	C0243126
28373627	872	876	lung	T023	C0024109
28373627	878	883	CMTMR	T109,T121	C0761898
28373627	886	893	labeled	T130	C1522485
28373627	894	898	hUCB	T031	C0162371
28373627	901	905	MNCs	T025	C0806987
28373627	911	919	observed	T169	C1441672
28373627	927	931	lung	T023	C0024109
28373627	935	957	fluorescent microscopy	T059	C0026022
28373627	959	970	DiR-labeled	T130,T196	C0034551
28373627	971	975	hUCB	T031	C0162371
28373627	978	982	MNCs	T025	C0806987
28373627	988	996	detected	T033	C0442726
28373627	1004	1008	lung	T023	C0024109
28373627	1019	1025	organs	T023	C0178784
28373627	1029	1051	bioluminescence images	T074	C2955764
28373627	1053	1059	Medial	T082	C0205098
28373627	1060	1069	thickness	T080	C1280412
28373627	1071	1073	RV	T023	C0225883
28373627	1076	1077	S	T023	C0018819
28373627	1080	1082	LV	T023	C0225897
28373627	1087	1089	AT	T081	C3655682
28373627	1092	1094	ET	T201	C0812388
28373627	1100	1113	significantly	T078	C0750502
28373627	1114	1122	improved	T033	C0184511
28373627	1137	1141	hUCB	T031	C0162371
28373627	1144	1147	MNC	T025	C0806987
28373627	1148	1163	transplantation	T061	C0935850
28373627	1164	1172	compared	T052	C1707455
28373627	1187	1191	mice	T015	C0025919
28373627	1200	1204	hUCB	T031	C0162371
28373627	1207	1210	MNC	T025	C0806987
28373627	1211	1226	transplantation	T061	C0935850
28373627	1228	1233	CMTMR	T109,T121	C0761898
28373627	1236	1244	positive	T033	C1446409
28373627	1245	1249	hUCB	T031	C0162371
28373627	1252	1256	MNCs	T025	C0806987
28373627	1262	1270	observed	T169	C1441672
28373627	1278	1282	lung	T023	C0024109
28373627	1297	1312	transplantation	T061	C0935850
28373627	1314	1329	Bioluminescence	T038	C0162404
28373627	1330	1337	signals	T067	C1710082
28373627	1343	1351	detected	T033	C0442726
28373627	1357	1365	strongly	T080	C0442821
28373627	1373	1377	lung	T023	C0024109
28373627	1392	1398	organs	T023	C0178784
28373627	1418	1433	transplantation	T061	C0935850
28373627	1439	1446	results	T033	C0683954
28373627	1447	1455	indicate	T033	C1444656
28373627	1461	1465	hUCB	T031	C0162371
28373627	1468	1472	MNCs	T025	C0806987
28373627	1477	1489	incorporated	T169	C0243126
28373627	1499	1503	lung	T023	C0024109
28373627	1504	1509	early	T079	C1279919
28373627	1516	1520	hUCB	T031	C0162371
28373627	1523	1526	MNC	T025	C0806987
28373627	1527	1542	transplantation	T061	C0935850
28373627	1547	1554	improve	T033	C0184511
28373627	1555	1558	MCT	T109,T131	C0085241
28373627	1561	1568	induced	T169	C0205263
28373627	1569	1571	PH	T046	C0020542

27418869|t|Dental Students ' Educational Environment and Perceived Stress: The University of Malaya Experience
27418869|a|An equitable and positive learning environment fosters deep self-directed learning in students and, consequently, good practice in their profession. Although demotivating weaknesses may lead to repeated day-to-day stress with a cascade of deleterious consequences at both personal and professional levels, a possible relationship between these parameters has not been reported. This study was undertaken to determine the relationship between students ' perceptions of their educational environment and their stress levels. Sixty-one first year students at the Dental Faculty, University of Malaya, Malaysia participated. The Dundee Ready Education Environment Measure (DREEM) was used to determine educational environment while self-rated perceived stress level was measured by the Depression Anxiety Stress Scale (DASS). Most students (62.39%) showed positive perceptions for the total and five domains of DREEM. The highest percentage was observed for " Students perception of learning " (64.04%) while the lowest was for " Students ' social self- perception " (60.32%). At the same time, 61% of students showed high perceived stress levels. However, this was not associated with their DREEM scores. Although a positive perception of their educational environment was found, minor corrective measures need to be implemented. Furthermore, longitudinal studies on an annual basis would provide useful input for strategic planning purposes.
27418869	0	15	Dental Students	T097	C0038493
27418869	18	41	Educational Environment	T069	C0681381
27418869	46	55	Perceived	T041	C0030971
27418869	56	62	Stress	T048	C0038443
27418869	68	88	University of Malaya	T073,T092	C0041740
27418869	89	99	Experience	T041	C0596545
27418869	126	146	learning environment	T082	C1510556
27418869	160	182	self-directed learning	T065	C0871321
27418869	186	194	students	T097	C0038493
27418869	219	227	practice	T041	C0237607
27418869	237	247	profession	T090	C0028811
27418869	258	281	demotivating weaknesses	T080	C0205556
27418869	303	313	day-to-day	T079	C0332173
27418869	314	320	stress	T048	C0038443
27418869	351	363	consequences	T078	C1547646
27418869	372	380	personal	T032	C1519021
27418869	385	397	professional	T090	C2698884
27418869	417	429	relationship	T080	C0439849
27418869	444	454	parameters	T033	C0449381
27418869	521	533	relationship	T080	C0439849
27418869	542	550	students	T097	C0038493
27418869	553	564	perceptions	T041	C0030971
27418869	574	597	educational environment	T069	C0681381
27418869	608	614	stress	T048	C0038443
27418869	644	652	students	T097	C0038493
27418869	660	674	Dental Faculty	T097	C0015536
27418869	676	696	University of Malaya	T073,T092	C0041740
27418869	698	706	Malaysia	T083	C0024552
27418869	707	719	participated	T169	C0679823
27418869	725	767	Dundee Ready Education Environment Measure	T170	C0282574
27418869	769	774	DREEM	T170	C0282574
27418869	798	821	educational environment	T069	C0681381
27418869	828	838	self-rated	T170	C4054119
27418869	839	848	perceived	T041	C0030971
27418869	849	855	stress	T048	C0038443
27418869	866	874	measured	T080	C0444706
27418869	882	913	Depression Anxiety Stress Scale	T170	C0282574
27418869	915	919	DASS	T170	C0282574
27418869	927	935	students	T097	C0038493
27418869	961	972	perceptions	T041	C0030971
27418869	1007	1012	DREEM	T170	C0282574
27418869	1056	1064	Students	T097	C0038493
27418869	1065	1075	perception	T041	C0030971
27418869	1079	1087	learning	T041	C0023185
27418869	1126	1134	Students	T097	C0038493
27418869	1150	1160	perception	T041	C0025361
27418869	1198	1206	students	T097	C0038493
27418869	1219	1228	perceived	T041	C0030971
27418869	1229	1242	stress levels	T033	C4034537
27418869	1266	1281	associated with	T080	C0332281
27418869	1288	1293	DREEM	T170	C0282574
27418869	1322	1332	perception	T041	C0030971
27418869	1342	1365	educational environment	T069	C0681381
27418869	1383	1402	corrective measures	T169	C1879489
27418869	1414	1425	implemented	T052	C1708476
27418869	1440	1460	longitudinal studies	T062	C0023981
27418869	1467	1479	annual basis	T079	C1254367
27418869	1511	1538	strategic planning purposes	T057	C1514981

27297967|t|Arsenic Triglutathione [As(GS)3] Transport by Multidrug Resistance Protein 1 (MRP1 / ABCC1) Is Selectively Modified by Phosphorylation of Tyr920/Ser921 and Glycosylation of Asn19/Asn23
27297967|a|The ATP-binding cassette (ABC) transporter multidrug resistance protein 1 (MRP1 / ABCC1) is responsible for the cellular export of a chemically diverse array of xenobiotics and endogenous compounds. Arsenic, a human carcinogen, is a high-affinity MRP1 substrate as arsenic triglutathione [As(GS)3]. In this study, marked differences in As(GS)3 transport kinetics were observed between MRP1 -enriched membrane vesicles prepared from human embryonic kidney 293 (HEK) (Km 3.8 µM and Vmax 307 pmol/mg per minute) and HeLa (Km 0.32 µM and Vmax 42 pmol/mg per minute) cells. Mutant MRP1 lacking N-linked glycosylation [Asn19/23/1006Gln; sugar-free (SF)-MRP1] expressed in either HEK293 or HeLa cells had low Km and Vmax values for As(GS)3, similar to HeLa wild-type (WT) MRP1. When prepared in the presence of phosphatase inhibitors, both WT- and SF-MRP1 -enriched membrane vesicles had a high Km value for As(GS)3 (3-6 µM), regardless of the cell line. Kinetic parameters of As(GS)3 for HEK - Asn19/23Gln-MRP1 were similar to those of HeLa / HEK - SF-MRP1 and HeLa-WT - MRP1, whereas those of single glycosylation mutants were like those of HEK-WT -MRP1. Mutation of 19 potential MRP1 phosphorylation sites revealed that HEK - Tyr920Phe/Ser921Ala-MRP1 transported As(GS)3 like HeLa-WT - MRP1, whereas individual HEK - Tyr920Phe- and - Ser921Ala-MRP1 mutants were similar to HEK-WT - MRP1. Together, these results suggest that Asn19/Asn23 glycosylation and Tyr920/Ser921 phosphorylation are responsible for altering the kinetics of MRP1 -mediated As(GS)3 transport. The kinetics of As(GS)3 transport by HEK - Asn19/23Gln/Tyr920Glu/Ser921Glu were similar to HEK-WT - MRP1, indicating that the phosphorylation -mimicking substitutions abrogated the influence of Asn19/23Gln glycosylation. Overall, these data suggest that cross-talk between MRP1 glycosylation and phosphorylation occurs and that phosphorylation of Tyr920 and Ser921 can switch MRP1 to a lower-affinity, higher-capacity As(GS)3 transporter, allowing arsenic detoxification over a broad concentration range.
27297967	0	22	Arsenic Triglutathione	T116	C0596621
27297967	24	31	As(GS)3	T116	C0596621
27297967	33	42	Transport	T043	C0005528
27297967	46	76	Multidrug Resistance Protein 1	T116,T123	C1451297
27297967	78	82	MRP1	T116,T123	C1451297
27297967	85	90	ABCC1	T116,T123	C1451297
27297967	107	115	Modified	T169	C0392747
27297967	119	134	Phosphorylation	T044	C1158886
27297967	138	151	Tyr920/Ser921	T087	C0002518
27297967	156	169	Glycosylation	T044	C0376322
27297967	173	184	Asn19/Asn23	T087	C0002518
27297967	189	227	ATP-binding cassette (ABC) transporter	T116,T123	C0242738
27297967	228	258	multidrug resistance protein 1	T116,T123	C1451297
27297967	260	264	MRP1	T116,T123	C1451297
27297967	267	272	ABCC1	T116,T123	C1451297
27297967	297	305	cellular	T025	C0007634
27297967	306	312	export	T067	C0699789
27297967	329	336	diverse	T080	C1880371
27297967	337	342	array	T082	C1510941
27297967	346	357	xenobiotics	T123,T131	C0043335
27297967	362	372	endogenous	T169	C0205227
27297967	373	382	compounds	T167	C0439861
27297967	384	391	Arsenic	T121,T131,T196	C0003818
27297967	395	400	human	T016	C0086418
27297967	401	411	carcinogen	T131	C0007090
27297967	418	431	high-affinity	T080	C0205556
27297967	432	436	MRP1	T116,T123	C1451297
27297967	437	446	substrate	T167	C3891814
27297967	450	472	arsenic triglutathione	T116	C0596621
27297967	474	481	As(GS)3	T116	C0596621
27297967	521	528	As(GS)3	T116	C0596621
27297967	529	538	transport	T043	C0005528
27297967	539	547	kinetics	T090	C2825046
27297967	570	574	MRP1	T116,T123	C1451297
27297967	585	593	membrane	T026	C0596901
27297967	594	602	vesicles	T026	C1622418
27297967	603	611	prepared	T052	C1521827
27297967	617	622	human	T016	C0086418
27297967	623	632	embryonic	T018	C0013935
27297967	633	639	kidney	T023	C0022646
27297967	640	649	293 (HEK)	T025	C2936239
27297967	651	653	Km	T081	C1706312
27297967	665	669	Vmax	T067	C1710637
27297967	698	702	HeLa	T025	C0018873
27297967	704	706	Km	T081	C1706312
27297967	719	723	Vmax	T067	C1710637
27297967	747	752	cells	T025	C0007634
27297967	754	760	Mutant	T116	C1564139
27297967	761	765	MRP1	T116,T123	C1451297
27297967	783	796	glycosylation	T044	C0376322
27297967	798	814	Asn19/23/1006Gln	T087	C0002518
27297967	827	836	(SF)-MRP1	T116,T123	C1451297
27297967	838	847	expressed	T045	C1171362
27297967	858	864	HEK293	T025	C2936239
27297967	868	878	HeLa cells	T025	C0018873
27297967	887	889	Km	T081	C1706312
27297967	894	898	Vmax	T067	C1710637
27297967	910	917	As(GS)3	T116	C0596621
27297967	919	926	similar	T080	C2348205
27297967	930	944	HeLa wild-type	T025	C0018873
27297967	950	954	MRP1	T116,T123	C1451297
27297967	961	969	prepared	T052	C1521827
27297967	977	985	presence	T033	C0150312
27297967	989	1011	phosphatase inhibitors	T121	C0597217
27297967	1018	1021	WT-	T116,T123	C1451297
27297967	1026	1033	SF-MRP1	T116,T123	C1451297
27297967	1044	1052	membrane	T026	C0596901
27297967	1053	1061	vesicles	T026	C1622418
27297967	1073	1075	Km	T081	C1706312
27297967	1086	1093	As(GS)3	T116	C0596621
27297967	1122	1131	cell line	T025	C0682523
27297967	1133	1151	Kinetic parameters	T033	C0449381
27297967	1155	1162	As(GS)3	T116	C0596621
27297967	1167	1170	HEK	T025	C2936239
27297967	1173	1189	Asn19/23Gln-MRP1	T116,T123	C1451297
27297967	1195	1202	similar	T080	C2348205
27297967	1215	1219	HeLa	T025	C0018873
27297967	1222	1225	HEK	T025	C2936239
27297967	1228	1235	SF-MRP1	T116,T123	C1451297
27297967	1240	1247	HeLa-WT	T025	C0018873
27297967	1250	1254	MRP1	T116,T123	C1451297
27297967	1273	1279	single	T081	C0205171
27297967	1280	1293	glycosylation	T044	C0376322
27297967	1294	1301	mutants	T116	C1564139
27297967	1321	1327	HEK-WT	T025	C2936239
27297967	1335	1343	Mutation	T045	C0026882
27297967	1350	1359	potential	T080	C3245505
27297967	1365	1380	phosphorylation	T044	C1158886
27297967	1381	1386	sites	T082	C0205145
27297967	1401	1404	HEK	T025	C2936239
27297967	1407	1431	Tyr920Phe/Ser921Ala-MRP1	T116,T123	C1451297
27297967	1432	1443	transported	T043	C0005528
27297967	1444	1451	As(GS)3	T116	C0596621
27297967	1457	1464	HeLa-WT	T025	C0018873
27297967	1467	1471	MRP1	T116,T123	C1451297
27297967	1492	1495	HEK	T025	C2936239
27297967	1498	1508	Tyr920Phe-	T116,T123	C1451297
27297967	1515	1529	Ser921Ala-MRP1	T116,T123	C1451297
27297967	1530	1537	mutants	T116	C1564139
27297967	1543	1550	similar	T080	C2348205
27297967	1554	1560	HEK-WT	T025	C2936239
27297967	1563	1567	MRP1	T116,T123	C1451297
27297967	1585	1592	results	T033	C0683954
27297967	1606	1617	Asn19/Asn23	T087	C0002518
27297967	1618	1631	glycosylation	T044	C0376322
27297967	1636	1649	Tyr920/Ser921	T087	C0002518
27297967	1650	1665	phosphorylation	T044	C1158886
27297967	1686	1694	altering	T169	C0392747
27297967	1699	1707	kinetics	T090	C2825046
27297967	1711	1715	MRP1	T116,T123	C1451297
27297967	1726	1733	As(GS)3	T116	C0596621
27297967	1734	1743	transport	T043	C0005528
27297967	1749	1757	kinetics	T090	C2825046
27297967	1761	1768	As(GS)3	T116	C0596621
27297967	1769	1778	transport	T043	C0005528
27297967	1782	1785	HEK	T025	C2936239
27297967	1788	1819	Asn19/23Gln/Tyr920Glu/Ser921Glu	T087	C0002518
27297967	1825	1832	similar	T080	C2348205
27297967	1836	1842	HEK-WT	T025	C2936239
27297967	1845	1849	MRP1	T116,T123	C1451297
27297967	1871	1886	phosphorylation	T044	C1158886
27297967	1926	1935	influence	T077	C4054723
27297967	1939	1950	Asn19/23Gln	T087	C0002518
27297967	1951	1964	glycosylation	T044	C0376322
27297967	2018	2022	MRP1	T116,T123	C1451297
27297967	2023	2036	glycosylation	T044	C0376322
27297967	2041	2056	phosphorylation	T044	C1158886
27297967	2073	2088	phosphorylation	T044	C1158886
27297967	2092	2098	Tyr920	T087	C0002518
27297967	2103	2109	Ser921	T087	C0002518
27297967	2121	2125	MRP1	T116,T123	C1451297
27297967	2131	2145	lower-affinity	T080	C0205556
27297967	2147	2162	higher-capacity	T080	C0205556
27297967	2163	2170	As(GS)3	T116	C0596621
27297967	2171	2182	transporter	T116,T123	C0596902
27297967	2193	2200	arsenic	T121,T131,T196	C0003818
27297967	2201	2215	detoxification	T043	C4235382
27297967	2223	2228	broad	T082	C0332464
27297967	2229	2242	concentration	T081	C1446561
27297967	2243	2248	range	T081	C1514721

27965563|t|Functional Connectivity Reveals Which Language the " Control Regions " Control during Bilingual Production
27965563|a|Bilingual studies have revealed critical roles for the dorsal anterior cingulate cortex (dACC) and the left caudate nucleus (Lcaudate) in controlling language processing, but how these regions manage activation of a bilingual 's two language s remains an open question. We addressed this question by identifying the functional connectivity (FC) of these control regions during a picture - naming task by bimodal bilinguals who were fluent in both a spoken and a signed language. To quantify language control processes, we measured the FC of the dACC and Lcaudate with a region specific to each language modality: left superior temporal gyrus (LSTG) for speech and left pre/postcentral gyrus (LPCG) for sign. Picture - naming occurred in either a single - or dual - language context. The results showed that in a single - language context, the dACC exhibited increased FC with the target language region, but not with the non-target language region. During the dual - language context when both languages were alternately the target language, the dACC showed strong FC to the LPCG, the region specific to the less proficien t (signed) language. By contrast, the Lcaudate revealed a strong connectivity to the LPCG in the single - language context and to the LSTG (the region specific to spoken language) in the dual - language context. Our findings suggest that the dACC monitors and supports the processing of the target language, and that the Lcaudate controls the selection of the less accessible language. The results support the hypothesis that language control processes adapt to task demands that vary due to different interactional contexts.
27965563	0	23	Functional Connectivity	T169	C1707489
27965563	24	31	Reveals	T080	C0443289
27965563	38	46	Language	T171	C0023008
27965563	53	60	Control	T169	C2587213
27965563	61	68	Regions	T082	C0205147
27965563	71	78	Control	T169	C2587213
27965563	86	95	Bilingual	T080	C0205556
27965563	96	106	Production	T052	C1706214
27965563	107	116	Bilingual	T080	C0205556
27965563	117	124	studies	T062	C2603343
27965563	130	138	revealed	T080	C0443289
27965563	139	147	critical	T080	C1511545
27965563	148	153	roles	T077	C1705810
27965563	162	194	dorsal anterior cingulate cortex	T029	C3495548
27965563	196	200	dACC	T029	C3495548
27965563	210	230	left caudate nucleus	T023	C2330782
27965563	232	240	Lcaudate	T023	C2330782
27965563	245	256	controlling	T169	C2587213
27965563	257	265	language	T171	C0023008
27965563	266	276	processing	T052	C1709694
27965563	292	299	regions	T082	C0205147
27965563	300	306	manage	UnknownType	C0677351
27965563	307	317	activation	T052	C1879547
27965563	323	332	bilingual	T080	C0205556
27965563	340	348	language	T171	C0023008
27965563	362	366	open	T082	C0175566
27965563	367	375	question	T170	C1522634
27965563	395	403	question	T170	C1522634
27965563	407	418	identifying	T041	C0020792
27965563	423	446	functional connectivity	T169	C1707489
27965563	448	450	FC	T169	C1707489
27965563	461	468	control	T169	C2587213
27965563	469	476	regions	T082	C0205147
27965563	486	493	picture	T073	C0441469
27965563	496	502	naming	T041	C0233735
27965563	503	507	task	T057	C3540678
27965563	511	529	bimodal bilinguals	T096	C0681850
27965563	539	545	fluent	T033	C4068804
27965563	556	562	spoken	T033	C0424919
27965563	569	584	signed language	T171	C0037078
27965563	589	597	quantify	T081	C1709793
27965563	598	606	language	T171	C0023008
27965563	607	614	control	T169	C2587213
27965563	615	624	processes	T067	C1522240
27965563	629	637	measured	T081	C0079809
27965563	642	644	FC	T169	C1707489
27965563	652	656	dACC	T029	C3495548
27965563	661	669	Lcaudate	T023	C2330782
27965563	677	683	region	T082	C0205147
27965563	684	692	specific	T080	C0205369
27965563	701	709	language	T171	C0023008
27965563	710	718	modality	T078	C0695347
27965563	720	748	left superior temporal gyrus	T023	C2339013
27965563	750	754	LSTG	T023	C2339013
27965563	760	766	speech	T040	C0037817
27965563	771	797	left pre/postcentral gyrus	T023	C2329204
27965563	799	803	LPCG	T023	C2329204
27965563	809	813	sign	T171	C0037078
27965563	815	822	Picture	T073	C0441469
27965563	825	831	naming	T041	C0233735
27965563	832	840	occurred	T052	C1709305
27965563	853	859	single	T081	C0205171
27965563	865	869	dual	T081	C0392762
27965563	872	880	language	T171	C0023008
27965563	881	888	context	T078	C0449255
27965563	894	901	results	T033	C0683954
27965563	919	925	single	T081	C0205171
27965563	928	936	language	T171	C0023008
27965563	937	944	context	T078	C0449255
27965563	950	954	dACC	T029	C3495548
27965563	955	964	exhibited	T169	C0870432
27965563	965	974	increased	T081	C0205217
27965563	975	977	FC	T169	C1707489
27965563	987	993	target	T169	C1521840
27965563	994	1002	language	T171	C0023008
27965563	1003	1009	region	T082	C0205147
27965563	1028	1038	non-target	T169	C0205245
27965563	1039	1047	language	T171	C0023008
27965563	1048	1054	region	T082	C0205147
27965563	1067	1071	dual	T081	C0392762
27965563	1074	1082	language	T171	C0023008
27965563	1083	1090	context	T078	C0449255
27965563	1101	1110	languages	T171	C0023008
27965563	1116	1127	alternately	T077	C1523987
27965563	1132	1138	target	T169	C1521840
27965563	1139	1147	language	T171	C0023008
27965563	1153	1157	dACC	T029	C3495548
27965563	1165	1171	strong	T080	C0442821
27965563	1172	1174	FC	T169	C1707489
27965563	1182	1186	LPCG	T023	C2329204
27965563	1192	1198	region	T082	C0205147
27965563	1199	1207	specific	T080	C0205369
27965563	1215	1219	less	T081	C0439092
27965563	1220	1229	proficien	T033	C1299581
27965563	1232	1249	(signed) language	T171	C0037078
27965563	1254	1262	contrast	T080	C1979874
27965563	1268	1276	Lcaudate	T023	C2330782
27965563	1277	1285	revealed	T080	C0443289
27965563	1288	1294	strong	T080	C0442821
27965563	1295	1307	connectivity	T169	C1707489
27965563	1315	1319	LPCG	T023	C2329204
27965563	1327	1333	single	T081	C0205171
27965563	1336	1344	language	T171	C0023008
27965563	1345	1352	context	T078	C0449255
27965563	1364	1368	LSTG	T023	C2339013
27965563	1374	1380	region	T082	C0205147
27965563	1381	1389	specific	T080	C0205369
27965563	1393	1399	spoken	T033	C0424919
27965563	1400	1408	language	T171	C0023008
27965563	1417	1421	dual	T081	C0392762
27965563	1424	1432	language	T171	C0023008
27965563	1433	1440	context	T078	C0449255
27965563	1446	1454	findings	T033	C0243095
27965563	1455	1462	suggest	T078	C1705535
27965563	1472	1476	dACC	T029	C3495548
27965563	1477	1485	monitors	T058	C1283169
27965563	1490	1498	supports	T077	C1521721
27965563	1503	1513	processing	T052	C1709694
27965563	1521	1527	target	T169	C1521840
27965563	1528	1536	language	T171	C0023008
27965563	1551	1559	Lcaudate	T023	C2330782
27965563	1560	1568	controls	T169	C2587213
27965563	1573	1582	selection	T052	C1707391
27965563	1590	1594	less	T081	C0439092
27965563	1595	1605	accessible	T082	C0444454
27965563	1606	1614	language	T171	C0023008
27965563	1620	1627	results	T033	C0683954
27965563	1628	1635	support	T077	C1521721
27965563	1640	1650	hypothesis	T078	C1512571
27965563	1656	1664	language	T171	C0023008
27965563	1665	1672	control	T169	C2587213
27965563	1673	1682	processes	T067	C1522240
27965563	1683	1688	adapt	T169	C0456081
27965563	1692	1696	task	T057	C3540678
27965563	1697	1704	demands	T052	C1272683
27965563	1710	1714	vary	T080	C0205419
27965563	1722	1731	different	T080	C1705242
27965563	1732	1745	interactional	T169	C1704675
27965563	1746	1754	contexts	T078	C0449255

28181679|t|Mechanism of motor coordination of masseter and temporalis muscles for increased masticatory efficiency in mice
28181679|a|The demand for the use of mice as animal models for elucidating the pathophysiologies and pathogeneses of oral motor disorders has been increasing in recent years, as more and more kinds of genetically modified mice that express functional disorders of the stomatognathic system become available. However, the fundamental characteristics of mouse jaw movements during mastication have yet to be fully elucidated. The purpose of this study was to investigate the roles of the masseter and temporalis muscles, and the mechanisms of motor coordination of these muscles for increasing masticatory efficiency in the closing phase in mice. Twenty-two male Jcl: ICR mice were divided into control (n = 8), masseter-hypofunction (n = 7) and temporalis - hypofunction groups (n = 7). Botulinum neurotoxin type A (BoNT⁄A) was used to induce muscle hypofunction. The masticatory movement path in the horizontal direction during the occlusal phase became unstable after BoNT⁄A injection into the masseter muscle. BoNT⁄A injection into the temporalis muscle decreased antero-posterior excursion of the late-closing phase corresponding to the power phase of the chewing cycle. These results suggest that the masseter plays an important role in stabilizing the grinding path, where the food bolus is ground by sliding the posterior teeth from back to front during the occlusal phase. The temporalis plays a major role in retracting the mandible more posteriorly in the early phase of closing, extending the grinding path. Masticatory efficiency is thus increased based on the coordination of activities by the masseter and temporalis muscles.
28181679	0	9	Mechanism	T169	C0441712
28181679	13	31	motor coordination	T042	C0237543
28181679	35	43	masseter	T023	C0024876
28181679	48	66	temporalis muscles	T023	C0039487
28181679	71	80	increased	T081	C0205217
28181679	81	92	masticatory	T042	C0024888
28181679	93	103	efficiency	T081	C0013682
28181679	107	111	mice	T015	C0025929
28181679	131	137	use of	T169	C1524063
28181679	138	142	mice	T015	C0025929
28181679	146	159	animal models	T008	C0599779
28181679	180	197	pathophysiologies	T169	C0031847
28181679	202	214	pathogeneses	T046	C0699748
28181679	218	222	oral	T082	C0442027
28181679	223	238	motor disorders	T047	C0221163
28181679	248	258	increasing	T169	C0442808
28181679	262	268	recent	T079	C0332185
28181679	269	274	years	T079	C0439234
28181679	293	298	kinds	T080	C0332307
28181679	302	313	genetically	T169	C0314603
28181679	323	327	mice	T015	C0025929
28181679	341	361	functional disorders	T046	C0277785
28181679	369	390	stomatognathic system	T022	C0038369
28181679	398	407	available	T169	C0470187
28181679	434	449	characteristics	T080	C1521970
28181679	453	462	mouse jaw	T024	C1511239
28181679	463	472	movements	T040	C0026649
28181679	473	479	during	T079	C0347984
28181679	480	491	mastication	T042	C0024888
28181679	545	550	study	T062	C2603343
28181679	558	569	investigate	T169	C1292732
28181679	574	579	roles	T077	C1705810
28181679	587	595	masseter	T023	C0024876
28181679	600	618	temporalis muscles	T023	C0039487
28181679	628	638	mechanisms	T169	C0441712
28181679	642	660	motor coordination	T042	C0237543
28181679	670	677	muscles	T024	C0026845
28181679	693	704	masticatory	T042	C0024888
28181679	705	715	efficiency	T081	C0013682
28181679	723	730	closing	T042	C1254358
28181679	731	736	phase	T079	C0205390
28181679	740	744	mice	T015	C0025929
28181679	746	756	Twenty-two	T081	C4284772
28181679	757	761	male	T032	C0086582
28181679	762	765	Jcl	T015	C0025929
28181679	767	775	ICR mice	T015	C0025925
28181679	781	788	divided	T169	C0332849
28181679	794	801	control	T096	C0009932
28181679	811	832	masseter-hypofunction	UnknownType	C0681860
28181679	845	855	temporalis	T023	C0039487
28181679	858	870	hypofunction	T046	C0679221
28181679	871	877	groups	UnknownType	C0681860
28181679	887	914	Botulinum neurotoxin type A	T116,T121,T131	C0006050
28181679	916	922	BoNT⁄A	T116,T121,T131	C0006050
28181679	936	942	induce	T169	C0205263
28181679	943	949	muscle	T024	C0026845
28181679	950	962	hypofunction	T046	C0679221
28181679	968	979	masticatory	T042	C0024888
28181679	980	993	movement path	T040	C0026649
28181679	1001	1011	horizontal	T082	C0205126
28181679	1012	1021	direction	T082	C0449738
28181679	1022	1028	during	T079	C0347984
28181679	1033	1041	occlusal	T029	C0447303
28181679	1042	1047	phase	T079	C0205390
28181679	1055	1063	unstable	T033	C0443343
28181679	1070	1076	BoNT⁄A	T116,T121,T131	C0006050
28181679	1077	1086	injection	T122	C1272883
28181679	1096	1111	masseter muscle	T023	C0024876
28181679	1113	1119	BoNT⁄A	T116,T121,T131	C0006050
28181679	1120	1129	injection	T122	C1272883
28181679	1139	1156	temporalis muscle	T023	C0039487
28181679	1157	1166	decreased	T081	C0205216
28181679	1167	1193	antero-posterior excursion	T169	C0205245
28181679	1201	1219	late-closing phase	T079	C0205390
28181679	1241	1252	power phase	T079	C0205390
28181679	1260	1273	chewing cycle	T042	C0024888
28181679	1281	1288	results	T169	C1274040
28181679	1289	1296	suggest	T078	C1705535
28181679	1306	1314	masseter	T023	C0024876
28181679	1315	1320	plays	T033	C0600138
28181679	1324	1333	important	T080	C3898777
28181679	1334	1338	role	T077	C1705810
28181679	1342	1353	stabilizing	T033	C0184512
28181679	1358	1371	grinding path	T042	C1254358
28181679	1383	1393	food bolus	T031	C1186706
28181679	1407	1414	sliding	T169	C0332246
28181679	1419	1428	posterior	T082	C0205095
28181679	1429	1434	teeth	T023	C0040426
28181679	1454	1460	during	T079	C0347984
28181679	1465	1473	occlusal	T029	C0447303
28181679	1474	1479	phase	T079	C0205390
28181679	1485	1495	temporalis	T023	C0039487
28181679	1496	1501	plays	T033	C0600138
28181679	1504	1509	major	T080	C0205164
28181679	1510	1514	role	T077	C1705810
28181679	1533	1541	mandible	T023	C0024687
28181679	1547	1558	posteriorly	T082	C0205095
28181679	1566	1571	early	T079	C1279919
28181679	1572	1577	phase	T079	C0205390
28181679	1581	1588	closing	T042	C1254358
28181679	1590	1599	extending	T082	C0439792
28181679	1604	1617	grinding path	T042	C1254358
28181679	1619	1630	Masticatory	T042	C0024888
28181679	1631	1641	efficiency	T081	C0013682
28181679	1650	1659	increased	T081	C0205217
28181679	1673	1685	coordination	T042	C0237543
28181679	1689	1699	activities	T052	C0441655
28181679	1707	1715	masseter	T023	C0024876
28181679	1720	1738	temporalis muscles	T023	C0039487

27784873|t|ATP release from bladder urothelium and serosa in a rat model of partial bladder outlet obstruction
27784873|a|Overactive bladder is one of the major health problem especially in elderly people. Adenosine triphosphate (ATP) is released from urinary bladder cells and acts as a smooth muscle contraction and sensory signal in micturition but little is known about the role of ATP release in the pathophysiology of overactive bladder. To assess the relationship between ATP and overactive bladder, we used a partial bladder outlet obstruction (pBOO) model in rats. The bladder caused several changes by pBOO: An increase in bladder weight, hypertrophy of sub-urothelium and sub-serosal area, and frequent non - voiding bladder contraction during urine storage. Basal ATP release from urothelium and serosa of pBOO rats was significantly higher than that of normal rats. Distention induced ATP release from urothelium of normal and pBOO rats had no significant change. However, distention - induced ATP release from serosa of pBOO rats was higher than that of normal. These findings may identify ATP especially released from serosa as one of causes of non - voiding contractions and overactive bladder symptoms.
27784873	0	3	ATP	T114,T121,T123	C0001480
27784873	4	11	release	T169	C1283071
27784873	17	35	bladder urothelium	T024	C0227692
27784873	40	46	serosa	T024	C0036760
27784873	56	61	model	T050	C0012644
27784873	65	99	partial bladder outlet obstruction	T047	C0005694
27784873	100	118	Overactive bladder	T047	C0878773
27784873	139	153	health problem	T033	C0243095
27784873	168	182	elderly people	T098	C0001792
27784873	184	206	Adenosine triphosphate	T114,T121,T123	C0001480
27784873	208	211	ATP	T114,T121,T123	C0001480
27784873	216	224	released	T169	C1283071
27784873	230	251	urinary bladder cells	T025	C0227599
27784873	266	291	smooth muscle contraction	T042	C1155937
27784873	296	310	sensory signal	T041	C0597440
27784873	314	325	micturition	T040	C0042034
27784873	364	367	ATP	T114,T121,T123	C0001480
27784873	383	398	pathophysiology	T046	C0277785
27784873	402	420	overactive bladder	T047	C0878773
27784873	457	460	ATP	T114,T121,T123	C0001480
27784873	465	483	overactive bladder	T047	C0878773
27784873	495	529	partial bladder outlet obstruction	T047	C0005694
27784873	531	535	pBOO	T047	C0005694
27784873	537	542	model	T050	C0012644
27784873	546	550	rats	T015	C0034693
27784873	556	563	bladder	T023	C0005682
27784873	590	594	pBOO	T047	C0005694
27784873	599	607	increase	T169	C0442805
27784873	611	618	bladder	T023	C0005682
27784873	619	625	weight	T081	C0043100
27784873	627	638	hypertrophy	T046	C0020564
27784873	642	656	sub-urothelium	T024	C0227598
27784873	661	677	sub-serosal area	T024	C0036760
27784873	692	695	non	T169	C1518422
27784873	698	725	voiding bladder contraction	T042	C0232850
27784873	733	738	urine	T031	C0042036
27784873	748	753	Basal	T082	C0205112
27784873	754	757	ATP	T114,T121,T123	C0001480
27784873	771	781	urothelium	T024	C0227692
27784873	786	792	serosa	T024	C0036760
27784873	796	800	pBOO	T047	C0005694
27784873	801	805	rats	T015	C0034693
27784873	851	855	rats	T015	C0034693
27784873	857	867	Distention	T033	C0005687
27784873	876	879	ATP	T114,T121,T123	C0001480
27784873	880	887	release	T169	C1283071
27784873	893	903	urothelium	T024	C0227692
27784873	918	922	pBOO	T047	C0005694
27784873	923	927	rats	T015	C0034693
27784873	964	974	distention	T033	C0005687
27784873	977	984	induced	T169	C0205263
27784873	985	988	ATP	T114,T121,T123	C0001480
27784873	989	996	release	T169	C1283071
27784873	1002	1008	serosa	T024	C0036760
27784873	1012	1016	pBOO	T047	C0005694
27784873	1017	1021	rats	T015	C0034693
27784873	1082	1085	ATP	T114,T121,T123	C0001480
27784873	1097	1105	released	T169	C1283071
27784873	1111	1117	serosa	T024	C0036760
27784873	1138	1141	non	T169	C1518422
27784873	1144	1164	voiding contractions	T042	C0232850
27784873	1169	1187	overactive bladder	T047	C0878773
27784873	1188	1196	symptoms	T184	C1457887

28356547|t|Mechanisms of iPS cell generation and beyond
28356547|a|The generation of induced pluripotent stem cells (iPSCs) achieved by overexpression of Oct4, Sox2, Klf4 and c-Myc, transformed our classical views of the cellular epigenetic landscape and delivered a new concept for cell and tissue engineering. In addition to iPSCs, several other cell types have also been generated by master transcription factor (TF)-mediated transdifferentiation. However, the critical molecular mechanisms amongst diverse cellular identity changes are not well understood. Through the investigation of reprogramming mechanisms, we recently revealed that over-expression of constitutive active Smad3 boosted not only iPSC generation, but also 3 other master TF -mediated conversions, from B cells to macrophages, myoblasts to adipocytes, and human fibroblasts to neurons. This demonstrated that there were common mechanisms underlying different master TF -mediated cell conversions. To illuminate such mechanisms further, we have recently performed CRISPR/Cas9 -mediated genome-wide knockout screening during reprogramming with a lentiviral gRNA library containing 90,000 gRNAs. This screening provided us with ~15 novel reprogramming roadblock genes as well as ~20 candidate genes essential for the reprogramming process but not for ES cell self-renewa l. This data set will be a valuable resource to further understand how overexpression of master TFs alters cellular identity, and to achieve more faithful, efficient cell conversions for regenerative medicine .(Presented at the 1934th Meeting, March 17, 2017).
28356547	14	22	iPS cell	T025	C2717959
28356547	23	33	generation	T052	C3146294
28356547	63	93	induced pluripotent stem cells	T025	C2717959
28356547	95	100	iPSCs	T025	C2717959
28356547	114	128	overexpression	T045	C1514559
28356547	132	136	Oct4	T116,T123	C0083838
28356547	138	142	Sox2	T116,T123	C0300483
28356547	144	148	Klf4	T116,T123	C0529085
28356547	153	158	c-Myc	T116,T123	C1454487
28356547	199	207	cellular	T025	C0007634
28356547	208	218	epigenetic	T091	C1655731
28356547	261	265	cell	T063	C0872130
28356547	270	288	tissue engineering	T061	C0596171
28356547	305	310	iPSCs	T025	C2717959
28356547	326	336	cell types	T170	C0449475
28356547	365	392	master transcription factor	T116,T123	C0040648
28356547	394	396	TF	T116,T123	C0040648
28356547	407	427	transdifferentiation	T043	C1955895
28356547	442	471	critical molecular mechanisms	T044	C3537153
28356547	488	505	cellular identity	T039	C1326581
28356547	568	581	reprogramming	T043	C3850096
28356547	620	635	over-expression	T045	C1514559
28356547	659	664	Smad3	T116,T123	C0529120
28356547	682	686	iPSC	T025	C2717959
28356547	687	697	generation	T052	C3146294
28356547	716	725	master TF	T116,T123	C0040648
28356547	736	747	conversions	T043	C1955895
28356547	754	761	B cells	T025	C0004561
28356547	765	776	macrophages	T025	C0024432
28356547	778	787	myoblasts	T025	C0596995
28356547	791	801	adipocytes	T025	C0206131
28356547	807	824	human fibroblasts	T025	C0016030
28356547	828	835	neurons	T025	C0027882
28356547	910	919	master TF	T116,T123	C0040648
28356547	930	946	cell conversions	T043	C1955895
28356547	1014	1025	CRISPR/Cas9	T044	C3658355
28356547	1036	1066	genome-wide knockout screening	T063	C4279981
28356547	1074	1087	reprogramming	T043	C3850096
28356547	1095	1118	lentiviral gRNA library	T028	C0599776
28356547	1137	1142	gRNAs	T114,T123	C0082774
28356547	1186	1199	reprogramming	T043	C3850096
28356547	1200	1215	roadblock genes	T028	C0017337
28356547	1241	1246	genes	T028	C0017337
28356547	1265	1286	reprogramming process	T043	C3850096
28356547	1299	1306	ES cell	T025	C0596508
28356547	1307	1318	self-renewa	T043	C1155711
28356547	1390	1404	overexpression	T045	C1514559
28356547	1408	1418	master TFs	T116,T123	C0040648
28356547	1426	1443	cellular identity	T039	C1326581
28356547	1485	1501	cell conversions	T043	C1955895
28356547	1506	1527	regenerative medicine	T091	C1257974

27935981|t|Sympathetic Hyperactivity, Increased Tyrosine Hydroxylase and Exaggerated Corpus Cavernosum Relaxations Associated with Oxidative Stress Plays a Major Role in the Penis Dysfunction in Townes Sickle Cell Mouse
27935981|a|Sickle cell disease patients display priapism that may progress to erectile dysfunction. However, little is known about the pathophysiological alterations of corpus cavernosum in sickle cell disease. Thus, this study aimed to evaluate the functional and molecular alterations of sympathetic machinery and nitric oxide-cyclic guanosine monophosphate signaling pathway in Townes transgenic sickle cell disease mice. Concentration-response curves to contractile (phenylephrine) and relaxant agents (acetylcholine and sodium nitroprusside) were obtained in corpus cavernosum strips from sickle and C57BL/6 (control) mice. Neurogenic contractions and nitrergic relaxations were obtained using electrical-field stimulation. Measurements of endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), phosphodiesterase-5 (PDE5) and α1A-, α1B- and α1D-adrenoceptor mRNA expressions and reactive-oxygen species were performed. Tyrosine hydroxylase phosphorylated at Ser-31 and total tyrosine hydroxylase protein expressions in cavernosal tissues were also measured. The neurogenic contractions were higher in the sickle cell disease group, in association with elevated tyrosine hydroxylase phosphorylated at Ser-31 and total tyrosine hydroxylase protein expression, as well as increased tyrosine hydroxylase mRNA expression. Likewise, phenylephrine - induced contractions were greater in the sickle mice, whereas α1A-, α1B- and α1D-adrenoceptor mRNA expression remained unchanged. Cavernosal relaxations to acetylcholine, sodium nitroprusside and EFS were higher in sickle mice, accompanied by decreased eNOS and nNOS, along with lower PDE5 mRNA expression. An increase of about 40% in reactive-oxygen species generation in corpus cavernosum from sickle mice was also detected. Our study shows that decreased nitric oxide bioavailability in erectile tissue due to increased oxidative stress leads to both sympathetic hyperactivity and dysregulation of nitric oxide signaling in corpus cavernosum from Townes sickle mice.
27935981	0	25	Sympathetic Hyperactivity	T047	C4285793
27935981	27	36	Increased	T081	C0205217
27935981	37	57	Tyrosine Hydroxylase	T116,T126	C0041491
27935981	62	73	Exaggerated	T080	C0442801
27935981	74	91	Corpus Cavernosum	T023	C0227937
27935981	92	103	Relaxations	T052	C0035028
27935981	104	119	Associated with	T080	C0332281
27935981	120	136	Oxidative Stress	T049	C0242606
27935981	163	180	Penis Dysfunction	T047	C0242350
27935981	184	202	Townes Sickle Cell	T047	C0002895
27935981	203	208	Mouse	T015	C0025936
27935981	209	228	Sickle cell disease	T047	C0002895
27935981	229	237	patients	T101	C0030705
27935981	246	254	priapism	T047	C0033117
27935981	264	272	progress	T169	C1280477
27935981	276	296	erectile dysfunction	T047	C0242350
27935981	333	351	pathophysiological	T039	C0031845
27935981	352	363	alterations	T078	C1515926
27935981	367	384	corpus cavernosum	T023	C0227937
27935981	388	407	sickle cell disease	T047	C0002895
27935981	448	458	functional	T169	C0205245
27935981	473	484	alterations	T078	C1515926
27935981	488	509	sympathetic machinery	T022	C0039044
27935981	514	575	nitric oxide-cyclic guanosine monophosphate signaling pathway	T044	C3271755
27935981	579	596	Townes transgenic	T015	C0025936
27935981	597	616	sickle cell disease	T047	C0002895
27935981	617	621	mice	T015	C0025929
27935981	623	652	Concentration-response curves	T081	C0683162
27935981	656	667	contractile	T121	C1254351
27935981	669	682	phenylephrine	T109,T121	C0031469
27935981	688	703	relaxant agents	T121	C0358430
27935981	705	718	acetylcholine	T109,T121,T123	C0001041
27935981	723	743	sodium nitroprusside	T109,T121	C0037533
27935981	750	758	obtained	T169	C1301820
27935981	762	779	corpus cavernosum	T023	C0227937
27935981	780	786	strips	T074	C1321564
27935981	792	798	sickle	T047	C0002895
27935981	803	810	C57BL/6	T015	C1521751
27935981	811	825	(control) mice	T096	C0009932
27935981	827	837	Neurogenic	T022	C0027763
27935981	838	850	contractions	T046	C1140999
27935981	855	864	nitrergic	T025	C0949753
27935981	865	876	relaxations	T052	C0035028
27935981	882	890	obtained	T169	C1301820
27935981	897	925	electrical-field stimulation	T061	C0013786
27935981	927	939	Measurements	T169	C0242485
27935981	943	976	endothelial nitric oxide synthase	T116,T126	C1565681
27935981	978	982	eNOS	T116,T126	C1565681
27935981	985	1015	neuronal nitric oxide synthase	T116,T126	C1565685
27935981	1017	1021	nNOS	T116,T126	C1565685
27935981	1024	1043	phosphodiesterase-5	T116,T126	C1454124
27935981	1045	1049	PDE5	T116,T126	C1454124
27935981	1055	1059	α1A-	T116,T192	C0389726
27935981	1061	1065	α1B-	T116,T192	C0291339
27935981	1070	1086	α1D-adrenoceptor	T116,T192	C0388151
27935981	1087	1103	mRNA expressions	T045	C1515670
27935981	1108	1131	reactive-oxygen species	T123,T196	C0162772
27935981	1137	1146	performed	T169	C0884358
27935981	1148	1168	Tyrosine hydroxylase	T116,T126	C0041491
27935981	1169	1183	phosphorylated	T044	C0031715
27935981	1187	1193	Ser-31	T116,T121,T123	C0036720
27935981	1204	1224	tyrosine hydroxylase	T116,T126	C0041491
27935981	1225	1244	protein expressions	T045	C1171362
27935981	1248	1266	cavernosal tissues	T024	C1709494
27935981	1277	1285	measured	T080	C0444706
27935981	1291	1301	neurogenic	T022	C0027763
27935981	1302	1314	contractions	T046	C1140999
27935981	1320	1326	higher	T080	C0205250
27935981	1334	1353	sickle cell disease	T047	C0002895
27935981	1354	1359	group	UnknownType	C0681860
27935981	1364	1375	association	T080	C0439849
27935981	1381	1389	elevated	T080	C3163633
27935981	1390	1410	tyrosine hydroxylase	T116,T126	C0041491
27935981	1411	1425	phosphorylated	T044	C0031715
27935981	1429	1435	Ser-31	T116,T121,T123	C0036720
27935981	1446	1466	tyrosine hydroxylase	T116,T126	C0041491
27935981	1467	1485	protein expression	T045	C1171362
27935981	1498	1507	increased	T081	C0205217
27935981	1508	1528	tyrosine hydroxylase	T116,T126	C0041491
27935981	1529	1544	mRNA expression	T045	C1515670
27935981	1556	1569	phenylephrine	T109,T121	C0031469
27935981	1572	1579	induced	T169	C0205263
27935981	1580	1592	contractions	T046	C1140999
27935981	1613	1619	sickle	T047	C0002895
27935981	1620	1624	mice	T015	C0025929
27935981	1634	1638	α1A-	T116,T192	C0389726
27935981	1640	1644	α1B-	T116,T192	C0291339
27935981	1649	1665	α1D-adrenoceptor	T116,T192	C0388151
27935981	1666	1681	mRNA expression	T045	C1515670
27935981	1691	1700	unchanged	T033	C0442739
27935981	1702	1712	Cavernosal	T023	C0227937
27935981	1713	1724	relaxations	T052	C0035028
27935981	1728	1741	acetylcholine	T109,T121,T123	C0001041
27935981	1743	1763	sodium nitroprusside	T109,T121	C0037533
27935981	1768	1771	EFS	T061	C0013786
27935981	1777	1783	higher	T080	C0205250
27935981	1787	1793	sickle	T047	C0002895
27935981	1794	1798	mice	T015	C0025929
27935981	1815	1824	decreased	T081	C0205216
27935981	1825	1829	eNOS	T116,T126	C1565681
27935981	1834	1838	nNOS	T116,T126	C1565685
27935981	1851	1856	lower	T052	C2003888
27935981	1857	1861	PDE5	T116,T126	C1454124
27935981	1862	1877	mRNA expression	T045	C1515670
27935981	1882	1890	increase	T169	C0442805
27935981	1907	1930	reactive-oxygen species	T123,T196	C0162772
27935981	1931	1941	generation	T052	C3146294
27935981	1945	1962	corpus cavernosum	T023	C0227937
27935981	1968	1974	sickle	T047	C0002895
27935981	1975	1979	mice	T015	C0025929
27935981	1989	1997	detected	T033	C0442726
27935981	2020	2029	decreased	T081	C0205216
27935981	2030	2042	nitric oxide	T121,T123,T197	C0028128
27935981	2043	2058	bioavailability	T081	C0005508
27935981	2062	2077	erectile tissue	T024	C1709494
27935981	2085	2094	increased	T081	C0205217
27935981	2095	2111	oxidative stress	T049	C0242606
27935981	2126	2151	sympathetic hyperactivity	T047	C4285793
27935981	2156	2169	dysregulation	T033	C0243095
27935981	2173	2195	nitric oxide signaling	T044	C1518333
27935981	2199	2216	corpus cavernosum	T023	C0227937
27935981	2229	2235	sickle	T047	C0002895
27935981	2236	2240	mice	T015	C0025929

28357982|t|Co-infection of Acipenserid herpesvirus 2 (AciHV-2) and Streptococcus iniae in cultured white sturgeon Acipenser transmontanus
28357982|a|A mortality event in cultured white sturgeon Acipenser transmontanus (Richardson, 1836) sub-adults was investigated. After transfer between farms, high mortality was observed in fish, associated with back arching, abnormal swimming, and ulcerative skin lesions. Necropsy of moribund individuals revealed hemorrhagic ascites and petechial hemorrhages in the coelomic peritoneum and serosa of internal organs. Acipenserid herpesvirus 2 (AciHV-2) was isolated from external tissue samples, then identified and genotyped by sequencing of the terminase and polymerase genes. In addition, Streptococcus iniae was recovered from internal organs of affected fish. Histologic changes were limited to interstitial hematopoietic areas of the kidney and consisted of small foci of necrosis accompanied by fibrin deposition, minimal inflammatory response, and small numbers of bacterial cocci compatible with streptococci. Identity was confirmed by partial sequencing of the 16S rRNA, rpoB, and gyrB genes. Genetic fingerprinting demonstrated a genetic profile distinct from S. iniae isolates recovered from previous outbreaks in wild and cultured fish in North America, South America, and the Caribbean. Although the isolates were resistant to white sturgeon complement in serum killing assays, in vivo challenges failed to fulfill Koch's postulates. However, the clinical presentation, coupled with consistent recovery of S. iniae and AciHV-2 from moribund fish, suggests viral and bacterial co-infection were the proximate cause of death. To our knowledge, this represents the first report of AciHV-2 and S. iniae co-infection in cultured white sturgeon.
28357982	0	12	Co-infection	T047	C0275524
28357982	16	41	Acipenserid herpesvirus 2	T005	C1935542
28357982	43	50	AciHV-2	T005	C1935542
28357982	56	75	Streptococcus iniae	T007	C0318186
28357982	79	87	cultured	T059	C0430400
28357982	88	102	white sturgeon	T013	C0327757
28357982	103	126	Acipenser transmontanus	T013	C0327757
28357982	129	144	mortality event	T081	C0205848
28357982	148	156	cultured	T059	C0430400
28357982	157	171	white sturgeon	T013	C0327757
28357982	172	195	Acipenser transmontanus	T013	C0327757
28357982	197	207	Richardson	T170	C0443048
28357982	215	225	sub-adults	T013	C0016163
28357982	230	242	investigated	T169	C1292732
28357982	267	272	farms	T092	C4279960
28357982	279	288	mortality	T081	C0205848
28357982	305	309	fish	T013	C0016163
28357982	311	326	associated with	T080	C0332281
28357982	327	339	back arching	T033	C0459190
28357982	341	349	abnormal	T033	C0205161
28357982	350	358	swimming	T056	C0039003
28357982	364	374	ulcerative	T047	C0041582
28357982	375	387	skin lesions	T047	C0037284
28357982	389	397	Necropsy	T060	C0004398
28357982	401	409	moribund	T033	C0424547
28357982	410	421	individuals	T013	C0016163
28357982	431	450	hemorrhagic ascites	T184	C0019086
28357982	455	476	petechial hemorrhages	T047	C0031256
28357982	484	492	coelomic	T030	C3686739
28357982	493	503	peritoneum	T024	C0031153
28357982	508	514	serosa	T024	C0036760
28357982	527	533	organs	T023	C0178784
28357982	535	560	Acipenserid herpesvirus 2	T005	C1935542
28357982	562	569	AciHV-2	T005	C1935542
28357982	598	612	tissue samples	T024	C1292533
28357982	634	643	genotyped	T032	C0017431
28357982	647	657	sequencing	T063	C1328887
28357982	665	674	terminase	T116,T126	C0076125
28357982	679	695	polymerase genes	T028	C1335440
28357982	710	729	Streptococcus iniae	T007	C0318186
28357982	749	764	internal organs	T023	C0178784
28357982	777	781	fish	T013	C0016163
28357982	783	801	Histologic changes	T169	C0392747
28357982	818	830	interstitial	T029	C0596790
28357982	831	850	hematopoietic areas	T024	C0229619
28357982	858	864	kidney	T023	C0022646
28357982	888	892	foci	T082	C0205234
28357982	896	904	necrosis	T042	C0027540
28357982	920	937	fibrin deposition	T046	C0333565
28357982	947	968	inflammatory response	T046	C1155266
28357982	991	1006	bacterial cocci	T007	C0314746
28357982	1023	1035	streptococci	T007	C0038402
28357982	1071	1081	sequencing	T059	C1294197
28357982	1089	1097	16S rRNA	T114	C3537372
28357982	1099	1103	rpoB	T028	C3656149
28357982	1109	1119	gyrB genes	T028	C0017337
28357982	1121	1143	Genetic fingerprinting	T063	C0600368
28357982	1159	1174	genetic profile	T059	C2986505
28357982	1189	1197	S. iniae	T007	C0318186
28357982	1244	1248	wild	T170	C0445392
28357982	1253	1261	cultured	T059	C0430400
28357982	1262	1266	fish	T013	C0016163
28357982	1270	1283	North America	T083	C0028405
28357982	1285	1298	South America	T083	C0037713
28357982	1308	1317	Caribbean	T083	C0206155
28357982	1332	1340	isolates	T123	C1764827
28357982	1346	1355	resistant	T169	C0332325
28357982	1359	1373	white sturgeon	T013	C0327757
28357982	1388	1393	serum	T031	C0229671
28357982	1394	1408	killing assays	T059	C0005507
28357982	1410	1417	in vivo	T062	C0681829
28357982	1447	1464	Koch's postulates	T170	C0162791
28357982	1479	1500	clinical presentation	T170	C2708283
28357982	1538	1546	S. iniae	T007	C0318186
28357982	1551	1558	AciHV-2	T005	C1935542
28357982	1564	1572	moribund	T033	C0424547
28357982	1573	1577	fish	T013	C0016163
28357982	1588	1593	viral	T005	C0042776
28357982	1598	1607	bacterial	T007	C0004611
28357982	1608	1620	co-infection	T047	C0275524
28357982	1640	1654	cause of death	T033	C0007465
28357982	1710	1717	AciHV-2	T005	C1935542
28357982	1722	1730	S. iniae	T007	C0318186
28357982	1731	1743	co-infection	T047	C0275524
28357982	1747	1755	cultured	T059	C0430400
28357982	1756	1770	white sturgeon	T013	C0327757

27988278|t|Right Ventricular Response During Exercise in Patients with Chronic Obstructive Pulmonary Disease
27988278|a|Right ventricular (RV) pump function is of essential clinical and prognostic importance in a variety of heart and lung diseases. While the evaluation of RV performance at rest has been implemented in the clinical setting, it is unknown whether this assessment during exercise may provide additional benefit. With this aim, we evaluated the exercise - induced pulmonary arterial systolic pressure (PASP) increase during exercise in patients with severe chronic obstructive pulmonary disease (COPD) as an expression of RV contractile reserve. Cardiopulmonary exercise testing (CPET) with synchronic echocardiography was performed in 81 patients. Patients were classified into two groups according to an exercise - induced PASP increase above 30mmHg (High PSAP) or below 30mmHg (Low PSAP) during maximal exercise. Patients were then followed for three years. Sixteen patients (20%) had low PSAP and 65 (80%) showed high PSAP. These were not significant clinical and functional differences. Low PSAP was associated with a significantly lower peak VO2 (mean (SD), 35 (2) % predicted) compared to high PSAP response (peak VO2 45 (3) % predicted), p=0.045. Factors associated with mortality were age and exercise - induced PASP. Seventeen patients died during the three years of follow-up (7 (39%) in the low PSAP group and only 10 (1%) in the high PSAP group, p=0.041). Cardiopulmonary exercise testing with a synchronic echocardiography may be a useful tool for the assessment of RV contractile reserve in severe COPD patients. Exercise - induced PSAP emerges as a possible prognostic factor in these patients.
27988278	0	17	Right Ventricular	T023	C0225883
27988278	18	26	Response	T032	C0871261
27988278	27	33	During	T079	C0347984
27988278	34	42	Exercise	T056	C0015259
27988278	46	54	Patients	T101	C0030705
27988278	60	97	Chronic Obstructive Pulmonary Disease	T047	C0024117
27988278	98	115	Right ventricular	T023	C0225883
27988278	117	119	RV	T023	C0225883
27988278	121	134	pump function	T042	C0080311
27988278	141	150	essential	T080	C0205224
27988278	151	159	clinical	T080	C0205210
27988278	164	174	prognostic	T170	C0220901
27988278	175	185	importance	T080	C3898777
27988278	191	198	variety	T077	C2346866
27988278	202	207	heart	T047	C0018799
27988278	212	225	lung diseases	T047	C0024115
27988278	237	247	evaluation	T058	C0220825
27988278	251	253	RV	T023	C0225883
27988278	254	265	performance	T052	C1882330
27988278	269	273	rest	T056	C0035253
27988278	302	318	clinical setting	T082	C3176918
27988278	347	357	assessment	T058	C0220825
27988278	358	364	during	T079	C0347984
27988278	365	373	exercise	T056	C0015259
27988278	386	396	additional	T169	C1524062
27988278	397	404	benefit	T081	C0814225
27988278	416	419	aim	T078	C1947946
27988278	424	433	evaluated	T058	C0220825
27988278	438	446	exercise	T056	C0015259
27988278	449	456	induced	T169	C0205263
27988278	457	493	pulmonary arterial systolic pressure	T060	C1168444
27988278	495	499	PASP	T060	C1168444
27988278	501	509	increase	T169	C0442805
27988278	510	516	during	T079	C0347984
27988278	517	525	exercise	T056	C0015259
27988278	529	537	patients	T101	C0030705
27988278	543	549	severe	T080	C0392364
27988278	550	587	chronic obstructive pulmonary disease	T047	C0024117
27988278	589	593	COPD	T047	C0024117
27988278	615	617	RV	T023	C0225883
27988278	618	637	contractile reserve	T081	C0392762
27988278	639	671	Cardiopulmonary exercise testing	T060	C2959886
27988278	673	677	CPET	T060	C2959886
27988278	684	711	synchronic echocardiography	T060	C0013516
27988278	716	725	performed	T169	C0884358
27988278	732	740	patients	T101	C0030705
27988278	742	750	Patients	T101	C0030705
27988278	756	766	classified	T185	C0008902
27988278	776	782	groups	T078	C0441833
27988278	799	807	exercise	T056	C0015259
27988278	810	817	induced	T169	C0205263
27988278	818	822	PASP	T060	C1168444
27988278	823	831	increase	T169	C0442805
27988278	846	850	High	T080	C0205250
27988278	851	855	PSAP	T060	C1168444
27988278	874	877	Low	T080	C0205251
27988278	878	882	PSAP	T060	C1168444
27988278	884	890	during	T079	C0347984
27988278	891	898	maximal	T080	C0205289
27988278	899	907	exercise	T056	C0015259
27988278	909	917	Patients	T101	C0030705
27988278	928	936	followed	T079	C0332282
27988278	947	952	years	T079	C0439234
27988278	962	970	patients	T101	C0030705
27988278	981	984	low	T080	C0205251
27988278	985	989	PSAP	T060	C1168444
27988278	1010	1014	high	T080	C0205250
27988278	1015	1019	PSAP	T060	C1168444
27988278	1032	1047	not significant	T033	C1273937
27988278	1048	1056	clinical	T080	C0205210
27988278	1061	1071	functional	T169	C0205245
27988278	1072	1083	differences	T081	C1705241
27988278	1085	1088	Low	T080	C0205251
27988278	1089	1093	PSAP	T060	C1168444
27988278	1098	1113	associated with	T080	C0332281
27988278	1116	1135	significantly lower	T081	C4055638
27988278	1136	1140	peak	T080	C0444505
27988278	1141	1144	VO2	T033	C0429627
27988278	1146	1150	mean	T081	C0444504
27988278	1152	1154	SD	T081	C0871420
27988278	1166	1175	predicted	T078	C0681842
27988278	1177	1185	compared	T052	C1707455
27988278	1189	1193	high	T080	C0205250
27988278	1194	1198	PSAP	T060	C1168444
27988278	1199	1207	response	T032	C0871261
27988278	1209	1213	peak	T080	C0444505
27988278	1214	1217	VO2	T033	C0429627
27988278	1227	1236	predicted	T078	C0681842
27988278	1248	1255	Factors	T169	C1521761
27988278	1256	1271	associated with	T080	C0332281
27988278	1272	1281	mortality	T081	C0178686
27988278	1287	1290	age	T032	C0001779
27988278	1295	1303	exercise	T056	C0015259
27988278	1306	1313	induced	T169	C0205263
27988278	1314	1318	PASP	T060	C1168444
27988278	1330	1338	patients	T101	C0030705
27988278	1344	1350	during	T079	C0347984
27988278	1361	1366	years	T079	C0439234
27988278	1370	1379	follow-up	T058	C1522577
27988278	1396	1399	low	T080	C0205251
27988278	1400	1404	PSAP	T060	C1168444
27988278	1405	1410	group	T078	C0441833
27988278	1435	1439	high	T080	C0205250
27988278	1440	1444	PSAP	T060	C1168444
27988278	1445	1450	group	T078	C0441833
27988278	1462	1494	Cardiopulmonary exercise testing	T060	C2959886
27988278	1502	1529	synchronic echocardiography	T060	C0013516
27988278	1559	1569	assessment	T058	C0220825
27988278	1573	1575	RV	T023	C0225883
27988278	1576	1595	contractile reserve	T081	C0392762
27988278	1599	1605	severe	T080	C0392364
27988278	1606	1610	COPD	T047	C0024117
27988278	1611	1619	patients	T101	C0030705
27988278	1621	1629	Exercise	T056	C0015259
27988278	1632	1639	induced	T169	C0205263
27988278	1640	1644	PSAP	T060	C1168444
27988278	1667	1684	prognostic factor	T201	C1514474
27988278	1694	1702	patients	T101	C0030705

28383311|t|Musculoskeletal pain profile of obese individuals attending a multidisciplinary weight management service
28383311|a|Obesity is associated with numerous chronic diseases, including musculoskeletal (MSK) pain, which impacts on quality of life (QoL). There is, however, limited research providing a comprehensive MSK pain profile of an obese cohort. This retrospective study utilized a patient database at a national weight management service (WMS). Following ethical approval, anonymized patient data were statistically analyzed to develop a pain profile, investigate relationships between pain, sleep, and function, and explore variables associated with having low back pain (LBP) and knee pain. Overall, 915 individuals attended the WMS from January 2011 to September 2015 [male, 35% (n=318; CI =32-38); female, 65% (n=597; CI =62-68); mean age 44.6]. Mean BMI was 50.7 kg/m2 [Class III obese (BMI ≥40 kg/m2), 92% (n=835; CI =91-94)]. Approximately 91% reported MSK pain: LBP, 69% (n=539; CI =65- 72) [mean NRS 7.4]; knee pain, 58% (n=447; CI =55-61) [mean NRS 6.8]. Class III obese and multi-site pain patients had lower QoL and physical activity levels, reduced sleep, and poorer physical function than less obese patients and those without pain (p<0.05). Relationships were found between demographic, pain, self-report, psychological, and functional measures (p<0.05). Patients who slept fewer hours and had poorer functional outcomes were more likely to have LBP; patients who were divorced, had lower QoL, and more frequent nocturia were more likely to have knee pain (p<0.05). Multi-site MSK pain is prevalent and severe in obese patients and is negatively associated with most self-report and functional outcomes. This high prevalence suggests pain management strategies must be considered when treating obesity.
28383311	0	20	Musculoskeletal pain	T033	C0026858
28383311	21	28	profile	T170	C1518848
28383311	32	37	obese	T047	C0028754
28383311	38	49	individuals	T098	C0027361
28383311	50	59	attending	T169	C1999232
28383311	62	105	multidisciplinary weight management service	T093	C0596660
28383311	106	113	Obesity	T047	C0028754
28383311	117	132	associated with	T080	C0332281
28383311	133	141	numerous	T081	C0439064
28383311	142	158	chronic diseases	T047	C0008679
28383311	160	169	including	T169	C0332257
28383311	170	196	musculoskeletal (MSK) pain	T033	C0026858
28383311	204	211	impacts	T080	C4049986
28383311	215	230	quality of life	T078	C0034380
28383311	232	235	QoL	T078	C0034380
28383311	286	299	comprehensive	T080	C1880156
28383311	300	308	MSK pain	T033	C0026858
28383311	309	316	profile	T170	C1518848
28383311	323	328	obese	T047	C0028754
28383311	329	335	cohort	T098	C0599755
28383311	342	361	retrospective study	T062	C2985505
28383311	373	380	patient	T101	C0030705
28383311	381	389	database	T170	C0242356
28383311	395	429	national weight management service	T093	C0596660
28383311	431	434	WMS	T093	C0596660
28383311	447	454	ethical	T078	C1136353
28383311	455	463	approval	T170	C2346845
28383311	465	475	anonymized	T170	C3858751
28383311	476	488	patient data	T170	C2707520
28383311	494	516	statistically analyzed	T062	C0871424
28383311	530	534	pain	T184	C0030193
28383311	535	542	profile	T170	C1518848
28383311	544	555	investigate	T169	C1292732
28383311	556	569	relationships	T080	C0439849
28383311	578	582	pain	T184	C0030193
28383311	584	589	sleep	T040	C0037313
28383311	595	603	function	T033	C0516981
28383311	617	626	variables	T080	C0439828
28383311	627	642	associated with	T080	C0332281
28383311	650	663	low back pain	T184	C0024031
28383311	665	668	LBP	T184	C0024031
28383311	674	683	knee pain	T033	C0231749
28383311	698	709	individuals	T098	C0027361
28383311	723	726	WMS	T093	C0596660
28383311	764	768	male	T098	C0025266
28383311	782	784	CI	T081	C0009667
28383311	794	800	female	T098	C0043210
28383311	814	816	CI	T081	C0009667
28383311	826	830	mean	T081	C0444504
28383311	831	834	age	T032	C0001779
28383311	842	846	Mean	T081	C0444504
28383311	847	850	BMI	T201	C1305855
28383311	877	882	obese	T047	C0028754
28383311	884	887	BMI	T201	C1305855
28383311	912	914	CI	T081	C0009667
28383311	925	938	Approximately	T080	C0332232
28383311	952	960	MSK pain	T033	C0026858
28383311	962	965	LBP	T184	C0024031
28383311	979	981	CI	T081	C0009667
28383311	992	996	mean	T081	C0444504
28383311	1007	1016	knee pain	T033	C0231749
28383311	1030	1032	CI	T081	C0009667
28383311	1042	1046	mean	T081	C0444504
28383311	1067	1072	obese	T047	C0028754
28383311	1077	1087	multi-site	T082	C1254362
28383311	1088	1092	pain	T184	C0030193
28383311	1093	1101	patients	T101	C0030705
28383311	1106	1111	lower	T052	C2003888
28383311	1112	1115	QoL	T078	C0034380
28383311	1120	1137	physical activity	T056	C0026606
28383311	1138	1144	levels	T080	C0441889
28383311	1146	1153	reduced	T080	C0392756
28383311	1154	1159	sleep	T040	C0037313
28383311	1165	1171	poorer	T080	C2700379
28383311	1172	1189	physical function	T033	C0516981
28383311	1195	1199	less	T080	C0547044
28383311	1200	1205	obese	T047	C0028754
28383311	1206	1214	patients	T101	C0030705
28383311	1225	1232	without	T080	C0332288
28383311	1233	1237	pain	T184	C0030193
28383311	1248	1261	Relationships	T080	C0439849
28383311	1281	1292	demographic	T090	C0011298
28383311	1294	1298	pain	T184	C0030193
28383311	1300	1311	self-report	T062	C0681906
28383311	1313	1326	psychological	T169	C0205486
28383311	1332	1342	functional	T169	C0205245
28383311	1343	1351	measures	T081	C0079809
28383311	1362	1370	Patients	T101	C0030705
28383311	1375	1392	slept fewer hours	T033	C0243095
28383311	1401	1407	poorer	T080	C2700379
28383311	1408	1427	functional outcomes	T033	C0243095
28383311	1453	1456	LBP	T184	C0024031
28383311	1458	1466	patients	T101	C0030705
28383311	1476	1484	divorced	T033	C0086170
28383311	1490	1495	lower	T052	C2003888
28383311	1496	1499	QoL	T078	C0034380
28383311	1510	1518	frequent	T079	C0332183
28383311	1519	1527	nocturia	T047	C0028734
28383311	1553	1562	knee pain	T033	C0231749
28383311	1573	1583	Multi-site	T082	C1254362
28383311	1584	1592	MSK pain	T033	C0026858
28383311	1596	1605	prevalent	T081	C0220900
28383311	1610	1616	severe	T080	C0205082
28383311	1620	1625	obese	T047	C0028754
28383311	1626	1634	patients	T101	C0030705
28383311	1642	1652	negatively	T033	C1513916
28383311	1653	1668	associated with	T080	C0332281
28383311	1690	1709	functional outcomes	T033	C0243095
28383311	1721	1731	prevalence	T081	C0220900
28383311	1741	1756	pain management	T061	C0002766
28383311	1792	1800	treating	T061	C0087111
28383311	1801	1808	obesity	T047	C0028754

28139296|t|Lignans from the fruits of Schisandra chinensis (Turcz.) Baill inhibit proprotein convertase subtilisin/kexin type 9 expression
28139296|a|Bioactivity-guided fractionation of the fruits of Schisandra chinensis, using the proprotein convertase subtilisin-kexin type 9 (PCSK9) mRNA expression screening assay, led to isolation of two previously unknown lignans, 14-tigloylschinlignan D and rel-(7R, 8R, 7'R, 8'R)-manglisin E, along with 28 known compounds. All structures were established by NMR spectroscopic data as well as CD and MS analysis. All isolates were tested for their inhibitory activities on the mRNA expression of PCSK9. Of the tested compounds, four of the compounds rel-(7R, 8R, 7'R, 8'R)-manglisin E, (-)-schisandrin C, schinlignan D, and (+)-schisandrol B potently inhibited PCSK9 mRNA expression with IC50 values of 3.15, 3.85, 0.36, and 1.10 μM, respectively. Furthermore, schinlignan D and (+)-schisandrol B were found to suppress PCSK9 protein expressions and schinlignan D deemed to increase low density lipoprotein receptor expression.
28139296	0	7	Lignans	T109	C0064971
28139296	17	23	fruits	T168	C0016767
28139296	27	62	Schisandra chinensis (Turcz.) Baill	T002	C0696946
28139296	63	70	inhibit	T052	C3463820
28139296	71	116	proprotein convertase subtilisin/kexin type 9	T028	C1426592
28139296	117	127	expression	T045	C0017262
28139296	128	160	Bioactivity-guided fractionation	T059	C0016640
28139296	168	174	fruits	T168	C0016767
28139296	178	198	Schisandra chinensis	T002	C0696946
28139296	210	255	proprotein convertase subtilisin-kexin type 9	T028	C1426592
28139296	257	262	PCSK9	T028	C1426592
28139296	264	279	mRNA expression	T045	C1515670
28139296	280	295	screening assay	T059	C1510438
28139296	304	313	isolation	T169	C0205409
28139296	317	320	two	T081	C0205448
28139296	321	339	previously unknown	T080	C0439673
28139296	340	347	lignans	T109	C0064971
28139296	349	372	14-tigloylschinlignan D	T109	C0064971
28139296	377	411	rel-(7R, 8R, 7'R, 8'R)-manglisin E	T109	C0064971
28139296	448	458	structures	T170	C0220807
28139296	464	475	established	T080	C0443211
28139296	479	496	NMR spectroscopic	T060	C0877853
28139296	497	501	data	T078	C1511726
28139296	513	515	CD	T059	C0008813
28139296	520	522	MS	T059	C0037813
28139296	523	531	analysis	T062	C0936012
28139296	551	557	tested	T169	C0039593
28139296	568	578	inhibitory	T052	C3463820
28139296	579	589	activities	T052	C0441655
28139296	597	612	mRNA expression	T045	C1515670
28139296	616	621	PCSK9	T028	C1426592
28139296	630	636	tested	T169	C0039593
28139296	648	652	four	T081	C0205450
28139296	670	704	rel-(7R, 8R, 7'R, 8'R)-manglisin E	T109	C0064971
28139296	706	723	(-)-schisandrin C	T109,T121	C0074176
28139296	725	738	schinlignan D	T109	C0064971
28139296	744	761	(+)-schisandrol B	T109,T121	C0074177
28139296	771	780	inhibited	T080	C0311403
28139296	781	786	PCSK9	T028	C1426592
28139296	787	802	mRNA expression	T045	C1515670
28139296	808	812	IC50	T081	C0600495
28139296	899	916	(+)-schisandrol B	T109,T121	C0074177
28139296	931	939	suppress	T169	C1260953
28139296	940	945	PCSK9	T116,T126	C4255394
28139296	946	965	protein expressions	T045	C1171362
28139296	970	983	schinlignan D	T109	C0064971
28139296	1003	1035	low density lipoprotein receptor	T116,T192	C0034821
28139296	1036	1046	expression	T045	C0597360

28303942|t|Signature of an aggregation - prone conformation of tau
28303942|a|The self-assembly of the microtubule associated tau protein into fibrillar cell inclusions is linked to a number of devastating neurodegenerative disorders collectively known as tauopathies. The mechanism by which tau self-assembles into pathological entities is a matter of much debate, largely due to the lack of direct experimental insights into the earliest stages of aggregation. We present pulsed double electron-electron resonance measurements of two key fibril - forming regions of tau, PHF6 and PHF6*, in transient as aggregation happens. By monitoring the end-to-end distance distribution of these segments as a function of aggregation time, we show that the PHF6((*)) regions dramatically extend to distances commensurate with extended β-strand structures within the earliest stages of aggregation, well before fibril formation. Combined with simulations, our experiments show that the extended β-strand conformational state of PHF6((*)) is readily populated under aggregating conditions, constituting a defining signature of aggregation - prone tau, and as such, a possible target for therapeutic interventions.
28303942	0	9	Signature	T087	C1514562
28303942	16	27	aggregation	T169	C0332621
28303942	30	35	prone	T082	C0033422
28303942	52	55	tau	T116,T123	C0085401
28303942	60	73	self-assembly	T044	C0872376
28303942	81	92	microtubule	T026	C0026046
28303942	93	103	associated	T080	C0332281
28303942	104	115	tau protein	T116,T123	C0085401
28303942	121	146	fibrillar cell inclusions	T026	C0230674
28303942	150	156	linked	T082	C0449379
28303942	162	168	number	T081	C0237753
28303942	184	211	neurodegenerative disorders	T047	C0524851
28303942	234	245	tauopathies	T047	C0949664
28303942	251	260	mechanism	T169	C0441712
28303942	270	273	tau	T116,T123	C0085401
28303942	274	288	self-assembles	T044	C0872376
28303942	294	306	pathological	T169	C1521733
28303942	307	315	entities	T071	C1551338
28303942	336	342	debate	T052	C0870392
28303942	344	351	largely	T081	C0549177
28303942	352	358	due to	T169	C0678226
28303942	371	377	direct	T080	C1947931
28303942	378	390	experimental	T080	C1517586
28303942	391	399	insights	T041	C0233820
28303942	409	424	earliest stages	T079	C2363430
28303942	428	439	aggregation	T169	C0332621
28303942	452	493	pulsed double electron-electron resonance	T059	C0022885
28303942	494	506	measurements	T169	C0242485
28303942	518	524	fibril	T026	C0225328
28303942	527	534	forming	T169	C1522492
28303942	535	542	regions	T082	C0205147
28303942	546	549	tau	T116,T123	C0085401
28303942	551	555	PHF6	T116,T123	C1608562
28303942	560	565	PHF6*	T116,T123	C0033684
28303942	570	579	transient	T079	C0205374
28303942	583	594	aggregation	T169	C0332621
28303942	622	641	end-to-end distance	T081	C0012751
28303942	642	654	distribution	T169	C1704711
28303942	678	686	function	T169	C0542341
28303942	690	701	aggregation	T169	C0332621
28303942	702	706	time	T079	C0040223
28303942	725	734	PHF6((*))	T116,T123	C0033684
28303942	735	742	regions	T082	C0205147
28303942	756	762	extend	T169	C0231448
28303942	766	775	distances	T081	C0012751
28303942	776	788	commensurate	T080	C0205163
28303942	794	802	extended	T082	C0231449
28303942	803	822	β-strand structures	T082	C0600383
28303942	834	849	earliest stages	T079	C2363430
28303942	853	864	aggregation	T169	C0332621
28303942	878	884	fibril	T026	C0225328
28303942	885	894	formation	T169	C1522492
28303942	896	904	Combined	T080	C0205195
28303942	910	921	simulations	T062	C0679083
28303942	927	938	experiments	T062	C0681814
28303942	953	961	extended	T082	C0231449
28303942	962	985	β-strand conformational	T082	C0600383
28303942	986	991	state	T169	C1442792
28303942	995	1004	PHF6((*))	T116,T123	C0033684
28303942	1032	1043	aggregating	T169	C0332621
28303942	1044	1054	conditions	T080	C0348080
28303942	1080	1089	signature	T087	C1514562
28303942	1093	1104	aggregation	T169	C0332621
28303942	1107	1112	prone	T082	C0033422
28303942	1113	1116	tau	T116,T123	C0085401
28303942	1142	1148	target	T169	C1521840
28303942	1153	1178	therapeutic interventions	T061	C0808232

27995510|t|Mechanisms of Global Cerebral Edema Formation in Aneurysmal Subarachnoid Hemorrhage
27995510|a|A growing body of clinical literature emphasizes the impact of cerebral edema in early brain injury following aneurysmal subarachnoid hemorrhage (aSAH). Aneurysm rupture itself initiates global cerebral edema in up to two thirds of cases. Although cerebral edema is not a universal feature of aSAH, it portends a poor clinical course, with quantitative analysis revealing a direct correlation between cerebral edema and poor outcome, including mortality and cognitive deficits. Mechanistically, global cerebral edema has been linked to global ischemia at the time of aneurysm rupture, dysfunction of autoregulation, blood breakdown products, neuroinflammation, and hyponatremia / endocrine abnormalities. At a molecular level, several culprits have been identified, including aquaporin-4, matrix metalloproteinase-9, SUR1 - TRPM4 cation channels, vascular endothelial growth factor, bradykinin, and others. Here, we review these cellular and molecular mechanisms of global cerebral edema formation in aSAH. Given the importance of edema to the outcome of patients with aSAH and its status as a highly modifiable pathological process, a better understanding of cerebral edema in aSAH promises to hasten the development of medical therapies to improve outcomes in this frequently devastating disease.
27995510	14	20	Global	T080	C2348867
27995510	21	35	Cerebral Edema	T046	C0006114
27995510	49	83	Aneurysmal Subarachnoid Hemorrhage	T046	C0751530
27995510	102	110	clinical	T080	C0205210
27995510	111	121	literature	T170	C0023866
27995510	147	161	cerebral edema	T046	C0006114
27995510	165	183	early brain injury	T037	C0270611
27995510	194	228	aneurysmal subarachnoid hemorrhage	T046	C0751530
27995510	230	234	aSAH	T046	C0751530
27995510	237	253	Aneurysm rupture	T047	C0162869
27995510	271	277	global	T080	C2348867
27995510	278	292	cerebral edema	T046	C0006114
27995510	332	346	cerebral edema	T046	C0006114
27995510	377	381	aSAH	T046	C0751530
27995510	402	417	clinical course	T079	C0449259
27995510	424	445	quantitative analysis	T081	C0034384
27995510	485	499	cerebral edema	T046	C0006114
27995510	504	516	poor outcome	T033	C3806166
27995510	579	585	global	T080	C2348867
27995510	586	600	cerebral edema	T046	C0006114
27995510	620	626	global	T080	C2348867
27995510	627	635	ischemia	T046	C0022116
27995510	651	667	aneurysm rupture	T047	C0162869
27995510	669	680	dysfunction	T077	C3887504
27995510	684	698	autoregulation	T038	C0019868
27995510	700	715	blood breakdown	T043	C2937287
27995510	716	724	products	T071	C1514468
27995510	726	743	neuroinflammation	T046	C1408627
27995510	749	761	hyponatremia	T047	C0020625
27995510	764	787	endocrine abnormalities	T190	C4025823
27995510	794	803	molecular	T080	C1521991
27995510	804	809	level	T080	C0441889
27995510	860	871	aquaporin-4	T116,T123	C0292777
27995510	873	899	matrix metalloproteinase-9	T116,T126	C0165519
27995510	901	905	SUR1	T116,T192	C3711621
27995510	908	929	TRPM4 cation channels	T116,T123	C1384655
27995510	931	965	vascular endothelial growth factor	T116,T123	C1171892
27995510	967	977	bradykinin	T116,T125	C0006100
27995510	1013	1021	cellular	T025	C0007634
27995510	1026	1035	molecular	T080	C1521991
27995510	1050	1056	global	T080	C2348867
27995510	1057	1071	cerebral edema	T046	C0006114
27995510	1085	1089	aSAH	T046	C0751530
27995510	1115	1120	edema	T184	C0013604
27995510	1139	1147	patients	T101	C0030705
27995510	1153	1157	aSAH	T046	C0751530
27995510	1166	1172	status	T080	C0449438
27995510	1196	1216	pathological process	T046	C0030660
27995510	1244	1258	cerebral edema	T046	C0006114
27995510	1262	1266	aSAH	T046	C0751530
27995510	1305	1322	medical therapies	T061	C0418981
27995510	1362	1373	devastating	T169	C0332663
27995510	1374	1381	disease	T047	C0012634

28467858|t|ANTI ANGIOGENIC EFFECT OF CHEBULAGIC ACID INVOLVES INHIBITION OF VEGFR2 AND GSK3β DEPENDENT SIGNALING PATHWAYS
28467858|a|Inhibition of angiogenesis is a useful strategy to prevent cancer growth, which targets new vessels that grow to nourish actively proliferating tumor cells. Endothelial cells can use a number of different pathways to cause angiogenesis and each step in these pathways can be targeted. The use of multi targeted drugs is gaining much importance in this scenario. Our previous results have shown the anti angiogenic effect of Chebulagic acid - a benzopyran tannin present in the fruits of Terminalia chebula. The present study was designed to examine the molecular mechanism of the anti angiogenic effect of chebulagic acid. Results of our investigations using molecular docking studies and HUVECs in culture suggested that Chebulagic acid inhibited GSK-3β dependent β-catenin phosphorylation, an important mediator of VE-cadherin / β-catenin signaling and VEGFR2 phosphorylation which is an important step involved in VEGF signaling. Chebulagic acid inhibits angiogenesis by blocking both VEGF / VEGFR2 and cell-cell contact dependent downstream signaling pathway.
28467858	0	22	ANTI ANGIOGENIC EFFECT	T033	C0243095
28467858	26	41	CHEBULAGIC ACID	T109,T121	C0653267
28467858	51	61	INHIBITION	T052	C3463820
28467858	65	71	VEGFR2	T044	C3549205
28467858	76	110	GSK3β DEPENDENT SIGNALING PATHWAYS	T044	C0037080
28467858	111	121	Inhibition	T052	C3463820
28467858	125	137	angiogenesis	T042	C0302600
28467858	150	158	strategy	T170	C0679716
28467858	162	169	prevent	T080	C2700409
28467858	170	183	cancer growth	T191	C1516170
28467858	191	198	targets	T169	C1521840
28467858	203	210	vessels	T023	C0005847
28467858	241	254	proliferating	T169	C1514485
28467858	255	266	tumor cells	T025	C0597032
28467858	268	285	Endothelial cells	T025	C0225336
28467858	316	324	pathways	T044	C0037080
28467858	334	346	angiogenesis	T042	C0302600
28467858	370	378	pathways	T044	C0037080
28467858	386	394	targeted	T169	C1521840
28467858	407	427	multi targeted drugs	T121	C1254351
28467858	509	531	anti angiogenic effect	T033	C0243095
28467858	535	550	Chebulagic acid	T109,T121	C0653267
28467858	555	565	benzopyran	T109	C0005078
28467858	566	572	tannin	T109,T121,T130	C1456509
28467858	588	594	fruits	T168	C0016767
28467858	598	616	Terminalia chebula	T002	C1193061
28467858	664	683	molecular mechanism	T044	C3537153
28467858	691	713	anti angiogenic effect	T033	C0243095
28467858	717	732	chebulagic acid	T109,T121	C0653267
28467858	770	795	molecular docking studies	T170	C3494274
28467858	800	806	HUVECs	T025	C3179121
28467858	810	817	culture	T059	C0007585
28467858	833	848	Chebulagic acid	T109,T121	C0653267
28467858	849	858	inhibited	T052	C3463820
28467858	859	865	GSK-3β	T116,T126	C0244988
28467858	866	875	dependent	T169	C3244310
28467858	876	885	β-catenin	T116,T123	C0105770
28467858	886	901	phosphorylation	T044	C1158886
28467858	928	939	VE-cadherin	T116,T129	C0300423
28467858	942	951	β-catenin	T116,T123	C0105770
28467858	952	961	signaling	T044	C0037080
28467858	966	972	VEGFR2	T116,T126,T192	C3849882
28467858	973	988	phosphorylation	T044	C1158886
28467858	1028	1042	VEGF signaling	T044	C3271788
28467858	1044	1059	Chebulagic acid	T109,T121	C0653267
28467858	1060	1068	inhibits	T052	C3463820
28467858	1069	1081	angiogenesis	T042	C0302600
28467858	1085	1093	blocking	T169	C0332206
28467858	1099	1103	VEGF	T116,T123	C1256770
28467858	1106	1112	VEGFR2	T116,T126,T192	C3849882
28467858	1117	1173	cell-cell contact dependent downstream signaling pathway	T044	C0037080

27787956|t|Relative importance of climate and mountain pine beetle outbreaks on the occurrence of large wildfires in the western USA
27787956|a|Extensive outbreaks of bark beetles have killed trees across millions of hectares of forests and woodlands in western North America. These outbreaks have led to spirited scientific, public, and policy debates about consequential increases in fire risk, especially in the wildland-urban interface (WUI), where homes and communities are at particular risk from wildfires. At the same time, large wildfires have become more frequent across this region. Widespread expectations that outbreaks increase extent, severity, and/or frequency of wildfires are based partly on visible and dramatic changes in foliar moisture content and other fuel properties following outbreaks, as well as associated modeling projections. A competing explanation is that increasing wildfires are driven primarily by climatic extremes, which are becoming more common with climate change. However, the relative importance of bark beetle outbreaks vs. climate on fire occurrence has not been empirically examined across very large areas and remains poorly understood. The most extensive outbreaks of tree - killing insects across the western United States have been of mountain pine beetle (MPB; Dendroctonus ponderosae), which have killed trees over >650,000 km(2), mostly in forests dominated by lodgepole pine (Pinus contorta). We show that outbreaks of MPB in lodgepole pine forests of the western United States have been less important than climatic variability for the occurrence of large fires over the past 29 years. In lodgepole pine forests in general, as well as those in the WUI, occurrence of large fires was determined primarily by current and antecedent high temperatures and low precipitation but was unaffected by preceding outbreaks. Trends of increasing co-occurrence of wildfires and outbreaks are due to a common climatic driver rather than interactions between these disturbances. Reducing wildfire risk hinges on addressing the underlying climatic drivers rather than treating beetle -affected forests.
27787956	35	55	mountain pine beetle	T204	C1032399
27787956	56	65	outbreaks	T169	C0220888
27787956	87	92	large	T081	C0549177
27787956	93	102	wildfires	T070	C2963164
27787956	110	117	western	T082	C1705493
27787956	118	121	USA	T083	C0041703
27787956	132	141	outbreaks	T169	C0220888
27787956	145	157	bark beetles	T204	C1019044
27787956	163	169	killed	T054	C0162388
27787956	170	175	trees	T002	C0040811
27787956	195	203	hectares	T081	C2348947
27787956	207	214	forests	T070	C0086312
27787956	219	228	woodlands	T070	C0086312
27787956	232	239	western	T082	C1705493
27787956	240	253	North America	T083	C0028405
27787956	261	270	outbreaks	T169	C0220888
27787956	304	310	public	T092	C0678367
27787956	364	368	fire	T070	C0700614
27787956	369	373	risk	T078	C0035647
27787956	393	417	wildland-urban interface	UnknownType	C0681784
27787956	419	422	WUI	UnknownType	C0681784
27787956	431	436	homes	T073	C0338046
27787956	441	452	communities	T096	C0009462
27787956	471	475	risk	T078	C0035647
27787956	481	490	wildfires	T070	C2963164
27787956	510	515	large	T081	C0549177
27787956	516	525	wildfires	T070	C2963164
27787956	564	570	region	T083	C0017446
27787956	601	610	outbreaks	T169	C0220888
27787956	620	626	extent	T082	C0439792
27787956	628	636	severity	T080	C0439793
27787956	658	667	wildfires	T070	C2963164
27787956	720	726	foliar	T073	C0729432
27787956	727	743	moisture content	T070	C1254365
27787956	754	769	fuel properties	T070	C3826029
27787956	780	789	outbreaks	T169	C0220888
27787956	878	887	wildfires	T070	C2963164
27787956	912	929	climatic extremes	T070	C1254365
27787956	967	981	climate change	T070	C2718051
27787956	1019	1030	bark beetle	T204	C1019044
27787956	1031	1040	outbreaks	T169	C0220888
27787956	1045	1052	climate	T070	C0008946
27787956	1056	1060	fire	T070	C0700614
27787956	1118	1123	large	T081	C0549177
27787956	1180	1189	outbreaks	T169	C0220888
27787956	1193	1197	tree	T002	C0040811
27787956	1200	1207	killing	T054	C0162388
27787956	1208	1215	insects	T204	C0021585
27787956	1227	1234	western	T082	C1705493
27787956	1235	1248	United States	T083	C0041703
27787956	1262	1282	mountain pine beetle	T204	C1032399
27787956	1284	1287	MPB	T204	C1032399
27787956	1289	1312	Dendroctonus ponderosae	T204	C1032399
27787956	1326	1332	killed	T054	C0162388
27787956	1333	1338	trees	T002	C0040811
27787956	1370	1377	forests	T070	C0086312
27787956	1391	1405	lodgepole pine	T002	C0330190
27787956	1407	1421	Pinus contorta	T002	C0330190
27787956	1437	1446	outbreaks	T169	C0220888
27787956	1450	1453	MPB	T204	C1032399
27787956	1457	1471	lodgepole pine	T002	C0330190
27787956	1472	1479	forests	T070	C0086312
27787956	1487	1494	western	T082	C1705493
27787956	1495	1508	United States	T083	C0041703
27787956	1539	1559	climatic variability	T070	C2718051
27787956	1582	1587	large	T081	C0549177
27787956	1588	1593	fires	T067	C0016141
27787956	1611	1616	years	T079	C0439234
27787956	1621	1635	lodgepole pine	T002	C0330190
27787956	1636	1643	forests	T070	C0086312
27787956	1680	1683	WUI	UnknownType	C0681784
27787956	1699	1704	large	T081	C0549177
27787956	1705	1710	fires	T067	C0016141
27787956	1739	1746	current	T070	C1705970
27787956	1762	1779	high temperatures	T067	C0563594
27787956	1784	1787	low	T080	C0205251
27787956	1788	1801	precipitation	T070	C0032931
27787956	1834	1843	outbreaks	T169	C0220888
27787956	1883	1892	wildfires	T070	C2963164
27787956	1897	1906	outbreaks	T169	C0220888
27787956	1927	1942	climatic driver	T169	C0205245
27787956	2005	2013	wildfire	T070	C2963164
27787956	2014	2018	risk	T078	C0035647
27787956	2055	2071	climatic drivers	T169	C0205245
27787956	2084	2092	treating	T169	C1522326
27787956	2093	2099	beetle	T204	C0009276
27787956	2110	2117	forests	T070	C0086312

27242101|t|Incidence of crown fracture and risk factors in the primary dentition: a prospective longitudinal study
27242101|a|Few studies have assessed the incidence and risk factors to crown fractures in preschool children. The aim of this study was to estimate the incidence of crown fracture in the primary dentition over a 1-year follow-up period, identify risk factors, and test the hypothesis that children with previous crown fracture are more prone to experience further cases of crown fracture independently of other risk factors. This study was developed in two phases: cross-sectional and prospective longitudinal study. The cross-sectional study was carried out 261 preschool children. The prospective longitudinal study was carried out 194 children allocated to two groups: exposed group (children with prior exposure to crown fracture) and non - exposed group (children without prior exposure). On both occasions, children were examined for the diagnosis of crown fracture and evaluation of lip coverage and overjet. The parents were interviewed with regard to the socioeconomic indicators. New cases of crown fracture were identified based on the comparison of the two examinations. Data analysis involved Pearson's chi-square test, McNemar's test, and Poisson regression with robust variance. Among the 261 children who participated in the cross-sectional study, 194 were re-examined (65 in the exposed group and 129 in the non - exposed group). The overall incidence of crown fracture was 55.7% (n = 108). The difference in percentage of increased risk of crown fracture in exposed and non - exposed groups was 13.4%. A greater incidence of crown fracture was found in the exposed group (64.6%; P < 0,001). The children exposed (RR: 1.30; 95% CI: 1.01-1.67) had a greater risk of developing new cases of crown fracture in comparison with the non - exposed group. The incidence of crown fracture was high and children with previous crown fracture had a greater risk of suffering new cases of crown fracture during the 1-year follow-up period.
27242101	0	9	Incidence	T081	C0021149
27242101	13	27	crown fracture	T037	C0458012
27242101	32	44	risk factors	T033	C0035648
27242101	52	69	primary dentition	T023	C3266841
27242101	73	103	prospective longitudinal study	T062	C0023981
27242101	134	143	incidence	T081	C0021149
27242101	148	160	risk factors	T033	C0035648
27242101	164	179	crown fractures	T037	C0458012
27242101	183	201	preschool children	T100	C0008100
27242101	245	254	incidence	T081	C0021149
27242101	258	272	crown fracture	T037	C0458012
27242101	280	297	primary dentition	T023	C3266841
27242101	312	321	follow-up	T058	C1522577
27242101	322	328	period	T079	C1948053
27242101	339	351	risk factors	T033	C0035648
27242101	366	376	hypothesis	T078	C1512571
27242101	382	390	children	T100	C0008059
27242101	396	404	previous	T079	C0205156
27242101	405	419	crown fracture	T037	C0458012
27242101	466	480	crown fracture	T037	C0458012
27242101	504	516	risk factors	T033	C0035648
27242101	558	573	cross-sectional	T062	C0010362
27242101	578	608	prospective longitudinal study	T062	C0023981
27242101	614	635	cross-sectional study	T062	C0010362
27242101	656	674	preschool children	T100	C0008100
27242101	680	710	prospective longitudinal study	T062	C0023981
27242101	731	739	children	T100	C0008059
27242101	765	778	exposed group	T098	C2348484
27242101	780	788	children	T100	C0008059
27242101	800	811	exposure to	T080	C0332157
27242101	812	826	crown fracture	T037	C0458012
27242101	832	835	non	T033	C1513916
27242101	838	851	exposed group	T098	C2348484
27242101	853	861	children	T100	C0008059
27242101	876	884	exposure	T080	C0332157
27242101	906	914	children	T100	C0008059
27242101	937	946	diagnosis	T033	C0011900
27242101	950	964	crown fracture	T037	C0458012
27242101	983	986	lip	T023	C0023759
27242101	1000	1007	overjet	T190	C0596028
27242101	1057	1081	socioeconomic indicators	T078	C1711331
27242101	1096	1110	crown fracture	T037	C0458012
27242101	1176	1189	Data analysis	T057	C0010992
27242101	1199	1224	Pearson's chi-square test	T170	C0237913
27242101	1226	1240	McNemar's test	T170	C0237913
27242101	1246	1264	Poisson regression	T170	C0034980
27242101	1270	1276	robust	T080	C2986815
27242101	1277	1285	variance	T080	C1711260
27242101	1301	1309	children	T100	C0008059
27242101	1334	1355	cross-sectional study	T062	C0010362
27242101	1389	1402	exposed group	T098	C2348484
27242101	1418	1421	non	T033	C1513916
27242101	1424	1437	exposed group	T098	C2348484
27242101	1452	1461	incidence	T081	C0021149
27242101	1465	1479	crown fracture	T037	C0458012
27242101	1533	1550	increased risk of	T033	C0332167
27242101	1551	1565	crown fracture	T037	C0458012
27242101	1581	1584	non	T033	C1513916
27242101	1587	1601	exposed groups	T098	C2348484
27242101	1623	1632	incidence	T081	C0021149
27242101	1636	1650	crown fracture	T037	C0458012
27242101	1706	1714	children	T100	C0008059
27242101	1759	1774	greater risk of	T033	C0332167
27242101	1799	1813	crown fracture	T037	C0458012
27242101	1837	1840	non	T033	C1513916
27242101	1843	1856	exposed group	T098	C2348484
27242101	1862	1871	incidence	T081	C0021149
27242101	1875	1889	crown fracture	T037	C0458012
27242101	1903	1911	children	T100	C0008059
27242101	1917	1925	previous	T079	C0205156
27242101	1926	1940	crown fracture	T037	C0458012
27242101	1947	1962	greater risk of	T033	C0332167
27242101	1986	2000	crown fracture	T037	C0458012
27242101	2019	2028	follow-up	T058	C1522577
27242101	2029	2035	period	T079	C1948053

27831982|t|Comparative Effectiveness of Treatments for Chronic Low Back Pain: A Multiple Treatment Comparison Analysis
27831982|a|A systematic review and network meta-analysis. To determine current treatment options of chronic low back pain (LBP) as defined by randomized controlled trials (RCTs) and to compare effectiveness of those treatments using a mixed-treatment comparison (MTC). It is important to provide an evidence-based assessment of the treatment options that exist for LBP. A systematic search of RCTs was conducted in MEDLINE and the Cochrane Collaboration Library from 1990 to 2014. From the selected studies, we extracted preoperative and postoperative ODI and VAS back pain scores, additional surgeries, and complications. Standard and network meta-analytic techniques were used. Twelve RCTs were included in the analysis: 5 total disk replacement (TDR) versus fusion; 1 TDR versus exercise and cognitive behavioral therapy (CBT); 5 fusion versus exercise and CBT; and 1 fusion versus physical therapy (PT). On the basis of MTC, with respect to ODI change scores, the pooled mean difference favoring fusion over exercise and CBT was 2.0 points (95% CI, -1.2 to 4.8). The pooled mean difference favoring TDR over exercise and CBT was 6.4 points (95% CI, 3.2-9.3). The pooled mean difference favoring fusion over PT was 8.8 points (95% CI, 4.1-13.6). The pooled mean differences favoring TDR over fusion was 4.4 points (95% CI, 2.37-6.63). For PT versus structured exercise with CBT, the pooled mean difference favoring exercise with CBT over PT was 6.8 points (95% CI, 1.5-12.8). For TDR versus PT, the pooled mean difference favoring TDR over PT was 13.2 points (95% CI, 8.0-18.4). Additional surgery rates were similar between treatment options. All 4 treatments provided some benefit to patients with chronic LBP. According to the MTC analysis, TDR may be the most effective treatment and PT the least effective treatment for chronic LBP. This review is based on a limited number of RCT studies and does not support any 1 treatment modality for all patients.
27831982	0	25	Comparative Effectiveness	T062	C2718022
27831982	29	39	Treatments	T061	C0087111
27831982	44	65	Chronic Low Back Pain	T047	C0457949
27831982	69	107	Multiple Treatment Comparison Analysis	T062	C4277638
27831982	110	127	systematic review	T170	C1955832
27831982	132	153	network meta-analysis	T062	C4277638
27831982	168	193	current treatment options	T061	C2827774
27831982	197	218	chronic low back pain	T047	C0457949
27831982	220	223	LBP	T047	C0457949
27831982	239	267	randomized controlled trials	T062	C0206035
27831982	269	273	RCTs	T062	C0206035
27831982	282	289	compare	T052	C1707455
27831982	290	303	effectiveness	T080	C1280519
27831982	313	323	treatments	T061	C0087111
27831982	332	358	mixed-treatment comparison	T062	C4277638
27831982	360	363	MTC	T062	C4277638
27831982	396	410	evidence-based	T078	C3887511
27831982	411	421	assessment	T058	C0220825
27831982	429	446	treatment options	T061	C0683525
27831982	462	465	LBP	T047	C0457949
27831982	469	486	systematic search	T062	C0035168
27831982	490	494	RCTs	T062	C0206035
27831982	512	519	MEDLINE	T170	C0025141
27831982	528	558	Cochrane Collaboration Library	T073,T092	C0023621
27831982	587	603	selected studies	T062	C2603343
27831982	618	630	preoperative	T079	C0445204
27831982	635	648	postoperative	T079	C0032790
27831982	649	652	ODI	T033	C2960603
27831982	657	677	VAS back pain scores	T081	C2732809
27831982	679	699	additional surgeries	T058	C2081627
27831982	705	718	complications	T046	C0009566
27831982	720	765	Standard and network meta-analytic techniques	T062	C4277638
27831982	784	788	RCTs	T062	C0206035
27831982	810	818	analysis	T062	C0936012
27831982	822	844	total disk replacement	T061	C2144940
27831982	846	849	TDR	T061	C2144940
27831982	858	864	fusion	T061	C0186045
27831982	868	871	TDR	T061	C2144940
27831982	879	887	exercise	T061	C1522704
27831982	892	920	cognitive behavioral therapy	T061	C0009244
27831982	922	925	CBT	T061	C0009244
27831982	930	936	fusion	T061	C0186045
27831982	944	952	exercise	T061	C1522704
27831982	957	960	CBT	T061	C0009244
27831982	968	974	fusion	T061	C0186045
27831982	982	998	physical therapy	T061	C0949766
27831982	1000	1002	PT	T061	C0949766
27831982	1021	1024	MTC	T062	C4277638
27831982	1042	1059	ODI change scores	T033	C2960603
27831982	1065	1087	pooled mean difference	T081	C1705241
27831982	1097	1103	fusion	T061	C0186045
27831982	1109	1117	exercise	T061	C1522704
27831982	1122	1125	CBT	T061	C0009244
27831982	1168	1190	pooled mean difference	T081	C1705241
27831982	1200	1203	TDR	T061	C2144940
27831982	1209	1217	exercise	T061	C1522704
27831982	1222	1225	CBT	T061	C0009244
27831982	1264	1286	pooled mean difference	T081	C1705241
27831982	1296	1302	fusion	T061	C0186045
27831982	1308	1310	PT	T061	C0949766
27831982	1350	1373	pooled mean differences	T081	C1705241
27831982	1383	1386	TDR	T061	C2144940
27831982	1392	1398	fusion	T061	C0186045
27831982	1439	1441	PT	T061	C0949766
27831982	1449	1468	structured exercise	T061	C1522704
27831982	1474	1477	CBT	T061	C0009244
27831982	1483	1505	pooled mean difference	T081	C1705241
27831982	1515	1523	exercise	T061	C1522704
27831982	1529	1532	CBT	T061	C0009244
27831982	1538	1540	PT	T061	C0949766
27831982	1580	1583	TDR	T061	C2144940
27831982	1591	1593	PT	T061	C0949766
27831982	1599	1621	pooled mean difference	T081	C1705241
27831982	1631	1634	TDR	T061	C2144940
27831982	1640	1642	PT	T061	C0949766
27831982	1690	1703	surgery rates	T081	C1521828
27831982	1725	1742	treatment options	T061	C0683525
27831982	1750	1760	treatments	T061	C0087111
27831982	1775	1782	benefit	T081	C0814225
27831982	1786	1794	patients	T101	C0030705
27831982	1800	1811	chronic LBP	T047	C0457949
27831982	1830	1842	MTC analysis	T062	C4277638
27831982	1844	1847	TDR	T061	C2144940
27831982	1859	1873	most effective	T080	C1704419
27831982	1874	1883	treatment	T061	C0087111
27831982	1888	1890	PT	T061	C0949766
27831982	1895	1910	least effective	T080	C1704419
27831982	1911	1920	treatment	T061	C0087111
27831982	1925	1936	chronic LBP	T047	C0457949
27831982	1943	1949	review	T170	C0282443
27831982	1964	1978	limited number	T081	C0449788
27831982	1982	1993	RCT studies	T062	C0206035
27831982	2021	2030	treatment	T061	C0087111
27831982	2031	2039	modality	T078	C0695347
27831982	2048	2056	patients	T101	C0030705

28424061|t|Young people, mental health practitioners and researchers co-produce a Transition Preparation Programme to improve outcomes and experience for young people leaving Child and Adolescent Mental Health Services (CAMHS)
28424061|a|In the UK young people attending child and adolescent mental health services (CAMHS) are required to move on, either through discharge or referral to an adult service, at age 17/18, a period of increased risk for onset of mental health problems and other complex psychosocial and physical changes. CAMHS transitions are often poorly managed with negative outcomes for young people. Better preparation may improve outcomes and experience. This study aimed to co-produce, with young people who had transitioned or were facing transition from CAMHS, a CAMHS Transition Preparation Programme (TPP), deliverable in routine NHS settings. Eighteen young people, aged 17-22, from three UK National Health Service (NHS) mental health foundation trusts participated in creative, participatory research workshops. Seven parents completed short questionnaires. Thirty clinical staff from two trusts took part in workshops to ensure deliverability of young people's ideas. Young people were offered co-research opportunities. Most young people felt anxious, fearful and uncertain on leaving CAMHS and perceived mental health services as uncaring. Participants outlined transition procedures and drafted a range of preparation activities, centred around dedicated Transition Peer Support and a transition booklet, which should be offered to all CAMHS leavers, irrespective of discharge or transfer to an adult service. Preparation should aim to build confidence to help young people take responsibility for themselves and flourish in the adult world: coping or getting through it was not enough. Some clinicians also felt anxious at transition and recognised the potential impact on young people of poor communication and lack of understanding between services. Parents would appreciate help to support their offspring during the transition period. Clinicians cited lack of funding and inflexible NHS procedures and policies as potential barriers to the implementation of young people's ideas. Nine young people took up co-research opportunities. Mental health services underestimate the anxiety of CAMHS leavers. Young people have clear ideas about the preparation they require to leave CAMHS with the confidence to take responsibility for their own health care. Close collaboration of NHS staff and researchers facilitates the implementation of research findings.
28424061	0	5	Young	T079	C0332239
28424061	6	12	people	T098	C0027361
28424061	14	27	mental health	T041	C0025353
28424061	28	41	practitioners	T097	C1306754
28424061	46	57	researchers	T097	C0035173
28424061	71	103	Transition Preparation Programme	T170	C0282574
28424061	115	123	outcomes	T169	C1274040
28424061	128	138	experience	T041	C0596545
28424061	143	148	young	T079	C0332239
28424061	149	155	people	T098	C0027361
28424061	164	207	Child and Adolescent Mental Health Services	T058	C0025355
28424061	209	214	CAMHS	T058	C0025355
28424061	223	225	UK	T083	C0041700
28424061	226	231	young	T079	C0332239
28424061	232	238	people	T098	C0027361
28424061	249	292	child and adolescent mental health services	T058	C0025355
28424061	294	299	CAMHS	T058	C0025355
28424061	341	350	discharge	T079	C1548175
28424061	354	365	referral to	T058	C2585021
28424061	369	382	adult service	T058	C0025355
28424061	387	390	age	T032	C0001779
28424061	400	406	period	T079	C1948053
28424061	410	419	increased	T081	C0205217
28424061	420	424	risk	T078	C0035647
28424061	429	437	onset of	T080	C0332162
28424061	438	460	mental health problems	T033	C1446377
28424061	471	478	complex	T080	C0439855
28424061	479	491	psychosocial	T169	C0542298
28424061	496	504	physical	T169	C0205485
28424061	505	512	changes	T169	C0392747
28424061	514	519	CAMHS	T058	C0025355
28424061	520	531	transitions	T052	C2700061
28424061	562	570	negative	T033	C0205160
28424061	571	579	outcomes	T169	C1274040
28424061	584	589	young	T079	C0332239
28424061	590	596	people	T098	C0027361
28424061	605	616	preparation	T052	C1521827
28424061	629	637	outcomes	T169	C1274040
28424061	642	652	experience	T041	C0596545
28424061	659	664	study	T062	C0008972
28424061	691	696	young	T079	C0332239
28424061	697	703	people	T098	C0027361
28424061	712	724	transitioned	T052	C2700061
28424061	740	750	transition	T052	C2700061
28424061	756	761	CAMHS	T058	C0025355
28424061	765	770	CAMHS	T058	C0025355
28424061	771	803	Transition Preparation Programme	T170	C0282574
28424061	805	808	TPP	T170	C0282574
28424061	826	833	routine	T080	C0205547
28424061	834	837	NHS	T058	C0027462
28424061	857	862	young	T079	C0332239
28424061	863	869	people	T098	C0027361
28424061	894	896	UK	T083	C0041700
28424061	897	920	National Health Service	T058	C0027462
28424061	922	925	NHS	T058	C0027462
28424061	985	1017	participatory research workshops	T065	C0242262
28424061	1025	1032	parents	T099	C0030551
28424061	1049	1063	questionnaires	T170	C0034394
28424061	1072	1086	clinical staff	T097	C0025106
28424061	1116	1125	workshops	T065	C0242262
28424061	1154	1159	young	T079	C0332239
28424061	1160	1168	people's	T098	C0027361
28424061	1169	1174	ideas	T078	C1254370
28424061	1176	1181	Young	T079	C0332239
28424061	1182	1188	people	T098	C0027361
28424061	1202	1227	co-research opportunities	T062	C0683937
28424061	1234	1239	young	T079	C0332239
28424061	1240	1246	people	T098	C0027361
28424061	1252	1259	anxious	T033	C0003467
28424061	1261	1268	fearful	T041	C0015726
28424061	1294	1299	CAMHS	T058	C0025355
28424061	1304	1313	perceived	T041	C0030971
28424061	1314	1336	mental health services	T058	C0025355
28424061	1350	1362	Participants	T098	C0679646
28424061	1372	1382	transition	T052	C2700061
28424061	1383	1393	procedures	T169	C2700391
28424061	1417	1439	preparation activities	T052	C0441655
28424061	1466	1476	Transition	T052	C2700061
28424061	1477	1489	Peer Support	T061	C0679740
28424061	1496	1506	transition	T052	C2700061
28424061	1507	1514	booklet	T073,T170	C0030258
28424061	1547	1552	CAMHS	T058	C0025355
28424061	1553	1560	leavers	T098	C1257890
28424061	1578	1587	discharge	T079	C1548175
28424061	1591	1599	transfer	T078	C3244299
28424061	1606	1619	adult service	T058	C0025355
28424061	1621	1632	Preparation	T052	C1521827
28424061	1653	1663	confidence	T041	C1704726
28424061	1672	1677	young	T079	C0332239
28424061	1678	1684	people	T098	C0027361
28424061	1690	1704	responsibility	T055	C0678341
28424061	1740	1745	adult	T100	C0001675
28424061	1746	1751	world	T098	C2700280
28424061	1803	1813	clinicians	T097	C0871685
28424061	1824	1831	anxious	T033	C0003467
28424061	1835	1845	transition	T052	C2700061
28424061	1875	1881	impact	T080	C4049986
28424061	1885	1890	young	T079	C0332239
28424061	1891	1897	people	T098	C0027361
28424061	1906	1919	communication	T054	C0009452
28424061	1924	1928	lack	T080	C0332268
28424061	1954	1962	services	T058	C0025355
28424061	1964	1971	Parents	T099	C0030551
28424061	1997	2004	support	T054	C0037438
28424061	2011	2020	offspring	T099	C0680063
28424061	2032	2042	transition	T052	C2700061
28424061	2043	2049	period	T079	C1948053
28424061	2051	2061	Clinicians	T097	C0871685
28424061	2068	2072	lack	T080	C0332268
28424061	2099	2102	NHS	T058	C0027462
28424061	2103	2113	procedures	T169	C2700391
28424061	2118	2126	policies	T170	C0242456
28424061	2140	2148	barriers	T080	C0205556
28424061	2156	2170	implementation	T052	C1708476
28424061	2174	2179	young	T079	C0332239
28424061	2180	2188	people's	T098	C0027361
28424061	2189	2194	ideas	T078	C1254370
28424061	2201	2206	young	T079	C0332239
28424061	2207	2213	people	T098	C0027361
28424061	2222	2247	co-research opportunities	T062	C0683937
28424061	2249	2271	Mental health services	T058	C0025355
28424061	2290	2297	anxiety	T033	C0003467
28424061	2301	2306	CAMHS	T058	C0025355
28424061	2307	2314	leavers	T098	C1257890
28424061	2316	2321	Young	T079	C0332239
28424061	2322	2328	people	T098	C0027361
28424061	2340	2345	ideas	T078	C1254370
28424061	2356	2367	preparation	T052	C1521827
28424061	2390	2395	CAMHS	T058	C0025355
28424061	2405	2415	confidence	T041	C1704726
28424061	2424	2438	responsibility	T055	C0678341
28424061	2453	2464	health care	T058	C0086388
28424061	2472	2485	collaboration	T054	C0282116
28424061	2489	2492	NHS	T058	C0027462
28424061	2493	2498	staff	T097	C0851286
28424061	2503	2514	researchers	T097	C0035173
28424061	2531	2545	implementation	T052	C1708476
28424061	2549	2557	research	T062	C0035168
28424061	2558	2566	findings	T169	C2607943

27744641|t|Somatosensory regulation of serotonin release in the central nucleus of the amygdala is mediated via corticotropin releasing factor and gamma-aminobutyric acid in the dorsal raphe nucleus
27744641|a|Noxious cutaneous stimulation increases, whereas innocuous cutaneous stimulation decreases serotonin (5-HT) release in the central nucleus of the amygdala (CeA) in anesthetized rats. In the present study, we investigated the contribution of corticotropin releasing factor (CRF) receptors and gamma-aminobutyric acid (GABA) receptors in the dorsal raphe nucleus (DRN) to those responses. Release of 5-HT in the CeA was monitored by microdialysis before and after 10- min stimulation by pinching or stroking. Increased 5-HT release in the CeA in response to pinching was abolished by CRF2 receptor antagonism in the DRN. Decreased 5-HT release in the CeA in response to stroking was abolished by either CRF1 receptor antagonism or GABAA receptor antagonism in the DRN. These results suggest that opposite responses of 5-HT release in the CeA to noxious versus innocuous stimulation of the skin are due to separate contributions of CRF2, CRF1 and GABAA receptors in the DRN.
27744641	0	13	Somatosensory	T023	C0682664
27744641	14	24	regulation	T038	C1327622
27744641	28	45	serotonin release	T043	C1979804
27744641	53	84	central nucleus of the amygdala	T023	C0175219
27744641	101	131	corticotropin releasing factor	T116,T121,T125	C0010132
27744641	136	159	gamma-aminobutyric acid	T116,T123	C0016904
27744641	167	187	dorsal raphe nucleus	T023	C0175392
27744641	188	217	Noxious cutaneous stimulation	T061	C1292856
27744641	218	227	increases	T169	C0442805
27744641	237	268	innocuous cutaneous stimulation	T061	C1292856
27744641	269	278	decreases	T081	C0547047
27744641	279	303	serotonin (5-HT) release	T043	C1979804
27744641	311	342	central nucleus of the amygdala	T023	C0175219
27744641	344	347	CeA	T023	C0175219
27744641	352	364	anesthetized	T033	C1720436
27744641	365	369	rats	T015	C0034693
27744641	386	391	study	T062	C2603343
27744641	396	408	investigated	T169	C1292732
27744641	429	475	corticotropin releasing factor (CRF) receptors	T116,T192	C0056373
27744641	480	520	gamma-aminobutyric acid (GABA) receptors	T116,T192	C0206518
27744641	528	548	dorsal raphe nucleus	T023	C0175392
27744641	550	553	DRN	T023	C0175392
27744641	575	590	Release of 5-HT	T109,T123	C0036751
27744641	598	601	CeA	T023	C0175219
27744641	619	632	microdialysis	T058	C0206056
27744641	654	657	min	T079	C0439232
27744641	658	669	stimulation	T070	C1948023
27744641	673	681	pinching	T037	C0418416
27744641	685	693	stroking	T061	C0556833
27744641	705	717	5-HT release	T043	C1979804
27744641	725	728	CeA	T023	C0175219
27744641	732	740	response	T032	C0871261
27744641	744	752	pinching	T037	C0418416
27744641	757	766	abolished	T080	C0849355
27744641	770	783	CRF2 receptor	T116,T192	C0529999
27744641	784	794	antagonism	T044	C1148560
27744641	802	805	DRN	T023	C0175392
27744641	817	829	5-HT release	T043	C1979804
27744641	837	840	CeA	T023	C0175219
27744641	856	864	stroking	T061	C0556833
27744641	869	878	abolished	T080	C0849355
27744641	889	902	CRF1 receptor	T116,T192	C0529997
27744641	903	913	antagonism	T044	C1148560
27744641	917	931	GABAA receptor	T116,T192	C0206518
27744641	932	942	antagonism	T044	C1148560
27744641	950	953	DRN	T023	C0175392
27744641	961	968	results	T169	C1274040
27744641	969	976	suggest	T078	C1705535
27744641	1004	1016	5-HT release	T043	C1979804
27744641	1024	1027	CeA	T023	C0175219
27744641	1031	1038	noxious	T080	C0205556
27744641	1046	1067	innocuous stimulation	T061	C1292856
27744641	1075	1079	skin	T022	C1123023
27744641	1091	1099	separate	T080	C0443299
27744641	1100	1113	contributions	T052	C1880177
27744641	1117	1121	CRF2	T116,T192	C0529999
27744641	1123	1127	CRF1	T116,T192	C0529997
27744641	1132	1147	GABAA receptors	T116,T192	C0206518
27744641	1155	1158	DRN	T023	C0175392

27544926|t|Folate - conjugated gene - carrying microbubbles with focused ultrasound for concurrent blood-brain barrier opening and local gene delivery
27544926|a|Previous studies have demonstrated that circulating DNA - encapsulated microbubbles (MBs) combined with focused ultrasound (FUS) can be used for local blood-brain barrier (BBB) opening and gene delivery. However, few studies focused on how to increase the efficiency of gene delivery to brain tumors after the released gene penetrating the BBB. Here, we proposed the use of folate - conjugated DNA - loaded cationic MBs (FCMBs). When combined with FUS as a trigger for BBB opening, FCMBs were converted into nanometer - sized vesicles that were transported to the brain parenchyma. The FCMBs can selectively aggregate around tumor cells that overexpressed the folate receptor, thus enhancing gene delivery via folate - stimulated endocytosis. Our results confirmed that FCMBs can carry DNA on the surface of the MB shell and have good targeting ability on C6 glioma cells. In addition, the optimized FUS parameters for FCMBs - enhanced gene delivery were confirmed by cell experiments (center frequency = 1 MHz; acoustic pressure = 700 kPa; pulse repetition frequency = 5 Hz; cycle number = 10000; exposure time = 1 min; FCMBs concentration = 4 × 10(7) MB/mL). In vivo data also indicated that FCMBs show better gene transfection efficiency than MBs without folate conjugation and the traditional approach of directly injecting the gene. This study described our novel development of multifunctional MBs for FUS - triggered gene delivery / therapy.
27544926	0	6	Folate	T109,T121,T127	C0178638
27544926	9	19	conjugated	T082	C0522529
27544926	20	24	gene	T028	C0017337
27544926	27	35	carrying	T045	C0872177
27544926	36	48	microbubbles	T074	C1258018
27544926	54	72	focused ultrasound	T061	C1517281
27544926	77	87	concurrent	T079	C0205420
27544926	88	107	blood-brain barrier	T023	C0005854
27544926	108	115	opening	T082	C1254362
27544926	120	125	local	T082	C0205276
27544926	126	139	gene delivery	T045	C0872177
27544926	140	148	Previous	T079	C0205156
27544926	149	156	studies	T062	C2603343
27544926	180	191	circulating	T169	C0175630
27544926	192	195	DNA	T114,T123	C0012854
27544926	198	210	encapsulated	T080	C0205223
27544926	211	223	microbubbles	T074	C1258018
27544926	225	228	MBs	T074	C1258018
27544926	230	238	combined	T080	C0205195
27544926	244	262	focused ultrasound	T061	C1517281
27544926	264	267	FUS	T061	C1517281
27544926	276	280	used	T169	C1524063
27544926	285	290	local	T082	C0205276
27544926	291	310	blood-brain barrier	T023	C0005854
27544926	312	315	BBB	T023	C0005854
27544926	317	324	opening	T082	C1254362
27544926	329	342	gene delivery	T045	C0872177
27544926	357	364	studies	T062	C2603343
27544926	365	372	focused	T169	C1285542
27544926	383	391	increase	T169	C0442805
27544926	396	406	efficiency	T081	C0013682
27544926	410	423	gene delivery	T045	C0872177
27544926	427	439	brain tumors	T191	C0006118
27544926	450	458	released	T169	C0391871
27544926	459	463	gene	T028	C0017337
27544926	464	475	penetrating	T169	C0205321
27544926	480	483	BBB	T023	C0005854
27544926	507	513	use of	T169	C1524063
27544926	514	520	folate	T109,T121,T127	C0178638
27544926	547	559	cationic MBs	T074	C1258018
27544926	561	566	FCMBs	T074	C1258018
27544926	574	582	combined	T080	C0205195
27544926	588	591	FUS	T061	C1517281
27544926	597	604	trigger	T080	C1444748
27544926	609	612	BBB	T023	C0005854
27544926	622	627	FCMBs	T074	C1258018
27544926	648	657	nanometer	T081	C0439202
27544926	660	665	sized	T082	C0456389
27544926	666	674	vesicles	T026	C1622418
27544926	685	696	transported	T043	C0005528
27544926	704	709	brain	T023	C0006104
27544926	710	720	parenchyma	T023	C0933845
27544926	726	731	FCMBs	T074	C1258018
27544926	748	757	aggregate	T080	C0205418
27544926	765	776	tumor cells	T025	C0597032
27544926	782	795	overexpressed	T045	C1514559
27544926	800	815	folate receptor	T116,T192	C2955669
27544926	822	831	enhancing	T052	C2349975
27544926	832	845	gene delivery	T045	C0872177
27544926	850	856	folate	T116,T192	C2955669
27544926	859	869	stimulated	T070	C1948023
27544926	870	881	endocytosis	T043	C0014139
27544926	887	894	results	T169	C1274040
27544926	895	904	confirmed	T080	C0521093
27544926	910	915	FCMBs	T074	C1258018
27544926	920	925	carry	T045	C0872177
27544926	926	929	DNA	T114,T123	C0012854
27544926	937	944	surface	T082	C0205148
27544926	952	954	MB	T074	C1258018
27544926	955	960	shell	T080	C1948022
27544926	970	974	good	T080	C0205170
27544926	975	984	targeting	T169	C1521840
27544926	985	992	ability	T081	C1516240
27544926	996	1011	C6 glioma cells	T025	C0007634
27544926	1040	1043	FUS	T061	C1517281
27544926	1044	1054	parameters	T077	C0549193
27544926	1059	1064	FCMBs	T074	C1258018
27544926	1067	1075	enhanced	T052	C2349975
27544926	1076	1089	gene delivery	T045	C0872177
27544926	1095	1107	confirmed by	T080	C0521093
27544926	1108	1112	cell	T025	C0007634
27544926	1113	1124	experiments	T062	C0681814
27544926	1126	1142	center frequency	T081	C1705502
27544926	1152	1169	acoustic pressure	T081	C4284008
27544926	1181	1186	pulse	T067	C1947910
27544926	1187	1197	repetition	T169	C0205341
27544926	1198	1207	frequency	T081	C1705502
27544926	1216	1221	cycle	T079	C1511572
27544926	1222	1228	number	T081	C0237753
27544926	1238	1246	exposure	T080	C0332157
27544926	1247	1251	time	T079	C0040223
27544926	1261	1266	FCMBs	T074	C1258018
27544926	1267	1280	concentration	T081	C1446561
27544926	1301	1308	In vivo	T082	C1515655
27544926	1309	1313	data	T078	C1511726
27544926	1319	1328	indicated	T033	C1444656
27544926	1334	1339	FCMBs	T074	C1258018
27544926	1345	1351	better	T080	C0332272
27544926	1352	1356	gene	T028	C0017337
27544926	1357	1369	transfection	T045	C0314641
27544926	1370	1380	efficiency	T081	C0013682
27544926	1386	1389	MBs	T074	C1258018
27544926	1390	1397	without	T080	C0332288
27544926	1398	1404	folate	T116,T192	C2955669
27544926	1405	1416	conjugation	T043	C1160466
27544926	1425	1436	traditional	T169	C0443324
27544926	1437	1445	approach	T082	C0449445
27544926	1449	1457	directly	T080	C1947931
27544926	1458	1467	injecting	T061	C1533685
27544926	1472	1476	gene	T028	C0017337
27544926	1483	1488	study	T062	C2603343
27544926	1503	1508	novel	T080	C0205314
27544926	1509	1520	development	T169	C1527148
27544926	1524	1539	multifunctional	T169	C0205245
27544926	1540	1543	MBs	T074	C1258018
27544926	1548	1551	FUS	T061	C1517281
27544926	1554	1563	triggered	T080	C1444748
27544926	1564	1577	gene delivery	T045	C0872177
27544926	1580	1587	therapy	T061	C0087111

28243464|t|Caring for relatives with agitation at home: a qualitative study of positive coping strategies
28243464|a|Trials of psychological interventions for reducing agitation in people with dementia living at home have been unsuccessful. To inform future interventions by identifying successful strategies of family carers with relatives with dementia and agitation living at home. Qualitative in-depth individual interviews were performed with 18 family carers. We used thematic analysis to identify emerging themes. Carers described initial surprise and then acceptance that agitation is a dementia symptom and learned to respond flexibly. Their strategies encompassed: prevention of agitation by familiar routine; reduction of agitation by addressing underlying causes and using distraction; prevention of escalation by risk enablement, not arguing; and control of their emotional responses by ensuring their relative's safety then walking away, carving out some time for themselves and using family and services for emotional and practical help. These strategies can be manualised and tested in future randomised controlled trials for clinical effectiveness in reducing agitation in people with dementia living at home. None. © The Royal College of Psychiatrists 2017. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) license.
28243464	0	6	Caring	T055	C0150499
28243464	11	20	relatives	T099	C0080103
28243464	26	35	agitation	T184	C0085631
28243464	39	43	home	T082	C0442519
28243464	47	64	qualitative study	T062	C0949415
28243464	68	76	positive	T033	C1446409
28243464	77	83	coping	T055	C0009967
28243464	84	94	strategies	T061	C0184661
28243464	95	101	Trials	T062	C0008976
28243464	105	132	psychological interventions	T058	C1879796
28243464	137	145	reducing	T080	C0392756
28243464	146	155	agitation	T184	C0085631
28243464	159	165	people	T098	C0027361
28243464	171	179	dementia	T048	C0497327
28243464	190	194	home	T082	C0442519
28243464	205	217	unsuccessful	T080	C1272705
28243464	236	249	interventions	T061	C0184661
28243464	265	275	successful	T080	C1272703
28243464	276	286	strategies	T061	C0184661
28243464	290	296	family	T099	C0015576
28243464	297	303	carers	T097	C0085537
28243464	309	318	relatives	T099	C0080103
28243464	324	332	dementia	T048	C0497327
28243464	337	346	agitation	T184	C0085631
28243464	357	361	home	T082	C0442519
28243464	363	374	Qualitative	T080	C0205556
28243464	384	405	individual interviews	T052	C0021822
28243464	411	420	performed	T169	C0884358
28243464	429	435	family	T099	C0015576
28243464	436	442	carers	T097	C0085537
28243464	452	469	thematic analysis	T062	C0949415
28243464	499	505	Carers	T097	C0085537
28243464	542	552	acceptance	T055	C0000899
28243464	558	567	agitation	T184	C0085631
28243464	573	581	dementia	T048	C0497327
28243464	582	589	symptom	T184	C1457887
28243464	594	601	learned	T041	C0023185
28243464	613	621	flexibly	T080	C0443220
28243464	629	639	strategies	T061	C0184661
28243464	653	663	prevention	T061	C0199176
28243464	667	676	agitation	T184	C0085631
28243464	680	688	familiar	T080	C0205309
28243464	698	707	reduction	T080	C0392756
28243464	711	720	agitation	T184	C0085631
28243464	763	774	distraction	T053	C4060717
28243464	776	786	prevention	T061	C0199176
28243464	790	800	escalation	T052	C4086266
28243464	804	819	risk enablement	T033	C0243095
28243464	838	845	control	T169	C2587213
28243464	855	874	emotional responses	T041	C0870485
28243464	893	903	relative's	T099	C0080103
28243464	904	910	safety	T068	C0036043
28243464	916	928	walking away	T033	C0243095
28243464	947	951	time	T079	C0040223
28243464	977	983	family	T099	C0015576
28243464	988	996	services	T058	C0018747
28243464	1001	1010	emotional	T033	C0849912
28243464	1025	1029	help	T080	C1269765
28243464	1037	1047	strategies	T061	C0184661
28243464	1087	1115	randomised controlled trials	T062	C0206035
28243464	1120	1142	clinical effectiveness	T080	C3850123
28243464	1146	1154	reducing	T080	C0392756
28243464	1155	1164	agitation	T184	C0085631
28243464	1168	1174	people	T098	C0027361
28243464	1180	1188	dementia	T048	C0497327
28243464	1199	1203	home	T082	C0442519

27444636|t|Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study
27444636|a|There are clinical situations where it might be appropriate to switch patients from immediate-release oxcarbazepine (OXC) to eslicarbazepine acetate (ESL). We investigated the effects of transitioning patients overnight from OXC to ESL. A retrospective, single-center study was conducted in which patients with drug-resistant focal epilepsy on a stable dose of immediate-release OXC for at least 4 weeks were switched overnight to ESL. Patients were switched because they experienced persistent seizures with OXC but were unable to tolerate increased OXC dosing due to adverse events. Tolerability was assessed using the Adverse Events Profile (AEP), quality of life was assessed using the Quality of Life in Epilepsy Inventory 10 (QOLIE-10), and alertness was assessed as reaction time using a subtest of the Test Battery for Attention Performance version 2.3. Assessments were performed immediately prior to and 5 days after switching from OXC to ESL (days 0 and 5, respectively). The analysis included 21 patients (12 women, 9 men; mean age 36 years). After switching from OXC to ESL, there were significant improvements in mean scores for AEP (P<.001), QOLIE-10 (P=.001), and alertness (P<.05). Adverse Events Profile total scores improved for 21/21 (100.0%) patients, QOLIE-10 total scores improved for 17/21 (81.0%) patients, and alertness scores improved for 16/21 (76.2%) patients. In this short-term, single-center study, an overnight switch from twice-daily OXC to once-daily ESL in patients with drug-resistant focal epilepsies resulted in improvements in side effects, quality of life, and alertness.
27444636	0	9	Overnight	T079	C0439583
27444636	10	19	switching	T058	C2936279
27444636	25	38	oxcarbazepine	T109,T121	C0069751
27444636	42	65	eslicarbazepine acetate	T109,T121	C2725262
27444636	70	89	observational study	T062	C1518527
27444636	100	119	clinical situations	T067	C0013956
27444636	138	149	appropriate	T080	C1548787
27444636	153	159	switch	T058	C2936279
27444636	160	168	patients	T101	C0030705
27444636	174	191	immediate-release	T122	C1708470
27444636	192	205	oxcarbazepine	T109,T121	C0069751
27444636	207	210	OXC	T109,T121	C0069751
27444636	215	238	eslicarbazepine acetate	T109,T121	C2725262
27444636	240	243	ESL	T109,T121	C2725262
27444636	249	261	investigated	T169	C1292732
27444636	266	276	effects of	T080	C1704420
27444636	291	299	patients	T101	C0030705
27444636	300	309	overnight	T079	C0439583
27444636	315	318	OXC	T109,T121	C0069751
27444636	322	325	ESL	T109,T121	C2725262
27444636	329	342	retrospective	T062	C0035363
27444636	344	363	single-center study	T062	C2603343
27444636	387	395	patients	T101	C0030705
27444636	401	415	drug-resistant	T038	C0013203
27444636	416	430	focal epilepsy	T047	C0014547
27444636	443	447	dose	T081	C0678766
27444636	451	468	immediate-release	T122	C1708470
27444636	469	472	OXC	T109,T121	C0069751
27444636	486	493	4 weeks	T079	C1442465
27444636	499	507	switched	T058	C2936279
27444636	508	517	overnight	T079	C0439583
27444636	521	524	ESL	T109,T121	C2725262
27444636	526	534	Patients	T101	C0030705
27444636	540	548	switched	T058	C2936279
27444636	574	584	persistent	T079	C0205322
27444636	585	593	seizures	T184	C0036572
27444636	599	602	OXC	T109,T121	C0069751
27444636	612	618	unable	T033	C1299582
27444636	622	630	tolerate	T080	C4053931
27444636	641	644	OXC	T109,T121	C0069751
27444636	645	651	dosing	T081	C0678766
27444636	659	673	adverse events	T046	C0041755
27444636	675	687	Tolerability	T080	C4053931
27444636	692	700	assessed	T052	C1516048
27444636	711	733	Adverse Events Profile	T170	C0282574
27444636	735	738	AEP	T170	C0282574
27444636	741	756	quality of life	T078	C0034380
27444636	761	769	assessed	T052	C1516048
27444636	780	820	Quality of Life in Epilepsy Inventory 10	T170	C0282574
27444636	822	830	QOLIE-10	T170	C0282574
27444636	837	846	alertness	T041	C1443086
27444636	851	859	assessed	T052	C1516048
27444636	863	876	reaction time	T079	C0034746
27444636	900	950	Test Battery for Attention Performance version 2.3	T073,T170	C0037585
27444636	952	963	Assessments	T058	C1261322
27444636	969	978	performed	T169	C0884358
27444636	979	990	immediately	T079	C0205548
27444636	991	999	prior to	T079	C0332152
27444636	1004	1010	5 days	T079	C1442466
27444636	1017	1026	switching	T058	C2936279
27444636	1032	1035	OXC	T109,T121	C0069751
27444636	1039	1042	ESL	T109,T121	C2725262
27444636	1044	1048	days	T079	C0439228
27444636	1077	1085	analysis	T062	C0936012
27444636	1098	1106	patients	T101	C0030705
27444636	1111	1116	women	T098	C0043210
27444636	1120	1123	men	T098	C0025266
27444636	1125	1142	mean age 36 years	T033	C0243095
27444636	1151	1160	switching	T058	C2936279
27444636	1166	1169	OXC	T109,T121	C0069751
27444636	1173	1176	ESL	T109,T121	C2725262
27444636	1201	1213	improvements	T077	C2986411
27444636	1217	1228	mean scores	T081	C0449820
27444636	1233	1236	AEP	T170	C0282574
27444636	1247	1255	QOLIE-10	T170	C0282574
27444636	1270	1279	alertness	T041	C1443086
27444636	1289	1311	Adverse Events Profile	T170	C0282574
27444636	1312	1324	total scores	T081	C0449820
27444636	1325	1333	improved	T033	C0184511
27444636	1353	1361	patients	T101	C0030705
27444636	1363	1371	QOLIE-10	T170	C0282574
27444636	1372	1384	total scores	T081	C0449820
27444636	1385	1393	improved	T033	C0184511
27444636	1412	1420	patients	T101	C0030705
27444636	1426	1435	alertness	T041	C1443086
27444636	1436	1442	scores	T081	C0449820
27444636	1443	1451	improved	T033	C0184511
27444636	1470	1478	patients	T101	C0030705
27444636	1488	1498	short-term	T079	C0443303
27444636	1500	1519	single-center study	T062	C2603343
27444636	1524	1533	overnight	T079	C0439583
27444636	1534	1540	switch	T058	C2936279
27444636	1546	1557	twice-daily	T079	C0585361
27444636	1558	1561	OXC	T109,T121	C0069751
27444636	1565	1575	once-daily	T079	C0556983
27444636	1576	1579	ESL	T109,T121	C2725262
27444636	1583	1591	patients	T101	C0030705
27444636	1597	1611	drug-resistant	T038	C0013203
27444636	1612	1628	focal epilepsies	T047	C0014547
27444636	1629	1637	resulted	T033	C2825142
27444636	1641	1653	improvements	T077	C2986411
27444636	1657	1669	side effects	T046	C0041755
27444636	1671	1686	quality of life	T078	C0034380
27444636	1692	1701	alertness	T041	C1443086

27931296|t|Intravenous and subcutaneous immunoglobulin G replacement therapy
27931296|a|Human polyclonal immunoglobulin G (IgG) for therapeutic use has been available for decades. This drug was developed for treatment of antibody deficiency (replacement therapy), although its use has expanded into many anti-inflammatory and immunomodulatory applications in recent years. This review focuses on IgG prescribing for replacement therapy. IgG for replacement is most often administered via the intravenous IgG (IVIG) or subcutaneous IgG (SCIG) routes. IVIG is usually administered every 34 weeks, and SCIG is usually administered weekly, although variations may be considered in all cases. Recently, a new product became available that uses hyaluronidase to facilitate absorption of large doses of SCIG less frequently (every 34 weeks, as with IVIG). There are important differences between the pharmacokinetics of these three routes of administration. IVIG therapy leads to high peaks and low troughs between infusions. IgG concentration fluctuates much less over time with SCIG. Hyaluronidase -facilitated SCIG is intermediate. SCIG may have lower bioavailability in comparison with IVIG and may require higher doses over time; this is not true for hyaluronidase SCIG. However, there are large variations in IgG half-life among individuals and with different products. Therefore, individualization of therapy is essential. Mild systemic flu-like adverse effects may affect up to 2025% of patients who receive IVIG, smaller fractions may experience more-severe symptoms, whereas anaphylaxis is exceedingly rare. General flu-like systemic adverse effects are minimal with SCIG (intermediate with hyaluronidase SCIG), but transient (24 hours), mild, local inflammatory symptoms at infusion sites are relatively common with both forms. Additional rare but important complications of IgG therapy include thrombotic events and hemolysis that can be seen at high doses with any route of administration. Renal adverse effects may occur with IVIG as well. The variety of IgG products and routes of administration available today creates many opportunities for physicians to work with patients to find the optimal therapy for all.
27931296	0	11	Intravenous	T116,T121,T129	C0085297
27931296	16	28	subcutaneous	T121,T129	C2048009
27931296	29	45	immunoglobulin G	T116,T121,T129	C0020852
27931296	46	65	replacement therapy	T061	C0279033
27931296	66	71	Human	T016	C0086418
27931296	72	82	polyclonal	T116,T129	C0312586
27931296	83	99	immunoglobulin G	T116,T121,T129	C0020852
27931296	101	104	IgG	T116,T121,T129	C0020852
27931296	110	125	therapeutic use	T080	C0039795
27931296	149	156	decades	T081	C2981279
27931296	163	167	drug	T121	C1254351
27931296	186	195	treatment	T169	C1522326
27931296	199	218	antibody deficiency	T047	C0003257
27931296	220	239	replacement therapy	T061	C0279033
27931296	255	258	use	T169	C0457083
27931296	282	299	anti-inflammatory	T080	C1515999
27931296	304	320	immunomodulatory	T061	C1963758
27931296	344	349	years	T079	C0439234
27931296	356	362	review	T170	C0282443
27931296	374	377	IgG	T116,T121,T129	C0020852
27931296	378	389	prescribing	T058	C0278329
27931296	394	413	replacement therapy	T061	C0279033
27931296	415	418	IgG	T116,T121,T129	C0020852
27931296	423	434	replacement	T061	C0279033
27931296	449	461	administered	T169	C1521801
27931296	470	485	intravenous IgG	T116,T121,T129	C0020852
27931296	487	491	IVIG	T116,T121,T129	C0020852
27931296	496	512	subcutaneous IgG	T116,T121,T129	C0020852
27931296	514	518	SCIG	T116,T121,T129	C0020852
27931296	528	532	IVIG	T116,T121,T129	C0020852
27931296	544	556	administered	T169	C1521801
27931296	566	571	weeks	T079	C0439230
27931296	577	581	SCIG	T116,T121,T129	C0020852
27931296	593	605	administered	T169	C1521801
27931296	606	612	weekly	T079	C0332174
27931296	659	664	cases	T169	C0868928
27931296	678	689	new product	T121	C1254351
27931296	717	730	hyaluronidase	T116,T121,T126	C0020197
27931296	745	755	absorption	T067	C2347023
27931296	759	770	large doses	T081	C0178602
27931296	774	778	SCIG	T116,T121,T129	C0020852
27931296	805	810	weeks	T079	C0439230
27931296	820	824	IVIG	T116,T121,T129	C0020852
27931296	871	887	pharmacokinetics	T169	C0031328
27931296	903	927	routes of administration	T169	C0013153
27931296	929	933	IVIG	T116,T121,T129	C0020852
27931296	934	941	therapy	T061	C0279033
27931296	986	995	infusions	T061	C0574032
27931296	997	1000	IgG	T116,T121,T129	C0020852
27931296	1051	1055	SCIG	T116,T121,T129	C0020852
27931296	1057	1070	Hyaluronidase	T116,T121,T126	C0020197
27931296	1084	1088	SCIG	T116,T121,T129	C0020852
27931296	1106	1110	SCIG	T116,T121,T129	C0020852
27931296	1120	1141	lower bioavailability	T081	C0005508
27931296	1161	1165	IVIG	T116,T121,T129	C0020852
27931296	1182	1194	higher doses	T081	C0178602
27931296	1227	1240	hyaluronidase	T116,T121,T126	C0020197
27931296	1241	1245	SCIG	T116,T121,T129	C0020852
27931296	1286	1289	IgG	T116,T121,T129	C0020852
27931296	1290	1299	half-life	T079	C0018517
27931296	1306	1317	individuals	T098	C0237401
27931296	1379	1386	therapy	T061	C0279033
27931296	1406	1414	systemic	T169	C0205373
27931296	1415	1439	flu-like adverse effects	T046	C0879626
27931296	1466	1474	patients	T101	C0030705
27931296	1487	1491	IVIG	T116,T121,T129	C0020852
27931296	1526	1546	more-severe symptoms	T033	C3846035
27931296	1556	1567	anaphylaxis	T046	C0002792
27931296	1597	1630	flu-like systemic adverse effects	T046	C0879626
27931296	1635	1642	minimal	T080	C0547040
27931296	1648	1652	SCIG	T116,T121,T129	C0020852
27931296	1672	1685	hyaluronidase	T116,T121,T126	C0020197
27931296	1686	1690	SCIG	T116,T121,T129	C0020852
27931296	1708	1716	24 hours	T079	C1442770
27931296	1731	1752	inflammatory symptoms	T184	C1457887
27931296	1756	1770	infusion sites	T082	C2697750
27931296	1840	1853	complications	T046	C0009566
27931296	1857	1860	IgG	T116,T121,T129	C0020852
27931296	1861	1868	therapy	T061	C0279033
27931296	1877	1894	thrombotic events	T046	C0040053
27931296	1899	1908	hemolysis	T046	C0019054
27931296	1929	1939	high doses	T081	C0444956
27931296	1949	1972	route of administration	T169	C0013153
27931296	1974	1979	Renal	T023	C0022646
27931296	1980	1995	adverse effects	T046	C0879626
27931296	2011	2015	IVIG	T116,T121,T129	C0020852
27931296	2040	2043	IgG	T116,T121,T129	C0020852
27931296	2057	2081	routes of administration	T169	C0013153
27931296	2129	2139	physicians	T097	C0031831
27931296	2153	2161	patients	T101	C0030705
27931296	2182	2189	therapy	T061	C0279033

27821385|t|Adjuvant Endocrine Therapy in Breast Cancer: A Novel e-Health Approach in Optimizing Treatment for Seniors (OPTIMUM): A Two- Group Controlled Comparison Pilot Study
27821385|a|In women with hormone receptor positive breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage. Nonadherence is a particular challenge in older women, even though they stand to benefit the most from AET. Therefore, a novel eHealth tool (OPTIMUM) that integrates real-time analysis of health administrative claims data was developed to provide point-of-care decision support for clinicians. The objectives of the study are to determine the effectiveness of a patient -specific, real-time eHealth alert delivered at point-of-care in reducing rates of AET discontinuation and to understand patient -level factors related to AET discontinuation as well as to assess integration of eHealth alerts regarding deviations from best practices in administration of AET by cancer care teams. A prospective, 2- group controlled comparison pilot study will be conducted at 2 urban, McGill University-affiliated hospitals, the Royal Victoria Hospital and St. Mary's Hospital. A minimum of 43 patients per study arm will be enrolled through site-level allocation. Follow-up is 1.5 years. Health care professionals at the intervention site will have access to the eHealth tool, which will report to them in real-time medical events with known associations to AET discontinuation, an AET adherence monitor, and a discontinuation alert. Cox proportional hazard ratios with 95% confidence intervals will estimate risks of AET discontinuation. Tests for significance will be 2-sided with a significance level of P<.05. This protocol has been approved and funded by the Canadian Institutes of Health Research. The study will evaluate site-level differences between AET discontinuation and AET adherence and assess care team actions at the intervention site. Participant enrollment into this project is expected to start September 2016 with primary data ready to present by June 2018. This study will offer an opportunity to verify the feasibility of integrating an eHealth tool that aims to improve the long-term management of breast cancer in a high-risk population by allowing more timely intervention to prevent or rapidly address AET discontinuation.
27821385	0	26	Adjuvant Endocrine Therapy	T061	C0279025
27821385	30	43	Breast Cancer	T191	C0678222
27821385	53	70	e-Health Approach	T170	C0282574
27821385	85	94	Treatment	T061	C0087111
27821385	99	106	Seniors	T102	C1456594
27821385	108	115	OPTIMUM	T170	C0282574
27821385	125	130	Group	T098	C1257890
27821385	153	164	Pilot Study	T062	C0031928
27821385	168	173	women	T098	C0043210
27821385	179	204	hormone receptor positive	T191	C1563119
27821385	205	218	breast cancer	T191	C0678222
27821385	220	246	adjuvant endocrine therapy	T061	C0279025
27821385	248	251	AET	T061	C0279025
27821385	256	271	associated with	T080	C0332281
27821385	286	294	survival	T052	C0038952
27821385	306	318	Nonadherence	T033	C0376405
27821385	354	359	women	T098	C0043210
27821385	409	412	AET	T061	C0279025
27821385	433	445	eHealth tool	T170	C0282574
27821385	447	454	OPTIMUM	T170	C0282574
27821385	472	490	real-time analysis	T062	C0936012
27821385	494	527	health administrative claims data	T058	C0086388
27821385	553	566	point-of-care	T078	C1547702
27821385	588	598	clinicians	T097	C0871685
27821385	649	662	effectiveness	T080	C1280519
27821385	668	675	patient	T101	C0030705
27821385	687	720	real-time eHealth alert delivered	T058	C0086388
27821385	724	737	point-of-care	T078	C1547702
27821385	759	762	AET	T061	C0279025
27821385	763	778	discontinuation	T058	C0457454
27821385	797	804	patient	T101	C0030705
27821385	831	834	AET	T061	C0279025
27821385	835	850	discontinuation	T058	C0457454
27821385	887	901	eHealth alerts	T058	C0086388
27821385	933	942	practices	T041	C0237607
27821385	946	960	administration	T061	C1533734
27821385	964	967	AET	T061	C0279025
27821385	971	977	cancer	T191	C0006826
27821385	978	988	care teams	T058	C0086388
27821385	1008	1013	group	T098	C1257890
27821385	1036	1047	pilot study	T062	C0031928
27821385	1078	1116	McGill University-affiliated hospitals	T073,T093	C0019994
27821385	1122	1145	Royal Victoria Hospital	T073,T093	C0019994
27821385	1150	1169	St. Mary's Hospital	T073,T093	C0019994
27821385	1187	1195	patients	T101	C0030705
27821385	1218	1226	enrolled	T058	C1516879
27821385	1235	1256	site-level allocation	T052	C1706778
27821385	1258	1267	Follow-up	T058	C1522577
27821385	1282	1307	Health care professionals	T097	C0018724
27821385	1315	1332	intervention site	T061	C0184661
27821385	1357	1369	eHealth tool	T170	C0282574
27821385	1400	1424	real-time medical events	T033	C0243095
27821385	1452	1455	AET	T061	C0279025
27821385	1456	1471	discontinuation	T058	C0457454
27821385	1476	1479	AET	T061	C0279025
27821385	1480	1489	adherence	T169	C1510802
27821385	1505	1520	discontinuation	T058	C0457454
27821385	1528	1558	Cox proportional hazard ratios	T081	C2985465
27821385	1568	1588	confidence intervals	T081	C0009667
27821385	1612	1615	AET	T061	C0279025
27821385	1616	1631	discontinuation	T058	C0457454
27821385	1633	1638	Tests	T170	C0392366
27821385	1679	1697	significance level	T062	C0814896
27821385	1758	1796	Canadian Institutes of Health Research	T093	C0596660
27821385	1853	1856	AET	T061	C0279025
27821385	1857	1872	discontinuation	T058	C0457454
27821385	1877	1880	AET	T061	C0279025
27821385	1881	1890	adherence	T169	C1510802
27821385	1902	1919	care team actions	T058	C0086388
27821385	1927	1944	intervention site	T061	C0184661
27821385	1946	1957	Participant	T098	C0679646
27821385	1958	1968	enrollment	T058	C1516879
27821385	2123	2134	feasibility	T062,T170	C0015730
27821385	2153	2165	eHealth tool	T170	C0282574
27821385	2191	2200	long-term	T079	C0443252
27821385	2201	2211	management	T058	C0376636
27821385	2215	2228	breast cancer	T191	C0678222
27821385	2234	2243	high-risk	T033	C0332167
27821385	2244	2254	population	T098	C1257890
27821385	2279	2291	intervention	T061	C0184661
27821385	2322	2325	AET	T061	C0279025
27821385	2326	2341	discontinuation	T058	C0457454

28236014|t|The SmartOR: a distributed sensor network to improve operating room efficiency
28236014|a|Despite the significant expense of OR time, best practice achieves only 70% efficiency. Compounding this problem is a lack of real-time data. Most current OR utilization programs require manual data entry. Automated systems require installation and maintenance of expensive tracking hardware throughout the institution. This study developed an inexpensive, automated OR utilization system and analyzed data from multiple operating rooms. OR activity was deconstructed into four room states. A sensor network was then developed to automatically capture these states using only three sensors, a local wireless network, and a data capture computer. Two systems were then installed into two ORs, recordings captured 24/7. The SmartOR recorded the following events: any room activity, patient entry/exit time, anesthesia time, laparoscopy time, room turnover time, and time of preoperative patient identification by the surgeon. From November 2014 to December 2015, data on 1003 cases were collected. The mean turnover time was 36 min, and 38% of cases met the institutional goal of ≤30 min. Data analysis also identified outlier cases (>1 SD from mean) in the domains of time from patient entry into the OR to intubation (11% of cases) and time from extubation to patient exiting the OR (11% of cases). Time from surgeon identification of patient to scheduled procedure start time was 11 min (institution bylaws require 20 min before scheduled start time), yet OR teams required 22 min on average to bring a patient into the room after surgeon identification. The SmartOR automatically and reliably captures data on OR room state and, in real time, identifies outlier cases that may be examined closer to improve efficiency. As no manual entry is required, the data are indisputable and allow OR teams to maintain a patient -centric focus.
28236014	4	11	SmartOR	T062	C0700032
28236014	27	33	sensor	T073	C0183210
28236014	34	41	network	T169	C1882071
28236014	45	52	improve	T033	C0184511
28236014	53	67	operating room	T073,T093	C0029064
28236014	68	78	efficiency	T081	C0013682
28236014	91	102	significant	T078	C0750502
28236014	103	110	expense	T081	C0680864
28236014	114	116	OR	T073,T093	C0029064
28236014	117	121	time	T079	C0040223
28236014	128	136	practice	T057	C0033284
28236014	155	165	efficiency	T081	C0013682
28236014	167	178	Compounding	T080	C0205198
28236014	205	214	real-time	T079	C1550177
28236014	215	219	data	T078	C1511726
28236014	226	233	current	T079	C0521116
28236014	234	236	OR	T073,T093	C0029064
28236014	237	248	utilization	T169	C0042153
28236014	249	257	programs	T169	C3484370
28236014	258	265	require	T169	C1514873
28236014	266	272	manual	T169	C0175674
28236014	273	283	data entry	T170	C1705654
28236014	285	302	Automated systems	T170	C0596139
28236014	303	310	require	T169	C1514873
28236014	328	339	maintenance	T052	C0024501
28236014	343	352	expensive	T080	C0205556
28236014	353	370	tracking hardware	T074	C0025080
28236014	386	397	institution	T073,T093	C0018704
28236014	404	409	study	T062	C2603343
28236014	423	434	inexpensive	T080	C0205556
28236014	436	445	automated	T169	C0205554
28236014	446	448	OR	T073,T093	C0029064
28236014	449	460	utilization	T169	C0042153
28236014	461	467	system	T169	C0449913
28236014	472	480	analyzed	T062	C0936012
28236014	481	485	data	T078	C1511726
28236014	491	499	multiple	T081	C0439064
28236014	500	515	operating rooms	T073,T093	C0029064
28236014	517	519	OR	T073,T093	C0029064
28236014	520	528	activity	T052	C0441655
28236014	557	561	room	T073,T093	C0029064
28236014	562	568	states	T169	C1442792
28236014	572	578	sensor	T073	C0183210
28236014	579	586	network	T169	C1882071
28236014	609	622	automatically	T033	C3842331
28236014	637	643	states	T169	C1442792
28236014	661	668	sensors	T073	C0183210
28236014	672	677	local	T082	C0205276
28236014	678	686	wireless	T073	C1520154
28236014	687	694	network	T169	C1882071
28236014	702	714	data capture	T062	C0010995
28236014	715	723	computer	T073	C0009622
28236014	729	736	systems	T169	C0449913
28236014	766	769	ORs	T073,T093	C0029064
28236014	771	781	recordings	T073	C3273359
28236014	801	808	SmartOR	T062	C0700032
28236014	832	838	events	T051	C0441471
28236014	844	848	room	T073,T093	C0029064
28236014	849	857	activity	T052	C0441655
28236014	859	866	patient	T101	C0030705
28236014	867	882	entry/exit time	T079	C1254367
28236014	884	899	anesthesia time	T033	C2223561
28236014	901	912	laparoscopy	T060	C0031150
28236014	913	917	time	T079	C0040223
28236014	919	923	room	T073,T093	C0029064
28236014	924	937	turnover time	T079	C0040223
28236014	943	947	time	T079	C0040223
28236014	951	963	preoperative	T079	C0445204
28236014	964	971	patient	T101	C0030705
28236014	972	986	identification	T041	C0020792
28236014	994	1001	surgeon	T097	C0582175
28236014	1008	1016	November	T079	C3828767
28236014	1025	1033	December	T080	C3830550
28236014	1040	1044	data	T078	C1511726
28236014	1053	1058	cases	T169	C0868928
28236014	1079	1083	mean	T081	C0444504
28236014	1084	1097	turnover time	T079	C0040223
28236014	1121	1126	cases	T169	C0868928
28236014	1135	1148	institutional	T073,T093	C0018704
28236014	1166	1179	Data analysis	T057	C0010992
28236014	1185	1195	identified	T041	C0020792
28236014	1204	1209	cases	T169	C0868928
28236014	1214	1216	SD	T081	C0871420
28236014	1222	1226	mean	T081	C0444504
28236014	1246	1250	time	T079	C0040223
28236014	1256	1263	patient	T101	C0030705
28236014	1279	1281	OR	T073,T093	C0029064
28236014	1285	1295	intubation	T061	C0021925
28236014	1304	1309	cases	T169	C0868928
28236014	1315	1319	time	T079	C0040223
28236014	1325	1335	extubation	T061	C0553891
28236014	1339	1346	patient	T101	C0030705
28236014	1359	1361	OR	T073,T093	C0029064
28236014	1370	1375	cases	T169	C0868928
28236014	1378	1382	Time	T079	C0040223
28236014	1388	1395	surgeon	T097	C0582175
28236014	1396	1410	identification	T041	C0020792
28236014	1414	1421	patient	T101	C0030705
28236014	1425	1444	scheduled procedure	T080	C0205539
28236014	1445	1455	start time	T079	C1301880
28236014	1468	1479	institution	T073,T093	C0018704
28236014	1480	1486	bylaws	T089	C0006540
28236014	1487	1494	require	T169	C1514873
28236014	1509	1518	scheduled	T079	C1571999
28236014	1525	1529	time	T079	C0040223
28236014	1536	1544	OR teams	T080	C0520261
28236014	1545	1553	required	T169	C1514873
28236014	1564	1571	average	T081	C1510992
28236014	1583	1590	patient	T101	C0030705
28236014	1600	1604	room	T073,T093	C0029064
28236014	1611	1618	surgeon	T097	C0582175
28236014	1619	1633	identification	T041	C0020792
28236014	1639	1646	SmartOR	T062	C0700032
28236014	1647	1660	automatically	T033	C3842331
28236014	1665	1673	reliably	T170	C3858758
28236014	1683	1687	data	T078	C1511726
28236014	1691	1693	OR	T073,T093	C0029064
28236014	1694	1698	room	T073,T093	C0029064
28236014	1699	1704	state	T169	C1442792
28236014	1713	1722	real time	T079	C1550177
28236014	1724	1734	identifies	T080	C0205396
28236014	1743	1748	cases	T169	C0868928
28236014	1761	1769	examined	T033	C0332128
28236014	1780	1787	improve	T033	C0184511
28236014	1788	1798	efficiency	T081	C0013682
28236014	1806	1812	manual	T169	C0175674
28236014	1822	1830	required	T169	C1514873
28236014	1836	1840	data	T078	C1511726
28236014	1845	1857	indisputable	T080	C0205556
28236014	1868	1876	OR teams	T080	C0520261
28236014	1880	1888	maintain	T052	C0024501
28236014	1891	1898	patient	T101	C0030705

28107427|t|Serine Phosphorylation of SLP76 Is Dispensable for T Cell Development but Modulates Helper T Cell Function
28107427|a|The adapter protein SLP76 is a key orchestrator of T cell receptor (TCR) signal transduction. We previously identified a negative feedback loop that modulates T cell activation, involving phosphorylation of Ser376 of SLP76 by the hematopoietic progenitor kinase 1 (HPK1). However, the physiological relevance of this regulatory mechanism was still unknown. To address this question, we generated a SLP76-S376A - expressing knock-in mouse strain and investigated the effects of Ser376 mutation on T cell development and function. We report here that SLP76-S376A - expressing mice exhibit normal thymocyte development and no detectable phenotypic alterations in mature T cell subsets or other lymphoid and myeloid cell lineages. Biochemical analyses revealed that mutant T cells were hypersensitive to TCR stimulation. Indeed, phosphorylation of several signaling proteins, including SLP76 itself, phospholipase Cγ1 and the protein kinases AKT and ERK1 / 2, was increased. These modifications correlated with increased Th1-type and decreased Th2-type cytokine production by SLP76-S376A T cells, but did not result in significant changes of proliferative capacity nor activation - induced cell death susceptibility. Hence, our results reveal that SLP76-Ser376 phosphorylation does not mediate all HPK1 -dependent regulatory effects in T cells but it fine-tunes helper T cell responses.
28107427	0	6	Serine	T116,T121,T123	C0036720
28107427	7	22	Phosphorylation	T044	C1158886
28107427	26	31	SLP76	T116,T123	C0296250
28107427	51	69	T Cell Development	T043	C1515126
28107427	74	83	Modulates	UnknownType	C0544633
28107427	84	97	Helper T Cell	T025	C0018894
28107427	98	106	Function	T043	C0007613
28107427	111	126	adapter protein	T116,T123	C1449886
28107427	127	132	SLP76	T116,T123	C0296250
28107427	158	173	T cell receptor	T116,T129,T192	C0034790
28107427	175	178	TCR	T116,T129,T192	C0034790
28107427	180	199	signal transduction	T043	C0037083
28107427	228	250	negative feedback loop	T067	C0949702
28107427	256	265	modulates	UnknownType	C0544633
28107427	266	283	T cell activation	T043	C1155065
28107427	295	310	phosphorylation	T044	C1158886
28107427	314	320	Ser376	T116,T121,T123	C0036720
28107427	324	329	SLP76	T116,T123	C0296250
28107427	337	370	hematopoietic progenitor kinase 1	T116,T121,T126	C0531166
28107427	372	376	HPK1	T116,T121,T126	C0531166
28107427	392	405	physiological	T169	C0205463
28107427	406	415	relevance	T080	C2347946
28107427	424	434	regulatory	T077	C1704735
28107427	435	444	mechanism	T169	C0441712
28107427	505	516	SLP76-S376A	T028	C1334333
28107427	519	529	expressing	T045	C0017262
28107427	530	538	knock-in	T062	C1517676
28107427	539	551	mouse strain	T015	C0026809
28107427	556	568	investigated	T169	C1292732
28107427	584	599	Ser376 mutation	T045	C0596611
28107427	603	621	T cell development	T043	C1515126
28107427	626	634	function	T043	C0007613
28107427	656	667	SLP76-S376A	T028	C1334333
28107427	670	680	expressing	T045	C0017262
28107427	681	685	mice	T015	C0026809
28107427	694	700	normal	T080	C0205307
28107427	701	722	thymocyte development	T043	C1515432
28107427	730	740	detectable	T201	C3830527
28107427	741	751	phenotypic	T032	C0031437
28107427	752	763	alterations	T078	C1515926
28107427	767	773	mature	T079	C0205286
28107427	774	788	T cell subsets	T025	C0080202
28107427	798	806	lymphoid	T025	C0024264
28107427	811	818	myeloid	T025	C0369715
28107427	819	832	cell lineages	T078	C0282637
28107427	834	854	Biochemical analyses	T059	C0430027
28107427	869	875	mutant	T049	C0596988
28107427	876	883	T cells	T025	C0039194
28107427	889	903	hypersensitive	T046	C0020517
28107427	907	910	TCR	T116,T129,T192	C0034790
28107427	911	922	stimulation	T044	C2259054
28107427	932	947	phosphorylation	T044	C1158886
28107427	959	977	signaling proteins	T116,T123	C1335962
28107427	989	994	SLP76	T116,T123	C0296250
28107427	1003	1020	phospholipase Cγ1	T116,T126	C0753837
28107427	1029	1048	protein kinases AKT	T116,T126	C0164786
28107427	1053	1057	ERK1	T116,T126	C0082529
28107427	1060	1061	2	T116,T126	C0170168
28107427	1067	1076	increased	T081	C0205217
28107427	1084	1097	modifications	T033	C3840684
28107427	1098	1108	correlated	T080	C1707520
28107427	1114	1123	increased	T081	C0205217
28107427	1124	1132	Th1-type	T025	C0242632
28107427	1137	1146	decreased	T081	C0205216
28107427	1147	1155	Th2-type	T025	C0242633
28107427	1156	1175	cytokine production	T040	C1327413
28107427	1179	1190	SLP76-S376A	T028	C1334333
28107427	1191	1198	T cells	T025	C0039194
28107427	1245	1267	proliferative capacity	T043	C1155046
28107427	1259	1267	capacity	T033	C1998319
28107427	1272	1282	activation	T043	C2248112
28107427	1285	1292	induced	T169	C0205263
28107427	1293	1303	cell death	T043	C0007587
28107427	1304	1318	susceptibility	T169	C1264642
28107427	1331	1338	results	T033	C0683954
28107427	1339	1345	reveal	T080	C0443289
28107427	1351	1363	SLP76-Ser376	T116,T123	C0296250
28107427	1364	1379	phosphorylation	T044	C1158886
28107427	1401	1405	HPK1	T116,T121,T126	C0531166
28107427	1417	1427	regulatory	T077	C1704735
28107427	1439	1446	T cells	T025	C0039194
28107427	1465	1478	helper T cell	T025	C0018894
28107427	1479	1488	responses	T032	C0871261

27894158|t|Craving behavioral intervention for internet gaming disorder: remediation of functional connectivity of the ventral striatum
27894158|a|Psychobehavioral intervention is an effective treatment of Internet addiction, including Internet gaming disorder (IGD). However, the neural mechanisms underlying its efficacy remain unclear. Cortical - ventral striatum (VS) circuitry is a common target of psychobehavioral interventions in drug addiction, and cortical - VS dysfunction has been reported in IGD; hence, the primary aim of the study was to investigate how the VS circuitry responds to psychobehavioral interventions in IGD. In a cross-sectional study, we examined resting-state functional connectivity of the VS in 74 IGD subjects (IGDs) and 41 healthy controls (HCs). In a follow-up craving behavioral intervention (CBI) study, of the 74 IGD subjects, 20 IGD subjects received CBI (CBI+) and 16 IGD subjects did not (CBI-). All participants were scanned twice with similar time interval to assess the effects of CBI. IGD subjects showed greater resting-state functional connectivity of the VS to left inferior parietal lobule (lIPL), right inferior frontal gyrus and left middle frontal gyrus, in positive association with the severity of IGD. Moreover, compared with CBI-, CBI+ showed significantly greater decrease in VS - lIPL connectivity, along with amelioration in addiction severity following the intervention. These findings demonstrated that functional connectivity between VS and lIPL, each presumably mediating gaming craving and attentional bias, may be a potential biomarker of the efficacy of psychobehavioral intervention. These results also suggested that non-invasive techniques such as transcranial magnetic or direct current stimulation targeting the VS - lIPL circuitry may be used in the treatment of Internet gaming disorders.
27894158	0	7	Craving	T055	C0870371
27894158	8	31	behavioral intervention	T061	C0004933
27894158	36	60	internet gaming disorder	T048	C0004930
27894158	62	73	remediation	T061	C4277695
27894158	77	87	functional	T169	C0205245
27894158	88	100	connectivity	T169	C1707489
27894158	108	124	ventral striatum	T023	C0750950
27894158	125	154	Psychobehavioral intervention	T061	C0004933
27894158	171	180	treatment	T061	C0087111
27894158	184	192	Internet	T073	C0282111
27894158	193	202	addiction	T048	C0085281
27894158	214	238	Internet gaming disorder	T048	C0004930
27894158	240	243	IGD	T048	C0004930
27894158	259	265	neural	T169	C3714606
27894158	266	276	mechanisms	T169	C0441712
27894158	292	300	efficacy	T080	C1280519
27894158	317	325	Cortical	T029	C0005898
27894158	328	344	ventral striatum	T023	C0750950
27894158	346	348	VS	T023	C0750950
27894158	350	359	circuitry	UnknownType	C0260041
27894158	365	371	common	T081	C0205214
27894158	372	378	target	T169	C1521840
27894158	382	412	psychobehavioral interventions	T061	C0004933
27894158	416	430	drug addiction	T048	C1510472
27894158	436	444	cortical	T029	C0005898
27894158	447	449	VS	T023	C0750950
27894158	450	461	dysfunction	T077	C3887504
27894158	483	486	IGD	T048	C0004930
27894158	518	523	study	T062	C2603343
27894158	551	553	VS	T023	C0750950
27894158	554	563	circuitry	UnknownType	C0260041
27894158	576	606	psychobehavioral interventions	T061	C0004933
27894158	610	613	IGD	T048	C0004930
27894158	620	641	cross-sectional study	T062	C0010362
27894158	655	668	resting-state	T033	C0679218
27894158	669	679	functional	T169	C0205245
27894158	680	692	connectivity	T169	C1707489
27894158	700	702	VS	T023	C0750950
27894158	709	712	IGD	T048	C0004930
27894158	713	721	subjects	T098	C0080105
27894158	723	727	IGDs	T048	C0004930
27894158	736	752	healthy controls	T080	C2986479
27894158	754	757	HCs	T080	C2986479
27894158	765	774	follow-up	T058	C1522577
27894158	775	806	craving behavioral intervention	T061	C0004933
27894158	808	811	CBI	T061	C0004933
27894158	813	818	study	T062	C2603343
27894158	830	833	IGD	T048	C0004930
27894158	834	842	subjects	T098	C0080105
27894158	847	850	IGD	T048	C0004930
27894158	851	859	subjects	T098	C0080105
27894158	860	868	received	T080	C1514756
27894158	869	872	CBI	T061	C0004933
27894158	874	878	CBI+	T078	C0441833
27894158	887	890	IGD	T048	C0004930
27894158	891	899	subjects	T098	C0080105
27894158	909	913	CBI-	T078	C0441833
27894158	920	932	participants	T098	C0679646
27894158	938	945	scanned	T060	C0441633
27894158	965	978	time interval	T079	C0872291
27894158	982	988	assess	T058	C0184514
27894158	993	1003	effects of	T080	C1704420
27894158	1004	1007	CBI	T061	C0004933
27894158	1009	1012	IGD	T048	C0004930
27894158	1013	1021	subjects	T098	C0080105
27894158	1029	1036	greater	T081	C1704243
27894158	1037	1050	resting-state	T033	C0679218
27894158	1051	1061	functional	T169	C0205245
27894158	1062	1074	connectivity	T169	C1707489
27894158	1082	1084	VS	T023	C0750950
27894158	1088	1117	left inferior parietal lobule	T023	C2323393
27894158	1119	1123	lIPL	T023	C2323393
27894158	1126	1154	right inferior frontal gyrus	T023	C2338392
27894158	1159	1184	left middle frontal gyrus	T023	C2338540
27894158	1189	1197	positive	T033	C1446409
27894158	1198	1209	association	T080	C0439849
27894158	1219	1227	severity	T080	C0439793
27894158	1231	1234	IGD	T048	C0004930
27894158	1246	1254	compared	T052	C1707455
27894158	1260	1264	CBI-	T078	C0441833
27894158	1266	1270	CBI+	T078	C0441833
27894158	1278	1299	significantly greater	T081	C4055637
27894158	1300	1308	decrease	T081	C0547047
27894158	1312	1314	VS	T023	C0750950
27894158	1317	1321	lIPL	T023	C2323393
27894158	1322	1334	connectivity	T169	C1707489
27894158	1347	1359	amelioration	T169	C1301676
27894158	1363	1372	addiction	T048	C0085281
27894158	1373	1381	severity	T080	C0439793
27894158	1396	1408	intervention	T061	C0004933
27894158	1416	1424	findings	T033	C0243095
27894158	1443	1453	functional	T169	C0205245
27894158	1454	1466	connectivity	T169	C1707489
27894158	1475	1477	VS	T023	C0750950
27894158	1482	1486	lIPL	T023	C2323393
27894158	1514	1520	gaming	T073	C0042649
27894158	1521	1528	craving	T055	C0870371
27894158	1533	1549	attentional bias	T041	C4277667
27894158	1560	1569	potential	T080	C3245505
27894158	1570	1579	biomarker	T201	C0005516
27894158	1587	1595	efficacy	T080	C1280519
27894158	1599	1628	psychobehavioral intervention	T061	C0004933
27894158	1636	1643	results	T033	C2825142
27894158	1664	1676	non-invasive	T169	C0205303
27894158	1677	1687	techniques	T169	C0449851
27894158	1696	1717	transcranial magnetic	T061	C0436548
27894158	1721	1747	direct current stimulation	T061	C3850024
27894158	1762	1764	VS	T023	C0750950
27894158	1767	1771	lIPL	T023	C2323393
27894158	1772	1781	circuitry	UnknownType	C0260041
27894158	1801	1810	treatment	T061	C0087111
27894158	1814	1839	Internet gaming disorders	T048	C0004930

27236033|t|LDLR, ApoB and ApoE genes polymorphisms and classical risk factors in premature coronary artery disease
27236033|a|Lipoproteins play a central role in the development of atherosclerotic disease. So, with their ability to affect lipid levels, the LDLR, ApoB and ApoE polymorphisms could be one of the factors influencing development of atherosclerosis. This hypothesis has been tested in different populations with conflicting results. The purpose of the present study was to investigate the association between the LDLR, ApoB and ApoE genes polymorphisms with premature CAD (PCAD) in Egyptians. One hundred thirty-five patients of PCAD and one hundred thirty-two ages and sex matched control subjects were included in the study. LDLR and ApoB genes polymorphisms were analyzed by polymerase chain reaction (PCR). The ApoE genotypes were identified by multiplex amplification refractory mutation system (multi-AMRS). We found that LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele increased the risk of PCAD by 1.8, 2.1 and 12.1 respectively. The present study proved that smoking, metabolic syndrome, ApoB X(+)X(+) genotype and ApoE E4 allele were independent risk factors for the development of PCAD. This is the first study investigate the association between low density lipoprotein receptor, apolipoprotein B and apolipoprotein E genes polymorphisms with PCAD and lipid levels in Egyptians and we concluded that the LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele may be associated with an increased risk for development of PCAD by elevated levels of total cholesterol (TC) and low density lipoprotein (LDLc). The coexistence of CAD risk factors with LDLR A(+)A(+) genotype, ApoB X(+) allele and ApoE E4 allele may increase the risk of the development of PCAD in Egyptian patients.
27236033	0	4	LDLR	T028	C1366529
27236033	6	10	ApoB	T028	C1412471
27236033	15	25	ApoE genes	T028	C1412481
27236033	26	39	polymorphisms	T045	C0678951
27236033	54	66	risk factors	T033	C0035648
27236033	70	103	premature coronary artery disease	T047	C1867743
27236033	104	116	Lipoproteins	T116,T123	C0023820
27236033	144	155	development	T169	C1527148
27236033	159	182	atherosclerotic disease	T047	C0004153
27236033	217	229	lipid levels	T034	C0428460
27236033	235	239	LDLR	T028	C1366529
27236033	241	245	ApoB	T028	C1412471
27236033	250	254	ApoE	T028	C1412481
27236033	255	268	polymorphisms	T045	C0678951
27236033	309	320	development	T169	C1527148
27236033	324	339	atherosclerosis	T047	C0004153
27236033	346	356	hypothesis	T078	C1512571
27236033	366	372	tested	T170	C0392366
27236033	386	397	populations	T081	C0032659
27236033	464	475	investigate	T169	C1292732
27236033	504	508	LDLR	T028	C1366529
27236033	510	514	ApoB	T028	C1412471
27236033	519	529	ApoE genes	T028	C1412481
27236033	530	543	polymorphisms	T045	C0678951
27236033	549	562	premature CAD	T047	C1867743
27236033	564	568	PCAD	T047	C1867743
27236033	573	582	Egyptians	T098	C0337801
27236033	608	616	patients	T101	C0030705
27236033	620	624	PCAD	T047	C1867743
27236033	652	656	ages	T032	C0001779
27236033	661	664	sex	T032	C1522384
27236033	718	722	LDLR	T028	C1366529
27236033	727	737	ApoB genes	T028	C1412471
27236033	738	751	polymorphisms	T045	C0678951
27236033	757	765	analyzed	T062	C0936012
27236033	769	794	polymerase chain reaction	T063	C0032520
27236033	796	799	PCR	T063	C0032520
27236033	806	810	ApoE	T028	C1412481
27236033	811	820	genotypes	T032	C0017431
27236033	840	890	multiplex amplification refractory mutation system	T059	C2732542
27236033	892	902	multi-AMRS	T059	C2732542
27236033	919	932	LDLR A(+)A(+)	T028	C1366529
27236033	933	941	genotype	T032	C0017431
27236033	943	952	ApoB X(+)	T028	C1412471
27236033	953	959	allele	T028	C0002085
27236033	964	971	ApoE E4	T028	C1412481
27236033	972	978	allele	T028	C0002085
27236033	1001	1005	PCAD	T047	C1867743
27236033	1071	1078	smoking	T055	C0037369
27236033	1080	1098	metabolic syndrome	T047	C0524620
27236033	1100	1113	ApoB X(+)X(+)	T028	C1412471
27236033	1114	1122	genotype	T032	C0017431
27236033	1127	1134	ApoE E4	T028	C1412481
27236033	1135	1141	allele	T028	C0002085
27236033	1159	1171	risk factors	T033	C0035648
27236033	1180	1191	development	T169	C1527148
27236033	1195	1199	PCAD	T047	C1867743
27236033	1225	1236	investigate	T169	C1292732
27236033	1261	1293	low density lipoprotein receptor	T028	C1366529
27236033	1295	1311	apolipoprotein B	T028	C1412471
27236033	1316	1338	apolipoprotein E genes	T028	C1412481
27236033	1339	1352	polymorphisms	T045	C0678951
27236033	1358	1362	PCAD	T047	C1867743
27236033	1367	1379	lipid levels	T034	C0428460
27236033	1383	1392	Egyptians	T098	C0337801
27236033	1419	1432	LDLR A(+)A(+)	T028	C1366529
27236033	1433	1441	genotype	T032	C0017431
27236033	1443	1452	ApoB X(+)	T028	C1412471
27236033	1453	1459	allele	T028	C0002085
27236033	1464	1471	ApoE E4	T028	C1412481
27236033	1472	1478	allele	T028	C0002085
27236033	1486	1501	associated with	T080	C0332281
27236033	1524	1535	development	T169	C1527148
27236033	1539	1543	PCAD	T047	C1867743
27236033	1556	1588	levels of total cholesterol (TC)	T059	C0201950
27236033	1593	1616	low density lipoprotein	T059	C0202116
27236033	1618	1622	LDLc	T059	C0202116
27236033	1644	1647	CAD	T047	C1867743
27236033	1648	1660	risk factors	T033	C0035648
27236033	1666	1679	LDLR A(+)A(+)	T028	C1366529
27236033	1680	1688	genotype	T032	C0017431
27236033	1690	1699	ApoB X(+)	T028	C1412471
27236033	1700	1706	allele	T028	C0002085
27236033	1711	1718	ApoE E4	T028	C1412481
27236033	1719	1725	allele	T028	C0002085
27236033	1755	1766	development	T169	C1527148
27236033	1770	1774	PCAD	T047	C1867743
27236033	1778	1786	Egyptian	T098	C0337801
27236033	1787	1795	patients	T101	C0030705

28497418|t|Assessing time-of-flight signal-to-noise ratio gains within the myocardium and subsequent reductions in administered activity in cardiac PET studies
28497418|a|Time-of-flight (TOF) is known to increase signal-to-noise ratio (SNR) and facilitate reductions in administered activity. Established measures of SNR gain are derived from areas of uniform uptake, which is not applicable to the heterogeneous uptake in cardiac PET images using fluoro-deoxyglucose (FDG). This study aimed to develop a technique to quantify SNR gains within the myocardium due to TOF. Reference TOF SNR gains were measured in 88 FDG oncology patients. Phantom data were used to translate reference SNR gains and validate a method of quantifying SNR gains within the myocardium from parametric images produced from multiple replicate images. This technique was applied to 13 FDG cardiac viability patients. Reference TOF SNR gains of +23% ± 8.5% were measured in oncology patients. Measurements of SNR gain from the phantom data were in agreement and showed the parametric image technique to be sufficiently robust. SNR gains within the myocardium in the viability patients were +21% ± 2.8%. A method to quantify SNR gains from TOF within the myocardium has been developed and evaluated. SNR gains within the myocardium are comparable to those observed by established methods. This allows guidance for protocol optimization for TOF systems in cardiac PET.
28497418	10	24	time-of-flight	T081	C2348791
28497418	25	46	signal-to-noise ratio	T081	C2986823
28497418	47	52	gains	T081	C1517378
28497418	64	74	myocardium	T024	C0027061
28497418	90	100	reductions	T080	C0392756
28497418	104	116	administered	T169	C1521801
28497418	117	125	activity	T052	C0441655
28497418	129	136	cardiac	T023	C0018787
28497418	137	140	PET	T060	C0032743
28497418	141	148	studies	T062	C2603343
28497418	149	163	Time-of-flight	T081	C2348791
28497418	165	168	TOF	T081	C2348791
28497418	191	212	signal-to-noise ratio	T081	C2986823
28497418	214	217	SNR	T081	C2986823
28497418	234	244	reductions	T080	C0392756
28497418	248	260	administered	T169	C1521801
28497418	261	269	activity	T052	C0441655
28497418	295	298	SNR	T081	C2986823
28497418	299	303	gain	T081	C1517378
28497418	401	408	cardiac	T023	C0018787
28497418	409	412	PET	T060	C0032743
28497418	413	419	images	T170	C1704922
28497418	426	445	fluoro-deoxyglucose	T109,T130	C0046056
28497418	447	450	FDG	T109,T130	C0046056
28497418	458	463	study	T062	C2603343
28497418	483	492	technique	T169	C0449851
28497418	496	504	quantify	T081	C1709793
28497418	505	508	SNR	T081	C2986823
28497418	509	514	gains	T081	C1517378
28497418	526	536	myocardium	T024	C0027061
28497418	544	547	TOF	T081	C2348791
28497418	559	562	TOF	T081	C2348791
28497418	563	566	SNR	T081	C2986823
28497418	567	572	gains	T081	C1517378
28497418	593	596	FDG	T109,T130	C0046056
28497418	597	614	oncology patients	T101	C0030705
28497418	616	623	Phantom	T073	C0282611
28497418	624	628	data	T078	C1511726
28497418	662	665	SNR	T081	C2986823
28497418	666	671	gains	T081	C1517378
28497418	697	708	quantifying	T081	C1709793
28497418	709	712	SNR	T081	C2986823
28497418	713	718	gains	T081	C1517378
28497418	730	740	myocardium	T024	C0027061
28497418	746	763	parametric images	T060	C2986793
28497418	778	803	multiple replicate images	T170	C1704922
28497418	810	819	technique	T169	C0449851
28497418	838	841	FDG	T109,T130	C0046056
28497418	842	849	cardiac	T023	C0018787
28497418	850	859	viability	T080	C0443348
28497418	860	868	patients	T101	C0030705
28497418	880	883	TOF	T081	C2348791
28497418	884	887	SNR	T081	C2986823
28497418	888	893	gains	T081	C1517378
28497418	926	943	oncology patients	T101	C0030705
28497418	961	964	SNR	T081	C2986823
28497418	965	969	gain	T081	C1517378
28497418	979	986	phantom	T073	C0282611
28497418	987	991	data	T078	C1511726
28497418	1025	1041	parametric image	T060	C2986793
28497418	1042	1051	technique	T169	C0449851
28497418	1071	1077	robust	T080	C2986815
28497418	1079	1082	SNR	T081	C2986823
28497418	1083	1088	gains	T081	C1517378
28497418	1100	1110	myocardium	T024	C0027061
28497418	1118	1127	viability	T080	C0443348
28497418	1128	1136	patients	T101	C0030705
28497418	1167	1175	quantify	T081	C1709793
28497418	1176	1179	SNR	T081	C2986823
28497418	1180	1185	gains	T081	C1517378
28497418	1191	1194	TOF	T081	C2348791
28497418	1206	1216	myocardium	T024	C0027061
28497418	1251	1254	SNR	T081	C2986823
28497418	1255	1260	gains	T081	C1517378
28497418	1272	1282	myocardium	T024	C0027061
28497418	1287	1297	comparable	T052	C1707455
28497418	1319	1330	established	T080	C0443211
28497418	1331	1338	methods	T169	C0449851
28497418	1365	1373	protocol	T170	C0442711
28497418	1374	1386	optimization	T052	C2698650
28497418	1391	1394	TOF	T081	C2348791
28497418	1406	1413	cardiac	T023	C0018787
28497418	1414	1417	PET	T060	C0032743

28324211|t|GEORG-SCHMORL-PRIZE OF THE GERMAN SPINE SOCIETY (DWG) 2016: Comparison of in vitro osteogenic potential of iliac crest and degenerative facet joint bone autografts for intervertebral fusion in lumbar spinal stenosis
28324211|a|The promotion of spinal fusion using bone autografts is largely mediated by the osteoinductive potential of progenitors / mesenchymal stem cells (MSC) that reside in the marrow spaces of cancellous bone. Iliac crest is the common autograft donor site, but its use presents an increased risk for donor site pain, morbidity and infection. Degenerative bone samples harvested during facetectomy might provide an alternative viable source of osteoinductive autografts. In this study, we conducted an intra-individual comparison of the osteogenic potential of isolated low passage MSC from both sources. Iliac crest and degenerative facet joints were harvested from eight consecutive patients undergoing transforaminal lumbar interspinal fusion due to lumbar spinal stenosis. MSC were isolated by collagenase digestion, selected by plastic adherence and minimally expanded for downstream assays. Clonogenic and osteogenic potential was evaluated by colony formation assays in control and osteogenic culture medium. Osteogenic properties, including alkaline phosphatase (ALP) induction, matrix mineralization and type I collagen mRNA and protein expression were characterized using quantitative histochemical staining and reverse transcription PCR. Spontaneous adipogenesis was analysed by adipocyte enumeration and gene expression analysis of adipogenic markers. Average colony-forming efficiency in osteogenic medium was equal between iliac crest (38 ± 12%) and facet joint (36 ± 11%). Osteogenic potential at the clonal level was 55 ± 26 and 68 ± 17% for iliac crest and facet joint MSC, respectively. Clonogenic and osteogenic potential were significantly negatively associated with donor age. Osteogenic differentiation led to significant induction of ALP activity in iliac crest (sixfold) and facet joint (eightfold) MSC. Matrix mineralization quantified by Alizarin red staining was increased by osteogenic differentiation, yet similar between both MSC sources. Protein expression of type I collagen was enhanced during osteogenesis and significantly greater in iliac crest MSC. Correspondingly, COL1A2 mRNA expression was higher in osteogenically differentiated MSC from iliac crest. Adipocyte numbers showed significant differences between iliac crest (63 ± 60) and facet joint (18 ± 15) MSC under osteogenic conditions. Negative (GREM1) and positive (FABP4) adipogenic markers were not differentially expressed between sources. MSC from iliac crest and degenerative facet joints largely display similar clonogenic and osteogenic properties in vitro. Differences at the molecular level are not likely to impair the osteoinductive capacity of facet joint MSC. Bone autografts from facetectomy would be viable alternatives as bone autografts for intervertebral spinal fusion in lumbar spinal stenosis.
28324211	0	19	GEORG-SCHMORL-PRIZE	T073	C0080049
28324211	23	47	THE GERMAN SPINE SOCIETY	T092	C1561598
28324211	49	52	DWG	T092	C1561598
28324211	60	70	Comparison	T052	C1707455
28324211	74	82	in vitro	T080	C1533691
28324211	83	93	osteogenic	T042	C0029433
28324211	94	103	potential	T080	C3245505
28324211	107	118	iliac crest	T023	C0223651
28324211	123	135	degenerative	T169	C1880269
28324211	136	147	facet joint	T030	C0224521
28324211	148	163	bone autografts	T061	C0440800
28324211	168	182	intervertebral	T029	C0442106
28324211	183	189	fusion	T061	C0037935
28324211	193	215	lumbar spinal stenosis	T047	C0158288
28324211	233	246	spinal fusion	T061	C0037935
28324211	253	268	bone autografts	T061	C0440800
28324211	296	310	osteoinductive	T042	C0029433
28324211	311	320	potential	T080	C3245505
28324211	324	335	progenitors	T025	C0038250
28324211	338	360	mesenchymal stem cells	T025	C1257975
28324211	362	365	MSC	T025	C1257975
28324211	386	392	marrow	T023	C0376152
28324211	393	399	spaces	T030	C0229984
28324211	403	418	cancellous bone	T024	C0222660
28324211	420	431	Iliac crest	T023	C0223651
28324211	446	455	autograft	T061	C0440800
28324211	456	466	donor site	T029	C1444716
28324211	492	501	increased	T081	C0205217
28324211	502	506	risk	T078	C0035647
28324211	511	521	donor site	T029	C1444716
28324211	522	526	pain	T184	C0030193
28324211	528	537	morbidity	T081	C0026538
28324211	542	551	infection	T046	C3714514
28324211	553	565	Degenerative	T169	C1880269
28324211	566	570	bone	T023	C0262950
28324211	571	578	samples	T167	C0370003
28324211	596	607	facetectomy	T061	C0546528
28324211	654	668	osteoinductive	T042	C0029433
28324211	669	679	autografts	T061	C0440800
28324211	689	694	study	T062	C2603343
28324211	712	728	intra-individual	T098	C0237401
28324211	729	739	comparison	T052	C1707455
28324211	747	757	osteogenic	T042	C0029433
28324211	758	767	potential	T080	C3245505
28324211	792	795	MSC	T025	C1257975
28324211	815	826	Iliac crest	T023	C0223651
28324211	831	843	degenerative	T169	C1880269
28324211	844	856	facet joints	T030	C0224521
28324211	895	903	patients	T101	C0030705
28324211	915	955	transforaminal lumbar interspinal fusion	T061	C0037935
28324211	963	985	lumbar spinal stenosis	T047	C0158288
28324211	987	990	MSC	T025	C1257975
28324211	1008	1029	collagenase digestion	T059	C0022885
28324211	1043	1050	plastic	T167	C0032167
28324211	1051	1060	adherence	T169	C1510802
28324211	1088	1105	downstream assays	T059	C0005507
28324211	1107	1117	Clonogenic	T080	C0205556
28324211	1122	1132	osteogenic	T042	C0029433
28324211	1133	1142	potential	T080	C3245505
28324211	1160	1183	colony formation assays	T059	C0009385
28324211	1187	1194	control	T130	C0973172
28324211	1199	1209	osteogenic	T042	C0029433
28324211	1210	1224	culture medium	T130	C0010454
28324211	1226	1236	Osteogenic	T042	C0029433
28324211	1237	1247	properties	T080	C0871161
28324211	1259	1279	alkaline phosphatase	T116,T126	C0002059
28324211	1281	1284	ALP	T116,T126	C0002059
28324211	1286	1295	induction	T169	C0205263
28324211	1297	1303	matrix	T024	C0005962
28324211	1304	1318	mineralization	T042	C1533591
28324211	1323	1343	type I collagen mRNA	T114,T123	C0035696
28324211	1348	1366	protein expression	T045	C1171362
28324211	1392	1404	quantitative	T081	C0392762
28324211	1405	1427	histochemical staining	T059	C0487602
28324211	1432	1457	reverse transcription PCR	T063	C0599161
28324211	1471	1483	adipogenesis	T044	C0596843
28324211	1500	1509	adipocyte	T025	C0206131
28324211	1510	1521	enumeration	T080	C1707927
28324211	1526	1550	gene expression analysis	T063	C1880945
28324211	1554	1564	adipogenic	T044	C0596843
28324211	1565	1572	markers	T201	C0005516
28324211	1582	1607	colony-forming efficiency	T081	C0013682
28324211	1611	1621	osteogenic	T042	C0029433
28324211	1622	1628	medium	T130	C0010454
28324211	1647	1658	iliac crest	T023	C0223651
28324211	1674	1685	facet joint	T030	C0224521
28324211	1698	1708	Osteogenic	T042	C0029433
28324211	1709	1718	potential	T080	C3245505
28324211	1726	1732	clonal	T024	C1522642
28324211	1733	1738	level	T080	C0441889
28324211	1768	1779	iliac crest	T023	C0223651
28324211	1784	1795	facet joint	T030	C0224521
28324211	1796	1799	MSC	T025	C1257975
28324211	1815	1825	Clonogenic	T080	C0205556
28324211	1830	1840	osteogenic	T042	C0029433
28324211	1841	1850	potential	T080	C3245505
28324211	1897	1902	donor	T098	C0013018
28324211	1903	1906	age	T032	C0001779
28324211	1908	1934	Osteogenic differentiation	T042	C0029433
28324211	1967	1979	ALP activity	T044	C1149888
28324211	1983	1994	iliac crest	T023	C0223651
28324211	2009	2020	facet joint	T030	C0224521
28324211	2033	2036	MSC	T025	C1257975
28324211	2038	2044	Matrix	T024	C0005962
28324211	2045	2059	mineralization	T042	C1533591
28324211	2074	2086	Alizarin red	T109,T130	C0051163
28324211	2087	2095	staining	T059	C0487602
28324211	2100	2109	increased	T081	C0205217
28324211	2113	2139	osteogenic differentiation	T042	C0029433
28324211	2166	2169	MSC	T025	C1257975
28324211	2179	2197	Protein expression	T045	C1171362
28324211	2201	2216	type I collagen	T116,T123	C0041455
28324211	2237	2249	osteogenesis	T042	C0029433
28324211	2279	2290	iliac crest	T023	C0223651
28324211	2291	2294	MSC	T025	C1257975
28324211	2313	2324	COL1A2 mRNA	T114,T123	C0035696
28324211	2325	2335	expression	T045	C1515670
28324211	2350	2379	osteogenically differentiated	T042	C0029433
28324211	2380	2383	MSC	T025	C1257975
28324211	2389	2400	iliac crest	T023	C0223651
28324211	2402	2411	Adipocyte	T025	C0206131
28324211	2412	2419	numbers	T081	C0237753
28324211	2459	2470	iliac crest	T023	C0223651
28324211	2485	2496	facet joint	T030	C0224521
28324211	2507	2510	MSC	T025	C1257975
28324211	2517	2527	osteogenic	T042	C0029433
28324211	2540	2548	Negative	T033	C0205160
28324211	2550	2555	GREM1	T116,T123	C1438932
28324211	2561	2569	positive	T033	C1446409
28324211	2571	2576	FABP4	T116,T123	C1312689
28324211	2578	2588	adipogenic	T044	C0596843
28324211	2589	2596	markers	T201	C0005516
28324211	2648	2651	MSC	T025	C1257975
28324211	2657	2668	iliac crest	T023	C0223651
28324211	2673	2685	degenerative	T169	C1880269
28324211	2686	2698	facet joints	T030	C0224521
28324211	2723	2733	clonogenic	T080	C0205556
28324211	2738	2748	osteogenic	T042	C0029433
28324211	2760	2768	in vitro	T080	C1533691
28324211	2770	2781	Differences	T080	C1705242
28324211	2789	2798	molecular	T080	C1521991
28324211	2799	2804	level	T080	C0441889
28324211	2823	2829	impair	T081	C0547047
28324211	2834	2848	osteoinductive	T042	C0029433
28324211	2849	2857	capacity	T080	C3245505
28324211	2861	2872	facet joint	T030	C0224521
28324211	2873	2876	MSC	T025	C1257975
28324211	2878	2893	Bone autografts	T061	C0440800
28324211	2899	2910	facetectomy	T061	C0546528
28324211	2943	2958	bone autografts	T061	C0440800
28324211	2963	2977	intervertebral	T029	C0442106
28324211	2978	2991	spinal fusion	T061	C0037935
28324211	2995	3017	lumbar spinal stenosis	T047	C0158288

27780501|t|Definition and application of precision medicine
27780501|a|"No abstract".
27780501	0	10	Definition	T170	C1704788
27780501	15	26	application	T169	C0457083
27780501	30	48	precision medicine	T061	C2718059

28428818|t|Does parent-child agreement vary based on presenting problems? Results from a UK clinical sample
28428818|a|Discrepancies are often found between child and parent reports of child psychopathology, nevertheless the role of the child's presenting difficulties in relation to these is underexplored. This study investigates whether parent-child agreement on the conduct and emotional scales of the Strengths and Difficulties Questionnaire (SDQ) varied as a result of certain child characteristics, including the child's presenting problems to clinical services, age and gender. The UK -based sample consisted of 16,754 clinical records of children aged 11-17, the majority of which were female (57%) and White (76%). The dataset was provided by the Child Outcomes Research Consortium, which collects outcome measures from child services across the UK. Clinicians reported the child's presenting difficulties, and parents and children completed the SDQ. Using correlation analysis, the main findings indicated that agreement varied as a result of the child's difficulties for reports of conduct problems, and this seemed to be related to the presence or absence of externalising difficulties in the child's presentation. This was not the case for reports of emotional difficulties. In addition, agreement was higher when reporting problems not consistent with the child's presentation; for instance, agreement on conduct problems was greater for children presenting with internalising problems. Lastly, the children's age and gender did not seem to have an impact on agreement. These findings demonstrate that certain child presenting difficulties, and in particular conduct problems, may be related to informant agreement and need to be considered in clinical practice and research. Trial Registration This study was observational and as such did not require trial registration.
28428818	5	17	parent-child	T099	C0260096
28428818	18	27	agreement	T054	C0680240
28428818	42	61	presenting problems	T033	C2735056
28428818	63	70	Results	T169	C1274040
28428818	78	80	UK	T083	C0041700
28428818	97	110	Discrepancies	T033	C1290905
28428818	121	126	found	T033	C0150312
28428818	135	151	child and parent	T099	C0260096
28428818	152	159	reports	T170	C0025102
28428818	163	184	child psychopathology	T091	C3826585
28428818	215	222	child's	T100	C0008059
28428818	223	246	presenting difficulties	T033	C2735056
28428818	250	258	relation	T099	C0080103
28428818	291	296	study	T062	C2603343
28428818	297	309	investigates	T169	C1292732
28428818	318	330	parent-child	T099	C0260096
28428818	331	340	agreement	T054	C0680240
28428818	348	355	conduct	T170	C4055208
28428818	360	376	emotional scales	T170	C4055070
28428818	384	424	Strengths and Difficulties Questionnaire	T170	C3472494
28428818	426	429	SDQ	T170	C3472494
28428818	443	449	result	T169	C1274040
28428818	461	466	child	T100	C0008059
28428818	467	482	characteristics	T080	C1521970
28428818	484	493	including	T169	C0332257
28428818	498	505	child's	T100	C0008059
28428818	506	525	presenting problems	T033	C2735056
28428818	529	546	clinical services	T058	C1704289
28428818	548	551	age	T032	C0001779
28428818	556	562	gender	T032	C0079399
28428818	568	570	UK	T083	C0041700
28428818	578	584	sample	T098	C2348150
28428818	605	621	clinical records	T170	C1299495
28428818	625	633	children	T100	C0008059
28428818	634	638	aged	T032	C0001779
28428818	673	679	female	T032	C0086287
28428818	690	695	White	T098	C0007457
28428818	707	714	dataset	T170	C0150098
28428818	719	727	provided	T052	C1999230
28428818	735	769	Child Outcomes Research Consortium	T097	C1880171
28428818	786	802	outcome measures	T081	C0086749
28428818	808	822	child services	T058	C0008079
28428818	834	836	UK	T083	C0041700
28428818	838	848	Clinicians	T097	C0871685
28428818	849	857	reported	T058	C0700287
28428818	862	869	child's	T100	C0008059
28428818	870	893	presenting difficulties	T033	C2735056
28428818	899	906	parents	T099	C0030551
28428818	911	919	children	T100	C0008059
28428818	920	929	completed	T080	C0205197
28428818	934	937	SDQ	T170	C3472494
28428818	945	965	correlation analysis	T062,T170	C0010101
28428818	976	984	findings	T169	C2607943
28428818	985	994	indicated	T033	C1444656
28428818	1000	1009	agreement	T054	C0680240
28428818	1022	1028	result	T169	C1274040
28428818	1036	1043	child's	T100	C0008059
28428818	1044	1056	difficulties	T080	C0332218
28428818	1061	1068	reports	T170	C0025102
28428818	1072	1088	conduct problems	T033	C0243095
28428818	1112	1119	related	T080	C0439849
28428818	1127	1135	presence	T033	C0150312
28428818	1139	1146	absence	T169	C0332197
28428818	1150	1176	externalising difficulties	T033	C0243095
28428818	1184	1191	child's	T100	C0008059
28428818	1192	1204	presentation	T078	C0449450
28428818	1223	1227	case	T169	C0868928
28428818	1232	1239	reports	T170	C0025102
28428818	1243	1265	emotional difficulties	T048	C0677660
28428818	1280	1289	agreement	T054	C0680240
28428818	1294	1300	higher	T080	C0205250
28428818	1306	1315	reporting	T058	C0700287
28428818	1316	1324	problems	T033	C0033213
28428818	1329	1344	consistent with	T078	C0332290
28428818	1349	1356	child's	T100	C0008059
28428818	1357	1369	presentation	T078	C0449450
28428818	1385	1394	agreement	T054	C0680240
28428818	1398	1414	conduct problems	T033	C0243095
28428818	1419	1426	greater	T081	C1704243
28428818	1431	1439	children	T100	C0008059
28428818	1440	1450	presenting	T078	C0449450
28428818	1456	1478	internalising problems	T033	C0243095
28428818	1492	1502	children's	T100	C0008059
28428818	1503	1506	age	T032	C0001779
28428818	1511	1517	gender	T032	C0079399
28428818	1542	1548	impact	T080	C4049986
28428818	1552	1561	agreement	T054	C0680240
28428818	1569	1577	findings	T169	C2607943
28428818	1603	1608	child	T100	C0008059
28428818	1609	1632	presenting difficulties	T033	C2735056
28428818	1652	1668	conduct problems	T033	C0243095
28428818	1677	1684	related	T080	C0439849
28428818	1688	1697	informant	T169	C1550484
28428818	1698	1707	agreement	T054	C0680240
28428818	1723	1733	considered	T078	C0750591
28428818	1737	1754	clinical practice	T057	C0205897
28428818	1759	1767	research	T062	C0008972
28428818	1769	1787	Trial Registration	T058	C1514821
28428818	1803	1816	observational	T062	C1518527
28428818	1845	1863	trial registration	T058	C1514821

28530715|t|Nanofluidic device for continuous multiparameter quality assurance of biologics
28530715|a|Process analytical technology (PAT) is critical for the manufacture of high - quality biologics as it enables continuous, real-time and on-line/at-line monitoring during biomanufacturing processes. The conventional analytical tools currently used have many restrictions to realizing the PAT of current and future biomanufacturing. Here we describe a nanofluidic device for the continuous monitoring of biologics ' purity and bioactivity with high sensitivity, resolution and speed. Periodic and angled nanofilter arrays served as the molecular sieve structures to conduct a continuous size -based analysis of biologics. A multiparameter quality monitoring of three separate commercial biologic samples within 50 minutes has been demonstrated, with 20 µl of sample consumption, inclusive of dead volume in the reservoirs. Additionally, a proof-of-concept prototype system, which integrates an on-line sample-preparation system and the nanofluidic device, was demonstrated for at-line monitoring. Thus, the system is ideal for on-site monitoring, and the real-time quality assurance of biologics throughout the biomanufacturing processes.
28530715	0	18	Nanofluidic device	T074	C0025080
28530715	23	33	continuous	T078	C0549178
28530715	34	48	multiparameter	T077	C0549193
28530715	49	66	quality assurance	T057	C0178932
28530715	70	79	biologics	T121,T123	C0005522
28530715	80	109	Process analytical technology	T090	C0039421
28530715	111	114	PAT	T090	C0039421
28530715	136	147	manufacture	T057	C0870840
28530715	151	155	high	T080	C0205250
28530715	158	165	quality	T080	C0332306
28530715	166	175	biologics	T121,T123	C0005522
28530715	190	200	continuous	T078	C0549178
28530715	202	211	real-time	T079	C1550177
28530715	216	242	on-line/at-line monitoring	T052	C0441655
28530715	250	276	biomanufacturing processes	T067	C1522240
28530715	282	294	conventional	T080	C0439858
28530715	295	311	analytical tools	T170	C0178476
28530715	367	370	PAT	T090	C0039421
28530715	393	409	biomanufacturing	T067	C1522240
28530715	430	448	nanofluidic device	T074	C0025080
28530715	457	467	continuous	T078	C0549178
28530715	468	478	monitoring	T052	C0441655
28530715	482	491	biologics	T121,T123	C0005522
28530715	494	500	purity	UnknownType	C0678739
28530715	505	516	bioactivity	T080	C0205556
28530715	522	526	high	T080	C0205250
28530715	527	538	sensitivity	T169	C0332324
28530715	540	550	resolution	T081	C1706463
28530715	555	560	speed	T081	C0678536
28530715	582	599	nanofilter arrays	T082	C1510941
28530715	614	640	molecular sieve structures	T082	C0678594
28530715	654	664	continuous	T078	C0549178
28530715	665	669	size	T082	C0456389
28530715	677	685	analysis	T062	C0936012
28530715	689	698	biologics	T121,T123	C0005522
28530715	702	716	multiparameter	T077	C0549193
28530715	717	724	quality	T080	C0332306
28530715	725	735	monitoring	T052	C0441655
28530715	765	773	biologic	T121,T123	C0005522
28530715	774	781	samples	T167	C0370003
28530715	837	855	sample consumption	T039	C1947907
28530715	870	881	dead volume	T077	C1707639
28530715	889	899	reservoirs	T073	C1705182
28530715	917	933	proof-of-concept	T078	C3887511
28530715	934	950	prototype system	T170	C3161035
28530715	980	1005	sample-preparation system	T073	C1704459
28530715	1014	1032	nanofluidic device	T074	C0025080
28530715	1055	1073	at-line monitoring	T052	C0441655
28530715	1085	1091	system	T073	C1704459
28530715	1105	1123	on-site monitoring	T052	C0441655
28530715	1133	1142	real-time	T079	C1550177
28530715	1143	1160	quality assurance	T057	C0178932
28530715	1164	1173	biologics	T121,T123	C0005522
28530715	1189	1215	biomanufacturing processes	T067	C1522240

27761076|t|Elicitation of Phenolics from the Micropropagated Endangered Medicinal Plant Calligonum polygonoides L. (Polygonoaceae)
27761076|a|Calligonum polygonoides L. subsp. comosum (L'Hér.) Sosk. is a plant species belonging to family Polygonaceae. Susceptibility to threaten, presence of various chemical constituents, and many medicinal effects reported for this plant in addition to rareness of in vitro culture studies have fuelled the need for its micropropagation and phytochemical investigations of the produced cultures. To employ in vitro culture technique for ex situ conservation of C. polygonoides, using the fruit as an explant; establish callus and cell suspension cultures from in vitro germinated plantlets; investigate the production of phenolics through callus, redifferentiated shoot, and cell suspension cultures; attempt to enhance cell capacity to accumulate phenolics using salicylic acid and yeast extract and provide a brief demonstration of biosynthetic pathway leading to phenolic production. Modified Murashige and Skoog media supplemented with growth hormones such as kinetin, 1-naphthaleneacetic acid, 6-benzylaminopurine, and indole-3-acetic acid were used to establish callus, redifferentiated shoots, and cell suspension cultures. Elicitation of cell suspension culture was performed using salicylic acid and yeast extracts. A reversed phase-high performance liquid chromatography method for determination of phenolic content in the aforementioned cultures was developed. The unorganized callus and cell suspension cultures contained fewer amounts of phenolic compounds than redifferentiated shoots. Elicitation produced massive quantitative reprogramming of phenolic content. The present study offers an alternative and renewable source for this valuable natural plant, provide a chance to improve secondary metabolite yield and serve as a useful tool for studying the biosynthesis of these compounds and its regulation in plant cells. In vitro culture techniques provided a strategy for ex situ conservation of the endangered C. polygonoides .Unorganized callus and cell suspension cultures accumulated less phenolic content than re-differentiated shoots. Elicitation produced massive quantitative reprogramming of phenolic content. Phenolic biosynthesis was discussed briefly. Abbreviation used: H2O2: Hydrogen peroxide, Kin: Kinetin, NAA: Naphthaleneacetic acid, BAP: 6-benzylaminopurine, IAA: Indole-3-acetic acid, HPLC: High-performance liquid chromatography.
27761076	0	11	Elicitation	T059	C0684295
27761076	15	24	Phenolics	T109,T121	C0359916
27761076	34	49	Micropropagated	T059	C1446951
27761076	50	60	Endangered	T098	C2717882
27761076	61	76	Medicinal Plant	T002	C0032100
27761076	77	102	Calligonum polygonoides L	T002	C2999495
27761076	105	118	Polygonoaceae	T002	C0524882
27761076	120	145	Calligonum polygonoides L	T002	C2999495
27761076	154	161	comosum	T002	C2999494
27761076	182	187	plant	T002	C0032098
27761076	188	195	species	T185	C1705920
27761076	209	215	family	T077	C1704727
27761076	216	228	Polygonaceae	T002	C0524882
27761076	230	244	Susceptibility	T169	C1264642
27761076	278	286	chemical	T103	C0220806
27761076	287	299	constituents	T167	C0729650
27761076	310	327	medicinal effects	T169	C0728866
27761076	346	351	plant	T002	C0032098
27761076	379	387	in vitro	T080	C1533691
27761076	388	403	culture studies	T059	C1449619
27761076	434	450	micropropagation	T059	C1446951
27761076	455	468	phytochemical	T109,T123	C0577749
27761076	469	483	investigations	T169	C1292732
27761076	500	508	cultures	T059	C0430400
27761076	520	528	in vitro	T080	C1533691
27761076	529	546	culture technique	T059	C1449619
27761076	551	571	ex situ conservation	T059	C0033085
27761076	575	590	C. polygonoides	T002	C2999495
27761076	602	607	fruit	T168	C0016767
27761076	614	621	explant	T025	C1514137
27761076	633	639	callus	T002	C2700394
27761076	644	668	cell suspension cultures	T059	C0007585
27761076	674	682	in vitro	T080	C1533691
27761076	683	693	germinated	T038	C0242735
27761076	694	703	plantlets	T002	C0032098
27761076	705	716	investigate	T169	C1292732
27761076	721	731	production	T052	C1883254
27761076	735	744	phenolics	T109,T121	C0359916
27761076	753	759	callus	T002	C2700394
27761076	761	777	redifferentiated	T043	C0007589
27761076	778	783	shoot	T002	C2700376
27761076	789	813	cell suspension cultures	T059	C0007585
27761076	834	838	cell	T025	C0007634
27761076	839	847	capacity	T081	C1516240
27761076	851	861	accumulate	T033	C4055506
27761076	862	871	phenolics	T109,T121	C0359916
27761076	878	892	salicylic acid	T109,T121	C0036079
27761076	897	910	yeast extract	T109,T121	C0873195
27761076	948	968	biosynthetic pathway	T044	C1721101
27761076	980	988	phenolic	T109,T121	C0359916
27761076	989	999	production	T052	C1883254
27761076	1001	1009	Modified	T169	C0392747
27761076	1010	1019	Murashige	T130	C0010454
27761076	1024	1035	Skoog media	T130	C0010454
27761076	1036	1048	supplemented	T169	C2348609
27761076	1054	1069	growth hormones	T116,T121,T125	C0037663
27761076	1078	1085	kinetin	T114,T121	C0049579
27761076	1087	1111	1-naphthaleneacetic acid	T109	C0044494
27761076	1113	1132	6-benzylaminopurine	T109	C1433730
27761076	1138	1158	indole-3-acetic acid	T109,T125	C0936060
27761076	1182	1188	callus	T002	C2700394
27761076	1190	1206	redifferentiated	T043	C0007589
27761076	1207	1213	shoots	T002	C2700376
27761076	1219	1243	cell suspension cultures	T059	C0007585
27761076	1245	1256	Elicitation	T059	C0684295
27761076	1260	1283	cell suspension culture	T059	C0007585
27761076	1304	1318	salicylic acid	T109,T121	C0036079
27761076	1323	1337	yeast extracts	T109,T121	C0873195
27761076	1341	1394	reversed phase-high performance liquid chromatography	T059	C0008562
27761076	1406	1419	determination	T059	C1148554
27761076	1423	1431	phenolic	T109,T121	C0359916
27761076	1447	1470	aforementioned cultures	T059	C0430400
27761076	1502	1508	callus	T002	C2700394
27761076	1513	1537	cell suspension cultures	T059	C0007585
27761076	1565	1583	phenolic compounds	T109,T121	C0359916
27761076	1589	1605	redifferentiated	T043	C0007589
27761076	1606	1612	shoots	T002	C2700376
27761076	1614	1625	Elicitation	T059	C0684295
27761076	1643	1655	quantitative	T081	C0392762
27761076	1673	1681	phenolic	T109,T121	C0359916
27761076	1703	1708	study	T062	C2603343
27761076	1719	1730	alternative	T077	C1523987
27761076	1770	1777	natural	T169	C0205296
27761076	1778	1783	plant	T002	C0032098
27761076	1813	1833	secondary metabolite	T123	C0870883
27761076	1871	1879	studying	T062	C2603343
27761076	1884	1896	biosynthesis	T169	C0005572
27761076	1906	1915	compounds	T103	C1706082
27761076	1924	1934	regulation	T038	C1327622
27761076	1938	1943	plant	T002	C0032098
27761076	1944	1949	cells	T025	C0007634
27761076	1951	1959	In vitro	T080	C1533691
27761076	1960	1978	culture techniques	T059	C1449619
27761076	2003	2023	ex situ conservation	T059	C0033085
27761076	2031	2041	endangered	T098	C2717882
27761076	2042	2057	C. polygonoides	T002	C2999495
27761076	2071	2077	callus	T002	C2700394
27761076	2082	2106	cell suspension cultures	T059	C0007585
27761076	2107	2118	accumulated	T033	C4055506
27761076	2124	2132	phenolic	T109,T121	C0359916
27761076	2146	2163	re-differentiated	T043	C0007589
27761076	2164	2170	shoots	T002	C2700376
27761076	2172	2183	Elicitation	T059	C0684295
27761076	2201	2213	quantitative	T081	C0392762
27761076	2231	2239	phenolic	T109,T121	C0359916
27761076	2249	2257	Phenolic	T109,T121	C0359916
27761076	2258	2270	biosynthesis	T169	C0005572
27761076	2313	2317	H2O2	T121,T130,T197	C0020281
27761076	2319	2336	Hydrogen peroxide	T121,T130,T197	C0020281
27761076	2338	2341	Kin	T114,T121	C0049579
27761076	2343	2350	Kinetin	T114,T121	C0049579
27761076	2352	2355	NAA	T109	C0027377
27761076	2357	2379	Naphthaleneacetic acid	T109	C0027377
27761076	2381	2384	BAP	T109	C1433730
27761076	2386	2405	6-benzylaminopurine	T109	C1433730
27761076	2407	2410	IAA	T109,T125	C0936060
27761076	2412	2432	Indole-3-acetic acid	T109,T125	C0936060
27761076	2434	2438	HPLC	T059	C0008562
27761076	2440	2478	High-performance liquid chromatography	T059	C0008562

27610122|t|Consecutive Endovascular Treatment of 20 Ruptured Very Small (<3 mm) Anterior Communicating Artery Aneurysms
27610122|a|Small aneurysms located at the anterior communicating artery carry significant procedural challenges due to a complex anatomy. Recent advances in endovascular technologies have expanded the use of coil embolization for small aneurysm treatment. However, limited reports describe their safety and efficacy profiles in very small anterior communicating artery aneurysms. We sought to review and report the immediate and long-term clinical as well as radiographic outcomes of consecutive patients with ruptured very small anterior communicating artery aneurysms treated with current endovascular coil embolization techniques. A prospectively maintained single-institution neuroendovascular database was accessed to identify consecutive cases of very small (<3 mm) ruptured anterior communicating artery aneurysms treated endovascularly between 2006 and 2013. A total of 20 patients with ruptured very small (<3 mm) anterior communicating artery aneurysms were consecutively treated with coil embolization. The average maximum diameter was 2.66 ± 0.41 mm. Complete aneurysm occlusion was achieved for 17 (85%) aneurysms and near-complete aneurysm occlusion for 3 (15%) aneurysms. Intraoperative perforation was seen in 2 (10%) patients without any clinical worsening or need for an external ventricular drain. A thromboembolic event occurred in 1 (5 %) patient without clinical worsening or radiologic infarct. Median clinical follow-up was 12 (±14.1) months and median imaging follow-up was 12 (±18.4) months. This report describes the largest series of consecutive endovascular treatments of ruptured very small anterior communicating artery aneurysms. These findings suggest that coil embolization of very small aneurysms in this location can be performed with acceptable rates of complications and recanalization.
27610122	0	11	Consecutive	T080	C1707491
27610122	12	34	Endovascular Treatment	T061	C2936204
27610122	41	49	Ruptured	T169	C0443294
27610122	55	60	Small	T081	C0700321
27610122	69	108	Anterior Communicating Artery Aneurysms	T047	C0740386
27610122	109	114	Small	T081	C0700321
27610122	115	124	aneurysms	T047	C0740386
27610122	140	169	anterior communicating artery	T023	C0149562
27610122	227	234	anatomy	T017	C0700276
27610122	255	280	endovascular technologies	T061	C2936204
27610122	306	323	coil embolization	T061	C0189713
27610122	328	333	small	T081	C0700321
27610122	334	342	aneurysm	T047	C0740386
27610122	343	352	treatment	T169	C1522326
27610122	394	400	safety	T068	C0036043
27610122	405	413	efficacy	T080	C1280519
27610122	431	436	small	T081	C0700321
27610122	437	476	anterior communicating artery aneurysms	T047	C0740386
27610122	527	545	long-term clinical	T080	C0085415
27610122	557	578	radiographic outcomes	T080	C0085415
27610122	582	593	consecutive	T080	C1707491
27610122	594	602	patients	T101	C0030705
27610122	608	616	ruptured	T169	C0443294
27610122	622	627	small	T081	C0700321
27610122	628	667	anterior communicating artery aneurysms	T047	C0740386
27610122	689	730	endovascular coil embolization techniques	T061	C0189713
27610122	778	804	neuroendovascular database	T170	C0242356
27610122	856	861	small	T081	C0700321
27610122	870	878	ruptured	T169	C0443294
27610122	879	918	anterior communicating artery aneurysms	T047	C0740386
27610122	979	987	patients	T101	C0030705
27610122	993	1001	ruptured	T169	C0443294
27610122	1007	1012	small	T081	C0700321
27610122	1021	1060	anterior communicating artery aneurysms	T047	C0740386
27610122	1066	1079	consecutively	T080	C1707491
27610122	1093	1110	coil embolization	T061	C0189713
27610122	1132	1140	diameter	T081	C1301886
27610122	1170	1188	aneurysm occlusion	T061	C0189724
27610122	1215	1224	aneurysms	T047	C0740386
27610122	1243	1261	aneurysm occlusion	T061	C0189724
27610122	1274	1283	aneurysms	T047	C0740386
27610122	1285	1299	Intraoperative	T079	C0456904
27610122	1300	1311	perforation	T033	C0549099
27610122	1332	1340	patients	T101	C0030705
27610122	1353	1371	clinical worsening	T078	C1546960
27610122	1387	1413	external ventricular drain	T061	C0844106
27610122	1417	1437	thromboembolic event	T046	C0040038
27610122	1458	1465	patient	T101	C0030705
27610122	1474	1492	clinical worsening	T078	C1546960
27610122	1496	1514	radiologic infarct	T046	C0021308
27610122	1532	1541	follow-up	T058	C1522577
27610122	1557	1563	months	T079	C0439231
27610122	1583	1592	follow-up	T058	C1522577
27610122	1608	1614	months	T079	C0439231
27610122	1660	1671	consecutive	T080	C1707491
27610122	1672	1695	endovascular treatments	T061	C2936204
27610122	1699	1707	ruptured	T169	C0443294
27610122	1713	1718	small	T081	C0700321
27610122	1719	1758	anterior communicating artery aneurysms	T047	C0740386
27610122	1788	1805	coil embolization	T061	C0189713
27610122	1814	1819	small	T081	C0700321
27610122	1820	1829	aneurysms	T047	C0740386
27610122	1838	1846	location	T082	C0450429
27610122	1889	1902	complications	T046	C0009566
27610122	1907	1921	recanalization	T061	C0034771

27538372|t|Mitochondrial pyruvate dehydrogenase phosphatase 1 regulates the early differentiation of cardiomyocytes from mouse embryonic stem cells
27538372|a|Mitochondria are crucial for maintaining the properties of embryonic stem cells (ESCs) and for regulating their subsequent differentiation into diverse cell lineages, including cardiomyocytes. However, mitochondrial regulators that manage the rate of differentiation or cell fate have been rarely identified. This study aimed to determine the potential mitochondrial factor that controls the differentiation of ESCs into cardiac myocytes. We induced cardiomyocyte differentiation from mouse ESCs (mESCs) and performed microarray assays to assess messenger RNA (mRNA) expression changes at differentiation day 8 (D8) compared with undifferentiated mESCs (D0). Among the differentially expressed genes, Pdp1 expression was significantly decreased (27-fold) on D8 compared to D0, which was accompanied by suppressed mitochondrial indices, including ATP levels, membrane potential, ROS and mitochondrial Ca(2+). Notably, Pdp1 overexpression significantly enhanced the mitochondrial indices and pyruvate dehydrogenase activity and reduced the expression of cardiac differentiation marker mRNA and the cardiac differentiation rate compared to a mock control. In confirmation of this, a knockdown of the Pdp1 gene promoted the expression of cardiac differentiation marker mRNA and the cardiac differentiation rate. In conclusion, our results suggest that mitochondrial PDP1 is a potential regulator that controls cardiac differentiation at an early differentiation stage in ESCs.
27538372	0	50	Mitochondrial pyruvate dehydrogenase phosphatase 1	T028	C1418818
27538372	71	104	differentiation of cardiomyocytes	T043	C1817118
27538372	110	136	mouse embryonic stem cells	T025	C4042879
27538372	137	149	Mitochondria	T026	C0026237
27538372	196	216	embryonic stem cells	T025	C0596508
27538372	218	222	ESCs	T025	C0596508
27538372	260	275	differentiation	T043	C0007589
27538372	289	302	cell lineages	T078	C0282637
27538372	314	328	cardiomyocytes	T025	C0225828
27538372	339	363	mitochondrial regulators	T123	C0574031
27538372	380	403	rate of differentiation	T081	C1521828
27538372	407	416	cell fate	T043	C1540661
27538372	490	510	mitochondrial factor	T116,T123	C0033684
27538372	529	552	differentiation of ESCs	T043	C1514964
27538372	558	574	cardiac myocytes	T025	C0225828
27538372	587	616	cardiomyocyte differentiation	T043	C1817118
27538372	622	632	mouse ESCs	T025	C4042879
27538372	634	639	mESCs	T025	C4042879
27538372	655	672	microarray assays	T059	C1449575
27538372	683	696	messenger RNA	T114,T123	C0035696
27538372	698	702	mRNA	T114,T123	C0035696
27538372	704	714	expression	T045	C0040649
27538372	726	747	differentiation day 8	T033	C0243095
27538372	749	751	D8	T033	C0243095
27538372	767	783	undifferentiated	T080	C0205618
27538372	784	789	mESCs	T025	C4042879
27538372	821	836	expressed genes	T028	C0017337
27538372	838	842	Pdp1	T028	C1418818
27538372	843	853	expression	T045	C0017262
27538372	895	897	D8	T033	C0243095
27538372	910	912	D0	T080	C0205618
27538372	939	949	suppressed	T169	C1260953
27538372	950	963	mitochondrial	T026	C0026237
27538372	964	971	indices	T170	C0918012
27538372	983	986	ATP	T114,T121,T123	C0001480
27538372	995	1013	membrane potential	T043	C1156295
27538372	1015	1018	ROS	T044	C3894464
27538372	1023	1043	mitochondrial Ca(2+)	T043	C1658623
27538372	1054	1058	Pdp1	T028	C1418818
27538372	1059	1073	overexpression	T045	C0017262
27538372	1101	1114	mitochondrial	T026	C0026237
27538372	1115	1122	indices	T170	C0918012
27538372	1127	1158	pyruvate dehydrogenase activity	T044	C1151688
27538372	1175	1185	expression	T045	C0040649
27538372	1189	1212	cardiac differentiation	T043	C2247990
27538372	1213	1224	marker mRNA	T045	C0872263
27538372	1233	1256	cardiac differentiation	T043	C2247990
27538372	1257	1261	rate	T081	C1521828
27538372	1317	1326	knockdown	T063	C2350567
27538372	1334	1343	Pdp1 gene	T028	C1418818
27538372	1357	1367	expression	T045	C0040649
27538372	1371	1394	cardiac differentiation	T043	C2247990
27538372	1395	1406	marker mRNA	T045	C0872263
27538372	1415	1438	cardiac differentiation	T043	C2247990
27538372	1439	1443	rate	T081	C1521828
27538372	1485	1503	mitochondrial PDP1	T028	C1418818
27538372	1543	1566	cardiac differentiation	T043	C2247990
27538372	1579	1600	differentiation stage	T079	C1254367
27538372	1604	1608	ESCs	T025	C0596508

28130404|t|Tissue reservoirs of antiviral T cell immunity in persistent human CMV infection
28130404|a|T cell responses to viruses are initiated and maintained in tissue sites; however, knowledge of human antiviral T cells is largely derived from blood. Cytomegalovirus (CMV) persists in most humans, requires T cell immunity to control, yet tissue immune responses remain undefined. Here, we investigated human CMV -specific T cells, virus persistence and CMV -associated T cell homeostasis in blood, lymphoid, mucosa l and secretory tissues of 44 CMV seropositive and 28 seronegative donors. CMV -specific T cells were maintained in distinct distribution patterns, highest in blood, bone marrow (BM), or lymph nodes (LN), with the frequency and function in blood distinct from tissues. CMV genomes were detected predominantly in lung and also in spleen, BM, blood and LN. High frequencies of activated CMV -specific T cells were found in blood and BM samples with low virus detection, whereas in lung, CMV -specific T cells were present along with detectable virus. In LNs, CMV -specific T cells exhibited quiescent phenotypes independent of virus. Overall, T cell differentiation was enhanced in sites of viral persistence with age. Together, our results suggest tissue T cell reservoirs for CMV control shaped by both viral and tissue - intrinsic factors, with global effects on homeostasis of tissue T cells over the lifespan.
28130404	0	6	Tissue	T024	C0040300
28130404	21	30	antiviral	T033	C0243095
28130404	31	46	T cell immunity	T040	C1817907
28130404	61	66	human	T016	C0086418
28130404	67	80	CMV infection	T047	C0010823
28130404	81	87	T cell	T025	C0039194
28130404	88	97	responses	T042	C0301872
28130404	101	108	viruses	T005	C0042776
28130404	141	147	tissue	T024	C0040300
28130404	177	182	human	T016	C0086418
28130404	183	192	antiviral	T033	C0243095
28130404	193	200	T cells	T025	C0039194
28130404	225	230	blood	T031	C0005767
28130404	232	247	Cytomegalovirus	T005	C0010825
28130404	249	252	CMV	T005	C0010825
28130404	271	277	humans	T016	C0086418
28130404	288	303	T cell immunity	T040	C1817907
28130404	320	326	tissue	T024	C0040300
28130404	327	343	immune responses	T042	C0301872
28130404	384	389	human	T016	C0086418
28130404	390	393	CMV	T005	C0010825
28130404	390	393	CMV	T005	C0010825
28130404	404	411	T cells	T025	C0039194
28130404	413	418	virus	T005	C0042776
28130404	419	430	persistence	T081	C1547035
28130404	435	438	CMV	T005	C0010825
28130404	451	457	T cell	T025	C0039194
28130404	458	469	homeostasis	T038	C0019868
28130404	473	478	blood	T031	C0005767
28130404	480	488	lymphoid	T024	C0024296
28130404	490	496	mucosa	T024	C0026724
28130404	503	520	secretory tissues	T024	C0040300
28130404	527	530	CMV	T005	C0010825
28130404	531	543	seropositive	T080	C0521143
28130404	551	563	seronegative	T034	C0521144
28130404	564	570	donors	T098	C0013018
28130404	572	575	CMV	T005	C0010825
28130404	586	593	T cells	T025	C0039194
28130404	622	643	distribution patterns	T082	C0449775
28130404	656	661	blood	T031	C0005767
28130404	663	674	bone marrow	T024	C0005953
28130404	676	678	BM	T024	C0005953
28130404	684	695	lymph nodes	T023	C0024204
28130404	697	699	LN	T023	C0024204
28130404	711	720	frequency	T080	C1561548
28130404	725	733	function	T169	C0542341
28130404	737	742	blood	T031	C0005767
28130404	757	764	tissues	T024	C0040300
28130404	766	769	CMV	T005	C0010825
28130404	770	777	genomes	T028	C0017428
28130404	783	791	detected	T033	C0442726
28130404	809	813	lung	T023	C0024109
28130404	826	832	spleen	T023	C0037993
28130404	834	836	BM	T024	C0005953
28130404	838	843	blood	T031	C0005767
28130404	848	850	LN	T023	C0024204
28130404	882	885	CMV	T005	C0010825
28130404	896	903	T cells	T025	C0039194
28130404	918	923	blood	T031	C0005767
28130404	928	930	BM	T024	C0005953
28130404	931	938	samples	T167	C0370003
28130404	948	963	virus detection	T043	C1154657
28130404	976	980	lung	T023	C0024109
28130404	982	985	CMV	T005	C0010825
28130404	996	1003	T cells	T025	C0039194
28130404	1039	1044	virus	T005	C0042776
28130404	1049	1052	LNs	T023	C0024204
28130404	1054	1057	CMV	T005	C0010825
28130404	1068	1075	T cells	T025	C0039194
28130404	1096	1106	phenotypes	T032	C0031437
28130404	1122	1127	virus	T005	C0042776
28130404	1138	1144	T cell	T025	C0039194
28130404	1145	1160	differentiation	T043	C0007589
28130404	1165	1173	enhanced	T052	C2349975
28130404	1186	1191	viral	T169	C0521026
28130404	1192	1203	persistence	T081	C1547035
28130404	1244	1250	tissue	T024	C0040300
28130404	1251	1257	T cell	T025	C0039194
28130404	1273	1276	CMV	T005	C0010825
28130404	1277	1284	control	T058	C0085557
28130404	1300	1305	viral	T169	C0521026
28130404	1310	1316	tissue	T024	C0040300
28130404	1319	1336	intrinsic factors	T116,T121,T123	C0021918
28130404	1361	1372	homeostasis	T038	C0019868
28130404	1376	1382	tissue	T024	C0040300
28130404	1383	1390	T cells	T025	C0039194
28130404	1400	1408	lifespan	T102	C0870809

27790175|t|Predictors and Moderators of Spontaneous Pretend Play in Children with and without Autism Spectrum Disorder
27790175|a|Although pretend play has long been linked to children's normative cognitive development, inconsistent findings call for greater rigor in examining this relation (Lillard et al., 2013). Spontaneous pretend play is often impacted in atypical development, notably in autism spectrum disorder (ASD). Since ASD traits exist along a continuum in the general population, investigating how pretend play varies across the range of ASD symptoms by indexing variations in ASD traits in both typically developing and ASD populations may provide insight into how ASD symptoms may influence the relation between pretend play and associated processes in cognitive development. This study used rigorous observational methods to assess spontaneous pretend play. Specifically, 5- min free-play sessions with two discrete toy sets were double-coded by blinded coders (coder assignment counterbalanced). Key facets of pretense development [attribution of pretend properties (APP), object substitution (OS), imaginary objects] were examined. These facets of pretend play production were then analyzed in relation to ASD symptoms, as well as plausible, long-theorized correlates [theory of mind (ToM), verbal ability, familiarity, and interest in specific toys]. Forty children (Mage = 6;5, SDage = 1.45; 29 males), six of whom met the threshold for ASD diagnosis via parent -reported ASD symptoms, participated in play sessions and completed measures of verbal IQ and ToM. Besides the measure of child ASD symptoms, parents completed a survey of their child's interest in and familiarity with the play session toys. Overall, greater ToM predicted more APP, and more interest in the toys presented predicted more OS. In terms of overall pretend play production, two results were counterintuitive. First, among children with more ASD symptoms, verbal ability marginally negatively predicted pretend play production. Second, among children with fewer ASD symptoms, ToM negatively predicted pretend play production. Further probing revealed that the negative effect of ASD symptoms on pretend play was simultaneously moderated by both variables: low ToM and high verbal ability both related to less pretend play production among children with more ASD symptoms. Implications for assessment and subsequent treatment for pretend ability among children with varying degrees of ASD symptoms, as well as for future research, are discussed.
27790175	0	10	Predictors	T078	C2698872
27790175	15	25	Moderators	T080	C1881878
27790175	29	40	Spontaneous	T169	C0205359
27790175	41	53	Pretend Play	T041	C2371970
27790175	57	65	Children	T100	C0008059
27790175	83	107	Autism Spectrum Disorder	T048	C1510586
27790175	117	129	pretend play	T041	C2371970
27790175	154	164	children's	T100	C0008059
27790175	165	174	normative	T080	C0205307
27790175	175	196	cognitive development	T041	C0679035
27790175	198	210	inconsistent	T080	C0442809
27790175	211	219	findings	T033	C0243095
27790175	246	255	examining	T169	C1292732
27790175	261	269	relation	T080	C0439849
27790175	294	305	Spontaneous	T169	C0205359
27790175	306	318	pretend play	T041	C2371970
27790175	340	348	atypical	T080	C0205182
27790175	349	360	development	T039	C0243107
27790175	373	397	autism spectrum disorder	T048	C1510586
27790175	399	402	ASD	T048	C1510586
27790175	411	414	ASD	T048	C1510586
27790175	415	421	traits	T032	C0599883
27790175	436	445	continuum	T082	C0595960
27790175	453	471	general population	T098	C0683971
27790175	473	486	investigating	T169	C1292732
27790175	491	503	pretend play	T041	C2371970
27790175	531	534	ASD	T048	C1510586
27790175	535	543	symptoms	T184	C1457887
27790175	556	566	variations	T080	C0205419
27790175	570	573	ASD	T048	C1510586
27790175	574	580	traits	T032	C0599883
27790175	614	617	ASD	T048	C1510586
27790175	618	629	populations	T098	C1257890
27790175	659	662	ASD	T048	C1510586
27790175	663	671	symptoms	T184	C1457887
27790175	690	698	relation	T080	C0439849
27790175	707	719	pretend play	T041	C2371970
27790175	748	769	cognitive development	T041	C0679035
27790175	776	781	study	T062	C2603343
27790175	787	817	rigorous observational methods	T062	C0870991
27790175	828	839	spontaneous	T169	C0205359
27790175	840	852	pretend play	T041	C2371970
27790175	871	874	min	T079	C0439232
27790175	875	893	free-play sessions	T058	C1254363
27790175	903	911	discrete	T080	C0443299
27790175	912	915	toy	T073	C0040565
27790175	942	956	blinded coders	T073	C1707428
27790175	1007	1027	pretense development	T041	C0025361
27790175	1029	1062	attribution of pretend properties	T080	C0871161
27790175	1064	1067	APP	T080	C0871161
27790175	1070	1089	object substitution	T052	C1706204
27790175	1091	1093	OS	T052	C1706204
27790175	1096	1113	imaginary objects	T041	C0025361
27790175	1120	1128	examined	T169	C1292732
27790175	1146	1158	pretend play	T041	C2371970
27790175	1159	1169	production	T041	C0025361
27790175	1180	1188	analyzed	T062	C0936012
27790175	1192	1200	relation	T080	C0439849
27790175	1204	1207	ASD	T048	C1510586
27790175	1208	1216	symptoms	T184	C1457887
27790175	1267	1281	theory of mind	T078	C0935573
27790175	1283	1286	ToM	T078	C0935573
27790175	1289	1303	verbal ability	T041	C1145677
27790175	1305	1316	familiarity	T041	C0600269
27790175	1322	1330	interest	T041	C0543488
27790175	1334	1342	specific	T080	C0205369
27790175	1343	1347	toys	T073	C0040565
27790175	1356	1364	children	T100	C0008059
27790175	1395	1400	males	T032	C0086582
27790175	1423	1432	threshold	T080	C0449864
27790175	1437	1440	ASD	T048	C1510586
27790175	1441	1450	diagnosis	T033	C0011900
27790175	1455	1461	parent	T099	C0030551
27790175	1472	1475	ASD	T048	C1510586
27790175	1476	1484	symptoms	T184	C1457887
27790175	1502	1515	play sessions	T058	C1254363
27790175	1530	1538	measures	T081	C0079809
27790175	1542	1551	verbal IQ	T032	C0582577
27790175	1556	1559	ToM	T078	C0935573
27790175	1573	1580	measure	T081	C0079809
27790175	1584	1589	child	T100	C0008059
27790175	1590	1593	ASD	T048	C1510586
27790175	1594	1602	symptoms	T184	C1457887
27790175	1604	1611	parents	T099	C0030551
27790175	1624	1630	survey	T170	C0038951
27790175	1640	1647	child's	T100	C0008059
27790175	1648	1656	interest	T041	C0543488
27790175	1664	1675	familiarity	T041	C0600269
27790175	1685	1697	play session	T058	C1254363
27790175	1698	1702	toys	T073	C0040565
27790175	1721	1724	ToM	T078	C0935573
27790175	1725	1734	predicted	T078	C0681842
27790175	1740	1743	APP	T080	C0871161
27790175	1754	1762	interest	T041	C0543488
27790175	1770	1774	toys	T073	C0040565
27790175	1785	1794	predicted	T078	C0681842
27790175	1800	1802	OS	T052	C1706204
27790175	1824	1836	pretend play	T041	C2371970
27790175	1837	1847	production	T041	C0025361
27790175	1897	1905	children	T100	C0008059
27790175	1916	1919	ASD	T048	C1510586
27790175	1920	1928	symptoms	T184	C1457887
27790175	1930	1944	verbal ability	T041	C1145677
27790175	1967	1976	predicted	T078	C0681842
27790175	1977	1989	pretend play	T041	C2371970
27790175	1990	2000	production	T041	C0025361
27790175	2016	2024	children	T100	C0008059
27790175	2036	2039	ASD	T048	C1510586
27790175	2040	2048	symptoms	T184	C1457887
27790175	2050	2053	ToM	T078	C0935573
27790175	2065	2074	predicted	T078	C0681842
27790175	2075	2087	pretend play	T041	C2371970
27790175	2088	2098	production	T041	C0025361
27790175	2153	2156	ASD	T048	C1510586
27790175	2157	2165	symptoms	T184	C1457887
27790175	2169	2181	pretend play	T041	C2371970
27790175	2234	2237	ToM	T078	C0935573
27790175	2247	2261	verbal ability	T041	C1145677
27790175	2283	2295	pretend play	T041	C2371970
27790175	2313	2321	children	T100	C0008059
27790175	2332	2335	ASD	T048	C1510586
27790175	2336	2344	symptoms	T184	C1457887
27790175	2389	2398	treatment	T061	C0087111
27790175	2403	2418	pretend ability	T032	C0085732
27790175	2425	2433	children	T100	C0008059
27790175	2458	2461	ASD	T048	C1510586
27790175	2462	2470	symptoms	T184	C1457887

28089452|t|Co-Folding of a FliF - FliG Split Domain Forms the Basis of the MS:C Ring Interface within the Bacterial Flagellar Motor
28089452|a|The interface between the membrane (MS) and cytoplasmic (C) rings of the bacterial flagellar motor couples torque generation to rotation within the membrane. The structure of the C-terminal helices of the integral membrane protein FliF (FliFC) bound to the N terminal domain of the switch complex protein FliG (FliGN) reveals that FliGN folds around FliFC to produce a topology that closely resembles both the middle and C-terminal domains of FliG. The interface is consistent with solution-state nuclear magnetic resonance, small-angle X-ray scattering, in vivo interaction studies, and cellular motility assays. Co-folding with FliFC induces substantial conformational changes in FliGN and suggests that FliF and FliG have the same stoichiometry within the rotor. Modeling the FliFC: FliGN complex into cryo-electron microscopy rotor density updates the architecture of the middle and upper switch complex and shows how domain shuffling of a conserved interaction module anchors the cytoplasmic rotor to the membrane.
28089452	0	10	Co-Folding	T044	C0162847
28089452	16	20	FliF	T116,T123	C1429736
28089452	23	27	FliG	T116,T123	C1429735
28089452	28	40	Split Domain	T087	C1514562
28089452	64	83	MS:C Ring Interface	T026	C3157051
28089452	95	120	Bacterial Flagellar Motor	T043	C3156185
28089452	147	155	membrane	T026	C0596901
28089452	157	159	MS	T026	C0596901
28089452	165	176	cytoplasmic	T026	C0521449
28089452	178	179	C	T026	C0521449
28089452	181	219	rings of the bacterial flagellar motor	T043	C3156185
28089452	228	234	torque	T067	C0376590
28089452	235	245	generation	T052	C3146294
28089452	249	257	rotation	T169	C0035868
28089452	269	277	membrane	T026	C0596901
28089452	300	318	C-terminal helices	T082	C1704821
28089452	326	351	integral membrane protein	T116	C0021699
28089452	352	356	FliF	T116,T123	C1429736
28089452	358	363	FliFC	T116,T123	C1429736
28089452	378	395	N terminal domain	T087	C1514562
28089452	403	430	switch complex protein FliG	T116,T123	C1429735
28089452	432	437	FliGN	T116,T123	C1429735
28089452	452	457	FliGN	T116,T123	C1429735
28089452	458	463	folds	T044	C0162847
28089452	471	476	FliFC	T116,T123	C1429736
28089452	490	498	topology	T075	C0026336
28089452	531	537	middle	T087	C1514562
28089452	542	560	C-terminal domains	T087	C1514562
28089452	564	568	FliG	T116,T123	C1429735
28089452	603	644	solution-state nuclear magnetic resonance	T070	C0028580
28089452	646	674	small-angle X-ray scattering	T059	C1537058
28089452	676	703	in vivo interaction studies	T062	C0681829
28089452	709	733	cellular motility assays	T059	C1955924
28089452	735	745	Co-folding	T044	C0162847
28089452	751	756	FliFC	T116,T123	C1429736
28089452	765	799	substantial conformational changes	T044	C0301641
28089452	803	808	FliGN	T116,T123	C1429735
28089452	827	831	FliF	T116,T123	C1429736
28089452	836	840	FliG	T116,T123	C1429736
28089452	855	868	stoichiometry	T081	C0597526
28089452	880	885	rotor	T043	C0920694
28089452	900	905	FliFC	T116,T123	C1429736
28089452	907	912	FliGN	T116,T123	C1429735
28089452	926	950	cryo-electron microscopy	T059	C0597705
28089452	951	964	rotor density	T033	C0243095
28089452	1014	1028	switch complex	T116,T123	C1429735
28089452	1043	1049	domain	T087	C1514562
28089452	1075	1093	interaction module	T077	C1709061
28089452	1094	1101	anchors	T044	C1622508
28089452	1106	1123	cytoplasmic rotor	T026	C3157051
28089452	1131	1139	membrane	T026	C0596901

27846748|t|Beneficial effects of natural eggshell membrane (NEM) on multiple indices of arthritis in collagen-induced arthritic rats
27846748|a|This study was performed to evaluate the potential efficacy of natural eggshell membrane (NEM) in collagen-induced arthritic rats, a well-established rodent model of inflammation and rheumatoid arthritis. Rats with developing type II collagen-induced arthritis (CIA) were treated once daily by oral gavage on study days -14 to 17 with vehicle or NEM (52 mg/kg body weight). Rats were euthanized on study day 17. Efficacy was assessed by daily ankle caliper measurements, ankle diameter expressed as area under the curve (AUCd0-17), and histopathologic evaluation of ankles and knees. Serum biomarkers of cartilage function and inflammation [collagen type II C-telopeptide (CTXII), cartilage oligomeric matrix protein (COMP), and alpha-2-macroglobulin (A2M)] were measured by ELISA. Treatment with NEM resulted in significant beneficial effects on the daily ankle diameter measurements and ankle diameter AUC. Ankle and knee histopathology scores were significantly reduced (36% and 43% reduction of summed individual histopathology scores for ankle and knee, respectively; p < 0.05) toward normal for rats given NEM compared to vehicle controls. The percent reduction of serum CTXII, COMP, and A2M in NEM - treated rats ranged from 30% to 72% (p < 0.05). NEM significantly improved multiple aspects of inflammatory arthritis including inflammation, pannus, cartilage damage, bone resorption, and periosteal bone formation. This study provides further support for the use of CTXII, COMP, and A2M as relevant biomarkers that were responsive to NEM.
27846748	0	18	Beneficial effects	UnknownType	C0683156
27846748	22	47	natural eggshell membrane	T109,T121	C3651790
27846748	49	52	NEM	T109,T121	C3651790
27846748	77	86	arthritis	T047	C0003864
27846748	90	116	collagen-induced arthritic	T050	C0971858
27846748	117	121	rats	T015	C0034721
27846748	127	132	study	T062	C2603343
27846748	150	158	evaluate	T058	C0220825
27846748	163	181	potential efficacy	T080	C1280519
27846748	185	210	natural eggshell membrane	T109,T121	C3651790
27846748	212	215	NEM	T109,T121	C3651790
27846748	220	246	collagen-induced arthritic	T050	C0971858
27846748	247	251	rats	T015	C0034721
27846748	272	300	rodent model of inflammation	T050	C1519106
27846748	305	325	rheumatoid arthritis	T047	C0003873
27846748	327	331	Rats	T015	C0034721
27846748	348	382	type II collagen-induced arthritis	T050	C0971858
27846748	384	387	CIA	T050	C0971858
27846748	407	412	daily	T079	C0332173
27846748	416	427	oral gavage	T169	C2698653
27846748	431	441	study days	T079	C2826182
27846748	457	464	vehicle	T122	C0042444
27846748	468	471	NEM	T109,T121	C3651790
27846748	482	493	body weight	T032	C0005910
27846748	496	500	Rats	T015	C0034721
27846748	506	516	euthanized	T062	C2983562
27846748	520	529	study day	T079	C2826182
27846748	534	542	Efficacy	T080	C1280519
27846748	547	555	assessed	T052	C1516048
27846748	559	564	daily	T079	C0332173
27846748	565	570	ankle	T029	C0003086
27846748	571	578	caliper	T074	C0175720
27846748	579	591	measurements	T169	C0242485
27846748	579	591	measurements	T169	C0242485
27846748	593	598	ankle	T029	C0003086
27846748	599	607	diameter	T081	C1301886
27846748	621	641	area under the curve	T081	C0376690
27846748	643	651	AUCd0-17	T081	C0376690
27846748	658	684	histopathologic evaluation	T091	C0677043
27846748	688	694	ankles	T029	C0003086
27846748	699	704	knees	T023	C0022742
27846748	706	711	Serum	T031	C0229671
27846748	712	722	biomarkers	T201	C0005516
27846748	726	744	cartilage function	T042	C0231581
27846748	749	761	inflammation	T046	C0021368
27846748	763	793	collagen type II C-telopeptide	T059	C2825914
27846748	795	800	CTXII	T059	C2825914
27846748	803	838	cartilage oligomeric matrix protein	T059	C3715143
27846748	840	844	COMP	T059	C3715143
27846748	851	872	alpha-2-macroglobulin	T059	C0523483
27846748	874	877	A2M	T059	C0523483
27846748	885	893	measured	T080	C0444706
27846748	897	902	ELISA	T059	C0014441
27846748	904	913	Treatment	T169	C0039798
27846748	919	922	NEM	T109,T121	C3651790
27846748	935	965	significant beneficial effects	UnknownType	C0683156
27846748	973	978	daily	T079	C0332173
27846748	979	984	ankle	T029	C0003086
27846748	985	993	diameter	T081	C1301886
27846748	994	1006	measurements	T169	C0242485
27846748	1011	1016	ankle	T029	C0003086
27846748	1017	1025	diameter	T081	C1301886
27846748	1026	1029	AUC	T081	C0376690
27846748	1031	1036	Ankle	T029	C0003086
27846748	1041	1045	knee	T023	C0022742
27846748	1046	1067	histopathology scores	T034	C0428093
27846748	1073	1094	significantly reduced	T080	C0392756
27846748	1108	1117	reduction	T080	C0392756
27846748	1139	1160	histopathology scores	T034	C0428093
27846748	1165	1170	ankle	T029	C0003086
27846748	1175	1179	knee	T023	C0022742
27846748	1223	1227	rats	T015	C0034721
27846748	1234	1237	NEM	T109,T121	C3651790
27846748	1293	1298	serum	T031	C0229671
27846748	1299	1304	CTXII	T059	C2825914
27846748	1306	1310	COMP	T059	C3715143
27846748	1316	1319	A2M	T059	C0523483
27846748	1323	1326	NEM	T109,T121	C3651790
27846748	1329	1336	treated	T169	C1522326
27846748	1337	1341	rats	T015	C0034721
27846748	1377	1380	NEM	T109,T121	C3651790
27846748	1424	1446	inflammatory arthritis	T047	C0003864
27846748	1457	1469	inflammation	T046	C0021368
27846748	1471	1477	pannus	T046	C0333350
27846748	1479	1495	cartilage damage	T037	C0549421
27846748	1497	1512	bone resorption	T042	C0005974
27846748	1518	1543	periosteal bone formation	T042	C0231565
27846748	1550	1555	study	T062	C2603343
27846748	1596	1601	CTXII	T116	C0631180
27846748	1603	1607	COMP	T116,T123	C0601900
27846748	1613	1616	A2M	T116,T123	C0002198
27846748	1629	1639	biomarkers	T201	C0005516
27846748	1664	1667	NEM	T109,T121	C3651790

28088177|t|A novel quantitative PCR detects Babesia infection in patients not identified by currently available non-nucleic acid amplification tests
28088177|a|Ticks transmit Babesia microti, the causative agents of babesiosis in North America and Europe. Babesiosis is now endemic in Northeastern USA and affects people of all ages. Babesia species infect erythrocytes and can be transmitted through blood transfusion. Whole blood and blood products, which are not tested for Babesia, can cause transfusion - transmitted babesiosis (TTB) resulting in severe consequences in the immuno-compromised patients. The purpose of this study was epidemiological evaluation of babesiosis in a tick-infested state. We examined blood samples from 192 patients who visited clinics during the active tick-borne diseases season, using a newly developed qPCR assay that uses the specific molecular beacon probe. Due to the absence of clear symptomology, clinical laboratories did not test 131 samples by IFA, FISH or microscopic examination of Giemsa-stained blood smears. Babesia infection was detected in all age groups by FISH and microscopy; notably patients >40 years of age represented 64% of tested samples and 13% were younger patients. We tested all samples using qPCR and found that 38% were positive for Babesia. Of 28 samples that were positive by FISH, 27 (96%) were also positive by qPCR indicating high congruency between nucleic acid based tests. Interestingly, of 78 asymptomatic samples not tested by FISH, 22 were positive by our qPCR. Direct detection of Babesia relies upon microscopic examination of patient blood smears, which is labor intensive, difficult to scale up, requires specific expertise and is hence, often not performed. In fact, a clinical laboratory examined only 23 of 86 blood samples obtained from two different counties by microscopy. By considering individuals positive for Babesia infection when results from currently available microscopy, FISH or serological tests were positive, we found that our qPCR is highly sensitive (96.2%) and showed a specificity of 70.5% for Babesia. Robust qPCR using specific probes can be highly useful for efficient and appropriate diagnosis of babesiosis in patients in conjunction with conventional diagnostics, or as a stand-alone test, especially for donated blood screening. The use of a nucleic acid amplification test based screening of blood and blood products could prevent TTB.
28088177	8	24	quantitative PCR	T063	C1709846
28088177	33	40	Babesia	T204	C0004572
28088177	41	50	infection	T046	C3714514
28088177	54	62	patients	T101	C0030705
28088177	101	137	non-nucleic acid amplification tests	T059	C1441475
28088177	138	143	Ticks	T204	C0040203
28088177	144	152	transmit	T169	C1444006
28088177	153	168	Babesia microti	T204	C0004574
28088177	174	190	causative agents	T033	C0449411
28088177	194	204	babesiosis	T047	C0004576
28088177	208	221	North America	T083	C0028405
28088177	226	232	Europe	T083	C0015176
28088177	234	244	Babesiosis	T047	C0004576
28088177	252	259	endemic	T047	C0277550
28088177	263	275	Northeastern	T083	C0017446
28088177	276	279	USA	T083	C0041703
28088177	292	298	people	T098	C0027361
28088177	306	310	ages	T032	C0001779
28088177	312	327	Babesia species	T204	C0004572
28088177	335	347	erythrocytes	T025	C0014792
28088177	359	370	transmitted	T046	C0242781
28088177	379	396	blood transfusion	T061	C0005841
28088177	398	409	Whole blood	T031	C0370231
28088177	414	428	blood products	T121	C0456388
28088177	455	462	Babesia	T204	C0004572
28088177	474	485	transfusion	T061	C0005841
28088177	488	499	transmitted	T046	C0242781
28088177	500	510	babesiosis	T047	C0004576
28088177	512	515	TTB	T047	C0004576
28088177	530	536	severe	T080	C0205082
28088177	537	549	consequences	T169	C0686907
28088177	557	575	immuno-compromised	T033	C0085393
28088177	576	584	patients	T101	C0030705
28088177	606	611	study	T062	C2603343
28088177	616	642	epidemiological evaluation	T062	C0002783
28088177	646	656	babesiosis	T047	C0004576
28088177	662	681	tick-infested state	T047	C0040196
28088177	686	694	examined	T033	C0332128
28088177	695	708	blood samples	T031	C0178913
28088177	718	726	patients	T101	C0030705
28088177	739	746	clinics	T073,T093	C0442592
28088177	765	784	tick-borne diseases	T047	C0040196
28088177	785	791	season	T079	C0036497
28088177	817	827	qPCR assay	T063	C1709846
28088177	851	873	molecular beacon probe	T114	C0028630
28088177	886	893	absence	T169	C0332197
28088177	903	915	symptomology	T184	C1457887
28088177	917	938	clinical laboratories	T073	C1882331
28088177	956	963	samples	T031	C0178913
28088177	967	970	IFA	T059	C0282647
28088177	972	976	FISH	T063	C0162789
28088177	980	1003	microscopic examination	T059	C0026018
28088177	1007	1021	Giemsa-stained	T109,T130	C0017542
28088177	1022	1034	blood smears	T059	C2238079
28088177	1036	1043	Babesia	T204	C0004572
28088177	1044	1053	infection	T046	C3714514
28088177	1074	1084	age groups	T100	C0027362
28088177	1088	1092	FISH	T063	C0162789
28088177	1097	1107	microscopy	T059	C0026018
28088177	1117	1125	patients	T101	C0030705
28088177	1130	1135	years	T079	C0439234
28088177	1139	1142	age	T032	C0001779
28088177	1169	1176	samples	T031	C0178913
28088177	1190	1197	younger	T079	C0332239
28088177	1198	1206	patients	T101	C0030705
28088177	1222	1229	samples	T031	C0178913
28088177	1236	1240	qPCR	T063	C1709846
28088177	1265	1273	positive	T033	C1446409
28088177	1278	1285	Babesia	T204	C0004572
28088177	1293	1300	samples	T031	C0178913
28088177	1311	1319	positive	T033	C1446409
28088177	1323	1327	FISH	T063	C0162789
28088177	1348	1356	positive	T033	C1446409
28088177	1360	1364	qPCR	T063	C1709846
28088177	1400	1424	nucleic acid based tests	T059	C0200932
28088177	1447	1459	asymptomatic	T033	C0231221
28088177	1460	1467	samples	T031	C0178913
28088177	1482	1486	FISH	T063	C0162789
28088177	1496	1504	positive	T033	C1446409
28088177	1512	1516	qPCR	T063	C1709846
28088177	1525	1534	detection	T061	C1511790
28088177	1538	1545	Babesia	T204	C0004572
28088177	1558	1581	microscopic examination	T059	C0026018
28088177	1585	1592	patient	T101	C0030705
28088177	1593	1605	blood smears	T059	C2238079
28088177	1730	1749	clinical laboratory	T073	C1882331
28088177	1750	1758	examined	T033	C0332128
28088177	1773	1786	blood samples	T031	C0178913
28088177	1815	1823	counties	T083	C0454664
28088177	1827	1837	microscopy	T059	C0026018
28088177	1854	1865	individuals	T098	C0237401
28088177	1866	1874	positive	T033	C1446409
28088177	1879	1886	Babesia	T204	C0004572
28088177	1887	1896	infection	T046	C3714514
28088177	1935	1945	microscopy	T059	C0026018
28088177	1947	1951	FISH	T063	C0162789
28088177	1955	1972	serological tests	T059	C0036743
28088177	1978	1986	positive	T033	C1446409
28088177	2006	2010	qPCR	T063	C1709846
28088177	2021	2030	sensitive	T169	C0332324
28088177	2052	2063	specificity	T081	C0037791
28088177	2077	2084	Babesia	T204	C0004572
28088177	2093	2097	qPCR	T063	C1709846
28088177	2113	2119	probes	T130	C0026381
28088177	2171	2180	diagnosis	T062	C1704656
28088177	2184	2194	babesiosis	T047	C0004576
28088177	2198	2206	patients	T101	C0030705
28088177	2240	2251	diagnostics	T062	C1511890
28088177	2302	2317	blood screening	T059	C1511226
28088177	2332	2363	nucleic acid amplification test	T059	C0200932
28088177	2370	2388	screening of blood	T059	C1511226
28088177	2393	2407	blood products	T121	C0456388
28088177	2422	2425	TTB	T047	C0004576

27876598|t|Antithrombotic activity of Batroxase, a metalloprotease from Bothrops atrox venom, in a model of venous thrombosis
27876598|a|Snake venoms are great sources of bioactive molecules, which may be used as models for new drugs. Toxins that interfere in hemostasis have received considerable attention over the years. This study aimed at the evaluation of the antithrombotic activity of Batroxase, a P-I metalloprotease from Bothrops atrox venom, in an animal model of venous thrombosis. The antithrombotic activity of Batroxase was tested in vivo in a model based on two factors of the Virchow's Triad: blood flow alterations (partial stenosis of the inferior vena cava), and vessel wall injury (10% ferric chloride for 5min), in comparison with sodium heparin (positive control) and saline (negative control). Bleeding / clotting time was assessed by a tail bleeding assay. The immunogenicity of Batroxase was also analyzed. Batroxase (12mg/kg) reduced thrombus formation in 81%, similarly to heparin (100U/kg), which reduced it in 85% in comparison with the saline group. Both Batroxase and heparin increased bleeding / clotting time in approximately 3 fold. Immunizations of rabbits with Batroxase do not result in detectable levels of antibodies against this metalloprotease. Batroxase presents antithrombotic activity in vivo. Moreover, its lack of immunogenicity increases the interest on its possible therapeutic potential over thrombogenic disorders.
27876598	0	23	Antithrombotic activity	T033	C0243095
27876598	27	36	Batroxase	T116,T126,T131	C4278231
27876598	40	55	metalloprotease	T116,T126	C0025543
27876598	61	81	Bothrops atrox venom	T109,T121	C4033446
27876598	88	93	model	T008	C0599779
27876598	97	114	venous thrombosis	T046	C0042487
27876598	115	127	Snake venoms	T123,T131	C0037380
27876598	149	168	bioactive molecules	T167	C3714412
27876598	191	197	models	T170	C3161035
27876598	206	211	drugs	T121	C0013227
27876598	213	219	Toxins	T123,T131	C0040549
27876598	238	248	hemostasis	T047	C0005779
27876598	295	300	years	T079	C0439234
27876598	307	312	study	T062	C2603343
27876598	326	336	evaluation	T078	C1550157
27876598	344	367	antithrombotic activity	T033	C0243095
27876598	371	380	Batroxase	T116,T126,T131	C4278231
27876598	384	403	P-I metalloprotease	T116,T126	C0025543
27876598	409	429	Bothrops atrox venom	T109,T121	C4033446
27876598	437	449	animal model	T008	C0599779
27876598	453	470	venous thrombosis	T046	C0042487
27876598	476	499	antithrombotic activity	T033	C0243095
27876598	503	512	Batroxase	T116,T126,T131	C4278231
27876598	524	531	in vivo	T082	C1515655
27876598	537	542	model	T008	C0599779
27876598	556	563	factors	T169	C1521761
27876598	571	586	Virchow's Triad	T170	C0282574
27876598	588	598	blood flow	T039	C0232338
27876598	612	628	partial stenosis	T020	C0333183
27876598	636	654	inferior vena cava	T023	C0042458
27876598	661	672	vessel wall	T023	C0229962
27876598	673	679	injury	T037	C0178314
27876598	685	700	ferric chloride	T121,T197	C0060229
27876598	731	745	sodium heparin	T109,T121	C0037513
27876598	747	763	positive control	T077	C1883676
27876598	769	775	saline	T167	C0036082
27876598	777	793	negative control	T077	C1947986
27876598	796	804	Bleeding	T201	C0550585
27876598	807	820	clotting time	T034	C2266672
27876598	844	858	bleeding assay	T046	C0019080
27876598	864	878	immunogenicity	T044	C1148560
27876598	882	891	Batroxase	T116,T126,T131	C4278231
27876598	911	920	Batroxase	T116,T126,T131	C4278231
27876598	939	957	thrombus formation	T033	C0243095
27876598	979	986	heparin	T109,T121,T123	C0019134
27876598	1045	1051	saline	T167	C0036082
27876598	1052	1057	group	T078	C0441833
27876598	1064	1073	Batroxase	T116,T126,T131	C4278231
27876598	1078	1085	heparin	T109,T121,T123	C0019134
27876598	1096	1104	bleeding	T201	C0550585
27876598	1107	1120	clotting time	T034	C2266672
27876598	1146	1159	Immunizations	T061	C0020971
27876598	1163	1170	rabbits	T015	C3887509
27876598	1176	1185	Batroxase	T116,T126,T131	C4278231
27876598	1214	1220	levels	T080	C0441889
27876598	1224	1234	antibodies	T116,T129	C0003241
27876598	1248	1263	metalloprotease	T116,T126	C0025543
27876598	1265	1274	Batroxase	T116,T126,T131	C4278231
27876598	1284	1307	antithrombotic activity	T033	C0243095
27876598	1308	1315	in vivo	T082	C1515655
27876598	1339	1353	immunogenicity	T044	C1148560
27876598	1393	1414	therapeutic potential	T080	C0205556
27876598	1420	1442	thrombogenic disorders	T047	C0012634

27801889|t|Differential transcriptome expression in human nucleus accumbens as a function of loneliness
27801889|a|Loneliness is associated with impaired mental and physical health. Studies of lonely individuals reported differential expression of inflammatory genes in peripheral leukocytes and diminished activation in brain reward regions such as nucleus accumbens, but could not address gene expression in the human brain. Here, we examined genome-wide RNA expression in post-mortem nucleus accumbens from donors (N=26) with known loneliness measures. Loneliness was associated with 1710 differentially expressed transcripts and genes from 1599 genes (DEGs; false discovery rate P<0.05, fold change ⩾|2|, controlling for confounds) previously associated with behavioral processes, neurological disease, psychological disorders, cancer, organismal injury and skeletal and muscular disorders, as well as networks of upstream RNA regulators. Furthermore, a number of DEGs were associated with Alzheimer's disease (AD) genes (that was correlated with loneliness in this sample, although gene expression analyses controlled for AD diagnosis). These results identify novel targets for future mechanistic studies of gene networks in nucleus accumbens and gene regulatory mechanisms across a variety of diseases exacerbated by loneliness. Molecular Psychiatry advance online publication, 1 November 2016; doi:10.1038/mp.2016.186.
27801889	0	12	Differential	T080	C1705242
27801889	13	26	transcriptome	T086	C3178810
27801889	27	37	expression	T045	C0017262
27801889	41	46	human	T016	C0086418
27801889	47	64	nucleus accumbens	T023	C0028633
27801889	82	92	loneliness	T033	C0023974
27801889	93	103	Loneliness	T033	C0023974
27801889	107	122	associated with	T080	C0332281
27801889	123	131	impaired	T046	C0684336
27801889	132	138	mental	T041	C0025353
27801889	143	158	physical health	T078	C0018684
27801889	171	189	lonely individuals	T098	C0237401
27801889	199	222	differential expression	T045	C1519516
27801889	226	238	inflammatory	T169	C0333348
27801889	239	244	genes	T028	C0017337
27801889	248	258	peripheral	T082	C0205100
27801889	259	269	leukocytes	T025	C0023516
27801889	274	284	diminished	T081	C0205216
27801889	285	295	activation	T045	C0017255
27801889	299	304	brain	T023	C0006104
27801889	305	319	reward regions	T029	C1273723
27801889	328	345	nucleus accumbens	T023	C0028633
27801889	369	384	gene expression	T045	C0017262
27801889	392	397	human	T016	C0086418
27801889	398	403	brain	T023	C0006104
27801889	423	449	genome-wide RNA expression	T045	C0017262
27801889	453	464	post-mortem	T060	C0004398
27801889	465	482	nucleus accumbens	T023	C0028633
27801889	488	494	donors	T098	C0013018
27801889	513	523	loneliness	T033	C0023974
27801889	524	532	measures	T081	C0079809
27801889	534	544	Loneliness	T033	C0023974
27801889	549	564	associated with	T080	C0332281
27801889	570	606	differentially expressed transcripts	T114	C1519595
27801889	611	616	genes	T028	C0017337
27801889	627	632	genes	T028	C0017337
27801889	634	638	DEGs	T028	C0017337
27801889	640	660	false discovery rate	T081	C1880720
27801889	725	740	associated with	T080	C0332281
27801889	741	761	behavioral processes	T053	C0004927
27801889	763	783	neurological disease	T047	C0027765
27801889	785	808	psychological disorders	T048	C0004936
27801889	810	816	cancer	T191	C0006826
27801889	818	828	organismal	T001	C0029235
27801889	829	835	injury	T037	C0178314
27801889	840	848	skeletal	T047	C0263661
27801889	853	871	muscular disorders	T047	C0026848
27801889	884	892	networks	T169	C1882071
27801889	896	904	upstream	T082	C0522505
27801889	905	919	RNA regulators	T028	C0017362
27801889	946	950	DEGs	T028	C0017337
27801889	956	971	associated with	T080	C0332281
27801889	972	991	Alzheimer's disease	T047	C0002395
27801889	993	995	AD	T047	C0002395
27801889	997	1002	genes	T028	C0017337
27801889	1013	1023	correlated	T080	C1707520
27801889	1029	1039	loneliness	T033	C0023974
27801889	1048	1054	sample	T167	C0370003
27801889	1065	1089	gene expression analyses	T063	C1880945
27801889	1105	1107	AD	T047	C0002395
27801889	1108	1117	diagnosis	T033	C0011900
27801889	1149	1156	targets	T169	C1521840
27801889	1168	1187	mechanistic studies	T062	C0242481
27801889	1191	1195	gene	T028	C0017337
27801889	1208	1225	nucleus accumbens	T023	C0028633
27801889	1230	1256	gene regulatory mechanisms	T045	C0017263
27801889	1277	1285	diseases	T047	C0012634
27801889	1301	1311	loneliness	T033	C0023974
27801889	1313	1360	Molecular Psychiatry advance online publication	T073,T170	C0034036
27801889	1364	1372	November	T079	C3828767

27284493|t|Sensitization to the motor stimulant effects of 3,4-methylenedioxypyrovalerone (MDPV) and cross-sensitization to methamphetamine in rats
27284493|a|In recent years, there has been a dramatic increase in abuse of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV), often in combination with other illicit stimulants. We sought to determine if repeated exposure to MDPV would produce sensitization to the motor stimulant effects of the drug, and whether cross-sensitization would develop with the stimulant effects of methamphetamine (METH). Male Sprague-Dawley rats were administered MDPV (1 or 5 mg/kg) or saline once daily for 5 days at 24 hour intervals, or were administered MDPV (1 mg/kg) or saline once daily for 5 days at 48 hour intervals. For cross-sensitization experiments, rats were administered METH (1 mg/kg) or MDPV (1 or 5 mg/kg) once daily for 5 days at 48 hour intervals, and following a 5 day incubation period, were given an acute challenge injection of either MDPV (0.5 mg/kg) or METH (0.5 mg/kg), respectively. Rats repeatedly administered MDPV (1 mg/kg) every 48 hours, but not every 24 hours, demonstrated increased motor activity when given either a subsequent challenge of MDPV (0.5 mg/kg i.p.) or METH (0.5 mg/kg), indicating the development of behavioral sensitization and cross-sensitization, respectively. Moreover, rats repeatedly administered METH (1 mg/kg) every 48 hours did not exhibit cross-sensitization to the motor stimulating effects of a subsequent challenge with MDPV (0.5 mg/kg). These results suggest that specific patterns of MDPV administration may lead to lasting changes in behavioral responses to subsequent METH exposure.
27284493	0	13	Sensitization	T040	C1325847
27284493	21	26	motor	T025	C0026609
27284493	27	36	stimulant	T121	C0304402
27284493	37	44	effects	T080	C1280500
27284493	48	78	3,4-methylenedioxypyrovalerone	T109	C2974592
27284493	80	84	MDPV	T109	C2974592
27284493	90	109	cross-sensitization	T040	C1325847
27284493	113	128	methamphetamine	T109,T131	C0025611
27284493	132	136	rats	T015	C0086893
27284493	147	152	years	T079	C0439234
27284493	180	188	increase	T081	C0205217
27284493	192	197	abuse	T048	C0013146
27284493	205	224	synthetic cathinone	T109,T121	C0054876
27284493	225	255	3,4-methylenedioxypyrovalerone	T109	C2974592
27284493	257	261	MDPV	T109	C2974592
27284493	273	284	combination	T080	C0205195
27284493	296	303	illicit	T169	C0332266
27284493	304	314	stimulants	T121	C0304402
27284493	342	350	repeated	T169	C0205341
27284493	351	362	exposure to	T080	C0332157
27284493	363	367	MDPV	T109	C2974592
27284493	382	395	sensitization	T040	C1325847
27284493	403	408	motor	T025	C0026609
27284493	409	418	stimulant	T121	C0304402
27284493	419	426	effects	T080	C1280500
27284493	434	438	drug	T121	C0013227
27284493	452	471	cross-sensitization	T040	C1325847
27284493	478	485	develop	T169	C1527148
27284493	495	504	stimulant	T121	C0304402
27284493	505	512	effects	T080	C1280500
27284493	516	531	methamphetamine	T109,T131	C0025611
27284493	533	537	METH	T109,T131	C0025611
27284493	540	544	Male	T032	C0086582
27284493	545	564	Sprague-Dawley rats	T015	C0034715
27284493	570	582	administered	T081	C0001555
27284493	583	587	MDPV	T109	C2974592
27284493	606	612	saline	T167	C0036082
27284493	613	623	once daily	T079	C0556983
27284493	630	634	days	T079	C0439228
27284493	641	645	hour	T079	C0439227
27284493	646	655	intervals	T079	C1272706
27284493	665	677	administered	T081	C0001555
27284493	678	682	MDPV	T109	C2974592
27284493	696	702	saline	T167	C0036082
27284493	703	713	once daily	T079	C0556983
27284493	720	724	days	T079	C0439228
27284493	731	735	hour	T079	C0439227
27284493	736	745	intervals	T079	C1272706
27284493	751	770	cross-sensitization	T040	C1325847
27284493	771	782	experiments	T062	C0205664
27284493	784	788	rats	T015	C0034715
27284493	794	806	administered	T081	C0001555
27284493	807	811	METH	T109,T131	C0025611
27284493	825	829	MDPV	T109	C2974592
27284493	845	855	once daily	T079	C0556983
27284493	862	866	days	T079	C0439228
27284493	873	877	hour	T079	C0439227
27284493	878	887	intervals	T079	C1272706
27284493	907	910	day	T079	C0439228
27284493	911	928	incubation period	T033	C1320226
27284493	960	969	injection	T122	C1272883
27284493	980	984	MDPV	T109	C2974592
27284493	1000	1004	METH	T109,T131	C0025611
27284493	1032	1036	Rats	T015	C0034715
27284493	1037	1047	repeatedly	T169	C0205341
27284493	1048	1060	administered	T081	C0001555
27284493	1061	1065	MDPV	T109	C2974592
27284493	1085	1090	hours	T079	C0439227
27284493	1109	1114	hours	T079	C0439227
27284493	1129	1138	increased	T081	C0205217
27284493	1139	1153	motor activity	T033	C0243095
27284493	1198	1202	MDPV	T109	C2974592
27284493	1223	1227	METH	T109,T131	C0025611
27284493	1256	1281	development of behavioral	T040	C2825534
27284493	1282	1295	sensitization	T040	C1325847
27284493	1300	1319	cross-sensitization	T040	C1325847
27284493	1345	1349	rats	T015	C0034715
27284493	1361	1373	administered	T081	C0001555
27284493	1374	1378	METH	T109,T131	C0025611
27284493	1398	1403	hours	T079	C0439227
27284493	1420	1439	cross-sensitization	T040	C1325847
27284493	1447	1452	motor	T025	C0026609
27284493	1453	1464	stimulating	T070	C1948023
27284493	1465	1472	effects	T080	C1280500
27284493	1504	1508	MDPV	T109	C2974592
27284493	1528	1535	results	T169	C1274040
27284493	1558	1566	patterns	T082	C0449774
27284493	1570	1574	MDPV	T109	C2974592
27284493	1575	1589	administration	T081	C0001555
27284493	1621	1631	behavioral	T053	C0004927
27284493	1632	1641	responses	T032	C0871261
27284493	1656	1660	METH	T109,T131	C0025611
27284493	1661	1669	exposure	T080	C0332157

28375952|t|Interprofessional Barriers: A Study of Quality Improvement Work Among Nurses and Physicians
28375952|a|This article studies interprofessional barriers between nurses and physicians in the context of quality improvement work. A total of 17 nurses and 10 physicians were interviewed at 2 hospitals in Sweden. The study uncovered a number of barriers relating to both the relative status of each group and their defined areas of responsibility.
28375952	0	26	Interprofessional Barriers	T033	C0243095
28375952	39	63	Quality Improvement Work	T057	C2936612
28375952	70	76	Nurses	T097	C0028661
28375952	81	91	Physicians	T097	C0031831
28375952	113	139	interprofessional barriers	T033	C0243095
28375952	148	154	nurses	T097	C0028661
28375952	159	169	physicians	T097	C0031831
28375952	177	184	context	T078	C0449255
28375952	188	212	quality improvement work	T057	C2936612
28375952	228	234	nurses	T097	C0028661
28375952	242	252	physicians	T097	C0031831
28375952	258	269	interviewed	T062	C0018260
28375952	275	284	hospitals	T073,T093	C0019994
28375952	288	294	Sweden	T083	C0038995
28375952	300	315	study uncovered	T169	C0439845
28375952	318	336	number of barriers	T033	C4296486
28375952	377	387	each group	T078	C0441833
28375952	406	429	areas of responsibility	T055	C0678341

27836684|t|Ketogenic diets improve behaviors associated with autism spectrum disorder in a sex - specific manner in the EL mouse
27836684|a|The core symptoms of autism spectrum disorder are poorly treated with current medications. Symptoms of autism spectrum disorder are frequently comorbid with a diagnosis of epilepsy and vice versa. Medically - supervised ketogenic diets are remarkably effective nonpharmacological treatments for epilepsy, even in drug -refractory cases. There is accumulating evidence that supports the efficacy of ketogenic diets in treating the core symptoms of autism spectrum disorders in animal models as well as limited reports of benefits in patients. This study tests the behavioral effects of ketogenic diet feeding in the EL mouse, a model with behavioral characteristics of autism spectrum disorder and comorbid epilepsy. Male and female EL mice were fed control diet or one of two ketogenic diet formulas ad libitum starting at 5weeks of age. Beginning at 8weeks of age, diet protocols continued and performance of each group on tests of sociability and repetitive behavior was assessed. A ketogenic diet improved behavioral characteristics of autism spectrum disorder in a sex - and test - specific manner; ketogenic diet never worsened relevant behaviors. Ketogenic diet feeding improved multiple measures of sociability and reduced repetitive behavior in female mice, with limited effects in males. Additional experiments in female mice showed that a less strict, more clinically - relevant diet formula was equally effective in improving sociability and reducing repetitive behavior. Taken together these results add to the growing number of studies suggesting that ketogenic and related diets may provide significant relief from the core symptoms of autism spectrum disorder, and suggest that in some cases there may be increased efficacy in females.
27836684	0	15	Ketogenic diets	T033	C0259972
27836684	16	23	improve	T080	C1272747
27836684	24	33	behaviors	T053	C0004927
27836684	34	49	associated with	T080	C0332281
27836684	50	74	autism spectrum disorder	T048	C1510586
27836684	80	83	sex	T053	C0036864
27836684	86	94	specific	T080	C0205369
27836684	95	101	manner	T082	C0449445
27836684	109	117	EL mouse	T015	C0025929
27836684	127	135	symptoms	T184	C1457887
27836684	139	163	autism spectrum disorder	T048	C1510586
27836684	168	174	poorly	T080	C0205169
27836684	175	187	treated with	T061	C0332293
27836684	188	195	current	T079	C0521116
27836684	196	207	medications	T121	C0013227
27836684	209	217	Symptoms	T184	C1457887
27836684	221	245	autism spectrum disorder	T048	C1510586
27836684	277	286	diagnosis	T060	C0430022
27836684	290	298	epilepsy	T047	C0014544
27836684	315	324	Medically	T169	C0205476
27836684	327	337	supervised	T080	C1269765
27836684	338	353	ketogenic diets	T033	C0259972
27836684	369	378	effective	T080	C1704419
27836684	379	397	nonpharmacological	T169	C0205245
27836684	398	408	treatments	T061	C0087111
27836684	413	421	epilepsy	T047	C0014544
27836684	431	435	drug	T121	C0013227
27836684	448	453	cases	T169	C0868928
27836684	477	485	evidence	T078	C3887511
27836684	504	512	efficacy	T080	C1280519
27836684	516	531	ketogenic diets	T033	C0259972
27836684	535	543	treating	T169	C1522326
27836684	553	561	symptoms	T184	C1457887
27836684	565	590	autism spectrum disorders	T048	C1510586
27836684	594	607	animal models	T008	C0599779
27836684	627	634	reports	T058	C0700287
27836684	638	646	benefits	T081	C0814225
27836684	650	658	patients	T101	C0030705
27836684	665	670	study	T062	C2603343
27836684	671	676	tests	T060	C0683443
27836684	681	691	behavioral	T053	C0004927
27836684	692	699	effects	T080	C1280500
27836684	703	717	ketogenic diet	T033	C0259972
27836684	718	725	feeding	T052	C2987508
27836684	733	741	EL mouse	T015	C0025929
27836684	745	750	model	T008	C0599779
27836684	756	766	behavioral	T053	C0004927
27836684	767	782	characteristics	T080	C1521970
27836684	786	810	autism spectrum disorder	T048	C1510586
27836684	824	832	epilepsy	T047	C0014544
27836684	834	838	Male	T032	C0086582
27836684	843	849	female	T032	C0086287
27836684	850	857	EL mice	T015	C0025929
27836684	863	866	fed	T052	C2987508
27836684	867	874	control	T080	C0243148
27836684	875	879	diet	T168	C0012155
27836684	894	908	ketogenic diet	T033	C0259972
27836684	909	917	formulas	T061	C0012164
27836684	918	928	ad libitum	T080	C1879743
27836684	929	937	starting	T079	C0439659
27836684	941	947	5weeks	T079	C0439230
27836684	951	954	age	T032	C0001779
27836684	956	965	Beginning	T079	C0439659
27836684	969	975	8weeks	T079	C0439230
27836684	979	982	age	T032	C0001779
27836684	984	988	diet	T168	C0012155
27836684	989	998	protocols	T170	C0442711
27836684	1013	1024	performance	T055	C0597198
27836684	1033	1038	group	UnknownType	C0681860
27836684	1042	1047	tests	T169	C0039593
27836684	1051	1062	sociability	T054	C0558182
27836684	1067	1086	repetitive behavior	T033	C1827547
27836684	1091	1099	assessed	T052	C1516048
27836684	1103	1117	ketogenic diet	T033	C0259972
27836684	1118	1126	improved	T033	C0184511
27836684	1127	1137	behavioral	T053	C0004927
27836684	1138	1153	characteristics	T080	C1521970
27836684	1157	1181	autism spectrum disorder	T048	C1510586
27836684	1187	1190	sex	T053	C0036864
27836684	1197	1201	test	T169	C0039593
27836684	1204	1212	specific	T080	C0205369
27836684	1213	1219	manner	T082	C0449445
27836684	1221	1235	ketogenic diet	T033	C0259972
27836684	1236	1241	never	T079	C1549495
27836684	1242	1250	worsened	T033	C1457868
27836684	1251	1259	relevant	T080	C2347946
27836684	1260	1269	behaviors	T053	C0004927
27836684	1271	1285	Ketogenic diet	T033	C0259972
27836684	1286	1293	feeding	T052	C2987508
27836684	1294	1302	improved	T033	C0184511
27836684	1303	1311	multiple	T081	C0439064
27836684	1312	1320	measures	T081	C0079809
27836684	1324	1335	sociability	T054	C0558182
27836684	1340	1347	reduced	T080	C0392756
27836684	1348	1367	repetitive behavior	T033	C1827547
27836684	1371	1382	female mice	T015	C0025929
27836684	1389	1396	limited	T169	C0439801
27836684	1397	1404	effects	T080	C1280500
27836684	1408	1413	males	T015	C0025929
27836684	1426	1437	experiments	T062	C0681814
27836684	1441	1452	female mice	T015	C0025929
27836684	1467	1471	less	T081	C0439092
27836684	1472	1478	strict	T080	C0205082
27836684	1485	1495	clinically	T080	C0205210
27836684	1498	1506	relevant	T080	C2347946
27836684	1507	1519	diet formula	T061	C0012164
27836684	1532	1541	effective	T080	C1704419
27836684	1545	1554	improving	T080	C1272745
27836684	1555	1566	sociability	T054	C0558182
27836684	1571	1579	reducing	T080	C0392756
27836684	1580	1599	repetitive behavior	T033	C1827547
27836684	1622	1629	results	T169	C1274040
27836684	1649	1655	number	T081	C0237753
27836684	1659	1666	studies	T062	C2603343
27836684	1667	1677	suggesting	T078	C1705535
27836684	1683	1692	ketogenic	T033	C0259972
27836684	1697	1710	related diets	T061	C0587059
27836684	1715	1722	provide	T052	C1999230
27836684	1756	1764	symptoms	T184	C1457887
27836684	1768	1792	autism spectrum disorder	T048	C1510586
27836684	1798	1805	suggest	T078	C1705535
27836684	1814	1818	some	T081	C0205392
27836684	1819	1824	cases	T169	C0868928
27836684	1838	1847	increased	T081	C0205217
27836684	1848	1856	efficacy	T080	C1280519
27836684	1860	1867	females	T015	C0025929

28054379|t|To wait or not to wait? Improving results when interviewing intoxicated witnesses to violence
28054379|a|Witnesses to violent crimes are often alcohol intoxicated, but few studies have investigated the impact of alcohol on witness reports. This study investigated how alcohol intoxication and time of interview affected reports of intimate partner violence (IPV). One hundred thirty six healthy men (N = 66) and women (N = 70) were randomized to an alcohol group (0.8g/kg for men, 0.75g/kg for women) (N = 70) or control group (N = 66), given juice. Participants consumed drinks in a laboratory setting before they witnessed an IPV scenario. Fifty percent of the intoxicated and sober participants were interviewed ten minutes after viewing the film and all participants were interviewed one week later. For the analyses, participants in the alcohol group were divided into two groups (moderately / highly intoxicated) based on their BAC-level. Ten minutes after viewing the event, highly (BAC = 0.08-0.15) intoxicated witnesses gave shorter, but as accurate, reports as moderately intoxicated / sober witnesses. All witnesses gave shorter and less accurate reports one week later compared to immediately after. However, an immediate interview increased completeness one week later. In general, time and high intoxication made witnesses give less detailed accounts of actions and verbal information, but not of objects. Highly intoxicated witnesses reported less actions and verbal information in all interviews, while information regarding objects was reported to a similar extent. At the present BAC-level, it is beneficial to conduct an immediate free recall interview with intoxicated witnesses to obtain a maximum amount of correct information and minimize the negative effect of time.
28054379	3	7	wait	T169	C1610166
28054379	18	22	wait	T169	C1610166
28054379	47	59	interviewing	T052	C0021822
28054379	60	71	intoxicated	T048	C0001969
28054379	72	81	witnesses	T098	C0682356
28054379	85	93	violence	T048	C0042693
28054379	94	103	Witnesses	T098	C0682356
28054379	107	121	violent crimes	T054	C0680472
28054379	132	151	alcohol intoxicated	T048	C0001969
28054379	174	186	investigated	T169	C1292732
28054379	191	208	impact of alcohol	UnknownType	C0680904
28054379	212	227	witness reports	T201	C4265456
28054379	240	252	investigated	T169	C1292732
28054379	257	277	alcohol intoxication	T048	C0001969
28054379	282	286	time	T079	C0040223
28054379	290	299	interview	T052	C0021822
28054379	309	316	reports	T201	C4265456
28054379	320	345	intimate partner violence	T053	C4042876
28054379	347	350	IPV	T053	C4042876
28054379	376	383	healthy	T080	C3898900
28054379	384	387	men	T098	C0025266
28054379	401	406	women	T098	C0043210
28054379	465	468	men	T098	C0025266
28054379	483	488	women	T098	C0043210
28054379	502	515	control group	T096	C0009932
28054379	532	537	juice	T168	C1268568
28054379	539	551	Participants	T098	C0679646
28054379	561	567	drinks	T168	C0001967
28054379	573	591	laboratory setting	T073,T093	C0022877
28054379	617	620	IPV	T053	C4042876
28054379	621	629	scenario	T169	C0683579
28054379	652	663	intoxicated	T048	C0001969
28054379	668	686	sober participants	T098	C0679646
28054379	692	703	interviewed	T052	C0021822
28054379	704	715	ten minutes	T079	C0439232
28054379	722	729	viewing	T041	C2371283
28054379	734	738	film	T073	C0681495
28054379	747	759	participants	T098	C0679646
28054379	777	785	one week	T079	C4082116
28054379	811	823	participants	T098	C0679646
28054379	831	838	alcohol	T048	C0001969
28054379	839	844	group	T078	C0441833
28054379	867	873	groups	T078	C0441833
28054379	875	885	moderately	T080	C0205081
28054379	888	894	highly	T080	C0205250
28054379	895	906	intoxicated	T048	C0001969
28054379	923	932	BAC-level	T034	C0428249
28054379	934	945	Ten minutes	T079	C0439232
28054379	952	959	viewing	T041	C2371283
28054379	964	969	event	T051	C0441471
28054379	979	982	BAC	T034	C0428249
28054379	996	1007	intoxicated	T048	C0001969
28054379	1008	1017	witnesses	T098	C0682356
28054379	1023	1030	shorter	T081	C1806781
28054379	1039	1047	accurate	T080	C0443131
28054379	1049	1056	reports	T201	C4265456
28054379	1060	1070	moderately	T080	C0205081
28054379	1071	1082	intoxicated	T048	C0001969
28054379	1091	1100	witnesses	T098	C0682356
28054379	1106	1115	witnesses	T098	C0682356
28054379	1121	1128	shorter	T081	C1806781
28054379	1133	1137	less	T080	C0547044
28054379	1138	1146	accurate	T080	C0443131
28054379	1147	1154	reports	T201	C4265456
28054379	1155	1163	one week	T079	C4082116
28054379	1213	1222	immediate	T079	C0205253
28054379	1223	1232	interview	T052	C0021822
28054379	1243	1255	completeness	T080	C0439812
28054379	1256	1264	one week	T079	C4082116
28054379	1284	1288	time	T079	C0040223
28054379	1298	1310	intoxication	T048	C0001969
28054379	1316	1325	witnesses	T098	C0682356
28054379	1331	1335	less	T080	C0547044
28054379	1336	1353	detailed accounts	T080	C1522508
28054379	1357	1364	actions	T052	C3266814
28054379	1369	1387	verbal information	T078	C1549471
28054379	1400	1407	objects	T072	C0347997
28054379	1416	1427	intoxicated	T048	C0001969
28054379	1428	1437	witnesses	T098	C0682356
28054379	1447	1451	less	T080	C0547044
28054379	1452	1459	actions	T052	C3266814
28054379	1464	1482	verbal information	T078	C1549471
28054379	1490	1500	interviews	T052	C0021822
28054379	1530	1537	objects	T072	C0347997
28054379	1587	1596	BAC-level	T034	C0428249
28054379	1629	1638	immediate	T079	C0205253
28054379	1644	1650	recall	T041	C0034770
28054379	1651	1660	interview	T052	C0021822
28054379	1666	1677	intoxicated	T048	C0001969
28054379	1678	1687	witnesses	T098	C0682356
28054379	1700	1707	maximum	T081	C0806909
28054379	1718	1725	correct	T080	C2349182
28054379	1726	1737	information	T078	C1533716
28054379	1742	1750	minimize	T081	C0547047
28054379	1755	1763	negative	T081	C0205216
28054379	1764	1770	effect	T080	C1280500
28054379	1774	1778	time	T079	C0040223

27871906|t|Adenosine, but not guanosine, protects vaginal epithelial cells from Trichomonas vaginalis cytotoxicity
27871906|a|Trichomonas vaginalis causes the most common non-viral sexually transmitted disease worldwide. The cytoadherence and cytotoxicity upon the vaginal epithelial cells are crucial for the infection. Extracellular nucleotides are released during cell damage and, along with their nucleosides, can activate purinoceptors. The opposing effects of nucleotides versus nucleosides are regulated by ectonucleotidases. Herein we evaluated the hemolysis and cytolysis induced by T. vaginalis, as well as the extracellular nucleotide hydrolysis along with the effects mediated by nucleotides and nucleosides on cytotoxicity. In addition, the gene expression of purinoceptors in host cells was determined. The hemolysis and cytolysis exerted by all T. vaginalis isolates presented positive Pearson correlation. All T. vaginalis isolates were able to hydrolyze nucleotides, showing higher NTPDase than ecto-5'-nucleotidase activity. The most cytotoxic isolate, TV-LACM6, hydrolyzes ATP, GTP with more efficiency than AMP and GMP. The vaginal epithelial cell line (HMVII) expressed the genes for all subtypes of P1, P2X and P2Y receptors. Finally, when nucleotides and nucleosides were tested, the cytotoxic effect elicited by TV-LACM6 was increased with nucleotides. In contrast, the cytotoxicity was reversed by adenosine in presence of EHNA, but not by guanosine, contributing to the understanding of the purinergic signaling role on T. vaginalis cytotoxicity.
27871906	0	9	Adenosine	T114,T121,T123	C0001443
27871906	19	28	guanosine	T114,T121	C0018330
27871906	39	63	vaginal epithelial cells	T025	C1987256
27871906	69	90	Trichomonas vaginalis	T204	C0040922
27871906	91	103	cytotoxicity	T049	C0596402
27871906	104	125	Trichomonas vaginalis	T204	C0040922
27871906	149	187	non-viral sexually transmitted disease	T047	C0036916
27871906	203	216	cytoadherence	T043	C0007613
27871906	221	233	cytotoxicity	T049	C0596402
27871906	243	267	vaginal epithelial cells	T025	C1987256
27871906	288	297	infection	T046	C3714514
27871906	313	324	nucleotides	T114	C0028630
27871906	345	356	cell damage	T049	C0599732
27871906	379	390	nucleosides	T114	C0028621
27871906	405	418	purinoceptors	T116,T192	C0034836
27871906	424	440	opposing effects	T080	C0205556
27871906	444	455	nucleotides	T114	C0028630
27871906	463	474	nucleosides	T114	C0028621
27871906	492	509	ectonucleotidases	T116,T126	C0377293
27871906	535	544	hemolysis	T046	C0019054
27871906	549	558	cytolysis	T043	C1536403
27871906	570	582	T. vaginalis	T204	C0040922
27871906	613	623	nucleotide	T114	C0028630
27871906	624	634	hydrolysis	T070	C0020291
27871906	670	681	nucleotides	T114	C0028630
27871906	686	697	nucleosides	T114	C0028621
27871906	701	713	cytotoxicity	T049	C0596402
27871906	732	747	gene expression	T045	C0017262
27871906	751	764	purinoceptors	T116,T192	C0034836
27871906	768	778	host cells	T026	C1819995
27871906	799	808	hemolysis	T046	C0019054
27871906	813	822	cytolysis	T043	C1536403
27871906	838	850	T. vaginalis	T204	C0040922
27871906	870	898	positive Pearson correlation	T081	C0871052
27871906	904	916	T. vaginalis	T204	C0040922
27871906	939	948	hydrolyze	T070	C0020291
27871906	949	960	nucleotides	T114	C0028630
27871906	977	984	NTPDase	T044	C1323427
27871906	990	1019	ecto-5'-nucleotidase activity	T044	C1149918
27871906	1030	1047	cytotoxic isolate	T169	C1511636
27871906	1049	1057	TV-LACM6	T204	C0040922
27871906	1059	1073	hydrolyzes ATP	T044	C1510699
27871906	1075	1078	GTP	T114	C0018353
27871906	1105	1108	AMP	T114,T121,T123	C0001465
27871906	1113	1116	GMP	T114,T123	C0018346
27871906	1122	1150	vaginal epithelial cell line	T025	C1987256
27871906	1152	1157	HMVII	T025	C1987256
27871906	1159	1178	expressed the genes	T045	C0017262
27871906	1187	1195	subtypes	T185	C0449560
27871906	1199	1201	P1	T116,T192	C0001471
27871906	1203	1206	P2X	T044	C3156874
27871906	1211	1224	P2Y receptors	T116,T192	C0390418
27871906	1240	1251	nucleotides	T114	C0028630
27871906	1256	1267	nucleosides	T114	C0028621
27871906	1285	1301	cytotoxic effect	T049	C0596402
27871906	1314	1322	TV-LACM6	T204	C0040922
27871906	1342	1353	nucleotides	T114	C0028630
27871906	1372	1384	cytotoxicity	T049	C0596402
27871906	1401	1410	adenosine	T114,T121,T123	C0001443
27871906	1426	1430	EHNA	T114,T121	C0050173
27871906	1443	1452	guanosine	T114,T121	C0018330
27871906	1495	1520	purinergic signaling role	T044	C3158762
27871906	1524	1536	T. vaginalis	T204	C0040922
27871906	1537	1549	cytotoxicity	T049	C0596402

27410251|t|Mother - Infant Emotion Regulation at Three Months: The Role of Maternal Anxiety, Depression and Parenting Stress
27410251|a|While the association between anxiety and postpartum depression is well known, few studies have investigated the relationship between these two states and parenting stress. Furthermore, a number of studies have found that postpartum depression affects mother - infant emotion regulation, but there has been only one study on anxiety and emotion regulation and no studies at all on parenting stress and emotion regulation. Therefore, the primary aim of our study is to identify, in a community sample of 71 mothers, the relationship between maternal depression, anxiety, and parenting stress. The second aim is to examine the relationship between anxiety, postpartum depression, and parenting stress and mother - infant emotion regulation assessed at 3 months. Mother - infant interaction was coded with a modified version of the Infant Caregiver and Engagement Phases (ICEP) using a microanalytic approach. The Edinburgh Postnatal Depression Scale (EPDS), State-Trait Anxiety Inventory (STAI), and Parenting Stress Index-Short Form (PSI-SF) were administered to the mothers to assess depression, anxiety, and parenting stress, respectively. Analysis revealed correlations between anxiety and depression, showing that parenting stress is associated with both states. In a laboratory observation, depression was correlated with both negative maternal states and negative dyadic matches as well as infant positive / mother negative mismatches; anxiety was correlated with both negative maternal states and infant negative states as well as mismatches involving one of the partners having a negative state. Multiple regression analysis showed that anxiety is a greater predictor than depression of less adequate styles of mother - infant emotion regulation. Parenting stress was not shown to predict such regulation.
27410251	0	6	Mother	T099	C0026591
27410251	9	15	Infant	T100	C0021270
27410251	16	34	Emotion Regulation	T041	C2370884
27410251	38	50	Three Months	T079	C4082119
27410251	56	60	Role	T077	C1705810
27410251	64	80	Maternal Anxiety	T041	C0746427
27410251	82	92	Depression	T048	C0011570
27410251	97	113	Parenting Stress	T048	C0086209
27410251	124	135	association	T080	C0439849
27410251	144	151	anxiety	T041	C0746427
27410251	156	177	postpartum depression	T048	C0221074
27410251	197	204	studies	T062	C0008972
27410251	210	222	investigated	T169	C1292732
27410251	227	239	relationship	T080	C0439849
27410251	258	264	states	T169	C1442792
27410251	269	285	parenting stress	T048	C0086209
27410251	312	319	studies	T062	C0008972
27410251	336	357	postpartum depression	T048	C0221074
27410251	366	372	mother	T099	C0026591
27410251	375	381	infant	T100	C0021270
27410251	382	400	emotion regulation	T041	C2370884
27410251	430	435	study	T062	C0008972
27410251	439	446	anxiety	T041	C0746427
27410251	451	469	emotion regulation	T041	C2370884
27410251	477	484	studies	T062	C0008972
27410251	495	511	parenting stress	T048	C0086209
27410251	516	534	emotion regulation	T041	C2370884
27410251	570	575	study	T062	C0008972
27410251	597	606	community	T096	C0009462
27410251	607	613	sample	T167	C0370003
27410251	620	627	mothers	T099	C0026591
27410251	633	645	relationship	T080	C0439849
27410251	654	673	maternal depression	T048	C0221074
27410251	675	682	anxiety	T041	C0746427
27410251	688	704	parenting stress	T048	C0086209
27410251	739	751	relationship	T080	C0439849
27410251	760	767	anxiety	T041	C0746427
27410251	769	790	postpartum depression	T048	C0221074
27410251	796	812	parenting stress	T048	C0086209
27410251	817	823	mother	T099	C0026591
27410251	826	832	infant	T100	C0021270
27410251	833	851	emotion regulation	T041	C2370884
27410251	852	860	assessed	T052	C1516048
27410251	864	872	3 months	T079	C4082119
27410251	874	880	Mother	T099	C0026591
27410251	883	889	infant	T100	C0021270
27410251	890	901	interaction	T169	C1704675
27410251	906	911	coded	T052	C0441655
27410251	919	927	modified	T080	C0205349
27410251	928	935	version	T170	C0333052
27410251	943	981	Infant Caregiver and Engagement Phases	T170	C0282574
27410251	983	987	ICEP	T170	C0282574
27410251	997	1019	microanalytic approach	T062	C0086912
27410251	1025	1061	Edinburgh Postnatal Depression Scale	T170	C0451144
27410251	1063	1067	EPDS	T170	C0451144
27410251	1070	1099	State-Trait Anxiety Inventory	T060,T170	C0683457
27410251	1101	1105	STAI	T060,T170	C0683457
27410251	1112	1145	Parenting Stress Index-Short Form	T170	C0282574
27410251	1147	1153	PSI-SF	T170	C0282574
27410251	1180	1187	mothers	T099	C0026591
27410251	1191	1197	assess	T058	C0184514
27410251	1198	1208	depression	T048	C0011570
27410251	1210	1217	anxiety	T041	C0746427
27410251	1223	1239	parenting stress	T048	C0086209
27410251	1255	1263	Analysis	T062	C0936012
27410251	1273	1285	correlations	T080	C1707520
27410251	1294	1301	anxiety	T041	C0746427
27410251	1306	1316	depression	T048	C0011570
27410251	1331	1347	parenting stress	T048	C0086209
27410251	1351	1366	associated with	T080	C0332281
27410251	1372	1378	states	T169	C1442792
27410251	1385	1407	laboratory observation	T034	C4283904
27410251	1409	1419	depression	T048	C0011570
27410251	1424	1434	correlated	T080	C1707520
27410251	1445	1453	negative	T033	C0205160
27410251	1454	1462	maternal	T033	C1858460
27410251	1463	1469	states	T169	C1442792
27410251	1474	1482	negative	T033	C0205160
27410251	1483	1497	dyadic matches	T080	C1708943
27410251	1509	1515	infant	T100	C0021270
27410251	1516	1524	positive	T033	C1446409
27410251	1527	1533	mother	T099	C0026591
27410251	1534	1542	negative	T033	C0205160
27410251	1543	1553	mismatches	T080	C1881865
27410251	1555	1562	anxiety	T041	C0746427
27410251	1567	1577	correlated	T080	C1707520
27410251	1588	1596	negative	T033	C0205160
27410251	1597	1605	maternal	T033	C1858460
27410251	1606	1612	states	T169	C1442792
27410251	1617	1623	infant	T100	C0021270
27410251	1624	1632	negative	T033	C0205160
27410251	1633	1639	states	T169	C1442792
27410251	1651	1661	mismatches	T080	C1881865
27410251	1683	1691	partners	T099	C0682323
27410251	1701	1709	negative	T033	C0205160
27410251	1710	1715	state	T169	C1442792
27410251	1717	1745	Multiple regression analysis	T080	C0681923
27410251	1758	1765	anxiety	T041	C0746427
27410251	1779	1788	predictor	T078	C2698872
27410251	1794	1804	depression	T048	C0011570
27410251	1813	1821	adequate	T080	C0205411
27410251	1822	1828	styles	T080	C0489654
27410251	1832	1838	mother	T099	C0026591
27410251	1841	1847	infant	T100	C0021270
27410251	1848	1866	emotion regulation	T041	C2370884
27410251	1868	1884	Parenting stress	T048	C0086209
27410251	1902	1909	predict	T078	C0681842
27410251	1915	1925	regulation	T041	C2370884

28005193|t|TREK-1 (K2P2.1) K(+) channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control
28005193|a|Atrial fibrillation (AF) is the most common cardiac arrhythmia. Concomitant heart failure (HF) poses a particular therapeutic challenge and is associated with prolonged atrial electrical refractoriness compared with non-failing hearts. We hypothesized that downregulation of atrial repolarizing TREK-1 (K2P2.1) K(+) channels contributes to electrical remodeling during AF with HF, and that TREK-1 gene transfer would provide rhythm control via normalization of atrial effective refractory periods in this AF subset. In patients with chronic AF and HF, atrial TREK-1 mRNA levels were reduced by 82% (left atrium) and 81% (right atrium) compared with sinus rhythm (SR) subjects. Human findings were recapitulated in a porcine model of atrial tachypacing-induced AF and reduced left ventricular function. TREK-1 mRNA (-66%) and protein (-61%) was suppressed in AF animals at 14-day follow-up compared with SR controls. Downregulation of repolarizing TREK-1 channels was associated with prolongation of atrial effective refractory periods versus baseline conditions, consistent with prior observations in humans with HF. In a preclinical therapeutic approach, pigs were randomized to either atrial Ad-TREK-1 gene therapy or sham treatment. Gene transfer effectively increased TREK-1 protein levels and attenuated atrial effective refractory period prolongation in the porcine AF model. Ad-TREK-1 increased the SR prevalence to 62% during follow-up in AF animals, compared to 35% in the untreated AF group. In conclusion, TREK-1 downregulation and rhythm control by Ad-TREK-1 transfer suggest mechanistic and potential therapeutic significance of TREK-1 channels in a subgroup of AF patients with HF and prolonged atrial effective refractory periods. Functional correction of ionic remodeling through TREK-1 gene therapy represents a novel paradigm to optimize and specify AF management.
28005193	0	29	TREK-1 (K2P2.1) K(+) channels	T116,T123	C0754471
28005193	34	44	suppressed	T169	C1260953
28005193	48	56	patients	T101	C0030705
28005193	62	81	atrial fibrillation	T047	C0004238
28005193	86	99	heart failure	T047	C0018801
28005193	104	111	provide	T052	C1999230
28005193	112	131	therapeutic targets	T169	C0302350
28005193	136	150	rhythm control	T080	C0243148
28005193	151	170	Atrial fibrillation	T047	C0004238
28005193	172	174	AF	T047	C0004238
28005193	195	213	cardiac arrhythmia	T033	C0003811
28005193	215	240	Concomitant heart failure	T047	C0018801
28005193	242	244	HF	T047	C0018801
28005193	265	276	therapeutic	T169	C0302350
28005193	277	286	challenge	T059	C1315011
28005193	310	319	prolonged	T079	C0439590
28005193	320	352	atrial electrical refractoriness	T040	C0034954
28005193	367	385	non-failing hearts	T023	C0018787
28005193	408	422	downregulation	T044	C0013081
28005193	426	445	atrial repolarizing	T042	C1371280
28005193	446	475	TREK-1 (K2P2.1) K(+) channels	T116,T123	C0754471
28005193	476	487	contributes	T052	C1880177
28005193	491	512	electrical remodeling	T046	C3658220
28005193	520	522	AF	T047	C0004238
28005193	528	530	HF	T047	C0018801
28005193	541	561	TREK-1 gene transfer	T063	C1517499
28005193	576	590	rhythm control	T080	C0243148
28005193	595	608	normalization	T062	C1882115
28005193	612	647	atrial effective refractory periods	T033	C0428938
28005193	656	658	AF	T047	C0004238
28005193	659	665	subset	T062	C2986480
28005193	670	678	patients	T101	C0030705
28005193	684	694	chronic AF	T047	C0694539
28005193	699	701	HF	T047	C0018801
28005193	703	716	atrial TREK-1	T116,T123	C0754471
28005193	717	721	mRNA	T114,T123	C0035696
28005193	722	728	levels	T080	C0441889
28005193	750	761	left atrium	T023	C0225860
28005193	772	784	right atrium	T023	C0225844
28005193	800	812	sinus rhythm	T033	C0232201
28005193	814	816	SR	T033	C0232201
28005193	818	826	subjects	T098	C0080105
28005193	828	833	Human	T016	C0086418
28005193	834	842	findings	T033	C0243095
28005193	867	880	porcine model	T075	C0026336
28005193	884	913	atrial tachypacing-induced AF	T047	C0004238
28005193	918	925	reduced	T080	C0392756
28005193	926	951	left ventricular function	T042	C0080310
28005193	953	959	TREK-1	T116,T123	C0754471
28005193	960	964	mRNA	T114,T123	C0035696
28005193	976	983	protein	T116,T123	C0754471
28005193	995	1005	suppressed	T169	C1260953
28005193	1009	1011	AF	T047	C0004238
28005193	1012	1019	animals	T008	C0003062
28005193	1040	1048	compared	T052	C1707455
28005193	1054	1056	SR	T033	C0232201
28005193	1067	1081	Downregulation	T044	C0013081
28005193	1085	1097	repolarizing	T042	C1371280
28005193	1098	1113	TREK-1 channels	T116,T123	C0754471
28005193	1134	1146	prolongation	T079	C0439590
28005193	1150	1185	atrial effective refractory periods	T033	C0428938
28005193	1193	1201	baseline	T081	C1442488
28005193	1214	1229	consistent with	T078	C0332290
28005193	1230	1235	prior	T079	C0332152
28005193	1236	1248	observations	T062	C0302523
28005193	1252	1258	humans	T016	C0086418
28005193	1264	1266	HF	T047	C0018801
28005193	1273	1284	preclinical	T080	C1709630
28005193	1285	1305	therapeutic approach	T169	C0302350
28005193	1307	1311	pigs	T015	C0039005
28005193	1317	1327	randomized	T062	C0034656
28005193	1338	1367	atrial Ad-TREK-1 gene therapy	T061	C0017296
28005193	1371	1385	sham treatment	T061	C0032042
28005193	1387	1400	Gene transfer	T063	C1517499
28005193	1401	1412	effectively	T080	C1280519
28005193	1413	1422	increased	T081	C0205217
28005193	1423	1437	TREK-1 protein	T116,T123	C0754471
28005193	1438	1444	levels	T080	C0441889
28005193	1449	1459	attenuated	T052	C0599946
28005193	1460	1494	atrial effective refractory period	T033	C0428938
28005193	1495	1507	prolongation	T079	C0439590
28005193	1515	1531	porcine AF model	T075	C0026336
28005193	1533	1542	Ad-TREK-1	T116,T123	C0754471
28005193	1557	1559	SR	T033	C0232201
28005193	1560	1570	prevalence	T081	C0033105
28005193	1598	1600	AF	T047	C0004238
28005193	1601	1608	animals	T008	C0003062
28005193	1610	1618	compared	T052	C1707455
28005193	1643	1645	AF	T047	C0004238
28005193	1656	1666	conclusion	T078	C1707478
28005193	1668	1674	TREK-1	T116,T123	C0754471
28005193	1675	1689	downregulation	T044	C0013081
28005193	1694	1708	rhythm control	T080	C0243148
28005193	1712	1730	Ad-TREK-1 transfer	T063	C1517499
28005193	1731	1738	suggest	T078	C1705535
28005193	1739	1776	mechanistic and potential therapeutic	T061	C0087111
28005193	1777	1789	significance	T078	C0750502
28005193	1793	1808	TREK-1 channels	T116,T123	C0754471
28005193	1814	1822	subgroup	T185	C1515021
28005193	1826	1828	AF	T047	C0004238
28005193	1829	1837	patients	T101	C0030705
28005193	1843	1845	HF	T047	C0018801
28005193	1850	1859	prolonged	T079	C0439590
28005193	1860	1895	atrial effective refractory periods	T033	C0428938
28005193	1897	1918	Functional correction	T169	C0205245
28005193	1947	1966	TREK-1 gene therapy	T061	C0017296
28005193	1980	1985	novel	T080	C0205314
28005193	1986	1994	paradigm	T062	C0681797
28005193	2019	2021	AF	T047	C0004238

27310660|t|The Origin of Selectivity in the Complexation of N-Methyl Amino Acids by Tetraphosphonate Cavitands
27310660|a|We report on the eligibility of tetraphosphonate resorcinarene cavitands for the molecular recognition of amino acids. We determined the crystal structure of 13 complexes of the tetraphosphonate cavitand Tiiii[H, CH3, CH3] with amino acids. (1) H NMR and (31) P NMR experiments and ITC analysis were performed to probe the binding between cavitand Tiiii[C3H7, CH3, C2H5] or the water - soluble counterpart Tiiii[C3H6Py(+)Cl(-), CH3, C2H5] and a selection of representative amino acids. The reported studies and results allowed us (i) to highlight the noncovalent interactions involved in the binding event in each case; (ii) to investigate the ability of tetraphosphonate cavitand receptors to discriminate between the different amino acids; (iii) to calculate the Ka values of the different complexes formed and evaluate the thermodynamic parameters of the complexation process, dissecting the entropic and enthalpic contributions; and (iv) to determine the solvent influence on the complexation selectivity. By moving from methanol to water, the complexation changed from entropy driven to entropy opposed, leading to a drop of almost three orders in the magnitude of the Ka. However, this reduction in binding affinity is associated with a dramatic increase in selectivity, since in aqueous solutions only N-methylated amino acids are effectively recognized. The thermodynamic profile of the binding does not change in PBS solution. The pivotal role played by cation-π interactions is demonstrated by the linear correlation found between the log Ka in methanol solution and the depth of (+)N-CH3 cavity inclusion in the molecular structures. These findings are relevant for the potential use of phosphonate cavitands as synthetic receptors for the detection of epigenetic modifications of histones in physiological media.
27310660	4	10	Origin	T079	C0439659
27310660	14	25	Selectivity	T052	C1707391
27310660	33	45	Complexation	T080	C0439855
27310660	49	69	N-Methyl Amino Acids	T116,T121,T123	C0002520
27310660	73	99	Tetraphosphonate Cavitands	T109	C1100347
27310660	103	109	report	T170	C0684224
27310660	117	128	eligibility	T080	C1548635
27310660	132	172	tetraphosphonate resorcinarene cavitands	T109	C1100347
27310660	181	202	molecular recognition	T044	C0599844
27310660	206	217	amino acids	T116,T121,T123	C0002520
27310660	222	232	determined	T080	C0521095
27310660	237	254	crystal structure	T104	C0444626
27310660	261	270	complexes	T080	C0439855
27310660	278	303	tetraphosphonate cavitand	T109	C1100347
27310660	304	322	Tiiii[H, CH3, CH3]	T109	C1100347
27310660	328	339	amino acids	T116,T121,T123	C0002520
27310660	345	346	H	T196	C0033727
27310660	347	350	NMR	T070	C0028580
27310660	360	361	P	T121,T197	C1601799
27310660	362	365	NMR	T070	C0028580
27310660	366	377	experiments	T062	C0681814
27310660	382	385	ITC	T074	C3689480
27310660	386	394	analysis	T062	C0936012
27310660	400	409	performed	T169	C0884358
27310660	413	418	probe	T060	C0419358
27310660	423	430	binding	T044	C1167622
27310660	431	438	between	T082	C0205103
27310660	439	447	cavitand	T109	C1100347
27310660	448	470	Tiiii[C3H7, CH3, C2H5]	T109	C1100347
27310660	478	483	water	T121,T197	C0043047
27310660	486	493	soluble	T080	C1948047
27310660	494	505	counterpart	T082	C0449719
27310660	506	538	Tiiii[C3H6Py(+)Cl(-), CH3, C2H5]	T109	C1100347
27310660	545	554	selection	T052	C1707391
27310660	558	572	representative	T052	C1882932
27310660	573	584	amino acids	T116,T121,T123	C0002520
27310660	590	598	reported	T170	C0684224
27310660	599	606	studies	T062	C2603343
27310660	611	618	results	T033	C0683954
27310660	651	675	noncovalent interactions	T070	C1537001
27310660	676	684	involved	T169	C1314939
27310660	692	699	binding	T044	C1167622
27310660	700	705	event	T051	C0441471
27310660	714	718	case	T169	C0868928
27310660	728	739	investigate	T169	C1292732
27310660	744	751	ability	T032	C0085732
27310660	755	780	tetraphosphonate cavitand	T109	C1100347
27310660	781	790	receptors	T116,T192	C0597357
27310660	794	806	discriminate	T080	C0205235
27310660	807	814	between	T082	C0205103
27310660	819	828	different	T080	C1705242
27310660	829	840	amino acids	T116,T121,T123	C0002520
27310660	851	860	calculate	T052	C1441506
27310660	865	867	Ka	UnknownType	C0678590
27310660	868	874	values	T081	C1522609
27310660	882	891	different	T080	C1705242
27310660	892	901	complexes	T080	C0439855
27310660	902	908	formed	T169	C0205431
27310660	913	921	evaluate	T058	C0220825
27310660	926	939	thermodynamic	T090	C0039808
27310660	940	950	parameters	T077	C0549193
27310660	958	970	complexation	T080	C0439855
27310660	971	978	process	T067	C1522240
27310660	980	990	dissecting	T169	C0205239
27310660	995	1003	entropic	T067	C0376522
27310660	1008	1017	enthalpic	T081	C0599530
27310660	1018	1031	contributions	T052	C1880177
27310660	1045	1054	determine	T059	C1148554
27310660	1059	1066	solvent	T130	C0037638
27310660	1067	1076	influence	T077	C4054723
27310660	1084	1096	complexation	T080	C0439855
27310660	1097	1108	selectivity	T052	C1707391
27310660	1113	1119	moving	T040	C0560560
27310660	1125	1133	methanol	T109,T131	C0001963
27310660	1137	1142	water	T121,T197	C0043047
27310660	1148	1160	complexation	T080	C0439855
27310660	1161	1168	changed	T169	C0392747
27310660	1174	1181	entropy	T067	C0376522
27310660	1182	1188	driven	T052	C1879547
27310660	1192	1199	entropy	T067	C0376522
27310660	1200	1207	opposed	T080	C0521124
27310660	1222	1226	drop	T081	C0547047
27310660	1243	1249	orders	T070	C1373200
27310660	1257	1266	magnitude	T081	C1704240
27310660	1274	1276	Ka	UnknownType	C0678590
27310660	1292	1301	reduction	T080	C0392756
27310660	1305	1312	binding	T044	C1167622
27310660	1313	1321	affinity	T070	C1510827
27310660	1325	1340	associated with	T080	C0332281
27310660	1352	1360	increase	T169	C0442805
27310660	1364	1375	selectivity	T052	C1707391
27310660	1386	1403	aqueous solutions	T121	C3255993
27310660	1409	1433	N-methylated amino acids	T116,T121,T123	C0002520
27310660	1438	1449	effectively	T080	C1704419
27310660	1450	1460	recognized	T044	C0599844
27310660	1466	1479	thermodynamic	T090	C0039808
27310660	1480	1487	profile	T059	C1979963
27310660	1495	1502	binding	T044	C1167622
27310660	1512	1518	change	T169	C0392747
27310660	1522	1534	PBS solution	T167	C0036082
27310660	1548	1552	role	T077	C1705810
27310660	1563	1584	cation-π interactions	T070	C1537001
27310660	1588	1600	demonstrated	T080	C0443289
27310660	1608	1614	linear	T082	C0205132
27310660	1615	1626	correlation	T080	C1707520
27310660	1633	1640	between	T082	C0205103
27310660	1645	1648	log	T081	C2986775
27310660	1649	1651	Ka	UnknownType	C0678590
27310660	1655	1663	methanol	T109,T131	C0001963
27310660	1664	1672	solution	T167	C0037633
27310660	1681	1686	depth	T082	C0205125
27310660	1690	1698	(+)N-CH3	T109	C0077172
27310660	1699	1705	cavity	T190	C1510420
27310660	1706	1715	inclusion	T080	C1512693
27310660	1723	1743	molecular structures	T085	C0026383
27310660	1751	1759	findings	T033	C0243095
27310660	1764	1772	relevant	T080	C2347946
27310660	1781	1790	potential	T080	C3245505
27310660	1791	1794	use	T169	C0457083
27310660	1798	1819	phosphonate cavitands	T109	C1100347
27310660	1823	1832	synthetic	T080	C2004457
27310660	1833	1842	receptors	T116,T192	C0597357
27310660	1851	1860	detection	T061	C1511790
27310660	1864	1874	epigenetic	T045	C1516924
27310660	1875	1888	modifications	T033	C3840684
27310660	1892	1900	histones	T116,T123	C0019652
27310660	1904	1917	physiological	T169	C0205463
27310660	1918	1923	media	T167	C1705217

27642003|t|Oral and oropharyngeal cancer and the role of sexual behaviour: a systematic review
27642003|a|This systematic review identified and evaluated the evidence for the role of sexual behaviours in the development of oropharyngeal cancers (OPCs) and oral cavity cancers (OCCs). Following the PRISMA guidelines, we identified observational and interventional studies reporting associations between several different sexual behaviours and OPC or OCC. Study quality was assessed independently by two reviewers using a validated scoring system. From 513 papers identified, 21, reporting on 20 studies, fulfilled the inclusion criteria. Two cohort studies were rated as moderate quality. The 18 case-control studies were rated as weak; nine comparing people with OPC or OCC to people without cancer, eight comparing HPV-positive to HPV-negative cancer patients and one comparing OPCs to other head and neck cancers. One study was a pooled analysis of seven of the included studies with some additional information. Twelve sexual behaviours were assessed and 69 associations reported. The studies differed in the comparisons made, the sexual behaviours assessed, and how these were reported and categorized, so no quantitative meta-analyses were appropriate. Most studies combined OPC and OCC. Several significantly increased risks were seen with a high number of lifetime sexual partners (nine studies) and with the practice of oral sex (five studies), although two studies found a significant negative association with OCC and ever performing oral sex. Two cohort studies of men and women in homosexual relationships found increases in oral cancer risk, and a cohort study of men married to women who had a history of cervical cancer also showed an increased risk of oral cancers. Results for other sexual behaviours were limited and inconsistent, and these included the following: younger age at first sexual intercourse, number of lifetime oral sex partners, the practice of oral - anal sex, the number of oral - anal sex partners, and ever performing anal sex. Only one study assessed casual sex, never or rare use of a condom and having a sexual partner with a history of genital warts, finding significant associations in the two former behaviours. The current evidence for sexual behaviours being risk factors for oral and oropharyngeal cancer is limited and inconsistent. Evidence suggests that the number of sexual partners and performing oral sex are associated with a greater risk. Furthermore men whose partners have had cervical cancer may have an increased risk. More studies looking at OPC specifically will be useful to determine whether these behaviours are subsite - selective.
27642003	0	4	Oral	T191	C0151546
27642003	9	29	oropharyngeal cancer	T191	C2349952
27642003	38	42	role	T077	C1705810
27642003	46	62	sexual behaviour	T053	C0036864
27642003	66	83	systematic review	T170	C1955832
27642003	89	106	systematic review	T170	C1955832
27642003	107	117	identified	T080	C0205396
27642003	136	144	evidence	T078	C3887511
27642003	153	157	role	T077	C1705810
27642003	161	178	sexual behaviours	T053	C0036864
27642003	186	197	development	T169	C1527148
27642003	201	222	oropharyngeal cancers	T191	C2349952
27642003	224	228	OPCs	T191	C2349952
27642003	234	253	oral cavity cancers	T191	C0151546
27642003	255	259	OCCs	T191	C0151546
27642003	262	271	Following	T079	C0332282
27642003	276	293	PRISMA guidelines	T170	C0162791
27642003	298	308	identified	T080	C0205396
27642003	309	322	observational	T062	C1518527
27642003	327	349	interventional studies	T062	C3274035
27642003	360	372	associations	T080	C0439849
27642003	381	388	several	T081	C0443302
27642003	389	398	different	T080	C1705242
27642003	399	416	sexual behaviours	T053	C0036864
27642003	421	424	OPC	T191	C2349952
27642003	428	431	OCC	T191	C0151546
27642003	433	438	Study	T062	C2603343
27642003	439	446	quality	T080	C0332306
27642003	451	459	assessed	T052	C1516048
27642003	460	473	independently	T169	C0332291
27642003	481	490	reviewers	T098	C1882950
27642003	491	496	using	T169	C1524063
27642003	499	523	validated scoring system	T170	C0282574
27642003	534	540	papers	T170	C1706852
27642003	541	551	identified	T080	C0205396
27642003	573	580	studies	T062	C2603343
27642003	582	591	fulfilled	T067	C1550543
27642003	596	614	inclusion criteria	T080	C1512693
27642003	620	634	cohort studies	T081	C0009247
27642003	640	645	rated	T052	C0871208
27642003	649	657	moderate	T080	C1881878
27642003	658	665	quality	T080	C0332306
27642003	674	694	case-control studies	T062	C0007328
27642003	700	705	rated	T052	C0871208
27642003	709	713	weak	T080	C1762617
27642003	720	729	comparing	T052	C1707455
27642003	730	736	people	T098	C0027361
27642003	742	745	OPC	T191	C2349952
27642003	749	752	OCC	T191	C0151546
27642003	756	762	people	T098	C0027361
27642003	763	770	without	T080	C0332288
27642003	771	777	cancer	T191	C0007097
27642003	785	794	comparing	T052	C1707455
27642003	795	807	HPV-positive	T034	C4288937
27642003	811	823	HPV-negative	T034	C1271959
27642003	824	830	cancer	T191	C0007097
27642003	831	839	patients	T101	C0030705
27642003	848	857	comparing	T052	C1707455
27642003	858	862	OPCs	T191	C2349952
27642003	872	876	head	T191	C0751177
27642003	881	893	neck cancers	T191	C0746787
27642003	899	904	study	T062	C2603343
27642003	911	926	pooled analysis	T062	C0936012
27642003	943	951	included	T169	C0332257
27642003	952	959	studies	T169	C1524063
27642003	970	980	additional	T169	C1524062
27642003	981	992	information	T078	C1533716
27642003	1001	1018	sexual behaviours	T053	C0036864
27642003	1024	1032	assessed	T052	C1516048
27642003	1040	1052	associations	T080	C0439849
27642003	1053	1061	reported	T058	C0700287
27642003	1067	1074	studies	T169	C1524063
27642003	1075	1083	differed	T080	C1705242
27642003	1091	1102	comparisons	T052	C1707455
27642003	1113	1130	sexual behaviours	T053	C0036864
27642003	1131	1139	assessed	T052	C1516048
27642003	1160	1168	reported	T058	C0700287
27642003	1173	1184	categorized	T052	C0871968
27642003	1189	1191	no	T169	C1518422
27642003	1192	1204	quantitative	T081	C0392762
27642003	1205	1218	meta-analyses	T062	C0920317
27642003	1224	1235	appropriate	T080	C1548787
27642003	1242	1249	studies	T169	C1524063
27642003	1250	1258	combined	T080	C0205195
27642003	1259	1262	OPC	T191	C2349952
27642003	1267	1270	OCC	T191	C0151546
27642003	1272	1279	Several	T081	C0443302
27642003	1280	1293	significantly	T078	C0750502
27642003	1294	1303	increased	T081	C0205217
27642003	1304	1309	risks	T078	C0035647
27642003	1315	1319	seen	T080	C0205397
27642003	1327	1331	high	T080	C0205250
27642003	1332	1338	number	T081	C0237753
27642003	1342	1350	lifetime	T079	C4071830
27642003	1351	1366	sexual partners	T098	C0036911
27642003	1373	1380	studies	T169	C1524063
27642003	1395	1403	practice	T169	C0884358
27642003	1407	1415	oral sex	T055	C0282348
27642003	1422	1429	studies	T169	C1524063
27642003	1445	1452	studies	T062	C2603343
27642003	1453	1458	found	T033	C0150312
27642003	1461	1472	significant	T078	C0750502
27642003	1473	1481	negative	T033	C0205160
27642003	1482	1493	association	T080	C0439849
27642003	1499	1502	OCC	T191	C0151546
27642003	1512	1522	performing	T169	C0884358
27642003	1523	1531	oral sex	T055	C0282348
27642003	1537	1551	cohort studies	T081	C0009247
27642003	1555	1558	men	T098	C0025266
27642003	1563	1568	women	T098	C0043210
27642003	1572	1596	homosexual relationships	T033	C0556477
27642003	1597	1602	found	T033	C0150312
27642003	1603	1612	increases	T169	C0442805
27642003	1616	1627	oral cancer	T191	C0151546
27642003	1628	1632	risk	T078	C0035647
27642003	1640	1652	cohort study	T081	C0009247
27642003	1656	1659	men	T098	C0025266
27642003	1660	1667	married	T033	C0555047
27642003	1671	1676	women	T098	C0043210
27642003	1687	1694	history	T169	C0019665
27642003	1698	1713	cervical cancer	T191	C4048328
27642003	1729	1738	increased	T081	C0205217
27642003	1739	1743	risk	T078	C0035647
27642003	1747	1759	oral cancers	T191	C0151546
27642003	1761	1768	Results	T169	C1274040
27642003	1779	1796	sexual behaviours	T053	C0036864
27642003	1802	1809	limited	T169	C0439801
27642003	1814	1826	inconsistent	T080	C0442809
27642003	1838	1846	included	T169	C0332257
27642003	1851	1860	following	T079	C0332282
27642003	1862	1869	younger	T079	C0332239
27642003	1870	1873	age	T032	C0001779
27642003	1877	1882	first	T081	C0205435
27642003	1883	1901	sexual intercourse	T040	C0009253
27642003	1903	1909	number	T081	C0237753
27642003	1913	1921	lifetime	T079	C4071830
27642003	1922	1930	oral sex	T055	C0282348
27642003	1931	1939	partners	T098	C0036911
27642003	1945	1953	practice	T169	C0884358
27642003	1957	1961	oral	T030	C0226896
27642003	1964	1972	anal sex	T055	C0282347
27642003	1978	1984	number	T081	C0237753
27642003	1988	1992	oral	T030	C0226896
27642003	1995	2003	anal sex	T055	C0282347
27642003	2004	2012	partners	T098	C0036911
27642003	2018	2022	ever	T079	C3887636
27642003	2023	2033	performing	T169	C0884358
27642003	2034	2042	anal sex	T055	C0282347
27642003	2053	2058	study	T062	C2603343
27642003	2059	2067	assessed	T052	C1516048
27642003	2068	2078	casual sex	T033	C0556472
27642003	2080	2093	never or rare	T033	C3843764
27642003	2094	2100	use of	T169	C1524063
27642003	2103	2109	condom	T074	C0677582
27642003	2123	2137	sexual partner	T098	C0036911
27642003	2145	2152	history	T169	C0019665
27642003	2156	2169	genital warts	T047	C0009663
27642003	2171	2178	finding	T033	C0243095
27642003	2179	2190	significant	T078	C0750502
27642003	2191	2203	associations	T080	C0439849
27642003	2222	2232	behaviours	T053	C0004927
27642003	2246	2254	evidence	T078	C3887511
27642003	2259	2276	sexual behaviours	T053	C0036864
27642003	2283	2295	risk factors	T033	C0035648
27642003	2300	2304	oral	T191	C0151546
27642003	2309	2329	oropharyngeal cancer	T191	C2349952
27642003	2333	2340	limited	T169	C0439801
27642003	2345	2357	inconsistent	T080	C0442809
27642003	2359	2367	Evidence	T078	C3887511
27642003	2368	2376	suggests	T078	C1705535
27642003	2386	2392	number	T081	C0237753
27642003	2396	2411	sexual partners	T098	C0036911
27642003	2416	2426	performing	T169	C0884358
27642003	2427	2435	oral sex	T055	C0282348
27642003	2440	2455	associated with	T080	C0332281
27642003	2458	2465	greater	T081	C1704243
27642003	2466	2470	risk	T078	C0035647
27642003	2484	2487	men	T098	C0025266
27642003	2494	2502	partners	T098	C0036911
27642003	2512	2527	cervical cancer	T191	C4048328
27642003	2540	2549	increased	T081	C0205217
27642003	2550	2554	risk	T078	C0035647
27642003	2561	2568	studies	T169	C1524063
27642003	2580	2583	OPC	T191	C2349952
27642003	2605	2611	useful	T080	C3827682
27642003	2615	2624	determine	T080	C0521095
27642003	2639	2649	behaviours	T053	C0036864
27642003	2654	2661	subsite	T082	C1710234
27642003	2664	2673	selective	T052	C1707391

28072649|t|Is Early Definitive Fixation of Bicondylar Tibial Plateau Fractures Safe? An Observational Cohort Study
28072649|a|The optimal treatment protocol for bicondylar plateau fractures remains controversial. Contrary to popular practice which favors a staged protocol in many high-energy fracture patterns, we have used early single-stage open reduction and internal fixation (ORIF) to treat these injuries whenever possible. The purpose of this study was to determine the complication rate and the functional and radiographic outcomes of this strategy. Retrospective cohort study and prospective data collection. Level I trauma center. One hundred one patients with 102 OTA/AO type 41-C bicondylar tibial plateau fractures were treated with early definitive ORIF, defined as nonstaged surgery performed within 72 hours from injury. A subset of patients was part of a longitudinal study and reported functional outcomes at 1 year. Early definitive ORIF. Primary outcome: reoperation rate, defined as any surgery within 12 months after the index operation; secondary outcomes: quality and stability of radiographic fracture reduction; and functional outcome [Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and short musculoskeletal functional assessment (SMFA)]. Nonstaged operative treatment of bicondylar plateau fractures was performed in 91.3% of the fractures during the study period. For those, early definitive ORIF (surgery within 72 hours from injury) was performed in 82.3% fractures. Mean time from injury to ORIF, for closed fractures, was 29.8 hours. Sixteen (15.7%) fractures, which were treated with early definitive ORIF, required an additional surgical procedure within 12 months. Complications included wound infection requiring surgical management, compartment syndrome requiring fasciotomies, nonunion, early fixation failure, and implant removal for discomfort. The reoperation rate was 12.7% if implant removal was excluded. At least 3 of the 4 radiographic criteria used to assess the adequacy of reduction were achieved in 95.1% of cases, and all 4 criteria were met in 59.8% of fractures. The Physical Component of the SF-36 at 12 months was 42.6, which is comparable to values reported in previous studies for operative treatment of bicondylar plateau fractures. In a model where surgery is performed without delay by experienced orthopaedic trauma surgeons, a large proportion of bicondylar tibial plateau fractures can be safely treated with early definitive ORIF. Early surgery was associated with satisfactory postoperative radiographic reductions. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
28072649	3	8	Early	T079	C1279919
28072649	9	28	Definitive Fixation	T061	C0016641
28072649	32	67	Bicondylar Tibial Plateau Fractures	T037	C2861532
28072649	77	90	Observational	T062	C1518527
28072649	91	103	Cohort Study	T081	C0009247
28072649	108	115	optimal	T080	C2698651
28072649	116	134	treatment protocol	T061	C0040808
28072649	139	167	bicondylar plateau fractures	T037	C2861532
28072649	259	279	high-energy fracture	T037	C0016658
28072649	303	308	early	T079	C1279919
28072649	322	358	open reduction and internal fixation	T061	C1297885
28072649	360	364	ORIF	T061	C1297885
28072649	369	374	treat	T169	C1292734
28072649	381	389	injuries	T037	C3263723
28072649	456	468	complication	T046	C0009566
28072649	469	473	rate	T081	C1521828
28072649	482	492	functional	T169	C1274040
28072649	497	509	radiographic	T070	C0444708
28072649	510	518	outcomes	T169	C1274040
28072649	537	563	Retrospective cohort study	T062	C2985505
28072649	568	579	prospective	T062	C0033522
28072649	580	595	data collection	T062	C0010995
28072649	597	618	Level I trauma center	T073,T093	C0040786
28072649	636	644	patients	T101	C0030705
28072649	671	706	bicondylar tibial plateau fractures	T037	C2861532
28072649	712	724	treated with	T061	C0332293
28072649	725	730	early	T079	C1279919
28072649	731	741	definitive	T079	C0443196
28072649	742	746	ORIF	T061	C1297885
28072649	769	776	surgery	T061	C0543467
28072649	808	814	injury	T037	C3263723
28072649	828	836	patients	T101	C0030705
28072649	851	869	longitudinal study	T062	C0023981
28072649	883	902	functional outcomes	T169	C1274040
28072649	914	919	Early	T079	C1279919
28072649	920	930	definitive	T079	C0443196
28072649	931	935	ORIF	T061	C1297885
28072649	937	944	Primary	T080	C0205225
28072649	945	952	outcome	T169	C1274040
28072649	954	965	reoperation	T061	C0035110
28072649	966	970	rate	T081	C1521828
28072649	987	994	surgery	T061	C0543467
28072649	1028	1037	operation	T061	C0543467
28072649	1039	1057	secondary outcomes	T169	C1274040
28072649	1059	1066	quality	T080	C0332306
28072649	1071	1080	stability	T080	C0205360
28072649	1084	1096	radiographic	T070	C0444708
28072649	1097	1115	fracture reduction	T061	C1112432
28072649	1121	1139	functional outcome	T169	C1274040
28072649	1141	1196	Medical Outcomes Study 36-Item Short-Form Health Survey	T170	C0451287
28072649	1198	1203	SF-36	T170	C0451287
28072649	1209	1252	short musculoskeletal functional assessment	T170	C0034394
28072649	1254	1258	SMFA	T170	C0034394
28072649	1272	1291	operative treatment	T061	C0543467
28072649	1295	1323	bicondylar plateau fractures	T037	C2861532
28072649	1354	1363	fractures	T037	C0016658
28072649	1400	1405	early	T079	C1279919
28072649	1406	1416	definitive	T079	C0443196
28072649	1417	1421	ORIF	T061	C1297885
28072649	1423	1430	surgery	T061	C0543467
28072649	1452	1458	injury	T037	C3263723
28072649	1483	1492	fractures	T037	C0016658
28072649	1509	1515	injury	T037	C3263723
28072649	1519	1523	ORIF	T061	C1297885
28072649	1529	1545	closed fractures	T037	C0016659
28072649	1579	1588	fractures	T037	C0016658
28072649	1601	1613	treated with	T061	C0332293
28072649	1614	1619	early	T079	C1279919
28072649	1620	1630	definitive	T079	C0443196
28072649	1631	1635	ORIF	T061	C1297885
28072649	1649	1678	additional surgical procedure	T061	C1706711
28072649	1697	1710	Complications	T046	C0009566
28072649	1720	1735	wound infection	T046	C0043241
28072649	1746	1765	surgical management	T058	C1515089
28072649	1767	1787	compartment syndrome	T047	C0009492
28072649	1798	1810	fasciotomies	T061	C0185188
28072649	1812	1820	nonunion	T033	C3897107
28072649	1822	1827	early	T079	C1279919
28072649	1828	1836	fixation	T061	C0589036
28072649	1837	1844	failure	T033	C0162643
28072649	1850	1865	implant removal	T061	C0561946
28072649	1870	1880	discomfort	T184	C0231218
28072649	1886	1897	reoperation	T061	C0035110
28072649	1898	1902	rate	T081	C1521828
28072649	1916	1931	implant removal	T061	C0561946
28072649	1966	1987	radiographic criteria	T170	C1511875
28072649	2007	2028	adequacy of reduction	T061	C0441610
28072649	2072	2080	criteria	T170	C1511875
28072649	2102	2111	fractures	T037	C0016658
28072649	2143	2148	SF-36	T170	C0451287
28072649	2235	2254	operative treatment	T061	C0543467
28072649	2258	2286	bicondylar plateau fractures	T037	C2861532
28072649	2305	2312	surgery	T061	C0543467
28072649	2355	2366	orthopaedic	T091	C0029355
28072649	2367	2382	trauma surgeons	T097	C0586908
28072649	2406	2441	bicondylar tibial plateau fractures	T037	C2861532
28072649	2456	2468	treated with	T061	C0332293
28072649	2469	2474	early	T079	C1279919
28072649	2475	2485	definitive	T079	C0443196
28072649	2486	2490	ORIF	T061	C1297885
28072649	2492	2497	Early	T079	C1279919
28072649	2498	2505	surgery	T061	C0543467
28072649	2539	2552	postoperative	T079	C0032790
28072649	2553	2565	radiographic	T070	C0444708
28072649	2566	2576	reductions	T061	C0441610

27292641|t|Joint Development Involves a Continuous Influx of Gdf5 - Positive Cells
27292641|a|Synovial joints comprise several tissue types, including articular cartilage, the capsule, and ligaments. All of these compartments are commonly assumed to originate from an early set of Gdf5 - expressing progenitors populating the interzone domain. Here, we provide evidence that joints develop through a continuous influx of cells into the interzone, where they contribute differentially to forming joint tissues. Using a knockin Gdf5 - CreER(T2) mouse, we show that early labeling of Gdf5 - positive interzone cells failed to mark the entire organ. Conversely, multiple Cre activation steps indicated a contribution of these cells to various joint compartments later in development. Spatiotemporal differences between Gdf5 and tdTomato reporter expression support the notion of a continuous recruitment process. Finally, differential contribution of Gdf5 - positive cells to various tissues suggests that the spatiotemporal dynamics of Gdf5 expression may instruct lineage divergence. This work supports the influx model of joint development, which may apply to other organogenic processes.
27292641	0	5	Joint	T030	C0224507
27292641	6	17	Development	T169	C1527148
27292641	29	39	Continuous	T078	C0549178
27292641	40	46	Influx	T080	C0443052
27292641	50	54	Gdf5	T028	C1333666
27292641	57	71	Positive Cells	T025	C0007634
27292641	72	87	Synovial joints	T030	C0224507
27292641	88	96	comprise	T052	C2700400
27292641	105	117	tissue types	T024	C2713035
27292641	129	148	articular cartilage	T024	C0007303
27292641	154	161	capsule	T023	C0206207
27292641	167	176	ligaments	T024	C0023685
27292641	191	203	compartments	T030	C0502723
27292641	259	263	Gdf5	T028	C1333666
27292641	266	276	expressing	T045	C0017262
27292641	277	288	progenitors	T025	C0038250
27292641	304	320	interzone domain	T082	C1254362
27292641	353	359	joints	T030	C0224507
27292641	378	388	continuous	T078	C0549178
27292641	389	395	influx	T080	C0443052
27292641	399	404	cells	T025	C0007634
27292641	414	423	interzone	T082	C1254362
27292641	436	446	contribute	T052	C1880177
27292641	447	461	differentially	T080	C0443199
27292641	465	472	forming	T169	C0205431
27292641	473	486	joint tissues	T024	C0224494
27292641	496	503	knockin	T063	C2350597
27292641	504	508	Gdf5	T028	C1333666
27292641	511	520	CreER(T2)	T028	C1511573
27292641	521	526	mouse	T015	C0025929
27292641	559	563	Gdf5	T028	C1333666
27292641	566	574	positive	T033	C1446409
27292641	575	584	interzone	T082	C1254362
27292641	585	590	cells	T025	C0007634
27292641	601	605	mark	T080	C0205556
27292641	610	622	entire organ	T023	C0178784
27292641	636	644	multiple	T081	C0439064
27292641	645	648	Cre	T028	C1511573
27292641	649	659	activation	T045	C0017255
27292641	666	675	indicated	T033	C1444656
27292641	678	690	contribution	T052	C1880177
27292641	700	705	cells	T025	C0007634
27292641	717	735	joint compartments	T030	C0502723
27292641	745	756	development	T169	C1527148
27292641	758	784	Spatiotemporal differences	T080	C1705242
27292641	793	797	Gdf5	T028	C1333666
27292641	802	810	tdTomato	T028	C0017337
27292641	820	830	expression	T045	C0017262
27292641	855	865	continuous	T078	C0549178
27292641	866	877	recruitment	T169	C0205245
27292641	878	885	process	T067	C1522240
27292641	896	908	differential	T080	C0443199
27292641	909	921	contribution	T052	C1880177
27292641	925	929	Gdf5	T028	C1333666
27292641	932	940	positive	T033	C1446409
27292641	941	946	cells	T025	C0007634
27292641	958	965	tissues	T024	C0040300
27292641	966	974	suggests	T078	C1705535
27292641	984	1007	spatiotemporal dynamics	T062	C0242481
27292641	1011	1015	Gdf5	T028	C1333666
27292641	1016	1026	expression	T045	C0017262
27292641	1040	1047	lineage	T078	C0282637
27292641	1048	1058	divergence	T082	C0443204
27292641	1083	1089	influx	T080	C0443052
27292641	1099	1104	joint	T030	C0224507
27292641	1105	1116	development	T169	C1527148
27292641	1143	1154	organogenic	T038	C0242290
27292641	1155	1164	processes	T038	C3714634

27680876|t|A Variant in the BACH2 Gene Is Associated With Susceptibility to Autoimmune Addison's Disease in Humans
27680876|a|Autoimmune Addison's disease (AAD) is a rare but highly heritable condition. The BACH2 protein plays a crucial role in T lymphocyte maturation, and allelic variation in its gene has been associated with a number of autoimmune conditions. We aimed to determine whether alleles of the rs3757247 single nucleotide polymorphism (SNP) in the BACH2 gene are associated with AAD. This case-control association study was performed in two phases using Taqman chemistry. In the first phase, the rs3757247 SNP was genotyped in 358 UK AAD subjects and 166 local control subjects. Genotype data were also available from 5154 healthy UK controls from the Wellcome Trust (WTCCC2) for comparison. In the second phase, the SNP was genotyped in a validation cohort comprising 317 Norwegian AAD subjects and 365 controls. The frequency of the minor T allele was significantly higher in subjects with AAD from the United Kingdom compared to both the local and WTCCC2 control cohorts (58% vs 45 and 48%, respectively) (local controls, P = 1.1 × 10(-4); odds ratio [OR], 1.68; 95% confidence interval [CI], 1.29-2.18; WTCCC2 controls, P = 1.4 × 10(-6); OR, 1.44; 95% CI, 1.23-1.69). This finding was replicated in the Norwegian validation cohort (P = .0015; OR, 1.41; 95% CI, 1.14-1.75). Subgroup analysis showed that this association is present in subjects with both isolated AAD (OR, 1.53; 95% CI, 1.22-1.92) and autoimmune polyglandular syndrome type 2 (OR, 1.37; 95% CI, 1.12-1.69) in the UK cohort, and with autoimmune polyglandular syndrome type 2 in the Norwegian cohort (OR, 1.58; 95% CI, 1.22-2.06). We have demonstrated, for the first time, that allelic variability at the BACH2 locus is associated with susceptibility to AAD. Given its association with multiple autoimmune conditions, BACH2 can be considered a "universal" autoimmune susceptibility locus.
27680876	2	9	Variant	T028	C0678941
27680876	17	27	BACH2 Gene	T028	C1422394
27680876	47	61	Susceptibility	T201	C0012655
27680876	65	93	Autoimmune Addison's Disease	T047	C0271737
27680876	97	103	Humans	T016	C0086418
27680876	104	132	Autoimmune Addison's disease	T047	C0271737
27680876	134	137	AAD	T047	C0271737
27680876	153	179	highly heritable condition	T047	C0019247
27680876	185	198	BACH2 protein	T116,T123	C1453878
27680876	223	246	T lymphocyte maturation	T043	C2246791
27680876	252	269	allelic variation	T033	C1953357
27680876	277	281	gene	T028	C0017337
27680876	291	306	associated with	T080	C0332281
27680876	319	340	autoimmune conditions	T046	C0004368
27680876	372	379	alleles	T028	C0002085
27680876	387	427	rs3757247 single nucleotide polymorphism	T086	C0752046
27680876	429	432	SNP	T086	C0752046
27680876	441	451	BACH2 gene	T028	C1422394
27680876	456	471	associated with	T080	C0332281
27680876	472	475	AAD	T047	C0271737
27680876	482	512	case-control association study	T062	C0007328
27680876	530	540	two phases	T079	C0205390
27680876	547	563	Taqman chemistry	T059	C1510438
27680876	572	583	first phase	T079	C0205390
27680876	589	602	rs3757247 SNP	T086	C0752046
27680876	607	616	genotyped	T032	C0017431
27680876	627	630	AAD	T047	C0271737
27680876	631	639	subjects	T098	C0080105
27680876	654	661	control	T096	C0009932
27680876	662	670	subjects	T098	C0080105
27680876	672	680	Genotype	T032	C0017431
27680876	681	685	data	T078	C1511726
27680876	716	735	healthy UK controls	T080	C2986479
27680876	745	768	Wellcome Trust (WTCCC2)	T062	C0007328
27680876	792	804	second phase	T079	C0205390
27680876	810	813	SNP	T086	C0752046
27680876	818	827	genotyped	T032	C0017431
27680876	833	850	validation cohort	T098	C0599755
27680876	866	875	Norwegian	T098	C0337812
27680876	876	879	AAD	T047	C0271737
27680876	880	888	subjects	T098	C0080105
27680876	897	905	controls	T096	C0009932
27680876	928	942	minor T allele	T028	C0002085
27680876	971	979	subjects	T098	C0080105
27680876	985	988	AAD	T047	C0271737
27680876	998	1012	United Kingdom	T083	C0041700
27680876	1044	1066	WTCCC2 control cohorts	T098	C0599755
27680876	1102	1116	local controls	T096	C0009932
27680876	1136	1146	odds ratio	T081	C0028873
27680876	1148	1150	OR	T081	C0028873
27680876	1163	1182	confidence interval	T081	C0009667
27680876	1184	1186	CI	T081	C0009667
27680876	1200	1215	WTCCC2 controls	T096	C0009932
27680876	1235	1237	OR	T081	C0028873
27680876	1249	1251	CI	T081	C0009667
27680876	1300	1327	Norwegian validation cohort	T062	C0086027
27680876	1340	1342	OR	T081	C0028873
27680876	1354	1356	CI	T081	C0009667
27680876	1370	1387	Subgroup analysis	T062	C0936012
27680876	1405	1416	association	T033	C0449380
27680876	1431	1439	subjects	T098	C0080105
27680876	1459	1462	AAD	T047	C0271737
27680876	1464	1466	OR	T081	C0028873
27680876	1478	1480	CI	T081	C0009667
27680876	1497	1537	autoimmune polyglandular syndrome type 2	T047	C0085860
27680876	1539	1541	OR	T081	C0028873
27680876	1553	1555	CI	T081	C0009667
27680876	1575	1584	UK cohort	T098	C0599755
27680876	1595	1635	autoimmune polyglandular syndrome type 2	T047	C0085860
27680876	1643	1659	Norwegian cohort	T098	C0599755
27680876	1661	1663	OR	T081	C0028873
27680876	1675	1677	CI	T081	C0009667
27680876	1738	1757	allelic variability	T080	C2986469
27680876	1765	1770	BACH2	T028	C1422394
27680876	1771	1776	locus	T082	C1708726
27680876	1780	1795	associated with	T080	C0332281
27680876	1796	1810	susceptibility	T201	C0012655
27680876	1814	1817	AAD	T047	C0271737
27680876	1829	1845	association with	T080	C0332281
27680876	1846	1876	multiple autoimmune conditions	T046	C0004368
27680876	1878	1883	BACH2	T028	C1422394
27680876	1904	1941	"universal" autoimmune susceptibility	T033	C0243095
27680876	1942	1947	locus	T082	C1708726

27981492|t|Sphincter -Preserving Surgery for Low Rectal Cancer: Do We Overshoot the Mark?
27981492|a|Intersphincteric resection (ISR) is an alternative to abdominoperineal resection (APR) for a selected subset of patients with low rectal cancer, combining equivalent oncological outcome and sphincter preservation. However, functional results are heterogeneous and often imperfect. The aim of the present investigation was to determine the long-term functional results and quality of life after ISR. One hundred forty-three consecutive patients who underwent surgery for low rectal cancer were analysed. Sixty patients received ISR and 83 patients APR, respectively. Kaplan-Meier estimate was used to analyse patients ' survival. The EORTC QLQ-C30, - C29 and the Wexner score were used to determine functional outcome and quality of life. ISR and APR were both associated with comparable morbidity and no mortality. Patients ' disease - and recurrence-free survival after ISR and APR were similar (p = 0.2872 and p = 0.4635). Closure of ileostomy was performed in 73% of all patients after ISR. Long-term outcome showed a rate of incontinence (Wexner score ≥10) in 66% of the patients. Despite this, patients ' quality of life was significantly better after ISR compared to APR in terms of abdominal complaints and psycho-emotional functioning. ISR is technically feasible with acceptable postoperative morbidity rates. Functional results following ISR are compromised by incontinence as the most important complication. However, long-term quality of life is superior to APR, which should be considered when selecting patients for ISR.
27981492	0	9	Sphincter	T023	C1409894
27981492	0	29	Sphincter -Preserving Surgery	T061	C0543467
27981492	34	51	Low Rectal Cancer	T191	C0007113
27981492	79	95	Intersphincteric	T023	C0229962
27981492	96	105	resection	T061	C0728940
27981492	107	110	ISR	T061	C0728940
27981492	133	159	abdominoperineal resection	T061	C2004459
27981492	161	164	APR	T061	C2004459
27981492	191	199	patients	T101	C0030705
27981492	205	222	low rectal cancer	T191	C0007113
27981492	245	264	oncological outcome	T080	C0085415
27981492	269	278	sphincter	T023	C1409894
27981492	279	291	preservation	T059	C0033085
27981492	302	320	functional results	T034	C0456984
27981492	325	338	heterogeneous	T080	C0019409
27981492	349	358	imperfect	T080	C1280014
27981492	418	427	long-term	T079	C0443252
27981492	428	446	functional results	T034	C0456984
27981492	451	466	quality of life	T078	C0034380
27981492	473	476	ISR	T061	C0728940
27981492	514	522	patients	T101	C0030705
27981492	537	544	surgery	T061	C0543467
27981492	549	566	low rectal cancer	T191	C0007113
27981492	588	596	patients	T101	C0030705
27981492	606	609	ISR	T061	C0728940
27981492	617	625	patients	T101	C0030705
27981492	626	629	APR	T061	C2004459
27981492	645	666	Kaplan-Meier estimate	T081	C1720943
27981492	687	695	patients	T101	C0030705
27981492	698	706	survival	T081	C0038954
27981492	712	725	EORTC QLQ-C30	T170	C4055104
27981492	729	732	C29	T170	C0282574
27981492	741	753	Wexner score	T081	C0449820
27981492	777	795	functional outcome	T033	C4034568
27981492	800	815	quality of life	T078	C0034380
27981492	817	820	ISR	T061	C0728940
27981492	825	828	APR	T061	C2004459
27981492	839	854	associated with	T080	C0332281
27981492	855	875	comparable morbidity	T033	C1822479
27981492	880	892	no mortality	T081	C0205848
27981492	894	902	Patients	T101	C0030705
27981492	905	912	disease	T047	C0012634
27981492	919	943	recurrence-free survival	T201	C2919551
27981492	950	953	ISR	T061	C0728940
27981492	958	961	APR	T061	C2004459
27981492	1004	1024	Closure of ileostomy	T061	C0192775
27981492	1053	1061	patients	T101	C0030705
27981492	1068	1071	ISR	T061	C0728940
27981492	1073	1082	Long-term	T079	C0443252
27981492	1083	1090	outcome	T169	C1274040
27981492	1108	1120	incontinence	T047	C0021167
27981492	1122	1134	Wexner score	T081	C0449820
27981492	1154	1162	patients	T101	C0030705
27981492	1178	1186	patients	T101	C0030705
27981492	1189	1204	quality of life	T078	C0034380
27981492	1236	1239	ISR	T061	C0728940
27981492	1252	1255	APR	T061	C2004459
27981492	1268	1288	abdominal complaints	T184	C0850768
27981492	1293	1321	psycho-emotional functioning	T169	C0542341
27981492	1323	1326	ISR	T061	C0728940
27981492	1367	1396	postoperative morbidity rates	T033	C1822479
27981492	1398	1416	Functional results	T034	C0456984
27981492	1427	1430	ISR	T061	C0728940
27981492	1450	1462	incontinence	T047	C0021167
27981492	1485	1497	complication	T046	C0009566
27981492	1508	1517	long-term	T079	C0443252
27981492	1518	1533	quality of life	T078	C0034380
27981492	1549	1552	APR	T061	C2004459
27981492	1596	1604	patients	T101	C0030705
27981492	1609	1612	ISR	T061	C0728940

27613895|t|Examination of the Involvement of Cholinergic - Associated Genes in Nicotine Behaviors in European and African Americans
27613895|a|Cigarette smoking is a physiologically harmful habit. Nicotinic acetylcholine receptors (nAChRs) are bound by nicotine and upregulated in response to chronic exposure to nicotine. It is known that upregulation of these receptors is not due to a change in mRNA of these genes, however, more precise details on the process are still uncertain, with several plausible hypotheses describing how nAChRs are upregulated. We have manually curated a set of genes believed to play a role in nicotine - induced nAChR upregulation. Here, we test the hypothesis that these genes are associated with and contribute risk for nicotine dependence (ND) and the number of cigarettes smoked per day (CPD). Studies with genotypic data on European and African Americans (EAs and AAs, respectively) were collected and a gene-based test was run to test for an association between each gene and ND and CPD. Although several novel genes were associated with CPD and ND at P < 0.05 in EAs and AAs, these associations did not survive correction for multiple testing. Previous associations between CHRNA3, CHRNA5, CHRNB4 and CPD in EAs were replicated. Our hypothesis-driven approach avoided many of the limitations inherent in pathway analyses and provided nominal evidence for association between cholinergic-related genes and nicotine behaviors. We evaluated the evidence for association between a manually curated set of genes and nicotine behaviors in European and African Americans. Although no genes were associated after multiple testing correction, this study has several strengths: by manually curating a set of genes we circumvented the limitations inherent in many pathway analyses and tested several genes that had not yet been examined in a human genetic study; gene-based tests are a useful way to test for association with a set of genes; and these genes were collected based on literature review and conversations with experts, highlighting the importance of scientific collaboration.
27613895	0	11	Examination	T058	C0220825
27613895	19	30	Involvement	T169	C1314939
27613895	34	45	Cholinergic	T169	C0599668
27613895	48	58	Associated	T080	C0439849
27613895	59	64	Genes	T028	C0017337
27613895	68	76	Nicotine	T109,T131	C0028040
27613895	77	86	Behaviors	T053	C0004927
27613895	90	98	European	T098	C0683983
27613895	103	120	African Americans	T098	C0085756
27613895	121	138	Cigarette smoking	T055	C0700219
27613895	144	159	physiologically	T169	C0205463
27613895	160	173	harmful habit	UnknownType	C0679788
27613895	175	208	Nicotinic acetylcholine receptors	T116,T192	C0034830
27613895	210	216	nAChRs	T116,T192	C0034830
27613895	222	230	bound by	T082	C0332297
27613895	231	239	nicotine	T109,T131	C0028040
27613895	244	255	upregulated	T044	C0949479
27613895	271	278	chronic	T079	C0205191
27613895	279	290	exposure to	T080	C0332157
27613895	291	299	nicotine	T109,T131	C0028040
27613895	318	330	upregulation	T044	C0949479
27613895	340	349	receptors	T116,T192	C0597357
27613895	376	380	mRNA	T114,T123	C0035696
27613895	390	395	genes	T028	C0017337
27613895	476	496	plausible hypotheses	T078	C1512571
27613895	512	518	nAChRs	T116,T192	C0034830
27613895	523	534	upregulated	T044	C0949479
27613895	544	560	manually curated	T052	C1707535
27613895	570	575	genes	T028	C0017337
27613895	603	611	nicotine	T109,T131	C0028040
27613895	614	621	induced	T169	C0205263
27613895	622	627	nAChR	T116,T192	C0034830
27613895	628	640	upregulation	T044	C0949479
27613895	660	670	hypothesis	T078	C1512571
27613895	682	687	genes	T028	C0017337
27613895	692	707	associated with	T080	C0332281
27613895	723	727	risk	T078	C0035647
27613895	732	751	nicotine dependence	T048	C0028043
27613895	753	755	ND	T048	C0028043
27613895	765	800	number of cigarettes smoked per day	T033	C0243095
27613895	802	805	CPD	T033	C0243095
27613895	808	815	Studies	T062	C2603343
27613895	821	830	genotypic	T032	C0017431
27613895	831	835	data	T078	C1511726
27613895	839	847	European	T098	C0683983
27613895	852	869	African Americans	T098	C0085756
27613895	871	874	EAs	T098	C0683983
27613895	879	882	AAs	T098	C0683983
27613895	919	934	gene-based test	T170	C0392366
27613895	946	950	test	T169	C0039593
27613895	958	969	association	T080	C0439849
27613895	983	987	gene	T028	C0017337
27613895	992	994	ND	T048	C0028043
27613895	999	1002	CPD	T033	C0243095
27613895	1021	1026	novel	T080	C0205314
27613895	1027	1032	genes	T028	C0017337
27613895	1038	1053	associated with	T080	C0332281
27613895	1054	1057	CPD	T033	C0243095
27613895	1062	1064	ND	T048	C0028043
27613895	1080	1083	EAs	T098	C0683983
27613895	1088	1091	AAs	T098	C0683983
27613895	1099	1111	associations	T080	C0439849
27613895	1116	1119	not	T169	C1518422
27613895	1128	1138	correction	T169	C1947976
27613895	1143	1159	multiple testing	T169	C0039593
27613895	1170	1182	associations	T080	C0439849
27613895	1191	1197	CHRNA3	T028	C1413403
27613895	1199	1205	CHRNA5	T028	C1413405
27613895	1207	1213	CHRNB4	T028	C1413410
27613895	1218	1221	CPD	T033	C0243095
27613895	1225	1228	EAs	T098	C0683983
27613895	1321	1337	pathway analyses	T170	C0868995
27613895	1351	1367	nominal evidence	T078	C3887511
27613895	1372	1383	association	T080	C0439849
27613895	1392	1411	cholinergic-related	T169	C0599668
27613895	1412	1417	genes	T028	C0017337
27613895	1422	1430	nicotine	T109,T131	C0028040
27613895	1431	1440	behaviors	T053	C0004927
27613895	1445	1454	evaluated	T058	C0220825
27613895	1459	1467	evidence	T078	C3887511
27613895	1472	1483	association	T080	C0439849
27613895	1494	1510	manually curated	T052	C1707535
27613895	1518	1523	genes	T028	C0017337
27613895	1528	1536	nicotine	T109,T131	C0028040
27613895	1537	1546	behaviors	T053	C0004927
27613895	1550	1558	European	T098	C0683983
27613895	1563	1580	African Americans	T098	C0683983
27613895	1591	1593	no	T033	C0205160
27613895	1594	1599	genes	T028	C0017337
27613895	1605	1615	associated	T080	C0439849
27613895	1622	1638	multiple testing	T169	C0039593
27613895	1639	1649	correction	T169	C1947976
27613895	1656	1661	study	T062	C2603343
27613895	1688	1705	manually curating	T052	C1707535
27613895	1715	1720	genes	T028	C0017337
27613895	1741	1752	limitations	T169	C0449295
27613895	1770	1786	pathway analyses	T170	C0868995
27613895	1791	1797	tested	T169	C0039593
27613895	1806	1811	genes	T028	C0017337
27613895	1848	1853	human	T016	C0086418
27613895	1854	1867	genetic study	T062	C2827447
27613895	1869	1885	gene-based tests	T170	C0392366
27613895	1906	1910	test	T169	C0039593
27613895	1915	1931	association with	T080	C0332281
27613895	1941	1946	genes	T028	C0017337
27613895	1958	1963	genes	T028	C0017337
27613895	1988	1998	literature	T170	C0023866
27613895	1999	2005	review	T169	C0699752
27613895	2010	2023	conversations	T054	C0871703
27613895	2029	2036	experts	T097	C1611835
27613895	2055	2065	importance	T080	C3898777
27613895	2069	2093	scientific collaboration	T054	C0282116

27346839|t|Long-term antibiofilm activity of carboxymethyl chitosan on mixed biofilm on silicone
27346839|a|Silicone voice prostheses are most frequently used in voice rehabilitation of laryngectomized patients. However, the functional device lifetimes are limited due to formation of mixed biofilms. Existing in vitro models simulating biofilm formation are restricted to only short-term periods. The goal of this study was to determine the effect of carboxymethyl chitosan on mixed biofilm formation of fungi and bacteria on silicone over a long-term period. Mixed species biofilms of Candida albicans, Candida tropicalis, Lactobacillus gasseri, Streptococcus salivarius, Rothia dentocariosa, and Staphylococcus epidermidis were cultivated on the surfaces of medical-grade silicone with and without addition of carboxymethyl chitosan. Biofilm kinetics was monitored using specially designed image analysis software to calculate the percentual surface covering of each platelet. Biofilm architecture was investigated by scanning electron microscopy. A cover of living mixed biofilm could be generated over 22 days on silicone and the maximum of 22% biofilm surface covering at day 22. However, less than 4% surface coverage was observed on the carboxymethyl chitosan - treated plates in the testing period. Scanning electron microscopy confirms that, on surfaces treated by carboxymethyl chitosan, the biofilm was less dense. In addition, there were fewer layers of cells and profuse cellular debris, together with degrading and morphologically altered yeast cells. Carboxymethyl chitosan may serve as a possible antibiofilm agent to limit biofilm formation on voice prostheses. NA Laryngoscope, 126:E404-E408, 2016.
27346839	0	9	Long-term	T079	C0443252
27346839	10	30	antibiofilm activity	T052	C0441655
27346839	34	56	carboxymethyl chitosan	T109,T121	C1744331
27346839	60	73	mixed biofilm	T007	C0081786
27346839	77	85	silicone	T109,T122	C0037114
27346839	86	94	Silicone	T109,T122	C0037114
27346839	95	111	voice prostheses	T074	C0087165
27346839	121	131	frequently	T079	C0332183
27346839	140	160	voice rehabilitation	T061	C0199531
27346839	164	179	laryngectomized	T061	C0023065
27346839	180	188	patients	T101	C0030705
27346839	203	220	functional device	T033	C1385354
27346839	221	230	lifetimes	T079	C4071830
27346839	235	242	limited	T169	C0439801
27346839	243	249	due to	T169	C0678226
27346839	250	259	formation	T169	C1522492
27346839	263	277	mixed biofilms	T007	C0081786
27346839	288	303	in vitro models	T062	C1515654
27346839	315	332	biofilm formation	T043	C1325881
27346839	337	347	restricted	T169	C0443288
27346839	356	366	short-term	T079	C0443303
27346839	367	374	periods	T079	C1948053
27346839	380	384	goal	T170	C0018017
27346839	393	398	study	T062	C2603343
27346839	420	426	effect	T080	C1280500
27346839	430	452	carboxymethyl chitosan	T109,T121	C1744331
27346839	456	479	mixed biofilm formation	T043	C1325881
27346839	483	488	fungi	T004	C0016832
27346839	493	501	bacteria	T007	C0004611
27346839	505	513	silicone	T109,T122	C0037114
27346839	521	530	long-term	T079	C0443252
27346839	531	537	period	T079	C1948053
27346839	545	552	species	T185	C1705920
27346839	553	561	biofilms	T007	C0081786
27346839	565	581	Candida albicans	T004	C0006837
27346839	583	601	Candida tropicalis	T004	C0319882
27346839	603	624	Lactobacillus gasseri	T007	C0317620
27346839	626	650	Streptococcus salivarius	T007	C0318179
27346839	652	671	Rothia dentocariosa	T007	C0318071
27346839	677	703	Staphylococcus epidermidis	T007	C0038174
27346839	709	719	cultivated	T067	C1254366
27346839	727	735	surfaces	T082	C0205148
27346839	739	761	medical-grade silicone	T109,T122	C0037114
27346839	791	813	carboxymethyl chitosan	T109,T121	C1744331
27346839	815	831	Biofilm kinetics	T070	C0022702
27346839	862	894	designed image analysis software	T170	C3203922
27346839	898	907	calculate	T052	C1441506
27346839	912	939	percentual surface covering	T169	C0205245
27346839	948	956	platelet	T025	C0005821
27346839	958	978	Biofilm architecture	T082	C1254362
27346839	983	995	investigated	T169	C1292732
27346839	999	1027	scanning electron microscopy	T059	C0026020
27346839	1031	1036	cover	T169	C1999244
27346839	1040	1046	living	T078	C0376558
27346839	1047	1060	mixed biofilm	T007	C0081786
27346839	1088	1092	days	T079	C0439228
27346839	1096	1104	silicone	T109,T122	C0037114
27346839	1113	1120	maximum	T081	C0806909
27346839	1128	1135	biofilm	T007	C0081786
27346839	1136	1152	surface covering	T169	C0205245
27346839	1156	1159	day	T079	C0439228
27346839	1173	1182	less than	T081	C0439092
27346839	1186	1202	surface coverage	T169	C1999244
27346839	1207	1215	observed	T169	C1441672
27346839	1223	1245	carboxymethyl chitosan	T109,T121	C1744331
27346839	1248	1255	treated	T169	C1522326
27346839	1270	1277	testing	T169	C0039593
27346839	1278	1284	period	T079	C1948053
27346839	1286	1314	Scanning electron microscopy	T059	C0026020
27346839	1315	1323	confirms	T033	C0750484
27346839	1333	1341	surfaces	T082	C0205148
27346839	1342	1349	treated	T169	C1522326
27346839	1353	1375	carboxymethyl chitosan	T109,T121	C1744331
27346839	1381	1388	biofilm	T007	C0081786
27346839	1393	1397	less	T080	C0547044
27346839	1398	1403	dense	T080	C0439794
27346839	1429	1434	fewer	T081	C0205388
27346839	1445	1450	cells	T025	C0007634
27346839	1455	1478	profuse cellular debris	T033	C4055264
27346839	1480	1488	together	T080	C1883357
27346839	1508	1531	morphologically altered	T190	C1260954
27346839	1532	1537	yeast	T004	C0043393
27346839	1532	1543	yeast cells	T025	C0007634
27346839	1545	1567	Carboxymethyl chitosan	T109,T121	C1744331
27346839	1583	1591	possible	T033	C0332149
27346839	1592	1609	antibiofilm agent	T167	C0439861
27346839	1619	1636	biofilm formation	T043	C1325881
27346839	1640	1656	voice prostheses	T074	C0087165
27346839	1661	1673	Laryngoscope	T074	C0180453

27306621|t|Cardiovascular magnetic resonance features of mechanical dyssynchrony in patients with left bundle branch block
27306621|a|Patients with left bundle branch block (LBBB) can exhibit mechanical dyssynchrony which may contribute to heart failure; such patients may benefit from cardiac resynchronization treatment (CRT). While cardiac magnetic resonance imaging (CMR) has become a common part of heart failure work-up, CMR features of mechanical dyssynchrony in patients with LBBB have not been well characterized. This study aims to investigate the potential of CMR to characterize mechanical features of LBBB. CMR examinations from 43 patients with LBBB on their electrocardiogram, but without significant focal structural abnormalities, and from 43 age- and gender -matched normal controls were retrospectively reviewed. The following mechanical features of LBBB were evaluated: septal flash (SF), apical rocking (AR), delayed aortic valve opening measured relative to both end-diastole (AVOED) and pulmonic valve opening (AVOPVO), delayed left-ventricular (LV) free-wall contraction, and curvatures of the septum and LV free-wall. Septal displacement curves were also generated, using feature -tracking techniques. The echocardiographic findings of LBBB were also reviewed in those subjects for whom they were available. LBBB was significantly associated with the presence of SF and AR; within the LBBB group, 79 % had SF and 65 % had AR. Delayed AVOED, AVOPVO, and delayed LV free-wall contraction were significantly associated with LBBB. AVOED and AVOPVO positively correlated with QRS duration and negatively correlated with ejection fraction. Hearts with electrocardiographic evidence of LBBB showed lower septal-to-LV free-wall curvature ratios at end-diastole compared to normal controls. CMR can be used to identify and evaluate mechanical dyssynchrony in patients with LBBB. None of the normal controls showed the mechanical features associated with LBBB. Moreover, not all patients with LBBB showed the same degree of mechanical dyssynchrony, which could have implications for CRT.
27306621	0	33	Cardiovascular magnetic resonance	T060	C0412692
27306621	46	56	mechanical	T022	C0598002
27306621	57	69	dyssynchrony	T047	C3160936
27306621	73	81	patients	T101	C0030705
27306621	87	111	left bundle branch block	T047	C0023211
27306621	112	120	Patients	T101	C0030705
27306621	126	150	left bundle branch block	T047	C0023211
27306621	152	156	LBBB	T047	C0023211
27306621	170	180	mechanical	T022	C0598002
27306621	181	193	dyssynchrony	T047	C3160936
27306621	218	231	heart failure	T047	C0018801
27306621	238	246	patients	T101	C0030705
27306621	264	299	cardiac resynchronization treatment	T061	C1167956
27306621	301	304	CRT	T061	C1167956
27306621	313	347	cardiac magnetic resonance imaging	T060	C0412692
27306621	349	352	CMR	T060	C0412692
27306621	382	395	heart failure	T047	C0018801
27306621	396	403	work-up	T060	C0750430
27306621	405	408	CMR	T060	C0412692
27306621	421	431	mechanical	T022	C0598002
27306621	432	444	dyssynchrony	T047	C3160936
27306621	448	456	patients	T101	C0030705
27306621	462	466	LBBB	T047	C0023211
27306621	549	552	CMR	T060	C0412692
27306621	569	579	mechanical	T022	C0598002
27306621	592	596	LBBB	T047	C0023211
27306621	598	601	CMR	T060	C0412692
27306621	623	631	patients	T101	C0030705
27306621	637	641	LBBB	T047	C0023211
27306621	651	668	electrocardiogram	T033	C0013798
27306621	694	699	focal	T082	C0205234
27306621	700	724	structural abnormalities	T047	C3274789
27306621	747	753	gender	T032	C0079399
27306621	763	778	normal controls	T080	C2705716
27306621	784	808	retrospectively reviewed	T062	C0035363
27306621	824	834	mechanical	T022	C0598002
27306621	847	851	LBBB	T047	C0023211
27306621	868	880	septal flash	T033	C3164858
27306621	882	884	SF	T033	C3164858
27306621	887	901	apical rocking	T033	C2039843
27306621	903	905	AR	T033	C2039843
27306621	908	975	delayed aortic valve opening measured relative to both end-diastole	T033	C2059410
27306621	977	982	AVOED	T033	C2059410
27306621	988	1010	pulmonic valve opening	T033	C0243095
27306621	1012	1018	AVOPVO	T033	C0243095
27306621	1021	1072	delayed left-ventricular (LV) free-wall contraction	T033	C2023494
27306621	1078	1119	curvatures of the septum and LV free-wall	T033	C0243095
27306621	1121	1147	Septal displacement curves	T201	C4069735
27306621	1175	1182	feature	T080	C2348519
27306621	1209	1226	echocardiographic	T060	C0013516
27306621	1239	1243	LBBB	T047	C0023211
27306621	1311	1315	LBBB	T047	C0023211
27306621	1334	1349	associated with	T080	C0332281
27306621	1366	1368	SF	T033	C3164858
27306621	1373	1375	AR	T033	C2039843
27306621	1388	1392	LBBB	T047	C0023211
27306621	1393	1398	group	T078	C0441833
27306621	1409	1411	SF	T033	C3164858
27306621	1425	1427	AR	T033	C2039843
27306621	1429	1442	Delayed AVOED	T033	C0243095
27306621	1444	1450	AVOPVO	T033	C0243095
27306621	1456	1488	delayed LV free-wall contraction	T033	C0243095
27306621	1508	1523	associated with	T080	C0332281
27306621	1524	1528	LBBB	T047	C0023211
27306621	1530	1535	AVOED	T033	C2059410
27306621	1540	1546	AVOPVO	T033	C0243095
27306621	1574	1586	QRS duration	T201	C0429025
27306621	1618	1635	ejection fraction	T060	C0489482
27306621	1637	1643	Hearts	T023	C0018787
27306621	1649	1669	electrocardiographic	T060	C0013516
27306621	1682	1686	LBBB	T047	C0023211
27306621	1694	1739	lower septal-to-LV free-wall curvature ratios	T081	C0392762
27306621	1743	1755	end-diastole	T079	C1562146
27306621	1768	1783	normal controls	T080	C2705716
27306621	1785	1788	CMR	T060	C0412692
27306621	1826	1836	mechanical	T022	C0598002
27306621	1837	1849	dyssynchrony	T047	C3160936
27306621	1853	1861	patients	T101	C0030705
27306621	1867	1871	LBBB	T047	C0023211
27306621	1885	1900	normal controls	T080	C2705716
27306621	1912	1922	mechanical	T022	C0598002
27306621	1932	1947	associated with	T080	C0332281
27306621	1948	1952	LBBB	T047	C0023211
27306621	1972	1980	patients	T101	C0030705
27306621	1986	1990	LBBB	T047	C0023211
27306621	2017	2027	mechanical	T022	C0598002
27306621	2028	2040	dyssynchrony	T047	C3160936
27306621	2076	2079	CRT	T061	C1167956

27534355|t|Mobility Experience of Persons with Visual Impairments in Indian Railway Station Environments
27534355|a|Mobility for persons with visual impairments in Indian railway stations poses multidimensional challenges for access to an inclusive travel experience. India is a home to about twenty million persons with diverse disabilities out of which about five million are persons with visual impairments. Diversity of passenger movements on a railway station including persons with visual impairments requires a Universal Design approach to respond to the accessibility issues in these contexts. This research study is based on a series of live on-site experiences conducted along with persons with visual impairments at New Delhi Railway Station. It also includes the generic studies carried out with other diversities of railway passengers including aging, gender and diverse physical abilities. It employs research methods like ethnography, focus group interactions and trace study to develop a deeper understanding of human and spatial parameters of mobility in railway station environments. A Universal Design perspective with a holistic understanding remains critical to the foundation of this research study. While it deals in specific requirements of persons with visual impairments, it also brings an illustration of handling diversity on a railway station from a unique Indian perspective. It concludes by highlighting and reinterpreting the Universal Design India Principles integrating the needs of persons with visual impairments in railway station environments. Brief recommendation for an inclusive mobility experience on railway station forms a vital part of this grounded research study.
27534355	0	8	Mobility	T080	C0449580
27534355	9	19	Experience	T041	C0596545
27534355	23	30	Persons	T098	C0027361
27534355	36	54	Visual Impairments	T033	C3665347
27534355	58	64	Indian	T083	C0021201
27534355	65	80	Railway Station	T073	C0442644
27534355	81	93	Environments	T082	C0014406
27534355	94	102	Mobility	T080	C0449580
27534355	107	114	persons	T098	C0027361
27534355	120	138	visual impairments	T033	C3665347
27534355	142	148	Indian	T083	C0021201
27534355	149	165	railway stations	T073	C0442644
27534355	204	210	access	T082	C0444454
27534355	227	233	travel	T056	C0040802
27534355	234	244	experience	T041	C0596545
27534355	246	251	India	T083	C0021201
27534355	286	293	persons	T098	C0027361
27534355	299	306	diverse	T080	C1880371
27534355	307	319	disabilities	T033	C0231170
27534355	356	363	persons	T098	C0027361
27534355	369	387	visual impairments	T033	C3665347
27534355	389	398	Diversity	T080	C1880371
27534355	402	411	passenger	T098	C0450048
27534355	412	421	movements	T040	C0026649
27534355	427	442	railway station	T073	C0442644
27534355	453	460	persons	T098	C0027361
27534355	466	484	visual impairments	T033	C3665347
27534355	496	521	Universal Design approach	T170	C0282574
27534355	540	553	accessibility	T080	C0814423
27534355	554	560	issues	T033	C0033213
27534355	570	578	contexts	T078	C0449255
27534355	585	599	research study	T062	C0681814
27534355	614	620	series	T081	C0205549
27534355	624	628	live	T052	C2982691
27534355	629	636	on-site	T082	C0205145
27534355	637	648	experiences	T041	C0596545
27534355	670	677	persons	T098	C0027361
27534355	683	701	visual impairments	T033	C3665347
27534355	705	714	New Delhi	UnknownType	C0681784
27534355	715	730	Railway Station	T073	C0442644
27534355	753	768	generic studies	T062	C2603343
27534355	792	803	diversities	T080	C1880371
27534355	807	825	railway passengers	T098	C0450058
27534355	836	841	aging	T032	C0001779
27534355	843	849	gender	T032	C0079399
27534355	854	861	diverse	T080	C1880371
27534355	862	870	physical	T169	C0205485
27534355	871	880	abilities	T032	C0085732
27534355	893	909	research methods	T062	C0086912
27534355	915	926	ethnography	T090	C0162319
27534355	928	933	focus	T169	C1285542
27534355	934	939	group	T098	C1257890
27534355	940	952	interactions	T169	C1704675
27534355	957	968	trace study	T062	C0242481
27534355	1006	1011	human	T016	C0086418
27534355	1016	1023	spatial	T082	C1254362
27534355	1024	1034	parameters	T033	C0449381
27534355	1038	1046	mobility	T080	C0449580
27534355	1050	1065	railway station	T073	C0442644
27534355	1066	1078	environments	T082	C0014406
27534355	1082	1110	Universal Design perspective	T170	C0282574
27534355	1184	1198	research study	T062	C0681814
27534355	1243	1250	persons	T098	C0027361
27534355	1256	1274	visual impairments	T033	C3665347
27534355	1319	1328	diversity	T080	C1880371
27534355	1334	1349	railway station	T073	C0442644
27534355	1364	1370	Indian	T098	C1524069
27534355	1371	1382	perspective	T080	C0205556
27534355	1417	1431	reinterpreting	T169	C1285553
27534355	1436	1469	Universal Design India Principles	T170	C0282574
27534355	1495	1502	persons	T098	C0027361
27534355	1508	1526	visual impairments	T033	C3665347
27534355	1530	1545	railway station	T073	C0442644
27534355	1546	1558	environments	T082	C0014406
27534355	1566	1580	recommendation	T078	C0034866
27534355	1598	1606	mobility	T080	C0449580
27534355	1607	1617	experience	T041	C0596545
27534355	1621	1636	railway station	T073	C0442644
27534355	1673	1687	research study	T062	C0681814

28097508|t|Preparation and evaluation of biopolymeric nanoparticles as drug delivery system in effective treatment of rheumatoid arthritis
28097508|a|The study purposes to evaluate nanocrystalline biopolymeric nanoparticles encapsulating methotrexate and dexamethasone with high biocompatibility, enhanced therapeutic efficacy and reduced toxicity. Chitosan nanoparticles were prepared by ionic gelation, and Methotrexate (MTX) and Dexamethasone (DEX) were loaded during the preparation and screened for their in vitro efficacy in HEK and RAW264.7 cells, ex vivo and in vivo efficacy. FTIR confirmed the involvement of phosphoric group of sTPP with amine groups of chitosan and also role of hydrogen bonding involved in the preparation of MTXCHNP and DEXCHNP. Controlled release patterns coupled with diffusion of drug were observed in two different buffers (PBS) at pH 7.4 and pH 5.8. The IC50 for MTXCHNP for HEK was 26.1 μg/ml and 7.7 μg/ml for RAW 264.7 cells. In DEXCHNP, the IC50 was 20.12 μg/ml for HEK and 7.37 μg/ml for RAW264.7 cells. Enhanced uptake of FITC - CHNP by RAW cells indicated internalization of nanoparticles by phagocytosis. The enhanced release of drug at lower pH justified increased cytotoxicity. Negligible ex-vivo hemolysis indicated the higher biocompatibility of the nanoparticles. (99m)Tc - CHNP exhibited maximum absorption in blood circulation in 3 h, followed by hepatic metabolism and renal clearance. Higher in-vivo anti-arthritic activity and antioxidant activity was observed post-intraperitoneal (i.p.) injections by both MTXCHNP and DEXCHNP when compared to MTX (0.75 mg/Kg by i.p. route) and DEX (0.2 mg/Kg/ i.p. /daily) per se. The nanocrystalline biopolymeric nanoparticles were stable, biocompatible and have potential to be administered through i.p. route with minimal toxicity and high efficacy.
28097508	0	11	Preparation	T052	C1521827
28097508	16	26	evaluation	T058	C0220825
28097508	30	42	biopolymeric	T116,T123	C0005554
28097508	43	56	nanoparticles	T073	C1450054
28097508	60	80	drug delivery system	T074	C0085104
28097508	94	103	treatment	T061	C0087111
28097508	107	127	rheumatoid arthritis	T047	C0003873
28097508	150	158	evaluate	T058	C0220825
28097508	159	174	nanocrystalline	T073	C1721058
28097508	175	187	biopolymeric	T116,T123	C0005554
28097508	188	201	nanoparticles	T073	C1450054
28097508	202	215	encapsulating	T080	C0205223
28097508	216	228	methotrexate	T109,T121	C0025677
28097508	233	246	dexamethasone	T109,T121	C0011777
28097508	257	273	biocompatibility	T044	C0596177
28097508	284	304	therapeutic efficacy	T080	C2348767
28097508	317	325	toxicity	T080	C0040539
28097508	327	335	Chitosan	T109,T121	C0162969
28097508	336	349	nanoparticles	T073	C1450054
28097508	355	363	prepared	T033	C4082130
28097508	367	381	ionic gelation	T067	C1522240
28097508	387	399	Methotrexate	T109,T121	C0025677
28097508	401	404	MTX	T109,T121	C0025677
28097508	410	423	Dexamethasone	T109,T121	C0011777
28097508	425	428	DEX	T109,T121	C0011777
28097508	435	441	loaded	T052	C1708715
28097508	453	464	preparation	T052	C1521827
28097508	469	477	screened	T059	C0373483
28097508	488	496	in vitro	T062	C0681828
28097508	509	512	HEK	T025	C2936239
28097508	517	531	RAW264.7 cells	T025	C4042840
28097508	533	540	ex vivo	T062	C0242481
28097508	545	552	in vivo	T062	C0681829
28097508	563	567	FTIR	T062	C0206055
28097508	597	613	phosphoric group	T104	C1254350
28097508	617	621	sTPP	T121,T130,T197	C0301008
28097508	627	639	amine groups	T109	C1879694
28097508	643	651	chitosan	T109,T121	C0162969
28097508	669	685	hydrogen bonding	T070	C0020276
28097508	702	713	preparation	T052	C1521827
28097508	717	724	MTXCHNP	T073	C1450054
28097508	729	736	DEXCHNP	T073	C1450054
28097508	738	756	Controlled release	T079	C0868939
28097508	779	788	diffusion	T070	C0012222
28097508	792	796	drug	T121	C1254351
28097508	828	835	buffers	T121,T130	C0006353
28097508	837	840	PBS	T121,T130	C0991865
28097508	845	847	pH	T081	C0020283
28097508	856	858	pH	T081	C0020283
28097508	868	872	IC50	T081	C0600495
28097508	877	884	MTXCHNP	T073	C1450054
28097508	889	892	HEK	T025	C2936239
28097508	926	941	RAW 264.7 cells	T025	C4042840
28097508	946	953	DEXCHNP	T073	C1450054
28097508	959	963	IC50	T081	C0600495
28097508	984	987	HEK	T025	C2936239
28097508	1007	1021	RAW264.7 cells	T025	C4042840
28097508	1049	1053	CHNP	T073	C1450054
28097508	1057	1066	RAW cells	T025	C0007634
28097508	1077	1092	internalization	T041	C0871786
28097508	1096	1109	nanoparticles	T073	C1450054
28097508	1113	1125	phagocytosis	T043	C0031308
28097508	1151	1155	drug	T121	C1254351
28097508	1165	1167	pH	T081	C0020283
28097508	1188	1200	cytotoxicity	T049	C0596402
28097508	1213	1220	ex-vivo	T062	C0242481
28097508	1221	1230	hemolysis	T034	C2945560
28097508	1252	1268	biocompatibility	T044	C0596177
28097508	1276	1289	nanoparticles	T073	C1450054
28097508	1291	1298	(99m)Tc	T130	C0303611
28097508	1301	1305	CHNP	T073	C1450054
28097508	1324	1334	absorption	T067	C2347023
28097508	1338	1355	blood circulation	T039	C0005775
28097508	1376	1394	hepatic metabolism	T042	C1373178
28097508	1399	1414	renal clearance	T042	C0232813
28097508	1423	1430	in-vivo	T062	C0681829
28097508	1431	1454	anti-arthritic activity	T033	C0243095
28097508	1459	1479	antioxidant activity	T044	C1148564
28097508	1493	1531	post-intraperitoneal (i.p.) injections	T061	C0021493
28097508	1540	1547	MTXCHNP	T073	C1450054
28097508	1552	1559	DEXCHNP	T073	C1450054
28097508	1577	1580	MTX	T109,T121	C0025677
28097508	1596	1606	i.p. route	T169	C1522583
28097508	1612	1615	DEX	T109,T121	C0011777
28097508	1628	1632	i.p.	T169	C1522583
28097508	1653	1668	nanocrystalline	T073	C1721058
28097508	1669	1681	biopolymeric	T116,T123	C0005554
28097508	1682	1695	nanoparticles	T073	C1450054
28097508	1701	1707	stable	T080	C0205360
28097508	1709	1722	biocompatible	T044	C0596177
28097508	1732	1741	potential	T080	C3245505
28097508	1769	1779	i.p. route	T169	C1522583
28097508	1793	1801	toxicity	T080	C0040539
28097508	1811	1819	efficacy	T080	C1280519

27473951|t|Assessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young children: study protocol for an individual participant data meta-analysis of randomised controlled trials
27473951|a|Disease incidence differs between males and females for some infectious or inflammatory diseases. Sex-differences in immune responses to some vaccines have also been observed, mostly to viral vaccines in adults. Little evidence is available on whether sex-differences occur in response to immunisation in infancy even though this is the age group in which most vaccines are administered. Factors other than sex, such as timing or coadministration of other vaccines, can also influence the immune response to vaccination. Individual participant data meta-analysis of randomised controlled trials of vaccines in healthy infants and young children will be conducted. Fully anonymised data from ∼170 randomised controlled trials of v accines for diphtheria, tetanus, Bordetella pertussis, polio, Haemophilus influenzae type B, hepatitis B, Streptococcus pneumoniae, Neisseria meningitidis, measles, mumps, rubella, varicella and rotavirus will be combined for analysis. Outcomes include measures of immunogenicity (immunoglobulins), reactogenicity, safety and disease -specific clinical efficacy. Data from trials of vaccines containing similar components will be combined in hierarchical models and the effect of sex and timing of vaccinations estimated for each outcome separately. Systematic reviews of published estimates of sex-differences cannot adequately answer questions in this field since such comparisons are never the main purpose of a clinical trial, thus a large degree of reporting bias exists in the published literature. Recent improvements in the widespread availability of individual participant data from randomised controlled trials makes it feasible to conduct extensive individual participant data meta-analyses which were previously impossible, thereby reducing the effect of publication or reporting bias on the understanding of the infant immune response. Preliminary results will be available in 2016 with final results available in 2019. No ethics review is required for secondary analyses of anonymised data.
27473951	0	9	Assessing	T052	C1516048
27473951	10	25	sex-differences	T032	C0036866
27473951	34	40	effect	T080	C1280500
27473951	44	50	timing	T079	C0449243
27473951	54	65	vaccination	T061	C0042196
27473951	69	83	immunogenicity	T038	C4277607
27473951	85	99	reactogenicity	T033	C1691781
27473951	104	124	efficacy of vaccines	T033	C3242199
27473951	128	133	young	T079	C0332239
27473951	134	142	children	T100	C0008059
27473951	144	158	study protocol	T170	C2348563
27473951	166	176	individual	T098	C0237401
27473951	177	188	participant	T098	C0679646
27473951	189	193	data	T078	C1511726
27473951	194	207	meta-analysis	T062	C0920317
27473951	211	239	randomised controlled trials	T062	C0206035
27473951	240	247	Disease	T047	C0012634
27473951	248	257	incidence	T081	C0021149
27473951	274	279	males	T032	C0086582
27473951	284	291	females	T032	C0086287
27473951	301	311	infectious	T047	C0009450
27473951	315	336	inflammatory diseases	T047	C1290884
27473951	338	353	Sex-differences	T032	C0036866
27473951	357	373	immune responses	T042	C0301872
27473951	382	390	vaccines	T121,T129	C0042210
27473951	426	440	viral vaccines	T121,T129	C0042742
27473951	444	450	adults	T100	C0001675
27473951	459	467	evidence	T078	C3887511
27473951	471	480	available	T169	C0470187
27473951	492	507	sex-differences	T032	C0036866
27473951	517	525	response	T033	C1704632
27473951	529	541	immunisation	T061	C0020971
27473951	545	552	infancy	T079	C0231330
27473951	577	586	age group	T100	C0027362
27473951	601	609	vaccines	T121,T129	C0042210
27473951	614	626	administered	T169	C1521801
27473951	628	635	Factors	T169	C1521761
27473951	647	650	sex	T032	C1522384
27473951	660	666	timing	T079	C0449243
27473951	670	686	coadministration	T061	C1533734
27473951	696	704	vaccines	T121,T129	C0042210
27473951	715	724	influence	T077	C4054723
27473951	729	744	immune response	T042	C0301872
27473951	748	759	vaccination	T061	C0042196
27473951	761	771	Individual	T098	C0237401
27473951	772	783	participant	T098	C0679646
27473951	784	788	data	T078	C1511726
27473951	789	802	meta-analysis	T062	C0920317
27473951	806	834	randomised controlled trials	T062	C0206035
27473951	838	846	vaccines	T121,T129	C0042210
27473951	858	865	infants	T100	C0021270
27473951	870	875	young	T079	C0332239
27473951	876	884	children	T100	C0008059
27473951	921	925	data	T078	C1511726
27473951	936	964	randomised controlled trials	T062	C0206035
27473951	970	977	accines	T121,T129	C0042210
27473951	982	992	diphtheria	T047	C0012546
27473951	994	1001	tetanus	T047	C0039614
27473951	1003	1023	Bordetella pertussis	T007	C0006017
27473951	1025	1030	polio	T047	C0032371
27473951	1032	1061	Haemophilus influenzae type B	T007	C0121772
27473951	1063	1074	hepatitis B	T047	C0019163
27473951	1076	1100	Streptococcus pneumoniae	T007	C0038410
27473951	1102	1124	Neisseria meningitidis	T007	C0027575
27473951	1126	1133	measles	T047	C0025007
27473951	1135	1140	mumps	T047	C0026780
27473951	1142	1149	rubella	T047	C0035920
27473951	1151	1160	varicella	T047	C0008049
27473951	1165	1174	rotavirus	T005	C0035870
27473951	1196	1204	analysis	T062	C0936012
27473951	1206	1214	Outcomes	T169	C1274040
27473951	1223	1231	measures	T169	C1879489
27473951	1235	1249	immunogenicity	T038	C4277607
27473951	1251	1266	immunoglobulins	T116,T129	C0021027
27473951	1269	1283	reactogenicity	T033	C1691781
27473951	1285	1291	safety	T068	C0036043
27473951	1296	1303	disease	T047	C0012634
27473951	1314	1331	clinical efficacy	T080	C3850123
27473951	1333	1337	Data	T078	C1511726
27473951	1343	1349	trials	T062	C0008976
27473951	1353	1361	vaccines	T121,T129	C0042210
27473951	1381	1391	components	T073	C0449432
27473951	1412	1424	hierarchical	T169	C0699032
27473951	1425	1431	models	T170	C3161035
27473951	1440	1446	effect	T080	C1280500
27473951	1450	1453	sex	T032	C1522384
27473951	1458	1464	timing	T079	C0449243
27473951	1468	1480	vaccinations	T061	C0042196
27473951	1500	1507	outcome	T169	C1274040
27473951	1520	1538	Systematic reviews	T170	C1955832
27473951	1542	1551	published	T057	C0034037
27473951	1565	1580	sex-differences	T032	C0036866
27473951	1599	1615	answer questions	T061	C0508431
27473951	1624	1629	field	T077	C1521738
27473951	1641	1652	comparisons	T052	C1707455
27473951	1672	1679	purpose	T169	C1285529
27473951	1685	1699	clinical trial	T062	C0008976
27473951	1708	1713	large	T081	C0549177
27473951	1714	1720	degree	T081	C0449286
27473951	1724	1733	reporting	T058	C0700287
27473951	1734	1738	bias	T078	C0242568
27473951	1739	1745	exists	T077	C2987476
27473951	1753	1762	published	T057	C0034037
27473951	1763	1773	literature	T170	C0023866
27473951	1782	1794	improvements	T077	C2986411
27473951	1802	1812	widespread	T082	C0205391
27473951	1813	1828	availability of	T169	C0470187
27473951	1829	1839	individual	T098	C0237401
27473951	1840	1851	participant	T098	C0679646
27473951	1852	1856	data	T078	C1511726
27473951	1862	1890	randomised controlled trials	T062	C0206035
27473951	1920	1929	extensive	T080	C0205231
27473951	1930	1940	individual	T098	C0237401
27473951	1941	1952	participant	T098	C0679646
27473951	1953	1957	data	T078	C1511726
27473951	1958	1971	meta-analyses	T062	C0920317
27473951	1983	1993	previously	T079	C0205156
27473951	1994	2004	impossible	T033	C0243095
27473951	2014	2022	reducing	T080	C0392756
27473951	2027	2033	effect	T080	C1280500
27473951	2037	2048	publication	T073,T170	C0034036
27473951	2052	2061	reporting	T058	C0700287
27473951	2062	2066	bias	T078	C0242568
27473951	2074	2087	understanding	T041	C0162340
27473951	2095	2101	infant	T100	C0021270
27473951	2102	2117	immune response	T042	C0301872
27473951	2119	2138	Preliminary results	T078	C1548161
27473951	2147	2156	available	T169	C0470187
27473951	2176	2183	results	T169	C1274040
27473951	2184	2193	available	T169	C0470187
27473951	2203	2205	No	T169	C0332197
27473951	2206	2212	ethics	T078	C0015000
27473951	2213	2219	review	T170	C0282443
27473951	2236	2254	secondary analyses	UnknownType	C0683944
27473951	2269	2273	data	T078	C1511726

28272254|t|Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis
28272254|a|Left ventricular hypertrophy (LVH) is commonly present in patients with hypertension (HT). According to the expert consensus document from American, angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blockers (ARBs) were recommended as 1st-line therapeutic drugs. However, none noticed the different efficacy between fat-soluble and selective β1-receptor blockers (FS-β-B) and other β-blockers on regression of LVH before. The aim of this analysis was to compare the efficacy of FS-β-B with the other 4 different classes of antihypertensive drugs (ACEI, ARBs, calcium channel blockers [CCBs], and diuretics) on regression of LVH. Relative trials were identified in the PubMed, Web of Science, OVID EBM Reviews and Cochrane databases, and the relevant papers were examined. We performed both traditional and Bayesian meta-analysis of randomized controlled trials (RCTs) about the regression of LVH. Sensitivity analysis and regression analysis were performed to explore possible sources of heterogeneity. Inconsistency analysis was performed to check whether the analysis of the trials in the network was indeed consistent. A total of 41 RCTs involving 2566 patients with HT and LVH were included in this analysis. Bayesian network meta-analysis indicated no statistically significant differences between these groups: FS-β-B and ACEI (MD, -7.09; 95% CI, -14.99, 1.27); FS-β-B and ARB (MD, -2.66; 95% Cl, -12.02, 6.31). Although FS-β-B showed greater efficacy when compared with diuretic (MD, 13.04; 95% CI, 3.38, 22.59) or CCB (MD, 10.90; 95% CI, 1.98, 19.49). The probabilities of being among the most efficacious treatments were: FS-β-B (72%), ARB (27%), ACEI (0.01%), CCB (0.00%), and diuretic (0.00%). Evidence from our analysis reveals that FS-β-B have potential to become 1st-line therapeutic drugs in HT and LVH patients. However, the real efficacy of FS-β-B on regression of LVH should be confirmed by further large, high quality trials considering the limitation of the study number.
28272254	13	23	β-blockers	T121	C0001645
28272254	27	37	regression	T046	C0597370
28272254	41	62	left ventricular mass	T033	C0455825
28272254	66	78	hypertension	T047	C0020538
28272254	79	87	patients	T101	C0030705
28272254	89	105	Bayesian network	T081,T170	C0026348
28272254	106	119	meta-analysis	T062	C0920317
28272254	120	148	Left ventricular hypertrophy	T047	C0149721
28272254	150	153	LVH	T047	C0149721
28272254	178	186	patients	T101	C0030705
28272254	192	204	hypertension	T047	C0020538
28272254	206	208	HT	T047	C0020538
28272254	228	253	expert consensus document	T170	C1301746
28272254	259	267	American	T098	C0596070
28272254	269	308	angiotensin-converting enzyme inhibitor	T121	C0003015
28272254	310	314	ACEI	T121	C0003015
28272254	320	349	angiotensin receptor blockers	T121	C0815017
28272254	351	355	ARBs	T121	C0815017
28272254	386	403	therapeutic drugs	T121	C0013227
28272254	441	449	efficacy	T080	C1280519
28272254	458	504	fat-soluble and selective β1-receptor blockers	T121	C0304516
28272254	506	512	FS-β-B	T121	C0304516
28272254	524	534	β-blockers	T121	C0001645
28272254	538	548	regression	T046	C0597370
28272254	552	555	LVH	T047	C0149721
28272254	580	588	analysis	T062	C0920317
28272254	596	603	compare	T052	C1707455
28272254	608	616	efficacy	T080	C1280519
28272254	620	626	FS-β-B	T121	C0304516
28272254	665	687	antihypertensive drugs	T121	C0003364
28272254	689	693	ACEI	T121	C0003015
28272254	695	699	ARBs	T121	C0815017
28272254	701	725	calcium channel blockers	T121	C0006684
28272254	727	731	CCBs	T121	C0006684
28272254	738	747	diuretics	T121	C0012798
28272254	752	762	regression	T046	C0597370
28272254	766	769	LVH	T047	C0149721
28272254	771	779	Relative	T080	C0205345
28272254	780	786	trials	T062	C0008976
28272254	810	816	PubMed	T170	C1138432
28272254	818	832	Web of Science	T170	C2349146
28272254	834	850	OVID EBM Reviews	T170	C0282443
28272254	855	873	Cochrane databases	T170	C0242356
28272254	892	898	papers	T170	C1706852
28272254	904	912	examined	T169	C1292732
28272254	948	956	Bayesian	T081,T170	C0026348
28272254	957	970	meta-analysis	T062	C0920317
28272254	974	1002	randomized controlled trials	T062	C0206035
28272254	1004	1008	RCTs	T062	C0206035
28272254	1020	1030	regression	T046	C0597370
28272254	1034	1037	LVH	T047	C0149721
28272254	1039	1059	Sensitivity analysis	T062	C0936012
28272254	1064	1083	regression analysis	T170	C0034980
28272254	1130	1143	heterogeneity	T080	C0019409
28272254	1145	1167	Inconsistency analysis	T062	C0936012
28272254	1203	1211	analysis	T062	C0920317
28272254	1219	1225	trials	T062	C0008976
28272254	1233	1240	network	T081,T170	C0026348
28272254	1252	1262	consistent	T078	C0332290
28272254	1278	1282	RCTs	T062	C0206035
28272254	1298	1306	patients	T101	C0030705
28272254	1312	1314	HT	T047	C0020538
28272254	1319	1322	LVH	T047	C0149721
28272254	1345	1353	analysis	T062	C0920317
28272254	1355	1371	Bayesian network	T081,T170	C0026348
28272254	1372	1385	meta-analysis	T062	C0920317
28272254	1399	1424	statistically significant	T081	C0237881
28272254	1451	1457	groups	T078	C0441833
28272254	1459	1465	FS-β-B	T121	C0304516
28272254	1470	1474	ACEI	T121	C0003015
28272254	1491	1493	CI	T081	C0009667
28272254	1510	1516	FS-β-B	T121	C0304516
28272254	1521	1524	ARB	T121	C0815017
28272254	1541	1543	Cl	T081	C0009667
28272254	1569	1575	FS-β-B	T121	C0304516
28272254	1591	1599	efficacy	T080	C1280519
28272254	1605	1613	compared	T052	C1707455
28272254	1619	1627	diuretic	T121	C0012798
28272254	1644	1646	CI	T081	C0009667
28272254	1664	1667	CCB	T121	C0006684
28272254	1684	1686	CI	T081	C0009667
28272254	1706	1719	probabilities	T081	C0033204
28272254	1744	1755	efficacious	T080	C1280519
28272254	1756	1766	treatments	T061	C0087111
28272254	1773	1779	FS-β-B	T121	C0304516
28272254	1787	1790	ARB	T121	C0815017
28272254	1798	1802	ACEI	T121	C0003015
28272254	1812	1815	CCB	T121	C0006684
28272254	1829	1837	diuretic	T121	C0012798
28272254	1865	1873	analysis	T062	C0920317
28272254	1887	1893	FS-β-B	T121	C0304516
28272254	1928	1945	therapeutic drugs	T121	C0013227
28272254	1949	1951	HT	T047	C0020538
28272254	1956	1959	LVH	T047	C0149721
28272254	1960	1968	patients	T101	C0030705
28272254	1988	1996	efficacy	T080	C1280519
28272254	2000	2006	FS-β-B	T121	C0304516
28272254	2010	2020	regression	T046	C0597370
28272254	2024	2027	LVH	T047	C0149721
28272254	2071	2078	quality	T080	C0332306
28272254	2079	2085	trials	T062	C0008976

27442784|t|Placental Pathologic Associations with Morbidly Adherent Placenta: Potential insights into Pathogenesis
27442784|a|The pathology that underlies morbidly adherent placenta (MAP) is poorly understood. The objective of this study was to describe the placental pathology, especially implantation site pathology, associated with MAP. This was a single institution, retrospective case-control study design examining placentas of patients who delivered between January 2008 and September 2013. MAP cases were defined by the need for clinical intervention at delivery beyond spontaneous placental delivery or simple manual extraction of the placenta. Controls consisted of patients with placentas sent for examination due to a history of maternal malignancy with no clinical suspicion of accreta. Placental pathologic findings of maternal vascular underperfusion (MVU), acute inflammation, chronic inflammation, fetal vascular obstruction and hemorrhage were recorded and compared using bivariable and multivariable analyses. Three categories of pathologic changes were seen more commonly in MAP placentas (N=101) than control placentas (N=110): chronic basal inflammation, villous changes of MVU and retromembranous and retromembranous / intervillous hemorrhage. In multivariable analyses adjusted for confounders, chronic basal villitis (aOR 5.6, 1.73-18.18), plasma cell deciduitis (aOR 2.63, 1.08-6.39), increased syncytial knots (aOR 3.92, 1.57-9.75), villous agglutination (aOR 24.85, 2.78-221.75), increased perivillous fibrin (aOR 5.08, 1.49-17.34), and the presence of subchorionic / intervillous thrombi (aOR 4.01, 1.63-9.86) remained associated with MAP. MAP is highly associated with evidence of intraparenchymal placental hemorrhage villous changes of MVU, and a lymphoplasmacytic infiltrate at the implantation site. The contribution of this basal chronic inflammatory infiltrate to MAP requires further investigation.
27442784	0	9	Placental	T018	C0032043
27442784	10	20	Pathologic	T169	C0205469
27442784	21	33	Associations	T080	C0439849
27442784	39	65	Morbidly Adherent Placenta	T046	C0405107
27442784	91	103	Pathogenesis	T046	C0699748
27442784	108	117	pathology	T169	C0205469
27442784	133	159	morbidly adherent placenta	T046	C0405107
27442784	161	164	MAP	T046	C0405107
27442784	236	245	placental	T018	C0032043
27442784	246	255	pathology	T169	C0205469
27442784	268	285	implantation site	T082	C0230992
27442784	286	295	pathology	T169	C0205469
27442784	297	312	associated with	T080	C0332281
27442784	313	316	MAP	T046	C0405107
27442784	329	335	single	T081	C0205171
27442784	336	347	institution	T093	C2607850
27442784	349	381	retrospective case-control study	T062	C0035363
27442784	399	408	placentas	T018	C0032043
27442784	412	420	patients	T101	C0030705
27442784	425	434	delivered	T033	C0566687
27442784	476	479	MAP	T046	C0405107
27442784	480	485	cases	T077	C1706256
27442784	515	523	clinical	T080	C0205210
27442784	524	536	intervention	T058	C1273869
27442784	540	548	delivery	T061	C0011209
27442784	556	567	spontaneous	T169	C0205359
27442784	568	586	placental delivery	T061	C0404381
27442784	597	614	manual extraction	T061	C0391874
27442784	622	630	placenta	T018	C0032043
27442784	632	640	Controls	T096	C0009932
27442784	654	662	patients	T101	C0030705
27442784	668	677	placentas	T018	C0032043
27442784	687	698	examination	T058	C0582103
27442784	708	715	history	T033	C0032967
27442784	719	727	maternal	T099	C0026591
27442784	728	738	malignancy	T191	C0006826
27442784	744	746	no	T033	C1513916
27442784	747	755	clinical	T080	C0205210
27442784	756	765	suspicion	T078	C0750491
27442784	769	776	accreta	T046	C0032044
27442784	778	787	Placental	T018	C0032043
27442784	788	807	pathologic findings	T033	C1317598
27442784	811	843	maternal vascular underperfusion	T047	C0012634
27442784	845	848	MVU	T047	C0012634
27442784	851	869	acute inflammation	T033	C0333361
27442784	871	891	chronic inflammation	T046	C0021376
27442784	893	898	fetal	T018	C0015965
27442784	899	919	vascular obstruction	T047	C1096458
27442784	924	934	hemorrhage	T046	C0019080
27442784	968	1005	bivariable and multivariable analyses	UnknownType	C0814907
27442784	1013	1023	categories	T170	C0683312
27442784	1027	1037	pathologic	T169	C0205469
27442784	1038	1045	changes	T169	C0392747
27442784	1073	1076	MAP	T046	C0405107
27442784	1077	1086	placentas	T018	C0032043
27442784	1100	1107	control	T096	C0009932
27442784	1108	1117	placentas	T018	C0032043
27442784	1127	1153	chronic basal inflammation	T046	C0021376
27442784	1163	1170	changes	T169	C0392747
27442784	1174	1177	MVU	T047	C0012634
27442784	1202	1217	retromembranous	T046	C0019080
27442784	1220	1243	intervillous hemorrhage	T046	C0269801
27442784	1248	1270	multivariable analyses	T081	C0026777
27442784	1284	1295	confounders	T169	C0009673
27442784	1297	1319	chronic basal villitis	T047	C1300128
27442784	1321	1324	aOR	T081	C0028873
27442784	1343	1365	plasma cell deciduitis	T033	C3899627
27442784	1367	1370	aOR	T081	C0028873
27442784	1389	1414	increased syncytial knots	T033	C3898771
27442784	1416	1419	aOR	T081	C0028873
27442784	1461	1464	aOR	T081	C0028873
27442784	1486	1514	increased perivillous fibrin	T033	C0243095
27442784	1516	1519	aOR	T081	C0028873
27442784	1559	1571	subchorionic	T046	C0087086
27442784	1574	1594	intervillous thrombi	T033	C3898711
27442784	1596	1599	aOR	T081	C0028873
27442784	1626	1641	associated with	T080	C0332281
27442784	1642	1645	MAP	T046	C0405107
27442784	1647	1650	MAP	T046	C0405107
27442784	1661	1676	associated with	T080	C0332281
27442784	1689	1726	intraparenchymal placental hemorrhage	T046	C0542014
27442784	1727	1734	villous	T080	C1519984
27442784	1735	1742	changes	T169	C0392747
27442784	1746	1749	MVU	T047	C0012634
27442784	1757	1785	lymphoplasmacytic infiltrate	T033	C1334467
27442784	1793	1810	implantation site	T082	C0230992
27442784	1837	1874	basal chronic inflammatory infiltrate	T033	C1333036
27442784	1878	1881	MAP	T046	C0405107

28454482|t|Effects of Environmental Factors and Metallic Electrodes on AC Electrical Conduction Through DNA Molecule
28454482|a|Deoxyribonucleic acid (DNA) is one of the best candidate materials for various device applications such as in electrodes for rechargeable batteries, biosensors, molecular electronics, medical - and biomedical - applications etc. Hence, it is worthwhile to examine the mechanism of charge transport in the DNA molecule, however, still a question without a clear answer is DNA a molecular conducting material (wire), semiconductor, or insulator? The answer, after the published data, is still ambiguous without any confirmed and clear scientific answer. DNA is found to be always surrounded with different electric charges, ions, and dipoles. These surrounding charges and electric barrier(s) due to metallic electrodes (as environmental factors (EFs)) play a substantial role when measuring the electrical conductivity through λ-double helix (DNA) molecule suspended between metallic electrodes. We found that strong frequency dependence of AC - complex conductivity comes from the electrical conduction of EFs. This leads to superimposing serious incorrect experimental data to measured ones. At 1 MHz, we carried out a first control experiment on electrical conductivity with and without the presence of DNA molecule. If there are possible electrical conduction due to stray ions and contribution of substrate, we will detected them. This control experiment revealed that there is an important role played by the environmental - charges around DNA molecule and any experiment should consider this role. We have succeeded to measure both electrical conductivity due to EFs (σ ENV) and electrical conductivity due to DNA molecule (σ DNA) independently by carrying the measurements at different DNA - lengths and subtracting the data. We carried out measurements as a function of frequency (f) and temperature (T) in the ranges 0.1 Hz < f < 1 MHz and 288 K < T < 343 K. The measured conductivity (σ MES) portrays a metal -like behavior at high frequencies near 1 MHz. However, we found that σ DNA was far from this behavior because the conduction due to EFs superimposes σ DNA, in particular at low frequencies. By measuring the electrical conductivity at different lengths: 40, 60, 80, and 100 nm, we have succeeded not only to separate the electrical conduction of the DNA molecule from all EFs effects that surround the molecule, but also to present accurate values of σ DNA and the dielectric constant of the molecule ε'DNA as a function of temperature and frequency. Furthermore, in order to explain these data, we present a model describing the electrical conduction through DNA molecule: DNA is a classical semiconductor with charges, dipoles and ions that result in creation of localized energy - states (LESs) in the extended bands and in the energy gap of the DNA molecule. This model explains clearly the mechanism of charge transfer mechanism in the DNA, and it sheds light on why the charge transfer through the DNA can lead to insulating, semiconducting, or metallic behavior on the same time. The model considers charges on DNA, in the extended bands, either could be free to move under electric field or localized in potential wells/hills. Localization of charges in DNA is an intrinsic structural - property of this solitaire molecule. At all temperatures, the expected increase in thermal - induced charge is attributed to the delocalization of holes (or/and electrons) in potential hills (or/and potential wells) which accurately accounts for the total electric and dielectric behavior through DNA molecule. We succeeded to fit the experiment al data to the proposed model with reasonable magnitudes of potential hills/wells that are in the energy range from 0.068 eV.
28454482	0	7	Effects	T080	C1280500
28454482	11	24	Environmental	T082	C0014406
28454482	25	32	Factors	T169	C1521761
28454482	37	45	Metallic	T197	C0025552
28454482	46	56	Electrodes	T074	C0013812
28454482	60	62	AC	T070	C0442830
28454482	63	84	Electrical Conduction	T081	C0013777
28454482	93	105	DNA Molecule	T114,T123	C0012854
28454482	106	133	Deoxyribonucleic acid (DNA)	T114,T123	C0012854
28454482	185	191	device	T073	C0699733
28454482	192	204	applications	T169	C4048755
28454482	216	226	electrodes	T074	C0013812
28454482	231	253	rechargeable batteries	T073	C0337088
28454482	255	265	biosensors	T075	C0600364
28454482	267	288	molecular electronics	T074	C0025080
28454482	290	297	medical	T074	C0025080
28454482	304	314	biomedical	T074	C0025080
28454482	317	329	applications	T169	C4048755
28454482	387	403	charge transport	T070	C0563548
28454482	411	423	DNA molecule	T114,T123	C0012854
28454482	477	480	DNA	T114,T123	C0012854
28454482	483	492	molecular	T080	C1521991
28454482	493	503	conducting	T070	C0457405
28454482	504	512	material	T167	C0520510
28454482	514	518	wire	T073	C1705105
28454482	521	534	semiconductor	T073	C0036623
28454482	539	548	insulator	T073	C3273359
28454482	658	661	DNA	T114,T123	C0012854
28454482	710	726	electric charges	T070	C0563548
28454482	728	732	ions	T196	C0022023
28454482	738	745	dipoles	UnknownType	C0813981
28454482	765	772	charges	T070	C0563548
28454482	777	796	electric barrier(s)	T073	C3273359
28454482	804	812	metallic	T197	C0025552
28454482	813	823	electrodes	T074	C0013812
28454482	828	841	environmental	T082	C0014406
28454482	842	849	factors	T169	C1521761
28454482	851	854	EFs	T169	C1521761
28454482	886	895	measuring	T080	C0444706
28454482	886	895	measuring	T080	C0444706
28454482	900	923	electrical conductivity	T081	C0013777
28454482	932	961	λ-double helix (DNA) molecule	T114,T123	C0012854
28454482	980	988	metallic	T197	C0025552
28454482	989	999	electrodes	T074	C0013812
28454482	1015	1021	strong	T080	C0442821
28454482	1022	1031	frequency	T079	C0439603
28454482	1046	1048	AC	T070	C0442830
28454482	1051	1058	complex	T080	C0439855
28454482	1059	1071	conductivity	T081	C0013777
28454482	1087	1108	electrical conduction	T067	C2747877
28454482	1112	1115	EFs	T169	C1521761
28454482	1163	1175	experimental	T062	C0681814
28454482	1184	1192	measured	T080	C0444706
28454482	1240	1250	experiment	T062	C0681814
28454482	1254	1277	electrical conductivity	T081	C0013777
28454482	1311	1323	DNA molecule	T114,T123	C0012854
28454482	1347	1368	electrical conduction	T081	C0013777
28454482	1382	1386	ions	T196	C0022023
28454482	1454	1464	experiment	T062	C0681814
28454482	1520	1533	environmental	T082	C0014406
28454482	1536	1543	charges	T070	C0563548
28454482	1551	1563	DNA molecule	T114,T123	C0012854
28454482	1572	1582	experiment	T062	C0681814
28454482	1631	1638	measure	T081	C0079809
28454482	1644	1667	electrical conductivity	T081	C0013777
28454482	1675	1678	EFs	T169	C1521761
28454482	1691	1714	electrical conductivity	T081	C0013777
28454482	1722	1734	DNA molecule	T114,T123	C0012854
28454482	1736	1741	σ DNA	T114,T123	C0012854
28454482	1773	1785	measurements	T169	C0242485
28454482	1799	1802	DNA	T114,T123	C0012854
28454482	1805	1812	lengths	T081	C1444754
28454482	1854	1866	measurements	T169	C0242485
28454482	1884	1897	frequency (f)	T079	C0376249
28454482	1902	1917	temperature (T)	T081	C0039476
28454482	1978	1986	measured	T080	C0444706
28454482	1987	1999	conductivity	T081	C0013777
28454482	2019	2024	metal	T197	C0025552
28454482	2043	2059	high frequencies	T079	C0205212
28454482	2095	2100	σ DNA	T114,T123	C0012854
28454482	2140	2150	conduction	T070	C0457405
28454482	2158	2161	EFs	T169	C1521761
28454482	2175	2180	σ DNA	T114,T123	C0012854
28454482	2199	2214	low frequencies	T079	C0205213
28454482	2219	2228	measuring	T080	C0444706
28454482	2233	2256	electrical conductivity	T081	C0013777
28454482	2270	2277	lengths	T081	C1444754
28454482	2346	2367	electrical conduction	T067	C2747877
28454482	2375	2387	DNA molecule	T114,T123	C0012854
28454482	2397	2400	EFs	T169	C1521761
28454482	2427	2435	molecule	T114,T123	C0012854
28454482	2476	2481	σ DNA	T114,T123	C0012854
28454482	2490	2509	dielectric constant	UnknownType	C0813980
28454482	2526	2531	ε'DNA	T114,T123	C0012854
28454482	2655	2676	electrical conduction	T067	C2747877
28454482	2685	2697	DNA molecule	T114,T123	C0012854
28454482	2699	2702	DNA	T114,T123	C0012854
28454482	2718	2731	semiconductor	T073	C0036623
28454482	2737	2744	charges	T070	C0563548
28454482	2746	2753	dipoles	UnknownType	C0813981
28454482	2758	2762	ions	T196	C0022023
28454482	2790	2799	localized	T169	C0475264
28454482	2800	2806	energy	T081	C1442080
28454482	2809	2815	states	T169	C1442792
28454482	2856	2866	energy gap	T070	C0013790
28454482	2874	2886	DNA molecule	T114,T123	C0012854
28454482	2933	2958	charge transfer mechanism	T070	C1254365
28454482	2966	2969	DNA	T114,T123	C0012854
28454482	3001	3016	charge transfer	T070	C1254365
28454482	3029	3032	DNA	T114,T123	C0012854
28454482	3045	3055	insulating	T070	C0457405
28454482	3057	3071	semiconducting	T070	C0457405
28454482	3076	3084	metallic	T197	C0025552
28454482	3132	3139	charges	T070	C0563548
28454482	3143	3146	DNA	T114,T123	C0012854
28454482	3206	3220	electric field	T070	C0337037
28454482	3237	3258	potential wells/hills	T082	C1254362
28454482	3260	3272	Localization	T169	C0475264
28454482	3276	3283	charges	T070	C0563548
28454482	3287	3290	DNA	T114,T123	C0012854
28454482	3297	3306	intrinsic	T169	C0439674
28454482	3307	3317	structural	T082	C0678594
28454482	3320	3328	property	T080	C0871161
28454482	3403	3410	thermal	T070	C0018837
28454482	3413	3420	induced	T169	C0205263
28454482	3421	3427	charge	T070	C0563548
28454482	3449	3472	delocalization of holes	T070	C1254365
28454482	3481	3490	electrons	T196	C0013852
28454482	3495	3510	potential hills	T082	C1254362
28454482	3519	3535	potential wells)	T082	C1254362
28454482	3576	3584	electric	T081	C0392762
28454482	3589	3608	dielectric behavior	T081	C0596437
28454482	3617	3629	DNA molecule	T114,T123	C0012854
28454482	3655	3665	experiment	T062	C0681814
28454482	3726	3747	potential hills/wells	T082	C1254362
28454482	3764	3770	energy	T081	C1442080

27865242|t|A study on knowledge and awareness about tuberculosis in senior school children in Bangalore, India
27865242|a|Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M. tuberculosis), commonly affecting the lungs. All health care professionals including the pharmacists provide a valuable public health role in promoting community awareness of TB particularly in reducing stigma attached to TB. Thus, creating awareness at a community level could play a vital role in control and prevention of TB. To determine whether educational intervention would affect the level of TB awareness among students of selected schools and pre-university colleges (PUCs) in Bangalore urban and Bangalore rural regions. The present study was conducted among the students of 8th, 9th, 10th and PUC in Bangalore rural and urban jurisdiction (n=2635). A questionnaire was designed in English and Kannada language, consisting of 20 questions with multiple-choice answers. A 30- minute visual health education was given on TB in English, followed by general pictorial presentation, and the data were collected as pre-test and post-test. Data collected from 2635 participants during pre - and post - education session revealed that mean score improved from 8.77±2.59 to 14.95±1.99. Impact of the education session showed a significant knowledge improvement about TB from 1.59% (pre - education) to 49.67% (post - education). The present study clearly demonstrated that a simple, 30- minute health education session did have a positive impact on knowledge and awareness about TB among school children as observed with increase in mean knowledge score from pre-test to post-test, indicating that empowerment of students could guide the community on various aspects of TB.
27865242	2	7	study	T062	C2603343
27865242	11	20	knowledge	T170	C0376554
27865242	25	34	awareness	T041	C0004448
27865242	41	53	tuberculosis	T047	C0041296
27865242	57	79	senior school children	T100	C0260267
27865242	83	92	Bangalore	T083	C0017446
27865242	94	99	India	T083	C0021201
27865242	100	112	Tuberculosis	T047	C0041296
27865242	114	116	TB	T047	C0041296
27865242	124	142	infectious disease	T047	C0009450
27865242	153	179	Mycobacterium tuberculosis	T007	C0026926
27865242	181	196	M. tuberculosis	T007	C0026926
27865242	208	217	affecting	T169	C0392760
27865242	222	227	lungs	T023	C0024109
27865242	233	258	health care professionals	T097	C0018724
27865242	273	284	pharmacists	T097	C0031323
27865242	304	322	public health role	T058	C0034024
27865242	326	335	promoting	T052	C0033414
27865242	336	345	community	T096	C0009462
27865242	346	355	awareness	T041	C0004448
27865242	359	361	TB	T047	C0041296
27865242	378	386	reducing	T080	C0392756
27865242	387	393	stigma	T033	C0277787
27865242	406	408	TB	T047	C0041296
27865242	425	434	awareness	T041	C0004448
27865242	440	455	community level	T096	C0009462
27865242	469	479	vital role	T077	C1705810
27865242	483	490	control	T169	C2587213
27865242	495	505	prevention	T080	C2700409
27865242	509	511	TB	T047	C0041296
27865242	534	558	educational intervention	T061	C0281163
27865242	565	571	affect	T041	C0001721
27865242	576	581	level	T080	C0441889
27865242	585	587	TB	T047	C0041296
27865242	588	597	awareness	T041	C0004448
27865242	604	612	students	T098	C0038492
27865242	616	624	selected	T052	C1707391
27865242	625	632	schools	T073,T092	C0036375
27865242	637	660	pre-university colleges	T073	C0557806
27865242	662	666	PUCs	T073	C0557806
27865242	671	686	Bangalore urban	T083	C0017446
27865242	691	700	Bangalore	T083	C0017446
27865242	701	714	rural regions	T082	C0178837
27865242	728	733	study	T062	C2603343
27865242	758	766	students	T098	C0038492
27865242	789	792	PUC	T073	C0557806
27865242	796	805	Bangalore	T083	C0017446
27865242	806	811	rural	T082	C0178837
27865242	816	821	urban	T083	C0442529
27865242	822	834	jurisdiction	T170	C0680647
27865242	847	860	questionnaire	T170	C0034394
27865242	865	873	designed	T052	C1707689
27865242	877	884	English	T171	C0376245
27865242	889	905	Kannada language	T171	C0574287
27865242	924	933	questions	T078	C0681799
27865242	939	954	multiple-choice	T052	C1707391
27865242	955	962	answers	T170	C1706817
27865242	970	976	minute	T079	C0439232
27865242	977	983	visual	T169	C0234621
27865242	984	1000	health education	T065	C0018701
27865242	1014	1016	TB	T047	C0041296
27865242	1020	1027	English	T171	C0376245
27865242	1049	1071	pictorial presentation	T170	C0600666
27865242	1081	1085	data	T078	C1511726
27865242	1091	1100	collected	T169	C1516698
27865242	1104	1112	pre-test	T079	C1254367
27865242	1117	1126	post-test	T079	C1254367
27865242	1128	1132	Data	T078	C1511726
27865242	1133	1142	collected	T169	C1516698
27865242	1153	1165	participants	T098	C0679646
27865242	1173	1176	pre	T079	C0332152
27865242	1183	1187	post	T079	C0687676
27865242	1190	1199	education	T065	C0018701
27865242	1200	1207	session	T077	C1883017
27865242	1208	1216	revealed	T080	C0443289
27865242	1222	1232	mean score	T033	C3533236
27865242	1233	1241	improved	T033	C0184511
27865242	1272	1278	Impact	T080	C4049986
27865242	1286	1295	education	T065	C0018701
27865242	1296	1303	session	T077	C1883017
27865242	1325	1334	knowledge	T170	C0376554
27865242	1335	1346	improvement	T077	C2986411
27865242	1353	1355	TB	T047	C0041296
27865242	1368	1371	pre	T079	C0332152
27865242	1374	1383	education	T065	C0018701
27865242	1396	1400	post	T079	C0687676
27865242	1403	1412	education	T065	C0018701
27865242	1427	1432	study	T062	C2603343
27865242	1473	1479	minute	T079	C0439232
27865242	1480	1496	health education	T065	C0018701
27865242	1497	1504	session	T077	C1883017
27865242	1516	1524	positive	T033	C1446409
27865242	1525	1531	impact	T080	C4049986
27865242	1535	1544	knowledge	T170	C0376554
27865242	1549	1558	awareness	T041	C0004448
27865242	1565	1567	TB	T047	C0041296
27865242	1574	1589	school children	T100	C0260267
27865242	1593	1601	observed	T169	C1441672
27865242	1607	1615	increase	T169	C0442805
27865242	1619	1639	mean knowledge score	T081	C0392762
27865242	1645	1653	pre-test	T079	C1254367
27865242	1657	1666	post-test	T079	C1254367
27865242	1684	1695	empowerment	T054	C0679959
27865242	1699	1707	students	T098	C0038492
27865242	1724	1733	community	T096	C0009462
27865242	1756	1758	TB	T047	C0041296

28166607|t|Recombinant fibrinogen reveals the differential roles of α- and γ-chain cross-linking and molecular heterogeneity in fibrin clot strain-stiffening
28166607|a|Essentials Fibrinogen circulates in human plasma as a complex mixture of heterogeneous molecular variants. We measured strain-stiffening of recombinantly produced fibrinogen upon clotting. Factor XIII and molecular heterogeneity alter clot elasticity at the protofibril and fiber level. This highlights the hitherto unknown role of molecular composition in fibrin clot mechanics. Background Fibrin plays a crucial role in haemostasis and wound healing by forming strain-stiffening fibrous networks that reinforce blood clots. The molecular origin of fibrin's strain-stiffening behavior remains poorly understood, primarily because plasma fibrinogen is a complex mixture of heterogeneous molecular variants and is often contaminated by plasma factors that affect clot properties. Objectives and methods To facilitate mechanistic dissection of fibrin nonlinear elasticity, we produced a homogeneous recombinant fibrinogen corresponding to the main variant in human plasma, termed rFib610. We characterized the structure of rFib610 clots using turbidimetry, microscopy and X-ray scattering. We used rheology to measure the strain-stiffening behavior of the clots and determined the fiber properties by modeling the clots as semi-flexible polymer networks. Results We show that addition of FXIII to rFib610 clots causes a dose-dependent stiffness increase at small deformations and renders the strain-stiffening response reversible. We find that γ-chain cross-linking contributes to clot elasticity by changing the force-extension behavior of the protofibrils, whereas α-chain cross-linking stiffens the fibers, as a consequence of tighter coupling between the constituent protofibrils. Interestingly, rFib610 protofibrils have a 25% larger bending rigidity than plasma -purified fibrin protofibrils and a delayed strain-stiffening, indicating that molecular heterogeneity influences clot mechanics at the protofibril scale. Conclusions Fibrinogen molecular heterogeneity and FXIII affect the mechanical function of fibrin clots by altering the nonlinear viscoelastic properties at the protofibril and fiber scale. This work provides a starting point to investigate the role of molecular heterogeneity of plasma fibrinogen in fibrin clot mechanics and haemostasis.
28166607	0	11	Recombinant	T116	C0034861
28166607	12	22	fibrinogen	T116,T121,T123	C0016006
28166607	35	47	differential	T080	C1705242
28166607	57	59	α-	T116,T123	C0033684
28166607	64	71	γ-chain	T116,T123	C0033684
28166607	72	85	cross-linking	T044	C0314675
28166607	90	99	molecular	T080	C1521991
28166607	100	113	heterogeneity	T080	C0019409
28166607	117	128	fibrin clot	T044	C3156338
28166607	129	146	strain-stiffening	T070	C0013764
28166607	158	168	Fibrinogen	T116,T121,T123	C0016006
28166607	169	179	circulates	T169	C0175630
28166607	183	188	human	T016	C0086418
28166607	189	195	plasma	T031	C0032105
28166607	201	208	complex	T104	C1704241
28166607	209	216	mixture	T167	C0439962
28166607	220	233	heterogeneous	T080	C0019409
28166607	234	243	molecular	T080	C1521991
28166607	244	252	variants	T080	C0205419
28166607	257	265	measured	T080	C0444706
28166607	266	283	strain-stiffening	T070	C0013764
28166607	287	300	recombinantly	T045	C0034865
28166607	310	320	fibrinogen	T116,T121,T123	C0016006
28166607	326	334	clotting	T042	C0005778
28166607	336	347	Factor XIII	T116,T121,T126	C0015528
28166607	352	361	molecular	T080	C1521991
28166607	362	375	heterogeneity	T080	C0019409
28166607	382	386	clot	T044	C3156338
28166607	387	397	elasticity	T070	C0013764
28166607	405	416	protofibril	T116,T121,T123	C0015982
28166607	421	426	fiber	T024	C1304649
28166607	479	488	molecular	T080	C1521991
28166607	489	500	composition	T080	C0205198
28166607	504	515	fibrin clot	T044	C3156338
28166607	516	525	mechanics	T070	C0376706
28166607	538	544	Fibrin	T116,T121,T123	C0015982
28166607	569	580	haemostasis	T042	C0019116
28166607	585	598	wound healing	T040	C0043240
28166607	610	627	strain-stiffening	T070	C0013764
28166607	628	644	fibrous networks	T026	C0243092
28166607	660	671	blood clots	T046	C0302148
28166607	677	686	molecular	T080	C1521991
28166607	697	705	fibrin's	T116,T121,T123	C0015982
28166607	706	723	strain-stiffening	T070	C0013764
28166607	778	784	plasma	T031	C0032105
28166607	785	795	fibrinogen	T116,T121,T123	C0016006
28166607	801	808	complex	T104	C1704241
28166607	809	816	mixture	T167	C0439962
28166607	820	833	heterogeneous	T080	C0019409
28166607	834	843	molecular	T080	C1521991
28166607	844	852	variants	T080	C0205419
28166607	882	896	plasma factors	T116,T123	C0033684
28166607	909	913	clot	T044	C3156338
28166607	914	924	properties	T080	C0871161
28166607	963	985	mechanistic dissection	T169	C0205245
28166607	989	995	fibrin	T116,T121,T123	C0015982
28166607	996	1016	nonlinear elasticity	T070	C0013764
28166607	1032	1043	homogeneous	T080	C1881065
28166607	1044	1055	recombinant	T116	C0034861
28166607	1056	1066	fibrinogen	T116,T121,T123	C0016006
28166607	1093	1100	variant	T080	C0205419
28166607	1104	1109	human	T016	C0086418
28166607	1110	1116	plasma	T031	C0032105
28166607	1125	1132	rFib610	T116,T121,T123	C0016006
28166607	1155	1164	structure	T082	C0678594
28166607	1168	1175	rFib610	T116,T121,T123	C0016006
28166607	1176	1181	clots	T044	C3156338
28166607	1188	1200	turbidimetry	T059	C0041394
28166607	1202	1212	microscopy	T059	C0026018
28166607	1217	1233	X-ray scattering	T059	C0043301
28166607	1243	1251	rheology	T059	C0599706
28166607	1255	1262	measure	T081	C0079809
28166607	1267	1284	strain-stiffening	T070	C0013764
28166607	1301	1306	clots	T044	C3156338
28166607	1326	1331	fiber	T024	C1304649
28166607	1332	1342	properties	T080	C0871161
28166607	1346	1354	modeling	T062	C0870071
28166607	1359	1364	clots	T044	C3156338
28166607	1368	1398	semi-flexible polymer networks	T169	C1882071
28166607	1433	1438	FXIII	T116,T121,T126	C0015528
28166607	1442	1449	rFib610	T116,T121,T123	C0016006
28166607	1450	1455	clots	T044	C3156338
28166607	1465	1489	dose-dependent stiffness	T080	C0018599
28166607	1508	1520	deformations	T169	C0333067
28166607	1537	1554	strain-stiffening	T070	C0013764
28166607	1589	1596	γ-chain	T116,T123	C0033684
28166607	1597	1610	cross-linking	T044	C0314675
28166607	1626	1630	clot	T044	C3156338
28166607	1631	1641	elasticity	T070	C0013764
28166607	1658	1682	force-extension behavior	T169	C0205245
28166607	1690	1702	protofibrils	T116,T121,T123	C0015982
28166607	1712	1719	α-chain	T116,T123	C0033684
28166607	1720	1733	cross-linking	T044	C0314675
28166607	1747	1753	fibers	T024	C1304649
28166607	1775	1791	tighter coupling	T169	C1948027
28166607	1816	1828	protofibrils	T116,T121,T123	C0015982
28166607	1845	1852	rFib610	T116,T121,T123	C0016006
28166607	1853	1865	protofibrils	T116,T121,T123	C0015982
28166607	1884	1900	bending rigidity	T080	C0018599
28166607	1906	1912	plasma	T031	C0032105
28166607	1923	1929	fibrin	T116,T121,T123	C0015982
28166607	1930	1942	protofibrils	T116,T121,T123	C0015982
28166607	1957	1974	strain-stiffening	T070	C0013764
28166607	1992	2001	molecular	T080	C1521991
28166607	2002	2015	heterogeneity	T080	C0019409
28166607	2016	2026	influences	T077	C4054723
28166607	2027	2031	clot	T044	C3156338
28166607	2032	2041	mechanics	T070	C0376706
28166607	2049	2066	protofibril scale	T116,T121,T123	C0015982
28166607	2080	2090	Fibrinogen	T116,T121,T123	C0016006
28166607	2091	2100	molecular	T080	C1521991
28166607	2101	2114	heterogeneity	T080	C0019409
28166607	2119	2124	FXIII	T116,T121,T126	C0015528
28166607	2136	2155	mechanical function	T169	C0542341
28166607	2159	2171	fibrin clots	T044	C3156338
28166607	2188	2221	nonlinear viscoelastic properties	T080	C0871161
28166607	2229	2240	protofibril	T026	C0230898
28166607	2245	2256	fiber scale	T024	C1304649
28166607	2297	2308	investigate	T169	C1292732
28166607	2321	2330	molecular	T080	C1521991
28166607	2331	2344	heterogeneity	T080	C0019409
28166607	2348	2354	plasma	T031	C0032105
28166607	2355	2365	fibrinogen	T116,T121,T123	C0016006
28166607	2369	2380	fibrin clot	T044	C3156338
28166607	2381	2390	mechanics	T070	C0376706
28166607	2395	2406	haemostasis	T042	C0019116

27866833|t|TP53 and 53BP1 Reunited
27866833|a|Identified as a TP53 - binding protein, 53BP1 is a key regulator of the cellular response to double-strand breaks, a TP53 -independent activity. Recent data have established a new TP53 -dependent function for 53BP1 in mitotic surveillance after centrosome loss.
27866833	0	4	TP53	T116,T123	C0080055
27866833	9	14	53BP1	T116,T123	C2982393
27866833	40	44	TP53	T116,T123	C0080055
27866833	47	62	binding protein	T116,T123	C0012940
27866833	64	69	53BP1	T116,T123	C2982393
27866833	79	88	regulator	T028	C0017362
27866833	96	137	cellular response to double-strand breaks	T043	C1155291
27866833	141	145	TP53	T116,T123	C0080055
27866833	159	167	activity	T043	C0007613
27866833	204	208	TP53	T116,T123	C0080055
27866833	220	228	function	T043	C0007613
27866833	233	238	53BP1	T116,T123	C2982393
27866833	242	262	mitotic surveillance	T043	C0026255
27866833	269	279	centrosome	T026	C0242608
27866833	280	284	loss	T081	C1517945

28247230|t|Update from the 4th Edition of the World Health Organization of Head and Neck Tumours: Tumours of the Oral Cavity and Mobile Tongue
28247230|a|There have been several additions and deletions in Chapter 4 on Tumours of the oral cavity and mobile tongue in the 2017 fourth edition of the World Health Organization Classification of Tumours of the Head and Neck. This chapter excludes the oropharynx, which now is a stand-alone chapter acknowledging the uniqueness of the oropharynx from the oral cavity. New entries in Chapter 4 include rhabdomyoma, haemangioma, schwannoma, neurofibroma and myofibroblastic sarcoma in the section titled Soft tissue and neural tumours. Discussion of salivary gland entities have been reduced and includes mucoepidermoid carcinoma and pleomorphic adenoma as the other salivary gland types are discussed elsewhere. In the Haematolymphoid tumours section, like the salivary gland section, only tumors that commonly present in the oral cavity are discussed in Chapter 4. Excluded entities in the updated classification include papillary hyperplasia, median rhomboid glossitis, keratoacanthoma, focal oral mucinosis, and secondary tumors. This article will summarize the changes in the new classification since the 2005 edition focusing on selected entities that have had significant changes along with new entries.
28247230	0	6	Update	T079	C1519814
28247230	16	60	4th Edition of the World Health Organization	T093	C0043237
28247230	64	85	Head and Neck Tumours	T191	C0018671
28247230	87	94	Tumours	T191	C0027651
28247230	102	113	Oral Cavity	T030	C0226896
28247230	118	131	Mobile Tongue	T023	C0040408
28247230	170	179	deletions	T052	C1880274
28247230	183	192	Chapter 4	T078	C1552857
28247230	196	203	Tumours	T191	C0027651
28247230	211	222	oral cavity	T030	C0226896
28247230	227	240	mobile tongue	T023	C0040408
28247230	260	267	edition	T170	C0441792
28247230	275	315	World Health Organization Classification	T170	C1301142
28247230	319	347	Tumours of the Head and Neck	T191	C0018671
28247230	375	385	oropharynx	T191	C0029295
28247230	402	421	stand-alone chapter	T170	C0005990
28247230	440	450	uniqueness	T080	C1710548
28247230	458	468	oropharynx	T191	C0029295
28247230	478	489	oral cavity	T030	C0226896
28247230	506	515	Chapter 4	T078	C1552857
28247230	524	535	rhabdomyoma	T191	C0035411
28247230	537	548	haemangioma	T191	C0018916
28247230	550	560	schwannoma	T191	C0027809
28247230	562	574	neurofibroma	T191	C0027830
28247230	579	602	myofibroblastic sarcoma	T191	C0334121
28247230	625	636	Soft tissue	T024	C0225317
28247230	641	655	neural tumours	T191	C0027858
28247230	671	685	salivary gland	T023	C0036098
28247230	705	712	reduced	T080	C0392756
28247230	717	725	includes	T052	C2700399
28247230	726	750	mucoepidermoid carcinoma	T191	C0206694
28247230	755	774	pleomorphic adenoma	T191	C0026277
28247230	788	808	salivary gland types	T023	C0036098
28247230	841	864	Haematolymphoid tumours	T191	C0598798
28247230	883	897	salivary gland	T023	C0036098
28247230	912	918	tumors	T191	C0027651
28247230	924	940	commonly present	T033	C0150312
28247230	948	959	oral cavity	T030	C0226896
28247230	977	986	Chapter 4	T078	C1552857
28247230	1021	1035	classification	T170	C1301142
28247230	1044	1065	papillary hyperplasia	T046	C0333984
28247230	1067	1092	median rhomboid glossitis	T019	C0155963
28247230	1094	1109	keratoacanthoma	T191	C0022572
28247230	1111	1131	focal oral mucinosis	T047	C0546384
28247230	1137	1153	secondary tumors	T191	C0027627
28247230	1206	1220	classification	T170	C1301142

27821359|t|Pupillary response abnormalities in depressive disorders
27821359|a|Depressive disorders lack objective physiological measurements to characterize the affected population and facilitate study of relevant mechanisms. The melanopsin - mediated light signaling pathway may contribute to seasonal variation and can be measured non-invasively by pupillometry. We prospectively studied changes in melanopsin - mediated pupillary constriction in 19 participants with major depressive disorder (MDD) and 10 control across the summer and winter solstices. The melanopsin - mediated response, as measured by the pupil's sustained constriction six s after a high intensity blue light stimulus, was marginally attenuated in those with MDD relative to controls (p =0.071). The participants with MDD unexpectedly showed a significantly reduced transient pupillary response to low intensity red (p =0.011) and blue light (p =0.013), but not high intensity red and blue light. Sustained pupillary constriction in response to high intensity blue light was more pronounced with increasing daylight hours (p =0.037) and was more strongly related to objectively measured versus estimated light exposure. Melanopsin - mediated impairments in pupil response may serve as a biological marker for vulnerability to depression in low light conditions. Assessment of these and other responses to light stimuli, such as response to low intensity light, may be useful for the study of the neurobiology of MDD and related mood disorders.
27821359	0	18	Pupillary response	T040	C4067879
27821359	19	32	abnormalities	T033	C1704258
27821359	36	56	depressive disorders	T048	C0011581
27821359	57	77	Depressive disorders	T048	C0011581
27821359	78	82	lack	T080	C0332268
27821359	83	92	objective	T080	C1571702
27821359	93	106	physiological	T169	C0205463
27821359	107	119	measurements	T169	C0242485
27821359	123	135	characterize	T052	C1880022
27821359	140	159	affected population	T201	C4285581
27821359	175	180	study	T062	C0008972
27821359	184	192	relevant	T080	C2347946
27821359	193	203	mechanisms	T169	C0441712
27821359	209	219	melanopsin	T116	C0670514
27821359	222	230	mediated	T041	C0870868
27821359	231	254	light signaling pathway	T044	C0037080
27821359	273	291	seasonal variation	T079	C0036496
27821359	303	311	measured	T080	C0444706
27821359	330	342	pupillometry	T060	C0260180
27821359	347	368	prospectively studied	T062	C0033522
27821359	380	390	melanopsin	T116	C0670514
27821359	393	401	mediated	T041	C0870868
27821359	402	424	pupillary constriction	T042	C3537108
27821359	431	443	participants	T101	C0030705
27821359	449	474	major depressive disorder	T048	C1269683
27821359	476	479	MDD	T048	C1269683
27821359	488	495	control	T096	C0009932
27821359	507	534	summer and winter solstices	T079	C1254367
27821359	540	550	melanopsin	T116	C0670514
27821359	553	570	mediated response	T041	C0870868
27821359	575	583	measured	T080	C0444706
27821359	591	621	pupil's sustained constriction	T033	C0728710
27821359	636	650	high intensity	UnknownType	C0683109
27821359	651	661	blue light	T070	C0303896
27821359	662	670	stimulus	T067	C0234402
27821359	687	697	attenuated	T052	C0599946
27821359	712	715	MDD	T048	C1269683
27821359	728	736	controls	T096	C0009932
27821359	738	739	p	T081	C1709380
27821359	753	765	participants	T101	C0030705
27821359	771	774	MDD	T048	C1269683
27821359	797	810	significantly	T078	C0750502
27821359	811	818	reduced	T080	C0392756
27821359	819	828	transient	T079	C0205374
27821359	829	847	pupillary response	T040	C4067879
27821359	851	864	low intensity	UnknownType	C0683108
27821359	865	868	red	T070	C0563227
27821359	870	871	p	T081	C1709380
27821359	884	894	blue light	T070	C0303896
27821359	896	897	p	T081	C1709380
27821359	915	929	high intensity	UnknownType	C0683109
27821359	930	933	red	T070	C0563227
27821359	938	948	blue light	T070	C0303896
27821359	960	982	pupillary constriction	T042	C3537108
27821359	986	994	response	T040	C4067879
27821359	998	1012	high intensity	UnknownType	C0683109
27821359	1013	1023	blue light	T070	C0303896
27821359	1049	1059	increasing	T169	C0442808
27821359	1060	1068	daylight	T070	C0023693
27821359	1069	1074	hours	T079	C0439227
27821359	1076	1077	p	T081	C1709380
27821359	1119	1130	objectively	T080	C1571702
27821359	1131	1139	measured	T080	C0444706
27821359	1147	1156	estimated	T081	C0750572
27821359	1157	1171	light exposure	T051	C1689916
27821359	1173	1183	Melanopsin	T116	C0670514
27821359	1186	1194	mediated	T041	C0870868
27821359	1195	1206	impairments	T169	C0221099
27821359	1210	1224	pupil response	T040	C4067879
27821359	1240	1257	biological marker	T201	C0005516
27821359	1262	1275	vulnerability	T033	C1821973
27821359	1279	1289	depression	T048	C0011570
27821359	1293	1302	low light	UnknownType	C0683108
27821359	1303	1313	conditions	T080	C0348080
27821359	1315	1325	Assessment	T058	C0220825
27821359	1345	1354	responses	T032	C0871261
27821359	1358	1363	light	T070	C0023693
27821359	1364	1371	stimuli	T067	C0234402
27821359	1381	1389	response	T032	C0871261
27821359	1393	1412	low intensity light	UnknownType	C0683108
27821359	1436	1441	study	T062	C0008972
27821359	1449	1461	neurobiology	T091	C0027817
27821359	1465	1468	MDD	T048	C1269683
27821359	1481	1495	mood disorders	T048	C0525045

27908539|t|Design, synthesis, molecular docking, anti-Proteus mirabilis and urease inhibition of new fluoroquinolone carboxylic acid derivatives
27908539|a|New hydroxamic acid, hydrazide and amide derivatives of ciprofloxacin in addition to their analogues of levofloxacin were prepared and identified by different spectroscopic techniques. Some of the prepared compounds revealed good activity against the urease splitting bacteria, Proteus mirabilis. The urease inhibitory activity was investigated using indophenol method. Most of the tested compounds showed better activity than the reference acetohydroxamic acid (AHA). The ciprofloxacin hydrazide derivative 3a and levofloxacin hydroxamic acid 7 experienced the highest activity (IC50 =1.22μM and 2.20μM, respectively). Molecular docking study revealed high spontaneous binding ability of the tested compounds to the active site of urease.
27908539	0	6	Design	T052	C1707689
27908539	8	17	synthesis	T052	C1883254
27908539	19	36	molecular docking	T170	C3494274
27908539	38	60	anti-Proteus mirabilis	T195	C0279516
27908539	65	71	urease	T116,T126	C0041945
27908539	72	82	inhibition	T039	C1524081
27908539	90	133	fluoroquinolone carboxylic acid derivatives	T121	C1254351
27908539	138	153	hydroxamic acid	T109	C0020314
27908539	155	164	hydrazide	T109	C0682951
27908539	169	186	amide derivatives	T109	C0002482
27908539	190	203	ciprofloxacin	T109,T121	C0008809
27908539	225	234	analogues	T104	C0243071
27908539	238	250	levofloxacin	T109,T195	C0282386
27908539	293	317	spectroscopic techniques	T169	C0449851
27908539	340	349	compounds	T121	C1254351
27908539	364	372	activity	T040	C2248397
27908539	385	391	urease	T116,T126	C0041945
27908539	402	410	bacteria	T007	C0004611
27908539	412	429	Proteus mirabilis	T007	C0033701
27908539	435	441	urease	T116,T126	C0041945
27908539	442	461	inhibitory activity	T040	C2248397
27908539	485	502	indophenol method	T059	C1318795
27908539	516	522	tested	T170	C0392366
27908539	523	532	compounds	T121	C1254351
27908539	547	555	activity	T040	C2248397
27908539	575	595	acetohydroxamic acid	T109,T121	C0050451
27908539	597	600	AHA	T109,T121	C0050451
27908539	607	644	ciprofloxacin hydrazide derivative 3a	T121	C1254351
27908539	649	679	levofloxacin hydroxamic acid 7	T121	C1254351
27908539	704	712	activity	T040	C2248397
27908539	714	718	IC50	T081	C0600495
27908539	754	777	Molecular docking study	T170	C3494274
27908539	804	819	binding ability	T044	C1167622
27908539	827	833	tested	T170	C0392366
27908539	834	843	compounds	T121	C1254351
27908539	851	862	active site	T169	C0205681
27908539	866	872	urease	T116,T126	C0041945

27782044|t|Normal Levels of Urinary CC16 Protein. Comments on Beamer et al. Association of Children's Urinary CC16 Levels with Arsenic Concentrations in Multiple Environmental Media. Int. J. Environ. Res. Public Health 2016, 13, 521
27782044|a|In 1937, Max Clara described a new type of cell in the human lung, which was later determined to be an exocrine secretory cell type containing granules composed of proteins [1].[...].
27782044	0	13	Normal Levels	T080	C0441889
27782044	17	24	Urinary	T031	C0042036
27782044	25	37	CC16 Protein	T116,T121	C1505089
27782044	39	76	Comments on Beamer et al. Association	T170	C0282574
27782044	80	90	Children's	T100	C0008059
27782044	91	98	Urinary	T031	C0042036
27782044	99	103	CC16	T116,T121	C1505089
27782044	104	110	Levels	T059	C0262923
27782044	116	138	Arsenic Concentrations	T059	C0373548
27782044	142	170	Multiple Environmental Media	T077	C1254372
27782044	231	240	Max Clara	T016	C0086418
27782044	265	269	cell	T025	C0007634
27782044	277	282	human	T016	C0086418
27782044	283	287	lung	T023	C0024109
27782044	325	373	exocrine secretory cell type containing granules	T026	C0230676
27782044	386	394	proteins	T116,T123	C0033684

28213926|t|Association of Hypercalcemia Before Treatment With Hypocalcemia After Treatment in Dogs With Primary Hyperparathyroidism
28213926|a|Development of hypocalcemia after treatment of hyperparathyroidism results in increased costs and risk of poorer outcomes. Previous studies have shown conflicting data about predictors of hypocalcemia after these procedures. The objective of this study was to investigate whether ionized calcium (iCa) concentrations before treatment are predictive of hypocalcemia or its clinical signs after surgical removal or heat ablation in dogs with primary hyperparathyroidism. Fifty-four dogs with primary hyperparathyroidism (29 female, 25 male; 49 retrospective, 5 prospective). Dogs were enrolled if they met the inclusion criteria: persistent hypercalcemia (iCa >1.41 mmol/L) due to primary hyperparathyroidism and absence of preemptive calcitriol treatment. All dogs were treated with parathyroidectomy (n = 37) or percutaneous ultrasound-guided heat ablation (n = 17). After treatment, iCa was monitored twice daily until plateau or intervention. There was a moderate correlation between before - treatment hypercalcemia and after-treatment hypocalcemia. The prospective study was terminated due to ethical concerns given findings in the retrospective section. All dogs were placed into groups according to their pretreatment iCa: 1.46-1.61 mmol/L, 1.62-1.71 mmol/L, iCa 1.72-1.81 mmol/L, or >1.81 mmol/L. After treatment, the mean lowest iCa for each group, respectively, was 1.19, 1.18, 1.13, and 1.01 mmol/L. There was a significant association between higher group and proportion of dogs with iCa <1.00 mmol/L (P = .014). This study demonstrates a moderate correlation between iCa concentration before treatment and hypocalcemia after treatment. Dogs with higher initial iCa concentrations should be treated to prevent rapid decline and development of clinical hypocalcemia.
28213926	0	11	Association	T080	C0439849
28213926	15	28	Hypercalcemia	T047	C0020437
28213926	29	35	Before	T079	C0332152
28213926	36	45	Treatment	T061	C0087111
28213926	51	63	Hypocalcemia	T047	C0020598
28213926	64	79	After Treatment	T058	C0001758
28213926	83	87	Dogs	T015	C0012984
28213926	93	120	Primary Hyperparathyroidism	T047	C0221002
28213926	121	132	Development	T169	C1527148
28213926	136	148	hypocalcemia	T047	C0020598
28213926	149	164	after treatment	T058	C0001758
28213926	168	187	hyperparathyroidism	T047	C0221002
28213926	188	195	results	T169	C1274040
28213926	199	208	increased	T081	C0205217
28213926	209	214	costs	T081	C0010186
28213926	219	223	risk	T078	C0035647
28213926	227	242	poorer outcomes	T033	C3806166
28213926	253	260	studies	T062	C2603343
28213926	272	283	conflicting	T033	C4061765
28213926	284	288	data	T078	C1511726
28213926	295	305	predictors	T078	C2698872
28213926	309	321	hypocalcemia	T047	C0020598
28213926	334	344	procedures	T169	C2700391
28213926	350	359	objective	T170	C0018017
28213926	368	373	study	T062	C2603343
28213926	381	392	investigate	T169	C1292732
28213926	401	416	ionized calcium	T123,T196	C0373561
28213926	418	421	iCa	T123,T196	C0373561
28213926	423	437	concentrations	T081	C1446561
28213926	438	444	before	T079	C0332152
28213926	445	454	treatment	T061	C0087111
28213926	459	469	predictive	T080	C0681890
28213926	473	485	hypocalcemia	T047	C0020598
28213926	493	507	clinical signs	T033	C3540840
28213926	514	530	surgical removal	T061	C0728940
28213926	534	547	heat ablation	T061	C0547070
28213926	551	555	dogs	T015	C0012984
28213926	561	588	primary hyperparathyroidism	T047	C0221002
28213926	601	605	dogs	T015	C0012984
28213926	611	638	primary hyperparathyroidism	T047	C0221002
28213926	643	649	female	T032	C0086287
28213926	654	658	male	T032	C0086582
28213926	663	676	retrospective	T080	C1514923
28213926	680	691	prospective	T058	C0184820
28213926	694	698	Dogs	T015	C0012984
28213926	729	747	inclusion criteria	T080	C1512693
28213926	749	759	persistent	T079	C0205322
28213926	760	773	hypercalcemia	T047	C0020437
28213926	775	778	iCa	T123,T196	C0373561
28213926	800	827	primary hyperparathyroidism	T047	C0221002
28213926	832	839	absence	T169	C0332197
28213926	843	853	preemptive	T080	C1456501
28213926	854	864	calcitriol	T109,T121,T127	C0006674
28213926	865	874	treatment	T061	C0087111
28213926	880	884	dogs	T015	C0012984
28213926	903	920	parathyroidectomy	T061	C0079989
28213926	933	945	percutaneous	T082	C0522523
28213926	946	977	ultrasound-guided heat ablation	T061	C2315106
28213926	988	1003	After treatment	T058	C0001758
28213926	1005	1008	iCa	T123,T196	C0373561
28213926	1013	1022	monitored	T058	C1283169
28213926	1041	1048	plateau	T081	C2964353
28213926	1052	1064	intervention	T061	C0184661
28213926	1078	1086	moderate	T080	C0205081
28213926	1087	1098	correlation	T080	C1707520
28213926	1107	1113	before	T079	C0332152
28213926	1116	1125	treatment	T061	C0087111
28213926	1126	1139	hypercalcemia	T047	C0020437
28213926	1144	1159	after-treatment	T058	C0001758
28213926	1160	1172	hypocalcemia	T047	C0020598
28213926	1178	1195	prospective study	T062	C0033522
28213926	1200	1210	terminated	T169	C2348570
28213926	1218	1234	ethical concerns	T078	C0086264
28213926	1241	1249	findings	T033	C0243095
28213926	1257	1270	retrospective	T080	C1514923
28213926	1284	1288	dogs	T015	C0012984
28213926	1306	1312	groups	T078	C0441833
28213926	1332	1344	pretreatment	T052	C3539076
28213926	1345	1348	iCa	T123,T196	C0373561
28213926	1386	1389	iCa	T123,T196	C0373561
28213926	1425	1440	After treatment	T058	C0001758
28213926	1446	1450	mean	T081	C2348143
28213926	1451	1457	lowest	T080	C1708760
28213926	1458	1461	iCa	T123,T196	C0373561
28213926	1471	1476	group	T078	C0441833
28213926	1543	1554	significant	T078	C0750502
28213926	1555	1566	association	T080	C0439849
28213926	1575	1581	higher	T080	C0205250
28213926	1582	1587	group	T078	C0441833
28213926	1592	1602	proportion	T081	C1709707
28213926	1606	1610	dogs	T015	C0012984
28213926	1616	1619	iCa	T123,T196	C0373561
28213926	1650	1655	study	T062	C2603343
28213926	1671	1679	moderate	T080	C0205081
28213926	1680	1691	correlation	T080	C1707520
28213926	1700	1703	iCa	T123,T196	C0373561
28213926	1704	1717	concentration	T081	C1446561
28213926	1718	1724	before	T079	C0332152
28213926	1725	1734	treatment	T061	C0087111
28213926	1739	1751	hypocalcemia	T047	C0020598
28213926	1752	1767	after treatment	T058	C0001758
28213926	1769	1773	Dogs	T015	C0012984
28213926	1779	1785	higher	T080	C0205250
28213926	1794	1797	iCa	T123,T196	C0373561
28213926	1798	1812	concentrations	T081	C1446561
28213926	1842	1855	rapid decline	T033	C2750110
28213926	1860	1871	development	T169	C1527148
28213926	1875	1883	clinical	T080	C0205210
28213926	1884	1896	hypocalcemia	T047	C0020598

28420030|t|Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline
28420030|a|1 ESGE / EASL recommend that, as the primary diagnostic modality for PSC, magnetic resonance cholangiography (MRC) should be preferred over endoscopic retrograde cholangiopancreatography (ERCP). Moderate quality evidence, strong recommendation. 2 ESGE / EASL suggest that ERCP can be considered if MRC plus liver biopsy is equivocal or contraindicated in patients with persisting clinical suspicion of PSC. The risks of ERCP have to be weighed against the potential benefit with regard to surveillance and treatment recommendations. Low quality evidence, weak recommendation. 6 ESGE / EASL suggest that, in patients with an established diagnosis of PSC, MRC should be considered before therapeutic ERCP. Weak recommendation, low quality evidence. 7 ESGE / EASL suggest performing endoscopic treatment with concomitant ductal sampling (brush cytology, endobiliary biopsies) of suspected significant strictures identified at MRC in PSC patients who present with symptoms likely to improve following endoscopic treatment. Strong recommendation, low quality evidence. 9 ESGE / EASL recommend weighing the anticipated benefits of biliary papillotomy / sphincterotomy against its risks on a case-by-case basis. Strong recommendation, moderate quality evidence. Biliary papillotomy / sphincterotomy should be considered especially after difficult cannulation. Strong recommendation, low quality evidence. 16 ESGE / EASL suggest routine administration of prophylactic antibiotics before ERCP in patients with PSC. Strong recommendation, low quality evidence. 17 EASL / ESGE recommend that cholangiocarcinoma (CCA) should be suspected in any patient with worsening cholestasis, weight loss, raised serum CA19-9, and/or new or progressive dominant stricture, particularly with an associated enhancing mass lesion. Strong recommendation, moderate quality evidence. 19 ESGE / EASL recommend ductal sampling (brush cytology, endobiliary biopsies) as part of the initial investigation for the diagnosis and staging of suspected CCA in patients with PSC. Strong recommendation, high quality evidence.
28420030	8	17	endoscopy	T060	C0014245
28420030	21	51	primary sclerosing cholangitis	T047	C0566602
28420030	53	99	European Society of Gastrointestinal Endoscopy	T093	C1708333
28420030	101	105	ESGE	T093	C1708333
28420030	111	158	European Association for the Study of the Liver	T093	C1708333
28420030	160	164	EASL	T093	C1708333
28420030	166	184	Clinical Guideline	T170	C0282451
28420030	187	191	ESGE	T093	C1708333
28420030	194	198	EASL	T093	C1708333
28420030	222	229	primary	T080	C0205225
28420030	230	240	diagnostic	T060	C0430022
28420030	241	249	modality	T078	C0695347
28420030	254	257	PSC	T047	C0566602
28420030	259	293	magnetic resonance cholangiography	T060	C1697842
28420030	295	298	MRC	T060	C1697842
28420030	325	371	endoscopic retrograde cholangiopancreatography	T060	C0008310
28420030	373	377	ERCP	T060	C0008310
28420030	380	388	Moderate	T080	C0205081
28420030	389	396	quality	T080	C0332306
28420030	397	405	evidence	T078	C3887511
28420030	407	413	strong	T080	C0442821
28420030	414	428	recommendation	T170	C1545264
28420030	432	436	ESGE	T093	C1708333
28420030	439	443	EASL	T093	C1708333
28420030	457	461	ERCP	T060	C0008310
28420030	483	486	MRC	T060	C1697842
28420030	492	504	liver biopsy	T060	C0193388
28420030	508	517	equivocal	T080	C0332241
28420030	521	536	contraindicated	T033	C0420587
28420030	540	548	patients	T101	C0030705
28420030	574	583	suspicion	T033	C0243095
28420030	587	590	PSC	T047	C0566602
28420030	596	601	risks	T078	C0035647
28420030	605	609	ERCP	T060	C0008310
28420030	641	650	potential	T080	C3245505
28420030	651	658	benefit	T081	C0814225
28420030	674	686	surveillance	T058	C0700325
28420030	691	700	treatment	T061	C0087111
28420030	701	716	recommendations	T170	C1545264
28420030	718	721	Low	T080	C0205251
28420030	722	729	quality	T080	C0332306
28420030	730	738	evidence	T078	C3887511
28420030	740	744	weak	T080	C1762617
28420030	745	759	recommendation	T170	C1545264
28420030	763	767	ESGE	T093	C1708333
28420030	770	774	EASL	T093	C1708333
28420030	792	800	patients	T101	C0030705
28420030	809	830	established diagnosis	T080	C0332139
28420030	834	837	PSC	T047	C0566602
28420030	839	842	MRC	T060	C1697842
28420030	871	882	therapeutic	T061	C0087111
28420030	883	887	ERCP	T060	C0008310
28420030	889	893	Weak	T080	C1762617
28420030	894	908	recommendation	T170	C1545264
28420030	910	913	low	T080	C0205251
28420030	914	921	quality	T080	C0332306
28420030	922	930	evidence	T078	C3887511
28420030	934	938	ESGE	T093	C1708333
28420030	941	945	EASL	T093	C1708333
28420030	965	975	endoscopic	T060	C0014245
28420030	976	985	treatment	T061	C0087111
28420030	991	1002	concomitant	T079	C0521115
28420030	1003	1009	ductal	T023	C0005400
28420030	1010	1018	sampling	T078	C0870078
28420030	1020	1034	brush cytology	T074	C0490961
28420030	1036	1056	endobiliary biopsies	T074	C1737508
28420030	1061	1070	suspected	T080	C0332147
28420030	1071	1082	significant	T078	C0750502
28420030	1083	1093	strictures	T190	C0597984
28420030	1108	1111	MRC	T060	C1697842
28420030	1115	1118	PSC	T047	C0566602
28420030	1119	1127	patients	T101	C0030705
28420030	1145	1153	symptoms	T184	C1457887
28420030	1164	1171	improve	T033	C0184511
28420030	1182	1192	endoscopic	T060	C0014245
28420030	1193	1202	treatment	T061	C0087111
28420030	1204	1210	Strong	T080	C0442821
28420030	1211	1225	recommendation	T170	C1545264
28420030	1227	1230	low	T080	C0205251
28420030	1231	1238	quality	T080	C0332306
28420030	1239	1247	evidence	T078	C3887511
28420030	1251	1255	ESGE	T093	C1708333
28420030	1258	1262	EASL	T093	C1708333
28420030	1263	1272	recommend	T170	C1545264
28420030	1286	1297	anticipated	T033	C3840775
28420030	1298	1306	benefits	T081	C0814225
28420030	1310	1329	biliary papillotomy	T061	C0085263
28420030	1332	1346	sphincterotomy	T061	C0948386
28420030	1359	1364	risks	T078	C0035647
28420030	1390	1396	Strong	T080	C0442821
28420030	1397	1411	recommendation	T170	C1545264
28420030	1413	1421	moderate	T080	C0205081
28420030	1422	1429	quality	T080	C0332306
28420030	1430	1438	evidence	T078	C3887511
28420030	1440	1459	Biliary papillotomy	T061	C0085263
28420030	1462	1476	sphincterotomy	T061	C0948386
28420030	1515	1524	difficult	T080	C0332218
28420030	1525	1536	cannulation	T061	C0917707
28420030	1538	1544	Strong	T080	C0442821
28420030	1545	1559	recommendation	T170	C1545264
28420030	1561	1564	low	T080	C0205251
28420030	1565	1572	quality	T080	C0332306
28420030	1573	1581	evidence	T078	C3887511
28420030	1586	1590	ESGE	T093	C1708333
28420030	1593	1597	EASL	T093	C1708333
28420030	1606	1628	routine administration	T061	C0204888
28420030	1632	1656	prophylactic antibiotics	T061	C0508354
28420030	1657	1663	before	T079	C0332152
28420030	1664	1668	ERCP	T060	C0008310
28420030	1672	1680	patients	T101	C0030705
28420030	1686	1689	PSC	T047	C0566602
28420030	1691	1697	Strong	T080	C0442821
28420030	1698	1712	recommendation	T170	C1545264
28420030	1714	1717	low	T080	C0205251
28420030	1718	1725	quality	T080	C0332306
28420030	1726	1734	evidence	T078	C3887511
28420030	1739	1743	EASL	T093	C1708333
28420030	1746	1750	ESGE	T093	C1708333
28420030	1751	1760	recommend	T170	C1545264
28420030	1766	1784	cholangiocarcinoma	T191	C0206698
28420030	1786	1789	CCA	T191	C0206698
28420030	1801	1810	suspected	T047	C0277540
28420030	1818	1825	patient	T101	C0030705
28420030	1831	1840	worsening	T033	C1820858
28420030	1841	1852	cholestasis	T047	C0008370
28420030	1854	1865	weight loss	T046	C2911645
28420030	1867	1873	raised	T080	C0442818
28420030	1874	1879	serum	T031	C0229671
28420030	1880	1886	CA19-9	T059	C0201551
28420030	1895	1898	new	T080	C0205314
28420030	1902	1913	progressive	T169	C0205329
28420030	1914	1922	dominant	T169	C1527180
28420030	1923	1932	stricture	T190	C0597984
28420030	1966	1975	enhancing	T052	C2349975
28420030	1976	1987	mass lesion	T191	C0746408
28420030	1989	1995	Strong	T080	C0442821
28420030	1996	2010	recommendation	T170	C1545264
28420030	2012	2020	moderate	T080	C0205081
28420030	2021	2028	quality	T080	C0332306
28420030	2029	2037	evidence	T078	C3887511
28420030	2042	2046	ESGE	T093	C1708333
28420030	2049	2053	EASL	T093	C1708333
28420030	2054	2063	recommend	T170	C1545264
28420030	2064	2070	ductal	T023	C0005400
28420030	2071	2079	sampling	T078	C0870078
28420030	2081	2095	brush cytology	T074	C0490961
28420030	2097	2117	endobiliary biopsies	T074	C1737508
28420030	2134	2141	initial	T079	C0205265
28420030	2142	2155	investigation	T058	C0220825
28420030	2164	2173	diagnosis	T033	C0011900
28420030	2178	2185	staging	T060	C0027646
28420030	2189	2198	suspected	T047	C0277540
28420030	2199	2202	CCA	T191	C0206698
28420030	2206	2214	patients	T101	C0030705
28420030	2220	2223	PSC	T047	C0566602
28420030	2225	2231	Strong	T080	C0442821
28420030	2232	2246	recommendation	T170	C1545264
28420030	2248	2252	high	T080	C0205250
28420030	2253	2260	quality	T080	C0332306
28420030	2261	2269	evidence	T078	C3887511

27858503|t|High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients
27858503|a|Extracellular vesicles (EVs) contain a wide range of RNA types with a reported prevalence of non-coding RNA. To date a comprehensive characterization of the protein coding transcripts in EVs is still lacking. We performed RNA-Sequencing (RNA-Seq) of 2 EV populations and identified a small fraction of transcripts that were expressed at significantly different levels in large oncosomes and exosomes, suggesting they may mediate specialized functions. However, these 2 EV populations exhibited a common mRNA signature that, in comparison to their donor cells, was significantly enriched in mRNAs encoding E2F transcriptional targets and histone proteins. These mRNAs are primarily expressed in the S-phase of the cell cycle, suggesting that they may be packaged into EVs during S-phase. In silico analysis using subcellular compartment transcriptome data from the ENCODE cell line compendium revealed that EV mRNAs originate from a cytoplasmic RNA pool. The EV signature was independently identified in plasma of patients with breast cancer by RNA-Seq. Furthermore, several transcripts differentially expressed in EVs from patients versus controls mirrored differential expression between normal and breast cancer tissues. Altogether, this largest high-throughput profiling of EV mRNA demonstrates that EVs carry tumor-specific alterations and can be interrogated as a source of cancer-derived cargo.
27858503	0	26	High-throughput sequencing	T063	C2936623
27858503	49	71	extracellular vesicles	T026	C3894683
27858503	84	88	mRNA	T114,T123	C0035696
27858503	89	98	signature	T169	C1704864
27858503	142	155	breast cancer	T191	C0678222
27858503	156	164	patients	T101	C0030705
27858503	165	187	Extracellular vesicles	T026	C3894683
27858503	189	192	EVs	T026	C3894683
27858503	218	221	RNA	T114	C0035668
27858503	258	272	non-coding RNA	T114	C0887909
27858503	298	314	characterization	T052	C1880022
27858503	322	348	protein coding transcripts	T114	C1519595
27858503	352	355	EVs	T026	C3894683
27858503	387	401	RNA-Sequencing	T062	C1328904
27858503	403	410	RNA-Seq	T062	C1328904
27858503	417	431	EV populations	T026	C3894683
27858503	467	478	transcripts	T114	C1519595
27858503	489	498	expressed	T045	C1515670
27858503	542	551	oncosomes	T026	C0243092
27858503	556	564	exosomes	T026	C2350332
27858503	606	615	functions	T043	C0007613
27858503	634	648	EV populations	T026	C3894683
27858503	668	672	mRNA	T114,T123	C0035696
27858503	673	682	signature	T169	C1704864
27858503	712	723	donor cells	T025	C0007634
27858503	755	760	mRNAs	T114,T123	C0035696
27858503	770	797	E2F transcriptional targets	T116,T123	C0146462
27858503	802	818	histone proteins	T116,T123	C0019652
27858503	826	831	mRNAs	T114,T123	C0035696
27858503	846	855	expressed	T045	C1515670
27858503	863	870	S-phase	T079	C0080129
27858503	878	888	cell cycle	T043	C0007586
27858503	932	935	EVs	T026	C3894683
27858503	943	950	S-phase	T079	C0080129
27858503	952	961	In silico	T066	C3489666
27858503	962	970	analysis	T062	C0936012
27858503	977	1000	subcellular compartment	T026	C0729605
27858503	1001	1014	transcriptome	T086	C3178810
27858503	1015	1019	data	T078	C1511726
27858503	1029	1035	ENCODE	T170	C0282574
27858503	1036	1045	cell line	T025	C0007600
27858503	1071	1073	EV	T026	C3894683
27858503	1074	1079	mRNAs	T114,T123	C0035696
27858503	1097	1117	cytoplasmic RNA pool	T114	C2827481
27858503	1123	1125	EV	T026	C3894683
27858503	1126	1135	signature	T169	C1704864
27858503	1168	1174	plasma	T031	C0032105
27858503	1178	1186	patients	T101	C0030705
27858503	1192	1205	breast cancer	T191	C0678222
27858503	1209	1216	RNA-Seq	T062	C1328904
27858503	1239	1250	transcripts	T114	C1519595
27858503	1266	1275	expressed	T045	C1515670
27858503	1279	1282	EVs	T026	C3894683
27858503	1288	1296	patients	T101	C0030705
27858503	1335	1345	expression	T045	C1515670
27858503	1354	1360	normal	T023	C0444070
27858503	1365	1386	breast cancer tissues	T023	C0444070
27858503	1413	1438	high-throughput profiling	T063	C2936623
27858503	1442	1444	EV	T026	C3894683
27858503	1445	1449	mRNA	T114,T123	C0035696
27858503	1468	1471	EVs	T026	C3894683
27858503	1478	1504	tumor-specific alterations	T045	C0026882
27858503	1544	1564	cancer-derived cargo	T044	C1519628

27884163|t|Chronic adiponectin deficiency leads to Alzheimer's disease -like cognitive impairments and pathologies through AMPK inactivation and cerebral insulin resistance in aged mice
27884163|a|Insulin resistance is the major pathogenesis underlying type 2 diabetes mellitus (T2DM) and these patients have doubled risk of Alzheimer's disease (AD). Increasing evidence suggests that insulin resistance plays an important role in AD pathogenesis, possibly due to abnormal GSK3β activation, causing intra- and extracellular amyloid-beta (Aβ) accumulation. Adiponectin (APN) is an adipokine with insulin-sensitizing and anti-inflammatory effects. Reduced circulatory APN level is associated with insulin resistance and T2DM. The role of APN in AD has not been elucidated. In this study, we aim to examine if adiponectin deficiency would lead to cerebral insulin resistance, cognitive decline and Alzheimer's-like pathology in mice. To study the role of adiponectin in cognitive functions, we employed adiponectin-knockout (APN-KO) mice and demonstrated chronic APN deficiency in their CNS. Behavioral tests were performed to study the cognitions of male APN-KO mice. Brains and tissue lysates were collected to study the pathophysiological and molecular changes in the brain of APN-KO mice. SH-SY5Y neuroblastoma cell line was used to study the molecular mechanism upon APN and insulin treatment. Aged APN -deficient mice displayed spatial memory and learning impairments, fear-conditioned memory deficit as well as anxiety. These mice also developed AD pathologies including increased cerebral Aβ42 level, Aβ deposition, hyperphosphorylated Tau proteins, microgliosis and astrogliosis with increased cerebral IL-1β and TNFα levels that associated with increased neuronal apoptosis and reduced synaptic proteins levels, suggesting APN deficiency may lead to neuronal and synaptic loss in the brain. AD pathologies -associated APN - KO mice displayed attenuated AMPK phosphorylation and impaired insulin signaling including decreased Akt induction and increased GSK3β activation in the hippocampus and frontal cortex. Aged APN -KO mice developed hippocampal insulin resistance with reduced pAkt induction upon intracerebral insulin injection. Consistently, APN treatment in SH-SY5Y cells with insulin resistance and overexpressing Aβ induce higher pAkt levels through AdipoR1 upon insulin treatment whereas the induction was blocked by compound C, indicating APN can enhance neuronal insulin sensitivity through AMPK activation. Our results indicated that chronic APN deficiency inactivated AMPK causing insulin desensitization and elicited AD-like pathogenesis in aged mice which also developed significant cognitive impairments and psychiatric symptoms.
27884163	0	7	Chronic	T079	C0205191
27884163	8	30	adiponectin deficiency	T047	C2675518
27884163	40	59	Alzheimer's disease	T047	C0002395
27884163	66	87	cognitive impairments	T048	C0338656
27884163	92	103	pathologies	T091	C0030664
27884163	112	116	AMPK	T116,T126	C2350345
27884163	134	142	cerebral	T023	C0006104
27884163	143	161	insulin resistance	T046	C0021655
27884163	165	169	aged	T032	C0001779
27884163	170	174	mice	T015	C0026809
27884163	175	193	Insulin resistance	T046	C0021655
27884163	207	219	pathogenesis	T046	C0699748
27884163	231	255	type 2 diabetes mellitus	T047	C0011860
27884163	257	261	T2DM	T047	C0011860
27884163	273	281	patients	T101	C0030705
27884163	295	299	risk	T078	C0035647
27884163	303	322	Alzheimer's disease	T047	C0002395
27884163	324	326	AD	T047	C0002395
27884163	363	381	insulin resistance	T046	C0021655
27884163	412	424	pathogenesis	T046	C0699748
27884163	451	456	GSK3β	T116,T126	C0244989
27884163	457	467	activation	T044	C0014429
27884163	477	483	intra-	T026	C0175996
27884163	488	501	extracellular	T026	C0521119
27884163	502	514	amyloid-beta	T116	C3484390
27884163	516	518	Aβ	T116	C3484390
27884163	534	545	Adiponectin	T116,T123	C0389071
27884163	547	550	APN	T116,T123	C0389071
27884163	558	567	adipokine	T116,T123	C1955907
27884163	597	622	anti-inflammatory effects	T080	C1515999
27884163	644	647	APN	T116,T123	C0389071
27884163	673	691	insulin resistance	T046	C0021655
27884163	696	700	T2DM	T047	C0011860
27884163	714	717	APN	T116,T123	C0389071
27884163	721	723	AD	T047	C0002395
27884163	757	762	study	T062	C2603343
27884163	785	807	adiponectin deficiency	T047	C2675518
27884163	785	807	adiponectin deficiency	T047	C2675518
27884163	822	830	cerebral	T023	C0006104
27884163	831	849	insulin resistance	T046	C0021655
27884163	851	868	cognitive decline	T048	C0338656
27884163	873	899	Alzheimer's-like pathology	T046	C0699748
27884163	903	907	mice	T015	C0026809
27884163	912	917	study	T062	C2603343
27884163	930	941	adiponectin	T116,T123	C0389071
27884163	945	964	cognitive functions	T041	C0392335
27884163	978	998	adiponectin-knockout	T050	C1522225
27884163	999	1012	(APN-KO) mice	T015	C0206745
27884163	1030	1037	chronic	T079	C0205191
27884163	1038	1052	APN deficiency	T047	C2675518
27884163	1062	1065	CNS	T022	C3714787
27884163	1067	1083	Behavioral tests	T060	C0683444
27884163	1102	1107	study	T062	C2603343
27884163	1112	1122	cognitions	T041	C0009240
27884163	1126	1130	male	T032	C0086582
27884163	1131	1142	APN-KO mice	T015	C0206745
27884163	1144	1150	Brains	T023	C0006104
27884163	1155	1161	tissue	T024	C0040300
27884163	1162	1169	lysates	T072	C1881488
27884163	1188	1193	study	T062	C2603343
27884163	1221	1238	molecular changes	T044	C1148560
27884163	1246	1251	brain	T023	C0006104
27884163	1255	1266	APN-KO mice	T015	C0206745
27884163	1268	1299	SH-SY5Y neuroblastoma cell line	T025	C0007600
27884163	1312	1317	study	T062	C2603343
27884163	1322	1341	molecular mechanism	T044	C3537153
27884163	1347	1350	APN	T116,T123	C0389071
27884163	1355	1372	insulin treatment	T061	C0745343
27884163	1374	1378	Aged	T032	C0001779
27884163	1379	1382	APN	T116,T123	C0389071
27884163	1394	1398	mice	T015	C0026809
27884163	1409	1423	spatial memory	T041	C0814087
27884163	1428	1436	learning	T041	C0023185
27884163	1437	1448	impairments	T046	C0684336
27884163	1450	1466	fear-conditioned	T041	C1510535
27884163	1467	1481	memory deficit	T048	C0233794
27884163	1493	1500	anxiety	T033	C0003467
27884163	1508	1512	mice	T015	C0026809
27884163	1528	1530	AD	T047	C0002395
27884163	1531	1542	pathologies	T046	C0699748
27884163	1563	1571	cerebral	T023	C0006104
27884163	1572	1576	Aβ42	T116,T123	C0169424
27884163	1584	1586	Aβ	T116	C3484390
27884163	1599	1631	hyperphosphorylated Tau proteins	T116,T123	C0085401
27884163	1633	1645	microgliosis	T046	C3686874
27884163	1650	1662	astrogliosis	T046	C0017639
27884163	1678	1686	cerebral	T023	C0006104
27884163	1687	1692	IL-1β	T116,T129	C0021753
27884163	1697	1701	TNFα	T116,T129	C1456820
27884163	1740	1758	neuronal apoptosis	T043	C1660771
27884163	1771	1779	synaptic	T030	C0229984
27884163	1780	1795	proteins levels	T034	C0428479
27884163	1808	1822	APN deficiency	T047	C2675518
27884163	1835	1843	neuronal	T129	C0521390
27884163	1869	1874	brain	T023	C0006104
27884163	1876	1878	AD	T047	C0002395
27884163	1879	1890	pathologies	T169	C1521733
27884163	1903	1906	APN	T116,T123	C0389071
27884163	1909	1916	KO mice	T015	C0206745
27884163	1938	1942	AMPK	T116,T126	C2350345
27884163	1943	1958	phosphorylation	T044	C0031715
27884163	1972	1989	insulin signaling	T044	C1512804
27884163	2010	2013	Akt	T116,T126	C0014442
27884163	2038	2043	GSK3β	T116,T126	C0244989
27884163	2044	2054	activation	T044	C0014429
27884163	2062	2073	hippocampus	T023	C0019564
27884163	2078	2092	frontal cortex	T023	C0016733
27884163	2094	2098	Aged	T032	C0001779
27884163	2099	2102	APN	T116,T123	C0389071
27884163	2107	2111	mice	T015	C0026809
27884163	2122	2133	hippocampal	T023	C0019564
27884163	2134	2152	insulin resistance	T046	C0021655
27884163	2166	2170	pAkt	T116,T126	C0014442
27884163	2200	2217	insulin injection	T061	C0199782
27884163	2233	2236	APN	T116,T123	C0389071
27884163	2237	2246	treatment	T061	C0087111
27884163	2250	2263	SH-SY5Y cells	UnknownType	C0815000
27884163	2269	2287	insulin resistance	T046	C0021655
27884163	2292	2306	overexpressing	T045	C1171362
27884163	2307	2309	Aβ	T116	C3484390
27884163	2324	2328	pAkt	T116,T126	C0014442
27884163	2344	2351	AdipoR1	T116,T192	C1259440
27884163	2357	2374	insulin treatment	T061	C0745343
27884163	2401	2408	blocked	T046	C0028778
27884163	2412	2422	compound C	T103	C1706082
27884163	2435	2438	APN	T116,T123	C0389071
27884163	2451	2459	neuronal	T129	C0521390
27884163	2460	2479	insulin sensitivity	T046	C0920563
27884163	2488	2492	AMPK	T116,T126	C2350345
27884163	2532	2539	chronic	T079	C0205191
27884163	2540	2554	APN deficiency	T047	C2675518
27884163	2567	2571	AMPK	T116,T126	C2350345
27884163	2617	2637	AD-like pathogenesis	T046	C0699748
27884163	2641	2645	aged	T032	C0001779
27884163	2646	2650	mice	T015	C0026809
27884163	2684	2705	cognitive impairments	T048	C0338656
27884163	2710	2730	psychiatric symptoms	T184	C0233401

27621953|t|Intrapartum Cervical Laceration and Subsequent Pregnancy Outcomes
27621953|a|The objective of this study was to describe pregnancy outcomes, including cervical insufficiency and preterm birth, in the subsequent pregnancy following an intrapartum cervical laceration. Retrospective cohort of women with their first two consecutive singleton pregnancies carried to ≥ 20(0/7) weeks ' gestation within a tertiary health care system from 2002 to 2012. Cervical laceration cases were identified by ICD9 codes and included if suture repair was required. In this study, 55 women were confirmed to have a cervical laceration in the first delivery; 43 lacerations after vaginal delivery (VD) and 12 after cesarean delivery (CD). The median gestational age of the first delivery was 40(0/7) weeks and the median birth weight 3,545 g; these did not differ between VD and CD. In the second pregnancy, 2 of 55 women (4.6%) had a prophylactic cerclage placed; 1 carried to term and the other delivered at 35(6/7) weeks. In total, four women (9.3%) delivered the second pregnancy < 37 weeks: three had a prior term VD and one had a prior 34 weeks VD. There was only one case of recurrent cervical laceration, occurring in the setting of vaginal deliveries. Obstetric cervical lacerations are uncommon. Complications in the following pregnancy were low, despite lack of additional prophylactic cerclage use.
27621953	0	11	Intrapartum	T079	C0456337
27621953	12	31	Cervical Laceration	T037	C0007851
27621953	47	65	Pregnancy Outcomes	T033	C0032972
27621953	70	79	objective	T170	C0018017
27621953	88	93	study	T062	C2603343
27621953	110	128	pregnancy outcomes	T033	C0032972
27621953	140	162	cervical insufficiency	T047	C1401059
27621953	167	180	preterm birth	T033	C0151526
27621953	200	209	pregnancy	T040	C0032961
27621953	210	219	following	T079	C0332282
27621953	223	234	intrapartum	T079	C0456337
27621953	235	254	cervical laceration	T037	C0007851
27621953	270	276	cohort	T098	C0599755
27621953	280	285	women	T098	C0043210
27621953	307	318	consecutive	T080	C1707491
27621953	319	340	singleton pregnancies	T040	C0341899
27621953	362	367	weeks	T079	C0439230
27621953	370	379	gestation	T040	C0032961
27621953	389	416	tertiary health care system	T093	C0018696
27621953	436	455	Cervical laceration	T037	C0007851
27621953	456	461	cases	T077	C1706256
27621953	467	477	identified	T080	C0205396
27621953	481	491	ICD9 codes	T170	C1550213
27621953	496	504	included	T169	C0332257
27621953	508	521	suture repair	T061	C0087111
27621953	526	534	required	T169	C1514873
27621953	544	549	study	T062	C2603343
27621953	554	559	women	T098	C0043210
27621953	565	574	confirmed	T033	C0750484
27621953	585	604	cervical laceration	T037	C0007851
27621953	618	626	delivery	T040	C0005615
27621953	631	642	lacerations	T037	C0043246
27621953	649	665	vaginal delivery	T061	C1541822
27621953	666	670	(VD)	T061	C1541822
27621953	684	701	cesarean delivery	T061	C0007876
27621953	702	706	(CD)	T061	C0007876
27621953	712	718	median	T081	C0876920
27621953	719	734	gestational age	T032	C0017504
27621953	748	756	delivery	T040	C0005615
27621953	769	774	weeks	T079	C0439230
27621953	783	789	median	T081	C0876920
27621953	790	802	birth weight	T032	C0005612
27621953	826	832	differ	T080	C1705242
27621953	841	843	VD	T061	C1541822
27621953	848	850	CD	T061	C0007876
27621953	866	875	pregnancy	T040	C0032961
27621953	885	890	women	T098	C0043210
27621953	904	916	prophylactic	T169	C0445202
27621953	917	925	cerclage	T061	C0195681
27621953	936	943	carried	T052	C0206243
27621953	947	951	term	T040	C0233324
27621953	966	975	delivered	T033	C0151526
27621953	987	992	weeks	T079	C0439230
27621953	997	1002	total	T080	C0439810
27621953	1009	1014	women	T098	C0043210
27621953	1022	1031	delivered	T033	C0151526
27621953	1043	1052	pregnancy	T040	C0032961
27621953	1058	1063	weeks	T079	C0439230
27621953	1077	1082	prior	T079	C0332152
27621953	1083	1087	term	T040	C0233324
27621953	1088	1090	VD	T061	C1541822
27621953	1105	1110	prior	T079	C0332152
27621953	1114	1119	weeks	T079	C0439230
27621953	1120	1122	VD	T061	C1541822
27621953	1143	1147	case	T077	C1706256
27621953	1151	1160	recurrent	T079	C2945760
27621953	1161	1180	cervical laceration	T037	C0007851
27621953	1182	1191	occurring	T052	C1709305
27621953	1199	1206	setting	T169	C0868928
27621953	1210	1228	vaginal deliveries	T061	C1541822
27621953	1230	1239	Obstetric	T169	C0205484
27621953	1240	1260	cervical lacerations	T037	C0007851
27621953	1265	1273	uncommon	T080	C0522498
27621953	1275	1288	Complications	T046	C0009566
27621953	1296	1305	following	T079	C0332282
27621953	1306	1315	pregnancy	T040	C0032961
27621953	1321	1324	low	T080	C0205251
27621953	1334	1338	lack	T080	C0332268
27621953	1353	1365	prophylactic	T169	C0445202
27621953	1366	1374	cerclage	T061	C0195681

27855102|t|Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals
27855102|a|To assess the adequacy of reporting of non-inferiority trials alongside the consistency and utility of current recommended analyses and guidelines. Review of randomised clinical trials that used a non-inferiority design published between January 2010 and May 2015 in medical journals that had an impact factor >10 (JAMA Internal Medicine, Archives Internal Medicine, PLOS Medicine, Annals of Internal Medicine, BMJ, JAMA, Lancet and New England Journal of Medicine). Ovid (MEDLINE). We searched for non-inferiority trials and assessed the following: choice of non-inferiority margin and justification of margin; power and significance level for sample size; patient population used and how this was defined; any missing data methods used and assumptions declared and any sensitivity analyses used. A total of 168 trial publications were included. Most trials concluded non-inferiority (132; 79%). The non-inferiority margin was reported for 98% (164), but less than half reported any justification for the margin (77; 46%). While most chose two different analyses (91; 54%) the most common being intention-to-treat (ITT) or modified ITT and per-protocol, a large number of articles only chose to conduct and report one analysis (65; 39%), most commonly the ITT analysis. There was lack of clarity or inconsistency between the type I error rate and corresponding CIs for 73 (43%) articles. Missing data were rarely considered with (99; 59%) not declaring whether imputation techniques were used. Reporting and conduct of non-inferiority trials is inconsistent and does not follow the recommendations in available statistical guidelines, which are not wholly consistent themselves. Authors should clearly describe the methods used and provide clear descriptions of and justifications for their design and primary analysis. Failure to do this risks misleading conclusions being drawn, with consequent effects on clinical practice.
27855102	0	15	Non-inferiority	T033	C0243095
27855102	16	22	trials	T062	C0008976
27855102	33	41	inferior	T082	C0542339
27855102	45	62	systematic review	T170	C1955832
27855102	66	75	reporting	T062	C0011000
27855102	85	101	medical journals	T073,T170	C0162443
27855102	105	111	assess	T052	C1516048
27855102	116	124	adequacy	T080	C0205411
27855102	128	137	reporting	T062	C0011000
27855102	141	156	non-inferiority	T033	C0243095
27855102	157	163	trials	T062	C0008976
27855102	178	189	consistency	T080	C0332529
27855102	194	201	utility	T080	C3827682
27855102	205	212	current	T079	C0521116
27855102	213	224	recommended	T078	C0034866
27855102	225	233	analyses	T062	C0936012
27855102	238	248	guidelines	T170	C0162791
27855102	250	256	Review	T078	C1552617
27855102	260	270	randomised	T062	C0034656
27855102	271	286	clinical trials	T062	C0008976
27855102	299	314	non-inferiority	T033	C0243095
27855102	315	321	design	T052	C1707689
27855102	322	331	published	T057	C0034037
27855102	340	347	January	T080	C3829466
27855102	357	360	May	T079	C3812381
27855102	369	385	medical journals	T073,T170	C0162443
27855102	398	404	impact	T080	C4049986
27855102	405	411	factor	T169	C1521761
27855102	417	439	JAMA Internal Medicine	T170	C0282574
27855102	441	467	Archives Internal Medicine	T170	C0282574
27855102	469	482	PLOS Medicine	T170	C0282574
27855102	484	511	Annals of Internal Medicine	T170	C0282574
27855102	513	516	BMJ	T170	C0282574
27855102	518	522	JAMA	T170	C0282574
27855102	524	566	Lancet and New England Journal of Medicine	T170	C0282574
27855102	569	573	Ovid	T170	C0282574
27855102	575	582	MEDLINE	T170	C0025141
27855102	588	596	searched	T052	C1706202
27855102	601	616	non-inferiority	T033	C0243095
27855102	617	623	trials	T062	C0008976
27855102	628	636	assessed	T052	C1516048
27855102	662	677	non-inferiority	T033	C0243095
27855102	678	684	margin	T081	C0392762
27855102	689	702	justification	T033	C0566251
27855102	706	712	margin	T081	C0392762
27855102	724	736	significance	T078	C0750502
27855102	737	742	level	T080	C0441889
27855102	747	758	sample size	T081	C0242618
27855102	760	778	patient population	T081	C2361270
27855102	822	826	data	T078	C1511726
27855102	827	834	methods	T170	C0025663
27855102	844	855	assumptions	T080	C0205556
27855102	873	884	sensitivity	T081	C0036667
27855102	885	893	analyses	T062	C0936012
27855102	902	907	total	T080	C0439810
27855102	915	920	trial	T062	C0008976
27855102	921	933	publications	T073,T170	C0034036
27855102	954	960	trials	T062	C0008976
27855102	971	986	non-inferiority	T033	C0243095
27855102	1003	1018	non-inferiority	T033	C0243095
27855102	1019	1025	margin	T081	C0392762
27855102	1030	1038	reported	T170	C0684224
27855102	1086	1099	justification	T033	C0566251
27855102	1108	1114	margin	T080	C0205556
27855102	1147	1156	different	T080	C1705242
27855102	1157	1165	analyses	T062	C0936012
27855102	1185	1191	common	T081	C0205214
27855102	1198	1216	intention-to-treat	T062	C2718028
27855102	1218	1221	ITT	T062	C2718028
27855102	1226	1234	modified	T169	C0392747
27855102	1235	1238	ITT	T062	C2718028
27855102	1243	1255	per-protocol	T169	C1698058
27855102	1265	1271	number	T081	C0237753
27855102	1275	1283	articles	T170	C1706852
27855102	1298	1305	conduct	T169	C0205245
27855102	1310	1316	report	T170	C0684224
27855102	1321	1329	analysis	T062	C0936012
27855102	1346	1354	commonly	T081	C0205214
27855102	1359	1371	ITT analysis	T062	C2718028
27855102	1383	1387	lack	T080	C0332268
27855102	1391	1398	clarity	T080	C2963144
27855102	1402	1415	inconsistency	T080	C0442809
27855102	1428	1434	type I	T185	C0441729
27855102	1435	1440	error	T080	C0743559
27855102	1441	1445	rate	T081	C1521828
27855102	1464	1467	CIs	T081	C0009667
27855102	1481	1489	articles	T170	C1706852
27855102	1491	1498	Missing	T080	C1705492
27855102	1499	1503	data	T078	C1511726
27855102	1516	1526	considered	T078	C0750591
27855102	1564	1574	imputation	T081	C2699638
27855102	1575	1585	techniques	T169	C0449851
27855102	1597	1606	Reporting	T062	C0011000
27855102	1611	1618	conduct	T169	C0205245
27855102	1622	1637	non-inferiority	T033	C0243095
27855102	1638	1644	trials	T062	C0008976
27855102	1648	1660	inconsistent	T080	C0442809
27855102	1685	1700	recommendations	T078	C0034866
27855102	1704	1713	available	T169	C0470187
27855102	1714	1736	statistical guidelines	T170	C0162791
27855102	1759	1769	consistent	T080	C0332529
27855102	1782	1789	Authors	T097	C3812881
27855102	1805	1813	describe	T078	C1552738
27855102	1818	1825	methods	T170	C0025663
27855102	1835	1842	provide	T052	C1999230
27855102	1849	1861	descriptions	T170	C0678257
27855102	1869	1883	justifications	T033	C0566251
27855102	1894	1900	design	T062	C0015320
27855102	1905	1912	primary	T080	C0205225
27855102	1913	1921	analysis	T062	C0936012
27855102	1923	1930	Failure	T169	C0231175
27855102	1959	1970	conclusions	T078	C1707478
27855102	1989	1999	consequent	T033	C3845876
27855102	2000	2007	effects	T080	C1280500
27855102	2011	2028	clinical practice	T062	C0008972

27547341|t|Fitness implications of seasonal climate variation in Columbian ground squirrels
27547341|a|The influence of climate change on the fitness of wild populations is often studied in the context of the spring onset of the reproductive season. This focus is relevant for climate influences on reproductive success, but neglects other fitness -relevant periods (e.g., autumn preparation for overwintering). We examined variation in climate variables (temperature, rainfall, snowfall, and snowpack) across the full annual cycle of Columbian ground squirrels (Urocitellus columbianus) for 21 years. We investigated seasonal climate variables that were associated with fitness variables, climate variables that exhibited directional changes across the study period, and finally observed declines in fitness (-0.03 units/year; total decline = 37%) that were associated with directional changes in climate variables. Annual fitness of adult female ground squirrels was positively associated with spring temperature (r = 0.69) and early summer rainfall (r = 0.56) and negatively associated with spring snow conditions (r = -0.44 to -0.66). Across the 21 years, spring snowmelt has become significantly delayed (r = 0.48) and summer rainfall became significantly reduced (r = -0.53). Using a standardized partial regression model, we found that directional changes in the timing of spring snowmelt and early summer rainfall (i.e., progressively drier summers) had moderate influences on annual fitness, with the latter statistically significant (ρ = -0.314 and 0.437, respectively). The summer period corresponds to prehibernation fattening of young and adult ground squirrels. Had we focused on a single point in time (viz. the onset of the breeding season), we would have underestimated the influences of climate change on our population. Rather, we obtained a comprehensive understanding of the influences of climate change on individual fitness by investigating the full lifecycle.
27547341	0	7	Fitness	T056	C1456706
27547341	24	50	seasonal climate variation	T070	C2584332
27547341	54	80	Columbian ground squirrels	T015	C1015596
27547341	85	94	influence	T077	C4054723
27547341	98	112	climate change	T070	C2718051
27547341	120	127	fitness	T056	C1456706
27547341	131	135	wild	T170	C0445392
27547341	136	147	populations	T098	C1257890
27547341	187	193	spring	T079	C0241232
27547341	207	226	reproductive season	T079	C0035156
27547341	255	262	climate	T070	C0008946
27547341	263	273	influences	T077	C4054723
27547341	277	289	reproductive	T040	C0035150
27547341	318	325	fitness	T056	C1456706
27547341	336	343	periods	T079	C1948053
27547341	351	357	autumn	T079	C0238715
27547341	374	387	overwintering	T079	C0241737
27547341	415	422	climate	T070	C0008946
27547341	423	432	variables	T080	C0439828
27547341	434	445	temperature	T081	C0039476
27547341	447	455	rainfall	T070	C0034640
27547341	457	465	snowfall	T070	C0037386
27547341	471	479	snowpack	T070	C0037386
27547341	497	509	annual cycle	T079	C1254367
27547341	513	539	Columbian ground squirrels	T015	C1015596
27547341	541	564	Urocitellus columbianus	T015	C1015596
27547341	596	622	seasonal climate variables	T070	C2584332
27547341	633	648	associated with	T080	C0332281
27547341	649	656	fitness	T056	C1456706
27547341	657	666	variables	T080	C0439828
27547341	668	675	climate	T070	C0008946
27547341	676	685	variables	T080	C0439828
27547341	701	712	directional	T082	C0449738
27547341	713	720	changes	T169	C0392747
27547341	732	744	study period	T079	C1948053
27547341	779	786	fitness	T056	C1456706
27547341	837	852	associated with	T080	C0332281
27547341	853	864	directional	T082	C0449738
27547341	865	872	changes	T169	C0392747
27547341	876	883	climate	T070	C0008946
27547341	884	893	variables	T080	C0439828
27547341	895	901	Annual	T079	C0332181
27547341	902	909	fitness	T056	C1456706
27547341	913	918	adult	T100	C0001675
27547341	919	925	female	T032	C0086287
27547341	926	942	ground squirrels	T015	C1015596
27547341	958	973	associated with	T080	C0332281
27547341	974	980	spring	T079	C0241232
27547341	981	992	temperature	T081	C0039476
27547341	1014	1020	summer	T079	C0241301
27547341	1021	1029	rainfall	T070	C0034640
27547341	1056	1071	associated with	T080	C0332281
27547341	1072	1078	spring	T079	C0241232
27547341	1079	1094	snow conditions	T070	C0037386
27547341	1138	1144	spring	T079	C0241232
27547341	1145	1153	snowmelt	T070	C0037386
27547341	1202	1208	summer	T079	C0241301
27547341	1209	1217	rainfall	T070	C0034640
27547341	1268	1305	standardized partial regression model	T170	C3161035
27547341	1321	1332	directional	T082	C0449738
27547341	1333	1340	changes	T169	C0392747
27547341	1358	1364	spring	T079	C0241232
27547341	1365	1373	snowmelt	T070	C0037386
27547341	1384	1390	summer	T079	C0241301
27547341	1391	1399	rainfall	T070	C0034640
27547341	1427	1434	summers	T079	C0241301
27547341	1449	1459	influences	T077	C4054723
27547341	1463	1469	annual	T079	C0332181
27547341	1470	1477	fitness	T056	C1456706
27547341	1495	1520	statistically significant	T081	C0237881
27547341	1563	1576	summer period	T079	C0241301
27547341	1592	1616	prehibernation fattening	T040	C0019516
27547341	1620	1625	young	T079	C0332239
27547341	1630	1635	adult	T100	C0001675
27547341	1636	1652	ground squirrels	T015	C1015596
27547341	1674	1694	single point in time	T079	C1292424
27547341	1718	1726	breeding	T040	C0006159
27547341	1727	1733	season	T079	C0036497
27547341	1769	1779	influences	T077	C4054723
27547341	1783	1797	climate change	T070	C2718051
27547341	1805	1815	population	T098	C1257890
27547341	1874	1884	influences	T077	C4054723
27547341	1888	1902	climate change	T070	C2718051
27547341	1917	1924	fitness	T056	C1456706
27547341	1928	1941	investigating	T169	C1292732
27547341	1951	1960	lifecycle	T079	C0023675

28472129|t|Copy number variation of FCGR genes in etiopathogenesis of sarcoidosis
28472129|a|We have previously revealed that, in contrast to polymorphism of FCGR2B and FCGR3B, polymorphism of FCGR2A, FCGR2C and FCGR3A genes, encoding receptors for Fc fragment of immunoglobulin G (Fcγ receptors), play a role in increased level of circulating immune complexes with occurrence of Mycobacterium tuberculosis heat shock proteins in patients with sarcoidosis. However, this immunocomplexemia might also be caused by decreased clearance by immune cells due to a changed copy number of FCGR genes. Thus, the next step of our study was to evaluate copy number variation of FCGR2A, FCGR2B, FCGR2C, FCGR3A and FCGR3B in this disease. The analysis was carried out by real-time quantitative PCR on 104 patients and 110 healthy volunteers. Despite previously detected variation in allele / genotype frequencies of FCGR in sarcoidosis and its particular stages, there was no copy number variation of the tested genes between sarcoidosis or its stages and healthy control, as well as between stages themselves. A relevant increase in copy number of FCGR2C and FCGR3B in Stage IV of sarcoidosis vs. other stages and controls was detected, but this observation was based on a limited number of Stage IV patients. Hence, polymorphism of FCGR genes seems to be more important than their copy number variation in etiopathogenesis of sarcoidosis in patients from the Polish population.
28472129	0	21	Copy number variation	T086	C1511518
28472129	25	35	FCGR genes	T028	C0017337
28472129	39	55	etiopathogenesis	T169	C1510540
28472129	59	70	sarcoidosis	T047	C0036202
28472129	120	132	polymorphism	T045	C0678951
28472129	136	142	FCGR2B	T028	C1414554
28472129	147	153	FCGR3B	T028	C1414556
28472129	155	167	polymorphism	T045	C0678951
28472129	171	177	FCGR2A	T028	C1414553
28472129	179	185	FCGR2C	T028	C1521989
28472129	190	202	FCGR3A genes	T028	C1414555
28472129	204	212	encoding	T052	C2700640
28472129	213	258	receptors for Fc fragment of immunoglobulin G	T116,T129,T192	C0034805
28472129	260	273	Fcγ receptors	T116,T129,T192	C0034805
28472129	291	300	increased	T081	C0205217
28472129	301	306	level	T080	C0441889
28472129	310	321	circulating	T169	C0175630
28472129	322	338	immune complexes	T116,T129	C0003313
28472129	344	354	occurrence	T079	C2745955
28472129	358	384	Mycobacterium tuberculosis	T007	C0026926
28472129	385	404	heat shock proteins	T116,T123	C0018850
28472129	408	416	patients	T101	C0030705
28472129	422	433	sarcoidosis	T047	C0036202
28472129	449	466	immunocomplexemia	T184	C0037088
28472129	491	500	decreased	T081	C0205216
28472129	501	510	clearance	T080	C0449297
28472129	514	526	immune cells	T025	C0007634
28472129	536	543	changed	T169	C0392747
28472129	544	555	copy number	T081	C1707513
28472129	559	569	FCGR genes	T028	C0017337
28472129	611	619	evaluate	T058	C0220825
28472129	620	641	copy number variation	T086	C1511518
28472129	645	651	FCGR2A	T028	C1414553
28472129	653	659	FCGR2B	T028	C1414554
28472129	661	667	FCGR2C	T028	C1521989
28472129	669	675	FCGR3A	T028	C1414555
28472129	680	686	FCGR3B	T028	C1414556
28472129	695	702	disease	T047	C0012634
28472129	708	716	analysis	T062	C0936012
28472129	736	762	real-time quantitative PCR	T063	C3179034
28472129	770	778	patients	T101	C0030705
28472129	787	805	healthy volunteers	T098	C1708335
28472129	826	834	detected	T033	C0442726
28472129	835	844	variation	T086	C1511518
28472129	848	854	allele	T028	C0002085
28472129	857	865	genotype	T032	C0017431
28472129	866	877	frequencies	T081	C0017270
28472129	881	885	FCGR	T028	C0017337
28472129	889	900	sarcoidosis	T047	C0036202
28472129	920	926	stages	T079	C1306673
28472129	941	962	copy number variation	T086	C1511518
28472129	977	982	genes	T028	C0017337
28472129	991	1002	sarcoidosis	T047	C0036202
28472129	1010	1016	stages	T079	C1306673
28472129	1021	1036	healthy control	T080	C2986479
28472129	1057	1063	stages	T079	C1306673
28472129	1087	1095	increase	T169	C0442805
28472129	1099	1110	copy number	T081	C1707513
28472129	1114	1120	FCGR2C	T028	C1521989
28472129	1125	1131	FCGR3B	T028	C1414556
28472129	1135	1143	Stage IV	T080	C0205585
28472129	1147	1158	sarcoidosis	T047	C0036202
28472129	1169	1175	stages	T079	C1306673
28472129	1180	1188	controls	T096	C0009932
28472129	1193	1201	detected	T033	C0442726
28472129	1212	1223	observation	T062	C0302523
28472129	1257	1265	Stage IV	T080	C0205585
28472129	1266	1274	patients	T101	C0030705
28472129	1283	1295	polymorphism	T045	C0678951
28472129	1299	1309	FCGR genes	T028	C0017337
28472129	1348	1369	copy number variation	T086	C1511518
28472129	1373	1389	etiopathogenesis	T169	C1510540
28472129	1393	1404	sarcoidosis	T047	C0036202
28472129	1408	1416	patients	T101	C0030705
28472129	1426	1443	Polish population	T098	C0220896

27391263|t|Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study
27391263|a|Molecular characterization of cancer samples is hampered by tumor tissue availability in metastatic castration-resistant prostate cancer (mCRPC) patients. We reported the results of prospective PETRUS study of biomarker assessment in paired primary prostatic tumors, metastatic biopsies and circulating tumor cells (CTCs). Among 54 mCRPC patients enrolled, 38 (70%) had biopsies containing more than 50% tumour cells. 28 (52%) patients were analyzed for both tissue samples and CTCs. FISH for AR - amplification and TMPRSS2 - ERG translocation were successful in 54% and 32% in metastatic biopsies and primary tumors, respectively. By comparing CellSearch and filtration (ISET)-enrichment combined to four color immunofluorescent staining, we showed that CellSearch and ISET isolated distinct subpopulations of CTCs: CTCs undergoing epithelial-to-mesenchymal transition, CTC clusters and large CTCs with cytomorphological characteristics but no detectable markers were isolated using ISET. Epithelial CTCs detected by the CellSearch were mostly lost during the ISET-filtration. AR - amplification was detected in CellSearch -captured CTCs, but not in ISET -enriched CTCs which harbor exclusively AR gain of copies. Eighty-eight percent concordance for ERG-rearrangement was observed between metastatic biopsies and CTCs even if additional ERG-alteration patterns were detected in ISET -enriched CTCs indicating a higher heterogeneity in CTCs. Molecular screening of metastatic biopsies is achievable in a multicenter context. Our data indicate that CTCs detected by the CellSearch and the ISET-filtration systems are not only phenotypically but also genetically different. Close attention must be paid to CTC characterization since neither approach tested here fully reflects the tremendous phenotypic and genetic heterogeneity present in CTCs from mCRPC patients.
27391263	0	10	Phenotypic	T033	C1852220
27391263	15	36	genetic heterogeneity	T032	C0242960
27391263	40	52	tumor tissue	T024	C0475358
27391263	57	80	circulating tumor cells	T025	C0027625
27391263	84	92	patients	T101	C0030705
27391263	98	145	metastatic castration-resistant prostate cancer	T191	C1328504
27391263	149	155	report	T170	C0684224
27391263	165	189	PETRUS prospective study	T062	C0033522
27391263	190	234	Molecular characterization of cancer samples	T170	C1513386
27391263	238	246	hampered	T080	C0311403
27391263	250	262	tumor tissue	T024	C0475358
27391263	279	326	metastatic castration-resistant prostate cancer	T191	C1328504
27391263	328	333	mCRPC	T191	C1328504
27391263	335	343	patients	T101	C0030705
27391263	348	356	reported	T058	C0700287
27391263	361	368	results	T169	C1274040
27391263	372	396	prospective PETRUS study	T062	C0033522
27391263	400	420	biomarker assessment	T063	C1879847
27391263	439	455	prostatic tumors	T191	C0376358
27391263	457	467	metastatic	T191	C0027627
27391263	468	476	biopsies	T060	C0005558
27391263	481	504	circulating tumor cells	T025	C0027625
27391263	506	510	CTCs	T025	C0027625
27391263	522	527	mCRPC	T191	C1328504
27391263	528	536	patients	T101	C0030705
27391263	560	568	biopsies	T060	C0005558
27391263	594	606	tumour cells	T025	C0431085
27391263	617	625	patients	T101	C0030705
27391263	631	639	analyzed	T062	C0936012
27391263	649	663	tissue samples	T024	C0475358
27391263	668	672	CTCs	T025	C0027625
27391263	674	678	FISH	T063	C0162789
27391263	683	685	AR	T028	C1367578
27391263	688	701	amplification	T063	C1517480
27391263	706	713	TMPRSS2	T028	C1336641
27391263	716	719	ERG	T028	C0599295
27391263	720	733	translocation	T045	C1315049
27391263	768	778	metastatic	T191	C0027627
27391263	779	787	biopsies	T060	C0005558
27391263	792	806	primary tumors	T191	C0677930
27391263	835	845	CellSearch	T059	C0200925
27391263	850	866	filtration (ISET	T059	C0200925
27391263	902	928	immunofluorescent staining	T059	C1318793
27391263	945	955	CellSearch	T059	C0200925
27391263	960	964	ISET	T059	C0200925
27391263	965	973	isolated	T169	C0205409
27391263	983	997	subpopulations	T059,T062	C0596289
27391263	1001	1005	CTCs	T025	C0027625
27391263	1007	1011	CTCs	T025	C0027625
27391263	1023	1059	epithelial-to-mesenchymal transition	T043	C1523298
27391263	1061	1073	CTC clusters	T025	C0027625
27391263	1078	1083	large	T081	C0549177
27391263	1084	1088	CTCs	T025	C0027625
27391263	1094	1111	cytomorphological	T080	C0332437
27391263	1112	1127	characteristics	T080	C1521970
27391263	1135	1145	detectable	T201	C3830527
27391263	1146	1153	markers	T201	C0005516
27391263	1159	1167	isolated	T169	C0205409
27391263	1174	1178	ISET	T059	C0200925
27391263	1180	1190	Epithelial	T080	C0221908
27391263	1191	1195	CTCs	T025	C0027625
27391263	1196	1204	detected	T033	C0442726
27391263	1212	1222	CellSearch	T059	C0200925
27391263	1251	1266	ISET-filtration	T059	C0200925
27391263	1268	1270	AR	T028	C1367578
27391263	1273	1286	amplification	T063	C1517480
27391263	1291	1299	detected	T033	C0442726
27391263	1303	1313	CellSearch	T059	C0200925
27391263	1324	1328	CTCs	T025	C0027625
27391263	1341	1345	ISET	T059	C0200925
27391263	1356	1360	CTCs	T025	C0027625
27391263	1386	1388	AR	T028	C1367578
27391263	1397	1403	copies	T081	C0178655
27391263	1442	1459	ERG-rearrangement	T049	C2826127
27391263	1481	1491	metastatic	T191	C0027627
27391263	1492	1500	biopsies	T060	C0005558
27391263	1505	1509	CTCs	T025	C0027625
27391263	1529	1543	ERG-alteration	T049	C2826127
27391263	1558	1566	detected	T033	C0442726
27391263	1570	1574	ISET	T059	C0200925
27391263	1585	1589	CTCs	T025	C0027625
27391263	1603	1609	higher	T080	C0205250
27391263	1610	1623	heterogeneity	T080	C0019409
27391263	1627	1631	CTCs	T025	C0027625
27391263	1633	1642	Molecular	T080	C1521991
27391263	1643	1652	screening	T058	C1710032
27391263	1656	1666	metastatic	T191	C0027627
27391263	1667	1675	biopsies	T060	C0005558
27391263	1695	1714	multicenter context	T062	C0206012
27391263	1720	1724	data	T078	C1511726
27391263	1739	1743	CTCs	T025	C0027625
27391263	1744	1752	detected	T033	C0442726
27391263	1760	1770	CellSearch	T059	C0200925
27391263	1779	1802	ISET-filtration systems	T059	C0200925
27391263	1816	1830	phenotypically	T032	C0031437
27391263	1840	1851	genetically	T169	C0314603
27391263	1852	1861	different	T080	C1705242
27391263	1895	1898	CTC	T025	C0027625
27391263	1899	1915	characterization	T052	C1880022
27391263	1939	1945	tested	T169	C0039593
27391263	1981	1991	phenotypic	T033	C1852220
27391263	1996	2017	genetic heterogeneity	T032	C0242960
27391263	2029	2033	CTCs	T025	C0027625
27391263	2039	2044	mCRPC	T191	C1328504
27391263	2045	2053	patients	T101	C0030705

28297629|t|Genomics of Myeloproliferative Neoplasms
28297629|a|Myeloproliferative neoplasms (MPN s) are a group of related clonal hematologic disorders characterized by excess accumulation of one or more myeloid cell lineages and a tendency to transform to acute myeloid leukemia. Deregulated JAK2 signaling has emerged as the central phenotypic driver of BCR -ABL1-negative MPNs and a unifying therapeutic target. In addition, MPNs show unexpected layers of genetic complexity, with multiple abnormalities associated with disease progression, interactions between inherited factors and phenotype driver mutations, and effects related to the order in which mutations are acquired. Although morphology and clinical laboratory analysis continue to play an important role in defining these conditions, genomic analysis is providing a platform for better disease definition, more accurate diagnosis, direction of therapy, and refined prognostication. There is an emerging consensus with regard to many prognostic factors, but there is a clear need to synthesize genomic findings into robust, clinically actionable and widely accepted scoring systems as well as the need to standardize the laboratory methodologies that are used.
28297629	0	8	Genomics	T091	C0887950
28297629	12	40	Myeloproliferative Neoplasms	T191	C0027022
28297629	41	69	Myeloproliferative neoplasms	T191	C0027022
28297629	71	74	MPN	T191	C0027022
28297629	101	107	clonal	T024	C1522642
28297629	108	129	hematologic disorders	T047	C0018939
28297629	147	153	excess	T080	C1979886
28297629	154	166	accumulation	T033	C4055506
28297629	182	203	myeloid cell lineages	T025	C0887899
28297629	235	257	acute myeloid leukemia	T191	C0023467
28297629	259	270	Deregulated	T052	C1880287
28297629	271	275	JAK2	T028	C1334291
28297629	276	285	signaling	T038	C3537152
28297629	313	323	phenotypic	T032	C0031437
28297629	334	357	BCR -ABL1-negative MPNs	T191	C1292772
28297629	373	384	therapeutic	T169	C0302350
28297629	385	391	target	T169	C1521840
28297629	406	410	MPNs	T191	C0027022
28297629	416	426	unexpected	T033	C0853141
28297629	437	444	genetic	T169	C0017399
28297629	462	484	multiple abnormalities	T019	C0000772
28297629	485	500	associated with	T080	C0332281
28297629	501	520	disease progression	T046	C0242656
28297629	522	534	interactions	T045	C0596610
28297629	543	552	inherited	T169	C0439660
28297629	553	560	factors	T169	C1521761
28297629	565	574	phenotype	T032	C0031437
28297629	575	591	driver mutations	T045	C0026882
28297629	597	604	effects	T080	C1280500
28297629	635	644	mutations	T045	C0026882
28297629	649	657	acquired	T080	C0439661
28297629	668	678	morphology	T080	C0332437
28297629	683	711	clinical laboratory analysis	T058	C1254363
28297629	777	793	genomic analysis	T059	C0022885
28297629	809	817	platform	T075	C1710360
28297629	829	847	disease definition	T170	C0679227
28297629	854	862	accurate	T080	C0443131
28297629	863	872	diagnosis	T033	C0011900
28297629	887	894	therapy	T061	C0087111
28297629	908	923	prognostication	T058	C0033325
28297629	946	955	consensus	T054	C0376298
28297629	976	994	prognostic factors	T201	C1514474
28297629	1036	1043	genomic	T028	C0017428
28297629	1044	1052	findings	T169	C2607943
28297629	1058	1064	robust	T080	C2986815
28297629	1099	1107	accepted	T080	C1272684
28297629	1108	1123	scoring systems	T170	C0282574
28297629	1147	1158	standardize	T065	C0851345
28297629	1163	1187	laboratory methodologies	T170	C0449309

27887026|t|Chaetomium thermophilum formate dehydrogenase has high activity in the reduction of hydrogen carbonate (HCO3 -) to formate
27887026|a|While formate dehydrogenases (FDHs) have been used for cofactor recycling in chemoenzymatic synthesis, the ability of FDH to reduce CO2 could also be utilized in the conversion of CO2 to useful products via formate (HCOO(-)). In this study, we investigated the reduction of CO2 in the form of hydrogen carbonate (HCO3(-)) to formate by FDHs from Candida methylica (CmFDH) and Chaetomium thermophilum (CtFDH) in a NADH -dependent reaction. The catalytic performance with HCO3(-) as a substrate was evaluated by measuring the kinetic rates and conducting productivity assays. CtFDH showed a higher efficiency in converting HCO3(-) to formate than CmFDH, whereas CmFDH was better in the oxidation of formate. The pH optimum of the reduction was at pH 7-8. However, the high concentrations of HCO3(-) reduced the reaction rate. CtFDH was modeled in the presence of HCO3(-) showing that it fits to the active site. The active site setting for hydride transfer in CO2 reduction was modeled. The hydride donated by NADH would form a favorable contact to the carbon atom of HCO3(-), resulting in a surplus of electrons within the molecule. This would cause the complex formed by hydrogen carbonate and the hydride to break into formate and hydroxide ions.
27887026	0	23	Chaetomium thermophilum	T004	C1225414
27887026	24	45	formate dehydrogenase	T116,T126	C0016570
27887026	71	80	reduction	T070	C0301630
27887026	84	102	hydrogen carbonate	T197	C0973231
27887026	104	110	HCO3 -	T197	C0973231
27887026	115	122	formate	T109,T130	C0220832
27887026	129	151	formate dehydrogenases	T116,T126	C0016570
27887026	153	157	FDHs	T116,T126	C0016570
27887026	178	186	cofactor	T123	C0178555
27887026	187	196	recycling	T068	C0282114
27887026	200	224	chemoenzymatic synthesis	T044	C1511130
27887026	241	244	FDH	T116,T126	C0016570
27887026	255	258	CO2	T123,T197	C0007012
27887026	289	299	conversion	T169	C0439836
27887026	303	306	CO2	T123,T197	C0007012
27887026	317	325	products	T071	C1514468
27887026	330	337	formate	T109,T130	C0220832
27887026	339	346	HCOO(-)	T109,T130	C0220832
27887026	367	379	investigated	T169	C1292732
27887026	384	393	reduction	T070	C0301630
27887026	397	400	CO2	T123,T197	C0007012
27887026	416	434	hydrogen carbonate	T197	C0973231
27887026	436	443	HCO3(-)	T197	C0973231
27887026	448	455	formate	T109,T130	C0220832
27887026	459	463	FDHs	T116,T126	C0016570
27887026	469	486	Candida methylica	T004	C1011924
27887026	488	493	CmFDH	T116,T126	C0016570
27887026	499	522	Chaetomium thermophilum	T004	C1225414
27887026	524	529	CtFDH	T116,T126	C0016570
27887026	536	540	NADH	T114,T121,T123	C0027289
27887026	552	560	reaction	T169	C0443286
27887026	566	587	catalytic performance	T044	C0243102
27887026	593	600	HCO3(-)	T197	C0973231
27887026	606	615	substrate	T167	C3891814
27887026	633	642	measuring	T080	C0444706
27887026	647	660	kinetic rates	T079	C1254367
27887026	676	695	productivity assays	T059	C1510438
27887026	697	702	CtFDH	T116,T126	C0016570
27887026	719	729	efficiency	T081	C0013682
27887026	733	743	converting	T169	C0439836
27887026	744	751	HCO3(-)	T197	C0973231
27887026	755	762	formate	T109,T130	C0220832
27887026	768	773	CmFDH	T116,T126	C0016570
27887026	783	788	CmFDH	T116,T126	C0016570
27887026	807	816	oxidation	T044	C0030011
27887026	820	827	formate	T109,T130	C0220832
27887026	833	835	pH	T081	C0020283
27887026	851	860	reduction	T070	C0301630
27887026	868	870	pH	T081	C0020283
27887026	889	908	high concentrations	T081	C1446561
27887026	912	919	HCO3(-)	T197	C0973231
27887026	932	945	reaction rate	T079	C0678608
27887026	947	952	CtFDH	T116,T126	C0016570
27887026	984	991	HCO3(-)	T197	C0973231
27887026	1020	1031	active site	T169	C0205681
27887026	1037	1048	active site	T169	C0205681
27887026	1061	1077	hydride transfer	T044	C1148560
27887026	1081	1084	CO2	T123,T197	C0007012
27887026	1085	1094	reduction	T070	C0301630
27887026	1112	1127	hydride donated	T044	C1148560
27887026	1131	1135	NADH	T114,T121,T123	C0027289
27887026	1174	1185	carbon atom	T196	C0007009
27887026	1189	1196	HCO3(-)	T197	C0973231
27887026	1224	1233	electrons	T196	C0013852
27887026	1245	1253	molecule	T167	C0567416
27887026	1294	1312	hydrogen carbonate	T197	C0973231
27887026	1321	1328	hydride	T196	C0003075
27887026	1343	1350	formate	T109,T130	C0220832
27887026	1355	1369	hydroxide ions	T196	C0220853

27802488|t|In Vivo 3-Dimensional Strain Mapping Confirms Large Optic Nerve Head Deformations Following Horizontal Eye Movements
27802488|a|To measure lamina cribrosa (LC) strains (deformations) following abduction and adduction in healthy subjects and to compare them with those resulting from a relatively high acute intraocular pressure (IOP) elevation. A total of 16 eyes from 8 healthy subjects were included. Among the 16 eyes, 11 had peripapillary atrophy (PPA). For each subject, both optic nerve heads (ONHs) were imaged using optical coherence tomography (OCT) at baseline (twice), in different gaze positions (adduction and abduction of 20°) and following an acute IOP elevation of approximately 20 mm Hg from baseline (via ophthalmodynamometry). Strains of LC for all loading scenarios were mapped using a three-dimensional tracking algorithm. In all 16 eyes, LC strains induced by adduction and abduction were 5.83% ± 3.78% and 3.93% ± 2.57%, respectively, and both significantly higher than the control strains measured from the repeated baseline acquisitions (P < 0.01). Strains of LC in adduction were on average higher than those in abduction, but the difference was not statistically significant (P = 0.07). Strains of LC induced by IOP elevations (on average 21.13 ± 7.61 mm Hg) were 6.41% ± 3.21% and significantly higher than the control strains (P < 0.0005). Gaze - induced LC strains in the PPA group were on average larger than those in the non-PPA group; however, the relationship was not statistically significant. Our results confirm that horizontal eye movements generate significant ONH strains, which is consistent with our previous estimations using finite element analysis. Further studies are needed to explore a possible link between ONH strains induced by eye movements and axonal loss in optic neuropathies.
27802488	0	7	In Vivo	T082	C1515655
27802488	8	21	3-Dimensional	T082	C0450363
27802488	22	36	Strain Mapping	T052	C1283195
27802488	37	45	Confirms	T080	C0521093
27802488	46	51	Large	T081	C0549177
27802488	52	68	Optic Nerve Head	T023	C0029127
27802488	69	81	Deformations	T190	C0302142
27802488	82	91	Following	T079	C0332282
27802488	92	116	Horizontal Eye Movements	T039	C0015413
27802488	120	127	measure	T081	C0079809
27802488	128	143	lamina cribrosa	T023	C0229114
27802488	145	147	LC	T023	C0229114
27802488	149	156	strains	T190	C0302142
27802488	158	170	deformations	T190	C0302142
27802488	172	181	following	T079	C0332282
27802488	182	191	abduction	T039	C0231456
27802488	196	205	adduction	T169	C0231457
27802488	209	225	healthy subjects	T098	C1708335
27802488	233	240	compare	T052	C1707455
27802488	257	266	resulting	T169	C1274040
27802488	274	284	relatively	T080	C0205345
27802488	285	289	high	T080	C0205250
27802488	290	295	acute	T079	C0205178
27802488	296	316	intraocular pressure	T042	C0021888
27802488	318	321	IOP	T042	C0021888
27802488	323	332	elevation	T082	C0702240
27802488	336	341	total	T080	C0439810
27802488	348	352	eyes	T023	C0015392
27802488	360	376	healthy subjects	T098	C1708335
27802488	382	390	included	T052	C2700399
27802488	405	409	eyes	T023	C0015392
27802488	418	439	peripapillary atrophy	T033	C1719838
27802488	441	444	PPA	T033	C1719838
27802488	451	455	each	T081	C1457900
27802488	456	463	subject	T096	C0681850
27802488	470	487	optic nerve heads	T023	C0029127
27802488	489	493	ONHs	T023	C0029127
27802488	500	506	imaged	T170	C1704922
27802488	513	541	optical coherence tomography	T060	C0920367
27802488	543	546	OCT	T060	C0920367
27802488	551	559	baseline	T081	C1442488
27802488	561	566	twice	T081	C1948050
27802488	572	581	different	T080	C1705242
27802488	582	586	gaze	T074	C0590323
27802488	587	596	positions	T082	C0733755
27802488	598	607	adduction	T169	C0231457
27802488	612	621	abduction	T039	C0231456
27802488	634	643	following	T079	C0332282
27802488	647	652	acute	T079	C0205178
27802488	653	656	IOP	T042	C0021888
27802488	657	666	elevation	T082	C0702240
27802488	670	683	approximately	T080	C0332232
27802488	690	692	Hg	T131,T196	C0025424
27802488	698	706	baseline	T081	C1442488
27802488	712	732	ophthalmodynamometry	T060	C0029085
27802488	735	742	Strains	T190	C0302142
27802488	746	748	LC	T023	C0229114
27802488	757	774	loading scenarios	T169	C0683579
27802488	780	786	mapped	T170	C3858752
27802488	795	812	three-dimensional	T082	C0450363
27802488	813	821	tracking	T082	C0546881
27802488	822	831	algorithm	T170	C0002045
27802488	843	847	eyes	T023	C0015392
27802488	849	851	LC	T023	C0229114
27802488	852	859	strains	T190	C0302142
27802488	860	867	induced	T169	C0205263
27802488	871	880	adduction	T169	C0231457
27802488	885	894	abduction	T039	C0231456
27802488	956	976	significantly higher	T081	C4055637
27802488	986	993	control	T096	C0009932
27802488	994	1001	strains	T190	C0302142
27802488	1002	1010	measured	T080	C0444706
27802488	1020	1028	repeated	T169	C0205341
27802488	1029	1037	baseline	T081	C1442488
27802488	1038	1050	acquisitions	T052	C1706701
27802488	1063	1070	Strains	T190	C0302142
27802488	1074	1076	LC	T023	C0229114
27802488	1080	1089	adduction	T169	C0231457
27802488	1098	1105	average	T081	C1510992
27802488	1106	1112	higher	T080	C0205250
27802488	1127	1136	abduction	T039	C0231456
27802488	1146	1156	difference	T080	C1705242
27802488	1165	1190	statistically significant	T081	C0237881
27802488	1203	1210	Strains	T190	C0302142
27802488	1214	1216	LC	T023	C0229114
27802488	1217	1224	induced	T169	C0205263
27802488	1228	1231	IOP	T042	C0021888
27802488	1232	1242	elevations	T082	C0702240
27802488	1247	1254	average	T081	C1510992
27802488	1271	1273	Hg	T131,T196	C0025424
27802488	1298	1318	significantly higher	T081	C4055637
27802488	1328	1335	control	T096	C0009932
27802488	1336	1343	strains	T190	C0302142
27802488	1358	1362	Gaze	T074	C0590323
27802488	1365	1372	induced	T169	C0205263
27802488	1373	1375	LC	T023	C0229114
27802488	1376	1383	strains	T190	C0302142
27802488	1391	1394	PPA	T033	C1719838
27802488	1395	1400	group	T101	C0030705
27802488	1409	1416	average	T081	C1510992
27802488	1417	1423	larger	T081	C0549177
27802488	1442	1455	non-PPA group	T101	C0030705
27802488	1470	1482	relationship	T080	C0439849
27802488	1491	1516	statistically significant	T081	C0237881
27802488	1522	1529	results	T033	C0683954
27802488	1530	1537	confirm	T080	C1456348
27802488	1543	1567	horizontal eye movements	T039	C0015413
27802488	1568	1576	generate	T080	C0205556
27802488	1577	1588	significant	T078	C0750502
27802488	1589	1592	ONH	T023	C0029127
27802488	1593	1600	strains	T190	C0302142
27802488	1611	1626	consistent with	T078	C0332290
27802488	1631	1639	previous	T079	C0205156
27802488	1640	1651	estimations	T041	C0680844
27802488	1658	1681	finite element analysis	T170	C0600552
27802488	1683	1698	Further studies	T062	C2603343
27802488	1723	1731	possible	T033	C0332149
27802488	1745	1748	ONH	T023	C0029127
27802488	1749	1756	strains	T190	C0302142
27802488	1757	1764	induced	T169	C0205263
27802488	1768	1781	eye movements	T039	C0015413
27802488	1786	1797	axonal loss	T033	C1832338
27802488	1801	1819	optic neuropathies	T047	C0029132

27601594|t|Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
27601594|a|Purpose: Some forms of chemotherapy can enhance antitumor immunity through immunogenic cell death, resulting in increased T-cell activation and tumor infiltration. Such effects could potentially sensitize tumors to immunotherapies, including checkpoint blockade. We investigated whether platinum - and taxane -based chemotherapy for ovarian cancer induces immunologic changes consistent with this possibility. Experimental Design: Matched pre - and post - neoadjuvant chemotherapy tumor samples from 26 high-grade serous carcinoma (HGSC) patients were analyzed by immunohistochemistry (IHC) for a large panel of immune cells and associated factors. The prognostic significance of post - chemotherapy TIL patterns was assessed in an expanded cohort (n = 90).Results: Neoadjuvant chemotherapy was associated with increased densities of CD3 (+), CD8 (+), CD8 (+) TIA-1 (+), PD-1 (+) and CD20 (+) TIL. Other immune subsets and factors were unchanged, including CD79a (+) CD138 (+) plasma cells, CD68 (+) macrophages, and MHC class I on tumor cells. Immunosuppressive cell types were also unchanged, including FoxP3 (+) PD-1 (+) cells (putative regulatory T cells), IDO-1 (+) cells, and PD-L1 (+) cells (both macrophages and tumor cells). Hierarchical clustering revealed three response patterns: (i) TIL (high) tumors showed increases in multiple immune markers after chemotherapy; (ii) TIL (low) tumors underwent similar increases, achieving patterns indistinguishable from the first group; and (iii) TIL (negative) cases generally remained negative. Despite the dramatic increases seen in the first two patterns, post- chemotherapy TIL showed limited prognostic significance.Conclusions: Chemotherapy augments pre-existing TIL responses but fails to relieve major immune-suppressive mechanisms or confer significant prognostic benefit. Our findings provide rationale for multipronged approaches to immunotherapy tailored to the baseline features of the tumor microenvironment. Clin Cancer Res; 23(4); 925-34. ©2016 AACR.
27601594	0	24	Neoadjuvant Chemotherapy	T061	C4272610
27601594	28	42	Ovarian Cancer	T191	C0029925
27601594	72	101	Tumor-Infiltrating Lymphocyte	T025	C0079722
27601594	102	110	Response	T039	C0301909
27601594	142	155	Immunotherapy	T061	C0278348
27601594	179	191	chemotherapy	T061	C0392920
27601594	204	213	antitumor	T080	C2986475
27601594	214	222	immunity	T039	C0020964
27601594	231	242	immunogenic	T169	C0872192
27601594	243	253	cell death	T043	C0007587
27601594	278	295	T-cell activation	T043	C1155065
27601594	300	318	tumor infiltration	T191	C4060690
27601594	361	367	tumors	T191	C0027651
27601594	371	386	immunotherapies	T061	C0278348
27601594	398	417	checkpoint blockade	T043	C1155873
27601594	443	451	platinum	T196	C0032207
27601594	458	464	taxane	T109,T121	C0215136
27601594	472	484	chemotherapy	T061	C0392920
27601594	489	503	ovarian cancer	T191	C0029925
27601594	512	523	immunologic	T169	C0205470
27601594	566	585	Experimental Design	T062	C0015320
27601594	595	598	pre	T079	C0332152
27601594	605	609	post	T079	C0687676
27601594	612	636	neoadjuvant chemotherapy	T061	C4272610
27601594	637	650	tumor samples	T024	C0475358
27601594	659	686	high-grade serous carcinoma	T191	C3839280
27601594	688	692	HGSC	T191	C3839280
27601594	720	740	immunohistochemistry	T060	C0021044
27601594	742	745	IHC	T060	C0021044
27601594	768	780	immune cells	T025	C0312740
27601594	836	840	post	T079	C0687676
27601594	843	855	chemotherapy	T061	C0392920
27601594	856	859	TIL	T025	C0079722
27601594	897	903	cohort	T098	C0599755
27601594	922	946	Neoadjuvant chemotherapy	T061	C4272610
27601594	990	993	CD3	T116,T129	C0108779
27601594	999	1002	CD8	T129	C0085358
27601594	1008	1011	CD8	T129	C0085358
27601594	1016	1021	TIA-1	T116,T129	C1429678
27601594	1027	1031	PD-1	T116,T129,T192	C2986635
27601594	1040	1044	CD20	T116,T129	C0054946
27601594	1049	1052	TIL	T025	C0079722
27601594	1113	1118	CD79a	T116,T192	C0286618
27601594	1123	1128	CD138	T116,T123	C1609943
27601594	1133	1145	plasma cells	T025	C0032112
27601594	1147	1151	CD68	T116,T129	C0108799
27601594	1156	1167	macrophages	T025	C0024432
27601594	1173	1184	MHC class I	T116,T129	C0019629
27601594	1188	1199	tumor cells	T025	C0597032
27601594	1201	1218	Immunosuppressive	T047	C4048329
27601594	1219	1223	cell	T025	C0007634
27601594	1261	1266	FoxP3	T116,T123	C4282118
27601594	1271	1275	PD-1	T116,T129,T192	C2986635
27601594	1280	1285	cells	T025	C0039198
27601594	1296	1314	regulatory T cells	T025	C0039198
27601594	1317	1322	IDO-1	T116,T126	C3529891
27601594	1338	1343	PD-L1	T129	C4300350
27601594	1360	1371	macrophages	T025	C0024432
27601594	1376	1387	tumor cells	T025	C0597032
27601594	1390	1413	Hierarchical clustering	T062	C1881045
27601594	1452	1455	TIL	T025	C0079722
27601594	1463	1469	tumors	T191	C0027651
27601594	1499	1513	immune markers	T080	C0162489
27601594	1520	1532	chemotherapy	T061	C4272610
27601594	1539	1542	TIL	T025	C0079722
27601594	1654	1657	TIL	T025	C0079722
27601594	1659	1667	negative	T033	C0205160
27601594	1694	1702	negative	T033	C0205160
27601594	1773	1785	chemotherapy	T061	C0392920
27601594	1786	1789	TIL	T025	C0079722
27601594	1842	1854	Chemotherapy	T061	C4272610
27601594	1877	1880	TIL	T025	C0079722
27601594	1881	1890	responses	T039	C0301909
27601594	1918	1947	immune-suppressive mechanisms	T047	C1840264
27601594	2052	2065	immunotherapy	T061	C0278348
27601594	2107	2129	tumor microenvironment	T070	C2936626

28529121|t|Patient-centred care and shared decision-making in Chile: Rising momentum for progress and implementation in clinical practice
28529121|a|The Chilean legislation establishes that patients have rights and responsibilities in regards to their healthcare. This is an important statement as it declares that people must be informed and become actively involved in their care; meanwhile, the health system needs to coordinate the provision of personalised and effective services. Although patient-centred care (PCC) and shared decision-making (SDM) are relatively new concepts in Chile, the country is experiencing an interesting political momentum to create more interventions to achieve PCC and SDM and explore clinical implementation. Currently, research efforts in Chile have focused on better understanding the state of the art related to both concepts and how new clinical approaches could help to operationalize them.
28529121	0	20	Patient-centred care	T058	C0017313
28529121	25	47	shared decision-making	T041	C3179495
28529121	51	56	Chile	T083	C0008107
28529121	78	86	progress	T169	C1280477
28529121	91	105	implementation	T052	C1708476
28529121	109	126	clinical practice	T057	C0205897
28529121	131	138	Chilean	T098	C0239045
28529121	139	150	legislation	T089	C0018719
28529121	168	176	patients	T101	C0030705
28529121	182	188	rights	T078	C0030706
28529121	230	240	healthcare	T058	C0086388
28529121	263	272	statement	T078	C1710187
28529121	293	299	people	T098	C0027361
28529121	355	359	care	T058	C0086388
28529121	376	389	health system	T093	C0018696
28529121	454	462	services	T058	C0199168
28529121	473	493	patient-centred care	T058	C0017313
28529121	495	498	PCC	T058	C0017313
28529121	504	526	shared decision-making	T041	C3179495
28529121	528	531	SDM	T041	C3179495
28529121	552	560	concepts	T078	C0178566
28529121	564	569	Chile	T083	C0008107
28529121	575	582	country	T083	C0454664
28529121	648	661	interventions	T058	C1273869
28529121	673	676	PCC	T058	C0017313
28529121	681	684	SDM	T041	C3179495
28529121	697	705	clinical	T080	C0205210
28529121	706	720	implementation	T052	C1708476
28529121	753	758	Chile	T083	C0008107
28529121	833	841	concepts	T078	C0178566
28529121	854	873	clinical approaches	T061	C0008971

28165368|t|Reducing Low Birth Weight among African Americans in the Midwest: A Look at How Faith - Based Organizations Are Poised to Inform and Influence Health Communication on the Developmental Origins of Health and Disease (DOHaD)
28165368|a|Low birth weight (LBW) rates remain the highest among African Americans despite public health efforts to address these disparities; with some of the highest racial disparities in the Midwest (Kansas). The Developmental Origins of Health and Disease (DOHaD) perspective offers an explanation for how LBW contributes to racial health disparities among African Americans and informs a community directed health communication framework for creating sustainable programs to address these disparities. Trusted community organizations such as faith - based organizations are well situated to explain health communication gaps that may occur over the life course. These entities are underutilized in core health promotion programming targeting underserved populations and can prove essential for addressing developmental origins of LBW among African Americans. Extrapolating from focus group data collected from African American church populations as part of a social marketing health promotion project on cancer prevention, we theoretically consider how a similar communication framework and approach may apply to address LBW disparities. Stratified focus groups (n = 9) were used to discover emergent themes about disease prevention, and subsequently applied to explore how faith - based organizations (FBOs) inform strategic health care (media) advocacy and health promotion that potentially apply to address LBW among African Americans. We argue that FBOs are poised to meet health promotion and health communication needs among African American women who face social barriers in health.
28165368	0	8	Reducing	T080	C0392756
28165368	9	25	Low Birth Weight	T033	C0024032
28165368	32	49	African Americans	T098	C0085756
28165368	57	64	Midwest	T083	C0026081
28165368	80	85	Faith	T078	C0681191
28165368	88	93	Based	T169	C1527178
28165368	94	107	Organizations	T092	C1561598
28165368	122	128	Inform	T057	C1552002
28165368	133	142	Influence	T077	C4054723
28165368	143	163	Health Communication	T058	C1512347
28165368	171	214	Developmental Origins of Health and Disease	T062	C0002783
28165368	216	221	DOHaD	T062	C0002783
28165368	223	239	Low birth weight	T033	C0024032
28165368	241	244	LBW	T033	C0024032
28165368	246	251	rates	T081	C1521828
28165368	263	270	highest	T080	C1522410
28165368	277	294	African Americans	T098	C0085756
28165368	303	309	public	T092	C0678367
28165368	310	316	health	T078	C0018684
28165368	342	353	disparities	T033	C1171307
28165368	372	379	highest	T080	C1522410
28165368	380	398	racial disparities	T033	C0682075
28165368	406	413	Midwest	T083	C0026081
28165368	415	421	Kansas	T083	C0022497
28165368	428	471	Developmental Origins of Health and Disease	T062	C0002783
28165368	473	478	DOHaD	T062	C0002783
28165368	502	513	explanation	T170	C0681841
28165368	522	525	LBW	T033	C0024032
28165368	526	537	contributes	T052	C1880177
28165368	541	547	racial	T098	C0034510
28165368	548	566	health disparities	T033	C1171307
28165368	573	590	African Americans	T098	C0085756
28165368	595	602	informs	T057	C1552002
28165368	605	614	community	T096	C0009462
28165368	615	623	directed	T080	C1441547
28165368	624	644	health communication	T058	C1512347
28165368	645	654	framework	T169	C0449913
28165368	668	679	sustainable	T169	C0443318
28165368	680	688	programs	T169	C3484370
28165368	706	717	disparities	T033	C1171307
28165368	719	726	Trusted	T054	C0237935
28165368	727	736	community	T096	C0009462
28165368	737	750	organizations	T092	C1561598
28165368	759	764	faith	T078	C0681191
28165368	767	772	based	T169	C1527178
28165368	767	772	based	T169	C1527178
28165368	773	786	organizations	T092	C1561598
28165368	816	836	health communication	T058	C1512347
28165368	837	841	gaps	T079	C1254367
28165368	851	856	occur	T052	C1709305
28165368	866	877	life course	T079	C1510618
28165368	885	893	entities	T071	C1551338
28165368	898	911	underutilized	T169	C0042153
28165368	915	948	core health promotion programming	T058	C0679897
28165368	949	958	targeting	T169	C1521840
28165368	959	982	underserved populations	T098	C0872319
28165368	997	1006	essential	T080	C0205224
28165368	1022	1035	developmental	T080	C0458003
28165368	1036	1043	origins	T079	C0439659
28165368	1047	1050	LBW	T033	C0024032
28165368	1057	1074	African Americans	T098	C0085756
28165368	1101	1106	group	UnknownType	C0681860
28165368	1107	1121	data collected	T033	C4019276
28165368	1127	1143	African American	T098	C0085756
28165368	1144	1150	church	T073	C0562324
28165368	1151	1162	populations	T098	C1257890
28165368	1176	1192	social marketing	T057	C0037424
28165368	1193	1217	health promotion project	T058	C0018738
28165368	1221	1238	cancer prevention	T061	C0281206
28165368	1272	1279	similar	T080	C2348205
28165368	1280	1293	communication	T058	C1512347
28165368	1294	1303	framework	T169	C0449913
28165368	1308	1316	approach	T082	C0449445
28165368	1321	1326	apply	T169	C4048755
28165368	1338	1341	LBW	T033	C0024032
28165368	1342	1353	disparities	T033	C1171307
28165368	1355	1378	Stratified focus groups	UnknownType	C0681860
28165368	1392	1396	used	T169	C1524063
28165368	1400	1408	discover	T052	C1880355
28165368	1409	1417	emergent	T078	C0750573
28165368	1418	1424	themes	UnknownType	C0869035
28165368	1431	1449	disease prevention	T061	C0679698
28165368	1455	1467	subsequently	T079	C0332282
28165368	1468	1475	applied	T169	C4048755
28165368	1491	1496	faith	T078	C0681191
28165368	1499	1504	based	T169	C1527178
28165368	1505	1518	organizations	T092	C1561598
28165368	1520	1524	FBOs	T092	C1561598
28165368	1526	1532	inform	T057	C1552002
28165368	1533	1542	strategic	T041	C0679199
28165368	1543	1554	health care	T058	C0086388
28165368	1563	1571	advocacy	T057	C0680792
28165368	1576	1592	health promotion	T058	C0018738
28165368	1598	1609	potentially	T080	C3245505
28165368	1610	1615	apply	T169	C4048755
28165368	1627	1630	LBW	T033	C0024032
28165368	1637	1654	African Americans	T098	C0085756
28165368	1670	1674	FBOs	T092	C1561598
28165368	1689	1693	meet	T067	C1550543
28165368	1694	1710	health promotion	T058	C0018738
28165368	1715	1735	health communication	T058	C1512347
28165368	1736	1741	needs	T080	C0027552
28165368	1748	1764	African American	T098	C0085756
28165368	1765	1770	women	T098	C0043210
28165368	1780	1786	social	T169	C0728831
28165368	1787	1795	barriers	T078	C1254370
28165368	1799	1805	health	T078	C0018684

27994578|t|Comparative In silico Analysis of Butyrate Production Pathways in Gut Commensals and Pathogens
27994578|a|Biosynthesis of butyrate by commensal bacteria plays a crucial role in maintenance of human gut health while dysbiosis in gut microbiome has been linked to several enteric disorders. Contrastingly, butyrate shows cytotoxic effects in patients with oral diseases like periodontal infections and oral cancer. In addition to these host associations, few syntrophic bacteria couple butyrate degradation with sulfate reduction and methane production. Thus, it becomes imperative to understand the distribution of butyrate metabolism pathways and delineate differences in substrate utilization between pathogens and commensals. The bacteria utilize four pathways for butyrate production with different initial substrates (Pyruvate, 4-aminobutyrate, Glutarate and Lysine) which follow a polyphyletic distribution. A comprehensive mining of complete / draft bacterial genomes indicated conserved juxtaposed genomic arrangement in all these pathways. This gene context information was utilized for an accurate annotation of butyrate production pathways in bacterial genomes. Interestingly, our analysis showed that inspite of a beneficial impact of butyrate in gut, not only commensals, but a few gut pathogens also possess butyrogenic pathways. The results further illustrated that all the gut commensal bacteria (Faecalibacterium, Roseburia, Butyrivibrio, and commensal species of Clostridia etc) ferment pyruvate for butyrate production. On the contrary, the butyrogenic gut pathogen Fusobacterium utilizes different amino acid metabolism pathways like those for Glutamate (4-aminobutyrate and Glutarate) and Lysine for butyrogenesis which leads to a concomitant release of harmful by-products like ammonia in the process. The findings in this study indicate that commensals and pathogens in gut have divergently evolved to produce butyrate using distinct pathways. No such evolutionary selection was observed in oral pathogens (Porphyromonas and Filifactor) which showed presence of pyruvate as well as amino acid fermenting pathways which might be because the final product butyrate is itself known to be cytotoxic in oral diseases. This differential utilization of butyrogenic pathways in gut pathogens and commensals has an enormous ecological impact taking into consideration the immense influence of butyrate on different disorders in humans. The results of this study can potentially guide bioengineering experiments to design therapeutics / probiotics by manipulation of butyrate biosynthesis gene clusters in bacteria.
27994578	12	21	In silico	T066	C3489666
27994578	22	30	Analysis	T062	C0936012
27994578	34	42	Butyrate	T109	C0220802
27994578	43	62	Production Pathways	T044	C1721101
27994578	66	80	Gut Commensals	T001	C4018878
27994578	85	94	Pathogens	T001	C0450254
27994578	95	119	Biosynthesis of butyrate	T044	C1157706
27994578	123	141	commensal bacteria	T007	C0004611
27994578	181	190	human gut	T023	C0699819
27994578	191	197	health	T078	C0018684
27994578	204	213	dysbiosis	T046	C3658208
27994578	217	231	gut microbiome	T001	C4018878
27994578	259	276	enteric disorders	T047	C0012634
27994578	293	301	butyrate	T109	C0220802
27994578	308	325	cytotoxic effects	T169	C1511636
27994578	329	337	patients	T101	C0030705
27994578	343	356	oral diseases	T047	C0026636
27994578	362	384	periodontal infections	T047	C0747479
27994578	389	400	oral cancer	T191	C0153381
27994578	423	440	host associations	T067	C0596306
27994578	446	465	syntrophic bacteria	T007	C0004611
27994578	466	493	couple butyrate degradation	T044	C1158140
27994578	499	516	sulfate reduction	T044	C1159420
27994578	521	539	methane production	T040	C1855163
27994578	587	599	distribution	T169	C1704711
27994578	603	631	butyrate metabolism pathways	T044	C1158849
27994578	636	657	delineate differences	T080	C1705242
27994578	661	682	substrate utilization	T169	C0042153
27994578	691	700	pathogens	T001	C0450254
27994578	705	715	commensals	T007	C0004611
27994578	721	729	bacteria	T007	C0004611
27994578	743	751	pathways	T044	C1704259
27994578	756	775	butyrate production	T044	C1157706
27994578	799	809	substrates	T167	C3891814
27994578	811	819	Pyruvate	T109,T123	C0244104
27994578	821	836	4-aminobutyrate	T116,T121,T123	C0178649
27994578	838	847	Glutarate	T109	C0017816
27994578	852	858	Lysine	T116,T121,T123	C0024337
27994578	875	887	polyphyletic	T185	C1709533
27994578	888	900	distribution	T169	C1704711
27994578	904	924	comprehensive mining	T033	C0243095
27994578	928	936	complete	T080	C0205197
27994578	939	944	draft	T170	C1547277
27994578	945	962	bacterial genomes	T028	C0085238
27994578	973	993	conserved juxtaposed	T082	C1254362
27994578	994	1013	genomic arrangement	T082	C1704972
27994578	1027	1035	pathways	T044	C1704259
27994578	1042	1066	gene context information	T170	C0872179
27994578	1087	1106	accurate annotation	T170	C1706814
27994578	1110	1138	butyrate production pathways	T044	C1157706
27994578	1142	1159	bacterial genomes	T028	C0085238
27994578	1180	1188	analysis	T062	C0936012
27994578	1214	1231	beneficial impact	T080	C4049986
27994578	1235	1243	butyrate	T109	C0220802
27994578	1247	1250	gut	T023	C0699819
27994578	1261	1271	commensals	T001	C4018878
27994578	1283	1296	gut pathogens	T033	C4072750
27994578	1310	1330	butyrogenic pathways	T044	C1157706
27994578	1377	1399	gut commensal bacteria	T007	C0004611
27994578	1401	1417	Faecalibacterium	T007	C1229075
27994578	1419	1428	Roseburia	T007	C0995401
27994578	1430	1442	Butyrivibrio	T007	C0315034
27994578	1448	1479	commensal species of Clostridia	T007	C0009054
27994578	1485	1501	ferment pyruvate	T044	C1327317
27994578	1506	1525	butyrate production	T044	C1157706
27994578	1548	1572	butyrogenic gut pathogen	T033	C4072750
27994578	1573	1586	Fusobacterium	T007	C0016878
27994578	1606	1636	amino acid metabolism pathways	T044	C1510864
27994578	1652	1661	Glutamate	T116,T123	C0220839
27994578	1663	1678	4-aminobutyrate	T116,T121,T123	C0178649
27994578	1683	1692	Glutarate	T109	C0017816
27994578	1698	1704	Lysine	T116,T121,T123	C0024337
27994578	1709	1722	butyrogenesis	T044	C1157706
27994578	1740	1751	concomitant	T079	C0521115
27994578	1763	1770	harmful	T080	C0205556
27994578	1771	1782	by-products	T071	C1514468
27994578	1788	1795	ammonia	T121,T197	C0002607
27994578	1853	1863	commensals	T001	C4018878
27994578	1868	1884	pathogens in gut	T033	C4072750
27994578	1921	1929	butyrate	T109	C0220802
27994578	1936	1953	distinct pathways	T044	C1704259
27994578	2002	2016	oral pathogens	T001	C0450254
27994578	2018	2031	Porphyromonas	T007	C0206347
27994578	2036	2046	Filifactor	T007	C1082714
27994578	2073	2123	pyruvate as well as amino acid fermenting pathways	T044	C1156744
27994578	2165	2173	butyrate	T109	C0220802
27994578	2196	2205	cytotoxic	T169	C1511636
27994578	2209	2222	oral diseases	T047	C0026636
27994578	2257	2277	butyrogenic pathways	T044	C1157706
27994578	2281	2294	gut pathogens	T033	C4072750
27994578	2299	2309	commensals	T001	C4018878
27994578	2317	2343	enormous ecological impact	T067	C0282165
27994578	2374	2391	immense influence	T077	C4054723
27994578	2395	2403	butyrate	T109	C0220802
27994578	2486	2500	bioengineering	T090	C2717958
27994578	2501	2512	experiments	T062	C0868962
27994578	2523	2535	therapeutics	T169	C0302350
27994578	2538	2548	probiotics	T007	C0525033
27994578	2552	2564	manipulation	T063	C0017387
27994578	2568	2589	butyrate biosynthesis	T044	C1157706
27994578	2590	2603	gene clusters	T028	C0017258
27994578	2607	2615	bacteria	T007	C0004611

27570111|t|Glucose metabolism - weighted imaging with chemical exchange-sensitive MRI of 2-deoxyglucose (2DG) in brain: Sensitivity and biological sources
27570111|a|Recent proof-of-principle studies have demonstrated the feasibility of measuring the uptake and metabolism of non-labeled 2-deoxy-D-glucose (2DG) by a chemical exchange-sensitive spin-lock (CESL) MRI approach. In order to gain better understanding of this new approach, we performed dynamic in vivo CESL MRI on healthy rat brains with an intravenous injection of 2DG under various conditions at 9.4T. For three 2DG doses of 0.25, 0.5 and 1g/kg, we found that 2DG - CESL signals increased linearly with injection dose at the initial (<20min) but not the later period (>40min) suggesting time-dependent differential weightings of 2DG transport and metabolism. Remaining 2DG - CESL studies were performed with 0.25g/kg 2DG. Since a higher isoflurane level reduces glucose metabolism and increases blood flow, 2DG - CESL was measured under 0.5%, 1.5% and 2.2% isoflurane. The 2DG - CESL signal was reduced at higher isoflurane levels correlating well with the 2DG phosphorylation in the intracellular space. To detect regional heterogeneities of glucose metabolism, 2DG - CESL with 0.33×0.33×1.50mm(3) resolution was obtained, which indeed showed a higher response in the cortex compared to the corpus callosum. Lastly, unlike CESL MRI with the injection of non-transportable mannitol, the 2DG - CESL response decreased with an increased spin-lock pulse power confirming that 2DG - CESL is dominated by chemical exchange processes in the extravascular space. Taken together, our results showed that 2DG - CESL MRI signals mainly indicate glucose transport and metabolism and may be a useful biomarker for metabolic studies of normal and diseased brains.
27570111	0	18	Glucose metabolism	T044	C0596620
27570111	21	37	weighted imaging	T060	C0011923
27570111	43	74	chemical exchange-sensitive MRI	T060	C0024485
27570111	78	92	2-deoxyglucose	T109	C4049845
27570111	94	97	2DG	T109	C4049845
27570111	102	107	brain	T023	C0006104
27570111	109	120	Sensitivity	T081	C1511883
27570111	125	135	biological	T080	C0205460
27570111	136	143	sources	T033	C0449416
27570111	144	177	Recent proof-of-principle studies	T062	C2603343
27570111	229	235	uptake	T039	C0243144
27570111	240	250	metabolism	T040	C0025519
27570111	266	283	2-deoxy-D-glucose	T109	C4049845
27570111	285	288	2DG	T109	C4049845
27570111	295	352	chemical exchange-sensitive spin-lock (CESL) MRI approach	T060	C0024485
27570111	427	434	dynamic	T169	C0729333
27570111	435	442	in vivo	T082	C1515655
27570111	443	451	CESL MRI	T060	C0024485
27570111	455	462	healthy	T080	C3898900
27570111	463	466	rat	T015	C0086893
27570111	467	473	brains	T023	C0006104
27570111	482	503	intravenous injection	T169	C0021494
27570111	507	510	2DG	T109	C4049845
27570111	555	558	2DG	T109	C4049845
27570111	559	564	doses	T081	C0178602
27570111	603	606	2DG	T109	C4049845
27570111	609	613	CESL	T060	C0024485
27570111	614	621	signals	T067	C1710082
27570111	622	631	increased	T081	C0205217
27570111	646	655	injection	T061	C1533685
27570111	656	660	dose	T081	C0178602
27570111	772	775	2DG	T109	C4049845
27570111	776	785	transport	T043	C0005528
27570111	790	800	metabolism	T040	C0025519
27570111	812	815	2DG	T109	C4049845
27570111	818	822	CESL	T060	C0024485
27570111	860	863	2DG	T109	C4049845
27570111	873	879	higher	T080	C0205250
27570111	880	890	isoflurane	T109,T121	C0022180
27570111	891	896	level	T080	C0441889
27570111	897	904	reduces	T080	C0392756
27570111	905	923	glucose metabolism	T044	C0596620
27570111	928	937	increases	T169	C0442805
27570111	938	948	blood flow	T039	C0232338
27570111	950	953	2DG	T109	C4049845
27570111	956	960	CESL	T060	C0024485
27570111	965	973	measured	T080	C0444706
27570111	1000	1010	isoflurane	T109,T121	C0022180
27570111	1016	1019	2DG	T109	C4049845
27570111	1022	1026	CESL	T060	C0024485
27570111	1027	1033	signal	T067	C1710082
27570111	1038	1045	reduced	T080	C0392756
27570111	1049	1055	higher	T080	C0205250
27570111	1056	1066	isoflurane	T109,T121	C0022180
27570111	1100	1103	2DG	T109	C4049845
27570111	1104	1119	phosphorylation	T044	C0031715
27570111	1127	1146	intracellular space	T030	C0682581
27570111	1158	1182	regional heterogeneities	T102	C0086833
27570111	1186	1204	glucose metabolism	T044	C0596620
27570111	1206	1209	2DG	T109	C4049845
27570111	1212	1216	CESL	T060	C0024485
27570111	1289	1295	higher	T080	C0205250
27570111	1312	1318	cortex	T023	C0007776
27570111	1335	1350	corpus callosum	T023	C0010090
27570111	1367	1375	CESL MRI	T060	C0024485
27570111	1385	1394	injection	T061	C1533685
27570111	1398	1424	non-transportable mannitol	T109,T121	C0024730
27570111	1430	1433	2DG	T109	C4049845
27570111	1436	1440	CESL	T060	C0024485
27570111	1450	1459	decreased	T081	C0205216
27570111	1468	1477	increased	T081	C0205217
27570111	1478	1499	spin-lock pulse power	T081	C3854080
27570111	1516	1519	2DG	T109	C4049845
27570111	1522	1526	CESL	T060	C0024485
27570111	1543	1551	chemical	T103	C0220806
27570111	1552	1560	exchange	T201	C4019011
27570111	1561	1570	processes	T067	C1522240
27570111	1578	1597	extravascular space	T082	C1254362
27570111	1639	1642	2DG	T109	C4049845
27570111	1645	1653	CESL MRI	T060	C0024485
27570111	1654	1661	signals	T067	C1710082
27570111	1678	1695	glucose transport	T043	C0178666
27570111	1700	1710	metabolism	T044	C0596620
27570111	1731	1740	biomarker	T201	C0005516
27570111	1745	1754	metabolic	T169	C0311400
27570111	1755	1762	studies	T062	C2603343
27570111	1766	1772	normal	T023	C0006104
27570111	1777	1785	diseased	T047	C0012634
27570111	1786	1792	brains	T023	C0006104

28217611|t|Pyoderma gangrenosum: A clinician's nightmare
28217611|a|Pyoderma gangrenosum (PG) is a rare disease and that affecting specifically the sole of the foot, is even rarer. Here, we report the case of a 54-year- old female admitted with a painful ulcer on the sole of the right foot which was initially treated with empirical antibiotics and debridement. The disease was found to spread rapidly after each debridement. The culture reports were negative; rheumatology workup and Doppler study were within normal limits. A clinical suspicion of PG was made and was confirmed with tissue biopsy. She was started on oral steroids following which she dramatically improved. Thus, when a patient presents with a rapidly expanding painful ulcer in a vascular limb that is refractory to antibiotic treatment and exacerbating on debridement, it is imperative to consider the possibility of PG.
28217611	0	20	Pyoderma gangrenosum	T047	C0085652
28217611	24	35	clinician's	T097	C0871685
28217611	36	45	nightmare	T184	C0028084
28217611	46	66	Pyoderma gangrenosum	T047	C0085652
28217611	68	70	PG	T047	C0085652
28217611	77	89	rare disease	T047	C0678236
28217611	126	142	sole of the foot	T029	C0230463
28217611	168	174	report	T170	C0684224
28217611	198	201	old	T079	C0580836
28217611	202	208	female	T032	C0086287
28217611	209	217	admitted	T058	C0184666
28217611	225	232	painful	T184	C0030193
28217611	233	238	ulcer	T047	C0041582
28217611	246	268	sole of the right foot	T029	C0230463
28217611	289	301	treated with	T061	C0332293
28217611	312	323	antibiotics	T195	C0003232
28217611	328	339	debridement	T061	C0011079
28217611	345	352	disease	T047	C0012634
28217611	373	380	rapidly	T080	C0456962
28217611	392	403	debridement	T061	C0011079
28217611	409	424	culture reports	T034	C2061903
28217611	430	438	negative	T033	C0205160
28217611	440	452	rheumatology	T091	C0035452
28217611	453	459	workup	T060	C0750430
28217611	464	477	Doppler study	T060	C0554756
28217611	490	503	normal limits	T033	C0442816
28217611	507	515	clinical	T080	C0205210
28217611	516	525	suspicion	T078	C0750491
28217611	529	531	PG	T047	C0085652
28217611	564	577	tissue biopsy	T060	C3864006
28217611	587	611	started on oral steroids	T061	C0419839
28217611	645	653	improved	T033	C0184511
28217611	668	675	patient	T101	C0030705
28217611	692	699	rapidly	T080	C0456962
28217611	710	717	painful	T184	C0030193
28217611	718	723	ulcer	T047	C0041582
28217611	729	742	vascular limb	T023	C0015385
28217611	751	761	refractory	T169	C0205269
28217611	765	785	antibiotic treatment	T061	C0338237
28217611	790	802	exacerbating	T080	C1444749
28217611	806	817	debridement	T061	C0011079
28217611	867	869	PG	T047	C0085652

28074357|t|The Longitudinal Effects of Parenting on Adaptive Behavior in Children with Fragile X Syndrome
28074357|a|Several studies have reported declines in adaptive behavior amongst children with fragile X syndrome (FXS) starting in middle childhood. We examined the effects of maternal responsivity on adaptive behavior in 55 children with FXS visited 5-6 times in their homes from early through middle childhood. Our analyses indicated that sustained maternal responsivity had a significant positive impact on the trajectories of communication and to a lesser extent other adaptive behavior domains through middle childhood with many effects remaining significant after controlling for autism symptoms and developmental level. For children who showed declines in adaptive behavior during middle childhood, sustained high levels of maternal responsivity minimized the amount of decline observed in the communication, socialization, and daily living domains.
28074357	4	16	Longitudinal	T082	C0205127
28074357	17	27	Effects of	T080	C1704420
28074357	28	37	Parenting	T055	C0679001
28074357	41	58	Adaptive Behavior	T055	C0085880
28074357	62	70	Children	T100	C0008059
28074357	76	94	Fragile X Syndrome	T047	C0016667
28074357	103	110	studies	T062	C2603343
28074357	125	133	declines	T080	C0392756
28074357	137	154	adaptive behavior	T055	C0085880
28074357	163	171	children	T100	C0008059
28074357	177	195	fragile X syndrome	T047	C0016667
28074357	197	200	FXS	T047	C0016667
28074357	214	220	middle	T079	C1254367
28074357	221	230	childhood	T079	C0231335
28074357	235	243	examined	T033	C0332128
28074357	248	258	effects of	T080	C1704420
28074357	259	267	maternal	T099	C0026591
28074357	268	280	responsivity	T041	C2371924
28074357	284	301	adaptive behavior	T055	C0085880
28074357	308	316	children	T100	C0008059
28074357	322	325	FXS	T047	C0016667
28074357	353	358	homes	T073,T092	C0442513
28074357	378	384	middle	T079	C1254367
28074357	385	394	childhood	T079	C0231335
28074357	400	408	analyses	T062	C0936012
28074357	424	433	sustained	T169	C0443318
28074357	434	442	maternal	T099	C0026591
28074357	443	455	responsivity	T041	C2371924
28074357	462	473	significant	T078	C0750502
28074357	474	489	positive impact	T080	C4049986
28074357	497	509	trajectories	T082	C1254362
28074357	513	526	communication	T054	C0009452
28074357	556	573	adaptive behavior	T055	C0085880
28074357	574	581	domains	T077	C1516778
28074357	590	596	middle	T079	C1254367
28074357	597	606	childhood	T079	C0231335
28074357	617	624	effects	T080	C1280500
28074357	635	646	significant	T078	C0750502
28074357	653	664	controlling	T067	C2239193
28074357	669	684	autism symptoms	T033	C4314700
28074357	689	708	developmental level	T040	C0008071
28074357	714	722	children	T100	C0008059
28074357	734	742	declines	T080	C0392756
28074357	746	763	adaptive behavior	T055	C0085880
28074357	771	777	middle	T079	C1254367
28074357	778	787	childhood	T079	C0231335
28074357	789	798	sustained	T169	C0443318
28074357	799	810	high levels	T080	C0441889
28074357	814	822	maternal	T099	C0026591
28074357	823	835	responsivity	T041	C2371924
28074357	836	845	minimized	T080	C1524031
28074357	860	867	decline	T080	C0392756
28074357	868	876	observed	T169	C1441672
28074357	884	897	communication	T054	C0009452
28074357	899	912	socialization	T065	C0037447
28074357	918	938	daily living domains	UnknownType	C0683251

27337992|t|Glomerulonephritis With Masked Monotypic Immunoglobulin Deposits and Concurrent Lymphomatous Infiltration
27337992|a|Kidney injury can be a complication of hematopoietic neoplasia by both direct and indirect mechanisms. Virtually all lymphomas and plasma cell dyscrasias can show kidney involvement, including parenchymal infiltration and by secondary injury. Recently, a unique form of glomerulonephritis with masked monotypic immunoglobulin deposits has been reported, which shows frequent association with hematopoietic neoplasia and a propensity for progressive kidney disease. In many instances, these cases are likely diagnosed as glomerulonephritis with dominant C3 due to the absence of immunoglobulin staining by routine immunofluorescence microscopy. The patient reported here showed lymphomatous infiltration on kidney biopsy and mesangial proliferative glomerulonephritis with dominant staining for C3 without immunoglobulins on initial immunofluorescence; however, monotypic immunoglobulin G κ light chain was revealed after additional immunofluorescence staining was performed on the paraffin-embedded tissue. This patient's case highlights the evolving state of kidney biopsy interpretation and the expanding spectrum of kidney disease in the setting of hematopoietic neoplasia.
27337992	0	18	Glomerulonephritis	T047	C0017658
27337992	31	64	Monotypic Immunoglobulin Deposits	T046	C0333585
27337992	69	79	Concurrent	T079	C0205420
27337992	80	105	Lymphomatous Infiltration	T191	C2960101
27337992	106	119	Kidney injury	T037	C0160420
27337992	129	141	complication	T046	C0009566
27337992	145	168	hematopoietic neoplasia	T191	C0376544
27337992	177	183	direct	T080	C1947931
27337992	188	196	indirect	T080	C0439852
27337992	197	207	mechanisms	T169	C0441712
27337992	223	232	lymphomas	T191	C0024299
27337992	237	259	plasma cell dyscrasias	T047	C1136084
27337992	269	275	kidney	T023	C0022646
27337992	276	287	involvement	T169	C1314939
27337992	299	310	parenchymal	T023	C0227628
27337992	299	323	parenchymal infiltration	T046	C0332448
27337992	341	347	injury	T037	C0043251
27337992	376	394	glomerulonephritis	T047	C0017658
27337992	407	440	monotypic immunoglobulin deposits	T046	C0333585
27337992	498	521	hematopoietic neoplasia	T191	C0376544
27337992	543	554	progressive	T169	C0205329
27337992	555	569	kidney disease	T047	C0022658
27337992	613	622	diagnosed	T033	C0011900
27337992	626	644	glomerulonephritis	T047	C0017658
27337992	650	658	dominant	T169	C1527180
27337992	659	661	C3	T047	C4087273
27337992	684	698	immunoglobulin	T116,T129	C0021027
27337992	684	707	immunoglobulin staining	T033	C1704680
27337992	719	748	immunofluorescence microscopy	T059	C0079604
27337992	754	761	patient	T101	C0030705
27337992	783	808	lymphomatous infiltration	T191	C2960101
27337992	812	825	kidney biopsy	T060	C0194073
27337992	830	872	mesangial proliferative glomerulonephritis	T047	C0221238
27337992	878	886	dominant	T169	C1527180
27337992	887	895	staining	T033	C1704680
27337992	900	902	C3	T047	C4087273
27337992	911	926	immunoglobulins	T116,T129	C0021027
27337992	938	956	immunofluorescence	T059	C0079604
27337992	967	995	monotypic immunoglobulin G κ	T116,T121,T129	C0020852
27337992	996	1007	light chain	T116,T129	C0021036
27337992	1038	1065	immunofluorescence staining	T059	C0079604
27337992	1087	1111	paraffin-embedded tissue	T024	C1519524
27337992	1118	1127	patient's	T101	C0030705
27337992	1166	1179	kidney biopsy	T060	C0194073
27337992	1225	1239	kidney disease	T047	C0022658
27337992	1258	1281	hematopoietic neoplasia	T191	C0376544

27299091|t|Simultaneous Bilateral Femur Neck Fracture in A Young Adult with Chronic Renal Failure - A Case Report and Review of Literature
27299091|a|Pathological bilateral femoral neck fracture due to renal osteodystrophy is rare. This is a report of a chronic renal failure patient who had sustained bilateral intra-capsular displaced fracture neck of femur following an episode of convulsion and the difficulties encountered in early diagnosis and treatment. The pathophysiology of renal osteodystrophy and the treatment of hip fractures in patients with renal failure are also discussed. A 23 years old male patient admitted with h/o dysuria, pyuria and loss of appetite since 3 months. He was a known case of chronic renal failure and reflux nephropathy. On investigating, patient's renal parameters were high and he was started with haemodialysis. The next day patient had c/o bilateral hip pain and inability to move bilateral lower limbs following an episode of seizure. Radiograph of pelvis showed vertical sub capital fractures of bilateral neck of femur. In this patient, considering his age, general condition & prognosis, an elective surgery in the form of bilateral uncemented modular bipolar hemiarthroplasty was done. Overall risk of hip fracture among patients with chronic renal failure is considerably higher than in the general population, independent of age and gender. Simultaneous spontaneous bilateral fractures of the femoral neck are rare and a delayed diagnosis is usual. The study of etiological factors of these fractures is essential to guide us in choosing the treatment of choice. Obviously patient's age, life expectancy as well as renal co morbidity has an influence over deciding treatment and outcome.
27299091	0	12	Simultaneous	T079	C0521115
27299091	13	22	Bilateral	T082	C0238767
27299091	23	42	Femur Neck Fracture	T037	C0015806
27299091	48	59	Young Adult	T100	C0238598
27299091	65	86	Chronic Renal Failure	T047	C0022661
27299091	91	102	Case Report	T170	C0085973
27299091	107	127	Review of Literature	T170	C0282441
27299091	128	140	Pathological	T169	C1521733
27299091	141	150	bilateral	T082	C0238767
27299091	151	172	femoral neck fracture	T037	C0015806
27299091	180	200	renal osteodystrophy	T047	C0035086
27299091	204	208	rare	T080	C0522498
27299091	220	226	report	T170	C0684224
27299091	232	253	chronic renal failure	T047	C0022661
27299091	254	261	patient	T101	C0030705
27299091	270	279	sustained	T169	C0443318
27299091	280	289	bilateral	T082	C0238767
27299091	290	304	intra-capsular	T082	C0205151
27299091	315	337	fracture neck of femur	T037	C0015806
27299091	351	361	episode of	T079	C0332189
27299091	362	372	convulsion	T184	C4048158
27299091	381	405	difficulties encountered	T058	C0422301
27299091	409	424	early diagnosis	T060	C0596473
27299091	429	438	treatment	T061	C0087111
27299091	444	459	pathophysiology	T046	C0277785
27299091	463	483	renal osteodystrophy	T047	C0035086
27299091	492	501	treatment	T061	C0087111
27299091	505	518	hip fractures	T037	C0019557
27299091	522	530	patients	T101	C0030705
27299091	536	549	renal failure	T047	C0035078
27299091	575	580	years	T079	C0439234
27299091	585	589	male	T032	C0086582
27299091	590	597	patient	T101	C0030705
27299091	612	623	h/o dysuria	T184	C0013428
27299091	625	631	pyuria	T033	C0034359
27299091	636	652	loss of appetite	T047	C0003123
27299091	661	667	months	T079	C0439231
27299091	692	713	chronic renal failure	T047	C0022661
27299091	718	736	reflux nephropathy	T047	C3495566
27299091	741	754	investigating	T169	C1292732
27299091	756	765	patient's	T101	C0030705
27299091	766	771	renal	T023	C0022646
27299091	772	782	parameters	T077	C0549193
27299091	788	792	high	T080	C0205250
27299091	804	811	started	T080	C1272689
27299091	817	830	haemodialysis	T061	C0019004
27299091	836	844	next day	T079	C0439228
27299091	845	852	patient	T101	C0030705
27299091	857	870	c/o bilateral	T082	C0238767
27299091	871	879	hip pain	T184	C0019559
27299091	884	901	inability to move	T033	C0558185
27299091	902	911	bilateral	T082	C0238767
27299091	912	923	lower limbs	T023	C0023216
27299091	937	947	episode of	T079	C0332189
27299091	948	955	seizure	T184	C0036572
27299091	957	977	Radiograph of pelvis	T060	C0412672
27299091	985	1015	vertical sub capital fractures	T037	C0559863
27299091	1019	1028	bilateral	T082	C0238767
27299091	1029	1042	neck of femur	T023	C0015815
27299091	1052	1059	patient	T101	C0030705
27299091	1077	1080	age	T032	C0001779
27299091	1082	1099	general condition	T033	C1142435
27299091	1102	1111	prognosis	T058	C0033325
27299091	1116	1132	elective surgery	T061	C0206058
27299091	1148	1157	bilateral	T082	C0238767
27299091	1158	1184	uncemented modular bipolar	T169	C0449913
27299091	1185	1201	hemiarthroplasty	T061	C0744743
27299091	1206	1210	done	T080	C1272695
27299091	1212	1224	Overall risk	T078	C0035647
27299091	1228	1240	hip fracture	T037	C0019557
27299091	1247	1255	patients	T101	C0030705
27299091	1261	1282	chronic renal failure	T047	C0022661
27299091	1299	1305	higher	T080	C0205250
27299091	1318	1336	general population	T098	C0683971
27299091	1338	1352	independent of	T169	C0332291
27299091	1353	1356	age	T032	C0001779
27299091	1361	1367	gender	T032	C0079399
27299091	1369	1381	Simultaneous	T079	C0521115
27299091	1382	1393	spontaneous	T169	C0205359
27299091	1394	1403	bilateral	T082	C0238767
27299091	1404	1433	fractures of the femoral neck	T037	C0015806
27299091	1438	1442	rare	T080	C0522498
27299091	1449	1466	delayed diagnosis	T080	C2718036
27299091	1470	1475	usual	T080	C3538928
27299091	1481	1486	study	T062	C2603343
27299091	1490	1509	etiological factors	T169	C0015127
27299091	1519	1528	fractures	T037	C0016658
27299091	1557	1565	choosing	T052	C1707391
27299091	1570	1579	treatment	T061	C0087111
27299091	1583	1589	choice	T055	C0008300
27299091	1601	1610	patient's	T101	C0030705
27299091	1611	1614	age	T032	C0001779
27299091	1616	1631	life expectancy	T102	C0023671
27299091	1649	1661	co morbidity	T078	C0009488
27299091	1669	1678	influence	T077	C4054723
27299091	1693	1702	treatment	T061	C0087111
27299091	1707	1714	outcome	T169	C1274040

28286864|t|In Vivo Expansion of Melanoma -Specific T Cells Using Microneedle Arrays Coated with Immune-Polyelectrolyte Multilayers
28286864|a|Microneedles (MNs) are micron-scale polymeric or metallic structures that offer distinct advantages for vaccines by efficiently targeting skin -resident immune cells, eliminating injection-associated pain, and improving patient compliance. These advantages, along with recent studies showing therapeutic benefits achieved using traditional intradermal injections in human cancer patients, suggest MN delivery might enhance cancer vaccines and immunotherapies. We recently developed a new class of polyelectrolyte multilayers based on the self-assembly of model peptide antigens and molecular toll-like receptor agonists (TLRa) into ultrathin, conformal coatings. Here, we reasoned that these immune polyelectrolyte multilayers (iPEMs) might be a useful platform for assembling cancer vaccine components on MN arrays for intradermal delivery from these substrates. Using conserved human melanoma antigens and a potent TLRa vaccine adjuvant, CpG, we show that iPEMs can be assembled on MNs in an automated fashion. These films, prepared with up to 128 layers, are approximately 200 nm thick but provide cancer vaccine cargo loading >225 μg/cm(2). In cell culture, iPEM cargo released from MNs is internalized by primary dendritic cells, promotes activation of these cells, and expands T cells during coculture. In mice, application of iPEM -coated MNs results in the codelivery of tumor antigen and CpG through the skin, expanding tumor -specific T cells during initial MN applications and resulting in larger memory recall responses during a subsequent booster MN application. This study support MNs coated with PEMs built from tumor vaccine components as a well-defined, modular system for generating tumor -specific immune responses, enabling new approaches that can be explored in combination with checkpoint blockade or other combination cancer therapies.
28286864	0	7	In Vivo	T082	C1515655
28286864	8	17	Expansion	T043	C0007595
28286864	21	29	Melanoma	T191	C0025202
28286864	40	47	T Cells	T025	C0039194
28286864	54	65	Microneedle	T074	C0027551
28286864	85	119	Immune-Polyelectrolyte Multilayers	T122	C0005479
28286864	120	132	Microneedles	T074	C0027551
28286864	134	137	MNs	T074	C0027551
28286864	156	165	polymeric	T104,T122	C0032521
28286864	169	188	metallic structures	T073	C3273359
28286864	224	232	vaccines	T121,T129	C0042210
28286864	258	262	skin	T022	C1123023
28286864	273	285	immune cells	T025	C0312740
28286864	299	324	injection-associated pain	T184	C1096717
28286864	340	347	patient	T101	C0030705
28286864	348	358	compliance	T055	C1321605
28286864	396	403	studies	T062	C2603343
28286864	460	482	intradermal injections	T061	C0021489
28286864	486	491	human	T016	C0086418
28286864	492	507	cancer patients	T101	C1516213
28286864	517	519	MN	T074	C0027551
28286864	520	528	delivery	T169	C1705822
28286864	543	558	cancer vaccines	T116,T121,T129	C0376659
28286864	563	578	immunotherapies	T061	C0021083
28286864	617	644	polyelectrolyte multilayers	T122	C0005479
28286864	658	671	self-assembly	T044	C0872376
28286864	681	697	peptide antigens	T129	C0003320
28286864	702	739	molecular toll-like receptor agonists	T121	C0243192
28286864	741	745	TLRa	T121	C0243192
28286864	752	781	ultrathin, conformal coatings	T080	C1522408
28286864	812	846	immune polyelectrolyte multilayers	T122	C0005479
28286864	848	853	iPEMs	T122	C0005479
28286864	897	911	cancer vaccine	T116,T121,T129	C0376659
28286864	912	922	components	T077	C1705248
28286864	926	928	MN	T074	C0027551
28286864	940	960	intradermal delivery	T061	C0021489
28286864	972	982	substrates	T167	C3891814
28286864	1000	1005	human	T016	C0086418
28286864	1006	1023	melanoma antigens	T116,T129	C2936596
28286864	1037	1049	TLRa vaccine	T121	C0243192
28286864	1050	1058	adjuvant	T169	C1522673
28286864	1060	1063	CpG	T121,T129	C0042210
28286864	1078	1083	iPEMs	T122	C0005479
28286864	1104	1107	MNs	T074	C0027551
28286864	1139	1144	films	T080	C1522408
28286864	1221	1235	cancer vaccine	T116,T121,T129	C0376659
28286864	1268	1280	cell culture	T059	C0007585
28286864	1282	1286	iPEM	T122	C0005479
28286864	1307	1310	MNs	T074	C0027551
28286864	1338	1353	dendritic cells	T025	C0011306
28286864	1364	1374	activation	T052	C1879547
28286864	1384	1389	cells	T025	C0007634
28286864	1403	1410	T cells	T025	C0039194
28286864	1418	1427	coculture	T059	C0282547
28286864	1432	1436	mice	T015	C0025929
28286864	1438	1449	application	T058	C0185125
28286864	1453	1457	iPEM	T122	C0005479
28286864	1466	1469	MNs	T074	C0027551
28286864	1499	1504	tumor	T191	C0027651
28286864	1505	1512	antigen	T129	C0003320
28286864	1517	1520	CpG	T121,T129	C0042210
28286864	1533	1537	skin	T022	C1123023
28286864	1549	1554	tumor	T191	C0027651
28286864	1565	1572	T cells	T025	C0039194
28286864	1588	1590	MN	T074	C0027551
28286864	1591	1603	applications	T058	C0185125
28286864	1628	1651	memory recall responses	T041	C0679063
28286864	1680	1682	MN	T074	C0027551
28286864	1683	1694	application	T058	C0185125
28286864	1701	1706	study	T062	C2603343
28286864	1715	1718	MNs	T074	C0027551
28286864	1731	1735	PEMs	T122	C0005479
28286864	1747	1752	tumor	T191	C0027651
28286864	1753	1760	vaccine	T121,T129	C0042210
28286864	1821	1826	tumor	T191	C0027651
28286864	1837	1853	immune responses	T042	C0301872
28286864	1903	1914	combination	T080	C0205195
28286864	1949	1960	combination	T080	C0205195
28286864	1961	1977	cancer therapies	T061	C0920425

28475081|t|Effectiveness of silver diamine fluoride in caries prevention and arrest: a systematic literature review
28475081|a|This study aimed to evaluate the scientific evidence regarding the effectiveness of silver diamine fluoride (SDF) in preventing and arresting caries in the primary dentition and permanent first molars. A systematic review (SR) was performed by 2 independent reviewers using 3 electronic databases (PubMed, ScienceDirect, and Scopus). The database search employed the following key words: " topical fluorides " AND " children " AND " clinical trials "; " topical fluorides " OR " silver diamine fluoride " AND " randomized controlled trial "; " silver diamine fluoride " AND " children " OR " primary dentition " AND " tooth decay "; " silver diamine fluoride " OR " sodium fluoride varnish " AND " early childhood caries "; and " silver diamine fluoride " AND " children ". Inclusion criteria were articles published in English, from 2005 to January 2016, on clinical studies using SDF as a treatment intervention to evaluate caries arrest in children with primary dentition and/or permanent first molars. Database searches provided 821 eligible publications, of which 33 met the inclusion criteria. After the abstracts were prescreened, 25 articles were dismissed based on exclusion criteria. The remaining 8 full-text articles were assessed for eligibility. Of these, 7 publications were included in the SR. These included 1 study assessing the effectiveness of SDF at different concentrations; 3 studies comparing SDF with other interventions; 2 investigations comparing SDF at different application frequencies and with other interventions; and 1 study comparing semiannual SDF applications versus a control group. The literature indicates that SDF is a preventive treatment for dental caries in community settings. At concentrations of 30% and 38%, SDF shows potential as an alternative treatment for caries arrest in the primary dentition and permanent first molars. To establish guidelines, more studies are needed to fully assess the effectiveness of SDF and to determine the appropriate application frequency.
28475081	0	13	Effectiveness	T080	C1280519
28475081	17	40	silver diamine fluoride	T197	C0074538
28475081	44	61	caries prevention	T058	C1960644
28475081	66	72	arrest	T079	C0237477
28475081	76	104	systematic literature review	T170	C1955832
28475081	110	115	study	T062	C2603343
28475081	125	133	evaluate	T058	C0220825
28475081	138	157	scientific evidence	T078	C3887511
28475081	172	185	effectiveness	T080	C1280519
28475081	189	212	silver diamine fluoride	T197	C0074538
28475081	214	217	SDF	T197	C0074538
28475081	222	232	preventing	T058	C1960644
28475081	237	246	arresting	T079	C0237477
28475081	247	253	caries	T047	C0011334
28475081	261	268	primary	T080	C0205225
28475081	269	278	dentition	T023	C0011443
28475081	283	305	permanent first molars	T023	C0582449
28475081	309	326	systematic review	T170	C1955832
28475081	328	330	SR	T170	C1955832
28475081	363	372	reviewers	T098	C1882950
28475081	381	401	electronic databases	T170	C3841595
28475081	403	409	PubMed	T170	C1138432
28475081	411	424	ScienceDirect	T170	C3841595
28475081	430	436	Scopus	T170	C3841595
28475081	443	451	database	T170	C3841595
28475081	452	458	search	T052	C1706202
28475081	495	512	topical fluorides	T122,T197	C0016328
28475081	521	529	children	T100	C0008059
28475081	538	553	clinical trials	T062	C0008976
28475081	559	576	topical fluorides	T122,T197	C0016328
28475081	584	607	silver diamine fluoride	T197	C0074538
28475081	616	643	randomized controlled trial	T062,T170	C0206034
28475081	649	672	silver diamine fluoride	T197	C0074538
28475081	681	689	children	T100	C0008059
28475081	697	704	primary	T080	C0205225
28475081	705	714	dentition	T023	C0011443
28475081	723	734	tooth decay	T047	C0011334
28475081	740	763	silver diamine fluoride	T197	C0074538
28475081	771	794	sodium fluoride varnish	T122	C0011379
28475081	803	818	early childhood	T079	C0599196
28475081	819	825	caries	T047	C0011334
28475081	835	858	silver diamine fluoride	T197	C0074538
28475081	867	875	children	T100	C0008059
28475081	879	897	Inclusion criteria	T080	C1512693
28475081	903	911	articles	T170	C1706852
28475081	925	932	English	T171	C0376245
28475081	947	954	January	T080	C3829466
28475081	964	980	clinical studies	T062	C0008972
28475081	987	990	SDF	T197	C0074538
28475081	996	1018	treatment intervention	UnknownType	C0814449
28475081	1022	1030	evaluate	T058	C0220825
28475081	1031	1037	caries	T047	C0011334
28475081	1038	1044	arrest	T079	C0237477
28475081	1048	1056	children	T100	C0008059
28475081	1062	1069	primary	T080	C0205225
28475081	1070	1079	dentition	T023	C0011443
28475081	1087	1109	permanent first molars	T023	C0582449
28475081	1111	1119	Database	T170	C3841595
28475081	1120	1128	searches	T052	C1706202
28475081	1151	1163	publications	T073,T170	C0034036
28475081	1185	1203	inclusion criteria	T080	C1512693
28475081	1215	1224	abstracts	T170	C0600678
28475081	1230	1241	prescreened	T052	C0441655
28475081	1246	1254	articles	T170	C1706852
28475081	1279	1297	exclusion criteria	T169	C0680251
28475081	1315	1333	full-text articles	T170	C1706852
28475081	1339	1347	assessed	T052	C1516048
28475081	1377	1389	publications	T073,T170	C0034036
28475081	1411	1413	SR	T170	C1955832
28475081	1432	1437	study	T062	C2603343
28475081	1452	1465	effectiveness	T080	C1280519
28475081	1469	1472	SDF	T197	C0074538
28475081	1486	1500	concentrations	T080	C0205556
28475081	1504	1511	studies	T062	C2603343
28475081	1522	1525	SDF	T197	C0074538
28475081	1537	1550	interventions	T058	C1273869
28475081	1554	1568	investigations	T058	C0220825
28475081	1579	1582	SDF	T197	C0074538
28475081	1596	1607	application	T058	C0185125
28475081	1608	1619	frequencies	T079	C0439603
28475081	1635	1648	interventions	T058	C1273869
28475081	1656	1661	study	T062	C2603343
28475081	1672	1682	semiannual	T079	C1254367
28475081	1683	1686	SDF	T197	C0074538
28475081	1687	1699	applications	T058	C0185125
28475081	1709	1722	control group	T096	C0009932
28475081	1728	1738	literature	T170	C0023866
28475081	1754	1757	SDF	T197	C0074538
28475081	1763	1801	preventive treatment for dental caries	T058	C1960644
28475081	1795	1801	caries	T047	C0011334
28475081	1805	1814	community	T096	C0009462
28475081	1828	1842	concentrations	T080	C0205556
28475081	1859	1862	SDF	T197	C0074538
28475081	1885	1906	alternative treatment	UnknownType	C0683466
28475081	1911	1917	caries	T047	C0011334
28475081	1918	1924	arrest	T079	C0237477
28475081	1932	1939	primary	T080	C0205225
28475081	1940	1949	dentition	T023	C0011443
28475081	1954	1976	permanent first molars	T023	C0582449
28475081	1991	2001	guidelines	T170	C0162791
28475081	2036	2042	assess	T058	C0184514
28475081	2047	2060	effectiveness	T080	C1280519
28475081	2064	2067	SDF	T197	C0074538
28475081	2101	2112	application	T058	C0185125
28475081	2113	2122	frequency	T079	C0439603

27941728|t|Prevalence of Psychiatric Disorders among Female Juvenile Offenders
27941728|a|Inmates of Juvenile Developmental Centers are the special group of youth population who are in conflict with law. They are vulnerable to psychiatric illness. The objective of this study was to see the prevalence and type of psychiatric disorders in institutionalized female juvenile offenders and non-offenders of same age, sex and socioeconomic group in the community. The association of mental disorders was examined in 43 female inmates of Juvenile Development Centers and 43 randomly selected comparison subjects in community. One stage-structured assessment of psychopathology was carried out by using a structured and valid Bangla version of the Development and Well-Being Assessment (DAWBA). Development and Well-Being Assessment generated psychiatric diagnosis was assigned based on ICD-10 diagnostic criteria for research. The result revealed that, of those who were in conflict with law, 93% had mental disorder, whereas 14% of non-offenders had psychiatric disorder. Among the offenders with psychiatric disorders, most of them (32.6%) suffered from Major Depressive Disorder (MDD), followed by combined MDD & Post Traumatic Stress Disorder (PTSD). On the other hand, among the non-offenders with psychiatric disorder 9.3% suffered from MDD. It can be concluded that considerable psychiatric disorders are prevalent among the female juvenile offenders with comparison to non-offenders. Broad -based replication study could confirm these findings.
27941728	0	10	Prevalence	T081	C0683919
27941728	14	35	Psychiatric Disorders	T048	C3841734
27941728	42	48	Female	T032	C0086287
27941728	49	67	Juvenile Offenders	T098	C0022443
27941728	68	75	Inmates	T098	C0033167
27941728	79	109	Juvenile Developmental Centers	T093	C1708333
27941728	118	125	special	T080	C0205555
27941728	126	131	group	T098	C1257890
27941728	135	140	youth	T100	C0087178
27941728	141	151	population	T098	C1257890
27941728	163	171	conflict	T055	C0009671
27941728	177	180	law	T089	C0728724
27941728	191	201	vulnerable	T169	C0332324
27941728	205	224	psychiatric illness	T048	C1404970
27941728	230	239	objective	T170	C0018017
27941728	248	253	study	T062	C2603343
27941728	269	279	prevalence	T081	C0683919
27941728	284	288	type	T080	C0332307
27941728	292	313	psychiatric disorders	T048	C3841734
27941728	317	334	institutionalized	T033	C0562359
27941728	335	341	female	T032	C0086287
27941728	342	360	juvenile offenders	T098	C0022443
27941728	365	378	non-offenders	T098	C1257890
27941728	382	386	same	T080	C0445247
27941728	387	390	age	T032	C0001779
27941728	392	395	sex	T032	C1522384
27941728	400	419	socioeconomic group	T080	C0086996
27941728	427	436	community	T096	C0009462
27941728	442	453	association	T041	C0004083
27941728	457	473	mental disorders	T048	C0004936
27941728	478	486	examined	T033	C0332128
27941728	493	499	female	T032	C0086287
27941728	500	507	inmates	T098	C0033167
27941728	511	539	Juvenile Development Centers	T093	C1708333
27941728	547	555	randomly	T080	C0439605
27941728	556	564	selected	T052	C1707391
27941728	565	575	comparison	T052	C1707455
27941728	576	584	subjects	T096	C0681850
27941728	588	597	community	T096	C0009462
27941728	599	630	One stage-structured assessment	T058	C1254363
27941728	634	649	psychopathology	T091	C0033927
27941728	677	687	structured	T169	C1300196
27941728	692	697	valid	T080	C2349099
27941728	698	704	Bangla	T171	C0023008
27941728	705	712	version	T170	C0333052
27941728	720	757	Development and Well-Being Assessment	T058	C1254363
27941728	759	764	DAWBA	T058	C1254363
27941728	767	804	Development and Well-Being Assessment	T058	C1254363
27941728	815	826	psychiatric	T169	C0205487
27941728	827	836	diagnosis	T033	C0011900
27941728	859	865	ICD-10	T170	C1137110
27941728	866	885	diagnostic criteria	T170	C0679228
27941728	890	898	research	T062	C0035168
27941728	904	910	result	T033	C0683954
27941728	911	919	revealed	T080	C0443289
27941728	947	955	conflict	T055	C0009671
27941728	961	964	law	T089	C0728724
27941728	974	989	mental disorder	T048	C0004936
27941728	1006	1019	non-offenders	T098	C1257890
27941728	1024	1044	psychiatric disorder	T048	C3841734
27941728	1056	1065	offenders	T098	C0699726
27941728	1071	1092	psychiatric disorders	T048	C3841734
27941728	1129	1154	Major Depressive Disorder	T048	C1269683
27941728	1156	1159	MDD	T048	C1269683
27941728	1174	1182	combined	T080	C0205195
27941728	1183	1186	MDD	T048	C1269683
27941728	1189	1219	Post Traumatic Stress Disorder	T048	C0038436
27941728	1221	1225	PTSD	T048	C0038436
27941728	1257	1270	non-offenders	T098	C1257890
27941728	1276	1296	psychiatric disorder	T048	C3841734
27941728	1316	1319	MDD	T048	C1269683
27941728	1331	1340	concluded	T078	C1707478
27941728	1346	1358	considerable	T080	C4288581
27941728	1359	1380	psychiatric disorders	T048	C3841734
27941728	1385	1394	prevalent	T081	C0683919
27941728	1405	1411	female	T032	C0086287
27941728	1412	1430	juvenile offenders	T098	C0022443
27941728	1436	1446	comparison	T052	C1707455
27941728	1450	1463	non-offenders	T098	C1257890
27941728	1465	1470	Broad	T082	C0332464
27941728	1478	1495	replication study	UnknownType	C0681825
27941728	1502	1509	confirm	T080	C1456348
27941728	1516	1524	findings	T033	C0243095

28244917|t|In Vivo Three-Dimensional Patellar Mechanics: Normal Knees Compared with Domed and Anatomic Patellar Components
28244917|a|Patellofemoral complications are a major cause of revision surgery following total knee arthroplasty (TKA). High forces occurring at the patellofemoral articulation coupled with a small patellofemoral contact area pose substantial design challenges. In this study, the three-dimensional (3D) in vivo mechanics of domed and anatomically shaped patellar components were compared with those of native patellae. Ten normal knees, 10 treated with an LCS-PS (low contact stress-posterior stabilized) TKA (anatomically shaped patellar component), and 10 treated with a PFC Sigma RP-PS (press-fit condylar Sigma rotating platform-posterior stabilized) TKA (domed patellar component) were analyzed under fluoroscopic surveillance while the patient performed a weight-bearing deep knee bend from full knee extension to maximum knee flexion. Relevant bone geometries were segmented out from computed tomography (CT) scans, and computer-assisted-design (CAD) models of the implanted components were obtained from the manufacturer. Three-dimensional patellofemoral kinematics were obtained using a 3D -to- 2D registration process. Contact mechanics were calculated using a distance map between the articulating patellar and femoral surfaces. Both patellar component designs exhibited good rotational kinematics and tracked well within the femoral trochlea when compared with the normal patella. The contact areas in the TKA groups peaked at 60° of knee flexion (mean and standard deviation, 201 ± 63.4 mm for the LCS-PS group and 218 ± 95.4 mm for the Sigma RP-PS group), and the areas were substantially smaller than those previously reported for the normal patella. Contact points in the TKA groups stayed close to the center of the patellar components. Both designs performed satisfactorily, although patellofemoral contact areas were reduced in comparison with those in the native patella. Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
28244917	0	7	In Vivo	T082	C1515655
28244917	8	25	Three-Dimensional	T082	C0450363
28244917	26	34	Patellar	T023	C0030647
28244917	35	44	Mechanics	T070	C0376706
28244917	46	52	Normal	T080	C0205307
28244917	53	58	Knees	T023	C0022742
28244917	59	67	Compared	T052	C1707455
28244917	73	78	Domed	T082	C0444914
28244917	83	91	Anatomic	T080	C0220784
28244917	92	100	Patellar	T023	C0030647
28244917	101	111	Components	T073	C1708963
28244917	112	126	Patellofemoral	T030	C0447801
28244917	127	140	complications	T169	C1171258
28244917	162	178	revision surgery	T061	C0035110
28244917	179	188	following	T079	C0332282
28244917	189	212	total knee arthroplasty	T061	C0086511
28244917	214	217	TKA	T061	C0086511
28244917	220	224	High	T080	C0205250
28244917	225	231	forces	T067	C0441722
28244917	249	276	patellofemoral articulation	T030	C0447801
28244917	277	284	coupled	T169	C1948027
28244917	292	297	small	T081	C0700321
28244917	298	312	patellofemoral	T030	C0447801
28244917	313	325	contact area	T082	C0205146
28244917	343	349	design	T052	C1707689
28244917	370	375	study	T062	C2603343
28244917	381	398	three-dimensional	T082	C0450363
28244917	400	402	3D	T082	C0450363
28244917	404	411	in vivo	T082	C1515655
28244917	412	421	mechanics	T070	C0376706
28244917	425	430	domed	T082	C0444914
28244917	435	447	anatomically	T080	C0220784
28244917	448	454	shaped	T082	C0332479
28244917	455	463	patellar	T023	C0030647
28244917	464	474	components	T073	C1708963
28244917	480	488	compared	T052	C1707455
28244917	503	509	native	T169	C0302891
28244917	510	518	patellae	T023	C0030647
28244917	524	530	normal	T080	C0205307
28244917	531	536	knees	T023	C0022742
28244917	541	553	treated with	T061	C0332293
28244917	557	609	LCS-PS (low contact stress-posterior stabilized) TKA	T061	C0086511
28244917	611	623	anatomically	T080	C0220784
28244917	624	630	shaped	T082	C0332479
28244917	631	639	patellar	T023	C0030647
28244917	640	649	component	T073	C1708963
28244917	659	671	treated with	T061	C0332293
28244917	674	759	PFC Sigma RP-PS (press-fit condylar Sigma rotating platform-posterior stabilized) TKA	T061	C0086511
28244917	761	766	domed	T082	C0444914
28244917	767	775	patellar	T023	C0030647
28244917	776	785	component	T073	C1708963
28244917	792	800	analyzed	T062	C0936012
28244917	807	819	fluoroscopic	T060	C0016356
28244917	820	832	surveillance	T169	C0220920
28244917	843	850	patient	T101	C0030705
28244917	851	860	performed	T169	C0884358
28244917	863	877	weight-bearing	T033	C0085086
28244917	878	882	deep	T082	C0205125
28244917	883	892	knee bend	T033	C0243095
28244917	898	902	full	T080	C0443225
28244917	903	917	knee extension	T033	C2237139
28244917	921	928	maximum	T081	C0806909
28244917	929	941	knee flexion	T033	C0240114
28244917	973	982	segmented	T082	C0441635
28244917	992	1011	computed tomography	T060	C0412645
28244917	1013	1015	CT	T060	C0412645
28244917	1017	1022	scans	T060	C0441633
28244917	1028	1052	computer-assisted-design	T066	C0162517
28244917	1054	1057	CAD	T066	C0162517
28244917	1059	1065	models	T170	C3161035
28244917	1073	1082	implanted	T074	C0021102
28244917	1083	1093	components	T073	C1708963
28244917	1131	1148	Three-dimensional	T082	C0450363
28244917	1149	1163	patellofemoral	T030	C0447801
28244917	1164	1174	kinematics	T091	C0600169
28244917	1197	1199	3D	T082	C0450363
28244917	1205	1207	2D	T082	C1705052
28244917	1230	1247	Contact mechanics	T070	C0376706
28244917	1253	1263	calculated	T052	C1441506
28244917	1272	1284	distance map	T073	C0024779
28244917	1297	1318	articulating patellar	T023	C0030647
28244917	1323	1339	femoral surfaces	T029	C0828554
28244917	1346	1354	patellar	T023	C0030647
28244917	1355	1364	component	T073	C1708963
28244917	1383	1387	good	T080	C0205170
28244917	1388	1409	rotational kinematics	T091	C0600169
28244917	1438	1454	femoral trochlea	T023	C0223886
28244917	1460	1468	compared	T052	C1707455
28244917	1478	1484	normal	T080	C0205307
28244917	1485	1492	patella	T023	C0030647
28244917	1498	1511	contact areas	T082	C0205146
28244917	1519	1522	TKA	T061	C0086511
28244917	1523	1529	groups	T078	C0441833
28244917	1547	1559	knee flexion	T033	C0240114
28244917	1561	1565	mean	T081	C0444504
28244917	1570	1588	standard deviation	T081	C0871420
28244917	1612	1624	LCS-PS group	T078	C0441833
28244917	1651	1668	Sigma RP-PS group	T078	C0441833
28244917	1679	1684	areas	T082	C0205146
28244917	1704	1711	smaller	T080	C0547044
28244917	1734	1742	reported	T170	C0684224
28244917	1751	1757	normal	T080	C0205307
28244917	1758	1765	patella	T023	C0030647
28244917	1767	1781	Contact points	T082	C3714763
28244917	1789	1792	TKA	T061	C0086511
28244917	1793	1799	groups	T078	C0441833
28244917	1820	1826	center	T082	C0205099
28244917	1834	1842	patellar	T023	C0030647
28244917	1843	1853	components	T073	C1708963
28244917	1860	1867	designs	T052	C1707689
28244917	1868	1877	performed	T169	C0884358
28244917	1878	1892	satisfactorily	T080	C0205410
28244917	1903	1917	patellofemoral	T030	C0447801
28244917	1918	1931	contact areas	T082	C0205146
28244917	1937	1944	reduced	T080	C0392756
28244917	1948	1958	comparison	T052	C1707455
28244917	1977	1983	native	T169	C0302891
28244917	1984	1991	patella	T023	C0030647

27932462|t|Salmonella Co-opts Host Cell Chaperone -mediated Autophagy for Intracellular Growth
27932462|a|Salmonella enterica are invasive intracellular pathogens that replicate within a membrane - bound compartment inside infected host cells known as the Salmonella - containing vacuole. How Salmonella obtains nutrients for growth within this intracellular niche despite the apparent isolation is currently not known. Recent studies have indicated the importance of glucose and related carbon sources for tissue colonization and intracellular proliferation within host cells during Salmonella infections, although none have been found to be essential. We found that wild-type Salmonella are capable of replicating within infected host cells in the absence of both exogenous sugars and/or amino acids. Furthermore, mutants defective in glucose uptake or dependent upon peptides for growth also showed no significant loss in intracellular replication, suggesting host - derived peptides can supply both carbon units and amino acids. Here, we show that intracellular Salmonella recruit the host proteins LAMP-2A and Hsc73, key components of the host protein turnover pathway known as chaperone -mediated autophagy involved in transport of cytosolic proteins to the lysosome for degradation. Host- derived peptides are shown to provide a significant contribution toward the intracellular growth of Salmonella The results reveal a means whereby intracellular Salmonella gain access to the host cell cytosol from within its membrane - bound compartment to acquire nutrients. Furthermore, this study provides an explanation as to how Salmonella evades activation of autophagy mechanisms as part of the innate immune response.
27932462	0	10	Salmonella	T007	C0036111
27932462	19	28	Host Cell	T026	C1819995
27932462	29	38	Chaperone	T116,T123	C0243041
27932462	49	58	Autophagy	T043	C0004391
27932462	63	76	Intracellular	T082	C0178719
27932462	77	83	Growth	T040	C0178747
27932462	84	103	Salmonella enterica	T007	C0445750
27932462	108	116	invasive	T080	C0205281
27932462	117	130	intracellular	T082	C0178719
27932462	131	140	pathogens	T001	C0450254
27932462	146	155	replicate	T080	C1883725
27932462	165	173	membrane	T026	C0596901
27932462	176	181	bound	T052	C1145667
27932462	182	193	compartment	T082	C1948049
27932462	201	209	infected	T033	C0439663
27932462	210	220	host cells	T026	C1819995
27932462	234	244	Salmonella	T007	C0036111
27932462	247	257	containing	T169	C0332256
27932462	258	265	vacuole	T026	C0042219
27932462	271	281	Salmonella	T007	C0036111
27932462	282	289	obtains	T169	C1301820
27932462	290	299	nutrients	T168	C0678695
27932462	304	310	growth	T040	C0178747
27932462	323	342	intracellular niche	T082	C0178719
27932462	355	363	apparent	T078	C0750489
27932462	364	373	isolation	T059	C0220862
27932462	405	412	studies	T062	C2603343
27932462	418	427	indicated	T033	C1444656
27932462	432	442	importance	T080	C3898777
27932462	446	453	glucose	T109,T121,T123	C0017725
27932462	458	465	related	T080	C0439849
27932462	466	472	carbon	T196	C0007009
27932462	473	480	sources	T033	C0449416
27932462	485	491	tissue	T024	C0040300
27932462	492	504	colonization	T033	C4289767
27932462	509	522	intracellular	T082	C0178719
27932462	523	536	proliferation	T169	C1514485
27932462	544	554	host cells	T026	C1819995
27932462	562	583	Salmonella infections	T047	C0036117
27932462	621	630	essential	T080	C0205224
27932462	646	655	wild-type	T028	C1883559
27932462	656	666	Salmonella	T007	C0036111
27932462	682	693	replicating	T080	C1883725
27932462	701	709	infected	T033	C0439663
27932462	710	720	host cells	T026	C1819995
27932462	728	735	absence	T169	C0332197
27932462	744	753	exogenous	T169	C0205228
27932462	754	760	sugars	T109,T121	C0242209
27932462	768	779	amino acids	T116,T121,T123	C0002520
27932462	794	801	mutants	T049	C0596988
27932462	802	811	defective	T169	C0332452
27932462	815	829	glucose uptake	T043	C1159527
27932462	833	842	dependent	T080	C1701901
27932462	848	856	peptides	T116	C0030956
27932462	861	867	growth	T040	C0178747
27932462	883	894	significant	T078	C0750502
27932462	895	899	loss	T081	C1517945
27932462	903	916	intracellular	T082	C0178719
27932462	917	928	replication	T080	C1883725
27932462	941	945	host	T001	C1167395
27932462	948	955	derived	T080	C1441547
27932462	956	964	peptides	T116	C0030956
27932462	981	987	carbon	T196	C0007009
27932462	988	993	units	T081	C0439148
27932462	998	1009	amino acids	T116,T121,T123	C0002520
27932462	1030	1043	intracellular	T082	C0178719
27932462	1044	1054	Salmonella	T007	C0036111
27932462	1067	1071	host	T001	C1167395
27932462	1072	1080	proteins	T116,T123	C0033684
27932462	1081	1088	LAMP-2A	T116,T129	C0125272
27932462	1093	1098	Hsc73	T116,T123	C1527505
27932462	1100	1103	key	T077	C1706198
27932462	1104	1114	components	T116,T123	C1179435
27932462	1122	1126	host	T001	C1167395
27932462	1127	1143	protein turnover	T044	C0597297
27932462	1144	1151	pathway	T044	C1704259
27932462	1161	1170	chaperone	T116,T123	C0243041
27932462	1181	1190	autophagy	T043	C0004391
27932462	1203	1212	transport	T043	C0599895
27932462	1216	1234	cytosolic proteins	T116,T123	C1333198
27932462	1242	1250	lysosome	T026	C0024369
27932462	1255	1266	degradation	T044	C0597297
27932462	1274	1281	derived	T080	C1441547
27932462	1282	1290	peptides	T116	C0030956
27932462	1314	1325	significant	T078	C0750502
27932462	1326	1338	contribution	T052	C1880177
27932462	1350	1363	intracellular	T082	C0178719
27932462	1364	1370	growth	T040	C0178747
27932462	1374	1384	Salmonella	T007	C0036111
27932462	1389	1396	results	T033	C0683954
27932462	1420	1433	intracellular	T082	C0178719
27932462	1434	1444	Salmonella	T007	C0036111
27932462	1445	1449	gain	T081	C1517378
27932462	1450	1456	access	T082	C0444454
27932462	1464	1481	host cell cytosol	T026	C2752457
27932462	1498	1506	membrane	T026	C0596901
27932462	1509	1514	bound	T052	C1145667
27932462	1515	1526	compartment	T082	C1948049
27932462	1530	1537	acquire	T052	C1706701
27932462	1538	1547	nutrients	T168	C0678695
27932462	1567	1572	study	T062	C2603343
27932462	1573	1581	provides	T052	C1999230
27932462	1585	1596	explanation	T170	C0681841
27932462	1607	1617	Salmonella	T007	C0036111
27932462	1618	1624	evades	T040	C1654934
27932462	1625	1635	activation	T052	C1879547
27932462	1639	1648	autophagy	T043	C0004391
27932462	1649	1659	mechanisms	T169	C0441712
27932462	1675	1697	innate immune response	T032	C0020969

27940059|t|Use of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients: a case series
27940059|a|This case series reports on the safety and efficacy of the levonorgestrel 52-mg intrauterine system in adolescent and young adult solid organ transplant recipients. All patients used the device for contraception, with no documented cases of disseminated pelvic infection or unplanned pregnancy.
27940059	11	25	levonorgestrel	T109,T121,T125	C0023566
27940059	32	51	intrauterine system	T169	C1522228
27940059	55	65	adolescent	T100	C0205653
27940059	70	81	young adult	T100	C0238598
27940059	82	104	solid organ transplant	T061	C0730400
27940059	105	115	recipients	T101	C0376387
27940059	119	130	case series	T062	C0150093
27940059	136	147	case series	T062	C0150093
27940059	148	155	reports	T062,T170	C0242278
27940059	163	169	safety	T080	C0678800
27940059	174	182	efficacy	T080	C0598333
27940059	190	204	levonorgestrel	T109,T121,T125	C0023566
27940059	211	230	intrauterine system	T169	C1522228
27940059	234	244	adolescent	T100	C0205653
27940059	249	260	young adult	T100	C0238598
27940059	261	283	solid organ transplant	T061	C0730400
27940059	284	294	recipients	T101	C0376387
27940059	300	308	patients	T101	C0030705
27940059	318	324	device	T074	C0009886
27940059	329	342	contraception	T061	C0700589
27940059	352	362	documented	T058	C1301725
27940059	372	384	disseminated	T082	C0205221
27940059	385	401	pelvic infection	T047	C0030790
27940059	405	424	unplanned pregnancy	T033	C0041747

28503759|t|Evaluation of Weight Change During Carboplatin Therapy in Dogs With Appendicular Osteosarcoma
28503759|a|The prevalence of cancer cachexia in veterinary medicine has not been studied widely, and as of yet, no definitive diagnostic criteria effectively assess this syndrome in veterinary patients. (1) To determine the patterns of weight change in dogs with appendicular osteosarcoma treated with amputation and single-agent carboplatin during the course of adjuvant chemotherapy; and (2) to determine whether postoperative weight change is a negative prognostic indicator for survival time in dogs with osteosarcoma. Eighty-eight dogs diagnosed with appendicular osteosarcoma. Animals were accrued from 3 veterinary teaching hospitals. Retrospective, multi-institutional study. Dogs diagnosed with appendicular osteosarcoma and treated with limb amputation followed by a minimum of 4 doses of single-agent carboplatin were included. Data analyzed in each patient included signalment, tumor site, preoperative serum alkaline phosphatase activity (ALP), and body weight (kg) at each carboplatin treatment. A slight increase in weight occurred over the course of chemotherapy, but this change was not statistically significant. Weight change did not have a significant effect on survival. Institution, patient sex, and serum ALP activity did not have a significant effect on survival. Weight change was not a prognostic factor in these dogs, and weight loss alone may not be a suitable method of determining cancer cachexia in dogs with appendicular osteosarcoma.
28503759	0	10	Evaluation	T058	C0220825
28503759	14	27	Weight Change	T033	C0005911
28503759	35	54	Carboplatin Therapy	T061	C2960156
28503759	58	62	Dogs	T015	C1280551
28503759	68	80	Appendicular	T023	C0003617
28503759	81	93	Osteosarcoma	T191	C0029463
28503759	98	108	prevalence	T081	C0220900
28503759	112	127	cancer cachexia	T191	C1391732
28503759	131	150	veterinary medicine	T091	C0042615
28503759	164	171	studied	T062	C2603343
28503759	209	228	diagnostic criteria	T170	C0679228
28503759	241	247	assess	T058	C0184514
28503759	253	261	syndrome	T047	C0039082
28503759	265	284	veterinary patients	T001	C1705908
28503759	307	315	patterns	T080	C1272746
28503759	319	332	weight change	T033	C0005911
28503759	336	340	dogs	T015	C1280551
28503759	346	358	appendicular	T023	C0003617
28503759	359	371	osteosarcoma	T191	C0029463
28503759	372	379	treated	T169	C1522326
28503759	385	395	amputation	T061	C0002688
28503759	400	424	single-agent carboplatin	T109,T121	C0079083
28503759	436	442	course	T079	C0750729
28503759	446	467	adjuvant chemotherapy	T061	C0085533
28503759	498	511	postoperative	T079	C0032790
28503759	512	525	weight change	T033	C0005911
28503759	531	539	negative	T033	C0205160
28503759	540	560	prognostic indicator	T201	C1514474
28503759	565	578	survival time	T201	C2919552
28503759	582	586	dogs	T015	C1280551
28503759	592	604	osteosarcoma	T191	C0029463
28503759	619	623	dogs	T015	C1280551
28503759	624	633	diagnosed	T033	C0011900
28503759	639	651	appendicular	T023	C0003617
28503759	652	664	osteosarcoma	T191	C0029463
28503759	666	673	Animals	T008	C0003062
28503759	694	723	veterinary teaching hospitals	T073,T093	C0019994
28503759	725	738	Retrospective	T062	C0035363
28503759	740	765	multi-institutional study	T062	C1096776
28503759	767	771	Dogs	T015	C1280551
28503759	772	781	diagnosed	T033	C0011900
28503759	787	799	appendicular	T023	C0003617
28503759	800	812	osteosarcoma	T191	C0029463
28503759	817	824	treated	T169	C1522326
28503759	830	845	limb amputation	T061	C0002689
28503759	873	878	doses	T081	C0178602
28503759	882	906	single-agent carboplatin	T109,T121	C0079083
28503759	922	926	Data	T078	C1511726
28503759	927	935	analyzed	T062	C0936012
28503759	944	951	patient	T001	C1705908
28503759	961	971	signalment	T080	C0205556
28503759	973	983	tumor site	T082	C0475445
28503759	985	997	preoperative	T079	C0445204
28503759	998	1003	serum	T031	C0229671
28503759	1004	1033	alkaline phosphatase activity	T044	C1149888
28503759	1035	1038	ALP	T044	C1149888
28503759	1045	1056	body weight	T032	C0005910
28503759	1070	1081	carboplatin	T109,T121	C0079083
28503759	1082	1091	treatment	T169	C0039798
28503759	1095	1110	slight increase	T169	C0442805
28503759	1114	1120	weight	T032	C0005910
28503759	1139	1145	course	T079	C0750729
28503759	1149	1161	chemotherapy	T061	C3665472
28503759	1172	1178	change	T033	C0005911
28503759	1187	1212	statistically significant	T081	C0237881
28503759	1214	1227	Weight change	T033	C0005911
28503759	1243	1261	significant effect	T080	C1280500
28503759	1265	1273	survival	T169	C0220921
28503759	1288	1299	patient sex	T032	C0150831
28503759	1305	1310	serum	T031	C0229671
28503759	1311	1323	ALP activity	T044	C1149888
28503759	1339	1357	significant effect	T080	C1280500
28503759	1361	1369	survival	T169	C0220921
28503759	1371	1384	Weight change	T033	C0005911
28503759	1395	1412	prognostic factor	T201	C1514474
28503759	1422	1426	dogs	T015	C1280551
28503759	1432	1443	weight loss	T033	C1262477
28503759	1472	1478	method	T170	C0025663
28503759	1494	1509	cancer cachexia	T191	C1391732
28503759	1513	1517	dogs	T015	C1280551
28503759	1523	1535	appendicular	T023	C0003617
28503759	1536	1548	osteosarcoma	T191	C0029463

27359086|t|Functional Analysis of a Bacterial Antifreeze Protein Indicates a Cooperative Effect between Its Two Ice-Binding Domains
27359086|a|Antifreeze proteins make up a class of ice-binding proteins (IBPs) that are possessed and expressed by certain cold - adapted organisms to enhance their freezing tolerance. Here we report the biophysical and functional characterization of an IBP discovered in a bacterium recovered from a deep glacial ice core drilled at Vostok Station, Antarctica (IBPv). Our study showed that the recombinant protein rIBPv exhibited a thermal hysteresis of 2 °C at concentrations of >50 μM, effectively inhibited ice recrystallization, and enhanced bacterial viability during freeze-thaw cycling. Circular dichroism scans indicated that rIBPv mainly consists of β strands, and its denaturing temperature was 53.5 °C. Multiple-sequence alignment of homologous IBPs predicted that IBPv contains two ice-binding domains, a feature unique among known IBPs. To examine functional differences between the IBPv domains, each domain was cloned, expressed, and purified. The second domain (domain B) expressed greater ice binding activity. Data from thermal hysteresis and gel filtration assays supported the idea that the two domains cooperate to achieve a higher ice binding effect by forming heterodimers. However, physical linkage of the domains was not required for this effect.
27359086	0	10	Functional	T169	C0205245
27359086	11	19	Analysis	T062	C0936012
27359086	25	34	Bacterial	T007	C0004611
27359086	35	53	Antifreeze Protein	T116,T123	C0103575
27359086	66	77	Cooperative	T033	C0243095
27359086	78	84	Effect	T080	C1280500
27359086	101	112	Ice-Binding	T044	C1323394
27359086	113	120	Domains	T087	C1514562
27359086	121	140	Antifreeze proteins	T116,T123	C0103575
27359086	160	180	ice-binding proteins	T116,T123	C0033684
27359086	182	186	IBPs	T116,T123	C0033684
27359086	211	220	expressed	T045	C1171362
27359086	232	236	cold	T070	C0009267
27359086	239	246	adapted	T040	C0001400
27359086	247	256	organisms	T001	C0029235
27359086	260	267	enhance	T052	C2349975
27359086	274	292	freezing tolerance	T038	C1326875
27359086	313	324	biophysical	T038	C1511162
27359086	329	339	functional	T169	C0205245
27359086	340	356	characterization	T052	C1880022
27359086	363	366	IBP	T116,T123	C0033684
27359086	383	392	bacterium	T007	C0004611
27359086	410	414	deep	T082	C0205125
27359086	415	422	glacial	T070	C1449600
27359086	423	431	ice core	T197	C0020746
27359086	443	469	Vostok Station, Antarctica	T083	C0454691
27359086	471	475	IBPv	T116,T123	C0033684
27359086	482	487	study	T062	C2603343
27359086	504	523	recombinant protein	T116	C0034861
27359086	524	529	rIBPv	T116	C0034861
27359086	542	549	thermal	T070	C0018837
27359086	550	560	hysteresis	T033	C0243095
27359086	572	586	concentrations	T081	C1446561
27359086	610	619	inhibited	T080	C0311403
27359086	620	623	ice	T197	C0020746
27359086	624	641	recrystallization	T070	C0010423
27359086	647	655	enhanced	T052	C2349975
27359086	656	675	bacterial viability	T070	C1563772
27359086	683	702	freeze-thaw cycling	T070	C2718051
27359086	704	728	Circular dichroism scans	T059	C0008813
27359086	744	749	rIBPv	T116	C0034861
27359086	769	778	β strands	T082	C0600383
27359086	788	798	denaturing	T044	C0301642
27359086	799	810	temperature	T081	C0039476
27359086	824	851	Multiple-sequence alignment	T063	C0080143
27359086	855	870	homologous IBPs	T116	C1512488
27359086	886	890	IBPv	T116,T123	C0033684
27359086	904	915	ice-binding	T044	C1323394
27359086	904	923	ice-binding domains	T087	C1514562
27359086	935	941	unique	T080	C1710548
27359086	954	958	IBPs	T116,T123	C0033684
27359086	971	981	functional	T169	C0205245
27359086	1006	1018	IBPv domains	T087	C1514562
27359086	1025	1031	domain	T087	C1514562
27359086	1036	1042	cloned	T059,T063	C0598888
27359086	1044	1053	expressed	T045	C1171362
27359086	1059	1067	purified	T169	C1998793
27359086	1073	1086	second domain	T087	C1514562
27359086	1088	1096	domain B	T087	C1514562
27359086	1098	1107	expressed	T045	C1171362
27359086	1116	1136	ice binding activity	T044	C1323394
27359086	1148	1155	thermal	T070	C0018837
27359086	1156	1166	hysteresis	T033	C0243095
27359086	1171	1192	gel filtration assays	T059	C0008559
27359086	1225	1232	domains	T087	C1514562
27359086	1263	1281	ice binding effect	T044	C1323394
27359086	1293	1305	heterodimers	T104	C0596448
27359086	1340	1347	domains	T087	C1514562

28110451|t|The importance of various stages of succession in preservation of biodiversity among riparian birds in northern Iran
28110451|a|Every stage of succession may provide certain species with habitat requirements which are impossible in other stages of succession. This study attempts to evaluate the different stages of succession in terms of composition and structure of bird populations in Hyrcanian forests. Bird - habitat relationships were investigated by comparing vegetation characteristics in three successional stages including late, initial stage, and urban areas. Bird richness, diversity, and abundance were measured within a 25-m radius of each of the 120 sampling points in various stages of succession and urban areas from May to April (2014) in the Ziarat catchment. This study indicated that every stage of succession may support certain species. Based on bird - habitat associations along the various stages of succession, two groups were distinguished. Conventional comparative analysis separated two groups of understory birds: interior specialists and edge specialists. The interior-specialist group was positively correlated with the number of dead trees, tall trees with high values of dbh and height and canopy cover. In contrast, edge specialists groups mainly included terrestrial insectivores and were positively correlated with open area and shrub cover, and percentage of shrub cover between 1 and 2 m in height. In summary, bird communities in Hyrcanian forests are highly dynamic in different vegetation covers suggesting that it is critical to increase diverse and abundant bird populations by conserving forests composed of mosaics of differently disturbed stands and mature forest patches.
28110451	18	25	various	T081	C0439064
28110451	26	32	stages	T079	C1306673
28110451	36	46	succession	T081	C0242538
28110451	50	62	preservation	T169	C0728887
28110451	66	78	biodiversity	T080	C0282469
28110451	85	99	riparian birds	T012	C0005595
28110451	103	111	northern	T082	C1709269
28110451	112	116	Iran	T083	C0022065
28110451	117	122	Every	T080	C1948061
28110451	123	128	stage	T079	C1306673
28110451	132	142	succession	T081	C0242538
28110451	147	154	provide	T052	C1999230
28110451	155	162	certain	T080	C0205423
28110451	163	170	species	T185	C1705920
28110451	176	183	habitat	T082	C0871648
28110451	184	196	requirements	T169	C1514873
28110451	227	233	stages	T079	C1306673
28110451	237	247	succession	T081	C0242538
28110451	254	259	study	T062	C2603343
28110451	285	294	different	T080	C1705242
28110451	295	301	stages	T079	C1306673
28110451	305	315	succession	T081	C0242538
28110451	328	339	composition	UnknownType	C0679983
28110451	344	353	structure	T082	C0678594
28110451	357	361	bird	T012	C0005595
28110451	362	373	populations	T081	C0032659
28110451	377	394	Hyrcanian forests	T070	C0086312
28110451	396	400	Bird	T012	C0005595
28110451	403	410	habitat	T082	C0871648
28110451	411	424	relationships	T080	C0439849
28110451	430	442	investigated	T169	C1292732
28110451	446	455	comparing	T052	C1707455
28110451	456	466	vegetation	T169	C0205245
28110451	467	482	characteristics	T080	C1521970
28110451	492	504	successional	T081	C0242538
28110451	505	511	stages	T079	C1306673
28110451	512	521	including	T169	C0332257
28110451	522	526	late	T079	C0205087
28110451	528	541	initial stage	T079	C1306673
28110451	547	558	urban areas	T082	C0178876
28110451	560	564	Bird	T012	C0005595
28110451	575	584	diversity	T080	C1880371
28110451	590	599	abundance	T080	C2346714
28110451	605	613	measured	T080	C0444706
28110451	614	620	within	T082	C0332285
28110451	623	634	25-m radius	T081	C1306504
28110451	654	669	sampling points	T082	C1254362
28110451	673	680	various	T081	C0439064
28110451	681	687	stages	T079	C1306673
28110451	691	701	succession	T081	C0242538
28110451	706	717	urban areas	T082	C0178876
28110451	750	756	Ziarat	T083	C0030211
28110451	757	766	catchment	T083	C0007403
28110451	773	778	study	T062	C2603343
28110451	779	788	indicated	T033	C1444656
28110451	794	799	every	T080	C1948061
28110451	800	805	stage	T079	C1306673
28110451	809	819	succession	T081	C0242538
28110451	840	847	species	T185	C1705920
28110451	849	854	Based	T169	C1527178
28110451	858	862	bird	T012	C0005595
28110451	865	872	habitat	T082	C0871648
28110451	873	885	associations	T080	C0439849
28110451	896	903	various	T081	C0439064
28110451	904	910	stages	T079	C1306673
28110451	914	924	succession	T081	C0242538
28110451	926	929	two	T081	C0205448
28110451	930	936	groups	UnknownType	C0681860
28110451	942	955	distinguished	T080	C0205615
28110451	957	969	Conventional	T080	C0439858
28110451	970	990	comparative analysis	T062	C0683941
28110451	991	1000	separated	T080	C0443299
28110451	1001	1004	two	T081	C0205448
28110451	1005	1011	groups	UnknownType	C0681860
28110451	1015	1031	understory birds	T012	C0005595
28110451	1033	1053	interior specialists	UnknownType	C0681860
28110451	1058	1074	edge specialists	UnknownType	C0681860
28110451	1080	1105	interior-specialist group	UnknownType	C0681860
28110451	1110	1120	positively	T033	C1446409
28110451	1121	1131	correlated	T080	C1707520
28110451	1141	1147	number	T081	C0237753
28110451	1151	1155	dead	T040	C0011065
28110451	1156	1161	trees	T002	C0040811
28110451	1163	1167	tall	T032	C0489786
28110451	1168	1173	trees	T002	C0040811
28110451	1179	1183	high	T080	C0205250
28110451	1184	1190	values	T080	C0042295
28110451	1194	1197	dbh	T081	C0392762
28110451	1202	1208	height	T032	C0489786
28110451	1213	1225	canopy cover	T080	C0205556
28110451	1240	1263	edge specialists groups	UnknownType	C0681860
28110451	1271	1279	included	T169	C0332257
28110451	1280	1291	terrestrial	T080	C0205556
28110451	1292	1304	insectivores	T015	C0021584
28110451	1314	1324	positively	T033	C1446409
28110451	1325	1335	correlated	T080	C1707520
28110451	1341	1345	open	T082	C0175566
28110451	1346	1350	area	T082	C0205146
28110451	1355	1366	shrub cover	T082	C1254362
28110451	1372	1382	percentage	T081	C0439165
28110451	1386	1397	shrub cover	T082	C1254362
28110451	1419	1425	height	T032	C0489786
28110451	1439	1443	bird	T012	C0005595
28110451	1444	1455	communities	T096	C0009462
28110451	1459	1476	Hyrcanian forests	T070	C0086312
28110451	1481	1487	highly	T080	C0205250
28110451	1488	1495	dynamic	T169	C0729333
28110451	1499	1508	different	T080	C1705242
28110451	1509	1526	vegetation covers	T082	C1254362
28110451	1527	1537	suggesting	T078	C1705535
28110451	1549	1557	critical	T080	C1511545
28110451	1561	1569	increase	T169	C0442805
28110451	1570	1577	diverse	T080	C1880371
28110451	1582	1590	abundant	T080	C2346714
28110451	1591	1595	bird	T012	C0005595
28110451	1596	1607	populations	T081	C0032659
28110451	1622	1629	forests	T070	C0086312
28110451	1642	1649	mosaics	T082	C0439750
28110451	1653	1664	differently	T080	C1705242
28110451	1665	1681	disturbed stands	T082	C1254362
28110451	1686	1692	mature	T079	C0205286
28110451	1693	1707	forest patches	T082	C1254362

28268114|t|S. mansoni - T. cruzi co-infection modulates arginase-1 / iNOS expression, liver and heart disease in mice
28268114|a|Although Schistosoma species and Trypanosoma cruzi share common endemic areas, co-infections by these parasites remains overlooked. By using a murine model of S. mansoni and T. cruzi co-infection, we investigated if and to what extent these infections might interact to change the pathological outcomes typically observed when the host is infected by a single parasite species. Swiss mice were randomized into four groups: uninfected (NI) and those infected by S. mansoni (SM), T. cruzi (TC) or co-infected (SM + TC). After 120 days of S. mansoni infection, T. cruzi was concurrently inoculated and the infection occurred for 30 days. Taken together, we identified that the overlap of Th2 (schistosomiasis) and Th1 (Chagas disease) immunological patterns changes the host resistance against both pathogens. Beyond impairing the control of granulomatous inflammation, T. cruzi parasitemia and parasitism in co-infected animals, the Th2 inflammatory response against S. mansoni elicits the activation of the arginase-1 pathway to the detriment of inducible oxide nitric synthase (iNOS) expression and nitric oxide (NO) production, contributing to the liver damage, with minor effects on heart pathology.
28268114	0	10	S. mansoni	T204	C0036319
28268114	13	21	T. cruzi	T204	C0041221
28268114	22	34	co-infection	T047	C0275524
28268114	35	44	modulates	T082	C0443264
28268114	45	55	arginase-1	T116,T126	C2743700
28268114	58	62	iNOS	T116,T126	C1565683
28268114	63	73	expression	T045	C1171362
28268114	75	80	liver	T047	C0023895
28268114	85	98	heart disease	T047	C0018799
28268114	102	106	mice	T015	C0025929
28268114	116	135	Schistosoma species	T204	C0036319
28268114	140	157	Trypanosoma cruzi	T204	C0041221
28268114	171	184	endemic areas	T033	C2732661
28268114	186	199	co-infections	T047	C0275524
28268114	209	218	parasites	T204	C0030498
28268114	250	262	murine model	T075	C0026339
28268114	266	276	S. mansoni	T204	C0036319
28268114	281	289	T. cruzi	T204	C0041221
28268114	290	302	co-infection	T047	C0275524
28268114	307	319	investigated	T169	C1292732
28268114	348	358	infections	T046	C3714514
28268114	388	400	pathological	T169	C1521733
28268114	401	409	outcomes	T169	C1274040
28268114	420	428	observed	T169	C1441672
28268114	438	442	host	T001	C1167395
28268114	446	454	infected	T046	C3714514
28268114	467	475	parasite	T204	C0030498
28268114	476	483	species	T185	C1705920
28268114	485	495	Swiss mice	T015	C0162416
28268114	501	511	randomized	T062	C0034656
28268114	522	528	groups	T078	C0441833
28268114	530	540	uninfected	T169	C0521118
28268114	542	544	NI	T169	C0521118
28268114	568	578	S. mansoni	T204	C0036319
28268114	580	582	SM	T204	C0036319
28268114	585	593	T. cruzi	T204	C0041221
28268114	595	597	TC	T204	C0041221
28268114	602	613	co-infected	T047	C0275524
28268114	615	617	SM	T204	C0036319
28268114	620	622	TC	T204	C0041221
28268114	643	653	S. mansoni	T204	C0036319
28268114	654	663	infection	T046	C3714514
28268114	665	673	T. cruzi	T204	C0041221
28268114	691	701	inoculated	T061	C2987620
28268114	710	719	infection	T046	C3714514
28268114	781	788	overlap	T079	C1948020
28268114	792	795	Th2	T025	C0242633
28268114	797	812	schistosomiasis	T047	C0036323
28268114	818	821	Th1	T025	C0242632
28268114	823	837	Chagas disease	T047	C0041234
28268114	839	852	immunological	T169	C0205470
28268114	853	861	patterns	T082	C0449774
28268114	874	878	host	T001	C1167395
28268114	879	889	resistance	T039	C1514892
28268114	903	912	pathogens	T001	C0450254
28268114	921	930	impairing	T169	C0221099
28268114	935	942	control	T169	C2587213
28268114	946	972	granulomatous inflammation	T046	C0553697
28268114	974	982	T. cruzi	T204	C0041221
28268114	983	994	parasitemia	T047	C0242723
28268114	999	1009	parasitism	T070	C0677482
28268114	1013	1024	co-infected	T047	C0275524
28268114	1025	1032	animals	T008	C0003062
28268114	1038	1041	Th2	T025	C0242633
28268114	1042	1063	inflammatory response	T046	C1155266
28268114	1072	1082	S. mansoni	T204	C0036319
28268114	1095	1105	activation	T052	C1879547
28268114	1113	1123	arginase-1	T116,T126	C2743700
28268114	1124	1131	pathway	T077	C1705987
28268114	1139	1148	detriment	T169	C1883709
28268114	1152	1183	inducible oxide nitric synthase	T116,T126	C1565683
28268114	1185	1189	iNOS	T116,T126	C1565683
28268114	1191	1201	expression	T045	C1171362
28268114	1206	1218	nitric oxide	T121,T123,T197	C0028128
28268114	1220	1222	NO	T121,T123,T197	C0028128
28268114	1224	1234	production	T057	C0033268
28268114	1256	1268	liver damage	T046	C0151763
28268114	1275	1280	minor	T080	C0205165
28268114	1281	1288	effects	T080	C2348382
28268114	1292	1297	heart	T023	C0018787
28268114	1298	1307	pathology	T091	C0030664

28183822|t|DEVELOPMENT OF A TECHNIQUE FOR DETERMINATION OF PULMONARY ARTERY PULSE WAVE VELOCITY IN HORSES
28183822|a|Calcification of the tunica media of the axial pulmonary arteries (PA) has been reported in a large proportion of racehorses. In humans, medial calcification is a significant cause of arterial stiffening and is implicated in the pathogenesis of cardiac, cerebral and renal microvascular diseases. Pulse wave velocity (PWV) provides a measure of arterial stiffness. This study aimed to develop a technique to determine PA - PWV in horses, and secondarily to investigate a potential association between PA - PWV and arterial fibro-calcification. A dual pressure sensor catheter (PSC) was placed in the main PA of 10 sedated horses. The pressure waves were used to determine PWV along the PA, using the statistical phase offset method. Histological analysis of the PA was performed to investigate the presence of fibro-calcified lesions. The mean (±SD) PWV was 2.3±0.7m/s in the proximal PA trunk and 1.1±0.1m/s further distal (15cm) in a main PA branch. The mean (±SD) of mean arterial pressures in the proximal PA trunk was 30.1±5.2mmHg, and 22.0±6.0mmHg further distal (15cm) within the main PA branch. The mean (±SD) pulse pressure in the proximal PA trunk was 15.0±4.7mmHg, and 13.5±3.3mmHg further distal (15cm) within the main PA branch. Moderate to severe lesions of the tunica media of the PAs were observed in 7 horses, but a correlation with PWV could not be established yet. Pulmonary artery PWV may be determined in standing horses. The technique described may allow further investigation of the effect of calcification of large PAs in the pathogenesis of equine pulmonary circulatory disorders.
28183822	17	26	TECHNIQUE	T169	C0449851
28183822	31	44	DETERMINATION	T059	C1148554
28183822	48	64	PULMONARY ARTERY	T023	C0034052
28183822	65	84	PULSE WAVE VELOCITY	T081	C3494431
28183822	88	94	HORSES	T015	C0019944
28183822	95	108	Calcification	T042	C1533591
28183822	116	128	tunica media	T024	C0162867
28183822	136	160	axial pulmonary arteries	T023	C0034052
28183822	162	164	PA	T023	C0034052
28183822	189	205	large proportion	T081	C1709707
28183822	209	219	racehorses	T008	C1561445
28183822	224	230	humans	T016	C0086418
28183822	232	252	medial calcification	T046	C0333491
28183822	279	298	arterial stiffening	T039	C0599949
28183822	324	336	pathogenesis	T046	C0699748
28183822	340	347	cardiac	T023	C0018787
28183822	349	357	cerebral	T023	C0006104
28183822	362	367	renal	T023	C0022646
28183822	368	381	microvascular	T169	C0443258
28183822	382	390	diseases	T047	C0012634
28183822	392	411	Pulse wave velocity	T081	C3494431
28183822	413	416	PWV	T081	C3494431
28183822	440	458	arterial stiffness	T039	C0599949
28183822	513	515	PA	T023	C0034052
28183822	518	521	PWV	T081	C3494431
28183822	525	531	horses	T015	C0019944
28183822	596	598	PA	T023	C0034052
28183822	601	604	PWV	T081	C3494431
28183822	609	637	arterial fibro-calcification	T046	C1168153
28183822	641	670	dual pressure sensor catheter	T074	C0581447
28183822	672	675	PSC	T074	C0581447
28183822	695	702	main PA	T023	C0034052
28183822	709	716	sedated	T033	C0235195
28183822	717	723	horses	T015	C0019944
28183822	729	743	pressure waves	T042	C0597324
28183822	767	770	PWV	T081	C3494431
28183822	781	783	PA	T023	C0034052
28183822	795	826	statistical phase offset method	T081	C2825570
28183822	828	849	Histological analysis	UnknownType	C0679557
28183822	857	859	PA	T023	C0034052
28183822	905	928	fibro-calcified lesions	T042	C1533591
28183822	934	938	mean	T081	C0444504
28183822	945	948	PWV	T081	C3494431
28183822	971	988	proximal PA trunk	T023	C2954153
28183822	1004	1018	further distal	T082	C0205108
28183822	1031	1045	main PA branch	T023	C1282007
28183822	1051	1055	mean	T081	C0444504
28183822	1065	1069	mean	T081	C0444504
28183822	1070	1088	arterial pressures	T042	C0232108
28183822	1096	1113	proximal PA trunk	T023	C2954153
28183822	1149	1163	further distal	T082	C0205108
28183822	1182	1196	main PA branch	T023	C1282007
28183822	1202	1206	mean	T081	C0444504
28183822	1213	1227	pulse pressure	T040	C0949236
28183822	1235	1252	proximal PA trunk	T023	C2954153
28183822	1288	1302	further distal	T082	C0205108
28183822	1321	1335	main PA branch	T023	C1282007
28183822	1349	1363	severe lesions	T033	C0221198
28183822	1371	1383	tunica media	T024	C0162867
28183822	1391	1394	PAs	T023	C0034052
28183822	1414	1420	horses	T015	C0019944
28183822	1445	1448	PWV	T081	C3494431
28183822	1479	1495	Pulmonary artery	T023	C0034052
28183822	1496	1499	PWV	T081	C3494431
28183822	1530	1536	horses	T015	C0019944
28183822	1611	1624	calcification	T042	C1533591
28183822	1634	1637	PAs	T023	C0034052
28183822	1645	1667	pathogenesis of equine	T047	C0019940
28183822	1668	1699	pulmonary circulatory disorders	T047	C0178272

27798174|t|Are TMCs the Mechanotransduction Channels of Vertebrate Hair Cells?
27798174|a|Sensory transduction in vertebrate hair cells and the molecules that mediate it have long been of great interest. Some components of the mechanotransduction apparatus have been identified, most as deafness gene products. Although prior candidates for the mechanotransduction channel have been proposed, each has faded with new evidence. Now, two strong candidates, TMC1 and TMC2 (transmembrane channel-like), have emerged from discovery of deafness genes in humans and mice. They are expressed at the right time during development: exactly at the onset of mechanosensitivity. They are expressed in the right place: in hair cells but not surrounding cells. Fluorescently tagged TMCs localize to the tips of stereocilia, the site of the transduction channels. TMCs bind other proteins essential for mechanosensation, suggesting a larger transduction complex. Although TMC1 and TMC2 can substitute for each other, genetic deletion of both renders mouse hair cells mechanically insensitive. Finally, the conductance and Ca(2+) selectivity of the transduction channels depend on the TMC proteins, differing when hair cells express one or the other TMC, and differing if TMC1 harbors a point mutation. Some contrary evidence has emerged: a current activated in hair cells by negative pressure, with some similarity to the transduction current, persists in TMC knock-outs. But it is not clear that this anomalous current is carried by the same proteins. Further evidence is desired, such as production of a mechanically gated conductance by pure TMCs. But the great majority of evidence is consistent with these TMCs as pore-forming subunits of the long-sought hair-cell transduction channel.
27798174	4	8	TMCs	T116	C0021699
27798174	13	32	Mechanotransduction	T044	C1138568
27798174	33	41	Channels	T116,T123	C0022009
27798174	45	55	Vertebrate	T010	C0042567
27798174	56	66	Hair Cells	T025	C0018496
27798174	68	75	Sensory	T080	C0445254
27798174	76	88	transduction	T043	C0037083
27798174	92	102	vertebrate	T010	C0042567
27798174	103	113	hair cells	T025	C0018496
27798174	122	131	molecules	T167	C0567416
27798174	205	224	mechanotransduction	T044	C1138568
27798174	265	278	deafness gene	T028	C0017337
27798174	323	342	mechanotransduction	T044	C1138568
27798174	343	350	channel	T116,T123	C0022009
27798174	433	437	TMC1	T116,T123	C1257638
27798174	442	446	TMC2	T116,T123	C3502798
27798174	495	504	discovery	T052	C1880355
27798174	508	522	deafness genes	T028	C0017337
27798174	526	532	humans	T016	C0086418
27798174	537	541	mice	T015	C0025929
27798174	552	561	expressed	T045	C1171362
27798174	587	598	development	T040	C0678723
27798174	624	642	mechanosensitivity	T032	C0871261
27798174	653	662	expressed	T045	C1171362
27798174	686	696	hair cells	T025	C0018496
27798174	717	722	cells	T025	C0007634
27798174	724	744	Fluorescently tagged	T059	C0079367
27798174	745	749	TMCs	T116	C0021699
27798174	750	758	localize	T082	C0392752
27798174	774	785	stereocilia	T026	C0230626
27798174	803	815	transduction	T043	C0037083
27798174	816	824	channels	T116,T123	C0022009
27798174	826	830	TMCs	T116	C0021699
27798174	831	835	bind	T044	C1167622
27798174	842	850	proteins	T116,T123	C0033684
27798174	865	881	mechanosensation	T032	C0871261
27798174	903	915	transduction	T043	C0037083
27798174	916	923	complex	T080	C0439855
27798174	934	938	TMC1	T116,T123	C1742143
27798174	943	947	TMC2	T116,T123	C3502797
27798174	979	995	genetic deletion	T045	C0017260
27798174	1012	1017	mouse	T015	C0025929
27798174	1018	1028	hair cells	T025	C0018496
27798174	1029	1053	mechanically insensitive	T033	C4282382
27798174	1068	1079	conductance	UnknownType	C0678840
27798174	1084	1090	Ca(2+)	T121,T196	C0596235
27798174	1110	1122	transduction	T043	C0037083
27798174	1123	1131	channels	T116,T123	C0022009
27798174	1146	1158	TMC proteins	T116	C0021699
27798174	1175	1185	hair cells	T025	C0018496
27798174	1186	1193	express	T045	C0017262
27798174	1211	1214	TMC	T028	C1336807
27798174	1233	1237	TMC1	T028	C1424345
27798174	1248	1262	point mutation	T049	C0162735
27798174	1302	1309	current	T043	C0162585
27798174	1310	1319	activated	T052	C1879547
27798174	1323	1333	hair cells	T025	C0018496
27798174	1337	1354	negative pressure	T042	C0596287
27798174	1384	1396	transduction	T043	C0037083
27798174	1397	1404	current	T043	C0162585
27798174	1418	1421	TMC	T028	C1336807
27798174	1422	1432	knock-outs	T050	C1522225
27798174	1464	1473	anomalous	T033	C3277934
27798174	1474	1481	current	T043	C0162585
27798174	1505	1513	proteins	T116,T123	C0033684
27798174	1568	1598	mechanically gated conductance	T044	C1153472
27798174	1607	1611	TMCs	T116,T123	C1742143
27798174	1673	1677	TMCs	T116	C0021699
27798174	1681	1702	pore-forming subunits	T169	C1321758
27798174	1710	1731	long-sought hair-cell	T025	C0018496
27798174	1732	1744	transduction	T043	C0037083
27798174	1745	1752	channel	T116,T123	C0022009

27445856|t|High-Intensity Intermittent Training Positively Affects Aerobic and Anaerobic Performance in Judo Athletes Independently of Exercise Mode
27445856|a|The present study investigated the effects of high-intensity intermittent training (HIIT) on lower - and upper-body graded exercise and high-intensity intermittent exercise (HIIE, four Wingate bouts) performance, and on physiological and muscle damage markers responses in judo athletes. Thirty-five subjects were randomly allocated to a control group (n = 8) or to one of the following HIIT groups (n = 9 for each) and tested pre- and post -four weeks (2 training d·wk(-1)): (1) lower-body cycle-ergometer; (2) upper-body cycle-ergometer; (3) uchi-komi (judo technique entrance). All HIIT were constituted by two blocks of 10 sets of 20 s of all out effort interspersed by 10 s set intervals and 5-min between blocks. For the upper-body group there was an increase in maximal aerobic power in graded upper-body exercise test (12.3%). The lower-body group increased power at onset blood lactate in graded upper-body exercise test (22.1%). The uchi-komi group increased peak power in upper - (16.7%) and lower-body (8.5%), while the lower-body group increased lower-body mean power (14.2%) during the HIIE. There was a decrease in the delta blood lactate for the uchi-komi training group and in the third and fourth bouts for the upper-body training group. Training induced testosterone-cortisol ratio increased in the lower-body HIIE for the lower-body (14.9%) and uchi-komi (61.4%) training groups. Thus, short-duration low-volume HIIT added to regular judo training was able to increase upper-body aerobic power, lower - and upper-body HIIE performance.
27445856	0	36	High-Intensity Intermittent Training	T056	C4277545
27445856	37	47	Positively	T033	C1446409
27445856	48	55	Affects	T080	C1280500
27445856	56	63	Aerobic	T061	C0001701
27445856	68	89	Anaerobic Performance	T056	C3841233
27445856	93	97	Judo	T056	C0079650
27445856	98	106	Athletes	T097	C0238703
27445856	124	137	Exercise Mode	T056	C0015259
27445856	173	180	effects	T080	C1280500
27445856	184	220	high-intensity intermittent training	T056	C4277545
27445856	222	226	HIIT	T056	C4277545
27445856	231	236	lower	T023	C1268088
27445856	243	253	upper-body	T023	C1268087
27445856	254	269	graded exercise	T056	C0015259
27445856	274	310	high-intensity intermittent exercise	T056	C4277545
27445856	312	316	HIIE	T056	C4277545
27445856	338	349	performance	T052	C1882330
27445856	358	371	physiological	T169	C0205463
27445856	376	389	muscle damage	T020	C0410158
27445856	390	407	markers responses	T033	C0243095
27445856	411	415	judo	T056	C0079650
27445856	416	424	athletes	T097	C0238703
27445856	438	446	subjects	T098	C0080105
27445856	452	470	randomly allocated	T062	C0034656
27445856	476	489	control group	T096	C0009932
27445856	525	529	HIIT	T056	C4277545
27445856	530	536	groups	T078	C0441833
27445856	558	578	tested pre- and post	T170	C0032919
27445856	618	628	lower-body	T023	C1268088
27445856	629	644	cycle-ergometer	T061	C2107077
27445856	661	676	cycle-ergometer	T061	C2107077
27445856	682	691	uchi-komi	T169	C0449851
27445856	693	716	judo technique entrance	T169	C0449851
27445856	723	727	HIIT	T056	C4277545
27445856	865	875	upper-body	T023	C1268087
27445856	876	881	group	T078	C0441833
27445856	895	903	increase	T169	C0442805
27445856	907	928	maximal aerobic power	T201	C2371107
27445856	939	949	upper-body	T023	C1268087
27445856	950	963	exercise test	T033	C0429687
27445856	977	987	lower-body	T023	C1268088
27445856	988	993	group	T078	C0441833
27445856	994	1003	increased	T169	C0442805
27445856	1004	1009	power	T201	C2371107
27445856	1013	1032	onset blood lactate	T109,T121,T123	C3824990
27445856	1043	1053	upper-body	T023	C1268087
27445856	1054	1067	exercise test	T033	C0429687
27445856	1081	1096	uchi-komi group	T078	C0441833
27445856	1097	1106	increased	T169	C0442805
27445856	1121	1126	upper	T023	C1268087
27445856	1141	1151	lower-body	T023	C1268088
27445856	1170	1180	lower-body	T023	C1268088
27445856	1187	1196	increased	T169	C0442805
27445856	1197	1207	lower-body	T023	C1268088
27445856	1238	1242	HIIE	T056	C4277545
27445856	1256	1264	decrease	T081	C0547047
27445856	1272	1291	delta blood lactate	T109,T121,T123	C3824990
27445856	1300	1318	uchi-komi training	T065	C0559197
27445856	1319	1324	group	T078	C0441833
27445856	1367	1377	upper-body	T023	C1268087
27445856	1378	1386	training	T065	C0220931
27445856	1387	1392	group	T078	C0441833
27445856	1394	1402	Training	T065	C0220931
27445856	1411	1432	testosterone-cortisol	T081	C4035023
27445856	1433	1438	ratio	T081	C0456603
27445856	1439	1448	increased	T169	C0442805
27445856	1456	1466	lower-body	T023	C1268088
27445856	1467	1471	HIIE	T056	C4277545
27445856	1480	1490	lower-body	T023	C1268088
27445856	1503	1529	uchi-komi (61.4%) training	T065	C0559197
27445856	1530	1536	groups	T078	C0441833
27445856	1544	1558	short-duration	T080	C0439593
27445856	1570	1574	HIIT	T056	C4277545
27445856	1584	1605	regular judo training	T065	C0220931
27445856	1618	1626	increase	T169	C0442805
27445856	1627	1637	upper-body	T023	C1268087
27445856	1638	1651	aerobic power	T201	C2371107
27445856	1653	1658	lower	T023	C1268088
27445856	1665	1675	upper-body	T023	C1268087
27445856	1676	1680	HIIE	T056	C4277545
27445856	1681	1692	performance	T052	C1882330

27905972|t|A new parametric model to assess delay and compression of mortality
27905972|a|A decrease in mortality across all ages causes a shift of the age pattern of mortality, or mortality delay, while differences in the rate of decrease across ages cause a change in the shape of the age-at-death distribution, mortality compression or expansion. Evidence exists for both compression and delay of mortality. Existing parametric models to describe the full age pattern of mortality are not able to capture mortality delay versus mortality compression. More recent models that assess delay versus compression mostly focused on the adult or old ages alone and did not distinguish mortality compression below and above the modal age at death, although they represent different mechanisms. This paper presents a new parametric model that describes the full age pattern of mortality and assesses compression - at different stages of life - and delay of mortality: the CoDe model. The model includes 10 parameters, of which five are constant over time. The five time -varying parameters reflect delay of mortality and compression of mortality in infancy, adolescence, young adulthood, late adulthood, and old age. The model describes infant and background mortality by two simple functions, uses a mixed logistic model with different slopes in adult, middle, and old age, and includes the modal age at death as a parameter to account for the delay in mortality. Applying the CoDe model to age - specific probabilities of death for Japanese, French, American, and Danish men and women between 1950 and 2010 showed a very good fit of the full age pattern of mortality. Delay of mortality explained about two-thirds of the increase in life expectancy at birth, whereas compression of mortality due to mortality declines in young age explained about one-third. No strong compression of mortality in late adulthood age was observed. Mortality compression in old age has had a small negative impact on life expectancy. The CoDe model proved a valid instrument for describing the full age pattern of mortality and for disentangling the effects of mortality delay and compression - at different stages of life - on the increase in life expectancy.
27905972	6	22	parametric model	T170	C3161035
27905972	26	32	assess	T052	C1516048
27905972	33	38	delay	T079	C0205421
27905972	43	54	compression	T080	C0392756
27905972	58	67	mortality	T081	C0205848
27905972	70	78	decrease	T081	C0547047
27905972	82	91	mortality	T081	C0205848
27905972	103	107	ages	T032	C0001779
27905972	130	133	age	T032	C0001779
27905972	134	141	pattern	T082	C0449774
27905972	145	154	mortality	T081	C0205848
27905972	159	168	mortality	T081	C0205848
27905972	169	174	delay	T079	C0205421
27905972	182	193	differences	T080	C1705242
27905972	201	205	rate	T081	C1521828
27905972	209	217	decrease	T081	C0547047
27905972	225	229	ages	T032	C0001779
27905972	252	257	shape	T082	C0332479
27905972	265	277	age-at-death	T033	C1546180
27905972	278	290	distribution	T169	C1704711
27905972	292	301	mortality	T081	C0205848
27905972	302	313	compression	T080	C0392756
27905972	317	326	expansion	T169	C0442805
27905972	328	336	Evidence	T078	C3887511
27905972	353	364	compression	T080	C0392756
27905972	369	374	delay	T079	C0205421
27905972	378	387	mortality	T081	C0205848
27905972	398	415	parametric models	T170	C3161035
27905972	437	440	age	T032	C0001779
27905972	441	448	pattern	T082	C0449774
27905972	452	461	mortality	T081	C0205848
27905972	486	495	mortality	T081	C0205848
27905972	496	501	delay	T079	C0205421
27905972	509	518	mortality	T081	C0205848
27905972	519	530	compression	T080	C0392756
27905972	544	550	models	T170	C3161035
27905972	563	568	delay	T079	C0205421
27905972	576	587	compression	T080	C0392756
27905972	610	615	adult	T100	C0001675
27905972	619	627	old ages	T098	C1999167
27905972	658	667	mortality	T081	C0205848
27905972	668	679	compression	T080	C0392756
27905972	700	709	modal age	T032	C0001779
27905972	713	718	death	T033	C1306577
27905972	744	753	different	T080	C1705242
27905972	754	764	mechanisms	T169	C0441712
27905972	771	776	paper	T170	C1706852
27905972	792	808	parametric model	T170	C3161035
27905972	833	836	age	T032	C0001779
27905972	837	844	pattern	T082	C0449774
27905972	848	857	mortality	T081	C0205848
27905972	871	882	compression	T080	C0392756
27905972	888	897	different	T080	C1705242
27905972	898	912	stages of life	T079	C0680083
27905972	919	924	delay	T079	C0205421
27905972	928	937	mortality	T081	C0205848
27905972	943	953	CoDe model	T170	C3161035
27905972	959	964	model	T170	C3161035
27905972	977	987	parameters	T077	C0549193
27905972	1007	1015	constant	T080	C1948059
27905972	1021	1025	time	T079	C0040223
27905972	1036	1040	time	T079	C0040223
27905972	1050	1060	parameters	T077	C0549193
27905972	1069	1074	delay	T079	C0205421
27905972	1078	1087	mortality	T081	C0205848
27905972	1092	1103	compression	T080	C0392756
27905972	1107	1116	mortality	T081	C0205848
27905972	1120	1127	infancy	T079	C0231330
27905972	1129	1140	adolescence	T079	C0001578
27905972	1142	1157	young adulthood	T100	C0680085
27905972	1159	1173	late adulthood	T079	C0700597
27905972	1179	1186	old age	T098	C1999167
27905972	1192	1197	model	T170	C3161035
27905972	1208	1214	infant	T100	C0021270
27905972	1230	1239	mortality	T081	C0205848
27905972	1254	1263	functions	T169	C0542341
27905972	1272	1292	mixed logistic model	T081,T170	C0023965
27905972	1298	1307	different	T080	C1705242
27905972	1308	1314	slopes	T081	C0807955
27905972	1318	1323	adult	T100	C0001675
27905972	1325	1331	middle	T079	C0026062
27905972	1337	1344	old age	T098	C1999167
27905972	1363	1372	modal age	T032	C0001779
27905972	1376	1381	death	T033	C1306577
27905972	1387	1396	parameter	T077	C0549193
27905972	1416	1421	delay	T079	C0205421
27905972	1425	1434	mortality	T081	C0205848
27905972	1449	1459	CoDe model	T170	C3161035
27905972	1463	1466	age	T032	C0001779
27905972	1469	1477	specific	T080	C0205369
27905972	1478	1491	probabilities	T081	C0033204
27905972	1495	1500	death	T033	C1306577
27905972	1505	1513	Japanese	T098	C1556094
27905972	1515	1521	French	T098	C1556084
27905972	1523	1531	American	T098	C0596070
27905972	1537	1543	Danish	T098	C1257890
27905972	1544	1547	men	T098	C0025266
27905972	1552	1557	women	T098	C0043210
27905972	1615	1618	age	T032	C0001779
27905972	1619	1626	pattern	T082	C0449774
27905972	1630	1639	mortality	T081	C0205848
27905972	1641	1646	Delay	T079	C0205421
27905972	1650	1659	mortality	T081	C0205848
27905972	1694	1702	increase	T169	C0442805
27905972	1706	1721	life expectancy	T102	C0023671
27905972	1725	1730	birth	T040	C0005615
27905972	1740	1751	compression	T080	C0392756
27905972	1755	1764	mortality	T081	C0205848
27905972	1772	1790	mortality declines	T081	C0282251
27905972	1794	1803	young age	T033	C4061789
27905972	1841	1852	compression	T080	C0392756
27905972	1856	1865	mortality	T081	C0205848
27905972	1869	1887	late adulthood age	T079	C0700597
27905972	1902	1911	Mortality	T081	C0205848
27905972	1912	1923	compression	T080	C0392756
27905972	1927	1934	old age	T098	C1999167
27905972	1970	1985	life expectancy	T102	C0023671
27905972	1991	2001	CoDe model	T170	C3161035
27905972	2052	2055	age	T032	C0001779
27905972	2056	2063	pattern	T082	C0449774
27905972	2067	2076	mortality	T081	C0205848
27905972	2114	2123	mortality	T081	C0205848
27905972	2124	2129	delay	T079	C0205421
27905972	2134	2145	compression	T080	C0392756
27905972	2151	2160	different	T080	C1705242
27905972	2161	2175	stages of life	T079	C0680083
27905972	2185	2193	increase	T169	C0442805
27905972	2197	2212	life expectancy	T102	C0023671

28063101|t|Elimination and molecular identification of endophytic bacterial contaminants during in vitro propagation of Bambusa balcooa
28063101|a|Bambusa balcooa is an economically important, multipurpose bamboo species, decidedly used in construction industry. Availability of natural bamboo is depleting very rapidly due to accelerated deforestation and its unrestrained use. The large number and timely supply of saplings are the need of the hour for the restoration of bamboo stands. Micropropagation, being the potent alternative for season independent rapid regeneration, is restricted in bamboo because of endophytic contamination. An in vitro attempt has been taken to overcome the endophytic contamination by using broad spectrum antibiotics as surface sterilant as well as a media component. Ampicillin sodium salt (5 mg/ml for 30 min) as a surface sterilant was found as the best treatment for high bud breaking (80%) coupled with high branching and low contamination (20%) but it was found ineffective to control the contamination during multiplication stage. Then, two endophytes were isolated and minimum inhibitory concentration was determined through antibiotic susceptibility test for successful eradication at multiplication stage. Finally, contamination free cultures were obtained when streptocycline (100 μg/ml) and gentamicin sulphate (75 μg/ml) were added into the medium. The two isolated endophytes, BB1 and BB2, were identified through 16S rDNA techniques and NCBI-BLAST algorithm with 99% sequence similarity with those of Janibacter sp. (KX423734) and Serratia marcescens strain (KX423735). To our knowledge, this is the first report for B. balcooa where antibiotics were used as surface sterilant as well as medium component, to control endophytic bacterial contaminants, followed by their identification.
28063101	0	11	Elimination	T059	C0022885
28063101	16	40	molecular identification	T059	C0200925
28063101	44	54	endophytic	T033	C3842357
28063101	55	64	bacterial	T007	C0004611
28063101	65	77	contaminants	T167	C2827365
28063101	85	93	in vitro	T080	C1533691
28063101	94	105	propagation	T059	C0022885
28063101	109	124	Bambusa balcooa	T002	C1687334
28063101	125	140	Bambusa balcooa	T002	C1687334
28063101	147	159	economically	T080	C0205556
28063101	160	170	important,	T080	C3898777
28063101	171	183	multipurpose	T080	C0205556
28063101	184	190	bamboo	T002	C3669026
28063101	191	198	species	T185	C1705920
28063101	218	239	construction industry	T090	C0682031
28063101	265	271	bamboo	T002	C3669026
28063101	275	284	depleting	T169	C0333668
28063101	305	316	accelerated	T169	C0521110
28063101	317	330	deforestation	T069	C0079201
28063101	395	403	saplings	T002	C0032098
28063101	424	428	hour	T079	C0439227
28063101	437	448	restoration	T052	C0441655
28063101	452	458	bamboo	T002	C3669026
28063101	467	483	Micropropagation	T059	C0022885
28063101	518	524	season	T079	C0036497
28063101	543	555	regeneration	T067	C1254366
28063101	574	580	bamboo	T002	C3669026
28063101	592	602	endophytic	T033	C3842357
28063101	603	616	contamination	T078	C2349974
28063101	621	637	in vitro attempt	T059,T062	C3850137
28063101	669	679	endophytic	T033	C3842357
28063101	680	693	contamination	T078	C2349974
28063101	703	729	broad spectrum antibiotics	T195	C0003232
28063101	741	750	sterilant	T167	C3853614
28063101	764	779	media component	T167	C1705217
28063101	781	803	Ampicillin sodium salt	T109,T195	C0282052
28063101	838	847	sterilant	T167	C3853614
28063101	870	879	treatment	T169	C1522326
28063101	889	892	bud	T002	C2700462
28063101	893	901	breaking	T080	C0443161
28063101	908	915	coupled	T169	C1948027
28063101	926	935	branching	T082	C0205384
28063101	940	943	low	T080	C0205251
28063101	944	957	contamination	T078	C2349974
28063101	1008	1021	contamination	T078	C2349974
28063101	1029	1043	multiplication	T081	C2911648
28063101	1044	1049	stage	T079	C1306673
28063101	1061	1071	endophytes	T004	C1265415
28063101	1077	1085	isolated	T169	C0205409
28063101	1090	1122	minimum inhibitory concentration	T059	C0427978
28063101	1146	1156	antibiotic	T195	C0003232
28063101	1157	1176	susceptibility test	T059	C0022885
28063101	1192	1203	eradication	T052	C0441655
28063101	1207	1221	multiplication	T081	C2911648
28063101	1238	1251	contamination	T078	C2349974
28063101	1252	1256	free	T169	C0332296
28063101	1257	1265	cultures	T059	C0430400
28063101	1285	1299	streptocycline	T109,T121	C0605608
28063101	1316	1335	gentamicin sulphate	T109,T195	C0546866
28063101	1367	1373	medium	T167	C1705217
28063101	1383	1391	isolated	T169	C0205409
28063101	1392	1402	endophytes	T004	C1265415
28063101	1404	1407	BB1	T004	C1265415
28063101	1412	1415	BB2	T004	C1265415
28063101	1441	1449	16S rDNA	T114,T123	C0012933
28063101	1450	1460	techniques	T059	C0004642
28063101	1465	1485	NCBI-BLAST algorithm	T170	C0002045
28063101	1495	1503	sequence	T086	C0162326
28063101	1504	1514	similarity	T080	C2348205
28063101	1529	1543	Janibacter sp.	T007	C1017401
28063101	1545	1553	KX423734	T007	C1017401
28063101	1559	1578	Serratia marcescens	T007	C0036766
28063101	1579	1585	strain	T001	C1518614
28063101	1587	1595	KX423735	T007	C0036766
28063101	1645	1655	B. balcooa	T002	C1687334
28063101	1662	1673	antibiotics	T195	C0003232
28063101	1695	1704	sterilant	T167	C3853614
28063101	1716	1732	medium component	T167	C1705217
28063101	1745	1755	endophytic	T033	C3842357
28063101	1756	1765	bacterial	T007	C0004611
28063101	1766	1778	contaminants	T167	C2827365
28063101	1798	1812	identification	T080	C0205396

27914987|t|Tetrabromobisphenol A activates the hepatic interferon pathway in rats
27914987|a|Tetrabromobisphenol A (TBBPA) is a widely used flame retardant in printed circuit boards, paper, and textiles. In a two-year study, TBBPA showed evidence of uterine tumors in female Wistar-Han rats and liver and colon tumors in B6C3F1 mice. In order to gain further insight into early gene and pathway changes leading to cancer, we exposed female Wistar Han rats to TBBPA at 0, 25, 250, or 1000mg/kg (oral gavage in corn oil, 5×/ week) for 13 weeks. Because at the end of the TBBPA exposure period, there were no treatment-related effects on body weights, liver or uterus lesions, and liver and uterine organ weights were within 10% of controls, only the high dose animals were analyzed. Analysis of the hepatic and uterine transcriptomes showed TBBPA -induced changes primarily in the liver (1000mg/kg), with 159 transcripts corresponding to 132 genes differentially expressed compared to controls (FDR=0.05). Pathway analysis showed activation of interferon (IFN) and metabolic networks. TBBPA induced few molecular changes in the uterus. Activation of the interferon pathway in the liver occurred after 13-weeks of TBBPA exposure, and with longer term TBBPA exposure this may lead to immunomodulatory changes that contribute to carcinogenic processes.
27914987	0	21	Tetrabromobisphenol A	T109	C0076220
27914987	22	31	activates	T052	C1879547
27914987	36	43	hepatic	T023	C0023884
27914987	44	62	interferon pathway	T044	C1512834
27914987	66	70	rats	T015	C0034721
27914987	71	92	Tetrabromobisphenol A	T109	C0076220
27914987	94	99	TBBPA	T109	C0076220
27914987	118	133	flame retardant	T120	C0016198
27914987	137	159	printed circuit boards	T073	C1707396
27914987	161	166	paper	T073	C0030351
27914987	172	180	textiles	T073	C0039717
27914987	187	195	two-year	T079	C0439234
27914987	196	201	study	T062	C2603343
27914987	203	208	TBBPA	T109	C0076220
27914987	228	242	uterine tumors	T191	C0042138
27914987	246	252	female	T032	C0086287
27914987	253	268	Wistar-Han rats	T015	C2700261
27914987	273	278	liver	T191	C0023903
27914987	283	295	colon tumors	T191	C0009375
27914987	299	310	B6C3F1 mice	T015	C2698297
27914987	356	360	gene	T028	C0017337
27914987	365	372	pathway	T044	C1704259
27914987	392	398	cancer	T191	C0027651
27914987	411	417	female	T032	C0086287
27914987	418	433	Wistar Han rats	T015	C2700261
27914987	437	442	TBBPA	T109	C0076220
27914987	472	483	oral gavage	T169	C2698653
27914987	487	495	corn oil	T109,T168	C0010029
27914987	501	505	week	T079	C0439230
27914987	514	519	weeks	T079	C0439230
27914987	547	552	TBBPA	T109	C0076220
27914987	553	561	exposure	T080	C0332157
27914987	613	625	body weights	T032	C0005910
27914987	627	632	liver	T033	C0577053
27914987	636	650	uterus lesions	T033	C0567079
27914987	656	661	liver	T023	C0736253
27914987	666	679	uterine organ	T023	C0736936
27914987	680	687	weights	T081	C0043100
27914987	707	715	controls	T096	C0009932
27914987	731	735	dose	T081	C0178602
27914987	736	743	animals	T008	C0003062
27914987	749	757	analyzed	T062	C0936012
27914987	759	767	Analysis	T062	C0936012
27914987	775	782	hepatic	T023	C0023884
27914987	787	794	uterine	T023	C0042149
27914987	795	809	transcriptomes	T086	C3178810
27914987	817	822	TBBPA	T109	C0076220
27914987	857	862	liver	T023	C0023884
27914987	885	896	transcripts	T114	C1519595
27914987	918	923	genes	T028	C0017337
27914987	939	948	expressed	T045	C0017262
27914987	961	969	controls	T096	C0009932
27914987	982	998	Pathway analysis	T170	C0868995
27914987	1006	1016	activation	T052	C1879547
27914987	1020	1030	interferon	T116,T121,T129	C0021747
27914987	1032	1035	IFN	T116,T121,T129	C0021747
27914987	1041	1059	metabolic networks	T044	C1706062
27914987	1061	1066	TBBPA	T109	C0076220
27914987	1104	1110	uterus	T023	C0042149
27914987	1112	1122	Activation	T052	C1879547
27914987	1130	1148	interferon pathway	T044	C1512834
27914987	1156	1161	liver	T023	C0023884
27914987	1177	1185	13-weeks	T079	C0439230
27914987	1189	1194	TBBPA	T109	C0076220
27914987	1195	1203	exposure	T080	C0332157
27914987	1226	1231	TBBPA	T109	C0076220
27914987	1232	1240	exposure	T080	C0332157
27914987	1258	1274	immunomodulatory	T061	C1963758
27914987	1275	1282	changes	T169	C0392747
27914987	1302	1324	carcinogenic processes	T191	C0596263

28160457|t|Associations between human breast milk hormones and adipocytokines and infant growth and body composition in the first 6 months of life
28160457|a|Much is to be learnt about human breast milk (HBM). The purpose of this study is to extend our knowledge of HBM by investigating the role of maternal body mass index (BMI), sex and stage of lactation (month 1 vs. 6) on HBM insulin, glucose, leptin, IL-6 and TNF-α and their associations with infant body composition. Thirty-seven exclusively breastfeeding infants (n = 37; 16♀, 21♂), and their mothers (19-47 kg m(-2)) were studied at 1 and 6 months of lactation. Infants had body composition measured (using dual-energy X-ray absorptiometry) and HBM collected. A significant interaction between maternal BMI and infant sex on insulin levels (p = 0.0322) was observed such that insulin was 229% higher in obese mothers nursing female infants than in normal weight mothers nursing female infants and 179% higher than obese mothers nursing male infants. For leptin, a significant association with BMI category was observed (p < 0.0001) such that overweight and obese mothers had 96.5% and 315.1% higher leptin levels than normal weight mothers, respectively. Leptin was also found to have a significant (p = 0.0004) 33.7% decrease from months 1 to 6, controlling for BMI category and sex. A significant inverse relationship between month 1 leptin levels and infant length (p = 0.0257), percent fat (p = 0.0223), total fat mass (p = 0.0226) and trunk fat mass (p = 0.0111) at month 6 was also found. No associations or interactions were observed for glucose, TNF-α or IL-6. These data demonstrate that maternal BMI, infant sex and stage of lactation affect the compositional make-up of insulin and leptin.
28160457	0	12	Associations	T080	C0439849
28160457	21	38	human breast milk	T109,T121	C0885503
28160457	39	47	hormones	T125	C0019932
28160457	52	66	adipocytokines	T116,T123	C1955907
28160457	71	84	infant growth	T039	C0205714
28160457	89	105	body composition	T032	C0005885
28160457	113	135	first 6 months of life	T033	C3280927
28160457	163	180	human breast milk	T109,T121	C0885503
28160457	182	185	HBM	T109,T121	C0885503
28160457	244	247	HBM	T109,T121	C0885503
28160457	277	285	maternal	T033	C1858460
28160457	286	301	body mass index	T201	C1305855
28160457	303	306	BMI	T201	C1305855
28160457	309	312	sex	T032	C0079399
28160457	317	335	stage of lactation	T042	C0022925
28160457	355	358	HBM	T109,T121	C0885503
28160457	359	366	insulin	T116,T121,T125	C0021641
28160457	368	375	glucose	T109,T121,T123	C0017725
28160457	377	383	leptin	T116,T125	C0299583
28160457	385	389	IL-6	T116,T129	C0021760
28160457	394	399	TNF-α	T116,T129	C1456820
28160457	410	422	associations	T080	C0439849
28160457	428	434	infant	T100	C0021270
28160457	435	451	body composition	T032	C0005885
28160457	478	499	breastfeeding infants	T033	C1623041
28160457	530	537	mothers	T033	C1623040
28160457	589	598	lactation	T042	C0022925
28160457	600	607	Infants	T100	C0021270
28160457	612	637	body composition measured	T201	C1285593
28160457	645	677	dual-energy X-ray absorptiometry	T060	C1510486
28160457	683	686	HBM	T109,T121	C0885503
28160457	712	723	interaction	T169	C1704675
28160457	732	740	maternal	T033	C1858460
28160457	741	744	BMI	T201	C1305855
28160457	749	759	infant sex	T032	C0079399
28160457	763	777	insulin levels	T059	C0202098
28160457	814	837	insulin was 229% higher	T034	C0428405
28160457	841	846	obese	T047	C0028754
28160457	847	854	mothers	T099	C0026591
28160457	863	877	female infants	T033	C2222300
28160457	886	899	normal weight	T033	C2712185
28160457	900	907	mothers	T099	C0026591
28160457	908	915	nursing	T040	C0006147
28160457	908	915	nursing	T040	C0006147
28160457	916	930	female infants	T033	C2222300
28160457	952	957	obese	T047	C0028754
28160457	958	965	mothers	T099	C0026591
28160457	974	986	male infants	T033	C2216472
28160457	992	998	leptin	T116,T125	C0299583
28160457	1014	1025	association	T080	C0439849
28160457	1031	1034	BMI	T201	C1305855
28160457	1080	1090	overweight	T184	C0497406
28160457	1095	1100	obese	T047	C0028754
28160457	1101	1108	mothers	T099	C0026591
28160457	1130	1150	higher leptin levels	T033	C2747815
28160457	1156	1169	normal weight	T033	C2712185
28160457	1170	1177	mothers	T099	C0026591
28160457	1193	1199	Leptin	T116,T125	C0299583
28160457	1301	1304	BMI	T201	C1305855
28160457	1318	1321	sex	T032	C0079399
28160457	1337	1344	inverse	T080	C0439850
28160457	1345	1357	relationship	T080	C0439849
28160457	1374	1380	leptin	T116,T125	C0299583
28160457	1381	1387	levels	T080	C0441889
28160457	1392	1405	infant length	T033	C0455806
28160457	1420	1431	percent fat	T033	C0518026
28160457	1446	1460	total fat mass	T032	C3656665
28160457	1478	1492	trunk fat mass	T032	C3656665
28160457	1536	1548	associations	T080	C0439849
28160457	1552	1564	interactions	T169	C1704675
28160457	1583	1590	glucose	T109,T121,T123	C0017725
28160457	1592	1597	TNF-α	T116,T129	C1456820
28160457	1601	1605	IL-6	T116,T129	C0021760
28160457	1635	1643	maternal	T033	C1858460
28160457	1644	1647	BMI	T201	C1305855
28160457	1649	1655	infant	T100	C0021270
28160457	1656	1659	sex	T032	C0079399
28160457	1664	1682	stage of lactation	T042	C0022925
28160457	1719	1726	insulin	T116,T121,T125	C0021641
28160457	1731	1737	leptin	T116,T125	C0299583

28527513|t|Enzymatic biosynthesis of novel neobavaisoflavone glucosides via Bacillus UDP - glycosyltransferase
28527513|a|The present study was designed to perform structural modifications of of neobavaisoflavone (NBIF), using an in vitro enzymatic glycosylation reaction, in order to improve its water-solubility. Two novel glucosides of NBIF were obtained from an enzymatic glycosylation by UDP - glycosyltransferase. The glycosylated products were elucidated by LC-MS, HR-ESI-MS, and NMR analysis. The HPLC peaks were integrated and the concentrations in sample solutions were calculated. The MTT assay was used to detect the cytotoxic activity of compounds in cancer cell lines. Based on the spectroscopic analyses, the two novel glucosides were identified as neobavaisoflavone-4'-O-β-D-glucopyranoside (1) and neobavaisoflavone-4', 7-di-O-β-D-glucopyranoside (2). Additionally, the water-solubilities of compounds 1 and 2 were approximately 175.1- and 4 031.9-fold higher than that of the substrate, respectively. Among the test compounds, only NBIF exhibited weak cytotoxicity against four human cancer cell lines, with IC50 values ranging from 63.47 to 72.81 µmol·L(-1). These results suggest that in vitro enzymatic glycosylation is a powerful approach to structural modification, improving water-solubility.
28527513	0	22	Enzymatic biosynthesis	T044	C0596522
28527513	26	31	novel	T080	C0205314
28527513	32	60	neobavaisoflavone glucosides	T109,T121	C2934343
28527513	65	73	Bacillus	T007	C0004587
28527513	74	77	UDP	T114,T123	C0041986
28527513	80	99	glycosyltransferase	T116,T126	C0085249
28527513	142	166	structural modifications	T104	C3890228
28527513	173	190	neobavaisoflavone	T109,T121	C2934343
28527513	192	196	NBIF	T109,T121	C2934343
28527513	208	216	in vitro	T080	C1533691
28527513	217	226	enzymatic	T116,T126	C0014442
28527513	227	249	glycosylation reaction	T070	C0017982
28527513	263	270	improve	T033	C0184511
28527513	275	291	water-solubility	T081	C0597682
28527513	297	302	novel	T080	C0205314
28527513	303	313	glucosides	T109	C0017765
28527513	317	321	NBIF	T109,T121	C2934343
28527513	344	353	enzymatic	T116,T126	C0014442
28527513	354	367	glycosylation	T070	C0017982
28527513	371	374	UDP	T114,T123	C0041986
28527513	377	396	glycosyltransferase	T116,T126	C0085249
28527513	402	423	glycosylated products	T109,T121	C2934343
28527513	443	448	LC-MS	T059	C0872318
28527513	450	459	HR-ESI-MS	T059	C0596495
28527513	465	477	NMR analysis	T070	C0028580
28527513	483	487	HPLC	T059	C0008562
28527513	488	493	peaks	T080	C0444505
28527513	518	532	concentrations	T081	C1446561
28527513	536	552	sample solutions	T167	C0037633
28527513	558	568	calculated	T052	C1441506
28527513	574	583	MTT assay	T059	C0201596
28527513	607	625	cytotoxic activity	T049	C0596402
28527513	629	638	compounds	T080	C0205198
28527513	642	659	cancer cell lines	T025	C0085983
28527513	674	687	spectroscopic	T090	C2713504
28527513	688	696	analyses	T062	C0936012
28527513	706	711	novel	T080	C0205314
28527513	712	722	glucosides	T109	C0017765
28527513	742	788	neobavaisoflavone-4'-O-β-D-glucopyranoside (1)	T109,T121	C2934343
28527513	793	845	neobavaisoflavone-4', 7-di-O-β-D-glucopyranoside (2)	T109,T121	C2934343
28527513	865	883	water-solubilities	T081	C0597682
28527513	887	904	compounds 1 and 2	T109,T121	C2934343
28527513	948	954	higher	T080	C0205250
28527513	972	981	substrate	T167	C3891814
28527513	1012	1021	compounds	T080	C0205198
28527513	1028	1032	NBIF	T109,T121	C2934343
28527513	1043	1047	weak	T080	C1762617
28527513	1048	1060	cytotoxicity	T049	C0596402
28527513	1074	1097	human cancer cell lines	T025	C0085983
28527513	1104	1115	IC50 values	T081	C0600495
28527513	1183	1191	in vitro	T080	C1533691
28527513	1192	1201	enzymatic	T116,T126	C0014442
28527513	1202	1215	glycosylation	T070	C0017982
28527513	1242	1265	structural modification	T061	C0581602
28527513	1267	1276	improving	T080	C1272745
28527513	1277	1293	water-solubility	T081	C0597682

28459124|t|Museum specimen data reveal emergence of a plant disease may be linked to increases in the insect vector population
28459124|a|The emergence rate of new plant diseases is increasing due to novel introductions, climate change, and changes in vector populations, posing risks to agricultural sustainability. Assessing and managing future disease risks depends on understanding the causes of contemporary and historical emergence events. Since the mid-1990s, potato growers in the western United States, Mexico, and Central America have experienced severe yield loss from Zebra Chip disease and have responded by increasing insecticide use to suppress populations of the insect vector, the potato psyllid, Bactericera cockerelli (Hemiptera: Triozidae). Despite the severe nature of Zebra Chip outbreaks, the causes of emergence remain unknown. We tested the hypotheses that 1) B. cockerelli occupancy has increased over the last century in California and 2) such increases are related to climate change, specifically warmer winters. We compiled a dataset of 87,000 museum specimen occurrence records across the order Hemiptera collected between 1900 and 2014. We then analyzed changes in B. cockerelli distribution using a hierarchical occupancy model using changes in background species lists to correct for collecting effort. We found evidence that B. cockerelli occupancy has increased over the last century. However, these changes appear to be unrelated to climate changes, at least at the scale of our analysis. To the extent that species occupancy is related to abundance, our analysis provides the first quantitative support for the hypothesis that B. cockerelli population abundance has increased, but further work is needed to link B. cockerelli population dynamics to Zebra Chip epidemics. Finally, we demonstrate how this historical macro-ecological approach provides a general framework for comparative risk assessment of future pest and insect vector outbreaks. This article is protected by copyright. All rights reserved.
28459124	0	6	Museum	T073	C0026863
28459124	7	15	specimen	T167	C0370003
28459124	16	20	data	T078	C1511726
28459124	43	56	plant disease	T047	C0032080
28459124	74	83	increases	T169	C0442805
28459124	91	104	insect vector	T204	C0021573
28459124	91	115	insect vector population	T098	C1257890
28459124	120	134	emergence rate	T081	C1521828
28459124	142	156	plant diseases	T047	C0032080
28459124	160	170	increasing	T169	C0442808
28459124	199	213	climate change	T070	C2718051
28459124	219	226	changes	T169	C0392747
28459124	230	248	vector populations	T098	C1257890
28459124	257	262	risks	T078	C0035647
28459124	266	278	agricultural	T090	C0001829
28459124	266	293	agricultural sustainability	T169	C0205245
28459124	295	317	Assessing and managing	T052	C0441655
28459124	325	332	disease	T047	C0012634
28459124	333	338	risks	T078	C0035647
28459124	378	422	contemporary and historical emergence events	T051	C0441471
28459124	445	459	potato growers	T097	C0027363
28459124	467	488	western United States	T083	C0041703
28459124	490	496	Mexico	T083	C0025885
28459124	502	517	Central America	T083	C0007674
28459124	542	552	yield loss	T081	C0392762
28459124	558	576	Zebra Chip disease	T047	C0012634
28459124	610	621	insecticide	T131	C0021576
28459124	638	649	populations	T098	C1257890
28459124	657	670	insect vector	T204	C0021573
28459124	676	690	potato psyllid	T204	C1502411
28459124	692	714	Bactericera cockerelli	T204	C1502411
28459124	716	725	Hemiptera	T204	C0018992
28459124	727	736	Triozidae	T204	C1007295
28459124	768	778	Zebra Chip	T047	C0012634
28459124	779	788	outbreaks	T067	C0012652
28459124	844	854	hypotheses	T078	C1512571
28459124	863	876	B. cockerelli	T204	C1502411
28459124	877	886	occupancy	T080	C2827063
28459124	891	900	increased	T081	C0205217
28459124	915	922	century	T121,T127	C0719214
28459124	926	936	California	T083	C0006754
28459124	974	988	climate change	T070	C2718051
28459124	1003	1017	warmer winters	T079	C0241737
28459124	1033	1040	dataset	T170	C0150098
28459124	1051	1057	museum	T073	C0026863
28459124	1058	1066	specimen	T167	C0370003
28459124	1078	1085	records	T170	C0034869
28459124	1103	1112	Hemiptera	T204	C0018992
28459124	1154	1162	analyzed	T062	C0936012
28459124	1174	1187	B. cockerelli	T204	C1502411
28459124	1209	1237	hierarchical occupancy model	T170	C3161035
28459124	1266	1273	species	T185	C1705920
28459124	1266	1279	species lists	T170	C0745732
28459124	1323	1331	evidence	T078	C3887511
28459124	1337	1350	B. cockerelli	T204	C1502411
28459124	1351	1360	occupancy	T080	C2827063
28459124	1365	1374	increased	T081	C0205217
28459124	1389	1396	century	T121,T127	C0719214
28459124	1447	1462	climate changes	T070	C2718051
28459124	1493	1501	analysis	T062	C0936012
28459124	1522	1529	species	T185	C1705920
28459124	1530	1539	occupancy	T080	C2827063
28459124	1569	1577	analysis	T062	C0936012
28459124	1626	1636	hypothesis	T078	C1512571
28459124	1642	1655	B. cockerelli	T204	C1502411
28459124	1656	1666	population	T098	C1257890
28459124	1681	1690	increased	T081	C0205217
28459124	1727	1740	B. cockerelli	T204	C1502411
28459124	1741	1751	population	T098	C1257890
28459124	1752	1760	dynamics	T070	C3826426
28459124	1764	1774	Zebra Chip	T047	C0012634
28459124	1764	1784	Zebra Chip epidemics	T047	C0277548
28459124	1819	1855	historical macro-ecological approach	T082	C0449445
28459124	1889	1916	comparative risk assessment	T058	C0086930
28459124	1927	1931	pest	T204	C0684063
28459124	1936	1949	insect vector	T204	C0021573
28459124	1950	1959	outbreaks	T067	C0012652

28019021|t|Multiparametric estimation of brain hemodynamics with MR fingerprinting ASL
28019021|a|Assessment of brain hemodynamics without exogenous contrast agents is of increasing importance in clinical applications. This study aims to develop an MR perfusion technique that can provide noncontrast and multiparametric estimation of hemodynamic markers. We devised an arterial spin labeling (ASL) method based on the principle of MR fingerprinting (MRF), referred to as MRF-ASL. By taking advantage of the rich information contained in MRF sequence, up to seven hemodynamic parameters can be estimated concomitantly. Feasibility demonstration, flip angle optimization, comparison with Look-Locker ASL, reproducibility test, sensitivity to hypercapnia challenge, and initial clinical application in an intracranial steno-occlusive process, Moyamoya disease, were performed to evaluate this technique. Magnetic resonance fingerprinting ASL provided estimation of up to seven parameters, including B1+, tissue T1, cerebral blood flow (CBF), tissue bolus arrival time (BAT), pass-through arterial BAT, pass-through blood volume, and pass-through blood travel time. Coefficients of variation of the estimated parameters ranged from 0.2 to 9.6%. Hypercapnia resulted in an increase in CBF by 57.7%, and a decrease in BAT by 13.7 and 24.8% in tissue and vessels, respectively. Patients with Moyamoya disease showed diminished CBF and lengthened BAT that could not be detected with regular ASL. Magnetic resonance fingerprinting ASL is a promising technique for noncontrast, multiparametric perfusion assessment. Magn Reson Med, 2016. © 2016 International Society for Magnetic Resonance in Medicine.
28019021	0	26	Multiparametric estimation	T062	C1513748
28019021	30	48	brain hemodynamics	T042	C4042806
28019021	54	75	MR fingerprinting ASL	T060	C3891302
28019021	76	86	Assessment	T058	C0220825
28019021	90	108	brain hemodynamics	T042	C4042806
28019021	117	126	exogenous	T169	C0205228
28019021	127	142	contrast agents	T130	C0009924
28019021	149	159	increasing	T169	C0442808
28019021	160	170	importance	T080	C3898777
28019021	174	195	clinical applications	UnknownType	C0869019
28019021	227	249	MR perfusion technique	T060	C4287652
28019021	267	278	noncontrast	T033	C2825493
28019021	283	309	multiparametric estimation	T062	C1513748
28019021	313	324	hemodynamic	T042	C0019010
28019021	325	332	markers	T074	C2745888
28019021	348	370	arterial spin labeling	T060	C3891302
28019021	372	375	ASL	T060	C3891302
28019021	410	427	MR fingerprinting	T060	C0024485
28019021	429	432	MRF	T060	C0024485
28019021	435	443	referred	T169	C0205543
28019021	450	457	MRF-ASL	T060	C3891302
28019021	491	502	information	T078	C1533716
28019021	516	528	MRF sequence	T060	C0024485
28019021	542	553	hemodynamic	T042	C0019010
28019021	554	564	parameters	T033	C0449381
28019021	572	581	estimated	T081	C0750572
28019021	582	595	concomitantly	T079	C0521115
28019021	597	622	Feasibility demonstration	T062,T170	C0015730
28019021	624	634	flip angle	T080	C2348681
28019021	635	647	optimization	T052	C2698650
28019021	649	659	comparison	T052	C1707455
28019021	665	680	Look-Locker ASL	T060	C3891302
28019021	682	702	reproducibility test	T080	C1514863
28019021	704	715	sensitivity	T169	C0332324
28019021	719	740	hypercapnia challenge	T033	C0020440
28019021	754	774	clinical application	UnknownType	C0869019
28019021	781	817	intracranial steno-occlusive process	T061	C0394264
28019021	819	835	Moyamoya disease	T047	C0026654
28019021	842	851	performed	T169	C0884358
28019021	869	878	technique	T169	C0449851
28019021	880	917	Magnetic resonance fingerprinting ASL	T060	C3891302
28019021	918	926	provided	T052	C1999230
28019021	953	963	parameters	T033	C0449381
28019021	975	978	B1+	T081	C0392762
28019021	980	986	tissue	T023	C0459385
28019021	987	989	T1	T081	C2697938
28019021	991	1010	cerebral blood flow	T033	C0428714
28019021	1012	1015	CBF	T033	C0428714
28019021	1018	1024	tissue	T024	C0040300
28019021	1025	1043	bolus arrival time	T033	C0243095
28019021	1045	1048	BAT	T033	C0243095
28019021	1064	1072	arterial	T023	C0003842
28019021	1073	1076	BAT	T033	C0243095
28019021	1091	1103	blood volume	T201	C0005850
28019021	1122	1139	blood travel time	T060	C0919393
28019021	1141	1153	Coefficients	T081	C1707429
28019021	1157	1166	variation	T080	C0205419
28019021	1174	1183	estimated	T081	C0750572
28019021	1184	1194	parameters	T033	C0449381
28019021	1220	1231	Hypercapnia	T033	C0020440
28019021	1247	1255	increase	T169	C0442805
28019021	1259	1262	CBF	T033	C0428714
28019021	1279	1287	decrease	T081	C0547047
28019021	1291	1294	BAT	T033	C0243095
28019021	1316	1322	tissue	T024	C0040300
28019021	1327	1334	vessels	T023	C0005847
28019021	1350	1358	Patients	T101	C0030705
28019021	1364	1380	Moyamoya disease	T047	C0026654
28019021	1388	1398	diminished	T081	C0205216
28019021	1399	1402	CBF	T033	C0428714
28019021	1407	1417	lengthened	T169	C0392744
28019021	1418	1421	BAT	T033	C0243095
28019021	1427	1448	could not be detected	T033	C0442737
28019021	1454	1461	regular	T080	C0205272
28019021	1462	1465	ASL	T060	C3891302
28019021	1467	1504	Magnetic resonance fingerprinting ASL	T060	C3891302
28019021	1520	1529	technique	T169	C0449851
28019021	1534	1545	noncontrast	T033	C2825493
28019021	1547	1562	multiparametric	T062	C1513748
28019021	1563	1583	perfusion assessment	T058	C4038600
28019021	1614	1670	International Society for Magnetic Resonance in Medicine	T073,T093	C0018720

27423415|t|MALDI-TOF mass spectrometry for the identification of lactic acid bacteria isolated from a French cheese: The Maroilles
27423415|a|In this study we identified the culturable population of mesophilic lactic acid bacteria (LAB) from a French cheese Maroilles made either with raw or pasteurized milk using MALDI-TOF mass spectrometry (MS). Samples from rind and heart of Maroilles cheese were used, the LAB were selected on MRS agar at 30°C and 197 Gram-positive and catalase-negative strains were subjected to identification by MALDI-TOF MS profiling. All strains were unambiguously identified: 105 strains from Maroilles made with raw milk (38 on the rind and 67 in the heart) and 92 strains from Maroilles made with pasteurized milk (39 on the rind and 53 in the heart). MALDI-TOF MS identification allowed identification of three genera belonging to LAB including Lactobacillus, Enterococcus and Leuconostoc. Lactobacillus was the most represented genus with seven species: Lactobacillus plantarum (L. plantarum), L. paracasei, L. curvatus, L. rhamnosus, L. fructivorans, L. parabuchneri, L. brevis found in Maroilles made with both kind of milk. The correlation between the 16S rDNA -based identification performed on selected strains and those obtained by MALDI-TOF-MS demonstrates that this fast, economically affordable, robust and reliable method for bacteria characterisation stands as an attractive alternative to the commonly-used methods and its application in food industry is discussed.
27423415	0	27	MALDI-TOF mass spectrometry	T062	C1518101
27423415	36	50	identification	T080	C0205396
27423415	54	74	lactic acid bacteria	T007	C0678170
27423415	75	83	isolated	T169	C0205409
27423415	91	104	French cheese	T168	C0007968
27423415	110	119	Maroilles	T168	C0007968
27423415	128	133	study	T062	C2603343
27423415	137	147	identified	T080	C0205396
27423415	152	162	culturable	T059	C0430400
27423415	163	173	population	T098	C1257890
27423415	177	187	mesophilic	T080	C0205556
27423415	188	208	lactic acid bacteria	T007	C0678170
27423415	210	213	LAB	T007	C0678170
27423415	222	245	French cheese Maroilles	T168	C0007968
27423415	263	266	raw	T167	C1442323
27423415	270	286	pasteurized milk	T168	C3687546
27423415	293	320	MALDI-TOF mass spectrometry	T062	C1518101
27423415	322	324	MS	T059	C0037813
27423415	327	334	Samples	T167	C0370003
27423415	340	344	rind	T082	C1254362
27423415	349	354	heart	T082	C1254362
27423415	358	374	Maroilles cheese	T168	C0007968
27423415	390	393	LAB	T007	C0678170
27423415	411	419	MRS agar	T109,T121,T130	C0001771
27423415	436	449	Gram-positive	T034	C0855278
27423415	454	471	catalase-negative	T044	C3822681
27423415	472	479	strains	T080	C0456178
27423415	498	512	identification	T080	C0205396
27423415	516	528	MALDI-TOF MS	T062	C1518101
27423415	529	538	profiling	T169	C2003903
27423415	544	551	strains	T080	C0456178
27423415	571	581	identified	T080	C0205396
27423415	587	594	strains	T080	C0456178
27423415	600	609	Maroilles	T168	C0007968
27423415	620	628	raw milk	T167	C1442323
27423415	640	644	rind	T082	C1254362
27423415	659	664	heart	T082	C1254362
27423415	673	680	strains	T080	C0456178
27423415	686	695	Maroilles	T168	C0007968
27423415	706	722	pasteurized milk	T168	C3687546
27423415	734	738	rind	T082	C1254362
27423415	753	758	heart	T082	C1254362
27423415	761	773	MALDI-TOF MS	T062	C1518101
27423415	774	788	identification	T080	C0205396
27423415	797	811	identification	T080	C0205396
27423415	815	820	three	T081	C0205449
27423415	821	827	genera	T185	C0008902
27423415	841	844	LAB	T007	C0678170
27423415	855	868	Lactobacillus	T007	C0022938
27423415	870	882	Enterococcus	T007	C0085494
27423415	887	898	Leuconostoc	T007	C0023411
27423415	900	913	Lactobacillus	T007	C0022938
27423415	939	944	genus	T185	C1708235
27423415	950	955	seven	T081	C0205453
27423415	956	963	species	T185	C1705920
27423415	965	988	Lactobacillus plantarum	T007	C0317608
27423415	990	1002	L. plantarum	T007	C0317608
27423415	1005	1017	L. paracasei	T007	C1080735
27423415	1019	1030	L. curvatus	T007	C0317598
27423415	1032	1044	L. rhamnosus	T007	C0317597
27423415	1046	1061	L. fructivorans	T007	C0317607
27423415	1063	1078	L. parabuchneri	T007	C1072848
27423415	1080	1089	L. brevis	T007	C0317604
27423415	1099	1108	Maroilles	T168	C0007968
27423415	1132	1136	milk	T168	C2825079
27423415	1142	1153	correlation	T080	C1707520
27423415	1166	1174	16S rDNA	T114,T123	C0012933
27423415	1182	1196	identification	T080	C0205396
27423415	1219	1226	strains	T080	C0456178
27423415	1249	1261	MALDI-TOF-MS	T062	C1518101
27423415	1316	1322	robust	T080	C2986815
27423415	1327	1335	reliable	T170	C3858758
27423415	1336	1342	method	T170	C0025663
27423415	1347	1355	bacteria	T007	C0004611
27423415	1356	1372	characterisation	T052	C1880022
27423415	1430	1437	methods	T170	C0025663
27423415	1461	1474	food industry	T057	C0524863

28128970|t|Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
28128970|a|This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 report focuses primarily on the revised and novel parts of the document. The most significant changes include: (1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (2) for each of the groups A to D, escalation strategies for pharmacologic treatments are proposed; (3) the concept of deescalation of therapy is introduced in the treatment assessment scheme; (4) nonpharmacologic therapies are comprehensively presented; and (5) the importance of comorbid conditions in managing chronic obstructive pulmonary disease is reviewed.
28128970	0	15	Global Strategy	T062	C0035171
28128970	24	33	Diagnosis	T062	C1704656
28128970	35	45	Management	T058	C0376636
28128970	51	61	Prevention	T062	C1706420
28128970	65	97	Chronic Obstructive Lung Disease	T047	C0024117
28128970	111	133	GOLD Executive Summary	T170	C0282574
28128970	139	156	Executive Summary	T170	C0282574
28128970	164	179	Global Strategy	T062	C0035171
28128970	188	197	Diagnosis	T062	C1704656
28128970	199	209	Management	T058	C0376636
28128970	215	225	Prevention	T062	C1706420
28128970	229	233	COPD	T047	C0024117
28128970	235	289	Global Initiative for Chronic Obstructive Lung Disease	T170	C0282574
28128970	291	295	GOLD	T170	C0282574
28128970	302	308	report	T170	C0684224
28128970	334	341	revised	T061	C1527075
28128970	365	373	document	T170	C1301746
28128970	396	403	changes	T169	C0392747
28128970	421	431	assessment	T058	C0220825
28128970	435	472	chronic obstructive pulmonary disease	T047	C0024117
28128970	493	501	separate	T080	C0443299
28128970	506	528	spirometric assessment	T060	C0037981
28128970	534	552	symptom evaluation	T058	C3494438
28128970	554	565	ABCD groups	T098	C1257890
28128970	589	596	derived	T080	C1441547
28128970	614	630	patient symptoms	T033	C1317600
28128970	641	651	history of	T033	C0332119
28128970	652	665	exacerbations	T033	C4086268
28128970	687	693	groups	T098	C1257890
28128970	702	712	escalation	T052	C4086266
28128970	713	723	strategies	T062	C0035171
28128970	728	741	pharmacologic	T169	C0205464
28128970	742	752	treatments	T061	C0087111
28128970	757	765	proposed	T080	C1553874
28128970	775	782	concept	T078	C0178566
28128970	786	798	deescalation	T061	C3651014
28128970	802	809	therapy	T061	C0087111
28128970	831	840	treatment	T061	C0087111
28128970	841	851	assessment	T058	C0220825
28128970	852	858	scheme	T170	C1519193
28128970	864	890	nonpharmacologic therapies	UnknownType	C0548233
28128970	911	920	presented	T078	C0449450
28128970	948	967	comorbid conditions	T033	C1275743
28128970	971	979	managing	T058	C0184516
28128970	980	1017	chronic obstructive pulmonary disease	T047	C0024117
28128970	1021	1029	reviewed	T080	C1709940

27381582|t|Antidiabetic potential of bioactive molecules coated chitosan nanoparticles in experimental rats
27381582|a|The present study was carried out to examine the antidiabetic effects of chitosan nanoparticles (CNPs) loaded with (Stevia rebaudiana leaf extract - SRLE) bioactive molecules in a rat model of streptozotocin (STZ) induced diabetes mellitus. Successful crosslinking of the bioactive molecules to the chitosan nanoparticles was confirmed by Fourier Transform Infrared Spectroscopy (FTIR). The colloidal characteristics of the synthesized nanoparticles were revealed by X-ray Diffraction (XRD) analysis. Morphological analysis by Transmission Electron Microscopy (TEM) revealed that the bioactive molecule -loaded CNPs were well-dispersed and spherical or polygonal in shape with an average size of<73.27nm than the z-average value (327nm) as measured by Dynamic Light Scattering (DLS). SRLE CNP - treated diabetic rats showed a significant reduction in their mean fasting blood glucose level compared with the diabetic control group. The serum levels of various enzymes viz., serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), alkaline phosphatases (ALP), lipid peroxidation, and antioxidant such as catalase (CAT), reduced glutathione (GSH), and superoxide dismutase (SOD) in the SRLE CNP - treated group were closer to normal levels than those in the diabetic control group.
27381582	0	12	Antidiabetic	T121	C0935929
27381582	13	22	potential	T080	C3245505
27381582	26	45	bioactive molecules	T167	C3714412
27381582	53	75	chitosan nanoparticles	T109,T121	C0162969
27381582	79	91	experimental	T080	C1517586
27381582	92	96	rats	T015	C0034721
27381582	109	114	study	T062	C2603343
27381582	146	158	antidiabetic	T121	C0935929
27381582	159	169	effects of	T080	C1704420
27381582	170	192	chitosan nanoparticles	T109,T121	C0162969
27381582	194	198	CNPs	T109,T121	C0162969
27381582	213	243	Stevia rebaudiana leaf extract	T109,T121	C3267306
27381582	246	250	SRLE	T109,T121	C3267306
27381582	252	271	bioactive molecules	T167	C3714412
27381582	277	280	rat	T015	C0034721
27381582	281	286	model	T050	C0012644
27381582	290	304	streptozotocin	T109,T195	C0038432
27381582	306	309	STZ	T109,T195	C0038432
27381582	311	318	induced	T169	C0205263
27381582	319	336	diabetes mellitus	T050	C0011853
27381582	349	361	crosslinking	T070	C0178576
27381582	369	388	bioactive molecules	T167	C3714412
27381582	396	418	chitosan nanoparticles	T109,T121	C0162969
27381582	436	475	Fourier Transform Infrared Spectroscopy	T062	C0206055
27381582	477	481	FTIR	T062	C0206055
27381582	488	513	colloidal characteristics	T080	C1521970
27381582	521	532	synthesized	T052	C1883254
27381582	533	546	nanoparticles	T109,T121	C0162969
27381582	564	596	X-ray Diffraction (XRD) analysis	T059	C0599643
27381582	598	611	Morphological	T082	C0543482
27381582	612	620	analysis	T062	C0936012
27381582	624	656	Transmission Electron Microscopy	T059	C0678118
27381582	658	661	TEM	T059	C0678118
27381582	681	699	bioactive molecule	T167	C3714412
27381582	708	712	CNPs	T109,T121	C0162969
27381582	718	732	well-dispersed	T080	C0205556
27381582	737	746	spherical	T082	C0332501
27381582	750	759	polygonal	T082	C2347622
27381582	763	768	shape	T082	C0332479
27381582	777	789	average size	T082	C0456389
27381582	810	825	z-average value	T081	C1883591
27381582	849	873	Dynamic Light Scattering	T059	C1882368
27381582	875	878	DLS	T059	C1882368
27381582	881	885	SRLE	T109,T121	C3267306
27381582	886	889	CNP	T109,T121	C0162969
27381582	892	899	treated	T169	C1522326
27381582	900	908	diabetic	T050	C0011853
27381582	909	913	rats	T015	C0034721
27381582	923	934	significant	T078	C0750502
27381582	935	944	reduction	T081	C0547047
27381582	959	986	fasting blood glucose level	T034	C1261430
27381582	1005	1013	diabetic	T050	C0011853
27381582	1014	1027	control group	T096	C0009932
27381582	1033	1038	serum	T031	C0229671
27381582	1039	1045	levels	T080	C0441889
27381582	1057	1064	enzymes	T116,T126	C0014442
27381582	1071	1110	serum glutamic oxaloacetic transaminase	T116,T126	C0242192
27381582	1112	1116	SGOT	T116,T126	C0242192
27381582	1119	1154	serum glutamic pyruvic transaminase	T116,T126	C0376147
27381582	1156	1160	SGPT	T116,T126	C0376147
27381582	1163	1184	alkaline phosphatases	T116,T126	C0002059
27381582	1186	1189	ALP	T116,T126	C0002059
27381582	1192	1210	lipid peroxidation	T044	C0023775
27381582	1216	1227	antioxidant	T121	C0003402
27381582	1236	1244	catalase	T116,T126	C0007367
27381582	1246	1249	CAT	T116,T126	C0007367
27381582	1252	1271	reduced glutathione	T034	C0034917
27381582	1273	1276	GSH	T034	C0034917
27381582	1283	1303	superoxide dismutase	T116,T121,T126	C0038838
27381582	1305	1308	SOD	T116,T121,T126	C0038838
27381582	1317	1321	SRLE	T109,T121	C3267306
27381582	1322	1325	CNP	T109,T121	C0162969
27381582	1328	1335	treated	T169	C1522326
27381582	1336	1341	group	T078	C0441833
27381582	1357	1363	normal	T080	C0205307
27381582	1364	1370	levels	T080	C0441889
27381582	1389	1397	diabetic	T050	C0011853
27381582	1398	1411	control group	T096	C0009932

27861593|t|Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon
27861593|a|Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing- antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin. Forty patients with chronic HCV (80% with cirrhosis) were enrolled in the study, 28 received triple therapy (Group A) with pegylated-interferon and ribavirin for 4 weeks followed by the addition of a PI (telaprevir, boceprevir or simeprevir), and 12 patients received an interferon -free regimen (Group B) with simeprevir and sofosbuvir. Phagocytosis and oxidative burst capacity were analyzed by flow cytometry at baseline, week 4, and week 8 of therapy. In neutrophils from Group A patients, oxidative burst rate and oxidative enzymatic activity per cell significantly decreased throughout the study period (p = 0.014 and p = 0.010, respectively). Pairwise comparisons showed a decrease between baseline and week 4 and 8 of therapy. No differences were observed after the introduction of the PI. The oxidative enzymatic activity per cell in monocytes significantly decrease during the study period (p = 0.042) due to a decrease from baseline to week 8 of therapy (p = 0.037) in patients from Group A. None of these findings were observed in Group B patients. Cytokine secretion did not significantly change during the study in both groups. In conclusion, our data suggest that the use interferon (rather than the PI) has a deleterious effect on neutrophil and monocyte phagocytic and oxidative burst capacity in this cohort of patients with HCV -related advanced liver fibrosis.
27861593	0	10	Neutrophil	T025	C0027950
27861593	15	23	Monocyte	T025	C0026473
27861593	24	32	Function	T043	C0007613
27861593	36	44	Patients	T101	C0030705
27861593	50	69	Chronic Hepatitis C	T047	C0524910
27861593	81	98	Antiviral Therapy	T061	C0280274
27861593	104	112	Regimens	T061	C0040808
27861593	124	143	Protease Inhibitors	T121	C0033607
27861593	161	171	Interferon	T116,T121,T129	C0021747
27861593	172	186	Real-life data	T078	C1511726
27861593	197	206	increased	T081	C0205217
27861593	207	216	incidence	T081	C0021149
27861593	220	240	bacterial infections	T047	C0004623
27861593	244	252	patients	T101	C0030705
27861593	267	280	liver disease	T047	C0023895
27861593	281	290	receiving	T080	C1514756
27861593	293	311	protease inhibitor	T121	C0033607
27861593	313	315	PI	T121	C0033607
27861593	328	345	antiviral regimen	T061	C0040808
27861593	354	365	hepatitis C	T005	C0220847
27861593	367	370	HCV	T005	C0220847
27861593	441	444	PIs	T121	C0033607
27861593	458	481	innate immune responses	T032	C0020969
27861593	494	517	inhibition of proteases	T039	C1524081
27861593	539	563	anti-bacterial functions	T039	C0544570
27861593	567	578	neutrophils	T025	C0027950
27861593	583	592	monocytes	T025	C0026473
27861593	610	615	study	T077	C1706256
27861593	624	630	assess	T058	C0184514
27861593	631	661	phagocytic and oxidative burst	T043	C0085416
27861593	662	670	capacity	T081	C1516240
27861593	674	685	neutrophils	T025	C0027950
27861593	690	699	monocytes	T025	C0026473
27861593	714	722	patients	T101	C0030705
27861593	723	732	receiving	T080	C1514756
27861593	735	737	PI	T121	C0033607
27861593	750	767	antiviral regimen	T061	C0040808
27861593	786	804	cytokine secretion	T043	C1327414
27861593	811	821	neutrophil	T025	C0027950
27861593	822	833	stimulation	T043	C0007613
27861593	839	848	flagellin	T116,T123	C0016194
27861593	856	864	patients	T101	C0030705
27861593	870	881	chronic HCV	T047	C0524910
27861593	892	901	cirrhosis	T047	C0023890
27861593	924	929	study	T077	C1706256
27861593	934	942	received	T080	C1514756
27861593	943	957	triple therapy	T061	C0087111
27861593	959	966	Group A	T185	C0441835
27861593	973	993	pegylated-interferon	T116,T121,T129	C0021747
27861593	998	1007	ribavirin	T114,T121	C0035525
27861593	1014	1019	weeks	T079	C0439230
27861593	1050	1052	PI	T121	C0033607
27861593	1054	1064	telaprevir	T116,T121	C1876229
27861593	1066	1076	boceprevir	T116,T121	C1738934
27861593	1080	1090	simeprevir	T109,T121	C2605855
27861593	1100	1108	patients	T101	C0030705
27861593	1109	1117	received	T080	C1514756
27861593	1121	1131	interferon	T116,T121,T129	C0021747
27861593	1121	1145	interferon -free regimen	T061	C0040808
27861593	1147	1154	Group B	T185	C0008902
27861593	1161	1171	simeprevir	T109,T121	C2605855
27861593	1176	1186	sofosbuvir	T114,T121	C2976303
27861593	1188	1220	Phagocytosis and oxidative burst	T043	C0085416
27861593	1221	1229	capacity	T081	C1516240
27861593	1247	1261	flow cytometry	T059	C0016263
27861593	1265	1273	baseline	T081	C1442488
27861593	1275	1279	week	T079	C0439230
27861593	1287	1291	week	T079	C0439230
27861593	1297	1304	therapy	T061	C0087111
27861593	1309	1320	neutrophils	T025	C0027950
27861593	1326	1333	Group A	T185	C0441835
27861593	1334	1342	patients	T101	C0030705
27861593	1344	1359	oxidative burst	T043	C0085416
27861593	1360	1364	rate	T081	C1521828
27861593	1369	1378	oxidative	T169	C0311404
27861593	1379	1406	enzymatic activity per cell	T044	C2267219
27861593	1421	1430	decreased	T081	C0205216
27861593	1446	1458	study period	T079	C1254367
27861593	1500	1520	Pairwise comparisons	T081	C0086766
27861593	1530	1538	decrease	T081	C0547047
27861593	1547	1555	baseline	T081	C1442488
27861593	1560	1564	week	T079	C0439230
27861593	1576	1583	therapy	T061	C0087111
27861593	1624	1636	introduction	T061	C1293116
27861593	1644	1646	PI	T121	C0033607
27861593	1652	1661	oxidative	T169	C0311404
27861593	1662	1689	enzymatic activity per cell	T044	C2267219
27861593	1693	1702	monocytes	T025	C0026473
27861593	1717	1725	decrease	T081	C0547047
27861593	1737	1749	study period	T079	C1254367
27861593	1771	1779	decrease	T081	C0547047
27861593	1785	1793	baseline	T081	C1442488
27861593	1797	1801	week	T079	C0439230
27861593	1807	1814	therapy	T061	C0087111
27861593	1830	1838	patients	T101	C0030705
27861593	1844	1851	Group A	T185	C0441835
27861593	1867	1875	findings	T169	C2607943
27861593	1893	1900	Group B	T185	C0008902
27861593	1901	1909	patients	T101	C0030705
27861593	1911	1929	Cytokine secretion	T043	C1327414
27861593	1970	1975	study	T077	C1706256
27861593	1984	1990	groups	T078	C0441833
27861593	2011	2015	data	T078	C1511726
27861593	2037	2047	interferon	T116,T121,T129	C0021747
27861593	2065	2067	PI	T121	C0033607
27861593	2075	2093	deleterious effect	T080	C1280500
27861593	2097	2107	neutrophil	T025	C0027950
27861593	2112	2120	monocyte	T025	C0026473
27861593	2121	2151	phagocytic and oxidative burst	T043	C0085416
27861593	2152	2160	capacity	T081	C1516240
27861593	2169	2175	cohort	T098	C0599755
27861593	2179	2187	patients	T101	C0030705
27861593	2193	2196	HCV	T005	C0220847
27861593	2206	2229	advanced liver fibrosis	T047	C0239946

27752009|t|Prevalence and presentation of tuberculosis among hemodialysis patients in Khartoum, Sudan
27752009|a|Tuberculosis (TB) is a major health problem in the developing countries. There are limited data about the prevalence of TB patients on maintenance hemodialysis (HD) in Sudan. The aim of this study is to identify the prevalence and presentation of TB among Sudanese maintenance HD patients. This is a hospital -based descriptive study. The participants of the study are all HD patients distributed in 13 HD centers in Khartoum and Khartoum North Provinces in Sudan. All patients attended the HD centers from November 1, 2014 to February 1, 2015, were interviewed by a questionnaire focused on personal and clinical data. Those who were diagnosed as having active TB were studied regarding their clinical presentation, presence of comorbidities, site of TB, and methods used on diagnosis. The total number of HD patients during the study period was 1328 patients. We found 19 patients who already diagnosed and treated for TB infection. The prevalence rate of TB among HD patients is 1.4%. The mean age of patient was 44.53±8.69 years, 89.5% of them were males. The majority of them have comorbidities: 31.6%% have hypertension and 21.1% have diabetes. Extrapulmonary TB was the major presentation (57.9%) mainly tuberculous lymphadenitis (26.3%). The pulmonary presentation was found to be 42.1%. The diagnosis of TB was supported by microbiological evidence of alcohol acid-fast Bacilli present in sputum smear (21%), histological diagnosis (31.6%), polymerase chain reaction (21%), and imaging in (26.3%). Patients on maintenance HD are at an increased risk of TB and diagnosis of TB among HD patients need a high index of suspicion. There is a great need for establishing a screening scheme for TB among HD patients and further epidemiological studies are needed to fully evaluate this problem.
27752009	0	10	Prevalence	T081	C0033105
27752009	15	27	presentation	T078	C0449450
27752009	31	43	tuberculosis	T047	C0041296
27752009	50	62	hemodialysis	T061	C0019004
27752009	63	71	patients	T101	C0030705
27752009	75	83	Khartoum	UnknownType	C0681784
27752009	85	90	Sudan	T083	C0038642
27752009	91	103	Tuberculosis	T047	C0041296
27752009	105	107	TB	T047	C0041296
27752009	120	126	health	T078	C0018684
27752009	127	134	problem	T033	C0033213
27752009	142	162	developing countries	T080	C0011750
27752009	174	186	limited data	T078	C1511726
27752009	197	207	prevalence	T081	C0033105
27752009	211	213	TB	T047	C0041296
27752009	214	222	patients	T101	C0030705
27752009	226	237	maintenance	T052	C0024501
27752009	238	250	hemodialysis	T061	C0019004
27752009	252	254	HD	T061	C0019004
27752009	259	264	Sudan	T083	C0038642
27752009	294	302	identify	T080	C0205396
27752009	307	317	prevalence	T081	C0033105
27752009	322	334	presentation	T078	C0449450
27752009	338	340	TB	T047	C0041296
27752009	347	355	Sudanese	T098	C0241297
27752009	356	367	maintenance	T052	C0024501
27752009	368	370	HD	T061	C0019004
27752009	371	379	patients	T101	C0030705
27752009	391	399	hospital	T073,T093	C0019994
27752009	419	424	study	T062	C2603343
27752009	430	442	participants	T098	C0679646
27752009	450	455	study	T062	C2603343
27752009	464	466	HD	T061	C0019004
27752009	467	475	patients	T101	C0030705
27752009	476	487	distributed	T169	C1704711
27752009	494	504	HD centers	T073,T093	C0475309
27752009	508	516	Khartoum	UnknownType	C0681784
27752009	521	545	Khartoum North Provinces	UnknownType	C0681784
27752009	549	554	Sudan	T083	C0038642
27752009	560	568	patients	T101	C0030705
27752009	582	592	HD centers	T073,T093	C0475309
27752009	598	606	November	T079	C3828767
27752009	618	626	February	T080	C3830166
27752009	641	652	interviewed	T052	C0021822
27752009	658	671	questionnaire	T170	C0034394
27752009	672	679	focused	T169	C1285542
27752009	683	691	personal	T078	C1511726
27752009	696	709	clinical data	T170	C1516606
27752009	726	735	diagnosed	T033	C0011900
27752009	746	755	active TB	T047	C0041296
27752009	785	793	clinical	T080	C0205210
27752009	794	806	presentation	T078	C0449450
27752009	808	816	presence	T033	C0150312
27752009	820	833	comorbidities	T078	C0009488
27752009	835	839	site	T082	C0205145
27752009	843	845	TB	T047	C0041296
27752009	851	858	methods	T170	C0025663
27752009	867	876	diagnosis	T033	C0011900
27752009	888	894	number	T081	C0237753
27752009	898	900	HD	T061	C0019004
27752009	901	909	patients	T101	C0030705
27752009	921	926	study	T062	C2603343
27752009	927	933	period	T079	C1948053
27752009	943	951	patients	T101	C0030705
27752009	965	973	patients	T101	C0030705
27752009	986	995	diagnosed	T033	C0011900
27752009	1000	1007	treated	T169	C1522326
27752009	1012	1024	TB infection	T047	C0041296
27752009	1030	1040	prevalence	T081	C0033105
27752009	1041	1045	rate	T081	C1521828
27752009	1049	1051	TB	T047	C0041296
27752009	1058	1060	HD	T061	C0019004
27752009	1061	1069	patients	T101	C0030705
27752009	1088	1091	age	T032	C0001779
27752009	1095	1102	patient	T101	C0030705
27752009	1118	1123	years	T079	C0439234
27752009	1144	1149	males	T032	C0086582
27752009	1177	1190	comorbidities	T078	C0009488
27752009	1204	1216	hypertension	T047	C0020538
27752009	1232	1240	diabetes	T047	C0011847
27752009	1242	1259	Extrapulmonary TB	T047	C0679362
27752009	1274	1286	presentation	T078	C0449450
27752009	1302	1327	tuberculous lymphadenitis	T047	C0041316
27752009	1341	1350	pulmonary	T023	C0024109
27752009	1351	1363	presentation	T078	C0449450
27752009	1391	1400	diagnosis	T033	C0011900
27752009	1404	1406	TB	T047	C0041296
27752009	1424	1439	microbiological	T091	C0025952
27752009	1440	1448	evidence	T078	C3887511
27752009	1452	1501	alcohol acid-fast Bacilli present in sputum smear	T034	C0555122
27752009	1509	1531	histological diagnosis	UnknownType	C0679557
27752009	1541	1566	polymerase chain reaction	T063	C0032520
27752009	1578	1588	imaging in	T060	C0011923
27752009	1598	1606	Patients	T101	C0030705
27752009	1610	1621	maintenance	T052	C0024501
27752009	1622	1624	HD	T061	C0019004
27752009	1635	1644	increased	T081	C0205217
27752009	1645	1649	risk	T078	C0035647
27752009	1653	1655	TB	T047	C0041296
27752009	1660	1669	diagnosis	T033	C0011900
27752009	1673	1675	TB	T047	C0041296
27752009	1682	1684	HD	T061	C0019004
27752009	1685	1693	patients	T101	C0030705
27752009	1715	1724	suspicion	T041	C0242114
27752009	1767	1776	screening	T058	C1710032
27752009	1777	1783	scheme	T170	C1519193
27752009	1788	1790	TB	T047	C0041296
27752009	1797	1799	HD	T061	C0019004
27752009	1800	1808	patients	T101	C0030705
27752009	1821	1844	epidemiological studies	T062	C0002783
27752009	1879	1886	problem	T033	C0033213

28051899|t|Serious Games for Health: The Potential of Metadata
28051899|a|Numerous serious games and health games exist, either as commercial products (typically with a focus on entertaining a broad user group) or smaller games and game prototypes, often resulting from research projects (typically tailored to a smaller user group with a specific health characteristic). A major drawback of existing health games is that they are not very well described and attributed with (machine -readable, quantitative, and qualitative) metadata such as the characterizing goal of the game, the target user group, or expected health effects well proven in scientific studies. This makes it difficult or even impossible for end users to find and select the most appropriate game for a specific situation (e.g., health needs). Therefore, the aim of this article was to motivate the need and potential / benefit of metadata for the description and retrieval of health games and to describe a descriptive model for the qualitative description of games for health. It was not the aim of the article to describe a stable, running system (portal) for health games. This will be addressed in future work. Building on previous work toward a metadata format for serious games, a descriptive model for the formal description of games for health is introduced. For the conceptualization of this model, classification schemata of different existing health game repositories are considered. The classification schema consists of three levels: a core set of mandatory descriptive fields relevant for all games for health application areas, a detailed level with more comprehensive, optional information about the games, and so-called extension as level three with specific descriptive elements relevant for dedicated health games application areas, for example, cardio training. A metadata format provides a technical framework to describe, find, and select appropriate health games matching the needs of the end user. Future steps to improve, apply, and promote the metadata format in the health games market are discussed.
28051899	8	13	Games	T056	C0150593
28051899	18	24	Health	T078	C0018684
28051899	30	39	Potential	T080	C3245505
28051899	43	51	Metadata	T170	C1708992
28051899	69	74	games	T056	C0150593
28051899	79	85	health	T078	C0018684
28051899	86	91	games	T056	C0150593
28051899	109	128	commercial products	T073	C1547887
28051899	177	187	user group	T098	C1705429
28051899	200	205	games	T056	C0150593
28051899	210	214	game	T056	C0150593
28051899	248	265	research projects	T062	C0700032
28051899	299	309	user group	T098	C1705429
28051899	326	332	health	T078	C0018684
28051899	333	347	characteristic	T080	C1521970
28051899	379	385	health	T078	C0018684
28051899	386	391	games	T056	C0150593
28051899	454	461	machine	T073	C0336779
28051899	473	485	quantitative	T081	C0392762
28051899	491	502	qualitative	T080	C0205556
28051899	504	512	metadata	T170	C1708992
28051899	525	539	characterizing	T052	C1880022
28051899	540	544	goal	T170	C0018017
28051899	552	556	game	T056	C0150593
28051899	562	568	target	T169	C1521840
28051899	569	579	user group	T098	C1705429
28051899	593	599	health	T078	C0018684
28051899	600	607	effects	T080	C1280500
28051899	623	641	scientific studies	T059	C0947630
28051899	690	699	end users	T098	C1706077
28051899	740	744	game	T056	C0150593
28051899	760	769	situation	T080	C0018759
28051899	777	783	health	T078	C0018684
28051899	784	789	needs	T080	C0027552
28051899	807	810	aim	T078	C1947946
28051899	819	826	article	T170	C1706852
28051899	847	851	need	T080	C0027552
28051899	856	865	potential	T080	C3245505
28051899	868	875	benefit	T081	C0814225
28051899	879	887	metadata	T170	C1708992
28051899	896	907	description	T170	C0678257
28051899	925	931	health	T078	C0018684
28051899	932	937	games	T056	C0150593
28051899	968	973	model	T170	C3161035
28051899	982	993	qualitative	T080	C0205556
28051899	994	1005	description	T170	C0678257
28051899	1009	1014	games	T056	C0150593
28051899	1019	1025	health	T078	C0018684
28051899	1042	1045	aim	T078	C1947946
28051899	1053	1060	article	T170	C1706852
28051899	1111	1117	health	T078	C0018684
28051899	1118	1123	games	T056	C0150593
28051899	1158	1162	work	T057	C0043227
28051899	1185	1189	work	T057	C0043227
28051899	1199	1207	metadata	T170	C1708992
28051899	1208	1214	format	T170	C1301627
28051899	1227	1232	games	T056	C0150593
28051899	1248	1253	model	T170	C3161035
28051899	1269	1280	description	T170	C0678257
28051899	1284	1289	games	T056	C0150593
28051899	1294	1300	health	T078	C0018684
28051899	1324	1341	conceptualization	T077	C1706427
28051899	1350	1355	model	T170	C3161035
28051899	1357	1371	classification	T185	C0008902
28051899	1372	1380	schemata	T170	C0871287
28051899	1403	1409	health	T078	C0018684
28051899	1410	1414	game	T056	C0150593
28051899	1415	1427	repositories	T073	C3847505
28051899	1448	1462	classification	T185	C0008902
28051899	1463	1469	schema	T170	C0871287
28051899	1488	1494	levels	T080	C0441889
28051899	1498	1502	core	T082	C0444669
28051899	1556	1561	games	T056	C0150593
28051899	1566	1572	health	T078	C0018684
28051899	1573	1584	application	T169	C4048755
28051899	1603	1608	level	T080	C0441889
28051899	1619	1632	comprehensive	T080	C1880156
28051899	1665	1670	games	T056	C0150593
28051899	1699	1704	level	T080	C0441889
28051899	1769	1775	health	T078	C0018684
28051899	1776	1781	games	T056	C0150593
28051899	1782	1793	application	T169	C4048755
28051899	1814	1820	cardio	T023	C0018787
28051899	1821	1829	training	T065	C0220931
28051899	1833	1841	metadata	T170	C1708992
28051899	1842	1848	format	T170	C1301627
28051899	1860	1869	technical	T169	C0449851
28051899	1922	1928	health	T078	C0018684
28051899	1929	1934	games	T056	C0150593
28051899	1948	1953	needs	T080	C0027552
28051899	1965	1969	user	T098	C1705429
28051899	2019	2027	metadata	T170	C1708992
28051899	2028	2034	format	T170	C1301627
28051899	2042	2048	health	T078	C0018684
28051899	2049	2054	games	T056	C0150593
28051899	2055	2061	market	T169	C0525052

28442243|t|Abnormal neural precursor cell regulation in the early postnatal Fragile X mouse hippocampus
28442243|a|The regulation of neural precursor cells (NPCs) is indispensable for a properly functioning brain. Abnormalities in NPC proliferation, differentiation, survival, or integration have been linked to various neurological diseases including Fragile X syndrome. Yet, no studies have examined NPCs from the early postnatal Fragile X mouse hippocampus despite the importance of this developmental time point, which marks the highest expression level of FMRP, the protein missing in Fragile X, in the rodent hippocampus and is when hippocampal NPCs have migrated to the dentate gyrus (DG) to give rise to lifelong neurogenesis. In this study, we examined NPCs from the early postnatal hippocampus and DG of Fragile X mice (Fmr1 - KO). Immunocytochemistry on neurospheres showed increased Nestin expression and decreased Ki67 expression, which collectively indicated aberrant NPC biology. Intriguingly, flow cytometric analysis of the expression of the antigens CD15, CD24, CD133, GLAST, and PSA-NCAM showed a decreased proportion of neural stem cells (GLAST(+)CD15(+)CD133(+)) and an increased proportion of neuroblasts (PSA-NCAM(+)CD15(+)) in the DG of P7 Fmr1 - KO mice. This was mirrored by lower expression levels of Nestin and the mitotic marker phospho-histone H3 in vivo in the P9 hippocampus, as well as a decreased proportion of cells in the G2/M phases of the P7 DG. Thus, the absence of FMRP leads to fewer actively cycling NPCs, coinciding with a decrease in neural stem cells and an increase in neuroblasts. Together, these results show the importance of FMRP in the developing hippocampal formation and suggest abnormalities in cell cycle regulation in Fragile X.
28442243	0	8	Abnormal	T033	C0205161
28442243	9	30	neural precursor cell	T025	C1113654
28442243	31	41	regulation	T043	C1155872
28442243	49	54	early	T079	C1279919
28442243	55	64	postnatal	T079	C0443281
28442243	65	74	Fragile X	T047	C0016667
28442243	75	80	mouse	T015	C0025929
28442243	81	92	hippocampus	T023	C0019564
28442243	97	107	regulation	T043	C1155872
28442243	111	133	neural precursor cells	T025	C1113654
28442243	135	139	NPCs	T025	C1113654
28442243	144	157	indispensable	T080	C0205224
28442243	185	190	brain	T023	C0006104
28442243	192	205	Abnormalities	T033	C1704258
28442243	209	226	NPC proliferation	T043	C3155886
28442243	228	243	differentiation	T043	C1514964
28442243	245	253	survival	T043	C0007620
28442243	258	269	integration	T043	C0007613
28442243	298	319	neurological diseases	T047	C2359473
28442243	330	348	Fragile X syndrome	T047	C0016667
28442243	355	357	no	T033	C1513916
28442243	358	365	studies	T062	C0008972
28442243	380	384	NPCs	T025	C1113654
28442243	394	399	early	T079	C1279919
28442243	400	409	postnatal	T079	C0443281
28442243	410	419	Fragile X	T047	C0016667
28442243	420	425	mouse	T015	C0025929
28442243	426	437	hippocampus	T023	C0019564
28442243	450	460	importance	T080	C3898777
28442243	469	482	developmental	T080	C0458003
28442243	483	493	time point	T079	C2348792
28442243	511	518	highest	T080	C1522410
28442243	519	535	expression level	T081	C3244092
28442243	539	543	FMRP	T116,T123	C0118036
28442243	549	556	protein	T116,T123	C0033684
28442243	557	564	missing	T080	C1705492
28442243	568	577	Fragile X	T047	C0016667
28442243	586	592	rodent	T015	C0035804
28442243	593	604	hippocampus	T023	C0019564
28442243	617	628	hippocampal	T023	C0019564
28442243	629	633	NPCs	T025	C1113654
28442243	655	668	dentate gyrus	T023	C0152314
28442243	670	672	DG	T023	C0152314
28442243	690	698	lifelong	T079	C4274169
28442243	699	711	neurogenesis	T040	C0814002
28442243	740	744	NPCs	T025	C1113654
28442243	754	759	early	T079	C1279919
28442243	760	769	postnatal	T079	C0443281
28442243	770	781	hippocampus	T023	C0019564
28442243	786	788	DG	T023	C0152314
28442243	792	801	Fragile X	T047	C0016667
28442243	802	806	mice	T015	C0025929
28442243	808	812	Fmr1	T028	C1414649
28442243	815	817	KO	T050	C1522225
28442243	820	839	Immunocytochemistry	T059	C0242349
28442243	843	855	neurospheres	T025	C0007635
28442243	863	872	increased	T081	C0205217
28442243	873	879	Nestin	T116,T123	C0068575
28442243	880	890	expression	T045	C1171362
28442243	895	904	decreased	T081	C0205216
28442243	905	909	Ki67	T116,T129,T130	C0208804
28442243	910	920	expression	T045	C1171362
28442243	960	963	NPC	T025	C1113654
28442243	987	1011	flow cytometric analysis	T059	C0016263
28442243	1019	1029	expression	T045	C1171362
28442243	1037	1050	antigens CD15	T109,T129	C0080188
28442243	1052	1056	CD24	T116,T129	C0054948
28442243	1058	1063	CD133	T116,T129	C0673028
28442243	1065	1070	GLAST	T116,T123	C1529083
28442243	1076	1084	PSA-NCAM	T116,T123	C0533925
28442243	1094	1103	decreased	T081	C0205216
28442243	1104	1114	proportion	T081	C1709707
28442243	1118	1161	neural stem cells (GLAST(+)CD15(+)CD133(+))	T025	C1113654
28442243	1169	1178	increased	T081	C0205217
28442243	1179	1189	proportion	T081	C1709707
28442243	1193	1225	neuroblasts (PSA-NCAM(+)CD15(+))	T025	C0814005
28442243	1233	1235	DG	T023	C0152314
28442243	1239	1241	P7	T079	C0443281
28442243	1242	1246	Fmr1	T028	C1414649
28442243	1249	1251	KO	T050	C1522225
28442243	1252	1256	mice	T015	C0025929
28442243	1285	1302	expression levels	T081	C3244092
28442243	1306	1312	Nestin	T116,T123	C0068575
28442243	1321	1328	mitotic	T080	C1513354
28442243	1329	1335	marker	T201	C0005516
28442243	1336	1354	phospho-histone H3	T116,T123	C0019647
28442243	1355	1362	in vivo	T082	C1515655
28442243	1370	1372	P9	T079	C0443281
28442243	1373	1384	hippocampus	T023	C0019564
28442243	1399	1408	decreased	T081	C0205216
28442243	1409	1419	proportion	T081	C1709707
28442243	1423	1428	cells	T025	C0007634
28442243	1436	1447	G2/M phases	T043	C1517347
28442243	1455	1457	P7	T079	C0443281
28442243	1458	1460	DG	T023	C0152314
28442243	1472	1479	absence	T169	C0332197
28442243	1483	1487	FMRP	T116,T123	C0118036
28442243	1520	1524	NPCs	T025	C1113654
28442243	1544	1552	decrease	T081	C0547047
28442243	1556	1573	neural stem cells	T025	C1113654
28442243	1581	1589	increase	T169	C0442805
28442243	1593	1604	neuroblasts	T025	C0814005
28442243	1622	1629	results	T033	C0683954
28442243	1639	1649	importance	T080	C3898777
28442243	1653	1657	FMRP	T116,T123	C0118036
28442243	1676	1687	hippocampal	T023	C0019564
28442243	1688	1697	formation	T169	C1522492
28442243	1710	1723	abnormalities	T033	C1704258
28442243	1727	1748	cell cycle regulation	T043	C1155872
28442243	1752	1761	Fragile X	T047	C0016667

27773678|t|Heart rate variability: Pre-deployment predictor of post-deployment PTSD symptoms
27773678|a|Heart rate variability is a physiological measure associated with autonomic nervous system activity. This study hypothesized that lower pre-deployment HRV would be associated with higher post-deployment post-traumatic stress disorder (PTSD) symptoms. Three-hundred-forty-three Army National Guard soldiers enrolled in the Warriors Achieving Resilience (WAR) study were analyzed. The primary outcome was PTSD symptom severity using the PTSD Checklist - Military version (PCL) measured at baseline, 3- and 12- month post-deployment. Heart rate variability predictor variables included: high frequency power (HF) and standard deviation of the normal cardiac inter-beat interval (SDNN). Generalized linear mixed models revealed that the pre-deployment PCL * ln(HF) interaction term was significant (p<0.0001). Pre-deployment SDNN was not a significant predictor of post-deployment PCL. Covariates included age, pre-deployment PCL, race / ethnicity, marital status, tobacco use, childhood abuse, pre-deployment traumatic brain injury, and previous combat zone deployment. Pre-deployment heart rate variability predicts post-deployment PTSD symptoms in the context of higher pre-deployment PCL scores.
27773678	0	10	Heart rate	T201	C0018810
27773678	11	22	variability	T077	C2827666
27773678	24	38	Pre-deployment	T079	C1254367
27773678	39	48	predictor	T078	C2698872
27773678	52	67	post-deployment	T079	C1254367
27773678	68	72	PTSD	T048	C0038436
27773678	73	81	symptoms	T184	C1457887
27773678	82	92	Heart rate	T201	C0018810
27773678	93	104	variability	T077	C2827666
27773678	148	172	autonomic nervous system	T022	C0004388
27773678	173	181	activity	T052	C0441655
27773678	188	193	study	T062	C2603343
27773678	218	232	pre-deployment	T079	C1254367
27773678	233	236	HRV	T039	C2350828
27773678	269	284	post-deployment	T079	C1254367
27773678	285	315	post-traumatic stress disorder	T048	C0038436
27773678	317	321	PTSD	T048	C0038436
27773678	323	331	symptoms	T184	C1457887
27773678	359	387	Army National Guard soldiers	T097	C0524647
27773678	404	445	Warriors Achieving Resilience (WAR) study	T062	C2603343
27773678	473	480	outcome	T169	C1274040
27773678	485	489	PTSD	T048	C0038436
27773678	490	497	symptom	T184	C1457887
27773678	498	506	severity	T080	C0392364
27773678	517	521	PTSD	T048	C0038436
27773678	522	531	Checklist	T170	C0451524
27773678	534	542	Military	T097	C3245458
27773678	543	550	version	T170	C0333052
27773678	552	555	PCL	T170	C0451524
27773678	569	577	baseline	T081	C1442488
27773678	590	595	month	T079	C0439231
27773678	596	611	post-deployment	T079	C1254367
27773678	613	623	Heart rate	T201	C0018810
27773678	624	635	variability	T077	C2827666
27773678	636	645	predictor	T078	C2698872
27773678	646	655	variables	T080	C0439828
27773678	666	686	high frequency power	T081	C3854080
27773678	688	690	HF	T081	C3854080
27773678	696	714	standard deviation	T081	C0871420
27773678	729	747	cardiac inter-beat	T042	C0425583
27773678	748	756	interval	T079	C1272706
27773678	758	762	SDNN	T079	C1272706
27773678	777	796	linear mixed models	T170	C3161035
27773678	815	829	pre-deployment	T079	C1254367
27773678	830	833	PCL	T170	C0451524
27773678	836	854	ln(HF) interaction	T081	C0237688
27773678	888	902	Pre-deployment	T079	C1254367
27773678	903	907	SDNN	T079	C1272706
27773678	930	939	predictor	T078	C2698872
27773678	943	958	post-deployment	T079	C1254367
27773678	959	962	PCL	T170	C0451524
27773678	964	974	Covariates	T080	C0439828
27773678	984	987	age	T032	C0001779
27773678	989	1003	pre-deployment	T079	C1254367
27773678	1004	1007	PCL	T170	C0451524
27773678	1009	1013	race	T098	C0034510
27773678	1016	1025	ethnicity	T098	C0015031
27773678	1027	1041	marital status	T102	C0024819
27773678	1043	1054	tobacco use	T055	C0543414
27773678	1056	1071	childhood abuse	T048	C0008060
27773678	1073	1087	pre-deployment	T079	C1254367
27773678	1088	1110	traumatic brain injury	T037	C0876926
27773678	1125	1136	combat zone	T082	C1710706
27773678	1137	1147	deployment	T052	C2825812
27773678	1149	1163	Pre-deployment	T079	C1254367
27773678	1164	1174	heart rate	T201	C0018810
27773678	1175	1186	variability	T077	C2827666
27773678	1196	1211	post-deployment	T079	C1254367
27773678	1212	1216	PTSD	T048	C0038436
27773678	1217	1225	symptoms	T184	C1457887
27773678	1251	1265	pre-deployment	T079	C1254367
27773678	1266	1269	PCL	T170	C0451524
27773678	1270	1276	scores	T081	C0449820

27449845|t|Externally Connected Zirconia Abutments with Standard Platform are Successful Long Term in Anterior Regions
27449845|a|Performance of zirconia abutments for implant-supported single-tooth crowns in esthetic areas: a retrospective study up to 12-year follow-up. Passos SP, Linke B, Larjava H, French D. Clin Oral Implants Res 2016;27(1):47-54. Information not available Retrospective cohort study.
27449845	0	20	Externally Connected	T082	C1254362
27449845	21	29	Zirconia	T121,T197	C0078814
27449845	30	39	Abutments	T074	C0000866
27449845	78	87	Long Term	T079	C1254367
27449845	91	107	Anterior Regions	T029	C0005898
27449845	108	119	Performance	T052	C1882330
27449845	123	131	zirconia	T121,T197	C0078814
27449845	132	141	abutments	T074	C0000866
27449845	146	183	implant-supported single-tooth crowns	T061	C3642534
27449845	187	201	esthetic areas	T029	C0005898
27449845	205	224	retrospective study	T062	C0035363
27449845	231	238	12-year	T079	C0439234
27449845	239	248	follow-up	T058	C1522577
27449845	358	384	Retrospective cohort study	T062	C0035363

27788427|t|Enhancement of docosahexaenoic acid synthesis by manipulation of antioxidant capacity and prevention of oxidative damage in Schizochytrium sp
27788427|a|Oxygen-mediated cell damage is an important issue in aerobic fermentation. In order to counteract these problems, effect of ascorbic acid on cell growth and docosahexaenoic acid (DHA) production was investigated in Schizochytrium sp. Addition of 9g/L ascorbic acid resulted in 16.16% and 30.44% improvement in cell dry weight (CDW) and DHA yield, respectively. Moreover, the total antioxidant capacity (T-AOC) of cells decreased from 2.17 at 12h to 0 at 60h and did not recover, while ascorbic acid addition could extend the time of arrival zero with the reduced intracellular ROS. However, ROS levels still increased after 72h. Therefore, to further solve the problem of high ROS levels and low T-AOC of cells after 72h, a two-point addition strategy was proposed. With this strategy, DHA yield was further increased to 38.26g/L. This work innovatively investigated the feasibility of manipulating Schizochytrium sp. cultivation through ROS level and T-AOC.
27788427	0	11	Enhancement	T052	C2349975
27788427	15	35	docosahexaenoic acid	T109,T121	C0556150
27788427	36	45	synthesis	T052	C1883254
27788427	49	61	manipulation	T169	C0205245
27788427	65	85	antioxidant capacity	T081	C0392762
27788427	90	100	prevention	T080	C2700409
27788427	104	113	oxidative	T169	C0311404
27788427	114	120	damage	T169	C1883709
27788427	124	141	Schizochytrium sp	T204	C0997292
27788427	142	169	Oxygen-mediated cell damage	T049	C0599732
27788427	186	191	issue	T033	C0033213
27788427	195	215	aerobic fermentation	T043	C0007613
27788427	246	254	problems	T033	C0033213
27788427	256	265	effect of	T080	C1704420
27788427	266	279	ascorbic acid	T109,T121,T127	C0003968
27788427	283	294	cell growth	T043	C0007595
27788427	299	319	docosahexaenoic acid	T109,T121	C0556150
27788427	321	324	DHA	T109,T121	C0556150
27788427	326	336	production	T052	C1883254
27788427	341	353	investigated	T169	C1292732
27788427	357	374	Schizochytrium sp	T204	C0997292
27788427	376	384	Addition	T169	C1883712
27788427	393	406	ascorbic acid	T109,T121,T127	C0003968
27788427	437	448	improvement	T077	C2986411
27788427	452	467	cell dry weight	T081	C0392762
27788427	469	472	CDW	T081	C0392762
27788427	478	481	DHA	T109,T121	C0556150
27788427	482	487	yield	T081	C0392762
27788427	517	543	total antioxidant capacity	T081	C0392762
27788427	545	550	T-AOC	T081	C0392762
27788427	555	560	cells	T025	C0007634
27788427	561	570	decreased	T081	C0205216
27788427	608	619	not recover	T033	C0243095
27788427	627	640	ascorbic acid	T109,T121,T127	C0003968
27788427	641	649	addition	T169	C1883712
27788427	667	671	time	T079	C0040223
27788427	675	682	arrival	T169	C1555577
27788427	683	687	zero	T081	C0919414
27788427	697	704	reduced	T080	C0392756
27788427	705	718	intracellular	T082	C0178719
27788427	719	722	ROS	T123	C1537052
27788427	733	736	ROS	T123	C1537052
27788427	737	743	levels	T080	C0441889
27788427	750	759	increased	T081	C0205217
27788427	803	810	problem	T033	C0033213
27788427	814	818	high	T080	C0205250
27788427	819	822	ROS	T123	C1537052
27788427	823	829	levels	T080	C0441889
27788427	834	837	low	T080	C0205251
27788427	838	843	T-AOC	T081	C0392762
27788427	847	852	cells	T025	C0007634
27788427	866	893	two-point addition strategy	T062	C0035171
27788427	918	926	strategy	T062	C0035171
27788427	928	931	DHA	T109,T121	C0556150
27788427	932	937	yield	T081	C0392762
27788427	950	959	increased	T081	C0205217
27788427	996	1008	investigated	T169	C1292732
27788427	1028	1040	manipulating	T169	C0205245
27788427	1041	1058	Schizochytrium sp	T204	C0997292
27788427	1060	1071	cultivation	T062	C0242481
27788427	1080	1083	ROS	T123	C1537052
27788427	1084	1089	level	T080	C0441889
27788427	1094	1099	T-AOC	T081	C0392762

27746055|t|The course of cognitive functioning after first-episode of psychosis: A six month follow-up study
27746055|a|Our aim with the present study was to evaluate rank-order and mean-level cognitive functioning stability among first-episode psychosis (FEP) patients, measured using the Cambridge Neuropsychological Test Automated Battery (CANTAB), over a six month period. We also aimed to examine longitudinal measurement invariance and identify factors-such as age, gender, educational level, treatment and psychopathological change scores -potentially linked to cognitive change among patients. In addition, correlations between objectively measured and subjectively evaluated cognitive functioning were estimated. Neuropsychological assessments were administered to 85 patients after the initial stabilisation of their psychosis; 82 of the patients were retested. Subjectively perceived cognitive functioning was measured using a subscale derived from the Estonian version of the Subjective Well-Being Under Neuroleptic Scale (SWN-K-E). On average, executive functioning and processing speed improved significantly, while memory test scores decreased significantly, over time. Very high rank-order stability (r=0.80 to 0.94, p<0.001) was observed with all measured ability scores. Confirmatory factor analysis revealed the loadings of a single (broad ability) factor model were equal across both measurement occasions, but the lack of intercept invariance suggested that mean -level comparisons are more appropriately carried out at a subtest level. On average psychopathology scores and antipsychotics doses declined over time, with the latter also significantly correlating with better executive functioning. Gender was a significant moderator of some domains of cognitive performance, and decline tended to be somewhat more pronounced for women. The results also indicated the lack of any relationship between objective and subjective measurements of cognitive functioning.
27746055	14	35	cognitive functioning	T041	C0392335
27746055	42	55	first-episode	T079	C0439615
27746055	59	68	psychosis	T048	C0033975
27746055	82	97	follow-up study	T058	C3274571
27746055	145	155	rank-order	T062,T170	C0871206
27746055	171	192	cognitive functioning	T041	C0392335
27746055	193	202	stability	UnknownType	C0679855
27746055	209	222	first-episode	T079	C0439615
27746055	223	232	psychosis	T048	C0033975
27746055	234	237	FEP	T048	C0033975
27746055	239	247	patients	T101	C0025360
27746055	268	319	Cambridge Neuropsychological Test Automated Battery	T074	C0025080
27746055	321	327	CANTAB	T074	C0025080
27746055	380	415	longitudinal measurement invariance	T081	C0392762
27746055	445	448	age	T032	C0001779
27746055	450	456	gender	T032	C0079399
27746055	458	475	educational level	T033	C0013658
27746055	477	486	treatment	T061	C0087111
27746055	491	509	psychopathological	T091	C0033927
27746055	510	516	change	T169	C0392747
27746055	517	523	scores	T081	C0449820
27746055	547	563	cognitive change	T048	C1392786
27746055	570	578	patients	T101	C0025360
27746055	614	634	objectively measured	T058	C0509852
27746055	639	661	subjectively evaluated	T080	C0439655
27746055	662	683	cognitive functioning	T041	C0392335
27746055	700	718	Neuropsychological	T091	C0027903
27746055	719	730	assessments	T058	C1261322
27746055	755	763	patients	T101	C0025360
27746055	782	795	stabilisation	T061	C1293130
27746055	805	814	psychosis	T048	C0033975
27746055	826	834	patients	T101	C0025360
27746055	873	894	cognitive functioning	T041	C0392335
27746055	942	1011	Estonian version of the Subjective Well-Being Under Neuroleptic Scale	T170	C0282574
27746055	1013	1020	SWN-K-E	T170	C0282574
27746055	1035	1056	executive functioning	T041	C0935584
27746055	1061	1077	processing speed	T041	C0870302
27746055	1108	1126	memory test scores	T081	C0392762
27746055	1168	1193	high rank-order stability	T062,T170	C0871206
27746055	1251	1265	ability scores	T081	C0392762
27746055	1267	1295	Confirmatory factor analysis	T080	C0870334
27746055	1382	1393	measurement	T169	C0242485
27746055	1421	1441	intercept invariance	T081	C0392762
27746055	1457	1461	mean	T081	C0444504
27746055	1469	1480	comparisons	T052	C1707455
27746055	1547	1562	psychopathology	T091	C0033927
27746055	1563	1569	scores	T081	C0449820
27746055	1574	1588	antipsychotics	T121	C0040615
27746055	1589	1594	doses	T081	C0178602
27746055	1650	1661	correlating	T080	C1707520
27746055	1674	1695	executive functioning	T041	C0935584
27746055	1697	1703	Gender	T032	C0079399
27746055	1751	1772	cognitive performance	T041	C0392335
27746055	1778	1792	decline tended	T046	C0234985
27746055	1828	1833	women	T098	C0043210
27746055	1899	1908	objective	T058	C0509852
27746055	1913	1936	subjective measurements	T080	C0439655
27746055	1940	1961	cognitive functioning	T041	C0392335

28202494|t|Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions
28202494|a|Strict regulation of stem cell metabolism is essential for tissue functions and tumor suppression. In this study, we investigated the role of fumarate hydratase (Fh1), a key component of the mitochondrial tricarboxylic acid (TCA) cycle and cytosolic fumarate metabolism, in normal and leukemic hematopoiesis. Hematopoiesis - specific Fh1 deletion (resulting in endogenous fumarate accumulation and a genetic TCA cycle block reflected by decreased maximal mitochondrial respiration) caused lethal fetal liver hematopoietic defects and hematopoietic stem cell (HSC) failure. Reexpression of extramitochondrial Fh1 (which normalized fumarate levels but not maximal mitochondrial respiration) rescued these phenotypes, indicating the causal role of cellular fumarate accumulation. However, HSCs lacking mitochondrial Fh1 (which had normal fumarate levels but defective maximal mitochondrial respiration) failed to self-renew and displayed lymphoid differentiation defects. In contrast, leukemia -initiating cells lacking mitochondrial Fh1 efficiently propagated Meis1 / Hoxa9 -driven leukemia. Thus, we identify novel roles for fumarate metabolism in HSC maintenance and hematopoietic differentiation and reveal a differential requirement for mitochondrial Fh1 in normal hematopoiesis and leukemia propagation.
28202494	0	18	Fumarate hydratase	T116,T126	C0016799
28202494	33	52	metabolic regulator	T169	C0205245
28202494	56	79	hematopoietic stem cell	T025	C0018956
28202494	80	89	functions	T043	C0007613
28202494	97	131	regulation of stem cell metabolism	T040	C1159402
28202494	149	165	tissue functions	T042	C1254358
28202494	170	187	tumor suppression	T044	C1519692
28202494	224	228	role	T077	C1705810
28202494	232	250	fumarate hydratase	T116,T126	C0016799
28202494	252	255	Fh1	T116,T126	C0016799
28202494	264	273	component	T116,T123	C1179435
28202494	281	294	mitochondrial	T026	C0026237
28202494	295	325	tricarboxylic acid (TCA) cycle	T044	C1148560
28202494	330	339	cytosolic	T026	C1383501
28202494	340	359	fumarate metabolism	T044	C1157809
28202494	364	370	normal	T042	C0018951
28202494	375	397	leukemic hematopoiesis	T042	C0018951
28202494	399	412	Hematopoiesis	T042	C0018951
28202494	415	423	specific	T080	C0205369
28202494	424	427	Fh1	T028	C1366530
28202494	428	436	deletion	T045	C0017260
28202494	451	461	endogenous	T169	C0205227
28202494	462	470	fumarate	T109,T121	C0220833
28202494	490	497	genetic	T169	C0314603
28202494	498	507	TCA cycle	T044	C1148560
28202494	508	513	block	T169	C0332206
28202494	527	536	decreased	T081	C0205216
28202494	537	544	maximal	T080	C0205289
28202494	545	558	mitochondrial	T026	C0026237
28202494	559	570	respiration	T043	C0282636
28202494	579	597	lethal fetal liver	T018	C1517162
28202494	598	619	hematopoietic defects	T019	C0000768
28202494	624	647	hematopoietic stem cell	T025	C0018956
28202494	649	652	HSC	T025	C0018956
28202494	654	661	failure	T169	C0231174
28202494	663	675	Reexpression	T045	C0017262
28202494	679	697	extramitochondrial	T026	C0026237
28202494	698	701	Fh1	T028	C1366530
28202494	720	728	fumarate	T109,T121	C0220833
28202494	729	735	levels	T080	C0441889
28202494	744	751	maximal	T080	C0205289
28202494	752	765	mitochondrial	T026	C0026237
28202494	766	777	respiration	T043	C0282636
28202494	793	803	phenotypes	T032	C0031437
28202494	827	831	role	T077	C1705810
28202494	835	865	cellular fumarate accumulation	T043	C0007613
28202494	876	880	HSCs	T025	C0018956
28202494	881	888	lacking	T080	C0332268
28202494	889	902	mitochondrial	T026	C0026237
28202494	903	906	Fh1	T028	C1366530
28202494	918	924	normal	T080	C0205307
28202494	925	933	fumarate	T109,T121	C0220833
28202494	934	940	levels	T080	C0441889
28202494	945	954	defective	T169	C0332452
28202494	955	962	maximal	T080	C0205289
28202494	963	976	mitochondrial	T026	C0026237
28202494	977	988	respiration	T043	C0282636
28202494	990	996	failed	T169	C0231175
28202494	1000	1010	self-renew	T169	C0205245
28202494	1025	1033	lymphoid	T025	C0086574
28202494	1034	1049	differentiation	T043	C0007589
28202494	1050	1057	defects	T019	C0000768
28202494	1072	1080	leukemia	T191	C0023418
28202494	1093	1098	cells	T025	C0007634
28202494	1099	1106	lacking	T080	C0332268
28202494	1107	1120	mitochondrial	T026	C0026237
28202494	1121	1124	Fh1	T028	C1366530
28202494	1148	1153	Meis1	T028	C1334501
28202494	1156	1161	Hoxa9	T028	C1333922
28202494	1170	1178	leukemia	T191	C0023418
28202494	1204	1209	roles	T077	C1705810
28202494	1214	1222	fumarate	T109,T121	C0220833
28202494	1223	1233	metabolism	T043	C1524026
28202494	1237	1240	HSC	T025	C0018956
28202494	1241	1252	maintenance	T052	C0024501
28202494	1257	1286	hematopoietic differentiation	T043	C2262995
28202494	1313	1324	requirement	T169	C1514873
28202494	1329	1342	mitochondrial	T026	C0026237
28202494	1343	1346	Fh1	T028	C1366530
28202494	1350	1356	normal	T080	C0205307
28202494	1357	1370	hematopoiesis	T042	C0018951
28202494	1375	1383	leukemia	T191	C0023418
28202494	1384	1395	propagation	T169	C0205245

27596934|t|Comparison of methods for isolating primary hepatocytes from mini pigs
27596934|a|Successful porcine hepatocyte isolation is crucial for the development of bioartificial liver devices and hepatocyte transplantation. Serva collagenase NB grades are formulated collagenases that are suitable for various tissue isolation applications. N-acetylcysteine (NAC) can improve the viability of human hepatocytes. The aim of this study was to compare the effectiveness of two collagenases and effect of NAC on hepatocyte isolation from porcine liver tissue. Porcine hepatocytes were isolated using the perfusion method from Bama mini pigs assigned to the Serva NB 4 group (n=6), the Serva NB 8 group (n=6), or the NB 8 + NAC group (n=6). Viability and yield were defined as fresh hepatocytes and their spheroids formation after 24-hour rocker culture in serum-free medium. Metabolic function was assessed by gene expression, albumin, and urea synthesis. All procedures resulted in successful hepatocyte isolation. Cells from the NB 8 + NAC group had (97.8±1.9)% viability, which was higher than the NB 8 group with (94.4±2.4)% and the NB 4 group with (94.5±3.2)% (P<.001). The final cell yield reached (11.8±1.0)×10(9) cells in the NB 8 + NAC group, compared to (9.5±2.1)×10(9) cells in the NB 8 group (P<.01) and (9.1±1.1) ×10(9) cells in the NB 4 group (P<.001). The secretion of albumin was superior in the NB 8 + NAC group at a concentration of (425.8±35.3) ng/mL compared to the NB 8 group (339.1±32.6) ng/mL (P <.001) and NB 4 group (293.6±43.3) ng/mL (P <.01). The injury of hepatocytes also decreased in the NB 8 + NAC group (P<.01). The data are presented as means ± SD. Formulated collagenase Serva NB 8 and NAC could improve the porcine hepatocyte isolation, resulting in higher yields of viable cells.
27596934	26	35	isolating	T059	C0220862
27596934	36	43	primary	T080	C0205225
27596934	44	55	hepatocytes	T025	C0227525
27596934	61	70	mini pigs	T015	C0039011
27596934	82	89	porcine	T015	C0039005
27596934	90	100	hepatocyte	T025	C0227525
27596934	101	110	isolation	T059	C0220862
27596934	130	141	development	T169	C1527148
27596934	145	172	bioartificial liver devices	T074	C0336562
27596934	177	203	hepatocyte transplantation	T061	C1998344
27596934	205	232	Serva collagenase NB grades	T116,T121,T126	C0162745
27596934	248	260	collagenases	T116,T121,T126	C0162745
27596934	291	297	tissue	T024	C0040300
27596934	298	307	isolation	T059	C0220862
27596934	322	338	N-acetylcysteine	T116,T121	C0001047
27596934	340	343	NAC	T116,T121	C0001047
27596934	361	370	viability	T080	C0443348
27596934	374	379	human	T016	C0086418
27596934	380	391	hepatocytes	T025	C0227525
27596934	434	447	effectiveness	T080	C1280519
27596934	455	467	collagenases	T116,T121,T126	C0162745
27596934	472	481	effect of	T080	C1704420
27596934	482	485	NAC	T116,T121	C0001047
27596934	489	499	hepatocyte	T025	C0227525
27596934	500	509	isolation	T059	C0220862
27596934	515	522	porcine	T015	C0039005
27596934	523	535	liver tissue	T023	C0736268
27596934	537	544	Porcine	T015	C0039005
27596934	545	556	hepatocytes	T025	C0227525
27596934	562	570	isolated	T059	C0220862
27596934	581	597	perfusion method	T061	C0031001
27596934	608	617	mini pigs	T015	C0039011
27596934	634	644	Serva NB 4	T116,T121,T126	C0162745
27596934	645	650	group	T078	C0441833
27596934	662	672	Serva NB 8	T116,T121,T126	C0162745
27596934	673	678	group	T078	C0441833
27596934	693	697	NB 8	T116,T121,T126	C0162745
27596934	700	703	NAC	T116,T121	C0001047
27596934	704	709	group	T078	C0441833
27596934	717	726	Viability	T080	C0443348
27596934	759	770	hepatocytes	T025	C0227525
27596934	781	800	spheroids formation	T033	C1844596
27596934	815	829	rocker culture	T059	C0430400
27596934	833	850	serum-free medium	T130	C0085414
27596934	852	870	Metabolic function	T040	C0025519
27596934	887	902	gene expression	T045	C0017262
27596934	904	911	albumin	T116,T123	C0001924
27596934	917	921	urea	T109,T121,T123	C0041942
27596934	922	931	synthesis	T038	C0220781
27596934	971	981	hepatocyte	T025	C0227525
27596934	982	991	isolation	T059	C0220862
27596934	993	998	Cells	T025	C0007634
27596934	1008	1012	NB 8	T116,T121,T126	C0162745
27596934	1015	1018	NAC	T116,T121	C0001047
27596934	1019	1024	group	T078	C0441833
27596934	1041	1050	viability	T080	C0443348
27596934	1078	1082	NB 8	T116,T121,T126	C0162745
27596934	1083	1088	group	T078	C0441833
27596934	1114	1118	NB 4	T116,T121,T126	C0162745
27596934	1119	1124	group	T078	C0441833
27596934	1162	1166	cell	T025	C0007634
27596934	1198	1203	cells	T025	C0007634
27596934	1211	1215	NB 8	T116,T121,T126	C0162745
27596934	1218	1221	NAC	T116,T121	C0001047
27596934	1222	1227	group	T078	C0441833
27596934	1257	1262	cells	T025	C0007634
27596934	1270	1274	NB 8	T116,T121,T126	C0162745
27596934	1275	1280	group	T078	C0441833
27596934	1310	1315	cells	T025	C0007634
27596934	1323	1327	NB 4	T116,T121,T126	C0162745
27596934	1328	1333	group	T078	C0441833
27596934	1348	1357	secretion	T038	C0036536
27596934	1361	1368	albumin	T116,T123	C0001924
27596934	1389	1393	NB 8	T116,T121,T126	C0162745
27596934	1396	1399	NAC	T116,T121	C0001047
27596934	1400	1405	group	T078	C0441833
27596934	1463	1467	NB 8	T116,T121,T126	C0162745
27596934	1468	1473	group	T078	C0441833
27596934	1507	1511	NB 4	T116,T121,T126	C0162745
27596934	1512	1517	group	T078	C0441833
27596934	1551	1557	injury	T037	C0178314
27596934	1561	1572	hepatocytes	T025	C0227525
27596934	1595	1599	NB 8	T116,T121,T126	C0162745
27596934	1602	1605	NAC	T116,T121	C0001047
27596934	1606	1611	group	T078	C0441833
27596934	1647	1657	means ± SD	T081	C0444504
27596934	1670	1692	collagenase Serva NB 8	T116,T121,T126	C0162745
27596934	1697	1700	NAC	T116,T121	C0001047
27596934	1719	1726	porcine	T015	C0039005
27596934	1727	1737	hepatocyte	T025	C0227525
27596934	1738	1747	isolation	T059	C0220862
27596934	1779	1791	viable cells	T025	C1441322

27832198|t|Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology
27832198|a|Southeast Asia is an epicenter of multidrug-resistant Plasmodium falciparum strains. Selective pressures on the subcontinent have recurrently produced several allelic variants of parasite drug resistance genes, including the P. falciparum chloroquine resistance transporter (pfcrt). Despite significant reductions in the deployment of the 4-aminoquinoline drug chloroquine (CQ), which selected for the mutant pfcrt alleles that halted CQ efficacy decades ago, the parasite pfcrt locus is continuously evolving. This is highlighted by the presence of a highly mutated allele, Cam734 pfcrt, which has acquired the singular ability to confer parasite CQ resistance without an associated fitness cost. Here, we used pfcrt -specific zinc-finger nucleases to genetically dissect this allele in the pathogenic setting of asexual blood-stage infection. Comparative analysis of drug resistance and growth profiles of recombinant parasites that express Cam734 or variants thereof, Dd2 (the most common Southeast Asian variant), or wild-type pfcrt, revealed previously unknown roles for PfCRT mutations in modulating parasite susceptibility to multiple antimalarial agents. These results were generated in the GC03 strain, used in multiple earlier pfcrt studies, and might differ in natural isolates harboring this allele. Results presented herein show that Cam734 -mediated CQ resistance is dependent on the rare A144F mutation that has not been observed beyond Southeast Asia, and reveal distinct impacts of this and other Cam734 -specific mutations on CQ resistance and parasite growth rates. Biochemical assays revealed a broad impact of mutant PfCRT isoforms on parasite metabolism, including nucleoside triphosphate levels, hemoglobin catabolism and disposition of heme, as well as digestive vacuole volume and pH. Results from our study provide new insights into the complex molecular basis and physiological impact of PfCRT -mediated antimalarial drug resistance, and inform ongoing efforts to characterize novel pfcrt alleles that can undermine the efficacy of first-line antimalarial drug regimens.
27832198	0	9	Evolution	T045	C0015219
27832198	13	20	Fitness	T045	C3824713
27832198	21	33	Cost-Neutral	T033	C0243095
27832198	34	40	Mutant	T049	C0596988
27832198	41	46	PfCRT	T116,T123	C0962247
27832198	58	71	P. falciparum	T204	C0032150
27832198	72	88	4-Aminoquinoline	T109,T121	C0048060
27832198	89	104	Drug Resistance	T038	C0013203
27832198	123	130	Altered	T169	C0392747
27832198	131	139	Parasite	T204	C0030498
27832198	140	150	Metabolism	T040	C0025519
27832198	155	172	Digestive Vacuole	T026	C1167024
27832198	173	183	Physiology	T091	C0031842
27832198	184	198	Southeast Asia	T083	C0003983
27832198	218	237	multidrug-resistant	T032	C0242640
27832198	238	267	Plasmodium falciparum strains	T204	C0032150
27832198	343	350	allelic	T028	C0002085
27832198	351	359	variants	T028	C0678941
27832198	363	371	parasite	T204	C0030498
27832198	372	387	drug resistance	T038	C0013203
27832198	388	393	genes	T028	C0017337
27832198	409	457	P. falciparum chloroquine resistance transporter	T028	C0017337
27832198	459	464	pfcrt	T028	C0017337
27832198	487	497	reductions	T061	C0441610
27832198	505	515	deployment	T052	C2825812
27832198	523	539	4-aminoquinoline	T109,T121	C0048060
27832198	540	544	drug	T121	C1254351
27832198	545	556	chloroquine	T109,T121	C0008269
27832198	558	560	CQ	T109,T121	C0008269
27832198	586	592	mutant	T028	C0678941
27832198	593	598	pfcrt	T028	C0017337
27832198	599	606	alleles	T028	C0002085
27832198	619	621	CQ	T109,T121	C0008269
27832198	622	630	efficacy	T080	C1280519
27832198	648	656	parasite	T204	C0030498
27832198	657	662	pfcrt	T028	C0017337
27832198	663	668	locus	T082	C1708726
27832198	736	742	highly	T080	C0205250
27832198	743	750	mutated	T045	C0026882
27832198	751	757	allele	T028	C0002085
27832198	759	771	Cam734 pfcrt	T028	C0017337
27832198	823	831	parasite	T204	C0030498
27832198	832	834	CQ	T109,T121	C0008269
27832198	835	845	resistance	T038	C0013203
27832198	868	875	fitness	T045	C3824713
27832198	876	880	cost	T080	C4049986
27832198	896	901	pfcrt	T028	C0017337
27832198	912	933	zinc-finger nucleases	T116,T126	C0597094
27832198	937	956	genetically dissect	T169	C0205239
27832198	962	968	allele	T028	C0002085
27832198	976	986	pathogenic	T033	C3816499
27832198	998	1027	asexual blood-stage infection	T046	C3714514
27832198	1029	1049	Comparative analysis	T062	C0683941
27832198	1053	1068	drug resistance	T038	C0013203
27832198	1073	1079	growth	T040	C0018270
27832198	1092	1113	recombinant parasites	T204	C0030498
27832198	1119	1126	express	T045	C0017262
27832198	1127	1133	Cam734	T028	C0017337
27832198	1137	1145	variants	T028	C0678941
27832198	1155	1158	Dd2	T028	C0017337
27832198	1176	1191	Southeast Asian	T083	C0003983
27832198	1192	1199	variant	T028	C0678941
27832198	1205	1214	wild-type	T028	C1883559
27832198	1215	1220	pfcrt	T028	C0017337
27832198	1260	1265	PfCRT	T116,T123	C0962247
27832198	1266	1275	mutations	T045	C0026882
27832198	1290	1298	parasite	T204	C0030498
27832198	1326	1345	antimalarial agents	T121	C0003374
27832198	1383	1387	GC03	T028	C0017337
27832198	1388	1394	strain	T001	C1518614
27832198	1421	1426	pfcrt	T028	C0017337
27832198	1427	1434	studies	T062	C2603343
27832198	1488	1494	allele	T028	C0002085
27832198	1531	1537	Cam734	T028	C0017337
27832198	1548	1550	CQ	T109,T121	C0008269
27832198	1551	1561	resistance	T038	C0013203
27832198	1587	1592	A144F	T045	C0026882
27832198	1593	1601	mutation	T045	C0026882
27832198	1636	1650	Southeast Asia	T083	C0003983
27832198	1672	1679	impacts	T080	C4049986
27832198	1698	1704	Cam734	T028	C0017337
27832198	1715	1724	mutations	T045	C0026882
27832198	1728	1730	CQ	T109,T121	C0008269
27832198	1731	1741	resistance	T038	C0013203
27832198	1746	1754	parasite	T204	C0030498
27832198	1755	1767	growth rates	T079	C0449249
27832198	1769	1787	Biochemical assays	T059	C0005507
27832198	1805	1811	impact	T080	C4049986
27832198	1815	1821	mutant	T049	C0596988
27832198	1822	1827	PfCRT	T116,T123	C0962247
27832198	1828	1836	isoforms	T116	C0597298
27832198	1840	1848	parasite	T204	C0030498
27832198	1849	1859	metabolism	T040	C0025519
27832198	1871	1894	nucleoside triphosphate	T114	C0597106
27832198	1895	1901	levels	T080	C0441889
27832198	1903	1924	hemoglobin catabolism	T044	C1157963
27832198	1944	1948	heme	T109,T123	C0018966
27832198	1961	1978	digestive vacuole	T026	C1167024
27832198	1979	1985	volume	T081	C0449468
27832198	1990	1992	pH	T081	C0020283
27832198	2047	2070	complex molecular basis	T170	C4246449
27832198	2075	2088	physiological	T169	C0205463
27832198	2089	2095	impact	T080	C4049986
27832198	2099	2104	PfCRT	T116,T123	C0962247
27832198	2115	2127	antimalarial	T121	C0003374
27832198	2128	2143	drug resistance	T038	C0013203
27832198	2194	2199	pfcrt	T028	C0017337
27832198	2200	2207	alleles	T028	C0002085
27832198	2231	2239	efficacy	T080	C1280519
27832198	2254	2271	antimalarial drug	T121	C0003374
27832198	2272	2280	regimens	T061	C0040808

27618157|t|Immobilization of Lipase from Pseudomonas fluorescens on Porous Polyurea and Its Application in Kinetic Resolution of Racemic 1-Phenylethanol
27618157|a|A porous polyurea (PPU) was prepared through a simple protocol by reacting toluene diisocyanate with water in binary solvent of water - acetone. Its amine group was determined through spectrophotometric absorbance based on its iminization with p-nitrobenzaldehyde amines. PPU was then used as a novel polymer support for enzyme immobilization, through activation by glutaraldehyde followed by immobilization of an enzyme, lipase from Pseudomonas fluorescens (PFL), via covalent bonding with the amine groups of lipase molecules. Influences of glutaraldehyde and enzyme concentration and pH in the process were studied. The results revealed that the activity of the immobilized PFL reached a maximum at GA concentration of 0.17 mol/L and at pH 8. Immobilization rate of 60% or higher for PFL was obtained under optimized condition with an enzyme activity of 283 U/mg. The porous structure of PPU, prior to and after GA activation and PFL immobilization, was characterized. The activity of the immobilized PFL at different temperature and pH and its stability at 40 °C as well as its reusability were tested. The immobilized enzyme was finally used as enantioselective catalyst in kinetic resolution of racemic 1- ph enylethanol (1-PEOH), and its performance compared with the free PFL. The results demonstrate that the enzyme activity and stability were greatly improved for the immobilized PFL, and highly pure enantiomers from racemic 1-PEOH were effectively achieved using the immobilized PFL. Noticeable deactivation of PFL in the resolution was observed by acetaldehyde in situ formed. In addition, the immobilized PFL was readily recovered from the reaction system for reuse. A total of 73% of the initial activity was retained after 5 repeated reuse cycles. This work provides a novel route to preparation of a polyurea porous material and its enzyme immobilization, leading to a novel type of immobilized enzyme for efficient kinetic resolution of racemic molecules.
27618157	0	14	Immobilization	T033	C0231441
27618157	18	24	Lipase	T116,T121,T126	C0023764
27618157	30	53	Pseudomonas fluorescens	T007	C0033811
27618157	57	72	Porous Polyurea	T109	C0071695
27618157	81	92	Application	T169	C4048755
27618157	96	114	Kinetic Resolution	T059	C1441514
27618157	118	125	Racemic	T167	C3641126
27618157	126	141	1-Phenylethanol	T109	C0066419
27618157	144	159	porous polyurea	T109	C0071695
27618157	161	164	PPU	T109	C0071695
27618157	170	178	prepared	T033	C4082130
27618157	196	204	protocol	T170	C0442711
27618157	217	237	toluene diisocyanate	T109,T131	C0205976
27618157	243	248	water	T121,T197	C0043047
27618157	252	266	binary solvent	T130	C0037638
27618157	270	275	water	T121,T197	C0043047
27618157	278	285	acetone	T109,T121	C0001002
27618157	291	302	amine group	T109	C1879694
27618157	326	344	spectrophotometric	T059	C0037805
27618157	345	355	absorbance	T081	C1547008
27618157	369	380	iminization	T070	C1254365
27618157	386	412	p-nitrobenzaldehyde amines	T109	C0029224
27618157	414	417	PPU	T109	C0071695
27618157	437	442	novel	T080	C0205314
27618157	443	458	polymer support	T120	C1254355
27618157	463	469	enzyme	T116,T126	C0014442
27618157	470	484	immobilization	T033	C0231441
27618157	494	504	activation	T052	C1879547
27618157	508	522	glutaraldehyde	T109,T122,T130	C0017814
27618157	535	549	immobilization	T033	C0231441
27618157	556	562	enzyme	T116,T126	C0014442
27618157	564	570	lipase	T116,T121,T126	C0023764
27618157	576	599	Pseudomonas fluorescens	T007	C0033811
27618157	601	604	PFL	T116,T121,T126	C0023764
27618157	611	627	covalent bonding	T070	C1254365
27618157	637	649	amine groups	T109	C1879694
27618157	653	669	lipase molecules	T116,T121,T126	C0023764
27618157	685	699	glutaraldehyde	T109,T122,T130	C0017814
27618157	704	710	enzyme	T116,T126	C0014442
27618157	711	724	concentration	T081	C1446561
27618157	729	731	pH	T081	C0020283
27618157	729	731	pH	T081	C0020283
27618157	739	746	process	T067	C1522240
27618157	765	772	results	T034	C0456984
27618157	791	799	activity	T044	C0243102
27618157	807	818	immobilized	T033	C0231441
27618157	819	822	PFL	T116,T121,T126	C0023764
27618157	844	846	GA	T109,T122,T130	C0017814
27618157	847	860	concentration	T081	C1446561
27618157	882	884	pH	T081	C0020283
27618157	888	902	Immobilization	T033	C0231441
27618157	929	932	PFL	T116,T121,T126	C0023764
27618157	952	961	optimized	T080	C2698651
27618157	980	995	enzyme activity	T044	C0243102
27618157	1013	1029	porous structure	T080	C0080037
27618157	1033	1036	PPU	T109	C0071695
27618157	1057	1059	GA	T109,T122,T130	C0017814
27618157	1060	1070	activation	T052	C1879547
27618157	1075	1078	PFL	T116,T121,T126	C0023764
27618157	1079	1093	immobilization	T033	C0231441
27618157	1118	1126	activity	T044	C0243102
27618157	1134	1145	immobilized	T033	C0231441
27618157	1146	1149	PFL	T116,T121,T126	C0023764
27618157	1163	1174	temperature	T081	C0039476
27618157	1179	1181	pH	T081	C0020283
27618157	1190	1199	stability	T044	C0014439
27618157	1224	1235	reusability	T033	C3841253
27618157	1253	1264	immobilized	T033	C0231441
27618157	1265	1271	enzyme	T116,T126	C0014442
27618157	1292	1317	enantioselective catalyst	T067	C0175921
27618157	1321	1339	kinetic resolution	T059	C1441514
27618157	1343	1350	racemic	T167	C3641126
27618157	1351	1368	1- ph enylethanol	T109	C0066419
27618157	1354	1356	ph	T081	C0020283
27618157	1370	1376	1-PEOH	T109	C0066419
27618157	1422	1425	PFL	T116,T121,T126	C0023764
27618157	1460	1475	enzyme activity	T044	C0243102
27618157	1480	1489	stability	T044	C0014439
27618157	1520	1531	immobilized	T033	C0231441
27618157	1532	1535	PFL	T116,T121,T126	C0023764
27618157	1553	1564	enantiomers	T104	C0599473
27618157	1570	1577	racemic	T167	C3641126
27618157	1578	1584	1-PEOH	T109	C0066419
27618157	1621	1632	immobilized	T033	C0231441
27618157	1633	1636	PFL	T116,T121,T126	C0023764
27618157	1665	1668	PFL	T116,T121,T126	C0023764
27618157	1676	1686	resolution	T059	C1441514
27618157	1703	1715	acetaldehyde	T109	C0000966
27618157	1716	1723	in situ	T082	C0444498
27618157	1749	1760	immobilized	T033	C0231441
27618157	1761	1764	PFL	T116,T121,T126	C0023764
27618157	1777	1786	recovered	T033	C1709863
27618157	1796	1804	reaction	T169	C0443286
27618157	1816	1821	reuse	T033	C3841253
27618157	1853	1861	activity	T044	C0243102
27618157	1866	1874	retained	T169	C0333118
27618157	1883	1891	repeated	T169	C0205341
27618157	1892	1897	reuse	T033	C3841253
27618157	1898	1904	cycles	T079	C0001289
27618157	1927	1932	novel	T080	C0205314
27618157	1942	1953	preparation	T052	C1521827
27618157	1959	1983	polyurea porous material	T109	C0071695
27618157	1992	1998	enzyme	T116,T126	C0014442
27618157	1999	2013	immobilization	T033	C0231441
27618157	2028	2033	novel	T080	C0205314
27618157	2042	2053	immobilized	T033	C0231441
27618157	2054	2060	enzyme	T116,T126	C0014442
27618157	2075	2093	kinetic resolution	T059	C1441514
27618157	2097	2114	racemic molecules	T167	C3641126

27617011|t|An Improved Culture Method for Selective Isolation of Campylobacter jejuni from Wastewater
27617011|a|Campylobacter jejuni is one of the leading foodborne pathogens worldwide. C. jejuni is isolated from a wide range of foods, domestic animals, wildlife, and environmental sources. The currently available culture-based isolation methods are not highly effective for wastewater samples due to the low number of C. jejuni in the midst of competing bacteria. To detect and isolate C. jejuni from wastewater samples, in this study, we evaluated a few different enrichment conditions using five different antibiotics (i.e., cefoperazone, vancomycin, trimethoprim, polymyxin B, and rifampicin), to which C. jejuni is intrinsically resistant. The selectivity of each enrichment condition was measured with C t value using quantitative real-time PCR, and multiplex PCR to determine Campylobacter species. In addition, the efficacy of Campylobacter isolation on different culture media after selective enrichment was examined by growing on Bolton and Preston agar plates. The addition of polymyxin B, rifampicin, or both to the Bolton selective supplements enhanced the selective isolation of C. jejuni. The results of 16S rDNA sequencing also revealed that Enterococcus spp. and Pseudomonas aeruginosa are major competing bacteria in the enrichment conditions. Although it is known to be difficult to isolate Campylobacter from samples with heavy contamination, this study well exhibited that the manipulation of antibiotic selective pressure improves the isolation efficiency of fastidious Campylobacter from wastewater.
27617011	12	26	Culture Method	T059	C0430400
27617011	41	50	Isolation	T059	C0220862
27617011	54	74	Campylobacter jejuni	T007	C0006819
27617011	80	90	Wastewater	T069	C3494254
27617011	91	111	Campylobacter jejuni	T007	C0006819
27617011	134	143	foodborne	T169	C3242390
27617011	144	153	pathogens	T001	C0450254
27617011	165	174	C. jejuni	T007	C0006819
27617011	178	186	isolated	T169	C0205409
27617011	208	213	foods	T168	C0016452
27617011	215	231	domestic animals	T008	C0003063
27617011	233	241	wildlife	T008	C0003070
27617011	247	260	environmental	T082	C0014406
27617011	261	268	sources	T033	C0449416
27617011	294	325	culture-based isolation methods	T059	C0430400
27617011	355	365	wastewater	T069	C3494254
27617011	366	373	samples	T167	C0370003
27617011	399	408	C. jejuni	T007	C0006819
27617011	435	443	bacteria	T007	C0004611
27617011	459	466	isolate	T169	C0205409
27617011	467	476	C. jejuni	T007	C0006819
27617011	482	492	wastewater	T069	C3494254
27617011	493	500	samples	T167	C0370003
27617011	510	515	study	T062	C2603343
27617011	589	600	antibiotics	T195	C0003232
27617011	608	620	cefoperazone	T109,T195	C0007552
27617011	622	632	vancomycin	T116,T195	C0042313
27617011	634	646	trimethoprim	T109,T195	C0041041
27617011	648	659	polymyxin B	T116,T195	C0032535
27617011	665	675	rifampicin	T109,T195	C0035608
27617011	687	696	C. jejuni	T007	C0006819
27617011	714	723	resistant	T169	C0332325
27617011	804	830	quantitative real-time PCR	T063	C3179034
27617011	836	849	multiplex PCR	T063	C3179032
27617011	863	884	Campylobacter species	T007	C1264818
27617011	903	911	efficacy	T080	C1280519
27617011	915	928	Campylobacter	T007	C0006813
27617011	929	938	isolation	T059	C0220862
27617011	952	965	culture media	T130	C0010454
27617011	982	992	enrichment	T130	C3503937
27617011	1020	1026	Bolton	T130	C1720273
27617011	1031	1050	Preston agar plates	T130	C1720273
27617011	1068	1079	polymyxin B	T116,T195	C0032535
27617011	1081	1091	rifampicin	T109,T195	C0035608
27617011	1108	1136	Bolton selective supplements	T130	C1720273
27617011	1160	1169	isolation	T059	C0220862
27617011	1173	1182	C. jejuni	T007	C0006819
27617011	1199	1207	16S rDNA	T114,T123	C0012933
27617011	1208	1218	sequencing	T059	C1294197
27617011	1238	1255	Enterococcus spp.	T007	C1295823
27617011	1260	1282	Pseudomonas aeruginosa	T007	C0033809
27617011	1303	1311	bacteria	T007	C0004611
27617011	1382	1389	isolate	T169	C0205409
27617011	1390	1403	Campylobacter	T007	C0006813
27617011	1409	1416	samples	T167	C0370003
27617011	1428	1441	contamination	T078	C2349974
27617011	1478	1490	manipulation	T078	C1515926
27617011	1494	1523	antibiotic selective pressure	T033	C0427965
27617011	1537	1546	isolation	T059	C0220862
27617011	1547	1557	efficiency	T081	C0013682
27617011	1572	1585	Campylobacter	T007	C0006813
27617011	1591	1601	wastewater	T069	C3494254

28531851|t|Comparative life cycle assessment study on environmental impact of oil production from micro-algae and terrestrial oilseed crops
28531851|a|In this study the LCA methodology is applied in order to satisfy two goals: i) to evaluate the hot spots in site-specific production chain of biodiesel from terrestrial and micro-algae feedstock; ii) to compare quantitatively, utilizing primary data, the impacts of the first generation in respect to the third generation bio-fuels. Results show that micro-algae are neither competitive yet with traditional oil crops nor with fossil fuel. The use of renewable technologies as photovoltaics and biogas self production might increase the competitiveness of micro-algae oil. Further investigations are however necessary to optimize their production chain and to increase the added value of co-products.
28531851	12	22	life cycle	T079	C0023675
28531851	23	39	assessment study	T062	C2603343
28531851	43	63	environmental impact	T067	C0282165
28531851	67	70	oil	T109	C0028908
28531851	71	81	production	T057	C0033268
28531851	87	98	micro-algae	T204	C0002028
28531851	103	114	terrestrial	T082	C0562020
28531851	115	128	oilseed crops	T002	C0242775
28531851	147	162	LCA methodology	T059	C0201683
28531851	224	233	hot spots	T082	C1521990
28531851	237	250	site-specific	T082	C0449604
28531851	251	261	production	T057	C0033268
28531851	271	280	biodiesel	T109	C2717894
28531851	286	297	terrestrial	T082	C0562020
28531851	302	313	micro-algae	T204	C0002028
28531851	314	323	feedstock	T168	C0003050
28531851	340	354	quantitatively	T081	C0392762
28531851	366	378	primary data	T078	C2827398
28531851	451	460	bio-fuels	T109	C2717891
28531851	480	491	micro-algae	T204	C0002028
28531851	537	540	oil	T109	C0028908
28531851	541	546	crops	T002	C0242775
28531851	556	567	fossil fuel	T167	C0016613
28531851	580	589	renewable	T169	C3178762
28531851	590	602	technologies	T090	C0039421
28531851	606	619	photovoltaics	T090	C0039421
28531851	624	630	biogas	T109	C2717893
28531851	636	646	production	T057	C0033268
28531851	666	681	competitiveness	T057	C0013550
28531851	685	696	micro-algae	T204	C0002028
28531851	697	700	oil	T109	C0028908
28531851	710	724	investigations	T170	C1552578
28531851	765	775	production	T057	C0033268
28531851	817	828	co-products	T071	C1514468

28271030|t|High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting
28271030|a|α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER "knock-in" mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreER(T2) mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing. We utilized CRISPR-Cas9 technology to insert an IRES-CreER(T2) sequence into the 3' UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreER(T2) mice. Recombination efficiency in GCG (+) pancreatic α-cells and glucagon-like peptide 1 positive (GLP1(+)) enteroendocrine L-cells was measured in Gcg-CreER(T2); Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood. Tamoxifen injection of Gcg-CreER(T2); Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreER(T2) allele were phenotypically normal. We successfully derived a Gcg-CreER(T2) mouse line that expresses CreER(T2) in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types.
28271030	14	39	Glucagon-CreER mouse line	T025	C1513528
28271030	53	64	CRISPR-Cas9	T063	C0814038
28271030	74	88	gene targeting	T063	C0242613
28271030	89	96	α-cells	T025	C0030280
28271030	127	136	cell type	T170	C0449475
28271030	140	157	pancreatic islets	T023	C0022131
28271030	192	200	glucagon	T116,T121,T125	C0017687
28271030	213	234	plasma glucose levels	T034	C0455280
28271030	247	254	fasting	T033	C0015663
28271030	256	262	α-cell	T025	C0030280
28271030	263	274	dysfunction	T077	C3887504
28271030	293	301	glucagon	T116,T121,T125	C0017687
28271030	302	311	secretion	T038	C0036536
28271030	326	332	type 1	T047	C0011854
28271030	337	352	type 2 diabetes	T047	C0011860
28271030	423	438	pathophysiology	T169	C0031847
28271030	442	449	α-cells	T025	C0030280
28271030	476	489	gene ablation	T063	C1513384
28271030	493	503	activation	T045	C0017255
28271030	520	527	α-cells	T025	C0030280
28271030	579	586	β-cells	T025	C0030281
28271030	597	609	Glucagon-Cre	T025	C1513528
28271030	614	651	Glucagon-CreER transgenic mouse lines	T025	C1513528
28271030	671	680	transgene	T028	C0282641
28271030	681	690	silencing	T045	C0598496
28271030	715	751	Glucagon-CreER "knock-in" mouse line	T025	C1513528
28271030	763	771	glucagon	T116,T121,T125	C0017687
28271030	772	790	haploinsufficiency	T049	C2936267
28271030	833	855	gene deletion analyses	T059	C1294202
28271030	891	920	Glucagon-CreER(T2) mouse line	T025	C1513528
28271030	948	956	glucagon	T028	C1333664
28271030	957	967	expression	T045	C1171362
28271030	1001	1010	transgene	T028	C0282641
28271030	1011	1020	silencing	T045	C0598496
28271030	1034	1056	CRISPR-Cas9 technology	T063	C0814038
28271030	1070	1093	IRES-CreER(T2) sequence	T086	C1512886
28271030	1103	1109	3' UTR	T086,T123	C0600600
28271030	1117	1125	Glucagon	T028	C1333664
28271030	1127	1130	Gcg	T028	C1333664
28271030	1132	1137	locus	T028	C0678933
28271030	1141	1167	mouse embryonic stem cells	T025	C4042879
28271030	1169	1173	ESCs	T025	C4042879
28271030	1185	1188	ESC	T025	C4042879
28271030	1189	1195	clones	T025	C0009013
28271030	1220	1225	mouse	T015	C0025929
28271030	1226	1237	blastocysts	T018	C1281743
28271030	1248	1266	Gcg-CreER(T2) mice	T015	C0025936
28271030	1268	1281	Recombination	T045	C0034865
28271030	1296	1299	GCG	T116,T121,T125	C0017687
28271030	1304	1322	pancreatic α-cells	T025	C0030280
28271030	1327	1359	glucagon-like peptide 1 positive	T116	C0061355
28271030	1361	1368	GLP1(+)	T116	C0061355
28271030	1370	1393	enteroendocrine L-cells	T025	C2333553
28271030	1410	1423	Gcg-CreER(T2)	T015	C0025936
28271030	1425	1444	Rosa26-LSL-YFP mice	T015	C0025936
28271030	1445	1453	injected	T061	C0021485
28271030	1459	1468	tamoxifen	T109,T121	C0039286
28271030	1476	1493	fetal development	T039	C0015928
28271030	1498	1507	adulthood	T079	C0700597
28271030	1509	1518	Tamoxifen	T109,T121	C0039286
28271030	1519	1528	injection	T061	C0021485
28271030	1532	1545	Gcg-CreER(T2)	T015	C0025936
28271030	1547	1566	Rosa26-LSL-YFP mice	T015	C0025936
28271030	1580	1593	recombination	T045	C0034865
28271030	1612	1632	Rosa26-LSL-YFP locus	T028	C0678933
28271030	1636	1645	perinatal	T079	C0178795
28271030	1650	1655	adult	T100	C0001675
28271030	1656	1663	α-cells	T025	C0030280
28271030	1724	1731	α-cells	T025	C0030280
28271030	1742	1747	adult	T100	C0001675
28271030	1748	1771	enteroendocrine L-cells	T025	C2333553
28271030	1779	1783	Mice	T015	C0025929
28271030	1784	1794	homozygous	T032	C0019904
28271030	1803	1816	Gcg-CreER(T2)	T028	C0017337
28271030	1817	1823	allele	T028	C0002085
28271030	1878	1902	Gcg-CreER(T2) mouse line	T025	C1513528
28271030	1908	1917	expresses	T045	C0017262
28271030	1918	1927	CreER(T2)	T028	C0017337
28271030	1931	1949	pancreatic α-cells	T025	C0030280
28271030	1954	1977	enteroendocrine L-cells	T025	C2333553
28271030	1997	2011	preproglucagon	T028	C1333664
28271030	2012	2027	gene expression	T045	C0017262
28271030	2035	2039	mice	T015	C0025929
28271030	2099	2119	genetic manipulation	T063	C0178659
28271030	2142	2152	cell types	T170	C0449475

27626099|t|Peptide -Mediated Interference of PB2 - eIF4G1 Interaction Inhibits Influenza A Viruses ' Replication in Vitro and in Vivo
27626099|a|Influenza viruses are obligate parasites that hijack the host cellular system. Previous results have shown that the influenza virus PB2 subunit confers a dependence of host eukaryotic translation initiation factor 4-γ 1 (eIF4G1) for viral mRNA translation. Here, we demonstrated that peptide -mediated interference of the PB2 - eIF4G1 interaction inhibited virus replication in vitro and in vivo. Remarkably, intranasal administration of the peptide provided 100% protection against lethal challenges of influenza A viruses in BALB/c mice, including H1N1, H5N1, and H7N9 influenza virus subtypes. Mapping of the PB2 protein indicated that the eIF4G1 binding sites resided within the PB2 cap - binding domain. Virtual docking analysis suggested that the inhibitory peptide associated with the conserved amino acid residues that were essential to PB2 cap-binding activity. Overall, our results identified the PB2 - eIF4G1 interactive site as a druggable target for influenza therapeutics.
27626099	0	7	Peptide	T116	C0030956
27626099	18	30	Interference	T070	C0042730
27626099	34	37	PB2	T116,T123	C0753209
27626099	40	46	eIF4G1	T116,T123	C1505487
27626099	47	58	Interaction	T044	C0872079
27626099	59	67	Inhibits	T052	C3463820
27626099	68	87	Influenza A Viruses	T005	C0029347
27626099	90	101	Replication	T043	C0042774
27626099	102	110	in Vitro	T062	C0681828
27626099	115	122	in Vivo	T062	C0681829
27626099	123	140	Influenza viruses	T005	C0029341
27626099	145	163	obligate parasites	T204	C0562628
27626099	169	200	hijack the host cellular system	T043	C1154502
27626099	239	258	influenza virus PB2	T116,T123	C1611366
27626099	291	342	host eukaryotic translation initiation factor 4-γ 1	T116,T123	C1505487
27626099	344	350	eIF4G1	T116,T123	C1505487
27626099	356	378	viral mRNA translation	T046	C1154505
27626099	407	414	peptide	T116	C0030956
27626099	425	437	interference	T070	C0042730
27626099	445	448	PB2	T116,T123	C0753209
27626099	451	457	eIF4G1	T116,T123	C1505487
27626099	458	469	interaction	T044	C0872079
27626099	470	479	inhibited	T052	C3463820
27626099	480	497	virus replication	T043	C0042774
27626099	498	506	in vitro	T062	C0681828
27626099	511	518	in vivo	T062	C0681829
27626099	532	557	intranasal administration	T061	C0001560
27626099	565	572	peptide	T116	C0030956
27626099	587	597	protection	T033	C1545588
27626099	606	612	lethal	T033	C3151529
27626099	613	623	challenges	T058	C0805586
27626099	627	646	influenza A viruses	T005	C0029347
27626099	650	661	BALB/c mice	T015	C0025919
27626099	673	677	H1N1	T005	C1615607
27626099	679	683	H5N1	T005	C1613950
27626099	689	718	H7N9 influenza virus subtypes	T005	C3658219
27626099	720	727	Mapping	T063	C0949728
27626099	735	746	PB2 protein	T116,T123	C0753209
27626099	766	772	eIF4G1	T116,T123	C1505487
27626099	773	786	binding sites	T192	C0005456
27626099	806	813	PB2 cap	T116,T123	C0753209
27626099	816	830	binding domain	T044	C1149343
27626099	832	856	Virtual docking analysis	T170	C3494274
27626099	876	886	inhibitory	T052	C3463820
27626099	887	894	peptide	T116	C0030956
27626099	895	910	associated with	T080	C0332281
27626099	925	944	amino acid residues	T116,T121,T123	C0002520
27626099	968	971	PB2	T116,T123	C0753209
27626099	972	992	cap-binding activity	T059	C0201711
27626099	1030	1033	PB2	T116,T123	C0753209
27626099	1036	1042	eIF4G1	T116,T123	C1505487
27626099	1043	1059	interactive site	T192	C0005456
27626099	1065	1074	druggable	T121	C1254351
27626099	1086	1095	influenza	T047	C0021400
27626099	1096	1108	therapeutics	T061	C0087111

28099370|t|A Course -Based Approach to the Doctor of Nursing Practice Project: Supporting Student Growth From Concept to Completion
28099370|a|We describe a course -based approach to the doctor of nursing practice project in which students work in groups of 8 to 12 with a faculty member to complete individual final projects that require a minimum of 360 practicum hours in 3- semester -long courses. Project teams include agency or community -based mentors. Project findings are disseminated through written and oral reports. This approach preserves faculty resources and provides students with mentoring, opportunities for reflection, and time for project development.
28099370	2	8	Course	T079	C0750729
28099370	16	24	Approach	T082	C0449445
28099370	32	38	Doctor	T097	C0031831
28099370	42	66	Nursing Practice Project	T062	C0008967
28099370	79	86	Student	T098	C0038492
28099370	99	106	Concept	T078	C0178566
28099370	110	120	Completion	T080	C0205197
28099370	135	141	course	T079	C0750729
28099370	149	157	approach	T082	C0449445
28099370	165	171	doctor	T097	C0031831
28099370	175	199	nursing practice project	T062	C0008967
28099370	209	217	students	T098	C0038492
28099370	218	222	work	T057	C0043227
28099370	226	232	groups	T078	C0441833
28099370	251	265	faculty member	T097	C0015535
28099370	269	277	complete	T080	C0205197
28099370	295	303	projects	T077	C1709701
28099370	319	326	minimum	T080	C1524031
28099370	334	343	practicum	T065	C0032929
28099370	344	349	hours	T079	C0439227
28099370	356	364	semester	T079	C2348178
28099370	371	378	courses	T079	C0750729
28099370	380	393	Project teams	T096	C0871489
28099370	402	408	agency	T092	C0237463
28099370	412	421	community	T096	C0009462
28099370	429	436	mentors	T098	C0025369
28099370	438	454	Project findings	T033	C0243095
28099370	459	471	disseminated	T082	C0205221
28099370	480	487	written	T170	C0684224
28099370	492	504	oral reports	T170	C0684224
28099370	511	519	approach	T082	C0449445
28099370	530	537	faculty	T097	C0015535
28099370	538	547	resources	T169	C0024752
28099370	561	569	students	T098	C0038492
28099370	575	584	mentoring	T065	C4255266
28099370	586	599	opportunities	T078	C1254370
28099370	604	614	reflection	T054	C0037397
28099370	620	624	time	T079	C0040223
28099370	629	648	project development	T169	C1527148

28122243|t|Opposing Roles of Acetylation and Phosphorylation in LIFR - Dependent Self-Renewal Growth Signaling in Mouse Embryonic Stem Cells
28122243|a|LIF promotes self-renewal of mouse embryonic stem cells (mESCs), and in its absence, the cells differentiate. LIF binds to the LIF receptor (LIFR) and activates the JAK-STAT3 pathway, but it remains unknown how the receptor complex triggers differentiation or self-renewal. Here, we report that the LIFR cytoplasmic domain contains a self-renewal domain within the juxtamembrane region and a differentiation domain within the C-terminal region. The differentiation domain contains four SPXX repeats that are phosphorylated by MAPK to restrict STAT3 activation; the self-renewal domain is characterized by a 3K motif that is acetylated by p300. In mESCs, acetyl- LIFR undergoes homodimerization, leading to STAT3 hypo- or hyper-activation depending on the presence or absence of gp130. LIFR - activated STAT3 restricts differentiation via cytokine induction. Thus, LIFR acetylation and serine phosphorylation differentially promote stem cell self-renewal and differentiation.
28122243	9	14	Roles	T080	C1521970
28122243	18	29	Acetylation	T044	C0001038
28122243	34	49	Phosphorylation	T044	C0031715
28122243	53	57	LIFR	T116,T129,T192	C0125607
28122243	60	69	Dependent	T169	C3244310
28122243	70	82	Self-Renewal	T043	C1155711
28122243	83	89	Growth	T040	C0018270
28122243	90	99	Signaling	T044	C0037080
28122243	103	129	Mouse Embryonic Stem Cells	T025	C4042879
28122243	130	133	LIF	T116,T129	C0125606
28122243	143	155	self-renewal	T043	C1155711
28122243	159	185	mouse embryonic stem cells	T025	C4042879
28122243	187	192	mESCs	T025	C4042879
28122243	206	213	absence	T080	C0332268
28122243	219	224	cells	T025	C0007634
28122243	225	238	differentiate	T169	C2945687
28122243	240	243	LIF	T116,T129	C0125606
28122243	257	269	LIF receptor	T116,T129,T192	C0125607
28122243	271	275	LIFR	T116,T129,T192	C0125607
28122243	281	290	activates	T052	C1879547
28122243	295	312	JAK-STAT3 pathway	T044	C0037080
28122243	321	336	remains unknown	T080	C0439673
28122243	345	361	receptor complex	T026	C1523873
28122243	362	370	triggers	T080	C1444748
28122243	371	386	differentiation	T169	C2945687
28122243	390	402	self-renewal	T043	C1155711
28122243	429	433	LIFR	T116,T129,T192	C0125607
28122243	434	452	cytoplasmic domain	T026	C1511625
28122243	464	476	self-renewal	T043	C1155711
28122243	477	483	domain	T169	C1880389
28122243	495	515	juxtamembrane region	T026	C1622525
28122243	522	537	differentiation	T169	C2945687
28122243	538	544	domain	T169	C1880389
28122243	556	573	C-terminal region	T087	C1707271
28122243	579	594	differentiation	T169	C2945687
28122243	595	601	domain	T169	C1880389
28122243	616	628	SPXX repeats	T116	C0030956
28122243	638	652	phosphorylated	T044	C0031715
28122243	656	660	MAPK	T116,T126	C0752312
28122243	664	672	restrict	T169	C0443288
28122243	673	689	STAT3 activation	T043	C2248236
28122243	695	707	self-renewal	T043	C1155711
28122243	708	714	domain	T169	C1880389
28122243	737	745	3K motif	T116	C0660452
28122243	754	764	acetylated	T044	C0001038
28122243	777	782	mESCs	T025	C4042879
28122243	792	796	LIFR	T116,T129,T192	C0125607
28122243	807	823	homodimerization	T044	C1512485
28122243	836	841	STAT3	T116,T123	C0253050
28122243	842	867	hypo- or hyper-activation	T052	C1879547
28122243	868	877	depending	T169	C3244310
28122243	885	893	presence	T033	C0150312
28122243	897	904	absence	T169	C0332197
28122243	908	913	gp130	T116,T129,T192	C0082758
28122243	915	919	LIFR	T116,T129,T192	C0125607
28122243	922	931	activated	T052	C1879547
28122243	932	937	STAT3	T116,T123	C0253050
28122243	938	947	restricts	T169	C0443288
28122243	948	963	differentiation	T169	C2945687
28122243	968	976	cytokine	T116,T129	C0079189
28122243	977	986	induction	T169	C0205263
28122243	994	998	LIFR	T116,T129,T192	C0125607
28122243	999	1010	acetylation	T044	C0001038
28122243	1015	1037	serine phosphorylation	T044	C1519253
28122243	1038	1052	differentially	T169	C2945687
28122243	1061	1070	stem cell	T025	C0038250
28122243	1071	1083	self-renewal	T043	C1155711
28122243	1088	1103	differentiation	T169	C2945687

28389629|t|Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1 -mediated AMPK and JNK activation
28389629|a|mTOR activation suppresses autophagy by phosphorylating ULK1 at S757 and suppressing its enzymatic activity. Here we report that feedback activation of mTOR in the PI-3 kinase pathway by two p70 S6 kinase (S6K1) inhibitors (PF-4708671 and A77 1726, the active metabolite of an immunosuppressive drug leflunomide) or by S6K1 knockdown did not suppress but rather induced autophagy. Suppression of S6K1 activity led to the phosphorylation and activation of AMPK, which then phosphorylated ULK1 at S555. While mTOR feedback activation led to increased phosphorylation of ULK1 at S757, this modification did not the disrupt ULK1 - AMPK interaction nor dampen ULK1 S555 phosphorylation and the induction of autophagy. In addition, inhibition of S6K1 activity led to JNK activation, which also contributed to autophagy. 5Z-7-oxozeaenol, a specific inhibitor of TAK1, or TAK1 siRNA blocked A77 1726 -induced activation of AMPK and JNK, and LC3 lipidation. Taken together, our study establishes S6K1 as a key player in the PI-3 kinase pathway to suppress autophagy through inhibiting AMPK and JNK in a TAK1 -dependent manner.
28389629	0	10	Inhibition	T040	C2248397
28389629	14	27	p70 S6 kinase	T116,T126	C2827383
28389629	29	33	S6K1	T116,T126	C2827383
28389629	35	43	activity	T044	C0243102
28389629	47	55	A77 1726	T109,T121	C0100724
28389629	61	78	active metabolite	T123	C0870883
28389629	82	93	leflunomide	T109,T121	C0063041
28389629	103	112	autophagy	T043	C0004391
28389629	121	125	TAK1	T116,T126	C0379816
28389629	136	140	AMPK	T116,T126	C2350345
28389629	145	148	JNK	T116,T126	C0291988
28389629	149	159	activation	T045	C0599177
28389629	160	164	mTOR	T116,T126	C1307407
28389629	165	175	activation	T045	C0599177
28389629	176	186	suppresses	T169	C1260953
28389629	187	196	autophagy	T043	C0004391
28389629	200	215	phosphorylating	T044	C1158886
28389629	216	220	ULK1	T116,T126	C1313678
28389629	233	244	suppressing	T169	C1260953
28389629	249	267	enzymatic activity	T044	C2267219
28389629	298	308	activation	T045	C0599177
28389629	312	316	mTOR	T116,T126	C1307407
28389629	324	335	PI-3 kinase	T116,T126	C0044602
28389629	336	343	pathway	T044	C0037080
28389629	351	364	p70 S6 kinase	T116,T126	C2827383
28389629	366	370	S6K1	T116,T126	C2827383
28389629	372	382	inhibitors	T121	C0014432
28389629	384	394	PF-4708671	T109,T121	C2976138
28389629	399	407	A77 1726	T109,T121	C0100724
28389629	413	430	active metabolite	T123	C0870883
28389629	437	459	immunosuppressive drug	T121,T129	C0021081
28389629	460	471	leflunomide	T109,T121	C0063041
28389629	479	483	S6K1	T028	C1419748
28389629	484	493	knockdown	T063	C2350567
28389629	502	510	suppress	T169	C1260953
28389629	530	539	autophagy	T043	C0004391
28389629	541	552	Suppression	T169	C1260953
28389629	556	560	S6K1	T116,T126	C2827383
28389629	561	569	activity	T044	C1537044
28389629	581	596	phosphorylation	T044	C1158886
28389629	601	611	activation	T045	C0599177
28389629	615	619	AMPK	T116,T126	C2350345
28389629	632	646	phosphorylated	T044	C1158886
28389629	647	651	ULK1	T116,T126	C1313678
28389629	667	671	mTOR	T116,T126	C1307407
28389629	681	691	activation	T045	C0599177
28389629	709	724	phosphorylation	T044	C1158886
28389629	728	732	ULK1	T116,T126	C1313678
28389629	780	784	ULK1	T116,T126	C1313678
28389629	787	791	AMPK	T116,T126	C2350345
28389629	792	803	interaction	T044	C0872079
28389629	815	819	ULK1	T116,T126	C1313678
28389629	825	840	phosphorylation	T044	C1158886
28389629	849	858	induction	T169	C0205263
28389629	862	871	autophagy	T043	C0004391
28389629	886	896	inhibition	T040	C2248397
28389629	900	904	S6K1	T116,T126	C2827383
28389629	905	913	activity	T044	C0243102
28389629	921	924	JNK	T116,T126	C0291988
28389629	925	935	activation	T045	C0599177
28389629	963	972	autophagy	T043	C0004391
28389629	974	989	5Z-7-oxozeaenol	T121	C1254351
28389629	1002	1011	inhibitor	T121	C0014432
28389629	1015	1019	TAK1	T116,T126	C0379816
28389629	1024	1028	TAK1	T116,T126	C0379816
28389629	1029	1034	siRNA	T114,T123	C1099354
28389629	1043	1051	A77 1726	T109,T121	C0100724
28389629	1061	1071	activation	T045	C0599177
28389629	1075	1079	AMPK	T116,T126	C2350345
28389629	1084	1087	JNK	T116,T126	C0291988
28389629	1093	1096	LC3	T116	C3540600
28389629	1097	1107	lipidation	T044	C1157479
28389629	1147	1151	S6K1	T116,T126	C2827383
28389629	1175	1186	PI-3 kinase	T116,T126	C0044602
28389629	1187	1194	pathway	T044	C0037080
28389629	1198	1206	suppress	T169	C1260953
28389629	1207	1216	autophagy	T043	C0004391
28389629	1225	1235	inhibiting	T052	C3463820
28389629	1236	1240	AMPK	T116,T126	C2350345
28389629	1245	1248	JNK	T116,T126	C0291988
28389629	1254	1258	TAK1	T116,T126	C0379816

27745564|t|How should proxies of cognitive reserve be evaluated in a population of healthy older adults?
27745564|a|While some tools have been developed to estimate an individual's cognitive reserve (CR), no study has assessed the adequacy of the method used for assessing these CR proxy indicators. Therefore, we aimed to determine the most appropriate method to estimate CR by comparing two approaches: (1) the common assessment of CR proxies in the literature (e.g. years of education) and (2) the calculation of a comprehensive index based on most significant parameters used in the estimation of CR. Data on CR proxies (i.e. education, occupation, and leisure activities) were obtained in a sample of 204 older adults. Regression analyses were used to develop the two indices of CR (i.e. ICR-standard and ICR-detailed) and to determine which index best represented the level of one's CR. The ICR-standard was calculated using a combination of the three most common measures of reserve in the literature: number of schooling years, complexity of the primary occupation, and amount of current participation in stimulating activities. The ICR-detailed was calculated using the most significant parameters (established in initial analyses) of CR: highest level of education combined with the number of training courses, last occupation, and amount of current participation in social and intellectual activities. The comparison of both indices showed that higher levels of ICR-standard and ICR-detailed were associated with a greater minimization of the effects of age on cognition. However, the ICR-detailed was more strongly associated to this minimization than the ICR-standard, suggesting that the ICR-detailed best reflect one's CR. This study is the first to show that it is of great importance to question methods measuring CR proxies in order to develop a clinical tool allowing a comprehensive and accurate estimation of CR.
27745564	11	18	proxies	T169	C1521761
27745564	22	39	cognitive reserve	T041	C2936352
27745564	43	52	evaluated	T058	C0220825
27745564	58	68	population	T098	C1257890
27745564	72	79	healthy	T080	C3898900
27745564	80	92	older adults	T098	C0001792
27745564	105	110	tools	T170	C1516602
27745564	134	142	estimate	T081	C0750572
27745564	146	158	individual's	T098	C0027361
27745564	159	176	cognitive reserve	T041	C2936352
27745564	178	180	CR	T041	C2936352
27745564	196	204	assessed	T052	C1516048
27745564	209	217	adequacy	T080	C0205410
27745564	257	259	CR	T041	C2936352
27745564	260	265	proxy	T169	C1521761
27745564	320	331	appropriate	T080	C1548787
27745564	342	350	estimate	T081	C0750572
27745564	351	353	CR	T041	C2936352
27745564	391	397	common	T081	C0205214
27745564	398	408	assessment	T058	C0220825
27745564	412	414	CR	T041	C2936352
27745564	415	422	proxies	T169	C1521761
27745564	430	440	literature	T170	C0023866
27745564	447	465	years of education	T081	C4054327
27745564	479	490	calculation	T052	C1441506
27745564	496	509	comprehensive	T080	C1880156
27745564	510	515	index	T170	C0918012
27745564	525	541	most significant	T080	C1299394
27745564	542	552	parameters	T033	C0449381
27745564	565	575	estimation	T041	C0680844
27745564	579	581	CR	T041	C2936352
27745564	591	593	CR	T041	C2936352
27745564	594	601	proxies	T169	C1521761
27745564	608	617	education	T065	C0013621
27745564	619	629	occupation	T090	C0028811
27745564	635	653	leisure activities	T056	C0023292
27745564	688	700	older adults	T098	C0001792
27745564	702	721	Regression analyses	T170	C0034980
27745564	751	758	indices	T170	C0918012
27745564	762	764	CR	T041	C2936352
27745564	771	783	ICR-standard	T170	C0918012
27745564	788	800	ICR-detailed	T170	C0918012
27745564	825	830	index	T170	C0918012
27745564	867	869	CR	T041	C2936352
27745564	875	887	ICR-standard	T170	C0918012
27745564	892	902	calculated	T052	C1441506
27745564	911	922	combination	T080	C0205195
27745564	941	947	common	T081	C0205214
27745564	948	956	measures	T081	C0079809
27745564	960	967	reserve	T041	C2936352
27745564	975	985	literature	T170	C0023866
27745564	987	1012	number of schooling years	T081	C4054327
27745564	1014	1024	complexity	T080	C0439855
27745564	1040	1050	occupation	T090	C0028811
27745564	1066	1073	current	T079	C0521116
27745564	1074	1087	participation	T169	C0679823
27745564	1091	1102	stimulating	T070	C1948023
27745564	1103	1113	activities	T052	C0441655
27745564	1119	1131	ICR-detailed	T170	C0918012
27745564	1136	1146	calculated	T052	C1441506
27745564	1157	1173	most significant	T080	C1299394
27745564	1174	1184	parameters	T033	C0449381
27745564	1201	1208	initial	T079	C0205265
27745564	1209	1217	analyses	T062	C0936012
27745564	1222	1224	CR	T041	C2936352
27745564	1226	1252	highest level of education	T033	C4264309
27745564	1253	1261	combined	T080	C0205195
27745564	1281	1297	training courses	T065	C0040607
27745564	1299	1303	last	T080	C1517741
27745564	1304	1314	occupation	T090	C0028811
27745564	1320	1326	amount	T081	C1265611
27745564	1338	1351	participation	T169	C0679823
27745564	1355	1361	social	T054	C2371613
27745564	1366	1389	intellectual activities	T065	C0013652
27745564	1395	1405	comparison	T052	C1707455
27745564	1414	1421	indices	T170	C0918012
27745564	1451	1463	ICR-standard	T170	C0918012
27745564	1468	1480	ICR-detailed	T170	C0918012
27745564	1486	1501	associated with	T080	C0332281
27745564	1504	1511	greater	T081	C1704243
27745564	1512	1524	minimization	T080	C0392756
27745564	1532	1542	effects of	T080	C1704420
27745564	1543	1546	age	T032	C0001779
27745564	1550	1559	cognition	T041	C0009240
27745564	1574	1586	ICR-detailed	T170	C0918012
27745564	1605	1615	associated	T080	C0332281
27745564	1624	1636	minimization	T080	C0392756
27745564	1646	1658	ICR-standard	T170	C0918012
27745564	1680	1692	ICR-detailed	T170	C0918012
27745564	1712	1714	CR	T041	C2936352
27745564	1762	1767	great	T081	C0549177
27745564	1768	1778	importance	T080	C3898777
27745564	1799	1808	measuring	T080	C0444706
27745564	1809	1811	CR	T041	C2936352
27745564	1812	1819	proxies	T169	C1521761
27745564	1842	1855	clinical tool	T170	C1516602
27745564	1867	1880	comprehensive	T080	C1880156
27745564	1885	1893	accurate	T080	C0443131
27745564	1894	1904	estimation	T041	C0680844
27745564	1908	1910	CR	T041	C2936352

28262340|t|Gain-of-function mutation in SCN5A causes ventricular arrhythmias and early onset atrial fibrillation
28262340|a|Mutations in SCN5A, the gene encoding the α-subunit of the cardiac sodium channel (NaV1.5), are associated with a broad spectrum of inherited cardiac arrhythmia disorders. The purpose of this study was to identify the genetic and functional determinants underlying a Dutch family that presented with a combined phenotype of ventricular arrhythmias with a likely adrenergic component, either in isolation or in combination with a mildly decreased heart function and early onset (<55 years) atrial fibrillation. We performed next generation sequencing in the proband of a two- generation Dutch family and demonstrated a novel missense mutation in SCN5A-(p.M1851V) which co-segregated with the clinical phenotype in the family. We functionally evaluated the putative genetic defect by patch clamp electrophysiological studies in human embryonic kidney cells transfected with mutant or wild-type Nav1.5. The current inactivation was slower and recovery from inactivation was faster in SCN5A-M1851V channels. The voltage dependence of inactivation was shifted towards more positive potentials and consequently, a larger TTX - sensitive window current was observed in SCN5A-M1851V channels. Furthermore, a higher upstroke velocity was observed for the SCN5A-M1851V channels, while the depolarization voltage was more negative, both indicating increased excitability. This mutation leads to a gain-of-function mechanism based on increased channel availability and increased window current, fitting the observed clinical phenotype of (likely adrenergic-induced) ventricular arrhythmias and atrial fibrillation. These findings further expand the range of cardiac arrhythmias associated with mutations in SCN5A.
28262340	0	25	Gain-of-function mutation	T045	C0026882
28262340	29	34	SCN5A	T028	C1419864
28262340	42	65	ventricular arrhythmias	T047	C0085612
28262340	70	81	early onset	T033	C1833334
28262340	82	101	atrial fibrillation	T047	C0004238
28262340	102	111	Mutations	T045	C0026882
28262340	115	120	SCN5A	T028	C1419864
28262340	126	130	gene	T028	C0017337
28262340	131	139	encoding	T052	C2700640
28262340	161	168	cardiac	T023	C0018787
28262340	169	192	sodium channel (NaV1.5)	T116,T123	C0037492
28262340	222	230	spectrum	T077	C2827424
28262340	234	243	inherited	T169	C0439660
28262340	244	272	cardiac arrhythmia disorders	T033	C0003811
28262340	294	299	study	T062	C2603343
28262340	320	327	genetic	T169	C0314603
28262340	332	355	functional determinants	T169	C1521761
28262340	369	374	Dutch	T098	C0013331
28262340	375	381	family	T099	C0015576
28262340	413	422	phenotype	T032	C0031437
28262340	426	449	ventricular arrhythmias	T047	C0085612
28262340	464	474	adrenergic	T169	C0599756
28262340	475	484	component	T077	C1705248
28262340	496	505	isolation	T169	C0205409
28262340	512	523	combination	T080	C0205195
28262340	548	562	heart function	T042	C0232164
28262340	567	578	early onset	T033	C1833334
28262340	584	589	years	T079	C0439234
28262340	591	610	atrial fibrillation	T047	C0004238
28262340	630	640	generation	T079	C0079411
28262340	641	651	sequencing	T086	C0162326
28262340	659	666	proband	T099	C1948021
28262340	677	687	generation	T079	C0079411
28262340	688	693	Dutch	T098	C0013331
28262340	694	700	family	T099	C0015576
28262340	726	743	missense mutation	T045	C0599155
28262340	747	763	SCN5A-(p.M1851V)	T028	C1419864
28262340	793	801	clinical	T080	C0205210
28262340	802	811	phenotype	T032	C0031437
28262340	819	825	family	T099	C0015576
28262340	830	842	functionally	T169	C0205245
28262340	866	873	genetic	T169	C0314603
28262340	874	880	defect	T169	C1457869
28262340	884	895	patch clamp	T062	C0920630
28262340	896	924	electrophysiological studies	T060	C0850293
28262340	928	943	human embryonic	T018	C0868971
28262340	944	956	kidney cells	T025	C0553257
28262340	957	968	transfected	T063	C0040669
28262340	974	980	mutant	T049	C0596988
28262340	984	1000	wild-type Nav1.5	T028	C1419864
28262340	1006	1013	current	T070	C1705970
28262340	1014	1026	inactivation	T169	C0544461
28262340	1056	1068	inactivation	T169	C0544461
28262340	1083	1104	SCN5A-M1851V channels	T116,T123	C0037492
28262340	1110	1117	voltage	T081	C0598352
28262340	1118	1128	dependence	T169	C3244310
28262340	1132	1144	inactivation	T169	C0544461
28262340	1170	1178	positive	T033	C1446409
28262340	1179	1189	potentials	T080	C3245505
28262340	1217	1220	TTX	T109,T123,T131	C0039705
28262340	1223	1232	sensitive	T169	C0332324
28262340	1233	1247	window current	T070	C1705970
28262340	1264	1285	SCN5A-M1851V channels	T116,T123	C0037492
28262340	1309	1326	upstroke velocity	T081	C0439830
28262340	1348	1369	SCN5A-M1851V channels	T116,T123	C0037492
28262340	1381	1403	depolarization voltage	T081	C0598352
28262340	1413	1421	negative	T033	C0205160
28262340	1468	1476	mutation	T045	C0026882
28262340	1488	1514	gain-of-function mechanism	T169	C0441712
28262340	1534	1541	channel	T116,T123	C0037492
28262340	1569	1583	window current	T070	C1705970
28262340	1606	1614	clinical	T080	C0205210
28262340	1615	1624	phenotype	T032	C0031437
28262340	1656	1679	ventricular arrhythmias	T047	C0085612
28262340	1684	1703	atrial fibrillation	T047	C0004238
28262340	1711	1719	findings	T033	C0243095
28262340	1748	1767	cardiac arrhythmias	T033	C0003811
28262340	1784	1793	mutations	T045	C0026882
28262340	1797	1802	SCN5A	T028	C1419864

27444328|t|Extra carbohydrate binding module contributes to the processivity and catalytic activity of a non-modular hydrolase family 5 endoglucanase from Fomitiporia mediterranea MF3/22
27444328|a|FmEG from Fomitiporia mediterranea is a non-modular endoglucanase composed of a 24-amino acids extension and 13-amino acids linker-like peptide at the N-terminus and a 312-amino acids GH5 catalytic domain (CD) at the C-terminus. In this study, six FmEG derivatives with deletion of N-terminal fragments or fusion with an extra family 1 carbohydrate-binding module (CBM1) was constructed in order to evaluate the contribution of CBM1 to FmEG processivity and catalytic activity. FmEG showed a weak processivity and released cellobiose (G2) and cellotriose (G3) as main end products, and cellotriose (G4) as minor end product from filter paper (FP), but more amount of G4 was released from regenerated amorphous cellulose (RAC). All derivatives had similar activity on carboxymethylcellulose (CMC) with the same optimal pH (7.0) and temperature (50°C). However, fusing an extra CBM1 to FmEG△24 or FmEG△37 with flexible peptide significantly improved its processivity and catalytic activity to FP and RAC. Overall, 1.79- and 1.84-fold increases in the soluble /insoluble product ratio on FP, and 1.38- and 1.39-fold increases on RAC, compared to FmEG△24, were recorded for CBM1 - FmEG△24 and CBM1 -linker- FmEG△24, respectively. Meanwhile, they displayed 2.64- and 2.67-fold more activity on RAC, and 1.68- and 1.77-fold on FP, respectively. Similar improvement was also obtained for CBM1 -linker- FmEG△37 as compared with FmEG△37. Interestingly, fusion of an extra CBM1 with FmEG also caused an alteration of cleavage pattern on insoluble celluloses. Our results suggest that such improvements in processivity and catalytic activity may arise from CBM1 binding affinity. The N-terminal 24- or 37-amino acids may serve as linker for sufficient spatial separation of the two domains required for processivity and catalytic activity. In addition, deletion of the N-terminal 24- or 37-amino acids led to significant reduction in thermostability but not the enzymatic activity.
27444328	6	33	carbohydrate binding module	T116,T192	C0108401
27444328	34	45	contributes	T052	C1880177
27444328	53	65	processivity	T080	C0205556
27444328	70	88	catalytic activity	T044	C0243102
27444328	94	115	non-modular hydrolase	T116,T126	C0020289
27444328	123	138	5 endoglucanase	T116,T126	C0384886
27444328	144	175	Fomitiporia mediterranea MF3/22	T004	C1225186
27444328	176	180	FmEG	T116,T126	C0384886
27444328	186	210	Fomitiporia mediterranea	T004	C1225186
27444328	216	241	non-modular endoglucanase	T116,T126	C0384886
27444328	256	270	24-amino acids	T116,T121,T123	C0002520
27444328	271	280	extension	T169	C0231448
27444328	285	299	13-amino acids	T116,T121,T123	C0002520
27444328	300	319	linker-like peptide	T116	C0030956
27444328	327	337	N-terminus	T087	C1514562
27444328	344	359	312-amino acids	T116,T121,T123	C0002520
27444328	360	380	GH5 catalytic domain	T087	C0600499
27444328	382	384	CD	T087	C0600499
27444328	393	403	C-terminus	T087	C1514562
27444328	424	428	FmEG	T116,T126	C0384886
27444328	446	454	deletion	T052	C1880274
27444328	458	478	N-terminal fragments	T116	C0030935
27444328	482	488	fusion	T116,T123	C0162768
27444328	503	539	family 1 carbohydrate-binding module	T116,T192	C0108401
27444328	541	545	CBM1	T116,T192	C0108401
27444328	588	600	contribution	T052	C1880177
27444328	604	608	CBM1	T116,T192	C0108401
27444328	612	616	FmEG	T116,T126	C0384886
27444328	617	629	processivity	T080	C0205556
27444328	634	652	catalytic activity	T044	C0243102
27444328	654	658	FmEG	T116,T126	C0384886
27444328	673	685	processivity	T080	C0205556
27444328	699	709	cellobiose	T109	C0007630
27444328	711	713	G2	T109	C0007630
27444328	719	730	cellotriose	T109,T122	C1690565
27444328	732	734	G3	T109,T122	C1690565
27444328	739	756	main end products	T071	C1514468
27444328	762	773	cellotriose	T109,T122	C1690565
27444328	775	777	G4	T109,T122	C1690565
27444328	782	799	minor end product	T071	C1514468
27444328	805	817	filter paper	T074	C0180859
27444328	819	821	FP	T074	C0180859
27444328	843	845	G4	T109,T122	C1690565
27444328	864	895	regenerated amorphous cellulose	T109,T123	C0007648
27444328	897	900	RAC	T109,T123	C0007648
27444328	907	918	derivatives	T109,T122	C1690565
27444328	943	965	carboxymethylcellulose	T109,T121	C0007068
27444328	967	970	CMC	T109,T121	C0007068
27444328	981	993	same optimal	T080	C2698651
27444328	994	996	pH	T081	C0020283
27444328	1007	1018	temperature	T081	C0039476
27444328	1052	1056	CBM1	T116,T192	C0108401
27444328	1060	1067	FmEG△24	T116,T126	C0384886
27444328	1071	1078	FmEG△37	T116,T126	C0384886
27444328	1084	1100	flexible peptide	T116	C0030956
27444328	1128	1140	processivity	T080	C0205556
27444328	1145	1163	catalytic activity	T169	C1264638
27444328	1167	1169	FP	T074	C0180859
27444328	1174	1177	RAC	T109,T123	C0007648
27444328	1225	1232	soluble	T080	C1948047
27444328	1252	1257	ratio	T081	C0456603
27444328	1261	1263	FP	T074	C0180859
27444328	1302	1305	RAC	T109,T123	C0007648
27444328	1319	1326	FmEG△24	T116,T126	C0384886
27444328	1346	1350	CBM1	T116,T192	C0108401
27444328	1353	1360	FmEG△24	T116,T126	C0384886
27444328	1365	1369	CBM1	T116,T192	C0108401
27444328	1379	1386	FmEG△24	T116,T126	C0384886
27444328	1438	1461	2.67-fold more activity	T033	C0243095
27444328	1465	1468	RAC	T109,T123	C0007648
27444328	1497	1499	FP	T074	C0180859
27444328	1557	1561	CBM1	T116,T192	C0108401
27444328	1571	1578	FmEG△37	T116,T126	C0384886
27444328	1596	1603	FmEG△37	T116,T126	C0384886
27444328	1639	1643	CBM1	T116,T192	C0108401
27444328	1649	1653	FmEG	T116,T126	C0384886
27444328	1669	1679	alteration	T078	C1515926
27444328	1683	1699	cleavage pattern	T067	C0596311
27444328	1703	1723	insoluble celluloses	T109,T123	C0007648
27444328	1771	1783	processivity	T080	C0205556
27444328	1788	1806	catalytic activity	T169	C1264638
27444328	1822	1826	CBM1	T116,T192	C0108401
27444328	1827	1843	binding affinity	T044	C0033618
27444328	1849	1881	N-terminal 24- or 37-amino acids	T116,T121,T123	C0002520
27444328	1917	1935	spatial separation	T082	C1254362
27444328	1943	1954	two domains	T087	C1514562
27444328	1968	1980	processivity	T080	C0205556
27444328	1985	2003	catalytic activity	T169	C1264638
27444328	2018	2026	deletion	T052	C1880274
27444328	2034	2066	N-terminal 24- or 37-amino acids	T116,T121,T123	C0002520
27444328	2074	2095	significant reduction	T080	C0392756
27444328	2099	2114	thermostability	T070	C0597571
27444328	2127	2145	enzymatic activity	T044	C0243102

27606170|t|Trends in Behavior-Analytic Gambling Research and Treatment
27606170|a|The purpose of the present review was to analyze research outcomes for all gambling studies reported in the behavior analysis literature. We used the search term " gambling " to identify articles that were published in behaviorally oriented journals between the years 1992 and 2012 and categorized the content of each article as empirical or conceptual. Next, we examined and categorized the empirical articles by inclusion of an experimental manipulation and treatment to alleviate at least some aspect of pathological gambling, participant population used, type of gambling task employed in the research, whether the participants in the study actually gambled, and the behavioral phenomena of interest. The results show that the rate of publication of gambling research has increased in the last 6 years, and a vast majority of articles are empirical. Of the empirical articles, examinations of treatment techniques or methods are scarce; slot machine play is the most represented form of gambling, and slightly greater than half of the research included compensation based on gambling outcomes within experiments. We discuss implications and future directions based on these observations of the published literature.
27606170	0	6	Trends	T079	C1521798
27606170	10	36	Behavior-Analytic Gambling	T055	C0016995
27606170	37	45	Research	T062	C0004939
27606170	50	59	Treatment	T061	C0087111
27606170	64	71	purpose	T169	C1285529
27606170	87	93	review	T078	C1552617
27606170	101	108	analyze	T062	C0936012
27606170	109	117	research	T062	C0004939
27606170	118	126	outcomes	T033	C2015879
27606170	135	143	gambling	T055	C0016995
27606170	144	151	studies	T062	C2603343
27606170	152	160	reported	T170	C0684224
27606170	168	185	behavior analysis	T062	C0935545
27606170	186	196	literature	T170	C0023866
27606170	224	232	gambling	T055	C0016995
27606170	238	246	identify	T041	C0020792
27606170	247	255	articles	T170	C1706852
27606170	266	275	published	T170	C1704324
27606170	279	291	behaviorally	T053	C0004927
27606170	292	300	oriented	T033	C3842076
27606170	301	309	journals	T073,T170	C0162443
27606170	346	357	categorized	T052	C0871968
27606170	362	369	content	T077	C0456205
27606170	378	385	article	T170	C1706852
27606170	389	398	empirical	T080	C1880496
27606170	402	412	conceptual	T077	C1254372
27606170	423	431	examined	T033	C0332128
27606170	436	447	categorized	T052	C0871968
27606170	452	461	empirical	T080	C1880496
27606170	462	470	articles	T170	C1706852
27606170	474	483	inclusion	T080	C1512693
27606170	490	502	experimental	T080	C1517586
27606170	503	515	manipulation	T061	C0947647
27606170	520	529	treatment	T061	C0087111
27606170	533	542	alleviate	T061	C0441610
27606170	557	563	aspect	T080	C1879746
27606170	567	579	pathological	T169	C1521733
27606170	580	588	gambling	T055	C0016995
27606170	590	612	participant population	T098	C0679646
27606170	627	635	gambling	T055	C0016995
27606170	636	640	task	T057	C3540678
27606170	641	649	employed	T033	C0557351
27606170	657	665	research	T062	C0004939
27606170	679	691	participants	T098	C0679646
27606170	699	704	study	T062	C2603343
27606170	714	721	gambled	T055	C0016995
27606170	731	741	behavioral	T053	C0004927
27606170	742	751	phenomena	T067	C1882365
27606170	755	763	interest	T041	C0543488
27606170	769	776	results	T033	C0683954
27606170	791	795	rate	T081	C1521828
27606170	799	810	publication	T073,T170	C0034036
27606170	814	822	gambling	T055	C0016995
27606170	823	831	research	T062	C0004939
27606170	836	845	increased	T081	C0205217
27606170	878	886	majority	T081	C0205393
27606170	890	898	articles	T170	C1706852
27606170	903	912	empirical	T080	C1880496
27606170	921	930	empirical	T080	C1880496
27606170	931	939	articles	T170	C1706852
27606170	941	953	examinations	T058	C0582103
27606170	957	966	treatment	T061	C0087111
27606170	967	977	techniques	T169	C0449851
27606170	981	988	methods	T170	C0025663
27606170	1001	1013	slot machine	T073	C3273359
27606170	1014	1018	play	T055	C0016995
27606170	1026	1030	most	T081	C0205393
27606170	1031	1042	represented	T052	C1882932
27606170	1051	1059	gambling	T055	C0016995
27606170	1074	1081	greater	T081	C1704243
27606170	1099	1107	research	T062	C0004939
27606170	1117	1129	compensation	T080	C0205432
27606170	1130	1135	based	T169	C1527178
27606170	1139	1147	gambling	T055	C0016995
27606170	1148	1156	outcomes	T033	C2015879
27606170	1164	1175	experiments	T062	C0681814
27606170	1188	1200	implications	UnknownType	C0814846
27606170	1205	1211	future	T079	C0016884
27606170	1212	1222	directions	T082	C0439755
27606170	1223	1228	based	T169	C1527178
27606170	1238	1250	observations	T078	C1554188
27606170	1258	1278	published literature	T170	C0023866

27384676|t|Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149
27384676|a|To explore a more effective treatment for newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), we conducted a phase 4 study of the cisplatin, dexamethasone, gemcitabine, pegaspargase (DDGP) regimen. The primary end point was the 2-year progression-free survival (PFS) after the protocol treatment. Secondary endpoints included response rate (RR), overall survival (OS) and median survival time (MST). The interim analysis included data only from March 2011 to September 2013, who received six cycles of DDGP chemotherapy. A total of 25 eligible patients were enrolled. Seventeen patients (17/24, 70.83%) achieved complete response (CR) and four (4/24, 16.67%) achieved partial response (PR), three (3/24, 12.50%) had progressive disease (PD). The RR after treatment was 87.50%. After a median follow-up duration of 24.67 months (range 4-48 months). The 2-year PFS and OS rate were 61.80% (95% CI, 42.00% to 81.60%) and 68.50 % (95% CI, 48.70% to 88.30%), respectively. The MST was 36.55 months (95% CI, 29.41 months to 43.70 months). Grade 3/4 leukopenia occurred in fourteen patients (58.33%) and grade 3/4 thrombocytopenia occurred in eleven patients (45.83%). Twelve patients (50.00%) experienced Activated Partial Phromboplastin Ptime (APTT) elongation and fourteen patients (58.33%) experienced hypofibrinogenemia. In conclusion, DDGP regimen is an effective and tolerated treatment for newly diagnosed, advanced-stage ENKTL. This trial was registered at www.ClinicalTrials.gov as #NCT01501149.
27384676	0	8	Efficacy	T080	C1280519
27384676	13	19	safety	T080	C0678800
27384676	23	32	cisplatin	T121,T197	C0008838
27384676	34	47	dexamethasone	T109,T121	C0011777
27384676	49	60	gemcitabine	T114,T121	C0045093
27384676	65	77	pegaspargase	T116,T121,T126	C0071568
27384676	79	83	DDGP	T121	C1254351
27384676	85	92	regimen	T061	C0040808
27384676	96	111	newly diagnosed	T080	C1518321
27384676	113	127	advanced-stage	T080	C0205179
27384676	128	169	extranodal natural killer/T-cell lymphoma	T191	C1955906
27384676	171	178	interim	T079	C2827738
27384676	179	187	analysis	T062	C0936012
27384676	193	200	phase 4	T079	C0439562
27384676	201	206	study	T062	C2603343
27384676	237	246	effective	T080	C1704419
27384676	247	256	treatment	T169	C0039798
27384676	261	276	newly diagnosed	T080	C1518321
27384676	278	292	advanced-stage	T080	C0205179
27384676	293	346	extranodal natural killer/T-cell lymphoma, nasal type	T191	C0392788
27384676	348	353	ENKTL	T191	C0392788
27384676	371	378	phase 4	T079	C0439562
27384676	379	384	study	T062	C2603343
27384676	392	401	cisplatin	T121,T197	C0008838
27384676	403	416	dexamethasone	T109,T121	C0011777
27384676	418	429	gemcitabine	T114,T121	C0045093
27384676	431	443	pegaspargase	T116,T121,T126	C0071568
27384676	445	449	DDGP	T121	C1254351
27384676	451	458	regimen	T061	C0040808
27384676	472	481	end point	T080	C2349179
27384676	497	522	progression-free survival	T081	C0242792
27384676	524	527	PFS	T081	C0242792
27384676	539	557	protocol treatment	T061	C0040808
27384676	569	578	endpoints	T080	C2349179
27384676	588	601	response rate	T079	C0237629
27384676	603	605	RR	T079	C0237629
27384676	608	624	overall survival	T081	C4086681
27384676	626	628	OS	T081	C4086681
27384676	634	654	median survival time	T079	C2986586
27384676	656	659	MST	T079	C2986586
27384676	666	673	interim	T079	C2827738
27384676	674	682	analysis	T062	C0936012
27384676	692	696	data	T078	C1511726
27384676	741	749	received	T080	C1514756
27384676	764	768	DDGP	T121	C1254351
27384676	769	781	chemotherapy	T061	C3665472
27384676	797	805	eligible	T080	C1548635
27384676	806	814	patients	T101	C0030705
27384676	840	848	patients	T101	C0030705
27384676	874	891	complete response	T033	C1275810
27384676	893	895	CR	T033	C1275810
27384676	930	946	partial response	T033	C1521726
27384676	948	950	PR	T033	C1521726
27384676	978	997	progressive disease	T047	C1335499
27384676	999	1001	PD	T047	C1335499
27384676	1008	1010	RR	T079	C0237629
27384676	1017	1026	treatment	T169	C0039798
27384676	1047	1053	median	T081	C0876920
27384676	1054	1063	follow-up	T058	C1522577
27384676	1064	1072	duration	T079	C0449238
27384676	1082	1088	months	T079	C0439231
27384676	1101	1107	months	T079	C0439231
27384676	1121	1124	PFS	T081	C0242792
27384676	1129	1136	OS rate	T081	C0038954
27384676	1154	1156	CI	T081	C0009667
27384676	1193	1195	CI	T081	C0009667
27384676	1234	1237	MST	T079	C2986586
27384676	1248	1254	months	T079	C0439231
27384676	1260	1262	CI	T081	C0009667
27384676	1270	1276	months	T079	C0439231
27384676	1286	1292	months	T079	C0439231
27384676	1295	1300	Grade	T185	C0441800
27384676	1305	1315	leukopenia	T047	C0023530
27384676	1316	1324	occurred	T079	C2745955
27384676	1337	1345	patients	T101	C0030705
27384676	1359	1364	grade	T185	C0441800
27384676	1369	1385	thrombocytopenia	T047	C0040034
27384676	1386	1394	occurred	T079	C2745955
27384676	1405	1413	patients	T101	C0030705
27384676	1431	1439	patients	T101	C0030705
27384676	1461	1499	Activated Partial Phromboplastin Ptime	T059	C0030605
27384676	1501	1505	APTT	T059	C0030605
27384676	1507	1517	elongation	T033	C0240671
27384676	1531	1539	patients	T101	C0030705
27384676	1561	1579	hypofibrinogenemia	T047	C0553681
27384676	1596	1600	DDGP	T121	C1254351
27384676	1601	1608	regimen	T061	C0040808
27384676	1615	1624	effective	T080	C1704419
27384676	1629	1638	tolerated	T033	C0013220
27384676	1639	1648	treatment	T169	C0039798
27384676	1653	1668	newly diagnosed	T080	C1518321
27384676	1670	1684	advanced-stage	T080	C0205179
27384676	1685	1690	ENKTL	T191	C0392788
27384676	1697	1702	trial	T062	C0008976
27384676	1707	1717	registered	T058	C1514821
27384676	1721	1743	www.ClinicalTrials.gov	T170	C2349146

27878205|t|Iterative Development and Evaluation of a Pharmacogenomic -Guided Clinical Decision Support System for Warfarin Dosing
27878205|a|Pharmacogenomic -guided dosing has the potential to improve patient outcomes but its implementation has been met with clinical challenges. Our objective was to develop and evaluate a clinical decision support system (CDSS) for pharmacogenomic -guided warfarin dosing designed for physicians and pharmacists. Twelve physicians and pharmacists completed 6 prescribing tasks using simulated patient scenarios in two iterations (development and validation phases) of a newly developed pharmacogenomic -driven CDSS prototype. For each scenario, usability was measured via efficiency, recorded as time to task completion, and participants ' perceived satisfaction which were compared using Kruskal-Wallis and Mann Whitney U tests, respectively. Debrief interviews were conducted and qualitatively analyzed. Usability findings from the first (i.e. development) iteration were incorporated into the CDSS design for the second (i.e. validation) iteration. During the CDSS validation iteration, participants took more time to complete tasks with a median (IQR) of 183 (124-247) seconds versus 101 (73.5-197) seconds in the development iteration (p=0.01). This increase in time on task was due to the increase in time spent in the CDSS corresponding to several design changes. Efficiency differences that were observed between pharmacists and physicians in the development iteration were eliminated in the validation iteration. The increased use of the CDSS corresponded to a greater acceptance of CDSS recommended doses in the validation iteration (4% in the first iteration vs. 37.5% in the second iteration, p<0.001). Overall satisfaction did not change statistically between the iterations but the qualitative analysis revealed greater trust in the second prototype. A pharmacogenomic -guided CDSS has been developed using warfarin as the test drug. The final CDSS prototype was trusted by prescribers and significantly increased the time using the tool and acceptance of the recommended doses. This study is an important step toward incorporating pharmacogenomics into CDSS design for clinical testing.
27878205	0	9	Iterative	T033	C1854293
27878205	10	21	Development	T169	C1527148
27878205	26	36	Evaluation	T058	C0220825
27878205	42	57	Pharmacogenomic	T091	C1138555
27878205	66	98	Clinical Decision Support System	T170	C0525070
27878205	103	118	Warfarin Dosing	T081	C0366686
27878205	119	134	Pharmacogenomic	T091	C1138555
27878205	143	149	dosing	T081	C0178602
27878205	179	186	patient	T101	C0030705
27878205	204	218	implementation	T052	C1708476
27878205	237	245	clinical	T080	C0205210
27878205	246	256	challenges	T058	C0805586
27878205	291	299	evaluate	T058	C0220825
27878205	302	334	clinical decision support system	T170	C0525070
27878205	336	340	CDSS	T170	C0525070
27878205	346	361	pharmacogenomic	T091	C1138555
27878205	370	385	warfarin dosing	T081	C0366686
27878205	386	394	designed	T052	C1707689
27878205	399	409	physicians	T097	C0031831
27878205	414	425	pharmacists	T097	C0031323
27878205	434	444	physicians	T097	C0031831
27878205	449	460	pharmacists	T097	C0031323
27878205	473	484	prescribing	T058	C0278329
27878205	485	490	tasks	T057	C3540678
27878205	497	514	simulated patient	T065	C3825675
27878205	515	524	scenarios	T169	C0683579
27878205	532	542	iterations	T033	C1854293
27878205	544	555	development	T169	C1527148
27878205	560	570	validation	T062	C1519941
27878205	571	577	phases	T079	C0205390
27878205	600	615	pharmacogenomic	T091	C1138555
27878205	624	628	CDSS	T170	C0525070
27878205	629	638	prototype	T080	C0205556
27878205	649	657	scenario	T169	C0683579
27878205	659	668	usability	T170	C1510648
27878205	673	681	measured	T080	C0444706
27878205	686	696	efficiency	T081	C0013682
27878205	698	706	recorded	T170	C0034869
27878205	710	733	time to task completion	T201	C1316026
27878205	739	751	participants	T098	C0679646
27878205	754	763	perceived	T041	C0030971
27878205	764	776	satisfaction	T041	C0242428
27878205	803	842	Kruskal-Wallis and Mann Whitney U tests	T170	C0282574
27878205	896	918	qualitatively analyzed	T059	C0022885
27878205	920	929	Usability	T170	C1510648
27878205	960	971	development	T169	C1527148
27878205	973	982	iteration	T033	C1854293
27878205	1010	1014	CDSS	T170	C0525070
27878205	1015	1021	design	T052	C1707689
27878205	1030	1036	second	T079	C0457385
27878205	1043	1053	validation	T062	C1519941
27878205	1055	1064	iteration	T033	C1854293
27878205	1077	1081	CDSS	T170	C0525070
27878205	1082	1092	validation	T062	C1519941
27878205	1093	1102	iteration	T033	C1854293
27878205	1104	1116	participants	T098	C0679646
27878205	1127	1149	time to complete tasks	T201	C1316026
27878205	1157	1163	median	T082	C0549183
27878205	1187	1194	seconds	T079	C0457385
27878205	1217	1224	seconds	T079	C0457385
27878205	1232	1243	development	T169	C1527148
27878205	1244	1253	iteration	T033	C1854293
27878205	1269	1277	increase	T169	C0442805
27878205	1281	1293	time on task	T079	C0871530
27878205	1309	1317	increase	T169	C0442805
27878205	1321	1325	time	T079	C0040223
27878205	1339	1343	CDSS	T170	C0525070
27878205	1369	1375	design	T052	C1707689
27878205	1385	1395	Efficiency	T081	C0013682
27878205	1435	1446	pharmacists	T097	C0031323
27878205	1451	1461	physicians	T097	C0031831
27878205	1469	1480	development	T169	C1527148
27878205	1481	1490	iteration	T033	C1854293
27878205	1514	1524	validation	T062	C1519941
27878205	1525	1534	iteration	T033	C1854293
27878205	1540	1549	increased	T081	C0205217
27878205	1561	1565	CDSS	T170	C0525070
27878205	1606	1610	CDSS	T170	C0525070
27878205	1623	1628	doses	T081	C0178602
27878205	1636	1646	validation	T062	C1519941
27878205	1647	1656	iteration	T033	C1854293
27878205	1674	1683	iteration	T033	C1854293
27878205	1701	1707	second	T079	C0457385
27878205	1708	1717	iteration	T033	C1854293
27878205	1737	1749	satisfaction	T041	C0242428
27878205	1791	1801	iterations	T033	C1854293
27878205	1810	1830	qualitative analysis	T059	C0022885
27878205	1861	1867	second	T079	C0457385
27878205	1868	1877	prototype	T080	C0205556
27878205	1881	1896	pharmacogenomic	T091	C1138555
27878205	1905	1909	CDSS	T170	C0525070
27878205	1935	1943	warfarin	T109,T121,T131	C0043031
27878205	1956	1960	drug	T121	C1254351
27878205	1972	1976	CDSS	T170	C0525070
27878205	1977	1986	prototype	T080	C0205556
27878205	2032	2041	increased	T081	C0205217
27878205	2046	2050	time	T079	C0040223
27878205	2061	2065	tool	T033	C0871532
27878205	2100	2105	doses	T081	C0178602
27878205	2160	2176	pharmacogenomics	T091	C1138555
27878205	2182	2186	CDSS	T170	C0525070
27878205	2187	2193	design	T052	C1707689
27878205	2198	2214	clinical testing	T062	C1516634

28509623|t|Gastrostomy in patients with prion disease
28509623|a|Patients with prion diseases can live for long periods of time in a state of akinetic mutism given appropriate management of their symptoms. To study symptom support in these cases, we performed gastrostomies on 3 patients with V180I genetic Creutzfeldt-Jakob disease (CJD) who had become akinetic and mute, and compared them to 14 other similar patients being fed by tube. In the 3 gastrostomy cases, there were no direct complications due to the gastrostomy or tube feeding, nor were there episodes of discontinuation of tube feeding or initiation of continuous drip infusion due to severe complications. Antibiotics were administered for mild infections, a complication of CJD, with 0.2% and 8.8% of the total time after gastrostomy being used for intravenous or transluminal administration, respectively. We compared the present patient series with that of our previous report statistically, and found that patients undergoing gastrostomy required significantly fewer discontinuations of tube feeding than those who did not. No significant difference in antibiotic administration was found between groups, however. It is our conclusion that gastrostomy should be allowed for symptom support in akinetic patients with prion disease, but adequate informed consent must be provided to the patient's family.
28509623	0	11	Gastrostomy	T061	C0017196
28509623	15	23	patients	T101	C0030705
28509623	29	42	prion disease	T047	C0162534
28509623	43	51	Patients	T101	C0030705
28509623	57	71	prion diseases	T047	C0162534
28509623	72	80	can live	T052	C0038952
28509623	85	105	long periods of time	T079	C1948053
28509623	120	135	akinetic mutism	T047	C0001889
28509623	154	182	management of their symptoms	T061	C1536570
28509623	193	200	symptom	T184	C1457887
28509623	238	251	gastrostomies	T061	C0017196
28509623	257	265	patients	T101	C0030705
28509623	271	310	V180I genetic Creutzfeldt-Jakob disease	T047	C0022336
28509623	312	315	CJD	T047	C0022336
28509623	332	340	akinetic	T169	C0233568
28509623	345	349	mute	T033	C0278249
28509623	389	397	patients	T101	C0030705
28509623	404	415	fed by tube	T061	C0041281
28509623	426	437	gastrostomy	T061	C0017196
28509623	456	479	no direct complications	T033	C4032686
28509623	491	502	gastrostomy	T061	C0017196
28509623	506	518	tube feeding	T061	C0041281
28509623	535	546	episodes of	T079	C0332189
28509623	547	562	discontinuation	T058	C0457454
28509623	566	578	tube feeding	T061	C0041281
28509623	582	620	initiation of continuous drip infusion	T061	C0574032
28509623	628	648	severe complications	T033	C3495031
28509623	650	679	Antibiotics were administered	T061	C0199779
28509623	684	699	mild infections	T047	C0004623
28509623	703	715	complication	T078	C2362589
28509623	719	722	CJD	T047	C0022336
28509623	767	778	gastrostomy	T061	C0017196
28509623	794	805	intravenous	T082	C0348016
28509623	809	836	transluminal administration	T169	C1522231
28509623	876	890	patient series	T101	C0030705
28509623	954	962	patients	T101	C0030705
28509623	974	985	gastrostomy	T061	C0017196
28509623	1015	1031	discontinuations	T058	C0457454
28509623	1035	1047	tube feeding	T061	C0041281
28509623	1072	1097	No significant difference	T033	C3842396
28509623	1101	1126	antibiotic administration	T061	C0199779
28509623	1145	1151	groups	T078	C0441833
28509623	1188	1199	gastrostomy	T061	C0017196
28509623	1222	1229	symptom	T184	C1457887
28509623	1241	1249	akinetic	T169	C0233568
28509623	1250	1258	patients	T101	C0030705
28509623	1264	1277	prion disease	T047	C0162534
28509623	1283	1291	adequate	T080	C0205411
28509623	1301	1308	consent	T169	C1511481
28509623	1333	1349	patient's family	T099	C0015576

27524991|t|Temperature and Plant Genotype Alter Alkaloid Concentrations in Ryegrass Infected with an Epichloë Endophyte and This Affects an Insect Herbivore
27524991|a|Asexual Epichloë endophytes colonize agricultural forage grasses in a relationship which is mutually beneficial and provides the host plant with protection against herbivorous insects. The endophyte strain AR37 (Epichloë festucae var. lolii) produces epoxy-janthitrem alkaloids and is the only endophyte known to provide ryegrass with resistance against porina larvae (Wiseana cervinata (Walker)), a major pasture pest in cooler areas of New Zealand. This study examined the effect of temperature on concentrations of epoxy-janthitrems in AR37 - infected ryegrass and determined how the resulting variations in concentration affected consumption, growth and survival of porina larvae. Twenty replicate pairs of perennial (Lolium perenne L.) and Italian ryegrass (L. multiflorum Lam.) plants with and without endophyte were prepared by cloning, with one of each pair grown at either high (20°C) or low (7°C) temperature. After 10 weeks, herbage on each plant was harvested, divided into leaf and pseudostem, then freeze dried and ground. Leaf and pseudostem material was then incorporated separately into semi - synthetic diets which were fed to porina larvae in a bioassay over 3 weeks. Epoxy-janthitrem concentrations within the plant materials and the semi - synthetic diets were analyzed by high performance liquid chromatography. AR37 - infected ryegrass grown at high temperature contained high in plant a concentrations of epoxy-janthitrem (30.6 μg/g in leaves and 83.9 μg/g in pseudostems) that had a strong anti-feedant effect on porina larvae when incorporated into their diets, reducing their survival by 25-42% on pseudostems. In comparison, in planta epoxy-janthitrem concentrations in AR37 - infected ryegrass grown at low temperature were very low (0.67 μg/g in leaves and 7.4 μg/g in pseudostems) resulting in a small anti-feedant effect in perennial but not in Italian ryegrass. Although alkaloid concentrations were greatly reduced by low temperature this reduction did not occur until after 4 weeks of exposure. Alkaloid concentrations were slightly lower in Italian than in perennial ryegrass and concentrations were higher in the pseudostems when compared with the leaves. In conclusion, epoxy-janthitrems expressed by the AR37 endophyte show strong activity against porina larvae. However, when ryegrass plants are grown at a constant low temperature for an extended period of time in planta epoxy-janthitrem concentrations are greatly reduced and are less effective against this pasture pest.
27524991	0	11	Temperature	T081	C0039476
27524991	16	21	Plant	T002	C0032098
27524991	22	30	Genotype	T032	C0017431
27524991	31	36	Alter	T078	C1515926
27524991	37	45	Alkaloid	T109,T123,T131	C0301258
27524991	46	60	Concentrations	T081	C1446561
27524991	64	72	Ryegrass	T002	C0023969
27524991	73	81	Infected	T046	C3714514
27524991	90	108	Epichloë Endophyte	T004	C1265415
27524991	118	125	Affects	T169	C0392760
27524991	129	135	Insect	T204	C0021585
27524991	136	145	Herbivore	T008	C0562691
27524991	154	173	Epichloë endophytes	T004	C1265415
27524991	174	182	colonize	T033	C4289767
27524991	183	210	agricultural forage grasses	T002	C0023969
27524991	216	228	relationship	T080	C0439849
27524991	238	246	mutually	T080	C1709100
27524991	247	257	beneficial	T081	C0814225
27524991	262	270	provides	T052	C1999230
27524991	275	285	host plant	UnknownType	C0868970
27524991	291	301	protection	T033	C1545588
27524991	302	309	against	T080	C0521124
27524991	310	321	herbivorous	T008	C0562691
27524991	322	329	insects	T204	C0021585
27524991	335	344	endophyte	T004	C1265415
27524991	345	351	strain	T001	C1518614
27524991	352	356	AR37	T004	C1265415
27524991	358	386	Epichloë festucae var. lolii	T004	C1265415
27524991	397	413	epoxy-janthitrem	T109	C0014630
27524991	414	423	alkaloids	T109,T123,T131	C0301258
27524991	440	449	endophyte	T004	C1265415
27524991	459	466	provide	T052	C1999230
27524991	467	475	ryegrass	T002	C0023969
27524991	481	491	resistance	T039	C1514892
27524991	492	499	against	T080	C0521124
27524991	500	513	porina larvae	T204	C0023047
27524991	515	541	Wiseana cervinata (Walker)	T204	C0026593
27524991	546	551	major	T080	C0205164
27524991	552	559	pasture	T002	C0018210
27524991	560	564	pest	T008	C0869004
27524991	568	574	cooler	T070	C0009267
27524991	575	580	areas	T082	C0205146
27524991	584	595	New Zealand	T083	C0027978
27524991	602	607	study	T062	C2603343
27524991	608	616	examined	T033	C0332128
27524991	621	627	effect	T080	C1280500
27524991	631	642	temperature	T081	C0039476
27524991	646	660	concentrations	T081	C1446561
27524991	664	681	epoxy-janthitrems	T109	C0014630
27524991	685	689	AR37	T004	C1265415
27524991	692	700	infected	T046	C3714514
27524991	701	709	ryegrass	T002	C0023969
27524991	714	724	determined	T080	C0521095
27524991	733	742	resulting	T169	C1274040
27524991	743	753	variations	T080	C0205419
27524991	757	770	concentration	T081	C1446561
27524991	771	779	affected	T169	C0392760
27524991	780	791	consumption	T039	C1947907
27524991	793	799	growth	T040	C0018270
27524991	804	812	survival	T052	C0038952
27524991	816	829	porina larvae	T204	C0023047
27524991	838	847	replicate	T080	C1883725
27524991	848	853	pairs	T080	C1709450
27524991	857	866	perennial	T002	C0330103
27524991	868	885	Lolium perenne L.	T002	C0331558
27524991	891	898	Italian	T083	C0022277
27524991	899	907	ryegrass	T002	C0023969
27524991	909	928	L. multiflorum Lam.	T002	C0331557
27524991	930	936	plants	T002	C0032098
27524991	954	963	endophyte	T004	C1265415
27524991	969	977	prepared	T033	C4082130
27524991	981	988	cloning	T062	C0009015
27524991	1007	1011	pair	T080	C1709450
27524991	1012	1017	grown	T067	C2911660
27524991	1028	1032	high	T080	C0205250
27524991	1043	1046	low	T080	C0205251
27524991	1053	1064	temperature	T081	C0039476
27524991	1082	1089	herbage	T002	C0019240
27524991	1098	1103	plant	T002	C0032098
27524991	1108	1117	harvested	T078	C1516695
27524991	1119	1126	divided	T169	C0332849
27524991	1132	1136	leaf	T002	C0242724
27524991	1141	1151	pseudostem	T033	C0243095
27524991	1158	1170	freeze dried	T059	C0016698
27524991	1175	1181	ground	T067	C1522240
27524991	1183	1187	Leaf	T002	C0242724
27524991	1192	1202	pseudostem	T033	C0243095
27524991	1203	1211	material	T167	C0520510
27524991	1221	1233	incorporated	T169	C0243126
27524991	1234	1244	separately	T080	C0443299
27524991	1250	1254	semi	T081	C2825407
27524991	1257	1266	synthetic	T080	C2004457
27524991	1267	1272	diets	T168	C0012155
27524991	1284	1287	fed	T052	C2987508
27524991	1291	1304	porina larvae	T204	C0023047
27524991	1310	1318	bioassay	T059	C0005507
27524991	1333	1349	Epoxy-janthitrem	T109	C0014630
27524991	1350	1364	concentrations	T081	C1446561
27524991	1376	1381	plant	T002	C0032098
27524991	1382	1391	materials	T167	C0520510
27524991	1400	1404	semi	T081	C2825407
27524991	1407	1416	synthetic	T080	C2004457
27524991	1417	1422	diets	T168	C0012155
27524991	1428	1436	analyzed	T062	C0936012
27524991	1440	1444	high	T080	C0205250
27524991	1445	1456	performance	T052	C1882330
27524991	1457	1478	liquid chromatography	T059	C0008565
27524991	1480	1484	AR37	T004	C1265415
27524991	1487	1495	infected	T046	C3714514
27524991	1496	1504	ryegrass	T002	C0023969
27524991	1505	1510	grown	T067	C2911660
27524991	1514	1518	high	T080	C0205250
27524991	1519	1530	temperature	T081	C0039476
27524991	1541	1545	high	T080	C0205250
27524991	1549	1554	plant	T002	C0032098
27524991	1557	1571	concentrations	T081	C1446561
27524991	1575	1591	epoxy-janthitrem	T109	C0014630
27524991	1606	1612	leaves	T002	C0242724
27524991	1630	1641	pseudostems	T033	C0243095
27524991	1654	1660	strong	T080	C0442821
27524991	1661	1673	anti-feedant	T033	C0243095
27524991	1674	1680	effect	T080	C1280500
27524991	1684	1697	porina larvae	T204	C0023047
27524991	1703	1715	incorporated	T169	C0243126
27524991	1727	1732	diets	T168	C0012155
27524991	1734	1742	reducing	T080	C0392756
27524991	1749	1757	survival	T052	C0038952
27524991	1771	1782	pseudostems	T033	C0243095
27524991	1787	1797	comparison	T052	C1707455
27524991	1802	1808	planta	T002	C0032098
27524991	1809	1825	epoxy-janthitrem	T109	C0014630
27524991	1826	1840	concentrations	T081	C1446561
27524991	1844	1848	AR37	T004	C1265415
27524991	1851	1859	infected	T046	C3714514
27524991	1860	1868	ryegrass	T002	C0023969
27524991	1869	1874	grown	T067	C2911660
27524991	1878	1881	low	T080	C0205251
27524991	1882	1893	temperature	T081	C0039476
27524991	1904	1907	low	T080	C0205251
27524991	1922	1928	leaves	T002	C0242724
27524991	1945	1956	pseudostems	T033	C0243095
27524991	1958	1967	resulting	T169	C1274040
27524991	1973	1978	small	T081	C0700321
27524991	1979	1991	anti-feedant	T033	C0243095
27524991	1992	1998	effect	T080	C1280500
27524991	2002	2011	perennial	T002	C0330103
27524991	2023	2030	Italian	T083	C0022277
27524991	2031	2039	ryegrass	T002	C0023969
27524991	2050	2058	alkaloid	T109,T123,T131	C0301258
27524991	2059	2073	concentrations	T081	C1446561
27524991	2079	2086	greatly	T033	C3840786
27524991	2087	2094	reduced	T080	C0392756
27524991	2098	2101	low	T080	C0205251
27524991	2102	2113	temperature	T081	C0039476
27524991	2119	2128	reduction	T080	C0392756
27524991	2137	2142	occur	T052	C1709305
27524991	2166	2174	exposure	T080	C0332157
27524991	2176	2184	Alkaloid	T109,T123,T131	C0301258
27524991	2185	2199	concentrations	T081	C1446561
27524991	2205	2213	slightly	T080	C0750482
27524991	2214	2219	lower	T080	C0205251
27524991	2223	2230	Italian	T083	C0022277
27524991	2239	2248	perennial	T002	C0330103
27524991	2249	2257	ryegrass	T002	C0023969
27524991	2262	2276	concentrations	T081	C1446561
27524991	2282	2288	higher	T080	C0205250
27524991	2296	2307	pseudostems	T033	C0243095
27524991	2313	2321	compared	T052	C1707455
27524991	2331	2337	leaves	T002	C0242724
27524991	2342	2352	conclusion	T078	C1707478
27524991	2354	2371	epoxy-janthitrems	T109	C0014630
27524991	2372	2381	expressed	T169	C0205245
27524991	2389	2393	AR37	T004	C1265415
27524991	2394	2403	endophyte	T004	C1265415
27524991	2409	2415	strong	T080	C0442821
27524991	2416	2424	activity	T052	C0441655
27524991	2425	2432	against	T080	C0521124
27524991	2433	2446	porina larvae	T204	C0023047
27524991	2462	2470	ryegrass	T002	C0023969
27524991	2471	2477	plants	T002	C0032098
27524991	2482	2487	grown	T067	C2911660
27524991	2493	2501	constant	T080	C1948059
27524991	2502	2505	low	T080	C0205251
27524991	2506	2517	temperature	T081	C0039476
27524991	2525	2533	extended	T082	C0231449
27524991	2534	2548	period of time	T079	C1948053
27524991	2552	2558	planta	T002	C0032098
27524991	2559	2575	epoxy-janthitrem	T109	C0014630
27524991	2576	2590	concentrations	T081	C1446561
27524991	2595	2602	greatly	T033	C3840786
27524991	2603	2610	reduced	T080	C0392756
27524991	2619	2623	less	T081	C0439092
27524991	2624	2633	effective	T080	C1704419
27524991	2634	2641	against	T080	C0521124
27524991	2647	2654	pasture	T002	C0018210
27524991	2655	2659	pest	T008	C0869004

27919332|t|Effects of ionizing radiation on the mammalian brain
27919332|a|Epidemiological studies on the atomic-bomb survivors, cancer survivors and occupational cohorts provide strong evidence for multifaceted damage to brain after ionizing radiation. Radiation - induced late effects may manifest as brain tumors or cognitive impairment. Decreased neurogenesis and differentiation, alteration in neural structure and synaptic plasticity as well as increased oxidative stress and inflammation are suggested to contribute to adverse effects in the brain. In addition to neural stems cells, several brain -specific mature cell types including endothelial and glial cells are negatively affected by ionizing radiation. Radiation - induced enhancement of endothelial cell apoptosis results in disruption of the vascular system and the blood brain barrier. Activated microglia create inflammatory environment that negatively affects neuronal structures and results in decreased synaptic plasticity. Although the molecular mechanisms involved in radiation - induced brain injury remain elusive, first strategies for prevention and amelioration are being developed. Drug -based prevention and treatment focus mainly on the inhibition of oxidative stress and inflammation. Cell replacement therapy holds great promise as first animal studies using transplantation of neural stem cells to irradiated brain have been successful in restoring memory and cognition deficits. This review summarizes the epidemiological and biological data on radiation - induced brain damage and describes prevention and therapy methods to avoid and ameliorate these adverse effects, respectively.
27919332	0	10	Effects of	T080	C1704420
27919332	11	29	ionizing radiation	T070	C0034538
27919332	37	46	mammalian	T015	C0024660
27919332	47	52	brain	T023	C0006104
27919332	53	76	Epidemiological studies	T062	C0002783
27919332	84	105	atomic-bomb survivors	T101	C0206194
27919332	107	123	cancer survivors	T101	C1516231
27919332	128	140	occupational	T169	C0521127
27919332	141	148	cohorts	T098	C0599755
27919332	177	189	multifaceted	T082	C0205291
27919332	190	196	damage	T169	C1883709
27919332	200	205	brain	T023	C0006104
27919332	212	230	ionizing radiation	T070	C0034538
27919332	232	241	Radiation	T070	C0034538
27919332	244	251	induced	T169	C0205263
27919332	257	264	effects	T080	C1280500
27919332	269	277	manifest	T169	C0205319
27919332	281	293	brain tumors	T191	C0006118
27919332	297	317	cognitive impairment	T048	C0338656
27919332	319	328	Decreased	T081	C0205216
27919332	329	341	neurogenesis	T040	C0814002
27919332	346	361	differentiation	T043	C0007589
27919332	363	373	alteration	T078	C1515926
27919332	377	393	neural structure	T026	C0682678
27919332	398	417	synaptic plasticity	T042	C0027880
27919332	429	438	increased	T081	C0205217
27919332	439	455	oxidative stress	T049	C0242606
27919332	460	472	inflammation	T046	C0021368
27919332	490	500	contribute	T052	C1880177
27919332	504	519	adverse effects	T046	C0879626
27919332	527	532	brain	T023	C0006104
27919332	549	567	neural stems cells	T025	C1113654
27919332	577	582	brain	T023	C0006104
27919332	593	599	mature	T079	C0205286
27919332	600	610	cell types	T025	C0007634
27919332	621	632	endothelial	T025	C0225336
27919332	637	648	glial cells	T025	C0027836
27919332	664	672	affected	T169	C0392760
27919332	676	694	ionizing radiation	T070	C0034538
27919332	696	705	Radiation	T070	C0034538
27919332	708	715	induced	T169	C0205263
27919332	716	727	enhancement	T052	C2349975
27919332	731	747	endothelial cell	T025	C0225336
27919332	748	757	apoptosis	T043	C0162638
27919332	769	779	disruption	T169	C0332453
27919332	787	802	vascular system	T022	C0489903
27919332	811	830	blood brain barrier	T023	C0005854
27919332	832	841	Activated	T052	C1879547
27919332	842	851	microglia	T025	C0206116
27919332	859	871	inflammatory	T046	C0021368
27919332	872	883	environment	T082	C1254362
27919332	908	927	neuronal structures	T026	C0682678
27919332	943	952	decreased	T081	C0205216
27919332	953	972	synaptic plasticity	T042	C0027880
27919332	987	996	molecular	T080	C1521991
27919332	997	1007	mechanisms	T169	C0441712
27919332	1020	1029	radiation	T070	C0034538
27919332	1032	1039	induced	T169	C0205263
27919332	1040	1052	brain injury	T037	C0270611
27919332	1090	1100	prevention	T080	C2700409
27919332	1105	1117	amelioration	T169	C1301676
27919332	1139	1143	Drug	T121	C1254351
27919332	1151	1161	prevention	T080	C2700409
27919332	1166	1175	treatment	T169	C1522326
27919332	1196	1206	inhibition	T052	C3463820
27919332	1210	1226	oxidative stress	T049	C0242606
27919332	1231	1243	inflammation	T046	C0021368
27919332	1245	1269	Cell replacement therapy	T061	C0279033
27919332	1299	1305	animal	T008	C0003062
27919332	1320	1335	transplantation	T061	C0040732
27919332	1339	1356	neural stem cells	T025	C1113654
27919332	1360	1376	irradiated brain	T023	C0006104
27919332	1401	1410	restoring	T061	C1283255
27919332	1411	1417	memory	T041	C0025260
27919332	1422	1440	cognition deficits	T048	C0009241
27919332	1469	1484	epidemiological	T169	C1516907
27919332	1489	1499	biological	T080	C0205460
27919332	1500	1504	data	T078	C1511726
27919332	1508	1517	radiation	T070	C0034538
27919332	1520	1527	induced	T169	C0205263
27919332	1528	1540	brain damage	T037	C0270611
27919332	1555	1565	prevention	T080	C2700409
27919332	1570	1585	therapy methods	T169	C0039798
27919332	1599	1609	ameliorate	T169	C1301676
27919332	1616	1631	adverse effects	T046	C0879626

27943546|t|Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies
27943546|a|To determine the impact of race and ethnicity on the efficacy, body weight and hypoglycaemia incidence with vildagliptin treatment in patients with type 2 diabetes mellitus using patient-level data from the vildagliptin clinical trial programme. Data from 22 randomized, placebo-controlled global and local (Japan, China) registration studies of vildagliptin (50 mg once-daily or twice-daily) of ≥12-week duration were analysed by race (Caucasian [n = 2764] and Asian [n = 2232]) and by ethnicity (Japanese, Chinese, and Indian). The placebo-subtracted differences in the change in glycated haemoglobin (HbA1c) and body weight from baseline to week 12 or week 24 were evaluated by race or ethnicity using repeated measure analysis of unstructured covariance. Hypoglycaemia incidences were summarized using descriptive statistics. The HbA1c reduction from baseline with vildagliptin was similar across the racial / ethnic subgroups (-0.83% ± 0.02% to -1.01% ± 0.05%). Placebo-corrected HbA1c reduction was similar between Caucasian (-0.68% ± 0.03%) and Asian (-0.80% ± 0.03%) patients (P value for interaction = .56); analysis by race and ethnicity showed better efficacy (P < .02) in Japanese patients. Japanese patients were drug-naïve and treated with a single oral anti-diabetes drug only; they showed no response to placebo. Weight neutrality of vildagliptin was demonstrated in all groups (0.47 ± 0.11 kg to -0.29 ± 0.08 kg). Hypoglycaemic events (≥1) were infrequent in all ethnic subgroups. The glycaemic efficacy of vildagliptin was similar in Caucasian and Asian patients. The slightly better efficacy observed in Japanese patients was driven by the absence of placebo effect and might be explained by their earlier stage of diabetes compared to other subgroups.
27943546	0	6	Effect	T080	C1280500
27943546	10	14	race	T098	C0034510
27943546	19	28	ethnicity	T098	C0015031
27943546	32	44	vildagliptin	T109,T121	C1570906
27943546	45	53	efficacy	T080	C1280519
27943546	57	72	pooled analysis	UnknownType	C0814924
27943546	76	84	phase II	T062	C0282460
27943546	89	100	III studies	T062	C0282461
27943546	118	124	impact	T080	C4049986
27943546	128	132	race	T098	C0034510
27943546	137	146	ethnicity	T098	C0015031
27943546	154	162	efficacy	T080	C1280519
27943546	164	175	body weight	T032	C0005910
27943546	180	193	hypoglycaemia	T047	C0020615
27943546	194	203	incidence	T081	C0021149
27943546	209	221	vildagliptin	T109,T121	C1570906
27943546	222	231	treatment	T061	C0087111
27943546	235	243	patients	T101	C0030705
27943546	249	273	type 2 diabetes mellitus	T047	C0011860
27943546	280	298	patient-level data	T170	C1516606
27943546	308	320	vildagliptin	T109,T121	C1570906
27943546	321	345	clinical trial programme	T062	C0008976
27943546	347	351	Data	T078	C1511726
27943546	372	390	placebo-controlled	T062	C1706408
27943546	391	397	global	T080	C2348867
27943546	402	407	local	T082	C0205276
27943546	409	414	Japan	T083	C0022341
27943546	416	421	China	T083	C0008115
27943546	423	443	registration studies	T062	C0008972
27943546	447	459	vildagliptin	T109,T121	C1570906
27943546	467	477	once-daily	T079	C0556983
27943546	481	492	twice-daily	T079	C0585361
27943546	532	536	race	T098	C0034510
27943546	538	547	Caucasian	T098	C0043157
27943546	563	568	Asian	T098	C0078988
27943546	588	597	ethnicity	T098	C0015031
27943546	599	607	Japanese	T098	C1556094
27943546	609	616	Chinese	T098	C0152035
27943546	622	628	Indian	T098	C1524069
27943546	635	665	placebo-subtracted differences	T078	C0032041
27943546	683	703	glycated haemoglobin	T116,T123	C0017853
27943546	705	710	HbA1c	T116,T123	C0017853
27943546	716	727	body weight	T032	C0005910
27943546	733	741	baseline	T081	C1442488
27943546	745	749	week	T079	C0439230
27943546	756	760	week	T079	C0439230
27943546	782	786	race	T098	C0034510
27943546	790	799	ethnicity	T098	C0015031
27943546	860	873	Hypoglycaemia	T047	C0020615
27943546	874	884	incidences	T081	C0021149
27943546	935	940	HbA1c	T116,T123	C0017853
27943546	941	950	reduction	T061	C0441610
27943546	956	964	baseline	T081	C1442488
27943546	970	982	vildagliptin	T109,T121	C1570906
27943546	1006	1012	racial	T098	C0034510
27943546	1015	1031	ethnic subgroups	T098	C0015031
27943546	1068	1085	Placebo-corrected	T078	C0032041
27943546	1086	1091	HbA1c	T116,T123	C0017853
27943546	1092	1101	reduction	T061	C0441610
27943546	1122	1131	Caucasian	T098	C0043157
27943546	1153	1158	Asian	T098	C0078988
27943546	1176	1184	patients	T101	C0030705
27943546	1230	1234	race	T098	C0034510
27943546	1239	1248	ethnicity	T098	C0015031
27943546	1263	1271	efficacy	T080	C1280519
27943546	1285	1293	Japanese	T098	C1556094
27943546	1294	1302	patients	T101	C0030705
27943546	1304	1312	Japanese	T098	C1556094
27943546	1313	1321	patients	T101	C0030705
27943546	1342	1354	treated with	T061	C0332293
27943546	1364	1368	oral	T030	C0226896
27943546	1369	1387	anti-diabetes drug	T121	C1254351
27943546	1421	1428	placebo	T122	C1696465
27943546	1430	1436	Weight	T032	C0005910
27943546	1437	1447	neutrality	T078	C0680444
27943546	1451	1463	vildagliptin	T109,T121	C1570906
27943546	1488	1494	groups	T098	C1257890
27943546	1532	1552	Hypoglycaemic events	T047	C0342312
27943546	1581	1597	ethnic subgroups	T098	C0015031
27943546	1603	1612	glycaemic	T109	C0005802
27943546	1613	1621	efficacy	T080	C1280519
27943546	1625	1637	vildagliptin	T109,T121	C1570906
27943546	1653	1662	Caucasian	T098	C0043157
27943546	1667	1672	Asian	T098	C0078988
27943546	1673	1681	patients	T101	C0030705
27943546	1703	1711	efficacy	T080	C1280519
27943546	1724	1732	Japanese	T098	C1556094
27943546	1733	1741	patients	T101	C0030705
27943546	1771	1785	placebo effect	T078	C0032041
27943546	1835	1843	diabetes	T047	C0011847
27943546	1862	1871	subgroups	T098	C1257890

27975020|t|Divided and Sliding Superficial Temporal Artery Flap for Primary Donor-site Closure
27975020|a|Superficial temporal artery (STA) flaps are often used for reconstruction of hair-bearing areas. However, primary closure of the donor site is not easy when the size of the necessary skin island is relatively large. In such cases, skin grafts are needed at the donor site, resulting in baldness. We have solved this issue by applying the divided and sliding flap technique, which was first reported for primary donor-site closure of a latissimus dorsi musculocutaneous flap. We applied this technique to the hair-bearing STA flap, where primary donor-site closure is extremely beneficial for preventing baldness consequent to skin grafting. The STA flap was divided into 3, and creation of large flap was possible. Therefore, we concluded that the divided and sliding STA flap could at least partially solve the donor-site problem. Although further investigation is necessary to validate the maximum possible flap size, this technique may be applicable to at least small defects that are common after skin cancer ablation or trauma.
27975020	0	7	Divided	T169	C0332849
27975020	12	19	Sliding	T169	C0332246
27975020	20	47	Superficial Temporal Artery	T023	C0226130
27975020	48	52	Flap	T023	C0038925
27975020	57	64	Primary	T080	C0205225
27975020	65	75	Donor-site	T029	C1444716
27975020	76	83	Closure	T061	C0185003
27975020	84	111	Superficial temporal artery	T023	C0226130
27975020	113	116	STA	T023	C0226130
27975020	118	123	flaps	T023	C0038925
27975020	143	157	reconstruction	T061	C0524865
27975020	161	179	hair-bearing areas	T029	C0005898
27975020	190	205	primary closure	T061	C0441503
27975020	213	223	donor site	T029	C1444716
27975020	245	249	size	T082	C0456389
27975020	267	278	skin island	T022	C1123023
27975020	293	298	large	T081	C0549177
27975020	315	326	skin grafts	T023	C0040748
27975020	345	355	donor site	T029	C1444716
27975020	370	378	baldness	T047	C0002170
27975020	422	429	divided	T169	C0332849
27975020	434	441	sliding	T169	C0332246
27975020	442	446	flap	T023	C0038925
27975020	447	456	technique	T169	C0449851
27975020	487	513	primary donor-site closure	T061	C0441503
27975020	519	552	latissimus dorsi musculocutaneous	T023	C0224362
27975020	553	557	flap	T023	C0038925
27975020	575	584	technique	T169	C0449851
27975020	592	608	hair-bearing STA	T023	C0226130
27975020	609	613	flap	T023	C0038925
27975020	621	647	primary donor-site closure	T061	C0441503
27975020	676	686	preventing	T080	C2700409
27975020	687	695	baldness	T047	C0002170
27975020	710	723	skin grafting	T061	C0037297
27975020	729	732	STA	T023	C0226130
27975020	733	737	flap	T023	C0038925
27975020	742	749	divided	T169	C0332849
27975020	762	770	creation	T052	C1706214
27975020	780	784	flap	T023	C0038925
27975020	832	839	divided	T169	C0332849
27975020	844	851	sliding	T169	C0332246
27975020	852	855	STA	T023	C0226130
27975020	856	860	flap	T023	C0038925
27975020	896	906	donor-site	T029	C1444716
27975020	907	914	problem	T033	C0033213
27975020	933	946	investigation	T058	C0220825
27975020	963	971	validate	T062	C1519941
27975020	976	983	maximum	T081	C0806909
27975020	984	992	possible	T033	C0332149
27975020	993	997	flap	T023	C0038925
27975020	998	1002	size	T082	C0456389
27975020	1009	1018	technique	T169	C0449851
27975020	1049	1054	small	T081	C0700321
27975020	1055	1062	defects	T169	C0243067
27975020	1085	1096	skin cancer	T191	C0007114
27975020	1097	1105	ablation	T061	C0547070
27975020	1109	1115	trauma	T037	C3714660

27682280|t|Avulsions of Triceps Brachii: associated injuries and surgical treatment; a case series
27682280|a|This study reports the clinical presentations, intra -operative findings, type of the treatments, outcome of the treatment and specially associated injuries in patients with the avulsion of the distal end of the triceps brachii (TB) tendon. We studied 6 patients with rupture or avulsion of the distal end of the TB tendon. The medical records, imaging files, clinical outcomes at the final follow up visit were reviewed. The clinical outcomes were assessed by Mayo Elbow Score at the final follow-up visit. All patients were male, 4 of them having injury in the left hand as the non-dominant hand. Mean age of them was 34.5 years. All cases had small bony fleck in the posterior of elbow in lateral radiograph. Three patients had associated injuries -including intra-articular fractures and medial collateral ligament rupture. In one case V-Y plasty of the distal TB was done. In 4 patients the results of surgery were excellent, one was good and one was fair. Although TB tendon rupture is rare, it should be -considered in differential diagnosis of the upper -extremity trauma and its associated injuries should be addressed properly.
27682280	0	9	Avulsions	T037	C0262386
27682280	13	28	Triceps Brachii	T023	C0559502
27682280	41	49	injuries	T037	C3263722
27682280	54	72	surgical treatment	T061	C0543467
27682280	93	98	study	T062	C2603343
27682280	111	133	clinical presentations	T170	C2708283
27682280	135	151	intra -operative	T079	C0456904
27682280	152	160	findings	T033	C0243095
27682280	174	184	treatments	T061	C0087111
27682280	186	193	outcome	T169	C1274040
27682280	201	210	treatment	T061	C0087111
27682280	236	244	injuries	T037	C3263722
27682280	248	256	patients	T101	C0030705
27682280	266	274	avulsion	T037	C0262386
27682280	282	292	distal end	T082	C0205108
27682280	300	327	triceps brachii (TB) tendon	T023	C0448542
27682280	342	350	patients	T101	C0030705
27682280	356	363	rupture	T037	C3203359
27682280	367	375	avulsion	T037	C0262386
27682280	383	393	distal end	T082	C0205108
27682280	401	410	TB tendon	T023	C0448542
27682280	416	431	medical records	T170	C0025102
27682280	433	446	imaging files	T170	C0242193
27682280	448	456	clinical	T080	C0205210
27682280	457	465	outcomes	T169	C1274040
27682280	479	494	follow up visit	T058	C0589121
27682280	514	522	clinical	T080	C0205210
27682280	523	531	outcomes	T169	C1274040
27682280	549	565	Mayo Elbow Score	T170	C0282574
27682280	579	594	follow-up visit	T058	C0589121
27682280	600	608	patients	T101	C0030705
27682280	614	618	male	T032	C0086582
27682280	637	643	injury	T037	C3263722
27682280	651	660	left hand	T023	C0230371
27682280	681	685	hand	T023	C0018563
27682280	692	695	age	T032	C0001779
27682280	713	718	years	T079	C0439234
27682280	740	744	bony	T169	C0443157
27682280	745	750	fleck	T037	C0009938
27682280	771	776	elbow	T029	C0013769
27682280	780	798	lateral radiograph	T060	C0202571
27682280	806	814	patients	T101	C0030705
27682280	830	838	injuries	T037	C3263722
27682280	850	865	intra-articular	T082	C0442108
27682280	866	875	fractures	T037	C0016658
27682280	880	914	medial collateral ligament rupture	T037	C0840716
27682280	928	938	V-Y plasty	T061	C0087111
27682280	946	952	distal	T082	C0205108
27682280	953	955	TB	T023	C0559502
27682280	971	979	patients	T101	C0030705
27682280	995	1002	surgery	T061	C0543467
27682280	1059	1068	TB tendon	T023	C0448542
27682280	1069	1076	rupture	T037	C3203359
27682280	1127	1136	diagnosis	T062	C1704656
27682280	1144	1167	upper -extremity trauma	UnknownType	C0749817
27682280	1187	1195	injuries	T037	C3263722

28042065|t|Civil Society -Driven Drug Policy Reform for Health and Human Welfare - India
28042065|a|The lack of adequate access to opioids in India as analgesics and for agonist therapies, forces millions to live with severe unalleviated pain, or languish with suffering associated with drug dependence. Although India is a major opium exporter, the excessively prohibitive 1985 narcotics law formulated to control harmful use of drugs, impeded the availability and access to opioids for medical and scientific purposes. Amendment of this law in 2014 established a new national regulatory framework for improved access to essential opioid analgesics. This article reflects on key elements and processes that led to this landmark achievement. Unlike quick timelines associated with effecting policy reforms for law enforcement, realizing the 2014 drug policy change primarily to mitigate human suffering, was a 22-year-long process. The most exacting challenges included recognizing the multilayered complexities of the prior policy framework and understanding their adverse impact on field practices to chart an appropriate and viable path for reform. The evolution of an informal civil society movement involving health care professionals, lawyers, media, policy analysts, government officials, and the public was pivotal in addressing these challenges and garnering momentum for reform. The success of the effort for improving access to opioid medications was underpinned by a three-pronged strategy of 1) persuading the executive arm of the government to take interim enabling measures; 2) leveraging judicial intervention through public interest litigation; and 3) crafting a viable policy document for legislative approval and implementation. We hope our findings are useful for realizing drug policy reforms, given the current transformed global policy mandates emphasizing humanitarian, healthcare, and quality-of-life considerations.
28042065	0	13	Civil Society	UnknownType	C0680324
28042065	22	40	Drug Policy Reform	UnknownType	C0815220
28042065	45	51	Health	T078	C0018684
28042065	56	69	Human Welfare	T095	C0037440
28042065	72	77	India	T083	C0021201
28042065	82	86	lack	T080	C0332268
28042065	90	98	adequate	T080	C0205411
28042065	109	116	opioids	T109,T121,T131	C0242402
28042065	120	125	India	T083	C0021201
28042065	129	139	analgesics	T109,T121,T131	C0002771
28042065	148	155	agonist	T121	C2987634
28042065	156	165	therapies	T061	C0087111
28042065	196	202	severe	T080	C0205082
28042065	203	220	unalleviated pain	T184	C0030193
28042065	225	233	languish	T080	C1762617
28042065	239	248	suffering	T048	C0683278
28042065	265	280	drug dependence	T048	C1510472
28042065	291	296	India	T083	C0021201
28042065	308	313	opium	T109,T121	C0029112
28042065	314	322	exporter	T097	C0402574
28042065	340	351	prohibitive	T054	C0683610
28042065	357	370	narcotics law	T089	C0027413
28042065	385	392	control	T080	C0243148
28042065	393	413	harmful use of drugs	T048	C0013146
28042065	427	439	availability	T169	C0470187
28042065	444	450	access	T082	C0444454
28042065	454	461	opioids	T109,T121,T131	C0242402
28042065	466	473	medical	UnknownType	C0678312
28042065	478	488	scientific	T062	C0683933
28042065	489	497	purposes	T169	C1285529
28042065	499	508	Amendment	T170	C0680532
28042065	517	520	law	T170	C1947938
28042065	547	576	national regulatory framework	T089	C0220868
28042065	590	596	access	T082	C0444454
28042065	600	609	essential	T080	C0205224
28042065	610	627	opioid analgesics	T109,T121	C0002772
28042065	707	718	achievement	T053	C0001072
28042065	769	783	policy reforms	UnknownType	C0815220
28042065	788	803	law enforcement	T064	C0162469
28042065	824	835	drug policy	UnknownType	C0683727
28042065	856	864	mitigate	T067	C1553901
28042065	865	881	human suffering,	T048	C0683278
28042065	964	989	multilayered complexities	T033	C0037431
28042065	1003	1019	policy framework	T170	C0242456
28042065	1044	1051	adverse	T080	C0205169
28042065	1052	1058	impact	UnknownType	C0814716
28042065	1122	1128	reform	T064	C0206597
28042065	1159	1181	civil society movement	T054	C0680411
28042065	1192	1217	health care professionals	T097	C1704312
28042065	1219	1226	lawyers	T097	C0086530
28042065	1228	1233	media	T097	C4054555
28042065	1235	1250	policy analysts	T097	C0870132
28042065	1252	1272	government officials	T097	C0242304
28042065	1282	1288	public	T098	C0034035
28042065	1321	1331	challenges	T058	C0805586
28042065	1359	1365	reform	UnknownType	C0680438
28042065	1371	1378	success	T054	C0597535
28042065	1407	1413	access	T080	C0018748
28042065	1417	1423	opioid	T109,T121,T131	C0242402
28042065	1424	1435	medications	T058	C0150270
28042065	1501	1532	executive arm of the government	T097	C0335161
28042065	1541	1548	interim	T079	C2827738
28042065	1558	1566	measures	T170	C0033107
28042065	1582	1603	judicial intervention	T064	C0178362
28042065	1612	1618	public	T098	C0034035
28042065	1619	1627	interest	T098	C0021729
28042065	1628	1638	litigation	T068	C0079706
28042065	1647	1680	crafting a viable policy document	T064	C0242440
28042065	1685	1705	legislative approval	T064	C0680796
28042065	1710	1724	implementation	T052	C1708476
28042065	1772	1791	drug policy reforms	UnknownType	C0683727
28042065	1823	1829	global	T080	C2348867
28042065	1830	1836	policy	T170	C0242456
28042065	1837	1845	mandates	UnknownType	C0814715
28042065	1858	1870	humanitarian	T095	C0037440
28042065	1872	1882	healthcare	T058	C0086388
28042065	1888	1903	quality-of-life	T078	C0034380
28042065	1904	1918	considerations	T033	C0518609

28393819|t|Morphology of root canal surface: A reflection on the process of cementation of the composite relined glass fiber post
28393819|a|The present study was conducted to evaluate the bond strength in the different root thirds (premolars and maxillary central incisors) of composite relined glass fiber posts compared to untreated glass fiber posts cemented with dual- or chemical-cure cements. Sixty human single-rooted premolars (flat canal) (n = 15) and 12 maxillary central incisors were used (round canal) (n = 3). The teeth were sectioned, and the roots received endodontic treatment. The standardized preparation of the canals was carried out, and the roots were randomly divided into four groups according to the cementation systems: G1: cemented posts (dual: Ambar / Allcem); G2: relined posts (dual: Ambar / Allcem); G3: cemented posts (chemical: Fusion Duralink / Cement Post); and G4: relined posts (chemical: Fusion Duralink / Cement Post). The roots were cut to give two slices of each third of the root canal per specimen. Push-out test was conducted at a speed of 0.5 mm/min. Data were analyzed by analysis of variance and Tukey's post hoc test (α = 0.05). There was no statistically significant difference between groups for the premolars (flat canal) (P = 0.959). There was a significant difference in the central incisors between the middle and apical thirds in the cemented group when using the dual system (P = 0.04) and between the middle and apical thirds (P = 0.003) and cervical and apical thirds (P = 0.033) when using the chemical system. Due to the anatomy of the root canal, flat canal of the premolars does not require relining, but round canal of the maxillary central incisors demands it for more secure in the bond strength.
28393819	0	10	Morphology	T080	C0332437
28393819	14	32	root canal surface	T030	C0086881
28393819	65	76	cementation	T061	C0007656
28393819	84	93	composite	T122	C0009570
28393819	94	101	relined	T061	C0086121
28393819	102	113	glass fiber	T122,T131	C0060317
28393819	114	118	post	T122	C0449939
28393819	167	180	bond strength	T081	C0678599
28393819	198	209	root thirds	T023	C0040452
28393819	211	220	premolars	T023	C1704302
28393819	225	251	maxillary central incisors	T023	C0227042
28393819	256	265	composite	T122	C0009570
28393819	266	273	relined	T061	C0086121
28393819	274	285	glass fiber	T122,T131	C0060317
28393819	286	291	posts	T122	C0449939
28393819	314	325	glass fiber	T122,T131	C0060317
28393819	326	340	posts cemented	T074	C0450142
28393819	355	376	chemical-cure cements	T120	C0449920
28393819	384	389	human	T016	C0086418
28393819	390	403	single-rooted	T029	C0447368
28393819	404	413	premolars	T023	C1704302
28393819	415	425	flat canal	T030	C0086881
28393819	443	469	maxillary central incisors	T023	C0227042
28393819	481	492	round canal	T030	C0086881
28393819	507	512	teeth	T023	C0040426
28393819	518	527	sectioned	T061	C0185115
28393819	537	542	roots	T023	C0040452
28393819	552	572	endodontic treatment	T061	C0700632
28393819	591	616	preparation of the canals	T061	C0282543
28393819	642	647	roots	T023	C0040452
28393819	680	686	groups	T098	C1257890
28393819	704	715	cementation	T061	C0007656
28393819	729	743	cemented posts	T074	C0450142
28393819	751	756	Ambar	T109,T122	C4078139
28393819	759	765	Allcem	T122	C0005479
28393819	772	785	relined posts	T122	C0449939
28393819	793	798	Ambar	T109,T122	C4078139
28393819	801	807	Allcem	T122	C0005479
28393819	814	828	cemented posts	T074	C0450142
28393819	830	838	chemical	T103	C0220806
28393819	840	855	Fusion Duralink	T122	C0005479
28393819	858	869	Cement Post	T074	C0450142
28393819	880	893	relined posts	T122	C0449939
28393819	895	903	chemical	T103	C0220806
28393819	905	920	Fusion Duralink	T122	C0005479
28393819	923	934	Cement Post	T074	C0450142
28393819	941	946	roots	T023	C0040452
28393819	968	974	slices	T167	C1519355
28393819	996	1006	root canal	T030	C0086881
28393819	1011	1019	specimen	T167	C0370003
28393819	1021	1034	Push-out test	T059	C0022885
28393819	1097	1117	analysis of variance	T081	C0002780
28393819	1122	1143	Tukey's post hoc test	T059	C0022885
28393819	1183	1205	significant difference	T080	C1705242
28393819	1214	1220	groups	T098	C1257890
28393819	1229	1238	premolars	T023	C1704302
28393819	1240	1250	flat canal	T030	C0086881
28393819	1307	1323	central incisors	T023	C1541679
28393819	1336	1342	middle	T029	C0447381
28393819	1347	1360	apical thirds	T029	C2004463
28393819	1368	1376	cemented	T061	C0007656
28393819	1377	1382	group	T098	C1257890
28393819	1437	1443	middle	T029	C0447381
28393819	1448	1461	apical thirds	T029	C2004463
28393819	1478	1486	cervical	T029	C0447355
28393819	1491	1504	apical thirds	T029	C2004463
28393819	1532	1547	chemical system	T059	C0201682
28393819	1560	1567	anatomy	T017	C0700276
28393819	1575	1585	root canal	T030	C0086881
28393819	1587	1597	flat canal	T030	C0086881
28393819	1605	1614	premolars	T023	C1704302
28393819	1632	1640	relining	T061	C0086121
28393819	1646	1657	round canal	T030	C0086881
28393819	1665	1691	maxillary central incisors	T023	C0227042
28393819	1726	1739	bond strength	T081	C0678599

27598153|t|Nicotine Suppressed Fetal Adrenal StAR Expression via YY1 Mediated- Histone Deacetylation Modification Mechanism
27598153|a|Steroidogenic acute regulatory (StAR) protein plays a pivotal role in steroidogenesis. Previously, we have demonstrated that prenatal nicotine exposure suppressed fetal adrenal steroidogenesis via steroidogenic factor 1 deacetylation. This study further explored the potential role of the transcriptional repressor Yin Yang 1 (YY1) in nicotine -mediated StAR inhibition. Nicotine was subcutaneously administered (1.0 mg/kg) to pregnant rats twice per day and NCI-H295A cells were treated with nicotine. StAR and YY1 expression were analyzed by real-time PCR, immunohistochemistry, and Western blotting. Histone modifications and the interactions between the YY1 and StAR promoter were assessed using chromatin immunoprecipitation (ChIP). Prenatal nicotine exposure increased YY1 expression and suppressed StAR expression. ChIP assay showed that there was a decreasing trend for histone acetylation at the StAR promoter in fetal adrenal glands, whereas H3 acetyl-K14 at the YY1 promoter presented an increasing trend following nicotine exposure. Furthermore, in nicotine - treated NCI-H295A cells, nicotine enhanced YY1 expression and inhibited StAR expression. ChIP assay showed that histone acetylation decreased at the StAR promoter in NCI-H295A cells and that the interaction between the YY1 and StAR promoter increased. These data indicated that YY1 -medicated histone deacetylation modification in StAR promoters might play an important role in the inhibitory effect of nicotine on StAR expression.
27598153	0	8	Nicotine	T109,T131	C0028040
27598153	9	19	Suppressed	T169	C1260953
27598153	20	33	Fetal Adrenal	T023	C0229565
27598153	34	38	StAR	T116	C0290758
27598153	39	49	Expression	T045	C1171362
27598153	54	57	YY1	T116,T123	C0903890
27598153	68	89	Histone Deacetylation	T044	C1156201
27598153	90	102	Modification	T169	C0392747
27598153	103	112	Mechanism	T169	C0441712
27598153	113	158	Steroidogenic acute regulatory (StAR) protein	T116	C0290758
27598153	183	198	steroidogenesis	T044	C0597513
27598153	238	246	prenatal	T079	C2828394
27598153	247	255	nicotine	T109,T131	C0028040
27598153	256	264	exposure	T080	C0332157
27598153	265	275	suppressed	T169	C1260953
27598153	276	289	fetal adrenal	T023	C0229565
27598153	290	305	steroidogenesis	T044	C0597513
27598153	310	332	steroidogenic factor 1	T116,T123	C0171961
27598153	333	346	deacetylation	T044	C1511737
27598153	402	427	transcriptional repressor	T116,T123	C1336789
27598153	428	438	Yin Yang 1	T116,T123	C0903890
27598153	440	443	YY1	T116,T123	C0903890
27598153	448	456	nicotine	T109,T131	C0028040
27598153	467	471	StAR	T116	C0290758
27598153	472	482	inhibition	T052	C3463820
27598153	484	492	Nicotine	T109,T131	C0028040
27598153	497	524	subcutaneously administered	T033	C1736929
27598153	540	548	pregnant	T040	C0032961
27598153	549	553	rats	T015	C0034721
27598153	572	587	NCI-H295A cells	T025	C0007634
27598153	593	600	treated	T169	C1522326
27598153	606	614	nicotine	T109,T131	C0028040
27598153	616	620	StAR	T116	C0290758
27598153	625	628	YY1	T116,T123	C0903890
27598153	629	639	expression	T045	C1171362
27598153	657	670	real-time PCR	T063	C1709846
27598153	672	692	immunohistochemistry	T060	C0021044
27598153	698	714	Western blotting	T059,T063	C0005863
27598153	716	737	Histone modifications	T044	C1156199
27598153	746	758	interactions	T169	C1704675
27598153	771	774	YY1	T116,T123	C0903890
27598153	779	792	StAR promoter	T028	C1420453
27598153	798	806	assessed	T052	C1516048
27598153	813	842	chromatin immunoprecipitation	T059	C1328856
27598153	844	848	ChIP	T059	C1328856
27598153	851	859	Prenatal	T079	C2828394
27598153	860	868	nicotine	T109,T131	C0028040
27598153	869	877	exposure	T080	C0332157
27598153	878	887	increased	T169	C0442808
27598153	888	891	YY1	T116,T123	C0903890
27598153	892	902	expression	T045	C1171362
27598153	907	917	suppressed	T169	C1260953
27598153	918	922	StAR	T116	C0290758
27598153	923	933	expression	T045	C1171362
27598153	935	939	ChIP	T059	C1328856
27598153	940	945	assay	T059	C1510438
27598153	970	980	decreasing	T033	C0442797
27598153	991	1010	histone acetylation	T044	C1156200
27598153	1018	1031	StAR promoter	T028	C1420453
27598153	1035	1055	fetal adrenal glands	T023	C0229565
27598153	1065	1078	H3 acetyl-K14	T044	C2752447
27598153	1086	1098	YY1 promoter	T028	C1421565
27598153	1112	1122	increasing	T169	C0442808
27598153	1139	1147	nicotine	T109,T131	C0028040
27598153	1148	1156	exposure	T080	C0332157
27598153	1174	1182	nicotine	T109,T131	C0028040
27598153	1185	1192	treated	T169	C1522326
27598153	1193	1208	NCI-H295A cells	T025	C0007634
27598153	1210	1218	nicotine	T109,T131	C0028040
27598153	1228	1231	YY1	T116,T123	C0903890
27598153	1232	1242	expression	T045	C1171362
27598153	1247	1256	inhibited	T052	C3463820
27598153	1257	1261	StAR	T116	C0290758
27598153	1262	1272	expression	T045	C1171362
27598153	1274	1278	ChIP	T059	C1328856
27598153	1279	1284	assay	T059	C1510438
27598153	1297	1316	histone acetylation	T044	C1156200
27598153	1317	1326	decreased	T033	C0442797
27598153	1334	1347	StAR promoter	T028	C1420453
27598153	1351	1366	NCI-H295A cells	T025	C0007634
27598153	1380	1391	interaction	T169	C1704675
27598153	1404	1407	YY1	T116,T123	C0903890
27598153	1412	1425	StAR promoter	T028	C1420453
27598153	1426	1435	increased	T169	C0442808
27598153	1463	1466	YY1	T116,T123	C0903890
27598153	1478	1499	histone deacetylation	T044	C1156201
27598153	1500	1512	modification	T169	C0392747
27598153	1516	1530	StAR promoters	T028	C1420453
27598153	1567	1584	inhibitory effect	T052	C3463820
27598153	1588	1596	nicotine	T109,T131	C0028040
27598153	1600	1604	StAR	T028	C1420453
27598153	1605	1615	expression	T045	C0017262

27384243|t|Conditional ablation of myeloid TNF increases lesion volume after experimental stroke in mice, possibly via altered ERK1/2 signaling
27384243|a|Microglia are activated following cerebral ischemia and increase their production of the neuro - and immunomodulatory cytokine tumor necrosis factor (TNF). To address the function of TNF from this cellular source in focal cerebral ischemia we used TNF conditional knock out mice (LysMcreTNF(fl/fl)) in which the TNF gene was deleted in cells of the myeloid lineage, including microglia. The deletion reduced secreted TNF levels in lipopolysaccharide -stimulated cultured primary microglia by ~93%. Furthermore, phosphorylated-ERK / ERK ratios were significantly decreased in naïve LysMcreTNF(fl/fl) mice demonstrating altered ERK signal transduction. Micro-PET using (18)[F]-fluorodeoxyglucose immediately after focal cerebral ischemia showed increased glucose uptake in LysMcreTNF(fl/fl) mice, representing significant metabolic changes, that translated into increased infarct volumes at 24 hours and 5 days compared to littermates (TNFfl/fl). In naïve LysMcreTNF(fl/fl) mice cytokine levels were low and comparable to littermates. At 6 hours, TNF producing microglia were reduced by 56% in the ischemic cortex in LysMcreTNF(fl/fl) mice compared to littermate mice, whereas no TNF(+) leukocytes were detected. At 24 hours, pro-inflammatory cytokine (TNF, IL-1β, IL-6, IL-5 and CXCL1) levels were significantly lower in LysMcreTNF(fl/fl) mice, despite comparable infiltrating leukocyte populations. Our results identify microglia l TNF as beneficial and neuroprotective in the acute phase and as a modulator of neuroinflammation at later time points after experimental ischemia, which may contribute to regenerative recovery.
27384243	12	20	ablation	T061	C0547070
27384243	24	31	myeloid	T080	C0439677
27384243	32	35	TNF	T116,T129	C0041368
27384243	46	52	lesion	T033	C0221198
27384243	53	59	volume	T081	C0449468
27384243	66	93	experimental stroke in mice	T050	C0012644
27384243	116	132	ERK1/2 signaling	T044	C2611831
27384243	133	142	Microglia	T025	C0206116
27384243	167	184	cerebral ischemia	T047	C0917798
27384243	222	227	neuro	T123	C0949370
27384243	234	250	immunomodulatory	T121,T129	C0005525
27384243	251	259	cytokine	T116,T129	C0079189
27384243	260	281	tumor necrosis factor	T116,T129	C0041368
27384243	283	286	TNF	T116,T129	C0041368
27384243	304	312	function	T169	C0542341
27384243	316	319	TNF	T116,T129	C0041368
27384243	330	345	cellular source	T033	C0449416
27384243	349	372	focal cerebral ischemia	T047	C0917798
27384243	381	384	TNF	T116,T129	C0041368
27384243	397	431	knock out mice (LysMcreTNF(fl/fl))	T015	C0206745
27384243	445	453	TNF gene	T028	C0812246
27384243	458	465	deleted	T052	C1880274
27384243	469	474	cells	T025	C0007634
27384243	482	497	myeloid lineage	T078	C0282637
27384243	509	518	microglia	T025	C0206116
27384243	524	532	deletion	T045	C0017260
27384243	550	553	TNF	T116,T129	C0041368
27384243	554	560	levels	T080	C0441889
27384243	564	582	lipopolysaccharide	T109	C0023810
27384243	595	621	cultured primary microglia	T025	C0007635
27384243	644	662	phosphorylated-ERK	T116,T126	C0752312
27384243	665	668	ERK	T116,T126	C0752312
27384243	669	675	ratios	T081	C0456603
27384243	708	736	naïve LysMcreTNF(fl/fl) mice	T015	C0026809
27384243	759	762	ERK	T116,T126	C0752312
27384243	763	782	signal transduction	T043	C0037083
27384243	784	793	Micro-PET	T060	C0032743
27384243	800	826	(18)[F]-fluorodeoxyglucose	T109,T130	C0046056
27384243	845	868	focal cerebral ischemia	T047	C0917798
27384243	886	900	glucose uptake	T043	C1159527
27384243	904	926	LysMcreTNF(fl/fl) mice	T015	C0026809
27384243	953	962	metabolic	T040	C0025519
27384243	963	970	changes	T169	C0392747
27384243	1003	1010	infarct	T046	C0021308
27384243	1011	1018	volumes	T081	C0449468
27384243	1037	1041	days	T079	C0439228
27384243	1054	1076	littermates (TNFfl/fl)	T015	C0026809
27384243	1081	1109	naïve LysMcreTNF(fl/fl) mice	T015	C0026809
27384243	1110	1118	cytokine	T116,T129	C0079189
27384243	1119	1125	levels	T080	C0441889
27384243	1153	1164	littermates	T015	C0026809
27384243	1178	1181	TNF	T116,T129	C0041368
27384243	1192	1201	microglia	T025	C0206116
27384243	1229	1244	ischemic cortex	T046	C0022116
27384243	1248	1270	LysMcreTNF(fl/fl) mice	T015	C0026809
27384243	1283	1298	littermate mice	T015	C0026809
27384243	1311	1317	TNF(+)	T028	C0812246
27384243	1318	1328	leukocytes	T025	C0023516
27384243	1357	1382	pro-inflammatory cytokine	T116,T129	C0079189
27384243	1384	1387	TNF	T116,T129	C0041368
27384243	1389	1394	IL-1β	T116,T129	C0021753
27384243	1396	1400	IL-6	T116,T129	C0021760
27384243	1402	1406	IL-5	T116,T129	C0021759
27384243	1411	1416	CXCL1	T116,T123	C0635817
27384243	1418	1424	levels	T080	C0441889
27384243	1453	1475	LysMcreTNF(fl/fl) mice	T015	C0026809
27384243	1509	1530	leukocyte populations	T025	C0023516
27384243	1553	1562	microglia	T025	C0206116
27384243	1565	1568	TNF	T116,T129	C0041368
27384243	1587	1602	neuroprotective	T169	C0815279
27384243	1610	1621	acute phase	T079	C0439557
27384243	1644	1661	neuroinflammation	T046	C0021368
27384243	1702	1710	ischemia	T046	C0022116
27384243	1736	1757	regenerative recovery	T040	C2004454

27692274|t|Sleep characteristics in type 1 diabetes and associations with glycemic control: systematic review and meta-analysis
27692274|a|The association between inadequate sleep and type 2 diabetes has garnered much attention, but little is known about sleep and type 1 diabetes (T1D). Our objectives were to conduct a systematic review and meta-analysis comparing sleep in persons with and without T1D, and to explore relationships between sleep and glycemic control in T1D. Studies were identified from Medline and Scopus. Studies reporting measures of sleep in T1D patients and controls, and/or associations between sleep and glycemic control, were selected. A total of 22 studies were eligible for the meta-analysis. Children with T1D had shorter sleep duration (mean difference [MD] = -26.4 minutes; 95% confidence interval [CI] = -35.4, -17.7) than controls. Adults with T1D reported poorer sleep quality (MD in standardized sleep quality score = 0.51; 95% CI = 0.33, 0.70), with higher scores reflecting worse sleep quality) than controls, but there was no difference in self - reported sleep duration. Adults with TID who reported sleeping >6 hours had lower hemoglobin A1c (HbA1c) levels than those sleeping ≤6 hours (MD = -0.24%; 95% CI = -0.47, -0.02), and participants reporting good sleep quality had lower HbA1c than those with poor sleep quality (MD = -0.19%; 95% CI = -0.30, -0.08). The estimated prevalence of obstructive sleep apnea (OSA) in adults with TID was 51.9% (95% CI = 31.2, 72.6). Patients with moderate-to-severe OSA had a trend toward higher HbA1c (MD = 0.39%, 95% CI = -0.08, 0.87). T1D was associated with poorer sleep and high prevalence of OSA. Poor sleep quality, shorter sleep duration, and OSA were associated with suboptimal glycemic control in T1D patients.
27692274	0	5	Sleep	T040	C0037313
27692274	6	21	characteristics	T080	C1521970
27692274	25	40	type 1 diabetes	T047	C0011854
27692274	45	57	associations	T080	C0439849
27692274	63	79	glycemic control	T061	C1638311
27692274	81	98	systematic review	T170	C1955832
27692274	103	116	meta-analysis	T062	C0920317
27692274	121	132	association	T080	C0439849
27692274	141	157	inadequate sleep	T033	C1822020
27692274	162	177	type 2 diabetes	T047	C0011860
27692274	221	226	known	T080	C0205309
27692274	233	238	sleep	T040	C0037313
27692274	243	258	type 1 diabetes	T047	C0011854
27692274	260	263	T1D	T047	C0011854
27692274	270	280	objectives	T078	C2985627
27692274	299	316	systematic review	T170	C1955832
27692274	321	334	meta-analysis	T062	C0920317
27692274	335	344	comparing	T052	C1707455
27692274	345	350	sleep	T040	C0037313
27692274	354	361	persons	T098	C0027361
27692274	379	382	T1D	T047	C0011854
27692274	399	412	relationships	T080	C0439849
27692274	421	426	sleep	T040	C0037313
27692274	431	447	glycemic control	T061	C1638311
27692274	451	454	T1D	T047	C0011854
27692274	456	463	Studies	T062	C2603343
27692274	469	479	identified	T080	C0205396
27692274	485	492	Medline	T170	C0025141
27692274	497	503	Scopus	T170	C0282574
27692274	505	512	Studies	T062	C2603343
27692274	513	522	reporting	T062	C0011000
27692274	523	531	measures	T081	C0079809
27692274	535	540	sleep	T040	C0037313
27692274	544	547	T1D	T047	C0011854
27692274	548	556	patients	T101	C0030705
27692274	561	569	controls	T096	C0009932
27692274	578	590	associations	T080	C0439849
27692274	599	604	sleep	T040	C0037313
27692274	609	625	glycemic control	T061	C1638311
27692274	632	640	selected	T052	C1707391
27692274	656	663	studies	T062	C2603343
27692274	669	677	eligible	T080	C1548635
27692274	686	699	meta-analysis	T062	C0920317
27692274	701	709	Children	T100	C0008059
27692274	715	718	T1D	T047	C0011854
27692274	723	745	shorter sleep duration	T033	C0424574
27692274	747	762	mean difference	T081	C0392762
27692274	764	766	MD	T081	C0392762
27692274	776	783	minutes	T079	C0439232
27692274	789	808	confidence interval	T081	C0009667
27692274	810	812	CI	T081	C0009667
27692274	835	843	controls	T096	C0009932
27692274	845	851	Adults	T100	C0001675
27692274	857	860	T1D	T047	C0011854
27692274	861	869	reported	T169	C0205245
27692274	870	890	poorer sleep quality	T046	C1262141
27692274	892	894	MD	T081	C0392762
27692274	898	910	standardized	T080	C1442989
27692274	911	924	sleep quality	T033	C0424563
27692274	925	930	score	T081	C0449820
27692274	943	945	CI	T081	C0009667
27692274	966	972	higher	T080	C0205250
27692274	973	979	scores	T081	C0449820
27692274	991	996	worse	T033	C1457868
27692274	997	1010	sleep quality	T033	C0424563
27692274	1017	1025	controls	T096	C0009932
27692274	1041	1054	no difference	T033	C3842396
27692274	1058	1062	self	T078	C0036588
27692274	1065	1073	reported	T169	C0205245
27692274	1074	1088	sleep duration	T033	C0424574
27692274	1090	1096	Adults	T100	C0001675
27692274	1102	1105	TID	T047	C0011854
27692274	1110	1118	reported	T169	C0205245
27692274	1119	1127	sleeping	T040	C0037313
27692274	1131	1136	hours	T079	C0439227
27692274	1141	1146	lower	T052	C2003888
27692274	1147	1176	hemoglobin A1c (HbA1c) levels	T059	C0474680
27692274	1188	1196	sleeping	T040	C0037313
27692274	1200	1205	hours	T079	C0439227
27692274	1207	1209	MD	T081	C0392762
27692274	1224	1226	CI	T081	C0009667
27692274	1248	1260	participants	T098	C0679646
27692274	1271	1275	good	T080	C0205170
27692274	1276	1289	sleep quality	T033	C0424563
27692274	1294	1299	lower	T052	C2003888
27692274	1300	1305	HbA1c	T116,T123	C0019018
27692274	1322	1340	poor sleep quality	T046	C1262141
27692274	1342	1344	MD	T081	C0392762
27692274	1359	1361	CI	T081	C0009667
27692274	1383	1392	estimated	T081	C0750572
27692274	1393	1403	prevalence	T081	C0033105
27692274	1407	1446	obstructive sleep apnea (OSA) in adults	T047	C3472696
27692274	1452	1455	TID	T047	C0011854
27692274	1471	1473	CI	T081	C0009667
27692274	1489	1497	Patients	T101	C0030705
27692274	1503	1521	moderate-to-severe	T080	C1299393
27692274	1522	1525	OSA	T047	C0520679
27692274	1532	1537	trend	T079	C1521798
27692274	1545	1557	higher HbA1c	T033	C2919483
27692274	1559	1561	MD	T081	C0392762
27692274	1575	1577	CI	T081	C0009667
27692274	1594	1597	T1D	T047	C0011854
27692274	1602	1617	associated with	T080	C0332281
27692274	1618	1630	poorer sleep	T046	C1262141
27692274	1635	1650	high prevalence	T081	C1512456
27692274	1654	1657	OSA	T047	C0520679
27692274	1659	1677	Poor sleep quality	T046	C1262141
27692274	1679	1686	shorter	T080	C1282927
27692274	1687	1701	sleep duration	T033	C0424574
27692274	1707	1710	OSA	T047	C0520679
27692274	1716	1731	associated with	T080	C0332281
27692274	1732	1742	suboptimal	T080	C2984009
27692274	1743	1759	glycemic control	T061	C1638311
27692274	1763	1766	T1D	T047	C0011854
27692274	1767	1775	patients	T101	C0030705

28538990|t|Measuring nonlinear signal combination using EEG
28538990|a|Relatively little is known about the processes, both linear and nonlinear, by which signals are combined beyond V1. By presenting two stimulus components simultaneously, flickering at different temporal frequencies (frequency tagging) while measuring steady-state visual evoked potentials, we can assess responses to the individual components, including direct measurements of suppression on each other, and various nonlinear responses to their combination found at intermodulation frequencies. The result is a rather rich dataset of frequencies at which responses can be found. We presented pairs of sinusoidal gratings at different temporal frequencies, forming plaid patterns that were " coherent " (looking like a checkerboar d) and " noncoherent " (looking like a pair of transparently overlaid gratings), and found clear intermodulation responses to compound stimuli, indicating nonlinear summation. This might have been attributed to cross-orientation suppression except that the pattern of intermodulation responses differed for coherent and noncoherent patterns, whereas the effects of suppression (measured at the component frequencies) did not. A two-stage model of nonlinear summation involving conjunction detection with a logical AND gate described the data well, capturing the difference between coherent and noncoherent plaids over a wide array of possible response frequencies. Multistimulus frequency -tagged EEG in combination with computational modeling may be a very valuable tool in studying the conjunction of these signals. In the current study the results suggest a second-order mechanism responding selectively to coherent plaid patterns.
28538990	0	9	Measuring	T080	C0444706
28538990	10	19	nonlinear	T080	C0205556
28538990	20	26	signal	T067	C1710082
28538990	27	38	combination	T080	C0205195
28538990	45	48	EEG	T060	C0013819
28538990	49	59	Relatively	T080	C0205345
28538990	86	95	processes	T067	C1522240
28538990	102	108	linear	T082	C0205132
28538990	113	122	nonlinear	T080	C0205556
28538990	133	140	signals	T067	C1710082
28538990	145	153	combined	T080	C0205195
28538990	161	163	V1	T029	C0038446
28538990	183	191	stimulus	T067	C0234402
28538990	192	202	components	T077	C1705248
28538990	203	217	simultaneously	T079	C0521115
28538990	219	229	flickering	T033	C0243095
28538990	233	242	different	T080	C1705242
28538990	243	263	temporal frequencies	T079	C0871500
28538990	265	274	frequency	T081	C0871396
28538990	275	282	tagging	T074	C0183825
28538990	290	299	measuring	T080	C0444706
28538990	300	312	steady-state	T070	C0678587
28538990	313	337	visual evoked potentials	T042	C0015217
28538990	346	352	assess	T058	C0184514
28538990	353	362	responses	T032	C0871261
28538990	381	391	components	T077	C1705248
28538990	403	409	direct	T080	C1947931
28538990	410	422	measurements	T169	C0242485
28538990	426	437	suppression	T046	C0221103
28538990	465	474	nonlinear	T080	C0205556
28538990	475	484	responses	T032	C0871261
28538990	494	505	combination	T080	C0205195
28538990	515	530	intermodulation	T080	C0205556
28538990	531	542	frequencies	T081	C0871396
28538990	548	554	result	T034	C0456984
28538990	572	579	dataset	T170	C0150098
28538990	583	594	frequencies	T081	C0871396
28538990	604	613	responses	T032	C0871261
28538990	641	646	pairs	T080	C1709450
28538990	650	669	sinusoidal gratings	T082	C1254362
28538990	673	682	different	T080	C1705242
28538990	683	703	temporal frequencies	T079	C0871500
28538990	713	727	plaid patterns	T033	C0243095
28538990	740	748	coherent	T033	C4068804
28538990	752	778	looking like a checkerboar	T082	C0456340
28538990	788	799	noncoherent	T033	C0243095
28538990	818	822	pair	T080	C1709450
28538990	826	839	transparently	T080	C0522503
28538990	840	857	overlaid gratings	T082	C0456341
28538990	876	891	intermodulation	T080	C0205556
28538990	892	901	responses	T032	C0871261
28538990	905	913	compound	T080	C0205198
28538990	914	921	stimuli	T067	C0234402
28538990	934	943	nonlinear	T080	C0205556
28538990	944	953	summation	T042	C0234109
28538990	990	1007	cross-orientation	T082	C1704322
28538990	1008	1019	suppression	T046	C0221103
28538990	1036	1043	pattern	T082	C0449774
28538990	1047	1062	intermodulation	T080	C0205556
28538990	1063	1072	responses	T032	C0871261
28538990	1073	1081	differed	T080	C0205556
28538990	1086	1094	coherent	T033	C4068804
28538990	1099	1110	noncoherent	T033	C0243095
28538990	1111	1119	patterns	T082	C0449774
28538990	1133	1143	effects of	T080	C1704420
28538990	1144	1155	suppression	T046	C0221103
28538990	1173	1182	component	T077	C1705248
28538990	1183	1194	frequencies	T081	C0871396
28538990	1207	1222	two-stage model	T170	C3161035
28538990	1226	1235	nonlinear	T080	C0205556
28538990	1236	1245	summation	T042	C0234109
28538990	1256	1267	conjunction	T078	C2699427
28538990	1268	1277	detection	T061	C1511790
28538990	1285	1292	logical	T077	C1705253
28538990	1293	1301	AND gate	T170	C0282574
28538990	1316	1320	data	T078	C1511726
28538990	1341	1351	difference	T081	C1705241
28538990	1360	1368	coherent	T033	C4068804
28538990	1373	1384	noncoherent	T033	C0243095
28538990	1385	1391	plaids	T082	C1254362
28538990	1404	1409	array	T082	C1510941
28538990	1413	1421	possible	T033	C0332149
28538990	1422	1442	response frequencies	T079	C0237629
28538990	1444	1457	Multistimulus	T080	C0205556
28538990	1458	1467	frequency	T081	C0871396
28538990	1476	1479	EEG	T060	C0013819
28538990	1483	1494	combination	T080	C0205195
28538990	1500	1522	computational modeling	T066	C3850009
28538990	1567	1578	conjunction	T078	C2699427
28538990	1588	1595	signals	T067	C1710082
28538990	1612	1617	study	T062	C2603343
28538990	1622	1629	results	T034	C0456984
28538990	1640	1662	second-order mechanism	T042	C0597439
28538990	1674	1685	selectively	T080	C0205556
28538990	1689	1697	coherent	T033	C4068804
28538990	1698	1712	plaid patterns	T033	C0243095

28524704|t|Radiation from wireless technology elevates blood glucose and body temperature in 40-year-old type 1 diabetic male
28524704|a|A type 1 diabetic male reports multiple instances when his blood glucose was dramatically elevated by the presence of microwave radiation from wireless technology and plummeted when the radiation exposure ended. In one instance, his body temperature elevated in addition to his blood glucose. Both remained elevated for nearly 48 h after exposure with the effect gradually decreasing. Possible mechanisms for microwave radiation elevating blood glucose include effects on glucose transport proteins and ion channels, insulin conformational changes and oxidative stress. Temperature elevation may be caused by microwave radiation - triggered Ca (2+) efflux, a mechanism similar to malignant hyperthermia. The potential for radiation from wireless technology to cause serious biological effects has important implications and necessitates a reevaluation of its near-ubiquitous presence, especially in hospitals and medical facilities.
28524704	0	9	Radiation	T070	C0851346
28524704	15	34	wireless technology	T073	C1520154
28524704	35	43	elevates	T080	C3163633
28524704	44	57	blood glucose	T109	C0005802
28524704	62	78	body temperature	T032	C0005903
28524704	94	109	type 1 diabetic	T047	C0011854
28524704	110	114	male	T032	C0086582
28524704	117	132	type 1 diabetic	T047	C0011854
28524704	133	137	male	T032	C0086582
28524704	174	187	blood glucose	T109	C0005802
28524704	205	213	elevated	T080	C3163633
28524704	221	229	presence	T080	C3854307
28524704	233	252	microwave radiation	T070	C0026051
28524704	258	277	wireless technology	T073	C1520154
28524704	301	319	radiation exposure	T037	C0015333
28524704	348	364	body temperature	T032	C0005903
28524704	365	373	elevated	T080	C3163633
28524704	393	406	blood glucose	T109	C0005802
28524704	422	430	elevated	T080	C3163633
28524704	453	461	exposure	T080	C0332157
28524704	488	498	decreasing	T033	C0442797
28524704	524	543	microwave radiation	T070	C0026051
28524704	544	553	elevating	T080	C3163633
28524704	554	567	blood glucose	T109	C0005802
28524704	587	613	glucose transport proteins	T116,T123	C0017742
28524704	618	630	ion channels	T116,T123	C0022009
28524704	632	639	insulin	T116,T121,T125	C0021641
28524704	640	662	conformational changes	T044	C0301641
28524704	667	683	oxidative stress	T049	C0242606
28524704	685	706	Temperature elevation	T033	C0243095
28524704	714	720	caused	T169	C0015127
28524704	724	743	microwave radiation	T070	C0026051
28524704	746	755	triggered	T080	C1444748
28524704	756	763	Ca (2+)	T121,T196	C0596235
28524704	764	770	efflux	T043	C0007613
28524704	795	817	malignant hyperthermia	T047	C0024591
28524704	837	846	radiation	T070	C0851346
28524704	852	871	wireless technology	T073	C1520154
28524704	875	880	cause	T169	C0015127
28524704	889	907	biological effects	T038	C0599269
28524704	990	998	presence	T080	C3854307
28524704	1014	1023	hospitals	T073,T093	C0019994
28524704	1028	1046	medical facilities	T073,T093	C0018704

27356936|t|" Bridge Proteins " Link Inflammation and Metabolic Diseases: Potential Targets for Therapeutics
27356936|a|Clinical observations support the postulate that chronic low - grade inflammation underlies metabolic diseases and inflammatory mediators can trigger some metabolic diseases. In disorder condition, what is the first one: metabolic diseases cause inflammation or conversely? This "chicken or egg" type question was hard to answer. However, instead of focusing on this difficult issue, we should ask another challenging question: what are the links between inflammation and metabolic diseases? Seizing the key from this chaos may be the best way to solve the problem and break the cycle. To answer this question, we review the regulators (such as NF-κB, PPARs, mTOR, and STAT3) that have important roles in both metabolism and inflammation. These " bridge proteins " that link metabolic diseases and inflammation not only increase our understanding of these two diseases, but also provide potential targets for therapeutics and practical clinical applications.
27356936	2	17	Bridge Proteins	T116,T123	C0033684
27356936	25	37	Inflammation	T046	C0021368
27356936	42	60	Metabolic Diseases	T047	C0025517
27356936	72	79	Targets	T169	C1521840
27356936	84	96	Therapeutics	T169	C0302350
27356936	97	118	Clinical observations	T058	C3889687
27356936	146	153	chronic	T079	C0205191
27356936	154	157	low	T080	C0205251
27356936	160	165	grade	T185	C0441800
27356936	166	178	inflammation	T046	C0021368
27356936	189	207	metabolic diseases	T047	C0025517
27356936	212	234	inflammatory mediators	T121	C0243042
27356936	239	246	trigger	T080	C1444748
27356936	252	270	metabolic diseases	T047	C0025517
27356936	275	283	disorder	T047	C0012634
27356936	284	293	condition	T080	C0348080
27356936	318	336	metabolic diseases	T047	C0025517
27356936	343	355	inflammation	T046	C0021368
27356936	398	406	question	T170	C1522634
27356936	464	473	difficult	T080	C0332218
27356936	474	479	issue	T033	C0033213
27356936	515	523	question	T170	C1522634
27356936	538	543	links	T052	C2986575
27356936	552	564	inflammation	T046	C0021368
27356936	569	587	metabolic diseases	T047	C0025517
27356936	615	620	chaos	T033	C4049797
27356936	654	661	problem	T033	C0033213
27356936	698	706	question	T170	C1522634
27356936	722	732	regulators	T121,T129	C0005525
27356936	742	747	NF-κB	T116,T129	C0079904
27356936	749	754	PPARs	T116,T192	C0166418
27356936	756	760	mTOR	T116	C1254349
27356936	766	771	STAT3	T116,T123	C0253050
27356936	807	817	metabolism	T040	C0025519
27356936	822	834	inflammation	T046	C0021368
27356936	844	859	bridge proteins	T116,T123	C0033684
27356936	872	890	metabolic diseases	T047	C0025517
27356936	895	907	inflammation	T046	C0021368
27356936	917	925	increase	T169	C0442805
27356936	957	965	diseases	T047	C0012634
27356936	994	1001	targets	T169	C1521840
27356936	1006	1018	therapeutics	T169	C0302350
27356936	1033	1041	clinical	T080	C0205210
27356936	1042	1054	applications	T169	C0205245

28088240|t|Feasibility of an altruistic sperm donation program in Canada: results from a population-based model
28088240|a|Stringent donor - screening criteria and legislation prohibiting payment for donor gametes have contributed to the radical decline of donor insemination (DI) using sperm provided by Canadian men. Thus, many individuals rely on imported sperm. This paper examines the feasibility of an altruistic sperm donation (ASD) program to meet the needs of Canadians. Using Canadian census data, published literature and expert opinions, two population-based, top-down mathematical models were developed to estimate the supply and demand for donor sperm and the feasibility of an ASD program. It was estimated that 63 donors would pass Canadian screening criteria, which would provide 1,575 donations. The demand for DI by women was 7,866 samples (4,319 same sex couples, 1,287 single women and 2,260 heterosexual couples). Considerable effort would be necessary to create the required increase in awareness of the program and change in societal behaviour towards sperm donation for an ASD program to be feasible in Canada.
28088240	0	11	Feasibility	T062,T170	C0015730
28088240	18	28	altruistic	T033	C0564563
28088240	29	43	sperm donation	T055	C0871414
28088240	44	51	program	T058	C0679897
28088240	55	61	Canada	T083	C0006823
28088240	78	100	population-based model	T170	C3161035
28088240	101	116	Stringent donor	T098	C0013018
28088240	119	137	screening criteria	T078	C0243161
28088240	142	153	legislation	T089	C0023252
28088240	166	173	payment	T081	C0680264
28088240	178	183	donor	T098	C0013018
28088240	184	191	gametes	T025	C2718310
28088240	224	231	decline	T080	C0392756
28088240	235	253	donor insemination	T061	C0021588
28088240	255	257	DI	T061	C0021588
28088240	265	270	sperm	T025	C0037868
28088240	283	291	Canadian	T033	C0238884
28088240	292	295	men	T098	C0025266
28088240	308	319	individuals	T098	C0237401
28088240	328	336	imported	T057	C0699788
28088240	337	342	sperm	T025	C0037868
28088240	368	379	feasibility	T062,T170	C0015730
28088240	386	396	altruistic	T033	C0564563
28088240	397	411	sperm donation	T055	C0871414
28088240	413	416	ASD	T055	C0871414
28088240	418	425	program	T058	C0679897
28088240	447	456	Canadians	T033	C0238884
28088240	464	472	Canadian	T033	C0238884
28088240	473	479	census	T081	C0007663
28088240	480	484	data	T078	C1511726
28088240	486	506	published literature	T073,T170	C0034036
28088240	511	526	expert opinions	T077	C0600219
28088240	528	578	two population-based, top-down mathematical models	T170	C0876936
28088240	632	637	donor	T098	C0013018
28088240	638	643	sperm	T025	C0037868
28088240	652	663	feasibility	T062,T170	C0015730
28088240	670	673	ASD	T055	C0871414
28088240	674	681	program	T058	C0679897
28088240	708	714	donors	T098	C0013018
28088240	726	734	Canadian	T033	C0238884
28088240	735	753	screening criteria	T078	C0243161
28088240	781	790	donations	T055	C0871414
28088240	807	809	DI	T061	C0021588
28088240	813	818	women	T098	C0043210
28088240	844	852	same sex	T098	C0019898
28088240	853	860	couples	T099	C0010222
28088240	875	880	women	T098	C0043210
28088240	891	903	heterosexual	T098	C1527360
28088240	904	911	couples	T099	C0010222
28088240	976	984	increase	T169	C0442805
28088240	988	997	awareness	T041	C0004448
28088240	1005	1012	program	T058	C0679897
28088240	1027	1045	societal behaviour	T054	C0037397
28088240	1054	1068	sperm donation	T055	C0871414
28088240	1076	1079	ASD	T055	C0871414
28088240	1080	1087	program	T058	C0679897
28088240	1106	1112	Canada	T083	C0006823

28184394|t|Tracing cytotoxic effects of small organic Se species in human liver cells back to total cellular Se and Se metabolites
28184394|a|Small selenium (Se) species play a major role in the metabolism, excretion and dietary supply of the essential trace element selenium. Human cells provide a valuable tool for investigating currently unresolved issues on the cellular mechanisms of Se toxicity and metabolism. In this study, we developed two isotope dilution inductively coupled plasma tandem-mass spectrometry based methods and applied them to human hepatoma cells (HepG2) in order to quantitatively elucidate total cellular Se concentrations and cellular Se species transformations in relation to the cytotoxic effects of four small organic Se species. Species - and incubation time - dependent results were obtained: the two major urinary excretion metabolites trimethylselenonium (TMSe) and methyl-2-acetamido-2-deoxy-1-seleno-β-d-galactopyranoside (SeSugar 1) were taken up by the HepG2 cells in an unmodified manner and did not considerably contribute to the Se pool. In contrast, Se-methylselenocysteine (MeSeCys) and selenomethionine (SeMet) were taken up in higher amounts, they were largely incorporated by the cells (most likely into proteins) and metabolized to other small Se species. Two new metabolites of MeSeCys, namely γ-glutamyl-Se-methylselenocysteine and Se-methylselenoglutathione, were identified by means of HPLC-electrospray-ionization-Orbitrap-MS. They are certainly involved in the (de-)toxification modes of Se metabolism and require further investigation.
28184394	8	17	cytotoxic	T169	C1511636
28184394	18	28	effects of	T080	C1704420
28184394	35	42	organic	T080	C0747055
28184394	43	53	Se species	T121,T197	C3536924
28184394	57	62	human	T016	C0086418
28184394	63	74	liver cells	T025	C0227525
28184394	89	97	cellular	T025	C0007634
28184394	98	100	Se	T121,T123,T196	C0036581
28184394	105	107	Se	T121,T123,T196	C0036581
28184394	108	119	metabolites	T123	C0870883
28184394	126	134	selenium	T121,T123,T196	C0036581
28184394	136	138	Se	T121,T123,T196	C0036581
28184394	173	183	metabolism	T040	C0025519
28184394	185	194	excretion	T039	C0221102
28184394	199	213	dietary supply	T168	C0242295
28184394	221	230	essential	T080	C0205224
28184394	231	244	trace element	T123,T196	C0040577
28184394	245	253	selenium	T196	C2348282
28184394	255	260	Human	T016	C0086418
28184394	261	266	cells	T025	C0007634
28184394	295	308	investigating	T169	C1292732
28184394	319	329	unresolved	T080	C0443342
28184394	330	336	issues	T033	C0033213
28184394	344	352	cellular	T025	C0007634
28184394	353	363	mechanisms	T169	C0441712
28184394	367	369	Se	T121,T123,T196	C0036581
28184394	370	378	toxicity	T037	C0600688
28184394	383	393	metabolism	T040	C0025519
28184394	427	443	isotope dilution	T059	C3826096
28184394	444	495	inductively coupled plasma tandem-mass spectrometry	T059	C1553183
28184394	514	521	applied	T169	C4048755
28184394	530	535	human	T016	C0086418
28184394	536	550	hepatoma cells	T025	C0677626
28184394	552	557	HepG2	T025	C0677626
28184394	571	585	quantitatively	T081	C0392762
28184394	602	610	cellular	T025	C0007634
28184394	611	613	Se	T121,T123,T196	C0036581
28184394	614	628	concentrations	T081	C1446561
28184394	633	641	cellular	T025	C0007634
28184394	642	652	Se species	T121,T197	C3536924
28184394	653	668	transformations	T169	C0205245
28184394	688	697	cytotoxic	T169	C1511636
28184394	698	708	effects of	T080	C1704420
28184394	720	727	organic	T080	C0747055
28184394	728	738	Se species	T121,T197	C3536924
28184394	740	747	Species	T121,T197	C3536924
28184394	754	769	incubation time	T033	C1320226
28184394	772	781	dependent	T080	C0851827
28184394	782	789	results	T169	C1274040
28184394	795	803	obtained	T169	C1301820
28184394	819	836	urinary excretion	T039	C0221102
28184394	837	848	metabolites	T123	C0870883
28184394	849	868	trimethylselenonium	T109,T121	C0077197
28184394	870	874	TMSe	T109,T121	C0077197
28184394	880	937	methyl-2-acetamido-2-deoxy-1-seleno-β-d-galactopyranoside	T123	C0574031
28184394	939	948	SeSugar 1	T123	C0574031
28184394	971	982	HepG2 cells	T025	C0677626
28184394	1050	1052	Se	T121,T123,T196	C0036581
28184394	1053	1057	pool	T169	C2349200
28184394	1072	1095	Se-methylselenocysteine	T109,T121	C0074299
28184394	1097	1104	MeSeCys	T109,T121	C0074299
28184394	1110	1126	selenomethionine	T116,T121	C0036584
28184394	1128	1133	SeMet	T116,T121	C0036584
28184394	1152	1166	higher amounts	T081	C1265611
28184394	1206	1211	cells	T025	C0007634
28184394	1230	1238	proteins	T116,T123	C0033684
28184394	1244	1255	metabolized	T043	C1524026
28184394	1271	1281	Se species	T121,T197	C3536924
28184394	1291	1302	metabolites	T123	C0870883
28184394	1306	1313	MeSeCys	T109,T121	C0074299
28184394	1322	1356	γ-glutamyl-Se-methylselenocysteine	T109,T121	C0965784
28184394	1361	1387	Se-methylselenoglutathione	T123	C0574031
28184394	1394	1404	identified	T080	C0205396
28184394	1417	1457	HPLC-electrospray-ionization-Orbitrap-MS	T059	C0596495
28184394	1478	1486	involved	T169	C1314939
28184394	1494	1511	(de-)toxification	T040	C3825974
28184394	1521	1523	Se	T121,T123,T196	C0036581
28184394	1524	1534	metabolism	T040	C0025519
28184394	1555	1568	investigation	T169	C1292732

28046142|t|Nitrogen utilization efficiency and prediction of nitrogen excretion in sheep offered fresh perennial ryegrass ()
28046142|a|Nitrogen excretion from sheep production systems is an important source of nitrate, ammonia, and nitrous oxide responsible for groundwater pollution and global warming. The present study aimed to identify key parameters influencing N utilization efficiency and develop prediction equations for manure N, feces N, and urine N outputs in sheep. Data used were collected from 82 sheep offered fresh perennial ryegrass () as the sole diet in 6 metabolism experiments (data from non-grass-only diets were not used). Sheep were from breeds of Highlander, Texel, Scottish Blackface, and Swaledale at the age of 5 to 18 mo and weighing from 24.5 to 62.7 kg. Herbage was harvested daily from 6 swards of contrasting harvest dates (May to December), offering wide variation in feed value to cover the range that would be offered in most practical farm situations. Before the commencement of each study, the experimental sward was harvested at a residual height of 4 cm and allowed to grow for 2 to 4 wk to target an average pregrazing sward height in a range of 8 to 15 cm depending on the time of year. Sheep were housed in individual pens for 14 d and then transferred to individual metabolism crates for 4 d with feed intake and feces and urine outputs measured. Data were analyzed using the linear mixed model procedure to develop prediction equations for feces N, urine N, and manure N outputs using N intake, herbage chemical composition, and digestibility with effects of sex, breed, and experimental periods removed. Nitrogen intake was the best single predictor for N output in feces, urine, and manure, and the value for prediction of manure N output was greater than those for feces N and urine N (0.86 vs. 0.70 and 0.77, respectively; < 0.001). Animal BW and herbage DM, ether extract, NDF, ADF, water soluble carbohydrate, and DE concentrations and N digestibility were also used to predict N outputs because N intake may not be available in commercial practice. The prediction equations for N utilizatio n efficiency indicated that increasing feeding level and ME concentration and reducing N concentration could improve N utilization efficiency and shift N excretion into feces rather than urine (< 0.001). The equations developed in the current study provide an approach for sheep producers to quantify N excretion against production and, consequently, to develop their own mitigation strategies to reduce the environmental impact of sheep production systems.
28046142	0	20	Nitrogen utilization	T044	C1158469
28046142	21	31	efficiency	T081	C0013682
28046142	36	46	prediction	T078	C0681842
28046142	50	58	nitrogen	T123,T196	C0028158
28046142	59	68	excretion	T039	C0221102
28046142	72	77	sheep	T015	C0036945
28046142	78	85	offered	T033	C1444648
28046142	86	110	fresh perennial ryegrass	T002	C0331558
28046142	114	122	Nitrogen	T123,T196	C0028158
28046142	123	132	excretion	T039	C0221102
28046142	138	143	sheep	T015	C0036945
28046142	144	162	production systems	T082	C0557759
28046142	189	196	nitrate	T197	C0699857
28046142	198	205	ammonia	T121,T197	C0002607
28046142	211	224	nitrous oxide	T121,T123,T197	C0028215
28046142	241	252	groundwater	T082	C0596631
28046142	253	262	pollution	T069	C0392355
28046142	267	281	global warming	T069	C0206217
28046142	295	300	study	T062	C2603343
28046142	310	318	identify	T080	C0205396
28046142	319	333	key parameters	T077	C1706198
28046142	346	359	N utilization	T044	C1158469
28046142	360	370	efficiency	T081	C0013682
28046142	383	393	prediction	T078	C0681842
28046142	394	403	equations	T077	C0552449
28046142	408	414	manure	T167	C0024765
28046142	415	416	N	T123,T196	C0028158
28046142	418	423	feces	T031	C0015733
28046142	424	425	N	T123,T196	C0028158
28046142	431	436	urine	T031	C0042036
28046142	437	438	N	T123,T196	C0028158
28046142	439	446	outputs	T077	C1709366
28046142	450	455	sheep	T015	C0036945
28046142	457	461	Data	T078	C1511726
28046142	490	495	sheep	T015	C0036945
28046142	496	503	offered	T033	C1444648
28046142	504	528	fresh perennial ryegrass	T002	C0331558
28046142	539	548	sole diet	T168	C0012155
28046142	554	564	metabolism	T040	C0025519
28046142	565	576	experiments	T062	C0681814
28046142	578	582	data	T078	C1511726
28046142	588	608	non-grass-only diets	T168	C0012155
28046142	614	622	not used	T169	C0445107
28046142	625	630	Sheep	T015	C0036945
28046142	641	647	breeds	T185	C1704650
28046142	651	661	Highlander	T098	C0027361
28046142	663	668	Texel	T015	C1297013
28046142	670	688	Scottish Blackface	T015	C0324108
28046142	694	703	Swaledale	T015	C1296242
28046142	711	714	age	T032	C0001779
28046142	726	728	mo	T079	C0439231
28046142	764	771	Herbage	T002	C0242775
28046142	776	785	harvested	T067	C1522240
28046142	786	791	daily	T079	C0332173
28046142	799	805	swards	T002	C2700402
28046142	821	828	harvest	T067	C1522240
28046142	829	834	dates	T079	C0011008
28046142	854	862	offering	T033	C1444648
28046142	868	877	variation	T080	C0205419
28046142	905	910	range	T081	C1514721
28046142	925	932	offered	T033	C1444648
28046142	951	966	farm situations	T082	C0557759
28046142	1000	1005	study	T062	C2603343
28046142	1011	1023	experimental	T080	C1517586
28046142	1024	1029	sward	T002	C2700402
28046142	1034	1043	harvested	T067	C1522240
28046142	1049	1064	residual height	T032	C0489786
28046142	1088	1092	grow	T040	C0018270
28046142	1104	1106	wk	T079	C0439230
28046142	1110	1116	target	T169	C1521840
28046142	1139	1144	sward	T002	C2700402
28046142	1145	1151	height	T032	C0489786
28046142	1157	1162	range	T081	C1514721
28046142	1177	1186	depending	T169	C3244310
28046142	1194	1206	time of year	T081	C0556970
28046142	1208	1213	Sheep	T015	C0036945
28046142	1219	1225	housed	T082	C0557759
28046142	1252	1253	d	T079	C0439228
28046142	1263	1277	transferred to	T033	C4049693
28046142	1289	1299	metabolism	T040	C0025519
28046142	1313	1314	d	T079	C0439228
28046142	1320	1324	feed	T052	C3853577
28046142	1325	1331	intake	T169	C1512806
28046142	1336	1341	feces	T031	C0015733
28046142	1346	1351	urine	T031	C0042036
28046142	1352	1359	outputs	T077	C1709366
28046142	1370	1374	Data	T078	C1511726
28046142	1380	1388	analyzed	T062	C0936012
28046142	1399	1427	linear mixed model procedure	T081	C0023732
28046142	1439	1449	prediction	T078	C0681842
28046142	1450	1459	equations	T077	C0552449
28046142	1464	1469	feces	T031	C0015733
28046142	1473	1478	urine	T031	C0042036
28046142	1486	1492	manure	T167	C0024765
28046142	1493	1494	N	T123,T196	C0028158
28046142	1495	1502	outputs	T077	C1709366
28046142	1509	1517	N intake	T033	C0556048
28046142	1519	1526	herbage	T002	C0242775
28046142	1527	1547	chemical composition	T070	C0243176
28046142	1553	1566	digestibility	T067	C1522240
28046142	1572	1582	effects of	T080	C1704420
28046142	1583	1586	sex	T032	C0079399
28046142	1588	1593	breed	T185	C1704650
28046142	1612	1619	periods	T079	C1948053
28046142	1620	1627	removed	T080	C0849355
28046142	1629	1637	Nitrogen	T123,T196	C0028158
28046142	1638	1644	intake	T169	C1512806
28046142	1653	1657	best	T080	C1522427
28046142	1658	1674	single predictor	T078	C2698872
28046142	1679	1680	N	T123,T196	C0028158
28046142	1681	1687	output	T077	C1709366
28046142	1691	1696	feces	T031	C0015733
28046142	1698	1703	urine	T031	C0042036
28046142	1709	1715	manure	T167	C0024765
28046142	1735	1745	prediction	T078	C0681842
28046142	1749	1755	manure	T167	C0024765
28046142	1756	1757	N	T123,T196	C0028158
28046142	1758	1764	output	T077	C1709366
28046142	1769	1776	greater	T081	C1704243
28046142	1792	1797	feces	T031	C0015733
28046142	1798	1799	N	T123,T196	C0028158
28046142	1804	1809	urine	T031	C0042036
28046142	1810	1811	N	T123,T196	C0028158
28046142	1861	1867	Animal	T008	C0003062
28046142	1868	1870	BW	T032	C0005910
28046142	1875	1882	herbage	T002	C0242775
28046142	1883	1885	DM	T167	C0439861
28046142	1887	1900	ether extract	T081	C0457929
28046142	1902	1905	NDF	T168	C0012173
28046142	1907	1910	ADF	T168	C0012173
28046142	1912	1938	water soluble carbohydrate	T059	C0201929
28046142	1966	1967	N	T123,T196	C0028158
28046142	1968	1981	digestibility	T067	C1522240
28046142	2000	2007	predict	T078	C0681842
28046142	2008	2009	N	T123,T196	C0028158
28046142	2010	2017	outputs	T077	C1709366
28046142	2026	2027	N	T123,T196	C0028158
28046142	2028	2034	intake	T169	C1512806
28046142	2039	2055	not be available	T080	C0686905
28046142	2059	2078	commercial practice	T078	C0009433
28046142	2084	2094	prediction	T078	C0681842
28046142	2095	2104	equations	T077	C0552449
28046142	2109	2121	N utilizatio	T044	C1158469
28046142	2124	2134	efficiency	T081	C0013682
28046142	2150	2160	increasing	T169	C0442808
28046142	2161	2168	feeding	T052	C2987508
28046142	2169	2174	level	T080	C0441889
28046142	2179	2181	ME	T081	C1442080
28046142	2182	2195	concentration	T081	C1446561
28046142	2200	2208	reducing	T080	C0392756
28046142	2209	2224	N concentration	T033	C0456228
28046142	2231	2238	improve	T033	C0184511
28046142	2239	2252	N utilization	T044	C1158469
28046142	2253	2263	efficiency	T081	C0013682
28046142	2274	2275	N	T123,T196	C0028158
28046142	2276	2285	excretion	T039	C0221102
28046142	2291	2296	feces	T031	C0015733
28046142	2297	2308	rather than	T033	C3897775
28046142	2309	2314	urine	T031	C0042036
28046142	2330	2339	equations	T077	C0552449
28046142	2365	2370	study	T062	C2603343
28046142	2382	2390	approach	T082	C0449445
28046142	2395	2400	sheep	T015	C0036945
28046142	2401	2410	producers	T098	C1709696
28046142	2414	2422	quantify	T081	C1709793
28046142	2423	2424	N	T123,T196	C0028158
28046142	2425	2434	excretion	T039	C0221102
28046142	2443	2453	production	T057	C0033268
28046142	2494	2515	mitigation strategies	T062	C0035171
28046142	2519	2525	reduce	T080	C0392756
28046142	2530	2550	environmental impact	T067	C0282165
28046142	2554	2559	sheep	T015	C0036945
28046142	2560	2578	production systems	T082	C0557759

27449818|t|Estradiol prodrugs (EP) for efficient oral estrogen treatment and abolished effects on estrogen modulated liver functions
27449818|a|Oral compared to parenteral estrogen administration is characterized by reduced systemic but prominent hepatic estrogenic effects on lipids, hemostatic factors, GH -/ IGF I axis, angiotensinogen. In order to avoid such adverse metabolic effects of oral treatment, estradiol (E2) prodrugs (EP) were designed which bypass the liver tissue as inactive molecules. Carbone17-OH sulfonamide [-O2-NH2] substituted esters of E2 (EC508, others) were synthesized and tested for carbonic anhydrase II (CA-II) binding. CA II in erythrocytes is thought to oppose extraction of EP from portal vein blood during liver passage. Ovariectomized (OVX, day minus 14) rats were orally treated once daily from day 1-3. Sacrifice day 4. Uteri were dissected and weighed. Cholesterol fractions and angiotensinogen were determined in plasma. Oral E2 and ethinyl estradiol (EE) generated dose related uterine growth and important hepatic estrogenic effects. EP induced uterine growth at about hundred-fold lower doses. This was possible with almost absent effects on plasma cholesterol or angiotensinogen. Preliminary pharmacokinetic studies with EC508 used intravenous and oral administration in male rats. Resulting blood levels revealed complete oral bioavailability. Further high blood - but low plasma concentrations indicated erythrocyte binding of EC508 in vivo as potential mechanism of low extraction at liver passage. Very high systemic estrogenicity combined with markedly lower or absent adverse hepatic estrogenic effects is evidence for a systemic release of E2 from sulfonamide EP. In conclusion, tested oral EP bypass the liver in erythrocytes furnishing systemic estradiol at hydrolysis. This mechanism avoids the hepatic estrogenic impact of conventional oral estrogen therapy.
27449818	0	9	Estradiol	T109,T121,T125	C0014912
27449818	10	18	prodrugs	T120	C0033262
27449818	20	22	EP	T120	C0033262
27449818	38	42	oral	T061	C0001563
27449818	43	61	estrogen treatment	T169	C3173348
27449818	87	95	estrogen	T109,T121,T125	C0014939
27449818	106	121	liver functions	T042	C0232741
27449818	122	126	Oral	T061	C0001563
27449818	139	149	parenteral	T061	C0259961
27449818	150	173	estrogen administration	T169	C3173348
27449818	202	210	systemic	T169	C0205373
27449818	225	232	hepatic	T029	C0205054
27449818	233	251	estrogenic effects	T033	C0877035
27449818	255	261	lipids	T109	C0023779
27449818	263	281	hemostatic factors	T042	C0019116
27449818	283	285	GH	T116,T121,T125	C0037663
27449818	289	294	IGF I	T116,T123	C0021665
27449818	301	316	angiotensinogen	T116,T123	C0003017
27449818	349	366	metabolic effects	T039	C2945675
27449818	370	384	oral treatment	T061	C0001563
27449818	386	395	estradiol	T109,T121,T125	C0014912
27449818	397	399	E2	T109,T121,T125	C0014912
27449818	401	409	prodrugs	T120	C0033262
27449818	411	413	EP	T120	C0033262
27449818	446	458	liver tissue	T023	C0736268
27449818	482	535	Carbone17-OH sulfonamide [-O2-NH2] substituted esters	T104	C1254350
27449818	539	541	E2	T109,T121,T125	C0014912
27449818	543	548	EC508	T109,T121,T125	C0014912
27449818	590	611	carbonic anhydrase II	T116,T126	C0007034
27449818	613	618	CA-II	T116,T126	C0007034
27449818	620	627	binding	T044	C1149286
27449818	629	634	CA II	T116,T126	C0007034
27449818	638	650	erythrocytes	T025	C0014792
27449818	686	688	EP	T120	C0033262
27449818	694	711	portal vein blood	T024	C2324289
27449818	719	724	liver	T023	C0023884
27449818	725	732	passage	T082	C0439799
27449818	734	748	Ovariectomized	T033	C3687559
27449818	750	753	OVX	T033	C3687559
27449818	769	773	rats	T015	C0034721
27449818	779	793	orally treated	T061	C0001563
27449818	836	841	Uteri	T023	C0042149
27449818	847	856	dissected	T169	C0205239
27449818	861	868	weighed	T059	C3827964
27449818	870	891	Cholesterol fractions	T059	C0201950
27449818	896	911	angiotensinogen	T059	C0523500
27449818	931	937	plasma	T031	C0032105
27449818	939	946	Oral E2	T200	C0360514
27449818	951	968	ethinyl estradiol	T109,T121,T125	C0015011
27449818	970	972	EE	T109,T121,T125	C0015011
27449818	997	1004	uterine	T023	C0042149
27449818	1005	1011	growth	T040	C0018270
27449818	1026	1033	hepatic	T029	C0205054
27449818	1034	1052	estrogenic effects	T033	C0877035
27449818	1054	1056	EP	T120	C0033262
27449818	1065	1079	uterine growth	T042	C1326619
27449818	1163	1169	plasma	T031	C0032105
27449818	1170	1181	cholesterol	T109,T123	C0008377
27449818	1185	1200	angiotensinogen	T116,T123	C0003017
27449818	1214	1237	pharmacokinetic studies	T062	C0201734
27449818	1243	1248	EC508	T109,T121,T125	C0014912
27449818	1254	1265	intravenous	T082	C0013125
27449818	1270	1289	oral administration	T061	C0001563
27449818	1293	1297	male	T032	C0086582
27449818	1298	1302	rats	T015	C0034721
27449818	1345	1349	oral	T061	C0001563
27449818	1350	1365	bioavailability	T081	C0005508
27449818	1380	1385	blood	T031	C0005767
27449818	1396	1402	plasma	T031	C0032105
27449818	1428	1439	erythrocyte	T025	C0014792
27449818	1440	1447	binding	T052	C1145667
27449818	1451	1456	EC508	T109,T121,T125	C0014912
27449818	1457	1464	in vivo	T082	C1515655
27449818	1509	1514	liver	T023	C0023884
27449818	1515	1522	passage	T082	C0439799
27449818	1534	1542	systemic	T169	C0205373
27449818	1543	1556	estrogenicity	T109,T121,T125	C0014939
27449818	1604	1611	hepatic	T029	C0205054
27449818	1612	1630	estrogenic effects	T033	C0877035
27449818	1649	1657	systemic	T169	C0205373
27449818	1669	1671	E2	T109,T121,T125	C0014912
27449818	1677	1691	sulfonamide EP	T120	C0033262
27449818	1715	1719	oral	T061	C0001563
27449818	1720	1722	EP	T120	C0033262
27449818	1734	1739	liver	T023	C0023884
27449818	1743	1755	erythrocytes	T025	C0014792
27449818	1767	1775	systemic	T169	C0205373
27449818	1776	1785	estradiol	T109,T121,T125	C0014912
27449818	1789	1799	hydrolysis	T070	C0020291
27449818	1827	1834	hepatic	T029	C0205054
27449818	1835	1845	estrogenic	UnknownType	C0720298
27449818	1869	1873	oral	T061	C0001563
27449818	1874	1890	estrogen therapy	T061	C0279494

28485130|t|Fluorescence hyperspectral imaging (fHSI) using a spectrally resolved detector array
28485130|a|The ability to resolve multiple fluorescent emissions from different biological targets in video rate applications, such as endoscopy and intraoperative imaging, has traditionally been limited by the use of filter-based imaging systems. Hyperspectral imaging (HSI) facilitates the detection of both spatial and spectral information in a single data acquisition, however, instrumentation for HSI is typically complex, bulky and expensive. We sought to overcome these limitations using a novel robust and low cost HSI camera based on a spectrally resolved detector array (SRDA). We integrated this HSI camera into a wide-field reflectance-based imaging system operating in the near-infrared range to assess the suitability for in vivo imaging of exogenous fluorescent contrast agents. Using this fluorescence HSI (fHSI) system, we were able to accurately resolve the presence and concentration of at least 7 fluorescent dyes in solution. We also demonstrate high spectral unmixing precision, signal linearity with dye concentration and at depth in tissue mimicking phantoms, and delineate 4 fluorescent dyes in vivo. Our approach, including statistical background removal, could be directly generalised to broader spectral ranges, for example, to resolve tissue reflectance or autofluorescence and in future be tailored to video rate applications requiring snapshot HSI data acquisition.
28485130	0	34	Fluorescence hyperspectral imaging	T060	C0430022
28485130	36	40	fHSI	T060	C0430022
28485130	50	60	spectrally	T080	C0205556
28485130	61	69	resolved	T033	C3714811
28485130	70	84	detector array	T074	C0025080
28485130	100	107	resolve	T077	C2699488
28485130	108	116	multiple	T081	C0439064
28485130	117	138	fluorescent emissions	T067	C1522240
28485130	144	153	different	T080	C1705242
28485130	154	164	biological	T080	C0205460
28485130	165	172	targets	T169	C1521840
28485130	176	199	video rate applications	UnknownType	C0869019
28485130	209	218	endoscopy	T060	C0014245
28485130	223	245	intraoperative imaging	T060	C3898703
28485130	270	277	limited	T169	C0439801
28485130	292	304	filter-based	T080	C0205556
28485130	305	321	imaging systems.	T074	C0025080
28485130	322	343	Hyperspectral imaging	T060	C0430022
28485130	345	348	HSI	T060	C0430022
28485130	366	375	detection	T061	C1511790
28485130	384	391	spatial	T082	C0037775
28485130	396	404	spectral	T081	C1883073
28485130	405	416	information	T078	C1533716
28485130	422	445	single data acquisition	T052	C0441655
28485130	456	471	instrumentation	T080	C0021632
28485130	476	479	HSI	T060	C0430022
28485130	493	500	complex	T080	C0439855
28485130	502	507	bulky	T081	C0392762
28485130	512	521	expensive	T080	C0205556
28485130	536	544	overcome	T052	C2983310
28485130	551	562	limitations	T169	C0449295
28485130	571	576	novel	T080	C0205314
28485130	577	583	robust	T080	C2986815
28485130	588	596	low cost	T081	C0392762
28485130	597	600	HSI	T060	C0430022
28485130	601	607	camera	T074	C0179533
28485130	619	653	spectrally resolved detector array	T074	C0025080
28485130	655	659	SRDA	T074	C0025080
28485130	665	675	integrated	T066	C1705422
28485130	681	684	HSI	T060	C0430022
28485130	685	691	camera	T074	C0179533
28485130	699	709	wide-field	T033	C0243095
28485130	710	727	reflectance-based	T059	C1514813
28485130	728	742	imaging system	T073	C2697665
28485130	743	752	operating	T169	C0205245
28485130	760	773	near-infrared	T080	C1532326
28485130	774	779	range	T081	C1514721
28485130	783	789	assess	T058	C0184514
28485130	810	825	in vivo imaging	T059	C1708481
28485130	829	838	exogenous	T169	C0205228
28485130	839	866	fluorescent contrast agents	T130	C0009924
28485130	879	895	fluorescence HSI	T060	C0430022
28485130	897	901	fHSI	T060	C0430022
28485130	903	909	system	T169	C0449913
28485130	927	937	accurately	T080	C0443131
28485130	938	945	resolve	T077	C2699488
28485130	950	958	presence	T080	C3854307
28485130	963	976	concentration	T081	C1446561
28485130	991	1007	fluorescent dyes	T130	C0016320
28485130	1011	1019	solution	T167	C0037633
28485130	1041	1045	high	T080	C0205250
28485130	1046	1063	spectral unmixing	T066	C2827423
28485130	1064	1073	precision	T080	C1706245
28485130	1075	1081	signal	T067	C1710082
28485130	1082	1091	linearity	T080	C0205556
28485130	1097	1100	dye	T130	C0013343
28485130	1101	1114	concentration	T081	C1446561
28485130	1122	1127	depth	T082	C0205125
28485130	1131	1137	tissue	T024	C0040300
28485130	1138	1147	mimicking	T070	C4042849
28485130	1148	1156	phantoms	T073	C0282611
28485130	1162	1171	delineate	T033	C0243095
28485130	1174	1190	fluorescent dyes	T130	C0016320
28485130	1191	1198	in vivo	T082	C1515655
28485130	1214	1223	including	T169	C0332257
28485130	1224	1235	statistical	T080	C0205556
28485130	1236	1246	background	T077	C1706907
28485130	1265	1273	directly	T080	C1947931
28485130	1274	1285	generalised	T082	C0205246
28485130	1289	1305	broader spectral	T074	C1138667
28485130	1306	1312	ranges	T081	C1514721
28485130	1330	1337	resolve	T077	C2699488
28485130	1338	1344	tissue	T024	C0040300
28485130	1345	1356	reflectance	T059	C1514813
28485130	1360	1376	autofluorescence	T059	C0544711
28485130	1384	1390	future	T079	C0016884
28485130	1406	1429	video rate applications	UnknownType	C0869019
28485130	1449	1452	HSI	T060	C0430022
28485130	1453	1469	data acquisition	T052	C0441655

27859264|t|Inwardly rectifying K(+) channels are major contributors to flow - induced vasodilatation in resistance arteries
27859264|a|Endothelial inwardly rectifying K(+) (Kir2.1) channels regulate flow - induced vasodilatation via nitric oxide (NO) in mouse mesenteric resistance arteries. Deficiency of Kir2.1 channels results in elevated blood pressure and increased vascular resistance. Flow - induced vasodilatation in human resistance arteries is also regulated by inwardly rectifying K(+) channels. This study presents the first direct evidence that Kir channels play a critical role in physiological endothelial responses to flow. Inwardly rectifying K(+) (Kir) channels are known to be sensitive to flow, but their role in flow - induced endothelial responses is not known. The goal of this study is to establish the role of Kir channels in flow - induced vasodilatation and to provide first insights into the mechanisms responsible for Kir signalling in this process. First, we establish that primary endothelial cells isolated from murine mesenteric arteries express functional Kir2.1 channels sensitive to shear stress. Then, using the Kir2.1(+/-) heterozygous mouse model, we establish that downregulation of Kir2.1 results in significant decrease in shear - activated Kir currents and inhibition of endothelium -dependent flow - induced vasodilatation (FIV) assayed in pressurized mesenteric arteries pre-constricted with endothelin-1. Deficiency in Kir2.1 also results in the loss of flow - induced phosphorylation of eNOS and Akt, as well as inhibition of NO generation. All the effects are fully rescued by endothelial cell (EC)-specific overexpression of Kir2.1. A component of FIV that is Kir independent is abrogated by blocking Ca(2+) -sensitive K(+) channels. Kir2.1 has no effect on endothelium -independent and K(+) - induced vasodilatation in denuded arteries. Kir2.1(+/-) mice also show increased mean blood pressure measured by carotid artery cannulation and increased microvascular resistance measured using a tail-cuff. Importantly, blocking Kir channels also inhibits flow - induced vasodilatation in human subcutaneous adipose microvessels. Endothelial Kir channels contribute to FIV of mouse mesenteric arteries via an NO -dependent mechanism, whereas Ca(2+) -sensitive K(+) channels mediate FIV via an NO -independent pathway. Kir2 channels also regulate vascular resistance and blood pressure. Finally, Kir channels also contribute to FIV in human subcutaneous microvessels.
27859264	0	33	Inwardly rectifying K(+) channels	T116,T123	C0214230
27859264	60	64	flow	T039	C0232338
27859264	67	74	induced	T169	C0205263
27859264	75	89	vasodilatation	T042	C0042401
27859264	93	103	resistance	T169	C4281815
27859264	104	112	arteries	T023	C0003842
27859264	113	124	Endothelial	T025	C0225336
27859264	125	167	inwardly rectifying K(+) (Kir2.1) channels	T116,T123	C0527555
27859264	168	176	regulate	T038	C1327622
27859264	177	181	flow	T039	C0232338
27859264	184	191	induced	T169	C0205263
27859264	192	206	vasodilatation	T042	C0042401
27859264	211	223	nitric oxide	T121,T123,T197	C0028128
27859264	225	227	NO	T121,T123,T197	C0028128
27859264	232	237	mouse	T015	C0025929
27859264	238	268	mesenteric resistance arteries	T023	C0025465
27859264	270	280	Deficiency	T169	C0011155
27859264	284	299	Kir2.1 channels	T116,T123	C0527555
27859264	311	334	elevated blood pressure	T033	C0497247
27859264	339	368	increased vascular resistance	T033	C0520890
27859264	370	374	Flow	T039	C0232338
27859264	377	384	induced	T169	C0205263
27859264	385	399	vasodilatation	T042	C0042401
27859264	403	408	human	T016	C0086418
27859264	409	419	resistance	T169	C4281815
27859264	420	428	arteries	T023	C0003842
27859264	437	446	regulated	T038	C1327622
27859264	450	483	inwardly rectifying K(+) channels	T116,T123	C0214230
27859264	522	530	evidence	T078	C3887511
27859264	536	548	Kir channels	T116,T123	C0214230
27859264	565	569	role	T077	C1705810
27859264	573	586	physiological	T169	C0205463
27859264	587	598	endothelial	T025	C0225336
27859264	599	608	responses	T043	C0007613
27859264	612	616	flow	T039	C0232338
27859264	618	657	Inwardly rectifying K(+) (Kir) channels	T116,T123	C0214230
27859264	687	691	flow	T039	C0232338
27859264	703	707	role	T077	C1705810
27859264	711	715	flow	T039	C0232338
27859264	718	725	induced	T169	C0205263
27859264	726	737	endothelial	T025	C0225336
27859264	738	747	responses	T043	C0007613
27859264	805	809	role	T077	C1705810
27859264	813	825	Kir channels	T116,T123	C0214230
27859264	829	833	flow	T039	C0232338
27859264	836	843	induced	T169	C0205263
27859264	844	858	vasodilatation	T042	C0042401
27859264	898	908	mechanisms	T169	C0441712
27859264	925	928	Kir	T116,T123	C0214230
27859264	929	939	signalling	T043	C0037083
27859264	948	955	process	T067	C1522240
27859264	982	989	primary	T080	C0205225
27859264	990	1007	endothelial cells	T025	C0225336
27859264	1008	1016	isolated	T169	C0205409
27859264	1022	1028	murine	T015	C0026809
27859264	1029	1048	mesenteric arteries	T023	C0025465
27859264	1057	1067	functional	T169	C0205245
27859264	1068	1083	Kir2.1 channels	T116,T123	C0527555
27859264	1097	1109	shear stress	T070	C1171318
27859264	1127	1138	Kir2.1(+/-)	T028	C1416584
27859264	1139	1151	heterozygous	T032	C0019425
27859264	1152	1163	mouse model	T050	C2986594
27859264	1183	1197	downregulation	T044	C0013081
27859264	1201	1207	Kir2.1	T116,T123	C0527555
27859264	1231	1239	decrease	T081	C0547047
27859264	1243	1248	shear	T070	C1171318
27859264	1251	1260	activated	T052	C1879547
27859264	1261	1264	Kir	T116,T123	C0214230
27859264	1265	1273	currents	T070	C1254365
27859264	1278	1288	inhibition	T052	C3463820
27859264	1292	1303	endothelium	T024	C0014257
27859264	1315	1319	flow	T039	C0232338
27859264	1322	1329	induced	T169	C0205263
27859264	1330	1344	vasodilatation	T042	C0042401
27859264	1346	1349	FIV	T042	C0042401
27859264	1362	1393	pressurized mesenteric arteries	T023	C0025465
27859264	1415	1427	endothelin-1	T116,T123	C0079281
27859264	1429	1439	Deficiency	T169	C0011155
27859264	1443	1449	Kir2.1	T116,T123	C0527555
27859264	1470	1474	loss	T081	C1517945
27859264	1478	1482	flow	T039	C0232338
27859264	1485	1492	induced	T169	C0205263
27859264	1493	1508	phosphorylation	T044	C1158886
27859264	1512	1516	eNOS	T116,T126	C1565681
27859264	1521	1524	Akt	T116,T126	C0164786
27859264	1537	1547	inhibition	T052	C3463820
27859264	1551	1553	NO	T121,T123,T197	C0028128
27859264	1554	1564	generation	T052	C3146294
27859264	1574	1581	effects	T080	C1280500
27859264	1603	1619	endothelial cell	T025	C0225336
27859264	1621	1623	EC	T025	C0225336
27859264	1634	1648	overexpression	T045	C1514559
27859264	1652	1658	Kir2.1	T116,T123	C0527555
27859264	1675	1678	FIV	T042	C0042401
27859264	1687	1690	Kir	T116,T123	C0214230
27859264	1719	1727	blocking	T169	C0332206
27859264	1728	1759	Ca(2+) -sensitive K(+) channels	T116,T123	C0949653
27859264	1761	1767	Kir2.1	T116,T123	C0527555
27859264	1772	1781	no effect	T080	C1301751
27859264	1785	1796	endothelium	T024	C0014257
27859264	1814	1818	K(+)	T116,T123	C0214230
27859264	1821	1828	induced	T169	C0205263
27859264	1829	1843	vasodilatation	T042	C0042401
27859264	1847	1863	denuded arteries	T023	C0003842
27859264	1865	1876	Kir2.1(+/-)	T028	C1416584
27859264	1877	1881	mice	T015	C0025929
27859264	1892	1921	increased mean blood pressure	T033	C0497247
27859264	1934	1948	carotid artery	T023	C0007272
27859264	1949	1960	cannulation	T061	C0917707
27859264	1965	1999	increased microvascular resistance	T033	C0520890
27859264	2017	2026	tail-cuff	T059	C0022885
27859264	2041	2049	blocking	T169	C0332206
27859264	2050	2062	Kir channels	T116,T123	C0214230
27859264	2068	2076	inhibits	T052	C3463820
27859264	2077	2081	flow	T039	C0232338
27859264	2084	2091	induced	T169	C0205263
27859264	2092	2106	vasodilatation	T042	C0042401
27859264	2110	2115	human	T016	C0086418
27859264	2116	2128	subcutaneous	T082	C0443315
27859264	2129	2136	adipose	T024	C0001527
27859264	2137	2149	microvessels	T023	C2350570
27859264	2151	2162	Endothelial	T025	C0225336
27859264	2163	2175	Kir channels	T116,T123	C0214230
27859264	2190	2193	FIV	T042	C0042401
27859264	2197	2202	mouse	T015	C0025929
27859264	2203	2222	mesenteric arteries	T023	C0025465
27859264	2230	2232	NO	T121,T123,T197	C0028128
27859264	2244	2253	mechanism	T169	C0441712
27859264	2263	2294	Ca(2+) -sensitive K(+) channels	T116,T123	C0949653
27859264	2303	2306	FIV	T042	C0042401
27859264	2314	2316	NO	T121,T123,T197	C0028128
27859264	2330	2337	pathway	T044	C0037080
27859264	2339	2352	Kir2 channels	T116	C0259080
27859264	2358	2366	regulate	T038	C1327622
27859264	2367	2386	vascular resistance	T039	C0042380
27859264	2391	2405	blood pressure	T040	C0005823
27859264	2416	2428	Kir channels	T116,T123	C0214230
27859264	2448	2451	FIV	T042	C0042401
27859264	2455	2460	human	T016	C0086418
27859264	2461	2473	subcutaneous	T082	C0443315
27859264	2474	2486	microvessels	T023	C2350570

27447421|t|The relationship between hemorheological parameters and mortality in critically ill patients with and without sepsis
27447421|a|The prognostic scoring systems for mortality of intensive care patients estimate clinical outcome using several physiological and biochemical parameters. In altered hemodynamic conditions of critically ill patients, hemorheological variables may play a significant role in appropriate tissue perfusion. We investigated if hemorheological parameters are altered in critical status and if they could be markers of mortality. 112 patients (67.8 ± 12 years, 58 males, 54 females) treated in intensive care unit with different non-surgical diseases were investigated. Routine laboratory parameters and prognostic scores were determined and hemorheological variables (hematocrit, plasma and whole blood viscosity, red blood cell aggregation and deformability) were measured on the 1st and the 2nd day after admission. ICU scores predicted 35.2-41.3% mortality rate, real mortality in intensive care unit was 37.5%, while 30-day mortality was 46.6%. Whole blood viscosity (WBV) and red blood cell (RBC) deformability were lower, red blood cell aggregation was higher in septic than in nonseptic patients (p < 0.05). In septic patients calcium was increased, osmolality was decreased, while in nonseptic patients WBV and RBC aggregation were higher in nonsurvivors compared to survivors (p < 0.05). Worsening of RBC deformability from day 1 to day 2 predicted higher mortality (p < 0.05). Calcium and osmolality level were associated with outcome in sepsis. Whole blood viscosity, red blood cell aggregation and change in red blood cell deformability could predict mortality in nonseptic patients and they may add prognostic information over the ICU scores. Further investigations are needed to evaluate the benefit of our findings in clinical practice.
27447421	4	16	relationship	T080	C0439849
27447421	25	40	hemorheological	T039	C0206502
27447421	41	51	parameters	T033	C0449381
27447421	56	65	mortality	T081	C0178686
27447421	69	83	critically ill	T047	C0010340
27447421	84	92	patients	T101	C0030705
27447421	110	116	sepsis	T047	C0243026
27447421	121	131	prognostic	T058	C0033325
27447421	132	147	scoring systems	T170	C0282574
27447421	152	161	mortality	T081	C0178686
27447421	165	179	intensive care	T058	C0085559
27447421	180	188	patients	T101	C0030705
27447421	189	197	estimate	T081	C0750572
27447421	198	214	clinical outcome	T033	C0243095
27447421	229	242	physiological	T169	C0205463
27447421	247	258	biochemical	T169	C0205474
27447421	259	269	parameters	T033	C0449381
27447421	282	293	hemodynamic	T042	C0019010
27447421	294	304	conditions	T080	C0348080
27447421	308	322	critically ill	T047	C0010340
27447421	323	331	patients	T101	C0030705
27447421	333	348	hemorheological	T039	C0206502
27447421	349	358	variables	T059	C1134627
27447421	402	408	tissue	T024	C0040300
27447421	409	418	perfusion	T061	C0031001
27447421	423	435	investigated	T169	C1292732
27447421	439	454	hemorheological	T039	C0206502
27447421	455	465	parameters	T033	C0449381
27447421	481	496	critical status	T033	C0184770
27447421	518	525	markers	T201	C0005516
27447421	529	538	mortality	T081	C0178686
27447421	544	552	patients	T101	C0030705
27447421	564	569	years	T079	C0439234
27447421	574	579	males	T032	C0086582
27447421	584	591	females	T032	C0086287
27447421	593	600	treated	T169	C1522326
27447421	604	623	intensive care unit	T073,T093	C0021708
27447421	639	651	non-surgical	T169	C1518388
27447421	652	660	diseases	T047	C0012634
27447421	666	678	investigated	T169	C1292732
27447421	688	709	laboratory parameters	T059	C0022885
27447421	714	731	prognostic scores	T081	C0449821
27447421	752	767	hemorheological	T039	C0206502
27447421	768	777	variables	T059	C1134627
27447421	779	789	hematocrit	T033	C0518014
27447421	791	797	plasma	T031	C0032105
27447421	802	813	whole blood	T031	C0370231
27447421	814	823	viscosity	T070	C0042784
27447421	825	839	red blood cell	T025	C0014792
27447421	840	851	aggregation	T043	C0007580
27447421	856	869	deformability	T043	C0014774
27447421	876	884	measured	T080	C0444706
27447421	918	927	admission	T058	C0184666
27447421	929	939	ICU scores	T081	C0392762
27447421	961	975	mortality rate	T081	C0205848
27447421	982	991	mortality	T081	C0178686
27447421	995	1014	intensive care unit	T073,T093	C0021708
27447421	1039	1048	mortality	T081	C0178686
27447421	1060	1081	Whole blood viscosity	T034	C1261453
27447421	1083	1086	WBV	T034	C1261453
27447421	1092	1126	red blood cell (RBC) deformability	T043	C0014774
27447421	1139	1153	red blood cell	T025	C0014792
27447421	1154	1165	aggregation	T043	C0007580
27447421	1170	1176	higher	T080	C0205250
27447421	1180	1186	septic	T169	C0333534
27447421	1195	1204	nonseptic	T169	C3496294
27447421	1205	1213	patients	T101	C0030705
27447421	1229	1235	septic	T047	C0243026
27447421	1236	1244	patients	T101	C0030705
27447421	1245	1252	calcium	T121,T123,T196	C0006675
27447421	1257	1266	increased	T081	C0205217
27447421	1268	1278	osmolality	T201	C0086741
27447421	1283	1292	decreased	T081	C0205216
27447421	1313	1321	patients	T101	C0030705
27447421	1322	1325	WBV	T034	C1261453
27447421	1330	1333	RBC	T025	C0014792
27447421	1334	1345	aggregation	T043	C0007580
27447421	1351	1357	higher	T080	C0205250
27447421	1361	1373	nonsurvivors	T098	C1257890
27447421	1386	1395	survivors	T101	C0206194
27447421	1408	1417	Worsening	T080	C0332271
27447421	1421	1424	RBC	T025	C0014792
27447421	1425	1438	deformability	T043	C0014774
27447421	1469	1475	higher	T080	C0205250
27447421	1476	1485	mortality	T081	C0178686
27447421	1498	1505	Calcium	T059	C0201925
27447421	1510	1526	osmolality level	T034	C0428311
27447421	1532	1547	associated with	T080	C0332281
27447421	1559	1565	sepsis	T047	C0243026
27447421	1567	1578	Whole blood	T031	C0370231
27447421	1579	1588	viscosity	T070	C0042784
27447421	1590	1604	red blood cell	T025	C0014792
27447421	1605	1616	aggregation	T043	C0007580
27447421	1631	1645	red blood cell	T025	C0014792
27447421	1646	1659	deformability	T043	C0014774
27447421	1674	1683	mortality	T081	C0178686
27447421	1687	1696	nonseptic	T169	C3496294
27447421	1697	1705	patients	T101	C0030705
27447421	1723	1733	prognostic	T058	C0033325
27447421	1734	1745	information	T078	C1533716
27447421	1755	1765	ICU scores	T081	C0392762
27447421	1775	1789	investigations	T058	C0220825
27447421	1804	1812	evaluate	T058	C0220825
27447421	1832	1840	findings	T033	C0243095
27447421	1844	1861	clinical practice	T057	C0205897

27294935|t|Field Measurements and Numerical Simulations of Temperature and Moisture in Highway Engineering Using a Frequency Domain Reflectometry Sensor
27294935|a|This paper presents a systematic pioneering study on the use of agricultural - purpose frequency domain reflectometry (FDR) sensors to monitor temperature and moisture of a subgrade in highway extension and reconstruction engineering. The principle of agricultural - purpose FDR sensors and the process for embedding this kind of sensors for subgrade engineering purposes are introduced. Based on field measured weather data, a numerical analysis model for temperature and moisture content in the subgrade's soil is built. Comparisons of the temperature and moisture data obtained from numerical simulation and FDR -based measurements are conducted. The results show that: (1) the embedding method and process, data acquisition, and remote transmission presented are reasonable; (2) the temperature and moisture changes are coordinated with the atmospheric environment and they are also in close agreement with numerical calculations; (3) the change laws of both are consistent at positions where the subgrade is compacted uniformly. These results suggest that the data measured by the agricultural - purpose FDR sensors are reliable. The findings of this paper enable a new and effective real-time monitoring method for a subgrade's temperature and moisture changes, and thus broaden the application of agricultural - purpose FDR sensors.
27294935	0	5	Field	T082	C1254362
27294935	6	18	Measurements	T169	C0242485
27294935	23	44	Numerical Simulations	T066	C0009609
27294935	48	59	Temperature	T081	C0039476
27294935	64	72	Moisture	T167	C0868994
27294935	76	95	Highway Engineering	UnknownType	C0681605
27294935	104	141	Frequency Domain Reflectometry Sensor	T073	C0183210
27294935	164	174	systematic	T169	C0220922
27294935	175	191	pioneering study	T062	C2603343
27294935	199	205	use of	T169	C1524063
27294935	206	218	agricultural	T090	C0001829
27294935	221	228	purpose	T169	C1285529
27294935	229	273	frequency domain reflectometry (FDR) sensors	T073	C0183210
27294935	277	284	monitor	T169	C1441672
27294935	285	296	temperature	T081	C0039476
27294935	301	309	moisture	T167	C0868994
27294935	327	334	highway	T082	C0840965
27294935	335	344	extension	T169	C0231448
27294935	349	375	reconstruction engineering	T057	C0578393
27294935	381	390	principle	T078	C1254370
27294935	394	406	agricultural	T090	C0001829
27294935	409	416	purpose	T169	C1285529
27294935	417	428	FDR sensors	T073	C0183210
27294935	437	444	process	T067	C1522240
27294935	449	458	embedding	T059	C1707903
27294935	472	479	sensors	T073	C0183210
27294935	493	504	engineering	T090	C0014279
27294935	505	513	purposes	T169	C1285529
27294935	539	544	field	T082	C1254362
27294935	545	553	measured	T080	C0444706
27294935	554	561	weather	T070	C0043085
27294935	562	566	data	T078	C1511726
27294935	570	594	numerical analysis model	T170	C3161035
27294935	599	610	temperature	T081	C0039476
27294935	615	623	moisture	T167	C0868994
27294935	650	654	soil	T167	C0037592
27294935	665	676	Comparisons	T052	C1707455
27294935	684	695	temperature	T081	C0039476
27294935	700	708	moisture	T167	C0868994
27294935	709	713	data	T078	C1511726
27294935	728	748	numerical simulation	T066	C0009609
27294935	753	756	FDR	T073	C0183210
27294935	764	776	measurements	T169	C0242485
27294935	796	803	results	T169	C1274040
27294935	823	839	embedding method	T059	C1707903
27294935	844	851	process	T067	C1522240
27294935	853	869	data acquisition	T067	C1522240
27294935	875	894	remote transmission	T070	C1521797
27294935	895	904	presented	T078	C0449450
27294935	929	940	temperature	T081	C0039476
27294935	945	953	moisture	T167	C0868994
27294935	954	961	changes	T169	C0392747
27294935	966	977	coordinated	T169	C0700114
27294935	987	1010	atmospheric environment	T082	C0014406
27294935	1053	1075	numerical calculations	T052	C1441506
27294935	1085	1091	change	T169	C0392747
27294935	1109	1119	consistent	T078	C0332290
27294935	1123	1132	positions	T082	C0733755
27294935	1155	1164	compacted	T033	C1333134
27294935	1165	1174	uniformly	T080	C0205375
27294935	1182	1189	results	T169	C1274040
27294935	1190	1197	suggest	T078	C1705535
27294935	1207	1211	data	T078	C1511726
27294935	1212	1220	measured	T080	C0444706
27294935	1228	1240	agricultural	T090	C0001829
27294935	1243	1250	purpose	T169	C1285529
27294935	1251	1262	FDR sensors	T073	C0183210
27294935	1281	1289	findings	T033	C0243095
27294935	1321	1330	effective	T080	C1704419
27294935	1331	1340	real-time	T079	C1550177
27294935	1341	1351	monitoring	T057	C0014416
27294935	1352	1358	method	T170	C0025663
27294935	1376	1387	temperature	T081	C0039476
27294935	1392	1400	moisture	T167	C0868994
27294935	1401	1408	changes	T169	C0392747
27294935	1446	1458	agricultural	T090	C0001829
27294935	1461	1468	purpose	T169	C1285529
27294935	1469	1480	FDR sensors	T073	C0183210

28319640|t|The Corneal Epithelial Barrier and Its Developmental Role in Isolating Corneal Epithelial and Conjunctival Cells From One Another
28319640|a|During development, the corneal epithelium (CE) and the conjunctiva are derived from the surface ectoderm. Here we have examined how, during development, the cells of these two issues become isolated from each other. Epithelia from the anterior eyes of chicken embryos were labeled with the fluorescent, lipophilic dye, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI). DiI was placed on the epithelial surface of the developing anterior eye and its diffusion was monitored by fluorescence microscopy. Concomitant morphologic changes in the surface cells of these epithelial were examined by scanning electron microscopy. Immunofluorescence was used to analyze the expression of cytokeratin K3, ZO-1, N-cadherin and Connexin-43 and the function of gap junctions was analyzed using a cut-loading with the fluorescent dye rhodamine-dextran. Prior to embryonic day 8 (E 8), DiI placed on the surface of the CE spreads throughout all the epithelial cells of the anterior eye. When older eyes were similarly labeled, dye diffusion was restricted to the CE. Similarly, diffusion of DiI placed on the conjunctival surface after E 8 was restricted to the conjunctiva. Scanning electron microscopy showed that developmentally (1) physical separations progressively form between the cells of the CE and those of the conjunctiva, and (2) by E 8 these separations form a ring that completely encompasses the cornea. The functional restriction of gap junctions between these tissues did not occur until E 14. During ocular development, a barrier to the diffusion of DiI forms between the contiguous CE and conjunctiva prior to the differential expression of gap junctions within these tissues.
28319640	4	22	Corneal Epithelial	T025	C1182610
28319640	23	30	Barrier	T033	C1704511
28319640	39	52	Developmental	T080	C0458003
28319640	61	70	Isolating	T169	C0205409
28319640	71	89	Corneal Epithelial	T025	C1182610
28319640	94	112	Conjunctival Cells	T025	C1182611
28319640	137	148	development	T169	C1527148
28319640	154	172	corneal epithelium	T024	C0459875
28319640	174	176	CE	T024	C0459875
28319640	186	197	conjunctiva	T023	C0009758
28319640	219	235	surface ectoderm	T018	C1515087
28319640	250	258	examined	T033	C0332128
28319640	271	282	development	T169	C1527148
28319640	288	293	cells	T025	C0007634
28319640	321	329	isolated	T169	C0205409
28319640	347	356	Epithelia	T024	C0014609
28319640	366	379	anterior eyes	T023	C0003151
28319640	383	398	chicken embryos	T018	C0008046
28319640	404	411	labeled	T130	C1522485
28319640	421	432	fluorescent	T130	C0016320
28319640	434	448	lipophilic dye	T130	C0013343
28319640	450	516	1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate	T109	C2350183
28319640	518	521	DiI	T109	C2350183
28319640	524	527	DiI	T109	C2350183
28319640	546	564	epithelial surface	T026	C2327105
28319640	583	595	anterior eye	T023	C0003151
28319640	604	613	diffusion	T070	C0012222
28319640	631	654	fluorescence microscopy	T059	C0026022
28319640	668	679	morphologic	T080	C0332437
28319640	680	687	changes	T169	C0392747
28319640	695	728	surface cells of these epithelial	T026	C2327105
28319640	734	742	examined	T033	C0332128
28319640	746	774	scanning electron microscopy	T059	C0026020
28319640	776	794	Immunofluorescence	T059	C0079604
28319640	819	829	expression	T045	C1171362
28319640	833	847	cytokeratin K3	T116,T123	C1313613
28319640	849	853	ZO-1	T116,T123	C3503764
28319640	855	865	N-cadherin	T116,T123	C0027215
28319640	870	881	Connexin-43	T116,T123	C0110613
28319640	890	898	function	T039	C0031843
28319640	902	915	gap junctions	T030	C0206117
28319640	920	928	analyzed	T062	C0936012
28319640	937	948	cut-loading	T081	C0392762
28319640	958	973	fluorescent dye	T130	C0016320
28319640	974	991	rhodamine-dextran	T109,T130	C0073196
28319640	1002	1011	embryonic	T042	C0013936
28319640	1012	1015	day	T079	C0439228
28319640	1019	1020	E	T042	C0013936
28319640	1025	1028	DiI	T109	C2350183
28319640	1043	1050	surface	T082	C0205148
28319640	1058	1060	CE	T024	C0459875
28319640	1061	1068	spreads	T080	C0332261
28319640	1088	1104	epithelial cells	T025	C0014597
28319640	1112	1124	anterior eye	T023	C0003151
28319640	1131	1141	older eyes	T023	C0015392
28319640	1157	1164	labeled	T130	C1522485
28319640	1166	1169	dye	T130	C0013343
28319640	1170	1179	diffusion	T070	C0012222
28319640	1184	1194	restricted	T169	C0443288
28319640	1202	1204	CE	T024	C0459875
28319640	1217	1226	diffusion	T070	C0012222
28319640	1230	1233	DiI	T109	C2350183
28319640	1248	1260	conjunctival	T023	C0009758
28319640	1261	1268	surface	T082	C0205148
28319640	1275	1276	E	T042	C0013936
28319640	1283	1293	restricted	T169	C0443288
28319640	1301	1312	conjunctiva	T023	C0009758
28319640	1314	1342	Scanning electron microscopy	T059	C0026020
28319640	1355	1370	developmentally	T169	C1527148
28319640	1375	1395	physical separations	T033	C4060664
28319640	1396	1409	progressively	T169	C0205329
28319640	1427	1432	cells	T025	C1182610
28319640	1440	1442	CE	T024	C0459875
28319640	1460	1471	conjunctiva	T023	C0009758
28319640	1484	1485	E	T042	C0013936
28319640	1494	1505	separations	T169	C0205245
28319640	1513	1517	ring	T023	C0229119
28319640	1550	1556	cornea	T023	C0010031
28319640	1562	1572	functional	T169	C0205245
28319640	1573	1584	restriction	T169	C0443288
28319640	1588	1601	gap junctions	T030	C0206117
28319640	1616	1623	tissues	T024	C0014609
28319640	1632	1637	occur	T052	C1709305
28319640	1644	1645	E	T042	C0013936
28319640	1657	1675	ocular development	T042	C1517080
28319640	1679	1686	barrier	T033	C1704511
28319640	1694	1703	diffusion	T070	C0012222
28319640	1707	1710	DiI	T109	C2350183
28319640	1729	1739	contiguous	T082	C0205283
28319640	1740	1742	CE	T024	C0459875
28319640	1747	1758	conjunctiva	T023	C0009758
28319640	1772	1784	differential	T080	C1705242
28319640	1785	1795	expression	T045	C1171362
28319640	1799	1812	gap junctions	T030	C0206117
28319640	1826	1833	tissues	T024	C0014609

28481342|t|Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma
28481342|a|The contributions of coding mutations to tumorigenesis are relatively well known; however, little is known about somatic alterations in noncoding DNA. Here we describe GECCO (Genomic Enrichment Computational Clustering Operation) to analyze somatic noncoding alterations in 308 pancreatic ductal adenocarcinomas (PDAs) and identify commonly mutated regulatory regions. We find recurrent noncoding mutations to be enriched in PDA pathways, including axon guidance and cell adhesion, and newly identified processes, including transcription and homeobox genes. We identified mutations in protein binding sites correlating with differential expression of proximal genes and experimentally validated effects of mutations on expression. We developed an expression modulation score that quantifies the strength of gene regulation imposed by each class of regulatory elements, and found the strongest elements were most frequently mutated, suggesting a selective advantage. Our detailed single-cancer analysis of noncoding alterations identifies regulatory mutations as candidates for diagnostic and prognostic markers, and suggests new mechanisms for tumor evolution.
28481342	0	40	Recurrent noncoding regulatory mutations	T045	C0026882
28481342	44	76	pancreatic ductal adenocarcinoma	T191	C1335302
28481342	81	94	contributions	T052	C1880177
28481342	98	114	coding mutations	T045	C0026882
28481342	118	131	tumorigenesis	T191	C0007621
28481342	190	209	somatic alterations	T049	C0544886
28481342	213	226	noncoding DNA	T114,T123	C0021920
28481342	318	347	somatic noncoding alterations	T049	C0544886
28481342	355	388	pancreatic ductal adenocarcinomas	T191	C1335302
28481342	390	394	PDAs	T191	C1335302
28481342	418	444	mutated regulatory regions	T086	C0004793
28481342	454	483	recurrent noncoding mutations	T045	C0026882
28481342	502	505	PDA	T191	C1335302
28481342	506	514	pathways	T044	C1704259
28481342	526	539	axon guidance	T043	C2984268
28481342	544	557	cell adhesion	T043	C0007577
28481342	569	579	identified	T080	C0205396
28481342	580	589	processes	T067	C1522240
28481342	601	614	transcription	T045	C0040649
28481342	619	633	homeobox genes	T028	C0017347
28481342	638	648	identified	T080	C0205396
28481342	649	658	mutations	T045	C0026882
28481342	662	683	protein binding sites	T087	C1514535
28481342	701	713	differential	T080	C0443199
28481342	714	724	expression	T045	C0017262
28481342	728	736	proximal	T082	C0205107
28481342	737	742	genes	T028	C0017337
28481342	772	782	effects of	T080	C1704420
28481342	783	792	mutations	T045	C0026882
28481342	796	806	expression	T045	C0017262
28481342	824	851	expression modulation score	T081	C0392762
28481342	857	867	quantifies	T081	C1709793
28481342	872	880	strength	T078	C0808080
28481342	884	899	gene regulation	T045	C0017263
28481342	925	944	regulatory elements	T028	C0017362
28481342	970	978	elements	T028	C0017362
28481342	1056	1078	single-cancer analysis	T059	C0022885
28481342	1082	1103	noncoding alterations	T045	C0026882
28481342	1115	1135	regulatory mutations	T045	C0026882
28481342	1139	1149	candidates	T080	C0205556
28481342	1154	1164	diagnostic	T201	C1511876
28481342	1169	1187	prognostic markers	T080	C1514475
28481342	1206	1216	mechanisms	T169	C0441712
28481342	1221	1236	tumor evolution	T191	C0007621

27317655|t|Systematic and detailed analysis of behavioural tests in the rat middle cerebral artery occlusion model of stroke: Tests for long-term assessment
27317655|a|In order to test therapeutics, functional assessments are required. In pre-clinical stroke research, there is little consensus regarding the most appropriate behavioural tasks to assess deficits, especially when testing over extended times in milder models with short occlusion times and small lesion volumes. In this study, we comprehensively assessed 16 different behavioural tests, with the aim of identifying those that show robust, reliable and stable deficits for up to two months. These tasks are regularly used in stroke research, as well as being useful for examining striatal dysfunction in models of Huntington's and Parkinson's disease. Two cohorts of male Wistar rats underwent the intraluminal filament model of middle cerebral artery occlusion (30 min) and were imaged 24 h later. This resulted in primarily subcortical infarcts, with a small amount of cortical damage. Animals were tested, along with sham and naïve groups at 24 h, seven days, and one and two months. Following behavioural testing, brains were processed and striatal neuronal counts were performed alongside measurements of total brain and white matter atrophy. The staircase, adjusting steps, rotarod and apomorphine -induced rotations were the most reliable for assessing long-term deficits in the 30 min transient middle cerebral artery occlusion model of stroke.
27317655	0	10	Systematic	T169	C0220922
27317655	15	32	detailed analysis	T062	C0936012
27317655	36	53	behavioural tests	T060	C0683444
27317655	61	64	rat	T015	C0034721
27317655	65	97	middle cerebral artery occlusion	T020	C0740391
27317655	98	103	model	T008	C0887965
27317655	107	113	stroke	T047	C0038454
27317655	115	120	Tests	T170	C0392366
27317655	125	145	long-term assessment	T052	C1516048
27317655	163	175	therapeutics	T061	C0087111
27317655	177	199	functional assessments	T060	C0278372
27317655	217	229	pre-clinical	T080	C1709630
27317655	230	236	stroke	T047	C0038454
27317655	237	245	research	T062	C0035168
27317655	304	321	behavioural tasks	T060	C0683444
27317655	332	340	deficits	T080	C2987487
27317655	396	402	models	T008	C0887965
27317655	408	429	short occlusion times	T081	C1632851
27317655	434	446	small lesion	T033	C0221198
27317655	434	454	small lesion volumes	T081	C0449468
27317655	464	469	study	T062	C2603343
27317655	490	498	assessed	T052	C1516048
27317655	512	529	behavioural tests	T060	C0683444
27317655	575	581	robust	T080	C2986815
27317655	583	591	reliable	T170	C3858758
27317655	596	611	stable deficits	T080	C2987487
27317655	626	632	months	T079	C0439231
27317655	668	674	stroke	T047	C0038454
27317655	675	683	research	T062	C0035168
27317655	723	743	striatal dysfunction	T047	C0007760
27317655	747	753	models	T008	C0887965
27317655	757	769	Huntington's	T047	C0020179
27317655	774	793	Parkinson's disease	T047	C0030567
27317655	799	806	cohorts	T098	C0599755
27317655	810	814	male	T032	C0086582
27317655	815	826	Wistar rats	T015	C0034716
27317655	841	868	intraluminal filament model	T170	C3161035
27317655	872	904	middle cerebral artery occlusion	T020	C0740391
27317655	909	912	min	T079	C0439232
27317655	923	929	imaged	T060	C0011923
27317655	933	934	h	T079	C0439227
27317655	969	989	subcortical infarcts	T047	C0007785
27317655	1014	1029	cortical damage	T037	C0270611
27317655	1031	1038	Animals	T015	C0034716
27317655	1063	1084	sham and naïve groups	T098	C1257890
27317655	1091	1092	h	T079	C0439227
27317655	1100	1104	days	T079	C0439228
27317655	1122	1128	months	T079	C0439231
27317655	1140	1159	behavioural testing	T060	C0683444
27317655	1161	1167	brains	T023	C0006104
27317655	1187	1211	striatal neuronal counts	T081	C0439157
27317655	1259	1264	brain	T023	C0006104
27317655	1269	1289	white matter atrophy	T190	C4022735
27317655	1295	1304	staircase	T060	C0178091
27317655	1306	1321	adjusting steps	T060	C0178091
27317655	1323	1330	rotarod	T060	C0178091
27317655	1335	1346	apomorphine	T109,T121	C0003596
27317655	1335	1365	apomorphine -induced rotations	T060	C0178091
27317655	1413	1421	deficits	T080	C2987487
27317655	1432	1435	min	T079	C0439232
27317655	1446	1478	middle cerebral artery occlusion	T020	C0740391
27317655	1479	1484	model	T008	C0887965
27317655	1488	1494	stroke	T047	C0038454

27806921|t|Simulating the potential role of media coverage and infected bats in the 2014 Ebola outbreak
27806921|a|Multiple epidemiological models have been developed to model the transmission dynamics of Ebola virus (EBOV) disease in West Africa in 2014 because the severity of the epidemic is commonly overestimated. A compartmental model that incorporates the media impact and the effect of infected bats was constructed and calibrated using data reported until the end of 2014. The final cumulative number of deaths and confirmed cases were estimated to be 1.0921×10(4) (95% CI 9.7706×10(3)-1.2072×10(4)) and 1.5193×10(4) (95% CI 1.3593×10(4)-1.6795×10(4)), respectively. The epidemic was estimated to end on June 2015, which was similar to the data reported by the World Health Organization. A sensitivity analysis indicated that an increase of either the media impact or the number of infectious bats that are captured daily can increase the cumulative number of confirmed cases / deaths. Of the considered epidemiological parameters, only the media coverage can significantly reduce both the peak time and the value of the cumulative confirmed cases / deaths. Thus, we propose 'the cumulative confirmed cases and deaths ' as another media mechanism. In conclusion, the media impact contributed to the control of the 2014 Ebola outbreak, and infectious bats may be a potential source of the epidemic.
27806921	0	10	Simulating	T062	C0679083
27806921	15	24	potential	T080	C3245505
27806921	25	29	role	T077	C1705810
27806921	33	47	media coverage	T057	C0681284
27806921	52	60	infected	T033	C0439663
27806921	61	65	bats	T015	C0008139
27806921	78	83	Ebola	T047	C0282687
27806921	84	92	outbreak	T067	C0012652
27806921	102	117	epidemiological	T169	C1516907
27806921	118	124	models	T075	C0026336
27806921	135	144	developed	T169	C1527148
27806921	158	179	transmission dynamics	T078	C0040722
27806921	183	209	Ebola virus (EBOV) disease	T047	C0282687
27806921	213	224	West Africa	T083	C0001747
27806921	245	253	severity	T080	C0392364
27806921	261	269	epidemic	T067	C0014499
27806921	299	318	compartmental model	T170	C2986731
27806921	341	353	media impact	T080	C4049986
27806921	362	368	effect	T080	C1280500
27806921	372	380	infected	T033	C0439663
27806921	381	385	bats	T015	C0008139
27806921	406	416	calibrated	T081	C0006751
27806921	423	427	data	T078	C1511726
27806921	470	480	cumulative	T080	C1511559
27806921	481	497	number of deaths	T081	C0205848
27806921	502	511	confirmed	T033	C0750484
27806921	512	517	cases	T077	C1706256
27806921	523	532	estimated	T081	C0750572
27806921	557	559	CI	T081	C0009667
27806921	609	611	CI	T081	C0009667
27806921	658	666	epidemic	T067	C0014499
27806921	671	680	estimated	T081	C0750572
27806921	712	719	similar	T080	C2348205
27806921	727	731	data	T078	C1511726
27806921	732	740	reported	T058	C0700287
27806921	748	773	World Health Organization	T093	C0043237
27806921	777	797	sensitivity analysis	T062	C0936012
27806921	798	807	indicated	T033	C1444656
27806921	816	824	increase	T169	C0442805
27806921	839	851	media impact	T080	C4049986
27806921	859	865	number	T081	C0237753
27806921	869	879	infectious	T080	C1550587
27806921	880	884	bats	T015	C0008139
27806921	903	908	daily	T079	C0332173
27806921	913	921	increase	T169	C0442805
27806921	926	936	cumulative	T080	C1511559
27806921	937	943	number	T081	C0237753
27806921	947	956	confirmed	T033	C0750484
27806921	957	962	cases	T077	C1706256
27806921	965	971	deaths	T081	C0205848
27806921	991	1017	epidemiological parameters	T169	C1516907
27806921	1028	1042	media coverage	T057	C0681284
27806921	1077	1086	peak time	T033	C3840073
27806921	1095	1100	value	T081	C1522609
27806921	1108	1118	cumulative	T080	C1511559
27806921	1119	1128	confirmed	T033	C0750484
27806921	1129	1134	cases	T077	C1706256
27806921	1137	1143	deaths	T081	C0205848
27806921	1167	1177	cumulative	T080	C1511559
27806921	1178	1187	confirmed	T033	C0750484
27806921	1188	1193	cases	T077	C1706256
27806921	1198	1204	deaths	T081	C0205848
27806921	1218	1223	media	T170	C0009458
27806921	1224	1233	mechanism	T169	C0441712
27806921	1254	1266	media impact	T080	C4049986
27806921	1286	1293	control	T080	C0243148
27806921	1306	1311	Ebola	T047	C0282687
27806921	1312	1320	outbreak	T067	C0012652
27806921	1326	1336	infectious	T080	C1550587
27806921	1337	1341	bats	T015	C0008139
27806921	1351	1360	potential	T080	C3245505
27806921	1361	1367	source	T033	C0449416
27806921	1375	1383	epidemic	T067	C0014499

28056457|t|Personalised Medicine: A New Approach to Improving Health in Indigenous Australian Populations
28056457|a|Personalised medicine is a newly emerging field with much to offer to all populations in improved clinical treatment options. Since the 1970s, clinicians and researchers have all been working towards improving the health of Indigenous Australians. However, there has been little research on the impact of genetics on Indigenous health, how genetic and environmental factors interact to contribute to poor health in Indigenous people, and how genetic factors specific to Indigenous people affect their responses to particular treatments. This short review highlights the urgent need for more genetic studies specific to Indigenous people in order to provide more appropriate care and to improve health outcomes. This paper explores why genetic work with Indigenous communities has been limited, how personalised medicine could benefit Indigenous communities, and highlights a number of specific instances in which personalised medicine has been critical for improving morbidity and mortality in other high-risk groups. In order to take the next step in advancing the health of Indigenous peoples, targeted research into the genetic factors behind chronic diseases is critically needed. This research may allow clinicians a better understanding of how genetic factors interact with environmental factors to influence an Indigenous Australian's individual risk of disease, prognosis, and response to therapies. It is hoped that this knowledge will produce clinical interventions that will help deliver clearly targeted, more appropriate care to this at-risk population.
28056457	0	21	Personalised Medicine	T061	C2718059
28056457	29	37	Approach	T082	C0449445
28056457	41	50	Improving	T080	C1272745
28056457	51	57	Health	T078	C0018684
28056457	61	71	Indigenous	T102	C1512704
28056457	72	94	Australian Populations	T098	C0238711
28056457	95	116	Personalised medicine	T061	C2718059
28056457	137	142	field	T090	C0805661
28056457	169	180	populations	T098	C1257890
28056457	184	192	improved	T033	C0184511
28056457	193	211	clinical treatment	T061	C1516635
28056457	212	219	options	T169	C1518601
28056457	238	248	clinicians	T097	C0871685
28056457	253	264	researchers	T097	C0035173
28056457	295	304	improving	T080	C1272745
28056457	309	315	health	T078	C0018684
28056457	319	329	Indigenous	T102	C1512704
28056457	330	341	Australians	T098	C0238711
28056457	374	382	research	T062	C0035168
28056457	390	396	impact	T080	C4049986
28056457	400	408	genetics	T169	C0017399
28056457	412	422	Indigenous	T102	C1512704
28056457	423	429	health	T078	C0018684
28056457	435	442	genetic	T169	C0314603
28056457	447	468	environmental factors	T169	C1516998
28056457	469	477	interact	T169	C1704675
28056457	495	506	poor health	T033	C0683321
28056457	510	527	Indigenous people	T098	C0079891
28056457	537	544	genetic	T169	C0314603
28056457	545	552	factors	T169	C1521761
28056457	553	561	specific	T080	C0205369
28056457	565	582	Indigenous people	T098	C0079891
28056457	596	630	responses to particular treatments	T201	C0521982
28056457	643	649	review	T170	C0282443
28056457	686	701	genetic studies	T062	C2827447
28056457	702	710	specific	T080	C0205369
28056457	714	731	Indigenous people	T098	C0079891
28056457	757	768	appropriate	T080	C1548787
28056457	769	773	care	T058	C0086388
28056457	781	788	improve	T033	C0184511
28056457	789	804	health outcomes	T170	C1550208
28056457	811	816	paper	T170	C1706852
28056457	830	842	genetic work	T062	C2827447
28056457	848	858	Indigenous	T102	C1512704
28056457	859	870	communities	T096	C0009462
28056457	893	914	personalised medicine	T061	C2718059
28056457	921	928	benefit	T081	C0814225
28056457	929	939	Indigenous	T102	C1512704
28056457	940	951	communities	T096	C0009462
28056457	980	988	specific	T080	C0205369
28056457	989	998	instances	T078	C1550608
28056457	1008	1029	personalised medicine	T061	C2718059
28056457	1039	1047	critical	T080	C1511545
28056457	1052	1061	improving	T080	C1272745
28056457	1062	1071	morbidity	T081	C0026538
28056457	1076	1085	mortality	T081	C0205848
28056457	1095	1104	high-risk	T033	C0332167
28056457	1105	1111	groups	T098	C1257890
28056457	1161	1167	health	T078	C0018684
28056457	1171	1189	Indigenous peoples	T098	C0079891
28056457	1191	1199	targeted	T169	C1521840
28056457	1200	1208	research	T062	C0035168
28056457	1218	1225	genetic	T169	C0314603
28056457	1226	1233	factors	T169	C1521761
28056457	1241	1257	chronic diseases	T047	C0008679
28056457	1285	1293	research	T062	C0035168
28056457	1304	1314	clinicians	T097	C0871685
28056457	1324	1337	understanding	T041	C0162340
28056457	1345	1352	genetic	T169	C0314603
28056457	1353	1360	factors	T169	C1521761
28056457	1361	1369	interact	T169	C1704675
28056457	1375	1396	environmental factors	T169	C1516998
28056457	1400	1409	influence	T077	C4054723
28056457	1413	1423	Indigenous	T102	C1512704
28056457	1424	1436	Australian's	T098	C0238711
28056457	1437	1447	individual	T098	C0237401
28056457	1448	1452	risk	T078	C0035647
28056457	1456	1463	disease	T047	C0012634
28056457	1465	1474	prognosis	T058	C0033325
28056457	1480	1501	response to therapies	T201	C0521982
28056457	1525	1534	knowledge	T170	C0376554
28056457	1548	1556	clinical	T080	C0205210
28056457	1557	1570	interventions	T058	C1273869
28056457	1602	1610	targeted	T169	C1521840
28056457	1617	1628	appropriate	T080	C1548787
28056457	1629	1633	care	T058	C0086388
28056457	1642	1649	at-risk	T080	C1444641
28056457	1650	1660	population	T098	C0079891

28464907|t|Nodal skip metastasis in thoracic esophageal squamous cell carcinoma: a cohort study
28464907|a|Nodal skip metastasis is a prognostic factor in some sites of malignancies, but its role in esophageal cancer is still unclear. The present study aimed to investigate occurrence and effect of nodal skip metastases in thoracic esophageal squamous cell carcinoma. All 578 patients undergoing esophagectomy for thoracic esophageal squamous cell carcinoma at the Center for Esophageal Diseases located in Padova between January 1992 and December 2010 were retrospectively evaluated. Selection criteria were R0 resection, pathological M0 stage and pathological lymph node involvement. Patients receiving neoadjuvant therapy were excluded. The selection identified 88 patients with lymph node involvement confirmed by pathological evaluation. Sixteen patients (18.2%) had nodal skip metastasis. Adjusting for the number of lymph node metastases, patient with nodal skip metastasis had similar 5-year overall survival (14% vs. 13%, p = 0.93) and 5-year disease free survival (14% vs. 9%, p = 0.48) compared to patients with both peritumoral and distant lymph node metastases. The risk difference of nodal skip metastasis was: -24.1% (95% C.I. -43.1% to -5.2%) in patients with more than one lymph node metastasis compared to those with one lymph node metastasis; -2.3% (95% C.I. -29.8% to 25.2%) in middle thoracic esophagus and -23.0% (95% C.I. -47.8% to 1.8%) in lower thoracic esophagus compared to upper thoracic esophagus; 18.1% (95% C.I. 3.2% to 33.0%) in clinical N0 stage vs. clinical N+ stage. Nodal skip metastasis is a common pattern of metastatic lymph involvement in thoracic esophageal squamous cell carcinoma. However, neither overall survival nor disease free survival are associated with nodal skip metastasis occurrence.
28464907	0	5	Nodal	T082	C0443268
28464907	6	10	skip	T033	C0560435
28464907	11	21	metastasis	T191	C0596869
28464907	25	68	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	72	84	cohort study	T081	C0009247
28464907	85	90	Nodal	T082	C0443268
28464907	91	95	skip	T033	C0560435
28464907	96	106	metastasis	T191	C0596869
28464907	112	129	prognostic factor	T201	C1514474
28464907	147	159	malignancies	T191	C4282132
28464907	177	194	esophageal cancer	T191	C0014859
28464907	204	211	unclear	T033	C3845108
28464907	240	251	investigate	T169	C1292732
28464907	267	273	effect	T080	C1280500
28464907	277	282	nodal	T082	C0443268
28464907	283	287	skip	T033	C0560435
28464907	302	345	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	355	363	patients	T101	C0030705
28464907	375	388	esophagectomy	T061	C0085198
28464907	393	436	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	444	474	Center for Esophageal Diseases	T093	C1708333
28464907	486	492	Padova	UnknownType	C0681784
28464907	501	508	January	T080	C3829466
28464907	518	526	December	T080	C3830550
28464907	537	562	retrospectively evaluated	T062	C0035363
28464907	564	582	Selection criteria	T080	C0242801
28464907	588	600	R0 resection	T033	C0677874
28464907	602	614	pathological	T169	C1521733
28464907	615	623	M0 stage	T033	C0445034
28464907	628	640	pathological	T169	C1521733
28464907	641	663	lymph node involvement	T033	C0806692
28464907	665	673	Patients	T101	C1516213
28464907	684	703	neoadjuvant therapy	T061	C0600558
28464907	747	755	patients	T101	C0030705
28464907	761	783	lymph node involvement	T033	C0806692
28464907	797	809	pathological	T169	C1521733
28464907	810	820	evaluation	T058	C0220825
28464907	830	838	patients	T101	C1516213
28464907	851	856	nodal	T082	C0443268
28464907	857	861	skip	T033	C0560435
28464907	862	872	metastasis	T191	C0596869
28464907	902	923	lymph node metastases	T191	C0596869
28464907	925	932	patient	T101	C1516213
28464907	938	943	nodal	T082	C0443268
28464907	944	948	skip	T033	C0560435
28464907	949	959	metastasis	T191	C0596869
28464907	979	995	overall survival	T081	C4086681
28464907	1031	1052	disease free survival	T081	C0242793
28464907	1088	1096	patients	T101	C0030705
28464907	1107	1118	peritumoral	T082	C3897941
28464907	1123	1130	distant	T082	C0443203
28464907	1131	1152	lymph node metastases	T191	C0596869
28464907	1177	1182	nodal	T082	C0443268
28464907	1183	1187	skip	T033	C0560435
28464907	1188	1198	metastasis	T191	C0596869
28464907	1216	1219	C.I	T081	C0009667
28464907	1241	1249	patients	T101	C0030705
28464907	1269	1290	lymph node metastasis	T191	C0596869
28464907	1318	1339	lymph node metastasis	T191	C0596869
28464907	1352	1355	C.I	T081	C0009667
28464907	1377	1383	middle	T082	C0444598
28464907	1384	1402	thoracic esophagus	T023	C0227188
28464907	1419	1422	C.I	T081	C0009667
28464907	1443	1448	lower	T082	C0441994
28464907	1449	1467	thoracic esophagus	T023	C0227188
28464907	1480	1485	upper	T082	C1282910
28464907	1486	1504	thoracic esophagus	T023	C0227188
28464907	1517	1521	C.I.	T081	C0009667
28464907	1540	1548	clinical	T080	C0205210
28464907	1549	1557	N0 stage	T033	C0441959
28464907	1562	1570	clinical	T080	C0205210
28464907	1571	1579	N+ stage	T033	C1272457
28464907	1581	1586	Nodal	T082	C0443268
28464907	1587	1591	skip	T033	C0560435
28464907	1592	1602	metastasis	T191	C0596869
28464907	1626	1654	metastatic lymph involvement	T033	C0806692
28464907	1658	1701	thoracic esophageal squamous cell carcinoma	T191	C0861674
28464907	1712	1719	neither	T080	C4284892
28464907	1720	1736	overall survival	T081	C4086681
28464907	1741	1762	disease free survival	T081	C0242793
28464907	1767	1782	associated with	T080	C0332281
28464907	1783	1788	nodal	T082	C0443268
28464907	1789	1793	skip	T033	C0560435
28464907	1794	1804	metastasis	T191	C0596869

27512256|t|The effects of gait time and trunk acceleration ratio during stair climbing in old-old adult females
27512256|a|[Purpose] This study investigated the effects of gait time and trunk acceleration ratio in old-old adult females during stair climbing. [Subjects and Methods] Twenty-five older adult females who were able to walk independently volunteered for this study and were categorized into two age groups (older adults or old-old adults). Gait time and trunk acceleration ratio were measured using an accelerometer during stair climbing. [Results] Gait time and trunk acceleration ratio when climbing stairs were significantly higher in the old-old age group than in the older adults group. [Conclusions] These findings suggest that old-old females have decreased upper trunk control. In addition, gait time and the trunk acceleration ratio during stair climbing are useful clinical markers for predicting function and balance control ability in old-old elderly populations.
27512256	4	11	effects	T080	C1280500
27512256	15	19	gait	T033	C0016928
27512256	20	24	time	T079	C0040223
27512256	29	34	trunk	T029	C0460005
27512256	35	47	acceleration	T067	C0000894
27512256	48	53	ratio	T081	C0456603
27512256	61	75	stair climbing	T056	C1290942
27512256	79	92	old-old adult	T098	C0001792
27512256	93	100	females	T032	C0086287
27512256	116	121	study	T062	C2603343
27512256	139	146	effects	T080	C1280500
27512256	150	154	gait	T033	C0016928
27512256	155	159	time	T079	C0040223
27512256	164	169	trunk	T029	C0460005
27512256	170	182	acceleration	T067	C0000894
27512256	183	188	ratio	T081	C0456603
27512256	192	205	old-old adult	T098	C0001792
27512256	206	213	females	T032	C0086287
27512256	221	235	stair climbing	T056	C1290942
27512256	272	283	older adult	T098	C0001792
27512256	284	291	females	T032	C0086287
27512256	309	327	walk independently	T033	C0429979
27512256	328	339	volunteered	T098	C0020155
27512256	349	354	study	T062	C2603343
27512256	385	395	age groups	T100	C0027362
27512256	397	409	older adults	T098	C0001792
27512256	413	427	old-old adults	T098	C0001792
27512256	430	434	Gait	T033	C0016928
27512256	435	439	time	T079	C0040223
27512256	444	449	trunk	T029	C0460005
27512256	450	462	acceleration	T067	C0000894
27512256	463	468	ratio	T081	C0456603
27512256	492	505	accelerometer	T074	C0178951
27512256	513	527	stair climbing	T056	C1290942
27512256	539	543	Gait	T033	C0016928
27512256	544	548	time	T079	C0040223
27512256	553	558	trunk	T029	C0460005
27512256	559	571	acceleration	T067	C0000894
27512256	572	577	ratio	T081	C0456603
27512256	583	598	climbing stairs	T056	C1290942
27512256	618	624	higher	T080	C0205250
27512256	632	649	old-old age group	T098	C0001792
27512256	662	680	older adults group	T098	C0001792
27512256	702	710	findings	T033	C0243095
27512256	724	731	old-old	T098	C0001792
27512256	732	739	females	T032	C0086287
27512256	745	774	decreased upper trunk control	T033	C0426973
27512256	789	793	gait	T033	C0016928
27512256	794	798	time	T079	C0040223
27512256	807	812	trunk	T029	C0460005
27512256	813	825	acceleration	T067	C0000894
27512256	826	831	ratio	T081	C0456603
27512256	839	853	stair climbing	T056	C1290942
27512256	865	881	clinical markers	T080	C0008963
27512256	886	896	predicting	T078	C0681842
27512256	897	905	function	T169	C0542341
27512256	910	917	balance	T040	C0014653
27512256	918	933	control ability	T032	C0085732
27512256	937	964	old-old elderly populations	T098	C0001792

27485749|t|Adenosine A2A receptors in the olfactory bulb suppress rapid eye movement sleep in rodents
27485749|a|Rapid eye movement (REM) sleep behavior disorder in humans is often accompanied by a reduced ability to smell and detect odors, and olfactory bulbectomized rats exhibit increased REM sleep, suggesting that the olfactory bulb (OB) is involved in REM-sleep regulation. However, the molecular mechanism of REM-sleep regulation by the OB is unknown. Adenosine promotes sleep and its A2A receptors (A2AR) are expressed in the OB. We hypothesized that A2AR in the OB regulate REM sleep. Bilateral microinjections of the A2AR antagonist SCH58261 into the rat OB increased REM sleep, whereas microinjections of the A2AR agonist CGS21680 decreased REM sleep. Similar to the A2AR antagonist, selective A2AR knockdown by adeno-associated virus carrying short-hairpin RNA for A2AR in the rat OB increased REM sleep. Using chemogenetics on the basis of designer receptors exclusively activated by designer drugs, we demonstrated that the inhibition of A2AR neurons increased REM sleep, whereas the activation of these neurons decreased REM sleep. Moreover, using a conditional anterograde axonal tract-tracing approach, we found that OB A2AR neurons innervate the piriform cortex and olfactory tubercle. These novel findings indicate that adenosine suppresses REM sleep via A2AR in the OB of rodents.
27485749	0	23	Adenosine A2A receptors	T116,T192	C0255998
27485749	31	45	olfactory bulb	T023	C1281094
27485749	46	54	suppress	T169	C1260953
27485749	55	79	rapid eye movement sleep	T041	C0037322
27485749	83	90	rodents	T015	C0035804
27485749	91	139	Rapid eye movement (REM) sleep behavior disorder	T048	C0751772
27485749	143	149	humans	T016	C0086418
27485749	176	183	reduced	T080	C0392756
27485749	184	200	ability to smell	T033	C2712084
27485749	205	217	detect odors	T040	C1301543
27485749	223	246	olfactory bulbectomized	T033	C0243095
27485749	247	251	rats	T015	C0086893
27485749	260	269	increased	T081	C0205217
27485749	270	279	REM sleep	T041	C0037322
27485749	301	315	olfactory bulb	T023	C1281094
27485749	317	319	OB	T023	C1281094
27485749	336	345	REM-sleep	T041	C0037322
27485749	346	356	regulation	T038	C1327622
27485749	371	390	molecular mechanism	T044	C1148560
27485749	394	403	REM-sleep	T041	C0037322
27485749	404	414	regulation	T038	C1327622
27485749	422	424	OB	T023	C1281094
27485749	437	446	Adenosine	T114,T121,T123	C0001443
27485749	456	461	sleep	T040	C0037313
27485749	470	483	A2A receptors	T116,T192	C0255998
27485749	485	489	A2AR	T116,T192	C0255998
27485749	495	504	expressed	T045	C0597360
27485749	512	514	OB	T023	C1281094
27485749	537	541	A2AR	T116,T192	C0255998
27485749	549	551	OB	T023	C1281094
27485749	552	560	regulate	T038	C1327622
27485749	561	570	REM sleep	T041	C0037322
27485749	572	597	Bilateral microinjections	T061	C0025991
27485749	605	629	A2AR antagonist SCH58261	T109,T121	C0387956
27485749	639	642	rat	T015	C0086893
27485749	643	645	OB	T023	C1281094
27485749	646	655	increased	T081	C0205217
27485749	656	665	REM sleep	T041	C0037322
27485749	675	690	microinjections	T061	C0025991
27485749	698	719	A2AR agonist CGS21680	T121	C2987634
27485749	720	729	decreased	T081	C0205216
27485749	730	739	REM sleep	T041	C0037322
27485749	756	771	A2AR antagonist	T109,T121	C0387956
27485749	783	787	A2AR	T028	C1412246
27485749	788	797	knockdown	T063	C2350567
27485749	801	823	adeno-associated virus	T005	C0001417
27485749	833	850	short-hairpin RNA	T114	C2930586
27485749	855	859	A2AR	T028	C1412246
27485749	867	870	rat	T015	C0034693
27485749	871	873	OB	T023	C1281094
27485749	874	883	increased	T081	C0205217
27485749	884	893	REM sleep	T041	C0037322
27485749	901	914	chemogenetics	T091	C0017398
27485749	931	949	designer receptors	T116,T192	C0597357
27485749	962	971	activated	T052	C1879547
27485749	975	989	designer drugs	T131	C0011684
27485749	1016	1026	inhibition	T042	C0027790
27485749	1030	1034	A2AR	T116,T192	C0255998
27485749	1035	1042	neurons	T025	C0027882
27485749	1043	1052	increased	T081	C0205217
27485749	1053	1062	REM sleep	T041	C0037322
27485749	1076	1086	activation	T052	C1879547
27485749	1096	1103	neurons	T025	C0027882
27485749	1104	1113	decreased	T081	C0205216
27485749	1114	1123	REM sleep	T041	C0037322
27485749	1155	1196	anterograde axonal tract-tracing approach	T062	C0242481
27485749	1212	1214	OB	T023	C1281094
27485749	1215	1219	A2AR	T116,T192	C0255998
27485749	1220	1227	neurons	T025	C0027882
27485749	1242	1257	piriform cortex	T023	C0228280
27485749	1262	1280	olfactory tubercle	T023	C0917714
27485749	1317	1326	adenosine	T114,T121,T123	C0001443
27485749	1327	1337	suppresses	T169	C1260953
27485749	1338	1347	REM sleep	T041	C0037322
27485749	1352	1356	A2AR	T116,T192	C0255998
27485749	1364	1366	OB	T023	C1281094
27485749	1370	1377	rodents	T015	C0035804

28513195|t|Binge drinking: Health impact, prevalence, correlates and interventions
28513195|a|Binge drinking (also called heavy episodic drinking, risky single-occasion drinking etc.) is a major public health problem. This paper provides an overview of recently published evidence concerning the definition and measuremen t, prevalence rates, health impact, demographic and psychosocial correlates of, and interventions for, binge drinking. Narrative review. Mostly occurring among young people at weekends, binge drinking increases the risk of both acute (e.g. injuries) and long-term negative consequences (e.g. alcohol disorders). Binge drinkers tend to be extrovert, impulsive and sensation-seeking. Stress, anxiety, traumatic events and depression are also related to binge drinking. Both alcohol-related behaviour of parents and general parenting (e.g. parenting styles, monitoring) are also important. Other major risk factors for binge drinking are frequently spending time with friends who drink, and the drinking norms observed in the wider social environment (e.g. school, community, culture). Emergency departments, birthday parties, fraternities and the workplace serve as settings for interventions; these are increasingly delivered via digital and mobile technology. There is evidence of small-sized effects across approaches (brief interventions, personalised normative feedback, protective behavioural strategies etc.) and populations. A more consistent terminology, investigating multi-level influences and identifying the most effective intervention components are challenges for future research.
28513195	0	14	Binge drinking	T055	C0556346
28513195	16	29	Health impact	T058	C3494320
28513195	31	41	prevalence	T081	C0033106
28513195	43	53	correlates	T041	C0871178
28513195	58	71	interventions	T061	C0184661
28513195	72	86	Binge drinking	T055	C0556346
28513195	100	123	heavy episodic drinking	T048	C0687132
28513195	131	146	single-occasion	T079	C1254367
28513195	147	155	drinking	T055	C0001948
28513195	173	194	public health problem	T033	C1398682
28513195	240	258	published evidence	T170	C0993637
28513195	274	284	definition	T170	C1704788
28513195	289	299	measuremen	T169	C0242485
28513195	303	319	prevalence rates	T081	C0220900
28513195	321	334	health impact	T058	C3494320
28513195	336	347	demographic	T062	C0011289
28513195	352	375	psychosocial correlates	T041	C0871178
28513195	384	397	interventions	T061	C0184661
28513195	403	417	binge drinking	T055	C0556346
28513195	419	435	Narrative review	UnknownType	C0815257
28513195	460	465	young	T079	C0332239
28513195	466	472	people	T098	C0027361
28513195	476	484	weekends	T079	C0680190
28513195	486	500	binge drinking	T055	C0556346
28513195	501	510	increases	T169	C0442805
28513195	515	519	risk	T078	C0035647
28513195	528	533	acute	T079	C0205178
28513195	540	548	injuries	T037	C3263722
28513195	554	563	long-term	T079	C0443252
28513195	573	585	consequences	T169	C0686907
28513195	592	609	alcohol disorders	T048	C0001956
28513195	612	626	Binge drinkers	T033	C0556335
28513195	638	647	extrovert	T041	C0557871
28513195	649	658	impulsive	T055	C0021125
28513195	663	680	sensation-seeking	T055	C0871336
28513195	682	688	Stress	T048	C0038443
28513195	690	697	anxiety	T033	C0003467
28513195	699	708	traumatic	T169	C0332663
28513195	709	715	events	T051	C0441471
28513195	720	730	depression	T048	C0011570
28513195	740	747	related	T080	C0439849
28513195	751	765	binge drinking	T055	C0556346
28513195	772	808	alcohol-related behaviour of parents	T054	C0085092
28513195	821	830	parenting	T054	C0085092
28513195	837	853	parenting styles	T080	C1510623
28513195	855	865	monitoring	T058	C1283169
28513195	899	911	risk factors	T033	C0035648
28513195	916	930	binge drinking	T055	C0556346
28513195	955	959	time	T079	C0040223
28513195	965	972	friends	T098	C0079382
28513195	977	982	drink	T055	C0001948
28513195	992	1006	drinking norms	T054	C0740872
28513195	1029	1047	social environment	T078	C0037414
28513195	1054	1060	school	T073,T092	C0036375
28513195	1062	1071	community	T096	C0009462
28513195	1073	1080	culture	T169	C0220814
28513195	1083	1104	Emergency departments	T058	C0374899
28513195	1106	1114	birthday	T079	C2826645
28513195	1115	1122	parties	T077	C1518904
28513195	1124	1136	fraternities	T092	C1561598
28513195	1145	1154	workplace	T082	C0162579
28513195	1177	1190	interventions	T061	C0184661
28513195	1229	1258	digital and mobile technology	T090	C0039421
28513195	1269	1277	evidence	T078	C3887511
28513195	1293	1300	effects	T080	C1280500
28513195	1308	1318	approaches	T169	C1292724
28513195	1320	1339	brief interventions	T058	C0814459
28513195	1341	1353	personalised	T032	C1519021
28513195	1354	1372	normative feedback	T041	C2911691
28513195	1374	1396	protective behavioural	T053	C4060711
28513195	1397	1407	strategies	T041	C0679199
28513195	1418	1429	populations	T098	C1257890
28513195	1449	1460	terminology	T170	C0028275
28513195	1462	1475	investigating	T169	C1292732
28513195	1488	1498	influences	T077	C4054723
28513195	1524	1533	effective	T080	C1280519
28513195	1534	1546	intervention	T061	C0184661
28513195	1577	1583	future	T079	C0016884
28513195	1584	1592	research	T062	C0035168

27934977|t|Real-time observation of protein aggregates in pharmaceutical formulations using liquid cell electron microscopy
27934977|a|Understanding the properties of protein-based therapeutics is a common goal of biologists and physicians. Technical barriers in the direct observation of small proteins or therapeutic agents can limit our knowledge of how they function in solution and in the body. Electron microscopy (EM) imaging performed in a liquid environment permits us to peer into the active world of cells and molecules at the nanoscale. Here, we employ liquid cell EM to directly visualize a protein-based therapeutic in its native conformation and aggregate state in a time-resolved manner. In combination with quantitative analyses, information from this work contributes new molecular insights toward understanding the behaviours of immunotherapies in a solution state that mimics the human body.
27934977	0	9	Real-time	T079	C1550177
27934977	10	21	observation	T062	C0302523
27934977	25	43	protein aggregates	T116	C3850144
27934977	47	74	pharmaceutical formulations	T077	C1705957
27934977	81	112	liquid cell electron microscopy	T059	C0026019
27934977	131	141	properties	T080	C0871161
27934977	145	171	protein-based therapeutics	T121	C0872285
27934977	192	202	biologists	T097	C0334861
27934977	207	217	physicians	T097	C0031831
27934977	219	237	Technical barriers	T080	C0205556
27934977	245	251	direct	T080	C1947931
27934977	252	263	observation	T062	C0302523
27934977	267	281	small proteins	T116,T123	C0033684
27934977	285	303	therapeutic agents	T121	C1611640
27934977	340	348	function	T169	C0542341
27934977	352	360	solution	T167	C0037633
27934977	372	376	body	T016	C0242821
27934977	378	397	Electron microscopy	T059	C0026019
27934977	399	401	EM	T059	C0026019
27934977	403	410	imaging	T060	C0011923
27934977	426	432	liquid	T167	C0302908
27934977	433	444	environment	T082	C0014406
27934977	489	494	cells	T025	C0007634
27934977	499	508	molecules	T167	C0567416
27934977	516	525	nanoscale	T080	C0205556
27934977	543	557	liquid cell EM	T059	C0026019
27934977	582	607	protein-based therapeutic	T121	C0872285
27934977	615	634	native conformation	T082	C0033625
27934977	639	648	aggregate	T080	C0205418
27934977	649	654	state	T169	C1442792
27934977	660	680	time-resolved manner	T080	C0205556
27934977	702	723	quantitative analyses	T059	C0200767
27934977	725	736	information	T078	C1533716
27934977	768	777	molecular	T080	C1521991
27934977	778	786	insights	T041	C0233820
27934977	826	841	immunotherapies	T061	C0021083
27934977	847	855	solution	T167	C0037633
27934977	856	861	state	T169	C1442792
27934977	878	888	human body	T016	C0242821

28207880|t|Skeletal muscle metabolic adaptations to endurance exercise training are attainable in mice with simvastatin treatment
28207880|a|We tested the hypothesis that a 6-week regimen of simvastatin would attenuate skeletal muscle adaptation to low-intensity exercise. Male C57BL/6J wildtype mice were subjected to 6-weeks of voluntary wheel running or normal cage activities with or without simvastatin treatment (20 mg/kg/d, n = 7-8 per group). Adaptations in in vivo fatigue resistance were determined by a treadmill running test, and by ankle plantarflexor contractile assessment. The tibialis anterior, gastrocnemius, and plantaris muscles were evaluated for exercised -induced mitochondrial adaptations (i.e., biogenesis, function, autophagy). There was no difference in weekly wheel running distance between control and simvastatin - treated mice (P = 0.51). Trained mice had greater treadmill running distance (296%, P<0.001), and ankle plantarflexor contractile fatigue resistance (9%, P<0.05) compared to sedentary mice, independent of simvastatin treatment. At the cellular level, trained mice had greater mitochondrial biogenesis (e.g., ~2-fold greater PGC1α expression, P<0.05) and mitochondrial content (e.g., 25% greater citrate synthase activity, P<0.05), independent of simvastatin treatment. Mitochondrial autophagy -related protein contents were greater in trained mice (e.g., 40% greater Bnip3, P<0.05), independent of simvastatin treatment. However, Drp1, a marker of mitochondrial fission, was less in simvastatin treated mice, independent of exercise training, and there was a significant interaction between training and statin treatment (P<0.022) for LC3-II protein content, a marker of autophagy flux. These data indicate that whole body and skeletal muscle adaptations to endurance exercise training are attainable with simvastatin treatment, but simvastatin may have side effects on muscle mitochondrial maintenance via autophagy, which could have long-term implications on muscle health.
28207880	0	15	Skeletal muscle	T024	C0242692
28207880	26	37	adaptations	T038	C0392673
28207880	41	50	endurance	T079	C0031808
28207880	51	68	exercise training	T056	C4279936
28207880	73	83	attainable	T052	C0599946
28207880	87	91	mice	T015	C0025929
28207880	97	108	simvastatin	T109,T121	C0074554
28207880	109	118	treatment	T061	C0087111
28207880	133	143	hypothesis	T078	C1512571
28207880	158	165	regimen	T061	C0040808
28207880	169	180	simvastatin	T109,T121	C0074554
28207880	187	196	attenuate	T052	C0599946
28207880	197	212	skeletal muscle	T024	C0242692
28207880	213	223	adaptation	T038	C0392673
28207880	227	249	low-intensity exercise	T056	C0015259
28207880	251	255	Male	T032	C0086582
28207880	256	278	C57BL/6J wildtype mice	T015	C0025929
28207880	308	331	voluntary wheel running	T056	C0035953
28207880	342	346	cage	T073	C0179512
28207880	347	357	activities	T052	C0441655
28207880	374	385	simvastatin	T109,T121	C0074554
28207880	386	395	treatment	T061	C0087111
28207880	429	440	Adaptations	T038	C0392673
28207880	444	451	in vivo	T062	C0681829
28207880	452	459	fatigue	T184	C0015672
28207880	460	470	resistance	T169	C4281815
28207880	492	514	treadmill running test	T060	C0087110
28207880	523	542	ankle plantarflexor	T023	C0581542
28207880	543	554	contractile	T039	C0026820
28207880	571	588	tibialis anterior	T023	C0242690
28207880	590	603	gastrocnemius	T023	C0242691
28207880	609	626	plantaris muscles	T023	C0242693
28207880	632	641	evaluated	T058	C0220825
28207880	646	655	exercised	T056	C0015259
28207880	665	678	mitochondrial	T026	C0026237
28207880	679	690	adaptations	T038	C0392673
28207880	698	708	biogenesis	T070	C0005495
28207880	710	718	function	T169	C0542341
28207880	720	729	autophagy	T043	C0004391
28207880	742	755	no difference	T033	C3842396
28207880	766	788	wheel running distance	T052	C0441655
28207880	809	820	simvastatin	T109,T121	C0074554
28207880	823	830	treated	T169	C1522326
28207880	831	835	mice	T015	C0025929
28207880	848	855	Trained	T065	C0220931
28207880	856	860	mice	T015	C0025929
28207880	873	890	treadmill running	T056	C2712999
28207880	891	899	distance	T081	C0012751
28207880	921	940	ankle plantarflexor	T023	C0581542
28207880	941	952	contractile	T039	C0026820
28207880	953	960	fatigue	T184	C0015672
28207880	961	971	resistance	T169	C4281815
28207880	1007	1011	mice	T015	C0025929
28207880	1028	1039	simvastatin	T109,T121	C0074554
28207880	1040	1049	treatment	T061	C0087111
28207880	1058	1072	cellular level	T025	C0007634
28207880	1074	1081	trained	T065	C0220931
28207880	1082	1086	mice	T015	C0025929
28207880	1099	1123	mitochondrial biogenesis	T043	C3494456
28207880	1147	1152	PGC1α	T116,T123	C1570275
28207880	1153	1163	expression	T045	C1171362
28207880	1177	1190	mitochondrial	T026	C0026237
28207880	1218	1234	citrate synthase	T116,T126	C0008855
28207880	1235	1243	activity	T044	C0243102
28207880	1269	1280	simvastatin	T109,T121	C0074554
28207880	1281	1290	treatment	T061	C0087111
28207880	1292	1305	Mitochondrial	T026	C0026237
28207880	1306	1315	autophagy	T043	C0004391
28207880	1325	1332	protein	T116,T123	C0033684
28207880	1358	1365	trained	T065	C0220931
28207880	1366	1370	mice	T015	C0025929
28207880	1390	1395	Bnip3	T116,T123	C1699488
28207880	1421	1432	simvastatin	T109,T121	C0074554
28207880	1433	1442	treatment	T061	C0087111
28207880	1453	1457	Drp1	T116,T126	C1957127
28207880	1461	1467	marker	T201	C0005516
28207880	1471	1492	mitochondrial fission	T043	C0230871
28207880	1506	1517	simvastatin	T109,T121	C0074554
28207880	1518	1525	treated	T169	C1522326
28207880	1526	1530	mice	T015	C0025929
28207880	1547	1564	exercise training	T056	C4279936
28207880	1594	1605	interaction	T169	C1704675
28207880	1614	1622	training	T065	C0220931
28207880	1634	1643	treatment	T061	C0087111
28207880	1658	1672	LC3-II protein	T116,T123	C3711208
28207880	1673	1680	content	T081	C1446561
28207880	1684	1690	marker	T201	C0005516
28207880	1694	1703	autophagy	T043	C0004391
28207880	1735	1745	whole body	T017	C0444584
28207880	1750	1765	skeletal muscle	T024	C0242692
28207880	1766	1777	adaptations	T038	C0392673
28207880	1781	1790	endurance	T079	C0031808
28207880	1791	1808	exercise training	T056	C4279936
28207880	1813	1823	attainable	T052	C0599946
28207880	1829	1840	simvastatin	T109,T121	C0074554
28207880	1841	1850	treatment	T061	C0087111
28207880	1856	1867	simvastatin	T109,T121	C0074554
28207880	1877	1889	side effects	T046	C0879626
28207880	1893	1899	muscle	T024	C0026845
28207880	1900	1913	mitochondrial	T026	C0026237
28207880	1930	1939	autophagy	T043	C0004391
28207880	1958	1967	long-term	T079	C0443252
28207880	1984	1990	muscle	T024	C0026845
28207880	1991	1997	health	T078	C0018684

27526663|t|Differential control and function of Arabidopsis ProDH1 and ProDH2 genes on infection with biotrophic and necrotrophic pathogens
27526663|a|Arabidopsis contains two proline dehydrogenase (ProDH) genes, ProDH1 and ProDH2, encoding for homologous and functional isoenzymes. Although ProDH1 has been studied extensively, especially under abiotic stress, ProDH2 has only started to be analysed in recent years. These genes display distinctive expression patterns and show weak transcriptional co-regulation, but are both activated in pathogen - infected tissues. We have demonstrated previously that Arabidopsis plants with silenced ProDH1 / 2 expression fail to trigger defences against the hemibiotrophic bacterial pathogen Pseudomonas syringae pv. tomato AvrRpm1 (Pst-AvrRpm1), and that ProDH1 and ProDH2 are differentially regulated by salicylic acid (SA). In the current work, we used prodh1 and prodh2 single- mutant plants to assess the particular contribution of each gene to resistance against Pst-AvrRpm1 and the necrotrophic fungal pathogen Botrytis cinerea. In addition, we studied the sensitivity of ProDH1 and ProDH2 to the jasmonic acid (JA) defence pathway. We found that ProDH1 and ProDH2 are both necessary to achieve maximum resistance against Pst-AvrRpm1 and B. cinerea. However, ProDH2 has a major effect on early restriction of B. cinerea growth. Interestingly, ProDH1 is up-regulated by SA and JA, whereas ProDH2 is only activated by JA, and both genes display transcriptional inter-regulation at basal and infection conditions. These studies provide the first evidence of the contribution of ProDH2 to disease resistance, and describe the differential regulation and non-redundant but complementary function of both enzyme isoforms in infected tissues, providing support for a fundamental role of ProDH in the control of biotrophic and necrotrophic pathogens.
27526663	13	20	control	T080	C0243148
27526663	25	33	function	T169	C0542341
27526663	37	48	Arabidopsis	T002	C0162741
27526663	49	55	ProDH1	T028	C1418945
27526663	60	72	ProDH2 genes	T028	C1424903
27526663	76	85	infection	T046	C3714514
27526663	91	101	biotrophic	T033	C0243095
27526663	106	118	necrotrophic	T033	C0243095
27526663	119	128	pathogens	T001	C0450254
27526663	129	140	Arabidopsis	T002	C0162741
27526663	154	189	proline dehydrogenase (ProDH) genes	T028	C1418945
27526663	191	197	ProDH1	T028	C1418945
27526663	202	208	ProDH2	T028	C1424903
27526663	210	218	encoding	T052	C2700640
27526663	223	233	homologous	T116	C1512488
27526663	238	248	functional	T169	C0205245
27526663	249	259	isoenzymes	T116,T126	C0022173
27526663	270	276	ProDH1	T028	C1418945
27526663	324	338	abiotic stress	T046	C0449430
27526663	340	346	ProDH2	T028	C1424903
27526663	389	394	years	T079	C0439234
27526663	402	407	genes	T028	C0017337
27526663	428	438	expression	T045	C0017262
27526663	439	447	patterns	T082	C0449774
27526663	457	461	weak	T080	C1762617
27526663	462	491	transcriptional co-regulation	T045	C1158770
27526663	506	515	activated	T052	C1879547
27526663	519	527	pathogen	T001	C0450254
27526663	530	538	infected	T033	C0439663
27526663	539	546	tissues	T024	C0040300
27526663	585	603	Arabidopsis plants	T002	C0162741
27526663	609	617	silenced	T045	C0598496
27526663	618	624	ProDH1	T028	C1418945
27526663	627	628	2	T028	C1424903
27526663	629	639	expression	T045	C0017262
27526663	640	644	fail	T169	C0231175
27526663	656	664	defences	T040	C1154988
27526663	677	691	hemibiotrophic	T033	C0243095
27526663	692	701	bacterial	T007	C0004611
27526663	702	710	pathogen	T001	C0450254
27526663	711	750	Pseudomonas syringae pv. tomato AvrRpm1	T007	C0317966
27526663	752	763	Pst-AvrRpm1	T007	C0317966
27526663	775	781	ProDH1	T028	C1418945
27526663	786	792	ProDH2	T028	C1424903
27526663	812	821	regulated	T064	C0851285
27526663	825	839	salicylic acid	T109,T121	C0036079
27526663	841	843	SA	T109,T121	C0036079
27526663	875	881	prodh1	T002	C0162741
27526663	886	892	prodh2	T002	C0162741
27526663	901	907	mutant	T049	C0596988
27526663	908	914	plants	T002	C0032098
27526663	961	965	gene	T028	C0017337
27526663	969	979	resistance	T169	C4281815
27526663	988	999	Pst-AvrRpm1	T007	C0317966
27526663	1008	1020	necrotrophic	T033	C0243095
27526663	1021	1036	fungal pathogen	T004	C3826297
27526663	1037	1053	Botrytis cinerea	T004	C0579190
27526663	1083	1094	sensitivity	T169	C0332324
27526663	1098	1104	ProDH1	T028	C1418945
27526663	1109	1115	ProDH2	T028	C1424903
27526663	1123	1136	jasmonic acid	T109	C0064138
27526663	1138	1140	JA	T109	C0064138
27526663	1142	1149	defence	T040	C1154988
27526663	1150	1157	pathway	T044	C1704259
27526663	1173	1179	ProDH1	T116,T126	C3657000
27526663	1184	1190	ProDH2	T116,T126	C3657000
27526663	1229	1239	resistance	T169	C4281815
27526663	1248	1259	Pst-AvrRpm1	T007	C0317966
27526663	1264	1274	B. cinerea	T004	C0579190
27526663	1285	1291	ProDH2	T116,T126	C3657000
27526663	1320	1331	restriction	T169	C0443288
27526663	1335	1345	B. cinerea	T004	C0579190
27526663	1346	1352	growth	T040	C0018270
27526663	1369	1375	ProDH1	T028	C1418945
27526663	1379	1391	up-regulated	T044	C0041904
27526663	1395	1397	SA	T109,T121	C0036079
27526663	1402	1404	JA	T109	C0064138
27526663	1414	1420	ProDH2	T028	C1424903
27526663	1429	1438	activated	T052	C1879547
27526663	1442	1444	JA	T109	C0064138
27526663	1455	1460	genes	T028	C0017337
27526663	1469	1501	transcriptional inter-regulation	T045	C1158770
27526663	1505	1510	basal	T082	C0205112
27526663	1515	1524	infection	T046	C3714514
27526663	1525	1535	conditions	T080	C0348080
27526663	1601	1607	ProDH2	T028	C1424903
27526663	1611	1629	disease resistance	T040	C1136180
27526663	1661	1671	regulation	T064	C0851285
27526663	1694	1716	complementary function	T169	C0542341
27526663	1725	1740	enzyme isoforms	T116,T126	C0022173
27526663	1744	1752	infected	T033	C0439663
27526663	1753	1760	tissues	T024	C0040300
27526663	1806	1811	ProDH	T028	C1418945
27526663	1830	1840	biotrophic	T033	C0243095
27526663	1845	1857	necrotrophic	T033	C0243095
27526663	1858	1867	pathogens	T001	C0450254

28390176|t|Cucurbitacin B Protects Against Pressure Overload Induced Cardiac Hypertrophy
28390176|a|Lack of effective anti-cardiac hypertrophy drugs creates a major cause for the increasing prevalence of heart failure. In the present study, we determined the anti-hypertrophy and anti-fibrosis potential of a natural plant triterpenoid, Cucurbitacin B both in vitro and in vivo. Aortic banding (AB) was performed to induce cardiac hypertrophy. After 1 week of surgery, mice were receive cucurbitacin B treatment (Gavage, 0.2 mg/kg body weight /2 day). After 4 weeks of AB, cucurbitacin B demonstrated a strong anti-hypertrophy and -fibrosis ability as evidenced by decreased of heart weight, myocardial cell cross-sectional area and interstitial fibrosis, ameliorated of systolic and diastolic abnormalities, normalized in gene expression of hypertrophic and fibrotic markers, reserved microvascular density in pressure overload induced hypertrophic mice. Cucurbitacin B also showed significant hypertrophy inhibitory effect in phenylephrine stimulated cardiomyocytes. The Cucurbitacin B -mediated mitigated cardiac hypertrophy was attributable to the increasing level of autophagy, which was associated with the blockade of Akt / mTOR / FoxO3a signal pathway, validated by SC79, MK2206, and 3-MA, the Akt agonist, inhibitor and autophagy inhibitor in vitro. The overexpression of constitutively active Akt completely abolished the Cucurbitacin B -mediated protection of cardiac hypertrophy in human cardiomyocytes AC16. Collectively, our findings suggest that cucurbitacin B protects against cardiac hypertrophy through increasing the autophagy level in cardiomyocytes, which is associated with the inhibition of Akt / mTOR / FoxO3a signal axis. J. Cell. Biochem. 9999: 1-12, 2017. © 2017 Wiley Periodicals, Inc.
28390176	0	14	Cucurbitacin B	T109,T121	C0056580
28390176	32	40	Pressure	T184	C0497233
28390176	41	49	Overload	UnknownType	C0684338
28390176	58	77	Cardiac Hypertrophy	T046	C1383860
28390176	96	126	anti-cardiac hypertrophy drugs	T121	C1254351
28390176	143	148	cause	T169	C0015127
28390176	168	178	prevalence	T081	C0033105
28390176	182	195	heart failure	T047	C0018801
28390176	237	253	anti-hypertrophy	T033	C0243095
28390176	258	271	anti-fibrosis	T033	C0243095
28390176	272	281	potential	T080	C3245505
28390176	287	300	natural plant	T002	C0032098
28390176	301	313	triterpenoid	T109	C1519655
28390176	315	329	Cucurbitacin B	T109,T121	C0056580
28390176	335	343	in vitro	T062	C0681828
28390176	348	355	in vivo	T062	C0681829
28390176	357	371	Aortic banding	T061	C0185014
28390176	373	375	AB	T061	C0185014
28390176	401	420	cardiac hypertrophy	T046	C1383860
28390176	438	445	surgery	T061	C0543467
28390176	447	451	mice	T015	C0025929
28390176	465	479	cucurbitacin B	T109,T121	C0056580
28390176	480	489	treatment	T061	C0087111
28390176	491	497	Gavage	T169	C2698653
28390176	509	520	body weight	T032	C0005910
28390176	547	549	AB	T061	C0185014
28390176	551	565	cucurbitacin B	T109,T121	C0056580
28390176	588	604	anti-hypertrophy	T033	C0243095
28390176	609	618	-fibrosis	T033	C0243095
28390176	656	661	heart	T023	C0018787
28390176	662	668	weight	T081	C0043100
28390176	670	685	myocardial cell	T025	C0225828
28390176	686	706	cross-sectional area	T201	C2923394
28390176	711	732	interstitial fibrosis	T046	C0240035
28390176	749	757	systolic	T079	C0039155
28390176	762	771	diastolic	T201	C0012000
28390176	772	785	abnormalities	T033	C0205161
28390176	801	816	gene expression	T045	C0017262
28390176	820	832	hypertrophic	T046	C0020564
28390176	837	845	fibrotic	T169	C0334129
28390176	846	853	markers	T201	C0005516
28390176	864	885	microvascular density	T080	C3272839
28390176	889	897	pressure	T184	C0497233
28390176	898	906	overload	UnknownType	C0684338
28390176	915	927	hypertrophic	T046	C0020564
28390176	928	932	mice	T015	C0025929
28390176	934	948	Cucurbitacin B	T109,T121	C0056580
28390176	973	984	hypertrophy	T046	C0020564
28390176	985	1002	inhibitory effect	T033	C0243095
28390176	1006	1019	phenylephrine	T109,T121	C0031469
28390176	1020	1030	stimulated	T070	C1948023
28390176	1031	1045	cardiomyocytes	T025	C0225828
28390176	1051	1065	Cucurbitacin B	T109,T121	C0056580
28390176	1076	1085	mitigated	T067	C1553901
28390176	1086	1105	cardiac hypertrophy	T046	C1383860
28390176	1150	1159	autophagy	T043	C0004391
28390176	1171	1186	associated with	T080	C0332281
28390176	1191	1199	blockade	T169	C0332206
28390176	1203	1206	Akt	T116,T126	C0164786
28390176	1209	1213	mTOR	T116,T126	C1453984
28390176	1216	1222	FoxO3a	T116,T123	C1506134
28390176	1223	1237	signal pathway	T044	C0037080
28390176	1252	1256	SC79	T109	C4307495
28390176	1258	1264	MK2206	T109,T121	C2933427
28390176	1270	1274	3-MA	T114	C0047569
28390176	1280	1283	Akt	T116,T126	C0164786
28390176	1284	1291	agonist	T121	C2987634
28390176	1293	1302	inhibitor	T120	C0243077
28390176	1307	1316	autophagy	T043	C0004391
28390176	1317	1326	inhibitor	T120	C0243077
28390176	1327	1335	in vitro	T062	C0681828
28390176	1341	1355	overexpression	T045	C1514559
28390176	1381	1384	Akt	T116,T126	C0164786
28390176	1410	1424	Cucurbitacin B	T109,T121	C0056580
28390176	1449	1468	cardiac hypertrophy	T046	C1383860
28390176	1472	1477	human	T016	C0086418
28390176	1478	1497	cardiomyocytes AC16	T025	C0225828
28390176	1539	1553	cucurbitacin B	T109,T121	C0056580
28390176	1571	1590	cardiac hypertrophy	T046	C1383860
28390176	1614	1623	autophagy	T043	C0004391
28390176	1633	1647	cardiomyocytes	T025	C0225828
28390176	1658	1673	associated with	T080	C0332281
28390176	1678	1688	inhibition	T043	C1519312
28390176	1692	1695	Akt	T116,T126	C0164786
28390176	1698	1702	mTOR	T116,T126	C1453984
28390176	1705	1711	FoxO3a	T116,T123	C1506134
28390176	1712	1723	signal axis	T044	C0037080

27348675|t|Gender Authorship Trends of Plastic Surgery Research in the United States
27348675|a|An increasing number of women are entering the medical profession, but plastic surgery remains a male - dominated profession, especially within academia. As academic aspirations and advancement depend largely on research productivity, the authors assessed the number of articles authored by women published in the journal Plastic and Reconstructive Surgery. Original articles in Plastic and Reconstructive Surgery published during the years 1970, 1980, 1990, 2000, 2004, and 2014 were analyzed. First and senior authors with an M.D. degree and U.S. institutional affiliation were categorized by gender. Authorship trends were compared with those from other specialties. Findings were placed in the context of gender trends among plastic surgery residents in the United States. The percentage of female authors in Plastic and Reconstructive Surgery increased from 2.4 percent in 1970 to 13.3 percent in 2014. Over the same time period, the percentage of female plastic surgery residents increased from 2.6 percent to 32.5 percent. By 2014, there were more female first authors (19.1 percent) than senior authors (7.7 percent) (p < 0.001). As a field, plastic surgery had fewer female authors than other medical specialties including pediatrics, obstetrics and gynecology, general surgery, internal medicine, and radiation oncology (p < 0.05). The increase in representation of female authors in plastic surgery is encouraging but lags behind advances in other specialties. Understanding reasons for these trends may help improve gender equity in academic plastic surgery.
27348675	0	6	Gender	T032	C0079399
27348675	7	17	Authorship	T057	C0004351
27348675	18	24	Trends	T079	C0040833
27348675	28	43	Plastic Surgery	T091	C0038911
27348675	44	52	Research	T062	C0035168
27348675	60	73	United States	T083	C0041703
27348675	77	87	increasing	T169	C0442808
27348675	98	103	women	T098	C0043210
27348675	121	139	medical profession	T091	C0814933
27348675	145	160	plastic surgery	T091	C0038911
27348675	171	175	male	T032	C0086582
27348675	178	187	dominated	T054	C0037413
27348675	188	198	profession	T090	C0028811
27348675	218	226	academia	T092	C1510747
27348675	231	239	academic	T092	C1510747
27348675	240	251	aspirations	T041	C0004056
27348675	286	294	research	T062	C0035168
27348675	295	307	productivity	T081	C0033269
27348675	313	320	authors	T097	C3812881
27348675	321	329	assessed	T052	C1516048
27348675	344	352	articles	T170	C1706852
27348675	365	370	women	T098	C0043210
27348675	371	380	published	T057	C0034037
27348675	388	430	journal Plastic and Reconstructive Surgery	T170	C0282574
27348675	488	497	published	T057	C0034037
27348675	579	585	senior	T098	C0001792
27348675	586	593	authors	T097	C3812881
27348675	602	605	M.D	T170	C1512018
27348675	607	613	degree	T170	C0542560
27348675	669	675	gender	T032	C0079399
27348675	677	687	Authorship	T057	C0004351
27348675	688	694	trends	T079	C0040833
27348675	731	742	specialties	T091	C0037778
27348675	783	789	gender	T032	C0079399
27348675	790	796	trends	T079	C0040833
27348675	803	818	plastic surgery	T091	C0038911
27348675	836	849	United States	T083	C0041703
27348675	869	875	female	T032	C0086287
27348675	876	883	authors	T097	C3812881
27348675	922	931	increased	T081	C0205217
27348675	1027	1033	female	T032	C0086287
27348675	1034	1049	plastic surgery	T091	C0038911
27348675	1060	1069	increased	T081	C0205217
27348675	1129	1135	female	T032	C0086287
27348675	1142	1149	authors	T097	C3812881
27348675	1177	1184	authors	T097	C3812881
27348675	1224	1239	plastic surgery	T091	C0038911
27348675	1250	1256	female	T032	C0086287
27348675	1257	1264	authors	T097	C3812881
27348675	1276	1295	medical specialties	T091	C0037778
27348675	1306	1316	pediatrics	T091	C0030755
27348675	1318	1343	obstetrics and gynecology	T091	C1274104
27348675	1345	1360	general surgery	T091	C1274039
27348675	1362	1379	internal medicine	T091	C0021782
27348675	1385	1403	radiation oncology	T091	C0243005
27348675	1420	1428	increase	T169	C0442805
27348675	1432	1446	representation	T052	C1882932
27348675	1450	1456	female	T032	C0086287
27348675	1457	1464	authors	T097	C3812881
27348675	1468	1483	plastic surgery	T091	C0038911
27348675	1533	1544	specialties	T091	C0037778
27348675	1578	1584	trends	T079	C0040833
27348675	1602	1608	gender	T032	C0079399
27348675	1619	1627	academic	T092	C1510747
27348675	1628	1643	plastic surgery	T091	C0038911

28543041|t|The added value of cardiac index and pulse pressure variation monitoring to mean arterial pressure - guided volume therapy in moderate-risk abdominal surgery (COGUIDE): a pragmatic multicentre randomised controlled trial
28543041|a|There is disagreement regarding the benefits of goal-directed therapy in moderate-risk abdominal surgery. Therefore, we tested the hypothesis that the addition of non-invasive cardiac index and pulse pressure variation monitoring to mean arterial pressure -based goal-directed therapy would reduce the incidence of postoperative complications in patients having moderate-risk abdominal surgery. In this pragmatic multicentre randomised controlled trial, we randomly allocated 244 patients by envelope drawing in a 1:1 fashion, stratified per centre. All patients had mean arterial pressure, cardiac index and pulse pressure variation measured continuously. In one group, healthcare professionals were blinded to cardiac index and pulse pressure variation values and were asked to guide haemodynamic therapy only based on mean arterial pressure (control group). In the second group, cardiac index and pulse pressure variation values were displayed and kept within target ranges following a pre-defined algorithm (CI-PPV group). The primary endpoint was the incidence of postoperative complications within 30 days. One hundred and seventy-five patients were eligible for final analysis. Overall complication rates were similar (42/94 (44.7%) vs. 38/81 (46.9%) in the control and CI-PPV groups, respectively; p = 0.95). The CI-PPV group had lower mean (SD) pulse pressure variation values (9.5 (2.0)% vs. 11.9 (4.6)%; p = 0.003) and higher mean (SD) cardiac indices (2.76 (0.62) l min(-1) .m(-2) vs. 2.53 (0.66) l min(-1) .m(-2); p = 0.004) than the control group. In moderate-risk abdominal surgery, we observed no additional value of cardiac index and pulse pressure variation - guided haemodynamic therapy to mean arterial pressure - guided volume therapy with regard to postoperative complications.
28543041	4	9	added	T169	C1524062
28543041	10	15	value	T081	C1522609
28543041	19	32	cardiac index	T033	C0428776
28543041	37	51	pulse pressure	T040	C0949236
28543041	52	61	variation	T080	C0205419
28543041	62	72	monitoring	T058	C1283169
28543041	76	98	mean arterial pressure	T033	C0428886
28543041	101	122	guided volume therapy	T061	C0087111
28543041	126	157	moderate-risk abdominal surgery	T061	C2066139
28543041	159	166	COGUIDE	T061	C0087111
28543041	171	180	pragmatic	T062	C3658312
28543041	181	192	multicentre	T062	C0206012
28543041	193	220	randomised controlled trial	T062	C0206035
28543041	230	242	disagreement	UnknownType	C0681800
28543041	257	265	benefits	T081	C0814225
28543041	269	290	goal-directed therapy	T061	C1271494
28543041	294	325	moderate-risk abdominal surgery	T061	C2066139
28543041	341	347	tested	T170	C0392366
28543041	352	362	hypothesis	T078	C1512571
28543041	372	380	addition	T169	C0332287
28543041	384	396	non-invasive	T169	C0205303
28543041	397	410	cardiac index	T033	C0428776
28543041	415	429	pulse pressure	T040	C0949236
28543041	430	439	variation	T080	C0205419
28543041	440	450	monitoring	T058	C1283169
28543041	454	476	mean arterial pressure	T033	C0428886
28543041	484	505	goal-directed therapy	T061	C1271494
28543041	512	518	reduce	T080	C0392756
28543041	523	532	incidence	T081	C0021149
28543041	536	563	postoperative complications	T046	C0032787
28543041	567	575	patients	T101	C0030705
28543041	583	614	moderate-risk abdominal surgery	T061	C2066139
28543041	624	633	pragmatic	T062	C3658312
28543041	634	645	multicentre	T062	C0206012
28543041	646	673	randomised controlled trial	T062	C0206035
28543041	678	696	randomly allocated	T062	C0034656
28543041	701	709	patients	T101	C0030705
28543041	713	729	envelope drawing	T170	C0013113
28543041	748	758	stratified	T080	C0205363
28543041	775	783	patients	T101	C0030705
28543041	788	810	mean arterial pressure	T033	C0428886
28543041	812	825	cardiac index	T033	C0428776
28543041	830	844	pulse pressure	T040	C0949236
28543041	845	854	variation	T080	C0205419
28543041	855	863	measured	T080	C0444706
28543041	864	876	continuously	T078	C0549178
28543041	885	890	group	T078	C0441833
28543041	892	916	healthcare professionals	T097	C0018724
28543041	922	929	blinded	T062	C0150108
28543041	933	946	cardiac index	T033	C0428776
28543041	951	965	pulse pressure	T040	C0949236
28543041	966	975	variation	T080	C0205419
28543041	976	982	values	T081	C1522609
28543041	1007	1027	haemodynamic therapy	T061	C0087111
28543041	1042	1064	mean arterial pressure	T033	C0428886
28543041	1066	1079	control group	T096	C0009932
28543041	1096	1101	group	T078	C0441833
28543041	1103	1116	cardiac index	T033	C0428776
28543041	1121	1135	pulse pressure	T040	C0949236
28543041	1136	1145	variation	T080	C0205419
28543041	1146	1152	values	T081	C1522609
28543041	1158	1167	displayed	T169	C0870432
28543041	1184	1190	target	T169	C1521840
28543041	1191	1197	ranges	T081	C1514721
28543041	1210	1231	pre-defined algorithm	T170	C0002045
28543041	1233	1245	CI-PPV group	T078	C0441833
28543041	1252	1268	primary endpoint	T130	C2986535
28543041	1277	1286	incidence	T081	C0021149
28543041	1290	1317	postoperative complications	T046	C0032787
28543041	1318	1332	within 30 days	T033	C3845590
28543041	1363	1371	patients	T101	C0030705
28543041	1377	1385	eligible	T080	C1548635
28543041	1390	1395	final	T079	C3853528
28543041	1396	1404	analysis	T062	C0936012
28543041	1406	1413	Overall	T080	C1561607
28543041	1414	1432	complication rates	T046	C0009566
28543041	1486	1493	control	T096	C0009932
28543041	1498	1511	CI-PPV groups	T078	C0441833
28543041	1542	1554	CI-PPV group	T078	C0441833
28543041	1559	1564	lower	T080	C0205251
28543041	1565	1569	mean	T081	C0444504
28543041	1571	1573	SD	T081	C0871420
28543041	1575	1589	pulse pressure	T040	C0949236
28543041	1590	1599	variation	T080	C0205419
28543041	1600	1606	values	T081	C1522609
28543041	1651	1657	higher	T080	C0205250
28543041	1658	1662	mean	T081	C0444504
28543041	1664	1666	SD	T081	C0871420
28543041	1668	1683	cardiac indices	T033	C0428776
28543041	1768	1781	control group	T096	C0009932
28543041	1786	1817	moderate-risk abdominal surgery	T061	C2066139
28543041	1822	1830	observed	T169	C1441672
28543041	1834	1850	additional value	T170	C0439062
28543041	1854	1867	cardiac index	T033	C0428776
28543041	1872	1886	pulse pressure	T040	C0949236
28543041	1887	1896	variation	T080	C0205419
28543041	1899	1926	guided haemodynamic therapy	T061	C0087111
28543041	1930	1952	mean arterial pressure	T033	C0428886
28543041	1955	1976	guided volume therapy	T061	C0087111
28543041	1992	2019	postoperative complications	T046	C0032787

28509318|t|The duration of pregnancy in ecologically-challenged area. The effects of environmental pollution with aromatic hydrocarbons on the angiogenesis and elements of the mesenchymal tissue of the human placenta
28509318|a|The literature presents only few reports regarding the effects of elevated levels of aromatic hydrocarbons (AH) on the functions of the human placenta. The effects of environmental contamination with AH (including phenol and 1-hydroxypyrene) have certain negative effects on parenchymal organs such as human placenta. The paper aimed to assess the effects of elevated levels of AH on the placental angiogenesis and elements of the mesenchymal tissue of the placenta. Tissue material from 50 afterbirths from Płock constituted a study group, whereas 50 afterbirths from Kutno constituted a control group. Immunohistochemical reactions with the peroxidase method using LSAB kits (DAKO) were performed. The extent and intensity of reactions were analysed. The levels of phenols and 1-hydroxypyrene in the excreted urine of pregnant women (undergoing delivery) were detected using gas chromatography and colorimetry. The levels of phenol and 1-hydroxypyrene in the excreted urine were demonstrated to be statistically significantly higher in patients living in the area of Płock. Statistically significantly higher expression of antibodies indicating placental angiogenesis was observed in the placentas in the Płock group (p < 0.01). Moreover, lower expression of vimentin indicating reactions with proteins in mesenchymal cells was observed in the Kutno group (p < 0.01). Pregnancy in the environment with elevated levels of aromatic hydrocarbons has detrimental effects on the human placenta. The foetus is protected by activation of adaptation and compensation mechanisms that are manifested as significant angiogenesis and greater development and differentiation of mesenchymal cells compared to the control group.
28509318	4	12	duration	T079	C0449238
28509318	16	25	pregnancy	T040	C0032961
28509318	29	57	ecologically-challenged area	T082	C0565987
28509318	63	70	effects	T080	C1280500
28509318	74	97	environmental pollution	T069	C0014419
28509318	103	124	aromatic hydrocarbons	T109	C0020245
28509318	132	144	angiogenesis	T042	C0302600
28509318	165	183	mesenchymal tissue	T018	C0162415
28509318	191	196	human	T016	C0086418
28509318	197	205	placenta	T018	C0032043
28509318	210	220	literature	T170	C0023866
28509318	261	268	effects	T080	C1280500
28509318	272	280	elevated	T080	C3163633
28509318	281	287	levels	T080	C0441889
28509318	291	312	aromatic hydrocarbons	T109	C0020245
28509318	314	316	AH	T109	C0020245
28509318	342	347	human	T016	C0086418
28509318	348	356	placenta	T018	C0032043
28509318	362	369	effects	T080	C1280500
28509318	373	400	environmental contamination	T069	C0014419
28509318	406	408	AH	T109	C0020245
28509318	420	426	phenol	T109,T121	C0070570
28509318	431	446	1-hydroxypyrene	T109,T131	C0044415
28509318	461	469	negative	T033	C0205160
28509318	470	477	effects	T080	C1280500
28509318	481	499	parenchymal organs	T029	C0524464
28509318	508	513	human	T016	C0086418
28509318	514	522	placenta	T018	C0032043
28509318	554	561	effects	T080	C1280500
28509318	565	573	elevated	T080	C3163633
28509318	574	580	levels	T080	C0441889
28509318	584	586	AH	T109	C0020245
28509318	594	603	placental	T018	C0032043
28509318	604	616	angiogenesis	T042	C0302600
28509318	637	655	mesenchymal tissue	T018	C0162415
28509318	663	671	placenta	T018	C0032043
28509318	673	688	Tissue material	T024	C0457457
28509318	697	708	afterbirths	T018	C0392917
28509318	714	719	Płock	UnknownType	C0681784
28509318	734	745	study group	UnknownType	C0681860
28509318	758	769	afterbirths	T018	C0392917
28509318	775	780	Kutno	UnknownType	C0681784
28509318	795	808	control group	T096	C0009932
28509318	810	866	Immunohistochemical reactions with the peroxidase method	T059	C0021067
28509318	873	882	LSAB kits	T170	C0282574
28509318	910	916	extent	T082	C0439792
28509318	949	957	analysed	T062	C0936012
28509318	963	969	levels	T080	C0441889
28509318	973	980	phenols	T109,T121	C0070570
28509318	985	1000	1-hydroxypyrene	T109,T131	C0044415
28509318	1008	1016	excreted	T039	C0221102
28509318	1017	1022	urine	T031	C0042036
28509318	1026	1040	pregnant women	T098	C0033011
28509318	1053	1061	delivery	T040	C0005615
28509318	1068	1076	detected	T061	C1511790
28509318	1083	1101	gas chromatography	T059	C0008555
28509318	1106	1117	colorimetry	T059	C0009407
28509318	1123	1129	levels	T080	C0441889
28509318	1133	1139	phenol	T109,T121	C0070570
28509318	1144	1159	1-hydroxypyrene	T109,T131	C0044415
28509318	1167	1175	excreted	T039	C0221102
28509318	1176	1181	urine	T031	C0042036
28509318	1206	1233	statistically significantly	T081	C0237881
28509318	1234	1240	higher	T080	C0205250
28509318	1244	1252	patients	T101	C0030705
28509318	1275	1280	Płock	UnknownType	C0681784
28509318	1282	1309	Statistically significantly	T081	C0237881
28509318	1310	1316	higher	T080	C0205250
28509318	1317	1327	expression	T045	C1171362
28509318	1331	1341	antibodies	T116,T129	C0003241
28509318	1353	1362	placental	T018	C0032043
28509318	1363	1375	angiogenesis	T042	C0302600
28509318	1380	1388	observed	T169	C1441672
28509318	1396	1405	placentas	T018	C0032043
28509318	1413	1424	Płock group	T098	C1257890
28509318	1447	1452	lower	T080	C0205251
28509318	1453	1463	expression	T045	C1171362
28509318	1467	1475	vimentin	T116,T123	C0042666
28509318	1514	1531	mesenchymal cells	T025	C1257975
28509318	1536	1544	observed	T169	C1441672
28509318	1552	1563	Kutno group	T098	C1257890
28509318	1576	1585	Pregnancy	T040	C0032961
28509318	1593	1604	environment	T082	C0014406
28509318	1610	1618	elevated	T080	C3163633
28509318	1619	1625	levels	T080	C0441889
28509318	1629	1650	aromatic hydrocarbons	T109	C0020245
28509318	1667	1674	effects	T080	C1280500
28509318	1682	1687	human	T016	C0086418
28509318	1688	1696	placenta	T018	C0032043
28509318	1702	1708	foetus	T018	C0015965
28509318	1725	1735	activation	T052	C1879547
28509318	1739	1749	adaptation	T038	C0392673
28509318	1754	1777	compensation mechanisms	T039	C0152058
28509318	1801	1812	significant	T078	C0750502
28509318	1813	1825	angiogenesis	T042	C0302600
28509318	1830	1837	greater	T081	C1704243
28509318	1838	1849	development	T039	C0243107
28509318	1854	1869	differentiation	T169	C2945687
28509318	1873	1890	mesenchymal cells	T025	C1257975
28509318	1907	1920	control group	T096	C0009932

27908689|t|PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
27908689|a|Statin treatment and variants in the gene encoding HMG-CoA reductase are associated with reductions in both the concentration of LDL cholesterol and the risk of coronary heart disease, but also with modest hyperglycaemia, increased bodyweight, and modestly increased risk of type 2 diabetes, which in no way offsets their substantial benefits. We sought to investigate the associations of LDL cholesterol -lowering PCSK9 variants with type 2 diabetes and related biomarkers to gauge the likely effects of PCSK9 inhibitors on diabetes risk. In this mendelian randomisation study, we used data from cohort studies, randomised controlled trials, case control studies, and genetic consortia to estimate associations of PCSK9 genetic variants with LDL cholesterol, fasting blood glucose, HbA1c, fasting insulin, bodyweight, waist-to-hip ratio, BMI, and risk of type 2 diabetes, using a standardised analysis plan, meta-analyses, and weighted gene-centric scores. Data were available for more than 550 000 individuals and 51 623 cases of type 2 diabetes. Combined analyses of four independent PCSK9 variants (rs11583680, rs11591147, rs2479409, and rs11206510) scaled to 1 mmol/L lower LDL cholesterol showed associations with increased fasting glucose (0·09 mmol/L, 95% CI 0·02 to 0·15), bodyweight (1·03 kg, 0·24 to 1·82), waist-to-hip ratio (0·006, 0·003 to 0·010), and an odds ratio for type diabetes of 1·29 (1·11 to 1·50). Based on the collected data, we did not identify associations with HbA1c (0·03%, -0·01 to 0·08), fasting insulin (0·00%, -0·06 to 0·07), and BMI (0·11 kg/m(2), -0·09 to 0·30). PCSK9 variants associated with lower LDL cholesterol were also associated with circulating higher fasting glucose concentration, bodyweight, and waist-to-hip ratio, and an increased risk of type 2 diabetes. In trials of PCSK9 inhibitor drugs, investigators should carefully assess these safety outcomes and quantify the risks and benefits of PCSK9 inhibitor treatment, as was previously done for statins. British Heart Foundation, and University College London Hospitals NHS Foundation Trust (UCLH) National Institute for Health Research (NIHR) Biomedical Research Centre.
27908689	0	5	PCSK9	T028	C1426592
27908689	6	22	genetic variants	T028	C0678941
27908689	27	31	risk	T078	C0035647
27908689	35	50	type 2 diabetes	T047	C0011860
27908689	54	83	mendelian randomisation study	T062	C2718019
27908689	84	90	Statin	T109,T121	C0360714
27908689	91	100	treatment	T061	C0087111
27908689	105	125	variants in the gene	T028	C0678941
27908689	135	152	HMG-CoA reductase	T116,T126	C0020374
27908689	173	183	reductions	T080	C0392756
27908689	196	209	concentration	T081	C1446561
27908689	213	228	LDL cholesterol	T109,T123	C0023824
27908689	237	241	risk	T078	C0035647
27908689	245	267	coronary heart disease	T047	C0010068
27908689	290	304	hyperglycaemia	T047	C0020456
27908689	306	326	increased bodyweight	T033	C0043094
27908689	341	350	increased	T081	C0205217
27908689	351	355	risk	T078	C0035647
27908689	359	374	type 2 diabetes	T047	C0011860
27908689	441	452	investigate	T169	C1292732
27908689	473	488	LDL cholesterol	T109,T123	C0023824
27908689	499	504	PCSK9	T028	C1426592
27908689	505	513	variants	T028	C0678941
27908689	519	534	type 2 diabetes	T047	C0011860
27908689	547	557	biomarkers	T201	C0005516
27908689	589	605	PCSK9 inhibitors	T121	C4051515
27908689	609	622	diabetes risk	T081	C1171304
27908689	632	661	mendelian randomisation study	T062	C2718019
27908689	671	675	data	T078	C1511726
27908689	681	695	cohort studies	T081	C0009247
27908689	697	725	randomised controlled trials	T062	C0206035
27908689	727	747	case control studies	T062	C0007328
27908689	799	804	PCSK9	T028	C1426592
27908689	805	821	genetic variants	T028	C0678941
27908689	827	842	LDL cholesterol	T109,T123	C0023824
27908689	844	865	fasting blood glucose	T034	C1261430
27908689	867	872	HbA1c	T116,T123	C0019018
27908689	874	881	fasting	T033	C0015663
27908689	882	889	insulin	T116,T121,T125	C0021641
27908689	891	901	bodyweight	T032	C0005910
27908689	903	921	waist-to-hip ratio	T032	C0205682
27908689	923	926	BMI	T201	C1305855
27908689	932	936	risk	T078	C0035647
27908689	940	955	type 2 diabetes	T047	C0011860
27908689	965	991	standardised analysis plan	T062	C0936012
27908689	993	1006	meta-analyses	T062	C0920317
27908689	1012	1040	weighted gene-centric scores	T081	C0449820
27908689	1042	1046	Data	T078	C1511726
27908689	1084	1095	individuals	T098	C0237401
27908689	1116	1131	type 2 diabetes	T047	C0011860
27908689	1133	1150	Combined analyses	T062	C0936012
27908689	1171	1176	PCSK9	T028	C1426592
27908689	1177	1185	variants	T028	C0678941
27908689	1187	1197	rs11583680	T028	C0678941
27908689	1199	1209	rs11591147	T028	C0678941
27908689	1211	1220	rs2479409	T028	C0678941
27908689	1226	1236	rs11206510	T028	C0678941
27908689	1263	1278	LDL cholesterol	T109,T123	C0023824
27908689	1304	1329	increased fasting glucose	T033	C0920108
27908689	1366	1376	bodyweight	T032	C0005910
27908689	1402	1420	waist-to-hip ratio	T032	C0205682
27908689	1453	1463	odds ratio	T081	C0028873
27908689	1473	1481	diabetes	T047	C0011847
27908689	1519	1528	collected	T078	C1516695
27908689	1529	1533	data	T078	C1511726
27908689	1573	1578	HbA1c	T116,T123	C0019018
27908689	1603	1610	fasting	T033	C0015663
27908689	1611	1618	insulin	T116,T121,T125	C0021641
27908689	1647	1650	BMI	T201	C1305855
27908689	1682	1687	PCSK9	T028	C1426592
27908689	1688	1696	variants	T028	C0678941
27908689	1719	1734	LDL cholesterol	T109,T123	C0023824
27908689	1773	1795	higher fasting glucose	T033	C0920108
27908689	1796	1809	concentration	T081	C1446561
27908689	1811	1821	bodyweight	T032	C0005910
27908689	1827	1845	waist-to-hip ratio	T032	C0205682
27908689	1864	1868	risk	T078	C0035647
27908689	1872	1887	type 2 diabetes	T047	C0011860
27908689	1892	1898	trials	T062	C0008976
27908689	1902	1917	PCSK9 inhibitor	T121	C4051515
27908689	1918	1923	drugs	T121	C0013227
27908689	1925	1938	investigators	T097	C0035173
27908689	1989	1997	quantify	T081	C1709793
27908689	2002	2007	risks	T078	C0035647
27908689	2012	2020	benefits	T081	C0814225
27908689	2024	2039	PCSK9 inhibitor	T121	C4051515
27908689	2040	2049	treatment	T061	C0087111
27908689	2078	2085	statins	T109,T121	C0360714
27908689	2087	2111	British Heart Foundation	T092	C0016617
27908689	2117	2173	University College London Hospitals NHS Foundation Trust	T092	C0035172
27908689	2175	2179	UCLH	T092	C0035172
27908689	2181	2253	National Institute for Health Research (NIHR) Biomedical Research Centre	T092	C0035172

28084988|t|Screening for Food Insecurity in Six Veterans Administration Clinics for the Homeless, June-December 2015
28084988|a|We assessed findings from a food-insecurity screening of a national sample of Veterans Administration clinics for homeless and formerly homeless veterans. We reviewed results from initial screenings administered at 6 Veterans Administration primary care clinics for the homeless and responses from clinic staff members interviewed about the screening program. A total of 270 patients were screened. The average age was 53 years, and most were male (93.1%). Screening showed a high prevalence of food insecurity. Of the 270, 48.5% reported they experienced food insecurity in the previous 3 months, 55.0% reported averaging 2 meals a day, and 27.3% averaged 1 meal a day. Eighty-seven percent prepared their own meals, relying on food they bought (54.2%), help from friends and family (19.1%), and soup kitchens and food pantries (22%); 47.3% received Supplemental Nutrition Assistance Program benefits (food stamps). Additionally, of those who screened positive for food insecurity 19.8% had diabetes or prediabetes, and 43.5% reported hypoglycemia symptoms when without food. Clinic staff members responded positively to the screening program and described it as a good rapport builder with patients. Integrating screening for food insecurity among patients in clinical settings was well received by both patients and health care providers. Addressing these positive findings of food insecurity requires a multidisciplinary health care approach.
28084988	0	9	Screening	T058	C0220908
28084988	14	29	Food Insecurity	T080	C3494174
28084988	37	68	Veterans Administration Clinics	T073,T093	C0020030
28084988	77	85	Homeless	T098	C0019863
28084988	109	117	assessed	T052	C1516048
28084988	118	126	findings	T033	C0243095
28084988	134	149	food-insecurity	T080	C3494174
28084988	150	159	screening	T058	C0220908
28084988	165	180	national sample	T170	C0038951
28084988	184	215	Veterans Administration clinics	T073,T093	C0020030
28084988	220	228	homeless	T098	C0019863
28084988	242	259	homeless veterans	T098	C0019863
28084988	264	272	reviewed	T080	C1709940
28084988	273	280	results	T169	C1274040
28084988	286	293	initial	T079	C0205265
28084988	294	304	screenings	T058	C0220908
28084988	323	367	Veterans Administration primary care clinics	T073,T093	C0020030
28084988	376	384	homeless	T098	C0019863
28084988	389	398	responses	T041	C2911692
28084988	404	410	clinic	T073,T093	C0442592
28084988	411	424	staff members	T097	C1552089
28084988	425	436	interviewed	T052	C0021822
28084988	447	456	screening	T058	C0220908
28084988	457	464	program	T169	C3484370
28084988	481	489	patients	T101	C0030705
28084988	495	503	screened	T058	C0220908
28084988	517	520	age	T032	C0001779
28084988	528	533	years	T079	C1510829
28084988	549	553	male	T032	C0086582
28084988	563	572	Screening	T058	C0220908
28084988	582	597	high prevalence	T081	C1512456
28084988	601	616	food insecurity	T080	C3494174
28084988	636	644	reported	T058	C0700287
28084988	662	677	food insecurity	T080	C3494174
28084988	696	702	months	T079	C0439231
28084988	710	718	reported	T058	C0700287
28084988	731	736	meals	T056	C1998602
28084988	739	742	day	T079	C0439505
28084988	765	769	meal	T056	C1998602
28084988	772	775	day	T079	C0439505
28084988	817	822	meals	T052	C3468944
28084988	835	839	food	T168	C0016452
28084988	871	878	friends	T098	C0079382
28084988	883	889	family	T099	C0015576
28084988	903	916	soup kitchens	T073	C0557653
28084988	921	934	food pantries	T073	C0557779
28084988	957	998	Supplemental Nutrition Assistance Program	T064	C3494397
28084988	999	1007	benefits	T081	C0814225
28084988	1009	1020	food stamps	T064	C0681144
28084988	1050	1058	screened	T058	C0220908
28084988	1059	1067	positive	T033	C1514241
28084988	1072	1087	food insecurity	T080	C3494174
28084988	1098	1106	diabetes	T047	C0011847
28084988	1110	1121	prediabetes	T047	C0362046
28084988	1142	1154	hypoglycemia	T047	C0020615
28084988	1155	1163	symptoms	T184	C1457887
28084988	1177	1181	food	T168	C0016452
28084988	1183	1189	Clinic	T073,T093	C0442592
28084988	1190	1203	staff members	T097	C1552089
28084988	1204	1213	responded	T041	C2911692
28084988	1214	1224	positively	T033	C3843166
28084988	1232	1241	screening	T058	C0220908
28084988	1242	1249	program	T169	C3484370
28084988	1277	1284	rapport	T080	C0680241
28084988	1298	1306	patients	T101	C0030705
28084988	1320	1329	screening	T058	C0220908
28084988	1334	1349	food insecurity	T080	C3494174
28084988	1356	1364	patients	T101	C0030705
28084988	1368	1385	clinical settings	T082	C3176918
28084988	1412	1420	patients	T101	C0030705
28084988	1425	1446	health care providers	T097	C0018724
28084988	1465	1482	positive findings	T033	C1514241
28084988	1486	1501	food insecurity	T080	C3494174
28084988	1513	1530	multidisciplinary	T057	C0242479
28084988	1531	1542	health care	T058	C0086388

27590051|t|Generation and analyses of human synthetic antibody libraries and their application for protein microarrays
27590051|a|Antibody -based proteomics offers distinct advantages in the analysis of complex samples for discovery and validation of biomarkers associated with disease. However, its large-scale implementation requires tools and technologies that allow development of suitable antibody or antibody fragments in a high-throughput manner. To address this we designed and constructed two human synthetic antibody fragment (scFv) libraries denoted HelL-11 and HelL-13. By the use of phage display technology, in total 466 unique scFv antibodies specific for 114 different antigens were generated. The specificities of these antibodies were analyzed in a variety of immunochemical assays and a subset was further evaluated for functionality in protein microarray applications. This high-throughput approach demonstrates the ability to rapidly generate a wealth of reagents not only for proteome research, but potentially also for diagnostics and therapeutics. In addition, this work provides a great example on how a synthetic approach can be used to optimize library designs. By having precise control of the diversity introduced into the antigen - binding sites, synthetic libraries offer increased understanding of how different diversity contributes to antibody binding reactivity and stability, thereby providing the key to future library optimization.
27590051	0	10	Generation	T052	C3146294
27590051	15	23	analyses	T062	C0936012
27590051	27	32	human	T016	C0086418
27590051	33	61	synthetic antibody libraries	T170	C0598139
27590051	72	83	application	T169	C4048755
27590051	88	107	protein microarrays	T075	C1136348
27590051	108	116	Antibody	T116,T129	C0003241
27590051	124	134	proteomics	T091	C0872252
27590051	169	177	analysis	T062	C0936012
27590051	189	196	samples	T077	C2347026
27590051	201	210	discovery	T052	C1880355
27590051	215	225	validation	T062	C1519941
27590051	229	239	biomarkers	T201	C0005516
27590051	240	255	associated with	T080	C0332281
27590051	256	263	disease	T047	C0012634
27590051	290	304	implementation	T052	C1708476
27590051	314	319	tools	T073	C0336791
27590051	324	336	technologies	T063	C1513384
27590051	348	359	development	T169	C1527148
27590051	372	380	antibody	T116,T129	C0003241
27590051	384	402	antibody fragments	T116,T129	C0003241
27590051	408	430	high-throughput manner	T170	C0872047
27590051	480	485	human	T016	C0086418
27590051	486	530	synthetic antibody fragment (scFv) libraries	T170	C0598139
27590051	539	546	HelL-11	T116,T129	C0003241
27590051	551	558	HelL-13	T116,T129	C0003241
27590051	574	598	phage display technology	T063	C3494191
27590051	620	635	scFv antibodies	T116,T129	C0003241
27590051	663	671	antigens	T129	C0003320
27590051	715	725	antibodies	T116,T129	C0003241
27590051	756	777	immunochemical assays	T059	C0519671
27590051	834	852	protein microarray	T075	C1136348
27590051	853	865	applications	T169	C4048755
27590051	872	896	high-throughput approach	T170	C0872047
27590051	944	950	wealth	T080	C0699759
27590051	954	962	reagents	T130	C0034760
27590051	976	984	proteome	T116,T123	C0751973
27590051	985	993	research	T062	C0035168
27590051	1020	1031	diagnostics	T062	C1511890
27590051	1036	1048	therapeutics	T061	C0087111
27590051	1150	1165	library designs	T170	C0598139
27590051	1200	1209	diversity	T080	C1880371
27590051	1230	1237	antigen	T129	C0003320
27590051	1240	1253	binding sites	T192	C0005456
27590051	1255	1274	synthetic libraries	T170	C0598139
27590051	1322	1331	diversity	T080	C1880371
27590051	1347	1355	antibody	T116,T129	C0003241
27590051	1356	1374	binding reactivity	T052	C1145667
27590051	1379	1388	stability	T080	C0205360
27590051	1426	1433	library	T170	C0598139
27590051	1434	1446	optimization	T052	C2698650

27828958|t|Historical Environment Is Reflected in Modern Population Genetics and Biogeography of an Island Endemic Lizard (Xantusia riversiana reticulata)
27828958|a|The restricted distribution and isolation of island endemics often produces unique genetic and phenotypic diversity of conservation interest to management agencies. However, these isolated species, especially those with sensitive life history traits, are at high risk for the adverse effects of genetic drift and habitat degradation by non-native wildlife. Here, we study the population genetic diversity, structure, and stability of a classic " island giant " (Xantusia riversiana, the Island Night Lizard) on San Clemente Island, California following the removal of feral goats. Using DNA microsatellites, we found that this population is reasonably genetically robust despite historical grazing, with similar effective population sizes and genetic diversity metrics across all sampling locations irrespective of habitat type and degree of degradation. However, we also found strong site-specific patterns of genetic variation and low genetic diversity compared to mainland congeners, warranting continued special management as an island endemic. We identify both high and low elevation areas that remain valuable repositories of genetic diversity and provide a case study for other low-dispersal coastal organisms in the face of future climate change.
27828958	0	10	Historical	T079	C0681698
27828958	11	22	Environment	T082	C0014406
27828958	39	65	Modern Population Genetics	T090	C0017404
27828958	70	82	Biogeography	T090	C2936603
27828958	89	95	Island	T083	C0022130
27828958	96	103	Endemic	T169	C0243130
27828958	104	110	Lizard	T014	C0023916
27828958	112	142	Xantusia riversiana reticulata	T014	C0999100
27828958	148	171	restricted distribution	T169	C1704711
27828958	176	185	isolation	T169	C0205409
27828958	189	195	island	T083	C0022130
27828958	196	204	endemics	T169	C0243130
27828958	227	234	genetic	T070	C0042333
27828958	239	249	phenotypic	T032	C0031437
27828958	250	259	diversity	T080	C1880371
27828958	263	275	conservation	T080	C2347858
27828958	288	298	management	T090	C3273539
27828958	299	307	agencies	T092	C0237463
27828958	324	332	isolated	T169	C0205409
27828958	333	340	species	T185	C1705920
27828958	364	373	sensitive	T169	C0332324
27828958	374	386	life history	T032	C0598779
27828958	387	393	traits	T032	C0599883
27828958	402	411	high risk	T033	C0332167
27828958	420	435	adverse effects	T046	C0879626
27828958	439	452	genetic drift	T045	C0917892
27828958	457	464	habitat	T082	C0871648
27828958	465	476	degradation	T169	C0243125
27828958	480	499	non-native wildlife	T008	C0003070
27828958	510	515	study	T062	C2603343
27828958	520	530	population	T098	C1257890
27828958	531	548	genetic diversity	T070	C0042333
27828958	550	559	structure	T082	C0678594
27828958	565	574	stability	T080	C0205360
27828958	590	602	island giant	T014	C0023916
27828958	606	625	Xantusia riversiana	T014	C0999100
27828958	631	650	Island Night Lizard	T014	C0023916
27828958	655	674	San Clemente Island	T083	C0022130
27828958	676	686	California	T083	C0006754
27828958	701	708	removal	T052	C1883720
27828958	712	723	feral goats	T015	C1510458
27828958	731	734	DNA	T114,T123	C0012854
27828958	735	750	microsatellites	T114,T123	C1519302
27828958	771	781	population	T098	C1257890
27828958	796	807	genetically	T169	C0314603
27828958	808	814	robust	T080	C2986815
27828958	823	833	historical	T079	C0681698
27828958	834	841	grazing	T040	C3178952
27828958	866	882	population sizes	T081	C0032683
27828958	887	904	genetic diversity	T070	C0042333
27828958	924	932	sampling	T078	C0870078
27828958	933	942	locations	T083	C0017446
27828958	959	966	habitat	T082	C0871648
27828958	976	997	degree of degradation	T080	C0205556
27828958	1029	1042	site-specific	T082	C0449604
27828958	1043	1051	patterns	T082	C0449774
27828958	1055	1072	genetic variation	T070	C0042333
27828958	1081	1098	genetic diversity	T070	C0042333
27828958	1111	1129	mainland congeners	T014	C0035161
27828958	1160	1170	management	T090	C3273539
27828958	1177	1183	island	T083	C0022130
27828958	1184	1191	endemic	T169	C0243130
27828958	1210	1214	high	T080	C0205250
27828958	1219	1222	low	T080	C0205251
27828958	1223	1238	elevation areas	T082	C0702240
27828958	1260	1272	repositories	T073	C3847505
27828958	1276	1293	genetic diversity	T070	C0042333
27828958	1308	1318	case study	T170	C0085973
27828958	1329	1342	low-dispersal	T070	C1254365
27828958	1343	1350	coastal	T082	C0557760
27828958	1351	1360	organisms	T001	C0029235
27828958	1376	1382	future	T079	C0016884
27828958	1383	1397	climate change	T070	C2718051

27651178|t|HELLP Syndrome
27651178|a|The hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome is frequently observed in mothers whose offspring have long-chain fatty acid oxidation defects. We previously found that fatty acid oxidation is compromised not only in these inborn errors of metabolism but also in human umbilical vein endothelial cells (HUVECs) from all pregnancies complicated by the HELLP syndrome. Sirtuins are oxidized nicotinamide adenine dinucleotide (NAD(+))dependent deacetylases linked to the metabolic status of the cell. SIRT 4 is known to have regulatory functions in fatty acid oxidation. The HELLP syndrome is often associated with short-term hypoxia. We studied sirtuins (SIRT 1, SIRT 3, and SIRT 4) in HUVECs from pregnancies complicated by the HELLP syndrome and uncomplicated pregnancies exposed to hypoxia (n = 7 controls, 7 HELLP; 0, 10, 60, or 120 minutes of 2% O2). Protein levels of SIRT 4 were significantly higher in HUVECs from HELLP compared to control after 60 and 120 minutes of hypoxia. The NAD(+) levels increased in a time - dependent manner.
27651178	0	14	HELLP Syndrome	T047	C0162739
27651178	19	93	hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome	T047	C2903579
27651178	108	116	observed	T169	C1441672
27651178	120	127	mothers	T099	C0026591
27651178	134	143	offspring	T099	C0680063
27651178	149	170	long-chain fatty acid	T109,T123	C0522095
27651178	171	180	oxidation	T044	C0030011
27651178	181	188	defects	T169	C0243067
27651178	215	235	fatty acid oxidation	T044	C1158366
27651178	239	250	compromised	T033	C2945640
27651178	269	296	inborn errors of metabolism	T019,T047	C0025521
27651178	309	347	human umbilical vein endothelial cells	T025	C3179121
27651178	349	355	HUVECs	T025	C3179121
27651178	366	389	pregnancies complicated	T047	C0032962
27651178	397	411	HELLP syndrome	T047	C0162739
27651178	413	421	Sirtuins	T116,T126	C1136177
27651178	426	434	oxidized	T044	C0030011
27651178	435	499	nicotinamide adenine dinucleotide (NAD(+))dependent deacetylases	T044	C2613148
27651178	514	523	metabolic	T169	C0311400
27651178	524	530	status	T080	C0449438
27651178	538	542	cell	T025	C0007634
27651178	544	550	SIRT 4	T116,T126	C2002817
27651178	568	588	regulatory functions	T038	C1327622
27651178	592	612	fatty acid oxidation	T044	C1158366
27651178	618	632	HELLP syndrome	T047	C0162739
27651178	642	657	associated with	T080	C0332281
27651178	658	668	short-term	T079	C0443303
27651178	669	676	hypoxia	T046	C0242184
27651178	681	688	studied	T062	C2603343
27651178	689	697	sirtuins	T116,T126	C1136177
27651178	699	705	SIRT 1	T116,T126	C1101544
27651178	707	713	SIRT 3	T116,T126	C1143857
27651178	719	725	SIRT 4	T116,T126	C2002817
27651178	730	736	HUVECs	T025	C3179121
27651178	742	765	pregnancies complicated	T047	C0032962
27651178	773	787	HELLP syndrome	T047	C0162739
27651178	792	805	uncomplicated	T080	C0443334
27651178	806	817	pregnancies	T040	C0032961
27651178	818	825	exposed	T080	C0332157
27651178	829	836	hypoxia	T046	C0242184
27651178	844	852	controls	T096	C0009932
27651178	856	861	HELLP	T047	C0162739
27651178	895	897	O2	T121,T123,T196	C0030054
27651178	900	907	Protein	T116,T123	C0033684
27651178	908	914	levels	T080	C0441889
27651178	918	924	SIRT 4	T116,T126	C2002817
27651178	930	943	significantly	T078	C0750502
27651178	944	950	higher	T080	C0205250
27651178	954	960	HUVECs	T025	C3179121
27651178	966	971	HELLP	T047	C0162739
27651178	972	980	compared	T052	C1707455
27651178	984	991	control	T096	C0009932
27651178	1020	1027	hypoxia	T046	C0242184
27651178	1033	1039	NAD(+)	T114,T121,T123	C0027270
27651178	1040	1046	levels	T080	C0441889
27651178	1047	1056	increased	T081	C0205217
27651178	1062	1066	time	T079	C0040223
27651178	1069	1078	dependent	T169	C3244310

28166877|t|Effects of display curvature, display zone, and task duration on legibility and visual fatigue during visual search task
28166877|a|This study examined the effects of display curvature (400, 600, 1200 mm, and flat), display zone (5 zones), and task duration (15 and 30 min) on legibility and visual fatigue. Each participant completed two 15-min visual search task sets at each curvature setting. The 600-mm and 1200-mm settings yielded better results than the flat setting in terms of legibility and perceived visual fatigue. Relative to the corresponding centre zone, the outermost zones of the 1200-mm and flat settings showed a decrease of 8%-37% in legibility, whereas those of the flat setting showed an increase of 26%-45% in perceived visual fatigue. Across curvature s, legibility decreased by 2%-8%, whereas perceived visual fatigue increased by 22% during the second task set. The two task sets induced an increase of 102% in the eye complaint score and a decrease of 0.3 Hz in the critical fusion frequency, both of which indicated an increase in visual fatigue. In summary, a curvature of around 600 mm, central display zones, and frequent breaks are recommended to improve legibility and reduce visual fatigue.
28166877	11	18	display	T169	C0870432
28166877	19	28	curvature	T082	C0205134
28166877	30	37	display	T169	C0870432
28166877	38	42	zone	T082	C1710706
28166877	48	52	task	UnknownType	C0679599
28166877	53	61	duration	T079	C0449238
28166877	65	75	legibility	T033	C0870803
28166877	80	94	visual fatigue	T047	C0004095
28166877	102	120	visual search task	UnknownType	C0679599
28166877	156	163	display	T169	C0870432
28166877	164	173	curvature	T082	C0205134
28166877	198	202	flat	T082	C0205324
28166877	205	212	display	T169	C0870432
28166877	213	217	zone	T082	C1710706
28166877	221	226	zones	T082	C1710706
28166877	233	237	task	UnknownType	C0679599
28166877	238	246	duration	T079	C0449238
28166877	266	276	legibility	T033	C0870803
28166877	281	295	visual fatigue	T047	C0004095
28166877	302	313	participant	T098	C0679646
28166877	335	353	visual search task	UnknownType	C0679599
28166877	367	376	curvature	T082	C0205134
28166877	377	384	setting	T082	C0442307
28166877	409	417	settings	T082	C0442307
28166877	450	454	flat	T082	C0205324
28166877	455	462	setting	T082	C0442307
28166877	475	485	legibility	T033	C0870803
28166877	500	514	visual fatigue	T047	C0004095
28166877	546	552	centre	T082	C0205099
28166877	553	557	zone	T082	C1710706
28166877	573	578	zones	T082	C1710706
28166877	598	602	flat	T082	C0205324
28166877	603	611	settings	T082	C0442307
28166877	643	653	legibility	T033	C0870803
28166877	676	680	flat	T082	C0205324
28166877	681	688	setting	T082	C0442307
28166877	699	707	increase	T169	C0442805
28166877	722	731	perceived	T041	C0030971
28166877	732	746	visual fatigue	T047	C0004095
28166877	755	764	curvature	T082	C0205134
28166877	768	778	legibility	T033	C0870803
28166877	779	788	decreased	T081	C0205216
28166877	807	816	perceived	T041	C0030971
28166877	817	831	visual fatigue	T047	C0004095
28166877	832	841	increased	T169	C0442805
28166877	867	875	task set	UnknownType	C0679599
28166877	885	894	task sets	UnknownType	C0679599
28166877	906	914	increase	T169	C0442805
28166877	930	949	eye complaint score	T081	C0449820
28166877	982	1007	critical fusion frequency	T034	C0234697
28166877	1036	1044	increase	T169	C0442805
28166877	1048	1062	visual fatigue	T047	C0004095
28166877	1078	1087	curvature	T082	C0205134
28166877	1106	1113	central	T082	C0205099
28166877	1114	1121	display	T169	C0870432
28166877	1122	1127	zones	T082	C1710706
28166877	1142	1148	breaks	T082	C0449647
28166877	1168	1175	improve	T033	C0184511
28166877	1176	1186	legibility	T033	C0870803
28166877	1198	1212	visual fatigue	T047	C0004095

27861771|t|High-density lipoprotein -associated sphingosine-1-phosphate activity in heterozygous familial hypercholesterolaemia
27861771|a|Patients with heterozygous familial hypercholesterolaemia (FH) suffer from high plasma cholesterol and an environment of increased oxidative stress. We examined its potential effects on high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) content (HDL - S1P) and HDL -mediated protection against oxidative stress, both with and without statin treatment. In a case-control study, HDL was isolated from 12 FH patients with and without statin treatment and from 12 healthy controls. The HDL - S1P content and the capacity of HDL to protect cardiomyocytes against oxidative stress in vitro were measured. HDL -associated S1P was significantly correlated with cell protection, but not with HDL-cholesterol or apolipoprotein AI. The latter did not correlate with HDL -mediated cell protection. Neither the HDL - S1P content nor HDL protective capacity differed between nontreated FH patients and controls. The relative amounts of apolipoprotein AI and apolipoprotein M were similar between controls and FH patients. Statin treatment had no effect on any of these measures. The FH environment is not detrimental to HDL - S1P content or HDL - S1P -mediated cell protection. Statin treatment does not modulate HDL function in this regard.
27861771	0	24	High-density lipoprotein	T116,T123	C0023821
27861771	37	60	sphingosine-1-phosphate	T109	C0074992
27861771	73	116	heterozygous familial hypercholesterolaemia	T047	C0342882
27861771	117	125	Patients	T101	C0030705
27861771	131	174	heterozygous familial hypercholesterolaemia	T047	C0342882
27861771	176	178	FH	T047	C0342882
27861771	180	186	suffer	T184	C0751408
27861771	192	215	high plasma cholesterol	T033	C0858226
27861771	223	234	environment	T082	C0014406
27861771	248	264	oxidative stress	T049	C0242606
27861771	303	327	high-density lipoprotein	T116,T123	C0023821
27861771	329	332	HDL	T116,T123	C0023821
27861771	345	368	sphingosine-1-phosphate	T109	C0074992
27861771	370	373	S1P	T109	C0074992
27861771	384	387	HDL	T116,T123	C0023821
27861771	390	393	S1P	T109	C0074992
27861771	399	402	HDL	T116,T123	C0023821
27861771	413	448	protection against oxidative stress	T039	C3823580
27861771	472	488	statin treatment	T058	C1314135
27861771	495	513	case-control study	T062	C0007328
27861771	515	518	HDL	T116,T123	C0023821
27861771	523	531	isolated	T169	C0205409
27861771	540	542	FH	T047	C0342882
27861771	543	551	patients	T101	C0030705
27861771	569	585	statin treatment	T058	C1314135
27861771	598	614	healthy controls	T080	C2986479
27861771	620	623	HDL	T116,T123	C0023821
27861771	626	629	S1P	T109	C0074992
27861771	658	661	HDL	T116,T123	C0023821
27861771	665	672	protect	T033	C1545588
27861771	673	687	cardiomyocytes	T025	C0225828
27861771	696	712	oxidative stress	T049	C0242606
27861771	713	721	in vitro	T062	C0681828
27861771	737	740	HDL	T116,T123	C0023821
27861771	753	756	S1P	T109	C0074992
27861771	791	806	cell protection	T039	C0524828
27861771	821	836	HDL-cholesterol	T109,T123	C0023822
27861771	840	857	apolipoprotein AI	T116,T123	C0085201
27861771	893	896	HDL	T116,T123	C0023821
27861771	907	922	cell protection	T039	C0524828
27861771	936	939	HDL	T116,T123	C0023821
27861771	942	945	S1P	T109	C0074992
27861771	958	961	HDL	T116,T123	C0023821
27861771	1010	1012	FH	T047	C0342882
27861771	1013	1021	patients	T101	C0030705
27861771	1060	1077	apolipoprotein AI	T116,T123	C0085201
27861771	1082	1098	apolipoprotein M	T116,T123	C1438565
27861771	1133	1135	FH	T047	C0342882
27861771	1136	1144	patients	T101	C0030705
27861771	1146	1162	Statin treatment	T058	C1314135
27861771	1207	1209	FH	T047	C0342882
27861771	1210	1221	environment	T082	C0014406
27861771	1244	1247	HDL	T116,T123	C0023821
27861771	1250	1253	S1P	T109	C0074992
27861771	1265	1268	HDL	T116,T123	C0023821
27861771	1271	1274	S1P	T109	C0074992
27861771	1285	1300	cell protection	T039	C0524828
27861771	1302	1318	Statin treatment	T058	C1314135
27861771	1337	1340	HDL	T116,T123	C0023821

27470998|t|Disparities in treatment and survival for women with endometrial cancer: A contemporary national cancer database registry analysis
27470998|a|The study aim was to identify contemporary socioeconomic, racial, ethnic, and facility-related factors associated with stage at diagnosis, receipt of cancer treatment, and survival in women with endometrial cancer (EC). Women diagnosed with EC between 1998 and 2010 were identified from the National Cancer Database. Variables associated with the outcomes of interest were assessed using multivariable Cox proportional hazards and logistic regression. Among 228,511 women identified, the percentage of blacks with stage IIIC/IV disease at diagnosis was nearly twice that of non-Hispanic whites (17.8% vs 9.8%; P<0.001). Patients with advanced disease who were insured with Medicare were less likely to receive standard-of-care postoperative radiotherapy and/or chemotherapy than those with private insurance (odds ratio: OR 0.80, P<0.001), as were those residing in the South (reference) in comparison to the Northeast, Atlantic, Great Lakes, and Midwest regions (OR 1.3-1.7, all P<0.001). Those residing in the Mountain region were even less likely to receive appropriate treatment (OR 0.7, P<0.001). Five-year stage IIIC/IV survival was 42.8% for non-Hispanic whites vs 24.6% for blacks (hazard ratio 1.3, P<0.001). Other factors associated with inferior 5-year survival included payer status (not insured, Medicaid, Medicare, vs private, ORs 1.2-1.3, all P<0.01), and treatment at low-volume centers (<5 vs ≥30cases/year, HR 1.3, P<0.001). Socioeconomic, geographic and facility-related factors predict advanced endometrial cancer stage, failure to receive cancer care, and shorter survival. Black women had especially poor survival. Nationwide standardization and concentration of treatment at high-volume centers may improve outcomes.
27470998	0	11	Disparities	T080	C1955989
27470998	15	24	treatment	T169	C0039798
27470998	29	37	survival	T169	C0220921
27470998	42	47	women	T098	C0043210
27470998	53	71	endometrial cancer	T191	C0007103
27470998	75	87	contemporary	T080	C0205556
27470998	88	130	national cancer database registry analysis	T062	C0242481
27470998	161	173	contemporary	T080	C0205556
27470998	174	187	socioeconomic	T102	C0037464
27470998	189	195	racial	T169	C1521761
27470998	197	203	ethnic	T169	C1521761
27470998	209	233	facility-related factors	T169	C1521761
27470998	234	249	associated with	T080	C0332281
27470998	250	268	stage at diagnosis	T185	C1514952
27470998	270	277	receipt	T170	C0282574
27470998	281	287	cancer	T191	C0006826
27470998	288	297	treatment	T169	C0039798
27470998	303	311	survival	T169	C0220921
27470998	315	320	women	T098	C0043210
27470998	326	344	endometrial cancer	T191	C0007103
27470998	346	348	EC	T191	C0007103
27470998	351	356	Women	T098	C0043210
27470998	372	374	EC	T191	C0007103
27470998	422	446	National Cancer Database	T170	C0242356
27470998	448	457	Variables	T080	C0439828
27470998	458	473	associated with	T080	C0332281
27470998	478	486	outcomes	T080	C0085415
27470998	504	512	assessed	T052	C1516048
27470998	519	557	multivariable Cox proportional hazards	T081,T170	C0010235
27470998	562	581	logistic regression	T062	C0206031
27470998	597	602	women	T098	C0043210
27470998	603	613	identified	T080	C0205396
27470998	619	629	percentage	T081	C0439165
27470998	633	639	blacks	T098	C0005680
27470998	645	679	stage IIIC/IV disease at diagnosis	T185	C1514952
27470998	705	724	non-Hispanic whites	T098	C1257890
27470998	751	759	Patients	T101	C0030705
27470998	765	781	advanced disease	UnknownType	C0679246
27470998	804	812	Medicare	T064	C0018717
27470998	833	840	receive	T080	C1514756
27470998	841	857	standard-of-care	T061	C2936643
27470998	858	884	postoperative radiotherapy	T061	C0436206
27470998	892	904	chemotherapy	T061	C3665472
27470998	921	938	private insurance	T064	C3845555
27470998	940	950	odds ratio	T081	C0028873
27470998	952	954	OR	T081	C0028873
27470998	985	993	residing	T052	C2982691
27470998	1001	1006	South	T082	C1710133
27470998	1008	1017	reference	T081	C0034925
27470998	1040	1049	Northeast	T082	C1709272
27470998	1051	1059	Atlantic	T083	C0004166
27470998	1061	1072	Great Lakes	T083	C0018224
27470998	1078	1093	Midwest regions	T083	C0017446
27470998	1095	1097	OR	T081	C0028873
27470998	1127	1135	residing	T052	C2982691
27470998	1143	1158	Mountain region	T083	C0684035
27470998	1184	1191	receive	T080	C1514756
27470998	1204	1213	treatment	T169	C0039798
27470998	1215	1217	OR	T081	C0028873
27470998	1243	1256	stage IIIC/IV	T201	C1300072
27470998	1257	1265	survival	T169	C0220921
27470998	1280	1299	non-Hispanic whites	T098	C1257890
27470998	1313	1319	blacks	T098	C0005680
27470998	1321	1333	hazard ratio	T081	C2985465
27470998	1355	1362	factors	T169	C1521761
27470998	1363	1378	associated with	T080	C0332281
27470998	1395	1403	survival	T169	C0220921
27470998	1413	1418	payer	T098	C1257890
27470998	1419	1425	status	T080	C0449438
27470998	1440	1448	Medicaid	T064	C0025071
27470998	1450	1458	Medicare	T064	C0018717
27470998	1472	1475	ORs	T081	C0028873
27470998	1502	1511	treatment	T169	C0039798
27470998	1515	1533	low-volume centers	T073,T093	C1552416
27470998	1556	1558	HR	T081	C2985465
27470998	1574	1587	Socioeconomic	T102	C0037464
27470998	1589	1599	geographic	T077	C0017444
27470998	1604	1628	facility-related factors	T169	C1521761
27470998	1637	1664	advanced endometrial cancer	T191	C0007103
27470998	1665	1670	stage	T201	C1300072
27470998	1683	1690	receive	T080	C1514756
27470998	1691	1702	cancer care	T061	C0920687
27470998	1716	1724	survival	T169	C0220921
27470998	1726	1731	Black	T098	C0005680
27470998	1732	1737	women	T098	C0043210
27470998	1758	1766	survival	T169	C0220921
27470998	1768	1794	Nationwide standardization	T062	C0038136
27470998	1799	1812	concentration	T058	C1254363
27470998	1816	1825	treatment	T169	C0039798
27470998	1829	1848	high-volume centers	T073,T093	C1552416
27470998	1861	1869	outcomes	T080	C0085415

27530243|t|Drug-drug interactions of cytostatics with regular medicines in lung cancer patients
27530243|a|Lung cancer patients have a high risk for drug-drug interactions, as they use numerous types of concomitant medicines including antineoplastic agents, cancer treatment co-medication, and medicines aimed at several types of comorbidities. The primary objective of this study is to determine the incidence and the clinical relevance of the drug-drug interactions between antineoplastic agents and regular medication used by lung cancer patients. Secondary objectives are (i) to determine the effectiveness of the medication review by the hospital pharmacists concerned, (ii) to establish which patients are most at risk of drug-drug interactions and (iii) to determine whether physicians comply with advice given by hospital pharmacists. This prospective study was undertaken in a Dutch hospital pharmacy, at Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam. All lung cancer patients receiving one or more cytotoxic agents during the period 21 June 2010 till 2 December 2014 at OLVG were included. The medication list of the patients was obtained electronically from the community pharmacy and checked for interactions by a hospital pharmacist. Interactions that required intervention according to the national database were the only ones taken into account. Interventions were recorded in the patients ' electronic chart s. All medication reviews were cross-checked and analyzed by an independent pharmacist at the end of the study period. Prevalence and clinical relevance of drug-drug interactions between antineoplastic agents and other types of medication in lung cancer patients. A total of 298 lung cancer patients were included in this study. In 53 patients (18%), a total of 73 interactions with potential clinical relevance were found. The most frequent interaction was between cytostatics and coumarins while the most relevant one was between cisplatin and furosemide. According to statistical analysis, gender as well as the number of drugs prescribed were significant predictors for drug-drug interactions. Eighty-four percent of the interactions were discovered by pharmacists during daily routine. In 92% of the cases, the pulmonary physicians complied with the advice of the pharmacist. Eighteen percent of lung cancer patients treated with cytotoxic therapy had one or more relevant drug-drug interactions. This study shows that medication surveillance by a hospital pharmacist is necessary to prevent possible negative drug-drug interactions. Further research should focus on the clinical outcome of the interactions as well as on interactions between cytostatics and alternative medicines and/or over-the-counter medicines.
27530243	0	22	Drug-drug interactions	T044	C0687133
27530243	26	37	cytostatics	T121	C0010858
27530243	43	60	regular medicines	T121	C0013227
27530243	64	75	lung cancer	T191	C0242379
27530243	76	84	patients	T101	C0030705
27530243	85	96	Lung cancer	T191	C0242379
27530243	97	105	patients	T101	C0030705
27530243	127	149	drug-drug interactions	T044	C0687133
27530243	181	192	concomitant	T079	C0521115
27530243	193	202	medicines	T121	C0013227
27530243	213	234	antineoplastic agents	T109,T121	C0003392
27530243	236	252	cancer treatment	T061	C0920425
27530243	253	266	co-medication	T121	C0013227
27530243	272	281	medicines	T121	C0013227
27530243	272	281	medicines	T121	C0013227
27530243	308	321	comorbidities	T078	C0009488
27530243	397	405	clinical	T080	C0205210
27530243	406	415	relevance	T080	C2347946
27530243	423	445	drug-drug interactions	T044	C0687133
27530243	454	475	antineoplastic agents	T109,T121	C0003392
27530243	480	498	regular medication	T121	C0013227
27530243	507	518	lung cancer	T191	C0242379
27530243	519	527	patients	T101	C0030705
27530243	575	588	effectiveness	T080	C1280519
27530243	596	606	medication	T121	C0013227
27530243	621	641	hospital pharmacists	T097	C0402002
27530243	677	685	patients	T101	C0030705
27530243	695	702	at risk	T080	C1444641
27530243	706	728	drug-drug interactions	T044	C0687133
27530243	760	770	physicians	T097	C0031831
27530243	799	819	hospital pharmacists	T097	C0402002
27530243	826	843	prospective study	T062	C0033522
27530243	864	887	Dutch hospital pharmacy	T058	C0031321
27530243	892	918	Onze Lieve Vrouwe Gasthuis	T083	C0017446
27530243	920	924	OLVG	T083	C0017446
27530243	927	936	Amsterdam	T083	C0017446
27530243	942	953	lung cancer	T191	C0242379
27530243	954	962	patients	T101	C0030705
27530243	985	1001	cytotoxic agents	T121	C0304497
27530243	1057	1061	OLVG	T083	C0017446
27530243	1081	1091	medication	T121	C0013227
27530243	1104	1112	patients	T101	C0030705
27530243	1150	1168	community pharmacy	T093	C0009478
27530243	1185	1197	interactions	T044	C0687133
27530243	1203	1222	hospital pharmacist	T097	C0402002
27530243	1224	1236	Interactions	T044	C0687133
27530243	1251	1263	intervention	T061	C0184661
27530243	1281	1298	national database	T170	C0242356
27530243	1338	1351	Interventions	T061	C0184661
27530243	1373	1381	patients	T101	C0030705
27530243	1384	1400	electronic chart	T170	C0282574
27530243	1408	1418	medication	T121	C0013227
27530243	1465	1487	independent pharmacist	T097	C0031323
27530243	1535	1543	clinical	T080	C0205210
27530243	1544	1553	relevance	T080	C2347946
27530243	1557	1579	drug-drug interactions	T044	C0687133
27530243	1588	1609	antineoplastic agents	T109,T121	C0003392
27530243	1629	1639	medication	T121	C0013227
27530243	1643	1654	lung cancer	T191	C0242379
27530243	1655	1663	patients	T101	C0030705
27530243	1680	1691	lung cancer	T191	C0242379
27530243	1692	1700	patients	T101	C0030705
27530243	1736	1744	patients	T101	C0030705
27530243	1766	1778	interactions	T044	C0687133
27530243	1794	1802	clinical	T080	C0205210
27530243	1803	1812	relevance	T080	C2347946
27530243	1843	1854	interaction	T044	C0687133
27530243	1867	1878	cytostatics	T121	C0010858
27530243	1883	1892	coumarins	T109,T121	C0010207
27530243	1933	1942	cisplatin	T121,T197	C0008838
27530243	1947	1957	furosemide	T109,T121	C0016860
27530243	1972	1992	statistical analysis	T062	C0871424
27530243	1994	2000	gender	T032	C0079399
27530243	2026	2042	drugs prescribed	T121	C3166216
27530243	2048	2070	significant predictors	T078	C2698872
27530243	2075	2097	drug-drug interactions	T044	C0687133
27530243	2126	2138	interactions	T044	C0687133
27530243	2158	2169	pharmacists	T097	C0031323
27530243	2217	2237	pulmonary physicians	T097	C1555769
27530243	2270	2280	pharmacist	T097	C0031323
27530243	2302	2313	lung cancer	T191	C0242379
27530243	2314	2322	patients	T101	C0030705
27530243	2336	2353	cytotoxic therapy	T061	C0677881
27530243	2370	2378	relevant	T080	C2347946
27530243	2379	2401	drug-drug interactions	T044	C0687133
27530243	2425	2435	medication	T121	C0013227
27530243	2454	2473	hospital pharmacist	T097	C0402002
27530243	2507	2538	negative drug-drug interactions	T046	C0678798
27530243	2577	2593	clinical outcome	T081	C0086749
27530243	2601	2613	interactions	T044	C0687133
27530243	2628	2640	interactions	T044	C0687133
27530243	2649	2660	cytostatics	T121	C0010858
27530243	2665	2686	alternative medicines	T091	C0002346
27530243	2711	2720	medicines	T121	C0013227

27706190|t|Influence of Different Levels of Lipoic Acid Synthase Gene Expression on Diabetic Nephropathy
27706190|a|Oxidative stress is implicated in the pathogenesis of diabetic nephropathy (DN) but outcomes of many clinical trials are controversial. To define the role of antioxidants in kidney protection during the development of diabetic nephropathy, we have generated a novel genetic antioxidant mouse model with over- or under-expression of lipoic acid synthase gene (Lias). These models have been mated with Ins2Akita/+ mice, a type I diabetic mouse model. We compare the major pathologic changes and oxidative stress status in two new strains of the mice with controls. Our results show that Ins2Akita/+ mice with under-expressed Lias gene, exhibit higher oxidative stress and more severe DN features (albuminuria, glomerular basement membrane thickening and mesangial matrix expansion). In contrast, Ins2Akita/+ mice with highly - expressed Lias gene display lower oxidative stress and less DN pathologic changes. Our study demonstrates that strengthening endogenous antioxidant capacity could be an effective strategy for prevention and treatment of DN.
27706190	0	9	Influence	T077	C4054723
27706190	13	22	Different	T080	C1705242
27706190	23	29	Levels	T079	C1306673
27706190	33	53	Lipoic Acid Synthase	T028	C1424272
27706190	54	69	Gene Expression	T045	C0017262
27706190	73	93	Diabetic Nephropathy	T047	C0011881
27706190	94	110	Oxidative stress	T049	C0242606
27706190	132	144	pathogenesis	T046	C0699748
27706190	148	168	diabetic nephropathy	T047	C0011881
27706190	170	172	DN	T047	C0011881
27706190	178	186	outcomes	T169	C1274040
27706190	195	210	clinical trials	T062	C0008976
27706190	244	248	role	T077	C1705810
27706190	252	264	antioxidants	T121	C0003402
27706190	268	274	kidney	T023	C0022646
27706190	286	292	during	T079	C0347984
27706190	297	308	development	T169	C1527148
27706190	312	332	diabetic nephropathy	T047	C0011881
27706190	342	351	generated	T052	C3146294
27706190	354	359	novel	T080	C0205314
27706190	360	391	genetic antioxidant mouse model	T050	C2986594
27706190	397	422	over- or under-expression	T045	C0017262
27706190	426	451	lipoic acid synthase gene	T028	C1424272
27706190	453	457	Lias	T028	C1424272
27706190	466	472	models	T050	C2986594
27706190	483	488	mated	T040	C1260875
27706190	494	510	Ins2Akita/+ mice	T015	C0025929
27706190	514	529	type I diabetic	T047	C0836995
27706190	530	541	mouse model	T050	C2986594
27706190	546	553	compare	T052	C1707455
27706190	558	563	major	T080	C0205164
27706190	564	582	pathologic changes	T034	C4086730
27706190	587	603	oxidative stress	T049	C0242606
27706190	604	610	status	T080	C0449438
27706190	637	641	mice	T015	C0025929
27706190	661	668	results	T169	C1274040
27706190	679	695	Ins2Akita/+ mice	T015	C0025929
27706190	701	716	under-expressed	T045	C0017262
27706190	717	726	Lias gene	T028	C1424272
27706190	736	742	higher	T080	C0205250
27706190	743	759	oxidative stress	T049	C0242606
27706190	764	768	more	T081	C0205172
27706190	769	775	severe	T080	C0205082
27706190	776	778	DN	T047	C0011881
27706190	779	787	features	T080	C2348519
27706190	789	800	albuminuria	T033	C0001925
27706190	802	841	glomerular basement membrane thickening	T033	C0445347
27706190	846	872	mesangial matrix expansion	T033	C3553722
27706190	888	904	Ins2Akita/+ mice	T015	C0025929
27706190	910	916	highly	T080	C0205250
27706190	919	928	expressed	T045	C0017262
27706190	929	938	Lias gene	T028	C1424272
27706190	939	946	display	T169	C0870432
27706190	947	952	lower	T080	C0205251
27706190	953	969	oxidative stress	T049	C0242606
27706190	974	978	less	T080	C0547044
27706190	979	981	DN	T047	C0011881
27706190	982	1000	pathologic changes	T034	C4086730
27706190	1006	1011	study	T062	C2603343
27706190	1012	1024	demonstrates	T052	C3687625
27706190	1044	1054	endogenous	T169	C0205227
27706190	1055	1066	antioxidant	T121	C0003402
27706190	1067	1075	capacity	T081	C1516240
27706190	1088	1121	effective strategy for prevention	UnknownType	C0679723
27706190	1126	1135	treatment	T169	C1522326
27706190	1139	1141	DN	T047	C0011881

28178386|t|Evaluating a dignity care intervention for palliative care in the community setting: community nurses ' perspectives
28178386|a|To evaluate a dignity care intervention provided by community nurses seeking to address dignity concerns for people with advanced and life-limiting conditions. Evidence would suggest that dying people fear a loss of dignity and a central focus of palliative care is to assist people to die with dignity. Whilst community nurses have a key role to play in the delivery of palliative care, specific interventions for dignity are lacking. A mixed methods study using online survey and focus group interviews and thematic analysis to examine data. Twenty four community nurses implemented the dignity care intervention for people with advanced and life-limiting conditions were recruited from four pilot sites across Ireland. Four focus group interviews and on line survey were conducted between March-June 2015. The community nurses found the dignity care intervention useful. It helped the nurses to provide holistic end-of-life care and assisted in the overall assessment of palliative care patients, identifying areas that might not otherwise have been noted. Whilst it was a useful tool for communication, they noted that it stimulated some emotionally sensitive conversations for which they felt unprepared. Implementing the dignity care intervention in practice was challenging. However, the dignity care intervention facilitated holistic assessment and identified patient dignity-related concerns that may not have been otherwise identified. Further support is required to overcome barriers and enable dignity-conserving care. Ensuring dignity is a key aspect of palliative and end-of-life care; however, community nurses may not feel equipped to address this aspect of care. Implementing a dignity care intervention can assist in identifying patient dignity-related concerns and provision of holistic care. Community nurses need more training to assist in difficult conversations relating to dignity and end-of-life care.
28178386	0	10	Evaluating	T058	C0220825
28178386	13	20	dignity	T078	C2713415
28178386	21	25	care	T052	C1947933
28178386	26	38	intervention	T061	C0184661
28178386	43	58	palliative care	T091	C0030231
28178386	66	83	community setting	T096	C0009462
28178386	85	101	community nurses	T097	C0557521
28178386	104	116	perspectives	T078	C0871586
28178386	120	128	evaluate	T058	C0220825
28178386	131	138	dignity	T078	C2713415
28178386	139	143	care	T052	C1947933
28178386	144	156	intervention	T061	C0184661
28178386	169	185	community nurses	T097	C0557521
28178386	205	212	dignity	T078	C2713415
28178386	213	221	concerns	T078	C2699424
28178386	226	232	people	T098	C0027361
28178386	238	246	advanced	T080	C0205179
28178386	251	275	life-limiting conditions	T033	C1517874
28178386	277	285	Evidence	T078	C3887511
28178386	305	317	dying people	T101	C0871503
28178386	318	322	fear	T041	C0015726
28178386	325	329	loss	T081	C1517945
28178386	333	340	dignity	T078	C2713415
28178386	347	360	central focus	T033	C0517484
28178386	364	379	palliative care	T091	C0030231
28178386	386	392	assist	T080	C1269765
28178386	393	399	people	T098	C0027361
28178386	403	406	die	T040	C0011065
28178386	412	419	dignity	T078	C2713415
28178386	428	444	community nurses	T097	C0557521
28178386	476	484	delivery	T058	C0011211
28178386	488	503	palliative care	T091	C0030231
28178386	514	527	interventions	T061	C0184661
28178386	532	539	dignity	T078	C2713415
28178386	544	551	lacking	T080	C0332268
28178386	555	574	mixed methods study	T062	C2603343
28178386	581	594	online survey	T170	C0038951
28178386	599	621	focus group interviews	T062	C0018260
28178386	626	643	thematic analysis	T062	C0936012
28178386	655	659	data	T078	C1511726
28178386	673	689	community nurses	T097	C0557521
28178386	690	701	implemented	T052	C1708476
28178386	706	713	dignity	T078	C2713415
28178386	714	718	care	T052	C1947933
28178386	719	731	intervention	T061	C0184661
28178386	736	742	people	T098	C0027361
28178386	748	756	advanced	T080	C0205179
28178386	761	785	life-limiting conditions	T033	C1517874
28178386	791	800	recruited	T052	C2949735
28178386	830	837	Ireland	T083	C0022067
28178386	844	866	focus group interviews	T062	C0018260
28178386	871	885	on line survey	T170	C0038951
28178386	930	946	community nurses	T097	C0557521
28178386	947	952	found	T033	C0243095
28178386	957	964	dignity	T078	C2713415
28178386	965	969	care	T052	C1947933
28178386	970	982	intervention	T061	C0184661
28178386	1005	1011	nurses	T097	C0557521
28178386	1023	1048	holistic end-of-life care	T091	C0282561
28178386	1053	1061	assisted	T080	C1269765
28178386	1069	1087	overall assessment	T058	C0220825
28178386	1091	1106	palliative care	T091	C0030231
28178386	1107	1115	patients	T101	C0030705
28178386	1200	1204	tool	T170	C0025663
28178386	1209	1222	communication	T054	C0009452
28178386	1243	1253	stimulated	T070	C1948023
28178386	1259	1270	emotionally	T041	C0013987
28178386	1271	1280	sensitive	T169	C0332324
28178386	1281	1294	conversations	T054	C0871703
28178386	1327	1339	Implementing	T052	C1708476
28178386	1344	1351	dignity	T078	C2713415
28178386	1352	1356	care	T052	C1947933
28178386	1357	1369	intervention	T061	C0184661
28178386	1412	1419	dignity	T078	C2713415
28178386	1420	1424	care	T052	C1947933
28178386	1425	1437	intervention	T061	C0184661
28178386	1450	1469	holistic assessment	T058	C0220825
28178386	1474	1484	identified	T080	C0205396
28178386	1485	1492	patient	T101	C0030705
28178386	1493	1508	dignity-related	T078	C2713415
28178386	1509	1517	concerns	T078	C2699424
28178386	1551	1561	identified	T080	C0205396
28178386	1603	1611	barriers	T080	C0679881
28178386	1623	1641	dignity-conserving	T078	C2713415
28178386	1642	1646	care	T052	C1947933
28178386	1657	1664	dignity	T078	C2713415
28178386	1670	1680	key aspect	T080	C1879746
28178386	1684	1715	palliative and end-of-life care	T061	C2032843
28178386	1726	1742	community nurses	T097	C0557521
28178386	1781	1787	aspect	T080	C1879746
28178386	1791	1795	care	T052	C1947933
28178386	1797	1809	Implementing	T052	C1708476
28178386	1812	1819	dignity	T078	C2713415
28178386	1820	1824	care	T052	C1947933
28178386	1825	1837	intervention	T061	C0184661
28178386	1842	1848	assist	T080	C1269765
28178386	1852	1863	identifying	T080	C0205396
28178386	1864	1871	patient	T101	C0030705
28178386	1872	1887	dignity-related	T078	C2713415
28178386	1888	1896	concerns	T078	C2699424
28178386	1901	1910	provision	T058	C1283218
28178386	1914	1927	holistic care	T091	C0282561
28178386	1929	1945	Community nurses	T097	C0557521
28178386	1956	1964	training	T065	C0220931
28178386	1968	1974	assist	T080	C1269765
28178386	1978	1987	difficult	T080	C0332218
28178386	1988	2001	conversations	T054	C0871703
28178386	2014	2021	dignity	T078	C2713415
28178386	2026	2042	end-of-life care	T058	C0039548

27486953|t|Comparison of semiologies between tilt-induced psychogenic nonsyncopal collapse and psychogenic nonepileptic seizures
27486953|a|We sought to characterize the clinical features of tilt-induced psychogenic nonsyncopal collapse (PNSC) from a cohort of young patients and to compare the semiologies between PNSC and EEG -confirmed psychogenic nonepileptic seizures (PNES). A PNSC diagnosis was made if a clinical event occurred during tilt-table testing that the patient regarded as fainting, but neither hypotension nor EEG changes were present. A diagnosis of PNSC was made in 17.6% of all patients referred during the 15-month study period. Cohorts with psychogenic nonsyncopal collapse (n=40) and PNES (n=40) did not differ in age (15.5±2.2 versus 14.6±2.7, p=.11) or female gender (80% versus 72.5%, p=.43). Psychogenic nonsyncopal collapse events were briefer than PNES events (median: 45 versus 201.5s, p<.001). Negative motor signs (head drop, body limpness) predominated in PNSC (85% versus 20%, p<.001), while the positive motor signs of convulsion occurred more often with PNES (90% versus 30%, p<.001). Behavioral arrest (25% versus 32.5%, p=.46) and eye closure (85% versus 72.5%, p=.21) did not differ between PNSC and PNES. Patients with PNSC were more likely to be tearful before (30% versus 7.5%, p=.02) and after (62.5% versus 7.5%, p<.001) an event. In conclusion, although overlap exists, the features of PNSC generally appear similar to neurally mediated syncope, while the features of PNES generally appear similar to epileptic seizures. Psychogenic nonsyncopal collapse and PNES likely represent similar disorders that differ primarily by clinical semiologies and referral patterns.
27486953	14	25	semiologies	T090	C0871335
27486953	47	79	psychogenic nonsyncopal collapse	T048	C0004936
27486953	84	95	psychogenic	T048	C1142430
27486953	96	117	nonepileptic seizures	T047	C2236802
27486953	148	156	clinical	T080	C0205210
27486953	157	165	features	T080	C2348519
27486953	182	214	psychogenic nonsyncopal collapse	T048	C0004936
27486953	216	220	PNSC	T048	C0004936
27486953	229	235	cohort	T098	C0599755
27486953	239	244	young	T079	C0332239
27486953	245	253	patients	T101	C0030705
27486953	273	284	semiologies	T090	C0871335
27486953	293	297	PNSC	T048	C0004936
27486953	302	305	EEG	T060	C0013819
27486953	317	328	psychogenic	T048	C1142430
27486953	329	350	nonepileptic seizures	T047	C2236802
27486953	352	356	PNES	T047	C2236802
27486953	361	365	PNSC	T048	C0004936
27486953	366	375	diagnosis	T033	C0011900
27486953	390	404	clinical event	T078	C3831076
27486953	421	439	tilt-table testing	T060	C0242880
27486953	449	456	patient	T101	C0030705
27486953	469	477	fainting	T184	C0039070
27486953	483	490	neither	T033	C3843060
27486953	491	502	hypotension	T033	C0020649
27486953	507	510	EEG	T060	C0013819
27486953	511	518	changes	T169	C0392747
27486953	535	544	diagnosis	T033	C0011900
27486953	548	552	PNSC	T048	C0004936
27486953	578	586	patients	T101	C0030705
27486953	622	628	period	T079	C1948053
27486953	630	637	Cohorts	T098	C0599755
27486953	643	675	psychogenic nonsyncopal collapse	T048	C0004936
27486953	687	691	PNES	T047	C2236802
27486953	717	720	age	T032	C0001779
27486953	758	771	female gender	T032	C0086287
27486953	799	831	Psychogenic nonsyncopal collapse	T048	C0004936
27486953	857	861	PNES	T047	C2236802
27486953	905	925	Negative motor signs	T033	C0243095
27486953	927	936	head drop	T033	C0243095
27486953	938	951	body limpness	T033	C0243095
27486953	969	973	PNSC	T048	C0004936
27486953	1010	1030	positive motor signs	T033	C0243095
27486953	1034	1044	convulsion	T184	C4048158
27486953	1070	1074	PNES	T047	C2236802
27486953	1101	1118	Behavioral arrest	T033	C0243095
27486953	1149	1160	eye closure	T033	C0243095
27486953	1210	1214	PNSC	T048	C0004936
27486953	1219	1223	PNES	T047	C2236802
27486953	1225	1233	Patients	T101	C0030705
27486953	1239	1243	PNSC	T048	C0004936
27486953	1267	1274	tearful	T033	C0424109
27486953	1348	1353	event	T051	C0441471
27486953	1379	1386	overlap	T079	C1948020
27486953	1399	1407	features	T080	C2348519
27486953	1411	1415	PNSC	T048	C0004936
27486953	1444	1469	neurally mediated syncope	T047	C0340850
27486953	1481	1489	features	T080	C2348519
27486953	1493	1497	PNES	T047	C2236802
27486953	1526	1544	epileptic seizures	T047	C0014544
27486953	1546	1578	Psychogenic nonsyncopal collapse	T048	C0004936
27486953	1583	1587	PNES	T047	C2236802
27486953	1613	1622	disorders	T047	C0012634
27486953	1648	1656	clinical	T080	C0205210
27486953	1657	1668	semiologies	T090	C0871335

27818989|t|SimAlba: A Spatial Microsimulation Approach to the Analysis of Health Inequalities
27818989|a|This paper presents applied geographical research based on a spatial microsimulation model, SimAlba, aimed at estimating geographically sensitive health variables in Scotland. SimAlba has been developed in order to answer a variety of " what-if" policy questions pertaining to health policy in Scotland. Using the SimAlba model, it is possible to simulate the distributions of previously unknown variables at the small area level such as smoking, alcohol consumption, mental well-being, and obesity. The SimAlba microdataset has been created by combining Scottish Health Survey and Census data using a deterministic reweighting spatial microsimulation algorithm developed for this purpose. The paper presents SimAlba outputs for Scotland's largest city, Glasgow, and examines the spatial distribution of the simulated variables for small geographical areas in Glasgow as well as the effects on individuals of different policy scenario outcomes. In simulating previously unknown spatial data, a wealth of new perspectives can be examined and explored. This paper explores a small set of those potential avenues of research and shows the power of spatial microsimulation modeling in an urban context.
27818989	0	7	SimAlba	UnknownType	C0681943
27818989	11	43	Spatial Microsimulation Approach	UnknownType	C0681943
27818989	51	59	Analysis	T062	C0936012
27818989	63	82	Health Inequalities	T080	C1955989
27818989	103	132	applied geographical research	T062	C0242481
27818989	144	173	spatial microsimulation model	UnknownType	C0681943
27818989	175	182	SimAlba	UnknownType	C0681943
27818989	204	218	geographically	T082	C1517526
27818989	219	228	sensitive	T169	C0332324
27818989	229	235	health	T078	C0018684
27818989	236	245	variables	T080	C0439828
27818989	249	257	Scotland	T083	C0036453
27818989	259	266	SimAlba	UnknownType	C0681943
27818989	298	304	answer	T170	C1706817
27818989	307	314	variety	T077	C2346866
27818989	320	335	what-if" policy	T170	C0242456
27818989	336	345	questions	T170	C1522634
27818989	360	373	health policy	T089	C0018735
27818989	377	385	Scotland	T083	C0036453
27818989	397	410	SimAlba model	UnknownType	C0681943
27818989	430	438	simulate	T062	C0679083
27818989	443	456	distributions	T169	C1704711
27818989	460	470	previously	T079	C0205156
27818989	471	478	unknown	T080	C0439673
27818989	479	488	variables	T080	C0439828
27818989	496	512	small area level	T062	C0085564
27818989	521	528	smoking	T055	C0037369
27818989	530	549	alcohol consumption	T055	C0001948
27818989	551	568	mental well-being	T033	C0424578
27818989	574	581	obesity	T047	C0028754
27818989	587	607	SimAlba microdataset	UnknownType	C0681943
27818989	638	660	Scottish Health Survey	T062	C0018762
27818989	665	671	Census	T081	C0007663
27818989	672	676	data	T078	C1511726
27818989	711	744	spatial microsimulation algorithm	T170	C0002045
27818989	764	771	purpose	T169	C1285529
27818989	792	799	SimAlba	UnknownType	C0681943
27818989	812	822	Scotland's	T083	C0036453
27818989	823	830	largest	T081	C0443228
27818989	831	835	city	T083	C0008848
27818989	837	844	Glasgow	UnknownType	C0681784
27818989	863	883	spatial distribution	T082	C0037775
27818989	891	900	simulated	T062	C0679083
27818989	901	910	variables	T080	C0439828
27818989	915	920	small	T081	C0700321
27818989	921	939	geographical areas	UnknownType	C0681784
27818989	943	950	Glasgow	UnknownType	C0681784
27818989	966	973	effects	T080	C1280500
27818989	977	988	individuals	T098	C0027361
27818989	992	1001	different	T080	C1705242
27818989	1002	1008	policy	T170	C0242456
27818989	1009	1017	scenario	T169	C0683579
27818989	1018	1026	outcomes	T169	C1274040
27818989	1031	1041	simulating	T062	C0679083
27818989	1042	1052	previously	T079	C0205156
27818989	1053	1060	unknown	T080	C0439673
27818989	1061	1073	spatial data	T062	C0814926
27818989	1077	1083	wealth	T080	C0699759
27818989	1087	1090	new	T080	C0205314
27818989	1111	1119	examined	T033	C0332128
27818989	1124	1132	explored	T033	C0243095
27818989	1145	1153	explores	T033	C0243095
27818989	1156	1161	small	T081	C0700321
27818989	1175	1184	potential	T080	C3245505
27818989	1196	1204	research	T062	C0035168
27818989	1219	1224	power	T081	C3854080
27818989	1228	1260	spatial microsimulation modeling	UnknownType	C0681943
27818989	1267	1272	urban	T080	C2700386
27818989	1273	1280	context	T078	C0449255

28285800|t|Perspectives on cardiovascular effects of incretin -based drugs: From bedside to bench, return trip
28285800|a|Recently, cardiovascular outcome trials with glucose -lowering drugs used in type 2 diabetes mellitus, namely glucagon-like peptide-1 receptor agonists (GLP-1RA), liraglutide and semaglutide, showed a reduction in cardiovascular events, which had not been observed in trials with other incretin -based drugs, such as lixisenatide or with dipeptidyl peptidase-4 inhibitors (DPP4i). Mechanisms underlying the observed cardiovascular differences between DPP4i and GLP1-RA, and across individual GLP1-RA are poorly understood. This review is aimed at collecting and summarizing available evidence from experimental and mechanistic studies on the action of GLP1-RA and DPP4i on the cardiovascular system, both deriving from clinical and pre-clinical sources. The results of cardiovascular outcome trials are interpreted on the basis of the experimental preclinical data available, paying particular attention to the heart failure results, and suggesting some novel intriguing hypotheses to explain some of the unexpected findings of cardioprotection of incretin -based drugs. In particular, we discuss the possible contribution to the incretin cardiovascular effects of a direct cardiac action of GLP-1 metabolites through GLP-1 receptor -independent pathways, and of DPP4 substrates other than GLP-1.
28285800	0	12	Perspectives	T078	C1254370
28285800	16	30	cardiovascular	T022	C0007226
28285800	31	41	effects of	T080	C1704420
28285800	42	50	incretin	T116,T121,T125	C1562292
28285800	58	63	drugs	T121	C1254351
28285800	110	124	cardiovascular	T022	C0007226
28285800	125	132	outcome	T169	C1274040
28285800	133	139	trials	T062	C0008976
28285800	145	152	glucose	T109,T121,T123	C0017725
28285800	163	168	drugs	T121	C1254351
28285800	177	201	type 2 diabetes mellitus	T047	C0011860
28285800	210	242	glucagon-like peptide-1 receptor	T192	C0378073
28285800	243	251	agonists	T121	C0243192
28285800	253	260	GLP-1RA	T121	C0243192
28285800	263	274	liraglutide	T116,T121,T125	C1456408
28285800	279	290	semaglutide	T116,T123	C3885068
28285800	301	310	reduction	T081	C0547047
28285800	314	335	cardiovascular events	T033	C1320716
28285800	368	374	trials	T062	C0008976
28285800	386	394	incretin	T116,T121,T125	C1562292
28285800	402	407	drugs	T121	C1254351
28285800	417	429	lixisenatide	T116,T121	C2973895
28285800	438	471	dipeptidyl peptidase-4 inhibitors	T121	C1827106
28285800	473	478	DPP4i	T121	C1827106
28285800	481	491	Mechanisms	T169	C0441712
28285800	516	530	cardiovascular	T022	C0007226
28285800	531	542	differences	T080	C1705242
28285800	551	556	DPP4i	T121	C1827106
28285800	561	568	GLP1-RA	T121	C0243192
28285800	592	599	GLP1-RA	T121	C0243192
28285800	628	634	review	T170	C0282443
28285800	684	692	evidence	T078	C3887511
28285800	698	710	experimental	T062	C0681814
28285800	715	734	mechanistic studies	T062	C0681814
28285800	742	748	action	T052	C3266814
28285800	752	759	GLP1-RA	T121	C0243192
28285800	764	769	DPP4i	T121	C1827106
28285800	777	798	cardiovascular system	T022	C0007226
28285800	819	827	clinical	T081	C0011001
28285800	832	852	pre-clinical sources	T081	C0011001
28285800	858	865	results	T169	C1274040
28285800	869	883	cardiovascular	T022	C0007226
28285800	884	891	outcome	T169	C1274040
28285800	892	898	trials	T062	C0008976
28285800	935	947	experimental	T062	C0681814
28285800	948	964	preclinical data	T170	C1516606
28285800	1011	1024	heart failure	T047	C0018801
28285800	1025	1032	results	T169	C1274040
28285800	1071	1081	hypotheses	T078	C1512571
28285800	1116	1124	findings	T169	C2607943
28285800	1128	1144	cardioprotection	T169	C0205245
28285800	1148	1156	incretin	T116,T121,T125	C1562292
28285800	1164	1169	drugs	T121	C1254351
28285800	1230	1238	incretin	T116,T121,T125	C1562292
28285800	1239	1253	cardiovascular	T022	C0007226
28285800	1254	1264	effects of	T080	C1704420
28285800	1274	1281	cardiac	T023	C0018787
28285800	1282	1288	action	T052	C3266814
28285800	1292	1297	GLP-1	T116	C0061355
28285800	1298	1309	metabolites	T123	C0870883
28285800	1318	1332	GLP-1 receptor	T192	C0378073
28285800	1346	1354	pathways	T044	C1704259
28285800	1363	1367	DPP4	T116,T126,T129	C0081937
28285800	1368	1378	substrates	T167	C3891814
28285800	1390	1395	GLP-1	T116	C0061355

27490343|t|Microarray-Based Analysis of Methylation of 1st Trimester Trisomic Placentas from Down Syndrome, Edwards Syndrome and Patau Syndrome
27490343|a|Methylation -based non-invasive prenatal testing of fetal aneuploidies is an alternative method that could possibly improve fetal aneuploidy diagnosis, especially for trisomy 13(T13) and trisomy 18(T18). Our aim was to study the methylation landscape in placenta DNA from trisomy 13, 18 and 21 pregnancies in an attempt to find trisomy -specific methylation differences better suited for non-invasive prenatal diagnosis. We have conducted high-resolution methylation specific bead chip microarray analyses assessing more than 450,000 CpGs analyzing placentas from 12 T21 pregnancies, 12 T18 pregnancies and 6 T13 pregnancies. We have compared the methylation landscape of the trisomic placentas to the methylation landscape from normal placental DNA and to maternal blood cell DNA. Comparing trisomic placentas to normal placentas we identified 217 and 219 differentially methylated CpGs for CVS T18 and CVS T13, respectively (delta β>0.2, FDR<0.05), but only three differentially methylated CpGs for T21. However, the methylation differences was only modest (delta β<0.4), making them less suitable as diagnostic markers. Gene ontology enrichment analysis revealed that the gene set connected to the T18 differentially methylated CpGs was highly enriched for GO terms related to" DNA binding " and " transcription factor binding " coupled to the RNA polymerase II transcription. In the gene set connected to the T13 differentially methylated CpGs we found no significant enrichments.
27490343	0	25	Microarray-Based Analysis	T059	C1449575
27490343	29	40	Methylation	T044	C0025723
27490343	44	57	1st Trimester	T079	C0032979
27490343	58	76	Trisomic Placentas	T018	C0032043
27490343	82	95	Down Syndrome	T047	C0013080
27490343	97	132	Edwards Syndrome and Patau Syndrome	T047	C0495645
27490343	133	144	Methylation	T044	C0025723
27490343	152	203	non-invasive prenatal testing of fetal aneuploidies	T170	C3656117
27490343	210	221	alternative	T077	C1523987
27490343	222	228	method	T059	C0871511
27490343	249	256	improve	T033	C0184511
27490343	257	335	fetal aneuploidy diagnosis, especially for trisomy 13(T13) and trisomy 18(T18)	T059	C4034670
27490343	341	344	aim	T078	C1947946
27490343	352	357	study	T062	C2603343
27490343	362	373	methylation	T044	C0025723
27490343	374	383	landscape	T082	C0870781
27490343	387	395	placenta	T018	C0032043
27490343	396	399	DNA	T114,T123	C0012854
27490343	405	426	trisomy 13, 18 and 21	T049	C3869535
27490343	427	438	pregnancies	T040	C0032961
27490343	461	468	trisomy	T049	C0041107
27490343	479	490	methylation	T044	C0025723
27490343	491	502	differences	T080	C1705242
27490343	521	533	non-invasive	T169	C0205303
27490343	534	552	prenatal diagnosis	T058	C1456692
27490343	572	587	high-resolution	T059	C1719039
27490343	588	599	methylation	T044	C0025723
27490343	609	638	bead chip microarray analyses	T059	C1449575
27490343	639	648	assessing	T052	C1516048
27490343	667	671	CpGs	T114,T123	C0282523
27490343	682	691	placentas	T018	C0032043
27490343	700	703	T21	T049	C3537167
27490343	704	715	pregnancies	T040	C0032961
27490343	720	723	T18	T049	C3537048
27490343	724	735	pregnancies	T040	C0032961
27490343	742	745	T13	T049	C2936830
27490343	746	757	pregnancies	T040	C0032961
27490343	780	791	methylation	T044	C0025723
27490343	792	801	landscape	T082	C0870781
27490343	809	827	trisomic placentas	T018	C0032043
27490343	835	846	methylation	T044	C0025723
27490343	847	856	landscape	T082	C0870781
27490343	862	868	normal	T080	C0205307
27490343	869	878	placental	T018	C0032043
27490343	879	882	DNA	T114,T123	C0012854
27490343	890	898	maternal	T033	C1858460
27490343	899	909	blood cell	T025	C0005773
27490343	910	913	DNA	T114,T123	C0012854
27490343	925	943	trisomic placentas	T018	C0032043
27490343	947	953	normal	T080	C0205307
27490343	954	963	placentas	T018	C0032043
27490343	990	1004	differentially	T080	C0443199
27490343	1005	1015	methylated	T044	C0025723
27490343	1016	1020	CpGs	T114,T123	C0282523
27490343	1025	1028	CVS	T060	C0008509
27490343	1029	1032	T18	T049	C3537048
27490343	1037	1040	CVS	T060	C0008509
27490343	1041	1044	T13	T049	C2936830
27490343	1099	1113	differentially	T080	C0443199
27490343	1114	1124	methylated	T044	C0025723
27490343	1125	1129	CpGs	T114,T123	C0282523
27490343	1134	1137	T21	T049	C3537167
27490343	1152	1163	methylation	T044	C0025723
27490343	1164	1175	differences	T080	C1705242
27490343	1236	1254	diagnostic markers	T201	C1511876
27490343	1256	1269	Gene ontology	T170	C1138831
27490343	1270	1280	enrichment	T081	C4086355
27490343	1281	1289	analysis	T062	C0936012
27490343	1290	1298	revealed	T080	C0443289
27490343	1308	1316	gene set	T028	C0017337
27490343	1317	1326	connected	T052	C2986575
27490343	1334	1337	T18	T049	C3537048
27490343	1338	1352	differentially	T080	C0443199
27490343	1353	1363	methylated	T044	C0025723
27490343	1364	1368	CpGs	T114,T123	C0282523
27490343	1373	1379	highly	T080	C0205250
27490343	1393	1395	GO	T170	C1138831
27490343	1414	1425	DNA binding	T045	C1148673
27490343	1434	1462	transcription factor binding	T045	C1149367
27490343	1465	1472	coupled	T169	C1948027
27490343	1480	1497	RNA polymerase II	T116,T126	C0035679
27490343	1498	1511	transcription	T045	C0040649
27490343	1520	1528	gene set	T028	C0017337
27490343	1529	1538	connected	T052	C2986575
27490343	1546	1549	T13	T049	C2936830
27490343	1550	1564	differentially	T080	C0443199
27490343	1565	1575	methylated	T044	C0025723
27490343	1576	1580	CpGs	T114,T123	C0282523
27490343	1590	1604	no significant	T033	C1273937
27490343	1605	1616	enrichments	T081	C4086355

28211020|t|Goal-directed fluid restriction during brain surgery: a prospective randomized controlled trial
28211020|a|The value of goal-directed fluid therapy in neurosurgical patients, where brain swelling is a major concern, is unknown. The aim of our study was to evaluate the effect of an intraoperative goal-directed fluid restriction (GDFR) strategy on the postoperative outcome of high - risk patients undergoing brain surgery. High - risk patients undergoing brain surgery were randomly assigned to a usual care group (control group) or a GDFR group. In the GDFR group, (1) fluid maintenance was restricted to 3 ml/kg/h of a crystalloid solution and (2) colloid boluses were allowed only in case of hypotension associated with a low cardiac index and a high stroke volume variation. The primary outcome variable was ICU length of stay, and secondary outcomes were lactates at the end of surgery, postoperative complications, hospital length of stay, mortality at day 30, and costs. A total of 73 patients from the GDFR group were compared with 72 patients from the control group. Before surgery, the two groups were comparable. During surgery, the GDFR group received less colloid (1.9 ± 1.1 vs. 3.9 ± 1.6 ml/kg/h, p = 0.021) and less crystalloid (3 ± 0 vs. 5.0 ± 2.8 ml/kg/h, p < 0.001) than the control group. ICU length of stay was shorter (3 days [1-5] vs. 6 days [3-11], p = 0.001) and ICU costs were lower in the GDFR group. The total number of complications (46 vs. 99, p = 0.043) and the proportion of patients who developed one or more complications (19.2 vs. 34.7%, p = 0.034) were smaller in the GDFR group. Hospital length of stay and costs, as well as mortality at 30 day, were not significantly reduced. In high - risk patients undergoing brain surgery, intraoperative GDFR was associated with a reduction in ICU length of stay and costs, and a decrease in postoperative morbidity. Trial registration Chinese Clinical Trial Registry ChiCTR-TRC-13003583, Registered 20 Aug, 2013.
28211020	0	31	Goal-directed fluid restriction	T061	C0204700
28211020	39	52	brain surgery	T061	C0195775
28211020	68	95	randomized controlled trial	T062	C0206035
28211020	109	136	goal-directed fluid therapy	T061	C0204700
28211020	140	162	neurosurgical patients	T101	C0030705
28211020	170	184	brain swelling	T046	C0006114
28211020	232	237	study	T062	C2603343
28211020	245	253	evaluate	T058	C0220825
28211020	258	264	effect	T080	C1280500
28211020	271	285	intraoperative	T079	C0456904
28211020	286	317	goal-directed fluid restriction	T061	C0204700
28211020	319	323	GDFR	T061	C0204700
28211020	341	354	postoperative	T079	C0032790
28211020	366	370	high	T080	C0205250
28211020	373	377	risk	T078	C0035647
28211020	378	386	patients	T101	C0030705
28211020	398	411	brain surgery	T061	C0195775
28211020	413	417	High	T080	C0205250
28211020	420	424	risk	T078	C0035647
28211020	425	433	patients	T101	C0030705
28211020	445	458	brain surgery	T061	C0195775
28211020	493	497	care	T055	C0150499
28211020	498	503	group	T078	C0441833
28211020	505	518	control group	T096	C0009932
28211020	525	529	GDFR	T061	C0204700
28211020	530	535	group	T078	C0441833
28211020	544	548	GDFR	T061	C0204700
28211020	549	554	group	T078	C0441833
28211020	560	565	fluid	T031	C0005889
28211020	566	577	maintenance	T052	C0024501
28211020	582	592	restricted	T169	C0443288
28211020	611	631	crystalloid solution	T121	C0056562
28211020	640	655	colloid boluses	T121	C1254351
28211020	685	696	hypotension	T033	C0020649
28211020	697	712	associated with	T080	C0332281
28211020	715	718	low	T080	C0205251
28211020	719	732	cardiac index	T033	C0428776
28211020	739	757	high stroke volume	T033	C0520872
28211020	758	767	variation	T080	C0205419
28211020	802	805	ICU	T073,T093	C0021708
28211020	806	820	length of stay	T079	C0023303
28211020	850	858	lactates	T109	C0022924
28211020	873	880	surgery	T061	C0543467
28211020	882	895	postoperative	T079	C0032790
28211020	896	909	complications	T046	C0009566
28211020	911	919	hospital	T073,T093	C0019994
28211020	920	934	length of stay	T079	C0023303
28211020	936	945	mortality	T081	C0178686
28211020	949	952	day	T079	C0439228
28211020	961	966	costs	T081	C0010186
28211020	982	990	patients	T101	C0030705
28211020	1000	1004	GDFR	T061	C0204700
28211020	1005	1010	group	T078	C0441833
28211020	1033	1041	patients	T101	C0030705
28211020	1051	1064	control group	T096	C0009932
28211020	1073	1080	surgery	T061	C0543467
28211020	1090	1096	groups	T078	C0441833
28211020	1121	1128	surgery	T061	C0543467
28211020	1134	1138	GDFR	T061	C0204700
28211020	1139	1144	group	T078	C0441833
28211020	1154	1158	less	T080	C0547044
28211020	1159	1166	colloid	T122	C0009361
28211020	1216	1220	less	T080	C0547044
28211020	1221	1232	crystalloid	T121	C0056562
28211020	1283	1296	control group	T096	C0009932
28211020	1298	1301	ICU	T073,T093	C0021708
28211020	1302	1316	length of stay	T079	C0023303
28211020	1321	1328	shorter	T081	C1806781
28211020	1332	1336	days	T079	C0439228
28211020	1349	1353	days	T079	C0439228
28211020	1377	1380	ICU	T073,T093	C0021708
28211020	1381	1386	costs	T081	C0010186
28211020	1392	1397	lower	T080	C0205251
28211020	1405	1409	GDFR	T061	C0204700
28211020	1410	1415	group	T078	C0441833
28211020	1421	1433	total number	T081	C4288115
28211020	1437	1450	complications	T046	C0009566
28211020	1482	1492	proportion	T081	C1709707
28211020	1496	1504	patients	T101	C0030705
28211020	1531	1544	complications	T046	C0009566
28211020	1578	1585	smaller	T080	C0547044
28211020	1593	1597	GDFR	T061	C0204700
28211020	1598	1603	group	T078	C0441833
28211020	1605	1613	Hospital	T073,T093	C0019994
28211020	1614	1628	length of stay	T079	C0023303
28211020	1633	1638	costs	T081	C0010186
28211020	1651	1660	mortality	T081	C0178686
28211020	1667	1670	day	T079	C0439228
28211020	1695	1702	reduced	T080	C0392756
28211020	1707	1711	high	T080	C0205250
28211020	1714	1718	risk	T078	C0035647
28211020	1719	1727	patients	T101	C0030705
28211020	1739	1752	brain surgery	T061	C0195775
28211020	1754	1768	intraoperative	T079	C0456904
28211020	1769	1773	GDFR	T061	C0204700
28211020	1778	1793	associated with	T080	C0332281
28211020	1796	1805	reduction	T080	C0392756
28211020	1809	1812	ICU	T073,T093	C0021708
28211020	1813	1827	length of stay	T079	C0023303
28211020	1832	1837	costs	T081	C0010186
28211020	1845	1853	decrease	T081	C0547047
28211020	1857	1870	postoperative	T079	C0032790
28211020	1871	1880	morbidity	T081	C0026538

27598421|t|Culex quinquefasciatus from Rio de Janeiro Is Not Competent to Transmit the Local Zika Virus
27598421|a|The Americas have suffered a dramatic epidemic of Zika since May in 2015, when Zika virus (ZIKV) was first detected in Brazil. Mosquitoes belonging to subgenus Stegomyia of Aedes, particularly Aedes aegypti, are considered the primary vectors of ZIKV. However, the rapid spread of the virus across the continent raised several concerns about the transmission dynamics, especially about potential mosquito vectors. The purpose of this work was to assess the vector competence of the house mosquito Culex quinquefasciatus from an epidemic Zika area, Rio de Janeiro, Brazil, for local circulating ZIKV isolates. Culex quinquefasciatus and Ae. aegypti (positive control of ZIKV infection) from Rio de Janeiro were orally exposed to two ZIKV strains isolated from human cases from Rio de Janeiro (Rio-U1 and Rio-S1). Fully engorged mosquitoes were held in incubators at 26 ± 1°C, 12 h:12 h light:dark cycle and 70 ± 10% humidity. For each combination mosquito population- ZIKV strain, 30 specimens were examined for infection, dissemination and transmission rates, at 7, 14 and 21 days after virus exposure by analyzing body (thorax plus abdomen), head and saliva respectively. Infection rates were minimal to completely absent in all Cx. quinquefasciatus - virus combinations and were significantly high for Ae. aegypti. Moreover, dissemination and transmission were not detected in any Cx. quinquefasciatus mosquitoes whatever the incubation period and the ZIKV isolate. In contrast, Ae. aegypti ensured high viral dissemination and moderate to very high transmission. The southern house mosquito Cx. quinquefasciatus from Rio de Janeiro was not competent to transmit local strains of ZIKV. Thus, there is no experimental evidence that Cx. quinquefasciatus likely plays a role in the ZIKV transmission. Consequently, at least in Rio, mosquito control to reduce ZIKV transmission should remain focused on Ae. aegypti.
27598421	0	22	Culex quinquefasciatus	T204	C0322806
27598421	28	42	Rio de Janeiro	UnknownType	C0681784
27598421	46	59	Not Competent	T033	C0243095
27598421	63	71	Transmit	T043	C1160716
27598421	82	92	Zika Virus	T005	C0318793
27598421	97	105	Americas	T083	C0002454
27598421	122	139	dramatic epidemic	T067	C0014499
27598421	143	147	Zika	T005	C0318793
27598421	172	182	Zika virus	T005	C0318793
27598421	184	188	ZIKV	T005	C0318793
27598421	200	208	detected	T033	C0442726
27598421	212	218	Brazil	T083	C0006137
27598421	220	230	Mosquitoes	T204	C0026584
27598421	244	252	subgenus	T077	C1883697
27598421	253	271	Stegomyia of Aedes	T204	C0322859
27598421	286	299	Aedes aegypti	T204	C0322859
27598421	320	335	primary vectors	T204	C4277713
27598421	339	343	ZIKV	T005	C0318793
27598421	364	370	spread	T080	C0332261
27598421	378	383	virus	T005	C0042776
27598421	395	404	continent	T083	C0454690
27598421	439	451	transmission	T043	C1160716
27598421	452	460	dynamics	T070	C3826426
27598421	489	505	mosquito vectors	T204	C4277713
27598421	539	545	assess	T052	C1516048
27598421	550	556	vector	T204	C4277713
27598421	557	567	competence	T080	C0086035
27598421	575	612	house mosquito Culex quinquefasciatus	T204	C0322806
27598421	621	629	epidemic	T067	C0014499
27598421	630	655	Zika area, Rio de Janeiro	UnknownType	C0681784
27598421	657	663	Brazil	T083	C0006137
27598421	675	686	circulating	T169	C0175630
27598421	687	691	ZIKV	T005	C0318793
27598421	692	700	isolates	T123	C1764827
27598421	702	724	Culex quinquefasciatus	T204	C0322806
27598421	729	740	Ae. aegypti	T204	C0322859
27598421	742	758	positive control	T077	C1883676
27598421	762	776	ZIKV infection	T047	C0276289
27598421	783	797	Rio de Janeiro	UnknownType	C0681784
27598421	825	829	ZIKV	T005	C0318793
27598421	830	837	strains	T001	C1518614
27598421	838	846	isolated	T169	C0205409
27598421	852	863	human cases	T062	C0178693
27598421	869	883	Rio de Janeiro	UnknownType	C0681784
27598421	911	919	engorged	T169	C0700140
27598421	920	930	mosquitoes	T204	C0026584
27598421	944	954	incubators	T073	C0021178
27598421	978	994	light:dark cycle	T079	C2718082
27598421	1008	1016	humidity	T070	C0869465
27598421	1027	1038	combination	T080	C0205195
27598421	1039	1047	mosquito	T204	C0026584
27598421	1060	1064	ZIKV	T005	C0318793
27598421	1065	1071	strain	T001	C1518614
27598421	1076	1085	specimens	T167	C0370003
27598421	1104	1113	infection	T047	C0276289
27598421	1115	1128	dissemination	T033	C0243095
27598421	1133	1151	transmission rates	T081	C1521828
27598421	1180	1185	virus	T005	C0042776
27598421	1186	1194	exposure	T080	C0332157
27598421	1208	1212	body	T017	C0460148
27598421	1214	1220	thorax	T029	C0817096
27598421	1226	1233	abdomen	T029	C0000726
27598421	1236	1240	head	T029	C0018670
27598421	1245	1251	saliva	T031	C0036087
27598421	1266	1281	Infection rates	T033	C0243095
27598421	1287	1294	minimal	T080	C1524031
27598421	1309	1315	absent	T169	C0332197
27598421	1323	1343	Cx. quinquefasciatus	T204	C0322806
27598421	1346	1351	virus	T005	C0042776
27598421	1352	1364	combinations	T080	C0205195
27598421	1374	1392	significantly high	T081	C4055637
27598421	1397	1408	Ae. aegypti	T204	C0322859
27598421	1420	1433	dissemination	T033	C0243095
27598421	1438	1450	transmission	T043	C1160716
27598421	1456	1468	not detected	T033	C0442737
27598421	1476	1496	Cx. quinquefasciatus	T204	C0322806
27598421	1497	1507	mosquitoes	T204	C0026584
27598421	1521	1538	incubation period	T033	C1320226
27598421	1547	1551	ZIKV	T005	C0318793
27598421	1552	1559	isolate	T123	C1764827
27598421	1574	1585	Ae. aegypti	T204	C0322859
27598421	1599	1618	viral dissemination	T033	C0243095
27598421	1645	1657	transmission	T043	C1160716
27598421	1663	1707	southern house mosquito Cx. quinquefasciatus	T204	C0322806
27598421	1713	1727	Rio de Janeiro	UnknownType	C0681784
27598421	1732	1745	not competent	T033	C0243095
27598421	1749	1757	transmit	T043	C1160716
27598421	1764	1771	strains	T001	C1518614
27598421	1775	1779	ZIKV	T005	C0318793
27598421	1796	1820	no experimental evidence	T080	C0332125
27598421	1826	1846	Cx. quinquefasciatus	T204	C0322806
27598421	1874	1878	ZIKV	T005	C0318793
27598421	1879	1891	transmission	T043	C1160716
27598421	1919	1922	Rio	UnknownType	C0681784
27598421	1924	1940	mosquito control	T057	C0026581
27598421	1951	1955	ZIKV	T005	C0318793
27598421	1956	1968	transmission	T043	C1160716
27598421	1994	2005	Ae. aegypti	T204	C0322859

28344199|t|Association of Toll-Like Receptor 4 on Human Monocyte Subsets and Vulnerability Characteristics of Coronary Plaque as Assessed by 64-Slice Multidetector Computed Tomography
28344199|a|Although Toll-like receptor 4 (TLR-4) is involved in monocyte activation in patients with accelerated forms of atherosclerosis, the relationship between the expression of TLR-4 on circulating monocyte s and coronary plaque vulnerability has not previously been evaluated. We investigated this relationship using 64-slice multidetector computed tomography (MDCT) in patients with stable angina pectoris (SAP).Methods and Results:We enrolled 65 patients with SAP who underwent MDCT. Three monocyte subsets (CD14(++)CD16(-), CD14(++)CD16(+), and CD14(+)CD16(+)) and expression of TLR-4 were measured by flow cytometry. Intracoronary plaques were assessed by 64-slice MDCT. We defined vulnerability of intracoronary plaques according to the presence of positive remodeling (remodeling index >1.05) and/or low CT attenuation (<35 HU). The circulating CD14(++)CD16(+)monocytes more frequently expressed TLR-4 than CD14(++)CD16(-) and CD14(+)CD16(+)monocytes (P<0.001). The relative proportion of the expression of TLR-4 on CD14(++)CD16(+)monocytes was significantly greater in patients with vulnerable plaque compared with those without (10.4 [4.1-14.5] % vs. 4.5 [2.8-7.8] %, P=0.012). In addition, the relative proportion of TLR-4 expression on CD14(++)CD16(+)monocytes positively correlated with the remodeling index (r=0.28, P=0.025) and negatively correlated with CT attenuation value (r=-0.31, P=0.013). Upregulation of TLR-4 on CD14(++)CD16(+)monocytes might be associated with coronary plaque vulnerability in patients with SAP.
28344199	0	11	Association	T080	C0439849
28344199	15	35	Toll-Like Receptor 4	T116,T192	C1411976
28344199	39	44	Human	T016	C0086418
28344199	45	53	Monocyte	T025	C0026473
28344199	54	61	Subsets	T185	C1515021
28344199	66	79	Vulnerability	T033	C1821973
28344199	80	95	Characteristics	T080	C1521970
28344199	99	107	Coronary	T023	C0018787
28344199	108	114	Plaque	T033	C0332461
28344199	118	126	Assessed	T052	C1516048
28344199	130	172	64-Slice Multidetector Computed Tomography	T060	C3179130
28344199	182	202	Toll-like receptor 4	T116,T192	C1411976
28344199	204	209	TLR-4	T116,T192	C1411976
28344199	226	245	monocyte activation	T043	C1155075
28344199	249	257	patients	T101	C0030705
28344199	263	274	accelerated	T169	C0521110
28344199	284	299	atherosclerosis	T047	C0004153
28344199	305	317	relationship	T080	C0439849
28344199	330	340	expression	T045	C0597360
28344199	344	349	TLR-4	T116,T192	C1411976
28344199	353	364	circulating	T169	C0175630
28344199	365	373	monocyte	T025	C0026473
28344199	380	388	coronary	T023	C0018787
28344199	389	395	plaque	T033	C0332461
28344199	396	409	vulnerability	T033	C1821973
28344199	434	443	evaluated	T058	C0220825
28344199	466	478	relationship	T080	C0439849
28344199	485	527	64-slice multidetector computed tomography	T060	C3179130
28344199	529	533	MDCT	T060	C3179130
28344199	538	546	patients	T101	C0030705
28344199	552	574	stable angina pectoris	T047	C0340288
28344199	576	579	SAP	T047	C0340288
28344199	616	624	patients	T101	C0030705
28344199	630	633	SAP	T047	C0340288
28344199	648	652	MDCT	T060	C3179130
28344199	660	668	monocyte	T025	C0026473
28344199	669	676	subsets	T185	C1515021
28344199	678	693	CD14(++)CD16(-)	T025	C0026473
28344199	695	710	CD14(++)CD16(+)	T025	C0026473
28344199	716	730	CD14(+)CD16(+)	T025	C0026473
28344199	736	746	expression	T045	C0597360
28344199	750	755	TLR-4	T116,T192	C1411976
28344199	773	787	flow cytometry	T059	C0016263
28344199	789	802	Intracoronary	T023	C0018787
28344199	803	810	plaques	T033	C0332461
28344199	816	824	assessed	T052	C1516048
28344199	828	841	64-slice MDCT	T060	C3179130
28344199	854	867	vulnerability	T033	C1821973
28344199	871	884	intracoronary	T023	C0018787
28344199	885	892	plaques	T033	C0332461
28344199	922	941	positive remodeling	T046	C3854505
28344199	943	959	remodeling index	T033	C0243095
28344199	978	980	CT	T060	C0040405
28344199	981	992	attenuation	T081	C2986722
28344199	1007	1018	circulating	T169	C0175630
28344199	1019	1043	CD14(++)CD16(+)monocytes	T025	C0026473
28344199	1060	1069	expressed	T045	C0597360
28344199	1070	1075	TLR-4	T116,T192	C1411976
28344199	1081	1096	CD14(++)CD16(-)	T025	C0026473
28344199	1101	1124	CD14(+)CD16(+)monocytes	T025	C0026473
28344199	1167	1177	expression	T045	C0597360
28344199	1181	1186	TLR-4	T116,T192	C1411976
28344199	1190	1214	CD14(++)CD16(+)monocytes	T025	C0026473
28344199	1244	1252	patients	T101	C0030705
28344199	1258	1275	vulnerable plaque	T033	C0332461
28344199	1394	1399	TLR-4	T116,T192	C1411976
28344199	1400	1410	expression	T045	C0597360
28344199	1414	1438	CD14(++)CD16(+)monocytes	T025	C0026473
28344199	1450	1460	correlated	T080	C1707520
28344199	1470	1486	remodeling index	T033	C0243095
28344199	1520	1530	correlated	T080	C1707520
28344199	1536	1538	CT	T060	C0040405
28344199	1539	1556	attenuation value	T081	C2986722
28344199	1577	1589	Upregulation	T044	C0949479
28344199	1593	1598	TLR-4	T116,T192	C1411976
28344199	1602	1626	CD14(++)CD16(+)monocytes	T025	C0026473
28344199	1636	1651	associated with	T080	C0332281
28344199	1652	1660	coronary	T023	C0018787
28344199	1661	1667	plaque	T033	C0332461
28344199	1668	1681	vulnerability	T033	C1821973
28344199	1685	1693	patients	T101	C0030705
28344199	1699	1702	SAP	T047	C0340288

27717775|t|The Effect of l-Arginine on Dural Healing After Experimentally Induced Dural Defect in a Rat Model
27717775|a|Incomplete repair of the dura mater may result in numerous complications such as cerebrospinal fluid leakage and meningitis. For this reason, accurate repair of the dura mater is essential. In this study, the effect of systemic and local supplementation of l-arginine on dural healing was evaluated. Thirty male Wistar rats were used and divided into control, local, and systemic l-arginine groups, with 10 rats in each. In each group, a 5-mm experimental incision was made at the lumbar segment of the dura mater and cerebrospinal fluid leakage was induced. Each group was divided into 2 subgroups and at the end of the first and sixth weeks, the rats were killed and the damaged segments of the dura were separated, histologically evaluated and the dural healing indicators including cell types, granulation tissue formation, collagen deposit, and vascularization were compared between groups. The systematic supplementation of l-arginine showed a significant effect in dural healing compared with the control group. After the first week, granulation formation increased considerably (P < 0.031), and after 6 weeks, collagen deposition and neovascularization were significantly different compared with the control group (P < 0.030; P < 0.009). In comparison between different groups at the end of the first and sixth weeks, maximum changes in healing indicators were observed in the systemic group and the least variations were related to the control group. The systemic supplementation of l-arginine may accelerate dural healing by increasing the level of granulation tissue formation, collagen deposition, and vascularization.
27717775	4	10	Effect	T080	C1280500
27717775	14	24	l-Arginine	T116,T121,T123	C0003765
27717775	28	41	Dural Healing	T040	C0043240
27717775	63	70	Induced	T169	C0205263
27717775	71	76	Dural	T023	C0013313
27717775	77	83	Defect	T169	C1457869
27717775	89	92	Rat	T015	C0034693
27717775	93	98	Model	T075	C0026339
27717775	99	109	Incomplete	T080	C0205257
27717775	110	116	repair	T040	C0043240
27717775	124	134	dura mater	T023	C0013313
27717775	139	145	result	T169	C1274040
27717775	149	157	numerous	T081	C0439064
27717775	158	171	complications	T046	C0009566
27717775	180	207	cerebrospinal fluid leakage	T047	C0023182
27717775	212	222	meningitis	T047	C0025289
27717775	241	249	accurate	T080	C0443131
27717775	250	256	repair	T040	C0043240
27717775	264	274	dura mater	T023	C0013313
27717775	278	287	essential	T080	C0205224
27717775	308	314	effect	T080	C1280500
27717775	318	326	systemic	T169	C0205373
27717775	331	336	local	T082	C0205276
27717775	337	352	supplementation	T169	C2348609
27717775	356	366	l-arginine	T116,T121,T123	C0003765
27717775	370	383	dural healing	T040	C0043240
27717775	406	410	male	T032	C0086582
27717775	411	422	Wistar rats	T015	C0034716
27717775	437	444	divided	T169	C0332849
27717775	450	457	control	T096	C0009932
27717775	459	464	local	T082	C0205276
27717775	470	478	systemic	T169	C0205373
27717775	479	489	l-arginine	T116,T121,T123	C0003765
27717775	490	496	groups	T078	C0441833
27717775	506	510	rats	T015	C0034716
27717775	528	533	group	T078	C0441833
27717775	542	563	experimental incision	T061	C0184898
27717775	580	612	lumbar segment of the dura mater	T029	C2330954
27717775	617	644	cerebrospinal fluid leakage	T047	C0023182
27717775	649	656	induced	T169	C0205263
27717775	663	668	group	T078	C0441833
27717775	673	680	divided	T169	C0332849
27717775	688	697	subgroups	T185	C1515021
27717775	736	741	weeks	T079	C0439230
27717775	747	751	rats	T015	C0034716
27717775	757	763	killed	T058	C0015187
27717775	772	779	damaged	T169	C1883709
27717775	780	788	segments	T082	C0441635
27717775	796	800	dura	T023	C0013313
27717775	806	815	separated	T080	C0443299
27717775	817	831	histologically	T169	C0205462
27717775	850	863	dural healing	T040	C0043240
27717775	864	874	indicators	T169	C1522602
27717775	885	895	cell types	T025	C0007634
27717775	897	915	granulation tissue	T024	C0018180
27717775	916	925	formation	T169	C1522492
27717775	927	935	collagen	T116	C0009325
27717775	936	943	deposit	T169	C0333562
27717775	949	964	vascularization	T169	C0042382
27717775	970	978	compared	T052	C1707455
27717775	987	993	groups	T078	C0441833
27717775	999	1009	systematic	T169	C0220922
27717775	1010	1025	supplementation	T169	C2348609
27717775	1029	1039	l-arginine	T116,T121,T123	C0003765
27717775	1049	1060	significant	T078	C0750502
27717775	1061	1067	effect	T080	C1280500
27717775	1071	1084	dural healing	T040	C0043240
27717775	1085	1093	compared	T052	C1707455
27717775	1103	1116	control group	T096	C0009932
27717775	1134	1138	week	T079	C0439230
27717775	1140	1151	granulation	T024	C0018180
27717775	1152	1161	formation	T169	C1522492
27717775	1162	1171	increased	T081	C0205217
27717775	1210	1215	weeks	T079	C0439230
27717775	1217	1225	collagen	T116	C0009325
27717775	1226	1236	deposition	T169	C0333562
27717775	1241	1259	neovascularization	T046	C0027686
27717775	1279	1288	different	T080	C1705242
27717775	1289	1297	compared	T052	C1707455
27717775	1307	1320	control group	T096	C0009932
27717775	1348	1358	comparison	T052	C1707455
27717775	1367	1376	different	T080	C1705242
27717775	1377	1383	groups	T078	C0441833
27717775	1418	1423	weeks	T079	C0439230
27717775	1425	1432	maximum	T081	C0806909
27717775	1433	1440	changes	T169	C0392747
27717775	1444	1451	healing	T040	C0043240
27717775	1452	1462	indicators	T169	C1522602
27717775	1468	1476	observed	T169	C1441672
27717775	1484	1492	systemic	T169	C0205373
27717775	1493	1498	group	T078	C0441833
27717775	1513	1523	variations	T080	C0205419
27717775	1544	1557	control group	T096	C0009932
27717775	1563	1571	systemic	T169	C0205373
27717775	1572	1587	supplementation	T169	C2348609
27717775	1591	1601	l-arginine	T116,T121,T123	C0003765
27717775	1606	1616	accelerate	T169	C0521110
27717775	1617	1630	dural healing	T040	C0043240
27717775	1634	1644	increasing	T169	C0442808
27717775	1649	1654	level	T080	C0441889
27717775	1658	1676	granulation tissue	T024	C0018180
27717775	1677	1686	formation	T169	C1522492
27717775	1688	1696	collagen	T116	C0009325
27717775	1697	1707	deposition	T169	C0333562
27717775	1713	1728	vascularization	T169	C0042382

28415132|t|Genetic alterations in mesiodens as revealed by targeted next-generation sequencing and gene co-occurrence network analysis
28415132|a|Mesiodens is the most common type of supernumerary tooth which includes a population prevalence of 0.15%-1.9%. Alongside evidence that the condition is heritable, mutations in single genes have been reported in few human supernumerary tooth cases. Gene sequencing methods in tradition way are time-consuming and labor-intensive, whereas next-generation sequencing and bioinformatics are cost-effective for large samples and target sizes. We describe the application of a targeted next-generation sequencing (NGS) and bioinformatics approach to samples from 17 mesiodens patients. Subjects were diagnosed on the basis of panoramic radiograph. A total of 101 candidate genes which were captured custom genes were sequenced on the Illumina HiSeq 2500. Multistep bioinformatics processing was performed including variant identification, base calling, and in silico analysis of putative disease - causing variants. Targeted capture identified 88 non-synonymous, rare, exonic variants involving 42 of the 101 candidate genes. Moreover, we investigated gene co-occurrence relationships between the genomic alterations and identified 88 significant relationships among 18 most recurrent driver alterations. Our search for co-occurring genetic alterations revealed that such alterations interact cooperatively to drive mesiodens. We discovered a gene co-occurrence network in mesiodens patients with functionally enriched gene groups in the sonic hedgehog (SHH), bone morphogenetic proteins (BMP), and wingless integrated (WNT) signaling pathways.
28415132	0	19	Genetic alterations	T045	C0026882
28415132	23	32	mesiodens	T047	C0266030
28415132	36	44	revealed	T080	C0443289
28415132	48	56	targeted	T169	C1521840
28415132	57	83	next-generation sequencing	T063	C2936622
28415132	88	92	gene	T028	C0017337
28415132	93	106	co-occurrence	T079	C2745955
28415132	107	123	network analysis	T062	C4277638
28415132	124	133	Mesiodens	T047	C0266030
28415132	146	152	common	T081	C0205214
28415132	153	157	type	T080	C0332307
28415132	161	180	supernumerary tooth	T033	C0040457
28415132	198	208	population	T098	C1257890
28415132	209	219	prevalence	T081	C0033105
28415132	245	253	evidence	T078	C3887511
28415132	263	272	condition	T080	C0348080
28415132	276	285	heritable	T169	C0439660
28415132	287	296	mutations	T045	C0026882
28415132	307	312	genes	T028	C0017337
28415132	339	344	human	T016	C0086418
28415132	345	364	supernumerary tooth	T033	C0040457
28415132	365	370	cases	T169	C0868928
28415132	372	395	Gene sequencing methods	T063	C1328887
28415132	417	431	time-consuming	T080	C3827829
28415132	436	451	labor-intensive	T098	C0022866
28415132	461	487	next-generation sequencing	T063	C2936622
28415132	492	506	bioinformatics	T091	C1140694
28415132	511	525	cost-effective	T057	C1511536
28415132	530	543	large samples	T081	C0871429
28415132	548	554	target	T169	C1521840
28415132	555	560	sizes	T081	C0242618
28415132	578	589	application	T169	C4048755
28415132	595	603	targeted	T169	C1521840
28415132	604	630	next-generation sequencing	T063	C2936622
28415132	632	635	NGS	T063	C2936622
28415132	641	655	bioinformatics	T091	C1140694
28415132	668	675	samples	T081	C0871429
28415132	684	693	mesiodens	T047	C0266030
28415132	694	702	patients	T101	C0030705
28415132	704	712	Subjects	T098	C2349001
28415132	718	727	diagnosed	T033	C0011900
28415132	744	764	panoramic radiograph	T060	C0034579
28415132	781	796	candidate genes	T028	C1332838
28415132	824	829	genes	T028	C0017337
28415132	835	844	sequenced	T063	C1328887
28415132	852	871	Illumina HiSeq 2500	T074	C0025080
28415132	883	897	bioinformatics	T091	C1140694
28415132	898	908	processing	T052	C1709694
28415132	913	922	performed	T169	C0884358
28415132	933	940	variant	T080	C0205419
28415132	941	955	identification	T080	C0205396
28415132	957	969	base calling	T059	C1294197
28415132	975	984	in silico	T066	C3489666
28415132	985	993	analysis	T062	C0936012
28415132	997	1013	putative disease	T047	C0012634
28415132	1016	1023	causing	T169	C0678227
28415132	1024	1032	variants	T080	C0205419
28415132	1034	1042	Targeted	T169	C1521840
28415132	1051	1061	identified	T080	C0205396
28415132	1065	1079	non-synonymous	T045	C0599155
28415132	1081	1085	rare	T080	C0522498
28415132	1087	1093	exonic	T045	C1519323
28415132	1094	1102	variants	T080	C0205419
28415132	1127	1142	candidate genes	T028	C1332838
28415132	1157	1169	investigated	T169	C1292732
28415132	1170	1174	gene	T028	C0017337
28415132	1175	1188	co-occurrence	T079	C2745955
28415132	1189	1202	relationships	T080	C0439849
28415132	1215	1234	genomic alterations	T045	C0026882
28415132	1239	1249	identified	T080	C0205396
28415132	1253	1264	significant	T078	C0750502
28415132	1265	1278	relationships	T080	C0439849
28415132	1293	1302	recurrent	T079	C2945760
28415132	1310	1321	alterations	T045	C0026882
28415132	1327	1333	search	T052	C1706202
28415132	1338	1350	co-occurring	T079	C2745955
28415132	1351	1370	genetic alterations	T045	C0026882
28415132	1371	1379	revealed	T080	C0443289
28415132	1390	1401	alterations	T045	C0026882
28415132	1402	1410	interact	T169	C1704675
28415132	1434	1443	mesiodens	T047	C0266030
28415132	1448	1458	discovered	T052	C1880355
28415132	1461	1465	gene	T028	C0017337
28415132	1466	1479	co-occurrence	T079	C2745955
28415132	1480	1487	network	T169	C1882071
28415132	1491	1500	mesiodens	T047	C0266030
28415132	1501	1509	patients	T101	C0030705
28415132	1537	1541	gene	T028	C0017337
28415132	1542	1548	groups	T078	C0441833
28415132	1556	1570	sonic hedgehog	T116,T123	C0258846
28415132	1572	1575	SHH	T116,T123	C0258846
28415132	1578	1605	bone morphogenetic proteins	T116,T123	C0053932
28415132	1607	1610	BMP	T116,T123	C0053932
28415132	1617	1636	wingless integrated	T116,T123	C0753137
28415132	1638	1641	WNT	T116,T123	C0753137
28415132	1643	1661	signaling pathways	T044	C0037080

27799920|t|Genetic Identification of a PilT Motor in Geobacter sulfurreducens Reveals a Role for Pilus Retraction in Extracellular Electron Transfer
27799920|a|The metal - reducing bacterium Geobacter sulfurreducens requires the expression of conductive pili to reduce iron oxides and to wire electroactive biofilms, but the role of pilus retraction in these functions has remained elusive. Here we show that of the four PilT proteins encoded in the genome of G. sulfurreducens, PilT3 powered pilus retraction in planktonic cells of a PilT - deficient strain of P. aeruginosa and restored the dense mutant biofilms to wild-type levels. Furthermore, PilT3 and PilT4 rescued the twitching motility defect of the PilT - deficient mutant. However, PilT4 was the only paralog whose inactivation in G. sulfurreducens lead to phenotypes associated with the hyperpiliation of non-retractile mutants such as enhanced adhesion and biofilm-forming abilities. In addition, PilT4 was required to reduce iron oxides. Taken together, the results indicate that PilT4 is the motor ATPase of G. sulfurreducens pili and reveal a previously unrecognized role for pilus retraction in extracellular electron transfer, a strategy that confers on Geobacter spp. an adaptive advantage for metal reduction in the natural environment.
27799920	0	22	Genetic Identification	T059	C0796344
27799920	28	38	PilT Motor	T116,T123	C1720835
27799920	42	66	Geobacter sulfurreducens	T007	C1005676
27799920	77	81	Role	T077	C1705810
27799920	86	102	Pilus Retraction	T043	C1326523
27799920	106	119	Extracellular	T026	C0521119
27799920	120	137	Electron Transfer	T044	C0013846
27799920	142	147	metal	T197	C0025552
27799920	150	158	reducing	T070	C0301630
27799920	159	168	bacterium	T007	C0004611
27799920	169	193	Geobacter sulfurreducens	T007	C1005676
27799920	207	217	expression	T045	C0017262
27799920	221	231	conductive	T080	C0205556
27799920	232	236	pili	T026	C0031921
27799920	240	246	reduce	T070	C0301630
27799920	247	258	iron oxides	T121,T197	C0060240
27799920	271	293	electroactive biofilms	T007	C0081786
27799920	303	307	role	T077	C1705810
27799920	311	327	pilus retraction	T043	C1326523
27799920	337	346	functions	T043	C0007613
27799920	399	412	PilT proteins	T116,T123	C1720835
27799920	413	420	encoded	T052	C2700640
27799920	428	434	genome	T028	C0017428
27799920	438	455	G. sulfurreducens	T007	C1005676
27799920	457	462	PilT3	T116,T123	C1720835
27799920	471	487	pilus retraction	T043	C1326523
27799920	491	507	planktonic cells	T025	C0007634
27799920	513	517	PilT	T116,T123	C1720835
27799920	520	529	deficient	T169	C0011155
27799920	530	536	strain	T001	C1518614
27799920	540	553	P. aeruginosa	T007	C0033809
27799920	558	566	restored	T052	C0441655
27799920	571	576	dense	T080	C0439794
27799920	577	583	mutant	T028	C0678941
27799920	584	592	biofilms	T007	C0081786
27799920	596	605	wild-type	T028	C1883559
27799920	606	612	levels	T080	C0441889
27799920	627	632	PilT3	T116,T123	C1720835
27799920	637	642	PilT4	T116,T123	C1720835
27799920	655	673	twitching motility	T043	C1752724
27799920	688	692	PilT	T116,T123	C1720835
27799920	695	704	deficient	T169	C0011155
27799920	705	711	mutant	T028	C0678941
27799920	722	727	PilT4	T116,T123	C1720835
27799920	741	748	paralog	T185	C0008902
27799920	755	767	inactivation	T169	C0544461
27799920	771	788	G. sulfurreducens	T007	C1005676
27799920	797	807	phenotypes	T032	C0031437
27799920	808	823	associated with	T080	C0332281
27799920	828	842	hyperpiliation	T043	C0007613
27799920	846	868	non-retractile mutants	T028	C0678941
27799920	886	894	adhesion	T040	C0004614
27799920	939	944	PilT4	T116,T123	C1720835
27799920	961	967	reduce	T070	C0301630
27799920	968	979	iron oxides	T121,T197	C0060240
27799920	1023	1028	PilT4	T116,T123	C1720835
27799920	1042	1048	ATPase	T116,T126	C1706373
27799920	1052	1069	G. sulfurreducens	T007	C1005676
27799920	1070	1074	pili	T026	C0031921
27799920	1099	1111	unrecognized	T080	C4288068
27799920	1112	1116	role	T077	C1705810
27799920	1121	1137	pilus retraction	T043	C1326523
27799920	1141	1154	extracellular	T026	C0521119
27799920	1155	1172	electron transfer	T044	C0013846
27799920	1201	1214	Geobacter spp	T007	C1012737
27799920	1242	1247	metal	T197	C0025552
27799920	1248	1257	reduction	T070	C0301630
27799920	1265	1284	natural environment	T082	C0557745

28270097|t|Factors influencing the level of patients using the internet to gather information before anaesthesia: a single-centre survey of 815 patients in Switzerland: The internet for patient information before anaesthesia
28270097|a|Aim of this study was to identify factors associated with patients using the internet to find information about their upcoming surgery in general, and more specifically about anaesthesia. With Ethics committee approval, 1000 consecutive patients seen before elective surgery in the anaesthesia preoperative clinic of a Swiss Level 2 hospital were asked to complete a questionnaire. Primary outcome were patients using the internet to gather any medical information related to their upcoming hospital stay, secondary outcome patients using the internet to gather information regarding the upcoming anaesthesia. Multiple regression was performed to identify independent factors associated with internet use. Eighty-two percent of the patients (n = 815) participated. 97% of those were ASA physical status 1 or 2; 83% (n = 676) had experience with previous anaesthetics, 86% (n = 700) reported to use the internet in general. Overall, about one-third of the participants used the internet to learn more about their medical condition, 26% regarding their upcoming surgical procedure. Only 7% (n = 55) obtained information about the anaesthetic. In multivariate analyses, factors associated with internet use were generally doing so, and planned moderate compared to minor surgery; not using the internet was associated with previous anaesthetic experience. Of those who did not use the Internet to learn about their anaesthetic, 34% indicated that they would have visited a trusted website. Only few patients used the internet to obtain information about their upcoming procedure and the anaesthetic part played an even smaller role. However, many patients would have appreciated guidance to find trustworthy internet sites. German Clinical Trials Register (DRKS00005434; date of registration: 27(th) December 2013); date of enrolment of first patient: 1st August 2013; study retrospectively registered.
28270097	0	7	Factors	T169	C1521761
28270097	8	19	influencing	T077	C4054723
28270097	24	29	level	T080	C0441889
28270097	33	41	patients	T101	C0030705
28270097	52	60	internet	T073	C0282111
28270097	71	82	information	T078	C1533716
28270097	90	101	anaesthesia	T061	C0002903
28270097	105	125	single-centre survey	T170	C0038951
28270097	133	141	patients	T101	C0030705
28270097	145	156	Switzerland	T083	C0039021
28270097	162	170	internet	T073	C0282111
28270097	175	194	patient information	T170	C1955348
28270097	202	213	anaesthesia	T061	C0002903
28270097	248	255	factors	T169	C1521761
28270097	256	271	associated with	T080	C0332281
28270097	272	280	patients	T101	C0030705
28270097	291	299	internet	T073	C0282111
28270097	303	307	find	T033	C0243095
28270097	308	319	information	T078	C1533716
28270097	332	340	upcoming	T079	C1254367
28270097	341	348	surgery	T061	C0543467
28270097	352	359	general	T082	C0205246
28270097	370	382	specifically	T080	C0205369
28270097	389	400	anaesthesia	T061	C0002903
28270097	407	423	Ethics committee	T097	C0085546
28270097	424	432	approval	T080	C0205540
28270097	439	450	consecutive	T080	C1707491
28270097	451	459	patients	T101	C0030705
28270097	472	488	elective surgery	T061	C0206058
28270097	496	507	anaesthesia	T061	C0002903
28270097	508	527	preoperative clinic	T073,T093	C0442592
28270097	533	555	Swiss Level 2 hospital	T073,T093	C0019994
28270097	570	578	complete	T080	C0205197
28270097	581	594	questionnaire	T170	C0034394
28270097	604	611	outcome	T169	C1274040
28270097	617	625	patients	T101	C0030705
28270097	636	644	internet	T073	C0282111
28270097	659	666	medical	T169	C0205476
28270097	667	678	information	T078	C1533716
28270097	679	686	related	T080	C0439849
28270097	696	704	upcoming	T079	C1254367
28270097	705	718	hospital stay	T079	C3489408
28270097	730	737	outcome	T169	C1274040
28270097	738	746	patients	T101	C0030705
28270097	757	765	internet	T073	C0282111
28270097	776	787	information	T078	C1533716
28270097	802	810	upcoming	T079	C1254367
28270097	811	822	anaesthesia	T061	C0002903
28270097	824	843	Multiple regression	T080	C0681923
28270097	848	857	performed	T169	C0884358
28270097	861	869	identify	T080	C0205396
28270097	870	889	independent factors	T169	C1521761
28270097	890	905	associated with	T080	C0332281
28270097	906	914	internet	T073	C0282111
28270097	915	918	use	T169	C0457083
28270097	920	930	Eighty-two	T081	C0392762
28270097	931	938	percent	T081	C0439165
28270097	946	954	patients	T101	C0030705
28270097	965	977	participated	T169	C0679823
28270097	997	1018	ASA physical status 1	T033	C1531504
28270097	1022	1023	2	T033	C1531505
28270097	1043	1053	experience	T041	C0596545
28270097	1059	1067	previous	T079	C0205156
28270097	1068	1080	anaesthetics	T121	C0002932
28270097	1108	1111	use	T169	C0457083
28270097	1116	1124	internet	T073	C0282111
28270097	1128	1135	general	T082	C0205246
28270097	1152	1161	one-third	T081	C0392762
28270097	1169	1181	participants	T098	C0679646
28270097	1182	1186	used	T033	C1273517
28270097	1191	1199	internet	T073	C0282111
28270097	1226	1243	medical condition	T033	C3843040
28270097	1265	1273	upcoming	T079	C1254367
28270097	1274	1292	surgical procedure	T061	C0543467
28270097	1311	1319	obtained	T169	C1301820
28270097	1320	1331	information	T078	C1533716
28270097	1342	1353	anaesthetic	T121	C0002932
28270097	1358	1379	multivariate analyses	T081	C0026777
28270097	1381	1388	factors	T169	C1521761
28270097	1389	1404	associated with	T080	C0332281
28270097	1405	1413	internet	T073	C0282111
28270097	1414	1417	use	T169	C0457083
28270097	1447	1454	planned	T169	C1301732
28270097	1455	1463	moderate	T080	C1881878
28270097	1464	1472	compared	T052	C1707455
28270097	1476	1481	minor	T080	C0205165
28270097	1482	1489	surgery	T061	C0543467
28270097	1491	1500	not using	T169	C0445107
28270097	1505	1513	internet	T073	C0282111
28270097	1518	1533	associated with	T080	C0332281
28270097	1543	1554	anaesthetic	T121	C0002932
28270097	1555	1565	experience	T041	C0596545
28270097	1596	1604	Internet	T073	C0282111
28270097	1626	1637	anaesthetic	T121	C0002932
28270097	1643	1652	indicated	T033	C1444656
28270097	1692	1699	website	T170	C2349146
28270097	1710	1718	patients	T101	C0030705
28270097	1719	1723	used	T033	C1273517
28270097	1728	1736	internet	T073	C0282111
28270097	1740	1746	obtain	T169	C1301820
28270097	1747	1758	information	T078	C1533716
28270097	1771	1779	upcoming	T079	C1254367
28270097	1780	1789	procedure	T169	C2700391
28270097	1798	1809	anaesthetic	T121	C0002932
28270097	1858	1866	patients	T101	C0030705
28270097	1890	1898	guidance	T058	C0150600
28270097	1902	1906	find	T033	C0243095
28270097	1907	1918	trustworthy	T080	C0205556
28270097	1919	1933	internet sites	T170	C2349146
28270097	1935	1957	German Clinical Trials	T062	C0008976
28270097	1958	1966	Register	T170	C0034975
28270097	1982	2002	date of registration	T079	C2985881
28270097	2011	2019	December	T080	C3830550
28270097	2027	2031	date	T079	C0011008
28270097	2035	2044	enrolment	T062	C4041024
28270097	2054	2061	patient	T101	C0030705
28270097	2067	2073	August	T080	C3831448
28270097	2080	2101	study retrospectively	T062	C0035363

28323937|t|TERT, BRAF and NRAS in primary thyroid cancer and metastatic disease
28323937|a|Little is known about the frequency of key mutations in thyroid cancer metastases and its relationship with the primary tumor genotype. To evaluate the frequency of TERT promoter (TERTp), BRAF and NRAS mutations in metastatic thyroid carcinomas, analyzing primary thyroid tumors, lymph node metastases (LNM) and distant metastases. Mutation analysis was performed in 437 tissue samples from 204 patients, mainly with papillary thyroid carcinomas (PTC) (n=180), including 196 LNM and 56 distant metastases. All the distant metastases included corresponded to radioiodine -refractory metastatic tissue. We found the following mutation frequency in primary PTC, LNM and distant metastases, respectively: TERTp - 12.9%, 10.5%, and 52.4%; BRAF - 44.6%, 41.7%, and 23.8%; NRAS - 1.2%, 1.3%, and 14.3%. There was a significant concordance between the primary tumor genotype and the corresponding LNM for all the genes, in particular BRAF -mutated PTC. The overall concordance between primary tumors and respective distant metastases was low. In the group of patients with PTC, we found a high frequency of TERTp mutations and a low frequency of BRAF mutations in distant metastases, in comparison to the paired primary tumors. When present in distant metastases, BRAF mutations frequently coexisted with TERTp mutations. When the genotype of primary tumors is compared with the genotype of LNM, the concordance is high for all the genes studied. On the other hand, distant metastases show an enrichment in TERTp mutations and a decrease in BRAF mutations. TERTp mutations may play a role in distant metastases.
28323937	0	4	TERT	T116,T126	C0754515
28323937	6	10	BRAF	T116,T123	C1259929
28323937	15	19	NRAS	T116,T126	C0079975
28323937	23	45	primary thyroid cancer	T191	C2217687
28323937	50	68	metastatic disease	T191	C0027627
28323937	95	121	frequency of key mutations	T080	C3178846
28323937	125	139	thyroid cancer	T191	C0007115
28323937	140	150	metastases	T191	C0027627
28323937	181	194	primary tumor	T191	C0677930
28323937	195	203	genotype	T032	C0017431
28323937	221	230	frequency	T080	C3178846
28323937	234	238	TERT	T028	C1367342
28323937	239	247	promoter	T028	C0314621
28323937	249	254	TERTp	T028	C0314621
28323937	257	261	BRAF	T028	C0812241
28323937	266	270	NRAS	T028	C0027260
28323937	271	280	mutations	T049	C1516197
28323937	284	294	metastatic	T191	C0027627
28323937	295	313	thyroid carcinomas	T191	C0549473
28323937	325	347	primary thyroid tumors	T191	C2217687
28323937	349	370	lymph node metastases	T191	C0686619
28323937	372	375	LNM	T191	C0686619
28323937	381	399	distant metastases	T185	C1269798
28323937	401	418	Mutation analysis	T059	C0796357
28323937	440	454	tissue samples	T024	C0475358
28323937	464	472	patients	T101	C1516213
28323937	486	514	papillary thyroid carcinomas	T191	C0238463
28323937	516	519	PTC	T191	C0238463
28323937	544	547	LNM	T191	C0686619
28323937	555	573	distant metastases	T185	C1269798
28323937	583	601	distant metastases	T185	C1269798
28323937	627	638	radioiodine	T121,T130,T131,T196	C1441129
28323937	651	661	metastatic	T191	C0027627
28323937	662	668	tissue	T024	C0040300
28323937	693	711	mutation frequency	T080	C3178846
28323937	715	722	primary	T191	C0677930
28323937	723	726	PTC	T191	C0238463
28323937	728	731	LNM	T191	C0686619
28323937	736	754	distant metastases	T185	C1269798
28323937	770	775	TERTp	T028	C0314621
28323937	803	807	BRAF	T028	C0812241
28323937	835	839	NRAS	T028	C0027260
28323937	889	900	concordance	T080	C0332529
28323937	913	926	primary tumor	T191	C0677930
28323937	927	935	genotype	T032	C0017431
28323937	958	961	LNM	T191	C0686619
28323937	974	979	genes	T028	C0017337
28323937	995	999	BRAF	T028	C0812241
28323937	1009	1012	PTC	T191	C0238463
28323937	1026	1037	concordance	T080	C0332529
28323937	1046	1060	primary tumors	T191	C0677930
28323937	1076	1094	distant metastases	T185	C1269798
28323937	1120	1128	patients	T101	C1516213
28323937	1134	1137	PTC	T191	C0238463
28323937	1168	1173	TERTp	T028	C0314621
28323937	1174	1183	mutations	T049	C1516197
28323937	1207	1211	BRAF	T028	C0812241
28323937	1212	1221	mutations	T049	C1516197
28323937	1225	1243	distant metastases	T185	C1269798
28323937	1273	1287	primary tumors	T191	C0677930
28323937	1305	1323	distant metastases	T185	C1269798
28323937	1325	1329	BRAF	T028	C0812241
28323937	1330	1339	mutations	T049	C1516197
28323937	1366	1371	TERTp	T028	C0314621
28323937	1372	1381	mutations	T049	C1516197
28323937	1392	1400	genotype	T032	C0017431
28323937	1404	1418	primary tumors	T191	C0677930
28323937	1440	1448	genotype	T032	C0017431
28323937	1452	1455	LNM	T191	C0686619
28323937	1461	1472	concordance	T080	C0332529
28323937	1493	1498	genes	T028	C0017337
28323937	1527	1545	distant metastases	T185	C1269798
28323937	1568	1573	TERTp	T028	C0314621
28323937	1574	1583	mutations	T049	C1516197
28323937	1602	1606	BRAF	T028	C0812241
28323937	1607	1616	mutations	T049	C1516197
28323937	1618	1623	TERTp	T028	C0314621
28323937	1624	1633	mutations	T049	C1516197
28323937	1653	1671	distant metastases	T185	C1269798

27775984|t|Hydrofiber Dressing Saturated With Mafenide Acetate Extends the Duration of Antimicrobial Activity
27775984|a|Mafenide acetate is used in some burn wounds for its ability to penetrate eschar but requires frequent uncomfortable dressing changes for its application. The authors hypothesize that hydrofiber dressings will hold mafenide acetate solution for an extended period of time and maintain antimicrobial activity longer than traditional gauze, thus possibly obviating the need for frequent dressing changes. Four experimental arms included: 1) hydrofiber, stored on a dry well plate as control, 2) gauze saturated with 2.5% mafenide acetate, stored on nonsterile porcine skin, 3) hydrofiber saturated with mafenide acetate, stored on dry well plate, and 4) hydrofiber saturated with mafenide acetate, stored on nonsterile porcine skin. At 0, 24, 48, and 72 hours, a 1-cm disk was cut from the dressing sheet of each study arm, placed on agar plates seeded with Staphylococcus aureus and Pseudomonas aeruginosa, and incubated for 24 hours, and the zone of inhibition was measured. A zone of 2 mm or greater was indicative of susceptibility. Each arm of the experiment was performed four times to demonstrate reproducibility. Plain hydrofiber (control) demonstrated no zone of inhibition at any time point, thereby possessing no antimicrobial activity alone. Gauze saturated with mafenide acetate did not reliably demonstrate antimicrobial activity beyond 0 hours. Hydrofiber saturated with mafenide acetate, whether stored on a dry well plate or nonsterile porcine skin, consistently possessed sustained antimicrobial activity as demonstrated by zones of inhibition greater than 2 mm to both S. aureus and P. aeruginosa. Mafenide acetate - soaked hydrofiber dressings stay moist and maintain antimicrobial activity against S. aureus and P. aeruginosa for at least 72 hours without repeated soaks.
27775984	0	10	Hydrofiber	T074	C3845922
27775984	11	19	Dressing	T074	C0013119
27775984	20	29	Saturated	T070	C0522534
27775984	35	51	Mafenide Acetate	T109,T121	C0024453
27775984	52	59	Extends	T082	C0439792
27775984	64	72	Duration	T079	C0449238
27775984	76	98	Antimicrobial Activity	T034	C1271650
27775984	99	115	Mafenide acetate	T109,T121	C0024453
27775984	132	143	burn wounds	T037	C0006434
27775984	152	159	ability	T032	C0085732
27775984	163	172	penetrate	T169	C0205321
27775984	173	179	eschar	T046	C0521172
27775984	193	201	frequent	T079	C0332183
27775984	216	232	dressing changes	T061	C0085671
27775984	241	252	application	UnknownType	C0869019
27775984	258	265	authors	T097	C3812881
27775984	266	277	hypothesize	T078	C1512571
27775984	283	303	hydrofiber dressings	T074	C0013119
27775984	314	339	mafenide acetate solution	T109,T121	C0024453
27775984	347	355	extended	T082	C0439792
27775984	356	370	period of time	T079	C1948053
27775984	384	406	antimicrobial activity	T034	C1271650
27775984	419	436	traditional gauze	T074	C0590323
27775984	452	461	obviating	T080	C0849355
27775984	475	483	frequent	T079	C0332183
27775984	484	500	dressing changes	T061	C0085671
27775984	507	524	experimental arms	T098	C2349001
27775984	538	548	hydrofiber	T074	C3845922
27775984	550	556	stored	T169	C1698986
27775984	562	565	dry	T080	C0205222
27775984	566	576	well plate	T082	C4283957
27775984	580	587	control	T167	C1550141
27775984	592	597	gauze	T074	C0590323
27775984	598	607	saturated	T070	C0522534
27775984	618	634	mafenide acetate	T109,T121	C0024453
27775984	636	642	stored	T169	C1698986
27775984	657	669	porcine skin	T061	C0191501
27775984	674	684	hydrofiber	T074	C3845922
27775984	685	694	saturated	T070	C0522534
27775984	700	716	mafenide acetate	T109,T121	C0024453
27775984	718	724	stored	T169	C1698986
27775984	728	731	dry	T080	C0205222
27775984	732	742	well plate	T082	C4283957
27775984	751	761	hydrofiber	T074	C0025080
27775984	762	771	saturated	T070	C0522534
27775984	777	793	mafenide acetate	T109,T121	C0024453
27775984	795	801	stored	T169	C1698986
27775984	816	828	porcine skin	T061	C0191501
27775984	851	856	hours	T079	C0439227
27775984	865	869	disk	T082	C2348299
27775984	887	901	dressing sheet	T074	C0013119
27775984	910	919	study arm	T098	C2349001
27775984	931	942	agar plates	T109,T121,T130	C0001771
27775984	943	949	seeded	T059	C1705192
27775984	955	976	Staphylococcus aureus	T007	C0038172
27775984	981	1003	Pseudomonas aeruginosa	T007	C0033809
27775984	1009	1018	incubated	T059	C1439852
27775984	1026	1031	hours	T079	C0439227
27775984	1041	1045	zone	T082	C1710706
27775984	1049	1059	inhibition	T052	C3463820
27775984	1064	1072	measured	T080	C0444706
27775984	1076	1080	zone	T082	C1710706
27775984	1092	1099	greater	T081	C1704243
27775984	1104	1114	indicative	T052	C1882932
27775984	1118	1132	susceptibility	T169	C0231204
27775984	1139	1142	arm	T098	C2349001
27775984	1150	1160	experiment	T062	C0681814
27775984	1165	1174	performed	T169	C0884358
27775984	1180	1185	times	T081	C1632851
27775984	1201	1216	reproducibility	T080	C1514863
27775984	1218	1234	Plain hydrofiber	T074	C3845922
27775984	1236	1243	control	T167	C1550141
27775984	1261	1265	zone	T082	C1710706
27775984	1269	1279	inhibition	T052	C3463820
27775984	1287	1297	time point	T079	C2348792
27775984	1307	1317	possessing	T078	C3154893
27775984	1321	1343	antimicrobial activity	T034	C1271650
27775984	1351	1356	Gauze	T074	C0590323
27775984	1357	1366	saturated	T070	C0522534
27775984	1372	1388	mafenide acetate	T109,T121	C0024453
27775984	1418	1440	antimicrobial activity	T034	C1271650
27775984	1450	1455	hours	T079	C0439227
27775984	1457	1467	Hydrofiber	T074	C3845922
27775984	1468	1477	saturated	T070	C0522534
27775984	1483	1499	mafenide acetate	T109,T121	C0024453
27775984	1521	1524	dry	T080	C0205222
27775984	1525	1535	well plate	T082	C4283957
27775984	1550	1562	porcine skin	T061	C0191501
27775984	1577	1586	possessed	T078	C3154893
27775984	1587	1596	sustained	T169	C0443318
27775984	1597	1619	antimicrobial activity	T034	C1271650
27775984	1639	1644	zones	T082	C1710706
27775984	1648	1658	inhibition	T052	C3463820
27775984	1659	1666	greater	T081	C1704243
27775984	1685	1694	S. aureus	T007	C0038172
27775984	1699	1712	P. aeruginosa	T007	C0033809
27775984	1714	1730	Mafenide acetate	T109,T121	C0024453
27775984	1733	1760	soaked hydrofiber dressings	T169	C0694642
27775984	1766	1771	moist	T080	C0205381
27775984	1785	1807	antimicrobial activity	T034	C1271650
27775984	1816	1825	S. aureus	T007	C0038172
27775984	1830	1843	P. aeruginosa	T007	C0033809
27775984	1860	1865	hours	T079	C0439227
27775984	1874	1882	repeated	T169	C0205341
27775984	1883	1888	soaks	T061	C0204774

27758943|t|Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation: An Observational Cohort Study
27758943|a|We sought to determine the risk of stroke / thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups. We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR. A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke / thromboembolism and bleeding. Use of warfarin was associated with higher bleeding risk in all eGFR groups; hazard ratios 1.23 (95% confidence interval [CI], 0.97-1.56), 1.26 (95% CI, 1.14-1.40), 1.18 (95% CI, 1.07-1.31), 1.11 (95% CI, 0.87-1.42), 2.01 (95% CI, 1.14-3.54) in patients with eGFR ≥90, 60 to 89, 30 to 59, 15 to 29, and <15 mL/min per 1.73 m(2), respectively. Use of warfarin was associated with lower risk of stroke / thromboembolism in patients with eGFR ≥15 mL/min per 1.73 m(2); hazard ratios 0.57 (95% CI, 0.43-0.76), 0.57 (95% CI, 0.51-0.64), 0.48 (95% CI, 0.44-0.54), 0.60 (95% CI, 0.45-0.80) in patients with eGFR ≥90, 60 to 89, 30 to 59, and 15 to 29 mL/min per 1.73 m(2), respectively. Use of warfarin was not associated with lower risk of stroke / thromboembolism in patients with eGFR <15 mL/min per 1.73 m(2); hazard ratio 1.18 (95% CI, 0.58-2.40). In patients with atrial fibrillation, the risk of stroke and bleeding was associated with levels of renal function. Warfarin treatment was associated with higher risk of bleeding in all eGFR groups and lower risk of stroke in patients with eGFR ≥15 mL/min per 1.73 m(2).
27758943	0	14	Renal Function	T042	C0232804
27758943	23	27	Risk	T078	C0035647
27758943	31	37	Stroke	T047	C0038454
27758943	42	50	Bleeding	T046	C0019080
27758943	54	62	Patients	T101	C0030705
27758943	68	87	Atrial Fibrillation	T047	C0004238
27758943	92	118	Observational Cohort Study	T081	C0009247
27758943	146	150	risk	T078	C0035647
27758943	154	160	stroke	T047	C0038454
27758943	163	178	thromboembolism	T046	C0040038
27758943	183	191	bleeding	T046	C0019080
27758943	192	207	associated with	T080	C0332281
27758943	216	230	renal function	T042	C0232804
27758943	234	242	patients	T101	C0030705
27758943	248	267	atrial fibrillation	T047	C0004238
27758943	276	280	risk	T078	C0035647
27758943	284	290	stroke	T047	C0038454
27758943	295	303	bleeding	T046	C0019080
27758943	304	319	associated with	T080	C0332281
27758943	320	338	warfarin treatment	T061	C0750388
27758943	351	387	estimated glomerular filtration rate	T059	C3811844
27758943	389	393	eGFR	T059	C3811844
27758943	395	401	groups	T078	C0441833
27758943	433	445	cohort study	T081	C0009247
27758943	459	467	patients	T101	C0030705
27758943	484	515	nonvalvular atrial fibrillation	T047	C0004238
27758943	549	553	eGFR	T059	C3811844
27758943	573	581	patients	T101	C0030705
27758943	603	607	eGFR	T059	C3811844
27758943	621	629	baseline	T081	C1442488
27758943	635	641	levels	T080	C0441889
27758943	651	655	eGFR	T059	C3811844
27758943	661	676	associated with	T080	C0332281
27758943	684	688	risk	T078	C0035647
27758943	692	698	stroke	T047	C0038454
27758943	701	716	thromboembolism	T046	C0040038
27758943	721	729	bleeding	T046	C0019080
27758943	738	746	warfarin	T109,T121,T131	C0043031
27758943	751	766	associated with	T080	C0332281
27758943	774	782	bleeding	T046	C0019080
27758943	783	787	risk	T078	C0035647
27758943	795	799	eGFR	T059	C3811844
27758943	800	806	groups	T078	C0441833
27758943	808	821	hazard ratios	T081	C2985465
27758943	832	851	confidence interval	T081	C0009667
27758943	853	855	CI	T081	C0009667
27758943	880	882	CI	T081	C0009667
27758943	906	908	CI	T081	C0009667
27758943	932	934	CI	T081	C0009667
27758943	958	960	CI	T081	C0009667
27758943	976	984	patients	T101	C0030705
27758943	990	994	eGFR	T059	C3811844
27758943	1081	1089	warfarin	T109,T121,T131	C0043031
27758943	1094	1109	associated with	T080	C0332281
27758943	1116	1120	risk	T078	C0035647
27758943	1124	1130	stroke	T047	C0038454
27758943	1133	1148	thromboembolism	T046	C0040038
27758943	1152	1160	patients	T101	C0030705
27758943	1166	1170	eGFR	T059	C3811844
27758943	1197	1210	hazard ratios	T081	C2985465
27758943	1221	1223	CI	T081	C0009667
27758943	1247	1249	CI	T081	C0009667
27758943	1273	1275	CI	T081	C0009667
27758943	1299	1301	CI	T081	C0009667
27758943	1317	1325	patients	T101	C0030705
27758943	1331	1335	eGFR	T059	C3811844
27758943	1417	1425	warfarin	T109,T121,T131	C0043031
27758943	1434	1449	associated with	T080	C0332281
27758943	1456	1460	risk	T078	C0035647
27758943	1464	1470	stroke	T047	C0038454
27758943	1473	1488	thromboembolism	T046	C0040038
27758943	1492	1500	patients	T101	C0030705
27758943	1506	1510	eGFR	T059	C3811844
27758943	1537	1549	hazard ratio	T081	C2985465
27758943	1560	1562	CI	T081	C0009667
27758943	1579	1587	patients	T101	C0030705
27758943	1593	1612	atrial fibrillation	T047	C0004238
27758943	1618	1622	risk	T078	C0035647
27758943	1626	1632	stroke	T047	C0038454
27758943	1637	1645	bleeding	T046	C0019080
27758943	1650	1665	associated with	T080	C0332281
27758943	1676	1690	renal function	T042	C0232804
27758943	1692	1710	Warfarin treatment	T061	C0750388
27758943	1715	1730	associated with	T080	C0332281
27758943	1731	1737	higher	T080	C0205250
27758943	1738	1742	risk	T078	C0035647
27758943	1746	1754	bleeding	T046	C0019080
27758943	1762	1766	eGFR	T059	C3811844
27758943	1767	1773	groups	T078	C0441833
27758943	1778	1783	lower	T080	C0205251
27758943	1784	1788	risk	T078	C0035647
27758943	1792	1798	stroke	T047	C0038454
27758943	1802	1810	patients	T101	C0030705
27758943	1816	1820	eGFR	T059	C3811844

27821419|t|Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy
27821419|a|Vast parts of mammalian genomes encode for transcripts that are not further translated into proteins. The purpose of the majority of such noncoding ribonucleic acids (RNAs) remained paradoxical for a long time. However, a growing body of evidence demonstrates that long noncoding RNAs are dynamically expressed in different cell types, diseases, or developmental stages to execute a wide variety of regulatory roles at virtually every step of gene expression and translation. Indeed, long noncoding RNAs influence gene expression via epigenetic modulations, through regulating alternative splicing, or by acting as molecular sponges. The abundance of long noncoding RNAs in the cardiovascular system indicates that they may be part of a complex regulatory network governing physiology and pathology of the heart. In this review, we discuss the multifaceted functions of long noncoding RNAs and highlight the current literature with an emphasis on cardiac development and disease. Furthermore, as the enormous spectrum of long noncoding RNAs potentially opens up new avenues for diagnosis and prevention of heart failure, we ultimately evaluate the futuristic prospects of long noncoding RNAs as biomarkers, and therapeutic targets for the treatment of cardiovascular disorders, as well.
27821419	0	19	Long Noncoding RNAs	T114	C2982391
27821419	23	47	Cardiovascular Pathology	T047	C0741949
27821419	49	58	Diagnosis	T062	C1704656
27821419	64	71	Therapy	T061	C0087111
27821419	86	95	mammalian	T015	C0024660
27821419	96	103	genomes	T028	C0017428
27821419	104	110	encode	T052	C2700640
27821419	115	126	transcripts	T114	C1519595
27821419	148	172	translated into proteins	T045	C1519614
27821419	178	185	purpose	T169	C1285529
27821419	193	201	majority	T080	C0205164
27821419	210	237	noncoding ribonucleic acids	T114	C0887909
27821419	238	244	(RNAs)	T114	C0887909
27821419	254	265	paradoxical	T080	C0205310
27821419	294	301	growing	T169	C0442808
27821419	310	318	evidence	T078	C3887511
27821419	319	331	demonstrates	T052	C3687625
27821419	337	356	long noncoding RNAs	T114	C2982391
27821419	361	372	dynamically	T169	C0729333
27821419	373	382	expressed	T045	C0017262
27821419	386	395	different	T080	C1705242
27821419	396	406	cell types	T025	C0007634
27821419	408	416	diseases	T047	C0012634
27821419	421	441	developmental stages	T079	C0870411
27821419	445	452	execute	T052	C1705848
27821419	455	467	wide variety	T077	C2346866
27821419	471	487	regulatory roles	T077	C1704735
27821419	491	500	virtually	T080	C0205556
27821419	507	511	step	T077	C1261552
27821419	515	530	gene expression	T045	C0017262
27821419	535	546	translation	T045	C1519614
27821419	556	575	long noncoding RNAs	T114	C2982391
27821419	576	585	influence	T077	C4054723
27821419	586	601	gene expression	T045	C0017262
27821419	606	628	epigenetic modulations	T045	C1516924
27821419	638	648	regulating	T045	C0017263
27821419	649	669	alternative splicing	T045	C0002345
27821419	687	704	molecular sponges	T080	C0205556
27821419	710	719	abundance	T080	C2346714
27821419	723	742	long noncoding RNAs	T114	C2982391
27821419	750	771	cardiovascular system	T022	C0007226
27821419	809	816	complex	T080	C0439855
27821419	817	835	regulatory network	T044	C1720950
27821419	836	845	governing	T067	C2239193
27821419	846	856	physiology	T039	C1254359
27821419	861	870	pathology	T046	C0030660
27821419	878	883	heart	T023	C0018787
27821419	916	928	multifaceted	T082	C0205291
27821419	929	938	functions	T169	C0542341
27821419	942	961	long noncoding RNAs	T114	C2982391
27821419	980	998	current literature	T170	C0023866
27821419	1019	1038	cardiac development	T039	C2263229
27821419	1043	1050	disease	T047	C0012634
27821419	1052	1063	Furthermore	T082	C1517331
27821419	1072	1080	enormous	T080	C0205231
27821419	1093	1112	long noncoding RNAs	T114	C2982391
27821419	1113	1124	potentially	T080	C3245505
27821419	1138	1145	avenues	T082	C1254362
27821419	1150	1159	diagnosis	T062	C1704656
27821419	1164	1174	prevention	T061	C0199176
27821419	1178	1191	heart failure	T047	C0018801
27821419	1220	1240	futuristic prospects	T079	C1552610
27821419	1244	1263	long noncoding RNAs	T114	C2982391
27821419	1267	1277	biomarkers	T201	C0005516
27821419	1283	1294	therapeutic	T169	C0302350
27821419	1295	1302	targets	T114	C0028622
27821419	1311	1320	treatment	T061	C0087111
27821419	1324	1348	cardiovascular disorders	T047	C0007222

28509716|t|Multicenter Patch Testing With Methylchloroisothizoline/Methylisothiazolinone in 100 and 200 ppm Within the International Contact Dermatitis Research Group
28509716|a|The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P < 0.001). Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 μg/cm) diagnoses significantly more contact allergy than 0.01% (dose, 3 μg/cm), without resulting in more adverse reactions. Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series.
28509716	0	25	Multicenter Patch Testing	T060	C0030646
28509716	31	77	Methylchloroisothizoline/Methylisothiazolinone	T109	C4294478
28509716	108	155	International Contact Dermatitis Research Group	T093	C1708333
28509716	160	172	preservative	T122	C0033086
28509716	173	222	methylchloroisothiazolinone/methylisothiazolinone	T109	C4294478
28509716	224	230	MCI/MI	T109	C4294478
28509716	248	266	contact sensitizer	T129	C0009841
28509716	324	331	optimal	T080	C2698651
28509716	332	342	patch test	T060	C0030646
28509716	343	356	concentration	T081	C1446561
28509716	360	366	MCI/MI	T109	C4294478
28509716	393	400	aqueous	T080	C0599956
28509716	402	405	aq.	T080	C0599956
28509716	445	463	literature reviews	T170	C0282441
28509716	472	483	recommended	T078	C0034866
28509716	493	506	concentration	T081	C1446561
28509716	516	519	aq.	T080	C0599956
28509716	542	571	international baseline series	T170	C0282574
28509716	577	580	aim	T078	C1947946
28509716	589	594	study	T062	C0008972
28509716	602	608	verify	T169	C1711411
28509716	613	627	recommendation	T078	C0034866
28509716	655	665	patch test	T060	C0030646
28509716	666	673	results	T034	C0456984
28509716	679	690	consecutive	T080	C1707491
28509716	691	704	patch testing	T060	C0030646
28509716	710	716	MCI/MI	T109	C4294478
28509716	736	743	clinics	T073,T093	C0442592
28509716	757	766	countries	T083	C0454664
28509716	778	783	world	T098	C2700280
28509716	818	829	consecutive	T080	C1707491
28509716	830	838	patients	T101	C0030705
28509716	844	854	dermatitis	T047	C0011616
28509716	860	871	dermatology	T091	C0011627
28509716	872	879	clinics	T073,T093	C0442592
28509716	895	904	countries	T083	C0454664
28509716	910	922	patch tested	T060	C0030646
28509716	928	934	MCI/MI	T109	C4294478
28509716	941	944	aq.	T080	C0599956
28509716	953	961	parallel	T062	C2826345
28509716	967	973	MCI/MI	T109	C4294478
28509716	980	983	aq.	T080	C0599956
28509716	1015	1030	baseline series	T170	C0282574
28509716	1032	1047	Contact allergy	T047	C0162820
28509716	1051	1057	MCI/MI	T109	C4294478
28509716	1111	1119	patients	T101	C0030705
28509716	1147	1177	Methylchloroisothiazolinone/MI	T109	C4294478
28509716	1184	1187	aq.	T080	C0599956
28509716	1189	1193	dose	T081	C0178602
28509716	1204	1213	diagnoses	T033	C0011900
28509716	1214	1232	significantly more	T081	C4055637
28509716	1233	1248	contact allergy	T047	C0162820
28509716	1261	1265	dose	T081	C0178602
28509716	1285	1297	resulting in	T169	C0332294
28509716	1303	1320	adverse reactions	T046	C0559546
28509716	1322	1352	Methylchloroisothiazolinone/MI	T109	C4294478
28509716	1362	1365	aq.	T080	C0599956
28509716	1386	1398	continuously	T078	C0549178
28509716	1411	1440	international baseline series	T170	C0282574

27929135|t|Early life vaccination: Generation of adult - quality memory CD8+ T cells in infant mice using non-replicating adenoviral vectors
27929135|a|Intracellular pathogens represent a serious threat during early life. Importantly, even though the immune system of newborns may be characterized as developmentally immature, with a propensity to develop Th2 immunity, significant CD8+ T-cell responses may still be elicited in the context of optimal priming. Replication deficient adenoviral vectors have been demonstrated to induce potent CD8+ T-cell response in mice, primates and humans. The aim of the present study was therefore to assess whether replication-deficient adenovectors could overcome the risk of overwhelming antigen stimulation during the first period of life and provide a pertinent alternative in infant vaccinology. To address this, infant mice were vaccinated with three different adenoviral vectors and the CD8+ T-cell response after early life vaccination was explored. We assessed the frequency, polyfunctionality and in vivo cytotoxicity of the elicited memory CD8+ T cells, as well as the potential of these cells to respond to secondary infections and confer protection. We further tested the impact of maternal immunity against our replication-deficient adenoviral vector during early life vaccination. Overall, our results indicate that memory CD8+ T cells induced by adenoviral vectors in infant mice are of good quality and match those elicited in the adult host.
27929135	0	5	Early	T079	C1279919
27929135	6	10	life	T078	C0376558
27929135	11	22	vaccination	T061	C0042196
27929135	24	34	Generation	T052	C3146294
27929135	38	43	adult	T008	C0596888
27929135	46	53	quality	T080	C0332306
27929135	54	60	memory	T025	C0682639
27929135	61	73	CD8+ T cells	T025	C0242629
27929135	77	83	infant	T008	C0920362
27929135	84	88	mice	T015	C0025929
27929135	95	110	non-replicating	T045	C1511692
27929135	111	129	adenoviral vectors	T114	C1510800
27929135	130	143	Intracellular	T082	C0178719
27929135	144	153	pathogens	T001	C0450254
27929135	166	173	serious	T080	C0205404
27929135	174	180	threat	T078	C0749385
27929135	188	193	early	T079	C1279919
27929135	194	198	life	T078	C0376558
27929135	229	242	immune system	T022	C0020962
27929135	246	254	newborns	T100	C0021289
27929135	279	294	developmentally	T039	C0243107
27929135	295	303	immature	T080	C0205252
27929135	312	322	propensity	T081	C2718044
27929135	334	337	Th2	T025	C0242633
27929135	338	346	immunity	T039	C0020964
27929135	348	359	significant	T078	C0750502
27929135	360	371	CD8+ T-cell	T025	C0242629
27929135	372	381	responses	T043	C1318468
27929135	395	403	elicited	T080	C0449265
27929135	422	429	optimal	T080	C2698651
27929135	430	437	priming	T169	C0871133
27929135	439	460	Replication deficient	T045	C1511692
27929135	461	479	adenoviral vectors	T114	C1510800
27929135	506	512	induce	T169	C0205263
27929135	520	531	CD8+ T-cell	T025	C0242629
27929135	532	540	response	T043	C1318468
27929135	544	548	mice	T015	C0026809
27929135	550	558	primates	T015	C0033147
27929135	563	569	humans	T016	C0086418
27929135	632	653	replication-deficient	T045	C1511692
27929135	654	666	adenovectors	T114	C1510800
27929135	673	681	overcome	T052	C2983310
27929135	686	690	risk	T078	C0035647
27929135	694	706	overwhelming	T081	C1704243
27929135	707	726	antigen stimulation	T039	C2250751
27929135	738	750	first period	T079	C0580206
27929135	754	758	life	T078	C0376558
27929135	773	782	pertinent	T080	C2347946
27929135	783	794	alternative	T077	C1523987
27929135	798	804	infant	T100	C0021270
27929135	805	816	vaccinology	T061	C0042196
27929135	835	841	infant	T008	C0920362
27929135	842	846	mice	T015	C0025929
27929135	852	862	vaccinated	T033	C1519885
27929135	884	902	adenoviral vectors	T114	C1510800
27929135	911	922	CD8+ T-cell	T025	C0242629
27929135	923	931	response	T043	C1318468
27929135	938	943	early	T079	C1279919
27929135	944	948	life	T078	C0376558
27929135	949	960	vaccination	T061	C0042196
27929135	991	1000	frequency	T079	C0439603
27929135	1002	1019	polyfunctionality	T169	C0205245
27929135	1032	1044	cytotoxicity	T049	C0596402
27929135	1052	1060	elicited	T080	C0449265
27929135	1061	1067	memory	T025	C0682639
27929135	1068	1080	CD8+ T cells	T025	C0242629
27929135	1097	1106	potential	T080	C3245505
27929135	1116	1121	cells	T025	C0242629
27929135	1125	1132	respond	T032	C0871261
27929135	1136	1156	secondary infections	T047	C0442886
27929135	1168	1178	protection	T061	C0150259
27929135	1191	1197	tested	T169	C0039593
27929135	1202	1208	impact	T080	C4049986
27929135	1212	1220	maternal	T033	C1858460
27929135	1221	1229	immunity	T039	C0020964
27929135	1230	1237	against	T080	C0521124
27929135	1242	1263	replication-deficient	T045	C1511692
27929135	1264	1281	adenoviral vector	T114	C1510800
27929135	1289	1294	early	T079	C1279919
27929135	1295	1299	life	T078	C0376558
27929135	1300	1311	vaccination	T061	C0042196
27929135	1313	1320	Overall	T080	C1561607
27929135	1348	1354	memory	T025	C0682639
27929135	1355	1367	CD8+ T cells	T025	C0242629
27929135	1368	1375	induced	T169	C0205263
27929135	1379	1397	adenoviral vectors	T114	C1510800
27929135	1401	1407	infant	T008	C0920362
27929135	1408	1412	mice	T015	C0025929
27929135	1425	1432	quality	T080	C0332306
27929135	1437	1442	match	T080	C1708943
27929135	1449	1457	elicited	T080	C0449265
27929135	1465	1470	adult	T008	C0596888
27929135	1471	1475	host	T001	C1167395

27882558|t|Effects of voice-sparing cricotracheal resection on phonation in women
27882558|a|Individuals with idiopathic subglottic stenosis (SGS) are at risk for voice disorders prior to and following surgical management. This study examined the nature and severity of voice disorders in patients with SGS before and after a revised cricotracheal resection (CTR) procedure designed to minimize adverse effects on voice function. Eleven women with idiopathic SGS provided presurgical and postsurgical audio recordings. Voice Handicap Index (VHI) scores were also collected. Cepstral, signal-to-noise, periodicity, and fundamental frequency (F0) analyses were undertaken for connected speech and sustained vowel samples. Listeners made auditory - perceptual ratings of overall quality and monotonicity. Paired samples statistical analyses revealed that mean F0 decreased from 215 Hz (standard deviation [SD] = 40 Hz) to 201 Hz (SD = 65 Hz) following surgery. In general, VHI scores decreased after surgery. Voice disorder severity based on the Cepstral Spectral Index of Dysphonia (KayPentax, Montvale, NJ) for sustained vowels decreased (improved) from 41 (SD = 41) to 25 (SD = 21) points; no change was observed for connected speech. Semitone SD (2.2 semitones) did not change from pre- to posttreatment. Auditory - perceptual ratings demonstrated similar results. These preliminary results indicate that this revised CTR procedure is promising in minimizing adverse voice effects while offering a longer-term surgical outcome for SGS. Further research is needed to determine causal factors for pretreatment voice disorders, as well as to optimize treatments in this population. 4. Laryngoscope, 2016.
27882558	0	10	Effects of	T080	C1704420
27882558	25	48	cricotracheal resection	T061	C4291730
27882558	52	61	phonation	T042	C0031577
27882558	65	70	women	T098	C0043210
27882558	71	82	Individuals	T098	C0027361
27882558	88	118	idiopathic subglottic stenosis	T047	C2931158
27882558	120	123	SGS	T047	C2931158
27882558	132	136	risk	T078	C0035647
27882558	141	156	voice disorders	T047	C0042940
27882558	170	179	following	T079	C0332282
27882558	180	199	surgical management	T058	C1515089
27882558	206	211	study	T062	C2603343
27882558	212	220	examined	T033	C0332128
27882558	236	244	severity	T080	C0439793
27882558	248	263	voice disorders	T047	C0042940
27882558	267	275	patients	T101	C0030705
27882558	281	284	SGS	T047	C2931158
27882558	312	351	cricotracheal resection (CTR) procedure	T061	C4291730
27882558	352	360	designed	T052	C1707689
27882558	373	388	adverse effects	T080	C1280500
27882558	392	406	voice function	T039	C0541586
27882558	415	420	women	T098	C0043210
27882558	426	440	idiopathic SGS	T047	C2931158
27882558	441	449	provided	T052	C1999230
27882558	450	461	presurgical	T079	C0445204
27882558	466	478	postsurgical	T079	C0032790
27882558	479	495	audio recordings	UnknownType	C0681505
27882558	497	530	Voice Handicap Index (VHI) scores	T201	C3472512
27882558	541	550	collected	T169	C1516698
27882558	562	577	signal-to-noise	T081	C2986823
27882558	579	590	periodicity	T079	C0031084
27882558	596	617	fundamental frequency	T079	C0439603
27882558	619	621	F0	T079	C0439603
27882558	652	668	connected speech	T033	C4280380
27882558	673	682	sustained	T169	C0443318
27882558	683	696	vowel samples	T170	C0871955
27882558	698	707	Listeners	T098	C1257890
27882558	713	721	auditory	T169	C0439825
27882558	724	734	perceptual	T041	C0030971
27882558	735	742	ratings	T052	C0871208
27882558	754	761	quality	T080	C0332306
27882558	766	778	monotonicity	UnknownType	C0241704
27882558	780	815	Paired samples statistical analyses	T062	C0871424
27882558	816	824	revealed	T080	C0443289
27882558	835	837	F0	T079	C0439603
27882558	838	847	decreased	T081	C0205216
27882558	861	879	standard deviation	T081	C0871420
27882558	881	883	SD	T081	C0871420
27882558	905	907	SD	T081	C0871420
27882558	917	926	following	T079	C0332282
27882558	927	934	surgery	T061	C0543467
27882558	948	958	VHI scores	T201	C3472512
27882558	959	968	decreased	T081	C0205216
27882558	975	982	surgery	T061	C0543467
27882558	984	998	Voice disorder	T047	C0042940
27882558	999	1007	severity	T080	C0392364
27882558	1021	1044	Cepstral Spectral Index	T170	C0918012
27882558	1048	1057	Dysphonia	T048	C1527344
27882558	1059	1068	KayPentax	T073,T092	C0683757
27882558	1070	1078	Montvale	UnknownType	C0681784
27882558	1080	1082	NJ	T083	C0027971
27882558	1088	1097	sustained	T169	C0443318
27882558	1098	1104	vowels	T170	C0871955
27882558	1105	1114	decreased	T081	C0205216
27882558	1116	1124	improved	T033	C0184511
27882558	1135	1137	SD	T081	C0871420
27882558	1151	1153	SD	T081	C0871420
27882558	1168	1177	no change	T033	C0442739
27882558	1182	1190	observed	T169	C1441672
27882558	1195	1211	connected speech	T033	C4280380
27882558	1222	1224	SD	T081	C0871420
27882558	1261	1265	pre-	T079	C2709094
27882558	1269	1282	posttreatment	T079	C2709088
27882558	1284	1292	Auditory	T169	C0439825
27882558	1295	1305	perceptual	T041	C0030971
27882558	1306	1313	ratings	T052	C0871208
27882558	1335	1342	results	T169	C1274040
27882558	1350	1369	preliminary results	T078	C1548161
27882558	1397	1410	CTR procedure	T061	C4291730
27882558	1446	1451	voice	T040	C0042939
27882558	1452	1459	effects	T080	C1280500
27882558	1477	1488	longer-term	T079	C0443252
27882558	1489	1505	surgical outcome	T080	C0085415
27882558	1510	1513	SGS	T047	C2931158
27882558	1523	1531	research	T062	C0035168
27882558	1562	1569	factors	T169	C1521761
27882558	1574	1586	pretreatment	T079	C2709094
27882558	1587	1602	voice disorders	T047	C0042940
27882558	1627	1637	treatments	T061	C0087111
27882558	1646	1656	population	T098	C1257890

28409370|t|A plea for thoracoscopic resection of solitary pulmonary nodule in cancer patients
28409370|a|Solitary pulmonary nodules (SPN) are frequently detected in cancer patients. These lesions are often considered as pulmonary metastases and increasingly treated by non-surgical techniques without histological confirmation. The aim of this study is to determine the histological nature of SPN resected by thoracoscopy and to identify risk factors of malignancy. Single-institution retrospective analysis of all consecutive patients with previously known malignancies who underwent thoracoscopic resection of SPN with unknown diagnosis between 2001 and 2014. One hundred and forty cancer patients underwent thoracoscopic resection of a SPN. The resected SPN was benign in 34 patients (24.3%) and malignant in 106 patients. The latter were metastasis in 70 patients (50%) and a primary lung cancer in 36 patients (25.7%). Upon univariate analysis, malignancy was significantly associated with age >60 years, disease -free interval ≥24 months, SPN size >8 mm, upper lobe localization and SUVmax > 2.5 on PET-CT. Upon multivariate analysis, upper lobe localization and SUVmax > 2.5 were associated with malignancy. Smoking was significantly associated with SPN containing primary lung cancer. In this series, only 50% of SPN in patients with known malignant disease were pulmonary metastases and 25% had a newly diagnosed NSCLC. Smoking was associated with primary lung cancer but no other predictor was found to allow the distinction between pulmonary metastasis and lung cancer. These results endorse the need of histological confirmation of SPN in patients with previous malignancies to avoid diagnostic uncertainty and suboptimal treatments.
28409370	11	24	thoracoscopic	T058	C0039989
28409370	25	34	resection	T061	C0015252
28409370	38	63	solitary pulmonary nodule	T191	C2350019
28409370	67	73	cancer	T191	C0006826
28409370	74	82	patients	T101	C0030705
28409370	83	109	Solitary pulmonary nodules	T191	C2350019
28409370	111	114	SPN	T191	C2350019
28409370	131	139	detected	T033	C0442726
28409370	143	149	cancer	T191	C0006826
28409370	150	158	patients	T101	C0030705
28409370	166	173	lesions	T033	C0577916
28409370	198	218	pulmonary metastases	T191	C0153676
28409370	223	235	increasingly	T169	C0442808
28409370	236	243	treated	T169	C1522326
28409370	247	270	non-surgical techniques	T061	C0087111
28409370	279	291	histological	T169	C0205462
28409370	292	304	confirmation	T033	C0750484
28409370	348	360	histological	T169	C0205462
28409370	361	367	nature	T169	C1262865
28409370	371	374	SPN	T191	C2350019
28409370	375	383	resected	T080	C1521996
28409370	387	399	thoracoscopy	T058	C0039989
28409370	416	428	risk factors	T033	C0035648
28409370	432	442	malignancy	T191	C4282132
28409370	444	485	Single-institution retrospective analysis	T062	C0035363
28409370	493	504	consecutive	T080	C1707491
28409370	505	513	patients	T101	C0030705
28409370	536	548	malignancies	T191	C4282132
28409370	563	576	thoracoscopic	T058	C0039989
28409370	577	586	resection	T061	C0015252
28409370	590	593	SPN	T191	C2350019
28409370	599	606	unknown	T080	C0439673
28409370	607	616	diagnosis	T033	C0011900
28409370	662	668	cancer	T191	C0006826
28409370	669	677	patients	T101	C0030705
28409370	688	701	thoracoscopic	T058	C0039989
28409370	702	711	resection	T061	C0015252
28409370	717	720	SPN	T191	C2350019
28409370	726	734	resected	T080	C1521996
28409370	735	738	SPN	T191	C2350019
28409370	743	749	benign	T080	C0205183
28409370	756	764	patients	T101	C0030705
28409370	777	786	malignant	T080	C0205282
28409370	794	802	patients	T101	C0030705
28409370	820	830	metastasis	T191	C0027627
28409370	837	845	patients	T101	C0030705
28409370	858	865	primary	T080	C0205225
28409370	866	877	lung cancer	T191	C0242379
28409370	884	892	patients	T101	C0030705
28409370	907	926	univariate analysis	T062	C0683962
28409370	928	938	malignancy	T191	C4282132
28409370	957	972	associated with	T080	C0332281
28409370	973	976	age	T032	C0001779
28409370	981	986	years	T079	C1510829
28409370	988	995	disease	T047	C0012634
28409370	1002	1010	interval	T079	C1272706
28409370	1015	1021	months	T079	C0439231
28409370	1023	1026	SPN	T191	C2350019
28409370	1027	1031	size	T082	C0475440
28409370	1039	1049	upper lobe	T023	C0225756
28409370	1050	1062	localization	T169	C0475264
28409370	1067	1073	SUVmax	T081	C2986846
28409370	1083	1089	PET-CT	T060	C1699633
28409370	1096	1117	multivariate analysis	T081	C0026777
28409370	1119	1129	upper lobe	T023	C0225756
28409370	1130	1142	localization	T169	C0475264
28409370	1147	1153	SUVmax	T081	C2986846
28409370	1165	1180	associated with	T080	C0332281
28409370	1181	1191	malignancy	T191	C4282132
28409370	1193	1200	Smoking	T055	C0037369
28409370	1219	1234	associated with	T080	C0332281
28409370	1235	1238	SPN	T191	C2350019
28409370	1250	1257	primary	T080	C0205225
28409370	1258	1269	lung cancer	T191	C0242379
28409370	1279	1285	series	T081	C0205549
28409370	1299	1302	SPN	T191	C2350019
28409370	1306	1314	patients	T101	C0030705
28409370	1326	1343	malignant disease	T047	C0442867
28409370	1349	1369	pulmonary metastases	T191	C0153676
28409370	1384	1399	newly diagnosed	T080	C1518321
28409370	1400	1405	NSCLC	T191	C0007131
28409370	1407	1414	Smoking	T055	C0037369
28409370	1419	1434	associated with	T080	C0332281
28409370	1435	1442	primary	T080	C0205225
28409370	1443	1454	lung cancer	T191	C0242379
28409370	1459	1461	no	T033	C1513916
28409370	1468	1477	predictor	T078	C2698872
28409370	1521	1541	pulmonary metastasis	T191	C0153676
28409370	1546	1557	lung cancer	T191	C0242379
28409370	1593	1605	histological	T169	C0205462
28409370	1606	1618	confirmation	T033	C0750484
28409370	1622	1625	SPN	T191	C2350019
28409370	1629	1637	patients	T101	C0030705
28409370	1643	1651	previous	T079	C0205156
28409370	1652	1664	malignancies	T191	C4282132
28409370	1674	1684	diagnostic	T169	C0348026
28409370	1685	1696	uncertainty	T033	C0087130
28409370	1701	1711	suboptimal	T080	C2984009
28409370	1712	1722	treatments	T061	C0087111

28344590|t|Proteome Profiling of Paulownia Seedlings Infected with Phytoplasma
28344590|a|Phytoplasma is an insect - transmitted pathogen that causes witches' broom disease in many plants. Paulownia witches' broom is one of the most destructive diseases threatening Paulownia production. The molecular mechanisms associated with this disease have been investigated by transcriptome sequencing, but changes in protein abundance have not been investigated with isobaric tags for relative and absolute quantitation. Previous results have shown that methyl methane sulfonate (MMS) can help Paulownia seedlings recover from the symptoms of witches' broom and reinstate a healthy morphology. In this study, a transcriptomic-assisted proteomic technique was used to analyze the protein changes in phytoplasma - infected Paulownia tomentosa seedlings, phytoplasma - infected seedlings treated with 20 and 60 mg·L(-1) MMS, and healthy seedlings. A total of 2,051 proteins were obtained, 879 of which were found to be differentially abundant in pairwise comparisons between the sample groups. Among the differentially abundant proteins, 43 were related to Paulownia witches' broom disease and many of them were annotated to be involved in photosynthesis, expression of dwarf symptom, energy production, and cell signal pathways.
28344590	0	8	Proteome	T116,T123	C0751973
28344590	9	18	Profiling	T059	C0444680
28344590	22	31	Paulownia	T002	C1008086
28344590	32	41	Seedlings	T002	C0242437
28344590	42	50	Infected	T033	C0439663
28344590	56	67	Phytoplasma	T007	C1004784
28344590	68	79	Phytoplasma	T007	C1004784
28344590	86	92	insect	T204	C0021585
28344590	95	106	transmitted	T169	C0332289
28344590	107	115	pathogen	T001	C0450254
28344590	128	150	witches' broom disease	T047	C0012634
28344590	159	165	plants	T002	C0032098
28344590	167	176	Paulownia	T002	C1008086
28344590	177	191	witches' broom	T047	C0012634
28344590	223	231	diseases	T047	C0012634
28344590	244	253	Paulownia	T002	C1008086
28344590	254	264	production	T057	C0033268
28344590	270	290	molecular mechanisms	T044	C1148560
28344590	312	319	disease	T047	C0012634
28344590	330	342	investigated	T169	C1292732
28344590	346	370	transcriptome sequencing	T059	C4086963
28344590	376	383	changes	T169	C0392747
28344590	387	394	protein	T116,T123	C0033684
28344590	395	404	abundance	T080	C2346714
28344590	419	431	investigated	T169	C1292732
28344590	437	489	isobaric tags for relative and absolute quantitation	T059	C0022885
28344590	500	507	results	T169	C1274040
28344590	524	548	methyl methane sulfonate	T109,T121,T131	C0025706
28344590	550	553	MMS	T109,T121,T131	C0025706
28344590	564	573	Paulownia	T002	C1008086
28344590	574	583	seedlings	T002	C0242437
28344590	584	596	recover from	T080	C0521108
28344590	601	609	symptoms	T184	C1457887
28344590	613	627	witches' broom	T047	C0012634
28344590	632	641	reinstate	T079	C0678335
28344590	644	651	healthy	T080	C3898900
28344590	652	662	morphology	T080	C0332437
28344590	672	677	study	T062	C2603343
28344590	681	724	transcriptomic-assisted proteomic technique	T059	C1327760
28344590	737	744	analyze	T062	C0936012
28344590	749	756	protein	T116,T123	C0033684
28344590	757	764	changes	T169	C0392747
28344590	768	779	phytoplasma	T007	C1004784
28344590	782	790	infected	T033	C0439663
28344590	791	810	Paulownia tomentosa	T002	C1008151
28344590	811	820	seedlings	T002	C0242437
28344590	822	833	phytoplasma	T007	C1004784
28344590	836	844	infected	T033	C0439663
28344590	845	854	seedlings	T002	C0242437
28344590	855	862	treated	T169	C1522326
28344590	887	890	MMS	T109,T121,T131	C0025706
28344590	896	903	healthy	T080	C3898900
28344590	904	913	seedlings	T002	C0242437
28344590	932	940	proteins	T116,T123	C0033684
28344590	1001	1009	abundant	T080	C2346714
28344590	1013	1033	pairwise comparisons	T081	C0086766
28344590	1053	1059	groups	T078	C0441833
28344590	1086	1094	abundant	T080	C2346714
28344590	1095	1103	proteins	T116,T123	C0033684
28344590	1124	1133	Paulownia	T002	C1008086
28344590	1134	1156	witches' broom disease	T047	C0012634
28344590	1207	1221	photosynthesis	T070	C0031764
28344590	1237	1250	dwarf symptom	T184	C1457887
28344590	1252	1258	energy	T081	C1442080
28344590	1259	1269	production	T169	C0391871
28344590	1275	1279	cell	T025	C3178867
28344590	1280	1295	signal pathways	T044	C0037080

28158248|t|Modeling the flux of metabolites in the juvenile hormone biosynthesis pathway using generalized additive models and ordinary differential equations
28158248|a|Juvenile hormone (JH) regulates development and reproductive maturation in insects. The corpora allata (CA) from female adult mosquitoes synthesize fluctuating levels of JH, which have been linked to the ovarian development and are influenced by nutritional signals. The rate of JH biosynthesis is controlled by the rate of flux of isoprenoids in the pathway, which is the outcome of a complex interplay of changes in precursor pools and enzyme levels. A comprehensive study of the changes in enzymatic activities and precursor pool sizes have been previously reported for the mosquito Aedes aegypti JH biosynthesis pathway. In the present studies, we used two different quantitative approaches to describe and predict how changes in the individual metabolic reactions in the pathway affect JH synthesis. First, we constructed generalized additive models (GAMs) that described the association between changes in specific metabolite concentrations with changes in enzymatic activities and substrate concentrations. Changes in substrate concentrations explained 50% or more of the model deviances in 7 of the 13 metabolic steps analyzed. Addition of information on enzymatic activities almost always improved the fitness of GAMs built solely based on substrate concentrations. GAMs were validated using experimental data that were not included when the model was built. In addition, a system of ordinary differential equations (ODE) was developed to describe the instantaneous changes in metabolites as a function of the levels of enzymatic catalytic activities. The results demonstrated the ability of the models to predict changes in the flux of metabolites in the JH pathway, and can be used in the future to design and validate experimental manipulations of JH synthesis.
28158248	0	8	Modeling	T062	C0870071
28158248	13	17	flux	T070	C2348693
28158248	21	32	metabolites	T123	C0870883
28158248	40	56	juvenile hormone	T125	C0022439
28158248	57	69	biosynthesis	T038	C0220781
28158248	70	77	pathway	T044	C1704259
28158248	84	111	generalized additive models	T075	C0026336
28158248	116	147	ordinary differential equations	T170	C0282574
28158248	148	164	Juvenile hormone	T125	C0022439
28158248	166	168	JH	T125	C0022439
28158248	180	191	development	T169	C1527148
28158248	196	219	reproductive maturation	T040	C0036887
28158248	223	230	insects	T204	C0021585
28158248	236	250	corpora allata	T023	C0010085
28158248	252	254	CA	T023	C0010085
28158248	261	267	female	T032	C0086287
28158248	268	284	adult mosquitoes	T204	C0026584
28158248	296	307	fluctuating	T079	C0231241
28158248	308	314	levels	T080	C0441889
28158248	318	320	JH	T125	C0022439
28158248	352	371	ovarian development	T042	C1160265
28158248	394	405	nutritional	T080	C1521739
28158248	406	413	signals	T043	C0037083
28158248	419	423	rate	T081	C1521828
28158248	427	429	JH	T125	C0022439
28158248	430	442	biosynthesis	T038	C0220781
28158248	464	468	rate	T081	C1521828
28158248	472	476	flux	T070	C2348693
28158248	480	491	isoprenoids	T109	C0682996
28158248	499	506	pathway	T044	C1704259
28158248	555	562	changes	T169	C0392747
28158248	566	575	precursor	T167	C3891814
28158248	586	592	enzyme	T116,T126	C0014442
28158248	593	599	levels	T080	C0441889
28158248	603	616	comprehensive	T080	C1880156
28158248	617	622	study	T062	C2603343
28158248	630	637	changes	T169	C0392747
28158248	641	661	enzymatic activities	T044	C0243102
28158248	666	675	precursor	T167	C3891814
28158248	725	733	mosquito	T204	C0026584
28158248	734	747	Aedes aegypti	T204	C0322859
28158248	748	750	JH	T125	C0022439
28158248	751	763	biosynthesis	T038	C0220781
28158248	764	771	pathway	T044	C1704259
28158248	788	795	studies	T062	C2603343
28158248	819	842	quantitative approaches	UnknownType	C0681919
28158248	871	878	changes	T169	C0392747
28158248	897	906	metabolic	T169	C0311400
28158248	907	916	reactions	T169	C0443286
28158248	924	931	pathway	T044	C1704259
28158248	939	941	JH	T125	C0022439
28158248	942	951	synthesis	T038	C0220781
28158248	975	1002	generalized additive models	T075	C0026336
28158248	1004	1008	GAMs	T075	C0026336
28158248	1049	1056	changes	T169	C0392747
28158248	1069	1079	metabolite	T123	C0870883
28158248	1080	1094	concentrations	T081	C0457929
28158248	1100	1107	changes	T169	C0392747
28158248	1111	1131	enzymatic activities	T044	C0243102
28158248	1136	1145	substrate	T167	C3891814
28158248	1146	1160	concentrations	T081	C0457929
28158248	1162	1169	Changes	T169	C0392747
28158248	1173	1182	substrate	T167	C3891814
28158248	1183	1197	concentrations	T081	C0457929
28158248	1227	1232	model	T075	C0026336
28158248	1258	1267	metabolic	T169	C0311400
28158248	1268	1273	steps	T077	C1261552
28158248	1274	1282	analyzed	T062	C0936012
28158248	1311	1331	enzymatic activities	T044	C0243102
28158248	1359	1366	fitness	T052	C2349186
28158248	1370	1374	GAMs	T075	C0026336
28158248	1397	1406	substrate	T167	C3891814
28158248	1407	1421	concentrations	T081	C0457929
28158248	1423	1427	GAMs	T075	C0026336
28158248	1449	1461	experimental	T080	C1517586
28158248	1462	1466	data	T078	C1511726
28158248	1541	1572	ordinary differential equations	T170	C0282574
28158248	1574	1577	ODE	T170	C0282574
28158248	1623	1630	changes	T169	C0392747
28158248	1634	1645	metabolites	T123	C0870883
28158248	1651	1659	function	T169	C0542341
28158248	1667	1673	levels	T080	C0441889
28158248	1677	1707	enzymatic catalytic activities	T044	C0243102
28158248	1713	1720	results	T169	C1274040
28158248	1753	1759	models	T075	C0026336
28158248	1771	1778	changes	T169	C0392747
28158248	1786	1790	flux	T070	C2348693
28158248	1794	1805	metabolites	T123	C0870883
28158248	1813	1815	JH	T125	C0022439
28158248	1816	1823	pathway	T044	C1704259
28158248	1858	1864	design	T052	C1707689
28158248	1869	1877	validate	T062	C1519941
28158248	1878	1890	experimental	T080	C1517586
28158248	1891	1904	manipulations	T169	C0205245
28158248	1908	1910	JH	T125	C0022439
28158248	1911	1920	synthesis	T038	C0220781

27669322|t|The Peptidoglycan Pattern of Staphylococcus carnosus TM300 - Detailed Analysis and Variations Due to Genetic and Metabolic Influences
27669322|a|The Gram-positive bacterium Staphylococcus carnosus (S. carnosus) TM300 is an apathogenic staphylococcal species commonly used in meat starter cultures. As with all Gram-positive bacteria, its cytoplasmic membrane is surrounded by a thick peptidoglycan (PGN) or murein sacculus consisting of several layers of glycan strands cross-linked by peptides. In contrast to pathogenic staphylococci, mainly Staphylococcus aureus (S. aureus), the chemical composition of S. carnosus PGN is not well studied so far. UPLC/MS analysis of enzymatically digested S. carnosus TM300 PGN revealed substantial differences in its composition compared to the known pattern of S. aureus. While in S. aureus the uncross-linked stem peptide consists of a pentapeptide, in S. carnosus, this part of the PGN is shortened to tripeptides. Furthermore, we found the PGN composition to vary when cells were incubated under certain conditions. The collective overproduction of HlyD, FtsE and FtsX -a putative protein complex interacting with penicillin-binding protein 2 (PBP2)-caused the reappearance of classical penta stem peptides. In addition, under high sugar conditions, tetra stem peptides occur due to overflow metabolism. This indicates that S. carnosus TM300 cells adapt to various conditions by modification of their PGN.
27669322	4	17	Peptidoglycan	T109,T123	C0030958
27669322	18	25	Pattern	T082	C0449774
27669322	29	58	Staphylococcus carnosus TM300	T007	C0318127
27669322	61	78	Detailed Analysis	T062	C0936012
27669322	83	93	Variations	T070	C0042333
27669322	101	108	Genetic	T028	C0017337
27669322	113	122	Metabolic	T169	C0311400
27669322	123	133	Influences	T077	C4054723
27669322	138	161	Gram-positive bacterium	T007	C0018154
27669322	162	205	Staphylococcus carnosus (S. carnosus) TM300	T007	C0318127
27669322	212	223	apathogenic	T033	C0243095
27669322	224	238	staphylococcal	T007	C0038170
27669322	239	246	species	T185	C1705920
27669322	264	268	meat	T168	C0025017
27669322	269	285	starter cultures	T059	C0430400
27669322	299	321	Gram-positive bacteria	T007	C0018154
27669322	327	347	cytoplasmic membrane	T026	C0007603
27669322	351	361	surrounded	T082	C1282914
27669322	367	372	thick	T080	C1280412
27669322	373	386	peptidoglycan	T109,T123	C0030958
27669322	388	391	PGN	T109,T123	C0030958
27669322	396	411	murein sacculus	T026	C1325812
27669322	434	440	layers	T082	C1254362
27669322	444	458	glycan strands	T109,T121	C0032594
27669322	459	471	cross-linked	T169	C0332220
27669322	475	483	peptides	T116	C0030956
27669322	500	510	pathogenic	T033	C3816499
27669322	511	524	staphylococci	T007	C0038170
27669322	533	554	Staphylococcus aureus	T007	C0038172
27669322	556	565	S. aureus	T007	C0038172
27669322	572	592	chemical composition	T070	C0243176
27669322	596	607	S. carnosus	T007	C0318127
27669322	608	611	PGN	T109,T123	C0030958
27669322	624	631	studied	T062	C2603343
27669322	640	656	UPLC/MS analysis	T059	C4053724
27669322	660	682	enzymatically digested	T059	C0519157
27669322	683	700	S. carnosus TM300	T007	C0318127
27669322	701	704	PGN	T109,T123	C0030958
27669322	745	756	composition	T070	C0243176
27669322	779	786	pattern	T082	C0449774
27669322	790	799	S. aureus	T007	C0038172
27669322	810	819	S. aureus	T007	C0038172
27669322	824	838	uncross-linked	T033	C0243095
27669322	839	851	stem peptide	T116	C0030956
27669322	866	878	pentapeptide	T116	C0030956
27669322	883	894	S. carnosus	T007	C0318127
27669322	913	916	PGN	T109,T123	C0030958
27669322	920	929	shortened	T080	C1282927
27669322	933	944	tripeptides	T116	C0030956
27669322	972	975	PGN	T109,T123	C0030958
27669322	976	987	composition	T070	C0243176
27669322	1001	1006	cells	T025	C0007634
27669322	1012	1021	incubated	T059	C1439852
27669322	1052	1077	collective overproduction	T046	C0030660
27669322	1081	1085	HlyD	T123	C0019053
27669322	1087	1091	FtsE	T116,T123	C0033684
27669322	1096	1100	FtsX	T116,T123	C1430498
27669322	1104	1128	putative protein complex	T116,T123	C1180347
27669322	1129	1140	interacting	T169	C1704675
27669322	1146	1174	penicillin-binding protein 2	T116,T126	C0135892
27669322	1176	1180	PBP2	T116,T126	C0135892
27669322	1193	1205	reappearance	T080	C0700364
27669322	1209	1218	classical	T169	C0443177
27669322	1219	1238	penta stem peptides	T116	C0030956
27669322	1259	1263	high	T080	C0205250
27669322	1264	1269	sugar	T109,T121	C0242209
27669322	1270	1280	conditions	T080	C0348080
27669322	1282	1301	tetra stem peptides	T116	C0030956
27669322	1315	1334	overflow metabolism	T040	C0025519
27669322	1356	1373	S. carnosus TM300	T007	C0318127
27669322	1374	1379	cells	T025	C0007634
27669322	1397	1407	conditions	T080	C0348080
27669322	1411	1423	modification	T033	C3840684
27669322	1433	1436	PGN	T109,T123	C0030958

27644855|t|Assessment of groundwater vulnerability in the Daule aquifer, Ecuador, using the susceptibility index method
27644855|a|The Guayas region in Ecuador is economically very important, producing 68% of the national crops. The main agricultural activities threaten the groundwater therein with nitrate contamination given the large fertiliser and water needs. The present work tests the applicability of the susceptibility index assessment method in evaluating the impact of agricultural activities on groundwater quality, using as a case study an aquifer of the Guayas river basin in Ecuador. The index adapts four parameters of the DRASTIC method and incorporated a new land use parameter. Results show that the areas highly vulnerable to contamination are located in irrigation perimeters of dominant paddy fields associated with the high recharge rates in the alluvial deposits. Respectively, moderately vulnerable and low - vulnerability areas correspond to aquatic environments and forests, semi-natural zones and water bodies. One of the main contributions of the Daule aquifer vulnerability is likely its wide, flat topography. A great part of the aquifer is at high risk of contamination by nitrates if a code of good agricultural practices is not applied. Therefore the implementation of a monitoring network to control the nitrates concentrations is the first step to assure groundwater quality for drinking purposes.
27644855	14	25	groundwater	T082	C0596631
27644855	26	39	vulnerability	T080	C0332157
27644855	47	60	Daule aquifer	T070	C3178977
27644855	62	69	Ecuador	T083	C0013593
27644855	81	108	susceptibility index method	T059	C0871511
27644855	113	126	Guayas region	T083	C0017446
27644855	130	137	Ecuador	T083	C0013593
27644855	191	205	national crops	T002	C0242775
27644855	216	239	agricultural activities	T090	C0001829
27644855	253	264	groundwater	T082	C0596631
27644855	278	285	nitrate	T197	C0699857
27644855	286	299	contamination	T078	C2349974
27644855	316	326	fertiliser	T073,T131	C0015919
27644855	331	336	water	T121,T197	C0043047
27644855	337	342	needs	T080	C0027552
27644855	392	430	susceptibility index assessment method	T059	C0871511
27644855	459	482	agricultural activities	T090	C0001829
27644855	486	497	groundwater	T082	C0596631
27644855	498	505	quality	T080	C0332306
27644855	532	539	aquifer	T070	C3178977
27644855	547	553	Guayas	T083	C0017446
27644855	554	565	river basin	T082	C0205146
27644855	569	576	Ecuador	T083	C0013593
27644855	618	632	DRASTIC method	T059	C0871511
27644855	656	664	land use	UnknownType	C0814835
27644855	698	703	areas	T082	C0205146
27644855	704	710	highly	T080	C0205250
27644855	711	721	vulnerable	T080	C0332157
27644855	725	738	contamination	T078	C2349974
27644855	754	764	irrigation	T068	C2936278
27644855	765	775	perimeters	T082	C1295726
27644855	788	800	paddy fields	T082	C0562975
27644855	848	865	alluvial deposits	T197	C0055863
27644855	881	891	moderately	T080	C0205081
27644855	892	902	vulnerable	T080	C0332157
27644855	907	910	low	T080	C0205251
27644855	913	926	vulnerability	T080	C0332157
27644855	927	932	areas	T082	C0205146
27644855	947	967	aquatic environments	T067	C0563034
27644855	972	979	forests	T070	C0086312
27644855	981	999	semi-natural zones	T082	C1710706
27644855	1004	1016	water bodies	T067	C2584335
27644855	1055	1068	Daule aquifer	T070	C3178977
27644855	1069	1082	vulnerability	T080	C0332157
27644855	1097	1101	wide	T082	C0332464
27644855	1103	1118	flat topography	T082	C0870781
27644855	1140	1147	aquifer	T070	C3178977
27644855	1154	1180	high risk of contamination	T033	C4060526
27644855	1184	1192	nitrates	T197	C0699857
27644855	1206	1210	good	T080	C0205170
27644855	1211	1233	agricultural practices	T090	C0001829
27644855	1284	1313	monitoring network to control	T033	C0243095
27644855	1318	1326	nitrates	T197	C0699857
27644855	1327	1341	concentrations	T081	C1446561
27644855	1370	1381	groundwater	T082	C0596631
27644855	1382	1389	quality	T080	C0332306
27644855	1394	1402	drinking	T167	C0599638
27644855	1403	1411	purposes	T169	C1285529

27638646|t|Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories
27638646|a|There is a great need for improved diagnostic and prognostic accuracy of potential cardiac toxicity in drug development. This study reports the evaluation of several commercially available biomarker kits by 3 institutions (SRI, Eli Lilly, and Pfizer) for the discrimination between myocardial degeneration / necrosis and cardiac hypertrophy as well as the assessment of the interlaboratory and interplatform variation in results. Serum concentrations of natriuretic peptides (N-terminal pro-atrial natriuretic peptide [NT-proANP] and N-terminal pro-brain natriuretic peptide [NT-proBNP]), cardiac and skeletal troponins (cTnI, cTnT, and sTnI), myosin light chain 3 (Myl3), and fatty acid binding protein 3 (FABP3) were assessed in rats treated with minoxidil (MNX) and isoproterenol (ISO). MNX caused increased heart -to- body weight ratios and prominent elevations in NT-proANP and NT-proBNP concentrations detected at 24-hr postdose without elevation in troponins, Myl3, or FABP3 and with no abnormal histopathological findings. ISO caused ventricular leukocyte infiltration, myocyte fibrosis, and necrosis with increased concentrations of the natriuretic peptides, cardiac troponins, and Myl3. These results reinforce the advantages of a multimarker strategy in elucidating the underlying cause of cardiac insult and detecting myocardial tissue damage at 24-hr posttreatment. The interlaboratory and interplatform comparison analyses also showed that the data obtained from different laboratories and platforms are highly correlated and reproducible, making these biomarkers widely applicable in preclinical studies.
27638646	0	10	Evaluation	T052	C1516048
27638646	14	30	Cardiac Toxicity	T037	C0876994
27638646	31	41	Biomarkers	T201	C0005516
27638646	45	49	Rats	T015	C0034693
27638646	65	77	Laboratories	T073,T093	C0022877
27638646	104	112	improved	T033	C0184511
27638646	113	123	diagnostic	T080	C0598285
27638646	128	138	prognostic	T170	C0220901
27638646	139	147	accuracy	T080	C0443131
27638646	161	177	cardiac toxicity	T037	C0876994
27638646	181	197	drug development	T091	C0872152
27638646	204	209	study	T062	C2603343
27638646	210	217	reports	T062	C0011000
27638646	222	232	evaluation	T052	C1516048
27638646	257	266	available	T169	C0470187
27638646	267	281	biomarker kits	T201	C0005516
27638646	287	299	institutions	T093	C2607850
27638646	301	304	SRI	T093	C2607850
27638646	306	315	Eli Lilly	T093	C0331851
27638646	321	327	Pfizer	T093	C0331888
27638646	360	383	myocardial degeneration	T046	C0027046
27638646	386	394	necrosis	T047	C1442837
27638646	399	418	cardiac hypertrophy	T046	C1383860
27638646	434	444	assessment	T052	C1516048
27638646	452	467	interlaboratory	T080	C2986928
27638646	472	485	interplatform	T080	C0205556
27638646	486	495	variation	T080	C0205419
27638646	499	506	results	T169	C1274040
27638646	508	528	Serum concentrations	T081	C0683149
27638646	532	552	natriuretic peptides	T116,T121,T125	C1144709
27638646	554	595	N-terminal pro-atrial natriuretic peptide	T116,T123	C0027481
27638646	597	606	NT-proANP	T116,T123	C0027481
27638646	612	652	N-terminal pro-brain natriuretic peptide	T116,T123	C0754710
27638646	654	663	NT-proBNP	T116,T123	C0754710
27638646	667	674	cardiac	T023	C0018787
27638646	679	687	skeletal	T082	C0521324
27638646	688	697	troponins	T116,T123	C0041199
27638646	699	703	cTnI	T116,T123	C1305957
27638646	705	709	cTnT	T116,T123	C3538889
27638646	715	719	sTnI	T116,T123	C0033684
27638646	722	742	myosin light chain 3	T116,T123	C0027108
27638646	744	748	Myl3	T116,T123	C0027108
27638646	755	783	fatty acid binding protein 3	T116,T123	C1721418
27638646	785	790	FABP3	T116,T123	C1721418
27638646	797	805	assessed	T052	C1516048
27638646	809	813	rats	T015	C0034693
27638646	814	821	treated	T169	C1522326
27638646	827	836	minoxidil	T109,T121	C0026196
27638646	838	841	MNX	T109,T121	C0026196
27638646	847	860	isoproterenol	T109,T121	C0022245
27638646	862	865	ISO	T109,T121	C0022245
27638646	868	871	MNX	T109,T121	C0026196
27638646	879	888	increased	T081	C0205217
27638646	889	894	heart	T023	C0018787
27638646	900	911	body weight	T032	C0005910
27638646	912	918	ratios	T081	C0456603
27638646	933	943	elevations	T082	C0702240
27638646	947	956	NT-proANP	T116,T123	C0027481
27638646	961	970	NT-proBNP	T116,T123	C0754710
27638646	971	985	concentrations	T081	C1446561
27638646	986	994	detected	T033	C0442726
27638646	1004	1012	postdose	T079	C0439568
27638646	1021	1030	elevation	T082	C0702240
27638646	1034	1043	troponins	T116,T123	C0041199
27638646	1045	1049	Myl3	T116,T123	C0027108
27638646	1054	1059	FABP3	T116,T123	C1721418
27638646	1069	1071	no	T033	C1513916
27638646	1072	1080	abnormal	T033	C0205161
27638646	1081	1098	histopathological	T169	C0243140
27638646	1099	1107	findings	T033	C0243095
27638646	1109	1112	ISO	T109,T121	C0022245
27638646	1120	1131	ventricular	T082	C1522565
27638646	1132	1154	leukocyte infiltration	T033	C0333361
27638646	1156	1172	myocyte fibrosis	T046	C0151654
27638646	1178	1186	necrosis	T042	C0027540
27638646	1192	1201	increased	T081	C0205217
27638646	1202	1216	concentrations	T081	C1446561
27638646	1224	1244	natriuretic peptides	T116,T121,T125	C1144709
27638646	1246	1253	cardiac	T023	C0018787
27638646	1254	1263	troponins	T116,T123	C0041199
27638646	1269	1273	Myl3	T116,T123	C0027108
27638646	1281	1288	results	T169	C1274040
27638646	1379	1393	cardiac insult	T047	C0018799
27638646	1398	1407	detecting	T033	C0442726
27638646	1408	1418	myocardial	T024	C0027061
27638646	1419	1432	tissue damage	T037	C0010957
27638646	1442	1455	posttreatment	T079	C2709088
27638646	1461	1476	interlaboratory	T080	C2986928
27638646	1481	1494	interplatform	T080	C0205556
27638646	1495	1505	comparison	T052	C1707455
27638646	1506	1514	analyses	T062	C0936012
27638646	1536	1540	data	T078	C1511726
27638646	1565	1577	laboratories	T073,T093	C0022877
27638646	1582	1591	platforms	T080	C0205556
27638646	1603	1613	correlated	T080	C1707520
27638646	1645	1655	biomarkers	T201	C0005516
27638646	1663	1673	applicable	T080	C1706839
27638646	1677	1696	preclinical studies	T062	C1709631

27922526|t|Air Pollutant Exposure Within a Few Days of Delivery and Placental Abruption in Japan
27922526|a|Placental abruption is an emergency obstetric complication. Although the etiology of abruption is not fully understood, acute stimuli, such as ischemia and/or inflammation, are associated with rupture of the decidual artery, resulting in placental separation. Ischemia and inflammation are acute biologic effects of air pollution. Using a case-crossover design, we tested the hypothesis that a short-term increase in exposure to air pollutants is a potential trigger of placental abruption. We received data for western Japan (Kyushu-Okinawa Districts) from the Japan Perinatal Registry Network database. From 2005 to 2010, 821 singleton pregnant women with placental abruption were identified. We assigned daily concentrations of air pollutants, including nitrogen dioxide (NO2), suspended particulate matter, ozone, and sulfur dioxide (SO2), from the nearest monitoring station to the respective delivery hospital of each woman. Because information on the onset day of abruption was not obtained, we assumed the case day to be 1 day before the day of delivery. Exposure to NO2 at 2 days' lag was associated with placental abruption (temperature adjusted odds ratio per 10 ppb increase = 1.4; 95% confidence interval = 1.1, 1.8). The association patterns were similar, when we restricted to participants who delivered by emergency cesarean (1.4, 1.1, 1.9), or who delivered after 35 weeks of gestation (1.4, 1.0, 2.0). There was no association with suspended particulate matter, ozone, or SO2. We observed an association between NO2 exposure at 2 days before the day of delivery and placental abruption in pregnant Japanese women.
27922526	0	13	Air Pollutant	T131	C0001869
27922526	14	22	Exposure	T080	C0332157
27922526	44	52	Delivery	T061	C0011209
27922526	57	76	Placental Abruption	T046	C0000832
27922526	80	85	Japan	T083	C0022341
27922526	86	105	Placental abruption	T046	C0000832
27922526	112	144	emergency obstetric complication	T046	C0178292
27922526	159	167	etiology	T169	C1314792
27922526	171	180	abruption	T046	C0000832
27922526	206	211	acute	T079	C0205178
27922526	212	219	stimuli	T067	C0234402
27922526	229	237	ischemia	T046	C0022116
27922526	245	257	inflammation	T046	C0021368
27922526	263	278	associated with	T080	C0332281
27922526	279	309	rupture of the decidual artery	T047	C0155760
27922526	324	344	placental separation	T042	C0233170
27922526	346	354	Ischemia	T046	C0022116
27922526	359	371	inflammation	T046	C0021368
27922526	376	381	acute	T079	C0205178
27922526	382	390	biologic	T080	C0205460
27922526	391	398	effects	T080	C1280500
27922526	402	415	air pollution	T069	C0001873
27922526	425	446	case-crossover design	T062	C4288565
27922526	462	472	hypothesis	T078	C1512571
27922526	480	490	short-term	T079	C0443303
27922526	491	499	increase	T169	C0442805
27922526	503	511	exposure	T080	C0332157
27922526	515	529	air pollutants	T131	C0001869
27922526	535	544	potential	T080	C3245505
27922526	545	552	trigger	T201	C0032930
27922526	556	575	placental abruption	T046	C0000832
27922526	589	593	data	T078	C1511726
27922526	598	611	western Japan	T083	C0017446
27922526	613	637	Kyushu-Okinawa Districts	T083	C0017446
27922526	648	689	Japan Perinatal Registry Network database	T170	C0242356
27922526	714	723	singleton	T099	C1313913
27922526	724	738	pregnant women	T098	C0033011
27922526	744	763	placental abruption	T046	C0000832
27922526	793	798	daily	T079	C0332173
27922526	799	813	concentrations	T081	C1265611
27922526	817	831	air pollutants	T131	C0001869
27922526	843	859	nitrogen dioxide	T131,T197	C0028160
27922526	861	864	NO2	T131,T197	C0028160
27922526	867	895	suspended particulate matter	T131	C1510837
27922526	897	902	ozone	T103	C0030106
27922526	908	922	sulfur dioxide	T131,T197	C0038777
27922526	924	927	SO2	T131,T197	C0038777
27922526	947	965	monitoring station	T073	C1883167
27922526	984	992	delivery	T061	C0011209
27922526	993	1001	hospital	T073,T093	C0019994
27922526	1010	1015	woman	T098	C0043210
27922526	1025	1036	information	T078	C1533716
27922526	1044	1053	onset day	T079	C0449244
27922526	1057	1066	abruption	T046	C0000832
27922526	1100	1104	case	T169	C0868928
27922526	1117	1120	day	T079	C0439228
27922526	1132	1135	day	T079	C0439228
27922526	1139	1147	delivery	T061	C0011209
27922526	1149	1157	Exposure	T080	C0332157
27922526	1161	1164	NO2	T131,T197	C0028160
27922526	1184	1199	associated with	T080	C0332281
27922526	1200	1219	placental abruption	T046	C0000832
27922526	1221	1232	temperature	T081	C0039476
27922526	1242	1252	odds ratio	T081	C0028873
27922526	1264	1272	increase	T169	C0442805
27922526	1284	1303	confidence interval	T081	C0009667
27922526	1321	1332	association	T080	C0439849
27922526	1378	1390	participants	T098	C0679646
27922526	1395	1404	delivered	T061	C0011209
27922526	1408	1426	emergency cesarean	T061	C0558380
27922526	1451	1460	delivered	T061	C0011209
27922526	1467	1488	35 weeks of gestation	T079	C0233042
27922526	1516	1530	no association	T033	C1513916
27922526	1536	1564	suspended particulate matter	T131	C1510837
27922526	1566	1571	ozone	T103	C0030106
27922526	1576	1579	SO2	T131,T197	C0038777
27922526	1596	1607	association	T080	C0439849
27922526	1616	1619	NO2	T131,T197	C0028160
27922526	1620	1628	exposure	T080	C0332157
27922526	1634	1638	days	T079	C0439228
27922526	1650	1653	day	T079	C0439228
27922526	1657	1665	delivery	T061	C0011209
27922526	1670	1689	placental abruption	T046	C0000832
27922526	1693	1716	pregnant Japanese women	T098	C0033011

28179361|t|A microbial signature for Crohn's disease
28179361|a|A decade of microbiome studies has linked IBD to an alteration in the gut microbial community of genetically predisposed subjects. However, existing profiles of gut microbiome dysbiosis in adult IBD patients are inconsistent among published studies, and did not allow the identification of microbial signatures for CD and UC. Here, we aimed to compare the faecal microbiome of CD with patients having UC and with non - IBD subjects in a longitudinal study. We analysed a cohort of 2045 non - IBD and IBD faecal samples from four countries (Spain, Belgium, the UK and Germany), applied a 16S rRNA sequencing approach and analysed a total dataset of 115 million sequences. In the Spanish cohort, dysbiosis was found significantly greater in patients with CD than with UC, as shown by a more reduced diversity, a less stable microbial community and eight microbial groups were proposed as a specific microbial signature for CD. Tested against the whole cohort, the signature achieved an overall sensitivity of 80% and a specificity of 94%, 94%, 89% and 91% for the detection of CD versus healthy controls, patients with anorexia, IBS and UC, respectively. Although UC and CD share many epidemiologic, immunologic, therapeutic and clinical features, our results showed that they are two distinct subtypes of IBD at the microbiome level. For the first time, we are proposing microbiomarkers to discriminate between CD and non - CD independently of geographical regions.
28179361	2	11	microbial	T001	C0599840
28179361	12	21	signature	T169	C1704864
28179361	26	41	Crohn's disease	T047	C0010346
28179361	44	50	decade	T081	C2981279
28179361	54	64	microbiome	T001	C1956108
28179361	65	72	studies	T062	C2603343
28179361	84	87	IBD	T047	C0021390
28179361	94	104	alteration	T078	C1515926
28179361	112	115	gut	T023	C0699819
28179361	116	125	microbial	T001	C0599840
28179361	126	135	community	T096	C0009462
28179361	139	150	genetically	T169	C0314603
28179361	151	162	predisposed	T169	C0231203
28179361	163	171	subjects	T098	C0080105
28179361	191	199	profiles	T059	C1979963
28179361	203	206	gut	T023	C0699819
28179361	207	217	microbiome	T001	C1956108
28179361	218	227	dysbiosis	T046	C3658208
28179361	231	236	adult	T100	C0001675
28179361	237	240	IBD	T047	C0021390
28179361	241	249	patients	T101	C0030705
28179361	254	266	inconsistent	T080	C0442809
28179361	273	282	published	T057	C0034037
28179361	283	290	studies	T062	C2603343
28179361	314	328	identification	T080	C0205396
28179361	332	341	microbial	T001	C0599840
28179361	342	352	signatures	T169	C1704864
28179361	357	359	CD	T047	C0010346
28179361	364	366	UC	T047	C0009324
28179361	377	382	aimed	T078	C1947946
28179361	386	393	compare	T052	C1707455
28179361	398	404	faecal	T031	C0015733
28179361	405	415	microbiome	T001	C1956108
28179361	419	421	CD	T047	C0010346
28179361	427	435	patients	T101	C0030705
28179361	443	445	UC	T047	C0009324
28179361	455	458	non	T169	C0332197
28179361	461	464	IBD	T047	C0021390
28179361	465	473	subjects	T098	C0080105
28179361	479	497	longitudinal study	T062	C0023981
28179361	513	519	cohort	T098	C0599755
28179361	528	531	non	T169	C0332197
28179361	534	537	IBD	T047	C0021390
28179361	542	545	IBD	T047	C0021390
28179361	546	552	faecal	T031	C0015733
28179361	553	560	samples	T167	C0370003
28179361	571	580	countries	T083	C0454664
28179361	582	587	Spain	T083	C0037747
28179361	589	596	Belgium	T083	C0004950
28179361	602	604	UK	T083	C0041700
28179361	609	616	Germany	T083	C0017480
28179361	629	648	16S rRNA sequencing	T059	C3258987
28179361	679	686	dataset	T170	C0150098
28179361	702	711	sequences	T086	C0162327
28179361	720	727	Spanish	T098	C0086409
28179361	728	734	cohort	T098	C0599755
28179361	736	745	dysbiosis	T046	C3658208
28179361	756	777	significantly greater	T081	C4055637
28179361	781	789	patients	T101	C0030705
28179361	795	797	CD	T047	C0010346
28179361	808	810	UC	T047	C0009324
28179361	831	838	reduced	T080	C0392756
28179361	839	848	diversity	T080	C1880371
28179361	857	863	stable	T080	C0205360
28179361	864	873	microbial	T001	C0599840
28179361	874	883	community	T096	C0009462
28179361	894	903	microbial	T001	C0599840
28179361	904	910	groups	T078	C0441833
28179361	916	924	proposed	T080	C1553874
28179361	930	938	specific	T080	C0205369
28179361	939	948	microbial	T001	C0599840
28179361	949	958	signature	T169	C1704864
28179361	963	965	CD	T047	C0010346
28179361	967	973	Tested	T169	C0039593
28179361	992	998	cohort	T098	C0599755
28179361	1004	1013	signature	T169	C1704864
28179361	1034	1045	sensitivity	T081	C0036667
28179361	1059	1070	specificity	T081	C0037791
28179361	1104	1113	detection	T061	C1511790
28179361	1117	1119	CD	T047	C0010346
28179361	1127	1134	healthy	T080	C3898900
28179361	1135	1143	controls	T096	C0009932
28179361	1145	1153	patients	T101	C0030705
28179361	1159	1167	anorexia	T047	C0003123
28179361	1169	1172	IBS	T047	C0022104
28179361	1177	1179	UC	T047	C0009324
28179361	1204	1206	UC	T047	C0009324
28179361	1211	1213	CD	T047	C0010346
28179361	1225	1238	epidemiologic	T169	C0014508
28179361	1240	1251	immunologic	T169	C0205470
28179361	1253	1264	therapeutic	T169	C0302350
28179361	1269	1277	clinical	T080	C0205210
28179361	1278	1286	features	T080	C2348519
28179361	1292	1299	results	T169	C1274040
28179361	1334	1342	subtypes	T185	C0449560
28179361	1346	1349	IBD	T047	C0021390
28179361	1357	1367	microbiome	T001	C1956108
28179361	1368	1373	level	T080	C0441889
28179361	1383	1388	first	T080	C1279901
28179361	1389	1393	time	T079	C0040223
28179361	1412	1427	microbiomarkers	T201	C0005516
28179361	1431	1443	discriminate	T080	C0205235
28179361	1452	1454	CD	T047	C0010346
28179361	1459	1462	non	T169	C0332197
28179361	1465	1467	CD	T047	C0010346
28179361	1485	1505	geographical regions	T083	C0017446

28361230|t|Acute kidney injury and fluid overload in infants and children after cardiac surgery
28361230|a|Acute kidney injury is a common and serious complication after congenital heart surgery, particularly among infants. This comorbidity has been independently associated with adverse outcomes including an increase in mortality. Postoperative acute kidney injury has a complex pathophysiology with many risk factors, and therefore no single medication or therapy has been demonstrated to be effective for treatment or prevention. However, it has been established that the associated fluid overload is one of the major determinants of morbidity, particularly in infants after cardiac surgery. Therefore, in the absence of an intervention to prevent acute kidney injury, much of the effort to improve outcomes has focused on treating and preventing fluid overload. Early renal replacement therapy, often in the form of peritoneal dialysis, has been shown to be safe and beneficial in infants with oliguria after heart surgery. As understanding of the pathophysiology of acute kidney injury and the ability to confidently diagnose it earlier continues to evolve, it is likely that novel preventative and therapeutic interventions will be available in the future.
28361230	0	19	Acute kidney injury	T037	C2609414
28361230	24	38	fluid overload	T047	C0546817
28361230	42	49	infants	T100	C0021270
28361230	54	62	children	T100	C0008059
28361230	69	84	cardiac surgery	T061	C0018821
28361230	85	104	Acute kidney injury	T037	C2609414
28361230	121	128	serious	T080	C0205404
28361230	129	141	complication	T046	C0009566
28361230	148	172	congenital heart surgery	T061	C2037615
28361230	193	200	infants	T100	C0021270
28361230	207	218	comorbidity	T078	C0009488
28361230	242	257	associated with	T080	C0332281
28361230	258	274	adverse outcomes	T046	C0879626
28361230	288	296	increase	T169	C0442805
28361230	300	309	mortality	T081	C0178686
28361230	311	324	Postoperative	T079	C0032790
28361230	325	344	acute kidney injury	T037	C2609414
28361230	359	374	pathophysiology	T169	C0031847
28361230	385	397	risk factors	T033	C0035648
28361230	413	433	no single medication	T033	C0746919
28361230	437	444	therapy	T033	C0746919
28361230	473	482	effective	T080	C1704419
28361230	487	496	treatment	T061	C0087111
28361230	500	510	prevention	T080	C2700409
28361230	565	579	fluid overload	T047	C0546817
28361230	600	612	determinants	T169	C1521761
28361230	616	625	morbidity	T081	C0026538
28361230	643	650	infants	T100	C0021270
28361230	657	672	cardiac surgery	T061	C0018821
28361230	692	699	absence	T169	C0332197
28361230	706	718	intervention	T061	C0184661
28361230	730	749	acute kidney injury	T037	C2609414
28361230	773	780	improve	T080	C1272747
28361230	781	789	outcomes	T080	C0085415
28361230	805	813	treating	T169	C0039798
28361230	818	828	preventing	T080	C2700409
28361230	829	843	fluid overload	T047	C0546817
28361230	845	850	Early	T079	C1279919
28361230	851	876	renal replacement therapy	T061	C0206074
28361230	899	918	peritoneal dialysis	T061	C0031139
28361230	941	945	safe	T068	C0036043
28361230	950	960	beneficial	T081	C0814225
28361230	964	971	infants	T100	C0021270
28361230	977	985	oliguria	T047	C0028961
28361230	992	1005	heart surgery	T061	C0018821
28361230	1031	1046	pathophysiology	T169	C0031847
28361230	1050	1069	acute kidney injury	T037	C2609414
28361230	1101	1109	diagnose	T033	C0011900
28361230	1166	1178	preventative	T080	C2700409
28361230	1183	1208	therapeutic interventions	T061	C0808232

27802570|t|Overall Quality Properties of Kiwifruit Treated by Cinnamaldehyde and Citral: Microbial, Antioxidant Capacity during Cold Storage
27802570|a|This work was undertaken to evaluate the microbiological characteristics and antioxidant and physiological activities in kiwifruits (Actinida deliciosa var. Qinmei) with/without cinnamaldehyde (C1) and citral (C2) fumigation treatments (5 μL/L) during 0, 3, 6, 9, and 12 d of storage at 4 °C. Essential oils (EOs) treatment lowered the total viable counts, yeast, and mold to 1.54, 2.36, and 2.05 log CFU/g, respectively. Moreover, EOs improved the antioxidant activities of kiwifruit. They enhanced phenolics and flavonoids content in fruit tissue by 49.48% at day 3 and 56.93% at day 6, respectively. In addition, ascorbic acid in treated groups had the lower losing rate. Similarly, MDA (malondialdehyde), H2 O2 (hydrogen peroxide), and (•) O2(-) (superoxide anion) production were effectively decreased in the range of 27.27% to 54.38%. Physicochemical characteristics showed that kiwifruits from treated group maintained higher levels of flesh luminosity and firmness. EOs also decreased the levels of reducing sugar by 45.97% at day 3, and increased the content of soluble protein and hydrolyzed amino acid. Therefore, postharvest EOs treatment has positive effects on delaying senescence and enhancing antioxidant capacities in kiwifruit.
27802570	8	26	Quality Properties	T080	C0871161
27802570	30	39	Kiwifruit	T168	C0440282
27802570	40	50	Treated by	T061	C0332293
27802570	51	65	Cinnamaldehyde	T109,T121	C0055754
27802570	70	76	Citral	T109,T121	C0055809
27802570	78	87	Microbial	T001	C0599840
27802570	89	109	Antioxidant Capacity	T044	C1148564
27802570	117	129	Cold Storage	T059	C0010405
27802570	158	166	evaluate	T058	C0220825
27802570	171	186	microbiological	T170	C0025953
27802570	187	202	characteristics	T080	C1521970
27802570	207	218	antioxidant	T044	C1148564
27802570	223	247	physiological activities	T039	C0031843
27802570	251	261	kiwifruits	T168	C0440282
27802570	263	281	Actinida deliciosa	T002	C0971874
27802570	308	322	cinnamaldehyde	T109,T121	C0055754
27802570	332	338	citral	T109,T121	C0055809
27802570	344	354	fumigation	T068	C0016804
27802570	355	365	treatments	T169	C1522326
27802570	406	413	storage	T169	C1698986
27802570	423	437	Essential oils	T109	C0028908
27802570	439	442	EOs	T109	C0028908
27802570	444	453	treatment	T169	C1522326
27802570	472	485	viable counts	T081	C0750480
27802570	487	492	yeast	T004	C0043393
27802570	498	502	mold	T004	C0369241
27802570	562	565	EOs	T109	C0028908
27802570	579	601	antioxidant activities	T044	C1148564
27802570	605	614	kiwifruit	T168	C0440282
27802570	621	629	enhanced	T052	C2349975
27802570	630	639	phenolics	T109,T121	C0359916
27802570	644	654	flavonoids	T109	C0596577
27802570	666	671	fruit	T168	C0016767
27802570	672	678	tissue	T025	C1514137
27802570	746	759	ascorbic acid	T109,T121,T127	C0003968
27802570	763	770	treated	T169	C1522326
27802570	771	777	groups	T078	C0441833
27802570	799	803	rate	T081	C1521828
27802570	816	819	MDA	T109,T123	C0024643
27802570	821	836	malondialdehyde	T109,T123	C0024643
27802570	839	844	H2 O2	T121,T130,T197	C0020281
27802570	846	863	hydrogen peroxide	T121,T130,T197	C0020281
27802570	874	879	O2(-)	T196	C0038836
27802570	881	897	superoxide anion	T196	C0038836
27802570	915	926	effectively	T080	C1704419
27802570	927	936	decreased	T081	C0205216
27802570	971	1002	Physicochemical characteristics	T080	C1521970
27802570	1015	1025	kiwifruits	T168	C0440282
27802570	1031	1038	treated	T169	C1522326
27802570	1039	1044	group	T078	C0441833
27802570	1073	1089	flesh luminosity	T080	C0009393
27802570	1094	1102	firmness	T080	C1545487
27802570	1104	1107	EOs	T109	C0028908
27802570	1113	1122	decreased	T081	C0205216
27802570	1137	1151	reducing sugar	T109	C0026492
27802570	1176	1185	increased	T081	C0205217
27802570	1201	1216	soluble protein	T116,T123	C0033684
27802570	1232	1242	amino acid	T116,T121,T123	C0002520
27802570	1267	1270	EOs	T109	C0028908
27802570	1271	1280	treatment	T169	C1522326
27802570	1285	1301	positive effects	T080	C1280500
27802570	1314	1324	senescence	T038	C3546449
27802570	1329	1338	enhancing	T052	C2349975
27802570	1339	1361	antioxidant capacities	T044	C1148564
27802570	1365	1374	kiwifruit	T168	C0440282

28213659|t|Profiles of mental health care professionals based on work role performance
28213659|a|The worldwide burden of mental disorders is considerable, and on the rise, putting pressure on health care systems. Current reforms aim to improve the efficiency of mental health care systems by increasing service integration in communities and strengthening primary mental health care. In this context, mental health care professionals (MHPs) are increasingly required to work on interdisciplinary teams in a variety of settings. Little is known, however, about the profiles of MHPs in relation to their perceived work role performance. MHPs in Quebec (N = 315) from four local service networks completed a self-administered questionnaire eliciting information on individual and team characteristics, as well as team processes and states. Profiles of MHPs were created using a two-step cluster analysis. Five profiles were generated. MHPs belonging to profiles labelled senior medical outpatient specialized care MHPs and senior psychosocial outpatient specialized care MHPs perceived themselves as more performing than MHPs in other profiles. The profile labelled low-collaborators was significantly less performing than all other groups. Two other profiles were identified, positioned between the aforementioned groups in terms of the perceived performance of MHPs: the junior primary care MHPs and the diversified specialized care MHPs. Seniority within the team, delivering specialized type of care, and positive team processes were all features associated with profiles where perceived work performance was high. Overall, this study supports the case for initiatives aimed at improving stability and interdisciplinary collaboration in health teams, especially in primary care.
28213659	0	8	Profiles	T081	C0237801
28213659	12	44	mental health care professionals	T097	C1704312
28213659	54	75	work role performance	T033	C0243095
28213659	100	116	mental disorders	T048	C0004936
28213659	171	190	health care systems	T093	C0018696
28213659	200	207	reforms	T064	C0206597
28213659	227	237	efficiency	T081	C0013682
28213659	241	267	mental health care systems	T093	C0018696
28213659	282	289	service	T057	C0557854
28213659	290	301	integration	T054	C3494302
28213659	305	316	communities	T096	C0009462
28213659	335	361	primary mental health care	T061	C0184643
28213659	380	412	mental health care professionals	T097	C1704312
28213659	414	418	MHPs	T097	C1704312
28213659	457	480	interdisciplinary teams	T058	C0086390
28213659	543	551	profiles	T081	C0237801
28213659	555	559	MHPs	T097	C1704312
28213659	581	590	perceived	T041	C0030971
28213659	591	612	work role performance	T033	C0243095
28213659	614	618	MHPs	T097	C1704312
28213659	622	628	Quebec	T083	C0034390
28213659	649	671	local service networks	T170	C0282574
28213659	684	715	self-administered questionnaire	T170	C0034394
28213659	741	751	individual	T098	C0237401
28213659	756	760	team	T058	C0086390
28213659	761	776	characteristics	T080	C1521970
28213659	816	824	Profiles	T081	C0237801
28213659	828	832	MHPs	T097	C1704312
28213659	854	879	two-step cluster analysis	T062	C0009085
28213659	886	894	profiles	T081	C0237801
28213659	911	915	MHPs	T097	C1704312
28213659	929	937	profiles	T081	C0237801
28213659	947	953	senior	T098	C0001792
28213659	954	972	medical outpatient	T033	C3845697
28213659	973	989	specialized care	T058	C0086388
28213659	990	994	MHPs	T097	C1704312
28213659	999	1005	senior	T098	C0001792
28213659	1006	1018	psychosocial	T201	C0518884
28213659	1006	1029	psychosocial outpatient	T101	C0029921
28213659	1030	1046	specialized care	T058	C0086388
28213659	1047	1051	MHPs	T097	C1704312
28213659	1097	1101	MHPs	T097	C1704312
28213659	1111	1119	profiles	T081	C0237801
28213659	1142	1159	low-collaborators	T094	C2827395
28213659	1227	1235	profiles	T081	C0237801
28213659	1241	1251	identified	T080	C0205396
28213659	1314	1323	perceived	T041	C0030971
28213659	1339	1343	MHPs	T097	C1704312
28213659	1349	1368	junior primary care	T058	C0086388
28213659	1369	1373	MHPs	T097	C1704312
28213659	1382	1410	diversified specialized care	T058	C0086388
28213659	1411	1415	MHPs	T097	C1704312
28213659	1417	1426	Seniority	T098	C0001792
28213659	1455	1479	specialized type of care	T058	C0086388
28213659	1543	1551	profiles	T081	C0237801
28213659	1558	1567	perceived	T041	C0030971
28213659	1682	1713	interdisciplinary collaboration	T058	C0597720
28213659	1717	1729	health teams	T058	C0086390
28213659	1745	1757	primary care	T058	C0033137

28334854|t|The burden of HPV -related diseases in Italy, 2001-12
28334854|a|Human papillomavirus (HPV) infection is the main cause of cervical cancer and plays a relevant role in the development of genital warts and of the cancer of penis and anus, head / neck, oropharynx and genitourinary system. The aim of this study is the evaluation of hospitalizations due to HPV-related pathologies in 2001-12 in Italy. The national hospital discharge forms were provided by the Ministry of Health. The HPV -related hospitalizations were identified using specific diagnostic codes, accordingly to the ICD-9-CM coding system. The proportion of hospitalizations of potentially HPV-related pathologies, obtained from the literature, was evaluated as well as the hospitalization rates (hr) and their trend over time. Uterine cervical cancer and CIN III accounted for 40% of hospitalizations (hr: 15.6/100 000 and 17.6/100 000, respectively). Head / neck and oropharynx pathologies accounted for 24.5% of cases (hr: 16/100 000 and 3.9/100 000, in males and females, respectively), followed by genital warts (17.3% of hospitalizations; hr: 7.5/100 000 in males and 8.52/100 000 in females), anal (8.1% of hospitalizations), genitourinary (7.7%) and penis cancers (2.2%). The study, even if limited to the evaluation of hospitalizations, points out how HPV-related pathologies continue to be a relevant public health issue in Italy with a high impact on population.
28334854	14	17	HPV	T005	C0021344
28334854	27	35	diseases	T047	C0012634
28334854	39	44	Italy	T083	C0022277
28334854	54	90	Human papillomavirus (HPV) infection	T047	C0343641
28334854	112	127	cervical cancer	T191	C0007847
28334854	161	172	development	T169	C1527148
28334854	176	189	genital warts	T047	C1398518
28334854	201	207	cancer	T191	C0006826
28334854	211	216	penis	T023	C0030851
28334854	221	225	anus	T023	C0003461
28334854	227	231	head	T029	C0018670
28334854	234	238	neck	T029	C0027530
28334854	240	250	oropharynx	T029	C0521367
28334854	255	275	genitourinary system	T022	C0042066
28334854	293	298	study	T062	C2603343
28334854	306	316	evaluation	T169	C1292732
28334854	320	336	hospitalizations	T058	C0019993
28334854	344	367	HPV-related pathologies	T047	C0343641
28334854	382	387	Italy	T083	C0022277
28334854	393	420	national hospital discharge	T058	C0586003
28334854	421	426	forms	T073	C0376315
28334854	448	466	Ministry of Health	T093	C1274109
28334854	472	475	HPV	T005	C0021344
28334854	485	501	hospitalizations	T058	C0019993
28334854	533	543	diagnostic	T169	C0348026
28334854	544	549	codes	T170	C0805701
28334854	570	578	ICD-9-CM	T170	C1137112
28334854	579	592	coding system	T185	C2347818
28334854	612	628	hospitalizations	T058	C0019993
28334854	644	667	HPV-related pathologies	T047	C0343641
28334854	687	697	literature	T170	C0023866
28334854	703	712	evaluated	T169	C1292732
28334854	728	749	hospitalization rates	T081	C1521828
28334854	751	753	hr	T081	C1521828
28334854	765	770	trend	T079	C1521798
28334854	776	780	time	T079	C0040223
28334854	782	805	Uterine cervical cancer	T191	C0007847
28334854	810	817	CIN III	T191	C0851140
28334854	839	855	hospitalizations	T058	C0019993
28334854	857	859	hr	T081	C1521828
28334854	907	911	Head	T029	C0018670
28334854	914	918	neck	T029	C0027530
28334854	923	933	oropharynx	T029	C0521367
28334854	934	945	pathologies	T169	C1521733
28334854	969	974	cases	T169	C0868928
28334854	976	978	hr	T081	C1521828
28334854	1011	1016	males	T032	C0086582
28334854	1021	1028	females	T032	C0086287
28334854	1057	1070	genital warts	T047	C1398518
28334854	1081	1097	hospitalizations	T058	C0019993
28334854	1099	1101	hr	T081	C1521828
28334854	1118	1123	males	T032	C0086582
28334854	1144	1151	females	T032	C0086287
28334854	1154	1158	anal	T191	C0153446
28334854	1168	1184	hospitalizations	T058	C0019993
28334854	1187	1200	genitourinary	T191	C0751569
28334854	1212	1225	penis cancers	T191	C0153601
28334854	1238	1243	study	T062	C2603343
28334854	1268	1278	evaluation	T169	C1292732
28334854	1282	1298	hospitalizations	T058	C0019993
28334854	1315	1338	HPV-related pathologies	T047	C0343641
28334854	1365	1378	public health	T078	C0018684
28334854	1379	1384	issue	T033	C0033213
28334854	1388	1393	Italy	T083	C0022277
28334854	1406	1412	impact	T080	C4049986
28334854	1416	1426	population	T098	C1257890

28526360|t|The FLASHE Study: Survey Development, Dyadic Perspectives, and Participant Characteristics
28526360|a|The National Cancer Institute developed the Family Life, Activity, Sun, Health, and Eating (FLASHE) Study to examine multiple cancer preventive behaviors within parent - adolescent dyads. The purpose of creating FLASHE was to enable the examination of physical activity, diet, and other cancer preventive behaviors and potential correlates among parent - adolescent dyads. FLASHE surveys were developed from a process involving literature reviews, scientific input from experts in the field, cognitive testing, and usability testing. This cross-sectional, web-based study of parents and their adolescent children (aged 12-17 years) was administered between April and October 2014. The nationwide sample consisted of 1,573 parent - adolescent dyads (1,699 parents and 1,581 adolescents) who returned all FLASHE surveys. FLASHE assessed parent and adolescent reports of several intrapersonal and interpersonal domains (including psychosocial variables, parenting, and the community and home environments). On a subset of example FLASHE items across these domains, responses of parents and adolescents within the same dyads were positively and significantly correlated (r =0.32-0.63). Analyses were run in 2015-2016. FLASHE data present multiple opportunities for studying research questions among individuals or dyads, including the ability to examine similarity between parents and adolescents on many constructs relevant to cancer preventive behaviors. FLASHE data are publicly available for researchers and practitioners to help advance research on cancer preventive health behaviors.
28526360	4	16	FLASHE Study	T170	C0038951
28526360	18	24	Survey	T170	C0038951
28526360	25	36	Development	T169	C1527148
28526360	38	44	Dyadic	T098	C0870454
28526360	63	74	Participant	T098	C0679646
28526360	75	90	Characteristics	T080	C1521970
28526360	95	120	National Cancer Institute	T093	C1513882
28526360	135	146	Family Life	T054	C0015608
28526360	148	156	Activity	T052	C0441655
28526360	158	161	Sun	T070	C0038817
28526360	163	169	Health	T078	C0018684
28526360	175	181	Eating	T040	C0013470
28526360	183	189	FLASHE	T170	C0038951
28526360	191	196	Study	T170	C0038951
28526360	217	234	cancer preventive	T061	C0281206
28526360	235	244	behaviors	T055	C0018687
28526360	252	258	parent	T099	C0030551
28526360	261	271	adolescent	T100	C0205653
28526360	272	277	dyads	T098	C0870454
28526360	303	309	FLASHE	T170	C0038951
28526360	343	360	physical activity	T056	C0026606
28526360	362	366	diet	T168	C0012155
28526360	378	405	cancer preventive behaviors	T061	C0281206
28526360	437	443	parent	T099	C0030551
28526360	446	456	adolescent	T100	C0205653
28526360	457	462	dyads	T098	C0870454
28526360	464	478	FLASHE surveys	T170	C0038951
28526360	519	537	literature reviews	T170	C0282441
28526360	539	549	scientific	T090	C0036397
28526360	550	555	input	T077	C1708517
28526360	561	568	experts	T097	C0009817
28526360	583	600	cognitive testing	T060	C0204471
28526360	630	645	cross-sectional	T062	C0010362
28526360	647	662	web-based study	T062	C2603343
28526360	666	673	parents	T099	C0030551
28526360	684	694	adolescent	T100	C0205653
28526360	695	703	children	T099	C0680063
28526360	727	739	administered	T169	C1621583
28526360	748	753	April	T079	C3715024
28526360	758	765	October	T079	C3828732
28526360	813	819	parent	T099	C0030551
28526360	822	832	adolescent	T100	C0205653
28526360	833	838	dyads	T098	C0870454
28526360	846	853	parents	T099	C0030551
28526360	864	875	adolescents	T100	C0205653
28526360	894	908	FLASHE surveys	T170	C0038951
28526360	910	916	FLASHE	T170	C0038951
28526360	926	932	parent	T099	C0030551
28526360	937	947	adolescent	T100	C0205653
28526360	985	998	interpersonal	T080	C3476070
28526360	1018	1040	psychosocial variables	T080	C0033963
28526360	1042	1051	parenting	T054	C0085092
28526360	1061	1070	community	T080	C0563116
28526360	1075	1092	home environments	T082	C0442519
28526360	1118	1124	FLASHE	T170	C0038951
28526360	1153	1162	responses	T078	C1547656
28526360	1166	1173	parents	T099	C0030551
28526360	1178	1189	adolescents	T100	C0205653
28526360	1206	1211	dyads	T098	C0870454
28526360	1246	1256	correlated	T081	C0010100
28526360	1305	1311	FLASHE	T170	C0038951
28526360	1361	1379	research questions	T078	C0681799
28526360	1386	1397	individuals	T098	C0027361
28526360	1401	1406	dyads	T098	C0870454
28526360	1422	1429	ability	T032	C0085732
28526360	1441	1451	similarity	T080	C2348205
28526360	1460	1467	parents	T099	C0030551
28526360	1472	1483	adolescents	T100	C0205653
28526360	1515	1542	cancer preventive behaviors	T061	C0281206
28526360	1544	1550	FLASHE	T170	C0038951
28526360	1583	1594	researchers	T097	C0035173
28526360	1599	1612	practitioners	T097	C0017319
28526360	1629	1637	research	T062	C0035168
28526360	1641	1658	cancer preventive	T061	C0281206
28526360	1659	1675	health behaviors	T055	C0018687

27548784|t|Acute Kinematic and Kinetic Adaptations to Wearable Resistance During Sprint Acceleration
27548784|a|Macadam, P, Simperingham, KD, and Cronin, JB. Acute kinematic and kinetic adaptations to wearable resistance during sprint acceleration. J Strength Cond Res 31(5): 1297-1304, 2017- Wearable resistance (WR) in the form of weighted vests and shorts enables movement-specific sprint running to be performed under load. The purpose of this study was to determine the acute changes in kinematics and kinetics when an additional load equivalent to 3% body mass (BM) was attached to the anterior or posterior surface of the lower limbs during sprint running. Nineteen male rugby athletes (age: 19.7 ± 2.3 years; body mass: 96.1 ± 16.5 kg; height: 181 ± 6.5 cm) volunteered to participate in the study. Subjects performed six 20 m sprints in a randomized fashion wearing no resistance or 3% BM affixed to the anterior (quadriceps and tibialis anterior) or posterior (hamstring and gastrocnemius) surface of the lower limbs (2 sprints per condition). Optojump and radar were used to quantify sprint times, horizontal velocity, contact and flight times, and step length and frequency. A repeated measures analysis of variance with post hoc contrasts was used to determine differences (p ≤ 0.05) between conditions. No significant differences were found between the anterior and posterior WR conditions in any of the variables of interest. There was no significant change in sprint times over the initial 10 m, however, the 10-20 m split times were significantly slower (-2.2 to -2.9%) for the WR conditions compared with the unloaded sprints. A significant change in the relative force-velocity (F-v) slope (-10.5 to -10.9%) and theoretical maximum velocity (V0) (-5.4 to -6.5%) was found, whereas a nonsignificant increase in theoretical maximum force (F0) (4.9-5.2%) occurred. Wearable resistance of 3% BM may be a suitable training modality to enhance sprint acceleration performance by overloading the athlete without negatively affecting sprint running technique.
27548784	0	5	Acute	T079	C0205178
27548784	6	15	Kinematic	T070	C1254365
27548784	20	27	Kinetic	T070	C0022702
27548784	28	39	Adaptations	T038	C0392673
27548784	43	62	Wearable Resistance	T169	C4281815
27548784	70	89	Sprint Acceleration	T067	C0000894
27548784	136	141	Acute	T079	C0205178
27548784	142	151	kinematic	T070	C1254365
27548784	156	163	kinetic	T070	C0022702
27548784	164	175	adaptations	T038	C0392673
27548784	179	198	wearable resistance	T169	C4281815
27548784	206	225	sprint acceleration	T067	C0000894
27548784	271	290	Wearable resistance	T169	C4281815
27548784	292	294	WR	T169	C4281815
27548784	311	319	weighted	T081	C0043100
27548784	320	325	vests	T073	C0453884
27548784	330	336	shorts	T073	C0453933
27548784	345	377	movement-specific sprint running	T056	C0035953
27548784	384	393	performed	T169	C0884358
27548784	400	404	load	T078	C1254370
27548784	426	431	study	T170	C0085973
27548784	453	458	acute	T079	C0205178
27548784	459	466	changes	T169	C0392747
27548784	470	480	kinematics	T070	C1254365
27548784	485	493	kinetics	T070	C0022702
27548784	513	517	load	T078	C1254370
27548784	535	544	body mass	T033	C0518010
27548784	546	548	BM	T033	C0518010
27548784	570	578	anterior	T082	C0205094
27548784	582	591	posterior	T082	C0205095
27548784	592	599	surface	T082	C0205148
27548784	607	618	lower limbs	T023	C0023216
27548784	626	640	sprint running	T056	C0035953
27548784	651	655	male	T032	C0086582
27548784	656	661	rugby	T056	C0035945
27548784	662	670	athletes	T097	C0238703
27548784	672	675	age	T032	C0001779
27548784	688	693	years	T079	C0439234
27548784	695	704	body mass	T033	C0518010
27548784	722	728	height	T032	C0489786
27548784	744	755	volunteered	T098	C0020155
27548784	759	770	participate	T169	C0679823
27548784	778	783	study	T170	C0085973
27548784	785	793	Subjects	T098	C0080105
27548784	794	803	performed	T169	C0884358
27548784	813	820	sprints	T056	C0871707
27548784	826	844	randomized fashion	T062	C2986910
27548784	856	866	resistance	T169	C4281815
27548784	873	875	BM	T033	C0518010
27548784	891	899	anterior	T082	C0205094
27548784	901	911	quadriceps	T023	C0224440
27548784	916	924	tibialis	T023	C1710422
27548784	925	933	anterior	T082	C0205094
27548784	938	947	posterior	T082	C0205095
27548784	949	958	hamstring	T023	C0584895
27548784	963	976	gastrocnemius	T023	C0242691
27548784	978	985	surface	T082	C0205148
27548784	993	1004	lower limbs	T023	C0023216
27548784	1008	1015	sprints	T056	C0871707
27548784	1020	1029	condition	T080	C0348080
27548784	1032	1040	Optojump	T073	C3273359
27548784	1045	1050	radar	T073	C0034513
27548784	1064	1072	quantify	T081	C1709793
27548784	1073	1085	sprint times	T081	C1632851
27548784	1087	1097	horizontal	T082	C0205126
27548784	1098	1106	velocity	T081	C0439830
27548784	1108	1132	contact and flight times	T081	C0392762
27548784	1138	1149	step length	T033	C0427126
27548784	1154	1163	frequency	T079	C0439603
27548784	1167	1205	repeated measures analysis of variance	T081	C0002780
27548784	1211	1229	post hoc contrasts	T081	C0392762
27548784	1252	1263	differences	T081	C1705241
27548784	1283	1293	conditions	T080	C0348080
27548784	1295	1321	No significant differences	T033	C3842396
27548784	1345	1353	anterior	T082	C0205094
27548784	1358	1367	posterior	T082	C0205095
27548784	1368	1370	WR	T169	C4281815
27548784	1371	1381	conditions	T080	C0348080
27548784	1396	1405	variables	T080	C0439828
27548784	1429	1450	no significant change	T033	C0442739
27548784	1454	1466	sprint times	T081	C1632851
27548784	1511	1522	split times	T081	C1632851
27548784	1573	1575	WR	T169	C4281815
27548784	1576	1586	conditions	T080	C0348080
27548784	1614	1621	sprints	T056	C0871707
27548784	1625	1643	significant change	T080	C3854148
27548784	1651	1686	relative force-velocity (F-v) slope	T081	C0808376
27548784	1709	1737	theoretical maximum velocity	T081	C0439830
27548784	1739	1741	V0	T081	C0439830
27548784	1807	1832	theoretical maximum force	T067	C0441722
27548784	1834	1836	F0	T067	C0441722
27548784	1859	1878	Wearable resistance	T169	C4281815
27548784	1885	1887	BM	T033	C0518010
27548784	1906	1914	training	T061	C0454374
27548784	1915	1923	modality	T078	C0695347
27548784	1935	1954	sprint acceleration	T067	C0000894
27548784	1955	1966	performance	T055	C0597198
27548784	1986	1993	athlete	T097	C0238703
27548784	2023	2037	sprint running	T056	C0035953
27548784	2038	2047	technique	T169	C0449851

27568025|t|Foliar uptake of fog in coastal California shrub species
27568025|a|Understanding plant water uptake is important in ecosystems that experience periodic drought. In many Mediterranean -type climates like coastal California, plants are subject to significant drought and wildfire disturbance. During the dry summer months, coastal shrub species are often exposed to leaf wetting from overnight fog events. This study sought to determine whether foliar uptake of fog occurs in shrub species and how this uptake affects physiology and fuel condition. In a controlled greenhouse experiment, dominant California shrub species were exposed to isotopically labeled fog water and plant responses were measured. Potted plants were covered at the base to prevent root uptake. The deuterium label was detected in the leaves of four out of five species and in the stems of two of the species. While there was a minimal effect of foliar water uptake on live fuel moisture, several species had lower xylem tension and greater photosynthetic rates after overnight fog treatments, especially Salvia leucophylla. Coastal fog may provide a moisture source for many species during the summer drought, but the utilization of this water source may vary based on foliar morphology, phenology and plant water balance. From this study, it appears that drought -deciduous species (Artemisia californica and Salvia leucophylla) benefit more from overnight fog events than evergreen species (Adenostoma fasciculatum, Baccharis pilularis and Ceanothus megacarpus). This differential response to fog exposure among California shrub species may affect species distributions and physiological tolerances under future climate scenarios.
27568025	0	6	Foliar	T002	C0032098
27568025	7	13	uptake	T039	C0243144
27568025	17	20	fog	T070	C0450030
27568025	24	42	coastal California	T083	C0006754
27568025	43	48	shrub	T002	C0032098
27568025	49	56	species	T185	C1705920
27568025	71	76	plant	T002	C0032098
27568025	77	89	water uptake	T040	C0013123
27568025	106	116	ecosystems	T070	C0162358
27568025	133	141	periodic	T079	C0332182
27568025	142	149	drought	T070	C0013140
27568025	159	172	Mediterranean	T083	C0282645
27568025	179	187	climates	T070	C0008946
27568025	193	211	coastal California	T083	C0006754
27568025	213	219	plants	T002	C0032098
27568025	247	254	drought	T070	C0013140
27568025	259	267	wildfire	T070	C1254365
27568025	268	279	disturbance	T080	C2699787
27568025	296	302	summer	T079	C0241301
27568025	303	309	months	T079	C0439231
27568025	311	318	coastal	T083	C0017446
27568025	319	324	shrub	T002	C0032098
27568025	325	332	species	T185	C1705920
27568025	354	358	leaf	T002	C0242724
27568025	359	366	wetting	T080	C0205381
27568025	372	381	overnight	T079	C0439583
27568025	382	385	fog	T070	C0450030
27568025	386	392	events	T051	C0441471
27568025	433	439	foliar	T002	C0032098
27568025	440	446	uptake	T039	C0243144
27568025	450	453	fog	T070	C0450030
27568025	464	469	shrub	T002	C0032098
27568025	470	477	species	T185	C1705920
27568025	491	497	uptake	T040	C0013123
27568025	506	516	physiology	T039	C0031843
27568025	553	574	greenhouse experiment	T069	C0206218
27568025	585	595	California	T083	C0006754
27568025	596	601	shrub	T002	C0032098
27568025	602	609	species	T185	C1705920
27568025	615	625	exposed to	T080	C0332157
27568025	626	646	isotopically labeled	T062	C0022261
27568025	647	650	fog	T070	C0450030
27568025	651	656	water	T121,T197	C0043047
27568025	661	666	plant	T002	C0032098
27568025	667	676	responses	T032	C0871261
27568025	682	690	measured	T080	C0444706
27568025	699	705	plants	T002	C0032098
27568025	742	746	root	T002	C0242726
27568025	747	753	uptake	T040	C0013123
27568025	759	768	deuterium	T196	C0011744
27568025	795	801	leaves	T002	C0242724
27568025	822	829	species	T185	C1705920
27568025	841	846	stems	T002	C0242767
27568025	861	868	species	T185	C1705920
27568025	896	905	effect of	T080	C1704420
27568025	906	912	foliar	T002	C0032098
27568025	913	925	water uptake	T040	C0013123
27568025	939	947	moisture	T167	C0868994
27568025	957	964	species	T185	C1705920
27568025	975	980	xylem	T002	C1720877
27568025	981	988	tension	T070	C1254365
27568025	1001	1021	photosynthetic rates	T070	C0031764
27568025	1028	1037	overnight	T079	C0439583
27568025	1038	1041	fog	T070	C0450030
27568025	1042	1052	treatments	T169	C1522326
27568025	1065	1083	Salvia leucophylla	T002	C1943240
27568025	1085	1092	Coastal	T083	C0017446
27568025	1093	1096	fog	T070	C0450030
27568025	1111	1119	moisture	T167	C0868994
27568025	1136	1143	species	T185	C1705920
27568025	1155	1161	summer	T079	C0241301
27568025	1162	1169	drought	T070	C0013140
27568025	1199	1211	water source	T081	C0043062
27568025	1230	1247	foliar morphology	T032	C0597253
27568025	1249	1258	phenology	T080	C0205556
27568025	1263	1268	plant	T002	C0032098
27568025	1269	1282	water balance	T040	C0016284
27568025	1317	1324	drought	T070	C0013140
27568025	1336	1343	species	T185	C1705920
27568025	1345	1366	Artemisia californica	T002	C0487793
27568025	1371	1389	Salvia leucophylla	T002	C1943240
27568025	1409	1418	overnight	T079	C0439583
27568025	1419	1422	fog	T070	C0450030
27568025	1423	1429	events	T051	C0441471
27568025	1445	1452	species	T185	C1705920
27568025	1454	1477	Adenostoma fasciculatum	T002	C1068315
27568025	1479	1498	Baccharis pilularis	T002	C0032098
27568025	1503	1523	Ceanothus megacarpus	T002	C1030155
27568025	1544	1552	response	T032	C0871261
27568025	1556	1559	fog	T070	C0450030
27568025	1560	1568	exposure	T080	C0332157
27568025	1575	1585	California	T083	C0006754
27568025	1586	1591	shrub	T002	C0032098
27568025	1592	1599	species	T185	C1705920
27568025	1611	1618	species	T185	C1705920
27568025	1619	1632	distributions	T169	C1704711
27568025	1637	1650	physiological	T169	C0205463
27568025	1651	1661	tolerances	T080	C1704410
27568025	1675	1682	climate	T070	C0008946
27568025	1683	1692	scenarios	T169	C0683579

27755951|t|Construction of recombinant adenovirus Ad-rat PLCγ2 and its effects on apoptosis of rat liver cell BRL-3A in vitro
27755951|a|Although the role of PLCγ2 in apoptotic response has been reported, too little is known about whether PLCγ2 induces liver cell apoptosis during liver regeneration. Therefore, this study firstly packaged Ad-PLCγ2 recombinant adenovirus and primarily evaluated its effect on apoptosis of rat liver cell BRL-3A in vitro. Following ten days of co-transfection of pHBAd-MCMV-GFP-PLCγ2 and pHBAd-BHG into HEK293 cells, viral cytopathic effect (CPE) was apparent. Following three rounds of amplification, tissue culture infectious dose 50 (TCID50) assay showed that the titer value reached 1×1010 PFU/mL. After 24 h of transfection of recombinant adenovirus into BRL-3A cells, transfection efficiency of adenovirus into BRL-3A cells was above 90% when obsereved under fluorescent microscopy. qRT-PCR and Western blot assays showed mRNA and protein levels of PLCγ2 were significantly elevated in the transfected BRL-3A cells. Flow cytometric analysis showed that, compared with the control and Ad-GFP groups, cell apoptosis rate of Ad-PLCγ2 group were significantly increased (P<0.01), and the cell cycle in Ad-PLCγ2 group was arrested at G1 phase which was manifested by a marked increase (P<0.01) in the percentage of G1 phase cells and a great decrease (P<0.01) in the percentage of S and G2 / M phase cells. It was concluded from above results that recombinant adenovirus Ad-PLCγ2 was packaged successfully, and could promote cell apoptosis by arresting the transition from G1 to S phase of BRL-3A cells.
27755951	16	51	recombinant adenovirus Ad-rat PLCγ2	T114	C1510800
27755951	60	67	effects	T080	C1280500
27755951	71	80	apoptosis	T043	C0162638
27755951	84	87	rat	T015	C0034693
27755951	88	98	liver cell	T025	C0227525
27755951	99	105	BRL-3A	T025	C0227525
27755951	106	114	in vitro	T059,T062	C3850137
27755951	136	141	PLCγ2	T116,T126	C0662760
27755951	145	154	apoptotic	T080	C1516044
27755951	155	163	response	T033	C0243095
27755951	217	222	PLCγ2	T116,T126	C0662760
27755951	231	241	liver cell	T025	C0227525
27755951	242	251	apoptosis	T043	C0162638
27755951	259	277	liver regeneration	T042	C0023907
27755951	295	300	study	T062	C2603343
27755951	318	349	Ad-PLCγ2 recombinant adenovirus	T114	C1510800
27755951	378	384	effect	T080	C1280500
27755951	388	397	apoptosis	T043	C0162638
27755951	401	404	rat	T015	C0034693
27755951	405	415	liver cell	T025	C0227525
27755951	416	422	BRL-3A	T025	C0227525
27755951	423	431	in vitro	T059,T062	C3850137
27755951	447	451	days	T079	C0439228
27755951	455	470	co-transfection	T063	C0040669
27755951	474	494	pHBAd-MCMV-GFP-PLCγ2	T114,T123	C0032136
27755951	499	508	pHBAd-BHG	T114,T123	C0032136
27755951	514	526	HEK293 cells	T025	C2936239
27755951	528	551	viral cytopathic effect	T049	C0010827
27755951	553	556	CPE	T046	C0333467
27755951	598	611	amplification	T067	C1521871
27755951	613	646	tissue culture infectious dose 50	T081	C1883346
27755951	648	654	TCID50	T081	C1883346
27755951	656	661	assay	T059	C1510438
27755951	678	689	titer value	T081	C0475208
27755951	727	739	transfection	T063	C0040669
27755951	743	765	recombinant adenovirus	T114	C1510800
27755951	771	783	BRL-3A cells	T025	C0227525
27755951	785	797	transfection	T063	C0040669
27755951	798	808	efficiency	T081	C0013682
27755951	812	822	adenovirus	T005	C0001483
27755951	828	840	BRL-3A cells	T025	C0227525
27755951	876	898	fluorescent microscopy	T059	C0026022
27755951	900	907	qRT-PCR	T063	C1514628
27755951	912	931	Western blot assays	T059,T063	C0005863
27755951	939	943	mRNA	T114,T123	C0035696
27755951	948	962	protein levels	T034	C0428479
27755951	966	971	PLCγ2	T116,T126	C0662760
27755951	1007	1018	transfected	T063	C0040669
27755951	1019	1031	BRL-3A cells	T025	C0227525
27755951	1033	1057	Flow cytometric analysis	T059	C0200904
27755951	1089	1096	control	T096	C0009932
27755951	1101	1114	Ad-GFP groups	T114	C1510800
27755951	1116	1130	cell apoptosis	T043	C0162638
27755951	1131	1135	rate	T081	C1521828
27755951	1139	1153	Ad-PLCγ2 group	T114	C1510800
27755951	1201	1211	cell cycle	T043	C0007586
27755951	1215	1229	Ad-PLCγ2 group	T114	C1510800
27755951	1234	1242	arrested	T043	C1155873
27755951	1246	1254	G1 phase	T079	C0079395
27755951	1313	1323	percentage	T081	C0439165
27755951	1327	1335	G1 phase	T079	C0079395
27755951	1336	1341	cells	T025	C0007634
27755951	1379	1389	percentage	T081	C0439165
27755951	1393	1394	S	T079	C0080129
27755951	1399	1401	G2	T079	C0079396
27755951	1404	1411	M phase	T043	C1450044
27755951	1412	1417	cells	T025	C0007634
27755951	1447	1454	results	T034	C0456984
27755951	1460	1491	recombinant adenovirus Ad-PLCγ2	T114	C1510800
27755951	1529	1536	promote	T052	C0033414
27755951	1537	1551	cell apoptosis	T043	C0162638
27755951	1555	1564	arresting	T043	C1155873
27755951	1569	1579	transition	T043	C1516334
27755951	1585	1587	G1	T079	C0079395
27755951	1591	1598	S phase	T079	C0080129
27755951	1602	1614	BRL-3A cells	T025	C0227525

27270538|t|Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml
27270538|a|The European Society of Urogenital Radiology has built the Prostate Imaging Reporting and Data System (PI-RADS) for standardizing the diagnosis of prostate cancer (PCa). This study evaluated the PI-RADS diagnosis method in patients with prostate-specific antigen (PSA) <20 ng/ml. A total of 133 patients with PSA <20 ng/ml were prospectively recruited. T2-weighted (T2WI) and diffusion-weighted (DWI) magnetic resonance images of the prostate were acquired before a 12-core transrectal prostate biopsy. Each patient's peripheral zone was divided into six regions on the images; each region corresponded to two of the 12 biopsy cores. T2WI, DWI, and T2WI + DWI scores were computed according to PI-RADS. The diagnostic accuracy of the PI-RADS score was evaluated using histopathology of prostate biopsies as the reference standard. PCa was histologically diagnosed in 169 (21.2%) regions. Increased PI-RADS score correlated positively with increased cancer detection rate. The cancer detection rate for scores 1 to 5 was 2.8%, 15.0%, 34.6%, 52.6%, and 88.9%, respectively, using T2WI and 12.0%, 20.2%, 48.0%, 85.7%, and 93.3%, respectively, using DWI. For T2WI + DWI, the cancer detection rate was 1.5% (score 2), 13.5% (scores 3-4), 41.3% (scores 5-6), 75.9% (scores 7-8), and 92.3% (scores 9-10). The area under the curve for cancer detection was 0.700 (T2WI), 0.735 (DWI) and 0.749 (T2WI + DWI). The sensitivity and specificity were 53.8% and 89.2%, respectively, when using scores 5-6 as the cutoff value for T2WI + DWI. The PI-RADS score correlates with the PCa detection rate in patients with PSA <20 ng/ml. The summed score of T2WI + DWI has the highest accuracy in detection of PCa. However, the sensitivity should be further improved.
27270538	18	60	Prostate Imaging Reporting and Data System	T170	C4284879
27270538	65	91	Magnetic Resonance Imaging	T060	C0024485
27270538	92	101	Diagnosis	T062	C1704656
27270538	105	120	Prostate Cancer	T191	C0376358
27270538	124	132	Patients	T101	C0030705
27270538	138	163	Prostate-specific Antigen	T116,T126,T129	C0138741
27270538	178	218	European Society of Urogenital Radiology	T093	C1708333
27270538	233	275	Prostate Imaging Reporting and Data System	T170	C4284879
27270538	277	284	PI-RADS	T170	C4284879
27270538	308	317	diagnosis	T062	C1704656
27270538	321	336	prostate cancer	T191	C0376358
27270538	338	341	PCa	T191	C0376358
27270538	349	354	study	T062	C2603343
27270538	369	376	PI-RADS	T170	C4284879
27270538	377	393	diagnosis method	T060	C0430022
27270538	397	405	patients	T101	C0030705
27270538	411	436	prostate-specific antigen	T116,T126,T129	C0138741
27270538	438	441	PSA	T116,T126,T129	C0138741
27270538	469	477	patients	T101	C0030705
27270538	483	486	PSA	T116,T126,T129	C0138741
27270538	527	538	T2-weighted	T060	C0011923
27270538	540	544	T2WI	T060	C0011923
27270538	550	600	diffusion-weighted (DWI) magnetic resonance images	T060	C0598801
27270538	608	616	prostate	T023	C0033572
27270538	640	675	12-core transrectal prostate biopsy	T060	C0401641
27270538	682	691	patient's	T101	C0030705
27270538	692	707	peripheral zone	T029	C0458696
27270538	744	750	images	T170	C1704254
27270538	794	806	biopsy cores	T060	C3846093
27270538	808	812	T2WI	T060	C0011923
27270538	814	817	DWI	T060	C0598801
27270538	823	827	T2WI	T060	C0011923
27270538	830	833	DWI	T060	C0598801
27270538	834	840	scores	T081	C0449820
27270538	868	875	PI-RADS	T170	C4284879
27270538	881	900	diagnostic accuracy	T080	C0598285
27270538	908	915	PI-RADS	T170	C4284879
27270538	916	921	score	T081	C0449820
27270538	942	956	histopathology	T091	C0677043
27270538	960	977	prostate biopsies	T060	C0194804
27270538	1005	1008	PCa	T191	C0376358
27270538	1013	1037	histologically diagnosed	UnknownType	C0679557
27270538	1072	1079	PI-RADS	T170	C4284879
27270538	1080	1085	score	T081	C0449820
27270538	1123	1139	cancer detection	T058	C1516193
27270538	1140	1144	rate	T081	C1521828
27270538	1150	1166	cancer detection	T058	C1516193
27270538	1167	1171	rate	T081	C1521828
27270538	1176	1182	scores	T081	C0449820
27270538	1252	1256	T2WI	T060	C0011923
27270538	1320	1323	DWI	T060	C0598801
27270538	1329	1333	T2WI	T060	C0011923
27270538	1336	1339	DWI	T060	C0598801
27270538	1345	1361	cancer detection	T058	C1516193
27270538	1362	1366	rate	T081	C1521828
27270538	1377	1382	score	T081	C0449820
27270538	1394	1400	scores	T081	C0449820
27270538	1414	1420	scores	T081	C0449820
27270538	1434	1440	scores	T081	C0449820
27270538	1458	1464	scores	T081	C0449820
27270538	1501	1517	cancer detection	T058	C1516193
27270538	1529	1533	T2WI	T060	C0011923
27270538	1543	1546	DWI	T060	C0598801
27270538	1559	1563	T2WI	T060	C0011923
27270538	1566	1569	DWI	T060	C0598801
27270538	1651	1657	scores	T081	C0449820
27270538	1686	1690	T2WI	T060	C0011923
27270538	1693	1696	DWI	T060	C0598801
27270538	1702	1709	PI-RADS	T170	C4284879
27270538	1710	1715	score	T081	C0449820
27270538	1736	1749	PCa detection	T061	C0281186
27270538	1750	1754	rate	T081	C1521828
27270538	1758	1766	patients	T101	C0030705
27270538	1772	1775	PSA	T116,T126,T129	C0138741
27270538	1798	1803	score	T081	C0449820
27270538	1807	1811	T2WI	T060	C0011923
27270538	1814	1817	DWI	T060	C0598801
27270538	1859	1862	PCa	T191	C0376358

27977319|t|The relationship between thiamine and two symbioses: Root nodule symbiosis and arbuscular mycorrhiza
27977319|a|Lotus japonicus THIC is expressed in all organs, and the encoded protein catalyzes thiamine biosynthesis. Loss of function produces chlorosis, a typical thiamine -deficiency phenotype, and mortality. To investigate thiamine's role in symbiosis, we focused on THI1, a thiamine-biosynthesis gene expressed in roots, nodules, and seeds. The thi1 mutant had green leaves, but formed small nodules and immature seeds. These phenotypes were rescued by THI1 complementation and by exogenous thiamine. Thus, THI1 is required for nodule enlargement and seed maturation. On the other hand, colonization by arbuscular mycorrhiza (AM) fungus Rhizophagus irregularis was not affected in the thi1 mutant or by exogenous thiamine. However, spores of R. irregularis stored more thiamine than the source (host plants), despite lacking thiamine biosynthesis genes. Therefore, disturbance of the thiamine supply would affect progeny phenotypes such as spore formation and hyphal growth. Further investigation will be required to elucidate thiamine's effect on AM.
27977319	25	33	thiamine	T109,T127	C0039840
27977319	42	51	symbioses	T070	C0039029
27977319	53	64	Root nodule	T002	C1720942
27977319	65	74	symbiosis	T070	C0039029
27977319	79	100	arbuscular mycorrhiza	T004	C1138420
27977319	101	116	Lotus japonicus	T002	C1940771
27977319	117	121	THIC	T028	C0017337
27977319	125	134	expressed	T045	C0017262
27977319	142	148	organs	T002	C0032098
27977319	158	173	encoded protein	T116,T123	C0033684
27977319	174	183	catalyzes	T070	C0007382
27977319	184	205	thiamine biosynthesis	T044	C1157735
27977319	207	223	Loss of function	T033	C0243095
27977319	233	242	chlorosis	T047	C0008272
27977319	254	262	thiamine	T109,T127	C0039840
27977319	275	284	phenotype	T032	C0031437
27977319	290	299	mortality	T081	C0205848
27977319	316	326	thiamine's	T109,T127	C0039840
27977319	335	344	symbiosis	T070	C0039029
27977319	360	364	THI1	T028	C0017337
27977319	368	394	thiamine-biosynthesis gene	T028	C0017337
27977319	395	404	expressed	T045	C0017262
27977319	408	413	roots	T002	C0242726
27977319	415	422	nodules	T002	C1720942
27977319	428	433	seeds	T002	C0036563
27977319	439	450	thi1 mutant	T028	C0678941
27977319	455	467	green leaves	T002	C0242724
27977319	480	485	small	T081	C0700321
27977319	486	493	nodules	T002	C1720942
27977319	498	506	immature	T080	C0205252
27977319	507	512	seeds	T002	C0036563
27977319	520	530	phenotypes	T032	C0031437
27977319	547	551	THI1	T028	C0017337
27977319	552	567	complementation	T045	C0178654
27977319	575	584	exogenous	T169	C0205228
27977319	585	593	thiamine	T109,T127	C0039840
27977319	601	605	THI1	T028	C0017337
27977319	622	628	nodule	T002	C1720942
27977319	629	640	enlargement	T169	C0542341
27977319	645	660	seed maturation	T039	C2265562
27977319	681	693	colonization	T033	C4289767
27977319	697	718	arbuscular mycorrhiza	T004	C1138420
27977319	720	722	AM	T004	C1138420
27977319	724	730	fungus	T004	C0016832
27977319	731	754	Rhizophagus irregularis	T004	C2664655
27977319	779	790	thi1 mutant	T028	C0678941
27977319	797	806	exogenous	T169	C0205228
27977319	807	815	thiamine	T109,T127	C0039840
27977319	826	832	spores	T004	C0038029
27977319	836	850	R. irregularis	T004	C2664655
27977319	863	871	thiamine	T109,T127	C0039840
27977319	889	900	host plants	UnknownType	C0868970
27977319	919	946	thiamine biosynthesis genes	T028	C0017337
27977319	978	986	thiamine	T109,T127	C0039840
27977319	1007	1014	progeny	T099	C0680063
27977319	1015	1025	phenotypes	T032	C0031437
27977319	1034	1049	spore formation	T043	C1159442
27977319	1054	1067	hyphal growth	T043	C1156247
27977319	1121	1131	thiamine's	T109,T127	C0039840
27977319	1142	1144	AM	T004	C1138420

27686487|t|Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study
27686487|a|The structural MR imaging correlates of cognitive impairment in multiple sclerosis are still debated. This study assessed lesional and atrophy measures of white matter and gray matter involvement in patients with MS acquired in 7 European sites to identify the MR imaging variables most closely associated with cognitive dysfunction. Brain dual-echo, 3D T1-weighted, and double inversion recovery scans were acquired at 3T from 62 patients with relapsing-remitting MS and 65 controls. Patients with at least 2 neuropsychological tests with abnormal findings were considered cognitively impaired. Focal WM and cortical lesions were identified, and volumetric measures from WM, cortical GM, the hippocampus, and deep GM nuclei were obtained. Age - and site -adjusted models were used to compare lesion and volumetric MR imaging variables between patients with MS who were cognitively impaired and cognitively preserved. A multivariate analysis identified MR imaging variables associated with cognitive scores and disability. Twenty-three patients (38%) were cognitively impaired. Compared with those with who were cognitively preserved, patients with MS with cognitive impairment had higher T2 and T1 lesion volumes and a trend toward a higher number of cortical lesions. Significant brain, cortical GM, hippocampal, deep GM nuclei, and WM atrophy was found in patients with MS with cognitive impairment versus those who were cognitively preserved. Hippocampal and deep GM nuclei atrophy were the best predictors of cognitive impairment, while WM atrophy was the best predictor of disability. Hippocampal and deep GM nuclei atrophy are key factors associated with cognitive impairment in MS. These MR imaging measures could be applied in a multicenter context, with cognition as clinical outcome.
27686487	0	11	Hippocampal	T023	C0019564
27686487	16	32	Deep Gray Matter	T024	C0018220
27686487	33	39	Nuclei	T026	C0007610
27686487	40	47	Atrophy	T046	C0333641
27686487	75	95	Cognitive Impairment	T048	C0338656
27686487	99	101	MS	T047	C0026769
27686487	105	122	Multicenter Study	T062	C1096776
27686487	127	148	structural MR imaging	T060	C0024485
27686487	163	183	cognitive impairment	T048	C0338656
27686487	187	205	multiple sclerosis	T047	C0026769
27686487	230	235	study	T062	C1096776
27686487	245	253	lesional	T033	C0221198
27686487	258	265	atrophy	T046	C0333641
27686487	266	274	measures	T081	C0079809
27686487	278	290	white matter	T024	C0682708
27686487	295	306	gray matter	T024	C0018220
27686487	307	318	involvement	T169	C1314939
27686487	322	330	patients	T101	C0030705
27686487	336	338	MS	T047	C0026769
27686487	353	367	European sites	T083	C0015176
27686487	384	394	MR imaging	T060	C0024485
27686487	418	433	associated with	T080	C0332281
27686487	434	455	cognitive dysfunction	T048	C0338656
27686487	457	462	Brain	T023	C0006104
27686487	463	472	dual-echo	T060	C0011923
27686487	474	488	3D T1-weighted	T060	C0011923
27686487	494	525	double inversion recovery scans	T060	C0441633
27686487	543	545	3T	T060	C2985394
27686487	554	562	patients	T101	C0030705
27686487	588	590	MS	T047	C0026769
27686487	598	606	controls	T096	C0009932
27686487	608	616	Patients	T101	C0030705
27686487	633	657	neuropsychological tests	T060	C0027902
27686487	663	680	abnormal findings	T033	C2826279
27686487	697	717	cognitively impaired	T048	C0338656
27686487	725	727	WM	T024	C0682708
27686487	732	740	cortical	T023	C0007776
27686487	741	748	lesions	T033	C0221198
27686487	770	780	volumetric	T082	C0445383
27686487	781	789	measures	T081	C0079809
27686487	795	797	WM	T024	C0682708
27686487	799	807	cortical	T023	C0007776
27686487	808	810	GM	T024	C0018220
27686487	816	827	hippocampus	T023	C0019564
27686487	833	840	deep GM	T024	C0018220
27686487	841	847	nuclei	T026	C0007610
27686487	863	866	Age	T032	C0001779
27686487	873	877	site	T082	C0205145
27686487	888	894	models	T075	C0026336
27686487	908	915	compare	T052	C1707455
27686487	916	922	lesion	T033	C0221198
27686487	927	937	volumetric	T082	C0445383
27686487	938	948	MR imaging	T060	C0024485
27686487	967	975	patients	T101	C0030705
27686487	981	983	MS	T047	C0026769
27686487	993	1013	cognitively impaired	T048	C0338656
27686487	1018	1039	cognitively preserved	T033	C3808562
27686487	1043	1064	multivariate analysis	T081	C0026777
27686487	1076	1086	MR imaging	T060	C0024485
27686487	1097	1112	associated with	T080	C0332281
27686487	1113	1129	cognitive scores	T081	C0449820
27686487	1134	1144	disability	T048	C0338656
27686487	1159	1167	patients	T101	C0030705
27686487	1179	1199	cognitively impaired	T048	C0338656
27686487	1201	1209	Compared	T052	C1707455
27686487	1235	1256	cognitively preserved	T033	C3808562
27686487	1258	1266	patients	T101	C0030705
27686487	1272	1274	MS	T047	C0026769
27686487	1280	1300	cognitive impairment	T048	C0338656
27686487	1312	1314	T2	T060	C0011923
27686487	1319	1321	T1	T060	C0011923
27686487	1322	1328	lesion	T033	C0221198
27686487	1329	1336	volumes	T081	C0449468
27686487	1375	1383	cortical	T023	C0007776
27686487	1384	1391	lesions	T033	C0221198
27686487	1405	1410	brain	T023	C0006104
27686487	1412	1420	cortical	T023	C0007776
27686487	1421	1423	GM	T024	C0018220
27686487	1425	1436	hippocampal	T023	C0019564
27686487	1438	1445	deep GM	T024	C0018220
27686487	1446	1452	nuclei	T026	C0007610
27686487	1458	1460	WM	T024	C0682708
27686487	1461	1468	atrophy	T046	C0333641
27686487	1482	1490	patients	T101	C0030705
27686487	1496	1498	MS	T047	C0026769
27686487	1504	1524	cognitive impairment	T048	C0338656
27686487	1547	1568	cognitively preserved	T033	C3808562
27686487	1570	1581	Hippocampal	T023	C0019564
27686487	1586	1593	deep GM	T024	C0018220
27686487	1594	1600	nuclei	T026	C0007610
27686487	1601	1608	atrophy	T046	C0333641
27686487	1623	1633	predictors	T078	C2698872
27686487	1637	1657	cognitive impairment	T048	C0338656
27686487	1665	1667	WM	T024	C0682708
27686487	1668	1675	atrophy	T046	C0333641
27686487	1689	1698	predictor	T078	C2698872
27686487	1702	1712	disability	T048	C0338656
27686487	1714	1725	Hippocampal	T023	C0019564
27686487	1730	1737	deep GM	T024	C0018220
27686487	1738	1744	nuclei	T026	C0007610
27686487	1745	1752	atrophy	T046	C0333641
27686487	1761	1768	factors	T169	C1521761
27686487	1769	1784	associated with	T080	C0332281
27686487	1785	1805	cognitive impairment	T048	C0338656
27686487	1809	1811	MS	T047	C0026769
27686487	1819	1829	MR imaging	T060	C0024485
27686487	1830	1838	measures	T081	C0079809
27686487	1861	1872	multicenter	T062	C1096776
27686487	1873	1880	context	T078	C0449255
27686487	1887	1896	cognition	T041	C0009240
27686487	1900	1908	clinical	T080	C0205210
27686487	1909	1916	outcome	T169	C1274040

27932568|t|Targeting HIF2 in Clear Cell Renal Cell Carcinoma
27932568|a|Inactivation of the von Hippel-Lindau tumor-suppressor protein (pVHL) is the signature "truncal" event in clear cell renal cell carcinoma, which is the most common form of kidney cancer. pVHL is part of a ubiquitin ligase the targets the α subunit of the hypoxia-inducible factor (HIF) transcription factor for destruction when oxygen is available. Preclinical studies strongly suggest that deregulation of HIF, and particularly HIF2, drives pVHL -defective renal carcinogenesis. Although HIF2α was classically considered undruggable, structural and chemical work by Rick Bruick and Kevin Gardner at University of Texas Southwestern laid the foundation for the development of small molecule direct HIF2α antagonists (PT2385 and the related tool compound PT2399) by Peloton Therapeutics that block the dimerization of HIF2α with its partner protein ARNT1. These compounds inhibit clear cell renal cell carcinoma growth in preclinical models, and PT2385 has now entered the clinic. Nonetheless, the availability of such compounds, together with clustered regularly interspaced short palindromic repeat (CRISPR)-based gene editing approaches, has revealed a previously unappreciated heterogeneity among clear cell renal carcinomas and patient -derived xenografts with respect to HIF2 dependence, suggesting that predictive biomarkers will be needed to optimize the use of such agents in the clinic.
27932568	0	9	Targeting	T169	C1521840
27932568	10	14	HIF2	T116,T123	C1436532
27932568	18	49	Clear Cell Renal Cell Carcinoma	T191	C0279702
27932568	70	112	von Hippel-Lindau tumor-suppressor protein	T116,T126	C1566585
27932568	114	118	pVHL	T116,T126	C1566585
27932568	127	152	signature "truncal" event	T033	C0243095
27932568	156	187	clear cell renal cell carcinoma	T191	C0279702
27932568	222	235	kidney cancer	T191	C1378703
27932568	237	241	pVHL	T116,T126	C1566585
27932568	255	271	ubiquitin ligase	T116,T126	C0077678
27932568	276	283	targets	T169	C1521840
27932568	288	297	α subunit	T116	C0599220
27932568	305	356	hypoxia-inducible factor (HIF) transcription factor	T116,T123	C1528322
27932568	361	372	destruction	T052	C1948029
27932568	399	410	Preclinical	T080	C1709630
27932568	411	418	studies	T062	C0008972
27932568	441	453	deregulation	T049	C1514542
27932568	457	460	HIF	T116,T123	C1528322
27932568	479	483	HIF2	T116,T123	C1436532
27932568	492	496	pVHL	T116,T126	C1566585
27932568	508	528	renal carcinogenesis	T191	C1378703
27932568	539	544	HIF2α	T116,T123	C0538487
27932568	572	583	undruggable	T080	C0205556
27932568	617	628	Rick Bruick	T170	C0805191
27932568	633	646	Kevin Gardner	T170	C0805191
27932568	650	682	University of Texas Southwestern	T073,T092	C0041740
27932568	726	740	small molecule	T109	C1328819
27932568	748	765	HIF2α antagonists	T120	C0243076
27932568	767	773	PT2385	T109,T121	C3896783
27932568	804	810	PT2399	T120	C0243076
27932568	815	835	Peloton Therapeutics	T093	C0815266
27932568	841	846	block	T169	C0332206
27932568	851	863	dimerization	T044	C1323327
27932568	867	872	HIF2α	T116,T123	C0538487
27932568	890	903	protein ARNT1	T116,T123	C1506870
27932568	921	967	inhibit clear cell renal cell carcinoma growth	T043	C1512773
27932568	971	989	preclinical models	T170	C1514292
27932568	995	1001	PT2385	T109,T121	C3896783
27932568	1022	1028	clinic	T073,T093	C0442592
27932568	1063	1077	such compounds	T121	C1254351
27932568	1093	1149	clustered regularly interspaced short palindromic repeat	T114	C3658200
27932568	1151	1157	CRISPR	T114	C3658200
27932568	1165	1188	gene editing approaches	T063	C4277689
27932568	1216	1243	unappreciated heterogeneity	T080	C0019409
27932568	1250	1277	clear cell renal carcinomas	T191	C0279702
27932568	1282	1289	patient	T101	C0030705
27932568	1299	1309	xenografts	T061	C0520484
27932568	1326	1330	HIF2	T116,T123	C1436532
27932568	1359	1380	predictive biomarkers	T123	C0041366
27932568	1399	1407	optimize	T052	C2698650
27932568	1419	1430	such agents	T121	C1254351
27932568	1438	1444	clinic	T073,T093	C0442592

27694780|t|Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature
27694780|a|Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention of venous thromboembolism, stroke and systemic arterial valve embolism. It acts directly on thrombin presenting in a dynamic and predictable way, which does not require monitoring these patients. Therefore, we consider the need to assess whether their use increases the risk of bleeding involved before any dental treatment. We performed a systematic review with a bibliographic search in PubMed / Medline along with the Cochrane Library. We excluded articles dealing with all anticoagulants other than dabigatran, and works about surgical treatments in anatomical locations other than the oral cavity. We included a total of 13 papers of which 1 was a randomized clinical trial, 9 narrative literature reviews, 1 case series, 2 clinical cases and 1 expert opinion. Because we did not obtain any properly designed clinical trials, we were unable to conduct a meta-analysis. Currently, there is no consensus on the procedure to be followed in patients taking dabigatran. However, all authors agree to treat each case individually in accordance to the risk of embolism, postoperative bleeding and renal function. Also, it is necessary to perform minimally invasive interventions, and take the appropriate local anti-hemolytic measures.
27694780	0	10	Dabigatran	T109,T121	C2348066
27694780	18	36	oral anticoagulant	T109,T121	C0354604
27694780	38	48	Guidelines	T170	C0162791
27694780	62	85	oral surgery procedures	T061	C0524861
27694780	100	124	review of the literature	T170	C0282441
27694780	125	135	Dabigatran	T109,T121	C2348066
27694780	162	166	drug	T121	C1254351
27694780	191	205	anticoagulants	T121	C0003280
27694780	227	249	venous thromboembolism	T047	C1861172
27694780	251	257	stroke	T047	C0038454
27694780	262	294	systemic arterial valve embolism	UnknownType	C0149876
27694780	316	324	thrombin	T116,T121,T126	C0040018
27694780	410	418	patients	T101	C0030705
27694780	480	489	increases	T169	C0442805
27694780	494	510	risk of bleeding	T033	C3251812
27694780	531	547	dental treatment	T061	C0011331
27694780	589	609	bibliographic search	UnknownType	C0260071
27694780	613	619	PubMed	T170	C1138432
27694780	622	629	Medline	T170	C0025141
27694780	645	661	Cochrane Library	T073,T093	C0023625
27694780	701	715	anticoagulants	T121	C0003280
27694780	727	737	dabigatran	T109,T121	C2348066
27694780	755	774	surgical treatments	T061	C0543467
27694780	778	798	anatomical locations	T029	C0923870
27694780	814	825	oral cavity	T030	C0226896
27694780	877	902	randomized clinical trial	T062,T170	C0206034
27694780	906	934	narrative literature reviews	UnknownType	C0815257
27694780	938	949	case series	T062	C0150093
27694780	953	967	clinical cases	T077	C1706256
27694780	974	988	expert opinion	T077	C0600219
27694780	1038	1053	clinical trials	T062	C0008976
27694780	1083	1096	meta-analysis	T062	C0920317
27694780	1121	1130	consensus	T054	C0376298
27694780	1138	1147	procedure	T061	C0543467
27694780	1166	1174	patients	T101	C0030705
27694780	1182	1192	dabigatran	T109,T121	C2348066
27694780	1274	1278	risk	T078	C0035647
27694780	1282	1290	embolism	T046	C0013922
27694780	1292	1314	postoperative bleeding	T046	C0032788
27694780	1319	1333	renal function	T042	C0232804
27694780	1378	1400	invasive interventions	T061	C4048276
27694780	1433	1456	anti-hemolytic measures	T061	C0199176

28146402|t|A Multicenter Study of Early Anti-inflammatory Treatment in Patients With Acute Anterior Cruciate Ligament Tear
28146402|a|It is increasingly recognized that biochemical abnormalities of the joint precede radiographic abnormalities of posttraumatic osteoarthritis (PTOA) by as much as decades. A growing body of evidence strongly suggests that the progression from anterior cruciate ligament (ACL) injury to PTOA is multifactorial, involving the interplay between biomechanical disturbances and biochemical homeostasis of articular cartilage. The purposes of this randomized study using an acute ACL injury model were to (1) evaluate the natural progression of inflammatory and chondrodegenerative biomarkers, (2) evaluate the relationship between subjective reports of pain and inflammatory and chondrodegenerative biomarkers, and (3) determine if postinjury arthrocentesis and corticosteroid injection offer the ability to alter this biochemical cascade. Randomized controlled trial; Level of evidence, 2. A total of 49 patients were randomized to 4 groups: group 1 (corticosteroid at 4 days after ACL injury, placebo injection of saline at 2 weeks), group 2 (placebo at 4 days after ACL injury, corticosteroid at 2 weeks), group 3 (corticosteroid at both time intervals), or a placebo group (saline injections at both time intervals). Patient-reported outcome measures and synovial biomarkers were collected at approximately 4 days, 11 days, and 5 weeks after injury. The change between the time points was assessed for all variables using Wilcoxon tests, and the relationship between changes in outcome scores and biomarkers were assessed by calculating Spearman ρ. Outcomes and biomarkers were also compared between the 4 groups using Kruskal-Wallis tests. No adverse events or infections were observed in any study patients. With the exception of matrix metalloproteinase 1 (MMP-1) and tumor necrosis factor-inducible gene 6 (TSG-6), chondrodegenerative markers worsened over the first 5 weeks while all patient-reported outcomes improved during this time, regardless of treatment group. Patient-reported outcomes did not differ between patients receiving corticosteroid injections and the placebo group. However, increases in C-telopeptide of type II collagen (CTX-II), associated with collagen type II breakdown, were significantly greater in the placebo group (1.32 ± 1.10 ng/mL) than in either of the groups that received the corticosteroid injection within the first several days after injury (group 1: 0.23 ± 0.27 ng/mL [P = .01]; group 3: 0.19 ± 0.34 ng/mL [P = .01]). PTOA begins at the time of injury and results early on in dramatic matrix changes in the knee. However, it is encouraging that early intervention with an anti-inflammatory agent was able to affect biomarkers of chondral degeneration. Should early intervention lead to meaningful changes in either the onset or severity of symptomatic PTOA, the current treatment paradigm for patients with ACL injury may have to be restructured to include early aspiration and intra-articular intervention. ClinicalTrials.gov identifier: NCT01692756.
28146402	2	19	Multicenter Study	T062	C1096776
28146402	23	28	Early	T079	C1279919
28146402	29	46	Anti-inflammatory	T121	C0003209
28146402	47	56	Treatment	T169	C0039798
28146402	60	68	Patients	T101	C0030705
28146402	74	111	Acute Anterior Cruciate Ligament Tear	T037	C2584975
28146402	147	158	biochemical	T169	C0205474
28146402	159	172	abnormalities	T020	C0221430
28146402	180	185	joint	T030	C0022417
28146402	194	220	radiographic abnormalities	T033	C1704258
28146402	224	252	posttraumatic osteoarthritis	T046	C2894027
28146402	254	258	PTOA	T046	C2894027
28146402	337	348	progression	T046	C0242656
28146402	354	393	anterior cruciate ligament (ACL) injury	T037	C2584975
28146402	397	401	PTOA	T046	C2894027
28146402	405	419	multifactorial	T033	C1837655
28146402	453	479	biomechanical disturbances	T080	C2699787
28146402	484	495	biochemical	T169	C0205474
28146402	496	507	homeostasis	T038	C0019868
28146402	511	530	articular cartilage	T024	C0007303
28146402	553	569	randomized study	T062	C0242481
28146402	579	595	acute ACL injury	T037	C2584975
28146402	596	601	model	T075	C0026336
28146402	627	634	natural	T169	C0205296
28146402	635	646	progression	T169	C0449258
28146402	650	662	inflammatory	T201	C0005516
28146402	667	697	chondrodegenerative biomarkers	T201	C0005516
28146402	716	728	relationship	T080	C0439849
28146402	737	755	subjective reports	T170	C0684224
28146402	759	763	pain	T184	C0030193
28146402	768	780	inflammatory	T201	C0005516
28146402	785	815	chondrodegenerative biomarkers	T201	C0005516
28146402	838	863	postinjury arthrocentesis	T061	C0204854
28146402	868	882	corticosteroid	T121	C3536709
28146402	883	892	injection	T061	C0021485
28146402	925	944	biochemical cascade	T044	C1704259
28146402	946	973	Randomized controlled trial	T062	C0206035
28146402	975	980	Level	T080	C0441889
28146402	984	992	evidence	T078	C3887511
28146402	1011	1019	patients	T101	C0030705
28146402	1025	1035	randomized	T062	C0034656
28146402	1041	1047	groups	T078	C0441833
28146402	1049	1056	group 1	T170	C0441861
28146402	1058	1072	corticosteroid	T121	C3536709
28146402	1078	1082	days	T079	C0439228
28146402	1089	1099	ACL injury	T037	C2584975
28146402	1101	1108	placebo	T122	C1696465
28146402	1109	1118	injection	T061	C1533685
28146402	1122	1128	saline	T167	C0036082
28146402	1134	1139	weeks	T079	C0439230
28146402	1142	1149	group 2	T170	C0441865
28146402	1151	1158	placebo	T122	C1696465
28146402	1164	1168	days	T079	C0439228
28146402	1175	1185	ACL injury	T037	C2584975
28146402	1187	1201	corticosteroid	T121	C3536709
28146402	1207	1212	weeks	T079	C0439230
28146402	1215	1222	group 3	T170	C0441869
28146402	1224	1238	corticosteroid	T121	C3536709
28146402	1247	1261	time intervals	T079	C0872291
28146402	1269	1276	placebo	T122	C1696465
28146402	1277	1282	group	T078	C0441833
28146402	1284	1290	saline	T167	C0036082
28146402	1291	1301	injections	T061	C1533685
28146402	1310	1324	time intervals	T079	C0872291
28146402	1327	1360	Patient-reported outcome measures	T058	C4277735
28146402	1365	1373	synovial	T023	C1550315
28146402	1374	1384	biomarkers	T201	C0005516
28146402	1419	1423	days	T079	C0439228
28146402	1428	1432	days	T079	C0439228
28146402	1440	1445	weeks	T079	C0439230
28146402	1452	1458	injury	T037	C3263723
28146402	1464	1470	change	T169	C0392747
28146402	1483	1494	time points	T079	C0439547
28146402	1499	1507	assessed	T052	C1516048
28146402	1516	1525	variables	T080	C0439828
28146402	1532	1546	Wilcoxon tests	T170	C0871608
28146402	1556	1568	relationship	T080	C0439849
28146402	1577	1584	changes	T169	C0392747
28146402	1588	1602	outcome scores	T033	C4274403
28146402	1607	1617	biomarkers	T201	C0005516
28146402	1623	1631	assessed	T052	C1516048
28146402	1647	1657	Spearman ρ	T062,T170	C0872006
28146402	1659	1667	Outcomes	T080	C0085415
28146402	1672	1682	biomarkers	T201	C0005516
28146402	1716	1722	groups	T078	C0441833
28146402	1729	1749	Kruskal-Wallis tests	T170	C1708614
28146402	1751	1768	No adverse events	T033	C1963761
28146402	1772	1782	infections	T046	C3714514
28146402	1804	1809	study	T062	C2603343
28146402	1810	1818	patients	T101	C0030705
28146402	1842	1868	matrix metalloproteinase 1	T116,T126	C0127082
28146402	1870	1875	MMP-1	T116,T126	C0127082
28146402	1881	1919	tumor necrosis factor-inducible gene 6	T116,T123	C0033684
28146402	1921	1926	TSG-6	T116,T123	C0033684
28146402	1929	1956	chondrodegenerative markers	T201	C0005516
28146402	1983	1988	weeks	T079	C0439230
28146402	1999	2024	patient-reported outcomes	T170	C2987124
28146402	2046	2050	time	T079	C0040223
28146402	2066	2075	treatment	T169	C0039798
28146402	2076	2081	group	T078	C0441833
28146402	2083	2108	Patient-reported outcomes	T170	C2987124
28146402	2132	2140	patients	T101	C0030705
28146402	2141	2150	receiving	T080	C1514756
28146402	2151	2165	corticosteroid	T121	C3536709
28146402	2166	2176	injections	T061	C0021485
28146402	2185	2192	placebo	T122	C1696465
28146402	2193	2198	group	T078	C0441833
28146402	2209	2218	increases	T169	C0442805
28146402	2222	2255	C-telopeptide of type II collagen	T116,T123	C3849640
28146402	2257	2263	CTX-II	T116,T123	C3849640
28146402	2266	2281	associated with	T080	C0332281
28146402	2282	2298	collagen type II	T116,T123	C0009331
28146402	2299	2308	breakdown	T044	C1157968
28146402	2344	2351	placebo	T122	C1696465
28146402	2352	2357	group	T078	C0441833
28146402	2400	2406	groups	T078	C0441833
28146402	2412	2420	received	T080	C1514756
28146402	2425	2439	corticosteroid	T121	C3536709
28146402	2440	2449	injection	T061	C0021485
28146402	2475	2479	days	T079	C0439228
28146402	2486	2492	injury	T037	C3263723
28146402	2494	2501	group 1	T170	C0441861
28146402	2532	2539	group 3	T170	C0441869
28146402	2571	2575	PTOA	T046	C2894027
28146402	2590	2594	time	T079	C0040223
28146402	2598	2604	injury	T037	C3263723
28146402	2617	2622	early	T079	C1279919
28146402	2638	2644	matrix	T024	C0005962
28146402	2645	2652	changes	T169	C0392747
28146402	2660	2664	knee	T023	C0022742
28146402	2698	2703	early	T079	C1279919
28146402	2704	2716	intervention	T061	C0184661
28146402	2725	2748	anti-inflammatory agent	T121	C0003209
28146402	2768	2778	biomarkers	T201	C0005516
28146402	2782	2803	chondral degeneration	T169	C1880269
28146402	2812	2817	early	T079	C1279919
28146402	2818	2830	intervention	T061	C0184661
28146402	2850	2857	changes	T169	C0392747
28146402	2872	2877	onset	T080	C0332162
28146402	2881	2889	severity	T080	C0439793
28146402	2893	2904	symptomatic	T169	C0231220
28146402	2905	2909	PTOA	T046	C2894027
28146402	2923	2932	treatment	T169	C0039798
28146402	2946	2954	patients	T101	C0030705
28146402	2960	2970	ACL injury	T037	C2584975
28146402	3010	3015	early	T079	C1279919
28146402	3016	3026	aspiration	T061	C0349707
28146402	3031	3046	intra-articular	T169	C1522204
28146402	3047	3059	intervention	T061	C0184661

28460030|t|Subcutaneous cardioverter defibrillator has longer time to therapy but is less cardiotoxic than transvenous cardioverter defibrillator. Study carried out in a preclinical porcine model
28460030|a|Totally subcutaneous implantable cardioverter defibrillator (S-ICD) delivers higher shock energy and can have longer time to therapy compared to transvenous implantable cardioverter defibrillator (T-ICD). Aim of the study was to compare time to therapy and to investigate cardiac, cerebral and systemic injuries of S-ICD and T-ICD shocks delivered after ventricular fibrillation (VF) induction. Fourteen pigs were randomly implanted with a S-ICD (n = 7) or a T-ICD (n = 7). Five VF episodes were induced in each pig. For each VF episode, up to two shocks could be delivered by the T-ICD or the S-ICD to terminate the arrhythmia. Cardiac, systemic, and cerebral toxicity were monitored. Mean time to therapy was longer in the S-ICD group compared to the T-ICD group (19[18; 23] s vs. 9 [7; 10] s; P = 0.001, respectively). High-sensitivity troponin T levels were significantly higher in the T-ICD group from 1 to 24 h after the procedure (P ≤ 0.02). Creatine phosphokinase activity levels were significantly higher in the S-ICD group, at 3, 6, and 24 h after the procedure (P ≤ 0.05). Lactate levels were not significantly different between groups. S100 protein level was similar in both groups at 1 h after the procedure and then decreased in the T-ICD group compared to the S-ICD group (P = 0.04). Time to therapy in S-ICD was twice as long as for T-ICD, but didn't induce relevant brain injury. Conversely, S-ICD shocks were less cardiotoxic than T-ICD shocks.
28460030	0	39	Subcutaneous cardioverter defibrillator	T074	C3694431
28460030	44	50	longer	T080	C0205166
28460030	51	55	time	T079	C0040223
28460030	59	66	therapy	T061	C0087111
28460030	79	90	cardiotoxic	T037	C0876994
28460030	96	134	transvenous cardioverter defibrillator	T074	C0810516
28460030	136	141	Study	T062	C2603343
28460030	159	170	preclinical	T080	C1709630
28460030	193	244	subcutaneous implantable cardioverter defibrillator	T074	C3694431
28460030	246	251	S-ICD	T074	C3694431
28460030	262	281	higher shock energy	T033	C1536257
28460030	295	301	longer	T080	C0205166
28460030	302	306	time	T079	C0040223
28460030	310	317	therapy	T061	C0087111
28460030	318	326	compared	T052	C1707455
28460030	330	380	transvenous implantable cardioverter defibrillator	T074	C0810516
28460030	382	387	T-ICD	T074	C0810516
28460030	401	406	study	T062	C2603343
28460030	414	421	compare	T052	C1707455
28460030	422	426	time	T079	C0040223
28460030	430	437	therapy	T061	C0087111
28460030	445	456	investigate	T169	C1292732
28460030	457	464	cardiac	T037	C0178314
28460030	466	474	cerebral	T037	C0270611
28460030	479	496	systemic injuries	T037	C0178314
28460030	500	505	S-ICD	T074	C3694431
28460030	510	515	T-ICD	T074	C0810516
28460030	516	522	shocks	T033	C1536257
28460030	539	563	ventricular fibrillation	T047	C0042510
28460030	565	567	VF	T047	C0042510
28460030	569	578	induction	T169	C0205263
28460030	589	593	pigs	T015	C3665571
28460030	599	607	randomly	T080	C0439605
28460030	608	617	implanted	T033	C2828363
28460030	625	630	S-ICD	T074	C3694431
28460030	644	649	T-ICD	T074	C0810516
28460030	664	666	VF	T047	C0042510
28460030	697	700	pig	T015	C3665571
28460030	711	713	VF	T047	C0042510
28460030	733	739	shocks	T033	C1536257
28460030	766	771	T-ICD	T074	C0810516
28460030	779	784	S-ICD	T074	C3694431
28460030	802	812	arrhythmia	T033	C0003811
28460030	814	821	Cardiac	T037	C0876994
28460030	823	831	systemic	T037	C0600688
28460030	837	854	cerebral toxicity	T037	C0270611
28460030	876	880	time	T079	C0040223
28460030	884	891	therapy	T061	C0087111
28460030	896	902	longer	T080	C0205166
28460030	910	915	S-ICD	T074	C3694431
28460030	916	921	group	T078	C0441833
28460030	922	930	compared	T052	C1707455
28460030	938	943	T-ICD	T074	C0810516
28460030	944	949	group	T078	C0441833
28460030	1007	1034	High-sensitivity troponin T	T059	C3827339
28460030	1035	1041	levels	T080	C0441889
28460030	1075	1080	T-ICD	T074	C0810516
28460030	1081	1086	group	T078	C0441833
28460030	1100	1101	h	T079	C0439227
28460030	1112	1121	procedure	T061	C0087111
28460030	1134	1165	Creatine phosphokinase activity	T044	C1150462
28460030	1166	1172	levels	T080	C0441889
28460030	1206	1211	S-ICD	T074	C3694431
28460030	1212	1217	group	T078	C0441833
28460030	1235	1236	h	T079	C0439227
28460030	1247	1256	procedure	T061	C0087111
28460030	1269	1283	Lactate levels	T034	C1304767
28460030	1325	1331	groups	T078	C0441833
28460030	1333	1345	S100 protein	T116,T123	C0027758
28460030	1372	1378	groups	T078	C0441833
28460030	1384	1385	h	T079	C0439227
28460030	1396	1405	procedure	T061	C0087111
28460030	1432	1437	T-ICD	T074	C0810516
28460030	1438	1443	group	T078	C0441833
28460030	1444	1452	compared	T052	C1707455
28460030	1460	1465	S-ICD	T074	C3694431
28460030	1466	1471	group	T078	C0441833
28460030	1492	1499	therapy	T061	C0087111
28460030	1503	1508	S-ICD	T074	C3694431
28460030	1534	1539	T-ICD	T074	C0810516
28460030	1568	1580	brain injury	T037	C0270611
28460030	1594	1599	S-ICD	T074	C3694431
28460030	1600	1606	shocks	T033	C1536257
28460030	1617	1628	cardiotoxic	T037	C0876994
28460030	1634	1639	T-ICD	T074	C0810516
28460030	1640	1646	shocks	T033	C1536257

28464071|t|Chemical composition and amino acid digestibility of soybean meal produced in the United States, China, Argentina, Brazil, or India
28464071|a|An experiment was conducted to compare nutritional composition of soybean meal (SBM) produced in China, Argentina, Brazil, the U.S ., or India and the apparent ileal digestibility (AID) and the standardized ileal digestibility (SID) of CP and AA in these SBM when fed to growing pigs. Five sources of SBM from China, Argentina, Brazil, and the U.S ., and 4 sources from India were collected for a total of 24 sources of SBM. All samples were analyzed for energy, DM, and nutrients, and each source was included in a cornstarch based diet in which SBM was the only AA contributing ingredient. An N-free diet was also formulated. Twenty-five barrows (initial BW: 30.53 ± 1.73 kg) were equipped with a T-cannula in the distal ileum and randomly allotted to a 25 × 8 Youden square design with 25 diets and 8 periods. Results indicate that the concentration of CP was greater (< 0.05) in SBM from Brazil and India (49.3 and 49.5%, respectively) than in SBM from China, Argentina, or the U.S. (45.1, 46.7, and 47.3%, respectively, as-fed basis). The concentration of most indispensable AA followed the same pattern as CP with the exception that SBM from the U.S. contained more (< 0.05) indispensable AA than SBM from China or Argentina. However, SBM from India contained more (< 0.05) trypsin inhibitors than SBM from the other countries. A greater (< 0.05) AID and SID of CP and most AA was observed in SBM from the U.S. compared with SBM from Brazil, Argentina, and India, but there were no differences between SBM from the U.S. and SBM from China. However, because of the lower concentration of AA in SBM from China, the concentration of standardized ileal digestible AA in SBM from China was less (< 0.05) than in SBM from the U.S. Soybean meal from the U.S. or Brazil had less (< 0.05) variability in SID values than SBM from Argentina, China, or India. In conclusion, the SID of CP and AA is dependent on the country where the SBM is produced. This difference and the variability within each country should be evaluated when formulating diets for pigs.
28464071	0	20	Chemical composition	T070	C0243176
28464071	25	35	amino acid	T116,T121,T123	C0002520
28464071	36	49	digestibility	T081	C0392762
28464071	53	65	soybean meal	T168	C0037733
28464071	82	95	United States	T083	C0041703
28464071	97	102	China	T083	C0008115
28464071	104	113	Argentina	T083	C0003761
28464071	115	121	Brazil	T083	C0006137
28464071	126	131	India	T083	C0021201
28464071	171	182	nutritional	T080	C1521739
28464071	183	194	composition	T070	C0243176
28464071	198	210	soybean meal	T168	C0037733
28464071	212	215	SBM	T168	C0037733
28464071	229	234	China	T083	C0008115
28464071	236	245	Argentina	T083	C0003761
28464071	247	253	Brazil	T083	C0006137
28464071	259	262	U.S	T083	C0041703
28464071	269	274	India	T083	C0021201
28464071	283	311	apparent ileal digestibility	T081	C0392762
28464071	313	316	AID	T081	C0392762
28464071	326	358	standardized ileal digestibility	T081	C0392762
28464071	360	363	SID	T081	C0392762
28464071	368	370	CP	T116,T123	C0033684
28464071	375	377	AA	T116,T121,T123	C0002520
28464071	387	390	SBM	T168	C0037733
28464071	411	415	pigs	T015	C0039005
28464071	433	436	SBM	T168	C0037733
28464071	442	447	China	T083	C0008115
28464071	449	458	Argentina	T083	C0003761
28464071	460	466	Brazil	T083	C0006137
28464071	476	479	U.S	T083	C0041703
28464071	502	507	India	T083	C0021201
28464071	552	555	SBM	T168	C0037733
28464071	587	593	energy	T081	C1442080
28464071	595	597	DM	T167	C1720884
28464071	603	612	nutrients	T168	C0678695
28464071	648	669	cornstarch based diet	T109,T121	C1384515
28464071	679	682	SBM	T168	C0037733
28464071	696	698	AA	T116,T121,T123	C0002520
28464071	712	722	ingredient	T120	C1550600
28464071	727	738	N-free diet	T168	C0012155
28464071	848	860	distal ileum	T029	C0227327
28464071	895	915	Youden square design	T062	C0035171
28464071	924	929	diets	T168	C0012155
28464071	936	943	periods	T079	C1948053
28464071	971	984	concentration	T081	C0457929
28464071	988	990	CP	T116,T123	C0033684
28464071	1015	1018	SBM	T168	C0037733
28464071	1024	1030	Brazil	T083	C0006137
28464071	1035	1040	India	T083	C0021201
28464071	1080	1083	SBM	T168	C0037733
28464071	1089	1094	China	T083	C0008115
28464071	1096	1105	Argentina	T083	C0003761
28464071	1114	1117	U.S	T083	C0041703
28464071	1176	1189	concentration	T081	C0457929
28464071	1212	1214	AA	T116,T121,T123	C0002520
28464071	1244	1246	CP	T116,T123	C0033684
28464071	1271	1274	SBM	T168	C0037733
28464071	1284	1287	U.S	T083	C0041703
28464071	1327	1329	AA	T116,T121,T123	C0002520
28464071	1335	1338	SBM	T168	C0037733
28464071	1344	1349	China	T083	C0008115
28464071	1353	1362	Argentina	T083	C0003761
28464071	1373	1376	SBM	T168	C0037733
28464071	1382	1387	India	T083	C0021201
28464071	1412	1430	trypsin inhibitors	T116,T121,T123	C0041242
28464071	1436	1439	SBM	T168	C0037733
28464071	1455	1464	countries	T083	C0454664
28464071	1485	1488	AID	T081	C0392762
28464071	1493	1496	SID	T081	C0392762
28464071	1500	1502	CP	T116,T123	C0033684
28464071	1512	1514	AA	T116,T121,T123	C0002520
28464071	1531	1534	SBM	T168	C0037733
28464071	1544	1547	U.S	T083	C0041703
28464071	1563	1566	SBM	T168	C0037733
28464071	1572	1578	Brazil	T083	C0006137
28464071	1580	1589	Argentina	T083	C0003761
28464071	1595	1600	India	T083	C0021201
28464071	1640	1643	SBM	T168	C0037733
28464071	1653	1656	U.S	T083	C0041703
28464071	1662	1665	SBM	T168	C0037733
28464071	1671	1676	China	T083	C0008115
28464071	1708	1721	concentration	T081	C0457929
28464071	1725	1727	AA	T116,T121,T123	C0002520
28464071	1731	1734	SBM	T168	C0037733
28464071	1740	1745	China	T083	C0008115
28464071	1751	1764	concentration	T081	C0457929
28464071	1768	1797	standardized ileal digestible	T081	C0392762
28464071	1798	1800	AA	T116,T121,T123	C0002520
28464071	1804	1807	SBM	T168	C0037733
28464071	1813	1818	China	T083	C0008115
28464071	1845	1848	SBM	T168	C0037733
28464071	1858	1861	U.S	T083	C0041703
28464071	1885	1888	U.S	T083	C0041703
28464071	1893	1899	Brazil	T083	C0006137
28464071	1933	1936	SID	T081	C0392762
28464071	1949	1952	SBM	T168	C0037733
28464071	1958	1967	Argentina	T083	C0003761
28464071	1969	1974	China	T083	C0008115
28464071	1979	1984	India	T083	C0021201
28464071	2005	2008	SID	T081	C0392762
28464071	2012	2014	CP	T116,T123	C0033684
28464071	2019	2021	AA	T116,T121,T123	C0002520
28464071	2042	2049	country	T083	C0454664
28464071	2060	2063	SBM	T168	C0037733
28464071	2125	2132	country	T083	C0454664
28464071	2158	2175	formulating diets	T061	C0012164
28464071	2180	2184	pigs	T015	C0039005

28058593|t|Ceftaroline fosamil for community-acquired pneumonia and skin and skin structure infections: a systematic review
28058593|a|Background Ceftaroline is a parentally administered cephalosporin that has an in vitro expanded spectrum of activity compared with other cephalosporins yet data is conflicting regarding its place in therapy. Aim of the Review To compare the efficacy and safety of ceftaroline against standard antibiotic regimens for community-acquired pneumonia (CAP) and complicated skin and skin structure infections (cSSSIs). Method The databases of MEDLINE, EBSCO, and Embase were searched up to June 2016. Manual review of references was completed and experts in the field were contacted for unpublished data. Randomized controlled trials of ceftaroline in CAP or cSSSI populations were included. Outcomes included clinical cure, mortality, adverse events, serious adverse events, and discontinuation due to adverse events. Meta-analysis was used to pool results for these outcomes. We performed subgroup analyses for gram positive infections in CAP and infections caused by methicillin-resistant Staphylococcus aureus in cSSSIs. Risk of bias was assessed for all studies. Results Six trials (three for each indication) were included, each of which had an unclear or high risk of bias in at least one domain. For CAP, ceftaroline was significantly more efficacious in achieving clinical cure than ceftriaxone [risk ratio (RR) 1.11, 95% confidence interval (CI) 1.04-1.19; I(2) = 47%]. For cSSSIs, there was no significant difference in clinical cure between ceftaroline and vancomycin plus aztreonam (RR 1.01, 95% CI 0.97-1.05; I(2) = 0%). No differences were found for overall mortality, serious adverse events, discontinuation due to adverse events, and overall adverse events. Conclusion Ceftaroline is a viable therapeutic alternative for patients with CAP and cSSSIs, yet identified risks of bias and poor external validity preclude it from being recommended as a first-line agent.
28058593	0	19	Ceftaroline fosamil	T109,T195	C2001525
28058593	24	52	community-acquired pneumonia	T047	C0694549
28058593	57	61	skin	T022	C1123023
28058593	66	91	skin structure infections	T046	C3714514
28058593	95	112	systematic review	T170	C1955832
28058593	124	135	Ceftaroline	T109,T195	C2001525
28058593	152	164	administered	T169	C1621583
28058593	165	178	cephalosporin	T109,T195	C3536856
28058593	191	199	in vitro	T080	C1533691
28058593	200	208	expanded	T082	C0205229
28058593	221	229	activity	T044	C1321418
28058593	230	238	compared	T052	C1707455
28058593	250	264	cephalosporins	T109,T195	C3536856
28058593	269	273	data	T078	C1511726
28058593	312	319	therapy	T061	C0087111
28058593	332	338	Review	T170	C1955832
28058593	342	349	compare	T052	C1707455
28058593	354	362	efficacy	T080	C1280519
28058593	367	373	safety	T068	C0036043
28058593	377	388	ceftaroline	T109,T195	C2001525
28058593	406	416	antibiotic	T195	C0003232
28058593	417	425	regimens	T061	C0040808
28058593	430	458	community-acquired pneumonia	T047	C0694549
28058593	460	463	CAP	T047	C0694549
28058593	469	515	complicated skin and skin structure infections	T046	C3714514
28058593	517	523	cSSSIs	T046	C3714514
28058593	537	546	databases	T170	C0242356
28058593	550	557	MEDLINE	T170	C0025141
28058593	559	564	EBSCO	T170	C0242356
28058593	570	576	Embase	T170	C0242356
28058593	608	649	Manual review of references was completed	T170	C3259354
28058593	654	661	experts	T097	C1522486
28058593	694	710	unpublished data	T170	C0887929
28058593	712	740	Randomized controlled trials	T062	C0206035
28058593	744	755	ceftaroline	T109,T195	C2001525
28058593	759	762	CAP	T047	C0694549
28058593	766	771	cSSSI	T046	C3714514
28058593	772	783	populations	T098	C1257890
28058593	799	807	Outcomes	T169	C1274040
28058593	817	830	clinical cure	T033	C3640840
28058593	832	841	mortality	T081	C0205848
28058593	843	857	adverse events	T046	C0877248
28058593	859	881	serious adverse events	T033	C1519255
28058593	887	902	discontinuation	T061	C4288399
28058593	910	924	adverse events	T046	C0877248
28058593	926	939	Meta-analysis	T170	C0282458
28058593	975	983	outcomes	T169	C1274040
28058593	998	1006	subgroup	T185	C1515021
28058593	1007	1015	analyses	T062	C0936012
28058593	1020	1044	gram positive infections	T047	C0085426
28058593	1048	1051	CAP	T047	C0694549
28058593	1056	1066	infections	T046	C3714514
28058593	1077	1120	methicillin-resistant Staphylococcus aureus	T007	C1265292
28058593	1124	1130	cSSSIs	T046	C3714514
28058593	1132	1136	Risk	T078	C0035647
28058593	1140	1144	bias	T078	C0242568
28058593	1166	1173	studies	T062	C2603343
28058593	1187	1193	trials	T062	C0681815
28058593	1274	1278	risk	T078	C0035647
28058593	1282	1286	bias	T078	C0242568
28058593	1315	1318	CAP	T047	C0694549
28058593	1320	1331	ceftaroline	T109,T195	C2001525
28058593	1355	1366	efficacious	T080	C1280519
28058593	1380	1393	clinical cure	T033	C3640840
28058593	1399	1410	ceftriaxone	T109,T195	C0007561
28058593	1412	1422	risk ratio	T081	C0242492
28058593	1424	1426	RR	T081	C0242492
28058593	1438	1457	confidence interval	T081	C0009667
28058593	1459	1461	CI	T081	C0009667
28058593	1491	1497	cSSSIs	T046	C3714514
28058593	1538	1551	clinical cure	T033	C3640840
28058593	1560	1571	ceftaroline	T109,T195	C2001525
28058593	1576	1586	vancomycin	T116,T195	C0042313
28058593	1592	1601	aztreonam	T109,T195	C0004521
28058593	1603	1605	RR	T081	C0242492
28058593	1616	1618	CI	T081	C0009667
28058593	1680	1689	mortality	T081	C0205848
28058593	1691	1713	serious adverse events	T033	C1519255
28058593	1715	1730	discontinuation	T061	C4288399
28058593	1738	1752	adverse events	T046	C0877248
28058593	1766	1780	adverse events	T046	C0877248
28058593	1793	1804	Ceftaroline	T109,T195	C2001525
28058593	1817	1840	therapeutic alternative	T061	C0949216
28058593	1845	1853	patients	T101	C0030705
28058593	1859	1862	CAP	T047	C0694549
28058593	1867	1873	cSSSIs	T046	C3714514
28058593	1890	1895	risks	T078	C0035647
28058593	1899	1903	bias	T078	C0242568
28058593	1908	1930	poor external validity	T033	C2924039
28058593	1971	1987	first-line agent	T195	C0003232

27688320|t|Draft Genome Sequence of Salmonella enterica subsp. enterica Serovar Orion Strain CRJJGF_00093 (Phylum Gammaproteobacteria)
27688320|a|Here, we report a 4.70-Mbp draft genome sequence of Salmonella enterica subsp. enterica serovar Orion strain CRJJGF_00093, isolated from a dog in 2005.
27688320	0	21	Draft Genome Sequence	T086	C0162326
27688320	25	94	Salmonella enterica subsp. enterica Serovar Orion Strain CRJJGF_00093	T007	C1275777
27688320	96	102	Phylum	T185	C1709533
27688320	103	122	Gammaproteobacteria	T007	C0751988
27688320	133	139	report	T170	C0684224
27688320	151	172	draft genome sequence	T086	C0162326
27688320	176	245	Salmonella enterica subsp. enterica serovar Orion strain CRJJGF_00093	T007	C1275777
27688320	247	255	isolated	T169	C0205409
27688320	263	266	dog	T015	C0012984

28258403|t|Structural properties and psychometric improvements of the Health Literacy Questionnaire in a Slovak population
28258403|a|Health literacy is an important determinant of health and health equity and therefore requires robust measurement. The aim was to examine the psychometric properties of the Slovak version of the Health Literacy Questionnaire (HLQ) including revised wording of response categories. A cross-sectional survey of the general Slovak adult population (N = 360, mean age 39) was conducted with the HLQ following its translation and cultural adaptation. Psychometric tests (confirmatory factor analysis, Cronbach's alpha, composite reliability) and association (linear regression, ANOVA) with sociodemographic variables were undertaken. The performance of alternative version of response options were explored with the Mann-Whittney U test and item response theory. A highly restrictive nine-factor confirmatory factor analysis showed acceptable fit [χ (2)WLSMV = 1684 (df = 866), p < 0.0001; CFI = 0.943, TLI = 0.938, RMSEA = 0.051, WRMR = 1.297] and reliability was acceptable (range 0.73-0.84). The revised response categories had a better distribution with lower average scores in three domains, compared with the original, and improved item information curves. The nine HLQ scales are robust, providing a fine-grained assessment of health literacy. The revised response options improve psychometric properties and are recommended for future studies.
28258403	0	10	Structural	T082	C0678594
28258403	11	21	properties	T080	C0871161
28258403	26	38	psychometric	T060	C0033920
28258403	39	51	improvements	T077	C2986411
28258403	59	88	Health Literacy Questionnaire	T170	C0034394
28258403	94	100	Slovak	T098	C0337822
28258403	101	111	population	T098	C1257890
28258403	112	127	Health literacy	T065	C2362527
28258403	144	155	determinant	T169	C1521761
28258403	159	165	health	T078	C0018684
28258403	170	183	health equity	T080	C4042901
28258403	207	213	robust	T080	C2986815
28258403	214	225	measurement	T169	C0242485
28258403	254	266	psychometric	T060	C0033920
28258403	267	277	properties	T080	C0871161
28258403	285	291	Slovak	T083	C0206579
28258403	292	299	version	T170	C0333052
28258403	307	336	Health Literacy Questionnaire	T170	C0034394
28258403	338	341	HLQ	T170	C0034394
28258403	353	368	revised wording	T169	C0392747
28258403	372	391	response categories	T041	C2911692
28258403	395	417	cross-sectional survey	T062	C0010362
28258403	433	439	Slovak	T098	C0337822
28258403	440	456	adult population	T098	C1257890
28258403	484	493	conducted	T169	C0884358
28258403	503	506	HLQ	T170	C0034394
28258403	507	516	following	T079	C0332282
28258403	521	532	translation	T170	C0040712
28258403	537	556	cultural adaptation	UnknownType	C0680439
28258403	558	570	Psychometric	T060	C0033920
28258403	571	576	tests	T170	C0392366
28258403	578	606	confirmatory factor analysis	T080	C0870334
28258403	608	624	Cronbach's alpha	T170	C0392366
28258403	626	647	composite reliability	T170	C0392366
28258403	653	664	association	T080	C0439849
28258403	666	683	linear regression	T081	C0023733
28258403	685	690	ANOVA	T081	C0002780
28258403	697	723	sociodemographic variables	T080	C0439828
28258403	745	756	performance	T052	C1882330
28258403	760	779	alternative version	T170	C0333052
28258403	783	791	response	T032	C0871261
28258403	792	799	options	T169	C1518601
28258403	823	843	Mann-Whittney U test	T081	C0242927
28258403	848	868	item response theory	T062,T170	C0870753
28258403	872	878	highly	T080	C0205250
28258403	879	890	restrictive	T033	C1704513
28258403	903	931	confirmatory factor analysis	T080	C0870334
28258403	939	949	acceptable	T080	C1879533
28258403	950	953	fit	T052	C2349186
28258403	997	1000	CFI	T080	C0870334
28258403	1010	1013	TLI	T170	C0918012
28258403	1023	1028	RMSEA	T081	C0392762
28258403	1038	1042	WRMR	T081	C0392762
28258403	1056	1067	reliability	T081	C2347947
28258403	1072	1082	acceptable	T080	C1879533
28258403	1084	1089	range	T081	C1514721
28258403	1106	1113	revised	T169	C0392747
28258403	1114	1133	response categories	T041	C2911692
28258403	1140	1146	better	T080	C0332272
28258403	1147	1159	distribution	T169	C1704711
28258403	1165	1170	lower	T080	C0205251
28258403	1171	1185	average scores	T081	C0449820
28258403	1204	1212	compared	T052	C1707455
28258403	1236	1244	improved	T033	C0184511
28258403	1245	1249	item	T071	C1551338
28258403	1250	1268	information curves	T078	C1533716
28258403	1279	1282	HLQ	T170	C0034394
28258403	1283	1289	scales	T170	C0349674
28258403	1294	1300	robust	T080	C2986815
28258403	1327	1337	assessment	T058	C0220825
28258403	1341	1356	health literacy	T065	C2362527
28258403	1362	1369	revised	T169	C0392747
28258403	1370	1378	response	T032	C0871261
28258403	1379	1386	options	T169	C1518601
28258403	1387	1394	improve	T033	C0184511
28258403	1395	1407	psychometric	T060	C0033920
28258403	1408	1418	properties	T080	C0871161
28258403	1427	1438	recommended	T078	C0034866
28258403	1443	1449	future	T079	C0016884
28258403	1450	1457	studies	T062	C2603343

27371819|t|The nurse-patient communication: voices from nursing students
27371819|a|Effective communication skills have been found to be one of the pivotal factors in building positive interpersonal relationships. Little is known about nursing undergraduates ' perspectives on communicating with patients. This study aimed to explore nursing students' perspectives and experiences of nurse-patient communication in their clinical placement. The participants included 21 second-year undergraduates and 21 first-year master's students. Interviews were conducted in Cantonese and then transcribed in Chinese and translated into English. A content analysis approach was adopted to analyze the data. Five themes emerged from the interview data. 'The necessity of nurse-patient communication ' reveals why the students valued nurse-patient communication. 'The conversation contents ' describes the content of the conversations that students typically had with patients. The third theme is ' self-reflection on the nurse-patient communication '. The last two themes, 'the communication pattern in different hospital settings ' and 'the obstacles impeding nurse-patient communication ', are about the students' communication styles in different hospitals and the barriers they encounter. To improve students' communication skills, educators and clinical staff should listen to students, enhance students' reflective skills and strengthen their confidence. Through understanding students' difficulties in the nurse-patient communication experience and the skills that they lack, educators can provide them with helpful recommendations to improve their communication skills in clinical practice. The results of this study reveal that students' nurse-patient communication skills need to be improved.
27371819	4	31	nurse-patient communication	T054	C0870983
27371819	45	61	nursing students	T097	C0038496
27371819	62	92	Effective communication skills	T032	C0870313
27371819	126	141	pivotal factors	T169	C1521761
27371819	154	190	positive interpersonal relationships	T054	C0021797
27371819	214	236	nursing undergraduates	T097	C0038496
27371819	239	251	perspectives	UnknownType	C0678958
27371819	255	268	communicating	T169	C0205196
27371819	274	282	patients	T101	C0030705
27371819	289	294	study	T062	C2603343
27371819	312	329	nursing students'	T097	C0038496
27371819	330	342	perspectives	UnknownType	C0678958
27371819	347	358	experiences	T041	C0596545
27371819	362	389	nurse-patient communication	T054	C0870983
27371819	399	407	clinical	T080	C0205210
27371819	408	417	placement	T080	C1524072
27371819	423	435	participants	T098	C0679646
27371819	448	474	second-year undergraduates	T098	C0682177
27371819	482	510	first-year master's students	T098	C0682177
27371819	512	522	Interviews	T052	C0021822
27371819	541	550	Cantonese	T171	C0023008
27371819	575	582	Chinese	T171	C0008120
27371819	603	610	English	T171	C0376245
27371819	614	630	content analysis	T062	C0681915
27371819	631	639	approach	T082	C0449445
27371819	667	671	data	T078	C1511726
27371819	678	684	themes	UnknownType	C0869035
27371819	702	716	interview data	T078	C1511726
27371819	736	763	nurse-patient communication	T054	C0870983
27371819	766	773	reveals	T080	C0443289
27371819	782	790	students	T098	C0038492
27371819	798	825	nurse-patient communication	T054	C0870983
27371819	832	853	conversation contents	T033	C0582166
27371819	870	898	content of the conversations	T033	C0582166
27371819	904	912	students	T098	C0038492
27371819	932	940	patients	T101	C0030705
27371819	952	957	theme	UnknownType	C0869035
27371819	963	978	self-reflection	T033	C0243095
27371819	986	1013	nurse-patient communication	T054	C0870983
27371819	1030	1036	themes	UnknownType	C0869035
27371819	1043	1077	communication pattern in different	T033	C4061885
27371819	1078	1095	hospital settings	T073,T093	C0019994
27371819	1126	1153	nurse-patient communication	T054	C0870983
27371819	1171	1180	students'	T098	C0038492
27371819	1181	1201	communication styles	T080	C0205556
27371819	1215	1224	hospitals	T073,T093	C0019994
27371819	1247	1256	encounter	T053	C1947978
27371819	1261	1268	improve	T033	C0184511
27371819	1269	1278	students'	T098	C0038492
27371819	1279	1299	communication skills	T032	C0870313
27371819	1301	1310	educators	T097	C0259853
27371819	1315	1329	clinical staff	T097	C0851286
27371819	1347	1355	students	T098	C0038492
27371819	1357	1364	enhance	T052	C2349975
27371819	1365	1374	students'	T098	C0038492
27371819	1375	1392	reflective skills	T055	C0678856
27371819	1414	1424	confidence	T041	C1704726
27371819	1434	1447	understanding	T041	C0162340
27371819	1448	1457	students'	T098	C0038492
27371819	1458	1470	difficulties	T080	C0332218
27371819	1478	1505	nurse-patient communication	T054	C0870983
27371819	1506	1516	experience	T041	C0596545
27371819	1525	1531	skills	T055	C0678856
27371819	1548	1557	educators	T097	C0259853
27371819	1588	1603	recommendations	T078	C0034866
27371819	1607	1614	improve	T033	C0184511
27371819	1621	1641	communication skills	T032	C0870313
27371819	1645	1662	clinical practice	T057	C0205897
27371819	1684	1689	study	T062	C2603343
27371819	1690	1696	reveal	T080	C0443289
27371819	1702	1711	students'	T098	C0038492
27371819	1712	1739	nurse-patient communication	T054	C0870983
27371819	1740	1746	skills	T032	C0870313
27371819	1758	1766	improved	T033	C0184511

28239461|t|Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers
28239461|a|The aim of this study was to validate previously described diagnostic and prognostic microRNA expression profiles in tissue samples from patients with pancreatic cancer and other periampullary cancers. Expression of 46 selected microRNAs was studied in formalin -fixed paraffin-embedded tissue from patients with resected pancreatic ductal adenocarcinoma (n = 165), ampullary cancer (n=59), duodenal cancer (n = 6), distal common bile duct cancer (n = 21), and gastric cancer (n = 20); chronic pancreatitis (n = 39); and normal pancreas (n = 35). The microRNAs were analyzed by PCR using the Fluidigm platform. Twenty-two microRNAs were significantly differently expressed in patients with pancreatic cancer when compared to healthy controls and chronic pancreatitis patients; 17 miRNAs were upregulated (miR-21-5p, - 23a-3p, - 31-5p, - 34c-5p, - 93-3p, - 135b-3p, - 155-5p, - 186-5p, - 196b-5p, - 203, - 205-5p, - 210, - 222-3p, - 451, - 492, - 614, and miR-622) and 5 were downregulated (miR-122-5p, - 130b-3p, - 216b, - 217, and miR-375). MicroRNAs were grouped into diagnostic indices of varying complexity. Ten microRNAs associated with prognosis were identified (let-7 g, miR-29a-5p, - 34a-5p, - 125a-3p, - 146a-5p, - 187, - 205-5p, - 212-3p, - 222-5p, and miR-450b-5p). Prognostic indices based on differences in expression of 2 different microRNAs were constructed for pancreatic and ampullary cancer combined and separately (30, 5, and 21 indices). The study confirms that pancreatic cancer tissue has a microRNA expression profile that is different from that of other periampullary cancers, chronic pancreatitis, and normal pancreas. We identified prognostic microRNAs and microRNA indices that were associated with shorter overall survival in patients with radically resected pancreatic cancer.
28239461	0	6	Tissue	T024	C0040300
28239461	7	15	MicroRNA	T114,T123	C1101610
28239461	28	38	diagnostic	T201	C1511876
28239461	43	64	prognostic biomarkers	T080	C1514475
28239461	68	76	patients	T101	C0030705
28239461	82	92	resectable	T061	C0015252
28239461	93	125	pancreatic ductal adenocarcinoma	T191	C1335302
28239461	130	151	periampullary cancers	T191	C1335377
28239461	156	159	aim	T078	C1947946
28239461	168	173	study	T062	C2603343
28239461	211	221	diagnostic	T169	C0348026
28239461	226	236	prognostic	T170	C0220901
28239461	237	245	microRNA	T114,T123	C1101610
28239461	246	265	expression profiles	T081	C1956267
28239461	269	275	tissue	T024	C0040300
28239461	289	297	patients	T101	C0030705
28239461	303	320	pancreatic cancer	T191	C0235974
28239461	331	352	periampullary cancers	T191	C1335377
28239461	354	364	Expression	T045	C0017262
28239461	380	389	microRNAs	T114,T123	C1101610
28239461	405	413	formalin	T109,T121,T131	C0949307
28239461	421	445	paraffin-embedded tissue	T024	C1519524
28239461	451	459	patients	T101	C0030705
28239461	465	473	resected	T061	C0015252
28239461	474	506	pancreatic ductal adenocarcinoma	T191	C1335302
28239461	518	534	ampullary cancer	T191	C0262401
28239461	543	558	duodenal cancer	T191	C0541912
28239461	568	574	distal	T082	C0205108
28239461	575	598	common bile duct cancer	T191	C0740277
28239461	613	627	gastric cancer	T191	C0024623
28239461	638	658	chronic pancreatitis	T047	C0149521
28239461	673	688	normal pancreas	T033	C0940731
28239461	703	712	microRNAs	T114,T123	C1101610
28239461	730	733	PCR	T063	C0032520
28239461	744	761	Fluidigm platform	T170	C0282574
28239461	774	783	microRNAs	T114,T123	C1101610
28239461	815	824	expressed	T045	C0017262
28239461	828	836	patients	T101	C0030705
28239461	842	859	pancreatic cancer	T191	C0235974
28239461	877	893	healthy controls	T080	C2986479
28239461	898	918	chronic pancreatitis	T047	C0149521
28239461	919	927	patients	T101	C0030705
28239461	932	938	miRNAs	T114,T123	C1101610
28239461	944	955	upregulated	T044	C0041904
28239461	957	966	miR-21-5p	T028	C1537719
28239461	970	976	23a-3p	T028	C1842758
28239461	980	985	31-5p	T028	C1537742
28239461	989	995	34c-5p	T028	C1537747
28239461	999	1004	93-3p	T028	C1537750
28239461	1008	1015	135b-3p	T028	C1537788
28239461	1019	1025	155-5p	T028	C1537811
28239461	1029	1035	186-5p	T028	C1537820
28239461	1039	1047	196b-5p,	T028	C1537832
28239461	1050	1053	203	T028	C1537841
28239461	1057	1063	205-5p	T114	C4284346
28239461	1067	1070	210	T028	C1537846
28239461	1074	1080	222-3p	T028	C1537860
28239461	1084	1087	451	T028	C1826031
28239461	1091	1094	492	T028	C1826046
28239461	1098	1101	614	T028	C1826193
28239461	1107	1114	miR-622	T028	C1826201
28239461	1127	1140	downregulated	T044	C0013081
28239461	1142	1152	miR-122-5p	T028	C1865068
28239461	1156	1163	130b-3p	T028	C1537780
28239461	1167	1171	216b	T028	C2239687
28239461	1175	1178	217	T028	C1537853
28239461	1184	1191	miR-375	T028	C1537896
28239461	1194	1203	MicroRNAs	T114,T123	C1101610
28239461	1222	1232	diagnostic	T169	C0348026
28239461	1252	1262	complexity	T080	C0439855
28239461	1268	1277	microRNAs	T114,T123	C1101610
28239461	1278	1293	associated with	T080	C0332281
28239461	1294	1303	prognosis	T058	C0033325
28239461	1321	1328	let-7 g	T114,T123	C1621390
28239461	1330	1340	miR-29a-5p	T028	C1835841
28239461	1344	1350	34a-5p	T028	C1537745
28239461	1354	1361	125a-3p	T028	C1537770
28239461	1365	1372	146a-5p	T028	C1826002
28239461	1376	1379	187	T028	C1537821
28239461	1383	1389	205-5p	T114	C4284346
28239461	1393	1399	212-3p	T028	C1537848
28239461	1403	1409	222-5p	T028	C1537860
28239461	1415	1426	miR-450b-5p	T028	C2239697
28239461	1429	1447	Prognostic indices	T081	C0033326
28239461	1472	1482	expression	T045	C0017262
28239461	1498	1507	microRNAs	T114,T123	C1101610
28239461	1529	1539	pancreatic	T191	C0235974
28239461	1544	1560	ampullary cancer	T191	C0262401
28239461	1614	1619	study	T062	C2603343
28239461	1634	1651	pancreatic cancer	T191	C0235974
28239461	1652	1658	tissue	T024	C0040300
28239461	1665	1673	microRNA	T114,T123	C1101610
28239461	1674	1692	expression profile	T081	C1956267
28239461	1730	1751	periampullary cancers	T191	C1335377
28239461	1753	1773	chronic pancreatitis	T047	C0149521
28239461	1779	1794	normal pancreas	T033	C0940731
28239461	1810	1820	prognostic	T170	C0220901
28239461	1821	1830	microRNAs	T114,T123	C1101610
28239461	1835	1843	microRNA	T114,T123	C1101610
28239461	1862	1877	associated with	T080	C0332281
28239461	1886	1902	overall survival	T081	C4086681
28239461	1906	1914	patients	T101	C0030705
28239461	1930	1938	resected	T061	C0015252
28239461	1939	1956	pancreatic cancer	T191	C0235974

28329231|t|Cardiac protective effects of remote ischaemic preconditioning in children undergoing tetralogy of fallot repair surgery: a randomized controlled trial
28329231|a|Remote ischaemic preconditioning (RIPC) by inducing brief ischaemia in distant tissues protects the heart against myocardial ischaemia-reperfusion injury (IRI) in children undergoing open-heart surgery, although its effectiveness in adults with comorbidities is controversial. The effectiveness and mechanism of RIPC with respect to myocardial IRI in children with tetralogy of Fallot (ToF), a severe cyanotic congenital cardiac disease, undergoing open heart surgery are unclear. We hypothesized that RIPC can confer cardioprotection in children undergoing ToF repair surgery. Overall, 112 ToF children undergoing radical open cardiac surgery using cardiopulmonary bypass (CPB) were randomized to either a RIPC group (n = 55) or a control group (n = 57). The RIPC protocol consisted of three cycles of 5-min lower limb occlusion and 5-min reperfusion using a cuff-inflator. Serum inflammatory cytokines and cardiac injury markers were measured before surgery and after CPB. Right ventricle outflow tract (RVOT) tissues were collected during the surgery to assess hypoxia-inducible factor (Hif)-1α and other signalling proteins. Cardiac mitochondrial injury was assessed by electron microscopy. The primary results showed that the length of stay in the intensive care unit (ICU) was longer in the control group than in the RIPC group (52.30 ± 13.43 h vs. 47.55 ± 10.34 h, respectively, P = 0.039). Patients in the control group needed longer post-operative ventilation time compared to the RIPC group (35.02 ± 6.56 h vs. 31.96 ± 6.60 h, respectively, P = 0.016). The levels of post-operative serum troponin-T at 12 and 18 h, CK-MB at 24 h, as well as the serum h-FABP levels at 6 h, after CPB were significantly lower, which was coincident with significantly higher protein expression of cardiac Hif-1α, p-Akt, p-STAT3, p-STAT5, and p-eNOS and less vacuolization of mitochondria in the RIPC group compared to the control group. In ToF children undergoing open heart surgery, RIPC attenuates myocardial IRI and improves the short-term prognosis.
28329231	0	7	Cardiac	T023	C0018787
28329231	8	26	protective effects	T033	C1545588
28329231	30	62	remote ischaemic preconditioning	T061	C0376466
28329231	66	74	children	T100	C0008059
28329231	86	120	tetralogy of fallot repair surgery	T061	C0397326
28329231	124	151	randomized controlled trial	T062	C0206035
28329231	152	184	Remote ischaemic preconditioning	T061	C0376466
28329231	186	190	RIPC	T061	C0376466
28329231	195	203	inducing	T169	C0205263
28329231	210	219	ischaemia	T046	C0022116
28329231	223	230	distant	T082	C0443203
28329231	231	238	tissues	T024	C0040300
28329231	239	247	protects	T033	C1545588
28329231	252	257	heart	T023	C0018787
28329231	258	265	against	T080	C0521124
28329231	266	276	myocardial	T024	C0027061
28329231	277	305	ischaemia-reperfusion injury	T037	C0035126
28329231	307	310	IRI	T037	C0035126
28329231	315	323	children	T100	C0008059
28329231	335	353	open-heart surgery	T061	C0189745
28329231	368	381	effectiveness	T080	C1280519
28329231	385	391	adults	T100	C0001675
28329231	397	410	comorbidities	T078	C0009488
28329231	433	446	effectiveness	T080	C1280519
28329231	451	460	mechanism	T169	C0441712
28329231	464	468	RIPC	T061	C0376466
28329231	485	495	myocardial	T024	C0027061
28329231	496	499	IRI	T037	C0035126
28329231	503	511	children	T100	C0008059
28329231	517	536	tetralogy of Fallot	T019	C0039685
28329231	538	541	ToF	T019	C0039685
28329231	546	552	severe	T080	C0205082
28329231	553	561	cyanotic	T169	C0332580
28329231	562	572	congenital	T080	C1744681
28329231	573	588	cardiac disease	T047	C0018799
28329231	601	619	open heart surgery	T061	C0189745
28329231	624	631	unclear	T033	C3845108
28329231	654	658	RIPC	T061	C0376466
28329231	670	686	cardioprotection	T169	C0205245
28329231	690	698	children	T100	C0008059
28329231	710	728	ToF repair surgery	T061	C0397326
28329231	743	746	ToF	T019	C0039685
28329231	747	755	children	T100	C0008059
28329231	767	774	radical	T080	C0439807
28329231	775	795	open cardiac surgery	T061	C0189745
28329231	796	801	using	T169	C1524063
28329231	802	824	cardiopulmonary bypass	T061	C0007202
28329231	826	829	CPB	T061	C0007202
28329231	836	846	randomized	T080	C0439605
28329231	859	863	RIPC	T061	C0376466
28329231	864	869	group	UnknownType	C0681860
28329231	884	897	control group	T096	C0009932
28329231	912	916	RIPC	T061	C0376466
28329231	917	925	protocol	T061	C0040808
28329231	926	935	consisted	T080	C0332529
28329231	961	981	lower limb occlusion	T061	C0190956
28329231	992	1003	reperfusion	T061	C0027054
28329231	1012	1025	cuff-inflator	T074	C3881496
28329231	1027	1032	Serum	T031	C0229671
28329231	1033	1045	inflammatory	T169	C0333348
28329231	1046	1055	cytokines	T116,T129	C0079189
28329231	1060	1074	cardiac injury	T037	C0018805
28329231	1075	1082	markers	T201	C0005516
28329231	1088	1096	measured	T080	C0444706
28329231	1097	1103	before	T079	C0332152
28329231	1104	1111	surgery	T061	C0543467
28329231	1116	1121	after	T079	C0687676
28329231	1122	1125	CPB	T061	C0007202
28329231	1127	1156	Right ventricle outflow tract	T030	C0225892
28329231	1158	1162	RVOT	T030	C0225892
28329231	1164	1171	tissues	T024	C0040300
28329231	1177	1186	collected	T169	C1516698
28329231	1187	1193	during	T079	C0347984
28329231	1198	1205	surgery	T061	C0543467
28329231	1216	1249	hypoxia-inducible factor (Hif)-1α	T116,T123	C0965644
28329231	1254	1259	other	T080	C0205394
28329231	1260	1270	signalling	T038	C3537152
28329231	1271	1279	proteins	T116,T123	C0033684
28329231	1281	1288	Cardiac	T023	C0018787
28329231	1289	1302	mitochondrial	T026	C0026237
28329231	1326	1345	electron microscopy	T059	C0026019
28329231	1359	1366	results	T169	C1274040
28329231	1383	1397	length of stay	T079	C0023303
28329231	1405	1424	intensive care unit	T073,T093	C0021708
28329231	1426	1429	ICU	T073,T093	C0021708
28329231	1435	1441	longer	T080	C0205166
28329231	1449	1462	control group	T096	C0009932
28329231	1475	1479	RIPC	T061	C0376466
28329231	1480	1485	group	UnknownType	C0681860
28329231	1550	1558	Patients	T101	C0030705
28329231	1566	1579	control group	T096	C0009932
28329231	1587	1593	longer	T080	C0205166
28329231	1594	1608	post-operative	T079	C0032790
28329231	1609	1625	ventilation time	T033	C0456238
28329231	1626	1634	compared	T052	C1707455
28329231	1642	1646	RIPC	T061	C0376466
28329231	1647	1652	group	UnknownType	C0681860
28329231	1729	1743	post-operative	T079	C0032790
28329231	1744	1760	serum troponin-T	T034	C1318385
28329231	1777	1782	CK-MB	T059	C0523584
28329231	1807	1826	serum h-FABP levels	T034	C1254360
28329231	1841	1844	CPB	T061	C0007202
28329231	1850	1863	significantly	T078	C0750502
28329231	1864	1869	lower	T080	C0205251
28329231	1881	1891	coincident	T079	C0205420
28329231	1897	1910	significantly	T078	C0750502
28329231	1911	1917	higher	T080	C0205250
28329231	1918	1936	protein expression	T045	C1171362
28329231	1948	1954	Hif-1α	T116,T123	C0965644
28329231	1963	1970	p-STAT3	T116,T123	C1530116
28329231	1972	1979	p-STAT5	T116,T123	C1121634
28329231	1985	1991	p-eNOS	T116,T126	C0669365
28329231	1996	2000	less	T081	C0439092
28329231	2001	2014	vacuolization	T033	C0010840
28329231	2018	2030	mitochondria	T026	C0026237
28329231	2038	2042	RIPC	T061	C0376466
28329231	2043	2048	group	UnknownType	C0681860
28329231	2049	2057	compared	T052	C1707455
28329231	2065	2078	control group	T096	C0009932
28329231	2083	2086	ToF	T019	C0039685
28329231	2087	2095	children	T100	C0008059
28329231	2107	2125	open heart surgery	T061	C0189745
28329231	2127	2131	RIPC	T061	C0376466
28329231	2143	2153	myocardial	T024	C0027061
28329231	2154	2157	IRI	T037	C0035126
28329231	2162	2170	improves	T033	C0184511
28329231	2175	2185	short-term	T079	C0443303
28329231	2186	2195	prognosis	T201	C3854082

28051263|t|Psychological factors associated with NAFLD / NASH: a systematic review
28051263|a|Nonalcoholic fatty liver disease (NAFLD) represents one of the most common chronic liver diseases worldwide. So far, the pathogenesis of NAFLD and its more severe variant nonalcoholic steatohepatitis (NASH) is yet unclear, with many mechanisms being proposed as possible causes. This article aims to review the psychological factors associated with NAFLD / NASH. Three main categories of factors have been investigated: emotional, cognitive and behavioral. Five electronic databases were searched, limited to studies published in the English language, during the period 2005-2015: PubMed, Thomson ISI - Web of Science, Scopus, ProQuest, and ScienceDirect. Results indicated the most relevant emotional factors to be depression and anxiety. The areas of investigation for cognitive functioning concern those contents and processes related to the ability to initiate and maintain lifestyle changes. The most important behavioral factors identified are physical activity, nutrition / food intake and substance consumption: coffee, alcohol, cigarettes. Some of the factors identified act as protective factors, other as vulnerability factors. NAFLD / NASH may be considered a cognitive-behavioral disease, the most effective management being lifestyle changes, with emphasis on diet and exercise.
28051263	0	21	Psychological factors	T041	C0033898
28051263	22	37	associated with	T080	C0332281
28051263	38	43	NAFLD	T047	C0400966
28051263	46	50	NASH	T047	C3241937
28051263	54	71	systematic review	T170	C1955832
28051263	72	104	Nonalcoholic fatty liver disease	T047	C0400966
28051263	106	111	NAFLD	T047	C0400966
28051263	147	169	chronic liver diseases	T047	C0341439
28051263	193	205	pathogenesis	T046	C0699748
28051263	209	214	NAFLD	T047	C0400966
28051263	228	234	severe	T080	C0205082
28051263	243	271	nonalcoholic steatohepatitis	T047	C3241937
28051263	273	277	NASH	T047	C3241937
28051263	305	315	mechanisms	T169	C0441712
28051263	372	378	review	T078	C1552617
28051263	383	404	psychological factors	T041	C0033898
28051263	405	420	associated with	T080	C0332281
28051263	421	426	NAFLD	T047	C0400966
28051263	429	433	NASH	T047	C3241937
28051263	460	467	factors	T169	C1521761
28051263	478	490	investigated	T169	C1292732
28051263	492	501	emotional	T033	C0849912
28051263	503	512	cognitive	T169	C1516691
28051263	517	527	behavioral	T053	C0004927
28051263	534	554	electronic databases	T170	C3841595
28051263	606	622	English language	T171	C0376245
28051263	635	641	period	T079	C1948053
28051263	653	659	PubMed	T170	C1138432
28051263	661	689	Thomson ISI - Web of Science	T170	C0242356
28051263	691	697	Scopus	T170	C0242356
28051263	699	707	ProQuest	T170	C0242356
28051263	713	726	ScienceDirect	T170	C0242356
28051263	764	773	emotional	T033	C0849912
28051263	774	781	factors	T169	C1521761
28051263	788	798	depression	T048	C0011570
28051263	803	810	anxiety	T033	C0003467
28051263	825	838	investigation	T169	C1292732
28051263	843	864	cognitive functioning	T041	C0392335
28051263	879	887	contents	T077	C0456205
28051263	892	901	processes	T067	C1522240
28051263	928	936	initiate	T169	C1704686
28051263	950	967	lifestyle changes	T054	C0870811
28051263	988	998	behavioral	T053	C0004927
28051263	999	1006	factors	T169	C1521761
28051263	1022	1039	physical activity	T056	C0026606
28051263	1041	1050	nutrition	T040	C1442959
28051263	1053	1064	food intake	T040	C0013470
28051263	1069	1078	substance	T167	C0439861
28051263	1079	1090	consumption	T039	C1947907
28051263	1092	1098	coffee	T168	C0009237
28051263	1100	1107	alcohol	T168	C0001967
28051263	1109	1119	cigarettes	T073	C0677453
28051263	1133	1140	factors	T169	C1521761
28051263	1159	1177	protective factors	T055	C0679688
28051263	1188	1209	vulnerability factors	T033	C0035648
28051263	1211	1216	NAFLD	T047	C0400966
28051263	1219	1223	NASH	T047	C3241937
28051263	1244	1272	cognitive-behavioral disease	T048	C0556006
28051263	1293	1303	management	T058	C0376636
28051263	1310	1327	lifestyle changes	T054	C0870811
28051263	1346	1350	diet	T168	C0012155
28051263	1355	1363	exercise	T056	C0015259

27738068|t|Cryoballoon ablation of persistent atrial fibrillation: feasibility and safety of left atrial roof ablation with generation of conduction block in addition to antral pulmonary vein isolation
27738068|a|Although the generation of linear lesions by ablation improves success rates in patients with persistent atrial fibrillation (AF), the procedure has been considered unsuitable for cryoablation balloon catheter technologies. We developed a technique for linear ablations, using second-generation cryoballoon technology. This was a single-arm, prospective study in 76 patients with persistent AF treated consecutively at our centre. Cryoablation was performed using a 28 mm second-generation cryoballoon. The first cryoenergy application was performed in close proximity to the position during isolation of the left superior pulmonary vein (PV). Sequential overlapping freezes were applied along the left atrial (LA) roof by slight clockwise rotation of the sheath in combination with slight retraction of the sheath and incremental advancement of the cryoballoon, until reaching the original position for right superior PV isolation. The acute endpoint was the creation of a roofline, defined as complete conduction block across the LA roof >120 ms and ascending activation across the posterior LA wall. Acute success in roofline generation was achieved in 88% of patients, applying on average five (median 4-6) freezes with nadir temperature of -40°C (-36 to -44°C). In five patients, conduction block could not be achieved. No phrenic nerve injuries occurred during roofline generation. Generation of linear roofline lesions is possible with the second-generation cryoballoon. The technique can be used in combination with PV isolation to treat persistent AF with good acute success rates, short procedure times, and acceptable safety concerns. If validated by further studies, the method would be an appealing alternative to radiofrequency ablation techniques.
27738068	0	20	Cryoballoon ablation	T061	C4289728
27738068	24	54	persistent atrial fibrillation	T046	C2585653
27738068	56	67	feasibility	T169	C0457083
27738068	72	78	safety	T068	C0036043
27738068	82	93	left atrial	T023	C0225860
27738068	94	107	roof ablation	T061	C0547070
27738068	127	143	conduction block	T047	C0018794
27738068	159	190	antral pulmonary vein isolation	T061	C3544330
27738068	225	232	lesions	T033	C0221198
27738068	236	244	ablation	T061	C0547070
27738068	245	253	improves	T033	C0184511
27738068	262	267	rates	T081	C1521828
27738068	271	279	patients	T101	C0030705
27738068	285	315	persistent atrial fibrillation	T046	C2585653
27738068	317	319	AF	T047	C0004238
27738068	326	335	procedure	T061	C0184661
27738068	371	413	cryoablation balloon catheter technologies	T061	C4289728
27738068	430	439	technique	T169	C0449851
27738068	444	460	linear ablations	T061	C0547070
27738068	468	508	second-generation cryoballoon technology	T061	C4289728
27738068	521	531	single-arm	T062	C2826346
27738068	533	550	prospective study	T062	C0033522
27738068	557	565	patients	T101	C0030705
27738068	571	584	persistent AF	T046	C2585653
27738068	585	592	treated	T169	C1522326
27738068	614	620	centre	T093	C1274109
27738068	622	634	Cryoablation	T061	C4289728
27738068	663	692	second-generation cryoballoon	T074	C0025080
27738068	704	714	cryoenergy	T070	C0009264
27738068	750	759	proximity	T082	C1514583
27738068	783	792	isolation	T061	C3544330
27738068	800	828	left superior pulmonary vein	T023	C0226682
27738068	830	832	PV	T023	C0226682
27738068	835	845	Sequential	T080	C1705294
27738068	846	857	overlapping	T079	C1948020
27738068	858	865	freezes	T070	C0016701
27738068	889	910	left atrial (LA) roof	T023	C0225860
27738068	957	968	combination	T080	C0205195
27738068	981	991	retraction	T033	C0332523
27738068	1010	1021	incremental	T081	C1705117
27738068	1041	1052	cryoballoon	T074	C0025080
27738068	1095	1112	right superior PV	T023	C0226671
27738068	1113	1122	isolation	T061	C3544330
27738068	1128	1133	acute	T079	C0205178
27738068	1134	1142	endpoint	T201	C2347784
27738068	1165	1173	roofline	T169	C0332206
27738068	1195	1211	conduction block	T047	C0018794
27738068	1223	1230	LA roof	T023	C0225860
27738068	1253	1263	activation	T052	C1879547
27738068	1275	1292	posterior LA wall	T029	C2323884
27738068	1294	1299	Acute	T079	C0205178
27738068	1311	1319	roofline	T169	C0332206
27738068	1354	1362	patients	T101	C0030705
27738068	1402	1409	freezes	T070	C0016701
27738068	1415	1420	nadir	T080	C1708760
27738068	1421	1432	temperature	T081	C0039476
27738068	1466	1474	patients	T101	C0030705
27738068	1476	1492	conduction block	T047	C0018794
27738068	1519	1541	phrenic nerve injuries	T037	C3274504
27738068	1558	1577	roofline generation	T169	C0332206
27738068	1600	1616	roofline lesions	T033	C0221198
27738068	1638	1667	second-generation cryoballoon	T074	C0025080
27738068	1673	1682	technique	T169	C0449851
27738068	1698	1709	combination	T080	C0205195
27738068	1715	1727	PV isolation	T061	C3544330
27738068	1731	1736	treat	T169	C1522326
27738068	1737	1750	persistent AF	T046	C2585653
27738068	1775	1780	rates	T081	C1521828
27738068	1782	1803	short procedure times	T079	C0040223
27738068	1820	1826	safety	T068	C0036043
27738068	1827	1835	concerns	T078	C2699424
27738068	1840	1849	validated	T062	C1519941
27738068	1861	1868	studies	T062	C0008972
27738068	1874	1880	method	T169	C0449851
27738068	1918	1941	radiofrequency ablation	T061	C0850292
27738068	1942	1952	techniques	T169	C0449851

27932585|t|Structural and functional characterization of the TYW3 / Taw3 class of SAM-dependent methyltransferases
27932585|a|S-adenosylmethionine (SAM)-dependent methyltransferases regulate a wide range of biological processes through the modification of proteins, nucleic acids, polysaccharides, as well as various metabolites. TYW3 / Taw3 is a SAM-dependent methyltransferase responsible for the formation of a tRNA modification known as wybutosine and its derivatives that are required for accurate decoding in protein synthesis. Here, we report the crystal structure of Taw3, a homolog of TYW3 from Sulfolobus solfataricus, which revealed a novel α/β fold. The sequence motif (S/T)xSSCxGR and invariant aspartate and histidine, conserved in TYW3 / Taw3, cluster to form the catalytic center. These structural and sequence features indicate that TYW3 / Taw3 proteins constitute a distinct class of SAM-dependent methyltransferases. Using site-directed mutagenesis along with in vivo complementation assays combined with mass spectrometry as well as ligand docking and cofactor binding assays, we have identified the active site of TYW3 and residues essential for cofactor binding and methyltransferase activity.
27932585	50	54	TYW3	T116,T123	C0033684
27932585	57	61	Taw3	T116,T123	C0033684
27932585	71	103	SAM-dependent methyltransferases	T116,T126	C0969403
27932585	104	159	S-adenosylmethionine (SAM)-dependent methyltransferases	T116,T126	C0969403
27932585	160	168	regulate	T038	C1327622
27932585	185	205	biological processes	T038	C3714634
27932585	218	230	modification	T044	C2752381
27932585	234	242	proteins	T116,T123	C0033684
27932585	244	257	nucleic acids	T114,T123	C0028606
27932585	259	274	polysaccharides	T109,T121	C0032594
27932585	295	306	metabolites	T123	C0870883
27932585	308	312	TYW3	T116,T123	C0033684
27932585	315	319	Taw3	T116,T123	C0033684
27932585	325	356	SAM-dependent methyltransferase	T116,T126	C0969403
27932585	392	409	tRNA modification	T045	C1158758
27932585	419	429	wybutosine	T114	C1171957
27932585	481	489	decoding	T045	C1519614
27932585	493	510	protein synthesis	T044	C0597295
27932585	532	549	crystal structure	T026	C0230587
27932585	553	557	Taw3	T116,T123	C0033684
27932585	572	576	TYW3	T116,T123	C0033684
27932585	582	605	Sulfolobus solfataricus	T194	C0995927
27932585	630	638	α/β fold	T044	C0162847
27932585	660	671	S/T)xSSCxGR	T087	C0002518
27932585	686	695	aspartate	T116,T123	C0085845
27932585	700	709	histidine	T116,T121,T123	C0019602
27932585	724	728	TYW3	T116,T123	C0033684
27932585	731	735	Taw3	T116,T123	C0033684
27932585	737	744	cluster	T081	C1704332
27932585	757	766	catalytic	T067	C0175921
27932585	781	791	structural	T116	C1510464
27932585	796	804	sequence	T087	C0002518
27932585	828	832	TYW3	T116,T123	C0033684
27932585	835	839	Taw3	T116,T123	C0033684
27932585	880	912	SAM-dependent methyltransferases	T116,T126	C0969403
27932585	920	945	site-directed mutagenesis	T045	C0079870
27932585	957	987	in vivo complementation assays	T059,T063	C0017381
27932585	1002	1019	mass spectrometry	T059	C0037813
27932585	1031	1045	ligand docking	T044	C1522290
27932585	1050	1066	cofactor binding	T044	C1323251
27932585	1067	1073	assays	T059	C1510438
27932585	1098	1109	active site	T169	C0205681
27932585	1113	1117	TYW3	T116,T123	C0033684
27932585	1145	1161	cofactor binding	T044	C1323251
27932585	1166	1192	methyltransferase activity	T044	C1152247

27542694|t|Development of a liquid chromatography-tandem mass spectrometry method for quantitative analysis of trace d-amino acids
27542694|a|d-Amino acids have recently attracted much attention in various research fields including medical, clinical and food industry due to their important biological functions that differ from l-amino acid. Most chiral amino acid separation techniques require complicated derivatization procedures in order to achieve the desirable chromatographic behavior and detectability. Thus, the aim of this research is to develop a highly sensitive analytical method for the enantioseparation of chiral amino acids without any derivatization process using liquid chromatography-tandem mass spectrometry (LC-MS/MS). By optimizing MS/MS parameters, we established a quantification method that allowed the simultaneous analysis of 18 d-amino acids with high sensitivity and reproducibility. Additionally, we applied the method to food sample (vinegar) for the validation, and successfully quantified trace levels of d-amino acids in samples. These results demonstrated the applicability and feasibility of the LC-MS/MS method as a novel, effective tool for d-amino acid measurement in various biological samples.
27542694	0	11	Development	T169	C1527148
27542694	17	63	liquid chromatography-tandem mass spectrometry	T059	C4049918
27542694	64	70	method	T169	C0449851
27542694	75	96	quantitative analysis	UnknownType	C0681919
27542694	100	105	trace	T081	C0442822
27542694	106	119	d-amino acids	T116,T121,T123	C0002520
27542694	120	133	d-Amino acids	T116,T121,T123	C0002520
27542694	139	147	recently	T079	C0332185
27542694	163	172	attention	T041	C0004268
27542694	184	199	research fields	T062	C0242481
27542694	200	209	including	T169	C0332257
27542694	210	217	medical	T169	C0205476
27542694	219	227	clinical	T080	C0205210
27542694	232	245	food industry	T057	C0524863
27542694	259	268	important	T080	C3898777
27542694	269	289	biological functions	T038	C3714634
27542694	307	319	l-amino acid	T116,T121,T123	C0002520
27542694	326	332	chiral	T067	C3539649
27542694	333	343	amino acid	T116,T121,T123	C0002520
27542694	344	354	separation	T059	C1441514
27542694	355	365	techniques	T169	C0449851
27542694	366	373	require	T169	C1514873
27542694	374	385	complicated	T169	C0231242
27542694	386	400	derivatization	T067	C0596319
27542694	401	411	procedures	T169	C0025664
27542694	436	445	desirable	T080	C0205556
27542694	446	461	chromatographic	T080	C0205556
27542694	475	488	detectability	T033	C0442726
27542694	500	503	aim	T078	C1947946
27542694	512	520	research	T062	C0035168
27542694	527	534	develop	T169	C1527148
27542694	537	553	highly sensitive	T080	C0439822
27542694	554	571	analytical method	T170	C0178476
27542694	580	597	enantioseparation	T059	C1441514
27542694	601	607	chiral	T067	C3539649
27542694	608	619	amino acids	T116,T121,T123	C0002520
27542694	632	646	derivatization	T067	C0596319
27542694	647	654	process	T067	C1522240
27542694	661	707	liquid chromatography-tandem mass spectrometry	T059	C4049918
27542694	709	717	LC-MS/MS	T059	C4049918
27542694	723	733	optimizing	T052	C2698650
27542694	734	739	MS/MS	T059	C2123592
27542694	740	750	parameters	T077	C0549193
27542694	755	766	established	T080	C0443211
27542694	769	783	quantification	T081	C1709793
27542694	784	790	method	T169	C0449851
27542694	808	820	simultaneous	T079	C0521115
27542694	821	829	analysis	T062	C0936012
27542694	836	849	d-amino acids	T116,T121,T123	C0002520
27542694	855	871	high sensitivity	T067	C2346484
27542694	876	891	reproducibility	T080	C1514863
27542694	910	917	applied	T169	C4048755
27542694	922	928	method	T169	C0449851
27542694	932	943	food sample	T167	C0444315
27542694	945	952	vinegar	T109,T121,T130	C0148405
27542694	962	972	validation	T062	C1519941
27542694	991	1001	quantified	T081	C1709793
27542694	1002	1014	trace levels	T081	C0442822
27542694	1018	1031	d-amino acids	T116,T121,T123	C0002520
27542694	1035	1042	samples	T167	C0370003
27542694	1050	1057	results	T034	C0456984
27542694	1075	1088	applicability	T080	C1706839
27542694	1093	1104	feasibility	T080	C0205556
27542694	1112	1120	LC-MS/MS	T059	C4049918
27542694	1121	1127	method	T169	C0449851
27542694	1133	1138	novel	T080	C0205314
27542694	1140	1149	effective	T080	C1704419
27542694	1159	1171	d-amino acid	T116,T121,T123	C0002520
27542694	1172	1183	measurement	T169	C0242485
27542694	1195	1213	biological samples	T077	C2347026

28239454|t|Transcriptional analysis of blaNDM-1 and copy number alteration under carbapenem stress
28239454|a|New Delhi metallo beta-lactamase is known to compromise carbapenem therapy and leading to treatment failure. However, their response to carbapenem stress is not clearly known. Here, we have investigated the transcriptional response of blaNDM-1 and plasmid copy number alteration under carbapenem exposure. Three blaNDM-1 harboring plasmids representing three incompatibility types (IncFIC, IncA/C and IncK) were inoculated in LB broth with and without imipenem, meropenem and ertapenem. After each 1 h total RNA was isolated, immediately reverse transcribed into cDNA and quantitative real time PCR was used for transcriptional expression of blaNDM-1. Horizontal transferability and stability of the plasmids encoding blaNDM-1 were also determined. Changes in copy number of blaNDM-1 harboring plasmids under the exposure of different carbapenems were determined by real time PCR. Clonal relatedness among the isolates was determined by pulsed field gel electrophoresis. Under carbapenem stress over an interval of time there was a sharp variation in the transcriptional expression of blaNDM-1 although it did not follow a specific pattern. All blaNDM-1 carrying plasmids were transferable by conjugation. These plasmids were highly stable and complete loss was observed between 92(nd) to 96(th) serial passages when antibiotic pressure was withdrawn. High copy number of blaNDM-1 was found for IncF type plasmids compared to the other replicon types. This study suggests that the single dose of carbapenem pressure does not significantly influence the expression of blaNDM-1 and also focus on the stability of this gene as well as the change in copy number with respect to the incompatible type of plasmid harboring resistance determinant.
28239454	0	15	Transcriptional	T045	C0040649
28239454	16	24	analysis	T062	C0936012
28239454	28	36	blaNDM-1	T028	C0017337
28239454	41	52	copy number	T081	C1707513
28239454	53	63	alteration	T078	C1515926
28239454	70	80	carbapenem	T109,T195	C0006968
28239454	81	87	stress	T033	C0038435
28239454	88	120	New Delhi metallo beta-lactamase	T116,T126	C2973511
28239454	133	143	compromise	T033	C2945640
28239454	144	154	carbapenem	T109,T195	C0006968
28239454	155	162	therapy	T061	C0087111
28239454	178	195	treatment failure	T033	C0162643
28239454	212	220	response	T032	C0871261
28239454	224	234	carbapenem	T109,T195	C0006968
28239454	235	241	stress	T033	C0038435
28239454	295	310	transcriptional	T045	C0040649
28239454	311	319	response	T032	C0871261
28239454	323	331	blaNDM-1	T028	C0017337
28239454	336	343	plasmid	T114,T123	C0032136
28239454	344	355	copy number	T081	C1707513
28239454	356	366	alteration	T078	C1515926
28239454	373	383	carbapenem	T109,T195	C0006968
28239454	384	392	exposure	T080	C0332157
28239454	400	408	blaNDM-1	T028	C0017337
28239454	419	427	plasmids	T114,T123	C0032136
28239454	470	476	IncFIC	T114,T123	C0032136
28239454	478	484	IncA/C	T114,T123	C0032136
28239454	489	493	IncK	T114,T123	C0032136
28239454	514	522	LB broth	T130	C0010454
28239454	540	548	imipenem	T109,T195	C0020933
28239454	550	559	meropenem	T109,T195	C0066005
28239454	564	573	ertapenem	T109,T195	C1120106
28239454	596	599	RNA	T114	C0035668
28239454	604	612	isolated	T169	C0205409
28239454	626	645	reverse transcribed	T045	C0035380
28239454	651	655	cDNA	T114	C0006556
28239454	660	686	quantitative real time PCR	T063	C3179034
28239454	700	726	transcriptional expression	T045	C0040649
28239454	730	738	blaNDM-1	T028	C0017337
28239454	740	766	Horizontal transferability	T045	C0887912
28239454	771	780	stability	T080	C0205360
28239454	788	796	plasmids	T114,T123	C0032136
28239454	797	805	encoding	T052	C2700640
28239454	806	814	blaNDM-1	T028	C0017337
28239454	837	844	Changes	T169	C0392747
28239454	848	859	copy number	T081	C1707513
28239454	863	871	blaNDM-1	T028	C0017337
28239454	882	890	plasmids	T114,T123	C0032136
28239454	901	909	exposure	T080	C0332157
28239454	923	934	carbapenems	T109,T195	C0006968
28239454	954	967	real time PCR	T063	C1709846
28239454	969	975	Clonal	T024	C1522642
28239454	998	1006	isolates	T123	C1764827
28239454	1025	1057	pulsed field gel electrophoresis	T059	C0085117
28239454	1065	1075	carbapenem	T109,T195	C0006968
28239454	1076	1082	stress	T033	C0038435
28239454	1091	1107	interval of time	T079	C0872291
28239454	1120	1135	sharp variation	T080	C0205419
28239454	1143	1169	transcriptional expression	T045	C0040649
28239454	1173	1181	blaNDM-1	T028	C0017337
28239454	1220	1227	pattern	T082	C0449774
28239454	1233	1241	blaNDM-1	T028	C0017337
28239454	1251	1259	plasmids	T114,T123	C0032136
28239454	1281	1292	conjugation	T045	C0009757
28239454	1300	1308	plasmids	T114,T123	C0032136
28239454	1321	1327	stable	T080	C0205360
28239454	1341	1345	loss	T081	C1517945
28239454	1384	1399	serial passages	T062	C0036718
28239454	1405	1415	antibiotic	T195	C0003232
28239454	1416	1424	pressure	T081	C4284008
28239454	1429	1438	withdrawn	T052	C2349954
28239454	1445	1456	copy number	T081	C1707513
28239454	1460	1468	blaNDM-1	T028	C0017337
28239454	1483	1501	IncF type plasmids	T114,T123	C1458238
28239454	1524	1532	replicon	T114,T123	C0035142
28239454	1569	1580	single dose	T081	C0178602
28239454	1584	1594	carbapenem	T109,T195	C0006968
28239454	1595	1603	pressure	T081	C4284008
28239454	1627	1636	influence	T077	C4054723
28239454	1641	1651	expression	T045	C0017262
28239454	1655	1663	blaNDM-1	T028	C0017337
28239454	1686	1695	stability	T080	C0205360
28239454	1704	1708	gene	T028	C0017337
28239454	1724	1730	change	T169	C0392747
28239454	1734	1745	copy number	T081	C1707513
28239454	1787	1794	plasmid	T114,T123	C0032136
28239454	1805	1815	resistance	T169	C4281815
28239454	1816	1827	determinant	T169	C1521761

28233874|t|Comprehensive analysis of long non-coding RNAs highlights their spatio-temporal expression patterns and evolutional conservation in Sus scrofa
28233874|a|Despite modest sequence conservation and rapid evolution, long non-coding RNAs (lncRNAs) appear to be conserved in expression pattern and function. However, analysis of lncRNAs across tissues and developmental stages remains largely uncharacterized in mammals. Here, we systematically investigated the lncRNAs of the Guizhou miniature pig (Sus scrofa), which was widely used as biomedical model. We performed RNA sequencing across 9 organs and 3 developmental skeletal muscle, and developed a filtering pipeline to identify 10,813 lncRNAs (9,075 novel). Conservation patterns analysis revealed that 57% of pig lncRNAs showed homology to humans and mice based on genome alignment. 5,455 lncRNAs exhibited typical hallmarks of regulatory molecules, such as high spatio-temporal specificity. Notably, conserved lncRNAs exhibited higher tissue specificity than pig - specific lncRNAs and were significantly enriched in testis and ovary. Weighted co-expression network analysis revealed a set of conserved lncRNAs that are likely involved in postnatal muscle development. Based on the high degree of similarity in the structure, organization, and dynamic expression of pig lncRNAs compared with human and mouse lncRNAs, we propose that these lncRNAs play an important role in organ physiology and development in mammals. Our results provide a resource for studying animal evolution, morphological complexity, breeding, and biomedical research.
28233874	0	13	Comprehensive	T080	C1880156
28233874	14	22	analysis	T062	C0936012
28233874	26	30	long	T080	C0205166
28233874	31	46	non-coding RNAs	T114	C0887909
28233874	64	79	spatio-temporal	T080	C0205556
28233874	80	99	expression patterns	T059,T063	C0752248
28233874	104	115	evolutional	T045	C0015219
28233874	116	128	conservation	T080	C2347858
28233874	132	142	Sus scrofa	T015	C1135183
28233874	158	166	sequence	T086	C0162327
28233874	167	179	conservation	T080	C2347858
28233874	184	189	rapid	T080	C0456962
28233874	190	199	evolution	T045	C0015219
28233874	201	205	long	T080	C0205166
28233874	206	221	non-coding RNAs	T114	C0887909
28233874	223	230	lncRNAs	T114	C0887909
28233874	245	254	conserved	T086	C0009802
28233874	258	276	expression pattern	T059,T063	C0752248
28233874	281	289	function	T039	C0031843
28233874	300	308	analysis	T062	C0936012
28233874	312	319	lncRNAs	T114	C0887909
28233874	327	334	tissues	T024	C0040300
28233874	339	359	developmental stages	T079	C0870411
28233874	376	391	uncharacterized	T080	C0205556
28233874	395	402	mammals	T015	C0024660
28233874	413	427	systematically	T169	C0220922
28233874	428	440	investigated	T169	C1292732
28233874	445	452	lncRNAs	T114	C0887909
28233874	460	467	Guizhou	T083	C0017446
28233874	468	481	miniature pig	T015	C0024660
28233874	483	493	Sus scrofa	T015	C1135183
28233874	521	537	biomedical model	T075	C0026339
28233874	542	551	performed	T169	C0884358
28233874	552	566	RNA sequencing	T059,T063	C0917793
28233874	576	582	organs	T023	C0178784
28233874	589	602	developmental	T080	C0458003
28233874	603	618	skeletal muscle	T024	C0242692
28233874	636	654	filtering pipeline	T170	C0025663
28233874	674	681	lncRNAs	T114	C0887909
28233874	697	709	Conservation	T080	C2347858
28233874	710	727	patterns analysis	T059,T063	C0752248
28233874	728	736	revealed	T080	C0443289
28233874	749	752	pig	T015	C1135183
28233874	753	760	lncRNAs	T114	C0887909
28233874	768	776	homology	T080	C2697616
28233874	780	786	humans	T016	C0086418
28233874	791	795	mice	T015	C0025929
28233874	805	821	genome alignment	T063	C0080143
28233874	829	836	lncRNAs	T114	C0887909
28233874	855	864	hallmarks	T080	C0205556
28233874	868	878	regulatory	T077	C1704735
28233874	879	888	molecules	T167	C0567416
28233874	898	902	high	T080	C0205250
28233874	903	918	spatio-temporal	T080	C0205556
28233874	919	930	specificity	T081	C0037791
28233874	941	950	conserved	T086	C0009802
28233874	951	958	lncRNAs	T114	C0887909
28233874	969	975	higher	T080	C0205250
28233874	976	994	tissue specificity	T042	C2713393
28233874	1000	1003	pig	T015	C1135183
28233874	1006	1014	specific	T080	C0205369
28233874	1015	1022	lncRNAs	T114	C0887909
28233874	1032	1045	significantly	T078	C0750502
28233874	1058	1064	testis	T023	C0039597
28233874	1069	1074	ovary	T023	C0029939
28233874	1076	1084	Weighted	T170	C4291660
28233874	1085	1098	co-expression	T045	C0017262
28233874	1099	1115	network analysis	T170	C0868995
28233874	1116	1124	revealed	T080	C0443289
28233874	1134	1143	conserved	T086	C0009802
28233874	1144	1151	lncRNAs	T114	C0887909
28233874	1168	1176	involved	T169	C1314939
28233874	1180	1189	postnatal	T079	C0443281
28233874	1190	1208	muscle development	T042	C0949649
28233874	1223	1227	high	T080	C0205250
28233874	1228	1234	degree	T081	C0449286
28233874	1238	1248	similarity	T080	C2348205
28233874	1256	1265	structure	T082	C0678594
28233874	1267	1279	organization	T039	C0029237
28233874	1285	1292	dynamic	T169	C0729333
28233874	1293	1303	expression	T045	C0017262
28233874	1307	1310	pig	T015	C1135183
28233874	1311	1318	lncRNAs	T114	C0887909
28233874	1319	1327	compared	T052	C1707455
28233874	1333	1338	human	T016	C0086418
28233874	1343	1348	mouse	T015	C0025929
28233874	1349	1356	lncRNAs	T114	C0887909
28233874	1380	1387	lncRNAs	T114	C0887909
28233874	1396	1405	important	T080	C3898777
28233874	1406	1410	role	T170	C3871154
28233874	1414	1419	organ	T023	C0178784
28233874	1420	1430	physiology	T091	C0031842
28233874	1435	1446	development	T038	C0242290
28233874	1450	1457	mammals	T015	C0024660
28233874	1463	1470	results	T033	C2825142
28233874	1471	1478	provide	T052	C1999230
28233874	1481	1489	resource	T078	C0178514
28233874	1494	1502	studying	T059	C0947630
28233874	1503	1509	animal	T008	C0003062
28233874	1510	1519	evolution	T045	C0015219
28233874	1521	1534	morphological	T082	C0543482
28233874	1547	1555	breeding	T040	C0178477
28233874	1561	1580	biomedical research	T062	C0005540

28471447|t|MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer
28471447|a|Lung cancer is the major form of cancer resulting in cancer-related mortality around the world. MicroRNAs are endogenous small non-coding single-stranded RNAs, which can engage in the regulation of gene expression. In this study, miR-18a-5p significantly upregulated in non-small cell lung cancer (NSCLC) tissues and NSCLC cell lines, suggesting an oncogenic function in lung cancer. Additionally, miR-18a-5p can promote carcinogenesis by directly targeting interferon regulatory factor 2 (IRF2). Further experiments indicated that IRF2 can increase cell apoptosis, inhibit cell proliferation and migration ability. Our study demonstrates that miR-18a-5p promotes autophagy in NSCLC. Collectively, these results indicate that miR-18a-5p can not only promote NSCLC by suppressing IRF2, but also will be a promising target in the near future.
28471447	0	15	MicroRNA-18a-5p	T114,T123	C1101610
28471447	16	25	functions	T169	C0542341
28471447	32	40	oncogene	T028	C0029016
28471447	44	52	directly	T080	C1947931
28471447	53	62	targeting	T044	C1159372
28471447	63	67	IRF2	T116,T123	C0063701
28471447	71	82	lung cancer	T191	C0242379
28471447	83	94	Lung cancer	T191	C0242379
28471447	102	107	major	T080	C0205164
28471447	116	122	cancer	T191	C0006826
28471447	123	135	resulting in	T169	C0332294
28471447	136	150	cancer-related	T033	C2826292
28471447	151	160	mortality	T081	C0205848
28471447	161	167	around	T078	C0750503
28471447	172	177	world	T098	C2700280
28471447	179	188	MicroRNAs	T114,T123	C1101610
28471447	193	203	endogenous	T169	C0205227
28471447	204	241	small non-coding single-stranded RNAs	T114	C2936494
28471447	267	296	regulation of gene expression	T045	C0017263
28471447	313	323	miR-18a-5p	T114,T123	C1101610
28471447	338	349	upregulated	T044	C0041904
28471447	353	379	non-small cell lung cancer	T191	C0007131
28471447	381	386	NSCLC	T191	C0007131
28471447	388	395	tissues	T024	C0475358
28471447	400	405	NSCLC	T191	C0007131
28471447	406	416	cell lines	T025	C0085983
28471447	432	441	oncogenic	T028	C0029016
28471447	442	450	function	T045	C0314627
28471447	454	465	lung cancer	T191	C0242379
28471447	481	491	miR-18a-5p	T114,T123	C1101610
28471447	496	503	promote	T052	C0033414
28471447	504	518	carcinogenesis	T191	C0596263
28471447	522	530	directly	T080	C1947931
28471447	531	540	targeting	T044	C1159372
28471447	541	571	interferon regulatory factor 2	T116,T123	C0063701
28471447	573	577	IRF2	T116,T123	C0063701
28471447	615	619	IRF2	T116,T123	C0063701
28471447	624	632	increase	T169	C0442805
28471447	633	637	cell	T025	C0334227
28471447	638	647	apoptosis	T043	C0162638
28471447	649	675	inhibit cell proliferation	T043	C1156236
28471447	680	697	migration ability	T043	C1524058
28471447	727	737	miR-18a-5p	T114,T123	C1101610
28471447	738	746	promotes	T052	C0033414
28471447	747	756	autophagy	T043	C0004391
28471447	760	765	NSCLC	T191	C0007131
28471447	787	794	results	T169	C1274040
28471447	795	803	indicate	T078	C3146298
28471447	809	819	miR-18a-5p	T114,T123	C1101610
28471447	833	840	promote	T052	C0033414
28471447	841	846	NSCLC	T191	C0007131
28471447	850	861	suppressing	T169	C1260953
28471447	862	866	IRF2	T116,T123	C0063701
28471447	897	903	target	T169	C1521840
28471447	911	915	near	T080	C1706276
28471447	916	922	future	T079	C0016884

28027117|t|Precision Medicine Starts With Preanalytics: Real-Time Assessment of Tissue Fixation Quality by Ultrasound Time-of-Flight Analysis
28027117|a|Personalized medicine promises diagnosis and treatment of disease at the individual level and relies heavily on clinical specimen integrity and diagnostic assay quality. Preanalytics, the collection and handling steps of a clinical specimen before immunohistochemistry or other clinical assay, are critically important to enable the correct diagnosis of disease. However, the effects of preanalytics are often overlooked due to a lack of standardization and limited assessment tools to quantify their variation. Here, we report a novel real-time ultrasound time-of-flight instrument that is capable of monitoring and imaging the critical step in formalin fixation, diffusion of the fixative into tissue, which provides a quantifiable quality metric for tissue fixation in the clinical laboratory ensuring consistent downstream molecular assay results. We analyzed hundreds of tissue specimens from 34 distinct human tissue types and 12 clinically relevant diseased tissues for diffusion and fixation metrics. Our measurements can be converted into tissue diffusivity constants that correlate with the apparent diffusion constant calculated using magnetic resonance imaging (R=0.83), despite the differences in the approaches, indicating that our approach is biophysically plausible. Using data collected from time-of-flight analysis of many tissues, we have therefore developed a novel rapid fixation program that could ensure high-quality downstream assay results for a broad range of human tissue types.
28027117	0	18	Precision Medicine	T061	C2718059
28027117	31	43	Preanalytics	T061	C0087111
28027117	45	54	Real-Time	T079	C1550177
28027117	55	65	Assessment	T052	C1516048
28027117	69	84	Tissue Fixation	T059	C0085254
28027117	85	92	Quality	T080	C0332306
28027117	107	121	Time-of-Flight	T081	C3815220
28027117	122	130	Analysis	T062	C0936012
28027117	131	152	Personalized medicine	T061	C2718059
28027117	162	171	diagnosis	T033	C0011900
28027117	176	185	treatment	T061	C0087111
28027117	189	196	disease	T047	C0012634
28027117	204	214	individual	T098	C0237401
28027117	215	220	level	T080	C0441889
28027117	243	270	clinical specimen integrity	T080	C0807860
28027117	275	285	diagnostic	T169	C0348026
28027117	286	291	assay	T059	C1510438
28027117	292	299	quality	T080	C0332306
28027117	301	313	Preanalytics	T061	C0087111
28027117	319	329	collection	T169	C1516698
28027117	334	342	handling	T059	C0037793
28027117	343	348	steps	T077	C1261552
28027117	354	371	clinical specimen	T167	C0370003
28027117	379	399	immunohistochemistry	T060	C0021044
28027117	409	423	clinical assay	T059	C1510438
28027117	440	449	important	T080	C3898777
28027117	472	481	diagnosis	T033	C0011900
28027117	485	492	disease	T047	C0012634
28027117	518	530	preanalytics	T061	C0087111
28027117	561	565	lack	T080	C0332268
28027117	569	584	standardization	T062	C0038136
28027117	589	596	limited	T169	C0439801
28027117	597	613	assessment tools	T170	C1516602
28027117	617	625	quantify	T081	C1709793
28027117	632	641	variation	T080	C0205419
28027117	661	666	novel	T080	C0205314
28027117	667	713	real-time ultrasound time-of-flight instrument	T074	C0348000
28027117	733	743	monitoring	T058	C1283169
28027117	748	755	imaging	T060	C0011923
28027117	769	773	step	T077	C1261552
28027117	777	794	formalin fixation	T059	C3536615
28027117	796	805	diffusion	T070	C0012222
28027117	813	821	fixative	T130	C0016184
28027117	827	833	tissue	T024	C0040300
28027117	865	872	quality	T080	C0332306
28027117	873	879	metric	T109,T121	C0699680
28027117	884	899	tissue fixation	T059	C0085254
28027117	907	926	clinical laboratory	T073,T093	C0022877
28027117	936	946	consistent	T078	C0332290
28027117	958	973	molecular assay	T059	C1510438
28027117	974	981	results	T169	C1274040
28027117	1007	1023	tissue specimens	T024	C1292533
28027117	1041	1053	human tissue	T024	C0440744
28027117	1067	1086	clinically relevant	T080	C2347946
28027117	1087	1095	diseased	T047	C0012634
28027117	1096	1103	tissues	T024	C0040300
28027117	1108	1117	diffusion	T070	C0012222
28027117	1122	1130	fixation	T061	C0185023
28027117	1131	1138	metrics	T109,T121	C0699680
28027117	1144	1156	measurements	T169	C0242485
28027117	1179	1207	tissue diffusivity constants	T081	C0392762
28027117	1213	1222	correlate	T080	C1707520
28027117	1241	1259	diffusion constant	T081	C1522609
28027117	1260	1270	calculated	T052	C1441506
28027117	1277	1303	magnetic resonance imaging	T060	C0024485
28027117	1326	1337	differences	T080	C1705242
28027117	1403	1412	plausible	T033	C0332149
28027117	1420	1424	data	T078	C1511726
28027117	1440	1454	time-of-flight	T081	C3815220
28027117	1455	1463	analysis	T062	C0936012
28027117	1472	1479	tissues	T024	C0040300
28027117	1511	1516	novel	T080	C0205314
28027117	1517	1539	rapid fixation program	T170	C0282574
28027117	1582	1587	assay	T059	C1510438
28027117	1588	1595	results	T169	C1274040
28027117	1617	1629	human tissue	T024	C0440744

27399912|t|Expression of WNT10A Gene in Oral Squamous Cell Carcinoma
27399912|a|Oral squamous cell carcinoma (OSCC) constitutes the most frequent malignant tumour of the oral cavity. Considering the significant roles the Wnt family plays in physiological and pathological events, this study aims to investigate WNT10A gene expression in OSCC. The cohort was composed of 59 specimens: 49 with OSCC and 10 controls. Total RNA from the samples was extracted, cDNA was synthesized and Real-time PCR analyses were performed, with β-ACTIN as internal control. The number of OSCC samples for the 4 TNM stages was: 5 (10.2%) stage I, 10 (20.4%) stage II, 9 (18.3%) stage III, and 25 (51.1%) stage IV. For Real-Time PCR analysis, significant difference was found between control samples and OSCC stage IV (p < 0.01). Higher levels of WNT10A expression was observed in OSCC stage IV suggesting a potential role in tumour progression.
27399912	0	10	Expression	T045	C0017262
27399912	14	25	WNT10A Gene	T028	C1422222
27399912	29	57	Oral Squamous Cell Carcinoma	T191	C0585362
27399912	58	86	Oral squamous cell carcinoma	T191	C0585362
27399912	88	92	OSCC	T191	C0585362
27399912	110	114	most	T081	C0205393
27399912	115	123	frequent	T079	C0332183
27399912	124	140	malignant tumour	T191	C0006826
27399912	148	159	oral cavity	T030	C0226896
27399912	177	188	significant	T078	C0750502
27399912	189	194	roles	T077	C1705810
27399912	199	209	Wnt family	T028	C0935995
27399912	219	232	physiological	T039	C1254359
27399912	237	249	pathological	T169	C1521733
27399912	250	256	events	T169	C0205245
27399912	263	268	study	T062	C2603343
27399912	277	288	investigate	T169	C1292732
27399912	289	300	WNT10A gene	T028	C1422222
27399912	301	311	expression	T045	C0017262
27399912	315	319	OSCC	T191	C0585362
27399912	325	331	cohort	T081	C0009247
27399912	351	360	specimens	T167	C0370003
27399912	370	374	OSCC	T191	C0585362
27399912	382	390	controls	T078	C1550040
27399912	392	397	Total	T080	C0439810
27399912	398	401	RNA	T114	C0035668
27399912	411	418	samples	T167	C0370003
27399912	423	432	extracted	T061	C0185115
27399912	434	438	cDNA	T114	C0006556
27399912	443	454	synthesized	T052	C1883254
27399912	459	481	Real-time PCR analyses	T059	C2732732
27399912	487	496	performed	T169	C0884358
27399912	503	510	β-ACTIN	T028	C1384510
27399912	514	530	internal control	T081	C0034925
27399912	536	542	number	T081	C0237753
27399912	546	550	OSCC	T191	C0585362
27399912	551	558	samples	T167	C0370003
27399912	569	579	TNM stages	T185	C1515169
27399912	595	602	stage I	T191	C0861585
27399912	615	623	stage II	T191	C0861598
27399912	635	644	stage III	T191	C0861611
27399912	661	669	stage IV	T191	C0861624
27399912	675	697	Real-Time PCR analysis	T059	C2732732
27399912	699	710	significant	T078	C0750502
27399912	711	721	difference	T080	C1705242
27399912	726	731	found	T033	C0150312
27399912	740	755	control samples	T078	C1550040
27399912	760	773	OSCC stage IV	T191	C0861624
27399912	786	792	Higher	T080	C0205250
27399912	793	799	levels	T080	C0441889
27399912	803	809	WNT10A	T028	C1422222
27399912	810	820	expression	T045	C0017262
27399912	825	833	observed	T169	C1441672
27399912	837	850	OSCC stage IV	T191	C0861624
27399912	851	861	suggesting	T078	C1705535
27399912	864	873	potential	T080	C3245505
27399912	874	878	role	T077	C1705810
27399912	882	900	tumour progression	T191	C0178874

27578983|t|EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
27578983|a|The aim of this research was to examine the molecular and clinical features that are related with EGFR-tyrosine kinase inhibitor (EGFR-TKI) efficacy in previously treated patients with squamous cell carcinoma of the lung (SCCL). This retrospective study included 67 SCCL patients with obtainable lung cancer tissue and records on EGFR-TKI treatment response and survival. EGFR protein expression in lung cancer tissue was measured by immunohistochemistry with a specific antibody that recognizes the intracellular domain (ID) of EGFR. PTEN expression in lung cancer tissue was also evaluated with immunohistochemistry. PI3KCA gene amplification was detected by quantitative real-time polymerase chain reaction, and FGFR1 amplification was assessed by fluorescent in situ hybridization. EGFR ID expression (hazard ratio [HR] 0.53, P=0.022) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (HR 0.43, P=0.022) were significantly related with progression - free survival following EGFR-TKIs treatment. PTEN expression (HR 0.52, P=0.025) was significantly related to overall survival. The group of EGFR - positive or PTEN - positive patients with ECOG PS of 0 or 1 had better clinical outcomes than patients who were EGFR - negative and PTEN - negative or who had poor ECOG PS with longer median progression - free survival (2.1 vs 1.0 months, P=0.05) and overall survival (6.2 vs 2.1 months, P=0.05). EGFR expression using an ID -specific antibody and PTEN protein expression may be used to identify SCCL patients who might benefit from EGFR-TKI treatment.
27578983	0	12	EGFR protein	T116,T192	C1739039
27578983	13	23	expression	T045	C1171362
27578983	41	54	intracellular	T082	C0178719
27578983	55	61	domain	T087	C1514562
27578983	62	70	antibody	T116,T129	C0003241
27578983	75	79	PTEN	T116,T126	C1430988
27578983	84	101	clinical outcomes	T080	C0085415
27578983	105	130	squamous cell lung cancer	T191	C0149782
27578983	131	139	patients	T101	C0030705
27578983	145	183	EGFR-tyrosine kinase inhibitor therapy	T061	C3899317
27578983	188	191	aim	T078	C1947946
27578983	200	208	research	T062	C0035168
27578983	216	223	examine	T058	C0582103
27578983	228	237	molecular	T080	C1521991
27578983	242	250	clinical	T080	C0205210
27578983	251	259	features	T080	C2348519
27578983	282	312	EGFR-tyrosine kinase inhibitor	T061	C3899317
27578983	314	322	EGFR-TKI	T061	C3899317
27578983	324	332	efficacy	T080	C1280519
27578983	347	354	treated	T033	C0332154
27578983	355	363	patients	T101	C0030705
27578983	369	404	squamous cell carcinoma of the lung	T191	C0149782
27578983	406	410	SCCL	T191	C0149782
27578983	418	437	retrospective study	T062	C0035363
27578983	450	454	SCCL	T191	C0149782
27578983	455	463	patients	T101	C0030705
27578983	469	479	obtainable	T052	C1706701
27578983	480	491	lung cancer	T191	C0684249
27578983	492	498	tissue	T024	C0040300
27578983	503	510	records	T170	C0034869
27578983	514	532	EGFR-TKI treatment	T061	C3899317
27578983	533	541	response	T032	C0871261
27578983	546	554	survival	T052	C0038952
27578983	556	568	EGFR protein	T116,T192	C1739039
27578983	569	579	expression	T045	C1171362
27578983	583	594	lung cancer	T191	C0684249
27578983	595	601	tissue	T024	C0040300
27578983	606	614	measured	T080	C0444706
27578983	618	638	immunohistochemistry	T060	C0021044
27578983	655	663	antibody	T116,T129	C0003241
27578983	669	679	recognizes	T041	C0524637
27578983	684	697	intracellular	T082	C0178719
27578983	698	704	domain	T087	C1514562
27578983	706	708	ID	T087	C1514562
27578983	713	717	EGFR	T116,T192	C1739039
27578983	719	723	PTEN	T116,T126	C1430988
27578983	724	734	expression	T045	C1171362
27578983	738	749	lung cancer	T191	C0684249
27578983	750	756	tissue	T024	C0040300
27578983	766	775	evaluated	T058	C0220825
27578983	781	801	immunohistochemistry	T060	C0021044
27578983	803	828	PI3KCA gene amplification	T049	C3273085
27578983	833	841	detected	T033	C0442726
27578983	845	893	quantitative real-time polymerase chain reaction	T063	C3179034
27578983	899	918	FGFR1 amplification	T049	C1517090
27578983	923	931	assessed	T052	C1516048
27578983	935	968	fluorescent in situ hybridization	T063	C0162789
27578983	970	974	EGFR	T116,T192	C1739039
27578983	975	977	ID	T087	C1514562
27578983	978	988	expression	T045	C1171362
27578983	1027	1092	Eastern Cooperative Oncology Group (ECOG) performance status (PS)	T201	C1520224
27578983	1117	1130	significantly	T078	C0750502
27578983	1144	1155	progression	T191	C0178874
27578983	1158	1162	free	T169	C0332296
27578983	1163	1171	survival	T052	C0038952
27578983	1182	1201	EGFR-TKIs treatment	T061	C3899317
27578983	1203	1207	PTEN	T116,T126	C1430988
27578983	1208	1218	expression	T045	C1171362
27578983	1242	1255	significantly	T078	C0750502
27578983	1267	1274	overall	T080	C1561607
27578983	1275	1283	survival	T052	C0038952
27578983	1289	1294	group	T078	C0441833
27578983	1298	1302	EGFR	T116,T192	C1739039
27578983	1305	1313	positive	T033	C1446409
27578983	1317	1321	PTEN	T116,T126	C1430988
27578983	1324	1332	positive	T033	C1446409
27578983	1333	1341	patients	T101	C0030705
27578983	1347	1354	ECOG PS	T201	C1520224
27578983	1369	1393	better clinical outcomes	T033	C1333602
27578983	1399	1407	patients	T101	C0030705
27578983	1417	1421	EGFR	T116,T192	C1739039
27578983	1424	1432	negative	T033	C0205160
27578983	1437	1441	PTEN	T116,T126	C1430988
27578983	1444	1452	negative	T033	C0205160
27578983	1464	1468	poor	T080	C0542537
27578983	1469	1476	ECOG PS	T201	C1520224
27578983	1489	1495	median	T081	C0876920
27578983	1496	1507	progression	T191	C0178874
27578983	1510	1514	free	T169	C0332296
27578983	1515	1523	survival	T052	C0038952
27578983	1556	1563	overall	T080	C1561607
27578983	1564	1572	survival	T052	C0038952
27578983	1602	1606	EGFR	T116,T192	C1739039
27578983	1607	1617	expression	T045	C1171362
27578983	1627	1629	ID	T087	C1514562
27578983	1640	1648	antibody	T116,T129	C0003241
27578983	1653	1665	PTEN protein	T116,T126	C1430988
27578983	1666	1676	expression	T045	C1171362
27578983	1692	1700	identify	T080	C0205396
27578983	1701	1705	SCCL	T191	C0149782
27578983	1706	1714	patients	T101	C0030705
27578983	1725	1732	benefit	T081	C0086387
27578983	1738	1756	EGFR-TKI treatment	T061	C3899317

28329001|t|Experimental demonstration of the possible role of Acanthamoeba polyphaga in the infection and disease progression in Buruli Ulcer (BU) using ICR mice
28329001|a|The transmission of Buruli ulcer (BU), caused by Mycobacterium ulcerans (MU), remains puzzling although a number of hypothesis including through bites of infected aquatic insects have been proposed. We report the results of experiments using ICR mice that give credence to our hypothesis that Acanthamoeba species may play a role in BU transmission. We cocultured MU N2 and MU 1615 which expresses red fluorescent protein (RFP) and Acanthamoeba polyphaga (AP), and confirmed infected AP by Ziehl-Neelsen (ZN) staining. We tested for viability of MU inside AP and observed strong RFP signals inside both trophozoites and cysts after 3 and 42 days of coculturing respectively. ICR mice were topically treated, either on shaved intact or shaved pinpricked rumps, with one of the following; MU N2 only (2.25 x 106 colony forming units [CFU] / ml), MU N2: AP coculture (2.96 x 104 CFU: 1.6 x 106 cells/ml), AP only (1.6 x 106 cells/ml), PYG medium and sterile distilled water. Both MU N2 only and MU N2: AP elicited reddening on day (D) 31; edema on D 45 and D 44 respectively, and ulcers on D 49 at pinpricked sites only. To ascertain infectivity and pathogenicity of MU N2 only and MU N2: AP, and compare their virulence, the standard mouse footpad inoculation method was used. MU N2: AP elicited reddening in footpads by D 3 compared to D 14 with MU N2 only of the same dose of MU N2 (2.96 x 104 CFU). ZN-stained MU were observed in both thin sectioned and homogenized lesions, and aspirates from infected sites. Viable MU N2 were recovered from cultures of the homogenates and aspirates. This study demonstrates in ICR mice MU transmission via passive infection, and shows that punctures in the skin are prerequisite for infection, and that coculturing of MU with AP enhances pathogenesis.
28329001	0	12	Experimental	T080	C1517586
28329001	13	26	demonstration	T078	C0449450
28329001	51	73	Acanthamoeba polyphaga	T204	C0320459
28329001	81	90	infection	T046	C3714514
28329001	95	114	disease progression	T046	C0242656
28329001	118	130	Buruli Ulcer	T047	C0085568
28329001	132	134	BU	T047	C0085568
28329001	142	150	ICR mice	T015	C0025925
28329001	155	167	transmission	T046	C0242781
28329001	171	183	Buruli ulcer	T047	C0085568
28329001	185	187	BU	T047	C0085568
28329001	200	222	Mycobacterium ulcerans	T007	C0317759
28329001	224	226	MU	T007	C0317759
28329001	267	277	hypothesis	T078	C1512571
28329001	296	301	bites	T037	C0005658
28329001	305	313	infected	T033	C0439663
28329001	314	329	aquatic insects	T204	C0021585
28329001	353	359	report	T170	C0684224
28329001	364	371	results	T169	C1274040
28329001	375	386	experiments	T062	C0681814
28329001	393	401	ICR mice	T015	C0025925
28329001	428	438	hypothesis	T078	C1512571
28329001	444	464	Acanthamoeba species	T204	C0000879
28329001	484	486	BU	T047	C0085568
28329001	487	499	transmission	T046	C0242781
28329001	504	514	cocultured	T059	C0430400
28329001	515	520	MU N2	T007	C0317759
28329001	525	532	MU 1615	T007	C0317759
28329001	539	572	expresses red fluorescent protein	T116	C0960938
28329001	574	577	RFP	T116	C0960938
28329001	583	605	Acanthamoeba polyphaga	T204	C0320459
28329001	607	609	AP	T204	C0320459
28329001	626	634	infected	T033	C0439663
28329001	635	637	AP	T204	C0320459
28329001	641	668	Ziehl-Neelsen (ZN) staining	T059	C1318721
28329001	684	693	viability	T070	C1563772
28329001	697	699	MU	T007	C0317759
28329001	707	709	AP	T204	C0320459
28329001	730	733	RFP	T116	C0960938
28329001	734	741	signals	T043	C0037083
28329001	754	766	trophozoites	T204	C0686882
28329001	771	776	cysts	T026	C0243092
28329001	792	796	days	T079	C0439228
28329001	800	811	coculturing	T059	C0282547
28329001	826	834	ICR mice	T015	C0025925
28329001	850	857	treated	T169	C1522326
28329001	869	875	shaved	T033	C2028339
28329001	876	882	intact	T080	C0205266
28329001	886	892	shaved	T033	C2028339
28329001	893	909	pinpricked rumps	T029	C0006497
28329001	938	943	MU N2	T007	C0317759
28329001	961	981	colony forming units	T081	C0553561
28329001	983	986	CFU	T081	C0553561
28329001	995	1000	MU N2	T007	C0317759
28329001	1002	1004	AP	T204	C0320459
28329001	1005	1014	coculture	T059	C0282547
28329001	1027	1030	CFU	T081	C0553561
28329001	1053	1055	AP	T204	C0320459
28329001	1083	1093	PYG medium	T130	C0010454
28329001	1098	1121	sterile distilled water	T121,T197	C0790233
28329001	1128	1133	MU N2	T007	C0317759
28329001	1143	1148	MU N2	T007	C0317759
28329001	1150	1152	AP	T204	C0320459
28329001	1162	1171	reddening	T184	C0016382
28329001	1175	1178	day	T079	C0439228
28329001	1180	1181	D	T079	C0439228
28329001	1187	1192	edema	T184	C0013604
28329001	1196	1197	D	T079	C0439228
28329001	1205	1206	D	T079	C0439228
28329001	1228	1234	ulcers	T047	C0041582
28329001	1238	1239	D	T079	C0439228
28329001	1246	1262	pinpricked sites	T082	C0205145
28329001	1282	1293	infectivity	T080	C0030657
28329001	1298	1311	pathogenicity	T032	C1136169
28329001	1315	1320	MU N2	T007	C0317759
28329001	1330	1335	MU N2	T007	C0317759
28329001	1337	1339	AP	T204	C0320459
28329001	1345	1352	compare	T052	C1707455
28329001	1359	1368	virulence	T038	C0042765
28329001	1374	1415	standard mouse footpad inoculation method	T059	C0022885
28329001	1426	1431	MU N2	T007	C0317759
28329001	1433	1435	AP	T204	C0320459
28329001	1445	1454	reddening	T184	C0016382
28329001	1458	1466	footpads	T023	C2985236
28329001	1470	1471	D	T079	C0439228
28329001	1474	1482	compared	T052	C1707455
28329001	1486	1487	D	T079	C0439228
28329001	1496	1501	MU N2	T007	C0317759
28329001	1527	1532	MU N2	T007	C0317759
28329001	1545	1548	CFU	T081	C0553561
28329001	1551	1561	ZN-stained	T059	C1318721
28329001	1562	1564	MU	T007	C0317759
28329001	1618	1625	lesions	T033	C0221198
28329001	1631	1640	aspirates	T031	C0370199
28329001	1646	1654	infected	T033	C0439663
28329001	1655	1660	sites	T082	C0205145
28329001	1669	1674	MU N2	T007	C0317759
28329001	1695	1703	cultures	T059	C0430400
28329001	1711	1722	homogenates	T072	C3829671
28329001	1727	1736	aspirates	T031	C0370199
28329001	1743	1748	study	T062	C2603343
28329001	1765	1773	ICR mice	T015	C0025925
28329001	1774	1776	MU	T007	C0317759
28329001	1777	1789	transmission	T046	C0242781
28329001	1794	1801	passive	T080	C3686820
28329001	1802	1811	infection	T046	C3714514
28329001	1828	1837	punctures	T037	C0033119
28329001	1845	1849	skin	T022	C1123023
28329001	1871	1880	infection	T046	C3714514
28329001	1891	1902	coculturing	T059	C0282547
28329001	1906	1908	MU	T007	C0317759
28329001	1914	1916	AP	T204	C0320459
28329001	1917	1925	enhances	T052	C2349975
28329001	1926	1938	pathogenesis	T046	C0699748

28473531|t|Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer
28473531|a|RAS and its downstream cascades transmit cellular signals resulting in increased transcription of genes involved in cell growth and division. Protein-coding gene targets of RAS signaling have been characterized extensively, but long non-coding RNAs (lncRNA) regulated by these processes have not. Using a custom-designed lncRNA microarray, we identified the lncRNA Orilnc1 as a genetic target of RAS that is critical for RAS oncogenicity. Orilnc1 expression was regulated by RAS-RAF-MEK-ERK signaling via the transcription factor AP1. Orilnc1 was highly expressed in BRAF-mutant cancers such as melanoma. Silencing of Orilnc1 blocked tumor cell proliferation and growth in vitro and in vivo. Additionally, Orilnc1 blockade reduced expression of Cyclin E1 and induced G1/S cell cycle arrest in tumor cells. Taken together, our results identify Orilnc1 as a novel, non-protein mediator of RAS/RAF activation which may serve as a therapeutic target in RAS/RAF-driven cancers.
28473531	0	13	Oncogenic RAS	T028	C0034678
28473531	14	23	regulates	T045	C0017263
28473531	24	51	long non-coding RNA Orilnc1	T114,T123	C3494264
28473531	55	60	human	T016	C0086418
28473531	61	67	cancer	T191	C0007097
28473531	68	71	RAS	T028	C0034678
28473531	80	99	downstream cascades	T028	C0017337
28473531	100	108	transmit	T169	C0332289
28473531	109	125	cellular signals	T043	C0037083
28473531	126	138	resulting in	T169	C0332294
28473531	139	148	increased	T081	C0205217
28473531	149	171	transcription of genes	T045	C0040649
28473531	184	195	cell growth	T043	C0007595
28473531	200	208	division	T043	C0007590
28473531	210	229	Protein-coding gene	T028	C3839127
28473531	230	237	targets	T169	C1521840
28473531	241	254	RAS signaling	T044	C1514731
28473531	265	278	characterized	T052	C1880022
28473531	296	316	long non-coding RNAs	T114,T123	C3494264
28473531	318	324	lncRNA	T114,T123	C3494264
28473531	326	335	regulated	T045	C0017263
28473531	345	354	processes	T067	C1522240
28473531	373	406	custom-designed lncRNA microarray	T075	C3853655
28473531	411	421	identified	T080	C0205396
28473531	426	440	lncRNA Orilnc1	T114,T123	C3494264
28473531	446	453	genetic	T169	C0314603
28473531	454	460	target	T169	C1521840
28473531	464	467	RAS	T028	C0034678
28473531	476	484	critical	T080	C1511545
28473531	489	492	RAS	T028	C0034678
28473531	493	505	oncogenicity	T201	C3828709
28473531	507	514	Orilnc1	T114,T123	C3494264
28473531	515	525	expression	T045	C0017262
28473531	530	539	regulated	T045	C0017263
28473531	543	568	RAS-RAF-MEK-ERK signaling	T044	C0037080
28473531	577	601	transcription factor AP1	T026	C3888349
28473531	603	610	Orilnc1	T114,T123	C3494264
28473531	622	631	expressed	T045	C0017262
28473531	635	646	BRAF-mutant	T049	C1511021
28473531	647	654	cancers	T191	C0007097
28473531	663	671	melanoma	T191	C0025202
28473531	673	682	Silencing	T045	C0598496
28473531	686	693	Orilnc1	T114,T123	C3494264
28473531	694	701	blocked	T169	C0332206
28473531	702	726	tumor cell proliferation	T043	C0596290
28473531	731	737	growth	T043	C0007595
28473531	738	746	in vitro	T080	C1533691
28473531	751	758	in vivo	T082	C1515655
28473531	774	781	Orilnc1	T114,T123	C3494264
28473531	782	790	blockade	T169	C0332206
28473531	791	798	reduced	T080	C0392756
28473531	799	809	expression	T045	C1171362
28473531	813	822	Cyclin E1	T116,T123	C1259807
28473531	827	834	induced	T169	C0205263
28473531	835	857	G1/S cell cycle arrest	T044	C1517339
28473531	861	872	tumor cells	T025	C0597032
28473531	894	901	results	T169	C1274040
28473531	902	910	identify	T080	C0205396
28473531	911	918	Orilnc1	T114,T123	C3494264
28473531	924	929	novel	T080	C0205314
28473531	955	973	RAS/RAF activation	T040	C2265359
28473531	995	1006	therapeutic	T169	C0302350
28473531	1007	1013	target	T169	C1521840
28473531	1017	1039	RAS/RAF-driven cancers	T191	C0007097

27445319|t|Morphological and enzymatic response of the thermotolerant fungus Fomes sp. EUM1 in solid state fermentation under thermal stress
27445319|a|Thermotolerance of the fungus Fomes sp. EUM1 was evaluated in solid state fermentation (SSF). This thermotolerant strain improved both hyphal invasiveness (38%) and length (17%) in adverse thermal conditions exceeding 30°C and to a maximum of 40°C. In contrast, hyphal branching decreased by 46% at 45°C. The production of cellulases over corn stover increased 1.6-fold in 30°C culture conditions, xylanases increased 2.8-fold at 40°C, while laccase production improved 2.7-fold at 35°C. Maximum production of lignocellulolytic enzymes was obtained at elevated temperatures in shorter fermentation times (8 to 6 days), although the proteases appeared as a thermal stress response associated with a drop in lignocellulolytic activities. Novel and multiple isoenzymes of xylanase (four bands) and cellulase (six bands) were secreted in the range of 20-150 kDa during growth in adverse temperature conditions. However, only a single laccase isoenzyme (46 kDa) was detected. This is the first report describing the advantages of a thermotolerant white-rot fungus in SSF. These results have important implications for large-scale SSF, where effects of metabolic heat are detrimental to growth and enzyme production, which are severely affected by the formation of high temperature gradients.
27445319	0	13	Morphological	T080	C0332437
27445319	18	36	enzymatic response	T044	C0243102
27445319	44	58	thermotolerant	T039	C3544386
27445319	59	65	fungus	T004	C0016832
27445319	66	80	Fomes sp. EUM1	T004	C3052531
27445319	84	108	solid state fermentation	T044	C0015852
27445319	115	122	thermal	T081	C0039476
27445319	123	129	stress	T033	C0038435
27445319	130	145	Thermotolerance	T039	C3544386
27445319	153	159	fungus	T004	C0016832
27445319	160	174	Fomes sp. EUM1	T004	C3052531
27445319	192	216	solid state fermentation	T044	C0015852
27445319	218	221	SSF	T044	C0015852
27445319	229	243	thermotolerant	T039	C3544386
27445319	244	250	strain	T004	C3052531
27445319	265	271	hyphal	T004	C0521057
27445319	272	284	invasiveness	T080	C1301757
27445319	295	301	length	T081	C1444754
27445319	311	326	adverse thermal	T081	C0039476
27445319	327	337	conditions	T080	C0348080
27445319	392	408	hyphal branching	T043	C1156247
27445319	409	418	decreased	T081	C0205216
27445319	439	449	production	T052	C1883254
27445319	453	463	cellulases	T116,T126	C1260229
27445319	469	480	corn stover	T002	C0010028
27445319	481	490	increased	T081	C0205217
27445319	508	515	culture	T130	C0010454
27445319	516	526	conditions	T080	C0348080
27445319	528	537	xylanases	T116,T126	C0014442
27445319	538	547	increased	T081	C0205217
27445319	572	579	laccase	T116,T126	C0064566
27445319	580	590	production	T052	C1883254
27445319	626	636	production	T052	C1883254
27445319	640	665	lignocellulolytic enzymes	T116,T126	C0014442
27445319	682	690	elevated	T080	C3163633
27445319	691	703	temperatures	T081	C0039476
27445319	715	727	fermentation	T044	C0015852
27445319	728	733	times	T081	C1632851
27445319	742	746	days	T079	C0439228
27445319	762	771	proteases	T116,T126	C0030940
27445319	786	793	thermal	T081	C0039476
27445319	794	800	stress	T033	C0038435
27445319	801	809	response	T032	C0871261
27445319	810	825	associated with	T080	C0332281
27445319	836	864	lignocellulolytic activities	T044	C0243102
27445319	885	895	isoenzymes	T116,T126	C0022173
27445319	899	907	xylanase	T116,T126	C0014442
27445319	925	934	cellulase	T116,T121,T126	C0007641
27445319	995	1001	growth	T043	C0007595
27445319	1005	1024	adverse temperature	T081	C0039476
27445319	1025	1035	conditions	T080	C0348080
27445319	1060	1067	laccase	T116,T126	C0064566
27445319	1068	1077	isoenzyme	T116,T126	C0022173
27445319	1091	1099	detected	T033	C0442726
27445319	1119	1125	report	T170	C0684224
27445319	1157	1171	thermotolerant	T039	C3544386
27445319	1172	1188	white-rot fungus	T004	C0597972
27445319	1192	1195	SSF	T044	C0015852
27445319	1203	1210	results	T169	C1274040
27445319	1243	1258	large-scale SSF	T044	C0015852
27445319	1266	1273	effects	T080	C1280500
27445319	1277	1286	metabolic	T040	C0025519
27445319	1287	1291	heat	T070	C0018837
27445319	1296	1307	detrimental	T169	C0001688
27445319	1311	1317	growth	T043	C0007595
27445319	1322	1328	enzyme	T116,T126	C0014442
27445319	1329	1339	production	T052	C1883254
27445319	1360	1368	affected	T169	C0392760
27445319	1376	1385	formation	T169	C1522492
27445319	1394	1405	temperature	T081	C0039476
27445319	1406	1415	gradients	T081	C0812409

27629156|t|Simultaneous determination of eight metabolites of organophosphate and pyrethroid pesticides in urine
27629156|a|A simultaneous method for quantifying eight metabolites of organophosphate pesticides and pyrethroid pesticides in urine samples has been established. The analytes were extracted using liquid-liquid extraction coupled with WCX solid phase extraction (SPE) cartridges. Eight metabolites were chemically derivatized before analysis using gas chromatography-tandem mass spectrometry (GC-MS-MS). The separation was performed on a HP-5MS capillary column (30 m × 0.25 mm × 0.25 µm) with temperature programming. The detection was performed under electro-spray ionization (ESI) in multiple reaction monitoring (MRM) mode. An internal standard method was used. The extraction solvent, types of SPE cartridges and eluents were optimized by comparing the sample recoveries under different conditions. The results showed that the calibration curves of the five organophosphorus pesticides metabolites were linear in the range of 0.2-200 μg/L (r(2) ≥ 0.992) and that of the three pyrethroid pesticides metabolites were linear in the range of 0.025-250 μg/L (r(2) ≥ 0.991). The limits of detection (LODs, S/N ≥ 3) and the limits of quantification (LOQs, S/N ≥ 10) of the eight metabolites were 0.008-0.833 μg/L and 0.25-2.5 μg/L, respectively. The recoveries of the eight metabolites ranged from 54.08% to 82.49%. This efficient, stable, and cost-effective method is adequate to handle the large number of samples required for surveying the exposure level of organophosphorus and pyrethroid pesticides in the general population.
27629156	0	12	Simultaneous	T079	C0521115
27629156	13	26	determination	T059	C1148554
27629156	36	47	metabolites	T123	C0870883
27629156	51	66	organophosphate	T109	C1452958
27629156	71	92	pyrethroid pesticides	T109,T121	C0360431
27629156	96	101	urine	T031	C0042036
27629156	104	116	simultaneous	T079	C0521115
27629156	117	123	method	T169	C0025664
27629156	128	139	quantifying	T081	C1709793
27629156	146	157	metabolites	T123	C0870883
27629156	161	187	organophosphate pesticides	T109,T131	C0360429
27629156	192	213	pyrethroid pesticides	T109,T121	C0360431
27629156	217	230	urine samples	T031	C1610733
27629156	240	251	established	T080	C0443211
27629156	257	265	analytes	T167	C0443354
27629156	271	280	extracted	T059	C0684295
27629156	287	311	liquid-liquid extraction	T059	C3178840
27629156	312	319	coupled	T169	C1948027
27629156	325	368	WCX solid phase extraction (SPE) cartridges	T074	C0179630
27629156	329	357	solid phase extraction (SPE)	T059	C1720880
27629156	376	387	metabolites	T123	C0870883
27629156	423	431	analysis	T062	C0936012
27629156	438	481	gas chromatography-tandem mass spectrometry	T059	C4054903
27629156	483	491	GC-MS-MS	T059	C4054903
27629156	498	508	separation	T059	C1441514
27629156	513	522	performed	T169	C0884358
27629156	528	551	HP-5MS capillary column	T074	C0687238
27629156	584	595	temperature	T081	C0039476
27629156	596	607	programming	T170	C0009607
27629156	613	622	detection	T061	C1511790
27629156	627	636	performed	T169	C0884358
27629156	643	667	electro-spray ionization	T059	C1516801
27629156	669	672	ESI	T059	C1516801
27629156	677	716	multiple reaction monitoring (MRM) mode	T169	C0205245
27629156	721	745	internal standard method	T170	C0025663
27629156	760	770	extraction	T059	C0684295
27629156	771	778	solvent	T130	C0037638
27629156	780	785	types	T080	C0332307
27629156	789	792	SPE	T059	C1720880
27629156	793	803	cartridges	T074	C0179630
27629156	808	815	eluents	T130	C3469601
27629156	821	830	optimized	T052	C2698650
27629156	834	843	comparing	T052	C1707455
27629156	848	854	sample	T167	C0370003
27629156	855	865	recoveries	T052	C0237820
27629156	872	881	different	T080	C1705242
27629156	882	892	conditions	T080	C0348080
27629156	898	905	results	T169	C1274040
27629156	922	933	calibration	T081	C0006751
27629156	934	940	curves	T081	C0392762
27629156	953	980	organophosphorus pesticides	T109,T131	C0360429
27629156	981	992	metabolites	T123	C0870883
27629156	998	1004	linear	T082	C0205132
27629156	1012	1017	range	T081	C1514721
27629156	1071	1092	pyrethroid pesticides	T109,T121	C0360431
27629156	1093	1104	metabolites	T123	C0870883
27629156	1110	1116	linear	T082	C0205132
27629156	1124	1129	range	T081	C1514721
27629156	1168	1187	limits of detection	T081	C2718050
27629156	1189	1193	LODs	T081	C2718050
27629156	1212	1236	limits of quantification	T081	C0392762
27629156	1238	1242	LOQs	T081	C0392762
27629156	1267	1278	metabolites	T123	C0870883
27629156	1338	1348	recoveries	T052	C0237820
27629156	1362	1373	metabolites	T123	C0870883
27629156	1374	1380	ranged	T081	C1514721
27629156	1409	1418	efficient	T080	C0442799
27629156	1420	1426	stable	T080	C0205360
27629156	1432	1446	cost-effective	T169	C0220812
27629156	1447	1453	method	T170	C0025663
27629156	1457	1465	adequate	T080	C0205411
27629156	1496	1503	samples	T167	C0370003
27629156	1517	1526	surveying	T170	C0038951
27629156	1531	1545	exposure level	T081	C0024971
27629156	1549	1565	organophosphorus	T109	C1452958
27629156	1570	1591	pyrethroid pesticides	T109,T121	C0360431
27629156	1607	1617	population	T098	C1257890

27899295|t|Prevalence and correlates of binge eating disorder related features in the community
27899295|a|Binge eating disorder (BED) is associated with high levels of obesity and psychological suffering, but little is known about 1) the distribution of features of BED in the general population and 2) their consequences for weight development and psychological distress in young adulthood. We investigated the prevalence of features of BED and their association with body mass index (BMI) and psychological distress among men (n = 2423) and women (n = 2825) from the longitudinal community-based FinnTwin16 cohort (born 1975-1979). Seven eating -related cognitions and behaviors similar to the defining features of BED were extracted from the Eating Disorder Inventory-2 and were assessed at a mean age of 24. BMI and psychological distress, measured with the General Health Questionnaire, were assessed at ages 24 and 34. We assessed prevalence of the features and their association with BMI and psychological distress cross-sectionally and prospectively. More than half of our participants reported at least one feature of BED; clustering of several features in one individual was less common, particularly among men. The most frequently reported feature was ' stuffing oneself with food ', whereas the least common was ' eating or drinking in secrecy '. All individual features of BED and their clustering particularly were associated with higher BMI and more psychological distress cross-sectionally. Prospectively, the clustering of features of BED predicted increase in psychological distress but not additional weight gain when baseline BMI was accounted for. In summary, although some features of BED were common, the clustering of several features in one individual was not. The features were cumulatively associated with BMI and psychological distress and predicted further increase in psychological distress over ten years of follow-up.
27899295	0	10	Prevalence	T081	C0220900
27899295	15	25	correlates	T080	C1707520
27899295	29	50	binge eating disorder	T048	C0596170
27899295	59	67	features	T080	C2348519
27899295	75	84	community	T096	C0009462
27899295	85	106	Binge eating disorder	T048	C0596170
27899295	108	111	BED	T048	C0596170
27899295	116	131	associated with	T080	C0332281
27899295	132	136	high	T080	C0205250
27899295	137	143	levels	T080	C0441889
27899295	147	154	obesity	T047	C0028754
27899295	159	182	psychological suffering	T048	C0815107
27899295	217	229	distribution	T169	C1704711
27899295	233	241	features	T080	C2348519
27899295	245	248	BED	T048	C0596170
27899295	256	274	general population	T098	C0683971
27899295	305	311	weight	T032	C0005910
27899295	312	323	development	T169	C1527148
27899295	328	350	psychological distress	T048	C0815107
27899295	354	369	young adulthood	T100	C0680085
27899295	374	386	investigated	T169	C1292732
27899295	391	401	prevalence	T081	C0220900
27899295	405	413	features	T080	C2348519
27899295	417	420	BED	T048	C0596170
27899295	431	442	association	T080	C0439849
27899295	448	463	body mass index	T201	C1305855
27899295	465	468	BMI	T201	C1305855
27899295	474	496	psychological distress	T048	C0815107
27899295	503	506	men	T098	C0025266
27899295	522	527	women	T098	C0043210
27899295	548	594	longitudinal community-based FinnTwin16 cohort	T081	C0009247
27899295	619	625	eating	T040	C0013470
27899295	635	645	cognitions	T041	C0009240
27899295	650	659	behaviors	T053	C0004927
27899295	684	692	features	T080	C2348519
27899295	696	699	BED	T048	C0596170
27899295	724	751	Eating Disorder Inventory-2	T170	C0451138
27899295	780	783	age	T032	C0001779
27899295	791	794	BMI	T201	C1305855
27899295	799	821	psychological distress	T048	C0815107
27899295	841	869	General Health Questionnaire	T060	C0451182
27899295	876	884	assessed	T052	C1516048
27899295	888	892	ages	T032	C0001779
27899295	916	926	prevalence	T081	C0220900
27899295	934	942	features	T080	C2348519
27899295	953	964	association	T080	C0439849
27899295	970	973	BMI	T201	C1305855
27899295	978	1000	psychological distress	T048	C0815107
27899295	1001	1018	cross-sectionally	T062	C0010362
27899295	1023	1036	prospectively	T062	C0033522
27899295	1060	1072	participants	T098	C0679646
27899295	1095	1102	feature	T080	C2348519
27899295	1106	1109	BED	T048	C0596170
27899295	1111	1121	clustering	T081	C1704332
27899295	1133	1141	features	T080	C2348519
27899295	1149	1159	individual	T098	C0237401
27899295	1196	1199	men	T098	C0025266
27899295	1230	1237	feature	T080	C2348519
27899295	1244	1270	stuffing oneself with food	T033	C0243095
27899295	1305	1334	eating or drinking in secrecy	T033	C0243095
27899295	1342	1352	individual	T098	C0237401
27899295	1353	1361	features	T080	C2348519
27899295	1365	1368	BED	T048	C0596170
27899295	1379	1389	clustering	T081	C1704332
27899295	1408	1423	associated with	T080	C0332281
27899295	1431	1434	BMI	T201	C1305855
27899295	1444	1466	psychological distress	T048	C0815107
27899295	1467	1484	cross-sectionally	T082	C1254362
27899295	1486	1499	Prospectively	T082	C1254362
27899295	1505	1515	clustering	T081	C1704332
27899295	1519	1527	features	T080	C2348519
27899295	1531	1534	BED	T048	C0596170
27899295	1557	1579	psychological distress	T048	C0815107
27899295	1599	1610	weight gain	T033	C0043094
27899295	1616	1624	baseline	T081	C1442488
27899295	1625	1628	BMI	T201	C1305855
27899295	1674	1682	features	T080	C2348519
27899295	1686	1689	BED	T048	C0596170
27899295	1695	1701	common	T081	C0205214
27899295	1707	1717	clustering	T081	C1704332
27899295	1729	1737	features	T080	C2348519
27899295	1745	1755	individual	T098	C0237401
27899295	1769	1777	features	T080	C2348519
27899295	1796	1811	associated with	T080	C0332281
27899295	1812	1815	BMI	T201	C1305855
27899295	1820	1842	psychological distress	T048	C0815107
27899295	1877	1899	psychological distress	T048	C0815107
27899295	1909	1914	years	T079	C0439234
27899295	1918	1927	follow-up	T058	C1522577

28382143|t|Albumin -to- Alkaline Phosphatase Ratio: A Novel Prognostic Index of Overall Survival in Cisplatin -based Chemotherapy - treated Patients with Metastatic Nasopharyngeal Carcinoma
28382143|a|The Albumin -to- Alkaline Phosphatase Ratio (AAPR) has been recently revealed as a prognostic index for hepatocellular carcinoma, whereas its role in metastatic nasopharyngeal cancer (NPC) remains unclear. The aim of this study was to evaluate the clinical value of AAPR in patients with metastatic NPC. We retrospectively reviewed 209 metastatic NPC patients treated with cisplatin -based regimens. Survival data were calculated using the Kaplan-Meier method and were compared using the log-rank test. Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression methodology. The optimal cutoff level of AAPR for assessing overall survival (OS) was 0.447, which was determined by R software. An AAPR less than 0.447 was significantly associated with a higher lactate dehydrogenase (LDH) level (273 vs. 185 U/L, P = 0.004), a higher EBV DNA viral load (5.59×10(5) vs. 3.49×10(4) copies/ml, P = 0.001), and more liver and bone metastases (P = 0.005 and P = 0.001, respectively). Additionally, patients with an AAPR < 0.447 had a shorter overall survival and progression-free survival (hazard ratio: 3.269, 95% confidence interval: 1.710-6.248; HR: 2.295, 95% confidence interval: 1.217-4.331, respectively) than those with an AAPR ≥ 0.447. Our study suggested that the AAPR might be a novel prognostic factor in metastatic NPC patients treated with cisplatin -based regimens. However, a prospective study to validate its prognostic value is needed, and the mechanisms underlying the low AAPR and poor survival in metastatic NPC need to be further investigated.
28382143	0	7	Albumin	T116,T123	C0001924
28382143	13	33	Alkaline Phosphatase	T116,T126	C0002059
28382143	34	39	Ratio	T081	C0456603
28382143	49	59	Prognostic	T170	C0220901
28382143	60	65	Index	T170	C0918012
28382143	69	85	Overall Survival	T081	C4086681
28382143	89	98	Cisplatin	T121,T197	C0008838
28382143	106	118	Chemotherapy	T061	C3665472
28382143	121	128	treated	T169	C1522326
28382143	129	137	Patients	T101	C0030705
28382143	143	178	Metastatic Nasopharyngeal Carcinoma	T191	C1377919
28382143	183	190	Albumin	T116,T123	C0001924
28382143	196	216	Alkaline Phosphatase	T116,T126	C0002059
28382143	217	222	Ratio	T081	C0456603
28382143	224	228	AAPR	T034	C1254595
28382143	262	272	prognostic	T170	C0220901
28382143	273	278	index	T170	C0918012
28382143	283	307	hepatocellular carcinoma	T191	C2239176
28382143	329	361	metastatic nasopharyngeal cancer	T191	C1377919
28382143	363	366	NPC	T191	C1377919
28382143	389	392	aim	T078	C1947946
28382143	401	406	study	T062	C2603343
28382143	414	422	evaluate	T058	C0220825
28382143	427	441	clinical value	T080	C0449440
28382143	445	449	AAPR	T034	C1254595
28382143	453	461	patients	T101	C0030705
28382143	467	481	metastatic NPC	T191	C1377919
28382143	486	501	retrospectively	T080	C1514923
28382143	502	510	reviewed	T080	C1709940
28382143	515	529	metastatic NPC	T191	C1377919
28382143	530	538	patients	T101	C0030705
28382143	539	551	treated with	T061	C0332293
28382143	552	561	cisplatin	T121,T197	C0008838
28382143	569	577	regimens	T061	C0040808
28382143	579	592	Survival data	T081	C0038954
28382143	598	608	calculated	T052	C1441506
28382143	619	638	Kaplan-Meier method	T081	C1720943
28382143	682	692	Univariate	T062	C0683962
28382143	697	727	multivariate survival analyses	T062	C0038953
28382143	753	800	Cox proportional hazards regression methodology	T081,T170	C0010235
28382143	806	813	optimal	T080	C2698651
28382143	814	820	cutoff	T169	C1442160
28382143	821	826	level	T080	C0441889
28382143	830	834	AAPR	T034	C1254595
28382143	839	848	assessing	T058	C0184514
28382143	849	865	overall survival	T081	C4086681
28382143	867	869	OS	T081	C4086681
28382143	892	905	determined by	T080	C0521095
28382143	906	916	R software	T170	C0037589
28382143	921	925	AAPR	T034	C1254595
28382143	960	975	associated with	T080	C0332281
28382143	978	984	higher	T080	C0205250
28382143	985	1018	lactate dehydrogenase (LDH) level	T034	C1318159
28382143	1051	1076	higher EBV DNA viral load	T033	C3808257
28382143	1136	1141	liver	T191	C0494165
28382143	1146	1161	bone metastases	T191	C0153690
28382143	1217	1225	patients	T101	C0030705
28382143	1234	1238	AAPR	T034	C1254595
28382143	1261	1277	overall survival	T081	C4086681
28382143	1299	1307	survival	T169	C0220921
28382143	1309	1321	hazard ratio	T081	C2985465
28382143	1334	1353	confidence interval	T081	C0009667
28382143	1368	1370	HR	T081	C2985465
28382143	1383	1402	confidence interval	T081	C0009667
28382143	1450	1454	AAPR	T034	C1254595
28382143	1468	1473	study	T062	C2603343
28382143	1493	1497	AAPR	T034	C1254595
28382143	1515	1525	prognostic	T170	C0220901
28382143	1536	1550	metastatic NPC	T191	C1377919
28382143	1551	1559	patients	T101	C0030705
28382143	1560	1572	treated with	T061	C0332293
28382143	1573	1582	cisplatin	T121,T197	C0008838
28382143	1590	1598	regimens	T061	C0040808
28382143	1611	1628	prospective study	T062	C0033522
28382143	1645	1655	prognostic	T170	C0220901
28382143	1681	1691	mechanisms	T169	C0441712
28382143	1707	1710	low	T080	C0205251
28382143	1711	1715	AAPR	T034	C1254595
28382143	1720	1724	poor	T080	C0542537
28382143	1725	1733	survival	T169	C0220921
28382143	1737	1751	metastatic NPC	T191	C1377919
28382143	1771	1783	investigated	T169	C1292732

28053655|t|An investigation of fungal contamination on the surface of medicinal herbs in China
28053655|a|The dried parts of medicinal herbs are susceptible to the infection of fungi during p re- or post-harvest procedure. This study aimed to investigate the presence of fungi and their metabolites mycotoxins on the surface of medicinal herbs collected from China. Forty-five retail samples of 15 different medicinal herbs were collected from 3 different regions in China. Then the potential fungi were immediately washed off from the surface of each sample with 0.1% Tween-20 followed by incubation of the rinse on petri-dish with potato dextrose agar containing chloramphenicol at 28 °C. The obtained fungi were isolated as single colonies and then characterized by morphology and molecular identification using internal transcribed spacer (ITS) sequencing with extracted DNA. Meanwhile, the mycotoxin -producing potential of the isolates was studied by liquid chromatography-tandem mass spectrometry (LC-MS / MS). A total of 126 fungi were identified from the surface of samples by morphology and ITS sequencing, with Aspergillus and Penicillium genera as the predominant contaminants. The mycotoxin -producing potential analysis showed that 6 of 8 A. versicolor isolates could produce sterigmatocystin. All 3 A. aculeatus isolates produced ochratoxin A, but only 1 of 3 A. flavus strains produced aflatoxins B1 and B2 without G1 and G2. Although the sample contamination ratios were high (≥95.6%), there was no significant difference (χ(2) = 1.05, P = 1.0) among the samples from 3 regions, which demonstrates the prevalent fungal contamination in the herbal medicines. The prevalent contamination phenomenon of fungi and high potential risk of sterigmatocystin and ochratoxin A were observed in 45 medicinal herbs collected from China.
28053655	3	16	investigation	T062	C0683933
28053655	20	40	fungal contamination	T033	C2609331
28053655	48	55	surface	T082	C0205148
28053655	59	74	medicinal herbs	T002	C0025125
28053655	78	83	China	T083	C0008115
28053655	88	93	dried	T080	C1512080
28053655	103	118	medicinal herbs	T002	C0025125
28053655	123	134	susceptible	T169	C0231204
28053655	142	151	infection	T046	C3714514
28053655	155	160	fungi	T004	C0016832
28053655	170	199	re- or post-harvest procedure	T052	C0441655
28053655	206	211	study	T062	C2603343
28053655	221	232	investigate	T062	C0683933
28053655	249	254	fungi	T004	C0016832
28053655	265	276	metabolites	T123	C0870883
28053655	277	287	mycotoxins	T109,T131	C0026955
28053655	295	302	surface	T082	C0205148
28053655	306	321	medicinal herbs	T002	C0025125
28053655	322	331	collected	T169	C1516698
28053655	337	342	China	T083	C0008115
28053655	362	369	samples	T081	C0033206
28053655	386	401	medicinal herbs	T002	C0025125
28053655	434	441	regions	T083	C0017446
28053655	445	450	China	T083	C0008115
28053655	471	476	fungi	T004	C0016832
28053655	494	500	washed	T078	C1548982
28053655	514	521	surface	T082	C0205148
28053655	530	536	sample	T081	C0033206
28053655	547	555	Tween-20	T109,T121	C0041415
28053655	568	578	incubation	T059	C0022885
28053655	586	591	rinse	T052	C1882955
28053655	595	605	petri-dish	T074	C1322960
28053655	611	631	potato dextrose agar	T130	C3266617
28053655	643	658	chloramphenicol	T109,T195	C0008168
28053655	682	687	fungi	T004	C0016832
28053655	693	701	isolated	T169	C0205409
28053655	712	720	colonies	T081	C0439158
28053655	747	757	morphology	T080	C0332437
28053655	762	786	molecular identification	T059	C0022885
28053655	793	837	internal transcribed spacer (ITS) sequencing	T059	C1294197
28053655	853	856	DNA	T114,T123	C0012854
28053655	873	882	mycotoxin	T109,T131	C0026955
28053655	911	919	isolates	T123	C1764827
28053655	935	981	liquid chromatography-tandem mass spectrometry	T059	C4049918
28053655	983	988	LC-MS	T059	C4049918
28053655	991	993	MS	T059	C0037813
28053655	1011	1016	fungi	T004	C0016832
28053655	1042	1049	surface	T082	C0205148
28053655	1053	1060	samples	T081	C0033206
28053655	1064	1074	morphology	T080	C0332437
28053655	1079	1093	ITS sequencing	T059	C1294197
28053655	1100	1111	Aspergillus	T004	C0004034
28053655	1116	1127	Penicillium	T004	C0030843
28053655	1128	1134	genera	T185	C1708235
28053655	1154	1166	contaminants	T167	C2827365
28053655	1172	1181	mycotoxin	T109,T131	C0026955
28053655	1231	1244	A. versicolor	T004	C0319924
28053655	1245	1253	isolates	T123	C1764827
28053655	1268	1284	sterigmatocystin	T109,T123,T131	C0038274
28053655	1292	1304	A. aculeatus	T004	C1080950
28053655	1305	1313	isolates	T123	C1764827
28053655	1323	1335	ochratoxin A	T109,T121	C0069299
28053655	1353	1362	A. flavus	T004	C0004036
28053655	1363	1370	strains	T080	C0456178
28053655	1380	1393	aflatoxins B1	T109,T131	C0085180
28053655	1398	1400	B2	T109,T123,T131	C0050929
28053655	1409	1411	G1	T109,T123,T131	C0050931
28053655	1416	1418	G2	T109,T123,T131	C0050932
28053655	1433	1439	sample	T081	C0033206
28053655	1440	1453	contamination	T033	C2609331
28053655	1550	1557	samples	T081	C0033206
28053655	1565	1572	regions	T083	C0017446
28053655	1607	1627	fungal contamination	T033	C2609331
28053655	1635	1651	herbal medicines	T121	C2240391
28053655	1667	1680	contamination	T033	C2609331
28053655	1695	1700	fungi	T004	C0016832
28053655	1720	1724	risk	T078	C0035647
28053655	1728	1744	sterigmatocystin	T109,T123,T131	C0038274
28053655	1749	1761	ochratoxin A	T109,T121	C0069299
28053655	1782	1797	medicinal herbs	T002	C0025125
28053655	1798	1807	collected	T169	C1516698
28053655	1813	1818	China	T083	C0008115

27299182|t|Anti-inflammatory and antimicrobial coumarins from the stems of Eurya chinensis
27299182|a|Two new coumarins, named (±)-euryacoumarin A (1) and 6-demethylobtusinin (2), and one new natural coumarin, named euryacoumarin B (3), along with two known compounds, scopoletin (4) and obtusinol (5), were isolated from the stems of Eurya chinensis. Their structures were elucidated by means of extensive spectroscopic methods and comparison with data reported in the literatures. Compound 1 exhibited significant inhibition of LPS-induced nitric oxide (NO) production in RAW264.7 cells with IC50 value of 35.64 ± 1.73 μM, and showed marginal antibacterial activities against Bacillus subtilis and B. cereus with MIC values of 50.59 ± 2.12 and 35.42 ± 0.96 μM, respectively.
27299182	0	17	Anti-inflammatory	T121	C0003209
27299182	22	35	antimicrobial	T121	C1136254
27299182	36	45	coumarins	T109,T121	C0010207
27299182	55	60	stems	T002	C0242767
27299182	64	79	Eurya chinensis	T002	C1050417
27299182	88	97	coumarins	T109,T121	C0010207
27299182	105	124	(±)-euryacoumarin A	T109,T121	C0010207
27299182	133	152	6-demethylobtusinin	T109,T121	C0010207
27299182	170	186	natural coumarin	T109,T121	C0010207
27299182	194	209	euryacoumarin B	T109,T121	C0010207
27299182	247	257	scopoletin	T109,T123	C0036447
27299182	266	275	obtusinol	T123	C0574031
27299182	286	294	isolated	T169	C0205409
27299182	304	309	stems	T002	C0242767
27299182	313	328	Eurya chinensis	T002	C1050417
27299182	336	346	structures	T082	C0678594
27299182	385	406	spectroscopic methods	T059	C0022885
27299182	411	421	comparison	T052	C1707455
27299182	427	431	data	T078	C1511726
27299182	448	459	literatures	T170	C0023866
27299182	461	471	Compound 1	T109,T121	C0010206
27299182	494	504	inhibition	T052	C3463820
27299182	508	548	LPS-induced nitric oxide (NO) production	T043	C0007613
27299182	552	566	RAW264.7 cells	T025	C4042840
27299182	572	576	IC50	T081	C0600495
27299182	623	636	antibacterial	T195	C0279516
27299182	637	647	activities	T169	C0205177
27299182	656	673	Bacillus subtilis	T007	C0004595
27299182	678	687	B. cereus	T007	C0004590
27299182	693	703	MIC values	T034	C1304747

27249236|t|Anthology of Venezuelan psychiatry
27249236|a|Reception of Psychiatry in Venezuela since the 19th Century to the late 20th Century merits a historical approach. The following work proposes to research some of the very origins of Venezuelan psychiatry and its possible influence on contemporary mental health practice. Through documental research, the early works of local authors from the 19th Century through 20th Century finals: Carlos Arvelo, Lisandro Alvarado, Francisco Herrera Luque, Jose Luis Vethencourt and Jose Solanes, are subjected to study. This journey illustrates a descriptive panoramic view which allows to better comprenhend the current state of our psychiatry. In a brief introduction the most important events are described, since the arrival of Pinel's ideas, followed by the early research paperworks published and the beginnings of the academic teachings of this specialty in Venezuela and displaying the main contemporary research groups thorough the country.
27249236	0	9	Anthology	T170	C0600644
27249236	13	23	Venezuelan	T098	C0241664
27249236	24	34	psychiatry	T091	C0033873
27249236	35	44	Reception	T080	C0205556
27249236	48	58	Psychiatry	T091	C0033873
27249236	62	71	Venezuela	T083	C0042469
27249236	181	189	research	T062	C0035168
27249236	218	228	Venezuelan	T098	C0241664
27249236	229	239	psychiatry	T091	C0033873
27249236	257	266	influence	T077	C4054723
27249236	283	305	mental health practice	T058	C0086388
27249236	340	351	early works	T057	C0043227
27249236	355	368	local authors	T097	C3812881
27249236	420	433	Carlos Arvelo	T016	C0086418
27249236	435	452	Lisandro Alvarado	T016	C0086418
27249236	454	477	Francisco Herrera Luque	T016	C0086418
27249236	479	500	Jose Luis Vethencourt	T016	C0086418
27249236	505	517	Jose Solanes	T016	C0086418
27249236	657	667	psychiatry	T091	C0033873
27249236	674	692	brief introduction	T169	C0579004
27249236	712	718	events	T051	C0441471
27249236	744	751	arrival	T052	C1706079
27249236	755	762	Pinel's	T016	C0086418
27249236	763	768	ideas	T078	C1254370
27249236	812	821	published	T057	C0034037
27249236	848	866	academic teachings	UnknownType	C0681341
27249236	888	897	Venezuela	T083	C0042469
27249236	902	912	displaying	T169	C0870432
27249236	922	950	contemporary research groups	UnknownType	C0681822
27249236	951	971	thorough the country	T083	C0042469

28440461|t|The role of miR-451 in the switching between proliferation and migration in malignant glioma cells: AMPK signaling, mTOR modulation and Rac1 activation required
28440461|a|Glioblastoma multiforme (GBM), WHO grade IV astrocytoma, is the most common primary neoplasm of the central nervous system (CNS) and has the highest malignancy and mortality rates. The invasive nature of GBM complicates surgical resection and restricts chemotherapeutic access, contributing to poor patient prognosis. The migration of tumor cells is closely related to the tumor cell proliferation. The acquisition of migratory capability, in addition to intracellular factors, is proposed to be a crucial mechanism during the progression of invasion. Using qRT-PCR analysis, we determined that the expression of miR-451 in glioma tissue was lower than in control brain tissue, especially in the central portions of the tumor. In glioma cell lines, we found that decreased miR-451 expression suppressed tumor cell proliferation but enhanced migration with a concomitant low level of CAB39 / AMPK / mTOR pathway activation and high level of Rac1 / cofilin pathway activation, respectively. Notably, the effect of miR-451 on cytological behavior and on the activation of mTOR and Rac1 was limited when AMPKα1 expression was knocked-down with a synthetic shRNA. We suggest that the glioma microenvironment results in heterogeneity of miR-451 expression. Our data indicated that miR-451 relays environmental signals by upregulating the activity of AMPK signaling, thereby modulating the activation of mTOR and Rac1 / cofilin which, in turn, play key roles in glioma cell proliferation and migration, respectively. Our results highlight the need to consider opposing roles of a therapeutic target which, while suppressing tumor cell proliferation, could also promote cell infiltration.
28440461	12	19	miR-451	T114	C2603907
28440461	45	58	proliferation	T169	C1514485
28440461	63	72	migration	T039	C1533574
28440461	76	92	malignant glioma	T191	C0555198
28440461	93	98	cells	T025	C0007634
28440461	100	104	AMPK	T116,T121,T126	C0252214
28440461	105	114	signaling	T038	C3537152
28440461	116	120	mTOR	T116,T126	C1307407
28440461	121	131	modulation	T082	C0443264
28440461	136	140	Rac1	T116,T126	C0139880
28440461	141	151	activation	T045	C0599177
28440461	161	184	Glioblastoma multiforme	T191	C1621958
28440461	186	189	GBM	T191	C1621958
28440461	192	216	WHO grade IV astrocytoma	T191	C0017636
28440461	237	253	primary neoplasm	T191	C0677930
28440461	261	283	central nervous system	T022	C3714787
28440461	285	288	CNS	T022	C3714787
28440461	310	320	malignancy	T191	C4282132
28440461	325	340	mortality rates	T081	C0205848
28440461	346	361	invasive nature	T080	C0205281
28440461	365	368	GBM	T191	C1621958
28440461	381	399	surgical resection	T061	C0728940
28440461	414	437	chemotherapeutic access	T061	C0870057
28440461	460	467	patient	T101	C0030705
28440461	468	477	prognosis	T058	C0033325
28440461	483	492	migration	T039	C1533574
28440461	496	507	tumor cells	T025	C0597032
28440461	534	544	tumor cell	T025	C0597032
28440461	545	558	proliferation	T169	C1514485
28440461	564	575	acquisition	T052	C1706701
28440461	579	588	migratory	T169	C0232901
28440461	589	599	capability	T080	C2698977
28440461	616	629	intracellular	T082	C0178719
28440461	630	637	factors	T169	C1521761
28440461	659	676	crucial mechanism	T169	C0441712
28440461	688	699	progression	T169	C0449258
28440461	703	711	invasion	T033	C1269955
28440461	719	726	qRT-PCR	T063	C1514628
28440461	727	735	analysis	T062	C0936012
28440461	760	770	expression	T045	C0017262
28440461	774	781	miR-451	T028	C1826031
28440461	785	791	glioma	T191	C0017638
28440461	792	798	tissue	T024	C0040300
28440461	817	837	control brain tissue	T023	C0459385
28440461	857	864	central	T082	C0205099
28440461	865	873	portions	T082	C0449719
28440461	881	886	tumor	T191	C0027651
28440461	891	897	glioma	T191	C0017638
28440461	898	908	cell lines	T025	C0085983
28440461	924	933	decreased	T081	C0205216
28440461	934	941	miR-451	T028	C1826031
28440461	942	952	expression	T045	C0017262
28440461	953	963	suppressed	T169	C1260953
28440461	964	974	tumor cell	T025	C0597032
28440461	975	988	proliferation	T169	C1514485
28440461	1002	1011	migration	T039	C1533574
28440461	1019	1030	concomitant	T079	C0521115
28440461	1044	1049	CAB39	T116,T123	C2715759
28440461	1052	1056	AMPK	T116,T121,T126	C0252214
28440461	1059	1063	mTOR	T116,T126	C1307407
28440461	1064	1082	pathway activation	T169	C1514528
28440461	1101	1105	Rac1	T116,T126	C0139880
28440461	1108	1115	cofilin	T116,T123	C0056080
28440461	1116	1134	pathway activation	T169	C1514528
28440461	1173	1180	miR-451	T114	C2603907
28440461	1184	1204	cytological behavior	T169	C0205471
28440461	1216	1226	activation	T045	C0599177
28440461	1230	1234	mTOR	T116,T126	C1307407
28440461	1239	1243	Rac1	T116,T126	C0139880
28440461	1261	1267	AMPKα1	T116,T126	C1739697
28440461	1268	1278	expression	T045	C1171362
28440461	1303	1312	synthetic	T052	C1883254
28440461	1313	1318	shRNA	T114	C2930586
28440461	1340	1346	glioma	T191	C0017638
28440461	1347	1363	microenvironment	T070	C2936626
28440461	1375	1388	heterogeneity	T080	C0019409
28440461	1392	1399	miR-451	T028	C1826031
28440461	1400	1410	expression	T045	C0017262
28440461	1436	1443	miR-451	T114	C2603907
28440461	1476	1488	upregulating	T044	C0041904
28440461	1505	1509	AMPK	T116,T121,T126	C0252214
28440461	1510	1519	signaling	T038	C3537152
28440461	1529	1539	modulating	T082	C0443264
28440461	1544	1554	activation	T045	C0599177
28440461	1558	1562	mTOR	T116,T126	C1307407
28440461	1567	1571	Rac1	T116,T126	C0139880
28440461	1574	1581	cofilin	T116,T123	C0056080
28440461	1616	1622	glioma	T191	C0017638
28440461	1628	1641	proliferation	T169	C1514485
28440461	1646	1655	migration	T039	C1533574
28440461	1734	1745	therapeutic	T169	C0302350
28440461	1766	1777	suppressing	T169	C1260953
28440461	1778	1788	tumor cell	T025	C0597032
28440461	1789	1802	proliferation	T169	C1514485
28440461	1823	1827	cell	T025	C0007634
28440461	1828	1840	infiltration	T046	C0332448

28096973|t|A fission yeast cell-based system for multidrug resistant HIV-1 proteases
28096973|a|HIV-1 protease (PR) is an essential enzyme for viral production. Thus, PR inhibitors (PIs) are the most effective class of anti-HIV drugs. However, the main challenge to the successful use of PI drugs in patient treatment is the emergence of multidrug resistant PRs (mdrPRs). This study aimed to develop a fission yeast cell-based system for rapid testing of new PIs that combat mdrPRs. Three mdrPRs were isolated from HIV-infected patients that carried seven (M7PR), ten (M10PR) and eleven (M11PR) PR gene mutations, respectively. They were cloned and expressed in fission yeast under an inducible promoter to allow the measurement of PR -specific proteolysis and drug resistance. The results showed that all three mdrPRs maintained their abilities to proteolyze HIV viral substrates (MA ↓ CA and p6) and to confer drug resistance. Production of these proteins in the fission yeast caused cell growth inhibition, oxidative stress and altered mitochondrial morphologies that led to cell death. Five investigational PIs were used to test the utility of the established yeast system with an FDA - approved PI drug Darunavir (DRV) as control. All six compounds suppressed the wildtype PR (wtPR) and the M7PR -mediated activities. However, none of them were able to suppress the M10PR or the M11PR. The three clinically isolated mdrPRs maintained their viral proteolytic activities and drug resistance in the fission yeast. Furthermore, those viral mdrPR activities were coupled with the induction of growth inhibition and cell death, which could be used to test the PI activities. Indeed, the five investigational PIs and DRV suppressed the wtPR in fission yeast as they did in mammalian cells. Significantly, two of the high level mdrPRs (M10PR and M11PR) were resistant to all of the existing PI drugs including DRV. This observation underscores the importance of continued searching for new PIs against mdrPRs.
28096973	2	15	fission yeast	T004	C0178453
28096973	2	33	fission yeast cell-based system	T062	C1520210
28096973	38	57	multidrug resistant	T032	C0242640
28096973	58	73	HIV-1 proteases	T116,T126	C0917721
28096973	74	88	HIV-1 protease	T116,T126	C0917721
28096973	90	92	PR	T116,T126	C0917721
28096973	110	116	enzyme	T116,T126	C0014442
28096973	121	137	viral production	T043	C0042774
28096973	145	158	PR inhibitors	T121	C0162714
28096973	160	163	PIs	T121	C0162714
28096973	197	211	anti-HIV drugs	T121	C0376565
28096973	266	268	PI	T121	C0162714
28096973	269	274	drugs	T121	C0013227
28096973	278	285	patient	T101	C0030705
28096973	286	295	treatment	T061	C0087111
28096973	316	339	multidrug resistant PRs	T116,T126	C0917721
28096973	341	347	mdrPRs	T116,T126	C0917721
28096973	355	360	study	T062	C2603343
28096973	380	393	fission yeast	T004	C0178453
28096973	380	411	fission yeast cell-based system	T062	C1520210
28096973	422	429	testing	T169	C0039593
28096973	437	440	PIs	T121	C0162714
28096973	453	459	mdrPRs	T116,T126	C0917721
28096973	467	473	mdrPRs	T116,T126	C0917721
28096973	493	505	HIV-infected	T047	C0019693
28096973	506	514	patients	T101	C0030705
28096973	535	539	M7PR	T116,T126	C0917721
28096973	547	552	M10PR	T116,T126	C0917721
28096973	566	571	M11PR	T116,T126	C0917721
28096973	573	575	PR	T116,T126	C0917721
28096973	576	590	gene mutations	T045	C0596611
28096973	616	622	cloned	T059,T063	C0598888
28096973	627	636	expressed	T045	C0017262
28096973	640	653	fission yeast	T004	C0178453
28096973	663	681	inducible promoter	T114,T123	C0086860
28096973	710	712	PR	T116,T126	C0917721
28096973	723	734	proteolysis	T044	C0597304
28096973	739	754	drug resistance	T038	C0013203
28096973	790	796	mdrPRs	T116,T126	C0917721
28096973	827	837	proteolyze	T044	C0597304
28096973	838	841	HIV	T005	C0019682
28096973	842	858	viral substrates	T167	C3891814
28096973	860	862	MA	T116,T123	C0042738
28096973	865	867	CA	T116,T123	C0042738
28096973	872	874	p6	T116,T126	C0917721
28096973	890	905	drug resistance	T038	C0013203
28096973	927	935	proteins	T116,T126	C0917721
28096973	943	956	fission yeast	T004	C0178453
28096973	964	986	cell growth inhibition	T043	C2244509
28096973	988	1004	oxidative stress	T049	C0242606
28096973	1009	1043	altered mitochondrial morphologies	T033	C4014650
28096973	1056	1066	cell death	T043	C0007587
28096973	1073	1088	investigational	T080	C1517586
28096973	1089	1092	PIs	T121	C0162714
28096973	1142	1154	yeast system	T062	C1520210
28096973	1163	1166	FDA	T093	C0041714
28096973	1169	1177	approved	T080	C0205540
28096973	1178	1180	PI	T121	C0162714
28096973	1181	1185	drug	T121	C0013227
28096973	1186	1195	Darunavir	T109,T121	C1435444
28096973	1197	1200	DRV	T109,T121	C1435444
28096973	1205	1212	control	T096	C0009932
28096973	1222	1231	compounds	T121	C0162714
28096973	1232	1242	suppressed	T169	C1260953
28096973	1247	1255	wildtype	T028	C1883559
28096973	1247	1258	wildtype PR	T116,T126	C0917721
28096973	1260	1264	wtPR	T116,T126	C0917721
28096973	1274	1278	M7PR	T116,T126	C0917721
28096973	1289	1299	activities	T052	C0441655
28096973	1336	1344	suppress	T169	C1260953
28096973	1349	1354	M10PR	T116,T126	C0917721
28096973	1362	1367	M11PR	T116,T126	C0917721
28096973	1399	1405	mdrPRs	T116,T126	C0917721
28096973	1423	1428	viral	T005	C0042776
28096973	1429	1451	proteolytic activities	T044	C0597304
28096973	1456	1471	drug resistance	T038	C0013203
28096973	1479	1492	fission yeast	T004	C0178453
28096973	1513	1524	viral mdrPR	T116,T126	C0917721
28096973	1525	1535	activities	T044	C0597304
28096973	1558	1567	induction	T169	C0205263
28096973	1571	1588	growth inhibition	T043	C2244509
28096973	1593	1603	cell death	T043	C0007587
28096973	1637	1639	PI	T121	C0162714
28096973	1640	1650	activities	T052	C0441655
28096973	1669	1684	investigational	T080	C1517586
28096973	1685	1688	PIs	T121	C0162714
28096973	1693	1696	DRV	T109,T121	C1435444
28096973	1697	1707	suppressed	T169	C1260953
28096973	1712	1716	wtPR	T116,T126	C0917721
28096973	1720	1733	fission yeast	T004	C0178453
28096973	1749	1764	mammalian cells	T025	C1512977
28096973	1803	1809	mdrPRs	T116,T126	C0917721
28096973	1811	1816	M10PR	T116,T126	C0917721
28096973	1821	1826	M11PR	T116,T126	C0917721
28096973	1833	1842	resistant	T169	C0332325
28096973	1866	1868	PI	T121	C0162714
28096973	1869	1874	drugs	T121	C0013227
28096973	1885	1888	DRV	T109,T121	C1435444
28096973	1965	1968	PIs	T121	C0162714
28096973	1977	1983	mdrPRs	T116,T126	C0917721

28125006|t|Support Vector Machine Classification of Drunk Driving Behaviour
28125006|a|Alcohol is the root cause of numerous traffic accidents due to its pharmacological action on the human central nervous system. This study conducted a detection process to distinguish drunk driving from normal driving under simulated driving conditions. The classification was performed by a support vector machine (SVM) classifier trained to distinguish between these two classes by integrating both driving performance and physiological measurements. In addition, principal component analysis was conducted to rank the weights of the features. The standard deviation of R-R intervals (SDNN), the root mean square value of the difference of the adjacent R-R interval series (RMSSD), low frequency (LF), high frequency (HF), the ratio of the low and high frequencies (LF/HF), and average blink duration were the highest weighted features in the study. The results show that SVM classification can successfully distinguish drunk driving from normal driving with an accuracy of 70%. The driving performance data and the physiological measurements reported by this paper combined with air - alcohol concentration could be integrated using the support vector regression classification method to establish a better early warning model, thereby improving vehicle safety.
28125006	0	22	Support Vector Machine	T081	C2699740
28125006	23	37	Classification	T185	C0008902
28125006	41	54	Drunk Driving	T048	C0556374
28125006	55	64	Behaviour	T053	C0004927
28125006	65	72	Alcohol	T168	C0001967
28125006	94	102	numerous	T081	C0439064
28125006	103	120	traffic accidents	T037	C0000932
28125006	132	154	pharmacological action	T044	C1148560
28125006	162	167	human	T016	C0086418
28125006	168	190	central nervous system	T022	C3714787
28125006	197	202	study	T062	C2603343
28125006	215	232	detection process	T033	C0442726
28125006	236	247	distinguish	T169	C0205245
28125006	248	261	drunk driving	T048	C0556374
28125006	267	273	normal	T080	C0205307
28125006	274	281	driving	T056	C0004379
28125006	288	297	simulated	T169	C0205245
28125006	298	305	driving	T056	C0004379
28125006	306	316	conditions	T080	C0348080
28125006	322	336	classification	T185	C0008902
28125006	356	378	support vector machine	T081	C2699740
28125006	380	383	SVM	T081	C2699740
28125006	385	395	classifier	T169	C4291659
28125006	407	418	distinguish	T169	C0205245
28125006	437	444	classes	T170	C0456387
28125006	465	484	driving performance	UnknownType	C0681592
28125006	489	502	physiological	T169	C0205463
28125006	503	515	measurements	T169	C0242485
28125006	530	558	principal component analysis	T081	C0429865
28125006	576	580	rank	T170	C0699794
28125006	585	592	weights	T081	C0043100
28125006	600	608	features	T080	C1521970
28125006	614	649	standard deviation of R-R intervals	T081	C0871420
28125006	651	655	SDNN	T081	C0871420
28125006	662	738	root mean square value of the difference of the adjacent R-R interval series	T081	C2347976
28125006	740	745	RMSSD	T081	C2347976
28125006	748	761	low frequency	T079	C0205213
28125006	763	765	LF	T079	C0205213
28125006	768	782	high frequency	T079	C0205212
28125006	784	786	HF	T079	C0205212
28125006	793	830	ratio of the low and high frequencies	T081	C0392762
28125006	832	837	LF/HF	T081	C0392762
28125006	844	866	average blink duration	T081	C0392762
28125006	876	883	highest	T080	C1522410
28125006	884	901	weighted features	T080	C1521970
28125006	909	914	study	T062	C2603343
28125006	938	941	SVM	T081	C2699740
28125006	942	956	classification	T185	C0008902
28125006	974	985	distinguish	T169	C0205245
28125006	986	999	drunk driving	T048	C0556374
28125006	1005	1011	normal	T080	C0205307
28125006	1012	1019	driving	T056	C0004379
28125006	1028	1036	accuracy	T080	C0443131
28125006	1049	1068	driving performance	UnknownType	C0681592
28125006	1069	1073	data	T078	C1511726
28125006	1082	1095	physiological	T169	C0205463
28125006	1096	1108	measurements	T169	C0242485
28125006	1109	1117	reported	T058	C0700287
28125006	1126	1131	paper	T170	C0684224
28125006	1146	1149	air	T167	C0001861
28125006	1152	1159	alcohol	T168	C0001967
28125006	1160	1173	concentration	T081	C0392762
28125006	1183	1193	integrated	T169	C0205245
28125006	1204	1229	support vector regression	T081	C2699740
28125006	1230	1244	classification	T185	C0008902
28125006	1245	1251	method	T170	C0025663
28125006	1274	1279	early	T079	C1279919
28125006	1280	1287	warning	T064	C0871599
28125006	1288	1293	model	T170	C3161035
28125006	1313	1327	vehicle safety	T089	C0681627

28282510|t|CXCR4 (CD184) expression on stem cell harvest and CD34(+) cells post-transplant
28282510|a|CXCR4 is a receptor for stromal-derived factor-1 (SDF-1), a molecule that has a chemotactic activity for lymphocytes and is important in homing of hematopoietic stem cells to their adult marrow. We evaluated the CXCR4 (CD184) expression in the harvest cells and in the post-transplant bone marrow (BM) and its relation to engraftment, as determined by the consensus criteria and chimerism. This is a prospective study which included 30 patients undergoing hematopoietic stem cell transplantation; 15 patients received autograft and 15 patients received allograft on dates between January 2012 and May 2014. We assessed CD184 (CXCR4) using flow cytometry in the harvest cells together with post-transplant BM assessment on Day 28 and Day 90 for complete morphologic, molecular studies, and detection of CD184 expression on CD34(+) cells with chimerism studies on total peripheral blood mononuclear cells. Diagnoses of the enrolled patients were as follows: seven (24.1%) with acute myeloid leukemia, eight (27.6%) with multiple myeloma, four (13.8%) with acute lymphoblastic leukemia, three (10.3%) with non-Hodgkin lymphoma, two (6.9%) with myelodysplastic syndromes, two (6.9%) with aplastic anemia, two (6.9%) with chronic myeloid leukemia, one (3.4%) with Hodgkin lymphoma, and one (3.4%) with plasmacytomas. One patient died and was excluded from the study because there were not enough data about engraftment. There was no statistical significance between the level of CD184 in stem cell harvest and the prediction of successful engraftment (p>0.05) as well as in Day 28 BM sample (p>0.05), whereas there was a statistical significance between the level of CD184 in Day 90 BM sample and the occurrence of successful engraftment (p=0.002). SDF-1 / CXCR4 axis plays a crucial role in engraftment; however, more studies are warranted to assess their expression post-transplant. Evaluating the ligand (chemokine, SDF-1) or its receptor (CXCR4) may serve as potential surrogate markers for assessment of engraftment.
28282510	0	5	CXCR4	T116,T192	C2352110
28282510	7	12	CD184	T116,T192	C2352110
28282510	14	24	expression	T045	C1171362
28282510	28	45	stem cell harvest	T061	C0411265
28282510	50	57	CD34(+)	T116,T129	C0054953
28282510	58	63	cells	T025	C0007634
28282510	64	79	post-transplant	T079	C1254367
28282510	80	85	CXCR4	T116,T192	C2352110
28282510	91	99	receptor	T116,T192	C0597357
28282510	104	128	stromal-derived factor-1	T116,T129	C0218504
28282510	130	135	SDF-1	T116,T129	C0218504
28282510	140	148	molecule	T167	C0567416
28282510	160	171	chemotactic	T043	C0008018
28282510	172	180	activity	T052	C0441655
28282510	185	196	lymphocytes	T025	C0024264
28282510	217	223	homing	T043	C0007613
28282510	227	251	hematopoietic stem cells	T025	C0018956
28282510	261	273	adult marrow	T024	C0005953
28282510	278	287	evaluated	T058	C0220825
28282510	292	297	CXCR4	T116,T192	C2352110
28282510	299	304	CD184	T116,T192	C2352110
28282510	306	316	expression	T045	C1171362
28282510	324	337	harvest cells	T025	C0038250
28282510	349	364	post-transplant	T079	C1254367
28282510	365	376	bone marrow	T024	C0005953
28282510	378	380	BM	T024	C0005953
28282510	390	398	relation	T080	C0439849
28282510	402	413	engraftment	T039	C0301944
28282510	436	454	consensus criteria	T170	C0935549
28282510	459	468	chimerism	T032	C0333678
28282510	480	497	prospective study	T062	C0033522
28282510	516	524	patients	T101	C0030705
28282510	536	575	hematopoietic stem cell transplantation	T061	C0472699
28282510	580	588	patients	T101	C0030705
28282510	589	597	received	T080	C1514756
28282510	598	607	autograft	T061	C0040736
28282510	615	623	patients	T101	C0030705
28282510	624	632	received	T080	C1514756
28282510	633	642	allograft	T061	C0040739
28282510	690	698	assessed	T052	C1516048
28282510	699	704	CD184	T116,T192	C2352110
28282510	706	711	CXCR4	T116,T192	C2352110
28282510	719	733	flow cytometry	T059	C0016263
28282510	741	754	harvest cells	T025	C0038250
28282510	769	784	post-transplant	T079	C1254367
28282510	785	787	BM	T024	C0005953
28282510	788	798	assessment	T058	C0220825
28282510	824	832	complete	T080	C0205197
28282510	833	844	morphologic	T082	C0543482
28282510	846	863	molecular studies	T059	C2236970
28282510	869	878	detection	T061	C1511790
28282510	882	887	CD184	T116,T192	C2352110
28282510	888	898	expression	T045	C1171362
28282510	902	909	CD34(+)	T116,T129	C0054953
28282510	910	915	cells	T025	C0007634
28282510	921	930	chimerism	T032	C0333678
28282510	942	947	total	T080	C0439810
28282510	948	982	peripheral blood mononuclear cells	T025	C1321301
28282510	984	993	Diagnoses	T033	C0011900
28282510	1010	1018	patients	T101	C0030705
28282510	1055	1077	acute myeloid leukemia	T191	C0023467
28282510	1098	1114	multiple myeloma	T191	C0026764
28282510	1134	1162	acute lymphoblastic leukemia	T191	C0023449
28282510	1183	1203	non-Hodgkin lymphoma	T191	C0024305
28282510	1221	1246	myelodysplastic syndromes	T191	C3463824
28282510	1264	1279	aplastic anemia	T047	C0002874
28282510	1297	1321	chronic myeloid leukemia	T191	C0023473
28282510	1339	1355	Hodgkin lymphoma	T191	C0019829
28282510	1377	1390	plasmacytomas	T191	C0032131
28282510	1396	1403	patient	T101	C0030705
28282510	1404	1408	died	T033	C1546956
28282510	1417	1425	excluded	T052	C2828389
28282510	1435	1440	study	T062	C0008972
28282510	1482	1493	engraftment	T039	C0301944
28282510	1505	1507	no	T033	C1513916
28282510	1508	1532	statistical significance	T081	C0237881
28282510	1545	1550	level	T034	C0428479
28282510	1554	1559	CD184	T116,T192	C2352110
28282510	1563	1580	stem cell harvest	T061	C0411265
28282510	1589	1599	prediction	T078	C0681842
28282510	1603	1613	successful	T080	C1272703
28282510	1614	1625	engraftment	T039	C0301944
28282510	1656	1665	BM sample	T031	C0438737
28282510	1696	1720	statistical significance	T081	C0237881
28282510	1733	1738	level	T034	C0428479
28282510	1742	1747	CD184	T116,T192	C2352110
28282510	1758	1767	BM sample	T031	C0438737
28282510	1776	1786	occurrence	T079	C2745955
28282510	1790	1800	successful	T080	C1272703
28282510	1801	1812	engraftment	T039	C0301944
28282510	1824	1829	SDF-1	T116,T129	C0218504
28282510	1832	1837	CXCR4	T116,T192	C2352110
28282510	1867	1878	engraftment	T039	C0301944
28282510	1919	1925	assess	T052	C1516048
28282510	1932	1942	expression	T045	C1171362
28282510	1943	1958	post-transplant	T079	C1254367
28282510	1983	1992	chemokine	T116,T129	C0282554
28282510	1994	1999	SDF-1	T116,T129	C0218504
28282510	2008	2016	receptor	T116,T192	C0597357
28282510	2018	2023	CXCR4	T116,T192	C2352110
28282510	2038	2047	potential	T080	C3245505
28282510	2048	2065	surrogate markers	T080	C0086589
28282510	2070	2080	assessment	T058	C0220825
28282510	2084	2095	engraftment	T039	C0301944

27656565|t|Evaluation of Outcome Following Coronectomy for the Management of Mandibular Third Molars in Close Proximity to Inferior Alveolar Nerve
27656565|a|Iatrogenic damage to Inferior Alveolar Nerve (IAN) is a significant risk factor following prophylactic or therapeutic removal of impacted mandibular third molar. The risk to IAN injury increases many fold, when the third molar root overlaps the nerve canal as identified by the radiographic imaging. Various methods like orthodontic assisted extraction, staged removal of tooth or coronectomy have been advocated to reduce the incidence of IAN injury in high risk cases with variable outcome. The aim of present study was to evaluate the fate of the root (resorbed, exfoliated, covered by bone) after coronectomy or intentional root retention of impacted mandibular 3(rd) molars in patients with high risk for inferior alveolar nerve damage as evaluated by the intra oral periapical radiograph. Twenty impacted mandibular third molar teeth, in 18 patients with high risk of injury to IAN based on Rood's Criteria in an intra oral periapical radiographic examination, between the age group of 18 to 40 years, were included in the study. Preoperatively the impacted third molars were evaluated clinically as well as radiographically. Pederson Difficulty Index and Winter's Classification of impacted tooth was recorded. Coronectomy was done at the cemento enamel junction leaving the roots 2-3mm below the alveolar crest and primary closure was done. Patients were evaluated periodically for two years at six months interval. Post operative pain, swelling, IAN injury or any other complications were observed and recorded. None of the patients had IAN injury and none required second surgical removal. There was no incidence of post-operative infection and none required second surgical intervention. However, two of our patients had failed coronectomy (10%) due to mobilization of roots intra operatively and the roots were removed. One patient developed profuse bleeding intra-operatively in the failed coronectomy case. One patient had temporary lingual nerve paresthesia. Coronectomy procedure is effective in controlling inferior alveolar nerve injury following third molar surgery, in radiographically evaluated high risk cases and it has very low incidence of complications.
27656565	0	10	Evaluation	T058	C0220825
27656565	14	21	Outcome	T169	C1274040
27656565	32	43	Coronectomy	T061	C2958928
27656565	52	62	Management	T169	C0039798
27656565	66	76	Mandibular	T023	C0024687
27656565	77	89	Third Molars	T023	C0026369
27656565	99	108	Proximity	T082	C1709211
27656565	112	135	Inferior Alveolar Nerve	T023	C0162406
27656565	136	146	Iatrogenic	T080	C0439669
27656565	147	153	damage	T169	C1883709
27656565	157	180	Inferior Alveolar Nerve	T023	C0162406
27656565	182	185	IAN	T023	C0162406
27656565	204	215	risk factor	T033	C0035648
27656565	226	238	prophylactic	T061	C0199176
27656565	242	296	therapeutic removal of impacted mandibular third molar	T061	C0398942
27656565	310	313	IAN	T023	C0162406
27656565	314	320	injury	T037	C0161479
27656565	321	330	increases	T081	C0205217
27656565	351	367	third molar root	T023	C2323255
27656565	381	392	nerve canal	T023	C0229962
27656565	414	434	radiographic imaging	T060	C0457276
27656565	444	451	methods	T061	C0087111
27656565	457	488	orthodontic assisted extraction	T061	C0040440
27656565	490	513	staged removal of tooth	T061	C0040440
27656565	517	528	coronectomy	T061	C2958928
27656565	563	572	incidence	T081	C0021149
27656565	576	579	IAN	T023	C0162406
27656565	580	586	injury	T037	C0161479
27656565	590	599	high risk	T033	C0332167
27656565	611	627	variable outcome	T033	C0243095
27656565	633	636	aim	T078	C1947946
27656565	661	669	evaluate	T058	C0220825
27656565	686	690	root	T023	C0040452
27656565	692	700	resorbed	T047	C0040451
27656565	702	712	exfoliated	T042	C0040439
27656565	714	721	covered	T169	C0439844
27656565	725	729	bone	T023	C0262950
27656565	737	748	coronectomy	T061	C2958928
27656565	752	763	intentional	T080	C1283828
27656565	764	778	root retention	T047	C0155952
27656565	782	814	impacted mandibular 3(rd) molars	T046	C0399551
27656565	818	826	patients	T101	C0030705
27656565	832	841	high risk	T033	C0332167
27656565	846	869	inferior alveolar nerve	T023	C0162406
27656565	870	876	damage	T037	C0161479
27656565	880	889	evaluated	T058	C0220825
27656565	897	929	intra oral periapical radiograph	T060	C0846744
27656565	938	975	impacted mandibular third molar teeth	T046	C0399551
27656565	983	991	patients	T101	C0030705
27656565	997	1006	high risk	T033	C0332167
27656565	1010	1016	injury	T037	C0161479
27656565	1020	1023	IAN	T023	C0162406
27656565	1033	1048	Rood's Criteria	T170	C0282574
27656565	1055	1101	intra oral periapical radiographic examination	T060	C0846744
27656565	1115	1124	age group	T100	C0027362
27656565	1172	1186	Preoperatively	T033	C0178808
27656565	1191	1212	impacted third molars	T023	C0341034
27656565	1218	1238	evaluated clinically	T058	C4084924
27656565	1268	1293	Pederson Difficulty Index	T170	C0918012
27656565	1298	1321	Winter's Classification	T185	C0008902
27656565	1325	1339	impacted tooth	T190	C0040456
27656565	1354	1365	Coronectomy	T061	C2958928
27656565	1382	1405	cemento enamel junction	T023	C0227011
27656565	1418	1423	roots	T023	C0040452
27656565	1440	1454	alveolar crest	T029	C0005898
27656565	1459	1474	primary closure	T061	C0441503
27656565	1485	1493	Patients	T101	C0030705
27656565	1499	1508	evaluated	T058	C0220825
27656565	1509	1521	periodically	T079	C0332182
27656565	1550	1558	interval	T079	C1272706
27656565	1560	1579	Post operative pain	T184	C0030201
27656565	1581	1589	swelling	T033	C0038999
27656565	1591	1594	IAN	T023	C0162406
27656565	1595	1601	injury	T037	C0161479
27656565	1615	1628	complications	T046	C0009566
27656565	1634	1642	observed	T169	C1441672
27656565	1669	1677	patients	T101	C0030705
27656565	1682	1685	IAN	T023	C0162406
27656565	1686	1692	injury	T037	C0161479
27656565	1711	1717	second	T081	C0205436
27656565	1718	1734	surgical removal	T061	C0040440
27656565	1762	1786	post-operative infection	T046	C0038941
27656565	1805	1811	second	T081	C0205436
27656565	1812	1833	surgical intervention	T033	C0549433
27656565	1855	1863	patients	T101	C0030705
27656565	1868	1874	failed	T169	C0231175
27656565	1875	1886	coronectomy	T061	C2958928
27656565	1900	1912	mobilization	T061	C0185112
27656565	1916	1921	roots	T023	C0040452
27656565	1922	1939	intra operatively	T079	C0456904
27656565	1948	1953	roots	T023	C0040452
27656565	1972	1979	patient	T101	C0030705
27656565	1998	2006	bleeding	T046	C0019080
27656565	2007	2024	intra-operatively	T079	C0456904
27656565	2032	2038	failed	T169	C0231175
27656565	2039	2050	coronectomy	T061	C2958928
27656565	2061	2068	patient	T101	C0030705
27656565	2073	2082	temporary	T079	C0205374
27656565	2083	2096	lingual nerve	T023	C0023740
27656565	2097	2108	paresthesia	T047	C0030554
27656565	2110	2121	Coronectomy	T061	C2958928
27656565	2135	2144	effective	T080	C1704419
27656565	2148	2159	controlling	T067	C2239193
27656565	2160	2183	inferior alveolar nerve	T023	C0162406
27656565	2184	2190	injury	T037	C0161479
27656565	2201	2220	third molar surgery	T061	C0577760
27656565	2242	2251	evaluated	T058	C0220825
27656565	2252	2261	high risk	T033	C0332167
27656565	2284	2287	low	T080	C0205251
27656565	2288	2297	incidence	T081	C0021149
27656565	2301	2314	complications	T046	C0009566

27837915|t|Toward optimizing dental implant performance: Surface characterization of Ti and TiZr implant materials
27837915|a|Targeting understanding enhanced osseointegration kinetics, the goal of this study was to characterize the surface morphology and composition of Ti and TiZr dental implant substrates subjected to one of two surface treatments developed by Straumann. These two treatments are typically known as SLA and SLActive, with the latter resulting in more rapid osseointegration. A range of techniques was applied to characterize four different substrate / surface treatment combinations (TiSLA, TiSLActive, TiZrSLA, and TiZrSLActive). Contact angle measurements establish establish their hydrophilic / hydrophobic nature. Surface morphology was probed with scanning electron microscopy. X-ray diffraction, Raman μ-spectroscopy, and X-ray photoelectron spectroscopy were used to elucidate the composition of the near- surface region. Consistent with previous work, surface morphology was found to differ only at the nanoscale, with both SLActive substrates displaying nano - protrusions. Spectroscopic data indicate that all substrates exhibit surface films of titanium oxide displaying near TiO2 stoichiometry. Raman μ-spectroscopy reveals that amorphous TiO2 is most likely the only phase present on TiSLA, whilst rutile - TiO2 is also evidenced on TiSLActive, TiZrSLA, and TiZrSLActive. For TiZr alloy substrates, there is no evidence of discrete phases of oxidized Zr. X-ray photoelectron spectra demonstrate that all samples are terminated by adventitious carbon, with it being somewhat thicker (∼1nm) on TiSLA and TiZrSLA. Given previous in vivo studies, acquired data suggest that both nanoscale protrusions, and a thinner layer of adventitious carbon contribute to the more rapid osseointegration of SLActive dental implants. Composition of the surface oxide layer is apparently less important in determining osseointegration kinetics.
27837915	7	17	optimizing	T052	C2698650
27837915	18	32	dental implant	T074	C0392413
27837915	46	53	Surface	T082	C0205148
27837915	54	70	characterization	T052	C1880022
27837915	74	76	Ti	T196	C0040302
27837915	81	85	TiZr	T197	C4041873
27837915	86	103	implant materials	T122	C0440216
27837915	104	113	Targeting	T169	C1521840
27837915	128	136	enhanced	T052	C2349975
27837915	137	153	osseointegration	T042	C0079949
27837915	154	162	kinetics	T070	C0022702
27837915	168	172	goal	T170	C0018017
27837915	181	186	study	T062	C2603343
27837915	194	206	characterize	T052	C1880022
27837915	211	218	surface	T082	C0205148
27837915	219	229	morphology	T080	C0332437
27837915	234	245	composition	T201	C0486616
27837915	249	251	Ti	T196	C0040302
27837915	256	260	TiZr	T197	C4041873
27837915	261	275	dental implant	T074	C0392413
27837915	276	286	substrates	T167	C3891814
27837915	311	318	surface	T082	C0205148
27837915	319	329	treatments	T169	C1522326
27837915	364	374	treatments	T169	C1522326
27837915	398	401	SLA	T074	C0392413
27837915	406	414	SLActive	T074	C0392413
27837915	450	455	rapid	T080	C0456962
27837915	456	472	osseointegration	T042	C0079949
27837915	485	495	techniques	T169	C0449851
27837915	500	507	applied	T169	C4048755
27837915	511	523	characterize	T052	C1880022
27837915	529	538	different	T080	C1705242
27837915	539	548	substrate	T082	C0205148
27837915	551	558	surface	T082	C0205148
27837915	559	568	treatment	T169	C1522326
27837915	569	581	combinations	T080	C0205195
27837915	583	588	TiSLA	T074	C0392413
27837915	590	600	TiSLActive	T074	C0392413
27837915	602	609	TiZrSLA	T074	C0392413
27837915	615	627	TiZrSLActive	T074	C0392413
27837915	630	637	Contact	T169	C0332158
27837915	638	643	angle	T082	C0205143
27837915	644	656	measurements	T169	C0242485
27837915	683	694	hydrophilic	T080	C0475370
27837915	697	708	hydrophobic	T080	C0598629
27837915	717	724	Surface	T082	C0205148
27837915	725	735	morphology	T080	C0332437
27837915	752	780	scanning electron microscopy	T059	C0026020
27837915	782	799	X-ray diffraction	T059	C0043301
27837915	801	821	Raman μ-spectroscopy	T059	C0037815
27837915	827	859	X-ray photoelectron spectroscopy	T059	C2700282
27837915	887	898	composition	T201	C0486616
27837915	912	919	surface	T082	C0205148
27837915	928	943	Consistent with	T078	C0332290
27837915	944	952	previous	T079	C0205156
27837915	959	966	surface	T082	C0205148
27837915	967	977	morphology	T080	C0332437
27837915	991	997	differ	T080	C1705242
27837915	1010	1019	nanoscale	T081	C1553036
27837915	1031	1039	SLActive	T074	C0392413
27837915	1040	1050	substrates	T167	C3891814
27837915	1051	1061	displaying	T169	C0870432
27837915	1062	1066	nano	T081	C1553036
27837915	1069	1080	protrusions	T190	C0333056
27837915	1082	1095	Spectroscopic	T059	C0037812
27837915	1096	1100	data	T078	C1511726
27837915	1119	1129	substrates	T167	C3891814
27837915	1138	1145	surface	T082	C0205148
27837915	1146	1151	films	T080	C1522408
27837915	1155	1169	titanium oxide	T121,T197	C0145999
27837915	1186	1190	TiO2	T121,T197	C0145999
27837915	1191	1204	stoichiometry	T081	C0597526
27837915	1206	1226	Raman μ-spectroscopy	T059	C0037815
27837915	1227	1234	reveals	T080	C0443289
27837915	1240	1249	amorphous	T080	C1979848
27837915	1250	1254	TiO2	T121,T197	C0145999
27837915	1279	1284	phase	T079	C0205390
27837915	1285	1292	present	T033	C0150312
27837915	1296	1301	TiSLA	T074	C0392413
27837915	1310	1316	rutile	T121,T197	C0141060
27837915	1319	1323	TiO2	T121,T197	C0145999
27837915	1332	1341	evidenced	T078	C3887511
27837915	1345	1355	TiSLActive	T074	C0392413
27837915	1357	1364	TiZrSLA	T074	C0392413
27837915	1370	1382	TiZrSLActive	T074	C0392413
27837915	1388	1392	TiZr	T197	C4041873
27837915	1393	1398	alloy	T122,T197	C0002154
27837915	1399	1409	substrates	T167	C3891814
27837915	1423	1431	evidence	T078	C3887511
27837915	1435	1443	discrete	T080	C0443299
27837915	1444	1450	phases	T079	C0205390
27837915	1454	1462	oxidized	T044	C0030011
27837915	1463	1465	Zr	T196	C0043506
27837915	1467	1494	X-ray photoelectron spectra	T059	C2700282
27837915	1516	1523	samples	T167	C0370003
27837915	1528	1538	terminated	T078	C1692758
27837915	1542	1554	adventitious	T080	C1517294
27837915	1555	1561	carbon	T196	C0007009
27837915	1586	1593	thicker	T080	C1280412
27837915	1604	1609	TiSLA	T074	C0392413
27837915	1614	1621	TiZrSLA	T074	C0392413
27837915	1629	1637	previous	T079	C0205156
27837915	1638	1653	in vivo studies	T062	C0681829
27837915	1655	1663	acquired	T080	C0439661
27837915	1664	1668	data	T078	C1511726
27837915	1687	1696	nanoscale	T081	C1553036
27837915	1697	1708	protrusions	T190	C0333056
27837915	1716	1723	thinner	T080	C0205168
27837915	1724	1729	layer	T080	C1522408
27837915	1733	1745	adventitious	T080	C1517294
27837915	1746	1752	carbon	T196	C0007009
27837915	1753	1763	contribute	T052	C1880177
27837915	1776	1781	rapid	T080	C0456962
27837915	1782	1798	osseointegration	T042	C0079949
27837915	1802	1810	SLActive	T074	C0392413
27837915	1811	1826	dental implants	T074	C0392413
27837915	1828	1839	Composition	T201	C0486616
27837915	1847	1854	surface	T082	C0205148
27837915	1855	1860	oxide	T197	C0030015
27837915	1861	1866	layer	T080	C1522408
27837915	1881	1885	less	T080	C0547044
27837915	1886	1895	important	T080	C3898777
27837915	1911	1927	osseointegration	T042	C0079949
27837915	1928	1936	kinetics	T070	C0022702

28545365|t|Role of infrared spectroscopy and imaging in cancer diagnosis
28545365|a|FTIR imaging has been used to diagnose and differentiate the molecular differences between normal and diseased tissues. The differences correspond to the distribution and structure of lipids, proteins, nucleic acids as well as other metabolites. These differences depended on the type and the grade of cancer. The sensitivity of chemotherapy drugs on individual specific was also discussed. Here, we emphasize that FTIR spectroscopy and imaging can be considered as a promising technique and will find its place on the detection of this dreadful disease because of high sensitivity, accuracy and inexpensive technique. Now the medical community started using and accepting this technique for early stage cancer detection. But, this technique endures several challenges on its application into the diagnosis of cancer in regards of sample preparations, data interpretation, and data analysis. In general, more research is needed in this field and it is necessary to understand the morphology and biology of the sample before using the spectroscopy and imaging because invaluable information to be figured out.
28545365	8	29	infrared spectroscopy	T059	C0260249
28545365	34	41	imaging	T060	C0079595
28545365	45	51	cancer	T191	C0006826
28545365	52	61	diagnosis	T033	C0011900
28545365	62	66	FTIR	T062	C0206055
28545365	67	74	imaging	T060	C0079595
28545365	92	100	diagnose	T033	C0011900
28545365	105	118	differentiate	T080	C0205615
28545365	123	132	molecular	T080	C1521991
28545365	133	144	differences	T080	C1705242
28545365	153	159	normal	T024	C0040300
28545365	164	172	diseased	T047	C0012634
28545365	173	180	tissues	T024	C0040300
28545365	186	197	differences	T080	C1705242
28545365	216	228	distribution	T169	C1704711
28545365	233	242	structure	T082	C0678594
28545365	246	252	lipids	T109	C0023779
28545365	254	262	proteins	T116,T123	C0033684
28545365	264	277	nucleic acids	T114,T123	C0028606
28545365	295	306	metabolites	T123	C0870883
28545365	314	325	differences	T080	C1705242
28545365	342	346	type	T033	C0872066
28545365	364	370	cancer	T191	C0006826
28545365	376	387	sensitivity	T169	C0332324
28545365	391	403	chemotherapy	T061	C3665472
28545365	404	409	drugs	T121	C1254351
28545365	413	423	individual	T098	C0237401
28545365	477	494	FTIR spectroscopy	T062	C0206055
28545365	499	506	imaging	T060	C0079595
28545365	540	549	technique	T169	C0449851
28545365	581	590	detection	T061	C1511790
28545365	599	615	dreadful disease	T047	C0012634
28545365	627	643	high sensitivity	T059	C1441604
28545365	645	653	accuracy	T080	C4035952
28545365	670	679	technique	T169	C0449851
28545365	689	706	medical community	T073,T093	C1562642
28545365	740	749	technique	T169	C0449851
28545365	754	765	early stage	T079	C2363430
28545365	766	772	cancer	T191	C0006826
28545365	773	782	detection	T061	C1511790
28545365	794	803	technique	T169	C0449851
28545365	820	830	challenges	T058	C0805586
28545365	859	868	diagnosis	T033	C0011900
28545365	872	878	cancer	T191	C0006826
28545365	893	912	sample preparations	T059	C3824791
28545365	914	933	data interpretation	T058	C0262707
28545365	939	952	data analysis	T057	C0010992
28545365	971	979	research	T062	C0035168
28545365	1042	1052	morphology	T080	C0332437
28545365	1057	1064	biology	T091	C0005532
28545365	1096	1108	spectroscopy	T062	C0206055
28545365	1113	1120	imaging	T060	C0079595
28545365	1129	1139	invaluable	T080	C1511545
28545365	1140	1151	information	T078	C1533716

28395554|t|Monitoring proteolytic processing events by quantitative mass spectrometry
28395554|a|Protease activity plays a key role in a wide variety of biological processes including gene expression, protein turnover and development. misregulation of these proteins has been associated with many cancer types such as prostate, breast, and skin cancer. thus, the identification of protease substrates will provide key information to understand proteolysis -related pathologies. Areas covered: Proteomics -based methods to investigate proteolysis activity, focusing on substrate identification, protease specificity and their applications in systems biology are reviewed. Their quantification strategies, challenges and pitfalls are underlined and the biological implications of protease malfunction are highlighted. Expert commentary: Dysregulated protease activity is a hallmark for some disease pathologies such as cancer. Current biochemical approaches are low throughput and some are limited by the amount of sample required to obtain reliable results. Mass spectrometry based proteomics provides a suitable platform to investigate protease activity, providing information about substrate specificity and mapping cleavage sites.
28395554	0	10	Monitoring	T058	C1283169
28395554	11	33	proteolytic processing	T044	C1514570
28395554	34	40	events	T051	C0441471
28395554	44	74	quantitative mass spectrometry	T059	C3525763
28395554	75	92	Protease activity	T044	C1150095
28395554	105	109	role	T170	C3871154
28395554	131	151	biological processes	T038	C3714634
28395554	152	161	including	T169	C0332257
28395554	162	177	gene expression	T045	C0017262
28395554	179	195	protein turnover	T044	C0597297
28395554	200	211	development	T040	C0678723
28395554	213	226	misregulation	T033	C0243095
28395554	236	244	proteins	T116,T123	C0033684
28395554	254	269	associated with	T080	C0332281
28395554	275	287	cancer types	T033	C0872066
28395554	296	304	prostate	T191	C0376358
28395554	306	312	breast	T191	C0006142
28395554	318	329	skin cancer	T191	C0007114
28395554	341	355	identification	T080	C0205396
28395554	359	367	protease	T116,T126	C0030940
28395554	368	378	substrates	T167	C3891814
28395554	384	391	provide	T052	C1999230
28395554	396	407	information	T078	C1533716
28395554	411	421	understand	T041	C0162340
28395554	422	433	proteolysis	T044	C0597304
28395554	443	454	pathologies	T091	C0030664
28395554	462	469	covered	T169	C0439844
28395554	471	481	Proteomics	T091	C0872252
28395554	489	496	methods	T170	C0025663
28395554	500	511	investigate	T169	C1292732
28395554	512	533	proteolysis activity,	T044	C0597304
28395554	546	555	substrate	T167	C3891814
28395554	556	570	identification	T080	C0205396
28395554	572	580	protease	T116,T126	C0030940
28395554	581	592	specificity	UnknownType	C0678612
28395554	603	615	applications	T061	C0441485
28395554	619	634	systems biology	T091	C1450477
28395554	639	647	reviewed	T080	C1709940
28395554	655	669	quantification	T081	C1709793
28395554	682	692	challenges	T058	C0805586
28395554	697	705	pitfalls	T080	C0205556
28395554	729	739	biological	T080	C0205460
28395554	756	764	protease	T116,T126	C0030940
28395554	765	776	malfunction	T169	C0231174
28395554	794	811	Expert commentary	T077	C0600219
28395554	813	825	Dysregulated	T033	C0243095
28395554	826	843	protease activity	T044	C1150095
28395554	849	857	hallmark	T080	C0205556
28395554	867	874	disease	T047	C0012634
28395554	875	886	pathologies	T091	C0030664
28395554	895	901	cancer	T191	C0006826
28395554	903	910	Current	T079	C0521116
28395554	911	922	biochemical	T169	C0205474
28395554	923	933	approaches	T169	C1292724
28395554	938	941	low	T080	C0205251
28395554	942	952	throughput	T081	C0392762
28395554	966	973	limited	T169	C0439801
28395554	981	987	amount	T081	C1265611
28395554	991	997	sample	T077	C2347026
28395554	998	1006	required	T169	C1514873
28395554	1010	1016	obtain	T169	C1301820
28395554	1026	1033	results	T034	C0456984
28395554	1035	1052	Mass spectrometry	T059	C0037813
28395554	1059	1069	proteomics	T091	C0872252
28395554	1070	1078	provides	T052	C1999230
28395554	1081	1089	suitable	T080	C3900053
28395554	1090	1098	platform	T075	C1710360
28395554	1102	1113	investigate	T169	C1292732
28395554	1114	1131	protease activity	T044	C1150095
28395554	1133	1142	providing	T052	C1999230
28395554	1143	1154	information	T078	C1533716
28395554	1161	1182	substrate specificity	T081	C0038592
28395554	1187	1194	mapping	T059	C0030944
28395554	1195	1209	cleavage sites	T087	C0002518

27698916|t|Diet - and Genetically-induced Obesity Produces Alterations in the Microbiome, Inflammation and Wnt Pathway in the Intestine of Apc(+/1638N) Mice: Comparisons and Contrasts
27698916|a|Obesity is an established risk factor for colorectal cancer (CRC). Our previous study indicated that obesity increases activity of the pro-tumorigenic Wnt-signaling. Presently, we sought to further advance our understanding of the mechanisms by which obesity promotes CRC by examining associations between microbiome, inflammation and Wnt-signaling in Apc(+/1638N) mice whose obesity was induced by one of two modalities, diet - or genetically-induced obesity. Three groups were employed: Apc(+/1638N) Lepr(+/+) fed a low fat diet (10% fat), Apc(+/1638N) Lepr(+/+) fed a high fat diet (60% fat, diet - induced obesity), and Apc(+/1638N) Lepr(db/db) fed a low fat diet (genetically-induced obesity). All animals received diets for 16 weeks from 8 to 24 weeks of age. The abundance of 19 bowel cancer -associated bacterial taxa were examined by real-time PCR. The abundance of Turicibacter and Desulfovibrio decreased, but F. prausnitizii increased, in diet - induced obese mice (p < 0.05). In contrast, in genetically-induced obese mice, Bifidobacterium, A. muciniphila and E. rectale decreased, but Peptostrptococcus, and E. coli increased (p < 0.05). Both diet - and genetically-induced obesity altered the expression of genes involved in bacterial recognition (MyD88) and increased inflammation as indicated by elevated levels of cytokines (IFNγ and TNF-α for genetically-induced obesity, and IL-6 for diet - induced obesity). The elevated inflammation was associated with altered expression of genes that are integral components of the Wnt-signaling cascade in a fashion indicating its activation. These findings demonstrate that the composition of the small intestinal microbiome is affected differently in diet - and genetically-induced obesity, but both are associated with elevated intestinal inflammation and alterations of the Wnt pathway towards enhancing tumorigenesis.
27698916	0	4	Diet	T168	C0012155
27698916	11	30	Genetically-induced	T045	C0017391
27698916	31	38	Obesity	T047	C0028754
27698916	67	77	Microbiome	T001	C2985398
27698916	79	91	Inflammation	T033	C3889047
27698916	96	107	Wnt Pathway	T044	C1520113
27698916	115	124	Intestine	T023	C0021853
27698916	128	140	Apc(+/1638N)	T028	C0162832
27698916	141	145	Mice	T015	C0025933
27698916	173	180	Obesity	T047	C0028754
27698916	199	210	risk factor	T033	C0035648
27698916	215	232	colorectal cancer	T191	C1527249
27698916	234	237	CRC	T191	C1527249
27698916	274	281	obesity	T047	C0028754
27698916	308	323	pro-tumorigenic	T191	C0007621
27698916	324	337	Wnt-signaling	T044	C1520113
27698916	424	431	obesity	T047	C0028754
27698916	441	444	CRC	T191	C1527249
27698916	479	489	microbiome	T001	C2985398
27698916	491	503	inflammation	T033	C3889047
27698916	508	521	Wnt-signaling	T044	C1520113
27698916	525	537	Apc(+/1638N)	T028	C0162832
27698916	538	542	mice	T015	C0025933
27698916	549	556	obesity	T047	C0028754
27698916	583	593	modalities	T078	C0695347
27698916	595	599	diet	T168	C0012155
27698916	605	624	genetically-induced	T045	C0017391
27698916	625	632	obesity	T047	C0028754
27698916	662	674	Apc(+/1638N)	T028	C0162832
27698916	675	684	Lepr(+/+)	T028	C1366515
27698916	715	727	Apc(+/1638N)	T028	C0162832
27698916	728	737	Lepr(+/+)	T028	C1366515
27698916	744	757	high fat diet	T061	C0521974
27698916	763	766	fat	T109,T121	C0015677
27698916	768	772	diet	T168	C0012155
27698916	775	782	induced	T169	C0205263
27698916	783	790	obesity	T047	C0028754
27698916	797	809	Apc(+/1638N)	T028	C0162832
27698916	810	821	Lepr(db/db)	T028	C1366515
27698916	828	840	low fat diet	T061	C0242970
27698916	842	861	genetically-induced	T045	C0017391
27698916	862	869	obesity	T047	C0028754
27698916	876	883	animals	T015	C0025933
27698916	906	911	weeks	T079	C0439230
27698916	925	930	weeks	T079	C0439230
27698916	959	971	bowel cancer	T191	C0346627
27698916	984	998	bacterial taxa	T007	C0004611
27698916	1016	1029	real-time PCR	T063	C1709846
27698916	1048	1060	Turicibacter	T007	C1214082
27698916	1065	1078	Desulfovibrio	T007	C0011731
27698916	1079	1088	decreased	T081	C0205216
27698916	1094	1109	F. prausnitizii	T007	C0317558
27698916	1124	1128	diet	T168	C0012155
27698916	1131	1138	induced	T169	C0205263
27698916	1139	1149	obese mice	T015	C0025933
27698916	1178	1197	genetically-induced	T045	C0017391
27698916	1198	1208	obese mice	T015	C0025933
27698916	1210	1225	Bifidobacterium	T007	C0005380
27698916	1227	1241	A. muciniphila	T007	C1490590
27698916	1246	1256	E. rectale	T007	C0317478
27698916	1257	1266	decreased	T081	C0205216
27698916	1272	1289	Peptostrptococcus	T007	C0030967
27698916	1295	1302	E. coli	T007	C0014834
27698916	1303	1312	increased	T081	C0205217
27698916	1330	1334	diet	T168	C0012155
27698916	1341	1360	genetically-induced	T045	C0017391
27698916	1361	1368	obesity	T047	C0028754
27698916	1381	1400	expression of genes	T045	C0017262
27698916	1413	1422	bacterial	T080	C0521009
27698916	1436	1441	MyD88	T028	C1417530
27698916	1447	1456	increased	T081	C0205217
27698916	1457	1469	inflammation	T033	C3889047
27698916	1486	1494	elevated	T080	C3163633
27698916	1505	1514	cytokines	T116,T129	C0079189
27698916	1516	1520	IFNγ	T116,T121,T129	C3539881
27698916	1525	1530	TNF-α	T116,T129	C1456820
27698916	1535	1554	genetically-induced	T045	C0017391
27698916	1555	1562	obesity	T047	C0028754
27698916	1568	1572	IL-6	T116,T129	C0021760
27698916	1577	1581	diet	T168	C0012155
27698916	1584	1591	induced	T169	C0205263
27698916	1592	1599	obesity	T047	C0028754
27698916	1606	1614	elevated	T080	C3163633
27698916	1615	1627	inflammation	T046	C0021368
27698916	1656	1675	expression of genes	T045	C0017262
27698916	1712	1733	Wnt-signaling cascade	T044	C1520113
27698916	1762	1772	activation	T043	C2244452
27698916	1829	1856	small intestinal microbiome	T001	C2985398
27698916	1884	1888	diet	T168	C0012155
27698916	1895	1914	genetically-induced	T045	C0017391
27698916	1915	1922	obesity	T047	C0028754
27698916	1953	1961	elevated	T080	C3163633
27698916	1962	1985	intestinal inflammation	T033	C3889047
27698916	2009	2020	Wnt pathway	T044	C1520113
27698916	2039	2052	tumorigenesis	T191	C0007621

27467249|t|Juicer Provides a One-Click System for Analyzing Loop-Resolution Hi-C Experiments
27467249|a|Hi-C experiments explore the 3D structure of the genome, generating terabases of data to create high-resolution contact maps. Here, we introduce Juicer, an open-source tool for analyzing terabase-scale Hi-C datasets. Juicer allows users without a computational background to transform raw sequence data into normalized contact maps with one click. Juicer produces a hic file containing compressed contact matrices at many resolutions, facilitating visualization and analysis at multiple scales. Structural features, such as loops and domains, are automatically annotated. Juicer is available as open source software at http://aidenlab.org/juicer/.
27467249	0	6	Juicer	T170	C0037589
27467249	7	15	Provides	T052	C1999230
27467249	39	48	Analyzing	T062	C0936012
27467249	49	81	Loop-Resolution Hi-C Experiments	T059	C0200892
27467249	82	98	Hi-C experiments	T059	C0200892
27467249	111	123	3D structure	T082	C0026377
27467249	131	137	genome	T028	C0017428
27467249	139	149	generating	T052	C3146294
27467249	150	167	terabases of data	T170	C0150098
27467249	178	193	high-resolution	T059	C1719039
27467249	194	206	contact maps	T170	C0814036
27467249	227	233	Juicer	T170	C0037589
27467249	238	254	open-source tool	T170	C0037589
27467249	269	283	terabase-scale	T081	C0392762
27467249	284	297	Hi-C datasets	T170	C0150098
27467249	299	305	Juicer	T170	C0037589
27467249	313	318	users	T098	C1706077
27467249	319	326	without	T080	C0332288
27467249	329	342	computational	T052	C1880157
27467249	343	353	background	T077	C1706907
27467249	357	366	transform	T062	C1705163
27467249	367	384	raw sequence data	T170	C0026382
27467249	401	413	contact maps	T170	C0814036
27467249	430	436	Juicer	T170	C0037589
27467249	448	456	hic file	T170	C0242193
27467249	468	478	compressed	T169	C0332260
27467249	479	495	contact matrices	T082	C1704640
27467249	504	515	resolutions	T081	C1706463
27467249	530	543	visualization	T041	C0175631
27467249	548	556	analysis	T062	C0936012
27467249	560	575	multiple scales	T081	C0392762
27467249	577	596	Structural features	T082	C0026377
27467249	606	611	loops	T026	C1516509
27467249	616	623	domains	T044	C0599845
27467249	629	642	automatically	T066	C0004374
27467249	643	652	annotated	T080	C1552720
27467249	654	660	Juicer	T170	C0037589
27467249	677	681	open	T080	C1996904
27467249	682	688	source	T081	C0011001
27467249	689	697	software	T073,T170	C0037585

27553875|t|Estimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains
27553875|a|One of the serious threats facing the administration of antiretroviral therapy to human immunodeficiency virus (HIV-1) infected patients is the reported increasing prevalence of transmitted drug resistance. However, given that HIV-1 drug-resistant strains are often less fit than the wild-type strains, it is expected that drug-resistant strains that are present during the primary phase of the HIV-1 infection are replaced by the fitter wild-type strains. This replacement of HIV-1 resistant mutations involves the emergence of wild-type strains by a process of backward mutation. How quickly the replacement happens is dependent on the class of HIV-1 mutation group. We estimate the backward mutation rates and relative fitness of various mutational groups known to confer HIV-1 drug resistance. We do this by fitting a stochastic model to data for individuals who were originally infected by an HIV-1 strain carrying any one of the known drug resistance -conferring mutations and observed over a period of time to see whether the resistant strain is replaced. To do this, we seek a distribution, generated from simulations of the stochastic model, that best describes the observed (clinical data) replacement times of a given mutation. We found that Lamivudine/Emtricitabine -associated mutations have a distinctly higher, backward mutation rate and low relative fitness compared to the other classes (as has been reported before) while protease inhibitors -associated mutations have a slower backward mutation rate and high relative fitness. For the other mutation classes, we found more uncertainty in their estimates.
27553875	18	23	HIV-1	T005	C0019704
27553875	24	32	backward	T082	C0439784
27553875	33	46	mutation rate	T080	C3178846
27553875	52	78	transmitted drug-resistant	T038	C0013203
27553875	79	86	strains	T001	C1518614
27553875	106	113	threats	T078	C0749385
27553875	143	165	antiretroviral therapy	T061	C1963724
27553875	169	197	human immunodeficiency virus	T005	C0019704
27553875	199	204	HIV-1	T005	C0019704
27553875	206	214	infected	T047	C2363741
27553875	215	223	patients	T101	C0030705
27553875	240	261	increasing prevalence	T081	C1512456
27553875	265	292	transmitted drug resistance	T038	C0013203
27553875	314	319	HIV-1	T005	C0019704
27553875	320	334	drug-resistant	T038	C0013203
27553875	335	342	strains	T001	C1518614
27553875	371	380	wild-type	T028	C1883559
27553875	381	388	strains	T001	C1518614
27553875	410	424	drug-resistant	T038	C0013203
27553875	425	432	strains	T001	C1518614
27553875	461	468	primary	T080	C0205225
27553875	469	474	phase	T079	C0205390
27553875	482	497	HIV-1 infection	T047	C2363741
27553875	502	510	replaced	T169	C0559956
27553875	525	534	wild-type	T028	C1883559
27553875	535	542	strains	T001	C1518614
27553875	549	560	replacement	T169	C0559956
27553875	564	579	HIV-1 resistant	T033	C1836231
27553875	580	589	mutations	T045	C0026882
27553875	616	625	wild-type	T028	C1883559
27553875	626	633	strains	T001	C1518614
27553875	639	646	process	T067	C1522240
27553875	650	658	backward	T082	C0439784
27553875	659	667	mutation	T045	C0026882
27553875	685	696	replacement	T169	C0559956
27553875	708	717	dependent	T169	C3244310
27553875	734	739	HIV-1	T005	C0019704
27553875	740	748	mutation	T045	C0026882
27553875	749	754	group	T078	C0441833
27553875	772	780	backward	T082	C0439784
27553875	781	795	mutation rates	T080	C3178846
27553875	828	838	mutational	T045	C0026882
27553875	839	845	groups	T078	C0441833
27553875	862	867	HIV-1	T005	C0019704
27553875	868	883	drug resistance	T038	C0013203
27553875	909	925	stochastic model	T062	C0871922
27553875	929	933	data	T078	C1511726
27553875	938	949	individuals	T098	C0237401
27553875	970	978	infected	T033	C0439663
27553875	985	990	HIV-1	T005	C0019704
27553875	991	997	strain	T001	C1518614
27553875	1028	1043	drug resistance	T038	C0013203
27553875	1056	1065	mutations	T045	C0026882
27553875	1086	1100	period of time	T201	C3259132
27553875	1120	1129	resistant	T169	C0332325
27553875	1130	1136	strain	T001	C1518614
27553875	1140	1148	replaced	T169	C0559956
27553875	1172	1184	distribution	T169	C1704711
27553875	1201	1212	simulations	T062	C0679083
27553875	1220	1236	stochastic model	T062	C0871922
27553875	1262	1270	observed	T169	C1441672
27553875	1272	1285	clinical data	T170	C1516606
27553875	1287	1298	replacement	T169	C0559956
27553875	1299	1304	times	T081	C1632851
27553875	1316	1324	mutation	T045	C0026882
27553875	1340	1364	Lamivudine/Emtricitabine	T109,T195	C1977395
27553875	1377	1386	mutations	T045	C0026882
27553875	1413	1421	backward	T082	C0439784
27553875	1422	1435	mutation rate	T080	C3178846
27553875	1444	1452	relative	T080	C0205345
27553875	1453	1460	fitness	T056	C1456706
27553875	1483	1490	classes	T170	C0456387
27553875	1527	1546	protease inhibitors	T121	C0033607
27553875	1559	1568	mutations	T045	C0026882
27553875	1583	1591	backward	T082	C0439784
27553875	1592	1605	mutation rate	T080	C3178846
27553875	1615	1623	relative	T080	C0205345
27553875	1624	1631	fitness	T056	C1456706
27553875	1647	1655	mutation	T045	C0026882
27553875	1656	1663	classes	T170	C0456387
27553875	1700	1709	estimates	T081	C0750572

27763528|t|Up-Regulation of Claudin-6 in the Distal Lung Impacts Secondhand Smoke -Induced Inflammation
27763528|a|It has long been understood that increased epithelial permeability contributes to inflammation observed in many respiratory diseases. Recently, evidence has revealed that environmental exposure to noxious material such as cigarette smoke reduces tight junction barrier integrity, thus enhancing inflammatory conditions. Claudin-6 (Cldn6) is a tetraspanin transmembrane protein found within the tight junctional complex and is implicated in maintaining lung epithelial barriers. To test the hypothesis that increased Cldn6 ameliorates inflammation at the respiratory barrier, we utilized the Tet-On inducible transgenic system to conditionally over-express Clnd6 in the distal lung. Cldn6 transgenic (TG) and control mice were continuously provided doxycycline from postnatal day (PN) 30 until euthanasia date at PN90. A subset of Cldn6 TG and control mice were also subjected to daily secondhand tobacco smoke (SHS) via a nose only inhalation system from PN30-90 and compared to room air (RA) controls. Animals were euthanized on PN90 and lungs were harvested for histological and molecular characterization. Bronchoalveolar lavage fluid (BALF) was procured for the assessment of inflammatory cells and molecules. Quantitative RT-PCR and immunoblotting revealed increased Cldn6 expression in TG vs. control animals and SHS decreased Cldn6 expression regardless of genetic up-regulation. Histological evaluations revealed no adverse pulmonary remodeling via Hematoxylin and Eosin (H&amp;E) staining or any qualitative alterations in the abundance of type II pneumocytes or proximal non-ciliated epithelial cells via staining for cell specific propeptide of Surfactant Protein-C (proSP-C) or Club Cell Secretory Protein (CCSP), respectively. Immunoblotting and qRT-PCR confirmed the differential expression of Cldn6 and the pro-inflammatory cytokines TNF-α and IL-1β. As a general theme, inflammation induced by SHS exposure was influenced by the availability of Cldn6. These data reveal captivating information suggesting a role for Cldn6 in lungs exposed to tobacco smoke. Further research is critically necessary in order to fully explain roles for tight junctional components such as Cldn6 and other related molecules in lungs coping with exposure.
27763528	0	13	Up-Regulation	T044	C0041904
27763528	17	26	Claudin-6	T116	C0909824
27763528	34	40	Distal	T082	C0205108
27763528	41	45	Lung	T023	C0024109
27763528	54	70	Secondhand Smoke	T037	C0375734
27763528	80	92	Inflammation	T046	C0021368
27763528	136	146	epithelial	T080	C0221908
27763528	147	159	permeability	T070	C0031164
27763528	175	187	inflammation	T046	C0021368
27763528	205	225	respiratory diseases	T047	C0035204
27763528	264	286	environmental exposure	T037	C0014412
27763528	290	306	noxious material	T131	C1254354
27763528	315	330	cigarette smoke	T131	C0239059
27763528	339	353	tight junction	T030	C0242358
27763528	354	361	barrier	T024	C0225694
27763528	362	371	integrity	T080	C1947912
27763528	388	411	inflammatory conditions	UnknownType	C0544805
27763528	413	422	Claudin-6	T116	C0909824
27763528	424	429	Cldn6	T116	C0909824
27763528	436	469	tetraspanin transmembrane protein	T116	C0021699
27763528	487	511	tight junctional complex	T030	C0229984
27763528	545	569	lung epithelial barriers	T024	C0225694
27763528	609	614	Cldn6	T116	C0909824
27763528	627	639	inflammation	T046	C0021368
27763528	647	666	respiratory barrier	T024	C0225694
27763528	701	718	transgenic system	T028	C0282641
27763528	736	748	over-express	T045	C1514559
27763528	749	754	Clnd6	T116,T123	C1570898
27763528	762	768	distal	T082	C0205108
27763528	769	773	lung	T023	C0024109
27763528	775	791	Cldn6 transgenic	T015	C0025936
27763528	793	795	TG	T015	C0025936
27763528	801	808	control	T008	C1511501
27763528	809	813	mice	T015	C0025929
27763528	841	852	doxycycline	T109,T195	C0013090
27763528	858	871	postnatal day	T079	C1254367
27763528	873	875	PN	T079	C1254367
27763528	886	896	euthanasia	T058	C1136183
27763528	905	909	PN90	T079	C1254367
27763528	923	931	Cldn6 TG	T015	C0025936
27763528	936	943	control	T008	C1511501
27763528	944	948	mice	T015	C0025929
27763528	972	977	daily	T079	C0332173
27763528	978	1002	secondhand tobacco smoke	T037	C0375734
27763528	1004	1007	SHS	T037	C0375734
27763528	1015	1019	nose	T023	C0028429
27763528	1025	1042	inhalation system	T022	C0460002
27763528	1048	1055	PN30-90	T079	C1254367
27763528	1072	1080	room air	T033	C3846005
27763528	1082	1084	RA	T033	C3846005
27763528	1096	1103	Animals	T008	C0003062
27763528	1109	1119	euthanized	T058	C1136183
27763528	1123	1127	PN90	T079	C1254367
27763528	1132	1137	lungs	T023	C0024109
27763528	1157	1169	histological	T169	C0205462
27763528	1174	1200	molecular characterization	T052	C1880022
27763528	1202	1230	Bronchoalveolar lavage fluid	T031	C0006279
27763528	1232	1236	BALF	T031	C0006279
27763528	1259	1269	assessment	T058	C0220825
27763528	1273	1291	inflammatory cells	T025	C0440752
27763528	1296	1305	molecules	T167	C0567416
27763528	1307	1326	Quantitative RT-PCR	T063	C0599161
27763528	1331	1345	immunoblotting	T059	C0020985
27763528	1365	1370	Cldn6	T116,T123	C1570898
27763528	1371	1381	expression	T045	C1171362
27763528	1385	1387	TG	T015	C0025936
27763528	1392	1407	control animals	T008	C1511501
27763528	1412	1415	SHS	T037	C0375734
27763528	1426	1431	Cldn6	T116,T123	C1570898
27763528	1432	1442	expression	T045	C1171362
27763528	1465	1478	up-regulation	T044	C0041904
27763528	1480	1492	Histological	T169	C0205462
27763528	1493	1504	evaluations	T058	C0220825
27763528	1525	1534	pulmonary	T023	C0024109
27763528	1550	1590	Hematoxylin and Eosin (H&amp;E) staining	T059	C0523207
27763528	1629	1638	abundance	T080	C2346714
27763528	1642	1661	type II pneumocytes	T025	C0225700
27763528	1665	1703	proximal non-ciliated epithelial cells	T025	C0014597
27763528	1708	1716	staining	T059	C0487602
27763528	1721	1725	cell	T025	C0007634
27763528	1735	1769	propeptide of Surfactant Protein-C	T116,T123	C1454562
27763528	1771	1778	proSP-C	T116,T123	C1454562
27763528	1783	1810	Club Cell Secretory Protein	T116,T121	C1505368
27763528	1812	1816	CCSP	T116,T121	C1505368
27763528	1833	1847	Immunoblotting	T059	C0020985
27763528	1852	1859	qRT-PCR	T063	C1514628
27763528	1887	1897	expression	T045	C1171362
27763528	1901	1906	Cldn6	T116,T123	C1570898
27763528	1915	1941	pro-inflammatory cytokines	T129	C0021054
27763528	1942	1947	TNF-α	T116,T129	C0041368
27763528	1952	1957	IL-1β	T116,T129	C0021753
27763528	1979	1991	inflammation	T046	C0021368
27763528	2003	2006	SHS	T037	C0375734
27763528	2007	2015	exposure	T033	C0243095
27763528	2054	2059	Cldn6	T116,T123	C1570898
27763528	2125	2130	Cldn6	T116,T123	C1570898
27763528	2134	2139	lungs	T023	C0024109
27763528	2140	2147	exposed	T033	C0243095
27763528	2151	2164	tobacco smoke	T131	C0439994
27763528	2243	2270	tight junctional components	T030	C0229984
27763528	2279	2284	Cldn6	T116	C0909824
27763528	2303	2312	molecules	T167	C0567416
27763528	2316	2321	lungs	T023	C0024109
27763528	2334	2342	exposure	T033	C0243095

27401811|t|Matrix solid-phase dispersion combined to liquid chromatography-tandem mass spectrometry for the determination of paraben preservatives in mollusks
27401811|a|A method for the extraction and determination of seven parabens, esters of 4-hydroxybenzoic acid, widely used as preservatives in personal care products, pharmaceuticals, etc., and two chlorinated derivatives (mono- and di-chloro methyl paraben) from mollusk samples was developed by combining matrix solid-phase dispersion (MSPD) and liquid chromatography-tandem mass spectrometry. MSPD parameters, such as solvent, solid support and clean-up sorbent, were optimized. Besides, since blank problems were observed for some parabens, these were investigated and blanks were tackled by precleaning all sorbents prior to use. Under final conditions, 0.5g of freeze-dried mollusk were dispersed with 1.2g of silica and packed into a cartridge containing 3g of C18, as on-line clean-up sorbent. This cartridge was eluted with 10mL of acetonitrile, evaporated and reconstituted in methanol for analysis. In the validation stage, successful linearity (R(2)>0.999), recoveries (between 71 and 117% for most analytes), precision (RSD lower than 21%) and limits of detection and quantification (LOD and LOQ, lower than 0.4 and 1.4ngg(-1) dry weight respectively) levels were achieved. Finally, the new methodology was applied to mussel, clam and cockle samples. Methyl paraben was above the LOQ in five of the six samples (not found in one clam sample) at concentrations up to 7ngg(-1) dry weight. Ethyl paraben was found above the LOQ in mussel and cockle samples at a concentration level around 0.3ngg(-1). n-Propyl paraben was only above the LOQ in one mussel sample.
27401811	0	29	Matrix solid-phase dispersion	T059	C0022885
27401811	42	88	liquid chromatography-tandem mass spectrometry	T059	C4049918
27401811	97	110	determination	T059	C1148554
27401811	114	121	paraben	T109,T121	C0030398
27401811	122	135	preservatives	T122	C0033086
27401811	139	147	mollusks	T204	C0026391
27401811	150	175	method for the extraction	T170	C0449341
27401811	180	193	determination	T059	C1148554
27401811	203	211	parabens	T109,T121	C0030398
27401811	213	219	esters	T109	C0014898
27401811	223	244	4-hydroxybenzoic acid	T109,T121,T123	C0048323
27401811	261	274	preservatives	T122	C0033086
27401811	278	300	personal care products	T167	C4288402
27401811	302	317	pharmaceuticals	T121	C1254351
27401811	333	356	chlorinated derivatives	T109	C0020247
27401811	358	363	mono-	T109,T121	C0066415
27401811	368	392	di-chloro methyl paraben	T109,T121	C0066415
27401811	399	406	mollusk	T204	C0026391
27401811	407	414	samples	T077	C2347026
27401811	442	471	matrix solid-phase dispersion	T059	C0022885
27401811	473	477	MSPD	T059	C0022885
27401811	483	529	liquid chromatography-tandem mass spectrometry	T059	C4049918
27401811	531	546	MSPD parameters	T170	C2825207
27401811	556	563	solvent	T130	C0037638
27401811	565	578	solid support	T130	C1254353
27401811	583	599	clean-up sorbent	T130	C1254353
27401811	606	615	optimized	T052	C2698650
27401811	670	678	parabens	T109,T121	C0030398
27401811	691	703	investigated	T169	C1292732
27401811	731	742	precleaning	T052	C1947930
27401811	747	755	sorbents	T130	C1254353
27401811	802	814	freeze-dried	T059	C0016698
27401811	815	822	mollusk	T204	C0026391
27401811	828	837	dispersed	T082	C0332624
27401811	851	857	silica	T122,T197	C0037098
27401811	862	868	packed	T052	C2828395
27401811	876	885	cartridge	T170	C1553461
27401811	903	906	C18	T109	C0029224
27401811	919	935	clean-up sorbent	T130	C1254353
27401811	942	951	cartridge	T170	C1553461
27401811	976	988	acetonitrile	T109	C0050456
27401811	990	1000	evaporated	T070	C0596539
27401811	1005	1018	reconstituted	T052	C0441655
27401811	1022	1030	methanol	T109,T131	C0001963
27401811	1035	1043	analysis	T062	C0936012
27401811	1052	1062	validation	T062	C1519941
27401811	1105	1115	recoveries	T052	C0237820
27401811	1146	1154	analytes	T167	C0443354
27401811	1157	1166	precision	T080	C1706245
27401811	1192	1211	limits of detection	T081	C2718050
27401811	1216	1230	quantification	T081	C0392762
27401811	1232	1235	LOD	T081	C2718050
27401811	1240	1243	LOQ	T062	C1519941
27401811	1275	1285	dry weight	T081	C1439839
27401811	1300	1306	levels	T080	C0441889
27401811	1339	1350	methodology	T170	C0969625
27401811	1366	1372	mussel	T204	C0026871
27401811	1374	1378	clam	T204	C0008894
27401811	1383	1389	cockle	T204	C0453050
27401811	1390	1397	samples	T077	C2347026
27401811	1399	1413	Methyl paraben	T109,T121	C0066415
27401811	1428	1431	LOQ	T081	C0392762
27401811	1451	1458	samples	T077	C2347026
27401811	1477	1481	clam	T204	C0008894
27401811	1482	1488	sample	T077	C2347026
27401811	1493	1507	concentrations	T081	C1446561
27401811	1523	1533	dry weight	T081	C1439839
27401811	1535	1548	Ethyl paraben	T109,T121	C0059788
27401811	1569	1572	LOQ	T081	C0392762
27401811	1576	1582	mussel	T204	C0026871
27401811	1587	1593	cockle	T204	C0453050
27401811	1594	1601	samples	T077	C2347026
27401811	1607	1626	concentration level	T081	C1446561
27401811	1646	1662	n-Propyl paraben	T109,T121	C0072238
27401811	1682	1685	LOQ	T081	C0392762
27401811	1693	1699	mussel	T204	C0026871
27401811	1700	1706	sample	T077	C2347026

27632714|t|CHOROIDAL VASCULARITY INDEX: A Novel Optical Coherence Tomography Based Parameter in Patients With Exudative Age-Related Macular Degeneration
27632714|a|To evaluate choroidal structural changes in exudative age-related macular degeneration (AMD) using choroidal vascularity index computed from image binarization on spectral domain optical coherence tomography with enhanced depth imaging. This prospective case series included 42 consecutive patients with unilateral exudative AMD. Choroidal images were segmented into luminal area and stromal area. Choroidal vascularity index was defined as the ratio of luminal area to total choroid area. Mean choroidal vascularity index and mean choroidal thickness between study and fellow eyes of the same patient with dry AMD were compared using Student's t-test. There was a significantly lower choroidal vascularity index in eyes with exudative AMD (60.14 ± 4.55 vs. 62.75 ± 4.82, P < 0.01). Luminal area (P < 0.01) was decreased in eyes with exudative AMD but there was no significant difference in total choroid area (P = 0.05) and choroidal thickness (P = 0.93) between study and fellow eyes. Eyes with exudative AMD demonstrated reduced choroidal vascularity index but insignificant differences in choroidal thickness compared with their fellow eyes. Choroidal vascularity index may be a potential noninvasive tool for studying structural changes in choroid and monitoring choroidal disease in exudative AMD.
27632714	0	27	CHOROIDAL VASCULARITY INDEX	T081	C0392762
27632714	37	65	Optical Coherence Tomography	T060	C0920367
27632714	72	81	Parameter	T077	C0549193
27632714	85	93	Patients	T101	C0030705
27632714	99	141	Exudative Age-Related Macular Degeneration	T047	C0271084
27632714	154	163	choroidal	T023	C0008520
27632714	164	174	structural	T082	C0678594
27632714	186	228	exudative age-related macular degeneration	T047	C0271084
27632714	230	233	AMD	T047	C0242383
27632714	241	268	choroidal vascularity index	T081	C0392762
27632714	269	277	computed	T052	C1880157
27632714	305	349	spectral domain optical coherence tomography	T060	C0920367
27632714	364	377	depth imaging	T060	C0011923
27632714	396	407	case series	T062	C0150093
27632714	420	431	consecutive	T080	C1707491
27632714	432	440	patients	T101	C0030705
27632714	446	456	unilateral	T082	C0205092
27632714	457	470	exudative AMD	T047	C0271084
27632714	472	481	Choroidal	T023	C0008520
27632714	482	488	images	T060	C0011923
27632714	509	516	luminal	T082	C0524462
27632714	517	521	area	T082	C0205146
27632714	540	567	Choroidal vascularity index	T081	C0392762
27632714	587	592	ratio	T081	C0456603
27632714	596	603	luminal	T082	C0524462
27632714	604	608	area	T082	C0205146
27632714	626	630	area	T082	C0205146
27632714	632	636	Mean	T081	C0444504
27632714	637	664	choroidal vascularity index	T081	C0392762
27632714	669	673	mean	T081	C0444504
27632714	674	693	choroidal thickness	T081	C0392762
27632714	702	707	study	T062	C2603343
27632714	719	723	eyes	T023	C0015392
27632714	736	743	patient	T101	C0030705
27632714	753	756	AMD	T047	C0242383
27632714	777	793	Student's t-test	T081,T170	C0871453
27632714	807	826	significantly lower	T081	C4055638
27632714	827	854	choroidal vascularity index	T081	C0392762
27632714	858	862	eyes	T023	C0015392
27632714	868	881	exudative AMD	T047	C0271084
27632714	925	937	Luminal area	T082	C0524462
27632714	953	962	decreased	T081	C0205216
27632714	966	970	eyes	T023	C0015392
27632714	976	989	exudative AMD	T047	C0271084
27632714	1004	1029	no significant difference	T033	C3842396
27632714	1047	1051	area	T082	C0205146
27632714	1106	1111	study	T062	C2603343
27632714	1123	1127	eyes	T023	C0015392
27632714	1129	1133	Eyes	T023	C0015392
27632714	1139	1152	exudative AMD	T047	C0271084
27632714	1166	1173	reduced	T080	C0392756
27632714	1174	1201	choroidal vascularity index	T081	C0392762
27632714	1220	1231	differences	T080	C1705242
27632714	1282	1286	eyes	T023	C0015392
27632714	1288	1315	Choroidal vascularity index	T081	C0392762
27632714	1325	1334	potential	T080	C3245505
27632714	1335	1351	noninvasive tool	T033	C0243095
27632714	1356	1364	studying	T062	C2603343
27632714	1365	1375	structural	T082	C0678594
27632714	1387	1394	choroid	T023	C0008520
27632714	1410	1427	choroidal disease	T047	C0008521
27632714	1431	1444	exudative AMD	T047	C0271084

27655308|t|Low literacy and written drug information: information-seeking, leaflet evaluation and preferences, and roles for images
27655308|a|Background Low-literate patients are at risk to misinterpret written drug information. For the (co-) design of targeted patient information, it is key to involve this group in determining their communication barriers and information needs. Objective To gain insight into how people with low literacy use and evaluate written drug information, and to identify ways in which they feel the patient leaflet can be improved, and in particular how images could be used. Setting Food banks and an education institution for Dutch language training in the Netherlands. Method Semi-structured focus groups and individual interviews were held with low-literate participants (n = 45). The thematic framework approach was used for analysis to identify themes in the data. Main outcome measure Low-literate people's experience with patient information leaflets, ideas for improvements, and perceptions on possible uses for visuals. Results Patient information leaflets were considered discouraging to use, and information difficult to find and understand. Many rely on alternative information sources. The leaflet should be shorter, and improved in terms of organisation, legibility and readability. Participants thought images could increase the leaflet's appeal, help ask questions, provide an overview, help understand textual information, aid recall, reassure, and even lead to increased confidence, empowerment and feeling of safety. Conclusion Already at the stages of paying attention to the leaflet and maintaining interest in the message, low-literate patients experience barriers in the communication process through written drug information. Short, structured, visual / textual explanations can lower the motivational threshold to use the leaflet, improve understanding, and empower the low-literate target group.
27655308	0	12	Low literacy	T033	C1401894
27655308	17	41	written drug information	T170	C0033081
27655308	43	62	information-seeking	T033	C0392349
27655308	64	71	leaflet	T170	C3273178
27655308	72	82	evaluation	T078	C1550157
27655308	87	98	preferences	T078	C0558295
27655308	114	120	images	T170	C1704922
27655308	132	144	Low-literate	T098	C1518028
27655308	145	153	patients	T101	C0030705
27655308	161	165	risk	T078	C0035647
27655308	182	206	written drug information	T170	C0033081
27655308	241	260	patient information	T170	C1955348
27655308	288	293	group	T098	C1257890
27655308	315	337	communication barriers	T078	C0009454
27655308	342	353	information	T078	C1533716
27655308	396	402	people	T098	C0027361
27655308	408	420	low literacy	T033	C1401894
27655308	438	462	written drug information	T170	C0033081
27655308	508	515	patient	T101	C0030705
27655308	516	523	leaflet	T170	C3273178
27655308	563	569	images	T170	C1704922
27655308	593	603	Food banks	T092	C1561598
27655308	611	632	education institution	T073,T092	C0036375
27655308	637	651	Dutch language	T171	C0376241
27655308	652	660	training	T065	C0220931
27655308	668	679	Netherlands	T083	C0027778
27655308	704	716	focus groups	T096	C0016400
27655308	721	731	individual	T098	C0237401
27655308	732	742	interviews	T052	C0021822
27655308	758	783	low-literate participants	T098	C1518028
27655308	798	825	thematic framework approach	T077	C1254372
27655308	874	878	data	T078	C1511726
27655308	885	892	outcome	T169	C1274040
27655308	901	922	Low-literate people's	T098	C1518028
27655308	923	933	experience	T078	C1533716
27655308	939	958	patient information	T170	C1955348
27655308	959	967	leaflets	T170	C3273178
27655308	969	974	ideas	T078	C1254370
27655308	979	991	improvements	T077	C2986411
27655308	997	1008	perceptions	T041	C0030971
27655308	1030	1037	visuals	T169	C0234621
27655308	1047	1066	Patient information	T170	C1955348
27655308	1067	1075	leaflets	T170	C3273178
27655308	1117	1128	information	T078	C1533716
27655308	1151	1161	understand	T041	C0162340
27655308	1188	1207	information sources	T033	C0683836
27655308	1213	1220	leaflet	T170	C3273178
27655308	1265	1277	organisation	T169	C1300196
27655308	1279	1289	legibility	T033	C0870803
27655308	1294	1305	readability	T080	C0871211
27655308	1307	1319	Participants	T098	C0679646
27655308	1328	1334	images	T170	C1704922
27655308	1354	1363	leaflet's	T170	C3273178
27655308	1381	1390	questions	T170	C1522634
27655308	1403	1411	overview	T170	C0814812
27655308	1429	1436	textual	T170	C1527021
27655308	1437	1448	information	T078	C1533716
27655308	1454	1460	recall	T041	C0034770
27655308	1499	1509	confidence	T041	C1704726
27655308	1511	1522	empowerment	T054	C0679959
27655308	1538	1544	safety	T068	C0036043
27655308	1606	1613	leaflet	T170	C3273178
27655308	1655	1676	low-literate patients	T098	C1518028
27655308	1677	1687	experience	T041	C0596545
27655308	1688	1717	barriers in the communication	T078	C0009454
27655308	1734	1758	written drug information	T170	C0033081
27655308	1779	1785	visual	T169	C0234621
27655308	1788	1795	textual	T170	C1527021
27655308	1796	1808	explanations	T170	C0681841
27655308	1857	1864	leaflet	T170	C3273178
27655308	1866	1873	improve	T033	C0184511
27655308	1874	1887	understanding	T041	C0162340
27655308	1905	1930	low-literate target group	T098	C1518028

28514301|t|Unusual axillary metastasis of recurrent nasopharyngeal cancer: A case report
28514301|a|Nasopharyngeal carcinoma (NPC) has a high propensity of metastasis. The most commonly described sites of distant metastasis are the bones, lungs, and liver, whereas axillary metastasis is seldom reported. We hereby present the case of a 66-year-old man with NPC, cT2N2M0, at diagnosis. He had completed chemoradiotherapy and been disease-free for 7 years. After that period, late recurrence in the form of a solitary axillary lymph node metastasis was detected and confirmed by core-needle biopsy. The lesion was chemoresistant but responded to salvage radiotherapy at a dose of 65 Gy in 21 fractions. Post-radiotherapy positron emission tomography scan showed no evidence of disease. We suggested that long-term follow-up of NPC patients is important because a late relapse may occur at an unusual site. Aggressive management of solitary metastasis may achieve good outcome.
28514301	0	7	Unusual	T080	C2700116
28514301	8	27	axillary metastasis	T191	C0684830
28514301	31	40	recurrent	T079	C2945760
28514301	41	62	nasopharyngeal cancer	T191	C0153392
28514301	78	102	Nasopharyngeal carcinoma	T191	C2931822
28514301	104	107	NPC	T191	C2931822
28514301	134	144	metastasis	T046	C4255448
28514301	174	179	sites	T029	C0005898
28514301	191	201	metastasis	T046	C4255448
28514301	210	215	bones	T023	C0262950
28514301	217	222	lungs	T023	C0024109
28514301	228	233	liver	T023	C0023884
28514301	243	262	axillary metastasis	T191	C0684830
28514301	305	309	case	T077	C1706256
28514301	327	330	man	T032	C0086582
28514301	336	339	NPC	T191	C2931822
28514301	341	348	cT2N2M0	T185	C0475284
28514301	353	362	diagnosis	T033	C0011900
28514301	381	398	chemoradiotherapy	T061	C0436307
28514301	408	420	disease-free	T081	C0242793
28514301	427	432	years	T079	C0439234
28514301	458	468	recurrence	T046	C2825055
28514301	486	525	solitary axillary lymph node metastasis	UnknownType	C0741344
28514301	530	538	detected	T033	C0442726
28514301	543	552	confirmed	T033	C0750484
28514301	556	574	core-needle biopsy	T060	C1318309
28514301	580	586	lesion	T033	C0221198
28514301	591	605	chemoresistant	T039	C1514892
28514301	623	643	salvage radiotherapy	T061	C1522449
28514301	649	653	dose	T081	C0034620
28514301	698	731	positron emission tomography scan	T060	C0032743
28514301	739	761	no evidence of disease	T033	C1518340
28514301	781	800	long-term follow-up	T058	C1517942
28514301	804	816	NPC patients	T101	C0030705
28514301	840	852	late relapse	T033	C4054664
28514301	869	881	unusual site	T029	C0005898
28514301	883	904	Aggressive management	T058	C0376636
28514301	917	927	metastasis	T046	C4255448
28514301	945	952	outcome	T080	C0085415

28351298|t|Aberrant gene - specific DNA methylation signature analysis in cervical cancer
28351298|a|Multicomponent molecular modifications such as DNA methylation may offer sensitive and specific cervical intraepithelial neoplasia and cervical cancer biomarkers. In this study, we tested cervical tissues at various stages of tumor progression for 5-methylcytosine and 5-hydroxymethylcytosine levels and also DNA promoter methylation profile of a panel of genes for its diagnostic potential. In total, 5-methylcytosine, 5-hydroxymethylcytosine, and promoter methylation of 33 genes were evaluated by reversed-phase high-performance liquid chromatography, enzyme-linked immunosorbent assay based technique, and bisulfate-based next generation sequencing. The 5-methylcytosine and 5-hydroxymethylcytosine contents were significantly reduced in squamous cell carcinoma and receiver operating characteristic curve analysis showed a significant difference in (1) 5-methylcytosine between normal and squamous cell carcinoma tissues (area under the curve = 0.946) and (2) 5-hydroxymethylcytosine levels among normal, squamous intraepithelial lesions and squamous cell carcinoma. Analyses of our next generation sequencing results and data from five independent published studies consisting of 191 normal, 10 low-grade squamous intraepithelial lesions, 21 high-grade squamous intraepithelial lesions, and 335 malignant tissues identified a panel of nine genes (ARHGAP6, DAPK1, HAND2, NKX2-2, NNAT, PCDH10, PROX1, PITX2, and RAB6C) which could effectively discriminate among the various groups with sensitivity and specificity of 80%-100% (p < 0.05). Furthermore, 12 gene promoters (ARHGAP6, HAND2, LHX9, HEY2, NKX2-2, PCDH10, PITX2, PROX1, TBX3, IKBKG, RAB6C, and DAPK1) were also methylated in one or more of the cervical cancer cell lines tested. The global and gene - specific methylation of the panel of genes identified in our study may serve as useful biomarkers for the early detection and clinical management of cervical cancer.
28351298	0	8	Aberrant	T080	C0443127
28351298	9	13	gene	T028	C0017337
28351298	16	24	specific	T080	C0205369
28351298	25	40	DNA methylation	T044	C0376452
28351298	51	59	analysis	T062	C0936012
28351298	63	78	cervical cancer	T191	C4048328
28351298	94	103	molecular	T080	C1521991
28351298	104	117	modifications	T169	C0392747
28351298	126	141	DNA methylation	T044	C0376452
28351298	152	161	sensitive	T169	C0332324
28351298	166	174	specific	T080	C0205369
28351298	175	209	cervical intraepithelial neoplasia	T191	C0206708
28351298	214	229	cervical cancer	T191	C4048328
28351298	230	240	biomarkers	T123	C0041366
28351298	250	255	study	T062	C2603343
28351298	260	266	tested	T169	C0039593
28351298	267	275	cervical	T029	C0027530
28351298	276	283	tissues	T024	C0040300
28351298	287	294	various	T081	C0439064
28351298	295	301	stages	T079	C1306673
28351298	305	322	tumor progression	T191	C0178874
28351298	327	343	5-methylcytosine	T114,T123	C0049308
28351298	348	371	5-hydroxymethylcytosine	T109	C0049241
28351298	372	378	levels	T080	C0441889
28351298	388	391	DNA	T114,T123	C0012854
28351298	392	400	promoter	T028	C0314621
28351298	401	412	methylation	T044	C0376452
28351298	413	420	profile	T059	C1979963
28351298	435	440	genes	T028	C0017337
28351298	449	459	diagnostic	T169	C0348026
28351298	460	469	potential	T080	C3245505
28351298	481	497	5-methylcytosine	T114,T123	C0049308
28351298	499	522	5-hydroxymethylcytosine	T109	C0049241
28351298	528	536	promoter	T028	C0314621
28351298	537	548	methylation	T044	C0376452
28351298	555	560	genes	T028	C0017337
28351298	579	632	reversed-phase high-performance liquid chromatography	T059	C0008562
28351298	634	667	enzyme-linked immunosorbent assay	T059	C0014441
28351298	674	683	technique	T169	C0449851
28351298	689	731	bisulfate-based next generation sequencing	T063	C2936622
28351298	737	753	5-methylcytosine	T114,T123	C0049308
28351298	758	781	5-hydroxymethylcytosine	T109	C0049241
28351298	796	809	significantly	T078	C0750502
28351298	810	817	reduced	T080	C0392756
28351298	821	844	squamous cell carcinoma	T191	C0007137
28351298	849	888	receiver operating characteristic curve	T081	C0034772
28351298	889	897	analysis	T062	C0936012
28351298	907	918	significant	T078	C0750502
28351298	919	929	difference	T080	C1705242
28351298	937	953	5-methylcytosine	T114,T123	C0049308
28351298	962	968	normal	T080	C0205307
28351298	973	996	squamous cell carcinoma	T191	C0007137
28351298	997	1004	tissues	T024	C0040300
28351298	1006	1026	area under the curve	T081	C0376690
28351298	1044	1067	5-hydroxymethylcytosine	T109	C0049241
28351298	1068	1074	levels	T080	C0441889
28351298	1081	1087	normal	T033	C0221198
28351298	1089	1121	squamous intraepithelial lesions	T191	C0333873
28351298	1126	1149	squamous cell carcinoma	T191	C0007137
28351298	1151	1159	Analyses	T062	C0936012
28351298	1167	1193	next generation sequencing	T063	C2936622
28351298	1194	1201	results	T169	C1274040
28351298	1206	1210	data	T078	C1511726
28351298	1233	1250	published studies	T170	C1704324
28351298	1269	1275	normal	T033	C0221198
28351298	1280	1322	low-grade squamous intraepithelial lesions	T191	C1302773
28351298	1327	1370	high-grade squamous intraepithelial lesions	T191	C0333875
28351298	1380	1389	malignant	T191	C0006826
28351298	1390	1397	tissues	T024	C0040300
28351298	1398	1408	identified	T080	C0205396
28351298	1420	1424	nine	T081	C0205455
28351298	1425	1430	genes	T028	C0017337
28351298	1432	1439	ARHGAP6	T028	C1412523
28351298	1441	1446	DAPK1	T028	C1413906
28351298	1448	1453	HAND2	T028	C1415467
28351298	1455	1461	NKX2-2	T028	C1417735
28351298	1463	1467	NNAT	T028	C1417747
28351298	1469	1475	PCDH10	T028	C1421975
28351298	1477	1482	PROX1	T028	C1418951
28351298	1484	1489	PITX2	T028	C1418596
28351298	1495	1500	RAB6C	T028	C1424353
28351298	1514	1525	effectively	T080	C1704419
28351298	1526	1538	discriminate	T080	C0205235
28351298	1549	1556	various	T081	C0439064
28351298	1557	1563	groups	UnknownType	C0681860
28351298	1569	1580	sensitivity	T169	C0332324
28351298	1585	1596	specificity	T080	C0205369
28351298	1637	1651	gene promoters	T028	C0314621
28351298	1653	1660	ARHGAP6	T028	C1412523
28351298	1662	1667	HAND2	T028	C1415467
28351298	1669	1673	LHX9	T028	C1422495
28351298	1675	1679	HEY2	T028	C1415525
28351298	1681	1687	NKX2-2	T028	C1417735
28351298	1689	1695	PCDH10	T028	C1421975
28351298	1697	1702	PITX2	T028	C1418596
28351298	1704	1709	PROX1	T028	C1418951
28351298	1711	1715	TBX3	T028	C1420613
28351298	1717	1722	IKBKG	T028	C1416380
28351298	1724	1729	RAB6C	T028	C1424353
28351298	1735	1740	DAPK1	T028	C1413906
28351298	1752	1762	methylated	T044	C0376452
28351298	1785	1800	cervical cancer	T191	C4048328
28351298	1801	1811	cell lines	T025	C0007600
28351298	1812	1818	tested	T169	C0039593
28351298	1824	1830	global	T080	C2348867
28351298	1835	1839	gene	T028	C0017337
28351298	1842	1850	specific	T080	C0205369
28351298	1851	1862	methylation	T044	C0376452
28351298	1879	1884	genes	T028	C0017337
28351298	1885	1895	identified	T080	C0205396
28351298	1903	1908	study	T062	C2603343
28351298	1922	1928	useful	T080	C3827682
28351298	1929	1939	biomarkers	T123	C0041366
28351298	1954	1963	detection	T061	C1511790
28351298	1968	1987	clinical management	T058	C1516615
28351298	1991	2006	cervical cancer	T191	C4048328

28265530|t|Discontinued Splenogonadal Fusion and Bilateral Empty Scrotum in an 18- Month -Old Boy
28265530|a|Splenogonadal fusion is a rare benign congenital anomaly defined as the presence of splenic tissue adherent to gonads. It was first described in 1883 by Bostroem, a German pathologist. We present a case of an 18- month -old boy who was referred as a case of bilateral empty scrotum since birth. During routine laparoscopic exploration, right vas deferens and testicular vessels were entering the right internal inguinal ring so right inguinal exploration was done, which revealed blind ending vas deferens and testicular vessels and the left testis was found intra-abdominally near the left internal ring with a mass on its upper pole. Wedge biopsy was taken from the upper pole of the testicle (site of the mass) for tissue diagnosis followed by orchidopexy. Histology showed splenic tissue. Although splenogonadal fusion is a rare condition, surgeons should be aware of this rare disease entity to avoid unnecessary aggressive interventions such as orchiectomy.
28265530	0	12	Discontinued	T033	C1444662
28265530	13	33	Splenogonadal Fusion	T019	C0266636
28265530	38	61	Bilateral Empty Scrotum	T019	C1261504
28265530	72	77	Month	T032	C1510828
28265530	83	86	Boy	T100	C0870221
28265530	87	107	Splenogonadal fusion	T019	C0266636
28265530	113	117	rare	T080	C0522498
28265530	125	143	congenital anomaly	T019	C0000768
28265530	171	185	splenic tissue	T024	C0771377
28265530	186	194	adherent	T169	C0334154
28265530	198	204	gonads	T023	C0018067
28265530	240	248	Bostroem	T016	C0086418
28265530	252	258	German	T098	C1556085
28265530	259	270	pathologist	T097	C0334866
28265530	285	289	case	T077	C1706256
28265530	300	305	month	T032	C1510828
28265530	311	314	boy	T100	C0870221
28265530	337	341	case	T077	C1706256
28265530	345	368	bilateral empty scrotum	T019	C1261504
28265530	389	396	routine	T080	C0205547
28265530	397	409	laparoscopic	T060	C0521291
28265530	410	421	exploration	T061	C1280903
28265530	423	441	right vas deferens	T023	C0228039
28265530	446	464	testicular vessels	T023	C4266473
28265530	483	511	right internal inguinal ring	T023	C0932530
28265530	515	529	right inguinal	T029	C0230318
28265530	530	541	exploration	T061	C1280903
28265530	567	579	blind ending	T033	C0243095
28265530	580	592	vas deferens	T023	C0042360
28265530	597	615	testicular vessels	T023	C4266473
28265530	624	635	left testis	T023	C0227998
28265530	646	663	intra-abdominally	T082	C1512910
28265530	678	691	internal ring	T030	C1512866
28265530	699	703	mass	T184	C0577573
28265530	711	721	upper pole	T023	C0227991
28265530	723	735	Wedge biopsy	T060	C0192152
28265530	755	781	upper pole of the testicle	T023	C0227991
28265530	783	787	site	T029	C1515974
28265530	795	799	mass	T184	C0577573
28265530	805	821	tissue diagnosis	T185	C1546905
28265530	834	845	orchidopexy	T061	C0194907
28265530	847	856	Histology	T059	C0344441
28265530	864	878	splenic tissue	T024	C0771377
28265530	889	909	splenogonadal fusion	T019	C0266636
28265530	915	919	rare	T080	C0522498
28265530	920	929	condition	T047	C0012634
28265530	931	939	surgeons	T097	C0582175
28265530	964	976	rare disease	T047	C0678236
28265530	993	1004	unnecessary	T058	C0376708
28265530	1016	1029	interventions	T061	C0808232
28265530	1038	1049	orchiectomy	T061	C0029189

28003464|t|Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells
28003464|a|Novel APOBEC1 target 1 (Nat1) (also known as " p97 ," " Dap5 ," and " Eif4g2 ") is a ubiquitously expressed cytoplasmic protein that is homologous to the C-terminal two thirds of eukaryotic translation initiation factor 4G (Eif4g1). We previously showed that Nat1 - null mouse embryonic stem cells (mES cells) are resistant to differentiation. In the current study, we found that NAT1 and eIF4G1 share many binding proteins, such as the eukaryotic translation initiation factors eIF3 and eIF4A and ribosomal proteins. However, NAT1 did not bind to eIF4E or poly(A)-binding proteins, which are critical for cap-dependent translation initiation. In contrast, compared with eIF4G1, NAT1 preferentially interacted with eIF2, fragile X mental retardation proteins (FMR), and related proteins and especially with members of the proline-rich and coiled-coil-containing protein 2 (PRRC2) family. We also found that Nat1 - null mES cells possess a transcriptional profile similar, although not identical, to the ground state, which is established in wild-type mES cells when treated with inhibitors of the ERK and glycogen synthase kinase 3 (GSK3) signaling pathways. In Nat1 - null mES cells, the ERK pathway is suppressed even without inhibitors. Ribosome profiling revealed that translation of mitogen-activated protein kinase kinase kinase 3 (Map3k3) and son of sevenless homolog 1 (Sos1) is suppressed in the absence of Nat1 Forced expression of Map3k3 induced differentiation of Nat1 - null mES cells. These data collectively show that Nat1 is involved in the translation of proteins that are required for cell differentiation.
28003464	0	4	Nat1	T116,T126	C1527469
28003464	5	13	promotes	T052	C0033414
28003464	14	25	translation	T045	C1519614
28003464	38	46	proteins	T116,T123	C0033684
28003464	52	58	induce	T169	C0205263
28003464	59	74	differentiation	T043	C0007589
28003464	78	104	mouse embryonic stem cells	T025	C4042879
28003464	105	110	Novel	T080	C0205314
28003464	111	127	APOBEC1 target 1	T116,T126	C4308137
28003464	129	133	Nat1	T116,T126	C1527469
28003464	152	155	p97	T116,T126	C0246486
28003464	161	165	Dap5	T116,T123	C1452460
28003464	175	181	Eif4g2	T116,T123	C1452460
28003464	203	212	expressed	T045	C1171362
28003464	213	232	cytoplasmic protein	T116,T123	C1333198
28003464	241	251	homologous	T080	C2697616
28003464	259	269	C-terminal	T087	C1707271
28003464	284	327	eukaryotic translation initiation factor 4G	T116,T123	C1505487
28003464	329	335	Eif4g1	T116,T123	C1505487
28003464	364	368	Nat1	T028	C1417602
28003464	371	402	null mouse embryonic stem cells	T025	C4042879
28003464	404	413	mES cells	T025	C4042879
28003464	419	428	resistant	T169	C0332325
28003464	432	447	differentiation	T043	C0007589
28003464	464	469	study	T062	C2603343
28003464	485	489	NAT1	T116,T126	C1527469
28003464	494	500	eIF4G1	T116,T123	C1505487
28003464	512	528	binding proteins	T116,T123	C0242210
28003464	542	583	eukaryotic translation initiation factors	T116,T123	C1136317
28003464	584	588	eIF3	T116,T123	C0752615
28003464	593	598	eIF4A	T116,T123	C0058984
28003464	603	621	ribosomal proteins	T116,T123	C0035552
28003464	632	636	NAT1	T116,T126	C1527469
28003464	653	658	eIF4E	T116,T123	C4077502
28003464	662	686	poly(A)-binding proteins	T116,T123	C0071346
28003464	711	747	cap-dependent translation initiation	T045	C3268337
28003464	776	782	eIF4G1	T116,T123	C1505487
28003464	784	788	NAT1	T116,T126	C1527469
28003464	804	814	interacted	T169	C1704675
28003464	820	824	eIF2	T116,T123	C0013729
28003464	826	863	fragile X mental retardation proteins	T116,T123	C0118036
28003464	865	868	FMR	T116,T123	C0118036
28003464	883	891	proteins	T116,T123	C0033684
28003464	927	976	proline-rich and coiled-coil-containing protein 2	T116,T123	C0033684
28003464	978	983	PRRC2	T116,T123	C0033684
28003464	985	991	family	T116,T123	C1335532
28003464	1012	1016	Nat1	T028	C1417602
28003464	1019	1033	null mES cells	T025	C4042879
28003464	1044	1067	transcriptional profile	T045	C0040649
28003464	1090	1099	identical	T080	C0205280
28003464	1146	1155	wild-type	T028	C1883559
28003464	1156	1165	mES cells	T025	C4042879
28003464	1171	1178	treated	T169	C1522326
28003464	1184	1194	inhibitors	T121	C1519313
28003464	1202	1205	ERK	T044	C3179234
28003464	1210	1236	glycogen synthase kinase 3	T116,T126	C0244989
28003464	1238	1242	GSK3	T116,T126	C0244989
28003464	1244	1262	signaling pathways	T044	C0037080
28003464	1267	1271	Nat1	T028	C1417602
28003464	1274	1288	null mES cells	T025	C4042879
28003464	1294	1305	ERK pathway	T044	C3179234
28003464	1309	1319	suppressed	T169	C1260953
28003464	1333	1343	inhibitors	T121	C1519313
28003464	1345	1353	Ribosome	T026	C0035553
28003464	1354	1363	profiling	T059	C1979963
28003464	1378	1389	translation	T045	C1519614
28003464	1393	1441	mitogen-activated protein kinase kinase kinase 3	T028	C1442513
28003464	1443	1449	Map3k3	T028	C1442513
28003464	1455	1481	son of sevenless homolog 1	T028	C1420314
28003464	1483	1487	Sos1	T028	C1420314
28003464	1492	1502	suppressed	T169	C1260953
28003464	1510	1517	absence	T169	C0332197
28003464	1521	1525	Nat1	T028	C1417602
28003464	1533	1543	expression	T045	C1171362
28003464	1547	1553	Map3k3	T028	C1442513
28003464	1554	1561	induced	T169	C0205263
28003464	1562	1577	differentiation	T043	C0007589
28003464	1581	1585	Nat1	T028	C1417602
28003464	1588	1602	null mES cells	T025	C4042879
28003464	1610	1614	data	T078	C1511726
28003464	1638	1642	Nat1	T028	C1417602
28003464	1662	1673	translation	T045	C1519614
28003464	1677	1685	proteins	T116,T123	C0033684
28003464	1708	1728	cell differentiation	T043	C0007589

28004225|t|Modeling viscous dissipation during vocal fold contact: the influence of tissue viscosity and thickness with implications for hydration
28004225|a|The mechanics of vocal fold contact during phonation is known to play a crucial role in both normal and pathological speech production, though the underlying physics is not well understood. Herein, a viscoelastic model of the stresses during vocal fold contact is developed. This model assumes the cover to be a poroelastic structure wherein interstitial fluid translocates in response to mechanical squeezing. The maximum interstitial fluid pressure is found to generally increase with decreasing viscous dissipation and/or decreasing tissue elasticity. A global minimum in the total contact stress, comprising interstitial fluid pressure and elastic stress in the tissue, is observed over the studied dimensionless parameter range. Interestingly, physiologically reasonable estimates for the governing parameters fall within this global minimum region. The model is validated against prior experimental and computational work, wherein the predicted contact stress magnitude and impact duration agree well with published results. Lastly, observations of the potential relationship between vocal fold hydration and increased risk of tissue damage are discussed based upon model predictions of stress as functions of cover layer thickness and viscosity.
28004225	0	8	Modeling	T062	C0870071
28004225	9	28	viscous dissipation	T040	C1662975
28004225	36	46	vocal fold	T023	C0042930
28004225	47	54	contact	T042	C1254358
28004225	60	69	influence	T077	C4054723
28004225	73	79	tissue	T024	C0040300
28004225	80	89	viscosity	T070	C0042784
28004225	94	103	thickness	T080	C1280412
28004225	126	135	hydration	T033	C1321013
28004225	140	149	mechanics	T042	C1254358
28004225	153	163	vocal fold	T023	C0042930
28004225	164	171	contact	T042	C1254358
28004225	179	188	phonation	T042	C0031577
28004225	229	235	normal	T080	C0205307
28004225	240	252	pathological	T169	C1521733
28004225	253	270	speech production	T040	C0037817
28004225	336	354	viscoelastic model	T170	C3161035
28004225	362	370	stresses	T033	C4270731
28004225	378	388	vocal fold	T023	C0042930
28004225	389	396	contact	T042	C1254358
28004225	416	421	model	T170	C3161035
28004225	434	439	cover	T023	C0507777
28004225	448	469	poroelastic structure	T080	C0205556
28004225	478	496	interstitial fluid	T031	C0162367
28004225	497	509	translocates	T169	C0205245
28004225	525	545	mechanical squeezing	T169	C0205245
28004225	551	558	maximum	T081	C0806909
28004225	559	577	interstitial fluid	T031	C0162367
28004225	578	586	pressure	T081	C4284008
28004225	609	617	increase	T169	C0442805
28004225	623	633	decreasing	T033	C0442797
28004225	634	653	viscous dissipation	T040	C1662975
28004225	661	671	decreasing	T033	C0442797
28004225	672	689	tissue elasticity	T033	C1562328
28004225	693	707	global minimum	T081	C0392762
28004225	715	735	total contact stress	T033	C4270731
28004225	748	766	interstitial fluid	T031	C0162367
28004225	767	775	pressure	T081	C4284008
28004225	780	794	elastic stress	T070	C0038442
28004225	802	808	tissue	T024	C0040300
28004225	839	862	dimensionless parameter	T081	C1880866
28004225	863	868	range	T081	C1514721
28004225	885	900	physiologically	T169	C0205463
28004225	901	921	reasonable estimates	T169	C0205245
28004225	940	950	parameters	T033	C0449381
28004225	968	989	global minimum region	T081	C0392762
28004225	995	1000	model	T170	C3161035
28004225	1028	1040	experimental	T080	C1517586
28004225	1045	1058	computational	T052	C1880157
28004225	1059	1063	work	T057	C0043227
28004225	1077	1086	predicted	T078	C0681842
28004225	1087	1101	contact stress	T033	C4270731
28004225	1102	1111	magnitude	T081	C1704240
28004225	1116	1122	impact	T080	C4049986
28004225	1123	1131	duration	T079	C0449238
28004225	1148	1165	published results	T169	C1274040
28004225	1175	1187	observations	T062	C0302523
28004225	1205	1217	relationship	T080	C0439849
28004225	1226	1236	vocal fold	T023	C0042930
28004225	1237	1246	hydration	T033	C1321013
28004225	1251	1260	increased	T081	C0205217
28004225	1261	1265	risk	T078	C0035647
28004225	1269	1282	tissue damage	T037	C0010957
28004225	1308	1313	model	T170	C3161035
28004225	1314	1325	predictions	T078	C0681842
28004225	1329	1335	stress	T033	C4270731
28004225	1339	1348	functions	T169	C0542341
28004225	1352	1357	cover	T023	C0507777
28004225	1358	1363	layer	T023	C0934502
28004225	1364	1373	thickness	T080	C1280412
28004225	1378	1387	viscosity	T070	C0042784

27515958|t|Gut Microbiota and Alcoholic Liver Disease
27515958|a|The gut-liver axis model has often explained liver disease physiopathology. Among the latter we can mention Non-Alcoholic Liver Steatosis (NAFLD), Liver Steatohepatitis (NASH), liver cirrhosis. In this frame an altered Intestinal Permeability (IP) is the gate for antigenic / toxic substances from gut lumen until target organs such as liver in NAFLD. Altered intestinal permeability was discovered almost forty years ago as consequence of acute and chronic alcohol ingestion. Alcohol Liver Disease (ALD) is a systemic pathology whose beginning and end belong to the intestine. Several recent evidences from the literature show how gut microbiota composition can be altered by alcohol, affects IP and can be modulated by several nonpharmacological and pharmacological agents, becoming the target for ALD treatment. In this review we describe the definition of ALD, gut microbiota composition in healthy and ALD, definition and role of IP in ALD physiopathology and emerging evidences on gut microbiota modulation in ALD treatment from preliminary clinical and non-clinical studies.
27515958	0	14	Gut Microbiota	T001	C4018878
27515958	19	42	Alcoholic Liver Disease	T047	C0023896
27515958	47	67	gut-liver axis model	T075	C0026339
27515958	88	101	liver disease	T047	C0023895
27515958	102	117	physiopathology	T169	C0031847
27515958	151	180	Non-Alcoholic Liver Steatosis	T047	C0400966
27515958	182	187	NAFLD	T047	C0400966
27515958	190	211	Liver Steatohepatitis	T047	C3241937
27515958	213	217	NASH	T047	C3241937
27515958	220	235	liver cirrhosis	T047	C0023890
27515958	262	285	Intestinal Permeability	T042	C0232645
27515958	287	289	IP	T042	C0232645
27515958	307	316	antigenic	T129	C0003320
27515958	319	335	toxic substances	T131	C0444631
27515958	341	350	gut lumen	T030	C0836213
27515958	357	370	target organs	T082	C0807185
27515958	379	384	liver	T023	C0023884
27515958	388	393	NAFLD	T047	C0400966
27515958	403	426	intestinal permeability	T042	C0232645
27515958	483	518	acute and chronic alcohol ingestion	T055	C0001948
27515958	520	541	Alcohol Liver Disease	T047	C0023896
27515958	543	546	ALD	T047	C0023896
27515958	553	571	systemic pathology	T169	C0205469
27515958	610	619	intestine	T023	C0021853
27515958	655	665	literature	T170	C0023866
27515958	675	689	gut microbiota	T001	C4018878
27515958	690	701	composition	T201	C0486616
27515958	709	727	altered by alcohol	T109,T121	C0001975
27515958	737	739	IP	T042	C0232645
27515958	751	760	modulated	T082	C0443264
27515958	772	790	nonpharmacological	T167	C0439861
27515958	795	817	pharmacological agents	T121	C1254351
27515958	843	846	ALD	T047	C0023896
27515958	847	856	treatment	T061	C0087111
27515958	903	906	ALD	T047	C0023896
27515958	908	922	gut microbiota	T001	C4018878
27515958	923	934	composition	T201	C0486616
27515958	938	945	healthy	T080	C3898900
27515958	950	953	ALD	T047	C0023896
27515958	978	980	IP	T042	C0232645
27515958	984	987	ALD	T047	C0023896
27515958	988	1003	physiopathology	T169	C0031847
27515958	1030	1044	gut microbiota	T001	C4018878
27515958	1045	1055	modulation	T082	C0443264
27515958	1059	1062	ALD	T047	C0023896
27515958	1063	1072	treatment	T061	C0087111
27515958	1078	1098	preliminary clinical	T062	C0008972
27515958	1103	1123	non-clinical studies	T062	C2603343

28198835|t|Methane -based in situ temperature rise measurement in a diode-pumped rubidium laser
28198835|a|We measured active zone temperature rise of an operational diode-pumped rubidium laser non-perturbatively with methane -based near-infrared tunable diode laser spectroscopy (TDLAS). For a Rb+ methane diode-pumped alkali laser (DPAL), the temperature rise was obtained. Especially, the temperature differences (∼10 K) between lasing and un-lasing cases were well identified, which demonstrated a high sensitivity of the method. To our knowledge, this is the first demonstration of extending the methane -based TDLAS method to DPAL study.
28198835	0	7	Methane	T109	C0025617
28198835	15	22	in situ	T082	C0444498
28198835	23	34	temperature	T081	C0039476
28198835	35	39	rise	T169	C0442805
28198835	40	51	measurement	T169	C0242485
28198835	57	84	diode-pumped rubidium laser	T073	C1269092
28198835	88	96	measured	T080	C0444706
28198835	97	108	active zone	T082	C1254362
28198835	109	120	temperature	T081	C0039476
28198835	121	125	rise	T169	C0442805
28198835	132	143	operational	T052	C0336913
28198835	144	171	diode-pumped rubidium laser	T073	C1269092
28198835	172	190	non-perturbatively	T033	C4035914
28198835	196	203	methane	T109	C0025617
28198835	211	224	near-infrared	T070	C1289901
28198835	225	232	tunable	T169	C0205245
28198835	233	257	diode laser spectroscopy	T073	C1269092
28198835	259	264	TDLAS	T073	C1269092
28198835	273	276	Rb+	T196	C0035930
28198835	277	284	methane	T109	C0025617
28198835	285	310	diode-pumped alkali laser	T074	C0259975
28198835	312	316	DPAL	T074	C0259975
28198835	323	334	temperature	T081	C0039476
28198835	335	339	rise	T169	C0442805
28198835	370	381	temperature	T081	C0039476
28198835	382	393	differences	T080	C1705242
28198835	480	496	high sensitivity	T067	C2346484
28198835	504	510	method	T170	C0025663
28198835	579	586	methane	T109	C0025617
28198835	594	599	TDLAS	T073	C1269092
28198835	600	606	method	T170	C0025663
28198835	610	614	DPAL	T074	C0259975
28198835	615	620	study	T062	C2603343

27394375|t|Ictal unilateral blinking is an unreliable lateralizing sign in tuberous sclerosis complex
27394375|a|Ictal unilateral blinking is an uncommon but reportedly reliable lateralizing sign, indicating an ipsilateral seizure focus. We aimed to determine its lateralizing utility in patients with tuberous sclerosis complex (TSC). We reviewed the video-EEGs of 92 children with TSC and drug-resistant epilepsy. Eleven (12%) had seizures with unilateral blinking, of which 10 underwent epilepsy surgery. Lateralization of seizures was inferred from other semiology, ictal scalp EEG and outcome following tuberectomy. Seizures manifesting with unilateral blinking were focal motor in four patients, focal motor evolving into epileptic spasms in six, and epileptic spasms with focal features in one. Associated unilateral facial contraction was seen in five patients and arm jerking in four. Lateralized scalp ictal rhythms were seen in seven patients. Following tuberectomies, seven patients are seizure free and two had >90% reduction. Overall lateralization of seizures with unilateral blinking was contralateral in six patients and ipsilateral in four. When unilateral blinking was early in seizures, overall lateralization was more often contralateral (6/7 patients, PPV 85%). Ictal unilateral blinking is not infrequent but unreliable in lateralizing seizures in TSC. Unrecognized seizure propagation to contralateral symptomatogenic regions and potentially different mechanisms may account for the variable lateralization.
27394375	0	5	Ictal	T184	C0036572
27394375	6	16	unilateral	T082	C0205092
27394375	17	25	blinking	T042	C0005757
27394375	32	42	unreliable	T078	C0749770
27394375	43	60	lateralizing sign	T033	C2139233
27394375	64	90	tuberous sclerosis complex	T191	C0041341
27394375	91	96	Ictal	T184	C0036572
27394375	97	107	unilateral	T082	C0205092
27394375	108	116	blinking	T042	C0005757
27394375	123	131	uncommon	T080	C0522498
27394375	156	173	lateralizing sign	T033	C2139233
27394375	189	200	ipsilateral	T082	C0441989
27394375	201	214	seizure focus	T184	C0036572
27394375	242	262	lateralizing utility	T033	C2139233
27394375	266	274	patients	T101	C0030705
27394375	280	306	tuberous sclerosis complex	T191	C0041341
27394375	308	311	TSC	T191	C0041341
27394375	330	340	video-EEGs	T060	C0430801
27394375	347	355	children	T100	C0008059
27394375	361	364	TSC	T191	C0041341
27394375	369	392	drug-resistant epilepsy	T047	C1096063
27394375	411	419	seizures	T184	C0036572
27394375	425	435	unilateral	T082	C0205092
27394375	436	444	blinking	T042	C0005757
27394375	468	476	epilepsy	T047	C0014544
27394375	477	484	surgery	T061	C0543467
27394375	486	500	Lateralization	T033	C2139233
27394375	504	512	seizures	T184	C0036572
27394375	537	546	semiology	T033	C4013974
27394375	548	553	ictal	T184	C0036572
27394375	554	563	scalp EEG	T060	C0430784
27394375	568	575	outcome	T169	C1274040
27394375	586	597	tuberectomy	T061	C0087111
27394375	599	607	Seizures	T184	C0036572
27394375	625	635	unilateral	T082	C0205092
27394375	636	644	blinking	T042	C0005757
27394375	650	661	focal motor	T033	C3551483
27394375	670	678	patients	T101	C0030705
27394375	680	691	focal motor	T184	C3697219
27394375	706	722	epileptic spasms	T047	C1527366
27394375	735	751	epileptic spasms	T047	C1527366
27394375	757	771	focal features	T033	C1848821
27394375	791	801	unilateral	T082	C0205092
27394375	802	820	facial contraction	T047	C0270871
27394375	838	846	patients	T101	C0030705
27394375	851	862	arm jerking	T033	C0231530
27394375	872	883	Lateralized	T033	C2139233
27394375	884	889	scalp	T023	C0036270
27394375	890	895	ictal	T184	C0036572
27394375	896	903	rhythms	T033	C0871269
27394375	923	931	patients	T101	C0030705
27394375	943	956	tuberectomies	T061	C0087111
27394375	964	972	patients	T101	C0030705
27394375	977	989	seizure free	T033	C1299590
27394375	1007	1016	reduction	T080	C0392756
27394375	1018	1040	Overall lateralization	T033	C2139233
27394375	1044	1052	seizures	T184	C0036572
27394375	1058	1068	unilateral	T082	C0205092
27394375	1069	1077	blinking	T042	C0005757
27394375	1082	1095	contralateral	T082	C0441988
27394375	1103	1111	patients	T101	C0030705
27394375	1142	1152	unilateral	T082	C0205092
27394375	1153	1161	blinking	T042	C0005757
27394375	1175	1183	seizures	T184	C0036572
27394375	1185	1207	overall lateralization	T033	C2139233
27394375	1223	1236	contralateral	T082	C0441988
27394375	1242	1250	patients	T101	C0030705
27394375	1262	1267	Ictal	T184	C0036572
27394375	1268	1278	unilateral	T082	C0205092
27394375	1279	1287	blinking	T042	C0005757
27394375	1291	1305	not infrequent	T079	C0332183
27394375	1310	1320	unreliable	T078	C0749770
27394375	1324	1336	lateralizing	T033	C2139233
27394375	1337	1345	seizures	T184	C0036572
27394375	1349	1352	TSC	T191	C0041341
27394375	1354	1366	Unrecognized	T080	C4288068
27394375	1367	1374	seizure	T184	C0036572
27394375	1375	1386	propagation	T169	C0205245
27394375	1390	1403	contralateral	T082	C0441988
27394375	1404	1427	symptomatogenic regions	T082	C0205147
27394375	1454	1464	mechanisms	T169	C0441712
27394375	1485	1493	variable	T080	C0439828
27394375	1494	1508	lateralization	T033	C2139233

27443945|t|Pain and alcohol consumption among older adults: findings from the World Health Organization Study on global AGEing and adult health, Wave 1
27443945|a|To investigate cross-sectional associations between self-reported recent pain and alcohol use / abstinence, and previous - day pain and previous - week alcohol consumption in adults aged 50 + in six low - and middle-income countries (LMICs). The WHO Study on global AGEing and adult health (SAGE) Wave 1 (2007-2010) in China, Ghana, India, Mexico, Russia and South Africa is the data source. Prevalence of alcohol use / abstinence is reported by previous - day and previous - month pain. Multinomial logistic regressions (crude and adjusted for sex and country) tested associations between recent pain and alcohol use in the pooled multicountry sample. Across the six SAGE countries, about one-third of respondents reported alcohol use, being highest in Russia (74%) and lowest in India (16%). Holding the effects of sex and country constant, compared with abstainers, people with previous - day pain were more likely to be previous - day or other users. With regard to the quantity and frequency of alcohol use, people with previous - day pain were more likely to be non-heavy drinkers. Overall, we found that, in this population of older adults in six LMICs, recent pain was associated with moderate use of alcohol, although there were differences between countries. The findings provide a platform for country - specific research to better understand bi-directional associations between pain and alcohol in older adults.
27443945	0	4	Pain	T184	C0030193
27443945	9	28	alcohol consumption	T055	C0001948
27443945	35	47	older adults	T098	C0001792
27443945	49	57	findings	T033	C0243095
27443945	67	92	World Health Organization	T093	C0043237
27443945	93	98	Study	T062	C2603343
27443945	102	108	global	T080	C2348867
27443945	109	115	AGEing	T040	C0001811
27443945	120	125	adult	T100	C0001675
27443945	126	132	health	T078	C0018684
27443945	144	155	investigate	T169	C1292732
27443945	156	171	cross-sectional	T062	C0010362
27443945	172	184	associations	T080	C0439849
27443945	193	206	self-reported	T062	C0681906
27443945	214	218	pain	T184	C0030193
27443945	223	234	alcohol use	T055	C0001948
27443945	237	247	abstinence	T055	C0678274
27443945	253	261	previous	T079	C0205156
27443945	264	267	day	T079	C0439228
27443945	268	272	pain	T184	C0030193
27443945	277	285	previous	T079	C0205156
27443945	288	292	week	T079	C0439230
27443945	293	312	alcohol consumption	T055	C0001948
27443945	316	322	adults	T100	C0001675
27443945	340	343	low	T033	C1331016
27443945	350	363	middle-income	T080	C0870890
27443945	364	373	countries	T083	C0454664
27443945	375	380	LMICs	T083	C0454664
27443945	387	390	WHO	T093	C0043237
27443945	391	396	Study	T062	C2603343
27443945	400	406	global	T080	C2348867
27443945	407	413	AGEing	T040	C0001811
27443945	418	423	adult	T100	C0001675
27443945	424	430	health	T078	C0018684
27443945	432	436	SAGE	T062	C2603343
27443945	460	465	China	T083	C0008115
27443945	467	472	Ghana	T083	C0017516
27443945	474	479	India	T083	C0021201
27443945	481	487	Mexico	T083	C0025885
27443945	489	495	Russia	T083	C0035970
27443945	500	512	South Africa	T083	C0037712
27443945	520	531	data source	T081	C0011001
27443945	533	543	Prevalence	T081	C0220900
27443945	547	558	alcohol use	T055	C0001948
27443945	561	571	abstinence	T055	C0678274
27443945	587	595	previous	T079	C0205156
27443945	598	601	day	T079	C0439228
27443945	606	614	previous	T079	C0205156
27443945	617	622	month	T079	C0439231
27443945	623	627	pain	T184	C0030193
27443945	629	640	Multinomial	T081	C1709090
27443945	641	661	logistic regressions	T062	C0206031
27443945	663	668	crude	T109	C0031264
27443945	686	689	sex	T032	C1522384
27443945	694	701	country	T083	C0454664
27443945	703	709	tested	T169	C0039593
27443945	710	722	associations	T080	C0439849
27443945	738	742	pain	T184	C0030193
27443945	747	758	alcohol use	T055	C0001948
27443945	766	772	pooled	T167	C1709595
27443945	773	785	multicountry	T083	C0454664
27443945	786	792	sample	T167	C1709595
27443945	809	813	SAGE	T062	C2603343
27443945	814	823	countries	T083	C0454664
27443945	844	855	respondents	T098	C0282122
27443945	865	876	alcohol use	T055	C0001948
27443945	884	891	highest	T080	C1522410
27443945	895	901	Russia	T083	C0035970
27443945	912	918	lowest	T080	C1708760
27443945	922	927	India	T083	C0021201
27443945	947	954	effects	T080	C1280500
27443945	958	961	sex	T032	C1522384
27443945	966	973	country	T083	C0454664
27443945	974	982	constant	T080	C1948059
27443945	984	992	compared	T052	C1707455
27443945	998	1008	abstainers	T033	C0457801
27443945	1010	1016	people	T098	C0027361
27443945	1022	1030	previous	T079	C0205156
27443945	1033	1036	day	T079	C0439228
27443945	1037	1041	pain	T184	C0030193
27443945	1065	1073	previous	T079	C0205156
27443945	1076	1079	day	T079	C0439228
27443945	1083	1094	other users	T101	C0683007
27443945	1115	1123	quantity	T081	C1265611
27443945	1128	1137	frequency	T081	C1705502
27443945	1141	1152	alcohol use	T055	C0001948
27443945	1154	1160	people	T098	C0027361
27443945	1166	1174	previous	T079	C0205156
27443945	1177	1180	day	T079	C0439228
27443945	1181	1185	pain	T184	C0030193
27443945	1209	1227	non-heavy drinkers	T033	C0556299
27443945	1261	1271	population	T098	C1257890
27443945	1275	1287	older adults	T098	C0001792
27443945	1295	1300	LMICs	T083	C0454664
27443945	1309	1313	pain	T184	C0030193
27443945	1318	1333	associated with	T080	C0332281
27443945	1334	1357	moderate use of alcohol	T055	C0814443
27443945	1379	1390	differences	T080	C1705242
27443945	1399	1408	countries	T083	C0454664
27443945	1414	1422	findings	T033	C0243095
27443945	1433	1441	platform	T075	C1710360
27443945	1446	1453	country	T083	C0454664
27443945	1456	1464	specific	T080	C0205369
27443945	1465	1473	research	T062	C0035168
27443945	1484	1494	understand	T041	C0162340
27443945	1495	1509	bi-directional	T080	C1706937
27443945	1510	1522	associations	T080	C0439849
27443945	1531	1535	pain	T184	C0030193
27443945	1540	1547	alcohol	T109,T121	C0001975
27443945	1551	1563	older adults	T098	C0001792

27473877|t|Expressing sexuality in nursing homes. The experience of older women: A qualitative study
27473877|a|In nursing homes, a number of barriers to the expression of sexuality exist, such as the lack of privacy, certain attitudes on behalf of the staff and the family, the lack of a sexual partner, and physical limitations. The aim of this study was to describe the lived experience of sexuality in elderly Spanish women residing in nursing homes. A qualitative phenomenological approach was followed. Data were collected over an 18- month period between 2013 and 2015. Purposeful sampling was conducted with Spanish residents in nursing homes in Madrid. Data were collected using unstructured and semi-structured interviews. The data were analyzed using thematic analysis. Twenty female residents participated. Three main themes emerged from the data: a) expressing sexuality, b) sexuality as a duty and c) respecting vows. Female residents reported key elements influencing how they manage their sexuality in Nursing Homes. These results serve to improve our understanding regarding the expression of sexuality in older female nursing home residents.
27473877	0	10	Expressing	T055	C0565975
27473877	11	20	sexuality	T053	C0036915
27473877	24	37	nursing homes	T073,T093	C0028688
27473877	43	53	experience	T055	C0683573
27473877	57	68	older women	T098	C0043210
27473877	72	89	qualitative study	T062	C0949415
27473877	93	106	nursing homes	T073,T093	C0028688
27473877	120	128	barriers	T080	C4045969
27473877	136	146	expression	T055	C0565975
27473877	150	159	sexuality	T053	C0036915
27473877	160	165	exist	T077	C2987476
27473877	179	194	lack of privacy	T033	C2712041
27473877	204	213	attitudes	T041	C0004271
27473877	231	236	staff	T097	C0028698
27473877	245	251	family	T099	C0015576
27473877	267	281	sexual partner	T098	C0036911
27473877	287	307	physical limitations	T033	C0243095
27473877	325	330	study	T062	C0949415
27473877	351	367	lived experience	T055	C0683573
27473877	371	380	sexuality	T053	C0036915
27473877	384	405	elderly Spanish women	T098	C3161473
27473877	418	431	nursing homes	T073,T093	C0028688
27473877	435	472	qualitative phenomenological approach	T062	C0949415
27473877	487	491	Data	T078	C1511726
27473877	497	506	collected	T062	C0010995
27473877	519	531	month period	T079	C0439231
27473877	566	574	sampling	T078	C0870078
27473877	594	611	Spanish residents	T098	C2347958
27473877	615	628	nursing homes	T073,T093	C0028688
27473877	632	638	Madrid	T083	C0017446
27473877	640	644	Data	T078	C1511726
27473877	666	709	unstructured and semi-structured interviews	T052	C0021822
27473877	715	719	data	T078	C1511726
27473877	725	733	analyzed	T062	C0936012
27473877	740	757	thematic analysis	T062	C0242481
27473877	766	772	female	T032	C0086287
27473877	773	782	residents	T098	C2347958
27473877	808	814	themes	UnknownType	C0869035
27473877	832	836	data	T078	C1511726
27473877	841	851	expressing	T055	C0565975
27473877	852	861	sexuality	T053	C0036915
27473877	866	875	sexuality	T053	C0036915
27473877	881	885	duty	T058	C0028702
27473877	904	908	vows	T079	C1254367
27473877	910	916	Female	T032	C0086287
27473877	917	926	residents	T098	C2347958
27473877	970	976	manage	T058	C0184516
27473877	983	992	sexuality	T053	C0036915
27473877	996	1009	Nursing Homes	T073,T093	C0028688
27473877	1074	1084	expression	T055	C0565975
27473877	1088	1097	sexuality	T053	C0036915
27473877	1101	1113	older female	T032	C0086287
27473877	1114	1126	nursing home	T073,T093	C0028688
27473877	1127	1136	residents	T098	C2347958

27878992|t|FUSCA3 interacting with LEAFY COTYLEDON2 controls lateral root formation through regulating YUCCA4 gene expression in Arabidopsis thaliana
27878992|a|Lateral root (LR) development is a post-embryonic organogenesis event that gives rise to most of the underground parts of higher plants. Auxin promotes LR formation, but the molecular mechanisms involved in this process are still not well understood. We analyzed LR formation induced by FUSCA3 (FUS3), a B3 domain transcription factor, which may function by promoting auxin biosynthesis during this process. We identified FUS3 -interacting proteins that function in LR formation. In addition, we searched for the common targets of both FUS3 and its interacting protein. The role of their interactions in regulating auxin accumulation and LR initiation was examined. We identified LEAFY COTYLEDON2 (LEC2) as an interacting factor of FUS3, and demonstrated that these two homologous B3 transcription factors interact to bind to the auxin biosynthesis gene YUCCA4 (YUC4) and synergistically activate its transcription during LR formation. Furthermore, FUS3 expression is activated by LEC2 in LR initiation. The observations indicate that the FUS3 - LEC2 complex functions as a key regulator in auxin -regulated LR formation. The results of this study provide new information for understanding the mechanisms of LR regulation.
27878992	0	6	FUSCA3	T116,T123	C1619888
27878992	24	40	LEAFY COTYLEDON2	T116,T123	C1611037
27878992	41	49	controls	T080	C0243148
27878992	50	72	lateral root formation	T040	C1817571
27878992	81	91	regulating	T045	C0017263
27878992	92	98	YUCCA4	T028	C0017337
27878992	99	114	gene expression	T045	C0017262
27878992	118	138	Arabidopsis thaliana	T002	C0162740
27878992	139	168	Lateral root (LR) development	T040	C1655049
27878992	174	202	post-embryonic organogenesis	T042	C1656560
27878992	252	257	parts	T185	C2698828
27878992	268	274	plants	T002	C0032098
27878992	276	281	Auxin	T109,T123	C0004409
27878992	291	303	LR formation	T040	C1817571
27878992	313	333	molecular mechanisms	T044	C3537153
27878992	351	358	process	T067	C1522240
27878992	402	414	LR formation	T040	C1817571
27878992	415	422	induced	T169	C0205263
27878992	426	432	FUSCA3	T116,T123	C1619888
27878992	434	438	FUS3	T116,T123	C1619888
27878992	443	473	B3 domain transcription factor	T116,T123	C0040648
27878992	485	493	function	T169	C0542341
27878992	507	525	auxin biosynthesis	T044	C1157303
27878992	538	545	process	T067	C1522240
27878992	550	560	identified	T080	C0205396
27878992	561	565	FUS3	T116,T123	C1619888
27878992	579	587	proteins	T116,T123	C0033684
27878992	593	601	function	T169	C0542341
27878992	605	617	LR formation	T040	C1817571
27878992	659	666	targets	T169	C1521840
27878992	675	679	FUS3	T116,T123	C1619888
27878992	700	707	protein	T116,T123	C0033684
27878992	713	717	role	T077	C1705810
27878992	727	739	interactions	T169	C1704675
27878992	743	753	regulating	T038	C1327622
27878992	754	759	auxin	T109,T123	C0004409
27878992	760	772	accumulation	T033	C4055506
27878992	777	790	LR initiation	T040	C1655049
27878992	808	818	identified	T080	C0205396
27878992	819	835	LEAFY COTYLEDON2	T116,T123	C1611037
27878992	837	841	LEC2	T116,T123	C1611037
27878992	849	867	interacting factor	T116,T123	C0033684
27878992	871	875	FUS3	T116,T123	C1619888
27878992	909	944	homologous B3 transcription factors	T116,T123	C0040648
27878992	969	987	auxin biosynthesis	T044	C1157303
27878992	988	992	gene	T028	C0017337
27878992	993	999	YUCCA4	T028	C0017337
27878992	1001	1005	YUC4	T028	C0017337
27878992	1011	1026	synergistically	T080	C2986495
27878992	1027	1035	activate	T169	C1515877
27878992	1040	1053	transcription	T045	C0040649
27878992	1061	1073	LR formation	T040	C1817571
27878992	1088	1092	FUS3	T116,T123	C1619888
27878992	1093	1103	expression	T045	C1171362
27878992	1107	1116	activated	T052	C1879547
27878992	1120	1124	LEC2	T116,T123	C1611037
27878992	1128	1141	LR initiation	T040	C1655049
27878992	1147	1159	observations	T062	C0302523
27878992	1178	1182	FUS3	T116,T123	C1619888
27878992	1185	1189	LEC2	T116,T123	C1611037
27878992	1190	1197	complex	T116,T123	C1180347
27878992	1198	1207	functions	T169	C0542341
27878992	1217	1226	regulator	T116,T123	C0033684
27878992	1230	1235	auxin	T109,T123	C0004409
27878992	1247	1259	LR formation	T040	C1817571
27878992	1333	1343	mechanisms	T044	C3537153
27878992	1347	1349	LR	T002	C0242726
27878992	1350	1360	regulation	T038	C1327622

28424384|t|Minor physical anomalies and dermatoglyphic signs in affective disorders: A systematic review
28424384|a|The increased prevalence of minor physical anomalies (MPAs) and the abnormalities of dermatoglyphic patterns may be physical manifestations of neurodevelopmental disruption in affective disorders. This paper aims to review the current state of knowledge on the frequency of MPAs and dermatoglyphic abnormalities in mood disorders. A MEDLINE, PsychInfo and Web of Science search was carried out to collect all publications on the frequency of MPAs and on dermatoglyphic traits in bipolar disorder and unipolar depression. 24 studies on MPAs, 19 on dermatoglyphics, and 5 dealing with both were found with discrepant findings. The relative contribution of neurodevelopmental retardation to the aetiology of affective disorders remains undetermined, the field is open for further research. Increased recognition of neurodevelopmental processes in the origin of affective disorders may allow for earlier and more effective intervention and prevention.
28424384	0	24	Minor physical anomalies	T019	C0000768
28424384	29	43	dermatoglyphic	T029	C0221916
28424384	53	72	affective disorders	T048	C0525045
28424384	76	93	systematic review	T170	C1955832
28424384	98	107	increased	T081	C0205217
28424384	108	118	prevalence	T081	C0220900
28424384	122	146	minor physical anomalies	T019	C0000768
28424384	148	152	MPAs	T019	C0000768
28424384	162	202	abnormalities of dermatoglyphic patterns	T019	C0432333
28424384	210	218	physical	T169	C0205485
28424384	219	233	manifestations	T169	C0205319
28424384	237	266	neurodevelopmental disruption	UnknownType	C0679378
28424384	270	289	affective disorders	T048	C0525045
28424384	310	316	review	T170	C1955832
28424384	355	364	frequency	T079	C0439603
28424384	368	372	MPAs	T019	C0000768
28424384	377	405	dermatoglyphic abnormalities	T019	C0432333
28424384	409	423	mood disorders	T048	C0525045
28424384	427	434	MEDLINE	T170	C0025141
28424384	436	445	PsychInfo	T170	C0242356
28424384	450	471	Web of Science search	T170	C0242356
28424384	503	515	publications	T073,T170	C0034036
28424384	523	532	frequency	T079	C0439603
28424384	536	540	MPAs	T019	C0000768
28424384	548	569	dermatoglyphic traits	T190	C4025116
28424384	573	589	bipolar disorder	T048	C0005586
28424384	594	613	unipolar depression	T048	C0041696
28424384	618	625	studies	T062	C2603343
28424384	629	633	MPAs	T019	C0000768
28424384	641	656	dermatoglyphics	T059	C0011624
28424384	698	708	discrepant	T033	C1290905
28424384	709	717	findings	T169	C2607943
28424384	723	731	relative	T080	C0205345
28424384	732	744	contribution	T052	C1880177
28424384	748	778	neurodevelopmental retardation	UnknownType	C0679378
28424384	786	795	aetiology	T169	C1314792
28424384	799	818	affective disorders	T048	C0525045
28424384	871	879	research	T062	C0035168
28424384	881	890	Increased	T169	C0442805
28424384	891	902	recognition	T041	C0524637
28424384	906	924	neurodevelopmental	T042	C0599855
28424384	925	934	processes	T067	C1522240
28424384	942	948	origin	T079	C0439659
28424384	952	971	affective disorders	T048	C0525045
28424384	1003	1012	effective	T080	C1704419
28424384	1013	1025	intervention	T061	C0184661
28424384	1030	1040	prevention	T061	C0199176

28074211|t|Safe Practices for Copy and Paste in the EHR. Systematic Review, Recommendations, and Novel Model for Health IT Collaboration
28074211|a|Copy and paste functionality can support efficiency during clinical documentation, but may promote inaccurate documentation with risks for patient safety. The Partnership for Health IT Patient Safety was formed to gather data, conduct analysis, educate, and disseminate safe practices for safer care using health information technology (IT). To characterize copy and paste events in clinical care, identify safety risks, describe existing evidence, and develop implementable practice recommendations for safe reuse of information via copy and paste. The Partnership 1) reviewed 12 reported safety events, 2) solicited expert input, and 3) performed a systematic literature review (2010 to January 2015) to identify publications addressing frequency, perceptions / attitudes, patient safety risks, existing guidance, and potential interventions and mitigation practices. The literature review identified 51 publications that were included. Overall, 66% to 90% of clinicians routinely use copy and paste. One study of diagnostic errors found that copy and paste led to 2.6% of errors in which a missed diagnosis required patients to seek additional unplanned care. Copy and paste can promote note bloat, internal inconsistencies, error propagation, and documentation in the wrong patient chart. Existing guidance identified specific responsibilities for authors, organizations, and electronic health record (EHR) developers. Analysis of 12 reported copy and paste safety events was congruent with problems identified from the literature review. Despite regular copy and paste use, evidence regarding direct risk to patient safety remains sparse, with significant study limitations. Drawing on existing evidence, the Partnership developed four safe practice recommendations: 1) Provide a mechanism to make copy and paste material easily identifiable; 2) Ensure the provenance of copy and paste material is readily available; 3) Ensure adequate staff training and education; 4) Ensure copy and paste practices are regularly monitored, measured, and assessed.
28074211	0	4	Safe	T082	C0557723
28074211	5	14	Practices	T041	C0237607
28074211	19	33	Copy and Paste	T169	C0205245
28074211	41	44	EHR	T170	C2362543
28074211	46	63	Systematic Review	T170	C1955832
28074211	65	80	Recommendations	T078	C0034866
28074211	86	91	Novel	T080	C0205314
28074211	92	97	Model	T170	C3161035
28074211	102	111	Health IT	T066	C2936756
28074211	112	125	Collaboration	T054	C0282116
28074211	126	140	Copy and paste	T169	C0205245
28074211	141	154	functionality	T169	C0205245
28074211	167	177	efficiency	T081	C0013682
28074211	185	193	clinical	T080	C0205210
28074211	194	207	documentation	T170	C0920316
28074211	217	224	promote	T052	C0033414
28074211	225	235	inaccurate	T080	C0443236
28074211	236	249	documentation	T170	C0920316
28074211	255	260	risks	T078	C0035647
28074211	265	279	patient safety	T058	C1113679
28074211	285	296	Partnership	T092	C1711206
28074211	301	310	Health IT	T066	C2936756
28074211	311	325	Patient Safety	T058	C1113679
28074211	347	351	data	T078	C1511726
28074211	353	369	conduct analysis	T058	C0509592
28074211	371	378	educate	T065	C0039401
28074211	384	395	disseminate	T082	C0205221
28074211	396	400	safe	T082	C0557723
28074211	401	410	practices	T041	C0237607
28074211	415	420	safer	T082	C0557723
28074211	421	425	care	T052	C1947933
28074211	432	461	health information technology	T066	C2936756
28074211	463	465	IT	T066	C2936756
28074211	471	483	characterize	T052	C1880022
28074211	484	498	copy and paste	T169	C0205245
28074211	499	505	events	T051	C0441471
28074211	509	517	clinical	T080	C0205210
28074211	518	522	care	T052	C1947933
28074211	524	532	identify	T080	C0205396
28074211	533	539	safety	T058	C1113679
28074211	540	545	risks	T078	C0035647
28074211	556	564	existing	T077	C2987476
28074211	565	573	evidence	T078	C3887511
28074211	579	586	develop	T169	C1527148
28074211	601	609	practice	T041	C0237607
28074211	610	625	recommendations	T078	C0034866
28074211	630	634	safe	T082	C0557723
28074211	635	640	reuse	T052	C2699072
28074211	644	655	information	T078	C1533716
28074211	660	674	copy and paste	T169	C0205245
28074211	680	691	Partnership	T092	C1711206
28074211	695	703	reviewed	T080	C1709940
28074211	707	715	reported	T058	C0700287
28074211	716	729	safety events	T170	C3699460
28074211	734	756	solicited expert input	T077	C1708517
28074211	765	774	performed	T169	C0884358
28074211	777	805	systematic literature review	T170	C0282441
28074211	815	822	January	T080	C3829466
28074211	832	840	identify	T080	C0205396
28074211	841	853	publications	T073,T170	C0034036
28074211	865	874	frequency	T079	C0376249
28074211	876	887	perceptions	T041	C0030971
28074211	890	899	attitudes	T041	C0004271
28074211	901	915	patient safety	T058	C1113679
28074211	916	921	risks	T078	C0035647
28074211	923	931	existing	T077	C2987476
28074211	932	940	guidance	T058	C0150600
28074211	974	984	mitigation	T078	C1706602
28074211	985	994	practices	T041	C0237607
28074211	1000	1017	literature review	T170	C0282441
28074211	1018	1028	identified	T080	C0205396
28074211	1032	1044	publications	T073,T170	C0034036
28074211	1055	1063	included	T169	C0332257
28074211	1088	1098	clinicians	T097	C0871685
28074211	1099	1108	routinely	T080	C0205547
28074211	1113	1127	copy and paste	T169	C0205245
28074211	1133	1138	study	T062	C2603343
28074211	1142	1159	diagnostic errors	T080	C0011922
28074211	1171	1185	copy and paste	T169	C0205245
28074211	1201	1207	errors	T080	C0011922
28074211	1226	1235	diagnosis	T033	C0011900
28074211	1236	1244	required	T169	C1514873
28074211	1245	1253	patients	T101	C0030705
28074211	1262	1272	additional	T169	C1524062
28074211	1283	1287	care	T052	C1947933
28074211	1289	1303	Copy and paste	T169	C0205245
28074211	1328	1336	internal	T082	C0205102
28074211	1354	1359	error	T080	C0743559
28074211	1377	1390	documentation	T170	C0920316
28074211	1404	1411	patient	T101	C0030705
28074211	1412	1417	chart	T170	C0684240
28074211	1419	1427	Existing	T077	C2987476
28074211	1428	1436	guidance	T058	C0150600
28074211	1437	1447	identified	T080	C0205396
28074211	1457	1473	responsibilities	T055	C0678341
28074211	1478	1485	authors	T097	C3812881
28074211	1487	1500	organizations	T093	C1708333
28074211	1506	1530	electronic health record	T170	C2362543
28074211	1532	1535	EHR	T170	C2362543
28074211	1549	1557	Analysis	T062	C0936012
28074211	1564	1572	reported	T058	C0700287
28074211	1573	1587	copy and paste	T169	C0205245
28074211	1588	1601	safety events	T170	C3699460
28074211	1606	1615	congruent	T080	C0439853
28074211	1621	1629	problems	T078	C1546466
28074211	1630	1640	identified	T080	C0205396
28074211	1650	1667	literature review	T170	C0282441
28074211	1685	1699	copy and paste	T169	C0205245
28074211	1705	1713	evidence	T078	C3887511
28074211	1724	1735	direct risk	T078	C0035647
28074211	1739	1753	patient safety	T058	C1113679
28074211	1787	1792	study	T062	C2603343
28074211	1793	1804	limitations	T169	C0449295
28074211	1817	1825	existing	T077	C2987476
28074211	1826	1834	evidence	T078	C3887511
28074211	1840	1851	Partnership	T092	C1711206
28074211	1852	1861	developed	T169	C1527148
28074211	1867	1871	safe	T082	C0557723
28074211	1872	1880	practice	T041	C0237607
28074211	1881	1896	recommendations	T078	C0034866
28074211	1911	1920	mechanism	T169	C0441712
28074211	1929	1943	copy and paste	T169	C0205245
28074211	1960	1972	identifiable	T080	C0205396
28074211	1988	1998	provenance	T077	C1709753
28074211	2002	2016	copy and paste	T169	C0205245
28074211	2037	2046	available	T169	C0470187
28074211	2058	2066	adequate	T080	C0205411
28074211	2067	2081	staff training	T065	C0681113
28074211	2086	2095	education	T065	C0013621
28074211	2107	2121	copy and paste	T169	C0205245
28074211	2122	2131	practices	T041	C0237607
28074211	2136	2145	regularly	T080	C0205272
28074211	2146	2155	monitored	T058	C0150369
28074211	2157	2165	measured	T080	C0444706
28074211	2171	2179	assessed	T052	C1516048

28221018|t|Low Efficiency Upconversion Nanoparticles for High-Resolution Coalignment of Near-Infrared and Visible Light Paths on a Light Microscope
28221018|a|The combination of near-infrared (NIR) and visible wavelengths in light microscopy for biological studies is increasingly common. For example, many fields of biology are developing the use of NIR for optogenetics, in which an NIR laser induces a change in gene expression and/or protein function. One major technical barrier in working with both NIR and visible light on an optical microscope is obtaining their precise coalignment at the imaging plane position. Photon upconverting particles (UCPs) can bridge this gap as they are excited by NIR light but emit in the visible range via an anti-Stokes luminescence mechanism. Here, two different UCPs have been identified, high- efficiency micro (540)- UCPs and lower efficiency nano (545)- UCPs, that respond to NIR light and emit visible light with high photostability even at very high NIR power densities (>25 000 Suns). Both of these UCPs can be rapidly and reversibly excited by visible and NIR light and emit light at visible wavelengths detectable with standard emission settings used for Green Fluorescent Protein (GFP), a commonly used genetically encoded fluorophore. However, the high efficiency micro (540)- UCPs were suboptimal for NIR and visible light coalignment, due to their larger size and spatial broadening from particle -to- particle energy transfer consistent with a long-lived excited state and saturated power dependence. In contrast, the lower efficiency nano - UCPs were superior for precise coalignment of the NIR beam with the visible light path (∼2 μm versus ∼8 μm beam broadening, respectively) consistent with limited particle -to- particle energy transfer, superlinear power dependence for emission, and much smaller particle size. Furthermore, the nano - UCPs were superior to a traditional two- camera method for NIR and visible light path alignment in an in vivo Infrared-Laser-Evoked Gene Operator (IR-LEGO) optogenetics assay in the budding yeast Saccharomyces cerevisiae. In summary, nano - UCPs are powerful new tools for coaligning NIR and visible light paths on a light microscope.
28221018	28	41	Nanoparticles	T073	C1450053
28221018	46	61	High-Resolution	T059	C1719039
28221018	62	73	Coalignment	T081	C1706765
28221018	77	90	Near-Infrared	T070	C1289901
28221018	95	108	Visible Light	T070	C0242377
28221018	120	136	Light Microscope	T074	C0491970
28221018	156	169	near-infrared	T070	C1289901
28221018	171	174	NIR	T070	C1289901
28221018	180	199	visible wavelengths	T070	C0242377
28221018	203	219	light microscopy	T059	C0430389
28221018	224	242	biological studies	T059	C0005507
28221018	295	302	biology	T091	C0005532
28221018	329	332	NIR	T070	C1289901
28221018	337	349	optogenetics	T063	C3494301
28221018	363	372	NIR laser	T070	C1289901
28221018	393	408	gene expression	T045	C0017262
28221018	416	432	protein function	T044	C1527118
28221018	444	461	technical barrier	T067	C1710348
28221018	483	486	NIR	T070	C1289901
28221018	491	504	visible light	T070	C0242377
28221018	511	529	optical microscope	T059	C0026018
28221018	557	568	coalignment	T081	C1706765
28221018	576	598	imaging plane position	T082	C1254362
28221018	600	606	Photon	T167	C0086805
28221018	607	629	upconverting particles	T104	C0597177
28221018	631	635	UCPs	T104	C0597177
28221018	653	656	gap	T082	C3887622
28221018	669	676	excited	T052	C0549255
28221018	680	689	NIR light	T070	C1289901
28221018	694	698	emit	T070	C0596835
28221018	706	719	visible range	T070	C0242377
28221018	727	761	anti-Stokes luminescence mechanism	T080	C4054591
28221018	783	787	UCPs	T104	C0597177
28221018	816	826	efficiency	T081	C0013682
28221018	827	832	micro	T077	C3811161
28221018	840	844	UCPs	T104	C0597177
28221018	855	865	efficiency	T081	C0013682
28221018	866	870	nano	T081	C1553036
28221018	878	882	UCPs	T104	C0597177
28221018	900	909	NIR light	T070	C1289901
28221018	919	932	visible light	T070	C0242377
28221018	943	957	photostability	T080	C0205360
28221018	976	979	NIR	T070	C1289901
28221018	1026	1030	UCPs	T104	C0597177
28221018	1061	1068	excited	T052	C0549255
28221018	1072	1079	visible	T070	C0242377
28221018	1084	1093	NIR light	T070	C1289901
28221018	1098	1108	emit light	T070	C0596835
28221018	1112	1131	visible wavelengths	T070	C0242377
28221018	1157	1165	emission	T070	C0596835
28221018	1184	1209	Green Fluorescent Protein	T116,T130	C0120285
28221018	1211	1214	GFP	T116,T130	C0120285
28221018	1233	1252	genetically encoded	T045	C0314627
28221018	1253	1264	fluorophore	T121,T130	C0598447
28221018	1284	1294	efficiency	T081	C0013682
28221018	1295	1300	micro	T077	C3811161
28221018	1308	1312	UCPs	T104	C0597177
28221018	1318	1328	suboptimal	T080	C2984009
28221018	1333	1336	NIR	T070	C1289901
28221018	1341	1354	visible light	T070	C0242377
28221018	1355	1366	coalignment	T081	C1706765
28221018	1381	1387	larger	T081	C0549177
28221018	1388	1392	size	T082	C0456389
28221018	1397	1415	spatial broadening	T082	C0332464
28221018	1421	1429	particle	T104	C0597177
28221018	1435	1443	particle	T104	C0597177
28221018	1444	1459	energy transfer	T044	C0014274
28221018	1489	1502	excited state	T033	C3833702
28221018	1558	1568	efficiency	T081	C0013682
28221018	1569	1573	nano	T081	C1553036
28221018	1576	1580	UCPs	T104	C0597177
28221018	1607	1618	coalignment	T081	C1706765
28221018	1626	1634	NIR beam	T070	C1289901
28221018	1644	1657	visible light	T070	C0242377
28221018	1683	1687	beam	T070	C0260186
28221018	1688	1698	broadening	T082	C0332464
28221018	1738	1746	particle	T104	C0597177
28221018	1752	1760	particle	T104	C0597177
28221018	1761	1776	energy transfer	T044	C0014274
28221018	1811	1819	emission	T070	C0596835
28221018	1838	1851	particle size	T081	C0030608
28221018	1870	1874	nano	T081	C1553036
28221018	1877	1881	UCPs	T104	C0597177
28221018	1918	1924	camera	T074	C0179533
28221018	1936	1939	NIR	T070	C1289901
28221018	1944	1957	visible light	T070	C0242377
28221018	1963	1972	alignment	T081	C1706765
28221018	1979	1986	in vivo	T082	C1515655
28221018	1987	2051	Infrared-Laser-Evoked Gene Operator (IR-LEGO) optogenetics assay	T063	C3494301
28221018	2073	2097	Saccharomyces cerevisiae	T004	C0036025
28221018	2111	2115	nano	T081	C1553036
28221018	2118	2122	UCPs	T104	C0597177
28221018	2150	2160	coaligning	T081	C1706765
28221018	2161	2164	NIR	T070	C1289901
28221018	2169	2182	visible light	T070	C0242377
28221018	2194	2210	light microscope	T074	C0491970

27434112|t|Phenozan, a Synthetic Phenolic Antioxidant, Inhibits the Development of Spontaneous Tumors in Rats and Mice
27434112|a|Synthetic phenolic antioxidant β-(4-hydroxy-3,5-di-tert-butylphenyl) propionic acid, named phenozan, is a potential antiepileptic drug. In pre-clinical trials this substance did not manifest any toxicity, and also inhibited the development of some spontaneous tumors in animals. The purpose of this study was to evaluate inhibiting effect of phenozan on spontaneous carcinogenesis in rats and mice. In experiments with rats LIO and mice SHR of local breeding, with high spontaneous tumor incidence, phenozan was dissolved in sunflower oil and administered by gavage in therapeutic dose 5 mg/kg 3 times per week for 18 months. There were no any signs of toxicity and differences in weight of animals during the phenozan treatment compared with the control (sunflower oil). Phenozan significantly reduced the overall incidence and multiplicity of all tumors but only multiplicity of malignant tumors, compared with the control. Moreover a significant decrease of overall incidence and multiplicity was observed in pituitary and breast tumors in females and only overall multiplicity of tumors of pituitary and lymphoid tissue in males. In mice phenozan reduced overall incidence and multiplicity of lung tumors (in females) and also overall multiplicity of all tumors (in females) and only malignant tumors (in males). These findings allow us to classify phenozan as anticarcinogenic agent. Anticarcinogenic activity of phenozan is important because clinical study of this drug as the possible antiepileptic drug goes along and it is known that such drugs are designed for long-term use.
27434112	0	8	Phenozan	T109,T121	C0060186
27434112	12	30	Synthetic Phenolic	T109,T121	C0359916
27434112	31	42	Antioxidant	T121	C0003402
27434112	44	52	Inhibits	T052	C3463820
27434112	57	68	Development	T169	C1527148
27434112	72	83	Spontaneous	T169	C0205359
27434112	84	90	Tumors	T191	C0027651
27434112	94	98	Rats	T015	C0034721
27434112	103	107	Mice	T015	C0025929
27434112	108	126	Synthetic phenolic	T109,T121	C0359916
27434112	127	138	antioxidant	T121	C0003402
27434112	139	191	β-(4-hydroxy-3,5-di-tert-butylphenyl) propionic acid	T121	C1254351
27434112	199	207	phenozan	T109,T121	C0060186
27434112	214	223	potential	T080	C3245505
27434112	224	242	antiepileptic drug	T121	C0003299
27434112	247	259	pre-clinical	T080	C1709630
27434112	260	266	trials	T062	C0008976
27434112	272	281	substance	T167	C0439861
27434112	290	298	manifest	T169	C0205319
27434112	303	311	toxicity	T037	C0600688
27434112	322	331	inhibited	T052	C3463820
27434112	336	347	development	T169	C1527148
27434112	356	367	spontaneous	T169	C0205359
27434112	368	374	tumors	T191	C0027651
27434112	378	385	animals	T008	C0003062
27434112	407	412	study	T062	C2603343
27434112	420	428	evaluate	T058	C0220825
27434112	429	439	inhibiting	T052	C3463820
27434112	440	449	effect of	T080	C1704420
27434112	450	458	phenozan	T109,T121	C0060186
27434112	462	473	spontaneous	T169	C0205359
27434112	474	488	carcinogenesis	T191	C0596263
27434112	492	496	rats	T015	C0034721
27434112	501	505	mice	T015	C0025929
27434112	510	521	experiments	T062	C0681814
27434112	527	535	rats LIO	T015	C0034721
27434112	540	548	mice SHR	T015	C0025929
27434112	552	557	local	T082	C0205276
27434112	558	566	breeding	T040	C0178477
27434112	573	577	high	T080	C0205250
27434112	578	589	spontaneous	T169	C0205359
27434112	590	595	tumor	T191	C0027651
27434112	596	605	incidence	T081	C0021149
27434112	607	615	phenozan	T109,T121	C0060186
27434112	633	646	sunflower oil	T109,T168	C0075639
27434112	651	663	administered	T169	C1621583
27434112	667	673	gavage	T169	C2698653
27434112	677	688	therapeutic	T169	C0302350
27434112	689	693	dose	T081	C0178602
27434112	704	709	times	T081	C1632851
27434112	714	718	week	T079	C0439230
27434112	726	732	months	T079	C0439231
27434112	761	769	toxicity	T037	C0600688
27434112	774	785	differences	T081	C1705241
27434112	789	795	weight	T032	C0005910
27434112	799	806	animals	T008	C0003062
27434112	818	826	phenozan	T109,T121	C0060186
27434112	837	845	compared	T052	C1707455
27434112	855	862	control	T096	C0009932
27434112	864	877	sunflower oil	T109,T168	C0075639
27434112	880	888	Phenozan	T109,T121	C0060186
27434112	889	902	significantly	T078	C0750502
27434112	903	910	reduced	T080	C0392756
27434112	915	922	overall	T080	C1561607
27434112	923	932	incidence	T081	C0021149
27434112	937	949	multiplicity	T081	C0449822
27434112	957	963	tumors	T191	C0027651
27434112	973	985	multiplicity	T081	C0449822
27434112	989	1005	malignant tumors	T191	C0006826
27434112	1007	1015	compared	T052	C1707455
27434112	1025	1032	control	T096	C0009932
27434112	1045	1056	significant	T078	C0750502
27434112	1057	1065	decrease	T081	C0547047
27434112	1069	1076	overall	T080	C1561607
27434112	1077	1086	incidence	T081	C0021149
27434112	1091	1103	multiplicity	T081	C0449822
27434112	1120	1129	pituitary	T191	C0032019
27434112	1134	1147	breast tumors	T191	C1458155
27434112	1151	1158	females	T032	C0086287
27434112	1168	1175	overall	T080	C1561607
27434112	1176	1188	multiplicity	T081	C0449822
27434112	1192	1198	tumors	T191	C0027651
27434112	1202	1211	pituitary	T023	C0032005
27434112	1216	1231	lymphoid tissue	T024	C0024296
27434112	1235	1240	males	T032	C0086582
27434112	1245	1249	mice	T015	C0025929
27434112	1250	1258	phenozan	T109,T121	C0060186
27434112	1267	1274	overall	T080	C1561607
27434112	1275	1284	incidence	T081	C0021149
27434112	1289	1301	multiplicity	T081	C0449822
27434112	1305	1316	lung tumors	T191	C0024121
27434112	1321	1328	females	T032	C0086287
27434112	1339	1346	overall	T080	C1561607
27434112	1347	1359	multiplicity	T081	C0449822
27434112	1367	1373	tumors	T191	C0027651
27434112	1378	1385	females	T032	C0086287
27434112	1396	1412	malignant tumors	T191	C0006826
27434112	1417	1422	males	T032	C0086582
27434112	1461	1469	phenozan	T109,T121	C0060186
27434112	1473	1495	anticarcinogenic agent	T121	C0085169
27434112	1497	1513	Anticarcinogenic	T121	C0085169
27434112	1514	1522	activity	T052	C0441655
27434112	1526	1534	phenozan	T109,T121	C0060186
27434112	1538	1547	important	T080	C3898777
27434112	1556	1570	clinical study	T062	C0008972
27434112	1579	1583	drug	T121	C1254351
27434112	1600	1618	antiepileptic drug	T121	C0003299
27434112	1656	1661	drugs	T121	C1254351
27434112	1679	1688	long-term	T079	C0443252
27434112	1689	1692	use	T169	C0457083

28381379|t|Clinical outcomes of ERCP -related retroperitoneal perforations
28381379|a|Endoscopic retrograde cholangiopancreatography (ERCP)-related perforations represent rare but often severe conditions. While lesions with intraperitoneal perforation have an almost imperative indication to surgery, whether or not to manage retroperitoneal perforations surgically is still an area of debate. The aim of the present work was to review the available clinical evidence on the operatively and medically treated ERCP -related retroperitoneal perforations. From MEDLINE / PubMed databases 137 patients with retroperitoneal perforation were included from 12 studies that met the selection criteria for data investigation and analysis. Twenty-four patients were treated by prompt surgery; 113 were primarily managed conservatively and about 20% of these patients required surgery subsequently. Overall, the morbidity and mortality were 15.4% and 6.6%, respectively. Although most patients with retroperitoneal perforation may benefit from a non-operative management, a considerable number of patients fail to respond to medical treatment and require surgery afterwards. Identifying those patients who are at highest risk of poor outcome after conservative treatment should be considered a research priority.
28381379	0	8	Clinical	T080	C0205210
28381379	9	17	outcomes	T080	C0085415
28381379	21	25	ERCP	T060	C0008310
28381379	35	50	retroperitoneal	T030	C0035359
28381379	51	63	perforations	T033	C0549099
28381379	64	110	Endoscopic retrograde cholangiopancreatography	T060	C0008310
28381379	112	116	ERCP	T060	C0008310
28381379	126	138	perforations	T033	C0549099
28381379	164	170	severe	T080	C0205082
28381379	171	181	conditions	T080	C0348080
28381379	189	196	lesions	T033	C0221198
28381379	202	217	intraperitoneal	T082	C0442120
28381379	218	229	perforation	T033	C0549099
28381379	256	266	indication	T078	C3146298
28381379	270	277	surgery	T061	C0543467
28381379	304	319	retroperitoneal	T030	C0035359
28381379	320	332	perforations	T033	C0549099
28381379	333	343	surgically	T061	C0543467
28381379	428	436	clinical	T080	C0205210
28381379	437	445	evidence	T078	C3887511
28381379	453	464	operatively	T079	C1882154
28381379	469	478	medically	T169	C0205476
28381379	479	486	treated	T061	C0087111
28381379	487	491	ERCP	T060	C0008310
28381379	501	516	retroperitoneal	T030	C0035359
28381379	517	529	perforations	T033	C0549099
28381379	536	543	MEDLINE	T170	C0025141
28381379	546	552	PubMed	T170	C1138432
28381379	553	562	databases	T170	C0242356
28381379	567	575	patients	T101	C0030705
28381379	581	596	retroperitoneal	T030	C0035359
28381379	597	608	perforation	T033	C0549099
28381379	652	670	selection criteria	T080	C0242801
28381379	675	679	data	T078	C1511726
28381379	680	693	investigation	T170	C1552578
28381379	698	706	analysis	T062	C0936012
28381379	720	728	patients	T101	C0030705
28381379	734	741	treated	T061	C0087111
28381379	752	759	surgery	T061	C0543467
28381379	788	802	conservatively	T061	C0459914
28381379	826	834	patients	T101	C0030705
28381379	844	851	surgery	T061	C0543467
28381379	879	888	morbidity	T081	C0026538
28381379	893	902	mortality	T081	C0205848
28381379	952	960	patients	T101	C0030705
28381379	966	981	retroperitoneal	T030	C0035359
28381379	982	993	perforation	T033	C0549099
28381379	998	1005	benefit	T081	C0814225
28381379	1013	1037	non-operative management	T033	C0243095
28381379	1064	1072	patients	T101	C0030705
28381379	1092	1099	medical	T169	C0205476
28381379	1100	1109	treatment	T061	C0087111
28381379	1122	1129	surgery	T061	C0543467
28381379	1160	1168	patients	T101	C0030705
28381379	1188	1192	risk	T078	C0035647
28381379	1201	1208	outcome	T080	C0085415
28381379	1215	1237	conservative treatment	T061	C0459914
28381379	1261	1269	research	T062	C0035168

28167866|t|The Role of Metal-on-Metal Bearings in Total Hip Arthroplasty and Hip Resurfacing: Review Article
28167866|a|The current role of metal-on-metal (MoM) bearings in hip arthroplasty remains controversial. The low wear offered by MoM bearings compared to metal-on-polyethylene and the possibility of a lower risk of dislocation with larger head sizes, encouraged a trend towards the re-introduction of the MoM bearing couple. However, recent evidence has shown that not all designs of the MoM bearing have been successful. The purpose of this paper is to provide an update on the use of MoM bearings and address the following issues: (1) the reintroduction of metal-on-metal bearings in total hip arthroplasty, (2) the failure of metal-on-metal bearings in stemmed total hip arthroplasty, (3) the role of metal-on-metal hip resurfacing in modern orthopaedics and (4) metal-on-metal hip resurfacing versus total hip arthroplasty. A literature search strategy was conducted using various search terms in MEDLINE and Embase. The highest quality articles that met the inclusion criteria and best answered the topics of focus of this review were selected. Key search terms included ' metal-on-metal ', ' total hip arthroplasty ' and ' hip resurfacing '. The initial search retrieved 1240 articles. Twenty-two articles were selected and used in the review. Metal-on-metal hip resurfacing is still a suitable treatment option in specific patient populations with the appropriate implant design and surgical skill, while stemmed metal-on-metal total hip arthroplasty should be avoided in all patient populations. Continued follow-up of patients undergoing metal-on-metal hip resurfacing is critical in order to further understand the long-term outcomes of these patients and why certain complications tend to occur with this procedure.
28167866	12	35	Metal-on-Metal Bearings	T074	C3494213
28167866	39	61	Total Hip Arthroplasty	T061	C0040508
28167866	66	81	Hip Resurfacing	T061	C1719285
28167866	83	97	Review Article	T170	C0282443
28167866	118	147	metal-on-metal (MoM) bearings	T074	C3494213
28167866	151	167	hip arthroplasty	T061	C0186193
28167866	215	227	MoM bearings	T074	C3494213
28167866	240	261	metal-on-polyethylene	T074	C3880938
28167866	287	300	lower risk of	T081	C3538919
28167866	301	312	dislocation	T037	C0012691
28167866	318	335	larger head sizes	T080	C0205556
28167866	350	355	trend	T079	C1521798
28167866	368	383	re-introduction	T061	C0376495
28167866	391	402	MoM bearing	T074	C3494213
28167866	427	435	evidence	T078	C3887511
28167866	474	485	MoM bearing	T074	C3494213
28167866	496	506	successful	T080	C1272703
28167866	572	584	MoM bearings	T074	C3494213
28167866	627	641	reintroduction	T061	C0376495
28167866	645	668	metal-on-metal bearings	T074	C3494213
28167866	672	694	total hip arthroplasty	T061	C0040508
28167866	715	738	metal-on-metal bearings	T074	C3494213
28167866	742	772	stemmed total hip arthroplasty	T061	C0040508
28167866	790	820	metal-on-metal hip resurfacing	T061	C1955625
28167866	831	843	orthopaedics	T091	C0029355
28167866	852	882	metal-on-metal hip resurfacing	T061	C1955625
28167866	890	912	total hip arthroplasty	T061	C0040508
28167866	916	926	literature	T170	C0023866
28167866	934	942	strategy	T041	C0679199
28167866	987	994	MEDLINE	T170	C0025141
28167866	999	1005	Embase	T170	C0242356
28167866	1019	1035	quality articles	T170	C1706852
28167866	1049	1067	inclusion criteria	T080	C1512693
28167866	1114	1120	review	T170	C0282443
28167866	1164	1178	metal-on-metal	T074	C3494213
28167866	1184	1206	total hip arthroplasty	T061	C0040508
28167866	1215	1230	hip resurfacing	T061	C1719285
28167866	1268	1276	articles	T170	C1706852
28167866	1289	1297	articles	T170	C1706852
28167866	1328	1334	review	T170	C0282443
28167866	1336	1366	Metal-on-metal hip resurfacing	T074	C3881498
28167866	1387	1396	treatment	T061	C0087111
28167866	1407	1415	specific	T080	C0205369
28167866	1416	1435	patient populations	T081	C2361270
28167866	1445	1456	appropriate	T080	C1548787
28167866	1457	1471	implant design	T061	C0021107
28167866	1506	1543	metal-on-metal total hip arthroplasty	T074	C3881498
28167866	1565	1588	all patient populations	T081	C2361270
28167866	1600	1609	follow-up	T058	C1522577
28167866	1613	1621	patients	T101	C0030705
28167866	1633	1663	metal-on-metal hip resurfacing	T061	C1955625
28167866	1667	1675	critical	T080	C1511545
28167866	1711	1720	long-term	T079	C0443252
28167866	1721	1729	outcomes	T080	C0085415
28167866	1739	1747	patients	T101	C0030705
28167866	1764	1777	complications	T046	C0009566

28103582|t|AMPK - autophagy inhibition sensitizes icaritin - induced anti-colorectal cancer cell activity
28103582|a|The current research studied the potential effect of autophagy on icaritin - induced anti-colorectal cancer (CRC) cell activity. Treatment of icaritin in both primary and established (HT-29) CRC cells induced feedback activation of autophagy, evidenced by p62 degradation, Beclin-1 and autophagy-related gene-5 (ATG-5) upregulation, as well as light chain 3B (LC3B)- GFP puncta formation. Pharmacological inhibiting of autophagy dramatically potentiated icaritin - induced CRC cell death and apoptosis. Meanwhile, shRNA -mediated knockdown of Beclin-1 or ATG-5 also sensitized icaritin - induced CRC cell death and apoptosis. Icaritin activated AMP-activated protein kinase (AMPK) signaling in CRC cells, functioning as the upstream signaling for autophagy activation. shRNA / siRNA -mediated knockdown of AMPKα1 inhibited icaritin - induced autophagy activation, but exacerbated CRC cell death. On the other hand, the AMPK activator compound 13 (C13) or the autophagy activator MHY1485 attenuated icaritin - induced cytotoxicity. In nude mice, icaritin (oral administration)- induced HT-29 tumor growth inhibition was potentiated when combined with AMPKα1 shRNA knockdown in tumors. We conclude that feedback activation of AMPK - autophagy pathway could be a primary resistance factor of icaritin.
28103582	0	4	AMPK	T116,T126	C2350345
28103582	7	16	autophagy	T043	C0004391
28103582	17	27	inhibition	T052	C3463820
28103582	39	47	icaritin	T109,T123	C1567768
28103582	50	57	induced	T169	C0205263
28103582	58	80	anti-colorectal cancer	T033	C0243095
28103582	81	94	cell activity	T043	C0007613
28103582	99	106	current	T079	C0521116
28103582	107	115	research	T062	C0035168
28103582	128	144	potential effect	T080	C1280500
28103582	148	157	autophagy	T043	C0004391
28103582	161	169	icaritin	T109,T123	C1567768
28103582	172	179	induced	T169	C0205263
28103582	180	202	anti-colorectal cancer	T033	C0243095
28103582	204	207	CRC	T191	C1527249
28103582	209	222	cell activity	T043	C0007613
28103582	224	233	Treatment	T169	C1522326
28103582	237	245	icaritin	T109,T123	C1567768
28103582	254	261	primary	T080	C0205225
28103582	266	277	established	T080	C0443211
28103582	279	284	HT-29	T025	C0282639
28103582	286	289	CRC	T191	C1527249
28103582	290	295	cells	T025	C0007634
28103582	296	303	induced	T169	C0205263
28103582	304	323	feedback activation	T052	C1879547
28103582	327	336	autophagy	T043	C0004391
28103582	351	354	p62	T028	C1420393
28103582	355	366	degradation	T044	C0314674
28103582	368	376	Beclin-1	T028	C1412785
28103582	381	405	autophagy-related gene-5	T028	C1825497
28103582	407	412	ATG-5	T028	C1825497
28103582	414	426	upregulation	T044	C0041904
28103582	439	453	light chain 3B	T116	C1311384
28103582	455	459	LC3B	T116	C1311384
28103582	462	465	GFP	T116,T130	C0120285
28103582	473	482	formation	T169	C1522492
28103582	484	499	Pharmacological	T169	C0205464
28103582	500	510	inhibiting	T052	C3463820
28103582	514	523	autophagy	T043	C0004391
28103582	549	557	icaritin	T109,T123	C1567768
28103582	560	567	induced	T169	C0205263
28103582	568	571	CRC	T191	C1527249
28103582	572	582	cell death	T043	C0007587
28103582	587	596	apoptosis	T043	C0162638
28103582	609	614	shRNA	T114	C2930586
28103582	625	634	knockdown	T063	C2350567
28103582	638	646	Beclin-1	T028	C1412785
28103582	650	655	ATG-5	T028	C1825497
28103582	672	680	icaritin	T109,T123	C1567768
28103582	683	690	induced	T169	C0205263
28103582	691	694	CRC	T191	C1527249
28103582	695	705	cell death	T043	C0007587
28103582	710	719	apoptosis	T043	C0162638
28103582	721	729	Icaritin	T109,T123	C1567768
28103582	730	739	activated	T052	C1879547
28103582	740	768	AMP-activated protein kinase	T116,T126	C2350345
28103582	770	774	AMPK	T116,T126	C2350345
28103582	776	785	signaling	T043	C0037083
28103582	789	792	CRC	T191	C1527249
28103582	793	798	cells	T025	C0007634
28103582	800	811	functioning	T169	C0542341
28103582	828	837	signaling	T043	C0037083
28103582	842	851	autophagy	T043	C0004391
28103582	852	862	activation	T052	C1879547
28103582	864	869	shRNA	T114	C2930586
28103582	872	877	siRNA	T114,T123	C1099354
28103582	888	897	knockdown	T063	C2350567
28103582	901	907	AMPKα1	T028	C1418897
28103582	908	917	inhibited	T080	C0311403
28103582	918	926	icaritin	T109,T123	C1567768
28103582	929	936	induced	T169	C0205263
28103582	937	946	autophagy	T043	C0004391
28103582	947	957	activation	T052	C1879547
28103582	963	974	exacerbated	T080	C1444749
28103582	975	978	CRC	T191	C1527249
28103582	979	989	cell death	T043	C0007587
28103582	1014	1018	AMPK	T116,T126	C2350345
28103582	1029	1040	compound 13	T121	C1254351
28103582	1042	1045	C13	T121	C1254351
28103582	1054	1063	autophagy	T043	C0004391
28103582	1074	1081	MHY1485	T109,T121	C3661263
28103582	1082	1092	attenuated	T052	C0599946
28103582	1093	1101	icaritin	T109,T123	C1567768
28103582	1104	1111	induced	T169	C0205263
28103582	1112	1124	cytotoxicity	T049	C0596402
28103582	1129	1138	nude mice	T015	C0025932
28103582	1140	1148	icaritin	T109,T123	C1567768
28103582	1150	1169	oral administration	T061	C0001563
28103582	1172	1179	induced	T169	C0205263
28103582	1180	1185	HT-29	T025	C0282639
28103582	1186	1198	tumor growth	T191	C0598934
28103582	1199	1209	inhibition	T052	C3463820
28103582	1245	1251	AMPKα1	T028	C1418897
28103582	1252	1257	shRNA	T114	C2930586
28103582	1258	1267	knockdown	T063	C2350567
28103582	1271	1277	tumors	T191	C0027651
28103582	1296	1315	feedback activation	T052	C1879547
28103582	1319	1323	AMPK	T116,T126	C2350345
28103582	1326	1335	autophagy	T043	C0004391
28103582	1336	1343	pathway	T044	C0037080
28103582	1363	1373	resistance	T169	C4281815
28103582	1374	1380	factor	T169	C1521761
28103582	1384	1392	icaritin	T109,T123	C1567768

28103878|t|Synthetic circuits that process multiple light and chemical signal inputs
28103878|a|Multi-signal processing circuits are essential for rational design of sophisticated synthetic systems with good controllability and modularity, therefore, enable construction of high-level networks. Moreover, light - inducible systems provide fast and reversible means for spatiotemporal control of gene expression. Here, in HEK 293 cells, we present combinatory genetic circuits responding to light and chemical signals, simultaneously. We first constructed a dual input circuit converting different light intensities into varying of the sensitivity of the promoter to a chemical inducer (doxycycline). Next, we generated a ternary input circuit, which responded to light, doxycycline and cumate. This circuit allowed us to use different combinations of blue light and the two chemical inducers to generate gradual output values over two orders of magnitude. Overall, in this study, we devise genetic circuits sensing and processing light and chemical inducers. Our work may provide insights into bio-computation and fine-tuning expression of the transgene.
28103878	0	9	Synthetic	T080	C2004457
28103878	10	18	circuits	T044	C1720951
28103878	32	40	multiple	T081	C0439064
28103878	41	46	light	T070	C0023693
28103878	51	59	chemical	T103	C0220806
28103878	60	66	signal	T067	C1710082
28103878	67	73	inputs	T077	C1708517
28103878	74	86	Multi-signal	T067	C1710082
28103878	87	97	processing	T052	C1709694
28103878	98	106	circuits	T044	C1720951
28103878	134	140	design	T052	C1707689
28103878	158	167	synthetic	T080	C2004457
28103878	168	175	systems	T169	C0449913
28103878	181	185	good	T080	C0205170
28103878	186	201	controllability	T169	C2587213
28103878	206	216	modularity	T077	C1709061
28103878	236	248	construction	T169	C0205245
28103878	252	271	high-level networks	T169	C1882071
28103878	283	288	light	T070	C0023693
28103878	291	300	inducible	T169	C0205263
28103878	301	308	systems	T169	C0449913
28103878	317	321	fast	T080	C0456962
28103878	326	336	reversible	T169	C0205343
28103878	337	342	means	T077	C1704970
28103878	347	369	spatiotemporal control	T169	C2587213
28103878	373	388	gene expression	T045	C0017262
28103878	399	412	HEK 293 cells	T025	C2936239
28103878	425	436	combinatory	T080	C0205195
28103878	437	453	genetic circuits	T044	C1720951
28103878	454	464	responding	T039	C1659608
28103878	468	473	light	T070	C0023693
28103878	478	486	chemical	T103	C0220806
28103878	487	494	signals	T067	C1710082
28103878	496	510	simultaneously	T079	C0521115
28103878	521	532	constructed	T169	C0205245
28103878	535	545	dual input	T077	C1708517
28103878	546	553	circuit	T044	C1720951
28103878	565	574	different	T080	C1705242
28103878	575	592	light intensities	T070	C0596836
28103878	613	624	sensitivity	T080	C2349185
28103878	632	640	promoter	T114,T123	C0086860
28103878	646	654	chemical	T103	C0220806
28103878	655	662	inducer	T167	C3898767
28103878	664	675	doxycycline	T109,T195	C0013090
28103878	699	712	ternary input	T077	C1708517
28103878	713	720	circuit	T044	C1720951
28103878	728	737	responded	T039	C1659608
28103878	741	746	light	T070	C0023693
28103878	748	759	doxycycline	T109,T195	C0013090
28103878	764	770	cumate	T109,T123	C0285770
28103878	777	784	circuit	T044	C1720951
28103878	813	825	combinations	T080	C0205195
28103878	829	839	blue light	T070	C0303896
28103878	852	860	chemical	T103	C0220806
28103878	861	869	inducers	T167	C3898767
28103878	890	903	output values	T170	C1285164
28103878	923	932	magnitude	T081	C1704240
28103878	951	956	study	T062	C2603343
28103878	968	984	genetic circuits	T044	C1720951
28103878	985	992	sensing	T044	C1655954
28103878	997	1007	processing	T052	C1709694
28103878	1008	1013	light	T070	C0023693
28103878	1018	1026	chemical	T103	C0220806
28103878	1027	1035	inducers	T167	C3898767
28103878	1072	1087	bio-computation	T170	C1136291
28103878	1104	1114	expression	T045	C0017262
28103878	1122	1131	transgene	T028	C0282641

28122925|t|Interprofessional primary care team meetings: a qualitative approach comparing observations with personal opinions
28122925|a|The number of people with multiple chronic conditions requiring primary care services increases. Professionals from different disciplines collaborate and coordinate care to deal with the complex health care needs. There is lack of information on current practices regarding interprofessional team (IPT) meetings. This study aimed to improve our understanding of the process of interprofessional collaboration in primary care team meetings in the Netherlands by observing the current practice and exploring personal opinions. Qualitative study involving observations of team meeting s and interviews with participants. Eight different IPT meetings (n = 8) in different primary care practices were observed by means of video recordings. Experiences were explored by conducting individual semi-structured interviews (n = 60) with participants (i.e. health care professionals from different disciplines) of the observed team meetings. The data were analysed by means of content analysis. Most participants expressed favourable opinions about their team meetings. However, observations showed that team meetings were more or less hectic, and lacked a clear structure and team coordinator or leader. There appears to be a discrepancy between findings from observations and interviews. From the interviews, four main themes were extracted: (1) Team structure and composition, (2) Patient-centredness, (3) Interaction and (4) Attitude and motivation. IPT meetings could benefit from improvements in structure, patient-centredness and leadership by the chairpersons. Given the discrepancy between observations and interviews, it would appear useful to improve team members ' awareness of aspects that could be improved before training them in dealing with specific challenges.
28122925	0	17	Interprofessional	T054	C0021799
28122925	18	30	primary care	T058	C0033137
28122925	31	44	team meetings	T058	C0589031
28122925	48	59	qualitative	T080	C0205556
28122925	60	68	approach	T082	C0449445
28122925	79	91	observations	T062	C0302523
28122925	97	105	personal	T032	C1519021
28122925	106	114	opinions	UnknownType	C0683292
28122925	129	135	people	T098	C0027361
28122925	141	168	multiple chronic conditions	T047	C3266262
28122925	179	200	primary care services	T058	C0018747
28122925	201	210	increases	T169	C0442805
28122925	212	225	Professionals	T097	C0679924
28122925	241	252	disciplines	T057	C0013996
28122925	253	264	collaborate	T054	C0282116
28122925	269	279	coordinate	T169	C0700114
28122925	280	284	care	T052	C1947933
28122925	310	327	health care needs	T058	C0086388
28122925	338	342	lack	T080	C0332268
28122925	346	357	information	T078	C1533716
28122925	389	406	interprofessional	T054	C0021799
28122925	407	426	team (IPT) meetings	T058	C0589031
28122925	433	438	study	T062	C2603343
28122925	492	509	interprofessional	T054	C0021799
28122925	510	523	collaboration	T054	C0282116
28122925	527	539	primary care	T058	C0033137
28122925	540	553	team meetings	T058	C0589031
28122925	561	572	Netherlands	T083	C0027778
28122925	590	606	current practice	T057	C0033284
28122925	621	629	personal	T032	C1519021
28122925	630	638	opinions	UnknownType	C0683292
28122925	640	657	Qualitative study	T062	C0949415
28122925	668	680	observations	T062	C0302523
28122925	684	696	team meeting	T058	C0589031
28122925	703	713	interviews	T058	C0683518
28122925	719	731	participants	T098	C0679646
28122925	749	761	IPT meetings	T058	C0589031
28122925	783	805	primary care practices	T058	C0033137
28122925	832	848	video recordings	T073	C0042650
28122925	850	861	Experiences	T041	C0596545
28122925	901	927	semi-structured interviews	UnknownType	C0681913
28122925	942	954	participants	T098	C0679646
28122925	961	986	health care professionals	T097	C0018724
28122925	1002	1013	disciplines	T057	C0013996
28122925	1031	1044	team meetings	T058	C0589031
28122925	1050	1054	data	T078	C1511726
28122925	1060	1068	analysed	T062	C0936012
28122925	1081	1097	content analysis	T062	C0681915
28122925	1104	1116	participants	T098	C0679646
28122925	1138	1146	opinions	UnknownType	C0683292
28122925	1159	1172	team meetings	T058	C0589031
28122925	1183	1195	observations	T062	C0302523
28122925	1208	1221	team meetings	T058	C0589031
28122925	1252	1258	lacked	T080	C0332268
28122925	1281	1297	team coordinator	T097	C1711307
28122925	1301	1307	leader	T097	C0401960
28122925	1331	1342	discrepancy	T033	C1290905
28122925	1351	1359	findings	T033	C0243095
28122925	1365	1377	observations	T062	C0302523
28122925	1382	1392	interviews	T052	C0021822
28122925	1403	1413	interviews	T052	C0021822
28122925	1452	1482	Team structure and composition	T098	C1257890
28122925	1488	1507	Patient-centredness	T058	C0243024
28122925	1513	1524	Interaction	T054	C0021797
28122925	1533	1541	Attitude	T041	C0004271
28122925	1546	1556	motivation	T041	C0026605
28122925	1558	1570	IPT meetings	T058	C0589031
28122925	1590	1602	improvements	T077	C2986411
28122925	1617	1636	patient-centredness	T058	C0243024
28122925	1641	1651	leadership	T054	C0023181
28122925	1659	1671	chairpersons	T097	C1524106
28122925	1683	1694	discrepancy	T033	C1290905
28122925	1703	1715	observations	T062	C0302523
28122925	1720	1730	interviews	T052	C0021822
28122925	1758	1765	improve	T077	C2986411
28122925	1766	1778	team members	T096	C1551024
28122925	1781	1790	awareness	T041	C0004448
28122925	1794	1801	aspects	T080	C1879746
28122925	1816	1824	improved	T077	C2986411
28122925	1832	1840	training	T065	C0220931
28122925	1871	1881	challenges	T058	C0805586

27655704|t|Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype
27655704|a|Substantial controversy exists regarding the differences in tumor subtypes between male breast cancer (MBC) and female breast cancer (FBC). This is the largest population-based study to compare MBC and FBC patients. Using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2012, a retrospective, population-based cohort study was conducted to investigate tumor subtype - specific differences in various characteristics, overall survival (OS) and breast cancer-specific mortality (BCSM) between males and females. In all, 181,814 BC patients (1,516 male and 180,298 female) were eligible for this study. The male patients were more likely to be black, older, and have lower histological grades, more advanced stages, larger tumors, more lymph node and distant metastases and human epidermal growth factor receptor 2 (HER2)- negative tumors (each p<0.05). A matched analysis showed that the 2-year OS was 91.2% and 93.7% and that the BCSM was 2.2% and 2.5% for male and female patients, respectively. The univariate analysis showed that male triple-negative (TN), hormone receptor (HoR)-positive/HER2-positive and HoR-positive/HER2-negative patients had poorer OS (p <0.01). Meanwhile, the HoR-positive/HER2-positive and TN subtypes were associated with a higher BCSM in MBC patients (p<0.01). The multivariate analysis revealed that TN MBC patients had poorer OS and BCSM (p<0.05). Simultaneously, the results showed that male patients in the HoR-positive/HER2-negative subgroup were less likely to die of BC when adjusting for other factors (p<0.05). The analysis of 2-year OS and BCSM among the BC subtypes showed clear differences between MBC and FBC patients with the TN subtype; these differences warrant further investigation.
27655704	0	6	Poorer	T080	C0542537
27655704	7	20	breast cancer	T191	C0678222
27655704	21	29	survival	T169	C0220921
27655704	30	38	outcomes	T169	C1274040
27655704	42	47	males	T032	C0086582
27655704	53	60	females	T032	C0086287
27655704	86	99	tumor subtype	T185	C1519691
27655704	145	156	differences	T080	C1705242
27655704	160	174	tumor subtypes	T185	C1519691
27655704	183	201	male breast cancer	T191	C0238033
27655704	203	206	MBC	T191	C0238033
27655704	212	232	female breast cancer	T191	C0007104
27655704	234	237	FBC	T191	C0007104
27655704	252	259	largest	T081	C0443228
27655704	260	282	population-based study	T062	C1709599
27655704	286	293	compare	T052	C1707455
27655704	294	297	MBC	T191	C0238033
27655704	302	305	FBC	T191	C0007104
27655704	306	314	patients	T101	C0030705
27655704	322	326	data	T078	C1511726
27655704	327	335	obtained	T169	C1301820
27655704	343	401	Surveillance, Epidemiology, and End Results (SEER) program	T093	C0242638
27655704	420	433	retrospective	T080	C1514923
27655704	435	464	population-based cohort study	T062	C1709599
27655704	482	493	investigate	T169	C1292732
27655704	494	507	tumor subtype	T185	C1519691
27655704	510	518	specific	T080	C0205369
27655704	519	530	differences	T080	C1705242
27655704	534	541	various	T081	C0439064
27655704	542	557	characteristics	T080	C1521970
27655704	559	575	overall survival	T081	C4086681
27655704	577	579	OS	T081	C4086681
27655704	585	617	breast cancer-specific mortality	T081	C1516192
27655704	619	623	BCSM	T081	C1516192
27655704	633	638	males	T032	C0086582
27655704	643	650	females	T032	C0086287
27655704	668	670	BC	T191	C0678222
27655704	671	679	patients	T101	C0030705
27655704	687	691	male	T032	C0086582
27655704	704	710	female	T032	C0086287
27655704	717	725	eligible	T080	C1548635
27655704	735	740	study	T062	C2603343
27655704	746	750	male	T032	C0086582
27655704	751	759	patients	T101	C0030705
27655704	783	788	black	T098	C0005680
27655704	790	795	older	T098	C0001792
27655704	806	811	lower	T080	C0205251
27655704	812	831	histological grades	T033	C1298736
27655704	833	853	more advanced stages	T079	C0205390
27655704	855	861	larger	T081	C0549177
27655704	862	868	tumors	T191	C0027651
27655704	870	874	more	T081	C0205172
27655704	875	885	lymph node	T023	C0024204
27655704	890	908	distant metastases	T191	C0027627
27655704	913	953	human epidermal growth factor receptor 2	T116,T126,T192	C1702024
27655704	955	959	HER2	T116,T126,T192	C1702024
27655704	962	970	negative	T033	C0205160
27655704	971	977	tumors	T191	C0027651
27655704	995	1011	matched analysis	T080	C0085145
27655704	1035	1037	OS	T081	C4086681
27655704	1071	1075	BCSM	T081	C1516192
27655704	1098	1102	male	T032	C0086582
27655704	1107	1113	female	T032	C0086287
27655704	1114	1122	patients	T101	C0030705
27655704	1142	1161	univariate analysis	T062	C0683962
27655704	1174	1178	male	T032	C0086582
27655704	1179	1194	triple-negative	T033	C2348819
27655704	1196	1198	TN	T033	C2348819
27655704	1201	1246	hormone receptor (HoR)-positive/HER2-positive	T034	C3898879
27655704	1251	1277	HoR-positive/HER2-negative	T034	C1254360
27655704	1278	1286	patients	T101	C0030705
27655704	1291	1297	poorer	T080	C0542537
27655704	1298	1300	OS	T081	C4086681
27655704	1327	1353	HoR-positive/HER2-positive	T101	C0030705
27655704	1358	1360	TN	T033	C2348819
27655704	1361	1369	subtypes	T185	C0449560
27655704	1375	1390	associated with	T080	C0332281
27655704	1393	1399	higher	T080	C0205250
27655704	1400	1404	BCSM	T081	C1516192
27655704	1408	1411	MBC	T191	C0238033
27655704	1412	1420	patients	T101	C0030705
27655704	1435	1456	multivariate analysis	T081	C0026777
27655704	1457	1465	revealed	T080	C0443289
27655704	1471	1473	TN	T033	C2348819
27655704	1474	1477	MBC	T191	C0238033
27655704	1478	1486	patients	T101	C0030705
27655704	1491	1497	poorer	T080	C0542537
27655704	1498	1500	OS	T081	C4086681
27655704	1505	1509	BCSM	T081	C1516192
27655704	1540	1547	results	T169	C1274040
27655704	1560	1564	male	T032	C0086582
27655704	1565	1573	patients	T101	C0030705
27655704	1581	1616	HoR-positive/HER2-negative subgroup	T185	C1515021
27655704	1622	1626	less	T081	C0439092
27655704	1634	1640	to die	T033	C0243095
27655704	1644	1646	BC	T191	C0678222
27655704	1694	1702	analysis	T062	C0936012
27655704	1713	1715	OS	T081	C4086681
27655704	1720	1724	BCSM	T081	C1516192
27655704	1735	1737	BC	T191	C0678222
27655704	1738	1746	subtypes	T101	C0030705
27655704	1754	1759	clear	T080	C2963144
27655704	1760	1771	differences	T080	C1705242
27655704	1780	1783	MBC	T191	C0238033
27655704	1788	1791	FBC	T191	C0007104
27655704	1792	1800	patients	T101	C0030705
27655704	1810	1812	TN	T033	C2348819
27655704	1813	1820	subtype	T185	C0449560
27655704	1828	1839	differences	T080	C1705242
27655704	1848	1855	further	T082	C1517331
27655704	1856	1869	investigation	T058	C0220825

27690192|t|Systemic Collyriclum faba (Trematoda: Collyriclidae) Infection in a Wild Common Raven (Corvus corax)
27690192|a|A hatch-year Common Raven (Corvus corax) with subcutaneous and internal pseudocysts, filled with fluid, containing a pair of adult trematodes and numerous eggs consistent with Collyriclum faba, died near a riverbank in California, US. While C. faba is incidental in many Passeriformes, this case was a fatal systemic infection.
27690192	0	8	Systemic	T169	C0205373
27690192	9	25	Collyriclum faba	T204	C0322043
27690192	27	36	Trematoda	T204	C0040818
27690192	38	51	Collyriclidae	T204	C3444348
27690192	53	62	Infection	T046	C3714514
27690192	80	85	Raven	T012	C1449597
27690192	87	99	Corvus corax	T012	C1449597
27690192	103	113	hatch-year	T079	C0439234
27690192	121	126	Raven	T012	C1449597
27690192	128	140	Corvus corax	T012	C1449597
27690192	147	159	subcutaneous	T082	C0443315
27690192	164	172	internal	T082	C0205102
27690192	173	184	pseudocysts	T020	C0333161
27690192	198	203	fluid	T167	C1704353
27690192	218	222	pair	T080	C1709450
27690192	226	231	adult	T204	C0563200
27690192	232	242	trematodes	T204	C0040818
27690192	247	255	numerous	T081	C0439064
27690192	256	260	eggs	T204	C0562677
27690192	277	293	Collyriclum faba	T204	C0322043
27690192	295	299	died	T033	C1306577
27690192	320	330	California	T083	C0006754
27690192	332	334	US	T083	C0041703
27690192	342	349	C. faba	T204	C0322043
27690192	353	363	incidental	T169	C0444507
27690192	372	385	Passeriformes	T012	C0600537
27690192	403	408	fatal	T080	C1302234
27690192	409	427	systemic infection	T047	C0243026

28194574|t|Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
28194574|a|Severe neonatal autosomal-dominant polycystic kidney disease (ADPKD) is rare and easily confused with recessive PKD. Managing such infants is difficult and often unsuccessful. A female infant with massive renal enlargement, respiratory compromise and hyponatraemia was treated with the arginine vasopressin receptor 2 antagonist tolvaptan. This resolved hyponatraemia, and there was no further increase in renal size. Tolvaptan may be a useful treatment for severe neonatal PKD.
28194574	0	9	Tolvaptan	T109,T121	C1176308
28194574	10	19	treatment	T061	C0087111
28194574	31	39	neonatal	T100	C0021289
28194574	40	84	autosomal-dominant polycystic kidney disease	T019,T047	C0085413
28194574	92	100	neonatal	T100	C0021289
28194574	101	145	autosomal-dominant polycystic kidney disease	T019,T047	C0085413
28194574	147	152	ADPKD	T019,T047	C0085413
28194574	187	200	recessive PKD	T019,T047	C0085548
28194574	202	210	Managing	T058	C0376636
28194574	216	223	infants	T100	C0021289
28194574	263	276	female infant	T033	C2222300
28194574	282	307	massive renal enlargement	T033	C0542518
28194574	309	331	respiratory compromise	T033	C4228652
28194574	336	349	hyponatraemia	T047	C0877169
28194574	371	402	arginine vasopressin receptor 2	T116,T192	C3711287
28194574	403	413	antagonist	T120	C0243076
28194574	414	423	tolvaptan	T109,T121	C1176308
28194574	439	452	hyponatraemia	T047	C0877169
28194574	479	487	increase	T169	C0442805
28194574	491	501	renal size	T201	C0745522
28194574	503	512	Tolvaptan	T109,T121	C1176308
28194574	529	538	treatment	T061	C0087111
28194574	550	558	neonatal	T100	C0021289
28194574	559	562	PKD	T047	C0022680

28055920|t|Robust DLPP With Nongreedy ℓ₁$-Norm Minimization and Maximization
28055920|a|Recently, discriminant locality preserving projection based on L1-norm (DLPP-L1) was developed for robust subspace learning and image classification. It obtains projection vectors by greedy strategy, i.e., all projection vectors are optimized individually through maximizing the objective function. Thus, the obtained solution does not necessarily best optimize the corresponding trace ratio optimization algorithm, which is the essential objective function for general dimensionality reduction. It results in insufficient recognition accuracy. To tackle this problem, we propose a nongreedy algorithm to solve the trace ratio formula of DLPP-L1, and analyze its convergence. Experimental results on three databases illustrate the effectiveness of our proposed algorithm.
28055920	0	6	Robust	T080	C2986815
28055920	7	11	DLPP	T081	C0392762
28055920	17	48	Nongreedy ℓ₁$-Norm Minimization	T080	C0205556
28055920	53	65	Maximization	T080	C0205556
28055920	76	136	discriminant locality preserving projection based on L1-norm	T081	C0392762
28055920	138	145	DLPP-L1	T081	C0392762
28055920	165	171	robust	T080	C2986815
28055920	172	189	subspace learning	T041	C0023185
28055920	194	199	image	T170	C1704922
28055920	200	214	classification	T185	C0008902
28055920	227	237	projection	T082	C0348018
28055920	238	245	vectors	T082	C0442335
28055920	249	264	greedy strategy	T062	C0035171
28055920	276	286	projection	T082	C0348018
28055920	287	294	vectors	T082	C0442335
28055920	330	340	maximizing	T080	C0205556
28055920	345	354	objective	T080	C1571702
28055920	355	363	function	T169	C0542341
28055920	384	392	solution	T170	C1706817
28055920	446	480	trace ratio optimization algorithm	T170	C0002045
28055920	505	514	objective	T080	C1571702
28055920	515	523	function	T169	C0542341
28055920	536	560	dimensionality reduction	T170	C0282574
28055920	589	600	recognition	T041	C0237818
28055920	601	609	accuracy	T080	C0443131
28055920	648	667	nongreedy algorithm	T170	C0002045
28055920	681	700	trace ratio formula	T170	C0489829
28055920	704	711	DLPP-L1	T081	C0392762
28055920	729	740	convergence	T052	C2700387
28055920	772	781	databases	T170	C0242356
28055920	827	836	algorithm	T170	C0002045

28132389|t|An Improved Method for Identifying Specific DNA-Protein-Binding Sites In Vitro
28132389|a|Binding of proteins to specific DNA sequences is essential for a variety of cellular processes such as DNA replication, transcription and responses to external stimuli. Chromatin immunoprecipitation is widely used for determining intracellular DNA fragments bound by a specific protein. However, the subsequent specific or accurate DNA-protein-binding sequence is usually determined by DNA footprinting. Here, we report an alternative method for identifying specific sites of DNA-protein-binding (designated SSDP) in vitro. This technique is mainly dependent on antibody-antigen immunity, simple and convenient, while radioactive isotope labeling and optimization of partial degradation by deoxyribonuclease (DNase) are avoided. As an example, the specific binding sequence of a target promoter by DdrO (a DNA damage response protein from Deinococcus radiodurans) in vitro was determined by the developed method. The central sequence of the binding site could be easily located using this technique.
28132389	3	11	Improved	T033	C0184511
28132389	12	18	Method	T169	C0449851
28132389	35	69	Specific DNA-Protein-Binding Sites	T192	C0005456
28132389	70	78	In Vitro	T080	C1533691
28132389	79	86	Binding	T044	C1167622
28132389	90	98	proteins	T116,T123	C0033684
28132389	102	124	specific DNA sequences	T086	C0162326
28132389	128	137	essential	T080	C0205224
28132389	144	151	variety	T077	C2346866
28132389	155	173	cellular processes	T043	C1325880
28132389	182	197	DNA replication	T045	C0598312
28132389	199	212	transcription	T045	C0040649
28132389	217	246	responses to external stimuli	T038	C1154577
28132389	248	277	Chromatin immunoprecipitation	T059	C1328856
28132389	309	322	intracellular	T082	C0178719
28132389	323	336	DNA fragments	UnknownType	C0684192
28132389	337	342	bound	T044	C1167622
28132389	348	364	specific protein	T116,T123	C0033684
28132389	379	389	subsequent	T079	C0332282
28132389	390	398	specific	T080	C0205369
28132389	402	439	accurate DNA-protein-binding sequence	T087	C0002518
28132389	451	464	determined by	T080	C0521095
28132389	465	481	DNA footprinting	T063	C0282579
28132389	492	498	report	T170	C0684224
28132389	514	520	method	T169	C0449851
28132389	537	551	specific sites	T082	C0449604
28132389	555	574	DNA-protein-binding	T044	C1167622
28132389	587	591	SSDP	T044	C1167622
28132389	593	601	in vitro	T080	C1533691
28132389	608	617	technique	T169	C0449851
28132389	628	637	dependent	T080	C0851827
28132389	641	657	antibody-antigen	T129	C0368675
28132389	658	666	immunity	T039	C0020964
28132389	668	674	simple	T080	C0205352
28132389	679	689	convenient	T080	C3831015
28132389	697	708	radioactive	T070	C0034553
28132389	709	725	isotope labeling	T062	C0022261
28132389	730	742	optimization	T052	C2698650
28132389	746	753	partial	T081	C0728938
28132389	754	765	degradation	T169	C0243125
28132389	769	786	deoxyribonuclease	T116,T121,T126	C0011522
28132389	788	793	DNase	T116,T121,T126	C0011522
28132389	814	821	example	T077	C1707959
28132389	827	852	specific binding sequence	T087	C0002518
28132389	858	864	target	T169	C1521840
28132389	865	873	promoter	T114,T123	C0086860
28132389	877	881	DdrO	T116,T123	C0033684
28132389	885	912	DNA damage response protein	T116,T123	C0033684
28132389	918	941	Deinococcus radiodurans	T007	C0544157
28132389	943	951	in vitro	T080	C1533691
28132389	956	969	determined by	T080	C0521095
28132389	984	990	method	T169	C0449851
28132389	996	1012	central sequence	T087	C0002518
28132389	1020	1032	binding site	T192	C0005456
28132389	1042	1048	easily	T033	C0332219
28132389	1068	1077	technique	T169	C0449851

28381880|t|20S immunoproteasomes remove formaldehyde - damaged cytoplasmic proteins suppressing caspase-independent cell death
28381880|a|Immunoproteasomes are known for their involvement in antigen presentation. However, their broad tissue presence and other evidence are indicative of nonimmune functions. We examined a role for immunoproteasomes in cellular responses to the endogenous and environmental carcinogen formaldehyde (FA) that binds to cytosolic and nuclear proteins producing proteotoxic stress and genotoxic DNA - histone crosslinks. We found that immunoproteasomes were important for suppression of a caspase-independent cell death and the long-term survival of FA-treated cells. All major genotoxic responses to FA, including replication inhibition and activation of the transcription factor p53 and the apical ATM and ATR kinases, were unaffected by immunoproteasome inactivity. Immunoproteasome inhibition enhanced activation of the cytosolic protein damage sensor HSF1, elevated levels of K48-polyubiquitinated cytoplasmic proteins and increased depletion of unconjugated ubiquitin. We further found that FA induced the disassembly of 26S immunoproteasomes, but not standard 26S proteasomes, releasing the 20S catalytic immunoproteasome. FA-treated cells also had higher amounts of small activators PA28αβ and PA28γ bound to 20S particles. Our findings highlight the significance of nonnuclear damage in FA injury and reveal a major role for immunoproteasomes in elimination of FA-damaged cytoplasmic proteins through ubiquitin - independent proteolysis.
28381880	0	21	20S immunoproteasomes	T116,T126	C0014442
28381880	29	41	formaldehyde	T109,T121,T131	C0016564
28381880	44	51	damaged	T169	C1883709
28381880	52	72	cytoplasmic proteins	T116,T123	C1333198
28381880	73	84	suppressing	T169	C1260953
28381880	85	115	caspase-independent cell death	T043	C3820502
28381880	116	133	Immunoproteasomes	T116,T126	C0014442
28381880	154	165	involvement	T169	C1314939
28381880	169	189	antigen presentation	T043	C0206431
28381880	206	211	broad	T082	C0332464
28381880	212	218	tissue	T024	C0040300
28381880	219	227	presence	T033	C0150312
28381880	238	246	evidence	T169	C0332120
28381880	251	264	indicative of	T078	C0392360
28381880	265	284	nonimmune functions	T039	C0031843
28381880	309	326	immunoproteasomes	T116,T126	C0014442
28381880	330	348	cellular responses	T043	C1817908
28381880	356	366	endogenous	T169	C0205227
28381880	371	395	environmental carcinogen	T131	C0007091
28381880	396	408	formaldehyde	T109,T121,T131	C0016564
28381880	410	412	FA	T109,T121,T131	C0016564
28381880	428	437	cytosolic	T026	C1383501
28381880	442	458	nuclear proteins	T116,T123	C0028589
28381880	469	487	proteotoxic stress	T046	C0449430
28381880	492	501	genotoxic	T049	C0598309
28381880	502	505	DNA	T114,T123	C0012854
28381880	508	515	histone	T116,T123	C0019652
28381880	516	526	crosslinks	T070	C0178576
28381880	542	559	immunoproteasomes	T116,T126	C0014442
28381880	565	574	important	T080	C3898777
28381880	579	590	suppression	T169	C1260953
28381880	596	626	caspase-independent cell death	T043	C3820502
28381880	635	644	long-term	T079	C0443252
28381880	645	653	survival	T169	C0220921
28381880	657	673	FA-treated cells	T025	C0007634
28381880	685	694	genotoxic	T049	C0598309
28381880	695	704	responses	T032	C0871261
28381880	708	710	FA	T109,T121,T131	C0016564
28381880	722	744	replication inhibition	T045	C1511692
28381880	749	759	activation	T052	C1879547
28381880	767	791	transcription factor p53	T116,T123	C0080055
28381880	800	806	apical	T082	C0205111
28381880	807	810	ATM	T116,T126	C3711796
28381880	815	826	ATR kinases	T116,T126	C3711837
28381880	833	843	unaffected	T077	C2986417
28381880	847	863	immunoproteasome	T116,T126	C0014442
28381880	864	874	inactivity	T080	C3244312
28381880	893	903	inhibition	T052	C3463820
28381880	904	912	enhanced	T052	C2349975
28381880	913	923	activation	T052	C1879547
28381880	931	940	cytosolic	T026	C1383501
28381880	941	948	protein	T116,T123	C0033684
28381880	949	955	damage	T169	C1883709
28381880	956	967	sensor HSF1	T116,T123	C0121235
28381880	969	984	elevated levels	T080	C0441889
28381880	988	1009	K48-polyubiquitinated	T044	C3820607
28381880	1010	1030	cytoplasmic proteins	T116,T123	C1333198
28381880	1035	1044	increased	T081	C0205217
28381880	1045	1054	depletion	T169	C0333668
28381880	1058	1070	unconjugated	T080	C0522530
28381880	1071	1080	ubiquitin	T116,T123	C0041538
28381880	1104	1106	FA	T109,T121,T131	C0016564
28381880	1107	1114	induced	T169	C0205263
28381880	1119	1130	disassembly	T052	C1707798
28381880	1134	1155	26S immunoproteasomes	T116,T126	C0014442
28381880	1174	1189	26S proteasomes	T116,T126	C0286330
28381880	1205	1235	20S catalytic immunoproteasome	T116,T126	C0014442
28381880	1237	1253	FA-treated cells	T025	C0007634
28381880	1263	1277	higher amounts	T081	C1265611
28381880	1287	1304	activators PA28αβ	T116,T123	C0753808
28381880	1309	1314	PA28γ	T116,T123	C0893173
28381880	1324	1337	20S particles	T116,T126	C0014442
28381880	1366	1378	significance	T078	C0750502
28381880	1382	1399	nonnuclear damage	T169	C1883709
28381880	1403	1405	FA	T109,T121,T131	C0016564
28381880	1441	1458	immunoproteasomes	T116,T126	C0014442
28381880	1477	1487	FA-damaged	T169	C1883709
28381880	1488	1508	cytoplasmic proteins	T116,T123	C1333198
28381880	1517	1526	ubiquitin	T116,T123	C0041538
28381880	1529	1540	independent	T078	C0085862
28381880	1541	1552	proteolysis	T044	C0597304

27451448|t|Yersinia ruckeri Isolates Recovered from Diseased Atlantic Salmon (Salmo salar) in Scotland Are More Diverse than Those from Rainbow Trout (Oncorhynchus mykiss) and Represent Distinct Subpopulations
27451448|a|Yersinia ruckeri is the etiological agent of enteric redmouth (ERM) disease of farmed salmonids. Enteric redmouth disease is traditionally associated with rainbow trout (Oncorhynchus mykiss, Walbaum), but its incidence in Atlantic salmon (Salmo salar) is increasing. Yersinia ruckeri isolates recovered from diseased Atlantic salmon have been poorly characterized, and very little is known about the relationship of the isolates associated with these two species. Phenotypic approaches were used to characterize 109 Y. ruckeri isolates recovered over a 14-year period from infected Atlantic salmon in Scotland; 26 isolates from infected rainbow trout were also characterized. Biotyping, serotyping, and comparison of outer membrane protein profiles identified 19 Y. ruckeri clones associated with Atlantic salmon but only five associated with rainbow trout; none of the Atlantic salmon clones occurred in rainbow trout and vice versa These findings suggest that distinct subpopulations of Y. ruckeri are associated with each species. A new O serotype (designated O8) was identified in 56 biotype 1 Atlantic salmon isolates and was the most common serotype identified from 2006 to 2011 and in 2014, suggesting an increased prevalence during the time period sampled. Rainbow trout isolates were represented almost exclusively by the same biotype 2, serotype O1 clone that has been responsible for the majority of ERM outbreaks in this species within the United Kingdom since the 1980s. However, the identification of two biotype 2, serotype O8 isolates in rainbow trout suggests that vaccines containing serotypes O1 and O8 should be evaluated in both rainbow trout and Atlantic salmon for application in Scotland. Vaccination plays an important role in protecting Atlantic salmon against the bacterial pathogen Yersinia ruckeri, but, in recent years, there has been an increasing incidence of vaccine breakdown in salmon. This is largely because current vaccines are aimed at rainbow trout and are based on serotypes specific for this species. A wider range of serotypes is responsible for infection in Atlantic salmon, but very little is known about the diversity of these strains and their relationships to those recovered from rainbow trout. In the present study, we demonstrate that Y. ruckeri isolates recovered from diseased Atlantic salmon in Scotland are more diverse than those from rainbow trout; furthermore, isolates from the two species represent distinct subpopulations. In addition, a new O serotype was identified that is responsible for a significant proportion of the disease in Atlantic salmon. Our findings are likely to have important implications for the development of improved vaccines against Y. ruckeri.
27451448	0	16	Yersinia ruckeri	T007	C1257868
27451448	17	25	Isolates	T123	C3494793
27451448	26	40	Recovered from	T080	C0521108
27451448	41	49	Diseased	T047	C0012634
27451448	50	65	Atlantic Salmon	T013	C0327949
27451448	67	78	Salmo salar	T013	C0327949
27451448	83	91	Scotland	T083	C0036453
27451448	125	138	Rainbow Trout	T013	C0036108
27451448	140	159	Oncorhynchus mykiss	T013	C0036108
27451448	165	174	Represent	T052	C1882932
27451448	184	198	Subpopulations	T098	C1257890
27451448	199	215	Yersinia ruckeri	T007	C1257868
27451448	223	240	etiological agent	T169	C1314792
27451448	244	260	enteric redmouth	T047	C0275759
27451448	262	265	ERM	T047	C0275759
27451448	267	274	disease	T047	C0012634
27451448	285	294	salmonids	T013	C0036129
27451448	296	320	Enteric redmouth disease	T047	C0275759
27451448	338	353	associated with	T080	C0332281
27451448	354	367	rainbow trout	T013	C0036108
27451448	369	388	Oncorhynchus mykiss	T013	C0036108
27451448	390	397	Walbaum	T013	C0036108
27451448	408	417	incidence	T081	C0021149
27451448	421	436	Atlantic salmon	T013	C0327949
27451448	438	449	Salmo salar	T013	C0327949
27451448	454	464	increasing	T169	C0442808
27451448	466	482	Yersinia ruckeri	T007	C1257868
27451448	483	491	isolates	T123	C3494793
27451448	492	506	recovered from	T080	C0521108
27451448	507	515	diseased	T047	C0012634
27451448	516	531	Atlantic salmon	T013	C0327949
27451448	542	562	poorly characterized	T052	C1880022
27451448	599	611	relationship	T080	C0439849
27451448	619	627	isolates	T123	C3494793
27451448	628	643	associated with	T080	C0332281
27451448	654	661	species	T185	C1705920
27451448	663	673	Phenotypic	T032	C0031437
27451448	715	725	Y. ruckeri	T007	C1257868
27451448	726	734	isolates	T123	C3494793
27451448	772	780	infected	T033	C0439663
27451448	781	796	Atlantic salmon	T013	C0327949
27451448	800	808	Scotland	T083	C0036453
27451448	813	821	isolates	T123	C3494793
27451448	827	835	infected	T033	C0439663
27451448	836	849	rainbow trout	T013	C0036108
27451448	860	873	characterized	T052	C1880022
27451448	875	884	Biotyping	T059	C0441707
27451448	886	896	serotyping	T059	C0036759
27451448	902	912	comparison	T052	C1707455
27451448	916	930	outer membrane	T026	C1167331
27451448	931	947	protein profiles	T034	C3463810
27451448	962	972	Y. ruckeri	T007	C1257868
27451448	973	979	clones	T024	C1522642
27451448	980	995	associated with	T080	C0332281
27451448	996	1011	Atlantic salmon	T013	C0327949
27451448	1026	1041	associated with	T080	C0332281
27451448	1042	1055	rainbow trout	T013	C0036108
27451448	1069	1084	Atlantic salmon	T013	C0327949
27451448	1085	1091	clones	T024	C1522642
27451448	1104	1117	rainbow trout	T013	C0036108
27451448	1139	1147	findings	T033	C0243095
27451448	1170	1184	subpopulations	T098	C1257890
27451448	1188	1198	Y. ruckeri	T007	C1257868
27451448	1203	1218	associated with	T080	C0332281
27451448	1224	1231	species	T185	C1705920
27451448	1239	1249	O serotype	T170	C0449549
27451448	1284	1296	56 biotype 1	T170	C0449562
27451448	1297	1312	Atlantic salmon	T013	C0327949
27451448	1313	1321	isolates	T123	C3494793
27451448	1346	1354	serotype	T170	C0449943
27451448	1411	1431	increased prevalence	T081	C1512456
27451448	1464	1477	Rainbow trout	T013	C0036108
27451448	1478	1486	isolates	T123	C3494793
27451448	1492	1503	represented	T052	C1882932
27451448	1535	1544	biotype 2	T170	C0449562
27451448	1546	1557	serotype O1	T170	C0449549
27451448	1610	1613	ERM	T047	C0275759
27451448	1632	1639	species	T185	C1705920
27451448	1651	1665	United Kingdom	T083	C0041700
27451448	1718	1727	biotype 2	T170	C0449562
27451448	1729	1740	serotype O8	T170	C0449549
27451448	1741	1749	isolates	T123	C3494793
27451448	1753	1766	rainbow trout	T013	C0036108
27451448	1781	1789	vaccines	T121,T129	C0042210
27451448	1801	1820	serotypes O1 and O8	T170	C0449549
27451448	1849	1862	rainbow trout	T013	C0036108
27451448	1867	1882	Atlantic salmon	T013	C0327949
27451448	1902	1910	Scotland	T083	C0036453
27451448	1912	1923	Vaccination	T061	C0042196
27451448	1962	1977	Atlantic salmon	T013	C0327949
27451448	1990	1999	bacterial	T007	C0004611
27451448	2009	2025	Yersinia ruckeri	T007	C1257868
27451448	2067	2077	increasing	T169	C0442808
27451448	2078	2087	incidence	T081	C0021149
27451448	2091	2098	vaccine	T121,T129	C0042210
27451448	2112	2118	salmon	T013	C0036110
27451448	2152	2160	vaccines	T121,T129	C0042210
27451448	2174	2187	rainbow trout	T013	C0036108
27451448	2205	2214	serotypes	T170	C0449943
27451448	2233	2240	species	T185	C1705920
27451448	2259	2268	serotypes	T170	C0449943
27451448	2288	2297	infection	T046	C3714514
27451448	2301	2316	Atlantic salmon	T013	C0327949
27451448	2372	2379	strains	T013	C0327949
27451448	2390	2403	relationships	T080	C0439849
27451448	2413	2427	recovered from	T080	C0521108
27451448	2428	2441	rainbow trout	T013	C0036108
27451448	2485	2495	Y. ruckeri	T007	C1257868
27451448	2496	2504	isolates	T123	C3494793
27451448	2505	2519	recovered from	T080	C0521108
27451448	2520	2528	diseased	T047	C0012634
27451448	2529	2544	Atlantic salmon	T013	C0327949
27451448	2548	2556	Scotland	T083	C0036453
27451448	2590	2603	rainbow trout	T013	C0036108
27451448	2618	2626	isolates	T123	C3494793
27451448	2640	2647	species	T185	C1705920
27451448	2648	2657	represent	T052	C1882932
27451448	2667	2681	subpopulations	T098	C1257890
27451448	2702	2712	O serotype	T170	C0449549
27451448	2754	2765	significant	T078	C0750502
27451448	2766	2776	proportion	T081	C1709707
27451448	2784	2791	disease	T047	C0012634
27451448	2795	2810	Atlantic salmon	T013	C0327949
27451448	2816	2824	findings	T033	C0243095
27451448	2875	2907	development of improved vaccines	T062	C0597634
27451448	2916	2926	Y. ruckeri	T007	C1257868

28266821|t|Randomized Crossover Trial of Amoxapine Versus Vitamin B12 for Retrograde Ejaculation
28266821|a|To compare the efficacy and safety of amoxapine and vitamin B12 for treating retrograde ejaculation (RE). Between May 2009 and November 2012, this open-label, randomized, crossover study enrolled 26 men suffering with RE at Department of Reproductive Medicine, Omori Hospital. Patients were randomly allocated into two groups (n=13 each). The amoxapine - B12 group received amoxapine (50 mg daily for 4 weeks, orally) followed (after a 1- week washout period) by vitamin B12 (500 μg three-times daily for 4 weeks). The B12 - amoxapine group received the opposite regimen. All pa-tients masturbated to ejaculation at least twice during each treatment period. The primary outcome was antegrade ejaculation of semen, as reported by the patient, on more than one occasion during either treatment period (defined as treatment success). Any adverse events were noted. Success rates were compared between treatments using Fisher's exact test. One patient (B12 - amoxapine group) withdrew for personal reasons (breakdown of marital relations); all other patients completed the study. Overall success rate was 88% (22/25). Success rate was higher for amoxapine than for vitamin B12 (80%, 20/25 vs 16%, 4/25; P<0.0001). 18 patients were responsive to amoxapine but not to vitamin B12, 2 patients were responsive to vitamin B12 but not amoxapine, 2 patients were responsive to both drugs, and 3 patients had no response to either drug. One patient (4%) reported sleepiness and 2 (8%) reported constipation while receiving amoxapine. No adverse events were reported during vitamin B12 treatment. Amoxapine may be an effective, safe and well-tolerated therapy for RE.
28266821	0	10	Randomized	T062	C0034656
28266821	11	26	Crossover Trial	T062	C0150097
28266821	30	39	Amoxapine	T109,T121	C0002644
28266821	47	58	Vitamin B12	T109,T121,T127	C0042845
28266821	63	85	Retrograde Ejaculation	T046	C0403673
28266821	101	109	efficacy	T080	C1280519
28266821	114	120	safety	T068	C0036043
28266821	124	133	amoxapine	T109,T121	C0002644
28266821	138	149	vitamin B12	T109,T121,T127	C0042845
28266821	154	162	treating	T061	C0087111
28266821	163	185	retrograde ejaculation	T046	C0403673
28266821	187	189	RE	T046	C0403673
28266821	200	203	May	T079	C3812381
28266821	213	221	November	T079	C3828767
28266821	233	243	open-label	T062	C1709323
28266821	245	255	randomized	T062	C0034656
28266821	257	272	crossover study	T062	C0150097
28266821	285	288	men	T098	C0025266
28266821	304	306	RE	T046	C0403673
28266821	310	361	Department of Reproductive Medicine, Omori Hospital	T093	C0596660
28266821	363	371	Patients	T101	C0030705
28266821	429	438	amoxapine	T109,T121	C0002644
28266821	441	444	B12	T109,T121,T127	C0042845
28266821	451	459	received	T080	C1514756
28266821	460	469	amoxapine	T109,T121	C0002644
28266821	477	482	daily	T079	C0332173
28266821	489	494	weeks	T079	C0439230
28266821	496	502	orally	T169	C1527415
28266821	525	529	week	T079	C0439230
28266821	530	544	washout period	T079	C1710661
28266821	549	560	vitamin B12	T109,T121,T127	C0042845
28266821	557	560	B12	T109,T121,T127	C0042845
28266821	581	586	daily	T079	C0332173
28266821	593	598	weeks	T079	C0439230
28266821	605	608	B12	T109,T121,T127	C0042845
28266821	611	620	amoxapine	T109,T121	C0002644
28266821	627	635	received	T080	C1514756
28266821	649	656	regimen	T061	C0040808
28266821	662	671	pa-tients	T101	C0030705
28266821	672	683	masturbated	T055	C0024906
28266821	687	698	ejaculation	T040	C0013746
28266821	726	735	treatment	T061	C0087111
28266821	736	742	period	T079	C1948053
28266821	768	777	antegrade	T082	C0589502
28266821	778	789	ejaculation	T040	C0013746
28266821	793	798	semen	T031	C2756969
28266821	819	826	patient	T101	C0030705
28266821	868	877	treatment	T061	C0087111
28266821	878	884	period	T079	C1948053
28266821	897	914	treatment success	T080	C0679864
28266821	921	935	adverse events	T046	C0877248
28266821	948	961	Success rates	T081	C1521828
28266821	984	994	treatments	T061	C0087111
28266821	1001	1020	Fisher's exact test	T170	C1708064
28266821	1026	1033	patient	T101	C0030705
28266821	1035	1038	B12	T109,T121,T127	C0042845
28266821	1041	1050	amoxapine	T109,T121	C0002644
28266821	1102	1119	marital relations	T054	C0024818
28266821	1132	1140	patients	T101	C0030705
28266821	1170	1182	success rate	T081	C1521828
28266821	1200	1212	Success rate	T081	C1521828
28266821	1228	1237	amoxapine	T109,T121	C0002644
28266821	1247	1258	vitamin B12	T109,T121,T127	C0042845
28266821	1299	1307	patients	T101	C0030705
28266821	1313	1323	responsive	T169	C0205342
28266821	1327	1336	amoxapine	T109,T121	C0002644
28266821	1348	1359	vitamin B12	T109,T121,T127	C0042845
28266821	1363	1371	patients	T101	C0030705
28266821	1377	1387	responsive	T169	C0205342
28266821	1391	1402	vitamin B12	T109,T121,T127	C0042845
28266821	1411	1420	amoxapine	T109,T121	C0002644
28266821	1424	1432	patients	T101	C0030705
28266821	1438	1448	responsive	T169	C0205342
28266821	1457	1462	drugs	T061	C3687832
28266821	1470	1478	patients	T101	C0030705
28266821	1483	1494	no response	T033	C4282382
28266821	1505	1509	drug	T061	C3687832
28266821	1515	1522	patient	T101	C0030705
28266821	1537	1547	sleepiness	T033	C0013144
28266821	1568	1580	constipation	T184	C0009806
28266821	1587	1596	receiving	T080	C1514756
28266821	1597	1606	amoxapine	T109,T121	C0002644
28266821	1608	1625	No adverse events	T033	C1963761
28266821	1647	1658	vitamin B12	T109,T121,T127	C0042845
28266821	1659	1668	treatment	T061	C0087111
28266821	1670	1679	Amoxapine	T109,T121	C0002644
28266821	1690	1699	effective	T080	C1704419
28266821	1710	1724	well-tolerated	T033	C0243095
28266821	1725	1732	therapy	T061	C0087111
28266821	1737	1739	RE	T046	C0403673

27426278|t|Prevalence and Self-recognition of Chronic Constipation: Results of an Internet Survey
27426278|a|Although chronic constipation is a common symptom, to date no international consensus has been reached regarding its definition. The aims of this study were (1) to investigate defecation habits and (2) to examine the prevalence of constipation using the Japanese Society of Internal Medicine (JSIM) and the Rome III criteria using an online survey. An online questionnaire composed of items on the frequency, interval, form of defecation, the management, and self-recognition of constipation (reference standard of constipation) was created. A total of 5155 valid responses were received. In addition, constipation symptoms were evaluated through a survey using the JSIM and the Rome III criteria. In the internet survey, 28.4% of the respondents considered themselves to be constipated. Stratified by sex, significantly more females (37.5%) than males (19.1%) considered themselves to be constipated (P < 0.001). The prevalence of constipation among the respondents was 28.0% using the Rome III, but only 10.1% using the JSIM. The diagnostic accuracy was 73.2% for the Rome III and 78.1% for the JSIM, while the diagnostic specificity was 81.1% for the Rome III and 97.5% for the JSIM. However, the diagnostic sensitivities for both measures were low, at 52.2% and 29.2% for the Rome III and the JSIM, respectively. The online survey developed for this study was able to provide clarification regarding defecation patterns. The results also suggest a discrepancy between the self-recognized prevalence of constipation in Japan and prevalence of constipation based on the JSIM criteria.
27426278	0	10	Prevalence	T081	C0033105
27426278	15	31	Self-recognition	T041	C0524637
27426278	35	55	Chronic Constipation	T184	C0401149
27426278	71	86	Internet Survey	T170	C0038951
27426278	96	116	chronic constipation	T184	C0401149
27426278	129	136	symptom	T184	C1457887
27426278	149	162	international	T078	C1512888
27426278	163	172	consensus	T054	C0376298
27426278	233	238	study	T062	C2603343
27426278	251	262	investigate	T169	C1292732
27426278	263	273	defecation	T040	C0011135
27426278	274	280	habits	T055	C0018464
27426278	304	314	prevalence	T081	C0033105
27426278	318	330	constipation	T184	C0009806
27426278	341	378	Japanese Society of Internal Medicine	T093	C1708333
27426278	380	384	JSIM	T093	C1708333
27426278	394	411	Rome III criteria	T170	C0282574
27426278	421	434	online survey	T170	C0038951
27426278	446	459	questionnaire	T170	C0034394
27426278	485	494	frequency	T079	C0439603
27426278	496	504	interval	T079	C1272706
27426278	514	524	defecation	T040	C0011135
27426278	530	540	management	T057	C1273870
27426278	546	562	self-recognition	T041	C0524637
27426278	566	578	constipation	T184	C0009806
27426278	580	598	reference standard	T081	C0034925
27426278	602	614	constipation	T184	C0009806
27426278	651	660	responses	T170	C1706817
27426278	689	701	constipation	T184	C0009806
27426278	702	710	symptoms	T184	C1457887
27426278	716	725	evaluated	T058	C0220825
27426278	736	742	survey	T170	C0038951
27426278	753	757	JSIM	T093	C1708333
27426278	766	783	Rome III criteria	T170	C0282574
27426278	792	807	internet survey	T170	C0038951
27426278	822	833	respondents	T098	C0282122
27426278	862	873	constipated	T184	C0009806
27426278	875	885	Stratified	T080	C0205363
27426278	889	892	sex	T032	C0079399
27426278	913	920	females	T032	C0086287
27426278	934	939	males	T032	C0086582
27426278	976	987	constipated	T184	C0009806
27426278	1005	1015	prevalence	T081	C0033105
27426278	1019	1031	constipation	T184	C0009806
27426278	1042	1053	respondents	T098	C0282122
27426278	1074	1082	Rome III	T170	C0282574
27426278	1109	1113	JSIM	T093	C1708333
27426278	1119	1138	diagnostic accuracy	T080	C0598285
27426278	1157	1165	Rome III	T170	C0282574
27426278	1184	1188	JSIM	T093	C1708333
27426278	1200	1222	diagnostic specificity	T081	C1511884
27426278	1241	1249	Rome III	T170	C0282574
27426278	1268	1272	JSIM	T093	C1708333
27426278	1287	1311	diagnostic sensitivities	T081	C1511883
27426278	1321	1329	measures	T081	C0079809
27426278	1367	1375	Rome III	T170	C0282574
27426278	1384	1388	JSIM	T093	C1708333
27426278	1408	1421	online survey	T170	C0038951
27426278	1441	1446	study	T062	C2603343
27426278	1467	1480	clarification	T052	C2986669
27426278	1491	1501	defecation	T040	C0011135
27426278	1502	1510	patterns	T055	C0018464
27426278	1539	1550	discrepancy	T033	C1290905
27426278	1563	1578	self-recognized	T041	C0524637
27426278	1579	1589	prevalence	T081	C0033105
27426278	1593	1605	constipation	T184	C0009806
27426278	1609	1614	Japan	T083	C0022341
27426278	1619	1629	prevalence	T081	C0033105
27426278	1633	1645	constipation	T184	C0009806
27426278	1659	1663	JSIM	T093	C1708333

27976878|t|Worldwide Occurrence of Mycotoxins in Cereals and Cereal - Derived Food Products: Public Health Perspectives of Their Co-occurrence
27976878|a|Cereal grains and their processed food products are frequently contaminated with mycotoxins. Among many, five major mycotoxins of aflatoxins, ochratoxins, fumonisins, deoxynivalenol, and zearalenone are of significant public health concern as they can cause adverse effects in humans. Being airborne or soilborne, the cosmopolitan nature of mycotoxigenic fungi contribute to the worldwide occurrence of mycotoxins. On the basis of the global occurrence data reported during the past 10 years, the incidences and maximum levels in raw cereal grains were 55% and 1642 μg/kg for aflatoxins, 29% and 1164 μg/kg for ochratoxin A, 61% and 71,121 μg/kg for fumonisins, 58% and 41,157 μg/kg, for deoxynivalenol, and 46% and 3049 μg/kg for zearalenone. The concentrations of mycotoxins tend to be lower in processed food products; the incidences varied depending on the individual mycotoxins, possibly due to the varying stability during processing and distribution of mycotoxins. It should be noted that more than one mycotoxin, produced by a single or several fungal species, may occur in various combinations in a given sample or food. Most studies reported additive or synergistic effects, suggesting that these mixtures may pose a significant threat to public health, particularly to infants and young children. Therefore, information on the co-occurrence of mycotoxins and their interactive toxicity is summarized in this paper.
27976878	0	9	Worldwide	T082	C0332464
27976878	10	20	Occurrence	T079	C2745955
27976878	24	34	Mycotoxins	T109,T131	C0026955
27976878	38	45	Cereals	T168	C0007757
27976878	50	56	Cereal	T168	C0007757
27976878	59	66	Derived	T080	C1441547
27976878	67	80	Food Products	T168	C0681562
27976878	82	88	Public	T092	C0678367
27976878	89	95	Health	T078	C0018684
27976878	96	108	Perspectives	T078	C1254370
27976878	132	145	Cereal grains	T168	C0007757
27976878	156	165	processed	T067	C1522240
27976878	166	179	food products	T168	C0681562
27976878	195	207	contaminated	T169	C0205279
27976878	213	223	mycotoxins	T109,T131	C0026955
27976878	237	241	five	T081	C0205451
27976878	242	247	major	T080	C0205164
27976878	248	258	mycotoxins	T109,T131	C0026955
27976878	262	272	aflatoxins	T109,T131	C0001734
27976878	274	285	ochratoxins	T109,T131	C0028816
27976878	287	297	fumonisins	T109,T131	C0304082
27976878	299	313	deoxynivalenol	T109,T131	C0057445
27976878	319	330	zearalenone	T109,T131	C0043454
27976878	350	356	public	T092	C0678367
27976878	357	363	health	T078	C0018684
27976878	364	371	concern	T078	C2699424
27976878	384	389	cause	T169	C0015127
27976878	390	405	adverse effects	T046	C0879626
27976878	409	415	humans	T016	C0086418
27976878	423	431	airborne	T169	C3242389
27976878	435	444	soilborne	T169	C0205245
27976878	463	469	nature	T080	C0449783
27976878	473	492	mycotoxigenic fungi	T004	C0016832
27976878	511	520	worldwide	T082	C0332464
27976878	521	531	occurrence	T079	C2745955
27976878	535	545	mycotoxins	T109,T131	C0026955
27976878	554	559	basis	T169	C1527178
27976878	567	573	global	T080	C2348867
27976878	574	584	occurrence	T079	C2745955
27976878	585	589	data	T078	C1511726
27976878	590	598	reported	T058	C0700287
27976878	629	639	incidences	T081	C0021149
27976878	644	651	maximum	T081	C0806909
27976878	652	658	levels	T080	C0441889
27976878	662	665	raw	T080	C1709843
27976878	666	679	cereal grains	T168	C0007757
27976878	708	718	aflatoxins	T109,T131	C0001734
27976878	743	755	ochratoxin A	T109,T121	C0069299
27976878	782	792	fumonisins	T109,T131	C0304082
27976878	820	834	deoxynivalenol	T109,T131	C0057445
27976878	863	874	zearalenone	T109,T131	C0043454
27976878	880	894	concentrations	T081	C1446561
27976878	898	908	mycotoxins	T109,T131	C0026955
27976878	920	925	lower	T080	C0205251
27976878	929	938	processed	T067	C1522240
27976878	939	952	food products	T168	C0681562
27976878	958	968	incidences	T081	C0021149
27976878	1004	1014	mycotoxins	T109,T131	C0026955
27976878	1025	1031	due to	T169	C0678226
27976878	1036	1043	varying	T169	C0392747
27976878	1044	1053	stability	T080	C0205360
27976878	1054	1060	during	T079	C0347984
27976878	1061	1071	processing	T057	C0016487
27976878	1076	1088	distribution	T169	C1704711
27976878	1092	1102	mycotoxins	T109,T131	C0026955
27976878	1142	1151	mycotoxin	T109,T131	C0026955
27976878	1153	1161	produced	T169	C0678227
27976878	1167	1173	single	T081	C0205171
27976878	1177	1184	several	T081	C0443302
27976878	1185	1191	fungal	T004	C0016832
27976878	1192	1199	species	T185	C1705920
27976878	1214	1221	various	T081	C0439064
27976878	1222	1234	combinations	T080	C0205195
27976878	1246	1252	sample	T167	C0444315
27976878	1256	1260	food	T168	C0016452
27976878	1267	1274	studies	T062	C2603343
27976878	1275	1283	reported	T058	C0700287
27976878	1284	1292	additive	T080	C0442796
27976878	1296	1307	synergistic	T080	C2986495
27976878	1308	1315	effects	T080	C1280500
27976878	1317	1327	suggesting	T078	C1705535
27976878	1339	1347	mixtures	T167	C0439962
27976878	1359	1370	significant	T078	C0750502
27976878	1371	1377	threat	T078	C0749385
27976878	1381	1387	public	T092	C0678367
27976878	1388	1394	health	T078	C0018684
27976878	1412	1419	infants	T100	C0021270
27976878	1424	1438	young children	T100	C0728836
27976878	1451	1462	information	T078	C1533716
27976878	1487	1497	mycotoxins	T109,T131	C0026955
27976878	1508	1519	interactive	T169	C1704675
27976878	1520	1528	toxicity	T037	C0600688
27976878	1532	1542	summarized	T170	C0242482

27760149|t|BEST: Next-Generation Biomedical Entity Search Tool for Knowledge Discovery from Biomedical Literature
27760149|a|As the volume of publications rapidly increases, searching for relevant information from the literature becomes more challenging. To complement standard search engines such as PubMed, it is desirable to have an advanced search tool that directly returns relevant biomedical entities such as targets, drugs, and mutations rather than a long list of articles. Some existing tools submit a query to PubMed and process retrieved abstracts to extract information at query time, resulting in a slow response time and limited coverage of only a fraction of the PubMed corpus. Other tools preprocess the PubMed corpus to speed up the response time; however, they are not constantly updated, and thus produce outdated results. Further, most existing tools cannot process sophisticated queries such as searches for mutations that co-occur with query terms in the literature. To address these problems, we introduce BEST, a biomedical entity search tool. BEST returns, as a result, a list of 10 different types of biomedical entities including genes, diseases, drugs, targets, transcription factors, miRNAs, and mutations that are relevant to a user's query. To the best of our knowledge, BEST is the only system that processes free text queries and returns up-to-date results in real time including mutation information in the results. BEST is freely accessible at http://best.korea.ac.kr.
27760149	0	4	BEST	T170	C0282574
27760149	6	21	Next-Generation	T079	C1254367
27760149	22	51	Biomedical Entity Search Tool	T170	C0282574
27760149	56	65	Knowledge	T170	C0376554
27760149	66	75	Discovery	T052	C1880355
27760149	81	102	Biomedical Literature	T078	C0025120
27760149	110	116	volume	T080	C1690016
27760149	120	132	publications	T073,T170	C0034036
27760149	133	140	rapidly	T080	C0456962
27760149	141	150	increases	T081	C0205217
27760149	152	161	searching	T052	C1706202
27760149	166	174	relevant	T080	C2347946
27760149	175	186	information	T078	C1533716
27760149	196	206	literature	T170	C0023866
27760149	220	231	challenging	T033	C0243095
27760149	247	255	standard	T080	C1442989
27760149	256	270	search engines	T170	C2348167
27760149	279	285	PubMed	T170	C1138432
27760149	293	302	desirable	T080	C0205556
27760149	314	334	advanced search tool	T170	C2348167
27760149	340	348	directly	T080	C1947931
27760149	349	356	returns	T080	C0332156
27760149	357	365	relevant	T080	C2347946
27760149	366	376	biomedical	T080	C0205556
27760149	377	385	entities	T071	C1551338
27760149	394	401	targets	T074	C0085104
27760149	403	408	drugs	T121	C0013227
27760149	414	423	mutations	T045	C0026882
27760149	466	474	existing	T033	C0243095
27760149	475	480	tools	T170	C0037589
27760149	481	487	submit	T169	C1515023
27760149	490	495	query	T170	C1522634
27760149	499	505	PubMed	T170	C1138432
27760149	510	517	process	T067	C1522240
27760149	528	537	abstracts	T170	C0600678
27760149	549	560	information	T078	C1533716
27760149	564	569	query	T170	C1522634
27760149	570	574	time	T079	C0040223
27760149	576	585	resulting	T169	C1274040
27760149	591	595	slow	T080	C0439834
27760149	605	609	time	T079	C0040223
27760149	614	621	limited	T169	C0439801
27760149	622	630	coverage	T169	C1999244
27760149	641	652	fraction of	T081	C1264633
27760149	657	670	PubMed corpus	T170	C1138432
27760149	678	683	tools	T170	C0037589
27760149	684	694	preprocess	T066	C1882455
27760149	699	712	PubMed corpus	T170	C1138432
27760149	738	742	time	T079	C0040223
27760149	766	776	constantly	T080	C1948059
27760149	777	784	updated	T079	C1519814
27760149	795	802	produce	T169	C0678227
27760149	803	811	outdated	T170	C3645590
27760149	812	819	results	T169	C1274040
27760149	844	849	tools	T170	C0037589
27760149	857	864	process	T067	C1522240
27760149	865	878	sophisticated	T080	C0205556
27760149	879	886	queries	T170	C1522634
27760149	895	903	searches	T052	C1706202
27760149	908	917	mutations	T045	C0026882
27760149	923	931	co-occur	T052	C1709305
27760149	937	942	query	T170	C1522634
27760149	956	966	literature	T170	C0023866
27760149	985	993	problems	T033	C0033213
27760149	998	1007	introduce	T169	C1292748
27760149	1008	1012	BEST	T170	C0282574
27760149	1016	1045	biomedical entity search tool	T170	C0282574
27760149	1047	1051	BEST	T170	C0282574
27760149	1052	1059	returns	T080	C0332156
27760149	1066	1072	result	T169	C1274040
27760149	1087	1096	different	T080	C1705242
27760149	1106	1116	biomedical	T080	C0205556
27760149	1117	1125	entities	T071	C1551338
27760149	1126	1135	including	T169	C0332257
27760149	1136	1141	genes	T028	C0017337
27760149	1143	1151	diseases	T047	C0012634
27760149	1153	1158	drugs	T121	C0013227
27760149	1160	1167	targets	T074	C0085104
27760149	1169	1190	transcription factors	T116,T123	C0040648
27760149	1192	1198	miRNAs	T114,T123	C1101610
27760149	1204	1213	mutations	T045	C0026882
27760149	1223	1231	relevant	T080	C2347946
27760149	1244	1249	query	T170	C1522634
27760149	1270	1279	knowledge	T170	C0376554
27760149	1281	1285	BEST	T170	C0282574
27760149	1298	1304	system	T169	C0449913
27760149	1310	1319	processes	T067	C1522240
27760149	1325	1329	text	T170	C1527021
27760149	1330	1337	queries	T170	C1522634
27760149	1342	1349	returns	T080	C0332156
27760149	1350	1360	up-to-date	T033	C0243095
27760149	1361	1368	results	T169	C1274040
27760149	1372	1381	real time	T079	C1550177
27760149	1382	1391	including	T169	C0332257
27760149	1392	1400	mutation	T045	C0026882
27760149	1401	1412	information	T078	C1533716
27760149	1420	1427	results	T169	C1274040
27760149	1429	1433	BEST	T170	C0282574

28540536|t|Effects of robot-assisted upper limb rehabilitation in stroke patients: a systematic review with meta-analysis
28540536|a|Technology-supported training is emerging as a solution to support therapists in their efforts providing high-intensity, repetitive, and task-specific treatment, in order to enhance the recovery process. The aim of this review is to assess the effectiveness of different robotic devices (end-effector and exoskeleton robots) in comparison with any other type of intervention. Furthermore, we aim to assess whether or not better improvements are obtained in the sub-acute phase after stroke onset than in the chronic phase. A research was conducted in the electronic bibliographic databases Cochrane, MEDLINE, and EMBASE. A total of 17 studies were included: 14 randomized controlled trials, 2 systematic reviews, and one meta-analysis. Fugl-Meyer and modified Ashworth scale were selected to measure primary outcomes, i.e., motor function and muscle tone. Functional independence measure and motor activity log were selected to measure secondary outcomes, i.e., activities of daily living. In comparison with conventional therapy, the robot-assisted rehabilitation is more effective in improving upper limb motor function recovery, especially in chronic stroke patients. No significant improvements are observed in the reduction of muscle tone or daily living activities. The present systematic review shows that the use of robotic devices can positively affect the recovery of arm function in patients with stroke.
28540536	11	51	robot-assisted upper limb rehabilitation	T061	C0034991
28540536	55	61	stroke	T047	C0038454
28540536	62	70	patients	T101	C0030705
28540536	74	91	systematic review	T170	C1955832
28540536	97	110	meta-analysis	T170	C0282458
28540536	111	140	Technology-supported training	T065	C0220931
28540536	178	188	therapists	T097	C0871525
28540536	216	230	high-intensity	T185	C4081854
28540536	232	242	repetitive	T169	C0205341
28540536	248	271	task-specific treatment	T061	C0087111
28540536	297	313	recovery process	T040	C2004454
28540536	355	368	effectiveness	T080	C1280519
28540536	382	397	robotic devices	T073	C0336537
28540536	399	411	end-effector	T073	C0336537
28540536	416	434	exoskeleton robots	T073	C0336537
28540536	439	449	comparison	T052	C1707455
28540536	473	485	intervention	T061	C0184661
28540536	572	587	sub-acute phase	T079	C0205390
28540536	594	600	stroke	T047	C0038454
28540536	601	606	onset	T080	C0332162
28540536	619	632	chronic phase	T079	C0457343
28540536	636	644	research	T062	C0035168
28540536	666	700	electronic bibliographic databases	T170	C0242356
28540536	701	709	Cochrane	T170	C0242356
28540536	711	718	MEDLINE	T170	C0025141
28540536	724	730	EMBASE	T170	C0282574
28540536	746	753	studies	T062	C2603343
28540536	772	800	randomized controlled trials	T062	C0206035
28540536	804	822	systematic reviews	T170	C1955832
28540536	832	845	meta-analysis	T170	C0282458
28540536	862	885	modified Ashworth scale	T170	C0451002
28540536	911	927	primary outcomes	T169	C1274040
28540536	935	949	motor function	T038	C0234130
28540536	954	965	muscle tone	T042	C0026841
28540536	967	998	Functional independence measure	T170	C0451172
28540536	1003	1021	motor activity log	T081	C2986775
28540536	1047	1065	secondary outcomes	T169	C1274040
28540536	1073	1099	activities of daily living	T056	C0001288
28540536	1104	1114	comparison	T052	C1707455
28540536	1120	1140	conventional therapy	T061	C2945704
28540536	1146	1175	robot-assisted rehabilitation	T061	C0034991
28540536	1197	1206	improving	T077	C2986411
28540536	1207	1217	upper limb	T023	C1140618
28540536	1218	1232	motor function	T038	C0234130
28540536	1233	1241	recovery	T040	C2004454
28540536	1257	1271	chronic stroke	T047	C3536593
28540536	1272	1280	patients	T101	C0030705
28540536	1343	1354	muscle tone	T042	C0026841
28540536	1358	1381	daily living activities	T056	C0001288
28540536	1395	1412	systematic review	T170	C1955832
28540536	1435	1450	robotic devices	T073	C0336537
28540536	1477	1485	recovery	T040	C2004454
28540536	1489	1501	arm function	T038	C3714634
28540536	1505	1513	patients	T101	C0030705
28540536	1519	1525	stroke	T047	C0038454

27550556|t|Examining the relationship between home literacy environment and neural correlates of phonological processing in beginning readers with and without a familial risk for dyslexia: an fMRI study
27550556|a|Developmental dyslexia is a language - based learning disability characterized by persistent difficulty in learning to read. While an understanding of genetic contributions is emerging, the ways the environment affects brain functioning in children with developmental dyslexia are poorly understood. A relationship between the home literacy environment (HLE) and neural correlates of reading has been identified in typically developing children, yet it remains unclear whether similar effects are observable in children with a genetic predisposition for dyslexia. Understanding environmental contributions is important given that we do not understand why some genetically at-risk children do not develop dyslexia. Here, we investigate for the first time the relationship between HLE and the neural correlates of phonological processing in beginning readers with (FHD+, n = 29) and without (FHD-, n = 21) a family history of developmental dyslexia. We further controlled for socioeconomic status to isolate the neurobiological mechanism by which HLE affects reading development. Group differences revealed stronger correlation of HLE with brain activation in the left inferior / middle frontal and right fusiform gyri in FHD- compared to FHD+ children, suggesting greater impact of HLE on manipulation of phonological codes and recruitment of orthographic representations in typically developing children. In contrast, activation in the right precentral gyrus showed a significantly stronger correlation with HLE in FHD+ compared to FHD- children, suggesting emerging compensatory networks in genetically at-risk children. Overall, our results suggest that genetic predisposition for dyslexia alters contributions of HLE to early reading skills before formal reading instruction, which has important implications for educational practice and intervention models.
27550556	14	26	relationship	T080	C0439849
27550556	27	34	between	T082	C0205103
27550556	40	48	literacy	T169	C0023864
27550556	49	60	environment	T082	C0014406
27550556	65	71	neural	T169	C3714606
27550556	72	82	correlates	T080	C1707520
27550556	86	109	phonological processing	T041	C1510627
27550556	113	122	beginning	T079	C0439659
27550556	123	130	readers	UnknownType	C0681860
27550556	150	163	familial risk	T080	C0686731
27550556	168	176	dyslexia	T048	C0476254
27550556	181	191	fMRI study	T060	C3515983
27550556	192	214	Developmental dyslexia	T048	C0920296
27550556	220	228	language	T171	C0023008
27550556	231	236	based	T169	C1527178
27550556	237	256	learning disability	T048	C0751265
27550556	257	270	characterized	T052	C1880022
27550556	285	295	difficulty	T080	C0332218
27550556	299	315	learning to read	T041	C2371288
27550556	326	339	understanding	T041	C0162340
27550556	343	350	genetic	T169	C0314603
27550556	351	364	contributions	T052	C1880177
27550556	391	402	environment	T082	C0014406
27550556	403	410	affects	T041	C0001721
27550556	411	428	brain functioning	T042	C0678908
27550556	432	440	children	T100	C0008059
27550556	446	468	developmental dyslexia	T048	C0920296
27550556	473	479	poorly	T080	C0205169
27550556	480	490	understood	T041	C0162340
27550556	494	506	relationship	T080	C0439849
27550556	507	514	between	T082	C0205103
27550556	519	544	home literacy environment	T082	C0442519
27550556	546	549	HLE	T082	C0442519
27550556	555	561	neural	T169	C3714606
27550556	562	572	correlates	T080	C1707520
27550556	576	583	reading	T056	C0034754
27550556	593	603	identified	T080	C0205396
27550556	607	616	typically	T080	C3538928
27550556	617	627	developing	T067	C0870861
27550556	628	636	children	T100	C0008059
27550556	653	660	unclear	T033	C3845108
27550556	669	676	similar	T080	C2348205
27550556	677	684	effects	T080	C1280500
27550556	689	699	observable	T169	C1441672
27550556	703	711	children	T100	C0008059
27550556	719	741	genetic predisposition	T032	C0314657
27550556	746	754	dyslexia	T048	C0476254
27550556	756	769	Understanding	T041	C0162340
27550556	770	783	environmental	T082	C0014406
27550556	784	797	contributions	T052	C1880177
27550556	801	810	important	T080	C3898777
27550556	825	831	do not	T033	C3840725
27550556	832	842	understand	T041	C0162340
27550556	852	863	genetically	T169	C0314603
27550556	864	871	at-risk	T080	C1444641
27550556	872	880	children	T100	C0008059
27550556	881	887	do not	T033	C3840725
27550556	896	904	dyslexia	T048	C0476254
27550556	915	926	investigate	T169	C1292732
27550556	950	962	relationship	T080	C0439849
27550556	963	970	between	T082	C0205103
27550556	971	974	HLE	T082	C0442519
27550556	983	989	neural	T169	C3714606
27550556	990	1000	correlates	T080	C1707520
27550556	1004	1027	phonological processing	T041	C1510627
27550556	1031	1040	beginning	T079	C0439659
27550556	1041	1048	readers	UnknownType	C0681860
27550556	1055	1059	FHD+	T033	C1272269
27550556	1082	1086	FHD-	T033	C1513916
27550556	1098	1138	family history of developmental dyslexia	T033	C1272269
27550556	1166	1186	socioeconomic status	T080	C0086996
27550556	1190	1197	isolate	T169	C0205409
27550556	1202	1217	neurobiological	T080	C0205494
27550556	1218	1227	mechanism	T169	C0441712
27550556	1237	1240	HLE	T082	C0442519
27550556	1241	1248	affects	T041	C0001721
27550556	1249	1268	reading development	T041	C0871997
27550556	1270	1275	Group	UnknownType	C0681860
27550556	1276	1287	differences	T054	C0021228
27550556	1288	1296	revealed	T080	C0443289
27550556	1297	1305	stronger	T080	C0442821
27550556	1306	1317	correlation	T080	C1707520
27550556	1321	1324	HLE	T082	C0442519
27550556	1330	1335	brain	T023	C0006104
27550556	1336	1346	activation	T052	C1879547
27550556	1354	1367	left inferior	T023	C2327613
27550556	1370	1384	middle frontal	T023	C0152297
27550556	1389	1408	right fusiform gyri	T023	C2338890
27550556	1412	1416	FHD-	T033	C1513916
27550556	1417	1425	compared	T052	C1707455
27550556	1429	1433	FHD+	T033	C1272269
27550556	1434	1442	children	T100	C0008059
27550556	1455	1462	greater	T081	C1704243
27550556	1463	1469	impact	T080	C4049986
27550556	1473	1476	HLE	T082	C0442519
27550556	1480	1492	manipulation	T053	C0018578
27550556	1496	1514	phonological codes	T170	C0282574
27550556	1534	1562	orthographic representations	T170	C0282574
27550556	1566	1575	typically	T080	C3538928
27550556	1576	1586	developing	T067	C0870861
27550556	1587	1595	children	T100	C0008059
27550556	1610	1620	activation	T052	C1879547
27550556	1628	1650	right precentral gyrus	T023	C2331927
27550556	1660	1682	significantly stronger	T081	C4055637
27550556	1683	1694	correlation	T080	C1707520
27550556	1700	1703	HLE	T082	C0442519
27550556	1707	1711	FHD+	T033	C1272269
27550556	1712	1720	compared	T052	C1707455
27550556	1724	1728	FHD-	T033	C1513916
27550556	1729	1737	children	T100	C0008059
27550556	1759	1771	compensatory	T169	C0231186
27550556	1772	1780	networks	T169	C1882071
27550556	1784	1795	genetically	T169	C0314603
27550556	1796	1803	at-risk	T080	C1444641
27550556	1804	1812	children	T100	C0008059
27550556	1827	1834	results	T169	C1274040
27550556	1835	1842	suggest	T078	C1705535
27550556	1848	1870	genetic predisposition	T032	C0314657
27550556	1875	1883	dyslexia	T048	C0476254
27550556	1884	1890	alters	T169	C0392747
27550556	1891	1904	contributions	T052	C1880177
27550556	1908	1911	HLE	T082	C0442519
27550556	1921	1935	reading skills	T080	C0871220
27550556	1943	1949	formal	T080	C0205307
27550556	1950	1957	reading	T056	C0034754
27550556	1958	1969	instruction	T170	C1442085
27550556	2008	2028	educational practice	T062,T170	C0162587
27550556	2033	2052	intervention models	T170	C3161035

27801735|t|Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study
27801735|a|Blockade of inhibitory immune checkpoints is currently arising as a potential immunologic option for tumor therapy. Inhibition of programmed cell death protein 1 and/or its specific ligand programmed death-ligand 1 (PD-L1) was effective in clinical trials in advanced melanoma, non-small cell lung cancer (NSCLC) bladder and kidney cancer. The predictive role of the immunohistochemical (IHC) expression of PD-L1 is highly debated. Different reagents, clones, cutoffs of cell expression and subjective interpretation of PD-L1 immunoreactivity in epithelial cells and lymphocytes are the main issue. In this study we selected 58 consecutive NSCLC surgical specimens that underwent pathologic examination from January 2014 to July 2015. Using a tissue microarray approach we evaluated the IHC expression of PD-L1 in tumor-infiltrating lymphocytes and tumor cells (TCs) and compared the ICH staining with tumor histology, grade and the age of the tissue blocks. The main new finding was the fading of PD-L1 IHC expression in TCs in tissues processed in 2014 compared with 2015. PD-L1 expression in tumor-infiltrating lymphocytes in the 2 years was similar. We also found a significant higher immunoreactivity of TCs in high grade NSCLC and in the squamous carcinoma histotype compared with low grade tumors and the adenocarcinoma histology (P=0.013). We demonstrated that the IHC evaluation of PD-L1 in NSCLC archival tissues is feasible and can be implemented in a routine pathology setting, but it should be carefully assessed in tissue blocks older than 1 year.
27801735	0	6	Fading	T081	C0205216
27801735	7	16	With Time	T079	C0332311
27801735	20	25	PD-L1	T129	C4300350
27801735	26	42	Immunoreactivity	T044	C0597879
27801735	46	73	Non-Small Cells Lung Cancer	T191	C0007131
27801735	74	81	Tissues	T024	C0040300
27801735	85	105	Methodological Study	T057	C0025662
27801735	106	114	Blockade	T169	C0332206
27801735	118	147	inhibitory immune checkpoints	T043	C1155874
27801735	184	195	immunologic	T169	C0205470
27801735	196	202	option	T169	C1518601
27801735	207	220	tumor therapy	T061	C0920425
27801735	222	232	Inhibition	T052	C3463820
27801735	236	267	programmed cell death protein 1	T116,T129,T192	C2986635
27801735	288	294	ligand	T103	C0023688
27801735	295	320	programmed death-ligand 1	T129	C4300350
27801735	322	327	PD-L1	T129	C4300350
27801735	346	361	clinical trials	T062	C0008976
27801735	365	373	advanced	T080	C0205179
27801735	374	382	melanoma	T191	C0025202
27801735	384	410	non-small cell lung cancer	T191	C0007131
27801735	412	417	NSCLC	T191	C0007131
27801735	419	426	bladder	T191	C0005695
27801735	431	444	kidney cancer	T191	C1378703
27801735	473	492	immunohistochemical	T059	C1441616
27801735	494	497	IHC	T059	C1441616
27801735	499	509	expression	T045	C1171362
27801735	513	518	PD-L1	T129	C4300350
27801735	548	556	reagents	T130	C0034760
27801735	558	564	clones	T024	C1522642
27801735	577	581	cell	T025	C0007634
27801735	582	592	expression	T045	C1171362
27801735	597	607	subjective	T080	C0439655
27801735	608	622	interpretation	T033	C0438231
27801735	626	631	PD-L1	T129	C4300350
27801735	632	648	immunoreactivity	T044	C0597879
27801735	652	668	epithelial cells	T025	C0014597
27801735	673	684	lymphocytes	T025	C0024264
27801735	698	703	issue	T033	C0033213
27801735	746	751	NSCLC	T191	C0007131
27801735	752	770	surgical specimens	T024	C1292533
27801735	786	808	pathologic examination	T060	C4086729
27801735	814	821	January	T080	C3829466
27801735	830	834	July	T080	C3829447
27801735	856	875	microarray approach	T059	C1449575
27801735	893	907	IHC expression	T059	C1441616
27801735	911	916	PD-L1	T129	C4300350
27801735	920	950	tumor-infiltrating lymphocytes	T025	C0079722
27801735	955	966	tumor cells	T025	C0597032
27801735	968	971	TCs	T025	C0597032
27801735	990	1002	ICH staining	T059	C1441616
27801735	1008	1023	tumor histology	T091	C1516204
27801735	1025	1030	grade	T185	C0919553
27801735	1050	1063	tissue blocks	T024	C0040300
27801735	1078	1085	finding	T033	C0243095
27801735	1094	1100	fading	T081	C0205216
27801735	1104	1109	PD-L1	T129	C4300350
27801735	1110	1124	IHC expression	T059	C1441616
27801735	1128	1131	TCs	T025	C0597032
27801735	1135	1142	tissues	T024	C0040300
27801735	1181	1186	PD-L1	T129	C4300350
27801735	1187	1197	expression	T045	C0017262
27801735	1201	1231	tumor-infiltrating lymphocytes	T025	C0079722
27801735	1241	1246	years	T079	C0439234
27801735	1251	1258	similar	T080	C2348205
27801735	1276	1294	significant higher	T080	C1299395
27801735	1295	1311	immunoreactivity	T044	C0597879
27801735	1315	1318	TCs	T025	C0597032
27801735	1322	1332	high grade	T080	C0205082
27801735	1333	1338	NSCLC	T191	C0007131
27801735	1350	1368	squamous carcinoma	T191	C0007137
27801735	1369	1378	histotype	T201	C0449574
27801735	1393	1402	low grade	T080	C1282907
27801735	1403	1409	tumors	T091	C0019638
27801735	1418	1432	adenocarcinoma	T191	C0001418
27801735	1433	1442	histology	T091	C0019638
27801735	1479	1493	IHC evaluation	T059	C1441616
27801735	1497	1502	PD-L1	T129	C4300350
27801735	1506	1511	NSCLC	T191	C0007131
27801735	1512	1528	archival tissues	T024	C0040300
27801735	1577	1594	pathology setting	T091	C0030664
27801735	1635	1648	tissue blocks	T024	C0040300
27801735	1662	1666	year	T079	C0439234

28509710|t|Ultrasound-guided pericardiocentesis: a novel parasternal approach
28509710|a|The aim of this study was to evaluate a novel pericardiocentesis technique using an in-plane parasternal medial -to- lateral approach with the use of a high-frequency probe in patients with cardiac tamponade. Echocardiography is pivotal in the diagnosis of pericardial effusion and tamponade physiology. Ultrasound guidance for pericardiocentesis is currently considered the standard of care. Several approaches have been described recently, which differ mainly on the site of puncture (subxiphoid, apical, or parasternal). Although they share the use of low-frequency probes, there is absence of complete control of needle trajectory and real-time needle visualization. An in-plane and real-time technique has only been described anecdotally. A retrospective analysis of 11 patients (63% men, mean age: 37.7±21.2 years) presenting with cardiac tamponade admitted to the tertiary-care emergency department and treated with parasternal medial-to-lateral in-plane pericardiocentesis was carried out. The underlying causes of cardiac tamponade were different among the population. All the pericardiocentesis were successfully performed in the emergency department, without complications, relieving the hemodynamic instability. The mean time taken to perform the eight- step procedure was 309±76.4 s, with no procedure-related complications. The parasternal medial-to-lateral in-plane pericardiocentesis is a new technique theoretically free of complications and it enables real-time monitoring of needle trajectory. For the first time, a pericardiocentesis approach with a medial-to-lateral needle trajectory and real-time, in-plane, needle visualization was performed in a tamponade patient population .This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/.
28509710	0	17	Ultrasound-guided	T060	C0442973
28509710	18	36	pericardiocentesis	T060	C0397466
28509710	46	57	parasternal	T082	C0442146
28509710	58	66	approach	T169	C1292724
28509710	83	88	study	T062	C2603343
28509710	96	104	evaluate	T058	C0220825
28509710	113	131	pericardiocentesis	T060	C0397466
28509710	132	141	technique	T169	C0449851
28509710	151	159	in-plane	T082	C1254362
28509710	160	171	parasternal	T082	C0442146
28509710	172	178	medial	T082	C0205098
28509710	184	191	lateral	T082	C0205093
28509710	192	200	approach	T169	C1292724
28509710	210	216	use of	T169	C1524063
28509710	219	233	high-frequency	T079	C0205212
28509710	234	239	probe	T074	C0182400
28509710	243	251	patients	T101	C0030705
28509710	257	274	cardiac tamponade	T047	C0007177
28509710	276	292	Echocardiography	T060	C0013516
28509710	311	320	diagnosis	T033	C0011900
28509710	324	344	pericardial effusion	T047	C0031039
28509710	349	358	tamponade	T047	C0007177
28509710	359	369	physiology	T039	C0031843
28509710	371	390	Ultrasound guidance	T060	C0442973
28509710	395	413	pericardiocentesis	T060	C0397466
28509710	442	458	standard of care	T061	C2936643
28509710	468	478	approaches	T169	C1292724
28509710	536	540	site	T082	C0205145
28509710	544	552	puncture	T037	C0033119
28509710	554	564	subxiphoid	T082	C4039027
28509710	566	572	apical	T082	C0205111
28509710	577	588	parasternal	T082	C0442146
28509710	615	621	use of	T169	C1524063
28509710	622	635	low-frequency	T079	C0205213
28509710	636	642	probes	T074	C0182400
28509710	664	672	complete	T080	C0205197
28509710	673	680	control	T080	C0243148
28509710	684	690	needle	T074	C0027551
28509710	691	701	trajectory	T082	C1254362
28509710	706	715	real-time	T079	C1550177
28509710	716	722	needle	T074	C0027551
28509710	723	736	visualization	T060	C0178707
28509710	741	749	in-plane	T082	C1254362
28509710	754	763	real-time	T079	C1550177
28509710	764	773	technique	T169	C0449851
28509710	813	835	retrospective analysis	T062	C0035363
28509710	842	850	patients	T101	C0030705
28509710	856	859	men	T098	C0025266
28509710	866	869	age	T032	C0001779
28509710	881	886	years	T079	C1510829
28509710	904	921	cardiac tamponade	T047	C0007177
28509710	922	930	admitted	T058	C0184666
28509710	938	951	tertiary-care	T058	C3494403
28509710	952	972	emergency department	T058	C0374899
28509710	977	984	treated	T169	C1522326
28509710	990	1001	parasternal	T082	C0442146
28509710	1002	1028	medial-to-lateral in-plane	T082	C1302283
28509710	1029	1047	pericardiocentesis	T060	C0397466
28509710	1080	1086	causes	T169	C0015127
28509710	1090	1107	cardiac tamponade	T047	C0007177
28509710	1133	1143	population	T098	C1257890
28509710	1153	1171	pericardiocentesis	T060	C0397466
28509710	1207	1227	emergency department	T058	C0374899
28509710	1229	1250	without complications	T033	C4032686
28509710	1266	1289	hemodynamic instability	T047	C0948268
28509710	1300	1304	time	T079	C0040223
28509710	1333	1337	step	T077	C1261552
28509710	1338	1347	procedure	T169	C2700391
28509710	1369	1403	no procedure-related complications	T033	C4032686
28509710	1409	1420	parasternal	T082	C0442146
28509710	1421	1447	medial-to-lateral in-plane	T082	C1302283
28509710	1448	1466	pericardiocentesis	T060	C0397466
28509710	1476	1485	technique	T169	C0449851
28509710	1500	1521	free of complications	T033	C4032686
28509710	1537	1546	real-time	T079	C1550177
28509710	1547	1557	monitoring	T058	C1283169
28509710	1561	1567	needle	T074	C0027551
28509710	1568	1578	trajectory	T082	C1254362
28509710	1602	1620	pericardiocentesis	T060	C0397466
28509710	1621	1629	approach	T082	C0449445
28509710	1637	1654	medial-to-lateral	T082	C1302283
28509710	1655	1661	needle	T074	C0027551
28509710	1662	1672	trajectory	T082	C1254362
28509710	1677	1686	real-time	T079	C1550177
28509710	1688	1696	in-plane	T082	C1254362
28509710	1698	1704	needle	T074	C0027551
28509710	1705	1718	visualization	T060	C0178707
28509710	1738	1747	tamponade	T047	C0007177
28509710	1748	1766	patient population	T101	C0030705

28473015|t|MESOTHELIAL CELL ADHERENCE TO VASCULAR PROSTHESES AND THEIR SUBSEQUENT GROWTH IN VITRO
28473015|a|Cell seeding may decrease the thrombogenicity of implanted vascular grafts, but its application is hampered by the limited availability of autologous endothelial cells. Human peritoneal mesothelial cells have blood flow supporting qualities and are readily available. This study investigated the adherence of mesothelial cells to vascular prostheses and their subsequent growth in vitro. Circular pieces of various vascular prosthetic materials were seeded with 51Chromium-labeled mesothelial and endothelial cells and left for either 5, 15, 30, 60, and 120 minutes. The unattached cells were removed and the degree of cell attachment was measured. The number of mesothelial cells to Dacron increased during the first 60 min up to 35.2 % of the seeded inoculum where after a plateau was reached. Scanning electron microscopy showed spreaded mesothelial cells adherent to the Dacron fibers. A significant increase in adherence was observed after preincubation of Dacron with 10 μg/mL fibronectin, but no improvement was found after preincubation with human serum albumin or gelatin. Mesothelial cells adhered better to Gelcoated than to Gelsealed or plain Dacron. The adherence of mesothelial cells to ePTFE (Teflon) was significantly poorer. No significant differences in adherence were found between mesothelial and endothelial cells. Mesothelial cell growth on Dacron resulted in a modest increase in the number of viable cells during 27 days, which implies biocompatibility of Dacron and mesothelial cells in vitro.
28473015	0	16	MESOTHELIAL CELL	T025	C0225335
28473015	17	26	ADHERENCE	T169	C0334154
28473015	30	49	VASCULAR PROSTHESES	T074	C0005846
28473015	60	70	SUBSEQUENT	T079	C0332282
28473015	71	77	GROWTH	T040	C0018270
28473015	78	86	IN VITRO	T080	C1533691
28473015	87	91	Cell	T025	C0007634
28473015	92	99	seeding	T059	C1705192
28473015	104	112	decrease	T081	C0547047
28473015	117	132	thrombogenicity	T046	C0040053
28473015	136	145	implanted	T074	C0021102
28473015	146	161	vascular grafts	T074	C0879126
28473015	210	225	availability of	T169	C0470187
28473015	226	236	autologous	T080	C0439859
28473015	237	254	endothelial cells	T025	C0225336
28473015	256	261	Human	T016	C0086418
28473015	262	272	peritoneal	T029	C0442034
28473015	273	290	mesothelial cells	T025	C0225335
28473015	296	306	blood flow	T039	C0232338
28473015	307	327	supporting qualities	T080	C0332306
28473015	336	353	readily available	T169	C0470187
28473015	366	378	investigated	T169	C1292732
28473015	383	392	adherence	T169	C0334154
28473015	396	413	mesothelial cells	T025	C0225335
28473015	417	436	vascular prostheses	T074	C0005846
28473015	447	457	subsequent	T079	C0332282
28473015	458	464	growth	T040	C0018270
28473015	465	473	in vitro	T080	C1533691
28473015	475	483	Circular	T082	C1282913
28473015	484	490	pieces	T081	C2982836
28473015	502	510	vascular	T080	C1801960
28473015	511	531	prosthetic materials	T122	C0444752
28473015	537	543	seeded	T059	C1705192
28473015	549	567	51Chromium-labeled	T121,T130,T196	C0303212
28473015	568	579	mesothelial	T025	C0225335
28473015	584	601	endothelial cells	T025	C0225336
28473015	645	652	minutes	T079	C0439232
28473015	658	668	unattached	T033	C3841381
28473015	669	674	cells	T025	C0007634
28473015	680	687	removed	T080	C0849355
28473015	696	702	degree	T081	C0449286
28473015	706	710	cell	T025	C0007634
28473015	711	721	attachment	T052	C1947904
28473015	726	734	measured	T080	C0444706
28473015	740	746	number	T081	C0237753
28473015	750	767	mesothelial cells	T025	C0225335
28473015	771	777	Dacron	T109,T122	C0947693
28473015	778	787	increased	T081	C0205217
28473015	808	811	min	T079	C0439232
28473015	832	838	seeded	T059	C1705192
28473015	839	847	inoculum	T167	C0439861
28473015	862	869	plateau	T081	C2964353
28473015	874	881	reached	T033	C0243095
28473015	883	911	Scanning electron microscopy	T059	C0026020
28473015	919	927	spreaded	T080	C0332261
28473015	928	945	mesothelial cells	T025	C0225335
28473015	946	954	adherent	T169	C0334154
28473015	962	975	Dacron fibers	T109,T122	C0947693
28473015	979	990	significant	T078	C0750502
28473015	991	999	increase	T169	C0442805
28473015	1003	1012	adherence	T169	C0334154
28473015	1017	1025	observed	T169	C1441672
28473015	1032	1045	preincubation	T059	C0022885
28473015	1049	1055	Dacron	T109,T122	C0947693
28473015	1070	1081	fibronectin	T116,T123	C0016055
28473015	1087	1101	no improvement	T033	C3844714
28473015	1106	1111	found	T033	C0150312
28473015	1118	1131	preincubation	T059	C0022885
28473015	1137	1142	human	T016	C0086418
28473015	1143	1156	serum albumin	T116	C0036773
28473015	1160	1167	gelatin	T116,T121,T122	C0017237
28473015	1169	1186	Mesothelial cells	T025	C0225335
28473015	1187	1194	adhered	T067	C3714578
28473015	1205	1214	Gelcoated	T080	C1522408
28473015	1223	1232	Gelsealed	T080	C0205556
28473015	1236	1248	plain Dacron	T109,T122	C0947693
28473015	1254	1263	adherence	T169	C0334154
28473015	1267	1284	mesothelial cells	T025	C0225335
28473015	1288	1293	ePTFE	T109,T122	C0015312
28473015	1295	1301	Teflon	T109,T122	C0699518
28473015	1307	1320	significantly	T078	C0750502
28473015	1321	1327	poorer	T080	C2700379
28473015	1329	1343	No significant	T033	C1273937
28473015	1344	1355	differences	T080	C1705242
28473015	1359	1368	adherence	T169	C0334154
28473015	1374	1379	found	T033	C0150312
28473015	1388	1399	mesothelial	T025	C0225335
28473015	1404	1421	endothelial cells	T025	C0225336
28473015	1423	1439	Mesothelial cell	T025	C0225335
28473015	1440	1446	growth	T040	C0018270
28473015	1450	1456	Dacron	T109,T122	C0947693
28473015	1457	1465	resulted	T169	C1274040
28473015	1471	1486	modest increase	T169	C0442805
28473015	1494	1500	number	T081	C0237753
28473015	1504	1516	viable cells	T025	C1441322
28473015	1527	1531	days	T079	C0439228
28473015	1547	1563	biocompatibility	T044	C0596177
28473015	1567	1573	Dacron	T109,T122	C0947693
28473015	1578	1595	mesothelial cells	T025	C0225335
28473015	1596	1604	in vitro	T080	C1533691

27395784|t|Lateral hypothalamus orexinergic system modulates the stress effect on pentylenetetrazol induced seizures through corticotropin releasing hormone receptor type 1
27395784|a|Stress is a trigger factor for seizure initiation which activates hypothalamic pituitary adrenal (HPA) axis as well other brain areas. In this respect, corticotropin releasing hormone (CRH) and lateral hypothalamus (LH) orexinergic system are involved in seizure occurrence. In this study, we investigated the role of LH area and orexin expression in (mediation of) stress effect on pentylenetetrazol (PTZ) - induced seizures with hippocampal involvement. Two mild foot shock stresses were applied to intact and adrenalectomized animals; with or without CRHr1 blocking (NBI 27914) in the LH area. Then, changes in orexin production were evaluated by RT-PCR. Intravenous PTZ infusion (25 mg/ml) - induced convulsions were scored upon modified Racine scale. Finally, hippocampal glutamate and GABA were evaluated to study excitability changes. We demonstrated that the duration and severity of convulsions in stress - induced as well as adrenalectomized group were increased. Plasma corticosterone (CRT) level and orexin mRNA expression were built up in the stress and/or seizure groups. Furthermore, glutamate and GABA content was increased and decreased respectively due to stress and seizures. In contrast, rats receiving CRHr1 inhibitor showed reduced severity and duration of seizures, increased GABA, decreased glutamate and corticosterone and also orexin mRNA compared to the inhibitor free rats. Stress and adrenalectomy induced augmenting effect on seizure severity and duration and the subsequent reduction due to CRHr1 blocking with parallel orexin mRNA changes, indicated the likely involvement of CRH1r induced orexin expression of the LH in gating stress effect on convulsions.
27395784	0	39	Lateral hypothalamus orexinergic system	T022	C0460002
27395784	40	49	modulates	T082	C0443264
27395784	54	60	stress	T046	C0449430
27395784	61	67	effect	T080	C1280500
27395784	71	88	pentylenetetrazol	T109,T121	C0030903
27395784	89	96	induced	T169	C0205263
27395784	97	105	seizures	T184	C0036572
27395784	114	161	corticotropin releasing hormone receptor type 1	T116,T192	C0529997
27395784	162	168	Stress	T046	C0449430
27395784	174	200	trigger factor for seizure	T201	C1303052
27395784	201	211	initiation	T169	C1704686
27395784	218	227	activates	T052	C1879547
27395784	228	269	hypothalamic pituitary adrenal (HPA) axis	T022	C0597719
27395784	260	263	HPA	T022	C0597719
27395784	284	289	brain	T023	C0006104
27395784	290	295	areas	T082	C0205146
27395784	314	345	corticotropin releasing hormone	T116,T121,T125	C0010132
27395784	346	351	(CRH)	T116,T121,T125	C0010132
27395784	356	376	lateral hypothalamus	T029	C0020654
27395784	356	400	lateral hypothalamus (LH) orexinergic system	T022	C0460002
27395784	378	380	LH	T029	C0020654
27395784	405	413	involved	T169	C1314939
27395784	417	424	seizure	T184	C0036572
27395784	425	435	occurrence	T079	C2745955
27395784	445	450	study	T062	C2603343
27395784	455	467	investigated	T169	C1292732
27395784	472	476	role	T169	C0542341
27395784	480	487	LH area	T029	C0020654
27395784	492	498	orexin	T116,T123	C1113688
27395784	499	509	expression	T045	C1171362
27395784	514	523	mediation	UnknownType	C0814912
27395784	528	534	stress	T046	C0449430
27395784	535	541	effect	T080	C1280500
27395784	545	562	pentylenetetrazol	T109,T121	C0030903
27395784	563	568	(PTZ)	T109,T121	C0030903
27395784	571	578	induced	T169	C0205263
27395784	579	587	seizures	T184	C0036572
27395784	593	604	hippocampal	T023	C0019564
27395784	605	616	involvement	T169	C1314939
27395784	622	626	mild	T080	C4316743
27395784	627	646	foot shock stresses	T046	C0449430
27395784	652	659	applied	T169	C4048755
27395784	663	669	intact	T080	C0205266
27395784	674	690	adrenalectomized	T061	C0001632
27395784	691	698	animals	T008	C0003062
27395784	716	721	CRHr1	T116,T192	C0529997
27395784	722	730	blocking	T169	C0332206
27395784	732	741	NBI 27914	T109	C1174222
27395784	750	757	LH area	T029	C0020654
27395784	765	772	changes	T169	C0392747
27395784	776	782	orexin	T116,T123	C1113688
27395784	799	808	evaluated	T058	C0220825
27395784	812	818	RT-PCR	T063	C0599161
27395784	820	831	Intravenous	T082	C0348016
27395784	832	835	PTZ	T109,T121	C0030903
27395784	836	844	infusion	T061	C0574032
27395784	858	865	induced	T169	C0205263
27395784	866	877	convulsions	T184	C4048158
27395784	883	889	scored	T081	C0449820
27395784	895	916	modified Racine scale	T170	C0282574
27395784	927	938	hippocampal	T023	C0019564
27395784	939	948	glutamate	T116,T123	C0220839
27395784	953	957	GABA	T116,T123	C0016904
27395784	963	972	evaluated	T058	C0220825
27395784	976	981	study	T062	C2603343
27395784	982	994	excitability	T184	C0235169
27395784	995	1002	changes	T169	C0392747
27395784	1029	1037	duration	T079	C0449238
27395784	1042	1050	severity	T080	C0439793
27395784	1054	1065	convulsions	T184	C4048158
27395784	1069	1075	stress	T046	C0449430
27395784	1078	1085	induced	T169	C0205263
27395784	1097	1113	adrenalectomized	T061	C0001632
27395784	1125	1134	increased	T081	C0205217
27395784	1136	1142	Plasma	T031	C0032105
27395784	1143	1157	corticosterone	T109,T121,T125	C0010124
27395784	1158	1163	(CRT)	T109,T121,T125	C0010124
27395784	1174	1180	orexin	T028	C1415500
27395784	1181	1196	mRNA expression	T045	C1515670
27395784	1218	1224	stress	T046	C0449430
27395784	1232	1239	seizure	T184	C0036572
27395784	1240	1246	groups	T078	C0441833
27395784	1261	1270	glutamate	T116,T123	C0220839
27395784	1275	1279	GABA	T116,T123	C0016904
27395784	1292	1301	increased	T081	C0205217
27395784	1306	1315	decreased	T081	C0205216
27395784	1336	1342	stress	T046	C0449430
27395784	1347	1355	seizures	T184	C0036572
27395784	1370	1374	rats	T015	C0034721
27395784	1385	1390	CRHr1	T116,T192	C0529997
27395784	1391	1400	inhibitor	T080	C1999216
27395784	1408	1415	reduced	T080	C0392756
27395784	1416	1424	severity	T080	C0439793
27395784	1429	1437	duration	T079	C0449238
27395784	1441	1449	seizures	T184	C0036572
27395784	1451	1460	increased	T081	C0205217
27395784	1461	1465	GABA	T116,T123	C0016904
27395784	1467	1476	decreased	T081	C0205216
27395784	1477	1486	glutamate	T116,T123	C0220839
27395784	1491	1505	corticosterone	T109,T121,T125	C0010124
27395784	1515	1521	orexin	T116,T123	C1113688
27395784	1522	1526	mRNA	T114,T123	C0035696
27395784	1527	1535	compared	T052	C1707455
27395784	1543	1552	inhibitor	T080	C1999216
27395784	1558	1562	rats	T015	C0034721
27395784	1564	1570	Stress	T046	C0449430
27395784	1575	1588	adrenalectomy	T061	C0001632
27395784	1589	1596	induced	T169	C0205263
27395784	1597	1607	augmenting	T169	C0442808
27395784	1608	1614	effect	T080	C1280500
27395784	1618	1625	seizure	T184	C0036572
27395784	1626	1634	severity	T080	C0439793
27395784	1639	1647	duration	T079	C0449238
27395784	1667	1676	reduction	T080	C0392756
27395784	1684	1689	CRHr1	T116,T192	C0529997
27395784	1690	1698	blocking	T169	C0332206
27395784	1713	1719	orexin	T028	C1415500
27395784	1720	1724	mRNA	T114,T123	C0035696
27395784	1725	1732	changes	T169	C0392747
27395784	1734	1743	indicated	T033	C1444656
27395784	1755	1766	involvement	T169	C1314939
27395784	1770	1775	CRH1r	T116,T192	C0529997
27395784	1776	1783	induced	T169	C0205263
27395784	1784	1790	orexin	T116,T123	C1113688
27395784	1791	1801	expression	T061	C0185117
27395784	1809	1811	LH	T029	C0020654
27395784	1822	1828	stress	T046	C0449430
27395784	1829	1835	effect	T080	C1280500
27395784	1839	1850	convulsions	T184	C4048158

28324284|t|Nonoperative Management or 'Watch and Wait' for Rectal Cancer with Complete Clinical Response After Neoadjuvant Chemoradiotherapy: A Critical Appraisal
28324284|a|There is increasing interest in nonoperative management (NOM) for rectal cancer with complete clinical response (cCR) after neoadjuvant chemoradiation (nCRT). The aim of this systematic review was to summarize the available data on NOM, with the intention of formulating standardized protocols on which to base future investigations. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted. A highly sensitive literature search identified all relevant studies published between January 2004 and December 2016. Data extraction and quality assessment was performed independently by two authors, and resolved by consensus with a third reviewer. In total, 15 studies, including 920 patients, met the inclusion criteria; 575 (62.5%) of these patients underwent NOM after cCR, with the remaining patients forming a surgical control group. The weighted mean follow-up was 39.4 (12.7) months in the NOM group and 39.8 (5.1) months in the surgery group. The pooled regrowth rate in the NOM group was 21.3% at a mean of 15.6 (7.0) months. Surgical salvage was possible and was undertaken in 93.2% of these patients. Overall survival in the NOM group was 91.7%, while disease-free survival was 82.7%. For the comparison proctectomy group, pooled rates of local recurrence, overall survival, and disease-free survival were 8.4, 92.4, and 87.5%, respectively. NOM may be a feasible option for surgically eligible rectal cancer patients with cCR after nCRT. Before such a strategy can be widely implemented, further prospective data are required with standardized definitions, diagnostic criteria, and management protocols, with an emphasis on shared patient-provider decision making and patient-centered outcomes.
28324284	0	23	Nonoperative Management	T058	C1254363
28324284	48	61	Rectal Cancer	T191	C0007113
28324284	67	93	Complete Clinical Response	T033	C4050094
28324284	100	129	Neoadjuvant Chemoradiotherapy	T061	C0436307
28324284	184	207	nonoperative management	T058	C1254363
28324284	209	212	NOM	T058	C1254363
28324284	218	231	rectal cancer	T191	C0007113
28324284	237	263	complete clinical response	T033	C4050094
28324284	265	268	cCR	T033	C4050094
28324284	276	302	neoadjuvant chemoradiation	T061	C0436307
28324284	304	308	nCRT	T061	C0436307
28324284	327	344	systematic review	T170	C1955832
28324284	384	387	NOM	T058	C1254363
28324284	423	445	standardized protocols	T170	C0442711
28324284	470	484	investigations	T058	C1261322
28324284	488	505	systematic review	T170	C1955832
28324284	520	586	Preferred Reporting Items for Systematic Reviews and Meta-Analyses	T170	C0282574
28324284	588	594	PRISMA	T170	C0282574
28324284	596	606	guidelines	T170	C0162791
28324284	641	658	literature search	T170	C0178732
28324284	683	690	studies	T062	C2603343
28324284	709	716	January	T080	C3829466
28324284	726	734	December	T080	C3830550
28324284	741	756	Data extraction	T062	C1707635
28324284	761	779	quality assessment	T080	C0205556
28324284	815	822	authors	T097	C3812881
28324284	840	849	consensus	T054	C0376298
28324284	863	871	reviewer	T097	C1707338
28324284	886	893	studies	T062	C2603343
28324284	909	917	patients	T101	C0030705
28324284	968	976	patients	T101	C0030705
28324284	987	990	NOM	T058	C1254363
28324284	997	1000	cCR	T033	C4050094
28324284	1021	1029	patients	T101	C0030705
28324284	1040	1062	surgical control group	T078	C0441833
28324284	1082	1091	follow-up	T058	C1522577
28324284	1108	1114	months	T079	C0439231
28324284	1122	1131	NOM group	T078	C0441833
28324284	1147	1153	months	T079	C0439231
28324284	1161	1174	surgery group	T078	C0441833
28324284	1187	1195	regrowth	T033	C0243095
28324284	1208	1217	NOM group	T078	C0441833
28324284	1252	1258	months	T079	C0439231
28324284	1260	1276	Surgical salvage	T058	C0587668
28324284	1327	1335	patients	T101	C0030705
28324284	1337	1353	Overall survival	T081	C4086681
28324284	1361	1370	NOM group	T078	C0441833
28324284	1388	1409	disease-free survival	T081	C0242793
28324284	1440	1451	proctectomy	T061	C0193062
28324284	1452	1457	group	T101	C0030705
28324284	1493	1509	overall survival	T081	C4086681
28324284	1515	1536	disease-free survival	T081	C0242793
28324284	1578	1581	NOM	T058	C1254363
28324284	1611	1621	surgically	T058	C0587668
28324284	1631	1644	rectal cancer	T191	C0007113
28324284	1645	1653	patients	T101	C0030705
28324284	1659	1662	cCR	T033	C4050094
28324284	1669	1673	nCRT	T061	C0436307
28324284	1745	1749	data	T062	C0010995
28324284	1781	1792	definitions	T170	C1704788
28324284	1794	1813	diagnostic criteria	T170	C0679228
28324284	1819	1839	management protocols	T170	C0542547
28324284	1868	1884	patient-provider	T097	C0018724
28324284	1885	1900	decision making	T041	C0011109
28324284	1905	1930	patient-centered outcomes	T062	C1518914

27456062|t|Somatic Therapy of a Mouse SMA Model with a U7 snRNA Gene Correcting SMN2 Splicing
27456062|a|Spinal Muscular Atrophy is due to the loss of SMN1 gene function. The duplicate gene SMN2 produces some, but not enough, SMN protein because most transcripts lack exon 7. Thus, promoting the inclusion of this exon is a therapeutic option. We show that a somatic gene therapy using the gene for a modified U7 RNA which stimulates this splicing has a profound and persistent therapeutic effect on the phenotype of a severe Spinal Muscular Atrophy mouse model. To this end, the U7 gene and vector and the production of pure, highly concentrated self-complementary (sc) adenovirus - associated virus 9 vector particles were optimized. Introduction of the functional vector into motoneurons of newborn Spinal Muscular Atrophy mice by intracerebroventricular injection led to a highly significant, dose-dependent increase in life span and improvement of muscle functions. Besides the central nervous system, the therapeutic U7 RNA was expressed in the heart and liver which may additionally have contributed to the observed therapeutic efficacy. This approach provides an additional therapeutic option for Spinal Muscular Atrophy and could also be adapted to treat other diseases of the central nervous system with regulatory small RNA genes.
27456062	0	15	Somatic Therapy	T061	C0037645
27456062	21	26	Mouse	T015	C0025929
27456062	27	30	SMA	T047	C0026847
27456062	31	36	Model	T050	C0012644
27456062	44	57	U7 snRNA Gene	T028	C2678677
27456062	69	73	SMN2	T028	C1420258
27456062	74	82	Splicing	T045	C0035687
27456062	83	106	Spinal Muscular Atrophy	T047	C0026847
27456062	110	116	due to	T169	C0678226
27456062	121	125	loss	T081	C1517945
27456062	129	133	SMN1	T028	C1420257
27456062	134	147	gene function	T045	C0314627
27456062	153	167	duplicate gene	T028	C0600497
27456062	168	172	SMN2	T028	C1420258
27456062	204	215	SMN protein	T116,T123	C4283935
27456062	229	240	transcripts	T114	C1519595
27456062	246	252	exon 7	T114,T123	C0015295
27456062	274	283	inclusion	T080	C1512693
27456062	292	296	exon	T114,T123	C0015295
27456062	302	313	therapeutic	T169	C0302350
27456062	314	320	option	T169	C1518601
27456062	337	357	somatic gene therapy	T061	C0037645
27456062	358	363	using	T169	C1524063
27456062	368	372	gene	T028	C0017337
27456062	379	394	modified U7 RNA	T028	C2678677
27456062	417	425	splicing	T045	C0035687
27456062	432	440	profound	T080	C0439808
27456062	445	455	persistent	T079	C0205322
27456062	456	474	therapeutic effect	T201	C1527144
27456062	482	491	phenotype	T032	C0031437
27456062	497	503	severe	T080	C0205082
27456062	504	527	Spinal Muscular Atrophy	T047	C0026847
27456062	528	539	mouse model	T050	C2986594
27456062	558	565	U7 gene	T028	C2678677
27456062	570	576	vector	T114	C0017397
27456062	599	603	pure	T080	C0205556
27456062	605	611	highly	T080	C0205250
27456062	625	659	self-complementary (sc) adenovirus	T005	C0001483
27456062	662	672	associated	T080	C0332281
27456062	673	680	virus 9	T005	C0001483
27456062	681	697	vector particles	T121	C1520007
27456062	703	712	optimized	T052	C2698650
27456062	734	744	functional	T169	C0205245
27456062	745	751	vector	T114	C0017397
27456062	757	768	motoneurons	T025	C0026609
27456062	772	779	newborn	T079	C2939425
27456062	780	803	Spinal Muscular Atrophy	T047	C0026847
27456062	804	808	mice	T015	C0025929
27456062	812	835	intracerebroventricular	T082	C0595818
27456062	836	845	injection	T061	C1533685
27456062	855	873	highly significant	T080	C1299395
27456062	875	889	dose-dependent	T081	C1512045
27456062	890	898	increase	T169	C0442805
27456062	902	911	life span	T102	C0870809
27456062	916	927	improvement	T077	C2986411
27456062	931	947	muscle functions	T042	C0231484
27456062	961	983	central nervous system	T022	C3714787
27456062	989	1000	therapeutic	T169	C0302350
27456062	1001	1007	U7 RNA	T028	C2678677
27456062	1012	1021	expressed	T045	C0017262
27456062	1029	1034	heart	T023	C0018787
27456062	1039	1044	liver	T023	C0023884
27456062	1073	1084	contributed	T052	C1880177
27456062	1092	1100	observed	T169	C1441672
27456062	1101	1121	therapeutic efficacy	T080	C2348767
27456062	1128	1136	approach	T082	C0449445
27456062	1137	1145	provides	T052	C1999230
27456062	1149	1159	additional	T169	C1524062
27456062	1160	1171	therapeutic	T169	C0302350
27456062	1172	1178	option	T169	C1518601
27456062	1183	1206	Spinal Muscular Atrophy	T047	C0026847
27456062	1236	1241	treat	T061	C0087111
27456062	1242	1247	other	T080	C0205394
27456062	1248	1256	diseases	T047	C0012634
27456062	1264	1286	central nervous system	T022	C3714787
27456062	1292	1318	regulatory small RNA genes	T028	C0017337

27454738|t|Co-ChIP enables genome-wide mapping of histone mark co-occurrence at single-molecule resolution
27454738|a|Histone modifications play an important role in chromatin organization and transcriptional regulation, but despite the large amount of genome-wide histone modification data collected in different cells and tissues, little is known about co-occurrence of modifications on the same nucleosome. Here we present a genome-wide quantitative method for combinatorial indexed chromatin immunoprecipitation (co-ChIP) to characterize co-occurrence of histone modifications on nucleosomes. Using co-ChIP, we study the genome-wide co-occurrence of 14 chromatin marks (70 pairwise combinations), and find previously undescribed co-occurrence patterns, including the co-occurrence of H3K9me1 and H3K27ac in super-enhancers. Finally, we apply co-ChIP to measure the distribution of the bivalent H3K4me3 - H3K27me3 domains in two distinct mouse embryonic stem cell (mESC) states and in four adult tissues. We observe dynamic changes in 5,786 regions and discover both loss and de novo gain of bivalency in key tissue-specific regulatory genes, suggesting a functional role for bivalent domains during different stages of development. These results show that co-ChIP can reveal the complex interactions between histone modifications.
27454738	0	7	Co-ChIP	T059	C1328856
27454738	16	35	genome-wide mapping	T062	C0079435
27454738	39	51	histone mark	T087	C1257775
27454738	52	65	co-occurrence	T079	C2745955
27454738	69	95	single-molecule resolution	T077	C2699488
27454738	96	117	Histone modifications	T044	C1156199
27454738	126	135	important	T080	C3898777
27454738	136	140	role	T077	C1705810
27454738	144	166	chromatin organization	T045	C1156187
27454738	171	197	transcriptional regulation	T045	C1158770
27454738	215	227	large amount	T081	C3869890
27454738	231	242	genome-wide	T028	C0017428
27454738	243	263	histone modification	T044	C1156199
27454738	264	268	data	T078	C1511726
27454738	269	278	collected	T078	C1516695
27454738	282	291	different	T080	C1705242
27454738	292	297	cells	T025	C0007634
27454738	302	309	tissues	T024	C0040300
27454738	333	346	co-occurrence	T079	C2745955
27454738	350	363	modifications	T044	C1156199
27454738	376	386	nucleosome	T116,T123	C0028623
27454738	396	403	present	T078	C0449450
27454738	406	437	genome-wide quantitative method	T062	C1510568
27454738	442	463	combinatorial indexed	T170	C0918012
27454738	464	493	chromatin immunoprecipitation	T059	C1328856
27454738	495	502	co-ChIP	T059	C1328856
27454738	520	533	co-occurrence	T079	C2745955
27454738	537	558	histone modifications	T044	C1156199
27454738	562	573	nucleosomes	T116,T123	C0028623
27454738	581	588	co-ChIP	T059	C1328856
27454738	593	598	study	T062	C0681814
27454738	603	614	genome-wide	T028	C0017428
27454738	615	628	co-occurrence	T079	C2745955
27454738	635	650	chromatin marks	T087	C1257775
27454738	655	676	pairwise combinations	T080	C0205195
27454738	711	724	co-occurrence	T079	C2745955
27454738	725	733	patterns	T082	C0449774
27454738	749	762	co-occurrence	T079	C2745955
27454738	766	773	H3K9me1	T028	C0314621
27454738	778	785	H3K27ac	T028	C0314621
27454738	789	804	super-enhancers	T086	C0004793
27454738	818	823	apply	T169	C4048755
27454738	824	831	co-ChIP	T059	C1328856
27454738	835	842	measure	T081	C0079809
27454738	847	859	distribution	T169	C1704711
27454738	867	875	bivalent	T081	C0392762
27454738	876	883	H3K4me3	T028	C0314621
27454738	886	894	H3K27me3	T028	C0314621
27454738	895	902	domains	T087	C1514562
27454738	919	944	mouse embryonic stem cell	T025	C4042879
27454738	946	950	mESC	T025	C4042879
27454738	971	984	adult tissues	T024	C0040300
27454738	989	996	observe	T169	C1441672
27454738	997	1004	dynamic	T169	C0729333
27454738	1005	1012	changes	T081	C0443172
27454738	1034	1042	discover	T052	C1880355
27454738	1048	1052	loss	T081	C1517945
27454738	1057	1064	de novo	T078	C1515568
27454738	1065	1069	gain	T081	C1517378
27454738	1073	1082	bivalency	T081	C0392762
27454738	1090	1105	tissue-specific	T024	C1955394
27454738	1106	1122	regulatory genes	T028	C0017362
27454738	1124	1134	suggesting	T078	C1705535
27454738	1137	1152	functional role	T077	C1705810
27454738	1157	1165	bivalent	T081	C0392762
27454738	1166	1173	domains	T087	C1514562
27454738	1191	1197	stages	T079	C1306673
27454738	1201	1212	development	T169	C1527148
27454738	1220	1227	results	T033	C0683954
27454738	1238	1245	co-ChIP	T059	C1328856
27454738	1250	1256	reveal	T080	C0443289
27454738	1261	1281	complex interactions	T169	C1704675
27454738	1290	1311	histone modifications	T044	C1156199

27984052|t|Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well
27984052|a|Beta-adrenergic receptor blockers (β-blockers) are an appropriate treatment for patients having systemic hypertension (HTN) who have concomitant ischemic heart disease (IHD), heart failure, obstructive cardiomyopathy, aortic dissection or certain cardiac arrhythmias. β-Blockers can be used in combination with other antiHTN drugs to achieve maximal blood pressure control. Labetalol can be used in HTN emergencies and urgencies. β-Blockers may be useful in HTN patients having a hyperkinetic circulation (palpitations, tachycardia, HTN, and anxiety), migraine headache, and essential tremor. β-Blockers are highly heterogeneous with respect to various pharmacologic properties: degree of intrinsic sympathomimetic activity, membrane stabilizing activity, β1 selectivity, α1-adrenergic blocking effects, tissue solubility, routes of systemic elimination, potencies and duration of action, and specific properties may be important in the selection of a drug for clinical use. β-Blocker usage to reduce perioperative myocardial ischemia and cardiovascular (CV) complications may not benefit as many patients as was once hoped, and may actually cause harm in some individuals. Currently the best evidence supports perioperative β-blocker use in two patient groups: patients undergoing vascular surgery with known IHD or multiple risk factors for it, and for those patients already receiving β-blockers for known CV conditions.
27984052	0	33	Beta-Adrenergic Receptor Blockers	T121	C0001645
27984052	37	49	Hypertension	T047	C0020538
27984052	66	99	Beta-adrenergic receptor blockers	T121	C0001645
27984052	101	111	β-blockers	T121	C0001645
27984052	132	141	treatment	T061	C0087111
27984052	146	154	patients	T101	C0030705
27984052	162	183	systemic hypertension	T047	C0020538
27984052	185	188	HTN	T047	C0020538
27984052	199	233	concomitant ischemic heart disease	T047	C0151744
27984052	235	238	IHD	T047	C0151744
27984052	241	254	heart failure	T047	C0018801
27984052	256	282	obstructive cardiomyopathy	T047	C0007194
27984052	284	301	aortic dissection	T047	C0340643
27984052	313	332	cardiac arrhythmias	T033	C0003811
27984052	334	344	β-Blockers	T121	C0001645
27984052	383	396	antiHTN drugs	T121	C0003364
27984052	408	438	maximal blood pressure control	T040	C1753303
27984052	440	449	Labetalol	T109,T121	C0022860
27984052	465	480	HTN emergencies	T047	C0745136
27984052	485	494	urgencies	T047	C0745138
27984052	496	506	β-Blockers	T121	C0001645
27984052	524	527	HTN	T047	C0020538
27984052	528	536	patients	T101	C0030705
27984052	546	558	hyperkinetic	T080	C0233574
27984052	559	570	circulation	T039	C0005775
27984052	572	584	palpitations	T033	C0030252
27984052	586	597	tachycardia	T046	C0039231
27984052	599	602	HTN	T047	C0020538
27984052	608	615	anxiety	T033	C0003467
27984052	618	635	migraine headache	T047	C0149931
27984052	641	657	essential tremor	T047	C0270736
27984052	659	669	β-Blockers	T121	C0001645
27984052	681	694	heterogeneous	T080	C0019409
27984052	719	743	pharmacologic properties	T070	C2350477
27984052	745	789	degree of intrinsic sympathomimetic activity	T033	C0877014
27984052	791	820	membrane stabilizing activity	T169	C0205245
27984052	822	836	β1 selectivity	T044	C1152727
27984052	838	868	α1-adrenergic blocking effects	T044	C1152724
27984052	870	887	tissue solubility	T080	C0037628
27984052	889	919	routes of systemic elimination	T033	C0231360
27984052	921	930	potencies	T038	C0678792
27984052	935	953	duration of action	T079	C0449238
27984052	1003	1039	selection of a drug for clinical use	T062	C0013175
27984052	1041	1056	β-Blocker usage	T169	C0728866
27984052	1067	1080	perioperative	T079	C1518988
27984052	1081	1100	myocardial ischemia	T047	C0151744
27984052	1105	1138	cardiovascular (CV) complications	T046	C0161816
27984052	1163	1171	patients	T101	C0030705
27984052	1277	1290	perioperative	T079	C1518988
27984052	1291	1304	β-blocker use	T169	C0728866
27984052	1312	1326	patient groups	T101	C0030705
27984052	1328	1336	patients	T101	C0030705
27984052	1348	1364	vascular surgery	T061	C0042381
27984052	1376	1379	IHD	T047	C0151744
27984052	1383	1404	multiple risk factors	T033	C2321260
27984052	1427	1435	patients	T101	C0030705
27984052	1454	1464	β-blockers	T121	C0001645
27984052	1475	1488	CV conditions	T046	C0161816

27795701|t|Targeted therapy in gastric cancer
27795701|a|Gastric cancer is the fourth most common cancer worldwide. Surgery in combination with multimodal therapy provides the only curative therapy until now. The importance of targeted therapy became clear over the last few years. Due to the implication of HER2 and angiogenesis -directed targeted therapies major advances in the treatment of gastric cancer could be reached. Nevertheless, benefits in survival remain unsatisfactory and the development of resistance to monoclonal antibodies is arising. A comprehensive and comparative literature research was performed to evaluate the status of HER2 and angiogenesis -directed targeted therapy in gastric cancer. Up to now, trastuzumab and ramucirumab are the only agents showing remarkable benefits in the therapy for the patients suffering from gastric cancer. The limitations of targeted therapies in gastric cancer are mainly associated with the development of secondary resistance. Addition of targeted therapy in second-line treatment is beneficial when compared with chemotherapy alone. Nevertheless, results in first-line treatment remain modest. Therefore, new therapeutic agents and combinations in the first-line treatment of gastric cancer are urgently needed and remain to be validated in clinical trials.
27795701	0	16	Targeted therapy	T061	C2985566
27795701	20	34	gastric cancer	T191	C0024623
27795701	35	49	Gastric cancer	T191	C0024623
27795701	76	82	cancer	T191	C0006826
27795701	94	101	Surgery	T061	C0543467
27795701	122	140	multimodal therapy	T061	C0009429
27795701	159	175	curative therapy	T033	C1273390
27795701	205	221	targeted therapy	T061	C2985566
27795701	253	258	years	T079	C0439234
27795701	271	282	implication	T169	C1314939
27795701	286	290	HER2	T028	C0242957
27795701	295	307	angiogenesis	T042	C0302600
27795701	318	336	targeted therapies	T061	C2985566
27795701	359	368	treatment	T061	C0087111
27795701	372	386	gastric cancer	T191	C0024623
27795701	485	495	resistance	T169	C4281815
27795701	499	520	monoclonal antibodies	T116,T129	C0003250
27795701	535	548	comprehensive	T080	C1880156
27795701	553	564	comparative	T062	C1579762
27795701	565	575	literature	T170	C0023866
27795701	576	584	research	T062	C0035168
27795701	602	610	evaluate	T058	C0220825
27795701	625	629	HER2	T028	C0242957
27795701	634	646	angiogenesis	T042	C0302600
27795701	657	673	targeted therapy	T061	C2985566
27795701	677	691	gastric cancer	T191	C0024623
27795701	704	715	trastuzumab	T116,T121,T129	C0728747
27795701	720	731	ramucirumab	T116,T129	C2742502
27795701	745	751	agents	T109,T121	C0003392
27795701	787	794	therapy	T061	C0087111
27795701	803	811	patients	T101	C0030705
27795701	827	841	gastric cancer	T191	C0024623
27795701	862	880	targeted therapies	T061	C2985566
27795701	884	898	gastric cancer	T191	C0024623
27795701	955	965	resistance	T169	C4281815
27795701	979	995	targeted therapy	T061	C2985566
27795701	999	1020	second-line treatment	T061	C1710038
27795701	1054	1066	chemotherapy	T061	C3665472
27795701	1088	1095	results	T033	C0808233
27795701	1099	1119	first-line treatment	T061	C1708063
27795701	1150	1168	therapeutic agents	T121	C1611640
27795701	1173	1185	combinations	T121	C0013162
27795701	1193	1213	first-line treatment	T061	C1708063
27795701	1217	1231	gastric cancer	T191	C0024623
27795701	1282	1297	clinical trials	T062	C0008976

27389831|t|Longitudinal live imaging of retinal α-synuclein :: GFP deposits in a transgenic mouse model of Parkinson's Disease / Dementia with Lewy Bodies
27389831|a|Abnormal α-synuclein (α-syn) accumulation in the CNS may underlie neuronal cell and synaptic dysfunction leading to motor and cognitive deficits in synucleinopathies including Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Multiple groups demonstrated α-syn accumulation in CNS accessory structures, including the eyes and olfactory terminals, as well as in peripheral organs of Parkinsonian patients. Retinal imaging studies of mice overexpressing fused α-syn :: GFP were conducted to evaluate the presence and progression of retinal pathology in a PD / DLB transgenic mouse model. Bright-field image retinal maps and fluorescent images were acquired at 1-month intervals for 3 months. Retinal imaging revealed the accumulation of GFP -tagged α-syn in retinal ganglion cell layer and in the edges of arterial blood vessels in the transgenic mice. Double labeling studies confirmed that the α-syn :: GFP -positive cells were retinal ganglion cells containing α-syn. Accumulation of α-syn persisted in the same cells and increased with age. Accumulation of α-syn :: GFP was reduced by immunization with single chain antibodies against α-syn. In conclusion, longitudinal live imaging of the retina in the PDGF - α-syn :: GFP mice might represent a useful, non-invasive tool to monitor the fate of α-syn accumulation in the CNS and to evaluate the therapeutic effects of compounds targeting α-syn.
27389831	0	25	Longitudinal live imaging	T060	C1881134
27389831	29	36	retinal	T023	C0035298
27389831	37	48	α-synuclein	T116,T123	C0285890
27389831	52	55	GFP	T116,T130	C0120285
27389831	56	64	deposits	T020	C0235972
27389831	70	92	transgenic mouse model	T015	C0025936
27389831	96	115	Parkinson's Disease	T047	C0030567
27389831	118	143	Dementia with Lewy Bodies	T047	C0752347
27389831	144	152	Abnormal	T116,T123	C0311448
27389831	153	164	α-synuclein	T116,T123	C0285890
27389831	166	171	α-syn	T116,T123	C0285890
27389831	173	185	accumulation	T033	C4055506
27389831	193	196	CNS	T022	C3714787
27389831	210	223	neuronal cell	T025	C0027882
27389831	228	236	synaptic	T030	C0039062
27389831	237	248	dysfunction	T046	C0277785
27389831	260	265	motor	T033	C0521654
27389831	270	288	cognitive deficits	T033	C3277798
27389831	292	309	synucleinopathies	T047	C0524851
27389831	320	339	Parkinson's disease	T047	C0030567
27389831	341	343	PD	T047	C0030567
27389831	349	374	Dementia with Lewy Bodies	T047	C0752347
27389831	376	379	DLB	T047	C0752347
27389831	411	416	α-syn	T116,T123	C0285890
27389831	417	429	accumulation	T033	C4055506
27389831	433	436	CNS	T022	C3714787
27389831	437	457	accessory structures	T023	C0000905
27389831	473	477	eyes	T023	C0015392
27389831	482	501	olfactory terminals	T023	C0028938
27389831	517	527	peripheral	T082	C0205100
27389831	528	534	organs	T023	C0178784
27389831	538	550	Parkinsonian	T047	C0242422
27389831	551	559	patients	T101	C0030705
27389831	561	568	Retinal	T023	C0035298
27389831	569	584	imaging studies	T060	C1881134
27389831	588	592	mice	T015	C0025936
27389831	593	607	overexpressing	T045	C1514559
27389831	614	619	α-syn	T116,T123	C0285890
27389831	623	626	GFP	T116,T130	C0120285
27389831	645	653	evaluate	T058	C0220825
27389831	671	682	progression	T169	C0449258
27389831	686	693	retinal	T023	C0035298
27389831	694	703	pathology	T091	C0030664
27389831	709	711	PD	T047	C0030567
27389831	714	717	DLB	T047	C0752347
27389831	718	740	transgenic mouse model	T015	C0025936
27389831	742	760	Bright-field image	T059	C0441073
27389831	761	773	retinal maps	T070	C0237660
27389831	778	796	fluorescent images	T060	C0430876
27389831	846	853	Retinal	T023	C0035298
27389831	854	861	imaging	T060	C1881134
27389831	875	887	accumulation	T033	C4055506
27389831	891	894	GFP	T116,T130	C0120285
27389831	903	908	α-syn	T116,T123	C0285890
27389831	912	939	retinal ganglion cell layer	T025	C0035316
27389831	960	968	arterial	T082	C0221464
27389831	969	982	blood vessels	T023	C0005847
27389831	990	1005	transgenic mice	T015	C0025936
27389831	1007	1030	Double labeling studies	T062	C0242481
27389831	1050	1055	α-syn	T116,T123	C0285890
27389831	1059	1062	GFP	T116,T130	C0120285
27389831	1073	1078	cells	T025	C0007634
27389831	1084	1106	retinal ganglion cells	T025	C0035316
27389831	1118	1123	α-syn	T116,T123	C0285890
27389831	1125	1137	Accumulation	T033	C4055506
27389831	1141	1146	α-syn	T116,T123	C0285890
27389831	1169	1174	cells	T025	C0007634
27389831	1194	1197	age	T032	C0001779
27389831	1199	1211	Accumulation	T033	C4055506
27389831	1215	1220	α-syn	T116,T123	C0285890
27389831	1224	1227	GFP	T116,T130	C0120285
27389831	1243	1255	immunization	T061	C0020971
27389831	1261	1284	single chain antibodies	T129	C1883036
27389831	1293	1298	α-syn	T116,T123	C0285890
27389831	1315	1340	longitudinal live imaging	T060	C1881134
27389831	1348	1354	retina	T023	C0035298
27389831	1362	1366	PDGF	T116,T123	C0032200
27389831	1369	1374	α-syn	T116,T123	C0285890
27389831	1378	1381	GFP	T116,T130	C0120285
27389831	1382	1386	mice	T015	C0025936
27389831	1413	1425	non-invasive	T169	C0205303
27389831	1454	1459	α-syn	T116,T123	C0285890
27389831	1460	1472	accumulation	T033	C4055506
27389831	1480	1483	CNS	T022	C3714787
27389831	1491	1499	evaluate	T058	C0220825
27389831	1504	1523	therapeutic effects	T201	C1527144
27389831	1527	1536	compounds	T121	C1254351
27389831	1537	1546	targeting	T169	C1521840
27389831	1547	1552	α-syn	T116,T123	C0285890

28266689|t|Local induction of inflammation affects bone formation
28266689|a|To explore the influence of inflammatory processes on bone formation, we applied a new in vivo screening model. Confined biological pockets were first created in rabbits as a response to implanted bone cement discs. These biomembrane pockets were subsequently used to study the effects of inflammatory stimuli on ectopic bone formation within biphasic calcium phosphate (BCP) constructs loaded with TNF-α, lipopolysaccharide (LPS) or lipoteichoic acid (LTA), all with or without bone morphogenetic protein (BMP)-2. Analysis of bone formation after 12 weeks demonstrated that the inflammatory mediators were not bone - inductive in combination with the BCP alone, but inhibited or enhanced BMP -induced bone formation. LPS was associated with a strong inhibition of bone formation by BMP-2, while LTA and TNF-α showed a positive interaction with BMP-2. Since the biomembrane pockets did not interfere with bone formation and prevented the leakage of pro-inflammatory compounds to the surrounding tissue, the biomembrane model can be used for in vivo approaches to study local inflammation in conjunction with new bone formation. Using this model, it was shown that the modulation of the inflammatory response could be beneficial or detrimental to the subsequent bone formation process. The co-delivery of inflammatory factors and bone -related growth factors should be further explored as a strategy to enhance the bone-forming efficacy of bone substitutes.
28266689	0	5	Local	T082	C0205276
28266689	6	15	induction	T061	C0857127
28266689	19	31	inflammation	T046	C0021368
28266689	40	54	bone formation	T042	C0029433
28266689	70	79	influence	T077	C4054723
28266689	83	105	inflammatory processes	T046	C0021368
28266689	109	123	bone formation	T042	C0029433
28266689	142	149	in vivo	T082	C1515655
28266689	150	159	screening	T058	C1710032
28266689	160	165	model	T050	C0012644
28266689	176	186	biological	T080	C0205460
28266689	187	194	pockets	T082	C1254362
28266689	217	224	rabbits	T015	C3887509
28266689	242	251	implanted	T033	C2828363
28266689	252	269	bone cement discs	T122	C0005934
28266689	277	288	biomembrane	T026	C0682529
28266689	289	296	pockets	T082	C1254362
28266689	344	356	inflammatory	T169	C0333348
28266689	357	364	stimuli	T067	C0234402
28266689	368	390	ectopic bone formation	T046	C0029396
28266689	398	424	biphasic calcium phosphate	T122,T197	C0210087
28266689	426	429	BCP	T122,T197	C0210087
28266689	431	441	constructs	T052	C1706853
28266689	454	459	TNF-α	T116,T129	C1456820
28266689	461	479	lipopolysaccharide	T109	C0023810
28266689	481	484	LPS	T109	C0023810
28266689	489	506	lipoteichoic acid	T109	C0065067
28266689	508	511	LTA	T109	C0065067
28266689	526	533	without	T080	C0332288
28266689	534	568	bone morphogenetic protein (BMP)-2	T116,T123	C0527443
28266689	582	596	bone formation	T042	C0029433
28266689	634	656	inflammatory mediators	T121	C0243042
28266689	666	670	bone	T024	C0005931
28266689	673	682	inductive	T078	C0085978
28266689	722	731	inhibited	T080	C0311403
28266689	735	743	enhanced	T052	C2349975
28266689	744	747	BMP	T116,T123	C0053932
28266689	757	771	bone formation	T042	C0029433
28266689	773	776	LPS	T109	C0023810
28266689	806	816	inhibition	T052	C3463820
28266689	820	834	bone formation	T042	C0029433
28266689	838	843	BMP-2	T116,T123	C0527443
28266689	851	854	LTA	T109	C0065067
28266689	859	864	TNF-α	T116,T129	C1456820
28266689	874	882	positive	T033	C1446409
28266689	883	894	interaction	T169	C1704675
28266689	900	905	BMP-2	T116,T123	C0527443
28266689	917	928	biomembrane	T026	C0682529
28266689	929	936	pockets	T082	C1254362
28266689	937	954	did not interfere	T080	C0521103
28266689	960	974	bone formation	T042	C0029433
28266689	993	1000	leakage	T046	C0015376
28266689	1004	1020	pro-inflammatory	T169	C0333348
28266689	1021	1030	compounds	T080	C0205198
28266689	1050	1056	tissue	T024	C0040300
28266689	1062	1073	biomembrane	T026	C0682529
28266689	1074	1079	model	T050	C0012644
28266689	1096	1103	in vivo	T082	C1515655
28266689	1124	1129	local	T082	C0205276
28266689	1130	1142	inflammation	T046	C0021368
28266689	1146	1157	conjunction	T078	C2699427
28266689	1163	1181	new bone formation	T042	C0029433
28266689	1194	1199	model	T050	C0012644
28266689	1223	1233	modulation	T169	C0392747
28266689	1241	1262	inflammatory response	T046	C1155266
28266689	1272	1282	beneficial	T080	C3827682
28266689	1286	1297	detrimental	T046	C0879626
28266689	1316	1338	bone formation process	T042	C0029433
28266689	1344	1355	co-delivery	T169	C0391871
28266689	1359	1371	inflammatory	T169	C0333348
28266689	1372	1379	factors	T169	C1521761
28266689	1384	1388	bone	T024	C0005931
28266689	1398	1412	growth factors	T116,T123	C0018284
28266689	1457	1464	enhance	T052	C2349975
28266689	1469	1481	bone-forming	T042	C0029433
28266689	1482	1490	efficacy	T080	C1280519
28266689	1494	1510	bone substitutes	T122	C0243003

27460729|t|Bioinformatic analysis of RNA-seq data unveiled critical genes in rectal adenocarcinoma
27460729|a|RNA-seq data of rectal adenocarcinoma (READ) were analyzed with bioinformatics tools to unveil potential biomarkers in the disease. RNA-seq data of READ were downloaded from The Cancer Genome Atlas (TCGA) database. Differential analysis was performed with package edgeR. False discovery rate (FDR) < 0.05 and |log2 (fold change)|>1 were set as cut-off values to screen out differentially expressed genes (DEGs). Gene coexpression network was constructed with package Ebcoexpress. Gene Ontology enrichment analysis was performed for the DEGs in the gene coexpression network with DAVID online tool. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis was also performed for the genes with KOBASS 2.0. A total of 620 DEGs, 3ated genes, and 231 down-regulated genes, were identified from 163 READ samples and 9 normal controls. A gene coexpression network consisting of 71 DEGs and 253 edges were constructed. Genes were associated with ribosome and focal adhesion functions. Three modules were identified, in which genes were involved in muscle contraction, negative regulation of glial cell proliferation and extracellular matrix organization functions, respectively. Several critical hub genes were disclosed, such as RPS2, MMP1, MMP11 and FAM83H. Thirteen relevant small molecule drugs were identified, such as scriptaid and spaglumic acid. A total of 8 TFs and 5 miRNAs were acquired, such as MYC, NFY, STAT5A, miR-29, miR-200 and miR-19. Several critical genes and relevant drugs, TFs and miRNAs were revealed in READ. These findings could advance the understanding about the disease and benefit therapy development.
27460729	0	13	Bioinformatic	T091	C1140694
27460729	14	22	analysis	T062	C0936012
27460729	26	33	RNA-seq	T086	C0162327
27460729	34	38	data	T078	C1511726
27460729	48	62	critical genes	T028	C0017337
27460729	66	87	rectal adenocarcinoma	T191	C0149978
27460729	88	95	RNA-seq	T086	C0162327
27460729	96	100	data	T078	C1511726
27460729	104	125	rectal adenocarcinoma	T191	C0149978
27460729	127	131	READ	T191	C0149978
27460729	138	146	analyzed	T062	C0936012
27460729	152	172	bioinformatics tools	T091	C1140694
27460729	176	203	unveil potential biomarkers	T201	C0005516
27460729	211	218	disease	T047	C0012634
27460729	220	227	RNA-seq	T086	C0162327
27460729	228	232	data	T078	C1511726
27460729	236	240	READ	T191	C0149978
27460729	262	285	The Cancer Genome Atlas	T062	C3273927
27460729	287	291	TCGA	T062	C3273927
27460729	293	301	database	T170	C0242356
27460729	316	324	analysis	T062	C0936012
27460729	329	338	performed	T169	C0884358
27460729	344	357	package edgeR	T170	C0282574
27460729	359	379	False discovery rate	T081	C1880720
27460729	381	384	FDR	T081	C1880720
27460729	461	491	differentially expressed genes	T028	C0017337
27460729	493	497	DEGs	T028	C0017337
27460729	500	517	Gene coexpression	T045	C0017262
27460729	518	525	network	T044	C1720950
27460729	547	566	package Ebcoexpress	T170	C0282574
27460729	568	581	Gene Ontology	T170	C1138831
27460729	593	601	analysis	T062	C0936012
27460729	606	615	performed	T169	C0884358
27460729	624	628	DEGs	T028	C0017337
27460729	636	653	gene coexpression	T045	C0017262
27460729	654	661	network	T169	C1882071
27460729	667	684	DAVID online tool	T073,T170	C0029038
27460729	686	704	Kyoto Encyclopedia	T170	C0014095
27460729	708	713	Genes	T028	C0017337
27460729	718	725	Genomes	T028	C0017428
27460729	745	753	analysis	T062	C0936012
27460729	763	772	performed	T169	C0884358
27460729	781	786	genes	T028	C0017337
27460729	792	798	KOBASS	T073,T170	C0029038
27460729	819	823	DEGs	T028	C0017337
27460729	831	836	genes	T028	C0017337
27460729	846	860	down-regulated	T044	C0013081
27460729	861	866	genes	T028	C0017337
27460729	873	883	identified	T080	C0205396
27460729	893	897	READ	T191	C0149978
27460729	912	927	normal controls	T080	C2705716
27460729	931	948	gene coexpression	T045	C0017262
27460729	949	956	network	T169	C1882071
27460729	974	978	DEGs	T028	C0017337
27460729	1011	1016	Genes	T028	C0017337
27460729	1022	1037	associated with	T080	C0332281
27460729	1038	1046	ribosome	T026	C0035553
27460729	1051	1065	focal adhesion	T026	C0887870
27460729	1066	1075	functions	T169	C0542341
27460729	1083	1090	modules	T044	C1959595
27460729	1096	1106	identified	T080	C0205396
27460729	1117	1122	genes	T028	C0017337
27460729	1140	1158	muscle contraction	T039	C0026820
27460729	1160	1207	negative regulation of glial cell proliferation	T043	C2610375
27460729	1212	1245	extracellular matrix organization	T043	C1160609
27460729	1246	1255	functions	T169	C0542341
27460729	1288	1297	hub genes	T028	C0017337
27460729	1322	1326	RPS2	T028	C1419718
27460729	1328	1332	MMP1	T028	C1417199
27460729	1334	1339	MMP11	T028	C1366519
27460729	1344	1350	FAM83H	T028	C1825168
27460729	1361	1369	relevant	T080	C2347946
27460729	1370	1390	small molecule drugs	T121	C1254351
27460729	1396	1406	identified	T080	C0205396
27460729	1416	1425	scriptaid	T109,T121	C0917681
27460729	1430	1444	spaglumic acid	T109,T121	C2348231
27460729	1459	1462	TFs	T116,T123	C0040648
27460729	1467	1475	5 miRNAs	T114,T123	C1101610
27460729	1499	1502	MYC	T028	C0086661
27460729	1504	1507	NFY	T116,T123	C0910920
27460729	1509	1515	STAT5A	T028	C1335875
27460729	1517	1523	miR-29	T114	C2605694
27460729	1525	1532	miR-200	T114	C2713655
27460729	1537	1543	miR-19	T114	C2933761
27460729	1562	1567	genes	T028	C0017337
27460729	1572	1580	relevant	T080	C2347946
27460729	1581	1586	drugs	T061	C3687832
27460729	1588	1591	TFs	T116,T123	C0040648
27460729	1596	1602	miRNAs	T114,T123	C1101610
27460729	1620	1624	READ	T191	C0149978
27460729	1683	1690	disease	T047	C0012634
27460729	1703	1722	therapy development	T170	C1328820

27274524|t|Eosinophilic Gastroenteritis as a Rare Cause of Recurrent Epigastric Pain
27274524|a|Eosinophilic gastroenteritis (EGE) is a rare inflammatory disorder of gastrointestinal tract characterized by eosinophilic infiltration of the bowel wall. It can mimic many gastrointestinal disorders due to its wide spectrum of presentations. Diagnose is mostly based on excluding other disorders and a high suspicion. Here we report a case of 26 year old man with a history of sever epigastric pain followed by nausea, vomiting since a few days before admission with final diagnosis of EGE.
27274524	0	28	Eosinophilic Gastroenteritis	T047	C1262481
27274524	34	38	Rare	T080	C0522498
27274524	39	44	Cause	T169	C0015127
27274524	48	73	Recurrent Epigastric Pain	UnknownType	C0743544
27274524	74	102	Eosinophilic gastroenteritis	T047	C1262481
27274524	104	107	EGE	T047	C1262481
27274524	119	140	inflammatory disorder	T047	C1290884
27274524	144	166	gastrointestinal tract	T022	C0017189
27274524	167	180	characterized	T052	C1880022
27274524	184	209	eosinophilic infiltration	T046	C0333390
27274524	217	227	bowel wall	T023	C0021853
27274524	247	273	gastrointestinal disorders	T047	C0017178
27274524	285	315	wide spectrum of presentations	T033	C0243095
27274524	317	325	Diagnose	T033	C0011900
27274524	345	354	excluding	T169	C0332196
27274524	355	360	other	T080	C0205394
27274524	361	370	disorders	T047	C0012634
27274524	377	381	high	T080	C0205250
27274524	382	391	suspicion	T041	C0242114
27274524	401	414	report a case	T170	C0007320
27274524	421	425	year	T079	C0439234
27274524	426	429	old	T079	C0580836
27274524	430	433	man	T098	C0025266
27274524	441	448	history	T033	C0262926
27274524	452	473	sever epigastric pain	T184	C0232493
27274524	486	492	nausea	T184	C0027497
27274524	494	502	vomiting	T184	C0042963
27274524	511	514	few	T081	C0205388
27274524	515	519	days	T079	C0439228
27274524	520	526	before	T079	C0332152
27274524	527	536	admission	T058	C0030673
27274524	548	557	diagnosis	T033	C0011900
27274524	561	564	EGE	T047	C1262481

27478387|t|Amphetamine Withdrawal Differentially Increases the Expression of Organic Cation Transporter 3 and Serotonin Transporter in Limbic Brain Regions
27478387|a|Amphetamine withdrawal increases anxiety and stress sensitivity related to blunted ventral hippocampus (vHipp) and enhances the central nucleus of the amygdala (CeA) serotonin responses. Extracellular serotonin levels are regulated by the serotonin transporter (SERT) and organic cation transporter 3 (OCT3), and vHipp OCT3 expression is enhanced during 24 hours of amphetamine withdrawal, while SERT expression is unaltered. Here, we tested whether OCT3 and SERT expression in the CeA is also affected during acute withdrawal to explain opposing regional alterations in limbic serotonergic neurotransmission and if respective changes continued with two weeks of withdrawal. We also determined whether changes in transporter expression were confined to these regions. Male rats received amphetamine or saline for two weeks followed by 24 hours or two weeks of withdrawal, with transporter expression measured using Western immunoblot. OCT3 and SERT expression increased in the CeA at both withdrawal timepoints. In the vHipp, OCT3 expression increased only at 24 hours of withdrawal, with an equivalent pattern seen in the dorsomedial hypothalamus. No changes were evident in any other regions sampled. These regionally specific changes in limbic OCT3 and SERT expression may partially contribute to the serotonergic imbalance and negative affect during amphetamine withdrawal.
27478387	0	22	Amphetamine Withdrawal	T048	C0236665
27478387	52	62	Expression	T045	C1171362
27478387	66	94	Organic Cation Transporter 3	T116,T123	C1453697
27478387	99	120	Serotonin Transporter	T116,T123	C0170657
27478387	124	130	Limbic	T022	C0023715
27478387	131	144	Brain Regions	T023	C0006104
27478387	145	167	Amphetamine withdrawal	T048	C0236665
27478387	178	185	anxiety	T033	C0003467
27478387	190	196	stress	T033	C0038435
27478387	220	227	blunted	T080	C1997138
27478387	228	235	ventral	T082	C1704448
27478387	236	247	hippocampus	T023	C0019564
27478387	249	254	vHipp	T023	C0019564
27478387	273	304	central nucleus of the amygdala	T023	C0175219
27478387	306	309	CeA	T023	C0175219
27478387	311	320	serotonin	T109,T123	C0036751
27478387	321	330	responses	T032	C0871261
27478387	332	345	Extracellular	T026	C0521119
27478387	346	355	serotonin	T109,T123	C0036751
27478387	356	362	levels	T080	C0441889
27478387	384	405	serotonin transporter	T116,T123	C0170657
27478387	407	411	SERT	T116,T123	C0170657
27478387	417	445	organic cation transporter 3	T116,T123	C1453697
27478387	447	451	OCT3	T116,T123	C1453697
27478387	458	463	vHipp	T023	C0019564
27478387	464	468	OCT3	T116,T123	C1453697
27478387	469	479	expression	T045	C1171362
27478387	499	507	24 hours	T079	C1442770
27478387	511	533	amphetamine withdrawal	T048	C0236665
27478387	541	545	SERT	T116,T123	C0170657
27478387	546	556	expression	T045	C1171362
27478387	595	599	OCT3	T116,T123	C1453697
27478387	604	608	SERT	T116,T123	C0170657
27478387	609	619	expression	T045	C1171362
27478387	627	630	CeA	T023	C0175219
27478387	661	671	withdrawal	T048	C2825032
27478387	716	722	limbic	T022	C0023715
27478387	723	753	serotonergic neurotransmission	T043	C2262837
27478387	795	804	two weeks	T079	C4082118
27478387	808	818	withdrawal	T048	C2825032
27478387	858	869	transporter	T116,T123	C0596902
27478387	870	880	expression	T045	C1171362
27478387	913	917	Male	T032	C0086582
27478387	918	922	rats	T015	C0004728
27478387	932	943	amphetamine	T109,T121,T123	C0002658
27478387	947	953	saline	T167	C0036082
27478387	958	967	two weeks	T079	C4082118
27478387	980	988	24 hours	T079	C1442770
27478387	992	1001	two weeks	T079	C4082118
27478387	1005	1015	withdrawal	T048	C2825032
27478387	1022	1033	transporter	T116,T123	C0596902
27478387	1034	1044	expression	T045	C1171362
27478387	1060	1078	Western immunoblot	T059	C0949466
27478387	1080	1084	OCT3	T116,T123	C1453697
27478387	1089	1093	SERT	T116,T123	C0170657
27478387	1094	1104	expression	T045	C1171362
27478387	1122	1125	CeA	T023	C0175219
27478387	1134	1144	withdrawal	T048	C2825032
27478387	1164	1169	vHipp	T023	C0019564
27478387	1171	1175	OCT3	T116,T123	C1453697
27478387	1176	1186	expression	T045	C1171362
27478387	1205	1213	24 hours	T079	C1442770
27478387	1217	1227	withdrawal	T048	C2825032
27478387	1268	1292	dorsomedial hypothalamus	T023	C0013055
27478387	1294	1304	No changes	T033	C0442739
27478387	1331	1338	regions	T029	C0005898
27478387	1385	1391	limbic	T022	C0023715
27478387	1392	1396	OCT3	T116,T123	C1453697
27478387	1401	1405	SERT	T116,T123	C0170657
27478387	1406	1416	expression	T045	C1171362
27478387	1449	1461	serotonergic	T109,T123	C0036751
27478387	1462	1471	imbalance	T184	C1397014
27478387	1476	1491	negative affect	T033	C1513916
27478387	1499	1521	amphetamine withdrawal	T048	C0236665

28506602|t|Ventricular tachycardia score - A novel method for wide QRS complex tachycardia differentiation - Explained
28506602|a|Philosophy, merits and limitations of a novel method for wide QRS complex tachycardia differentiation, based on a scoring system and called the ventricular tachycardia (VT) score, were explained. The following criteria were assigned one point: initial dominant R wave in V1; initial r>40 ms in V1 or V2; notched S in V1; initial R wave in a VR; lead II RWPT ≥50 ms; and absence of an RS in leads V1-V6. Atrioventricular dissociation (including fusion / capture beats and partial dissociation) was assigned two points. We recommend ≥3 VT score points for a firm diagnosis of VT. A cut-off ≥1 point can be used for diagnosis of VT when highest overall accuracy rather than error - free diagnosis is desired. However, in case of VT score of 0-2 (i.e., not fully diagnostic ECG), we recommend using other options (electrophysiological study, clinical data, previous and following ECGs, etc.) for confirming the diagnosis.
28506602	0	23	Ventricular tachycardia	T047	C0042514
28506602	24	29	score	T081	C0449820
28506602	34	39	novel	T080	C0205314
28506602	40	46	method	T059	C0871511
28506602	51	67	wide QRS complex	T033	C0235475
28506602	68	79	tachycardia	T046	C0039231
28506602	80	95	differentiation	T169	C2945687
28506602	108	118	Philosophy	T090	C0031534
28506602	120	126	merits	T081	C0814225
28506602	131	142	limitations	T169	C0449295
28506602	148	153	novel	T080	C0205314
28506602	154	160	method	T059	C0871511
28506602	165	181	wide QRS complex	T033	C0235475
28506602	182	193	tachycardia	T046	C0039231
28506602	194	209	differentiation	T169	C2945687
28506602	211	216	based	T169	C1527178
28506602	222	236	scoring system	T170	C0282574
28506602	252	275	ventricular tachycardia	T047	C0042514
28506602	277	279	VT	T047	C0042514
28506602	281	286	score	T081	C0449820
28506602	360	375	dominant R wave	T033	C0429091
28506602	383	390	initial	T079	C0205265
28506602	412	421	notched S	T081	C0392762
28506602	429	436	initial	T079	C0205265
28506602	437	443	R wave	T033	C0429091
28506602	449	451	VR	T042	C3537202
28506602	453	465	lead II RWPT	T081	C0392762
28506602	478	485	absence	T169	C0332197
28506602	492	494	RS	T080	C0205556
28506602	511	540	Atrioventricular dissociation	T046	C2882262
28506602	552	558	fusion	T046	C0232213
28506602	579	599	partial dissociation	T046	C2882262
28506602	629	638	recommend	T078	C0034866
28506602	642	644	VT	T047	C0042514
28506602	645	657	score points	T081	C0449820
28506602	669	678	diagnosis	T060	C0430022
28506602	682	684	VT	T047	C0042514
28506602	699	704	point	T081	C1552961
28506602	712	716	used	T169	C1524063
28506602	721	730	diagnosis	T060	C0430022
28506602	734	736	VT	T047	C0042514
28506602	742	749	highest	T080	C1522410
28506602	750	757	overall	T080	C1561607
28506602	758	766	accuracy	T080	C0598285
28506602	767	778	rather than	T033	C3897775
28506602	779	784	error	T080	C0743559
28506602	787	791	free	T080	C1880497
28506602	792	801	diagnosis	T060	C0430022
28506602	805	812	desired	T041	C0871633
28506602	826	830	case	T169	C0868928
28506602	834	836	VT	T047	C0042514
28506602	837	842	score	T081	C0449820
28506602	867	881	diagnostic ECG	T060	C1623258
28506602	887	896	recommend	T078	C0034866
28506602	903	908	other	T080	C0205394
28506602	909	916	options	T169	C1518601
28506602	918	944	electrophysiological study	T060	C0850293
28506602	946	959	clinical data	T170	C1516606
28506602	984	988	ECGs	T060	C1623258
28506602	1015	1024	diagnosis	T060	C0430022

27348285|t|Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting
27348285|a|Despite intensive pharmacotherapy, a considerable number of patients with severe asthma have inadequate disease control. Patients with severe asthma who experience exacerbations consume significant health care resources. To assess health care resource utilization and associated costs among patients with persistent severe asthma who experienced exacerbations compared with patients with persistent but nonsevere asthma. This retrospective analysis of a national administrative claims database identified patients aged ≥ 12 years who had at least 1 medical claim with an asthma diagnosis in 2012 and had continuous medical and pharmacy coverage under a commercial or Medicare Advantage plan from January 1, 2012, to December 31, 2013. Patients were assigned to 1 of 2 mutually exclusive cohorts - persistent asthma (PA) or severe asthma (SA)-according to an established algorithm based on asthma -related health care resource use and pharmacy claims for controller medication. SA patients were required to meet PA criteria and also have evidence of ≥2 asthma exacerbations in 2012. Asthma -related health care resource utilization and costs were computed from asthma medication use (rescue and controller therapy) and medical claims with an asthma diagnosis in the primary position in 2012 and 2013. Adherence to controller therapy was assessed over 365 days by using the proportion of days covered (PDC), starting with the first claim for controller therapy in 2012. Differences between the PA and SA cohorts were analyzed by t-test for continuous variables and chi-square test for categorical variables. Asthma -related costs in 2013 were also analyzed using a generalized linear model with a gamma distribution and log link, adjusted for patient demographics (age, gender, region, and insurance type) and Quan-Charlson comorbidity score. A total of 65,359 patients were included: 63,597 (97.3%) PA patients and 1,762 SA patients (2.7%). Compared with the PA cohort, the SA cohort was older (mean age = 50.8 years vs. 46.5 years, P < 0.001) and had higher mean comorbidity score (1.47 vs. 1.31, P< 0.001). The mean count of all asthma medications fills was 2.2-fold (2012) and 2.1-fold (2013) higher in the SA cohort, compared with the PA cohort (P< 0.001). Mean PDC for all oral and inhaled controller therapy was also higher in the SA cohort compared with the PA cohort (0.80 vs. 0.65, P< 0.001). SA patients had a significantly greater mean count of asthma -related hospitalizations, emergency room visits, and ambulatory visits in 2012 and 2013 (P< 0.001). Unadjusted mean annual asthma -related costs in the SA versus PA cohorts were $6,496 versus $2,739 (P < 0.001) in 2012 and $5,174 versus $1,775 (P< 0.001) in 2013. Higher asthma -related costs were driven by greater mean annual asthma medication costs in 2012 ($4,545 vs. $1,738, P< 0.001) and 2013 ($4,068 vs. $1,348, P< 0.001). Adjusted mean annual asthma -related costs in 2013 were $3,336 greater (cost ratio =2.878, P< 0.001) in the SA cohort, and adjusted mean annual asthma medication costs were $2,672 higher (cost ratio=2.982, P< 0.001) in the SA cohort. Patients with SA who experienced 2 or more exacerbations had 2.1-fold greater use of controller medications across both study years and were more adherent to controller therapy than patients with PA. Despite more intensive pharmacotherapy, SA patients incurred 2.9-fold higher adjusted asthma -related costs and 3-fold higher adjusted asthma medication costs than PA patients. Patients with SA consistently demonstrated a higher rate of health care utilization. Funding for this study (HO-14-14443) was provided by GlaxoSmithKline (GSK). All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors. Albers, Forshag, and Yancey are employees of GSK and hold stock in GSK. Dalal, Nagar, and Ortega were employees of GSK at the time this research was conducted. Chastek and Korrer are employees of Optum, which received consulting fees from GSK for research related to this study. Study concept and design were contributed by Chastek, Nagar, and Dalal. Korrer took the lead in data collection, along with Chastek, and data interpretation was performed by Chastek, Ortega, Forshag, and Dalal. The manuscript was written by Chastek and Dalal and revised by Albers and Yancy, assisted by the other authors.
27348285	0	15	Economic Burden	T081	C1512163
27348285	19	26	Illness	T184	C0221423
27348285	33	41	Patients	T101	C0030705
27348285	47	60	Severe Asthma	T033	C0581126
27348285	74	86	Care Setting	T073,T093	C4034203
27348285	105	120	pharmacotherapy	T061	C0013216
27348285	137	143	number	T081	C0237753
27348285	147	155	patients	T101	C0030705
27348285	161	174	severe asthma	T033	C0581126
27348285	180	190	inadequate	T080	C0205412
27348285	191	198	disease	T047	C0012634
27348285	199	206	control	T080	C0243148
27348285	208	216	Patients	T101	C0030705
27348285	222	235	severe asthma	T033	C0581126
27348285	240	250	experience	T041	C0596545
27348285	251	264	exacerbations	T033	C0349790
27348285	285	306	health care resources	T081	C0683535
27348285	311	317	assess	T052	C1516048
27348285	318	338	health care resource	T081	C0683535
27348285	339	350	utilization	T169	C0042153
27348285	366	371	costs	T081	C0085123
27348285	378	386	patients	T101	C0030705
27348285	392	402	persistent	T079	C0205322
27348285	403	416	severe asthma	T033	C0581126
27348285	421	432	experienced	T041	C0596545
27348285	433	446	exacerbations	T033	C0349790
27348285	461	469	patients	T101	C0030705
27348285	475	485	persistent	T079	C0205322
27348285	500	506	asthma	T047	C0004096
27348285	513	526	retrospective	T080	C1514923
27348285	527	535	analysis	T062	C0936012
27348285	541	580	national administrative claims database	T170	C0242356
27348285	581	591	identified	T080	C0205396
27348285	592	600	patients	T101	C0030705
27348285	601	605	aged	T032	C0001779
27348285	611	616	years	T079	C0439234
27348285	636	649	medical claim	UnknownType	C0586198
27348285	658	664	asthma	T047	C0004096
27348285	665	674	diagnosis	T033	C0011900
27348285	702	709	medical	T033	C2136534
27348285	714	731	pharmacy coverage	T033	C2114292
27348285	740	750	commercial	T170	C0680536
27348285	754	777	Medicare Advantage plan	T064	C3844556
27348285	822	830	Patients	T101	C0030705
27348285	836	844	assigned	T169	C1516050
27348285	874	881	cohorts	T098	C0599755
27348285	884	901	persistent asthma	T047	C3266628
27348285	903	905	PA	T047	C3266628
27348285	910	923	severe asthma	T033	C0581126
27348285	925	927	SA	T033	C0581126
27348285	957	966	algorithm	T170	C0002045
27348285	976	982	asthma	T047	C0004096
27348285	992	1012	health care resource	T081	C0683535
27348285	1013	1016	use	T169	C0457083
27348285	1021	1036	pharmacy claims	T033	C2114292
27348285	1041	1062	controller medication	T121	C0013227
27348285	1064	1066	SA	T033	C0581126
27348285	1067	1075	patients	T101	C0030705
27348285	1093	1097	meet	T067	C1550543
27348285	1098	1100	PA	T047	C3266628
27348285	1101	1109	criteria	T078	C0243161
27348285	1124	1132	evidence	T078	C3887511
27348285	1139	1159	asthma exacerbations	T033	C0349790
27348285	1169	1175	Asthma	T047	C0004096
27348285	1185	1205	health care resource	T081	C0683535
27348285	1206	1217	utilization	T169	C0042153
27348285	1222	1227	costs	T081	C0085123
27348285	1233	1241	computed	T052	C1880157
27348285	1247	1253	asthma	T047	C0004096
27348285	1254	1264	medication	T058	C2081612
27348285	1265	1268	use	T169	C0457083
27348285	1270	1276	rescue	T169	C0039798
27348285	1281	1299	controller therapy	T169	C0039798
27348285	1305	1319	medical claims	UnknownType	C0586198
27348285	1328	1334	asthma	T047	C0004096
27348285	1335	1344	diagnosis	T033	C0011900
27348285	1352	1368	primary position	T082	C0444508
27348285	1387	1396	Adherence	T169	C1510802
27348285	1400	1418	controller therapy	T169	C0039798
27348285	1423	1431	assessed	T052	C1516048
27348285	1441	1445	days	T079	C0439228
27348285	1459	1485	proportion of days covered	T079	C1254367
27348285	1487	1490	PDC	T079	C1254367
27348285	1517	1522	claim	UnknownType	C0586198
27348285	1527	1545	controller therapy	T169	C0039798
27348285	1555	1566	Differences	T080	C1705242
27348285	1579	1581	PA	T047	C3266628
27348285	1586	1588	SA	T033	C0581126
27348285	1589	1596	cohorts	T098	C0599755
27348285	1602	1610	analyzed	T062	C0936012
27348285	1614	1620	t-test	T170	C0871472
27348285	1625	1645	continuous variables	T080	C0439828
27348285	1650	1665	chi-square test	T170	C0008041
27348285	1670	1691	categorical variables	T080	C0439828
27348285	1693	1699	Asthma	T047	C0004096
27348285	1709	1714	costs	T081	C0085123
27348285	1733	1741	analyzed	T062	C0936012
27348285	1762	1774	linear model	T081	C0023732
27348285	1782	1800	gamma distribution	T081	C1708185
27348285	1805	1813	log link	T081,T170	C0026348
27348285	1815	1823	adjusted	T169	C0456081
27348285	1828	1835	patient	T101	C0030705
27348285	1836	1848	demographics	T185	C1698647
27348285	1850	1853	age	T032	C0001779
27348285	1855	1861	gender	T032	C0079399
27348285	1863	1869	region	T083	C0017446
27348285	1875	1889	insurance type	T170	C0680873
27348285	1895	1926	Quan-Charlson comorbidity score	T081	C0449820
27348285	1946	1954	patients	T101	C0030705
27348285	1985	1987	PA	T047	C3266628
27348285	1988	1996	patients	T101	C0030705
27348285	2007	2009	SA	T033	C0581126
27348285	2010	2018	patients	T101	C0030705
27348285	2027	2035	Compared	T052	C1707455
27348285	2045	2047	PA	T047	C3266628
27348285	2048	2054	cohort	T098	C0599755
27348285	2060	2062	SA	T033	C0581126
27348285	2063	2069	cohort	T098	C0599755
27348285	2074	2079	older	T098	C3826770
27348285	2081	2089	mean age	T032	C0001779
27348285	2097	2102	years	T079	C0439234
27348285	2112	2117	years	T079	C0439234
27348285	2150	2167	comorbidity score	T081	C0449820
27348285	2217	2223	asthma	T047	C0004096
27348285	2224	2235	medications	T058	C2081612
27348285	2296	2298	SA	T033	C0581126
27348285	2299	2306	cohort,	T098	C0599755
27348285	2307	2315	compared	T052	C1707455
27348285	2325	2327	PA	T047	C3266628
27348285	2328	2334	cohort	T098	C0599755
27348285	2352	2355	PDC	T079	C1254367
27348285	2364	2368	oral	T122	C1272919
27348285	2373	2380	inhaled	T040	C0004048
27348285	2381	2399	controller therapy	T061	C0087111
27348285	2423	2425	SA	T033	C0581126
27348285	2426	2432	cohort	T098	C0599755
27348285	2433	2441	compared	T052	C1707455
27348285	2451	2453	PA	T047	C3266628
27348285	2454	2460	cohort	T098	C0599755
27348285	2488	2490	SA	T033	C0581126
27348285	2491	2499	patients	T101	C0030705
27348285	2520	2538	greater mean count	T081	C1704243
27348285	2542	2548	asthma	T047	C0004096
27348285	2558	2574	hospitalizations	T058	C0019993
27348285	2576	2597	emergency room visits	T058	C0586082
27348285	2603	2620	ambulatory visits	T033	C4035875
27348285	2673	2679	asthma	T047	C0004096
27348285	2689	2694	costs	T081	C0010186
27348285	2702	2704	SA	T033	C0581126
27348285	2712	2714	PA	T047	C3266628
27348285	2715	2722	cohorts	T098	C0599755
27348285	2821	2827	asthma	T047	C0004096
27348285	2837	2842	costs	T081	C0010186
27348285	2878	2884	asthma	T047	C0004096
27348285	2885	2895	medication	T058	C2081612
27348285	2896	2901	costs	T081	C0010186
27348285	2980	2988	Adjusted	T169	C0456081
27348285	3001	3007	asthma	T047	C0004096
27348285	3017	3022	costs	T081	C0010186
27348285	3052	3062	cost ratio	T081	C0392762
27348285	3088	3090	SA	T033	C0581126
27348285	3091	3097	cohort	T098	C0599755
27348285	3103	3111	adjusted	T169	C0456081
27348285	3124	3130	asthma	T047	C0004096
27348285	3131	3141	medication	T058	C2081612
27348285	3142	3147	costs	T081	C0010186
27348285	3203	3205	SA	T033	C0581126
27348285	3206	3212	cohort	T098	C0599755
27348285	3214	3222	Patients	T101	C0030705
27348285	3228	3230	SA	T033	C0581126
27348285	3235	3246	experienced	T041	C0596545
27348285	3257	3270	exacerbations	T033	C0349790
27348285	3292	3295	use	T169	C0457083
27348285	3299	3321	controller medications	T061	C0087111
27348285	3340	3345	years	T079	C0439234
27348285	3360	3368	adherent	T169	C0334154
27348285	3372	3390	controller therapy	T169	C0039798
27348285	3396	3404	patients	T101	C0030705
27348285	3410	3412	PA	T047	C3266628
27348285	3437	3452	pharmacotherapy	T061	C0013216
27348285	3454	3456	SA	T033	C0581126
27348285	3457	3465	patients	T101	C0030705
27348285	3491	3499	adjusted	T169	C0456081
27348285	3500	3506	asthma	T047	C0004096
27348285	3516	3521	costs	T081	C0010186
27348285	3540	3548	adjusted	T169	C0456081
27348285	3549	3555	asthma	T047	C0004096
27348285	3556	3566	medication	T058	C2081612
27348285	3567	3572	costs	T081	C0010186
27348285	3578	3580	PA	T047	C3266628
27348285	3581	3589	patients	T101	C0030705
27348285	3591	3599	Patients	T101	C0030705
27348285	3605	3607	SA	T033	C0581126
27348285	3608	3620	consistently	T078	C0332290
27348285	3651	3662	health care	T058	C0086388
27348285	3663	3674	utilization	T169	C0042153
27348285	3676	3683	Funding	T081	C0243098
27348285	3693	3698	study	T062	C2603343
27348285	3729	3744	GlaxoSmithKline	T093	C1552903
27348285	3746	3749	GSK	T093	C1552903
27348285	3763	3770	authors	T097	C3812881
27348285	3771	3775	meet	T067	C1550543
27348285	3780	3788	criteria	T078	C0243161
27348285	3793	3803	authorship	T057	C0004351
27348285	3821	3872	International Committee for Medical Journal Editors	T096	C2699414
27348285	3874	3880	Albers	T170	C0805191
27348285	3882	3889	Forshag	T170	C0805191
27348285	3895	3901	Yancey	T170	C0805191
27348285	3906	3915	employees	T097	C0599987
27348285	3919	3922	GSK	T093	C1552903
27348285	3941	3944	GSK	T093	C1552903
27348285	3946	3951	Dalal	T170	C0805191
27348285	3953	3958	Nagar	T170	C0805191
27348285	3964	3970	Ortega	T170	C0805191
27348285	3976	3985	employees	T097	C0599987
27348285	3989	3992	GSK	T093	C1552903
27348285	4000	4004	time	T079	C0040223
27348285	4010	4018	research	T062	C0035168
27348285	4034	4041	Chastek	T170	C0805191
27348285	4046	4052	Korrer	T170	C0805191
27348285	4057	4066	employees	T097	C0599987
27348285	4070	4075	Optum	T093	C0596660
27348285	4092	4107	consulting fees	T081	C0015751
27348285	4113	4116	GSK	T093	C1552903
27348285	4121	4129	research	T062	C0035168
27348285	4146	4151	study	T062	C2603343
27348285	4153	4166	Study concept	T078	C0178566
27348285	4171	4177	design	T052	C1707689
27348285	4183	4194	contributed	T052	C1880177
27348285	4198	4205	Chastek	T170	C0805191
27348285	4207	4212	Nagar	T170	C0805191
27348285	4218	4223	Dalal	T170	C0805191
27348285	4225	4231	Korrer	T170	C0805191
27348285	4249	4264	data collection	T062	C0010995
27348285	4277	4284	Chastek	T170	C0805191
27348285	4290	4309	data interpretation	T081	C0010998
27348285	4327	4334	Chastek	T170	C0805191
27348285	4336	4342	Ortega	T170	C0805191
27348285	4344	4351	Forshag	T170	C0805191
27348285	4357	4362	Dalal	T170	C0805191
27348285	4368	4378	manuscript	T073,T170	C0600659
27348285	4394	4401	Chastek	T170	C0805191
27348285	4406	4411	Dalal	T170	C0805191
27348285	4416	4423	revised	T169	C3244319
27348285	4427	4433	Albers	T170	C0805191
27348285	4438	4443	Yancy	T170	C0805191
27348285	4445	4453	assisted	T080	C1269765
27348285	4467	4474	authors	T097	C3812881

27482315|t|Preoperative ultrasonographic findings of internal jugular veins and carotid arteries in kidney transplant recipients
27482315|a|Hemodialysis via the internal jugular vein (IJV) has been widely used for patients with end stage renal disease (ESRD) patients, as they have a higher risk of arterial diseases. We investigated the ultrasonographic findings of the IJV and carotid artery (CA) in recipients of kidney transplantation (KT) and identified factors influencing IJV / CA abnormalities. We enrolled 120 adult KT recipients. Patients in group A (n = 57) had a history of IJV hemodialysis, while those in group B (n = 63) were not yet on dialysis or undergoing dialysis methods not involving the IJV. The day before surgery, we evaluated the state of the IJV and CA using ultrasonography. We followed patients with IJV stenosis for six months after KT. Ultrasonography revealed that four patients (7%) in group A had IJV abnormalities, while no patients in group B had abnormalities (P = 0.118). Of the four patients with abnormalities, one with 57.4% stenosis normalized during follow- up. However, another patient with 90.1% stenosis progressed to occlusion, while the two patients with total occlusion remained the same. Twenty patients in group A (n = 11) and B (n = 9) had several CA abnormalities (P = 0.462). Upon multivariate analysis with stepwise selection, height and age were significantly correlated with IJV stenosis (P = 0.043, odds ratio = 0.9) and CA abnormality (P = 0.012, odds ratio = 1.1), respectively. IJV abnormalities (especially with a history of IJV hemodialysis) and CA abnormalities may be present in ESRD patients. Therefore, we recommend ultrasonographic evaluation before catheterization.
27482315	0	12	Preoperative	T079	C0445204
27482315	13	29	ultrasonographic	T060	C0041618
27482315	30	38	findings	T033	C0243095
27482315	42	64	internal jugular veins	T023	C0226550
27482315	69	85	carotid arteries	T023	C0007272
27482315	89	117	kidney transplant recipients	T033	C4304779
27482315	118	130	Hemodialysis	T061	C0019004
27482315	139	160	internal jugular vein	T023	C0226550
27482315	162	165	IJV	T023	C0226550
27482315	192	200	patients	T101	C0030705
27482315	206	229	end stage renal disease	T047	C0022661
27482315	231	235	ESRD	T047	C0022661
27482315	237	245	patients	T101	C0030705
27482315	262	273	higher risk	T033	C3843761
27482315	277	294	arterial diseases	T047	C0852949
27482315	316	332	ultrasonographic	T060	C0041618
27482315	333	341	findings	T033	C0243095
27482315	349	352	IJV	T023	C0226550
27482315	357	371	carotid artery	T023	C0007272
27482315	373	375	CA	T023	C0007272
27482315	380	390	recipients	T098	C1709854
27482315	394	416	kidney transplantation	T061	C0022671
27482315	418	420	KT	T061	C0022671
27482315	457	460	IJV	T190	C4073270
27482315	463	479	CA abnormalities	T190	C4073203
27482315	497	502	adult	T100	C0001675
27482315	503	505	KT	T061	C0022671
27482315	506	516	recipients	T101	C0376387
27482315	518	526	Patients	T101	C0030705
27482315	530	537	group A	T185	C0441835
27482315	553	563	history of	T033	C0332119
27482315	564	567	IJV	T023	C0226550
27482315	568	580	hemodialysis	T061	C0019004
27482315	597	604	group B	T185	C0441836
27482315	630	638	dialysis	T061	C0011946
27482315	653	669	dialysis methods	T061	C0011946
27482315	688	691	IJV	T023	C0226550
27482315	697	700	day	T079	C0439228
27482315	708	715	surgery	T061	C0543467
27482315	747	750	IJV	T023	C0226550
27482315	755	757	CA	T023	C0007272
27482315	764	779	ultrasonography	T060	C0041618
27482315	793	801	patients	T101	C0030705
27482315	807	819	IJV stenosis	T047	C0340755
27482315	824	834	six months	T079	C4082120
27482315	841	843	KT	T061	C0022671
27482315	845	860	Ultrasonography	T060	C0041618
27482315	880	888	patients	T101	C0030705
27482315	897	904	group A	T185	C0441835
27482315	909	926	IJV abnormalities	T190	C4073270
27482315	937	945	patients	T101	C0030705
27482315	949	956	group B	T185	C0441836
27482315	961	974	abnormalities	T190	C4073270
27482315	1000	1008	patients	T101	C0030705
27482315	1014	1027	abnormalities	T190	C4073270
27482315	1044	1052	stenosis	T047	C0340755
27482315	1071	1081	follow- up	T058	C1522577
27482315	1100	1107	patient	T101	C0030705
27482315	1119	1127	stenosis	T047	C0340755
27482315	1142	1151	occlusion	T046	C0028778
27482315	1167	1175	patients	T101	C0030705
27482315	1187	1196	occlusion	T046	C0028778
27482315	1223	1231	patients	T101	C0030705
27482315	1235	1242	group A	T185	C0441835
27482315	1256	1257	B	T185	C0441836
27482315	1278	1294	CA abnormalities	T190	C4073203
27482315	1313	1334	multivariate analysis	T081	C0026777
27482315	1360	1366	height	T032	C0489786
27482315	1371	1374	age	T032	C0001779
27482315	1410	1422	IJV stenosis	T047	C0340755
27482315	1457	1471	CA abnormality	T190	C4073203
27482315	1517	1534	IJV abnormalities	T190	C4073270
27482315	1554	1564	history of	T033	C0332119
27482315	1565	1568	IJV	T023	C0226550
27482315	1569	1581	hemodialysis	T061	C0019004
27482315	1587	1603	CA abnormalities	T190	C4073203
27482315	1622	1626	ESRD	T047	C0022661
27482315	1627	1635	patients	T101	C0030705
27482315	1661	1677	ultrasonographic	T060	C0041618
27482315	1678	1688	evaluation	T058	C0220825
27482315	1696	1711	catheterization	T061	C0007430

28504165|t|Calcium silicate nanowires - An effective alternative for improving mechanical properties of chitosan - hydroxyethyl methacrylate (HEMA) copolymer nanocomposites
28504165|a|Nanowires of calcium silicate were successfully synthesized by ultrasonic irradiation process and incorporated into chitosan and hydroxyetheyl methacrylate (HEMA) copolymer matrix by solution blending for efficacious preparation of biodegradable nanocomposites. Remarkable improvement in mechanical properties of the nanocomposites was noticed after micro-tensile analysis. Enlarged surface area and higher aspect ratio of CaSiO3 nanowires were the key factors responsible for such improvement. This was supported by EDS and XRD analysis in terms of proper distribution of nanofiller through the copolymer matrix and corresponding rise in percentage crystallanity respectively. Contact angle and biodegradation studies further clarified that nano - CaSiO3 did not affect the hydrophilicity and general degradation route of chitosan copolymer respectively. This renders the nano - CaSiO3 as an ideal substitute for preparing high performance nanocomposites to be applicable for biomedical applications.
28504165	0	16	Calcium silicate	T121,T197	C0054483
28504165	17	26	nanowires	T073	C1721063
28504165	58	67	improving	T033	C0184511
28504165	68	89	mechanical properties	T081	C0392762
28504165	93	101	chitosan	T109,T121	C0162969
28504165	104	129	hydroxyethyl methacrylate	T109,T122	C0063127
28504165	131	135	HEMA	T109,T122	C0063127
28504165	137	146	copolymer	T104	C0596383
28504165	147	161	nanocomposites	T073	C1721059
28504165	162	171	Nanowires	T073	C1721063
28504165	175	191	calcium silicate	T121,T197	C0054483
28504165	210	221	synthesized	T052	C1883254
28504165	225	247	ultrasonic irradiation	T070	C1456803
28504165	278	286	chitosan	T109,T121	C0162969
28504165	291	317	hydroxyetheyl methacrylate	T109,T122	C0063127
28504165	319	323	HEMA	T109,T122	C0063127
28504165	325	334	copolymer	T104	C0596383
28504165	394	407	biodegradable	T109,T122	C0597998
28504165	408	422	nanocomposites	T073	C1721059
28504165	450	471	mechanical properties	T081	C0392762
28504165	479	493	nanocomposites	T073	C1721059
28504165	512	534	micro-tensile analysis	T059	C0002778
28504165	536	557	Enlarged surface area	T033	C2825141
28504165	585	591	CaSiO3	T130,T131,T197	C0892056
28504165	592	601	nanowires	T073	C1721063
28504165	615	622	factors	T169	C1521761
28504165	679	682	EDS	T059	C2699997
28504165	687	699	XRD analysis	T059	C0043301
28504165	735	745	nanofiller	T073	C0729441
28504165	758	767	copolymer	T104	C0596383
28504165	801	825	percentage crystallanity	T033	C2825141
28504165	840	853	Contact angle	T033	C2825141
28504165	858	872	biodegradation	T070	C0005482
28504165	904	908	nano	T081	C1553036
28504165	911	917	CaSiO3	T130,T131,T197	C0892056
28504165	937	951	hydrophilicity	T080	C0475370
28504165	964	981	degradation route	T169	C0243125
28504165	985	993	chitosan	T109,T121	C0162969
28504165	994	1003	copolymer	T104	C0596383
28504165	1035	1039	nano	T081	C1553036
28504165	1042	1048	CaSiO3	T130,T131,T197	C0892056
28504165	1103	1117	nanocomposites	T073	C1721059
28504165	1139	1162	biomedical applications	T091	C0005539

27588139|t|Clinicopathological relevance of kinesin family member 18A expression in invasive breast cancer
27588139|a|Recently, kinesin motor proteins have been focused on as targets for cancer therapy. Kinesins are microtubule -based motor proteins that mediate diverse functions within the cell, including the transport of vesicles, organelles, chromosomes and protein complexes, as well as the movement of microtubules. In the current study, the expression of kinesin family member 18A (KIF18A), a member of kinesin superfamily, was investigated in breast cancer using immunohistochemistry, and its effect on breast cancer prognosis was examined. KIF18A expression level was significantly associated with lymph node metastasis (P=0.047). In patients with high levels of KIF18A expression, survival was significantly poorer compared to patients with low levels of KIF18A expression (disease-free survival, P=0.030). Multivariate analysis revealed that venous invasion (hazard ratio, 9.22; 95% confidence interval, 3.90-23.66; P<0.001) and KIF18A expression (hazard ratio, 3.20; 95% confidence interval, 1.34-6.09; P=0.010) were independent predictive factors for lymph node metastasis. KIF18A may be a useful predictive marker for lymph node metastasis in breast cancer, which could facilitate curative adjuvant treatment.
27588139	0	19	Clinicopathological	T091	C0030667
27588139	33	58	kinesin family member 18A	T116,T126	C1610793
27588139	59	69	expression	T045	C1171362
27588139	73	95	invasive breast cancer	T191	C0853879
27588139	106	113	kinesin	T116,T126	C0085139
27588139	114	128	motor proteins	T116,T123	C1720835
27588139	153	160	targets	T169	C1521840
27588139	165	179	cancer therapy	T061	C0920425
27588139	181	189	Kinesins	T116,T126	C0085139
27588139	194	205	microtubule	T116,T123	C0026042
27588139	213	227	motor proteins	T116,T123	C1720835
27588139	241	258	diverse functions	T169	C0542341
27588139	270	274	cell	T025	C0007634
27588139	290	299	transport	T043	C0005528
27588139	303	311	vesicles	T026	C1622418
27588139	313	323	organelles	T026	C0029219
27588139	325	336	chromosomes	T026	C0008633
27588139	341	358	protein complexes	T116,T123	C1180347
27588139	375	399	movement of microtubules	T043	C1156033
27588139	427	437	expression	T045	C1171362
27588139	441	466	kinesin family member 18A	T116,T126	C1610793
27588139	468	474	KIF18A	T116,T126	C1610793
27588139	479	508	member of kinesin superfamily	T116,T126	C0085139
27588139	514	526	investigated	T169	C1292732
27588139	530	543	breast cancer	T191	C0006142
27588139	550	570	immunohistochemistry	T060	C0021044
27588139	590	603	breast cancer	T191	C0006142
27588139	628	634	KIF18A	T116,T126	C1610793
27588139	635	651	expression level	T081	C3244092
27588139	670	685	associated with	T080	C0332281
27588139	686	707	lymph node metastasis	T191	C0686619
27588139	722	730	patients	T101	C0030705
27588139	751	757	KIF18A	T116,T126	C1610793
27588139	758	768	expression	T045	C1171362
27588139	770	778	survival	T052	C0038952
27588139	816	824	patients	T101	C0030705
27588139	844	850	KIF18A	T116,T126	C1610793
27588139	851	861	expression	T045	C1171362
27588139	863	884	disease-free survival	T081	C0242793
27588139	896	917	Multivariate analysis	T081	C0026777
27588139	932	947	venous invasion	T033	C1710625
27588139	949	961	hazard ratio	T081	C2985465
27588139	973	992	confidence interval	T081	C0009667
27588139	1019	1025	KIF18A	T116,T126	C1610793
27588139	1026	1036	expression	T045	C1171362
27588139	1038	1050	hazard ratio	T081	C2985465
27588139	1062	1081	confidence interval	T081	C0009667
27588139	1120	1138	predictive factors	T170	C0683956
27588139	1143	1164	lymph node metastasis	T191	C0686619
27588139	1166	1172	KIF18A	T116,T126	C1610793
27588139	1189	1199	predictive	T170	C0683956
27588139	1200	1206	marker	T201	C0005516
27588139	1211	1232	lymph node metastasis	T191	C0686619
27588139	1236	1249	breast cancer	T191	C0006142
27588139	1274	1291	curative adjuvant	T033	C3846124
27588139	1292	1301	treatment	T061	C0087111

27754397|t|Total Energy Expenditure in Obese Kuwaiti Primary School Children Assessed by the Doubly-Labeled Water Technique
27754397|a|The aim of this pilot study was to assess body composition and total energy expenditure (TEE) in 35 obese 7-9 years old Kuwaiti children (18 girls and 17 boys). Total body water (TBW) and TEE were assessed by doubly-labeled water technique. TBW was derived from the intercept of the elimination rate of deuterium and TEE from the difference in elimination rates of (18)O and deuterium. TBW was used to estimate fat-free mass (FFM), using hydration factors for different ages and gender. Fat mass (FM) was calculated as the difference between body weight and FFM. Body weight was not statistically different but TBW was significantly higher (p = 0.018) in boys (44.9% ± 3.3%) than girls (42.4% ± 3.0%), while girls had significantly higher estimated FM (45.2 ± 3.9 weight % versus 41.6% ± 4.3%; p = 0.014). TEE was significantly higher in boys (2395 ± 349 kcal/day) compared with girls (1978 ± 169 kcal/day); p = 0.001. Estimated physical activity level (PAL) was significantly higher in boys; 1.61 ± 0.167 versus 1.51 ± 0.870; p = 0.034. Our results provide the first dataset of TEE in 7-9 years old obese Kuwaiti children and highlight important gender differences to be considered during the development of school based interventions targeted to combat childhood obesity.
27754397	0	24	Total Energy Expenditure	T033	C0429629
27754397	28	33	Obese	T047	C0028754
27754397	34	56	Kuwaiti Primary School	T073,T092	C0036375
27754397	57	65	Children	T100	C0008059
27754397	66	74	Assessed	T052	C1516048
27754397	82	112	Doubly-Labeled Water Technique	T169	C0449851
27754397	129	140	pilot study	T062	C0031928
27754397	148	154	assess	T052	C1516048
27754397	176	200	total energy expenditure	T033	C0429629
27754397	202	205	TEE	T033	C0429629
27754397	213	218	obese	T047	C0028754
27754397	223	228	years	T079	C0439234
27754397	233	240	Kuwaiti	T098	C1257890
27754397	241	249	children	T100	C0008059
27754397	254	259	girls	T100	C0870604
27754397	267	271	boys	T100	C0870221
27754397	274	290	Total body water	T033	C0429632
27754397	292	295	TBW	T033	C0429632
27754397	301	304	TEE	T033	C0429629
27754397	310	318	assessed	T052	C1516048
27754397	322	352	doubly-labeled water technique	T169	C0449851
27754397	354	357	TBW	T033	C0429632
27754397	379	388	intercept	T081	C3146232
27754397	396	412	elimination rate	T033	C0231360
27754397	416	425	deuterium	T196	C0011744
27754397	430	433	TEE	T033	C0429629
27754397	443	453	difference	T081	C1705241
27754397	457	474	elimination rates	T033	C0231360
27754397	478	483	(18)O	T121,T196	C0030061
27754397	488	497	deuterium	T196	C0011744
27754397	499	502	TBW	T033	C0429632
27754397	515	523	estimate	T081	C0750572
27754397	524	537	fat-free mass	T033	C0424679
27754397	539	542	FFM	T033	C0424679
27754397	551	560	hydration	T067	C0596317
27754397	561	568	factors	T169	C1521761
27754397	583	587	ages	T032	C0001779
27754397	592	598	gender	T032	C0079399
27754397	600	608	Fat mass	T032	C3656665
27754397	610	612	FM	T032	C3656665
27754397	618	628	calculated	T052	C1441506
27754397	636	646	difference	T081	C1705241
27754397	655	666	body weight	T032	C0005910
27754397	671	674	FFM	T033	C0424679
27754397	676	687	Body weight	T032	C0005910
27754397	696	719	statistically different	T081	C1705241
27754397	724	727	TBW	T033	C0429632
27754397	732	752	significantly higher	T080	C0205250
27754397	768	772	boys	T100	C0870221
27754397	793	798	girls	T100	C0870604
27754397	821	826	girls	T100	C0870604
27754397	831	851	significantly higher	T080	C0205250
27754397	852	861	estimated	T081	C0750572
27754397	862	864	FM	T032	C3656665
27754397	919	922	TEE	T033	C0429629
27754397	927	947	significantly higher	T080	C0205250
27754397	951	955	boys	T100	C0870221
27754397	992	997	girls	T100	C0870604
27754397	1032	1041	Estimated	T081	C0750572
27754397	1042	1065	physical activity level	T033	C3694575
27754397	1067	1070	PAL	T033	C3694575
27754397	1076	1096	significantly higher	T080	C0205250
27754397	1100	1104	boys	T100	C0870221
27754397	1155	1162	results	T169	C1274040
27754397	1181	1188	dataset	T170	C0150098
27754397	1192	1195	TEE	T033	C0429629
27754397	1203	1208	years	T079	C0439234
27754397	1213	1218	obese	T047	C0028754
27754397	1219	1226	Kuwaiti	T098	C1257890
27754397	1227	1235	children	T100	C0008059
27754397	1260	1278	gender differences	T032	C0036866
27754397	1322	1348	school based interventions	T058	C0679800
27754397	1368	1385	childhood obesity	T047	C2362324

28251753|t|Optomechanical Control of Quantum Yield in Trans-Cis Ultrafast Photoisomerization of a Retinal Chromophore Model
28251753|a|The quantum yield of a photochemical reaction is one of the most fundamental quantities in photochemistry, as it measures the efficiency of the transduction of light energy into chemical energy. Nature has evolved photoreceptors in which the reactivity of a chromophore is enhanced by its molecular environment to achieve high quantum yields. The retinal chromophore sterically constrained inside rhodopsin proteins represents an outstanding example of such a control. In a more general framework, mechanical forces acting on a molecular system can strongly modify its reactivity. Herein, we show that the exertion of tensile forces on a simplified retinal chromophore model provokes a substantial and regular increase in the trans-to-cis photoisomerization quantum yield in a counterintuitive way, as these extension forces facilitate the formation of the more compressed cis photoisomer. A rationale for the mechanochemical effect on this photoisomerization mechanism is also proposed.
28251753	0	22	Optomechanical Control	T169	C0443254
28251753	26	39	Quantum Yield	T081	C0392762
28251753	43	81	Trans-Cis Ultrafast Photoisomerization	T044	C0596342
28251753	87	94	Retinal	T109,T121,T127	C0035331
28251753	95	106	Chromophore	T120	C0596335
28251753	107	112	Model	T075	C0026336
28251753	117	130	quantum yield	T081	C0392762
28251753	136	158	photochemical reaction	T070	C2350502
28251753	178	200	fundamental quantities	T081	C1265611
28251753	204	218	photochemistry	T090	C0031739
28251753	257	306	transduction of light energy into chemical energy	T043	C0376451
28251753	308	314	Nature	T078	C0349590
28251753	327	341	photoreceptors	T025	C0031760
28251753	355	365	reactivity	UnknownType	C0678596
28251753	371	382	chromophore	T120	C0596335
28251753	402	423	molecular environment	T082	C0014406
28251753	440	454	quantum yields	T081	C0392762
28251753	460	467	retinal	T109,T121,T127	C0035331
28251753	468	479	chromophore	T120	C0596335
28251753	510	528	rhodopsin proteins	T116,T123	C0035499
28251753	611	628	mechanical forces	T067	C0563538
28251753	641	657	molecular system	T080	C1521991
28251753	682	692	reactivity	UnknownType	C0678596
28251753	731	745	tensile forces	T081	C0039526
28251753	762	769	retinal	T109,T121,T127	C0035331
28251753	770	781	chromophore	T120	C0596335
28251753	782	787	model	T075	C0026336
28251753	799	831	substantial and regular increase	T080	C0205556
28251753	839	870	trans-to-cis photoisomerization	T044	C0596342
28251753	871	884	quantum yield	T081	C0392762
28251753	986	1001	cis photoisomer	T104	C1254350
28251753	1005	1014	rationale	T078	C2699007
28251753	1023	1045	mechanochemical effect	T070	C2350457
28251753	1054	1082	photoisomerization mechanism	T070	C2350502

27677676|t|Early second-trimester plasma levels of NT-proBNP in women who subsequently develop early-onset preeclampsia
27677676|a|Plasma levels of NT-proBNP are elevated in women with preeclampsia at the time of diagnosis. The objective of this case-control study was to evaluate N-terminal proBNP (NT-proBNP) in maternal plasma as an early second-trimester biomarker for prediction of early-onset preeclampsia. In early second-trimester samples, women who later developed preeclampsia at gestational age 34 wk + 0 or earlier (n = 16) had similar plasma levels of NT-proBNP (median 51.8, range 26.1-131.9 pg/ml) as women with uncomplicated pregnancy outcomes (n = 43) (53.0, 14.9-184.2 pg/ml). The early second-trimester level of NT-proBNP cannot therefore be used as a predictive biomarker of early-onset preeclampsia.
27677676	0	5	Early	T079	C1279919
27677676	6	22	second-trimester	T079	C0032980
27677676	23	29	plasma	T031	C0032105
27677676	30	36	levels	T080	C0441889
27677676	40	49	NT-proBNP	T116,T123	C0754710
27677676	53	58	women	T098	C0033011
27677676	84	95	early-onset	T033	C1833334
27677676	96	108	preeclampsia	T046	C0032914
27677676	109	115	Plasma	T031	C0032105
27677676	116	122	levels	T080	C0441889
27677676	126	135	NT-proBNP	T116,T123	C0754710
27677676	140	148	elevated	T080	C3163633
27677676	152	157	women	T098	C0033011
27677676	163	175	preeclampsia	T046	C0032914
27677676	183	187	time	T079	C0040223
27677676	191	200	diagnosis	T033	C0011900
27677676	224	242	case-control study	T062	C0007328
27677676	250	258	evaluate	T058	C0220825
27677676	259	276	N-terminal proBNP	T116,T123	C0754710
27677676	278	287	NT-proBNP	T116,T123	C0754710
27677676	292	300	maternal	T033	C1858460
27677676	301	307	plasma	T031	C0032105
27677676	314	319	early	T079	C1279919
27677676	320	336	second-trimester	T079	C0032980
27677676	337	346	biomarker	T201	C0005516
27677676	351	361	prediction	T078	C0681842
27677676	365	376	early-onset	T033	C1833334
27677676	377	389	preeclampsia	T046	C0032914
27677676	394	399	early	T079	C1279919
27677676	400	416	second-trimester	T079	C0032980
27677676	417	424	samples	T167	C0370003
27677676	426	431	women	T098	C0033011
27677676	452	464	preeclampsia	T046	C0032914
27677676	468	489	gestational age 34 wk	T079	C0233041
27677676	526	532	plasma	T031	C0032105
27677676	533	539	levels	T080	C0441889
27677676	543	552	NT-proBNP	T116,T123	C0754710
27677676	594	599	women	T098	C0033011
27677676	605	618	uncomplicated	T080	C0443334
27677676	619	637	pregnancy outcomes	T033	C0032972
27677676	677	682	early	T079	C1279919
27677676	683	699	second-trimester	T079	C0032980
27677676	700	705	level	T080	C0441889
27677676	709	718	NT-proBNP	T116,T123	C0754710
27677676	749	759	predictive	T080	C0681890
27677676	760	769	biomarker	T201	C0005516
27677676	773	784	early-onset	T033	C1833334
27677676	785	797	preeclampsia	T046	C0032914

28125165|t|Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study
28125165|a|Deregulation of the cell cycle by mechanisms that lead to elevated activities of cyclin-dependent kinases (CDK) is a feature of many human diseases, cancer in particular. We identified small-molecule inhibitors that selectively inhibit CDK7, the kinase that phosphorylates cell-cycle CDKs to promote their activities. To investigate the selectivity of these inhibitors we used a combination of structural, biophysical, and modelling approaches. We determined the crystal structures of the CDK7 -selective compounds ICEC0942 and ICEC0943 bound to CDK2, and used these to build models of inhibitor binding to CDK7. Molecular dynamics (MD) simulations of inhibitors bound to CDK2 and CDK7 generated possible models of inhibitor binding. To experimentally validate these models, we gathered isothermal titration calorimetry (ITC) binding data for recombinant wild-type and binding site mutants of CDK7 and CDK2. We identified specific residues of CDK7, notably Asp155, that are involved in determining inhibitor selectivity. Our MD simulations also show that the flexibility of the G-rich and activation loops of CDK7 is likely an important determinant of inhibitor specificity similar to CDK2.
28125165	0	9	Inhibitor	T121	C0014432
28125165	26	51	Cyclin-Dependent Kinase 7	T116,T126	C0255652
28125165	55	65	Structural	T082	C0678594
28125165	67	80	Thermodynamic	T090	C0039808
28125165	86	95	Modelling	T062,T170	C0600115
28125165	96	101	Study	T062	C2603343
28125165	102	132	Deregulation of the cell cycle	T049	C1516331
28125165	136	146	mechanisms	T169	C0441712
28125165	169	179	activities	T052	C0441655
28125165	183	207	cyclin-dependent kinases	T116,T126	C0243045
28125165	209	212	CDK	T116,T126	C0243045
28125165	235	240	human	T016	C0086418
28125165	241	249	diseases	T047	C0012634
28125165	251	257	cancer	T191	C0006826
28125165	287	301	small-molecule	T109	C1328819
28125165	302	312	inhibitors	T121	C0014432
28125165	330	337	inhibit	T052	C3463820
28125165	338	342	CDK7	T116,T126	C0255652
28125165	348	354	kinase	T116,T126	C0031727
28125165	360	374	phosphorylates	T044	C0031715
28125165	375	385	cell-cycle	T043	C0007586
28125165	386	390	CDKs	T116,T126	C0243045
28125165	394	401	promote	T052	C0033414
28125165	408	418	activities	T052	C0441655
28125165	460	470	inhibitors	T121	C0014432
28125165	496	506	structural	T082	C0678594
28125165	508	519	biophysical	T091	C0005553
28125165	525	534	modelling	T062,T170	C0600115
28125165	565	583	crystal structures	T104	C0444626
28125165	591	595	CDK7	T116,T126	C0255652
28125165	607	616	compounds	T121	C1254351
28125165	617	625	ICEC0942	T121	C1254351
28125165	630	638	ICEC0943	T121	C1254351
28125165	648	652	CDK2	T116,T126	C0108855
28125165	678	684	models	T170	C0026344
28125165	688	697	inhibitor	T121	C0014432
28125165	709	713	CDK7	T116,T126	C0255652
28125165	715	750	Molecular dynamics (MD) simulations	T066	C2717775
28125165	754	764	inhibitors	T121	C0014432
28125165	774	778	CDK2	T116,T126	C0108855
28125165	783	787	CDK7	T116,T126	C0255652
28125165	807	813	models	T170	C0026344
28125165	817	826	inhibitor	T121	C0014432
28125165	839	853	experimentally	T062	C0681814
28125165	869	875	models	T170	C0026344
28125165	889	921	isothermal titration calorimetry	T074	C3689480
28125165	923	926	ITC	T074	C3689480
28125165	936	940	data	T078	C1511726
28125165	945	956	recombinant	T116	C0034861
28125165	957	966	wild-type	T028	C1883559
28125165	971	983	binding site	T192	C0005456
28125165	984	991	mutants	T116	C1564139
28125165	995	999	CDK7	T116,T126	C0255652
28125165	1004	1008	CDK2	T116,T126	C0108855
28125165	1033	1041	residues	T077	C1709915
28125165	1045	1049	CDK7	T116,T126	C0255652
28125165	1059	1065	Asp155	T116,T123	C0004015
28125165	1100	1109	inhibitor	T121	C0014432
28125165	1127	1141	MD simulations	T066	C2717775
28125165	1180	1186	G-rich	T169	C0205681
28125165	1191	1207	activation loops	T169	C0205681
28125165	1211	1215	CDK7	T116,T126	C0255652
28125165	1254	1263	inhibitor	T121	C0014432
28125165	1264	1275	specificity	UnknownType	C0678612
28125165	1287	1291	CDK2	T116,T126	C0108855

28534189|t|National Trends in Bariatric Surgery 2012-2015: Demographics, Procedure Selection, Readmissions, and Cost
28534189|a|Bariatric surgery is widely accepted as the best treatment for obesity and type 2 diabetes mellitus (T2DM). The Roux-en-Y gastric bypass (RYGB) and the sleeve gastrectomy (SG) have become the predominant bariatric procedures in the USA over the last several years, although the most recent trends in selection are unknown. The objective of this study is to assess selection trends, readmission rates, and cost of bariatric procedures in the USA from 2012 to 2015. We used the Premier database from 2012 to 2015 to examine trends in incidence of RYGB, adjustable gastric banding (LAGB), and SG; readmissions; and cost. Multivariate regression was performed to identify predictors of readmission. The proportion of SG went up from 38 to 63% while the RYGB decreased from 44 to 30% over this time period. LAGB has decreased in use from 13 to 2%. In comparison to RYGB, readmission was less likely for SG (OR 0.64), males (OR 0.91), and more likely for black race (OR 1.27). The overall proportion of patients seeking RYGB with type 2 diabetes was higher than with SG (36 versus 25%), but SG has now overtaken RYGB as the most common procedure among diabetics. The SG is less costly than RYGB ($11,183 versus $13,485). There is a continued overall trend in the increased popularity of the SG and decreased utilization of the RYGB and LAGB, although growth of the SG appears to be slowing. This is also true among patients with type 2 diabetes mellitus. Regardless of surgery type, underinsured and African-American race were more likely to be readmitted.
28534189	0	8	National	T082	C0681788
28534189	9	15	Trends	T079	C1521798
28534189	19	36	Bariatric Surgery	T061	C1456587
28534189	48	60	Demographics	T090	C0011298
28534189	62	71	Procedure	T061	C0087111
28534189	72	81	Selection	T052	C1707391
28534189	83	95	Readmissions	T058	C0030700
28534189	101	105	Cost	T081	C0010186
28534189	106	123	Bariatric surgery	T061	C1456587
28534189	155	164	treatment	T061	C0087111
28534189	169	176	obesity	T047	C0028754
28534189	181	205	type 2 diabetes mellitus	T047	C0011860
28534189	207	211	T2DM	T047	C0011860
28534189	218	242	Roux-en-Y gastric bypass	T061	C0585179
28534189	244	248	RYGB	T061	C0585179
28534189	258	276	sleeve gastrectomy	T061	C3160799
28534189	278	280	SG	T061	C3160799
28534189	298	309	predominant	T080	C1542147
28534189	310	330	bariatric procedures	T061	C1456587
28534189	338	341	USA	T083	C0041703
28534189	396	402	trends	T079	C1521798
28534189	433	442	objective	T170	C0018017
28534189	451	456	study	T062	C2603343
28534189	480	486	trends	T079	C1521798
28534189	488	499	readmission	T058	C0030700
28534189	500	505	rates	T081	C1521828
28534189	511	515	cost	T081	C0010186
28534189	519	539	bariatric procedures	T061	C1456587
28534189	547	550	USA	T083	C0041703
28534189	582	598	Premier database	T170	C0242356
28534189	628	634	trends	T079	C1521798
28534189	638	647	incidence	T081	C0021149
28534189	651	655	RYGB	T061	C0585179
28534189	657	683	adjustable gastric banding	T061	C1532765
28534189	685	689	LAGB	T061	C1532765
28534189	696	698	SG	T061	C3160799
28534189	700	712	readmissions	T058	C0030700
28534189	718	722	cost	T081	C0010186
28534189	724	747	Multivariate regression	T081	C0026777
28534189	774	784	predictors	T078	C2698872
28534189	788	799	readmission	T058	C0030700
28534189	805	815	proportion	T081	C1709707
28534189	819	821	SG	T061	C3160799
28534189	855	859	RYGB	T061	C0585179
28534189	860	869	decreased	T081	C0205216
28534189	908	912	LAGB	T061	C1532765
28534189	917	926	decreased	T081	C0205216
28534189	952	962	comparison	T052	C1707455
28534189	966	970	RYGB	T061	C0585179
28534189	972	983	readmission	T058	C0030700
28534189	993	999	likely	T078	C0750492
28534189	1004	1006	SG	T061	C3160799
28534189	1018	1023	males	T032	C0086582
28534189	1044	1050	likely	T078	C0750492
28534189	1055	1065	black race	T098	C0005680
28534189	1081	1088	overall	T080	C1561607
28534189	1103	1111	patients	T101	C0030705
28534189	1120	1124	RYGB	T061	C0585179
28534189	1130	1145	type 2 diabetes	T047	C0011860
28534189	1150	1156	higher	T080	C0205250
28534189	1167	1169	SG	T061	C3160799
28534189	1191	1193	SG	T061	C3160799
28534189	1212	1216	RYGB	T061	C0585179
28534189	1236	1245	procedure	T061	C0087111
28534189	1252	1261	diabetics	T033	C0241863
28534189	1267	1269	SG	T061	C3160799
28534189	1290	1294	RYGB	T061	C0585179
28534189	1342	1349	overall	T080	C1561607
28534189	1350	1355	trend	T079	C1521798
28534189	1363	1372	increased	T081	C0205217
28534189	1391	1393	SG	T061	C3160799
28534189	1398	1407	decreased	T081	C0205216
28534189	1427	1431	RYGB	T061	C0585179
28534189	1436	1440	LAGB	T061	C1532765
28534189	1465	1467	SG	T061	C3160799
28534189	1515	1523	patients	T101	C0030705
28534189	1529	1553	type 2 diabetes mellitus	T047	C0011860
28534189	1569	1576	surgery	T061	C0543467
28534189	1577	1581	type	T080	C0332307
28534189	1600	1621	African-American race	T098	C0085756
28534189	1632	1638	likely	T078	C0750492
28534189	1645	1655	readmitted	T058	C0030700

27465939|t|microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue -Derived Stromal Cells on Prostate Cancer
27465939|a|Adipose-derived stromal cell (ASC), known as one of the mesenchymal stem cells (MSCs), is a promising tool for regenerative medicine; however, the effect of ASCs on tumor growth has not been studied sufficiently. We investigated the hypothesis that ASCs have an inhibitory effect on metastatic tumor progression. To evaluate the in vitro inhibitory effect of ASCs on metastatic prostate cancer (PCa), direct coculture and indirect separate culture experiments with PC3M-luc2 cells and human ASCs were performed, and ASCs were administered to PC3M-luc2 cell -derived tumor -bearing nude mice for in vivo experiment. We also performed exosome microRNA (miRNA) array analysis to explore a mechanistic insight into the effect of ASCs on PCa cell proliferation / apoptosis. Both in vitro and in vivo experiments exhibited the inhibitory effect of ASCs on PC3M-luc2 cell proliferation, inducing apoptosis and PCa growth, respectively. Among upregulated miRNAs in ASCs compared with fibroblasts, we focused on miR-145, which was known as a tumor suppressor. ASC -derived conditioned medium (CM) significantly inhibited PC3M-luc2 cell proliferation, inducing apoptosis, but the effect was canceled by miR-145 knockdown in ASCs. ASC miR-145 knockdown CM also reduced the expression of Caspase 3 / 7 with increased antiapoptotic protein, BclxL, expression in PC3M-luc2 cells. This study provides preclinical data that ASCs inhibit PCa growth, inducing PCa cell apoptosis with reduced activity of BclxL, at least in part, by miR-145, including exosomes released from ASCs, suggesting that ASC administration could be a novel and promising therapeutic strategy in patients with PCa.
27465939	0	12	microRNA-145	T114	C2716184
27465939	26	36	Inhibitory	T052	C3463820
27465939	37	43	Effect	T080	C1280500
27465939	47	61	Adipose Tissue	T024	C0001527
27465939	71	84	Stromal Cells	T025	C0162597
27465939	88	103	Prostate Cancer	T191	C0600139
27465939	104	138	Adipose-derived stromal cell (ASC)	T025	C0162597
27465939	160	189	mesenchymal stem cells (MSCs)	T025	C1257975
27465939	215	236	regenerative medicine	T091	C1257974
27465939	251	257	effect	T080	C1280500
27465939	261	265	ASCs	T025	C0162597
27465939	269	281	tumor growth	T191	C0598934
27465939	320	332	investigated	T169	C1292732
27465939	337	347	hypothesis	T078	C1512571
27465939	353	357	ASCs	T025	C0162597
27465939	366	376	inhibitory	T052	C3463820
27465939	377	383	effect	T080	C1280500
27465939	387	415	metastatic tumor progression	T191	C0178874
27465939	420	428	evaluate	T052	C1516048
27465939	433	441	in vitro	T080	C1533691
27465939	442	452	inhibitory	T052	C3463820
27465939	453	459	effect	T080	C1280500
27465939	463	467	ASCs	T025	C0162597
27465939	471	503	metastatic prostate cancer (PCa)	T191	C0936223
27465939	512	521	coculture	T059	C0282547
27465939	544	563	culture experiments	T059	C0430400
27465939	569	584	PC3M-luc2 cells	T025	C0682523
27465939	589	594	human	T016	C0086418
27465939	595	599	ASCs	T025	C0162597
27465939	620	624	ASCs	T025	C0162597
27465939	630	642	administered	T169	C1521801
27465939	646	660	PC3M-luc2 cell	T025	C0682523
27465939	670	675	tumor	T033	C3273930
27465939	685	694	nude mice	T015	C0025932
27465939	699	706	in vivo	T082	C1515655
27465939	707	717	experiment	T062	C0681814
27465939	737	744	exosome	T026	C2350332
27465939	745	761	microRNA (miRNA)	T114,T123	C1101610
27465939	762	776	array analysis	T059	C1449653
27465939	790	809	mechanistic insight	T169	C0441712
27465939	819	825	effect	T080	C1280500
27465939	829	833	ASCs	T025	C0162597
27465939	837	845	PCa cell	T025	C0597032
27465939	846	859	proliferation	T043	C0596290
27465939	862	871	apoptosis	T043	C0162638
27465939	878	886	in vitro	T080	C1533691
27465939	891	898	in vivo	T082	C1515655
27465939	899	910	experiments	T062	C0681814
27465939	925	935	inhibitory	T052	C3463820
27465939	936	942	effect	T080	C1280500
27465939	946	950	ASCs	T025	C0162597
27465939	954	963	PC3M-luc2	T025	C0682523
27465939	964	982	cell proliferation	T043	C0596290
27465939	993	1002	apoptosis	T043	C0162638
27465939	1007	1010	PCa	T191	C0936223
27465939	1011	1017	growth	T191	C1516170
27465939	1039	1050	upregulated	T044	C0041904
27465939	1051	1057	miRNAs	T114,T123	C1101610
27465939	1061	1065	ASCs	T025	C0162597
27465939	1080	1091	fibroblasts	T025	C0016030
27465939	1107	1114	miR-145	T028	C1537799
27465939	1137	1153	tumor suppressor	T028	C0079427
27465939	1155	1158	ASC	T025	C0162597
27465939	1168	1191	conditioned medium (CM)	T130	C0162518
27465939	1206	1215	inhibited	T052	C3463820
27465939	1216	1225	PC3M-luc2	T025	C0682523
27465939	1226	1244	cell proliferation	T043	C0596290
27465939	1255	1264	apoptosis	T043	C0162638
27465939	1274	1280	effect	T080	C1280500
27465939	1297	1304	miR-145	T028	C1537799
27465939	1305	1314	knockdown	T063	C2350567
27465939	1318	1322	ASCs	T025	C0162597
27465939	1324	1327	ASC	T025	C0162597
27465939	1328	1335	miR-145	T028	C1537799
27465939	1336	1345	knockdown	T063	C2350567
27465939	1346	1348	CM	T130	C0162518
27465939	1366	1376	expression	T045	C1171362
27465939	1380	1389	Caspase 3	T116,T126	C0291573
27465939	1392	1393	7	T116,T126	C0537969
27465939	1409	1422	antiapoptotic	T120	C2986514
27465939	1423	1430	protein	T116,T123	C0033684
27465939	1432	1437	BclxL	T116,T123	C0219472
27465939	1439	1449	expression	T045	C1171362
27465939	1453	1468	PC3M-luc2 cells	T025	C0682523
27465939	1475	1480	study	T062	C2603343
27465939	1490	1501	preclinical	T080	C1709630
27465939	1512	1516	ASCs	T025	C0162597
27465939	1517	1524	inhibit	T052	C3463820
27465939	1525	1528	PCa	T191	C0936223
27465939	1529	1535	growth	T191	C1516170
27465939	1546	1549	PCa	T191	C0936223
27465939	1550	1554	cell	T025	C0007634
27465939	1555	1564	apoptosis	T043	C0162638
27465939	1578	1586	activity	T052	C0441655
27465939	1590	1595	BclxL	T116,T123	C0219472
27465939	1618	1625	miR-145	T028	C1537799
27465939	1637	1645	exosomes	T026	C2350332
27465939	1660	1664	ASCs	T025	C0162597
27465939	1682	1685	ASC	T025	C0162597
27465939	1686	1700	administration	T169	C1521801
27465939	1732	1743	therapeutic	T169	C0302350
27465939	1756	1764	patients	T101	C0030705
27465939	1770	1773	PCa	T191	C0936223

27334669|t|Self-assembled polymeric vectors mixtures: characterization of the polymorphism and existence of synergistic effects in photodynamic therapy
27334669|a|The objective of this work was to assess the relation between the purity of polymeric self-assemblies vectors solution and their photodynamic therapeutic efficiency. For this, several amphiphilic block copolymers of poly(ethyleneoxide-b-ε-caprolactone) have been used to form self-assemblies with different morphologies (micelles, worm-like micelles or vesicles). In a first step, controlled mixtures of preformed micelles and vesicles have been characterized both by dynamic light scattering and asymmetrical flow field flow fractionation (AsFlFFF). For this, a custom-made program, STORMS, was developed to analyze DLS data in a thorough manner by providing a large set of fitting parameters. This showed that DLS only sensed the larger vesicles when the micelles / vesicles ratio was 80/20 w/w. On the other hand, AsFlFFF allowed clear detection of the presence of micelles when this same ratio was as low as 10/90. Subsequently, the photodynamic therapy efficiency of various controlled mixtures was assessed using multicellular spheroids when a photosensitizer, pheophorbide a, was encapsulated in the polymer self-assemblies. Some mixtures were shown to be as efficient as monomorphous systems. In some cases, mixtures were found to exhibit a higher PDT efficiency compared to the individual nano - objects, revealing a synergistic effect for the efficient delivery of the photosensitizer. Polymorphous vectors can therefore be superior in therapeutic applications.
27334669	0	14	Self-assembled	T044	C0872376
27334669	15	24	polymeric	T104,T122	C0032521
27334669	25	32	vectors	T074	C0085104
27334669	33	41	mixtures	T167	C0439962
27334669	43	59	characterization	T052	C1880022
27334669	67	79	polymorphism	T080	C1882417
27334669	97	108	synergistic	T080	C2986495
27334669	109	116	effects	T080	C1280500
27334669	120	140	photodynamic therapy	T061	C0031740
27334669	207	213	purity	T081	C1882508
27334669	217	226	polymeric	T104,T122	C0032521
27334669	227	242	self-assemblies	T044	C0872376
27334669	243	250	vectors	T074	C0085104
27334669	251	259	solution	T167	C0037633
27334669	270	294	photodynamic therapeutic	T061	C0031740
27334669	295	305	efficiency	T081	C0013682
27334669	325	336	amphiphilic	T121,T122	C0002671
27334669	337	353	block copolymers	T104	C0596383
27334669	357	393	poly(ethyleneoxide-b-ε-caprolactone)	T109	C1258138
27334669	417	432	self-assemblies	T044	C0872376
27334669	448	460	morphologies	T080	C0332437
27334669	462	470	micelles	T109	C0025938
27334669	472	490	worm-like micelles	T109	C0025938
27334669	494	502	vesicles	T080	C0332437
27334669	522	541	controlled mixtures	T167	C0439962
27334669	555	563	micelles	T109	C0025938
27334669	568	576	vesicles	T080	C0332437
27334669	609	633	dynamic light scattering	T059	C1882368
27334669	638	680	asymmetrical flow field flow fractionation	T059	C1135847
27334669	682	689	AsFlFFF	T059	C1135847
27334669	704	715	custom-made	T052	C1880202
27334669	716	723	program	T073,T170	C0037585
27334669	725	731	STORMS	T073,T170	C0037585
27334669	758	761	DLS	T059	C1882368
27334669	762	766	data	T078	C1511726
27334669	824	834	parameters	T077	C0549193
27334669	853	856	DLS	T059	C1882368
27334669	873	879	larger	T081	C0549177
27334669	880	888	vesicles	T080	C0332437
27334669	898	906	micelles	T109	C0025938
27334669	909	917	vesicles	T080	C0332437
27334669	918	923	ratio	T081	C0456603
27334669	958	965	AsFlFFF	T059	C1135847
27334669	980	989	detection	T033	C0442726
27334669	1009	1017	micelles	T109	C0025938
27334669	1033	1038	ratio	T081	C0456603
27334669	1078	1098	photodynamic therapy	T061	C0031740
27334669	1099	1109	efficiency	T081	C0013682
27334669	1121	1140	controlled mixtures	T167	C0439962
27334669	1174	1183	spheroids	T033	C1844596
27334669	1191	1206	photosensitizer	T121	C0162713
27334669	1208	1222	pheophorbide a	T109,T121	C0070716
27334669	1228	1240	encapsulated	T080	C0205223
27334669	1248	1255	polymer	T104,T122	C0032521
27334669	1256	1271	self-assemblies	T044	C0872376
27334669	1307	1316	efficient	T080	C0442799
27334669	1320	1340	monomorphous systems	T033	C0700329
27334669	1357	1365	mixtures	T167	C0439962
27334669	1397	1400	PDT	T061	C0031740
27334669	1401	1411	efficiency	T081	C0013682
27334669	1439	1443	nano	T081	C1553036
27334669	1446	1453	objects	T072	C0347997
27334669	1467	1478	synergistic	T080	C2986495
27334669	1479	1485	effect	T080	C1280500
27334669	1504	1512	delivery	T070	C3850077
27334669	1520	1535	photosensitizer	T121	C0162713
27334669	1537	1549	Polymorphous	T080	C1882417
27334669	1550	1557	vectors	T074	C0085104
27334669	1587	1611	therapeutic applications	T169	C0039798

28054956|t|A Strategy to Establish a Quality Assurance / Quality Control Plan for the Application of Biosensors for the Detection of E. coli in Water
28054956|a|Rapid bacterial detection using biosensors is a novel approach for microbiological testing applications. Validation of such methods is an obstacle in the adoption of new bio-sensing technologies for water testing. Therefore, establishing a quality assurance and quality control (QA / QC) plan is essential to demonstrate accuracy and reliability of the biosensor method for the detection of E. coli in drinking water samples. In this study, different reagents and assay conditions including temperatures, holding time, E. coli strains and concentrations, dissolving agents, salinity and pH effects, quality of substrates of various suppliers of 4-methylumbelliferyl glucuronide (MUG), and environmental water samples were included in the QA / QC plan and used in the assay optimization and documentation. Furthermore, the procedural QA / QC for the monitoring of drinking water samples was established to validate the performance of the biosensor platform for the detection of E. coli using a culture -based standard technique. Implementing the developed QA / QC plan, the same level of precision and accuracy was achieved using both the standard and the biosensor methods. The established procedural QA / QC for the biosensor will provide a reliable tool for a near real-time monitoring of E. coli in drinking water samples to both industry and regulatory authorities.
28054956	2	10	Strategy	T041	C0679199
28054956	14	23	Establish	T080	C0443211
28054956	26	43	Quality Assurance	T057	C0178932
28054956	46	61	Quality Control	T169	C0034378
28054956	62	66	Plan	T169	C1301732
28054956	75	86	Application	T169	C4048755
28054956	90	100	Biosensors	T075	C0600364
28054956	109	118	Detection	T061	C1511790
28054956	122	129	E. coli	T007	C0014834
28054956	133	138	Water	T167	C0599638
28054956	139	144	Rapid	T080	C0456962
28054956	145	154	bacterial	T007	C0004611
28054956	155	164	detection	T061	C1511790
28054956	171	181	biosensors	T075	C0600364
28054956	187	192	novel	T080	C0205314
28054956	193	201	approach	T082	C0449445
28054956	206	229	microbiological testing	T059	C1294312
28054956	230	242	applications	T169	C4048755
28054956	244	254	Validation	T062	C1519941
28054956	263	270	methods	T170	C0025663
28054956	309	333	bio-sensing technologies	T059	C0005567
28054956	338	351	water testing	T057	C0920675
28054956	364	376	establishing	T080	C0443211
28054956	379	396	quality assurance	T057	C0178932
28054956	401	416	quality control	T169	C0034378
28054956	418	420	QA	T057	C0178932
28054956	423	425	QC	T169	C0034378
28054956	427	431	plan	T169	C1301732
28054956	435	444	essential	T080	C0205224
28054956	460	468	accuracy	T080	C0443131
28054956	473	484	reliability	T081	C2347947
28054956	492	501	biosensor	T075	C0600364
28054956	502	508	method	T170	C0025663
28054956	517	526	detection	T061	C1511790
28054956	530	537	E. coli	T007	C0014834
28054956	541	555	drinking water	T167	C0599638
28054956	556	563	samples	T167	C0370003
28054956	580	589	different	T080	C1705242
28054956	590	598	reagents	T130	C0034760
28054956	603	608	assay	T059	C1510438
28054956	630	642	temperatures	T081	C0039476
28054956	644	656	holding time	T079	C0040223
28054956	658	665	E. coli	T007	C0014834
28054956	666	673	strains	T001	C1518614
28054956	678	692	concentrations	T081	C1446561
28054956	694	711	dissolving agents	T130	C0037638
28054956	713	721	salinity	T034	C1956027
28054956	726	728	pH	T081	C0020283
28054956	729	736	effects	T080	C1280500
28054956	738	745	quality	T080	C0332306
28054956	749	759	substrates	T167	C3891814
28054956	771	780	suppliers	T097	C0470689
28054956	784	816	4-methylumbelliferyl glucuronide	T109,T121	C0048514
28054956	818	821	MUG	T109,T121	C0048514
28054956	828	847	environmental water	T170	C1547971
28054956	848	855	samples	T167	C0370003
28054956	877	879	QA	T057	C0178932
28054956	882	884	QC	T169	C0034378
28054956	885	889	plan	T169	C1301732
28054956	906	911	assay	T059	C1510438
28054956	912	924	optimization	T052	C2698650
28054956	929	942	documentation	T170	C0920316
28054956	961	971	procedural	T169	C1292724
28054956	972	974	QA	T057	C0178932
28054956	977	979	QC	T169	C0034378
28054956	988	998	monitoring	T058	C1283169
28054956	1002	1016	drinking water	T167	C0599638
28054956	1017	1024	samples	T167	C0370003
28054956	1029	1040	established	T080	C0443211
28054956	1057	1068	performance	T052	C1882330
28054956	1076	1085	biosensor	T075	C0600364
28054956	1086	1094	platform	T075	C1710360
28054956	1103	1112	detection	T061	C1511790
28054956	1116	1123	E. coli	T007	C0014834
28054956	1132	1139	culture	T059	C0430402
28054956	1147	1155	standard	T080	C1442989
28054956	1156	1165	technique	T169	C0449851
28054956	1194	1196	QA	T057	C0178932
28054956	1199	1201	QC	T169	C0034378
28054956	1202	1206	plan	T169	C1301732
28054956	1217	1222	level	T080	C0441889
28054956	1226	1235	precision	T080	C1706245
28054956	1240	1248	accuracy	T080	C0443131
28054956	1277	1285	standard	T080	C1442989
28054956	1294	1303	biosensor	T075	C0600364
28054956	1304	1311	methods	T170	C0025663
28054956	1317	1328	established	T080	C0443211
28054956	1329	1339	procedural	T169	C1292724
28054956	1340	1342	QA	T057	C0178932
28054956	1345	1347	QC	T169	C0034378
28054956	1356	1365	biosensor	T075	C0600364
28054956	1406	1426	real-time monitoring	T058	C1283169
28054956	1430	1437	E. coli	T007	C0014834
28054956	1441	1455	drinking water	T167	C0599638
28054956	1456	1463	samples	T167	C0370003
28054956	1472	1480	industry	T057	C0021267
28054956	1485	1507	regulatory authorities	T064	C2981655

27446852|t|Duodenal Villous Atrophy in a TTG - Negative Patient Taking Olmesartan: A Case Report and Review of the Literature
27446852|a|Olmesartan, an angiotensin II receptor antagonist used to treat hypertension, is associated with few adverse effects. Here, a case of severe sprue-like enteropathy and acute kidney injury is described in a 68-year-old male taking olmesartan for 3-4 years. He presented to hospital with a five-week history of diarrhea, vomiting, and a 20 lb weight loss. Anti-TTG was negative with a normal IgA. Biopsies of the distal duodenum and duodenal cap revealed marked blunting of the villi with near complete villous atrophy of the biopsies from the bulb. There was an increase in intraepithelial lymphocytes as well as neutrophils in the surface epithelium. The patient's diarrhea improved upon discontinuation of olmesartan and he returned to his previous weight. Repeat endoscopy four months later demonstrated complete resolution of inflammatory change with normal villous architecture. Long-term olmesartan use is associated with severe sprue-like enteropathy. The mechanism of intestinal injury is unknown. Duodenal biopsy results may mimic other enteropathies such as celiac disease. Physicians should consider medications as potential etiologies of enteropathy.
27446852	0	24	Duodenal Villous Atrophy	T033	C2677378
27446852	30	33	TTG	T059	C2116871
27446852	36	44	Negative	T033	C0205160
27446852	45	52	Patient	T101	C0030705
27446852	60	70	Olmesartan	T109,T121	C1098320
27446852	74	85	Case Report	T170	C0085973
27446852	90	114	Review of the Literature	T170	C0282441
27446852	115	125	Olmesartan	T109,T121	C1098320
27446852	130	164	angiotensin II receptor antagonist	T121	C0521942
27446852	173	178	treat	T061	C0087111
27446852	179	191	hypertension	T047	C0020538
27446852	196	211	associated with	T080	C0332281
27446852	216	231	adverse effects	T046	C0879626
27446852	249	255	severe	T080	C0205082
27446852	256	278	sprue-like enteropathy	T047	C0021831
27446852	283	302	acute kidney injury	T037	C2609414
27446852	333	337	male	T032	C0086582
27446852	345	355	olmesartan	T109,T121	C1098320
27446852	364	369	years	T079	C0439234
27446852	387	395	hospital	T073,T093	C0019994
27446852	413	420	history	T033	C0262926
27446852	424	432	diarrhea	T184	C0011991
27446852	434	442	vomiting	T184	C0042963
27446852	456	467	weight loss	T033	C1262477
27446852	469	477	Anti-TTG	T033	C2673846
27446852	482	490	negative	T033	C0205160
27446852	498	504	normal	T080	C0205307
27446852	505	508	IgA	T116,T129	C0020835
27446852	510	518	Biopsies	T060	C0005558
27446852	526	541	distal duodenum	T023	C0013303
27446852	546	558	duodenal cap	T023	C1284424
27446852	575	583	blunting	T080	C1997138
27446852	591	596	villi	T023	C0227266
27446852	616	631	villous atrophy	T047	C0267456
27446852	639	647	biopsies	T060	C0005558
27446852	657	661	bulb	T023	C0227300
27446852	676	684	increase	T169	C0442805
27446852	688	703	intraepithelial	T082	C1512942
27446852	704	715	lymphocytes	T025	C0024264
27446852	727	738	neutrophils	T025	C0027950
27446852	746	764	surface epithelium	T029	C1182809
27446852	770	779	patient's	T101	C0030705
27446852	780	788	diarrhea	T184	C0011991
27446852	789	797	improved	T033	C0184511
27446852	803	818	discontinuation	T058	C0457454
27446852	822	832	olmesartan	T109,T121	C1098320
27446852	865	871	weight	T032	C0005910
27446852	880	889	endoscopy	T060	C0014245
27446852	895	901	months	T079	C0439231
27446852	930	940	resolution	T046	C1514893
27446852	944	956	inflammatory	T169	C0333348
27446852	957	963	change	T169	C0392747
27446852	969	975	normal	T080	C0205307
27446852	976	983	villous	T023	C0227266
27446852	998	1007	Long-term	T079	C0443252
27446852	1008	1018	olmesartan	T109,T121	C1098320
27446852	1026	1041	associated with	T080	C0332281
27446852	1042	1048	severe	T080	C0205082
27446852	1049	1071	sprue-like enteropathy	T047	C0021831
27446852	1077	1086	mechanism	T169	C0441712
27446852	1090	1107	intestinal injury	T037	C0564863
27446852	1120	1135	Duodenal biopsy	T060	C0399805
27446852	1160	1173	enteropathies	T047	C0021831
27446852	1182	1196	celiac disease	T047	C0007570
27446852	1198	1208	Physicians	T097	C0031831
27446852	1225	1236	medications	T058	C2081612
27446852	1240	1249	potential	T080	C3245505
27446852	1250	1260	etiologies	T169	C1314792
27446852	1264	1275	enteropathy	T047	C0021831

27768063|t|Safety Precautions and Operating Procedures in an (A) BSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures
27768063|a|Biosafety level 4 (BSL-4) suit laboratories are specifically designed to study high-consequence pathogens for which neither infection prophylaxes nor treatment options exist. The hallmarks of these laboratories are: custom-designed airtight doors, dedicated supply and exhaust airflow systems, a negative-pressure environment, and mandatory use of positive-pressure ("space") suits. The risk for laboratory specialists working with highly pathogenic agents is minimized through rigorous training and adherence to stringent safety protocols and standard operating procedures. Researchers perform the majority of their work in BSL-2 laboratories and switch to BSL-4 suit laboratories when work with a high-consequence pathogen is required. Collaborators and scientists considering BSL-4 projects should be aware of the challenges associated with BSL-4 research both in terms of experimental technical limitations in BSL-4 laboratory space and the increased duration of such experiments. Tasks such as entering and exiting the BSL-4 suit laboratories are considerably more complex and time-consuming compared to BSL-2 and BSL-3 laboratories. The focus of this particular article is to address basic biosafety concerns and describe the entrance and exit procedures for the BSL-4 laboratory at the NIH / NIAID Integrated Research Facility at Fort Detrick. Such procedures include checking external systems that support the BSL-4 laboratory, and inspecting and donning positive-pressure suits, entering the laboratory, moving through air pressure - resistant doors, and connecting to air-supply hoses. We will also discuss moving within and exiting the BSL-4 suit laboratories, including using the chemical shower and removing and storing positive-pressure suits.
27768063	0	18	Safety Precautions	T058	C0150755
27768063	23	43	Operating Procedures	T170	C3889288
27768063	54	59	BSL-4	T170	C1443939
27768063	60	70	Laboratory	T073,T093	C0022877
27768063	75	92	Biosafety Level 4	T170	C1443939
27768063	93	108	Suit Laboratory	T073,T093	C0022877
27768063	109	140	Suite Entry and Exit Procedures	T170	C0442711
27768063	141	158	Biosafety level 4	T170	C1443939
27768063	160	165	BSL-4	T170	C1443939
27768063	167	184	suit laboratories	T073,T093	C0022877
27768063	202	210	designed	T052	C1707689
27768063	214	219	study	T062	C2603343
27768063	220	246	high-consequence pathogens	T001	C0450254
27768063	265	274	infection	T046	C3714514
27768063	275	286	prophylaxes	T061	C0199176
27768063	291	300	treatment	T061	C0087111
27768063	339	351	laboratories	T073,T093	C0022877
27768063	357	372	custom-designed	T052	C1707689
27768063	373	387	airtight doors	T073	C0557698
27768063	399	405	supply	T169	C1561604
27768063	410	433	exhaust airflow systems	T073	C3273359
27768063	437	466	negative-pressure environment	T074	C1961760
27768063	489	522	positive-pressure ("space") suits	T073	C0376610
27768063	537	547	laboratory	T073,T093	C0022877
27768063	548	559	specialists	T097	C0035173
27768063	580	597	pathogenic agents	T001	C0450254
27768063	628	636	training	T065	C0220931
27768063	664	680	safety protocols	T170	C0677563
27768063	685	714	standard operating procedures	T170	C3889288
27768063	716	727	Researchers	T097	C0035173
27768063	740	748	majority	T080	C0205164
27768063	758	762	work	T057	C0043227
27768063	766	771	BSL-2	T170	C1443937
27768063	772	784	laboratories	T073,T093	C0022877
27768063	799	804	BSL-4	T170	C1443939
27768063	805	822	suit laboratories	T073,T093	C0022877
27768063	840	865	high-consequence pathogen	T001	C0450254
27768063	879	892	Collaborators	T094	C2827395
27768063	897	907	scientists	T097	C0402112
27768063	920	925	BSL-4	T170	C1443939
27768063	926	934	projects	T062	C0700032
27768063	958	968	challenges	T033	C0033213
27768063	969	984	associated with	T080	C0332281
27768063	985	990	BSL-4	T170	C1443939
27768063	991	999	research	T062	C0035168
27768063	1017	1029	experimental	T080	C1517586
27768063	1030	1039	technical	T169	C0449851
27768063	1040	1051	limitations	T169	C0449295
27768063	1055	1060	BSL-4	T170	C1443939
27768063	1061	1071	laboratory	T073,T093	C0022877
27768063	1072	1077	space	T082	C1883067
27768063	1086	1095	increased	T081	C0205217
27768063	1096	1104	duration	T079	C0449238
27768063	1113	1124	experiments	T062	C0681814
27768063	1140	1148	entering	T169	C0205245
27768063	1153	1160	exiting	T169	C0205245
27768063	1165	1170	BSL-4	T170	C1443939
27768063	1171	1188	suit laboratories	T073,T093	C0022877
27768063	1211	1218	complex	T080	C0439855
27768063	1223	1237	time-consuming	T080	C3827829
27768063	1238	1246	compared	T052	C1707455
27768063	1250	1255	BSL-2	T170	C1443937
27768063	1260	1265	BSL-3	T170	C1443938
27768063	1266	1278	laboratories	T073,T093	C0022877
27768063	1309	1316	article	T170	C1706852
27768063	1323	1330	address	T170	C0376649
27768063	1337	1346	biosafety	T068	C0036043
27768063	1347	1355	concerns	T078	C2699424
27768063	1373	1401	entrance and exit procedures	T170	C0442711
27768063	1410	1415	BSL-4	T170	C1443939
27768063	1416	1426	laboratory	T073,T093	C0022877
27768063	1434	1437	NIH	T093	C0027468
27768063	1440	1445	NIAID	T093	C1513895
27768063	1446	1474	Integrated Research Facility	T073	C0598009
27768063	1497	1507	procedures	T170	C0442711
27768063	1559	1564	BSL-4	T170	C1443939
27768063	1565	1575	laboratory	T073,T093	C0022877
27768063	1604	1627	positive-pressure suits	T073	C0376610
27768063	1642	1652	laboratory	T073,T093	C0022877
27768063	1669	1681	air pressure	T070	C0001876
27768063	1684	1693	resistant	T169	C0332325
27768063	1694	1699	doors	T073	C0557698
27768063	1719	1735	air-supply hoses	T074	C0181222
27768063	1758	1764	moving	T040	C0560560
27768063	1776	1783	exiting	T169	C0205245
27768063	1788	1793	BSL-4	T170	C1443939
27768063	1794	1811	suit laboratories	T073,T093	C0022877
27768063	1833	1841	chemical	T103	C0220806
27768063	1842	1848	shower	T073	C0541748
27768063	1853	1861	removing	T052	C1883720
27768063	1866	1873	storing	T169	C1698986
27768063	1874	1897	positive-pressure suits	T073	C0376610

27515303|t|Anatomic variations of levator scapulae in a normal cohort: an MRI study
27515303|a|Accessory attachments of the levator scapulae (LS) muscle have been described in the literature in previous cadaveric studies, but there is little knowledge about the incidence and distribution. Knowledge of LS accessory attachments is relevant to clinicians working in the fields of radiology, surgery, neurology, and musculoskeletal medicine. The purpose of this study was to explore the incidence and spectrum of LS caudal accessory attachments in vivo using magnetic resonance (MR) imaging in a young cohort. MR images of the cervical spine were obtained from 37 subjects (13 males and 24 females) aged 18-36 years using an axial T1-weighted spin echo sequence acquired from a 3-Tesla MR scanner. The LS muscle was identified, and the presence of caudal accessory attachments was recorded and described. LS caudal accessory attachments were identified in 16 subjects (4 right, 6 left, and 6 bilateral; 12 female). Ten had unilateral accessory attachments to the serratus anterior, serratus posterior superior or the first/second rib. Four had bilateral accessory attachments to serratus anterior. One had bilateral accessory attachments to serratus posterior superior and unilateral accessory attachment to serratus anterior. One had bilateral attachments to both muscles. Both unilateral and bilateral LS caudal accessory attachments were present in nearly half of the subjects examined. They were relatively more frequent in females than males. The findings indicate that these accessory attachments are common, and in some cases, those accessory attachments can occur bilaterally and to more than one site.
27515303	0	19	Anatomic variations	T070	C3494476
27515303	23	39	levator scapulae	T023	C0224368
27515303	45	51	normal	T080	C0205307
27515303	52	58	cohort	T098	C0599755
27515303	63	72	MRI study	T060	C3515983
27515303	73	94	Accessory attachments	T074	C0492275
27515303	102	130	levator scapulae (LS) muscle	T023	C0224368
27515303	141	150	described	T078	C1552738
27515303	158	168	literature	T170	C0023866
27515303	172	180	previous	T079	C0205156
27515303	181	190	cadaveric	T017	C0006629
27515303	191	198	studies	T062	C2603343
27515303	213	219	little	T081	C0700321
27515303	220	229	knowledge	T170	C0376554
27515303	240	249	incidence	T081	C0021149
27515303	254	266	distribution	T169	C1704711
27515303	268	277	Knowledge	T170	C0376554
27515303	281	283	LS	T023	C0224368
27515303	284	305	accessory attachments	T074	C0492275
27515303	309	317	relevant	T080	C2347946
27515303	321	331	clinicians	T097	C0871685
27515303	332	339	working	T057	C0043227
27515303	347	353	fields	T077	C2346620
27515303	357	366	radiology	T091	C0034599
27515303	368	375	surgery	T091	C0038894
27515303	377	386	neurology	T091	C0027855
27515303	392	407	musculoskeletal	T169	C0497254
27515303	408	416	medicine	T091	C0025118
27515303	438	443	study	T062	C2603343
27515303	463	472	incidence	T081	C0021149
27515303	489	491	LS	T023	C0224368
27515303	492	498	caudal	T029	C0205097
27515303	499	520	accessory attachments	T074	C0492275
27515303	521	528	in vivo	T082	C1515655
27515303	529	534	using	T169	C1524063
27515303	535	566	magnetic resonance (MR) imaging	T060	C0024485
27515303	572	577	young	T079	C0332239
27515303	578	584	cohort	T098	C0599755
27515303	586	588	MR	T060	C0024485
27515303	589	595	images	T170	C1704254
27515303	603	617	cervical spine	T023	C0728985
27515303	623	631	obtained	T169	C1301820
27515303	640	648	subjects	T169	C1550501
27515303	653	658	males	T032	C0086582
27515303	666	673	females	T032	C0086287
27515303	675	679	aged	T032	C0001779
27515303	686	691	years	T079	C0439234
27515303	701	737	axial T1-weighted spin echo sequence	T169	C1519249
27515303	754	772	3-Tesla MR scanner	T060	C2985394
27515303	778	787	LS muscle	T023	C0224368
27515303	792	802	identified	T080	C0205396
27515303	812	820	presence	T033	C0150312
27515303	824	830	caudal	T029	C0205097
27515303	831	852	accessory attachments	T074	C0492275
27515303	870	879	described	T078	C1552738
27515303	881	883	LS	T023	C0224368
27515303	884	890	caudal	T029	C0205097
27515303	891	912	accessory attachments	T074	C0492275
27515303	918	928	identified	T080	C0205396
27515303	935	943	subjects	T169	C1550501
27515303	947	952	right	T082	C0205090
27515303	956	960	left	T082	C0205091
27515303	968	977	bilateral	T082	C0238767
27515303	982	988	female	T098	C0043210
27515303	999	1009	unilateral	T082	C0205092
27515303	1010	1031	accessory attachments	T074	C0492275
27515303	1039	1056	serratus anterior	T023	C0224349
27515303	1058	1085	serratus posterior superior	T023	C0224371
27515303	1106	1109	rib	T023	C0035561
27515303	1120	1129	bilateral	T082	C0238767
27515303	1130	1151	accessory attachments	T074	C0492275
27515303	1155	1172	serratus anterior	T023	C0224349
27515303	1182	1191	bilateral	T082	C0238767
27515303	1192	1213	accessory attachments	T074	C0492275
27515303	1217	1244	serratus posterior superior	T023	C0224371
27515303	1249	1259	unilateral	T082	C0205092
27515303	1260	1280	accessory attachment	T074	C0492275
27515303	1284	1301	serratus anterior	T023	C0224349
27515303	1311	1320	bilateral	T082	C0238767
27515303	1321	1332	attachments	T074	C0492275
27515303	1336	1340	both	T080	C1706086
27515303	1341	1348	muscles	T024	C0026845
27515303	1350	1354	Both	T080	C1706086
27515303	1355	1365	unilateral	T082	C0205092
27515303	1370	1379	bilateral	T082	C0238767
27515303	1380	1382	LS	T023	C0224368
27515303	1383	1389	caudal	T029	C0205097
27515303	1390	1411	accessory attachments	T074	C0492275
27515303	1417	1424	present	T033	C0150312
27515303	1435	1439	half	T081	C2825407
27515303	1447	1455	subjects	T169	C1550501
27515303	1456	1464	examined	T033	C0332128
27515303	1492	1500	frequent	T079	C0332183
27515303	1504	1511	females	T098	C0043210
27515303	1517	1522	males	T098	C0025266
27515303	1528	1536	findings	T033	C0243095
27515303	1537	1545	indicate	T033	C1444656
27515303	1557	1578	accessory attachments	T074	C0492275
27515303	1583	1589	common	T081	C0205214
27515303	1598	1602	some	T081	C0205392
27515303	1603	1608	cases	T169	C0868928
27515303	1616	1637	accessory attachments	T074	C0492275
27515303	1648	1659	bilaterally	T082	C0238767
27515303	1667	1676	more than	T081	C0439093
27515303	1677	1680	one	T081	C0205447
27515303	1681	1685	site	T082	C0205145

27998493|t|Periodontal status of tuberculosis patients - Is there a two-way link?
27998493|a|The influence of systemic disorders on periodontal tissues is well established. Amongst various chronic debilitating diseases, tuberculosis (TB) is one of the major health problems in most developing countries. Although it has a definite affinity for the lungs, it can affect any part of the body including the oral cavity. TB and periodontitis are the two distinct disease processes. But environmental and biological factors play a key role in etiopathogenesis of both the diseases. These factors alter tissue microenvironment leading to cascade of untoward events. To assess and compare the periodontal status of TB patients with that of non-TB subjects. 50 subjects were recruited and divided into 2 groups. Group A consisted of subjects suffering from TB serving as Test group while group B included non-TB subjects serving as Control group. Unpaired t-test was used. Statistically significant difference in probing pocket depth and bleeding on probing was found between groups A and B, with the difference being higher in group A subjects, thus concluding that periodontal status might be linked with TB.
27998493	0	18	Periodontal status	T034	C0031092
27998493	22	34	tuberculosis	T047	C0041296
27998493	35	43	patients	T101	C0030705
27998493	75	84	influence	T077	C4054723
27998493	88	106	systemic disorders	T047	C0442893
27998493	110	129	periodontal tissues	T024	C0031104
27998493	138	149	established	T080	C0443211
27998493	167	174	chronic	T079	C0205191
27998493	175	196	debilitating diseases	T047	C0012634
27998493	198	210	tuberculosis	T047	C0041296
27998493	212	214	TB	T047	C0041296
27998493	230	235	major	T080	C0205164
27998493	236	242	health	T078	C0018684
27998493	243	251	problems	T033	C0033213
27998493	260	280	developing countries	T080	C0011750
27998493	309	317	affinity	T070	C1510827
27998493	326	331	lungs	T023	C0024109
27998493	351	367	part of the body	T023	C0229962
27998493	382	393	oral cavity	T030	C0226896
27998493	395	397	TB	T047	C0041296
27998493	402	415	periodontitis	T047	C0031099
27998493	437	444	disease	T047	C0012634
27998493	445	454	processes	T067	C1522240
27998493	460	473	environmental	T082	C0014406
27998493	478	496	biological factors	T123	C0005515
27998493	508	512	role	T077	C1705810
27998493	516	532	etiopathogenesis	T169	C1510540
27998493	545	553	diseases	T047	C0012634
27998493	561	568	factors	T169	C1521761
27998493	569	574	alter	T078	C1515926
27998493	575	581	tissue	T024	C0040300
27998493	582	598	microenvironment	T082	C4072789
27998493	641	647	assess	T052	C1516048
27998493	652	659	compare	T052	C1707455
27998493	664	682	periodontal status	T034	C0031092
27998493	686	688	TB	T047	C0041296
27998493	689	697	patients	T101	C0030705
27998493	711	726	non-TB subjects	T098	C0080105
27998493	731	739	subjects	T098	C0080105
27998493	759	766	divided	T169	C0332849
27998493	774	780	groups	T078	C0441833
27998493	782	787	Group	T078	C0441833
27998493	803	811	subjects	T098	C0080105
27998493	827	829	TB	T047	C0041296
27998493	841	851	Test group	T078	C0441833
27998493	858	863	group	T078	C0441833
27998493	875	890	non-TB subjects	T098	C0080105
27998493	902	915	Control group	T096	C0009932
27998493	917	932	Unpaired t-test	T170	C1710574
27998493	969	979	difference	T080	C1705242
27998493	1008	1016	bleeding	T046	C0019080
27998493	1046	1052	groups	T078	C0441833
27998493	1071	1081	difference	T080	C1705242
27998493	1088	1094	higher	T080	C0205250
27998493	1098	1103	group	T078	C0441833
27998493	1106	1114	subjects	T098	C0080105
27998493	1137	1155	periodontal status	T034	C0031092
27998493	1177	1179	TB	T047	C0041296

28341196|t|The use of intraosseous needles for injection of contrast media for computed tomographic angiography of the thoracic aorta
28341196|a|The objective of this study is to evaluate the safety and quality of computed tomographic angiography of the thoracic aorta (CTA-TA) exams performed using intraosseous needle intravenous access (ION-IVA) for contrast media injection (CMI). All CTA-TA exams at the study institution performed between 1/1/2013 and 8/14/2015 were reviewed retrospectively to identify those exams which had been performed using ION-IVA (ION-exams). ION-exams were then analyzed to determine aortic attenuation and contrast-to-noise ratio (CNR). Linear regression was used to determine how injection rate and other variables affected image quality for ION-exams. Patient electronic medical records were reviewed to identify any adverse events related to CTA-TA or ION-IVA. 17 (∼0.2%) of 7401 exams were ION-exams. ION-exam CMI rates varied between 2.5 and 4 ml/s. Mean attenuation was 312 HU (SD 88 HU) and mean CNR was 25 (SD 9.9). A strong positive linear association between attenuation and injection rate was found. No immediate or delayed complications related to the ION-exams, or intraosseous needle use in general, occurred. For CTA-TA, ION-IVA appears to be a safe and effective route for CMI at rates up to 4 ml/s.
28341196	11	31	intraosseous needles	T074	C1322770
28341196	36	45	injection	T061	C1533685
28341196	49	63	contrast media	T130	C0009924
28341196	68	100	computed tomographic angiography	T060	C1536105
28341196	108	122	thoracic aorta	T023	C1522460
28341196	145	150	study	T062	C2603343
28341196	157	165	evaluate	T058	C0220825
28341196	170	176	safety	T068	C0036043
28341196	181	188	quality	T080	C0332306
28341196	192	224	computed tomographic angiography	T060	C1536105
28341196	232	246	thoracic aorta	T023	C1522460
28341196	248	254	CTA-TA	T060	C0430022
28341196	256	261	exams	T169	C4284036
28341196	278	316	intraosseous needle intravenous access	T060	C0430022
28341196	318	325	ION-IVA	T060	C0430022
28341196	331	355	contrast media injection	T060	C2733072
28341196	357	360	CMI	T060	C2733072
28341196	367	373	CTA-TA	T060	C0430022
28341196	374	379	exams	T169	C4284036
28341196	387	392	study	T062	C2603343
28341196	393	404	institution	T073,T093	C0018704
28341196	460	475	retrospectively	T080	C1514923
28341196	494	499	exams	T169	C4284036
28341196	531	538	ION-IVA	T060	C0430022
28341196	540	549	ION-exams	T059	C0022885
28341196	552	561	ION-exams	T059	C0022885
28341196	594	612	aortic attenuation	T033	C3281005
28341196	617	640	contrast-to-noise ratio	T081	C0456603
28341196	642	645	CNR	T081	C0456603
28341196	648	665	Linear regression	T081	C0023733
28341196	692	701	injection	T061	C1533685
28341196	702	706	rate	T081	C1521828
28341196	717	726	variables	T080	C0439828
28341196	736	749	image quality	T080	C0806487
28341196	754	763	ION-exams	T059	C0022885
28341196	765	772	Patient	T101	C0030705
28341196	773	799	electronic medical records	T170	C2362543
28341196	830	844	adverse events	T046	C0877248
28341196	856	862	CTA-TA	T060	C0430022
28341196	866	873	ION-IVA	T060	C0430022
28341196	894	899	exams	T169	C4284036
28341196	905	914	ION-exams	T059	C0022885
28341196	916	924	ION-exam	T059	C0022885
28341196	925	928	CMI	T060	C2733072
28341196	929	934	rates	T081	C1521828
28341196	966	970	Mean	T081	C0444504
28341196	971	982	attenuation	T052	C0599946
28341196	1009	1013	mean	T081	C0444504
28341196	1014	1017	CNR	T081	C0456603
28341196	1044	1052	positive	T033	C1446409
28341196	1080	1091	attenuation	T052	C0599946
28341196	1096	1105	injection	T061	C1533685
28341196	1106	1110	rate	T081	C1521828
28341196	1122	1159	No immediate or delayed complications	T033	C4032686
28341196	1175	1184	ION-exams	T059	C0022885
28341196	1189	1208	intraosseous needle	T074	C1322770
28341196	1239	1245	CTA-TA	T060	C0430022
28341196	1247	1254	ION-IVA	T060	C0430022
28341196	1300	1303	CMI	T060	C2733072

27722881|t|Fluoranthene degradation and binding mechanism study based on the active-site structure of ring-hydroxylating dioxygenase in Microbacterium paraoxydans JPM1
27722881|a|In this study, a gram-positive fluoranthene-degrading bacterial strain was isolated from crude oil in Dagang Oilfield and identified as Microbacterium paraoxydans JPM1 by the analysis of 16S rDNA sequence. After 25 days of incubation, the strain JPM1 could degrade 91.78 % of the initial amount of fluoranthene. Moreover, four metabolites 9-fluorenone-1-carboxylic acid, 9-fluorenone, phthalic acid, and benzoic acid were detected in the culture solution. The gene sequence encoding the aromatic-ring-hydroxylating dioxygenase was amplified in the strain JPM1 by PCR. Based on the translated protein sequence, a homology modeling method was applied to build the crystal structure of dioxygenase. Subsequently, the interaction mechanism between fluoranthene and the active site of dioxygenase was simulated and analyzed by molecular docking. Consequently, a feasible degrading pathway of fluoranthene in the strain JPM1 was proposed based on the metabolites and the interaction analyses. Additionally, the thermodynamic analysis showed that the strain JPM1 had high tolerance for fluoranthene, and the influence of fluoranthene for the bacterial growth activity was negligible under 100 to 400 mg L(-1) concentrations. Taken together, this study indicates that the strain JPM1 has high potential for further study in bioremediation of polycyclic aromatic hydrocarbon (PAH)- contaminated sites.
27722881	0	12	Fluoranthene	T109,T121	C0060514
27722881	13	24	degradation	T070	C0005482
27722881	29	36	binding	T044	C1167622
27722881	37	46	mechanism	T169	C0441712
27722881	47	52	study	T062	C2603343
27722881	66	77	active-site	T169	C0205681
27722881	78	87	structure	T082	C0678594
27722881	91	121	ring-hydroxylating dioxygenase	T116,T126	C0599874
27722881	125	156	Microbacterium paraoxydans JPM1	T007	C4153571
27722881	165	170	study	T062	C2603343
27722881	174	220	gram-positive fluoranthene-degrading bacterial	T007	C0018154
27722881	221	227	strain	T001	C1518614
27722881	232	240	isolated	T169	C0205409
27722881	246	255	crude oil	T109	C0031264
27722881	259	274	Dagang Oilfield	T070	C3179127
27722881	279	289	identified	T080	C0205396
27722881	293	324	Microbacterium paraoxydans JPM1	T007	C4153571
27722881	332	340	analysis	T062	C0936012
27722881	344	352	16S rDNA	T114	C3537372
27722881	353	361	sequence	T086	C0004793
27722881	372	376	days	T079	C0439228
27722881	380	390	incubation	T059	C1439852
27722881	396	402	strain	T001	C1518614
27722881	403	407	JPM1	T007	C4153571
27722881	437	444	initial	T079	C0205265
27722881	445	451	amount	T081	C1265611
27722881	455	467	fluoranthene	T109,T121	C0060514
27722881	484	495	metabolites	T123	C0870883
27722881	496	526	9-fluorenone-1-carboxylic acid	T123	C0574031
27722881	528	540	9-fluorenone	T109	C0050227
27722881	542	555	phthalic acid	T109	C0070968
27722881	561	573	benzoic acid	T109,T121	C0053225
27722881	595	611	culture solution	T130	C0010454
27722881	617	630	gene sequence	T086	C0004793
27722881	631	639	encoding	T052	C2700640
27722881	644	683	aromatic-ring-hydroxylating dioxygenase	T116,T126	C0599874
27722881	688	697	amplified	T045	C0017256
27722881	705	711	strain	T001	C1518614
27722881	712	716	JPM1	T007	C4153571
27722881	720	723	PCR	T063	C0032520
27722881	749	765	protein sequence	T087	C0002518
27722881	769	793	homology modeling method	T063	C1512489
27722881	819	836	crystal structure	T104	C0444626
27722881	840	851	dioxygenase	T116,T126	C0599874
27722881	871	882	interaction	T169	C1704675
27722881	883	892	mechanism	T169	C0441712
27722881	901	913	fluoranthene	T109,T121	C0060514
27722881	922	933	active site	T169	C0205681
27722881	937	948	dioxygenase	T116,T126	C0599874
27722881	953	962	simulated	T062	C0679083
27722881	967	975	analyzed	T062	C0936012
27722881	979	996	molecular docking	T063	C3494273
27722881	1023	1032	degrading	T070	C0005482
27722881	1033	1040	pathway	T044	C1704259
27722881	1044	1056	fluoranthene	T109,T121	C0060514
27722881	1064	1070	strain	T001	C1518614
27722881	1071	1075	JPM1	T007	C4153571
27722881	1102	1113	metabolites	T123	C0870883
27722881	1122	1142	interaction analyses	T081	C0237688
27722881	1162	1184	thermodynamic analysis	T062	C0936012
27722881	1201	1207	strain	T001	C1518614
27722881	1208	1212	JPM1	T007	C4153571
27722881	1217	1221	high	T080	C0205250
27722881	1222	1231	tolerance	T080	C1704410
27722881	1236	1248	fluoranthene	T109,T121	C0060514
27722881	1258	1267	influence	T077	C4054723
27722881	1271	1283	fluoranthene	T109,T121	C0060514
27722881	1292	1301	bacterial	T007	C0004611
27722881	1302	1308	growth	T040	C0018270
27722881	1322	1332	negligible	T080	C0332269
27722881	1359	1373	concentrations	T081	C1446561
27722881	1396	1401	study	T062	C2603343
27722881	1421	1427	strain	T001	C1518614
27722881	1428	1432	JPM1	T007	C4153571
27722881	1442	1451	potential	T080	C3245505
27722881	1464	1469	study	T062	C2603343
27722881	1473	1487	bioremediation	T069	C0598015
27722881	1491	1522	polycyclic aromatic hydrocarbon	T109	C0032458
27722881	1524	1527	PAH	T109	C0032458
27722881	1530	1542	contaminated	T169	C0205279
27722881	1543	1548	sites	T082	C0205145

28092734|t|Combined utilization of nutrients and sugar derived from wheat bran for d-Lactate fermentation by Sporolactobacillus inulinus YBS1-5
28092734|a|To decrease d-Lactate production cost, wheat bran, a low - cost waste of milling industry, was selected as the sole feedstock. First, the nutrients were recovered from wheat bran by acid protease hydrolysis. Then, cellulosic hydrolysates were prepared from protease -treated samples after acid pretreatment and enzymatic saccharification. The combined use of nutrients and hydrolysates as nitrogen and carbon sources for fermentation by S. inulinus YB1-5 resulted in d-Lactate levels of 99.5g/L, with an average production efficiency of 1.94g/L/h and a yield of 0.89g/g glucose. Moreover, fed-batch simultaneous saccharification and fermentation process at 40°C, 20% (w/v) solid loading and 20FPU/g solid cellulase concentration was obtained. d-Lactate concentrations, yield, productivity, and optical purity were 87.3g/L, 0.65g/g glucose, 0.81g/L/h and 99.1%, respectively. This study provided a feasible procedure that can help produce cellulosic d-Lactate using agricultural waste without external nutrient supplementation.
28092734	0	8	Combined	T080	C0205195
28092734	9	20	utilization	T169	C0042153
28092734	24	33	nutrients	T168	C0678695
28092734	38	43	sugar	T109,T121	C0242209
28092734	44	51	derived	T080	C1441547
28092734	57	67	wheat bran	T168	C0043138
28092734	72	81	d-Lactate	T109	C0522080
28092734	82	94	fermentation	T044	C0015852
28092734	98	132	Sporolactobacillus inulinus YBS1-5	T007	C0995848
28092734	136	144	decrease	T081	C0547047
28092734	145	154	d-Lactate	T109	C0522080
28092734	155	165	production	T057	C0033268
28092734	166	170	cost	T081	C0010186
28092734	172	182	wheat bran	T168	C0043138
28092734	186	189	low	T080	C0205251
28092734	192	196	cost	T081	C0010186
28092734	197	202	waste	T167	C0043045
28092734	206	213	milling	T073	C0599997
28092734	214	222	industry	T057	C0021267
28092734	271	280	nutrients	T168	C0678695
28092734	286	300	recovered from	T080	C0521108
28092734	301	311	wheat bran	T168	C0043138
28092734	315	319	acid	T103	C0001128
28092734	320	328	protease	T116,T126	C1947941
28092734	329	339	hydrolysis	T070	C0020291
28092734	347	370	cellulosic hydrolysates	T109	C0029224
28092734	390	398	protease	T116,T126	C1947941
28092734	408	415	samples	T167	C0370003
28092734	422	426	acid	T103	C0001128
28092734	427	439	pretreatment	T052	C3539076
28092734	444	453	enzymatic	T116,T126	C0014442
28092734	454	470	saccharification	T070	C0020291
28092734	476	484	combined	T080	C0205195
28092734	492	501	nutrients	T168	C0678695
28092734	506	518	hydrolysates	T109	C0029224
28092734	522	530	nitrogen	T123,T196	C0028158
28092734	535	541	carbon	T196	C0007009
28092734	542	549	sources	T033	C0449416
28092734	554	566	fermentation	T044	C0015852
28092734	570	587	S. inulinus YB1-5	T007	C0995848
28092734	600	609	d-Lactate	T109	C0522080
28092734	645	655	production	T057	C0033268
28092734	656	666	efficiency	T081	C0013682
28092734	703	710	glucose	T109,T121,T123	C0017725
28092734	732	744	simultaneous	T079	C0521115
28092734	745	761	saccharification	T070	C0020291
28092734	766	778	fermentation	T044	C0015852
28092734	779	786	process	T067	C1522240
28092734	806	811	solid	T167	C0302909
28092734	838	847	cellulase	T116,T121,T126	C0007641
28092734	848	861	concentration	T081	C1446561
28092734	876	885	d-Lactate	T109	C0522080
28092734	886	900	concentrations	T081	C1446561
28092734	909	921	productivity	T081	C0033269
28092734	927	934	optical	T070	C2350474
28092734	935	941	purity	T081	C1882508
28092734	964	971	glucose	T109,T121,T123	C0017725
28092734	1071	1081	cellulosic	T109,T123	C0007648
28092734	1082	1091	d-Lactate	T109	C0522080
28092734	1098	1110	agricultural	T090	C0001829
28092734	1111	1116	waste	T167	C0043045
28092734	1117	1124	without	T080	C0332288
28092734	1125	1133	external	T082	C0205101
28092734	1134	1158	nutrient supplementation	T168	C0242295

27651148|t|Striatal dopamine modulates timing of self-initiated saccades
27651148|a|The ability to adjust movement timing is essential in daily life. Explorations of the underlying neural mechanisms have reported a gradual increase or decrease in neuronal activity prior to self-timed movements within the cortico - basal ganglia loop. Previous studies in both humans and animals have shown that endogenous dopamine (DA) plays a modulatory role in self-timing. However, the specific site of dopaminergic regulation remains elusive because the systemic application of DA - related substances can directly alter both cortical and subcortical neuronal activities. To investigate the role of striatal DA in self-timing, we locally injected DA receptor agonists or antagonists into the striatum of two female monkeys (Macaca fuscata) while they performed two versions of the memory-guided saccade (MS) task. In the conventional, triggered MS task, animals made a saccade to the location of a previously flashed visual cue in response to the fixation point offset. In the self-timed MS task, monkeys were rewarded for making a self-initiated saccade within a predetermined time interval following the cue. Infusion of a small amount of a D1 or D2 antagonist led to early saccades in the self-timed, but not the triggered MS tasks, while infusion of DA agonists produced no consistent effect. We also found that local administration of nicotinic but not muscarinic acetylcholine receptor agonists and antagonists altered the timing of self-initiated saccades. Our data suggest that the timing of self-initiated movements may be regulated by the balance of signals in the direct and indirect basal ganglia pathways, as well as that between both hemispheres of the brain.
27651148	0	8	Striatal	T023	C0010097
27651148	9	17	dopamine	T109,T121,T123	C0013030
27651148	18	27	modulates	T082	C0443264
27651148	28	34	timing	T079	C0449243
27651148	38	52	self-initiated	T033	C0243095
27651148	53	61	saccades	T042	C0036019
27651148	84	92	movement	T040	C0026649
27651148	93	99	timing	T079	C0449243
27651148	159	165	neural	T025	C0027882
27651148	166	176	mechanisms	T169	C0441712
27651148	201	209	increase	T169	C0442805
27651148	213	221	decrease	T081	C0547047
27651148	225	233	neuronal	T025	C0027882
27651148	234	242	activity	T052	C0441655
27651148	252	262	self-timed	T079	C0449243
27651148	263	272	movements	T040	C0026649
27651148	284	291	cortico	T023	C0007776
27651148	294	307	basal ganglia	T023	C0004781
27651148	339	345	humans	T016	C0086418
27651148	350	357	animals	T008	C0003062
27651148	374	384	endogenous	T169	C0205227
27651148	385	393	dopamine	T109,T121,T123	C0013030
27651148	395	397	DA	T109,T121,T123	C0013030
27651148	407	417	modulatory	UnknownType	C0678672
27651148	418	422	role	T077	C1705810
27651148	426	437	self-timing	T079	C0449243
27651148	469	492	dopaminergic regulation	T042	C1819129
27651148	545	547	DA	T109,T121,T123	C0013030
27651148	550	568	related substances	T121	C1254351
27651148	593	601	cortical	T023	C0007776
27651148	606	617	subcortical	T023	C0815008
27651148	618	626	neuronal	T025	C0027882
27651148	627	637	activities	T052	C0441655
27651148	666	674	striatal	T023	C0010097
27651148	675	677	DA	T109,T121,T123	C0013030
27651148	681	692	self-timing	T079	C0449243
27651148	705	713	injected	T169	C1720154
27651148	714	725	DA receptor	T116,T192	C0034798
27651148	726	734	agonists	T121	C0243192
27651148	738	749	antagonists	T120	C0243076
27651148	759	767	striatum	T023	C0010097
27651148	775	781	female	T032	C0086287
27651148	782	789	monkeys	T015	C0026447
27651148	791	805	Macaca fuscata	T015	C1621298
27651148	848	879	memory-guided saccade (MS) task	T060	C0430022
27651148	888	900	conventional	T080	C0439858
27651148	912	919	MS task	T060	C0430022
27651148	921	928	animals	T008	C0003062
27651148	936	943	saccade	T042	C0036019
27651148	984	994	visual cue	T201	C2707266
27651148	1014	1035	fixation point offset	T033	C0243095
27651148	1044	1054	self-timed	T079	C0449243
27651148	1055	1062	MS task	T060	C0430022
27651148	1064	1071	monkeys	T015	C0026447
27651148	1099	1113	self-initiated	T033	C0243095
27651148	1114	1121	saccade	T042	C0036019
27651148	1145	1158	time interval	T079	C0872291
27651148	1173	1176	cue	T078	C0010439
27651148	1178	1186	Infusion	T061	C0574032
27651148	1210	1212	D1	T116,T192	C0058697
27651148	1216	1218	D2	T116,T192	C0058698
27651148	1219	1229	antagonist	T120	C0243076
27651148	1243	1251	saccades	T042	C0036019
27651148	1259	1269	self-timed	T079	C0449243
27651148	1293	1301	MS tasks	T060	C0430022
27651148	1309	1317	infusion	T061	C0574032
27651148	1321	1332	DA agonists	T121	C0178601
27651148	1342	1362	no consistent effect	T080	C1301751
27651148	1383	1403	local administration	UnknownType	C0678811
27651148	1407	1416	nicotinic	T109,T121,T127	C0027996
27651148	1425	1458	muscarinic acetylcholine receptor	T116,T192	C0034826
27651148	1459	1467	agonists	T121	C0243192
27651148	1472	1483	antagonists	T120	C0243076
27651148	1496	1502	timing	T079	C0449243
27651148	1506	1520	self-initiated	T033	C0243095
27651148	1521	1529	saccades	T042	C0036019
27651148	1557	1563	timing	T079	C0449243
27651148	1567	1581	self-initiated	T033	C0243095
27651148	1582	1591	movements	T040	C0026649
27651148	1599	1608	regulated	T038	C1327622
27651148	1616	1623	balance	T040	C0014653
27651148	1627	1634	signals	T067	C1710082
27651148	1642	1648	direct	T080	C1947931
27651148	1653	1661	indirect	T080	C0439852
27651148	1662	1675	basal ganglia	T023	C0004781
27651148	1676	1684	pathways	T044	C1704259
27651148	1715	1726	hemispheres	T023	C0228174
27651148	1734	1739	brain	T023	C0006104

27866508|t|New directions for psychiatric rehabilitation in the USA
27866508|a|American researchers have led the world in developing, evaluating, and disseminating evidence -based psychiatric rehabilitation practices for people with serious mental illness. Paradoxically, however, the USA lags behind most industrialized nations in providing access to high-quality mental health and psychiatric services. This essay examines several evidence-based practices developed in the USA, the spread of these practices, the barriers to ensuring availability to people who could benefit from these services, and some promising directions for overcoming the barriers. Factors influencing the growth and sustainment of effective client -centred practices include the availability of adequate and stable funding, committed leadership, and the influence of vested interests. Two strategies for promoting the spread and sustainment of well-implemented evidence-based practices are the adoption of fidelity scales and learning communities.
27866508	19	45	psychiatric rehabilitation	T061	C0204512
27866508	53	56	USA	T083	C0041703
27866508	57	65	American	T098	C0596070
27866508	66	77	researchers	T097	C0035173
27866508	91	96	world	T098	C2700280
27866508	100	110	developing	T169	C1527148
27866508	112	122	evaluating	T058	C0220825
27866508	128	141	disseminating	T082	C0205221
27866508	142	150	evidence	T078	C3887511
27866508	158	184	psychiatric rehabilitation	T061	C0204512
27866508	185	194	practices	T169	C1510541
27866508	199	205	people	T098	C0027361
27866508	211	218	serious	T080	C0205404
27866508	219	233	mental illness	T048	C0004936
27866508	263	266	USA	T083	C0041703
27866508	284	306	industrialized nations	T080	C0282613
27866508	320	326	access	T080	C0018748
27866508	330	342	high-quality	T058	C0034379
27866508	343	356	mental health	T058	C0025355
27866508	361	381	psychiatric services	T058	C3526598
27866508	388	393	essay	T170	C0684224
27866508	411	435	evidence-based practices	T169	C1510541
27866508	453	456	USA	T083	C0041703
27866508	478	487	practices	T058	C0034024
27866508	493	501	barriers	T033	C3260965
27866508	514	526	availability	T080	C0018748
27866508	530	536	people	T098	C0027361
27866508	547	554	benefit	T081	C0086387
27866508	566	574	services	T058	C0025355
27866508	610	620	overcoming	T052	C2983310
27866508	625	633	barriers	T033	C3260965
27866508	635	642	Factors	T169	C1521761
27866508	670	681	sustainment	T052	C0024501
27866508	685	694	effective	T080	C1704419
27866508	695	701	client	T096	C0008942
27866508	711	720	practices	T058	C0034024
27866508	733	745	availability	T169	C0470187
27866508	749	776	adequate and stable funding	T081	C0243098
27866508	778	798	committed leadership	T054	C0023181
27866508	808	817	influence	T077	C4054723
27866508	858	867	promoting	T052	C0033414
27866508	872	878	spread	T080	C0332261
27866508	883	894	sustainment	T052	C0024501
27866508	898	939	well-implemented evidence-based practices	T169	C1510541
27866508	948	956	adoption	T052	C1708476
27866508	960	975	fidelity scales	T054	C0680011
27866508	980	988	learning	T041	C0023185
27866508	989	1000	communities	T096	C0009462

28370728|t|Towards culturally competent paediatric oncology care. A qualitative study from the perspective of care providers
28370728|a|In order to gain more insight on the influence of ethnic diversity in paediatric cancer care, the perspectives of care providers were explored. Semi-structured interviews were conducted among 12 paediatric oncologists and 13 nurses of two different paediatric oncology wards and were analysed using a framework method. We found that care providers described the contact with Turkish and Moroccan parents as more difficult. They offered two reasons for this: (1) language barriers between care provider and parents hindered the exchange of information; (2) cultural barriers between care provider and parents about sharing the diagnosis and palliative perspective hindered communication. Care providers reported different solutions to deal with these barriers, such as using an interpreter and improving their cultural knowledge about their patients. They, however, were not using interpreters sufficiently and were unaware of the importance of eliciting parents ' perspectives. Communication techniques to overcome dilemmas between parents and care providers were not used and care providers were unaware of stereotypes and prejudice. Care providers should be offered insight in cultural barriers they are unaware of. Training in cultural competence might be a possibility to overcome manifest barriers.
28370728	8	53	culturally competent paediatric oncology care	T058	C3850087
28370728	57	74	qualitative study	T062	C0949415
28370728	84	95	perspective	T077	C1711364
28370728	99	113	care providers	T097	C0018724
28370728	151	160	influence	T077	C4054723
28370728	164	170	ethnic	T033	C0680174
28370728	171	180	diversity	T080	C1880371
28370728	184	194	paediatric	T091	C0030755
28370728	195	206	cancer care	T061	C0920687
28370728	212	224	perspectives	T077	C1711364
28370728	228	242	care providers	T097	C0018724
28370728	258	284	Semi-structured interviews	T058	C0683518
28370728	309	331	paediatric oncologists	T097	C0279158
28370728	339	345	nurses	T097	C0028661
28370728	363	388	paediatric oncology wards	T093	C0587485
28370728	398	406	analysed	T062	C0936012
28370728	415	431	framework method	T170	C0025663
28370728	447	461	care providers	T097	C0018724
28370728	489	496	Turkish	T098	C0549217
28370728	501	509	Moroccan	T098	C1257890
28370728	510	517	parents	T099	C0030551
28370728	576	593	language barriers	T033	C0237167
28370728	602	615	care provider	T097	C0018724
28370728	620	627	parents	T099	C0030551
28370728	628	636	hindered	T169	C0205245
28370728	641	664	exchange of information	T170	C0870706
28370728	670	687	cultural barriers	T058	C0810880
28370728	696	709	care provider	T097	C0018724
28370728	714	721	parents	T099	C0030551
28370728	740	749	diagnosis	T033	C0011900
28370728	754	764	palliative	T080	C1285530
28370728	765	776	perspective	T077	C1711364
28370728	777	785	hindered	T169	C0205245
28370728	786	799	communication	T054	C0009452
28370728	801	815	Care providers	T097	C0018724
28370728	835	844	solutions	T077	C2699488
28370728	864	872	barriers	T078	C0009454
28370728	891	902	interpreter	T097	C0150646
28370728	923	941	cultural knowledge	T170	C0376554
28370728	954	962	patients	T101	C0030705
28370728	994	1006	interpreters	T097	C0150646
28370728	1058	1067	eliciting	T048	C0474408
28370728	1068	1075	parents	T099	C0030551
28370728	1078	1090	perspectives	T077	C1711364
28370728	1092	1105	Communication	T054	C0009452
28370728	1106	1116	techniques	T169	C0449851
28370728	1129	1137	dilemmas	T068	C1510640
28370728	1146	1153	parents	T099	C0030551
28370728	1158	1172	care providers	T097	C0018724
28370728	1191	1205	care providers	T097	C0018724
28370728	1222	1233	stereotypes	T041	C3825635
28370728	1238	1247	prejudice	T055	C0033023
28370728	1249	1263	Care providers	T097	C0018724
28370728	1293	1310	cultural barriers	T058	C0810880
28370728	1332	1340	Training	T065	C0220931
28370728	1344	1363	cultural competence	T054	C0679748
28370728	1399	1407	manifest	T169	C0205319
28370728	1408	1416	barriers	T078	C0009454

27776910|t|The Outcomes Following Revision of Monoblock Metal on Metal Acetabular Components for Painful Micromotion in the Absence of Adverse Local Tissue Reaction to Metal
27776910|a|Revision hip arthroplasty for metal-on-metal arthroplasty (MOMA) in the presence of an adverse local tissue reaction (ALTR) has been associated with compromised outcomes. We hypothesized that revision of MOMA for painful micromotion of the cup, in the absence of ALTR, would have a more favorable outcome. We reviewed our database for Durom acetabular shell revision with minimum 24 months (24 months to 8 years) follow-up. Patients with a diagnosis of painful micromotion in the absence of pseudotumor was identified. At mid-term follow-up, 71 patients had undergone revision of a Durom MOMA. Twenty-seven of these (38%) were for painful micromotion (9 total hip arthroplasty, 18 hip resurfacing) of the cup alone. Following revision surgery, all patients reported resolution of the preoperative pain, as well as satisfactory outcome measures (mean scores: The Western Ontario and McMaster Universities Arthritis Index [WOMAC] 84.6, oxford hip score 84.7, Short Form Health Survey (SF-16) 51, University of California, Los Angeles (UCLA) 7.3). Radiologically, all cases demonstrated osseointegration of the revision shells; 1 case had zone-3 radiolucency that was nonprogressive. One patient had a dislocation treated by closed reduction at 10 weeks. Revision MOMA for painful micromotion of the shell in the absence of ALTR is not similar to revision for ALTR and is associated with predictable improvement in pain and quality of life.
27776910	4	12	Outcomes	T169	C1274040
27776910	13	22	Following	T079	C0332282
27776910	23	31	Revision	T079	C0439617
27776910	35	50	Monoblock Metal	T197	C0025552
27776910	54	59	Metal	T197	C0025552
27776910	60	81	Acetabular Components	T074	C0182473
27776910	86	93	Painful	T184	C0030193
27776910	94	105	Micromotion	T070	C0026597
27776910	113	120	Absence	T169	C0332197
27776910	124	153	Adverse Local Tissue Reaction	T046	C3854631
27776910	157	162	Metal	T197	C0025552
27776910	163	171	Revision	T079	C0439617
27776910	172	188	hip arthroplasty	T061	C0186193
27776910	193	220	metal-on-metal arthroplasty	T061	C0003893
27776910	222	226	MOMA	T061	C0003893
27776910	235	243	presence	T033	C0150312
27776910	250	279	adverse local tissue reaction	T046	C3854631
27776910	281	285	ALTR	T046	C3854631
27776910	296	311	associated with	T080	C0332281
27776910	324	332	outcomes	T169	C1274040
27776910	337	349	hypothesized	T078	C1512571
27776910	355	363	revision	T079	C0439617
27776910	367	371	MOMA	T061	C0003893
27776910	376	383	painful	T184	C0030193
27776910	384	395	micromotion	T070	C0026597
27776910	403	406	cup	T074	C0180231
27776910	415	422	absence	T169	C0332197
27776910	426	430	ALTR	T046	C3854631
27776910	450	467	favorable outcome	T033	C1333602
27776910	472	480	reviewed	T080	C1709940
27776910	485	493	database	T170	C0242356
27776910	498	520	Durom acetabular shell	T074	C0025080
27776910	521	529	revision	T079	C0439617
27776910	546	552	months	T079	C0439231
27776910	557	563	months	T079	C0439231
27776910	569	574	years	T079	C0439234
27776910	576	585	follow-up	T058	C1522577
27776910	587	595	Patients	T101	C0030705
27776910	603	612	diagnosis	T033	C0011900
27776910	616	623	painful	T184	C0030193
27776910	624	635	micromotion	T070	C0026597
27776910	643	650	absence	T169	C0332197
27776910	654	665	pseudotumor	T020	C0033844
27776910	685	703	mid-term follow-up	T058	C1522577
27776910	708	716	patients	T101	C0030705
27776910	731	739	revision	T079	C0439617
27776910	745	755	Durom MOMA	T061	C0003893
27776910	794	801	painful	T184	C0030193
27776910	802	813	micromotion	T070	C0026597
27776910	817	839	total hip arthroplasty	T061	C0040508
27776910	844	859	hip resurfacing	T061	C1719285
27776910	868	871	cup	T074	C0180231
27776910	889	905	revision surgery	T061	C0035110
27776910	911	919	patients	T101	C0030705
27776910	920	928	reported	T058	C0700287
27776910	929	939	resolution	T077	C2699488
27776910	947	959	preoperative	T079	C0445204
27776910	960	964	pain	T184	C0030193
27776910	977	989	satisfactory	T080	C0205410
27776910	990	1006	outcome measures	T081	C0086749
27776910	1008	1019	mean scores	T033	C3533236
27776910	1025	1082	Western Ontario and McMaster Universities Arthritis Index	T170	C3472647
27776910	1084	1089	WOMAC	T170	C3472647
27776910	1097	1113	oxford hip score	T201	C1998079
27776910	1120	1144	Short Form Health Survey	T062	C0018762
27776910	1146	1151	SF-16	T062	C0018762
27776910	1157	1181	University of California	T073,T092	C0041740
27776910	1183	1194	Los Angeles	T083	C0024015
27776910	1196	1200	UCLA	T073,T092	C0041740
27776910	1208	1222	Radiologically	UnknownType	C0748230
27776910	1228	1233	cases	T169	C0868928
27776910	1247	1263	osseointegration	T042	C0079949
27776910	1271	1279	revision	T079	C0439617
27776910	1280	1286	shells	T080	C1948022
27776910	1290	1294	case	T169	C0868928
27776910	1299	1318	zone-3 radiolucency	T067	C2827491
27776910	1328	1342	nonprogressive	T033	C3839460
27776910	1348	1355	patient	T101	C0030705
27776910	1362	1373	dislocation	T037	C0012691
27776910	1374	1381	treated	T061	C0087111
27776910	1385	1401	closed reduction	T061	C0177475
27776910	1408	1413	weeks	T079	C0439230
27776910	1415	1423	Revision	T079	C0439617
27776910	1424	1428	MOMA	T061	C0003893
27776910	1433	1440	painful	T184	C0030193
27776910	1441	1452	micromotion	T070	C0026597
27776910	1460	1465	shell	T074	C0025080
27776910	1473	1480	absence	T169	C0332197
27776910	1484	1488	ALTR	T046	C3854631
27776910	1507	1515	revision	T079	C0439617
27776910	1520	1524	ALTR	T046	C3854631
27776910	1532	1547	associated with	T080	C0332281
27776910	1548	1559	predictable	T078	C0681842
27776910	1560	1571	improvement	T077	C2986411
27776910	1575	1579	pain	T184	C0030193
27776910	1584	1599	quality of life	T078	C0034380

27588935|t|One-hour post-load hyperglycemia combined with HbA1c identifies pre-diabetic individuals with a higher cardio-metabolic risk burden
27588935|a|Evidence suggests that combining 1-hour plasma glucose ≥155 mg/dl during an oral glucose tolerance test (OGTT) with glycosylated hemoglobin (HbA1c) significantly increases their predictive power for incident diabetes, while their individual and joint associations with cardio-metabolic risk factors remain undefined. Herein, we evaluated whether 1-hour post-load plasma glucose ≥155 mg/dl combined with HbA1c may identify pre-diabetic individuals with a higher cardio-metabolic risk. Anthropometric and metabolic characteristics, insulin sensitivity and insulin secretion assessed by OGTT -derived indexes, carotid intima-media thickness (IMT), pulse pressure, and rate pressure product were evaluated in 1495 individuals. As compared with subjects with 1-hour post-load glucose <155 mg/dl, individuals with 1-hour post-load glucose ≥155 mg/dl exhibited a significantly worse cardio metabolic profile, both in the group with HbA1c <5.7%, and in the group with prediabetes (HbA1c 5.7-6.4%). Specifically, in both groups, subjects with 1-hour post-load glucose ≥155 mg/dl had higher fasting and 2-h post-load glucose (p < 0.0001 for all in both group s), higher HOMA-IR (p < 0.0001 in both groups), and carotid IMT (p = 0.05 in the group with HbA1c <5.7% and p = 0.03 in the group HbA1c 5.7-6.4%), as well as lower Matsuda index, insulinogenic index and disposition index (p < 0.0001 in both groups), and lower insulin - stimulated glucose disposal (p < 0.0001 in the group with HbA1c <5.7% and p = 0.03 in the group HbA1c 5.7-6.4%). Hyperglycemia at 1-hour during an OGTT may be a useful tool to identify a subset of individuals within HbA1c -defined glycemic categories at higher risk of developing type 2 diabetes and cardiovascular disease.
27588935	0	18	One-hour post-load	T079	C1439504
27588935	19	32	hyperglycemia	T047	C0020456
27588935	47	52	HbA1c	T116,T123	C0019018
27588935	64	76	pre-diabetic	T079	C1254367
27588935	77	88	individuals	T098	C0237401
27588935	103	131	cardio-metabolic risk burden	T201	C2321263
27588935	165	186	1-hour plasma glucose	T201	C0797930
27588935	208	235	oral glucose tolerance test	T060	C0029161
27588935	237	241	OGTT	T060	C0029161
27588935	248	271	glycosylated hemoglobin	T116,T123	C0019018
27588935	273	278	HbA1c	T116,T123	C0019018
27588935	331	339	incident	T067	C1551358
27588935	340	348	diabetes	T047	C0011847
27588935	401	430	cardio-metabolic risk factors	T201	C2321263
27588935	460	469	evaluated	T058	C0220825
27588935	478	509	1-hour post-load plasma glucose	T201	C0797930
27588935	535	540	HbA1c	T116,T123	C0019018
27588935	554	566	pre-diabetic	T079	C1254367
27588935	567	578	individuals	T098	C0237401
27588935	593	614	cardio-metabolic risk	T078	C0035647
27588935	616	630	Anthropometric	T060	C2459906
27588935	635	644	metabolic	T043	C1524026
27588935	645	660	characteristics	T080	C1521970
27588935	662	681	insulin sensitivity	T046	C0920563
27588935	686	703	insulin secretion	T043	C1256369
27588935	716	720	OGTT	T060	C0029161
27588935	730	737	indexes	T170	C0918012
27588935	739	769	carotid intima-media thickness	T201	C1960466
27588935	771	774	IMT	T201	C1960466
27588935	777	791	pulse pressure	T040	C0949236
27588935	797	810	rate pressure	T081	C1442094
27588935	824	833	evaluated	T058	C0220825
27588935	842	853	individuals	T098	C0237401
27588935	886	910	1-hour post-load glucose	T201	C0797930
27588935	923	934	individuals	T098	C0237401
27588935	940	964	1-hour post-load glucose	T201	C0797930
27588935	1008	1032	cardio metabolic profile	T039	C3853758
27588935	1046	1051	group	T098	C1257890
27588935	1057	1062	HbA1c	T116,T123	C0019018
27588935	1081	1086	group	T098	C1257890
27588935	1092	1103	prediabetes	T047	C0362046
27588935	1105	1110	HbA1c	T116,T123	C0019018
27588935	1144	1150	groups	T098	C1257890
27588935	1166	1190	1-hour post-load glucose	T201	C0797930
27588935	1206	1220	higher fasting	T034	C1261430
27588935	1225	1246	2-h post-load glucose	T034	C1318376
27588935	1275	1280	group	T098	C1257890
27588935	1292	1299	HOMA-IR	T059	C3639411
27588935	1320	1326	groups	T098	C1257890
27588935	1333	1344	carotid IMT	T201	C1960466
27588935	1362	1367	group	T098	C1257890
27588935	1373	1378	HbA1c	T116,T123	C0019018
27588935	1405	1410	group	T098	C1257890
27588935	1411	1416	HbA1c	T116,T123	C0019018
27588935	1445	1458	Matsuda index	T170	C0918012
27588935	1460	1479	insulinogenic index	T170	C0918012
27588935	1484	1501	disposition index	T170	C0918012
27588935	1522	1528	groups	T098	C1257890
27588935	1541	1548	insulin	T116,T121,T125	C0021641
27588935	1551	1561	stimulated	T061	C1292856
27588935	1562	1569	glucose	T109,T121,T123	C0017725
27588935	1598	1603	group	T098	C1257890
27588935	1609	1614	HbA1c	T116,T123	C0019018
27588935	1641	1646	group	T098	C1257890
27588935	1647	1652	HbA1c	T116,T123	C0019018
27588935	1664	1677	Hyperglycemia	T047	C0020456
27588935	1698	1702	OGTT	T060	C0029161
27588935	1719	1723	tool	T059	C0022885
27588935	1748	1759	individuals	T098	C0237401
27588935	1767	1772	HbA1c	T116,T123	C0019018
27588935	1782	1801	glycemic categories	T081	C1136206
27588935	1831	1846	type 2 diabetes	T047	C0011860
27588935	1851	1873	cardiovascular disease	T047	C0007222

27457997|t|Identification of a peroxisomal -targeted aldolase involved in chlorophyll biosynthesis and sugar metabolism in rice
27457997|a|Chlorophyll plays remarkable and critical roles in photosynthetic light-harvesting, energy transduction and plant development. In this study, we identified a rice Chl -deficient mutant, ygdl-1 (yellow green and droopy leaf-1), which showed yellow-green leaves throughout plant development with decreased content of Chls and carotene and an increased Chl a/b ratio. The ygdl-1 mutant also exhibited severe defects in chloroplast development, including disorganized grana stacks. Sequence analysis revealed that the mutant contained a T-DNA insertion within the promoter of a fructose-1,6-bisphosphate aldolase (OsAld-Y), which dramatically reduced the OsAld-Y mRNA level, and its identity was verified by transgenic complementation. Real-time PCR analysis showed that the expression levels of genes associated with chlorophyll biosynthesis and chloroplast development were concurrently altered in the ygdl-1 mutant. The expression of OsAld-Y - GFP fusion protein in tobacco epidermal cells showed that OsAld-Y was localized to the peroxisome. In addition, the analysis of primary carbon metabolites revealed the significantly reduced levels of sucrose and fructose in the mutant leaves, while the glucose content was similar to wild-type plants. Our results suggest that the OsAld-Y participates in Chl accumulation, chloroplast development and plant growth by influencing the photosynthetic rate of leaves and the sugar metabolism of rice.
27457997	20	31	peroxisomal	T026	C3546463
27457997	42	50	aldolase	T116,T126	C0016762
27457997	63	74	chlorophyll	T109,T123	C0008260
27457997	75	87	biosynthesis	T169	C0005572
27457997	92	97	sugar	T109,T121	C0242209
27457997	98	108	metabolism	T044	C0302820
27457997	112	116	rice	T168	C0035567
27457997	117	128	Chlorophyll	T109,T123	C0008260
27457997	168	200	photosynthetic light-harvesting,	T044	C1158303
27457997	201	220	energy transduction	T040	C1160185
27457997	225	242	plant development	T040	C0597252
27457997	252	257	study	T062	C2603343
27457997	275	279	rice	T168	C0035567
27457997	280	283	Chl	T109,T123	C0008260
27457997	295	301	mutant	T049	C0596988
27457997	303	309	ygdl-1	T049	C0596988
27457997	311	341	yellow green and droopy leaf-1	T049	C0596988
27457997	357	376	yellow-green leaves	T002	C0242724
27457997	388	405	plant development	T040	C0597252
27457997	432	436	Chls	T109,T123	C0008260
27457997	441	449	carotene	T109,T123	C0007269
27457997	467	470	Chl	T109,T123	C0008260
27457997	486	499	ygdl-1 mutant	T049	C0596988
27457997	515	521	severe	T080	C0205082
27457997	522	529	defects	T169	C1457869
27457997	533	544	chloroplast	T026	C0008266
27457997	545	556	development	T040	C0678723
27457997	581	593	grana stacks	T026	C0205715
27457997	595	612	Sequence analysis	T059,T063	C0162801
27457997	631	637	mutant	T049	C0596988
27457997	650	655	T-DNA	T114	C0075739
27457997	677	685	promoter	T114,T123	C0086860
27457997	691	725	fructose-1,6-bisphosphate aldolase	T116,T126	C0016762
27457997	727	734	OsAld-Y	T116,T126	C0016762
27457997	768	775	OsAld-Y	T116,T126	C0016762
27457997	776	780	mRNA	T114,T123	C0035696
27457997	781	786	level	T080	C0441889
27457997	821	847	transgenic complementation	T045	C0178654
27457997	849	871	Real-time PCR analysis	T059	C2732732
27457997	888	905	expression levels	T081	C3244092
27457997	909	914	genes	T028	C0017337
27457997	931	942	chlorophyll	T109,T123	C0008260
27457997	943	955	biosynthesis	T169	C0005572
27457997	960	971	chloroplast	T026	C0008266
27457997	972	983	development	T040	C0678723
27457997	1017	1030	ygdl-1 mutant	T049	C0596988
27457997	1036	1046	expression	T045	C1171362
27457997	1050	1057	OsAld-Y	T116,T126	C0016762
27457997	1060	1063	GFP	T116,T130	C0120285
27457997	1064	1078	fusion protein	T116,T123	C0162768
27457997	1082	1089	tobacco	T002	C0740009
27457997	1090	1105	epidermal cells	T025	C1179149
27457997	1118	1125	OsAld-Y	T116,T126	C0016762
27457997	1147	1157	peroxisome	T026	C0752063
27457997	1176	1184	analysis	T062	C0936012
27457997	1188	1214	primary carbon metabolites	T123	C0870883
27457997	1260	1267	sucrose	T109,T121,T123	C0038636
27457997	1272	1280	fructose	T109,T121	C0016745
27457997	1288	1294	mutant	T049	C0596988
27457997	1295	1301	leaves	T002	C0242724
27457997	1313	1320	glucose	T109,T121,T123	C0017725
27457997	1344	1360	wild-type plants	T002	C0330098
27457997	1391	1398	OsAld-Y	T116,T126	C0016762
27457997	1415	1418	Chl	T109,T123	C0008260
27457997	1419	1431	accumulation	T033	C4055506
27457997	1433	1444	chloroplast	T026	C0008266
27457997	1445	1456	development	T040	C0678723
27457997	1461	1473	plant growth	T040	C0597252
27457997	1493	1507	photosynthetic	T070	C0031764
27457997	1508	1512	rate	T081	C1521828
27457997	1516	1522	leaves	T002	C0242724
27457997	1531	1536	sugar	T109,T121	C0242209
27457997	1537	1547	metabolism	T044	C0302820
27457997	1551	1555	rice	T168	C0035567

27655516|t|Central apelin-13 administration modulates hypothalamic control of feeding
27655516|a|The 77 amino prepropeptide apelin has been isolated from bovine stomach tissue and several smaller fragments, including apelin-13, showed high affinity for the orphan APJ receptor. The distribution of apelinergic fibers and receptors in the hypothalamus may suggest a role of apelin-13 on energy balance regulation, albeit the studies reporting the acute effects of apelin on feeding control are inconsistent. Considering the possible involvement of apelinergic system on hypothalamic appetite controlling network, in the present study we evaluated in the rat the effects of intrahypothalamic apelin-13 injection on food intake and the involvement of orexigenic and anorexigenic hypothalamic peptides and neurotransmitters. Eighteen rats (6 for each group of treatment) were injected into the ARC with either vehicle or apelin-13 (1-2 μg/ rat). Food intake and hypothalamic peptide and neurotransmitter levels were evaluated 2 and 24 h after injection. Compared to vehicle, apelin-13 administration increased food intake both 2 and 24 h following treatment. This effect could be related to inhibited cocaine- and amphetamine-regulated transcript (CART) gene expression and serotonin (5-hydroxytryptamine, 5-HT) synthesis and release, and increased orexin A gene expression in the hypothalamus.
27655516	0	32	Central apelin-13 administration	T061	C1533734
27655516	8	17	apelin-13	T116,T123	C3179318
27655516	33	42	modulates	T082	C0443264
27655516	43	55	hypothalamic	T023	C0020663
27655516	56	63	control	T169	C2587213
27655516	67	74	feeding	T040	C0013470
27655516	82	108	amino prepropeptide apelin	T116,T123	C1531139
27655516	118	126	isolated	T169	C0205409
27655516	132	138	bovine	T015	C3667982
27655516	139	146	stomach	T023	C0038351
27655516	147	153	tissue	T024	C0040300
27655516	158	165	several	T081	C0443302
27655516	166	173	smaller	T080	C0547044
27655516	174	183	fragments	T031	C0486805
27655516	185	194	including	T169	C0332257
27655516	195	204	apelin-13	T116,T123	C3179318
27655516	213	217	high	T080	C0205250
27655516	218	226	affinity	T070	C1510827
27655516	235	254	orphan APJ receptor	T116,T192	C1137482
27655516	260	272	distribution	T169	C1704711
27655516	276	294	apelinergic fibers	T116,T123	C0033684
27655516	299	308	receptors	T116,T192	C1137482
27655516	316	328	hypothalamus	T023	C0020663
27655516	333	340	suggest	T078	C1705535
27655516	343	347	role	T077	C1705810
27655516	351	360	apelin-13	T116,T123	C3179318
27655516	364	389	energy balance regulation	T039	C1254359
27655516	402	409	studies	T062	C2603343
27655516	410	419	reporting	T062	C0011000
27655516	424	429	acute	T079	C0205178
27655516	430	437	effects	T080	C1280500
27655516	441	447	apelin	T116,T123	C3179318
27655516	451	458	feeding	T040	C0013470
27655516	459	466	control	T169	C2587213
27655516	471	483	inconsistent	T080	C0442809
27655516	501	509	possible	T033	C0332149
27655516	510	521	involvement	T169	C1314939
27655516	525	543	apelinergic system	T022	C0460002
27655516	547	568	hypothalamic appetite	T040	C0003618
27655516	569	580	controlling	T169	C2587213
27655516	581	588	network	T169	C1882071
27655516	605	610	study	T062	C2603343
27655516	631	634	rat	T015	C0034721
27655516	639	646	effects	T080	C1280500
27655516	650	687	intrahypothalamic apelin-13 injection	T061	C1533685
27655516	668	677	apelin-13	T116,T123	C3179318
27655516	691	702	food intake	T040	C0013470
27655516	711	722	involvement	T169	C1314939
27655516	726	736	orexigenic	T123	C0574031
27655516	741	775	anorexigenic hypothalamic peptides	T123	C0574031
27655516	780	797	neurotransmitters	T123	C0027908
27655516	808	812	rats	T015	C0034721
27655516	820	824	each	T081	C1457900
27655516	825	830	group	UnknownType	C0681860
27655516	834	843	treatment	T061	C0087111
27655516	850	858	injected	T169	C1720154
27655516	868	871	ARC	T116,T123	C1138248
27655516	884	891	vehicle	T122	C0042444
27655516	895	904	apelin-13	T116,T123	C3179318
27655516	914	917	rat	T015	C0034721
27655516	920	931	Food intake	T040	C0013470
27655516	936	956	hypothalamic peptide	T116	C0030956
27655516	961	977	neurotransmitter	T123	C0027908
27655516	978	984	levels	T080	C0441889
27655516	1011	1016	after	T079	C0687676
27655516	1017	1026	injection	T122	C1272883
27655516	1040	1047	vehicle	T122	C0042444
27655516	1049	1058	apelin-13	T116,T123	C3179318
27655516	1059	1073	administration	T061	C1533734
27655516	1074	1083	increased	T081	C0205217
27655516	1084	1095	food intake	T040	C0013470
27655516	1112	1121	following	T079	C0332282
27655516	1122	1131	treatment	T061	C0087111
27655516	1138	1144	effect	T080	C1280500
27655516	1165	1174	inhibited	T080	C0311403
27655516	1175	1220	cocaine- and amphetamine-regulated transcript	T028	C1824528
27655516	1222	1226	CART	T028	C1824528
27655516	1228	1243	gene expression	T045	C0017262
27655516	1248	1257	serotonin	T109,T123	C0036751
27655516	1259	1278	5-hydroxytryptamine	T109,T123	C0036751
27655516	1280	1284	5-HT	T109,T123	C0036751
27655516	1286	1295	synthesis	T044	C1154450
27655516	1313	1322	increased	T081	C0205217
27655516	1323	1331	orexin A	T116,T123	C0671870
27655516	1332	1347	gene expression	T045	C0017262
27655516	1355	1367	hypothalamus	T023	C0020663

28105595|t|Bioelectrochemical anaerobic sewage treatment technology for Arctic communities
28105595|a|This study describes a novel wastewater treatment technology suitable for small remote northern communities. The technology is based on an enhanced biodegradation of organic carbon through a combination of anaerobic methanogenic and microbial electrochemical (bioelectrochemical) degradation processes leading to biomethane production. The microbial electrochemical degradation is achieved in a membraneless flow -through bioanode - biocathode setup operating at an applied voltage below the water electrolysis threshold. Laboratory wastewater treatment tests conducted through a broad range of mesophilic and psychrophilic temperatures (5-23 °C) using synthetic wastewater showed a biochemical oxygen demand (BOD5) removal efficiency of 90-97% and an effluent BOD5 concentration as low as 7 mg L(-1). An electricity consumption of 0.6 kWh kg(-1) of chemical oxygen demand (COD) removed was observed. Low energy consumption coupled with enhanced methane production led to a net positive energy balance in the bioelectrochemical treatment system.
28105595	0	18	Bioelectrochemical	T059	C2350499
28105595	19	28	anaerobic	T080	C3641081
28105595	29	45	sewage treatment	T057	C0597443
28105595	46	56	technology	T090	C0039421
28105595	61	67	Arctic	T083	C0003740
28105595	68	79	communities	T096	C0009462
28105595	85	90	study	T062	C2603343
28105595	109	119	wastewater	T083	C0450237
28105595	120	129	treatment	T169	C1522326
28105595	130	140	technology	T090	C0039421
28105595	160	166	remote	T082	C0205157
28105595	167	175	northern	T082	C1709269
28105595	176	187	communities	T096	C0009462
28105595	193	203	technology	T090	C0039421
28105595	207	212	based	T169	C1527178
28105595	219	227	enhanced	T052	C2349975
28105595	228	242	biodegradation	T070	C0005482
28105595	246	260	organic carbon	T104	C0302333
28105595	286	295	anaerobic	T080	C3641081
28105595	296	308	methanogenic	T194	C0025621
28105595	313	322	microbial	T001	C0599840
28105595	323	338	electrochemical	T059	C2350499
28105595	340	358	bioelectrochemical	T059	C2350499
28105595	360	381	degradation processes	T169	C0243125
28105595	393	403	biomethane	T109	C0029224
28105595	404	414	production	T169	C1522492
28105595	420	429	microbial	T001	C0599840
28105595	430	445	electrochemical	T059	C2350499
28105595	446	457	degradation	T169	C0243125
28105595	475	492	membraneless flow	T033	C0243095
28105595	502	510	bioanode	T073	C0003103
28105595	513	523	biocathode	T073	C0007441
28105595	530	539	operating	T169	C3242339
28105595	546	553	applied	T169	C4048755
28105595	554	561	voltage	T081	C0598352
28105595	572	577	water	T121,T197	C0043047
28105595	578	590	electrolysis	T061	C0013829
28105595	591	600	threshold	T080	C0449864
28105595	602	612	Laboratory	T073,T093	C0022877
28105595	613	623	wastewater	T083	C0450237
28105595	624	633	treatment	T169	C1522326
28105595	634	639	tests	T170	C0392366
28105595	660	671	broad range	T082	C0332464
28105595	675	685	mesophilic	T080	C0205081
28105595	690	716	psychrophilic temperatures	T070	C0009264
28105595	733	742	synthetic	T080	C2004457
28105595	743	753	wastewater	T083	C0450237
28105595	763	788	biochemical oxygen demand	T059	C3826658
28105595	790	794	BOD5	T059	C3826658
28105595	796	803	removal	T052	C1883720
28105595	804	814	efficiency	T081	C0013682
28105595	832	840	effluent	T170	C1546612
28105595	841	845	BOD5	T059	C3826658
28105595	846	859	concentration	T081	C1446561
28105595	885	896	electricity	T070	C0013790
28105595	897	908	consumption	T169	C0457083
28105595	930	952	chemical oxygen demand	T038	C2936287
28105595	954	957	COD	T038	C2936287
28105595	959	966	removed	T080	C0849355
28105595	971	979	observed	T169	C1441672
28105595	981	984	Low	T080	C0205251
28105595	985	991	energy	T081	C1442080
28105595	992	1003	consumption	T169	C0457083
28105595	1017	1025	enhanced	T052	C2349975
28105595	1026	1033	methane	T109	C0025617
28105595	1034	1044	production	T169	C1522492
28105595	1058	1066	positive	T033	C1446409
28105595	1067	1073	energy	T081	C1442080
28105595	1074	1081	balance	T169	C0205415
28105595	1089	1107	bioelectrochemical	T059	C2350499
28105595	1108	1117	treatment	T169	C1522326
28105595	1118	1124	system	T169	C0449913

27358525|t|New Breast Pain Chart for Objective Record of Mastalgia
27358525|a|Mastalgia is the commonest affliction of mammary gland among ladies of the reproductive age group. Since etiopathogenesis and therapy are different for cyclical and noncyclical pain, it is imperative to ascertain the exact type correctly. This is usually done in the breast clinics by advising the patient to fill a pain diary over a period of 2 months over two menstrual cycles. The Cardiff pain chart records the severity of pain in the form of a triangle for mild to moderate pain and a square for severe pain. Moreover, Cardiff pain chart does not allow a patient to record the severity of pain on days of menses, as she has to put the letter "P" in the box. These problems have been resolved in the new breast pain chart. In the new pain chart, the lady records pain severity in the form of visual linear analogue scale score on every day of menstrual cycle. She enters her menstrual experience on a separate part of chart, which allows us to visualize the full month's pain severity in an uncluttered way.
27358525	0	3	New	T080	C0205314
27358525	4	15	Breast Pain	T184	C0024902
27358525	16	21	Chart	T074	C0007963
27358525	26	42	Objective Record	T170	C0034869
27358525	46	55	Mastalgia	T184	C0024902
27358525	56	65	Mastalgia	T184	C0024902
27358525	73	82	commonest	T081	C0205214
27358525	83	93	affliction	T041	C0018235
27358525	97	110	mammary gland	T023	C0929301
27358525	117	123	ladies	T098	C0043210
27358525	131	143	reproductive	T079	C0035156
27358525	144	153	age group	T100	C0027362
27358525	161	177	etiopathogenesis	T169	C1510540
27358525	182	189	therapy	T061	C0087111
27358525	194	203	different	T080	C1705242
27358525	208	216	cyclical	T184	C0405472
27358525	221	237	noncyclical pain	T184	C0405473
27358525	323	337	breast clinics	T073,T093	C3810844
27358525	354	361	patient	T101	C0030705
27358525	372	382	pain diary	T170	C0451366
27358525	390	396	period	T079	C1948053
27358525	402	408	months	T079	C0439231
27358525	418	434	menstrual cycles	T040	C0025329
27358525	440	466	Cardiff pain chart records	T074	C0007963
27358525	471	479	severity	T080	C0439793
27358525	483	487	pain	T184	C0030193
27358525	505	513	triangle	T077	C0205119
27358525	518	522	mild	T080	C2945599
27358525	526	539	moderate pain	T184	C0278139
27358525	546	552	square	T082	C0205120
27358525	557	568	severe pain	T033	C0278140
27358525	580	598	Cardiff pain chart	T074	C0007963
27358525	616	623	patient	T101	C0030705
27358525	627	633	record	T080	C2355580
27358525	638	646	severity	T080	C0439793
27358525	650	654	pain	T184	C0030193
27358525	658	662	days	T079	C0439228
27358525	666	672	menses	T040	C0025344
27358525	725	733	problems	T033	C0033213
27358525	744	752	resolved	T077	C2699488
27358525	760	763	new	T080	C0205314
27358525	764	775	breast pain	T184	C0024902
27358525	776	781	chart	T074	C0007963
27358525	790	793	new	T080	C0205314
27358525	794	804	pain chart	T074	C0007963
27358525	810	814	lady	T098	C0043210
27358525	815	822	records	T080	C2355580
27358525	823	827	pain	T184	C0030193
27358525	828	836	severity	T080	C0439793
27358525	852	886	visual linear analogue scale score	T201	C2960751
27358525	890	899	every day	T079	C0332173
27358525	903	918	menstrual cycle	T040	C0025329
27358525	935	944	menstrual	T040	C0025329
27358525	945	955	experience	T041	C0596545
27358525	978	983	chart	T074	C0007963
27358525	1004	1013	visualize	T082	C0449911
27358525	1023	1030	month's	T079	C0439231
27358525	1031	1035	pain	T184	C0030193
27358525	1036	1044	severity	T080	C0439793

28053186|t|AAV9 - NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease
28053186|a|Niemann-Pick type C (NPC) disease is a fatal inherited neurodegenerative disorder caused by loss-of-function mutations in the NPC1 or NPC2 gene. There is no effective way to treat NPC disease. In this study, we used adeno-associated virus (AAV) serotype 9 (AAV9) to deliver a functional NPC1 gene systemically into NPC1(-/-) mice at postnatal day 4. One single AAV9-NPC1 injection resulted in robust NPC1 expression in various tissues, including brain, heart, and lung. Strikingly, AAV9-mediated NPC1 delivery significantly promoted Purkinje cell survival, restored locomotor activity and coordination, and increased the lifespan of NPC1(-/-) mice. Our work suggests that AAV-based gene therapy is a promising means to treat NPC disease.
28053186	0	4	AAV9	T005	C1564874
28053186	7	11	NPC1	T028	C1417776
28053186	12	25	significantly	T078	C0750502
28053186	26	37	ameliorates	T033	C0243095
28053186	38	51	Purkinje cell	T025	C0034143
28053186	52	57	death	T043	C0007587
28053186	62	86	behavioral abnormalities	T048	C0233514
28053186	90	95	mouse	T015	C0025929
28053186	96	107	NPC disease	T047	C0220756
28053186	108	141	Niemann-Pick type C (NPC) disease	T047	C0220756
28053186	147	152	fatal	T080	C1302234
28053186	153	162	inherited	T169	C0439660
28053186	163	189	neurodegenerative disorder	T047	C0524851
28053186	200	216	loss-of-function	T033	C0243095
28053186	217	226	mutations	T045	C0026882
28053186	234	238	NPC1	T028	C1417776
28053186	242	251	NPC2 gene	T028	C1422736
28053186	282	287	treat	T169	C1292734
28053186	288	299	NPC disease	T047	C0220756
28053186	324	346	adeno-associated virus	T005	C1564874
28053186	348	351	AAV	T005	C1564874
28053186	353	363	serotype 9	T170	C0449943
28053186	365	369	AAV9	T005	C1564874
28053186	384	394	functional	T169	C0205245
28053186	395	404	NPC1 gene	T028	C1417776
28053186	405	417	systemically	T169	C0205373
28053186	423	432	NPC1(-/-)	T028	C1417776
28053186	433	437	mice	T015	C0206745
28053186	441	456	postnatal day 4	T061	C0419611
28053186	462	468	single	T081	C0205171
28053186	469	488	AAV9-NPC1 injection	T061	C0021485
28053186	501	507	robust	T080	C2986815
28053186	508	512	NPC1	T028	C1417776
28053186	513	523	expression	T045	C0017262
28053186	535	542	tissues	T024	C0040300
28053186	554	559	brain	T023	C0006104
28053186	561	566	heart	T023	C0018787
28053186	572	576	lung	T023	C0024109
28053186	590	603	AAV9-mediated	T054	C0086597
28053186	604	617	NPC1 delivery	T077	C1524066
28053186	618	631	significantly	T078	C0750502
28053186	632	640	promoted	T052	C0033414
28053186	641	654	Purkinje cell	T025	C0034143
28053186	655	663	survival	T052	C0038952
28053186	674	692	locomotor activity	T040	C0023946
28053186	697	709	coordination	T042	C0237543
28053186	715	724	increased	T081	C0205217
28053186	729	737	lifespan	T079	C1254367
28053186	741	750	NPC1(-/-)	T028	C1417776
28053186	751	755	mice	T015	C0206745
28053186	780	802	AAV-based gene therapy	T061	C0860404
28053186	827	832	treat	T169	C1292734
28053186	833	844	NPC disease	T047	C0220756

27575455|t|Maf1 -mediated regulation of yeast RNA polymerase III is correlated with CCA addition at the 3' end of tRNA precursors
27575455|a|In eukaryotic cells tRNA synthesis is negatively regulated by the protein Maf1, conserved from yeast to humans. Maf1 from yeast Saccharomyces cerevisiae mediates repression of trna transcription when cells are transferred from medium with glucose to medium with glycerol, a non-fermentable carbon source. The strain with deleted gene encoding Maf1 (maf1Δ) is viable but accumulates tRNA precursors. In this study tRNA precursors were analysed by RNA-Seq and Northern hybridization in wild type strain and maf1Δ mutant grown in glucose medium or upon shift to repressive conditions. A negative effect of maf1Δ mutant on the addition of the auxiliary CCA nucleotides to the 3' end of pre-tRNAs was observed in cells shifted to unfavourable growth conditions. This effect was reduced by overexpression of the yeast CCA1 gene encoding ATP(CTP):tRNA nucleotidyltransferase. The CCA sequence at the 3' end is important for export of tRNA precursors from the nucleus and essential for tRNA charging with amino acids. Data presented here indicate that CCA-addition to intron -containing end-processed tRNA precursors is a limiting step in tRNA maturation when there is no Maf1 mediated RNA polymerase III (Pol III) repression. The correlation between CCA synthesis and Pol III regulation by Maf1 could be important in coordination of tRNA transcription, processing and regulation of translation.
27575455	0	4	Maf1	T028	C1825934
27575455	15	25	regulation	T038	C1327622
27575455	29	34	yeast	T004	C0043393
27575455	35	53	RNA polymerase III	T116,T126	C0035680
27575455	57	67	correlated	T080	C1707520
27575455	73	107	CCA addition at the 3' end of tRNA	T045	C1158763
27575455	103	118	tRNA precursors	T114,T123	C0041133
27575455	122	138	eukaryotic cells	T025	C0015161
27575455	139	153	tRNA synthesis	T045	C1622985
27575455	157	167	negatively	T033	C0205160
27575455	168	177	regulated	T038	C1327622
27575455	185	197	protein Maf1	T116,T123	C0536951
27575455	214	219	yeast	T004	C0043393
27575455	223	229	humans	T016	C0086418
27575455	231	235	Maf1	T028	C1825934
27575455	241	246	yeast	T004	C0043393
27575455	247	271	Saccharomyces cerevisiae	T004	C0036025
27575455	281	291	repression	T045	C0920533
27575455	295	313	trna transcription	T045	C1158829
27575455	319	324	cells	T025	C0007634
27575455	346	352	medium	T130	C0010454
27575455	358	365	glucose	T109,T121,T123	C0017725
27575455	369	375	medium	T130	C0010454
27575455	381	389	glycerol	T109,T121,T123	C0017861
27575455	393	408	non-fermentable	T044	C0015852
27575455	409	415	carbon	T196	C0007009
27575455	416	422	source	T033	C0449416
27575455	428	434	strain	T001	C1518614
27575455	440	447	deleted	T033	C2069771
27575455	448	452	gene	T028	C0017337
27575455	453	461	encoding	T052	C2700640
27575455	462	466	Maf1	T028	C1825934
27575455	468	473	maf1Δ	T028	C1825934
27575455	478	484	viable	T080	C0443348
27575455	501	516	tRNA precursors	T114,T123	C0041133
27575455	526	531	study	T062	C2603343
27575455	532	547	tRNA precursors	T114,T123	C0041133
27575455	553	561	analysed	T062	C0936012
27575455	565	572	RNA-Seq	T059,T063	C0917793
27575455	577	599	Northern hybridization	T059,T063	C0599862
27575455	603	612	wild type	T028	C1883559
27575455	613	619	strain	T001	C1518614
27575455	624	629	maf1Δ	T028	C1825934
27575455	630	636	mutant	T028	C0678941
27575455	646	653	glucose	T109,T121,T123	C0017725
27575455	654	660	medium	T130	C0010454
27575455	678	699	repressive conditions	T080	C0348080
27575455	703	711	negative	T033	C0205160
27575455	712	718	effect	T080	C1280500
27575455	722	727	maf1Δ	T028	C1825934
27575455	728	734	mutant	T028	C0678941
27575455	742	810	addition of the auxiliary CCA nucleotides to the 3' end of pre-tRNAs	T045	C1158763
27575455	827	832	cells	T025	C0007634
27575455	857	863	growth	T040	C0018270
27575455	864	874	conditions	T080	C0348080
27575455	881	887	effect	T080	C1280500
27575455	892	899	reduced	T080	C0392756
27575455	903	917	overexpression	T045	C1514559
27575455	925	930	yeast	T004	C0043393
27575455	931	940	CCA1 gene	T028	C1413163
27575455	941	949	encoding	T052	C2700640
27575455	950	986	ATP(CTP):tRNA nucleotidyltransferase	T116,T126	C0077328
27575455	992	1004	CCA sequence	T086	C0004793
27575455	1036	1042	export	T067	C0699789
27575455	1046	1061	tRNA precursors	T114,T123	C0041133
27575455	1071	1078	nucleus	T026	C0007610
27575455	1097	1110	tRNA charging	T045	C1327001
27575455	1116	1127	amino acids	T116,T121,T123	C0002520
27575455	1129	1133	Data	T078	C1511726
27575455	1163	1227	CCA-addition to intron -containing end-processed tRNA precursors	T045	C1158763
27575455	1179	1185	intron	T114,T123	C0021920
27575455	1233	1246	limiting step	T077	C1261552
27575455	1250	1265	tRNA maturation	T045	C1158762
27575455	1283	1287	Maf1	T028	C1825934
27575455	1297	1315	RNA polymerase III	T116,T126	C0035680
27575455	1317	1324	Pol III	T116,T126	C0035680
27575455	1326	1336	repression	T045	C0920533
27575455	1342	1353	correlation	T080	C1707520
27575455	1362	1365	CCA	T086	C0004793
27575455	1366	1375	synthesis	T044	C1157592
27575455	1380	1387	Pol III	T116,T126	C0035680
27575455	1388	1398	regulation	T038	C1327622
27575455	1402	1406	Maf1	T028	C1825934
27575455	1429	1441	coordination	T169	C0700114
27575455	1445	1463	tRNA transcription	T045	C1158829
27575455	1465	1475	processing	T045	C1158762
27575455	1480	1505	regulation of translation	T043	C1157519

28179929|t|Tooth Discoloration Resulting from a Nano Zinc Oxide-Eugenol Sealer
28179929|a|A desirable quality of any endodontic sealer is its ability to be tooth color friendly. Therefore the aim of the present study was to evaluate the tooth discoloration potential of a nano zinc oxide-eugenol (NZOE) sealer. In order to evaluate tooth discoloration, the pulp chamber of 60 human maxillary central and lateral incisors were filled with one of the sealers, naming AH-26 (resin-based sealer), Pulpdent sealer (ZOE -based) and a NZOE experimental sealer. Color measurements was assessed at the baseline (before placement of sealers) (T0), 24 h (T1) and 72 h (T2) h, 1- week (T3), and 1- month (T4) after the placement of sealers using the Easy Shade spectrophotometer. Data were analyzed in SPSS software using one-way ANOVA, and repeated measured ANOVA. No significant differences were observed when the paired comparison test was performed (P>0.05). The tested NZOE sealer had similar tooth discoloration potential in comparison with AH-26 and ZOE sealer.
28179929	0	19	Tooth Discoloration	T033	C0040434
28179929	20	29	Resulting	T169	C0678226
28179929	37	41	Nano	T081	C1553036
28179929	42	60	Zinc Oxide-Eugenol	T122	C0043492
28179929	61	67	Sealer	T122	C0676273
28179929	80	87	quality	T080	C0332306
28179929	95	112	endodontic sealer	T122	C0676273
28179929	134	145	tooth color	T033	C0475833
28179929	146	154	friendly	T080	C2700214
28179929	189	194	study	T062	C2603343
28179929	215	234	tooth discoloration	T033	C0040434
28179929	235	244	potential	T080	C3245505
28179929	250	254	nano	T081	C1553036
28179929	255	273	zinc oxide-eugenol	T122	C0043492
28179929	275	279	NZOE	T122	C0043492
28179929	281	287	sealer	T122	C0676273
28179929	310	329	tooth discoloration	T033	C0040434
28179929	335	347	pulp chamber	T030	C0034099
28179929	354	359	human	T016	C0086418
28179929	360	377	maxillary central	T023	C0021156
28179929	382	398	lateral incisors	T023	C0021156
28179929	404	410	filled	T052	C1708059
28179929	427	434	sealers	T122	C0676273
28179929	443	448	AH-26	T104,T122	C0051001
28179929	450	468	resin-based sealer	T104,T122	C0051001
28179929	471	479	Pulpdent	T122,T197	C0072601
28179929	480	486	sealer	T122	C0676273
28179929	488	491	ZOE	T122	C0043492
28179929	506	510	NZOE	T122	C0043492
28179929	524	530	sealer	T122	C0676273
28179929	532	537	Color	T080	C0009393
28179929	538	550	measurements	T169	C0242485
28179929	571	579	baseline	T081	C1442488
28179929	581	597	before placement	T080	C1524072
28179929	601	608	sealers	T122	C0676273
28179929	619	620	h	T079	C0439227
28179929	633	634	h	T079	C0439227
28179929	640	641	h	T079	C0439227
28179929	646	650	week	T079	C0439230
28179929	664	669	month	T079	C0439231
28179929	698	705	sealers	T122	C0676273
28179929	716	744	Easy Shade spectrophotometer	T074	C0183400
28179929	746	750	Data	T078	C1511726
28179929	756	764	analyzed	T062	C0936012
28179929	768	781	SPSS software	T073,T170	C0037585
28179929	788	801	one-way ANOVA	T081	C1709320
28179929	825	830	ANOVA	T081	C0002780
28179929	864	872	observed	T169	C1441672
28179929	882	904	paired comparison test	T170	C0282574
28179929	940	944	NZOE	T122	C0043492
28179929	945	951	sealer	T122	C0676273
28179929	964	983	tooth discoloration	T033	C0040434
28179929	984	993	potential	T080	C3245505
28179929	997	1007	comparison	T052	C1707455
28179929	1013	1018	AH-26	T104,T122	C0051001
28179929	1023	1026	ZOE	T122	C0043492
28179929	1027	1033	sealer	T122	C0676273

27548895|t|Perceptual Learning in Children With Infantile Nystagmus: Effects on Visual Performance
27548895|a|To evaluate whether computerized training with a crowded or uncrowded letter-discrimination task reduces visual impairment (VI) in 6- to 11- year-old children with infantile nystagmus (IN) who suffer from increased foveal crowding, reduced visual acuity, and reduced stereopsis. Thirty-six children with IN were included. Eighteen had idiopathic IN and 18 had oculocutaneous albinism. These children were divided in two training groups matched on age and diagnosis: a crowded training group (n = 18) and an uncrowded training group (n = 18). Training occurred two times per week during 5 weeks (3500 trials per training). Eleven age - matched children with normal vision were included to assess baseline differences in task performance and test-retest learning. Main outcome measures were task - specific performance, distance and near visual acuity (DVA and NVA), intensity and extent of (foveal) crowding at 5 m and 40 cm, and stereopsis. Training resulted in task - specific improvements. Both training groups also showed uncrowded and crowded DVA improvements (0.10 ± 0.02 and 0.11 ± 0.02 logMAR) and improved stereopsis (670 ± 249″). Crowded NVA improved only in the crowded training group (0.15 ± 0.02 logMAR), which was also the only group showing a reduction in near crowding intensity (0.08 ± 0.03 logMAR). Effects were not due to test-retest learning. Perceptual learning with or without distractors reduces the extent of crowding and improves visual acuity in children with IN. Training with distractors improves near vision more than training with single optotypes. Perceptual learning also transfers to DVA and NVA under uncrowded and crowded conditions and even stereopsis. Learning curves indicated that improvements may be larger after longer training.
27548895	0	19	Perceptual Learning	T041	C0870923
27548895	23	31	Children	T100	C0008059
27548895	37	56	Infantile Nystagmus	T047	C1533172
27548895	58	65	Effects	T080	C1280500
27548895	69	75	Visual	T169	C0234621
27548895	76	87	Performance	T052	C1882330
27548895	91	99	evaluate	T058	C0220825
27548895	108	129	computerized training	T066	C0009609
27548895	137	184	crowded or uncrowded letter-discrimination task	T061	C0846701
27548895	193	210	visual impairment	T033	C3665347
27548895	212	214	VI	T033	C3665347
27548895	229	237	year-old	T079	C0439234
27548895	238	246	children	T100	C0008059
27548895	252	271	infantile nystagmus	T047	C1533172
27548895	273	275	IN	T047	C1533172
27548895	293	302	increased	T081	C0205217
27548895	303	318	foveal crowding	T033	C3540840
27548895	320	327	reduced	T080	C0392756
27548895	328	341	visual acuity	T201	C0042812
27548895	347	354	reduced	T080	C0392756
27548895	355	365	stereopsis	T041	C0011586
27548895	378	386	children	T100	C0008059
27548895	392	394	IN	T047	C1533172
27548895	400	408	included	T169	C0332257
27548895	423	433	idiopathic	T169	C0332240
27548895	434	436	IN	T047	C1533172
27548895	448	471	oculocutaneous albinism	T019	C0078918
27548895	479	487	children	T100	C0008059
27548895	493	500	divided	T169	C0332849
27548895	517	523	groups	T098	C1257890
27548895	535	538	age	T032	C0001779
27548895	543	552	diagnosis	T033	C0011900
27548895	556	563	crowded	T033	C3540840
27548895	564	578	training group	T098	C1257890
27548895	605	619	training group	T098	C1257890
27548895	630	638	Training	T065	C0220931
27548895	639	647	occurred	T052	C1709305
27548895	662	666	week	T079	C0439230
27548895	676	681	weeks	T079	C0439230
27548895	699	707	training	T065	C0220931
27548895	717	720	age	T032	C0001779
27548895	723	730	matched	T080	C1708943
27548895	731	739	children	T100	C0008059
27548895	745	758	normal vision	T033	C0234622
27548895	764	772	included	T169	C0332257
27548895	776	782	assess	T052	C1516048
27548895	783	791	baseline	T081	C1442488
27548895	792	803	differences	T081	C1705241
27548895	807	823	task performance	T061	C0039333
27548895	828	848	test-retest learning	T062	C0237828
27548895	855	871	outcome measures	T081	C0086749
27548895	877	881	task	T057	C3540678
27548895	884	892	specific	T080	C0205369
27548895	893	904	performance	T052	C1882330
27548895	906	914	distance	T201	C0429537
27548895	919	937	near visual acuity	T032	C0429541
27548895	939	942	DVA	T201	C0429537
27548895	947	950	NVA	T032	C0429541
27548895	953	962	intensity	T080	C0522510
27548895	967	976	extent of	T080	C0449269
27548895	978	984	foveal	T041	C0870583
27548895	986	994	crowding	T033	C3540840
27548895	1017	1027	stereopsis	T041	C0011586
27548895	1029	1037	Training	T065	C0220931
27548895	1038	1046	resulted	T169	C1274040
27548895	1050	1054	task	T057	C3540678
27548895	1057	1065	specific	T080	C0205369
27548895	1066	1078	improvements	T077	C2986411
27548895	1085	1100	training groups	T098	C1257890
27548895	1113	1122	uncrowded	T033	C0243095
27548895	1127	1134	crowded	T033	C3540840
27548895	1135	1138	DVA	T201	C0429537
27548895	1139	1151	improvements	T077	C2986411
27548895	1193	1201	improved	T033	C0184511
27548895	1202	1212	stereopsis	T041	C0011586
27548895	1227	1234	Crowded	T033	C3540840
27548895	1235	1238	NVA	T032	C0429541
27548895	1239	1247	improved	T033	C0184511
27548895	1260	1267	crowded	T033	C3540840
27548895	1268	1282	training group	T098	C1257890
27548895	1329	1334	group	T098	C1257890
27548895	1345	1354	reduction	T061	C0441610
27548895	1358	1362	near	T080	C1706276
27548895	1363	1371	crowding	T033	C3540840
27548895	1372	1381	intensity	T080	C0522510
27548895	1404	1411	Effects	T080	C1280500
27548895	1417	1420	not	T033	C1513916
27548895	1428	1448	test-retest learning	T062	C0237828
27548895	1450	1469	Perceptual learning	T041	C0870923
27548895	1486	1497	distractors	T074	C0180482
27548895	1498	1505	reduces	T080	C0392756
27548895	1510	1519	extent of	T080	C0449269
27548895	1520	1528	crowding	T033	C3540840
27548895	1533	1541	improves	T033	C0184511
27548895	1542	1555	visual acuity	T201	C0042812
27548895	1559	1567	children	T100	C0008059
27548895	1573	1575	IN	T047	C1533172
27548895	1577	1585	Training	T065	C0220931
27548895	1591	1602	distractors	T074	C0180482
27548895	1603	1611	improves	T033	C0184511
27548895	1612	1623	near vision	T033	C0442776
27548895	1624	1633	more than	T081	C0439093
27548895	1634	1642	training	T065	C0220931
27548895	1648	1664	single optotypes	T074	C0183370
27548895	1666	1685	Perceptual learning	T041	C0870923
27548895	1704	1707	DVA	T201	C0429537
27548895	1712	1715	NVA	T032	C0429541
27548895	1722	1731	uncrowded	T033	C0243095
27548895	1736	1754	crowded conditions	T033	C3540840
27548895	1764	1774	stereopsis	T041	C0011586
27548895	1776	1791	Learning curves	T041	C2936637
27548895	1807	1819	improvements	T077	C2986411
27548895	1827	1833	larger	T081	C0549177
27548895	1840	1846	longer	T080	C0205166
27548895	1847	1855	training	T065	C0220931

28235687|t|Immodin and its immune system supportive role in paclitaxel therapy of 4T1 mouse breast cancer
28235687|a|It is evident that standard chemotherapy agents may have an impact on both tumor and host immune system. Paclitaxel (PTX), a very potent anticancer drug from a taxane family, has achieved prominence in clinical oncology for its efficacy against a wide range of tumors including breast cancer. However, significant toxicity, such as myelosuppression, limit the effectiveness of Paclitaxel -based treatment regimens. Immodin (IM) is low molecular dialysate fraction of homogenate made from human leukocytes. It contains a mixture of substances from which so far have been described e.g. Imreg 1 and Imreg 2 formed by the dipeptide tyrosine-glycine and the tripeptide tyrosine-glycine-glycine, respectively. The aim of this study was to explore immunopharmacological activities of IM, using the strongly immunogenic 4T1 mouse breast cancer model, and evaluate its effect on the reactivity and the efficiency of PTX cancer therapy. The results highlight a potentially beneficial role for IM in alleviating PTX - induced toxicity, especially on the nonspecific immunity, during breast cancer therapy. Co-treatment exhibited an antitumor effect including reduced tumor growth, prolonged survival of tumor bearing mice, increased number of monocytes and lymphocytes in peripheral blood. In spleens, IM + PTX therapy elevated proportion of whole lymphocytes in the account of myelo-monocytic cells characteristic with low expression of CD11c+ and bearing Fc receptor (CD16 / 32) as well as T-lymphocytes, NK cells and dendritic cells. Accumulation of tumor - associated granulocytes in stroma of PTX - treated group and intensive 4T1 - necrosis / apoptosis in tumors after co-treatment were also recorded. These findings suggest the possibility of using IM alongside PTX treatment for maintaining the immune system functions and increasing patient survival.
28235687	0	7	Immodin	T121	C1254351
28235687	16	29	immune system	T022	C0020962
28235687	30	45	supportive role	T078	C0086939
28235687	49	59	paclitaxel	T109,T121	C0144576
28235687	60	67	therapy	T061	C0087111
28235687	71	80	4T1 mouse	T050	C2986594
28235687	81	94	breast cancer	T191	C0678222
28235687	101	108	evident	T078	C3887511
28235687	114	122	standard	T080	C1442989
28235687	123	142	chemotherapy agents	T109,T121	C0003392
28235687	155	161	impact	T080	C4049986
28235687	170	175	tumor	T191	C0027651
28235687	180	184	host	T001	C1167395
28235687	185	198	immune system	T022	C0020962
28235687	200	210	Paclitaxel	T109,T121	C0144576
28235687	212	215	PTX	T109,T121	C0144576
28235687	232	247	anticancer drug	T109,T121	C0003392
28235687	255	261	taxane	T109,T121	C0215136
28235687	297	314	clinical oncology	T091	C1274034
28235687	323	331	efficacy	T080	C1280519
28235687	347	352	range	T081	C1514721
28235687	356	362	tumors	T191	C0027651
28235687	373	386	breast cancer	T191	C0678222
28235687	397	408	significant	T078	C0750502
28235687	409	417	toxicity	T037	C0600688
28235687	427	443	myelosuppression	T033	C0854467
28235687	455	468	effectiveness	T080	C1280519
28235687	472	482	Paclitaxel	T109,T121	C0144576
28235687	490	508	treatment regimens	T061	C0040808
28235687	510	517	Immodin	T121	C1254351
28235687	519	521	IM	T121	C1254351
28235687	530	539	molecular	T080	C1521991
28235687	540	558	dialysate fraction	T121	C0011947
28235687	562	572	homogenate	T072	C3829671
28235687	583	588	human	T016	C0086418
28235687	589	599	leukocytes	T025	C0023516
28235687	615	622	mixture	T167	C0439962
28235687	626	636	substances	T167	C0439861
28235687	680	687	Imreg 1	T116,T121	C0063442
28235687	692	699	Imreg 2	T116	C0030956
28235687	700	706	formed	T169	C0205431
28235687	714	723	dipeptide	T116	C0012512
28235687	724	740	tyrosine-glycine	T116	C0012512
28235687	749	759	tripeptide	T116	C0030956
28235687	760	784	tyrosine-glycine-glycine	T116	C0030956
28235687	804	807	aim	T078	C1947946
28235687	816	821	study	T062	C2603343
28235687	837	858	immunopharmacological	T169	C0205464
28235687	859	869	activities	T052	C0441655
28235687	873	875	IM	T121	C1254351
28235687	896	907	immunogenic	T169	C0872192
28235687	908	917	4T1 mouse	T050	C2986594
28235687	918	931	breast cancer	T191	C0678222
28235687	932	937	model	T075	C0026336
28235687	943	951	evaluate	T169	C1292732
28235687	956	962	effect	T080	C1280500
28235687	970	980	reactivity	T169	C0443286
28235687	989	999	efficiency	T081	C0013682
28235687	1003	1006	PTX	T109,T121	C0144576
28235687	1007	1021	cancer therapy	T061	C0920425
28235687	1027	1034	results	T169	C1274040
28235687	1047	1058	potentially	T080	C3245505
28235687	1059	1074	beneficial role	UnknownType	C0683156
28235687	1079	1081	IM	T121	C1254351
28235687	1085	1096	alleviating	T081	C0547047
28235687	1097	1100	PTX	T109,T121	C0144576
28235687	1103	1110	induced	T169	C0205263
28235687	1111	1119	toxicity	T037	C0600688
28235687	1139	1150	nonspecific	T078	C0750540
28235687	1151	1159	immunity	T039	C0020964
28235687	1168	1181	breast cancer	T191	C0678222
28235687	1182	1189	therapy	T061	C0087111
28235687	1191	1203	Co-treatment	T058	C0814472
28235687	1217	1226	antitumor	T080	C2986475
28235687	1227	1233	effect	T080	C1280500
28235687	1244	1251	reduced	T080	C0392756
28235687	1252	1264	tumor growth	T191	C0598934
28235687	1266	1275	prolonged	T079	C0439590
28235687	1276	1284	survival	T169	C0220921
28235687	1288	1293	tumor	T191	C0027651
28235687	1302	1306	mice	T050	C2986594
28235687	1308	1317	increased	T081	C0205217
28235687	1328	1337	monocytes	T025	C0026473
28235687	1342	1353	lymphocytes	T025	C0024264
28235687	1357	1373	peripheral blood	T031	C0229664
28235687	1387	1389	IM	T121	C1254351
28235687	1392	1395	PTX	T109,T121	C0144576
28235687	1396	1403	therapy	T061	C0087111
28235687	1404	1412	elevated	T080	C3163633
28235687	1413	1423	proportion	T081	C1709707
28235687	1433	1444	lymphocytes	T025	C0024264
28235687	1463	1484	myelo-monocytic cells	T025	C0229659
28235687	1485	1499	characteristic	T080	C1521970
28235687	1509	1519	expression	T045	C1171362
28235687	1523	1529	CD11c+	T116,T129,T192	C0023395
28235687	1542	1553	Fc receptor	T116,T129,T192	C0034805
28235687	1555	1559	CD16	T116,T129,T192	C0108747
28235687	1562	1564	32	T116,T129,T192	C0054951
28235687	1577	1590	T-lymphocytes	T025	C0039194
28235687	1592	1600	NK cells	T025	C0022688
28235687	1605	1620	dendritic cells	T025	C0011306
28235687	1622	1634	Accumulation	T033	C4055506
28235687	1638	1643	tumor	T191	C0027651
28235687	1646	1656	associated	T080	C0332281
28235687	1657	1669	granulocytes	T025	C0018183
28235687	1673	1679	stroma	T023	C0927195
28235687	1683	1686	PTX	T109,T121	C0144576
28235687	1689	1696	treated	T169	C1522326
28235687	1697	1702	group	T078	C0441833
28235687	1717	1720	4T1	T025	C0597032
28235687	1723	1731	necrosis	T042	C0027540
28235687	1734	1743	apoptosis	T043	C0162638
28235687	1747	1753	tumors	T191	C0027651
28235687	1760	1772	co-treatment	T058	C0814472
28235687	1783	1791	recorded	T170	C0034869
28235687	1799	1807	findings	T033	C0243095
28235687	1841	1843	IM	T121	C1254351
28235687	1854	1857	PTX	T109,T121	C0144576
28235687	1858	1867	treatment	T061	C0087111
28235687	1888	1901	immune system	T022	C0020962
28235687	1902	1911	functions	T169	C0542341
28235687	1916	1926	increasing	T169	C0442808
28235687	1927	1934	patient	T101	C0030705
28235687	1935	1943	survival	T052	C0038952

28378026|t|Considerations on the Relevance of Cerebral Fusiform Aneurysms Observed During HIV Infection
28378026|a|Human immunodeficiency virus (HIV)-associated ectatic cerebral vasculitis (HIV - AECV) is a rare form of vasculitis with diffuse fusiform aneurysms. Its pathophysiology remains poorly understood. Although extensively described in children, it is still incompletely studied in adults. Our objective was to present five adult cases with emphasis on imaging findings and long-term evolution. From 2006 to 2014, we included 5 HIV - infected patients presenting with fusiform cerebral aneurysms. Vessels abnormalities were assessed with brain computed tomography (CT) angiography, magnetic resonance angiography (MRA) and/or digital subtraction angiography (DSA). All patients had MR assessment of the brain. Clinical and biological data were analyzed. Fusiform aneurysms of carotid terminations extending to middle and anterior cerebral arteries were bilateral in three patients and unilateral in one. More distal fusiform aneurysms were observed in four patients and saccular aneurysms in two patients, two patients suffered from ischemic lesions while none experienced hemorrhage. Unlike recent reviews, our study underlines the low hemorrhagic potential of HIV - AECV and long-term follow-up suggests a monophasic evolution under antiretroviral medication.
28378026	0	14	Considerations	T033	C0518609
28378026	22	31	Relevance	T080	C2347946
28378026	35	62	Cerebral Fusiform Aneurysms	T047	C0917996
28378026	79	92	HIV Infection	T047	C0019693
28378026	93	121	Human immunodeficiency virus	T005	C0019682
28378026	123	126	HIV	T005	C0019682
28378026	139	166	ectatic cerebral vasculitis	T047	C0238051
28378026	168	171	HIV	T005	C0019682
28378026	174	178	AECV	T047	C0238051
28378026	185	189	rare	T080	C0522498
28378026	190	194	form	T080	C0348078
28378026	198	208	vasculitis	T047	C0042384
28378026	214	221	diffuse	T082	C0205219
28378026	222	240	fusiform aneurysms	T190	C0333099
28378026	246	261	pathophysiology	T169	C0031847
28378026	298	309	extensively	T080	C0205231
28378026	323	331	children	T100	C0008059
28378026	345	357	incompletely	T080	C0205257
28378026	358	365	studied	T062	C2603343
28378026	369	375	adults	T100	C0001675
28378026	381	390	objective	T170	C0018017
28378026	411	416	adult	T100	C0001675
28378026	417	422	cases	T169	C0868928
28378026	440	456	imaging findings	T034	C1287399
28378026	461	470	long-term	T079	C0443252
28378026	471	480	evolution	T045	C0015219
28378026	515	518	HIV	T005	C0019682
28378026	521	529	infected	T033	C0439663
28378026	530	538	patients	T101	C0030705
28378026	555	582	fusiform cerebral aneurysms	T047	C0917996
28378026	584	605	Vessels abnormalities	T033	C0241657
28378026	611	619	assessed	T052	C1516048
28378026	625	630	brain	T023	C0006104
28378026	631	650	computed tomography	T060	C0040405
28378026	652	654	CT	T060	C0040405
28378026	656	667	angiography	T060	C0002978
28378026	669	699	magnetic resonance angiography	T060	C0243032
28378026	701	704	MRA	T060	C0243032
28378026	713	744	digital subtraction angiography	T060	C0002979
28378026	746	749	DSA	T060	C0002979
28378026	756	764	patients	T101	C0030705
28378026	769	771	MR	T060	C0024485
28378026	772	782	assessment	T058	C0220825
28378026	790	795	brain	T023	C0006104
28378026	797	805	Clinical	T170	C1516606
28378026	810	820	biological	T080	C0205460
28378026	821	825	data	T078	C1511726
28378026	831	839	analyzed	T062	C0936012
28378026	841	859	Fusiform aneurysms	T190	C0333099
28378026	863	870	carotid	T023	C0741968
28378026	871	883	terminations	UnknownType	C0678671
28378026	897	903	middle	T023	C0149566
28378026	908	934	anterior cerebral arteries	T023	C0149561
28378026	940	949	bilateral	T082	C0238767
28378026	959	967	patients	T101	C0030705
28378026	972	982	unilateral	T082	C0205092
28378026	996	1002	distal	T082	C0205108
28378026	1003	1021	fusiform aneurysms	T190	C0333099
28378026	1044	1052	patients	T101	C0030705
28378026	1057	1075	saccular aneurysms	T047	C2713497
28378026	1083	1091	patients	T101	C0030705
28378026	1097	1105	patients	T101	C0030705
28378026	1120	1128	ischemic	T047	C0007786
28378026	1129	1136	lesions	T033	C0221198
28378026	1160	1170	hemorrhage	T046	C0019080
28378026	1186	1193	reviews	T170	C0282443
28378026	1199	1204	study	T062	C2603343
28378026	1220	1223	low	T080	C0205251
28378026	1224	1235	hemorrhagic	T046	C0019080
28378026	1236	1245	potential	T080	C3245505
28378026	1249	1252	HIV	T005	C0019682
28378026	1255	1259	AECV	T047	C0238051
28378026	1264	1273	long-term	T079	C0443252
28378026	1274	1283	follow-up	T058	C1522577
28378026	1284	1292	suggests	T078	C1705535
28378026	1295	1305	monophasic	T079	C0205186
28378026	1306	1315	evolution	T045	C0015219
28378026	1322	1347	antiretroviral medication	T061	C1963724

28005982|t|Depot Dependent Effects of Dexamethasone on Gene Expression in Human Omental and Abdominal Subcutaneous Adipose Tissues from Obese Women
28005982|a|Glucocorticoids promote fat accumulation in visceral compared to subcutaneous depots, but the molecular mechanisms involved remain poorly understood. To identify long-term changes in gene expression that are differentially sensitive or responsive to glucocorticoids in these depots, paired samples of human omental (Om) and abdominal subcutaneous (Abdsc) adipose tissues obtained from obese women during elective surgery were cultured with the glucocorticoid receptor agonist dexamethasone (Dex, 0, 1, 10, 25 and 1000 nM) for 7 days. Dex regulated 32% of the 19,741 genes on the array, while 53% differed by Depot and 2.5% exhibited a Depot * Dex concentration interaction. Gene set enrichment analysis showed Dex regulation of the expected metabolic and inflammatory pathways in both depots. Cluster analysis of the 460 transcripts that exhibited an interaction of Depot and Dex concentration revealed sets of mRNAs for which the responses to Dex differed in magnitude, sensitivity or direction between the two depots as well as mRNAs that responded to Dex only in one depot. These transcripts were also clearly depot different in fresh adipose tissue and are implicated in processes that could affect adipose tissue distribution or functions (e.g. adipogenesis, triacylglycerol synthesis and storage, insulin action). Elucidation of the mechanisms underlying the depot differences in the effect of Dex on the expression of specific genes and pathways that regulate adipose function may offer novel insights into understanding the biology of visceral adipose tissues and their links to metabolic health.
28005982	0	5	Depot	T082	C1254362
28005982	27	40	Dexamethasone	T109,T121	C0011777
28005982	44	59	Gene Expression	T045	C0017262
28005982	63	68	Human	T016	C0086418
28005982	69	76	Omental	T023	C0028977
28005982	81	119	Abdominal Subcutaneous Adipose Tissues	T024	C1563741
28005982	125	130	Obese	T047	C0028754
28005982	131	136	Women	T098	C0043210
28005982	137	152	Glucocorticoids	T109,T125	C0017710
28005982	161	164	fat	T201	C0344335
28005982	165	177	accumulation	T033	C4055506
28005982	181	189	visceral	T082	C0442045
28005982	190	198	compared	T052	C1707455
28005982	202	214	subcutaneous	T082	C0443315
28005982	215	221	depots	T082	C1254362
28005982	231	251	molecular mechanisms	T044	C3537153
28005982	309	316	changes	T169	C0392747
28005982	320	335	gene expression	T045	C0017262
28005982	360	369	sensitive	T169	C0332324
28005982	373	383	responsive	T169	C0205342
28005982	387	402	glucocorticoids	T109,T125	C0017710
28005982	412	418	depots	T082	C1254362
28005982	438	443	human	T016	C0086418
28005982	444	451	omental	T023	C0028977
28005982	453	455	Om	T023	C0028977
28005982	461	507	abdominal subcutaneous (Abdsc) adipose tissues	T024	C1563741
28005982	508	516	obtained	T169	C1301820
28005982	522	527	obese	T047	C0028754
28005982	528	533	women	T098	C0043210
28005982	541	557	elective surgery	T061	C0206058
28005982	563	571	cultured	T059	C0040284
28005982	581	604	glucocorticoid receptor	T116,T192	C0034809
28005982	605	612	agonist	T121	C2987634
28005982	613	626	dexamethasone	T109,T121	C0011777
28005982	628	631	Dex	T109,T121	C0011777
28005982	671	674	Dex	T109,T121	C0011777
28005982	703	708	genes	T028	C0017337
28005982	716	721	array	T082	C1510941
28005982	745	750	Depot	T082	C1254362
28005982	772	777	Depot	T082	C1254362
28005982	780	783	Dex	T109,T121	C0011777
28005982	784	797	concentration	T081	C1446561
28005982	798	809	interaction	T169	C1704675
28005982	811	819	Gene set	T028	C0017337
28005982	831	839	analysis	T062	C0936012
28005982	847	850	Dex	T109,T121	C0011777
28005982	851	861	regulation	T038	C1327622
28005982	869	877	expected	T170	C1517001
28005982	878	887	metabolic	T169	C0311400
28005982	892	913	inflammatory pathways	T042	C1512758
28005982	922	928	depots	T082	C1254362
28005982	930	946	Cluster analysis	T062	C0009085
28005982	958	969	transcripts	T114	C1519595
28005982	988	999	interaction	T169	C1704675
28005982	1003	1008	Depot	T082	C1254362
28005982	1013	1016	Dex	T109,T121	C0011777
28005982	1031	1039	revealed	T080	C0443289
28005982	1048	1053	mRNAs	T114,T123	C0035696
28005982	1081	1084	Dex	T109,T121	C0011777
28005982	1097	1106	magnitude	T081	C1704240
28005982	1123	1132	direction	T082	C0449738
28005982	1149	1155	depots	T082	C1254362
28005982	1167	1172	mRNAs	T114,T123	C0035696
28005982	1191	1194	Dex	T109,T121	C0011777
28005982	1207	1212	depot	T082	C1254362
28005982	1220	1231	transcripts	T114	C1519595
28005982	1250	1255	depot	T082	C1254362
28005982	1275	1289	adipose tissue	T024	C0001527
28005982	1312	1321	processes	T067	C1522240
28005982	1340	1354	adipose tissue	T024	C0001527
28005982	1355	1367	distribution	T169	C0220927
28005982	1371	1380	functions	T042	C0232456
28005982	1387	1399	adipogenesis	T044	C0596843
28005982	1401	1426	triacylglycerol synthesis	T044	C1157337
28005982	1431	1438	storage	T043	C1327211
28005982	1440	1454	insulin action	T044	C1145751
28005982	1476	1486	mechanisms	T169	C0441712
28005982	1502	1507	depot	T082	C1254362
28005982	1537	1540	Dex	T109,T121	C0011777
28005982	1548	1558	expression	T045	C0017262
28005982	1571	1576	genes	T028	C0017337
28005982	1595	1603	regulate	T038	C1327622
28005982	1604	1611	adipose	T024	C0001527
28005982	1612	1620	function	T169	C0542341
28005982	1669	1676	biology	T091	C0005532
28005982	1680	1688	visceral	T082	C0442045
28005982	1689	1704	adipose tissues	T024	C0001527
28005982	1724	1733	metabolic	T169	C0311400
28005982	1734	1740	health	T080	C0018759

27847836|t|Obstructive Acute Pancreatitis Secondary to PEG Tube Migration
27847836|a|Percutaneous gastrostomy is a well-established method of providing enteral nutrition to patients incapable of oral intake, or for whom oral intake is insufficient to meet metabolic needs. In comparison to total parenteral nutrition, enteral feeding is advantageous in that it helps maintain gut mucosal integrity, which decreases the risk of bacterial translocation through the gastrointestinal tract. Complications include bleeding, aspiration, internal organ injury, perforation, periostomal leaks, tube dislodgement, and occlusion. Acute pancreatitis secondary to percutaneous gastrostomy tube migration is rare. We present a patient with acute obstructive pancreatitis secondary to percutaneous gastrostomy tube migration.
27847836	0	11	Obstructive	T169	C0549186
27847836	12	30	Acute Pancreatitis	T047	C0001339
27847836	44	52	PEG Tube	T074	C2985542
27847836	53	62	Migration	T033	C0549474
27847836	63	87	Percutaneous gastrostomy	T061	C0176751
27847836	110	116	method	T169	C0449851
27847836	130	147	enteral nutrition	T061	C0014327
27847836	151	159	patients	T101	C0030705
27847836	160	169	incapable	T033	C1550518
27847836	173	184	oral intake	T033	C0518037
27847836	198	209	oral intake	T033	C0518037
27847836	213	225	insufficient	T080	C0231180
27847836	234	243	metabolic	T169	C0311400
27847836	244	249	needs	T080	C0027552
27847836	268	294	total parenteral nutrition	T061	C0030548
27847836	296	311	enteral feeding	T058	C0086225
27847836	354	357	gut	T023	C0699819
27847836	358	365	mucosal	T024	C0026724
27847836	366	375	integrity	T080	C1947912
27847836	397	401	risk	T078	C0035647
27847836	405	428	bacterial translocation	T043	C0282583
27847836	441	463	gastrointestinal tract	T022	C0017189
27847836	465	478	Complications	T046	C0009566
27847836	487	495	bleeding	T046	C0019080
27847836	497	507	aspiration	T046	C0700198
27847836	509	530	internal organ injury	T037	C0332675
27847836	532	543	perforation	T047	C0151664
27847836	545	562	periostomal leaks	T047	C0341600
27847836	564	581	tube dislodgement	T037	C1608950
27847836	587	596	occlusion	T046	C0028778
27847836	598	616	Acute pancreatitis	T047	C0001339
27847836	630	659	percutaneous gastrostomy tube	T074	C2985542
27847836	660	669	migration	T033	C0549474
27847836	692	699	patient	T101	C0030705
27847836	705	710	acute	T079	C0205178
27847836	711	722	obstructive	T169	C0549186
27847836	723	735	pancreatitis	T047	C0030305
27847836	749	778	percutaneous gastrostomy tube	T074	C2985542
27847836	779	788	migration	T033	C0549474

28370605|t|Metabolite mapping by consecutive nanostructure and silver-assisted mass spectrometry imaging on tissue sections
28370605|a|Nanostructure-based mass spectrometry imaging (MSI) is a promising technology for molecular imaging of small molecules, without the complex chemical background typically encountered in matrix-assisted molecular imaging approaches. Here, we have enhanced these surfaces with silver (Ag) to provide a second tier of MSI data from a single sample. MSI data was acquired through the application of laser desorption/ionization mass spectrometry to biological samples imprinted onto desorption/ionization on silicon (DIOS) substrates. Following initial analysis, ultra-thin Ag layers were overlaid onto the followed by MSI analysis (Ag-DIOS MSI). This approach was first demonstrated for fingermark small molecules including environmental contaminants and sebum components. Subsequently, this bimodal method was translated to lipids and metabolites in fore-stomach sections from a 6-bromoisatin chemopreventative murine mouse model. DIOS MSI allowed mapping of common ions in fingermarks as well as 6-bromoisatin metabolites and lipids in murine fore-stomach. Furthermore, DIOS MSI was complemented by the Ag-DIOS MSI of Ag-adductable lipids such as wax esters in fingermarks and cholesterol in murine fore-stomach. Gastrointestinal acid condensation products of 6-bromoisatin, such as the 6,6'-dibromoindirubin mapped herein, are very challenging to isolate and characterize. By re-analyzing the same tissue imprints, this metabolite was readily detected by DIOS, placed in a tissue-specific spatial context, and subsequently overlaid with additional lipid distributions acquired using Ag-DIOS MSI. The ability to place metabolite and lipid classes in a tissue-specific context makes this novel method suited to MSI analyses where the collection of additional information from the same sample maximises resource use, and also maximises the number of annotated small molecules, in particular for metabolites that are typically undetectable with traditional platforms. Copyright © 2017 John Wiley & Sons, Ltd.
28370605	0	10	Metabolite	T123	C0870883
28370605	11	18	mapping	T052	C1283195
28370605	34	47	nanostructure	T073	C1450053
28370605	52	93	silver-assisted mass spectrometry imaging	T059	C0037813
28370605	97	112	tissue sections	T024	C2316368
28370605	113	158	Nanostructure-based mass spectrometry imaging	T059	C0037813
28370605	160	163	MSI	T059	C0037813
28370605	195	212	molecular imaging	T060	C1537028
28370605	216	231	small molecules	T109	C1328819
28370605	298	331	matrix-assisted molecular imaging	T060	C1537028
28370605	373	381	surfaces	T082	C0205148
28370605	387	393	silver	T196	C0037125
28370605	395	397	Ag	T196	C0037125
28370605	427	435	MSI data	T170	C0282574
28370605	458	466	MSI data	T170	C0282574
28370605	492	503	application	T169	C4048755
28370605	507	552	laser desorption/ionization mass spectrometry	T059	C0282597
28370605	556	574	biological samples	UnknownType	C0444062
28370605	590	622	desorption/ionization on silicon	T067	C1254366
28370605	624	628	DIOS	T067	C1254366
28370605	630	640	substrates	T167	C3891814
28370605	660	668	analysis	T062	C0936012
28370605	670	690	ultra-thin Ag layers	T080	C1522408
28370605	726	738	MSI analysis	T059	C0037813
28370605	740	751	Ag-DIOS MSI	T059	C0282597
28370605	806	821	small molecules	T109	C1328819
28370605	832	845	environmental	T082	C0014406
28370605	846	858	contaminants	T167	C2827365
28370605	863	868	sebum	T031	C0036511
28370605	933	939	lipids	T109	C0023779
28370605	944	955	metabolites	T123	C0870883
28370605	959	980	fore-stomach sections	T024	C1517295
28370605	988	1001	6-bromoisatin	T109,T123	C3493005
28370605	1002	1019	chemopreventative	T080	C3273128
28370605	1020	1038	murine mouse model	T050	C2986594
28370605	1040	1048	DIOS MSI	T059	C0037813
28370605	1057	1064	mapping	T052	C1283195
28370605	1075	1079	ions	T196	C0022023
28370605	1106	1119	6-bromoisatin	T109,T123	C3493005
28370605	1120	1131	metabolites	T123	C0870883
28370605	1136	1142	lipids	T109	C0023779
28370605	1146	1165	murine fore-stomach	T024	C1517295
28370605	1180	1188	DIOS MSI	T059	C0037813
28370605	1213	1224	Ag-DIOS MSI	T059	C0282597
28370605	1228	1248	Ag-adductable lipids	T109	C0023779
28370605	1257	1267	wax esters	T109	C0014898
28370605	1287	1298	cholesterol	T109,T123	C0008377
28370605	1302	1321	murine fore-stomach	T024	C1517295
28370605	1323	1344	Gastrointestinal acid	T031	C0017119
28370605	1345	1357	condensation	T067	C0596312
28370605	1358	1366	products	T123	C0566267
28370605	1370	1383	6-bromoisatin	T109,T123	C3493005
28370605	1397	1418	6,6'-dibromoindirubin	T123	C0574031
28370605	1458	1465	isolate	T059	C0220862
28370605	1470	1482	characterize	T052	C1880022
28370605	1509	1515	tissue	T024	C0040300
28370605	1531	1541	metabolite	T123	C0870883
28370605	1566	1570	DIOS	T067	C1254366
28370605	1584	1615	tissue-specific spatial context	T024	C1955394
28370605	1659	1678	lipid distributions	T043	C0007613
28370605	1694	1705	Ag-DIOS MSI	T059	C0282597
28370605	1728	1738	metabolite	T123	C0870883
28370605	1743	1748	lipid	T109	C0023779
28370605	1762	1777	tissue-specific	T024	C1955394
28370605	1820	1832	MSI analyses	T059	C0037813
28370605	1968	1983	small molecules	T109	C1328819
28370605	2003	2014	metabolites	T123	C0870883
28370605	2034	2046	undetectable	T201	C3827727

27608968|t|Congenital anomalies following use of isotretinoin: Emphasis on its legal aspects
27608968|a|We described a neonate with severe and multiple abnormalities following use of isotretinoin, in spite of the mother 's previous knowledge of drug complications. Initial physical examination after delivery showed congenital absence of both eyes and both auricles as well as anal atresia and a cleft palate. Due to severe respiratory distress and atresia of the anus, the neonate was admitted to a neonatal intensive care unit and underwent reconstructive surgery. The drug should not have been used during pregnancy. Using this drug within pregnancy with awareness of its side effects may have legal consequences.
27608968	0	20	Congenital anomalies	T019	C0000768
27608968	38	50	isotretinoin	T109,T121	C0022265
27608968	68	81	legal aspects	T064	C0022433
27608968	97	104	neonate	T100	C0021289
27608968	110	116	severe	T080	C0205082
27608968	121	143	multiple abnormalities	T019	C0000772
27608968	161	173	isotretinoin	T109,T121	C0022265
27608968	191	197	mother	T099	C0026591
27608968	210	219	knowledge	T170	C0376554
27608968	223	241	drug complications	T046	C1393201
27608968	251	271	physical examination	T058	C0031809
27608968	278	286	delivery	T061	C0011209
27608968	294	312	congenital absence	T019	C0332907
27608968	316	325	both eyes	T023	C0229118
27608968	335	343	auricles	T023	C0928075
27608968	355	367	anal atresia	T019	C0003466
27608968	374	386	cleft palate	T019	C0008925
27608968	395	401	severe	T080	C0205082
27608968	402	422	respiratory distress	T184	C0476273
27608968	427	434	atresia	T019	C0243066
27608968	442	446	anus	T023	C0003461
27608968	452	459	neonate	T100	C0021289
27608968	478	486	neonatal	T100	C0021289
27608968	487	506	intensive care unit	T073,T093	C0021708
27608968	521	543	reconstructive surgery	T061	C0524865
27608968	549	553	drug	T121	C1254351
27608968	587	596	pregnancy	T040	C0032961
27608968	609	613	drug	T121	C1254351
27608968	621	630	pregnancy	T040	C0032961
27608968	653	665	side effects	T046	C0041755
27608968	675	680	legal	T169	C1301860
27608968	681	693	consequences	T169	C0686907

27294436|t|Interpretation of verbal descriptors for response options commonly used in verbal rating scales in patient -reported outcome instruments
27294436|a|To assess the variation in the interpretation of common verbal descriptors (VDs) used in response scales and examine factors associated with those interpretations. Subjects were recruited through MediGuard and they assigned interpretation scores (11-point scale; 0 = lowest possible, 10 = highest possible) to five common sets of VDs: set one (none, mild, moderate, severe, very severe); set two (never, rarely, sometimes, often, always); set three (poor, fair, good, very good, excellent); set four (not at all, a little bit, moderately, quite a bit, extremely); and set five (not at all, a little bit, somewhat, quite a bit, very much). One-sample test for proportions and T-tests examined equality of proportions (anchors) and means scores (non-anchors) with the fixed intervals (0.0, 2.5, 5.0, 7.5, and 10.0). Ordinal regression examined adjusted associations between demographic / clinical factors and VD scores. Of the 350 subjects, 68 % were females and mean (SD) age was 56.9 (12.1). Two sets had two VDs with mean (95 % CI) scores not different than the fixed intervals. Set one had mild = 2.50 (2.33; 2.66) and moderate = 5.01 (4.89; 5.13) with 98.8 % (97.3 %; 100 %) assigning none = 0. Set five had a little bit = 2.35 (2.17; 2.53) and quite a bit = 7.65 (7.43; 7.87) with 95.0 % (95 % CI 91.7; 98.2) assigning not at all = 0. Significant associations (p ≤ 0.05) included age and education with somewhat and income and comorbidities with very severe. Age, sex, and education showed associations with other VDs albeit in nonsignificant models. Sets one and five yielded data closest to the fixed intervals. Demographic and clinical factors are associated with the interpretation of some VDs and should be adjusted for in analyses of non-randomized data.
27294436	0	14	Interpretation	T170	C0459471
27294436	18	24	verbal	T080	C0439824
27294436	18	36	verbal descriptors	T170	C0282354
27294436	41	49	response	T041	C2911692
27294436	50	57	options	T169	C1518601
27294436	75	95	verbal rating scales	T170	C0458261
27294436	99	106	patient	T101	C0030705
27294436	140	146	assess	T058	C0184514
27294436	151	160	variation	T080	C0205419
27294436	168	182	interpretation	T170	C0459471
27294436	193	199	verbal	T080	C0439824
27294436	193	211	verbal descriptors	T170	C0282354
27294436	213	216	VDs	T170	C0282354
27294436	226	234	response	T041	C2911692
27294436	226	241	response scales	T170	C0282574
27294436	246	253	examine	T169	C1292732
27294436	254	261	factors	T169	C1521761
27294436	262	272	associated	T080	C0332281
27294436	284	299	interpretations	T170	C0459471
27294436	301	309	Subjects	T098	C0080105
27294436	333	342	MediGuard	T170	C0282574
27294436	361	375	interpretation	T170	C0459471
27294436	376	382	scores	T081	C0449820
27294436	467	470	VDs	T170	C0282354
27294436	481	485	none	T081	C0549184
27294436	487	491	mild	T080	C2945599
27294436	493	501	moderate	T080	C0205081
27294436	503	509	severe	T080	C0205082
27294436	511	522	very severe	T080	C3641272
27294436	534	539	never	T079	C2003901
27294436	541	547	rarely	T080	C0522498
27294436	549	558	sometimes	T079	C1998882
27294436	560	565	often	T079	C0332183
27294436	567	573	always	T079	C2003902
27294436	587	591	poor	T080	C2700379
27294436	593	597	fair	T080	C2911689
27294436	599	603	good	T080	C0205170
27294436	605	614	very good	T080	C3641222
27294436	616	625	excellent	T080	C1961136
27294436	638	648	not at all	T033	C2984077
27294436	650	662	a little bit	T033	C2984078
27294436	664	674	moderately	T080	C0205081
27294436	676	687	quite a bit	T033	C2984080
27294436	689	698	extremely	T080	C0205403
27294436	715	725	not at all	T033	C2984077
27294436	727	739	a little bit	T033	C2984078
27294436	741	749	somewhat	T033	C2984079
27294436	751	762	quite a bit	T033	C2984080
27294436	764	773	very much	T080	C2984081
27294436	776	791	One-sample test	T170	C1709321
27294436	796	807	proportions	T081	C1709707
27294436	812	819	T-tests	T170	C0871472
27294436	829	837	equality	T080	C0205163
27294436	841	852	proportions	T081	C1709707
27294436	854	861	anchors	T098	C1257890
27294436	867	879	means scores	T081	C0449820
27294436	881	892	non-anchors	T098	C1257890
27294436	909	918	intervals	T079	C1272706
27294436	951	969	Ordinal regression	T170	C0034980
27294436	988	1000	associations	T080	C0439849
27294436	1009	1020	demographic	T078	C0011292
27294436	1023	1031	clinical	T080	C0205210
27294436	1032	1039	factors	T169	C1521761
27294436	1044	1046	VD	T170	C0282354
27294436	1047	1053	scores	T081	C0449820
27294436	1066	1074	subjects	T098	C0080105
27294436	1086	1093	females	T032	C0086287
27294436	1104	1106	SD	T081	C0871420
27294436	1108	1111	age	T032	C0001779
27294436	1146	1149	VDs	T170	C0282354
27294436	1166	1168	CI	T081	C0009667
27294436	1170	1176	scores	T081	C0449820
27294436	1206	1215	intervals	T079	C1272706
27294436	1229	1233	mild	T080	C2945599
27294436	1258	1266	moderate	T080	C0205081
27294436	1348	1360	a little bit	T033	C2984078
27294436	1385	1396	quite a bit	T033	C2984080
27294436	1435	1437	CI	T081	C0009667
27294436	1460	1470	not at all	T033	C2984077
27294436	1521	1524	age	T032	C0001779
27294436	1529	1538	education	T033	C0013658
27294436	1557	1563	income	T081	C0021162
27294436	1568	1581	comorbidities	T078	C0009488
27294436	1600	1603	Age	T032	C0001779
27294436	1605	1608	sex	T032	C0079399
27294436	1614	1623	education	T033	C0013658
27294436	1655	1658	VDs	T170	C0282354
27294436	1669	1690	nonsignificant models	T170	C3161035
27294436	1718	1722	data	T078	C1511726
27294436	1744	1753	intervals	T079	C1272706
27294436	1755	1766	Demographic	T078	C0011292
27294436	1771	1779	clinical	T080	C0205210
27294436	1780	1787	factors	T169	C1521761
27294436	1792	1802	associated	T080	C0332281
27294436	1812	1826	interpretation	T170	C0459471
27294436	1835	1838	VDs	T170	C0282354
27294436	1853	1861	adjusted	T169	C0456081
27294436	1869	1877	analyses	T062	C0936012
27294436	1881	1900	non-randomized data	T078	C1511726

27793507|t|Proliferating cell nuclear antigen prevents trinucleotide repeat expansions by promoting repeat deletion and hairpin removal
27793507|a|DNA base lesions and base excision repair (BER) within trinucleotide repeat (TNR) tracts modulate repeat instability through the coordination among the key BER enzymes DNA polymerase β, flap endonuclease 1 (FEN1) and DNA ligase I (LIG I). However, it remains unknown whether BER cofactors can also alter TNR stability. In this study, we discovered that proliferating cell nuclear antigen (PCNA), a cofactor of BER, promoted CAG repeat deletion and removal of a CAG repeat hairpin during BER in a duplex CAG repeat tract and CAG hairpin loop, respectively. We showed that PCNA stimulated LIG I activity on a nick across a small template loop during BER in a duplex (CAG)20 repeat tract promoting small repeat deletions. Surprisingly, we found that during BER in a hairpin loop, PCNA promoted reannealing of the upstream flap of a double-flap intermediate, thereby facilitating the formation of a downstream flap and stimulating FEN1 cleavage activity and hairpin removal. Our results indicate that PCNA plays a critical role in preventing CAG repeat expansions by modulating the structures of dynamic DNA via cooperation with BER enzymes. We provide the first evidence that PCNA prevents CAG repeat expansions during BER by promoting CAG repeat deletion and removal of a TNR hairpin.
27793507	0	34	Proliferating cell nuclear antigen	T116,T123	C0072108
27793507	35	43	prevents	T169	C1292733
27793507	44	75	trinucleotide repeat expansions	T049	C0524894
27793507	89	95	repeat	T114,T123	C0282537
27793507	96	104	deletion	T049	C0544883
27793507	109	116	hairpin	T114,T123	C2350253
27793507	117	124	removal	T052	C1883720
27793507	125	128	DNA	T114,T123	C0012854
27793507	129	141	base lesions	T169	C0205245
27793507	146	166	base excision repair	T045	C1158530
27793507	168	171	BER	T045	C1158530
27793507	180	213	trinucleotide repeat (TNR) tracts	T114,T123	C0282537
27793507	223	229	repeat	T114,T123	C0282537
27793507	254	266	coordination	T169	C0700114
27793507	281	284	BER	T045	C1158530
27793507	285	292	enzymes	T116,T126	C0014442
27793507	293	309	DNA polymerase β	T116,T126	C0525039
27793507	311	330	flap endonuclease 1	T116,T126	C0252912
27793507	332	336	FEN1	T116,T126	C0252912
27793507	342	354	DNA ligase I	T116,T126	C0114615
27793507	356	361	LIG I	T116,T126	C0114615
27793507	400	403	BER	T045	C1158530
27793507	404	413	cofactors	T109,T123	C0009235
27793507	429	432	TNR	T114,T123	C0282537
27793507	433	442	stability	T080	C0205360
27793507	452	457	study	T062	C2603343
27793507	478	512	proliferating cell nuclear antigen	T116,T123	C0072108
27793507	514	518	PCNA	T116,T123	C0072108
27793507	523	531	cofactor	T109,T123	C0009235
27793507	535	538	BER	T045	C1158530
27793507	549	559	CAG repeat	T114,T123	C0282537
27793507	560	568	deletion	T049	C0544883
27793507	573	580	removal	T052	C1883720
27793507	586	596	CAG repeat	T114,T123	C0282537
27793507	597	604	hairpin	T114,T123	C2350253
27793507	612	615	BER	T045	C1158530
27793507	621	627	duplex	T169	C0205173
27793507	628	644	CAG repeat tract	T114,T123	C0282537
27793507	649	665	CAG hairpin loop	T114,T123	C2350253
27793507	696	700	PCNA	T116,T123	C0072108
27793507	712	726	LIG I activity	T045	C1150775
27793507	752	765	template loop	T086	C0004793
27793507	773	776	BER	T045	C1158530
27793507	782	788	duplex	T169	C0205173
27793507	789	809	(CAG)20 repeat tract	T114,T123	C0282537
27793507	826	832	repeat	T114,T123	C0282537
27793507	833	842	deletions	T049	C0544883
27793507	879	882	BER	T045	C1158530
27793507	888	900	hairpin loop	T114,T123	C2350253
27793507	902	906	PCNA	T116,T123	C0072108
27793507	916	927	reannealing	T045	C0920681
27793507	935	948	upstream flap	T086	C0004793
27793507	954	965	double-flap	T086	C0004793
27793507	1020	1035	downstream flap	T086	C0004793
27793507	1052	1056	FEN1	T116,T126	C0252912
27793507	1052	1074	FEN1 cleavage activity	T045	C1323602
27793507	1079	1086	hairpin	T114,T123	C2350253
27793507	1087	1094	removal	T052	C1883720
27793507	1122	1126	PCNA	T116,T123	C0072108
27793507	1163	1184	CAG repeat expansions	T049	C0524894
27793507	1203	1213	structures	T082	C0678594
27793507	1225	1228	DNA	T114,T123	C0012854
27793507	1233	1244	cooperation	T169	C0700114
27793507	1250	1253	BER	T045	C1158530
27793507	1254	1261	enzymes	T116,T126	C0014442
27793507	1298	1302	PCNA	T116,T123	C0072108
27793507	1303	1311	prevents	T169	C1292733
27793507	1312	1333	CAG repeat expansions	T049	C0524894
27793507	1341	1344	BER	T045	C1158530
27793507	1358	1368	CAG repeat	T114,T123	C0282537
27793507	1369	1377	deletion	T049	C0544883
27793507	1382	1389	removal	T052	C1883720
27793507	1395	1398	TNR	T114,T123	C0282537
27793507	1399	1406	hairpin	T114,T123	C2350253

28306707|t|Severity of illness index for surgical departments in a Cuban hospital: a revalidation study
28306707|a|In the context of the evaluation of hospital services, the incorporation of severity indices allows an essential control variable for performance comparisons in time and space through risk adjustment. The severity index for surgical services was developed in 1999 and validated as a general index for surgical services. Sixteen years later the hospital context is different in many ways and a revalidation was considered necessary to guarantee its current usefulness. To evaluate the validity and reliability of the surgical services severity index to warrant its reasonable use under current conditions. A descriptive study was carried out in the General Surgery service of the " Hermanos Ameijeiras " Clinical Surgical Hospital of Havana, Cuba during the second half of 2010. We reviewed the medical records of 511 patients discharged from this service. Items were the same as the original index as were their weighted values. Conceptual or construct validity, criterion validity and inter-rater reliability as well as internal consistency of the proposed index were evaluated. Construct validity was expressed as a significant association between the value of the severity index for surgical services and discharge status. A significant association was also found, although weak, with length of hospital stay. Criterion validity was demonstrated through the correlation s between the severity index for surgical services and other similar indices. Regarding criterion validity, the Horn index showed a correlation of 0.722 (95% CI: 0.677-0.761) with our index. With the POSSUM score, correlation was 0.454 (95% CI: 0.388-0.514) with mortality risk and 0.539 (95% CI: 0.462-0.607) with morbidity risk. Internal consistency yielded a standardized Cronbach's alpha of 0.8; inter-rater reliability resulted in a reliability coefficient of 0.98 for the quantitative index and a weighted global Kappa coefficient of 0.87 for the ordinal surgical index of seve rity for surgical services (IGQ). The validity and reliability of the proposed index was satisfactory in all aspects evaluated. The surgical services severity index may be used in the original context and is easily adaptable to other contexts as well.
28306707	0	25	Severity of illness index	T081	C0036859
28306707	30	50	surgical departments	T093	C0587503
28306707	56	61	Cuban	T083	C0010435
28306707	62	70	hospital	T073,T093	C0019994
28306707	74	92	revalidation study	T062,T170	C0681836
28306707	115	125	evaluation	T058	C0220825
28306707	129	146	hospital services	T058	C3694485
28306707	169	185	severity indices	T081	C0036859
28306707	206	222	control variable	T081	C0683951
28306707	239	250	comparisons	T052	C1707455
28306707	277	292	risk adjustment	T058	C0035649
28306707	298	312	severity index	T081	C0036859
28306707	317	334	surgical services	T058	C0587668
28306707	376	389	general index	T170	C0918012
28306707	394	411	surgical services	T058	C0587668
28306707	437	445	hospital	T073,T093	C0019994
28306707	446	453	context	T078	C0449255
28306707	486	498	revalidation	T062	C1519941
28306707	549	559	usefulness	T080	C3827682
28306707	577	601	validity and reliability	T080	C0035036
28306707	609	626	surgical services	T058	C0587668
28306707	627	641	severity index	T081	C0036859
28306707	712	717	study	T062	C2603343
28306707	741	764	General Surgery service	T093	C0587503
28306707	774	793	Hermanos Ameijeiras	T073,T093	C0019994
28306707	796	822	Clinical Surgical Hospital	T093	C1136037
28306707	834	838	Cuba	T083	C0010435
28306707	887	902	medical records	T170	C0025102
28306707	910	929	patients discharged	T058	C0030685
28306707	976	990	original index	T170	C0918012
28306707	1005	1020	weighted values	T081	C0392762
28306707	1022	1032	Conceptual	T080	C0870330
28306707	1036	1054	construct validity	T080	C0681897
28306707	1056	1074	criterion validity	T081	C2699472
28306707	1079	1102	inter-rater reliability	T081	C0870740
28306707	1114	1134	internal consistency	T081	C0870731
28306707	1142	1156	proposed index	T081	C0036859
28306707	1173	1191	Construct validity	T080	C0681897
28306707	1260	1274	severity index	T081	C0036859
28306707	1279	1296	surgical services	T058	C0587668
28306707	1301	1317	discharge status	T033	C0586514
28306707	1381	1404	length of hospital stay	T079	C0023303
28306707	1406	1424	Criterion validity	T081	C2699472
28306707	1454	1465	correlation	T081	C0010100
28306707	1480	1494	severity index	T081	C0036859
28306707	1499	1516	surgical services	T058	C0587668
28306707	1535	1542	indices	T170	C0918012
28306707	1554	1572	criterion validity	T081	C2699472
28306707	1578	1588	Horn index	T081	C0036859
28306707	1598	1609	correlation	T081	C0010100
28306707	1650	1655	index	T081	C0036859
28306707	1666	1678	POSSUM score	T081	C0457451
28306707	1680	1691	correlation	T081	C0010100
28306707	1729	1738	mortality	T081	C0681679
28306707	1739	1743	risk	T078	C0035647
28306707	1781	1790	morbidity	T081	C0026538
28306707	1791	1795	risk	T078	C0035647
28306707	1797	1817	Internal consistency	T081	C0870731
28306707	1828	1857	standardized Cronbach's alpha	T081	C0392762
28306707	1866	1889	inter-rater reliability	T081	C0870740
28306707	1904	1927	reliability coefficient	T081	C2347947
28306707	1944	1962	quantitative index	T081	C0392762
28306707	1978	2002	global Kappa coefficient	T081	C2828391
28306707	2019	2049	ordinal surgical index of seve	T081	C0036859
28306707	2059	2076	surgical services	T058	C0587668
28306707	2088	2112	validity and reliability	T080	C0035036
28306707	2120	2134	proposed index	T081	C0036859
28306707	2182	2199	surgical services	T058	C0587668
28306707	2200	2214	severity index	T081	C0036859

28442859|t|Digital Myopericytoma: A Case Report and Systematic Literature Review
28442859|a|A myopericytoma (MP) is an exceedingly rare perivascular tumor of unknown etiology. Given their potential for mimicry and malignancy, MP tumors pose a unique challenge for surgeons and may be overlooked on differential diagnosis. We present a case report of an otherwise healthy 33-year-old right-hand dominant male who presented to our outpatient clinic with a 2-month history of painless swelling and erythema of the pulp of his left index finger. Subsequent plain film X-ray showed near-complete bony destruction of his distal phalanx. Pathological evaluation of an incisional biopsy showed a benign variant of MP. The lesion was treated by excision with tumor shelling, and there was no evidence of recurrence 81 days postoperatively. A systematic literature review of the management and outcome of all known cases of hand and wrist MP is presented.
28442859	0	7	Digital	T023	C0016129
28442859	8	21	Myopericytoma	T191	C1302808
28442859	25	36	Case Report	T170	C0007320
28442859	41	69	Systematic Literature Review	T170	C1955832
28442859	72	85	myopericytoma	T191	C1302808
28442859	87	89	MP	T191	C1302808
28442859	114	132	perivascular tumor	T191	C1335392
28442859	136	152	unknown etiology	T033	C0743626
28442859	166	175	potential	T080	C3245505
28442859	180	187	mimicry	T044	C0242943
28442859	192	202	malignancy	T191	C4282132
28442859	204	213	MP tumors	T191	C1302808
28442859	242	250	surgeons	T097	C0582175
28442859	276	298	differential diagnosis	T060	C0011906
28442859	313	324	case report	T170	C0007320
28442859	341	348	healthy	T080	C3898900
28442859	361	380	right-hand dominant	T032	C0344333
28442859	381	385	male	T098	C0025266
28442859	407	424	outpatient clinic	T073,T093	C0029916
28442859	451	459	painless	T169	C0234226
28442859	460	468	swelling	T033	C0038999
28442859	473	518	erythema of the pulp of his left index finger	T033	C2071552
28442859	531	547	plain film X-ray	T060	C1306645
28442859	555	568	near-complete	T080	C0205197
28442859	569	585	bony destruction	T033	C3810196
28442859	593	607	distal phalanx	T023	C0223821
28442859	609	621	Pathological	T046	C0030660
28442859	622	632	evaluation	T058	C0220825
28442859	639	656	incisional biopsy	T060	C0184922
28442859	666	680	benign variant	T191	C0086692
28442859	684	686	MP	T191	C1302808
28442859	692	698	lesion	T033	C0221198
28442859	714	722	excision	T061	C0728940
28442859	728	733	tumor	T191	C0027651
28442859	734	742	shelling	T061	C1283248
28442859	758	772	no evidence of	T080	C0332125
28442859	773	783	recurrence	T067	C0034897
28442859	792	807	postoperatively	T079	C0032790
28442859	847	857	management	T058	C0376636
28442859	862	869	outcome	T080	C0085415
28442859	883	888	cases	T170	C0085973
28442859	892	906	hand and wrist	T029	C0869996
28442859	907	909	MP	T191	C1302808

27298741|t|Cortical Reorganization following Injury Early in Life
27298741|a|The brain has a remarkable capacity for reorganization following injury, especially during the first years of life. Knowledge of structural reorganization and its consequences following perinatal injury is sparse. Here we studied changes in brain tissue volume, morphology, perfusion, and integrity in children with hemiplegia compared to typically developing children, using MRI. Children with hemiplegia demonstrated reduced total cerebral volume, with increased cerebrospinal fluid (CSF) and reduced total white matter volumes, with no differences in total gray matter volume, compared to typically developing children. An increase in cortical thickness at the hemisphere contralateral to the lesion (CLH) was detected in motor and language areas, which may reflect compensation for the gray matter loss in the lesion area or retention of ipsilateral pathways. In addition, reduced cortical thickness, perfusion, and surface area were detected in limbic areas. Increased CSF volume and precentral cortical thickness and reduced white matter volume were correlated with worse motor performance. Brain reorganization of the gray matter within the CLH, while not necessarily indicating better outcome, is suggested as a response to neuronal deficits following injury early in life.
27298741	0	8	Cortical	T023	C0007776
27298741	9	23	Reorganization	T078	C0680829
27298741	34	40	Injury	T037	C3263723
27298741	41	46	Early	T079	C1279919
27298741	50	54	Life	T078	C0376558
27298741	59	64	brain	T023	C0006104
27298741	82	90	capacity	T081	C1516240
27298741	95	109	reorganization	T078	C0680829
27298741	120	126	injury	T037	C3263723
27298741	156	161	years	T079	C0439234
27298741	165	169	life	T078	C0376558
27298741	184	209	structural reorganization	T078	C0680829
27298741	218	230	consequences	T169	C0686907
27298741	241	257	perinatal injury	T037	C2347482
27298741	296	308	brain tissue	T023	C0459385
27298741	309	315	volume	T081	C0449468
27298741	317	327	morphology	T080	C0332437
27298741	329	338	perfusion	T061	C0031001
27298741	344	353	integrity	T080	C1947912
27298741	357	365	children	T100	C0008059
27298741	371	381	hemiplegia	T184	C0018991
27298741	415	423	children	T100	C0008059
27298741	431	434	MRI	T060	C0024485
27298741	436	444	Children	T100	C0008059
27298741	450	460	hemiplegia	T184	C0018991
27298741	474	503	reduced total cerebral volume	T033	C4314627
27298741	510	539	increased cerebrospinal fluid	T033	C2747920
27298741	541	544	CSF	T031	C0007806
27298741	550	584	reduced total white matter volumes	T033	C3278845
27298741	591	605	no differences	T033	C3842396
27298741	609	614	total	T080	C0439810
27298741	615	626	gray matter	T024	C0018220
27298741	627	633	volume	T081	C0449468
27298741	668	676	children	T100	C0008059
27298741	681	689	increase	T169	C0442805
27298741	693	701	cortical	T023	C0007776
27298741	702	711	thickness	T080	C1280412
27298741	719	729	hemisphere	T023	C0228174
27298741	730	743	contralateral	T082	C0441988
27298741	751	757	lesion	T033	C0221198
27298741	759	762	CLH	T023	C0228174
27298741	768	776	detected	T033	C0442726
27298741	780	785	motor	T029	C0026607
27298741	790	804	language areas	T029	C3495412
27298741	845	856	gray matter	T024	C0018220
27298741	857	861	loss	T081	C1517945
27298741	869	875	lesion	T033	C0221198
27298741	876	880	area	T082	C0205146
27298741	897	908	ipsilateral	T082	C0441989
27298741	909	917	pathways	T023	C0815011
27298741	932	939	reduced	T080	C0392756
27298741	940	948	cortical	T023	C0007776
27298741	949	958	thickness	T080	C1280412
27298741	960	969	perfusion	T061	C0031001
27298741	975	987	surface area	T082	C1254362
27298741	993	1001	detected	T033	C0442726
27298741	1005	1011	limbic	T022	C0023715
27298741	1012	1017	areas	T029	C1273723
27298741	1019	1039	Increased CSF volume	T033	C2747920
27298741	1044	1063	precentral cortical	T023	C0228202
27298741	1064	1073	thickness	T080	C1280412
27298741	1078	1105	reduced white matter volume	T033	C3278845
27298741	1133	1150	motor performance	T040	C0870921
27298741	1152	1157	Brain	T023	C0006104
27298741	1158	1172	reorganization	T078	C0680829
27298741	1180	1191	gray matter	T024	C0018220
27298741	1203	1206	CLH	T023	C0228174
27298741	1248	1255	outcome	T169	C1274040
27298741	1287	1295	neuronal	T025	C0027882
27298741	1296	1304	deficits	T080	C2987487
27298741	1315	1321	injury	T037	C3263723
27298741	1322	1327	early	T079	C1279919
27298741	1331	1335	life	T078	C0376558

27242395|t|An Efficient and Reliable Statistical Method for Estimating Functional Connectivity in Large Scale Brain Networks Using Partial Correlation
27242395|a|Currently, network-oriented analysis of fMRI data has become an important tool for understanding brain organization and brain networks. Among the range of network modeling methods, partial correlation has shown great promises in accurately detecting true brain network connections. However, the application of partial correlation in investigating brain connectivity, especially in large-scale brain networks, has been limited so far due to the technical challenges in its estimation. In this paper, we propose an efficient and reliable statistical method for estimating partial correlation in large-scale brain network modeling. Our method derives partial correlation based on the precision matrix estimated via Constrained L1-minimization Approach (CLIME), which is a recently developed statistical method that is more efficient and demonstrates better performance than the existing methods. To help select an appropriate tuning parameter for sparsity control in the network estimation, we propose a new Dens-based selection method that provides a more informative and flexible tool to allow the users to select the tuning parameter based on the desired sparsity level. Another appealing feature of the Dens-based method is that it is much faster than the existing methods, which provides an important advantage in neuroimaging applications. Simulation studies show that the Dens-based method demonstrates comparable or better performance with respect to the existing methods in network estimation. We applied the proposed partial correlation method to investigate resting state functional connectivity using rs-fMRI data from the Philadelphia Neurodevelopmental Cohort (PNC) study. Our results show that partial correlation analysis removed considerable between-module marginal connections identified by full correlation analysis, suggesting these connections were likely caused by global effects or common connection to other nodes. Based on partial correlation, we find that the most significant direct connections are between homologous brain locations in the left and right hemisphere. When comparing partial correlation derived under different sparse tuning parameters, an important finding is that the sparse regularization has more shrinkage effects on negative functional connections than on positive connections, which supports previous findings that many of the negative brain connections are due to non-neurophysiological effects. An R package "DensParcorr" can be downloaded from CRAN for implementing the proposed statistical methods.
27242395	3	12	Efficient	T080	C0442799
27242395	17	25	Reliable	T080	C0205556
27242395	26	44	Statistical Method	T062	C1710191
27242395	49	59	Estimating	T081	C0750572
27242395	60	70	Functional	T169	C0205245
27242395	71	83	Connectivity	T082	C0449379
27242395	99	104	Brain	T023	C0006104
27242395	105	113	Networks	T040	C0598941
27242395	120	127	Partial	T081	C0728938
27242395	128	139	Correlation	T080	C1707520
27242395	151	167	network-oriented	T040	C0598941
27242395	168	176	analysis	T062	C0936012
27242395	180	184	fMRI	T060	C0376335
27242395	185	189	data	T078	C1511726
27242395	204	218	important tool	T073	C2827396
27242395	237	242	brain	T023	C0006104
27242395	243	255	organization	T039	C0029237
27242395	260	265	brain	T023	C0006104
27242395	266	274	networks	T040	C0598941
27242395	295	302	network	T040	C0598941
27242395	303	319	modeling methods	T170	C1554090
27242395	321	328	partial	T081	C0728938
27242395	329	340	correlation	T080	C1707520
27242395	380	389	detecting	T033	C0442726
27242395	395	400	brain	T023	C0006104
27242395	401	408	network	T040	C0598941
27242395	409	420	connections	T082	C0449379
27242395	450	457	partial	T081	C0728938
27242395	458	469	correlation	T080	C1707520
27242395	473	486	investigating	T169	C1292732
27242395	487	492	brain	T023	C0006104
27242395	493	505	connectivity	T082	C0449379
27242395	533	538	brain	T023	C0006104
27242395	539	547	networks	T040	C0598941
27242395	584	604	technical challenges	T067	C1710348
27242395	612	622	estimation	T081	C0750572
27242395	653	662	efficient	T080	C0442799
27242395	667	675	reliable	T080	C0205556
27242395	676	694	statistical method	T062	C1710191
27242395	699	709	estimating	T081	C0750572
27242395	710	717	partial	T081	C0728938
27242395	718	729	correlation	T080	C1707520
27242395	745	750	brain	T023	C0006104
27242395	751	758	network	T040	C0598941
27242395	759	767	modeling	T062	C0870071
27242395	773	779	method	T170	C0025663
27242395	788	795	partial	T081	C0728938
27242395	796	807	correlation	T080	C1707520
27242395	821	847	precision matrix estimated	T081	C0750572
27242395	852	888	Constrained L1-minimization Approach	T062	C1710191
27242395	890	895	CLIME	T062	C1710191
27242395	928	946	statistical method	T062	C1710191
27242395	960	969	efficient	T080	C0442799
27242395	994	1005	performance	T052	C1882330
27242395	1024	1031	methods	T170	C0025663
27242395	1063	1079	tuning parameter	T077	C0549193
27242395	1093	1100	control	T080	C0243148
27242395	1108	1115	network	T040	C0598941
27242395	1116	1126	estimation	T081	C0750572
27242395	1145	1172	Dens-based selection method	T062	C1710191
27242395	1194	1205	informative	T080	C2986490
27242395	1210	1218	flexible	T080	C0443220
27242395	1219	1223	tool	T170	C0037589
27242395	1257	1273	tuning parameter	T077	C0549193
27242395	1295	1303	sparsity	T082	C1254362
27242395	1304	1309	level	T080	C0441889
27242395	1344	1361	Dens-based method	T062	C1710191
27242395	1406	1413	methods	T170	C0025663
27242395	1456	1481	neuroimaging applications	T060	C0679575
27242395	1483	1501	Simulation studies	T062	C0679083
27242395	1516	1533	Dens-based method	T062	C1710191
27242395	1568	1579	performance	T052	C1882330
27242395	1609	1616	methods	T170	C0025663
27242395	1620	1627	network	T040	C0598941
27242395	1628	1638	estimation	T081	C0750572
27242395	1664	1671	partial	T081	C0728938
27242395	1672	1683	correlation	T080	C1707520
27242395	1684	1690	method	T170	C0025663
27242395	1694	1705	investigate	T169	C1292732
27242395	1706	1762	resting state functional connectivity using rs-fMRI data	T060	C4288291
27242395	1772	1822	Philadelphia Neurodevelopmental Cohort (PNC) study	T081	C0009247
27242395	1828	1835	results	T169	C1274040
27242395	1846	1853	partial	T081	C0728938
27242395	1854	1865	correlation	T080	C1707520
27242395	1866	1874	analysis	T062	C0936012
27242395	1911	1931	marginal connections	T082	C0449379
27242395	1951	1971	correlation analysis	T062,T170	C0010101
27242395	1990	2001	connections	T082	C0449379
27242395	2049	2059	connection	T082	C0449379
27242395	2069	2074	nodes	T023	C0746922
27242395	2085	2092	partial	T081	C0728938
27242395	2093	2104	correlation	T080	C1707520
27242395	2147	2158	connections	T082	C0449379
27242395	2182	2187	brain	T023	C0006104
27242395	2188	2197	locations	T029	C1515974
27242395	2205	2209	left	T023	C0228176
27242395	2214	2230	right hemisphere	T023	C0228175
27242395	2247	2254	partial	T081	C0728938
27242395	2255	2266	correlation	T080	C1707520
27242395	2291	2297	sparse	T082	C1254362
27242395	2298	2315	tuning parameters	T077	C0549193
27242395	2381	2398	shrinkage effects	T169	C0332513
27242395	2402	2410	negative	T033	C0205160
27242395	2411	2421	functional	T169	C0205245
27242395	2422	2433	connections	T082	C0449379
27242395	2442	2450	positive	T033	C1446409
27242395	2451	2462	connections	T082	C0449379
27242395	2514	2522	negative	T033	C0205160
27242395	2523	2528	brain	T023	C0006104
27242395	2529	2540	connections	T082	C0449379
27242395	2552	2582	non-neurophysiological effects	T039	C1372849
27242395	2587	2610	R package "DensParcorr"	T170	C0037589
27242395	2634	2638	CRAN	T170	C0282574
27242395	2669	2688	statistical methods	T062	C1710191

28295933|t|High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography - guided biopsy as compared with prostatectomy specimens
28295933|a|To determine the utility of our transgluteal magnetic resonance imaging (MRI)- guided prostate biopsy approach. A total of 960 biopsy series, taken within the period of 1 year, were evaluated, including 301 MRI-guided and 659 transrectal ultrasonography (TRUS)- guided biopsies. The positivity rate and proportion of high grade cancers were significantly higher in MRI-guided than in TRUS - guided biopsies. Of 301 MRI-guided biopsies, 65.4% contained cancer while 57.2% of 659 TRUS biopsies contained cancer (P = 0.016). Gleason grade 3 + 3 = 6 disease was observed in 16.8% of 197 MRI-guided and in 36.1% of 377 TRUS - guided biopsies (P < 0.001). There was also a markedly higher quantity of cancer tissue in MRI-guided biopsies. In all cancers, the mean cancer surface area was 64.8 ± 51.6 mm(2) in MRI-guided biopsies as compared with 23.0 ± 31.4 mm(2) in non-MRI-guided biopsies (P < 0.001). With respect to the tissue quantity, superiority of MRI-guided biopsy was highest in Gleason grade 3 + 3 = 6 cancers (20.9 ± 27.9 vs 5.1 ± 10.2 mm(2); P < 0.001) and in Gleason grade 3 + 4 = 7 cancers (59.7 ± 38.0 vs 17.7 ± 18.4 mm(2); P < 0.001). Comparison of biopsy Gleason grades with findings in prostatectomy specimens was possible in 80 patients with MRI-guided and in 170 patients with non-MRI-guided biopsies. This comparison showed a very high but almost identical concordance of TRUS - and MRI-guided biopsies with the prostatectomy specimen findings. With both approaches, undetected high-risk cancers were present in ~10% of patients with low-risk biopsy results. A significant difference was observed, however, in the proportion of patients who had clinically insignificant cancers and who underwent surgery. The proportion of patients with Gleason grade 3 + 3 = 6 carcinoma in their prostatectomy specimen was 11.2% in the post - TRUS biopsy cohort, but only 2.5% in the post - MRI biopsy cohort (P = 0.021). MRI-guided transgluteal prostate biopsy has a high detection rate for high-risk carcinomas, while the risk of detecting clinically insignificant carcinomas appears to be reduced. This may by itself lead to a reduction of unnecessary prostatectomies. Overtreatment may be further avoided by better applicability of molecular testing to MRI-guided biopsies because of the excessive amount of tissue available for analysis, especially in patients with potential low-risk carcinomas.
28295933	0	4	High	T080	C0205250
28295933	20	28	findings	T033	C0243095
28295933	29	37	obtained	T169	C1301820
28295933	43	55	transgluteal	T082	C0444462
28295933	56	82	magnetic resonance imaging	T060	C0024485
28295933	89	116	transrectal ultrasonography	T060	C0373345
28295933	119	132	guided biopsy	T060	C0456900
28295933	136	144	compared	T052	C1707455
28295933	150	163	prostatectomy	T061	C0033573
28295933	164	173	specimens	T077	C2347026
28295933	191	198	utility	T169	C0457083
28295933	206	218	transgluteal	T082	C0444462
28295933	219	245	magnetic resonance imaging	T060	C0024485
28295933	247	250	MRI	T060	C0024485
28295933	253	275	guided prostate biopsy	T060	C0456852
28295933	301	307	biopsy	T060	C0005558
28295933	308	314	series	T081	C0205549
28295933	333	339	period	T079	C1948053
28295933	345	349	year	T079	C0439234
28295933	356	365	evaluated	T058	C0220825
28295933	381	391	MRI-guided	T060	C0456854
28295933	400	427	transrectal ultrasonography	T060	C0373345
28295933	429	433	TRUS	T060	C0373345
28295933	436	451	guided biopsies	T060	C0456900
28295933	457	467	positivity	T033	C1446409
28295933	468	472	rate	T081	C1521828
28295933	477	487	proportion	T081	C1709707
28295933	491	501	high grade	T033	C1962917
28295933	502	509	cancers	T191	C0006826
28295933	515	535	significantly higher	T081	C4055637
28295933	539	549	MRI-guided	T060	C0456854
28295933	558	562	TRUS	T060	C0373345
28295933	565	580	guided biopsies	T060	C0456900
28295933	589	608	MRI-guided biopsies	T060	C0456854
28295933	626	632	cancer	T191	C0006826
28295933	652	656	TRUS	T060	C0373345
28295933	657	665	biopsies	T060	C0456900
28295933	666	675	contained	T169	C0332256
28295933	676	682	cancer	T191	C0006826
28295933	684	685	P	T081	C1709380
28295933	696	709	Gleason grade	T033	C3203027
28295933	732	740	observed	T169	C1441672
28295933	757	767	MRI-guided	T060	C0456854
28295933	788	792	TRUS	T060	C0373345
28295933	795	810	guided biopsies	T060	C0456900
28295933	812	813	P	T081	C1709380
28295933	850	856	higher	T080	C0205250
28295933	857	865	quantity	T081	C1265611
28295933	869	882	cancer tissue	T191	C0027656
28295933	886	905	MRI-guided biopsies	T060	C0456854
28295933	914	921	cancers	T191	C0006826
28295933	932	938	cancer	T191	C0006826
28295933	939	951	surface area	T082	C0205146
28295933	977	996	MRI-guided biopsies	T060	C0456854
28295933	1060	1061	P	T081	C1709380
28295933	1092	1098	tissue	T191	C0027656
28295933	1099	1107	quantity	T081	C1265611
28295933	1109	1120	superiority	T082	C1282910
28295933	1124	1141	MRI-guided biopsy	T060	C0456854
28295933	1146	1153	highest	T080	C1522410
28295933	1157	1170	Gleason grade	T033	C3203027
28295933	1181	1188	cancers	T191	C0006826
28295933	1223	1224	P	T081	C1709380
28295933	1241	1254	Gleason grade	T033	C3203027
28295933	1265	1272	cancers	T191	C0006826
28295933	1308	1309	P	T081	C1709380
28295933	1320	1330	Comparison	T052	C1707455
28295933	1334	1340	biopsy	T060	C0005558
28295933	1341	1355	Gleason grades	T033	C3203027
28295933	1361	1369	findings	T033	C0243095
28295933	1373	1386	prostatectomy	T061	C0033573
28295933	1387	1396	specimens	T077	C2347026
28295933	1416	1424	patients	T101	C0030705
28295933	1430	1440	MRI-guided	T060	C0456854
28295933	1452	1460	patients	T101	C0030705
28295933	1496	1506	comparison	T052	C1707455
28295933	1521	1525	high	T080	C0205250
28295933	1537	1546	identical	T080	C0205280
28295933	1562	1566	TRUS	T060	C0373345
28295933	1573	1592	MRI-guided biopsies	T060	C0456854
28295933	1602	1615	prostatectomy	T061	C0033573
28295933	1616	1624	specimen	T077	C2347026
28295933	1625	1633	findings	T033	C0243095
28295933	1657	1667	undetected	T033	C0442737
28295933	1668	1685	high-risk cancers	T191	C1512441
28295933	1691	1698	present	T033	C0150312
28295933	1710	1718	patients	T101	C0030705
28295933	1724	1732	low-risk	T081	C3538919
28295933	1733	1739	biopsy	T060	C0005558
28295933	1740	1747	results	T034	C0456984
28295933	1751	1762	significant	T078	C0750502
28295933	1778	1786	observed	T169	C1441672
28295933	1804	1814	proportion	T081	C1709707
28295933	1818	1826	patients	T101	C0030705
28295933	1835	1845	clinically	T080	C0205210
28295933	1846	1859	insignificant	T033	C1273937
28295933	1860	1867	cancers	T191	C0006826
28295933	1886	1893	surgery	T061	C0543467
28295933	1899	1909	proportion	T081	C1709707
28295933	1913	1921	patients	T101	C0030705
28295933	1927	1940	Gleason grade	T033	C3203027
28295933	1951	1960	carcinoma	T191	C0007097
28295933	1970	1983	prostatectomy	T061	C0033573
28295933	1984	1992	specimen	T077	C2347026
28295933	2010	2014	post	T079	C0687676
28295933	2017	2021	TRUS	T060	C0373345
28295933	2022	2028	biopsy	T060	C0005558
28295933	2029	2035	cohort	T098	C0599755
28295933	2058	2062	post	T079	C0687676
28295933	2065	2075	MRI biopsy	T060	C0456854
28295933	2076	2082	cohort	T098	C0599755
28295933	2084	2085	P	T081	C1709380
28295933	2096	2106	MRI-guided	T060	C0456854
28295933	2107	2119	transgluteal	T082	C0444462
28295933	2120	2135	prostate biopsy	T060	C0194804
28295933	2142	2146	high	T080	C0205250
28295933	2147	2156	detection	T061	C1511790
28295933	2157	2161	rate	T081	C1521828
28295933	2166	2186	high-risk carcinomas	T191	C1512441
28295933	2198	2202	risk	T078	C0035647
28295933	2206	2215	detecting	T061	C1511790
28295933	2216	2226	clinically	T080	C0205210
28295933	2227	2240	insignificant	T033	C1273937
28295933	2241	2251	carcinomas	T191	C0007097
28295933	2266	2273	reduced	T080	C0392756
28295933	2304	2313	reduction	T080	C0392756
28295933	2317	2344	unnecessary prostatectomies	T061	C0376707
28295933	2346	2359	Overtreatment	T058	C4046039
28295933	2410	2427	molecular testing	T059	C0752096
28295933	2431	2450	MRI-guided biopsies	T060	C0456854
28295933	2466	2475	excessive	T080	C0442802
28295933	2476	2482	amount	T081	C1265611
28295933	2486	2492	tissue	T191	C0027656
28295933	2493	2502	available	T169	C0470187
28295933	2507	2515	analysis	T062	C0936012
28295933	2531	2539	patients	T101	C0030705
28295933	2545	2554	potential	T080	C3245505
28295933	2555	2563	low-risk	T081	C3538919
28295933	2564	2574	carcinomas	T191	C0007097

27712587|t|TIPE2 Overexpression Suppresses the Proliferation, Migration, and Invasion in Prostate Cancer Cells by Inhibiting PI3K/Akt Signaling Pathway
27712587|a|Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2 (TNFAIP8L2, TIPE2) is involved in the invasion and metastasis of human tumors. However, the functional role of TIPE2 in prostate cancer remains unclear. In the present study, we explored the role of TIPE2 in prostate cancer and cancer progression including the molecular mechanism that drives TIPE2 -mediated oncogenesis. Our results showed that TIPE2 was lowly expressed in human prostate cancer tissues and cell lines. In addition, restored TIPE2 obviously inhibits proliferation in prostate cancer cells. TIPE2 overexpression also suppresses the epithelial-mesenchymal transition (EMT) process and migration / invasion in prostate cancer cells. Mechanistically, TIPE2 overexpression obviously inhibits the phosphorylation levels of phosphatidylinositol 3-kinase (PI3K) and Akt in prostate cancer cells. In conclusion, for the first time we demonstrated that TIPE2 overexpression may suppress proliferation, migration, and invasion in prostate cancer cells by inhibiting the PI3K/Akt signaling pathway. Therefore, TIPE2 might serve as a potential therapeutic target for human prostate cancer.
27712587	0	5	TIPE2	T116,T123	C2975187
27712587	6	20	Overexpression	T045	C1514559
27712587	21	31	Suppresses	T169	C1260953
27712587	36	49	Proliferation	T169	C1514485
27712587	51	60	Migration	T039	C1533574
27712587	66	74	Invasion	T033	C1269955
27712587	78	93	Prostate Cancer	T191	C0376358
27712587	94	99	Cells	T025	C0334227
27712587	103	113	Inhibiting	T044	C0021469
27712587	114	140	PI3K/Akt Signaling Pathway	T169	C2984369
27712587	141	197	Tumor necrosis factor-α (TNF-α)-induced protein 8-like 2	T116,T123	C2975187
27712587	199	208	TNFAIP8L2	T116,T123	C2975187
27712587	210	215	TIPE2	T116,T123	C2975187
27712587	236	244	invasion	T033	C1269955
27712587	249	259	metastasis	T191	C0027627
27712587	263	268	human	T016	C0086418
27712587	269	275	tumors	T191	C0027651
27712587	290	305	functional role	T077	C1705810
27712587	309	314	TIPE2	T116,T123	C2975187
27712587	318	333	prostate cancer	T191	C0376358
27712587	366	371	study	T062	C2603343
27712587	389	393	role	T170	C3871154
27712587	397	402	TIPE2	T116,T123	C2975187
27712587	406	421	prostate cancer	T191	C0376358
27712587	426	444	cancer progression	T046	C1947901
27712587	459	478	molecular mechanism	T044	C3537153
27712587	491	496	TIPE2	T116,T123	C2975187
27712587	507	518	oncogenesis	T191	C0007621
27712587	524	531	results	T034	C0456984
27712587	544	549	TIPE2	T116,T123	C2975187
27712587	554	559	lowly	T080	C0205251
27712587	560	569	expressed	T045	C1171362
27712587	573	578	human	T016	C0086418
27712587	579	594	prostate cancer	T191	C0376358
27712587	595	602	tissues	T024	C0040300
27712587	607	617	cell lines	T025	C0085983
27712587	641	646	TIPE2	T116,T123	C2975187
27712587	657	665	inhibits	T044	C0021469
27712587	666	679	proliferation	T169	C1514485
27712587	683	698	prostate cancer	T191	C0376358
27712587	699	704	cells	T025	C0334227
27712587	706	711	TIPE2	T116,T123	C2975187
27712587	712	726	overexpression	T045	C1514559
27712587	732	742	suppresses	T169	C1260953
27712587	747	780	epithelial-mesenchymal transition	T043	C1523298
27712587	782	785	EMT	T043	C1523298
27712587	799	808	migration	T039	C1533574
27712587	811	819	invasion	T033	C1269955
27712587	823	838	prostate cancer	T191	C0376358
27712587	839	844	cells	T025	C0334227
27712587	863	868	TIPE2	T116,T123	C2975187
27712587	869	883	overexpression	T045	C1514559
27712587	894	902	inhibits	T044	C0021469
27712587	907	922	phosphorylation	T044	C0031715
27712587	933	962	phosphatidylinositol 3-kinase	T116,T126	C2936824
27712587	964	968	PI3K	T116,T126	C2936824
27712587	974	977	Akt	T116,T126	C0164786
27712587	981	996	prostate cancer	T191	C0376358
27712587	997	1002	cells	T025	C0334227
27712587	1059	1064	TIPE2	T116,T123	C2975187
27712587	1065	1079	overexpression	T045	C1514559
27712587	1084	1092	suppress	T169	C1260953
27712587	1093	1106	proliferation	T169	C1514485
27712587	1108	1117	migration	T039	C1533574
27712587	1123	1131	invasion	T033	C1269955
27712587	1135	1150	prostate cancer	T191	C0376358
27712587	1151	1156	cells	T025	C0334227
27712587	1160	1170	inhibiting	T044	C0021469
27712587	1175	1201	PI3K/Akt signaling pathway	T169	C2984369
27712587	1214	1219	TIPE2	T116,T123	C2975187
27712587	1237	1246	potential	T080	C3245505
27712587	1247	1258	therapeutic	T169	C0302350
27712587	1259	1265	target	T104,T120	C1513403
27712587	1270	1275	human	T016	C0086418
27712587	1276	1291	prostate cancer	T191	C0376358

28272227|t|Effects of pulmonary static inflation with 50% xenon on oxygen impairment during cardiopulmonary bypass for stanford type A acute aortic dissection: A pilot study
28272227|a|The goal of this study was to investigate the effects of pulmonary static inflation with 50% xenon on postoperative oxygen impairment during cardiopulmonary bypass (CPB) for Stanford type A acute aortic dissection (AAD). This prospective single-center nonrandomized controlled clinical trial included 100 adult patients undergoing surgery for Stanford type A AAD at an academic hospital in China. Fifty subjects underwent pulmonary static inflation with 50% oxygen from January 2013 to January 2014, and 50 underwent inflation with 50% xenon from January 2014 to December 2014. During CPB, the lungs were inflated with either 50% xenon (xenon group) or 50% oxygen (control group) to maintain an airway pressure of 5 cm H2O. The primary outcome was oxygenation index (OI) value after intubation, and 10 minutes and 6 hours after the operation. The second outcome was cytokine and reactive oxygen species levels after intubation and 10 minutes, 6 hours, and 24 hours after the operation. Patients treated with xenon had lower OI levels compared to the control group before surgery (P = 0.002); however, there was no difference in postoperative values between the 2 groups. Following surgery, mean maximal OI values decreased by 18.8% and 33.8%, respectively, in the xenon and control groups. After surgery, the levels of interleukin-6 (IL-6), tumor necrosis factor alpha, and thromboxane B2 decreased by 23.5%, 9.1%, and 30.2%, respectively, in the xenon group, but increased by 10.8%, 26.2%, and 26.4%, respectively, in the control group. Moreover, IL-10 levels increased by 28% in the xenon group and decreased by 7.5% in the control group. There were significant time and treatment - time interaction effects on methane dicarboxylic aldehyde (P = 0.000 and P = 0.050, respectively) and myeloperoxidase (P = 0.000 and P = 0.001 in xenon and control groups, respectively). There was no difference in hospital mortality and 1-year survival rate between the 2 groups. Pulmonary static inflation with 50% xenon during CPB could attenuate OI decreases at the end of surgery for Stanford type A AAD. Thus, xenon may function by triggering anti-inflammatory responses and suppressing pro-inflammatory and oxidative effects.
28272227	0	10	Effects of	T080	C1704420
28272227	11	20	pulmonary	T023	C0024109
28272227	21	37	static inflation	T061	C1283105
28272227	47	52	xenon	T121,T196	C0043339
28272227	56	62	oxygen	T121,T123,T196	C0030054
28272227	63	73	impairment	T169	C0221099
28272227	81	103	cardiopulmonary bypass	T061	C0007202
28272227	108	147	stanford type A acute aortic dissection	T047	C0241868
28272227	151	162	pilot study	T062	C0031928
28272227	167	171	goal	T170	C0018017
28272227	180	185	study	T062	C2603343
28272227	209	219	effects of	T080	C1704420
28272227	220	229	pulmonary	T023	C0024109
28272227	230	246	static inflation	T061	C1283105
28272227	256	261	xenon	T121,T196	C0043339
28272227	265	278	postoperative	T079	C0032790
28272227	279	285	oxygen	T121,T123,T196	C0030054
28272227	286	296	impairment	T169	C0221099
28272227	304	326	cardiopulmonary bypass	T061	C0007202
28272227	328	331	CPB	T061	C0007202
28272227	337	376	Stanford type A acute aortic dissection	T047	C0241868
28272227	378	381	AAD	T047	C0241868
28272227	401	454	single-center nonrandomized controlled clinical trial	T062	C2985410
28272227	468	473	adult	T100	C0001675
28272227	474	482	patients	T101	C0030705
28272227	494	501	surgery	T061	C0543467
28272227	506	525	Stanford type A AAD	T047	C0241868
28272227	532	549	academic hospital	T073,T093	C0000872
28272227	553	558	China	T083	C0008115
28272227	585	594	pulmonary	T023	C0024109
28272227	595	611	static inflation	T061	C1283105
28272227	621	627	oxygen	T121,T123,T196	C0030054
28272227	633	640	January	T080	C3829466
28272227	649	656	January	T080	C3829466
28272227	680	689	inflation	T061	C1283105
28272227	699	704	xenon	T121,T196	C0043339
28272227	710	717	January	T080	C3829466
28272227	726	734	December	T080	C3830550
28272227	748	751	CPB	T061	C0007202
28272227	757	762	lungs	T023	C0024109
28272227	768	776	inflated	T061	C1283105
28272227	793	798	xenon	T121,T196	C0043339
28272227	800	811	xenon group	UnknownType	C0681860
28272227	820	826	oxygen	T121,T123,T196	C0030054
28272227	828	841	control group	T096	C0009932
28272227	858	873	airway pressure	T201	C0428719
28272227	891	906	primary outcome	T169	C1274040
28272227	911	928	oxygenation index	T059	C1278185
28272227	930	932	OI	T059	C1278185
28272227	934	939	value	T081	C1522609
28272227	946	956	intubation	T061	C0021925
28272227	965	972	minutes	T079	C0439232
28272227	979	984	hours	T079	C0439227
28272227	995	1004	operation	T061	C0543467
28272227	1010	1024	second outcome	T169	C1274040
28272227	1029	1037	cytokine	T116,T129	C0079189
28272227	1042	1065	reactive oxygen species	T123,T196	C0162772
28272227	1066	1072	levels	T080	C0441889
28272227	1079	1089	intubation	T061	C0021925
28272227	1097	1104	minutes	T079	C0439232
28272227	1108	1113	hours	T079	C0439227
28272227	1122	1127	hours	T079	C0439227
28272227	1138	1147	operation	T061	C0543467
28272227	1149	1157	Patients	T101	C0030705
28272227	1171	1176	xenon	T121,T196	C0043339
28272227	1187	1189	OI	T059	C1278185
28272227	1190	1196	levels	T080	C0441889
28272227	1213	1226	control group	T096	C0009932
28272227	1234	1241	surgery	T061	C0543467
28272227	1274	1287	no difference	T033	C3842396
28272227	1291	1304	postoperative	T079	C0032790
28272227	1305	1311	values	T081	C1522609
28272227	1326	1332	groups	UnknownType	C0681860
28272227	1344	1351	surgery	T061	C0543467
28272227	1353	1357	mean	T081	C0444504
28272227	1358	1365	maximal	T081	C0806909
28272227	1366	1368	OI	T059	C1278185
28272227	1369	1375	values	T081	C1522609
28272227	1376	1385	decreased	T081	C0205216
28272227	1427	1432	xenon	UnknownType	C0681860
28272227	1437	1451	control groups	T096	C0009932
28272227	1459	1466	surgery	T061	C0543467
28272227	1472	1478	levels	T080	C0441889
28272227	1482	1495	interleukin-6	T116,T129	C0021760
28272227	1497	1501	IL-6	T116,T129	C0021760
28272227	1504	1531	tumor necrosis factor alpha	T116,T129	C1456820
28272227	1537	1551	thromboxane B2	T109,T123	C0040059
28272227	1552	1561	decreased	T081	C0205216
28272227	1610	1621	xenon group	UnknownType	C0681860
28272227	1627	1636	increased	T081	C0205217
28272227	1686	1699	control group	T096	C0009932
28272227	1711	1716	IL-10	T116,T129	C0085295
28272227	1717	1723	levels	T080	C0441889
28272227	1724	1733	increased	T081	C0205217
28272227	1748	1759	xenon group	UnknownType	C0681860
28272227	1764	1773	decreased	T081	C0205216
28272227	1789	1802	control group	T096	C0009932
28272227	1827	1831	time	T079	C0040223
28272227	1836	1845	treatment	T061	C0087111
28272227	1848	1852	time	T079	C0040223
28272227	1853	1864	interaction	T169	C1704675
28272227	1865	1872	effects	T080	C1280500
28272227	1876	1905	methane dicarboxylic aldehyde	T123	C0574031
28272227	1950	1965	myeloperoxidase	T116,T126	C0027021
28272227	1994	1999	xenon	UnknownType	C0681860
28272227	2004	2018	control groups	T096	C0009932
28272227	2045	2058	no difference	T033	C3842396
28272227	2062	2080	hospital mortality	T080	C0085556
28272227	2092	2105	survival rate	T081	C0038954
28272227	2120	2126	groups	UnknownType	C0681860
28272227	2128	2137	Pulmonary	T023	C0024109
28272227	2138	2154	static inflation	T061	C1283105
28272227	2164	2169	xenon	T121,T196	C0043339
28272227	2177	2180	CPB	T061	C0007202
28272227	2197	2199	OI	T059	C1278185
28272227	2200	2209	decreases	T081	C0547047
28272227	2224	2231	surgery	T061	C0543467
28272227	2236	2255	Stanford type A AAD	T047	C0241868
28272227	2263	2268	xenon	T121,T196	C0043339
28272227	2273	2281	function	T169	C0542341
28272227	2296	2323	anti-inflammatory responses	T080	C1515999
28272227	2328	2339	suppressing	T169	C1260953
28272227	2340	2356	pro-inflammatory	T169	C0333348
28272227	2361	2370	oxidative	T169	C0311404
28272227	2371	2378	effects	T080	C1280500

27754781|t|Quantification of leakage of sub-micron aerosols through surgical masks and facemasks for pediatric use
27754781|a|Surgical respirators, surgical masks (SMs), and facemasks for pediatric use (FPUs) are routinely used in the U.S. healthcare industry as personal protective equipment (PPE) against infectious diseases. While N95s including surgical respirators have been routinely studied, SMs and FPUs have not received as much attention, particularly in the context of aerosolized threats. This is because SMs and PFUs are not designed to protect against sub-micron aerosols. However, with the possibility of new or re-emerging airborne diseases or bio-aerosol weapons lingering, combined with the limited availability of respirators and logistical issues associated with fit-testing millions, the general adult and pediatric populations may elect to wear SMs and FPUs, respectively, in the case of a pandemic or a bio-terrorist attack. When a person dons a PPE, gaps are created between the wearer's face and the PPE, and aerosols leaking through these gaps can be an important contributor to the risk of infection compared to filtered aerosols. To understand and quantify the contribution of leakage of aerosols through gaps, with particular emphasis on SMs and FPUs, this study investigated leakage of charge-neutralized, polydispersed, dried sodium-chloride aerosols across different brands of PPE. Different breathing rates, aerosol particle sizes, and gap sizes were considered. A few major findings of this study were: (a) leakage, is not a strong function of sub-micron aerosol size; (b) for the same gap size, leakage of aerosols through surgical respirators can often be higher than in SMs and FPUs; and (c) as the gap size increases, the increase in leakage through surgical respirators is higher compared for SMs and FPUs, implying that some SMs and FPUs that possess electret layers may be preferable to N95s that have not been fit-tested. The results obtained can also be used to explain conflicting findings from clinical studies on the effectiveness of SMs when compared to N95s and can be input into risk-assessment models to determine the increase in infection rate resulting from deployment of PPE under less-than-ideal conditions.
27754781	0	14	Quantification	T081	C1709793
27754781	18	25	leakage	T033	C4281748
27754781	29	39	sub-micron	T081	C0392762
27754781	40	48	aerosols	T073	C0001712
27754781	49	56	through	T169	C0332273
27754781	57	71	surgical masks	T074	C0181758
27754781	76	85	facemasks	T074	C0024861
27754781	90	99	pediatric	T080	C1521725
27754781	100	103	use	T169	C0457083
27754781	104	124	Surgical respirators	T074	C0677448
27754781	126	140	surgical masks	T074	C0181758
27754781	142	145	SMs	T074	C0181758
27754781	152	161	facemasks	T074	C0024861
27754781	166	175	pediatric	T080	C1521725
27754781	181	185	FPUs	T074	C0024861
27754781	213	216	U.S	T083	C0041703
27754781	218	237	healthcare industry	T093	C0525051
27754781	241	270	personal protective equipment	T073	C1443871
27754781	272	275	PPE	T073	C1443871
27754781	277	284	against	T080	C0521124
27754781	285	304	infectious diseases	T047	C0009450
27754781	312	316	N95s	T061	C2922048
27754781	317	326	including	T169	C0332257
27754781	327	347	surgical respirators	T074	C0677448
27754781	377	380	SMs	T074	C0181758
27754781	385	389	FPUs	T074	C0024861
27754781	395	407	not received	T033	C3845783
27754781	416	425	attention	T041	C0004268
27754781	447	454	context	T078	C0449255
27754781	458	469	aerosolized	T073	C0001712
27754781	470	477	threats	T078	C0749385
27754781	495	498	SMs	T074	C0181758
27754781	503	507	PFUs	T074	C0024861
27754781	528	535	protect	T169	C1553199
27754781	536	543	against	T080	C0521124
27754781	544	554	sub-micron	T081	C0392762
27754781	555	563	aerosols	T073	C0001712
27754781	617	625	airborne	T169	C3242389
27754781	626	634	diseases	T047	C0012634
27754781	638	667	bio-aerosol weapons lingering	T037	C0481107
27754781	669	677	combined	T080	C0205195
27754781	687	694	limited	T169	C0439801
27754781	695	710	availability of	T169	C0470187
27754781	711	722	respirators	T074	C0087153
27754781	745	760	associated with	T080	C0332281
27754781	761	772	fit-testing	T057	C0337137
27754781	795	800	adult	T100	C0001675
27754781	805	814	pediatric	T080	C1521725
27754781	815	826	populations	T098	C1257890
27754781	831	844	elect to wear	T033	C0243095
27754781	845	848	SMs	T074	C0181758
27754781	853	857	FPUs	T074	C0024861
27754781	890	898	pandemic	T067	C1615608
27754781	904	924	bio-terrorist attack	T051	C1443843
27754781	933	939	person	T098	C0027361
27754781	947	950	PPE	T073	C1443871
27754781	952	956	gaps	T082	C3887622
27754781	981	994	wearer's face	T029	C0015450
27754781	1003	1006	PPE	T073	C1443871
27754781	1012	1020	aerosols	T073	C0001712
27754781	1021	1028	leaking	T169	C0332234
27754781	1029	1036	through	T169	C0332273
27754781	1043	1047	gaps	T082	C3887622
27754781	1087	1104	risk of infection	T033	C0582147
27754781	1105	1113	compared	T052	C1707455
27754781	1117	1125	filtered	T068	C0016107
27754781	1126	1134	aerosols	T073	C0001712
27754781	1154	1162	quantify	T081	C1709793
27754781	1167	1179	contribution	T052	C1880177
27754781	1183	1190	leakage	T033	C4281748
27754781	1194	1202	aerosols	T073	C0001712
27754781	1203	1210	through	T169	C0332273
27754781	1211	1215	gaps	T082	C3887622
27754781	1245	1248	SMs	T074	C0181758
27754781	1253	1257	FPUs	T074	C0024861
27754781	1270	1282	investigated	T169	C1292732
27754781	1283	1290	leakage	T033	C4281748
27754781	1294	1312	charge-neutralized	T067	C2825492
27754781	1314	1327	polydispersed	T077	C3641149
27754781	1329	1334	dried	T080	C1512080
27754781	1335	1350	sodium-chloride	T121,T123,T197	C0037494
27754781	1351	1359	aerosols	T073	C0001712
27754781	1367	1376	different	T080	C1705242
27754781	1377	1383	brands	T170	C0592503
27754781	1387	1390	PPE	T073	C1443871
27754781	1392	1401	Different	T080	C1705242
27754781	1402	1417	breathing rates	T201	C0231832
27754781	1419	1426	aerosol	T073	C0001712
27754781	1427	1441	particle sizes	T081	C0030608
27754781	1447	1456	gap sizes	T082	C0456389
27754781	1480	1485	major	T080	C0205164
27754781	1486	1494	findings	T169	C2607943
27754781	1519	1526	leakage	T033	C4281748
27754781	1537	1543	strong	T080	C0442821
27754781	1544	1552	function	T169	C0542341
27754781	1556	1566	sub-micron	T081	C0392762
27754781	1567	1574	aerosol	T073	C0001712
27754781	1575	1579	size	T082	C0456389
27754781	1598	1606	gap size	T082	C0456389
27754781	1608	1615	leakage	T033	C4281748
27754781	1619	1627	aerosols	T073	C0001712
27754781	1628	1635	through	T169	C0332273
27754781	1636	1656	surgical respirators	T074	C0677448
27754781	1670	1676	higher	T080	C0205250
27754781	1685	1688	SMs	T074	C0181758
27754781	1693	1697	FPUs	T074	C0024861
27754781	1714	1722	gap size	T082	C0456389
27754781	1723	1732	increases	T169	C0442805
27754781	1738	1746	increase	T169	C0442805
27754781	1750	1757	leakage	T033	C4281748
27754781	1758	1765	through	T169	C0332273
27754781	1766	1786	surgical respirators	T074	C0677448
27754781	1797	1805	compared	T052	C1707455
27754781	1810	1813	SMs	T074	C0181758
27754781	1818	1822	FPUs	T074	C0024861
27754781	1843	1846	SMs	T074	C0181758
27754781	1851	1855	FPUs	T074	C0024861
27754781	1861	1868	possess	T078	C3154893
27754781	1869	1884	electret layers	T080	C0205556
27754781	1906	1910	N95s	T061	C2922048
27754781	1930	1940	fit-tested	T057	C0337137
27754781	2017	2033	clinical studies	T062	C0008972
27754781	2041	2054	effectiveness	T080	C1280519
27754781	2058	2061	SMs	T074	C0181758
27754781	2067	2075	compared	T052	C1707455
27754781	2079	2083	N95s	T061	C2922048
27754781	2106	2128	risk-assessment models	T170	C0282574
27754781	2146	2154	increase	T169	C0442805
27754781	2158	2167	infection	T046	C3714514
27754781	2168	2172	rate	T081	C1521828
27754781	2202	2205	PPE	T073	C1443871

27342342|t|Design and synthesis of pH - sensitive polymeric micelles for oral delivery of poorly water - soluble drugs
27342342|a|pH - sensitive polymer poly (polylactide-co-methacrylic acid)-b-poly (acrylic acid) was synthesized using atom transfer radical polymerization and ring-opening polymerization and characterized by gel permeation chromatography and (1)H NMR. The polymers can self-assemble to form micelles in aqueous medium, which respond rapidly to pH change within the gastrointestinal relevant pH range. Critical micelle concentrations and pH response behavior of the polymeri c micelle were investigated. Water - insoluble drug nifedipine was loaded and the drug - loading content can be controlled by tuning the composition of the polymers. The in vitro release studies indicate pH sensitivity enabled rapid drug release at the environment of simulated intestinal fluid (pH 7.36), the cumulative released amount of NFD reached more than 80% within 24 h, while only 35% in the simulated gastric fluid (pH 1.35). All the results showed that the pH - sensitive P(PLAMA-co-MAA)-b-PAA micelle may be a prospective candidate as oral drug delivery carrier for hydrophobic drugs with controlled release behavior.
27342342	0	6	Design	T052	C1707689
27342342	11	20	synthesis	T052	C1883254
27342342	24	26	pH	T081	C0020283
27342342	29	38	sensitive	T169	C0332324
27342342	39	48	polymeric	T104,T122	C0032521
27342342	49	57	micelles	T109	C0025938
27342342	62	66	oral	T030	C0226896
27342342	67	75	delivery	T074	C0085104
27342342	79	85	poorly	T080	C0542537
27342342	86	91	water	T121,T197	C0043047
27342342	94	101	soluble	T080	C1948047
27342342	102	107	drugs	T121	C0013227
27342342	108	110	pH	T081	C0020283
27342342	113	122	sensitive	T169	C0332324
27342342	123	130	polymer	T104,T122	C0032521
27342342	131	191	poly (polylactide-co-methacrylic acid)-b-poly (acrylic acid)	T104,T122	C0032521
27342342	196	207	synthesized	T052	C1883254
27342342	214	250	atom transfer radical polymerization	T067	C0314672
27342342	255	282	ring-opening polymerization	T067	C0314672
27342342	304	333	gel permeation chromatography	T059	C0008559
27342342	338	346	(1)H NMR	T060	C3850001
27342342	352	360	polymers	T104,T122	C0032521
27342342	365	378	self-assemble	T052	C1706853
27342342	387	395	micelles	T109	C0025938
27342342	399	413	aqueous medium	T121	C3255993
27342342	440	442	pH	T081	C0020283
27342342	443	449	change	T169	C0392747
27342342	461	477	gastrointestinal	T082	C0521362
27342342	478	486	relevant	T080	C2347946
27342342	487	489	pH	T081	C0020283
27342342	506	513	micelle	T109	C0025938
27342342	514	528	concentrations	T081	C1446561
27342342	533	535	pH	T081	C0020283
27342342	561	569	polymeri	T104,T122	C0032521
27342342	572	579	micelle	T109	C0025938
27342342	599	604	Water	T121,T197	C0043047
27342342	607	616	insoluble	T033	C0243095
27342342	617	621	drug	T121	C0013227
27342342	622	632	nifedipine	T109,T121	C0028066
27342342	637	643	loaded	T052	C1708715
27342342	652	656	drug	T121	C0013227
27342342	659	666	loading	T052	C1708715
27342342	707	718	composition	T201	C0486616
27342342	726	734	polymers	T104,T122	C0032521
27342342	740	748	in vitro	T080	C1533691
27342342	749	756	release	T070	C3850077
27342342	757	764	studies	T062	C0008972
27342342	774	776	pH	T081	C0020283
27342342	777	788	sensitivity	T169	C0332324
27342342	803	815	drug release	T070	C3850077
27342342	823	834	environment	T082	C0014406
27342342	848	864	intestinal fluid	T031	C0162367
27342342	866	868	pH	T081	C0020283
27342342	880	890	cumulative	T080	C1511559
27342342	910	913	NFD	T109,T121	C0028066
27342342	981	994	gastric fluid	T031	C2828094
27342342	996	998	pH	T081	C0020283
27342342	1038	1040	pH	T081	C0020283
27342342	1043	1052	sensitive	T169	C0332324
27342342	1053	1074	P(PLAMA-co-MAA)-b-PAA	T104,T122	C0032521
27342342	1075	1082	micelle	T109	C0025938
27342342	1117	1121	oral	T030	C0226896
27342342	1122	1126	drug	T121	C0013227
27342342	1127	1143	delivery carrier	T122	C0013161
27342342	1148	1159	hydrophobic	T080	C0598629
27342342	1160	1165	drugs	T121	C0013227
27342342	1171	1189	controlled release	T079	C0868939

27507385|t|A Practical Guide to Forensic Nursing: Incorporating forensic principles into nursing practice Amar Angela F and Sekula L Kathleen A Practical Guide to Forensic Nursing: Incorporating forensic principles into nursing practice 392pp US$59.95 Sigma Theta Tau International Honor Society of Nursing 9781940446349 1940446341 [Formula: see text
27507385|a|George Bernard Shaw described Britons and Americans as ' divided by a common language ', and that is made very clear in this fascinating publication that describes in depth the roles and responsibilities of forensic nurses in the US.
27507385	2	17	Practical Guide	T097	C0181090
27507385	21	37	Forensic Nursing	T091	C1721027
27507385	39	52	Incorporating	T169	C0332257
27507385	53	61	forensic	T091	C1721027
27507385	62	72	principles	T081	C1882460
27507385	78	94	nursing practice	T058	C0028687
27507385	95	108	Amar Angela F	T016	C0086418
27507385	113	130	Sekula L Kathleen	T016	C0086418
27507385	133	148	Practical Guide	T097	C0181090
27507385	152	168	Forensic Nursing	T091	C1721027
27507385	184	192	forensic	T091	C1721027
27507385	193	203	principles	T081	C1882460
27507385	209	225	nursing practice	T058	C0028687
27507385	340	359	George Bernard Shaw	T016	C0086418
27507385	370	377	Britons	T098	C0337925
27507385	382	391	Americans	T098	C0596070
27507385	397	404	divided	T169	C0332849
27507385	410	425	common language	T171	C0023008
27507385	465	488	fascinating publication	T073,T170	C0034036
27507385	517	543	roles and responsibilities	T170	C3890565
27507385	547	562	forensic nurses	T097	C0028661
27507385	570	572	US	T083	C0041703

27373689|t|A novel, lineage - primed prestalk cell subtype involved in the morphogenesis of D. discoideum
27373689|a|Dictyostelium morphogenesis requires the tip, which acts as an organizer and conducts orchestrated cell movement and cell differentiation. At the slug stage the tip region contains prestalk A (pstA) cells, which are usually recognized by their expression of reporter constructs that utilize a fragment of the promoter of the ecmA gene. Here, using the promoter region of the o-methyl transferase 12 gene (omt12) to drive reporter expression, we demonstrate the presence, also within the pstA region, of a novel prestalk cell subtype: the pstV(A) cells. Surprisingly, a sub-population of the vegetative cells express a pstV(A): GFP marker and, sort out to the tip, both when developing alone and when co-developed with an excess of unmarked cells. The development of such a purified GFP-marked population is greatly accelerated: by precocious cell aggregation and tip formation with accompanying precocious elevation of developmental gene transcription. We therefore suggest that the tip contains at least two prestalk cell subtypes: the developmentally - specified pstA cells and the lineage - primed pstV(A) cells. It is presumably the pstV(A) cells that play the dominant role in morphogenesis during the earlier stages of development. The basis for the lineage priming is, however, unclear because we can find no correlation between pstV(A) differentiation and nutrient status during growth or cell cycle position at the time of starvation, the two known determinants of probable cell fate.
27373689	9	16	lineage	T078	C0282637
27373689	19	25	primed	T169	C0871133
27373689	26	39	prestalk cell	T025	C0007634
27373689	40	47	subtype	T185	C0449560
27373689	64	77	morphogenesis	T040	C0026559
27373689	81	94	D. discoideum	T204	C0086149
27373689	95	108	Dictyostelium	T204	C0012120
27373689	109	122	morphogenesis	T040	C0026559
27373689	136	139	tip	T082	C1254362
27373689	158	167	organizer	T074	C2609570
27373689	181	207	orchestrated cell movement	T040	C1621968
27373689	212	232	cell differentiation	T043	C0007589
27373689	241	245	slug	T204	C0324024
27373689	256	266	tip region	T082	C1254362
27373689	276	299	prestalk A (pstA) cells	T025	C0007634
27373689	339	349	expression	T045	C0017262
27373689	353	372	reporter constructs	T028	C0206414
27373689	388	399	fragment of	T169	C0332255
27373689	404	412	promoter	T114,T123	C0033413
27373689	420	429	ecmA gene	T028	C1333497
27373689	447	462	promoter region	T114,T123	C0033413
27373689	470	498	o-methyl transferase 12 gene	T028	C0017337
27373689	500	505	omt12	T028	C0017337
27373689	516	536	reporter expression,	T045	C0017262
27373689	582	593	pstA region	T082	C1254362
27373689	606	619	prestalk cell	T025	C0007634
27373689	620	627	subtype	T185	C0449560
27373689	633	646	pstV(A) cells	T025	C0007634
27373689	686	702	vegetative cells	T043	C3714713
27373689	713	732	pstV(A): GFP marker	T045	C0017393
27373689	754	757	tip	T082	C1254362
27373689	826	840	unmarked cells	T025	C0007634
27373689	846	857	development	T169	C1527148
27373689	877	898	GFP-marked population	T025	C0007634
27373689	910	921	accelerated	T169	C0521110
27373689	937	953	cell aggregation	T043	C0007580
27373689	958	961	tip	T082	C1254362
27373689	962	971	formation	T169	C1522492
27373689	990	1000	precocious	T079	C1279930
27373689	1001	1010	elevation	T082	C0702240
27373689	1014	1027	developmental	T080	C0458003
27373689	1028	1046	gene transcription	T045	C0040649
27373689	1078	1081	tip	T082	C1254362
27373689	1104	1117	prestalk cell	T025	C0007634
27373689	1118	1126	subtypes	T185	C0449560
27373689	1132	1147	developmentally	T080	C0458003
27373689	1150	1170	specified pstA cells	T025	C0007634
27373689	1179	1186	lineage	T078	C0282637
27373689	1189	1195	primed	T169	C0871133
27373689	1196	1209	pstV(A) cells	T025	C0007634
27373689	1232	1245	pstV(A) cells	T025	C0007634
27373689	1277	1290	morphogenesis	T040	C0026559
27373689	1310	1316	stages	T079	C1306673
27373689	1320	1331	development	T043	C0815089
27373689	1351	1358	lineage	T078	C0282637
27373689	1359	1366	priming	T169	C0871133
27373689	1411	1422	correlation	T080	C1707520
27373689	1431	1454	pstV(A) differentiation	T043	C0007589
27373689	1459	1467	nutrient	T168	C0678695
27373689	1468	1474	status	T080	C0449438
27373689	1482	1488	growth	T040	C0018270
27373689	1492	1511	cell cycle position	T043	C0007586
27373689	1527	1537	starvation	T033	C0038187
27373689	1553	1565	determinants	T169	C1521761
27373689	1578	1587	cell fate	T043	C1540661

28127799|t|TBL1XR1 predicts isolated tumor cells and micrometastasis in patients with TNM stage I/II colorectal cancer
28127799|a|A considerable number of early stage colorectal cancer (CRC) patients may develop cancer relapse or metastasis after curative surgery. Isolated tumor cells (ITC) and micrometastasis in lymph nodes (LNMM), which are undetectable by conventional pathological examination, may be one primary reason. Detection of ITC / LNMM is time-consuming and cost-ineffective, we aimed to find biomarkers in primary CRC tissues to help predicting ITC / LNMM status. We enrolled 137 node-negative patients with early stage CRC in this study. Existence of ITC / LNMM was identified by immunohistological staining with cytokeratin 20 in resected lymph nodes. Expression of transducin (β)-like 1 X-linked receptor 1 (TBL1XR1) in primary CRC tissues was also investigated. Chi-square test was performed to reveal the correlations between ITC / LNMM and clinicopathological characteristics. Univariate and multivariate analyses were used to determine independent prognostic factors. Knock-down experiment together with proliferation and invasion assays were carried out to explore molecular mechanisms between TBL1XR1 and ITC / LNMM. 29.2% (40/137) patients were identified as ITC / LNMM positive and most of them (32/40 cases, 80%) showed high TBL1XR1 expression in primary CRC tissues. Both ITC / LNMM and TBL1XR1 expression were independent prognostic factors for disease relapse or metastasis. In vitro experiments demonstrated that TBL1XR1 can regulate the expression of VEGF-C and epithelial-mesenchymal transition proteins, thus mediate the process of lymph node metastasis. Identification of ITC / LNMM is significant in evaluating clinical outcome and guiding adjuvant chemotherapy for early stage CRC patients. TBL1XR1 overexpression in CRC tissues can serve as an efficient biomarker to predict the status of ITC / LNMM.
28127799	0	7	TBL1XR1	T116,T123	C1176196
28127799	8	16	predicts	T078	C0681842
28127799	17	37	isolated tumor cells	T033	C3829491
28127799	42	57	micrometastasis	T033	C1513276
28127799	61	69	patients	T101	C0030705
28127799	75	89	TNM stage I/II	T185	C1515169
28127799	90	107	colorectal cancer	T191	C1527249
28127799	110	129	considerable number	T081	C0237753
28127799	133	144	early stage	T079	C2363430
28127799	145	162	colorectal cancer	T191	C1527249
28127799	164	167	CRC	T191	C1527249
28127799	169	177	patients	T101	C0030705
28127799	190	204	cancer relapse	T191	C0699753
28127799	208	218	metastasis	T191	C0027627
28127799	225	241	curative surgery	T061	C1511562
28127799	243	263	Isolated tumor cells	T033	C3829491
28127799	265	268	ITC	T033	C3829491
28127799	274	289	micrometastasis	T033	C1513276
28127799	293	304	lymph nodes	T023	C0024204
28127799	306	310	LNMM	T191	C0024232
28127799	323	335	undetectable	T201	C3827727
28127799	339	351	conventional	T080	C0439858
28127799	352	376	pathological examination	T058	C0582103
28127799	389	403	primary reason	T078	C1549995
28127799	405	414	Detection	T061	C1511790
28127799	418	421	ITC	T033	C3829491
28127799	424	428	LNMM	T191	C0024232
28127799	432	446	time-consuming	T080	C3827829
28127799	451	467	cost-ineffective	T081	C0392762
28127799	472	477	aimed	T078	C1947946
28127799	481	485	find	T033	C0243095
28127799	486	496	biomarkers	T201	C0005516
28127799	500	507	primary	T080	C0205225
28127799	508	511	CRC	T191	C1527249
28127799	512	519	tissues	T024	C0040300
28127799	528	538	predicting	T078	C0681842
28127799	539	542	ITC	T033	C3829491
28127799	545	549	LNMM	T191	C0024232
28127799	550	556	status	T080	C0449438
28127799	574	587	node-negative	T033	C0678034
28127799	588	596	patients	T101	C0030705
28127799	602	613	early stage	T079	C2363430
28127799	614	617	CRC	T191	C1527249
28127799	626	631	study	T062	C0681814
28127799	633	642	Existence	T077	C2987476
28127799	646	649	ITC	T033	C3829491
28127799	652	656	LNMM	T191	C0024232
28127799	661	671	identified	T080	C0205396
28127799	675	702	immunohistological staining	T059	C0487602
28127799	708	722	cytokeratin 20	T116,T123	C0219510
28127799	726	734	resected	T080	C1521996
28127799	735	746	lymph nodes	T023	C0024204
28127799	748	758	Expression	T045	C1171362
28127799	762	803	transducin (β)-like 1 X-linked receptor 1	T116,T123	C1176196
28127799	805	812	TBL1XR1	T116,T123	C1176196
28127799	817	824	primary	T080	C0205225
28127799	825	828	CRC	T191	C1527249
28127799	829	836	tissues	T024	C0040300
28127799	846	858	investigated	T169	C1292732
28127799	860	875	Chi-square test	T170	C0008041
28127799	880	889	performed	T169	C0884358
28127799	893	899	reveal	T080	C0443289
28127799	904	916	correlations	T080	C1707520
28127799	925	928	ITC	T033	C3829491
28127799	931	935	LNMM	T191	C0024232
28127799	940	959	clinicopathological	T169	C1521733
28127799	960	975	characteristics	T080	C1521970
28127799	977	987	Univariate	T062	C0683962
28127799	992	1013	multivariate analyses	T081	C0026777
28127799	1037	1048	independent	T169	C0332291
28127799	1049	1067	prognostic factors	T201	C1514474
28127799	1069	1090	Knock-down experiment	T063	C2350567
28127799	1091	1099	together	T080	C1883357
28127799	1105	1118	proliferation	T046	C0334094
28127799	1123	1131	invasion	T046	C2699153
28127799	1132	1138	assays	T059	C0005507
28127799	1167	1187	molecular mechanisms	T044	C3537153
28127799	1196	1203	TBL1XR1	T116,T123	C1176196
28127799	1208	1211	ITC	T033	C3829491
28127799	1214	1218	LNMM	T191	C0024232
28127799	1235	1243	patients	T101	C0030705
28127799	1249	1259	identified	T080	C0205396
28127799	1263	1266	ITC	T033	C3829491
28127799	1269	1273	LNMM	T191	C0024232
28127799	1274	1282	positive	T033	C1446409
28127799	1326	1330	high	T080	C0205250
28127799	1331	1338	TBL1XR1	T116,T123	C1176196
28127799	1339	1349	expression	T045	C1171362
28127799	1353	1360	primary	T080	C0205225
28127799	1361	1364	CRC	T191	C1527249
28127799	1365	1372	tissues	T024	C0040300
28127799	1374	1378	Both	T080	C1706086
28127799	1379	1382	ITC	T033	C3829491
28127799	1385	1389	LNMM	T191	C0024232
28127799	1394	1401	TBL1XR1	T116,T123	C1176196
28127799	1402	1412	expression	T045	C1171362
28127799	1418	1429	independent	T169	C0332291
28127799	1430	1448	prognostic factors	T201	C1514474
28127799	1453	1468	disease relapse	T047	C0277556
28127799	1472	1482	metastasis	T191	C0027627
28127799	1484	1492	In vitro	T080	C1533691
28127799	1493	1504	experiments	T062	C0681814
28127799	1505	1517	demonstrated	T080	C0443289
28127799	1523	1530	TBL1XR1	T116,T123	C1176196
28127799	1535	1543	regulate	T169	C2587213
28127799	1548	1558	expression	T045	C1171362
28127799	1562	1568	VEGF-C	T116,T123	C0388911
28127799	1573	1595	epithelial-mesenchymal	T025	C1181295
28127799	1596	1615	transition proteins	T116,T123	C0033684
28127799	1634	1641	process	T067	C1522240
28127799	1645	1666	lymph node metastasis	T191	C0024232
28127799	1668	1682	Identification	T080	C0205396
28127799	1686	1689	ITC	T033	C3829491
28127799	1692	1696	LNMM	T191	C0024232
28127799	1700	1711	significant	T078	C0750502
28127799	1726	1742	clinical outcome	T169	C1274040
28127799	1755	1776	adjuvant chemotherapy	T061	C0085533
28127799	1781	1792	early stage	T079	C2363430
28127799	1793	1796	CRC	T191	C1527249
28127799	1797	1805	patients	T101	C0030705
28127799	1807	1814	TBL1XR1	T116,T123	C1176196
28127799	1815	1829	overexpression	T045	C0017262
28127799	1833	1836	CRC	T191	C1527249
28127799	1837	1844	tissues	T024	C0040300
28127799	1861	1870	efficient	T080	C0442799
28127799	1871	1880	biomarker	T201	C0005516
28127799	1884	1891	predict	T078	C0681842
28127799	1896	1902	status	T080	C0449438
28127799	1906	1909	ITC	T033	C3829491
28127799	1912	1916	LNMM	T191	C0024232

28469987|t|Efficacy of a multi-component psychosocial intervention program for caregivers of persons living with neurocognitive disorders, Alexandria, Egypt: A randomized controlled trial
28469987|a|Unlike other chronic diseases, dementia caregiving associated with enormous psychological burden, which stresses the need for caregivers -directed psychosocial interventions. Aim: This randomized controlled trial (RCT) was conducted to evaluate the short-term efficacy of a multi-component psychosocial intervention program for informal caregivers of persons with neurocognitive disorders in Alexandria, Egypt. Informal caregivers (120) were randomly assigned into intervention and control groups. The intervention group (60) participated in a multi-component program of 8 sessions, including psycho-education, group cognitive-behavioral therapy, and group social support. Program primary outcomes were assessed after program termination (post-1), and three months later (post-2). Measured outcomes included caregivers ' knowledge, depression and anxiety symptoms, and perceived burden. Caregivers ' depression, anxiety, and perceived burden demonstrated significant drop at post-1, and post-2 compared to the control group (P< 0.001). The intervention group showed significant negative absolute change on depression, anxiety, and perceived burden measures, while on the dementia -related knowledge measure, a significant positive absolute change was found at post-1, and post-2 (P< 0.001), in comparison to controls. All outcome measures recorded a large effect size; the highest was for knowledge (partial eta2 = 0.98), and the least was for perceived burden (partial eta2 = 0.71). A multi-component psychosocial intervention for caregivers of persons with neurocognitive disorders demonstrated a short-term efficacy in reducing their burden, depression, and anxiety, as well as improving caregivers ' knowledge. However, further research is needed to investigate long-term efficacy of the intervention.
28469987	0	8	Efficacy	T080	C1280519
28469987	14	55	multi-component psychosocial intervention	T061	C0454041
28469987	56	63	program	T061	C0599917
28469987	68	78	caregivers	T097	C0085537
28469987	82	89	persons	T098	C0027361
28469987	90	96	living	T078	C0376558
28469987	102	126	neurocognitive disorders	T048	C4041080
28469987	128	138	Alexandria	T083	C3831574
28469987	140	145	Egypt	T083	C0013715
28469987	149	176	randomized controlled trial	T062	C0206035
28469987	190	206	chronic diseases	T047	C0008679
28469987	208	216	dementia	T048	C0497327
28469987	217	227	caregiving	T054	C1328742
28469987	228	243	associated with	T080	C0332281
28469987	253	266	psychological	T169	C0205486
28469987	267	273	burden	T078	C2828008
28469987	303	313	caregivers	T097	C0085537
28469987	324	350	psychosocial interventions	T061	C0454041
28469987	362	389	randomized controlled trial	T062	C0206035
28469987	391	394	RCT	T062	C0206035
28469987	413	421	evaluate	T058	C0220825
28469987	426	436	short-term	T079	C0443303
28469987	437	445	efficacy	T080	C0087113
28469987	451	492	multi-component psychosocial intervention	T061	C0454041
28469987	493	500	program	T061	C0599917
28469987	514	524	caregivers	T097	C0085537
28469987	528	535	persons	T098	C0027361
28469987	541	565	neurocognitive disorders	T048	C4041080
28469987	569	579	Alexandria	T083	C3831574
28469987	581	586	Egypt	T083	C0013715
28469987	597	607	caregivers	T097	C0085537
28469987	628	636	assigned	T169	C1516050
28469987	642	654	intervention	T098	C2986530
28469987	659	673	control groups	T096	C0009932
28469987	679	697	intervention group	T098	C2986530
28469987	721	744	multi-component program	T169	C3484370
28469987	750	758	sessions	T051	C1883016
28469987	770	786	psycho-education	T065	C0871175
28469987	794	822	cognitive-behavioral therapy	T061	C0009244
28469987	834	848	social support	T054	C0037438
28469987	880	888	assessed	T052	C1516048
28469987	958	975	Measured outcomes	T081	C0086749
28469987	985	995	caregivers	T097	C0085537
28469987	998	1007	knowledge	T033	C1948177
28469987	1009	1019	depression	T184	C1579931
28469987	1024	1041	anxiety symptoms,	T033	C0860603
28469987	1046	1062	perceived burden	T033	C1821827
28469987	1064	1074	Caregivers	T097	C0085537
28469987	1077	1087	depression	T184	C1579931
28469987	1089	1096	anxiety	T033	C0003467
28469987	1102	1118	perceived burden	T033	C1821827
28469987	1132	1143	significant	T078	C0750502
28469987	1187	1200	control group	T096	C0009932
28469987	1217	1235	intervention group	T098	C2986530
28469987	1243	1254	significant	T078	C0750502
28469987	1255	1263	negative	T033	C0205160
28469987	1264	1279	absolute change	T078	C1549031
28469987	1283	1293	depression	T184	C1579931
28469987	1295	1302	anxiety	T033	C0003467
28469987	1308	1324	perceived burden	T033	C1821827
28469987	1325	1333	measures	T081	C0079809
28469987	1348	1356	dementia	T048	C0497327
28469987	1366	1375	knowledge	T033	C1948177
28469987	1387	1398	significant	T078	C0750502
28469987	1399	1407	positive	T033	C1446409
28469987	1408	1423	absolute change	T078	C1549031
28469987	1471	1481	comparison	T052	C1707455
28469987	1485	1493	controls	T080	C0243148
28469987	1499	1515	outcome measures	T081	C0086749
28469987	1533	1544	effect size	T081	C0814843
28469987	1566	1575	knowledge	T033	C1948177
28469987	1621	1637	perceived burden	T033	C1821827
28469987	1663	1704	multi-component psychosocial intervention	T061	C0454041
28469987	1709	1719	caregivers	T097	C0085537
28469987	1723	1730	persons	T098	C0027361
28469987	1736	1760	neurocognitive disorders	T048	C4041080
28469987	1776	1786	short-term	T079	C0443303
28469987	1787	1795	efficacy	T080	C0087113
28469987	1814	1820	burden	T078	C2828008
28469987	1822	1832	depression	T184	C1579931
28469987	1838	1845	anxiety	T033	C0003467
28469987	1858	1867	improving	T080	C1272745
28469987	1868	1878	caregivers	T097	C0085537
28469987	1881	1890	knowledge	T033	C1948177
28469987	1909	1917	research	T062	C0035168
28469987	1931	1942	investigate	T169	C1292732
28469987	1943	1952	long-term	T079	C0443252
28469987	1953	1961	efficacy	T080	C0087113
28469987	1969	1981	intervention	T061	C0184661

28429775|t|Fucoxanthin provides neuroprotection in models of traumatic brain injury via the Nrf2 - ARE and Nrf2 - autophagy pathways
28429775|a|Fucoxanthin is abundant in seaweed and is considered as a powerful antioxidant. It has been proposed to possess anti-cancer, anti-obesity and anti-diabetes effects. However, its roles in brain injury models have not been fully understood. The objective of this study was to investigate the neuroprotection of fucoxanthin in models of traumatic brain injury (TBI) and the role of the nuclear factor erythroid 2-related factor 2 (Nrf2)- antioxidant-response element (ARE) and Nrf2 - autophagy pathways in the putative neuroprotection. We found that fucoxanthin alleviated TBI -induced secondary brain injury, including neurological deficits, cerebral edema, brain lesion and neuronal apoptosis. Moreover, the up-regulation of malondialdehyde (MDA) and the activity of glutathione peroxidase (GPx) were reversed by fucoxanthin treatment. Furthermore, our in vitro studies demonstrated that fucoxanthin increased the neuron survival and reduced the reactive oxygen species (ROS) level. In addition, fucoxanthin activated the Nrf2 - ARE pathway and autophagy both in vivo and in vitro, which was proven by the results of immunohistochemistry, western blot and electrophoretic mobility shift assay (EMSA). However, fucoxanthin failed to provide neuroprotection and activated autophagy following TBI in Nrf2 (-/-) mice. In conclusion, our studies indicated that fucoxanthin provided neuroprotective effects in models of TBI, potentially via regulation of the Nrf2 - ARE and Nrf2 - autophagy pathways.
28429775	0	11	Fucoxanthin	T109	C0060808
28429775	21	36	neuroprotection	T043	C0598958
28429775	40	46	models	T075	C0026336
28429775	50	72	traumatic brain injury	T037	C0876926
28429775	81	85	Nrf2	T116,T123	C0289507
28429775	88	91	ARE	T114,T123	C3494205
28429775	96	100	Nrf2	T116,T123	C0289507
28429775	103	121	autophagy pathways	T043	C2265640
28429775	122	133	Fucoxanthin	T109	C0060808
28429775	137	145	abundant	T080	C2346714
28429775	149	156	seaweed	T204	C0036500
28429775	189	200	antioxidant	T121	C0003402
28429775	214	222	proposed	T080	C1553874
28429775	226	233	possess	T078	C3154893
28429775	234	245	anti-cancer	T033	C0243095
28429775	247	259	anti-obesity	T033	C0243095
28429775	264	277	anti-diabetes	T033	C0243095
28429775	278	285	effects	T080	C1280500
28429775	300	305	roles	T077	C1705810
28429775	309	321	brain injury	T037	C0270611
28429775	322	328	models	T075	C0026336
28429775	365	374	objective	T170	C0018017
28429775	383	388	study	T062	C2603343
28429775	396	407	investigate	T169	C1292732
28429775	412	427	neuroprotection	T043	C0598958
28429775	431	442	fucoxanthin	T109	C0060808
28429775	446	452	models	T075	C0026336
28429775	456	478	traumatic brain injury	T037	C0876926
28429775	480	483	TBI	T037	C0876926
28429775	493	497	role	T077	C1705810
28429775	505	548	nuclear factor erythroid 2-related factor 2	T116,T123	C0289507
28429775	550	554	Nrf2	T116,T123	C0289507
28429775	557	585	antioxidant-response element	T114,T123	C3494205
28429775	587	590	ARE	T114,T123	C3494205
28429775	596	600	Nrf2	T116,T123	C0289507
28429775	603	621	autophagy pathways	T043	C2265640
28429775	638	653	neuroprotection	T043	C0598958
28429775	669	680	fucoxanthin	T109	C0060808
28429775	692	695	TBI	T037	C0876926
28429775	705	714	secondary	T080	C0175668
28429775	715	727	brain injury	T037	C0270611
28429775	739	760	neurological deficits	T033	C0521654
28429775	762	776	cerebral edema	T046	C0006114
28429775	778	790	brain lesion	T047	C0221505
28429775	795	803	neuronal	T129	C0521390
28429775	804	813	apoptosis	T043	C0162638
28429775	829	842	up-regulation	T044	C0041904
28429775	846	861	malondialdehyde	T109,T123	C0024643
28429775	863	866	MDA	T109,T123	C0024643
28429775	876	884	activity	T052	C0441655
28429775	888	910	glutathione peroxidase	T116,T126	C0017822
28429775	912	915	GPx	T116,T126	C0017822
28429775	922	930	reversed	T169	C1555029
28429775	934	945	fucoxanthin	T109	C0060808
28429775	946	955	treatment	T169	C1522326
28429775	974	990	in vitro studies	T062	C0681828
28429775	1009	1020	fucoxanthin	T109	C0060808
28429775	1021	1030	increased	T169	C0442805
28429775	1035	1050	neuron survival	T043	C1819944
28429775	1055	1062	reduced	T080	C0392756
28429775	1067	1090	reactive oxygen species	T123,T196	C0162772
28429775	1092	1095	ROS	T123,T196	C0162772
28429775	1097	1102	level	T080	C0441889
28429775	1117	1128	fucoxanthin	T109	C0060808
28429775	1129	1138	activated	T052	C1879547
28429775	1143	1147	Nrf2	T116,T123	C0289507
28429775	1150	1153	ARE	T114,T123	C3494205
28429775	1154	1161	pathway	T077	C1705987
28429775	1166	1175	autophagy	T043	C0004391
28429775	1181	1188	in vivo	T062	C0681829
28429775	1193	1201	in vitro	T062	C0681828
28429775	1213	1219	proven	T080	C0456369
28429775	1227	1234	results	T169	C1274040
28429775	1238	1258	immunohistochemistry	T060	C0021044
28429775	1260	1272	western blot	T059	C0949466
28429775	1277	1313	electrophoretic mobility shift assay	T059	C0949632
28429775	1315	1319	EMSA	T059	C0949632
28429775	1331	1342	fucoxanthin	T109	C0060808
28429775	1343	1349	failed	T169	C0231175
28429775	1361	1376	neuroprotection	T043	C0598958
28429775	1381	1390	activated	T052	C1879547
28429775	1391	1400	autophagy	T043	C0004391
28429775	1411	1414	TBI	T037	C0876926
28429775	1418	1422	Nrf2	T028	C1417699
28429775	1429	1433	mice	T015	C0026809
28429775	1438	1448	conclusion	T078	C1707478
28429775	1454	1461	studies	T062	C2603343
28429775	1477	1488	fucoxanthin	T109	C0060808
28429775	1498	1521	neuroprotective effects	T169	C0815279
28429775	1525	1531	models	T075	C0026336
28429775	1535	1538	TBI	T037	C0876926
28429775	1540	1551	potentially	T080	C3245505
28429775	1556	1566	regulation	T038	C1327622
28429775	1574	1578	Nrf2	T116,T123	C0289507
28429775	1581	1584	ARE	T114,T123	C3494205
28429775	1589	1593	Nrf2	T116,T123	C0289507
28429775	1596	1614	autophagy pathways	T043	C2265640

28413509|t|Effects of siRNA -mediated suppression of HPV-11 L1 expression on the proliferation and apoptosis of vaginal epithelial cells
28413509|a|The aim of the present study was to investigate the effects of human papillomavirus (HPV) infection on the gynecological disease of vaginitis and to demonstrate how the small interfering RNA (siRNA) method may be used for HPV prevention in the clinic. Human vaginal epithelial cells were transfected with HPV-11 L1 expression vector and siRNA - HPV-11 L1 vectors and a control group was transfected with scrambled siRNA. Cell proliferation in each group was analyzed using the MTT assay and the expression of apoptosis -associated proteins was measured by western blot analysis. Compared with the control group, HPV-11 L1 mRNA and protein levels were significantly increased following transfection with the HPV-11 L1 expression vector in cells (P<0.05), but this result was significantly reversed by silencing of HPV-11 L1 (P<0.05). In addition, cell proliferation in the HPV-11 group was lower than that in the control group; however, cell proliferation was significantly increased in cells transfected with silenced L1 compared with that in the control group (P<0.05). Furthermore, silencing of HPV-11 L1 significantly decreased caspase-3 and caspase-9 expressions in cells, whereas the expression was increased in the HPV-11 L1 group (P<0.05). The present study suggested that siRNA -mediated silencing of HPV-11 L1 may have potential therapeutic applications for treating gynecological diseases associated with HPV-11 infection.
28413509	0	10	Effects of	T080	C1704420
28413509	11	16	siRNA	T114,T123	C1099354
28413509	27	38	suppression	T045	C0038855
28413509	42	51	HPV-11 L1	T028	C0017376
28413509	52	62	expression	T045	C0017262
28413509	70	83	proliferation	T043	C0596290
28413509	88	97	apoptosis	T043	C0162638
28413509	101	125	vaginal epithelial cells	T025	C1987256
28413509	130	133	aim	T078	C1947946
28413509	149	154	study	T062	C2603343
28413509	162	173	investigate	T169	C1292732
28413509	178	188	effects of	T080	C1704420
28413509	189	225	human papillomavirus (HPV) infection	T047	C0343641
28413509	233	254	gynecological disease	T047	C1384956
28413509	258	267	vaginitis	T047	C0042267
28413509	295	316	small interfering RNA	T114,T123	C1099354
28413509	318	323	siRNA	T114,T123	C1099354
28413509	348	351	HPV	T005	C0021344
28413509	352	362	prevention	T061	C0199176
28413509	370	376	clinic	T073,T093	C0442592
28413509	378	383	Human	T016	C0086418
28413509	384	408	vaginal epithelial cells	T025	C1987256
28413509	414	425	transfected	T063	C0040669
28413509	431	440	HPV-11 L1	T028	C0017376
28413509	441	458	expression vector	T114	C0599566
28413509	463	468	siRNA	T114,T123	C1099354
28413509	471	480	HPV-11 L1	T028	C0017376
28413509	481	488	vectors	T114	C0017397
28413509	495	508	control group	T096	C0009932
28413509	513	524	transfected	T063	C0040669
28413509	540	545	siRNA	T114,T123	C1099354
28413509	547	565	Cell proliferation	T043	C0596290
28413509	603	612	MTT assay	T059	C1510438
28413509	621	631	expression	T045	C1171362
28413509	635	644	apoptosis	T043	C0162638
28413509	657	665	proteins	T116,T123	C0033684
28413509	670	678	measured	T080	C0444706
28413509	682	703	western blot analysis	T059	C2121086
28413509	705	713	Compared	T052	C1707455
28413509	723	736	control group	T096	C0009932
28413509	738	747	HPV-11 L1	T028	C0017376
28413509	748	752	mRNA	T114,T123	C0035696
28413509	757	771	protein levels	T034	C0428479
28413509	791	800	increased	T081	C0205217
28413509	811	823	transfection	T063	C0040669
28413509	833	842	HPV-11 L1	T028	C0017376
28413509	843	860	expression vector	T114	C0599566
28413509	864	869	cells	T025	C0007634
28413509	926	935	silencing	T045	C0598496
28413509	939	948	HPV-11 L1	T028	C0017376
28413509	972	990	cell proliferation	T043	C0596290
28413509	998	1010	HPV-11 group	T078	C0441833
28413509	1015	1020	lower	T080	C0205251
28413509	1038	1051	control group	T096	C0009932
28413509	1062	1080	cell proliferation	T043	C0596290
28413509	1099	1108	increased	T081	C0205217
28413509	1112	1117	cells	T025	C0007634
28413509	1118	1129	transfected	T063	C0040669
28413509	1135	1143	silenced	T045	C0598496
28413509	1144	1146	L1	T028	C0017376
28413509	1173	1186	control group	T096	C0009932
28413509	1210	1219	silencing	T045	C0598496
28413509	1223	1232	HPV-11 L1	T028	C0017376
28413509	1247	1256	decreased	T081	C0205216
28413509	1257	1266	caspase-3	T028	C1413132
28413509	1271	1280	caspase-9	T028	C1332668
28413509	1281	1292	expressions	T045	C0017262
28413509	1296	1301	cells	T025	C0007634
28413509	1315	1325	expression	T045	C0017262
28413509	1330	1339	increased	T081	C0205217
28413509	1347	1356	HPV-11 L1	T028	C0017376
28413509	1385	1390	study	T062	C2603343
28413509	1406	1411	siRNA	T114,T123	C1099354
28413509	1422	1431	silencing	T045	C0598496
28413509	1435	1444	HPV-11 L1	T028	C0017376
28413509	1464	1488	therapeutic applications	T061	C0278296
28413509	1502	1524	gynecological diseases	T047	C1384956
28413509	1525	1540	associated with	T080	C0332281
28413509	1541	1547	HPV-11	T005	C1093046
28413509	1548	1557	infection	T046	C3714514

28199964|t|Blockade of Rho-associated protein kinase (ROCK) inhibits the contractility and invasion potential of cancer stem like cells
28199964|a|Recent studies have implicated the roles of cancer stem like cells (CSCs) in cancer metastasis. However, very limited knowledge exists at the molecular and cellular level to target CSCs for prevention of cancer metastasis. In this study, we examined the roles of contractile dynamics of CSCs in cell invasion and delineated the underlying molecular mechanisms of their distinct cell invasion potential. Using de-adhesion assay and atomic force microscopy, we show that CSCs derived from melanoma and breast cancer cell lines exhibit increased contractility compared to non-CSCs across all tumor types. In addition, CSCs possess increased ECM remodeling capacity as quantified by collagen degradation assay. More importantly, pharmacological blockade of Rho-associated protein kinase completely abolished the contractility and collagen degradation capacity of both CSCs and non-CSCs. In conclusion, our study demonstrates the importance of cell contractility in regulating invasiveness of CSCs and suggests that pharmacological targeting of ROCK pathway represents a novel strategy for targeting both CSCs and bulk population for the treatment of cancer metastasis.
28199964	0	8	Blockade	T169	C0332206
28199964	12	41	Rho-associated protein kinase	T116,T126	C0389995
28199964	43	47	ROCK	T116,T126	C0389995
28199964	49	57	inhibits	T052	C3463820
28199964	62	75	contractility	T043	C0007613
28199964	80	88	invasion	T046	C2699153
28199964	89	98	potential	T033	C0243095
28199964	102	124	cancer stem like cells	T025	C1956422
28199964	169	191	cancer stem like cells	T025	C1956422
28199964	193	197	CSCs	T025	C1956422
28199964	202	219	cancer metastasis	T191	C2939420
28199964	267	295	molecular and cellular level	T080	C0441889
28199964	299	305	target	T169	C1521840
28199964	306	310	CSCs	T025	C1956422
28199964	315	325	prevention	T080	C2700409
28199964	329	346	cancer metastasis	T191	C2939420
28199964	388	408	contractile dynamics	T070	C3826426
28199964	412	416	CSCs	T025	C1956422
28199964	420	433	cell invasion	T046	C2699153
28199964	464	484	molecular mechanisms	T044	C3537153
28199964	503	516	cell invasion	T046	C2699153
28199964	517	526	potential	T033	C0243095
28199964	534	551	de-adhesion assay	T059	C0022885
28199964	556	579	atomic force microscopy	T059	C0242849
28199964	594	598	CSCs	T025	C1956422
28199964	612	620	melanoma	T025	C1513095
28199964	625	649	breast cancer cell lines	T025	C1512505
28199964	658	667	increased	T081	C0205217
28199964	668	681	contractility	T043	C0007613
28199964	694	702	non-CSCs	T025	C0038250
28199964	714	725	tumor types	T033	C4263544
28199964	740	744	CSCs	T025	C1956422
28199964	753	762	increased	T081	C0205217
28199964	763	766	ECM	T024	C0015350
28199964	767	777	remodeling	UnknownType	C0678692
28199964	778	786	capacity	T081	C1516240
28199964	804	812	collagen	T116	C0009325
28199964	813	830	degradation assay	T059	C0022885
28199964	850	874	pharmacological blockade	T169	C0332206
28199964	878	907	Rho-associated protein kinase	T116,T126	C0389995
28199964	933	946	contractility	T043	C0007613
28199964	951	980	collagen degradation capacity	T044	C1157968
28199964	989	993	CSCs	T025	C1956422
28199964	998	1006	non-CSCs	T025	C0038250
28199964	1069	1082	contractility	T043	C0007613
28199964	1097	1109	invasiveness	T046	C0920779
28199964	1113	1117	CSCs	T025	C1956422
28199964	1136	1161	pharmacological targeting	T043	C0599894
28199964	1165	1169	ROCK	T116,T126	C0389995
28199964	1170	1177	pathway	T044	C1148560
28199964	1210	1219	targeting	T043	C0599894
28199964	1225	1229	CSCs	T025	C1956422
28199964	1258	1267	treatment	T061	C0087111
28199964	1271	1288	cancer metastasis	T191	C2939420

27809747|t|MiR 221 / 222 as new players in tamoxifen resistance
27809747|a|Breast cancer is the most frequent cancer in women. Despite advances in early detection and treatment, it has the second highest mortality rate after lung cancer. Around 85% of breast carcinomas are ER+; thus, antiestrogens like tamoxifen are beneficial. Although, tamoxifen is useful for many patients, plenty of patients respond poorly to initial therapy or recurrence occurs in about 30% of cases, because tamoxifen resistance happens. Drug resistance remains a major clinical obstacle to successful treatment of breast cancer and more than 90% of unsuccessful treatments are because of acquired resistance and MultiDrug Resistance (MDR) is a major contributor. MicroRNAs are members of a novel class of short noncoding RNAs. Besides to their various roles in gene expression, miRNAs are considered as important cancer therapeutic targets and biomarkers. Since 2005, when miRNA deregulation was first reported in breast cancer, more than 1000 reports have been published about miRNAs. Increasing number of studies showed the importance of miRNAs in antiestrogen therapy, especially on tamoxifen; thus, it is not surprising that these tiny molecules are involved in drug resistance. Due to the pivotal role of these known RNA molecules, in this review, we tried to illustrate the importance of the miRNAs as a new player in breast cancer pathogenesis. We have also focused on cancer drug resistance mechanisms highlighting the role of important oncomirs, miR 221 / 222, involved in cell cycle deregulation in breast cancer. The relationship between these oncomiRs with resistance to tamoxifen is also emphasized.
27809747	0	7	MiR 221	T028	C1537859
27809747	10	13	222	T028	C1537860
27809747	32	41	tamoxifen	T109,T121	C0039286
27809747	42	52	resistance	T038	C0013203
27809747	53	66	Breast cancer	T191	C0007104
27809747	88	94	cancer	T191	C0006826
27809747	98	103	women	T098	C0043210
27809747	125	140	early detection	T060	C0596473
27809747	145	154	treatment	T061	C0087111
27809747	182	196	mortality rate	T081	C0205848
27809747	203	214	lung cancer	T191	C0242379
27809747	230	247	breast carcinomas	T191	C0678222
27809747	252	255	ER+	T033	C1971473
27809747	263	276	antiestrogens	T121	C0014930
27809747	282	291	tamoxifen	T109,T121	C0039286
27809747	318	327	tamoxifen	T109,T121	C0039286
27809747	347	355	patients	T101	C0030705
27809747	367	375	patients	T101	C0030705
27809747	376	390	respond poorly	T033	C1320680
27809747	402	409	therapy	T061	C0087111
27809747	413	423	recurrence	T067	C0034897
27809747	462	471	tamoxifen	T109,T121	C0039286
27809747	472	482	resistance	T038	C0013203
27809747	492	507	Drug resistance	T038	C0013203
27809747	524	532	clinical	T080	C0205210
27809747	545	565	successful treatment	T201	C0521982
27809747	569	582	breast cancer	T191	C0007104
27809747	604	627	unsuccessful treatments	T033	C0438286
27809747	643	651	acquired	T080	C0439661
27809747	652	662	resistance	T038	C0013203
27809747	667	687	MultiDrug Resistance	T032	C0242640
27809747	688	693	(MDR)	T032	C0242640
27809747	718	727	MicroRNAs	T114,T123	C1101610
27809747	766	780	noncoding RNAs	T114	C0887909
27809747	816	831	gene expression	T045	C0017262
27809747	833	839	miRNAs	T114,T123	C1101610
27809747	868	874	cancer	T191	C0006826
27809747	875	894	therapeutic targets	T104,T120	C1513403
27809747	899	909	biomarkers	T201	C0005516
27809747	928	933	miRNA	T114,T123	C1101610
27809747	934	946	deregulation	T052	C1880287
27809747	969	982	breast cancer	T191	C0007104
27809747	999	1006	reports	T170	C0684224
27809747	1033	1039	miRNAs	T114,T123	C1101610
27809747	1062	1069	studies	T062	C2603343
27809747	1095	1101	miRNAs	T114,T123	C1101610
27809747	1105	1125	antiestrogen therapy	T061	C0854638
27809747	1141	1150	tamoxifen	T109,T121	C0039286
27809747	1195	1204	molecules	T167	C0567416
27809747	1221	1236	drug resistance	T038	C0013203
27809747	1277	1290	RNA molecules	T114	C0035668
27809747	1353	1359	miRNAs	T114,T123	C1101610
27809747	1379	1392	breast cancer	T191	C0007104
27809747	1393	1405	pathogenesis	T046	C0699748
27809747	1431	1437	cancer	T191	C0006826
27809747	1438	1453	drug resistance	T038	C0013203
27809747	1454	1464	mechanisms	T169	C0441712
27809747	1500	1508	oncomirs	T114,T123	C1101610
27809747	1510	1517	miR 221	T028	C1537859
27809747	1520	1523	222	T028	C1537860
27809747	1537	1560	cell cycle deregulation	T049	C1516331
27809747	1564	1577	breast cancer	T191	C0007104
27809747	1610	1618	oncomiRs	T114,T123	C1101610
27809747	1624	1634	resistance	T038	C0013203
27809747	1638	1647	tamoxifen	T109,T121	C0039286
27809747	1656	1666	emphasized	T080	C3898777

28478636|t|Advanced age is not a barrier to creating a functional arteriovenous fistula: a retrospective study
28478636|a|Arteriovenous fistulas (AVFs) are the recommended form of vascular access for hemodialysis. However, controversy exists regarding whether AVFs are suitable for elderly patients. Single-center retrospective review to investigate the impact of age on AVF outcomes. Five hundred and twenty-five patients with AVF creation were stratified based on age <65, 65-75, and >75 years. AVF outcomes including primary failure, AVF patency (primary, secondary, and functional), and AVF complications were studied for 3 years following AVF creation. The cohort was 63% male, 44% Caucasian, and 55% had diabetes or cardiovascular disease. 39% were aged <65 years, 33% 65-75 years, and 28% were aged >75 years. No differences in rates of primary failure, loss of primary patency, complications, or need for intervention were observed between age groups. There was a significant association of age with secondary patency and functional patency, with age >75 being an independent risk factor for shortened lifespan of the fistula. For patients aged >75 years, secondary patency at 3 years was 64% compared to 75%-78% for younger patients. Functional patency at 2 years was 69% for those aged >75 years compared to 78%-81% for younger patients. We found no difference in AVF maturation, primary patency, complications, or interventions in those over the age of 75 compared to younger counterparts. While secondary and functional patency rates were significantly lower in those aged >75 years, the magnitude of difference is likely not clinically relevant. Therefore, we recommend that advanced age alone should not preclude patients from AVF creation.
28478636	0	12	Advanced age	T098	C1999167
28478636	22	29	barrier	T169	C0443288
28478636	44	54	functional	T169	C0205245
28478636	55	76	arteriovenous fistula	T020	C1541850
28478636	80	99	retrospective study	T062	C0035363
28478636	100	122	Arteriovenous fistulas	T020	C1541850
28478636	124	128	AVFs	T020	C1541850
28478636	158	173	vascular access	T074	C0750138
28478636	178	190	hemodialysis	T061	C0019004
28478636	201	212	controversy	T054	C0680243
28478636	238	242	AVFs	T020	C1541850
28478636	260	267	elderly	T098	C0001792
28478636	268	276	patients	T101	C0030705
28478636	278	312	Single-center retrospective review	T062	C0035363
28478636	316	327	investigate	T169	C1292732
28478636	332	338	impact	T080	C4049986
28478636	342	345	age	T032	C0001779
28478636	349	352	AVF	T020	C1541850
28478636	353	361	outcomes	T169	C1274040
28478636	392	400	patients	T101	C0030705
28478636	406	409	AVF	T020	C1541850
28478636	410	418	creation	T052	C1706214
28478636	424	434	stratified	T080	C0205363
28478636	444	447	age	T032	C0001779
28478636	448	451	<65	T100	C0027362
28478636	453	458	65-75	T100	C0027362
28478636	464	467	>75	T100	C0027362
28478636	468	473	years	T079	C0439234
28478636	475	478	AVF	T020	C1541850
28478636	479	487	outcomes	T169	C1274040
28478636	498	505	primary	T080	C0205225
28478636	506	513	failure	T169	C0231174
28478636	515	518	AVF	T020	C1541850
28478636	519	526	patency	T042	C0042377
28478636	528	535	primary	T080	C0205225
28478636	537	546	secondary	T080	C0175668
28478636	552	562	functional	T169	C0205245
28478636	569	572	AVF	T020	C1541850
28478636	573	586	complications	T046	C0009566
28478636	606	611	years	T079	C0439234
28478636	622	625	AVF	T020	C1541850
28478636	626	634	creation	T052	C1706214
28478636	640	646	cohort	T098	C0599755
28478636	655	659	male	T098	C0025266
28478636	665	674	Caucasian	T098	C0043157
28478636	688	696	diabetes	T047	C0011847
28478636	700	722	cardiovascular disease	T047	C0007222
28478636	733	737	aged	T032	C0001779
28478636	738	741	<65	T100	C0027362
28478636	742	747	years	T079	C0439234
28478636	753	758	65-75	T100	C0027362
28478636	759	764	years	T079	C0439234
28478636	779	783	aged	T032	C0001779
28478636	784	787	>75	T100	C0027362
28478636	788	793	years	T079	C0439234
28478636	822	829	primary	T080	C0205225
28478636	830	837	failure	T169	C0231174
28478636	847	854	primary	T080	C0205225
28478636	855	862	patency	T042	C0042377
28478636	864	877	complications	T046	C0009566
28478636	891	903	intervention	T061	C0184661
28478636	926	936	age groups	T100	C0027362
28478636	962	973	association	T080	C0439849
28478636	977	980	age	T032	C0001779
28478636	986	995	secondary	T080	C0175668
28478636	996	1003	patency	T042	C0042377
28478636	1008	1018	functional	T169	C0205245
28478636	1019	1026	patency	T042	C0042377
28478636	1033	1036	age	T032	C0001779
28478636	1037	1040	>75	T100	C0027362
28478636	1062	1073	risk factor	T033	C0035648
28478636	1078	1087	shortened	T080	C1282927
28478636	1088	1096	lifespan	T079	C1254367
28478636	1117	1125	patients	T101	C0030705
28478636	1126	1130	aged	T032	C0001779
28478636	1131	1134	>75	T100	C0027362
28478636	1135	1140	years	T079	C0439234
28478636	1142	1151	secondary	T080	C0175668
28478636	1152	1159	patency	T042	C0042377
28478636	1165	1170	years	T079	C0439234
28478636	1203	1210	younger	T079	C0332239
28478636	1211	1219	patients	T101	C0030705
28478636	1221	1231	Functional	T169	C0205245
28478636	1232	1239	patency	T042	C0042377
28478636	1245	1250	years	T079	C0439234
28478636	1269	1273	aged	T032	C0001779
28478636	1274	1277	>75	T100	C0027362
28478636	1278	1283	years	T079	C0439234
28478636	1308	1315	younger	T079	C0332239
28478636	1316	1324	patients	T101	C0030705
28478636	1352	1355	AVF	T020	C1541850
28478636	1356	1366	maturation	T039	C1254042
28478636	1368	1375	primary	T080	C0205225
28478636	1376	1383	patency	T042	C0042377
28478636	1385	1398	complications	T046	C0009566
28478636	1403	1416	interventions	T061	C0184661
28478636	1435	1438	age	T032	C0001779
28478636	1442	1444	75	T100	C0027362
28478636	1457	1464	younger	T079	C0332239
28478636	1485	1494	secondary	T080	C0175668
28478636	1499	1509	functional	T169	C0205245
28478636	1510	1517	patency	T042	C0042377
28478636	1518	1523	rates	T081	C1521828
28478636	1558	1562	aged	T032	C0001779
28478636	1563	1566	>75	T100	C0027362
28478636	1567	1572	years	T079	C0439234
28478636	1666	1678	advanced age	T098	C1999167
28478636	1705	1713	patients	T101	C0030705
28478636	1719	1722	AVF	T020	C1541850
28478636	1723	1731	creation	T052	C1706214

27733154|t|Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma
27733154|a|This study addresses involvement of major 5-fluorouracil (5-FU) pathway genes in the prognosis of colorectal carcinoma patients. Testing set and two validation sets comprising paired tumor and adjacent mucosa tissue samples from 151 patients were used for transcript profiling of 15 5-FU pathway genes by quantitative real-time PCR and DNA methylation profiling by high resolution melting analysis. Intratumoral molecular profiles were correlated with clinical data of patients. Protein levels of two most relevant candidate markers were assessed by immunoblotting. Downregulation of DPYD and upregulation of PPAT, UMPS, RRM2, and SLC29A1 transcripts were found in tumors compared to adjacent mucosa in testing and validation sets of patients. Low RRM2 transcript level significantly associated with poor response to the first-line palliative 5-FU -based chemotherapy in the testing set and with poor disease-free interval of patients in the validation set irrespective of 5-FU treatment. UPP2 was strongly methylated while its transcript absent in both tumors and adjacent mucosa. DPYS methylation level was significantly higher in tumor tissues compared to adjacent mucosa samples. Low intratumoral level of UPB1 methylation was prognostic for poor disease-free interval of the patients (P = 0.0002). The rest of the studied 5-FU genes were not methylated in tumors or adjacent mucosa. The observed overexpression of several 5-FU activating genes and DPYD downregulation deduce that chemotherapy naïve colorectal tumors share favorable gene expression profile for 5-FU therapy. Low RRM2 transcript and UPB1 methylation levels present separate poor prognosis factors for colorectal carcinoma patients and should be further investigated.
27733154	0	17	Molecular profile	T169	C1704864
27733154	21	35	5-fluorouracil	T114,T121	C0016360
27733154	36	43	pathway	T044	C1704259
27733154	44	49	genes	T028	C0017337
27733154	53	73	colorectal carcinoma	T191	C0009402
27733154	79	84	study	T062	C2603343
27733154	116	130	5-fluorouracil	T114,T121	C0016360
27733154	132	136	5-FU	T114,T121	C0016360
27733154	138	145	pathway	T044	C1704259
27733154	146	151	genes	T028	C0017337
27733154	159	168	prognosis	T058	C0033325
27733154	172	192	colorectal carcinoma	T191	C0009402
27733154	193	201	patients	T101	C0030705
27733154	203	214	Testing set	T170	C0150098
27733154	223	238	validation sets	T170	C0282574
27733154	250	256	paired	T080	C1709450
27733154	257	262	tumor	T191	C0027651
27733154	267	275	adjacent	T082	C0205117
27733154	276	289	mucosa tissue	T024	C0026724
27733154	290	297	samples	T167	C0370003
27733154	307	315	patients	T101	C0030705
27733154	330	340	transcript	T114	C1519595
27733154	341	350	profiling	T063	C0079247
27733154	357	361	5-FU	T114,T121	C0016360
27733154	362	369	pathway	T044	C1704259
27733154	370	375	genes	T028	C0017337
27733154	379	405	quantitative real-time PCR	T063	C3179034
27733154	410	435	DNA methylation profiling	T063	C1880239
27733154	473	485	Intratumoral	T082	C1517564
27733154	486	504	molecular profiles	T169	C1704864
27733154	510	520	correlated	T080	C1707520
27733154	526	539	clinical data	T170	C1516606
27733154	543	551	patients	T101	C0030705
27733154	553	567	Protein levels	T034	C0428479
27733154	599	606	markers	T201	C0005516
27733154	624	638	immunoblotting	T059	C0020985
27733154	640	654	Downregulation	T044	C0013081
27733154	658	662	DPYD	T028	C1366555
27733154	667	679	upregulation	T044	C0041904
27733154	683	687	PPAT	T028	C1418780
27733154	689	693	UMPS	T028	C1421354
27733154	695	699	RRM2	T028	C1335649
27733154	705	712	SLC29A1	T028	C1420171
27733154	713	724	transcripts	T114	C1519595
27733154	739	745	tumors	T191	C0027651
27733154	746	754	compared	T052	C1707455
27733154	758	766	adjacent	T082	C0205117
27733154	767	773	mucosa	T024	C0026724
27733154	777	784	testing	T170	C0150098
27733154	789	804	validation sets	T170	C0282574
27733154	808	816	patients	T101	C0030705
27733154	822	826	RRM2	T028	C1335649
27733154	827	837	transcript	T114	C1519595
27733154	838	843	level	T080	C0441889
27733154	917	921	5-FU	T114,T121	C0016360
27733154	929	941	chemotherapy	T061	C3665472
27733154	949	960	testing set	T170	C0150098
27733154	975	996	disease-free interval	T079	C1272706
27733154	1000	1008	patients	T101	C0030705
27733154	1016	1030	validation set	T170	C0282574
27733154	1047	1051	5-FU	T114,T121	C0016360
27733154	1052	1061	treatment	T061	C0087111
27733154	1063	1067	UPP2	T028	C1427883
27733154	1072	1091	strongly methylated	T034	C1254360
27733154	1102	1112	transcript	T114	C1519595
27733154	1128	1134	tumors	T191	C0027651
27733154	1139	1147	adjacent	T082	C0205117
27733154	1148	1154	mucosa	T024	C0026724
27733154	1156	1160	DPYS	T028	C1414144
27733154	1161	1172	methylation	T044	C0376452
27733154	1173	1178	level	T080	C0441889
27733154	1207	1220	tumor tissues	T024	C0475358
27733154	1233	1241	adjacent	T082	C0205117
27733154	1242	1248	mucosa	T024	C0026724
27733154	1249	1256	samples	T167	C0370003
27733154	1262	1274	intratumoral	T082	C1517564
27733154	1275	1280	level	T080	C0441889
27733154	1284	1288	UPB1	T028	C1424165
27733154	1289	1300	methylation	T044	C0376452
27733154	1305	1315	prognostic	T170	C0220901
27733154	1325	1346	disease-free interval	T079	C1272706
27733154	1354	1362	patients	T101	C0030705
27733154	1401	1405	5-FU	T114,T121	C0016360
27733154	1406	1411	genes	T028	C0017337
27733154	1417	1431	not methylated	T034	C1254360
27733154	1435	1441	tumors	T191	C0027651
27733154	1445	1453	adjacent	T082	C0205117
27733154	1454	1460	mucosa	T024	C0026724
27733154	1475	1489	overexpression	T045	C0017262
27733154	1501	1505	5-FU	T114,T121	C0016360
27733154	1506	1522	activating genes	T028	C0017337
27733154	1527	1531	DPYD	T028	C1366555
27733154	1532	1546	downregulation	T044	C0013081
27733154	1559	1571	chemotherapy	T061	C3665472
27733154	1572	1595	naïve colorectal tumors	T191	C0009404
27733154	1612	1635	gene expression profile	T081	C1956267
27733154	1640	1644	5-FU	T114,T121	C0016360
27733154	1645	1652	therapy	T061	C0087111
27733154	1658	1662	RRM2	T028	C1335649
27733154	1663	1673	transcript	T114	C1519595
27733154	1678	1682	UPB1	T028	C1424165
27733154	1683	1694	methylation	T044	C0376452
27733154	1695	1701	levels	T080	C0441889
27733154	1724	1741	prognosis factors	T201	C1514474
27733154	1746	1766	colorectal carcinoma	T191	C0009402
27733154	1767	1775	patients	T101	C0030705
27733154	1798	1810	investigated	T169	C1292732

28515617|t|A modified subgradient extragradient method for solving monotone variational inequalities
28515617|a|In the setting of Hilbert space, a modified subgradient extragradient method is proposed for solving Lipschitz-continuous and monotone variational inequalities defined on a level set of a convex function. Our iterative process is relaxed and self-adaptive, that is, in each iteration, calculating two metric projections onto some half-spaces containing the domain is involved only and the step size can be selected in some adaptive ways. A weak convergence theorem for our algorithm is proved. We also prove that our method has [Formula: see text] convergence rate.
28515617	2	43	modified subgradient extragradient method	T170	C0282574
28515617	56	64	monotone	UnknownType	C0241704
28515617	65	76	variational	T080	C0205419
28515617	77	89	inequalities	T080	C0242503
28515617	108	121	Hilbert space	T170	C0282574
28515617	125	166	modified subgradient extragradient method	T170	C0282574
28515617	191	211	Lipschitz-continuous	T170	C0282574
28515617	216	224	monotone	UnknownType	C0241704
28515617	225	236	variational	T080	C0205419
28515617	237	249	inequalities	T080	C0242503
28515617	278	284	convex	T082	C0521163
28515617	285	293	function	T169	C0542341
28515617	299	308	iterative	T033	C1854293
28515617	309	316	process	T067	C1522240
28515617	320	327	relaxed	T080	C0542193
28515617	332	345	self-adaptive	T169	C0231193
28515617	364	373	iteration	T033	C1854293
28515617	398	409	projections	T082	C0348018
28515617	484	488	size	T082	C0456389
28515617	513	526	adaptive ways	T062	C3274373
28515617	535	546	convergence	T082	C0443193
28515617	547	554	theorem	T170	C0039828
28515617	563	572	algorithm	T170	C0002045
28515617	607	613	method	T170	C0025663
28515617	638	649	convergence	T082	C0443193
28515617	650	654	rate	T081	C1521828

27438403|t|Axially Chiral Dimeric Naphthalene and Naphthoquinone Metabolites, from Root Cultures of the West African Liana Triphyophyllum peltatum
27438403|a|Root cultures of the West African liana Triphyophyllum peltatum were initiated from stem explants of in vitro cultivated shoots. From these organ cultures, three new binaphthalenes, one binaphthoquinone, and two (bi)naphthalene glucosides were isolated, with substitution patterns related to those of the naphthylisoquinoline alkaloids, which are the "normal" main metabolites of T. peltatum. The structures of the diglucoside dioncoquinoside A (1) and of the axially chiral biaryls triphyoquinols A1 (3), A2 (4), and B (5), triphyoquinoside A (6), and triphyoquinone A (7) were elucidated by spectroscopic analysis (HRESIMS, 1D and 2D NMR) and by application of electronic circular dichroism (ECD) spectroscopy in combination with the exciton chirality method and quantum-chemical ECD calculations. The root cultures likewise produced the known alkaloids dioncophylline A (8), 5'-O-demethyldioncophylline A (9), dioncopeltine A (10), habropetaline A (11), and 5'-O-methyldioncophylline D (12a/b), the naphthalene glucoside plumbaside A (2), and the naphthoquinones plumbagin (13), droserone (14), and 8-hydroxydroserone (15).
27438403	0	7	Axially	T082	C0205131
27438403	8	14	Chiral	T067	C3539649
27438403	15	22	Dimeric	T104	C0596448
27438403	23	34	Naphthalene	T109,T121	C0027375
27438403	39	53	Naphthoquinone	T109	C0027388
27438403	54	65	Metabolites	T123	C0870883
27438403	72	76	Root	T002	C0242726
27438403	77	85	Cultures	T059	C0430400
27438403	93	105	West African	T083	C0001747
27438403	106	111	Liana	T002	C0032098
27438403	112	135	Triphyophyllum peltatum	T002	C1084542
27438403	136	140	Root	T002	C0242726
27438403	141	149	cultures	T059	C0430400
27438403	157	169	West African	T083	C0001747
27438403	170	175	liana	T002	C0032098
27438403	176	199	Triphyophyllum peltatum	T002	C1084542
27438403	220	224	stem	T002	C0242767
27438403	225	233	explants	T061	C0444933
27438403	237	245	in vitro	T080	C1533691
27438403	246	263	cultivated shoots	UnknownType	C0869005
27438403	276	290	organ cultures	T059	C0029205
27438403	302	316	binaphthalenes	T123	C0574031
27438403	322	338	binaphthoquinone	T123	C0574031
27438403	348	374	(bi)naphthalene glucosides	T123	C0574031
27438403	380	388	isolated	T169	C0205409
27438403	441	471	naphthylisoquinoline alkaloids	T109,T123,T131	C0301258
27438403	501	512	metabolites	T123	C0870883
27438403	516	527	T. peltatum	T002	C1084542
27438403	533	543	structures	T082	C0678594
27438403	551	580	diglucoside dioncoquinoside A	T123	C0574031
27438403	596	603	axially	T082	C0205131
27438403	604	610	chiral	T067	C3539649
27438403	611	636	biaryls triphyoquinols A1	T123	C0574031
27438403	642	644	A2	T123	C0574031
27438403	654	655	B	T123	C0574031
27438403	661	679	triphyoquinoside A	T123	C0574031
27438403	689	705	triphyoquinone A	T123	C0574031
27438403	729	751	spectroscopic analysis	T059	C0037812
27438403	753	760	HRESIMS	T059	C0037813
27438403	762	764	1D	T060	C0877853
27438403	769	775	2D NMR	T060	C0877853
27438403	799	847	electronic circular dichroism (ECD) spectroscopy	T070	C1519445
27438403	851	862	combination	T080	C0205195
27438403	872	896	exciton chirality method	T170	C0025663
27438403	901	934	quantum-chemical ECD calculations	T059	C0201805
27438403	940	944	root	T002	C0242726
27438403	945	953	cultures	T059	C0430400
27438403	982	991	alkaloids	T109,T121	C0002062
27438403	992	1008	dioncophylline A	T109,T123,T131	C0301258
27438403	1014	1043	5'-O-demethyldioncophylline A	T109,T123,T131	C0301258
27438403	1049	1064	dioncopeltine A	T109,T123,T131	C0301258
27438403	1071	1086	habropetaline A	T109,T123,T131	C0301258
27438403	1097	1124	5'-O-methyldioncophylline D	T109,T123,T131	C0301258
27438403	1138	1172	naphthalene glucoside plumbaside A	T109,T123,T131	C0301258
27438403	1186	1211	naphthoquinones plumbagin	T109,T123,T131	C0301258
27438403	1218	1227	droserone	T109,T123,T131	C0301258
27438403	1238	1256	8-hydroxydroserone	T109,T123,T131	C0301258

27213687|t|Nationwide reduction in the number of corneal transplantations for keratoconus following the implementation of cross-linking
27213687|a|Keratoconus is characterized by corneal ectasia and irregular astigmatism, which can lead to diminished vision and corneal scarring. Approximately 10-20% of patients with keratoconus eventually require a corneal transplant. Corneal cross-linking (CXL) is a relatively new treatment that may help prevent the need for corneal transplantation. Here, we investigated whether the introduction of CXL has reduced the number of corneal transplants performed annually. Data regarding the transplantation procedures performed in patients under the age of 50 years were extracted from the Dutch National Organ Transplant Registry. The number of corneal transplants performed prior to (i.e. in 2005 through 2007) and following the introduction of CXL (i.e. in 2012 through 2014) were compared. Furthermore, a trend analysis on annual keratoplasties over time was performed. Approximately 25% fewer corneal transplants were performed in the 3- year period following the introduction of CXL compared to the 3- year period prior to the introduction of CXL (201 versus 269 transplants, respectively; p = 0.005). Age, gender and visual acuity were similar between the patient groups in the two time periods. Trend analysis also demonstrated a significant decrease in the amount of corneal transplants (p = 0.001). Significantly fewer corneal transplants were performed for treating keratoconus following the nationwide introduction of CXL. This reduction suggests that corneal cross-linking can significantly reduce the need for corneal transplantation.
27213687	0	10	Nationwide	T082	C1254362
27213687	11	20	reduction	T081	C0547047
27213687	38	62	corneal transplantations	T061	C0010042
27213687	67	78	keratoconus	T047	C0022578
27213687	93	107	implementation	T052	C1708476
27213687	111	124	cross-linking	T061	C4065848
27213687	125	136	Keratoconus	T047	C0022578
27213687	157	172	corneal ectasia	T047	C0155135
27213687	177	198	irregular astigmatism	T047	C0152194
27213687	218	235	diminished vision	T047	C0042798
27213687	240	256	corneal scarring	T033	C0349702
27213687	282	290	patients	T101	C0030705
27213687	296	307	keratoconus	T047	C0022578
27213687	329	347	corneal transplant	T061	C0010042
27213687	349	370	Corneal cross-linking	T061	C4065848
27213687	372	375	CXL	T061	C4065848
27213687	397	406	treatment	T061	C0087111
27213687	442	465	corneal transplantation	T061	C0010042
27213687	476	488	investigated	T169	C1292732
27213687	501	513	introduction	T169	C0579004
27213687	517	520	CXL	T061	C4065848
27213687	547	566	corneal transplants	T061	C0010042
27213687	567	576	performed	T169	C0884358
27213687	577	585	annually	T079	C0332181
27213687	587	591	Data	T078	C1511726
27213687	606	632	transplantation procedures	T061	C0040732
27213687	633	642	performed	T169	C0884358
27213687	646	654	patients	T101	C0030705
27213687	665	668	age	T032	C0001779
27213687	675	680	years	T079	C0439234
27213687	705	745	Dutch National Organ Transplant Registry	T170	C0034975
27213687	761	780	corneal transplants	T061	C0010042
27213687	781	790	performed	T169	C0884358
27213687	846	858	introduction	T169	C0579004
27213687	862	865	CXL	T061	C4065848
27213687	899	907	compared	T052	C1707455
27213687	924	938	trend analysis	UnknownType	C0681702
27213687	942	948	annual	T079	C0332181
27213687	949	963	keratoplasties	T061	C0010042
27213687	978	987	performed	T169	C0884358
27213687	1013	1032	corneal transplants	T061	C0010042
27213687	1038	1047	performed	T169	C0884358
27213687	1058	1062	year	T079	C0439234
27213687	1084	1096	introduction	T169	C0579004
27213687	1100	1103	CXL	T061	C4065848
27213687	1104	1112	compared	T052	C1707455
27213687	1123	1127	year	T079	C0439234
27213687	1148	1160	introduction	T169	C0579004
27213687	1164	1167	CXL	T061	C4065848
27213687	1184	1195	transplants	T061	C0010042
27213687	1223	1226	Age	T032	C0001779
27213687	1228	1234	gender	T032	C0079399
27213687	1239	1252	visual acuity	T201	C0042812
27213687	1278	1285	patient	T101	C0030705
27213687	1304	1316	time periods	T079	C1948053
27213687	1318	1332	Trend analysis	UnknownType	C0681702
27213687	1365	1373	decrease	T081	C0547047
27213687	1391	1410	corneal transplants	T061	C0010042
27213687	1444	1463	corneal transplants	T061	C0010042
27213687	1492	1503	keratoconus	T047	C0022578
27213687	1518	1528	nationwide	T082	C1254362
27213687	1529	1541	introduction	T169	C0579004
27213687	1545	1548	CXL	T061	C4065848
27213687	1555	1564	reduction	T081	C0547047
27213687	1579	1600	corneal cross-linking	T061	C4065848
27213687	1619	1625	reduce	T080	C0392756
27213687	1639	1662	corneal transplantation	T061	C0010042

28179399|t|Differential proteomics profiling identifies LDPs and biological functions in high-fat diet - induced fatty livers
28179399|a|Eukaryotic cells store neutral lipids in cytoplasmic lipid droplets (LDs) enclosed in a monolayer of phospholipids and associated proteins [LD proteins (LDPs)]. Growing evidence has demonstrated that LDPs play important roles in the pathogenesis of liver diseases. However, the composition of liver LDPs and the role of their alterations in hepatosteatosis are not well-understood. In this study, we performed liver proteome and LD sub-proteome profiling to identify enriched proteins in LDs as LDPs, and quantified their changes in a high-fat diet (HFD)- induced fatty liver model. Among 5,000 quantified liver proteins, 101 were enriched by greater than 10-fold in the LD sub-proteome and were classified as LDPs. Differential profiling of LDPs in HFD - induced fatty liver provided a list of candidate LDPs for functional investigation. We tested the function of an upregulated LDP, S100a10, in vivo with adenovirus -mediated gene silencing and found, unexpectedly, that knockdown of S100a10 accelerated progression of HFD - induced liver steatosis. The S100A10 interactome revealed a connection between S100A10 and lipid transporting proteins, suggesting that S100A10 regulates the development and formation of LDs by transporting and trafficking. This study identified LD -enriched sub-proteome in homeostatic as well as HFD - induced fatty livers, providing a rich resource for the LDP research field.
28179399	0	33	Differential proteomics profiling	T059	C1327760
28179399	45	49	LDPs	T116,T123	C4277676
28179399	54	74	biological functions	T038	C3714634
28179399	78	91	high-fat diet	T168	C0453819
28179399	94	101	induced	T169	C0205263
28179399	102	114	fatty livers	T047	C0015695
28179399	115	131	Eukaryotic cells	T025	C0015161
28179399	138	152	neutral lipids	T109	C0023779
28179399	156	167	cytoplasmic	T026	C0521449
28179399	168	182	lipid droplets	T026	C0230704
28179399	184	187	LDs	T026	C0230704
28179399	203	212	monolayer	T023	C0934502
28179399	216	229	phospholipids	T109,T123	C0031676
28179399	234	253	associated proteins	T116,T123	C4277676
28179399	255	266	LD proteins	T116,T123	C4277676
28179399	268	272	LDPs	T116,T123	C4277676
28179399	315	319	LDPs	T116,T123	C4277676
28179399	348	360	pathogenesis	T046	C0699748
28179399	364	378	liver diseases	T047	C0023895
28179399	408	413	liver	T023	C0023884
28179399	414	418	LDPs	T116,T123	C4277676
28179399	456	471	hepatosteatosis	T047	C2711227
28179399	525	530	liver	T023	C0023884
28179399	531	539	proteome	T116,T123	C0751973
28179399	544	546	LD	T026	C0230704
28179399	547	569	sub-proteome profiling	T059	C1327760
28179399	591	599	proteins	T116,T123	C0033684
28179399	603	606	LDs	T026	C0230704
28179399	610	614	LDPs	T116,T123	C4277676
28179399	620	630	quantified	T081	C1709793
28179399	650	663	high-fat diet	T168	C0453819
28179399	665	668	HFD	T168	C0453819
28179399	671	678	induced	T169	C0205263
28179399	679	690	fatty liver	T047	C0015695
28179399	691	696	model	T075	C0026339
28179399	710	720	quantified	T081	C1709793
28179399	758	770	greater than	T081	C0439093
28179399	786	788	LD	T026	C0230704
28179399	789	801	sub-proteome	T116,T123	C0751973
28179399	825	829	LDPs	T116,T123	C4277676
28179399	831	853	Differential profiling	T059	C1327760
28179399	857	861	LDPs	T116,T123	C4277676
28179399	865	868	HFD	T168	C0453819
28179399	871	878	induced	T169	C0205263
28179399	879	890	fatty liver	T047	C0015695
28179399	920	924	LDPs	T116,T123	C4277676
28179399	984	995	upregulated	T044	C0041904
28179399	996	999	LDP	T116,T123	C4277676
28179399	1001	1008	S100a10	T028	C1419782
28179399	1010	1017	in vivo	T082	C1515655
28179399	1023	1033	adenovirus	T005	C0001483
28179399	1044	1058	gene silencing	T040	C1155285
28179399	1089	1098	knockdown	T045	C0920533
28179399	1102	1109	S100a10	T028	C1419782
28179399	1137	1140	HFD	T168	C0453819
28179399	1143	1150	induced	T169	C0205263
28179399	1151	1166	liver steatosis	T047	C2711227
28179399	1172	1179	S100A10	T116,T192	C0966870
28179399	1222	1229	S100A10	T116,T192	C0966870
28179399	1234	1261	lipid transporting proteins	T116,T123	C4277676
28179399	1279	1286	S100A10	T028	C1419782
28179399	1330	1333	LDs	T026	C0230704
28179399	1389	1391	LD	T026	C0230704
28179399	1402	1414	sub-proteome	T116,T123	C0751973
28179399	1418	1429	homeostatic	T038	C0019868
28179399	1441	1444	HFD	T168	C0453819
28179399	1447	1454	induced	T169	C0205263
28179399	1455	1467	fatty livers	T047	C0015695
28179399	1503	1506	LDP	T116,T123	C4277676
28179399	1507	1521	research field	T062	C0242481

28241985|t|Cardiogenic shock caused by a left midventricular obstruction during refeeding in a patient with anorexia nervosa
28241985|a|Refeeding syndrome occurs when reinstating nutrition to severely malnourished patients. It can sometimes be fatal, particularly as a result of cardiac involvement such as congestive heart failure and arrhythmias. The aim of this study was to report a case of cardiogenic shock that occurred during refeeding in a patient with anorexia nervosa (AN). The cardiogenic shock was due to a previously unrecognized mechanism, namely a transient left midventricular obstruction that completely disappeared after treatment. A 46-y-old woman with AN who had followed a carbohydrate - and a fat - deficient diet for >10 y was hospitalized for dyspnea on exertion. She had severely impaired cardiac systolic function on admission and was considered high risk for refeeding syndrome. During a stepwise increase of calories, she showed no electrolyte or mineral abnormalities characteristic of refeeding syndrome. After intravenous administration of a fat emulsion, the patient suffered from cardiogenic shock due to an unexpected mechanism, namely a left midventricular obstruction caused by cardiac hypercontraction, a thickened left ventricular wall, and intravascular volume depletion. With cessation of the fat emulsion and initiation of volume repletion she recovered from shock immediately and her echocardiogram returned to normal by discharge. This case illustrated a novel cause of cardiogenic shock during refeeding and the need for caution during the intravenous administration of a fat emulsion in patients with initial left ventricular systolic dysfunction.
28241985	0	17	Cardiogenic shock	T046	C0036980
28241985	30	49	left midventricular	T023	C0445027
28241985	50	61	obstruction	T046	C0028778
28241985	69	78	refeeding	T047	C0860549
28241985	84	91	patient	T101	C0030705
28241985	97	113	anorexia nervosa	T048	C0003125
28241985	114	132	Refeeding syndrome	T047	C0860549
28241985	133	139	occurs	T052	C1709305
28241985	170	178	severely	T080	C0205082
28241985	179	191	malnourished	T047	C0162429
28241985	192	200	patients	T101	C0030705
28241985	222	227	fatal	T080	C1302234
28241985	247	253	result	T169	C1274040
28241985	257	264	cardiac	T023	C0018787
28241985	265	276	involvement	T169	C1314939
28241985	285	309	congestive heart failure	T047	C0018802
28241985	314	325	arrhythmias	T033	C0003811
28241985	343	348	study	T062	C2603343
28241985	356	362	report	T058	C0700287
28241985	365	369	case	T169	C0868928
28241985	373	390	cardiogenic shock	T046	C0036980
28241985	396	404	occurred	T052	C1709305
28241985	412	421	refeeding	T047	C0860549
28241985	427	434	patient	T101	C0030705
28241985	440	456	anorexia nervosa	T048	C0003125
28241985	458	460	AN	T048	C0003125
28241985	467	484	cardiogenic shock	T046	C0036980
28241985	509	521	unrecognized	T080	C4288068
28241985	522	531	mechanism	T169	C0441712
28241985	542	551	transient	T079	C1254367
28241985	552	571	left midventricular	T023	C0445027
28241985	572	583	obstruction	T046	C0028778
28241985	618	627	treatment	T061	C0087111
28241985	640	645	woman	T098	C0043210
28241985	651	653	AN	T048	C0003125
28241985	673	685	carbohydrate	T109	C0012170
28241985	694	697	fat	T109,T168	C0012171
28241985	700	709	deficient	T169	C0011155
28241985	710	714	diet	T168	C0012155
28241985	729	741	hospitalized	T033	C0701159
28241985	746	753	dyspnea	T184	C0013404
28241985	757	765	exertion	T040	C0015264
28241985	775	783	severely	T080	C0205082
28241985	784	792	impaired	T169	C0221099
28241985	793	818	cardiac systolic function	T042	C1254358
28241985	822	831	admission	T058	C0184666
28241985	856	860	risk	T078	C0035647
28241985	865	883	refeeding syndrome	T047	C0860549
28241985	903	911	increase	T169	C0442805
28241985	915	923	calories	T081	C1556156
28241985	939	950	electrolyte	T121,T197	C0013832
28241985	954	961	mineral	T197	C0026162
28241985	962	975	abnormalities	T033	C1704258
28241985	994	1012	refeeding syndrome	T047	C0860549
28241985	1020	1064	intravenous administration of a fat emulsion	T109,T121	C0015667
28241985	1070	1077	patient	T101	C0030705
28241985	1092	1109	cardiogenic shock	T046	C0036980
28241985	1131	1140	mechanism	T169	C0441712
28241985	1151	1170	left midventricular	T023	C0445027
28241985	1171	1182	obstruction	T046	C0028778
28241985	1193	1217	cardiac hypercontraction	T046	C0030660
28241985	1221	1252	thickened left ventricular wall	T046	C0030660
28241985	1258	1288	intravascular volume depletion	T033	C0750310
28241985	1295	1304	cessation	T052	C1880019
28241985	1312	1324	fat emulsion	T109,T121	C0304483
28241985	1329	1339	initiation	T169	C1704686
28241985	1343	1359	volume repletion	T033	C0750310
28241985	1379	1384	shock	T046	C0036974
28241985	1405	1419	echocardiogram	T170	C2243117
28241985	1420	1431	returned to	T080	C0332156
28241985	1442	1451	discharge	T058	C0030685
28241985	1492	1509	cardiogenic shock	T046	C0036980
28241985	1517	1526	refeeding	T047	C0860549
28241985	1563	1607	intravenous administration of a fat emulsion	T109,T121	C0015667
28241985	1611	1619	patients	T101	C0030705
28241985	1633	1670	left ventricular systolic dysfunction	T047	C1277187

28176637|t|Personalized Medicine applied to Forensic Sciences: new advances and perspectives for a tailored forensic approach
28176637|a|Personalized medicine (PM), included in P5 medicine (Personalized, Predictive, Preventive, Participative and Precision medicine) is an innovative approach to the patient, emerging from the need to tailor and to fit the profile of each individual. PM promises to dramatically impact also on forensic sciences and justice system in ways we are only beginning to understand. The application of omics (genomic, transcriptomics, epigenetics/imprintomics, proteomic and metabolomics) is ever more fundamental in the so called " molecular autopsy ". Emerging fields of interest in forensic pathology are represented by diagnosis and detection of predisposing conditions to fatal thromboembolic and hypertensive events, determination of genetic variants related to sudden death, such as congenital long QT syndromes, demonstration of lesions vitality, identification of biological matrices and species diagnosis of a forensic trace on crime scenes without destruction of the DNA. The aim of this paper is to describe the state-of-art in the application of personalized medicine in forensic sciences, to understand the possibilities of integration in routine investigation of these procedures with classical post-mortem studies and to underline the importance of these new updates in medical examiners' armamentarium in determining cause of death or contributing factors to death.
28176637	0	21	Personalized Medicine	T061	C2718059
28176637	33	50	Forensic Sciences	T090	C1257940
28176637	97	114	forensic approach	UnknownType	C0681831
28176637	115	136	Personalized medicine	T061	C2718059
28176637	138	140	PM	T061	C2718059
28176637	155	166	P5 medicine	T121	C0013227
28176637	168	180	Personalized	T080	C1709510
28176637	182	192	Predictive	T080	C0681890
28176637	194	204	Preventive	T080	C2700409
28176637	206	219	Participative	T169	C0679823
28176637	224	233	Precision	T080	C1706245
28176637	234	242	medicine	T121	C0013227
28176637	250	269	innovative approach	T061	C1136080
28176637	277	284	patient	T101	C0030705
28176637	350	360	individual	T098	C0237401
28176637	362	364	PM	T061	C2718059
28176637	405	422	forensic sciences	T090	C1257940
28176637	513	520	genomic	T091	C0887950
28176637	522	537	transcriptomics	T091	C0017398
28176637	539	563	epigenetics/imprintomics	T091	C1655731
28176637	565	574	proteomic	T091	C0872252
28176637	579	591	metabolomics	T091	C1328813
28176637	637	654	molecular autopsy	T060	C0004398
28176637	689	707	forensic pathology	T091	C1450224
28176637	727	736	diagnosis	T033	C0011900
28176637	741	750	detection	T061	C1511790
28176637	754	777	predisposing conditions	T079	C0032946
28176637	781	786	fatal	T080	C1302234
28176637	787	801	thromboembolic	T046	C0040038
28176637	806	825	hypertensive events	T047	C0020538
28176637	844	860	genetic variants	T070	C0042333
28176637	879	884	death	T040	C0011065
28176637	894	922	congenital long QT syndromes	T047	C1141890
28176637	941	948	lesions	T033	C0221198
28176637	949	957	vitality	T033	C0424589
28176637	977	987	biological	T080	C0205460
28176637	988	996	matrices	T082	C1704640
28176637	1009	1018	diagnosis	T033	C0011900
28176637	1024	1038	forensic trace	T078	C3887511
28176637	1042	1054	crime scenes	T068	C0010325
28176637	1063	1085	destruction of the DNA	T049	C0012860
28176637	1128	1140	state-of-art	UnknownType	C0700033
28176637	1163	1184	personalized medicine	T061	C2718059
28176637	1188	1205	forensic sciences	T090	C1257940
28176637	1265	1278	investigation	T058	C0220825
28176637	1314	1333	post-mortem studies	T060	C0004398
28176637	1390	1408	medical examiners'	T097	C0025082
28176637	1409	1422	armamentarium	T169	C0449851
28176637	1447	1452	death	T040	C0011065
28176637	1480	1485	death	T040	C0011065

27635144|t|Antibacterial and Antibiofilm Effect of Low Viscosity Chitosan against Staphylococcus epidermidis
27635144|a|Aim. The aim of this study was to investigate the antibacterial and antibiofilm properties of low viscosity chitosan on S. epidermidis growth and biofilm formation. Methods and Results. The antibacterial and antibiofilm properties were investigated, during both planktonic growth and biofilm formation. This was performed using different concentrations in media and by coating on polystyrene surfaces. In addition, the bactericidal effect was investigated using a modified direct contact test. The results showed that low viscosity chitosan in media had both a bacteriostatic and bactericidal effect on planktonic growth and biofilm formation of S. epidermidis in a concentration dependent manner. Polystyrene discs coated with chitosan reduced both early biofilm formation (6 h) and late biofilm formation (18 h), as confirmed by scanning electron microscopy. The modified direct contact test showed a bactericidal effect. Conclusion. This study demonstrated that low viscosity chitosan has a bacteriostatic and bactericidal activity against S. epidermidis and that the activity is dependent on the amount of chitosan added. In addition, low viscosity chitosan reduced biofilm formation both when added to media and when coated on polystyrene surfaces. Significance and Impact of Study. Low viscosity chitosan could be a contribution to new treatment approaches of biofilm -related infections of S. epidermidis.
27635144	0	13	Antibacterial	T195	C0279516
27635144	18	29	Antibiofilm	T195	C0279516
27635144	40	62	Low Viscosity Chitosan	T109,T121	C0162969
27635144	71	97	Staphylococcus epidermidis	T007	C0038174
27635144	132	143	investigate	T169	C1292732
27635144	148	161	antibacterial	T195	C0279516
27635144	166	177	antibiofilm	T195	C0279516
27635144	192	214	low viscosity chitosan	T109,T121	C0162969
27635144	218	232	S. epidermidis	T007	C0038174
27635144	218	239	S. epidermidis growth	T034	C0427944
27635144	244	261	biofilm formation	T043	C1325881
27635144	288	301	antibacterial	T195	C0279516
27635144	306	317	antibiofilm	T195	C0279516
27635144	334	346	investigated	T169	C1292732
27635144	348	354	during	T079	C0347984
27635144	360	370	planktonic	T007,T204	C0032071
27635144	360	377	planktonic growth	T034	C0427944
27635144	382	399	biofilm formation	T043	C1325881
27635144	436	459	concentrations in media	T130	C0010454
27635144	478	498	polystyrene surfaces	T109,T122	C0032604
27635144	517	536	bactericidal effect	T039	C0544570
27635144	541	553	investigated	T169	C1292732
27635144	571	590	direct contact test	T059	C0022885
27635144	616	638	low viscosity chitosan	T109,T121	C0162969
27635144	659	673	bacteriostatic	T121	C0280050
27635144	678	697	bactericidal effect	T039	C0544570
27635144	701	711	planktonic	T007,T204	C0032071
27635144	701	718	planktonic growth	T034	C0427944
27635144	723	740	biofilm formation	T043	C1325881
27635144	744	758	S. epidermidis	T007	C0038174
27635144	796	813	Polystyrene discs	T109,T122	C0032604
27635144	826	834	chitosan	T109,T121	C0162969
27635144	854	871	biofilm formation	T043	C1325881
27635144	887	904	biofilm formation	T043	C1325881
27635144	929	957	scanning electron microscopy	T059	C0026020
27635144	972	991	direct contact test	T059	C0022885
27635144	1001	1020	bactericidal effect	T039	C0544570
27635144	1063	1085	low viscosity chitosan	T109,T121	C0162969
27635144	1067	1076	viscosity	T070	C0042784
27635144	1092	1106	bacteriostatic	T121	C0280050
27635144	1111	1132	bactericidal activity	T039	C0544570
27635144	1141	1155	S. epidermidis	T007	C0038174
27635144	1208	1216	chitosan	T109,T121	C0162969
27635144	1237	1259	low viscosity chitosan	T109,T121	C0162969
27635144	1260	1267	reduced	T080	C0392756
27635144	1268	1285	biofilm formation	T043	C1325881
27635144	1330	1350	polystyrene surfaces	T109,T122	C0032604
27635144	1352	1364	Significance	T078	C0750502
27635144	1386	1408	Low viscosity chitosan	T109,T121	C0162969
27635144	1390	1399	viscosity	T070	C0042784
27635144	1440	1449	treatment	T061	C0087111
27635144	1464	1471	biofilm	T007	C0081786
27635144	1464	1491	biofilm -related infections	T047	C0004623
27635144	1495	1509	S. epidermidis	T007	C0038174

27436024|t|Fractal analysis of the ischemic transition region in chronic ischemic heart disease using magnetic resonance imaging
27436024|a|To introduce a novel hypothesis and method to characterise pathomechanisms underlying myocardial ischemia in chronic ischemic heart disease by local fractal analysis (FA) of the ischemic myocardial transition region in perfusion imaging. Vascular mechanisms to compensate ischemia are regulated at various vascular scales with their superimposed perfusion pattern being hypothetically self-similar. Dedicated FA software (" FraktalWandler ") has been developed. Fractal dimensions during first-pass (FDfirst-pass) and recirculation (FDrecirculation) are hypothesised to indicate the predominating pathomechanism and ischemic severity, respectively. Twenty-six patients with evidence of myocardial ischemia in 108 ischemic myocardial segments on magnetic resonance imaging (MRI) were analysed. The 40th and 60th percentiles of FDfirst-pass were used for pathomechanical classification, assigning lesions with FDfirst-pass ≤ 2.335 to predominating coronary microvascular dysfunction (CMD) and ≥2.387 to predominating coronary artery disease (CAD). Optimal classification point in ROC analysis was FDfirst-pass = 2.358. FDrecirculation correlated moderately with per cent diameter stenosis in invasive coronary angiography in lesions classified CAD (r = 0.472, p = 0.001) but not CMD (r = 0.082, p = 0.600). The ischemic transition region may provide information on pathomechanical composition and severity of myocardial ischemia. FA of this region is feasible and may improve diagnosis compared to traditional noninvasive myocardial perfusion analysis. • A novel hypothesis and method is introduced to pathophysiologically characterise myocardial ischemia. • The ischemic transition region appears a meaningful diagnostic target in perfusion imaging. • Fractal analysis may characterise pathomechanical composition and severity of myocardial ischemia.
27436024	0	7	Fractal	T077	C0206163
27436024	8	16	analysis	T062	C0936012
27436024	24	50	ischemic transition region	T082	C1254362
27436024	54	84	chronic ischemic heart disease	T047	C0264694
27436024	91	117	magnetic resonance imaging	T060	C0024485
27436024	133	138	novel	T080	C0205314
27436024	139	149	hypothesis	T078	C1512571
27436024	154	160	method	T170	C0025663
27436024	177	192	pathomechanisms	T046	C0030660
27436024	204	223	myocardial ischemia	T047	C0151744
27436024	227	257	chronic ischemic heart disease	T047	C0264694
27436024	267	274	fractal	T077	C0206163
27436024	275	283	analysis	T062	C0936012
27436024	285	287	FA	T062	C0936012
27436024	296	304	ischemic	T169	C0475224
27436024	305	315	myocardial	T082	C1522564
27436024	316	333	transition region	T082	C1254362
27436024	337	354	perfusion imaging	T060	C2350393
27436024	356	364	Vascular	T023	C0005847
27436024	365	375	mechanisms	T169	C0441712
27436024	379	389	compensate	T080	C0205432
27436024	390	398	ischemia	T046	C0022116
27436024	403	412	regulated	T038	C1327622
27436024	424	432	vascular	T023	C0005847
27436024	433	439	scales	T170	C0349674
27436024	451	473	superimposed perfusion	T060	C2350393
27436024	474	481	pattern	T082	C0449774
27436024	488	502	hypothetically	T078	C1512571
27436024	503	515	self-similar	T080	C2348205
27436024	527	529	FA	T062	C0936012
27436024	530	538	software	T073,T170	C0037585
27436024	542	556	FraktalWandler	T170	C0037589
27436024	580	587	Fractal	T077	C0206163
27436024	588	598	dimensions	T081	C0439534
27436024	606	616	first-pass	T079	C0444693
27436024	618	630	FDfirst-pass	T079	C0444693
27436024	636	649	recirculation	T040	C1516559
27436024	651	666	FDrecirculation	T040	C1516559
27436024	672	684	hypothesised	T078	C1512571
27436024	715	729	pathomechanism	T046	C0030660
27436024	734	742	ischemic	T169	C0475224
27436024	743	751	severity	T080	C0439793
27436024	778	786	patients	T101	C0030705
27436024	804	823	myocardial ischemia	T047	C0151744
27436024	831	839	ischemic	T169	C0475224
27436024	840	850	myocardial	T082	C1522564
27436024	851	859	segments	T082	C0442059
27436024	863	889	magnetic resonance imaging	T060	C0024485
27436024	891	894	MRI	T060	C0024485
27436024	929	940	percentiles	T081	C1264641
27436024	944	956	FDfirst-pass	T079	C0444693
27436024	971	986	pathomechanical	T169	C0205469
27436024	987	1001	classification	T185	C0008902
27436024	1013	1020	lesions	T033	C0221198
27436024	1026	1038	FDfirst-pass	T079	C0444693
27436024	1064	1098	coronary microvascular dysfunction	T047	C2827469
27436024	1100	1103	CMD	T047	C2827469
27436024	1133	1156	coronary artery disease	T047	C3495826
27436024	1158	1161	CAD	T047	C3495826
27436024	1164	1171	Optimal	T080	C2698651
27436024	1172	1186	classification	T185	C0008902
27436024	1196	1199	ROC	T081	C1527113
27436024	1200	1208	analysis	T062	C0936012
27436024	1213	1225	FDfirst-pass	T079	C0444693
27436024	1235	1250	FDrecirculation	T040	C1516559
27436024	1251	1261	correlated	T080	C1707520
27436024	1278	1304	per cent diameter stenosis	T082	C3897965
27436024	1308	1316	invasive	T080	C0205281
27436024	1317	1337	coronary angiography	T060	C0085532
27436024	1341	1348	lesions	T033	C0221198
27436024	1360	1363	CAD	T047	C3495826
27436024	1395	1398	CMD	T047	C2827469
27436024	1427	1435	ischemic	T046	C0022116
27436024	1436	1446	transition	T052	C2700061
27436024	1447	1453	region	T029	C0005898
27436024	1466	1477	information	T078	C1533716
27436024	1481	1508	pathomechanical composition	T169	C0205469
27436024	1513	1521	severity	T080	C0439793
27436024	1525	1544	myocardial ischemia	T047	C0151744
27436024	1536	1544	ischemia	T046	C0022116
27436024	1546	1548	FA	T062	C0936012
27436024	1557	1563	region	T029	C0005898
27436024	1584	1591	improve	T033	C0184511
27436024	1592	1601	diagnosis	T033	C0011900
27436024	1614	1625	traditional	T169	C0443324
27436024	1626	1637	noninvasive	T185	C2986496
27436024	1638	1658	myocardial perfusion	T032	C0428857
27436024	1659	1667	analysis	T062	C0936012
27436024	1673	1678	novel	T080	C0205314
27436024	1679	1689	hypothesis	T078	C1512571
27436024	1694	1700	method	T170	C0025663
27436024	1718	1738	pathophysiologically	T169	C0031847
27436024	1752	1771	myocardial ischemia	T047	C0151744
27436024	1779	1787	ischemic	T046	C0022116
27436024	1788	1798	transition	T052	C2700061
27436024	1799	1805	region	T029	C0005898
27436024	1848	1865	perfusion imaging	T060	C2350393
27436024	1869	1876	Fractal	T077	C0206163
27436024	1877	1885	analysis	T062	C0936012
27436024	1935	1943	severity	T080	C0439793
27436024	1947	1966	myocardial ischemia	T047	C0151744
27436024	1958	1966	ischemia	T046	C0022116

27465497|t|Pivotal debates and controversies on the structure and function of the avian respiratory system: setting the record straight
27465497|a|Among the extant air-breathing vertebrates, the avian respiratory system is structurally the most complex and functionally the most efficient gas exchanger. Having been investigated for over four centuries, some aspects of its biology have been extremely challenging and highly contentious and others still remain unresolved. Here, while assessing the most recent findings, four notable aspects of the structure and function of the avian respiratory system are examined critically to highlight the questions, speculations, controversies and debates that have arisen from past research. The innovative techniques and experiments that were performed to answer particular research questions are emphasised. The features that are outlined here concern the arrangement of the airways, the path followed by the inspired air, structural features of the lung and the air and blood capillaries, and the level of cellular defence in the avian respiratory system. Hitherto, based on association with the proven efficiency of naturally evolved and human-made counter-current exchange systems rather than on definite experimental evidence, a counter-current gas exchange system was suggested to exist in the avian respiratory system and was used to explain its exceptional efficiency. However, by means of an elegant experiment in which the direction of the air - flow in the lung was reversed, a cross-current system was shown to be in operation instead. Studies of the arrangement of the airways and the blood vessels corroborated the existence of a cross-current system in the avian lung. While the avian respiratory system is ventilated tidally, like most other invaginated gas exchangers, the lung, specifically the paleopulmonic parabronchi, is ventilated unidirectionally and continuously in a caudocranial (back-to-front) direction by synchronized actions of the air sacs. The path followed by the inspired air in the lung - air sac system is now known to be controlled by a mechanism of aerodynamic valving and not by anatomical valves or sphincters, as was previously supposed. The structural strength of the air and blood capillaries is derived from: the interdependence between the air and blood capillaries; a tethering effect between the closely entwined respiratory units; the presence of epithelial - epithelial cell connections (retinacula or cross-bridges) that join the blood capillaries while separating the air capillaries; the abundance and intricate arrangement of the connective tissue elements, i.e. collagen, elastin, and smooth muscle fibres; the presence of type-IV collagen, especially in the basement membranes of the blood-gas barrier and the epithelial - epithelial cell connections; and a putative tensegrity state in the lung. Notwithstanding the paucity of free surface pulmonary macrophages, the respiratory surface of the avian lung is well protected from pathogens and particulates by an assortment of highly efficient phagocytic cells. In commercial poultry production, instead of weak pulmonary cellular defence, stressful husbandry practices such as overcrowding, force-feeding, and intense genetic manipulation for rapid weight gain and egg production may account for the reported susceptibility of birds to aerosol - transmitted diseases.
27465497	8	15	debates	T052	C0870392
27465497	20	33	controversies	T054	C0680243
27465497	41	50	structure	T017	C0700276
27465497	55	63	function	T040	C0678864
27465497	71	76	avian	T012	C0005595
27465497	77	95	respiratory system	T022	C0035237
27465497	109	115	record	T170	C0034869
27465497	142	167	air-breathing vertebrates	T010	C0042567
27465497	173	178	avian	T012	C0005595
27465497	179	197	respiratory system	T022	C0035237
27465497	201	213	structurally	T017	C0700276
27465497	223	230	complex	T080	C0439855
27465497	235	247	functionally	T169	C0542341
27465497	257	266	efficient	T080	C0442799
27465497	267	280	gas exchanger	T044	C1621574
27465497	337	344	aspects	T080	C1879746
27465497	489	497	findings	T033	C0243095
27465497	512	519	aspects	T080	C1879746
27465497	527	536	structure	T017	C0700276
27465497	541	549	function	T040	C0678864
27465497	557	562	avian	T012	C0005595
27465497	563	581	respiratory system	T022	C0035237
27465497	623	632	questions	T078	C0681799
27465497	634	646	speculations	T078	C1512571
27465497	648	661	controversies	T054	C0680243
27465497	666	673	debates	T052	C0870392
27465497	701	709	research	T062	C0035168
27465497	715	736	innovative techniques	T169	C0449851
27465497	741	752	experiments	T062	C0681814
27465497	794	812	research questions	T078	C0681799
27465497	833	841	features	T080	C1521970
27465497	896	903	airways	T023	C0458827
27465497	909	913	path	T082	C1254362
27465497	930	942	inspired air	T167	C1441399
27465497	944	954	structural	T017	C0700276
27465497	955	963	features	T080	C1521970
27465497	971	975	lung	T023	C0024109
27465497	984	987	air	T023	C0507816
27465497	992	1009	blood capillaries	T023	C0006901
27465497	1028	1044	cellular defence	T043	C1155076
27465497	1052	1057	avian	T012	C0005595
27465497	1058	1076	respiratory system	T022	C0035237
27465497	1125	1135	efficiency	T081	C0013682
27465497	1139	1156	naturally evolved	T169	C0205296
27465497	1161	1171	human-made	T080	C0522502
27465497	1172	1204	counter-current exchange systems	T038	C1160636
27465497	1229	1250	experimental evidence	T078	C3887511
27465497	1254	1289	counter-current gas exchange system	T038	C1160636
27465497	1320	1325	avian	T012	C0005595
27465497	1326	1344	respiratory system	T022	C0035237
27465497	1385	1395	efficiency	T081	C0013682
27465497	1429	1439	experiment	T062	C0681814
27465497	1453	1462	direction	T082	C0449738
27465497	1470	1473	air	T167	C0001861
27465497	1476	1480	flow	T070	C0806140
27465497	1488	1492	lung	T023	C0024109
27465497	1497	1505	reversed	T169	C1555029
27465497	1509	1529	cross-current system	T038	C1160636
27465497	1568	1575	Studies	T062	C2603343
27465497	1602	1609	airways	T023	C0458827
27465497	1618	1631	blood vessels	T023	C0005847
27465497	1664	1684	cross-current system	T038	C1160636
27465497	1692	1697	avian	T012	C0005595
27465497	1698	1702	lung	T023	C0024109
27465497	1714	1719	avian	T012	C0005595
27465497	1720	1738	respiratory system	T022	C0035237
27465497	1742	1752	ventilated	T169	C0231923
27465497	1778	1789	invaginated	T190	C0221224
27465497	1790	1804	gas exchangers	T044	C1621574
27465497	1810	1814	lung	T023	C0024109
27465497	1833	1858	paleopulmonic parabronchi	T023	C0225598
27465497	1863	1873	ventilated	T169	C0231923
27465497	1874	1890	unidirectionally	T082	C0449738
27465497	1913	1925	caudocranial	T023	C0037303
27465497	1927	1940	back-to-front	T082	C0449738
27465497	1942	1951	direction	T082	C0449738
27465497	1955	1967	synchronized	T079	C0439580
27465497	1968	1975	actions	T052	C3266814
27465497	1983	1991	air sacs	T023	C3826755
27465497	1997	2001	path	T082	C1254362
27465497	2018	2030	inspired air	T167	C1441399
27465497	2038	2042	lung	T023	C0024109
27465497	2045	2052	air sac	T023	C3826755
27465497	2053	2059	system	T022	C0460002
27465497	2079	2089	controlled	T169	C2587213
27465497	2095	2104	mechanism	T169	C0441712
27465497	2108	2127	aerodynamic valving	T067	C1254366
27465497	2139	2156	anatomical valves	T023	C1186983
27465497	2160	2170	sphincters	T023	C1409894
27465497	2204	2214	structural	T017	C0700276
27465497	2215	2223	strength	T078	C0808080
27465497	2231	2234	air	T023	C0507816
27465497	2239	2256	blood capillaries	T023	C0006901
27465497	2278	2293	interdependence	T169	C0205245
27465497	2306	2309	air	T023	C0507816
27465497	2314	2331	blood capillaries	T023	C0006901
27465497	2381	2398	respiratory units	T022	C0035237
27465497	2416	2426	epithelial	T025	C0014597
27465497	2429	2444	epithelial cell	T025	C0014597
27465497	2445	2456	connections	T082	C0449379
27465497	2458	2468	retinacula	T024	C0222330
27465497	2501	2518	blood capillaries	T023	C0006901
27465497	2540	2555	air capillaries	T023	C0507816
27465497	2561	2570	abundance	T080	C2346714
27465497	2575	2596	intricate arrangement	T082	C0449830
27465497	2604	2621	connective tissue	T024	C0009780
27465497	2637	2645	collagen	T116	C0009325
27465497	2647	2654	elastin	T116	C0013765
27465497	2660	2680	smooth muscle fibres	T025	C1135918
27465497	2698	2714	type-IV collagen	T116,T123	C0009333
27465497	2734	2752	basement membranes	T024	C0004799
27465497	2760	2777	blood-gas barrier	T030	C0005853
27465497	2786	2796	epithelial	T025	C0014597
27465497	2799	2814	epithelial cell	T025	C0014597
27465497	2815	2826	connections	T082	C0449379
27465497	2843	2859	tensegrity state	T080	C0205556
27465497	2867	2871	lung	T023	C0024109
27465497	2904	2916	free surface	T082	C0205148
27465497	2917	2938	pulmonary macrophages	T025	C0085236
27465497	2944	2955	respiratory	T169	C0521346
27465497	2956	2963	surface	T082	C0205148
27465497	2971	2976	avian	T012	C0005595
27465497	2977	2981	lung	T023	C0024109
27465497	3005	3014	pathogens	T001	C0450254
27465497	3019	3031	particulates	T167	C0457784
27465497	3059	3068	efficient	T080	C0442799
27465497	3069	3085	phagocytic cells	T025	C0031307
27465497	3101	3108	poultry	T012	C0032850
27465497	3109	3119	production	T057	C0033268
27465497	3132	3136	weak	T080	C1762617
27465497	3137	3146	pulmonary	T023	C0024109
27465497	3147	3163	cellular defence	T043	C1155076
27465497	3165	3174	stressful	T169	C0231297
27465497	3175	3184	husbandry	T090	C0003052
27465497	3203	3215	overcrowding	T033	C0243095
27465497	3217	3230	force-feeding	T033	C2230049
27465497	3236	3243	intense	T080	C0522510
27465497	3244	3264	genetic manipulation	T063	C0178659
27465497	3275	3286	weight gain	T033	C0043094
27465497	3291	3305	egg production	T040	C0029957
27465497	3335	3349	susceptibility	T201	C0012655
27465497	3353	3358	birds	T012	C0005595
27465497	3362	3369	aerosol	T073	C0001712
27465497	3372	3383	transmitted	T169	C0332289
27465497	3384	3392	diseases	T047	C0012634

28332476|t|New-onset hepatitis C virus -associated glomerulonephritis following sustained virologic response with direct-acting antiviral therapy
28332476|a|Glomerulonephritis (GN) is an important extra-hepatic manifestation of infection with hepatitis C virus (HCV). HCV -associated GN occurs due to HCV -induced lymphoproliferation, leading to the generation of pathogenic immune complexes, including complexes containing cryoglobulins. The management of HCV -associated extra-hepatic disease is focused on viral eradication, with direct-acting antiviral agents leading to high rates of sustained virologic remission. There have been a few reports of relapsing cryoglobulinemic vasculitis after sustained virologic remission was achieved with interferon-based therapies. This report presents two cases of new-onset HCV -associated GN that occurred after sustained virologic response was achieved with direct-acting antiviral (DAA) therapy.
28332476	10	27	hepatitis C virus	T005	C0220847
28332476	40	58	glomerulonephritis	T047	C0017658
28332476	79	97	virologic response	T033	C4053862
28332476	103	134	direct-acting antiviral therapy	T061	C0280274
28332476	135	153	Glomerulonephritis	T047	C0017658
28332476	155	157	GN	T047	C0017658
28332476	175	188	extra-hepatic	T082	C1517058
28332476	206	215	infection	T046	C3714514
28332476	221	238	hepatitis C virus	T005	C0220847
28332476	240	243	HCV	T005	C0220847
28332476	246	249	HCV	T005	C0220847
28332476	262	264	GN	T047	C0017658
28332476	279	282	HCV	T005	C0220847
28332476	292	311	lymphoproliferation	T033	C4014164
28332476	342	369	pathogenic immune complexes	T047	C0020951
28332476	402	415	cryoglobulins	T116,T129	C0010404
28332476	435	438	HCV	T005	C0220847
28332476	451	464	extra-hepatic	T082	C1517058
28332476	465	472	disease	T047	C0012634
28332476	487	492	viral	T005	C0042776
28332476	493	504	eradication	T058	C3178994
28332476	511	541	direct-acting antiviral agents	T121	C3653501
28332476	577	596	virologic remission	T033	C0544452
28332476	641	668	cryoglobulinemic vasculitis	T047	C0340992
28332476	685	704	virologic remission	T033	C0544452
28332476	723	749	interferon-based therapies	T061	C0279030
28332476	795	798	HCV	T005	C0220847
28332476	811	813	GN	T047	C0017658
28332476	844	862	virologic response	T033	C4053862
28332476	881	918	direct-acting antiviral (DAA) therapy	T061	C0280274

28537612|t|Proline -rich antimicrobial peptides targeting protein synthesis
28537612|a|Covering: up to 2017The innate immune system employs a broad array of antimicrobial peptides (AMPs) to attack invading microorganisms. While most AMPs act by permeabilizing the bacterial membrane, specific subclasses of AMPs have been identified that pass through membranes and inhibit bacterial growth by targeting fundamental intracellular processes. One such subclass is the proline -rich antimicrobial peptides (PrAMPs) that bind to the ribosome and interfere with the process of protein synthesis. A diverse range of PrAMPs have been identified in insects, such as bees, wasps and beetles, and crustaceans, such as crabs, as well as in mammals, such as cows, sheep, goats and pigs. Mechanistically, the best-characterized PrAMPs are the insect oncocins, such as Onc112, and bovine bactenecins, such as Bac7. Biochemical and structural studies have revealed that these PrAMPs bind within the ribosomal exit tunnel with a reverse orientation compared to a nascent polypeptide chain. The PrAMPs allow initiation but prevent the transition into the elongation phase of translation. Insight into the interactions of PrAMPs with their ribosomal target provides the opportunity to further develop these peptides as novel antimicrobial agents.
28537612	0	7	Proline	T116,T123	C0033382
28537612	14	36	antimicrobial peptides	T116,T121	C4084937
28537612	37	46	targeting	T169	C1521840
28537612	47	64	protein synthesis	T044	C0597295
28537612	89	109	innate immune system	T022	C0020962
28537612	126	131	array	T082	C1510941
28537612	135	157	antimicrobial peptides	T116,T121	C4084937
28537612	159	163	AMPs	T116,T121	C4084937
28537612	168	174	attack	T052	C3266814
28537612	175	198	invading microorganisms	T001	C0445623
28537612	211	215	AMPs	T116,T121	C4084937
28537612	223	237	permeabilizing	T169	C0205326
28537612	242	251	bacterial	T007	C0004611
28537612	252	260	membrane	T026	C0596901
28537612	271	281	subclasses	T185	C0445604
28537612	285	289	AMPs	T116,T121	C4084937
28537612	300	310	identified	T080	C0205396
28537612	329	338	membranes	T026	C0596901
28537612	343	350	inhibit	T052	C3463820
28537612	351	360	bacterial	T007	C0004611
28537612	361	367	growth	T040	C0018270
28537612	371	380	targeting	T169	C1521840
28537612	393	416	intracellular processes	T043	C1325880
28537612	427	435	subclass	T185	C0445604
28537612	443	450	proline	T116,T123	C0033382
28537612	457	479	antimicrobial peptides	T116,T121	C4084937
28537612	481	487	PrAMPs	T116,T121	C4084937
28537612	494	498	bind	T052	C1145667
28537612	506	514	ribosome	T026	C0035553
28537612	519	533	interfere with	T169	C0521102
28537612	538	545	process	T067	C1522240
28537612	549	566	protein synthesis	T044	C0597295
28537612	587	593	PrAMPs	T116,T121	C4084937
28537612	604	614	identified	T080	C0205396
28537612	618	625	insects	T204	C0021585
28537612	635	639	bees	T204	C0004923
28537612	641	646	wasps	T204	C0043041
28537612	651	658	beetles	T204	C0009276
28537612	664	675	crustaceans	T204	C0010395
28537612	685	690	crabs	T204	C0010260
28537612	706	713	mammals	T015	C0024660
28537612	723	727	cows	T015	C0007452
28537612	729	734	sheep	T015	C0036945
28537612	736	741	goats	T015	C1510458
28537612	746	750	pigs	T015	C0039005
28537612	773	791	best-characterized	T052	C1880022
28537612	792	798	PrAMPs	T116,T121	C4084937
28537612	807	813	insect	T204	C0021585
28537612	814	822	oncocins	T116,T123	C2936048
28537612	832	838	Onc112	T116	C1254349
28537612	844	850	bovine	T015	C3667982
28537612	851	862	bactenecins	T116,T121	C0052891
28537612	872	876	Bac7	T116,T121	C0285830
28537612	878	889	Biochemical	T169	C0205474
28537612	894	912	structural studies	T104	C1254350
28537612	918	926	revealed	T080	C0443289
28537612	938	944	PrAMPs	T116,T121	C4084937
28537612	945	949	bind	T052	C1145667
28537612	961	970	ribosomal	T026	C0035553
28537612	990	997	reverse	T169	C1555029
28537612	998	1009	orientation	T082	C1704322
28537612	1032	1049	polypeptide chain	T116	C1305923
28537612	1055	1061	PrAMPs	T116,T121	C4084937
28537612	1068	1078	initiation	T045	C1519613
28537612	1083	1090	prevent	T169	C1292733
28537612	1095	1105	transition	T052	C2700061
28537612	1115	1125	elongation	T045	C1157562
28537612	1126	1131	phase	T079	C0205390
28537612	1135	1146	translation	T044	C0597295
28537612	1165	1177	interactions	T169	C1704675
28537612	1181	1187	PrAMPs	T116,T121	C4084937
28537612	1199	1208	ribosomal	T026	C0035553
28537612	1209	1215	target	T169	C1521840
28537612	1216	1224	provides	T052	C1999230
28537612	1244	1251	further	T082	C1517331
28537612	1266	1274	peptides	T116	C0030956
28537612	1278	1283	novel	T080	C0205314
28537612	1284	1304	antimicrobial agents	T121	C1136254

27744574|t|TGFβ Contributes to the Anti-inflammatory Effects of Tauroursodeoxycholic Acid on an Animal Model of Acute Neuroinflammation
27744574|a|The bile acid conjugate tauroursodeoxycholic acid (TUDCA) is a neuroprotective agent in various animal models of neuropathologies. We have previously shown the anti-inflammatory properties of TUDCA in an animal model of acute neuroinflammation. Here, we present a new anti-inflammatory mechanism of TUDCA through the regulation of transforming growth factor β (TGFβ) pathway. The bacterial lipopolysaccharide (LPS) was injected intravenously (iv) on TGFβ reporter mice (Smad-binding element (SBE)/Tk-Luc) to study in their brains the real-time activation profile of the TGFβ pathway in a non-invasive way. The activation of the TGFβ pathway in the brain of SBE/Tk-Luc mice increased 24 h after LPS injection, compared to control animals. This activation peak increased further in mice treated with both LPS and TUDCA than in mice treated with LPS only. The enhanced TGFβ activation in mice treated with LPS and TUDCA correlated with both an increase in TGFβ3 transcript in mouse brain and an increase in TGFβ3 immunoreactivity in microglia / macrophages, endothelial cells, and neurons. Inhibition of the TGFβ receptor with SB431542 drug reverted the effect of TUDCA on microglia / macrophages activation and on TGFβ3 immunoreactivity. Under inflammatory conditions, treatment with TUDCA enhanced further the activation of TGFβ pathway in mouse brain and increased the expression of TGFβ3. Therefore, the induction of TGFβ3 by TUDCA might act as a positive feedback, increasing the initial activation of the TGFβ pathway by the inflammatory stimulus. Our findings provide proof-of-concept that TGFβ contributes to the anti-inflammatory effect of TUDCA under neuroinflammatory conditions.
27744574	0	4	TGFβ	T116,T123	C0040690
27744574	24	49	Anti-inflammatory Effects	T080	C1515999
27744574	53	78	Tauroursodeoxycholic Acid	T109,T121	C0075857
27744574	85	97	Animal Model	T050	C0012644
27744574	101	106	Acute	T079	C0205178
27744574	107	124	Neuroinflammation	T046	C0021368
27744574	129	138	bile acid	T109,T123	C0005390
27744574	149	174	tauroursodeoxycholic acid	T109,T121	C0075857
27744574	176	181	TUDCA	T109,T121	C0075857
27744574	188	209	neuroprotective agent	T121	C0242912
27744574	221	234	animal models	T050	C0012644
27744574	238	254	neuropathologies	T091	C0876934
27744574	285	313	anti-inflammatory properties	T080	C1515999
27744574	317	322	TUDCA	T109,T121	C0075857
27744574	329	341	animal model	T050	C0012644
27744574	345	350	acute	T079	C0205178
27744574	351	368	neuroinflammation	T046	C0021368
27744574	393	420	anti-inflammatory mechanism	T080	C1515999
27744574	424	429	TUDCA	T109,T121	C0075857
27744574	442	499	regulation of transforming growth factor β (TGFβ) pathway	T044	C1155369
27744574	505	514	bacterial	T080	C0521009
27744574	515	533	lipopolysaccharide	T109	C0023810
27744574	535	538	LPS	T109	C0023810
27744574	544	566	injected intravenously	T061	C1737200
27744574	575	579	TGFβ	T116,T123	C0040690
27744574	580	593	reporter mice	T015	C0025929
27744574	595	615	Smad-binding element	T116,T123	C1571580
27744574	617	620	SBE	T116,T123	C1571580
27744574	633	638	study	T062	C2603343
27744574	648	654	brains	T023	C0006104
27744574	659	687	real-time activation profile	T059	C1979963
27744574	695	707	TGFβ pathway	T044	C1155363
27744574	713	725	non-invasive	T169	C0205303
27744574	735	765	activation of the TGFβ pathway	T040	C2244559
27744574	773	778	brain	T023	C0006104
27744574	782	797	SBE/Tk-Luc mice	T015	C0025929
27744574	819	822	LPS	T109	C0023810
27744574	823	832	injection	T061	C1533685
27744574	846	861	control animals	T008	C1511501
27744574	868	878	activation	T052	C1879547
27744574	879	883	peak	T080	C0444505
27744574	905	909	mice	T015	C0025929
27744574	910	917	treated	T169	C1522326
27744574	928	931	LPS	T109	C0023810
27744574	936	941	TUDCA	T109,T121	C0075857
27744574	950	954	mice	T015	C0025929
27744574	955	962	treated	T169	C1522326
27744574	968	971	LPS	T109	C0023810
27744574	991	1006	TGFβ activation	T040	C2244559
27744574	1010	1014	mice	T015	C0025929
27744574	1015	1022	treated	T169	C1522326
27744574	1028	1031	LPS	T109	C0023810
27744574	1036	1041	TUDCA	T109,T121	C0075857
27744574	1066	1074	increase	T169	C0442805
27744574	1078	1094	TGFβ3 transcript	T116,T123	C0040690
27744574	1098	1103	mouse	T015	C0025929
27744574	1104	1109	brain	T023	C0006104
27744574	1117	1125	increase	T169	C0442805
27744574	1129	1134	TGFβ3	T116,T123	C0040690
27744574	1135	1151	immunoreactivity	T044	C0597879
27744574	1155	1164	microglia	T025	C0206116
27744574	1167	1178	macrophages	T025	C0024432
27744574	1180	1197	endothelial cells	T025	C0225336
27744574	1203	1210	neurons	T025	C0027882
27744574	1212	1222	Inhibition	T044	C0021469
27744574	1230	1243	TGFβ receptor	T116,T129,T192	C0076930
27744574	1249	1262	SB431542 drug	T109,T121	C1137338
27744574	1286	1291	TUDCA	T109,T121	C0075857
27744574	1295	1304	microglia	T043	C0007613
27744574	1307	1329	macrophages activation	T043	C2248379
27744574	1337	1342	TGFβ3	T116,T123	C0040690
27744574	1343	1359	immunoreactivity	T044	C0597879
27744574	1367	1390	inflammatory conditions	T046	C0021368
27744574	1392	1401	treatment	T169	C1522326
27744574	1407	1412	TUDCA	T109,T121	C0075857
27744574	1434	1460	activation of TGFβ pathway	T044	C1155363
27744574	1470	1475	brain	T023	C0006104
27744574	1480	1489	increased	T081	C0205217
27744574	1494	1504	expression	T045	C1171362
27744574	1508	1513	TGFβ3	T116,T123	C0040690
27744574	1530	1539	induction	T169	C0205263
27744574	1543	1548	TGFβ3	T116,T123	C0040690
27744574	1552	1557	TUDCA	T109,T121	C0075857
27744574	1592	1602	increasing	T169	C0442808
27744574	1615	1645	activation of the TGFβ pathway	T040	C2244559
27744574	1653	1665	inflammatory	T169	C0333348
27744574	1666	1674	stimulus	T067	C0234402
27744574	1719	1723	TGFβ	T116,T123	C0040690
27744574	1743	1767	anti-inflammatory effect	T080	C1515999
27744574	1771	1776	TUDCA	T109,T121	C0075857
27744574	1783	1811	neuroinflammatory conditions	T046	C0021368

28302782|t|Genome Sequences of Mycobacteriophages Jane and Sneeze, New Members of Cluster G
28302782|a|Jane and Sneeze are newly isolated phages of Mycobacterium smegmatis mc(2)155 from Hillsborough, NJ, and Palo Verde, Costa Rica, respectively. Both are cluster G, subcluster G1 mycobacteriophages. Notable nucleotide differences exist between genomes in the right half, including the presence of mycobacteriophage mobile element 1 (MPME1) in Jane.
28302782	0	16	Genome Sequences	T085	C2348746
28302782	20	54	Mycobacteriophages Jane and Sneeze	T005	C0026911
28302782	107	115	isolated	T169	C0205409
28302782	116	122	phages	T005	C0004651
28302782	126	158	Mycobacterium smegmatis mc(2)155	T007	C0317761
28302782	164	176	Hillsborough	T083	C3812217
28302782	178	180	NJ	T083	C0027971
28302782	186	196	Palo Verde	T083	C0017446
28302782	198	208	Costa Rica	T083	C0010182
28302782	258	276	mycobacteriophages	T005	C0026911
28302782	286	296	nucleotide	T114	C0028630
28302782	297	308	differences	T080	C1705242
28302782	323	330	genomes	T028	C0017428
28302782	376	393	mycobacteriophage	T005	C0026911
28302782	394	410	mobile element 1	T114,T123	C1257903

27660855|t|Discovery of Orally Efficacious Phosphoinositide-3-Kinase delta Inhibitors with Improved Metabolic Stability
27660855|a|Aberrant signaling of phosphoinositide-3-kinase delta (PI3K-delta) has been implicated in numerous pathologies including hematological malignancies and rheumatoid arthritis. Described in this manuscript is the discovery, optimization and in vivo evaluation of a novel series of pyridine-containing PI3K-delta inhibitors. This work led to the discovery of 35, a highly selective inhibitor of PI3K-delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.
27660855	0	9	Discovery	T052	C1880355
27660855	13	19	Orally	T030	C0226896
27660855	20	31	Efficacious	T080	C1704419
27660855	32	63	Phosphoinositide-3-Kinase delta	T116,T126	C1450115
27660855	64	74	Inhibitors	T121	C0014432
27660855	80	88	Improved	T033	C0184511
27660855	89	98	Metabolic	T169	C0311400
27660855	99	108	Stability	T080	C0205360
27660855	109	127	Aberrant signaling	T038	C3537152
27660855	131	162	phosphoinositide-3-kinase delta	T116,T126	C1450115
27660855	164	174	PI3K-delta	T116,T126	C1450115
27660855	208	219	pathologies	T046	C0677042
27660855	230	256	hematological malignancies	T191	C0376545
27660855	261	281	rheumatoid arthritis	T047	C0003873
27660855	319	328	discovery	T052	C1880355
27660855	330	342	optimization	T052	C2698650
27660855	347	354	in vivo	T082	C1515655
27660855	355	365	evaluation	T058	C0220825
27660855	387	406	pyridine-containing	T109	C0576798
27660855	407	417	PI3K-delta	T116,T126	C1450115
27660855	418	428	inhibitors	T121	C0014432
27660855	451	460	discovery	T052	C1880355
27660855	464	466	35	T121	C1254351
27660855	487	496	inhibitor	T121	C0014432
27660855	500	510	PI3K-delta	T116,T126	C1450115
27660855	539	562	pharmacokinetic profile	T169	C0031328
27660855	570	581	efficacious	T080	C1704419
27660855	587	599	rodent model	T050	C1519106
27660855	603	623	rheumatoid arthritis	T047	C0003873

28318461|t|The Event Chain of Survival in the Context of Music Festivals: A Framework for Improving Outcomes at Major Planned Events
28318461|a|Despite the best efforts of event producers and on-site medical teams, there are sometimes serious illnesses, life-threatening injuries, and fatalities related to music festival attendance. Producers, clinicians, and researchers are actively seeking ways to reduce the mortality and morbidity associated with these events. After analyzing the available literature on music festival health and safety, several major themes emerged. Principally, stakeholder groups planning in isolation from one another (ie, in silos) create fragmentation, gaps, and overlap in plans for major planned events (MPEs). The authors hypothesized that one approach to minimizing this fragmentation may be to create a framework to "connect the dots," or join together the many silos of professionals responsible for safety, security, health, and emergency planning at MPEs. Adapted from the well-established literature regarding the management of cardiac arrests, both in and out of hospital, the " chain of survival " concept is applied to the disparate groups providing services that support event safety in the context of music festivals. The authors propose this framework for describing, understanding, coordinating and planning around the integration of safety, security, health, and emergency service for events. The adapted Event Chain of Survival contains six interdependent links, including: (1) event producers; (2) police and security; (3) festival health; (4) on-site medical services; (5) ambulance services; and (6) off-site medical services. The authors argue that adapting and applying this framework in the context of MPEs in general, and music festivals specifically, has the potential to break down the current disconnected approach to event safety, security, health, and emergency planning. It offers a means of shifting the focus from a purely reactive stance to a more proactive, collaborative, and integrated approach. Improving health outcomes for music festival attendees, reducing gaps in planning, promoting consistency, and improving efficiency by reducing duplication of services will ultimately require coordination and collaboration from the beginning of event production to post-event reporting. Lund A, Turris SA. The Event Chain of Survival in the context of music festivals: a framework for improving outcomes at major planned events. Prehosp Disaster Med. 2017;32(4):1-7.
28318461	4	9	Event	T051	C0441471
28318461	10	27	Chain of Survival	T169	C0220921
28318461	35	42	Context	T078	C0449255
28318461	46	51	Music	T170	C0026867
28318461	52	61	Festivals	T052	C0015922
28318461	65	74	Framework	T077	C1254372
28318461	89	97	Outcomes	T170	C1550208
28318461	101	121	Major Planned Events	T051	C0441471
28318461	150	155	event	T051	C0441471
28318461	156	165	producers	T097	C0335088
28318461	170	191	on-site medical teams	T058	C0086390
28318461	221	230	illnesses	T184	C0221423
28318461	232	248	life-threatening	T033	C2826244
28318461	249	257	injuries	T037	C3263723
28318461	263	273	fatalities	T080	C0205556
28318461	285	290	music	T170	C0026867
28318461	291	299	festival	T052	C0015922
28318461	300	310	attendance	T052	C2827364
28318461	312	321	Producers	T097	C0335088
28318461	323	333	clinicians	T097	C0871685
28318461	339	350	researchers	T097	C0687734
28318461	391	400	mortality	T081	C0205848
28318461	405	414	morbidity	T081	C0026538
28318461	415	430	associated with	T080	C0332281
28318461	437	443	events	T051	C0441471
28318461	475	485	literature	T170	C0023866
28318461	489	494	music	T170	C0026867
28318461	495	503	festival	T052	C0015922
28318461	504	510	health	T078	C0018684
28318461	515	521	safety	T068	C0036043
28318461	566	584	stakeholder groups	T078	C0441833
28318461	585	593	planning	T169	C1301732
28318461	597	606	isolation	T169	C0205409
28318461	646	659	fragmentation	T080	C0205556
28318461	661	665	gaps	T080	C0205556
28318461	671	678	overlap	T079	C1948020
28318461	682	687	plans	T057	C0680834
28318461	692	712	major planned events	T051	C0441471
28318461	714	718	MPEs	T051	C0441471
28318461	725	732	authors	T097	C3812881
28318461	783	796	fragmentation	T080	C0205556
28318461	816	825	framework	T077	C1254372
28318461	884	897	professionals	T097	C0679924
28318461	914	920	safety	T068	C0036043
28318461	922	930	security	T077	C1519222
28318461	932	938	health	T078	C0018684
28318461	944	953	emergency	T067	C0013956
28318461	954	962	planning	T169	C1301732
28318461	966	970	MPEs	T051	C0441471
28318461	1006	1016	literature	T170	C0023866
28318461	1031	1041	management	T058	C0376636
28318461	1045	1089	cardiac arrests, both in and out of hospital	T046	C2936490
28318461	1097	1114	chain of survival	T169	C0220921
28318461	1143	1159	disparate groups	T078	C0441833
28318461	1170	1178	services	T057	C0557854
28318461	1184	1191	support	T077	C1521721
28318461	1192	1197	event	T051	C0441471
28318461	1198	1204	safety	T068	C0036043
28318461	1212	1219	context	T078	C0449255
28318461	1223	1228	music	T170	C0026867
28318461	1229	1238	festivals	T052	C0015922
28318461	1244	1251	authors	T097	C3812881
28318461	1265	1274	framework	T077	C1254372
28318461	1279	1289	describing	T080	C0205556
28318461	1291	1304	understanding	T041	C0162340
28318461	1306	1318	coordinating	T169	C0700114
28318461	1323	1331	planning	T169	C1301732
28318461	1343	1354	integration	T169	C0205245
28318461	1358	1364	safety	T068	C0036043
28318461	1366	1374	security	T077	C1519222
28318461	1376	1382	health	T078	C0018684
28318461	1388	1397	emergency	T067	C0013956
28318461	1398	1405	service	T057	C0557854
28318461	1410	1416	events	T051	C0441471
28318461	1430	1435	Event	T051	C0441471
28318461	1436	1453	Chain of Survival	T169	C0220921
28318461	1467	1487	interdependent links	T077	C1254372
28318461	1504	1509	event	T051	C0441471
28318461	1510	1519	producers	T097	C0335088
28318461	1525	1531	police	T097	C0085098
28318461	1536	1544	security	T077	C1519222
28318461	1550	1558	festival	T052	C0015922
28318461	1559	1565	health	T078	C0018684
28318461	1571	1595	on-site medical services	T058	C0199168
28318461	1601	1619	ambulance services	T074	C0002422
28318461	1629	1654	off-site medical services	T058	C0199168
28318461	1660	1667	authors	T097	C3812881
28318461	1706	1715	framework	T077	C1254372
28318461	1723	1730	context	T078	C0449255
28318461	1734	1738	MPEs	T051	C0441471
28318461	1755	1760	music	T170	C0026867
28318461	1761	1770	festivals	T052	C0015922
28318461	1854	1859	event	T051	C0441471
28318461	1860	1866	safety	T068	C0036043
28318461	1868	1876	security	T077	C1519222
28318461	1878	1884	health	T078	C0018684
28318461	1890	1899	emergency	T067	C0013956
28318461	1900	1908	planning	T169	C1301732
28318461	1990	1999	proactive	T054	C0037397
28318461	2001	2014	collaborative	T054	C0282116
28318461	2020	2039	integrated approach	T054	C0037397
28318461	2051	2066	health outcomes	T170	C1550208
28318461	2071	2076	music	T170	C0026867
28318461	2077	2085	festival	T052	C0015922
28318461	2106	2110	gaps	T080	C0205556
28318461	2114	2122	planning	T169	C1301732
28318461	2134	2145	consistency	T080	C0332529
28318461	2161	2171	efficiency	T081	C0013682
28318461	2184	2195	duplication	T169	C0332597
28318461	2199	2207	services	T057	C0557854
28318461	2232	2244	coordination	T169	C0700114
28318461	2249	2262	collaboration	T054	C0282116
28318461	2285	2290	event	T051	C0441471
28318461	2291	2301	production	T057	C0033268
28318461	2305	2325	post-event reporting	T057	C3242276
28318461	2327	2333	Lund A	T170	C0805191
28318461	2335	2344	Turris SA	T170	C0805191
28318461	2350	2355	Event	T051	C0441471
28318461	2356	2373	Chain of Survival	T169	C0220921
28318461	2381	2388	context	T078	C0449255
28318461	2392	2397	music	T170	C0026867
28318461	2398	2407	festivals	T052	C0015922
28318461	2411	2420	framework	T077	C1254372
28318461	2435	2443	outcomes	T170	C1550208
28318461	2447	2467	major planned events	T051	C0441471

28528555|t|Development and Evaluation of the ADHD Cognitions Scale for Adults
28528555|a|The clinical literature on ADHD in adults suggests that " overly positive " or optimistic cognitions may contribute to impairment and failure to use self-regulation skills in this population, yet the research literature on this topic is limited. We developed the ADHD Cognitions Scale (ACS), a brief self-report measure of ADHD -related thoughts, and evaluated its psychometric properties. We collected self-report measures, inculding the ACS, from two large community samples (Ns = 262, 304). The measure demonstrated a one-factor solution that replicated in the second sample. Evidence of good internal consistency and also convergent and divergent validity was obtained for both samples. Scores on the ACS correlated with functional impairment, time management problems, and avoidant coping strategies. With additional study, the ACS may be useful to identify and track maladaptive ADHD -related cognitions during cognitive-behavioral treatment, and to further study the role of these thoughts in ADHD -related impairment.
28528555	0	11	Development	T169	C1527148
28528555	16	26	Evaluation	T062	C0015194
28528555	34	38	ADHD	T048	C1263846
28528555	34	55	ADHD Cognitions Scale	T170	C0451081
28528555	60	66	Adults	T100	C0001675
28528555	71	90	clinical literature	T170	C0023866
28528555	94	98	ADHD	T048	C1263846
28528555	102	108	adults	T100	C0001675
28528555	125	140	overly positive	T041	C0009240
28528555	146	167	optimistic cognitions	T041	C0563183
28528555	186	196	impairment	T169	C0221099
28528555	201	208	failure	T055	C0680095
28528555	216	238	self-regulation skills	T055	C0678856
28528555	247	257	population	T098	C1257890
28528555	267	275	research	T062	C0035168
28528555	276	286	literature	T170	C0023866
28528555	330	334	ADHD	T048	C1263846
28528555	330	351	ADHD Cognitions Scale	T170	C0451081
28528555	353	356	ACS	T170	C0451081
28528555	367	378	self-report	T062	C2700446
28528555	379	386	measure	T081	C0079809
28528555	390	394	ADHD	T048	C1263846
28528555	404	412	thoughts	T041	C0039869
28528555	432	455	psychometric properties	T080	C0871161
28528555	470	481	self-report	T062	C2700446
28528555	482	490	measures	T081	C0079809
28528555	506	509	ACS	T170	C0451081
28528555	526	543	community samples	T096	C0009462
28528555	588	607	one-factor solution	T081	C0392762
28528555	613	623	replicated	T169	C0205173
28528555	638	644	sample	T096	C0009462
28528555	663	683	internal consistency	T081	C0870731
28528555	693	703	convergent	T080	C1510594
28528555	708	726	divergent validity	T080	C1510603
28528555	749	756	samples	T096	C0009462
28528555	758	764	Scores	T081	C0449820
28528555	772	775	ACS	T170	C0451081
28528555	792	813	functional impairment	T033	C4062321
28528555	815	839	time management problems	T033	C0033213
28528555	845	860	avoidant coping	T033	C0231426
28528555	861	871	strategies	T041	C0679199
28528555	889	894	study	T062	C2603343
28528555	900	903	ACS	T170	C0451081
28528555	940	951	maladaptive	T033	C0562443
28528555	952	956	ADHD	T048	C1263846
28528555	966	976	cognitions	T041	C0009240
28528555	984	1014	cognitive-behavioral treatment	T061	C0009244
28528555	1031	1036	study	T062	C2603343
28528555	1055	1063	thoughts	T041	C0039869
28528555	1067	1071	ADHD	T048	C1263846
28528555	1067	1091	ADHD -related impairment	T033	C4062321

28289109|t|Minding the Gap: Factors Associated With Primary Care Coordination of Adults in 11 Countries
28289109|a|Care coordination has been identified as a key strategy in improving the effectiveness, safety, and efficiency of the US health care system. Our objective was to determine whether population or health care system issues are associated with primary care coordination gaps in the United States and other high-income countries. We analyzed data from the 2013 Commonwealth Fund International Health Policy (IHP) survey with multivariate logistic regression analysis. Respondents were adult primary care patients from 11 countries: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, United Kingdom, and the United States. Poor primary care coordination was defined as participants reporting at least 3 gaps in the coordination of care out of a maximum of 5. Analyses were based on 13,958 respondents. The rate of poor primary care coordination was 5.2% (724/13,958 respondents) overall and highest in the United States, at 9.8% (137/1,395 respondents). Multivariate regression analysis among all respondents found that they were less likely to experience poor primary care coordination if their primary care physician often or always knew their medical history, spent sufficient time, involved them, and explained things well (odds ratio = 0.6 for each). Poor primary care coordination was more likely to occur among patients with chronic conditions (odds ratios = 1.4-2.1 depending on number) and patients younger than 65 years (odds ratios = 1.6-2.3 depending on age-group). Among US respondents, insurance status, health status, household income, and sex were not associated with poor primary care coordination. The United States had the highest rate of poor primary care coordination among the 11 high-income countries evaluated. An established relationship with a primary care physician was significantly associated with better care coordination, whereas being chronically ill or younger was associated with poorer care coordination.
28289109	12	15	Gap	T033	C4277599
28289109	17	24	Factors	T169	C1521761
28289109	25	40	Associated With	T080	C0332281
28289109	41	66	Primary Care Coordination	T058	C3509247
28289109	70	76	Adults	T100	C0001675
28289109	83	92	Countries	T083	C0454664
28289109	93	110	Care coordination	T058	C3509247
28289109	152	161	improving	T080	C1272745
28289109	166	179	effectiveness	T080	C1280519
28289109	181	187	safety	T068	C0036043
28289109	193	203	efficiency	T081	C0013682
28289109	211	213	US	T083	C0041703
28289109	214	232	health care system	T093	C0018696
28289109	238	247	objective	T170	C0018017
28289109	273	283	population	T081	C0032659
28289109	287	312	health care system issues	T033	C0497509
28289109	317	332	associated with	T080	C0332281
28289109	333	358	primary care coordination	T058	C3509247
28289109	359	363	gaps	T033	C4277599
28289109	371	384	United States	T083	C0041703
28289109	395	406	high-income	T033	C0948433
28289109	407	416	countries	T083	C0454664
28289109	449	507	Commonwealth Fund International Health Policy (IHP) survey	T170	C0038951
28289109	513	554	multivariate logistic regression analysis	UnknownType	C0681925
28289109	556	567	Respondents	T098	C0282122
28289109	573	591	adult primary care	T061	C1171177
28289109	592	600	patients	T101	C0030705
28289109	609	618	countries	T083	C0454664
28289109	620	629	Australia	T083	C0004340
28289109	631	637	Canada	T083	C0006823
28289109	639	645	France	T083	C0016674
28289109	647	654	Germany	T083	C0017480
28289109	660	671	Netherlands	T083	C0027778
28289109	673	684	New Zealand	T083	C0027978
28289109	686	692	Norway	T083	C0028423
28289109	694	700	Sweden	T083	C0038995
28289109	702	713	Switzerland	T083	C0039021
28289109	715	729	United Kingdom	T083	C0041700
28289109	739	752	United States	T083	C0041703
28289109	754	758	Poor	T080	C0542537
28289109	759	784	primary care coordination	T058	C3509247
28289109	800	812	participants	T098	C0679646
28289109	834	838	gaps	T033	C4277599
28289109	846	866	coordination of care	T058	C3509247
28289109	890	898	Analyses	T062	C0936012
28289109	920	931	respondents	T098	C0282122
28289109	937	941	rate	T081	C1521828
28289109	945	949	poor	T080	C0542537
28289109	950	975	primary care coordination	T058	C3509247
28289109	997	1008	respondents	T098	C0282122
28289109	1022	1029	highest	T080	C1522410
28289109	1037	1050	United States	T083	C0041703
28289109	1071	1082	respondents	T098	C0282122
28289109	1085	1117	Multivariate regression analysis	UnknownType	C0681925
28289109	1128	1139	respondents	T098	C0282122
28289109	1187	1191	poor	T080	C0542537
28289109	1192	1217	primary care coordination	T058	C3509247
28289109	1227	1249	primary care physician	T097	C0033131
28289109	1277	1292	medical history	T033	C0262926
28289109	1359	1369	odds ratio	T081	C0028873
28289109	1387	1391	Poor	T080	C0542537
28289109	1392	1417	primary care coordination	T058	C3509247
28289109	1449	1457	patients	T101	C0030705
28289109	1463	1481	chronic conditions	T033	C4315615
28289109	1483	1494	odds ratios	T081	C0028873
28289109	1530	1538	patients	T101	C0030705
28289109	1562	1573	odds ratios	T081	C0028873
28289109	1597	1606	age-group	T100	C0027362
28289109	1615	1629	US respondents	T098	C0282122
28289109	1631	1647	insurance status	T078	C0376629
28289109	1649	1662	health status	T080	C0018759
28289109	1664	1681	household income,	T033	C0557163
28289109	1686	1689	sex	T032	C0079399
28289109	1699	1714	associated with	T080	C0332281
28289109	1715	1719	poor	T080	C0542537
28289109	1720	1745	primary care coordination	T058	C3509247
28289109	1751	1764	United States	T083	C0041703
28289109	1773	1780	highest	T080	C1522410
28289109	1781	1785	rate	T081	C1521828
28289109	1789	1793	poor	T080	C0542537
28289109	1789	1819	poor primary care coordination	T058	C3509247
28289109	1833	1844	high-income	T098	C0019532
28289109	1845	1854	countries	T083	C0454664
28289109	1881	1893	relationship	T080	C0439849
28289109	1901	1923	primary care physician	T097	C0033131
28289109	1942	1957	associated with	T080	C0332281
28289109	1965	1982	care coordination	T058	C3509247
28289109	1998	2013	chronically ill	T047	C0008715
28289109	2029	2044	associated with	T080	C0332281
28289109	2045	2051	poorer	T080	C0542537
28289109	2052	2069	care coordination	T058	C3509247

27924038|t|FARNA: knowledgebase of inferred functions of non-coding RNA transcripts
27924038|a|Non-coding RNA (ncRNA) genes play a major role in control of heterogeneous cellular behavior. Yet, their functions are largely uncharacterized. Current available databases lack in-depth information of ncRNA functions across spectrum of various cells / tissues. Here, we present FARNA, a knowledgebase of inferred functions of 10,289 human ncRNA transcripts (2,734 microRNA and 7,555 long ncRNA) in 119 tissues and 177 primary cells of human. Since transcription factors (TFs) and TF co-factors (TcoFs) are crucial components of regulatory machinery for activation of gene transcription, cellular processes and diseases in which TFs and TcoFs are involved suggest functions of the transcripts they regulate. In FARNA, functions of a transcript are inferred from TFs and TcoFs whose genes co-express with the transcript controlled by these TFs and TcoFs in a considered cell / tissue. Transcripts were annotated using statistically enriched GO terms, pathways and diseases across cells / tissues based on guilt-by-association principle. Expression profiles across cells / tissues based on Cap Analysis of Gene Expression (CAGE) are provided. FARNA, having the most comprehensive function annotation of considered ncRNAs across widest spectrum of human cells / tissues, has a potential to greatly contribute to our understanding of ncRNA roles and their regulatory mechanisms in human. FARNA can be accessed at: http://cbrc.kaust.edu.sa/ farna.
27924038	0	5	FARNA	T170	C0022752
27924038	7	20	knowledgebase	T170	C0022752
27924038	33	42	functions	T045	C0314627
27924038	46	60	non-coding RNA	T114	C0887909
27924038	61	72	transcripts	T114	C1519595
27924038	73	87	Non-coding RNA	T114	C0887909
27924038	89	94	ncRNA	T114	C0887909
27924038	96	101	genes	T028	C0017337
27924038	115	119	role	T077	C1705810
27924038	123	130	control	T080	C0243148
27924038	134	147	heterogeneous	T080	C0019409
27924038	148	165	cellular behavior	T043	C0007613
27924038	178	187	functions	T045	C0314627
27924038	235	244	databases	T170	C0242356
27924038	259	270	information	T078	C1533716
27924038	274	279	ncRNA	T114	C0887909
27924038	280	289	functions	T045	C0314627
27924038	297	305	spectrum	T077	C2827424
27924038	317	322	cells	T025	C0007634
27924038	325	332	tissues	T024	C0040300
27924038	351	356	FARNA	T170	C0022752
27924038	360	373	knowledgebase	T170	C0022752
27924038	386	395	functions	T045	C0314627
27924038	406	411	human	T016	C0086418
27924038	412	417	ncRNA	T114	C0887909
27924038	418	429	transcripts	T114	C1519595
27924038	437	445	microRNA	T114,T123	C1101610
27924038	461	466	ncRNA	T114	C0887909
27924038	475	482	tissues	T024	C0040300
27924038	499	504	cells	T025	C0007634
27924038	508	513	human	T016	C0086418
27924038	521	542	transcription factors	T116,T123	C0040648
27924038	544	547	TFs	T116,T123	C0040648
27924038	553	566	TF co-factors	T123	C0178555
27924038	568	573	TcoFs	T123	C0178555
27924038	601	611	regulatory	T045	C0017263
27924038	626	636	activation	T045	C0017255
27924038	640	658	gene transcription	T045	C0040649
27924038	660	678	cellular processes	T043	C1325880
27924038	683	691	diseases	T047	C0012634
27924038	701	704	TFs	T116,T123	C0040648
27924038	709	714	TcoFs	T123	C0178555
27924038	736	745	functions	T045	C0314627
27924038	753	764	transcripts	T114	C1519595
27924038	770	778	regulate	T038	C1327622
27924038	783	788	FARNA	T170	C0022752
27924038	790	799	functions	T045	C0314627
27924038	805	815	transcript	T114	C1519595
27924038	834	837	TFs	T116,T123	C0040648
27924038	842	847	TcoFs	T123	C0178555
27924038	854	859	genes	T028	C0017337
27924038	860	870	co-express	T045	C0017262
27924038	880	890	transcript	T114	C1519595
27924038	911	914	TFs	T116,T123	C0040648
27924038	919	924	TcoFs	T123	C0178555
27924038	941	945	cell	T025	C0007634
27924038	948	954	tissue	T024	C0040300
27924038	956	967	Transcripts	T114	C1519595
27924038	973	982	annotated	T080	C1552720
27924038	1012	1020	GO terms	T170	C1138831
27924038	1022	1030	pathways	T077	C1705987
27924038	1035	1043	diseases	T047	C0012634
27924038	1051	1056	cells	T025	C0007634
27924038	1059	1066	tissues	T024	C0040300
27924038	1108	1127	Expression profiles	T081	C1956267
27924038	1135	1140	cells	T025	C0007634
27924038	1143	1150	tissues	T024	C0040300
27924038	1160	1191	Cap Analysis of Gene Expression	T063	C1880945
27924038	1193	1197	CAGE	T063	C1880945
27924038	1213	1218	FARNA	T170	C0022752
27924038	1236	1249	comprehensive	T080	C1880156
27924038	1259	1269	annotation	T170	C1706814
27924038	1284	1290	ncRNAs	T114	C0887909
27924038	1305	1313	spectrum	T077	C2827424
27924038	1317	1328	human cells	T034	C0427861
27924038	1331	1338	tissues	T024	C0040300
27924038	1346	1355	potential	T080	C3245505
27924038	1402	1407	ncRNA	T114	C0887909
27924038	1408	1413	roles	T077	C1705810
27924038	1424	1445	regulatory mechanisms	T045	C0017263
27924038	1449	1454	human	T016	C0086418
27924038	1456	1461	FARNA	T170	C0022752
27924038	1508	1513	farna	T170	C0022752

28103841|t|A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol
28103841|a|The U.S. Food and Drug Administration can set standards for cigarettes that could include reducing their nicotine content. Such a standard should improve public health without causing unintended serious consequences for sub-populations. This study evaluates the effect of progressive nicotine reduction in cigarettes on smoking behavior, toxicant exposure, and psychiatric symptoms in smokers with comorbid mood and/or anxiety disorders using a two-site, two-arm, double-blind, parallel group, randomized controlled trial (RCT) in four phases over 34 weeks. Adult smokers (N = 200) of 5 or more cigarettes per day will be randomized across two sites (Penn State and Massachusetts General). Participants must have not had a quit attempt in the prior month, nor be planning to quit in the next 6 months, meet criteria for a current or lifetime unipolar mood and/or anxiety disorder based on the structured Mini-International Neuropsychiatric Interview, and must not have an unstable medical or psychiatric condition. After a week of smoking their own cigarettes, participants receive two weeks of Spectrum research cigarettes with usual nicotine content (11.6 mg). After this baseline period, participants will be randomly assigned to continue smoking Spectrum research cigarettes that contain either (a) Usual Nicotine Content (11.6 mg); or (b) Reduced Nicotine Content: the nicotine content per cigarette is progressively reduced from approximately 11.6 mg to 0.2 mg in five steps over 18 weeks. At the end of the randomization phase, participants will be offered the choice to either (a) quit smoking with assistance, (b) continue smoking free research cigarettes, or (c) return to purchasing their own cigarettes, for the final 12 weeks of the study. The primary outcome measure is blood cotinine; key secondary outcomes are: exhaled carbon monoxide, urinary total NNAL- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol and 1-hydroxypyrene, oxidative stress biomarkers including 8-isoprostanes, measures of psychiatric symptoms (e.g., depression, anxiety), smoking behavior and dependence (e.g., cigarette consumption, quit attempts), and health effects (e.g., blood pressure, respiratory symptoms). Results from this study will inform FDA on the potential effects of regulating the nicotine content of cigarettes and help determine whether smokers with mood and/or anxiety disorders can safely transition to significantly reduced nicotine content cigarettes. TRN: NCT01928758, registered August 21, 2013.
28103841	30	42	double-blind	T062	C0013072
28103841	44	59	parallel-group,	T062	C2826345
28103841	60	87	randomized controlled trial	T062,T170	C0282440
28103841	91	118	reduced nicotine cigarettes	T073	C4287927
28103841	122	129	smokers	T033	C0337667
28103841	135	139	mood	T048	C0525045
28103841	147	164	anxiety disorders	T048	C0003469
28103841	196	229	U.S. Food and Drug Administration	T093	C0041714
28103841	238	247	standards	T080	C0175675
28103841	252	262	cigarettes	T073	C0677453
28103841	282	290	reducing	T080	C0392756
28103841	297	305	nicotine	T109,T131	C0028040
28103841	306	313	content	T081	C1264657
28103841	322	330	standard	T080	C1442989
28103841	346	359	public health	T058	C0699943
28103841	412	427	sub-populations	T098	C1257890
28103841	464	475	progressive	T169	C0205329
28103841	476	484	nicotine	T109,T131	C0028040
28103841	485	494	reduction	T080	C0392756
28103841	498	508	cigarettes	T073	C0677453
28103841	512	528	smoking behavior	T055	C0700219
28103841	530	538	toxicant	T131	C0599787
28103841	539	547	exposure	T080	C0332157
28103841	553	573	psychiatric symptoms	T184	C0233401
28103841	577	584	smokers	T033	C0337667
28103841	590	603	comorbid mood	T048	C0525045
28103841	611	628	anxiety disorders	T048	C0003469
28103841	656	668	double-blind	T062	C0013072
28103841	686	713	randomized controlled trial	T062,T170	C0282440
28103841	715	718	RCT	T062,T170	C0282440
28103841	750	755	Adult	T100	C0001675
28103841	756	763	smokers	T033	C0337667
28103841	787	797	cigarettes	T073	C0677453
28103841	843	853	Penn State	T073,T093	C0000872
28103841	858	879	Massachusetts General	T073,T093	C0020008
28103841	882	894	Participants	T098	C1708335
28103841	920	927	attempt	T055	C0700219
28103841	1034	1047	unipolar mood	T048	C0525045
28103841	1055	1071	anxiety disorder	T048	C0003469
28103841	1085	1141	structured Mini-International Neuropsychiatric Interview	UnknownType	C0681913
28103841	1164	1180	unstable medical	T048	C1410011
28103841	1184	1205	psychiatric condition	T048	C0033931
28103841	1223	1230	smoking	T055	C0700219
28103841	1241	1251	cigarettes	T073	C0677453
28103841	1253	1265	participants	T098	C1708335
28103841	1287	1315	Spectrum research cigarettes	T073	C0677453
28103841	1327	1335	nicotine	T109,T131	C0028040
28103841	1336	1343	content	T081	C1264657
28103841	1383	1395	participants	T098	C1708335
28103841	1434	1441	smoking	T055	C0700219
28103841	1442	1470	Spectrum research cigarettes	T073	C0677453
28103841	1501	1509	Nicotine	T109,T131	C0028040
28103841	1510	1517	Content	T081	C1264657
28103841	1536	1543	Reduced	T080	C0392756
28103841	1544	1552	Nicotine	T109,T131	C0028040
28103841	1553	1560	Content	T081	C1264657
28103841	1566	1574	nicotine	T109,T131	C0028040
28103841	1575	1582	content	T081	C1264657
28103841	1587	1596	cigarette	T073	C0677453
28103841	1614	1621	reduced	T080	C0392756
28103841	1727	1739	participants	T098	C1708335
28103841	1786	1793	smoking	T055	C0700219
28103841	1824	1831	smoking	T055	C0700219
28103841	1837	1856	research cigarettes	T073	C0677453
28103841	1896	1906	cigarettes	T073	C0677453
28103841	1976	1981	blood	T031	C0005767
28103841	1982	1990	cotinine	T109,T121	C0010194
28103841	2020	2027	exhaled	T040	C0231800
28103841	2028	2043	carbon monoxide	T131,T197	C0007018
28103841	2059	2110	NNAL- 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol	T109,T131	C0389836
28103841	2115	2130	1-hydroxypyrene	T109,T131	C0044415
28103841	2132	2148	oxidative stress	T049	C0242606
28103841	2149	2159	biomarkers	T201	C0005516
28103841	2170	2184	8-isoprostanes	T109,T130	C0295541
28103841	2198	2218	psychiatric symptoms	T184	C0233401
28103841	2226	2236	depression	T048	C0011570
28103841	2238	2245	anxiety	T033	C0003467
28103841	2248	2264	smoking behavior	T055	C0700219
28103841	2287	2308	cigarette consumption	T033	C0459840
28103841	2315	2323	attempts	T055	C0700219
28103841	2352	2366	blood pressure	T047	C0020538
28103841	2368	2388	respiratory symptoms	T184	C0037090
28103841	2427	2430	FDA	T093	C0041714
28103841	2474	2482	nicotine	T109,T131	C0028040
28103841	2483	2490	content	T081	C1264657
28103841	2494	2504	cigarettes	T073	C0677453
28103841	2532	2539	smokers	T033	C0337667
28103841	2545	2549	mood	T048	C0525045
28103841	2557	2574	anxiety disorders	T048	C0003469
28103841	2614	2649	reduced nicotine content cigarettes	T073	C4287927

27347631|t|Retroperitoneal hemorrhage after ureteroscopy without laser lithotripsy: an extreme example of an underreported event?
27347631|a|Retroperitoneal hemorrhage and an associated hematoma are uncommon but potentially serious complications following ureteroscopy with laser lithotripsy. However, no reports of serious bleeding complications have been published regarding ureteroscopy without laser lithotripsy in the management of stone disease. We report of such a case here and then review the current literature in order to discuss the incidence, risk factors, and management of such events.
27347631	0	26	Retroperitoneal hemorrhage	T046	C0151705
27347631	33	45	ureteroscopy	T060	C0401276
27347631	46	53	without	T080	C0332288
27347631	54	71	laser lithotripsy	T061	C0206099
27347631	98	111	underreported	T078	C1706613
27347631	112	117	event	T051	C0441471
27347631	119	145	Retroperitoneal hemorrhage	T046	C0151705
27347631	164	172	hematoma	T046	C0018944
27347631	177	185	uncommon	T080	C0522498
27347631	202	209	serious	T080	C0205404
27347631	210	223	complications	T046	C0009566
27347631	224	233	following	T079	C0332282
27347631	234	246	ureteroscopy	T060	C0401276
27347631	252	269	laser lithotripsy	T061	C0206099
27347631	280	290	no reports	T078	C1706613
27347631	294	301	serious	T080	C0205404
27347631	302	310	bleeding	T046	C0019080
27347631	311	324	complications	T046	C0009566
27347631	355	367	ureteroscopy	T060	C0401276
27347631	368	375	without	T080	C0332288
27347631	376	393	laser lithotripsy	T061	C0206099
27347631	401	411	management	T058	C0376636
27347631	415	428	stone disease	T031	C0042018
27347631	469	475	review	T170	C0282441
27347631	488	498	literature	T170	C0023866
27347631	523	532	incidence	T169	C0220856
27347631	534	546	risk factors	T033	C0035648
27347631	552	562	management	T058	C0376636
27347631	571	577	events	T051	C0441471

27909710|t|Intracellular distribution and stability of a luminescent rhenium(i) tricarbonyl tetrazolato complex using epifluorescence microscopy in conjunction with X-ray fluorescence imaging
27909710|a|Optical epifluorescence microscopy was used in conjunction with X-ray fluorescence imaging to monitor the stability and intracellular distribution of the luminescent rhenium(i) complex fac-[Re(CO)3(phen)L], where phen = 1,10-phenathroline and L = 5-(4-iodophenyl)tetrazolato, in 22Rv1 cells. The rhenium complex showed no signs of ancillary ligand dissociation, a conclusion based on data obtained via X-ray fluorescence imaging aligning iodine and rhenium distributions. A diffuse reticular localisation was detected for the complex in the nuclear / perinuclear region of cells, by either optical or X-ray fluorescence imaging techniques. X-ray fluorescence also showed that the rhenium complex disrupted the homeostasis of some biologically relevant elements, such as chlorine, potassium and zinc.
27909710	0	13	Intracellular	T082	C0178719
27909710	14	26	distribution	T169	C1704711
27909710	31	40	stability	T080	C0205360
27909710	46	57	luminescent	T130	C1450139
27909710	58	100	rhenium(i) tricarbonyl tetrazolato complex	T104	C1273031
27909710	107	133	epifluorescence microscopy	T059	C0026022
27909710	137	148	conjunction	T078	C2699427
27909710	154	180	X-ray fluorescence imaging	T060	C0037804
27909710	181	215	Optical epifluorescence microscopy	T059	C0026022
27909710	228	239	conjunction	T078	C2699427
27909710	245	271	X-ray fluorescence imaging	T060	C0037804
27909710	287	296	stability	T080	C0205360
27909710	301	314	intracellular	T082	C0178719
27909710	315	327	distribution	T169	C1704711
27909710	335	346	luminescent	T130	C1450139
27909710	347	386	rhenium(i) complex fac-[Re(CO)3(phen)L]	T104	C1273031
27909710	394	398	phen	T109	C0029224
27909710	401	419	1,10-phenathroline	T109	C0029224
27909710	424	425	L	T103	C0023688
27909710	428	455	5-(4-iodophenyl)tetrazolato	T109	C0039703
27909710	460	471	22Rv1 cells	T025	C1518174
27909710	477	492	rhenium complex	T104	C1273031
27909710	512	521	ancillary	T078	C1549485
27909710	522	528	ligand	T103	C0023688
27909710	529	541	dissociation	T067	C0598130
27909710	565	569	data	T078	C1511726
27909710	583	609	X-ray fluorescence imaging	T060	C0037804
27909710	619	625	iodine	T121,T123,T196	C0021968
27909710	630	637	rhenium	T196	C0035419
27909710	638	651	distributions	T169	C1704711
27909710	655	685	diffuse reticular localisation	T169	C0475264
27909710	707	714	complex	T104	C1273031
27909710	722	729	nuclear	T026	C0887871
27909710	732	750	perinuclear region	T026	C0230536
27909710	754	759	cells	T025	C1518174
27909710	771	778	optical	T059	C0026022
27909710	782	808	X-ray fluorescence imaging	T060	C0037804
27909710	809	819	techniques	T169	C0449851
27909710	821	839	X-ray fluorescence	T060	C0037804
27909710	861	876	rhenium complex	T104	C1273031
27909710	877	886	disrupted	T080	C0332454
27909710	891	902	homeostasis	T038	C0019868
27909710	911	941	biologically relevant elements	T123	C0574031
27909710	951	959	chlorine	T131,T196	C0008209
27909710	961	970	potassium	T123,T196	C0032821
27909710	975	979	zinc	T121,T123,T196	C0043481

27679696|t|Histopathological Evaluation of the Effectiveness of Glycyrrhizic Acid as a Radioprotector Against the Development of Radiation-Induced Lung Fibrosis
27679696|a|Radiotherapy of the thorax often causes lung inflammation leading to fibrosis. The aim of this study was to investigate whether the use of glycyrrhizic acid (GLA) could improve the development of lung fibrosis in irradiated animals. Wistar rats were divided into four groups. Group A rats received thoracic irradiation. Rats in group B received GLA and irradiation. Group C received GLA and no irradiation. Group D received no GLA and irradiation. GLA was administered at a dose of 4 mg/kg body weight using an intraperitoneal injection one hour before thoracic irradiation. Radiation therapy was delivered on a Cobalt-60 unit using a single fraction of 16 Gy. The animals were sacrificed at 32 weeks following thoracic irradiation. The lungs were dissected and blind histopathological evaluation was performed. Histopathologically, a decrease (statistically not significant) in the thickening of alveolar or bronchial wall, formation of fibrous bands, and superimposed collagen were noted in the animals in group B as compared to the animals in group A. In this experimental study, administration of GLA one hour before thoracic irradiation may be a protective agent against radiation-induced fibrosis in animals and this model could be used in future studies.
27679696	0	17	Histopathological	T169	C0243140
27679696	18	28	Evaluation	T058	C0220825
27679696	36	49	Effectiveness	T080	C1280519
27679696	53	70	Glycyrrhizic Acid	T109,T121	C0061751
27679696	76	90	Radioprotector	T061	C1318473
27679696	103	114	Development	T169	C1527148
27679696	118	149	Radiation-Induced Lung Fibrosis	T047	C0340126
27679696	150	162	Radiotherapy	T061	C1522449
27679696	170	176	thorax	T029	C0817096
27679696	190	207	lung inflammation	T047	C0032285
27679696	219	227	fibrosis	T047	C0034069
27679696	233	236	aim	T078	C1947946
27679696	245	250	study	T062	C2603343
27679696	258	269	investigate	T169	C1292732
27679696	289	306	glycyrrhizic acid	T109,T121	C0061751
27679696	308	311	GLA	T109,T121	C0061751
27679696	331	342	development	T169	C1527148
27679696	346	359	lung fibrosis	T047	C0034069
27679696	363	373	irradiated	T061	C1522449
27679696	374	381	animals	T008	C0003062
27679696	383	394	Wistar rats	T015	C0034716
27679696	418	424	groups	T078	C0441833
27679696	426	433	Group A	T078	C0441833
27679696	434	438	rats	T015	C0034693
27679696	448	468	thoracic irradiation	T061	C2169121
27679696	470	474	Rats	T015	C0034693
27679696	478	485	group B	T078	C0441833
27679696	495	498	GLA	T109,T121	C0061751
27679696	503	514	irradiation	T061	C1522449
27679696	516	523	Group C	T078	C0441833
27679696	533	536	GLA	T109,T121	C0061751
27679696	544	555	irradiation	T061	C1522449
27679696	557	564	Group D	T078	C0441833
27679696	577	580	GLA	T109,T121	C0061751
27679696	585	596	irradiation	T061	C1522449
27679696	598	601	GLA	T109,T121	C0061751
27679696	606	618	administered	T169	C1521801
27679696	624	628	dose	T081	C0178602
27679696	640	651	body weight	T032	C0005910
27679696	661	686	intraperitoneal injection	T061	C0021493
27679696	703	723	thoracic irradiation	T061	C2169121
27679696	725	742	Radiation therapy	T061	C1522449
27679696	762	771	Cobalt-60	T130,T196	C0303395
27679696	815	822	animals	T008	C0003062
27679696	861	881	thoracic irradiation	T061	C2169121
27679696	887	892	lungs	T023	C0024109
27679696	898	907	dissected	T169	C0205239
27679696	918	935	histopathological	T169	C0243140
27679696	936	946	evaluation	T058	C0220825
27679696	962	981	Histopathologically	T169	C0243140
27679696	985	993	decrease	T081	C0547047
27679696	1033	1043	thickening	T033	C0205400
27679696	1047	1055	alveolar	T023	C0225695
27679696	1059	1073	bronchial wall	T023	C1180039
27679696	1088	1101	fibrous bands	T020	C0334163
27679696	1120	1128	collagen	T116	C0009325
27679696	1147	1154	animals	T008	C0003062
27679696	1158	1165	group B	T078	C0441833
27679696	1185	1192	animals	T008	C0003062
27679696	1196	1203	group A	T078	C0441833
27679696	1213	1231	experimental study	T062	C0681814
27679696	1233	1247	administration	T081	C0001555
27679696	1251	1254	GLA	T109,T121	C0061751
27679696	1271	1291	thoracic irradiation	T061	C2169121
27679696	1301	1317	protective agent	T121	C0033613
27679696	1326	1352	radiation-induced fibrosis	T047	C0340126
27679696	1356	1363	animals	T008	C0003062
27679696	1373	1378	model	T050	C0012644

27349365|t|Supramolecular Recognition of Amino Acids by Twisted Cucurbit[14]uril
27349365|a|Binding interactions between twisted cucurbit[14]uril (tQ[14]) and twenty standard amino acids (AAs) have been investigated by NMR spectroscopy and isothermal titration calorimetry (ITC) in aqueous HCl solutions and in DMSO. The results showed that tQ[14] displays clear binding affinity for AAs with a positively charged side chain or containing an aromatic ring, but weaker binding affinity for AAs with hydrophobic or polar side chains, with the binding mode depending on the type of side chain present in the AAs.
27349365	0	26	Supramolecular Recognition	T044	C0599844
27349365	30	41	Amino Acids	T116,T121,T123	C0002520
27349365	45	69	Twisted Cucurbit[14]uril	T109	C1737934
27349365	70	77	Binding	T044	C1167622
27349365	78	90	interactions	T169	C1704675
27349365	91	98	between	T082	C0205103
27349365	99	123	twisted cucurbit[14]uril	T109	C1737934
27349365	124	132	(tQ[14])	T109	C1737934
27349365	144	152	standard	T080	C1442989
27349365	153	164	amino acids	T116,T121,T123	C0002520
27349365	165	170	(AAs)	T116,T121,T123	C0002520
27349365	181	193	investigated	T169	C1292732
27349365	197	213	NMR spectroscopy	T060	C0877853
27349365	218	250	isothermal titration calorimetry	T059	C0006779
27349365	251	256	(ITC)	T059	C0006779
27349365	260	267	aqueous	T121,T197	C0043047
27349365	268	281	HCl solutions	T130,T197	C0020259
27349365	289	293	DMSO	T109,T121	C0012403
27349365	299	306	results	T169	C1274040
27349365	319	325	tQ[14]	T109	C1737934
27349365	326	334	displays	T169	C0870432
27349365	341	348	binding	T044	C1167622
27349365	349	357	affinity	T070	C1510827
27349365	362	365	AAs	T116,T121,T123	C0002520
27349365	373	402	positively charged side chain	T104	C1254350
27349365	406	416	containing	T169	C0332256
27349365	420	433	aromatic ring	T109	C0020245
27349365	439	445	weaker	T080	C1762617
27349365	446	453	binding	T044	C1167622
27349365	454	462	affinity	T070	C1510827
27349365	467	470	AAs	T116,T121,T123	C0002520
27349365	476	487	hydrophobic	T120	C1254355
27349365	491	508	polar side chains	T120	C1254355
27349365	519	526	binding	T044	C1167622
27349365	527	531	mode	T169	C1513371
27349365	557	567	side chain	T104	C1254350
27349365	583	586	AAs	T116,T121,T123	C0002520

28281271|t|Development of Dual Quantitative Lateral Flow Immunoassay for the Detection of Mycotoxins
28281271|a|Lateral flow immunoassays have been widely used in recent years for detection of toxins, heavy metals, and biomarkers. To improve the efficiency of individual lateral flow immunoassays, multiplex analytical strips play an important role in the detection of several important analytes. In this chapter, development of a dual lateral flow immunoassay is presented for detection of a variety of low molecular weight molecules. Various buffers, additives, and materials are introduced and evaluated. Depending on the analyte to be tested, the technique allows for selection of optimum buffers, additives, and other materials.
28281271	15	57	Dual Quantitative Lateral Flow Immunoassay	T059	C0523404
28281271	66	75	Detection	T033	C0243095
28281271	79	89	Mycotoxins	T109,T131	C0026955
28281271	90	115	Lateral flow immunoassays	T059	C0523404
28281271	158	167	detection	T033	C0243095
28281271	171	177	toxins	T123,T131	C0040549
28281271	179	191	heavy metals	T196	C0347988
28281271	197	207	biomarkers	T201	C0005516
28281271	238	274	individual lateral flow immunoassays	T059	C0523404
28281271	286	303	analytical strips	T130	C0034759
28281271	334	343	detection	T033	C0243095
28281271	365	373	analytes	T167	C0443354
28281271	409	438	dual lateral flow immunoassay	T059	C0523404
28281271	456	465	detection	T033	C0243095
28281271	482	512	low molecular weight molecules	T167	C0567416
28281271	522	529	buffers	T121,T130	C0006353
28281271	531	540	additives	T167	C1550602
28281271	546	555	materials	T167	C0520510
28281271	603	610	analyte	T167	C0443354
28281271	629	638	technique	T169	C0449851
28281271	663	678	optimum buffers	T121,T130	C0006353
28281271	680	689	additives	T167	C1550602
28281271	701	710	materials	T167	C0520510

28063948|t|Cytokine IL-10, activators of PI3-kinase, agonists of α-2 adrenoreceptor and antioxidants prevent ischemia - induced cell death in rat hippocampal cultures
28063948|a|In the present work we compared the protective effect of anti-inflammatory cytokine IL-10 with the action of a PI3-kinase selective activator 740 Y-P, selective agonists of alpha-2 adrenoreceptor, guanfacine and UK-14,304, and compounds having antioxidant effect: recombinant human peroxiredoxin 6 and B27, in hippocampal cell culture during OGD (ischemia-like conditions). It has been shown that the response of cells to OGD in the control includes two phases. The first phase was accompanied by an increase in the frequency of spontaneous synchronous Ca(2+)-oscillations (SSCO) in neurons and Ca(2+) - pulse in astrocytes. Spontaneous Ca(2+) events in astrocytes during ischemia in control experiments disappeared. The second phase started after a few minutes of OGD and looked like a sharp/avalanche, global synchronic (within 20 s) increase in [Ca(2+)]i in many cells. Within 1 h after OGD, a mass death of cells, primarily astrocytes, was observed. To study the protective action of the compounds, cells were incubated in the presence of the neuroprotective agents for 10-40 min or 24 h before ischemia. All the neuroprotective agents delayed a global [Ca(2+)]i increase during OGD or completely inhibited this process and increased cell survival.
28063948	0	8	Cytokine	T116,T129	C0079189
28063948	9	14	IL-10	T116,T129	C0085295
28063948	16	26	activators	T121,T123	C0751968
28063948	30	40	PI3-kinase	T116,T126	C0044602
28063948	42	50	agonists	T121	C0243192
28063948	54	72	α-2 adrenoreceptor	T116,T192	C0034783
28063948	77	89	antioxidants	T121	C0003402
28063948	90	97	prevent	T080	C2700409
28063948	98	106	ischemia	T046	C0022116
28063948	109	116	induced	T169	C0205263
28063948	117	127	cell death	T043	C0007587
28063948	131	134	rat	T015	C0034693
28063948	135	146	hippocampal	T023	C0019564
28063948	147	155	cultures	T167	C3687726
28063948	192	209	protective effect	T080	C0205556
28063948	213	230	anti-inflammatory	T080	C1515999
28063948	231	239	cytokine	T116,T129	C0079189
28063948	240	245	IL-10	T116,T129	C0085295
28063948	255	261	action	T052	C3266814
28063948	267	277	PI3-kinase	T116,T126	C0044602
28063948	278	297	selective activator	T121,T123	C0751968
28063948	298	305	740 Y-P	T121	C1254351
28063948	307	325	selective agonists	T121	C0243192
28063948	329	351	alpha-2 adrenoreceptor	T116,T192	C0034783
28063948	353	363	guanfacine	T109,T121	C0079466
28063948	368	377	UK-14,304	T109,T121	C0147760
28063948	383	392	compounds	T121	C1254351
28063948	400	418	antioxidant effect	T039	C3179302
28063948	432	453	human peroxiredoxin 6	T116,T126	C1873178
28063948	458	461	B27	T121	C1254351
28063948	466	477	hippocampal	T023	C0019564
28063948	478	490	cell culture	T167	C3687726
28063948	491	501	during OGD	T043	C4236780
28063948	503	527	ischemia-like conditions	T033	C1317598
28063948	557	581	response of cells to OGD	T043	C4236780
28063948	589	596	control	T096	C0009932
28063948	610	616	phases	T079	C0205390
28063948	628	633	phase	T079	C0205390
28063948	656	664	increase	T169	C0442805
28063948	672	681	frequency	T079	C0439603
28063948	685	728	spontaneous synchronous Ca(2+)-oscillations	T043	C0600430
28063948	730	734	SSCO	T043	C0600430
28063948	739	746	neurons	T025	C0027882
28063948	751	757	Ca(2+)	T121,T196	C0596235
28063948	760	765	pulse	T039	C0391850
28063948	769	779	astrocytes	T025	C0004112
28063948	781	792	Spontaneous	T169	C0205359
28063948	793	799	Ca(2+)	T121,T196	C0596235
28063948	800	806	events	T051	C0441471
28063948	810	820	astrocytes	T025	C0004112
28063948	828	836	ischemia	T046	C0022116
28063948	840	859	control experiments	T096	C0009932
28063948	860	871	disappeared	T033	C0243095
28063948	884	889	phase	T079	C0205390
28063948	898	924	after a few minutes of OGD	T043	C4236780
28063948	943	958	sharp/avalanche	T033	C0243095
28063948	960	977	global synchronic	T033	C0243095
28063948	992	1000	increase	T169	C0442805
28063948	1005	1011	Ca(2+)	T121,T196	C0596235
28063948	1022	1027	cells	T025	C0007634
28063948	1040	1049	after OGD	T043	C4236780
28063948	1053	1072	mass death of cells	T043	C0007587
28063948	1084	1094	astrocytes	T025	C0004112
28063948	1123	1140	protective action	T080	C0205556
28063948	1148	1157	compounds	T121	C1254351
28063948	1159	1164	cells	T025	C0007634
28063948	1170	1179	incubated	T059	C1439852
28063948	1203	1225	neuroprotective agents	T121	C0242912
28063948	1255	1263	ischemia	T046	C0022116
28063948	1273	1295	neuroprotective agents	T121	C0242912
28063948	1296	1303	delayed	T079	C0205421
28063948	1314	1320	Ca(2+)	T121,T196	C0596235
28063948	1332	1342	during OGD	T043	C4236780
28063948	1346	1366	completely inhibited	T080	C0311403
28063948	1372	1379	process	T067	C1522240
28063948	1384	1393	increased	T081	C0205217
28063948	1394	1407	cell survival	T043	C0007620

27757335|t|Changes in the Dermal Structure during Cultured Epidermal Autograft Engraftment Process
27757335|a|The use of cultured epithelial autografts for the treatment of extensive burn wounds has become popular in recent years. We examined extensive burn wounds in 14 patients by using a combination of autograft and cultured epithelial autografts developed in Japan (JACE). We undertook a skin biopsy at 2, 4, and 6 weeks after transplantation with JACE. By using electron microscopy we observed the engraftment process. In transmission electron microscope findings, we recognized the engraftment process of JACE. Keratinocytes matured gradually. Collagen fibers formed thick bundles in the dermis layer. In scanning electron microscope findings, we observed papillary dermis development on the artificial dermis. After managing wound bed preparation by using artificial dermis, we were able to recognize the good result of grafting JACE on meshed 6:1 split thickness autografts. This is because the auto dermis from autograft extended under the JACE, binding between JACE, and the dermis became strong.
27757335	15	21	Dermal	T024	C0011646
27757335	39	57	Cultured Epidermal	T023	C0450138
27757335	58	67	Autograft	T122	C0559189
27757335	68	87	Engraftment Process	T061	C1961139
27757335	99	118	cultured epithelial	T023	C0450138
27757335	119	129	autografts	T122	C0559189
27757335	138	147	treatment	T061	C0087111
27757335	161	172	burn wounds	T037	C0006434
27757335	202	207	years	T079	C0439234
27757335	231	242	burn wounds	T037	C0006434
27757335	249	257	patients	T101	C0030705
27757335	284	293	autograft	T023	C0580671
27757335	298	317	cultured epithelial	T023	C0450138
27757335	318	328	autografts	T122	C0559189
27757335	342	347	Japan	T083	C0022341
27757335	349	353	JACE	T122	C0559189
27757335	371	382	skin biopsy	T060	C0150866
27757335	398	403	weeks	T079	C0439230
27757335	410	425	transplantation	T061	C0040732
27757335	431	435	JACE	T122	C0559189
27757335	446	465	electron microscopy	T059	C0026019
27757335	482	501	engraftment process	T061	C1961139
27757335	506	538	transmission electron microscope	T074	C0262880
27757335	539	547	findings	T033	C0243095
27757335	567	586	engraftment process	T061	C1961139
27757335	590	594	JACE	T122	C0559189
27757335	596	609	Keratinocytes	T025	C0022567
27757335	629	644	Collagen fibers	T023	C0221933
27757335	673	685	dermis layer	T024	C1182806
27757335	690	718	scanning electron microscope	T074	C0262878
27757335	719	727	findings	T033	C0243095
27757335	741	757	papillary dermis	T023	C0682598
27757335	758	769	development	T042	C1655760
27757335	777	794	artificial dermis	T122	C0206238
27757335	811	832	wound bed preparation	T067	C1522240
27757335	842	859	artificial dermis	T122	C0206238
27757335	906	914	grafting	T061	C1961139
27757335	915	919	JACE	T122	C0559189
27757335	950	960	autografts	T023	C0580671
27757335	987	993	dermis	T024	C0011646
27757335	999	1008	autograft	T023	C0580671
27757335	1028	1032	JACE	T122	C0559189
27757335	1050	1054	JACE	T122	C0559189
27757335	1064	1070	dermis	T024	C0011646

28462652|t|Sequential scapholunate and volar beak ligament reconstructions with flexor carpi radialis tendon grafts
28462652|a|The flexor carpi radialis tendon is considered by many the workhorse tendon in hand and wrist surgery. Some have expressed concerns about altering the mechanics of the wrist by sacrificing part or all of the flexor carpi radialis tendon. We present an interesting case of sequential scapholunate and volar beak ligament reconstructions using a flexor carpi radialis tendon autograft where a slip of tendon was harvested twice within three years, achieving a satisfactory clinical outcome at five years following the initial surgery.
28462652	0	10	Sequential	T080	C1705294
28462652	11	23	scapholunate	T023	C0447936
28462652	28	47	volar beak ligament	T024	C0023685
28462652	48	63	reconstructions	T061	C0524865
28462652	69	97	flexor carpi radialis tendon	T023	C0224884
28462652	98	104	grafts	T061	C1279739
28462652	109	137	flexor carpi radialis tendon	T023	C0224884
28462652	174	180	tendon	T023	C0039508
28462652	184	188	hand	T061	C0187067
28462652	193	206	wrist surgery	T061	C0187064
28462652	243	251	altering	T078	C1515926
28462652	256	265	mechanics	T070	C0376706
28462652	273	278	wrist	T029	C0043262
28462652	282	293	sacrificing	T061	C0554486
28462652	294	298	part	T023	C0229962
28462652	313	341	flexor carpi radialis tendon	T023	C0224884
28462652	377	387	sequential	T080	C1705294
28462652	388	400	scapholunate	T023	C0447936
28462652	405	424	volar beak ligament	T024	C0023685
28462652	425	440	reconstructions	T061	C0524865
28462652	449	477	flexor carpi radialis tendon	T023	C0224884
28462652	478	487	autograft	T061	C0040736
28462652	496	510	slip of tendon	T023	C0039508
28462652	515	524	harvested	T061	C0185480
28462652	544	549	years	T079	C0439234
28462652	563	575	satisfactory	T080	C0205410
28462652	576	584	clinical	T080	C0205210
28462652	585	592	outcome	T169	C1274040
28462652	601	606	years	T079	C0439234
28462652	629	636	surgery	T061	C0543467

27265179|t|Effects of grazing cow diet on volatile compounds as well as physicochemical and sensory characteristics of 12- month - ripened Montasio cheese
27265179|a|The aim of this study was to evaluate the effects of pasture type and cow feeding supplementation level on a 12- mo - ripened Montasio protected designation of origin (PDO) cheese, which is one of the most important PDO cheeses produced in northeast Italy. Cheeses were characterized for volatile compounds, color, mechanical variables, and sensory descriptors. Pasture type significantly affected most of the instrumental variables considered and, as a consequence, sensory properties were affected as well. Cheeses from the pasture characterized by a nutrient-rich vegetation type were higher in protein and lower in fat content. Furthermore, such cheeses, evaluated by a sensory panel, were more intense in color with a more pungent and less cow-like odor, in agreement with what found through instrumental analyses. Supplementation level resulted in less pronounced effects, limited to volatile compounds and texture properties, which were not detected by sensory analysis. The characterization of the 12- mo ripened Montasio cheese reported here is an important step for the valorization of this PDO product.
27265179	0	7	Effects	T080	C1280500
27265179	11	22	grazing cow	T040	C3178952
27265179	23	27	diet	T168	C0012155
27265179	31	49	volatile compounds	T120	C0443769
27265179	61	76	physicochemical	T070	C2350462
27265179	81	88	sensory	T080	C0445254
27265179	89	104	characteristics	T080	C1521970
27265179	112	117	month	T079	C0439231
27265179	120	143	ripened Montasio cheese	T168	C0007968
27265179	160	165	study	T062	C2603343
27265179	173	181	evaluate	T058	C0220825
27265179	186	193	effects	T080	C1280500
27265179	197	204	pasture	T082	C0442534
27265179	214	217	cow	T015	C0007452
27265179	218	225	feeding	T052	C2987508
27265179	226	241	supplementation	T168	C0242295
27265179	257	259	mo	T079	C0439231
27265179	262	278	ripened Montasio	T168	C0007968
27265179	279	310	protected designation of origin	T170	C1519193
27265179	312	315	PDO	T170	C1519193
27265179	317	323	cheese	T168	C0007968
27265179	360	363	PDO	T170	C1519193
27265179	364	371	cheeses	T168	C0007968
27265179	384	399	northeast Italy	T083	C0022277
27265179	401	408	Cheeses	T168	C0007968
27265179	414	427	characterized	T052	C1880022
27265179	432	450	volatile compounds	T120	C0443769
27265179	452	457	color	T080	C0009393
27265179	459	479	mechanical variables	T080	C0439828
27265179	485	492	sensory	T080	C0445254
27265179	493	504	descriptors	T170	C0282354
27265179	506	513	Pasture	T082	C0442534
27265179	519	532	significantly	T078	C0750502
27265179	533	541	affected	T169	C0392760
27265179	554	566	instrumental	T081	C1704339
27265179	567	576	variables	T080	C0439828
27265179	611	618	sensory	T080	C0445254
27265179	635	643	affected	T169	C0392760
27265179	653	660	Cheeses	T168	C0007968
27265179	670	677	pasture	T082	C0442534
27265179	678	691	characterized	T052	C1880022
27265179	697	710	nutrient-rich	T168	C0678695
27265179	711	721	vegetation	T168	C0032099
27265179	742	749	protein	T116,T123	C0033684
27265179	763	766	fat	T109,T168	C0012171
27265179	794	801	cheeses	T168	C0007968
27265179	803	812	evaluated	T058	C0220825
27265179	818	831	sensory panel	T097	C0027363
27265179	843	850	intense	T080	C0522510
27265179	854	859	color	T080	C0009393
27265179	872	879	pungent	T070	C0028884
27265179	889	902	cow-like odor	T070	C0028884
27265179	941	953	instrumental	T081	C1704339
27265179	954	962	analyses	T062	C0936012
27265179	964	979	Supplementation	T168	C0242295
27265179	1014	1021	effects	T080	C1280500
27265179	1034	1052	volatile compounds	T120	C0443769
27265179	1057	1064	texture	T080	C0449582
27265179	1104	1111	sensory	T080	C0445254
27265179	1112	1120	analysis	T062	C0936012
27265179	1126	1142	characterization	T052	C1880022
27265179	1154	1156	mo	T079	C0439231
27265179	1157	1180	ripened Montasio cheese	T168	C0007968
27265179	1224	1236	valorization	T081	C0600618
27265179	1245	1248	PDO	T170	C1519193
27265179	1249	1256	product	T071	C1514468

28495934|t|How Should I Study for the Exam? Self-Regulated Learning Strategies and Achievement in Introductory Biology
28495934|a|In college introductory science courses, students are challenged with mastering large amounts of disciplinary content while developing as autonomous and effective learners. Self-regulated learning (SRL) is the process of setting learning goals, monitoring progress toward them, and applying appropriate study strategies. SRL characterizes successful, "expert" learners, and develops with time and practice. In a large, undergraduate introductory biology course, we investigated: 1) what SRL strategies students reported using the most when studying for exams, 2) which strategies were associated with higher achievement and with grade improvement on exams, and 3) what study approaches students proposed to use for future exams. Higher - achieving students, and students whose exam grades improved in the first half of the semester, reported using specific cognitive and metacognitive strategies significantly more frequently than their lower - achieving peers. Lower - achieving students more frequently reported that they did not implement their planned strategies or, if they did, still did not improve their outcomes. These results suggest that many students entering introductory biology have limited knowledge of SRL strategies and/or limited ability to implement them, which can impact their achievement. Course -specific interventions that promote SRL development should be considered as integral pedagogical tools, aimed at fostering development of students ' lifelong learning skills.
28495934	27	31	Exam	UnknownType	C0681376
28495934	33	56	Self-Regulated Learning	T041	C1510634
28495934	57	67	Strategies	T065	C0237896
28495934	72	83	Achievement	T065,T170	C0237912
28495934	87	107	Introductory Biology	T091	C0005532
28495934	111	118	college	T073	C0557806
28495934	119	139	introductory science	T090	C0036397
28495934	140	147	courses	T065	C0013652
28495934	149	157	students	T098	C0038492
28495934	205	225	disciplinary content	T080	C0205556
28495934	246	256	autonomous	UnknownType	C0815096
28495934	261	270	effective	T080	C1704419
28495934	271	279	learners	T098	C0038492
28495934	281	304	Self-regulated learning	T041	C1510634
28495934	306	309	SRL	T041	C1510634
28495934	337	351	learning goals	T078	C2010704
28495934	364	372	progress	T169	C1280477
28495934	411	427	study strategies	T065	C0237896
28495934	429	432	SRL	T041	C1510634
28495934	468	476	learners	T098	C0038492
28495934	527	540	undergraduate	T170	C0683865
28495934	541	561	introductory biology	T091	C0005532
28495934	562	568	course	T065	C0013652
28495934	595	598	SRL	T041	C1510634
28495934	599	609	strategies	T065	C0237896
28495934	610	618	students	T098	C0038492
28495934	661	666	exams	UnknownType	C0681376
28495934	677	687	strategies	T065	C0237896
28495934	716	727	achievement	T053	C0001072
28495934	737	742	grade	T185	C0441800
28495934	743	754	improvement	T033	C0184511
28495934	758	763	exams	UnknownType	C0681376
28495934	794	802	students	T098	C0038492
28495934	830	835	exams	UnknownType	C0681376
28495934	837	843	Higher	T080	C0205250
28495934	846	855	achieving	T053	C0001072
28495934	856	864	students	T098	C0038492
28495934	870	878	students	T098	C0038492
28495934	885	889	exam	UnknownType	C0681376
28495934	890	896	grades	T185	C0441800
28495934	897	905	improved	T033	C0184511
28495934	913	923	first half	T033	C3843058
28495934	931	939	semester	T079	C2348178
28495934	965	974	cognitive	T041	C0009240
28495934	979	1003	metacognitive strategies	T041	C0870885
28495934	1023	1033	frequently	T079	C0332183
28495934	1045	1050	lower	T052	C2003888
28495934	1053	1062	achieving	T053	C0001072
28495934	1063	1068	peers	T098	C0679739
28495934	1070	1075	Lower	T052	C2003888
28495934	1078	1087	achieving	T053	C0001072
28495934	1088	1096	students	T098	C0038492
28495934	1102	1112	frequently	T079	C0332183
28495934	1164	1174	strategies	T065	C0237896
28495934	1220	1228	outcomes	T169	C1274040
28495934	1262	1270	students	T098	C0038492
28495934	1280	1300	introductory biology	T091	C0005532
28495934	1306	1313	limited	T169	C0439801
28495934	1314	1323	knowledge	T065	C0013621
28495934	1327	1330	SRL	T041	C1510634
28495934	1331	1341	strategies	T065	C0237896
28495934	1349	1356	limited	T169	C0439801
28495934	1394	1400	impact	T080	C4049986
28495934	1407	1418	achievement	T065,T170	C0237912
28495934	1420	1426	Course	T065	C0013652
28495934	1437	1450	interventions	T058	C0242687
28495934	1464	1467	SRL	T041	C1510634
28495934	1513	1530	pedagogical tools	T090	C1510624
28495934	1541	1550	fostering	T056	C0242298
28495934	1566	1574	students	T098	C0038492
28495934	1577	1585	lifelong	T079	C4274169
28495934	1586	1601	learning skills	T041	C0871370

27783838|t|Ultrasonographic Assessment of the Flexor Pollicis Longus Tendon After Plate Fixation
27783838|a|Rupture of the flexor pollicis longus tendon is a major complication after volar locking plate fixation of distal radius fracture. This study used ultrasonography to assess the flexor pollicis longus tendon and intermediate tissue. The study assessed 27 patients (28 wrists) who underwent removal of the volar locking plate. Before plate removal, radiography and ultrasonography were performed to assess the relation between the flexor pollicis longus tendon and the volar locking plate. Intraoperatively, the authors evaluated the intermediate tissues between the flexor pollicis longus tendon and the distal volar margin of the plate. Preoperative and intraoperative findings were compared. Intraoperative findings were strongly related to the distance between the flexor pollicis longus tendon and the volar locking plate on ultrasonography. The sensitivity of ultrasonography in detecting thin, membrane-like intermediate tissue through which the plate was visible was 95%, and the specificity was 89% if the distance between the flexor pollicis longus tendon and the plate was less than 0.7 mm. Compression of the flexor pollicis longus tendon was seen in 11 cases (39.3%), and this finding suggested the presence of thin, membrane-like intermediate tissue. The study results showed that ultrasonography could be used to identify the type of intermediate tissue between the flexor pollicis longus tendon and the volar locking plate. [Orthopedics. 2017; 40(1):e104-e108.].
27783838	0	27	Ultrasonographic Assessment	T060	C2315191
27783838	35	64	Flexor Pollicis Longus Tendon	T023	C0224887
27783838	71	85	Plate Fixation	T061	C0407295
27783838	86	130	Rupture of the flexor pollicis longus tendon	T037	C0580001
27783838	161	166	volar	T029	C0443349
27783838	167	189	locking plate fixation	T061	C0407295
27783838	193	215	distal radius fracture	T037	C0435585
27783838	233	248	ultrasonography	T060	C2315191
27783838	263	292	flexor pollicis longus tendon	T023	C0224887
27783838	297	316	intermediate tissue	T024	C0009780
27783838	340	348	patients	T101	C0030705
27783838	353	359	wrists	T029	C0043262
27783838	375	409	removal of the volar locking plate	T061	C0408173
27783838	418	431	plate removal	T061	C0408173
27783838	433	444	radiography	T060	C0845955
27783838	449	464	ultrasonography	T060	C2315191
27783838	515	544	flexor pollicis longus tendon	T023	C0224887
27783838	553	572	volar locking plate	T023	C1720969
27783838	574	590	Intraoperatively	T079	C0021891
27783838	618	638	intermediate tissues	T024	C0009780
27783838	651	680	flexor pollicis longus tendon	T023	C0224887
27783838	696	701	volar	T029	C0443349
27783838	716	721	plate	T023	C1720969
27783838	723	735	Preoperative	T033	C0178808
27783838	740	763	intraoperative findings	T033	C0231286
27783838	779	802	Intraoperative findings	T033	C0231286
27783838	853	882	flexor pollicis longus tendon	T023	C0224887
27783838	891	910	volar locking plate	T023	C1720969
27783838	914	929	ultrasonography	T060	C2315191
27783838	935	946	sensitivity	T081	C1511883
27783838	950	965	ultrasonography	T060	C2315191
27783838	999	1018	intermediate tissue	T024	C0009780
27783838	1037	1042	plate	T023	C1720969
27783838	1072	1083	specificity	T081	C1511884
27783838	1120	1149	flexor pollicis longus tendon	T023	C0224887
27783838	1158	1163	plate	T023	C1720969
27783838	1205	1234	flexor pollicis longus tendon	T023	C0224887
27783838	1328	1347	intermediate tissue	T024	C0009780
27783838	1379	1394	ultrasonography	T060	C2315191
27783838	1433	1452	intermediate tissue	T024	C0009780
27783838	1465	1494	flexor pollicis longus tendon	T023	C0224887
27783838	1503	1522	volar locking plate	T023	C1720969

27729085|t|Chordoma dedifferentiation after proton beam therapy: a case report and review of the literature
27729085|a|Chordoma is a rare invasive bone tumor that may occur anywhere along the neuraxis. A total of three primary histological varieties have been identified: conventional, chondroid, and dedifferentiated. We report a case of an 8-year-old white girl who presented with conventional chordoma, was treated with surgical resection and mixed proton and photon beam therapy, and had a recurrence in the resection cavity 2.5 years later with dedifferentiated morphology. The recurrent tumor did not express brachyury, a recently identified protein specific to tissue of notochordal origin. The short time period between radiation therapy and dedifferentiation, low dose of photons, and rarity of dedifferentiated skull base chordomas in pediatric patients should alert clinicians to the possibility of chordoma dedifferentiation after proton beam therapy.
27729085	0	26	Chordoma dedifferentiation	T191	C1266174
27729085	33	52	proton beam therapy	T061	C2169187
27729085	56	67	case report	T170	C0007320
27729085	72	96	review of the literature	T170	C0282441
27729085	97	105	Chordoma	T191	C0008487
27729085	111	115	rare	T080	C0522498
27729085	116	124	invasive	T080	C0205281
27729085	125	135	bone tumor	T191	C0005967
27729085	170	178	neuraxis	T082	C1522496
27729085	197	204	primary	T080	C0205225
27729085	205	227	histological varieties	T191	C0027652
27729085	238	248	identified	T080	C0205396
27729085	250	262	conventional	T191	C0008487
27729085	264	273	chondroid	T191	C1266173
27729085	279	295	dedifferentiated	T191	C1266174
27729085	300	306	report	T170	C0684224
27729085	309	313	case	T077	C1706256
27729085	331	336	white	T098	C0007457
27729085	337	341	girl	T100	C0870604
27729085	361	382	conventional chordoma	T191	C0008487
27729085	388	395	treated	T033	C0332154
27729085	401	419	surgical resection	T061	C0015252
27729085	424	429	mixed	T169	C0205430
27729085	430	436	proton	T070	C0729603
27729085	441	460	photon beam therapy	T061	C3539769
27729085	472	482	recurrence	T067	C0034897
27729085	490	506	resection cavity	T020	C1515091
27729085	528	555	dedifferentiated morphology	T191	C1266174
27729085	561	576	recurrent tumor	T191	C0521158
27729085	585	592	express	T045	C1171362
27729085	593	602	brachyury	T116,T123	C0170844
27729085	606	614	recently	T079	C0332185
27729085	615	625	identified	T080	C0205396
27729085	626	633	protein	T116,T123	C0033684
27729085	634	642	specific	T080	C0205369
27729085	646	652	tissue	T024	C0040300
27729085	656	667	notochordal	T018	C0028439
27729085	668	674	origin	T079	C0439659
27729085	680	685	short	T081	C1806781
27729085	686	697	time period	T079	C1948053
27729085	706	723	radiation therapy	T061	C2169187
27729085	728	745	dedifferentiation	T043	C2248595
27729085	747	755	low dose	T081	C0445550
27729085	759	766	photons	T167	C0086805
27729085	772	778	rarity	T080	C0522498
27729085	782	819	dedifferentiated skull base chordomas	T191	C2164487
27729085	823	832	pediatric	T080	C1521725
27729085	833	841	patients	T101	C0030705
27729085	849	854	alert	T169	C3665546
27729085	855	865	clinicians	T097	C0871685
27729085	873	884	possibility	T033	C0332149
27729085	888	914	chordoma dedifferentiation	T191	C1266174
27729085	921	940	proton beam therapy	T061	C2169187

28538498|t|Ghrelin Protects the Thymic Epithelium From Conditioning-Regimen - Induced Damage and Promotes the Restoration of CD4+ T Cells in Mice After Bone Marrow Transplantation
28538498|a|The delay in immune reconstitution after hematopoietic stem cell transplantation (HSCT), especially a delay in central immune reconstitution, leads to opportunistic infections and disease relapse after transplantation and affects the long-term outcome of HSCT. This delay is mainly attributable to thymic damage after myeloablative chemotherapy and radiotherapy METHODS: We established a model of allogeneic bone marrow transplantation (BMT) in mice and administered ghrelin (GRL) 7 days before the conditioning regimen or the day after BMT. All the GRL - treated mice, especially those administered GRL prior to the conditioning regimen, exhibited more intact thymic architecture and a more rapid restoration of CD4 T lymphocytes after BMT than those of the corresponding control mice. Moreover, the levels of T cell receptor excision circles (TRECs) were significantly higher in the mice treated with GRL prior to the conditioning regimen than in the control mice at 28 days after BMT. Our finding s suggest that GRL may be a novel potential therapeutic approach to protecting the thymic epithelium from conditioning-regimen - induced damage and promoting rapid and durable thymic and peripheral CD4 T cell recovery after HSCT.
28538498	0	7	Ghrelin	T116,T125	C0911014
28538498	8	16	Protects	T033	C1545588
28538498	21	38	Thymic Epithelium	T025	C0229951
28538498	44	64	Conditioning-Regimen	T061	C0376450
28538498	67	74	Induced	T169	C0205263
28538498	75	81	Damage	T169	C1883709
28538498	86	94	Promotes	T052	C0033414
28538498	99	110	Restoration	T061	C1283255
28538498	114	126	CD4+ T Cells	T025	C0039215
28538498	130	134	Mice	T015	C0026809
28538498	141	168	Bone Marrow Transplantation	T061	C0005961
28538498	173	178	delay	T079	C0205421
28538498	182	203	immune reconstitution	T033	C1960768
28538498	210	249	hematopoietic stem cell transplantation	T061	C0472699
28538498	251	255	HSCT	T061	C0472699
28538498	271	276	delay	T079	C0205421
28538498	288	309	immune reconstitution	T047	C1096197
28538498	320	344	opportunistic infections	T047	C0029118
28538498	349	364	disease relapse	T047	C0277556
28538498	371	386	transplantation	T061	C0040732
28538498	403	412	long-term	T079	C0443252
28538498	413	420	outcome	T080	C0085415
28538498	424	428	HSCT	T061	C0472699
28538498	435	440	delay	T079	C0205421
28538498	467	480	thymic damage	T037	C3897359
28538498	487	513	myeloablative chemotherapy	T061	C1513784
28538498	518	530	radiotherapy	T061	C1522449
28538498	543	554	established	T080	C0443211
28538498	566	576	allogeneic	T080	C1515895
28538498	577	604	bone marrow transplantation	T061	C0005961
28538498	606	609	BMT	T061	C0005961
28538498	614	618	mice	T015	C0026809
28538498	623	635	administered	T169	C1521801
28538498	636	643	ghrelin	T116,T125	C0911014
28538498	645	648	GRL	T116,T125	C0911014
28538498	652	656	days	T079	C0439228
28538498	668	688	conditioning regimen	T061	C0376450
28538498	706	709	BMT	T061	C0005961
28538498	719	722	GRL	T116,T125	C0911014
28538498	725	732	treated	T169	C1522326
28538498	733	737	mice	T015	C0026809
28538498	756	768	administered	T169	C1521801
28538498	769	772	GRL	T116,T125	C0911014
28538498	786	806	conditioning regimen	T061	C0376450
28538498	830	836	thymic	T023	C0040113
28538498	861	866	rapid	T080	C0456962
28538498	867	878	restoration	T061	C1283255
28538498	882	899	CD4 T lymphocytes	T025	C0039215
28538498	906	909	BMT	T061	C0005961
28538498	942	949	control	T080	C0243148
28538498	950	954	mice	T015	C0026809
28538498	980	1012	T cell receptor excision circles	T114	C1515131
28538498	1014	1019	TRECs	T114	C1515131
28538498	1026	1046	significantly higher	T081	C4055637
28538498	1054	1058	mice	T015	C0026809
28538498	1059	1071	treated with	T061	C0332293
28538498	1072	1075	GRL	T116,T125	C0911014
28538498	1089	1109	conditioning regimen	T061	C0376450
28538498	1122	1129	control	T080	C0243148
28538498	1130	1134	mice	T015	C0026809
28538498	1141	1145	days	T079	C0439228
28538498	1152	1155	BMT	T061	C0005961
28538498	1161	1168	finding	T033	C0243095
28538498	1184	1187	GRL	T116,T125	C0911014
28538498	1197	1202	novel	T080	C0205314
28538498	1203	1212	potential	T080	C3245505
28538498	1213	1224	therapeutic	T169	C0302350
28538498	1252	1258	thymic	T023	C0040113
28538498	1259	1269	epithelium	T024	C0014609
28538498	1275	1295	conditioning-regimen	T061	C0376450
28538498	1298	1305	induced	T169	C0205263
28538498	1306	1312	damage	T169	C1883709
28538498	1327	1332	rapid	T080	C0456962
28538498	1345	1351	thymic	T023	C0040113
28538498	1356	1366	peripheral	T082	C0205100
28538498	1367	1377	CD4 T cell	T025	C0039215
28538498	1378	1386	recovery	T040	C2004454
28538498	1393	1397	HSCT	T061	C0472699

27810033|t|Fracture of the os trigonum: A report of two cases and review of the literature
27810033|a|We report two cases of acute fractures of the os trigonum. The os trigonum fracture related to the first case was sustained following a hyper-plantar flexion injury during a game of soccer. The second case involved a patient who fell from height and also sustained open fractures of the left distal tibia and lateral malleolus as well as the right calcaneus. In both cases, a preliminary diagnosis of a posterior talar process fracture was made from the initial radiographs of the ankle. The correct diagnosis of an os trigonum fracture rather than a fracture of the posterior talar process was only made following further assessment with CT imaging. Given that the course of treatment is largely determined by imaging findings, CT for further imaging evaluation should be performed in cases of suspected acute bony injuries of the posterior ankle, particularly when the limitations of using radiographs for the assessment of such injuries are expected to be encountered.
27810033	0	8	Fracture	T037	C0016658
27810033	16	27	os trigonum	T023	C4282248
27810033	31	37	report	T170	C0007320
27810033	45	50	cases	T077	C1706256
27810033	55	79	review of the literature	T170	C0282441
27810033	83	89	report	T170	C0007320
27810033	94	99	cases	T170	C0007320
27810033	103	108	acute	T079	C0205178
27810033	109	118	fractures	T037	C0016658
27810033	126	137	os trigonum	T023	C4282248
27810033	143	154	os trigonum	T023	C4282248
27810033	155	163	fracture	T037	C0016658
27810033	185	189	case	T077	C1706256
27810033	194	203	sustained	T169	C0443318
27810033	216	237	hyper-plantar flexion	T042	C0231784
27810033	238	244	injury	T037	C0023220
27810033	254	258	game	T056	C0150593
27810033	262	268	soccer	T056	C0037393
27810033	281	285	case	T077	C1706256
27810033	297	304	patient	T101	C0030705
27810033	309	325	fell from height	T067	C1997329
27810033	335	344	sustained	T169	C0443318
27810033	345	359	open fractures	T037	C0016662
27810033	367	384	left distal tibia	T023	C0825759
27810033	389	406	lateral malleolus	T023	C0448227
27810033	422	437	right calcaneus	T023	C0817332
27810033	447	452	cases	T077	C1706256
27810033	456	467	preliminary	T079	C0439611
27810033	468	477	diagnosis	T033	C0011900
27810033	483	515	posterior talar process fracture	T037	C2214794
27810033	542	553	radiographs	T060	C1306645
27810033	561	566	ankle	T029	C0003086
27810033	580	589	diagnosis	T033	C0011900
27810033	596	607	os trigonum	T023	C4282248
27810033	608	616	fracture	T037	C0016658
27810033	631	670	fracture of the posterior talar process	T037	C2214794
27810033	703	713	assessment	T058	C0220825
27810033	719	729	CT imaging	T060	C0040405
27810033	756	765	treatment	T061	C0087111
27810033	791	798	imaging	T060	C0011923
27810033	809	811	CT	T060	C0040405
27810033	824	831	imaging	T060	C0011923
27810033	832	842	evaluation	T058	C0220825
27810033	866	871	cases	T077	C1706256
27810033	885	890	acute	T079	C0205178
27810033	891	904	bony injuries	T037	C0561852
27810033	912	927	posterior ankle	T029	C0817702
27810033	951	962	limitations	T169	C0449295
27810033	972	983	radiographs	T060	C1306645
27810033	992	1002	assessment	T058	C0220825
27810033	1011	1019	injuries	T037	C0561852
27810033	1039	1050	encountered	T058	C0422301

27577957|t|Adenosine arrests breast cancer cell motility by A3 receptor stimulation
27577957|a|In neutrophils, adenosine triphosphate (ATP) release and autocrine purinergic signaling regulate coordinated cell motility during chemotaxis. Here, we studied whether similar mechanisms regulate the motility of breast cancer cells. While neutrophils and benign human mammary epithelial cells (HMEC) form a single leading edge, MDA-MB-231 breast cancer cells possess multiple leading edges enriched with A3 adenosine receptors. Compared to HMEC, MDA-MB-231 cells overexpress the ectonucleotidases ENPP1 and CD73, which convert extracellular ATP released by the cells to adenosine that stimulates A3 receptors and promotes cell migration with frequent directional changes. However, exogenous adenosine added to breast cancer cells or the A3 receptor agonist IB-MECA dose - dependently arrested cell motility by simultaneous stimulation of multiple leading edges, doubling cell surface areas and significantly reducing migration velocity by up to 75 %. We conclude that MDA-MB-231 cells, HMEC, and neutrophils differ in the purinergic signaling mechanisms that regulate their motility patterns and that the subcellular distribution of A3 adenosine receptors in MDA-MB-231 breast cancer cells contributes to dysfunctional cell motility. These findings imply that purinergic signaling mechanisms may be potential therapeutic targets to interfere with the motility of breast cancer cells in order to reduce the spread of cancer cells and the risk of metastasis.
27577957	0	9	Adenosine	T114,T121,T123	C0001443
27577957	10	17	arrests	T169	C0205245
27577957	18	36	breast cancer cell	T025	C1512505
27577957	37	45	motility	T040	C0007608
27577957	49	60	A3 receptor	T116,T192	C0664494
27577957	61	72	stimulation	T070	C1948023
27577957	76	87	neutrophils	T025	C0027950
27577957	89	111	adenosine triphosphate	T114,T121,T123	C0001480
27577957	113	116	ATP	T114,T121,T123	C0001480
27577957	118	125	release	T169	C1283071
27577957	130	139	autocrine	T042	C0596138
27577957	140	160	purinergic signaling	T044	C3158762
27577957	161	169	regulate	T038	C0678661
27577957	182	195	cell motility	T040	C0007608
27577957	203	213	chemotaxis	T043	C0008018
27577957	248	258	mechanisms	T169	C0441712
27577957	259	267	regulate	T038	C0678661
27577957	272	280	motility	T040	C1510470
27577957	284	303	breast cancer cells	T025	C1512505
27577957	311	322	neutrophils	T025	C0027950
27577957	327	333	benign	T080	C0205183
27577957	334	347	human mammary	T023	C0929301
27577957	348	364	epithelial cells	T025	C0014597
27577957	366	370	HMEC	T025	C0014597
27577957	379	385	single	T081	C0205171
27577957	386	398	leading edge	T026	C1621433
27577957	400	410	MDA-MB-231	T050	C3898556
27577957	411	430	breast cancer cells	T025	C1512505
27577957	439	447	multiple	T081	C0439064
27577957	448	461	leading edges	T026	C1621433
27577957	476	498	A3 adenosine receptors	T116,T192	C0664494
27577957	512	516	HMEC	T025	C0014597
27577957	518	528	MDA-MB-231	T050	C3898556
27577957	529	534	cells	T025	C1512505
27577957	535	546	overexpress	T045	C1514559
27577957	551	574	ectonucleotidases ENPP1	T116,T126	C0084070
27577957	579	583	CD73	T116,T126,T129	C0000530
27577957	599	612	extracellular	T026	C0521119
27577957	613	616	ATP	T114,T121,T123	C0001480
27577957	617	625	released	T169	C1283071
27577957	633	638	cells	T025	C0007634
27577957	642	651	adenosine	T114,T121,T123	C0001443
27577957	657	667	stimulates	T070	C1948023
27577957	668	680	A3 receptors	T116,T192	C0664494
27577957	685	693	promotes	T052	C0033414
27577957	694	708	cell migration	T043	C1622501
27577957	714	722	frequent	T079	C0332183
27577957	723	734	directional	T040	C2246452
27577957	735	742	changes	T169	C0392747
27577957	763	772	adenosine	T114,T121,T123	C0001443
27577957	773	778	added	T169	C1524062
27577957	782	801	breast cancer cells	T025	C1512505
27577957	809	820	A3 receptor	T116,T192	C0664494
27577957	821	828	agonist	T121	C2987634
27577957	829	836	IB-MECA	T114	C0250131
27577957	837	841	dose	T081	C0178602
27577957	844	855	dependently	T080	C1701901
27577957	856	864	arrested	T169	C0205245
27577957	865	878	cell motility	T040	C0007608
27577957	882	894	simultaneous	T079	C0521115
27577957	895	906	stimulation	T070	C1948023
27577957	910	918	multiple	T081	C0439064
27577957	919	932	leading edges	T026	C1621433
27577957	934	942	doubling	T052	C1705764
27577957	943	955	cell surface	T026	C0699040
27577957	956	961	areas	T082	C0205146
27577957	980	988	reducing	T080	C0392756
27577957	989	998	migration	T043	C1622501
27577957	999	1007	velocity	T081	C0439830
27577957	1040	1050	MDA-MB-231	T050	C3898556
27577957	1051	1056	cells	T025	C1512505
27577957	1058	1062	HMEC	T025	C0014597
27577957	1068	1079	neutrophils	T025	C0027950
27577957	1094	1114	purinergic signaling	T044	C3158765
27577957	1115	1125	mechanisms	T169	C0441712
27577957	1131	1139	regulate	T038	C0678661
27577957	1146	1154	motility	T040	C0007608
27577957	1155	1163	patterns	T082	C0449774
27577957	1177	1188	subcellular	T026	C1258076
27577957	1189	1201	distribution	T169	C1704711
27577957	1205	1227	A3 adenosine receptors	T116,T192	C0664494
27577957	1231	1241	MDA-MB-231	T050	C3898556
27577957	1242	1261	breast cancer cells	T025	C1512505
27577957	1277	1290	dysfunctional	T077	C3887504
27577957	1291	1304	cell motility	T040	C0007608
27577957	1332	1352	purinergic signaling	T044	C3158765
27577957	1353	1363	mechanisms	T169	C0441712
27577957	1371	1380	potential	T080	C3245505
27577957	1381	1392	therapeutic	T169	C0302350
27577957	1393	1400	targets	T169	C1521840
27577957	1404	1418	interfere with	T169	C0521102
27577957	1423	1431	motility	T040	C0007608
27577957	1435	1454	breast cancer cells	T025	C1512505
27577957	1467	1473	reduce	T080	C0392756
27577957	1478	1484	spread	T080	C0332261
27577957	1488	1500	cancer cells	T025	C0334227
27577957	1509	1513	risk	T078	C0035647
27577957	1517	1527	metastasis	T046	C4255448

28117535|t|High HbA1c at onset cannot be used as a predictor for future metabolic control for the individual child with type 1 diabetes mellitus
28117535|a|To study how metabolic control at onset of type 1 diabetes correlates to metabolic control and clinical parameters during childhood until transition from pediatric care to adult diabetes care. Data at onset, three months, one, three, and five years after diagnosis and at transition, on HbA1c and clinical parameters, on 8084 patients in the Swedish pediatric quality registry, SWEDIABKIDS, were used. Of these patients, 26% had been referred to adult diabetes care by 2014. Children with HbA1c < 72 mmol/mol (8.7%) (20% of patients, low group) at diagnosis continued to have good metabolic control during childhood, in contrast to children with HbA1c > 114 mmol/mol (12.6%) (20% of patients, high group) at diagnosis, who continued to have high HbA1c at follow-up. For the individual, there was no significant correlation between high HbA1c at onset and during follow-up. During follow-up, children in the high group were more often smokers, less physically active, and more often had retinopathy than children in the low group (P < .01, .01, .03 respectively). High HbA1c at onset was associated with high HbA1c during follow-up on a group level, but it cannot be used as a predictor of future metabolic control on an individual level. These results emphasize the important work done by the diabetes team in the first years after diagnosis. It is important to continuously set high goals for the achievement of tight metabolic control, in order to decrease the risk of microvascular complications.
28117535	0	4	High	T080	C0205250
28117535	5	10	HbA1c	T116,T123	C0019018
28117535	14	19	onset	T080	C0332162
28117535	40	49	predictor	T078	C2698872
28117535	61	78	metabolic control	T044	C1513158
28117535	87	97	individual	T098	C0237401
28117535	98	103	child	T100	C0008059
28117535	109	133	type 1 diabetes mellitus	T047	C0011854
28117535	147	164	metabolic control	T044	C1513158
28117535	168	173	onset	T080	C0332162
28117535	177	192	type 1 diabetes	T047	C0011854
28117535	207	224	metabolic control	T044	C1513158
28117535	229	237	clinical	T080	C0205210
28117535	238	248	parameters	T033	C0449381
28117535	256	265	childhood	T079	C0231335
28117535	272	282	transition	T052	C2700061
28117535	288	302	pediatric care	T061	C3839839
28117535	306	311	adult	T100	C0001675
28117535	312	325	diabetes care	T061	C0150544
28117535	327	331	Data	T078	C1511726
28117535	335	340	onset	T080	C0332162
28117535	348	354	months	T079	C0439231
28117535	377	382	years	T079	C0439234
28117535	389	398	diagnosis	T033	C0011900
28117535	406	416	transition	T052	C2700061
28117535	421	426	HbA1c	T116,T123	C0019018
28117535	431	439	clinical	T080	C0205210
28117535	440	450	parameters	T033	C0449381
28117535	460	468	patients	T101	C0030705
28117535	476	523	Swedish pediatric quality registry, SWEDIABKIDS	T170	C0282574
28117535	545	553	patients	T101	C0030705
28117535	580	585	adult	T100	C0001675
28117535	586	599	diabetes care	T061	C0150544
28117535	609	617	Children	T100	C0008059
28117535	623	628	HbA1c	T116,T123	C0019018
28117535	658	666	patients	T101	C0030705
28117535	668	671	low	T080	C0205251
28117535	672	677	group	T098	C1257890
28117535	682	691	diagnosis	T033	C0011900
28117535	715	732	metabolic control	T044	C1513158
28117535	740	749	childhood	T079	C0231335
28117535	766	774	children	T100	C0008059
28117535	780	785	HbA1c	T116,T123	C0019018
28117535	817	825	patients	T101	C0030705
28117535	827	831	high	T080	C0205250
28117535	832	837	group	T098	C1257890
28117535	842	851	diagnosis	T033	C0011900
28117535	875	879	high	T080	C0205250
28117535	880	885	HbA1c	T116,T123	C0019018
28117535	889	898	follow-up	T058	C1522577
28117535	908	918	individual	T098	C0237401
28117535	930	944	no significant	T033	C1273937
28117535	945	956	correlation	T080	C1707520
28117535	965	969	high	T080	C0205250
28117535	970	975	HbA1c	T116,T123	C0019018
28117535	979	984	onset	T080	C0332162
28117535	996	1005	follow-up	T058	C1522577
28117535	1014	1023	follow-up	T058	C1522577
28117535	1025	1033	children	T100	C0008059
28117535	1041	1045	high	T080	C0205250
28117535	1046	1051	group	T098	C1257890
28117535	1068	1075	smokers	T033	C0337664
28117535	1082	1099	physically active	T033	C0556453
28117535	1120	1131	retinopathy	T047	C0035309
28117535	1137	1145	children	T100	C0008059
28117535	1153	1156	low	T080	C0205251
28117535	1157	1162	group	T098	C1257890
28117535	1197	1201	High	T080	C0205250
28117535	1202	1207	HbA1c	T116,T123	C0019018
28117535	1211	1216	onset	T080	C0332162
28117535	1221	1236	associated with	T080	C0332281
28117535	1237	1241	high	T080	C0205250
28117535	1242	1247	HbA1c	T116,T123	C0019018
28117535	1255	1264	follow-up	T058	C1522577
28117535	1270	1275	group	T098	C1257890
28117535	1310	1319	predictor	T078	C2698872
28117535	1330	1347	metabolic control	T044	C1513158
28117535	1354	1364	individual	T098	C0237401
28117535	1427	1435	diabetes	T047	C0011847
28117535	1436	1440	team	T096	C0871489
28117535	1466	1475	diagnosis	T033	C0011900
28117535	1513	1517	high	T080	C0205250
28117535	1518	1523	goals	T170	C0018017
28117535	1532	1543	achievement	T053	C0001072
28117535	1553	1570	metabolic control	T044	C1513158
28117535	1584	1592	decrease	T081	C0547047
28117535	1597	1601	risk	T078	C0035647
28117535	1605	1632	microvascular complications	T047	C3837959

27427881|t|Improving Care Transitions Across Healthcare Settings Through a Human Factors Approach
27427881|a|After more than two decades of research focused on care transition improvement and intervention development, unfavorable outcome measures associated with care transitions across healthcare settings persist. Readmissions rates remain an important outcome to target for intervention, adverse events associated with care transitions continue to be an issue, and patients are often dissatisfied with the quality of their care. Currently, interventions to improve care transitions are disease specific, require substantial financial investments in training allied healthcare professionals, or focus primarily on hospital-based discharge planning with mixed results. This complex situation requires a method of evaluation that can provide a comprehensive, in-depth, and context-driven investigation of potential risks to safe care transitions across healthcare settings, which can lead to the creation of effective, usable, and sustainable interventions. A systems' approach known as Human Factors and Ergonomics (HFE) evaluates the factors in a system that affect human performance. This article describes how HFE can complement and further strengthen efforts to improve care transitions.
27427881	0	9	Improving	T080	C1272745
27427881	10	26	Care Transitions	T058	C4019079
27427881	34	44	Healthcare	T058	C0086388
27427881	45	53	Settings	T082	C1254362
27427881	64	77	Human Factors	T033	C4035944
27427881	107	114	decades	T081	C2981279
27427881	118	126	research	T062	C0035168
27427881	138	153	care transition	T058	C4019079
27427881	154	165	improvement	T077	C2986411
27427881	170	182	intervention	T061	C0184661
27427881	183	194	development	T169	C1527148
27427881	196	215	unfavorable outcome	T033	C1519790
27427881	216	224	measures	T169	C1879489
27427881	225	240	associated with	T080	C0332281
27427881	241	257	care transitions	T058	C4019079
27427881	265	275	healthcare	T058	C0086388
27427881	276	284	settings	T082	C1254362
27427881	294	306	Readmissions	UnknownType	C0745042
27427881	307	312	rates	T081	C1264674
27427881	333	340	outcome	T169	C1274040
27427881	344	350	target	T169	C1521840
27427881	355	367	intervention	T061	C0184661
27427881	369	383	adverse events	T046	C0877248
27427881	384	399	associated with	T080	C0332281
27427881	400	416	care transitions	T058	C4019079
27427881	435	440	issue	T033	C0033213
27427881	446	454	patients	T101	C0030705
27427881	465	477	dissatisfied	T041	C0870433
27427881	487	494	quality	T080	C0332306
27427881	504	508	care	T052	C1947933
27427881	521	534	interventions	T061	C0184661
27427881	546	562	care transitions	T058	C4019079
27427881	567	574	disease	T047	C0012634
27427881	575	583	specific	T080	C0205369
27427881	593	604	substantial	T080	C0205556
27427881	605	626	financial investments	T058	C3826621
27427881	630	638	training	T065	C0220931
27427881	639	670	allied healthcare professionals	T097	C0002122
27427881	694	727	hospital-based discharge planning	T058	C1563179
27427881	753	770	complex situation	T080	C0205556
27427881	782	802	method of evaluation	T062	C2911685
27427881	822	835	comprehensive	T080	C1880156
27427881	837	845	in-depth	T082	C0205125
27427881	851	865	context-driven	T078	C1254370
27427881	866	879	investigation	T058	C0220825
27427881	883	898	potential risks	T033	C0035648
27427881	907	923	care transitions	T058	C4019079
27427881	931	941	healthcare	T058	C0086388
27427881	942	950	settings	T082	C1254362
27427881	974	982	creation	T052	C1706214
27427881	986	995	effective	T080	C1704419
27427881	997	1003	usable	T080	C0205556
27427881	1009	1020	sustainable	T169	C0443318
27427881	1021	1034	interventions	T061	C0184661
27427881	1065	1093	Human Factors and Ergonomics	T090	C0020120
27427881	1095	1098	HFE	T090	C0020120
27427881	1100	1109	evaluates	T170	C1550545
27427881	1114	1121	factors	T169	C1521761
27427881	1146	1163	human performance	T052	C0020115
27427881	1170	1177	article	T170	C1706852
27427881	1192	1195	HFE	T090	C0020120
27427881	1245	1252	improve	T080	C1272745
27427881	1253	1269	care transitions	T058	C4019079

27918168|t|The effect of therapist use of validation strategies on change in client emotion in individual dbt treatment sessions
27918168|a|Dialectical behavior therapy (DBT) is a treatment for borderline personality disorder, a disorder for which emotion dysregulation is central. Within DBT, there are 6 explicitly defined validation strategies that range hierarchically from validation level (VL) 1 to VL 6. To date, there have been no studies on the frequency of use of VLs in actual DBT sessions. The aim of the current study was to explore DBT therapists ' use of VLs and examine the relationship between VLs and change in a client emotion during therapy sessions. DBT treatment sessions (n = 121) across 35 participants in a DBT training clinic were coded for therapist use of VLs. A repeated-measures analysis of variance (ANOVA) was used to assess for change in therapist use of VLs over time and hierarchical linear modeling was used to correlate therapist use of these strategies with change in client emotion. Results indicated no significant relationship between overall frequency of VLs and change in client emotion. However, an increase in frequency of high VLs was associated with an increase in positive affect (PA) and a decrease in negative affect (NA) while an increase in frequency of low VLs was associated with a decrease in PA and no change in NA. An increase in frequency of VL 4 was associated with an increase in NA. VL 6 was associated with an increase in PA and a decrease in NA. Findings suggest that specific validation strategies may be related to session changes in affect and have implications for identifying potential mechanisms of change. (PsycINFO Database Record
27918168	4	10	effect	T080	C1280500
27918168	14	23	therapist	T097	C0871525
27918168	31	41	validation	T062	C1519941
27918168	42	52	strategies	T061	C0184661
27918168	66	72	client	T096	C0008942
27918168	73	80	emotion	T041	C0013987
27918168	95	98	dbt	T061	C1321145
27918168	99	108	treatment	T061	C0087111
27918168	109	117	sessions	T061	C0199393
27918168	118	146	Dialectical behavior therapy	T061	C1321145
27918168	148	151	DBT	T061	C1321145
27918168	158	167	treatment	T061	C0087111
27918168	172	203	borderline personality disorder	T048	C0006012
27918168	207	215	disorder	T047	C0012634
27918168	226	247	emotion dysregulation	T048	C0004936
27918168	267	270	DBT	T061	C1321145
27918168	303	313	validation	T062	C1519941
27918168	314	324	strategies	T061	C0184661
27918168	330	335	range	T081	C1514721
27918168	336	350	hierarchically	T169	C0699032
27918168	356	366	validation	T062	C1519941
27918168	367	372	level	T080	C0441889
27918168	374	376	VL	T080	C0441889
27918168	383	385	VL	T080	C0441889
27918168	417	424	studies	T062	C2603343
27918168	432	441	frequency	T081	C0871396
27918168	452	455	VLs	T080	C0441889
27918168	466	469	DBT	T061	C1321145
27918168	470	478	sessions	T061	C0199393
27918168	484	487	aim	T078	C1947946
27918168	503	508	study	T062	C2603343
27918168	524	527	DBT	T061	C1321145
27918168	528	538	therapists	T097	C0871525
27918168	548	551	VLs	T080	C0441889
27918168	556	563	examine	T058	C0582103
27918168	589	592	VLs	T080	C0441889
27918168	609	615	client	T096	C0008942
27918168	616	623	emotion	T041	C0013987
27918168	631	638	therapy	T061	C0087111
27918168	639	647	sessions	T061	C0199393
27918168	649	652	DBT	T061	C1321145
27918168	653	662	treatment	T061	C0087111
27918168	663	671	sessions	T061	C0199393
27918168	692	704	participants	T098	C0679646
27918168	710	713	DBT	T061	C1321145
27918168	723	729	clinic	T073,T093	C0442592
27918168	745	754	therapist	T097	C0871525
27918168	762	765	VLs	T080	C0441889
27918168	769	786	repeated-measures	T062	C0871881
27918168	787	807	analysis of variance	T081	C0002780
27918168	809	814	ANOVA	T081	C0002780
27918168	849	858	therapist	T097	C0871525
27918168	866	869	VLs	T080	C0441889
27918168	884	912	hierarchical linear modeling	T081	C0814910
27918168	935	944	therapist	T097	C0871525
27918168	958	968	strategies	T061	C0184661
27918168	984	990	client	T096	C0008942
27918168	991	998	emotion	T041	C0013987
27918168	1000	1007	Results	T033	C0683954
27918168	1062	1071	frequency	T081	C0871396
27918168	1075	1078	VLs	T080	C0441889
27918168	1093	1099	client	T096	C0008942
27918168	1100	1107	emotion	T041	C0013987
27918168	1133	1142	frequency	T081	C0871396
27918168	1151	1154	VLs	T080	C0441889
27918168	1190	1198	positive	T033	C1446409
27918168	1199	1205	affect	T041	C0001721
27918168	1207	1209	PA	T041	C0001721
27918168	1229	1237	negative	T033	C0205160
27918168	1238	1244	affect	T041	C0001721
27918168	1246	1248	NA	T041	C0001721
27918168	1271	1280	frequency	T081	C0871396
27918168	1288	1291	VLs	T080	C0441889
27918168	1326	1328	PA	T041	C0001721
27918168	1346	1348	NA	T041	C0001721
27918168	1365	1374	frequency	T081	C0871396
27918168	1378	1380	VL	T080	C0441889
27918168	1418	1420	NA	T041	C0001721
27918168	1422	1424	VL	T080	C0441889
27918168	1462	1464	PA	T041	C0001721
27918168	1483	1485	NA	T041	C0001721
27918168	1487	1495	Findings	T033	C0243095
27918168	1518	1528	validation	T062	C1519941
27918168	1529	1539	strategies	T061	C0184661
27918168	1529	1539	strategies	T061	C0184661
27918168	1558	1565	session	T061	C0199393
27918168	1577	1583	affect	T041	C0001721
27918168	1632	1642	mechanisms	T169	C0441712

27887018|t|Case report: imaging the clinical course of FOPE -a cause of adolescent knee pain
27887018|a|Focal periphyseal oedema (FOPE) is a rare MRI finding associated with pain in adolescent patients with very few reported cases. We present a case of FOPE in a 13-year-old girl and the only follow-up imaging available for an isolated presentation of this condition .This article describes a clinical course that correlates well with the imaging obtained. This article describes a clinical course that correlates well with the imaging obtained.
27887018	0	11	Case report	T170	C0007320
27887018	25	40	clinical course	T079	C0449259
27887018	44	48	FOPE	T037	C0474990
27887018	61	71	adolescent	T100	C0205653
27887018	72	81	knee pain	T033	C0231749
27887018	82	106	Focal periphyseal oedema	T037	C0474990
27887018	108	112	FOPE	T037	C0474990
27887018	124	127	MRI	T060	C0024485
27887018	128	135	finding	T033	C0243095
27887018	152	156	pain	T184	C0030193
27887018	160	170	adolescent	T100	C0205653
27887018	171	179	patients	T101	C0030705
27887018	185	208	very few reported cases	T033	C1860284
27887018	231	235	FOPE	T037	C0474990
27887018	253	257	girl	T100	C0870604
27887018	271	280	follow-up	T058	C1522577
27887018	281	288	imaging	T060	C0011923
27887018	306	314	isolated	T169	C0205409
27887018	315	327	presentation	T078	C0449450
27887018	336	345	condition	T047	C0012634
27887018	352	359	article	T170	C0007320
27887018	372	387	clinical course	T079	C0449259
27887018	393	403	correlates	T080	C1707520
27887018	418	425	imaging	T060	C0011923
27887018	441	448	article	T170	C0007320
27887018	461	476	clinical course	T079	C0449259
27887018	482	492	correlates	T080	C1707520
27887018	507	514	imaging	T060	C0011923

28526485|t|Improving the Sexual Health of Young People With Mobility Impairments: Challenges and Recommendations
28526485|a|This mixed-method study (a) describes challenges to providing sexual health services to youth with mobility impairments from the perspective of health care providers and experts and (b) describes and compares sexual health -related experiences of youth with mobility impairments. Secondary data analysis of My Path, a study focused on the transition to adulthood for youth with mobility impairments. Using an exploratory sequential design, qualitative data (n = 10) were analyzed using systematic content analysis followed by quantitative analysis of survey data (N = 337). Challenges included not talking about sex, managing sexual development, adaptation and instruction, parent roles, and safety. Survey data showed that youth with mobility impairments are diverse in their experiences with sexual behavior and sources of sexual health information. Although connected with primary care providers, few received information about sexual health. Interventions to improve youths ' well-being should include comprehensive care and education that promotes and supports healthy sexual development.
28526485	0	9	Improving	T080	C1272745
28526485	14	27	Sexual Health	T032	C2362326
28526485	31	43	Young People	T100	C0087178
28526485	49	69	Mobility Impairments	T033	C0518456
28526485	71	81	Challenges	T058	C0805586
28526485	86	101	Recommendations	T078	C0034866
28526485	107	125	mixed-method study	T062	C0681814
28526485	140	150	challenges	T058	C0805586
28526485	154	163	providing	T052	C1999230
28526485	164	177	sexual health	T032	C2362326
28526485	178	186	services	T058	C0018747
28526485	190	195	youth	T100	C0087178
28526485	201	221	mobility impairments	T033	C0518456
28526485	231	242	perspective	T082	C0449911
28526485	246	267	health care providers	T097	C0018724
28526485	272	279	experts	T097	C0009817
28526485	302	310	compares	T052	C1707455
28526485	311	324	sexual health	T032	C2362326
28526485	334	345	experiences	T041	C0596545
28526485	349	354	youth	T100	C0087178
28526485	360	380	mobility impairments	T033	C0518456
28526485	382	416	Secondary data analysis of My Path	UnknownType	C0683944
28526485	420	425	study	T062	C0681814
28526485	426	433	focused	T169	C1285542
28526485	441	451	transition	T052	C2700061
28526485	455	464	adulthood	T079	C0700597
28526485	469	474	youth	T100	C0087178
28526485	480	500	mobility impairments	T033	C0518456
28526485	511	540	exploratory sequential design	T062	C0035171
28526485	542	558	qualitative data	UnknownType	C0681942
28526485	573	581	analyzed	T062	C0936012
28526485	588	598	systematic	T169	C0220922
28526485	599	615	content analysis	T062	C0681915
28526485	628	664	quantitative analysis of survey data	UnknownType	C0681919
28526485	676	686	Challenges	T058	C0805586
28526485	687	695	included	T169	C0332257
28526485	696	707	not talking	T080	C0205556
28526485	714	717	sex	T032	C1522384
28526485	728	746	sexual development	T040	C0233896
28526485	748	758	adaptation	T040	C0000934
28526485	763	774	instruction	T170	C1442085
28526485	776	788	parent roles	T054	C0680075
28526485	794	800	safety	T068	C0036043
28526485	802	808	Survey	T170	C0038951
28526485	809	813	data	T078	C1511726
28526485	826	831	youth	T100	C0087178
28526485	837	857	mobility impairments	T033	C0518456
28526485	862	869	diverse	T080	C1880371
28526485	879	890	experiences	T041	C0596545
28526485	896	911	sexual behavior	T053	C0036864
28526485	916	923	sources	T033	C0449416
28526485	927	940	sexual health	T032	C2362326
28526485	941	952	information	T078	C1533716
28526485	963	972	connected	T052	C2986575
28526485	978	1000	primary care providers	T097	C0018724
28526485	1006	1014	received	T080	C1514756
28526485	1015	1026	information	T078	C1533716
28526485	1033	1046	sexual health	T032	C2362326
28526485	1048	1061	Interventions	T058	C1273869
28526485	1065	1072	improve	T033	C0184511
28526485	1073	1079	youths	T100	C0087178
28526485	1082	1092	well-being	T078	C0018684
28526485	1100	1107	include	T052	C2700399
28526485	1108	1126	comprehensive care	T058	C0009586
28526485	1131	1140	education	T065	C0018701
28526485	1146	1154	promotes	T052	C0033414
28526485	1159	1167	supports	T077	C1521721
28526485	1168	1175	healthy	T080	C3898900
28526485	1176	1194	sexual development	T040	C0233896

27754198|t|JS ISH-ECCR-3 A NOVEL ALGORITHM FOR THE CASE DETECTION OF THE MOST COMMON FORM OF ENDOCRINE HYPERTENSION
27754198|a|Primary aldosteronism (PA) involves more than 11% of patients referred to specialized hypertension centers and, therefore, is much more common than commonly held. Moreover, it causes a damage to the heart, blood vessels and kidneys, which translates into a high rate of cardiovascular events, in excess to the degree of blood pressure raise. Along with the notion that a timely diagnosis entails a fundamental step for the choice of an appropriate therapy, which can correct the arterial hypertension and the hypokalemia, this justifies efforts to search for PA in the majority of the patients with hypertension. Unfortunately, because of the lack of the classical signs, as spontaneous or drug-induced hypokalemia and related symptoms, PA deceives diagnosis in the majority of the cases .The identification of a curable form of primary aldosteronism can be beneficial particularly in some subgroups of patients, namely those with drug - resistant hypertension, who are at high risk of primary aldosteronism. An aggressive diagnostic approach is necessary in these patients, who can benefit most from an accurate diagnosis. Knowledge of the sodium intake and drug effects on the aldosterone-renin ratio is a key element for the diagnosis in these challenging cases .With the latest work-up endorsed by the Endocrine Society Guidelines and supported by the results of the AQUARR Study, the diagnostic algorithm for PA can be substantially simplified. This means skipping the so-called confirmatory tests in most cases and thus rendering the screening of PA feasible and affordable. Hence, most centers can nowadays exploit use of a cost - effective strategy to screen for patients with primary aldosteronism. At variance, the identification of primary aldosteronism subtypes, which involves adrenal vein sampling (AVS), should only be undertaken at tertiary referral centers that have experience in performing and interpreting this minimally invasive test .Overall, long-term cure biochemical cure can be consistently achieved when adrenalectomy is based on AVS - based identification of lateralized aldosterone excess. Moreover, long-term cure of hypertension, defined as no need for antihypertensive drug treatment, can be achieved in about 45% of the cases, with an additional 40% showing a marked improvement in blood pressure control. Lack of blood pressure normalization can be explained by misdiagnosis and/or concomitant essential hypertension.
27754198	0	13	JS ISH-ECCR-3	T170	C0679508
27754198	16	21	NOVEL	T080	C0205314
27754198	22	31	ALGORITHM	T170	C0002045
27754198	40	44	CASE	T169	C0868928
27754198	45	54	DETECTION	T061	C1511790
27754198	67	73	COMMON	T081	C0205214
27754198	74	78	FORM	T169	C1522492
27754198	82	104	ENDOCRINE HYPERTENSION	T047	C0264641
27754198	105	126	Primary aldosteronism	T047	C1384514
27754198	128	130	PA	T047	C1384514
27754198	158	166	patients	T101	C0030705
27754198	179	190	specialized	T077	C1704211
27754198	191	203	hypertension	T047	C0020538
27754198	204	211	centers	T073,T093	C0475309
27754198	241	247	common	T081	C0205214
27754198	281	287	causes	T169	C0015127
27754198	290	296	damage	T169	C1883709
27754198	304	309	heart	T023	C0018787
27754198	311	324	blood vessels	T023	C0005847
27754198	329	336	kidneys	T023	C0022646
27754198	362	371	high rate	T080	C0205082
27754198	375	396	cardiovascular events	T033	C1320716
27754198	401	407	excess	T080	C1979886
27754198	415	421	degree	T080	C0441889
27754198	425	445	blood pressure raise	T033	C0497247
27754198	476	482	timely	T080	C3827828
27754198	483	492	diagnosis	T060	C0430022
27754198	493	500	entails	T080	C0027552
27754198	503	514	fundamental	T169	C1527178
27754198	515	519	step	T077	C1261552
27754198	528	534	choice	T055	C0008300
27754198	541	552	appropriate	T080	C1548787
27754198	553	560	therapy	T061	C0087111
27754198	572	579	correct	T080	C2349182
27754198	584	605	arterial hypertension	T047	C0020538
27754198	614	625	hypokalemia	T033	C0020621
27754198	653	659	search	T061	C0557959
27754198	664	666	PA	T047	C1384514
27754198	674	682	majority	T080	C0205164
27754198	690	698	patients	T101	C0030705
27754198	704	716	hypertension	T047	C0020538
27754198	748	752	lack	T080	C0332268
27754198	760	769	classical	T169	C0443177
27754198	770	775	signs	T184	C0037088
27754198	795	819	drug-induced hypokalemia	T034	C0342591
27754198	824	831	related	T080	C0439849
27754198	832	840	symptoms	T184	C1457887
27754198	842	844	PA	T047	C1384514
27754198	854	863	diagnosis	T060	C0430022
27754198	871	879	majority	T080	C0205164
27754198	887	892	cases	T169	C0868928
27754198	898	912	identification	T080	C0205396
27754198	934	955	primary aldosteronism	T047	C1384514
27754198	990	994	some	T081	C0205392
27754198	995	1004	subgroups	T185	C1515021
27754198	1008	1016	patients	T101	C0030705
27754198	1036	1040	drug	T121	C0013227
27754198	1043	1052	resistant	T169	C0332325
27754198	1053	1065	hypertension	T047	C0020538
27754198	1078	1090	high risk of	T033	C0332167
27754198	1091	1112	primary aldosteronism	T047	C1384514
27754198	1128	1147	diagnostic approach	T060	C0430022
27754198	1151	1160	necessary	T169	C1514873
27754198	1170	1178	patients	T101	C0030705
27754198	1188	1195	benefit	T081	C0814225
27754198	1209	1217	accurate	T080	C0443131
27754198	1218	1227	diagnosis	T060	C0430022
27754198	1229	1238	Knowledge	T170	C0376554
27754198	1246	1259	sodium intake	T201	C0489645
27754198	1264	1276	drug effects	T169	C0728866
27754198	1284	1307	aldosterone-renin ratio	T201	C1114689
27754198	1333	1342	diagnosis	T060	C0430022
27754198	1364	1369	cases	T169	C0868928
27754198	1387	1394	work-up	T060	C0750430
27754198	1411	1439	Endocrine Society Guidelines	T170	C0162791
27754198	1444	1453	supported	T077	C1521721
27754198	1461	1468	results	T169	C1274040
27754198	1476	1488	AQUARR Study	T062	C2603343
27754198	1494	1514	diagnostic algorithm	T170	C0679508
27754198	1519	1521	PA	T047	C1384514
27754198	1543	1553	simplified	T052	C2986669
27754198	1589	1601	confirmatory	T080	C0521091
27754198	1602	1607	tests	T060	C0683443
27754198	1616	1621	cases	T169	C0868928
27754198	1631	1640	rendering	T052	C1999230
27754198	1645	1654	screening	T060	C1710031
27754198	1658	1660	PA	T047	C1384514
27754198	1698	1705	centers	T073,T093	C0475309
27754198	1727	1733	use of	T169	C1524063
27754198	1736	1740	cost	T081	C0010186
27754198	1743	1752	effective	T080	C1704419
27754198	1753	1761	strategy	T169	C2700391
27754198	1765	1771	screen	T058	C0220908
27754198	1776	1784	patients	T101	C0030705
27754198	1790	1811	primary aldosteronism	T047	C1384514
27754198	1816	1824	variance	T080	C1711260
27754198	1830	1844	identification	T080	C0205396
27754198	1848	1869	primary aldosteronism	T047	C1384514
27754198	1870	1878	subtypes	T185	C0449560
27754198	1895	1916	adrenal vein sampling	T060	C0457942
27754198	1918	1921	AVS	T060	C0457942
27754198	1953	1978	tertiary referral centers	T073,T093	C0587437
27754198	1989	1999	experience	T041	C0237607
27754198	2003	2013	performing	T055	C0597198
27754198	2018	2030	interpreting	T169	C1285553
27754198	2036	2059	minimally invasive test	T060	C0430022
27754198	2070	2079	long-term	T079	C0443252
27754198	2080	2084	cure	T077	C1880198
27754198	2085	2096	biochemical	T169	C0205474
27754198	2097	2101	cure	T077	C1880198
27754198	2109	2121	consistently	T080	C1524057
27754198	2136	2149	adrenalectomy	T061	C0001632
27754198	2153	2158	based	T169	C1527178
27754198	2162	2165	AVS	T060	C0457942
27754198	2168	2173	based	T169	C1527178
27754198	2174	2188	identification	T080	C0205396
27754198	2204	2215	aldosterone	T109,T121,T125	C0002006
27754198	2216	2222	excess	T080	C1979886
27754198	2234	2243	long-term	T079	C0443252
27754198	2244	2248	cure	T077	C1880198
27754198	2252	2264	hypertension	T047	C0020538
27754198	2277	2279	no	T169	C1518422
27754198	2280	2284	need	T080	C0027552
27754198	2289	2310	antihypertensive drug	T121	C0003364
27754198	2311	2320	treatment	T061	C0013216
27754198	2358	2363	cases	T169	C0868928
27754198	2373	2383	additional	T169	C1524062
27754198	2398	2404	marked	T080	C1706089
27754198	2405	2416	improvement	T077	C2986411
27754198	2420	2442	blood pressure control	T040	C1753303
27754198	2444	2448	Lack	T080	C0332268
27754198	2452	2466	blood pressure	T040	C0005823
27754198	2501	2513	misdiagnosis	T033	C0679838
27754198	2521	2532	concomitant	T079	C0521115
27754198	2533	2555	essential hypertension	T047	C0085580

28267102|t|Association Between Costs Related to Productivity Loss and Modified Risk Factors Among Users of the Brazilian National Health System
28267102|a|The aim of this study was to investigate the associations between costs related to productivity losses and its risk factors among users of the Brazilian National Health System. The public cost associated with productivity losses of 342 adults has been estimated, taking into account a period of 18 months. Costs related to productivity loss were estimate using data provided by the Brazilian National Health System (disability retirements) and absenteeism. Modifiable risk factors and unhealthy behaviors were assessed through interviews (physical inactivity, alcohol consumption, and smoking) and clinical assessments (obesity). Smoking and physical inactivity affected significantly the amount of money lost with productivity losses related to absenteeism. The presence of obesity generated higher expenditures with disability retirement, while low back pain and sleep disorder were the most relevant confounders in multivariate models for disability retirement and absenteeism. Among users of the Brazilian National Health System, obesity, smoking, and physical inactivity seem to have a significant effect on productivity losses associated with health problems. Moreover, low back pain and sleep quality seem variables few explored but with potential to affect health care costs.
28267102	0	11	Association	T080	C0439849
28267102	20	25	Costs	T081	C0010186
28267102	37	54	Productivity Loss	T033	C4062086
28267102	59	67	Modified	T169	C0392747
28267102	68	80	Risk Factors	T033	C0035648
28267102	87	92	Users	T098	C1706077
28267102	100	132	Brazilian National Health System	T093	C0018696
28267102	178	190	associations	T080	C0439849
28267102	199	204	costs	T081	C0010186
28267102	216	235	productivity losses	T033	C4062086
28267102	244	256	risk factors	T033	C0035648
28267102	263	268	users	T098	C1706077
28267102	276	308	Brazilian National Health System	T093	C0018696
28267102	314	325	public cost	T081	C0010186
28267102	326	341	associated with	T080	C0332281
28267102	342	361	productivity losses	T033	C4062086
28267102	369	375	adults	T100	C0001675
28267102	418	424	period	T079	C1948053
28267102	439	444	Costs	T081	C0010186
28267102	456	473	productivity loss	T033	C4062086
28267102	494	498	data	T078	C1511726
28267102	515	547	Brazilian National Health System	T093	C0018696
28267102	549	559	disability	T033	C0231170
28267102	560	571	retirements	T033	C0035345
28267102	577	588	absenteeism	T055	C1283330
28267102	590	600	Modifiable	T169	C0392747
28267102	601	613	risk factors	T033	C0035648
28267102	618	637	unhealthy behaviors	UnknownType	C0679788
28267102	643	651	assessed	T052	C1516048
28267102	660	670	interviews	T052	C0021822
28267102	672	691	physical inactivity	T056	C3890554
28267102	693	712	alcohol consumption	T055	C0001948
28267102	718	725	smoking	T055	C0037369
28267102	731	751	clinical assessments	T033	C3845884
28267102	753	760	obesity	T047	C0028754
28267102	763	770	Smoking	T055	C0037369
28267102	775	794	physical inactivity	T056	C3890554
28267102	795	803	affected	T169	C0392760
28267102	822	828	amount	T081	C1265611
28267102	832	837	money	T081	C0036245
28267102	838	842	lost	T169	C0745777
28267102	848	867	productivity losses	T033	C4062086
28267102	879	890	absenteeism	T055	C1283330
28267102	908	915	obesity	T047	C0028754
28267102	926	932	higher	T080	C0205250
28267102	933	945	expenditures	T081	C0031197
28267102	951	961	disability	T033	C0231170
28267102	962	972	retirement	T033	C0035345
28267102	980	993	low back pain	T184	C0024031
28267102	998	1012	sleep disorder	T047	C0851578
28267102	1027	1035	relevant	T080	C2347946
28267102	1036	1047	confounders	UnknownType	C0681885
28267102	1051	1070	multivariate models	T081	C0026777
28267102	1075	1085	disability	T033	C0231170
28267102	1086	1096	retirement	T033	C0035345
28267102	1101	1112	absenteeism	T055	C1283330
28267102	1120	1125	users	T098	C1706077
28267102	1133	1165	Brazilian National Health System	T093	C0018696
28267102	1167	1174	obesity	T047	C0028754
28267102	1176	1183	smoking	T055	C0037369
28267102	1189	1208	physical inactivity	T056	C3890554
28267102	1224	1235	significant	T078	C0750502
28267102	1236	1242	effect	T080	C1280500
28267102	1246	1265	productivity losses	T033	C4062086
28267102	1266	1281	associated with	T080	C0332281
28267102	1282	1297	health problems	T033	C2707292
28267102	1309	1322	low back pain	T184	C0024031
28267102	1327	1340	sleep quality	T033	C0424563
28267102	1346	1355	variables	T080	C0439828
28267102	1378	1387	potential	T080	C3245505
28267102	1391	1397	affect	T169	C0392760
28267102	1398	1415	health care costs	T081	C0085552

28534352|t|Tumor response and patient outcome after preoperative radiotherapy in locally advanced non-inflammatory breast cancer patients
28534352|a|The purpose of this analysis was to assess the tumor response and long-term outcome in patients treated with preoperative radiotherapy (PRT) without systemic therapy. Between 1997 and 2000, 134 patients with non-inflammatory locally advanced breast cancer (LABC) were treated with PRT. The tumor dose was 45 Gy in 15 fractions to the breast and to regional lymph nodes over 6 weeks. Radical mastectomy was performed 6 weeks after PRT to all patients and adjuvant systemic therapy was administered as per protocol. The measures of disease outcome were overall survival (OS) and disease-free survival (DFS) which estimated using the Kaplan-Meier method. Median follow-up was 74 months (range 4-216). Objective clinical tumor response after PRT was observed in 77.6% of the patients. Clinical complete tumor response (cCR) was achieved in 21.6% of the patients. Pathological CR in the breast was achieved in 15% of the patients. The 5- and 10- year OS were 55.1 and 37.8%, respectively. The 5- and 10- year DFS were 39.2 and 27%, respectively. Patients who achieved cCR had significantly longer OS in comparison with patients achieving clinical partial response (cPR) and clinical stable disease (cSD). Similarly, DFS of patients in the cCR group was longer compared with patients with cPR and cSD, yet without statistical significance. Our results showed that local control in LABC patients achieved by primary PRT, followed by radical mastectomy was comparable with the results reported in the literature. Complete pathologic response to PRT identified a subgroup of patients with a trend toward better DFS and OS.
28534352	0	14	Tumor response	T033	C4053910
28534352	19	34	patient outcome	T078	C1547647
28534352	41	66	preoperative radiotherapy	T061	C0436204
28534352	70	117	locally advanced non-inflammatory breast cancer	T191	C3495949
28534352	118	126	patients	T101	C0030705
28534352	147	155	analysis	T062	C0936012
28534352	163	169	assess	T052	C1516048
28534352	174	188	tumor response	T033	C4053910
28534352	193	202	long-term	T079	C0443252
28534352	203	210	outcome	T169	C1274040
28534352	214	222	patients	T101	C0030705
28534352	223	230	treated	T169	C1522326
28534352	236	261	preoperative radiotherapy	T061	C0436204
28534352	263	266	PRT	T061	C0436204
28534352	276	292	systemic therapy	T061	C1515119
28534352	321	329	patients	T101	C0030705
28534352	335	351	non-inflammatory	T033	C0442743
28534352	352	382	locally advanced breast cancer	T191	C3495949
28534352	384	388	LABC	T191	C3495949
28534352	395	402	treated	T169	C1522326
28534352	395	402	treated	T169	C1522326
28534352	408	411	PRT	T061	C0436204
28534352	417	422	tumor	T191	C0027651
28534352	423	427	dose	T081	C0178602
28534352	444	453	fractions	T081	C1264633
28534352	461	467	breast	T023	C0006141
28534352	475	495	regional lymph nodes	T023	C0729852
28534352	503	508	weeks	T079	C0439230
28534352	510	528	Radical mastectomy	T061	C0024884
28534352	533	542	performed	T169	C0884358
28534352	545	550	weeks	T079	C0439230
28534352	557	560	PRT	T061	C0436204
28534352	568	576	patients	T101	C0030705
28534352	581	589	adjuvant	T169	C1522673
28534352	590	606	systemic therapy	T061	C1515119
28534352	611	623	administered	T169	C1521801
28534352	631	639	protocol	T061	C0008971
28534352	645	653	measures	T081	C0079809
28534352	657	672	disease outcome	T033	C0679250
28534352	678	694	overall survival	T081	C4086681
28534352	696	698	OS	T081	C4086681
28534352	704	725	disease-free survival	T081	C0242793
28534352	727	730	DFS	T081	C0242793
28534352	738	747	estimated	T081	C0750572
28534352	758	777	Kaplan-Meier method	T062	C0038953
28534352	779	795	Median follow-up	T058	C1522577
28534352	803	809	months	T079	C0439231
28534352	811	816	range	T081	C1514721
28534352	825	834	Objective	T080	C1571702
28534352	835	843	clinical	T080	C0205210
28534352	844	858	tumor response	T033	C4053910
28534352	865	868	PRT	T061	C0436204
28534352	873	881	observed	T169	C1441672
28534352	898	906	patients	T101	C0030705
28534352	908	940	Clinical complete tumor response	T033	C4050094
28534352	942	945	cCR	T033	C4050094
28534352	951	959	achieved	T033	C0432600
28534352	976	984	patients	T101	C0030705
28534352	986	1001	Pathological CR	T033	C4050242
28534352	1009	1015	breast	T023	C0006141
28534352	1020	1028	achieved	T033	C0432600
28534352	1043	1051	patients	T101	C0030705
28534352	1068	1072	year	T079	C0439234
28534352	1073	1075	OS	T081	C4086681
28534352	1126	1130	year	T079	C0439234
28534352	1131	1134	DFS	T081	C0242793
28534352	1168	1176	Patients	T101	C0030705
28534352	1181	1189	achieved	T033	C0432600
28534352	1190	1193	cCR	T033	C4050094
28534352	1198	1218	significantly longer	T081	C4055637
28534352	1219	1221	OS	T081	C4086681
28534352	1225	1235	comparison	T052	C1707455
28534352	1241	1249	patients	T101	C0030705
28534352	1260	1285	clinical partial response	T033	C4050019
28534352	1287	1290	cPR	T033	C4050019
28534352	1296	1319	clinical stable disease	T033	C0677946
28534352	1321	1324	cSD	T033	C0677946
28534352	1338	1341	DFS	T081	C0242793
28534352	1345	1353	patients	T101	C0030705
28534352	1361	1364	cCR	T033	C4050094
28534352	1365	1370	group	T096	C0681850
28534352	1382	1390	compared	T052	C1707455
28534352	1396	1404	patients	T101	C0030705
28534352	1410	1413	cPR	T033	C4050019
28534352	1418	1421	cSD	T033	C0677946
28534352	1435	1459	statistical significance	T081	C0237881
28534352	1465	1472	results	T169	C1274040
28534352	1485	1498	local control	T169	C2587213
28534352	1502	1506	LABC	T191	C3495949
28534352	1507	1515	patients	T101	C0030705
28534352	1516	1524	achieved	T033	C0432600
28534352	1536	1539	PRT	T061	C0436204
28534352	1553	1571	radical mastectomy	T061	C0024884
28534352	1576	1586	comparable	T052	C1707455
28534352	1596	1603	results	T169	C1274040
28534352	1604	1612	reported	T170	C0684224
28534352	1620	1630	literature	T170	C0023866
28534352	1632	1660	Complete pathologic response	T033	C4050242
28534352	1664	1667	PRT	T061	C0436204
28534352	1681	1689	subgroup	T185	C1515021
28534352	1693	1701	patients	T101	C0030705
28534352	1709	1714	trend	T079	C1521798
28534352	1722	1728	better	T080	C0332272
28534352	1729	1732	DFS	T081	C0242793
28534352	1737	1739	OS	T081	C4086681

28078451|t|Slower but not faster unilateral fatiguing knee extensions alter contralateral limb performance without impairment of maximal torque output
28078451|a|The purpose of the present study was to examine the effects of unilateral fatigue of the knee extensors at different movement velocities on neuromuscular performance in the fatigued and non-fatigued leg. Unilateral fatigue of the knee extensors was induced in 11 healthy young men (23.7 ± 3.8 years) at slower (60°/s; FAT60) and faster movement velocities (240°/s; FAT240) using an isokinetic dynamometer. A resting control (CON) condition was included. The fatigue protocols consisted of five sets of 15 maximal concentric knee extensions using the dominant leg. Before and after fatigue, peak isokinetic torque (PIT) and time to PIT (TTP) of the knee extensors as well as electromyographic (EMG) activity of vastus medialis, vastus lateralis, and biceps femoris muscles were assessed at 60 and 240°/s movement velocities in the fatigued and non-fatigued leg. In the fatigue d leg, significantly greater PIT decrements were observed following FAT60 and FAT240 (11-19%) compared to CON (3-4%, p = .002, d = 2.3). Further, EMG activity increased in vastus lateralis and biceps femoris muscle following FAT240 only (8-28%, 0.018 ≤ p ≤ .024, d = 1.8). In the non-fatigued leg, shorter TTP values were found after the FAT60 protocol (11-15%, p = .023, d = 2.4). No significant changes were found for EMG data in the non-fatigued leg. The present study revealed that both slower and faster velocity fatiguing contractions failed to show any evidence of cross-over fatigue on PIT. However, unilateral knee extensor fatigue protocols conducted at slower movement velocities (i.e., 60°/s) appear to modulate torque production on the non-fatigued side (evident in shorter TTP values).
28078451	0	6	Slower	T080	C0439834
28078451	11	21	not faster	T080	C0205556
28078451	22	32	unilateral	T082	C0205092
28078451	33	42	fatiguing	T184	C0015672
28078451	43	58	knee extensions	T058	C2237190
28078451	59	64	alter	T169	C0392747
28078451	65	78	contralateral	T082	C0441988
28078451	79	83	limb	T023	C0015385
28078451	84	95	performance	T052	C1882330
28078451	96	103	without	T080	C0332288
28078451	104	114	impairment	T169	C0221099
28078451	118	125	maximal	T080	C0205289
28078451	126	132	torque	T067	C0376590
28078451	133	139	output	T077	C1709366
28078451	167	172	study	T062	C2603343
28078451	192	199	effects	T080	C1280500
28078451	203	213	unilateral	T082	C0205092
28078451	214	221	fatigue	T184	C0015672
28078451	229	243	knee extensors	T023	C0581537
28078451	247	256	different	T080	C1705242
28078451	257	265	movement	T040	C0026649
28078451	266	276	velocities	T081	C0439830
28078451	280	305	neuromuscular performance	T061	C0204036
28078451	313	321	fatigued	T184	C0015672
28078451	326	338	non-fatigued	T033	C1513916
28078451	339	342	leg	T023	C1140621
28078451	344	354	Unilateral	T082	C0205092
28078451	355	362	fatigue	T184	C0015672
28078451	370	384	knee extensors	T023	C0581537
28078451	389	396	induced	T169	C0205263
28078451	403	410	healthy	T080	C3898900
28078451	411	420	young men	T098	C0025266
28078451	433	438	years	T079	C0439234
28078451	443	449	slower	T080	C0439834
28078451	458	463	FAT60	T081	C0439830
28078451	469	475	faster	T080	C0205556
28078451	476	484	movement	T040	C0026649
28078451	485	495	velocities	T060	C0436191
28078451	505	511	FAT240	T081	C0439830
28078451	513	518	using	T169	C1524063
28078451	522	544	isokinetic dynamometer	T170	C0180571
28078451	548	579	resting control (CON) condition	T096	C0009932
28078451	584	592	included	T169	C0332257
28078451	598	605	fatigue	T184	C0015672
28078451	606	615	protocols	T170	C0282574
28078451	629	633	five	T081	C0205451
28078451	634	638	sets	T077	C1705195
28078451	645	652	maximal	T080	C0205289
28078451	653	663	concentric	T082	C0439744
28078451	664	679	knee extensions	T058	C2237190
28078451	690	702	dominant leg	T023	C1140621
28078451	704	710	Before	T079	C0332152
28078451	715	720	after	T079	C0687676
28078451	721	728	fatigue	T184	C0015672
28078451	730	752	peak isokinetic torque	T081	C0392762
28078451	754	757	PIT	T081	C0392762
28078451	763	774	time to PIT	T081	C0392762
28078451	776	779	TTP	T081	C0392762
28078451	788	802	knee extensors	T023	C0581537
28078451	814	846	electromyographic (EMG) activity	T033	C0429339
28078451	833	836	EMG	T074	C1138891
28078451	850	865	vastus medialis	T023	C0224445
28078451	867	883	vastus lateralis	T023	C0224444
28078451	889	911	biceps femoris muscles	T033	C2017878
28078451	917	925	assessed	T169	C0449622
28078451	943	951	movement	T040	C0026649
28078451	952	962	velocities	T060	C0436191
28078451	970	978	fatigued	T184	C0015672
28078451	996	999	leg	T023	C1140621
28078451	1008	1015	fatigue	T184	C0015672
28078451	1018	1021	leg	T023	C1140621
28078451	1037	1044	greater	T081	C1704243
28078451	1045	1048	PIT	T081	C0392762
28078451	1049	1059	decrements	T033	C0442797
28078451	1065	1073	observed	T169	C1441672
28078451	1084	1089	FAT60	T081	C0439830
28078451	1094	1100	FAT240	T081	C0439830
28078451	1110	1118	compared	T052	C1707455
28078451	1122	1125	CON	T096	C0009932
28078451	1162	1174	EMG activity	T033	C0429339
28078451	1175	1184	increased	T081	C0205217
28078451	1188	1204	vastus lateralis	T023	C0224444
28078451	1209	1230	biceps femoris muscle	T033	C2017878
28078451	1241	1247	FAT240	T081	C0439830
28078451	1309	1312	leg	T023	C1140621
28078451	1314	1321	shorter	T080	C0547044
28078451	1322	1332	TTP values	T080	C0042295
28078451	1338	1343	found	T033	C0150312
28078451	1354	1359	FAT60	T081	C0439830
28078451	1360	1368	protocol	T170	C0282574
28078451	1398	1412	No significant	T033	C1273937
28078451	1413	1420	changes	T169	C0392747
28078451	1426	1431	found	T033	C0150312
28078451	1436	1444	EMG data	T078	C1511726
28078451	1465	1468	leg	T023	C1140621
28078451	1482	1487	study	T062	C2603343
28078451	1507	1513	slower	T080	C0439834
28078451	1518	1524	faster	T080	C0205556
28078451	1525	1533	velocity	T060	C0436191
28078451	1534	1556	fatiguing contractions	T184	C0015672
28078451	1557	1563	failed	T169	C0231175
28078451	1576	1584	evidence	T078	C3887511
28078451	1588	1598	cross-over	T062	C0150097
28078451	1599	1606	fatigue	T184	C0015672
28078451	1610	1613	PIT	T081	C0392762
28078451	1624	1634	unilateral	T082	C0205092
28078451	1635	1648	knee extensor	T023	C0581537
28078451	1649	1656	fatigue	T184	C0015672
28078451	1657	1666	protocols	T170	C0282574
28078451	1680	1686	slower	T080	C0439834
28078451	1687	1695	movement	T040	C0026649
28078451	1696	1706	velocities	T060	C0436191
28078451	1740	1746	torque	T067	C0376590
28078451	1747	1757	production	T169	C0678227
28078451	1765	1782	non-fatigued side	T082	C1254362
28078451	1795	1802	shorter	T080	C0547044
28078451	1803	1813	TTP values	T080	C0042295

27634880|t|Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: a novel view of the metastasis of cancer cells to low- fibrinogen lymphatics and body cavities
27634880|a|Diluted (1%) plasma induces migration of malignant cell lines much more strongly than potent pro-metastatic factors. To characterize the factor(s) present in diluted plasma responsible for this phenomenon we performed i) heat inactivation, ii) dialysis, iii) proteinase K treatment, and iv) molecular size filtration studies. We found that this remarkable pro-migratory activity of diluted normal plasma is associated with a ~50-100-kD protein that interacts with GαI protein-coupled receptors and activates p42/44 MAPK and AKT signaling in target cells. Since this pro-migratory activity of 1% plasma decreases at higher plasma concentrations (> 20%), but is retained in serum, we hypothesized that fibrinogen may be involved as a chaperone of the protein(s). To identify the pro-migratory protein(s) present in diluted plasma and fibrinogen -depleted serum, we performed gel filtration and hydrophobic interaction chromatography followed by mass spectrometry analysis. We identified several putative protein candidates that were further tested in in vitro experiments. We found that this pro-migratory factor chaperoned by fibrinogen is vitronectin, which activates uPAR, and that this effect can be inhibited by fibrinogen. These results provide a novel mechanism for the metastasis of cancer cells to lymphatics and body cavities, in which the concentration of fibrinogen is low, and thus suggests that free vitronectin stimulates migration of tumor cells.
27634880	14	25	vitronectin	T116,T123	C0055023
27634880	38	64	migration-enhancing factor	T123	C0574031
27634880	69	81	cancer cells	T025	C0597032
27634880	82	92	chaperoned	T116,T123	C0243041
27634880	96	106	fibrinogen	T116,T121,T123	C0016006
27634880	128	138	metastasis	T046	C4255448
27634880	142	154	cancer cells	T025	C0597032
27634880	163	173	fibrinogen	T116,T121,T123	C0016006
27634880	174	184	lymphatics	T022	C0024235
27634880	189	202	body cavities	T030	C0333343
27634880	203	210	Diluted	T169	C1948037
27634880	216	222	plasma	T031	C0032105
27634880	231	240	migration	T043	C1622501
27634880	244	264	malignant cell lines	T025	C0334227
27634880	296	318	pro-metastatic factors	T169	C1521761
27634880	340	349	factor(s)	T169	C1521761
27634880	361	368	diluted	T169	C1948037
27634880	369	375	plasma	T031	C0032105
27634880	397	407	phenomenon	T067	C1882365
27634880	424	428	heat	T070	C0018837
27634880	429	441	inactivation	T169	C0544461
27634880	447	455	dialysis	T070	C0011945
27634880	462	474	proteinase K	T116,T126	C0059256
27634880	475	484	treatment	T169	C1522326
27634880	494	527	molecular size filtration studies	T068	C0016107
27634880	559	581	pro-migratory activity	T052	C0441655
27634880	585	592	diluted	T169	C1948037
27634880	600	606	plasma	T031	C0032105
27634880	639	646	protein	T116,T123	C0033684
27634880	667	696	GαI protein-coupled receptors	T116,T192	C0682972
27634880	711	722	p42/44 MAPK	T116,T126	C0752312
27634880	727	740	AKT signaling	T044	C1623484
27634880	751	756	cells	T025	C0007634
27634880	769	791	pro-migratory activity	T052	C0441655
27634880	798	804	plasma	T031	C0032105
27634880	825	846	plasma concentrations	T081	C0683150
27634880	875	880	serum	T031	C0229671
27634880	903	913	fibrinogen	T116,T121,T123	C0016006
27634880	935	944	chaperone	T116,T123	C0243041
27634880	952	962	protein(s)	T116,T123	C0033684
27634880	980	1004	pro-migratory protein(s)	T116,T123	C0033684
27634880	1016	1023	diluted	T169	C1948037
27634880	1024	1030	plasma	T031	C0032105
27634880	1035	1045	fibrinogen	T116,T121,T123	C0016006
27634880	1056	1061	serum	T031	C0229671
27634880	1076	1090	gel filtration	T059	C0008559
27634880	1095	1133	hydrophobic interaction chromatography	T059	C0008550
27634880	1146	1172	mass spectrometry analysis	T059	C0037813
27634880	1205	1212	protein	T116,T123	C0033684
27634880	1252	1260	in vitro	T080	C1533691
27634880	1261	1272	experiments	T062	C0681814
27634880	1293	1313	pro-migratory factor	T123	C0574031
27634880	1314	1324	chaperoned	T116,T123	C0243041
27634880	1328	1338	fibrinogen	T116,T121,T123	C0016006
27634880	1342	1353	vitronectin	T116,T123	C0055023
27634880	1418	1428	fibrinogen	T116,T121,T123	C0016006
27634880	1460	1469	mechanism	T044	C0678659
27634880	1478	1488	metastasis	T046	C4255448
27634880	1492	1504	cancer cells	T025	C0597032
27634880	1508	1518	lymphatics	T022	C0024235
27634880	1523	1536	body cavities	T030	C0333343
27634880	1551	1564	concentration	T081	C1264643
27634880	1568	1578	fibrinogen	T116,T121,T123	C0016006
27634880	1615	1626	vitronectin	T116,T123	C0055023
27634880	1638	1647	migration	T043	C1622501
27634880	1651	1662	tumor cells	T025	C0597032

28117729|t|The Association between Warning Label Requirements and Cigarette Smoking Prevalence by Education-Findings from the Global Adult Tobacco Survey (GATS)
28117729|a|The Guidelines for the implementation of Article 11 of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) require that cigarette health warning labels should include pictures and take up 50% or more of the principal display area. This study examined how the association between large pictorial warnings, those covering ≥50% of the front and back of the package, and the prevalence of cigarette smoking varies by educational attainment. We pooled individual-level tobacco use data from the Global Adult Tobacco Survey (GATS) in 18 countries between 2008 and 2013 and linked them with warning label requirements during the same period from the MPOWER database and reports regarding warnings. The respondents ' self-reported exposure to warnings was examined according to education. Logistic regressions were further employed to analyze education- specific associations between large pictorial warnings and smoking prevalence, and whether such association differed by education was examined using an interaction test. At the time of the survey, eight out of 18 countries had imposed graphic warning labels that covered ≥50% of the package. These warnings were associated with a 10.0% (OR = 0.89; 95% CI: 0.81, 0.97; p ≤ 0.01) lower cigarette smoking prevalence among adults with less than a secondary education or no formal education, but not among respondents with at least a secondary education. Less educated respondents were also less likely to be exposed to warnings in all 18 countries. The association between strong warnings and lower smoking prevalence among less educated respondents could be greater if their exposure to warnings increases. Prominent pictorial warning labels can potentially reduce health disparities resulting from smoking across different education levels.
28117729	4	15	Association	T080	C0439849
28117729	24	37	Warning Label	T170	C0687677
28117729	55	72	Cigarette Smoking	T055	C0700219
28117729	73	83	Prevalence	T081	C0220900
28117729	87	105	Education-Findings	T033	C0013658
28117729	115	142	Global Adult Tobacco Survey	T062	C0242481
28117729	144	148	GATS	T062	C0242481
28117729	154	164	Guidelines	T170	C0162791
28117729	173	187	implementation	T052	C1708476
28117729	209	287	World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC)	T093	C0043237
28117729	301	332	cigarette health warning labels	T170	C0687677
28117729	348	356	pictures	T073	C0441469
28117729	388	410	principal display area	T082	C1254362
28117729	417	422	study	T062	C2603343
28117729	423	431	examined	T033	C0332128
28117729	440	451	association	T080	C0439849
28117729	476	484	warnings	T064	C0871599
28117729	535	542	package	T073	C2700580
28117729	552	562	prevalence	T081	C0220900
28117729	566	583	cigarette smoking	T055	C0700219
28117729	594	616	educational attainment	T033	C0013658
28117729	628	656	individual-level tobacco use	T055	C0543414
28117729	657	661	data	UnknownType	C0814855
28117729	671	698	Global Adult Tobacco Survey	T062	C0242481
28117729	700	704	GATS	T062	C0242481
28117729	712	721	countries	T083	C0454664
28117729	765	778	warning label	T170	C0687677
28117729	824	839	MPOWER database	T170	C0242356
28117729	862	870	warnings	T064	C0871599
28117729	876	887	respondents	T098	C0282122
28117729	904	915	exposure to	T080	C0332157
28117729	916	924	warnings	T064	C0871599
28117729	929	937	examined	T033	C0332128
28117729	951	960	education	T033	C0013658
28117729	962	982	Logistic regressions	T062	C0206031
28117729	1016	1026	education-	T033	C0013658
28117729	1036	1048	associations	T080	C0439849
28117729	1073	1081	warnings	T064	C0871599
28117729	1086	1093	smoking	T055	C0700219
28117729	1094	1104	prevalence	T081	C0220900
28117729	1123	1134	association	T080	C0439849
28117729	1147	1156	education	T033	C0013658
28117729	1161	1169	examined	T033	C0332128
28117729	1179	1195	interaction test	T169	C0039593
28117729	1216	1222	survey	T062	C0242481
28117729	1240	1249	countries	T083	C0454664
28117729	1270	1284	warning labels	T170	C0687677
28117729	1310	1317	package	T073	C2700580
28117729	1325	1333	warnings	T064	C0871599
28117729	1364	1366	OR	T081	C0028873
28117729	1379	1381	CI	T081	C0009667
28117729	1395	1396	p	T081	C0033105
28117729	1411	1428	cigarette smoking	T055	C0700219
28117729	1429	1439	prevalence	T081	C0220900
28117729	1446	1452	adults	T100	C0001675
28117729	1470	1489	secondary education	T033	C1552030
28117729	1493	1512	no formal education	T033	C0557286
28117729	1528	1539	respondents	T098	C0282122
28117729	1556	1575	secondary education	T033	C1552030
28117729	1577	1590	Less educated	UnknownType	C0524325
28117729	1591	1602	respondents	T098	C0282122
28117729	1642	1650	warnings	T064	C0871599
28117729	1661	1670	countries	T083	C0454664
28117729	1676	1687	association	T080	C0439849
28117729	1703	1711	warnings	T064	C0871599
28117729	1722	1729	smoking	T055	C0700219
28117729	1730	1740	prevalence	T081	C0220900
28117729	1747	1760	less educated	UnknownType	C0524325
28117729	1761	1772	respondents	T098	C0282122
28117729	1799	1810	exposure to	T080	C0332157
28117729	1811	1819	warnings	T064	C0871599
28117729	1851	1865	warning labels	T170	C0687677
28117729	1889	1907	health disparities	T033	C1171307
28117729	1923	1930	smoking	T055	C0700219
28117729	1948	1964	education levels	T033	C0013658

28499328|t|Negative Psychological Consequences of Breast Cancer among Recently Diagnosed Ethnically Diverse Women
28499328|a|Breast cancer has psychological consequences that impact quality of life (QOL). We examined factors associated with negative psychological consequences of a breast cancer diagnosis, in a diverse sample of 910 recently diagnosed patients (378 African-American, 372 White, and 160 Latina). Patients completed an in-person interview as part of the Breast Cancer Care in Chicago study within an average of four months from diagnosis. The Cockburn negative psychological consequences of breast cancer screening scale was revised to focus on a breast cancer diagnosis. Path analysis assessed predictors of psychological consequences and potential mediators between race / ethnicity and psychological consequences. Compared to White counterparts, bivariate analysis showed African-American (β = 1.4, p < 0.05) and Latina (β = 3.6, p < 0.001) women reported greater psychological consequences. Strongest predictors (P < 0.05 for all) included unmet social support (β = 0.38), and provider trust (β = 0.12), followed by stage at diagnosis (β = 0.10) and perceived neighborhood social disorder (β = 0.09).The strongest mediator between race / ethnicity and psychological consequences was unmet social support. African-American and Latina women reported greater psychological consequences related to their breast cancer diagnosis; this disparity was mediated by differences in unmet social support. Social support represents a promising point of intervention.
28499328	0	8	Negative	T033	C0205160
28499328	9	22	Psychological	T169	C0205486
28499328	23	38	Consequences of	T169	C0686907
28499328	39	52	Breast Cancer	T191	C0006142
28499328	68	77	Diagnosed	T033	C0011900
28499328	78	88	Ethnically	T098	C0015031
28499328	89	96	Diverse	T080	C1880371
28499328	97	102	Women	T098	C0043210
28499328	103	116	Breast cancer	T191	C0006142
28499328	121	134	psychological	T169	C0205486
28499328	135	147	consequences	T169	C0686907
28499328	153	159	impact	T080	C4049986
28499328	160	175	quality of life	T078	C0034380
28499328	177	180	QOL	T078	C0034380
28499328	186	194	examined	T033	C0332128
28499328	203	218	associated with	T080	C0332281
28499328	219	227	negative	T033	C0205160
28499328	228	241	psychological	T169	C0205486
28499328	242	257	consequences of	T169	C0686907
28499328	260	273	breast cancer	T191	C0006142
28499328	274	283	diagnosis	T033	C0011900
28499328	290	297	diverse	T080	C1880371
28499328	298	304	sample	T077	C2347026
28499328	321	330	diagnosed	T033	C0011900
28499328	331	339	patients	T101	C0030705
28499328	345	361	African-American	T098	C0085756
28499328	367	372	White	T098	C0043157
28499328	382	388	Latina	T098	C1553378
28499328	391	399	Patients	T101	C0030705
28499328	400	409	completed	T080	C0205197
28499328	413	422	in-person	T098	C0027361
28499328	423	432	interview	T052	C0021822
28499328	448	466	Breast Cancer Care	T061	C0920687
28499328	470	477	Chicago	T083	C0008044
28499328	478	483	study	T062	C2603343
28499328	510	516	months	T079	C0439231
28499328	522	531	diagnosis	T033	C0011900
28499328	546	554	negative	T033	C0205160
28499328	555	568	psychological	T169	C0205486
28499328	569	584	consequences of	T169	C0686907
28499328	585	608	breast cancer screening	T060	C0199230
28499328	609	614	scale	T052	C1947916
28499328	641	654	breast cancer	T191	C0006142
28499328	655	664	diagnosis	T033	C0011900
28499328	666	679	Path analysis	T062	C0683963
28499328	680	688	assessed	T052	C1516048
28499328	689	699	predictors	T078	C2698872
28499328	703	716	psychological	T169	C0205486
28499328	717	729	consequences	T169	C0686907
28499328	762	766	race	T098	C0034510
28499328	769	778	ethnicity	T098	C0015031
28499328	783	796	psychological	T169	C0205486
28499328	797	809	consequences	T169	C0686907
28499328	823	828	White	T098	C0043157
28499328	843	861	bivariate analysis	UnknownType	C0681927
28499328	869	885	African-American	T098	C0085756
28499328	910	916	Latina	T098	C1553378
28499328	938	943	women	T098	C0043210
28499328	953	960	greater	T081	C1704243
28499328	961	974	psychological	T169	C0205486
28499328	975	987	consequences	T169	C0686907
28499328	989	998	Strongest	T080	C0442821
28499328	999	1009	predictors	T078	C2698872
28499328	1038	1043	unmet	T052	C3274904
28499328	1044	1058	social support	T054	C0037438
28499328	1084	1089	trust	T054	C0237935
28499328	1123	1132	diagnosis	T033	C0011900
28499328	1158	1170	neighborhood	T083	C0027569
28499328	1171	1186	social disorder	T033	C0850782
28499328	1229	1233	race	T098	C0034510
28499328	1236	1245	ethnicity	T098	C0015031
28499328	1250	1263	psychological	T169	C0205486
28499328	1264	1276	consequences	T169	C0686907
28499328	1281	1286	unmet	T052	C3274904
28499328	1287	1301	social support	T054	C0037438
28499328	1303	1319	African-American	T098	C0085756
28499328	1324	1330	Latina	T083	C0023122
28499328	1331	1336	women	T098	C0043210
28499328	1346	1353	greater	T081	C1704243
28499328	1354	1367	psychological	T169	C0205486
28499328	1368	1380	consequences	T169	C0686907
28499328	1398	1411	breast cancer	T191	C0006142
28499328	1412	1421	diagnosis	T033	C0011900
28499328	1428	1437	disparity	T033	C1171307
28499328	1469	1474	unmet	T052	C3274904
28499328	1475	1489	social support	T054	C0037438
28499328	1491	1505	Social support	T054	C0037438

28337281|t|C-MYC - induced upregulation of lncRNA SNHG12 regulates cell proliferation, apoptosis and migration in triple-negative breast cancer
28337281|a|Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, with a significantly higher recurrence and mortality rate. There is an urgent need to uncover the mechanism underlying TNBC and establish therapeutic targets. Long non-coding RNAs (lncRNAs) are involved in a series of biological functions and provide novel insights into the molecular mechanism of cancer. Based on their expression specificity and large number, lncRNAs are likely to serve as the basis for clinical applications in oncology. In our previous study, we utilized RNA sequencing (RNA-seq) to explore the lncRNAs expression profiles in TNBC and identified that small nucleolar RNA host gene 12 (SNHG12) was remarkably increased in TNBC. However, the role of SNHG12 in TNBC has not been clarified. Herein, we determine that SNHG12 is upregulated in TNBC, and its high expression is significantly correlated with tumor size and lymph node metastasis. Mechanistic investigations show that SNHG12 is a direct transcriptional target of c-MYC. Silencing SNHG12 expression inhibits TNBC cells proliferation and apoptosis promotion, whereas SNHG12 overexpression has the opposite effect. In addition, we reveal that SNHG12 may promote cells migration by regulating MMP13 expression. To the best of our knowledge, it is the first report indicating that SNHG12 is involved in breast cancer. Taken together, our findings suggest that SNHG12 contributes to the oncogenic potential of TNBC and may be a promising therapeutic target.
28337281	0	5	C-MYC	T028	C0079068
28337281	8	15	induced	T169	C0205263
28337281	16	28	upregulation	T044	C0041904
28337281	32	38	lncRNA	T114	C2982391
28337281	39	45	SNHG12	T028	C1823223
28337281	46	55	regulates	T038	C1327622
28337281	56	74	cell proliferation	T043	C0596290
28337281	76	85	apoptosis	T043	C0162638
28337281	90	99	migration	T043	C1622501
28337281	103	132	triple-negative breast cancer	T191	C3539878
28337281	133	162	Triple-negative breast cancer	T191	C3539878
28337281	164	168	TNBC	T191	C3539878
28337281	189	208	aggressive subtypes	T185	C0872379
28337281	212	225	breast cancer	T191	C0006142
28337281	248	254	higher	T080	C0205250
28337281	255	265	recurrence	T046	C2825055
28337281	270	284	mortality rate	T081	C0205848
28337281	325	334	mechanism	T169	C0441712
28337281	346	350	TNBC	T191	C3539878
28337281	365	376	therapeutic	T169	C0302350
28337281	377	384	targets	T169	C1521840
28337281	386	406	Long non-coding RNAs	T114	C2982391
28337281	408	415	lncRNAs	T114	C2982391
28337281	445	465	biological functions	T038	C3714634
28337281	502	521	molecular mechanism	T044	C1148560
28337281	525	531	cancer	T191	C0006826
28337281	548	558	expression	T045	C0017262
28337281	559	570	specificity	T081	C0037791
28337281	589	596	lncRNAs	T114	C2982391
28337281	634	642	clinical	T080	C0205210
28337281	643	655	applications	T169	C4048755
28337281	659	667	oncology	T058	C1555459
28337281	704	707	RNA	T114	C0035668
28337281	708	718	sequencing	T059	C1294197
28337281	720	727	RNA-seq	T059	C1294197
28337281	744	751	lncRNAs	T114	C2982391
28337281	752	771	expression profiles	T081	C1956267
28337281	775	779	TNBC	T191	C3539878
28337281	806	815	nucleolar	T029	C0521448
28337281	816	832	RNA host gene 12	T028	C1823223
28337281	834	840	SNHG12	T028	C1823223
28337281	870	874	TNBC	T191	C3539878
28337281	889	893	role	T077	C1705810
28337281	897	903	SNHG12	T028	C1823223
28337281	907	911	TNBC	T191	C3539878
28337281	962	968	SNHG12	T028	C1823223
28337281	972	983	upregulated	T044	C0041904
28337281	987	991	TNBC	T191	C3539878
28337281	1001	1005	high	T080	C0205250
28337281	1006	1016	expression	T045	C0017262
28337281	1034	1044	correlated	T080	C1707520
28337281	1050	1060	tumor size	T082	C0475440
28337281	1065	1087	lymph node metastasis.	T191	C0948627
28337281	1088	1099	Mechanistic	T169	C0441712
28337281	1100	1114	investigations	T062	C0683933
28337281	1125	1131	SNHG12	T028	C1823223
28337281	1144	1159	transcriptional	T045	C0040649
28337281	1160	1166	target	T169	C1521840
28337281	1170	1175	c-MYC	T028	C0079068
28337281	1177	1186	Silencing	T045	C0598496
28337281	1187	1193	SNHG12	T028	C1823223
28337281	1194	1204	expression	T045	C0017262
28337281	1214	1218	TNBC	T191	C3539878
28337281	1219	1238	cells proliferation	T043	C0596290
28337281	1243	1252	apoptosis	T043	C0162638
28337281	1272	1278	SNHG12	T028	C1823223
28337281	1279	1293	overexpression	T045	C0017262
28337281	1302	1310	opposite	T082	C1521805
28337281	1311	1317	effect	T080	C1280500
28337281	1347	1353	SNHG12	T028	C1823223
28337281	1366	1381	cells migration	T043	C1622501
28337281	1385	1395	regulating	T045	C0017263
28337281	1396	1401	MMP13	T028	C1417202
28337281	1402	1412	expression	T045	C0017262
28337281	1483	1489	SNHG12	T028	C1823223
28337281	1505	1518	breast cancer	T191	C0006142
28337281	1540	1548	findings	T033	C0243095
28337281	1562	1568	SNHG12	T028	C1823223
28337281	1588	1597	oncogenic	T191	C0598934
28337281	1598	1607	potential	T080	C3245505
28337281	1611	1615	TNBC	T191	C3539878
28337281	1639	1650	therapeutic	T169	C0302350
28337281	1651	1657	target	T169	C1521840

28034730|t|Association between postpartum depression and the practice of exclusive breastfeeding in the first three months of life
28034730|a|To investigate the association between postpartum depression and the occurrence of exclusive breastfeeding. This is a cross-sectional study conducted in the states of the Northeast region, during the vaccination campaign in 2010. The sample consisted of 2583 mother - child pairs, with children aged from 15 days to 3 months. The Edinburgh Postnatal Depression Scale was used to screen for postpartum depression. The outcome was lack of exclusive breastfeeding, defined as the occurrence of this practice in the 24h preceding the interview. Postpartum depression was the explanatory variable of interest and the covariates were: socioeconomic and demographic conditions; maternal health care; prenatal, delivery, and postnatal care; and the child's biological factors. Multivariate logistic regression analysis was conducted to control for possible confounding factors. Exclusive breastfeeding was observed in 50.8% of the infants and 11.8% of women had symptoms of postpartum depression. In the multivariate logistic regression analysis, a higher chance of exclusive breastfeeding absence was found among mothers with symptoms of postpartum depression (OR=1.67; p<0.001), among younger subjects (OR=1.89; p<0.001), those who reported receiving benefits from the Bolsa Família Program (OR=1.25; p=0.016), and those started antenatal care later during pregnancy (OR=2.14; p=0.032). Postpartum depression contributed to reducing the practice of exclusive breastfeeding. Therefore, this disorder should be included in the prenatal and early postpartum support guidelines for breastfeeding, especially in low socioeconomic status women.
28034730	0	11	Association	T080	C0439849
28034730	20	41	postpartum depression	T048	C0221074
28034730	50	58	practice	T041	C0032893
28034730	62	85	exclusive breastfeeding	T055	C0242205
28034730	105	111	months	T079	C0439231
28034730	115	119	life	T078	C0376558
28034730	123	134	investigate	T169	C1292732
28034730	139	150	association	T080	C0439849
28034730	159	180	postpartum depression	T048	C0221074
28034730	189	199	occurrence	T079	C2745955
28034730	203	226	exclusive breastfeeding	T055	C0242205
28034730	238	259	cross-sectional study	T062	C0010362
28034730	277	283	states	T083	C1301808
28034730	291	307	Northeast region	T083	C0017446
28034730	320	340	vaccination campaign	T058	C4279933
28034730	379	385	mother	T099	C0026591
28034730	388	393	child	T100	C0008059
28034730	394	399	pairs	T080	C1709450
28034730	406	414	children	T100	C0008059
28034730	415	419	aged	T032	C0001779
28034730	428	432	days	T079	C0439228
28034730	438	444	months	T079	C0439231
28034730	450	486	Edinburgh Postnatal Depression Scale	T170	C0451144
28034730	499	505	screen	T058	C0220908
28034730	510	531	postpartum depression	T048	C0221074
28034730	537	544	outcome	T169	C1274040
28034730	549	553	lack	T080	C0332268
28034730	557	580	exclusive breastfeeding	T055	C0242205
28034730	597	607	occurrence	T079	C2745955
28034730	616	624	practice	T078	C1254370
28034730	636	645	preceding	T079	C0332152
28034730	650	659	interview	T052	C0021822
28034730	661	682	Postpartum depression	T048	C0221074
28034730	691	711	explanatory variable	UnknownType	C0681885
28034730	732	742	covariates	UnknownType	C0814913
28034730	749	762	socioeconomic	T102	C0037464
28034730	767	789	demographic conditions	T078	C0011292
28034730	791	811	maternal health care	T058	C0024922
28034730	813	821	prenatal	T058	C0033052
28034730	823	831	delivery	T061	C0011209
28034730	837	851	postnatal care	T058	C0032782
28034730	861	887	child's biological factors	T080	C0205556
28034730	889	930	Multivariate logistic regression analysis	T081	C0026777
28034730	969	988	confounding factors	T169	C0009673
28034730	990	1013	Exclusive breastfeeding	T055	C0242205
28034730	1018	1026	observed	T169	C1441672
28034730	1043	1050	infants	T100	C0021270
28034730	1064	1069	women	T098	C0043210
28034730	1074	1082	symptoms	T184	C1457887
28034730	1086	1107	postpartum depression	T048	C0221074
28034730	1116	1157	multivariate logistic regression analysis	T081	C0026777
28034730	1178	1201	exclusive breastfeeding	T055	C0242205
28034730	1202	1209	absence	T169	C0332197
28034730	1226	1233	mothers	T099	C0026591
28034730	1239	1247	symptoms	T184	C1457887
28034730	1251	1272	postpartum depression	T048	C0221074
28034730	1299	1315	younger subjects	T098	C2349001
28034730	1365	1373	benefits	T081	C0814225
28034730	1383	1404	Bolsa Família Program	UnknownType	C0681136
28034730	1443	1457	antenatal care	T058	C0033052
28034730	1471	1480	pregnancy	T040	C0032961
28034730	1501	1522	Postpartum depression	T048	C0221074
28034730	1538	1546	reducing	T080	C0392756
28034730	1551	1559	practice	T078	C1254370
28034730	1563	1586	exclusive breastfeeding	T055	C0242205
28034730	1604	1612	disorder	T047	C0012634
28034730	1639	1647	prenatal	T058	C0033052
28034730	1652	1668	early postpartum	T079	C0233066
28034730	1669	1687	support guidelines	T170	C0282451
28034730	1692	1705	breastfeeding	T040	C0006147
28034730	1721	1745	low socioeconomic status	T081	C1328812
28034730	1746	1751	women	T098	C0043210

27794223|t|Semi-preparative HPLC separation followed by HPLC/UV and tandem mass spectrometric analysis of phorbol esters in Jatropha seed
27794223|a|Phorbol esters (PEs) are well known as the main toxic compounds in Jatropha curcas Linnaeus (JCL), the seed oil of which has been considered as a major feedstock for the production of biodiesel. In the present study, we investigated a series of PEs extracted from JCL seed kernels with methanol (MeOH), and identified more than seven components contained in the PEs. The isolation of main five components of a series of PEs was revised using a semi-preparative reversed phase HPLC analysis of ODS-3 column. The five peaks of components were successfully isolated, and peaks of J2, J3, J5, and J7 were assigned to be Jatropha factors C1, C2, C3, and C4/5, but J6 was a mixture of Jatropha factor C6 and its isomer based on the data of UV and LC-MS / MS, and J2 was identified using (1)H NMR analysis. By characterization using LC-MS / MS analysis, all components of a series of PEs were elucidated to be the 12-deoxy-16-hydroxyphorbol esters composed of isomeric form of dicarboxylic groups with same m/z value of 380.
27794223	0	32	Semi-preparative HPLC separation	T059	C0008562
27794223	33	44	followed by	T079	C0332283
27794223	45	52	HPLC/UV	T059	C4054774
27794223	57	91	tandem mass spectrometric analysis	T063	C0599748
27794223	95	109	phorbol esters	T109,T131	C0031586
27794223	113	121	Jatropha	T002	C0330579
27794223	122	126	seed	T002	C0036563
27794223	127	141	Phorbol esters	T109,T131	C0031586
27794223	143	146	PEs	T109,T131	C0031586
27794223	152	162	well known	T080	C0205309
27794223	170	174	main	T080	C1542147
27794223	175	180	toxic	T080	C1407029
27794223	181	190	compounds	T131	C1254354
27794223	194	218	Jatropha curcas Linnaeus	T002	C0330580
27794223	220	223	JCL	T002	C0330580
27794223	230	238	seed oil	T109,T123	C0032085
27794223	257	267	considered	T078	C0750591
27794223	273	278	major	T080	C0205164
27794223	297	307	production	T057	C0033268
27794223	311	320	biodiesel	T109	C2717894
27794223	337	342	study	T062	C0681814
27794223	347	359	investigated	T169	C1292732
27794223	362	368	series	T081	C0205549
27794223	372	375	PEs	T109,T131	C0031586
27794223	376	385	extracted	T061	C0185115
27794223	391	394	JCL	T002	C0330580
27794223	395	407	seed kernels	T002	C0036563
27794223	413	421	methanol	T109,T131	C0001963
27794223	423	427	MeOH	T109,T131	C0001963
27794223	434	444	identified	T080	C0205396
27794223	461	471	components	T131	C1254354
27794223	472	481	contained	T052	C2700400
27794223	489	492	PEs	T109,T131	C0031586
27794223	498	507	isolation	T169	C0205409
27794223	521	531	components	T131	C1254354
27794223	537	543	series	T081	C0205549
27794223	547	550	PEs	T109,T131	C0031586
27794223	555	562	revised	T061	C1527075
27794223	571	616	semi-preparative reversed phase HPLC analysis	T059	C2717789
27794223	620	632	ODS-3 column	T074	C0179909
27794223	643	648	peaks	T169	C1534709
27794223	652	662	components	T131	C1254354
27794223	681	689	isolated	T169	C0205409
27794223	695	700	peaks	T169	C1534709
27794223	704	706	J2	T169	C1534709
27794223	708	710	J3	T169	C1534709
27794223	712	714	J5	T169	C1534709
27794223	720	722	J7	T169	C1534709
27794223	728	736	assigned	T169	C1516050
27794223	743	751	Jatropha	T002	C0330579
27794223	752	759	factors	T169	C1521761
27794223	760	762	C1	T131	C1254354
27794223	764	766	C2	T131	C1254354
27794223	768	770	C3	T131	C1254354
27794223	776	780	C4/5	T131	C1254354
27794223	786	788	J6	T131	C1254354
27794223	795	802	mixture	T167	C0439962
27794223	806	814	Jatropha	T002	C0330579
27794223	815	821	factor	T169	C1521761
27794223	822	824	C6	T131	C1254354
27794223	833	839	isomer	T070	C0022203
27794223	853	857	data	T078	C1511726
27794223	861	863	UV	T059	C0260250
27794223	868	873	LC-MS	T059	C0920568
27794223	876	878	MS	T059	C0037813
27794223	891	901	identified	T080	C0205396
27794223	908	925	(1)H NMR analysis	T060	C3850001
27794223	930	946	characterization	T052	C1880022
27794223	953	958	LC-MS	T059	C0920568
27794223	961	972	MS analysis	T059	C0920568
27794223	978	988	components	T131	C1254354
27794223	994	1000	series	T081	C0205549
27794223	1004	1007	PEs	T109,T131	C0031586
27794223	1034	1067	12-deoxy-16-hydroxyphorbol esters	T131	C1254354
27794223	1080	1093	isomeric form	T070	C0022203
27794223	1097	1116	dicarboxylic groups	T120	C1254355
27794223	1127	1130	m/z	T067	C1705291

28499113|t|Social and Individual-Level Predictors of Alcohol Use Initiation and Escalation: Replicating and Extending Tests of Differential Effects
28499113|a|Although alcohol use is considered a developmental phenomenon, there is a relative dearth of studies disaggregating predictors of alcohol use initiation versus early escalation of drinking. One perspective that has emerged is that social levels of influence may be relevant for the initiation of drinking, whereas individual levels of influence may be relevant for the early escalation in level of drinking among initiators, which we refer to as the specificity hypothesis. A sample of alcohol - naive youth (n = 944; mean age = 12.16 years, SD = 0.96) was prospectively assessed for 3 years, spanning six waves of data collection. Both social (parental conflict, perceived prevalence of peer drinking) and individual-level (higher sensation seeking) variables uniquely predicted increases in the likelihood of alcohol initiation. Likewise, both social (perceived descriptive norms of peer drinking) and individual-level (lower school grades, higher sensation seeking) variables uniquely predicted escalation in level of drinking among initiators (although only marginally for sensation seeking). Overall, there was little support for the specificity hypothesis. Our findings suggest that to assume that social and individual-level processes differentially predict drinking outcomes may be a false dichotomy. Theoretical work may benefit from drawing from developmental models emphasizing the interplay between individual and environmental factors in the prediction of the early development of drinking. The emergence of drinking behaviors is likely to result from a developmental cascade of interacting variables that make the ontogeny of drinking unlikely to emerge from a single class of variables.
28499113	0	6	Social	T169	C0728831
28499113	11	27	Individual-Level	UnknownType	C0815261
28499113	28	38	Predictors	T078	C2698872
28499113	42	64	Alcohol Use Initiation	T055	C0001948
28499113	69	79	Escalation	T052	C4086266
28499113	81	92	Replicating	T169	C0205173
28499113	97	106	Extending	T082	C0439792
28499113	107	112	Tests	T169	C0039593
28499113	116	128	Differential	T080	C1705242
28499113	129	136	Effects	T080	C1280500
28499113	146	157	alcohol use	T055	C0001948
28499113	154	157	use	T169	C0457083
28499113	174	187	developmental	T080	C0458003
28499113	188	198	phenomenon	T067	C1882365
28499113	211	219	relative	T080	C0205345
28499113	220	226	dearth	T080	C0332268
28499113	230	237	studies	T062	C2603343
28499113	253	263	predictors	T078	C2698872
28499113	267	289	alcohol use initiation	T055	C0001948
28499113	275	278	use	T169	C0457083
28499113	279	289	initiation	T169	C1704686
28499113	297	302	early	T079	C1279919
28499113	303	313	escalation	T052	C4086266
28499113	317	325	drinking	T055	C0001948
28499113	331	342	perspective	T082	C0449445
28499113	352	359	emerged	T079	C0439659
28499113	368	374	social	T169	C0728831
28499113	375	381	levels	T080	C0441889
28499113	385	394	influence	T077	C4054723
28499113	402	410	relevant	T080	C2347946
28499113	419	429	initiation	T169	C1704686
28499113	433	441	drinking	T055	C0001948
28499113	451	468	individual levels	UnknownType	C0815261
28499113	472	481	influence	T077	C4054723
28499113	489	497	relevant	T080	C2347946
28499113	506	511	early	T079	C1279919
28499113	512	522	escalation	T052	C4086266
28499113	526	531	level	T080	C0441889
28499113	535	543	drinking	T055	C0001948
28499113	550	560	initiators	T098	C0027361
28499113	587	598	specificity	T081	C0037791
28499113	599	609	hypothesis	T078	C1512571
28499113	613	619	sample	T167	C0370003
28499113	623	630	alcohol	T109,T121	C0001975
28499113	633	644	naive youth	T100	C0087178
28499113	655	663	mean age	T081	C2348143
28499113	672	677	years	T079	C0439234
28499113	708	716	assessed	T052	C1516048
28499113	723	728	years	T079	C0439234
28499113	730	738	spanning	T102	C0870809
28499113	752	767	data collection	T062	C0010995
28499113	774	780	social	T169	C0728831
28499113	782	799	parental conflict	T033	C1999012
28499113	801	821	perceived prevalence	T081	C0220900
28499113	825	829	peer	T098	C0679739
28499113	830	838	drinking	T055	C0001948
28499113	844	860	individual-level	UnknownType	C0815261
28499113	862	868	higher	T080	C0205250
28499113	869	886	sensation seeking	T055	C0871336
28499113	888	897	variables	T080	C0439828
28499113	907	916	predicted	T078	C0681842
28499113	917	926	increases	T169	C0442805
28499113	934	944	likelihood	T081	C0033204
28499113	948	966	alcohol initiation	T055	C0001948
28499113	956	966	initiation	T169	C1704686
28499113	983	989	social	T169	C0728831
28499113	1001	1018	descriptive norms	T170	C0678257
28499113	1022	1026	peer	T098	C0679739
28499113	1027	1035	drinking	T055	C0001948
28499113	1041	1057	individual-level	UnknownType	C0815261
28499113	1059	1064	lower	T080	C0205251
28499113	1065	1078	school grades	T098	C1257890
28499113	1080	1086	higher	T080	C0205250
28499113	1087	1104	sensation seeking	T055	C0871336
28499113	1106	1115	variables	T080	C0439828
28499113	1125	1134	predicted	T078	C0681842
28499113	1135	1145	escalation	T052	C4086266
28499113	1149	1154	level	T080	C0441889
28499113	1158	1166	drinking	T055	C0001948
28499113	1173	1183	initiators	T098	C0027361
28499113	1199	1209	marginally	T082	C0205284
28499113	1214	1231	sensation seeking	T055	C0871336
28499113	1253	1267	little support	T077	C1521721
28499113	1276	1287	specificity	T081	C0037791
28499113	1288	1298	hypothesis	T078	C1512571
28499113	1304	1312	findings	T033	C0243095
28499113	1341	1347	social	T169	C0728831
28499113	1352	1368	individual-level	UnknownType	C0815261
28499113	1379	1393	differentially	T080	C1705242
28499113	1394	1401	predict	T078	C0681842
28499113	1402	1410	drinking	T055	C0001948
28499113	1411	1419	outcomes	T169	C1274040
28499113	1429	1444	false dichotomy	T052	C2919031
28499113	1446	1462	Theoretical work	T062,T170	C0039778
28499113	1480	1487	drawing	T170	C0013113
28499113	1493	1506	developmental	T080	C0458003
28499113	1507	1513	models	T170	C3161035
28499113	1530	1539	interplay	T169	C1704675
28499113	1548	1584	individual and environmental factors	T169	C1521761
28499113	1592	1602	prediction	T078	C0681842
28499113	1610	1615	early	T079	C1279919
28499113	1616	1627	development	T169	C1527148
28499113	1631	1639	drinking	T055	C0001948
28499113	1645	1654	emergence	T079	C0439659
28499113	1658	1676	drinking behaviors	T055	C0001948
28499113	1690	1696	result	T169	C1274040
28499113	1704	1725	developmental cascade	T080	C0458003
28499113	1729	1740	interacting	T169	C1704675
28499113	1741	1750	variables	T080	C0439828
28499113	1765	1773	ontogeny	T040	C1621967
28499113	1777	1785	drinking	T055	C0001948
28499113	1786	1794	unlikely	T033	C0750558
28499113	1798	1804	emerge	T079	C0439659
28499113	1812	1824	single class	T185	C0008902
28499113	1828	1837	variables	T080	C0439828

27511456|t|Quantification of intact plasma AGT consisting of oxidized and reduced conformations using a modified ELISA
27511456|a|The pleiotropic actions of the renin-angiotensin system (RAS) depend on the availability of angiotensinogen (AGT) which generates angiotensin I (ANG I) when cleaved by renin. Thus, quantification of the intact AGT (iAGT) concentrations is important to evaluate the actual renin substrate available. The iAGT conformation exists as oxidized AGT (oxi-AGT) and reduced AGT (red-AGT) in a disulfide bond, and oxi-AGT has a higher affinity for renin, which may exacerbate RAS - associated diseases. Accordingly, we determined iAGT, oxi-AGT, and red-AGT levels in plasma from rats and mice. Blood samples were obtained by cardiac puncture and then immediately mixed with an inhibitor solution containing a renin inhibitor. Total AGT (tAGT) levels were measured by tAGT ELISA which detects both cleaved and iAGT. iAGT levels were determined by iAGT ELISA which was found to only detect red-AGT. Thus, it was necessary to treat samples with dithiothreitol, a reducing agent, to quantify total iAGT concentration. tAGT levels in rat and mouse plasma were 1,839 ± 139 and 1,082 ± 77 ng/ml, respectively. iAGT levels were 53% of tAGT in rat plasma but only 22% in mouse plasma, probably reflecting the greater plasma renin activity in mice. The ratios of oxi-AGT and red-AGT were ∼4:1 (rat) and 16:1 (mouse). Plasma iAGT consists of oxi-AGT and red-AGT, suggesting that oxidative stress can influence ANG I generation by the AGT conformation switch. Furthermore, the lower availability of plasma iAGT in mice suggests that it may serve as a limiting factor in ANG I formation in this species.
27511456	0	14	Quantification	T081	C1709793
27511456	18	24	intact	T080	C0205266
27511456	25	31	plasma	T031	C0032105
27511456	32	35	AGT	T116,T123	C0003017
27511456	63	84	reduced conformations	T082	C0033625
27511456	102	107	ELISA	T059	C0014441
27511456	112	131	pleiotropic actions	T052	C3266814
27511456	139	163	renin-angiotensin system	T022	C0035096
27511456	165	168	RAS	T022	C0035096
27511456	184	199	availability of	T169	C0470187
27511456	200	215	angiotensinogen	T116,T123	C0003017
27511456	217	220	AGT	T116,T123	C0003017
27511456	228	237	generates	T052	C3146294
27511456	238	251	angiotensin I	T116,T123	C0003006
27511456	253	258	ANG I	T116,T123	C0003006
27511456	265	272	cleaved	T082	C0205242
27511456	276	281	renin	T116,T126	C0035094
27511456	289	303	quantification	T081	C1709793
27511456	311	317	intact	T080	C0205266
27511456	318	321	AGT	T116,T123	C0003017
27511456	323	327	iAGT	T116,T123	C0003017
27511456	329	343	concentrations	T081	C1264643
27511456	347	356	important	T080	C3898777
27511456	373	379	actual	T080	C0237400
27511456	380	395	renin substrate	T116,T123	C0003017
27511456	396	405	available	T169	C0470187
27511456	411	415	iAGT	T116,T123	C0003017
27511456	416	428	conformation	T082	C0033625
27511456	439	451	oxidized AGT	T116,T123	C0003017
27511456	453	460	oxi-AGT	T116,T123	C0003017
27511456	466	477	reduced AGT	T116,T123	C0003017
27511456	479	486	red-AGT	T116,T123	C0003017
27511456	493	507	disulfide bond	T087	C1511997
27511456	513	520	oxi-AGT	T116,T123	C0003017
27511456	527	533	higher	T080	C0205250
27511456	534	542	affinity	T070	C1510827
27511456	547	552	renin	T116,T126	C0035094
27511456	575	578	RAS	T022	C0035096
27511456	581	600	associated diseases	T046	C0243083
27511456	618	628	determined	T080	C0521095
27511456	629	633	iAGT	T116,T123	C0003017
27511456	635	642	oxi-AGT	T116,T123	C0003017
27511456	648	655	red-AGT	T116,T123	C0003017
27511456	656	662	levels	T080	C0441889
27511456	666	672	plasma	T031	C0032105
27511456	678	682	rats	T015	C0034693
27511456	687	691	mice	T015	C0025929
27511456	693	706	Blood samples	T031	C0178913
27511456	712	720	obtained	T169	C1301820
27511456	724	740	cardiac puncture	T059	C0022885
27511456	750	761	immediately	T079	C0205253
27511456	762	767	mixed	T169	C0205430
27511456	776	785	inhibitor	T120	C0243077
27511456	786	794	solution	T167	C0037633
27511456	795	805	containing	T169	C0332256
27511456	808	823	renin inhibitor	T121	C1960108
27511456	825	830	Total	T080	C0439810
27511456	831	834	AGT	T116,T123	C0003017
27511456	836	840	tAGT	T116,T123	C0003017
27511456	842	848	levels	T080	C0441889
27511456	854	862	measured	T080	C0444706
27511456	866	870	tAGT	T116,T123	C0003017
27511456	871	876	ELISA	T059	C0014441
27511456	883	890	detects	T033	C0442726
27511456	896	903	cleaved	T082	C0205242
27511456	908	912	iAGT	T116,T123	C0003017
27511456	914	918	iAGT	T116,T123	C0003017
27511456	919	925	levels	T080	C0441889
27511456	931	944	determined by	T080	C0521095
27511456	945	949	iAGT	T116,T123	C0003017
27511456	950	955	ELISA	T059	C0014441
27511456	980	986	detect	T033	C0442726
27511456	987	994	red-AGT	T116,T123	C0003017
27511456	1028	1035	samples	T031	C0178913
27511456	1041	1055	dithiothreitol	T109,T121	C0012789
27511456	1059	1073	reducing agent	T130	C0376446
27511456	1078	1086	quantify	T081	C1709793
27511456	1087	1092	total	T080	C0439810
27511456	1093	1097	iAGT	T116,T123	C0003017
27511456	1098	1111	concentration	T081	C1264643
27511456	1113	1117	tAGT	T116,T123	C0003017
27511456	1118	1124	levels	T080	C0441889
27511456	1128	1131	rat	T015	C0034693
27511456	1136	1141	mouse	T015	C0025929
27511456	1142	1148	plasma	T031	C0032105
27511456	1202	1206	iAGT	T116,T123	C0003017
27511456	1207	1213	levels	T080	C0441889
27511456	1226	1230	tAGT	T116,T123	C0003017
27511456	1234	1237	rat	T015	C0034693
27511456	1238	1244	plasma	T031	C0032105
27511456	1261	1266	mouse	T015	C0025929
27511456	1267	1273	plasma	T031	C0032105
27511456	1299	1306	greater	T081	C1704243
27511456	1307	1313	plasma	T031	C0032105
27511456	1314	1319	renin	T116,T126	C0035094
27511456	1320	1328	activity	T044	C0243102
27511456	1332	1336	mice	T015	C0025929
27511456	1342	1348	ratios	T081	C0456603
27511456	1352	1359	oxi-AGT	T116,T123	C0003017
27511456	1364	1371	red-AGT	T116,T123	C0003017
27511456	1383	1386	rat	T015	C0034693
27511456	1398	1403	mouse	T015	C0025929
27511456	1406	1412	Plasma	T031	C0032105
27511456	1413	1417	iAGT	T116,T123	C0003017
27511456	1430	1437	oxi-AGT	T116,T123	C0003017
27511456	1442	1449	red-AGT	T116,T123	C0003017
27511456	1451	1461	suggesting	T078	C1705535
27511456	1467	1483	oxidative stress	T049	C0242606
27511456	1488	1497	influence	T077	C4054723
27511456	1498	1503	ANG I	T116,T123	C0003006
27511456	1504	1514	generation	T052	C3146294
27511456	1522	1525	AGT	T116,T123	C0003017
27511456	1526	1538	conformation	T082	C0033625
27511456	1564	1569	lower	T052	C2003888
27511456	1570	1585	availability of	T169	C0470187
27511456	1586	1592	plasma	T031	C0032105
27511456	1593	1597	iAGT	T116,T123	C0003017
27511456	1601	1605	mice	T015	C0025929
27511456	1606	1614	suggests	T078	C1705535
27511456	1638	1646	limiting	T169	C0439801
27511456	1647	1653	factor	T169	C1521761
27511456	1657	1662	ANG I	T116,T123	C0003006
27511456	1663	1672	formation	T169	C1522492
27511456	1681	1688	species	T185	C1705920

27890470|t|sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
27890470|a|Pulmonary hypertension (PH) is a chronic cardiopulmonary disorder that if left untreated, progresses rapidly and is ultimately fatal. The World Health Organization (WHO) has classified PH into 5 distinct groups according to pathophysiology, hemodynamic characteristics, and clinical presentation. Dysfunction in the nitric oxide (NO) pathway plays a key role in the pulmonary hypertension disease process, including in WHO Groups 2 and 3 PH. PH is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway, which reduces cGMP production. cGMP regulates vascular tone, cellular proliferation, inflammation, and fibrosis and its depletion can lead to a variety of abnormalities, including pulmonary vasoconstriction, impaired vascular remodeling, and in situ thrombosis. This review will examine a novel class of drugs called sGC stimulators which directly stimulate sGC independently of NO, leading to increased production of cGMP.
27890470	0	15	sGC stimulators	T121	C3819023
27890470	17	25	Evidence	T078	C3887511
27890470	30	39	riociguat	T109,T121	C2717561
27890470	47	55	groups 1	T047	C2973725
27890470	60	84	4 pulmonary hypertension	T047	C2363973
27890470	85	107	Pulmonary hypertension	T046	C0020542
27890470	109	111	PH	T046	C0020542
27890470	118	125	chronic	T079	C0205191
27890470	126	150	cardiopulmonary disorder	T047	C0034072
27890470	175	185	progresses	T169	C1272688
27890470	186	193	rapidly	T080	C0456962
27890470	212	217	fatal	T080	C1302234
27890470	223	248	World Health Organization	T093	C0043237
27890470	250	253	WHO	T093	C0043237
27890470	259	269	classified	T185	C0008902
27890470	270	272	PH	T046	C0020542
27890470	289	295	groups	T078	C0441833
27890470	309	324	pathophysiology	T169	C0031847
27890470	326	337	hemodynamic	T042	C0019010
27890470	338	353	characteristics	T080	C1521970
27890470	359	380	clinical presentation	T170	C2708283
27890470	382	393	Dysfunction	T077	C3887504
27890470	401	426	nitric oxide (NO) pathway	T044	C1518332
27890470	451	473	pulmonary hypertension	T046	C0020542
27890470	474	489	disease process	T046	C0030660
27890470	504	507	WHO	T093	C0043237
27890470	508	516	Groups 2	T047	C3532326
27890470	521	525	3 PH	T047	C3698136
27890470	527	529	PH	T046	C0020542
27890470	533	548	associated with	T080	C0332281
27890470	549	572	endothelial dysfunction	T047	C0856169
27890470	574	582	impaired	T169	C0221099
27890470	583	598	synthesis of NO	T044	C1157570
27890470	604	616	insufficient	T080	C0231180
27890470	617	628	stimulation	T070	C1948023
27890470	636	716	NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway	T044	C3271755
27890470	724	731	reduces	T080	C0392756
27890470	732	736	cGMP	T114,T123	C0018338
27890470	737	747	production	T169	C0205245
27890470	749	753	cGMP	T114,T123	C0018338
27890470	764	777	vascular tone	T042	C0042396
27890470	779	801	cellular proliferation	T043	C0596290
27890470	803	815	inflammation	T046	C0021368
27890470	821	829	fibrosis	T046	C0016059
27890470	838	847	depletion	T169	C0333668
27890470	873	886	abnormalities	T033	C1704258
27890470	898	924	pulmonary vasoconstriction	T033	C1867424
27890470	926	934	impaired	T169	C0221099
27890470	935	954	vascular remodeling	T042	C3850148
27890470	960	978	in situ thrombosis	T033	C1867429
27890470	997	1004	examine	T033	C0332128
27890470	1007	1012	novel	T080	C0205314
27890470	1022	1027	drugs	T121	C0013227
27890470	1035	1050	sGC stimulators	T121	C3819023
27890470	1066	1075	stimulate	T070	C1948023
27890470	1076	1079	sGC	T116,T126,T192	C1097411
27890470	1080	1093	independently	T169	C0332291
27890470	1097	1099	NO	T121,T123,T197	C0028128
27890470	1112	1121	increased	T081	C0205217
27890470	1122	1132	production	T169	C0205245
27890470	1136	1140	cGMP	T114,T123	C0018338

28544601|t|The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier
28544601|a|A recent revision in thyroid tumor nomenclature has resulted in a change from a malignant diagnosis (noninvasive follicular variant of papillary thyroid carcinoma) to one that is nonmalignant (noninvasive follicular thyroid neoplasm with papillary-like nuclear features [NIFTP]). The objective of the current study was to evaluate the impact of this change on the performance of the Afirma gene expression classifier (GEC). The authors retrospectively analyzed consecutive thyroid fine-needle aspiration specimens with indeterminate diagnoses on which GEC was performed. Surgical pathology material was reviewed with the reclassification of nodules into NIFTP. GEC testing was performed on 384 fine-needle aspiration specimens diagnosed as atypia of undetermined significance (AUS) (304 cases) and suspicious for a follicular neoplasm (SFN) (80 cases) and yielded a suspicious result in 152 of the AUS cases (50%) and 50 of the SFN cases (63%). Thyroidectomy was performed on 177 patients. After reclassifying NIFTP, the positive predictive value of GEC decreased from 42% (95% confidence interval [95% CI], 39%-45%) to 24% (95% CI, 22%-26%) in the AUS group and from 23% (95% CI, 19%-27%) to 13% (95% CI, 9%-18%) in the SFN group. Total thyroidectomy was performed more frequently than a partial thyroidectomy in patients with AUS with a suspicious GEC result compared with pre-GEC controls (68% vs 49%; P = .037). Reclassification of NIFTP significantly decreases the positive predictive value of GEC in indeterminate thyroid nodules. Nevertheless, the majority of patients with indeterminate thyroid nodules with a suspicious GEC result in the study institution have undergone total thyroidectomy. This finding raises concerns over reliance on a suspicious GEC result by clinicians to justify total thyroidectomy. Cancer Cytopathol 2017. © 2017 American Cancer Society.
28544601	4	10	impact	T080	C4049986
28544601	14	90	noninvasive follicular thyroid neoplasm with papillary-like nuclear features	T191	C4287590
28544601	98	109	performance	T052	C1882330
28544601	117	150	Afirma gene expression classifier	T062	C0242481
28544601	172	185	thyroid tumor	T191	C0040136
28544601	186	198	nomenclature	T170	C0600281
28544601	231	240	malignant	T080	C0205282
28544601	241	250	diagnosis	T033	C0011900
28544601	252	313	noninvasive follicular variant of papillary thyroid carcinoma	T191	C0238463
28544601	330	342	nonmalignant	T080	C1518371
28544601	344	420	noninvasive follicular thyroid neoplasm with papillary-like nuclear features	T191	C4287590
28544601	422	427	NIFTP	T191	C4287590
28544601	460	465	study	T062	C2603343
28544601	486	492	impact	T080	C4049986
28544601	515	526	performance	T052	C1882330
28544601	534	567	Afirma gene expression classifier	T062	C0242481
28544601	569	572	GEC	T062	C0242481
28544601	587	611	retrospectively analyzed	T062	C0936012
28544601	624	654	thyroid fine-needle aspiration	T060	C0193787
28544601	655	664	specimens	T167	C0370003
28544601	684	693	diagnoses	T060	C0011911
28544601	703	706	GEC	T062	C0242481
28544601	722	749	Surgical pathology material	T167	C0520510
28544601	772	788	reclassification	T185	C0008902
28544601	792	799	nodules	T020	C0028259
28544601	805	810	NIFTP	T191	C4287590
28544601	812	815	GEC	T062	C0242481
28544601	845	867	fine-needle aspiration	T060	C0193787
28544601	868	877	specimens	T167	C0370003
28544601	878	887	diagnosed	T033	C0011900
28544601	891	926	atypia of undetermined significance	T033	C0243095
28544601	928	931	AUS	T033	C0243095
28544601	938	943	cases	T169	C0868928
28544601	966	985	follicular neoplasm	T191	C0474808
28544601	987	990	SFN	T191	C0474808
28544601	996	1001	cases	T169	C0868928
28544601	1049	1052	AUS	T033	C0243095
28544601	1053	1058	cases	T169	C0868928
28544601	1079	1082	SFN	T191	C0474808
28544601	1083	1088	cases	T169	C0868928
28544601	1096	1109	Thyroidectomy	T061	C0040145
28544601	1131	1139	patients	T101	C0030705
28544601	1147	1160	reclassifying	T185	C0008902
28544601	1161	1166	NIFTP	T191	C4287590
28544601	1181	1197	predictive value	T080	C1514307
28544601	1201	1204	GEC	T062	C0242481
28544601	1205	1214	decreased	T081	C0205216
28544601	1229	1248	confidence interval	T081	C0009667
28544601	1254	1256	CI	T081	C0009667
28544601	1280	1282	CI	T081	C0009667
28544601	1300	1303	AUS	T033	C0243095
28544601	1304	1309	group	T101	C0030705
28544601	1328	1330	CI	T081	C0009667
28544601	1353	1355	CI	T081	C0009667
28544601	1372	1375	SFN	T191	C0474808
28544601	1376	1381	group	T101	C0030705
28544601	1389	1402	thyroidectomy	T061	C0040145
28544601	1448	1461	thyroidectomy	T061	C0040145
28544601	1465	1473	patients	T101	C0030705
28544601	1479	1482	AUS	T033	C0243095
28544601	1501	1504	GEC	T062	C0242481
28544601	1526	1542	pre-GEC controls	T096	C0009932
28544601	1567	1583	Reclassification	T185	C0008902
28544601	1587	1592	NIFTP	T191	C4287590
28544601	1607	1616	decreases	T081	C0547047
28544601	1630	1646	predictive value	T080	C1514307
28544601	1650	1653	GEC	T062	C0242481
28544601	1671	1678	thyroid	T023	C0040132
28544601	1679	1686	nodules	T020	C0028259
28544601	1718	1726	patients	T101	C0030705
28544601	1746	1753	thyroid	T023	C0040132
28544601	1754	1761	nodules	T020	C0028259
28544601	1780	1783	GEC	T062	C0242481
28544601	1798	1803	study	T062	C2603343
28544601	1804	1815	institution	T093	C2607850
28544601	1837	1850	thyroidectomy	T061	C0040145
28544601	1872	1880	concerns	T078	C2699424
28544601	1911	1914	GEC	T062	C0242481
28544601	1925	1935	clinicians	T097	C0871685
28544601	1953	1966	thyroidectomy	T061	C0040145

28549760|t|Perception of food consumed at home and dietary intake: A nationwide study from Brazil
28549760|a|Perception of food consumed is a key factor in acknowledging the need for behavioral change to improve diet quality. We analyzed family dietary intake according to the head of household's perception of satisfaction with food consumed by the family. Households (n = 13,351) that participated in the Brazilian Household Budget Survey and the National Dietary Survey were classified as satisfied or dissatisfied with the food consumed in the home. We compared the family dietary intake of the two groups considering their socio-demographic characteristics. Satisfied families (n = 4429) reported statistically higher intake (in grams/1000 kcal) of vegetables (47.3 vs 33.7), fruits (46.9 vs 21.4), sugar-sweetened beverages (118 vs 71.7), milk and dairy (57.9 vs 34.6), and ultra-processed products (18.6 vs 9.8); and lower intake of rice (86.2 vs 112), beans (91.7 vs 136), and meat (76.5 vs 84.0) when compared to dissatisfied families (n = 1717). Among satisfied families, in the youngest group we found lower consumption of fruits and higher intake of sugar-sweetened beverages and ultra-processed products when compared to the oldest group. Also among satisfied families, those in the highest per capita income group presented higher intake of fruits and lower intake of beans than those in the lowest income group. Satisfied families in the highest income group also consumed more fruits and less beans than dissatisfied families in the same income group. Socio-demographic characteristics may influence perception of satisfaction with food consumed and potentially influence the success of public health efforts to offer nutrition guidance for families satisfied with diets that may or may not be comprised of healthy food and beverages.
28549760	0	10	Perception	T041	C0030971
28549760	14	27	food consumed	T052	C2983605
28549760	31	35	home	T092	C1547197
28549760	40	54	dietary intake	T040	C1286104
28549760	69	74	study	T062	C2603343
28549760	80	86	Brazil	T083	C0006137
28549760	87	97	Perception	T041	C0030971
28549760	101	114	food consumed	T052	C2983605
28549760	124	130	factor	T169	C1521761
28549760	161	178	behavioral change	T055	C0542299
28549760	182	189	improve	T033	C0184511
28549760	190	202	diet quality	T033	C2136285
28549760	207	215	analyzed	T062	C0936012
28549760	216	222	family	T099	C0015576
28549760	223	237	dietary intake	T040	C1286104
28549760	255	274	head of household's	T099	C0018677
28549760	275	285	perception	T041	C0030971
28549760	289	301	satisfaction	T041	C0242428
28549760	307	320	food consumed	T052	C2983605
28549760	328	334	family	T099	C0015576
28549760	336	346	Households	T099	C0020052
28549760	365	377	participated	T169	C0679823
28549760	385	394	Brazilian	T033	C0238815
28549760	395	404	Household	T099	C0020052
28549760	405	418	Budget Survey	T170	C0038951
28549760	427	450	National Dietary Survey	T170	C0038951
28549760	456	466	classified	T185	C0008902
28549760	470	479	satisfied	T170	C4084799
28549760	483	495	dissatisfied	T170	C4085546
28549760	505	518	food consumed	T052	C2983605
28549760	526	530	home	T092	C1547197
28549760	535	543	compared	T052	C1707455
28549760	548	554	family	T099	C0015576
28549760	555	569	dietary intake	T040	C1286104
28549760	581	587	groups	T078	C0441833
28549760	606	639	socio-demographic characteristics	T102	C0683970
28549760	641	650	Satisfied	T170	C4084799
28549760	651	659	families	T099	C0015576
28549760	671	679	reported	T058	C0700287
28549760	680	700	statistically higher	T080	C0205250
28549760	701	707	intake	T169	C1512806
28549760	732	742	vegetables	T168	C0042440
28549760	759	765	fruits	T168	C0016767
28549760	782	807	sugar-sweetened beverages	T168	C0005329
28549760	823	827	milk	T168	C0349374
28549760	832	837	dairy	T168	C0010947
28549760	858	882	ultra-processed products	T168	C0344355
28549760	902	907	lower	T080	C0205251
28549760	908	914	intake	T169	C1512806
28549760	918	922	rice	T168	C0035567
28549760	938	943	beans	T168	C0004896
28549760	963	967	meat	T168	C0025017
28549760	988	996	compared	T052	C1707455
28549760	1000	1012	dissatisfied	T170	C4085546
28549760	1013	1021	families	T099	C0015576
28549760	1040	1049	satisfied	T170	C4084799
28549760	1050	1058	families	T099	C0015576
28549760	1067	1075	youngest	T079	C1254367
28549760	1076	1081	group	T078	C0441833
28549760	1091	1096	lower	T080	C0205251
28549760	1097	1108	consumption	T052	C2983605
28549760	1112	1118	fruits	T168	C0016767
28549760	1123	1129	higher	T080	C0205250
28549760	1130	1136	intake	T169	C1512806
28549760	1140	1165	sugar-sweetened beverages	T168	C0005329
28549760	1170	1194	ultra-processed products	T168	C0344355
28549760	1200	1208	compared	T052	C1707455
28549760	1216	1222	oldest	T079	C1254367
28549760	1223	1228	group	T078	C0441833
28549760	1241	1250	satisfied	T170	C4084799
28549760	1251	1259	families	T099	C0015576
28549760	1282	1299	per capita income	UnknownType	C0681015
28549760	1300	1305	group	T078	C0441833
28549760	1306	1315	presented	T078	C0449450
28549760	1316	1322	higher	T080	C0205250
28549760	1323	1329	intake	T169	C1512806
28549760	1333	1339	fruits	T168	C0016767
28549760	1344	1349	lower	T080	C0205251
28549760	1350	1356	intake	T169	C1512806
28549760	1360	1365	beans	T168	C0004896
28549760	1384	1403	lowest income group	T098	C0024045
28549760	1405	1414	Satisfied	T170	C4084799
28549760	1415	1423	families	T099	C0015576
28549760	1431	1451	highest income group	T098	C0019532
28549760	1457	1465	consumed	T033	C3468056
28549760	1471	1477	fruits	T168	C0016767
28549760	1482	1486	less	T081	C0439092
28549760	1487	1492	beans	T168	C0004896
28549760	1498	1510	dissatisfied	T170	C4085546
28549760	1511	1519	families	T099	C0015576
28549760	1527	1544	same income group	T098	C0019532
28549760	1546	1579	Socio-demographic characteristics	T102	C0683970
28549760	1584	1593	influence	T077	C4054723
28549760	1594	1604	perception	T041	C0030971
28549760	1608	1620	satisfaction	T041	C0242428
28549760	1626	1639	food consumed	T052	C2983605
28549760	1644	1655	potentially	T080	C3245505
28549760	1656	1665	influence	T077	C4054723
28549760	1670	1677	success	T054	C0597535
28549760	1681	1694	public health	T058	C0699943
28549760	1712	1730	nutrition guidance	T058	C1667087
28549760	1735	1743	families	T099	C0015576
28549760	1744	1753	satisfied	T170	C4084799
28549760	1759	1764	diets	T168	C0012155
28549760	1788	1797	comprised	T052	C2700400
28549760	1801	1813	healthy food	T168	C0016452
28549760	1818	1827	beverages	T168	C0005329

27323673|t|Has dementia research lost its sense of reality? A descriptive analysis of eligibility criteria of Dutch dementia research protocols
27323673|a|A substantial proportion of dementia patients are excluded from research participation, while for extrapolation of the study findings, it is important that the research population represents the patient population. The aim of this study is to provide an analysis of dementia research and its exclusion criteria in order to get a clearer picture whether the research participants represent the general dementia population. Dementia studies registered at ToetsingOnline.nl between 2006-2015 were analysed. Study characteristics, funding and eligibility criteria were described and analysed using a standardised score sheet. The search yielded 103 usable study protocols. The number of trials has increased over the years, and 35% of the studies were industry - financed. Alzheimer's disease was the most researched type of dementia (84%). In observational studies the most frequently observed exclusion criterion is a neurological condition, while in drug studies and other intervention studies this is a somatic condition. Of all protocols, 86% had at least one exclusion criterion concerning comorbidity. Most studies focused on mild or moderate dementia (78%). Our study has shown that the distribution of dementia research over the different subtypes of dementia does not correspond with the prevalence of these subtypes in clinical practice. The research population in the protocols is not representative of the larger patient population. A greater number of dementia patients could derive benefit from the conducted research if the research agenda were more closely aligned with disease prevalence. A better representation of all dementia patients in research will help to meet the needs of these patients.
27323673	4	12	dementia	T048	C0497327
27323673	13	21	research	T062	C0035168
27323673	31	47	sense of reality	T078	C0871222
27323673	75	95	eligibility criteria	T080	C1516637
27323673	99	104	Dutch	T098	C0013331
27323673	105	113	dementia	T048	C0497327
27323673	114	132	research protocols	T062	C0205717
27323673	161	169	dementia	T048	C0497327
27323673	170	178	patients	T101	C0030705
27323673	197	205	research	T062	C0035168
27323673	206	219	participation	T169	C0679823
27323673	231	244	extrapolation	T033	C4289771
27323673	252	257	study	T062	C0008972
27323673	293	301	research	T062	C0035168
27323673	302	312	population	T081	C0032659
27323673	328	346	patient population	T081	C2361270
27323673	364	369	study	T062	C0008972
27323673	399	407	dementia	T048	C0497327
27323673	408	416	research	T062	C0035168
27323673	425	443	exclusion criteria	T169	C0680251
27323673	490	498	research	T062	C0035168
27323673	499	511	participants	T098	C0679646
27323673	534	542	dementia	T048	C0497327
27323673	543	553	population	T081	C0032659
27323673	555	563	Dementia	T048	C0497327
27323673	564	571	studies	T062	C0008972
27323673	586	603	ToetsingOnline.nl	T170	C0282574
27323673	627	635	analysed	T062	C0936012
27323673	637	642	Study	T062	C0008972
27323673	643	658	characteristics	T080	C1521970
27323673	660	667	funding	T081	C0243098
27323673	672	692	eligibility criteria	T080	C1516637
27323673	729	753	standardised score sheet	T081	C0449820
27323673	785	800	study protocols	T170	C2348563
27323673	816	822	trials	T062	C0008976
27323673	868	875	studies	T062	C0008972
27323673	881	889	industry	T057	C0021267
27323673	892	900	financed	T057	C0149692
27323673	902	921	Alzheimer's disease	T047	C0002395
27323673	935	945	researched	T062	C0035168
27323673	954	962	dementia	T048	C0497327
27323673	1024	1043	exclusion criterion	T169	C0680251
27323673	1049	1071	neurological condition	T033	C0260949
27323673	1082	1094	drug studies	T062	C0013175
27323673	1105	1125	intervention studies	T061	C0184661
27323673	1136	1153	somatic condition	T080	C2986476
27323673	1162	1171	protocols	T170	C2348563
27323673	1194	1213	exclusion criterion	T169	C0680251
27323673	1225	1236	comorbidity	T078	C0009488
27323673	1243	1250	studies	T062	C0008972
27323673	1262	1266	mild	T048	C3494623
27323673	1270	1287	moderate dementia	T048	C3494871
27323673	1299	1304	study	T062	C0008972
27323673	1324	1336	distribution	T082	C0037775
27323673	1340	1348	dementia	T048	C0497327
27323673	1349	1357	research	T062	C0035168
27323673	1377	1385	subtypes	T185	C0449560
27323673	1389	1397	dementia	T048	C0497327
27323673	1427	1437	prevalence	T081	C0220900
27323673	1447	1455	subtypes	T185	C0449560
27323673	1459	1476	clinical practice	T062	C0008967
27323673	1482	1490	research	T062	C0035168
27323673	1491	1501	population	T081	C0032659
27323673	1509	1518	protocols	T170	C2348563
27323673	1555	1573	patient population	T081	C2361270
27323673	1595	1603	dementia	T048	C0497327
27323673	1604	1612	patients	T101	C0030705
27323673	1653	1661	research	T062	C0035168
27323673	1669	1684	research agenda	T062	C0681798
27323673	1716	1734	disease prevalence	T081	C0683919
27323673	1767	1775	dementia	T048	C0497327
27323673	1776	1784	patients	T101	C0030705
27323673	1788	1796	research	T062	C0035168
27323673	1834	1842	patients	T101	C0030705

27371817|t|Metabolomic analysis of glycerophospholipid signatures of inflammation treated with non-steroidal anti-inflammatory drugs -induced- RAW264.7 cells using (1)H NMR and U-HPLC / Q-TOF-MS
27371817|a|Non-destructive proton nuclear magnetic resonance ((1)H NMR) spectroscopy and highly sensitive ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (U-HPLC / Q-TOF-MS) coupled to data processing methods were applied to analyze the metabolic profiling changes of glycerophospholipids (GPLs) in RAW264.7 cells from inflammation to prognosis. Analysis of (1)H NMR was shown that the models were grouped successfully, illustrating that all of them had significant differences. Based on the highly simple, accurate, non-targeted and non-destructively advantages of (1)H NMR, it could be used as a new screening tool of anti-inflammatory drugs in the metabolic profiling of GPLs. 58 GPLs were identified by U-HPLC / Q-TOF-MS, and 19 components were firstly identified in this study compared with our previous results. In addition, ten potential biomarkers were proved, of which phosphatidylcholine (PC) (16:0/18:1) and (18:0/18:1) changed consistently in three drug-induced groups and might be the important biomarkers. Compared with (1)H NMR, U-HPLC / Q-TOF-MS showed higher sensitivity and specificity and was more suitable for the determination of biomarkers apart from the deficiency of time-consuming sample preparation steps and unambiguous metabolite identification. Therefore, it is feasible to analyze the changes of GPLs during inflammation by combining (1)H NMR spectroscopy with U-HPLC / Q-TOF-MS. The metabolic profiling of GPLs provides valuable evidence for inflammation diagnosis and prognosis, and might unravel the mechanisms involved in inflammation progression.
27371817	0	11	Metabolomic	T091	C1328813
27371817	12	20	analysis	T169	C1524024
27371817	24	43	glycerophospholipid	T109	C0162448
27371817	58	70	inflammation	T046	C0021368
27371817	71	83	treated with	T061	C0332293
27371817	84	121	non-steroidal anti-inflammatory drugs	T121	C0003211
27371817	132	146	RAW264.7 cells	T025	C0024432
27371817	153	161	(1)H NMR	T060	C0877853
27371817	166	172	U-HPLC	T059	C0008562
27371817	175	183	Q-TOF-MS	T059	C0599827
27371817	184	257	Non-destructive proton nuclear magnetic resonance ((1)H NMR) spectroscopy	T060	C0877853
27371817	262	278	highly sensitive	T080	C0439822
27371817	279	318	ultra-performance liquid chromatography	T059	C0008562
27371817	319	362	quadrupole time-of-flight mass spectrometry	T059	C0599827
27371817	364	370	U-HPLC	T059	C0008562
27371817	373	381	Q-TOF-MS	T059	C0599827
27371817	394	409	data processing	T066	C0868941
27371817	410	417	methods	T170	C0025663
27371817	446	465	metabolic profiling	T091	C1328813
27371817	477	497	glycerophospholipids	T109	C0162448
27371817	499	503	GPLs	T109	C0162448
27371817	508	522	RAW264.7 cells	T025	C0024432
27371817	528	540	inflammation	T046	C0021368
27371817	544	553	prognosis	T058	C0033325
27371817	555	563	Analysis	T062	C0936012
27371817	567	575	(1)H NMR	T060	C0877853
27371817	595	601	models	T170	C3161035
27371817	607	614	grouped	T169	C1522242
27371817	675	686	differences	T080	C1705242
27371817	701	714	highly simple	T080	C0205352
27371817	716	724	accurate	T080	C0443131
27371817	775	783	(1)H NMR	T060	C0877853
27371817	829	852	anti-inflammatory drugs	T121	C0003209
27371817	860	879	metabolic profiling	T091	C1328813
27371817	883	887	GPLs	T109	C0162448
27371817	892	896	GPLs	T109	C0162448
27371817	902	912	identified	T080	C0205396
27371817	916	922	U-HPLC	T059	C0008562
27371817	925	933	Q-TOF-MS	T059	C0599827
27371817	966	976	identified	T080	C0205396
27371817	985	990	study	T062	C2603343
27371817	1044	1053	potential	T080	C3245505
27371817	1054	1064	biomarkers	T201	C0005516
27371817	1087	1106	phosphatidylcholine	T109,T121,T123	C1959616
27371817	1108	1110	PC	T109,T121,T123	C1959616
27371817	1140	1147	changed	T081	C0443172
27371817	1170	1182	drug-induced	T169	C0458082
27371817	1183	1189	groups	T078	C0441833
27371817	1217	1227	biomarkers	T201	C0005516
27371817	1243	1251	(1)H NMR	T060	C0877853
27371817	1253	1259	U-HPLC	T059	C0008562
27371817	1262	1270	Q-TOF-MS	T059	C0599827
27371817	1278	1284	higher	T080	C0205250
27371817	1285	1312	sensitivity and specificity	T081	C0036668
27371817	1343	1356	determination	T059	C1148554
27371817	1360	1370	biomarkers	T201	C0005516
27371817	1386	1396	deficiency	T080	C2987487
27371817	1400	1414	time-consuming	T080	C3827829
27371817	1415	1439	sample preparation steps	T059	C1720914
27371817	1456	1466	metabolite	T123	C0870883
27371817	1467	1481	identification	T080	C0205396
27371817	1524	1531	changes	T081	C1705241
27371817	1535	1539	GPLs	T109	C0162448
27371817	1547	1559	inflammation	T046	C0021368
27371817	1573	1594	(1)H NMR spectroscopy	T060	C0877853
27371817	1600	1606	U-HPLC	T059	C0008562
27371817	1609	1617	Q-TOF-MS	T059	C0599827
27371817	1623	1642	metabolic profiling	T091	C1328813
27371817	1646	1650	GPLs	T109	C0162448
27371817	1669	1677	evidence	T078	C3887511
27371817	1682	1694	inflammation	T046	C0021368
27371817	1695	1704	diagnosis	T033	C0011900
27371817	1709	1718	prognosis	T058	C0033325
27371817	1742	1752	mechanisms	T169	C0441712
27371817	1765	1777	inflammation	T046	C0021368
27371817	1778	1789	progression	T046	C0242656

27848238|t|A Tractable Method for Measuring Nanomaterial Risk Using Bayesian Networks
27848238|a|While control banding has been identified as a suitable framework for the evaluation and the determination of potential human health risks associated with exposure to nanomaterials (NMs), the approach currently lacks any implementation that enjoys widespread support. Large inconsistencies in characterisation data, toxicological measurements and exposure scenarios make it difficult to map and compare the risk associated with NMs based on physicochemical data, concentration and exposure route. Here we demonstrate the use of Bayesian networks as a reliable tool for NM risk estimation. This tool is tractable, accessible and scalable. Most importantly, it captures a broad span of data types, from complete, high quality data sets through to data sets with missing data and/or values with a relatively high spread of probability distribution. The tool is able to learn iteratively in order to further refine forecasts as the quality of data available improves. We demonstrate how this risk measurement approach works on NMs with varying degrees of risk potential, namely, carbon nanotubes, silver and titanium dioxide. The results afford even non-experts an accurate picture of the occupational risk probabilities associated with these NMs and, in doing so, demonstrated how NM risk can be evaluated into a tractable, quantitative risk comparator.
27848238	2	11	Tractable	T080	C0205556
27848238	12	18	Method	T170	C0025663
27848238	23	32	Measuring	T080	C0444706
27848238	33	45	Nanomaterial	T073	C1450053
27848238	46	50	Risk	T078	C0035647
27848238	57	74	Bayesian Networks	T170	C3161035
27848238	89	96	banding	T061	C0185014
27848238	149	159	evaluation	T078	C1550157
27848238	185	194	potential	T080	C3245505
27848238	195	200	human	T016	C0086418
27848238	201	213	health risks	T061	C0679809
27848238	230	241	exposure to	T080	C0332157
27848238	242	255	nanomaterials	T073	C1450053
27848238	257	260	NMs	T073	C1450053
27848238	296	310	implementation	T052	C1708476
27848238	385	389	data	T078	C1511726
27848238	391	404	toxicological	T038	C4042799
27848238	405	417	measurements	T169	C0242485
27848238	482	486	risk	T078	C0035647
27848238	503	506	NMs	T073	C1450053
27848238	516	531	physicochemical	T070	C2350461
27848238	532	536	data	T078	C1511726
27848238	538	551	concentration	T081	C1446561
27848238	556	570	exposure route	UnknownType	C0683172
27848238	603	620	Bayesian networks	T170	C3161035
27848238	635	639	tool	T169	C0449851
27848238	644	646	NM	T073	C1450053
27848238	647	651	risk	T078	C0035647
27848238	669	673	tool	T169	C0449851
27848238	677	686	tractable	T080	C0205556
27848238	688	698	accessible	T080	C0205556
27848238	703	711	scalable	T081	C0392762
27848238	759	763	data	T078	C1511726
27848238	791	798	quality	T080	C0332306
27848238	799	808	data sets	T170	C0150098
27848238	820	829	data sets	T170	C0150098
27848238	843	847	data	T078	C1511726
27848238	855	861	values	T081	C1522609
27848238	895	919	probability distribution	T081	C3826440
27848238	925	929	tool	T169	C0449851
27848238	1003	1010	quality	T080	C0332306
27848238	1014	1018	data	T078	C1511726
27848238	1063	1067	risk	T078	C0035647
27848238	1068	1079	measurement	T169	C0242485
27848238	1098	1101	NMs	T073	C1450053
27848238	1126	1130	risk	T078	C0035647
27848238	1131	1140	potential	T080	C3245505
27848238	1150	1166	carbon nanotubes	T104	C1138408
27848238	1168	1174	silver	T196	C0037125
27848238	1179	1195	titanium dioxide	T121,T197	C0076733
27848238	1221	1232	non-experts	T098	C0027361
27848238	1273	1277	risk	T078	C0035647
27848238	1314	1317	NMs	T073	C1450053
27848238	1353	1355	NM	T073	C1450053
27848238	1356	1360	risk	T078	C0035647
27848238	1368	1377	evaluated	T078	C1550157
27848238	1385	1394	tractable	T080	C0205556
27848238	1396	1408	quantitative	T081	C0392762
27848238	1409	1413	risk	T078	C0035647

27845744|t|Promoting Healthy Growth or Feeding Obesity? The Need for Evidence -Based Oversight of Infant Nutritional Supplement Claims
27845744|a|The Developmental Origins of Health and Disease (DOHaD) model recognizes growth in infancy and childhood as a fundamental determinant of lifespan health. Evidence of long-term health risks among small neonates who subsequently grow rapidly poses a challenge for interventions aiming to support healthy growth, not merely drive weight gain. Defining healthy growth beyond "getting bigger" is essential as infant and young child feeding industries expand. Liquid -based nutritional supplements, originally formulated for undernourished children, are increasingly marketed for and consumed by children generally. Clarifying the nature of the evidentiary base on which structure/function claims promoting " healthy growth " are constructed is important to curb invalid generalizations. Evidence points to changing social beliefs and cultural practices surrounding supplementary feeding, raising specific concerns about the long-term health consequences of an associated altered feeding culture, including reduced dietary variety and weight gain. Reassessing the evidence for and relevance of dietary supplements' " promoting healthy growth " claims for otherwise healthy children is both needed in a time of global obesity and an opportunity to refine intervention approaches among small children for whom rapid subsequent growth in early life augments risk for chronic disease. Scientific and health care partnerships are needed to consider current governmental oversight shortfalls in protecting vulnerable populations from overconsumption. This is important because we may be doing more harm than good.
27845744	0	9	Promoting	T052	C0033414
27845744	10	17	Healthy	T080	C3898900
27845744	18	24	Growth	T040	C0018270
27845744	28	35	Feeding	T052	C2987508
27845744	36	43	Obesity	T047	C0028754
27845744	49	53	Need	T080	C0027552
27845744	58	66	Evidence	T078	C3887511
27845744	87	93	Infant	T100	C0021270
27845744	94	116	Nutritional Supplement	T168	C0242295
27845744	128	171	Developmental Origins of Health and Disease	T170	C0282574
27845744	173	178	DOHaD	T170	C0282574
27845744	197	203	growth	T040	C0018270
27845744	207	214	infancy	T079	C0231330
27845744	219	228	childhood	T079	C0231335
27845744	261	269	lifespan	T102	C0870809
27845744	270	276	health	T078	C0018684
27845744	278	289	Evidence of	T169	C0332120
27845744	290	299	long-term	T079	C0443252
27845744	300	306	health	T078	C0018684
27845744	307	312	risks	T078	C0035647
27845744	319	324	small	T081	C0700321
27845744	325	333	neonates	T100	C0021289
27845744	351	355	grow	T067	C0870861
27845744	356	363	rapidly	T080	C0456962
27845744	386	399	interventions	T058	C1273869
27845744	418	425	healthy	T080	C3898900
27845744	426	432	growth	T040	C0018270
27845744	451	462	weight gain	T033	C0043094
27845744	473	480	healthy	T080	C3898900
27845744	481	487	growth	T040	C0018270
27845744	515	524	essential	T080	C0205224
27845744	528	534	infant	T100	C0021270
27845744	539	544	young	T079	C0332239
27845744	545	550	child	T100	C0008059
27845744	551	558	feeding	T052	C2987508
27845744	559	569	industries	T057	C0021267
27845744	578	584	Liquid	T167	C0302908
27845744	592	615	nutritional supplements	T168	C0242295
27845744	628	638	formulated	T168	C0016497
27845744	643	657	undernourished	T047	C0162429
27845744	658	666	children	T100	C0008059
27845744	672	684	increasingly	T169	C0442808
27845744	685	693	marketed	T057	C0683746
27845744	702	710	consumed	T052	C2983605
27845744	714	722	children	T100	C0008059
27845744	734	744	Clarifying	T052	C2986669
27845744	815	824	promoting	T052	C0033414
27845744	827	834	healthy	T080	C3898900
27845744	835	841	growth	T040	C0018270
27845744	863	872	important	T080	C3898777
27845744	906	914	Evidence	T078	C3887511
27845744	934	940	social	T169	C0728831
27845744	941	948	beliefs	T078	C0004951
27845744	953	961	cultural	T169	C0220814
27845744	962	971	practices	T041	C0237607
27845744	984	1005	supplementary feeding	T061	C0038847
27845744	1015	1023	specific	T080	C0205369
27845744	1024	1032	concerns	T078	C2699424
27845744	1043	1052	long-term	T079	C0443252
27845744	1053	1059	health	T078	C0018684
27845744	1060	1075	consequences of	T169	C0686907
27845744	1079	1089	associated	T080	C0332281
27845744	1090	1097	altered	T169	C0392747
27845744	1098	1105	feeding	T052	C2987508
27845744	1106	1113	culture	T169	C0220814
27845744	1125	1132	reduced	T080	C0392756
27845744	1133	1140	dietary	T168	C0012155
27845744	1141	1148	variety	T077	C2346866
27845744	1153	1164	weight gain	T033	C0043094
27845744	1166	1177	Reassessing	T052	C1516048
27845744	1182	1194	evidence for	T169	C0332120
27845744	1199	1208	relevance	T080	C2347946
27845744	1212	1232	dietary supplements'	T168	C0242295
27845744	1235	1244	promoting	T052	C0033414
27845744	1245	1252	healthy	T080	C3898900
27845744	1253	1259	growth	T040	C0018270
27845744	1283	1290	healthy	T080	C3898900
27845744	1291	1299	children	T100	C0008059
27845744	1308	1314	needed	T080	C0027552
27845744	1328	1334	global	T080	C2348867
27845744	1335	1342	obesity	T047	C0028754
27845744	1350	1361	opportunity	T062	C0683937
27845744	1372	1395	intervention approaches	T061	C0184661
27845744	1402	1407	small	T081	C0700321
27845744	1408	1416	children	T100	C0008059
27845744	1426	1431	rapid	T080	C0456962
27845744	1443	1449	growth	T040	C0018270
27845744	1473	1477	risk	T078	C0035647
27845744	1482	1497	chronic disease	T047	C0008679
27845744	1499	1509	Scientific	T090	C0036397
27845744	1514	1525	health care	T058	C0086388
27845744	1526	1538	partnerships	T092	C1711206
27845744	1543	1549	needed	T080	C0027552
27845744	1570	1582	governmental	UnknownType	C0680773
27845744	1629	1640	populations	T098	C1257890
27845744	1646	1661	overconsumption	T052	C0441655
27845744	1671	1680	important	T080	C3898777

27908503|t|Cobalt-60 Machines and Medical Linear Accelerators: Competing Technologies for External Beam Radiotherapy
27908503|a|Medical linear accelerators (linacs) and cobalt-60 machines are both mature technologies for external beam radiotherapy. A comparison is made between these two technologies in terms of infrastructure and maintenance, dosimetry, shielding requirements, staffing, costs, security, patient throughput and clinical use. Infrastructure and maintenance are more demanding for linacs due to the complex electric componentry. In dosimetry, a higher beam energy, modulated dose rate and smaller focal spot size mean that it is easier to create an optimised treatment with a linac for conformal dose coverage of the tumour while sparing healthy organs at risk. In shielding, the requirements for a concrete bunker are similar for cobalt-60 machines and linacs but extra shielding and protection from neutrons are required for linacs. Staffing levels can be higher for linacs and more staff training is required for linacs. Life cycle costs are higher for linacs, especially multi-energy linacs. Security is more complex for cobalt-60 machines because of the high activity radioactive source. Patient throughput can be affected by source decay for cobalt-60 machines but poor maintenance and breakdowns can severely affect patient throughput for linacs. In clinical use, more complex treatment techniques are easier to achieve with linacs, and the availability of electron beams on high - energy linacs can be useful for certain treatments. In summary, there is no simple answer to the question of the choice of either cobalt-60 machines or linacs for radiotherapy in low- and middle-income countries. In fact a radiotherapy department with a combination of technologies, including orthovoltage X-ray units, may be an option. Local needs, conditions and resources will have to be factored into any decision on technology taking into account the characteristics of both forms of teletherapy, with the primary goal being the sustainability of the radiotherapy service over the useful lifetime of the equipment.
27908503	0	18	Cobalt-60 Machines	T074	C0025080
27908503	23	50	Medical Linear Accelerators	T074	C0023730
27908503	52	74	Competing Technologies	T090	C0039421
27908503	79	105	External Beam Radiotherapy	T061	C1517033
27908503	106	133	Medical linear accelerators	T074	C0023730
27908503	135	141	linacs	T074	C0023730
27908503	147	165	cobalt-60 machines	T074	C0025080
27908503	182	194	technologies	T090	C0039421
27908503	199	225	external beam radiotherapy	T061	C1517033
27908503	229	239	comparison	T052	C1707455
27908503	266	278	technologies	T090	C0039421
27908503	291	305	infrastructure	T185	C1514880
27908503	310	321	maintenance	T052	C0024501
27908503	323	332	dosimetry	T059	C0034603
27908503	334	343	shielding	T033	C0243095
27908503	344	356	requirements	T169	C1514873
27908503	358	366	staffing	T057	C0087023
27908503	368	373	costs	T081	C0010186
27908503	375	383	security	T077	C1519222
27908503	385	392	patient	T101	C0030705
27908503	393	403	throughput	T081	C2986816
27908503	408	420	clinical use	T169	C0042153
27908503	422	436	Infrastructure	T185	C1514880
27908503	441	452	maintenance	T052	C0024501
27908503	462	471	demanding	T078	C0699784
27908503	476	482	linacs	T074	C0023730
27908503	494	522	complex electric componentry	T073	C3273359
27908503	527	536	dosimetry	T059	C0034603
27908503	540	546	higher	T080	C0205250
27908503	547	558	beam energy	T081	C1442080
27908503	560	569	modulated	T082	C0443264
27908503	570	579	dose rate	T081	C1512044
27908503	584	591	smaller	T080	C0547044
27908503	592	607	focal spot size	T080	C2348694
27908503	624	630	easier	T033	C0332219
27908503	634	640	create	T052	C1706214
27908503	644	653	optimised	T052	C2698650
27908503	654	663	treatment	T061	C0087111
27908503	671	676	linac	T074	C0023730
27908503	691	695	dose	T081	C0178602
27908503	696	704	coverage	T169	C1999244
27908503	712	718	tumour	T191	C0027651
27908503	733	747	healthy organs	T023	C0178784
27908503	751	755	risk	T078	C0035647
27908503	760	769	shielding	T033	C0243095
27908503	775	787	requirements	T169	C1514873
27908503	794	809	concrete bunker	T073	C3273359
27908503	826	844	cobalt-60 machines	T074	C0025080
27908503	849	855	linacs	T074	C0023730
27908503	866	875	shielding	T033	C0243095
27908503	880	890	protection	T033	C1545588
27908503	896	904	neutrons	T167	C0027946
27908503	922	928	linacs	T074	C0023730
27908503	930	945	Staffing levels	T033	C3845726
27908503	953	959	higher	T080	C0205250
27908503	964	970	linacs	T074	C0023730
27908503	980	994	staff training	T065	C0681113
27908503	1011	1017	linacs	T074	C0023730
27908503	1019	1035	Life cycle costs	T169	C0220812
27908503	1040	1046	higher	T080	C0205250
27908503	1051	1057	linacs	T074	C0023730
27908503	1070	1089	multi-energy linacs	T074	C0023730
27908503	1091	1099	Security	T077	C1519222
27908503	1108	1115	complex	T080	C0439855
27908503	1120	1138	cobalt-60 machines	T074	C0025080
27908503	1154	1158	high	T080	C0205250
27908503	1159	1167	activity	T052	C0441655
27908503	1168	1186	radioactive source	T122	C0182598
27908503	1188	1195	Patient	T101	C0030705
27908503	1196	1206	throughput	T081	C2986816
27908503	1214	1222	affected	T169	C0392760
27908503	1226	1232	source	T033	C0449416
27908503	1233	1238	decay	T067	C2700592
27908503	1243	1261	cobalt-60 machines	T074	C0025080
27908503	1266	1270	poor	T080	C0542537
27908503	1271	1282	maintenance	T052	C0024501
27908503	1287	1297	breakdowns	T066	C0014678
27908503	1311	1317	affect	T169	C0392760
27908503	1318	1325	patient	T101	C0030705
27908503	1326	1336	throughput	T081	C2986816
27908503	1341	1347	linacs	T074	C0023730
27908503	1352	1364	clinical use	T169	C0042153
27908503	1371	1378	complex	T080	C0439855
27908503	1379	1388	treatment	T061	C0087111
27908503	1389	1399	techniques	T169	C0449851
27908503	1404	1410	easier	T033	C0332219
27908503	1427	1433	linacs	T074	C0023730
27908503	1443	1458	availability of	T169	C0470187
27908503	1459	1473	electron beams	T073	C0013840
27908503	1477	1481	high	T080	C0205250
27908503	1484	1490	energy	T081	C1442080
27908503	1491	1497	linacs	T074	C0023730
27908503	1524	1534	treatments	T061	C0087111
27908503	1614	1632	cobalt-60 machines	T074	C0025080
27908503	1636	1642	linacs	T074	C0023730
27908503	1647	1659	radiotherapy	T061	C1522449
27908503	1663	1667	low-	T033	C1331016
27908503	1672	1685	middle-income	T080	C0870890
27908503	1686	1695	countries	T083	C0454664
27908503	1707	1730	radiotherapy department	T093	C0587444
27908503	1738	1749	combination	T080	C0205195
27908503	1753	1765	technologies	T090	C0039421
27908503	1777	1801	orthovoltage X-ray units	T092	C1704729
27908503	1813	1819	option	T169	C1518601
27908503	1821	1826	Local	T082	C0205276
27908503	1827	1832	needs	T080	C0027552
27908503	1834	1844	conditions	T080	C0348080
27908503	1849	1858	resources	T078	C0035201
27908503	1893	1901	decision	T041	C0679006
27908503	1905	1915	technology	T090	C0039421
27908503	1940	1955	characteristics	T080	C1521970
27908503	1973	1984	teletherapy	T061	C0419095
27908503	2003	2007	goal	T170	C0018017
27908503	2018	2032	sustainability	T169	C0205245
27908503	2040	2060	radiotherapy service	T093	C0587559
27908503	2077	2085	lifetime	T079	C4071830
27908503	2093	2102	equipment	T073	C0014672

28408903|t|Anti-bacterial and Anti-biofilm Evaluation of Thiazolopyrimidinone Derivatives Targeting the Histidine Kinase YycG Protein of Staphylococcus epidermidis
28408903|a|Staphylococcus epidermidis is one of the most important opportunistic pathogens in nosocomial infections. The main pathogenicity associated with S. epidermidis involves the formation of biofilms on implanted medical devices, biofilms dramatically decrease the efficacy of conventional antibiotics and the host immune system. This emphasizes the urgent need for designing novel anti-staphylococcal biofilm agents. Based on the findings that compound 5, targeting the histidine kinase domain of S. epidermidis YycG, possessed bactericidal activity against staphylococci, 39 derivatives of compound 5 with intact thiazolopyrimidinone core structures were newly designed, 7 derivatives were further screened to explore their anti-bacterial and anti-biofilm activities. The seven derivatives strongly inhibited the growth of S. epidermidis and Staphylococcus aureus in the minimal inhibitory concentration range of 1.56-6.25 μM. All the derivatives reduced the proportion of viable cells in mature biofilms. They all displayed low cytotoxicity on mammalian cells and were not hemolytic to human erythrocytes. The biofilm inhibition activities of four derivatives (H5-32, H5-33, H5-34, and H5-35) were further investigated under shearing forces, they all led to significant decreases in the biofilm formation of S. epidermidis. These results were suggestive that the seven derivatives of compound 5 have the potential to be developed into agents for eradicating biofilm -associated infections.
28408903	0	42	Anti-bacterial and Anti-biofilm Evaluation	T039	C0544570
28408903	46	78	Thiazolopyrimidinone Derivatives	T121	C1254351
28408903	93	109	Histidine Kinase	T116,T126	C0072399
28408903	110	152	YycG Protein of Staphylococcus epidermidis	T116,T126	C1870317
28408903	153	179	Staphylococcus epidermidis	T007	C0038174
28408903	223	232	pathogens	T001	C0450254
28408903	236	257	nosocomial infections	T047	C0205721
28408903	268	281	pathogenicity	T032	C1136169
28408903	282	297	associated with	T080	C0332281
28408903	298	312	S. epidermidis	T007	C0038174
28408903	339	347	biofilms	T007	C0081786
28408903	351	376	implanted medical devices	T074	C2735362
28408903	378	386	biofilms	T007	C0081786
28408903	413	421	efficacy	T080	C1280519
28408903	438	449	antibiotics	T195	C0003232
28408903	458	462	host	T001	C1167395
28408903	463	476	immune system	T022	C0020962
28408903	524	529	novel	T080	C0205314
28408903	530	564	anti-staphylococcal biofilm agents	T195	C0279516
28408903	593	603	compound 5	T121	C1254351
28408903	619	642	histidine kinase domain	T116,T126	C0072399
28408903	646	665	S. epidermidis YycG	T116,T126	C1870317
28408903	677	698	bactericidal activity	T039	C0544570
28408903	707	720	staphylococci	T007	C0038174
28408903	725	799	derivatives of compound 5 with intact thiazolopyrimidinone core structures	T104	C0243072
28408903	805	810	newly	T080	C0205314
28408903	821	834	7 derivatives	T104	C0243072
28408903	848	856	screened	T059	C0373483
28408903	874	916	anti-bacterial and anti-biofilm activities	T039	C0544570
28408903	922	939	seven derivatives	T121	C1254351
28408903	949	969	inhibited the growth	T043	C2244509
28408903	973	987	S. epidermidis	T007	C0038174
28408903	992	1013	Staphylococcus aureus	T007	C0038172
28408903	1021	1053	minimal inhibitory concentration	T059	C0427978
28408903	1085	1096	derivatives	T104	C0243072
28408903	1123	1135	viable cells	T025	C1441322
28408903	1146	1154	biofilms	T007	C0081786
28408903	1175	1178	low	T080	C0205251
28408903	1179	1191	cytotoxicity	T049	C0596402
28408903	1195	1210	mammalian cells	T025	C1512977
28408903	1224	1233	hemolytic	T034	C2945560
28408903	1237	1242	human	T016	C0086418
28408903	1243	1255	erythrocytes	T025	C0014792
28408903	1261	1268	biofilm	T007	C0081786
28408903	1269	1290	inhibition activities	T052	C3463820
28408903	1299	1310	derivatives	T104	C0243072
28408903	1312	1317	H5-32	T121	C1254351
28408903	1319	1324	H5-33	T121	C1254351
28408903	1326	1331	H5-34	T121	C1254351
28408903	1337	1342	H5-35	T121	C1254351
28408903	1376	1391	shearing forces	T070	C4061033
28408903	1438	1445	biofilm	T007	C0081786
28408903	1459	1473	S. epidermidis	T007	C0038174
28408903	1514	1545	seven derivatives of compound 5	T121	C1254351
28408903	1597	1608	eradicating	T061	C2728502
28408903	1609	1616	biofilm	T007	C0081786
28408903	1629	1639	infections	T046	C3714514

28399722|t|Safety and function of a prototype microprocessor -controlled knee prosthesis for low active transfemoral amputees switching from a mechanic knee prosthesis: a pilot study
28399722|a|Aim of this pilot study was to assess safety and functioning of a microprocessor -controlled knee prosthesis (MPK) after a short familiarization time and no structured physical therapy. Five elderly, low-active transfemoral amputees who were fitted with a standard non-microprocessor controlled knee prosthesis (NMPK) performed a baseline measurement consisting of a 3 D gait analysis, functional tests and questionnaires. The first follow-up consisted of the same test procedure and was performed with the MPK after 4 to 6 weeks of familiarization. After being refitted to their standard NMPK again, the subjects undertook the second follow-up which consisted of solely questionnaires 4 weeks later. Questionnaires and functional tests showed an increase in the perception of safety. Moreover, gait analysis revealed more physiologic knee and hip extension/flexion patterns when using the MPK. Our results showed that although the Genium with Cenior-Leg ruleset-MPK (GCL-MPK) might help to improve several safety -related outcomes as well as gait biomechanics the functional potential of the GCL-MPK may have been limited without specific training and a sufficient acclimation period. Implications for Rehabilitation Elderly transfemoral amputees are often limited in their activity by safety issues as well as insufficient functioning regarding the non microprocessor -controlled knee prostheses (NMPK), thing that could be eliminated with the use of suitable microprocessor -controlled prostheses (MPK). The safety and functioning of a prototype MPK (GCL-MPK) specifically designed for the needs of older and low-active transfemoral amputees was assessed in this pilot study. The GCL-MPK showed indicators of increased safety and more natural walking patterns in older and low-active transfemoral amputees in comparison to the standard NMPK already after a short acclimatisation time and no structured physical therapy. Regarding functional performance it seems as if providing older and low-active transfemoral amputees with the GCL-MPK alone without prescribing structured prosthesis training might be insufficient to achieve improvements over the standard NMPKs.
28399722	0	6	Safety	T068	C0036043
28399722	11	19	function	T169	C0542341
28399722	25	34	prototype	T080	C0332307
28399722	35	49	microprocessor	T073	C0026012
28399722	62	77	knee prosthesis	T061	C0086511
28399722	82	92	low active	T033	C0243095
28399722	93	114	transfemoral amputees	T061	C0002691
28399722	132	140	mechanic	T070	C0376706
28399722	141	156	knee prosthesis	T061	C0086511
28399722	160	171	pilot study	T062	C0031928
28399722	184	195	pilot study	T062	C0031928
28399722	210	216	safety	T068	C0036043
28399722	221	232	functioning	T169	C0205245
28399722	238	252	microprocessor	T073	C0026012
28399722	265	280	knee prosthesis	T061	C0086511
28399722	282	285	MPK	T061	C0086511
28399722	301	316	familiarization	T169	C0241888
28399722	317	321	time	T079	C0040223
28399722	326	328	no	T033	C1513916
28399722	329	339	structured	T082	C0678594
28399722	340	356	physical therapy	T061	C0949766
28399722	363	370	elderly	T098	C0001792
28399722	372	382	low-active	T033	C0243095
28399722	383	404	transfemoral amputees	T061	C0002691
28399722	428	436	standard	T080	C1442989
28399722	437	455	non-microprocessor	T073	C0026012
28399722	467	482	knee prosthesis	T061	C0086511
28399722	484	488	NMPK	T061	C0086511
28399722	502	510	baseline	T081	C1442488
28399722	511	522	measurement	T169	C0242485
28399722	539	556	3 D gait analysis	T060	C0558820
28399722	558	574	functional tests	T170	C3890579
28399722	579	593	questionnaires	T170	C0034394
28399722	605	614	follow-up	T058	C1522577
28399722	637	651	test procedure	T060	C0430022
28399722	679	682	MPK	T061	C0086511
28399722	705	720	familiarization	T169	C0241888
28399722	752	760	standard	T080	C1442989
28399722	761	765	NMPK	T061	C0086511
28399722	807	816	follow-up	T058	C1522577
28399722	843	857	questionnaires	T170	C0034394
28399722	873	887	Questionnaires	T170	C0034394
28399722	892	908	functional tests	T170	C3890579
28399722	949	955	safety	T068	C0036043
28399722	967	980	gait analysis	T060	C0558820
28399722	995	1006	physiologic	T169	C0205463
28399722	1007	1011	knee	T023	C0022742
28399722	1016	1019	hip	T023	C0019552
28399722	1020	1037	extension/flexion	T082	C0444509
28399722	1062	1065	MPK	T061	C0086511
28399722	1104	1138	Genium with Cenior-Leg ruleset-MPK	T061	C0086511
28399722	1140	1147	GCL-MPK	T061	C0086511
28399722	1179	1185	safety	T068	C0036043
28399722	1220	1232	biomechanics	T091	C0005537
28399722	1237	1247	functional	T169	C0205245
28399722	1265	1272	GCL-MPK	T061	C0086511
28399722	1338	1349	acclimation	T040	C0000934
28399722	1350	1356	period	T079	C0439531
28399722	1375	1389	Rehabilitation	T169	C0034992
28399722	1390	1397	Elderly	T098	C0001792
28399722	1398	1419	transfemoral amputees	T061	C0002691
28399722	1459	1465	safety	T068	C0036043
28399722	1497	1508	functioning	T169	C0205245
28399722	1523	1541	non microprocessor	T073	C0026012
28399722	1554	1569	knee prostheses	T061	C0086511
28399722	1571	1575	NMPK	T061	C0086511
28399722	1634	1648	microprocessor	T073	C0026012
28399722	1661	1671	prostheses	T061	C0086511
28399722	1673	1676	MPK	T061	C0086511
28399722	1683	1689	safety	T068	C0036043
28399722	1694	1705	functioning	T169	C0205245
28399722	1711	1720	prototype	T080	C0332307
28399722	1721	1724	MPK	T061	C0086511
28399722	1726	1733	GCL-MPK	T061	C0086511
28399722	1784	1794	low-active	T033	C0243095
28399722	1795	1816	transfemoral amputees	T061	C0002691
28399722	1838	1849	pilot study	T062	C0031928
28399722	1855	1862	GCL-MPK	T061	C0086511
28399722	1894	1900	safety	T068	C0036043
28399722	1910	1934	natural walking patterns	T056	C0080331
28399722	1948	1958	low-active	T033	C0243095
28399722	1959	1980	transfemoral amputees	T061	C0002691
28399722	2002	2010	standard	T080	C1442989
28399722	2011	2015	NMPK	T061	C0086511
28399722	2038	2053	acclimatisation	T040	C0000934
28399722	2054	2058	time	T079	C0040223
28399722	2063	2065	no	T033	C1513916
28399722	2066	2076	structured	T082	C0678594
28399722	2077	2093	physical therapy	T061	C0949766
28399722	2105	2115	functional	T169	C0205245
28399722	2163	2173	low-active	T033	C0243095
28399722	2174	2195	transfemoral amputees	T061	C0002691
28399722	2205	2212	GCL-MPK	T061	C0086511
28399722	2250	2269	prosthesis training	T061	C0150317
28399722	2325	2333	standard	T080	C1442989
28399722	2334	2339	NMPKs	T061	C0086511

27858508|t|Activation of transcription enforces the formation of distinct nuclear bodies in zebrafish embryos
27858508|a|Nuclear bodies are cellular compartments that lack lipid bilayers and harbor specific RNAs and proteins. Recent proposals that nuclear bodies form through liquid-liquid phase separation leave the question of how different nuclear bodies maintain their distinct identities unanswered. Here we investigate Cajal bodies (CBs), histone locus bodies (HLBs) and nucleoli - involved in assembly of the splicing machinery, histone mRNA 3' end processing, and rRNA processing, respectively - in the embryos of the zebrafish, Danio rerio. We take advantage of the transcriptional silence of the 1-cell embryo and follow nuclear body appearance as zygotic transcription becomes activated. CBs are present from fertilization onwards, while HLB and nucleolar components formed foci several hours later when histone genes and rDNA became active. HLB formation was blocked by transcription inhibition, suggesting nascent histone transcripts recruit HLB components like U7 snRNP. Surprisingly, we found that U7 base-pairing with nascent histone transcripts was not required for localization to HLBs. Rather, the type of Sm ring assembled on U7 determined its targeting to HLBs or CBs; the spliceosomal Sm ring targeted snRNAs to CBs while the specialized U7 Sm-ring localized to HLBs, demonstrating the contribution of protein constituents to the distinction among nuclear bodies. Thus, nucleolar, HLB, and CB components can mix in early embryogenesis when transcription is naturally or artificially silenced. These data support a model in which transcription of specific gene loci nucleates nuclear body components with high specificity and fidelity to perform distinct regulatory functions.
27858508	0	27	Activation of transcription	T045	C0162493
27858508	63	77	nuclear bodies	T026	C0230595
27858508	81	90	zebrafish	T013	C0043457
27858508	91	98	embryos	T018	C0013935
27858508	99	113	Nuclear bodies	T026	C0230595
27858508	118	139	cellular compartments	T030	C2335889
27858508	145	149	lack	T080	C0332268
27858508	150	164	lipid bilayers	T026	C0023768
27858508	176	184	specific	T080	C0205369
27858508	185	189	RNAs	T114	C0035668
27858508	194	202	proteins	T116,T123	C0033684
27858508	226	240	nuclear bodies	T026	C0230595
27858508	321	335	nuclear bodies	T026	C0230595
27858508	391	402	investigate	T169	C1292732
27858508	403	415	Cajal bodies	T026	C0751972
27858508	417	420	CBs	T026	C0751972
27858508	423	443	histone locus bodies	T026	C2752281
27858508	445	449	HLBs	T026	C2752281
27858508	455	463	nucleoli	T026	C0007609
27858508	494	512	splicing machinery	T045	C0314666
27858508	514	544	histone mRNA 3' end processing	T045	C1158725
27858508	550	565	rRNA processing	T045	C1156152
27858508	589	596	embryos	T018	C0013935
27858508	604	613	zebrafish	T013	C0043457
27858508	615	626	Danio rerio	T013	C0043457
27858508	691	697	embryo	T018	C0013935
27858508	709	721	nuclear body	T026	C0230595
27858508	736	743	zygotic	T018	C0043544
27858508	744	757	transcription	T045	C0040649
27858508	766	775	activated	T052	C1879547
27858508	777	780	CBs	T026	C0751972
27858508	798	811	fertilization	T040	C0015914
27858508	827	830	HLB	T026	C2752281
27858508	835	844	nucleolar	T026	C0007609
27858508	845	855	components	T026	C0243092
27858508	863	867	foci	T082	C0205234
27858508	893	900	histone	T116,T123	C0019652
27858508	901	906	genes	T028	C0017337
27858508	911	915	rDNA	T114,T123	C0012933
27858508	923	929	active	T169	C0205177
27858508	931	934	HLB	T026	C2752281
27858508	949	956	blocked	T169	C0332206
27858508	960	984	transcription inhibition	T045	C1514673
27858508	997	1024	nascent histone transcripts	T114	C1519595
27858508	1033	1036	HLB	T026	C2752281
27858508	1037	1047	components	T026	C0243092
27858508	1053	1061	U7 snRNP	T114,T123	C0162464
27858508	1094	1106	base-pairing	T044	C0600436
27858508	1112	1139	nascent histone transcripts	T114	C1519595
27858508	1161	1173	localization	T043	C1158693
27858508	1177	1181	HLBs	T026	C2752281
27858508	1255	1259	HLBs	T026	C2752281
27858508	1263	1266	CBs	T026	C0751972
27858508	1302	1308	snRNAs	T114,T123	C0035709
27858508	1312	1315	CBs	T026	C0751972
27858508	1362	1366	HLBs	T026	C2752281
27858508	1386	1398	contribution	T052	C1880177
27858508	1402	1409	protein	T116,T123	C0033684
27858508	1410	1422	constituents	T167	C0729650
27858508	1448	1462	nuclear bodies	T026	C0230595
27858508	1470	1479	nucleolar	T026	C0007609
27858508	1481	1484	HLB	T026	C2752281
27858508	1490	1492	CB	T026	C0751972
27858508	1493	1503	components	T026	C0243092
27858508	1515	1520	early	T079	C1279919
27858508	1521	1534	embryogenesis	T042	C0013936
27858508	1540	1553	transcription	T045	C0040649
27858508	1629	1642	transcription	T045	C0040649
27858508	1646	1654	specific	T080	C0205369
27858508	1655	1664	gene loci	T082	C1708726
27858508	1675	1687	nuclear body	T026	C0230595
27858508	1688	1698	components	T026	C0243092
27858508	1709	1720	specificity	T081	C0037791
27858508	1754	1764	regulatory	T077	C1704735
27858508	1765	1774	functions	T039	C0031843

27639988|t|Pharmacogenetic reactivation of the original engram evokes an extinguished fear memory
27639988|a|Fear memory extinction has several characteristic behavioral features, such as spontaneous recovery, renewal, and reinstatement, suggesting that extinction training does not erase the original association between the conditioned stimulus (CS) and the unconditioned stimulus (US). However, it is unclear whether reactivation of the original physical record of memory (i.e., memory trace) is sufficient to produce conditioned fear response after extinction. Here, we performed pharmacogenetic neuronal activation using transgenic mice expressing hM3Dq DREADD (designer receptor exclusively activated by designer drug) under the control of the activity - dependent c-fos gene promoter. Neuronal ensembles activated during fear - conditioned learning were tagged with hM3Dq and subsequently reactivated after extinction training. The mice exhibited significant freezing, even when the fear memory was no longer triggered by external CS, indicating that the artificial reactivation of a specific neuronal ensemble was sufficient to evoke the extinguished fear response. This freezing was not observed in non-fear-conditioned mice expressing hM3dq in the same brain areas. These results directly demonstrated that at least part of the original fear memory trace remains after extinction, and such residual plasticity might reflect the persistent memory.
27639988	0	28	Pharmacogenetic reactivation	T052	C4086768
27639988	36	44	original	T078	C0205313
27639988	45	51	engram	T041	C0679061
27639988	75	79	fear	T041	C0015726
27639988	80	86	memory	T041	C0025260
27639988	87	91	Fear	T041	C0015726
27639988	92	98	memory	T041	C0025260
27639988	99	109	extinction	T041	C0015347
27639988	122	136	characteristic	T080	C1521970
27639988	137	147	behavioral	T053	C0004927
27639988	148	156	features	T080	C2348519
27639988	166	177	spontaneous	T169	C0205359
27639988	178	186	recovery	T052	C0237820
27639988	188	195	renewal	T169	C0205245
27639988	201	214	reinstatement	T079	C0678335
27639988	232	242	extinction	T041	C0015347
27639988	243	251	training	T065	C0220931
27639988	271	279	original	T078	C0205313
27639988	280	291	association	T080	C0439849
27639988	304	365	conditioned stimulus (CS) and the unconditioned stimulus (US)	UnknownType	C0679068
27639988	398	410	reactivation	T052	C4086768
27639988	418	426	original	T078	C0205313
27639988	427	452	physical record of memory	T041	C0870873
27639988	460	472	memory trace	T041	C0870873
27639988	499	510	conditioned	T041	C0009647
27639988	511	515	fear	T041	C0015726
27639988	516	524	response	T032	C0871261
27639988	531	541	extinction	T041	C0015347
27639988	562	597	pharmacogenetic neuronal activation	T043	C0007613
27639988	604	619	transgenic mice	T015	C0025936
27639988	620	630	expressing	T045	C1171362
27639988	631	643	hM3Dq DREADD	T116,T192	C0682972
27639988	645	701	designer receptor exclusively activated by designer drug	T116,T192	C0682972
27639988	713	720	control	T080	C0243148
27639988	728	736	activity	T052	C0441655
27639988	739	748	dependent	T169	C3244310
27639988	749	759	c-fos gene	T028	C0085940
27639988	760	768	promoter	T028	C0314621
27639988	770	788	Neuronal ensembles	T025	C0027882
27639988	789	798	activated	T043	C1326120
27639988	806	810	fear	T041	C0015726
27639988	813	833	conditioned learning	T041	C0023185
27639988	851	856	hM3Dq	T116,T192	C0682972
27639988	874	885	reactivated	T052	C4086768
27639988	892	902	extinction	T041	C0015347
27639988	903	911	training	T065	C0220931
27639988	917	921	mice	T015	C0025936
27639988	944	952	freezing	T070	C0016701
27639988	968	972	fear	T041	C0015726
27639988	973	979	memory	T041	C0025260
27639988	994	1006	triggered by	T080	C1444748
27639988	1007	1015	external	T169	C0521134
27639988	1016	1018	CS	T041	C0234404
27639988	1040	1050	artificial	T080	C2004457
27639988	1051	1063	reactivation	T052	C4086768
27639988	1078	1095	neuronal ensemble	T025	C0027882
27639988	1137	1141	fear	T041	C0015726
27639988	1142	1150	response	T032	C0871261
27639988	1157	1165	freezing	T070	C0016701
27639988	1186	1211	non-fear-conditioned mice	T015	C0025936
27639988	1212	1222	expressing	T045	C1171362
27639988	1223	1228	hM3dq	T116,T192	C0682972
27639988	1241	1252	brain areas	T029	C1273723
27639988	1316	1324	original	T078	C0205313
27639988	1325	1329	fear	T041	C0015726
27639988	1330	1342	memory trace	T041	C0870873
27639988	1357	1367	extinction	T041	C0015347
27639988	1378	1386	residual	T080	C1609982
27639988	1387	1397	plasticity	T042	C0027880
27639988	1416	1426	persistent	T079	C0205322
27639988	1427	1433	memory	T041	C0025260

27397797|t|A parametric ribcage geometry model accounting for variations among the adult population
27397797|a|The objective of this study is to develop a parametric ribcage model that can account for morphological variations among the adult population. Ribcage geometries, including 12 pair of ribs, sternum, and thoracic spine, were collected from CT scans of 101 adult subjects through image segmentation, landmark identification (1016 for each subject), symmetry adjustment, and template mesh mapping (26,180 elements for each subject). Generalized procrustes analysis (GPA), principal component analysis (PCA), and regression analysis were used to develop a parametric ribcage model, which can predict nodal locations of the template mesh according to age, sex, height, and body mass index (BMI). Two regression models, a quadratic model for estimating the ribcage size and a linear model for estimating the ribcage shape, were developed. The results showed that the ribcage size was dominated by the height (p=0.000) and age - sex - interaction (p=0.007) and the ribcage shape was significantly affected by the age (p=0.0005), sex (p=0.0002), height (p=0.0064) and BMI (p=0.0000). Along with proper assignment of cortical bone thickness, material properties and failure properties, this parametric ribcage model can directly serve as the mesh of finite element ribcage models for quantifying effects of human characteristics on thoracic injury risks.
27397797	13	20	ribcage	T023	C0222762
27397797	30	35	model	T170	C3161035
27397797	36	46	accounting	T057	C0000938
27397797	51	61	variations	T080	C0205419
27397797	72	77	adult	T100	C0001675
27397797	78	88	population	T098	C1257890
27397797	93	102	objective	T170	C0018017
27397797	111	116	study	T062	C2603343
27397797	144	151	ribcage	T023	C0222762
27397797	152	157	model	T170	C3161035
27397797	179	192	morphological	T080	C0332437
27397797	193	203	variations	T080	C0205419
27397797	214	219	adult	T100	C0001675
27397797	220	230	population	T098	C1257890
27397797	232	239	Ribcage	T023	C0222762
27397797	240	250	geometries	T090	C0449829
27397797	265	277	pair of ribs	T023	C0035561
27397797	279	286	sternum	T023	C0038293
27397797	292	306	thoracic spine	T023	C0581269
27397797	328	336	CT scans	T060	C0040405
27397797	344	349	adult	T100	C0001675
27397797	350	358	subjects	T098	C0080105
27397797	367	385	image segmentation	T066	C2697664
27397797	387	395	landmark	T029	C0504075
27397797	396	410	identification	T080	C0205396
27397797	426	433	subject	T098	C0080105
27397797	436	444	symmetry	T033	C0332516
27397797	445	455	adjustment	T169	C0456081
27397797	461	469	template	T078	C1705542
27397797	470	474	mesh	T081	C1552983
27397797	475	482	mapping	T052	C1283195
27397797	491	499	elements	T077	C3812827
27397797	509	516	subject	T098	C0080105
27397797	519	550	Generalized procrustes analysis	T081	C0392762
27397797	552	555	GPA	T081	C0392762
27397797	558	586	principal component analysis	T081	C0429865
27397797	588	591	PCA	T081	C0429865
27397797	598	617	regression analysis	T170	C0034980
27397797	652	659	ribcage	T023	C0222762
27397797	660	665	model	T170	C3161035
27397797	685	690	nodal	T082	C0443268
27397797	691	700	locations	T082	C0450429
27397797	708	716	template	T078	C1705542
27397797	717	721	mesh	T081	C1552983
27397797	735	738	age	T032	C0001779
27397797	740	743	sex	T032	C1522384
27397797	745	751	height	T032	C0489786
27397797	757	772	body mass index	T201	C1305855
27397797	774	777	BMI	T201	C1305855
27397797	784	801	regression models	T170	C0034980
27397797	805	814	quadratic	T081	C2347976
27397797	815	820	model	T170	C3161035
27397797	825	835	estimating	T081	C0750572
27397797	840	847	ribcage	T023	C0222762
27397797	848	852	size	T082	C0456389
27397797	859	871	linear model	T081	C0023732
27397797	891	898	ribcage	T023	C0222762
27397797	899	904	shape	T082	C0332479
27397797	926	933	results	T169	C1274040
27397797	950	957	ribcage	T023	C0222762
27397797	958	962	size	T082	C0456389
27397797	984	990	height	T032	C0489786
27397797	1005	1008	age	T032	C0001779
27397797	1011	1014	sex	T032	C1522384
27397797	1017	1028	interaction	T169	C1704675
27397797	1047	1054	ribcage	T023	C0222762
27397797	1055	1060	shape	T082	C0332479
27397797	1095	1098	age	T032	C0001779
27397797	1111	1114	sex	T032	C1522384
27397797	1127	1133	height	T032	C0489786
27397797	1149	1152	BMI	T201	C1305855
27397797	1183	1193	assignment	T169	C1516050
27397797	1197	1210	cortical bone	T023	C0222652
27397797	1211	1220	thickness	T080	C1280412
27397797	1222	1230	material	T167	C0520510
27397797	1231	1241	properties	T080	C0871161
27397797	1246	1253	failure	T169	C0231174
27397797	1254	1264	properties	T080	C0871161
27397797	1282	1289	ribcage	T023	C0222762
27397797	1290	1295	model	T170	C3161035
27397797	1322	1326	mesh	T081	C1552983
27397797	1330	1344	finite element	T170	C0600552
27397797	1345	1352	ribcage	T023	C0222762
27397797	1353	1359	models	T170	C3161035
27397797	1364	1375	quantifying	T081	C1709793
27397797	1376	1383	effects	T080	C1280500
27397797	1387	1392	human	T016	C0086418
27397797	1393	1408	characteristics	T080	C1521970
27397797	1412	1427	thoracic injury	T037	C0039980

27522061|t|Development and Validation of a 10-Year Mortality Prediction Model: Meta-Analysis of Individual Participant Data From Five Cohorts of Older Adults in Developed and Developing Countries
27522061|a|Existing mortality prediction models for older adults have been each developed using a single study from the United States or Western Europe. We aimed to develop and validate a 10-year mortality prediction model for older adults using data from developed and developing countries. We used data from five cohorts, including data from 16 developed and developing countries: ELSA (English Longitudinal Study of Aging), HRS (Health and Retirement Study), MHAS (Mexican Health and Aging Study), SABE-Sao Paulo (The Health, Well-being and Aging), and SHARE (Survey on Health, Ageing and Retirement in Europe). 35,367 older adults were split into training (two thirds) and test (one third) data sets. Baseline predictors included age, sex, comorbidities, and functional and cognitive measures. We performed an individual participant data meta-analysis using a sex-stratified Cox proportional hazards model, with time to death as the time scale. We validated the model using Harrell's C statistic (discrimination) and the estimated slope between observed and predicted 10-year mortality risk across deciles of risk (calibration). During a median of 8.6 years, 8,325 participants died. The final model included age, sex, diabetes, heart disease, lung disease, cancer, smoking, alcohol use, body mass index, physical activity, self-reported health, difficulty with bathing, walking several blocks, and reporting date correctly. The model showed good discrimination (Harrell's C = 0.76) and calibration (slope = 1.005). Models for developed versus developing country cohorts performed equally well when applied to data from developing countries. A parsimonious mortality prediction model using data from multiple cohorts in developed and developing countries can be used to predict mortality in older adults in both settings.
27522061	0	11	Development	T169	C1527148
27522061	16	26	Validation	T062	C1519941
27522061	40	66	Mortality Prediction Model	T170	C0451318
27522061	68	81	Meta-Analysis	T062	C0920317
27522061	85	95	Individual	T098	C0237401
27522061	96	107	Participant	T098	C0679646
27522061	108	112	Data	T078	C1511726
27522061	123	130	Cohorts	T098	C0599755
27522061	140	146	Adults	T100	C0001675
27522061	150	159	Developed	T080	C0282613
27522061	164	184	Developing Countries	T080	C0011750
27522061	194	221	mortality prediction models	T170	C0451318
27522061	232	238	adults	T100	C0001675
27522061	254	263	developed	T169	C1527148
27522061	294	307	United States	T083	C0041703
27522061	311	325	Western Europe	T083	C0043129
27522061	339	346	develop	T169	C1527148
27522061	351	359	validate	T062	C1519941
27522061	370	396	mortality prediction model	T170	C0451318
27522061	407	413	adults	T100	C0001675
27522061	420	424	data	T078	C1511726
27522061	430	439	developed	T080	C0282613
27522061	444	464	developing countries	T080	C0011750
27522061	474	478	data	T078	C1511726
27522061	489	496	cohorts	T098	C0599755
27522061	508	512	data	T078	C1511726
27522061	521	530	developed	T080	C0282613
27522061	535	555	developing countries	T080	C0011750
27522061	557	561	ELSA	T062	C0242481
27522061	563	598	English Longitudinal Study of Aging	T062	C0242481
27522061	601	604	HRS	T062	C0242481
27522061	606	633	Health and Retirement Study	T062	C0242481
27522061	636	640	MHAS	T062	C0242481
27522061	642	672	Mexican Health and Aging Study	T062	C0242481
27522061	675	689	SABE-Sao Paulo	T062	C0242481
27522061	691	723	The Health, Well-being and Aging	T062	C0242481
27522061	730	735	SHARE	T062	C0242481
27522061	737	786	Survey on Health, Ageing and Retirement in Europe	T062	C0242481
27522061	802	808	adults	T100	C0001675
27522061	825	833	training	T080	C2673163
27522061	868	872	data	T078	C1511726
27522061	879	887	Baseline	T081	C1442488
27522061	888	898	predictors	T078	C2698872
27522061	908	911	age	T032	C0001779
27522061	913	916	sex	T032	C1522384
27522061	918	931	comorbidities	T078	C0009488
27522061	937	947	functional	T169	C0205245
27522061	952	961	cognitive	T169	C1516691
27522061	962	970	measures	T169	C1879489
27522061	988	998	individual	T098	C0237401
27522061	999	1010	participant	T098	C0679646
27522061	1011	1015	data	T078	C1511726
27522061	1016	1029	meta-analysis	T062	C0920317
27522061	1038	1083	sex-stratified Cox proportional hazards model	T170	C0282574
27522061	1090	1103	time to death	T079	C1301931
27522061	1111	1121	time scale	T079	C1254367
27522061	1126	1135	validated	T062	C1519941
27522061	1152	1173	Harrell's C statistic	T170	C0282574
27522061	1223	1231	observed	T169	C1441672
27522061	1236	1245	predicted	T078	C0681842
27522061	1254	1263	mortality	T081	C0026565
27522061	1264	1268	risk	T078	C0035647
27522061	1287	1291	risk	T078	C0035647
27522061	1293	1304	calibration	T081	C0006751
27522061	1343	1355	participants	T098	C0679646
27522061	1387	1390	age	T032	C0001779
27522061	1392	1395	sex	T032	C1522384
27522061	1397	1405	diabetes	T047	C0011847
27522061	1407	1420	heart disease	T047	C0018799
27522061	1422	1434	lung disease	T047	C0024115
27522061	1436	1442	cancer	T191	C0006826
27522061	1444	1451	smoking	T055	C0037369
27522061	1453	1464	alcohol use	T055	C0001948
27522061	1466	1481	body mass index	T201	C1305855
27522061	1483	1500	physical activity	T056	C0026606
27522061	1502	1522	self-reported health	T201	C4265455
27522061	1540	1547	bathing	T061	C0150141
27522061	1549	1571	walking several blocks	T170	C3827521
27522061	1665	1676	calibration	T081	C0006751
27522061	1705	1714	developed	T080	C0282613
27522061	1722	1740	developing country	T080	C0011750
27522061	1741	1748	cohorts	T098	C0599755
27522061	1788	1792	data	T078	C1511726
27522061	1798	1818	developing countries	T080	C0011750
27522061	1835	1861	mortality prediction model	T170	C0451318
27522061	1868	1872	data	T078	C1511726
27522061	1887	1894	cohorts	T098	C0599755
27522061	1898	1907	developed	T080	C0282613
27522061	1912	1932	developing countries	T080	C0011750
27522061	1956	1965	mortality	T081	C0026565
27522061	1975	1981	adults	T100	C0001675

27733749|t|Food security and the nutritional status of children in foster care: new horizons in the protection of a fragile population
27733749|a|The nutritional status of foster children, the quality of daily menus in group homes and the Food Security inside these organizations have been poorly studied and this study means to investigate them. A sample of 125 children, ranging in age from 0-17 years, among seven group homes (group A) was compared with 121 children of the general population we (group B). To evaluate nutritional status, BMI percentiles were used. Mean percentiles of both groups were compared through statistical analysis. Both nutritional and caloric daily distributions in each organization were obtained using the 24-hour recall method. A specific questionnaire was administered to evaluate Food Security. From the analysis of mean BMI -for- age (or height-for-length) percentiles, did not observe statistically significant differences between group A and group B. The average daily nutrient and calorie distribution in group homes proves to be nearly optimal with the exception of a slight excess in proteins and a slight deficiency in PUFAs. Moreover, a low intake of iron and calcium was revealed. All organizations obtained a " High Food Security " profile. Nutritional conditions of foster children are no worse than that of children of the general population. Foster care provides the necessary conditions to support their growth.
27733749	0	13	Food security	T080	C3178753
27733749	22	40	nutritional status	T033	C0392209
27733749	44	52	children	T100	C0008059
27733749	56	67	foster care	T073	C0599759
27733749	128	146	nutritional status	T033	C0392209
27733749	150	165	foster children	T099	C0337544
27733749	171	178	quality	T080	C0332306
27733749	182	193	daily menus	T168	C0016452
27733749	197	208	group homes	T073,T093	C0018257
27733749	217	230	Food Security	T080	C3178753
27733749	244	257	organizations	T092	C1561598
27733749	292	297	study	T062	C2603343
27733749	341	349	children	T100	C0008059
27733749	395	406	group homes	T073,T093	C0018257
27733749	408	415	group A	UnknownType	C0681860
27733749	439	447	children	T100	C0008059
27733749	455	473	general population	T098	C0683971
27733749	478	485	group B	UnknownType	C0681860
27733749	500	518	nutritional status	T033	C0392209
27733749	520	535	BMI percentiles	T033	C2227318
27733749	547	551	Mean	T081	C0444504
27733749	552	563	percentiles	T081	C1264641
27733749	572	578	groups	UnknownType	C0681860
27733749	601	621	statistical analysis	T062	C0871424
27733749	628	639	nutritional	T033	C0392209
27733749	644	671	caloric daily distributions	T033	C2164132
27733749	680	692	organization	T092	C1561598
27733749	725	738	recall method	T170	C0025663
27733749	751	764	questionnaire	T170	C0034394
27733749	794	807	Food Security	T080	C3178753
27733749	818	826	analysis	T062	C0936012
27733749	830	834	mean	T081	C0444504
27733749	835	838	BMI	T201	C1305855
27733749	845	848	age	T032	C0001779
27733749	872	883	percentiles	T081	C1264641
27733749	927	938	differences	T033	C3842396
27733749	947	954	group A	UnknownType	C0681860
27733749	959	966	group B	UnknownType	C0681860
27733749	972	979	average	T081	C1510992
27733749	980	985	daily	T079	C0332173
27733749	986	994	nutrient	T033	C0392209
27733749	999	1019	calorie distribution	T033	C0392209
27733749	1023	1034	group homes	T073,T093	C0018257
27733749	1048	1062	nearly optimal	T033	C0243095
27733749	1094	1100	excess	T080	C1979886
27733749	1104	1112	proteins	T168	C0453858
27733749	1126	1136	deficiency	T169	C0011155
27733749	1140	1145	PUFAs	T109,T123	C0032615
27733749	1159	1169	low intake	T033	C0231353
27733749	1173	1177	iron	T033	C0518043
27733749	1182	1189	calcium	T201	C0489458
27733749	1208	1221	organizations	T092	C1561598
27733749	1235	1253	High Food Security	T080	C3178753
27733749	1265	1287	Nutritional conditions	T033	C0392209
27733749	1291	1306	foster children	T099	C0337544
27733749	1333	1341	children	T100	C0008059
27733749	1349	1367	general population	T098	C0683971
27733749	1369	1380	Foster care	T073	C0599759
27733749	1394	1414	necessary conditions	T080	C0337645
27733749	1432	1438	growth	T040	C0018270

27321568|t|Efficacy of Intravenous Chlorothiazide for Refractory Acute Decompensated Heart Failure Unresponsive to Adjunct Metolazone
27321568|a|To assess the efficacy of intravenous chlorothiazide in patients with acute decompensated heart failure (ADHF) who were determined to be loop diuretic resistant and refractory to metolazone. Retrospective cohort study with patients serving as their own controls. Large, academic, tertiary care hospital. Forty-five patients with ADHF who had an inadequate response to high-dose loop diuretics and then received at least one dose of oral metolazone 5 mg or greater (metolazone index dose) followed by at least one dose of intravenous chlorothiazide 500 mg (chlorothiazide index dose) if the response to metolazone was considered inadequate, according to the institutional protocol, between February 4, 2013, and February 28, 2015, were included. If multiple doses of metolazone were administered, the last dose given before the chlorothiazide index dose was considered the index dose; the metolazone index dose had to have been administered more than 2 hours before the chlorothiazide index dose. Data for a total of 90 diuretic doses (45 metolazone, 45 chlorothiazide) were included in the analysis. The median dose of loop diuretic in intravenous furosemide equivalents given over the 24- hour period before the metolazone index dose was 400 mg. The average length of stay was 34.7 days, and in-hospital mortality was 35.6% (16/45 patients). The primary end point of a net-negative urine output of 500 ml or greater during the 12 hours after the index dose occurred in 42.2% (19/45 patients) and 35.5% (16/45 patients) for the chlorothiazide and metolazone doses, respectively (p=0.581). The median 12- hour urine output following administration of metolazone was 810 ml (interquartile range [IQR] 866 ml) versus 1075 ml (IQR 940 ml) following administration of chlorothiazide (p=0.363). Compared with metolazone, the chlorothiazide doses did not result in an increase in urine output of at least 500 ml during the 12 hours following the dose relative to the 12 hours before the dose (31.1% vs 22.2%, p=0.754). No significant difference in achievement of net-negative urine output of 500 ml or greater during the 12 hours following the chlorothiazide or metolazone dose was noted (42.2% for chlorothiazide vs 35.5% for metolazone, p=0.581). The addition of intravenous chlorothiazide did not result in improved diuresis in patients with ADHF determined to be refractory to loop diuretic s and adjunctive oral metolazone.
27321568	0	8	Efficacy	T080	C1280519
27321568	12	23	Intravenous	T082	C0348016
27321568	24	38	Chlorothiazide	T109,T121	C0008273
27321568	43	53	Refractory	T169	C0205269
27321568	54	87	Acute Decompensated Heart Failure	T047	C1609524
27321568	88	100	Unresponsive	T169	C0205269
27321568	104	111	Adjunct	T169	C1719882
27321568	112	122	Metolazone	T109,T121	C0025854
27321568	137	145	efficacy	T080	C1280519
27321568	149	160	intravenous	T082	C0348016
27321568	161	175	chlorothiazide	T109,T121	C0008273
27321568	179	187	patients	T101	C0030705
27321568	193	226	acute decompensated heart failure	T047	C1609524
27321568	228	232	ADHF	T047	C1609524
27321568	260	273	loop diuretic	T121	C0354100
27321568	274	283	resistant	T169	C0332325
27321568	288	298	refractory	T169	C0205269
27321568	302	312	metolazone	T109,T121	C0025854
27321568	314	340	Retrospective cohort study	T062	C2985505
27321568	346	354	patients	T101	C0030705
27321568	376	384	controls	T096	C0009932
27321568	386	391	Large	T081	C0549177
27321568	393	401	academic	T092	C1510747
27321568	403	425	tertiary care hospital	T073,T093	C0337954
27321568	438	446	patients	T101	C0030705
27321568	452	456	ADHF	T047	C1609524
27321568	468	478	inadequate	T080	C0205412
27321568	479	487	response	T032	C0871261
27321568	491	500	high-dose	T081	C0444956
27321568	501	515	loop diuretics	T121	C0354100
27321568	547	551	dose	T081	C0178602
27321568	555	559	oral	T082	C0442027
27321568	560	570	metolazone	T109,T121	C0025854
27321568	579	586	greater	T081	C1704243
27321568	588	598	metolazone	T109,T121	C0025854
27321568	599	609	index dose	T081	C0178602
27321568	636	640	dose	T081	C0178602
27321568	644	655	intravenous	T082	C0348016
27321568	656	670	chlorothiazide	T109,T121	C0008273
27321568	679	693	chlorothiazide	T109,T121	C0008273
27321568	694	704	index dose	T081	C0178602
27321568	725	735	metolazone	T109,T121	C0025854
27321568	751	761	inadequate	T080	C0205412
27321568	780	802	institutional protocol	T170	C0442711
27321568	880	885	doses	T081	C0178602
27321568	889	899	metolazone	T109,T121	C0025854
27321568	905	917	administered	T058	C0806914
27321568	928	932	dose	T081	C0178602
27321568	950	964	chlorothiazide	T109,T121	C0008273
27321568	965	975	index dose	T081	C0178602
27321568	995	1005	index dose	T081	C0178602
27321568	1011	1021	metolazone	T109,T121	C0025854
27321568	1022	1032	index dose	T081	C0178602
27321568	1050	1062	administered	T058	C0806914
27321568	1075	1080	hours	T079	C0439227
27321568	1092	1106	chlorothiazide	T109,T121	C0008273
27321568	1107	1117	index dose	T081	C0178602
27321568	1119	1123	Data	T078	C1511726
27321568	1142	1150	diuretic	T121	C0354100
27321568	1151	1156	doses	T081	C0178602
27321568	1161	1171	metolazone	T109,T121	C0025854
27321568	1176	1190	chlorothiazide	T109,T121	C0008273
27321568	1213	1221	analysis	T062	C0936012
27321568	1234	1238	dose	T081	C0178602
27321568	1242	1255	loop diuretic	T121	C0354100
27321568	1259	1270	intravenous	T082	C0348016
27321568	1271	1281	furosemide	T109,T121	C0016860
27321568	1313	1317	hour	T079	C0439227
27321568	1318	1324	period	T079	C1948053
27321568	1336	1346	metolazone	T109,T121	C0025854
27321568	1347	1357	index dose	T081	C0178602
27321568	1392	1396	stay	T079	C3489408
27321568	1406	1410	days	T079	C0439228
27321568	1416	1437	in-hospital mortality	T080	C0085556
27321568	1455	1463	patients	T101	C0030705
27321568	1478	1487	end point	T080	C2349179
27321568	1493	1505	net-negative	T033	C0205160
27321568	1506	1518	urine output	T201	C0232856
27321568	1554	1559	hours	T079	C0439227
27321568	1570	1580	index dose	T081	C0178602
27321568	1606	1614	patients	T101	C0030705
27321568	1633	1641	patients	T101	C0030705
27321568	1651	1665	chlorothiazide	T109,T121	C0008273
27321568	1670	1680	metolazone	T109,T121	C0025854
27321568	1681	1686	doses	T081	C0178602
27321568	1727	1731	hour	T079	C0439227
27321568	1732	1744	urine output	T201	C0232856
27321568	1755	1769	administration	T081	C0001555
27321568	1773	1783	metolazone	T109,T121	C0025854
27321568	1796	1815	interquartile range	T081	C1711350
27321568	1817	1820	IQR	T081	C1711350
27321568	1846	1849	IQR	T081	C1711350
27321568	1868	1882	administration	T081	C0001555
27321568	1886	1900	chlorothiazide	T109,T121	C0008273
27321568	1912	1920	Compared	T052	C1707455
27321568	1926	1936	metolazone	T109,T121	C0025854
27321568	1942	1956	chlorothiazide	T109,T121	C0008273
27321568	1957	1962	doses	T081	C0178602
27321568	1984	1992	increase	T169	C0442805
27321568	1996	2008	urine output	T201	C0232856
27321568	2042	2047	hours	T079	C0439227
27321568	2062	2066	dose	T081	C0178602
27321568	2086	2091	hours	T079	C0439227
27321568	2103	2107	dose	T081	C0178602
27321568	2179	2191	net-negative	T033	C0205160
27321568	2192	2204	urine output	T201	C0232856
27321568	2240	2245	hours	T079	C0439227
27321568	2260	2274	chlorothiazide	T109,T121	C0008273
27321568	2278	2288	metolazone	T109,T121	C0025854
27321568	2289	2293	dose	T081	C0178602
27321568	2315	2329	chlorothiazide	T109,T121	C0008273
27321568	2343	2353	metolazone	T109,T121	C0025854
27321568	2381	2392	intravenous	T082	C0348016
27321568	2393	2407	chlorothiazide	T109,T121	C0008273
27321568	2426	2434	improved	T033	C0184511
27321568	2435	2443	diuresis	T042	C0012797
27321568	2447	2455	patients	T101	C0030705
27321568	2461	2465	ADHF	T047	C1609524
27321568	2483	2493	refractory	T169	C0205269
27321568	2497	2510	loop diuretic	T121	C0354100
27321568	2517	2527	adjunctive	T169	C1719882
27321568	2528	2532	oral	T082	C0442027
27321568	2533	2543	metolazone	T109,T121	C0025854

27838489|t|Hypoxia / reoxygenation -induced HMGB1 translocation and release promotes islet proinflammatory cytokine production and early islet graft failure through TLRs signaling
27838489|a|High-mobility group box 1 (HMGB1) translocation and release, which is involved in several tissue types of ischemia-reperfusion injuries, activate innate immunity by inducing proinflammatory cytokine production through its interaction with toll-like receptors (TLRs). Our objective was to determine the role of HMGB1 and the degree of activation of TLR -related signal transduction pathways in hypoxia / reoxygenation (H / R)-induced proinflammatory cytokine production and intra-islet graft inflammation. After islets are exposed to hypoxia - reoxygenation for 24h, TLR2 / 4 expression and TLR -mediated signaling was up-regulated in islets, and HMGB1 was translocated from the nucleus to the cytoplasm and released to the extracellular space. With H / R exposure, proinflammatory cytokine production (IL-1β and TNF-α) and islet injury were significantly increased, and these effects depend on TLR2 / 4 signaling pathways. Exogenous HMGB1 also induces islet inflammation and increases the phosphorylation of STAT3, p38 and IκBα in wild-type islets. TLR2 deficiency in TLR2 - KO islets resulted in the inhibition of IL-1β production and STAT3 / p38 phosphorylation after HMGB1 exposure. TLR4 deficiency in TLR4 - KO islets resulted in the inhibition of TNF-α production and IκBα phosphorylation after HMGB1 exposure. Pre-incubation of the STAT3, p38, or NF-κB inhibitors significantly inhibited HMGB1 -induced IL-1β or TNF-α production in islets, but the effect of HMGB1 or H / R -induced islet injury was not counteracted by a separate treatment of the STAT3 inhibitor, p38 inhibitor, or NF-κB inhibitors. HMGB1 inhibition by ethyl pyruvate or blockade by neutralizing antibodies significantly decreased the phosphorylation of STAT3, p38 and IκBα, the production of IL-1β and TNF-α, and the islet injury in wild-type islets after exposure to H / R and significantly improved early islet graft failure. Thus, our results suggest that HMGB1 released from H / R induced islets works in an autocrine manner to up-regulate STAT or p38 and augment IL-1β production via TLR2, and up-regulate NF-κB and augment TNF-α production via TLR4 in intra-islet, which are associated with H / R -induced islet injury and early graft failure.
27838489	0	7	Hypoxia	T046	C0242184
27838489	10	23	reoxygenation	T061	C0087111
27838489	33	38	HMGB1	T116,T123	C0019796
27838489	39	52	translocation	T043	C0599893
27838489	57	64	release	T169	C0391871
27838489	74	79	islet	T023	C0022131
27838489	80	115	proinflammatory cytokine production	T040	C1327413
27838489	120	125	early	T079	C1279919
27838489	126	131	islet	T023	C0022131
27838489	132	145	graft failure	T046	C1262018
27838489	154	158	TLRs	T116,T192	C0670896
27838489	159	168	signaling	T044	C1514762
27838489	169	194	High-mobility group box 1	T116,T123	C0019796
27838489	196	201	HMGB1	T116,T123	C0019796
27838489	203	216	translocation	T043	C0599893
27838489	221	228	release	T169	C0391871
27838489	259	265	tissue	T024	C0040300
27838489	275	304	ischemia-reperfusion injuries	T037	C0035126
27838489	315	330	innate immunity	T032	C0020969
27838489	343	378	proinflammatory cytokine production	T040	C1327413
27838489	391	402	interaction	T169	C1704675
27838489	408	427	toll-like receptors	T116,T192	C0670896
27838489	429	433	TLRs	T116,T192	C0670896
27838489	479	484	HMGB1	T116,T123	C0019796
27838489	503	513	activation	T052	C1879547
27838489	517	520	TLR	T116,T192	C0670896
27838489	530	558	signal transduction pathways	T044	C0086982
27838489	562	569	hypoxia	T046	C0242184
27838489	572	585	reoxygenation	T061	C0087111
27838489	587	588	H	T046	C0242184
27838489	591	592	R	T061	C0087111
27838489	602	637	proinflammatory cytokine production	T040	C1327413
27838489	642	653	intra-islet	T023	C0022131
27838489	654	659	graft	T122	C0181074
27838489	660	672	inflammation	T046	C0021368
27838489	680	686	islets	T023	C0022131
27838489	691	698	exposed	T080	C0332157
27838489	702	709	hypoxia	T046	C0242184
27838489	712	725	reoxygenation	T061	C0087111
27838489	735	739	TLR2	T116,T192	C0754728
27838489	742	743	4	T116,T192	C1411976
27838489	744	754	expression	T045	C1171362
27838489	759	762	TLR	T116,T192	C0670896
27838489	773	782	signaling	T044	C1514762
27838489	787	799	up-regulated	T044	C0041904
27838489	803	809	islets	T023	C0022131
27838489	815	820	HMGB1	T116,T123	C0019796
27838489	825	837	translocated	T043	C0599893
27838489	847	854	nucleus	T026	C0007610
27838489	862	871	cytoplasm	T026	C0010834
27838489	876	884	released	T169	C0391871
27838489	892	911	extracellular space	T030	C0015352
27838489	918	919	H	T046	C0242184
27838489	922	923	R	T061	C0087111
27838489	924	932	exposure	T080	C0332157
27838489	934	969	proinflammatory cytokine production	T040	C1327413
27838489	971	976	IL-1β	T116,T129	C0021753
27838489	981	986	TNF-α	T116,T129	C1456820
27838489	992	997	islet	T023	C0022131
27838489	998	1004	injury	T037	C0178314
27838489	1063	1067	TLR2	T116,T192	C0754728
27838489	1070	1071	4	T116,T192	C1411976
27838489	1072	1090	signaling pathways	T044	C0037080
27838489	1102	1107	HMGB1	T116,T123	C0019796
27838489	1121	1126	islet	T023	C0022131
27838489	1127	1139	inflammation	T046	C0021368
27838489	1158	1173	phosphorylation	T044	C1158886
27838489	1177	1182	STAT3	T116,T123	C0253050
27838489	1184	1187	p38	T116,T126	C1120843
27838489	1192	1196	IκBα	T116,T123	C0126732
27838489	1210	1216	islets	T023	C0022131
27838489	1218	1222	TLR2	T116,T192	C0754728
27838489	1223	1233	deficiency	T169	C0011155
27838489	1237	1241	TLR2	T028	C1336634
27838489	1244	1246	KO	T063	C0599772
27838489	1247	1253	islets	T023	C0022131
27838489	1270	1280	inhibition	T052	C3463820
27838489	1284	1289	IL-1β	T116,T129	C0021753
27838489	1290	1300	production	T044	C0597295
27838489	1305	1310	STAT3	T116,T123	C0253050
27838489	1313	1316	p38	T116,T126	C1120843
27838489	1317	1332	phosphorylation	T044	C1158886
27838489	1339	1344	HMGB1	T116,T123	C0019796
27838489	1345	1353	exposure	T080	C0332157
27838489	1355	1359	TLR4	T116,T192	C1411976
27838489	1360	1370	deficiency	T169	C0011155
27838489	1374	1378	TLR4	T028	C1336636
27838489	1381	1383	KO	T063	C0599772
27838489	1384	1390	islets	T023	C0022131
27838489	1407	1417	inhibition	T052	C3463820
27838489	1421	1426	TNF-α	T116,T129	C1456820
27838489	1427	1437	production	T044	C0597295
27838489	1442	1446	IκBα	T116,T123	C0126732
27838489	1447	1462	phosphorylation	T044	C1158886
27838489	1469	1474	HMGB1	T116,T123	C0019796
27838489	1475	1483	exposure	T080	C0332157
27838489	1485	1499	Pre-incubation	T059	C0022885
27838489	1507	1512	STAT3	T116,T123	C0253050
27838489	1514	1517	p38	T116,T126	C1120843
27838489	1522	1527	NF-κB	T116,T129	C0079904
27838489	1553	1562	inhibited	T052	C3463820
27838489	1563	1568	HMGB1	T116,T123	C0019796
27838489	1578	1583	IL-1β	T116,T129	C0021753
27838489	1587	1592	TNF-α	T116,T129	C1456820
27838489	1593	1603	production	T044	C0597295
27838489	1607	1613	islets	T023	C0022131
27838489	1633	1638	HMGB1	T116,T123	C0019796
27838489	1642	1643	H	T046	C0242184
27838489	1646	1647	R	T061	C0087111
27838489	1657	1662	islet	T023	C0022131
27838489	1663	1669	injury	T037	C0178314
27838489	1722	1727	STAT3	T116,T123	C0253050
27838489	1739	1742	p38	T116,T126	C1120843
27838489	1757	1762	NF-κB	T116,T129	C0079904
27838489	1775	1780	HMGB1	T116,T123	C0019796
27838489	1781	1791	inhibition	T052	C3463820
27838489	1795	1809	ethyl pyruvate	T109,T121	C0208225
27838489	1813	1821	blockade	T169	C0332206
27838489	1838	1848	antibodies	T116,T129	C0003241
27838489	1877	1892	phosphorylation	T044	C1158886
27838489	1896	1901	STAT3	T116,T123	C0253050
27838489	1903	1906	p38	T116,T126	C1120843
27838489	1911	1915	IκBα	T116,T123	C0126732
27838489	1921	1931	production	T044	C0597295
27838489	1935	1940	IL-1β	T116,T129	C0021753
27838489	1945	1950	TNF-α	T116,T129	C1456820
27838489	1960	1965	islet	T023	C0022131
27838489	1966	1972	injury	T037	C0178314
27838489	1986	1992	islets	T023	C0022131
27838489	1999	2007	exposure	T080	C0332157
27838489	2011	2012	H	T046	C0242184
27838489	2015	2016	R	T061	C0087111
27838489	2044	2049	early	T079	C1279919
27838489	2050	2055	islet	T023	C0022131
27838489	2056	2069	graft failure	T046	C1262018
27838489	2102	2107	HMGB1	T116,T123	C0019796
27838489	2108	2116	released	T169	C0391871
27838489	2122	2123	H	T046	C0242184
27838489	2126	2127	R	T061	C0087111
27838489	2136	2142	islets	T023	C0022131
27838489	2155	2171	autocrine manner	T043	C3825249
27838489	2175	2186	up-regulate	T044	C0041904
27838489	2187	2191	STAT	T116,T123	C1366753
27838489	2195	2198	p38	T116,T126	C1120843
27838489	2211	2216	IL-1β	T116,T129	C0021753
27838489	2217	2227	production	T044	C0597295
27838489	2232	2236	TLR2	T116,T192	C0754728
27838489	2242	2253	up-regulate	T044	C0041904
27838489	2254	2259	NF-κB	T116,T129	C0079904
27838489	2272	2277	TNF-α	T116,T129	C1456820
27838489	2278	2288	production	T044	C0597295
27838489	2293	2297	TLR4	T116,T192	C1411976
27838489	2301	2312	intra-islet	T023	C0022131
27838489	2340	2341	H	T046	C0242184
27838489	2344	2345	R	T061	C0087111
27838489	2355	2360	islet	T023	C0022131
27838489	2361	2367	injury	T037	C0178314
27838489	2378	2391	graft failure	T046	C1262018

27604152|t|Characterisation of methicillin-resistant Staphylococcus aureus clinical isolates from animals in New Zealand, 2012-2013, and subclinical colonisation in dogs and cats in Auckland
27604152|a|To characterise methicillin-resistant Staphylococcus aureus (MRSA) isolates from infection sites in animals in New Zealand and assess the prevalence of subclinical MRSA colonisation in dogs and cats attending veterinary clinics in Auckland. MRSA isolates from clinical specimens obtained by the main New Zealand veterinary diagnostic laboratories between June 2012 and June 2013, were genotypically characterised by DNA microarray hybridisation analysis and spa typing. In addition, nasal or perineal skin swabs collected from a cross-sectional sample of dogs (n=361) and cats (n=225) attending 29 veterinary clinics in Auckland during the same period were analysed for MRSA by culture. Eight MRSA clinical isolates were submitted for characterisation by the participating laboratories. The isolates originated from five dogs, including two isolates from the same dog, one foal, and one isolate had no identification of the source. The strain - types identified were AK3 (ST-5 SCCmecIV t045; n=1), USA500 (ST8 SCCmecIV t064; n=1), WSPP (ST30 SCCmecIV t019; n=1), Rhine Hesse (ST5 SCCmecII t002; n=2), and EMRSA-15 (ST22 SCCmecIV t032; n=3). No MRSA were isolated from 586 cultured swabs. Methicillin-susceptible S. aureus were detected in 9/257 (3.5%) swabs and non-aureus staphylococci in 22/257 (8.5%) swabs. The estimated true MRSA subclinical colonisation prevalence was 0%, with an upper 95% CI boundary of 1.9% for cats and 1.4% for dogs. The modest number of MRSA isolates submitted for this study by the participating laboratories suggests clinical MRSA infection in animals in New Zealand continues to be sporadic. The wide variety of strain - types found mirrored the evolving strain - type diversity observed in humans. We cannot rule out bias due to the non-random sampling of dogs and cats, but the apparent colonisation prevalence of 0% was consistent with the low prevalence of subclinical colonisation in humans in New Zealand. These similarities indicate the epidemiology of animal and human MRSA infections are linked. In the last decade, the prevalence of human MRSA infections in New Zealand has steadily increased. This is the second published study of MRSA in animals in New Zealand. The results indicate clinical MRSA infection in animals remains sporadic, but the diversification of the strain - types may pose new therapeutic challenges to veterinarians, due to their diverse resistome.
27604152	0	16	Characterisation	T052	C1880022
27604152	20	63	methicillin-resistant Staphylococcus aureus	T007	C1265292
27604152	64	72	clinical	T080	C0205210
27604152	73	81	isolates	T123	C1764827
27604152	87	94	animals	T008	C0003062
27604152	98	109	New Zealand	T083	C0027978
27604152	126	137	subclinical	T080	C0205211
27604152	138	150	colonisation	T033	C2242741
27604152	154	158	dogs	T015	C0012984
27604152	163	167	cats	T015	C0007450
27604152	171	179	Auckland	UnknownType	C0681784
27604152	183	195	characterise	T052	C1880022
27604152	196	239	methicillin-resistant Staphylococcus aureus	T007	C1265292
27604152	241	245	MRSA	T007	C1265292
27604152	247	255	isolates	T123	C1764827
27604152	261	276	infection sites	T047	C0578491
27604152	280	287	animals	T008	C0003062
27604152	291	302	New Zealand	T083	C0027978
27604152	318	328	prevalence	T081	C0220900
27604152	332	343	subclinical	T080	C0205211
27604152	344	361	MRSA colonisation	T033	C2242741
27604152	365	369	dogs	T015	C0012984
27604152	374	378	cats	T015	C0007450
27604152	389	407	veterinary clinics	T073,T093	C2936717
27604152	411	419	Auckland	UnknownType	C0681784
27604152	421	425	MRSA	T007	C1265292
27604152	426	434	isolates	T123	C1764827
27604152	440	448	clinical	T080	C0205210
27604152	449	458	specimens	T167	C0370003
27604152	480	491	New Zealand	T083	C0027978
27604152	492	526	veterinary diagnostic laboratories	T073,T093	C0022877
27604152	535	539	June	T079	C3829443
27604152	549	553	June	T079	C3829443
27604152	565	592	genotypically characterised	T052	C1880022
27604152	596	633	DNA microarray hybridisation analysis	T063	C1522053
27604152	638	641	spa	T116,T129,T130	C0038164
27604152	642	648	typing	T059	C0087124
27604152	663	668	nasal	T023	C0222095
27604152	672	685	perineal skin	T023	C0222176
27604152	686	691	swabs	T167	C0183753
27604152	709	731	cross-sectional sample	T167	C0370003
27604152	735	739	dogs	T015	C0012984
27604152	752	756	cats	T015	C0007450
27604152	778	796	veterinary clinics	T073,T093	C2936717
27604152	800	808	Auckland	UnknownType	C0681784
27604152	825	831	period	T079	C1948053
27604152	837	845	analysed	T062	C0936012
27604152	850	854	MRSA	T007	C1265292
27604152	858	865	culture	T059	C2242979
27604152	873	877	MRSA	T007	C1265292
27604152	878	886	clinical	T080	C0205210
27604152	887	895	isolates	T123	C1764827
27604152	915	931	characterisation	T052	C1880022
27604152	953	965	laboratories	T073,T093	C0022877
27604152	971	979	isolates	T123	C1764827
27604152	1001	1005	dogs	T015	C0012984
27604152	1021	1029	isolates	T123	C1764827
27604152	1044	1047	dog	T015	C0012984
27604152	1053	1057	foal	T015	C3669731
27604152	1067	1074	isolate	T123	C1764827
27604152	1104	1110	source	T033	C0449416
27604152	1116	1122	strain	T001	C1518614
27604152	1125	1130	types	T080	C0332307
27604152	1131	1141	identified	T080	C0205396
27604152	1147	1165	AK3 (ST-5 SCCmecIV	T007	C1265292
27604152	1178	1198	USA500 (ST8 SCCmecIV	T007	C1265292
27604152	1211	1230	WSPP (ST30 SCCmecIV	T007	C1265292
27604152	1243	1268	Rhine Hesse (ST5 SCCmecII	T007	C1265292
27604152	1285	1308	EMRSA-15 (ST22 SCCmecIV	T007	C1265292
27604152	1324	1328	MRSA	T007	C1265292
27604152	1334	1342	isolated	T169	C0205409
27604152	1352	1366	cultured swabs	T167	C0183753
27604152	1368	1401	Methicillin-susceptible S. aureus	T007	C1265292
27604152	1407	1415	detected	T033	C0442726
27604152	1432	1437	swabs	T167	C0183753
27604152	1442	1466	non-aureus staphylococci	T007	C0038170
27604152	1484	1489	swabs	T167	C0183753
27604152	1510	1514	MRSA	T007	C1265292
27604152	1515	1526	subclinical	T080	C0205211
27604152	1527	1539	colonisation	T033	C2242741
27604152	1540	1550	prevalence	T081	C0220900
27604152	1577	1579	CI	T081	C0009667
27604152	1601	1605	cats	T015	C0007450
27604152	1619	1623	dogs	T015	C0012984
27604152	1629	1642	modest number	T081	C0237753
27604152	1646	1650	MRSA	T007	C1265292
27604152	1651	1659	isolates	T123	C1764827
27604152	1679	1684	study	T170	C0085973
27604152	1706	1718	laboratories	T073,T093	C0022877
27604152	1728	1736	clinical	T080	C0205210
27604152	1737	1751	MRSA infection	T047	C0343401
27604152	1755	1762	animals	T008	C0003062
27604152	1766	1777	New Zealand	T083	C0027978
27604152	1794	1802	sporadic	T079	C0205422
27604152	1824	1830	strain	T001	C1518614
27604152	1833	1838	types	T080	C0332307
27604152	1867	1873	strain	T001	C1518614
27604152	1876	1880	type	T080	C0332307
27604152	1881	1890	diversity	T080	C1880371
27604152	1903	1909	humans	T016	C0086418
27604152	1930	1934	bias	T078	C0242568
27604152	1946	1965	non-random sampling	T062	C0150105
27604152	1969	1973	dogs	T015	C0012984
27604152	1978	1982	cats	T015	C0007450
27604152	2001	2013	colonisation	T033	C4289767
27604152	2014	2024	prevalence	T081	C0220900
27604152	2035	2050	consistent with	T078	C0332290
27604152	2059	2069	prevalence	T081	C0220900
27604152	2073	2084	subclinical	T080	C0205211
27604152	2085	2097	colonisation	T033	C2242741
27604152	2101	2107	humans	T016	C0086418
27604152	2111	2122	New Zealand	T083	C0027978
27604152	2130	2142	similarities	T080	C2348205
27604152	2156	2168	epidemiology	T091	C0014507
27604152	2172	2178	animal	T008	C0003062
27604152	2183	2188	human	T016	C0086418
27604152	2189	2204	MRSA infections	T047	C0343401
27604152	2229	2235	decade	T081	C2981279
27604152	2241	2251	prevalence	T081	C0220900
27604152	2255	2260	human	T016	C0086418
27604152	2261	2276	MRSA infections	T047	C0343401
27604152	2280	2291	New Zealand	T083	C0027978
27604152	2305	2314	increased	T081	C0205217
27604152	2345	2350	study	T170	C0085973
27604152	2354	2358	MRSA	T007	C1265292
27604152	2362	2369	animals	T008	C0003062
27604152	2373	2384	New Zealand	T083	C0027978
27604152	2407	2415	clinical	T080	C0205210
27604152	2416	2430	MRSA infection	T047	C0343401
27604152	2434	2441	animals	T008	C0003062
27604152	2450	2458	sporadic	T079	C0205422
27604152	2468	2483	diversification	T057	C0680948
27604152	2491	2497	strain	T001	C1518614
27604152	2500	2505	types	T080	C0332307
27604152	2519	2530	therapeutic	T169	C0302350
27604152	2545	2558	veterinarians	T097	C0242856
27604152	2581	2590	resistome	T028	C2945710

28134554|t|VA eScreening program: Technology to improve care for post-9/11 veterans
28134554|a|The Veterans Health Administration (VHA) provides health care services to a growing number of veterans. There is ample support for the use of technology-based self-screening to support health care delivery. We developed the VA eScreening program for veterans to directly provide self-report mental and physical health information through a veteran-facing portal that communicates with the electronic medical records system. A total of 1,372 newly enrolling veterans in 2 cohorts participated in a study to assess veteran satisfaction, determine accessibility and clinical processes, measure screening differences, and examine connection to care between eScreening and paper screening. Veterans who completed eScreening were slightly more satisfied with screening than those who completed paper screening. Accessibility, rate of screening completion, and clinical processes were significantly better with eScreening than paper screening. Except for higher alcohol use in the paper-based cohort, veterans who completed paper and eScreening were similar in the rates of positive health screens. Connection to VA services, rate and speed of vesting in the health care system, and time to document required suicide risk assessments were better with the VA eScreening program than paper screening. The VA eScreening program is a unique and promising tool that may leverage limited resources to improve screening and care for veterans. (PsycINFO Database Record
28134554	0	21	VA eScreening program	T170	C0282574
28134554	23	33	Technology	T058	C0752189
28134554	45	49	care	T033	C0580931
28134554	54	72	post-9/11 veterans	T098	C0042610
28134554	77	107	Veterans Health Administration	T057	C0178672
28134554	109	112	VHA	T057	C0178672
28134554	123	143	health care services	T058	C0018747
28134554	167	175	veterans	T098	C0042610
28134554	215	246	technology-based self-screening	T058	C1254363
28134554	250	257	support	T054	C0037438
28134554	258	278	health care delivery	T058	C0011211
28134554	297	318	VA eScreening program	T170	C0282574
28134554	323	331	veterans	T098	C0042610
28134554	352	363	self-report	T170	C0684224
28134554	364	370	mental	T041	C0025353
28134554	375	390	physical health	T033	C0517226
28134554	391	402	information	T058	C0850397
28134554	413	434	veteran-facing portal	T170	C2349146
28134554	462	495	electronic medical records system	T170	C2362543
28134554	530	538	veterans	T098	C0042610
28134554	544	551	cohorts	T098	C0599755
28134554	579	585	assess	T058	C0184514
28134554	586	593	veteran	T098	C0042610
28134554	594	606	satisfaction	T041	C0242428
28134554	618	631	accessibility	T080	C0018748
28134554	636	644	clinical	T080	C0205210
28134554	645	654	processes	T067	C1522240
28134554	664	673	screening	T058	C1710032
28134554	674	685	differences	T080	C1705242
28134554	713	717	care	T033	C0580931
28134554	726	736	eScreening	T058	C1710032
28134554	741	756	paper screening	T058	C1710032
28134554	758	766	Veterans	T098	C0042610
28134554	781	791	eScreening	T058	C1710032
28134554	826	835	screening	T058	C1710032
28134554	861	876	paper screening	T058	C1710032
28134554	878	891	Accessibility	T080	C0018748
28134554	893	921	rate of screening completion	T081	C0392762
28134554	927	935	clinical	T080	C0205210
28134554	936	945	processes	T067	C1522240
28134554	977	987	eScreening	T058	C1710032
28134554	993	1008	paper screening	T058	C1710032
28134554	1028	1039	alcohol use	T055	C0001948
28134554	1047	1065	paper-based cohort	T098	C0599755
28134554	1067	1075	veterans	T098	C0042610
28134554	1090	1095	paper	T058	C1710032
28134554	1100	1110	eScreening	T058	C1710032
28134554	1131	1136	rates	T081	C1521828
28134554	1140	1148	positive	T033	C1446409
28134554	1149	1163	health screens	T058	C0220908
28134554	1179	1190	VA services	T058	C0018747
28134554	1192	1196	rate	T081	C1521828
28134554	1201	1206	speed	T080	C0456962
28134554	1225	1243	health care system	T093	C0018696
28134554	1249	1253	time	T079	C0040223
28134554	1257	1265	document	T058	C0175636
28134554	1275	1299	suicide risk assessments	T058	C0558000
28134554	1321	1342	VA eScreening program	T170	C0282574
28134554	1348	1363	paper screening	T058	C1710032
28134554	1369	1390	VA eScreening program	T170	C0282574
28134554	1417	1421	tool	T170	C0037589
28134554	1440	1447	limited	T169	C0439801
28134554	1448	1457	resources	T078	C0018741
28134554	1469	1478	screening	T058	C1710032
28134554	1483	1487	care	T033	C0580931
28134554	1492	1500	veterans	T098	C0042610

28121531|t|Workers not getting help they need to navigate the health care system
28121531|a|Health advocacy services connect employees with advisers who can answer questions and provide advice about using the often - Byzantine health care system. The number of companies offering such services has remained stagnant at about 24% since 2013, according to Optum, and it's a minority of companies that provide other kinds of help for dealing with the health care system.
28121531	0	7	Workers	T098	C1527116
28121531	20	24	help	T080	C1269765
28121531	30	34	need	T080	C0027552
28121531	51	69	health care system	T093	C0018696
28121531	70	94	Health advocacy services	T058	C0086388
28121531	103	112	employees	T097	C0599987
28121531	135	151	answer questions	T058	C0178895
28121531	156	163	provide	T052	C1999230
28121531	164	170	advice	T065	C0018701
28121531	187	192	often	T079	C0332183
28121531	195	204	Byzantine	T083	C0242840
28121531	205	223	health care system	T093	C0018696
28121531	239	248	companies	T073,T092	C0683757
28121531	263	271	services	T058	C0018747
28121531	332	337	Optum	T093	C0596660
28121531	350	358	minority	T080	C0205165
28121531	362	371	companies	T073,T092	C0683757
28121531	377	384	provide	T052	C1999230
28121531	400	404	help	T080	C1269765
28121531	426	444	health care system	T093	C0018696

28368473|t|Targeting MYC as a therapeutic intervention for anaplastic thyroid cancer
28368473|a|Recent studies showed that transcription of the MYC gene is driven by interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. A potent inhibitor, JQ1, which effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. It remains to be elucidated on the role of MYC in human ATC and whether JQ1 could effectively target MYC as a novel treatment modality. To understand underlying molecular mechanisms of JQ1's effects on human ATC, we evaluated the efficacy of JQ1 in human ATC cell lines and xenograft models. We determined the effects of JQ1 on proliferation and invasion in cell lines and xenograft tumors. We identified key regulators critical for JQ1 -affected proliferation and invasion of tumor cells. JQ1 markedly inhibited proliferation of 4 ATC cell lines by suppression of MYC and elevation of p21and p27 to decrease phosphorylated Rb to delay cell cycle progression from the G0/G1 phase to the S phase. JQ1 blocked cell invasion by attenuating epithelial mesenchymal transition signals. These cell-based studies were further confirmed in xenograft studies in that the size and rate of tumor growth was inhibited by JQ1 via inhibition of p21-Cyclin/CDK-Rb-E2F signaling. These results suggest targeting MYC protein could be a potential novel treatment modality for human ATC for which effective treatment options are limited.
28368473	0	9	Targeting	T169	C1521840
28368473	10	13	MYC	T028	C0086661
28368473	19	43	therapeutic intervention	T061	C0808232
28368473	48	73	anaplastic thyroid cancer	T191	C0238461
28368473	74	88	Recent studies	T062	C2603343
28368473	101	114	transcription	T045	C0040649
28368473	122	130	MYC gene	T028	C0086661
28368473	144	155	interaction	T169	C1704675
28368473	159	210	bromodomain and extraterminal domain (BET) proteins	T116,T123	C0033684
28368473	216	235	acetylated histones	T044	C2753333
28368473	239	248	chromatin	T116	C0008546
28368473	252	268	potent inhibitor	T121	C1254351
28368473	270	273	JQ1	T109,T121	C3252362
28368473	293	301	disrupts	T080	C0332454
28368473	306	317	interaction	T169	C1704675
28368473	321	333	BET proteins	T116,T123	C0033684
28368473	339	358	acetylated histones	T044	C2753333
28368473	375	385	suppresses	T169	C1260953
28368473	386	399	transcription	T045	C0040649
28368473	407	415	MYC gene	T028	C0086661
28368473	420	437	recently reported	T058	C0700287
28368473	443	446	JQ1	T109,T121	C3252362
28368473	447	456	decreased	T081	C0205216
28368473	457	470	thyroid tumor	T191	C0040136
28368473	471	477	growth	T191	C0598934
28368473	482	490	improved	T033	C0184511
28368473	491	499	survival	T169	C0220921
28368473	505	516	mouse model	T050	C2986594
28368473	520	545	anaplastic thyroid cancer	T191	C0238461
28368473	547	550	ATC	T191	C0238461
28368473	565	568	MYC	T028	C0086661
28368473	569	582	transcription	T045	C0040649
28368473	627	639	MYC in human	T116,T123	C1454487
28368473	640	643	ATC	T191	C0238461
28368473	656	659	JQ1	T080	C1999216
28368473	666	677	effectively	T080	C1704419
28368473	685	688	MYC	T116,T123	C1454487
28368473	694	718	novel treatment modality	T061	C0009429
28368473	745	765	molecular mechanisms	T044	C3537153
28368473	769	774	JQ1's	T080	C1999216
28368473	775	782	effects	T080	C1280500
28368473	786	791	human	T016	C0086418
28368473	792	795	ATC	T191	C0238461
28368473	800	809	evaluated	T058	C0220825
28368473	814	822	efficacy	T080	C1280519
28368473	826	829	JQ1	T080	C1999216
28368473	833	838	human	T016	C0086418
28368473	839	842	ATC	T191	C0238461
28368473	843	853	cell lines	T025	C0085983
28368473	858	874	xenograft models	T050	C1520166
28368473	894	901	effects	T080	C1280500
28368473	905	908	JQ1	T080	C1999216
28368473	912	925	proliferation	T169	C1514485
28368473	930	938	invasion	T033	C1269955
28368473	942	952	cell lines	T025	C0085983
28368473	957	966	xenograft	T061	C0520484
28368473	967	973	tumors	T191	C0027651
28368473	978	988	identified	T080	C0205396
28368473	989	1003	key regulators	T077	C1704735
28368473	1004	1012	critical	T080	C1511545
28368473	1017	1020	JQ1	T080	C1999216
28368473	1031	1044	proliferation	T169	C1514485
28368473	1049	1072	invasion of tumor cells	T033	C1269955
28368473	1074	1077	JQ1	T080	C1999216
28368473	1087	1096	inhibited	T080	C0311403
28368473	1097	1110	proliferation	T169	C1514485
28368473	1116	1119	ATC	T191	C0238461
28368473	1120	1130	cell lines	T025	C0085983
28368473	1134	1145	suppression	T169	C1260953
28368473	1149	1152	MYC	T116,T123	C1454487
28368473	1157	1166	elevation	T082	C0702240
28368473	1170	1180	p21and p27	T116	C0598086
28368473	1184	1192	decrease	T081	C0547047
28368473	1193	1207	phosphorylated	T044	C1158886
28368473	1208	1210	Rb	T116,T123	C0080113
28368473	1214	1230	delay cell cycle	T043	C0007586
28368473	1231	1242	progression	T169	C0449258
28368473	1252	1263	G0/G1 phase	T079	C0205390
28368473	1271	1278	S phase	T079	C0080129
28368473	1280	1283	JQ1	T080	C1999216
28368473	1284	1291	blocked	T169	C0332206
28368473	1292	1305	cell invasion	T033	C1269955
28368473	1321	1362	epithelial mesenchymal transition signals	T043	C1523298
28368473	1370	1388	cell-based studies	T062	C2603343
28368473	1402	1411	confirmed	T033	C0750484
28368473	1415	1424	xenograft	T061	C0520484
28368473	1425	1432	studies	T062	C2603343
28368473	1445	1449	size	T082	C0456389
28368473	1454	1458	rate	T081	C1521828
28368473	1462	1474	tumor growth	T191	C0598934
28368473	1479	1488	inhibited	T080	C0311403
28368473	1492	1495	JQ1	T080	C1999216
28368473	1500	1510	inhibition	T052	C3463820
28368473	1514	1545	p21-Cyclin/CDK-Rb-E2F signaling	T044	C0037080
28368473	1553	1560	results	T169	C1274040
28368473	1579	1590	MYC protein	T116,T123	C1454487
28368473	1602	1611	potential	T080	C3245505
28368473	1612	1636	novel treatment modality	T061	C0009429
28368473	1641	1646	human	T016	C0086418
28368473	1647	1650	ATC	T191	C0238461
28368473	1661	1670	effective	T080	C1704419
28368473	1671	1688	treatment options	T061	C0683525
28368473	1693	1700	limited	T169	C0439801

27334470|t|Genomic analysis of nontypeable pneumococci causing invasive pneumococcal disease in South Africa, 2003-2013
27334470|a|The capsular polysaccharide is the principal virulence factor of Streptococcus pneumoniae and a target for current pneumococcal vaccines. However, some pathogenic pneumococci are serologically nontypeable [nontypeable pneumococci (NTPn)]. Due to their relative rarity, NTPn are poorly characterized, and, as such, limited data exist which describe these organisms. We aimed to describe disease and genotypically characterize NTPn causing invasive pneumococcal disease in South Africa. Isolates were detected through national, laboratory - based surveillance for invasive pneumococcal disease in South Africa and characterized by whole genome analysis. We predicted ancestral serotypes (serotypes from which NTPn may have originated) for Group I NTPn using multilocus sequence typing and capsular region sequence analyses. Antimicrobial resistance patterns and mutations potentially causing nontypeability were identified. From 2003-2013, 39 (0.1 %, 39/32,824) NTPn were reported. Twenty-two (56 %) had partial capsular genes (Group I) and 17 (44 %) had complete capsular deletion of which 15 had replacement by other genes (Group II). Seventy-nine percent (31/39) of our NTPn isolates were derived from encapsulated S. pneumoniae. Ancestral serotypes 1 (27 %, 6/22) and 8 (14 %, 3/22) were most prevalent, and 59 % (13/22) of ancestral serotypes were serotypes included in the 13-valent pneumococcal conjugate vaccine. We identified a variety of mutations within the capsular region of Group I NTPn, some of which may be responsible for the nontypeable phenotype. Nonsusceptibility to tetracycline and erythromycin was higher in NTPn than encapsulated S. pneumoniae. NTPn are currently a rare cause of invasive pneumococcal disease in South Africa and represent a genetically diverse collection of isolates.
27334470	0	16	Genomic analysis	T059	C3854164
27334470	20	43	nontypeable pneumococci	T007	C0038410
27334470	52	81	invasive pneumococcal disease	T047	C1320214
27334470	85	97	South Africa	T083	C0037712
27334470	113	136	capsular polysaccharide	T109	C1979807
27334470	154	170	virulence factor	T109,T123,T131	C1136170
27334470	174	198	Streptococcus pneumoniae	T007	C0038410
27334470	205	211	target	T169	C1521840
27334470	224	245	pneumococcal vaccines	T121,T129	C0358314
27334470	261	271	pathogenic	T033	C3816499
27334470	272	283	pneumococci	T007	C0038410
27334470	288	313	serologically nontypeable	T170	C0449943
27334470	315	338	nontypeable pneumococci	T007	C0038410
27334470	340	344	NTPn	T007	C0038410
27334470	370	376	rarity	T080	C0522498
27334470	378	382	NTPn	T007	C0038410
27334470	394	407	characterized	T052	C1880022
27334470	431	435	data	T078	C1511726
27334470	463	472	organisms	T001	C0029235
27334470	495	502	disease	T047	C0012634
27334470	507	520	genotypically	T032	C0017431
27334470	521	533	characterize	T052	C1880022
27334470	534	538	NTPn	T007	C0038410
27334470	547	576	invasive pneumococcal disease	T047	C1320214
27334470	580	592	South Africa	T083	C0037712
27334470	594	602	Isolates	T123	C1764827
27334470	635	645	laboratory	T073,T093	C0022877
27334470	648	653	based	T078	C1705938
27334470	654	666	surveillance	T169	C0220920
27334470	671	700	invasive pneumococcal disease	T047	C1320214
27334470	704	716	South Africa	T083	C0037712
27334470	721	734	characterized	T052	C1880022
27334470	744	759	genome analysis	T059	C3854164
27334470	774	783	ancestral	T169	C0439660
27334470	784	793	serotypes	T170	C0449943
27334470	795	804	serotypes	T170	C0449943
27334470	816	820	NTPn	T007	C0038410
27334470	846	853	Group I	T078	C0441833
27334470	854	858	NTPn	T007	C0038410
27334470	865	891	multilocus sequence typing	T062	C2936544
27334470	896	911	capsular region	T082	C1254362
27334470	912	929	sequence analyses	T059,T063	C0162801
27334470	931	955	Antimicrobial resistance	T201	C1456627
27334470	956	964	patterns	T082	C0449774
27334470	969	978	mutations	T045	C0026882
27334470	979	990	potentially	T080	C3245505
27334470	999	1013	nontypeability	T170	C0449943
27334470	1019	1029	identified	T080	C0205396
27334470	1069	1073	NTPn	T007	C0038410
27334470	1089	1099	Twenty-two	T081	C4284772
27334470	1111	1118	partial	T081	C0728938
27334470	1119	1133	capsular genes	T028	C0017337
27334470	1135	1142	Group I	T078	C0441833
27334470	1162	1170	complete	T080	C0205197
27334470	1171	1188	capsular deletion	T045	C0017260
27334470	1205	1216	replacement	T169	C0559956
27334470	1226	1231	genes	T028	C0017337
27334470	1233	1241	Group II	T078	C0441833
27334470	1244	1256	Seventy-nine	T081	C3828184
27334470	1257	1264	percent	T081	C0439165
27334470	1280	1284	NTPn	T007	C0038410
27334470	1285	1293	isolates	T123	C1764827
27334470	1312	1324	encapsulated	T080	C0205223
27334470	1325	1338	S. pneumoniae	T007	C0038410
27334470	1350	1359	serotypes	T170	C0449943
27334470	1435	1444	ancestral	T169	C0439660
27334470	1445	1454	serotypes	T170	C0449943
27334470	1460	1469	serotypes	T170	C0449943
27334470	1486	1526	13-valent pneumococcal conjugate vaccine	T121,T129	C3152625
27334470	1555	1564	mutations	T045	C0026882
27334470	1576	1591	capsular region	T082	C1254362
27334470	1595	1602	Group I	T078	C0441833
27334470	1603	1607	NTPn	T007	C0038410
27334470	1650	1661	nontypeable	T170	C0449943
27334470	1662	1671	phenotype	T032	C0031437
27334470	1673	1690	Nonsusceptibility	T034	C2827756
27334470	1694	1706	tetracycline	T109,T195	C0039644
27334470	1711	1723	erythromycin	T109,T195	C0014806
27334470	1738	1742	NTPn	T007	C0038410
27334470	1748	1760	encapsulated	T080	C0205223
27334470	1761	1774	S. pneumoniae	T007	C0038410
27334470	1776	1780	NTPn	T007	C0038410
27334470	1811	1840	invasive pneumococcal disease	T047	C1320214
27334470	1844	1856	South Africa	T083	C0037712

27453830|t|Assessment and classification of protocol deviations
27453830|a|Deviations from the approved trial protocol are common during clinical trials. They have been conventionally classified as deviations or violations, depending on their impact on the trial. A new method has been proposed by which deviations are classified in five grades from 1 to 5. A deviation of Grade 1 has no impact on the subjects' well-being or on the quality of data. At the maximum, a deviation Grade 5 leads to the death of the subject. This method of classification was applied to deviations noted in the center over the last 3 years. It was observed that most deviations were of Grades 1 and 2, with fewer falling in Grades 3 and 4. There were no deviations that led to the death of the subject (Grade 5). This method of classification would help trial managers decide on the action to be taken on the occurrence of deviations, which would be based on their impact.
27453830	0	10	Assessment	T058	C0220825
27453830	15	29	classification	T185	C0008902
27453830	33	52	protocol deviations	T033	C1705236
27453830	53	63	Deviations	T033	C1705236
27453830	82	96	trial protocol	T170	C2599718
27453830	115	130	clinical trials	T062	C0008976
27453830	162	172	classified	T185	C0008902
27453830	176	186	deviations	T033	C1705236
27453830	190	200	violations	T062	C1709750
27453830	221	227	impact	T080	C4049986
27453830	235	240	trial	T062	C0008976
27453830	282	292	deviations	T033	C1705236
27453830	297	307	classified	T185	C0008902
27453830	316	334	grades from 1 to 5	T185	C0008902
27453830	338	347	deviation	T033	C1705236
27453830	351	358	Grade 1	T033	C0687695
27453830	363	365	no	T033	C1513916
27453830	366	372	impact	T080	C4049986
27453830	380	389	subjects'	T098	C2349001
27453830	390	400	well-being	T033	C0424578
27453830	411	426	quality of data	T080	C0242483
27453830	446	455	deviation	T033	C1705236
27453830	456	463	Grade 5	T185	C0441804
27453830	477	482	death	T033	C1306577
27453830	490	497	subject	T098	C2349001
27453830	514	528	classification	T185	C0008902
27453830	544	554	deviations	T033	C1705236
27453830	624	634	deviations	T033	C1705236
27453830	643	657	Grades 1 and 2	T185	C0008902
27453830	681	695	Grades 3 and 4	T185	C0008902
27453830	711	721	deviations	T033	C1705236
27453830	738	758	death of the subject	T033	C3897054
27453830	785	799	classification	T185	C0008902
27453830	811	816	trial	T062	C0008976
27453830	817	825	managers	T097	C0335141
27453830	866	876	occurrence	T079	C2745955
27453830	880	890	deviations	T033	C1705236
27453830	922	928	impact	T080	C4049986

27762482|t|Treatment of erythematotelangiectatic rosacea with the fractionation of high-fluence, long-pulsed 595-nm pulsed dye laser
27762482|a|Various lasers have been used for the treatment of erythematotelangiectatic rosacea (ETR) that does not respond to systemic or topical therapy. The pulsed dye lasers (PDLs) are an effective option for ETR, and the purpuragenic fluence proved to be superior until now. Given that purpura and subsequent possible postinflammatory hyperpigmentation (PIH) are occasionally unbearable in some patients, and several studies using the low nonpurpuragenic fluence were reported. To deliver the sufficient high fluence of a PDL without generating purpura, we designed the fractionation of high fluence using five passes and longer pulse duration (6 milliseconds) of a PDL in succession. A total of eight patients with ETR were enrolled in this study; all patients were treated with PDL 10 times at 2-week intervals. Erythema and telangiectasia scores, as well as improvement, were assessed by two physicians using the digital photographs. Moderate-to-marked improvement was achieved in most of the patients, and erythema and telangiectasia scores were significantly decreased. Purpura and PIH were not reported in all patients. The fractionation of high-fluence, long-pulsed 595 nm PDL is a very safe and effective treatment for ETR.
27762482	0	9	Treatment	T061	C0087111
27762482	13	45	erythematotelangiectatic rosacea	T047	C1449852
27762482	55	68	fractionation	T061	C3161031
27762482	72	84	high-fluence	T079	C0205212
27762482	105	121	pulsed dye laser	T074	C1289859
27762482	130	136	lasers	T073	C0023089
27762482	160	169	treatment	T061	C0087111
27762482	173	205	erythematotelangiectatic rosacea	T047	C1449852
27762482	207	210	ETR	T047	C1449852
27762482	237	245	systemic	T061	C1515119
27762482	249	264	topical therapy	T061	C0150349
27762482	270	287	pulsed dye lasers	T074	C1289859
27762482	289	293	PDLs	T074	C1289859
27762482	323	326	ETR	T047	C1449852
27762482	336	348	purpuragenic	T047	C0034150
27762482	349	356	fluence	T079	C0376249
27762482	401	408	purpura	T047	C0034150
27762482	433	467	postinflammatory hyperpigmentation	T046	C0333616
27762482	469	472	PIH	T046	C0333616
27762482	510	518	patients	T101	C0030705
27762482	554	569	nonpurpuragenic	T033	C0243095
27762482	570	577	fluence	T079	C0376249
27762482	619	631	high fluence	T079	C0205212
27762482	637	640	PDL	T074	C1289859
27762482	660	667	purpura	T047	C0034150
27762482	685	698	fractionation	T061	C3161031
27762482	702	714	high fluence	T079	C0205212
27762482	781	784	PDL	T074	C1289859
27762482	817	825	patients	T101	C0030705
27762482	831	834	ETR	T047	C1449852
27762482	868	876	patients	T101	C0030705
27762482	895	898	PDL	T074	C1289859
27762482	929	937	Erythema	T047	C0041834
27762482	942	956	telangiectasia	T047	C0039446
27762482	1010	1020	physicians	T097	C0031831
27762482	1031	1050	digital photographs	T170	C3899375
27762482	1111	1119	patients	T101	C0030705
27762482	1125	1133	erythema	T047	C0041834
27762482	1138	1152	telangiectasia	T047	C0039446
27762482	1190	1197	Purpura	T047	C0034150
27762482	1202	1205	PIH	T046	C0333616
27762482	1231	1239	patients	T101	C0030705
27762482	1245	1258	fractionation	T061	C3161031
27762482	1262	1274	high-fluence	T079	C0205212
27762482	1295	1298	PDL	T074	C1289859
27762482	1328	1337	treatment	T061	C0087111
27762482	1342	1345	ETR	T047	C1449852

27593936|t|TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183 - and miR-33a -mediated cell cycle regulation
27593936|a|Non-small cell lung cancer (NSCLC) remains one of the leading causes of death worldwide, and thus new molecular targets need to be identified to improve treatment efficacy. Although epidermal growth factor receptor (EGFR)/ KRAS mutation -driven lung tumorigenesis is well understood, the mechanism of EGFR / KRAS -independent signal activation remains elusive. Enhanced TFAP2C (transcription factor activating enhancer-binding protein 2C) expression is associated with poor prognosis in some types of cancer patients, but little is known of its relation with the pathogenesis of lung cancer. In the present study, we found that TFAP2C overexpression was associated with cell cycle activation and NSCLC cell tumorigenesis. Interestingly, TFAP2C blocked AKAP12 -mediated cyclin D1 inhibition by inducing the overexpression of oncogenic microRNA (miRNA)-183 and simultaneously activated cyclin-dependent kinase 6 -mediated cell cycle progression by downregulating tumor-suppressive miRNA-33a. In a mouse xenograft model, TFAP2C promoted lung tumorigenesis and disease aggressiveness via the miR-183 and miR-33a pathways. The study provides a mechanism of mitogenic and oncogenic signaling via two functionally opposed miRNAs and suggests that TFAP2C -induced cell cycle hyperactivation contributes to lung tumorigenesis.
27593936	0	6	TFAP2C	T116,T123	C1529556
27593936	16	20	lung	T023	C0024109
27593936	21	34	tumorigenesis	T191	C0596263
27593936	39	53	aggressiveness	T191	C2945759
27593936	62	69	miR-183	T114,T123	C1101610
27593936	76	83	miR-33a	T114,T123	C1101610
27593936	94	115	cell cycle regulation	T043	C1155872
27593936	116	142	Non-small cell lung cancer	T191	C0007131
27593936	144	149	NSCLC	T191	C0007131
27593936	188	193	death	T040	C0011065
27593936	194	203	worldwide	T098	C2700280
27593936	218	235	molecular targets	T104,T120	C1513403
27593936	269	287	treatment efficacy	T080	C0087113
27593936	298	330	epidermal growth factor receptor	T116,T126,T192	C0034802
27593936	332	336	EGFR	T028	C1414313
27593936	339	343	KRAS	T028	C1537502
27593936	344	352	mutation	T045	C0596611
27593936	361	365	lung	T023	C0024109
27593936	366	379	tumorigenesis	T191	C0596263
27593936	404	413	mechanism	T044	C0678659
27593936	417	421	EGFR	T116,T126,T192	C0034802
27593936	424	428	KRAS	T116,T123	C0763464
27593936	442	459	signal activation	UnknownType	C0678666
27593936	477	492	Enhanced TFAP2C	T116,T123	C1529556
27593936	494	553	transcription factor activating enhancer-binding protein 2C	T116,T123	C1529556
27593936	555	565	expression	T045	C1171362
27593936	569	584	associated with	T080	C0332281
27593936	590	599	prognosis	T201	C3854082
27593936	617	632	cancer patients	T101	C1516213
27593936	679	691	pathogenesis	T046	C0699748
27593936	695	706	lung cancer	T191	C0684249
27593936	723	728	study	T062	C2603343
27593936	744	750	TFAP2C	T116,T123	C1529556
27593936	751	765	overexpression	T045	C1514559
27593936	770	785	associated with	T080	C0332281
27593936	786	807	cell cycle activation	T043	C0007613
27593936	812	817	NSCLC	T191	C0007131
27593936	818	822	cell	T025	C0007634
27593936	823	836	tumorigenesis	T191	C0596263
27593936	853	859	TFAP2C	T116,T123	C1529556
27593936	860	867	blocked	T169	C0332206
27593936	868	874	AKAP12	T116,T123	C1454561
27593936	885	894	cyclin D1	T116,T123	C0174680
27593936	895	905	inhibition	T052	C3463820
27593936	922	936	overexpression	T045	C0017262
27593936	940	958	oncogenic microRNA	T028	C2825314
27593936	959	970	(miRNA)-183	T028	C1537817
27593936	1000	1025	cyclin-dependent kinase 6	T116,T126	C0252132
27593936	1036	1058	cell cycle progression	T043	C1516334
27593936	1062	1076	downregulating	T044	C0013081
27593936	1095	1104	miRNA-33a	T114,T123	C1101610
27593936	1111	1132	mouse xenograft model	T050	C2986594
27593936	1134	1140	TFAP2C	T116,T123	C3712863
27593936	1150	1154	lung	T023	C0024109
27593936	1155	1168	tumorigenesis	T191	C0596263
27593936	1173	1195	disease aggressiveness	T191	C2945759
27593936	1204	1211	miR-183	T114,T123	C1101610
27593936	1216	1223	miR-33a	T114,T123	C1101610
27593936	1224	1232	pathways	T044	C0037080
27593936	1238	1243	study	T062	C2603343
27593936	1255	1264	mechanism	T044	C0678659
27593936	1268	1277	mitogenic	T038	C3537152
27593936	1282	1301	oncogenic signaling	T038	C3537152
27593936	1356	1362	TFAP2C	T116,T123	C1529556
27593936	1372	1398	cell cycle hyperactivation	T043	C0007613
27593936	1414	1418	lung	T023	C0024109
27593936	1419	1432	tumorigenesis	T191	C0596263

27732647|t|Are Eyes a Mirror of the Soul? What Eye Wrinkles Reveal about a Horse's Emotional State
27732647|a|Finding valid indicators of emotional states is one of the biggest challenges in animal welfare science. Here, we investigated in horses whether variation in the expression of eye wrinkles caused by contraction of the inner eyebrow raiser reflects emotional valence. By confronting horses with positive and negative conditions, we aimed to induce positive and negative emotional states, hypothesising that positive emotions would reduce whereas negative emotions would increase eye wrinkle expression. Sixteen horses were individually exposed in a balanced order to two positive (grooming, food anticipation) and two negative condition s (food competition, waving a plastic bag). Each condition lasted for 60 seconds and was preceded by a 60 second control phase. Throughout both phases, pictures of the eyes were taken, and for each horse four pictures per condition and phase were randomly selected. Pictures were scored in random order and by two experimenters blind to condition and phase for six outcome measures: qualitative impression, eyelid shape, markedness of the wrinkles, presence of eye white, number of wrinkles, and the angle between the line through the eyeball and the highest wrinkle. The angle decreased during grooming and increased during food competition compared to control phase s, whereas the two phases did not differ during food anticipation and the plastic bag condition. No effects on the other outcome measures were detected. Taken together, we have defined a set of measures to assess eye wrinkle expression reliably, of which one measure was affected by the conditions the horses were exposed to. Variation in eye wrinkle expression might provide valuable information on horse welfare but further validation of specific measures across different conditions is needed.
27732647	4	8	Eyes	T023	C0015392
27732647	11	17	Mirror	T070	C0870904
27732647	25	29	Soul	T078	C1510643
27732647	36	39	Eye	T023	C0015392
27732647	40	48	Wrinkles	T190	C2729169
27732647	49	55	Reveal	T080	C0443289
27732647	64	71	Horse's	T015	C0019944
27732647	72	87	Emotional State	T041	C0935620
27732647	96	101	valid	T080	C2349099
27732647	102	112	indicators	T169	C1522602
27732647	116	132	emotional states	T041	C0935620
27732647	169	191	animal welfare science	T052	C0003061
27732647	202	214	investigated	T169	C1292732
27732647	218	224	horses	T015	C0019944
27732647	233	242	variation	T080	C0205419
27732647	250	260	expression	T080	C0700364
27732647	264	267	eye	T023	C0015392
27732647	268	276	wrinkles	T190	C2729169
27732647	287	298	contraction	T046	C1140999
27732647	306	319	inner eyebrow	T023	C0015420
27732647	327	335	reflects	T041	C0558058
27732647	336	353	emotional valence	T033	C0849912
27732647	370	376	horses	T015	C0019944
27732647	382	390	positive	T033	C1446409
27732647	395	403	negative	T033	C0205160
27732647	404	414	conditions	T080	C0348080
27732647	428	434	induce	T169	C0205263
27732647	435	443	positive	T033	C1446409
27732647	448	456	negative	T033	C0205160
27732647	457	473	emotional states	T041	C0935620
27732647	475	488	hypothesising	T078	C1512571
27732647	494	502	positive	T033	C1446409
27732647	503	511	emotions	T041	C0013987
27732647	518	524	reduce	T080	C0392756
27732647	533	541	negative	T033	C0205160
27732647	542	550	emotions	T041	C0013987
27732647	557	565	increase	T169	C0442805
27732647	566	569	eye	T023	C0015392
27732647	570	577	wrinkle	T190	C2729169
27732647	578	588	expression	T080	C0700364
27732647	598	604	horses	T015	C0019944
27732647	623	630	exposed	T080	C0332157
27732647	636	644	balanced	T169	C0205415
27732647	658	666	positive	T033	C1446409
27732647	668	676	grooming	T055	C0018249
27732647	678	695	food anticipation	T041	C0679106
27732647	705	713	negative	T033	C0205160
27732647	714	723	condition	T080	C0348080
27732647	727	731	food	T168	C0016452
27732647	732	743	competition	T054	C0679932
27732647	745	751	waving	T052	C0441655
27732647	754	765	plastic bag	T073	C3273359
27732647	773	782	condition	T080	C0348080
27732647	797	804	seconds	T079	C0457385
27732647	830	836	second	T079	C0457385
27732647	837	850	control phase	T079	C0205390
27732647	868	874	phases	T079	C0205390
27732647	876	884	pictures	T073	C0441468
27732647	892	896	eyes	T023	C0015392
27732647	922	927	horse	T015	C0019944
27732647	933	941	pictures	T073	C0441468
27732647	946	955	condition	T080	C0348080
27732647	960	965	phase	T079	C0205390
27732647	971	988	randomly selected	T052	C1707391
27732647	990	998	Pictures	T073	C0441468
27732647	1014	1026	random order	T080	C1705176
27732647	1038	1051	experimenters	T097	C0870526
27732647	1052	1057	blind	T062	C0150108
27732647	1061	1070	condition	T080	C0348080
27732647	1075	1080	phase	T079	C0205390
27732647	1089	1105	outcome measures	T081	C0086749
27732647	1107	1118	qualitative	T080	C0205556
27732647	1119	1129	impression	T080	C1998467
27732647	1131	1137	eyelid	T023	C0015426
27732647	1138	1143	shape	T082	C0332479
27732647	1145	1155	markedness	T080	C1706089
27732647	1163	1171	wrinkles	T190	C2729169
27732647	1173	1181	presence	T033	C0150312
27732647	1185	1194	eye white	T023	C0036410
27732647	1196	1202	number	T081	C0237753
27732647	1206	1214	wrinkles	T190	C2729169
27732647	1224	1229	angle	T082	C0205143
27732647	1259	1266	eyeball	T023	C0015392
27732647	1275	1282	highest	T080	C1522410
27732647	1283	1290	wrinkle	T190	C2729169
27732647	1296	1301	angle	T082	C0205143
27732647	1302	1311	decreased	T081	C0205216
27732647	1319	1327	grooming	T055	C0018249
27732647	1332	1341	increased	T081	C0205217
27732647	1349	1353	food	T168	C0016452
27732647	1354	1365	competition	T054	C0679932
27732647	1366	1374	compared	T052	C1707455
27732647	1378	1391	control phase	T079	C0205390
27732647	1411	1417	phases	T079	C0205390
27732647	1440	1457	food anticipation	T041	C0679106
27732647	1466	1477	plastic bag	T073	C3273359
27732647	1478	1487	condition	T080	C0348080
27732647	1489	1499	No effects	T080	C1301751
27732647	1513	1529	outcome measures	T081	C0086749
27732647	1535	1543	detected	T033	C0442726
27732647	1586	1594	measures	T081	C0079809
27732647	1598	1604	assess	T052	C1516048
27732647	1605	1608	eye	T023	C0015392
27732647	1609	1616	wrinkle	T190	C2729169
27732647	1617	1627	expression	T080	C0700364
27732647	1651	1658	measure	T081	C0079809
27732647	1663	1671	affected	T169	C0392760
27732647	1679	1689	conditions	T080	C0348080
27732647	1694	1700	horses	T015	C0019944
27732647	1706	1716	exposed to	T080	C0332157
27732647	1718	1727	Variation	T080	C0205419
27732647	1731	1734	eye	T023	C0015392
27732647	1735	1742	wrinkle	T190	C2729169
27732647	1743	1753	expression	T080	C0700364
27732647	1760	1767	provide	T168	C0359589
27732647	1777	1788	information	T078	C1533716
27732647	1792	1797	horse	T015	C0019944
27732647	1798	1805	welfare	T052	C0003061
27732647	1818	1828	validation	T062	C1519941
27732647	1832	1840	specific	T080	C0205369
27732647	1841	1849	measures	T081	C0079809
27732647	1857	1866	different	T080	C1705242
27732647	1867	1877	conditions	T080	C0348080

28439925|t|Work-related psychosocial stress and the risk of type 2 diabetes in later life
28439925|a|Although work-related psychosocial stress and type 2 diabetes mellitus (T2DM) have been investigated, the association between lifelong work stress and T2DM in later life remains unclear. This study examined whether high work stress increased the risk of T2DM risk in later life, accounting also for other sources of stress outside work, such as burden from household chores. From the population -based prospective study SNAC-K, 2719 diabetes-free participants aged ≥60 years were identified and followed up for 6 years. T2DM was ascertained by glycated haemoglobin level, self-report, hypoglycaemic medication use and clinical records. Levels of job control and demands over the whole working life were assessed by a validated matrix. Household chores load was assessed by hours spent on such chores. Multivariate logistic regression models were used to estimate the association between job strain and T2DM. During the 6- year follow-up, 154 incident cases of T2DM were identified. High job strain was associated with T2DM occurrence amongst the 60- year - old cohort (OR = 3.14, 95% CI: 1.27-7.77), and only amongst women (OR = 6.18, 95% CI: 1.22-31.26), but not in men. When taking into account household chores load, a more pronounced risk of T2DM was associated with high job strain in combination with heavy household chores load in women aged 60 years at baseline (OR = 9.45, 95% CI: 1.17-76.53). Work-related psychosocial stress may increase the risk of T2DM only amongst women in their early 60s. The risk can be amplified by high household chores load.
28439925	0	12	Work-related	T033	C1698590
28439925	13	32	psychosocial stress	UnknownType	C0679118
28439925	41	45	risk	T078	C0035647
28439925	49	64	type 2 diabetes	T047	C0011860
28439925	68	73	later	T079	C0205087
28439925	74	78	life	T078	C0376558
28439925	88	100	work-related	T033	C1698590
28439925	101	120	psychosocial stress	UnknownType	C0679118
28439925	125	149	type 2 diabetes mellitus	T047	C0011860
28439925	151	155	T2DM	T047	C0011860
28439925	167	179	investigated	T169	C1292732
28439925	185	196	association	T080	C0439849
28439925	205	213	lifelong	T079	C4274169
28439925	214	225	work stress	T033	C0344330
28439925	230	234	T2DM	T047	C0011860
28439925	238	243	later	T079	C0205087
28439925	244	248	life	T078	C0376558
28439925	257	264	unclear	T033	C3845108
28439925	271	276	study	T062	C2603343
28439925	277	285	examined	T033	C0332128
28439925	294	298	high	T080	C0205250
28439925	299	310	work stress	T033	C0344330
28439925	311	320	increased	T081	C0205217
28439925	325	329	risk	T078	C0035647
28439925	333	337	T2DM	T047	C0011860
28439925	338	342	risk	T078	C0035647
28439925	346	351	later	T079	C0205087
28439925	352	356	life	T078	C0376558
28439925	384	391	sources	T033	C0449416
28439925	395	401	stress	T033	C0038435
28439925	410	414	work	T057	C0043227
28439925	424	430	burden	T078	C2828008
28439925	436	452	household chores	T056	C0001288
28439925	463	473	population	T098	C1257890
28439925	481	498	prospective study	T062	C2603343
28439925	499	505	SNAC-K	T062	C0023981
28439925	512	538	diabetes-free participants	T098	C0679646
28439925	539	543	aged	T032	C0001779
28439925	548	553	years	T079	C0439234
28439925	559	569	identified	T080	C0205396
28439925	574	585	followed up	T058	C1522577
28439925	592	597	years	T079	C0439234
28439925	599	603	T2DM	T047	C0011860
28439925	608	622	ascertained by	T080	C0521093
28439925	623	643	glycated haemoglobin	T116,T123	C0017853
28439925	644	649	level	T080	C0441889
28439925	651	662	self-report	T062	C2700446
28439925	664	688	hypoglycaemic medication	T121	C0020616
28439925	689	692	use	T169	C0457083
28439925	697	713	clinical records	T170	C1299495
28439925	715	721	Levels	T080	C0441889
28439925	725	736	job control	T033	C0243095
28439925	741	748	demands	T033	C4062503
28439925	764	771	working	T057	C0043227
28439925	772	776	life	T078	C0376558
28439925	782	790	assessed	T052	C1516048
28439925	796	812	validated matrix	T062,T170	C0681836
28439925	814	830	Household chores	T056	C0001288
28439925	831	835	load	T081	C0085122
28439925	840	848	assessed	T052	C1516048
28439925	852	857	hours	T079	C0439227
28439925	872	878	chores	T056	C0026606
28439925	880	919	Multivariate logistic regression models	T081,T170	C0023965
28439925	933	941	estimate	T081	C0750572
28439925	946	957	association	T080	C0439849
28439925	966	976	job strain	T184	C2985217
28439925	981	985	T2DM	T047	C0011860
28439925	1001	1005	year	T079	C0439234
28439925	1006	1015	follow-up	T058	C1522577
28439925	1021	1029	incident	T067	C1551358
28439925	1030	1035	cases	T169	C0868928
28439925	1039	1043	T2DM	T047	C0011860
28439925	1049	1059	identified	T080	C0205396
28439925	1061	1065	High	T080	C0205250
28439925	1066	1076	job strain	T184	C2985217
28439925	1081	1096	associated with	T080	C0332281
28439925	1097	1101	T2DM	T047	C0011860
28439925	1102	1112	occurrence	T079	C2745955
28439925	1129	1133	year	T079	C0439234
28439925	1136	1146	old cohort	T098	C0599755
28439925	1148	1150	OR	T081	C0028873
28439925	1163	1165	CI	T081	C0009667
28439925	1196	1201	women	T098	C0043210
28439925	1203	1205	OR	T081	C0028873
28439925	1218	1220	CI	T081	C0009667
28439925	1246	1249	men	T098	C0025266
28439925	1276	1292	household chores	T056	C0001288
28439925	1293	1297	load	T081	C0085122
28439925	1317	1321	risk	T078	C0035647
28439925	1325	1329	T2DM	T047	C0011860
28439925	1334	1349	associated with	T080	C0332281
28439925	1350	1354	high	T080	C0205250
28439925	1355	1365	job strain	T184	C2985217
28439925	1369	1380	combination	T080	C0205195
28439925	1392	1408	household chores	T056	C0001288
28439925	1409	1413	load	T081	C0085122
28439925	1417	1422	women	T098	C0043210
28439925	1431	1436	years	T079	C0439234
28439925	1440	1448	baseline	T081	C1442488
28439925	1450	1452	OR	T081	C0028873
28439925	1465	1467	CI	T081	C0009667
28439925	1482	1494	Work-related	T033	C1698590
28439925	1495	1514	psychosocial stress	UnknownType	C0679118
28439925	1519	1527	increase	T169	C0442805
28439925	1532	1536	risk	T078	C0035647
28439925	1540	1544	T2DM	T047	C0011860
28439925	1558	1563	women	T098	C0043210
28439925	1588	1592	risk	T078	C0035647
28439925	1600	1609	amplified	T169	C0442805
28439925	1613	1617	high	T080	C0205250
28439925	1618	1634	household chores	T056	C0001288
28439925	1635	1639	load	T081	C0085122

28249118|t|Antenatal Determinants of Bronchopulmonary Dysplasia and Late Respiratory Disease in Preterm Infants
28249118|a|Rationale/Objectives: To identify antenatal risk factors associated with increased risk for BPD and respiratory disease during early childhood after preterm birth, we performed a prospective, longitudinal study of 587 preterm infants with gestational age <34 weeks and birth weights between 500-1250 grams. Data included perinatal information and assessments during the NICU admission and longitudinal follow-up by questionnaire until 2 years of age. After adjusting for covariates, maternal smoking prior to preterm birth increased the odds of having an infant with BPD by 2-fold(p=0.02). Maternal smoking was associated with prolonged mechanical ventilation and respiratory support during the NICU admission. Pre-existing hypertension was associated with a 2-fold(p=0.04) increase in odds for BPD. Lower gestational age and birth weight z-scores were associated with BPD. Preterm infants who were exposed to maternal smoking had higher rates of late respiratory disease during childhood. 22% of infants diagnosed with BPD and 34% of preterm infants without BPD had no clinical signs of late respiratory disease during early childhood. We conclude that maternal smoking and hypertension increase the odds for developing BPD after preterm birth, and that maternal smoking is strongly associated with increased odds for late respiratory morbidities during early childhood. These findings suggest that in addition to the BPD diagnosis at 36 weeks, other factors modulate late respiratory outcomes during childhood. We speculate that measures to reduce maternal smoking will not only lower the risk for preterm birth but also will improve late respiratory morbidities after preterm birth.
28249118	0	9	Antenatal	T079	C2828394
28249118	10	22	Determinants	T169	C1521761
28249118	26	52	Bronchopulmonary Dysplasia	T047	C0006287
28249118	57	81	Late Respiratory Disease	T047	C0035204
28249118	85	100	Preterm Infants	T100	C4048294
28249118	101	121	Rationale/Objectives	T170	C0018017
28249118	135	144	antenatal	T079	C2828394
28249118	145	157	risk factors	T033	C0035648
28249118	158	173	associated with	T080	C0332281
28249118	174	188	increased risk	T033	C0332167
28249118	193	196	BPD	T047	C0006287
28249118	201	220	respiratory disease	T047	C0035204
28249118	228	243	early childhood	T079	C0599196
28249118	250	263	preterm birth	T033	C0151526
28249118	268	277	performed	T169	C0884358
28249118	280	291	prospective	T062	C0033522
28249118	293	311	longitudinal study	T062	C0023981
28249118	319	334	preterm infants	T100	C4048294
28249118	340	355	gestational age	T032	C0017504
28249118	370	383	birth weights	T032	C0005612
28249118	408	412	Data	T078	C1511726
28249118	422	431	perinatal	T079	C0178795
28249118	432	443	information	T078	C1533716
28249118	448	459	assessments	T058	C1261322
28249118	471	485	NICU admission	T058	C2148604
28249118	490	512	longitudinal follow-up	T062	C0023981
28249118	516	529	questionnaire	T170	C0034394
28249118	572	582	covariates	T081	C1705098
28249118	584	600	maternal smoking	T033	C4062861
28249118	601	606	prior	T079	C0332152
28249118	610	623	preterm birth	T033	C0151526
28249118	624	633	increased	T169	C0442805
28249118	638	642	odds	T081	C0392762
28249118	656	662	infant	T100	C0021270
28249118	668	671	BPD	T047	C0006287
28249118	691	707	Maternal smoking	T033	C4062861
28249118	712	727	associated with	T080	C0332281
28249118	728	737	prolonged	T079	C0439590
28249118	738	760	mechanical ventilation	T061	C0199470
28249118	765	784	respiratory support	T074	C0221802
28249118	796	810	NICU admission	T058	C2148604
28249118	812	837	Pre-existing hypertension	T033	C2114056
28249118	842	857	associated with	T080	C0332281
28249118	875	883	increase	T169	C0442805
28249118	887	891	odds	T081	C0392762
28249118	896	899	BPD	T047	C0006287
28249118	907	922	gestational age	T032	C0017504
28249118	927	939	birth weight	T032	C0005612
28249118	940	948	z-scores	T081	C0871421
28249118	954	969	associated with	T080	C0332281
28249118	970	973	BPD	T047	C0006287
28249118	975	990	Preterm infants	T100	C4048294
28249118	1000	1010	exposed to	T080	C0332157
28249118	1011	1027	maternal smoking	T033	C4062861
28249118	1032	1038	higher	T080	C0205250
28249118	1039	1044	rates	T081	C1521828
28249118	1048	1072	late respiratory disease	T047	C0035204
28249118	1080	1089	childhood	T079	C0231335
28249118	1098	1105	infants	T100	C0021270
28249118	1106	1115	diagnosed	T033	C0011900
28249118	1121	1124	BPD	T047	C0006287
28249118	1136	1151	preterm infants	T100	C4048294
28249118	1160	1163	BPD	T047	C0006287
28249118	1171	1185	clinical signs	T033	C3540840
28249118	1189	1213	late respiratory disease	T047	C0035204
28249118	1221	1236	early childhood	T079	C0599196
28249118	1255	1271	maternal smoking	T033	C4062861
28249118	1276	1288	hypertension	T047	C0020538
28249118	1289	1297	increase	T169	C0442805
28249118	1302	1306	odds	T081	C0392762
28249118	1322	1325	BPD	T047	C0006287
28249118	1332	1345	preterm birth	T033	C0151526
28249118	1356	1372	maternal smoking	T033	C4062861
28249118	1385	1400	associated with	T080	C0332281
28249118	1401	1410	increased	T169	C0442805
28249118	1411	1415	odds	T081	C0392762
28249118	1420	1448	late respiratory morbidities	T047	C1301752
28249118	1456	1471	early childhood	T079	C0599196
28249118	1501	1515	in addition to	T169	C0332287
28249118	1520	1523	BPD	T047	C0006287
28249118	1524	1533	diagnosis	T033	C0011900
28249118	1553	1560	factors	T169	C1521761
28249118	1561	1569	modulate	T082	C0443264
28249118	1570	1595	late respiratory outcomes	T047	C0035204
28249118	1603	1612	childhood	T079	C0231335
28249118	1632	1640	measures	T169	C1879489
28249118	1644	1650	reduce	T080	C0392756
28249118	1651	1667	maternal smoking	T033	C4062861
28249118	1682	1687	lower	T052	C2003888
28249118	1692	1696	risk	T078	C0035647
28249118	1701	1714	preterm birth	T033	C0151526
28249118	1729	1736	improve	T033	C0184511
28249118	1737	1765	late respiratory morbidities	T047	C1301752
28249118	1772	1785	preterm birth	T033	C0151526

28432743|t|Global and local visual processing in autism: An objective assessment approach
28432743|a|We examined global and local visual processing in autism spectrum disorder (ASD) via a match-to-sample task using Kanizsa illusory contours (KIC). School-aged children with ASD (n = 28) and age-matched typically developing controls (n = 22; 7-13 years) performed a sequential match-to-sample between a solid shape (sample) and two illusory alternatives. We tracked eye gaze and behavioral performance in two task conditions: one with and one without local interference from background noise elements. While analyses revealed lower accuracy and longer reaction time in ASD in the condition with local interference only, eye tracking robustly captured ASD -related global atypicalities across both conditions. Specifically, relative to controls, children with ASD showed decreased fixations to KIC centers, indicating reduced global perception. Notably, they did not differ from controls in regard to fixations to local elements or touch response location. These results indicate impaired global perception in the absence of heightened local processing in ASD. They also underscore the utility of eye-tracking measures as objective indices of global / local visual processing strategies in ASD. Autism Res 2017. © 2017 International Society for Autism Research, Wiley Periodicals, Inc.
28432743	0	6	Global	T080	C2348867
28432743	11	16	local	T082	C0205276
28432743	17	34	visual processing	T041	C0589087
28432743	38	44	autism	T048	C0004352
28432743	49	69	objective assessment	T080	C1571702
28432743	70	78	approach	T082	C0449445
28432743	82	90	examined	T033	C0332128
28432743	91	97	global	T080	C2348867
28432743	102	107	local	T082	C0205276
28432743	108	125	visual processing	T041	C0589087
28432743	129	153	autism spectrum disorder	T048	C1510586
28432743	155	158	ASD	T048	C1510586
28432743	166	186	match-to-sample task	T057	C3540678
28432743	193	218	Kanizsa illusory contours	T041	C0016563
28432743	220	223	KIC	T041	C0016563
28432743	226	246	School-aged children	T100	C0260267
28432743	252	255	ASD	T048	C1510586
28432743	269	280	age-matched	T080	C1708943
28432743	302	310	controls	T096	C0009932
28432743	325	330	years	T079	C0439234
28432743	332	341	performed	T169	C0884358
28432743	381	392	solid shape	T082	C0332479
28432743	394	400	sample	T167	C0370003
28432743	410	431	illusory alternatives	T033	C4023083
28432743	436	443	tracked	T039	C0597666
28432743	444	452	eye gaze	T033	C0553544
28432743	457	467	behavioral	T053	C0004927
28432743	468	479	performance	T055	C0597198
28432743	487	491	task	T057	C3540678
28432743	492	502	conditions	T080	C0348080
28432743	529	534	local	T082	C0205276
28432743	529	547	local interference	T041	C0679066
28432743	564	569	noise	T067	C0028263
28432743	570	578	elements	T077	C1705248
28432743	586	594	analyses	T062	C0936012
28432743	595	603	revealed	T080	C0443289
28432743	604	609	lower	T080	C0205251
28432743	610	618	accuracy	T080	C0443131
28432743	623	629	longer	T080	C0205166
28432743	630	643	reaction time	T079	C0034746
28432743	647	650	ASD	T048	C1510586
28432743	658	667	condition	T080	C0348080
28432743	673	678	local	T082	C0205276
28432743	673	691	local interference	T041	C0679066
28432743	698	710	eye tracking	T039	C0597666
28432743	729	732	ASD	T048	C1510586
28432743	742	748	global	T080	C2348867
28432743	749	762	atypicalities	T033	C0205161
28432743	775	785	conditions	T080	C0348080
28432743	813	821	controls	T096	C0009932
28432743	823	831	children	T100	C0008059
28432743	837	840	ASD	T048	C1510586
28432743	848	857	decreased	T081	C0205216
28432743	858	867	fixations	T041	C0728733
28432743	871	882	KIC centers	T073,T092	C0683939
28432743	895	902	reduced	T080	C0392756
28432743	903	909	global	T080	C2348867
28432743	910	920	perception	T041	C0030971
28432743	940	950	not differ	T033	C3842396
28432743	956	964	controls	T096	C0009932
28432743	978	987	fixations	T041	C0728733
28432743	991	996	local	T082	C0205276
28432743	991	1005	local elements	T077	C1705248
28432743	1009	1023	touch response	T042	C0702221
28432743	1024	1032	location	T029	C1515974
28432743	1040	1047	results	T169	C1274040
28432743	1057	1065	impaired	T169	C0221099
28432743	1066	1072	global	T080	C2348867
28432743	1073	1083	perception	T041	C0030971
28432743	1102	1112	heightened	T080	C0442803
28432743	1113	1118	local	T082	C0205276
28432743	1119	1129	processing	T052	C1709694
28432743	1133	1136	ASD	T048	C1510586
28432743	1148	1158	underscore	T081	C0449820
28432743	1163	1170	utility	T169	C0457083
28432743	1174	1186	eye-tracking	T039	C0597666
28432743	1187	1195	measures	T081	C0079809
28432743	1199	1216	objective indices	T170	C0918012
28432743	1220	1226	global	T080	C2348867
28432743	1229	1234	local	T082	C0205276
28432743	1235	1263	visual processing strategies	T041	C0589087
28432743	1267	1270	ASD	T048	C1510586

28545217|t|A miniature bird -borne passive air sampler for monitoring halogenated flame retardants
28545217|a|Birds have been used intensively as biomonitors of halogenated flame retardants (HFRs), and several studies have reported elevated tissue concentrations and inter- individual variability for these contaminants. While diet is known to be an important exposure pathway for HFRs in birds, it has been suggested that exposure through air may represent an underestimated source of HFRs for certain species. However, a method was not available for measuring the atmospheric exposure of individual birds to HFRs or other semi-volatile contaminants. The goal of this study was to develop a bird -borne passive air sampler (PAS) enabling the determination of individual atmospheric exposure to gas - and particle-phase HFRs using the ring-billed gull (Larus delawarensis) nesting in the Montreal area (QC, Canada). The new miniaturized elliptical-shaped PAS (mean weight: 2.72g) was tested using two sorbent types during three exposure periods (one, two and three weeks). Results showed that PAS using polyurethane foam (PUF) combined with a glass fiber filter collected all major polybrominated diphenyl ethers (PBDEs) and exhibited better performance for collecting highly hydrophobic DecaBDE mixture congeners compared to the PAS using polydimethylsiloxane (PDMS). Emerging HFRs including hexabromobenzene, Dechlorane 604 Component B, and Dechlorane plus (DP) isomers also were sampled by the PUF -based PAS. Sampling rates for most HFRs were comparable between the three exposure periods. This novel bird -borne PAS provides valuable information on the non-dietary exposure of free-ranging birds to HFRs.
28545217	12	16	bird	T012	C0005595
28545217	24	43	passive air sampler	T074	C0178984
28545217	48	58	monitoring	T058	C1283169
28545217	59	87	halogenated flame retardants	T120	C0016198
28545217	88	93	Birds	T012	C0005595
28545217	124	135	biomonitors	T074	C0025080
28545217	139	167	halogenated flame retardants	T120	C0016198
28545217	169	173	HFRs	T120	C0016198
28545217	188	195	studies	T062	C2603343
28545217	219	225	tissue	T024	C0040300
28545217	226	240	concentrations	T081	C1446561
28545217	252	262	individual	T098	C0237401
28545217	263	274	variability	T077	C2827666
28545217	285	297	contaminants	T167	C2827365
28545217	305	309	diet	T168	C0012155
28545217	338	346	exposure	T080	C0332157
28545217	347	354	pathway	T077	C1705987
28545217	359	363	HFRs	T120	C0016198
28545217	367	372	birds	T012	C0005595
28545217	386	395	suggested	T078	C1705535
28545217	401	409	exposure	T080	C0332157
28545217	418	421	air	T167	C0001861
28545217	426	435	represent	T052	C1882932
28545217	454	460	source	T033	C0449416
28545217	464	468	HFRs	T120	C0016198
28545217	481	488	species	T185	C1705920
28545217	501	507	method	T170	C0025663
28545217	512	525	not available	T080	C0686905
28545217	530	539	measuring	T080	C0444706
28545217	544	555	atmospheric	T070	C0004178
28545217	556	564	exposure	T080	C0332157
28545217	568	578	individual	T098	C0237401
28545217	579	584	birds	T012	C0005595
28545217	588	592	HFRs	T120	C0016198
28545217	602	615	semi-volatile	T080	C1963547
28545217	616	628	contaminants	T167	C2827365
28545217	634	638	goal	T170	C0018017
28545217	647	652	study	T062	C2603343
28545217	670	674	bird	T012	C0005595
28545217	682	701	passive air sampler	T074	C0178984
28545217	703	706	PAS	T074	C0178984
28545217	721	734	determination	T059	C1148554
28545217	738	748	individual	T098	C0237401
28545217	749	760	atmospheric	T070	C0004178
28545217	761	769	exposure	T080	C0332157
28545217	773	776	gas	T104	C0017110
28545217	783	797	particle-phase	T104	C0597177
28545217	798	802	HFRs	T120	C0016198
28545217	813	829	ring-billed gull	T012	C1061035
28545217	831	849	Larus delawarensis	T012	C1061035
28545217	851	858	nesting	T053	C0870949
28545217	866	879	Montreal area	UnknownType	C0681784
28545217	881	883	QC	T083	C0034390
28545217	885	891	Canada	T083	C0006823
28545217	915	932	elliptical-shaped	T082	C1947977
28545217	933	936	PAS	T074	C0178984
28545217	938	949	mean weight	T081	C0043100
28545217	962	968	tested	T169	C0039593
28545217	975	992	two sorbent types	T059	C0022885
28545217	1006	1022	exposure periods	T079	C2826764
28545217	1051	1058	Results	T169	C1274040
28545217	1071	1074	PAS	T074	C0178984
28545217	1081	1098	polyurethane foam	T109	C0071696
28545217	1100	1103	PUF	T109	C0071696
28545217	1121	1132	glass fiber	T122,T131	C0060317
28545217	1133	1149	filter collected	UnknownType	C0545227
28545217	1160	1190	polybrominated diphenyl ethers	T109,T131	C2350562
28545217	1192	1197	PBDEs	T109,T131	C2350562
28545217	1213	1231	better performance	T052	C1882330
28545217	1236	1246	collecting	T169	C1516698
28545217	1247	1265	highly hydrophobic	T080	C0598629
28545217	1266	1273	DecaBDE	T109,T131	C2350562
28545217	1274	1281	mixture	T167	C0439962
28545217	1282	1291	congeners	T104	C0678518
28545217	1292	1303	compared to	T052	C1707455
28545217	1308	1311	PAS	T074	C0178984
28545217	1318	1338	polydimethylsiloxane	T109,T122	C0137758
28545217	1340	1344	PDMS	T109,T122	C0137758
28545217	1356	1360	HFRs	T120	C0016198
28545217	1371	1387	hexabromobenzene	T109	C0062598
28545217	1389	1415	Dechlorane 604 Component B	T109	C3180256
28545217	1421	1436	Dechlorane plus	T109	C2351195
28545217	1438	1440	DP	T109	C2351195
28545217	1442	1449	isomers	T070	C0022203
28545217	1460	1467	sampled	T060	C0441621
28545217	1475	1478	PUF	T109	C0071696
28545217	1486	1489	PAS	T074	C0178984
28545217	1491	1499	Sampling	T060	C0441621
28545217	1500	1505	rates	T081	C1521828
28545217	1515	1519	HFRs	T120	C0016198
28545217	1525	1535	comparable	T052	C1707455
28545217	1554	1570	exposure periods	T079	C2826764
28545217	1583	1587	bird	T012	C0005595
28545217	1595	1598	PAS	T074	C0178984
28545217	1608	1628	valuable information	T078	C1533716
28545217	1636	1656	non-dietary exposure	T080	C0332157
28545217	1660	1672	free-ranging	T033	C3845292
28545217	1673	1678	birds	T012	C0005595
28545217	1682	1686	HFRs	T120	C0016198

27977762|t|Pupil Sizes Scale with Attentional Load and Task Experience in a Multiple Object Tracking Task
27977762|a|Previous studies have related changes in attentional load to pupil size modulations. However, studies relating changes in attentional load and task experience on a finer scale to pupil size modulations are scarce. Here, we investigated how these changes affect pupil sizes. To manipulate attentional load, participants covertly tracked between zero and five objects among several randomly moving objects on a computer screen. To investigate effects of task experience, the experiment was conducted on three consecutive days. We found that pupil sizes increased with each increment in attentional load. Across days, we found systematic pupil size reductions. We compared the model fit for predicting pupil size modulations using attentional load, task experience, and task performance as predictors. We found that a model which included attentional load and task experience as predictors had the best model fit while adding performance as a predictor to this model reduced the overall model fit. Overall, results suggest that pupillometry provides a viable metric for precisely assessing attentional load and task experience in visuospatial tasks.
27977762	0	11	Pupil Sizes	T201	C0517965
27977762	12	17	Scale	T170	C0349674
27977762	23	39	Attentional Load	T170	C0589051
27977762	44	48	Task	T057	C3540678
27977762	49	59	Experience	T041	C0596545
27977762	65	73	Multiple	T081	C0439064
27977762	74	80	Object	T072	C0347997
27977762	81	89	Tracking	T082	C0546881
27977762	90	94	Task	T057	C3540678
27977762	125	132	changes	T169	C0392747
27977762	136	152	attentional load	T170	C0589051
27977762	156	166	pupil size	T201	C0517965
27977762	167	178	modulations	T082	C0443264
27977762	206	213	changes	T169	C0392747
27977762	217	233	attentional load	T170	C0589051
27977762	238	242	task	T057	C3540678
27977762	243	253	experience	T041	C0596545
27977762	265	270	scale	T170	C0349674
27977762	274	284	pupil size	T201	C0517965
27977762	285	296	modulations	T082	C0443264
27977762	318	330	investigated	T169	C1292732
27977762	341	348	changes	T169	C0392747
27977762	349	355	affect	T041	C0001721
27977762	356	367	pupil sizes	T201	C0517965
27977762	372	382	manipulate	T053	C0018578
27977762	383	399	attentional load	T170	C0589051
27977762	401	413	participants	T098	C0679646
27977762	423	430	tracked	T082	C0546881
27977762	439	443	zero	T081	C0919414
27977762	448	452	five	T081	C0205451
27977762	453	460	objects	T072	C0347997
27977762	475	483	randomly	T080	C0439605
27977762	491	498	objects	T072	C0347997
27977762	504	512	computer	T073	C0009622
27977762	513	519	screen	T073	C1705053
27977762	524	535	investigate	T169	C1292732
27977762	536	546	effects of	T080	C1704420
27977762	547	551	task	T057	C3540678
27977762	552	562	experience	T041	C0596545
27977762	596	601	three	T081	C0205449
27977762	602	613	consecutive	T080	C1707491
27977762	614	618	days	T079	C0439228
27977762	634	645	pupil sizes	T201	C0517965
27977762	666	675	increment	T081	C1705117
27977762	679	695	attentional load	T170	C0589051
27977762	704	708	days	T079	C0439228
27977762	719	729	systematic	T169	C0220922
27977762	730	740	pupil size	T201	C0517965
27977762	741	751	reductions	T080	C0392756
27977762	769	778	model fit	T080	C0870608
27977762	794	804	pupil size	T201	C0517965
27977762	805	816	modulations	T082	C0443264
27977762	823	839	attentional load	T170	C0589051
27977762	841	845	task	T057	C3540678
27977762	846	856	experience	T041	C0596545
27977762	862	878	task performance	T061	C0039333
27977762	882	892	predictors	T078	C2698872
27977762	910	915	model	T170	C3161035
27977762	931	947	attentional load	T170	C0589051
27977762	952	956	task	T057	C3540678
27977762	957	967	experience	T041	C0596545
27977762	971	981	predictors	T078	C2698872
27977762	995	1004	model fit	T080	C0870608
27977762	1018	1029	performance	T061	C0039333
27977762	1035	1044	predictor	T078	C2698872
27977762	1053	1058	model	T170	C3161035
27977762	1079	1088	model fit	T080	C0870608
27977762	1099	1106	results	T169	C1274040
27977762	1120	1132	pupillometry	T060	C0260180
27977762	1144	1150	viable	T080	C0443348
27977762	1151	1157	metric	T081	C0025867
27977762	1182	1198	attentional load	T170	C0589051
27977762	1203	1207	task	T057	C3540678
27977762	1208	1218	experience	T041	C0596545
27977762	1222	1234	visuospatial	T041	C0814069
27977762	1235	1240	tasks	T057	C3540678

28140366|t|Low-dose dynamic myocardial perfusion CT image reconstruction using pre-contrast normal-dose CT scan induced structure tensor total variation regularization
28140366|a|Dynamic myocardial perfusion CT (DMP-CT) imaging provides quantitative functional information for diagnosis and risk stratification of coronary artery disease by calculating myocardial perfusion hemodynamic parameter (MPHP) maps. However, the level of radiation delivered by dynamic sequential scan protocol can be potentially high. The purpose of this work is to develop a pre-contrast normal-dose scan induced structure tensor total variation regularization based on the penalized weighted least-squares (PWLS) criteria to improve the image quality of DMP-CT with a low-mAs CT acquisition. For simplicity, the present approach was termed as ' PWLS-ndiSTV '. Specifically, the ndiSTV regularization takes into account the spatial-temporal structure information of DMP-CT data and further exploits the higher order derivatives of the objective images to enhance denoising performance. Subsequently, an effective optimization algorithm based on the split-Bregman approach was adopted to minimize the associative objective function. Evaluations with modified dynamic XCAT phantom and preclinical porcine datasets have demonstrated that the proposed PWLS-ndiSTV approach can achieve promising gains over other existing approaches in terms of noise-induced artifacts mitigation, edge details preservation, and accurate MPHP maps calculation.
28140366	0	46	Low-dose dynamic myocardial perfusion CT image	T060	C1518002
28140366	47	61	reconstruction	T066	C0020912
28140366	68	100	pre-contrast normal-dose CT scan	T060	C0040405
28140366	109	156	structure tensor total variation regularization	T060	C0430022
28140366	157	188	Dynamic myocardial perfusion CT	T060	C2350390
28140366	190	196	DMP-CT	T060	C2350390
28140366	255	264	diagnosis	T033	C0011900
28140366	269	288	risk stratification	T062	C1514983
28140366	292	315	coronary artery disease	T047	C0010054
28140366	331	373	myocardial perfusion hemodynamic parameter	T061	C0204901
28140366	375	379	MPHP	T061	C0204901
28140366	400	428	level of radiation delivered	T081	C1299361
28140366	432	464	dynamic sequential scan protocol	T060	C0430022
28140366	472	488	potentially high	T080	C0205556
28140366	531	616	pre-contrast normal-dose scan induced structure tensor total variation regularization	T170	C3161035
28140366	630	662	penalized weighted least-squares	T081	C0023189
28140366	664	668	PWLS	T081	C0023189
28140366	694	707	image quality	T080	C0806487
28140366	711	717	DMP-CT	T060	C2350390
28140366	725	747	low-mAs CT acquisition	T060	C0040405
28140366	802	813	PWLS-ndiSTV	T170	C3161035
28140366	835	856	ndiSTV regularization	T170	C3161035
28140366	880	918	spatial-temporal structure information	T062	C3494293
28140366	922	928	DMP-CT	T060	C2350390
28140366	929	933	data	T078	C1511726
28140366	1019	1040	denoising performance	T080	C0205556
28140366	1069	1091	optimization algorithm	T170	C0002045
28140366	1105	1127	split-Bregman approach	T170	C0178476
28140366	1214	1234	dynamic XCAT phantom	T073	C0282611
28140366	1239	1267	preclinical porcine datasets	T170	C0150098
28140366	1304	1315	PWLS-ndiSTV	T170	C3161035
28140366	1396	1419	noise-induced artifacts	T068	C0085089
28140366	1420	1430	mitigation	T078	C1706602
28140366	1432	1457	edge details preservation	T169	C0205245
28140366	1472	1481	MPHP maps	T061	C0204901

28386881|t|Object substitution masking and its relationship with visual crowding
28386881|a|Object substitution masking (OSM) occurs when the perceptibility of a brief target is reduced by a trailing surround mask typically composed of four dots. Camp et al. (Journal of Experimental Psychology: Human Perception and Performance, 41, 940-957, 2015) found that crowding a target by adding adjacent flankers, in addition to OSM, had a more deleterious effect on performance than expected based on the combined individual effects of crowding and masking alone. The current experiments test why OSM and crowding interact in this way. In three experiments, target -flanker distance is manipulated whilst also varying mask duration in a digit identification task. The OSM effect-as indexed by the performance difference between unmasked and masked conditions -had a quadratic function with respect to target -flanker distance. Results suggest it is OSM affecting crowding rather than the converse: Masking seems to amplify crowding at intermediate target -distractor distances at the edge of the crowding interference zone. These results indicate that OSM and crowding share common mechanisms. The effect of OSM is possibly a consequence of changes to the types of feature detectors which are pooled together for target identification when that target must compete for processing with a trailing mask in addition to competition from adjacent flankers.
28386881	0	27	Object substitution masking	T041	C0871585
28386881	36	48	relationship	T080	C0439849
28386881	54	69	visual crowding	T041	C0042830
28386881	70	97	Object substitution masking	T041	C0871585
28386881	99	102	OSM	T041	C0871585
28386881	120	134	perceptibility	T041	C0042830
28386881	146	152	target	T042	C0597664
28386881	169	177	trailing	T048	C0233782
28386881	187	191	mask	T042	C0597664
28386881	214	223	four dots	T073	C3273359
28386881	238	325	Journal of Experimental Psychology: Human Perception and Performance, 41, 940-957, 2015	T073,T170	C0162443
28386881	338	346	crowding	T041	C0042830
28386881	349	355	target	T042	C0597664
28386881	366	374	adjacent	T082	C0205117
28386881	375	383	flankers	T073	C3273359
28386881	400	403	OSM	T041	C0871585
28386881	416	434	deleterious effect	T046	C0879626
28386881	438	449	performance	T055	C0597198
28386881	477	485	combined	T080	C0205195
28386881	486	496	individual	UnknownType	C0815195
28386881	497	504	effects	T080	C1280500
28386881	508	516	crowding	T041	C0042830
28386881	521	528	masking	T041	C0871585
28386881	548	559	experiments	T062	C0681814
28386881	569	572	OSM	T041	C0871585
28386881	577	585	crowding	T041	C0042830
28386881	586	594	interact	T052	C1881786
28386881	617	628	experiments	T062	C0681814
28386881	630	636	target	T042	C0597664
28386881	630	654	target -flanker distance	T081	C0012751
28386881	690	694	mask	T041	C0871585
28386881	695	703	duration	T079	C0449238
28386881	709	734	digit identification task	T057	C3540678
28386881	740	743	OSM	T041	C0871585
28386881	769	780	performance	T055	C0597198
28386881	781	791	difference	T080	C1705242
28386881	800	808	unmasked	T169	C0439845
28386881	813	830	masked conditions	T169	C0439844
28386881	838	856	quadratic function	T081	C2347976
28386881	873	879	target	T042	C0597664
28386881	921	924	OSM	T041	C0871585
28386881	935	943	crowding	T041	C0042830
28386881	970	977	Masking	T041	C0871585
28386881	987	994	amplify	T169	C0442805
28386881	995	1003	crowding	T041	C0042830
28386881	1020	1026	target	T042	C0597664
28386881	1020	1048	target -distractor distances	T081	C0012751
28386881	1068	1076	crowding	T041	C0042830
28386881	1077	1094	interference zone	T033	C0422966
28386881	1124	1127	OSM	T041	C0871585
28386881	1132	1140	crowding	T041	C0042830
28386881	1154	1164	mechanisms	T169	C0441712
28386881	1170	1176	effect	T080	C1280500
28386881	1180	1183	OSM	T041	C0871585
28386881	1198	1212	consequence of	T169	C0686907
28386881	1237	1254	feature detectors	T073	C0180392
28386881	1265	1280	pooled together	T169	C2349200
28386881	1285	1291	target	T042	C0597664
28386881	1292	1306	identification	T041	C0020792
28386881	1317	1323	target	T042	C0597664
28386881	1359	1367	trailing	T048	C0233782
28386881	1368	1372	mask	T042	C0597664
28386881	1405	1413	adjacent	T082	C0205117
28386881	1414	1422	flankers	T073	C3273359

28032216|t|Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT)
28032216|a|Despite a lower risk of nausea and vomiting in patients receiving radiotherapy to the upper abdomen (UA-RINV) with prophylactic 5-HT3 antagonist therapy, patients can still experience UA-RINV. The aim of this multicenter phase II study was to assess effectiveness, safety, and tolerability of protracted dual NK1-receptor and 5-HT3 antagonist prophylaxis against UA-RINV. Patients receiving fractionated radiotherapy with radiosensitizing chemotherapy received oral ondansetron 8 mg po q12 h and aprepitant 125/80/80 mg on a Monday, Wednesday, Friday schedules throughout radiotherapy. The primary outcome was complete response (CR) defined as no vomiting or rescue therapy during the entire observation period of radiotherapy (OP). Nausea, vomiting, and use of rescue medication were recorded in a modified version of the MASCC antiemesis tool completed twice weekly. Fifty-five patients were enrolled at 5 sites, 52 of whom were evaluable. 57.7% of patients (30/52, 95% CI 43.2-71.3%) achieved CR on study, with 73.1% (38/52, 95% CI 59.0-84.4%) who did not vomit, and 71.2% (37/52, 95% CI 56.9-82.9%) who did not use rescue medication during the OP. Overall, participants vomited or experienced significant nausea (SN) for an average of 6.8% (95% CI 11.4-21.0) and 8.4% (95% CI 4.2-12.7%) of time on study, respectively. Nausea was common with 32 (61.5%) reporting SN at any time during the OP. UA-RINV remains an important morbidity despite the advent of modern radiotherapy. Aprepitant and ondansetron as dosed in this trial was not superior to standard ondansetron monotherapy.
28032216	0	13	Effectiveness	T080	C1280519
28032216	17	27	aprepitant	T109,T121	C1176306
28032216	28	42	in addition to	T169	C0332287
28032216	43	54	ondansetron	T109,T121	C0061851
28032216	62	72	prevention	T080	C2700409
28032216	76	82	nausea	T184	C0027497
28032216	87	95	vomiting	T184	C0042963
28032216	106	152	fractionated radiotherapy to the upper abdomen	T061	C1997554
28032216	154	159	AVERT	T061	C1997554
28032216	171	176	lower	T052	C2003888
28032216	177	181	risk	T078	C0035647
28032216	185	191	nausea	T184	C0027497
28032216	196	204	vomiting	T184	C0042963
28032216	208	216	patients	T101	C0030705
28032216	227	260	radiotherapy to the upper abdomen	T061	C1997554
28032216	262	269	UA-RINV	T061	C1997554
28032216	276	313	prophylactic 5-HT3 antagonist therapy	T061	C2347899
28032216	315	323	patients	T101	C0030705
28032216	345	352	UA-RINV	T061	C1997554
28032216	358	361	aim	T078	C1947946
28032216	370	396	multicenter phase II study	T062	C1096776
28032216	404	410	assess	T052	C1516048
28032216	411	424	effectiveness	T080	C1280519
28032216	438	450	tolerability	T062	C3274448
28032216	454	482	protracted dual NK1-receptor	T116,T192	C0164209
28032216	487	503	5-HT3 antagonist	T109,T121	C0360055
28032216	504	515	prophylaxis	T061	C0199176
28032216	524	531	UA-RINV	T061	C1997554
28032216	533	541	Patients	T101	C0030705
28032216	552	577	fractionated radiotherapy	T061	C1522449
28032216	583	599	radiosensitizing	T061	C0436310
28032216	600	612	chemotherapy	T061	C3665472
28032216	622	626	oral	T082	C0442027
28032216	627	638	ondansetron	T109,T121	C0061851
28032216	657	667	aprepitant	T109,T121	C1176306
28032216	686	692	Monday	T079	C0585024
28032216	694	703	Wednesday	T079	C0585027
28032216	705	711	Friday	T079	C0585029
28032216	733	745	radiotherapy	T061	C1522449
28032216	751	758	primary	T080	C0205225
28032216	759	766	outcome	T080	C0085415
28032216	771	788	complete response	T033	C4050094
28032216	790	792	CR	T033	C4050094
28032216	805	816	no vomiting	T033	C0375548
28032216	820	834	rescue therapy	T061	C0085405
28032216	853	864	observation	T058	C0700325
28032216	865	871	period	T079	C1948053
28032216	875	887	radiotherapy	T061	C1522449
28032216	889	891	OP	T079	C1948053
28032216	894	900	Nausea	T184	C0027497
28032216	902	910	vomiting	T184	C0042963
28032216	923	940	rescue medication	T061	C0085405
28032216	960	968	modified	T169	C0392747
28032216	984	1005	MASCC antiemesis tool	T170	C3714902
28032216	1006	1015	completed	T080	C0205197
28032216	1016	1028	twice weekly	T079	C0556985
28032216	1030	1040	Fifty-five	T081	C0392762
28032216	1041	1049	patients	T101	C0030705
28032216	1112	1120	patients	T101	C0030705
28032216	1133	1135	CI	T081	C0009667
28032216	1157	1159	CR	T033	C4050094
28032216	1163	1168	study	T062	C2603343
28032216	1193	1195	CI	T081	C0009667
28032216	1212	1225	did not vomit	T033	C0375548
28032216	1249	1251	CI	T081	C0009667
28032216	1280	1297	rescue medication	T061	C0085405
28032216	1309	1311	OP	T079	C1948053
28032216	1322	1334	participants	T098	C0679646
28032216	1335	1342	vomited	T184	C0042963
28032216	1358	1376	significant nausea	T184	C0027497
28032216	1378	1380	SN	T184	C0027497
28032216	1389	1396	average	T081	C1510992
28032216	1410	1412	CI	T081	C0009667
28032216	1438	1440	CI	T081	C0009667
28032216	1463	1468	study	T062	C2603343
28032216	1484	1490	Nausea	T184	C0027497
28032216	1495	1501	common	T081	C0205214
28032216	1528	1530	SN	T184	C0027497
28032216	1538	1542	time	T079	C0040223
28032216	1554	1556	OP	T079	C1948053
28032216	1558	1565	UA-RINV	T061	C1997554
28032216	1577	1586	important	T080	C3898777
28032216	1587	1596	morbidity	T081	C0026538
28032216	1609	1615	advent	T052	C1706079
28032216	1626	1638	radiotherapy	T061	C1522449
28032216	1640	1650	Aprepitant	T109,T121	C1176306
28032216	1655	1666	ondansetron	T109,T121	C0061851
28032216	1684	1689	trial	T062	C0008976
28032216	1710	1718	standard	T080	C1442989
28032216	1719	1730	ondansetron	T109,T121	C0061851
28032216	1731	1742	monotherapy	T061	C0087111

28043566|t|Interferon-γ assay, a high-sensitivity, specific and appropriate method for detection of bovine tuberculosis in cattle
28043566|a|Bovine tuberculosis (TB) is an important zoonotic disease that is caused by Mycobacterium bovis. Eradication efforts in developed countries have reduced the prevalence of this disease significantly. TB can be difficult to diagnose based only on the clinical signs; therefore, it is usually diagnosed in the field with the tuberculin skin test and diagnostic blood tests, including the lymphocyte proliferation assay, the interferon (IFN)-γ assay, and enzyme-linked immunosorbent assay. The aim of this study was to compare the tuberculin and IFN-γ tests. A total of 110 animals were evaluated by tuberculin skin test (TST) and IFN-γ assay; the culture was selected as a gold standard. The animals were selected randomly from 700 cattle on dairy farms, aged 3-5 years and suspected of having TB. Ten cattle were positive using the TST and nine were positive by IFN-γ assay. All nine positive samples in the IFN-γ assay were positive in culture too. The observed errors in IFN-γ assay were less due to laboratorial tools. It is suggested that all positive samples in TST are also positive by IFN-γ too.
28043566	0	12	Interferon-γ	T116,T121,T129	C3539881
28043566	13	18	assay	T059	C1510438
28043566	22	38	high-sensitivity	T059	C1441604
28043566	40	48	specific	T080	C0205369
28043566	53	64	appropriate	T080	C1548787
28043566	65	71	method	T059	C0022885
28043566	76	85	detection	T061	C1511790
28043566	89	108	bovine tuberculosis	T047	C0041307
28043566	112	118	cattle	T015	C0007452
28043566	119	138	Bovine tuberculosis	T047	C0041307
28043566	140	142	TB	T047	C0041307
28043566	160	176	zoonotic disease	T047	C0043528
28043566	195	214	Mycobacterium bovis	T007	C0026917
28043566	216	227	Eradication	T058	C3178994
28043566	239	258	developed countries	T080	C0282613
28043566	264	271	reduced	T080	C0392756
28043566	276	286	prevalence	T081	C0220900
28043566	295	302	disease	T047	C0012634
28043566	318	320	TB	T047	C0041307
28043566	341	349	diagnose	T033	C0011900
28043566	368	382	clinical signs	T033	C3540840
28043566	409	418	diagnosed	T033	C0011900
28043566	441	461	tuberculin skin test	T060	C0041290
28043566	466	488	diagnostic blood tests	T060	C1959833
28043566	504	534	lymphocyte proliferation assay	T059	C0201614
28043566	540	558	interferon (IFN)-γ	T116,T121,T129	C3539881
28043566	559	564	assay	T059	C1510438
28043566	570	603	enzyme-linked immunosorbent assay	T059	C0014441
28043566	609	612	aim	T078	C1947946
28043566	621	626	study	T062	C2603343
28043566	646	656	tuberculin	T116,T129,T130	C0041289
28043566	661	666	IFN-γ	T116,T121,T129	C3539881
28043566	667	672	tests	T059	C0022885
28043566	689	696	animals	T008	C0003062
28043566	702	711	evaluated	T058	C0220825
28043566	715	735	tuberculin skin test	T060	C0041290
28043566	737	740	TST	T060	C0041290
28043566	746	751	IFN-γ	T116,T121,T129	C3539881
28043566	752	757	assay	T059	C1510438
28043566	763	770	culture	T059	C0430400
28043566	789	802	gold standard	T080	C0150110
28043566	808	815	animals	T008	C0003062
28043566	848	854	cattle	T015	C0007452
28043566	858	869	dairy farms	T082	C1254362
28043566	880	885	years	T079	C1510829
28043566	890	899	suspected	T078	C0750491
28043566	910	912	TB	T047	C0041307
28043566	918	924	cattle	T015	C0007452
28043566	930	938	positive	T033	C1446409
28043566	949	952	TST	T060	C0041290
28043566	967	975	positive	T033	C1446409
28043566	979	984	IFN-γ	T116,T121,T129	C3539881
28043566	985	990	assay	T059	C1510438
28043566	1001	1009	positive	T033	C1446409
28043566	1010	1017	samples	T077	C2347026
28043566	1025	1030	IFN-γ	T116,T121,T129	C3539881
28043566	1031	1036	assay	T059	C1510438
28043566	1042	1050	positive	T033	C1446409
28043566	1054	1061	culture	T059	C0430400
28043566	1071	1079	observed	T169	C1441672
28043566	1080	1086	errors	T080	C0743559
28043566	1090	1095	IFN-γ	T116,T121,T129	C3539881
28043566	1096	1101	assay	T059	C1510438
28043566	1119	1137	laboratorial tools	T059	C0022885
28043566	1164	1172	positive	T033	C1446409
28043566	1173	1180	samples	T077	C2347026
28043566	1184	1187	TST	T060	C0041290
28043566	1197	1205	positive	T033	C1446409
28043566	1209	1214	IFN-γ	T116,T121,T129	C3539881

27576941|t|Relationship between fear of falling and functional status in nursing home residents aged older than 65 years
27576941|a|The present study investigated the relationship between fear of falling and functional status, and sociodemographic and health-related factors in nursing home residents aged older than 65 years. The cross-sectional study involved 100 participants who were residents of a nursing home and aged older than 65 years. Fear of falling was assessed using the Falls Efficacy Scale. Functional status was assessed by four performance-based measures. Balance was assessed by the Berg Balance Scale, mobility by the Timed Up and Go test, lower limbs muscle strength by the Chair Rising Test and participants' functional ability by the motor Functional Independence Measure. There was a significant negative correlation between the Falls Efficacy Scale and Berg Balance Scale (P < 0.001), and motor Functional Independence Measure (P < 0.001) scores; and a positive correlation with the Timed Up and Go test (P < 0.001) and Chair Rising Test (P < 0.001) values. Falls Efficacy Scale score increase is associated with age, being a widower / widow and the number of falls in the previous year. Higher fear of falling is associated with an increase in the number of falls in the previous year and with a decrease in Berg Balance Scale score. The study found a significant associations between Falls Efficacy Scale score and all of the examined parameters of functional status, the number of falls in the previous year, age and marital status of widower / widow. The major finding was that poor balance and an increase in the number of falls in the previous year are independent factors significantly associated with the fear of falling. Geriatr Gerontol Int 2016; ••: ••-••.
27576941	0	12	Relationship	T080	C0439849
27576941	21	36	fear of falling	T033	C0877040
27576941	41	58	functional status	T080	C0870086
27576941	62	84	nursing home residents	T098	C0682287
27576941	85	95	aged older	T098	C0001792
27576941	104	109	years	T079	C0439234
27576941	122	127	study	T062	C2603343
27576941	128	140	investigated	T169	C1292732
27576941	145	157	relationship	T080	C0439849
27576941	166	181	fear of falling	T033	C0877040
27576941	186	203	functional status	T080	C0870086
27576941	209	225	sociodemographic	T078	C0011292
27576941	230	252	health-related factors	T078	C0018684
27576941	256	278	nursing home residents	T098	C0682287
27576941	298	303	years	T079	C0439234
27576941	309	330	cross-sectional study	T062	C0010362
27576941	344	356	participants	T098	C0679646
27576941	366	393	residents of a nursing home	T098	C0682287
27576941	417	422	years	T079	C0439234
27576941	424	439	Fear of falling	T033	C0877040
27576941	444	452	assessed	T052	C1516048
27576941	463	483	Falls Efficacy Scale	T170	C2584445
27576941	485	502	Functional status	T080	C0870086
27576941	507	515	assessed	T052	C1516048
27576941	552	559	Balance	T040	C0014653
27576941	564	572	assessed	T052	C1516048
27576941	580	598	Berg Balance Scale	T170	C1998325
27576941	600	608	mobility	UnknownType	C0547136
27576941	616	637	Timed Up and Go test,	T060	C1319201
27576941	638	649	lower limbs	T023	C0023216
27576941	650	665	muscle strength	T042	C0517349
27576941	673	690	Chair Rising Test	T170	C0392366
27576941	695	708	participants'	T098	C0679646
27576941	709	727	functional ability	T056	C0001288
27576941	735	772	motor Functional Independence Measure	T170	C0451172
27576941	798	818	negative correlation	T080	C1707520
27576941	831	851	Falls Efficacy Scale	T170	C2584445
27576941	856	874	Berg Balance Scale	T170	C1998325
27576941	892	948	motor Functional Independence Measure (P < 0.001) scores	T081	C0449820
27576941	956	976	positive correlation	T080	C1707520
27576941	986	1006	Timed Up and Go test	T060	C1319201
27576941	1023	1040	Chair Rising Test	T170	C0392366
27576941	1061	1087	Falls Efficacy Scale score	T081	C0449820
27576941	1100	1115	associated with	T080	C0332281
27576941	1116	1119	age	T032	C0001779
27576941	1129	1136	widower	T099	C0043174
27576941	1139	1144	widow	T099	C1510465
27576941	1153	1168	number of falls	T033	C0575126
27576941	1176	1189	previous year	T079	C0439234
27576941	1198	1213	fear of falling	T033	C0877040
27576941	1217	1232	associated with	T080	C0332281
27576941	1252	1267	number of falls	T033	C0575126
27576941	1275	1288	previous year	T079	C0439234
27576941	1312	1336	Berg Balance Scale score	T081	C0449820
27576941	1368	1380	associations	T080	C0439849
27576941	1389	1415	Falls Efficacy Scale score	T081	C0449820
27576941	1431	1439	examined	T033	C0332128
27576941	1440	1450	parameters	T077	C0549193
27576941	1454	1471	functional status	T080	C0870086
27576941	1477	1492	number of falls	T033	C0575126
27576941	1500	1513	previous year	T079	C0439234
27576941	1515	1518	age	T032	C0001779
27576941	1523	1537	marital status	T102	C0024819
27576941	1541	1548	widower	T099	C0043174
27576941	1551	1556	widow	T099	C1510465
27576941	1585	1597	poor balance	T033	C0234964
27576941	1621	1636	number of falls	T033	C0575126
27576941	1644	1657	previous year	T079	C0439234
27576941	1696	1711	associated with	T080	C0332281
27576941	1716	1731	fear of falling	T033	C0877040

28418900|t|Therapeutic inhibition of USP7 - PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated / deleted clones
28418900|a|Chronic Lymphocytic Leukemia (CLL) is a lymphoproliferative disorder with either indolent or aggressive clinical course. Current treatment regiments have significantly improved the overall outcomes even if higher risk subgroups - those harboring TP53 mutations or deletions of the short arm of chromosome 17 (del17p) - remain highly challenging. In the present work, we identified USP7, a known de-ubiquitinase with multiple roles in cellular homeostasis, as a potential therapeutic target in CLL. We demonstrated that in primary CLL samples and in CLL cell lines USP7 is: i) over-expressed through a mechanism involving miR-338-3p and miR-181b deregulation; ii) functionally activated by Casein Kinase 2 (CK2), an upstream interactor known to be deregulated in CLL; iii) effectively targeted by the USP7 inhibitor P5091. Treatment of primary CLL samples and cell lines with P5091 induces cell growth arrest and apoptosis, through the restoration of PTEN nuclear pool, both in TP53 - wild type and - null environment. Importantly, PTEN acts as the main tumor suppressive mediator along the USP7 - PTEN axis in a p53 dispensable manner. In conclusion, we propose USP7 as a new druggable target in CLL.
28418900	0	11	Therapeutic	T169	C0039798
28418900	12	22	inhibition	T052	C3463820
28418900	26	30	USP7	T116,T126	C1142946
28418900	33	37	PTEN	T116,T126	C1430988
28418900	49	77	chronic lymphocytic leukemia	T191	C0023434
28418900	93	101	overcome	T052	C2983310
28418900	102	106	TP53	T028	C0079419
28418900	107	114	mutated	T045	C0596611
28418900	117	124	deleted	T045	C0017260
28418900	125	131	clones	T025	C0009013
28418900	132	160	Chronic Lymphocytic Leukemia	T191	C0023434
28418900	162	165	CLL	T191	C0023434
28418900	172	200	lymphoproliferative disorder	T191	C0024314
28418900	213	221	indolent	T033	C1334168
28418900	225	251	aggressive clinical course	T033	C1332223
28418900	261	280	treatment regiments	T061	C0392920
28418900	300	308	improved	T033	C0184511
28418900	313	320	overall	T080	C1561607
28418900	321	329	outcomes	T080	C0085415
28418900	378	382	TP53	T028	C0079419
28418900	383	392	mutations	T045	C0596611
28418900	396	405	deletions	T045	C0017260
28418900	413	439	short arm of chromosome 17	T086	C0796349
28418900	441	447	del17p	T086	C0796349
28418900	502	512	identified	T080	C0205396
28418900	513	517	USP7	T116,T126	C1142946
28418900	527	542	de-ubiquitinase	T116,T126	C0294105
28418900	548	556	multiple	T081	C0439064
28418900	557	562	roles	T077	C1705810
28418900	566	586	cellular homeostasis	T043	C2244223
28418900	593	602	potential	T080	C3245505
28418900	603	614	therapeutic	T169	C0039798
28418900	625	628	CLL	T191	C0023434
28418900	654	661	primary	T080	C0205225
28418900	662	665	CLL	T191	C0023434
28418900	666	673	samples	T077	C2347026
28418900	681	684	CLL	T191	C0023434
28418900	685	695	cell lines	T025	C0085983
28418900	696	700	USP7	T116,T126	C1142946
28418900	708	722	over-expressed	T045	C1514559
28418900	733	742	mechanism	T169	C0441712
28418900	753	763	miR-338-3p	T114,T123	C1101610
28418900	768	776	miR-181b	T114,T123	C1101610
28418900	777	789	deregulation	T052	C1880287
28418900	808	817	activated	T052	C1879547
28418900	821	836	Casein Kinase 2	T116,T126	C0108555
28418900	838	841	CK2	T116,T126	C0108555
28418900	847	855	upstream	T082	C0522505
28418900	856	866	interactor	T116,T123	C0033684
28418900	879	890	deregulated	T052	C1880287
28418900	894	897	CLL	T191	C0023434
28418900	904	915	effectively	T080	C1704419
28418900	932	936	USP7	T116,T126	C1142946
28418900	937	946	inhibitor	T121	C0014432
28418900	947	952	P5091	T109,T121	C3500983
28418900	954	963	Treatment	T061	C0087111
28418900	967	974	primary	T080	C0205225
28418900	975	978	CLL	T191	C0023434
28418900	979	986	samples	T077	C2347026
28418900	991	1001	cell lines	T025	C0085983
28418900	1007	1012	P5091	T109,T121	C3500983
28418900	1021	1039	cell growth arrest	T043	C1371476
28418900	1044	1053	apoptosis	T043	C0162638
28418900	1082	1086	PTEN	T116,T126	C1430988
28418900	1109	1113	TP53	T028	C0079419
28418900	1116	1125	wild type	T028	C1883559
28418900	1132	1148	null environment	T082	C0014406
28418900	1163	1167	PTEN	T116,T126	C1430988
28418900	1185	1211	tumor suppressive mediator	T116,T123	C0597611
28418900	1222	1226	USP7	T116,T126	C1142946
28418900	1229	1233	PTEN	T116,T126	C1430988
28418900	1244	1247	p53	T116,T123	C0080055
28418900	1248	1259	dispensable	T169	C0332291
28418900	1294	1298	USP7	T116,T126	C1142946
28418900	1308	1324	druggable target	T104,T120	C1513403
28418900	1328	1331	CLL	T191	C0023434

27535586|t|Chitosan -functionalised poly(2-hydroxyethyl methacrylate) core-shell microgels as drug delivery carriers: salicylic acid loading and release
27535586|a|This work presents the evaluation of chitosan -functionalised poly(2-hydroxyethyl methacrylate) (CS / PHEMA) core-shell microgels as drug delivery carriers. CS / PHEMA microgels were prepared by emulsifier-free emulsion polymerisation with N,N '-methylenebisacrylamide (MBA) as a crosslinker. The study on drug loading, using salicylic acid (SA) as a model drug, was performed. The results showed that the encapsulation efficiency (EE) increased as drug -to- microgel ratio was increased. Higher EE can be achieved with the increase in degree of crosslinking, by increasing the amount of MBA from 0.01 g to 0.03 g. In addition, the highest EE (61.1%) was observed at pH 3. The highest release of SA (60%) was noticed at pH 2.4, while the lowest one (49.4%) was obtained at pH 7.4. Moreover, the highest release of SA was enhanced by the presence of 0.2 M NaCl. The pH - and ionic-sensitivity of CS / PHEMA could be useful as a sustained release delivery device, especially for oral delivery.
27535586	0	8	Chitosan	T109,T121	C0162969
27535586	25	58	poly(2-hydroxyethyl methacrylate)	T109,T122	C0032509
27535586	59	79	core-shell microgels	T122	C0013161
27535586	83	105	drug delivery carriers	T074	C0085104
27535586	107	121	salicylic acid	T109,T121	C0036079
27535586	122	141	loading and release	T169	C0205245
27535586	179	187	chitosan	T109,T121	C0162969
27535586	204	237	poly(2-hydroxyethyl methacrylate)	T109,T122	C0032509
27535586	239	241	CS	T109,T121	C0162969
27535586	244	249	PHEMA	T109,T122	C0032509
27535586	251	271	core-shell microgels	T122	C0013161
27535586	275	297	drug delivery carriers	T074	C0085104
27535586	299	301	CS	T109,T121	C0162969
27535586	304	309	PHEMA	T109,T122	C0032509
27535586	310	319	microgels	T122	C0013161
27535586	337	376	emulsifier-free emulsion polymerisation	T067	C0314672
27535586	382	410	N,N '-methylenebisacrylamide	T109,T130	C0067314
27535586	412	415	MBA	T109,T130	C0067314
27535586	422	433	crosslinker	T109	C0029224
27535586	439	460	study on drug loading	T062	C0013175
27535586	468	482	salicylic acid	T109,T121	C0036079
27535586	484	486	SA	T109,T121	C0036079
27535586	493	503	model drug	T121	C1254351
27535586	548	572	encapsulation efficiency	T067	C2348438
27535586	574	576	EE	T067	C2348438
27535586	591	595	drug	T121	C1254351
27535586	610	615	ratio	T081	C0456603
27535586	638	640	EE	T067	C2348438
27535586	688	700	crosslinking	T067	C1254366
27535586	730	733	MBA	T109,T130	C0067314
27535586	782	784	EE	T067	C2348438
27535586	809	811	pH	T081	C0020283
27535586	827	840	release of SA	T070	C3850077
27535586	862	864	pH	T081	C0020283
27535586	915	917	pH	T081	C0020283
27535586	945	958	release of SA	T070	C3850077
27535586	997	1001	NaCl	T121,T123,T197	C0037494
27535586	1007	1009	pH	T081	C0020283
27535586	1016	1033	ionic-sensitivity	T080	C0205556
27535586	1037	1039	CS	T109,T121	C0162969
27535586	1042	1047	PHEMA	T109,T122	C0032509
27535586	1069	1102	sustained release delivery device	T121	C1135768
27535586	1119	1132	oral delivery	T074	C0302620

28163288|t|Clinical significance of human intestinal spirochetosis: a retrospective study
28163288|a|The clinical and pathological features of human intestinal spirochetosis (HIS) are not well known. Here we report 55 patients with HIS who were diagnosed at our institution during the past 5 years. Seven patients presented with symptoms such as abdominal pain or diarrhea, while the others were incidentally diagnosed during screening colonoscopy. Most patients had non-specific endoscopic findings, including intestinal edema or erosion. The diagnosis of HIS was histologically confirmed via hematoxylin and eosin staining, periodic acid-Schiff staining, and/or immunohistochemistry using anti-Treponema pallidum antibody. Among the 55 patients, five were diagnosed with diseases other than HIS (amoebic colitis, three; ulcerative colitis, one). Sixteen patients were treated with either amoxicillin or metronidazole ;only metronidazole proved to be effective. The clinical significance of asymptomatic HIS remains unknown. Some case reports suggest a risk for increased severity in patients with immunodeficiency and/or sexually transmitted diseases. Therefore, aggressive treatment for HIS should be considered, particularly in high-risk patients.
28163288	0	21	Clinical significance	T033	C2826293
28163288	25	30	human	T016	C0086418
28163288	31	41	intestinal	T023	C0021853
28163288	42	55	spirochetosis	T047	C0037974
28163288	59	78	retrospective study	T062	C0035363
28163288	83	91	clinical	T080	C0205210
28163288	96	108	pathological	T169	C1521733
28163288	121	126	human	T016	C0086418
28163288	127	137	intestinal	T023	C0021853
28163288	138	151	spirochetosis	T047	C0037974
28163288	153	156	HIS	T047	C0037974
28163288	196	204	patients	T101	C0030705
28163288	210	213	HIS	T047	C0037974
28163288	223	232	diagnosed	T033	C0011900
28163288	240	251	institution	T073,T093	C0018704
28163288	283	291	patients	T101	C0030705
28163288	307	315	symptoms	T184	C1457887
28163288	324	338	abdominal pain	T184	C0000737
28163288	342	350	diarrhea	T184	C0011991
28163288	387	396	diagnosed	T033	C0011900
28163288	404	425	screening colonoscopy	T060	C1882982
28163288	432	440	patients	T101	C0030705
28163288	445	457	non-specific	T080	C0205370
28163288	458	468	endoscopic	T060	C0014245
28163288	469	477	findings	T033	C0243095
28163288	489	505	intestinal edema	T046	C1142262
28163288	509	516	erosion	T046	C1959609
28163288	522	531	diagnosis	T033	C0011900
28163288	535	538	HIS	T047	C0037974
28163288	543	557	histologically	T169	C0205462
28163288	572	602	hematoxylin and eosin staining	T059	C0523207
28163288	604	633	periodic acid-Schiff staining	T059	C0523213
28163288	642	662	immunohistochemistry	T060	C0021044
28163288	669	701	anti-Treponema pallidum antibody	T116,T129	C0003241
28163288	716	724	patients	T101	C0030705
28163288	736	745	diagnosed	T033	C0011900
28163288	751	759	diseases	T047	C0012634
28163288	771	774	HIS	T047	C0037974
28163288	776	791	amoebic colitis	T047	C0013370
28163288	800	818	ulcerative colitis	T047	C0009324
28163288	834	842	patients	T101	C0030705
28163288	848	860	treated with	T061	C0332293
28163288	868	879	amoxicillin	T109,T195	C0002645
28163288	883	896	metronidazole	T109,T121	C0025872
28163288	903	916	metronidazole	T109,T121	C0025872
28163288	930	939	effective	T080	C1704419
28163288	945	966	clinical significance	T033	C2826293
28163288	970	982	asymptomatic	T033	C0231221
28163288	983	986	HIS	T047	C0037974
28163288	995	1002	unknown	T080	C0439673
28163288	1009	1021	case reports	T170	C0085973
28163288	1032	1036	risk	T078	C0035647
28163288	1051	1059	severity	T080	C0439793
28163288	1063	1071	patients	T101	C0030705
28163288	1077	1093	immunodeficiency	T047	C0021051
28163288	1101	1130	sexually transmitted diseases	T047	C0036916
28163288	1143	1163	aggressive treatment	T061	C0087111
28163288	1168	1171	HIS	T047	C0037974
28163288	1210	1219	high-risk	T033	C0332167
28163288	1220	1228	patients	T101	C0030705

28058375|t|A rare cause of gastric obstruction: Lighters swallowing
28058375|a|The majority of swallowed foreign bodies are thrown spontaneously without causing complications in the digestive system. Multiple number of foreign bodies may be swallowed by psychiatric patients which delay diagnosis and increase the complication rate. Long and hard objects cannot pass through the pylorus, and may cause obstruction, ulceration, bleeding and perforation. Endoscopy is used as an effective method in such cases. An exploratory laparatomy was performed after unsuccessful endoscopic foreign object removal in a 28-year-old schizophrenic patient with gastric outlet obstruction due to multiple cigarette lighter swallowing. Ten lighters were removed from the stomach through gastrotomy and one more lighter was removed from the descending colon by milking through the anus. The aim of this paper is to discuss encountered difficulties in psychiatric patients who underwent surgery due to intake of foreign bodies.
28058375	2	6	rare	T080	C0522498
28058375	7	12	cause	T169	C0015127
28058375	16	35	gastric obstruction	T047	C0149700
28058375	37	45	Lighters	T073	C0336770
28058375	46	56	swallowing	T040	C0011167
28058375	61	69	majority	T080	C0205164
28058375	73	97	swallowed foreign bodies	T033	C0520753
28058375	102	108	thrown	T080	C0849355
28058375	109	122	spontaneously	T169	C0205359
28058375	123	130	without	T080	C0332288
28058375	131	138	causing	T169	C0678227
28058375	139	152	complications	T046	C0009566
28058375	160	176	digestive system	T022	C0012240
28058375	178	186	Multiple	T081	C0439064
28058375	187	193	number	T081	C0237753
28058375	197	211	foreign bodies	T037	C0016542
28058375	219	228	swallowed	T040	C0011167
28058375	232	252	psychiatric patients	T101	C0748064
28058375	259	274	delay diagnosis	T080	C2718036
28058375	279	287	increase	T169	C0442805
28058375	292	304	complication	T046	C0009566
28058375	305	309	rate	T081	C1521828
28058375	311	315	Long	T080	C0205166
28058375	320	324	hard	T080	C0018599
28058375	325	332	objects	T037	C0016542
28058375	357	364	pylorus	T023	C0034196
28058375	374	379	cause	T169	C0015127
28058375	380	391	obstruction	T046	C0028778
28058375	393	403	ulceration	T046	C3887532
28058375	405	413	bleeding	T046	C0019080
28058375	418	429	perforation	T033	C0549099
28058375	431	440	Endoscopy	T060	C0014245
28058375	444	448	used	T169	C1524063
28058375	455	464	effective	T080	C1704419
28058375	465	471	method	T169	C0449851
28058375	480	485	cases	T169	C0868928
28058375	490	512	exploratory laparatomy	T060	C0085704
28058375	517	526	performed	T169	C0884358
28058375	533	545	unsuccessful	T080	C1272705
28058375	546	556	endoscopic	T082	C0442418
28058375	557	571	foreign object	T037	C0016542
28058375	572	579	removal	T061	C0015252
28058375	597	610	schizophrenic	T048	C0036341
28058375	611	618	patient	T101	C0030705
28058375	624	650	gastric outlet obstruction	T047	C0162651
28058375	651	657	due to	T169	C0678226
28058375	658	666	multiple	T081	C0439064
28058375	667	684	cigarette lighter	T073	C0336770
28058375	685	695	swallowing	T040	C0011167
28058375	701	709	lighters	T073	C0336770
28058375	715	722	removed	T080	C0849355
28058375	732	739	stomach	T023	C0038351
28058375	740	747	through	T169	C0332273
28058375	748	758	gastrotomy	T061	C0192401
28058375	772	779	lighter	T073	C0336770
28058375	784	791	removed	T080	C0849355
28058375	801	817	descending colon	T023	C0227389
28058375	821	828	milking	T061	C0185115
28058375	829	836	through	T169	C0332273
28058375	841	845	anus	T023	C0003461
28058375	895	907	difficulties	T033	C0033213
28058375	911	931	psychiatric patients	T101	C0748064
28058375	946	953	surgery	T061	C0543467
28058375	954	960	due to	T169	C0678226
28058375	961	967	intake	T169	C1512806
28058375	971	985	foreign bodies	T037	C0016542

27539002|t|Effects of Smoke Generated by Electrocautery on the Larynx
27539002|a|The aim of this study was to investigate effects of smoke produced by electrocautery on the laryngeal mucosa. We used 16 healthy, adult female Wistar albino rats. We divided the rats into two groups. Eight rats were exposed to smoke for 60 min/d for 4 weeks, and eight rats were not exposed to smoke and served as controls. The experimental group was maintained in a plexiglass cabin during exposure to smoke. At the end of 4 weeks, rats were sacrificed under high-dose ketamine anesthesia. Each vocal fold was removed. An expert pathologist blinded to the experimental group evaluated the tissues for the following: epithelial distribution, inflammation, hyperplasia, and metaplasia. Mucosal cellular activities were assessed by immunohistochemical staining for Ki67. Results taken before and after effect were compared statistically. There was a significant difference in the extent of inflammation between the experimental group and the control group. Squamous metaplasia was detected in each group, but the difference was not significant. None of the larynges in either group developed hyperplasia. We showed increased tissue inflammation due to irritation by the smoke.
27539002	0	7	Effects	T080	C1280500
27539002	11	16	Smoke	T131	C0037366
27539002	17	26	Generated	T052	C3146294
27539002	30	44	Electrocautery	T074	C0180626
27539002	52	58	Larynx	T023	C0023078
27539002	63	66	aim	T078	C1947946
27539002	75	80	study	T062	C0008972
27539002	88	99	investigate	T058	C0220825
27539002	100	107	effects	T080	C1280500
27539002	111	116	smoke	T131	C0037366
27539002	117	125	produced	T052	C3146294
27539002	129	143	electrocautery	T074	C0180626
27539002	151	167	laryngeal mucosa	T024	C0023053
27539002	180	187	healthy	T080	C3898900
27539002	189	194	adult	T100	C0001675
27539002	195	201	female	T032	C0086287
27539002	202	220	Wistar albino rats	T015	C0684072
27539002	237	241	rats	T015	C0086893
27539002	251	257	groups	T096	C1642385
27539002	265	269	rats	T015	C0086893
27539002	275	285	exposed to	T080	C0332157
27539002	286	291	smoke	T131	C0037366
27539002	311	316	weeks	T079	C0439230
27539002	328	332	rats	T015	C0086893
27539002	353	358	smoke	T131	C0037366
27539002	373	381	controls	T096	C0009932
27539002	387	405	experimental group	T096	C1642385
27539002	426	436	plexiglass	T109,T122	C0600424
27539002	437	442	cabin	T073	C3273359
27539002	450	461	exposure to	T080	C0332157
27539002	462	467	smoke	T131	C0037366
27539002	485	490	weeks	T079	C0439230
27539002	492	496	rats	T015	C0086893
27539002	502	512	sacrificed	T078	C0681205
27539002	519	528	high-dose	T081	C0444956
27539002	529	537	ketamine	T109,T121	C0022614
27539002	538	548	anesthesia	T121	C4049933
27539002	555	565	vocal fold	T023	C0042930
27539002	570	577	removed	T080	C0849355
27539002	582	600	expert pathologist	T097	C0334901
27539002	616	634	experimental group	T096	C1642385
27539002	635	644	evaluated	T058	C0220825
27539002	649	656	tissues	T024	C0040300
27539002	676	686	epithelial	T024	C0014609
27539002	687	699	distribution	T169	C1704711
27539002	701	713	inflammation	T046	C0021368
27539002	715	726	hyperplasia	T046	C0020507
27539002	732	742	metaplasia	T049	C0025568
27539002	744	751	Mucosal	T024	C0026724
27539002	752	771	cellular activities	T043	C0007613
27539002	777	785	assessed	T052	C1516048
27539002	789	826	immunohistochemical staining for Ki67	T059	C4055454
27539002	828	835	Results	T034	C1254595
27539002	871	879	compared	T052	C1707455
27539002	880	893	statistically	T170	C0038208
27539002	907	918	significant	T078	C0750502
27539002	919	929	difference	T080	C1705242
27539002	937	943	extent	T082	C0439792
27539002	947	959	inflammation	T046	C0021368
27539002	972	990	experimental group	T096	C1642385
27539002	999	1012	control group	T096	C0009932
27539002	1014	1033	Squamous metaplasia	T049	C0025570
27539002	1038	1046	detected	T033	C0442726
27539002	1055	1060	group	T096	C1642385
27539002	1070	1080	difference	T080	C1705242
27539002	1085	1100	not significant	T033	C1273937
27539002	1102	1106	None	T033	C3843725
27539002	1114	1122	larynges	T023	C0023078
27539002	1133	1138	group	T096	C1642385
27539002	1149	1160	hyperplasia	T046	C0020507
27539002	1172	1181	increased	T081	C0205217
27539002	1182	1188	tissue	T024	C0040300
27539002	1189	1201	inflammation	T046	C0021368
27539002	1209	1219	irritation	T033	C1706307
27539002	1227	1232	smoke	T131	C0037366

27766200|t|Glomus tumor in teen and repetition pneumonia: Case report
27766200|a|Glomus tumors are uncommon tumors that are originated from smooth muscle cells of the neuromioarterials glomus bodies located in the arteriovenous anastomoses subcutaneous tissue or deep dermis of the extremities, mainly in the palms of the hands, wrists and subungual areas of the fingers. Carcinoid tumor, as the glomus tumor, can show an organoid pattern, increased vascularity, and uniform, round cells with eosinophilic cytoplasm, but usually are positive for cytokeratin and always stained with chromogranin and synaptophysin showing negative for smooth muscle markers which is presented in our case. Glomus tumors have a good prognosis and surgical resection is the treatment of choice. In our case, the patient underwent pulmonary bilobectomy because of the location of the tumor in the transition between the middle lobe and the basal bronchial trunk right lower lobe divisions. It is presented thus a glomus tumor with exceptional localization (pulmonary and bronchial) of benign histological features, according to most of the cases reported in the literature emphasizing their particular rare location, histological, and immunohistochemical profile, which helps the differential diagnosis with other most common tumors of bronchial location.
27766200	0	12	Glomus tumor	T191	C0017653
27766200	16	20	teen	T098	C1521910
27766200	25	35	repetition	T169	C0205341
27766200	36	45	pneumonia	T047	C0032285
27766200	47	58	Case report	T170	C0007320
27766200	59	72	Glomus tumors	T191	C0017653
27766200	77	85	uncommon	T080	C0522498
27766200	86	92	tumors	T191	C0027651
27766200	118	137	smooth muscle cells	T025	C1135918
27766200	145	176	neuromioarterials glomus bodies	T023	C0221936
27766200	177	184	located	T082	C0450429
27766200	192	217	arteriovenous anastomoses	T023	C0225984
27766200	218	237	subcutaneous tissue	T024	C0278403
27766200	241	245	deep	T082	C0205125
27766200	246	252	dermis	T024	C0011646
27766200	260	271	extremities	T023	C0278454
27766200	287	305	palms of the hands	T029	C0817662
27766200	307	313	wrists	T029	C0043262
27766200	318	333	subungual areas	T023	C0221997
27766200	341	348	fingers	T023	C0016129
27766200	350	365	Carcinoid tumor	T191	C0007095
27766200	374	386	glomus tumor	T191	C0017653
27766200	400	416	organoid pattern	T033	C1335133
27766200	418	427	increased	T081	C0205217
27766200	428	439	vascularity	T033	C4068833
27766200	445	452	uniform	T080	C0205375
27766200	454	465	round cells	T025	C0487470
27766200	471	493	eosinophilic cytoplasm	T025	C1513935
27766200	511	535	positive for cytokeratin	T033	C2825740
27766200	547	554	stained	T080	C2986582
27766200	560	572	chromogranin	T116,T123	C0008586
27766200	577	590	synaptophysin	T116,T123	C0085255
27766200	599	607	negative	T033	C1513916
27766200	612	625	smooth muscle	T024	C1267092
27766200	626	633	markers	T123	C0041365
27766200	643	652	presented	T078	C0449450
27766200	660	664	case	T077	C1706256
27766200	666	679	Glomus tumors	T191	C0017653
27766200	687	701	good prognosis	T033	C0278250
27766200	706	724	surgical resection	T061	C0728940
27766200	732	741	treatment	T061	C0087111
27766200	760	764	case	T077	C1706256
27766200	770	777	patient	T101	C0030705
27766200	788	809	pulmonary bilobectomy	T061	C0396580
27766200	825	833	location	T082	C0450429
27766200	841	846	tumor	T191	C0027651
27766200	854	864	transition	T052	C2700061
27766200	877	888	middle lobe	T023	C0225757
27766200	897	935	basal bronchial trunk right lower lobe	T023	C0225621
27766200	953	962	presented	T078	C0449450
27766200	970	982	glomus tumor	T191	C0017653
27766200	988	1012	exceptional localization	T169	C0475264
27766200	1014	1023	pulmonary	T080	C2709248
27766200	1028	1037	bronchial	T023	C0205039
27766200	1042	1048	benign	T080	C0205183
27766200	1049	1070	histological features	T033	C0449575
27766200	1097	1102	cases	T077	C1706256
27766200	1103	1111	reported	T058	C0700287
27766200	1119	1129	literature	T170	C0023866
27766200	1159	1163	rare	T080	C0522498
27766200	1164	1172	location	T082	C0450429
27766200	1174	1186	histological	T201	C0449574
27766200	1192	1211	immunohistochemical	T059	C1441616
27766200	1212	1219	profile	T059	C1979963
27766200	1237	1259	differential diagnosis	T060	C0011906
27766200	1276	1282	common	T081	C0205214
27766200	1283	1289	tumors	T191	C0027651
27766200	1293	1302	bronchial	T023	C0205039
27766200	1303	1311	location	T082	C0450429

27784172|t|Tzumin A and B, two new lignan derivatives from the barks of Sassafras tzumu
27784172|a|Two new lignan compounds, 5'-allyl-2,2'-dihydroxy-[1,1'-biphenyl]-5-carboxylic acid (1) and 4,4'-diallyl-[1,1'-biphenyl]-2,2'-diol (2), together with four known compounds (3-6), were isolated from the barks of Sassafras tzumu. The new compounds were determined by NMR ((1)H and (13)C NMR, HSQC, HMBC, (1)H-(1)H COSY, NOESY / ROESY), and MS analysis. Compounds 1-3 showed potent AChE inhibitory activities, with IC50 values of 2.00, 1.81 and 1.91 μM, respectively.
27784172	0	8	Tzumin A	T109	C0064971
27784172	13	14	B	T109	C0064971
27784172	24	30	lignan	T109	C0064971
27784172	31	42	derivatives	T104	C0243072
27784172	52	57	barks	T002	C0949119
27784172	61	76	Sassafras tzumu	T002	C1062063
27784172	85	101	lignan compounds	T109	C0064971
27784172	103	160	5'-allyl-2,2'-dihydroxy-[1,1'-biphenyl]-5-carboxylic acid	T109	C0064971
27784172	169	207	4,4'-diallyl-[1,1'-biphenyl]-2,2'-diol	T109,T121	C3849966
27784172	238	247	compounds	T103	C1706082
27784172	260	268	isolated	T169	C0205409
27784172	278	283	barks	T002	C0949119
27784172	287	302	Sassafras tzumu	T002	C1062063
27784172	312	321	compounds	T103	C1706082
27784172	327	340	determined by	T080	C0521095
27784172	341	350	NMR ((1)H	T060	C3850001
27784172	355	364	(13)C NMR	T060	C3850003
27784172	366	370	HSQC	T059	C0037812
27784172	372	376	HMBC	T059	C0037812
27784172	378	392	(1)H-(1)H COSY	T060	C0599863
27784172	394	399	NOESY	T060	C0599864
27784172	402	407	ROESY	T060	C0599865
27784172	414	416	MS	T059	C0037813
27784172	417	425	analysis	T062	C0936012
27784172	427	436	Compounds	T103	C1706082
27784172	455	459	AChE	T116,T126	C0001044
27784172	460	481	inhibitory activities	T039	C1524081
27784172	488	492	IC50	T081	C0600495

28347282|t|Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality
28347282|a|Although hyperuricemia is common after orthotopic liver transplantation (OLT), its relationship to mortality, progressive kidney disease, or the development of end stage renal disease (ESRD) is not well-described. Data from 304 patients undergoing OLT between 1996 and 2010 were used to assess the association of mean serum uric acid (UA) level in the 3- months post-OLT with mortality, doubling of creatinine, and ESRD incidence. Post-OLT survival to event outcomes according to UA level and eGFR was assessed using the Kaplan Meier method and multivariate Cox proportional hazards models. Mean UA level among the 204 patients with an eGFR level ≥60 ml/min/1.73 m(2) was 6.4 mg/dl compared to 7.9 mg/dl among the 100 patients with eGFR <60 (p < 0.0001). During a median of 4.6 years of follow-up, mortality rate, doubling of creatinine, and ESRD incidence were 48.9, 278.2, and 20.7 per 1000 person - years, respectively. In the first 5 years of follow-up, elevated UA was associated with mortality (Hazard Ratio, HR = 1.7; p = 0.045). However, among those with eGFR ≥ 60, UA level did not predict mortality (HR = 1.0; p = 0.95), and among those with eGFR < 60, elevated UA was a strong predictor of mortality (HR = 3.7[1.1, 12.0]; p = 0.03). UA was not associated with ESRD, but was associated with doubling of creatinine among diabetics (HR = 2.2[1.1, 4.3]; p = 0.025). In this post-OLT cohort, hyperuricemia independently predicted mortality, particularly among patients with eGFR < 60, and predicted doubling of creatinine among diabetics.
28347282	0	13	Hyperuricemia	T047	C0740394
28347282	20	52	orthotopic liver transplantation	T061	C0400447
28347282	64	76	associations	T080	C0439849
28347282	82	93	progression	T046	C0242656
28347282	97	110	renal disease	T047	C0022658
28347282	112	120	incident	T067	C1551358
28347282	121	144	end-stage renal disease	T047	C0022661
28347282	150	159	mortality	T081	C0178686
28347282	169	182	hyperuricemia	T047	C0740394
28347282	199	231	orthotopic liver transplantation	T061	C0400447
28347282	233	236	OLT	T061	C0400447
28347282	259	268	mortality	T081	C0178686
28347282	270	281	progressive	T169	C0205329
28347282	282	296	kidney disease	T047	C0022658
28347282	320	343	end stage renal disease	T047	C0022661
28347282	345	349	ESRD	T047	C0022661
28347282	374	378	Data	T078	C1511726
28347282	388	396	patients	T101	C0030705
28347282	408	411	OLT	T061	C0400447
28347282	458	469	association	T080	C0439849
28347282	473	477	mean	T081	C0444504
28347282	478	483	serum	T031	C0229671
28347282	484	493	uric acid	T109,T123	C0041980
28347282	495	497	UA	T109,T123	C0041980
28347282	499	504	level	T080	C0441889
28347282	515	521	months	T079	C0439231
28347282	522	530	post-OLT	T079	C1254367
28347282	536	545	mortality	T081	C0178686
28347282	559	569	creatinine	T109,T123	C0010294
28347282	575	579	ESRD	T047	C0022661
28347282	591	599	Post-OLT	T079	C1254367
28347282	640	642	UA	T109,T123	C0041980
28347282	643	648	level	T080	C0441889
28347282	653	657	eGFR	T059	C3811844
28347282	681	700	Kaplan Meier method	T062	C2827659
28347282	705	749	multivariate Cox proportional hazards models	T081,T170	C0010235
28347282	751	755	Mean	T081	C0444504
28347282	756	758	UA	T109,T123	C0041980
28347282	759	764	level	T080	C0441889
28347282	779	787	patients	T101	C0030705
28347282	796	800	eGFR	T059	C3811844
28347282	801	806	level	T080	C0441889
28347282	878	886	patients	T101	C0030705
28347282	892	896	eGFR	T059	C3811844
28347282	924	930	median	T082	C0549183
28347282	938	943	years	T079	C0439234
28347282	947	956	follow-up	T058	C1522577
28347282	958	972	mortality rate	T081	C0205848
28347282	986	996	creatinine	T109,T123	C0010294
28347282	1002	1006	ESRD	T047	C0022661
28347282	1053	1059	person	T098	C0027361
28347282	1062	1067	years	T079	C0439234
28347282	1098	1103	years	T079	C0439234
28347282	1107	1116	follow-up	T058	C1522577
28347282	1118	1126	elevated	T080	C3163633
28347282	1127	1129	UA	T109,T123	C0041980
28347282	1134	1149	associated with	T080	C0332281
28347282	1150	1159	mortality	T081	C0178686
28347282	1161	1173	Hazard Ratio	T081	C2985465
28347282	1175	1177	HR	T081	C2985465
28347282	1223	1227	eGFR	T059	C3811844
28347282	1234	1236	UA	T109,T123	C0041980
28347282	1237	1242	level	T080	C0441889
28347282	1259	1268	mortality	T081	C0178686
28347282	1270	1272	HR	T081	C2985465
28347282	1312	1316	eGFR	T059	C3811844
28347282	1323	1331	elevated	T080	C3163633
28347282	1332	1334	UA	T109,T123	C0041980
28347282	1348	1357	predictor	T078	C2698872
28347282	1361	1370	mortality	T081	C0178686
28347282	1372	1374	HR	T081	C2985465
28347282	1404	1406	UA	T109,T123	C0041980
28347282	1415	1430	associated with	T080	C0332281
28347282	1431	1435	ESRD	T047	C0022661
28347282	1445	1460	associated with	T080	C0332281
28347282	1473	1483	creatinine	T109,T123	C0010294
28347282	1490	1499	diabetics	T047	C0011847
28347282	1501	1503	HR	T081	C2985465
28347282	1541	1549	post-OLT	T079	C1254367
28347282	1550	1556	cohort	T098	C0599755
28347282	1558	1571	hyperuricemia	T047	C0740394
28347282	1586	1595	predicted	T078	C0681842
28347282	1596	1605	mortality	T081	C0178686
28347282	1626	1634	patients	T101	C0030705
28347282	1640	1644	eGFR	T059	C3811844
28347282	1655	1664	predicted	T078	C0681842
28347282	1677	1687	creatinine	T109,T123	C0010294
28347282	1694	1703	diabetics	T047	C0011847

27476625|t|Substance use and sexual function in juvenile idiopathic arthritis
27476625|a|To evaluate alcohol / tobacco / illicit drug use and sexual function in adolescent juvenile idiopathic arthritis (JIA) and healthy controls. 174 adolescents with pediatric rheumatic diseases were selected. A cross-sectional study with 54 JIA patients and 35 controls included demographic / anthropometric data and puberty markers assessments, physician -conducted CRAFFT (car / relax / alone / forget / friends / trouble) screen tool for substance abuse / dependence high risk and a questionnaire that evaluated sexual function, bullying and alcohol / tobacco / illicit drug use. Clinical / laboratorial data and treatment were also assessed in JIA. The median current age was similar between JIA patients and controls [15(10-19) vs. 15(12-18) years, p=0.506]. Frequencies of alcohol / tobacco / illicit drug use were high and similar in both JIA and controls (43% vs. 46%, p=0.829). However, age at alcohol onset was significantly higher in those with JIA [15(11-18) vs. 14(7-18) years, p=0.032], particularly in polyarticular onset (p=0.040). High risk for substance abuse / dependence (CRAFFT score ≥2) was found in both groups (13% vs. 15%, p=1.000), likewise bullying (p=0.088). Further analysis of JIA patients regarding alcohol / tobacco / illicit drug use showed that the median current age [17(14-19) vs. 13(10-19) years, p<0.001] and education years [11(6-13) vs. 7(3-12) years, p<0.001] were significant higher in those that used substances. Sexual activity was significantly higher in the former group (48% vs. 7%, p<0.001). A positive correlation was evidenced between CRAFFT score and current age in JIA patients (p=0.032, r=+0.296). A high risk for substance abuse / dependence was observed in both JIA and controls. JIA substance users were more likely to have sexual intercourse. Therefore, routine screening is suggested in all visits of JIA adolescents.
27476625	0	13	Substance use	T048	C0237123
27476625	18	33	sexual function	T040	C0278092
27476625	37	66	juvenile idiopathic arthritis	T047	C3495559
27476625	79	86	alcohol	T055	C0001948
27476625	89	96	tobacco	T055	C0543414
27476625	99	115	illicit drug use	T055	C0281875
27476625	120	135	sexual function	T040	C0278092
27476625	139	149	adolescent	T100	C0205653
27476625	150	179	juvenile idiopathic arthritis	T047	C3495559
27476625	181	184	JIA	T047	C3495559
27476625	190	206	healthy controls	T080	C2986479
27476625	212	223	adolescents	T100	C0205653
27476625	229	238	pediatric	T080	C1521725
27476625	239	257	rheumatic diseases	T047	C0035435
27476625	275	296	cross-sectional study	T062	C0010362
27476625	305	308	JIA	T047	C3495559
27476625	309	317	patients	T101	C0030705
27476625	325	333	controls	T096	C0009932
27476625	343	354	demographic	T090	C0011298
27476625	357	371	anthropometric	T062	C0003188
27476625	372	376	data	T078	C1511726
27476625	381	388	puberty	T033	C0429595
27476625	389	408	markers assessments	T169	C0220912
27476625	410	419	physician	T097	C0031831
27476625	431	437	CRAFFT	T061	C4274734
27476625	439	442	car	T073	C0004381
27476625	445	450	relax	T080	C0542193
27476625	453	458	alone	T102	C0679994
27476625	461	467	forget	T048	C0598853
27476625	470	477	friends	T098	C0079382
27476625	480	487	trouble	UnknownType	C0814062
27476625	505	520	substance abuse	T048	C0740858
27476625	523	533	dependence	T048	C0038580
27476625	534	543	high risk	T033	C0332167
27476625	550	563	questionnaire	T170	C0034394
27476625	569	578	evaluated	T058	C0220825
27476625	579	594	sexual function	T040	C0278092
27476625	596	604	bullying	T048	C0424318
27476625	609	616	alcohol	T055	C0001948
27476625	619	626	tobacco	T055	C0543414
27476625	629	645	illicit drug use	T055	C0281875
27476625	647	655	Clinical	T170	C1516606
27476625	658	675	laboratorial data	T170	C1517709
27476625	680	689	treatment	T061	C0087111
27476625	700	708	assessed	T052	C1516048
27476625	712	715	JIA	T047	C3495559
27476625	721	739	median current age	T079	C2598519
27476625	760	763	JIA	T047	C3495559
27476625	764	772	patients	T101	C0030705
27476625	764	772	patients	T101	C0030705
27476625	777	785	controls	T096	C0009932
27476625	811	816	years	T079	C0439234
27476625	843	850	alcohol	T055	C0001948
27476625	853	860	tobacco	T055	C0543414
27476625	863	879	illicit drug use	T055	C0281875
27476625	885	889	high	T080	C0205250
27476625	910	913	JIA	T047	C3495559
27476625	918	926	controls	T096	C0009932
27476625	960	963	age	T032	C0001779
27476625	967	974	alcohol	T055	C0001948
27476625	975	980	onset	T080	C0332162
27476625	985	1005	significantly higher	T081	C4055637
27476625	1020	1023	JIA	T047	C3495559
27476625	1048	1053	years	T079	C0439234
27476625	1081	1094	polyarticular	T047	C0162323
27476625	1095	1100	onset	T080	C0332162
27476625	1112	1121	High risk	T033	C0332167
27476625	1126	1141	substance abuse	T048	C0740858
27476625	1144	1154	dependence	T048	C0038580
27476625	1156	1162	CRAFFT	T061	C4274734
27476625	1163	1168	score	T081	C0449820
27476625	1191	1197	groups	T098	C1257890
27476625	1231	1239	bullying	T048	C0424318
27476625	1259	1267	analysis	T062	C0936012
27476625	1271	1274	JIA	T047	C3495559
27476625	1275	1283	patients	T101	C0030705
27476625	1294	1301	alcohol	T055	C0001948
27476625	1304	1311	tobacco	T055	C0543414
27476625	1314	1330	illicit drug use	T055	C0281875
27476625	1347	1365	median current age	T079	C2598519
27476625	1391	1396	years	T079	C0439234
27476625	1421	1426	years	T079	C0439234
27476625	1449	1454	years	T079	C0439234
27476625	1470	1488	significant higher	T081	C4055637
27476625	1520	1535	Sexual activity	T053	C0036864
27476625	1540	1560	significantly higher	T081	C4055637
27476625	1606	1614	positive	T033	C1446409
27476625	1615	1626	correlation	T080	C1707520
27476625	1649	1655	CRAFFT	T061	C4274734
27476625	1656	1661	score	T081	C0449820
27476625	1666	1677	current age	T079	C2598519
27476625	1681	1684	JIA	T047	C3495559
27476625	1685	1693	patients	T101	C0030705
27476625	1717	1726	high risk	T033	C0332167
27476625	1731	1746	substance abuse	T048	C0740858
27476625	1749	1759	dependence	T048	C0038580
27476625	1781	1784	JIA	T047	C3495559
27476625	1789	1797	controls	T096	C0009932
27476625	1799	1802	JIA	T047	C3495559
27476625	1803	1818	substance users	T098	C1257890
27476625	1844	1862	sexual intercourse	T033	C1314687
27476625	1875	1892	routine screening	T033	C3842345
27476625	1923	1926	JIA	T047	C3495559
27476625	1927	1938	adolescents	T100	C0205653

27466300|t|Transforming Growth Factor Beta 1 (TGF-β1) in Thyroid Cancer Patients: a View from the Peripheral Blood
27466300|a|Transforming growth factor beta (TGF-β) plays an important role in many pathophysiological conditions, including cancer. The level of TGF-β in patients with differentiated thyroid cancer (DTC) has not been examined so far. The aim of this study was to measure TGF-β concentration in serum samples and in PHA - stimulated whole blood culture in vitro and to analyze possible associations of TGF-β1 levels with leukocyte, lymphocyte and platelets counts, the histological type of thyroid cancer, and stage of disease. TGF-β1 was measured in 22 DTC patients and 20 healthy controls using the duoSet ELISA Development kit for human TGF-β1. The concentration of TGF-β1 in serum samples from both groups correlated positively with the platelet counts. There was no statistically significant difference in the serum concentrations of TGF-β1 between DTC patients and control subjects, but PHA stimulated whole blood cultures of DTC patients produced less TGF-β1 than those from controls. Additional studies are needed to determine the significance of these in vitro findings.
27466300	0	33	Transforming Growth Factor Beta 1	T116,T121,T123	C1704256
27466300	35	41	TGF-β1	T116,T121,T123	C1704256
27466300	46	60	Thyroid Cancer	T191	C0007115
27466300	61	69	Patients	T101	C0030705
27466300	87	103	Peripheral Blood	T031	C0229664
27466300	104	135	Transforming growth factor beta	T116,T123	C0040690
27466300	137	142	TGF-β	T116,T123	C0040690
27466300	176	194	pathophysiological	T169	C0031847
27466300	195	205	conditions	T080	C0348080
27466300	217	223	cancer	T191	C0006826
27466300	229	234	level	T080	C0441889
27466300	238	243	TGF-β	T116,T123	C0040690
27466300	247	255	patients	T101	C0030705
27466300	261	290	differentiated thyroid cancer	T191	C1337013
27466300	292	295	DTC	T191	C1337013
27466300	310	318	examined	T033	C0332128
27466300	343	348	study	T062	C2603343
27466300	364	369	TGF-β	T116,T123	C0040690
27466300	370	383	concentration	T081	C1446561
27466300	387	400	serum samples	T031	C1550100
27466300	408	411	PHA	T116,T129,T130	C0031858
27466300	414	424	stimulated	T044	C0038337
27466300	425	436	whole blood	T031	C0370231
27466300	437	444	culture	T059	C0200949
27466300	445	453	in vitro	T080	C1533691
27466300	461	468	analyze	T062	C0936012
27466300	494	500	TGF-β1	T116,T121,T123	C1704256
27466300	501	507	levels	T080	C0441889
27466300	513	522	leukocyte	T025	C0023516
27466300	524	534	lymphocyte	T025	C0024264
27466300	539	548	platelets	T025	C0005821
27466300	549	555	counts	T059	C0007584
27466300	561	573	histological	T169	C0205462
27466300	582	596	thyroid cancer	T191	C0007115
27466300	602	618	stage of disease	T060	C0699749
27466300	620	626	TGF-β1	T116,T121,T123	C1704256
27466300	646	649	DTC	T191	C1337013
27466300	650	658	patients	T101	C0030705
27466300	666	673	healthy	T080	C3898900
27466300	674	682	controls	T096	C0009932
27466300	693	721	duoSet ELISA Development kit	T074	C0812225
27466300	726	738	human TGF-β1	T116,T123	C0080222
27466300	744	757	concentration	T081	C1446561
27466300	761	767	TGF-β1	T116,T121,T123	C1704256
27466300	771	784	serum samples	T031	C1550100
27466300	795	801	groups	T098	C1257890
27466300	833	841	platelet	T025	C0005821
27466300	842	848	counts	T059	C0007584
27466300	863	888	statistically significant	T081	C0237881
27466300	907	927	serum concentrations	T081	C0683149
27466300	931	937	TGF-β1	T116,T121,T123	C1704256
27466300	946	949	DTC	T191	C1337013
27466300	950	958	patients	T101	C0030705
27466300	963	979	control subjects	T096	C0009932
27466300	985	988	PHA	T116,T129,T130	C0031858
27466300	989	999	stimulated	T044	C0038337
27466300	1000	1011	whole blood	T031	C0370231
27466300	1012	1020	cultures	T059	C0200949
27466300	1024	1027	DTC	T191	C1337013
27466300	1028	1036	patients	T101	C0030705
27466300	1051	1057	TGF-β1	T116,T121,T123	C1704256
27466300	1074	1082	controls	T096	C0009932
27466300	1095	1102	studies	T062	C2603343
27466300	1131	1143	significance	T078	C0750502
27466300	1153	1161	in vitro	T080	C1533691
27466300	1162	1170	findings	T033	C0243095

27822855|t|High-Throughput Genotyping with TaqMan Allelic Discrimination and Allele-Specific Genotyping Assays
27822855|a|Real-time PCR -based genotyping methods, such as TaqMan allelic discrimination assays and allele-specific genotyping, are particularly useful when screening a handful of single nucleotide polymorphisms in hundreds of samples; either derived from different individuals, tissues, or pre - amplified DNA. Although real-time PCR - based methods such as TaqMan are well-established, alternative methods, like allele-specific genotyping, are powerful alternatives, especially for genotyping short tandem repeat (STR) length polymorphisms. Here, we describe all relevant aspects when developing an assay for a new SNP or STR using either TaqMan or allele-specific genotyping, respectively, such as primer and probe design, optimization of reaction conditions, the experimental procedure for typing hundreds of samples, and finally the data evaluation. Our goal is to provide a guideline for developing genotyping assays using these two approaches that render reliable and reproducible genotype calls involving minimal optimization.
27822855	16	26	Genotyping	T059,T063	C3178894
27822855	32	61	TaqMan Allelic Discrimination	T059,T063	C3178894
27822855	66	99	Allele-Specific Genotyping Assays	T059,T063	C3178894
27822855	100	113	Real-time PCR	T063	C1709846
27822855	121	139	genotyping methods	T059,T063	C3178894
27822855	149	185	TaqMan allelic discrimination assays	T059,T063	C3178894
27822855	190	216	allele-specific genotyping	T059,T063	C3178894
27822855	235	241	useful	T080	C3827682
27822855	247	256	screening	T060	C0813145
27822855	270	301	single nucleotide polymorphisms	T086	C0752046
27822855	317	324	samples	T167	C0370003
27822855	346	355	different	T080	C1705242
27822855	356	367	individuals	T098	C0027361
27822855	369	376	tissues	T024	C0040300
27822855	381	384	pre	T079	C0332152
27822855	387	400	amplified DNA	T045	C0683230
27822855	411	424	real-time PCR	T063	C1709846
27822855	427	432	based	T169	C1527178
27822855	433	440	methods	T170	C0025663
27822855	449	455	TaqMan	T059,T063	C3178894
27822855	460	476	well-established	T080	C0443211
27822855	478	489	alternative	T077	C1523987
27822855	490	497	methods	T170	C0025663
27822855	504	530	allele-specific genotyping	T059,T063	C3178894
27822855	545	557	alternatives	T077	C1523987
27822855	574	584	genotyping	T059,T063	C3178894
27822855	585	604	short tandem repeat	T114,T123	C1519302
27822855	605	610	(STR)	T114,T123	C1519302
27822855	611	617	length	T081	C1444754
27822855	618	631	polymorphisms	T045	C0032529
27822855	655	663	relevant	T080	C2347946
27822855	664	671	aspects	T080	C1521970
27822855	677	687	developing	T169	C1527148
27822855	691	696	assay	T059	C1510438
27822855	707	710	SNP	T086	C0752046
27822855	714	717	STR	T114,T123	C1519302
27822855	731	737	TaqMan	T059,T063	C3178894
27822855	741	767	allele-specific genotyping	T059,T063	C3178894
27822855	791	797	primer	T114	C0206416
27822855	802	807	probe	T114,T130	C0012893
27822855	816	828	optimization	T052	C2698650
27822855	832	840	reaction	T169	C0443286
27822855	841	851	conditions	T080	C0348080
27822855	857	890	experimental procedure for typing	T059,T063	C3178894
27822855	903	910	samples	T167	C0370003
27822855	928	932	data	T078	C1511726
27822855	933	943	evaluation	T058	C0220825
27822855	949	953	goal	T170	C0018017
27822855	960	967	provide	T052	C1999230
27822855	970	979	guideline	T170	C0162791
27822855	984	994	developing	T169	C1527148
27822855	995	1012	genotyping assays	T059,T063	C3178894
27822855	1029	1039	approaches	T169	C1292724
27822855	1065	1077	reproducible	T080	C1514863
27822855	1078	1092	genotype calls	T059,T063	C3178894
27822855	1093	1102	involving	T169	C1314939
27822855	1103	1110	minimal	T080	C0547040
27822855	1111	1123	optimization	T052	C2698650

27846337|t|An Evolutionary Perspective on Basal Insulin in Diabetes Treatment: Basal Insulin in Primary Care
27846337|a|The DAWN2, HAT, and GAPP studies reaffirm that providers, patients, and family members experience numerous barriers to diabetes care, including the use of insulin. Strategies are provided as part of a shared decision-making process to help address some of the more common barriers experienced by patients.
27846337	3	27	Evolutionary Perspective	T078	C1254370
27846337	31	44	Basal Insulin	T116,T121	C0650607
27846337	48	56	Diabetes	T047	C0011847
27846337	57	66	Treatment	T169	C0039798
27846337	68	81	Basal Insulin	T116,T121	C0650607
27846337	85	97	Primary Care	T058	C0033137
27846337	102	107	DAWN2	T062	C0242481
27846337	109	112	HAT	T062	C0242481
27846337	118	130	GAPP studies	T062	C0242481
27846337	145	154	providers	T169	C1138603
27846337	156	164	patients	T101	C0030705
27846337	170	184	family members	T099	C0086282
27846337	196	204	numerous	T081	C0439064
27846337	205	213	barriers	T080	C0679881
27846337	217	225	diabetes	T047	C0011847
27846337	226	230	care	T052	C1947933
27846337	246	252	use of	T169	C1524063
27846337	253	260	insulin	T116,T121,T125	C0021641
27846337	262	272	Strategies	T041	C0679199
27846337	299	329	shared decision-making process	T041	C3179495
27846337	370	378	barriers	T080	C0679881
27846337	394	402	patients	T101	C0030705

27892857|t|Genotyping of German and Austrian Taylorella equigenitalis isolates using repetitive extragenic palindromic (REP) PCR and pulsed-field gel electrophoresis (PFGE)
27892857|a|A total of 124 Taylorella (T.) equigenitalis and five T. asinigenitalis field isolates collected between 2002 and 2014 were available for genotyping using REP- (repetitive extragenic palindromic) PCR and PFGE (pulsed-field gel electrophoresis). The study comprised 79 T. equigenitalis field isolates originating from ten defined breeds of German horses and revealed a spectrum of five REP (rep-E1-E4, rep-E3a) and 15 PFGE (TE-A1-A9, TE-B1-B3, TE-C, TE-E1, and TE-E2) genotypes. T. equigenitalis field isolates (n=40) obtained from Austrian Lipizzaner horses were differentiated into three REP (rep-E1, rep-E3a, and rep-E4) and three PFGE genotypes (TE-A2, TE-A5, and TE-D); those isolated from four Austrian Trotters belonged to the REP / PFGE genotype rep-E2/TE-A1. Interestingly, a T. equigenitalis isolate recovered from a Holsteiner stallion living in South Africa revealed the REP / PFGE genotype rep-E1/TE-A5 which was otherwise exclusively present in the majority of Austrian Lipizzaner horses in our study. The type strain included in this study revealed the genotype REP / PFGE rep-E1/TE-F. Six strains of T. asinigenitalis including the type strain were separated into three REP (rep-A1-A3) and six PFGE genotypes (TA-A1, TA-A2, TA-A3, TA-B, TA-C, TA-D). Overall, the generated REP and PFGE genotypes showed a good correlation, whereas REP-PCR proved to be a suitable method for molecular epidemiological screening of T. equigenitalis and T. asinigenitalis isolates that should be differentiated in detail by genotyping using PFGE.
27892857	0	10	Genotyping	T059	C1285573
27892857	14	20	German	T098	C1556085
27892857	25	33	Austrian	T098	C0337795
27892857	34	58	Taylorella equigenitalis	T007	C0318205
27892857	59	67	isolates	T123	C1764827
27892857	74	117	repetitive extragenic palindromic (REP) PCR	T063	C0032520
27892857	122	154	pulsed-field gel electrophoresis	T059	C0085117
27892857	156	160	PFGE	T059	C0085117
27892857	164	169	total	T080	C0439810
27892857	177	206	Taylorella (T.) equigenitalis	T007	C0318205
27892857	216	233	T. asinigenitalis	T007	C1036797
27892857	234	239	field	T077	C1521738
27892857	240	248	isolates	T123	C1764827
27892857	249	258	collected	T169	C1516698
27892857	286	295	available	T169	C0470187
27892857	300	310	genotyping	T059	C1285573
27892857	317	361	REP- (repetitive extragenic palindromic) PCR	T063	C0032520
27892857	366	370	PFGE	T059	C0085117
27892857	372	404	pulsed-field gel electrophoresis	T059	C0085117
27892857	411	416	study	T062	C2603343
27892857	430	446	T. equigenitalis	T007	C0318205
27892857	447	452	field	T077	C1521738
27892857	453	461	isolates	T123	C1764827
27892857	491	497	breeds	T040	C0006159
27892857	501	514	German horses	T015	C0019944
27892857	519	527	revealed	T080	C0443289
27892857	530	538	spectrum	T077	C2827424
27892857	547	550	REP	T086	C0004793
27892857	552	561	rep-E1-E4	T032	C0017431
27892857	563	570	rep-E3a	T032	C0017431
27892857	579	583	PFGE	T059	C0085117
27892857	585	593	TE-A1-A9	T032	C0017431
27892857	595	603	TE-B1-B3	T032	C0017431
27892857	605	609	TE-C	T032	C0017431
27892857	611	616	TE-E1	T032	C0017431
27892857	622	627	TE-E2	T032	C0017431
27892857	629	638	genotypes	T032	C0017431
27892857	640	656	T. equigenitalis	T007	C0318205
27892857	657	662	field	T077	C1521738
27892857	663	671	isolates	T123	C1764827
27892857	679	687	obtained	T169	C1301820
27892857	693	719	Austrian Lipizzaner horses	T015	C0324170
27892857	725	739	differentiated	T080	C0205556
27892857	751	754	REP	T086	C0004793
27892857	756	762	rep-E1	T032	C0017431
27892857	764	771	rep-E3a	T032	C0017431
27892857	777	783	rep-E4	T032	C0017431
27892857	795	799	PFGE	T059	C0085117
27892857	800	809	genotypes	T032	C0017431
27892857	811	816	TE-A2	T032	C0017431
27892857	818	823	TE-A5	T032	C0017431
27892857	829	833	TE-D	T032	C0017431
27892857	842	850	isolated	T169	C0205409
27892857	861	878	Austrian Trotters	T015	C0019944
27892857	895	898	REP	T086	C0004793
27892857	901	905	PFGE	T059	C0085117
27892857	906	914	genotype	T032	C0017431
27892857	915	927	rep-E2/TE-A1	T032	C0017431
27892857	946	962	T. equigenitalis	T007	C0318205
27892857	963	970	isolate	T123	C1764827
27892857	971	985	recovered from	T080	C0521108
27892857	988	1007	Holsteiner stallion	T015	C0019944
27892857	1008	1014	living	T078	C0376558
27892857	1018	1030	South Africa	T083	C0037712
27892857	1031	1039	revealed	T080	C0443289
27892857	1044	1047	REP	T086	C0004793
27892857	1050	1054	PFGE	T059	C0085117
27892857	1055	1063	genotype	T032	C0017431
27892857	1064	1076	rep-E1/TE-A5	T032	C0017431
27892857	1097	1108	exclusively	T078	C1548966
27892857	1109	1116	present	T033	C0150312
27892857	1124	1132	majority	T054	C0680220
27892857	1136	1162	Austrian Lipizzaner horses	T015	C0324170
27892857	1170	1175	study	T062	C2603343
27892857	1186	1192	strain	T001	C1518614
27892857	1210	1215	study	T062	C2603343
27892857	1216	1224	revealed	T080	C0443289
27892857	1229	1237	genotype	T032	C0017431
27892857	1238	1241	REP	T086	C0004793
27892857	1244	1248	PFGE	T059	C0085117
27892857	1249	1260	rep-E1/TE-F	T032	C0017431
27892857	1266	1273	strains	T001	C1518614
27892857	1277	1294	T. asinigenitalis	T007	C1036797
27892857	1314	1320	strain	T001	C1518614
27892857	1326	1335	separated	T080	C0443299
27892857	1347	1350	REP	T086	C0004793
27892857	1352	1361	rep-A1-A3	T032	C0017431
27892857	1371	1375	PFGE	T059	C0085117
27892857	1376	1385	genotypes	T032	C0017431
27892857	1387	1392	TA-A1	T032	C0017431
27892857	1394	1399	TA-A2	T032	C0017431
27892857	1401	1406	TA-A3	T032	C0017431
27892857	1408	1412	TA-B	T032	C0017431
27892857	1414	1418	TA-C	T032	C0017431
27892857	1420	1424	TA-D	T032	C0017431
27892857	1427	1435	Overall,	T080	C1561607
27892857	1440	1449	generated	T052	C3146294
27892857	1450	1453	REP	T086	C0004793
27892857	1458	1462	PFGE	T059	C0085117
27892857	1463	1472	genotypes	T032	C0017431
27892857	1482	1486	good	T080	C0205170
27892857	1487	1498	correlation	T080	C1707520
27892857	1508	1515	REP-PCR	T063	C0032520
27892857	1531	1546	suitable method	T059	C0871511
27892857	1551	1586	molecular epidemiological screening	T059	C1294203
27892857	1590	1606	T. equigenitalis	T007	C0318205
27892857	1611	1628	T. asinigenitalis	T007	C1036797
27892857	1629	1637	isolates	T123	C1764827
27892857	1653	1667	differentiated	T080	C0205556
27892857	1671	1677	detail	T080	C1522508
27892857	1681	1691	genotyping	T059	C1285573
27892857	1698	1702	PFGE	T059	C0085117

28214898|t|Early Development of Parvalbumin -, Somatostatin -, and Cholecystokinin -Expressing Neurons in Rat Brain following Prenatal Immune Activation and Maternal Iron Deficiency
28214898|a|Prenatal maternal infection and maternal iron deficiency during pregnancy are 2 early environmental insults associated with increased risk for schizophrenia in offspring. Substantial evidence suggests that abnormalities in inhibitory γ-aminobutyric acid (GABA) interneuron function, especially in the parvalbumin subtype of GABA interneuron, both developmentally and in adulthood, may contribute mechanistically to cognitive deficits and psychotic symptoms in schizophrenia. This study used a rat model to test whether prenatal immune activation with lipopolysaccharide (LPS; at gestation days, GD, 15 and 16) or maternal iron deficiency (from GD 2 to postnatal day P7) or the combination of both insults alters major subtypes of GABAergic interneurons (parvalbumin, somatostatin, cholecystokinin) in brain regions relevant to schizophrenia (medial and dorsolateral prefrontal cortex [PFC], hippocampal CA1 and dentate gyrus, ventral subiculum) in offspring at P14 or P28. Prenatal LPS treatment significantly increased the density of parvalbumin - immunoreactive neurons at P14 in the medial PFC, dorsolateral PFC, and ventral subiculum of offspring born from iron-sufficient but not iron-deficient dams. Prenatal LPS also increased cholecystokinin neuron density in the medial PFC at P28, under both iron-sufficient and iron-deficient conditions. We observed a large increase in parvalbumin neuron density from P14 to P28 in the medial PFC and subiculum across all birth groups, that was not observed in other brain regions, and significant decreases in somatostatin neuron density from P14 to P28 in all brain regions examined across all birth groups, indicating differential developmental trajectories for parvalbumin and somatostatin neurons in various brain regions during this early postnatal period. Thus, it appears that the medial PFC and ventral subiculum, brain regions involved in circuitry modulating ventral tegmental dopamine and nucleus accumbens activities, may be regions vulnerable to effects of prenatal LPS on specific subpopulations of interneurons. It is known that the timing of maturation and expansion of parvalbumin neurons in early development provides threshold levels of inhibition that trigger critical periods for cortical plasticity, leading to long-term circuit consolidation. Thus, our finding of increased parvalbumin neuron density at early developmental times might suggest a mechanism by which an acute prenatal insult like LPS exposure could produce long-term changes in prefrontal cortical or subicular function.
28214898	0	17	Early Development	T033	C1856550
28214898	21	32	Parvalbumin	T116,T123	C0030616
28214898	36	48	Somatostatin	T116,T121,T125	C0037659
28214898	56	71	Cholecystokinin	T116,T121,T125	C0008328
28214898	84	91	Neurons	T025	C0027882
28214898	95	104	Rat Brain	T023	C1882598
28214898	115	123	Prenatal	T079	C2828394
28214898	124	141	Immune Activation	T043	C1155000
28214898	146	170	Maternal Iron Deficiency	T047	C0240066
28214898	171	179	Prenatal	T079	C2828394
28214898	180	198	maternal infection	T033	C0239997
28214898	203	227	maternal iron deficiency	T047	C0240066
28214898	235	244	pregnancy	T040	C0032961
28214898	279	294	associated with	T080	C0332281
28214898	295	304	increased	T081	C0205217
28214898	305	309	risk	T078	C0035647
28214898	314	327	schizophrenia	T048	C0036341
28214898	331	340	offspring	T099	C0680063
28214898	342	362	Substantial evidence	T078	C3887511
28214898	377	390	abnormalities	T033	C1867987
28214898	394	443	inhibitory γ-aminobutyric acid (GABA) interneuron	T025	C0682694
28214898	405	424	γ-aminobutyric acid	T116,T123	C0016904
28214898	426	430	GABA	T116,T123	C0016904
28214898	444	452	function	T043	C0007613
28214898	472	483	parvalbumin	T116,T123	C0030616
28214898	484	491	subtype	T185	C0449560
28214898	495	511	GABA interneuron	T025	C0815002
28214898	538	550	in adulthood	T079	C2945655
28214898	586	604	cognitive deficits	T048	C0009241
28214898	609	627	psychotic symptoms	T184	C0871189
28214898	631	644	schizophrenia	T048	C0036341
28214898	664	667	rat	T015	C0034693
28214898	668	673	model	T050	C0012644
28214898	690	698	prenatal	T079	C2828394
28214898	699	716	immune activation	T043	C1155000
28214898	722	740	lipopolysaccharide	T109	C0023810
28214898	742	745	LPS	T109	C0023810
28214898	750	759	gestation	T040	C0032961
28214898	760	764	days	T079	C0439228
28214898	766	768	GD	T079	C0439228
28214898	784	808	maternal iron deficiency	T047	C0240066
28214898	815	817	GD	T079	C0439228
28214898	823	836	postnatal day	T079	C0439228
28214898	889	897	subtypes	T185	C0449560
28214898	901	923	GABAergic interneurons	T025	C0815002
28214898	925	936	parvalbumin	T116,T123	C0030616
28214898	938	950	somatostatin	T116,T121,T125	C0037659
28214898	952	967	cholecystokinin	T116,T121,T125	C0008328
28214898	972	985	brain regions	T029	C1273723
28214898	998	1011	schizophrenia	T048	C0036341
28214898	1013	1019	medial	T023	C0162783
28214898	1024	1054	dorsolateral prefrontal cortex	T023	C4019080
28214898	1056	1059	PFC	T023	C0162783
28214898	1062	1077	hippocampal CA1	T029	C0694598
28214898	1082	1095	dentate gyrus	T023	C0152314
28214898	1097	1114	ventral subiculum	T023	C3499061
28214898	1119	1128	offspring	T099	C0680063
28214898	1144	1152	Prenatal	T079	C2828394
28214898	1153	1156	LPS	T109	C0023810
28214898	1157	1166	treatment	T061	C0087111
28214898	1181	1190	increased	T081	C0205217
28214898	1195	1202	density	T081	C0178587
28214898	1206	1217	parvalbumin	T116,T123	C0030616
28214898	1220	1242	immunoreactive neurons	T025	C0027882
28214898	1257	1263	medial	T082	C0205098
28214898	1264	1267	PFC	T023	C0162783
28214898	1269	1285	dorsolateral PFC	T023	C4019080
28214898	1291	1308	ventral subiculum	T023	C3499061
28214898	1312	1321	offspring	T099	C0680063
28214898	1322	1326	born	T040	C0005615
28214898	1332	1347	iron-sufficient	T033	C0243095
28214898	1356	1375	iron-deficient dams	T033	C0243095
28214898	1377	1385	Prenatal	T079	C2828394
28214898	1386	1389	LPS	T109	C0023810
28214898	1395	1404	increased	T081	C0205217
28214898	1405	1420	cholecystokinin	T116,T121,T125	C0008328
28214898	1421	1427	neuron	T025	C0027882
28214898	1428	1435	density	T081	C0178587
28214898	1443	1449	medial	T082	C0205098
28214898	1450	1453	PFC	T023	C0162783
28214898	1473	1488	iron-sufficient	T033	C0243095
28214898	1493	1518	iron-deficient conditions	T033	C0243095
28214898	1540	1548	increase	T169	C0442805
28214898	1552	1563	parvalbumin	T116,T123	C0030616
28214898	1564	1570	neuron	T025	C0027882
28214898	1571	1578	density	T081	C0178587
28214898	1602	1608	medial	T082	C0205098
28214898	1609	1612	PFC	T023	C0162783
28214898	1617	1626	subiculum	T023	C3499061
28214898	1638	1650	birth groups	T078	C0441833
28214898	1683	1696	brain regions	T029	C1273723
28214898	1714	1723	decreases	T081	C0547047
28214898	1727	1739	somatostatin	T116,T121,T125	C0037659
28214898	1740	1746	neuron	T025	C0027882
28214898	1747	1754	density	T081	C0178587
28214898	1778	1791	brain regions	T029	C1273723
28214898	1812	1824	birth groups	T078	C0441833
28214898	1837	1876	differential developmental trajectories	T080	C0205556
28214898	1881	1892	parvalbumin	T116,T123	C0030616
28214898	1897	1909	somatostatin	T116,T121,T125	C0037659
28214898	1910	1917	neurons	T025	C0027882
28214898	1929	1942	brain regions	T029	C1273723
28214898	1955	1977	early postnatal period	T079	C0871109
28214898	2005	2011	medial	T082	C0205098
28214898	2012	2015	PFC	T023	C0162783
28214898	2020	2037	ventral subiculum	T023	C3499061
28214898	2039	2052	brain regions	T029	C1273723
28214898	2065	2085	circuitry modulating	T042	C1254358
28214898	2086	2112	ventral tegmental dopamine	T023	C1183185
28214898	2117	2134	nucleus accumbens	T023	C0028633
28214898	2135	2145	activities	T052	C0441655
28214898	2154	2161	regions	T029	C1273723
28214898	2176	2183	effects	T080	C1280500
28214898	2187	2195	prenatal	T079	C2828394
28214898	2196	2199	LPS	T109	C0023810
28214898	2212	2226	subpopulations	T185	C0008902
28214898	2230	2242	interneurons	T025	C0021792
28214898	2275	2285	maturation	T043	C1623343
28214898	2290	2299	expansion	T043	C0007595
28214898	2303	2314	parvalbumin	T116,T123	C0030616
28214898	2315	2322	neurons	T025	C0027882
28214898	2326	2343	early development	T033	C1856550
28214898	2353	2362	threshold	T080	C0449864
28214898	2363	2369	levels	T080	C0441889
28214898	2373	2383	inhibition	T042	C0027790
28214898	2397	2413	critical periods	T079	C0010339
28214898	2418	2437	cortical plasticity	T042	C0027880
28214898	2450	2481	long-term circuit consolidation	T041	C0679057
28214898	2504	2513	increased	T081	C0205217
28214898	2514	2525	parvalbumin	T116,T123	C0030616
28214898	2526	2532	neuron	T025	C0027882
28214898	2533	2540	density	T081	C0178587
28214898	2544	2569	early developmental times	T079	C0040223
28214898	2586	2595	mechanism	T169	C0441712
28214898	2608	2629	acute prenatal insult	T037	C0178314
28214898	2635	2638	LPS	T109	C0023810
28214898	2639	2647	exposure	T080	C0332157
28214898	2662	2671	long-term	T079	C0443252
28214898	2672	2679	changes	T169	C0392747
28214898	2683	2724	prefrontal cortical or subicular function	T042	C1254358

27638176|t|A Characeae Cells Plasma Membrane as a Model for Selection of Bioactive Compounds and Drugs: Interaction of HAMLET-Like Complexes with Ion Channels of Chara corallina Cells Plasmalemma
27638176|a|Interaction of a HAMLET-like La-OA cytotoxic complex (human α-lactalbumin - oleic acid) and its constituents with the excitable plasmalemma of giant Chara corallina cells was investigated. The voltage-clamp technique was used to study Ca(2+) and Cl(-) transient currents in the plasmalemma of intact cells. The action of the complex and OA on the target cell membrane has a dose-dependent character. It was found that the La-OA complex has an inhibiting effect on Ca(2+) current across the plasmalemma, while α-lactalbumin alone does not affect the electrophysiological characteristics of the cellular membrane. However, oleic acid blocks Ca(2+) current across the plasmalemma. This is accompanied by the induction of a non-selective conductivity in the cellular membrane, a decrease in the resting potential and plasma membrane resistance of algal cells. We propose that the cytotoxicity of La-OA and other HAMLET-like complexes is determined by oleic acid acting as a blocker of potential -dependent Ca(2+) channels in the plasma membrane of target cells. The presented results show that the study model of green algae C. corallina cells plasmalemma is a convenient tool for the investigation of ion channels in many animal cells.
27638176	2	11	Characeae	T002	C0996485
27638176	12	17	Cells	T025	C3178867
27638176	18	33	Plasma Membrane	T026	C0007603
27638176	39	44	Model	T170	C0086272
27638176	49	58	Selection	T052	C1707391
27638176	62	81	Bioactive Compounds	T167	C3714412
27638176	86	91	Drugs	T121	C1254351
27638176	93	104	Interaction	T169	C1704675
27638176	108	129	HAMLET-Like Complexes	T116,T121	C1686902
27638176	135	147	Ion Channels	T116,T123	C0022009
27638176	151	166	Chara corallina	T002	C1010950
27638176	167	172	Cells	T025	C3178867
27638176	173	184	Plasmalemma	T026	C0007603
27638176	185	196	Interaction	T169	C1704675
27638176	202	237	HAMLET-like La-OA cytotoxic complex	T116,T121	C1686902
27638176	245	258	α-lactalbumin	T116,T123	C0002287
27638176	261	271	oleic acid	T109,T121	C0028928
27638176	281	293	constituents	T167	C0729650
27638176	303	312	excitable	T184	C0857393
27638176	313	324	plasmalemma	T026	C0007603
27638176	334	349	Chara corallina	T002	C1010950
27638176	350	355	cells	T025	C3178867
27638176	360	372	investigated	T169	C1292732
27638176	378	401	voltage-clamp technique	T062	C0242623
27638176	414	419	study	T062	C2603343
27638176	420	426	Ca(2+)	T121,T196	C0596235
27638176	431	436	Cl(-)	T196	C0596019
27638176	437	455	transient currents	T043	C0162585
27638176	463	474	plasmalemma	T026	C0007603
27638176	478	490	intact cells	UnknownType	C0682538
27638176	496	502	action	T052	C3266814
27638176	510	517	complex	T104	C1704241
27638176	522	524	OA	T109,T121	C0028928
27638176	532	538	target	T169	C1521840
27638176	539	552	cell membrane	T026	C0007603
27638176	559	573	dose-dependent	T081	C1512045
27638176	607	620	La-OA complex	T116,T121	C1686902
27638176	628	638	inhibiting	T052	C3463820
27638176	639	645	effect	T080	C1280500
27638176	649	655	Ca(2+)	T121,T196	C0596235
27638176	656	663	current	T043	C0162585
27638176	675	686	plasmalemma	T026	C0007603
27638176	694	707	α-lactalbumin	T116,T123	C0002287
27638176	734	754	electrophysiological	T040	C2350528
27638176	755	770	characteristics	T080	C1521970
27638176	778	795	cellular membrane	T026	C3161472
27638176	806	816	oleic acid	T109,T121	C0028928
27638176	817	823	blocks	T169	C0332206
27638176	824	830	Ca(2+)	T121,T196	C0596235
27638176	831	838	current	T043	C0162585
27638176	850	861	plasmalemma	T026	C0007603
27638176	890	899	induction	T169	C0205263
27638176	919	931	conductivity	T043	C0007613
27638176	939	956	cellular membrane	T026	C3161472
27638176	960	968	decrease	T081	C0547047
27638176	976	993	resting potential	T043	C1704297
27638176	998	1013	plasma membrane	T026	C0007603
27638176	1014	1024	resistance	T169	C4281815
27638176	1028	1033	algal	T204	C0002028
27638176	1034	1039	cells	T025	C0007634
27638176	1061	1073	cytotoxicity	T049	C0596402
27638176	1077	1082	La-OA	T116,T121	C1686902
27638176	1093	1114	HAMLET-like complexes	T116,T121	C1686902
27638176	1132	1142	oleic acid	T109,T121	C0028928
27638176	1155	1162	blocker	T121	C0870261
27638176	1166	1175	potential	T080	C3245505
27638176	1187	1202	Ca(2+) channels	T116,T123	C0006685
27638176	1210	1225	plasma membrane	T026	C0007603
27638176	1229	1241	target cells	T025	C0221284
27638176	1257	1264	results	T169	C1274040
27638176	1279	1290	study model	T075	C0026336
27638176	1294	1305	green algae	T002	C0002032
27638176	1306	1318	C. corallina	T002	C1010950
27638176	1319	1324	cells	T025	C3178867
27638176	1325	1336	plasmalemma	T026	C0007603
27638176	1366	1379	investigation	T062	C0683933
27638176	1383	1395	ion channels	T116,T123	C0022009
27638176	1404	1416	animal cells	UnknownType	C0682517

28376393|t|A novel assay to measure tertiary and quaternary amines in wastewater: An indicator for NDMA wastewater precursors
28376393|a|This study examined the potential of using a novel bulk amine assay as an approximation for the tertiary and quaternary amine load in wastewaters and surface water samples, and this approximation was compared to N-nitrosodimethylamine (NDMA) formation potential using chloramines. An existing colorimetric method was examined and optimized for the detection of amines in environmental water samples. The method consists of liquid-liquid extraction followed by a catalyzed reaction to form a yet- undefined product that is known to be both a strong chromophore and fluorophore. Previous work verified that this reaction was effectively catalyzed by a number of compounds containing tertiary and quaternary amine moieties. Many tertiary and quaternary compounds are also efficient producers of NDMA under chloramination conditions, and a linear correlation was consequently derived from the bulk amine signals vs. NDMA formation potential in various wastewater samples (R(2) = 0.74; n = 24; p-value < 0.05). The results provide evidence that approximately 2% of the tertiary and quaternary amines measured can form NDMA and an estimated 0.01-1.3% of nitrogen in dissolved organic nitrogen originates from these bulk amines. The normalization of NDMA concentration by the amine measurement revealed that ozone effectively destroyed those tertiary and quaternary amine structures more likely to form NDMA in treated wastewater samples. This bulk amine assay illustrates that proxy measurements of tertiary and quaternary amines can be linked to the NDMA formation potential of a given sample, and this approach may prove useful as a characterizing tool for NDMA precursors in wastewater.
28376393	2	7	novel	T080	C0205314
28376393	8	13	assay	T059	C1510438
28376393	17	24	measure	T081	C0079809
28376393	25	33	tertiary	T197	C0597565
28376393	38	55	quaternary amines	T109	C0578399
28376393	59	69	wastewater	T069	C3494254
28376393	74	83	indicator	T169	C1522602
28376393	88	92	NDMA	T109,T131	C0012431
28376393	93	103	wastewater	T069	C3494254
28376393	104	114	precursors	T078	C1709634
28376393	120	125	study	T059	C0947630
28376393	126	134	examined	T033	C0332128
28376393	139	148	potential	T080	C3245505
28376393	160	165	novel	T080	C0205314
28376393	166	182	bulk amine assay	T059	C1510438
28376393	189	202	approximation	T080	C0332232
28376393	211	219	tertiary	T197	C0597565
28376393	224	240	quaternary amine	T109	C0578399
28376393	249	260	wastewaters	T069	C3494254
28376393	265	272	surface	T082	C0205148
28376393	273	286	water samples	T197	C1550678
28376393	297	310	approximation	T080	C0332232
28376393	315	323	compared	T052	C1707455
28376393	327	349	N-nitrosodimethylamine	T109,T131	C0012431
28376393	351	355	NDMA	T109,T131	C0012431
28376393	357	366	formation	T169	C1522492
28376393	367	376	potential	T080	C3245505
28376393	383	394	chloramines	T109	C0008164
28376393	408	427	colorimetric method	T059	C0009407
28376393	432	440	examined	T033	C0332128
28376393	463	472	detection	T033	C0442726
28376393	476	482	amines	T109	C0002508
28376393	486	499	environmental	T082	C0014406
28376393	500	513	water samples	T197	C1550678
28376393	519	525	method	T059	C0871511
28376393	538	562	liquid-liquid extraction	T059	C3178840
28376393	577	586	catalyzed	T169	C0205245
28376393	587	595	reaction	T067	C0596319
28376393	611	620	undefined	T078	C0750600
28376393	621	628	product	T071	C1514468
28376393	656	662	strong	T080	C0442821
28376393	663	674	chromophore	T120	C0596335
28376393	679	690	fluorophore	T121,T130	C0598447
28376393	725	733	reaction	T067	C0596319
28376393	750	759	catalyzed	T169	C0205245
28376393	765	771	number	T081	C0237753
28376393	775	784	compounds	T080	C0205198
28376393	796	804	tertiary	T197	C0597565
28376393	809	825	quaternary amine	T109	C0578399
28376393	826	834	moieties	T077	C3641152
28376393	841	849	tertiary	T197	C0597565
28376393	854	874	quaternary compounds	T109	C0578399
28376393	884	893	efficient	T080	C0442799
28376393	894	903	producers	T169	C0205245
28376393	907	911	NDMA	T109,T131	C0012431
28376393	918	932	chloramination	T070	C0002505
28376393	933	943	conditions	T080	C0348080
28376393	951	969	linear correlation	T080	C1707520
28376393	974	986	consequently	T033	C3845876
28376393	1004	1022	bulk amine signals	T067	C1710082
28376393	1027	1031	NDMA	T109,T131	C0012431
28376393	1032	1041	formation	T169	C1522492
28376393	1042	1051	potential	T080	C3245505
28376393	1063	1073	wastewater	T069	C3494254
28376393	1074	1081	samples	T167	C0370003
28376393	1141	1149	evidence	T078	C3887511
28376393	1155	1168	approximately	T080	C0332232
28376393	1179	1187	tertiary	T197	C0597565
28376393	1210	1218	measured	T080	C0444706
28376393	1228	1232	NDMA	T109,T131	C0012431
28376393	1240	1249	estimated	T081	C0750572
28376393	1263	1271	nitrogen	T123,T196	C0028158
28376393	1275	1312	dissolved organic nitrogen originates	T109	C0002508
28376393	1324	1335	bulk amines	T109	C0002508
28376393	1341	1354	normalization	T062	C1882115
28376393	1358	1362	NDMA	T109,T131	C0012431
28376393	1363	1376	concentration	T081	C1446561
28376393	1384	1389	amine	T109	C0002508
28376393	1390	1401	measurement	T169	C0242485
28376393	1416	1421	ozone	T103	C0030106
28376393	1422	1433	effectively	T080	C1704419
28376393	1434	1443	destroyed	T052	C1948029
28376393	1450	1458	tertiary	T197	C0597565
28376393	1463	1479	quaternary amine	T109	C0578399
28376393	1480	1490	structures	T082	C0678594
28376393	1511	1515	NDMA	T109,T131	C0012431
28376393	1519	1526	treated	T169	C1522326
28376393	1527	1537	wastewater	T069	C3494254
28376393	1538	1545	samples	T167	C0370003
28376393	1552	1568	bulk amine assay	T059	C1510438
28376393	1592	1604	measurements	T169	C0242485
28376393	1608	1616	tertiary	T197	C0597565
28376393	1621	1638	quaternary amines	T109	C0578399
28376393	1660	1664	NDMA	T109,T131	C0012431
28376393	1665	1674	formation	T169	C1522492
28376393	1675	1684	potential	T080	C3245505
28376393	1696	1702	sample	T167	C0370003
28376393	1732	1738	useful	T080	C3827682
28376393	1744	1758	characterizing	T052	C1880022
28376393	1759	1763	tool	T169	C0449851
28376393	1768	1772	NDMA	T109,T131	C0012431
28376393	1773	1783	precursors	T078	C1709634
28376393	1787	1797	wastewater	T069	C3494254

27387187|t|RF Ablation of Giant Hemangiomas Inducing Acute Renal Failure: A Report of Two Cases
27387187|a|In patients that require treatment for hepatic giant cavernous hemangiomas (GCH), radiofrequency ablation (RFA) has been suggested to represent a safe and effective alternative to invasive surgery. In a recent report of bipolar RFA, using two expandable needle electrodes, was uneventfully performed in patients with large GCH (>10 cm). The objective of this report is to present two cases in which bipolar RFA of symptomatic GCH was complicated by acute kidney injury. In 2015 we treated two patients for very large symptomatic GCH (15.7 and 25.0 cm) with bipolar RFA during open laparotomy. In both patients the urine showed a red-brown discoloration directly after the ablation. They became anuric and presented with progressive dyspnea, tachypnea, and tachycardia, requiring hemodialysis for a period of 1 month in one case. Lab results revealed hemepigment - induced acute kidney. Both patients fully recovered and both showed a complete relief of symptoms at 3 months following the procedure. RFA for large GCHs can cause hemepigment - induced acute kidney injury due to massive intravascular hemolysis. The presented cases suggest that caution is warranted and advocate an upper limit regarding the volume of GCHs that can be safely ablated.
27387187	0	11	RF Ablation	T061	C0850292
27387187	15	32	Giant Hemangiomas	T191	C0018916
27387187	33	41	Inducing	T169	C0205263
27387187	42	61	Acute Renal Failure	T047	C0022660
27387187	65	71	Report	T170	C0085973
27387187	79	84	Cases	T169	C0868928
27387187	88	96	patients	T101	C0030705
27387187	102	109	require	T169	C1514873
27387187	110	119	treatment	T169	C1522326
27387187	124	131	hepatic	T029	C0205054
27387187	132	159	giant cavernous hemangiomas	T191	C0018920
27387187	161	164	GCH	T191	C0018920
27387187	167	190	radiofrequency ablation	T061	C0850292
27387187	192	195	RFA	T061	C0850292
27387187	206	215	suggested	T078	C1705535
27387187	240	249	effective	T080	C1704419
27387187	250	261	alternative	T077	C1523987
27387187	265	273	invasive	T080	C0205281
27387187	274	281	surgery	T061	C0543467
27387187	295	301	report	T170	C0085973
27387187	305	316	bipolar RFA	T061	C0850292
27387187	328	356	expandable needle electrodes	T074	C0181967
27387187	375	384	performed	T169	C0884358
27387187	388	396	patients	T101	C0030705
27387187	402	407	large	T081	C0549177
27387187	408	411	GCH	T191	C0018920
27387187	444	450	report	T170	C0085973
27387187	469	474	cases	T169	C0868928
27387187	484	495	bipolar RFA	T061	C0850292
27387187	499	510	symptomatic	T169	C0231220
27387187	511	514	GCH	T191	C0018920
27387187	519	530	complicated	T169	C0231242
27387187	534	553	acute kidney injury	T037	C2609414
27387187	566	573	treated	T169	C1522326
27387187	578	586	patients	T101	C0030705
27387187	596	601	large	T081	C0549177
27387187	602	613	symptomatic	T169	C0231220
27387187	614	617	GCH	T191	C0018920
27387187	642	653	bipolar RFA	T061	C0850292
27387187	661	676	open laparotomy	T061	C0023038
27387187	686	694	patients	T101	C0030705
27387187	699	704	urine	T031	C0042036
27387187	714	737	red-brown discoloration	T033	C0522153
27387187	757	765	ablation	T061	C0547070
27387187	779	785	anuric	T047	C0003460
27387187	790	799	presented	T078	C0449450
27387187	805	824	progressive dyspnea	T033	C0239202
27387187	826	835	tachypnea	T033	C0231835
27387187	841	852	tachycardia	T046	C0039231
27387187	864	876	hemodialysis	T061	C0019004
27387187	883	889	period	T079	C1948053
27387187	895	900	month	T079	C0439231
27387187	908	912	case	T169	C0868928
27387187	914	925	Lab results	T170	C3244125
27387187	935	946	hemepigment	T120	C0031916
27387187	949	956	induced	T169	C0205263
27387187	957	969	acute kidney	T037	C2609414
27387187	976	984	patients	T101	C0030705
27387187	991	1000	recovered	T080	C0521108
27387187	1019	1027	complete	T080	C0205197
27387187	1028	1034	relief	T033	C0564405
27387187	1038	1046	symptoms	T184	C1457887
27387187	1052	1058	months	T079	C0439231
27387187	1073	1082	procedure	T169	C2700391
27387187	1084	1087	RFA	T061	C0850292
27387187	1092	1097	large	T081	C0549177
27387187	1098	1102	GCHs	T191	C0018920
27387187	1113	1124	hemepigment	T120	C0031916
27387187	1127	1134	induced	T169	C0205263
27387187	1135	1154	acute kidney injury	T037	C2609414
27387187	1162	1169	massive	T080	C0522501
27387187	1170	1193	intravascular hemolysis	T047	C0235574
27387187	1209	1214	cases	T169	C0868928
27387187	1291	1297	volume	T081	C0449468
27387187	1301	1305	GCHs	T191	C0018920
27387187	1325	1332	ablated	T061	C0547070

28092340|t|Decompression Surgery Alone Versus Decompression Plus Fusion in Symptomatic Lumbar Spinal Stenosis: A Swiss Prospective Multi-center Cohort Study with 3 Years of Follow-up
28092340|a|Retrospective analysis of a prospective, multicenter cohort study. To estimate the added effect of surgical fusion as compared to decompression surgery alone in symptomatic lumbar spinal stenosis patients with spondylolisthesis. The optimal surgical management of lumbar spinal stenosis patients with spondylolisthesis remains controversial. Patients of the LSOS with confirmed DLSS and spondylolisthesis were enrolled in this study. The outcomes of this study were Spinal Stenosis Measure (SSM) symptoms (score range 1-5, best-worst) and function (1-4) over time, measured at baseline, 6, 12, 24 and 36 months follow-up. In order to quantify the effect of fusion surgery as compared to decompression alone and number of decompressed levels, we used mixed effects models and accounted for the repeated observations in main outcomes (SSM symptoms and SSM function) over time. In addition to individual patients ' random effects, we also fitted random slopes for follow-up time points and compared these two approaches with Akaike's Information Criterion (AIC) and the chi-squared test. Confounders were adjusted with fixed effects for age, gender, BMI, diabetes, CIRS musculoskeletal disorders and duration of symptoms. One hundred and thirty-one patients undergoing decompression surgery alone (n = 85) or decompression plus fusion surgery (n = 46) were included in this study. In the multiple mixed effects model the adjusted effect of fusion versus decompression alone surgery on SSM symptoms was 0.06 (95% confidence interval, CI: -0.16 to 0.27) and -0.07 (95% CI: -0.25 to 0.10) on SSM function, respectively. Among the patients with degenerative lumbar spinal stenosis and spondylolisthesis our study confirms that in the two groups, decompression alone and decompression plus fusion, patients distinctively benefited from surgical treatment. When adjusted for confounders, fusion surgery was not associated with a more favorable outcome in both SSM scores as compared to decompression alone surgery. 3.
28092340	0	21	Decompression Surgery	T061	C0408670
28092340	35	48	Decompression	T061	C0408670
28092340	54	60	Fusion	T061	C0919636
28092340	64	75	Symptomatic	T169	C0231220
28092340	76	98	Lumbar Spinal Stenosis	T047	C0158288
28092340	102	107	Swiss	T098	C0241315
28092340	108	145	Prospective Multi-center Cohort Study	T062	C1709709
28092340	153	158	Years	T079	C0439234
28092340	162	171	Follow-up	T062	C0016441
28092340	172	194	Retrospective analysis	T062	C0035363
28092340	200	237	prospective, multicenter cohort study	T062	C1709709
28092340	261	267	effect	T080	C1280500
28092340	271	286	surgical fusion	T061	C0919636
28092340	302	323	decompression surgery	T061	C0408670
28092340	333	344	symptomatic	T169	C0231220
28092340	345	367	lumbar spinal stenosis	T047	C0158288
28092340	368	376	patients	T101	C0030705
28092340	382	399	spondylolisthesis	T047	C0038016
28092340	405	432	optimal surgical management	T058	C1515089
28092340	436	458	lumbar spinal stenosis	T047	C0158288
28092340	459	467	patients	T101	C0030705
28092340	473	490	spondylolisthesis	T047	C0038016
28092340	514	522	Patients	T101	C0030705
28092340	530	534	LSOS	T062	C0543472
28092340	550	554	DLSS	T047	C0410636
28092340	559	576	spondylolisthesis	T047	C0038016
28092340	599	604	study	T077	C1706256
28092340	610	618	outcomes	T062	C0086750
28092340	627	632	study	T077	C1706256
28092340	638	653	Spinal Stenosis	T020	C0037944
28092340	638	661	Spinal Stenosis Measure	T081	C0392762
28092340	663	666	SSM	T081	C0392762
28092340	668	676	symptoms	T184	C1457887
28092340	678	689	score range	T081	C0449820
28092340	711	719	function	T169	C0542341
28092340	726	735	over time	T079	C0040223
28092340	737	745	measured	T080	C0444706
28092340	749	757	baseline	T081	C1442488
28092340	776	782	months	T079	C0439231
28092340	783	792	follow-up	T062	C0016441
28092340	806	814	quantify	T081	C1709793
28092340	819	825	effect	T080	C1280500
28092340	829	843	fusion surgery	T061	C0919636
28092340	859	872	decompression	T061	C0408670
28092340	883	912	number of decompressed levels	T033	C0243095
28092340	928	935	effects	T080	C1280500
28092340	936	942	models	T075	C0026336
28092340	965	986	repeated observations	T062	C0302523
28092340	995	1003	outcomes	T062	C0086750
28092340	1005	1008	SSM	T081	C0392762
28092340	1009	1017	symptoms	T184	C1457887
28092340	1022	1025	SSM	T081	C0392762
28092340	1026	1034	function	T169	C0542341
28092340	1036	1045	over time	T079	C0040223
28092340	1073	1081	patients	T101	C0030705
28092340	1084	1098	random effects	T080	C1280500
28092340	1108	1128	fitted random slopes	T081	C0807955
28092340	1133	1142	follow-up	T033	C0589120
28092340	1143	1154	time points	T079	C0439547
28092340	1178	1188	approaches	T169	C1292724
28092340	1194	1224	Akaike's Information Criterion	T170	C0282574
28092340	1226	1229	AIC	T170	C0282574
28092340	1239	1255	chi-squared test	T170	C0237913
28092340	1257	1268	Confounders	T169	C0009673
28092340	1288	1301	fixed effects	T080	C1280500
28092340	1306	1309	age	T032	C0001779
28092340	1311	1317	gender	T032	C0079399
28092340	1319	1322	BMI	T201	C1305855
28092340	1324	1332	diabetes	T047	C0011847
28092340	1334	1338	CIRS	T081,T170	C0681889
28092340	1339	1364	musculoskeletal disorders	T047	C0026857
28092340	1369	1377	duration	T109,T121	C2926735
28092340	1381	1389	symptoms	T184	C1457887
28092340	1418	1426	patients	T101	C0030705
28092340	1438	1459	decompression surgery	T061	C0408670
28092340	1478	1491	decompression	T061	C0408670
28092340	1497	1511	fusion surgery	T061	C0919636
28092340	1543	1548	study	T077	C1706256
28092340	1557	1579	multiple mixed effects	T080	C1280500
28092340	1580	1585	model	T075	C0026336
28092340	1599	1605	effect	T080	C1280500
28092340	1609	1615	fusion	T061	C0919636
28092340	1623	1650	decompression alone surgery	T061	C0408670
28092340	1654	1657	SSM	T081	C0392762
28092340	1658	1666	symptoms	T184	C1457887
28092340	1681	1700	confidence interval	T081	C0009667
28092340	1702	1704	CI	T081	C0009667
28092340	1736	1738	CI	T081	C0009667
28092340	1758	1761	SSM	T081	C0392762
28092340	1762	1770	function	T169	C0542341
28092340	1796	1804	patients	T101	C0030705
28092340	1810	1845	degenerative lumbar spinal stenosis	T047	C0410636
28092340	1850	1867	spondylolisthesis	T047	C0038016
28092340	1872	1877	study	T077	C1706256
28092340	1903	1909	groups	T078	C0441833
28092340	1911	1924	decompression	T061	C0408670
28092340	1935	1948	decompression	T061	C0408670
28092340	1954	1960	fusion	T061	C0919636
28092340	1962	1970	patients	T101	C0030705
28092340	2000	2018	surgical treatment	T061	C0543467
28092340	2038	2049	confounders	T169	C0009673
28092340	2051	2065	fusion surgery	T061	C0919636
28092340	2074	2089	associated with	T080	C0332281
28092340	2107	2114	outcome	T062	C0086750
28092340	2123	2133	SSM scores	T081	C0392762
28092340	2149	2176	decompression alone surgery	T061	C0408670

27860505|t|Evolution of Inbreeding Avoidance and Inbreeding Preference through Mate Choice among Interacting Relatives
27860505|a|While extensive population genetic theory predicts conditions favoring evolution of self-fertilization versus outcrossing, there is no analogous theory that predicts conditions favoring evolution of inbreeding avoidance or inbreeding preference enacted through mate choice given obligate biparental reproduction. Multiple interacting processes complicate the dynamics of alleles underlying such inbreeding strategies, including sexual conflict, distributions of kinship, genetic drift, purging of mutation load, direct costs, and restricted kin discrimination. We incorporated these processes into an individual-based model to predict conditions where selection should increase or decrease frequencies of alleles causing inbreeding avoidance or inbreeding preference when females or males controlled mating. Selection for inbreeding avoidance occurred given strong inbreeding depression when either sex chose mates, while selection for inbreeding preference occurred given very weak inbreeding depression when females chose but never occurred when males chose. Selection for both strategies was constrained by direct costs and restricted kin discrimination. Purging was negligible, but allele frequencies were strongly affected by drift in small populations, while selection for inbreeding avoidance was weak in larger populations because inbreeding risk decreased. Therefore, while selection sometimes favored alleles underlying inbreeding avoidance or preference, evolution of such strategies may be much more restricted and stochastic than is commonly presumed.
27860505	0	9	Evolution	T045	C0015219
27860505	13	23	Inbreeding	T040	C0021144
27860505	24	33	Avoidance	T080	C2700409
27860505	38	48	Inbreeding	T040	C0021144
27860505	49	59	Preference	T078	C0558295
27860505	68	79	Mate Choice	T054	C0024909
27860505	98	107	Relatives	T099	C0080103
27860505	114	123	extensive	T080	C0205231
27860505	124	142	population genetic	T090	C0017404
27860505	143	149	theory	T078	C0871935
27860505	179	188	evolution	T045	C0015219
27860505	192	210	self-fertilization	T040	C0524618
27860505	218	229	outcrossing	T045	C0010366
27860505	243	259	analogous theory	T078	C0871935
27860505	294	303	evolution	T045	C0015219
27860505	307	317	inbreeding	T040	C0021144
27860505	318	327	avoidance	T080	C2700409
27860505	331	341	inbreeding	T040	C0021144
27860505	342	352	preference	T078	C0558295
27860505	369	380	mate choice	T054	C0024909
27860505	396	419	biparental reproduction	T040	C0035150
27860505	421	441	Multiple interacting	T169	C1704675
27860505	452	462	complicate	T169	C0231242
27860505	479	486	alleles	T028	C0002085
27860505	503	513	inbreeding	T040	C0021144
27860505	536	551	sexual conflict	T048	C1409687
27860505	553	566	distributions	T169	C1704711
27860505	570	577	kinship	T078	C0870772
27860505	579	592	genetic drift	T045	C0917892
27860505	605	618	mutation load	T081	C0524602
27860505	620	632	direct costs	T081	C1511972
27860505	638	648	restricted	T169	C0443288
27860505	649	667	kin discrimination	T043	C3893608
27860505	709	731	individual-based model	UnknownType	C0681948
27860505	760	769	selection	T054	C0024909
27860505	777	785	increase	T169	C0442805
27860505	789	797	decrease	T081	C0547047
27860505	798	820	frequencies of alleles	T081	C0017270
27860505	829	839	inbreeding	T040	C0021144
27860505	840	849	avoidance	T080	C2700409
27860505	853	863	inbreeding	T040	C0021144
27860505	864	874	preference	T078	C0558295
27860505	880	887	females	T032	C0086287
27860505	891	896	males	T032	C0086582
27860505	897	907	controlled	T169	C2587213
27860505	908	914	mating	T040	C1260875
27860505	916	925	Selection	T054	C0024909
27860505	930	940	inbreeding	T040	C0021144
27860505	941	950	avoidance	T080	C2700409
27860505	966	972	strong	T080	C0442821
27860505	973	994	inbreeding depression	T070	C4277723
27860505	1007	1010	sex	T032	C0079399
27860505	1011	1022	chose mates	T054	C0024909
27860505	1030	1039	selection	T054	C0024909
27860505	1044	1054	inbreeding	T040	C0021144
27860505	1055	1065	preference	T078	C0558295
27860505	1086	1090	weak	T080	C1762617
27860505	1091	1112	inbreeding depression	T070	C4277723
27860505	1118	1125	females	T032	C0086287
27860505	1126	1131	chose	T052	C1707391
27860505	1136	1141	never	T033	C3843461
27860505	1142	1150	occurred	T052	C1709305
27860505	1156	1161	males	T032	C0086582
27860505	1162	1167	chose	T052	C1707391
27860505	1169	1178	Selection	T054	C0024909
27860505	1203	1214	constrained	T077	C1707494
27860505	1218	1230	direct costs	T081	C1511972
27860505	1235	1245	restricted	T169	C0443288
27860505	1246	1264	kin discrimination	T043	C3893608
27860505	1278	1288	negligible	T080	C0332269
27860505	1294	1312	allele frequencies	T081	C0017270
27860505	1318	1326	strongly	T080	C0442821
27860505	1327	1335	affected	T169	C0392760
27860505	1339	1344	drift	T045	C0917892
27860505	1348	1353	small	T081	C0700321
27860505	1354	1365	populations	T081	C0032659
27860505	1373	1382	selection	T054	C0024909
27860505	1387	1397	inbreeding	T040	C0021144
27860505	1398	1407	avoidance	T080	C2700409
27860505	1412	1416	weak	T080	C1762617
27860505	1420	1426	larger	T081	C0549177
27860505	1427	1438	populations	T081	C0032659
27860505	1447	1457	inbreeding	T040	C0021144
27860505	1458	1462	risk	T078	C0035647
27860505	1463	1472	decreased	T081	C0205216
27860505	1491	1500	selection	T054	C0024909
27860505	1519	1526	alleles	T028	C0002085
27860505	1538	1548	inbreeding	T040	C0021144
27860505	1549	1558	avoidance	T080	C2700409
27860505	1562	1572	preference	T078	C0558295
27860505	1574	1583	evolution	T045	C0015219
27860505	1620	1630	restricted	T169	C0443288
27860505	1635	1645	stochastic	T081	C0038347

28512014|t|Expressional divergence of insect GOX genes: From specialist to generalist glucose oxidase
28512014|a|Insect herbivores often secrete glucose oxidase (GOX) onto plants to counteract plant defenses and potential pathogens. Whether generalist herbivores always have significantly higher GOX activities than their specialist counterparts at any comparable stage or conditions and how this is realized remain unknown. To address these two general questions, we subjected larvae of a pair of sister species differed mainly in host range, the generalist Helicoverpa armigera and its specialist counterpart Helicoverpa assulta, to the same sets of stage, protein to digestible carbohydrate (P:C) ratio, allelochemical or host plant treatments for simultaneous analyses of GOX transcripts and activities in their labial glands. GOX activity and transcripts are upregulated concurrently with food ingestion and body growth, downregulated with stopping ingestion and wandering for pupation in both species. The three tested host plants upregulated GOX transcripts, and to a lesser extent, GOX activity in both species. There were significant differences in both GOX transcripts and activity elicited by allelochemicals, but only in GOX transcripts by P:C ratios in both species. GOX activities were higher in H. armigera than H. assulta in all the comparable treatments, but GOX transcripts were significantly higher either in generalists or in specialists, depending on the developmental stages, host plants, P:C ratio and allelochemicals they encounter. These data indicate that the greater GOX activity in generalist herbivores is not achieved by greater transcription rate, but by greater transcript stability, greater translation rate, better enzyme stability and/or their combination.
28512014	0	12	Expressional	T045	C0017262
28512014	13	23	divergence	T082	C0443204
28512014	27	33	insect	T204	C0021585
28512014	34	43	GOX genes	T028	C1415468
28512014	75	90	glucose oxidase	T116,T126	C0017735
28512014	91	108	Insect herbivores	T204	C0021585
28512014	115	122	secrete	T043	C1327616
28512014	123	138	glucose oxidase	T116,T126	C0017735
28512014	140	143	GOX	T116,T126	C0017735
28512014	150	156	plants	T002	C0032098
28512014	160	170	counteract	T053	C1947978
28512014	171	176	plant	T002	C0032098
28512014	177	185	defenses	T077	C1880266
28512014	190	199	potential	T080	C3245505
28512014	200	209	pathogens	T001	C0450254
28512014	230	240	herbivores	T204	C0021585
28512014	253	273	significantly higher	T081	C4055637
28512014	274	277	GOX	T116,T126	C0017735
28512014	278	288	activities	T052	C0441655
28512014	311	323	counterparts	T053	C1947978
28512014	456	462	larvae	T204	C0023047
28512014	483	490	species	T185	C1705920
28512014	537	557	Helicoverpa armigera	T204	C1002429
28512014	577	588	counterpart	T053	C1947978
28512014	589	608	Helicoverpa assulta	T204	C1093556
28512014	637	644	protein	T116,T123	C0033684
28512014	648	658	digestible	T040	C0012238
28512014	659	671	carbohydrate	T168	C0453802
28512014	685	699	allelochemical	T123	C1135843
28512014	703	713	host plant	UnknownType	C0868970
28512014	714	724	treatments	T169	C1522326
28512014	754	757	GOX	T028	C1415468
28512014	758	769	transcripts	T114	C1519595
28512014	774	784	activities	T052	C0441655
28512014	794	807	labial glands	T023	C0226928
28512014	809	812	GOX	T028	C1415468
28512014	813	821	activity	T052	C0441655
28512014	826	837	transcripts	T114	C1519595
28512014	842	853	upregulated	T044	C0041904
28512014	872	876	food	T168	C0016452
28512014	877	886	ingestion	T038	C0232478
28512014	891	902	body growth	T040	C0231256
28512014	904	917	downregulated	T044	C0013081
28512014	932	941	ingestion	T038	C0232478
28512014	946	955	wandering	T053	C0233569
28512014	960	968	pupation	T040	C1326578
28512014	977	984	species	T185	C1705920
28512014	1003	1014	host plants	UnknownType	C0868970
28512014	1015	1026	upregulated	T044	C0041904
28512014	1027	1030	GOX	T028	C1415468
28512014	1031	1042	transcripts	T114	C1519595
28512014	1068	1071	GOX	T028	C1415468
28512014	1072	1080	activity	T052	C0441655
28512014	1089	1096	species	T185	C1705920
28512014	1141	1144	GOX	T028	C1415468
28512014	1145	1156	transcripts	T114	C1519595
28512014	1161	1169	activity	T052	C0441655
28512014	1182	1197	allelochemicals	T123	C1135843
28512014	1211	1214	GOX	T028	C1415468
28512014	1215	1226	transcripts	T114	C1519595
28512014	1249	1256	species	T185	C1705920
28512014	1258	1261	GOX	T116,T126	C0017735
28512014	1262	1272	activities	T052	C0441655
28512014	1288	1299	H. armigera	T204	C1002429
28512014	1305	1315	H. assulta	T204	C1093556
28512014	1354	1357	GOX	T028	C1415468
28512014	1358	1369	transcripts	T114	C1519595
28512014	1375	1395	significantly higher	T081	C4055637
28512014	1454	1474	developmental stages	T079	C0870411
28512014	1476	1487	host plants	UnknownType	C0868970
28512014	1503	1518	allelochemicals	T123	C1135843
28512014	1524	1533	encounter	T053	C1947978
28512014	1541	1545	data	T078	C1511726
28512014	1564	1571	greater	T081	C1704243
28512014	1572	1575	GOX	T116,T126	C0017735
28512014	1576	1584	activity	T052	C0441655
28512014	1599	1609	herbivores	T204	C0021585
28512014	1629	1636	greater	T081	C1704243
28512014	1637	1650	transcription	T045	C0040649
28512014	1672	1682	transcript	T114	C1519595
28512014	1702	1713	translation	T045	C1519614
28512014	1720	1743	better enzyme stability	T044	C0014439

27637575|t|Macrophages modulate the growth and differentiation of rhesus monkey embryonic trophoblasts
27637575|a|Immune cells within the endometrium at implantation are thought to play an important role in implantation, although their exact role is not well understood. A co-culture system of rhesus monkey embryos and maternal immune cells was established. Blastocysts obtained by in vitro fertilization were co-cultured with peripheral blood cells or decidual macrophages. Culture media were collected to assess secretions. Embryo growth was monitored, and trophoblasts were evaluated for proliferation, apoptosis, and differentiation. Embryonic trophoblast outgrowths were visible within 6 days of culture, and the area of embryo outgrowth was reduced when blastocysts were cultured with peripheral - derived or decidual macrophages. Trophoblast proliferation was not significantly affected with macrophage co-culture while chorionic gonadotropin secretion was increased. Trophoblast expression of CDH 11 and GJA1 was increased, suggesting that macrophages accelerate differentiation of peri-implantation trophoblasts. These results indicate an important role of macrophages in placentation and pregnancy success.
27637575	0	11	Macrophages	T025	C0024432
27637575	25	31	growth	T040	C0018270
27637575	36	51	differentiation	T043	C0007589
27637575	55	68	rhesus monkey	T015	C0024400
27637575	69	78	embryonic	T018	C0013935
27637575	79	91	trophoblasts	T018	C0041178
27637575	92	104	Immune cells	T025	C0312740
27637575	116	127	endometrium	T023	C0014180
27637575	131	143	implantation	T061	C0021107
27637575	167	176	important	T080	C3898777
27637575	177	181	role	T077	C1705810
27637575	185	197	implantation	T061	C0021107
27637575	251	268	co-culture system	T059	C0282547
27637575	272	285	rhesus monkey	T015	C0024400
27637575	286	293	embryos	T018	C0013935
27637575	298	319	maternal immune cells	T025	C0312740
27637575	324	335	established	T080	C0443211
27637575	337	348	Blastocysts	T018	C1281743
27637575	361	383	in vitro fertilization	T061	C0015915
27637575	389	400	co-cultured	T059	C0282547
27637575	406	428	peripheral blood cells	T025	C0005773
27637575	432	440	decidual	T029	C0521453
27637575	441	452	macrophages	T025	C0024432
27637575	454	467	Culture media	T130	C0010454
27637575	473	482	collected	T169	C1516698
27637575	493	503	secretions	T038	C0036536
27637575	505	511	Embryo	T018	C0013935
27637575	512	518	growth	T040	C0018270
27637575	523	532	monitored	T169	C0205245
27637575	538	550	trophoblasts	T018	C0041178
27637575	570	583	proliferation	T043	C0596290
27637575	585	594	apoptosis	T043	C0162638
27637575	600	615	differentiation	T043	C0007589
27637575	617	626	Embryonic	T018	C0013935
27637575	627	638	trophoblast	T018	C0041178
27637575	639	649	outgrowths	T043	C0007595
27637575	655	662	visible	T080	C0205379
27637575	672	676	days	T079	C0439228
27637575	680	687	culture	T059	C0007585
27637575	697	701	area	T082	C0205146
27637575	705	711	embryo	T018	C0013935
27637575	712	721	outgrowth	T040	C0018270
27637575	726	733	reduced	T080	C0392756
27637575	739	750	blastocysts	T018	C1281743
27637575	756	764	cultured	T059	C0007585
27637575	770	780	peripheral	T082	C0205100
27637575	783	790	derived	T080	C1441547
27637575	794	802	decidual	T029	C0521453
27637575	803	814	macrophages	T025	C0024432
27637575	816	827	Trophoblast	T018	C0041178
27637575	828	841	proliferation	T043	C0596290
27637575	846	863	not significantly	T033	C1273937
27637575	864	872	affected	T080	C1280500
27637575	878	888	macrophage	T025	C0024432
27637575	889	899	co-culture	T059	C0282547
27637575	906	928	chorionic gonadotropin	T116,T121,T125	C0018062
27637575	929	938	secretion	T042	C0312431
27637575	943	952	increased	T081	C0205217
27637575	954	965	Trophoblast	T018	C0041178
27637575	966	976	expression	T045	C1171362
27637575	980	986	CDH 11	T116,T123	C0033684
27637575	991	995	GJA1	T116,T123	C0033684
27637575	1000	1009	increased	T081	C0205217
27637575	1011	1021	suggesting	T078	C1705535
27637575	1027	1038	macrophages	T025	C0024432
27637575	1039	1049	accelerate	T169	C0521110
27637575	1050	1065	differentiation	T043	C0007589
27637575	1069	1086	peri-implantation	T061	C0021107
27637575	1087	1099	trophoblasts	T018	C0041178
27637575	1107	1114	results	T169	C1274040
27637575	1115	1123	indicate	T033	C1444656
27637575	1127	1136	important	T080	C3898777
27637575	1137	1141	role	T077	C1705810
27637575	1145	1156	macrophages	T025	C0024432
27637575	1160	1172	placentation	T042	C0032058
27637575	1177	1186	pregnancy	T040	C0032961
27637575	1187	1194	success	T054	C0597535

27508384|t|Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer
27508384|a|Despite significant advances in breast imaging, the ability to accurately detect Breast Cancer (BC) remains a challenge. With the discovery of key biomarkers and protein signatures for BC, proteomic technologies are currently poised to serve as an ideal diagnostic adjunct to imaging. Research studies have shown that breast tumors are associated with systemic changes in levels of both serum protein biomarkers (SPB) and tumor associated autoantibodies (TAAb). However, the independent contribution of SPB and TAAb expression data for identifying BC relative to a combinatorial SPB and TAAb approach has not been fully investigated. This study evaluates these contributions using a retrospective cohort of pre - biopsy serum samples with known clinical outcomes collected from a single site, thus minimizing potential site-to-site variation and enabling direct assessment of SPB and TAAb contributions to identify BC. All serum samples (n = 210) were collected prior to biopsy. These specimens were obtained from 18 participants with no evidence of breast disease (ND), 92 participants diagnosed with Benign Breast Disease (BBD) and 100 participants diagnosed with BC, including DCIS. All BBD and BC diagnoses were based on pathology results from biopsy. Statistical models were developed to differentiate BC from non-BC (i.e., BBD and ND) using expression data from SPB alone, TAAb alone, and a combination of SPB and TAAb. When SPB data was independently used for modeling, clinical sensitivity and specificity for detection of BC were 74.7% and 77.0%, respectively. When TAAb data was independently used, clinical sensitivity and specificity for detection of BC were 72.2% and 70.8%, respectively. When modeling integrated data from both SPB and TAAb, the clinical sensitivity and specificity for detection of BC improved to 81.0% and 78.8%, respectively. These data demonstrate the benefit of the integration of SPB and TAAb data and strongly support the further development of combinatorial proteomic approaches for detecting BC.
27508384	0	11	Integration	T066	C1705422
27508384	15	28	Serum Protein	T116,T123	C0036825
27508384	29	38	Biomarker	T201	C0005516
27508384	43	48	Tumor	T191	C0027651
27508384	60	72	Autoantibody	T116,T129	C0004358
27508384	73	83	Expression	T045	C1171362
27508384	84	88	Data	T078	C1511726
27508384	116	143	Blood-Based Proteomic Assay	T059	C1510438
27508384	156	169	Breast Cancer	T191	C0006142
27508384	202	216	breast imaging	T060	C1134632
27508384	244	250	detect	T033	C0442726
27508384	251	264	Breast Cancer	T191	C0006142
27508384	266	268	BC	T191	C0006142
27508384	313	327	key biomarkers	T201	C0005516
27508384	332	350	protein signatures	T034	C3463810
27508384	355	357	BC	T191	C0006142
27508384	359	368	proteomic	T059	C1327760
27508384	369	381	technologies	T090	C0039421
27508384	424	442	diagnostic adjunct	T058	C3161326
27508384	446	453	imaging	T060	C0011923
27508384	455	471	Research studies	T062	C0681814
27508384	488	501	breast tumors	T191	C0006142
27508384	506	521	associated with	T080	C0332281
27508384	522	530	systemic	T169	C0205373
27508384	531	538	changes	T169	C0392747
27508384	542	548	levels	T080	C0441889
27508384	557	581	serum protein biomarkers	T201	C0005516
27508384	583	586	SPB	T201	C0005516
27508384	592	623	tumor associated autoantibodies	T116,T129	C0004358
27508384	625	629	TAAb	T116,T129	C0004358
27508384	657	669	contribution	T052	C1880177
27508384	673	676	SPB	T201	C0005516
27508384	681	685	TAAb	T116,T129	C0004358
27508384	686	696	expression	T045	C1171362
27508384	697	701	data	T078	C1511726
27508384	718	720	BC	T191	C0006142
27508384	735	748	combinatorial	T080	C0205195
27508384	749	752	SPB	T201	C0005516
27508384	757	761	TAAb	T116,T129	C0004358
27508384	790	802	investigated	T169	C1292732
27508384	809	814	study	T062	C2603343
27508384	815	824	evaluates	T058	C0220825
27508384	831	844	contributions	T052	C1880177
27508384	853	873	retrospective cohort	T062	C2985505
27508384	877	880	pre	T079	C0332152
27508384	883	889	biopsy	T060	C0005558
27508384	890	903	serum samples	T031	C1550100
27508384	915	932	clinical outcomes	T034	C0456984
27508384	957	961	site	T029	C1515974
27508384	968	978	minimizing	T080	C0392756
27508384	989	1001	site-to-site	T082	C1254362
27508384	1002	1011	variation	T033	C1846356
27508384	1032	1042	assessment	T052	C1516048
27508384	1046	1049	SPB	T201	C0005516
27508384	1054	1058	TAAb	T116,T129	C0004358
27508384	1059	1072	contributions	T052	C1880177
27508384	1085	1087	BC	T191	C0006142
27508384	1093	1106	serum samples	T031	C1550100
27508384	1132	1140	prior to	T079	C0332152
27508384	1141	1147	biopsy	T060	C0005558
27508384	1155	1164	specimens	T167	C0370003
27508384	1187	1199	participants	T098	C0679646
27508384	1205	1234	no evidence of breast disease	T033	C1276755
27508384	1236	1238	ND	T033	C1276755
27508384	1244	1256	participants	T098	C0679646
27508384	1257	1266	diagnosed	T033	C0011900
27508384	1272	1293	Benign Breast Disease	T047	C0016034
27508384	1295	1298	BBD	T047	C0016034
27508384	1308	1320	participants	T098	C0679646
27508384	1321	1330	diagnosed	T033	C0011900
27508384	1336	1338	BC	T191	C0006142
27508384	1350	1354	DCIS	T191	C0007124
27508384	1360	1363	BBD	T047	C0016034
27508384	1368	1370	BC	T191	C0006142
27508384	1371	1380	diagnoses	T033	C0011900
27508384	1395	1404	pathology	T091	C0030664
27508384	1405	1412	results	T169	C1274040
27508384	1418	1424	biopsy	T060	C0005558
27508384	1426	1444	Statistical models	T081,T170	C0026348
27508384	1477	1479	BC	T191	C0006142
27508384	1499	1502	BBD	T047	C0016034
27508384	1507	1509	ND	T033	C1276755
27508384	1517	1527	expression	T045	C1171362
27508384	1528	1532	data	T078	C1511726
27508384	1538	1541	SPB	T201	C0005516
27508384	1549	1553	TAAb	T116,T129	C0004358
27508384	1567	1578	combination	T080	C0205195
27508384	1582	1585	SPB	T201	C0005516
27508384	1590	1594	TAAb	T116,T129	C0004358
27508384	1601	1604	SPB	T201	C0005516
27508384	1605	1609	data	T078	C1511726
27508384	1637	1645	modeling	T062	C0870071
27508384	1647	1667	clinical sensitivity	T062	C1516631
27508384	1672	1683	specificity	T081	C0037791
27508384	1701	1703	BC	T191	C0006142
27508384	1745	1749	TAAb	T116,T129	C0004358
27508384	1750	1754	data	T078	C1511726
27508384	1779	1799	clinical sensitivity	T062	C1516631
27508384	1804	1815	specificity	T081	C0037791
27508384	1820	1829	detection	T033	C0442726
27508384	1833	1835	BC	T191	C0006142
27508384	1877	1885	modeling	T062	C0870071
27508384	1886	1901	integrated data	T078	C1511726
27508384	1912	1915	SPB	T201	C0005516
27508384	1920	1924	TAAb	T116,T129	C0004358
27508384	1930	1950	clinical sensitivity	T062	C1516631
27508384	1955	1966	specificity	T081	C0037791
27508384	1984	1986	BC	T191	C0006142
27508384	2036	2040	data	T078	C1511726
27508384	2072	2083	integration	T066	C1705422
27508384	2087	2090	SPB	T201	C0005516
27508384	2095	2099	TAAb	T116,T129	C0004358
27508384	2100	2104	data	T078	C1511726
27508384	2202	2204	BC	T191	C0006142

28442401|t|TRIB3 downregulation enhances doxorubicin - induced cytotoxicity in gastric cancer cells
28442401|a|TRIB3, which is a pseudokinase known to regulate multiple pro-survival pathways, appears to be a potential therapeutic target for the treatment of human tumors. However, its precise role in cancer is controversial, as TRIB3 protein levels have been associated with both good and poor prognosis in cancer patients. Here, we investigated the significance of TRIB3 expression in the survival of gastric cancer cells exposed to anticancer drugs. We found that the tested anticancer drug, doxorubicin, induced cytotoxicity by decreasing TRIB3 transcription, which was followed by apoptotic cell death. Moreover, TRIB3 siRNA knockdown appeared to enhance doxorubicin - induced apoptosis in gastric cancer cells, concurrently with altering the expression of downstream apoptotic factors. Conversely, overexpression of TRIB3 significantly protected cells against doxorubicin - induced apoptosis. Our results indicate that downregulation of TRIB3 appears to promote cell death and enhance doxorubicin - induced apoptosis, supporting the anti-apoptotic role of TRIB3. The inductions of three classes of MAPKs failed to affect doxorubicin -mediated TRIB3 downregulation, while TRIB3 overexpression did not affect doxorubicin - induced MAPK activation. In sum, our findings indicate that TRIB3 plays an anti-apoptotic role in doxorubicin -treated gastric cancer cell lines, perhaps indicating that the status of TRIB3 expression in response to anticancer drugs, such as doxorubicin, irinotecan or oxaliplatin, may reflect the efficiency for cancer therapy.
28442401	0	5	TRIB3	T116,T123	C1259051
28442401	6	20	downregulation	T044	C0013081
28442401	21	29	enhances	T052	C2349975
28442401	30	41	doxorubicin	T109,T195	C0013089
28442401	44	51	induced	T169	C0458082
28442401	52	64	cytotoxicity	T049	C0596402
28442401	68	82	gastric cancer	T191	C0024623
28442401	83	88	cells	T025	C0334227
28442401	89	94	TRIB3	T116,T123	C1259051
28442401	107	119	pseudokinase	T116,T123	C0033684
28442401	129	168	regulate multiple pro-survival pathways	T038	C1327622
28442401	196	207	therapeutic	T061	C0087111
28442401	208	214	target	T169	C1521840
28442401	223	232	treatment	T061	C0920425
28442401	236	241	human	T016	C0086418
28442401	242	248	tumors	T191	C0027651
28442401	279	285	cancer	T191	C0006826
28442401	307	312	TRIB3	T116,T123	C1259051
28442401	313	327	protein levels	T034	C0428479
28442401	359	363	good	T033	C0278250
28442401	368	382	poor prognosis	T033	C0278252
28442401	386	401	cancer patients	T101	C1516213
28442401	445	450	TRIB3	T116,T123	C1259051
28442401	451	461	expression	T045	C1171362
28442401	469	477	survival	T043	C0007620
28442401	481	495	gastric cancer	T191	C0024623
28442401	496	501	cells	T025	C0334227
28442401	513	529	anticancer drugs	T109,T121	C0003392
28442401	549	555	tested	T169	C0039593
28442401	556	571	anticancer drug	T109,T121	C0003392
28442401	573	584	doxorubicin	T109,T195	C0013089
28442401	586	593	induced	T169	C0458082
28442401	594	606	cytotoxicity	T049	C0596402
28442401	621	626	TRIB3	T028	C1540055
28442401	627	640	transcription	T045	C0040649
28442401	664	684	apoptotic cell death	T043	C0162638
28442401	696	707	TRIB3 siRNA	T114,T123	C1099354
28442401	708	717	knockdown	T063	C2350567
28442401	730	737	enhance	T052	C2349975
28442401	738	749	doxorubicin	T109,T195	C0013089
28442401	752	759	induced	T169	C0458082
28442401	760	769	apoptosis	T043	C0162638
28442401	773	787	gastric cancer	T191	C0024623
28442401	788	793	cells	T025	C0334227
28442401	826	836	expression	T045	C1171362
28442401	840	850	downstream	T082	C0522506
28442401	851	868	apoptotic factors	T116,T123	C0763396
28442401	882	896	overexpression	T045	C1514559
28442401	900	905	TRIB3	T116,T123	C1259051
28442401	920	935	protected cells	T025	C0007634
28442401	944	955	doxorubicin	T109,T195	C0013089
28442401	958	965	induced	T169	C0458082
28442401	966	975	apoptosis	T043	C0162638
28442401	1003	1017	downregulation	T044	C0013081
28442401	1021	1026	TRIB3	T116,T123	C1259051
28442401	1038	1045	promote	T052	C0033414
28442401	1046	1056	cell death	T043	C0007587
28442401	1061	1068	enhance	T052	C2349975
28442401	1069	1080	doxorubicin	T109,T195	C0013089
28442401	1083	1090	induced	T169	C0458082
28442401	1091	1100	apoptosis	T043	C0162638
28442401	1117	1131	anti-apoptotic	T120	C2986514
28442401	1140	1145	TRIB3	T116,T123	C1259051
28442401	1151	1161	inductions	T045	C0017391
28442401	1182	1187	MAPKs	T116,T126	C0752312
28442401	1205	1216	doxorubicin	T109,T195	C0013089
28442401	1227	1232	TRIB3	T116,T123	C1259051
28442401	1233	1247	downregulation	T044	C0013081
28442401	1255	1260	TRIB3	T116,T123	C1259051
28442401	1261	1275	overexpression	T045	C1514559
28442401	1291	1302	doxorubicin	T109,T195	C0013089
28442401	1305	1312	induced	T169	C0458082
28442401	1313	1328	MAPK activation	T044	C1155551
28442401	1342	1350	findings	T033	C2825141
28442401	1365	1370	TRIB3	T116,T123	C1259051
28442401	1380	1394	anti-apoptotic	T120	C2986514
28442401	1403	1414	doxorubicin	T109,T195	C0013089
28442401	1424	1438	gastric cancer	T191	C0024623
28442401	1439	1449	cell lines	T025	C0334227
28442401	1489	1494	TRIB3	T116,T123	C1259051
28442401	1495	1505	expression	T045	C1171362
28442401	1521	1537	anticancer drugs	T109,T121	C0003392
28442401	1547	1558	doxorubicin	T109,T195	C0013089
28442401	1560	1570	irinotecan	T109,T121	C0123931
28442401	1574	1585	oxaliplatin	T109,T121	C0069717
28442401	1618	1632	cancer therapy	T061	C0920425

27545685|t|Genome-wide gene-environment interaction analysis of pesticide exposure and risk of Parkinson's disease
27545685|a|Genetic factors and environmental exposures, including pesticides, contribute to the risk of Parkinson's disease (PD). There have been few studies of gene and pesticide exposure interactions in PD, and all of the prior studies used a candidate gene approach. We performed the first genome-wide gene-environment interaction analysis of pesticide exposure and risk of Parkinson's disease. Analyses were performed using data on >700,000 single nucleotide polymorphisms (SNPs) in 364 discordant sibling pairs. In addition to testing for SNP - pesticide interaction effects, we also performed exploratory analyses of gene- pesticide interactions at the gene level. None of the gene-environment interaction results were significant after genome-wide correction for multiple testing (α = 1.5E-07 for SNP - level tests; α = 2.1E-06 for gene - level tests). Top results in the SNP - level tests provided suggestive evidence (P < 5.0E-06) that the effect of pesticide exposure on PD risk may be modified by SNPs in the ERCC6L2 gene (P = 2.4E-06), which was also supported by suggestive evidence in the gene - level analysis (P = 4.7E-05). None of the candidate genes assessed in prior studies of gene - pesticide interactions reached statistical support in this genome-wide screen. Although no significant interactions were identified, several of the genes with suggestive evidence of gene-environment interaction effects have biological plausibility for PD risk. Further investigation of the role of those genes in PD risk, particularly in the context of pesticide exposure, in large and carefully recruited samples is warranted.
27545685	0	11	Genome-wide	T028	C0017428
27545685	12	40	gene-environment interaction	T045	C0596609
27545685	41	49	analysis	T062	C0936012
27545685	53	71	pesticide exposure	T033	C2220281
27545685	76	80	risk	T078	C0035647
27545685	84	103	Parkinson's disease	T047	C0030567
27545685	104	111	Genetic	T169	C0314603
27545685	112	119	factors	T169	C1521761
27545685	124	147	environmental exposures	T037	C0014412
27545685	159	169	pesticides	T131	C0031253
27545685	189	193	risk	T078	C0035647
27545685	197	216	Parkinson's disease	T047	C0030567
27545685	218	220	PD	T047	C0030567
27545685	243	250	studies	T062	C0008972
27545685	263	281	pesticide exposure	T033	C2220281
27545685	282	294	interactions	T044	C0597202
27545685	298	300	PD	T047	C0030567
27545685	323	330	studies	T062	C0008972
27545685	338	352	candidate gene	T028	C1332838
27545685	353	361	approach	T082	C0449445
27545685	366	375	performed	T169	C0884358
27545685	386	397	genome-wide	T028	C0017428
27545685	398	426	gene-environment interaction	T045	C0596609
27545685	427	435	analysis	T062	C0936012
27545685	439	457	pesticide exposure	T033	C2220281
27545685	462	466	risk	T078	C0035647
27545685	470	489	Parkinson's disease	T047	C0030567
27545685	491	499	Analyses	T062	C0936012
27545685	505	514	performed	T169	C0884358
27545685	521	525	data	T078	C1511726
27545685	538	569	single nucleotide polymorphisms	T086	C0752046
27545685	571	575	SNPs	T086	C0752046
27545685	584	594	discordant	T077	C3639994
27545685	595	602	sibling	T099	C0037047
27545685	603	608	pairs	T080	C1709450
27545685	625	632	testing	T169	C0039593
27545685	637	640	SNP	T086	C0752046
27545685	643	664	pesticide interaction	T044	C0597202
27545685	665	672	effects	T080	C1280500
27545685	682	691	performed	T169	C0884358
27545685	704	712	analyses	T062	C0936012
27545685	722	744	pesticide interactions	T044	C0597202
27545685	752	756	gene	T028	C0017337
27545685	757	762	level	T080	C0441889
27545685	776	804	gene-environment interaction	T045	C0596609
27545685	805	812	results	T169	C1274040
27545685	818	829	significant	T078	C0750502
27545685	836	847	genome-wide	T028	C0017428
27545685	848	858	correction	T169	C1947976
27545685	872	879	testing	T169	C0039593
27545685	897	900	SNP	T086	C0752046
27545685	903	908	level	T080	C0441889
27545685	909	914	tests	T169	C0039593
27545685	932	936	gene	T028	C0017337
27545685	939	944	level	T080	C0441889
27545685	945	950	tests	T169	C0039593
27545685	957	964	results	T169	C1274040
27545685	972	975	SNP	T086	C0752046
27545685	978	983	level	T080	C0441889
27545685	984	989	tests	T169	C0039593
27545685	1010	1018	evidence	T169	C0332120
27545685	1020	1021	P	T081	C1709380
27545685	1042	1048	effect	T080	C1280500
27545685	1052	1070	pesticide exposure	T033	C2220281
27545685	1074	1076	PD	T047	C0030567
27545685	1077	1081	risk	T078	C0035647
27545685	1089	1100	modified by	T080	C0205349
27545685	1101	1105	SNPs	T086	C0752046
27545685	1113	1125	ERCC6L2 gene	T028	C3470154
27545685	1127	1128	P	T081	C1709380
27545685	1180	1188	evidence	T169	C0332120
27545685	1196	1200	gene	T028	C0017337
27545685	1203	1208	level	T080	C0441889
27545685	1209	1217	analysis	T062	C0936012
27545685	1219	1220	P	T081	C1709380
27545685	1245	1260	candidate genes	T028	C1332838
27545685	1261	1269	assessed	T052	C1516048
27545685	1279	1286	studies	T062	C0008972
27545685	1290	1294	gene	T028	C0017337
27545685	1297	1319	pesticide interactions	T044	C0597202
27545685	1328	1339	statistical	T081	C2348149
27545685	1356	1367	genome-wide	T028	C0017428
27545685	1385	1399	no significant	T033	C1273937
27545685	1400	1412	interactions	T044	C0597202
27545685	1418	1428	identified	T080	C0205396
27545685	1445	1450	genes	T028	C0017337
27545685	1467	1475	evidence	T169	C0332120
27545685	1479	1507	gene-environment interaction	T045	C0596609
27545685	1508	1515	effects	T080	C1280500
27545685	1549	1551	PD	T047	C0030567
27545685	1552	1556	risk	T078	C0035647
27545685	1566	1579	investigation	T058	C0220825
27545685	1601	1606	genes	T028	C0017337
27545685	1610	1612	PD	T047	C0030567
27545685	1613	1617	risk	T078	C0035647
27545685	1650	1668	pesticide exposure	T033	C2220281
27545685	1703	1710	samples	T167	C0370003

27506608|t|Adequacy of initial evaluation of fever in long-term care facilities
27506608|a|Febrile residents in long-term care facilities (LTCF) might be inadequately evaluated by caregivers. The present study aimed to examine the factors associated with inadequacy of initial fever evaluations by caregivers at night in LTCF. We carried out a cross-sectional study among a convenience sample of caregivers employed at 11 LTCF in Japan using a vignette-based questionnaire. The respondents were randomly assigned to one of two scenarios describing a mild or severe febrile episode in an LTCF resident at night. The respondents ' thinking patterns were classified based on influential factors in their fever evaluation. Associations between adequacy of evaluation and respondents ' characteristics were evaluated using generalized linear mixed models. A total of 34% of fever evaluations among caregivers were considered to be inadequate regarding the necessity for examination by a physician, due in most cases to underestimating the severity of the fever. Respondents ' thinking patterns in fever evaluation were significantly associated with the adequacy of the evaluation. Caregivers who placed particular importance on the preferences of residents and families versus other factors including the resident 's febrile condition, were more likely to make an inadequate evaluation than those who did not. Our findings here suggest that eagerness to comply with residents ' preference in fever evaluation could prompt caregivers not to call for an appropriate diagnostic procedure. Geriatr Gerontol Int 2016; ••: ••-••.
27506608	0	8	Adequacy	T080	C0205411
27506608	12	19	initial	T079	C0205265
27506608	20	30	evaluation	T058	C0220825
27506608	34	39	fever	T184	C0015967
27506608	43	68	long-term care facilities	T073,T093	C1708733
27506608	69	76	Febrile	T184	C0687681
27506608	77	86	residents	T098	C2347958
27506608	90	115	long-term care facilities	T073,T093	C1708733
27506608	117	121	LTCF	T073,T093	C1708733
27506608	132	144	inadequately	T080	C0205412
27506608	145	154	evaluated	T058	C0220825
27506608	158	168	caregivers	T097	C0085537
27506608	174	181	present	T079	C0521116
27506608	182	187	study	T062	C2603343
27506608	188	193	aimed	T078	C1947946
27506608	209	216	factors	T169	C1521761
27506608	217	232	associated with	T080	C0332281
27506608	233	243	inadequacy	T080	C0205412
27506608	247	254	initial	T079	C0205265
27506608	255	260	fever	T184	C0015967
27506608	261	272	evaluations	T058	C0220825
27506608	276	286	caregivers	T097	C0085537
27506608	290	295	night	T079	C0240526
27506608	299	303	LTCF	T073,T093	C1708733
27506608	322	343	cross-sectional study	T062	C0010362
27506608	352	370	convenience sample	T062	C0150095
27506608	374	384	caregivers	T097	C0085537
27506608	385	393	employed	T033	C0557351
27506608	400	404	LTCF	T073,T093	C1708733
27506608	408	413	Japan	T083	C0022341
27506608	422	450	vignette-based questionnaire	T170	C0034394
27506608	456	467	respondents	T098	C0282122
27506608	473	481	randomly	T080	C0439605
27506608	505	514	scenarios	T169	C0683579
27506608	528	532	mild	T080	C2945599
27506608	536	542	severe	T080	C0205082
27506608	543	550	febrile	T184	C0687681
27506608	551	558	episode	T079	C0332189
27506608	565	569	LTCF	T073,T093	C1708733
27506608	570	578	resident	T098	C2347958
27506608	582	587	night	T079	C0240526
27506608	593	604	respondents	T098	C0282122
27506608	607	624	thinking patterns	T041	C0039869
27506608	630	640	classified	T185	C0008902
27506608	650	661	influential	T077	C4054723
27506608	662	669	factors	T169	C1521761
27506608	679	684	fever	T184	C0015967
27506608	685	695	evaluation	T058	C0220825
27506608	697	709	Associations	T080	C0332281
27506608	718	726	adequacy	T080	C0205411
27506608	730	740	evaluation	T058	C0220825
27506608	745	756	respondents	T098	C0282122
27506608	759	774	characteristics	T080	C1521970
27506608	780	789	evaluated	T058	C0220825
27506608	796	827	generalized linear mixed models	T062	C0242481
27506608	847	852	fever	T184	C0015967
27506608	853	864	evaluations	T058	C0220825
27506608	871	881	caregivers	T097	C0085537
27506608	904	914	inadequate	T080	C0205412
27506608	929	938	necessity	T078	C1555447
27506608	943	954	examination	T058	C0582103
27506608	960	969	physician	T097	C0031831
27506608	1012	1020	severity	T080	C0205082
27506608	1028	1033	fever	T184	C0015967
27506608	1035	1046	Respondents	T098	C0282122
27506608	1049	1066	thinking patterns	T041	C0039869
27506608	1070	1075	fever	T184	C0015967
27506608	1076	1086	evaluation	T058	C0220825
27506608	1106	1121	associated with	T080	C0332281
27506608	1126	1134	adequacy	T080	C0205411
27506608	1142	1152	evaluation	T058	C0220825
27506608	1154	1164	Caregivers	T097	C0085537
27506608	1187	1197	importance	T080	C3898777
27506608	1205	1216	preferences	T078	C0558295
27506608	1220	1229	residents	T098	C2347958
27506608	1234	1242	families	T099	C0015576
27506608	1256	1263	factors	T169	C1521761
27506608	1278	1286	resident	T098	C2347958
27506608	1290	1297	febrile	T184	C0687681
27506608	1298	1307	condition	T080	C0348080
27506608	1337	1347	inadequate	T080	C0205412
27506608	1348	1358	evaluation	T058	C0220825
27506608	1387	1395	findings	T033	C0243095
27506608	1414	1423	eagerness	T041	C0424090
27506608	1439	1448	residents	T098	C2347958
27506608	1451	1461	preference	T078	C0558295
27506608	1465	1470	fever	T184	C0015967
27506608	1471	1481	evaluation	T058	C0220825
27506608	1488	1494	prompt	T169	C0871157
27506608	1495	1505	caregivers	T097	C0085537
27506608	1525	1536	appropriate	T080	C1548787
27506608	1537	1557	diagnostic procedure	T060	C0430022

27546025|t|Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography / tandem mass spectrometry
27546025|a|A remediable cause of poor treatment response in drug - susceptible tuberculosis (TB) patients may be low plasma levels of one or more of the first-line anti-TB drugs. The aim of this work was to develop an accurate and precise LC-MS / MS method for simultaneous quantification of all four first-line anti-TB drugs in plasma suitable for therapeutic drug monitoring (TDM). To adjust for degradation and losses during sample preparation, isotopically labeled compounds were used as internal standards. Plasma samples spiked with internal standards were extracted using protein precipitation with methanol and acetonitrile. Simultaneous separation of all four drugs was accomplished with a Chromolith Reversed-Phase column and mobile phases consisting of water, methanol, ammonium acetate and formic acid with subsequent mass spectrometric quantification. The linear range of the calibration curve for isoniazid was 0.5-10 mg/L, for rifampicin 0.75-30 mg/L, for ethambutol 0.25-10 mg/L and for pyrazinamide 4-80 mg/L. The lower limit of quantification was 0.5 mg/L, 0.75 mg/L, 0.25 mg/L and 4.0 mg/L, respectively. Precision estimated by the coefficient of variation was <15% for all four drugs. The LC-MS / MS method can readily be used for simultaneous quantification of first-line anti-TB drugs in plasma and is well suited for TDM.
27546025	0	12	Simultaneous	T079	C0521115
27546025	13	27	quantification	T081	C1709793
27546025	31	40	isoniazid	T109,T121	C0022209
27546025	42	52	rifampicin	T109,T195	C0035608
27546025	54	64	ethambutol	T109,T121	C0014964
27546025	69	81	pyrazinamide	T109,T121	C0034239
27546025	85	106	liquid chromatography	T059	C0008565
27546025	109	133	tandem mass spectrometry	T059	C2123592
27546025	136	146	remediable	T058	C1709895
27546025	156	179	poor treatment response	T033	C1320680
27546025	183	187	drug	T121	C1254351
27546025	190	201	susceptible	T169	C0231204
27546025	202	214	tuberculosis	T047	C0041296
27546025	216	218	TB	T047	C0041296
27546025	220	228	patients	T101	C0030705
27546025	236	239	low	T080	C0205251
27546025	240	246	plasma	T031	C0032105
27546025	247	253	levels	T080	C0441889
27546025	287	300	anti-TB drugs	T195	C0003237
27546025	306	309	aim	T078	C1947946
27546025	341	349	accurate	T080	C0443131
27546025	362	367	LC-MS	T059	C0872318
27546025	370	372	MS	T059	C0037813
27546025	384	396	simultaneous	T079	C0521115
27546025	397	411	quantification	T081	C1709793
27546025	435	448	anti-TB drugs	T195	C0003237
27546025	452	458	plasma	T031	C0032105
27546025	472	499	therapeutic drug monitoring	T061	C1720825
27546025	501	504	TDM	T061	C1720825
27546025	521	532	degradation	T169	C0243125
27546025	537	543	losses	T081	C1517945
27546025	551	569	sample preparation	T059	C3824791
27546025	571	601	isotopically labeled compounds	T196	C0022262
27546025	635	649	Plasma samples	T031	C0444263
27546025	686	695	extracted	T059	C0022885
27546025	702	723	protein precipitation	T059	C3815102
27546025	729	737	methanol	T109,T131	C0001963
27546025	742	754	acetonitrile	T109	C0050456
27546025	756	768	Simultaneous	T079	C0521115
27546025	769	779	separation	UnknownType	C0678621
27546025	792	797	drugs	T121	C0013227
27546025	822	854	Chromolith Reversed-Phase column	T075	C1705246
27546025	859	872	mobile phases	T130	C3469601
27546025	887	892	water	T121,T197	C0043047
27546025	894	902	methanol	T109,T131	C0001963
27546025	904	920	ammonium acetate	T109,T130	C0051704
27546025	925	936	formic acid	T109,T121,T130	C0016576
27546025	953	971	mass spectrometric	T059	C2123592
27546025	972	986	quantification	T081	C1709793
27546025	992	1004	linear range	T081	C1514721
27546025	1012	1029	calibration curve	T081	C0392762
27546025	1034	1043	isoniazid	T109,T121	C0022209
27546025	1065	1075	rifampicin	T109,T195	C0035608
27546025	1094	1104	ethambutol	T109,T121	C0014964
27546025	1126	1138	pyrazinamide	T109,T121	C0034239
27546025	1154	1183	lower limit of quantification	T081	C2826316
27546025	1247	1256	Precision	T079	C1547902
27546025	1257	1266	estimated	T081	C0750572
27546025	1274	1298	coefficient of variation	T081	C0681921
27546025	1321	1326	drugs	T121	C0013227
27546025	1332	1337	LC-MS	T059	C0872318
27546025	1340	1342	MS	T059	C0037813
27546025	1374	1386	simultaneous	T079	C0521115
27546025	1387	1401	quantification	T081	C1709793
27546025	1416	1429	anti-TB drugs	T195	C0003237
27546025	1433	1439	plasma	T031	C0032105
27546025	1463	1466	TDM	T061	C1720825

28315240|t|DTNB -Based Quantification of In Vitro Enzymatic N-Terminal Acetyltransferase Activity
28315240|a|We here describe a quick and easy method to quantitatively measure in vitro acetylation activity of not only N-terminal acetyltransferase (NAT) enzymes, but acetyltransferases using acetyl-coenzyme A as an acetyl donor in general.
28315240	0	4	DTNB	T109,T130	C0012788
28315240	12	26	Quantification	T081	C1709793
28315240	30	38	In Vitro	T080	C1533691
28315240	39	48	Enzymatic	T116,T126	C0014442
28315240	49	86	N-Terminal Acetyltransferase Activity	T044	C1151922
28315240	121	127	method	T170	C0025663
28315240	131	145	quantitatively	T081	C0392762
28315240	146	153	measure	T081	C0079809
28315240	154	162	in vitro	T080	C1533691
28315240	163	183	acetylation activity	T044	C0001038
28315240	196	224	N-terminal acetyltransferase	T116,T126	C0165507
28315240	226	229	NAT	T116,T126	C0165507
28315240	231	238	enzymes	T116,T126	C0014442
28315240	244	262	acetyltransferases	T116,T126	C0001068
28315240	269	286	acetyl-coenzyme A	T114,T123	C0001026
28315240	293	299	acetyl	T082	C2985512
28315240	300	305	donor	T080	C0205198
28315240	309	316	general	T082	C0205246

28459391|t|Nordic Walking Improves Gait Power Profiles at the Knee Joint in Parkinson's Disease
28459391|a|We investigated the impact of Nordic Walking (NW) on gait patterns in individuals with Parkinson's disease (PD) following a 6-week NW familiarization. Twelve participants with PD and healthy older adults took part in a gait analysis walking with and without poles (NP). Results showed larger knee power (knee extensor: K2) on the most affected leg in NW compared to NP (P=0.01). On the less affected side, larger power absorption (knee extensor: K3) was found during pre - swing (K3) compared to older adults in both NP and NW (P=0.01). NW showed longer stride length and single support time (P<0.01) compared to NP. Walking with poles improved gait spatial - temporal characteristics and power profile s at the knee joint both on the less and most affected sides in individuals with PD. NW could be beneficial to help regain a more functional gait pattern in PD.
28459391	0	14	Nordic Walking	T056	C0080331
28459391	15	23	Improves	T033	C0184511
28459391	24	28	Gait	T033	C0016928
28459391	29	34	Power	T081	C1442080
28459391	35	43	Profiles	T169	C2003903
28459391	51	61	Knee Joint	T030	C0022745
28459391	65	84	Parkinson's Disease	T047	C0030567
28459391	88	100	investigated	T058	C0220825
28459391	105	111	impact	T080	C4049986
28459391	115	129	Nordic Walking	T056	C0080331
28459391	131	133	NW	T056	C0080331
28459391	138	151	gait patterns	T040	C2371258
28459391	155	166	individuals	T098	C0237401
28459391	172	191	Parkinson's disease	T047	C0030567
28459391	193	195	PD	T047	C0030567
28459391	197	206	following	T079	C0332282
28459391	216	218	NW	T056	C0080331
28459391	243	255	participants	T098	C0679646
28459391	261	263	PD	T047	C0030567
28459391	268	275	healthy	T080	C3898900
28459391	276	288	older adults	T098	C0001792
28459391	304	308	gait	T033	C0016928
28459391	309	317	analysis	T062	C0936012
28459391	318	325	walking	T056	C0080331
28459391	343	348	poles	T074	C0182182
28459391	350	352	NP	T074	C0182182
28459391	355	362	Results	T033	C0683954
28459391	370	376	larger	T081	C0549177
28459391	377	381	knee	T023	C0022742
28459391	382	387	power	T081	C1442080
28459391	389	402	knee extensor	T023	C0581537
28459391	415	419	most	T081	C0205393
28459391	420	428	affected	T169	C0392760
28459391	429	432	leg	T023	C1140621
28459391	436	438	NW	T056	C0080331
28459391	439	447	compared	T052	C1707455
28459391	451	453	NP	T074	C0182182
28459391	471	475	less	T081	C0439092
28459391	476	484	affected	T169	C0392760
28459391	491	497	larger	T081	C0549177
28459391	498	503	power	T081	C1442080
28459391	504	514	absorption	T070	C0000854
28459391	516	529	knee extensor	T023	C0581537
28459391	552	555	pre	T079	C0332152
28459391	558	563	swing	T033	C2039052
28459391	569	577	compared	T052	C1707455
28459391	581	593	older adults	T098	C0001792
28459391	602	604	NP	T074	C0182182
28459391	609	611	NW	T056	C0080331
28459391	622	624	NW	T056	C0080331
28459391	632	652	longer stride length	T033	C2048876
28459391	657	663	single	T081	C0205171
28459391	664	671	support	T077	C1521721
28459391	672	676	time	T079	C0040223
28459391	686	694	compared	T052	C1707455
28459391	698	700	NP	T074	C0182182
28459391	702	709	Walking	T056	C0080331
28459391	715	720	poles	T074	C0182182
28459391	721	729	improved	T033	C0184511
28459391	730	734	gait	T033	C0016928
28459391	735	742	spatial	T082	C1704322
28459391	745	753	temporal	T079	C2362314
28459391	754	769	characteristics	T080	C1521970
28459391	774	779	power	T081	C1442080
28459391	780	787	profile	T169	C2003903
28459391	797	807	knee joint	T030	C0022745
28459391	820	824	less	T081	C0439092
28459391	829	833	most	T081	C0205393
28459391	834	842	affected	T169	C0392760
28459391	852	863	individuals	T098	C0237401
28459391	869	871	PD	T047	C0030567
28459391	873	875	NW	T056	C0080331
28459391	885	895	beneficial	T081	C0814225
28459391	904	910	regain	T081	C1517378
28459391	918	941	functional gait pattern	T040	C2371258
28459391	945	947	PD	T047	C0030567

27699206|t|Smooth versus Textured Surfaces: Feature -Based Category Selectivity in Human Visual Cortex
27699206|a|In fMRI studies, human lateral occipital (LO) cortex is thought to respond selectively to images of objects, compared with nonobjects. However, it remains unresolved whether all objects evoke equivalent levels of activity in LO, and, if not, which image features produce stronger activation. Here, we used an unbiased parametric texture model to predict preferred versus nonpreferred stimuli in LO. Observation and psychophysical results showed that predicted preferred stimuli (both objects and nonobjects) had smooth (rather than textured) surfaces. These predictions were confirmed using fMRI, for objects and nonobjects. Similar preferences were also found in the fusiform face area (FFA). Consistent with this: (1) FFA and LO responded more strongly to nonfreckled (smooth) faces, compared with otherwise identical freckled (textured) faces; and (2) strong functional connections were found between LO and FFA. Thus, LO and FFA may be part of an information - processing stream distinguished by feature -based category selectivity (smooth > textured).
27699206	0	6	Smooth	T080	C0205357
27699206	14	22	Textured	T080	C0205556
27699206	23	31	Surfaces	T082	C0205148
27699206	33	40	Feature	T080	C2348519
27699206	48	56	Category	T170	C0683312
27699206	57	68	Selectivity	T052	C1707391
27699206	72	77	Human	T016	C0086418
27699206	78	91	Visual Cortex	T023	C0042817
27699206	95	107	fMRI studies	T060	C0376335
27699206	109	114	human	T016	C0086418
27699206	115	144	lateral occipital (LO) cortex	T023	C0028785
27699206	182	188	images	T170	C1704922
27699206	192	199	objects	T072	C0347997
27699206	201	209	compared	T052	C1707455
27699206	215	225	nonobjects	T071	C1551338
27699206	247	257	unresolved	T080	C0443342
27699206	270	277	objects	T072	C0347997
27699206	284	294	equivalent	T080	C0205163
27699206	295	301	levels	T080	C0441889
27699206	305	313	activity	T052	C0441655
27699206	317	319	LO	T023	C0028785
27699206	340	354	image features	T080	C2346469
27699206	363	371	stronger	T080	C0442821
27699206	372	382	activation	T052	C1879547
27699206	401	434	unbiased parametric texture model	T170	C3161035
27699206	438	445	predict	T078	C0681842
27699206	446	455	preferred	T067	C0234402
27699206	463	483	nonpreferred stimuli	T067	C0234402
27699206	487	489	LO	T023	C0028785
27699206	491	502	Observation	T062	C0302523
27699206	507	529	psychophysical results	T169	C1274040
27699206	542	551	predicted	T078	C0681842
27699206	552	561	preferred	T078	C0558295
27699206	562	569	stimuli	T067	C0234402
27699206	576	583	objects	T072	C0347997
27699206	588	598	nonobjects	T071	C1551338
27699206	604	610	smooth	T080	C0205357
27699206	624	632	textured	T080	C0205556
27699206	634	642	surfaces	T082	C0205148
27699206	650	661	predictions	T078	C0681842
27699206	667	676	confirmed	T080	C0521093
27699206	683	687	fMRI	T060	C0376335
27699206	693	700	objects	T072	C0347997
27699206	705	715	nonobjects	T071	C1551338
27699206	725	736	preferences	T078	C0558295
27699206	760	778	fusiform face area	T022	C3536733
27699206	780	783	FFA	T022	C3536733
27699206	786	801	Consistent with	T078	C0332290
27699206	812	815	FFA	T022	C3536733
27699206	820	822	LO	T023	C0028785
27699206	850	861	nonfreckled	T080	C0205556
27699206	863	869	smooth	T080	C0205357
27699206	871	876	faces	T082	C0205148
27699206	878	886	compared	T052	C1707455
27699206	912	920	freckled	T033	C0016689
27699206	922	930	textured	T080	C0205556
27699206	932	937	faces	T082	C0205148
27699206	954	964	functional	T169	C0205245
27699206	965	976	connections	T082	C0449379
27699206	996	998	LO	T023	C0028785
27699206	1003	1006	FFA	T022	C3536733
27699206	1014	1016	LO	T023	C0028785
27699206	1021	1024	FFA	T022	C3536733
27699206	1043	1054	information	T078	C1533716
27699206	1057	1067	processing	T052	C1709694
27699206	1092	1099	feature	T080	C2348519
27699206	1107	1115	category	T170	C0683312
27699206	1116	1127	selectivity	T052	C1707391
27699206	1129	1135	smooth	T080	C0205357
27699206	1138	1146	textured	T080	C0205556

27842269|t|Using language for social interaction: Communication mechanisms promote recovery from chronic non-fluent aphasia
27842269|a|Clinical research highlights the importance of massed practice in the rehabilitation of chronic post-stroke aphasia. However, while necessary, massed practice may not be sufficient for ensuring progress in speech-language therapy. Motivated by recent advances in neuroscience, it has been claimed that using language as a tool for communication and social interaction leads to synergistic effects in left perisylvian eloquent areas. Here, we conducted a crossover randomized controlled trial to determine the influence of communicative language function on the outcome of intensive aphasia therapy. Eighteen individuals with left-hemisphere lesions and chronic non-fluent aphasia each received two types of training in counterbalanced order: (i) Intensive Language-Action Therapy (ILAT, an extended form of Constraint-Induced Aphasia Therapy) embedding verbal utterances in the context of communication and social interaction, and (ii) Naming Therapy focusing on speech production per se. Both types of training were delivered with the same high intensity (3.5 h per session) and duration (six consecutive working days), with therapy materials and number of utterances matched between treatment groups. A standardized aphasia test battery revealed significantly improved language performance with ILAT, independent of when this method was administered. In contrast, Naming Therapy tended to benefit language performance only when given at the onset of the treatment, but not when applied after previous intensive training. The current results challenge the notion that massed practice alone promotes recovery from chronic post-stroke aphasia. Instead, our results demonstrate that using language for communication and social interaction increases the efficacy of intensive aphasia therapy.
27842269	6	14	language	T171	C0023008
27842269	19	37	social interaction	T033	C0037420
27842269	39	52	Communication	T054	C0009452
27842269	86	93	chronic	T079	C0205191
27842269	94	112	non-fluent aphasia	T048	C0349390
27842269	113	130	Clinical research	T062	C0008972
27842269	160	175	massed practice	T170	C0870850
27842269	183	197	rehabilitation	T061	C0034991
27842269	201	208	chronic	T079	C0205191
27842269	209	220	post-stroke	T079	C1254367
27842269	221	228	aphasia	T048	C0003537
27842269	256	271	massed practice	T170	C0870850
27842269	307	315	progress	T169	C1280477
27842269	319	342	speech-language therapy	T058	C0037831
27842269	376	388	neuroscience	T091	C0027910
27842269	421	429	language	T171	C0023008
27842269	444	457	communication	T054	C0009452
27842269	462	480	social interaction	T033	C0037420
27842269	490	509	synergistic effects	T080	C1280500
27842269	513	544	left perisylvian eloquent areas	T029	C3495412
27842269	635	648	communicative	T054	C0009452
27842269	649	666	language function	T041	C0233732
27842269	674	681	outcome	T169	C1274040
27842269	685	710	intensive aphasia therapy	T061	C0087111
27842269	721	732	individuals	T098	C0237401
27842269	738	761	left-hemisphere lesions	T033	C2026233
27842269	766	773	chronic	T079	C0205191
27842269	774	792	non-fluent aphasia	T048	C0349390
27842269	820	828	training	T065	C0220931
27842269	832	853	counterbalanced order	T080	C1705176
27842269	859	892	Intensive Language-Action Therapy	T061	C0023017
27842269	894	898	ILAT	T061	C0023017
27842269	920	954	Constraint-Induced Aphasia Therapy	T061	C0087111
27842269	966	983	verbal utterances	T061	C2202690
27842269	1002	1015	communication	T054	C0009452
27842269	1020	1038	social interaction	T033	C0037420
27842269	1049	1063	Naming Therapy	T073,T170	C0037585
27842269	1076	1100	speech production per se	T060	C0037827
27842269	1116	1124	training	T065	C0220931
27842269	1193	1201	duration	T079	C0449238
27842269	1227	1231	days	T079	C0439228
27842269	1239	1246	therapy	T061	C0087111
27842269	1247	1256	materials	T167	C0520510
27842269	1261	1281	number of utterances	T033	C0243095
27842269	1298	1314	treatment groups	T061	C0087111
27842269	1331	1338	aphasia	T048	C0003537
27842269	1339	1351	test battery	T060	C0204458
27842269	1384	1392	language	T171	C0023008
27842269	1393	1404	performance	T055	C0597198
27842269	1410	1414	ILAT	T061	C0023017
27842269	1441	1447	method	T170	C0025663
27842269	1479	1493	Naming Therapy	T073,T170	C0037585
27842269	1512	1520	language	T171	C0023008
27842269	1569	1578	treatment	T061	C0087111
27842269	1626	1634	training	T065	C0220931
27842269	1682	1697	massed practice	T170	C0870850
27842269	1727	1734	chronic	T079	C0205191
27842269	1735	1746	post-stroke	T079	C1254367
27842269	1747	1754	aphasia	T048	C0003537
27842269	1800	1808	language	T171	C0023008
27842269	1813	1826	communication	T054	C0009452
27842269	1831	1849	social interaction	T033	C0037420
27842269	1876	1901	intensive aphasia therapy	T061	C0087111

27790295|t|Psychological and sexual effects of circumcision in adult males
27790295|a|Our aim was to investigate the psychological and sexual effects of circumcision in adult men, and analyze these changes following circumcision. We included 37 adults who applied to our clinic for circumcision and who did not have any psychiatric or urologic disorders and age -matched 30 controls in our study. Body Cathexis Scale (BCS), Liebowitz Social Anxiety Scale (LSAS), and Premature Ejaculation Diagnostic Tool (PEDT) were applied to the study group twice, once before and once three months after circumcision, and only once in the control group. Also, intravaginal ejaculation latency time (IELT) was noted and premature ejaculation (PE) evaluation was done. Intra- and intergroup comparisons were performed. The two groups were similar with regard to demographic data. Comparison of preoperative BCS and LSAS scores with the scores of the control group showed significant differences (p=0.003, p<0.001, and p<0.001, respectively). However, postoperative scores were similar to the scores obtained in the control group (p=0.768, p>0.05, and p>0.05, respectively). Scores of all scales showed significant improvements postoperatively. Also, PEDT scores and IELT changes before and after circumcision were significant in the study group, but not when compared to the control group. Our results indicated that social anxiety and anxiety levels decreased after circumcision in adult Turkish men, and their body gratification increased. We found that not being circumcised might negatively affect individuals in adulthood when it comes to body image and sexual satisfaction, however, both improve after circumcision.
27790295	0	13	Psychological	T169	C0205486
27790295	18	24	sexual	T053	C0036864
27790295	25	32	effects	T080	C1280500
27790295	36	48	circumcision	T061	C0008819
27790295	52	57	adult	T100	C0001675
27790295	58	63	males	T032	C0086582
27790295	68	71	aim	T078	C1947946
27790295	79	90	investigate	T169	C1292732
27790295	95	108	psychological	T169	C0205486
27790295	113	119	sexual	T053	C0036864
27790295	120	127	effects	T080	C1280500
27790295	131	143	circumcision	T061	C0008819
27790295	147	152	adult	T100	C0001675
27790295	153	156	men	T098	C0025266
27790295	176	183	changes	T169	C0392747
27790295	194	206	circumcision	T061	C0008819
27790295	223	229	adults	T100	C0001675
27790295	249	255	clinic	T073,T093	C0442592
27790295	260	272	circumcision	T061	C0008819
27790295	298	309	psychiatric	T048	C0004936
27790295	313	331	urologic disorders	T047	C0042075
27790295	336	339	age	T032	C0001779
27790295	352	360	controls	T096	C0009932
27790295	368	373	study	T062	C0008972
27790295	375	394	Body Cathexis Scale	T170	C0282574
27790295	396	399	BCS	T170	C0282574
27790295	402	432	Liebowitz Social Anxiety Scale	T170	C0282574
27790295	434	438	LSAS	T170	C0282574
27790295	445	482	Premature Ejaculation Diagnostic Tool	T170	C0282574
27790295	484	488	PEDT	T170	C0282574
27790295	510	521	study group	UnknownType	C0681860
27790295	550	562	three months	T079	C1442461
27790295	569	581	circumcision	T061	C0008819
27790295	604	617	control group	T096	C0009932
27790295	684	705	premature ejaculation	T046	C0033038
27790295	707	709	PE	T046	C0033038
27790295	711	721	evaluation	T058	C1261322
27790295	732	738	Intra-	T078	C0441833
27790295	743	753	intergroup	T078	C0441833
27790295	754	765	comparisons	T052	C1707455
27790295	790	796	groups	T078	C0441833
27790295	825	841	demographic data	T078	C1511726
27790295	843	853	Comparison	T052	C1707455
27790295	857	869	preoperative	T079	C0445204
27790295	870	873	BCS	T170	C0282574
27790295	878	882	LSAS	T170	C0282574
27790295	883	889	scores	T081	C0449820
27790295	899	905	scores	T081	C0449820
27790295	913	926	control group	T096	C0009932
27790295	934	945	significant	T078	C0750502
27790295	946	957	differences	T081	C1705241
27790295	1014	1027	postoperative	T079	C0032790
27790295	1028	1034	scores	T081	C0449820
27790295	1055	1061	scores	T081	C0449820
27790295	1078	1091	control group	T096	C0009932
27790295	1137	1143	Scores	T081	C0449820
27790295	1165	1176	significant	T078	C0750502
27790295	1177	1189	improvements	T077	C2986411
27790295	1190	1205	postoperatively	T079	C0032790
27790295	1213	1217	PEDT	T170	C0282574
27790295	1218	1224	scores	T081	C0449820
27790295	1234	1241	changes	T169	C0392747
27790295	1259	1271	circumcision	T061	C0008819
27790295	1277	1288	significant	T078	C0750502
27790295	1296	1307	study group	UnknownType	C0681860
27790295	1322	1330	compared	T052	C1707455
27790295	1338	1351	control group	T096	C0009932
27790295	1357	1364	results	T033	C2825142
27790295	1380	1394	social anxiety	T048	C0424166
27790295	1399	1413	anxiety levels	T033	C0564474
27790295	1414	1423	decreased	T081	C0205216
27790295	1430	1442	circumcision	T061	C0008819
27790295	1446	1451	adult	T100	C0001675
27790295	1452	1459	Turkish	T098	C0549217
27790295	1460	1463	men	T098	C0025266
27790295	1475	1479	body	T016	C0242821
27790295	1480	1493	gratification	T054	C0234057
27790295	1494	1503	increased	T081	C0205217
27790295	1529	1540	circumcised	T061	C0008819
27790295	1547	1557	negatively	T033	C0205160
27790295	1558	1564	affect	T041	C0001721
27790295	1565	1576	individuals	T098	C0027361
27790295	1577	1589	in adulthood	T079	C2945655
27790295	1607	1611	body	T016	C0242821
27790295	1622	1641	sexual satisfaction	T041	C0871356
27790295	1671	1683	circumcision	T061	C0008819

27752744|t|Incident fracture associated with increased risk of mortality even after adjusting for frailty status in elderly Japanese men: the Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study
27752744|a|Frail elderly individuals have elevated risks of both fracture and mortality. We found that incident fractures were associated with an increased risk of death even after adjusting for pre-fracture frailty status as represented by physical performance tests and laboratory tests for common geriatric diseases in community-dwelling elderly Japanese men. While fractures reportedly increase the risk of mortality, frailty may complicate this association, generating a false-positive result. We evaluated this association after adjusting for pre-fracture levels of frailty. We examined 1998 community-dwelling ambulatory men aged ≥65 years at baseline in the Fujiwara-kyo Osteoporosis Risk in Men Study for frailty status as represented by activities of daily living (ADL), physical performance tests (grip strength, one-foot standing balance with eyes open, timed 10-m walk), and laboratory sera tests. Participants were then followed for 5 years for incident clinical fractures and death. Effects of incident fracture on death were determined by Cox proportional hazards model with the first fracture during follow-up as a time-dependent predictor and with frailty status indices as covariates. We identified 111 fractures in 99 men and 138 deaths during the follow-up period (median follow-up, 4.5 years). Participants with incident fractures did not have significantly worse frailty statuses, but did show a significantly higher cumulative mortality rate than those without fractures (p = 0.0047). Age-adjusted hazard ratio (HR) of death for incident fracture was 3.57 (95 % confidence interval: 2.05, 6.24). When adjusted for physical performance, this decreased to 2.77 (1.51, 5.06), but remained significant. The HR showed no significant change when adjusted for laboratory test results (3.96 (2.26, 6.94)). Exclusion of deaths within the first 24 months of follow-up did not alter these results. Incident clinical fracture was associated with an elevated risk of death independently of pre-fracture levels of frailty in community-dwelling elderly men.
27752744	0	8	Incident	T067	C1551358
27752744	9	17	fracture	T037	C0016658
27752744	18	33	associated with	T080	C0332281
27752744	34	43	increased	T081	C0205217
27752744	44	48	risk	T078	C0035647
27752744	52	61	mortality	T081	C0205848
27752744	87	94	frailty	T033	C0424594
27752744	95	101	status	T080	C0449438
27752744	105	112	elderly	T098	C0001792
27752744	113	121	Japanese	T098	C1556094
27752744	122	125	men	T098	C0025266
27752744	131	190	Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Cohort Study	T081	C0009247
27752744	191	196	Frail	T033	C0871754
27752744	197	204	elderly	T098	C0001792
27752744	205	216	individuals	T098	C0237401
27752744	222	230	elevated	T080	C3163633
27752744	231	236	risks	T078	C0035647
27752744	245	253	fracture	T037	C0016658
27752744	258	267	mortality	T081	C0205848
27752744	283	291	incident	T067	C1551358
27752744	292	301	fractures	T037	C0016658
27752744	307	322	associated with	T080	C0332281
27752744	326	335	increased	T081	C0205217
27752744	336	340	risk	T078	C0035647
27752744	344	349	death	T033	C1306577
27752744	375	387	pre-fracture	T037	C0016658
27752744	388	395	frailty	T033	C0424594
27752744	396	402	status	T080	C0449438
27752744	421	447	physical performance tests	T060	C0679543
27752744	452	468	laboratory tests	T059	C0022885
27752744	480	489	geriatric	T080	C1704440
27752744	490	498	diseases	T047	C0012634
27752744	502	520	community-dwelling	T056	C4045975
27752744	521	528	elderly	T098	C0001792
27752744	529	537	Japanese	T098	C1556094
27752744	538	541	men	T098	C0025266
27752744	549	558	fractures	T037	C0016658
27752744	570	578	increase	T169	C0442805
27752744	583	587	risk	T078	C0035647
27752744	591	600	mortality	T081	C0205848
27752744	602	609	frailty	T033	C0424594
27752744	614	624	complicate	T169	C0231242
27752744	630	641	association	T080	C0439849
27752744	656	677	false-positive result	T033	C1112254
27752744	682	691	evaluated	T058	C0220825
27752744	697	708	association	T080	C0439849
27752744	729	741	pre-fracture	T037	C0016658
27752744	742	748	levels	T080	C0441889
27752744	752	759	frailty	T033	C0424594
27752744	764	772	examined	T033	C0332128
27752744	778	796	community-dwelling	T056	C4045975
27752744	797	807	ambulatory	T169	C0439841
27752744	808	811	men	T098	C0025266
27752744	812	816	aged	T032	C0001779
27752744	821	826	years	T079	C1510829
27752744	830	838	baseline	T081	C1442488
27752744	846	889	Fujiwara-kyo Osteoporosis Risk in Men Study	T081	C0009247
27752744	894	901	frailty	T033	C0424594
27752744	902	908	status	T080	C0449438
27752744	927	953	activities of daily living	T056	C0001288
27752744	955	958	ADL	T056	C0001288
27752744	961	987	physical performance tests	T060	C0679543
27752744	989	1002	grip strength	T081	C0429271
27752744	1004	1044	one-foot standing balance with eyes open	T033	C0516711
27752744	1046	1061	timed 10-m walk	T060	C2315460
27752744	1068	1089	laboratory sera tests	T059	C0022885
27752744	1079	1083	sera	T031	C0229671
27752744	1091	1103	Participants	T098	C0679646
27752744	1129	1134	years	T079	C0439234
27752744	1139	1147	incident	T067	C1551358
27752744	1148	1156	clinical	T080	C0205210
27752744	1157	1166	fractures	T037	C0016658
27752744	1171	1176	death	T033	C1306577
27752744	1178	1188	Effects of	T080	C1704420
27752744	1189	1197	incident	T067	C1551358
27752744	1198	1206	fracture	T037	C0016658
27752744	1210	1215	death	T033	C1306577
27752744	1235	1265	Cox proportional hazards model	T081,T170	C0033489
27752744	1281	1289	fracture	T037	C0016658
27752744	1297	1306	follow-up	T058	C1522577
27752744	1312	1336	time-dependent predictor	T078	C2698872
27752744	1346	1368	frailty status indices	T170	C4075886
27752744	1372	1382	covariates	T080	C0205556
27752744	1387	1397	identified	T080	C0205396
27752744	1402	1411	fractures	T037	C0016658
27752744	1418	1421	men	T098	C0025266
27752744	1430	1436	deaths	T033	C1306577
27752744	1448	1457	follow-up	T058	C1522577
27752744	1458	1464	period	T079	C1948053
27752744	1466	1472	median	T082	C2939193
27752744	1473	1482	follow-up	T058	C1522577
27752744	1488	1493	years	T079	C0439234
27752744	1496	1508	Participants	T098	C0679646
27752744	1514	1522	incident	T067	C1551358
27752744	1523	1532	fractures	T037	C0016658
27752744	1537	1565	not have significantly worse	T033	C0243095
27752744	1566	1573	frailty	T033	C0424594
27752744	1574	1582	statuses	T080	C0449438
27752744	1599	1612	significantly	T078	C0750502
27752744	1613	1619	higher	T080	C0205250
27752744	1620	1630	cumulative	T080	C1511559
27752744	1631	1645	mortality rate	T081	C0205848
27752744	1665	1674	fractures	T037	C0016658
27752744	1689	1701	Age-adjusted	T081	C4300468
27752744	1702	1714	hazard ratio	T081	C2985465
27752744	1716	1718	HR	T081	C2985465
27752744	1723	1728	death	T033	C1306577
27752744	1733	1741	incident	T067	C1551358
27752744	1742	1750	fracture	T037	C0016658
27752744	1766	1785	confidence interval	T081	C0009667
27752744	1818	1838	physical performance	T032	C2607857
27752744	1845	1854	decreased	T081	C0205216
27752744	1890	1901	significant	T078	C0750502
27752744	1907	1909	HR	T081	C2985465
27752744	1917	1938	no significant change	T033	C0442739
27752744	1957	1980	laboratory test results	T034	C1254360
27752744	2002	2011	Exclusion	T052	C2828389
27752744	2015	2021	deaths	T033	C1306577
27752744	2042	2048	months	T079	C0439231
27752744	2052	2061	follow-up	T058	C1522577
27752744	2066	2075	not alter	T033	C0243095
27752744	2082	2089	results	T034	C0456984
27752744	2091	2099	Incident	T067	C1551358
27752744	2100	2108	clinical	T080	C0205210
27752744	2109	2117	fracture	T037	C0016658
27752744	2122	2137	associated with	T080	C0332281
27752744	2141	2149	elevated	T080	C3163633
27752744	2150	2154	risk	T078	C0035647
27752744	2158	2163	death	T033	C1306577
27752744	2164	2177	independently	T033	C1299583
27752744	2181	2193	pre-fracture	T037	C0016658
27752744	2194	2200	levels	T080	C0441889
27752744	2204	2211	frailty	T033	C0424594
27752744	2215	2233	community-dwelling	T056	C4045975
27752744	2234	2241	elderly	T098	C0001792
27752744	2242	2245	men	T098	C0025266

27333594|t|Proteomic analysis of docetaxel resistance in human nasopharyngeal carcinoma cells using the two-dimensional gel electrophoresis method
27333594|a|Docetaxel -based chemotherapy has been recommended for advanced nasopharyngeal carcinoma (NPC). However, treatment failure often occurs because of acquired drug resistance. In this study, a docetaxel - resistant NPC cell line CNE-2R was established with increasing doses of docetaxel for more than 6 months. Two-dimensional gel electrophoresis and ESI-Q-TOF-MS were used to compare the differential expression of docetaxel - resistance - associated proteins between human NPC CNE-2 cells and docetaxel - resistant CNE-2R cells. As a result, 24 differentially expressed proteins were identified, including 11 proteins with increased expression and 13 proteins with decreased expression. These proteins function in diverse biological processes such as metabolism, signal transduction, calcium ion binding, immune response, proteolysis, and so on. Among these, α-enolase (ENO1), significantly upregulated in CNE-2R, was selected for detailed analysis. Inhibition of ENO1 by shRNA restored CNE-2R cells ' sensitivity to docetaxel. Moreover, overexpression of ENO1 could facilitate the development of acquired resistance of docetaxel in CNE-2 cells. Western blot and reverse-transcription PCR data of clinical samples confirmed that α-enolase was upregulated in docetaxel - resistant human NPC tissues. Finding such proteins might improve interpretation of the molecular mechanisms leading to the acquisition of docetaxel chemoresistance.
27333594	0	9	Proteomic	T091	C0872252
27333594	10	18	analysis	T062	C0936012
27333594	22	31	docetaxel	T109,T121	C0246415
27333594	32	42	resistance	T038	C0013203
27333594	46	51	human	T016	C0086418
27333594	52	76	nasopharyngeal carcinoma	T191	C2931822
27333594	77	82	cells	T025	C0597032
27333594	93	135	two-dimensional gel electrophoresis method	T059	C0013860
27333594	136	145	Docetaxel	T109,T121	C0246415
27333594	153	165	chemotherapy	T061	C3665472
27333594	175	186	recommended	T078	C0034866
27333594	200	224	nasopharyngeal carcinoma	T191	C2931822
27333594	226	229	NPC	T191	C2931822
27333594	241	258	treatment failure	T033	C0162643
27333594	283	291	acquired	T080	C0439661
27333594	292	307	drug resistance	T038	C0013203
27333594	317	322	study	T062	C0681814
27333594	326	335	docetaxel	T109,T121	C0246415
27333594	338	347	resistant	T038	C0013203
27333594	348	351	NPC	T191	C2931822
27333594	352	368	cell line CNE-2R	T025	C0085983
27333594	373	384	established	T080	C0443211
27333594	390	400	increasing	T169	C0442808
27333594	401	406	doses	T081	C0178602
27333594	410	419	docetaxel	T109,T121	C0246415
27333594	424	433	more than	T081	C0439093
27333594	436	442	months	T079	C0439231
27333594	444	479	Two-dimensional gel electrophoresis	T059	C0013860
27333594	484	496	ESI-Q-TOF-MS	T059	C0599827
27333594	510	517	compare	T052	C1707455
27333594	535	545	expression	T045	C1171362
27333594	549	558	docetaxel	T109,T121	C0246415
27333594	561	571	resistance	T038	C0013203
27333594	574	593	associated proteins	T116,T123	C0033684
27333594	602	607	human	T016	C0086418
27333594	608	611	NPC	T191	C2931822
27333594	612	623	CNE-2 cells	T025	C0007634
27333594	628	637	docetaxel	T109,T121	C0246415
27333594	640	649	resistant	T038	C0013203
27333594	650	662	CNE-2R cells	T025	C0007634
27333594	669	675	result	T033	C2825142
27333594	680	694	differentially	T080	C0443199
27333594	695	713	expressed proteins	T045	C1171362
27333594	719	729	identified	T080	C0205396
27333594	744	752	proteins	T116,T123	C0033684
27333594	758	767	increased	T081	C0205217
27333594	768	778	expression	T045	C1171362
27333594	786	794	proteins	T116,T123	C0033684
27333594	800	809	decreased	T081	C0205216
27333594	810	820	expression	T045	C1171362
27333594	828	845	proteins function	T044	C1527118
27333594	849	856	diverse	T080	C1880371
27333594	857	877	biological processes	T038	C3714634
27333594	886	896	metabolism	T169	C0025520
27333594	898	917	signal transduction	T043	C0037083
27333594	919	938	calcium ion binding	T044	C1148580
27333594	940	955	immune response	T042	C0301872
27333594	957	968	proteolysis	T044	C0597304
27333594	994	1003	α-enolase	T116,T126	C2364020
27333594	1005	1009	ENO1	T116,T126	C2364020
27333594	1041	1047	CNE-2R	T025	C0007634
27333594	1053	1061	selected	T052	C1707391
27333594	1075	1083	analysis	T062	C0936012
27333594	1085	1095	Inhibition	T052	C3463820
27333594	1099	1103	ENO1	T116,T126	C2364020
27333594	1107	1112	shRNA	T114	C2930586
27333594	1122	1134	CNE-2R cells	T025	C0007634
27333594	1137	1148	sensitivity	T169	C0332324
27333594	1152	1161	docetaxel	T109,T121	C0246415
27333594	1173	1187	overexpression	T045	C1514559
27333594	1191	1195	ENO1	T116,T126	C2364020
27333594	1217	1228	development	T169	C1527148
27333594	1232	1240	acquired	T080	C0439661
27333594	1241	1251	resistance	T038	C0013203
27333594	1255	1264	docetaxel	T109,T121	C0246415
27333594	1268	1279	CNE-2 cells	T025	C0007634
27333594	1281	1293	Western blot	T059,T063	C0005863
27333594	1298	1323	reverse-transcription PCR	T063	C0599161
27333594	1324	1328	data	T078	C1511726
27333594	1332	1348	clinical samples	T077	C2347026
27333594	1349	1358	confirmed	T080	C0521093
27333594	1364	1373	α-enolase	T116,T126	C2364020
27333594	1393	1402	docetaxel	T109,T121	C0246415
27333594	1405	1414	resistant	T038	C0013203
27333594	1415	1420	human	T016	C0086418
27333594	1421	1424	NPC	T191	C2931822
27333594	1425	1432	tissues	T024	C0040300
27333594	1434	1441	Finding	T033	C0243095
27333594	1447	1455	proteins	T116,T123	C0033684
27333594	1462	1469	improve	T033	C0184511
27333594	1470	1484	interpretation	T170	C0459471
27333594	1492	1512	molecular mechanisms	T044	C3537153
27333594	1513	1520	leading	T169	C1522538
27333594	1528	1539	acquisition	T052	C1706701
27333594	1543	1552	docetaxel	T109,T121	C0246415
27333594	1553	1568	chemoresistance	T038	C0013203

27619227|t|Comparative proteomic analysis reveals alterations in development and photosynthesis -related proteins in diploid and triploid rice
27619227|a|Polyploidy has pivotal influences on rice (Oryza sativa L.) morphology and physiology, and is very important for understanding rice domestication and improving agricultural traits. Diploid (DP) and triploid (TP) rice shows differences in morphological parameters, such as plant height, leaf length, leaf width and the physiological index of chlorophyll content. However, the underlying mechanisms determining these morphological differences are remain to be defined. To better understand the proteomic changes between DP and TP, tandem mass tags (TMT) mass spectrometry (MS) / MS was used to detect the significant changes to protein expression between DP and TP. Results indicated that both photosynthesis and metabolic pathways were highly significantly associated with proteomic alteration between DP and TP based on biological process and pathway enrichment analysis, and 13 higher abundance chloroplast proteins involving in these two pathways were identified in TP. Quantitative real-time PCR analysis demonstrated that 5 of the 13 chloroplast proteins ATPF, PSAA, PSAB, PSBB and RBL in TP were higher abundance compared with those in DP. This study integrates morphology, physiology and proteomic profiling alteration of DP and TP to address their underlying different molecular mechanisms. Our finding revealed that ATPF, PSAA, PSAB, PSBB and RBL can induce considerable expression changes in TP and may affect the development and growth of rice through photosynthesis and metabolic pathways.
27619227	12	30	proteomic analysis	T059	C0022885
27619227	39	50	alterations	T078	C1515926
27619227	54	65	development	T040	C0597252
27619227	70	84	photosynthesis	T070	C0031764
27619227	94	102	proteins	T116,T123	C0033684
27619227	106	113	diploid	T032	C0012568
27619227	118	126	triploid	T049	C3536727
27619227	127	131	rice	T002	C1140671
27619227	132	142	Polyploidy	T049	C0032578
27619227	155	165	influences	T077	C4054723
27619227	169	173	rice	T002	C1140671
27619227	175	190	Oryza sativa L.	T002	C1140671
27619227	192	202	morphology	T080	C0332437
27619227	207	217	physiology	T039	C0031843
27619227	259	263	rice	T002	C1140671
27619227	264	277	domestication	T078	C0175819
27619227	292	311	agricultural traits	T032	C0599883
27619227	313	320	Diploid	T032	C0012568
27619227	322	324	DP	T032	C0012568
27619227	330	338	triploid	T049	C3536727
27619227	340	342	TP	T049	C3536727
27619227	344	348	rice	T002	C1140671
27619227	355	366	differences	T080	C1705242
27619227	370	383	morphological	T080	C0332437
27619227	384	394	parameters	T033	C0449381
27619227	404	409	plant	T002	C0032098
27619227	410	416	height	T032	C0489786
27619227	418	422	leaf	T002	C0242724
27619227	423	429	length	T081	C1444754
27619227	431	435	leaf	T002	C0242724
27619227	436	441	width	T081	C0487742
27619227	450	463	physiological	T169	C0205463
27619227	464	469	index	T170	C0918012
27619227	473	484	chlorophyll	T109,T123	C0008260
27619227	485	492	content	T077	C0456205
27619227	518	528	mechanisms	T169	C0441712
27619227	547	560	morphological	T080	C0332437
27619227	561	572	differences	T080	C1705242
27619227	624	633	proteomic	T116,T123	C0033684
27619227	634	641	changes	T169	C0392747
27619227	650	652	DP	T032	C0012568
27619227	657	659	TP	T049	C3536727
27619227	661	706	tandem mass tags (TMT) mass spectrometry (MS)	T059	C2123592
27619227	709	711	MS	T059	C0037813
27619227	747	754	changes	T169	C0392747
27619227	758	776	protein expression	T045	C1171362
27619227	785	787	DP	T032	C0012568
27619227	792	794	TP	T049	C3536727
27619227	824	838	photosynthesis	T070	C0031764
27619227	843	861	metabolic pathways	T169	C1291081
27619227	888	903	associated with	T080	C0332281
27619227	904	924	proteomic alteration	T044	C1514563
27619227	933	935	DP	T032	C0012568
27619227	940	942	TP	T049	C3536727
27619227	952	970	biological process	T038	C3714634
27619227	975	1002	pathway enrichment analysis	T059	C0022885
27619227	1018	1027	abundance	T080	C2346714
27619227	1028	1048	chloroplast proteins	T116,T123	C3178938
27619227	1072	1080	pathways	T044	C1704259
27619227	1086	1096	identified	T080	C0205396
27619227	1100	1102	TP	T049	C3536727
27619227	1104	1139	Quantitative real-time PCR analysis	T063	C3179034
27619227	1170	1190	chloroplast proteins	T116,T123	C3178938
27619227	1191	1195	ATPF	T116,T123	C0033684
27619227	1197	1201	PSAA	T116,T123	C0033684
27619227	1203	1207	PSAB	T116,T123	C0084235
27619227	1209	1213	PSBB	T116,T123	C0033684
27619227	1218	1221	RBL	T116,T123	C0033684
27619227	1225	1227	TP	T049	C3536727
27619227	1240	1249	abundance	T080	C2346714
27619227	1273	1275	DP	T032	C0012568
27619227	1282	1287	study	T062	C2603343
27619227	1299	1309	morphology	T080	C0332437
27619227	1311	1321	physiology	T039	C0031843
27619227	1326	1345	proteomic profiling	T059	C1327760
27619227	1346	1356	alteration	T078	C1515926
27619227	1360	1362	DP	T032	C0012568
27619227	1367	1369	TP	T049	C3536727
27619227	1408	1428	molecular mechanisms	T044	C3537153
27619227	1456	1460	ATPF	T116,T123	C0033684
27619227	1462	1466	PSAA	T116,T123	C0033684
27619227	1468	1472	PSAB	T116,T123	C0084235
27619227	1474	1478	PSBB	T116,T123	C0033684
27619227	1483	1486	RBL	T116,T123	C0033684
27619227	1511	1521	expression	T045	C1171362
27619227	1522	1529	changes	T169	C0392747
27619227	1533	1535	TP	T049	C3536727
27619227	1555	1566	development	T040	C0597252
27619227	1571	1577	growth	T040	C0597252
27619227	1581	1585	rice	T002	C1140671
27619227	1594	1608	photosynthesis	T070	C0031764
27619227	1613	1631	metabolic pathways	T169	C1291081

28471656|t|4-Anilino-2-pyridylquinazolines and - pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2)
28471656|a|Multidrug resistance (MDR) mediated by ATP-binding cassette (ABC) transport proteins remains a major problem in the chemotherapeutic treatment of cancer and might be overcome by inhibition of the transporter. Because of the lack of understanding, the complex mechanisms involved in the transport process, in particular for breast cancer resistance protein (BCRP / ABCG2), there is a persistent need for studies of inhibitors of ABCG2. In this study, we investigated a systematic series of 4-substituted-2-pyridylquinazolines in terms of their inhibitory potency as well as selectivity toward ABCG2. For comparison, the quinazoline scaffold was reduced to the significantly smaller 4-methylpyrimidine basic structure. Furthermore, the cytotoxicity and the ability to reverse MDR was tested with the chemotherapeutic agents SN-38 and mitoxantrone (MX). Interaction of the compounds with ABCG2 was investigated by a colorimetric ATPase assay. Enzyme kinetic studies were carried out with Hoechst 33342 as fluorescent dye and substrate of ABCG2 to elucidate the compounds binding modes.
28471656	0	31	4-Anilino-2-pyridylquinazolines	T109	C0034407
28471656	38	49	pyrimidines	T114,T123	C0034289
28471656	60	66	Potent	T080	C0442821
28471656	71	79	Nontoxic	T080	C1518413
28471656	80	90	Inhibitors	T120	C0243077
28471656	94	126	Breast Cancer Resistance Protein	T116,T123	C0761993
28471656	128	133	ABCG2	T116,T123	C0761993
28471656	135	155	Multidrug resistance	T032	C0242640
28471656	157	160	MDR	T032	C0242640
28471656	174	219	ATP-binding cassette (ABC) transport proteins	T116,T123	C0242738
28471656	251	277	chemotherapeutic treatment	T061	C3665472
28471656	281	287	cancer	T191	C0027651
28471656	301	309	overcome	T052	C2983310
28471656	313	323	inhibition	T052	C3463820
28471656	331	342	transporter	T116,T123	C0596902
28471656	394	404	mechanisms	T169	C0441712
28471656	421	438	transport process	T044	C1519628
28471656	458	490	breast cancer resistance protein	T116,T123	C0761993
28471656	492	496	BCRP	T116,T123	C0761993
28471656	499	504	ABCG2	T116,T123	C0761993
28471656	549	559	inhibitors	T120	C0243077
28471656	563	568	ABCG2	T116,T123	C0761993
28471656	588	600	investigated	T169	C1292732
28471656	624	659	4-substituted-2-pyridylquinazolines	T109	C0034407
28471656	678	688	inhibitory	T052	C3463820
28471656	689	696	potency	T080	C3245505
28471656	708	719	selectivity	T081	C0037791
28471656	727	732	ABCG2	T116,T123	C0761993
28471656	754	774	quinazoline scaffold	T109	C0034407
28471656	816	834	4-methylpyrimidine	T114,T123	C0034289
28471656	869	881	cytotoxicity	T049	C0596402
28471656	901	908	reverse	T169	C1555029
28471656	909	912	MDR	T032	C0242640
28471656	933	956	chemotherapeutic agents	T121	C0729502
28471656	957	962	SN-38	T109,T121	C0142710
28471656	967	979	mitoxantrone	T109,T121	C0026259
28471656	981	983	MX	T109,T121	C0026259
28471656	986	997	Interaction	T169	C1704675
28471656	1005	1014	compounds	T103	C1706082
28471656	1020	1025	ABCG2	T116,T123	C0761993
28471656	1030	1042	investigated	T169	C1292732
28471656	1048	1060	colorimetric	T059	C1531834
28471656	1061	1067	ATPase	T116,T126	C0001473
28471656	1068	1073	assay	T059	C2717977
28471656	1075	1097	Enzyme kinetic studies	T090	C1516893
28471656	1120	1133	Hoechst 33342	T121	C0062907
28471656	1137	1152	fluorescent dye	T130	C0016320
28471656	1157	1166	substrate	T167	C3891814
28471656	1170	1175	ABCG2	T116,T123	C0761993
28471656	1193	1202	compounds	T103	C1706082
28471656	1203	1216	binding modes	T052	C1145667

27338347|t|Neonatal Heart -Enriched miR-708 Promotes Differentiation of Cardiac Progenitor Cells in Rats
27338347|a|Cardiovascular disease is becoming the leading cause of death throughout the world. However, adult hearts have limited potential for regeneration after pathological injury, partly due to the quiescent status of stem / progenitor cells. Reactivation of cardiac stem / progenitor cells to create more myocyte progeny is one of the key steps in the regeneration of a damaged heart. In this study, miR-708 was identified to be enriched in the neonatal cardiomyocytes of rats, but this has not yet been proven in adult humans. A lower level of miR-708 in c-kit(+) stem / progenitor cells was detected compared to non-progenitors. Overexpression of miR-708 induced cardiomyocyte differentiation of cardiac stem / progenitor cells. This finding strengthened the potential of applying miRNAs in the regeneration of injured hearts, and this indicates that miR-708 could be a novel candidate for treatment of heart diseases.
27338347	0	14	Neonatal Heart	T046	C1533637
27338347	25	32	miR-708	T114,T123	C1101610
27338347	42	57	Differentiation	T043	C0007589
27338347	61	85	Cardiac Progenitor Cells	T025	C4084729
27338347	89	93	Rats	T015	C0034693
27338347	94	116	Cardiovascular disease	T047	C0007222
27338347	141	155	cause of death	T033	C0007465
27338347	171	176	world	T098	C2700280
27338347	187	192	adult	T100	C0001675
27338347	193	199	hearts	T023	C0018787
27338347	227	239	regeneration	T042	C0034963
27338347	246	258	pathological	T169	C1521733
27338347	259	265	injury	T037	C3263723
27338347	305	309	stem	T025	C4084729
27338347	312	328	progenitor cells	T025	C0038250
27338347	330	342	Reactivation	T052	C4086768
27338347	346	358	cardiac stem	T025	C4084729
27338347	361	377	progenitor cells	T025	C0038250
27338347	393	400	myocyte	T025	C0596981
27338347	401	408	progeny	T025	C0038250
27338347	440	452	regeneration	T042	C0034963
27338347	458	465	damaged	T169	C1883709
27338347	466	471	heart	T023	C0018787
27338347	488	495	miR-708	T114,T123	C1101610
27338347	533	541	neonatal	T079	C2939425
27338347	542	556	cardiomyocytes	T025	C0225828
27338347	560	564	rats	T015	C0034693
27338347	602	607	adult	T100	C0001675
27338347	608	614	humans	T016	C0086418
27338347	633	640	miR-708	T114,T123	C1101610
27338347	644	652	c-kit(+)	T028	C1416655
27338347	653	657	stem	T025	C4084729
27338347	660	676	progenitor cells	T025	C0038250
27338347	702	717	non-progenitors	T025	C0007634
27338347	719	733	Overexpression	T045	C1514559
27338347	737	744	miR-708	T028	C2239706
27338347	753	766	cardiomyocyte	T025	C0225828
27338347	786	798	cardiac stem	T025	C4084729
27338347	801	817	progenitor cells	T025	C0038250
27338347	871	877	miRNAs	T114,T123	C1101610
27338347	885	897	regeneration	T042	C0034963
27338347	901	908	injured	T169	C0332664
27338347	909	915	hearts	T023	C0018787
27338347	941	948	miR-708	T114,T123	C1101610
27338347	980	989	treatment	T061	C0087111
27338347	993	1007	heart diseases	T047	C0018799

27252904|t|Comparison of the Effects of Subcutaneous Versus Continuous Infusion of Heparin on Key Inflammatory Parameters Following Sepsis
27252904|a|Sepsis is the result of the interaction between inflammatory mediators and coagulation pathway. Unfractionated heparin may play a role as an anti-inflammatory agent beyond its anticoagulatory effect in sepsis. As a result, it may cause reduction in organ failure rate in patients with sepsis due to its impact on both inflammatory and coagulation process. The aim of this study was to evaluate the anti-inflammatory effects of heparin in sepsis. Plasma plasminogen activator inhibitor-1 (PAI-1) as an inflammatory mediator and urinary necoutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney injury were investigated. This prospective, randomized controlled trial was conducted in a 32- bed intensive care unit. Thirty patients with sepsis were randomized to receive heparin infusion of 500 units/hour or 5000 units of heparin three times a day, subcutaneously. The plasma level of PAI-1 and urinary level of NGAL were determined at day 0, 2 and 7. The infusion group had a lower plasma PAI-1 level compared to the subcutaneous group at day 7 (11.3 ± 1.6 vs. 16.5 ± 4.2; P = 0.003). The urinary NGAL level was lower in the infusion group at day 2 (131.3 ± 11.9 vs. 151.2 ± 20.6; P = 0.014); however, at day 7 the NGAL level was decreased in the subcutaneous group as much as the infusion group and there was no significant difference between the two groups. There was no significant difference in the acute physiology and chronic health evaluation (APACHE) II and sequential organ failure assessment (SOFA) scores between the two groups at day 0, 2 and 7. Low-dose heparin infusion compared to subcutaneous heparin can decrease the plasma PAI-1 and urinary NGAL levels more rapidly. It can be related to anti-inflammatory effects of heparin, which may be more prominent in infusion route.
27252904	0	10	Comparison	T052	C1707455
27252904	18	28	Effects of	T080	C1704420
27252904	29	41	Subcutaneous	T061	C0576773
27252904	49	68	Continuous Infusion	T061	C0444889
27252904	72	79	Heparin	T109,T121,T123	C0019134
27252904	83	99	Key Inflammatory	T169	C0333348
27252904	100	110	Parameters	T077	C0549193
27252904	111	120	Following	T079	C0332282
27252904	121	127	Sepsis	T047	C0243026
27252904	128	134	Sepsis	T047	C0243026
27252904	142	148	result	T169	C1274040
27252904	156	167	interaction	T169	C1704675
27252904	176	198	inflammatory mediators	T121	C0243042
27252904	203	222	coagulation pathway	T044	C1704259
27252904	224	246	Unfractionated heparin	T121	C2825026
27252904	258	262	role	T077	C1705810
27252904	269	292	anti-inflammatory agent	T121	C0003209
27252904	304	326	anticoagulatory effect	T080	C1280500
27252904	330	336	sepsis	T047	C0243026
27252904	343	349	result	T169	C1274040
27252904	364	373	reduction	T080	C0392756
27252904	377	390	organ failure	T046	C0026766
27252904	391	395	rate	T081	C1521828
27252904	399	407	patients	T101	C0030705
27252904	413	419	sepsis	T047	C0243026
27252904	431	437	impact	T080	C4049986
27252904	446	458	inflammatory	T169	C0333348
27252904	463	482	coagulation process	T039	C1328723
27252904	488	491	aim	T078	C1947946
27252904	500	505	study	T062	C0681814
27252904	513	521	evaluate	T058	C0184514
27252904	526	551	anti-inflammatory effects	T080	C1515999
27252904	555	562	heparin	T109,T121,T123	C0019134
27252904	566	572	sepsis	T047	C0243026
27252904	574	580	Plasma	T031	C0032105
27252904	581	614	plasminogen activator inhibitor-1	T116,T123	C0030190
27252904	616	621	PAI-1	T116,T123	C0030190
27252904	629	650	inflammatory mediator	T121	C0243042
27252904	655	662	urinary	T080	C1524119
27252904	663	707	necoutrophil gelatinase-associated lipocalin	T116,T123	C2347341
27252904	709	713	NGAL	T116,T123	C2347341
27252904	720	726	marker	T201	C0005516
27252904	730	743	kidney injury	T037	C0160420
27252904	749	761	investigated	T169	C1292732
27252904	768	779	prospective	T062	C0033522
27252904	781	808	randomized controlled trial	T062	C0206035
27252904	832	835	bed	T082	C1547114
27252904	836	855	intensive care unit	T073,T093	C0021708
27252904	864	872	patients	T101	C0030705
27252904	878	884	sepsis	T047	C0243026
27252904	890	900	randomized	T062	C0034656
27252904	904	911	receive	T080	C1514756
27252904	912	919	heparin	T109,T121,T123	C0019134
27252904	920	928	infusion	T169	C1827465
27252904	936	946	units/hour	T081	C0456685
27252904	955	960	units	T081	C1519795
27252904	964	971	heparin	T109,T121,T123	C0019134
27252904	972	989	three times a day	T079	C0556984
27252904	991	1005	subcutaneously	T033	C1736929
27252904	1011	1017	plasma	T031	C0032105
27252904	1018	1023	level	T080	C0441889
27252904	1027	1032	PAI-1	T116,T123	C0030190
27252904	1037	1044	urinary	T080	C1524119
27252904	1045	1050	level	T080	C0441889
27252904	1054	1058	NGAL	T116,T123	C2347341
27252904	1078	1083	day 0	T033	C0243095
27252904	1085	1086	2	T033	C3842676
27252904	1091	1092	7	T033	C3842672
27252904	1098	1106	infusion	T169	C1827465
27252904	1107	1112	group	T078	C0441833
27252904	1119	1124	lower	T082	C0441994
27252904	1125	1131	plasma	T031	C0032105
27252904	1132	1137	PAI-1	T116,T123	C0030190
27252904	1138	1143	level	T080	C0441889
27252904	1144	1152	compared	T052	C1707455
27252904	1160	1178	subcutaneous group	T078	C0441833
27252904	1182	1187	day 7	T033	C3842672
27252904	1232	1239	urinary	T080	C1524119
27252904	1240	1244	NGAL	T116,T123	C2347341
27252904	1245	1250	level	T080	C0441889
27252904	1255	1260	lower	T082	C0441994
27252904	1268	1276	infusion	T169	C1827465
27252904	1277	1282	group	T078	C0441833
27252904	1286	1291	day 2	T033	C3842676
27252904	1348	1353	day 7	T033	C3842672
27252904	1358	1362	NGAL	T116,T123	C2347341
27252904	1363	1368	level	T080	C0441889
27252904	1373	1382	decreased	T081	C0205216
27252904	1390	1408	subcutaneous group	T078	C0441833
27252904	1424	1432	infusion	T169	C1827465
27252904	1433	1438	group	T078	C0441833
27252904	1453	1467	no significant	T080	C0205556
27252904	1468	1478	difference	T080	C1705242
27252904	1495	1501	groups	T078	C0441833
27252904	1513	1527	no significant	T080	C0205556
27252904	1528	1538	difference	T080	C1705242
27252904	1546	1604	acute physiology and chronic health evaluation (APACHE) II	T060	C0489438
27252904	1609	1658	sequential organ failure assessment (SOFA) scores	T033	C3494459
27252904	1675	1681	groups	T078	C0441833
27252904	1685	1690	day 0	T033	C0243095
27252904	1692	1693	2	T033	C3842676
27252904	1698	1699	7	T033	C3842672
27252904	1701	1709	Low-dose	T081	C0445550
27252904	1710	1717	heparin	T109,T121,T123	C0019134
27252904	1718	1726	infusion	T169	C1827465
27252904	1727	1735	compared	T052	C1707455
27252904	1739	1751	subcutaneous	T082	C0443315
27252904	1752	1759	heparin	T109,T121,T123	C0019134
27252904	1764	1772	decrease	T081	C0547047
27252904	1777	1783	plasma	T031	C0032105
27252904	1784	1789	PAI-1	T116,T123	C0030190
27252904	1794	1801	urinary	T080	C1524119
27252904	1802	1806	NGAL	T116,T123	C2347341
27252904	1807	1813	levels	T080	C0441889
27252904	1819	1826	rapidly	T080	C0456962
27252904	1838	1845	related	T080	C0439849
27252904	1849	1874	anti-inflammatory effects	T080	C1515999
27252904	1878	1885	heparin	T109,T121,T123	C0019134
27252904	1905	1914	prominent	T080	C0205402
27252904	1918	1932	infusion route	T169	C1827465

28301024|t|Comparison of Cone-Beam Computed Tomography and Intraoral Radiography in Detection of Recurrent Caries under Composite Restorations
28301024|a|Secondary caries is the most common cause of dental restoration failures. This study aimed to compare the diagnostic accuracy of conventional and digital intraoral radiography and cone beam computed tomography (CBCT) for detection of recurrent caries around composite restorations. mesio-occluso-distal (MOD) cavities were prepared using bur on 45 extracted sound human molar teeth. The teeth were divided into 3 groups. In the control group, cavities were restored with composite resin after etching and bonding (n=15). In Group 2, 500-μm thick wax was placed over the buccal, lingual and gingival walls and the cavities were restored with composite resin. Group 3 specimens were subjected to pH cycling and artificial caries were created on the buccal, lingual and gingival walls. The cavities were restored with composite. Conventional and digital photo-stimulable phosphor (PSP; Optime) radiographs and two CBCTs images (NewTom 3G and Cranex 3D) were obtained from them. Presence or absence of caries in the cavity walls was assessed on these images. Data were analyzed using Kappa statistic. The diagnostic accuracy of CBCT was significantly higher than that of digital and conventional intraoral radiography (p<0.05). The accuracy was 0.83, 0.78, 0.55 and 0.49 for CBCT Cranex 3D, CBCT NewTom 3G, conventional and digital intraoral radiography, respectively. CBCT has a higher diagnostic accuracy than digital and conventional intraoral radiography for detection of secondary caries around composite restorations.
28301024	0	10	Comparison	T052	C1707455
28301024	14	43	Cone-Beam Computed Tomography	T060	C1956110
28301024	48	69	Intraoral Radiography	T060	C0034575
28301024	73	82	Detection	T061	C1511790
28301024	86	102	Recurrent Caries	T047	C4290196
28301024	109	118	Composite	T122	C0009570
28301024	119	131	Restorations	T061	C0399059
28301024	132	148	Secondary caries	T047	C1882989
28301024	168	173	cause	T169	C0015127
28301024	177	204	dental restoration failures	T067	C0376494
28301024	238	257	diagnostic accuracy	T080	C0598285
28301024	261	273	conventional	T060	C0034575
28301024	278	307	digital intraoral radiography	T060	C0376512
28301024	312	341	cone beam computed tomography	T060	C1956110
28301024	343	347	CBCT	T060	C1956110
28301024	353	362	detection	T061	C1511790
28301024	366	382	recurrent caries	T047	C4290196
28301024	390	399	composite	T122	C0009570
28301024	400	412	restorations	T061	C0399059
28301024	414	434	mesio-occluso-distal	T029	C0447327
28301024	436	439	MOD	T029	C0447327
28301024	441	449	cavities	T047	C0011334
28301024	455	463	prepared	T033	C4082130
28301024	470	473	bur	T074	C0179470
28301024	496	501	human	T016	C0086418
28301024	502	513	molar teeth	T023	C0026367
28301024	519	524	teeth	T023	C0040426
28301024	545	551	groups	UnknownType	C0681860
28301024	560	573	control group	T096	C0009932
28301024	575	583	cavities	T047	C0011334
28301024	589	597	restored	T061	C1283255
28301024	603	618	composite resin	T122	C0009570
28301024	625	632	etching	T061	C0086261
28301024	637	644	bonding	T061	C0005926
28301024	656	661	Group	UnknownType	C0681860
28301024	678	681	wax	T122	C0180365
28301024	686	692	placed	T058	C1533810
28301024	702	708	buccal	T029	C1540415
28301024	710	717	lingual	T029	C0447311
28301024	722	736	gingival walls	T029	C0227114
28301024	745	753	cavities	T047	C0011334
28301024	759	767	restored	T061	C1283255
28301024	773	788	composite resin	T122	C0009570
28301024	790	795	Group	UnknownType	C0681860
28301024	798	807	specimens	T096	C0681850
28301024	826	836	pH cycling	T059	C0022885
28301024	841	851	artificial	T080	C2004457
28301024	852	858	caries	T047	C0162644
28301024	879	885	buccal	T029	C1540415
28301024	887	894	lingual	T029	C0447311
28301024	899	913	gingival walls	T029	C0227114
28301024	919	927	cavities	T047	C0011334
28301024	933	941	restored	T061	C1283255
28301024	947	956	composite	T122	C0009570
28301024	958	1034	Conventional and digital photo-stimulable phosphor (PSP; Optime) radiographs	T060	C0430022
28301024	1043	1055	CBCTs images	T060	C1956110
28301024	1057	1066	NewTom 3G	T074	C0025080
28301024	1071	1080	Cranex 3D	T074	C0025080
28301024	1107	1115	Presence	T033	C0150312
28301024	1119	1126	absence	T169	C0332197
28301024	1130	1136	caries	T047	C0011334
28301024	1144	1156	cavity walls	T030	C0011403
28301024	1161	1169	assessed	T052	C1516048
28301024	1179	1185	images	T060	C0498015
28301024	1187	1191	Data	T078	C1511726
28301024	1197	1205	analyzed	T062	C0936012
28301024	1212	1227	Kappa statistic	T081	C0392762
28301024	1233	1252	diagnostic accuracy	T080	C0598285
28301024	1256	1260	CBCT	T060	C1956110
28301024	1265	1285	significantly higher	T081	C4055637
28301024	1299	1306	digital	T060	C0376512
28301024	1311	1345	conventional intraoral radiography	T060	C0034575
28301024	1360	1368	accuracy	T080	C0443131
28301024	1403	1407	CBCT	T060	C1956110
28301024	1408	1417	Cranex 3D	T074	C0025080
28301024	1419	1423	CBCT	T060	C1956110
28301024	1424	1433	NewTom 3G	T074	C0025080
28301024	1435	1447	conventional	T060	C0034575
28301024	1452	1481	digital intraoral radiography	T060	C0376512
28301024	1497	1501	CBCT	T060	C1956110
28301024	1515	1534	diagnostic accuracy	T080	C0598285
28301024	1540	1547	digital	T060	C0376512
28301024	1552	1586	conventional intraoral radiography	T060	C0034575
28301024	1591	1600	detection	T061	C1511790
28301024	1604	1620	secondary caries	T047	C1882989
28301024	1628	1637	composite	T122	C0009570
28301024	1638	1650	restorations	T061	C0399059

28203549|t|Microbiological and Clinical Characteristics of Hypermucoviscous Klebsiella pneumoniae Isolates Associated with Invasive Infections in China
28203549|a|A distinctive syndrome caused by hypermucoviscous Klebsiella pneumoniae (HMKP) including pyogenic liver abscess (PLA) is now becoming a globally emerging disease. In the present study, 22.8% (84/369) of K. pneumoniae clinical isolates associated with various types of invasive infections were identified as HMKP, with 45.2% associated with PLA. Multivariate regression analysis showed that male patients with 41-50 years, PLA, diabetes mellitus, and hypertension were independent risk factors for HMKP infections. K2 (42.9%, 36/84) was the most common capsular serotype among HMKP isolates, followed by K1 (23.8%, 20/84). Seventy-five percentage of K1 HMKP isolates were associated with PLA, while K2 HMKP isolates accounted for more types of invasive infections. The positive rates of iutA, mrkD, aerobactin, iroN, and rmpA among HMKP isolates were significantly higher than those among non-HMKP isolates (p < 0.05). There was a correlation between magA, ybtS, alls, and wcaG and K1 isolates. Interestingly, mrkD was exclusively detected among HMKP (32.1%, 27/84) and K2 isolates (65.9%, 27/41). All K1 and K2 HMKP and non-HMKP isolates were positive for rmpA. Aerobactin was found among 95.0 and 97.5% of K1 and K2 isolates. ST23 was found to be the most prevalent ST among 69 HMKP isolates with K1, K2, K5, K20, and K57 (27.5%, 19/69) and was only found among K1 isolates. ST65 was the second most prevalent ST (26.1%, 18/69) and was also only found among K2 isolates. ST23-K1 HMKP isolates (84.2%, 16/19) were associated with PLA, while ST65-K2 isolates were correlated with more types of infections relative to ST23-K1 isolates. PFGE results showed that the homology of 84 HMKP isolates was diverse. Only five PFGE clusters with more than 75% similarity accounted for more than three isolates. These five PFGE clusters only accounted for 35 (41.7%, 35/84) isolates. In conclusion, our study first found that hypertension and male patients with 41-50 years old were independent risk factors. The composition of ST types and PFGE clusters among K. pneumoniae K2 isolates was more diverse than K1 isolates. K1 and K2 HMKP isolates had respective specific profiles of virulence - associated genes.
28203549	0	15	Microbiological	T170	C0025953
28203549	20	44	Clinical Characteristics	T201	C0683325
28203549	48	86	Hypermucoviscous Klebsiella pneumoniae	T007	C0001699
28203549	87	95	Isolates	T123	C1764827
28203549	96	111	Associated with	T080	C0332281
28203549	112	131	Invasive Infections	T047	C4285937
28203549	135	140	China	T083	C0008115
28203549	143	163	distinctive syndrome	T047	C0039082
28203549	164	173	caused by	T169	C0015127
28203549	174	212	hypermucoviscous Klebsiella pneumoniae	T007	C0001699
28203549	214	218	HMKP	T007	C0001699
28203549	230	252	pyogenic liver abscess	T047	C0267830
28203549	254	257	PLA	T047	C0267830
28203549	277	302	globally emerging disease	T047	C0872315
28203549	319	324	study	T062	C2603343
28203549	344	357	K. pneumoniae	T007	C0001699
28203549	367	375	isolates	T123	C1764827
28203549	376	391	associated with	T080	C0332281
28203549	392	405	various types	T080	C0332307
28203549	409	428	invasive infections	T047	C4285937
28203549	448	452	HMKP	T007	C0001699
28203549	465	480	associated with	T080	C0332281
28203549	481	484	PLA	T047	C0267830
28203549	486	518	Multivariate regression analysis	T081	C0026777
28203549	531	544	male patients	T032	C0150904
28203549	556	561	years	T079	C0439234
28203549	563	566	PLA	T047	C0267830
28203549	568	585	diabetes mellitus	T047	C0011849
28203549	591	603	hypertension	T047	C0020538
28203549	609	620	independent	T078	C0085862
28203549	621	633	risk factors	T033	C0035648
28203549	638	653	HMKP infections	T047	C0948802
28203549	655	657	K2	T170	C0449547
28203549	693	701	capsular	T082	C0205151
28203549	702	710	serotype	T170	C0449943
28203549	717	721	HMKP	T007	C0001699
28203549	722	730	isolates	T123	C1764827
28203549	744	746	K1	T170	C0449547
28203549	763	786	Seventy-five percentage	T081	C0439165
28203549	790	792	K1	T170	C0449547
28203549	793	797	HMKP	T007	C0001699
28203549	798	806	isolates	T123	C1764827
28203549	812	827	associated with	T080	C0332281
28203549	828	831	PLA	T047	C0267830
28203549	839	841	K2	T170	C0449547
28203549	842	846	HMKP	T007	C0001699
28203549	847	855	isolates	T123	C1764827
28203549	856	865	accounted	T078	C0750591
28203549	870	880	more types	T080	C0332307
28203549	884	903	invasive infections	T047	C4285937
28203549	909	917	positive	T033	C1446409
28203549	918	923	rates	T081	C1521828
28203549	927	931	iutA	T028	C0017337
28203549	933	937	mrkD	T028	C0017337
28203549	939	949	aerobactin	T028	C0017337
28203549	951	955	iroN	T028	C0017337
28203549	961	965	rmpA	T028	C0017337
28203549	972	976	HMKP	T007	C0001699
28203549	977	985	isolates	T123	C1764827
28203549	991	1011	significantly higher	T081	C4055637
28203549	1029	1037	non-HMKP	T007	C0001699
28203549	1038	1046	isolates	T123	C1764827
28203549	1071	1082	correlation	T080	C1707520
28203549	1091	1095	magA	T028	C0017337
28203549	1097	1101	ybtS	T028	C0017337
28203549	1103	1107	alls	T028	C0017337
28203549	1113	1117	wcaG	T028	C0017337
28203549	1122	1124	K1	T170	C0449547
28203549	1125	1133	isolates	T123	C1764827
28203549	1150	1154	mrkD	T028	C0017337
28203549	1159	1179	exclusively detected	T033	C0442726
28203549	1186	1190	HMKP	T007	C0001699
28203549	1210	1212	K2	T170	C0449547
28203549	1213	1221	isolates	T123	C1764827
28203549	1242	1244	K1	T170	C0449547
28203549	1249	1251	K2	T170	C0449547
28203549	1252	1256	HMKP	T007	C0001699
28203549	1261	1269	non-HMKP	T007	C0001699
28203549	1270	1278	isolates	T123	C1764827
28203549	1284	1292	positive	T033	C1446409
28203549	1297	1301	rmpA	T028	C0017337
28203549	1303	1313	Aerobactin	T028	C0017337
28203549	1318	1323	found	T033	C0150312
28203549	1348	1350	K1	T170	C0449547
28203549	1355	1357	K2	T170	C0449547
28203549	1358	1366	isolates	T123	C1764827
28203549	1368	1372	ST23	T170	C0449943
28203549	1377	1382	found	T033	C0150312
28203549	1393	1407	most prevalent	T079	C0332183
28203549	1408	1410	ST	T170	C0449943
28203549	1420	1424	HMKP	T007	C0001699
28203549	1425	1433	isolates	T123	C1764827
28203549	1439	1441	K1	T170	C0449547
28203549	1443	1445	K2	T170	C0449547
28203549	1447	1449	K5	T170	C0449547
28203549	1451	1454	K20	T170	C0449547
28203549	1460	1463	K57	T170	C0449547
28203549	1492	1497	found	T033	C0150312
28203549	1504	1506	K1	T170	C0449547
28203549	1507	1515	isolates	T123	C1764827
28203549	1517	1521	ST65	T170	C0449943
28203549	1537	1551	most prevalent	T079	C0332183
28203549	1552	1554	ST	T170	C0449943
28203549	1588	1593	found	T033	C0150312
28203549	1600	1602	K2	T170	C0449547
28203549	1603	1611	isolates	T123	C1764827
28203549	1613	1620	ST23-K1	T170	C0449547
28203549	1621	1625	HMKP	T007	C0001699
28203549	1626	1634	isolates	T123	C1764827
28203549	1655	1670	associated with	T080	C0332281
28203549	1671	1674	PLA	T047	C0267830
28203549	1682	1689	ST65-K2	T170	C0449547
28203549	1690	1698	isolates	T123	C1764827
28203549	1704	1714	correlated	T080	C1707520
28203549	1725	1744	types of infections	T185	C0457463
28203549	1757	1764	ST23-K1	T170	C0449547
28203549	1765	1773	isolates	T123	C1764827
28203549	1775	1779	PFGE	T059	C0085117
28203549	1780	1787	results	T169	C1274040
28203549	1804	1812	homology	T080	C2697616
28203549	1819	1823	HMKP	T007	C0001699
28203549	1824	1832	isolates	T123	C1764827
28203549	1837	1844	diverse	T080	C1880371
28203549	1851	1855	five	T081	C0205451
28203549	1856	1860	PFGE	T059	C0085117
28203549	1861	1869	clusters	T081	C1704332
28203549	1889	1899	similarity	T080	C2348205
28203549	1900	1909	accounted	T078	C0750591
28203549	1924	1929	three	T081	C0205449
28203549	1930	1938	isolates	T123	C1764827
28203549	1946	1950	five	T081	C0205451
28203549	1951	1955	PFGE	T059	C0085117
28203549	1956	1964	clusters	T081	C1704332
28203549	1970	1979	accounted	T078	C0750591
28203549	2002	2010	isolates	T123	C1764827
28203549	2031	2036	study	T062	C2603343
28203549	2043	2048	found	T033	C0150312
28203549	2054	2066	hypertension	T047	C0020538
28203549	2071	2084	male patients	T032	C0150904
28203549	2096	2101	years	T079	C0439234
28203549	2102	2105	old	T079	C0580836
28203549	2111	2122	independent	T078	C0085862
28203549	2123	2135	risk factors	T033	C0035648
28203549	2141	2152	composition	T201	C0486616
28203549	2156	2164	ST types	T170	C0449943
28203549	2169	2173	PFGE	T059	C0085117
28203549	2174	2182	clusters	T081	C1704332
28203549	2189	2202	K. pneumoniae	T007	C0001699
28203549	2203	2205	K2	T170	C0449547
28203549	2206	2214	isolates	T123	C1764827
28203549	2224	2231	diverse	T080	C1880371
28203549	2237	2239	K1	T170	C0449547
28203549	2240	2248	isolates	T123	C1764827
28203549	2250	2252	K1	T170	C0449547
28203549	2257	2259	K2	T170	C0449547
28203549	2260	2264	HMKP	T007	C0001699
28203549	2265	2273	isolates	T123	C1764827
28203549	2289	2306	specific profiles	T169	C2003903
28203549	2310	2319	virulence	T038	C0042765
28203549	2322	2332	associated	T078	C0750490
28203549	2333	2338	genes	T028	C0017337

27734402|t|Analysis of Pathological Activities of CCN2/CTGF in Muscle Dystrophy
27734402|a|CCN2 or connective tissue growth factor (CTGF) is a matricellular protein that regulates several cellular processes. In skeletal muscle, CTGF is a key modulator of fibrogenesis, is increased in pathological conditions such as muscular dystrophies, and plays a major role in the pathology outcome. Overexpression of CTGF in skeletal muscle of wild-type mice results in muscle damage, fibrosis, and reduction of strength. In contrast, a decrease in CTGF in dystrophic mice increases strength and reduces damage and fibrosis. Thus, CTGF is a relevant target to study in skeletal muscle pathology and its possible modulation by different treatments or potential new drugs to develop new strategies for the treatment of muscular dystrophies. We summarize the techniques used to detect CTGF in the skeletal muscle of dystrophic mdx mice.
27734402	0	8	Analysis	T062	C0936012
27734402	12	35	Pathological Activities	T169	C0205469
27734402	39	48	CCN2/CTGF	T116,T123	C0110610
27734402	52	68	Muscle Dystrophy	T047	C0026850
27734402	69	73	CCN2	T116,T123	C0110610
27734402	77	108	connective tissue growth factor	T116,T123	C0110610
27734402	110	114	CTGF	T116,T123	C0110610
27734402	121	142	matricellular protein	T116,T123	C0079323
27734402	166	184	cellular processes	T043	C1325880
27734402	189	204	skeletal muscle	T024	C0242692
27734402	206	210	CTGF	T116,T123	C0110610
27734402	233	245	fibrogenesis	T040	C0596570
27734402	263	286	pathological conditions	T046	C0030660
27734402	295	315	muscular dystrophies	T047	C0026850
27734402	347	364	pathology outcome	T033	C0679250
27734402	366	380	Overexpression	T045	C0017262
27734402	384	388	CTGF	T028	C1413791
27734402	392	407	skeletal muscle	T024	C0242692
27734402	411	425	wild-type mice	T015	C1520150
27734402	437	450	muscle damage	T020	C0410158
27734402	452	460	fibrosis	T046	C0016059
27734402	466	475	reduction	T080	C0392756
27734402	479	487	strength	T081	C0237897
27734402	504	512	decrease	T081	C0547047
27734402	516	520	CTGF	T028	C1413791
27734402	524	534	dystrophic	T169	C0333607
27734402	535	539	mice	T015	C0025929
27734402	540	549	increases	T169	C0442805
27734402	550	558	strength	T081	C0237897
27734402	563	570	reduces	T080	C0392756
27734402	571	577	damage	T169	C1883709
27734402	582	590	fibrosis	T046	C0016059
27734402	598	602	CTGF	T116,T123	C0110610
27734402	608	616	relevant	T080	C2347946
27734402	617	623	target	T169	C1521840
27734402	636	651	skeletal muscle	T024	C0242692
27734402	693	702	different	T080	C1705242
27734402	703	713	treatments	T061	C0087111
27734402	717	726	potential	T080	C3245505
27734402	727	730	new	T080	C0205314
27734402	731	736	drugs	T121	C1254351
27734402	740	747	develop	T169	C1527148
27734402	748	751	new	T080	C0205314
27734402	771	780	treatment	T061	C0087111
27734402	784	804	muscular dystrophies	T047	C0026850
27734402	823	833	techniques	T169	C0449851
27734402	842	848	detect	T033	C0442726
27734402	849	853	CTGF	T116,T123	C0110610
27734402	861	876	skeletal muscle	T024	C0242692
27734402	880	890	dystrophic	T169	C0333607
27734402	891	899	mdx mice	T015	C0206535

28390852|t|Cardiovascular comorbidity in patients with chronic obstructive pulmonary disease in the Canary Islands (CCECAN study)
28390852|a|Numerous studies have shown a high prevalence of cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to analyse the prevalence of cardiovascular risk factors and comorbidity in a Canary Islands population diagnosed with COPD, and compared it with data from the general population. A cross-sectional study was carried out in 300 patients with COPD and 524 subjects without respiratory disease (control group). The two groups were compared using standard bivariate methods. Logistic regression models were used to estimate the cardiovascular risks in COPD patients compared to control group. Patients with COPD showed a high prevalence of hypertension (72%), dyslipidaemia (73%), obesity (41%), diabetes type 2 (39%), and sleep apnoea syndrome (30%) from mild stages of the disease (GOLD 2009). There was a 22% prevalence of cardiac arrhythmia, 16% of ischaemic heart disease, 16% heart failure, 12% peripheral vascular disease, and 8% cerebrovascular disease. Compared to the control group, patients with COPD had a higher risk of dyslipidaemia (OR 3.24, 95% CI; 2.21-4.75), diabetes type 2 (OR 1.52, 95% CI; 1.01-2,28), and ischaemic heart disease (OR 2.34, 95% CI; 1.22-4.49). In the case of dyslipidaemia, an increased risk was obtained when adjusted for age, gender, and consumption of tobacco (OR 5.04, 95% CI; 2.36-10.74). Patients with COPD resident in the Canary Islands have a high prevalence of hypertension, dyslipidaemia, ischaemic heart disease, and cardiac arrhythmia. Compared to general population, patients with COPD have a significant increase in the risk of dyslipidaemia.
28390852	0	14	Cardiovascular	T029	C3887460
28390852	15	26	comorbidity	T078	C0009488
28390852	30	38	patients	T101	C0030705
28390852	44	81	chronic obstructive pulmonary disease	T047	C0024117
28390852	89	103	Canary Islands	T083	C0454662
28390852	105	117	CCECAN study	T062	C0008972
28390852	128	135	studies	T059	C0947630
28390852	149	164	high prevalence	T081	C1512456
28390852	168	190	cardiovascular disease	T047	C0007222
28390852	194	202	patients	T101	C0030705
28390852	208	245	chronic obstructive pulmonary disease	T047	C0024117
28390852	247	251	COPD	T047	C0024117
28390852	258	261	aim	T078	C1947946
28390852	270	275	study	T062	C0008972
28390852	283	305	analyse the prevalence	T081	C0033106
28390852	309	336	cardiovascular risk factors	T047	C0850624
28390852	341	352	comorbidity	T078	C0009488
28390852	358	372	Canary Islands	T083	C0454662
28390852	373	383	population	T081	C0032659
28390852	384	393	diagnosed	T033	C0011900
28390852	399	403	COPD	T047	C0024117
28390852	426	430	data	T078	C1511726
28390852	440	458	general population	T098	C0683971
28390852	462	483	cross-sectional study	T062	C0010362
28390852	507	515	patients	T101	C0030705
28390852	521	525	COPD	T047	C0024117
28390852	534	542	subjects	T098	C0080105
28390852	551	570	respiratory disease	T047	C0035242
28390852	572	585	control group	T096	C0009932
28390852	596	602	groups	T098	C1257890
28390852	608	616	compared	T052	C1707455
28390852	623	649	standard bivariate methods	UnknownType	C0681927
28390852	651	677	Logistic regression models	T062	C0871424
28390852	691	699	estimate	T081	C0750572
28390852	704	724	cardiovascular risks	T047	C0850624
28390852	728	732	COPD	T047	C0024117
28390852	733	741	patients	T101	C0030705
28390852	754	767	control group	T096	C0009932
28390852	769	777	Patients	T101	C0030705
28390852	783	787	COPD	T047	C0024117
28390852	797	812	high prevalence	T081	C1512456
28390852	816	828	hypertension	T047	C0020538
28390852	836	849	dyslipidaemia	T047	C0242339
28390852	857	864	obesity	T047	C0028754
28390852	872	887	diabetes type 2	T047	C0011860
28390852	899	920	sleep apnoea syndrome	T047	C0037315
28390852	937	958	stages of the disease	T060	C0699749
28390852	988	998	prevalence	T081	C0033105
28390852	1002	1020	cardiac arrhythmia	T033	C0003811
28390852	1029	1052	ischaemic heart disease	T047	C0010068
28390852	1058	1071	heart failure	T047	C0018801
28390852	1077	1104	peripheral vascular disease	T047	C0085096
28390852	1113	1136	cerebrovascular disease	T047	C0007820
28390852	1154	1167	control group	T096	C0009932
28390852	1169	1177	patients	T101	C0030705
28390852	1183	1187	COPD	T047	C0024117
28390852	1194	1205	higher risk	T033	C3843761
28390852	1209	1222	dyslipidaemia	T047	C0242339
28390852	1253	1268	diabetes type 2	T047	C0011860
28390852	1303	1326	ischaemic heart disease	T047	C0010068
28390852	1372	1385	dyslipidaemia	T047	C0242339
28390852	1390	1404	increased risk	T033	C3843761
28390852	1423	1431	adjusted	T169	C0456081
28390852	1436	1439	age	T032	C0001779
28390852	1441	1447	gender	T032	C0079399
28390852	1453	1475	consumption of tobacco	T055	C0543414
28390852	1507	1515	Patients	T101	C0030705
28390852	1521	1525	COPD	T047	C0024117
28390852	1526	1534	resident	T098	C2347958
28390852	1542	1556	Canary Islands	T083	C0454662
28390852	1564	1579	high prevalence	T081	C1512456
28390852	1583	1595	hypertension	T047	C0020538
28390852	1597	1610	dyslipidaemia	T047	C0242339
28390852	1612	1635	ischaemic heart disease	T047	C0010068
28390852	1641	1659	cardiac arrhythmia	T033	C0003811
28390852	1661	1669	Compared	T052	C1707455
28390852	1673	1691	general population	T098	C0683971
28390852	1693	1701	patients	T101	C0030705
28390852	1707	1711	COPD	T047	C0024117
28390852	1719	1730	significant	T081	C0237881
28390852	1731	1751	increase in the risk	T033	C3843761
28390852	1755	1768	dyslipidaemia	T047	C0242339

28348808|t|Meningitis due to Moraxella nonliquefaciens in a paediatric patient: a case report and review of the literature
28348808|a|Introduction. Moraxella nonliquefaciens is an unusual organism to be isolated from cerebral spinal fluid (CSF) and there exists only one case report of M. nonliquefaciens meningitis from a neonate. Moraxella species normally exist as part of the human upper respiratory tract flora and rarely cause invasive human disease. There are only a handful of case reports implicating the organism as a cause of endocarditis, bacteraemia, septic arthritis and endophthalmitis. Identification to the species level based on routine laboratory techniques has been challenging, with final identification often made through 16S rRNA sequencing. With the use of a newer diagnostic tool, matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) MS, we were able to rapidly identify the organism and initiate appropriate treatment. Case presentation. We present a rare care of M. nonliquefaciens meningitis in a paediatric patient with an underlying cranial anatomical defect due to Crouzon syndrome. She had been admitted to hospital 3 months previously with Streptococcus pneumoniae meningitis and mastoiditis, and returned to the emergency department with meningismus. CSF culture grew M. nonliquefaciens. She was treated with ceftriaxone with rapid improvement and eventually was taken for endoscopic surgical repair of a right encephalocele defect. Conclusion. The use of MALDI-TOF MS allowed for the rapid identification of the organism. The patient recovered with appropriate antimicrobial therapy and eventual surgical correction. An underlying anatomical defect should be considered in all patients who present with meningitis due to this unusual organism.
28348808	0	10	Meningitis	T047	C0025289
28348808	18	43	Moraxella nonliquefaciens	T007	C0317740
28348808	49	59	paediatric	T080	C1521725
28348808	60	67	patient	T101	C0030705
28348808	71	82	case report	T170	C0007320
28348808	87	111	review of the literature	T170	C0282441
28348808	126	151	Moraxella nonliquefaciens	T007	C0317740
28348808	166	174	organism	T001	C0029235
28348808	181	189	isolated	T169	C0205409
28348808	195	216	cerebral spinal fluid	T031	C0007806
28348808	218	221	CSF	T031	C0007806
28348808	249	260	case report	T170	C0007320
28348808	264	282	M. nonliquefaciens	T007	C0317740
28348808	283	293	meningitis	T047	C0025289
28348808	301	308	neonate	T100	C0021289
28348808	310	327	Moraxella species	T007	C1295861
28348808	358	363	human	T016	C0086418
28348808	364	387	upper respiratory tract	T023	C0458578
28348808	388	393	flora	T033	C0314761
28348808	411	419	invasive	T080	C0205281
28348808	420	425	human	T016	C0086418
28348808	426	433	disease	T047	C0012634
28348808	463	475	case reports	T170	C0007320
28348808	492	500	organism	T001	C0029235
28348808	506	511	cause	T078	C0085978
28348808	515	527	endocarditis	T047	C0014118
28348808	529	540	bacteraemia	T047	C0004610
28348808	542	558	septic arthritis	T047	C1692886
28348808	563	578	endophthalmitis	T047	C0014236
28348808	580	594	Identification	T080	C0205396
28348808	602	609	species	T185	C1705920
28348808	610	615	level	T080	C0441889
28348808	625	632	routine	T080	C0205547
28348808	633	654	laboratory techniques	T062	C0681902
28348808	682	687	final	T079	C3853528
28348808	688	702	identification	T080	C0205396
28348808	722	741	16S rRNA sequencing	T059	C3258987
28348808	767	782	diagnostic tool	T073	C2827396
28348808	784	857	matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) MS	T062	C1518101
28348808	883	891	identify	T080	C0205396
28348808	896	904	organism	T001	C0029235
28348808	909	917	initiate	T169	C1704686
28348808	930	939	treatment	T169	C1522326
28348808	973	977	rare	T080	C0522498
28348808	986	1004	M. nonliquefaciens	T007	C0317740
28348808	1005	1015	meningitis	T047	C0025289
28348808	1021	1031	paediatric	T080	C1521725
28348808	1032	1039	patient	T101	C0030705
28348808	1059	1084	cranial anatomical defect	T190	C4025787
28348808	1092	1108	Crouzon syndrome	T047	C0010273
28348808	1123	1143	admitted to hospital	T058	C0184666
28348808	1146	1152	months	T079	C0439231
28348808	1169	1193	Streptococcus pneumoniae	T007	C0038410
28348808	1194	1204	meningitis	T047	C0025289
28348808	1209	1220	mastoiditis	T047	C0024904
28348808	1242	1262	emergency department	T073,T093	C0562508
28348808	1268	1279	meningismus	T184	C0025287
28348808	1281	1292	CSF culture	T059	C0523175
28348808	1298	1316	M. nonliquefaciens	T007	C0317740
28348808	1326	1338	treated with	T061	C0332293
28348808	1339	1350	ceftriaxone	T109,T195	C0007561
28348808	1356	1361	rapid	T080	C0456962
28348808	1362	1373	improvement	T077	C2986411
28348808	1403	1422	endoscopic surgical	T060	C0282493
28348808	1423	1461	repair of a right encephalocele defect	T061	C0337413
28348808	1486	1498	MALDI-TOF MS	T062	C1518101
28348808	1515	1520	rapid	T080	C0456962
28348808	1521	1535	identification	T080	C0205396
28348808	1543	1551	organism	T001	C0029235
28348808	1557	1574	patient recovered	T032	C1115804
28348808	1592	1613	antimicrobial therapy	T061	C0338237
28348808	1627	1646	surgical correction	T061	C0087111
28348808	1662	1679	anatomical defect	T190	C0302142
28348808	1708	1716	patients	T101	C0030705
28348808	1734	1744	meningitis	T047	C0025289
28348808	1765	1773	organism	T001	C0029235

27606547|t|Cloud-based MOTIFSIM: Detecting Similarity in Large DNA Motif Data Sets
27606547|a|We developed the cloud-based MOTIFSIM on Amazon Web Services (AWS) cloud. The tool is an extended version from our web-based tool version 2.0, which was developed based on a novel algorithm for detecting similarity in multiple DNA motif data sets. This cloud -based version further allows researchers to exploit the computing resources available from AWS to detect similarity in multiple large-scale DNA motif data sets resulting from the next-generation sequencing technology. The tool is highly scalable with expandable AWS.
27606547	0	20	Cloud-based MOTIFSIM	T170	C0037589
27606547	22	31	Detecting	T033	C0442726
27606547	32	42	Similarity	T080	C2348205
27606547	52	61	DNA Motif	T086	C3178798
27606547	62	71	Data Sets	T170	C0150098
27606547	89	109	cloud-based MOTIFSIM	T170	C0037589
27606547	113	132	Amazon Web Services	T066	C1710664
27606547	134	137	AWS	T066	C1710664
27606547	139	144	cloud	T066	C4042841
27606547	150	154	tool	T170	C0037589
27606547	170	177	version	T170	C0333052
27606547	187	213	web-based tool version 2.0	T170	C0037589
27606547	252	261	algorithm	T170	C0002045
27606547	266	275	detecting	T033	C0442726
27606547	276	286	similarity	T080	C2348205
27606547	299	308	DNA motif	T086	C3178798
27606547	309	318	data sets	T170	C0150098
27606547	325	330	cloud	T066	C4042841
27606547	338	345	version	T170	C0333052
27606547	361	372	researchers	T097	C0035173
27606547	388	407	computing resources	T078	C0035201
27606547	423	426	AWS	T066	C1710664
27606547	430	436	detect	T033	C0442726
27606547	437	447	similarity	T080	C2348205
27606547	472	481	DNA motif	T086	C3178798
27606547	482	491	data sets	T170	C0150098
27606547	511	548	next-generation sequencing technology	T063	C2936622
27606547	554	558	tool	T170	C0037589
27606547	594	597	AWS	T066	C1710664

27628933|t|Double-Network Hydrogel with Tunable Mechanical Performance and Biocompatibility for the Fabrication of Stem Cells - Encapsulated Fibers and 3D Assemble
27628933|a|Fabrication of cell - encapsulated fibers could greatly contribute to tissue engineering and regenerative medicine. However, existing methods suffered from not only unavoidability of cell damaging conditions and/or sophisticated equipment, but also unavailability of proper materials to satisfy both mechanical and biological expectations. In this work, a simple method is proposed to prepare cell - encapsulated fibers with tunable mechanical strength and stretching behavior as well as diameter and microstructure. The hydrogel fibers are made from optimal combination of alginate and poly(N-iso-propylacrylamide)-poly(ethylene glycol), characteristics of double-network hydrogel, with enough stiffness and flexibility to create a variety of three dimensional structures like parallel helical and different knots without crack. Furthermore, such hydrogel fibers exhibit better compatibility as indicated by the viability, proliferation and expression of pluripotency markers of embryonic stem cells encapsulated after 4-day culture. The double-network hydrogel possesses specific quick responses to either of alginate lyase, EDTA or lower environmental temperature which facilitate the optional degradation of fibers or fibrous assemblies to release the cells encapsulated for subsequent assay or treatment.
27628933	0	23	Double-Network Hydrogel	T109,T121	C0063083
27628933	29	36	Tunable	T080	C0205556
27628933	37	59	Mechanical Performance	T052	C1882330
27628933	64	80	Biocompatibility	T044	C0596177
27628933	89	100	Fabrication	T170	C3494260
27628933	104	114	Stem Cells	T025	C0038250
27628933	117	136	Encapsulated Fibers	T109,T121	C0225326
27628933	141	152	3D Assemble	T082	C1254362
27628933	153	164	Fabrication	T170	C3494260
27628933	168	172	cell	T025	C0038250
27628933	175	194	encapsulated fibers	T109,T121	C0225326
27628933	209	219	contribute	T052	C1880177
27628933	223	241	tissue engineering	T061	C0596171
27628933	246	267	regenerative medicine	T091	C1257974
27628933	278	286	existing	T080	C2347662
27628933	287	294	methods	T169	C0449851
27628933	318	332	unavoidability	T080	C0205556
27628933	336	349	cell damaging	T049	C0599732
27628933	350	360	conditions	T080	C0348080
27628933	368	391	sophisticated equipment	T073	C0681588
27628933	402	416	unavailability	T080	C0686905
27628933	427	436	materials	T167	C0520510
27628933	453	463	mechanical	T169	C0443254
27628933	468	478	biological	T080	C0205460
27628933	479	491	expectations	T078	C0679138
27628933	501	505	work	T057	C0043227
27628933	509	515	simple	T080	C0205352
27628933	516	522	method	T169	C0449851
27628933	526	534	proposed	T080	C1553874
27628933	538	545	prepare	T052	C1521827
27628933	546	550	cell	T025	C0038250
27628933	553	572	encapsulated fibers	T109,T121	C0225326
27628933	578	585	tunable	T080	C0205556
27628933	586	605	mechanical strength	T081	C0039526
27628933	610	629	stretching behavior	T080	C0871161
27628933	641	649	diameter	T081	C1301886
27628933	654	668	microstructure	T104	C1254350
27628933	674	682	hydrogel	T109,T121	C0063083
27628933	683	689	fibers	T109,T121	C0225326
27628933	704	711	optimal	T080	C2698651
27628933	712	723	combination	T080	C0205195
27628933	727	735	alginate	T109,T122	C0102137
27628933	740	790	poly(N-iso-propylacrylamide)-poly(ethylene glycol)	T122	C0005479
27628933	811	834	double-network hydrogel	T109,T121	C0063083
27628933	848	857	stiffness	T184	C0427008
27628933	862	873	flexibility	T080	C0242808
27628933	877	883	create	T052	C1706214
27628933	886	893	variety	T077	C2346866
27628933	897	925	three dimensional structures	T082	C0026377
27628933	931	947	parallel helical	T082	C1254362
27628933	952	961	different	T080	C1705242
27628933	962	981	knots without crack	T082	C1254362
27628933	1001	1009	hydrogel	T109,T121	C0063083
27628933	1010	1016	fibers	T109,T121	C0225326
27628933	1025	1031	better	T080	C0332272
27628933	1032	1045	compatibility	T044	C0596177
27628933	1049	1058	indicated	T033	C1444656
27628933	1066	1075	viability	T080	C0443348
27628933	1077	1090	proliferation	T169	C1514485
27628933	1095	1105	expression	T169	C0205245
27628933	1109	1121	pluripotency	T169	C1514185
27628933	1122	1129	markers	T201	C0005516
27628933	1133	1153	embryonic stem cells	T025	C0596508
27628933	1154	1166	encapsulated	T080	C0205223
27628933	1173	1178	4-day	T033	C3840892
27628933	1179	1186	culture	T059	C0430400
27628933	1192	1215	double-network hydrogel	T109,T121	C0063083
27628933	1216	1225	possesses	T048	C0850310
27628933	1226	1234	specific	T080	C0205369
27628933	1235	1240	quick	T080	C0456962
27628933	1241	1250	responses	T032	C0871261
27628933	1264	1278	alginate lyase	T116,T126	C0051154
27628933	1280	1284	EDTA	T109,T121	C0013618
27628933	1294	1319	environmental temperature	T081	C2983601
27628933	1350	1361	degradation	T169	C0243125
27628933	1365	1371	fibers	T109,T121	C0225326
27628933	1375	1393	fibrous assemblies	T082	C1254362
27628933	1409	1414	cells	T025	C0038250
27628933	1415	1427	encapsulated	T080	C0205223
27628933	1432	1442	subsequent	T079	C0332282
27628933	1443	1448	assay	T059	C1510438
27628933	1452	1461	treatment	T061	C0087111

28464019|t|Radiologic assessment of quality of root canal fillings and periapical status in an Austrian subpopulation - An observational study
28464019|a|Progress in endodontic techniques and methodological advances have altered root canal therapy over the last decades. These techniques and methods need periodical documentation. This observational study determined the current prevalence of endodontic treatments, and investigated the relationship of various factors with the periapical status in a Lower Austrian subpopulation. One thousand orthopantomograms of first-time university adult patients radiographed at an outpatient clinic were evaluated. For each tooth, the presence of periradicular pathosis and/or endodontic treatment was recorded, as was the quality of (post-) endodontic treatment (homogeneity and length of root canal fillings; preparation failures; posts / screws; apicoectomies; coronal restorations). Two evaluators, blinded to each other, scored all teeth. In cases of disagreement, they joined for a consensus score. In all, 22,586 teeth were counted. Of these, 2,907 teeth (12.9%) had periapical pathosis, while 2,504 teeth had undergone root canal treatment. Of the endodontically treated teeth, 52% showed no radiographic signs of apical periodontitis, while 44.9% had overt apical lesions, and 3,1% revealed widened periodontal ligament space. The majority of the root canal fillings was inhomogeneous (70.4%); 75.4% were rated too short, and 3.8% too long. The presence of apical pathosis was significantly correlated (odds ratio (OR) 2.556 [confidence interval (CI) 2.076-3.146]; P<0.0001) with poor root canal fillings (length and homogeneity). Posts or screws positively affected periapical status (OR 1.853 [CI 1.219-2.819]; P = 0.004), but endodontically treated posterior teeth were infrequently restored (posts, 7.5%; screws, 2.7%). Best results were found for teeth with both appropriate endodontic treatment and adequate coronal restoration. A high prevalence of periradicular radiolucencies was observed with root canal filled teeth, along with high numbers of unmet treatment needs. Periapical health was associated with adequate root canal obturation and high-grade postendodontic restorations, and quality regarding these latter aspects is considered mandatory to promote periapical health.
28464019	0	21	Radiologic assessment	T060	C0043299
28464019	36	55	root canal fillings	T061	C0035848
28464019	60	77	periapical status	T082	C0729269
28464019	84	92	Austrian	T098	C0337795
28464019	93	106	subpopulation	T098	C1257890
28464019	112	131	observational study	T062	C1518527
28464019	132	140	Progress	T169	C1280477
28464019	144	165	endodontic techniques	T061	C0700632
28464019	207	225	root canal therapy	T061	C0035849
28464019	283	293	periodical	T170	C0031082
28464019	294	307	documentation	T170	C0920316
28464019	314	333	observational study	T062	C1518527
28464019	357	367	prevalence	T081	C0220900
28464019	371	393	endodontic treatments,	T061	C0700632
28464019	398	410	investigated	T169	C1292732
28464019	456	473	periapical status	T082	C0729269
28464019	485	493	Austrian	T098	C0337795
28464019	494	507	subpopulation	T098	C1257890
28464019	522	539	orthopantomograms	T060	C0034579
28464019	554	564	university	T073,T093	C0020028
28464019	571	579	patients	T101	C0030705
28464019	580	592	radiographed	T060	C1306645
28464019	599	616	outpatient clinic	T073,T093	C0029916
28464019	622	631	evaluated	T058	C0220825
28464019	642	647	tooth	T023	C0040426
28464019	653	661	presence	T033	C0150312
28464019	665	687	periradicular pathosis	T047	C0031028
28464019	695	715	endodontic treatment	T061	C0700632
28464019	760	780	endodontic treatment	T061	C0700632
28464019	782	793	homogeneity	T080	C1881065
28464019	808	827	root canal fillings	T061	C0035848
28464019	829	849	preparation failures	T033	C2938896
28464019	851	856	posts	T074	C0183062
28464019	859	865	screws	T074	C0301559
28464019	867	880	apicoectomies	T061	C0003571
28464019	882	902	coronal restorations	T061	C0204297
28464019	909	919	evaluators	T097	C1707957
28464019	921	928	blinded	T062	C0150108
28464019	944	950	scored	T081	C0449820
28464019	955	960	teeth	T023	C0040426
28464019	1016	1021	score	T081	C0449820
28464019	1038	1056	teeth were counted	T081	C0449772
28464019	1074	1079	teeth	T023	C0040426
28464019	1092	1111	periapical pathosis	T047	C0031028
28464019	1125	1130	teeth	T023	C0040426
28464019	1145	1165	root canal treatment	T061	C0035849
28464019	1174	1202	endodontically treated teeth	T047	C0376699
28464019	1218	1230	radiographic	T070	C0444708
28464019	1240	1260	apical periodontitis	T047	C4082298
28464019	1284	1298	apical lesions	T047	C1402310
28464019	1318	1352	widened periodontal ligament space	T047	C1290664
28464019	1374	1393	root canal fillings	T061	C0035848
28464019	1472	1480	presence	T033	C0150312
28464019	1484	1490	apical	T023	C0524789
28464019	1491	1499	pathosis	T047	C0012634
28464019	1504	1528	significantly correlated	T080	C1707520
28464019	1530	1540	odds ratio	T081	C0028873
28464019	1542	1544	OR	T081	C0028873
28464019	1553	1572	confidence interval	T081	C0009667
28464019	1574	1576	CI	T081	C0009667
28464019	1612	1631	root canal fillings	T061	C0035848
28464019	1644	1655	homogeneity	T080	C1881065
28464019	1658	1663	Posts	T074	C0183062
28464019	1667	1673	screws	T074	C0301559
28464019	1694	1711	periapical status	T082	C0729269
28464019	1713	1715	OR	T081	C0028873
28464019	1756	1794	endodontically treated posterior teeth	T047	C0376699
28464019	1813	1821	restored	T061	C0565067
28464019	1823	1828	posts	T074	C0183062
28464019	1836	1842	screws	T074	C0301559
28464019	1879	1884	teeth	T023	C0040426
28464019	1907	1927	endodontic treatment	T061	C0700632
28464019	1941	1960	coronal restoration	T061	C0204297
28464019	1964	1979	high prevalence	T081	C1512456
28464019	1983	2011	periradicular radiolucencies	T033	C1852169
28464019	2030	2053	root canal filled teeth	T023	C0040426
28464019	2088	2097	treatment	T061	C0087111
28464019	2105	2115	Periapical	T082	C0729269
28464019	2116	2122	health	T078	C0018684
28464019	2127	2142	associated with	T080	C0332281
28464019	2152	2173	root canal obturation	T061	C0035848
28464019	2189	2216	postendodontic restorations	T061	C2368673
28464019	2296	2306	periapical	T082	C0729269
28464019	2307	2313	health	T078	C0018684

28082609|t|Variation in the Intensity of Selection on Codon Bias over Time Causes Contrasting Patterns of Base Composition Evolution in Drosophila
28082609|a|Four-fold degenerate coding sites form a major component of the genome, and are often used to make inferences about selection and demography, so that understanding their evolution is important. Despite previous efforts, many questions regarding the causes of base composition changes at these sites in Drosophila remain unanswered. To shed further light on this issue, we obtained a new whole-genome polymorphism data set from D. simulans. We analyzed samples from the putatively ancestral range of D. simulans, as well as an existing polymorphism data set from an African population of D. melanogaster. By using D. yakuba as an outgroup, we found clear evidence for selection on 4-fold sites along both lineages over a substantial period, with the intensity of selection increasing with GC content. Based on an explicit model of base composition evolution, we suggest that the observed AT- biased substitution pattern in both lineages is probably due to an ancestral reduction in selection intensity, and is unlikely to be the result of an increase in mutational bias towards AT alone. By using two polymorphism-based methods for estimating selection coefficients over different timescales, we show that the selection intensity on codon usage has been rather stable in D. simulans in the recent past, but the long-term estimates in D. melanogaster are much higher than the short-term ones, indicating a continuing decline in selection intensity, to such an extent that the short-term estimates suggest that selection is only active in the most GC -rich parts of the genome. Finally, we provide evidence for complex evolutionary patterns in the putatively neutral short introns, which cannot be explained by the standard GC - biased gene conversion model. These results reveal a dynamic picture of base composition evolution.
28082609	0	9	Variation	T070	C0042333
28082609	17	26	Intensity	T080	C0522510
28082609	30	39	Selection	T045	C0036576
28082609	43	48	Codon	T086	C0009221
28082609	49	53	Bias	T078	C0242568
28082609	59	63	Time	T079	C0040223
28082609	71	91	Contrasting Patterns	T082	C0449774
28082609	95	111	Base Composition	T081	C0004790
28082609	112	121	Evolution	T045	C0015219
28082609	125	135	Drosophila	T204	C0013138
28082609	146	156	degenerate	T169	C1880269
28082609	157	169	coding sites	T028	C0079941
28082609	200	206	genome	T028	C0017428
28082609	252	261	selection	T045	C0036576
28082609	266	276	demography	T078	C0011292
28082609	306	315	evolution	T045	C0015219
28082609	395	411	base composition	T081	C0004790
28082609	412	419	changes	T169	C0392747
28082609	429	434	sites	T028	C0079941
28082609	438	448	Drosophila	T204	C0013138
28082609	498	503	issue	T033	C0033213
28082609	523	557	whole-genome polymorphism data set	T170	C3242346
28082609	563	574	D. simulans	T204	C0998507
28082609	579	587	analyzed	T062	C0936012
28082609	588	595	samples	T026	C0444241
28082609	635	646	D. simulans	T204	C0998507
28082609	671	692	polymorphism data set	T170	C3242346
28082609	723	738	D. melanogaster	T204	C0013139
28082609	749	758	D. yakuba	T204	C0998511
28082609	765	773	outgroup	T098	C0871022
28082609	790	798	evidence	T078	C3887511
28082609	803	812	selection	T045	C0036576
28082609	823	828	sites	T028	C0079941
28082609	840	848	lineages	T078	C0282637
28082609	856	874	substantial period	T079	C1948053
28082609	885	894	intensity	T080	C0522510
28082609	898	907	selection	T045	C0036576
28082609	924	934	GC content	T081	C1135899
28082609	957	962	model	T075	C0026339
28082609	966	982	base composition	T081	C0004790
28082609	983	992	evolution	T045	C0015219
28082609	1014	1022	observed	T169	C1441672
28082609	1027	1033	biased	T078	C0242568
28082609	1034	1054	substitution pattern	T082	C0449774
28082609	1063	1071	lineages	T078	C0282637
28082609	1094	1113	ancestral reduction	T080	C0392756
28082609	1117	1126	selection	T045	C0036576
28082609	1127	1136	intensity	T080	C0522510
28082609	1164	1170	result	T034	C0456984
28082609	1177	1185	increase	T169	C0442805
28082609	1189	1199	mutational	T045	C0026882
28082609	1200	1204	bias	T078	C0242568
28082609	1236	1262	polymorphism-based methods	T060	C0796451
28082609	1267	1277	estimating	T081	C0750572
28082609	1278	1287	selection	T045	C0036576
28082609	1288	1300	coefficients	T081	C1707429
28082609	1345	1354	selection	T045	C0036576
28082609	1355	1364	intensity	T080	C0522510
28082609	1368	1373	codon	T086	C0009221
28082609	1396	1402	stable	T080	C0205360
28082609	1406	1417	D. simulans	T204	C0998507
28082609	1446	1455	long-term	T079	C0443252
28082609	1456	1465	estimates	T081	C0750572
28082609	1469	1484	D. melanogaster	T204	C0013139
28082609	1494	1500	higher	T080	C0205250
28082609	1510	1520	short-term	T079	C0443303
28082609	1540	1550	continuing	T078	C0549178
28082609	1551	1558	decline	T081	C0282251
28082609	1562	1571	selection	T045	C0036576
28082609	1572	1581	intensity	T080	C0522510
28082609	1594	1600	extent	T082	C0439792
28082609	1610	1620	short-term	T079	C0443303
28082609	1621	1630	estimates	T081	C0750572
28082609	1644	1653	selection	T045	C0036576
28082609	1662	1668	active	T169	C0205177
28082609	1681	1683	GC	T081	C1135899
28082609	1703	1709	genome	T028	C0017428
28082609	1731	1739	evidence	T078	C3887511
28082609	1744	1751	complex	T080	C0439855
28082609	1752	1773	evolutionary patterns	T082	C0449774
28082609	1792	1813	neutral short introns	T114,T123	C0021920
28082609	1848	1856	standard	T081	C0034925
28082609	1857	1859	GC	T081	C1135899
28082609	1862	1868	biased	T078	C0242568
28082609	1869	1884	gene conversion	T045	C0017259
28082609	1885	1890	model	T075	C0026339
28082609	1898	1905	results	T034	C0456984
28082609	1915	1922	dynamic	T169	C0729333
28082609	1934	1950	base composition	T081	C0004790
28082609	1951	1960	evolution	T045	C0015219

28374022|t|A coarse-grained model for assisting the investigation of structure and dynamics of large nucleic acids by ion mobility spectrometry-mass spectrometry
28374022|a|Ion Mobility Spectrometry-Mass Spectrometry (IMS-MS) is a rapidly emerging tool for the investigation of nucleic acid structure and dynamics. IMS-MS determinations can provide valuable information regarding alternative topologies, folding intermediates, and conformational heterogeneities, which are not readily accessible to other analytical techniques. The leading strategies for data interpretation rely on computational and experimental approaches to correctly assign experimental observations to putative structures. A very effective strategy involves the application of molecular dynamics (MD) simulations to predict the structure of the analyte molecule, calculate its collision cross section (CCS), and then compare this computational value with the corresponding experimental data. While this approach works well for small nucleic acid species, analyzing larger nucleic acids of biological interest is hampered by the computational cost associated with capturing their extensive structure and dynamics in all-atom detail. In this report, we describe the implementation of a coarse graining (CG) approach to reduce the cost of the computational methods employed in the data interpretation workflow. Our framework employs a five-bead model to accurately represent each nucleotide in the nucleic acid structure. The beads are appropriately parameterized to enable the direct calculation of CCS values from CG models, thus affording the ability to pursue the analysis of larger, highly dynamic constructs. The validity of this approach was successfully confirmed by the excellent correlation between the CCS values obtained in parallel by all-atom and CG workflows.
28374022	2	22	coarse-grained model	T170	C3161035
28374022	27	36	assisting	T058	C1280910
28374022	41	54	investigation	T058	C0220825
28374022	58	67	structure	T082	C0678594
28374022	72	80	dynamics	T044	C0596957
28374022	90	103	nucleic acids	T114,T123	C0028606
28374022	107	150	ion mobility spectrometry-mass spectrometry	T059	C0037813
28374022	151	194	Ion Mobility Spectrometry-Mass Spectrometry	T059	C0037813
28374022	196	202	IMS-MS	T059	C0037813
28374022	226	230	tool	T073	C2827396
28374022	239	252	investigation	T058	C0220825
28374022	256	268	nucleic acid	T114,T123	C0028606
28374022	269	278	structure	T082	C0678594
28374022	283	291	dynamics	T044	C0596957
28374022	293	299	IMS-MS	T059	C0037813
28374022	300	314	determinations	T059	C1148554
28374022	319	326	provide	T052	C1999230
28374022	327	347	valuable information	T078	C1533716
28374022	358	369	alternative	T077	C1523987
28374022	370	380	topologies	T091	C0002812
28374022	382	389	folding	T044	C0162847
28374022	390	403	intermediates	T082	C0205103
28374022	409	423	conformational	T044	C0301641
28374022	424	439	heterogeneities	T032	C0242960
28374022	483	504	analytical techniques	T059	C2713613
28374022	533	537	data	T078	C1511726
28374022	538	552	interpretation	T170	C0459471
28374022	561	574	computational	T059	C4297010
28374022	579	591	experimental	T080	C1517586
28374022	616	622	assign	T169	C1516050
28374022	623	648	experimental observations	T062	C0302523
28374022	661	671	structures	T082	C0678594
28374022	680	689	effective	T080	C1704419
28374022	712	723	application	T169	C4048755
28374022	727	745	molecular dynamics	T044	C0596957
28374022	747	749	MD	T044	C0596957
28374022	751	762	simulations	UnknownType	C0681948
28374022	766	773	predict	T078	C0681842
28374022	778	787	structure	T082	C0678594
28374022	795	811	analyte molecule	T167	C0443354
28374022	813	822	calculate	T052	C1441506
28374022	827	850	collision cross section	T082	C0552389
28374022	852	855	CCS	T082	C0552389
28374022	867	874	compare	T052	C1707455
28374022	880	893	computational	T052	C1880157
28374022	894	899	value	T081	C1522609
28374022	923	935	experimental	T080	C1517586
28374022	936	940	data	T078	C1511726
28374022	983	995	nucleic acid	T114,T123	C0028606
28374022	1022	1035	nucleic acids	T114,T123	C0028606
28374022	1039	1049	biological	T080	C0205460
28374022	1078	1091	computational	T052	C1880157
28374022	1092	1096	cost	T169	C0220812
28374022	1097	1112	associated with	T080	C0332281
28374022	1129	1138	extensive	T080	C0205231
28374022	1139	1148	structure	T082	C0678594
28374022	1153	1161	dynamics	T044	C0596957
28374022	1165	1180	all-atom detail	T080	C1522508
28374022	1190	1196	report	T170	C0684224
28374022	1214	1228	implementation	T052	C1708476
28374022	1234	1263	coarse graining (CG) approach	T170	C3161035
28374022	1267	1273	reduce	T080	C0392756
28374022	1278	1282	cost	T169	C0220812
28374022	1290	1311	computational methods	T062	C1516769
28374022	1312	1320	employed	T033	C0557351
28374022	1328	1332	data	T078	C1511726
28374022	1333	1347	interpretation	T170	C0459471
28374022	1348	1356	workflow	T077	C1710679
28374022	1372	1379	employs	T033	C0557351
28374022	1382	1397	five-bead model	T170	C3161035
28374022	1401	1411	accurately	T080	C0443131
28374022	1412	1421	represent	T052	C1882932
28374022	1427	1437	nucleotide	T114	C0028630
28374022	1445	1457	nucleic acid	T114,T123	C0028606
28374022	1458	1467	structure	T082	C0678594
28374022	1532	1543	calculation	T052	C1441506
28374022	1547	1550	CCS	T082	C0552389
28374022	1551	1557	values	T081	C1522609
28374022	1563	1572	CG models	T170	C3161035
28374022	1615	1623	analysis	T062	C0936012
28374022	1627	1633	larger	T081	C0549177
28374022	1635	1649	highly dynamic	T169	C0729333
28374022	1650	1660	constructs	T114	C0598279
28374022	1666	1674	validity	T081	C2349101
28374022	1709	1721	confirmed by	T080	C0521093
28374022	1726	1735	excellent	T080	C1961136
28374022	1736	1747	correlation	T080	C1707520
28374022	1760	1763	CCS	T082	C0552389
28374022	1764	1770	values	T081	C1522609
28374022	1771	1779	obtained	T169	C1301820
28374022	1783	1791	parallel	T062	C2826345
28374022	1795	1803	all-atom	T077	C1710679
28374022	1808	1820	CG workflows	T077	C1710679

28495504|t|Renal arterial mycotic aneurysm after kidney transplantation
28495504|a|Mycotic aneurysm is a rare condition mostly attributable to Candida or Aspergillus species. About 20 cases of Candida -related arteritis have been reported in kidney transplant patients. Herein, we report the case of a 40-year- old man who received a kidney from a deceased donor in whom an accidental digestive wound was made during organ retrieval. He presented with sudden anuria 47 days after renal transplantation revealing a large mycotic aneurysm of the kidney graft renal artery. Organs derived from donors in whom a digestive breach is noticed should be used with caution.
28495504	0	31	Renal arterial mycotic aneurysm	T047	C0085808
28495504	38	60	kidney transplantation	T061	C0022671
28495504	61	77	Mycotic aneurysm	T047	C0085808
28495504	105	117	attributable	T078	C0449234
28495504	121	128	Candida	T004	C0006836
28495504	132	151	Aspergillus species	T004	C0004034
28495504	171	178	Candida	T004	C0006836
28495504	188	197	arteritis	T046	C0003860
28495504	220	237	kidney transplant	T061	C0022671
28495504	238	246	patients	T101	C0030705
28495504	259	265	report	T170	C0684224
28495504	312	318	kidney	T023	C0022646
28495504	335	340	donor	T098	C0013018
28495504	352	362	accidental	T169	C0521129
28495504	363	378	digestive wound	T037	C0850041
28495504	395	410	organ retrieval	T058	C0162438
28495504	437	443	anuria	T047	C0003460
28495504	458	479	renal transplantation	T061	C0022671
28495504	498	514	mycotic aneurysm	T047	C0085808
28495504	522	534	kidney graft	T024	C1720289
28495504	535	547	renal artery	T023	C0035065
28495504	549	555	Organs	T023	C0178784
28495504	569	575	donors	T098	C0013018
28495504	586	602	digestive breach	T037	C0850041
28495504	624	641	used with caution	T169	C1710588

27465797|t|Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose - induced molecular pathways
27465797|a|Considering the referred beneficial effects of protein restriction on diabetic nephropathy (DN) and the role of renal endothelium in its pathogenesis, we evaluated the effect of general control nonderepressible 2 (GCN2) kinase activation, a sensor of amino acid deprivation, on known detrimental molecular pathways in primary human glomerular endothelial cells (GEnC). GEnC were cultured under normal or high -glucose conditions in the presence or not of the GCN2 kinase activator, tryptophanol. Glucose transporter 1 (GLUT1) expression was assessed by western blotting and reactive oxygen species (ROS) using a fluorogenic probe. Activities of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and protein kinase C (PKC) were assessed by commercial activity assays, sorbitol colorimetrically, methylglyoxal by ELISA and O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins by western blotting. High glucose induced GLUT1 expression, increased ROS and inhibited GAPDH. Also it increased the polyol pathway product sorbitol, PKC activity, the level of the O-GlcNAc-modified proteins that produced by the hexosamine pathway and the advanced glycation endproducts' precursor methylglyoxal. Co-treatment of GEnC with tryptophanol restored the above high-glucose - induced alterations. Activation of GCN2 kinase protects GEnC from high-glucose - induced harmful molecular pathways. By inhibiting concurrently many pathways involved in DN pathogenesis, GCN2 kinase may serve as a pharmaceutical target for the treatment of DN.
27465797	0	10	Activation	T044	C0014429
27465797	14	55	general control nonderepressible 2 kinase	T116,T126	C2354171
27465797	56	64	protects	T033	C1545588
27465797	65	70	human	T016	C0086418
27465797	71	99	glomerular endothelial cells	T025	C1182791
27465797	113	125	high-glucose	T033	C0860803
27465797	128	135	induced	T169	C0205263
27465797	136	154	molecular pathways	T044	C1704259
27465797	202	209	protein	T116,T123	C0033684
27465797	210	221	restriction	T169	C0443288
27465797	225	245	diabetic nephropathy	T047	C0011881
27465797	247	249	DN	T047	C0011881
27465797	267	272	renal	T023	C0022646
27465797	273	284	endothelium	T024	C0014257
27465797	292	304	pathogenesis	T046	C0699748
27465797	309	318	evaluated	T058	C0220825
27465797	333	381	general control nonderepressible 2 (GCN2) kinase	T116,T126	C2354171
27465797	382	392	activation	T044	C0014429
27465797	396	402	sensor	T075	C0600364
27465797	406	416	amino acid	T116,T121,T123	C0002520
27465797	417	428	deprivation	T080	C0871712
27465797	451	469	molecular pathways	T044	C1704259
27465797	481	486	human	T016	C0086418
27465797	487	515	glomerular endothelial cells	T025	C1182791
27465797	517	521	GEnC	T025	C1182791
27465797	524	528	GEnC	T025	C1182791
27465797	534	542	cultured	T059	C0430400
27465797	559	563	high	T080	C0205250
27465797	559	583	high -glucose conditions	T047	C0020456
27465797	614	625	GCN2 kinase	T116,T126	C2354171
27465797	626	635	activator	T044	C2247123
27465797	637	649	tryptophanol	T116	C0526839
27465797	651	672	Glucose transporter 1	T116,T123	C0168458
27465797	674	679	GLUT1	T116,T123	C0168458
27465797	681	691	expression	T045	C1171362
27465797	696	704	assessed	T052	C1516048
27465797	708	724	western blotting	T059,T063	C0005863
27465797	729	752	reactive oxygen species	T123,T196	C0162772
27465797	754	757	ROS	T123,T196	C0162772
27465797	767	784	fluorogenic probe	T130	C0016321
27465797	786	796	Activities	T044	C0243102
27465797	800	840	glyceraldehyde 3-phosphate dehydrogenase	T116,T126	C3536868
27465797	842	847	GAPDH	T116,T126	C3536868
27465797	853	869	protein kinase C	T116,T126	C0033634
27465797	871	874	PKC	T116,T126	C0033634
27465797	881	889	assessed	T052	C1516048
27465797	893	919	commercial activity assays	T059	C0005507
27465797	921	929	sorbitol	T109,T121	C0037688
27465797	930	946	colorimetrically	T059	C1531834
27465797	948	961	methylglyoxal	T109,T130	C0034338
27465797	965	970	ELISA	T059	C0014441
27465797	975	1035	O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins	T116,T126	C0671368
27465797	1039	1055	western blotting	T059,T063	C0005863
27465797	1057	1069	High glucose	T033	C0860803
27465797	1070	1077	induced	T169	C0205263
27465797	1078	1083	GLUT1	T116,T123	C0168458
27465797	1084	1094	expression	T045	C1171362
27465797	1096	1105	increased	T081	C0205217
27465797	1106	1109	ROS	T123,T196	C0162772
27465797	1114	1123	inhibited	T080	C0311403
27465797	1124	1129	GAPDH	T116,T126	C3536868
27465797	1139	1148	increased	T081	C0205217
27465797	1153	1159	polyol	T109	C0071629
27465797	1160	1167	pathway	T044	C1704259
27465797	1176	1184	sorbitol	T109,T121	C0037688
27465797	1186	1189	PKC	T116,T126	C0033634
27465797	1190	1198	activity	T044	C0243102
27465797	1217	1243	O-GlcNAc-modified proteins	T116,T126	C0671368
27465797	1265	1275	hexosamine	T109,T123	C0019477
27465797	1276	1283	pathway	T044	C1704259
27465797	1292	1323	advanced glycation endproducts'	T109,T123	C0162574
27465797	1324	1333	precursor	T078	C1709634
27465797	1334	1347	methylglyoxal	T109,T130	C0034338
27465797	1349	1361	Co-treatment	T058	C0814472
27465797	1365	1369	GEnC	T025	C1182791
27465797	1375	1387	tryptophanol	T116	C0526839
27465797	1407	1419	high-glucose	T033	C0860803
27465797	1422	1429	induced	T169	C0205263
27465797	1443	1453	Activation	T044	C0014429
27465797	1457	1468	GCN2 kinase	T116,T126	C2354171
27465797	1478	1482	GEnC	T025	C1182791
27465797	1488	1500	high-glucose	T033	C0860803
27465797	1503	1510	induced	T169	C0205263
27465797	1519	1537	molecular pathways	T044	C1704259
27465797	1553	1565	concurrently	T079	C0205420
27465797	1571	1579	pathways	T044	C1704259
27465797	1592	1594	DN	T047	C0011881
27465797	1595	1607	pathogenesis	T046	C0699748
27465797	1609	1620	GCN2 kinase	T116,T126	C2354171
27465797	1636	1650	pharmaceutical	T091	C0031336
27465797	1651	1657	target	T169	C1521840
27465797	1666	1675	treatment	T061	C0087111
27465797	1679	1681	DN	T047	C0011881

27659547|t|The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study
27659547|a|Older people may suffer from stigmas linked to cancer and aging. Although some studies suggested that a negative view of cancer may increase the level of depression, such an association has never been studied in the elderly population. Similarly, even though it is established that a negative self-perception of aging has deleterious consequences on mental and physical health in normal aging, the influence in pathological contexts, such as oncology, has not been studied. The main aim of this study is thus to analyze the effect of these two stigmas on the health of elderly oncology patients. 101 patients suffering from a cancer (breast, gynecological, lung or hematological) were seen as soon as possible after their diagnosis. Their self-perception of age, cancer view and health (physical and mental) was assessed. Multiple regressions showed that patients with a more negative self-perception of aging and/or more negative cancer view reported poorer global health. We also observed that negative self-perception of aging was associated with worse physical and mental health, whereas negative cancer views were only linked to worse mental health. No interaction was observed between these two stigmas, suggesting that their action is independent. Older patients with cancer face double stigmatization, due to negative self-perception of aging and cancer, and these stigmas have impacts on global and mental health. Self-perception of aging is also linked to physical health. Longitudinal studies will be necessary to analyze the direction of the association between this double stigmatization and health.
27659547	17	33	self-perceptions	T041	C0242498
27659547	37	42	aging	T040	C0001811
27659547	44	50	cancer	T191	C0006826
27659547	60	68	physical	T169	C0205485
27659547	73	86	mental health	T041	C0025353
27659547	90	102	older people	T098	C3826770
27659547	108	114	cancer	T191	C0006826
27659547	116	139	A cross-sectional study	T062	C0010362
27659547	140	152	Older people	T098	C3826770
27659547	169	176	stigmas	T048	C0011570
27659547	187	193	cancer	T191	C0006826
27659547	198	203	aging	T040	C0001811
27659547	219	226	studies	T062	C2603343
27659547	244	252	negative	T033	C0205160
27659547	253	257	view	T082	C0449911
27659547	261	267	cancer	T191	C0006826
27659547	285	304	level of depression	T033	C1319226
27659547	341	348	studied	T062	C2603343
27659547	356	374	elderly population	T098	C0001792
27659547	424	432	negative	T033	C0205160
27659547	433	448	self-perception	T041	C0242498
27659547	452	457	aging	T040	C0001811
27659547	474	486	consequences	T169	C0686907
27659547	490	496	mental	T041	C0025353
27659547	501	516	physical health	T033	C4060919
27659547	527	532	aging	T040	C0001811
27659547	551	563	pathological	T169	C1521733
27659547	564	572	contexts	T078	C0449255
27659547	582	590	oncology	T191	C0027651
27659547	652	659	analyze	T062	C0936012
27659547	684	691	stigmas	T048	C0011570
27659547	699	705	health	T078	C0018684
27659547	709	716	elderly	T098	C0001792
27659547	717	725	oncology	T191	C0027651
27659547	726	734	patients	T101	C0030705
27659547	740	748	patients	T101	C0030705
27659547	766	772	cancer	T191	C0006826
27659547	774	780	breast	T191	C0006142
27659547	782	795	gynecological	T047	C0017411
27659547	797	801	lung	T191	C0242379
27659547	805	818	hematological	T047	C0018939
27659547	862	871	diagnosis	T033	C0011900
27659547	879	894	self-perception	T041	C0242498
27659547	898	901	age	T032	C0001779
27659547	903	909	cancer	T191	C0006826
27659547	919	925	health	T078	C0018684
27659547	927	935	physical	T033	C4060919
27659547	940	946	mental	T041	C0025353
27659547	971	982	regressions	T041	C0684321
27659547	995	1003	patients	T101	C0030705
27659547	1016	1024	negative	T033	C0205160
27659547	1025	1040	self-perception	T041	C0242498
27659547	1044	1049	aging	T040	C0001811
27659547	1062	1070	negative	T033	C0205160
27659547	1071	1077	cancer	T191	C0006826
27659547	1092	1098	poorer	T080	C2700379
27659547	1099	1112	global health	T091	C1456573
27659547	1136	1144	negative	T033	C0205160
27659547	1145	1160	self-perception	T041	C0242498
27659547	1164	1169	aging	T040	C0001811
27659547	1174	1189	associated with	T080	C0332281
27659547	1196	1204	physical	T033	C4060919
27659547	1209	1222	mental health	T041	C0025353
27659547	1232	1240	negative	T033	C0205160
27659547	1241	1247	cancer	T191	C0006826
27659547	1280	1293	mental health	T041	C0025353
27659547	1341	1348	stigmas	T048	C0011570
27659547	1382	1393	independent	T078	C0085862
27659547	1401	1409	patients	T101	C0030705
27659547	1415	1421	cancer	T191	C0006826
27659547	1434	1448	stigmatization	T078	C0038330
27659547	1457	1465	negative	T033	C0205160
27659547	1466	1481	self-perception	T041	C0242498
27659547	1485	1490	aging	T040	C0001811
27659547	1495	1501	cancer	T191	C0006826
27659547	1513	1520	stigmas	T048	C0011570
27659547	1548	1561	mental health	T041	C0025353
27659547	1563	1578	Self-perception	T041	C0242498
27659547	1582	1587	aging	T040	C0001811
27659547	1606	1621	physical health	T033	C4060919
27659547	1623	1643	Longitudinal studies	T062	C0023981
27659547	1665	1672	analyze	T062	C0936012
27659547	1726	1740	stigmatization	T078	C0038330
27659547	1745	1751	health	T078	C0018684

28476381|t|Unusual asymptomatic presentation of bladder cancer metastatic to the penis
28476381|a|Penile metastasis is an extremely rare event and mainly originate from primary pelvic tumor sites such us urinary bladder, gastro-intestinal tract and prostate and more rarely from respiratory system, bone tumors and melanoma. Here we describe the unusual presentation of two bladder urothelial cancer metastatic to the penis with no relevant clinical symptoms. Namely, a 69 years-old man with a warthy lesions of the foreskin and the glans misunderstood for a condylomata that at histological and immunohistochemical analysis showed a bladder urothelial carcinoma; and a 71 years-old man with reddish skin lesion of the glans, a previous history of bladder and urethral carcinoma and histological pagetoid spread of urothelial cancer to the glans. Recurrent bladder urothelial carcinoma is usually a visceral disease that rarely presents as a superficial asymptomatic skin lesion. The two reported cases were asymptomatic superficial penis metastases with a relatively slow growth and a fairy good prognosis after conservative surgical approach. Accurate clinical examination of the penis is mandatory for males with history of bladder cancer.
28476381	0	7	Unusual	T080	C2700116
28476381	8	33	asymptomatic presentation	T047	C0275522
28476381	37	51	bladder cancer	T191	C0005695
28476381	52	75	metastatic to the penis	T191	C0347002
28476381	76	93	Penile metastasis	T191	C0347002
28476381	100	120	extremely rare event	T047	C0678236
28476381	155	161	pelvic	T023	C0030797
28476381	162	173	tumor sites	T082	C0475445
28476381	182	197	urinary bladder	T023	C0005682
28476381	199	222	gastro-intestinal tract	T022	C0017189
28476381	227	235	prostate	T023	C0033572
28476381	257	275	respiratory system	T022	C0035237
28476381	277	288	bone tumors	T191	C0005967
28476381	293	301	melanoma	T191	C0025202
28476381	324	331	unusual	T080	C2700116
28476381	332	344	presentation	T078	C0449450
28476381	352	377	bladder urothelial cancer	T191	C0751571
28476381	378	391	metastatic to	T169	C0036525
28476381	396	401	penis	T023	C0030851
28476381	407	436	no relevant clinical symptoms	T033	C0231221
28476381	479	486	lesions	T033	C0221198
28476381	494	516	foreskin and the glans	UnknownType	C0545925
28476381	537	548	condylomata	T047	C0302180
28476381	557	569	histological	T059	C0019637
28476381	574	602	immunohistochemical analysis	T059	C1441616
28476381	612	640	bladder urothelial carcinoma	T191	C2145472
28476381	670	677	reddish	T080	C1260956
28476381	678	702	skin lesion of the glans	T033	C2168434
28476381	715	733	history of bladder	T033	C0567322
28476381	738	756	urethral carcinoma	T191	C2145472
28476381	761	789	histological pagetoid spread	T033	C1335292
28476381	793	810	urothelial cancer	T191	C2145472
28476381	811	823	to the glans	T023	C0227948
28476381	825	863	Recurrent bladder urothelial carcinoma	T191	C0278827
28476381	877	885	visceral	T023	C0042779
28476381	886	893	disease	T047	C0012634
28476381	932	944	asymptomatic	T033	C0231221
28476381	945	956	skin lesion	T047	C0037284
28476381	975	998	cases were asymptomatic	T033	C0231221
28476381	999	1027	superficial penis metastases	T191	C0347002
28476381	1064	1084	fairy good prognosis	T033	C0278250
28476381	1091	1121	conservative surgical approach	T169	C0449446
28476381	1132	1188	clinical examination of the penis is mandatory for males	T064	C0242803
28476381	1194	1219	history of bladder cancer	T033	C0567322

28490164|t|Contralateral Superior Cerebellar Artery Syndrome: A Consequence of Brain Herniation
28490164|a|Vascular compromise is a well-known consequence of brain herniation syndromes. Transtentorial brain herniation most often involves posterior cerebral arteries. However, isolated involvement of contralateral superior cerebellar artery (SCA) during unilateral impending brain herniation is reported only once and we present another case of this exceedingly rare entity. A 24-year-old man was referred to us with impending herniation due to a multiloculated hydrocephalus, and during the course of illness, he developed an isolated SCA ischemia in the opposite side of the most dilated entrapped horn. In the current article we discuss the probable pathophysiologic mechanisms of this phenomenon, as well as recommending more inclusive brain studies in cases suspected of Kernohan-Woltman notch phenomenon in unilateral brain herniation. The rationale for this commentary is that contralateral SCA transient ischemia or infarct might be the underdiagnosed underlying pathomechanism of ipsilateral hemiparesis occurring in many cases of this somehow vague phenomenon.
28490164	0	13	Contralateral	T082	C0441988
28490164	14	49	Superior Cerebellar Artery Syndrome	T046	C1384733
28490164	53	67	Consequence of	T169	C0686907
28490164	68	84	Brain Herniation	T190	C0553686
28490164	85	93	Vascular	T023	C0005847
28490164	94	104	compromise	T033	C2945640
28490164	121	135	consequence of	T169	C0686907
28490164	136	152	brain herniation	T190	C0553686
28490164	153	162	syndromes	T047	C0039082
28490164	164	178	Transtentorial	T082	C0522519
28490164	179	195	brain herniation	T190	C0553686
28490164	216	243	posterior cerebral arteries	T023	C0149576
28490164	254	262	isolated	T169	C0205409
28490164	263	274	involvement	T169	C1314939
28490164	278	291	contralateral	T082	C0441988
28490164	292	318	superior cerebellar artery	T023	C0149575
28490164	320	323	SCA	T023	C0149575
28490164	332	342	unilateral	T082	C0205092
28490164	343	352	impending	T079	C0332190
28490164	353	369	brain herniation	T190	C0553686
28490164	373	381	reported	T058	C0700287
28490164	440	444	rare	T080	C0522498
28490164	445	451	entity	T071	C1551338
28490164	467	470	man	T098	C0025266
28490164	495	504	impending	T079	C0332190
28490164	505	515	herniation	T190	C0019270
28490164	525	539	multiloculated	T082	C0205293
28490164	540	553	hydrocephalus	T047	C0020255
28490164	570	587	course of illness	T046	C0242656
28490164	605	613	isolated	T169	C0205409
28490164	614	617	SCA	T023	C0149575
28490164	618	626	ischemia	T046	C0022116
28490164	660	667	dilated	T033	C0700124
28490164	678	682	horn	T023	C0019939
28490164	699	706	article	T170	C1706852
28490164	731	747	pathophysiologic	T169	C0031847
28490164	748	758	mechanisms	T169	C0441712
28490164	767	777	phenomenon	T067	C1882365
28490164	808	817	inclusive	T169	C0332257
28490164	818	823	brain	T023	C0006104
28490164	841	850	suspected	T078	C0750491
28490164	854	887	Kernohan-Woltman notch phenomenon	T046	C0030660
28490164	891	901	unilateral	T082	C0205092
28490164	902	918	brain herniation	T190	C0553686
28490164	924	933	rationale	T078	C2699007
28490164	943	953	commentary	T170	C0282411
28490164	962	975	contralateral	T082	C0441988
28490164	976	979	SCA	T023	C0149575
28490164	980	998	transient ischemia	T047	C0022118
28490164	1002	1009	infarct	T046	C0021308
28490164	1023	1037	underdiagnosed	T033	C0243095
28490164	1049	1063	pathomechanism	T046	C0030660
28490164	1067	1078	ipsilateral	T082	C0441989
28490164	1079	1090	hemiparesis	T184	C0018989
28490164	1131	1136	vague	T080	C0205408
28490164	1137	1147	phenomenon	T067	C1882365

27518527|t|Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report
27518527|a|Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and comprises approximately 30% of all lymphomas. Patients typically present with a nonpainful mass in the neck, groin, or abdomen associated with constitutional symptoms. In this report, however, the authors describe a rare case of a 61- year -old woman with hyperprolactinemia, hypothyroidism, and acromegaly (elevation of insulin-like growth factor-1 [IGF-1]) with elevated growth hormone-releasing hormone (GHRH) in whom an MRI demonstrated diffuse enlargement of the pituitary gland. Despite medical treatment, the patient had persistent elevation of IGF-1. She underwent a transsphenoidal biopsy, which yielded a diagnosis of DLBCL with an activated B-cell immunophenotype with somatotroph hyperplasia. After stereo-tactic radiation therapy in combination with chemotherapy, she is currently in remission from her lymphoma and has normalized IGF-1 levels without medical therapy, 8 months after her histopathological diagnosis. This is the only reported case of its kind and displays the importance of a broad differential diagnosis, multidisciplinary evaluation, and critical intraoperative decision-making when treating atypical sellar lesions.
27518527	0	7	Primary	T080	C0205225
27518527	8	17	pituitary	T023	C0032005
27518527	18	47	diffuse large B-cell lymphoma	T191	C0079744
27518527	53	76	somatotroph hyperplasia	T190	C0342369
27518527	81	91	acromegaly	T047	C0001206
27518527	93	104	case report	T170	C0085973
27518527	105	134	Diffuse large B-cell lymphoma	T191	C0079744
27518527	136	141	DLBCL	T191	C0079744
27518527	155	161	common	T081	C0205214
27518527	162	166	type	T080	C0332307
27518527	170	190	non-Hodgkin lymphoma	T191	C0024305
27518527	230	239	lymphomas	T191	C0024299
27518527	241	249	Patients	T101	C0030705
27518527	260	267	present	T033	C0150312
27518527	275	285	nonpainful	T169	C0234226
27518527	286	290	mass	T033	C0577559
27518527	298	302	neck	T029	C0027530
27518527	304	309	groin	T029	C0018246
27518527	314	321	abdomen	T029	C0000726
27518527	322	337	associated with	T080	C0332281
27518527	338	361	constitutional symptoms	T184	C0009812
27518527	371	377	report	T170	C0684224
27518527	392	399	authors	T097	C3812881
27518527	411	415	rare	T080	C0522498
27518527	416	420	case	T169	C0868928
27518527	430	434	year	T079	C1510829
27518527	440	445	woman	T098	C0043210
27518527	451	469	hyperprolactinemia	T047	C0020514
27518527	471	485	hypothyroidism	T047	C0020676
27518527	491	501	acromegaly	T047	C0001206
27518527	503	512	elevation	T080	C0205250
27518527	516	544	insulin-like growth factor-1	T116,T123	C0021665
27518527	546	551	IGF-1	T116,T123	C0021665
27518527	559	567	elevated	T080	C0205250
27518527	568	600	growth hormone-releasing hormone	T116,T125	C0037668
27518527	602	606	GHRH	T116,T125	C0037668
27518527	619	622	MRI	T060	C0024485
27518527	623	635	demonstrated	T080	C0443289
27518527	636	678	diffuse enlargement of the pituitary gland	T184	C0877018
27518527	688	705	medical treatment	T061	C0418981
27518527	711	718	patient	T101	C0030705
27518527	723	733	persistent	T079	C0205322
27518527	734	743	elevation	T080	C0205250
27518527	747	752	IGF-1	T116,T123	C0021665
27518527	770	792	transsphenoidal biopsy	T060	C0176118
27518527	800	807	yielded	T052	C1999230
27518527	810	819	diagnosis	T033	C0011900
27518527	823	828	DLBCL	T191	C0079744
27518527	837	846	activated	T052	C1879547
27518527	847	853	B-cell	T025	C0004561
27518527	854	869	immunophenotype	T059	C0079611
27518527	875	898	somatotroph hyperplasia	T190	C0342369
27518527	906	937	stereo-tactic radiation therapy	T061	C3896609
27518527	941	952	combination	T080	C0205195
27518527	958	970	chemotherapy	T061	C3665472
27518527	979	988	currently	T079	C0521116
27518527	992	1001	remission	T191	C0687702
27518527	1011	1019	lymphoma	T191	C0024299
27518527	1028	1038	normalized	T062	C1882115
27518527	1039	1044	IGF-1	T116,T123	C0021665
27518527	1045	1051	levels	T080	C0441889
27518527	1060	1075	medical therapy	T061	C0418981
27518527	1079	1085	months	T079	C0439231
27518527	1096	1113	histopathological	T169	C0243140
27518527	1114	1123	diagnosis	T033	C0011900
27518527	1142	1150	reported	T170	C0684224
27518527	1151	1155	case	T169	C0868928
27518527	1207	1229	differential diagnosis	T060	C0011906
27518527	1231	1259	multidisciplinary evaluation	T060	C0729737
27518527	1265	1273	critical	T080	C1511545
27518527	1274	1288	intraoperative	T079	C0456904
27518527	1289	1304	decision-making	T041	C0011109
27518527	1310	1318	treating	T169	C1522326
27518527	1328	1334	sellar	T023	C0036609
27518527	1335	1342	lesions	T033	C0221198

27515250|t|A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia. Final results of the GIMEMA LAL 0904 study
27515250|a|In the GIMEMA LAL 0904 protocol, adult Ph+ acute lymphoblastic leukemia patients were treated with chemotherapy for induction and consolidation, followed by maintenance with imatinib. The protocol was subsequently amended and imatinib was incorporated in the induction and post - remission phase together with chemotherapy. Due to the toxicity of this combined approach, the protocol was further amended to a sequential scheme based on imatinib plus steroids as induction, followed by consolidation with chemotherapy plus imatinib and, when applicable, by a hematopoietic stem cell transplant. Fifty-one patients (median age: 45.9 years) were enrolled in the final sequential protocol, hereby reported. At the end of induction (day +50), 96% of evaluable patients (n=49) achieved a complete hematologic remission; after consolidation, all were in complete hematologic remission. No deaths in induction were recorded. Overall survival and disease-free survival at 60 months are 48.8% and 45.8%, respectively. At day +50 (end of the imatinib induction), a log - reduction of BCR-ABL1 levels >1.3 was associated with a significantly more prolonged disease-free survival (55.6%, C.I. 95%: 39.0-79.3 vs 20%, C.I. 95%: 5.8-69.1; p =0.03), overall survival (59.1%, C.I. 95%: 42.3-82.6 vs 20%, C.I. 95%: 5.8-69.1, p =0.02) and lower relapse incidence (20.5%, C.I. 95%: 7.2-38.6 vs 60.0%, C.I. 95%: 21.6-84.3, p =0.01). Mean BCR-ABL1 levels remained significantly higher in patients who subsequently relapsed. Finally, BCR-ABL1p190 patients showed a significantly faster molecular response than BCR-ABL1p210 patients (p =0.023). Thought the study was not powered to evaluate the role of allogeneic stem cell transplant, allografting positively impacted on overall survival and disease-free survival. A sequential approach with imatinib alone in induction, consolidated by chemotherapy plus imatinib followed by a stem cell transplant is a feasible, well-tolerated and effective strategy for adult Ph+ acute lymphoblastic leukemia, leading to the best long-term survival rates so far reported. Trial ID: NCT00458848.
27515250	2	12	sequential	T080	C1705294
27515250	13	21	approach	T082	C0449445
27515250	27	35	imatinib	T109,T121	C0935989
27515250	37	49	chemotherapy	T061	C3665472
27515250	54	64	transplant	T033	C3841811
27515250	69	74	adult	T100	C0001675
27515250	75	107	Ph+ acute lymphoblastic leukemia	T191	C1960397
27515250	109	114	Final	T079	C3853528
27515250	115	122	results	T033	C2825142
27515250	130	151	GIMEMA LAL 0904 study	T059	C0947630
27515250	159	183	GIMEMA LAL 0904 protocol	T170	C1507394
27515250	185	190	adult	T100	C0001675
27515250	191	223	Ph+ acute lymphoblastic leukemia	T191	C1960397
27515250	224	232	patients	T101	C0030705
27515250	238	245	treated	T169	C1522326
27515250	251	263	chemotherapy	T061	C3665472
27515250	268	277	induction	T061	C0857127
27515250	282	295	consolidation	T061	C1511484
27515250	309	320	maintenance	T052	C0024501
27515250	326	334	imatinib	T109,T121	C0935989
27515250	340	348	protocol	T170	C1507394
27515250	366	373	amended	T080	C1691222
27515250	378	386	imatinib	T109,T121	C0935989
27515250	391	403	incorporated	T169	C0243126
27515250	411	420	induction	T061	C0857127
27515250	425	429	post	T079	C0687676
27515250	432	447	remission phase	T033	C0544452
27515250	462	474	chemotherapy	T061	C3665472
27515250	487	495	toxicity	T037	C0600688
27515250	504	512	combined	T080	C0205195
27515250	513	521	approach	T082	C0449445
27515250	527	535	protocol	T170	C1507394
27515250	548	555	amended	T080	C1691222
27515250	561	571	sequential	T080	C1705294
27515250	588	596	imatinib	T109,T121	C0935989
27515250	602	610	steroids	T109	C0038317
27515250	614	623	induction	T061	C0857127
27515250	637	650	consolidation	T061	C1511484
27515250	656	668	chemotherapy	T061	C3665472
27515250	674	682	imatinib	T109,T121	C0935989
27515250	710	744	hematopoietic stem cell transplant	T061	C0472699
27515250	756	764	patients	T101	C0030705
27515250	773	776	age	T032	C0001779
27515250	783	788	years	T079	C1510829
27515250	811	816	final	T079	C3853528
27515250	817	827	sequential	T080	C1705294
27515250	828	836	protocol	T170	C1507394
27515250	845	853	reported	T058	C0700287
27515250	869	878	induction	T061	C0857127
27515250	907	915	patients	T101	C0030705
27515250	943	964	hematologic remission	T033	C0544452
27515250	972	985	consolidation	T061	C1511484
27515250	1008	1029	hematologic remission	T033	C0544452
27515250	1034	1040	deaths	T033	C1306577
27515250	1044	1053	induction	T061	C0857127
27515250	1059	1067	recorded	T080	C2355580
27515250	1077	1085	survival	T052	C0038952
27515250	1090	1111	disease-free survival	T081	C0242793
27515250	1118	1124	months	T079	C0439231
27515250	1163	1166	day	T079	C0439228
27515250	1183	1191	imatinib	T109,T121	C0935989
27515250	1192	1201	induction	T061	C0857127
27515250	1206	1209	log	T081	C2986775
27515250	1212	1221	reduction	T080	C0392756
27515250	1225	1233	BCR-ABL1	T116,T123	C0004891
27515250	1234	1240	levels	T080	C0441889
27515250	1250	1265	associated with	T080	C0332281
27515250	1268	1286	significantly more	T081	C4055637
27515250	1287	1296	prolonged	T079	C0439590
27515250	1297	1318	disease-free survival	T081	C0242793
27515250	1327	1330	C.I	T081	C0009667
27515250	1355	1358	C.I	T081	C0009667
27515250	1375	1376	p	T081	C1709380
27515250	1385	1401	overall survival	T081	C4086681
27515250	1410	1413	C.I	T081	C0009667
27515250	1438	1441	C.I	T081	C0009667
27515250	1458	1459	p	T081	C1709380
27515250	1471	1476	lower	T080	C0205251
27515250	1477	1484	relapse	T067	C0035020
27515250	1485	1494	incidence	T081	C0021149
27515250	1503	1506	C.I	T081	C0009667
27515250	1532	1535	C.I	T081	C0009667
27515250	1553	1554	p	T081	C1709380
27515250	1568	1576	BCR-ABL1	T116,T123	C0004891
27515250	1577	1583	levels	T080	C0441889
27515250	1593	1613	significantly higher	T081	C4055637
27515250	1617	1625	patients	T101	C0030705
27515250	1643	1651	relapsed	T079	C0205336
27515250	1662	1674	BCR-ABL1p190	T116,T123	C0004891
27515250	1675	1683	patients	T101	C0030705
27515250	1693	1706	significantly	T078	C0750502
27515250	1707	1713	faster	T080	C0456962
27515250	1714	1732	molecular response	T033	C4054479
27515250	1738	1750	BCR-ABL1p210	T116,T123	C0004891
27515250	1751	1759	patients	T101	C0030705
27515250	1761	1762	p	T081	C1709380
27515250	1784	1789	study	T062	C0008972
27515250	1809	1817	evaluate	T058	C0220825
27515250	1830	1861	allogeneic stem cell transplant	T061	C4255274
27515250	1863	1875	allografting	T061	C0040739
27515250	1876	1886	positively	T033	C3843166
27515250	1887	1895	impacted	T169	C0333125
27515250	1899	1915	overall survival	T081	C4086681
27515250	1920	1941	disease-free survival	T081	C0242793
27515250	1945	1955	sequential	T080	C1705294
27515250	1956	1964	approach	T082	C0449445
27515250	1970	1978	imatinib	T109,T121	C0935989
27515250	1988	1997	induction	T061	C0857127
27515250	1999	2011	consolidated	T061	C1511484
27515250	2015	2027	chemotherapy	T061	C3665472
27515250	2033	2041	imatinib	T109,T121	C0935989
27515250	2056	2076	stem cell transplant	T061	C1504389
27515250	2111	2120	effective	T080	C1704419
27515250	2121	2129	strategy	T169	C0449851
27515250	2134	2139	adult	T100	C0001675
27515250	2140	2172	Ph+ acute lymphoblastic leukemia	T191	C1960397
27515250	2194	2203	long-term	T079	C0443252
27515250	2204	2218	survival rates	T081	C0038954
27515250	2226	2234	reported	T058	C0700287

27663493|t|Biospark: scalable analysis of large numerical datasets from biological simulations and experiments using Hadoop and Spark
27663493|a|Data-parallel programming techniques can dramatically decrease the time needed to analyze large datasets. While these methods have provided significant improvements for sequencing-based analyses, other areas of biological informatics have not yet adopted them. Here, we introduce Biospark, a new framework for performing data-parallel analysis on large numerical datasets. Biospark builds upon the open source Hadoop and Spark projects, bringing domain-specific features for biology. Source code is licensed under the Apache 2.0 open source license and is available at the project website: https://www.assembla.com/spaces/roberts-lab-public/wiki/Biospark CONTACT: eroberts@jhu.eduSupplementary information: Supplementary data are available at Bioinformatics online.
27663493	0	8	Biospark	T170	C0037589
27663493	10	27	scalable analysis	T062	C0936012
27663493	37	55	numerical datasets	T081	C0243174
27663493	61	71	biological	T080	C0205460
27663493	72	83	simulations	T062	C0679083
27663493	88	99	experiments	T062	C0681814
27663493	106	122	Hadoop and Spark	T170	C0037589
27663493	219	227	datasets	T170	C0150098
27663493	241	248	methods	T170	C0025663
27663493	292	317	sequencing-based analyses	T059,T063	C0162801
27663493	334	356	biological informatics	T091	C1140694
27663493	403	411	Biospark	T170	C0037589
27663493	419	428	framework	T170	C1882937
27663493	476	494	numerical datasets	T081	C0243174
27663493	496	504	Biospark	T170	C0037589
27663493	533	549	Hadoop and Spark	T170	C0037589
27663493	550	558	projects	T077	C1709701
27663493	569	593	domain-specific features	T170	C0920998
27663493	598	605	biology	T091	C0005532

28429354|t|The role of the hippocampus and the function of calcitonin gene-related peptide in the mechanism of traumatic brain injury accelerating fracture-healing
28429354|a|This research attempts to identify the part the hippocampus plays in accelerated fracture-healing after traumatic brain injury as well as to test functions of calcitonin gene-related peptide (CGRP) during this process. Experiments were carried out on Male Sprague-Dawley rats that were split into four groups at random: TBI - fracture group, fracture - only group, TBI - only group, and control group. In the first week, blood specimen would be drawn from rats among the groups except those of the control group at three-time points (24, 72 and 168 hours) post - damage. These rats would be assessed from the neurological perspective based on their grades of performance in a sequence of tests 24 hours before and 12 hours after brain injury. Blood samples were also taken from the control group 24 hours before the injury, and whole brain tissues in the injured groups were harvested at 72 and 168 hours post - injury. We compared the serum CGRP concentration, the distribution of CGRP, the CGRP expression, and the expression of CGRP in the hippocampus, the expression of CGRP in the hippocampus, the expression of CGRP in the hippocampus, and the expression of CGRP in the brain by immunohistochemistry, Western blotting, RT - Of CGRP RNA expression levels. Neurological examinations suggested that the functions of the cerebral cortex, cerebellum, and brain stem showed significant differences pre - and post - injury (p < 0.001). ELISA analysis indicated a great density of CGRP in TBI - fracture group at different time points. Furthermore, in the TBI - fracture group, CGRP in both hippocampus and the whole brain showed a noticeable augment in RT-PCR and western blot analysis at 72 and 168 h post - injury, and only in this group, immunohistochemistry analysis indicated that CGRP was present in the hippocampus at 168 hours post - injury. We observed that the hippocampus and CGRP were responsible for quick bone-healing mechanisms. We suggest a role for the hippocampus in accelerated fracture healing. CGRP expression, as determined by IHC, cannot be observed in other groups, indicating that the hippocampus may be the specific component of the brain that responds to " big stress ".
28429354	16	27	hippocampus	T023	C0019564
28429354	48	79	calcitonin gene-related peptide	T116,T125	C0006669
28429354	100	122	traumatic brain injury	T037	C0876926
28429354	136	152	fracture-healing	T042	C0162542
28429354	201	212	hippocampus	T023	C0019564
28429354	234	250	fracture-healing	T042	C0162542
28429354	257	279	traumatic brain injury	T037	C0876926
28429354	312	343	calcitonin gene-related peptide	T116,T125	C0006669
28429354	345	349	CGRP	T116,T125	C0006669
28429354	409	428	Sprague-Dawley rats	T015	C0034715
28429354	455	461	groups	T078	C0441833
28429354	473	476	TBI	T037	C0876926
28429354	479	487	fracture	T037	C0016658
28429354	488	493	group	T078	C0441833
28429354	495	503	fracture	T037	C0016658
28429354	506	510	only	T081	C0205171
28429354	511	516	group	T078	C0441833
28429354	518	521	TBI	T037	C0876926
28429354	524	528	only	T081	C0205171
28429354	529	534	group	T078	C0441833
28429354	540	553	control group	T096	C0009932
28429354	574	588	blood specimen	T031	C0178913
28429354	609	613	rats	T015	C0034715
28429354	624	630	groups	T078	C0441833
28429354	651	664	control group	T096	C0009932
28429354	709	713	post	T079	C0687676
28429354	716	722	damage	T037	C0270611
28429354	730	734	rats	T015	C0034715
28429354	762	774	neurological	T080	C0205494
28429354	882	894	brain injury	T037	C0270611
28429354	896	909	Blood samples	T059	C1277698
28429354	935	948	control group	T096	C0009932
28429354	969	975	injury	T037	C0270611
28429354	987	1000	brain tissues	T023	C0459385
28429354	1008	1015	injured	T169	C0332664
28429354	1016	1022	groups	T078	C0441833
28429354	1028	1037	harvested	T061	C0185110
28429354	1058	1062	post	T079	C0687676
28429354	1065	1071	injury	T037	C0270611
28429354	1089	1094	serum	T031	C0229671
28429354	1095	1099	CGRP	T116,T125	C0006669
28429354	1100	1113	concentration	T081	C1446561
28429354	1135	1139	CGRP	T116,T125	C0006669
28429354	1145	1149	CGRP	T116,T125	C0006669
28429354	1150	1160	expression	T045	C1171362
28429354	1170	1180	expression	T045	C1171362
28429354	1184	1188	CGRP	T116,T125	C0006669
28429354	1196	1207	hippocampus	T023	C0019564
28429354	1213	1223	expression	T045	C1171362
28429354	1227	1231	CGRP	T116,T125	C0006669
28429354	1239	1250	hippocampus	T023	C0019564
28429354	1256	1266	expression	T045	C1171362
28429354	1270	1274	CGRP	T116,T125	C0006669
28429354	1282	1293	hippocampus	T023	C0019564
28429354	1303	1313	expression	T045	C1171362
28429354	1317	1321	CGRP	T116,T125	C0006669
28429354	1329	1334	brain	T023	C0006104
28429354	1338	1358	immunohistochemistry	T060	C0021044
28429354	1360	1376	Western blotting	T059	C0949466
28429354	1378	1380	RT	T045	C0035380
28429354	1386	1390	CGRP	T028	C0017337
28429354	1391	1405	RNA expression	T045	C1515670
28429354	1414	1439	Neurological examinations	T060	C0027853
28429354	1476	1491	cerebral cortex	T023	C0007776
28429354	1493	1503	cerebellum	T023	C0007765
28429354	1509	1519	brain stem	T023	C0006121
28429354	1551	1554	pre	T079	C0332152
28429354	1561	1565	post	T079	C0687676
28429354	1568	1574	injury	T037	C0270611
28429354	1588	1602	ELISA analysis	T059	C0014441
28429354	1632	1636	CGRP	T116,T125	C0006669
28429354	1640	1643	TBI	T037	C0876926
28429354	1646	1654	fracture	T037	C0016658
28429354	1655	1660	group	T078	C0441833
28429354	1707	1710	TBI	T037	C0876926
28429354	1713	1721	fracture	T037	C0016658
28429354	1722	1727	group	T078	C0441833
28429354	1729	1733	CGRP	T116,T125	C0006669
28429354	1742	1753	hippocampus	T023	C0019564
28429354	1762	1773	whole brain	T023	C1269537
28429354	1805	1811	RT-PCR	T063	C0599161
28429354	1816	1837	western blot analysis	T059	C0949466
28429354	1854	1858	post	T079	C0687676
28429354	1861	1867	injury	T037	C0270611
28429354	1873	1877	only	T081	C0205171
28429354	1893	1922	immunohistochemistry analysis	T060	C0021044
28429354	1938	1942	CGRP	T116,T125	C0006669
28429354	1962	1973	hippocampus	T023	C0019564
28429354	1987	1991	post	T079	C0687676
28429354	1994	2000	injury	T037	C0270611
28429354	2023	2034	hippocampus	T023	C0019564
28429354	2039	2043	CGRP	T116,T125	C0006669
28429354	2071	2083	bone-healing	T047	C3687232
28429354	2122	2133	hippocampus	T023	C0019564
28429354	2149	2165	fracture healing	T042	C0162542
28429354	2167	2171	CGRP	T116,T125	C0006669
28429354	2172	2182	expression	T045	C1171362
28429354	2201	2204	IHC	T060	C0021044
28429354	2234	2240	groups	T078	C0441833
28429354	2262	2273	hippocampus	T023	C0019564
28429354	2311	2316	brain	T023	C0006104
28429354	2336	2346	big stress	T046	C0449430

27519262|t|" Predictors of provider - initiated HIV testing and counseling refusal by outpatient department clients in Wolaita zone, Southern Ethiopia: a case control study "
27519262|a|"Despite different strategies designed to rapidly identify HIV infected individuals, majority of HIV -infected people are unaware of their sero-status in developing countries. The objective of this study was to assess predictors of provider -initiated HIV testing and counseling (PITC) refusal by outpatient department (OPD) clients in Wolaita zone, Southern Ethiopia. Facility based unmatched case control study was conducted on outpatient department clients in randomly selected seven health facilities in Wolaita zone, Southern Ethiopia in February 2012. A total of 291 participants (97 cases and 194 controls) were included in our study. Cases were patients who refused HIV test while controls were patients who tested for HIV after provider -initiated HIV testing and counseling (PITC) recommendation by outpatient department (OPD) clinicians. We used both quantitative and qualitative methods of data collection. Pretested interviewer administered questionnaires were used to collect quantitative data by trained nurses, and in-depth interview with 14 OPD clinicians was conducted by principal investigator to supplement quantitative findings. Bivariate and multivariate analyses were done to identify independent predictors of provider -initiated HIV testing and counseling refusal by OPD clients. Study participants who had stigmatizing attitude [AOR =6.09, (95 % CI: 1.70, 21.76)], who had perceived risk for HIV infection [AOR =5.23, (95 % CI: 2.22, 12.32)], who did not perceive the benefits of provider -initiated HIV testing and counseling [AOR =4.64, (95 % CI: 1.79, 12.01)], who did not get minimum recommended pretest information from their providers [AOR =2.98, (95 % CI: 1.06, 8.35)], who ever not heard of provider -initiated HIV testing and counseling service [AOR =2.41, (95 % CI: 1.14, 5.09)], and who were from urban area [AOR =2.40, (95 % CI =1.26, 4.57)] were more likely to refuse provider -initiated HIV testing and counseling service than their counterparts. Knowledge on HIV /AIDS, attitude towards people living with HIV /AIDS and perceived risk for HIV infection by clients were the major barriers for provider -initiated HIV testing and counseling acceptance. Health professionals working at outpatient department should give due attention to overcome these barriers so as to enhance HIV testing acceptance by their clients ." "JOURNAL ARTICLE"
27519262	2	12	Predictors	T078	C2698872
27519262	16	24	provider	T169	C1138603
27519262	37	48	HIV testing	T059	C1321876
27519262	53	63	counseling	T058	C0010210
27519262	64	71	refusal	T055	C0040809
27519262	75	96	outpatient department	T073,T093	C0557824
27519262	97	104	clients	T096	C0008942
27519262	108	120	Wolaita zone	UnknownType	C0681784
27519262	122	139	Southern Ethiopia	UnknownType	C0681784
27519262	143	161	case control study	T062	C0007328
27519262	223	235	HIV infected	T047	C0019693
27519262	236	247	individuals	T098	C0027361
27519262	261	274	HIV -infected	T047	C0019693
27519262	275	281	people	T098	C0027361
27519262	303	314	sero-status	T170	C0449943
27519262	318	338	developing countries	T080	C0011750
27519262	375	381	assess	T058	C0184514
27519262	382	392	predictors	T078	C2698872
27519262	396	404	provider	T169	C1138603
27519262	416	427	HIV testing	T059	C1321876
27519262	432	442	counseling	T058	C0010210
27519262	444	448	PITC	T058	C1254363
27519262	450	457	refusal	T055	C0040809
27519262	461	482	outpatient department	T073,T093	C0557824
27519262	484	487	OPD	T073,T093	C0557824
27519262	489	496	clients	T096	C0008942
27519262	500	512	Wolaita zone	UnknownType	C0681784
27519262	514	531	Southern Ethiopia	UnknownType	C0681784
27519262	533	541	Facility	T073	C1547538
27519262	558	576	case control study	T062	C0007328
27519262	594	615	outpatient department	T073,T093	C0557824
27519262	616	623	clients	T096	C0008942
27519262	651	668	health facilities	T073,T093	C0018704
27519262	672	684	Wolaita zone	UnknownType	C0681784
27519262	686	703	Southern Ethiopia	UnknownType	C0681784
27519262	737	749	participants	T098	C0679646
27519262	754	759	cases	T169	C0868928
27519262	768	776	controls	T096	C0009932
27519262	806	811	Cases	T169	C0868928
27519262	817	825	patients	T101	C0030705
27519262	830	837	refused	T052	C1705116
27519262	838	846	HIV test	T059	C1321876
27519262	853	861	controls	T096	C0009932
27519262	867	875	patients	T101	C0030705
27519262	880	886	tested	T170	C0392366
27519262	891	894	HIV	T005	C0019682
27519262	901	909	provider	T169	C1138603
27519262	921	932	HIV testing	T059	C1321876
27519262	937	947	counseling	T058	C0010210
27519262	949	953	PITC	T058	C1254363
27519262	973	994	outpatient department	T073,T093	C0557824
27519262	996	999	OPD	T073,T093	C0557824
27519262	1001	1011	clinicians	T097	C0871685
27519262	1026	1038	quantitative	T062	C1510568
27519262	1043	1062	qualitative methods	T062	C1510567
27519262	1066	1081	data collection	T062	C0010995
27519262	1083	1132	Pretested interviewer administered questionnaires	T170	C0034394
27519262	1154	1166	quantitative	T081	C0392762
27519262	1167	1171	data	T078	C1511726
27519262	1183	1189	nurses	T097	C0028661
27519262	1195	1213	in-depth interview	T052	C0021822
27519262	1222	1225	OPD	T073,T093	C0557824
27519262	1226	1236	clinicians	T097	C0871685
27519262	1254	1276	principal investigator	T097	C1521895
27519262	1291	1303	quantitative	T081	C0392762
27519262	1304	1312	findings	T169	C2607943
27519262	1314	1323	Bivariate	UnknownType	C0681927
27519262	1328	1349	multivariate analyses	T081	C0026777
27519262	1384	1394	predictors	T078	C2698872
27519262	1398	1406	provider	T169	C1138603
27519262	1418	1429	HIV testing	T059	C1321876
27519262	1434	1444	counseling	T058	C0010210
27519262	1445	1452	refusal	T055	C0040809
27519262	1456	1459	OPD	T073,T093	C0557824
27519262	1460	1467	clients	T096	C0008942
27519262	1475	1487	participants	T098	C0679646
27519262	1509	1517	attitude	T041	C0004271
27519262	1519	1522	AOR	T081	C0028873
27519262	1536	1538	CI	T081	C0009667
27519262	1563	1577	perceived risk	T080	C0814102
27519262	1582	1595	HIV infection	T047	C0019693
27519262	1597	1600	AOR	T081	C0028873
27519262	1614	1616	CI	T081	C0009667
27519262	1670	1678	provider	T169	C1138603
27519262	1690	1701	HIV testing	T059	C1321876
27519262	1706	1716	counseling	T058	C0010210
27519262	1718	1721	AOR	T081	C0028873
27519262	1735	1737	CI	T081	C0009667
27519262	1790	1797	pretest	T058	C0033101
27519262	1821	1830	providers	T169	C1138603
27519262	1832	1835	AOR	T081	C0028873
27519262	1849	1851	CI	T081	C0009667
27519262	1889	1897	provider	T169	C1138603
27519262	1909	1920	HIV testing	T059	C1321876
27519262	1925	1943	counseling service	T058	C0010210
27519262	1945	1948	AOR	T081	C0028873
27519262	1962	1964	CI	T081	C0009667
27519262	1998	2008	urban area	T082	C0178876
27519262	2010	2013	AOR	T081	C0028873
27519262	2027	2029	CI	T081	C0009667
27519262	2071	2079	provider	T169	C1138603
27519262	2091	2102	HIV testing	T059	C1321876
27519262	2107	2125	counseling service	T058	C0010210
27519262	2164	2173	HIV /AIDS	T047	C0497169
27519262	2175	2183	attitude	T041	C0004271
27519262	2192	2198	people	T098	C0027361
27519262	2211	2220	HIV /AIDS	T047	C0497169
27519262	2244	2257	HIV infection	T047	C0019693
27519262	2261	2268	clients	T096	C0008942
27519262	2297	2305	provider	T169	C1138603
27519262	2317	2328	HIV testing	T059	C1321876
27519262	2333	2343	counseling	T058	C0010210
27519262	2344	2354	acceptance	T055	C0000899
27519262	2356	2376	Health professionals	T097	C1704312
27519262	2388	2409	outpatient department	T073,T093	C0557824
27519262	2480	2491	HIV testing	T059	C1321876
27519262	2492	2502	acceptance	T055	C0000899
27519262	2512	2519	clients	T096	C0008942

27296942|t|Prediction of Clinically Significant Bleeding Following Wide-Field Endoscopic Resection of Large Sessile and Laterally Spreading Colorectal Lesions: A Clinical Risk Score
27296942|a|Clinically significant bleeding (CSPEB) is the most frequent adverse event following wide-field endoscopic mucosal resection (WF-EMR) of large sessile and laterally spreading colorectal lesions (LSL). There is limited knowledge regarding accurate prediction of CSPEB. We aimed to derive a score to predict the risk of CSPEB. Data on patient and lesion characteristics and outcomes from WF-EMRs of LSL ≥20 mm at 8 referral hospitals were analyzed. The cohort was divided at random into equal sized training and test groups. Independent predictors of CSPEB in the training cohort were identified by multiple logistic regression analysis and used to develop a risk score. The performance of this score was assessed in the independent test cohort. Over 80 months to June 2015, 2,128 patients with 2,424 LSL were referred for WF-EMR. Two thousand and twelve patients were eligible for analysis. There were 135 cases of CSPEB (6.7%). In the training cohort of 1,006 patients, the independent predictors of CSPEB were lesion size >30 mm (odds ratio (OR) 2.5), proximal colonic location (OR 2.3), presence of a major comorbidity (OR 1.5), and epinephrine in injection solution (OR 0.57). The derived risk score comprised lesion size >30 mm (2 points), proximal colon (2 points), presence of major comorbidity (1 point), and absence of epinephrine use (1 point). The probabilities of CSPEB for scores of 0, 1, 2, 3, 4, and ≥5 in the training cohort were 1.5, 2.0, 5.6, 7.8, 9.1, and 17.5% and were 0.9, 6.7, 4.9, 6.2, 9.0, and 15.7% in the test cohort. The probabilities of CSPEB in those with low (score 0-1), medium (score 2-4), and elevated (score 5-6) risk levels were 1.7, 7.1, and 17.5% in the training cohort and 3.4, 6.2, and 15.7% in the cohort. Patients at elevated risk of CSPEB can be identified using four readily available variables. This knowledge may improve the management of those undergoing WF-EMR and assist in designing studies evaluating CSPEB.
27296942	0	10	Prediction	T078	C0681842
27296942	14	45	Clinically Significant Bleeding	T046	C0019080
27296942	56	87	Wide-Field Endoscopic Resection	T061	C1700928
27296942	91	96	Large	T081	C0549177
27296942	97	104	Sessile	T080	C0205348
27296942	109	118	Laterally	T082	C0205093
27296942	119	128	Spreading	T080	C0332261
27296942	129	147	Colorectal Lesions	T033	C4062636
27296942	151	159	Clinical	T080	C0205210
27296942	160	164	Risk	T078	C0035647
27296942	165	170	Score	T081	C0449820
27296942	171	202	Clinically significant bleeding	T046	C0019080
27296942	204	209	CSPEB	T046	C0019080
27296942	223	231	frequent	T079	C0332183
27296942	232	245	adverse event	T046	C0877248
27296942	256	295	wide-field endoscopic mucosal resection	T061	C1700928
27296942	297	303	WF-EMR	T061	C1700928
27296942	308	313	large	T081	C0549177
27296942	314	321	sessile	T080	C0205348
27296942	326	335	laterally	T082	C0205093
27296942	336	345	spreading	T080	C0332261
27296942	346	364	colorectal lesions	T033	C4062636
27296942	366	369	LSL	T033	C4062636
27296942	409	417	accurate	T080	C0443131
27296942	418	428	prediction	T078	C0681842
27296942	432	437	CSPEB	T046	C0019080
27296942	460	465	score	T081	C0449820
27296942	481	485	risk	T078	C0035647
27296942	489	494	CSPEB	T046	C0019080
27296942	496	500	Data	T078	C1511726
27296942	504	511	patient	T101	C0030705
27296942	516	522	lesion	T033	C0221198
27296942	523	538	characteristics	T080	C1521970
27296942	543	551	outcomes	T080	C0085415
27296942	557	564	WF-EMRs	T061	C1700928
27296942	568	571	LSL	T033	C4062636
27296942	584	602	referral hospitals	T073,T093	C0019994
27296942	608	616	analyzed	T062	C0936012
27296942	622	628	cohort	T098	C0599755
27296942	644	650	random	T080	C0439605
27296942	656	667	equal sized	T080	C0205163
27296942	668	692	training and test groups	T078	C0441833
27296942	694	705	Independent	T078	C0085862
27296942	706	716	predictors	T078	C2698872
27296942	720	725	CSPEB	T046	C0019080
27296942	733	748	training cohort	T098	C0599755
27296942	754	764	identified	T080	C0205396
27296942	768	805	multiple logistic regression analysis	UnknownType	C0681925
27296942	828	832	risk	T078	C0035647
27296942	833	838	score	T081	C0449820
27296942	864	869	score	T081	C0449820
27296942	874	882	assessed	T052	C1516048
27296942	890	901	independent	T078	C0085862
27296942	902	913	test cohort	T098	C0599755
27296942	923	929	months	T079	C0439231
27296942	933	937	June	T079	C3829443
27296942	950	958	patients	T101	C0030705
27296942	970	973	LSL	T033	C4062636
27296942	992	998	WF-EMR	T061	C1700928
27296942	1024	1032	patients	T101	C0030705
27296942	1051	1059	analysis	T062	C0936012
27296942	1076	1081	cases	T077	C1706256
27296942	1085	1090	CSPEB	T046	C0019080
27296942	1106	1121	training cohort	T098	C0599755
27296942	1131	1139	patients	T101	C0030705
27296942	1145	1156	independent	T078	C0085862
27296942	1157	1167	predictors	T078	C2698872
27296942	1171	1176	CSPEB	T046	C0019080
27296942	1182	1193	lesion size	T082	C0449453
27296942	1202	1212	odds ratio	T081	C0028873
27296942	1214	1216	OR	T081	C0028873
27296942	1224	1232	proximal	T082	C0205107
27296942	1233	1249	colonic location	T082	C0450429
27296942	1251	1253	OR	T081	C0028873
27296942	1260	1268	presence	T080	C3854307
27296942	1274	1279	major	T080	C0205164
27296942	1280	1291	comorbidity	T078	C0009488
27296942	1293	1295	OR	T081	C0028873
27296942	1306	1317	epinephrine	T109,T121,T125	C0014563
27296942	1321	1339	injection solution	T122	C0991511
27296942	1341	1343	OR	T081	C0028873
27296942	1363	1367	risk	T078	C0035647
27296942	1368	1373	score	T081	C0449820
27296942	1384	1395	lesion size	T082	C0449453
27296942	1415	1423	proximal	T082	C0205107
27296942	1424	1429	colon	T023	C1281569
27296942	1442	1450	presence	T080	C3854307
27296942	1454	1459	major	T080	C0205164
27296942	1460	1471	comorbidity	T078	C0009488
27296942	1487	1494	absence	T169	C0332197
27296942	1498	1509	epinephrine	T109,T121,T125	C0014563
27296942	1510	1513	use	T169	C0457083
27296942	1529	1542	probabilities	T081	C0033204
27296942	1546	1551	CSPEB	T046	C0019080
27296942	1556	1562	scores	T081	C0449820
27296942	1595	1610	training cohort	T098	C0599755
27296942	1702	1713	test cohort	T098	C0599755
27296942	1719	1732	probabilities	T081	C0033204
27296942	1736	1741	CSPEB	T046	C0019080
27296942	1756	1759	low	T080	C0205251
27296942	1761	1766	score	T081	C0449820
27296942	1773	1779	medium	T081	C0439536
27296942	1781	1786	score	T081	C0449820
27296942	1797	1805	elevated	T080	C3163633
27296942	1807	1812	score	T081	C0449820
27296942	1818	1829	risk levels	T033	C2923839
27296942	1862	1877	training cohort	T098	C0599755
27296942	1909	1915	cohort	T098	C0599755
27296942	1917	1925	Patients	T101	C0030705
27296942	1929	1937	elevated	T080	C3163633
27296942	1938	1942	risk	T078	C0035647
27296942	1946	1951	CSPEB	T046	C0019080
27296942	1959	1969	identified	T080	C0205396
27296942	1999	2008	variables	T080	C0439828
27296942	2041	2051	management	T058	C0376636
27296942	2072	2078	WF-EMR	T061	C1700928
27296942	2093	2110	designing studies	T062	C0035171
27296942	2111	2121	evaluating	T058	C0220825
27296942	2122	2127	CSPEB	T046	C0019080

28300494|t|Three-dimensional morphological characterization of malocclusions with mandibular lateral displacement using cone-beam computed tomography
28300494|a|The purpose of this study was to evaluate the morphologic characteristics of MLD malocclusions using 3D imaging. MLD characteristics were examined using CBCT data in 40 subjects. A 3D Cephalometric analysis was developed to describe the spatial position of the mandible and temporal bones. Vertical dental heights were shorter and the posterior occlusal plane (POP) presented a steeper sagittal inclination on the shifted side (the side of the laterally displaced bony chin) than on the contralateral side. (p < 0.01). The MLD was related to a superiorly inclined POP Cant in the same direction (r = 0.82; p < 0.01). The shifted side condyle was dislocated medially and was smaller. Temporal bone sagittal inclination showed a more forward and medial inclination on the contralateral side (p < 0.01). A unilateral decrease in the vertical height of the dentition and the subsequent steeper occlusal plane inclinations correlated with (1) mandibular rotational displacement and condylar lateral displacement, (2) mandibular and condylar morphologic changes (3) changes in temporal bone position.
28300494	0	17	Three-dimensional	T082	C0450363
28300494	18	31	morphological	T082	C0543482
28300494	32	48	characterization	T052	C1880022
28300494	52	65	malocclusions	T047	C0024636
28300494	71	102	mandibular lateral displacement	T190	C0399554
28300494	109	138	cone-beam computed tomography	T060	C1956110
28300494	159	164	study	T062	C2603343
28300494	185	196	morphologic	T080	C0332437
28300494	197	212	characteristics	T080	C1521970
28300494	216	219	MLD	T190	C0399554
28300494	220	233	malocclusions	T047	C0024636
28300494	240	250	3D imaging	T060	C0887832
28300494	252	255	MLD	T190	C0399554
28300494	256	271	characteristics	T080	C1521970
28300494	292	296	CBCT	T060	C1956110
28300494	297	301	data	T078	C1511726
28300494	308	316	subjects	T098	C0080105
28300494	320	322	3D	T082	C0450363
28300494	323	345	Cephalometric analysis	T060	C0407698
28300494	376	392	spatial position	T082	C0733755
28300494	400	408	mandible	T023	C0024687
28300494	413	427	temporal bones	T023	C0039484
28300494	429	465	Vertical dental heights were shorter	T033	C0243095
28300494	474	498	posterior occlusal plane	T042	C0524544
28300494	500	503	POP	T042	C0524544
28300494	525	545	sagittal inclination	T033	C0243095
28300494	583	612	laterally displaced bony chin	T033	C0243095
28300494	626	644	contralateral side	T082	C0441988
28300494	662	665	MLD	T190	C0399554
28300494	683	702	superiorly inclined	T033	C0243095
28300494	703	711	POP Cant	T201	C4038832
28300494	773	780	condyle	T023	C0524414
28300494	785	795	dislocated	T037	C0012691
28300494	822	835	Temporal bone	T023	C0039484
28300494	836	856	sagittal inclination	T033	C0243095
28300494	883	901	medial inclination	T033	C0243095
28300494	909	927	contralateral side	T082	C0441988
28300494	942	952	unilateral	T082	C0205092
28300494	953	984	decrease in the vertical height	T033	C0243095
28300494	992	1001	dentition	T023	C0011443
28300494	1029	1056	occlusal plane inclinations	T033	C0243095
28300494	1077	1111	mandibular rotational displacement	T190	C0399554
28300494	1116	1124	condylar	T023	C0524414
28300494	1125	1145	lateral displacement	T169	C0333046
28300494	1151	1161	mandibular	T023	C0024687
28300494	1166	1174	condylar	T023	C0524414
28300494	1175	1186	morphologic	T080	C0332437
28300494	1187	1194	changes	T169	C0392747
28300494	1199	1206	changes	T169	C0392747
28300494	1210	1223	temporal bone	T023	C0039484
28300494	1224	1232	position	T082	C0733755

28266884|t|Intestinal micropatches for oral insulin delivery
28266884|a|Diabetes mellitus has become a major public health issue that has almost reached epidemic proportions worldwide. Injectable insulin has been typically utilized for the management of this chronic disease. However, lack of patient compliance with injectable formulations has spurred the development of oral insulin formulations, which although appealing, face several delivery challenges. We have developed novel mucoadhesive intestinal patches, several hundred micrometers in dimension (micropatches) that address the challenges of oral insulin delivery. The micropatches adhere to the intestinal mucosa, release their drug load rapidly within 30 min and are effective in lowering blood glucose levels in vivo. When insulin -loaded micropatches were administered with a permeation enhancer and protease inhibitor, a peak efficacy of 34% drop in blood glucose levels was observed within 3 h. Efficacy further improved to 41% when micropatches were administered in multiple doses. Here, we describe the design of micropatches as an oral insulin formulation and report their in vivo efficacy.
28266884	0	10	Intestinal	T023	C0021853
28266884	11	23	micropatches	T074	C0991556
28266884	28	32	oral	T082	C0442027
28266884	33	49	insulin delivery	T061	C3165280
28266884	50	67	Diabetes mellitus	T047	C0011849
28266884	87	106	public health issue	T078	C1554189
28266884	131	151	epidemic proportions	T169	C0220823
28266884	163	181	Injectable insulin	UnknownType	C0544377
28266884	218	228	management	T058	C0376636
28266884	237	252	chronic disease	T047	C0008679
28266884	263	289	lack of patient compliance	T033	C0376405
28266884	295	305	injectable	T121	C0086466
28266884	306	318	formulations	T077	C1705957
28266884	350	354	oral	T082	C0442027
28266884	355	362	insulin	T116,T121,T125	C0021641
28266884	363	375	formulations	T077	C1705957
28266884	416	424	delivery	T061	C1533734
28266884	425	435	challenges	T058	C0805586
28266884	461	473	mucoadhesive	T073	C0001516
28266884	474	484	intestinal	T023	C0021853
28266884	485	492	patches	T074	C0991556
28266884	510	521	micrometers	T081	C0439201
28266884	525	534	dimension	T081	C0439534
28266884	536	548	micropatches	T074	C0991556
28266884	567	577	challenges	T058	C0805586
28266884	581	585	oral	T082	C0442027
28266884	586	602	insulin delivery	T061	C3165280
28266884	608	620	micropatches	T074	C0991556
28266884	621	627	adhere	T067	C3714578
28266884	635	652	intestinal mucosa	T024	C0021839
28266884	668	672	drug	T121	C1254351
28266884	678	685	rapidly	T080	C0456962
28266884	708	717	effective	T080	C1704419
28266884	721	750	lowering blood glucose levels	T033	C0595883
28266884	751	758	in vivo	T082	C1515655
28266884	765	772	insulin	T116,T121,T125	C0021641
28266884	781	793	micropatches	T074	C0991556
28266884	799	811	administered	T061	C1533734
28266884	819	838	permeation enhancer	T121	C1254351
28266884	843	861	protease inhibitor	T121	C0033607
28266884	865	869	peak	T080	C0444505
28266884	870	878	efficacy	T080	C1280519
28266884	886	914	drop in blood glucose levels	T033	C0595883
28266884	940	948	Efficacy	T080	C1280519
28266884	978	990	micropatches	T074	C0991556
28266884	996	1008	administered	T061	C1533734
28266884	1012	1026	multiple doses	T201	C1960418
28266884	1060	1072	micropatches	T074	C0991556
28266884	1079	1083	oral	T082	C0442027
28266884	1084	1091	insulin	T116,T121,T125	C0021641
28266884	1092	1103	formulation	T077	C1705957
28266884	1121	1128	in vivo	T082	C1515655
28266884	1129	1137	efficacy	T080	C1280519

27500262|t|Well, I Wouldn't be Any Worse Off, Would I, Than I am Now? A Qualitative Study of Decision-Making, Hopes, and Realities of Adults With Type 1 Diabetes Undergoing Islet Cell Transplantation
27500262|a|For selected individuals with type 1 diabetes, pancreatic islet transplantation (IT) prevents recurrent severe hypoglycemia and optimizes glycemia, although ongoing systemic immunosuppression is needed. Our aim was to explore candidates and recipients ' expectations of transplantation, their experience of being on the waiting list, and (for recipients) the procedure and life posttransplant. Cross-sectional qualitative research design using semistructured interviews with 16 adults (8 pretransplant, 8 posttransplant; from 4 UK centers (n = 13) and 1 Canadian center (n = 3)). Interviews were audio-recorded, transcribed, and underwent inductive thematic analysis. Interviewees were aged (mean ± SD) 52 ± 10 years (range, 30-64); duration of diabetes, 36 ± 9 years (range, 21-56); 12 (75%) were women. Narrative accounts centered on expectations, hopes, and realities; decision-making; waiting and uncertainty; the procedure, hospital stay, and follow-up. Expected benefits included fewer severe hypoglycemic episodes, reduced need for insulin, preventing onset/progression of complications and improved psychological well-being. These were realized for most, at least in the short term. Most interviewees described well-informed, shared decision-making with clinicians and family, and managing their expectations. Although life "on the list" could be stressful, and immunosuppressant side effects were severe, interviewees reported " no regrets ." Posttransplant, interviewees experienced increased confidence, through freedom from hypoglycemia and regained glycemic control, which tempered any disappointment about continued reliance on insulin. Most viewed their transplant as a success, though several reflected upon setbacks and hidden hopes for becoming " insulin-free ." Independently undertaken interviews demonstrated realistic and balanced expectations of IT and indicate how to optimize the process and support for future IT candidates.
27500262	61	78	Qualitative Study	T062	C0949415
27500262	82	97	Decision-Making	T041	C0011109
27500262	99	104	Hopes	T041	C0392347
27500262	110	119	Realities	T078	C0871222
27500262	123	129	Adults	T100	C0001675
27500262	135	150	Type 1 Diabetes	T047	C0011854
27500262	162	188	Islet Cell Transplantation	T061	C0079646
27500262	202	213	individuals	T098	C0237401
27500262	219	234	type 1 diabetes	T047	C0011854
27500262	236	268	pancreatic islet transplantation	T061	C0079646
27500262	270	272	IT	T061	C0079646
27500262	300	312	hypoglycemia	T047	C0020615
27500262	317	335	optimizes glycemia	T061	C3267174
27500262	354	380	systemic immunosuppression	T061	C0021079
27500262	415	425	candidates	T098	C1257890
27500262	430	440	recipients	T101	C0376387
27500262	459	474	transplantation	T061	C0040732
27500262	509	521	waiting list	T033	C0586018
27500262	532	542	recipients	T101	C0376387
27500262	567	581	posttransplant	T079	C1254367
27500262	599	610	qualitative	T080	C0205556
27500262	611	626	research design	T062	C0035171
27500262	648	658	interviews	T058	C0683518
27500262	667	673	adults	T100	C0001675
27500262	677	690	pretransplant	T079	C1254367
27500262	694	708	posttransplant	T079	C1254367
27500262	717	719	UK	T083	C0041700
27500262	720	727	centers	T073,T093	C0475309
27500262	743	751	Canadian	T083	C0006823
27500262	752	758	center	T073,T093	C0475309
27500262	769	779	Interviews	T058	C0683518
27500262	785	799	audio-recorded	T058	C2316646
27500262	828	855	inductive thematic analysis	T062	C0936012
27500262	857	869	Interviewees	T098	C0489844
27500262	900	905	years	T079	C0439234
27500262	922	930	duration	T079	C0449238
27500262	934	942	diabetes	T047	C0011847
27500262	951	956	years	T079	C0439234
27500262	987	992	women	T098	C0043210
27500262	1025	1037	expectations	T078	C0679138
27500262	1039	1044	hopes	T041	C0392347
27500262	1050	1059	realities	T078	C0871222
27500262	1061	1076	decision-making	T041	C0011109
27500262	1118	1131	hospital stay	T079	C3489408
27500262	1137	1146	follow-up	T058	C1522577
27500262	1188	1209	hypoglycemic episodes	T047	C0745153
27500262	1211	1218	reduced	T080	C0392756
27500262	1228	1235	insulin	T116,T121,T125	C0021641
27500262	1269	1282	complications	T046	C0009566
27500262	1296	1320	psychological well-being	T033	C0424578
27500262	1385	1397	interviewees	T098	C0489844
27500262	1430	1445	decision-making	T041	C0011109
27500262	1451	1461	clinicians	T097	C0871685
27500262	1466	1472	family	T099	C0015576
27500262	1544	1553	stressful	T169	C0231297
27500262	1559	1576	immunosuppressant	T121,T129	C0021081
27500262	1577	1589	side effects	T046	C0879626
27500262	1595	1601	severe	T080	C0205082
27500262	1603	1615	interviewees	T098	C0489844
27500262	1627	1629	no	T033	C1513916
27500262	1630	1637	regrets	T041	C0080101
27500262	1641	1655	Posttransplant	T079	C1254367
27500262	1657	1669	interviewees	T098	C0489844
27500262	1692	1702	confidence	T041	C0237529
27500262	1712	1737	freedom from hypoglycemia	T033	C0243095
27500262	1751	1767	glycemic control	T061	C3267174
27500262	1831	1838	insulin	T116,T121,T125	C0021641
27500262	1858	1868	transplant	T061	C0040732
27500262	1933	1938	hopes	T041	C0392347
27500262	1954	1966	insulin-free	T033	C0243095
27500262	1995	2005	interviews	T058	C0683518
27500262	2058	2060	IT	T061	C0079646
27500262	2125	2127	IT	T061	C0079646
27500262	2128	2138	candidates	T098	C1257890

27503306|t|Preclinical fibrinolysis in patients with ST-segment elevation myocardial infarction in a rural region
27503306|a|In the current guidelines for the treatment of patients with ST-segment elevation myocardial infarction (STEMI), the European Society of Cardiology (ESC) recommends preclinical fibrinolysis as a reperfusion therapy if, due to long transportation times, no cardiac catheterisation is available within 90-120 min. However, there is little remaining in-depth expertise in this method because fibrinolysis is presently only rarely indicated. In a rural area in southwestern Germany, where an emergency primary percutaneous coronary intervention was not routinely available within 90-120 min, 156 STEMI patients underwent fibrinolysis with the plasminogen activator reteplase, performed by trained emergency physicians. The practicality of the treatment, as well as complications and the mortality of the patients in the preclinical phase until arrival at the hospital, were retrospectively studied. The mean time from onset of the symptoms to first medical contact was 114 ± 116 min. The mean interval to the start of fibrinolysis of 13.5 ± 6.4 min was within the 30 min mandated by the ESC. Patients with inferior STEMI represented the largest subgroup. Occurring in 39 cases (25 %), complications due to infarction were relatively common during the prehospital phase, including 15 cases (9.6 %) of cardiogenic shock, but in all cases the complications were manageable. No patient died before arrival at the hospital. As lysis - associated adverse effects, merely two uncomplicated mucosal haemorrhages and one case of mild allergic skin reactions were seen. In emergency situations with long transportation times to the nearest suitable cardiac catheterisation laboratory, preclinical fibrinolysis in STEMI still represents a workable method. Success of this strategy requires particularly strong training of the emergency physicians in ECG and lysis therapy, and co-operation with nearby cardiac centres.
27503306	0	11	Preclinical	T080	C1709630
27503306	12	24	fibrinolysis	T039	C0016017
27503306	28	36	patients	T101	C0030705
27503306	42	84	ST-segment elevation myocardial infarction	T047	C1536220
27503306	90	102	rural region	T082	C0178837
27503306	110	128	current guidelines	T170	C4291682
27503306	137	146	treatment	T061	C0087111
27503306	150	158	patients	T101	C0030705
27503306	164	206	ST-segment elevation myocardial infarction	T047	C1536220
27503306	208	213	STEMI	T047	C1536220
27503306	257	267	recommends	T078	C0034866
27503306	268	279	preclinical	T080	C1709630
27503306	280	292	fibrinolysis	T039	C0016017
27503306	298	317	reperfusion therapy	T061	C0035124
27503306	334	348	transportation	T078	C1554194
27503306	349	354	times	T079	C0040223
27503306	359	382	cardiac catheterisation	T058	C0018795
27503306	386	395	available	T169	C0470187
27503306	410	413	min	T079	C0439232
27503306	440	449	remaining	T080	C1527428
27503306	459	468	expertise	T080	C0870520
27503306	477	483	method	T169	C0449851
27503306	492	504	fibrinolysis	T039	C0016017
27503306	508	517	presently	T078	C0750528
27503306	523	529	rarely	T080	C0522498
27503306	530	539	indicated	T033	C1444656
27503306	546	556	rural area	T082	C0178837
27503306	560	572	southwestern	T082	C1710136
27503306	573	580	Germany	T083	C0017480
27503306	591	643	emergency primary percutaneous coronary intervention	T061	C1532297
27503306	652	661	routinely	T080	C0205547
27503306	662	671	available	T169	C0470187
27503306	686	689	min	T079	C0439232
27503306	695	700	STEMI	T047	C1536220
27503306	701	709	patients	T101	C0030705
27503306	720	732	fibrinolysis	T039	C0016017
27503306	742	773	plasminogen activator reteplase	T116,T121,T126	C0256103
27503306	775	787	performed by	T080	C1550369
27503306	796	805	emergency	T067	C0013956
27503306	806	816	physicians	T097	C0031831
27503306	822	834	practicality	T080	C0205556
27503306	842	851	treatment	T061	C0087111
27503306	864	877	complications	T046	C0009566
27503306	886	895	mortality	T081	C0205848
27503306	903	911	patients	T101	C0030705
27503306	919	930	preclinical	T080	C1709630
27503306	931	936	phase	T079	C0205390
27503306	943	950	arrival	T052	C1706079
27503306	958	966	hospital	T073,T093	C0019994
27503306	973	996	retrospectively studied	T062	C0035363
27503306	1002	1011	mean time	T079	C0040223
27503306	1017	1025	onset of	T080	C0332162
27503306	1030	1038	symptoms	T184	C1457887
27503306	1048	1063	medical contact	T058	C0582446
27503306	1078	1081	min	T079	C0439232
27503306	1087	1100	mean interval	T079	C1272706
27503306	1108	1113	start	T079	C0439659
27503306	1117	1129	fibrinolysis	T039	C0016017
27503306	1144	1147	min	T079	C0439232
27503306	1166	1169	min	T079	C0439232
27503306	1170	1178	mandated	T089	C0520248
27503306	1191	1199	Patients	T101	C0030705
27503306	1205	1219	inferior STEMI	T047	C2882099
27503306	1220	1231	represented	T052	C1882932
27503306	1236	1243	largest	T081	C0443228
27503306	1244	1252	subgroup	T185	C1515021
27503306	1270	1275	cases	T096	C0681850
27503306	1284	1297	complications	T046	C0009566
27503306	1305	1315	infarction	T046	C0021308
27503306	1332	1338	common	T081	C0205214
27503306	1350	1361	prehospital	T058	C2735050
27503306	1362	1367	phase	T079	C0205390
27503306	1382	1387	cases	T096	C0681850
27503306	1399	1416	cardiogenic shock	T046	C0036980
27503306	1429	1434	cases	T096	C0681850
27503306	1439	1452	complications	T046	C0009566
27503306	1458	1468	manageable	T033	C0243095
27503306	1473	1480	patient	T101	C0030705
27503306	1481	1485	died	T033	C1306577
27503306	1493	1500	arrival	T052	C1706079
27503306	1508	1516	hospital	T073,T093	C0019994
27503306	1521	1526	lysis	T046	C0024348
27503306	1529	1539	associated	T080	C0332281
27503306	1540	1555	adverse effects	T046	C0879626
27503306	1568	1581	uncomplicated	T080	C0443334
27503306	1582	1602	mucosal haemorrhages	T184	C0854375
27503306	1619	1647	mild allergic skin reactions	T047	C0863090
27503306	1653	1657	seen	T080	C0205397
27503306	1662	1682	emergency situations	T067	C0013956
27503306	1693	1707	transportation	T078	C1554194
27503306	1708	1713	times	T079	C0040223
27503306	1729	1737	suitable	T080	C3900053
27503306	1738	1761	cardiac catheterisation	T058	C0018795
27503306	1762	1772	laboratory	T073,T093	C0022877
27503306	1774	1785	preclinical	T080	C1709630
27503306	1786	1798	fibrinolysis	T039	C0016017
27503306	1802	1807	STEMI	T047	C1536220
27503306	1827	1842	workable method	T169	C0449851
27503306	1844	1851	Success	T054	C0597535
27503306	1860	1868	strategy	T041	C0679199
27503306	1891	1906	strong training	T065	C0220931
27503306	1914	1923	emergency	T067	C0013956
27503306	1924	1934	physicians	T097	C0031831
27503306	1938	1941	ECG	T060	C1623258
27503306	1946	1951	lysis	T046	C0024348
27503306	1952	1959	therapy	T061	C0087111
27503306	1965	1977	co-operation	T054	C0392337
27503306	1990	2005	cardiac centres	T073,T093	C0475309

27794068|t|C4b binding protein negatively regulates TLR1 / 2 response
27794068|a|TLR2 associates with TLR1 and recognizes microbial lipoproteins. Pam3CSK4, a triacylated lipoprotein, is anchored to the extracellular domain of TLR1 and TLR2 and induces pro-inflammatory signals. Here we show that C4b binding protein (C4BP), which is a complement pathway inhibitor, is a TLR2 -associated molecule. Immunoprecipitation assay using anti-TLR2 mAb shows that C4BP binds to TLR2. In C4BP-deficient mice, Pam3CSK4 - induced IL-6 levels were increased compared with wild type mice. In C4BP - expressing cells, Pam3CSK4 - induced IL-8 production was reduced depending on the C4BP expression levels. These results reveal the important role of C4BP in negative regulation of TLR1 / 2 - dependent pro-inflammatory cytokine production. Furthermore, using a fluorescent conjugated Pam3CSK4, we show that C4BP blocks the binding of Pam3CSK4 to TLR1 / 2. Finally, we show that exogenous C4BP also inhibits Pam3CSK4 - induced signaling leading to IL-8 production. Our results indicate C4BP binding to TLR2 and consequent neutralization of its activity otherwise inducing pro-inflammatory cytokine production. C4BP is a negative regulator of TLR1 / 2 activity.
27794068	0	19	C4b binding protein	T116,T129	C0056193
27794068	20	40	negatively regulates	T044	C0013081
27794068	41	45	TLR1	T116,T192	C0971363
27794068	48	49	2	T116,T192	C0754728
27794068	50	58	response	T032	C0871261
27794068	59	63	TLR2	T116,T192	C0754728
27794068	64	79	associates with	T080	C0332281
27794068	80	84	TLR1	T116,T192	C0971363
27794068	100	109	microbial	T001	C0599840
27794068	110	122	lipoproteins	T116,T123	C0023820
27794068	124	132	Pam3CSK4	T116,T123	C1698795
27794068	136	159	triacylated lipoprotein	T116,T123	C0023820
27794068	164	172	anchored	T044	C1624581
27794068	180	200	extracellular domain	T082	C1517050
27794068	204	208	TLR1	T116,T192	C0971363
27794068	213	217	TLR2	T116,T192	C0754728
27794068	222	229	induces	T169	C0205263
27794068	230	246	pro-inflammatory	T046	C0021368
27794068	247	254	signals	T038	C3537152
27794068	274	293	C4b binding protein	T116,T129	C0056193
27794068	295	299	C4BP	T116,T129	C0056193
27794068	313	331	complement pathway	T044	C1305430
27794068	332	341	inhibitor	T080	C1999216
27794068	348	352	TLR2	T116,T192	C0754728
27794068	375	400	Immunoprecipitation assay	T059	C0021069
27794068	407	420	anti-TLR2 mAb	T129	C0021054
27794068	432	436	C4BP	T116,T129	C0056193
27794068	437	445	binds to	T044	C1167622
27794068	446	450	TLR2	T116,T192	C0754728
27794068	455	469	C4BP-deficient	T028	C1413001
27794068	470	474	mice	T015	C0206745
27794068	476	484	Pam3CSK4	T116,T123	C1698795
27794068	487	494	induced	T169	C0205263
27794068	495	499	IL-6	T116,T129	C0021760
27794068	500	506	levels	T080	C0441889
27794068	512	521	increased	T081	C0205217
27794068	522	530	compared	T052	C1707455
27794068	536	550	wild type mice	T015	C0025929
27794068	555	559	C4BP	T116,T129	C0056193
27794068	562	572	expressing	T045	C1171362
27794068	573	578	cells	T025	C0007634
27794068	580	588	Pam3CSK4	T116,T123	C1698795
27794068	591	598	induced	T169	C0205263
27794068	599	614	IL-8 production	T040	C1819461
27794068	619	626	reduced	T080	C0392756
27794068	644	648	C4BP	T116,T129	C0056193
27794068	649	666	expression levels	T081	C3244092
27794068	682	688	reveal	T080	C0443289
27794068	711	715	C4BP	T116,T129	C0056193
27794068	719	738	negative regulation	T044	C0013081
27794068	742	746	TLR1	T116,T192	C0971363
27794068	749	750	2	T116,T192	C0754728
27794068	753	762	dependent	T116,T129	C0079189
27794068	763	779	pro-inflammatory	T046	C0021368
27794068	780	799	cytokine production	T040	C1327413
27794068	822	844	fluorescent conjugated	T130	C0016321
27794068	845	853	Pam3CSK4	T116,T123	C1698795
27794068	868	872	C4BP	T116,T129	C0056193
27794068	873	879	blocks	T169	C0332206
27794068	884	894	binding of	T044	C1167622
27794068	895	903	Pam3CSK4	T116,T123	C1698795
27794068	907	911	TLR1	T116,T192	C0971363
27794068	914	915	2	T116,T192	C0754728
27794068	939	948	exogenous	T169	C0205228
27794068	949	953	C4BP	T116,T129	C0056193
27794068	959	967	inhibits	T052	C3463820
27794068	968	976	Pam3CSK4	T116,T123	C1698795
27794068	979	996	induced signaling	T044	C1511122
27794068	1008	1023	IL-8 production	T040	C1819461
27794068	1046	1050	C4BP	T116,T129	C0056193
27794068	1051	1061	binding to	T044	C1167622
27794068	1062	1066	TLR2	T116,T192	C0754728
27794068	1071	1081	consequent	T033	C3845876
27794068	1082	1096	neutralization	T169	C2987668
27794068	1104	1112	activity	T044	C1152633
27794068	1132	1148	pro-inflammatory	T046	C0021368
27794068	1149	1168	cytokine production	T040	C1327413
27794068	1170	1174	C4BP	T116,T129	C0056193
27794068	1180	1198	negative regulator	T044	C0013081
27794068	1202	1206	TLR1	T116,T192	C0971363
27794068	1209	1210	2	T116,T192	C0754728
27794068	1211	1219	activity	T044	C1152633

28296885|t|Oral health in transition: The Hadza foragers of Tanzania
28296885|a|Conventional wisdom holds that a decline in oral health accompanies the transition from hunting and gathering to agriculture, given increased consumption of carbohydrates. This widely touted example of the mismatch between our biology and modern lifestyle has been intuited largely from the bioarchaeological record of the Neolithic Revolution in the New World. Recent studies of other populations have, however, challenged the universality of this assertion. Here, we present the first comprehensive study of oral health among a living population in transition from the bush to village life, the Hadza hunter - gatherers of Tanzania, to test the hypothesis that the shift from foraging to farming, or agricultural intensification, inevitably leads to increased periodontal disease, caries, and orthodontic disorders. Our results showed that women living in villages consuming a mostly agricultural diet exhibited more caries and periodontal disease than those living in the bush consuming a mostly wild-food diet. Furthermore, men living in the bush consuming mostly a wild-food diet had more than those living in the village consuming a mostly agricultural diet. These findings are explained by the high incidence of maize consumption in village settings, along with previously recognized variation in rate of caries between men and women. The unexpected discovery of high caries incidences for men in the bush is likely explained by heavy reliance on honey, and perhaps differential access to tobacco and marijuana. These data support the notions that mechanisms of cariogenesis are multifactorial and that the relationships between oral health and the shift from a predominantly wild-food diet to one dominated by cultigens are nuanced.
28296885	0	11	Oral health	T058	C0029162
28296885	15	25	transition	T052	C2700061
28296885	31	45	Hadza foragers	T098	C1257890
28296885	49	57	Tanzania	T083	C0039298
28296885	58	70	Conventional	T080	C0439858
28296885	91	98	decline	T081	C0547047
28296885	102	113	oral health	T058	C0029162
28296885	130	140	transition	T052	C2700061
28296885	146	153	hunting	T056	C4255216
28296885	158	167	gathering	T056	C2371489
28296885	171	182	agriculture	T090	C0001829
28296885	190	199	increased	T081	C0205217
28296885	200	211	consumption	T039	C1947907
28296885	215	228	carbohydrates	T109	C0012170
28296885	249	256	example	T077	C1707959
28296885	264	272	mismatch	T080	C1881865
28296885	285	292	biology	T091	C0005532
28296885	297	313	modern lifestyle	T054	C0023676
28296885	349	373	bioarchaeological record	T170	C0034869
28296885	381	401	Neolithic Revolution	T109,T121	C2948499
28296885	409	418	New World	T098	C2700280
28296885	427	434	studies	T062	C2603343
28296885	444	455	populations	T081	C0032659
28296885	507	516	assertion	T080	C1301625
28296885	545	558	comprehensive	T080	C1880156
28296885	559	564	study	T062	C2603343
28296885	568	579	oral health	T058	C0029162
28296885	588	605	living population	T098	C1257890
28296885	609	619	transition	T052	C2700061
28296885	629	633	bush	T002	C0330099
28296885	637	649	village life	T054	C0023676
28296885	655	660	Hadza	T098	C1257890
28296885	661	667	hunter	T097	C0239971
28296885	670	679	gatherers	T098	C1257890
28296885	683	691	Tanzania	T083	C0039298
28296885	705	715	hypothesis	T078	C1512571
28296885	725	730	shift	T052	C2700061
28296885	736	744	foraging	T055	C2752984
28296885	748	755	farming	T090	C0001829
28296885	760	788	agricultural intensification	T090	C0001827
28296885	810	819	increased	T081	C0205217
28296885	820	839	periodontal disease	T047	C0031090
28296885	841	847	caries	T047	C0011334
28296885	853	864	orthodontic	T169	C0332276
28296885	865	874	disorders	T047	C0012634
28296885	880	887	results	T169	C1274040
28296885	900	905	women	T098	C0043210
28296885	906	912	living	T080	C0337645
28296885	916	924	villages	T083	C0562518
28296885	925	934	consuming	T039	C1947907
28296885	944	956	agricultural	T002	C0242775
28296885	957	961	diet	T168	C0012155
28296885	977	983	caries	T047	C0011334
28296885	988	1007	periodontal disease	T047	C0031090
28296885	1019	1025	living	T080	C0337645
28296885	1033	1037	bush	T002	C0330099
28296885	1038	1047	consuming	T039	C1947907
28296885	1057	1071	wild-food diet	T168	C0012155
28296885	1086	1089	men	T098	C0025266
28296885	1090	1096	living	T080	C0337645
28296885	1104	1108	bush	T002	C0330099
28296885	1109	1118	consuming	T039	C1947907
28296885	1128	1142	wild-food diet	T168	C0012155
28296885	1163	1169	living	T080	C0337645
28296885	1177	1184	village	T083	C0562518
28296885	1185	1194	consuming	T039	C1947907
28296885	1204	1216	agricultural	T002	C0242775
28296885	1217	1221	diet	T168	C0012155
28296885	1229	1237	findings	T033	C0243095
28296885	1259	1263	high	T080	C0205250
28296885	1264	1273	incidence	T081	C0021149
28296885	1277	1282	maize	T168	C1138842
28296885	1283	1294	consumption	T039	C1947907
28296885	1298	1305	village	T083	C0562518
28296885	1349	1358	variation	T080	C0205419
28296885	1362	1366	rate	T081	C1521828
28296885	1370	1376	caries	T047	C0011334
28296885	1385	1388	men	T098	C0025266
28296885	1393	1398	women	T098	C0043210
28296885	1428	1432	high	T080	C0205250
28296885	1433	1439	caries	T047	C0011334
28296885	1440	1450	incidences	T081	C0021149
28296885	1455	1458	men	T098	C0025266
28296885	1466	1470	bush	T002	C0330099
28296885	1512	1517	honey	T168	C0019906
28296885	1554	1561	tobacco	T167	C0008038
28296885	1566	1576	marijuana.	T109,T121	C0024808
28296885	1583	1587	data	T078	C1511726
28296885	1613	1623	mechanisms	T169	C0441712
28296885	1627	1639	cariogenesis	T047	C0011334
28296885	1644	1658	multifactorial	T033	C1837655
28296885	1672	1685	relationships	T080	C0439849
28296885	1694	1705	oral health	T058	C0029162
28296885	1714	1719	shift	T052	C2700061
28296885	1741	1755	wild-food diet	T168	C0012155
28296885	1776	1785	cultigens	T002	C0242775

27608180|t|A Bayesian Network-Based Approach to Selection of Intervention Points in the Mitogen-Activated Protein Kinase Plant Defense Response Pathway
27608180|a|An important problem in computational biology is the identification of potential points of intervention that can lead to modified network behavior in a genetic regulatory network. We consider the problem of deducing the effect of individual genes on the behavior of the network in a statistical framework. In this article, we make use of biological information from the literature to develop a Bayesian network and introduce a method to estimate parameters of this network using data that are relevant to the biological phenomena under study. Then, we give a novel approach to select significant nodes in the network using a decision-theoretic approach. The proposed method is applied to the analysis of the mitogen-activated protein kinase pathway in the plant defense response to pathogens. Results from applying the method to experimental data show that the proposed approach is effective in selecting genes that play crucial roles in the biological phenomenon being studied.
27608180	2	33	Bayesian Network-Based Approach	T081	C0242198
27608180	37	46	Selection	T052	C1707391
27608180	50	62	Intervention	T052	C3266814
27608180	77	109	Mitogen-Activated Protein Kinase	T116,T126	C0752312
27608180	110	115	Plant	T002	C0032098
27608180	116	132	Defense Response	T040	C1154988
27608180	133	140	Pathway	T044	C0037080
27608180	154	161	problem	T033	C0033213
27608180	165	186	computational biology	T091	C0376528
27608180	194	208	identification	T080	C0205396
27608180	232	244	intervention	T052	C3266814
27608180	262	270	modified	T169	C0392747
27608180	271	278	network	T044	C1720950
27608180	293	319	genetic regulatory network	T044	C1720950
27608180	337	344	problem	T033	C0033213
27608180	361	367	effect	T080	C1280500
27608180	382	387	genes	T028	C0017337
27608180	411	418	network	T044	C1720950
27608180	424	445	statistical framework	T062	C0242481
27608180	455	462	article	T170	C0282420
27608180	479	489	biological	T080	C0205460
27608180	490	501	information	T078	C1533716
27608180	511	521	literature	T170	C0023866
27608180	535	551	Bayesian network	T081	C0242198
27608180	556	565	introduce	T169	C1292748
27608180	568	574	method	T170	C0025663
27608180	587	597	parameters	T033	C0449381
27608180	606	613	network	T044	C1720950
27608180	620	624	data	T078	C1511726
27608180	634	642	relevant	T080	C2347946
27608180	650	670	biological phenomena	T070	C0005520
27608180	677	682	study	T062	C2603343
27608180	700	705	novel	T080	C0205314
27608180	706	714	approach	T078	C1254370
27608180	725	736	significant	T078	C0750502
27608180	750	757	network	T044	C1720950
27608180	766	793	decision-theoretic approach	T170	C0011114
27608180	808	814	method	T170	C0025663
27608180	833	841	analysis	T062	C0936012
27608180	849	889	mitogen-activated protein kinase pathway	T043	C1518102
27608180	897	902	plant	T002	C0032098
27608180	903	919	defense response	T040	C1154988
27608180	923	932	pathogens	T001	C0450254
27608180	934	941	Results	T169	C1274040
27608180	960	966	method	T170	C0025663
27608180	970	982	experimental	T080	C1517586
27608180	983	987	data	T078	C1511726
27608180	1002	1019	proposed approach	T078	C1254370
27608180	1023	1032	effective	T080	C1704419
27608180	1036	1045	selecting	T052	C1707391
27608180	1046	1051	genes	T028	C0017337
27608180	1070	1075	roles	T077	C1705810
27608180	1083	1104	biological phenomenon	T070	C0005520

28269034|t|Neural correlates to automatic behavior estimations from RGB-D video in epilepsy unit
28269034|a|To augment neural monitoring, a minimally intrusive multi-modal capture system was designed and implemented in the epilepsy clinic. This system provides RGB-D audio-video synchronized with patient electrocorticography (ECoG), which records neural activity across cortex. We propose an automated approach to studying the human brain in a naturalistic setting. We demonstrate coarse functional mapping of ECoG electrodes correlated to contralateral arm movements. Motor electrode mapping was generated by analyzing continuous movement data recorded over several hours from epilepsy patients in hospital rooms. From these recordings we estimate the kinematics of patient hand movement behaviors using computer vision algorithms. We compare movement behaviors to neural data collected from ECoG, specifically high-γ (70-110 Hz) spectral features. We present a functional map of electrode responses to natural arm movements, generated using a statistical test. We demonstrate that our approach has the potential to aid in the development of automated functional brain mapping using continuous video and neural recordings of patients in clinical settings.
28269034	0	6	Neural	T025	C0027882
28269034	21	39	automatic behavior	T033	C0004377
28269034	57	68	RGB-D video	T170	C0150098
28269034	72	85	epilepsy unit	T073,T093	C1552757
28269034	97	114	neural monitoring	T061	C0513538
28269034	118	164	minimally intrusive multi-modal capture system	T060	C1513743
28269034	201	216	epilepsy clinic	T073,T093	C1552757
28269034	239	244	RGB-D	T170	C0150098
28269034	245	269	audio-video synchronized	T079	C0439580
28269034	275	282	patient	T101	C0030705
28269034	283	303	electrocorticography	T060	C0013805
28269034	305	309	ECoG	T060	C0013805
28269034	326	341	neural activity	T039	C0700630
28269034	342	355	across cortex	T023	C0007776
28269034	406	417	human brain	T023	C0006104
28269034	423	443	naturalistic setting	T062	C0935561
28269034	460	485	coarse functional mapping	T060	C1742736
28269034	489	493	ECoG	T060	C0013805
28269034	494	504	electrodes	T074	C0013812
28269034	519	532	contralateral	T082	C0441988
28269034	533	546	arm movements	T033	C0243095
28269034	548	571	Motor electrode mapping	T060	C1742736
28269034	589	623	analyzing continuous movement data	T078	C1511726
28269034	657	665	epilepsy	T047	C0014544
28269034	666	674	patients	T101	C0030705
28269034	678	692	hospital rooms	T073,T093	C0019994
28269034	705	715	recordings	T058	C0557070
28269034	732	742	kinematics	T091	C0600169
28269034	746	753	patient	T101	C0030705
28269034	754	777	hand movement behaviors	T033	C0575809
28269034	784	810	computer vision algorithms	T170	C0002045
28269034	823	841	movement behaviors	T053	C0004927
28269034	845	856	neural data	T078	C1511726
28269034	872	876	ECoG	T060	C0013805
28269034	942	979	functional map of electrode responses	T060	C1742736
28269034	983	1004	natural arm movements	T033	C0243095
28269034	1024	1040	statistical test	T170	C0237913
28269034	1122	1156	automated functional brain mapping	T060	C1742736
28269034	1174	1201	video and neural recordings	T170	C0282574
28269034	1205	1213	patients	T101	C0030705
28269034	1217	1234	clinical settings	T082	C3176918

28547383|t|Complete nucleotide sequence of a highly divergent cherry -associated luteovirus (ChALV) isolate from peach in South Korea
28547383|a|We determined the complete genome sequence of a highly divergent South Korean (SK) isolate of a cherry -associated luteovirus (ChALV) from peach. The ChALV - SK genome consists of 5,815 nucleotides, and contains five open reading frames (ORFs). A comparative analysis of the full genome showed only 73.1% nucleotide sequence identity with a recently described ChALV from the Czech Republic (CZ). Amino acid similarities of the individual ORFs between ChALV - SK and other luteoviruses range from 17.3 to 92%, which places the new isolate close to the species demarcation value for luteoviruses. Results show our ChALV - SK isolate to be highly diverged from the ChALV - CZ isolate.
28547383	0	8	Complete	T080	C0205197
28547383	9	28	nucleotide sequence	T086	C0004793
28547383	34	50	highly divergent	T080	C1705242
28547383	51	57	cherry	T002	C0330657
28547383	70	80	luteovirus	T005	C0206264
28547383	82	87	ChALV	T005	C0206264
28547383	89	96	isolate	T123	C1764827
28547383	102	107	peach	T002	C0330659
28547383	111	122	South Korea	T083	C0022773
28547383	141	149	complete	T080	C0205197
28547383	150	165	genome sequence	T085	C2348746
28547383	171	187	highly divergent	T080	C1705242
28547383	188	200	South Korean	T083	C0022773
28547383	202	204	SK	T083	C0022773
28547383	206	213	isolate	T123	C1764827
28547383	219	225	cherry	T002	C0330657
28547383	238	248	luteovirus	T005	C0206264
28547383	250	255	ChALV	T005	C0206264
28547383	262	267	peach	T002	C0330659
28547383	273	278	ChALV	T005	C0206264
28547383	281	283	SK	T083	C0022773
28547383	284	290	genome	T028	C0042720
28547383	284	290	genome	T028	C0042720
28547383	309	320	nucleotides	T114	C0028630
28547383	340	359	open reading frames	T028	C0079941
28547383	361	365	ORFs	T028	C0079941
28547383	370	390	comparative analysis	T063	C0796358
28547383	403	409	genome	T028	C0042720
28547383	428	447	nucleotide sequence	T086	C0004793
28547383	483	488	ChALV	T005	C0206264
28547383	498	512	Czech Republic	T083	C0206578
28547383	514	516	CZ	T083	C0206578
28547383	514	516	CZ	T083	C0206578
28547383	519	529	Amino acid	T116,T121,T123	C0002520
28547383	530	542	similarities	T081	C1710052
28547383	561	565	ORFs	T028	C0079941
28547383	574	579	ChALV	T005	C0206264
28547383	582	584	SK	T083	C0022773
28547383	595	607	luteoviruses	T005	C0206264
28547383	653	660	isolate	T123	C1764827
28547383	674	681	species	T185	C1705920
28547383	682	699	demarcation value	T033	C0243095
28547383	704	716	luteoviruses	T005	C0206264
28547383	735	740	ChALV	T005	C0206264
28547383	743	745	SK	T083	C0022773
28547383	746	753	isolate	T123	C1764827
28547383	760	775	highly diverged	T080	C1705242
28547383	785	790	ChALV	T005	C0206264
28547383	793	795	CZ	T083	C0206578
28547383	796	803	isolate	T123	C1764827

27896781|t|Multiplex Biomarker Approaches to Enable Point-of-Care Testing and Personalized Medicine
27896781|a|This chapter describes how current and future innovations driven by application of multiplex biomarker techniques can help in earlier and more efficacious treatment of patients, suffering from the world's most devastating and costly diseases. The application of new miniaturized biosensors and transducers will enable point-of-care testing by facilitating analysis of a single drop of a blood within the time span of a visit to the doctor's office. It is anticipated that the scoring algorithms used with future tests will incorporate both biochemical and clinical data, resulting in specific profiles for each patient or tested subject to enable personalized medicine approaches.
27896781	0	30	Multiplex Biomarker Approaches	T058	C0376583
27896781	34	40	Enable	T041	C1171285
27896781	41	62	Point-of-Care Testing	T058	C1319069
27896781	67	88	Personalized Medicine	T061	C2718059
27896781	94	101	chapter	T078	C1552857
27896781	116	123	current	T079	C0521116
27896781	128	134	future	T079	C0016884
27896781	135	146	innovations	T170	C0683888
27896781	157	168	application	T169	C4048755
27896781	172	202	multiplex biomarker techniques	T058	C0376583
27896781	232	243	efficacious	T080	C1704419
27896781	244	253	treatment	T169	C1522326
27896781	257	265	patients	T101	C0030705
27896781	267	276	suffering	T033	C0231303
27896781	286	293	world's	T098	C2700280
27896781	294	298	most	T081	C0205393
27896781	299	310	devastating	T080	C0205082
27896781	315	321	costly	T169	C0220812
27896781	322	330	diseases	T047	C0012634
27896781	336	347	application	T169	C4048755
27896781	355	367	miniaturized	T080	C1282927
27896781	368	378	biosensors	T075	C0600364
27896781	383	394	transducers	T074	C0040661
27896781	407	428	point-of-care testing	T058	C1319069
27896781	445	453	analysis	T062	C0936012
27896781	459	465	single	T081	C0205171
27896781	466	470	drop	T081	C4048603
27896781	476	481	blood	T031	C0005767
27896781	493	497	time	T079	C0040223
27896781	498	502	span	T077	C1711300
27896781	508	513	visit	T053	C0545082
27896781	521	536	doctor's office	T073,T093	C0031834
27896781	544	555	anticipated	T033	C3840775
27896781	565	572	scoring	T081	C0449820
27896781	573	583	algorithms	T170	C0002045
27896781	594	600	future	T079	C0016884
27896781	601	606	tests	T169	C0039593
27896781	612	623	incorporate	T169	C0243126
27896781	624	628	both	T080	C1706086
27896781	629	640	biochemical	T169	C0205474
27896781	645	653	clinical	T080	C0205210
27896781	654	658	data	T078	C1511726
27896781	660	672	resulting in	T169	C0332294
27896781	673	681	specific	T080	C0205369
27896781	682	690	profiles	T059	C1979963
27896781	700	707	patient	T101	C0030705
27896781	711	717	tested	T169	C0039593
27896781	718	725	subject	T167	C0370003
27896781	736	757	personalized medicine	T061	C2718059
27896781	758	768	approaches	T082	C0449445

28105138|t|Clinical and angiographic correlation of high-sensitivity C-reactive protein with acute ST elevation myocardial infarction
28105138|a|Vascular inflammation and associated ongoing inflammatory responses are considered as the critical culprits in the pathogenesis of acute atherothrombotic events such as acute coronary syndrome (ACS) and myocardial infarction (MI). ST segment elevation myocardial infarction (STEMI) is considered as one of the prominent clinical forms of ACS. Moreover, C-reactive protein (CRP) is an important acute phase prsotein, which may be estimated using high-sensitivity methods (hs-CRP), and its elevated level in body fluids reflects chronic inflammatory status. The circulating hs-CRP level has been proposed as a promising inflammatory marker of coronary artery disease (CAD). The present study investigated the correlation of hs-CRP level with clinical and angiographic features of STEMI, various other traditional risk factors, complications of myocardial infarction and angiographically significant CAD. Out of 190 patients with STEMI that were analyzed, the interval between symptom onset and reperfusion therapy (window period) varied from 0.5 to 24 h. The hs-CRP value was found to be higher in non-diabetic patients (0.61 mg/dl) compared with diabetic patients (0.87 mg/dl). Moreover, a significant correlation between hs-CRP and hs-troponin T was also recorded (P<0.001). However, there was no significant difference in the mean hs-CRP values in patients with or without mortality. It is considered that the present study will increase the understanding of atherosclerosis in general and may also have clinical applications in the targeting of therapy for this harmful disease.
28105138	0	8	Clinical	T080	C0205210
28105138	13	25	angiographic	T060	C0002978
28105138	26	37	correlation	T080	C1707520
28105138	41	76	high-sensitivity C-reactive protein	T116,T129	C0006560
28105138	82	122	acute ST elevation myocardial infarction	T047	C1303258
28105138	123	144	Vascular inflammation	T047	C0947751
28105138	168	190	inflammatory responses	T046	C1155266
28105138	238	250	pathogenesis	T046	C0699748
28105138	254	259	acute	T079	C0205178
28105138	260	276	atherothrombotic	T020	C1963943
28105138	277	283	events	T051	C0441471
28105138	292	315	acute coronary syndrome	T047	C0948089
28105138	317	320	ACS	T047	C0948089
28105138	326	347	myocardial infarction	T047	C0027051
28105138	349	351	MI	T047	C0027051
28105138	354	396	ST segment elevation myocardial infarction	T047	C1536220
28105138	398	403	STEMI	T047	C1536220
28105138	443	451	clinical	T080	C0205210
28105138	452	457	forms	T080	C0348078
28105138	461	464	ACS	T047	C0948089
28105138	476	494	C-reactive protein	T116,T129	C0006560
28105138	496	499	CRP	T116,T129	C0006560
28105138	517	537	acute phase prsotein	T116,T123	C0001347
28105138	568	592	high-sensitivity methods	T059	C3839560
28105138	594	600	hs-CRP	T059	C3839560
28105138	611	619	elevated	T080	C3163633
28105138	620	625	level	T034	C0428528
28105138	629	640	body fluids	T031	C0005889
28105138	650	670	chronic inflammatory	T046	C0021376
28105138	671	677	status	T080	C0449438
28105138	695	701	hs-CRP	T059	C3839560
28105138	702	707	level	T034	C0428528
28105138	741	753	inflammatory	T046	C0021368
28105138	754	760	marker	T201	C0005516
28105138	764	787	coronary artery disease	T047	C0010054
28105138	789	792	CAD	T047	C0010054
28105138	807	812	study	T062	C2603343
28105138	813	825	investigated	T169	C1292732
28105138	830	841	correlation	T080	C1707520
28105138	845	851	hs-CRP	T059	C3839560
28105138	852	857	level	T034	C0428528
28105138	863	871	clinical	T080	C0205210
28105138	876	888	angiographic	T060	C0002978
28105138	889	897	features	T080	C2348519
28105138	901	906	STEMI	T047	C1536220
28105138	934	946	risk factors	T033	C0035648
28105138	948	961	complications	T046	C0009566
28105138	965	986	myocardial infarction	T047	C0027051
28105138	991	1019	angiographically significant	T078	C0750502
28105138	1020	1023	CAD	T047	C0010054
28105138	1036	1044	patients	T101	C0030705
28105138	1050	1055	STEMI	T047	C1536220
28105138	1066	1074	analyzed	T062	C0936012
28105138	1080	1088	interval	T079	C1272706
28105138	1097	1110	symptom onset	T079	C4086878
28105138	1115	1134	reperfusion therapy	T061	C0035124
28105138	1136	1149	window period	T079	C1948053
28105138	1173	1174	h	T079	C0439227
28105138	1180	1186	hs-CRP	T059	C3839560
28105138	1219	1240	non-diabetic patients	T101	C0030705
28105138	1254	1262	compared	T052	C1707455
28105138	1268	1276	diabetic	T047	C0011847
28105138	1277	1285	patients	T101	C0030705
28105138	1324	1335	correlation	T080	C1707520
28105138	1344	1350	hs-CRP	T059	C3839560
28105138	1355	1368	hs-troponin T	T059	C3827339
28105138	1455	1461	hs-CRP	T059	C3839560
28105138	1462	1468	values	T080	C0042295
28105138	1472	1480	patients	T101	C0030705
28105138	1497	1506	mortality	T081	C0205848
28105138	1542	1547	study	T062	C2603343
28105138	1583	1598	atherosclerosis	T047	C0004153
28105138	1628	1649	clinical applications	T058	C1254363
28105138	1670	1677	therapy	T061	C0087111
28105138	1695	1702	disease	T047	C0012634

27382354|t|Effects of analgesics and antidepressants on TREK-2 and TRESK currents
27382354|a|TWIK-related K(+) channel-2 (TREK-2) and TWIK-related spinal cord K(+) (TRESK) channel are members of two-pore domain K(+) channel family. They are well expressed and help to set the resting membrane potential in sensory neurons. Modulation of TREK-2 and TRESK channels are involved in the pathogenesis of pain, and specifi c activators of TREK-2 and TRESK may be benefi cial for the treatment of pain symptoms. However, the effect of commonly used analgesics on TREK-2 and TRESK channels are not known. Here, we investigated the effect of analgesics on TREK-2 and TRESK channels. The effects of analgesics were examined in HEK cells transfected with TREK-2 or TRESK. Amitriptyline, citalopram, escitalopram, and fluoxetine significantly inhibited TREK-2 and TRESK currents in HEK cells (p<0.05, n=10). Acetaminophen, ibuprofen, nabumetone, and bupropion inhibited TRESK, but had no effect on TREK-2. These results show that all analgesics tested in this study inhibit TRESK activity. Further study is needed to identify the mechanisms by which the analgesics modulate TREK-2 and TRESK differently.
27382354	0	10	Effects of	T080	C1704420
27382354	11	21	analgesics	T109,T121,T131	C0002771
27382354	26	41	antidepressants	T121	C0003289
27382354	45	51	TREK-2	T116,T123	C1608682
27382354	56	61	TRESK	T116	C1311011
27382354	62	70	currents	T043	C0162585
27382354	71	98	TWIK-related K(+) channel-2	T116,T123	C1608682
27382354	100	106	TREK-2	T116,T123	C1608682
27382354	112	157	TWIK-related spinal cord K(+) (TRESK) channel	T116	C1311011
27382354	173	208	two-pore domain K(+) channel family	T116,T123	C0032824
27382354	224	233	expressed	T045	C1171362
27382354	254	280	resting membrane potential	T043	C0025251
27382354	284	299	sensory neurons	T025	C0027883
27382354	301	311	Modulation	T038	C3271963
27382354	315	321	TREK-2	T116,T123	C1608682
27382354	326	340	TRESK channels	T116	C1311011
27382354	361	373	pathogenesis	T046	C0699748
27382354	377	381	pain	T184	C0030193
27382354	387	396	specifi c	T080	C0205369
27382354	397	407	activators	T121	C3163331
27382354	411	417	TREK-2	T116,T123	C1608682
27382354	422	427	TRESK	T116	C1311011
27382354	435	446	benefi cial	T081	C0814225
27382354	455	464	treatment	T061	C0087111
27382354	468	472	pain	T184	C0030193
27382354	473	481	symptoms	T184	C1457887
27382354	496	505	effect of	T080	C1704420
27382354	520	530	analgesics	T109,T121,T131	C0002771
27382354	534	540	TREK-2	T116,T123	C1608682
27382354	545	559	TRESK channels	T116	C1311011
27382354	601	610	effect of	T080	C1704420
27382354	611	621	analgesics	T109,T121,T131	C0002771
27382354	625	631	TREK-2	T116,T123	C1608682
27382354	636	641	TRESK	T116	C1311011
27382354	642	650	channels	T116,T123	C0032824
27382354	656	666	effects of	T080	C1704420
27382354	667	677	analgesics	T109,T121,T131	C0002771
27382354	695	704	HEK cells	T025	C2936239
27382354	705	716	transfected	T063	C0040669
27382354	722	728	TREK-2	T116,T123	C1608682
27382354	732	737	TRESK	T116	C1311011
27382354	739	752	Amitriptyline	T109,T121	C0002600
27382354	754	764	citalopram	T109,T121	C0008845
27382354	766	778	escitalopram	T109,T121	C1099456
27382354	784	794	fluoxetine	T109,T121	C0016365
27382354	795	808	significantly	T078	C0750502
27382354	809	818	inhibited	T044	C3895263
27382354	819	825	TREK-2	T116,T123	C1608682
27382354	830	835	TRESK	T116	C1311011
27382354	836	844	currents	T043	C0162585
27382354	848	857	HEK cells	T025	C2936239
27382354	874	887	Acetaminophen	T109,T121	C0000970
27382354	889	898	ibuprofen	T109,T121	C0020740
27382354	900	910	nabumetone	T109,T121	C0068334
27382354	916	925	bupropion	T109,T121	C0085208
27382354	936	941	TRESK	T116	C1311011
27382354	951	960	no effect	T080	C1301751
27382354	964	970	TREK-2	T116,T123	C1608682
27382354	1000	1010	analgesics	T109,T121,T131	C0002771
27382354	1011	1017	tested	T169	C0039593
27382354	1032	1039	inhibit	T044	C3895263
27382354	1040	1045	TRESK	T116	C1311011
27382354	1046	1054	activity	T044	C1153450
27382354	1096	1106	mechanisms	T044	C0678659
27382354	1120	1130	analgesics	T109,T121,T131	C0002771
27382354	1140	1146	TREK-2	T116,T123	C1608682
27382354	1151	1156	TRESK	T116	C1311011

28351716|t|Diagnosis of retinal health in digital fundus images using continuous wavelet transform (CWT) and entropies
28351716|a|Vision is paramount to humans to lead an active personal and professional life. The prevalence of ocular diseases is rising, and diseases such as glaucoma, Diabetic Retinopathy (DR) and Age-related Macular Degeneration (AMD) are the leading causes of blindness in developed countries. Identifying these diseases in mass screening programmes is time-consuming, labor -intensive and the diagnosis can be subjective. The use of an automated computer aided diagnosis system will reduce the time taken for analysis and will also reduce the inter-observer subjective variabilities in image interpretation. In this work, we propose one such system for the automatic classification of normal from abnormal (DR, AMD, glaucoma) images. We had a total of 404 normal and 1082 abnormal fundus images in our database. As the first step, 2D-Continuous Wavelet Transform (CWT) decomposition on the fundus images of two classes was performed. Subsequently, energy features and various entropies namely Yager, Renyi, Kapoor, Shannon, and Fuzzy were extracted from the decomposed images. Then, adaptive synthetic sampling approach was applied to balance the normal and abnormal datasets. Next, the extracted features were ranked according to the significances using Particle Swarm Optimization (PSO). Thereupon, the ranked and selected features were used to train the random forest classifier using stratified 10-fold cross validation. Overall, the proposed system presented a performance rate of 92.48%, and a sensitivity and specificity of 89.37% and 95.58% respectively using 15 features. This novel system shows promise in detecting abnormal fundus images, and hence, could be a valuable adjunct eye health screening tool that could be employed in polyclinics, and thereby reduce the workload of specialists at hospitals.
28351716	0	9	Diagnosis	T033	C0011900
28351716	13	20	retinal	T023	C0035298
28351716	21	27	health	T078	C0018684
28351716	31	52	digital fundus images	T060	C0200189
28351716	59	87	continuous wavelet transform	T062	C2936326
28351716	89	92	CWT	T062	C2936326
28351716	98	107	entropies	T067	C0376522
28351716	108	114	Vision	T040	C0042789
28351716	131	137	humans	T016	C0086418
28351716	156	164	personal	T032	C1519021
28351716	169	186	professional life	T090	C2698884
28351716	192	202	prevalence	T081	C0220900
28351716	206	221	ocular diseases	T047	C0015397
28351716	237	245	diseases	T047	C0012634
28351716	254	262	glaucoma	T047	C0017601
28351716	264	284	Diabetic Retinopathy	T047	C0011884
28351716	286	288	DR	T047	C0011884
28351716	294	326	Age-related Macular Degeneration	T047	C0242383
28351716	328	331	AMD	T047	C0242383
28351716	341	348	leading	T169	C1522538
28351716	349	355	causes	T169	C0015127
28351716	359	368	blindness	T033	C0456909
28351716	372	391	developed countries	T080	C0282613
28351716	411	419	diseases	T047	C0012634
28351716	423	448	mass screening programmes	T058	C0024870
28351716	452	466	time-consuming	T080	C3827829
28351716	468	473	labor	T057	C0043227
28351716	493	502	diagnosis	T033	C0011900
28351716	510	520	subjective	T080	C0439655
28351716	536	577	automated computer aided diagnosis system	T060	C0011905
28351716	609	617	analysis	T062	C0936012
28351716	643	682	inter-observer subjective variabilities	T081	C0021713
28351716	686	706	image interpretation	T060,T062	C0020910
28351716	757	766	automatic	T169	C0205554
28351716	767	781	classification	T185	C0008902
28351716	785	791	normal	T080	C0205307
28351716	797	805	abnormal	T033	C0205161
28351716	807	809	DR	T047	C0011884
28351716	811	814	AMD	T047	C0242383
28351716	816	824	glaucoma	T047	C0017601
28351716	826	832	images	T070	C0237660
28351716	856	862	normal	T080	C0205307
28351716	872	880	abnormal	T033	C0205161
28351716	881	894	fundus images	T060	C0200189
28351716	902	910	database	T170	C0242356
28351716	931	962	2D-Continuous Wavelet Transform	T062	C2936326
28351716	964	967	CWT	T062	C2936326
28351716	990	1003	fundus images	T060	C0200189
28351716	1048	1054	energy	T081	C1442080
28351716	1076	1085	entropies	T067	C0376522
28351716	1169	1175	images	T070	C0237660
28351716	1202	1219	sampling approach	T170	C0449370
28351716	1247	1253	normal	T080	C0205307
28351716	1258	1266	abnormal	T033	C0205161
28351716	1267	1275	datasets	T170	C0150098
28351716	1355	1382	Particle Swarm Optimization	T170	C0282574
28351716	1384	1387	PSO	T170	C0282574
28351716	1488	1498	stratified	T080	C0205363
28351716	1507	1523	cross validation	T062	C0681935
28351716	1566	1582	performance rate	T081	C3533080
28351716	1600	1611	sensitivity	T081	C0036667
28351716	1616	1627	specificity	T081	C0037791
28351716	1726	1734	abnormal	T033	C0205161
28351716	1735	1748	fundus images	T060	C0200189
28351716	1789	1792	eye	T023	C0015392
28351716	1793	1799	health	T078	C0018684
28351716	1800	1814	screening tool	T058	C0220908
28351716	1841	1852	polyclinics	T073,T093	C0442592
28351716	1877	1885	workload	T081	C0085122
28351716	1889	1900	specialists	T097	C1611835
28351716	1904	1913	hospitals	T073,T093	C0019994

27330692|t|Evaluation of the Effects of Intravenous and Percutaneous Low Level Laser Therapy in the Management of Shoulder Myofascial Pain Syndrome
27330692|a|Myofascial pain syndrome (MPS) treatment is challenging with a high recurrence rate and still lacks a clear treatment frame. Therefore research on new, more efficient and long lasting effect treatment modalities is necessary. This study looked at the effects of intravenous laser therapy (IVL) and percutaneous low level laser (PLLL) in the management of shoulder MPS. In this randomized controlled trial, 30 patients fulfilling inclusion criteria were randomly equally allocated to 3 groups, control, IVL and PLLL. Control group received 12 sessions of placebo low level laser, IVL group received 12 sessions of IVL therapy, and PLLL group received 12 sessions of PLLL therapy. All patients were trained for better body posture, body mechanics, gentle massage of trigger points, stretching exercises of affected muscle (trapezius), and received 10 mg of oral nortriptyline regimen every night for 3 months. Outcomes included pain severity, functional disability, and quality of life. Patients were assessed using Numeric Rating Scale (NRS), Pain Disability Index (PDI), and Short Form Health Survey (SF-12). Data collected were analyzed using analysis of variance (ANOVA), Mann-Whitney and t tests. The mean of PDI and maximum pain intensity during day and night significantly reduced in both PLLL and IVL groups compared to control group. Although pain severity and PDI reduction was more pronounced in IVL group compared to PLLL group, the differences were not statistically significant. Also, quality of life statistically significantly improved in both IVL and PLLL groups compared to control group was more, and although higher in IVL group, the difference was not statistically significant when compared to PLLL group. No side effects were observed in the intervention groups. Intravenous laser and PLLL therapy had a positive effect on pain severity and PDI reduction, and quality of life in this study. Also no adverse event was recorded. Thus, intravenous lasers and PLLL therapy seem to be effective complementary modalities in managing patients with shoulder MPS.
27330692	0	10	Evaluation	T058	C0220825
27330692	18	28	Effects of	T080	C1704420
27330692	29	40	Intravenous	T082	C0348016
27330692	45	57	Percutaneous	T082	C0522523
27330692	58	81	Low Level Laser Therapy	T061	C0279027
27330692	89	99	Management	T061	C0002766
27330692	103	111	Shoulder	T029	C0037004
27330692	112	136	Myofascial Pain Syndrome	T047	C0027073
27330692	137	161	Myofascial pain syndrome	T047	C0027073
27330692	163	166	MPS	T047	C0027073
27330692	168	177	treatment	T061	C0087111
27330692	245	260	treatment frame	T061	C0087111
27330692	294	303	efficient	T080	C0442799
27330692	328	337	treatment	T061	C0087111
27330692	338	348	modalities	T078	C0695347
27330692	388	398	effects of	T080	C1704420
27330692	399	410	intravenous	T082	C0348016
27330692	411	424	laser therapy	T061	C1955835
27330692	426	429	IVL	T061	C1955835
27330692	435	447	percutaneous	T082	C0522523
27330692	448	463	low level laser	T061	C0279027
27330692	465	469	PLLL	T061	C0279027
27330692	478	488	management	T061	C0002766
27330692	492	500	shoulder	T029	C0037004
27330692	501	504	MPS	T047	C0027073
27330692	514	541	randomized controlled trial	T062	C0206035
27330692	546	554	patients	T101	C0030705
27330692	566	584	inclusion criteria	T080	C1512693
27330692	630	637	control	T096	C0009932
27330692	639	642	IVL	T098	C1257890
27330692	647	651	PLLL	T098	C1257890
27330692	653	666	Control group	T096	C0009932
27330692	691	698	placebo	T062	C1706408
27330692	699	714	low level laser	T061	C0279027
27330692	716	725	IVL group	T098	C1257890
27330692	750	761	IVL therapy	T061	C1955835
27330692	767	777	PLLL group	T098	C1257890
27330692	802	814	PLLL therapy	T061	C0279027
27330692	820	828	patients	T101	C0030705
27330692	846	852	better	T080	C0332272
27330692	853	865	body posture	T032	C1262869
27330692	867	881	body mechanics	T022	C0598002
27330692	883	897	gentle massage	T061	C0150347
27330692	901	915	trigger points	T029	C0458343
27330692	917	937	stretching exercises	T061	C0600080
27330692	941	949	affected	T169	C0392760
27330692	950	956	muscle	T024	C0026845
27330692	958	967	trapezius	T023	C0224361
27330692	992	996	oral	T082	C0442027
27330692	997	1010	nortriptyline	T109,T121	C0028420
27330692	1011	1018	regimen	T061	C0040808
27330692	1063	1076	pain severity	T080	C1507013
27330692	1078	1099	functional disability	T033	C0872173
27330692	1105	1120	quality of life	T078	C0034380
27330692	1122	1130	Patients	T101	C0030705
27330692	1151	1171	Numeric Rating Scale	T170	C4050142
27330692	1173	1176	NRS	T170	C4050142
27330692	1179	1200	Pain Disability Index	T170	C0282574
27330692	1202	1205	PDI	T170	C0282574
27330692	1212	1236	Short Form Health Survey	T170	C0451286
27330692	1238	1243	SF-12	T170	C1519135
27330692	1246	1260	Data collected	T033	C4019276
27330692	1266	1274	analyzed	T062	C0936012
27330692	1281	1301	analysis of variance	T081	C0002780
27330692	1303	1308	ANOVA	T081	C0002780
27330692	1311	1323	Mann-Whitney	T170	C1708930
27330692	1328	1335	t tests	T170	C0871472
27330692	1349	1352	PDI	T170	C0282574
27330692	1365	1379	pain intensity	T201	C1320357
27330692	1415	1422	reduced	T080	C0392756
27330692	1431	1435	PLLL	T098	C1257890
27330692	1440	1450	IVL groups	T098	C1257890
27330692	1463	1476	control group	T096	C0009932
27330692	1505	1508	PDI	T170	C0282574
27330692	1542	1551	IVL group	T098	C1257890
27330692	1564	1574	PLLL group	T098	C1257890
27330692	1601	1626	statistically significant	T081	C0237881
27330692	1634	1649	quality of life	T078	C0034380
27330692	1650	1677	statistically significantly	T081	C0237881
27330692	1695	1698	IVL	T098	C1257890
27330692	1703	1714	PLLL groups	T098	C1257890
27330692	1727	1740	control group	T096	C0009932
27330692	1774	1783	IVL group	T098	C1257890
27330692	1808	1833	statistically significant	T081	C0237881
27330692	1851	1861	PLLL group	T098	C1257890
27330692	1863	1878	No side effects	T033	C1963761
27330692	1900	1919	intervention groups	T098	C2986530
27330692	1921	1932	Intravenous	T082	C0348016
27330692	1933	1938	laser	T061	C1955835
27330692	1943	1955	PLLL therapy	T061	C0279027
27330692	1971	1977	effect	T080	C1280500
27330692	1981	1994	pain severity	T080	C1507013
27330692	1999	2002	PDI	T170	C0282574
27330692	2018	2033	quality of life	T078	C0034380
27330692	2054	2070	no adverse event	T033	C1963761
27330692	2091	2102	intravenous	T082	C0348016
27330692	2103	2109	lasers	T061	C1955835
27330692	2114	2126	PLLL therapy	T061	C0279027
27330692	2138	2147	effective	T080	C1704419
27330692	2162	2172	modalities	T078	C0695347
27330692	2176	2184	managing	T061	C0002766
27330692	2185	2193	patients	T101	C0030705
27330692	2199	2207	shoulder	T029	C0037004
27330692	2208	2211	MPS	T047	C0027073

28349200|t|Dispersal traits may reflect dispersal distances, but dispersers may not connect populations demographically
28349200|a|Ecological traits that reflect movement potential are often used as proxies for measured dispersal distances. Whether such traits reflect actual dispersal is often untested. Such tests are important because maximum dispersal distances may not be achieved and many dispersal events may be unsuccessful (without reproduction). For insects, many habitat patches harbour ' resident ' species that are present as larvae (sedentary) and adults (winged and dispersing), and ' itinerant ' species present only as adults that have dispersed from elsewhere and fail to reproduce. We tested whether itinerancy patterns were temporally consistent, and whether itinerant and resident species differed in wing morphology, a strong correlate of flight capability. Over 3 years and at multiple locations in a 22 km stream length, we sampled larvae and adults of caddisflies in the genus Ecnomus to categorize species as residents or itinerants. Flight capacity was measured using wing size (length and area) and shape parameters (aspect ratio and the second moment of wing area). Three species of Ecnomus were residents and three species were itinerants, and patterns were consistent over 3 years. On average, itinerant species had larger wings, suggesting a greater capacity to fly long distances. Wing shape differed between species, but did not differ systematically between residents and itinerants. Wing morphology was associated with actual but not effective dispersal of some species of Ecnomus. Morphological traits may have weak explanatory power for hypotheses regarding the demographic connectedness of populations, unless accompanied by data demonstrating which dispersers contribute new individuals to populations.
28349200	0	9	Dispersal	T169	C1704711
28349200	10	16	traits	T032	C0599883
28349200	29	38	dispersal	T169	C1704711
28349200	39	48	distances	T081	C0012751
28349200	54	64	dispersers	T001	C0029235
28349200	69	72	not	T169	C1518422
28349200	73	80	connect	T052	C2986575
28349200	81	92	populations	T081	C0032659
28349200	93	108	demographically	T062	C0011289
28349200	109	119	Ecological	T070	C0162358
28349200	120	126	traits	T032	C0599883
28349200	140	148	movement	T040	C0026649
28349200	149	158	potential	T080	C3245505
28349200	189	197	measured	T080	C0444706
28349200	198	207	dispersal	T169	C1704711
28349200	208	217	distances	T081	C0012751
28349200	232	238	traits	T032	C0599883
28349200	247	253	actual	T080	C0237400
28349200	254	263	dispersal	T169	C1704711
28349200	273	281	untested	T080	C3640292
28349200	288	293	tests	T169	C0039593
28349200	298	307	important	T080	C3898777
28349200	316	323	maximum	T081	C0806909
28349200	324	333	dispersal	T169	C1704711
28349200	334	343	distances	T081	C0012751
28349200	373	382	dispersal	T169	C1704711
28349200	383	389	events	T051	C0441471
28349200	397	409	unsuccessful	T080	C1272705
28349200	411	418	without	T080	C0332288
28349200	419	431	reproduction	T040	C0035150
28349200	438	445	insects	T204	C0021585
28349200	452	459	habitat	T082	C0871648
28349200	478	486	resident	T169	C0302891
28349200	489	496	species	T185	C1705920
28349200	506	513	present	T033	C0150312
28349200	517	523	larvae	T204	C0023047
28349200	525	534	sedentary	T080	C0205254
28349200	540	546	adults	T204	C0563200
28349200	548	554	winged	T033	C0243095
28349200	559	569	dispersing	T169	C1704711
28349200	578	587	itinerant	T169	C0205228
28349200	590	597	species	T185	C1705920
28349200	614	620	adults	T204	C0563200
28349200	631	640	dispersed	T169	C1704711
28349200	660	664	fail	T169	C0231175
28349200	668	677	reproduce	T040	C0035150
28349200	682	688	tested	T169	C0039593
28349200	697	707	itinerancy	T056	C0040802
28349200	708	716	patterns	T082	C0449774
28349200	722	732	temporally	T079	C0205374
28349200	733	743	consistent	T078	C0332290
28349200	757	766	itinerant	T169	C0205228
28349200	771	779	resident	T169	C0302891
28349200	780	787	species	T185	C1705920
28349200	788	796	differed	T080	C1705242
28349200	800	804	wing	T023	C0043189
28349200	805	815	morphology	T080	C0332437
28349200	819	825	strong	T080	C0442821
28349200	826	835	correlate	T080	C1707520
28349200	839	845	flight	T067	C2610507
28349200	846	856	capability	T080	C2698977
28349200	858	862	Over	T079	C0347984
28349200	863	870	3 years	T079	C0439234
28349200	878	886	multiple	T081	C0439064
28349200	887	896	locations	T082	C0450429
28349200	908	914	stream	T070	C0442540
28349200	915	921	length	T081	C1444754
28349200	934	940	larvae	T204	C0023047
28349200	945	951	adults	T204	C0563200
28349200	955	966	caddisflies	T204	C1003139
28349200	974	979	genus	T185	C1708235
28349200	980	987	Ecnomus	T204	C1203524
28349200	991	1001	categorize	T052	C0871968
28349200	1002	1009	species	T185	C1705920
28349200	1013	1022	residents	T169	C0302891
28349200	1026	1036	itinerants	T169	C0205228
28349200	1038	1044	Flight	T067	C2610507
28349200	1045	1053	capacity	T081	C1516240
28349200	1058	1066	measured	T080	C0444706
28349200	1073	1077	wing	T023	C0043189
28349200	1078	1082	size	T082	C0456389
28349200	1084	1090	length	T081	C1444754
28349200	1095	1099	area	T082	C0205146
28349200	1123	1135	aspect ratio	T081	C2346862
28349200	1144	1150	second	T081	C0205436
28349200	1151	1157	moment	T067	C0376590
28349200	1161	1165	wing	T023	C0043189
28349200	1166	1170	area	T082	C0205146
28349200	1173	1178	Three	T081	C0205449
28349200	1179	1186	species	T185	C1705920
28349200	1190	1197	Ecnomus	T204	C1203524
28349200	1203	1212	residents	T169	C0302891
28349200	1223	1230	species	T185	C1705920
28349200	1236	1246	itinerants	T169	C0205228
28349200	1252	1260	patterns	T082	C0449774
28349200	1266	1276	consistent	T080	C1948059
28349200	1277	1281	over	T079	C0347984
28349200	1282	1289	3 years	T079	C0439234
28349200	1294	1301	average	T081	C1510992
28349200	1303	1312	itinerant	T169	C0205228
28349200	1313	1320	species	T185	C1705920
28349200	1325	1331	larger	T081	C0549177
28349200	1332	1337	wings	T023	C0043189
28349200	1339	1349	suggesting	T078	C1705535
28349200	1352	1359	greater	T081	C1704243
28349200	1360	1368	capacity	T081	C1516240
28349200	1372	1375	fly	T056	C0441659
28349200	1376	1380	long	T080	C0205166
28349200	1381	1390	distances	T081	C0012751
28349200	1392	1396	Wing	T023	C0043189
28349200	1403	1411	differed	T080	C1705242
28349200	1420	1427	species	T185	C1705920
28349200	1420	1427	species	T185	C1705920
28349200	1437	1440	not	T169	C1518422
28349200	1448	1462	systematically	T169	C0220922
28349200	1471	1480	residents	T169	C0302891
28349200	1485	1495	itinerants	T169	C0205228
28349200	1497	1501	Wing	T023	C0043189
28349200	1502	1512	morphology	T080	C0332437
28349200	1517	1532	associated with	T080	C0332281
28349200	1533	1539	actual	T080	C0237400
28349200	1544	1547	not	T169	C1518422
28349200	1548	1557	effective	T080	C1704419
28349200	1558	1567	dispersal	T169	C1704711
28349200	1571	1575	some	T081	C0205392
28349200	1576	1583	species	T185	C1705920
28349200	1587	1594	Ecnomus	T204	C1203524
28349200	1596	1609	Morphological	T082	C0543482
28349200	1610	1616	traits	T032	C0599883
28349200	1626	1630	weak	T080	C1762617
28349200	1631	1648	explanatory power	T080	C0205556
28349200	1653	1663	hypotheses	T078	C1512571
28349200	1678	1703	demographic connectedness	T052	C2986575
28349200	1707	1718	populations	T081	C0032659
28349200	1742	1746	data	T078	C1511726
28349200	1767	1777	dispersers	T001	C0029235
28349200	1778	1788	contribute	T052	C1880177
28349200	1789	1792	new	T080	C0205314
28349200	1793	1804	individuals	T098	C1257890
28349200	1808	1819	populations	T081	C0032659